<SEC-DOCUMENT>0001601485-22-000022.txt : 20220330
<SEC-HEADER>0001601485-22-000022.hdr.sgml : 20220330
<ACCEPTANCE-DATETIME>20220330165620
ACCESSION NUMBER:		0001601485-22-000022
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		121
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220330
DATE AS OF CHANGE:		20220330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Angion Biomedica Corp.
		CENTRAL INDEX KEY:			0001601485
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				113430072
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39990
		FILM NUMBER:		22787301

	BUSINESS ADDRESS:	
		STREET 1:		51 CHARLES LINDBERGH BOULEVARD
		CITY:			UNIONDALE
		STATE:			NY
		ZIP:			11553
		BUSINESS PHONE:		(415) 655-4899

	MAIL ADDRESS:	
		STREET 1:		51 CHARLES LINDBERGH BOULEVARD
		CITY:			UNIONDALE
		STATE:			NY
		ZIP:			11553
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>angn-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:808f0db7-14af-45c6-a88e-e152464defe4,g:f048552f-f790-4462-b881-32982147c095,d:dee3699378af4447a4091414c0adfaa7--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:angn="http://www.angn.com/20211231" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>angn-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN183L2ZyYWc6OGIyNmFlYTQ3ZGQxNDRjMDg0ZDk5NDhjODIyMDgyZTQvdGFibGU6OTlhYjIxMWZkZmRlNGRkNTkzZjE1NTdjNWRmOTBmZDUvdGFibGVyYW5nZTo5OWFiMjExZmRmZGU0ZGQ1OTNmMTU1N2M1ZGY5MGZkNV84LTEtMS0xLTIyNzA1_29966fce-4622-4156-8557-308b9fc83f8a">2021</ix:nonNumeric><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN183L2ZyYWc6OGIyNmFlYTQ3ZGQxNDRjMDg0ZDk5NDhjODIyMDgyZTQvdGFibGU6OTlhYjIxMWZkZmRlNGRkNTkzZjE1NTdjNWRmOTBmZDUvdGFibGVyYW5nZTo5OWFiMjExZmRmZGU0ZGQ1OTNmMTU1N2M1ZGY5MGZkNV85LTEtMS0xLTIyNzA4_41518d83-3877-45b0-9130-bb42699a88f5">FY</ix:nonNumeric><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN183L2ZyYWc6OGIyNmFlYTQ3ZGQxNDRjMDg0ZDk5NDhjODIyMDgyZTQvdGFibGU6OTlhYjIxMWZkZmRlNGRkNTkzZjE1NTdjNWRmOTBmZDUvdGFibGVyYW5nZTo5OWFiMjExZmRmZGU0ZGQ1OTNmMTU1N2M1ZGY5MGZkNV8xMi0xLTEtMS0yMjcxNA_175d4cbc-86a4-4363-9d71-15810f5b4720">0001601485</ix:nonNumeric><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN183L2ZyYWc6OGIyNmFlYTQ3ZGQxNDRjMDg0ZDk5NDhjODIyMDgyZTQvdGFibGU6OTlhYjIxMWZkZmRlNGRkNTkzZjE1NTdjNWRmOTBmZDUvdGFibGVyYW5nZTo5OWFiMjExZmRmZGU0ZGQ1OTNmMTU1N2M1ZGY5MGZkNV8xMy0xLTEtMS0yMzk0OA_7e1b78dc-6742-4c82-8e19-aa3b21ab9e6e">False</ix:nonNumeric><ix:nonNumeric contextRef="ib2c20a51369c40ba8a350cc15fab95b0_I20211231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN180OTUvZnJhZzpmZjNhZGNhMWI4MGM0ZGYyYWRlZjk1YjI0MTc5YzA0Ni90ZXh0cmVnaW9uOmZmM2FkY2ExYjgwYzRkZjJhZGVmOTViMjQxNzljMDQ2XzEwOTk1MTE2MjgwMzg_088ef34c-af75-496c-8956-9dfa620079e5">1.0</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="angn-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf95c95dc2554e05bcfd8f1a4b0d4845_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i936ee8cbca4640f89962461f9dbfb53e_I20220325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i3a167605e6c646629b93a1d3439787b9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bc5ce1428404ed68895fc85d43b0940_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e83b2738e914f70885e201c75695d23_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea8b4e5177ca414aa1d42917857fa7fc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39a22dafc7b947b7b1c0010ac7f3da2a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06808f2a95374e118cce43e36bb8bd8a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc9576f67b6c4e84ac9a7860f4e882ba_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08c03f72f0b941539e5cdcb6bd71e375_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1c7b28f9b2847048f8bff454357f045_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88205c729a864e89b707c0e5f4a94101_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff68735442874854ba8906f0ce685f7a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49e1595df6544da1b62cb4cb76e2a870_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7785562bdf04065b88581e12664c38d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac2dd912c60747d0ad5686735d31aabd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib63d42df1d424dd7a089a2a61055a8d8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i627eb8ac3c1e4cdba53546b28b5c0c96_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a141da19f2749e9915716c7f48fd1ed_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcfdf8709ae1454db935f48886a3448d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacbac71171a247f19b7f67fb114cc51b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c2584c4d4d14f87943a1ff43186ef4d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if64d03bb45484664ab00b5e9ac3b4129_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50d5f86cb19d42ff8235b613207c2abe_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d292d5da1514f2bbaf90a5652db785c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e02d3c90cee46fb92a3c766d05f4b5a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56986948e86b485b8509172b9334c746_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd0806ead4944367a276b62a1b32bafa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86478d7cb5144b47ad734b74bf2a7754_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:NonIPORelatedStockTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica25c8fd34524de8a476208cd00f9f89_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:NonIPORelatedStockTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07f8bd8a51284654b005b52b3db91334_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:NonIPORelatedStockTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a9ed117e7fc46209cfe726bed834b25_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d21085dc3464fd4a077a8c4c29dc3df_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c5cb1b641df48b3990cc9378065cd00_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd74872b5622480ab9e4a8966ba04e3e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c838774341347d18b026f9d063c570d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88e560ec37ce491aadf9eb36b18848d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida615667cda8491fabc586af6ea6cb44_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd7eeb679a3a4b8b9e9dd842d2ac9f04_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc29760a066749a2a385abd329cceb8f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:NonIPORelatedStockTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03d5350f508b4144bc4917ef0ec5919e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:NonIPORelatedStockTransactionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38b7fad4d0a54f5b9f03bd9e2bdaa055_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e0337892efb4f628c26a60c7c2fcbaf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59b403c789684eb5976e604c15fb43a2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10126ff884f24cee9f145c0c6031e0c1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fd8ae3429f1487bb13c70c2678f3098_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5d656fe36d64dd28f480aaf15a0cf24_D20210201-20210201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="icf79e0bd44fc44b6add290a67ac03123_D20210209-20210209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-09</xbrli:startDate><xbrli:endDate>2021-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fba8513019e4003882ec149aeddb34b_I20210209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i670bd8e4908d4f42bafe357876fb520e_D20210209-20210209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-09</xbrli:startDate><xbrli:endDate>2021-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i166eae69229b4112968673ffefbf7d09_D20210209-20210209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-09</xbrli:startDate><xbrli:endDate>2021-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f34db6d61444fc0951ac5bca31c9cbc_D20210209-20210209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:IPOAndPrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-09</xbrli:startDate><xbrli:endDate>2021-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2518ef5cab941c1b5281fac0348fe6c_I20210210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6530fcd8ea6401a8a572f67df226036_I20210210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="operatingsegment"><xbrli:measure>angn:operatingSegment</xbrli:measure></xbrli:unit><xbrli:context id="ifb691fd4a711422cabfdecc00c444d4f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5ada18d76ea4a24976f7bb9e458c66c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22b6851c4c8c4d8e9f955da168470856_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">angn:NovaParkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2aaa47df28a24e29abd67cbe8873e02c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">angn:OhrCosmeticsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="entity"><xbrli:measure>angn:entity</xbrli:measure></xbrli:unit><xbrli:context id="i334eff8b0f0f4134b32ad37b7a4d1913_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">angn:OhrCosmeticsLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1527dbfa76d46b8a7b898736a11b2b6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if21e2f0448ee4d45b7742ead826a0858_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:ViforPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e92ffc10989447182476424cac89e3f_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:ViforPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if93bd2dd820c484eaec104d26be89685_I20210209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:ViforPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c1c861e844341b5a5e29c716ed55595_D20210209-20210209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:ViforPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-09</xbrli:startDate><xbrli:endDate>2021-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbbb8ca18fb34328a36cc3e05df1ac42_D20210209-20210209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:ViforPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-09</xbrli:startDate><xbrli:endDate>2021-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b2bdc42a04c4cd3af27c83384133f3b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3a0a0d452d744969da82c474ba19d42_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2020-11-06</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:ViforPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2c20a51369c40ba8a350cc15fab95b0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:ViforPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if19bda0412d14f569093c176591ee9a5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:ViforPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dfe036a9b474f76843bec13725495e1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:ViforPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76d34e6f4aa7484d9735bb67f83fe319_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:ViforPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e59113239ac414b95bede6314d45d5a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:ViforPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia83ec88a3b3147ed8f7108e7f8a10e0f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad4e3db6f2344adeaf53fa4f5bb5a0b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7afc7784bba7408fb2ba2c128f6657a8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e37997f6b2f47c0a98e68a4f9edef5e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i154b24e4e9944f218abc0f9cd65e80b0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b97b816eb8f487f8a5410b7dc6dc79b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc2c8fc18af04652b3b74961e635dbe6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c7ff22c3ff94a4d849562a284c0e1d2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85e948c0db004aec96a438029856e941_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">angn:WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic66825b0a3fc4dd6a295dc833b6cfb18_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i814f9685f6c74fbb94e17b68b38c9a50_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d1460718e76486b9ed354cf1c73b976_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf7783ebf66b4af79c0713536f5f2962_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e0cf619aa784005a71db89834b81180_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">angn:WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15bff6b964924bd2887e2adeffbf32c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">angn:WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic050e32ff85e44309aa662d9aef5ce48_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bc00b7b825d4ba3852fb7e87894c1cc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66adccbb9df94f8b89614b7fed22144e_I20210209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ce6c1160cbc4d2eb14e3ddc68c08191_D20210209-20210209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis">us-gaap:ConvertiblePreferredStockSubjectToMandatoryRedemptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-09</xbrli:startDate><xbrli:endDate>2021-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2df00ce29b94846875f1ca16bf13df4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">angn:MeasurementInputStrikePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4d6f862fa754573bef10ee164188288_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">angn:MeasurementInputStrikePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i209f579b21984d5987ce82e809b3b3f5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdd03f678bd444f78c9695d99f88f610_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5de6bc9b6694e62baba186bbdd4af73_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia35389eedc0a4461980878982b5787a2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia83dfc08acb543ae8924290c590ed65a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief2a3bab90b642da9d4fe8599569910c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1b7ad6b8d104df388410248585c728f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71c37180af7c40edb5bd3e902f2b71bc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7d86eb6878a4ef0b875c05988047754_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic94945863a1b4df4ab1f5e7d2e9530c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cfab8eface34dd4839fbb00af77dc97_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i306ddd1004714dec93e5d5ea85b3c8c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i992e93e0d3c3482bad88da73616728c5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ab54aa1e3014f50a5db232a28772555_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65a1a8317ce94459b14feb26feeb201c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i070cfb2f33fa400ab61eda85d18e3338_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e51cbe879fb441184f95b52afb2aeef_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb7ba2f1254942b1b3dca57b33e584e4_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">angn:A2020NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i028f1ad3777340c2a17441b369da80c7_I20210209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90d58066e44642be83973e6daa1dee34_D20210204-20210209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">angn:AdditionalConvertibleNotesAndViforConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-04</xbrli:startDate><xbrli:endDate>2021-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac7d715402754b8caf32b6a9c1cee1f7_I20210209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60078b3a55804ab1887cc07c853ff6f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1dc2e8c07c14adba2e9db115900a85b_D20210125-20210125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">angn:A2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-25</xbrli:startDate><xbrli:endDate>2021-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i902c379eaab14156a55d3f460019dc3b_I20210125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">angn:A2021PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54c2a1b829084a7b83834a08509335ce_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e0e18adc0424cde81f1a02ec6eea58c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i391c5213ee2846a09acad8d39f4acc78_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib18cd3fd172f47be9edcff38ff0ed63a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d2bddbdf568489b92aaf86fbd855a9d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60ac161568b9493f9839384faf16222a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7f5c1532cac4e2b998ae309d92d8edd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc8909f8292a435ca08e7ea8957de0e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7817467d29ec42488073e266808a1b4a_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaadc88b9cdc4d3b9741cddf31c97c95_D20210209-20210209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-09</xbrli:startDate><xbrli:endDate>2021-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if60e35a6de454aaba1b4e414c82f9bab_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6ed7c4e75a34a8e8f44a7115b92ba55_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92b1ec8f60c4409cbb367354f0969366_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92b73a2382864a80b71e3f51aef05903_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic47bf067546145a8a6fa9b871d43cefe_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cfa5bf5e100430bbe5f169211eb27e2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if41f90861d0545f185125b2fd6ebf84a_I20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6079bc9dc350474297feb207d4409628_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if16b69b23bb6477c809c732686e6c818_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:WarrantsIssuedWith2015NotesLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43c1a8313c78494992d014e2ea73ba94_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:WarrantsIssuedWith2015NotesLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27dc24aec76340a998ae99277f3efd2e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:WarrantsIssuedWith2016NotesLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5280c6af39144c0097d2718db5b41580_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:WarrantsIssuedWith2016NotesLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fc4689e5cff46898c878ceef7ce56cd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:WarrantsIssuedWith2017NotesLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id76d56a33e4f4a60bb37b2bc487fbad9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:WarrantsIssuedWith2017NotesLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79898ce5c218453fb0a55a7cb08aee82_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:WarrantsIssuedWith2018NotesLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib75e81811b1f43cb90f7a7a898c09ac1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:WarrantsIssuedWith2018NotesLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib18fedbfd53d471ca8ad9bda5ea20ac9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:WarrantsIssuedWithConversionOfNotesToCommonStockEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84612d7718b644af9a1cf862077b6bc7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:WarrantsIssuedWithConversionOfNotesToCommonStockEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibea121a245f649d6a99c181f5a14bd89_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:WarrantsIssuedWithUnitsInTheEquityOfferingEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i855a01903f014f53bf8b37778bc42c99_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:WarrantsIssuedWithUnitsInTheEquityOfferingEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i891c62a6c35b47e48378588b88bb112c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:BrokerWarrantsIssuedWithEquityOfferingEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0e5243bae824dccb7342c17c8cca4aa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:BrokerWarrantsIssuedWithEquityOfferingEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a61ee941a9e4d32b5dd2e580ef7e639_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:BrokerWarrantsIssuedWith2019NotesLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3279c6cb0327462d84d652b4f17138c3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:BrokerWarrantsIssuedWith2019NotesLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92b4a25f21264eb2b06953b7ef40a96f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:ConsultantWarrantsLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia49fffc648cc4ba7bc5e1c58b7adb469_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:ConsultantWarrantsLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie75149bd389348ac91dd0c486618b376_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:WarrantsIssuedWith2015Notes2016Notes2017NotesAnd2018NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b02e038496248b1bb8753bc722a0bb7_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59e2995c2115446d9af3ddecfb37c4fb_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01849912679d402f8b851a0ea52911e4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i444bffaeb5fd4c7dae715a0266b8d087_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i519304eebcb54dc99bfcc6afa7d63b44_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dfcdb12bfb34eb6b5ec1d691edc1a6b_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fa0c3e9d7c641a48770a0df7a146319_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="option"><xbrli:measure>angn:option</xbrli:measure></xbrli:unit><xbrli:context id="i0bf681e0236d4273af7ed9eb86410720_I20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f1573b2c4114052bab5a6fe444a4633_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfd7384fca0f46b6adea2d3695af1f7e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c20e7a2f2df45a3b8f60672c1031439_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">angn:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17fa801811ba45e3a75870ab1d78e1e1_D20210526-20210526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-26</xbrli:startDate><xbrli:endDate>2021-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1461dc15821341d7a6cca5de3d10b493_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49372af6f1524e94bc325a0b4866deb5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief165a389cc44da0a2f2c5c214517d94_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad85a45e0dbd4ab7a6756cc10a24ecbd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43a2b3ab97bd48fbbe083e2b87ed4fa9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac1a9fb579254c0480b5589b1c009eb5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61bbd5c3b1454d27b052909fc297f17e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieed9eb60e9b8413cacd41a553ad6bd3f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02a82bc7014f4eb19de71fe9d69bdca3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49f753c217c344e0805c4e8e7c263cd5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53245befe1874188ac185852fef3d5a1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83977ab456f040ddb39978debda8bbe4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0f25cf926ad4d1cb71681e8f131863c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8ec568c6dc54174abe4f2ad93aeceac_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcf59fe47e7a4763a6e2bceeb52dd3ad_I20170731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">angn:OhrCosmeticsLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1f1c87d61094a8385e1928cbcdef76b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">angn:OhrCosmeticsLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">angn:ImmediateFamilyOfDirectorAndChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d2bf22513e944e391d7fad6085a8765_I20131130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:OhrCosmeticsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65008406702b49f183286b36f4fbea14_D20131101-20131130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:OhrCosmeticsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-11-01</xbrli:startDate><xbrli:endDate>2013-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84aca19f2bf6464d955946950b093dca_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:OhrCosmeticsLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e21962d26f9431d9076d02be4f4d666_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:OhrCosmeticsLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f9aa6708d66419390b7f00e52079f31_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">angn:NovaParkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4da1e16a428f4e4aa7b45ff38eee1854_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">angn:NovaParkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19d9a4a649894b55b85b7b8ebaac451b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">angn:NovaParkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ed3c6aeb1c1419881dbc5be2cf6ddfe_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">angn:NovaParkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35fe645b7bfa4fde8dbbbdd2b80db240_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:NovaParkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f44decd2d424510858c214c0073163a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:NovaParkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i917e433688284eaa953fc3c2fc1e1b85_D20210209-20210209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">angn:DirectorsAndFamilyMemberOfChiefExecutiveOfficerDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-09</xbrli:startDate><xbrli:endDate>2021-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2962b55847164c55acf82150946c5fd6_I20210209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">angn:DirectorsAndFamilyMemberOfChiefExecutiveOfficerDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1f12f1c81f2458db6d959e118e59154_I20210209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">angn:PresidentAndChiefExecutiveOfficerAndDirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f17b2c4422d42688d50097720558178_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">angn:ConsultingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5c69981108b4d979649ac7fc1b0e400_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">angn:ConsultingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9131c9ee7eb4cf68ebd482f734ab577_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">angn:LegalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id853bebfd0c74da580bb31ede0e8af3e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">angn:LegalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30dc8694797e467d9c9068c898bcc9f8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">angn:FormerMemberOfTheBoardOfDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">angn:ConsultingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b7efeca53e04af18bee4dc3749aeaa9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">angn:FormerMemberOfTheBoardOfDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">angn:ConsultingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f608066967d490d9002d2bb0340bdf8_I20220225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6b23068ffab46b0a0c550ea36e51385_I20220301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i405a2449e3304874876b5c7f79fa0336_D20220301-20220301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001601485</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">angn:A2021IncentiveAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-01</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="idee3699378af4447a4091414c0adfaa7_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_____________________________________________</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N180Mzk4MDQ2NTE0MTAy_cb74fa5a-a963-4c6c-86a6-4dacf36ae2d8">10-K</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_____________________________________________</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGFibGU6M2VlMWE5NzEwYmNlNDYzZWFkYjJlNGIyMGQzZjJmYmQvdGFibGVyYW5nZTozZWUxYTk3MTBiY2U0NjNlYWRiMmU0YjIwZDNmMmZiZF8wLTAtMS0xLTIzODgw_0cf18247-e59b-4b8d-9af0-5f6fcdcca95d">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N18xMDk5NTExNjMwODEx_4dfc43b4-a9b9-4c7e-affe-86ee9a289f94"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N18xMDk5NTExNjMwODEx_45f46163-d3b4-4289-8f7e-01096336ab7b">December&#160;31</ix:nonNumeric>, 2021</ix:nonNumeric></span></div><div style="margin-top:10pt;padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:10pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGFibGU6MmYzOWY0YWQ2YmRkNGM4ZGEzMWQxZDY5Y2M3M2I2YWQvdGFibGVyYW5nZToyZjM5ZjRhZDZiZGQ0YzhkYTMxZDFkNjljYzczYjZhZF8wLTAtMS0xLTIyNjQ1_6d55091e-5828-45a5-86e6-9c53eda3cd8b">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;to </span></div><div style="margin-top:10pt;padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N180Mzk4MDQ2NTE0MTAz_9f685319-077d-4b4b-ae75-780b476c62cd">001-04321</ix:nonNumeric></span></div><div style="margin-top:10pt;padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N180Mzk4MDQ2NTE0MTA0_60ea76b2-0e3e-4a5d-92a1-676a51049492">ANGION BIOMEDICA CORP</ix:nonNumeric></span></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:10pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGFibGU6ZTI0YTg5ZmQ4NTBhNDY4NWEzNWM3YzFmNDhiOTRhNTUvdGFibGVyYW5nZTplMjRhODlmZDg1MGE0Njg1YTM1YzdjMWY0OGI5NGE1NV8wLTAtMS0xLTIyNjU0_3c244a5e-4d08-40f5-acfa-69314cf6bdd4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGFibGU6ZTI0YTg5ZmQ4NTBhNDY4NWEzNWM3YzFmNDhiOTRhNTUvdGFibGVyYW5nZTplMjRhODlmZDg1MGE0Njg1YTM1YzdjMWY0OGI5NGE1NV8wLTMtMS0xLTIyNjU4_85d122e0-773f-43b8-b3b3-8f352356b164">11-3430072</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGFibGU6ZTI0YTg5ZmQ4NTBhNDY4NWEzNWM3YzFmNDhiOTRhNTUvdGFibGVyYW5nZTplMjRhODlmZDg1MGE0Njg1YTM1YzdjMWY0OGI5NGE1NV8zLTAtMS0xLTIyNjYxL3RleHRyZWdpb246NjM5ZTQxYjhlYTUzNDEwZmJmZDcwZjUwZTg2OTcyOGZfMTA5OTUxMTYyNzg2Mg_e6c91538-17ae-4d6d-b994-b05ff339e042">51 Charles Lindbergh Boulevard</ix:nonNumeric>, <ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGFibGU6ZTI0YTg5ZmQ4NTBhNDY4NWEzNWM3YzFmNDhiOTRhNTUvdGFibGVyYW5nZTplMjRhODlmZDg1MGE0Njg1YTM1YzdjMWY0OGI5NGE1NV8zLTAtMS0xLTIyNjYxL3RleHRyZWdpb246NjM5ZTQxYjhlYTUzNDEwZmJmZDcwZjUwZTg2OTcyOGZfMTA5OTUxMTYyNzg3NA_22381e72-63dc-45e7-821b-eb8f27b945c9">Uniondale</ix:nonNumeric>, <ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGFibGU6ZTI0YTg5ZmQ4NTBhNDY4NWEzNWM3YzFmNDhiOTRhNTUvdGFibGVyYW5nZTplMjRhODlmZDg1MGE0Njg1YTM1YzdjMWY0OGI5NGE1NV8zLTAtMS0xLTIyNjYxL3RleHRyZWdpb246NjM5ZTQxYjhlYTUzNDEwZmJmZDcwZjUwZTg2OTcyOGZfMTA5OTUxMTYyNzg4Ng_642ecde0-f7e4-4f77-9b4f-6bab4882fde3">New York</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGFibGU6ZTI0YTg5ZmQ4NTBhNDY4NWEzNWM3YzFmNDhiOTRhNTUvdGFibGVyYW5nZTplMjRhODlmZDg1MGE0Njg1YTM1YzdjMWY0OGI5NGE1NV8zLTMtMS0xLTIyNjY4_699a2925-8b0f-4cde-8a78-b93bd2f69a21">11553</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N180Mzk4MDQ2NTE0MTA1_e3de84a4-c95a-4326-ba0b-3a896cbdb450">415</ix:nonNumeric>) <ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N180Mzk4MDQ2NTE0MTA2_298e80c7-3821-4771-8c29-535e66781613">655-4899</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGFibGU6OWZjYTU4MmJmZTA1NDBjZDhjZjEzNWQ2ODZjNDdlYWEvdGFibGVyYW5nZTo5ZmNhNTgyYmZlMDU0MGNkOGNmMTM1ZDY4NmM0N2VhYV8xLTAtMS0xLTIyNjc3_d61655e1-fd6e-4704-a54d-8c49f33abf9d">Common Stock, par value $0.01</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGFibGU6OWZjYTU4MmJmZTA1NDBjZDhjZjEzNWQ2ODZjNDdlYWEvdGFibGVyYW5nZTo5ZmNhNTgyYmZlMDU0MGNkOGNmMTM1ZDY4NmM0N2VhYV8xLTEtMS0xLTIyNjc5_96dd5e08-154b-4b96-8d2d-f4db54491716">ANGN</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGFibGU6OWZjYTU4MmJmZTA1NDBjZDhjZjEzNWQ2ODZjNDdlYWEvdGFibGVyYW5nZTo5ZmNhNTgyYmZlMDU0MGNkOGNmMTM1ZDY4NmM0N2VhYV8xLTItMS0xLTIyNjgy_8f6c8237-b9db-4ce3-ac0e-53eb47526995">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to section 12(g) of the Act: None. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N18yMTk5MDIzMjU4NTcx_217ed71c-32b5-495d-82c7-aedf74b66a59">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N18yMTk5MDIzMjYwMjY4_97607e5c-05af-4e40-bcde-7372e0b20b93">No</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N18yMTk5MDIzMjYwMjY5_61cc78d1-8d93-422d-acb3-5506d6cd672e">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-(&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N18yMTk5MDIzMjU4NTc0_f01fb144-21be-42ec-aae7-7fafae9e7864">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N18xMDk5NTExNjMyNDk2_3794a222-bce5-4d25-bfb8-a62c0dcf869c">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.451%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGFibGU6NjRhODE3N2MzNDc3NGRhNmExNmIzM2NlMTAxM2YwNWQvdGFibGVyYW5nZTo2NGE4MTc3YzM0Nzc0ZGE2YTE2YjMzY2UxMDEzZjA1ZF8xLTAtMS0xLTIyNjky_736867e0-d98d-4447-b4c3-4c1c4d4d73b8">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGFibGU6NjRhODE3N2MzNDc3NGRhNmExNmIzM2NlMTAxM2YwNWQvdGFibGVyYW5nZTo2NGE4MTc3YzM0Nzc0ZGE2YTE2YjMzY2UxMDEzZjA1ZF8xLTMtMS0xLTIyNjk0_faf49461-e039-4a5d-b559-4aa82b851a58">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGFibGU6NjRhODE3N2MzNDc3NGRhNmExNmIzM2NlMTAxM2YwNWQvdGFibGVyYW5nZTo2NGE4MTc3YzM0Nzc0ZGE2YTE2YjMzY2UxMDEzZjA1ZF8yLTMtMS0xLTIyNjk3_73ccbf28-7d34-461c-859f-643574a37683">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N180Mzk4MDQ2NTE0MTA5_4477f684-ab10-43ea-9642-541eb3529852">&#9744;</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N18yMTk5MDIzMjU4NTc1_c66ae668-94f3-49d6-82b0-8c5663af9183">&#9744;</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N18yNTk4_3794a222-bce5-4d25-bfb8-a62c0dcf869c">&#9746;</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of the voting stock and non-voting common stock held by non-affiliates of the registrant, based on the closing price of a share of the registrant&#8217;s common stock on June 30, 2021 as reported by the Nasdaq Global Select Market on such date, was approximately $<ix:nonFraction unitRef="usd" contextRef="icf95c95dc2554e05bcfd8f1a4b0d4845_I20210630" decimals="-6" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N18xMDk5NTExNjMxNDQ4_a8280e03-5e55-441d-b9f4-8a7f6f9b9e2d">365</ix:nonFraction>&#160;million. Shares of common stock held by each executive officer and director and by each entity affiliated with an executive officer or and director have been excluded from this computation. The determination of affiliate status for this purpose is not necessarily a conclusive determination for other purposes.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of the issuer&#8217;s common stock outstanding as of March&#160;25, 2022, was <ix:nonFraction unitRef="shares" contextRef="i936ee8cbca4640f89962461f9dbfb53e_I20220325" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N18yOTEy_7c0396f5-f0fe-44e0-9b7f-ed7dbe792f6c">29,958,064</ix:nonFraction>.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N18yMTk5MDIzMjU4NTg0_b5d52fe1-0e8c-4483-b0dc-e6fb45f09046" escape="true">Portions of the registrant&#8217;s definitive proxy statement relating to the 2022 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant&#8217;s fiscal year ended December 31, 2021, are incorporated by reference into Part III of this Annual Report on Form 10-K.</ix:nonNumeric></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="idee3699378af4447a4091414c0adfaa7_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:89.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_19">Item 1. Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_19">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_22">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_22">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_25">Item 1B. Unresolved Staff Comments </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_25">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_28">Item 2. Properties </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_28">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_31">Item 3. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_31">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_34">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_34">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_40">Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issue Purchases of Equity Securities</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_40">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_43">Item 6. Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_43">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_46">Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_46">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_79">Item 7A. Quantitative and Qualitative Disclosures </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_79">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_82">Item 8. Financial Statements and Supplementary Data</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_82">79</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_157">Item 9. Changes in and Disagreements with Accountants</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_157">115</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_160">Item 9A. Controls and Procedures </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_160">115</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_163">Item 9B. Other Information</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_163">116</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_525">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_525">116</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART III</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_169">Item 10. Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_169">117</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_172">Item 11. Executive Compensation </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_172">121</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_175">Item 12. Security ownership of certain beneficial owners and management and related stockholder matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_175">125</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_178">Item 13. Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_178">127</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_181">Item 14. Principal Accountant Fees</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_181">129</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART IV</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_187">Item 15. Exhibits </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_187">130</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_190">Item 16. Form 10-K Summary </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_190">131</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_193">Signature</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_193">132</a></span></div></td></tr></table></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span><br/></span></div><div id="idee3699378af4447a4091414c0adfaa7_13"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains &#8220;forward-looking statements&#8221; within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this Annual Report on Form 10-K are statements that could be deemed forward-looking statements reflecting the current beliefs and expectations of management with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. These statements are often identified by the use of words such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;if,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;positioned,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;until&#8221; and similar expressions or variations. Forward-looking statements contained in this Annual Report on Form 10-K include, but are not limited to, statements about:</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential benefits, activity, effectiveness and safety of our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success and timing of our preclinical studies and clinical trials, including the timing and availability of data from such clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the primary endpoints to be utilized in our clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, expansion, and costs of developing and commercializing our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our dependence on existing and future collaborators for commercializing product candidates in the collaboration;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our receipt and timing of any milestone payments or royalties under any existing or future research collaboration and license agreements or arrangements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential effects of the COVID-19 pandemic on our business and operations, results of operations and financial performance;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential adverse effects of any regional armed conflicts on our business and operations, results of operations and financial performance;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and growth of the potential markets for our product candidates and the ability to serve those markets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding our expenses and revenue, the sufficiency of our cash resources, and needs for additional financing;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the United States and other countries;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance of any future products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the implementation of our business model and strategic plans for our business and product candidates, including additional indications for which we may pursue;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding competition;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our anticipated growth strategies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the performance of third-party manufacturers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain development partnerships;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding federal, state, and foreign regulatory requirements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain intellectual property protection for our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the successful development for our sales and marketing capabilities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the hiring and retention of key scientific or management personnel; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the anticipated trends and challenges in our business and the market in which we operate.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:30.6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We caution you that the foregoing list may not contain all of the forward-looking statements made in this Annual Report on Form 10-K.</span></div><div style="text-align:justify;text-indent:30.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:30.6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We discuss many of these risks in greater detail in &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management&#8217;s beliefs and assumptions only as of the date of this Annual Report on Form 10-K. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.</span></div><div style="text-align:justify;text-indent:30.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:30.6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">addition</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report on Form 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</span></div><div style="text-align:justify;text-indent:30.6pt"><span><br/></span></div><div style="text-align:justify;text-indent:30.6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Annual Report on Form 10-K also contains estimates, projections and other information concerning our industry, our business and the markets for certain drugs, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Trademarks</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:30.6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Annual Report on Form 10-K includes trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included in this Annual Report on Form 10-K are the property of their respective owners.</span></div><div style="text-align:justify;text-indent:30.6pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risk Factors Summary</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the principal factors that cause an investment in the company to be speculative or risky:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Relating to Our Financial Position and Need for Additional Capital</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We are a clinical-stage biopharmaceutical company with no products approved for sale and we have not generated any product revenue to date, which makes it difficult to assess our future viability.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">To achieve our goals we will require substantial additional funding, for which capital may not be available to us on acceptable terms, or at all, and, if not so available, may require us to delay, limit, reduce or cease our clinical trials or operations.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Relating to the Development and Regulatory Approval of Our Product Candidates </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">COVID-19 could adversely impact our business, including our clinical trials and financial condition.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Product development and regulatory approval involve a lengthy and expensive process with uncertain outcomes. We cannot be certain ANG-3070 or any of our other product candidates will receive or maintain regulatory approval and, without regulatory approval, we and our collaborators will not be able to market our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Delays or difficulties in the commencement, enrollment and completion of clinical trials could result in increased costs to us and delay or limit our ability to obtain regulatory approval for ANG-3070 and our other product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Clinical failure can occur at any stage of clinical development, and the results of earlier clinical trials are not necessarily predictive of future results.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our clinical trials could be disrupted by the uncertainty of war due to the aggressive actions taken by Russia which, if this occurs, could delay our ability to complete our clinical trials.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Even if we successfully complete ongoing and planned clinical trials of one or more of our product candidates, the product candidates may fail for other reasons.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our product candidates may have undesirable side effects which may delay or halt clinical development or prevent marketing approval or, if approval is received, require them to be taken off the market, require them to include safety warnings, or otherwise limit their sales.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Clinical trials of our product candidates may not uncover all possible adverse effects that patients may experience or be indicative of the effect of our product candidates post approval in the general population.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Due to the significant resources required for the development and commercialization of our product candidates, we must prioritize development of certain product candidates and/or certain disease indications. We may expend our limited resources on product candidates or indications that do not yield a successful product and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If manufacturers obtain approval for generic versions of our products or product candidates, our business will be materially harmed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Relating to Collaborations and Commercialization of Our Product Candidates</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we are able to develop and obtain regulatory approval for any of our product candidates, our business will be materially harmed if we are unable to successfully commercialize such approved products. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we fail to develop market opportunities for ANG-3070 or any future products are smaller than we believe they are, our potential to generate revenue may be adversely affected, and our business may suffer.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Relating to Our Business and Strategy</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We face competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We currently depend on single third-party suppliers for the manufacture and supply of drug substance and potential future commercial product supplies for our product candidates, and any performance failure on the part of our supplier could delay the development and potential commercialization of our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We depend on third-party contractors for a substantial portion of our operations and may not be able to control their work as effectively as if we performed these functions ourselves. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for or commercialize our product candidates, if approved.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Relating to Our Intellectual Property</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection. If our patent position and potential regulatory exclusivity do not adequately protect our product candidates, others could compete against us more directly, which would harm our business, possibly materially.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we do not obtain protection under the Hatch-Waxman Act and similar legislation outside of the United States by extending the patent terms and obtaining data exclusivity for our product candidates, our business may be materially harmed.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We may infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us from commercializing or increase the costs of commercializing our product candidates.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Relating to Our Common Stock </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our stock price may be volatile and you may not be able to resell shares of our common stock at or above the price you paid.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We identified material weaknesses in our internal control over financial reporting and we may identify additional material weaknesses in the future that may cause us to fail to meet our reporting obligations or result in material misstatements of our financial statements. If we fail to remediate any material weaknesses or if we otherwise fail to establish and maintain effective control over financial reporting, our ability to accurately and timely report our financial results could be adversely affected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="idee3699378af4447a4091414c0adfaa7_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part I</span></div><div id="idee3699378af4447a4091414c0adfaa7_19"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address chronic and progressive fibrotic diseases. Our goal is to transform the treatment paradigm for patients suffering from these potentially life-threatening conditions for which there are no approved medicines or where existing approved medicines have known limitations. Our lead product candidate is ANG-3070, a highly selective oral tyrosine kinase receptor inhibitor (TKI) in development as a treatment for fibrotic diseases, particularly in the kidney and lung. ANG-3070 has demonstrated activity as an anti-fibrotic agent in a variety of animal models. A Phase 1 healthy volunteer study, which was designed to support clinical development in multiple indications, demonstrated ANG-3070 has a favorable safety and PK profile, producing plasma concentrations which exceeded the levels necessary for activity in animal models of proteinuric kidney diseases. Enrollment is ongoing in a dose-finding Phase 2 trial of ANG-3070 in primary proteinuric kidney diseases (PPKDs) and we expect to file an IND in idiopathic pulmonary fibrosis (IPF) by the end of 2022.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to work with our license partner Vifor International, Ltd, (Vifor Pharma) on the process of closing out our analyses of data from the 2021 clinical trial readouts of ANG-3777, a hepatocyte growth factor (HGF) mimetic that was formerly our lead product candidate until December 2021. We do not intend to continue the clinical development  plan for ANG-3777 set forth in the Vifor License, which had included a Phase 3 study for the prevention of AKI in patients undergoing cardiac surgery involving cardiopulmonary bypass who were thought to be at risk for AKI (CSA-AKI) and a Phase 4 confirmatory study in donor kidney transplant patients who were at risk for developing delayed graft function (DGF), given that we do not believe the earlier Phase 2 and Phase 3 clinical trial results in the respective indications support regulatory approval. We have no funds budgeted for additional clinical trials for ANG-3777.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also continuing to develop our preclinical programs. Our ROCK2 program is targeted towards the treatment of fibrotic diseases. Our CYP11B2 program is targeted towards diseases related to aldosterone synthase dysregulation.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ANG-3070 for Fibrotic Diseases.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate is ANG-3070, a highly selective oral small molecule TKI we are developing as a potential treatment for fibrotic diseases. TKIs are one of the largest classes of newly approved drugs, with more than 25 approved molecules worldwide targeting pathways believed to affect relevant diseases. However, tyrosine kinases are ubiquitous proteins and there is significant overlap in their structures and binding sites. This can lead to binding against unintended tyrosine kinase targets and these off-target effects are largely responsible for the toxicity associated with TKIs. While no TKI can be entirely selective due to close structural homology of the various tyrosine kinases, ANG-3070 was designed with the intent of enhancing inhibition of kinases involved in inflammation and the progression of fibrosis while minimizing binding to kinases thought responsible for adverse or off-target effects. ANG-3070 demonstrated target engagement as an anti-fibrotic agent in a variety of animal models across different organ systems and has shown </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the ability to inhibit pro-fibrotic tyrosine kinases at exposures achievable by oral administration. We reported positive data from a Phase 1 healthy volunteer study in August of 2021 and are actively enrolling patients in JUNIPER, a randomized, multi-center, double-blind, and placebo-controlled global dose-finding Phase 2 trial to evaluate ANG-3070 in patients with primary proteinuric kidney diseases (PPKDs). We hold global rights to ANG-3070.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potential advantages for ANG-3070 include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">Significant Addressable Kidney Fibrosis Markets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The PPKDs of Focal Segmental Glomerular Sclerosis (FSGS), Immunoglobulin A Nephropathy (IgAN), Alport Syndrome, and Membranous Nephropathy (MN) together affect over 250,000 patients in the U.S. alone. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Significant Addressable Pulmonary Fibrosis Markets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. 2021 projected worldwide sales for the two approved drugs for IPF will be approximately $3.8 billion despite the fact that fewer than 30% of IPF patients in the U.S. are prescribed either drug and approximately half of IPF patients discontinue these therapies within 12 months.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">Promising Drug Exposure Profile</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the Phase 1 healthy volunteer study, ANG-3070 demonstrated ANG-3070 can achieve drug exposures exceeding plasma concentrations in which activity was demonstrated in animal models of proteinuric kidney diseases and pulmonary fibrosis.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As such, ANG-3070 is being investigated for both twice-daily (BID) and once-daily (QD) dosing.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">Encouraging Adverse Event Profile</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The safety and tolerability profile in the Phase 1 study was encouraging given the recognized incidence and severity of gastrointestinal side effects in approved kinase inhibitors, particularly nausea, vomiting, and diarrhea.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ANG-3070 for Renal Fibrosis. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While PPKDs like FSGS, IgAN, MN, and Alport often have different root causes, each condition often progresses to kidney fibrosis and end-stage renal disease. There is only one approved therapy for any PPKD, budesonide for IgAN.  In December 2021, we enrolled the first patient into JUNIPER, our randomized, double-blind, placebo-controlled global dose-finding Phase 2 trial intended to assess ANG-3070 in adult patients with FSGS or IgAN, two types of PPKD. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ANG-3070 for Pulmonary Fibrosis. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pulmonary fibrosis is characterized by progressive scarring (fibrosis) of the lungs, which leads to their deterioration and destruction. Over time, lung scarring in patients progresses and breathing becomes difficult, often resulting in the lungs failing to take in enough oxygen to meet the body&#8217;s needs. IPF is an aggressive form of lung disease with a median survival of two to three years from diagnosis. There are two drugs approved for IPF, the kinase inhibitor nintedanib (OFEV</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and the pyridine pirfenidone (Esbriet</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). We plan to file an IND for ANG-3070 in the IPF indication by the end of 2022.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ANG-3777, an HGF Mimetic for Acute Organ Injury</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANG-3777 was designed to mimic the biological activity of HGF and to treat acute organ injuries, such as delayed graft function, where there are no approved therapies. HGF activates the c-Met receptor, which triggers a cascade of pathways with a central role in tissue repair and organ recovery that has been well established. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2021, we reported topline results from two clinical trials of ANG-3777. The first was a Phase 3 trial of ANG-3777 to treat AKI in patients who were at risk for developing DGF. The second was an exploratory Phase 2 trial for the prevention of CSA-AKI. While neither trial achieved statistical significance on its primary endpoint, we believe ANG-3777 demonstrated biologic activity in both trials. We continue to work with our license partner Vifor International, Ltd. (Vifor Pharma) on the process of closing out our analyses of data from these trials. We do not intend to continue the clinical development plan for ANG-3777 set forth in the Vifor License, which had included a Phase 3 study in CSA-AKI and a Phase 4 confirmatory study in DGF. There are no funds budgeted for additional clinical trials for ANG-3777.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In November 2020, we entered into a license agreement (the Vifor License) with Vifor Pharma, granting Vifor Pharma global rights (excluding Greater China) to develop, manufacture and commercialize ANG-3777 in all therapeutic, prophylactic and diagnostic uses for renal indications, including forms of AKI, and congestive heart failure (collectively, the Renal Indications). Pursuant to the Vifor License, we received an upfront license payment of $30 million in November 2020, and a $30 million equity investment, $5 million of which we received in January 2021 and $25 million of which we received contemporaneously with the closing of our Initial Public offering (IPO).  Although the Vifor License includes additional milestone and royalty objectives, we do not expect to receive any clinical, post-approval, or sales milestones, or royalties, as we do not intend to continue to pursue the clinical development plan set forth in the Vifor License. In 2022, we and Vifor Pharma continue to complete planned analyses of the results of the clinical trials announced in the fourth quarter of 2021 and discuss the future of the collaboration on the basis of such analyses. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Preclinical Pipeline</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a wholly-owned preclinical pipeline of internally-developed programs, including a ROCK2 inhibitors programs for fibrotic diseases, and CYP11B2 inhibitor program. Our goal is to select clinical lead candidates for one or more of these programs and begin IND-enabling studies by the end of 2022.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ROCK2 Inhibitors for Fibrotic Diseases.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our ROCK2 program includes a number of highly selective, oral small molecule inhibitors of ROCK2 developed internally as a potential treatment for fibrotic and other diseases. Rho-associated coiled-coil forming protein kinase (ROCK) signal transduction pathways are implicated in the development of fibrosis. Inhibition of ROCK isoforms ROCK1 and ROCK2 has shown promise in fibrosis and dual </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROCK1/ROCK2 inhibitors have been used to treat conditions including hemorrhagic stroke and glaucoma. However, ROCK1 inhibition has been associated with hypotension (low blood pressure) and enhanced vascular permeability. Recent scientific work using specific genetic or pharmacological reduction of ROCK2 indicates ROCK2 inhibition by itself can result in anti-fibrotic activity without causing hypotension. These findings informed our strategy to develop a ROCK2-specific inhibitor, with the goal of minimizing ROCK1 inhibition, as a potential treatment for fibrosis and other diseases. We believe this approach could translate into a product candidate with enhanced tolerability potentially supporting long-term systemic use. We hold global rights to our ROCK2 inhibitor program.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CYP11B2 Inhibitors</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have created a selection of molecules with high specificity to CYP11B2 (aldosterone synthase) relative to CYP11B1, which we are investigating for the purpose of targeting aldosterone-related diseases, which include resistant hypertension, congestive heart failure, renal fibrosis and primary hyperaldosteronism. We hold global rights to our CYP11B2 inhibitor program.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercialization</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, ANG-3070, is a highly selective, oral small molecule TKI we are developing as a potential treatment for fibrotic diseases, particularly of the kidney and lung. We reported positive data from a Phase 1 healthy volunteer study in August of 2021 and have enrolled the first patients in JUNIPER, a randomized, multi-center, double-blind, and placebo-controlled global dose-finding Phase 2 trial to evaluate ANG-3070 in patients with primary proteinuric kidney diseases (PPKDs). We hold global rights to ANG-3070, including all commercial rights. As we advance the program, we will evaluate how to successfully commercialize ANG-3070. We do not intend to continue the clinical development plan for ANG-3777 set forth in the Vifor License, which had included a Phase 3 study in CSA-AKI and a Phase 4 confirmatory study in DGF.   </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pipeline and company strategy were originated and are supported by a management team with extensive experience and expertise in clinical research and development, business development, and commercialization. Our President and Chief Executive Officer, Jay Venkatesan, M.D., was the founder and CEO of Alpine BioSciences (acquired by Cascadian Therapeutics, which was subsequently acquired by Seagen), was a key investor in Mavupharma Inc. (acquired by AbbVie), and is a former portfolio manager of Ayer Capital and director of Brookside Capital Partners (the hedge fund group affiliated with Bain Capital). Our Chief Medical Officer and Head of Research, John F. Neylan, M.D., is a nephrologist who has held leadership roles at Keryx Biopharmaceuticals, Genzyme Corporation, and Wyeth Corporation. Our Chief Business Officer and General Counsel, Jennifer J. Rhodes, has held leadership roles at Pfizer Inc., Medivation Inc., and Adamas Pharmaceuticals, Inc. These individuals and other members of our senior management team have contributed to the clinical development, registration and/or commercialization of a multitude of approved drug products.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company History</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were founded in 1998. From our incorporation through 2014, our efforts were primarily focused on researching pathways related to serious organ diseases and applying our medicinal chemistry expertise towards creating potential therapeutics to address the unmet medical needs of patients. Since 2014, we have focused on the clinical development of our ANG-3070 and ANG-3777 programs and translational work necessary to bring our pipeline programs to the clinic. ANG-3070 is now our lead clinical asset. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate operations are based in San Francisco, California, our clinical development and regulatory teams are primarily located in Boston, Massachusetts, and our discovery and research programs are based in Uniondale, New York.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focused on discovering, developing, and commercializing novel small molecule therapeutics to address fibrotic diseases, particularly of the kidney and lung. Our goal is to transform the treatment paradigm for patients </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">suffering from these potentially life-threatening conditions for which there are no approved medicines or where existing approved medicines have recognized limitations. The key tenets of our business strategy are to:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:25.26pt">Develop ANG-3070 in multiple renal fibrosis indications.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe ANG-3070 can address a large unmet medical need in patients with PPKDs progressing towards renal fibrosis and end-stage renal disease. We are currently enrolling JUNIPER, a global Phase 2 trial of ANG-3070. JUNIPER is a randomized, double-blind, placebo-controlled dose-finding trial intended to assess ANG-3070 in adult patients with FSGS or IgAN, two types of PPKDs. The trial will enroll 100 patients equally among four treatment arms: 200mg ANG-3070 once daily, 400mg ANG-3070 once daily, 300mg ANG-3070 twice daily, and placebo with dosing for 12 weeks. The primary endpoint in the study is the percentage reduction in urinary protein/creatinine ratio (UPCR) at week 12. Topline data from this trial should be available in the first half of 2023.</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:25.26pt">Develop ANG-3070 in Idiopathic Pulmonary Fibrosis. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given multiple animal models demonstrating the activity of ANG-3070 activity in pulmonary fibrosis, we intend to complete IND-enabling work and file an IND by the end of 2022 for a Phase 2 trial of ANG-3070 in IPF, a chronic, life-threatening condition. There are two medicines currently approved for IPF by regulators, pirfenidone and nintedanib. However, we believe additional therapies are needed to treat IPF, since approximately half of IPF patients discontinue taking these approved medicines within one year. Fewer than one-third of IPF patients are currently prescribed pirfenidone or nintedanib. Despite this, the two medicines together are projected to sell $3.8 billion worldwide in 2021.</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:25.26pt">Advancement of our earlier-stage programs. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ROCK2 inhibitor program is designed to advance a potent and highly selective inhibitor of ROCK2, with minimal inhibition of ROCK1, which we believe could translate into a therapeutic with enhanced tolerability in patients with fibrotic diseases. We are also developing proprietary CYP11B2 inhibitors for the purpose of targeting aldosterone-related diseases. We expect to nominate a lead compound and initiate IND-enabling studies for at least one of these earlier-stage programs by the end of 2022.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Pipeline</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities are primarily focused on discovering and investigating novel small molecule therapeutics to address fibrotic diseases. All our pipeline programs were developed internally and are wholly owned by Angion. Anticipated milestones are reflected in the chart below:</span></div><div style="margin-top:10pt"><img src="angn-20211231_g1.jpg" alt="angn-20211231_g1.jpg" style="height:186px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANG-3070, Our Lead Product Candidate</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, ANG-3070, is a highly selective, oral small molecule TKI developed internally as a potential treatment for fibrotic diseases, particularly in the kidney and lung. ANG-3070 has demonstrated positive results in a Phase 1 healthy volunteer study, proof of concept in a variety of animal models as an anti-fibrotic agent, and the ability </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to inhibit pro-fibrosis tyrosine kinases at levels achievable with oral administration.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within fibrosis, we believe there is promising therapeutic potential for ANG 3070 in PPKDs, a group of kidney diseases characterized by excess urinary protein excretion, and in types of pulmonary fibrosis, particularly IPF.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we reported positive final data on a Phase 1 study of ANG-3070 in healthy volunteers. In December 2021 we enrolled the first patient in &#8220;JUNIPER&#8221;, a randomized, multi-center, double-blind, and placebo-controlled </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">global dose-finding Phase 2 study in PPKD patients focused on FSGS and IgAN. We plan to file an IND for ANG-3070 in IPF by the end of 2022.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fibrotic Diseases and Tyrosine Kinase Inhibitors </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fibrosis is a part of the body&#8217;s natural healing response to organ injury. When it becomes dysregulated, fibrosis can be highly detrimental to a normal organ&#8217;s architecture and function, potentially leading to death from organ failure. Two major organs commonly impacted by fibrosis are the kidney and the lung.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Renal or kidney fibrosis is the underlying pathological process leading to progression of chronic kidney disease (CKD), a disease affecting more than 10% of the world&#8217;s population, and renal fibrosis is currently also the best predictor of disease progression. No specific anti-fibrotic therapeutics currently exist to combat renal fibrosis.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pulmonary or lung fibrosis is a disease which occurs when lung tissue becomes damaged or scarred. The resulting thickened, stiff tissue makes it more difficult for lungs to work properly. As pulmonary fibrosis worsens, patients have progressive shortness of breath and face increasing restrictions on activities of daily living. Pulmonary fibrosis is a family of over 200 different diseases, including IPF. At this time, pulmonary fibrosis is not reversible and remains a terminal disease.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TKIs are known to affect a wide array of biochemical pathways, including the mediation of tissue inflammation and fibrosis. TKIs are one of the largest classes of newly approved drugs, with more than 25 approved molecules worldwide targeting pathways believed to affect relevant diseases. However, tyrosine kinases are ubiquitous proteins and there is significant overlap in their structures and binding sites. This can lead to binding against unintended tyrosine kinase targets and these off-target effects are largely responsible for the toxicity associated with TKIs.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANG-3070 was designed with the intent of having enhanced inhibition of kinases involved in inflammation and the progression of fibrosis while minimizing binding to kinases thought responsible for adverse or off-target effects. Four kinase receptors targeted by ANG-3070 include platelet-derived growth factor receptor alpha and beta (PDGFR&#945; and PDGFR&#946;, respectively) and Discoidin Domain Receptors 1 and 2 (DDR1 and DDR2). ANG-3070 has demonstrated potent, low nanomolar IC</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:1.4pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s (a standard measure of drug potency) to these tyrosine kinase receptors as shown in the figure below. PDGFR&#945;, PDGFR&#946;, DDR1, and DDR2 are implicated in a number of diseases and targeting them effectively could provide a therapeutic benefit to patients with renal and pulmonary fibrosis. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><img src="angn-20211231_g2.jpg" alt="angn-20211231_g2.jpg" style="height:300px;margin-bottom:5pt;vertical-align:text-bottom;width:291px"/></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PDGFR&#945; and PDGFR&#946; are expressed in renal mesenchymal cells (i.e., glomerular mesangial cells) or cells with stem-cell like properties capable of maturing into a variety of critical cell types and in vascular smooth-muscle cells. In addition, they are expressed in interstitial cortical fibroblasts forming the skeleton of the kidney and medullary pericytes responsible for blood flow through the kidneys. In human renal disease, PDGFR&#945; is upregulated in glomerulus as well as arterial smooth muscle cells and endothelial cells.  Activation of PDGFR&#946; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">specifically in renal mesenchymal cells is sufficient to induce and drive progressive glomerulosclerosis and interstitial renal fibrosis. Being able to downregulate or prevent these targets could be beneficial to patients with related renal diseases.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In patients with early, but not late stage, IPF, cells responsible for the ability of the lung to exchange oxygen, cells lining the inside of blood vessels, and fibroblasts making up the structure of the lung express increased PDGFR&#946;. PDGFR&#945; is expressed in these same cells in IPF patients, plus in lung immune cells. During pulmonary fibrosis, both PDGFR&#945; and PDGFR&#946; are involved in pro-fibrotic activity, suggesting a therapy specific to these targets might exert beneficial anti-fibrotic effects for patients with IPF.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DDR1 is a tyrosine kinase transmembrane receptor of collagens, expressed in several cell types and organs, including the gastrointestinal tract, brain, lung, mammary gland, and kidney. Despite collagen being the most abundant protein in the body, DDR1 is not induced or activated under normal conditions. Several studies show DDR1 is overexpressed in pathological conditions and participates in tissue adaptation to acute and chronic inflammatory lesions, including renal inflammation and fibrosis. In a mouse model of Alport&#8217;s Syndrome (AS), for example, deletion of DDR1 delays renal fibrosis. Other animal studies suggest DDR1 could play an important role in IPF, mediating the creation of permanent pulmonary surface cell lesions. Targeting DDR1 with an effective therapeutic would help reduce some of the adverse effects related to DDR1 activation, potentially helping patients with DDR1-related diseases.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In contrast to DDR1&#8217;s primary expression in epithelial cells and activation by multiple types of collagens, DDR2 is abundantly expressed in fibroblasts. In the early phase of fibrosis in IPF, TGF-&#946; induces expression of DDR2 in lung fibroblasts and synergizes with the resulting downstream signals to accelerate formation of fibrotic tissue. In later stages of fibrosis with the fibrotic process is already established, the DDR2/ERK axis promotes the oversynthesis of extracellular matrix components, resulting in massive fibrosis. Given these roles in pro-fibrotic pathways, targeting DDR2 could help prevent or reduce fibrosis in patients with chronic fibrotic disease.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disease Overviews and Markets</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, ANG-3070, is a highly selective, oral small molecule TKI developed internally as a potential treatment for renal and pulmonary fibrosis. In December 2021, we enrolled the first patient in &#8220;JUNIPER&#8221; a randomized, multi-center, double-blind, and placebo-controlled global dose-finding Phase 2 study in PPKD patients with FSGS and IgAN. We plan to file an IND for ANG-3070 in IPF at the end of 2022. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Primary Proteinuric Kidney Disease (PPKD)</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A common thread among certain kidney diseases is the presence of abnormal levels of protein in the urine, or proteinuria. This is an indication of damaged kidneys and the presence of potentially serious disease. PPKDs share proteinuria as the common primary means of diagnosis.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the differences in root causes among various PPKDs, they have a common path of disease progression as seen in the figure below. PPKDs typically move from proteinuria, through the development of fibrosis, chronic kidney disease, and eventually to end-stage renal disease and kidney failure resulting in transplantation or death. Therefore, we are developing ANG-3070 to address the fibrosis experienced by PPKD patients regardless of the root etiology of their specific condition. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><img src="angn-20211231_g3.jpg" alt="angn-20211231_g3.jpg" style="height:279px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Four types of PPKDs include IgA nephropathy, Alport Syndrome, Focal Segmental Glomerulosclerosis, and Membranous Nephropathy.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Focal Segmental Glomerulosclerosis (FSGS) is a rare form of nephrotic disease (disease in which kidney damage allows proteins to leak into the urine) in which scar tissue develops in the glomeruli, the structures in the kidneys responsible for filtering waste from the blood. FSGS accounts for about 40% of adults with nephrotic syndrome and about 20% of children with nephrotic syndrome. In many cases, the cause of FSGS is unknown (idiopathic). In other cases, the scarring may occur because of another condition such as HIV infection, sickle cell disease, obesity, autoimmune diseases, or genetic causes. It is estimated that FSGS affects up to 40,000 patients in the United States, with a similar prevalence in Europe. More than 5,400 patients in the United States are diagnosed with FSGS every year, a number likely underestimated because of the limited number of biopsies performed to confirm the diagnosis. The disease adversely affects those of African descent more than other demographics. Current treatments for FSGS, corticosteroids and immunosuppressive drugs, are effective only in 25% to 35% of patients. Both of these therapeutic options were developed decades ago for non-renal indications and have been repurposed for FSGS given no approved therapy currently exists for this indication.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IgA nephropathy (IgAN) is the most common glomerulonephritis (GN, the inflammation of the cells in the kidney responsible for filtering the blood) globally and is responsible for between 10% and 20% of all GN in the United States. The prevalence in estimated at up to 150,000 in the United States. IgAN is caused by deposits of immunoglobulin A in the glomeruli caused by aberrant glycosylation, thereby disrupting renal function and causing blood in the urine (hematuria) and proteinuria. IgAN progresses steadily over time, with approximately 30% to 40% of patients developing ESRD over 20 to 30 years, including 20% of children who develop ESRD within 20 years of diagnosis. In 2021, the FDA granted accelerated approval for budesonide, a type of corticosteroid addressing the inflammatory component of IgAN, for IgAN patients based upon a percentage reduction in protein to creatinine ratio at nine months.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Membranous Nephropathy (MN) occurs when the glomeruli become damaged or thickened resulting in proteinuria. MN is often caused by some type of autoimmune activity. As protein leakage increases, so does the risk of long-term kidney damage. In the U.S., it is estimated around 3,000 patients per year will be diagnosed with MN, with an estimated prevalence of under 40,000. There are currently no approved drugs for MN.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alport Syndrome (AS) is a genetic renal disease and is the second most common inherited cause of kidney failure. AS affects approximately 30,000 to 60,000 people in the United States. AS is caused by a genetic defect in type IV collagen, a component of the glomerular basement membrane in the kidney, resulting in defects in its structure and function. In some patients with inherited AS, the disease can progress very rapidly leading to kidney failure in early adulthood. As in other forms of PPKD, progressive fibrosis plays an important role in the pathophysiology and progression of AS. With no currently approved therapies to stop progressive loss of kidney function, AS represents a rare disorder with significant unmet need.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Pulmonary Fibrosis</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pulmonary fibrosis is characterized by progressive scarring (fibrosis) of the lungs, which leads to their deterioration and destruction. Over time, patients&#8217; lung scarring progresses and breathing becomes difficult, often resulting in the lungs failing to take in enough oxygen to meet the body&#8217;s needs. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPF is an aggressive form of pulmonary fibrosis with a median survival of two to three years from diagnosis. The course of the disease is highly variable. Certain patients become seriously ill within a few months, while others may survive for five years or longer. Most deaths in IPF occur from progression of pulmonary fibrosis leading to respiratory failure. According to the NIH, approximately 140,000 people in the United States have IPF, and approximately 30,000 to 40,000 new cases are diagnosed each year, usually affecting people between the ages of 50 to 70. EU incidence rates are estimated to be similar. Over half are undiagnosed in the mild category alone, while more could be underdiagnosed. The disease is of unknown cause and represents an important area of unmet medical need.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Systemic sclerosis with interstitial lung disease is a complex immune disorder characterized by progressive pulmonary fibrosis. Systemic sclerosis (SSc), also known as scleroderma, is caused by dysfunctional interplay between fibrosis, vascular, and immunological pathways. Interstitial lung disease (ILD) is a common complication of systemic sclerosis and is its leading cause of morbidity and mortality accounting for 35% of disease specific mortality. SSc-ILD usually develops within the first five years of the disease, with 30-40% of SSc patients developing </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinically significant SSc-ILD. The U.S. prevalence of SSc-ILD is estimated to be over 60,000 with about 9,000 diagnosed each year.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are currently two approved therapies for IPF, pirfenidone (Esbriet&#174;, sold by Roche/Genentech) and the kinase inhibitor nintedanib (OFEV&#174;, sold by Boehringer-Ingelheim). Nintedanib is also approved for SSc-ILD patients. Both drugs have known tolerability challenges for patients. Diarrhea and nausea are very common side effects, with 62% of patients taking nintedanib reporting diarrhea and 29% reporting nausea according to its drug label. Similarly, diarrhea was reported by 26% and nausea by 36% of patients taking pirfenidone according to its label. Patient convenience is also a recognized challenge, with nintedanib required to be dosed twice per day with food and pirfenidone three times per day with food after a three-step titration over the first two weeks. Patient drop-out rates for both drugs are substantial, with 43.8% of patients on nintedanib and 51.5% of patients on pirfenidone dropping out after 12 months. Neither therapy demonstrated an impact on patient survival in the clinical trials forming the basis for their approval. Due to the recognized limitations of these approved medicines, under 30% of U.S. patients diagnosed with IPF, despite it being a life threatening disease, are prescribed nintedanib or pirfenidone.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite these drawbacks to tolerability, convenience, and efficacy, pirfenidone and nintedanib generated approximately $3.8 billion in combined 2021 worldwide sales. If we are able to demonstrate in clinical trials ANG-3070 provides IPF patients with an alternative treatment option with a more acceptable tolerability, convenience, and/or efficacy profile, we would expect ANG-3070, if approved, to compete successfully with these two approved medicines. However, there is no guarantee ANG-3070 will be able to achieve these goals or, if it does, generate comparable revenues.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Solution: ANG-3070 for the Treatment of Renal and Pulmonary Fibrosis</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By targeting tyrosine kinases receptors involved in fibrogenesis such as PDGFR&#945;, PDGFR&#946;, DDR1, and DDR2, ANG-3070 could be an important potential therapeutic addressing a number of fibrotic conditions in the kidney and lung. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we reported positive final data from a Phase 1 study of ANG-3070 in healthy volunteers. Key findings from the study included:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">ANG-3070 achieved drug exposures in humans exceeding exposures in which activity was demonstrated in animal models of proteinuric kidney diseases</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Encouraging safety and tolerability profile, particularly given the well-recognized incidence and severity of gastrointestinal side effects in approved TKIs</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Pharmacokinetic data supportive of potential once-daily oral dosing for ANG-3070</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As represented in the figure below, in Part A, healthy volunteers were given ascending single doses of ANG-3070 ranging from 50 mg to 600 mg to assess the safety, tolerability, pharmacokinetics and food effect of ANG-3070 at different doses. In Part B, healthy volunteers were given either twice-daily doses ranging from 50 mg to 500 mg under fasting conditions over two weeks or once-per-day doses ranging of 400 mg and 600 mg with meals over two weeks.</span></div><div style="margin-top:10pt"><img src="angn-20211231_g4.jpg" alt="angn-20211231_g4.jpg" style="height:241px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANG-3070 was generally well-tolerated at all doses and there were no Serious Adverse Events reported at any dose schedule or level. The reported (non-serious) Adverse Events (AEs) were seen mostly at higher doses, 600 mg administered once daily and 500 mg administered twice daily over two weeks. These AEs included nausea, abdominal cramps, and diarrhea. Generally, these AEs were mild to moderate.</span></div><div style="margin-top:10pt"><img src="angn-20211231_g5.jpg" alt="angn-20211231_g5.jpg" style="height:345px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacokinetic highlights from the Phase 1 study included:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">ANG-3070 was rapidly absorbed within 1-2 hours under fasting conditions;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Dosing with food delayed absorption to 3-4 hours with no change in exposure but lower incidence of nausea when given with food;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Mean half-life (T</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:1.4pt;vertical-align:baseline">1/2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) of 15-21 hours and small/no accumulation in blood after 14 days supports either once or twice per day dosing; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Urinary excretion less than 3%, suggesting dose reduction in patients with kidney disease may not be required</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An important finding from the Phase 1 study was human exposure levels as measured by AUC between 0-24 hours after dosing exceeded active exposure levels seen in the preclinical animal studies of ANG-3070. The figure below compares exposure levels in the passive Heymann&#8217;s nephritis rat model of MN with the exposure levels seen in the Phase 1 study. The blue box indicates the dose range where ANG-3070 was demonstrated to be active in the MN rat model. The pair of bars on the left side notes a 15 mg/kg dose in rats provided equivalent drug exposure to 3 mg/kg or about 200 mg once daily dose in humans. The next set of bars to the right show the upper end of a 50 mg/kg dose in rats was equivalent to the 6mg/kg or about 400 mg once daily in humans. A human dose of 250 mg twice a day, which was well-tolerated in the Phase 1 study, provides ANG-3070 exposures well above those seen as necessary for activity in animal models. Finally, the multi-colored bar on the right side of the graph shows the no adverse event level in non-human primates was not seen until about 250 mg/kg, or an equivalent human dose of about 5,600 mg once daily. Taken together, these exposure data demonstrate a large margin between doses seen as active in animal studies and much higher dose levels required to show toxicity in animal models.</span></div><div style="margin-top:10pt"><img src="angn-20211231_g6.jpg" alt="angn-20211231_g6.jpg" style="height:562px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon the Phase 1 study data, in December 2021 we enrolled the first patient in JUNIPER, a randomized, multi-center, double-blind, and placebo-controlled global Phase 2 dose finding study in PPKD patients focused on FSGS and IgAN. The study plan is to enroll appropriately 100 patients at a 1:1:1:1 ratio to ANG-3070, 200 mg QD (once daily), 400 mg QD, 300 mg BID (twice daily), or placebo (QD or BID) administered daily for 12 weeks. The primary endpoint is the percentage change in urinary protein/creatinine ratio (UPCR) at week 12. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key enrollment criteria for the study include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Diagnosis of IgAN or primary FSGS confirmed by past renal biopsy or genetic forms of FSGS on standard of care (SoC) for at least 12 weeks prior to enrollment</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">eGFR &gt; 40mL/min/1.73m2, urinary protein &gt; 1g/day, stable blood pressure, SoC background therapy of ACEi or ARB with up to 20 patients with and eGFR </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&gt;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 30 but &lt; 40mL/min/1.73m</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">2</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Any other RAAS/SGLT-2/immunomodulatory medications must be stable for prior 12 weeks.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goals of the JUNIPER study are:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Provide enough information of effect of ANG-3070 on proteinuria to determine a regulatory strategy in PPKD patients</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Determine the proper dose for subsequent studies</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Discover whether the proper dose may be different for IgAN patients than FSGS patients</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Gather additional safety, tolerability, biomarker, and PK/PD data on ANG-3070</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also planning a Phase 1B study in patients with IPF, to begin in 2022. The preliminary plan is to enroll IPF patients who are either treatment na&#239;ve or have been proven intolerant of approved therapies to evaluate the pharmacokinetics and safety and tolerability of ANG-3070. Subsequently, we are planning a Phase 2 study where the primary endpoint is likely to be pulmonary function tests at 6-12 months and we expect this trial to also compare multiple doses of ANG-3070 against placebo. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Phase 1 data in healthy volunteers, the clinical plans for ANG-3070 in kidney and pulmonary fibrosis are supported by a broad program of preclinical animal studies. ANG-3070 has demonstrated activity in preclinical models across renal and pulmonary fibrosis.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANG-3777</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANG-3777 was designed to be a first-in-class hepatocyte growth factor (HGF) mimetic. We engineered ANG-3777 to mimic the biological activity of HGF in activating critical pathways in the body&#8217;s natural organ repair process following an acute organ injury. In 2021, we reported the results of three clinical trials of ANG-3777. None of the trials were positive on their primary endpoints, but we believe ANG-3777 demonstrated biologic activity in the Phase 3 trial of kidney transplant patients with delayed graft function (DGF) and in the Phase 2 trial in patients at risk for acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass (CSA-AKI). </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to work with our license partner Vifor Pharma on the process of closing out our analyses of data from the 2021 clinical trial readouts. We do not intend to continue the clinical development plan for ANG-3777 set forth in the Vifor License, which had included a Phase 3 study in CSA-AKI and a Phase 4 confirmatory study in DGF, given these clinical results. There are no funds budgeted for additional clinical trials for ANG-3777.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Preclinical Pipeline</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to select clinical lead candidates for one or more of these preclinical programs and begin IND-enabling studies by the end of 2022.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">ROCK2 Program for Fibrotic and Other Diseases</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ROCK2 program includes a number of highly selective, oral, small molecule inhibitors of ROCK2 developed internally as a potential treatment for fibrotic and other diseases. Rho-associated coiled-coil forming protein kinase (ROCK) signal transduction pathways are implicated in the development of fibrosis. Inhibition of the ROCK isoforms ROCK1 and ROCK2 has shown promise in treating fibrosis in animal models. However, use of a non-isoform-specific ROCK inhibitor (i.e., dually inhibits ROCK1 and ROCK2) has been associated with inducing hypotension. Recent scientific work using specific genetic or pharmacological inhibition of ROCK2 indicates ROCK2 inhibition alone can result in anti-fibrotic activity without causing hypotension. These findings informed our strategy to develop ROCK2-specific inhibitors as a potential treatment for fibrosis.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple dual ROCK1/2 inhibitors have received regulatory approval, including ripasudil (Glanatec&#174;), which is approved in Japan for treating glaucoma and ocular hypertension, fasudil (Eril</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), which is approved in Japan and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">China for treating cerebral vasospasm in hemorrhagic stroke, and netarsudil (Rhopressa&#174;), which is approved in the United States for the treatment of glaucoma. The ROCK2-selective inhibitor belumosudil has been approved by the FDA for the treatment of chronic graft-versus-host disease.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elevated expression of ROCK2 has been implicated in a number of chronic fibrotic conditions and other diseases. ROCK2 is significantly upregulated in fibrotic kidneys in both pediatric and adult patients, with ROCK2 levels positively correlated with the severity of the fibrosis. Study of ROCK2 inhibition in the unilateral ureteral obstruction (UUO) model of renal fibrosis showed ROCK2 inhibition alleviates renal fibrosis. Furthermore, in a mouse model of IPF, researchers found mice with either ROCK1 or ROCK2 genetically deleted were protected from bleomycin-induced IPF, indicating specifically targeting either ROCK isoform would be an effective therapeutic strategy against IPF. ROCK2 expression </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has also been associated with co-expression of fibrotic liver markers. Elevated ROCK2 levels are seen in cardiac hypertrophy, cardiac fibrosis and diastolic dysfunction. ROCK2 has also been shown to play a role in neurodegenerative disorders such as amyotrophic lateral sclerosis, Parkinson's disease and Alzheimer's disease. As a result, we believe a potent ROCK2 inhibitor should prevent disease progression in chronic fibrotic diseases and potentially be useful in a variety of other cardiac and neurodegenerative disorders.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dual ROCK1/2 inhibitors can have problematic side effects including hypotension and increased vascular permeability. In an </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> analysis measuring binding affinity for ROCK2 and ROCK1, our ROCK2 selective inhibitors show much stronger binding affinity for ROCK2 versus ROCK1. We believe high selectivity for ROCK2 could provide enhanced tolerability, potentially supporting long-term systemic use.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">CYP11B2 (Aldosterone Synthase) Inhibitor Program</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aldosterone is a hormone produced in the adrenal glands which helps control the body's blood pressure by causing the kidneys to retain salt and excrete potassium, thereby increasing water retention, blood volume and blood pressure. CYP11B2 is a member of the broad cytochrome P450 family and is responsible for the biosynthesis of aldosterone. There are a number of diseases associated with dysregulated aldosterone, including primary hyperaldosteronism (Conn's Syndrome), refractory hypertension, congestive heart failure and kidney fibrosis. As a result, we believe inhibition of CYP11B2 could potentially be used in aldosterone-related diseases.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The renin-angiotensin-aldosterone system (RAAS) is responsible for producing aldosterone to maintain blood pressure. Two major approaches to modulating the RAAS pathway are angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs). There are eighteen FDA-approved ACE inhibitors/ARBs, and while these drugs are generally quite effective in controlling hypertension, aldosterone breakthrough or escape happens in approximately 10% to 50% of patients depending on the duration of therapy studied and the definition of 'breakthrough'. Aldosterone excess is estimated to be the primary cause in approximately 20% of patients with resistant hypertension, or nearly 2 million patients in the United States alone.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Two hormonal mineralocorticoid receptor antagonists (MRAs), spironolactone and eplerenone, plus a non-steroidal MRA (finerenone), are also involved in blocking the effects of aldosterone. MRAs act by binding to the mineralocorticoid receptor to prevent aldosterone from having its biologic effect on blood pressure and renal excretion and absorption of salt and potassium. However, approved MRAs have the downside of increasing circulating levels of aldosterone, leading to increased activity of aldosterone through its non-MR mechanisms. Aldosterone acts on the vascular system by inducing oxidative stress, inflammation, fibrosis and endothelial dysfunction through both MR-dependent and MR-independent pathways. As such, increased levels of aldosterone have direct deleterious effects on the progression of congestive heart failure and renal fibrosis.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have created a selection of molecules with high specificity to CYP11B2 relative to CYP11B1 and continue work towards selecting a clinical lead for the program.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely upon third-party contract manufacturing organizations to manufacture and supply product candidates for our clinical trials, and we will rely on such manufacturers to meet commercial demand. We expect this strategy will enable us to maintain a more efficient infrastructure, avoiding dependence on our own manufacturing facility and equipment, while simultaneously enabling us to focus our expertise on the clinical development and future commercialization of our products. Currently, we rely on and have agreements with a single third-party contract manufacturer to supply the drug substance for ANG-3070 and with a single third-party contract manufacturer to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacture all clinical trial supplies of ANG-3070. We currently have sufficient inventory of ANG 3070 to meet all requirements for our planned clinical trials. We expect to qualify additional suppliers for ANG 3070 drug substance and ANG 3070 clinical trials supplies to support future clinical trials, and we expect to enter into commercial supply agreements with such manufacturers prior to any potential approval of ANG 3070. ANG-3070 drug substance is manufactured via conventional organic synthetic procedures, starting from raw materials and reagents commercially available in large quantities. ANG-3070 drug product is manufactured via conventional pharmaceutical processing procedures, employing commercially available excipients and packaging materials. The procedure and equipment employed for manufacture and analysis are consistent with standard organic synthesis or pharmaceutical production, and are transferable to a range of manufacturing facilities, if needed.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in discussions with third party manufacturers to identify additional suppliers to produce our other product candidates.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are characterized by intense competition and rapid innovation. Although we believe our product candidates offer innovative therapeutic approaches and may provide significant advantages relative to current therapies in the treatment of acute organ damage and our other therapeutic areas, our competitors may be able to develop other compounds, drugs, or therapies capable of achieving similar or better results. Our potential competitors include major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies and universities and other research institutions. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. We believe the key competitive factors affecting the development and commercial success of our product candidates will be whether or not such product candidates are deemed to be safe and effective by relevant regulatory authorities, as well as their tolerability profile, reliability, convenience of dosing, price, and reimbursement.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to ANG-3070, clinical programs potentially competitive in PPKDs generally focus on immune system modification, repurposed or novel hemodynamic (blood pressure) modifiers, and other approaches. In contrast, we believe ANG-3070 is the only clinical-stage anti-fibrotic in development for PPKDs. Given the disease progression path for PPKDs, programs not specifically addressing renal fibrosis have the potential to be more complimentary than competitive. In 2021, Tarpeyo&#174; (budesonide) from Calliditas was granted accelerated approved by the FDA for IgAN, one form of PPKD. Phase 3 programs in PPKD include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Atrasentan from Chinook Pharmaceuticals (IgAN, FSGS, Alport)</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bardoxolone methyl from Reata Pharmaceuticals (Alport)</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Iptacopan from Novartis (IgAN)</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Narsoplimab form Omeros (IgAN)</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sibeprenlimab from Visterra/Otsuka Pharmaceuticals (IgAN)</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sparsenten from Travere Therapeutics (IgAN, FSGS)</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">DMX-200 from Dimerix (FSGS)</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 3 clinical programs potentially competitive with ANG-3070 in pulmonary fibrosis (IPF and SSc-ILD) include: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There are two approved therapies, pirfenidone (Esbriet&#174;, sold by Roche/Genentech) for IPF and nintedanib (OFEV&#174;, sold by Boehringer-Ingleheim) for IPF and SSc-ILD.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ORG-447 from Agomab Therapeutics for IPF</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PLN-74809 from Pliant Therapeutics for IPF</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PRM-151 from Roche/Genentech for IPF</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Taladegib from Endeavor Biosciences for IPF</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to competition for our ROCK2 inhibitor program: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Netarsudil ophthalmic solution from Aerie Pharmaceuticals, Inc. was first approved by the FDA in 2017 as a topical agent for reducing intraocular pressure in patients with open-angle glaucoma and ocular hypertension</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Kadmon Holdings, Inc.'s belumosudil (KD025), a ROCK2 inhibitor with reduced selectivity against ROCK1, in the clinic for several indications, and approved for chronic graft versus host disease </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fasudil developed by Asahi Kasei approved in Asia is being investigated by Woolsey Pharmaceuticals in ALS, retinopathy of prematurity, and dementia</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CXC007 from Redx Pharma Plc</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other ROCK2 inhibitors in preclinical development.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regarding competition for our CYP11B2 inhibitor program: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CIN-107 from CinCor Pharma is a CYP11B2 inhibitor in multiple Phase 2 trials for resistant hypertension, uncontrolled hypertension, and primary aldosteronism. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PB6440 from PhaseBio is a CYP11B2 inhibitor preparing for Phase 1 trials in 2022 in treatment resistant hypertension</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Across each of our development areas, other, potentially competitive, clinical-stage technologies are being developed. Also, companies developing preclinical molecules could decide to pursue development in our chosen indications and potentially compete with us. This could lead to commercial challenges as well as difficulties enrolling clinical trials if they were to target the same indications we are pursuing.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proprietary nature of, and protection for, our product candidates, processes and know-how are important to our business. We pursue various avenues of intellectual property protection, including consideration of patent, trademark, and trade secret strategies. We have sought patent protection in the United States and internationally for our programs relating to small molecule compounds with our tyrosine kinase inhibitors (including ANG-3070), HGF-like activity (including ANG-3777), our ROCK2 inhibitors and our CYP inhibitors. Our patent strategy seeks to protect our product candidates by filing patent applications, in the United States and in relevant foreign jurisdictions, and we pursue multi-faceted protection, as available, for example to relevant small molecule compounds and analogs, pharmaceutical compositions and related methods of manufacture and use. Our policy is to pursue, maintain and defend patent rights in order to protect the technology, inventions and improvements that are commercially important to our business. We also rely on trade secret protection for certain intellectual property that may be important to the development of our business and expect to pursue trademark registrations for brand names or other text or images that may provide commercial value.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and worldwide, issued patents have a presumptive term, assuming all maintenance fees are paid, of twenty years from their earliest non-provisional filing date. Certain jurisdictions offer opportunities to extend this term. For example, the U.S. Patent and Trademark Office (USPTO) may add term to a patent (referred to as Patent Term Adjustment) if delays by the USPTO of certain activities exceed prespecified durations, from which delays by the Applicant are subtracted. Additionally, many jurisdictions, including the United States and Europe, provide opportunities for extending the term of patents relating to approved pharmaceutical products or their approved uses. In the United States, a single patent can be extended per approved product, for a period (referred to as Patent Term Extension) of up to five years, depending on the dates of patent issuance relative to submission of an application for premarketing approval (i.e., of a New Drug Application or a Biologics License Application) under provisions of the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Act. Similar restoration of term is available in Europe under so-called Supplementary Protection Certificate rights, and extensions under similar policies may be available in other countries.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, if any, one or more of our patents may be eligible for limited Patent Term Extension under the Hatch-Waxman Act in the United States, Supplementary Protection Certificate in Europe.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success will depend in part on obtaining and maintaining patent protection and/or other intellectual property protection for our current and future product candidates, including for their use, production, formulation, etc., with commercially relevant terms; our commercial success may also depend in part on our ability to successfully defend our patent and/or other intellectual property rights against third-party challenges. Our ability to stop third parties from making, using, selling, offering to sell and/or importing our products may depend on the extent to which we have rights under valid and enforceable intellectual property rights that cover these activities. We cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially useful in protecting our product candidates, discovery programs and processes. Additionally, we cannot be certain that we will always be able to establish sufficient </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ownership rights to ensure complete or necessary control over our intellectual property rights as required in order to obtain, maintain, and/or enforce them. For these and more comprehensive risks related to our intellectual property, please see "Risk Factors&#8212;Risks Relating to Our Intellectual Property." The expiration dates of the patents discussed below assume in all cases that the appropriate maintenance, renewal, annuity, or other governmental fees are paid to maintain the patent(s) in force for the full extent of their term and any extension(s) thereof.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ANG-3070 Tyrosine Kinase Inhibitor Program</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 1, 2022, compound, pharmaceutical composition and methods of use claims to our kinase inhibitors are covered in patents issued in the United States. We also owned issued patents in Australia, Canada, China, Europe, Hong Kong, Israel, India, Japan; and a pending application in Canada. The European patent was validated in Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Luxembourg, Monaco, Netherlands, Norway, Poland, Portugal, Spain, Sweden, Switzerland/Liechtenstein, Turkey, and the United Kingdom. A continuation application is pending in the United States. These patents, and patents that may issue from the pending applications, provide patent protection until 2033, assuming payment of all appropriate annuities and/or maintenance fees.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed a PCT application directed to the use of ANG-3070 in the treatment of irritable bowel syndrome (IBS). Patents issuing from corresponding national applications will expire in 2040.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 1, 2022, we had filed three PCT applications relating to solid forms of ANG-3070, methods of treating fibrotic diseases, and biomarkers relating to ANG-3070, whose twenty-year presumed terms expire in 2041.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 1, 2022, we had filed a provisional patent application relating to gene expression levels associated with treatment comprising ANG-3070.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Hatch-Waxman Act, a single patent term restoration of up to five years in the United States may be available. We also may be eligible for similar restoration of term in Europe under supplementary protection certificate rights, and similar extensions in certain other countries.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ROCK2 Inhibitor Program</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent portfolio for the ROCK2 inhibitor program includes pending applications in the United States, Australia, Canada, China, Europe, Israel, India, and Japan, each of which would have presumed twenty-year terms expiring in 2038. We have also filed a Patent Cooperation Treaty (PCT) application and a provisional application, each of which recite claims to compounds, pharmaceutical compositions, and methods of use thereof. Any patents that may issue from national applications of the PCT application or the provisional application would have twenty-year presumed terms expiring between 2040 and 2041.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CYP11B2 Inhibitor Program</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent portfolio for the CYP11B2 inhibitor program includes pending applications in the United States, Australia, Canada, Europe, Israel, and Japan, each of which would have presumed twenty-year terms expiring in 2038. As of January 1, 2022, we owned issued patents in the United States that claim, among other things, ANG-3598 composition of matter, pharmaceutical compositions comprising ANG-3598, and methods of treating renal fibrosis. We also owned issued patents in Australia, China, Israel, and India. Each of the patents expire in 2035 and any patents that may issue from the pending applications have twenty-year presumed terms expiring in 2035.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">ANG-3777</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent portfolio for ANG-3777 includes patents and patent applications that describe and/or specifically claim pharmaceutical compositions whose active agent is ANG-3777 and uses thereof, as well as compounds structurally related to ANG-3777, pharmaceutical compositions and uses thereof. As of January 1, 2022, we owned issued patents in the United States that claim, among other things, pharmaceutical compositions comprising ANG-3777. We also owned issued patents in Australia, Canada, China, Europe, Hong Kong, Israel, and Japan. Granted European patents have been validated in the following European countries: Denmark, France, Germany, Hungary, Ireland, Italy, Luxembourg, Monaco, Netherlands, Sweden, Switzerland/Liechtenstein, and the United Kingdom.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have issued claims to pharmaceutical compositions containing ANG-3777 and methods of use that should remain in force, if the appropriate maintenance, renewal, annuity or other governmental fees are paid, in the United States until 2024, and in other jurisdictions until 2023.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An aqueous formulation of ANG-3777 and analogues of sufficient solubility for intravenous administration is the subject of claims in a patent issued in the United States that will expire in 2030 assuming continued payment of all maintenance fees.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have issued United States patents on the use of ANG-3777 and related compounds for the treatment of chronic obstructive pulmonary disease, (COPD), and scleroderma, which expire in 2028 and 2029, respectively.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have issued claims in the United States to solid forms of ANG-3777 which expires in 2040, and pending applications in Australia, Brazil, Canada, China, Eurasia, Europe, Israel, Japan, Korea, Mexico, New Zealand, Singapore, and the United States Patents issuing from these applications will expire in 2040.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed a PCT application directed to the use of ANG-3777 in the treatment of delayed graft function. Patents issuing from corresponding national applications will expire in 2040.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 1, 2022, we had filed two provisional patent applications relating to ANG-3777 whose twenty-year presumed terms expire in 2041.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Hatch-Waxman Act, a single patent term restoration of up to five years in the United States may be available. We also may be eligible for similar restoration of term in Europe under supplementary protection, certificate rights, and similar extensions in certain other countries.</span></div><div><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licenses and Collaborations</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreement with Vifor Pharma</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we granted Vifor Pharma, an exclusive, global (excluding Greater China), royalty-bearing license (the Vifor License), for the commercialization of ANG-3777 in all Renal Indications, beginning with DGF and CSA-AKI. The Vifor License also grants Vifor Pharma exclusive rights, with a right to sublicense subject to our consent for certain specified conditions, to develop and manufacture ANG-3777 for commercialization in Renal Indications worldwide (excluding Greater China) in cooperation with us or independently. We retain the right to develop and commercialize combination therapy products combining ANG-3777 with our other proprietary molecules, subject to Vifor Pharma's right of first negotiation with respect to global (excluding Greater China) rights to such combination therapy products in the Renal Indications. See Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. Although the Vifor License includes additional milestone and royalty objectives, we do not expect to receive any clinical, post-approval, or sales milestones, or royalties, as we do not intend to continue to pursue the clinical development plan for ANG-3777 , which had included a Phase 3 study for CSA-AKI and a phase 4 confirmatory study in DGF.. We and Vifor continue to complete the planned analyses of the results of the clinical trials announced in the fourth quarter of 2021 and discuss the future of the collaboration.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration with the University of Michigan</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into a subcontractor agreement with The Regents of the University of Michigan (UM), </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">under which we provide funding for identification of ANG-3070-responsive disease marker profiles in rodent models, and their intersection with existing data on patients with various forms of nephrotic kidney disease, to identify potential ANG-3070-responsive patient subsets. Under this agreement we obtain access to the Nephrotic Syndrome Study Network (NEPTUNE), an integrated group of academic centers, patient support organizations and clinical resources dedicated to advancing the treatment of kidney disorders. The goal of work under this agreement, which we support through a grant from the U.S. Department of Defense, is to identify human disease and drug response profiles based upon the genes, networks and pathways that correlate with the therapeutic activity of ANG-3070 in primary FSGS and other fibrotic renal diseases. We are obligated to provide to UM up to a total of $520,000 over the course of the project. We have an option to license and commercialize intellectual property generated during the term of the agreement that is solely owned by UM under commercially reasonable terms. See Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. On March 21, 2022, Angion provided written notice to UM of its intention to terminate the subcontractor agreement as Angion believes the work under the related U.S. Department of Defense grant to be complete.  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License Agreement with Ohr Cosmetics LLC.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2013, we granted Ohr an exclusive worldwide license, with the right to sublicense, under our patent rights covering one of our CYP26 inhibitors, for the use in treating conditions of the skin or hair. Sublicensees may not grant further sublicenses under our patent rights other than to affiliates of such sublicensees and entities with which sublicensees are collaborating for the research, development, manufacture and commercialization of the products. Ohr will pay us a royalty at a rate in the low single digits on gross revenue of products incorporating ANG&#8209;3522, and milestone payments potentially totaling up to $9.0 million based on achievement of sales milestones. Royalties and milestone payments will be paid until the later of 15 years from the first commercial sale of a licensed product or the last to expire licensed patent rights. The royalty rate is subject to adjustments under certain circumstances. The Ohr License represents a related-party transaction, as discussed in Note 15 in this Annual Report on Form 10-K below, and we believe the Ohr License was made on terms no less favorable to us than those we could obtain from unaffiliated third parties. No revenue from this license agreement was recognized during the year ended December 31, 2021. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation and Product Approval</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, marketing and promotion, distribution, post-approval monitoring and reporting, sampling, and import and export of drugs, such as those we are developing. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Drug Regulation</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act and its implementing regulations. FDA approval is required before any new drug can be marketed in the United States. Drugs are also subject to other federal, state and local statutes and regulations. Failure to comply with applicable FDA or other requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA clinical holds, refusal to approve pending applications, withdrawal of an approval, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process required by the FDA before product candidates may be marketed in the United States generally involves the following:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">completion of preclinical laboratory tests and animal studies, all performed in accordance with the FDA's Good Laboratory Practice (GLP) regulations;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">submission to the FDA of an investigational new drug application (IND) which must become effective before human clinical studies may begin and must be updated annually or when significant changes are made;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">approval by an independent institutional review board (IRB) representing each clinical site before a clinical study may be initiated;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">performance of adequate and well-controlled human clinical trials in accordance with good clinical practice (GCP) regulations to establish the safety and efficacy of the product candidate for each proposed indication;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">preparation of and submission to the FDA of a new drug application (NDA);</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">satisfactory completion of an FDA advisory committee review, if applicable;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">a determination by the FDA within 60 days of its receipt of an NDA to file the application for review;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility(ies) where the product is manufactured to assess compliance with current good manufacturing practice (cGMP) regulations, and of selected clinical investigation sites to assess compliance with GCP; and</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">FDA review and approval of an NDA to permit commercial marketing of the product for its particular labeled uses in the United States.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical and Clinical Studies</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preclinical and clinical testing and approval process can take many years and the actual time required to obtain approval, if any, may vary substantially based upon the type, complexity and novelty of the product or condition being treated.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical tests include laboratory evaluation of product chemistry, formulation and toxicity, as well as animal studies to assess the characteristics and potential safety and efficacy of the product. The conduct of preclinical tests must comply with federal regulations and requirements, including GLP. The results of preclinical testing are submitted to the FDA as part of an IND along with other information, including information about product chemistry, manufacturing and controls and any available human data or literature to support use of the product in humans. Long-term preclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The central focus of an IND submission is on the general investigational plan and the protocol(s) for human studies. An IND must become effective before human clinical trials may begin. An IND will automatically become effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to the proposed clinical studies. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before clinical studies can begin. A separate submission to an existing IND must also be made for each successive clinical trial conducted during product development along with any subsequent changes to the investigational plan.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical studies involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for participation in each clinical study. Clinical studies are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the efficacy criteria to be evaluated. A protocol for each clinical study and any subsequent protocol amendments must be submitted to the FDA as part of the IND. Additionally, approval must also be obtained from each clinical study site's IRB before a study may be initiated at the site, and the IRB must monitor the study until completed. Each year, sponsors must submit an annual progress report to FDA detailing the status of the clinical trial(s) under an IND, and sponsors must timely report to FDA any serious and unexpected adverse reactions, any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol, or any findings from other preclinical or clinical studies that suggest a significant risk in humans exposed to the drug. Sponsors generally must also register and report ongoing clinical studies and clinical study results to public registries, including the website maintained by the U.S. NIH, ClinicalTrials.gov.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of NDA approval, human clinical trials are typically divided into three or four phases. Although the phases are usually conducted sequentially, they may overlap or be combined.</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:25.3pt">Phase 1.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The drug is initially introduced into healthy human subjects or into patients with the target disease or condition. These studies are designed to evaluate the safety, dosage tolerance, metabolism and pharmacologic actions of the drug in humans, the side effects associated with increasing doses, and if possible, to gain early evidence on effectiveness.</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:25.3pt">Phase 2.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The drug is administered to a limited patient population to evaluate dosage tolerance and optimal dosage, identify possible adverse side effects and safety risks and preliminarily evaluate efficacy.</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:25.3pt">Phase 3.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The drug is administered to an expanded patient population, generally at geographically dispersed clinical study sites to generate enough data to statistically evaluate dosage, clinical effectiveness and safety, to establish the overall benefit-risk relationship of the investigational product and to provide an adequate basis for product approval.</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:25.3pt">Phase 4.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In some cases, the FDA may condition approval of an NDA for a product candidate on the sponsor's agreement to conduct additional clinical studies after approval. In other cases, a sponsor may voluntarily conduct additional clinical studies after approval to gain more information about the drug. Such post-approval studies are typically referred to as Phase 4 clinical studies.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA, the IRB or the clinical study sponsor may suspend or terminate a clinical study at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. We may also suspend or terminate a clinical study based on evolving business objectives and/or competitive climate.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points may be prior to the submission of an IND, at the end of Phase 2 and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date and for the FDA to provide advice on the next phase of development. Sponsors typically use the meeting at the end of Phase 2 to discuss their Phase 2 clinical results and present their plans for the pivotal Phase 3 clinical trial that they believe will support the approval of the new drug.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, must include methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product does not undergo unacceptable deterioration over its shelf life.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Submission of an NDA to the FDA</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development and testing are submitted to the FDA in the form of an NDA requesting approval to market the product for one or more indications. The submission of an NDA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An NDA must include all relevant data available from pertinent preclinical and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product's chemistry, manufacturing, controls and proposed labeling, among other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of a use of a product, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and effectiveness of the investigational product to the satisfaction of the FDA.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has 60 days from its receipt of an NDA to determine whether the application will be accepted for filing based on the agency's threshold determination that it is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an application for filing. In this event, the application must be resubmitted with the additional information and is subject to payment of additional user fees. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. Under the Prescription Drug User Fee Act (PDUFA) the FDA has agreed to certain performance goals in the review of NDAs through a two-tiered classification system, standard review and Priority Review. Priority Review designation is given to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists. According to PDUFA performance goals, the FDA endeavors to review applications subject to standard review within ten to twelve months, whereas the FDA's goal is to review Priority Review applications within six to eight months, depending on whether the drug is a new molecular entity.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, the FDA will typically inspect one or more clinical sites to assure that relevant study data was obtained in compliance with GCP requirements.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates the NDA and conducts inspections of manufacturing facilities, it may issue an approval letter or a complete response letter. A complete response letter indicates that the review cycle of the application is complete and the application is not ready for approval. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. Even with submission of this additional information, the FDA may ultimately decide that an application does not satisfy the regulatory criteria for approval. If, or when, the deficiencies have been addressed to the FDA's satisfaction in a resubmission of the application, the FDA will issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a condition of NDA approval, the FDA may require a Risk Evaluation and Mitigation Strategy (REMS) program to help ensure that the benefits of the drug outweigh its risks. If the FDA determines a REMS program is necessary during review of the application, the drug sponsor must agree to the REMS plan at the time of approval. A REMS program may be required to include various elements, such as a medication guide or patient package insert, a communication plan to educate healthcare providers of the drug's risks, or other elements to assure safe use, such as limitations on who may prescribe or dispense the drug, dispensing only under certain circumstances, special monitoring and the use of patient registries. In addition, all REMS programs must include a timetable to periodically assess the strategy following implementation.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, product approval may require substantial post-approval testing and surveillance to monitor the drug's safety and efficacy, and the FDA has the authority to prevent or limit further marketing of a product based on the results of these post-marketing programs. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing. Moreover, changes to the conditions established in an approved application, including changes in indications, labeling or manufacturing processes or facilities may require submission and FDA approval of a new NDA or NDA supplement before the changes can be implemented. An NDA supplement for a new indication typically requires clinical data similar to that supporting the original approval, and the FDA uses similar procedures in reviewing supplements as it does in reviewing original applications.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expedited Development and Review Programs</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA offers a number of expedited development and review programs for qualifying product candidates, one or more of which may be available for our current or future products.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New drug products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a Fast Track product has opportunities for frequent interactions with the review team during product development and, once an NDA is submitted, the product may be eligible for Priority Review. A Fast Track product may also be eligible for rolling review, where the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product intended to treat a serious or life-threatening disease or condition may also be eligible for Breakthrough Therapy designation to expedite its development and review. A product can receive Breakthrough Therapy designation if preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the Fast Track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product, including involvement of senior managers.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After an NDA is submitted for a product, including a product with a Fast Track designation and/or Breakthrough Therapy designation, the NDA may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as Priority Review and accelerated approval. A product is eligible for Priority Review if it has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition compared to marketed products. Depending on whether a drug contains a new molecular entity, Priority Review designation means the FDA's goal is to take action on the marketing application within six to eight months of the 60-day filing date, compared with ten to twelve months under standard review.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. In addition, the FDA currently requires </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orphan Drug Designation</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant Orphan Drug designation to a drug intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for this type of disease or condition will be recovered from sales in the United States for that drug. Orphan Drug designation must be requested before submitting an NDA. After the FDA grants Orphan Drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The Orphan Drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product with Orphan Drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to Orphan Drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications, including a full NDA, to market the same drug for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with Orphan Drug exclusivity. Orphan Drug exclusivity does not prevent FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. Among the other benefits of Orphan Drug designation are tax credits for certain research and a waiver of the application user fee.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A designated Orphan Drug may not receive Orphan Drug exclusivity if it is approved for a use that is broader than the indication for which it received Orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pediatric Use and Exclusivity</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even when not pursuing a pediatric indication, under the Pediatric Research Equity Act an NDA or supplement thereto must contain data that is adequate to assess the safety and effectiveness of the drug product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. With the enactment of the Food and Drug Administration Safety and Innovation Act in 2012, sponsors must also submit pediatric trial plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric trials the sponsor plans to conduct, including trial objectives and design, any deferral or waiver requests, and other information required by regulation. The FDA must then review the information submitted, consult with the sponsor, and agree upon a final plan. The FDA or the sponsor may request an amendment to the plan at any time. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, in the event the FDA issues a Written Request for pediatric data relating to a drug product, an NDA sponsor who submits such data may be entitled to pediatric exclusivity. Pediatric exclusivity is another type of non-patent marketing exclusivity which, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing exclusivity.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Approval Requirements</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an NDA is approved, a product will be subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to drug listing and registration, recordkeeping, periodic reporting, product sampling and distribution, adverse event reporting and advertising, marketing and promotion. Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. While physicians may prescribe for off-label uses, manufacturers may only promote for the approved indications and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is otherwise consistent with a product's FDA approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which FDA assesses an annual program fee for each product identified in an approved NDA. In addition, quality-control, drug manufacture, packaging and labeling procedures must continue to conform to cGMPs after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to periodic unannounced and announced inspections by the FDA and these state agencies, during which the agency inspects manufacturing facilities to assess compliance with cGMPs. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may withdraw approval of a product if compliance with regulatory requirements is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">fines, warning or untitled letters or holds on post-approval clinical studies;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">product seizure or detention, or refusal of the FDA to permit the import or export of products; or</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also require post-approval studies and clinical trials if the FDA finds that scientific data, including information regarding related drugs, deem it appropriate. The purpose of such studies would be to assess a known serious risk or signals of serious risk related to the drug or to identify an unexpected serious risk when available data indicate the potential for a serious risk. The FDA may also require a labeling change if it becomes aware of new safety information that it believes should be included in the labeling of a drug.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Hatch-Waxman Amendments</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ANDA Approval Process</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Drug Price Competition and Patent Term Restoration Act of 1984, known as the Hatch-Waxman Amendments, established abbreviated FDA approval procedures for drugs that are shown to be equivalent to proprietary drugs previously approved by the FDA through the NDA process. Approval to market and distribute these generic equivalent drugs is obtained by filing an abbreviated new drug application (ANDA) with the FDA. An ANDA is a comprehensive submission that contains (among other things), data and information pertaining to the active pharmaceutical ingredient, drug product formulation, specifications and stability of the generic drug, as well as analytical methods, manufacturing process validation data and quality control procedures. However, premarket applications for generic drugs are termed "abbreviated" because they generally do not include preclinical and clinical data to demonstrate safety and effectiveness. Instead, a generic applicant must demonstrate that its product is bioequivalent to a referenced proprietary drug. In certain situations, an applicant may obtain ANDA approval of a generic drug with a strength or dosage form that differs from the referenced proprietary drug pursuant to the filing and approval of an ANDA suitability petition. The FDA will approve the generic product as suitable for an ANDA application if it finds that the generic product does not raise new questions of safety and effectiveness as compared to the innovator product. A product is not eligible for ANDA approval if the FDA determines that it is not equivalent to the referenced proprietary drug or is intended for a different use and it is not otherwise subject to an approved suitability petition. However, such a product might be approved under an NDA, with supportive data from clinical trials.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">505(b)(2) NDAs</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 505(b)(2) of the FDCA, enacted as part of the Hatch-Waxman Amendments, permits the filing of an NDA where at least some of the information required for approval comes from clinical trials not conducted by or for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the applicant and which the applicant has not obtained a right of reference. Section 505(b)(2) can serve as a path to approval for modifications to previously approved drugs, such as new indications, formulations, dosage forms, or other conditions of use. If the 505(b)(2) applicant can establish that reliance on the FDA's previous findings of safety and effectiveness for the approved reference drug is scientifically appropriate, it may eliminate the need to conduct certain preclinical or clinical studies for the new product. The FDA may approve the new product for all, or some, of the label indications for which the reference drug has been approved, as well as for any new indication sought by the 505(b)(2) applicant.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orange Book Listing</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In seeking approval for a drug through an NDA, including a 505(b)(2) NDA, applicants are required to submit certain information to the FDA regarding any patents with claims covering the applicant's product or a method of using the product. Upon approval of the NDA, each of the patents is listed in the FDA's </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Approved Drug Products with Therapeutic Equivalence Evaluations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, known as the Orange Book. Any applicant that subsequently files an ANDA or 505(b)(2) application referencing the approved drug must certify to FDA, with respect to each patent listed for the approved drug in the Orange Book: (1) that no patent information was submitted to the FDA; (2) that such patent has expired; (3) the date on which such patent expires; or (4) that such patent is invalid or will not be infringed by the manufacture, use or sale of the drug product for which the application is submitted. This last certification is known as a "paragraph IV certification." For method of use patents, in lieu of submitting a certification, the applicant may elect to submit a "section viii statement" certifying that its proposed label does not contain (or carves out) any language regarding a patented method of use.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an ANDA or 505(b)(2) applicant does not challenge one or more listed patents through a paragraph IV certification, the FDA will not approve the ANDA or 505(b)(2) application until all the listed patents claiming the reference product have expired.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an ANDA or 505(b)(2) applicant provides a paragraph IV certification with its application, the applicant must send notice of the paragraph IV certification to the holder of the NDA for the reference product and all patent holders for the patent at issue within 20 days after the ANDA or Section 505(b)(2) application has been accepted for filing by the FDA. The NDA holder and patent owners may then initiate a patent infringement suit against the ANDA or 505(b)(2) applicant. Under the FDCA, the filing of a patent infringement suit within 45 days of the NDA holder's or patent owners' receipt of the notification regarding the paragraph IV certification automatically prevents the FDA from approving the ANDA or 505(b)(2) application until the earliest to occur of 30 months from the date the paragraph IV notice is received, the expiration of the patent, the settlement of the lawsuit or a court decision that the patent is invalid, unenforceable or not infringed. If the NDA holder or patent owners do not bring a patent infringement suit within the 45-day period, they may later bring a patent infringement suit under traditional patent law, but it will not invoke the 30-month stay of approval.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separate from applicable patent terms and the 30-month stay of approval for paragraph IV applications, the FDA will also refrain from approving an ANDA or 505(b)(2) application until all applicable non-patent exclusivity for the reference drug has expired.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Patent Exclusivity</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NDA holders may be entitled to different periods of non-patent exclusivity, during which the FDA cannot approve an ANDA or 505(b)(2) application that relies on the approved drug. For example, an applicant may obtain five years of non-patent exclusivity upon NDA approval of a new chemical entity (NCE) which is a drug that contains an active moiety that has not been previously approved by the FDA in any other NDA. During the five-year period of NCE exclusivity, the FDA cannot accept any application for a product that contains the same active moiety as the approved NCE; however, the FDA can accept an ANDA or 505(b)(2) application for the same active moiety after a four-year period if such application includes a paragraph IV certification.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a non-NCE drug may qualify for a three-year period of exclusivity for a change to a previously approved product, such as a new indication or condition of use, if one or more new clinical studies (other than bioavailability or bioequivalence studies) was essential to the approval of the application and was conducted or sponsored by the applicant. In such case, the FDA is precluded from approving any ANDA or 505(b)(2) application for the protected modification until after the three-year exclusivity period has concluded. However, unlike NCE exclusivity, the FDA can accept an application and being the review process during the exclusivity period.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other types of non-patent exclusivity include seven-year Orphan Drug exclusivity and six-month pediatric exclusivity (each discussed above).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International Regulation</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the United States, we could become subject to a variety of foreign regulations regarding development, approval, commercial sales and distribution of our products if we seek to market our product candidates in other jurisdictions. Whether or not we obtain FDA approval for a product, we must obtain the necessary approvals by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the product in those countries. The approval process varies from country to country and can involve additional product testing and additional review periods, and the time may be longer or shorter than that required to obtain FDA approval. The requirements governing, among other things, the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may negatively impact the regulatory process in others. If we fail to comply with applicable foreign regulatory requirements, we may be subject to fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Healthcare Laws</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to FDA restrictions on the marketing of pharmaceutical products, other foreign, federal and state healthcare regulatory laws restrict business practices in the pharmaceutical industry. These laws include, but are not limited to, federal and state anti-kickback, false claims, data privacy and security, and physician payment and drug pricing transparency laws.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute prohibits, among other things, any person or entity from knowingly and willfully offering, paying, soliciting, receiving or providing any remuneration, directly or indirectly, overtly or covertly, to induce or in return for purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or order of any good, facility, item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term "remuneration" has been broadly interpreted to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, formulary managers and beneficiaries on the other hand. Several courts have interpreted the statute's intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been violated. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. The majority of states also have anti-kickback laws, which establish similar prohibitions, and in some cases may apply to items or services reimbursed by any third-party payor, including commercial insurers.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false, fictitious or fraudulent claim for payment to, or approval by, the federal government, knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government, or knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. A claim includes "any request or demand" for money or property presented to the U.S. government. Actions under the civil False Claims Act may be brought by the Attorney General or as a </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> action by a private individual in the name of the government. Moreover, a claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The civil monetary penalties statute imposes penalties against any person who is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) created additional federal criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their implementing regulations, impose privacy, security and breach reporting obligations with respect to individually identifiable health information upon entities subject to the law, such as health plans, healthcare clearinghouses and certain healthcare providers, known as covered entities, and their respective business associates and their covered subcontractors that perform services for them that involve individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and certain other healthcare providers. The Affordable Care Act, as amended by the Health Care Education and Reconciliation Act (Affordable Care Act), imposed, among other things, new annual reporting requirements through the Physician Payments Sunshine Act for covered manufacturers for certain payments and "transfers of value" provided to physicians (as defined by statute), certain other health care professionals, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. In addition, certain states require implementation of compliance programs and compliance with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, impose restrictions on marketing practices and/or require the tracking and reporting of marketing expenditures and pricing information as well as gifts, compensation and other remuneration or items of value provided to physicians and other healthcare professionals and entities.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of fraud and abuse laws, including state anti-kickback and false claims laws, some of which apply to items or services reimbursed by any third-party payor, including commercial insurers, may be punishable by criminal and civil sanctions, including fines and civil monetary penalties, the possibility of exclusion from federal healthcare programs, including Medicare and Medicaid, disgorgement and corporate integrity agreements, which impose, among other things, rigorous operational and monitoring requirements on companies. Similar sanctions and penalties, as well as imprisonment, also can be imposed upon executive officers and employees of such companies.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and Reimbursement</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Significant uncertainty exists as to the coverage and reimbursement status of any newly approved product. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a payor-by-payor basis. One third-party payor's decision to cover a particular product does not ensure that other payors will also provide coverage for the product. As a result, the coverage determination process can require manufactures to provide scientific, clinical support, and commercial support for the use of a product to each payor separately. This can be a time-consuming process, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, third-party payors are increasingly reducing reimbursements for pharmaceutical products and services. The U.S. government and state legislatures have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Third-party payors are more and more challenging the prices charged, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical products, in addition to questioning their safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Pharmaceutical products may face competition from lower-priced products in foreign countries that have placed price controls on pharmaceutical products and may also compete with imported foreign products. Furthermore, there can be no assurance that a product will be considered medically reasonable and necessary for a specific indication or considered cost-effective by third-party payors in foreign or national-level systems. In the event that an adequate level of reimbursement is not established, then even if a product is approved by global regulatory authorities, it may adversely affect the ability of manufacturers to sell such product profitably.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Healthcare Reform</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and certain foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system. In March 2010, the Affordable Care Act was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States. By way of example, the Affordable Care Act increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%; required collection of rebates for drugs paid by Medicaid managed care organizations; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell certain "branded prescription drugs" to specified federal government programs, implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; expanded eligibility criteria for Medicaid programs; creates a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been judicial, executive branch and congressional challenges to certain aspects of the Affordable Care Act, and we expect there will be additional challenges and amendments to the Affordable Care Act in the future. By way of example, in 2017, Congress enacted the Tax Act, which eliminated the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the "individual mandate." On June 17, 2021. the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the Affordable Care Act will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. It is possible that the Affordable Care Act will be subject to judicial or congressional challenges in the future. It is also unclear how other efforts to challenge, repeal or replace the Affordable Care Act will impact the Affordable Care Act.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted since the Affordable Care Act was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year and reduced payments to several types of Medicare providers, which will remain in effect through 2031 absent additional congressional action, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several congressional inquiries and proposed and enacted legislation designed, among other things, to bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for pharmaceutical products. In July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">response to Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. No legislation or administrative actions have been finalized to implement these principles. In addition, Congress is considering drug pricing as part of other reform initiatives.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, mechanisms to encourage importation from other countries and bulk purchasing. Furthermore, there has been increased interest by third party payors and governmental authorities in reference pricing systems and publication of discounts and list prices.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data Privacy and Security</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical manufacturers may be subject to U.S. federal and state and foreign health information privacy, security and data breach notification laws, which may govern the collection, use, disclosure and protection of health-related and other personal information. In the United States, HIPAA imposes privacy, security and breach reporting obligations with respect to individually identifiable health information upon "covered entities" (health plans, health care clearinghouses and certain health care providers), and their respective business associates, and their covered subcontractors that create, received, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HIPAA mandates the reporting of certain breaches of health information to HHS, affected individuals and if the breach is large enough, the media. Entities that are found to be in violation of HIPAA as the result of a breach of unsecured protected health information, a complaint about privacy practices or an audit by HHS, may be subject to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance. Even when HIPAA does not apply, according to the Federal Trade Commission or the FTC, failing to take appropriate steps to keep consumers' personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act 15 U.S.C &#167; 45(a). The FTC expects a company's data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain state laws govern the privacy and security of health information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. For example, the CCPA became effective on January 1, 2020, which, among other things, creates new data privacy obligations for covered companies and provides new privacy rights to California residents, including the right to opt out of certain disclosures of their information. The CCPA also creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. Although the law includes limited exceptions, including for "protected health information" maintained by a covered entity or business associate, it may regulate or impact our processing of personal information depending on the context. Further, the CPRA was recently voted into law by California residents. The CPRA significantly amends the CCPA, and imposes additional data protection obligations on covered companies doing business in California, including additional consumer rights processes and opt outs for certain uses of sensitive data. It also creates a new California data protection agency specifically tasked to enforce the law, which would likely result in increased regulatory scrutiny of California businesses in the areas of data protection and security. The substantive requirements for businesses subject to the CPRA will go into effect on January 1, 2023, and become enforceable on July 1, 2023.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, the GDPR went into effect in May 2018, and imposes strict requirements for processing the personal data of data subjects within the European Economic Area and the United Kingdom. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Relatedly, following the United Kingdom's withdrawal from the European Economic Area and the European Union, and the expiry of the transition period, companies will have to comply with the GDPR and the GDPR as incorporated into United Kingdom national law, the latter regime having the ability to separately fine up to the greater of &#163;17.5 million or 4% of global turnover. The relationship between the United Kingdom and the European Union in relation to certain aspects of data </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">protection law remains unclear, for example around how data can lawfully be transferred between each jurisdiction, which may expose us to further compliance risk.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Resources</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had 71 full-time employees, who provide full time support to us, and 23 consultants who provide part time support to us.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 1, 2022, we had 39 full time employees and 14 part time consultants. None of our employees are represented by a labor union or covered by collective bargaining agreements and we consider our employee relations to be good. Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards and cash-based performance bonus awards.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have one primary business activity and operate as one reportable segment.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in the State of Delaware on April 6, 1998. Our corporate operations are based in San Francisco, California, our clinical development and regulatory teams are primarily located in Boston, Massachusetts, and our discovery and research programs are based in Uniondale, New York. Our principal executive offices are located at 51 Charles Lindbergh Boulevard, Uniondale, New York 11553, and our telephone number is (415) 655-4899. Our website address is www.angion.com. The information contained on, or that can be accessed through, our website will not be deemed to be incorporated by reference into and does not constitute part of this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the information requirements of the Securities Exchange Act of 1934, as amended, and we therefore file periodic reports, proxy statements and other information with the SEC relating to our business, financial statements and other matters. The SEC maintains an Internet site, www.sec.gov, that contains reports, proxy statements and other information regarding issuers such as Angion Biomedica Corp. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information about us, including free access to our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports, visit our website, www.angion.com. The information found on or accessible through our website is not incorporated into, and does not form a part of, this Annual Report on Form 10-K.</span></div><div id="idee3699378af4447a4091414c0adfaa7_22"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Investing in our common stock involves a high degree of risk. You should carefully consider the following risk factors, as well as the other information in this Annual Report on Form 10-K, including our consolidated financial statements and related notes, before deciding whether to invest in shares of our common stock. Many of the following risks and uncertainties are, and will be, exacerbated by the coronavirus disease 2019 (COVID-19) pandemic and any worsening of the global business and economic environment as a result. The occurrence of any of the adverse developments described in the following risk factors could materially and adversely harm our business, financial condition, results of operations or prospects. In that case, the trading price of our common stock could decline, and you may lose all or part of your investment.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Financial Position and Need for Additional Capital</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a clinical-stage biopharmaceutical company with no products approved for sale and we have not generated any product revenue to date, which makes it difficult to assess our future viability.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company. Drug development is a highly speculative undertaking and involves a substantial degree of risk. We have not yet submitted any product candidates for approval or received approval of any product candidate by regulatory authorities in any jurisdiction, including the United States Food and Drug Administration (FDA). We do not expect to generate revenue from product sales unless we, or we or our collaborators, obtain approval and commercialize our product candidates, which we do not expect to occur for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">several years, if ever. We expect to continue to incur net losses for the foreseeable future, and we expect our expenses and operating losses to increase substantially as we advance ANG-3070 and our other product candidates through clinical and preclinical development, seek regulatory approval for ANG-3070 or any of our other product candidates, and continue to incur expenses to protect our intellectual property, maintain our general and administrative support functions, including hiring additional personnel, and incur costs associated with operating as a public company.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while we have a license agreement with Vifor Pharma relating to ANG-3777 that contemplates upfront, regulatory and commercial milestone payments as well as royalties on sales of ANG-3777, we do not intend to continue the clinical development plan for ANG-3777 set forth in the Vifor License , which had included a Phase 3 study for CSA-AKI and a Phase 4 confirmatory study in DGF. Thus, it is unlikely we will receive any substantial revenue stream from milestone or royalty payments under the license agreement.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to enroll our clinical trials for ANG-3070 or if ANG-3070 or any of our other product candidates fail in ongoing clinical trials or do not gain regulatory approval, we may never generate revenue or become profitable. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">To achieve our goals we will require substantial additional funding, for which capital may not be available to us on acceptable terms, or at all, and, if not so available, may require us to delay, limit, reduce or cease our clinical trials or operations.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have invested and will continue to invest a significant portion of our efforts and financial resources in research and development activities. We are currently in the process of advancing ANG-3070 through a Phase 2 dose-finding clinical trial in 100 patients with Primary Proteinuria Kidney Diseases (PPKDs), specifically FSGS and IgAN patients, in the United States, Georgia, Bulgaria, Lithuania, Spain and Australia, and other product candidates through preclinical and potential clinical development. Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. We will require substantial additional future capital to complete clinical development, including additional clinical studies, and seek regulatory approval for ANG-3070 for any indication as well as to conduct the research, clinical and regulatory activities necessary to bring our other product candidates to market. Regulatory authorities in the United States and elsewhere could also require that we perform additional preclinical studies or clinical trials to receive or maintain regulatory approval of our product candidates, including ANG-3070, and our expenses would further increase beyond what we currently expect. Because successful development of our product candidates is uncertain, we are unable to estimate the actual funds we will require to complete research and development of such product candidates as well as the costs of commercializing any of our wholly-owned product candidates and those for which we retain the right to commercialize.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate our current cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements well into 2023. We have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of biotechnology products, we are unable to estimate the exact amount of our operating capital requirements. The amount and timing of our future funding requirements will depend on many factors, including, but not limited to:</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the scope, progress, results and costs of researching and developing ANG-3070 or other product candidates, and conducting preclinical studies and clinical trials;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the outcome of our ongoing and future clinical trials, including our ANG-3070 Phase 2 clinical trial in PPKD; </span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">whether we are able to take advantage of any FDA expedited development and approval programs for any of our product candidates;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the extent to which COVID-19 may impact our business, including our clinical trials and financial condition;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the willingness of the FDA and foreign regulatory authorities to accept the results of our ongoing ANG-3070 Phase 2 clinical trial, as well as our other completed and planned clinical trials and preclinical studies and other work;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the number and characteristics of product candidates that we pursue, including our product candidates in preclinical development;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the ability of our product candidates to progress through clinical development successfully;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">our need to expand our research and development activities, including to conduct additional clinical trials;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the costs of acquiring, licensing or investing in businesses, products, product candidates and technologies;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">our need and ability to hire additional personnel, including management, clinical development, medical and commercial personnel;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the costs associated with being a public company, including our need to implement additional internal systems and infrastructure, including financial and reporting systems;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the costs associated with securing and establishing manufacturing capabilities, as well as those associated with packaging, warehousing and distribution; and</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the economic and other terms, timing of and success of our existing licensing arrangements and any collaboration, licensing or other arrangements into which we may enter in the future and the timing and amount of payments thereunder.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time we can generate sufficient revenue from sales of ANG-3070 or any other product candidate, if ever, we expect to finance our operations through public or private equity offerings, debt financings or other sources of capital, including collaborations, licenses, credit or loan facilities, receipt of research contributions or grants, tax credits or a combination of one or more of these funding sources. Adequate funding may not be available to us on acceptable terms, or at all. This may be particularly true if global capital markets continue to experience extreme volatility due to the COVID-19 pandemic or armed conflict. To the extent we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through additional collaborations, or other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates ourselves.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to the Development and Regulatory Approval of Our Product Candidates </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 could adversely impact our business, including our clinical trials and financial condition.</span></div><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been and continue to be subject to risks related to public health crises such as the global pandemic associated with COVID-19. As COVID-19 continues to persist around the globe, we may continue to experience disruptions that could severely impact our business and clinical trials, including:</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">delays or difficulties in enrolling patients in our clinical trials, including our ANG-3070 Phase 2 study in PPKD with clinical sites in Eastern Europe, namely Georgia, Lithuania and Bulgaria;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures, the occurrence of which could affect the integrity of clinical trial data;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">risk that participants enrolled in our clinical trials will acquire COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">limitations in employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">delays in receiving authorizations from local regulatory authorities to initiate our planned clinical trials;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">interruption in global shipping that may affect the transport of clinical trial materials, such as investigational drug product used in our clinical trials;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">changes in local regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">interruptions or delays in preclinical studies due to restricted or limited operations at our research and development laboratory facilities;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees; and refusal of the FDA to accept data from clinical trials in affected geographies outside the United States.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuing to evaluate the impact of the COVID-19 restrictions on our expected pace of enrollment, as such impacts could delay the timing of topline results in our ongoing clinical trials.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global pandemic of COVID-19 continues to evolve. The extent to which COVID-19 may impact our business, including our clinical trials, and financial condition will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the geographic spread of the disease and its variants, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product development and regulatory approval involve a lengthy and expensive process with uncertain outcomes. We cannot be certain ANG-3070 or any of our other product candidates will receive or maintain regulatory approval and, without regulatory approval, we and our collaborators will not be able to market our product candidates.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no products approved for sale, and we cannot guarantee we will ever have approved products that we or our collaborators can market and sell. The development of a product candidate and issues relating to its approval and marketing are subject to extensive regulation by regulatory authorities, including the FDA in the United States and other regulatory authorities in other foreign countries, with regulations differing from country to country. We are not permitted to market our product candidates in the United States or elsewhere until we receive regulatory approval and/or marketing authorization, such as approval of an NDA from the FDA. We have not submitted any marketing applications for any of our product candidates.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New drug marketing applications must include extensive preclinical and clinical data and supporting information to establish the product candidate's safety and effectiveness for each desired indication. Such marketing applications must also include significant information regarding the chemistry, manufacturing, and controls for the product. Obtaining approval of our product candidates will be a lengthy, expensive, and uncertain process, and we may not be successful. Specifically, the review processes of the FDA and foreign regulatory authorities can take years to complete, and approval is never guaranteed. Even if a product is approved, the FDA or foreign regulatory authorities may limit the indications for which the product may be marketed, require extensive warnings on the product labeling or require expensive and time-consuming additional clinical trials or reporting as conditions of approval. The FDA or foreign regulatory authorities also may not approve our product candidates with the labeling that we believe is necessary or desirable for the successful commercialization of such product candidates. Obtaining regulatory approval for marketing of a product candidate in one country does not ensure we will be able to obtain regulatory approval in any other country.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or any foreign regulatory authorities can delay, limit or deny approval of our product candidates for many reasons, including:</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.55pt">our inability to demonstrate to the satisfaction of the FDA or the applicable foreign regulatory authority that any of our product candidates are safe and effective for the requested indication;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the FDA's or the applicable foreign regulatory authority's disagreement with our trial protocols or the interpretation of data from preclinical studies or clinical trials;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">our inability to demonstrate that the clinical and other benefits of any of our product candidates outweigh any safety or other perceived risks;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the FDA's or the applicable foreign regulatory authority's requirement for additional preclinical studies or clinical trials;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the FDA's or the applicable foreign regulatory authority's non-approval of the formulation, labeling or specifications of any of our product candidates;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the FDA's or the applicable foreign regulatory authority's failure to approve our manufacturing processes and facilities or the facilities of third-party manufacturers upon which we rely; or</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the potential for approval policies or regulations of the FDA or the applicable foreign regulatory authorities to significantly change in a manner rendering our clinical data insufficient for approval.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict whether our ongoing or future clinical trials of our product candidates will be successful, or whether regulators will agree with our conclusions regarding the preclinical studies and clinical trials we have conducted to date or that we conduct in the future. Accordingly, we may never receive approval of ANG-3070 or any of our other product candidates, or be authorized to market and sell our product candidates to customers. If we are unable to obtain approval from regulatory authorities for ANG-3070 or any of our other product candidates, we may not be able to generate sufficient revenue to become profitable or to continue our operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delays or difficulties in the commencement, enrollment and completion of clinical trials could result in increased costs to us and delay or limit our ability to obtain regulatory approval for ANG-3070 and our other product candidates.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delays in the commencement, enrollment, and completion of clinical trials could increase our product development costs or limit the regulatory approval of our product candidates. We are currently enrolling patients in our Phase 2 clinical trial of ANG-3070 for PPKD. Delays in any of our clinical trials may increase the amount of additional funding we will require to complete these trials. The commencement, enrollment, and completion of clinical trials can be delayed, challenged or suspended for a variety of reasons, including but not limited to:</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">severity of the disease under investigation;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">inability to obtain sufficient funds required for a clinical trial;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">inability to obtain Institutional Review Board (IRB) approval at participating institutions;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">our ability to effectively manage the clinical research organizations (CROs) we have engaged to conduct of our clinical trials;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the extent to which COVID-19 may impact our clinical trials and our or our CROs' ability to monitor such trials;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the extent to which the Russian invasion of Ukraine may impact our clinical trials and our or our CROs' ability to monitor such trials;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">availability and efficacy of approved medications or competing product candidates in development for the disease under investigation;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the patient eligibility criteria defined in the protocol;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the ability to attract and retain patients and the general willingness of patients to enroll, consent and complete participation in the trial;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the extent to which there is competition for patients to enroll in clinical trials;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the size of the patient population required for analysis of the trial's primary endpoint or endpoints;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">clinical holds, other regulatory objections to commencing or continuing a clinical trial, or the inability to obtain regulatory approval to commence a clinical trial in countries requiring such approvals;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">discussions with the FDA or foreign regulatory authorities regarding the scope or design of our clinical trials;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">severe or unexpected drug-related adverse effects experienced by patients; and</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">inability to timely manufacture sufficient quantities of the product candidate and other clinical supplies required for a clinical trial.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in regulatory requirements and related guidance related to regulatory approval may also occur and we may need to amend clinical trial protocols to reflect these changes. Amendments may require us to resubmit clinical trial protocols to IRBs for re-examination, which may impact the costs, timing or successful completion of our clinical trials. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, if we are required to conduct additional clinical trials or other preclinical studies of our product candidates beyond those contemplated, our ability to obtain or maintain regulatory approval of these product candidates and generate revenue from their sales would be similarly harmed</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical failure can occur at any stage of clinical development, and the results of earlier clinical trials are not necessarily predictive of future results.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical failure can occur at any stage of our clinical development. For example, in the fourth quarter of 2021, we disclosed the results of the ANG-3777 Phase 3 clinical trial for delayed graft function (DGF) and AKI associated with cardiac surgery involving cardiopulmonary bypass (CSA-AKI), neither of which met their primary endpoints despite the existence of encouraging pre-clinical and clinical data for ANG-3777 established prior to initiating such studies. Clinical trials may produce negative or inconclusive results, and we or our collaborators may decide, or regulators may require us, to conduct additional clinical trials or preclinical studies. In addition, data obtained from trials and studies are susceptible to various interpretations, and regulators may not interpret our data as favorably as we do, which may delay, limit or prevent regulatory approval. Success in preclinical studies and early clinical trials does not ensure subsequent clinical trials will generate the same or similar results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate. A number of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in Phase 3 registration trials, even after seeing promising results in earlier clinical trials. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the design of a clinical trial can determine whether its results will support approval of a product, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We have limited experience in designing clinical trials as we have never previously completed a Phase 3 registration trial with results sufficient to obtain regulatory approval or submitted an NDA to the FDA or a marketing application to any foreign regulatory authority, and we may be unable to design and execute a clinical trial to support regulatory approval. Further, clinical trials of potential products often reveal it is not practical or feasible to continue development efforts. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our ability to show statistical significance in our clinical trials may be affected by factors beyond our control. This could result in the need for additional clinical trials prior to submission of an NDA to the FDA or other marketing applications to foreign regulatory authorities.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can also be significant variability in safety and/or efficacy results between different trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in composition of the patient populations, adherence to the dosing regimen and other trial protocols, differences in drug lot manufacturing, and the rate of dropout among clinical trial participants. We do not know whether any preclinical or clinical trials we or any of our existing or future collaborators may conduct will demonstrate consistent or adequate efficacy and safety to obtain regulatory approval to market our product candidates.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If ANG-3070 or our other product candidates are the subject of clinical trial failures or are found to be unsafe or lack efficacy, we will not be able to obtain regulatory approval for them and our business would be harmed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials could be disrupted by the uncertainty of war due to the aggressive actions taken by Russia which, if this occurs, could delay our ability to complete our clinical trials.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently in the process of advancing ANG-3070 through a Phase 2 clinical trial in 100 patients with Primary Proteinuria Kidney Diseases (PPKD), specifically FSGS and IgAN patients, including trial sites in Georgia, Bulgaria and Lithuania. In late February 2022, Russia initiated significant military action against Ukraine, and given the proximity of Georgia, Bulgaria and Lithuania to Russia there may be significant uncertainty and unrest in these countries which could impair or delay the progress of our clinical trials in those countries. Further, in response to the Russian invasion of Ukraine, the U.S. and certain other countries imposed significant sanctions and trade actions against Russia, and the U.S. and certain other countries could impose further sanctions, trade restrictions and other retaliatory actions should the conflict continue or worsen. It is not possible to predict the broader consequences of the conflict, including related geopolitical tensions, and the measures and retaliatory actions taken by the U.S. and other countries in respect thereof, as well as any counter measures or retaliatory actions by Russia in response, is likely to cause regional instability, geopolitical shifts and could materially adversely affect global trade, currency exchange rates, regional economies and the global economy. In particular, while it is difficult to anticipate the impact of any of the foregoing on our clinical trials or our business, the conflict and actions taken in response to the conflict could increase our costs, disrupt our supply chain, impair the progress of our clinical trials, impair our ability to raise </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional capital when needed on acceptable terms, if at all, or otherwise adversely affect our business, financial condition and results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we successfully complete ongoing and planned clinical trials of one or more of our product candidates, the product candidates may fail for other reasons.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we successfully complete the clinical trials for one or more of our product candidates, such product candidates may fail for other reasons, including the possibility the product candidates will:</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">fail to receive the regulatory approvals required to market them as drugs;</span></div><div style="margin-top:1pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">be subject to proprietary rights held by others requiring the negotiation of a license agreement prior to marketing;</span></div><div style="margin-top:1pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">be difficult or expensive to manufacture on a commercial scale;</span></div><div style="margin-top:1pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">have adverse side effects that make their use less desirable;</span></div><div style="margin-top:1pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">not achieve reimbursement or sales levels sufficient for continued marketing; or</span></div><div style="margin-top:1pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">fail to compete with product candidates or other treatments commercialized by our competitors.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to receive and maintain the required regulatory approvals, secure our intellectual property rights, maintain an acceptable safety profile or fail to compete with our competitors' products, our business, financial condition, and results of operations could be materially and adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may have undesirable side effects which may delay or halt clinical development or prevent marketing approval or, if approval is received, require them to be taken off the market, require them to include safety warnings, or otherwise limit their sales.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of our clinical trials of our product candidates may show that such product candidates led to patient safety concerns or undesirable or unacceptable side effects, creating risk to the patient which is deemed to outweigh the potential benefits of treatment to that patient. Unforeseen side effects from any of our product candidates could arise either during clinical development or, if approved, after the approved product has been marketed. Any such event could interrupt, delay or halt such clinical trials, resulting in the denial of regulatory approval by the FDA and other regulatory authorities or result in restrictive label warnings, if approved. In light of widely publicized events concerning the safety risk of certain drug products, regulatory authorities, members of Congress, the Government Accounting Office, medical professionals and the general public have raised concerns about potential drug safety issues. These events have resulted in the withdrawal of drug products, revisions to drug labeling that further limit use of the drug products and establishment of risk management programs that may, for instance, restrict distribution of drug products. The increased attention to drug safety issues may result in a more cautious approach by the FDA to clinical trials. Data from clinical trials may receive greater scrutiny with respect to safety, which may make the FDA or other regulatory authorities more likely to terminate clinical trials before completion, or require longer or additional clinical trials that may result in substantial additional expense and a delay or failure in obtaining approval or approval for a more limited indication than originally sought.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANG-3070 is a tyrosine kinase inhibitor (TKI). TKIs are widely used across a range of indications. Depending on their specific targets, TKIs have been associated with several near and long-term side effects. They have been most extensively used in cancer where cardiopulmonary toxicity, myelosuppression, and gastrointestinal toxicity have been key side effects in addition to several others. TKIs have also been studied in fibrosis, with nintedanib being approved for IPF. Nintedanib has been associated with several side effects including severe liver injuries, arterial thromboembolic events and gastrointestinal disorders including diarrhea, nausea and vomiting, and risk of bleeding. Pirfenidone, with an unknown mechanism of action, has also been approved in IPF and has been associated with elevated liver enzymes, diarrhea, nausea vomiting, photosensitivity and rash.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe the preliminary safety and pharmacokinetic data from our Phase 1 healthy-volunteer study in Australia support the conduct of our ongoing Phase 2 clinical trial in PPKD and additional clinical trials, there can be no assurance similar or unforeseen side effects will not occur during such clinical trial. The range and potential severity of possible side effects from systemic therapies is significant.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates receives marketing approval and we or others later identify undesirable or unacceptable side effects caused by such products:</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">regulatory authorities may require the addition of labeling statements or specific warnings, including "Black Box" warnings if the FDA views the possible side effects as very severe;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">we may be required to change instructions regarding the way the product is administered, conduct additional clinical trials, or change the labeling of the product;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">we may be subject to limitations on how we may promote the product;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">sales of the product may decrease significantly;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">regulatory authorities may require us to take our approved product off the market;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">we may be subject to litigation or product liability claims; and</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">our reputation may suffer.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us or any potential future collaborators from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which, in turn, could delay or prevent us from generating significant revenues from the sale of our products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials of our product candidates may not uncover all possible adverse effects patients may experience or be indicative of the effect of our product candidates post approval in the general population.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are conducted in representative samples of the potential patient population, which may have significant variability. By design, clinical trials are based on a limited number of subjects and are of limited duration of exposure to the product, to determine whether the product candidate demonstrates the substantial evidence of efficacy and safety necessary to obtain regulatory approval. As with the results of any statistical sampling, we cannot be sure that any evidence of efficacy will be repeated in the general population or all side effects of our product candidates may be uncovered. It may be the case that only with a significantly larger number of patients exposed to the product candidate for a longer duration may a more complete safety and efficacy profile be identified Further, even larger clinical trials may not identify rare serious adverse events, and the duration of such studies may not be sufficient to identify when those events may occur particularly for adverse events or safety risks that could occur over time, such as the development and diagnosis of cancer. Other products have been approved by the regulatory authorities for which safety concerns have been uncovered following approval. Such safety concerns have led to labeling changes, restrictions on distribution through use of a REMS, or withdrawal of products from the market, and any of our product candidates may be subject to similar risks.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients treated with our products, if approved, may experience previously unreported adverse reactions, and it is possible that the FDA or other regulatory authorities may ask for additional safety data as a condition of, or in connection with, our efforts to obtain approval of our product candidates. If safety problems occur or are identified after our products, if any, reach the market, we may make the decision or be required by regulatory authorities to amend the labeling of our products, recall our products, or even withdraw approval for our products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Due to the significant resources required for the development and commercialization of our product candidates, we must prioritize development of certain product candidates and/or certain disease indications. We may expend our limited resources on product candidates or indications that do not yield a successful product and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to develop a pipeline of product candidates to treat potentially life-threatening acute organ injuries and fibrotic diseases. However, due to the significant resources required for the development of our product candidates, we must focus on specific indications and decide which product candidates to pursue and the amount of resources to allocate to each. For instance, in 2022, we plan to identify a lead candidate in one or more of our pre-clinical programs, but not in all such programs.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary focus is on advancing ANG-3070 in PPKD through our ongoing Phase 2 dose-finding study in that population and filing an IND to support the clinical development of ANG-3070 in IPF.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of any viable commercial product and may divert resources away from better opportunities. Similarly, our potential decisions to delay, terminate or collaborate with third parties in respect of certain programs may subsequently also prove to be suboptimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the viability or market potential of any of our programs or product candidates or misread trends in the biopharmaceutical industry, our business, financial condition and results of operations could be materially adversely affected. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forego or delay pursuit of opportunities with other product candidates or other diseases that may later prove to have greater commercial potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain development and commercialization rights.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws include: the U.S. federal Anti-Kickback Statute; U.S. federal civil and criminal false claims laws, including the civil False Claims Act; the federal fraud provision of the U.S. federal Health Insurance Portability and Accountability Act of 1996 (HIPAA); HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH; the FDCA; the U.S. Physician Payments Sunshine Act; federal consumer protection and unfair competition laws; analogous U.S. state laws and regulations, including state anti-kickback and false claims laws; and similar healthcare laws and regulations in the EU and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our current internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices, including our relationships with physicians and other healthcare providers, some of whom are compensated in the form of stock options for consulting services provided, may not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business and our ability to sell our products may be materially harmed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval for and commercialize our product candidates and affect the prices we may obtain.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (Affordable Care Act), was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been judicial, executive branch and congressional challenges to certain aspects of the Affordable Care Act, and we expect there will be additional challenges and amendments to the Affordable Care Act in the future. For example, legislation informally titled the Tax Cuts and Jobs Acts (TCJA) was enacted, which, among other things, removed penalties for not complying with the individual mandate to carry health insurance. On June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Congress. Thus, the Affordable Care Act will remain in effect in its current form. It is possible that the Affordable Care Act will be subject to judicial or congressional challenges in the future. It is unclear how such challenges or the health reform measures of the Biden administration will affect the Affordable Care Act or our business.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. In August 2011, the Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments, will remain in effect through 2031, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless additional congressional action is taken. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. In addition, on January 2, 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers, including hospitals, and an increase in the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that other healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates, if approved.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products. In July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. No legislation or administrative actions have been finalized to implement these principles. In addition, Congress is considering drug pricing as part of other reform initiatives.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individual states in the United States have become increasingly aggressive in implementing regulations designed to contain pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates, if approved, or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA's approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on single-source third party contract manufacturing organizations to manufacture and supply our product candidates, and if the FDA or foreign regulatory authorities do not approve these manufacturing facilities or if these organizations fail to perform, our ability to conduct clinical trials and obtain regulatory approval our product candidates may be harmed.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own facilities for clinical and commercial manufacturing of our product candidates, including ANG-3070, and we rely upon third-party contract manufacturing organizations to manufacture and supply product candidates for our clinical trials and we will rely in such manufacturers to meet commercial demand. Currently, we rely on and have agreements with a single third-party contract manufacturer to supply the drug substance for ANG-3070 and to manufacture all clinical trial supplies of ANG-3070. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the facilities at which ANG-3070 or any of our other product candidates are manufactured must be the subject of a satisfactory inspection before the FDA or the regulators in other jurisdictions approve the product candidate manufactured at that facility. We are completely dependent our third-party vendors for compliance with the current Good Manufacturing Practice requirements (cGMPs). requirements of United States and non-United States regulators for the manufacture of our active ingredients, drug products, and finished products. If our manufacturers cannot successfully manufacture material conforming to our specifications and cGMPs of any applicable governmental agency, our product candidates will not be approved or, if already approved, may be subject to recalls or demands by regulatory agencies to stop selling the product until manufacturing issues are resolved.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured the product candidates, including:</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.55pt">the possibility we are unable to enter into a manufacturing agreement with a third party to manufacture our product candidates;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the possible breach of the manufacturing agreements by the third parties because of factors beyond our control; and</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the possibility of termination or nonrenewal of the agreements by the third parties before we are able to arrange for a qualified replacement third-party manufacturer.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors could delay the development or approval of our product candidates, cause us to incur higher costs or prevent us from developing our product candidates successfully. Furthermore, if the supply chain for our clinical trial materials is interrupted or if any of our contract manufacturers fail to deliver the required clinical trial supplies on a timely basis and at commercially reasonable prices and we are unable to find one or more replacement manufacturers capable of production at a substantially equivalent cost, in substantially equivalent volumes and quality and on a timely basis, we may be unable to supply our clinical trial programs with clinical trial materials which could delay our programs and increase our costs.  For instance, we are conducting our ongoing Phase 2 of ANG-3070 in certain countries in Eastern Europe, namely Georgia, Bulgaria, and Lithuania.  If our supply chain in the region is interrupted for any reason, including the current war in Ukraine, the dosing of patients in our Phase 2 clinical trial could be slowed, delayed or stopped.  Further, such challenges could be compounded by the COVID-19 pandemic.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in structure of or funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed in a timely manner, which could negatively impact our business.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel, the maintenance of regulatory review timelines, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. The lack of appropriate funding or appropriate resource for the FDA, could have material adverse effect on our ability to develop ANG-3070 and our product candidates. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have and may continue to conduct future clinical trials outside of the United States. The FDA and other regulatory authorities may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are enrolling or plan to enroll patients in our Phase 2 clinical trial of ANG-3070 for PPKD in Georgia, Australia, Lithuania, Bulgaria, Spain, Italy and potentially other jurisdictions under separate clinical trial applications in such jurisdictions. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA. For example, the FDA requires the clinical trial to have been conducted in accordance with GCPs, and the FDA must be able to validate the data from the clinical trial through an onsite inspection if it deems such inspection necessary. In addition, when clinical trials are conducted only at sites outside of the United States, such trials may not be subject to IND review, meaning the FDA may not provide advance comment on the clinical protocols for the trials, and therefore there is an additional potential risk that the FDA could determine that the study design or protocol for a non-U.S. clinical trial was inadequate, which would likely require additional clinical trials in order to seek FDA approval. If the FDA does not </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accept data from our clinical trials of ANG-3070 and any future product candidates conducted outside the United States, it would likely result in the need for additional clinical trials, which would be costly and time consuming and delay or permanently halt our development of ANG-3070 and any future product candidates.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting clinical trials outside the United States also exposes us to additional risks, including risks associated with:</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">additional foreign regulatory requirements;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">foreign exchange fluctuations;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">patient monitoring and compliance;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">compliance with foreign manufacturing, customs, shipment and storage requirements;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">cultural differences in medical practice and clinical research; </span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">diminished protection of intellectual property in some countries, and</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">operational risks resulting from war and conflict certain countries or in proximity to the countries in which we are conducting our clinical trials.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If manufacturers obtain approval for generic versions of our products or product candidates, our business will be materially harmed.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our industry, much of an innovative product's commercial value is realized while it has patent protections and market exclusivity. When market exclusivity expires generic versions of the product can be approved and marketed, and there can be substantial decline in the innovative product's sales.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market exclusivity for our products is based upon patent rights and certain regulatory forms of exclusivity. If we are unable to secure or maintain our exclusivities, we may face generic competition that could materially impede our ability to effectively commercialize our products, including be reducing the price we can charge and reducing our market share.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANG-3070 and our other product candidates are protected by a number of granted and pending patent applications, and may be entitled to certain regulatory exclusivities if approved.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some countries, patent protections for our products may not exist because certain countries did not historically offer the right to obtain specific types of patents or we did not file patents in those markets. Also, the patent environment is unpredictable and the validity and enforceability of patents cannot be predicted with certainty.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, with regard to the potential for generic entry in the United States, under the U.S. Food, Drug and Cosmetic Act (FDCA) the FDA can approve an Abbreviated New Drug Application (ANDA) for a generic version of an approved branded drug without the ANDA applicant undertaking the clinical testing necessary to obtain approval to market a new drug. Generally, in place of such clinical studies, an ANDA applicant needs only to submit data demonstrating that its product has the same active ingredient(s), strength, dosage form, route of administration and that it is bioequivalent to the approved product.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDCA requires that an ANDA applicant certify either that its generic product does not infringe any of the patents listed by the owner of the branded drug in the Orange Book or that those patents are not enforceable. This process is known as a paragraph IV certification. Upon notice of a paragraph IV certification, a patent owner or NDA holder has 45 days to bring a patent infringement suit in federal district court against the company seeking ANDA approval of a product covered by one of the owner's patents. If this type of suit is commenced, the FDCA provides a 30-month stay on the FDA's approval of the competitor's application. If the litigation is resolved in favor of the ANDA applicant or the challenged patent expires during the 30-month stay period, the stay is lifted and the FDA may thereafter approve the application based on the standards for approval of ANDAs. Once an ANDA is approved by the FDA, the generic manufacturer may market and sell the generic form of the branded drug in competition with the branded medicine.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ANDA process can result in generic competition if the patents at issue are not upheld or if the generic competitor is found not to infringe the owner's patents. If this were to occur with respect to any of our product candidates after approval, our business could be materially harmed.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Collaborations and Commercialization of Our Product Candidates</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are able to develop and obtain regulatory approval for any of our product candidates, our business will be materially harmed if we are unable to successfully commercialize such approved products. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we receive regulatory approval of any product candidate, including ANG-3070, it is uncertain whether we will be able to successfully commercialize such product. Our marketing of any approved product will be limited to the product&#8217;s approved use and potentially subject to other limitations as set forth in its approved prescribing information and package insert. Accordingly, we cannot ensure any of our future approved products will be successfully developed, approved or commercialized. If we are unable to successfully commercialize our future approved products, we may not be able to generate sufficient revenue to operate our business. In particular, the future commercial success of any approved product is subject to a number of risks, including the following:</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the emergence of unknown side effects causing an approved drug to be taken off the market;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the receipt of market acceptance by physicians, hospitals, payers and patients; </span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">our ability to obtain meaningful pricing and reimbursement for any approved product, and</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">our ability to obtain, maintain or enforce our patents and other intellectual property rights related to our approved products.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our existing collaborations as well as additional collaboration arrangements we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our product candidates.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed certain rights with respect to ANG-3777 to Vifor Pharma, and in the future we may seek additional collaboration arrangements for the commercialization, or potentially for the development, of certain of our product candidates depending on the merits of retaining development and/or commercialization rights for ourselves as compared to entering into collaboration arrangements. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our existing and any future collaboration arrangements, will depend heavily our ability with our collaborators to develop and obtain approval of the any licensed product or product candidate and on the efforts and activities of our collaborators.  For instance, in November 2020, we entered into a license agreement (the Vifor License) with Vifor International, Ltd. (Vifor Pharma), granting Vifor Pharma global rights (excluding Greater China) to develop, manufacture and commercialize ANG-3777 in all therapeutic, prophylactic and diagnostic uses for renal indications and congestive heart failure. Pursuant to the Vifor License, we are eligible to receive certain clinical, post-approval, or sales milestone payments, and/or royalties, based upon the clinical development plan for ANG-3777 set forth in Vifor License. However, we do not expect to receive any such payments as we do not intend to continue to pursue the clinical development plan for ANG-3777 set forth in the Vifor License, which had included a Phase 3 study for CSA-AKI and a Phase 4 confirmatory study in DGF, for ANG-3777 based upon clinical trial results for ANG-3777 disclosed in the fourth quarter of 2021.    </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, our dependence on collaborative arrangements subjects us to a number of risks, including the risk we may never receive substantial economic benefit from the arrangements, we may not be able to control the amount and timing of resources our collaborators may devote to the product candidates; our collaborators may experience financial difficulties; business combinations or significant changes in a collaborator's business strategy may also adversely affect a collaborator's willingness or ability to complete its obligations under any arrangement; and collaboration arrangements may be terminated or allowed to expire, which would delay the development and may increase the cost of developing our product candidates. Any of these outcomes could harm our business.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, to the extent we decide to enter into additional collaboration agreements in the future, we may face significant competition in seeking appropriate collaborators. Moreover, collaboration arrangements are complex and time-consuming to negotiate, document, implement and maintain. We may not be successful in our efforts to prudently manage our existing collaborations or to enter new ones should we chose to do so. The terms of new collaborations or other arrangements that we may establish may not be favorable to us. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to develop market opportunities for ANG-3070 or any future products are smaller than we believe they are, our potential to generate revenue may be adversely affected, and our business may suffer.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The precise incidence and prevalence for all the conditions we currently or may intend to address with ANG-3070 or any future product candidates are unknown. Our projections of both the number of people who have the diseases we target, as well as the subset of people with these diseases who have the potential to benefit from </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treatment of ANG-3070 or any future product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics or market research, and may prove to be incorrect. Further, new trials may change the estimated incidence or prevalence of these diseases. The total addressable market across ANG-3070 and any future product candidates will ultimately depend upon, among other things, the diagnosis criteria included in the final label for each of ANG-3070 and any future product candidates approved for sale for these indications, the availability of alternative treatments and the safety, convenience, cost and efficacy of ANG-3070 and any future product candidates relative to such alternative treatments, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients in the United States and other major markets and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Business and Strategy</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. We have competitors in the United States, Europe, and other jurisdictions, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical and generic drug companies, and universities and other research institutions. Many of our competitors have greater financial and other resources, such as larger research and development staff and more experienced marketing and manufacturing organizations. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients, and manufacturing pharmaceutical products. These companies also have significantly greater research, sales, and marketing capabilities and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds potentially making the product candidates we develop obsolete. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or FDA approval or discovering, developing, and commercializing drugs for kidney, heart, liver, lung and other diseases we are targeting before we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. In addition, many universities and private and public research institutes may become active in our target disease areas.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to ANG-3070, Tarpeyo&#174; (budesonide) from Calliditas was granted accelerated approved by the FDA for IgAN, one form of PPKD. Phase 3 programs in PPKD include Atrasentan from Chinook Pharmaceuticals (IgAN, FSGS, Alport), Bardoxolone methyl from Reata Pharmaceuticals (Alport), Iptacopan from Novartis (IgAN), Narsoplimab form Omeros (IgAN), Sibeprenlimab from Visterra/Otsuka Pharmaceuticals (IgAN), Sparsenten from Travere Therapeutics (IgAN, FSGS), and DMX-200 from Dimerix (FSGS). There are two approved therapies, pirfenidone (Esbriet&#174;, sold by Roche/Genentech) for IPF and nintedanib (OFEV&#174;, sold by Boehringer-Ingleheim) for IPF and SSc-ILD. Phase 3 clinical programs potentially competitive with ANG-3070 in IPF include ORG-447 from Agomab Therapeutics, PLN-74809 from Pliant Therapeutics, PRM-151 from Roche/Genentech, and Taladegib from Endeavor Biosciences for IPF.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to competition for our ROCK2 inhibitor, netarsudil ophthalmic solution from Aerie Pharmaceuticals, Inc. was first approved by the FDA in 2017 as a topical agent for reducing intraocular pressure in patients with open-angle glaucoma and ocular hypertension. Other competition in clinical development include Kadmon Holdings, Inc.'s belumosudil (KD025), a ROCK2 inhibitor with reduced selectivity against ROCK1, in the clinic for several indications, including chronic graft versus host disease, systemic sclerosis and IPF. CXC007 from Redx Pharma is in Phase 1 trials. We are also aware of other ROCK2 inhibitors in preclinical development.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regarding competition for our CYP11B2 inhibitor, CIN-107 from CinCor Pharma is in multiple Phase 2 trials for resistant hypertension, uncontrolled hypertension, and primary aldosteronism. PB6440 from PhaseBio is preparing for Phase 1 trials in 2022 in treatment resistant hypertension</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our ability to successfully compete will depend on, among other things:</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">our ability to recruit and enroll patients for our clinical trials;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">our ability to design and successfully execute appropriate clinical trials;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">our ability to gain and to maintain positive relationships with regulatory authorities;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the efficacy, safety, and reliability of our product candidates;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the speed at which we develop our product candidates;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">our ability to commercialize and market any of our product candidates receiving regulatory approval;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the pricing of our products;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">adequate levels of reimbursement by government entities and by private health insurance plans;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">our ability to protect intellectual property rights and regulatory exclusivities related to our products;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">our ability to manufacture and sell commercial quantities of any approved products to the market; and</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">acceptance of our product candidates by downstream customers, including physicians, other healthcare providers, pharmacists, and patients.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our competitors market products more effective, safer, or less expensive than our products or product candidates, or if any, or these products reach the market sooner we may not achieve commercial success. In addition, the biopharmaceutical industry is characterized by rapid technological change. It may be difficult for us to stay abreast of the rapid changes in each area of research and development. If we fail to stay at the forefront of change, we may be unable to compete effectively. Products developed by our competitors may render our product candidates or products obsolete, less competitive or not economical.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently depend on single third-party suppliers for the manufacture and supply of drug substance and potential future commercial product supplies for our product candidates, and any performance failure on the part of our supplier could delay the development and potential commercialization of our product candidates.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that our drug substance supplier will continue to provide us with sufficient quantities of drug substance, or that our manufacturers will be able to produce sufficient quantities of drug product incorporating such drug substance, to satisfy our anticipated specifications and quality requirements, or that such quantities can be obtained at pricing necessary to sustain acceptable pharmaceutical margins for any of our product candidates, if approved. Our current dependence on a single supplier for our drug substance and the challenges we may face in obtaining adequate supply of drug substance involves several risks, including limited control over pricing, availability, quality and delivery schedules, and such risks may be heightened as a result of the COVID-19 pandemic. Any supply interruption in drug substance or drug product could materially harm our ability to complete our development program for such indications. In addition, any supply interruption in drug substance or drug product could materially harm our ability to complete our other development programs or satisfy commercial demand, if approved, until a new source of supply, if any, could be identified and qualified. For instance, we are conducting our ongoing Phase 2 of ANG-3070 in certain countries in Eastern Europe, namely Georgia, Bulgaria, and Lithuania. If our supply chain in the region is interrupted for any reason, including the current war in Ukraine, the dosing of patients in our Phase 2 clinical trial could be slowed, delayed or stopped. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on the part of our suppliers could delay the development and potential commercialization of our product candidates, including limiting supplies necessary for clinical trials and regulatory approvals, which would have a material adverse effect on our business.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, our current supplier of drug substance may not have the capacity to manufacture drug substance in the quantities that we believe will be sufficient to meet our future clinical needs or, in the case of any of our wholly-owned product candidates and those for which we retain the right to commercialize, anticipated market demand or to enable us to achieve the economies of scale necessary to reduce the manufacturing cost of applicable drug substance. While we are currently engaged in discussions with a potential second supplier for clinical and commercial drug substance, such negotiations may not lead to a definitive agreement on acceptable terms, or at all, which could have a material adverse effect on our business. With respect to any of our wholly-owned product candidates and those for which we retain the right to commercialize, we expect that we will be able to develop a supply chain with multiple suppliers and significantly decrease our cost of goods within the first several years of commercialization following the receipt of any approvals. However, if our contract manufacturer for drug substance is unable to source, or we are unable to purchase, sufficient quantities of materials necessary for the production of the drug substance for such product candidates, the ability of such product candidates to reach their market potential or to be timely launched, would be delayed or suffer from a shortage in supply, which would impair our ability to generate revenue from sales. If there is a disruption to our contract manufacturers' or suppliers' relevant operations, we could have no other means of producing drug substance until they restore the affected facilities or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we or they procure alternative manufacturing facilities. Additionally, any damage to or destruction of our contract manufacturers' or suppliers' facilities or equipment may significantly impair our ability to manufacture drug substance for our product candidates on a timely basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on third-party contractors for a substantial portion of our operations and may not be able to control their work as effectively as if we performed these functions ourselves. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for or commercialize our product candidates, if approved.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We outsource substantial portions of our operations to third-party service providers, including the conduct of preclinical studies and clinical trials, collection and analysis of data, and manufacturing. Our agreements with third-party service providers and CROs are on a study-by-study and project-by-project basis. Typically, we may terminate the agreements with notice and are responsible for the supplier's previously incurred costs. In addition, any CRO we retain will be subject to the FDA's and EMA's regulatory requirements and similar standards outside of the United States and Europe, and we do not have direct control over compliance with these regulations by these providers. Consequently, if these providers do not adhere to applicable governing practices and standards, the development and commercialization of our product candidates could be delayed or stopped, which could severely harm our business and financial condition.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have relied on third parties, our internal capacity to perform these functions is limited to contractual oversight. Outsourcing these functions involves the risk third parties may not perform to our standards, may not produce results in a timely manner or may fail to perform at all. This challenge has been made more difficult by the COVID-19 pandemic and resulting shelter-in-place and stay-at-home restrictions, which are driving greater dependency on electronic monitoring of trial sites. Such monitoring can be less reliable and creates additional exposure to data privacy and cybersecurity issues. Additionally, the facilities at which any of our product candidates are manufactured must be the subject of a satisfactory inspection before the FDA or the regulators in other jurisdictions approve the product candidate manufactured at that facility. We are completely dependent our third-party vendors for compliance with cGMP requirements of United States and non-United States regulators for the manufacture of our finished products. If our manufacturers cannot successfully manufacture material conforming to our specifications and cGMPs of any applicable governmental agency, our product candidates will not be approved or, if already approved, may be subject to recalls or demands by regulatory agencies to stop selling the product until manufacturing issues are resolved. In addition, our third-party service providers and CROs that perform nonclinical studies and clinical trials on our behalf must comply with applicable Good Laboratory Practice (GLP) requirements for animal testing and GCP requirements for clinical trials, where any failure to comply with such requirements could result in the FDA or other regulatory authorities refusing to accept data obtained in violation of such requirements and possibly initiating other enforcement action against us and our contractors.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our consultants monitor our third parties for performance and adherence to protocols. We have had to replace clinical sites because of poor enrollment. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties (including sensitive data such as personal information or clinical data), which could increase the risk this information will be misappropriated or compromised in connection with a security breach, cyber-attack or other security incident. There are a limited number of third-party service providers specializing in or having the expertise required to achieve our business objectives. Identifying, qualifying, and managing performance of third-party service providers can be difficult, time consuming, and cause delays in our development programs. We currently have a relatively small number of employees, which limits the internal resources we have available to identify and monitor third-party service providers. To the extent we are unable to identify, retain, and successfully manage the performance of third-party service providers in the future, our business may be adversely affected, and we may be subject to the imposition of civil or criminal penalties if their conduct of clinical trials violates applicable law.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to maintain a good relationship with our employees to maintain our operations. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A deterioration in our relationships with our employees could have an adverse impact on our business.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 4, 2022, we announced a reduction in force impacting somewhat less than half of our employees. Our decision to engage in this reduction results from an assessment of our internal resources needs, given the results of the Phase 3 study of ANG-3777 in patients at risk for DGF would likely not support a regulatory approval in that population and the results from a Phase 2 trial in CSA-AKI would not support a Phase 3 trial in the indication. This reduction was a cost-cutting measure across the organization to support our 2022 primary focus on the clinical </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development of its investigational asset ANG-3070, a highly selective, oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, particularly in the kidney and lung, as well as advancing preclinical assets to IND-enabling studies. This has caused substantial uncertainty as to job security for the rest of our employees. Maintaining good relationships with our employees and operating effectively and efficiently across our organization are crucial to our operations and our success. If we are unable to successfully maintain such relationships or manage the uncertainty as a result of the reduction in the number of our employees, and the complexity of operations, our business may be adversely affected. See "Item 1. Business&#8212;Human Capital Resources."</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to manage our business effectively if we are unable to attract and retain key personnel and consultants.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to attract or retain qualified management, finance, scientific, clinical, and commercial personnel and consultants due to the intense competition for qualified personnel and consultants among biotechnology, pharmaceutical, and other businesses. If we are not able to attract and retain necessary personnel and consultants to accomplish our business objectives, we may experience constraints significantly impeding the achievement of our development objectives, our ability to raise additional capital, and our ability to implement our business strategy.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent upon our senior management, particularly our Chief Executive Officer, Dr. Jay Venkatesan, as well as on the development, regulatory, commercialization, and business development expertise of the rest of our senior management and other senior personnel across preclinical, clinical, translational medicine, legal, and regulatory affairs. If we lose one or more of our executive officers or key employees or consultants, our ability to implement our business strategy successfully could be seriously harmed. Any of our executive officers, key employees, or consultants may terminate their employment and/or engagement with us at any time. Replacing executive officers, key employees, and consultants may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of, and commercialize products successfully. Competition to hire and retain employees and consultants from this limited pool is intense, and we may be unable to hire, train, retain, or motivate these additional key personnel and consultants. Our failure to retain key personnel or consultants could materially harm our business.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have scientific and clinical advisors and consultants who assist us in formulating and implementing our research, development, and clinical strategies. These advisors are not our employees and may have commitments to, or consulting or advisory contracts with, other entities limiting their availability to us and typically they will not enter into non-compete agreements with us. If a conflict of interest arises between their work for us and their work for another entity, we may lose their services. In addition, our advisors may have arrangements with other companies to assist those companies in developing products or technologies competitive with ours.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect a number of factors to cause our operating results to fluctuate on a quarterly and annual basis, which may make it difficult to predict our future performance.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical -stage biopharmaceutical company that has been operating since 1998. Our operations to date have been limited to researching and developing product candidates, including conducting preclinical studies and clinical trials. We have not yet obtained regulatory approvals for any of our product candidates. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a longer operating history or approved products on the market. Our financial condition and operating results are expected to significantly fluctuate from quarter-to-quarter or year-to-year due to a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these fluctuations include, but are not limited to:</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the timing and cost of, and level of investment in, research, development, including the needs for additional clinical trials, and, if approved, commercialization activities relating to our product candidates, which may change from time to time;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">delay in or the success of our clinical trials through all phases of clinical development, including our ongoing clinical trials of ANG-3070; </span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">potential adverse events associated with our product candidates potentially delaying or preventing approval or causing an approved drug to be taken off the market;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">any delays in regulatory review and approval by regulatory authorities of our product candidates in clinical development, including ANG-3070;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">our ability to obtain additional funding to develop our product candidates;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">our ability to commercialize and obtain market acceptance and reimbursement for our approved products; and</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">our dependency on third-party manufacturers to manufacture and distribute our products and key ingredients.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for a product candidate and may have to limit its commercialization.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of our product candidates in clinical trials and the sale of any products for which we may obtain marketing approval expose us to the risk of product liability claims. Product liability claims may be brought against us or our collaborators by participants enrolled in our clinical trials, patients, healthcare providers, or others using, administering, or selling our products. If we cannot successfully defend ourselves against any such claims, we would incur substantial liabilities. Regardless of merit or eventual outcome, product liability claims may result in:</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.55pt">withdrawal of clinical trial participants;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">termination of clinical trial sites or entire trial programs;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">costs of related litigation;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">substantial monetary awards to patients or other claimants;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">decreased demand for our product candidates and loss of revenues;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">impairment of our business reputation;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">diversion of management and scientific resources from our business operations; and</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the inability to commercialize our product candidates.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained limited product liability insurance coverage for our clinical trials in the United States and in selected other jurisdictions where we are conducting clinical trials. Our insurance coverage may not reimburse us or may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to product liability. Large judgments have been awarded in class action lawsuits based on drugs with unanticipated side effects. A successful product liability claim or series of claims brought against us, particularly if judgments exceed our insurance coverage, could decrease our cash resources and adversely affect our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include property, general liability, employment benefits liability, business automobile, workers' compensation, products liability, malicious invasion of our electronic systems, and clinical trials (U.S. and foreign), and directors' and officers', employment practices and fiduciary liability insurance. We do not know, however, if we will be able to maintain insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our financial position and results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Under the terms of the government grant funding we have received, the government may compel us to license to a third party, or suspend, terminate or withhold grant funding.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant amount of our discovery and initial clinical research has been funded principally by United States government grants and contracts. As with all other pharmaceutical research programs supported in part by federal research dollars, conducting research under federal grants required us to grant the U.S. government a nonexclusive, nontransferable, irrevocable, paid-up license for the government to practice or have the invention practiced on its behalf throughout the world. Under certain circumstances, the government can require the grantee to license a third party, or the government may take title and grant a license itself, known as march-in rights, which may occur if the invention is not brought to practical use within a reasonable time, if health or safety issues arise, if public use of the invention is in jeopardy, or if other legal requirements are not satisfied. Although, to our knowledge, the U.S. government has never forced a grantee to license a third party or taken title and granted a license itself, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">these march-in rights are available to the government, and we cannot assure you that the government will not exercise such rights in the future.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms and conditions of the government grant funding, we are obligated to comply with various reporting requirements and to take certain administrative actions. Material noncompliance with the terms and conditions of the grant funding may result in one or more enforcement actions by the grant agency. These enforcement actions include denying funds for the cost of funded activities, suspending the grant in whole or in part, pending corrective action, and withholding further grant awards. The grant agency may also terminate the grant for cause, or take other legally available remedies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset a portion of future taxable income, if any, until such unused losses expire, if ever. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an "ownership change," generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a rolling three-year period, the corporation's ability to use its pre-change net operating loss carryforwards (NOLs) and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income or taxes may be limited. We have not performed an analysis to assess whether an ownership change has occurred. There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs, or other unforeseen reasons, our existing NOLs could expire or otherwise become unavailable to offset future income tax liabilities. Under the TCJA, as modified by the Coronavirus Aid, Relief and Economic Security Act (the CARES Act), the amount of post-2017 NOLs that are permitted to deduct from U.S. federal income taxes for tax years beginning after December 31, 2020 is limited to 80% of our taxable income in such year, where taxable income is determined without regard to the NOL deduction itself. The TCJA, as modified by the CARES Act, generally eliminates the ability to carry back any NOLs to prior taxable years for tax years beginning after December 31, 2020, while allowing post-2017 unused NOLs to be carried forward indefinitely without expiration. Additionally, state NOLs generated in one state cannot be used to offset income generated in another state. For these reasons, even if we attain profitability, we may be unable to use a material portion of our NOLs and other tax attributes.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any claims relating to improper handling, storage or disposal of hazardous materials used in our business could be costly and delay our research and development efforts.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities involve the controlled use of potentially harmful hazardous materials, including volatile solvents and chemicals causing cancer. Our operations also produce hazardous waste products. We face the risk of contamination or injury from the use, storage, handling or disposal of these materials. We are subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. The cost of compliance with these laws and regulations could be significant, and current or future environmental regulations may impair our research, development or production efforts. If one of our employees were accidentally injured from the use, storage, handling, or disposal of these materials, the medical costs related to their treatment would be covered by our workers' compensation insurance policy. However, we do not carry specific hazardous waste insurance coverage and our general liability insurance policy specifically excludes coverage for damages and fines arising from hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be subject to criminal sanctions or fines or be held liable for damages, our operating licenses could be revoked, or we could be required to suspend or modify our operations and our research and development efforts.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Intellectual Property</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection. If our patent position and potential regulatory exclusivity do not adequately protect our product candidates, others could compete against us more directly, which would harm our business, possibly materially.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection of our current and future product candidates, and their methods of manufacture and use. Our ability to stop third parties from making, using, selling, offering to sell or importing our product candidates is dependent upon the extent to which we have rights under valid and enforceable patents and/or trade secrets that cover these </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activities. The patent positions of biotechnology and pharmaceutical companies can be highly uncertain and involve complex legal and factual questions. No consistent policy regarding the breadth of claims allowed in pharmaceutical patents has emerged to date in the United States or in many jurisdictions outside of the United States. Changes in either the patent laws or interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be issued in relevant jurisdictions from our present or future patent filings, or those we license from third parties, and further cannot predict the extent to which we will be able to enforce such issued claims in jurisdictions important to our business. If any patents we obtain or license are deemed invalid and unenforceable, our ability to commercialize or license our technology could be adversely affected.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that others have filed, and in the future may file, patent applications covering products and technologies that are similar, identical or competitive to ours, or that are otherwise important to our business. We cannot be certain that any patent filings owned by a third party will not have priority over patent applications filed or in-licensed by us, or that we or our licensors will not be involved in interference, opposition or invalidity proceedings before United States or foreign patent offices. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, and/or could allow third parties to commercialize our technology or products and compete directly with us, without payment to us. Furthermore, third party filings may issue as patents that are infringed by our manufacture or commercialization of our products. Licenses may not be available to such third party patents, and challenges to their validity or infringement may be expensive and may not succeed. If the breadth or strength of protection provided by our patents and patent applications is threatened, or if we are perceived or found to infringe intellectual property rights of others, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates, and could impede or preclude our ability to commercialize our products.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. We may become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, any of which could limit our ability to stop others from using or commercializing similar or identical technology and products, and/or limit the duration of the patent protection of our technology and products.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">we might not have been the first to make the inventions covered by our pending patent applications or patents;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">others may be able to develop a product similar to, or better than, ours in a way that is not covered by the claims of our patents;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">we might not have been the first to file patent applications for these inventions;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">others may independently develop similar or alternative technologies or duplicate any of our technologies;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">any patents that we have or obtain may not provide us with any competitive advantages;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">patents have limited term and geographic scope; we may not be able to secure patents that last long enough and are in relevant jurisdictions to effectively limit competition;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">we may not develop additional proprietary technologies that are patentable; or</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the patents of others may have an adverse effect on our business.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Without patent protection for our compounds, pharmaceutical compositions, or formulations of our product candidates, our ability to stop others from using or selling our product, or other competitive products including our compounds, may be limited.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the patent applications we hold or have in-licensed with respect to present or future product candidates fail to issue, if their breadth and/or strength of protection is limited or challenged, or if they fail to provide meaningful exclusivity for present or future product candidates, it could dissuade companies from collaborating with us to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">develop future candidates and threaten our ability to commercialize future commercial products. Any such outcome could have a materially adverse effect on our business.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or feasible. However, trade secrets are difficult to protect. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific collaborators, and other advisors may unintentionally or willfully disclose our information to competitors. Enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain protection under the Hatch-Waxman Act and similar legislation outside of the United States by extending the patent terms and obtaining data exclusivity for our product candidates, our business may be materially harmed.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, if any, one or more of our United States patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, we may not be granted an extension of patent term because, for example, of failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than what we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any trademarks we may obtain may be infringed or successfully challenged, resulting in harm to our business.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to rely on trademarks as one means to distinguish any of our product candidates that are approved for marketing from the products of our competitors. We have not yet selected trademarks for our product candidates, and have not yet begun the process of applying to register trademarks for our product candidates. Once we select trademarks and apply to register them, our trademark applications may not be approved. Third parties may oppose our trademark applications or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks, and we may not have adequate resources to enforce our trademarks.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, any proprietary name we propose to use with our product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States has enacted and implemented wide-ranging patent reform legislation. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the U.S. Congress, the Federal Courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce patents that we have obtained or licensed, or that we might obtain or license in the future. Similarly, changes in patent law and regulations in other countries or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have obtained or licensed or that we may obtain or license in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we choose to go to court to stop another party from using the inventions claimed in any patents we obtain, that individual or company has the right to ask the court to rule that such patents are invalid or should not be enforced against that third party. These lawsuits are expensive, would consume time and resources and would divert the attention of managerial and scientific personnel even if we were successful in stopping the infringement of such patents. In addition, there is a risk the court will decide that such patents are not valid and we do not have the right to stop the other party from using the inventions. There is also a risk that, even if the validity of such patents is upheld, the court will refuse to stop the other party on the grounds that such other party's activities do not infringe our patents. In addition, the United States Supreme Court has recently modified some tests used by the USPTO in granting patents over the past 20 years, which may decrease the likelihood that we will be able to obtain patents and increase the likelihood of challenge of any patents we obtain or license.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us from commercializing or increase the costs of commercializing our product candidates.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend in part on our ability to operate without infringing the proprietary rights of third parties. We cannot guarantee that our products or product candidates, or their manufacture or use, will not infringe third-party patents. Furthermore, a third party may claim we or our manufacturing or commercialization collaborators are using inventions covered by the third party's patent rights. It is also possible a third party might allege our products or product candidates, or their manufacture or use, incorporate or rely on trade secrets improperly received from the third party. A third party alleging violations of their intellectual property rights may go to court to stop us from engaging in our normal operations and activities, including making or selling our product candidates. Defense of such claims, regardless of their merit, are costly and could affect our results of operations and divert the attention of managerial and scientific personnel.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is a risk a court would decide that we or our commercialization collaborators are infringing the third party's intellectual property rights and would order us or our collaborators to stop relevant activities. In that event, we or our commercialization collaborators may not have a viable way to avoid the infringement and may need to halt commercialization of the relevant product. In addition, there is a risk a court will order us or our collaborators to pay the other party damages for having infringed the other party's intellectual property rights. In the future, we may agree to indemnify our commercial collaborators against certain intellectual property infringement claims brought by third parties. The pharmaceutical and biotechnology industries have produced a proliferation of patents, and it is not always clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are sued for patent or other intellectual property (e.g., trade secret, trademark, etc.) infringement, we could incur significant costs, and delays in our product development or commercialization.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in order to prevail in a suit alleging patent infringement, we would need to demonstrate that our products or methods either do not infringe the claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving invalidity of a patent is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, which may not be available, defend an infringement action or challenge the validity of the patents in court. Patent litigation is costly and time consuming.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain others have not filed patent applications or obtained issued patents for technology that we need to use to commercialize our products, at least because:</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">some patent applications in the United States may be maintained in secrecy until the patents are issued;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">patent applications in the United States are typically not published until 18 months after the priority date;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">even published patent applications and patents may be difficult or impossible to identify if their records in available databases are incomplete or inaccurate, or are in a language that is not readily amendable to searching in English; and</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">publications in the scientific literature often lag behind actual discoveries.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our most advanced programs are currently in clinical trials. Patent laws of various jurisdictions, including the United States, exempt clinical trial activities, and most or all preclinical work, from patent infringement. These exemptions expire when clinical work is completed and application for a commercialization license (e.g., a New Drug Application) is submitted to a relevant regulatory authority (e.g., the FDA). Accordingly, we cannot be confident that third parties will not allege patent infringement with respect to our existing products or programs merely because they have not yet done so.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors may have filed, and may in the future file, patent applications covering technology like ours. Any such patent application may have priority over our patent applications, which could further require us to obtain rights to issued patents covering such technologies. If another party has filed a United States patent application on inventions similar to ours, we may have to participate in an interference or derivation proceeding declared by the USPTO to determine priority of invention in the United States. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful if, unbeknownst to us, the other party had independently arrived at the same or similar invention prior to our own invention, resulting in a loss of our United States patent position with respect to such inventions, and granting such position to the third party, so that we may need to seek a license from such third party to continue our use of the technologies, which license might not be available, or might impose significant costs.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other countries have similar laws that permit secrecy of patent applications and may be entitled to priority over our applications in such jurisdictions.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may be subject to claims that we are infringing other intellectual property rights, such as trademarks or copyrights, or misappropriating the trade secrets of others, and to the extent that our employees, consultants or contractors use intellectual property or proprietary information owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have sufficient resources to bring actions alleging intellectual property infringement to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter significant delays in bringing our product candidates to market and be precluded from manufacturing or selling our product candidates. Furthermore, even if we are successful in proceedings relating to alleged intellectual property infringement or misappropriation, we may incur substantial costs and divert management's time and attention in pursuing these proceedings, which could have a material adverse effect on us.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our competitors may be able to sustain the costs of complex litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees due to the USPTO and non-United States patent agencies. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an event, our competitors might be able to enter the market and this circumstance could have a material adverse effect on our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Relating to Our Common Stock </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price may be volatile and you may not be able to resell shares of our common stock at or above the price you paid.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock could be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. These factors include those discussed in this "Risk Factors" section of this report and others such as:</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">results from, and any delays in, our clinical trials for ANG-3070;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">results of clinical trials of our competitors' products;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">competition from existing products or new products that may emerge;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">announcements by academic, guideline publishers or other third parties challenging the fundamental premises underlying our approach to treating PPKDs like FSGS and IgAN or IPF;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">failure or discontinuation of any of our research and development programs;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">manufacturing setbacks or delays of or issues with the supply of the materials for ANG-3070;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">announcements relating to future licensing, collaboration or development agreements;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">sales of our common stock by or announcements relating to our existing collaborators, including Vifor Pharma;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">acquisitions and sales of new products, technologies or businesses;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">quarterly variations in our results of operations or those of our future competitors;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">changes in earnings estimates or recommendations by securities analysts;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">announcements by us or our competitors of new products, significant contracts, commercial relationships, acquisitions or capital commitments;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">developments with respect to intellectual property rights;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">our commencement of, or involvement in, litigation;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">changes in financial estimates or guidance, including our ability to meet our future revenue and operating profit or loss estimates or guidance;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">any major changes in our board of directors or management;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">new legislation in the United States or relevant foreign jurisdictions relating to the sale or pricing of pharmaceuticals;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">FDA or other U.S. or foreign regulatory actions affecting us or our industry;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">product liability claims or other litigation or public concern about the safety of ANG-3070;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">market conditions in the pharmaceutical and biotechnology sectors; and</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">general economic conditions in the United States and abroad.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock markets in general, and the markets for pharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that may have been unrelated to the operating performance of the issuer. These broad market fluctuations may adversely affect the trading price or liquidity of our common stock. In the past, when the market price of a stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the issuer. If we were to become involved in securities litigation, we could incur substantial costs and resources and the attention of our management could be diverted from the operation of our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An active, liquid and orderly market for our common stock may not be sustained.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is currently listed on the Nasdaq Global Select Market under the symbol &#8220;ANGN&#8221;. The price for our common stock may vary and an active or liquid market in our common stock may not be sustained. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. An inactive market may also impair our ability to raise capital by selling shares and may impair our ability to acquire other businesses, applications, or technologies using our shares as consideration.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we sell shares of our common stock in future financings, stockholders may experience immediate dilution and, as a result, our stock price may decline.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may, from time to time, issue additional shares of common stock at a discount from the current trading price of our common stock, including pursuant to our 2021 Incentive Award Plan and 2021 Employee Stock Purchase Plan. As a result, our stockholders would experience immediate dilution upon the purchase of any shares of our common stock sold at such discount. In addition, as opportunities present themselves, we may enter into financing or similar arrangements in the future, including the issuance of debt securities, preferred stock or common stock. If we issue common stock or securities convertible into common stock, our common stockholders would experience additional dilution and, as a result, our stock price may decline.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We identified material weaknesses in our internal control over financial reporting and we may identify additional material weaknesses in the future that may cause us to fail to meet our reporting obligations or result in material misstatements of our financial statements. If we fail to remediate any material weaknesses or if we otherwise fail to establish and maintain effective control over financial reporting, our ability to accurately and timely report our financial results could be adversely affected.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have identified control deficiencies in the design and operation of our internal control over financial reporting that constituted material weaknesses. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The material weaknesses identified in our internal control over financial reporting related to (i) insufficient resources with knowledge and expertise in U.S. GAAP to properly evaluate certain complex transactions, including debt instruments and equity instruments; and (ii) insufficient financial reporting and close controls to ensure that incurred expenses are accrued at period end and deliverables from third party contractors are reviewed for accuracy. We have taken a number of actions to remediate these material weaknesses, including engaging SEC compliance and technical accounting consultants to assist in evaluating transactions for conformity with U.S. GAAP; hiring additional finance and accounting personnel to augment accounting staff and to provide more resources for complex accounting matters and financial reporting; and strengthening our financial reporting and close relating to incurred expenses by ensuring our data capture procedures are clearly defined and that responsible personnel, including supervisory personnel, have adequate training regarding the process and expectation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, we are still in the process of implementing these processes and controls and we cannot assure you that these measures will be sufficient to remediate the material weaknesses that have been identified or prevent future material weaknesses or significant deficiencies from occurring.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully remediate the existing material weaknesses in our internal control over financial reporting, or discover additional material weaknesses in the future, the accuracy and timing of our financial reporting, and our stock price, may be adversely affected and we may be unable to maintain compliance with the applicable stock exchange listing requirements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an "emerging growth company" and as a result of the reduced disclosure and governance requirements applicable to emerging growth companies, our common stock may be less attractive to investors.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an "emerging growth company," as defined in Jumpstart Our Business Act of 2012, (JOBS Act), and we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and obtaining stockholder approval of any golden parachute payments not previously approved. In addition, as an "emerging growth company," the JOBS Act allows us to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. We have elected to use this extended transition period under the JOBS Act. As a result, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make comparison of our financials to those of other public companies more difficult. Even after we no longer qualify as an emerging growth company, we may still qualify as a "smaller reporting company" </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which would allow us to take advantage of many of the same exemptions from disclosure requirements including not being required to comply for a period of time with the auditor attestation requirements of Section 404, and reduced disclosure obligations regarding executive compensation in this report and our periodic reports and proxy statements.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an emerging growth company or smaller reporting company.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have completed and may in the future complete related party transactions that were not and may not be conducted on an arm's length basis.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in the past and continue to be party to certain transactions with certain entities affiliated with Dr. Goldberg, director and Chairman Emeritus on our Board, as well as certain of his immediate family members. For instance, in November 2013, we granted Ohr Cosmetics, LLC (Ohr), an affiliated company, an exclusive worldwide license, with the right to sublicense, under our patent rights covering one of our CYP26 inhibitors, ANG-3522, for the use in treating conditions of the skin or hair. We own, and the family of Dr. Goldberg, owns approximately 2.4% and 80.6%, respectively, of the membership interests in Ohr. Dr. Goldberg's son is the manager of Ohr.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rent office and laboratory space in Uniondale, New York from NovaPark LLC (NovaPark), an affiliated company, under a lease that expires on June 20, 2026. The space that we rent is part of an approximately 110,000-square-foot general laboratory and development facility (NovaPark Facility) for biological and chemistry research owned by NovaPark. We own, and Dr. Goldberg, and Rina Kurz, Dr. Goldberg's spouse, own 10%, 45% and 45%, respectively, of the membership interests in NovaPark.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent changes in control or changes in our management without the consent of our board of directors. These provisions include the following:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the required approval of at least 66 2/3% of the shares entitled to vote at an election of directors to adopt, amend or repeal our amended and restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the requirement that a special meeting of stockholders may be called only by our chief executive officer or president or chairperson of the board of directors or by the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders' meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror's own slate of directors or otherwise attempting to obtain control of us.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to the anti-takeover provisions contained in Section 203 of the Delaware General Corporation Law. Under Section 203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction. For a description of our capital stock, see "Description of Capital Stock."</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws provide for an exclusive forum in the Court of Chancery of the State of Delaware for certain disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws provide that the Court of Chancery of the State of Delaware (or, in the event that the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of fiduciary duty, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our amended and restated certificate of incorporation and amended and restated bylaws also provide that the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action against us or any of our directors, officers, employees or agents and arising under the Securities Act. Nothing in our amended and restated certificate of incorporation or amended and restated bylaws precludes stockholders that assert claims under the Exchange Act from bringing such claims in state or federal court, subject to applicable law.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe these provisions may benefit us by providing increased consistency in the application of Delaware law and federal securities laws by chancellors and judges, as applicable, particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive-forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. If a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation and amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global credit and financial markets have experienced extreme volatility and disruptions in the past several years, including most recently as a result of the COVID-19 pandemic and the Russian invasion of Ukraine. Such volatility and disruptions have caused and may continue to cause severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be affected by litigation, government investigations and enforcement actions.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently operate in a number of jurisdictions in a highly regulated industry and we could be subject to litigation, government investigation and enforcement actions on a variety of matters in the United States. or foreign jurisdictions, including, without limitation, intellectual property, regulatory, product liability, environmental, whistleblower, false claims, privacy, anti-kickback, anti-bribery, securities, commercial, employment, and other claims and legal proceedings which may arise from conducting our business. Any determination that our operations or activities are not in compliance with existing laws or regulations could result in the imposition of fines, civil and criminal penalties, equitable remedies, including disgorgement, injunctive relief, and/or other sanctions against us, and remediation of any such findings could have an adverse effect on our business operations.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal proceedings, government investigations and enforcement actions can be expensive and time consuming. An adverse outcome resulting from any such proceeding, investigations or enforcement actions could result in significant damages awards, fines, penalties, exclusion from the federal healthcare programs, healthcare debarment, injunctive relief, product recalls, reputational damage and modifications of our business practices, which could have a material adverse effect on our business and results of operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures, reckless and/or negligent conduct or unauthorized activities that violates (i) the laws and regulations of the FDA and other regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities, (ii) manufacturing standards, (iii) federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad and (iv) laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct also could involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, creating fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government-funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations, any of which could have a negative impact on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we engage in an acquisition, reorganization or business combination, we will incur a variety of risks potentially adversely affecting our business operations or our stockholders.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time we have considered, and we will continue to consider in the future, strategic business initiatives intended to further the expansion and development of our business. These initiatives may include </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquiring businesses, technologies, or products or entering into a business combination with another company. If we pursue such a strategy, we could, among other things:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">issue equity securities dilutive to our current stockholders' percentage ownership;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">incur substantial debt straining our operations;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">spend substantial operational, financial, and management resources to integrate new businesses, technologies, and products;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">assume substantial actual or contingent liabilities;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">reprioritize our development programs and even cease development and commercialization of our product candidates; or</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">merge with, or otherwise enter into a business combination with, another company in which our stockholders would receive cash and/or shares of the other company on terms certain of our stockholders may not deem desirable.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we intend to evaluate and consider acquisitions, reorganizations, and business combinations in the future, we have no agreements or understandings with respect to any acquisition, reorganization, or business combination at this time.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security breaches, cyber-attacks or other disruptions or incidents could expose us to liability and affect our business and reputation.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent on our information technology systems and infrastructure for our business. We, our collaborators and our service providers collect, store, and transmit sensitive information including intellectual property, proprietary business information, clinical trial data and personal information in connection with our business operations. The secure maintenance of this information is critical to our operations and business strategy. Some of this information could be an attractive target of criminal attack by third parties with a wide range of motives and expertise, including organized criminal groups, "hacktivists," patient groups, disgruntled current or former employees, nation-state and nation-state supported actors and others. Cyber-attacks are of ever-increasing levels of sophistication, and despite our security measures, our information technology and infrastructure may be vulnerable to such attacks or may be breached, including due to employee error or malfeasance. We have implemented information security measures to protect our systems, proprietary information and sensitive data, including the personal information of clinical trial participants against the risk of inappropriate and unauthorized external use and disclosure and other types of compromise. However, despite these measures, and due to the ever changing information cyber-threat landscape, we cannot guarantee that these measures will be adequate to detect, prevent or mitigate security breaches and other incidents and we may be subject to data breaches through cyber-attacks, malicious code (such as viruses and worms), phishing attacks, social engineering schemes, and insider theft or misuse. Any such breach could compromise our networks and the information stored there could be accessed, modified, destroyed, publicly disclosed, lost or stolen. If our systems become compromised, we may not promptly discover the intrusion. Like other companies in our industry, we have experienced attacks to our data and systems, including malware and computer viruses. Any security breach of other incident, whether real or perceived, would cause us to lose product sales, and suffer reputational damage and loss of customer confidence. Such incidents could result in costs to respond to, investigate and remedy such incidents, notification obligations to affected individuals, government agencies, credit reporting agencies and other third parties, legal claims or proceedings, and liability under our contracts with other parties and federal and state laws that protect the privacy and security of personal information. If a security breach, cyber-attack, or other disruption is the result of state-sponsored activities, it may be considered an "act-of-war", potentially making us ineligible for reimbursement under our insurance policies covering such attacks. Any one of these events could cause our business to be materially harmed and our results of operations would be adversely impacted.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The occurrence of natural disasters, including a tornado, an earthquake, or fire, or any material failure, weakness, interruption, cyber-attack, security incident, war or any other catastrophic event, could disrupt our operations or the operations of third parties who provide vital support functions to us, which could have a material adverse effect on our business, results of operations, and financial condition.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and the third-party service providers on which we depend for various support functions, such as data storage, are vulnerable to damage from catastrophic events, such as power loss, natural disasters, terrorism, physical theft, power loss, war, state-sponsored attacks, telecommunications failure and similar unforeseen events beyond our control, as well as from internal and external security breaches, malware and viruses, denial or degradation of service attacks, ransomware, cyber events and other disruptive problems. Such events could </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">severely disrupt our operations and have a material adverse effect on our business, results of operations, financial condition, and prospects.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a natural disaster, power outage, security incident or other event occurred that prevented us from using all or a significant portion of our offices or other facilities, damaged critical infrastructure such as our data storage facilities, financial systems, or manufacturing resource planning and quality systems, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. In addition, the failure of our systems to operate effectively, maintenance problems, upgrading or transitioning to new platforms, or a breach in security could result in delays and reduce efficiency in our operations. Remediation of such problems could result in significant, unplanned capital investments.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, parties in our supply chain may be operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen, and severe adverse events. If such an event were to affect our supply chain, it could have a material adverse effect on our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to numerous and varying data privacy and security laws, regulations and standards, and our failure to comply could result in penalties and reputational damage.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to domestic and foreign laws and regulations concerning data privacy, information security and the protection of personal information including health information. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues which may affect our business and is expected to increase our compliance costs and exposure to liability. In the United States, numerous federal and state laws and regulations, including state security breach notification laws, federal and state health information privacy laws (including HIPAA), and federal and state consumer protection laws, govern the collection, use, disclosure, and protection of personal information. Each of these laws is subject to varying interpretations by courts and government agencies, creating complex compliance issues for us. For example, the California Consumer Privacy Act (CCPA) went into effect January 1, 2020. The CCPA, among other things, imposes new data privacy obligations on covered companies and provides expanded privacy rights to California residents, including the right to access, delete and opt out of certain disclosures of their information. The CCPA provides for civil penalties for violations, as well as a private right of action with statutory damages for certain data breaches, which may increase the frequency and likelihood of data breach litigation. Although the law includes limited exceptions, including for "protected health information" maintained by a covered entity or business associate, such exceptions may not apply to all of our operations and processing activities. Further, the California Privacy Rights Act (CPRA), recently passed in California. The CPRA imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It also creates a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. In addition, the CCPA has prompted a number of proposals for new federal and state privacy legislation that, if passed, could increase our potential liability, increase our compliance costs and adversely affect our business. If we fail to comply with applicable laws and regulations we could be subject to penalties or sanctions, including criminal penalties if we knowingly obtain or disclose individually identifiable health information in a manner that is not authorized or permitted by HIPAA or applicable state laws.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also or may become subject to rapidly evolving data protection laws, rules and regulations in foreign jurisdictions, including Canada, Australia, Brazil, Georgia and Europe. For example, the European Union General Data Protection Regulation (GDPR) governs certain collection and other processing activities involving personal data about individuals in the European Economic Area and the United Kingdom. Among other things, the GDPR imposes requirements regarding the security of personal data, the rights of data subjects to access and delete personal data, requires having lawful bases on which personal data can be processed and transferred outside of the European Economic Area, requires changes to informed consent practices, and requires more detailed notices for clinical trial participants and investigators. In addition, the GDPR imposes substantial fines for breaches and violations (up to the greater of &#8364;20 million or 4% of our annual global revenue). The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR. Relatedly, following </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the United Kingdom's withdrawal from the European Economic Area and the European Union, and the expiry of the transition period, companies will have to comply with the GDPR and the GDPR as incorporated into United Kingdom national law, the latter regime having the ability to separately fine up to the greater of &#163;17.5 million or 4% of global turnover. The relationship between the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, for example around how data can lawfully be transferred between each jurisdiction, which exposes us to further compliance risk.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with U.S. and foreign privacy and security laws, rules and regulations could require us to take on more onerous obligations in our contracts, require us to engage in costly compliance exercises, restrict our ability to collect, use and disclose data, or in some cases, impact our or our partners' or suppliers' ability to operate in certain jurisdictions. Each of these constantly evolving laws can be subject to varying interpretations. If we fail to comply with any such laws, rules or regulations, we may face government investigations and/or enforcement actions, fines, civil or criminal penalties, private litigation or adverse publicity that could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. tax legislation and future changes to applicable U.S. tax laws and regulations may have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in laws and policy relating to taxes may have an adverse effect on our business, financial condition and results of operations. For example, the U.S. government enacted significant tax reform legislation in 2017, which, as modified by the CARES Act, contains, certain provisions which may adversely affect us. Changes include, but are not limited to, a federal corporate income tax rate decrease to 21% for tax years beginning after December 31, 2017, a reduction to the maximum deduction allowed for net operating losses generated in tax years after December 31, 2017, eliminating carrybacks of net operating losses for tax years beginning after December 31, 2020, providing for indefinite carryforwards for losses generated in tax years after December 31, 2017, imposing significant additional limitations on the deductibility of interest, allowing for the accelerated expensing of capital expenditures, and putting into effect the migration from a "worldwide" system of taxation to a largely territorial system. The legislation is unclear in many respects and may continue to be subject to potential amendments, technical corrections, interpretations and implementing regulations by the Treasury and Internal Revenue Service, any of which may mitigate or increase certain adverse effects of the legislation. In addition, it is unclear how these U.S. federal income tax changes will affect state and local taxation. Generally, future changes in applicable U.S. tax laws and regulations, or their interpretation and application could have an adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of our technology and products could be significantly diminished.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, collaborators and other third parties with whom we do business include provisions requiring such parties to assign rights in inventions to us, we may be subject to claims that these employees, or we, have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, validity or enforceability of, or right to use, valuable intellectual property. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information. For example, the FDA, as part of its Transparency Initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that we may </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA's disclosure policies may change in the future, if at all. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The laws of some foreign countries do not protect proprietary rights to the same extent as do the laws of the United States, and we may encounter significant problems in securing and defending our intellectual property rights outside the United States.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in certain countries. The legal systems of certain countries, particularly certain developing countries, do not always favor the enforcement of patents, trade secrets, and other intellectual property rights, particularly those relating to pharmaceutical products, which could make it difficult for us to stop infringement of our patents, misappropriation of our trade secrets, or marketing of competing products in violation of our proprietary rights. Proceedings to enforce our intellectual property rights in foreign countries could result in substantial costs, divert our efforts and attention from other aspects of our business, and put our patents in these territories at risk of being invalidated or interpreted narrowly, or our patent applications at risk of not being granted, and could provoke third parties to assert claims against us. We may not prevail in all legal or other proceedings that we may initiate and, if we were to prevail, the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div id="idee3699378af4447a4091414c0adfaa7_25"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="idee3699378af4447a4091414c0adfaa7_28"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate operations are based in San Francisco, California, our clinical and regulatory operations are based in Newton, Massachusetts, and our discovery and research programs are based in Uniondale, New York. We currently occupy 100 square feet of temporary corporate office space in San Francisco under a bi-monthly lease. We also currently lease 6,157 square feet of clinical and regulatory space in Newton, Massachusetts under a lease that expires in June 2024 and 43,000 square feet of research and discovery space in Uniondale, New York under a lease that expires in June 2026 from NovaPark LLC, a related party. See "Certain Relationships and Related Party Transactions". In addition to these facilities, we rent approximately 2,105 square feet of office space in Fort Lee, New Jersey under a lease expiring in March 2022 and will not be renewed.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our facilities are suitable and adequate for our current needs, and that we will be able to obtain additional space, as needed, on commercially reasonable terms.</span></div><div id="idee3699378af4447a4091414c0adfaa7_31"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings. From time to time, we may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.</span></div><div id="idee3699378af4447a4091414c0adfaa7_34"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="idee3699378af4447a4091414c0adfaa7_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II</span></div><div id="idee3699378af4447a4091414c0adfaa7_40"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock trades under the symbol &#8220;ANGN&#8221; on the Nasdaq Global Select Market and has been publicly traded since February 5, 2021. Prior to this time, there was no public market for our common stock.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Proceeds from the Initial Public Offering and the Concurrent Private Placement</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February&#160;9, 2021, we closed our Initial Public Offering of 5,750,000 shares of our common stock at a public offering price of $16.00 per share, which includes the full exercise by the underwriters (Cowen and Company, LLC, Stifel, Nicolaus &amp; Company, Incorporated, H.C. Wainwright &amp; Co., LLC and Oppenheimer &amp; Co. Inc) of their option to purchase an additional 750,000 shares of common stock. Concurrently, we entered into a stock purchase agreement (the &#8220;Stock Purchase Agreement&#8221;) with Vifor Pharma, pursuant to which we agreed to sell 1,562,500 shares of our common stock to Vifor Pharma at a purchase price of $16.00 per share (the Concurrent Private Placement), equal to the offering price per share in our IPO. All of the shares of common stock issued and sold in our IPO were registered under the Securities Act pursuant to registration statements on Form S-1, as amended (Registration No. 333-252177), which were declared effective by the SEC on February&#160;4, 2021. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Initial Public Offering and Concurrent Private Placement, which both closed on February 9, 2021, generated aggregate net proceeds of approximately $107.0&#160;million, after deducting the underwriting discounts and commissions, private placement fee and estimated offering expenses of $10.0&#160;million. As of December 31, 2021, we have used approximately 50% of the aggregate net proceeds from our IPO.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no material changes in the planned use of proceeds from our IPO as described in our final prospectus filed with the SEC on February&#160;5, 2021 pursuant to Rule 424(b)(4), except that given the clinical trial data on ANG-3777 reported in the fourth quarter of 2021, we no longer intend to use the Use of Proceeds for the clinical development of ANG-3777.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no funds budgeted for additional clinical trials of ANG-3777. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders of Record </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;30, 2022, there were approximately 150 holders of record of shares of our common stock. This number does not reflect the beneficial holders of our common stock who hold shares in street name through brokerage accounts or other nominees. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our common stock. We intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors after considering our financial condition, results of operations, capital requirements, business prospects and other factors the board of directors deems relevant, and subject to the restrictions contained in any future financing instruments.</span></div><div><span><br/></span></div><div id="idee3699378af4447a4091414c0adfaa7_43"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Reserved</span></div><div style="margin-top:4pt;text-indent:22.5pt"><span><br/></span></div><div id="idee3699378af4447a4091414c0adfaa7_46"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes appearing elsewhere in this Annual Report on Form 10-K. In addition to the historical financial information, this discussion contains forward-looking statements that involve risk, assumptions and uncertainties, such as statements of our plans, objectives, expectations, intentions, forecasts and projections. Our actual results and the timing of selected events could differ materially from those discussed in these forward-looking statements as a result of several factors, including those set forth under the section of this Annual Report on Form 10-K titled "Risk Factors," which you should carefully read to gain an </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section titled "Forward-Looking Statements" at the beginning of this report.</span></div><div id="idee3699378af4447a4091414c0adfaa7_49"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address chronic and progressive fibrotic diseases. Our goal is to transform the treatment paradigm for patients suffering from these potentially life-threatening conditions for which there are no approved medicines or where existing approved medicines have limitations. Our lead product candidate, ANG-3070, is a highly selective oral tyrosine kinase receptor inhibitor (TKI) in development as a treatment for fibrotic diseases, particularly in the kidney and lung. Enrollment is ongoing in a dose-finding Phase 2 trial of ANG-3070 in primary proteinuric kidney diseases (PPKD) and we expect to file an IND in idiopathic pulmonary fibrosis (IPF) by the end of 2022. We are also continuing to develop our preclinical programs. Our ROCK2 program is targeted towards the treatment of fibrotic diseases. Our CYP11B2 program is targeted towards diseases related to aldosterone synthase dysregulation. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to January 2022 our lead product was ANG-3777, a hepatocyte growth factor (HGF) mimetic we were evaluating in multiple indications of acute organ injury, including delayed graft function (DGF) and for the treatment of AKI associated with cardiac surgery involving cardiopulmonary bypass (CSA-AKI). In 2021, we also studied ANG-3777 in patients with severe COVID-19 related pneumonia at high risk for acute respiratory distress syndrome (ARDS). On October 26, 2021, we announced the Phase 3 trial of ANG-3777 in DGF did not achieve its primary endpoint and the data were not expected to be sufficient evidence to support an indication in the studied DGF population. On December 9, 2021, we announced the Phase 2 trial of ANG-3777 in CSA-AKI did not achieve its primary endpoint. We do not intend to continue the clinical development plan for ANG-3777 set forth in the Vifor License, which had included a Phase 3 study in CSA-AKI and a Phase 4 confirmatory study in donor kidney transplant patients who were at risk for developing DGF, given we do not believe the earlier Phase 2 and Phase 3 clinical trial results in the respective indications support a regulatory approval. We have no funds budgeted for additional clinical trials for ANG-3777.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any products approved for sale and have not generated any revenue from product sales since our inception and do not expect to generate revenue from product sales unless we successfully develop and we or our collaborators commercialize our product candidates, which we do not expect to occur for several years, if ever. Our net losses were $54.6&#160;million and $80.1&#160;million for the years ended December&#160;31, 2021 and 2020, respectively. As of December&#160;31, 2021, we had an accumulated deficit of $215.1&#160;million. We expect to continue to incur net losses for the foreseeable future. As we seek to advance ANG-3070 in clinical trials and our other product candidates through preclinical development, our expenses and operating losses may increase over time.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we seek regulatory approval for any of our wholly-owned product candidates or those for which we retain the right to commercialize in the future, we would need to incur additional expenses as we expand our clinical, regulatory, quality, manufacturing and commercialization capabilities, incur significant commercialization expenses for marketing, sales, manufacturing and distribution if we obtain marketing approval for such product candidates. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third parties in the conduct of our preclinical studies and clinical trials and for manufacturing and supply of our product candidates. We have no internal manufacturing capabilities, and we expect to continue to rely on third parties, many of whom are single-source suppliers, for our preclinical study and clinical trial materials. In addition, we do not yet have a marketing or sales organization or commercial infrastructure. Accordingly, we will incur significant expenses to develop a marketing and sales organization and commercial infrastructure in advance of generating any product sales of wholly-owned product candidates or those for which we retain the right to commercialize. Furthermore, we will need to make continued investment in development studies, registration activities and the development of commercial support functions including quality assurance and safety pharmacovigilance before we will be in a position to sell any of our product candidates, if approved.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span><br/></span></div><div id="idee3699378af4447a4091414c0adfaa7_553"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Initial Public Offering and Concurrent Private Placement </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Initial Public Offering (IPO) and Concurrent Private Placement, which both closed on February 9, 2021, generated aggregate net proceeds of approximately $107.0&#160;million, after deducting the underwriting discounts and commissions, private placement fee and estimated offering expenses payable by us. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="idee3699378af4447a4091414c0adfaa7_55"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Update</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has placed strains on the providers of healthcare services, including the healthcare institutions where we conduct our clinical trials. These strains have resulted in institutions prohibiting the initiation of new clinical trials, enrollment in existing trials and restricting the on-site monitoring of clinical trials. We also follow FDA guidance on clinical trial conduct during the COVID-19 pandemic, including the remote monitoring of clinical data.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global pandemic of COVID-19 continues to rapidly evolve. The extent to which COVID-19 may continue impact our business, including our clinical trials, and financial condition will depend on future developments, which are highly uncertain due to the continuing emergence of new variants and cannot be predicted with confidence, such as the ultimate duration of the pandemic and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this time, we do not expect any disruption in our supply chain of drugs necessary to conduct our clinical trials, and we believe we will be able to supply the drug needs of our clinical trials in 2022. However, we are continuing to evaluate our clinical supply chain in light of the COVID-19 pandemic.</span></div><div id="idee3699378af4447a4091414c0adfaa7_58"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License, Collaboration and Grant Agreements</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Vifor Pharma</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020, we granted Vifor Pharma, an exclusive, global (excluding Greater China), royalty-bearing license, for the commercialization of ANG-3777 in all Renal Indications, beginning with DGF and CSA-AKI. The Vifor License also grants Vifor Pharma exclusive rights, with a right to sublicense subject to our consent for certain specified conditions, to develop and manufacture ANG-3777 for commercialization in Renal Indications worldwide (excluding Greater China) in cooperation with us or independently. We retain the right to develop and commercialize combination therapy products combining ANG-3777 with our other proprietary molecules, subject to Vifor Pharma's right of first negotiation with respect to global (excluding Greater China) rights to such combination therapy products in the Renal Indications.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the Vifor License and specifically based upon the clinical development plan for ANG-3777 set forth in the Vifor License, we are entitled to receive $80&#160;million in upfront and near-term clinical milestone payments, including $30&#160;million in up-front cash that was received in November 2020, and a $30&#160;million equity investment, a $5&#160;million convertible note that subsequently converted into common stock with the IPO and $25&#160;million of which was received in the Concurrent Private Placement with our IPO. We are also eligible to receive post-approval milestones of up to approximately $260.0&#160;million and sales-related milestones of up to $1.585&#160;billion, providing a total potential deal value of up to $1.925&#160;billion (subject to certain specified reductions and offsets), plus tiered royalties on net sales of ANG-3777 at royalty rates of up to 40%. Under the Vifor License, we are responsible for executing a pre-specified clinical development plan designed to obtain regulatory approvals of ANG-3777 for DGF and CSA-AKI. For the years ended December&#160;31, 2021 and 2020, we recognized license revenue related to the Vifor License of $27.5&#160;million and $0.2&#160;million, respectively. As of December&#160;31, 2021, we recorded $2.3&#160;million as the current portion of deferred revenue on the consolidated balance sheet related to the Vifor License. As of December 31, 2020, we recorded $29.8&#160;million as deferred revenue on the consolidated balance sheet related to the Vifor License.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 26, 2021, we announced that the Phase 3 trial of ANG-3777 in DGF did not achieve its primary endpoint and the data were not expected to be sufficient evidence to support an indication in the studied DGF population. On December 14, 2021, we announced that the Phase 2 trial of ANG-3777 in CSA-AKI did not achieve its primary endpoint. The Vifor License includes additional milestone and royalty objectives related to the clinical development plan for ANG-3777  and we do not expect to receive any clinical, post-approval, or sales milestones, or royalties, as we do not intend to continue to pursue such clinical development plan for ANG-3777, which had included a Phase 3 study for CSA-AKI and a Phase 4 confirmatory study in DGF. In 2022, we and Vifor Pharma continue to work to complete the planned analyses of the results of the clinical trials announced in the fourth quarter of 2021 and to discuss the future of the collaboration based upon such analyses.  As of December 31, 2021, we recorded the remaining performance obligation as current deferred revenue of $2.3&#160;million which is expected to be completed by the end of 2022. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="idee3699378af4447a4091414c0adfaa7_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results of Operations</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion summarizes the key factors our management believes are necessary for an understanding of our financial statements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any products approved for sale and have not generated any revenue from product sales. Our revenue to date primarily has been derived from government funding consisting of U.S. government grants and contracts, and revenue under our license agreements, specifically the Vifor License.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grant Revenue</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our grants and contracts reimburse us for direct and indirect costs relating to the grant projects and also provide us with a pre-negotiated profit margin on total direct and indirect costs of the grant award, excluding subcontractor costs, after giving effect to directly attributable costs and allowable overhead costs. Funds received from grants and contracts are generally deemed to be earned and recognized as revenue as allowable costs are incurred during the grant or contract period and the right to payment is realized.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Revenue</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our license agreements comprise elements of upfront license fees, milestone payments based on development and royalties based on net product sales. The timing of our operating cash flows may vary significantly from the recognition of the related revenue. Income from upfront payments is recognized when we satisfy the performance obligations in the contract, which can result in recognition at either a point in time or over the period of continued involvement. Other revenue, such as milestone payments, are recognized when achieved.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue to date has been generated from payments received pursuant to the Vifor License Agreement. We recognize revenue from upfront payments over the term of our estimated period of performance using a cost-based input method under Topic 606, Revenue from Contracts with Customers.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to receiving an upfront payment, we may also be entitled to milestones and other contingent payments upon achieving predefined objectives. If a milestone is considered probable of being reached, and if it is probable that a significant revenue reversal would not occur, the associated milestone amount would also be included in the transaction price.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that any license revenue we generate from any future collaboration partners, will fluctuate in the future as a result of the timing and amount of upfront, milestones and other collaboration agreement payments and other factors.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Grant Revenue</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cost of grant revenue primarily relates to personnel-related costs and expenses for grant projects.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, our research and development expenses have primarily related to discovery efforts and preclinical and clinical development of our product candidates. We recognize research and development expenses as they are incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Our research and development expenses consist primarily of:</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">personnel costs, including salaries, payroll taxes, employee benefits and stock-based compensation, for personnel in research and development functions;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">costs associated with medical affairs activities;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">fees paid to consultants, clinical testing sites and contract research organizations (CROs), including in connection with our preclinical studies and clinical trials, and other related clinical trial fees, such as for investigator grants, patient screening, laboratory work, clinical trial database management, clinical trial material management and statistical compilation, analysis and reporting;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">contracted research and license agreement fees with no alternative future use;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">costs related to acquiring, manufacturing and maintaining clinical trial materials and laboratory supplies;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">depreciation of equipment and facilities;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">legal expenses related to clinical trial agreements and material transfer agreements; and</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">costs related to preparation of regulatory submissions and compliance with regulatory requirements.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other than with respect to reimbursable expenses required to be recorded under our government grants and contracts, we do not allocate our expenses by product candidates. A significant amount of our direct research and development expenses include payroll and other personnel expenses for our departments that support multiple product candidate research and development programs and, other than as specified above, we do not record research and development expenses by product. However, research and development expenses were primarily driven by expenses relating to the development of ANG-3777 and ANG-3070 in 2021 and 2020. Of our total</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">research and development expenses for the years ended December 31, 2021 and 2020, 62% and 73%, respectively, of such expenses were from external third-party sources and the remaining 38% and 27%, respectively, were from internal sources. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our research and development expenses to be slightly lower in the near term, even though we will continue the development of our product candidates and continue to invest in research and development activities. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time consuming, and successful development of our product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs of the efforts that will be necessary to complete the remainder of the development of any of our clinical or preclinical product candidates or the period, if any, in which material net cash inflows from these product candidates may commence. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of:</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the scope, rate of progress and expense of our ongoing, as well as any additional, clinical trials and other research and development activities;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">future preclinical and clinical trial results;</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">obtaining market access and reimbursement approvals; and</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the timing and receipt of any regulatory approvals.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct preclinical or clinical trials beyond those that we currently anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in enrollment in any of our preclinical or clinical trials, we could be required to expend significant additional financial resources and time on the completion of our clinical development programs.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of personnel-related expenses, such as salaries, payroll taxes, employee benefits and stock-based compensation, for personnel in executive, operational, finance and human resources functions. Other significant general and administrative expenses include allocation of facilities costs, accounting and legal services and expenses associated with obtaining and maintaining patents. A portion of the general and administrative expenses are reimbursed through the overhead rates contained in our grants with the U.S. Government.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our general and administrative expenses to be generally consistent in the near term to support our continued research and development activities. We also expect to generally maintain our current level of expenses associated with operating as a public company, including expenses related to audit, legal, regulatory, and tax-related services associated with maintaining compliance with the rules and regulations of the SEC and standards applicable to companies listed on a national securities exchange, insurance expenses, investor relations activities and other administrative and professional services.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Notes Recorded at Fair Value</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected the fair value option for recognition of our convertible notes. Our convertible notes were subject to re-measurement each reporting period with gains and losses reported through our consolidated statements of operations. All of our convertible notes were converted into shares of our common stock upon the closing of our initial public offering. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liability Classified Series C Convertible Preferred Stock Recorded at Fair Value</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series C convertible preferred stock includes settlement features that result in liability classification. The initial carrying value of the Series C convertible preferred stock was accreted to the settlement value, the fair value of the securities to be issued upon the conversion of the Series C Preferred Stock. The discount to the settlement value was accreted to interest expense using the effective interest method. During 2020, certain of the convertible notes were exchanged for Series C convertible preferred stock. As the exchange was accounted for as a modification, the Series C convertible preferred stock that was exchanged for the convertible notes (the Exchanged Series C Shares) continued to be recorded at fair value. The Exchanged Series C Shares were subject to re-measurement each reporting with gains and losses reported through our consolidated statements of operations. All shares of our Series C convertible preferred stock converted into common stock in connection with the IPO.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrant Liability</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have accounted for certain of our freestanding warrants to purchase shares of our common stock as liabilities measured at fair value, in accordance with ASC 815, Derivatives and Hedging (ASC 815). The warrants are subject to re-measurement at each reporting period with gains and losses reported through our consolidated statements of operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Exchange Transaction Gain</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency transaction gains, primarily related to intercompany loans, are recorded as a component of other income (expense) in our consolidated statements of operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings in Equity Method Investment</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings in equity method investment represents our 10% interest in NovaPark that is accounted for under the equity method.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on our cash and cash equivalents.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="idee3699378af4447a4091414c0adfaa7_64"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison for the Years Ended December&#160;31, 2021 and 2020</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the periods indicated:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">$ Change</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">% Change</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(In thousands, except percentages)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Revenue:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contract revenue</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Grant revenue</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,881)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28,312&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,880&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25,432&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">883.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Operating expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of grant revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(757)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total operating expenses</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">67,619&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">58,153&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9,466&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Loss from operations</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(39,307)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(55,273)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15,966&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(28.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other income (expense), net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(15,266)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(24,834)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net loss</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(54,573)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(80,107)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">25,534</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:31.72pt">Not meaningful</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Revenue</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract revenue increased by $27.3&#160;million, from the year ended December&#160;31, 2020 to the year ended December&#160;31, 2021. The increase is attributable to revenue recognized related to the upfront payment from Vifor Pharma pursuant to the Vifor License Agreement entered into in 2020. As of December 31, 2021, we have substantially satisfied the performance obligation under the Agreement which caused an acceleration of the deferred revenue. We do not expect to receive any further substantial revenues under the Vifor License Agreement and we expect the remaining unearned revenue under the Vifor License Agreement to be recognized by the end of 2022. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grant Revenue</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant revenue decreased by $1.9&#160;million, or 70.0%, from the year ended December&#160;31, 2020 to the year ended December&#160;31, 2021. The decrease is primarily attributable to a decrease in reimbursable costs relating to our grant from the U.S. Department of Defense for the year ended December&#160;31, 2021. We do not expect to receive any further substantial grant revenues for the foreseeable future.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Grant Revenue</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of grant revenue decreased by $0.8&#160;million, or 63.6%, from the year ended December&#160;31, 2020 to the year ended December&#160;31, 2021. The decrease is primarily attributable to a decrease in personnel-related costs and expenses applied for the year ended December 31, 2021.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $9.7&#160;million, or 24.9%, from the year ended December&#160;31, 2020 to the year ended December&#160;31, 2021. The increase in research and development expenses was primarily due to an increase of $8.5 million in personnel-related expenses, including salaries, benefits and stock-based compensation expenses, as a result from increases in headcount and an increase of $1.0 million in CRO and CMO expenses from increased clinical and non-clinical trial activities, primarily related to the development of ANG-3777 and ANG-3070. These increases were partially offset by an employee retention credit of $1.2 million received in 2021 as a reduction to payroll taxes. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased by $0.5&#160;million, or 2.8%, from the year ended December&#160;31, 2020 to the year ended December&#160;31, 2021. The increase in general and administrative expenses was primarily due to an increase of $2.5 million of personnel-related expenses, including salaries, benefits and stock-based compensation expenses, resulting from increases in headcount and vesting of performance-based stock units upon IPO, and an increase of $2.7 million of corporate fees mainly due to purchase of business insurance, offset by a reduction of $5.1 million of professional fees for legal, consulting, accounting, tax and other services primarily associated with preparing us for our IPO in 2020.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other income (expense), net changed by a reduction in expense of $9.6&#160;million, from the year ended December&#160;31, 2020 to the year ended December&#160;31, 2021. This decrease in expense is primarily attributable to a reduction in interest expense of $7.0 million due to interest associated with convertible notes and Series C convertible preferred stock in 2020 that were converted into equity upon our IPO in February 2021 and an increase of $2.6 million in fair value of our warrant liability, convertible notes, and Series C convertible preferred stock for which we have elected the fair value option. The convertible notes and warrants both require re-measurement at each balance sheet date with gains and losses reported through our consolidated statement of operations.</span></div><div id="idee3699378af4447a4091414c0adfaa7_67"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources and Uses of Liquidity</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred losses and negative cash flows from operations since inception, and we anticipate that we will incur losses for at least the next several years. To date, we have not generated any revenue from product sales. We have funded our operations primarily through the receipt of grants, the sale of debt and equity securities, and proceeds from license agreements. In February 2021, we generated aggregate net proceeds of approximately $107.0&#160;million from our IPO and Concurrent Private Placement, after deducting the underwriting discounts and commissions. As of December&#160;31, 2021, we had $88.8&#160;million of cash and cash equivalents and an accumulated deficit of $215.1&#160;million.  </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to our IPO, we issued $36.2&#160;million in aggregate principal amount of convertible notes to various investors and we also issued 34,928 shares of Series C convertible preferred stock at $642.75 per share for gross proceeds of approximately $22.3&#160;million. Upon the closing of our IPO, all then outstanding convertible notes and shares of convertible preferred stock were converted into 5,870,829 shares of our common stock. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we were approved for and received a loan of approximately $0.9&#160;million from Hanmi Bank under the Coronavirus Aid, Relief and Economic Security Act (the CARES Act) and the Paycheck Protection Program (PPP) offered by the U.S. Small Business Administration (SBA). The loan was evidenced by a promissory note and agreement, dated April 21, 2020 (the PPP Note). The PPP Note proceeds were available to be used to pay for payroll costs, including salaries, commissions, and similar compensation, group health care benefits, and paid leaves; rent; utilities; and interest on certain other outstanding debt, if any. The interest rate on the PPP Note was a fixed rate of 1% per annum. The SBA approved our PPP Loan forgiveness application on May 26, 2021 for the entire principal amount of the PPP Loan and accrued interest. </span></div><div><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Cash Needs and Funding Requirements</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on our current operating plan, we believe that our cash and cash equivalents will be sufficient to fund our planned operations for at least 12 months, well into 2023, following the issuance date of our consolidated financial statements. However, we have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of biotechnology products, we are unable to estimate the exact amount of our operating capital requirements. The amount and timing of our future funding requirements will depend on many factors, including, but not limited to:</span></div><div style="margin-top:3pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the scope, progress, results and costs of researching and developing ANG-3070 or any other product candidates, and conducting preclinical studies and clinical trials;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.55pt">the outcome of our ongoing and future clinical trials, including our Phase 2 clinical trial of ANG-3070 in patients with PPKD;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.55pt">whether we are able to take advantage of any FDA expedited development and approval programs for any of our product candidates;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.55pt">the extent to which COVID-19 may impact our business, including our clinical trials and financial condition;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.55pt">the willingness of the FDA and foreign regulatory authorities to accept the results of our completed, ongoing, and planned clinical trials and preclinical studies and other work, as the basis for review and approval of ANG-3070;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the outcome, costs and timing of seeking and obtaining and maintaining FDA and any foreign regulatory approvals;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the number and characteristics of product candidates that we pursue, including our product candidates in preclinical development;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the ability of our product candidates to progress through clinical development successfully;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">our need to expand our research and development activities, including to conduct additional clinical trials;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">market acceptance of our product candidates, including physician adoption, market access, pricing and reimbursement;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the costs of acquiring, licensing or investing in businesses, products, product candidates and technologies;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">our need and ability to hire additional personnel, including management, clinical development, medical and commercial personnel;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the effect of competing technological, market developments and government policy;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the costs associated with being a public company, including our need to implement additional internal systems and infrastructure, including financial and reporting systems;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the costs associated with securing and establishing commercialization and manufacturing capabilities, as well as those associated with packaging, warehousing and distribution;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the costs associated with being a commercial company with approved products for sale, including our obligation to meet applicable healthcare laws and regulations and implement robust compliance programs;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the economic and other terms, timing of and success of our existing licensing arrangements and any collaboration, licensing or other arrangements into which we may enter in the future and timing and amount of payments thereunder; and</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">the timing, receipt and amount of sales and general commercial success of any future approved products, if any.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time as we or our collaborators can generate significant revenue from sales of ANG-3070 or any other product candidate, if ever, we expect to finance our operations through public or private equity offerings or debt financings or other sources of capital, including collaborations, licenses, credit or loan facilities, receipt of research contributions or grants, tax credit revenue or a combination of one or more of these funding sources. Adequate funding may not be available to us on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through additional collaborations, or other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates ourselves.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary Statement of Cash Flows</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of our net cash flow activity for the years ended December&#160;31, 2021 and 2020 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.913%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash provided by (used in)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating activities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(52,643)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(22,888)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Investing activities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(382)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financing activities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">107,171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">52,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Effect of foreign currency on cash</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net increase in cash</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">54,149&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29,036&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating activities</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2021, net cash used in operating activities was $52.6&#160;million, which primarily consisted of a net loss of $54.6&#160;million and a change in net operating assets and liabilities of $26.0&#160;million, partially offset by net non-cash charges of $27.8&#160;million. The net non-cash charges were primarily related to a $14.0&#160;million change in fair value of convertible notes, Series C convertible preferred stock and warrant liabilities, amortization of debt issuance costs of $1.9&#160;million, and stock-based compensation expense of $12.0&#160;million, partially offset by a gain of $0.9&#160;million from the forgiveness of our PPP loan. The change in net operating assets and liabilities was due to a decrease of $27.5&#160;million in deferred revenue due to substantial satisfaction of our performance obligation under the Vifor License Agreement, a decrease of $0.9&#160;million in accounts payable and accrued expenses due to timing of invoices and an increase of $0.8&#160;million in grants receivable due to the recognition of the qualified Australian tax credit, partially offset by a decrease of $4.0&#160;million in prepaid expenses and other current assets, primarily due to the subsequent receipt of $5.0&#160;million convertible note receivable under Vifor License Agreement in 2021.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, net cash used in operating activities was $22.9&#160;million, which primarily consisted of a net loss of $80.1&#160;million, partially offset by net non-cash charges of $31.5&#160;million and a change in net operating assets and liabilities of $25.8&#160;million. The net non-cash charges were primarily related to a $16.5 million change in fair value of convertible notes, Series C convertible preferred stock and warrant liabilities, amortization of debt issuance costs of $7.7 million, stock-based compensation expense of $4.7 million and placement agent fees of $1.7 million. The change in net operating assets and liabilities was due to an increase of $29.8 million in deferred revenue due to the upfront fee from the Vifor License Agreement and $3.7 million in accrued expenses due to increased clinical-related activities, partially offset by an increase of $2.0 million in prepaid expenses and other current assets and a decrease of $5.6 million in accounts payable due to our overall growth, increased research and development spending and timing of payments.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2021 and 2020, net cash used in investing activities of $0.4&#160;million and $41,000, respectively, was primarily used to purchase of fixed assets for research activities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2021, net cash provided by financing activities was $107.2&#160;million, primarily due to net proceeds of $107.5&#160;million from the IPO and Concurrent Private Placement, $1.8&#160;million from the exercise of warrants and stock options, and $0.3&#160;million from a sale and leaseback arrangement, partially offset by taxes paid related to net share settlement upon vesting of restricted stock awards of $2.5&#160;million. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2020, net cash provided by financing activities was $52.4 million, primarily due to net proceeds of $31.2&#160;million from the issuance of convertible notes and warrants, $20.0 million from the issuance of liability classified Series C convertible preferred stock net of issuance costs and $0.9 million in proceeds from our PPP loan.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="idee3699378af4447a4091414c0adfaa7_546"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Other Commitments</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contractual obligations as of December 31, 2021 (in thousands):</span></div><div style="margin-top:10pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:27.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">For the Year Ended Payments due by period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Less than 1 year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">1 to 3 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">3 to 5 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">More than 5 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,423&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financing obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:10pt;text-indent:22.5pt"><span><br/></span></div><div id="idee3699378af4447a4091414c0adfaa7_73"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our consolidated financial statements appearing elsewhere in this Annual Report.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical accounting policies requiring estimates, assumptions, and judgments that we believe have the most significant impact on our consolidated financial statements are described below.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Revenue</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for revenue earned from contracts with customers under Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASC 606"). Under ASC 606, we recognize revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements within the scope of ASC 606, we perform the following five steps:   &#160;&#160;&#160;&#160;</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Identify the contract(s) with a customer;</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Identify the performance obligations in the contract;</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Determine the transaction price;</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Allocate the transaction price to the performance obligations in the contract; and</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;Recognize revenue when (or as) we satisfy a performance obligation.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, we assess the goods or services promised within each contract, whether each promised good or service is distinct, and determine those that are performance obligations. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into agreements under which it may obtain upfront payments, milestone payments, royalty payments and other fees. Promises under these arrangements may include licenses of intellectual property, research services, including selection campaign research services for certain replacement targets, the obligation to share information during the research and the participation of alliance managers and in joint research committees, joint patent committees and joint steering committees. We assess these promises within the context of the agreements to determine the performance obligations.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Licenses of Intellectual Property</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: If a license to our intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, we recognize revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring proportional performance for purposes of recognizing revenue from non-refundable, upfront payments. We evaluate the measure of proportional performance each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We evaluate whether the regulatory and development milestones are considered probable of being reached and estimate the amounts to be included in the transaction price using the most likely amount method. We evaluate factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. At the end of each reporting period, we re-evaluate the probability of achievement of milestones and any related constraint, and if necessary, adjusts the estimate of the overall transaction price.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales-based milestones and royalties</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For sales-based royalties, including milestone payments based on the level of sales, we determine whether the sole or predominant item to which the royalties relate is a license. When the license is the sole or predominant item to which the sales-based royalty relates, we recognize revenue at the later of: (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any sales-based royalty revenue resulting from any license agreement.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is a contract liability, represents amounts received by us for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount expected to be recognized within one year from the consolidated balance sheet date based on the estimated performance period of the underlying performance obligation. The noncurrent portion of deferred revenue represents amounts expected to be recognized after one year through the end of the performance period of the performance obligation.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Using the cost-based input method, we recognize revenue based on actual costs incurred as a percentage of total estimated costs as we complete each performance obligation. As such, we use significant assumptions to determine the total estimated costs for us to complete the performance obligation identified under the Vifor License Agreement as well as the performance period. We reassess the total estimated costs and performance period at each reporting period. We changed the estimated costs significantly from $231.5 million at inception (November 2020) to $26.0 million as of December 31, 2021 and revised the performance period from 9.5 years to 2.2 years due to new information available at each reporting period. As of December 31, 2021, we determined we have substantially completed our performance obligation under the Vifor License Agreement. The effect of this change in estimate was an increase in contract revenue by $24.2&#160;million, a reduction in net loss by $24.2&#160;million and an increase in basic and diluted earnings per share by $0.86 for the year ended December&#160;31, 2021. See Note 3 in this Annual Report on Form 10-K for more information. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grant Revenue</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We concluded that our government grants are not within the scope of ASC 606 as they do not meet the definition of a contract with a customer. We have concluded that the grants meet the definition of a contribution and are non-reciprocal transactions, and have also concluded that Subtopic 958-605, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit-Entities-Revenue Recognition</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, does not apply, as we are a business entity and the grants are with governmental agencies.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of applicable guidance under GAAP, we developed a policy for the recognition of grant revenue when the allowable costs are incurred and the right to payment is realized.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe this policy is consistent with the overarching premise in ASC 606, to ensure that revenue recognition reflects the transfer of promised goods or services to customers in an amount that reflects the consideration that we expect to be entitled to in exchange for those goods or services, even though there is no exchange as defined in ASC 606. We believe the recognition of revenue as costs are incurred and amounts become realizable is analogous to the concept of transfer of control of a service over time under ASC 606.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs include, but are not limited to, payroll and personnel expenses, laboratory supplies, preclinical studies, compound manufacturing costs, consulting costs and allocated overhead, including rent, equipment, depreciation and utilities. Research and development cost may be offset by research and development refundable tax rebates received by our wholly-owned Australian subsidiary. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have agreements with various Contract Research Organizations ("CROs") and third-party vendors. We estimate research and development accruals of amounts due to the CRO based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. We include the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimated costs of research and development provided, but not yet invoiced, in accrued liabilities on the consolidated balance sheet. We record payments made to CROs under this arrangement in advance of the performance of the related services as prepaid expenses and other current assets until the services are rendered. We make judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, we adjust our accrued liabilities. For the years ended December&#160;31, 2021 and 2020, we have not experienced any material differences between accrued costs and actual costs incurred.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for all stock-based payments to employees and non-employees, including grants of stock options, restricted stock awards ("RSAs"), restricted stock units ("RSUs"), including restricted stock units with non-market performance and service conditions ("PSUs") to be recognized in the financial statements, based on their respective grant date fair values. We estimate the fair value of stock option grants using the Black-Scholes option pricing model. We value the RSAs, RSUs and PSUs based on the fair value of our common stock on the date of grant. The assumptions used in calculating the fair value of stock-based awards represent management's best estimates and involve inherent uncertainties and the application of management's judgment. We record expense for stock-based compensation related to stock options, RSAs and RSUs over the requisite service period. As the PSUs have a performance condition, we recognize compensation expense for each vesting tranche over the respective requisite service period of each tranche if and when our management deems probable that the performance conditions will be satisfied. We may recognize a cumulative true-up adjustment related to PSUs once a condition becomes probable of being satisfied if the related service period had commenced in a prior period. We record all stock-based compensation costs in general and administrative or research and development costs in the consolidated statements of operations based upon the respective employee or non-employee's roles within our company. We record forfeitures as they occur.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 9 in this Annual Report on Form 10-K for more information concerning certain of the specific assumptions we used in applying the Black-Scholes option pricing model to determine the estimated fair value of our stock options. Certain of such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our stock-based compensation could be materially different.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liability</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for certain common stock warrants outstanding as a liability, in accordance with ASC 815, at fair value and adjust the instruments to fair value at each reporting period. This liability is subject to re-measurement at each reporting period until exercised, and we recognize any change in fair value in the consolidated statements of operations as a component of other income (expense). We have estimated the fair value of the warrants issued by us using a variant of the Black Scholes option pricing model. We valued the underlying equity included in the Black Scholes option pricing model based on the equity value implied from sales of preferred and common stock.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record income taxes in accordance with ASC 740, Income Taxes (ASC 740), which provides for deferred taxes using an asset and liability approach. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. We determine deferred tax assets and liabilities based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which we expect the differences to reverse. We provide valuation allowances if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, we recognize the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span><br/></span></div><div id="idee3699378af4447a4091414c0adfaa7_538"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2, &#8220;Summary of Significant Accounting Policies&#8221; in the Notes to the Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K for a full description of recent accounting standards.</span></div><div id="idee3699378af4447a4091414c0adfaa7_76"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Emerging Growth Company and Smaller Reporting Company Status</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a smaller reporting company and an emerging growth company, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay the adoption of new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. Other exemptions and reduced reporting requirements under the JOBS Act for emerging growth companies include presentation of only two years of audited financial statements in a registration statement for an initial public offering, an exemption from the requirement to provide an auditor's report on internal controls over financial reporting pursuant to Sarbanes-Oxley Act of 2002, as amended (Sarbanes-Oxley) an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation, and less extensive disclosure about our executive compensation arrangements. We have elected to use the extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that (i) we are no longer an emerging growth company or (ii) we affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our consolidated financial statements may not be comparable to companies that comply with new or revised accounting standards as of public company effective dates.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will remain an emerging growth company until the earliest of (i) December 31, 2026, (ii) the last day of our first fiscal year in which we have total annual gross revenue of $1.07 billion or more, (iii) the date on which we are deemed to be a "large accelerated filer," as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (Exchange Act), which means the market value of equity securities that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter and (iv) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after we no longer qualify as an emerging growth company, we may still qualify as a "smaller reporting company" and/or &#8220;non-accelerated filer&#8221; which may allow us to take advantage of many of the same exemptions from disclosure requirements including not being required to comply for a period of time with the auditor attestation requirements of Section 404 of Sarbanes-Oxley, and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements.</span></div><div id="idee3699378af4447a4091414c0adfaa7_79"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item7A. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="idee3699378af4447a4091414c0adfaa7_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements of Angion Biomedica Corp, listed below are set forth in Item 8 of this Annual Report for the years ended December&#160;31, 2021 and 2020:</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANGION BIOMEDICA CORP.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.772%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_85">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (<ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184Mi9mcmFnOjg3YWI5OGQ1ZTU4ZjQ2YTc4Y2UyOTQ1MjRkMmQxM2ZkL3RhYmxlOmY1MmE3NjZkNzBiMjQ4NmViYWM0NDFiODlkNTBkNTE1L3RhYmxlcmFuZ2U6ZjUyYTc2NmQ3MGIyNDg2ZWJhYzQ0MWI4OWQ1MGQ1MTVfMi0wLTEtMS0yNTgzNy90ZXh0cmVnaW9uOmJkMjZmOGMxNTVjMzQ2MzRiZWNjZjc1NDhmZTczNWMxXzE2NDkyNjc0NDI0NjA_13ccedb3-303d-4672-b55f-80e4dcf5b9fd">Moss Adams LLP</ix:nonNumeric>, <ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184Mi9mcmFnOjg3YWI5OGQ1ZTU4ZjQ2YTc4Y2UyOTQ1MjRkMmQxM2ZkL3RhYmxlOmY1MmE3NjZkNzBiMjQ4NmViYWM0NDFiODlkNTBkNTE1L3RhYmxlcmFuZ2U6ZjUyYTc2NmQ3MGIyNDg2ZWJhYzQ0MWI4OWQ1MGQ1MTVfMi0wLTEtMS0yNTgzNy90ZXh0cmVnaW9uOmJkMjZmOGMxNTVjMzQ2MzRiZWNjZjc1NDhmZTczNWMxXzE2NDkyNjc0NDI0ODI_7a6351f5-c9ca-408b-8a92-f5ed87b19ebf">Seattle, Washington</ix:nonNumeric>, PCAOB ID: <ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184Mi9mcmFnOjg3YWI5OGQ1ZTU4ZjQ2YTc4Y2UyOTQ1MjRkMmQxM2ZkL3RhYmxlOmY1MmE3NjZkNzBiMjQ4NmViYWM0NDFiODlkNTBkNTE1L3RhYmxlcmFuZ2U6ZjUyYTc2NmQ3MGIyNDg2ZWJhYzQ0MWI4OWQ1MGQ1MTVfMi0wLTEtMS0yNTgzNy90ZXh0cmVnaW9uOmJkMjZmOGMxNTVjMzQ2MzRiZWNjZjc1NDhmZTczNWMxXzE2NDkyNjc0NDI0ODg_11d8821c-6eb3-4035-afe4-449e007caad5">659</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_85">80</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_88">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_88">81</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_91">Consolidated Statements of Operations and Comprehensive Loss </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_91">82</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_94">Consolidated Statements of Stockholders' Equity (Deficit)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_94">83</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_97">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_97">85</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_100">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_100">87</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="idee3699378af4447a4091414c0adfaa7_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Stockholders of </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Angion Biomedica Corp.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Angion Biomedica Corp. (the &#8220;Company&#8221;) as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity (deficit) and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2021 and 2020, and the consolidated results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures to respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Moss Adams LLP </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Seattle, Washington</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 30, 2022</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2018.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="idee3699378af4447a4091414c0adfaa7_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANGION BIOMEDICA CORP. </span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets </span></div><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:72.411%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfNC0xLTEtMS0yMjU0NQ_212ae75e-e451-44af-8d89-8b6381ade05a">88,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfNC0zLTEtMS0yMjU0NQ_632c065a-a4f3-465d-b3d9-cb2a8c149664">34,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Grants receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:GrantsReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfNS0xLTEtMS0yMjU0NQ_fdef8273-0695-430f-8c05-32ddc39c462f">806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:GrantsReceivableCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfNS0zLTEtMS0yMjU0NQ_418707dd-2eba-4493-8a92-9c82e3dd9cbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfNi0xLTEtMS0yMjU0NQ_49d67bf0-cf36-4f64-90c9-3b38470b40df">1,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfNi0zLTEtMS0yMjU0NQ_46c7cc0d-836d-474a-bf60-c10291ab62ea">7,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:17pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfNy0xLTEtMS0yMjU0NQ_2008d228-68ac-4812-99dc-abe994276340">91,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfNy0zLTEtMS0yMjU0NQ_e60ef7de-ef47-4b85-aef9-768e3417b72c">42,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfOC0xLTEtMS0yMjU0NQ_647a72cb-a31d-42e0-a982-f1962ec8fc38">451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfOC0zLTEtMS0yMjU0NQ_d88cd554-ddbd-4e7b-b4a8-5d0231921cd1">156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfOS0xLTEtMS0yMjU0NQ_245c07d6-ea8e-4696-9fee-17fdf43dd015">3,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfOS0zLTEtMS0yMjU0NQ_e437df95-9767-420a-88f1-532feacb4f19">4,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Investments in related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:Investments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTAtMS0xLTEtMjI1NDU_c45b82bd-397c-44dd-935d-245d33ab3f1f">723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:Investments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTAtMy0xLTEtMjI1NDU_2263dfb3-ec71-4526-a323-c63f5787d66f">822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTEtMS0xLTEtMjU0MTY_b6d7c8ac-8612-46fe-a6ef-f48e6b6750c9">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTEtMy0xLTEtMjU0MTY_cb8ed288-e454-464e-a105-a41f70c4cc72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTEtMS0xLTEtMjI1NDU_a29355bc-2c82-4702-837a-535e1cc10643">96,513</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTEtMy0xLTEtMjI1NDU_8f02b01c-a84a-40e8-b85f-e40211031418">47,347</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTQtMS0xLTEtMjI1NDU_04cbac64-d82e-4f6c-be9d-04313373c8c6">4,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTQtMy0xLTEtMjI1NDU_39fb05d4-4d64-40d7-942e-8a19fe974058">5,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTUtMS0xLTEtMjI1NDU_fdce8d4d-20bd-44f4-a085-8f5c3f6e1bad">3,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTUtMy0xLTEtMjI1NDU_0f947289-651d-4669-a850-bd5be7dd02e6">6,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Lease liability&#8212;current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTYtMS0xLTEtMjI1NDU_95af4f29-62ac-4773-967c-dc6a5df61895">894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTYtMy0xLTEtMjI1NDU_ab1e9aeb-1f59-4cab-92ad-ef42056e8cb0">611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Financing obligation&#8212;current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTgtMS0xLTEtMjU0MzU_01ef6498-8f22-48cd-8f5a-ec9997d69f70">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTgtMy0xLTEtMjU0MzU_49ed4676-df6b-49b9-9a02-152f0199fb55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Deferred revenue&#8212;current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTctMS0xLTEtMjI1NDU_524ff735-1b2e-4d98-963d-e8489f835d1f">2,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTctMy0xLTEtMjI1NDU_7416a51c-71a8-426d-aaa2-1e70b3215cd8">3,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="angn:WarrantLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTgtMS0xLTEtMjI1NDU_abd998ed-3b58-4628-8458-9333aa381692">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="angn:WarrantLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTgtMy0xLTEtMjI1NDU_0ab46054-c44a-40b6-bba2-6851458d114e">10,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Convertible promissory notes payable at fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:ShortTermNonBankLoansAndNotesPayable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTktMS0xLTEtMjI1NDU_6f0551ff-e8c2-44e5-b99e-c5eaca14750e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:ShortTermNonBankLoansAndNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTktMy0xLTEtMjI1NDU_cf760db7-e98d-4da1-89ee-bc96848a4797">51,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Series C convertible preferred stock at amortized cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjAtMS0xLTEtMjI1NDU_2205306e-7fbf-419f-ac5d-e4bad51fbf58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjAtMy0xLTEtMjI1NDU_6e2b06ef-9378-414d-b4fd-c7f2da50075c">26,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Series C convertible preferred stock at fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="angn:FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjEtMS0xLTEtMjI1NDU_e003f8d2-60e3-42e5-8892-00f8523f4f26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="angn:FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjEtMy0xLTEtMjI1NDU_0141068e-c660-4ca4-b262-9c25e53a3839">2,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Other short-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:OtherShortTermBorrowings" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjItMS0xLTEtMjI1NDU_5ecf5466-ec93-439c-812a-ec4bbccea225">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:OtherShortTermBorrowings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjItMy0xLTEtMjI1NDU_45e6b743-ef1e-4f06-97aa-21d474ab5e81">260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:17pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjMtMS0xLTEtMjI1NDU_a9b5faa7-55bc-4317-b3db-0adedf5219a5">11,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjMtMy0xLTEtMjI1NDU_45433aa9-6559-48da-9f40-c49ec39640a2">107,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Lease liability&#8212;noncurrent</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjQtMS0xLTEtMjI1NDU_7b36209c-0e49-4cdf-8a58-d9804139ad8e">3,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjQtMy0xLTEtMjI1NDU_98280d1a-3ca7-4ba4-aec2-07af731e6164">3,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Financing obligation&#8212;noncurrent</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjctMS0xLTEtMjY2Mzk_9b311185-d938-4052-b33c-b282274f69bb">235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjctMy0xLTEtMjY2Mzk_fcbed780-8e38-4f8b-8bbc-ac28f848869b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Deferred revenue&#8212;noncurrent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjUtMS0xLTEtMjI1NDU_41a95bf5-4c0b-4d19-9930-b66b95da993e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjUtMy0xLTEtMjI1NDU_699713ee-c7c4-4c12-a4bc-f50f874d12ce">25,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Other long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjYtMS0xLTEtMjI1NDU_ac13a78f-6250-4a03-89a0-6658c646f3ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjYtMy0xLTEtMjI1NDU_a3888096-68d0-494a-ae95-8540cff9ac69">635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjctMS0xLTEtMjI1NDU_6f2e055b-35f2-4e5c-845e-0e1655ee89d7">15,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjctMy0xLTEtMjI1NDU_25263604-5714-47c9-970a-82f619790647">137,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Commitments and contingencies&#8212;Note 11</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjgtMS0xLTEtMjI3MTk_3aa83f4c-5267-4e00-8409-f052128e1943"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjgtMy0xLTEtMjI3MTk_c5906189-36f9-4ea4-9933-62b70d1d6354"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Stockholders' equity (deficit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21.6pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzItMC0xLTEtMjI1NDUvdGV4dHJlZ2lvbjpiN2MyOTg0MzBjYzE0ZTMzODA3MjkxMzYyMmM4YjRhZF8xMDk5NTExNjI4MTAx_ae9a1064-d583-48dd-8cf0-a7b6ab4b34d5"><ix:nonFraction unitRef="usdPerShare" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzItMC0xLTEtMjI1NDUvdGV4dHJlZ2lvbjpiN2MyOTg0MzBjYzE0ZTMzODA3MjkxMzYyMmM4YjRhZF8xMDk5NTExNjI4MTAx_f29130b4-f33c-449a-b99e-4b078a686a95">0.01</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzItMC0xLTEtMjI1NDUvdGV4dHJlZ2lvbjpiN2MyOTg0MzBjYzE0ZTMzODA3MjkxMzYyMmM4YjRhZF8xMDk5NTExNjI4MDQx_41741cf2-a04e-4702-8717-3593403f32e2"><ix:nonFraction unitRef="shares" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzItMC0xLTEtMjI1NDUvdGV4dHJlZ2lvbjpiN2MyOTg0MzBjYzE0ZTMzODA3MjkxMzYyMmM4YjRhZF8xMDk5NTExNjI4MDQx_c6fb1a43-371b-4d32-a6fc-4b7013b88d66">30,000,000</ix:nonFraction></ix:nonFraction> authorized shares; <ix:nonFraction unitRef="shares" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzItMC0xLTEtMjI1NDUvdGV4dHJlZ2lvbjpiN2MyOTg0MzBjYzE0ZTMzODA3MjkxMzYyMmM4YjRhZF8xMDk5NTExNjI4MDU0_ddd09793-c39e-41a2-9489-3a6e56a05ec8">29,959,060</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzItMC0xLTEtMjI1NDUvdGV4dHJlZ2lvbjpiN2MyOTg0MzBjYzE0ZTMzODA3MjkxMzYyMmM4YjRhZF8xMDk5NTExNjI4MDY3_fbd19cdf-3cd8-4240-a510-18e050719269">15,632,809</ix:nonFraction> shares issued as of December 31, 2021 and 2020, respectively; <ix:nonFraction unitRef="shares" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzItMC0xLTEtMjI1NDUvdGV4dHJlZ2lvbjpiN2MyOTg0MzBjYzE0ZTMzODA3MjkxMzYyMmM4YjRhZF8xMDk5NTExNjI4MDgw_0712ab47-da47-4374-b8cc-5ef2bfe41db9">29,959,060</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzItMC0xLTEtMjI1NDUvdGV4dHJlZ2lvbjpiN2MyOTg0MzBjYzE0ZTMzODA3MjkxMzYyMmM4YjRhZF8xMDk5NTExNjI4MDkz_a4b85cd9-db2c-4468-82f5-cfe88a81f8ca">15,316,721</ix:nonFraction> shares outstanding as of December 31, 2021 and 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzItMS0xLTEtMjI1NDU_a230ece0-87a9-4817-a494-86edb5776281">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzItMy0xLTEtMjI1NDU_b38c6fd7-cabe-44cf-9f47-e92ae99a5641">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21.6pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Treasury stock, <ix:nonFraction unitRef="shares" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzMtMC0xLTEtMjI1NDUvdGV4dHJlZ2lvbjo2Y2RmM2VmZDQ4ZjA0OGI5YTM5MjhjZmQzZGY1Nzk1NV8xMDk5NTExNjI3OTA0_1ec7de2d-aaac-4e8b-ac91-c6a27114c66f">zero</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzMtMC0xLTEtMjI1NDUvdGV4dHJlZ2lvbjo2Y2RmM2VmZDQ4ZjA0OGI5YTM5MjhjZmQzZGY1Nzk1NV8xMDk5NTExNjI3ODg5_a79241ac-90fe-4128-9f7c-0dd9bb515cc2">316,088</ix:nonFraction> shares outstanding as of December 31, 2021 and 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzMtMS0xLTEtMjI1NDU_68dc9176-7b57-4de3-8381-c93a6f08359d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzMtMy0xLTEtMjI1NDU_d1695752-9e25-4f49-87db-08230fc3ffe6">1,846</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzQtMS0xLTEtMjI1NDU_19c77849-8a39-4c72-b54a-3bd6adeeb2b8">296,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzQtMy0xLTEtMjI1NDU_705ac362-edf9-41d4-a2e5-a14ee72e4c2f">72,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzUtMS0xLTEtMjI1NDU_fe6b0029-7ba9-43ca-b9db-f8105ec32f79">103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzUtMy0xLTEtMjI1NDU_d82115ad-eb29-42c7-88ca-c6b8cb919761">333</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzYtMS0xLTEtMjI1NDU_a14015bc-a6b7-438d-91ce-9f032708df77">215,135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzYtMy0xLTEtMjI1NDU_68d3ca83-65d9-4473-bddd-478162665156">160,562</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total stockholders' equity (deficit)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzctMS0xLTEtMjI1NDU_9c24c309-649c-4359-af9f-1784ec42a71a">81,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzctMy0xLTEtMjI1NDU_97809bab-988d-4109-896e-c1474f907aa7">90,449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Total liabilities and stockholders' equity (deficit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzgtMS0xLTEtMjI1NDU_0362a071-4f73-4775-a4b2-39ad4b13a6b0">96,513</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzgtMy0xLTEtMjI1NDU_9f3f37c6-83b9-47dc-9800-2e5927282109">47,347</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="idee3699378af4447a4091414c0adfaa7_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANGION BIOMEDICA CORP. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Loss </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Revenue:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Contract revenue</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMy0xLTEtMS0yMjU0NQ_cc3c8987-c06d-46ec-bfb3-12e25ef081a1">27,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMy0zLTEtMS0yMjU0NQ_b852958e-db4a-4368-93af-33c782466fdf">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Grant revenue</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfNC0xLTEtMS0yMjU0NQ_995d8679-2b7f-43c8-a016-a9651fb778a3">806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:RevenueNotFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfNC0zLTEtMS0yMjU0NQ_bf3205f1-644a-4dd1-ab16-0738cf100412">2,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total revenue</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfNS0xLTEtMS0yMjU0NQ_8857064c-5e92-4378-8691-4a7f93f4641a">28,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfNS0zLTEtMS0yMjU0NQ_70ff4fb7-2d8c-4658-8d10-667bc0328158">2,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Operating expenses:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Cost of grant revenue</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfOC0xLTEtMS0yMjU0NQ_0bb7c854-b9ce-467c-8fc6-a452f0e2f04b">433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfOC0zLTEtMS0yMjU0NQ_a26ee83d-7bae-4b10-aead-32b7b3abf547">1,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Research and development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfOS0xLTEtMS0yMjU0NQ_3686c769-ad00-4c63-a412-1a0c59378085">48,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfOS0zLTEtMS0yMjU0NQ_35fa219b-16d9-4187-8959-2e043af2cc76">38,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">General and administrative</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTAtMS0xLTEtMjI1NDU_bdd8254e-2faa-41b4-8a40-4a77007a2f75">18,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTAtMy0xLTEtMjI1NDU_0b724f55-80b3-42bd-8519-e1b58ec567e8">17,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total operating expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTEtMS0xLTEtMjI1NDU_1a9c0928-321b-4cd7-b72c-cdef98e334f2">67,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTEtMy0xLTEtMjI1NDU_c25e63fc-d965-4c17-a156-0c85d876179c">58,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Loss from operations</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTItMS0xLTEtMjI1NDU_d4d41917-74e9-4105-ad0d-b8487368e50f">39,307</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTItMy0xLTEtMjI1NDU_c2c198ed-61ca-4cc2-a41c-6b24f3df2aa7">55,273</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Other income (expense)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Change in fair value of warrant liability</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTQtMS0xLTEtMjI1NDU_c08958f2-87b8-47bb-b4e2-3e33157bc2fe">2,919</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTQtMy0xLTEtMjI1NDU_b1a3ac60-e484-423d-8452-a4c898b5707b">4,910</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Change in fair value of convertible notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTUtMS0xLTEtMjI1NDU_1e1f4445-4675-491e-ad1e-c14e8686760b">7,469</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTUtMy0xLTEtMjI1NDU_42a85e4b-700c-40a9-bd28-5e98b7f89224">11,353</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Change in fair value of Series C convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" sign="-" name="angn:FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTYtMS0xLTEtMjI1NDU_54c78360-9edc-40f9-b1cf-db2ff3d897f6">3,592</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" sign="-" name="angn:FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTYtMy0xLTEtMjI1NDU_20244d70-0359-4f93-a627-ea32ea498940">264</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Foreign exchange transaction gain (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTctMS0xLTEtMjI1NDU_3e333e12-97a9-4044-b41d-9d44e81cb319">245</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTctMy0xLTEtMjI1NDU_5bbebee1-d393-4c91-a3e8-7a7fce2f297e">668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Loss on disposal of fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTgtMS0xLTEtMjI1NDU_00dffd5f-481e-4316-91ab-403485b7d6ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTgtMy0xLTEtMjI1NDU_5596a917-ead0-4ecf-b74b-6e9bcc79553a">58</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Gain upon debt extinguishment </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTktMS0xLTEtMzc4MzI_2f8befe6-3f68-4b4f-823b-5a1b7e0c9a59">905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTktMy0xLTEtMzc4MzI_0f7518f9-24ac-4038-acbd-4d5e10319aa2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Losses in equity method investment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTktMS0xLTEtMjI1NDU_f76e8567-f0cc-43b1-91bb-0296d9805f64">99</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTktMy0xLTEtMjI1NDU_9e5142be-329b-4684-b0f3-405fa8ea8e06">71</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Interest income (expense), net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjAtMS0xLTEtMjI1NDU_bf7b59a8-210d-4a74-865a-86f776eba2db">1,847</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjAtMy0xLTEtMjI1NDU_67a63e83-2117-41dc-ac8f-1e5129bdecf9">8,846</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total other income (expense)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjEtMS0xLTEtMjI1NDU_dc0c084d-3ea8-4d90-9658-c495c74eff81">15,266</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjEtMy0xLTEtMjI1NDU_87090cfb-6a85-464d-a509-e1aafb9dd7fa">24,834</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Net loss</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjItMS0xLTEtMjI1NDU_811dc8e2-78ce-4d50-9048-f8960f79f901">54,573</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjItMy0xLTEtMjI1NDU_f024e993-06db-4a34-84dd-a47f4722ad41">80,107</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:30.6pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Foreign currency translation adjustment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjQtMS0xLTEtMjI1NDU_41a53d7e-8b59-443e-809b-9ce93f1a30fe">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjQtMy0xLTEtMjI1NDU_7ed6cc23-3497-4f28-8a4e-2e8906a48d51">333</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Comprehensive loss</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjUtMS0xLTEtMjI1NDU_cea26a49-fe66-44f0-8f60-27c973d344dd">54,343</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjUtMy0xLTEtMjI1NDU_b1f9d425-331b-442d-9a49-6948c48ec362">80,440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net loss per common share, basic and diluted</span></div></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjYtMS0xLTEtMjI1NDU_39427dc8-e2bb-4dd5-83bd-9b4a8cd54fac"><ix:nonFraction unitRef="usdPerShare" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjYtMS0xLTEtMjI1NDU_63fdd590-3976-4220-811b-3a502b6ba046">1.93</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjYtMy0xLTEtMjI1NDU_7043520e-5384-49da-9a1b-e2586f3b3a5b"><ix:nonFraction unitRef="usdPerShare" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjYtMy0xLTEtMjI1NDU_cf0476ad-e429-4060-b77d-7a0fa9dca8b0">5.43</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Weighted average common shares outstanding, basic and diluted</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjctMS0xLTEtMjI1NDU_4932bb72-d22d-45db-bcbb-740f62e5da34"><ix:nonFraction unitRef="shares" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjctMS0xLTEtMjI1NDU_e7255d3e-f3ba-40f1-aa37-7f7321e45e4e">28,244,825</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjctMy0xLTEtMjI1NDU_51d95e0f-7ab9-4851-bf2b-b69c43c4aa2b"><ix:nonFraction unitRef="shares" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjctMy0xLTEtMjI1NDU_59e6d4ab-b47b-4f2c-ae31-48b9655b7db2">14,762,120</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="idee3699378af4447a4091414c0adfaa7_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANGION BIOMEDICA CORP. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders' Equity (Deficit)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.275%"></td><td style="width:0.1%"></td></tr><tr style="height:31pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Common Stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Treasury Stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Paid-in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Accumulated Other Comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Accumulated </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Total </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Stockholders'</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Equity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(Deficit)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Amount</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Amount</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9e83b2738e914f70885e201c75695d23_I20191231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfOC0yLTEtMS0zODUyOQ_bdb1c98a-985c-498e-85f3-f10f7f5e8909">14,758,718</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e83b2738e914f70885e201c75695d23_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfOC00LTEtMS0zODUzMQ_7e03df8e-ba41-4f24-8e1f-df7d4b63b564">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iea8b4e5177ca414aa1d42917857fa7fc_I20191231" decimals="INF" sign="-" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfOC02LTEtMS0zODUzMQ_e9a3b5bb-365a-4c10-9317-f9abccb1f209">312,164</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iea8b4e5177ca414aa1d42917857fa7fc_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfOC04LTEtMS0zODUzMQ_3b9b6d80-3fb1-45a6-903d-fb8d6ecbf384">1,810</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39a22dafc7b947b7b1c0010ac7f3da2a_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfOC0xMC0xLTEtMzg1MzE_35c09781-0923-43cb-8777-934ffa76075b">63,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06808f2a95374e118cce43e36bb8bd8a_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfOC0xMi0xLTEtMzg1MzE_36f0cec1-507b-44e3-8a0a-a057d18149fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idc9576f67b6c4e84ac9a7860f4e882ba_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfOC0xNC0xLTEtMzg1MzE_034884a8-76e8-47d5-88e6-e1560d168ff8">80,455</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08c03f72f0b941539e5cdcb6bd71e375_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfOC0xNi0xLTEtMzg1MzE_1dfb6088-9e47-4911-9203-98bfba9618f3">18,586</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of broker warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1c7b28f9b2847048f8bff454357f045_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfOS0xMC0xLTEtMzg1MzU_1acdd01e-5114-4e4f-ab07-9af27becc75d">3,095</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfOS0xNi0xLTEtMzg1MzU_45a38030-4b61-4c4b-b883-a1a8ef24f419">3,095</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of broker warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88205c729a864e89b707c0e5f4a94101_D20200101-20201231" decimals="INF" name="angn:StockIssuedDuringPeriodSharesBrokerWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTAtMi0xLTEtMzg1MzU_fc90e211-c038-4af9-b7d4-fe80f3a53af0">572,946</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88205c729a864e89b707c0e5f4a94101_D20200101-20201231" decimals="-3" name="angn:StockIssuedDuringPeriodValueBrokerWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTAtNC0xLTEtMzg1MzU_9ae61e99-6c39-407e-bbb5-c59aa9f8ccbd">6</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1c7b28f9b2847048f8bff454357f045_D20200101-20201231" decimals="-3" sign="-" name="angn:StockIssuedDuringPeriodValueBrokerWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTAtMTAtMS0xLTM4NTM1_1b5fb614-e4b6-41d6-915b-fdd3427a50dd">2</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="angn:StockIssuedDuringPeriodValueBrokerWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTAtMTYtMS0xLTM4NTM1_05b372e0-2f8d-4b90-ad3d-eac19e41cc02">4</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88205c729a864e89b707c0e5f4a94101_D20200101-20201231" decimals="INF" name="angn:StockIssuedDuringPeriodSharesWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTEtMi0xLTEtMzg1Mzc_0600087c-e8bb-4e5a-832c-e9f18eb34764">93,349</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88205c729a864e89b707c0e5f4a94101_D20200101-20201231" decimals="-3" name="angn:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTEtNC0xLTEtMzg1NDA_31d214c4-6429-43f3-80ae-cd3f3840d9a9">1</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1c7b28f9b2847048f8bff454357f045_D20200101-20201231" decimals="-3" name="angn:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTEtMTAtMS0xLTM4NTQ2_d836827f-a884-4f56-b218-4a4aad09b10a">750</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="angn:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTEtMTYtMS0xLTM4NTQz_4aad4247-056b-49db-9e14-c24835bff65b">751</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88205c729a864e89b707c0e5f4a94101_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTItMi0xLTEtMzg1NDk_a6842fa0-dc39-477c-a761-65fe2cacdd23">194,427</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88205c729a864e89b707c0e5f4a94101_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTItNC0xLTEtMzg1NTI_06922b44-361c-4bd6-afc7-e233a6ae0be3">1</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1c7b28f9b2847048f8bff454357f045_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTItMTAtMS0xLTM4NTU1_897350a4-be43-469c-ace7-88bd4415351f">46</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTItMTYtMS0xLTM4NTU4_4ce4e5c0-c99e-4b63-8701-5ae19694c414">47</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Restricted stock units releases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88205c729a864e89b707c0e5f4a94101_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTMtMi0xLTEtMzg1NjE_ed1e0360-566d-459f-8f46-12e1e71cdf42">13,369</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Return of common stock to pay withholding taxes on restricted stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iff68735442874854ba8906f0ce685f7a_D20200101-20201231" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTQtNi0xLTEtMzg1NzA_d07dd5eb-8889-464c-a624-ec4e7039491d">3,924</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff68735442874854ba8906f0ce685f7a_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTQtOC0xLTEtMzg1NjQ_598ab050-57f4-4b69-a21c-ee1236c74801">36</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTQtMTYtMS0xLTM4NTY3_a72c78a2-9e22-427d-b9d8-bfffd0154eec">36</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1c7b28f9b2847048f8bff454357f045_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTUtMTAtMS0xLTM4NTcz_7441f262-96d7-4a1f-ac1f-29590ad9b9d7">4,716</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTUtMTYtMS0xLTM4NTcz_406eaacb-5a9d-44ea-aa51-9f7ef4443cbb">4,716</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49e1595df6544da1b62cb4cb76e2a870_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTYtMTItMS0xLTM4NTcz_4494f8be-7717-4999-91d1-0a5b46f0e9d0">333</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTYtMTYtMS0xLTM4NTcz_12c2055c-edf5-4d7b-99fb-fff1cb3aa98e">333</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7785562bdf04065b88581e12664c38d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTctMTQtMS0xLTM4NTcz_8b5866ea-8f75-4091-ad29-9454608b1c50">80,107</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTctMTYtMS0xLTM4NTcz_06b714d2-7708-4983-b7fc-e89d81d216c5">80,107</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iac2dd912c60747d0ad5686735d31aabd_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTgtMi0xLTEtMzg1MzM_2e0c214d-9380-43cd-929b-678ea2458e70">15,632,809</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac2dd912c60747d0ad5686735d31aabd_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTgtNC0xLTEtMzg1MzM_b26c5337-81e5-4e66-ad5f-e863d78c6369">156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib63d42df1d424dd7a089a2a61055a8d8_I20201231" decimals="INF" sign="-" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTgtNi0xLTEtMzg1MzM_35d4dc91-b972-440d-a375-88231eb05f15">316,088</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63d42df1d424dd7a089a2a61055a8d8_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTgtOC0xLTEtMzg1MzM_591971e1-7c45-4d18-a43e-d37e256ba2d9">1,846</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i627eb8ac3c1e4cdba53546b28b5c0c96_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTgtMTAtMS0xLTM4NTMz_80e1c196-bd5e-4937-98d6-35646b175cb6">72,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a141da19f2749e9915716c7f48fd1ed_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTgtMTItMS0xLTM4NTMz_e8a9fbfb-fc7e-4195-90cc-93b3760e3783">333</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcfdf8709ae1454db935f48886a3448d_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTgtMTQtMS0xLTM4NTMz_3f1fc45d-4d73-4b91-a2f3-5084564123d5">160,562</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTgtMTYtMS0xLTM4NTMz_be959392-f61b-4f11-8773-dd35dd85ab27">90,449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANGION BIOMEDICA CORP. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders' Equity (Deficit)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.073%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.232%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.193%"></td><td style="width:0.1%"></td></tr><tr style="height:31pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Common Stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Treasury Stock</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Paid-in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Accumulated Other Comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Accumulated </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Total </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Stockholders'</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Equity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(Deficit)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Amount</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Amount</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iac2dd912c60747d0ad5686735d31aabd_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOC0yLTEtMS0yNTY0Mw_fbc3b79d-b7b9-46fc-b5b2-e32574304ece">15,632,809</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac2dd912c60747d0ad5686735d31aabd_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOC00LTEtMS0yNTY0Mw_0ab42be0-c588-4344-bd50-a81ee18d5a8e">156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib63d42df1d424dd7a089a2a61055a8d8_I20201231" decimals="INF" sign="-" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOC02LTEtMS0yNTY0Mw_65feef5f-88b8-43dc-b68f-ffa9a0328306">316,088</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib63d42df1d424dd7a089a2a61055a8d8_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOC04LTEtMS0yNTY0Mw_ee76a2f3-ac59-47d4-9424-ed6575e6f140">1,846</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i627eb8ac3c1e4cdba53546b28b5c0c96_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOC0xMC0xLTEtMjU2NDM_bf54a672-4bf9-4032-b330-01bc5f595137">72,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a141da19f2749e9915716c7f48fd1ed_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOC0xMi0xLTEtMjU2NDM_29027b91-b506-4fed-a176-45e29174f0ef">333</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcfdf8709ae1454db935f48886a3448d_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOC0xNC0xLTEtMjU2NDM_7a169451-8a62-45c8-8d1e-f554666d6849">160,562</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOC0xNi0xLTEtMjU2NDM_a22bd435-7018-40bd-a780-476bdad7c1b1">90,449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon initial public offering, net of issuance costs, discount, and commissions of $<ix:nonFraction unitRef="usd" contextRef="iacbac71171a247f19b7f67fb114cc51b_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMy0wLTEtMS0yNTc4OS90ZXh0cmVnaW9uOjVlMTg5YzMyMWNkMzQ5NDFhZDdmZjRhMTA4YmNlMzFmXzEwOTk1MTE2Mjc5MTE_b1ec1b2c-4924-43d9-b232-22a6d538a434">9.3</ix:nonFraction>&#160;million</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c2584c4d4d14f87943a1ff43186ef4d_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOS0yLTEtMS0yNTY0Mw_b2128961-aafe-4b7c-81a3-543bbde8bb2c">5,750,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2584c4d4d14f87943a1ff43186ef4d_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOS00LTEtMS0yNTY0Mw_c54e6c80-ab3a-44b8-a7f7-b31ffcd4c493">58</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if64d03bb45484664ab00b5e9ac3b4129_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOS0xMC0xLTEtMjU2NDM_0818d534-8fbd-4fb1-8b63-804f38d4da16">82,657</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacbac71171a247f19b7f67fb114cc51b_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOS0xNi0xLTEtMjU2NDM_08363ac7-94b6-4247-9c4d-ba4047305d59">82,715</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon Concurrent Private Placement, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i50d5f86cb19d42ff8235b613207c2abe_D20210101-20211231" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNC0wLTEtMS0yNTgwNS90ZXh0cmVnaW9uOmIxMDgzNWQ3YTY2MzQxY2M4MzBmMWI3ZmQ4NDQ4MjNmXzEwOTk1MTE2Mjc4ODk_4bed1bca-a8a7-4fa4-b3f1-a26b2c2f68e4">0.7</ix:nonFraction>&#160;million</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d292d5da1514f2bbaf90a5652db785c_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNC0yLTEtMS0yNTczNQ_89dc7c64-31f8-4606-8d28-111155b72e91">1,562,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d292d5da1514f2bbaf90a5652db785c_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNC00LTEtMS0yNTczNQ_75345a05-40e1-4f69-9cc8-f0d72a473642">16</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e02d3c90cee46fb92a3c766d05f4b5a_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNC0xMC0xLTEtMjU3MzU_5248b3b3-cc7a-45db-8c5b-e0d4cfe72d4a">24,234</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50d5f86cb19d42ff8235b613207c2abe_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNC0xNi0xLTEtMjU3MzU_6fa9ae35-cc3d-4668-8645-08f26e24c6d3">24,250</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Conversion of convertible preferred stock into common stock upon IPO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56986948e86b485b8509172b9334c746_D20210101-20211231" decimals="INF" name="angn:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNS0yLTEtMS0yNTczNQ_d78a6312-b5a0-451e-8df0-02f4b3149672">2,234,640</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56986948e86b485b8509172b9334c746_D20210101-20211231" decimals="-3" name="angn:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNS00LTEtMS0yNTczNQ_e0e8fd9a-51ba-4bc2-8a9f-b83421658a0d">22</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd0806ead4944367a276b62a1b32bafa_D20210101-20211231" decimals="-3" name="angn:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNS0xMC0xLTEtMjU3MzU_f1cd7d38-6d24-44be-a609-05c4ffdd4427">35,732</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="angn:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNS0xNi0xLTEtMjU3MzU_4fd72843-fdb3-492a-9abf-9af738f253e1">35,754</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Conversion of convertible notes into common stock upon initial public offering</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c2584c4d4d14f87943a1ff43186ef4d_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNi0yLTEtMS0yNTczNQ_6c9dfa1a-3236-43ab-a72e-2ee9fbe9ea1d">3,636,189</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2584c4d4d14f87943a1ff43186ef4d_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNi00LTEtMS0yNTczNQ_7bdd2984-7d62-4045-92f5-04864465b64f">36</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if64d03bb45484664ab00b5e9ac3b4129_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNi0xMC0xLTEtMjU3MzU_99f70c9d-f06e-43dc-917d-20cd299fdcca">58,143</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacbac71171a247f19b7f67fb114cc51b_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNi0xNi0xLTEtMjU3MzU_a220ed8f-e0f8-4698-b8ce-50e8442395d8">58,179</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Conversion of convertible notes prior to IPO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86478d7cb5144b47ad734b74bf2a7754_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNy0yLTEtMS0yNTczNQ_bfbdc4d3-d28e-433b-bee6-c8113d1f7031">33,978</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica25c8fd34524de8a476208cd00f9f89_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNy0xMC0xLTEtMjU3MzU_e8b61886-5a51-4c16-b791-da7b968692a1">460</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07f8bd8a51284654b005b52b3db91334_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNy0xNi0xLTEtMjU3MzU_6870fbef-64b6-4d27-a0ba-7469b090d8ab">460</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net exercise of warrants upon initial public offering</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c2584c4d4d14f87943a1ff43186ef4d_D20210101-20211231" decimals="INF" name="angn:StockIssuedDuringPeriodSharesWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOC0yLTEtMS0yNTczNQ_0ca1cd6a-846f-400c-b257-5c578d15dfe2">844,335</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2584c4d4d14f87943a1ff43186ef4d_D20210101-20211231" decimals="-3" name="angn:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOC00LTEtMS0yNTczNQ_fabd1420-02a7-4d97-a983-1592094af1c5">9</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if64d03bb45484664ab00b5e9ac3b4129_D20210101-20211231" decimals="-3" name="angn:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOC0xMC0xLTEtMjU3MzU_601655c0-b782-44ee-bc2d-374101ab41c5">13,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacbac71171a247f19b7f67fb114cc51b_D20210101-20211231" decimals="-3" name="angn:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOC0xNi0xLTEtMjU3MzU_69e7ef24-51cd-4b15-8496-d4b6417c5ec4">13,509</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fractional shares paid out related to the forward stock split</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd0806ead4944367a276b62a1b32bafa_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOS0xMC0xLTEtMjU3MzU_498d4948-5a63-4679-983a-a6baafd2d288">10</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOS0xNi0xLTEtMjU3MzU_67a83a38-77a7-457e-ba01-bf26f73c0b9a">10</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Exercise of broker warrants</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56986948e86b485b8509172b9334c746_D20210101-20211231" decimals="INF" name="angn:StockIssuedDuringPeriodSharesBrokerWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTAtMi0xLTEtMjU2NDM_3f4e65a0-49b4-4800-b5a7-2d9a1f6b8db6">47,188</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Exercise of warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86478d7cb5144b47ad734b74bf2a7754_D20210101-20211231" decimals="INF" name="angn:StockIssuedDuringPeriodSharesWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTEtMi0xLTEtMjU2NDM_a9793bf4-9c68-499d-8929-dc2c70cb5b5c">130,529</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86478d7cb5144b47ad734b74bf2a7754_D20210101-20211231" decimals="-3" name="angn:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTEtNC0xLTEtMjU2NDM_24d43727-eab1-49c9-ae51-8b5d04e00021">2</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica25c8fd34524de8a476208cd00f9f89_D20210101-20211231" decimals="-3" name="angn:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTEtMTAtMS0xLTI1NjQz_71a17027-be4d-4a56-b2eb-2f96ac599ab6">859</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07f8bd8a51284654b005b52b3db91334_D20210101-20211231" decimals="-3" name="angn:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTEtMTYtMS0xLTI1NjQz_9501fdf0-c677-459e-86ba-1cc807d945aa">861</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56986948e86b485b8509172b9334c746_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTItMi0xLTEtMjU2NDM_106dec8d-6c52-41af-bebc-cdb33fb35349">152,939</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56986948e86b485b8509172b9334c746_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTItNC0xLTEtMjU2NDM_622dc7e3-0b58-4008-96b4-96404b89eef3">1</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd0806ead4944367a276b62a1b32bafa_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTItMTAtMS0xLTI1NjQz_3d1478ed-4f72-4d41-a193-4df68a13af3e">979</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTItMTYtMS0xLTI1NjQz_2c7c9b44-b75c-4dfb-a390-d00df6381152">980</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Restricted stock units releases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56986948e86b485b8509172b9334c746_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTMtMi0xLTEtMjU2NDM_e5145174-8443-4b7c-a62e-f935b2e89889">414,896</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56986948e86b485b8509172b9334c746_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTMtNC0xLTEtMjU2NDM_53622faa-c671-40eb-b714-c85ce609f100">4</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd0806ead4944367a276b62a1b32bafa_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTMtMTAtMS0xLTI1NjQz_446c3173-835a-4958-8044-b57856806126">14</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTMtMTYtMS0xLTI1NjQz_9dedcc51-78b6-4536-9748-3586c53e58e8">18</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Return of common stock to pay withholding taxes on restricted stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4a9ed117e7fc46209cfe726bed834b25_D20210101-20211231" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTQtNi0xLTEtMjU2NDM_5c5dd8a0-bb17-4078-987b-f8808847ddc1">164,855</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a9ed117e7fc46209cfe726bed834b25_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTQtOC0xLTEtMjU2NDM_aed1e016-4246-45c4-8de1-67f4b70ee04b">2,364</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd0806ead4944367a276b62a1b32bafa_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTQtMTAtMS0xLTI1NjQz_2039baa3-8a5b-49ca-9ab8-e5040582e393">94</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTQtMTYtMS0xLTI1NjQz_2bf113ab-2435-497f-a68c-a222faa64751">2,458</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Retirement of treasury stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i56986948e86b485b8509172b9334c746_D20210101-20211231" decimals="INF" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTUtMi0xLTEtMjU2NDM_6e2243f2-142b-4fb0-bf7a-a2d990bf0c7c">480,943</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56986948e86b485b8509172b9334c746_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTUtNC0xLTEtMjU2NDM_d1f62946-4151-4cc5-8fd4-7936925a8e72">4</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a9ed117e7fc46209cfe726bed834b25_D20210101-20211231" decimals="INF" name="us-gaap:TreasuryStockSharesRetired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTUtNi0xLTEtMjU2NDM_8454b7ed-1b9f-408d-874c-f6daac96a372">480,943</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a9ed117e7fc46209cfe726bed834b25_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTUtOC0xLTEtMjU2NDM_5bd1a06e-45a8-49c7-a12f-e4b99d2c7e61">4,210</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd0806ead4944367a276b62a1b32bafa_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTUtMTAtMS0xLTI1NjQz_53f33053-4106-4e8d-a5bf-a7be2e9c6a98">4,206</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTUtMTYtMS0xLTI1NjQz_374a1c89-b455-4774-ae4e-212c0ebb16e2">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Stock-based compensation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd0806ead4944367a276b62a1b32bafa_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTYtMTAtMS0xLTI1NjQz_e6590c0e-455a-4312-a6a3-daf47899d5d8">12,041</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTYtMTYtMS0xLTI1NjQz_a0bc39b4-118c-4120-a558-1a9d6ffbb376">12,041</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d21085dc3464fd4a077a8c4c29dc3df_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTgtMTItMS0xLTI1NzU5_6ef20a53-c550-479d-a785-6c4b736bd16a">230</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTgtMTYtMS0xLTI1NzU5_414f11f9-0fdb-4046-8f60-c9f5ed9cad6e">230</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net loss</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c5cb1b641df48b3990cc9378065cd00_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTctMTQtMS0xLTI1NjQz_f9689f14-c269-4b1e-96b0-165332f736ba">54,573</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTctMTYtMS0xLTI1NjQz_ec791904-d9ef-41e3-bf87-7e3b6365235c">54,573</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd74872b5622480ab9e4a8966ba04e3e_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTgtMi0xLTEtMjU2NDM_971ba20e-9fe1-4ac5-a6d1-abb376036887">29,959,060</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd74872b5622480ab9e4a8966ba04e3e_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTgtNC0xLTEtMjU2NDM_a5897f04-acef-4d36-9e08-2b8453fa14d5">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c838774341347d18b026f9d063c570d_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTgtNi0xLTEtMjU2NDM_6a3be143-d853-418a-a1d3-cb17c94bb9f8">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c838774341347d18b026f9d063c570d_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTgtOC0xLTEtMjU2NDM_b6424ad6-ee87-43a2-b1ac-edafe3597b39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88e560ec37ce491aadf9eb36b18848d0_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTgtMTAtMS0xLTI1NjQz_291b8193-a7e1-4aca-b9ef-a6a8d0ca4a72">296,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida615667cda8491fabc586af6ea6cb44_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTgtMTItMS0xLTI1NjQz_2b84e444-8ca7-425a-bb1f-81c95719c15f">103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd7eeb679a3a4b8b9e9dd842d2ac9f04_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTgtMTQtMS0xLTI1NjQz_7b1a5499-61ac-40bb-9b63-71938bc99a59">215,135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTgtMTYtMS0xLTI1NjQz_a274c701-e782-49bb-92c7-efc37131f910">81,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="idee3699378af4447a4091414c0adfaa7_97"></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANGION BIOMEDICA CORP. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cash flows from operating activities</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Net loss</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMy0xLTEtMS0yMjU0NQ_8e5bd2c2-e973-44db-be92-f1ac251d3b74">54,573</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMy0zLTEtMS0yMjU0NQ_96a42fac-06e0-4f37-8c6d-e9c10e5efad6">80,107</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Adjustments to reconcile net loss to net cash used in operating activities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNS0xLTEtMS0yMjU0NQ_71a7137f-0fb1-421a-a673-65ee7c3cff62">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNS0zLTEtMS0yMjU0NQ_8fa7fdfc-0295-42e9-a444-b24bf5decd7e">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Amortization of right of use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNi0xLTEtMS0yMjU0NQ_2b3127d6-29da-47e1-8eb0-229d2c032fd5">710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNi0zLTEtMS0yMjU0NQ_2dc3ccc9-893e-405f-af9d-4cec0513abea">530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNy0xLTEtMS0yMjU0NQ_1ff9de30-eb5d-4208-8cc1-240af9bc84ce">1,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNy0zLTEtMS0yMjU0NQ_557530de-af42-4ba8-a1e6-10f055acbf07">7,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Non-cash placement agent fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="angn:NonCashPlacementAgentFee" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfOC0xLTEtMS0yMjU0NQ_b6406c8a-c60f-44cc-9768-0c8470d9d646">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="angn:NonCashPlacementAgentFee" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfOC0zLTEtMS0yMjU0NQ_39d4ac98-ccc2-4799-a0ad-d6dc579c1ac4">1,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">PPP Loan forgiveness </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfOS0xLTEtMS0yNjU3Ng_ec3b8833-21f7-4815-acd1-c2f6d23ff958">905</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfOS0zLTEtMS0yODQxNw_e77ba8a2-1643-4a39-8fff-862c9769c9db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfOS0xLTEtMS0yMjU0NQ_4dbf3129-a649-44f8-86bf-959aaf762db6">12,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfOS0zLTEtMS0yMjU0NQ_0089943b-e2ac-411d-9b2e-405b0096bd72">4,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Change in fair value of convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMTEtMS0xLTEtMjI1NDU_1ec84b65-3c6b-408d-a95d-daf9cabc3047">7,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMTEtMy0xLTEtMjI1NDU_adc4364f-bbb9-46c0-b730-f6d988e71a72">11,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Change in fair value of Series C convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" sign="-" name="angn:FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMTItMS0xLTEtMjI1NDU_928c19a4-0dd3-45ad-991c-4834386f715b">3,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" sign="-" name="angn:FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMTItMy0xLTEtMjI1NDU_c5903efd-d7bc-48e4-b350-6df26b79abd5">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMTMtMS0xLTEtMjI1NDU_ae7874cb-6651-4449-a436-92b93af1e407">2,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMTMtMy0xLTEtMjI1NDU_f89f5a61-12c9-4547-90c4-400af8962f69">4,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Impairment of leased assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMTUtMS0xLTEtMjI1NDU_55bea137-27ce-4b2e-84ed-7c97be06a04f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseImpairmentLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMTUtMy0xLTEtMjI1NDU_dcc513ec-c382-44b1-a9ac-e9eb4125c312">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Losses from equity investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMTYtMS0xLTEtMjI1NDU_2b0c0c30-bf05-4e9f-a7fd-82726be47b74">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMTYtMy0xLTEtMjI1NDU_2f4f6dbb-bc8e-4a2b-9001-3eaeebcb7e05">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:8pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Distribution from equity investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMTctMS0xLTEtMjI1NDU_9fa3abd6-ad68-4826-8b73-9b0711beebca">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMTctMy0xLTEtMjI1NDU_d9d757d2-8385-4860-bfa9-adbc0bf01c99">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Changes in operating assets and liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Grants receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="angn:IncreaseDecreaseInGrantReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMTktMS0xLTEtMjI1NDU_344a552d-afc6-4394-8c02-372a9ebd5d0d">806</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" sign="-" name="angn:IncreaseDecreaseInGrantReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMTktMy0xLTEtMjI1NDU_418a96bf-6021-46ea-846a-7498661e1f08">440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjAtMS0xLTEtMjI1NDU_2a059c36-f076-4b46-8882-bc17a0308ba0">4,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjAtMy0xLTEtMjI1NDU_a3024b1d-e5d5-418f-b0d7-0d313b06a4f9">2,020</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:17pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Other assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjEtMS0xLTEtMjY0Mzc_ff8d6461-42f2-49a2-9e6d-b8ef44b7dbac">106</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjEtMy0xLTEtMjY0Mzc_9605f2f4-1580-4f00-ab28-8403a75ba550">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Accounts payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjEtMS0xLTEtMjI1NDU_e6c9a3f3-e238-40ab-9613-0979647566ef">866</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjEtMy0xLTEtMjI1NDU_3958ae02-a7cd-4b18-a419-bb6093fd97a5">5,607</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Accrued expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjItMS0xLTEtMjI1NDU_5cb0e351-dcf2-41f0-adc2-d3539e26aca9">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjItMy0xLTEtMjI1NDU_cbfa3d0f-dbd5-4d6b-993c-6f366a3dbdcd">3,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjMtMS0xLTEtMjI1NDU_e9073398-e981-49c0-94a4-0991f4df3051">713</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjMtMy0xLTEtMjI1NDU_cc6e5c10-0eea-4b60-aace-53d7d4a14283">560</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:17pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjUtMS0xLTEtMjI1NDU_775f9934-4153-44af-b05c-34170ed9c02c">27,506</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjUtMy0xLTEtMjI1NDU_e3518eb5-a38b-4ce9-9f60-e299a2290af1">29,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Net cash used in operating activities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjYtMS0xLTEtMjI1NDU_f0e54a41-2f19-487e-85f7-29e7009ab162">52,643</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjYtMy0xLTEtMjI1NDU_345defa0-32a0-4f0d-b990-096042d9bd08">22,888</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cash flows from investing activities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Purchase of fixed assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjgtMS0xLTEtMjI1NDU_b8ebe31b-7376-498a-9f3e-9dd028cf802b">382</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjgtMy0xLTEtMjI1NDU_f32fd42a-4aac-42af-ab40-ce66a14ef668">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Net cash used in investing activities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjktMS0xLTEtMjI1NDU_36d7067d-944e-4295-a35c-4d6705db56fd">382</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjktMy0xLTEtMjI1NDU_6f583cbf-d3a1-4b13-b964-6ba4aea3db74">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cash flows from financing activities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Net proceeds from issuance of common stock upon IPO and Concurrent Private Placement, net of discount, commissions and offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzItMS0xLTEtMjY0NTQ_12cfbbb4-3976-4a6b-a614-a0f7c87601b7">107,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzItMy0xLTEtMjY0NTQ_4bad7ce3-00ba-4b6f-9eb1-f18565191488">522</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:17pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Proceeds from issuance of convertible notes and warrants</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzItMS0xLTEtMjI1NDU_53f1b84c-a4ec-43fd-851b-db82d3f0a7a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzItMy0xLTEtMjI1NDU_aa01cf80-79ed-41c6-9311-36a789d4798a">31,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:17pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Proceeds from issuance of Series C convertible preferred stock, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzMtMS0xLTEtMjI1NDU_ad9ba722-a2d0-469a-8421-dac7ea50ac0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzMtMy0xLTEtMjI1NDU_3003ccbf-95c2-49e2-8ba8-9e3ca015571c">20,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:17pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Proceeds from loan from PPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzQtMS0xLTEtMjI1NDU_8f553c41-30bb-48b8-b7cc-b59aa775307d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzQtMy0xLTEtMjI1NDU_b2922e9f-99cf-4858-8781-dce4128b7d01">895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:17pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Proceeds from financing obligation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="angn:ProceedsFromFinancingObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzYtMS0xLTEtMjY0NjY_30e6428b-ba82-4ea1-922a-e5dc7b7eff05">302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="angn:ProceedsFromFinancingObligation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzYtMy0xLTEtMjY0NjY_1846b3b9-37da-49ba-bb69-bbfe55dc6a46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:17pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Proceeds from RSU settlement </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzctMS0xLTEtMjY0ODY_63477fdf-215c-467f-b9ef-72e3fc4f54c7">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzctMy0xLTEtMjY0ODY_cf062d31-8fcd-4d52-bf59-43571d71da3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:17pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Payment of financing obligation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzctMS0xLTEtMjY0NzY_10a48a76-9547-4d98-85d4-370edf7f76e3">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" sign="-" xsi:nil="true" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzctMy0xLTEtMjg0Mjc_11764892-17e4-4981-8b43-4b7505e91438"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:17pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Fractional share payments related to the forward stock split </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="angn:PaymentsForForwardStockSplitFractionalShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzktMS0xLTEtMjY1MTc_d62180e7-b4c6-4a19-b7b9-4dfc5a162216">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="angn:PaymentsForForwardStockSplitFractionalShares" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzktMy0xLTEtMjY1MTc_8fef9466-0f54-4bcd-a539-11e99299c310">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:17pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Taxes paid related to net share settlement upon vesting of restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzYtMS0xLTEtMjI1NDU_0f62631f-a5b2-4f6d-a36f-6c027bd5b06d">2,458</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzYtMy0xLTEtMjI1NDU_7451a7cd-bc59-4d58-8081-ba2f5f604a63">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:17pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Exercise of broker warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="angn:PaymentsForBrokerWarrantExercises" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzgtMS0xLTEtMjI1NDU_3d9cee32-39e5-42b8-b210-a4a4c111143d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" sign="-" name="angn:PaymentsForBrokerWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzgtMy0xLTEtMjI1NDU_3363616f-229e-494d-9e2a-2a9b7b7131a9">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:17pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Exercise of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzktMS0xLTEtMjI1NDU_2c039249-8545-415c-9096-0218e01d36f8">861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzktMy0xLTEtMjI1NDU_d8cc042f-c28f-4bdb-b6d4-887d66111d0c">751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:17pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDAtMS0xLTEtMjI1NDU_a71ba964-a46a-4dc2-85f1-3d967c70b773">980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDAtMy0xLTEtMjI1NDU_56f8bcf8-d004-45ac-bbd2-aff8a01f496b">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Net cash provided by financing activities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDEtMS0xLTEtMjI1NDU_53b93eb4-d77a-4932-a887-89efb54a7bdd">107,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDEtMy0xLTEtMjI1NDU_eab47076-309c-4580-8a53-3cbf0c1d2b67">52,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Effect of foreign currency on cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDItMS0xLTEtMjI1NDU_6f69a7a1-cdff-4d1c-b1c8-0e9c0b6610e3">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDItMy0xLTEtMjI1NDU_3c1a7a23-b978-4a1f-9c7c-051288184d11">444</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Net increase in cash and cash equivalents</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDMtMS0xLTEtMjI1NDU_4897acce-644a-438a-8c87-1826144cdbb6">54,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDMtMy0xLTEtMjI1NDU_21a35108-1576-4dd0-b8a2-eb28e8b79fec">29,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Cash and cash equivalents at the beginning of the period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDQtMS0xLTEtMjI1NDU_dda72b92-cfdb-45da-b21f-c8ed60189294">34,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i08c03f72f0b941539e5cdcb6bd71e375_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDQtMy0xLTEtMjI1NDU_0a3de56c-a316-46e4-a4e0-6129f0d2a305">5,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cash and cash equivalents at the end of the period</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDUtMS0xLTEtMjI1NDU_a0512131-f594-4cf5-94f4-a39b4dd85369">88,756</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDUtMy0xLTEtMjI1NDU_2a7a01a0-ee77-4333-9c56-8f96e7c317b1">34,607</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Cash paid for interest</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDYtMS0xLTEtMjI1NDU_4ced11f9-1326-4988-aa06-1949ec240a4a">7</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDYtMy0xLTEtMjI1NDU_835b6962-70ad-4cdd-90d2-415b33fbd747">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Supplemental disclosure of noncash investing and financing activities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Retirement of treasury stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="angn:StockRetired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDktMS0xLTEtMjI1NDU_b9045be2-fedd-43ba-8e39-b9882446057b">4,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="angn:StockRetired" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDktMy0xLTEtMjI1NDU_1832968e-8193-410b-90ec-38094477b782">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Conversion of convertible notes into common stock prior to IPO</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibc29760a066749a2a385abd329cceb8f_D20210101-20211231" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTUtMS0xLTEtMjY1MzY_e4a35182-5ab3-4894-9d72-91e7941d24c3">460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i03d5350f508b4144bc4917ef0ec5919e_D20200101-20201231" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTUtMy0xLTEtMjY1NDM_64f3652e-546e-42e9-a393-74d6928e7070">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:40.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Conversion of convertible notes to common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i38b7fad4d0a54f5b9f03bd9e2bdaa055_D20210101-20211231" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTYtMS0xLTEtMjY1MzY_d91c1344-0123-4dfc-90d1-be26aedccbd8">58,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i5e0337892efb4f628c26a60c7c2fcbaf_D20200101-20201231" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTYtMy0xLTEtMjY1NDM_d4c0a7ca-f415-4f62-856c-f5f057162013">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Conversion of Series C preferred stock to common stock upon IPO</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="iacbac71171a247f19b7f67fb114cc51b_D20210101-20211231" decimals="-3" name="us-gaap:ConversionOfStockAmountConverted1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTctMS0xLTEtMjY1MzY_24e68980-f697-4293-befd-6753e7942908">35,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i59b403c789684eb5976e604c15fb43a2_D20200101-20201231" decimals="-3" name="us-gaap:ConversionOfStockAmountConverted1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTctMy0xLTEtMjY1NDM_04ac9cdc-0075-481c-967d-0e6b0bb3ddc2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Net exercise of warrants upon IPO</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="iacbac71171a247f19b7f67fb114cc51b_D20210101-20211231" decimals="-3" name="angn:WarrantsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTgtMS0xLTEtMjY1MzY_92fababb-7c19-45d5-8c6a-5b608fd000b4">13,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i59b403c789684eb5976e604c15fb43a2_D20200101-20201231" decimals="-3" name="angn:WarrantsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTgtMy0xLTEtMjY1NDM_99ac06a1-8a58-42e0-9548-50ffb772ef28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Issuance of broker warrants with Series C convertible preferred stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="angn:IssuanceOfBrokerWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTAtMS0xLTEtMjI1NDU_da867fa8-171c-490d-b8b1-d7267b9ee9e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="angn:IssuanceOfBrokerWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTAtMy0xLTEtMjI1NDU_036af48d-84f9-44bd-b278-f64c851f189d">1,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Conversion of convertible notes to Series C convertible preferred stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i10126ff884f24cee9f145c0c6031e0c1_D20210101-20211231" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTEtMS0xLTEtMjI1NDU_28f1857d-77f8-4f63-b3de-d621ad521494">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1fd8ae3429f1487bb13c70c2678f3098_D20200101-20201231" decimals="-3" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTEtMy0xLTEtMjI1NDU_5f6ab47e-2d14-44f4-9779-8f49154d21ac">2,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Accrued interest premium for Series C convertible preferred stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="angn:AccruedInterestPremiumForConvertiblePreferredStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTItMS0xLTEtMjI1NDU_60e138ee-7564-45d8-95f2-13fdb576b14e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="angn:AccruedInterestPremiumForConvertiblePreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTItMy0xLTEtMjI1NDU_0148c6c5-37f3-4389-a49c-29f42707b089">295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Right of use assets exchanged for operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTMtMS0xLTEtMjI1NDU_eab45ddb-107a-4f98-abc0-9df7ac1afd28">624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTMtMy0xLTEtMjI1NDU_cd26cb76-c70c-4881-8b52-2ce64920be75">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Convertible notes issued in receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:NotesIssued1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTQtMS0xLTEtMjI1NDU_851fd121-74e4-4a2d-805e-3e28830d1610">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:NotesIssued1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTQtMy0xLTEtMjI1NDU_0491c7e2-e57d-4c55-9729-8f0cbab3b0d2">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Deferred offering costs in accrued expenses or accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTUtMS0xLTEtMjI1NDU_af48aab8-646d-4664-bf22-63e67a79b316">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTUtMy0xLTEtMjI1NDU_8ccebb43-75f5-4a08-ad95-6b0df37745bd">1,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Fixed assets purchased in accrued expenses or accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTYtMS0xLTEtMjI1NDU_1ace218d-ef0b-4882-b91f-b3acb8f6086b">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTYtMy0xLTEtMjI1NDU_55a15fe6-9e9e-44a5-b825-4b150c0f341e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="idee3699378af4447a4091414c0adfaa7_100"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANGION BIOMEDICA CORP.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:1pt"><span><br/></span></div><div id="idee3699378af4447a4091414c0adfaa7_103"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Note 1&#8212;<ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzI3NDg3NzkwNzM5MjA_26a1016e-ebdc-41fe-8548-c6f909d3ec82" continuedAt="i5caf051544464df6ba379bf1d1f359c6" escape="true">Description of the Business and Financial Condition</ix:nonNumeric></span></div><div style="text-indent:22.5pt"><span><br/></span></div><ix:continuation id="i5caf051544464df6ba379bf1d1f359c6" continuedAt="i991e537bda154374a536eb51a56d7440"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Angion Biomedica Corp. ("Angion" or", the "Company") is a clinical biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. The Company was incorporated in Delaware in 1998.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Forward Stock Split</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On January 25, 2021, the board of directors of the Company approved an amendment to the Company's certificate of incorporation to effect a forward stock split ("Forward Split") of shares of the Company's common stock on a one-for <ix:nonFraction unitRef="number" contextRef="ia5d656fe36d64dd28f480aaf15a0cf24_D20210201-20210201" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzI3NDg3NzkwNzM4Nzk_244ea3e7-a817-48c4-bae8-f4d34371bf42">1.55583</ix:nonFraction> basis, which was effected on February 1, 2021. All references to common stock, convertible preferred stock, warrants to purchase common stock, stock options, restricted stock awards ("RSAs"), restricted stock units ("RSUs"), including restricted stock units with non-market performance and service conditions ("PSUs"), per share amounts and related information contained in the consolidated financial statements have been retroactively adjusted to reflect the effect of the forward stock split for all periods presented. No fractional shares of the Company's common stock were issued in connection with the Forward Split. Any fractional share resulting from the Forward Split was rounded down to the nearest whole share, and any stockholder entitled to fractional shares as a result of the Forward Split will received a cash payment in lieu of receiving fractional shares. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initial Public Offering and the Concurrent Private Placement</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 9, 2021, the Company&#8217;s registration statement on Form S-1 (File No. 333-252177) relating to its initial public offering (IPO) of common stock became effective. The IPO closed on February 9, 2021 at which time the Company issued <ix:nonFraction unitRef="shares" contextRef="icf79e0bd44fc44b6add290a67ac03123_D20210209-20210209" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzEwOTk1MTE2NDY5MjE_66c02d7a-e93f-4034-bec6-2b6079512f31">5,750,000</ix:nonFraction> shares of its common stock at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2fba8513019e4003882ec149aeddb34b_I20210209" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzEwOTk1MTE2NDY5MzA_abd17eca-182e-402d-893c-bf91400789a9">16.00</ix:nonFraction> per share, which includes the full exercise by the underwriters of their option to purchase an additional <ix:nonFraction unitRef="shares" contextRef="i670bd8e4908d4f42bafe357876fb520e_D20210209-20210209" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzEwOTk1MTE2NDcxNTU_011c6d15-d279-4576-bdcd-add19d23a363">750,000</ix:nonFraction> shares of common stock. In addition to the shares being sold in the IPO, the Company sold an additional <ix:nonFraction unitRef="shares" contextRef="i166eae69229b4112968673ffefbf7d09_D20210209-20210209" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzEwOTk1MTE2NDgyNzE_9b1618e9-8f35-4d1b-9c14-316c18e9b340">1,562,500</ix:nonFraction> shares of its common stock at the public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2fba8513019e4003882ec149aeddb34b_I20210209" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzEwOTk1MTE2NDgzMzQ_738a2b36-7f6c-4b40-95d0-0a8935fa8d59">16.00</ix:nonFraction> per share to entities affiliated with Vifor International, Ltd., an existing stockholder (the &#8220;Concurrent Private Placement&#8221;) for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i166eae69229b4112968673ffefbf7d09_D20210209-20210209" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzEwOTk1MTE2NDg3Mzg_6e552a05-9c97-448a-947b-3cd9e16f6380">25.0</ix:nonFraction>&#160;million. Subsequent to the closing of the IPO, all of the outstanding shares of convertible preferred stock and outstanding convertible notes automatically converted into shares of common stock. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IPO and Concurrent Private Placement generated aggregate net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i5f34db6d61444fc0951ac5bca31c9cbc_D20210209-20210209" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzEwOTk1MTE2NTIxNTg_d830a9a4-d81a-4435-936f-32847ff0438d">107.0</ix:nonFraction>&#160;million, after deducting the underwriting discounts and commissions, private placement fee and estimated offering expenses payable by the Company.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the closing of the IPO, there were <ix:nonFraction unitRef="shares" contextRef="ia2518ef5cab941c1b5281fac0348fe6c_I20210210" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzEwOTk1MTE2NTA0NTI_708d2a94-b48a-4678-8542-8c5c3719863d">no</ix:nonFraction> shares of convertible preferred stock outstanding and there were <ix:nonFraction unitRef="usd" contextRef="ie6530fcd8ea6401a8a572f67df226036_I20210210" decimals="INF" name="us-gaap:ConvertibleNotesPayableCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzEwOTk1MTE2NTA1MjE_a843e67d-7f45-43db-a57f-4509946fb945">no</ix:nonFraction> convertible notes outstanding. In connection with the closing of the IPO, the Company restated its Restated Certificate of Incorporation to change the authorized capital stock to <ix:nonFraction unitRef="shares" contextRef="i2fba8513019e4003882ec149aeddb34b_I20210209" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzEwOTk1MTE2NTA3MDQ_01c173f3-da44-449b-a2ed-cd1c83c3496e">300,000,000</ix:nonFraction> shares designated as common stock, and <ix:nonFraction unitRef="shares" contextRef="i2fba8513019e4003882ec149aeddb34b_I20210209" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzEwOTk1MTE2NTA3NDc_5ee7a710-6468-4464-9019-afaa91bc94f6">10,000,000</ix:nonFraction> shares designated as preferred stock, with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2fba8513019e4003882ec149aeddb34b_I20210209" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzEwOTk1MTE2NTA4MDk_6f70f494-7627-4eca-a63f-a0b386d715d4">0.01</ix:nonFraction> per share and $<ix:nonFraction unitRef="usdPerShare" contextRef="i2fba8513019e4003882ec149aeddb34b_I20210209" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzEwOTk1MTE2NTA4Mjc_5359b8cc-dde7-488d-8c77-b2da9a555bf2">0.01</ix:nonFraction> per share, respectively. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company has devoted substantially all of its efforts and financial resources to conducting research and development activities, including drug discovery and pre-clinical studies and clinical trials, establishing and maintaining its intellectual property portfolio, organizing and staffing the Company, business planning, raising capital and providing general and administrative support for these operations. The Company has incurred losses from operations and negative cash flows from operating activities since inception and expects to continue to incur substantial losses for the next several years as it continues to fully develop and, if approved, commercialize its product candidates. As of December&#160;31, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzEwOTk1MTE2MzIyNjA_328da7f7-88fb-442e-a471-4a2c6b09af5c">88.8</ix:nonFraction> million in cash and cash equivalents and an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzEwOTk1MTE2MzIyNjg_e30d9eb8-c133-430c-beba-9885410a063d">215.1</ix:nonFraction> million. Prior to its IPO, the Company has funded its operations through United States government grants, the issuance of convertible notes (see Note 6), sales of convertible preferred stock and common stock (see Notes 7) and warrants (see Note 10) and licensing agreements (see Note 12).</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The planned expansion of the Company's clinical and discovery programs will require significant funds. Management expects to continue to incur significant expenses and to incur operating losses for the foreseeable </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANGION BIOMEDICA CORP.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i991e537bda154374a536eb51a56d7440">future. The Company has evaluated and concluded there are no conditions or events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern for a period of one year following the date these consolidated financial statements are issued and believes its existing cash and cash equivalents will be sufficient to meet the projected operating requirements well into 2023.</ix:continuation></span></div><div style="margin-top:3pt;text-indent:22.5pt"><span><br/></span></div><div id="idee3699378af4447a4091414c0adfaa7_106"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2&#8212;<ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzI3NDg3NzkwOTczNjI_b30a3801-6da2-431f-b5a3-215dfefe4364" continuedAt="ide5646248a68452d94ed336292d3aa9a" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ide5646248a68452d94ed336292d3aa9a" continuedAt="i1404e02947384a3b95a064716c4d63ff"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzI3NDg3NzkwOTczNjM_fbef25b4-0401-4a1f-99b7-f560aa0a7097" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company, its wholly owned subsidiary, Angion Biomedica Europe Limited, which was dissolved on March 16, 2021, and its wholly owned subsidiary, Angion Pty Ltd., which was established on August 22, 2019. The Company established Angion Pty Ltd., an Australian subsidiary, for the purpose of qualifying for research credits for studies conducted in Australia. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzI3NDg3NzkwOTczNjU_ee34133d-4899-4a2a-9d43-d9874cd5cdb2" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (&#8220;CODM&#8221;) in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as <ix:nonFraction unitRef="operatingsegment" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzIyOTg_5663b707-4743-4014-b950-04ed385b4026">one</ix:nonFraction> operating segment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzEwNDQ1MzYwNTI1MTE1_c2a80752-0663-4b7f-aac9-559fae1e8d74" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to the useful lives of long-lived assets, the measurement of stock-based compensation, change in fair value of warrant liabilities prior to IPO, accruals for research and development activities, income taxes and revenue recognition. The Company bases its estimates on historical experience and on other relevant assumptions that are reasonable under the circumstances. Actual results could materially differ from those estimates.</span></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzIxOTkwMjMyODM0OTM_e4ef9520-f0bb-4f98-a932-07ed1f4baa83" continuedAt="if308ad56228b447e897e34bfc999705d" escape="true">Foreign Currency Translation and Transactions</ix:nonNumeric></span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if308ad56228b447e897e34bfc999705d">The United States Dollar (&#8220;USD&#8221;) is the functional currency for the Company&#8217;s operations outside the United States. Accordingly, nonmonetary assets and liabilities originally acquired or assumed in other currencies are recorded in USD at the exchange rates in effect at the date they were acquired or assumed. Monetary assets and liabilities denominated in other currencies are translated into USD at the exchange rates in effect at the balance sheet date. Translation adjustments are recorded in other comprehensive income (loss) in the consolidated statements of operations. Gains and losses realized from non-USD transactions, including intercompany balances not considered as permanent investments, denominated in currencies other than an entity&#8217;s functional currency are included in other income (expense) in the accompanying consolidated statements of operations.</ix:continuation> </span></div><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzEwNDQ1MzYwNTI1MTE3_ce0095be-93ab-4e80-a8f7-48f19f8e875a" continuedAt="i2dd12678ba4c44e7a3d1ce0afecaf0ff" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company's cash and cash equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANGION BIOMEDICA CORP.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i1404e02947384a3b95a064716c4d63ff" continuedAt="ieb1b9c09a8ca4582a874d8237cfffc91"><ix:continuation id="i2dd12678ba4c44e7a3d1ce0afecaf0ff"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash equivalents in securities and money market funds with original maturities less than three months.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no financial instruments with off-balance sheet risk of loss.</span></div></ix:continuation><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzI3NDg3NzkwOTczNjY_7303d55d-9250-46f8-9bb6-6aa17f919bfb" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of December&#160;31, 2021 and 2020, the Company&#8217;s cash equivalents were held in institutions in the United States and included deposits in a money market fund which were unrestricted as to withdrawal or use.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:ReceivablesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzIxOTkwMjMyODM0OTQ_10f1d236-d136-484b-876e-a302c105d5d6" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grants Receivable</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grants receivable is comprised of unbilled amounts due from various grants from the National Institutes of Health ("NIH") and other U.S. government agencies for costs incurred prior to the period end under reimbursement contracts. All amounts are readily available for draw from the Federal Government Payment Management System and, accordingly, no allowance for doubtful amounts has been established. If amounts become uncollectible, they are charged to operations.</span></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:DeferredChargesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzI3NDg3NzkwOTczNjg_c7bb3289-ca17-4ce7-b003-0248cf836d8d" continuedAt="i3563ff86a5724fb69b8f63ee6ff44d00" escape="true">Deferred Offering Costs</ix:nonNumeric></span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3563ff86a5724fb69b8f63ee6ff44d00">Deferred offering costs consist of legal and accounting fees incurred through the balance sheet date that were directly related to the Company's IPO and were reflected as issuance costs upon the completion of the offering.</ix:continuation> Subsequent to the closing of the IPO, $<ix:nonFraction unitRef="usd" contextRef="ie6530fcd8ea6401a8a572f67df226036_I20210210" decimals="-5" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzEwOTk1MTE2ODk2ODc_74276198-4baf-4a61-a801-2a616a06a1c4">2.8</ix:nonFraction>&#160;million of deferred costs previously included in prepaid expenses and other current assets were netted with additional paid in capital in the consolidated balance sheets. As of December 31, 2021 and 2020, the Company recorded deferred offering costs of <ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="INF" name="us-gaap:DeferredOfferingCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzEwOTk1MTE2OTEwNDE_87c82d2d-37c8-428f-94db-30c00b1ead93">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-5" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzEwOTk1MTE2OTEwNDk_d98070b4-44e3-4944-9dd9-0e2f244a0c96">2.0</ix:nonFraction>&#160;million, respectively. </span></div><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzIxOTkwMjMyODM0ODk_b313193d-9779-4106-adfb-53b61b339915" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and leasehold improvements are stated at cost less accumulated depreciation and amortization. <ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzIxOTkwMjMyODM0OTA_10a4e0fe-63e6-4669-bd39-0fa7cd502ef7" continuedAt="i0e3edf75be3a4778bd757a6e6b50a816" escape="true">Depreciation and amortization is computed using the straight-line method over their estimated useful lives as follows:</ix:nonNumeric></span></div><div style="margin-top:10pt"><ix:continuation id="i0e3edf75be3a4778bd757a6e6b50a816" continuedAt="i25e5cc99b81e45f8b691bc49dbc951ea"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:67.668%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ifb691fd4a711422cabfdecc00c444d4f_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90YWJsZTo4NjQ3ZjI0MWJlNzg0NjM5YTU2MzIyOTA1ODg2MDlhOC90YWJsZXJhbmdlOjg2NDdmMjQxYmU3ODQ2MzlhNTYzMjI5MDU4ODYwOWE4XzEtMi0xLTEtMjQwNDA_77e40116-8dcd-44d8-acd3-e4d7c9f7b24d">5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furniture and fixtures</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ie5ada18d76ea4a24976f7bb9e458c66c_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90YWJsZTo4NjQ3ZjI0MWJlNzg0NjM5YTU2MzIyOTA1ODg2MDlhOC90YWJsZXJhbmdlOjg2NDdmMjQxYmU3ODQ2MzlhNTYzMjI5MDU4ODYwOWE4XzItMi0xLTEtMjQwNDA_b6dcf711-c9ff-478f-9134-93376fa52184">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shorter of useful life or lease term</span></td></tr></table></ix:continuation></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Normal repairs and maintenance costs are expensed as incurred.</span></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzYwNDczMTM5ODA3MTE_7117ea1b-7628-4482-b2d6-ece64b367ca0" continuedAt="ia8d2258ef8914ab596ad3000454d1b17" escape="true">Impairment of Long-Lived Assets</ix:nonNumeric></span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia8d2258ef8914ab596ad3000454d1b17">Long-lived assets, such as property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group to be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary.</ix:continuation> The impairment losses as of December&#160;31, 2021 and 2020 were <ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzY2MzQ_55bea137-27ce-4b2e-84ed-7c97be06a04f">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzEwOTk1MTE2NTc0MzU_dcc513ec-c382-44b1-a9ac-e9eb4125c312">58</ix:nonFraction>&#160;thousand, respectively.</span></div><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzI3NDg3NzkwOTczNjk_78c38ff2-a55d-42d6-9b67-ac6c2bc15228" continuedAt="i24ec55ff25e84010bebc85c0a8c44d2b" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are carried at fair value under GAAP. Fair value is determined using the principles of ASC 820, Fair Value Measurement. Fair value is described as the price that would be received to sell an asset or </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANGION BIOMEDICA CORP.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="ieb1b9c09a8ca4582a874d8237cfffc91" continuedAt="i7360bd38940c4c9cb7db195764700404"><ix:continuation id="i24ec55ff25e84010bebc85c0a8c44d2b"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy prioritizes and defines the inputs to valuation techniques as follows:</span></div><div style="margin-top:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1:&#160;&#160;&#160;&#160;Observable inputs such as quoted prices in active markets.</span></div><div style="margin-top:10pt;padding-left:76.5pt;text-indent:-49.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2:&#160;&#160;&#160;&#160;Inputs are observable for the asset or liability either directly or through corroboration with observable market data.</span></div><div style="margin-top:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3:&#160;&#160;&#160;&#160;Unobservable inputs.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inputs used to measure the fair value of an asset or a liability are categorized within levels of the fair value hierarchy. The fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the measurement. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's cash and cash equivalents, accounts payable and accrued expenses are carried at cost, which approximates fair value due to the short-term nature of these instruments.</span></div></ix:continuation><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzYwNDczMTM5ODA3MTI_badd1d7c-3c70-48d8-9db3-1b5dc5184b61" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its leases under ASC 842, Leases. Under this guidance, arrangements meeting the definition of a lease are classified as operating or finance leases, and are recorded on the consolidated balance sheets as both a right of use asset and a lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company's incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset results in straight-line rent expense over the lease term. Variable lease expenses are recorded when incurred.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In calculating the right of use assets and lease liabilities, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election, and recognizes rent expense on a straight-line basis over the lease term.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="angn:InvestmentsInRelatedPartiesPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzYwNDczMTM5ODA3MTM_8cdabbe7-5800-44a5-9fa3-feb0d1534fbc" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Related Party Entities</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds a <ix:nonFraction unitRef="number" contextRef="i22b6851c4c8c4d8e9f955da168470856_I20211231" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzkwMTA_6f1d0d7a-b268-4fb2-b925-dda0e876b6a3">10</ix:nonFraction>% and a <ix:nonFraction unitRef="number" contextRef="i2aaa47df28a24e29abd67cbe8873e02c_I20211231" decimals="3" name="angn:OtherInvestmentAndSecuritiesAtCostOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzkwMTk_0462d518-c5e4-4cf2-960c-1f3fcbe6327c">2.4</ix:nonFraction>% interest in <ix:nonFraction unitRef="entity" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="INF" name="angn:NumberOfRelatedPartyEntities" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzkwMzQ_7a81deeb-e065-44eb-b05d-2b8607aea32a">two</ix:nonFraction> entities, NovaPark, LLC ("NovaPark") and Ohr Cosmetics, LLC ("Ohr"), respectively. There is common ownership between the Director and Chairman Emeritus of the Company and each entity, and our Chief Executive Officer is also owns approximately <ix:nonFraction unitRef="number" contextRef="i334eff8b0f0f4134b32ad37b7a4d1913_D20210101-20211231" decimals="3" name="us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzk4OTU2MDQ3MjA0NDM_e72fee54-81e3-4f1c-ab77-87dfb1d84706">0.80</ix:nonFraction>% of the membership interests in Ohr. See Note 15. In accordance with ASC 323, Investments &#8212;Equity Method and Joint Ventures, the Company has significant influence but not control over NovaPark as its ownership in the limited liability company exceeds 3-5%. Accordingly, the Company records the NovaPark investment under the equity method of accounting. The Ohr investment is recorded at cost.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="angn:WarrantsAndRightsOutstandingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzYwNDczMTM5ODA3MjY_b0137a28-e08f-481f-aab4-9e6dd93035a6" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liability</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain common stock warrants outstanding as a liability, in accordance with ASC 815, Derivatives and Hedging, at fair value and adjusts the instruments to fair value at each reporting period. This liability is subject to re-measurement at each reporting period until exercised, and any change in fair value is recognized in the consolidated statements of operations as a component of other income (expense). The fair value of the warrants issued by the Company has been estimated using a variant of the Black Scholes option pricing model. The underlying equity included in the Black Scholes option pricing model was valued based on the closing price of common stock at each measurement date.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:DebtPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzI3NDg3NzkwOTczNzA_657753f0-e7eb-4b07-b384-f7e1c67412a1" continuedAt="i87a33bd24ed5485b968da1f7b9daf286" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes Payable at Fair Value</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under ASC 825</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Instruments ("ASC 825"), the Company has elected the fair value option for recognition of its convertible notes. In accordance with ASC 825, the Company recognizes these convertible notes at fair value with changes in fair value recognized in the consolidated statements of operations. The fair value option may be applied instrument by instrument, but it is irrevocable. As a result of applying the fair value option, direct costs and fees related to the convertible notes were recognized in general and administrative </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANGION BIOMEDICA CORP.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i7360bd38940c4c9cb7db195764700404" continuedAt="i551853e361b1499a9dcc58083082b772"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i87a33bd24ed5485b968da1f7b9daf286">expense in earnings as incurred and not deferred. The estimated fair value of the convertible notes was determined by utilizing a present value cash flow model and the values of the equity underlying the conversion options were estimated using company equity values implied from the Subject Company Transaction Method which includes the back-solve and scenario-based methods (Probability Weighted Expected Return Method). See Note 4. Accrued interest for the notes has been included in the change in fair value of convertible notes in the consolidated statements of operations. All outstanding convertible notes were converted into common stock upon the close of the IPO on February 9, 2021 and <ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="INF" name="us-gaap:ConvertibleNotesPayableCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzEwOTk1MTE2ODkwMjk_ae5208d4-a610-4f25-a2c7-a1b9e818645c">no</ix:nonFraction> balances remained outstanding as of December&#160;31, 2021.</ix:continuation> See Note 6.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="angn:FinancialInstrumentsSubjectToMandatoryRedemptionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzI3NDg3NzkwOTczNzE_1d2f9866-b573-4bf3-a5c7-295ed95981ff" continuedAt="i2688791dacaa4a4b90fa7cee64417e7d" escape="true">Convertible Preferred Stock</ix:nonNumeric></span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2688791dacaa4a4b90fa7cee64417e7d">Series C convertible preferred stock included settlement features that result in liability classification. The initial carrying value of the Series C convertible preferred stock was accreted to the settlement value, the fair value of the securities issued upon the conversion of the Series C convertible preferred stock. The discount to the settlement value was accreted to interest expense using the effective interest method. During 2020, certain convertible notes were exchanged for Series C convertible preferred stock. As the exchange was accounted for as a modification, the Series C convertible preferred stock that was exchanged for the convertible notes was recorded at fair value and subject to re-measurement at each reporting period with gains and losses reported through our consolidated statements of operations. All outstanding shares of convertible preferred stock were converted into common stock upon the close of the Company&#8217;s IPO on February 9, 2021.</ix:continuation> See Note 7. As of December&#160;31, 2021, there was <ix:nonFraction unitRef="shares" contextRef="ia1527dbfa76d46b8a7b898736a11b2b6_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzEwOTk1MTE2ODkwMzc_eed67914-25d8-46a2-94cb-748a090edbae">no</ix:nonFraction> convertible preferred stock outstanding.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:StockholdersEquityPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzYwNDczMTM5ODA3Mjc_05c5d2ed-ad39-4abe-8e09-bbb3767fc74c" continuedAt="i4a4988e71dac47caa7bea65d6f767847" escape="true">Treasury Stock</ix:nonNumeric></span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4a4988e71dac47caa7bea65d6f767847">The Company records the repurchase of shares of common stock at cost based on the settlement date of the transaction. These shares are classified as treasury stock, which is a reduction to stockholders' equity. Treasury stock is included in authorized and issued shares but excluded from outstanding shares. As of December&#160;31, 2021, all outstanding treasury shares were retired in October 2021 upon approval by the Board of Directors.</ix:continuation> </span></div><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzI3NDg3NzkwOTczNzI_76c1128e-c894-4e7b-8c63-c3950727cb97" continuedAt="iec14bdc6f3374bb0bc7e9172c80a81d2" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any products approved for sale and has not generated any revenue from product sales. The Company&#8217;s revenue to date has been primarily derived from government funding consisting of U.S. government grants and contracts, and revenue under its license agreements.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Revenue</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenue earned from contracts with customers under Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASC 606"). Under ASC 606, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps:   &#160;&#160;&#160;&#160;</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Identify the contract(s) with a customer;</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Identify the performance obligations in the contract;</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Determine the transaction price;</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Allocate the transaction price to the performance obligations in the contract; and</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;Recognize revenue when (or as) the Company satisfies a performance obligation.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company assesses the goods or services promised within each contract, whether each promised good or service is distinct, and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANGION BIOMEDICA CORP.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i551853e361b1499a9dcc58083082b772" continuedAt="i07ac6902760347059ae29b539668be75"><ix:continuation id="iec14bdc6f3374bb0bc7e9172c80a81d2"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements under which it may obtain upfront payments, milestone payments, royalty payments and other fees. Promises under these arrangements may include research licenses, research services, including selection campaign research services for certain replacement targets, the obligation to share information during the research and the participation of alliance managers and in joint research committees, joint patent committees and joint steering committees. The Company assesses these promises within the context of the agreements to determine the performance obligations.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Licenses of Intellectual Property</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: If a license to its intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring proportional performance for purposes of recognizing revenue from non-refundable, upfront payments. The Company evaluates the measure of proportional performance each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company evaluates whether the regulatory and development milestones are considered probable of being reached and estimate the amounts to be included in the transaction price using the most likely amount method. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones and any related constraint, and if necessary, adjust the estimate of the overall transaction price.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales-based milestones and royalties</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For sales-based royalties, including milestone payments based on the level of sales, the Company determines whether the sole or predominant item to which the royalties relate is a license. When the license is the sole or predominant item to which the sales-based royalty relates, the Company recognize revenue at the later of: (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any sales-based royalty revenue resulting from any license agreement.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is a contract liability, represents amounts received by the Company for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount expected to be recognized within one year from the consolidated balance sheet date based on the estimated performance period of the underlying performance obligation. The noncurrent portion of deferred revenue represents amounts expected to be recognized after one year through the end of the performance period of the performance obligation.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grant Revenue</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the Company's government grants are not within the scope of ASC Topic 606 as they do not meet the definition of a contract with a customer. The Company has concluded that the grants meet the definition of a contribution and are non-reciprocal transactions, and has also concluded that Subtopic 958-605, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit-Entities-Revenue Recognition</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, does not apply, as the Company is a business entity and the grants are with governmental agencies.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of applicable guidance under GAAP, the Company developed a policy for the recognition of grant revenue when the allowable costs are incurred and the right to payment is realized.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes this policy is consistent with the overarching premise in ASC Topic 606, to ensure that revenue recognition reflects the transfer of promised goods or services to customers in an amount that reflects the consideration that the Company expects to be entitled to in exchange for those goods or services, even though there is no exchange as defined in ASC Topic 606. The Company believes the recognition of revenue as costs are incurred and amounts become realizable is analogous to the concept of transfer of control of a service over time under ASC Topic 606.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANGION BIOMEDICA CORP.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i07ac6902760347059ae29b539668be75" continuedAt="i27f1f217e9aa4a379ba4e31b4c0371e1"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzI3NDg3NzkwOTczNzM_9399f277-61f3-44bb-9cd8-94fbc41333f5" continuedAt="i076b806e2e5b443dab36823f2700bfc6" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs include, but are not limited to, payroll and personnel expenses, laboratory supplies, preclinical studies, compound manufacturing costs, consulting costs and allocated overhead, including rent, equipment, depreciation and utilities. Research and development cost maybe offset by research and development refundable tax rebates received by our wholly-owned Australian subsidiary. </span></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i076b806e2e5b443dab36823f2700bfc6">The Company has agreements with various Contract Research Organizations ("CROs") and third-party vendors. Research and development accruals of amounts due to the CRO are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued liabilities on the consolidated balance sheet. Payments made to CROs under such arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. The Company makes judgments and estimates in determining the accrued expenses balance in each reporting period. As actual costs become known, the Company adjusts its accrued expenses.</ix:continuation> For the years ended December&#160;31, 2021 and 2020, the Company has not experienced any material differences between accrued costs and actual costs incurred.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzI3NDg3NzkwOTczNzQ_9f73064c-bf99-4fd4-a373-cdca3aca1330" continuedAt="ib7d6e28ff19542938e59d2c2afed86f3" escape="true">Advertising Costs</ix:nonNumeric></span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib7d6e28ff19542938e59d2c2afed86f3">Advertising costs are expensed as incurred.</ix:continuation> For the years ended December&#160;31, 2021 and 2020, advertising costs were not significant.</span></div><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzYwNDczMTM5ODA3Mjg_04ec4142-26f4-4950-84b1-5f3184a46cb4" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for all stock-based payments to employees and non-employees, including grants of stock options, RSAs, RSUs, including "PSUs" to be recognized in the financial statements, based on their respective grant date fair values. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The RSAs, RSUs and PSUs are valued based on the fair value of the Company's common stock on the date of grant. The assumptions used in calculating the fair value of stock-based awards represent management's best estimates and involve inherent uncertainties and the application of management's judgment. The Company records expense for stock-based compensation related to stock options, RSAs and RSUs over the requisite service period. As the PSUs have a performance condition, compensation expense is recognized for each vesting tranche over the respective requisite service period of each tranche if and when the Company's management deems probable that the performance conditions will be satisfied. The Company may recognize a cumulative true-up adjustment related to PSUs once a condition becomes probable of being satisfied if the related service period had commenced in a prior period. All share-based compensation costs are recorded in general and administrative or research and development costs in the consolidated statements of operations based upon the respective employees or non-employee's roles within the Company. Forfeitures are recorded as they occur.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzYwNDczMTM5ODA3Mjk_1837bb7d-4648-4684-a9e0-ebb9535b061a" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are recorded in accordance with ASC 740, Income Taxes ("ASC 740"), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</span></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzI3NDg3NzkwOTczNzU_7d324a8b-3327-44b2-ab84-4c5e88ceee41" continuedAt="i02cfa1aaa7614b88a6ab7f24cc4a4a48" escape="true">Net Loss Per Share</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANGION BIOMEDICA CORP.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i27f1f217e9aa4a379ba4e31b4c0371e1" continuedAt="i5d04d8f6564942538d3bfbd587dcf1eb"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i02cfa1aaa7614b88a6ab7f24cc4a4a48">Basic net loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share excludes the potential impact of convertible preferred stock, common stock options, warrants and unvested shares of restricted stock and restricted stock units because their effect would be anti-dilutive due to the Company's net loss. Since the Company had net losses for the years ended December&#160;31, 2021 and 2020, basic and diluted net loss per common share are the same.</ix:continuation></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzYwNDczMTM5ODA3MzA_31c90be7-324d-4358-8ac8-89b7cd84138c" continuedAt="i8dc261710c9f4b91bb276e4cd6b58e00" escape="true">Comprehensive Loss</ix:nonNumeric></span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8dc261710c9f4b91bb276e4cd6b58e00">Comprehensive loss represents the net loss for the period and other comprehensive income. Other comprehensive income reflects certain gains and losses that are recorded as a component of stockholders&#8217; deficit and are not reflected in the statements of operations. The Company&#8217;s other comprehensive income consists of foreign currency translation adjustments.</ix:continuation> </span></div><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzI3NDg3NzkwOTczNzY_d315bb8d-0ed1-476c-8645-a2a70dd7e62f" continuedAt="ic9c0d270f37042638686af2974bf837c" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. ASU No. 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. Early adoption is permitted for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company adopted this standard as of January 1, 2021, which did not have material impact on its consolidated financial statements and related disclosures. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes (ASU 2019-12), which is intended to simplify accounting for income taxes. It removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application. ASU 2019-12 was effective for the Company for fiscal years beginning after December 15, 2020, including interim periods therein. The Company adopted this standard as of January 1, 2021, which did not have material impact on its consolidated financial statements and related disclosures.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued ASU No. 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 (a consensus of the Emerging Issues Task Force). This update clarifies whether an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying the measurement alternative and how to account for certain forward contracts and purchased options to purchase securities. For public entities, this guidance was effective for fiscal years beginning after December 15, 2020. The Company adopted this standard as of January 1, 2021, which did not have material impact on its consolidated financial statements and related disclosures.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued ASU No. 2020-10, Codification Improvements. ASU 2020-10 provides amendments to a wide variety of topics in the FASB&#8217;s Accounting Standards Codification, which applies to all reporting entities within the scope of the affected accounting guidance. ASU 2020-10 was effective for the Company for fiscal years beginning after December 15, 2020, including interim periods therein. The Company adopted this standard as of January 1, 2021, which did not have material impact on its consolidated financial statements and related disclosures.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued Accounting Standards Update (ASU) 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. ASU 2021-10 requires business entities to disclose, in notes to their financial statements, information about certain types of government assistance they receive. ASU 2021-10 also adds a new Topic 832, Government Assistance, to the FASB&#8217;s Codification. ASU 2021-10 is effective for financial statements of all entities, including private companies, for annual periods beginning </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANGION BIOMEDICA CORP.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i5d04d8f6564942538d3bfbd587dcf1eb"><ix:continuation id="ic9c0d270f37042638686af2974bf837c"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">after December 15, 2021, with early application permitted. The Company adopted this standard as of January 1, 2021, which did not have material impact on its consolidated financial statements and related disclosures.</span></div><div><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments (ASU No. 2016-13), which requires an entity to utilize a new impairment model known as the current expected credit loss (&#8220;CECL&#8221;) model to estimate its lifetime &#8220;expected credit loss&#8221; and record an allowance that, when deducted from the amortized cost basis of the financial assets and certain other instruments, including but not limited to available-for-sale debt securities. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. As an emerging growth company, ASU No. 2016-13 is effective for the Company for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company is currently evaluating the impact of the adoption of ASU No. 2016-13 on its consolidated financial statements.</span></div></ix:continuation></ix:continuation><div style="margin-top:10pt;text-indent:22.5pt"><span><br/></span></div><div id="idee3699378af4447a4091414c0adfaa7_109"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3&#8212;<ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzI3NDg3NzkwNzYyMDU_32d716ae-45ed-4327-a0e8-96caad3af48e" continuedAt="ie7d289a9d2284c76b9333a743fdb8aeb" escape="true">Revenue and Deferred Revenue </ix:nonNumeric></span></div><ix:continuation id="ie7d289a9d2284c76b9333a743fdb8aeb" continuedAt="i023b16e19eb54cc4879f99fd9d316d34"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grant Revenue </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our grants and contracts reimburse us for direct and indirect costs relating to the grant projects and also provide us with a pre-negotiated profit margin on total direct and indirect costs of the grant award, excluding subcontractor costs, after giving effect to directly attributable costs and allowable overhead costs. Funds received from grants and contracts are generally deemed to be earned and recognized as revenue as allowable costs are incurred during the grant or contract period and the right to payment is realized. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2021 and 2020, the Company recognized grant revenue of $<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-5" name="us-gaap:RevenueNotFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2NjQ1NTA_e732ff6f-561a-4d87-be34-f1318b82c4b6">0.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-5" name="us-gaap:RevenueNotFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2NjQ1NTg_43620ead-d756-4a50-b429-3ce64e35490d">2.7</ix:nonFraction>&#160;million, respectively. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Revenue </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contract revenue has been generated from payments received pursuant to a license agreement (the "Vifor License") with Vifor International, Ltd. ("Vifor Pharma") with headquarters located in Switzerland. The Company recognized revenue from upfront payments over the term of our estimated period of performance using a cost-based input method under Topic 606. The Company expects to continue recognizing revenue from upfront payments related to the Vifor License using the cost-based input method.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Vifor License Agreement</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020, the Company entered into a license agreement with Vifor Pharma, granting Vifor Pharma global rights (excluding China, Taiwan, Hong Kong and Macau) to develop, manufacture and commercialize ANG-3777 in all therapeutic, prophylactic and diagnostic uses for renal indications, including forms of acute kidney injury (AKI), and congestive heart failure (collectively, the Renal Indications). Pursuant to the Vifor License, the Company received $<ix:nonFraction unitRef="usd" contextRef="if21e2f0448ee4d45b7742ead826a0858_D20201101-20201130" decimals="-6" name="angn:ContractWithCustomerUpfrontAndNearTermMilestonePaymentEntitledToReceive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzE2NDkyNjc0ODE0MDU_21e60417-a31b-4260-91ff-f6d66aac1590">60</ix:nonFraction>&#160;million in upfront and equity payments, including $<ix:nonFraction unitRef="usd" contextRef="i8e92ffc10989447182476424cac89e3f_I20201130" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2MzUxNzY_6ba1241d-0ff0-44b6-8287-86a20c3c0b40">30</ix:nonFraction>&#160;million in up-front cash received in November 2020, and a $<ix:nonFraction unitRef="usd" contextRef="if93bd2dd820c484eaec104d26be89685_I20210209" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2MzUxODQ_b0646bff-f0fc-49a8-a191-9a3e0262af1b">30</ix:nonFraction>&#160;million equity investment, $<ix:nonFraction unitRef="usd" contextRef="i7c1c861e844341b5a5e29c716ed55595_D20210209-20210209" decimals="-6" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2MzUxOTI_4d30aaf7-eb3a-4199-9303-70b740e998a2">5</ix:nonFraction>&#160;million of which was a convertible note that subsequently converted into common stock with the IPO and $<ix:nonFraction unitRef="usd" contextRef="icbbb8ca18fb34328a36cc3e05df1ac42_D20210209-20210209" decimals="-6" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2MzUyMDI_e94f25df-3551-4d8a-96e2-ffe7685a7154">25</ix:nonFraction>&#160;million of which was received in the Concurrent Private Placement with the Company&#8217;s IPO. The Company is also eligible to receive post-approval milestones of up to approximately $<ix:nonFraction unitRef="usd" contextRef="if21e2f0448ee4d45b7742ead826a0858_D20201101-20201130" decimals="-6" name="angn:ContractWithCustomerPostApprovalMilestonePaymentEntitledToReceive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2MzUyMTA_08a21b1b-2047-4021-a862-ebb91ca597f4">260.0</ix:nonFraction>&#160;million and sales-related milestones of up to $<ix:nonFraction unitRef="usd" contextRef="if21e2f0448ee4d45b7742ead826a0858_D20201101-20201130" decimals="-6" name="angn:ContractWithCustomerSalesRelatedMilestonePaymentEntitledToReceive" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2MzUyMjA_89bb7525-dbec-4e58-9184-c536a1c3e4e3">1.585</ix:nonFraction>&#160;billion, providing a total potential deal value of up to $<ix:nonFraction unitRef="usd" contextRef="if21e2f0448ee4d45b7742ead826a0858_D20201101-20201130" decimals="-6" name="angn:ContractWithCustomerMilestonePaymentsEntitledToReceive" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2MzUyMjg_4b5df9c7-9b20-4128-820d-a69edb96f5cf">1.925</ix:nonFraction>&#160;billion (subject to certain specified reductions and offsets), plus tiered royalties on net sales of ANG-3777 at royalty rates of up to <ix:nonFraction unitRef="number" contextRef="i8e92ffc10989447182476424cac89e3f_I20201130" decimals="2" name="angn:ContractWithCustomerRoyaltyRatesMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2MzUyMzY_59d42ac7-9f92-4152-b748-4687b10c2d12">40</ix:nonFraction>%. Under the Vifor License, the Company is responsible for executing a pre-specified clinical development plan designed to obtain regulatory approvals of ANG-3777 for delayed graft function (DGF) and AKI associated with cardiac surgery involving cardiopulmonary bypass (CSA-AKI). Based on the ANG-3777 clinical trial data disclosed in the fourth quarter of 2021, the Company does not expect to receive any </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANGION BIOMEDICA CORP.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i023b16e19eb54cc4879f99fd9d316d34" continuedAt="i565b0c85c7f1440d8fbbc0f2b7cb2267"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">additional clinical, post-approval, or sales milestones, or royalties, as it does not intend to continue to pursue the clinical development plan for ANG-3777 set forth in the Vifor License. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 26, 2021, the Company announced that its Phase 3 trial of ANG-3777 in DGF did not achieve its primary endpoint and the data from the Phase 3 trial was not expected to provide sufficient evidence to support an indication in the studied DGF population. On December 9, 2021, the Company announced its Phase 2 trial of ANG-3777 in CSA-AKI did not achieve its primary endpoint and the data from the Phase 2 trial was not expected to provide sufficient evidence to support a Phase 3 trial in the studied CSA-AKI population. Angion and Vifor continue to analyze data from the CSA-AKI trial. The Company does not intend to continue the clinical development plan for ANG-3777 set forth in the Vifor License, which had included a Phase 3 study in CSA-AKI and a Phase 4 confirmatory study in DGF. In 2022, we and Vifor Pharma continue to work  to complete the planned analyses of the results of the clinical trials announced in the fourth quarter of 2021 and to discuss the future of the collaboration based upon such analyses.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Vifor Pharma may terminate the Vifor License at its sole discretion upon the earlier of (i) the acceptance for filing of an NDA covering products incorporating ANG-3777 filed with the FDA (after completion of the relevant Phase 3 clinical trial for such products), or (ii) the third anniversary of the effective date of the Vifor License. Both the Company and Vifor Pharma may terminate the Vifor License in its entirety if the other is in material breach of the Vifor License and has not cured the breach (if curable) within <ix:nonNumeric contextRef="i2b2bdc42a04c4cd3af27c83384133f3b_D20210101-20211231" name="angn:ContractWithCustomerContractTerminationPeriodCurableBreach" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzI3NDg3NzkwNzYxNTA_714fda9c-e07e-4d11-ac96-4c125cddea07">60</ix:nonNumeric> days, or <ix:nonNumeric contextRef="i2b2bdc42a04c4cd3af27c83384133f3b_D20210101-20211231" name="angn:ContractWithCustomerContractTerminationPeriodIncurableBreach" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzI3NDg3NzkwNzYxNTE_a9577b36-cfb6-4216-998d-7777d2ed358a">90</ix:nonNumeric> days for incurable breach. In certain circumstances, in the event of the Company&#8217;s material breach of the Vifor License, Vifor Pharma may terminate the Vifor License with respect to certain major markets. In addition, both parties have the right to terminate the Vifor License upon insolvency of the other party. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company identified the following performance obligations in the Vifor License based upon the  clinical development plan for ANG-3777: (1) the global license (excluding greater China), (2) the development services, including the clinical development services including a post-approval confirmatory study, the technical development services and regulatory services and (3) the required participation on Joint Committees for coordination and oversight. The Company determined that the license is not capable of being distinct due to the specialized nature of the development services to be provided by the Company, and, accordingly, this promise was combined with the development services and participation in the joint committees as one single performance obligation. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to determine the transaction price, the Company evaluated all the payments to be received during the duration of the contract. Certain milestones and additional fees were considered variable consideration, which were not included in the transaction price at contract inception. The Company determined that the transaction price at the inception of the Vifor License is $<ix:nonFraction unitRef="usd" contextRef="ic3a0a0d452d744969da82c474ba19d42_I20201130" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2MzUyNDA_7b5f374b-2bd1-4af9-9803-9581504492b7">15.0</ix:nonFraction>&#160;million, which is <ix:nonFraction unitRef="number" contextRef="i8e92ffc10989447182476424cac89e3f_I20201130" decimals="INF" name="angn:ContractWithCustomerLiabilityPercentOfUpfrontPayment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2MzUyNDg_f8e01611-a3d4-42ff-bcff-48af31e2b432">50</ix:nonFraction>% of the $<ix:nonFraction unitRef="usd" contextRef="i8e92ffc10989447182476424cac89e3f_I20201130" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2MzUyNTI_6ba1241d-0ff0-44b6-8287-86a20c3c0b40">30.0</ix:nonFraction>&#160;million upfront payment due to the potential setoff defined in the contract. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the fourth quarter of 2021, the Company reported topline results from two ANG-3777 clinical trials under the Vifor License. The Company determined it will no longer continue the current clinical development plan for ANG 3777 DGF and CSA-AKI, which had included a Phase 3 study for CSA-AKI and a Phase 4 confirmatory study in DGF, given neither trial achieved statistical significance on its primary endpoint. In connection therewith, the Company adjusted the transaction price to include $<ix:nonFraction unitRef="usd" contextRef="ib2c20a51369c40ba8a350cc15fab95b0_I20211231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2Mzk2Njk_87c9e71a-a52e-40eb-b353-bbf0517b6f7e">15.0</ix:nonFraction>&#160;million in previously constrained variable consideration. As of December&#160;31, 2021, the Company concluded that it has significantly satisfied the performance obligation under Vifor License and will fully conclude the ANG-3777 project by the end of 2022. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Using the cost-based input method, the Company recognizes revenue based on actual costs incurred as a percentage of total estimated costs as the Company completes its performance obligation. The cumulative effect of revisions to estimated costs to complete the Company&#8217;s performance obligation will be recorded in the period in which changes are identified and amounts can be reasonably estimated. These actual costs consist primarily of internal full time equivalent (FTE) efforts and third-party contract costs related to the Vifor License.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company reassessed the performance period as the Company is currently closing out the planned analyses from both trials but does not intend to continue the clinical development plan for ANG-3777 set forth in the Vifor License,  which had included a Phase 3 study for CSA-AKI and a Phase 4 confirmatory study in DGF, given these clinical results. As such, the estimated date to fully conclude ANG-3777 by the end of December 2022 was determined to represent the completion of the Company&#8217;s performance obligation under the Vifor License. Additionally, the Company revised the total estimated costs for completion of the performance obligation to reflect </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANGION BIOMEDICA CORP.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i565b0c85c7f1440d8fbbc0f2b7cb2267"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the winding down of ANG-3777-related studies. The performance period is expected to end in the fourth quarter of 2022 instead of the fourth quarter of 2026. The effect of this change in estimate was an increase in contract revenue by $<ix:nonFraction unitRef="usd" contextRef="if19bda0412d14f569093c176591ee9a5_D20210101-20211231" decimals="-5" name="angn:RevenueFromContractWithCustomerIncludingAssessedTaxIncrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2NTUwODE_f570e383-f10c-44ca-a9e8-51e80d4a20cd">24.2</ix:nonFraction>&#160;million, a reduction in net loss by $<ix:nonFraction unitRef="usd" contextRef="if19bda0412d14f569093c176591ee9a5_D20210101-20211231" decimals="-5" name="angn:NetIncomeLossAttributableToParentIncrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2NTUzODQ_749f2ad0-4c59-4023-9da3-786843e5e8d3">24.2</ix:nonFraction>&#160;million and an increase in basic and diluted earnings per share by $<ix:nonFraction unitRef="usdPerShare" contextRef="if19bda0412d14f569093c176591ee9a5_D20210101-20211231" decimals="2" sign="-" name="angn:EarningsPerShareDilutedIncrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2NTUwOTM_6708173f-425b-43ef-a4fc-5a404bd115df"><ix:nonFraction unitRef="usdPerShare" contextRef="if19bda0412d14f569093c176591ee9a5_D20210101-20211231" decimals="2" sign="-" name="angn:EarningsPerShareBasicIncrease" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2NTUwOTM_e7df8b69-d069-43fd-afe5-a9822dc2fbac">0.86</ix:nonFraction></ix:nonFraction> for the year ended December&#160;31, 2021. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2021 and 2020, the Company recognized license revenue related to the Vifor License of $<ix:nonFraction unitRef="usd" contextRef="if19bda0412d14f569093c176591ee9a5_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2MzQ1NDU_6d778b23-755a-4664-bef0-3125a2f66ba9">27.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7dfe036a9b474f76843bec13725495e1_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2MzQ1NTM_ba307e69-14b8-418f-980a-0fab51ade91f">0.2</ix:nonFraction>&#160;million. As of December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i76d34e6f4aa7484d9735bb67f83fe319_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2MzQ4OTc_09857bfe-77aa-4a39-ab35-a209dc6bf361">2.3</ix:nonFraction>&#160;million was recorded as the current portion of deferred revenue on the consolidated balance sheet related to the Vifor License. As of December 31, 2020, $<ix:nonFraction unitRef="usd" contextRef="i2e59113239ac414b95bede6314d45d5a_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2MzUxMjE_2c00fcd6-0eb7-41a0-bf39-abfe214638ec">29.8</ix:nonFraction>&#160;million was recorded as deferred revenue on the consolidated balance sheet related to the Vifor License.</span></div></ix:continuation><div style="margin-top:3pt;text-indent:22.5pt"><span><br/></span></div><div id="idee3699378af4447a4091414c0adfaa7_112"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4&#8212;<ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90ZXh0cmVnaW9uOjg4ZDM5N2I0MTBhODQ4NTE4M2UwNzliNWRjZjI4MmNlXzI3NDg3NzkwNzIyNDI_f3d47705-dadc-490a-b40f-8dc927a2b8dc" continuedAt="i64e5004a828f4fb9a1b7630e4f7e7b7e" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i64e5004a828f4fb9a1b7630e4f7e7b7e" continuedAt="i06d0abf5c070466dbd663f7854eb37ca"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90ZXh0cmVnaW9uOjg4ZDM5N2I0MTBhODQ4NTE4M2UwNzliNWRjZjI4MmNlXzI3NDg3NzkwNzIyNDM_60feb9a8-af84-4af0-85bd-9420ff043a44" escape="true"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table classifies the Company's financial assets and liabilities measured at fair value on a recurring basis into the fair value hierarchy as of December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Fair Value Measured at December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Quoted Prices in </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Active Markets for </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Identical </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Assets (Level 1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Significant </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Other </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Observable </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Inputs (Level 2)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Significant </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unobservable </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Inputs (Level 3)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Assets included in:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash and cash equivalents&#8212;Money market securities  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ia83ec88a3b3147ed8f7108e7f8a10e0f_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzMtMS0xLTEtMjI1NDU_bdb5875e-cc8f-4717-91cb-0927bd0caa58">87,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="iad4e3db6f2344adeaf53fa4f5bb5a0b7_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzMtMy0xLTEtMjI1NDU_d21d2e99-aae6-4d0d-9aaf-64dc8a7893b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i7afc7784bba7408fb2ba2c128f6657a8_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzMtNS0xLTEtMjI1NDU_57d4a3ef-10e8-4b25-aefd-c376ba6914e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i2e37997f6b2f47c0a98e68a4f9edef5e_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzMtNy0xLTEtMjI1NDU_fc0b76f4-d995-42e9-84df-e950ebf7b893">87,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total fair value</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ia83ec88a3b3147ed8f7108e7f8a10e0f_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzQtMS0xLTEtMjI1NDU_190f460b-4229-420b-b86a-93da4a405f08">87,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="iad4e3db6f2344adeaf53fa4f5bb5a0b7_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzQtMy0xLTEtMjI1NDU_fa249819-187d-4685-8a03-a957e4415fd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i7afc7784bba7408fb2ba2c128f6657a8_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzQtNS0xLTEtMjI1NDU_4e91d6e7-427a-4258-8353-55e964153e35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i2e37997f6b2f47c0a98e68a4f9edef5e_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzQtNy0xLTEtMjI1NDU_202e5bcb-6dd7-4a61-8c8f-53aca427b477">87,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liabilities included in:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Warrants</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ia83ec88a3b3147ed8f7108e7f8a10e0f_I20211231" decimals="-3" name="angn:WarrantsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzctMS0xLTEtMjI1NDU_b1d70368-852e-4322-bc4a-fc9593c5ff3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="iad4e3db6f2344adeaf53fa4f5bb5a0b7_I20211231" decimals="-3" name="angn:WarrantsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzctMy0xLTEtMjI1NDU_c6d6a1f7-4a48-4b05-ae4c-378253c61b71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i7afc7784bba7408fb2ba2c128f6657a8_I20211231" decimals="-3" name="angn:WarrantsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzctNS0xLTEtMjI1NDU_ac7f9ed9-5019-4849-9d14-96bc64ccf565">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="i2e37997f6b2f47c0a98e68a4f9edef5e_I20211231" decimals="-3" name="angn:WarrantsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzctNy0xLTEtMjI1NDU_65c42599-1e27-4a8a-8dae-dd42e1ec9bca">114</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total fair value</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ia83ec88a3b3147ed8f7108e7f8a10e0f_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzktMS0xLTEtMjI1NDU_2c17491a-50fc-40c9-bc8e-96898a01a66e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="iad4e3db6f2344adeaf53fa4f5bb5a0b7_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzktMy0xLTEtMjI1NDU_c2ae1901-320e-4ddc-b658-fd92665c0747">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i7afc7784bba7408fb2ba2c128f6657a8_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzktNS0xLTEtMjI1NDU_afdf2b6a-1e92-4011-a188-05749147d533">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i2e37997f6b2f47c0a98e68a4f9edef5e_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzktNy0xLTEtMjI1NDU_2ed6f7ef-b411-43c5-81a1-bb0e15855ff9">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.642%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Fair Value Measured at December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Quoted Prices in </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Active Markets for </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Identical </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Assets (Level 1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Significant </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Other </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Observable </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Inputs (Level 2)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Significant </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unobservable </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Inputs (Level 3)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Assets included in:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash and cash equivalents&#8212;Money market securities  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i154b24e4e9944f218abc0f9cd65e80b0_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzMtMS0xLTEtMjI1NDU_ffdedd38-dacf-44b8-a1c9-e496bef832be">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3b97b816eb8f487f8a5410b7dc6dc79b_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzMtMy0xLTEtMjI1NDU_46073961-4365-4018-86be-f4f65ad014d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="idc2c8fc18af04652b3b74961e635dbe6_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzMtNS0xLTEtMjI1NDU_9091ef92-311e-4585-842e-184dc0868d04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1c7ff22c3ff94a4d849562a284c0e1d2_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzMtNy0xLTEtMjI1NDU_47649a28-8d27-456f-9667-796d745c97dc">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total fair value</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i154b24e4e9944f218abc0f9cd65e80b0_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzQtMS0xLTEtMjI1NDU_01ff4206-cd16-4d79-b6fd-c05611f30cde">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3b97b816eb8f487f8a5410b7dc6dc79b_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzQtMy0xLTEtMjI1NDU_7984b233-4984-44cb-b0ae-d5191fa3f7e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="idc2c8fc18af04652b3b74961e635dbe6_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzQtNS0xLTEtMjI1NDU_dec222eb-b415-4d40-a6c6-50aeb35cf9d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1c7ff22c3ff94a4d849562a284c0e1d2_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzQtNy0xLTEtMjI1NDU_0386ee11-8e5a-45e7-9400-d09793eb15c5">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liabilities included in:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Convertible notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i154b24e4e9944f218abc0f9cd65e80b0_I20201231" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzYtMS0xLTEtMjI1NDU_635daaf0-b3de-42a1-806e-791439aea82e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3b97b816eb8f487f8a5410b7dc6dc79b_I20201231" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzYtMy0xLTEtMjI1NDU_237039f3-b3dd-4649-a957-da4453fcd50c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="idc2c8fc18af04652b3b74961e635dbe6_I20201231" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzYtNS0xLTEtMjI1NDU_068a737c-95d9-44b5-8947-8cb3b2075b95">51,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1c7ff22c3ff94a4d849562a284c0e1d2_I20201231" decimals="-3" name="us-gaap:ConvertibleDebtFairValueDisclosures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzYtNy0xLTEtMjI1NDU_bc302cd0-fab3-4e22-b8ed-67d45ed24b88">51,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Warrants</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i154b24e4e9944f218abc0f9cd65e80b0_I20201231" decimals="-3" name="angn:WarrantsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzctMS0xLTEtMjI1NDU_ec199dd8-933b-4886-82db-0b294045f129">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3b97b816eb8f487f8a5410b7dc6dc79b_I20201231" decimals="-3" name="angn:WarrantsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzctMy0xLTEtMjI1NDU_66a6b5b9-e2b0-46b6-8e5b-ba252efb1a6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="idc2c8fc18af04652b3b74961e635dbe6_I20201231" decimals="-3" name="angn:WarrantsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzctNS0xLTEtMjI1NDU_a315fda2-5e48-46a4-bd64-54734ca4c5c7">10,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1c7ff22c3ff94a4d849562a284c0e1d2_I20201231" decimals="-3" name="angn:WarrantsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzctNy0xLTEtMjI1NDU_56260b0e-5b87-4fb4-b47d-48a47be74a32">10,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Series C convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i154b24e4e9944f218abc0f9cd65e80b0_I20201231" decimals="-3" name="angn:FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzgtMS0xLTEtMjc4MzI_9c01a6bb-0554-4465-bcaa-9e672ccae0a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3b97b816eb8f487f8a5410b7dc6dc79b_I20201231" decimals="-3" name="angn:FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzgtMy0xLTEtMjc4MzI_8741bc23-6178-4e8c-b950-8152a06d191d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="idc2c8fc18af04652b3b74961e635dbe6_I20201231" decimals="-3" name="angn:FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzgtNS0xLTEtMjc4MzI_28b4b9d7-521f-4ba2-a8bb-1b2a6952e26f">2,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1c7ff22c3ff94a4d849562a284c0e1d2_I20201231" decimals="-3" name="angn:FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzgtNy0xLTEtMjc4MzI_d5cbb0ac-dd28-47da-a188-13ed48c15310">2,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total fair value</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i154b24e4e9944f218abc0f9cd65e80b0_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzgtMS0xLTEtMjI1NDU_004568db-cbf3-477e-8eea-4b439c0dedc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3b97b816eb8f487f8a5410b7dc6dc79b_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzgtMy0xLTEtMjI1NDU_b9f5cfa5-9f6f-4080-9c68-ab0a83e804aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="idc2c8fc18af04652b3b74961e635dbe6_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzgtNS0xLTEtMjI1NDU_985014b8-e81a-465c-9266-808fb59c9fb2">64,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1c7ff22c3ff94a4d849562a284c0e1d2_I20201231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzgtNy0xLTEtMjI1NDU_be98cd4a-b51d-48af-a6a6-3ee0f6f4c674">64,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">___________________</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Included in cash and cash equivalents on the consolidated balance sheets. This balance includes cash requirements settled on a nightly basis.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANGION BIOMEDICA CORP.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i06d0abf5c070466dbd663f7854eb37ca" continuedAt="id76656a4cac54ef3b83e2e91507fe064"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers made among the three levels in the fair value hierarchy during periods presented.</span></div><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90ZXh0cmVnaW9uOjg4ZDM5N2I0MTBhODQ4NTE4M2UwNzliNWRjZjI4MmNlXzI3NDg3NzkwNzIyNDQ_168eddc1-ef0a-43e2-858c-8951b23a9530" escape="true"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in Level 3 liabilities measured at fair value (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Warrant <br/>Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Convertible <br/>Notes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Series C Convertible Preferred Stock at Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Balance&#8212;December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i85e948c0db004aec96a438029856e941_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzgtMS0xLTEtMjI1NDU_16794bb4-fe0f-47f9-8245-3856d38d15df">10,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ic66825b0a3fc4dd6a295dc833b6cfb18_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzgtMy0xLTEtMjI1NDU_db528185-6ef6-4954-8f12-a973a05ac054">51,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i814f9685f6c74fbb94e17b68b38c9a50_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzgtNS0xLTEtMjI1NDU_d0d14c26-9e9d-44b2-ba3d-dcef4612712f">2,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzgtNy0xLTEtMjI1NDU_1bcd7329-48ec-4954-83a2-f0b543b91423">64,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Conversion of convertible Series C convertible preferred stock into common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0d1460718e76486b9ed354cf1c73b976_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzItNS0xLTEtMjgwNDE_47cfb4c9-00cc-4c4c-93b1-7e3c96ca77f7">6,110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0d1460718e76486b9ed354cf1c73b976_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzItNy0xLTEtMjgwNDE_9a8a933e-4ed5-410a-980b-dcee6c2244df">6,110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Conversion of convertible notes into common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibf7783ebf66b4af79c0713536f5f2962_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzMtMy0xLTEtMjgwNDE_ddd842a7-8389-4b50-9bbd-dba3c1838576">58,639</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibf7783ebf66b4af79c0713536f5f2962_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzMtNy0xLTEtMjgwNDE_f56b8401-7f9e-4b99-b2aa-3bb9086813ae">58,639</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net exercise of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0e0cf619aa784005a71db89834b81180_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzQtMS0xLTEtMjgwNDE_959325c5-390e-41a3-845d-6e1973d6a735">13,509</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0e0cf619aa784005a71db89834b81180_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzQtNy0xLTEtMjgwNDE_56d803b4-ce76-485a-b777-5fe0d5a4ca2e">13,509</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0e0cf619aa784005a71db89834b81180_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzUtMS0xLTEtMjgwNDE_32d23ea4-9a5f-42ec-b087-c370f572c1d9">2,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibf7783ebf66b4af79c0713536f5f2962_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzUtMy0xLTEtMjgwNDE_b1c58919-5e0e-4a6c-ba9e-42c876e4790d">7,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0d1460718e76486b9ed354cf1c73b976_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzUtNS0xLTEtMjgwNDE_2fb2b9ea-bb8b-487a-a5de-82c9a0bbddd2">3,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzUtNy0xLTEtMjgwNDE_be20a23c-7e5f-4a5e-a0a0-6ffa1a699001">13,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Balance&#8212;December 31, 2021</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i15bff6b964924bd2887e2adeffbf32c6_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzYtMS0xLTEtMjgwNDE_52cac2f3-baf4-4f02-b170-7cf425ae9bdd">114</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ic050e32ff85e44309aa662d9aef5ce48_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzYtMy0xLTEtMjgwNDE_474c8748-3a51-46d3-985f-80d539e25bba">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3bc00b7b825d4ba3852fb7e87894c1cc_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzYtNS0xLTEtMjgwNDE_bc14d4c3-91d1-421f-97e4-3df4afa79fac">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzYtNy0xLTEtMjgwNDE_3a1f6dcb-ccf6-4232-917e-11d213799b06">114</ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used an option model to measure the fair value of the Notes (on conversion date). The values of the equity underlying the conversion options in the model were estimated using equity values implied from sales of convertible preferred stock. The fair value of the Notes was impacted by the model selected as well as assumptions surrounding unobservable inputs. Key unobservable inputs include the expected volatility of the underlying equity, and the timing of an expected liquidity event.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the warrants issued by the Company has been estimated using a variant of the Black Scholes option pricing model. The underlying equity included in the Black Scholes option pricing model was valued based on the equity value implied from sales of preferred and common stock at each measurement date. The fair value of the warrants was impacted by the model selected as well as assumptions surrounding unobservable inputs including the underlying equity value, expected volatility of the underlying equity, risk free interest rate and the expected term.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value adjustment during the year ended December&#160;31, 2021 was based on the final settlement amount using a conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i66adccbb9df94f8b89614b7fed22144e_I20210209" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90ZXh0cmVnaW9uOjg4ZDM5N2I0MTBhODQ4NTE4M2UwNzliNWRjZjI4MmNlXzEwOTk1MTE2MzI3MjA_cf31ea2d-8e79-4ed3-af4a-2672ee6e6287">11.57</ix:nonFraction> per share on February 9, 2021. Subsequent to the closing of the IPO, there were <ix:nonFraction unitRef="usd" contextRef="ie6530fcd8ea6401a8a572f67df226036_I20210210" decimals="INF" name="us-gaap:ConvertibleNotesPayableCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90ZXh0cmVnaW9uOjg4ZDM5N2I0MTBhODQ4NTE4M2UwNzliNWRjZjI4MmNlXzEwOTk1MTE2MzEzNzE_2b21533d-00e4-4161-9e4c-039438a46c03">no</ix:nonFraction> convertible notes outstanding.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series C Preferred Stock </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value adjustment during the year ended December&#160;31, 2021 was based on the final settlement amount using a conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i5ce6c1160cbc4d2eb14e3ddc68c08191_D20210209-20210209" decimals="2" name="angn:FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsConversionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90ZXh0cmVnaW9uOjg4ZDM5N2I0MTBhODQ4NTE4M2UwNzliNWRjZjI4MmNlXzEwOTk1MTE2MzM0MjQ_402e0b54-f97b-42ce-af10-bfeee6599292">11.57</ix:nonFraction> per share on February 9, 2021. Subsequent to the closing of the IPO, there were <ix:nonFraction unitRef="shares" contextRef="ia2518ef5cab941c1b5281fac0348fe6c_I20210210" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90ZXh0cmVnaW9uOjg4ZDM5N2I0MTBhODQ4NTE4M2UwNzliNWRjZjI4MmNlXzEwOTk1MTE2MzM0NDU_2389dde4-137f-448a-a401-2a67cc8e3125">no</ix:nonFraction> shares of convertible preferred stock outstanding. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liability</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value adjustment for the net exercise of warrants with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90ZXh0cmVnaW9uOjg4ZDM5N2I0MTBhODQ4NTE4M2UwNzliNWRjZjI4MmNlXzEwOTk1MTE2MzI3Mjg_e0166cd7-1d81-4e9a-ba41-08a2d8ed0a62">6.43</ix:nonFraction> during the year ended December&#160;31, 2021 was based on the final settlement amount using the IPO price on February 9, 2021. Subsequent to the closing of the IPO, the fair value of the warrants issued by the Company were estimated using a variant of the Black Scholes option pricing model. The underlying equity included in the Black Scholes option pricing model was valued based on the closing price of common stock at each measurement date.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANGION BIOMEDICA CORP.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="id76656a4cac54ef3b83e2e91507fe064"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, the fair value of the warrants increased by $<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-5" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90ZXh0cmVnaW9uOjg4ZDM5N2I0MTBhODQ4NTE4M2UwNzliNWRjZjI4MmNlXzEwOTk1MTE2MzM0Mjk_f9564913-a4cf-43fc-936b-d4270956bf90">2.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-5" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90ZXh0cmVnaW9uOjg4ZDM5N2I0MTBhODQ4NTE4M2UwNzliNWRjZjI4MmNlXzEwOTk1MTE2MzM0NTQ_260881d5-0fdd-4fc3-bad4-7bde14e4a208">4.9</ix:nonFraction>&#160;million, respectively. The change in fair value of warrant liability in both periods was recognized in the consolidated statements of operations. </span></div><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90ZXh0cmVnaW9uOjg4ZDM5N2I0MTBhODQ4NTE4M2UwNzliNWRjZjI4MmNlXzI3NDg3NzkwNzIyNDU_cd927d46-59e8-447d-a195-9fc740638112" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the Company's warrant liabilities that were categorized within Level 3 of the fair value hierarchy as of December&#160;31, 2021 and 2020 was as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Strike price</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib2df00ce29b94846875f1ca16bf13df4_I20211231" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTplNjE0MjQ0NGJhN2Q0ZmNmOWQ4YjMwM2IzMDNhYjFiNi90YWJsZXJhbmdlOmU2MTQyNDQ0YmE3ZDRmY2Y5ZDhiMzAzYjMwM2FiMWI2XzItMS0xLTEtMjI1NDU_7f1478f7-9aa5-4a0c-94e4-4b2ba8f15fe7">8.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="if4d6f862fa754573bef10ee164188288_I20201231" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTplNjE0MjQ0NGJhN2Q0ZmNmOWQ4YjMwM2IzMDNhYjFiNi90YWJsZXJhbmdlOmU2MTQyNDQ0YmE3ZDRmY2Y5ZDhiMzAzYjMwM2FiMWI2XzItMy0xLTEtMjI1NDU_6e1172de-0413-420a-87dc-cbddfc836a59">9.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractual term (years)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i209f579b21984d5987ce82e809b3b3f5_I20211231" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTplNjE0MjQ0NGJhN2Q0ZmNmOWQ4YjMwM2IzMDNhYjFiNi90YWJsZXJhbmdlOmU2MTQyNDQ0YmE3ZDRmY2Y5ZDhiMzAzYjMwM2FiMWI2XzMtMS0xLTEtMjI1NDU_d0ef87e0-139b-4002-82c4-5cd06392bcc4">1.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ibdd03f678bd444f78c9695d99f88f610_I20201231" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTplNjE0MjQ0NGJhN2Q0ZmNmOWQ4YjMwM2IzMDNhYjFiNi90YWJsZXJhbmdlOmU2MTQyNDQ0YmE3ZDRmY2Y5ZDhiMzAzYjMwM2FiMWI2XzMtMy0xLTEtMjI1NDU_aaaad5bb-5ede-480d-a41b-5f118c4a2927">4.9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Volatility (annual)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ie5de6bc9b6694e62baba186bbdd4af73_I20211231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTplNjE0MjQ0NGJhN2Q0ZmNmOWQ4YjMwM2IzMDNhYjFiNi90YWJsZXJhbmdlOmU2MTQyNDQ0YmE3ZDRmY2Y5ZDhiMzAzYjMwM2FiMWI2XzQtMS0xLTEtMjI1NDU_61a95a24-a631-4458-b2f0-5dbfe999d6ad">74.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ia35389eedc0a4461980878982b5787a2_I20201231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTplNjE0MjQ0NGJhN2Q0ZmNmOWQ4YjMwM2IzMDNhYjFiNi90YWJsZXJhbmdlOmU2MTQyNDQ0YmE3ZDRmY2Y5ZDhiMzAzYjMwM2FiMWI2XzQtMy0xLTEtMjI1NDU_e6f3d1c2-8aa0-448a-92db-0bc63d9adff2">86.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free rate</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ia83dfc08acb543ae8924290c590ed65a_I20211231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTplNjE0MjQ0NGJhN2Q0ZmNmOWQ4YjMwM2IzMDNhYjFiNi90YWJsZXJhbmdlOmU2MTQyNDQ0YmE3ZDRmY2Y5ZDhiMzAzYjMwM2FiMWI2XzUtMS0xLTEtMjI1NDU_9302e0e1-f6ac-487f-846a-3a0b345303e8">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ief2a3bab90b642da9d4fe8599569910c_I20201231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTplNjE0MjQ0NGJhN2Q0ZmNmOWQ4YjMwM2IzMDNhYjFiNi90YWJsZXJhbmdlOmU2MTQyNDQ0YmE3ZDRmY2Y5ZDhiMzAzYjMwM2FiMWI2XzUtMy0xLTEtMjI1NDU_161837a0-b70b-435a-8c1f-abf9b6c549ce">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield (per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ib1b7ad6b8d104df388410248585c728f_I20211231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTplNjE0MjQ0NGJhN2Q0ZmNmOWQ4YjMwM2IzMDNhYjFiNi90YWJsZXJhbmdlOmU2MTQyNDQ0YmE3ZDRmY2Y5ZDhiMzAzYjMwM2FiMWI2XzYtMS0xLTEtMjI1NDU_3a912990-053f-4d5b-a99e-57064989cff4">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i71c37180af7c40edb5bd3e902f2b71bc_I20201231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTplNjE0MjQ0NGJhN2Q0ZmNmOWQ4YjMwM2IzMDNhYjFiNi90YWJsZXJhbmdlOmU2MTQyNDQ0YmE3ZDRmY2Y5ZDhiMzAzYjMwM2FiMWI2XzYtMy0xLTEtMjI1NDU_fd4a9473-3d93-4974-8b36-46f003ca553d">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:3pt"><span><br/></span></div><div id="idee3699378af4447a4091414c0adfaa7_115"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5&#8212;<ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90ZXh0cmVnaW9uOjNjODdkMmRjNzc0ZDQ3YzY5MTdlZGJmNWUxYTQ2YTdhXzI3NDg3NzkwNjk4NTg_7cfbf7e1-602b-46b4-a32e-7f6b2ab95574" continuedAt="i76ad7f2df6c845e4903295768f552c85" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="i76ad7f2df6c845e4903295768f552c85" continuedAt="ic4c4fdfbf59c478aa61f24fcb189130a"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">R&amp;D tax credit receivable </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also recorded an Australian tax credit as provided by the Australian Taxation Office for qualified research and development expenditures incurred through its subsidiary, Savara Australia Pty. Limited. Under Australian tax law, Australia remits a research and development tax credit equal to 43.5% of qualified research and development expenditures, not to exceed established thresholds. During the year ended December&#160;31, 2021, the Company generated an Australian tax credit of $<ix:nonFraction unitRef="usd" contextRef="ia7d86eb6878a4ef0b875c05988047754_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90ZXh0cmVnaW9uOjNjODdkMmRjNzc0ZDQ3YzY5MTdlZGJmNWUxYTQ2YTdhXzE2NDkyNjc0NDYxOTI_e41c9954-bb65-4d9f-aeaf-8993a59ffbfe">0.8</ix:nonFraction>&#160;million which was included in prepaid expenses and other current assets on the consolidated balance sheets and the Company received the tax credit in January 2022. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><ix:continuation id="i25e5cc99b81e45f8b691bc49dbc951ea"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's property and equipment, net was comprised of the following (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ic94945863a1b4df4ab1f5e7d2e9530c2_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZToyMjg1NWY2ZTYzZTI0YWFhOWY3NWIzYTVmNDlhOGI5OC90YWJsZXJhbmdlOjIyODU1ZjZlNjNlMjRhYWE5Zjc1YjNhNWY0OWE4Yjk4XzItMi0xLTEtMjI1NDU_4e790f34-db33-4137-8f66-d1d890762234">866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i9cfab8eface34dd4839fbb00af77dc97_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZToyMjg1NWY2ZTYzZTI0YWFhOWY3NWIzYTVmNDlhOGI5OC90YWJsZXJhbmdlOjIyODU1ZjZlNjNlMjRhYWE5Zjc1YjNhNWY0OWE4Yjk4XzItNC0xLTEtMjI1NDU_33766cc9-01c1-4d9e-9ac1-6565da22ee0e">512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furniture and fixtures</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i306ddd1004714dec93e5d5ea85b3c8c6_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZToyMjg1NWY2ZTYzZTI0YWFhOWY3NWIzYTVmNDlhOGI5OC90YWJsZXJhbmdlOjIyODU1ZjZlNjNlMjRhYWE5Zjc1YjNhNWY0OWE4Yjk4XzMtMi0xLTEtMjI1NDU_5b87ecf9-2a96-4d58-9b91-81564de50c66">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i992e93e0d3c3482bad88da73616728c5_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZToyMjg1NWY2ZTYzZTI0YWFhOWY3NWIzYTVmNDlhOGI5OC90YWJsZXJhbmdlOjIyODU1ZjZlNjNlMjRhYWE5Zjc1YjNhNWY0OWE4Yjk4XzMtNC0xLTEtMjI1NDU_106f3c58-0e32-4012-83db-3eb3039b3f7c">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i2ab54aa1e3014f50a5db232a28772555_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZToyMjg1NWY2ZTYzZTI0YWFhOWY3NWIzYTVmNDlhOGI5OC90YWJsZXJhbmdlOjIyODU1ZjZlNjNlMjRhYWE5Zjc1YjNhNWY0OWE4Yjk4XzQtMi0xLTEtMjI1NDU_1176e4d9-121c-4f8e-bb81-2b5c1ec94c37">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i65a1a8317ce94459b14feb26feeb201c_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZToyMjg1NWY2ZTYzZTI0YWFhOWY3NWIzYTVmNDlhOGI5OC90YWJsZXJhbmdlOjIyODU1ZjZlNjNlMjRhYWE5Zjc1YjNhNWY0OWE4Yjk4XzQtNC0xLTEtMjI1NDU_56fe2e77-901c-4ef9-8ff2-53e3802b6a5b">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total property and equipment</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZToyMjg1NWY2ZTYzZTI0YWFhOWY3NWIzYTVmNDlhOGI5OC90YWJsZXJhbmdlOjIyODU1ZjZlNjNlMjRhYWE5Zjc1YjNhNWY0OWE4Yjk4XzUtMi0xLTEtMjI1NDU_6836d0e1-202a-49b1-82b7-0e122c70fa77">968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZToyMjg1NWY2ZTYzZTI0YWFhOWY3NWIzYTVmNDlhOGI5OC90YWJsZXJhbmdlOjIyODU1ZjZlNjNlMjRhYWE5Zjc1YjNhNWY0OWE4Yjk4XzUtNC0xLTEtMjI1NDU_716ffd60-ff9a-4fa9-a05e-6d5e2b362b3f">582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less: accumulated depreciation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZToyMjg1NWY2ZTYzZTI0YWFhOWY3NWIzYTVmNDlhOGI5OC90YWJsZXJhbmdlOjIyODU1ZjZlNjNlMjRhYWE5Zjc1YjNhNWY0OWE4Yjk4XzYtMi0xLTEtMjI1NDU_a197a896-90cf-4c94-9cbd-1f35622a4755">517</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZToyMjg1NWY2ZTYzZTI0YWFhOWY3NWIzYTVmNDlhOGI5OC90YWJsZXJhbmdlOjIyODU1ZjZlNjNlMjRhYWE5Zjc1YjNhNWY0OWE4Yjk4XzYtNC0xLTEtMjI1NDU_38d0e356-028d-49c3-881e-2ca657c3bfe2">426</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZToyMjg1NWY2ZTYzZTI0YWFhOWY3NWIzYTVmNDlhOGI5OC90YWJsZXJhbmdlOjIyODU1ZjZlNjNlMjRhYWE5Zjc1YjNhNWY0OWE4Yjk4XzctMi0xLTEtMjI1NDU_5fa791a2-a03d-4161-b2f1-f898a8ef1e5e">451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZToyMjg1NWY2ZTYzZTI0YWFhOWY3NWIzYTVmNDlhOGI5OC90YWJsZXJhbmdlOjIyODU1ZjZlNjNlMjRhYWE5Zjc1YjNhNWY0OWE4Yjk4XzctNC0xLTEtMjI1NDU_7a09684b-0275-4113-91f2-1b463ec80a0d">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the years ended December&#160;31, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90ZXh0cmVnaW9uOjNjODdkMmRjNzc0ZDQ3YzY5MTdlZGJmNWUxYTQ2YTdhXzIxMg_362d946e-7262-444f-a5c5-644919702ece"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90ZXh0cmVnaW9uOjNjODdkMmRjNzc0ZDQ3YzY5MTdlZGJmNWUxYTQ2YTdhXzIxMg_6f7a009b-3708-4627-a6f2-24d36b5c9260">0.1</ix:nonFraction></ix:nonFraction> million.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANGION BIOMEDICA CORP.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements (Continued)</span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="ic4c4fdfbf59c478aa61f24fcb189130a"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid and Other Current Assets</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90ZXh0cmVnaW9uOjNjODdkMmRjNzc0ZDQ3YzY5MTdlZGJmNWUxYTQ2YTdhXzI3NDg3NzkwNjk4NjA_f1eaedce-5a86-4eef-9098-a392df39394a" continuedAt="i1f151a09488841c88217ccce20d12a53" escape="true">Prepaid and other current assets were comprised of the following (in thousands):</ix:nonNumeric></span></div><div style="margin-top:10pt"><ix:continuation id="i1f151a09488841c88217ccce20d12a53"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred Offering costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:DeferredOfferingCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzItMi0xLTEtMjI1NDU_58739e6c-5170-4f69-87a0-10fd3c32497b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:DeferredOfferingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzItNC0xLTEtMjI1NDU_bcbc66d5-f566-45fb-b38b-052058c3e388">1,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid clinical fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="angn:PrepaidClinicalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzMtMi0xLTEtMjg3MTc_36e3e5d7-1e11-44de-b0e4-c61e8b86d50f">168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="angn:PrepaidClinicalFeesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzMtNC0xLTEtMjg3MTc_d7b15512-58f1-403d-b61a-132533947784">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Business insurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzQtMi0xLTEtMjg3MTc_73b8dbb0-1529-44dc-ba86-57d62498af3f">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:PrepaidInsurance" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzQtNC0xLTEtMjg3MTc_03eb03c0-1966-4c3a-a21a-c08f810bf3c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Security deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:DepositsAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzUtMi0xLTEtMjg3MDc_b49dbbd3-4170-42ed-9f00-05034b90c789">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:DepositsAssetsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzUtNC0xLTEtMjg3MDc_3e5471c9-5af3-49c3-81a6-3635ea854bf4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Convertible note receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzMtMi0xLTEtMjI1NDU_a7b8a4d8-e67e-4258-b4fc-5ac42280f872">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzMtNC0xLTEtMjI1NDU_6399b513-0132-4c38-978b-e0fbc9792002">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Angion Pty tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:PrepaidTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzQtMi0xLTEtMjI1NDU_77d69ea4-eb15-4766-ba31-40fa7d1fccb0">863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:PrepaidTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzQtNC0xLTEtMjI1NDU_356b02a6-9e91-4d1a-97bf-4562d62b1b5b">352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzUtMi0xLTEtMjI1NDU_c525a38f-3aad-48dd-ae80-1b4fd570dcbc">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzUtNC0xLTEtMjI1NDU_06486266-9665-48ed-b52d-e3ac3286f50d">360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total prepaid and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzYtMi0xLTEtMjMyNTc_c9591ba4-684d-41cf-b9e8-b611e31f49ee">1,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzYtNC0xLTEtMjMyNjI_54c00873-100e-4da7-b510-4fe19ac26957">7,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:10pt;text-indent:22.5pt"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90ZXh0cmVnaW9uOjNjODdkMmRjNzc0ZDQ3YzY5MTdlZGJmNWUxYTQ2YTdhXzI3NDg3NzkwNjk4NjE_2c4cdeab-f840-42cd-888b-1e21e6359564" escape="true"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses were comprised of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued compensation</span></div></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTpiMmY5ZDIxYTQxNTQ0M2FjODBiNmJiNjcwMjIyYzk2Mi90YWJsZXJhbmdlOmIyZjlkMjFhNDE1NDQzYWM4MGI2YmI2NzAyMjJjOTYyXzItMS0xLTEtMjI1NDU_bb9b6fb4-62e6-4f99-b39c-209221b12bae">1,274</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTpiMmY5ZDIxYTQxNTQ0M2FjODBiNmJiNjcwMjIyYzk2Mi90YWJsZXJhbmdlOmIyZjlkMjFhNDE1NDQzYWM4MGI2YmI2NzAyMjJjOTYyXzItMy0xLTEtMjI1NDU_ea2278ef-d747-4754-8ed2-94f060ee4e2a">3,154</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued direct research costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="angn:AccruedDirectResearchCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTpiMmY5ZDIxYTQxNTQ0M2FjODBiNmJiNjcwMjIyYzk2Mi90YWJsZXJhbmdlOmIyZjlkMjFhNDE1NDQzYWM4MGI2YmI2NzAyMjJjOTYyXzMtMS0xLTEtMjI1NDU_f77fe90a-ecd4-44c5-b31d-7b9d70c62077">1,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="angn:AccruedDirectResearchCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTpiMmY5ZDIxYTQxNTQ0M2FjODBiNmJiNjcwMjIyYzk2Mi90YWJsZXJhbmdlOmIyZjlkMjFhNDE1NDQzYWM4MGI2YmI2NzAyMjJjOTYyXzMtMy0xLTEtMjI1NDU_8845300b-9507-494b-b56c-dcf39e7feed5">1,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued operating expenses</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="angn:AccruedOperatingLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTpiMmY5ZDIxYTQxNTQ0M2FjODBiNmJiNjcwMjIyYzk2Mi90YWJsZXJhbmdlOmIyZjlkMjFhNDE1NDQzYWM4MGI2YmI2NzAyMjJjOTYyXzQtMS0xLTEtMjI1NDU_1711e0df-bcb0-4b46-855a-d7a90b30698b">749</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="angn:AccruedOperatingLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTpiMmY5ZDIxYTQxNTQ0M2FjODBiNmJiNjcwMjIyYzk2Mi90YWJsZXJhbmdlOmIyZjlkMjFhNDE1NDQzYWM4MGI2YmI2NzAyMjJjOTYyXzQtMy0xLTEtMjI1NDU_ddfc0149-52a5-4362-a478-e312089a9e85">707</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTpiMmY5ZDIxYTQxNTQ0M2FjODBiNmJiNjcwMjIyYzk2Mi90YWJsZXJhbmdlOmIyZjlkMjFhNDE1NDQzYWM4MGI2YmI2NzAyMjJjOTYyXzUtMS0xLTEtMjI1NDU_ff9e8995-d9bd-4017-ae3e-43c649ef586b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTpiMmY5ZDIxYTQxNTQ0M2FjODBiNmJiNjcwMjIyYzk2Mi90YWJsZXJhbmdlOmIyZjlkMjFhNDE1NDQzYWM4MGI2YmI2NzAyMjJjOTYyXzUtMy0xLTEtMjI1NDU_93f443c1-c6b7-43ef-8994-535dcdb05872">1,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total accrued expenses</span></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTpiMmY5ZDIxYTQxNTQ0M2FjODBiNmJiNjcwMjIyYzk2Mi90YWJsZXJhbmdlOmIyZjlkMjFhNDE1NDQzYWM4MGI2YmI2NzAyMjJjOTYyXzYtMS0xLTEtMjI1NDU_c9c59978-e68b-4083-8f3a-6b56cbe348e5">3,219</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTpiMmY5ZDIxYTQxNTQ0M2FjODBiNmJiNjcwMjIyYzk2Mi90YWJsZXJhbmdlOmIyZjlkMjFhNDE1NDQzYWM4MGI2YmI2NzAyMjJjOTYyXzYtMy0xLTEtMjI1NDU_5df531f9-fd5f-4f35-a82f-ba9a22210de0">6,665</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:10pt;text-indent:22.5pt"><span><br/></span></div><div id="idee3699378af4447a4091414c0adfaa7_118"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6&#8212;<ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTgvZnJhZzozNWNiYmU4ODliZjA0NzhjYWI1NWMyZGNlZDg5NWVmZC90ZXh0cmVnaW9uOjM1Y2JiZTg4OWJmMDQ3OGNhYjU1YzJkY2VkODk1ZWZkXzI3NDg3NzkwNzMyMjY_eb3d25a9-3a16-4d85-928f-452112bbf007" continuedAt="ib1a05c27695443a1afc4ce7bfffc8c88" escape="true">Convertible Notes Payable</ix:nonNumeric></span></div><ix:continuation id="ib1a05c27695443a1afc4ce7bfffc8c88"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company had convertible notes with an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i070cfb2f33fa400ab61eda85d18e3338_I20201231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTgvZnJhZzozNWNiYmU4ODliZjA0NzhjYWI1NWMyZGNlZDg5NWVmZC90ZXh0cmVnaW9uOjM1Y2JiZTg4OWJmMDQ3OGNhYjU1YzJkY2VkODk1ZWZkXzEwOTk1MTE2NDM2NTI_73a20a05-276b-4926-9e80-d45de8135436">39.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3e51cbe879fb441184f95b52afb2aeef_D20200101-20201231" decimals="-5" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTgvZnJhZzozNWNiYmU4ODliZjA0NzhjYWI1NWMyZGNlZDg5NWVmZC90ZXh0cmVnaW9uOjM1Y2JiZTg4OWJmMDQ3OGNhYjU1YzJkY2VkODk1ZWZkXzEwOTk1MTE2NDM2NzE_ba06165c-6569-4924-9ce3-56fb3484f2ff">1.8</ix:nonFraction> million accrued interest outstanding. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion of Convertible Notes Payable </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In January 2021, the Company issued <ix:nonFraction unitRef="shares" contextRef="ibb7ba2f1254942b1b3dca57b33e584e4_D20210101-20210131" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTgvZnJhZzozNWNiYmU4ODliZjA0NzhjYWI1NWMyZGNlZDg5NWVmZC90ZXh0cmVnaW9uOjM1Y2JiZTg4OWJmMDQ3OGNhYjU1YzJkY2VkODk1ZWZkXzEwOTk1MTE2NDM2OTM_98b79e99-b1fd-4e5b-baa9-c2031963f31f">33,978</ix:nonFraction> shares of common stock upon the conversion of certain of the outstanding 2020 Notes. In connection with the IPO in February 2021, with an IPO price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i028f1ad3777340c2a17441b369da80c7_I20210209" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTgvZnJhZzozNWNiYmU4ODliZjA0NzhjYWI1NWMyZGNlZDg5NWVmZC90ZXh0cmVnaW9uOjM1Y2JiZTg4OWJmMDQ3OGNhYjU1YzJkY2VkODk1ZWZkXzEwOTk1MTE2NDM2ODk_58939d62-73ce-4234-bae8-6d2e804a1dae">16.00</ix:nonFraction> per share, the remaining outstanding convertible notes were converted into <ix:nonFraction unitRef="shares" contextRef="i90d58066e44642be83973e6daa1dee34_D20210204-20210209" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTgvZnJhZzozNWNiYmU4ODliZjA0NzhjYWI1NWMyZGNlZDg5NWVmZC90ZXh0cmVnaW9uOjM1Y2JiZTg4OWJmMDQ3OGNhYjU1YzJkY2VkODk1ZWZkXzEwOTk1MTE2NDM2ODU_d626c2f2-5b05-4204-a39a-1b4f960004f3">3,636,189</ix:nonFraction> shares of the Company&#8217;s common stock based on a conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2fba8513019e4003882ec149aeddb34b_I20210209" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTgvZnJhZzozNWNiYmU4ODliZjA0NzhjYWI1NWMyZGNlZDg5NWVmZC90ZXh0cmVnaW9uOjM1Y2JiZTg4OWJmMDQ3OGNhYjU1YzJkY2VkODk1ZWZkXzEwOTk1MTE2NDM2ODE_d590078d-050c-44eb-8c2d-c8b5cab61d57">11.57</ix:nonFraction> per share. There were <ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="INF" name="us-gaap:ConvertibleNotesPayable" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTgvZnJhZzozNWNiYmU4ODliZjA0NzhjYWI1NWMyZGNlZDg5NWVmZC90ZXh0cmVnaW9uOjM1Y2JiZTg4OWJmMDQ3OGNhYjU1YzJkY2VkODk1ZWZkXzIxOTkwMjMyNzE1ODA_b445dad6-9a17-4c80-add5-a79e8cc1e19a">no</ix:nonFraction> convertible notes outstanding as of December&#160;31, 2021.</span></div></ix:continuation><div style="margin-top:3pt;text-indent:22.5pt"><span><br/></span></div><div id="idee3699378af4447a4091414c0adfaa7_121"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7&#8212; <ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="angn:FinancialInstrumentsSubjectToMandatoryRedemptionDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90ZXh0cmVnaW9uOmFmOGIwMTViMzA4MjQxOTRiMDBhMDkzMzczNDA1ZGUxXzI3NDg3NzkwNzMzODY_bb0cf308-0d39-45d2-a057-09d01dbf7526" continuedAt="i37db3e868d664dbbb6cd6e5eb63c840d" escape="true">Series C Convertible Preferred Stock </ix:nonNumeric></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i37db3e868d664dbbb6cd6e5eb63c840d"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:SharesSubjectToMandatoryRedemptionDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90ZXh0cmVnaW9uOmFmOGIwMTViMzA4MjQxOTRiMDBhMDkzMzczNDA1ZGUxXzI3NDg3NzkwNzM1Njg_7d63a821-bb74-4d5f-83c8-eb4bc295ab6b" escape="true"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate values recorded for the Series C convertible preferred stock as of December 31, 2020 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.201%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">At issuance </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Series C convertible preferred stock recorded at amortized cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Principal</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i2fba8513019e4003882ec149aeddb34b_I20210209" decimals="-3" name="angn:FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90YWJsZTowY2QwZGVkMDM5YTI0YWI5YTEzMDlkYjJjNjg3MTg5My90YWJsZXJhbmdlOjBjZDBkZWQwMzlhMjRhYjlhMTMwOWRiMmM2ODcxODkzXzItMi0xLTEtMjI1NDU_c4068058-2810-4c48-9f7d-481e855c4cad">22,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="angn:FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90YWJsZTowY2QwZGVkMDM5YTI0YWI5YTEzMDlkYjJjNjg3MTg5My90YWJsZXJhbmdlOjBjZDBkZWQwMzlhMjRhYjlhMTMwOWRiMmM2ODcxODkzXzItNC0xLTEtMjI1NDU_d086f200-7ddb-4546-8738-1dace6b5eddc">22,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Settlement premium</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i2fba8513019e4003882ec149aeddb34b_I20210209" decimals="-3" name="angn:FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90YWJsZTowY2QwZGVkMDM5YTI0YWI5YTEzMDlkYjJjNjg3MTg5My90YWJsZXJhbmdlOjBjZDBkZWQwMzlhMjRhYjlhMTMwOWRiMmM2ODcxODkzXzMtMi0xLTEtMjI1NDU_81bd1d9a-e0b7-4e51-ad10-de3053be3568">5,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="angn:FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90YWJsZTowY2QwZGVkMDM5YTI0YWI5YTEzMDlkYjJjNjg3MTg5My90YWJsZXJhbmdlOjBjZDBkZWQwMzlhMjRhYjlhMTMwOWRiMmM2ODcxODkzXzMtNC0xLTEtMjI1NDU_92ed6f7d-57f7-4c23-9764-9d6347ecee08">5,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Unamortized discounts and fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i2fba8513019e4003882ec149aeddb34b_I20210209" decimals="-3" name="angn:FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90YWJsZTowY2QwZGVkMDM5YTI0YWI5YTEzMDlkYjJjNjg3MTg5My90YWJsZXJhbmdlOjBjZDBkZWQwMzlhMjRhYjlhMTMwOWRiMmM2ODcxODkzXzQtMi0xLTEtMjI1NDU_eef968fb-dfd5-45af-80a3-aab7ade6eba9">9,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="angn:FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90YWJsZTowY2QwZGVkMDM5YTI0YWI5YTEzMDlkYjJjNjg3MTg5My90YWJsZXJhbmdlOjBjZDBkZWQwMzlhMjRhYjlhMTMwOWRiMmM2ODcxODkzXzQtNC0xLTEtMjI1NDU_8a02eb01-ced3-4b09-bb37-3ca65f9aa2a6">1,884</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net carrying amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i2fba8513019e4003882ec149aeddb34b_I20210209" decimals="-3" name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90YWJsZTowY2QwZGVkMDM5YTI0YWI5YTEzMDlkYjJjNjg3MTg5My90YWJsZXJhbmdlOjBjZDBkZWQwMzlhMjRhYjlhMTMwOWRiMmM2ODcxODkzXzUtMi0xLTEtMjI1NDU_c1abaaa1-63aa-4650-bfad-1d3ecba3e9b3">18,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90YWJsZTowY2QwZGVkMDM5YTI0YWI5YTEzMDlkYjJjNjg3MTg5My90YWJsZXJhbmdlOjBjZDBkZWQwMzlhMjRhYjlhMTMwOWRiMmM2ODcxODkzXzUtNC0xLTEtMjI1NDU_7e70a2d4-7198-4f1c-aa6f-05f65eee421c">26,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Series C convertible preferred stock recorded at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Series C convertible preferred stock issued in exchange for convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="angn:FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountIssuedInConvertibleNoteExchange" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90YWJsZTowY2QwZGVkMDM5YTI0YWI5YTEzMDlkYjJjNjg3MTg5My90YWJsZXJhbmdlOjBjZDBkZWQwMzlhMjRhYjlhMTMwOWRiMmM2ODcxODkzXzctNC0xLTEtMjI1NDU_16315876-797e-441e-b867-44fa4785d6ec">2,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Change in fair value of Series C convertible preferred stock exchanged for convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="angn:FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountAccumulatedChangeInFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90YWJsZTowY2QwZGVkMDM5YTI0YWI5YTEzMDlkYjJjNjg3MTg5My90YWJsZXJhbmdlOjBjZDBkZWQwMzlhMjRhYjlhMTMwOWRiMmM2ODcxODkzXzgtNC0xLTEtMjI1NDU_9cac9797-02e8-4352-90b3-3f1186bb2a36">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total Series C convertible preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="angn:FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90YWJsZTowY2QwZGVkMDM5YTI0YWI5YTEzMDlkYjJjNjg3MTg5My90YWJsZXJhbmdlOjBjZDBkZWQwMzlhMjRhYjlhMTMwOWRiMmM2ODcxODkzXzktNC0xLTEtMjI1NDU_1c84619e-0c22-4ed5-99f6-e7e8e3aec932">28,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion of Series C Convertible Preferred Stock</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In connection with the IPO in February 2021, with an initial public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i028f1ad3777340c2a17441b369da80c7_I20210209" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90ZXh0cmVnaW9uOmFmOGIwMTViMzA4MjQxOTRiMDBhMDkzMzczNDA1ZGUxXzEwOTk1MTE2MzU1NTY_bbce268e-708f-4854-bb94-738ffe6677da">16.00</ix:nonFraction> per share, all shares of Series C convertible preferred stock outstanding plus accrued dividends were automatically converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="iac7d715402754b8caf32b6a9c1cee1f7_I20210209" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90ZXh0cmVnaW9uOmFmOGIwMTViMzA4MjQxOTRiMDBhMDkzMzczNDA1ZGUxXzEwOTk1MTE2MzU1NjA_012db8e9-ba69-4300-9765-17337473fa78">2,234,640</ix:nonFraction> shares of common stock with a conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iac7d715402754b8caf32b6a9c1cee1f7_I20210209" decimals="2" name="angn:ConvertiblePreferredStockConversionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90ZXh0cmVnaW9uOmFmOGIwMTViMzA4MjQxOTRiMDBhMDkzMzczNDA1ZGUxXzEwOTk1MTE2MzU1NjY_9831a249-f149-44f2-b5f1-a8b56e44a49c">11.57</ix:nonFraction> per share. There were <ix:nonFraction unitRef="shares" contextRef="i60078b3a55804ab1887cc07c853ff6f7_I20211231" decimals="INF" name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90ZXh0cmVnaW9uOmFmOGIwMTViMzA4MjQxOTRiMDBhMDkzMzczNDA1ZGUxXzEwOTk1MTE2MzU1NzA_7845b10b-d38b-40e5-bd26-e4614ff0d940">no</ix:nonFraction> shares of convertible preferred stock outstanding as of December&#160;31, 2021.</span></div></ix:continuation><div style="margin-top:10pt;text-indent:22.5pt"><span><br/></span></div><div id="idee3699378af4447a4091414c0adfaa7_124"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8&#8212;<ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjQvZnJhZzoyZjVmODY2ZTc5ZDg0YWIwYWFjMDM2ZjIyZTNkNDY3NC90ZXh0cmVnaW9uOjJmNWY4NjZlNzlkODRhYjBhYWMwMzZmMjJlM2Q0Njc0XzI3NDg3NzkwNjk4NzY_2125281f-3a1e-4e84-b509-a9212a13a484" continuedAt="i7f736a594eea419c91b1720e814228be" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><ix:continuation id="i7f736a594eea419c91b1720e814228be"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Common Stock</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are not entitled to receive dividends, unless declared by the Board of Directors.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Treasury stock</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The retirement of treasury stock was recorded as a reduction of common stock and additional paid-in capital at the time such retirement was approved by our Board of Directors in October 2021.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, <ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="INF" name="us-gaap:TreasuryStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjQvZnJhZzoyZjVmODY2ZTc5ZDg0YWIwYWFjMDM2ZjIyZTNkNDY3NC90ZXh0cmVnaW9uOjJmNWY4NjZlNzlkODRhYjBhYWMwMzZmMjJlM2Q0Njc0XzEwOTk1MTE2MjkwMTE_94f181db-7ce2-489f-954f-e5e23f6ede7e">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-5" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjQvZnJhZzoyZjVmODY2ZTc5ZDg0YWIwYWFjMDM2ZjIyZTNkNDY3NC90ZXh0cmVnaW9uOjJmNWY4NjZlNzlkODRhYjBhYWMwMzZmMjJlM2Q0Njc0XzM2Nw_b396d9ca-95bc-4924-9c2a-3129822fad65">1.8</ix:nonFraction> million was included in treasury stock in the consolidated balance sheets.</span></div></ix:continuation><div style="margin-top:3pt;text-indent:22.5pt"><span><br/></span></div><div id="idee3699378af4447a4091414c0adfaa7_127"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9&#8212;<ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzI3NDg3NzkwNzU5Nzg_68113367-4fa8-4b86-9357-9ba40fae5969" continuedAt="i9cc8ab09b8864867bca5744ac344bd65" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i9cc8ab09b8864867bca5744ac344bd65" continuedAt="i34ec612f425a4d988498f9c0dd551a3a"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2015 Plan </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Company approved an Amended and Restated 2015 Equity Incentive Plan (the "2015 Plan") permitting the granting of incentive stock options, non-statutory stock options, restricted stock and other stock-based awards. Following the effectiveness of the 2021 Equity Incentive Plan ("2021 Plan"), the Company ceased making grants under the 2015 Plan. However, the 2015 Plan continues to govern the terms and conditions of the outstanding awards granted under it. Shares of common stock subject to awards granted under the 2015 Plan that cease to be subject to such awards by forfeiture or otherwise after the termination of the 2015 Plan will be available for issuance under the 2021 Plan. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Plan </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i34ec612f425a4d988498f9c0dd551a3a" continuedAt="i5678c597fc514151960eeb632a208c2d"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, the Company's board of directors approved the 2021 Plan which permits the granting of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards to employees, directors, officers and consultants. On January 25, 2021, shares of common stock equal to <ix:nonFraction unitRef="number" contextRef="id1dc2e8c07c14adba2e9db115900a85b_D20210125-20210125" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzEwOTk1MTE2Mzg5NjM_b2892bb9-8a7f-4db5-9716-a07cea0c7adb">11</ix:nonFraction>% of the post-IPO capitalization, with annual increases, up to a maximum of <ix:nonFraction unitRef="shares" contextRef="i902c379eaab14156a55d3f460019dc3b_I20210125" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzIxOTkwMjMyNzU5NzE_39c3fa8c-a50f-4403-8b83-1ac3b1732842">60,000,000</ix:nonFraction> shares of common stock were authorized for issuance under the 2021 Plan.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzI3NDg3NzkwNzU5ODY_070f771d-d65a-41ec-a661-7f6d138dd629" escape="true"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each employee and non-employee stock option grant was estimated on the date of grant using the Black-Scholes option-pricing model based on the following inputs:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i54c2a1b829084a7b83834a08509335ce_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo1NTM1NTc3MGU0Mzg0ZGFmYmRkYzRmZGVhODFhMmM2Mi90YWJsZXJhbmdlOjU1MzU1NzcwZTQzODRkYWZiZGRjNGZkZWE4MWEyYzYyXzItMS0xLTEtMjI1NDU_86793b66-f387-4ada-ba4b-30590355fd55">0.7</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i0e0e18adc0424cde81f1a02ec6eea58c_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo1NTM1NTc3MGU0Mzg0ZGFmYmRkYzRmZGVhODFhMmM2Mi90YWJsZXJhbmdlOjU1MzU1NzcwZTQzODRkYWZiZGRjNGZkZWE4MWEyYzYyXzItMy0xLTEtMjM1OTI_3406ee5a-6312-4df1-bc0a-b9d8321022d4">0.7</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Expected dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i54c2a1b829084a7b83834a08509335ce_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo1NTM1NTc3MGU0Mzg0ZGFmYmRkYzRmZGVhODFhMmM2Mi90YWJsZXJhbmdlOjU1MzU1NzcwZTQzODRkYWZiZGRjNGZkZWE4MWEyYzYyXzMtMS0xLTEtMjI1NDU_0de7cd4c-244d-4c53-8494-ac153ec0710a">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i0e0e18adc0424cde81f1a02ec6eea58c_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo1NTM1NTc3MGU0Mzg0ZGFmYmRkYzRmZGVhODFhMmM2Mi90YWJsZXJhbmdlOjU1MzU1NzcwZTQzODRkYWZiZGRjNGZkZWE4MWEyYzYyXzMtMy0xLTEtMjM1OTI_58696b4f-5425-4e96-a4d7-58fd97212409">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Expected term in years </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i54c2a1b829084a7b83834a08509335ce_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo1NTM1NTc3MGU0Mzg0ZGFmYmRkYzRmZGVhODFhMmM2Mi90YWJsZXJhbmdlOjU1MzU1NzcwZTQzODRkYWZiZGRjNGZkZWE4MWEyYzYyXzQtMS0xLTEtMjI1NDU_ce84a5ac-7686-43dd-adbf-167d62fe9316">6.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i0e0e18adc0424cde81f1a02ec6eea58c_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo1NTM1NTc3MGU0Mzg0ZGFmYmRkYzRmZGVhODFhMmM2Mi90YWJsZXJhbmdlOjU1MzU1NzcwZTQzODRkYWZiZGRjNGZkZWE4MWEyYzYyXzQtMy0xLTEtMjM1OTI_4942c145-cac3-4572-8110-1f7f7cff8861">5.9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i54c2a1b829084a7b83834a08509335ce_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo1NTM1NTc3MGU0Mzg0ZGFmYmRkYzRmZGVhODFhMmM2Mi90YWJsZXJhbmdlOjU1MzU1NzcwZTQzODRkYWZiZGRjNGZkZWE4MWEyYzYyXzUtMS0xLTEtMjI1NDUvdGV4dHJlZ2lvbjo2YmE1NzllYzcwNTM0ZTUxYjkyYzgzYjJjZWExMzQ3Ml8xMDk5NTExNjI3Nzk4_557775b0-763f-461d-9a02-5c90f44accd0">71.8</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i54c2a1b829084a7b83834a08509335ce_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo1NTM1NTc3MGU0Mzg0ZGFmYmRkYzRmZGVhODFhMmM2Mi90YWJsZXJhbmdlOjU1MzU1NzcwZTQzODRkYWZiZGRjNGZkZWE4MWEyYzYyXzUtMS0xLTEtMjI1NDUvdGV4dHJlZ2lvbjo2YmE1NzllYzcwNTM0ZTUxYjkyYzgzYjJjZWExMzQ3Ml8xMDk5NTExNjI3ODA2_484eadae-3ef4-4dad-97ec-648bd7c71d50">73.1</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i0e0e18adc0424cde81f1a02ec6eea58c_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo1NTM1NTc3MGU0Mzg0ZGFmYmRkYzRmZGVhODFhMmM2Mi90YWJsZXJhbmdlOjU1MzU1NzcwZTQzODRkYWZiZGRjNGZkZWE4MWEyYzYyXzUtMy0xLTEtMjM1OTIvdGV4dHJlZ2lvbjo4ODcxNDQ3NTkzYzQ0ZDI2OTJlYWZmOWUzY2E2NzQxM18xMDk5NTExNjI3Nzk4_0e4e22c0-ca85-4860-94c8-bba533647e4f">70.8</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i0e0e18adc0424cde81f1a02ec6eea58c_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo1NTM1NTc3MGU0Mzg0ZGFmYmRkYzRmZGVhODFhMmM2Mi90YWJsZXJhbmdlOjU1MzU1NzcwZTQzODRkYWZiZGRjNGZkZWE4MWEyYzYyXzUtMy0xLTEtMjM1OTIvdGV4dHJlZ2lvbjo4ODcxNDQ3NTkzYzQ0ZDI2OTJlYWZmOWUzY2E2NzQxM18xMDk5NTExNjI3ODA2_ed40a242-d68a-4c9d-b601-7c0376fc65d1">86.8</ix:nonFraction>%</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these inputs is subjective and generally requires significant judgment.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Term</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The expected term represents the period that the Company&#8217;s stock-based awards are expected to be outstanding and is determined using the simplified method, which is based on the mid-point between the contractual term and vesting period.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility&#8212;The Company determines volatility based on the historical volatilities of comparable publicly traded life science companies over a period equal to the expected term because it does not have sufficient trading history for its common stock price. The comparable companies were chosen based on the similar size, stage in the life cycle, or area of specialty. The Company will continue to apply this process until a sufficient amount of historical information regarding volatility on its own stock becomes available.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-Free</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Interest Rate</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Yield</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has never paid and has no plans to pay any dividends on its common stock. Therefore, the Company has used an expected dividend yield of <ix:nonFraction unitRef="number" contextRef="i54c2a1b829084a7b83834a08509335ce_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt-sec:numwordsen" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzYwNDczMTM5NzMyMTg_d0f7b5c3-5b3f-4351-b9a8-7d69f9c0baa1">zero</ix:nonFraction>.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> of Common Stock</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;For periods prior to the IPO, the Company determined the estimated fair value of its common stock using the Subject Company Transaction Method which includes the back-solve and scenario-based methods (Probability Weighted Expected Return Method) to arrive at estimated fair values. Subsequent to the IPO, the fair value was based on the closing price of the Company&#8217;s common stock on the grant date. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5678c597fc514151960eeb632a208c2d" continuedAt="i752157219d324c4b8cdf9a6aacc8f8a6"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were used to estimate the fair value of stock option awards: <ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzI3NDg3NzkwNzU5ODc_a4e171be-6979-4228-a833-30f6016cd09d" continuedAt="iedf8254784d446a69a806f940aa20bb7" escape="true">The following table summarizes information as of December&#160;31, 2021 and activity during 2021 related to the Company&#8217;s stock option plans:</ix:nonNumeric></span></div><div style="margin-top:10pt"><ix:continuation id="iedf8254784d446a69a806f940aa20bb7"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Number of <br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Weighted <br/>Average <br/>Exercise <br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Weighted <br/>Average <br/>Remaining <br/>Contractual <br/>Life (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Total <br/>Intrinsic <br/>Value <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzQtMS0xLTEtMjI1NDU_99baf1a9-33e1-41f0-8827-dcc85d904a40">3,479,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzQtMy0xLTEtMjI1NDU_0fac8fa1-e395-4519-bbb2-9cc22b80204b">6.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzQtNS0xLTEtMjI1NDU_a9aee26b-69a2-4c69-ae45-82b807a83b46">8.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzQtNy0xLTEtMjI1NDU_cdc051a7-f818-4cb5-8750-4775fb185016">15,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzUtMS0xLTEtMjI1NDU_0412f417-6b72-42b9-ae5a-8536ca8fa571">1,103,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzUtMy0xLTEtMjI1NDU_c867e42f-71c6-48e0-916c-b669aeccaa48">15.44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Options forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="shares" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzYtMS0xLTEtMjI1NDU_dbfc39ef-dda0-4434-a61a-194e18ee4ed7">189,388</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzYtMy0xLTEtMjI1NDU_d11dddd1-4c1f-4743-8cc4-e3b2333740ef">13.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Options exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="shares" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzctMS0xLTEtMjI1NDU_f488c0c7-4075-4ddc-8ddf-ff1890678fa6">152,939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzctMy0xLTEtMjI1NDU_fe74dff2-d15e-45fd-9807-62434c2af08c">6.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Options expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="shares" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzgtMS0xLTEtMjI1NDU_b56e9b51-2a87-4cdd-9fc6-a33a5cdf542a">10,963</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzgtMy0xLTEtMjI1NDU_9bf7c801-8f9c-4149-af6d-99a7aed61572">7.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzktMS0xLTEtMjI1NDU_409b1c02-9d63-494e-9606-0195b5df89db">4,230,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzktMy0xLTEtMjI1NDU_d87edc75-bcfa-4eb5-8251-264719c5a8f3">8.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzktNS0xLTEtMjI1NDU_d996bb07-ff1f-43fa-a119-1bd615be35f0">7.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzktNy0xLTEtMjI1NDU_22b34200-5d06-4cc2-864b-707806dfbba5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Options vested and exercisable</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzEwLTEtMS0xLTIyNTQ1_62e0f003-37de-4329-a5d4-43597dc36a8f">2,499,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzEwLTMtMS0xLTIyNTQ1_81c26f2a-ffdb-42b2-bd66-cae86487bbc8">7.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzEwLTUtMS0xLTIyNTQ1_d9764f60-d7ca-49a9-b49c-40010a089bcd">7.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzEwLTctMS0xLTIyNTQ1_5a633f3c-896d-49f2-a495-86cceb5bc00f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value in the above table is calculated as the difference between the estimated fair value of the Company's common stock price and the exercise price of the stock options. The weighted average grant date fair value per share for the stock option grants during the years ended December&#160;31, 2021 and 2020  were $<ix:nonFraction unitRef="usdPerShare" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzUyODg_1b406500-488f-422f-b847-06c7ea4a7ad0">10.25</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzUyOTU_51fd35f0-96d1-4845-8f89-22570f2e7bb4">5.48</ix:nonFraction>, respectively. As of December&#160;31, 2021, the total unrecognized compensation related to unvested stock option awards granted was $<ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzU0MTE_058008c3-c605-4b1a-a5a0-d4243f8cc491">6.1</ix:nonFraction> million, which the Company expects to recognize over a weighted-average period of approximately <ix:nonNumeric contextRef="i54c2a1b829084a7b83834a08509335ce_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzEwOTk1MTE2NDgxODU_103e7d61-46ec-4d52-bd72-a70f4a522bff">2.4</ix:nonNumeric> years.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock and Restricted Stock Units</span></div><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzMyOTg1MzQ4ODk4NzY_a660a85f-a4cd-4f97-9fd4-e0b41d230177" escape="true"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's RSA and RSU activity for the years ended December&#160;31, 2021 were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Shares of <br/>Restricted Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Weighted <br/>Average Grant <br/>Date Fair Value <br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Restricted <br/>Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Weighted <br/>Average Grant <br/>Date Fair Value <br/>Per Share</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i391c5213ee2846a09acad8d39f4acc78_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzQtMS0xLTEtMjI1NDU_8aace1e2-50b9-4c2e-9220-973705e41c77">14,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="i391c5213ee2846a09acad8d39f4acc78_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzQtMy0xLTEtMjI1NDU_fe8c0e0c-1785-4e3c-a22c-c581e3fb4b75">6.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="ib18cd3fd172f47be9edcff38ff0ed63a_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzQtNS0xLTEtMjI1NDU_adf0fba6-f9a8-42d0-ad5b-722e38c17efa">74,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib18cd3fd172f47be9edcff38ff0ed63a_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzQtNy0xLTEtMjI1NDU_015214dd-b48b-4db4-9e84-f7242d5e434b">7.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="shares" contextRef="i5d2bddbdf568489b92aaf86fbd855a9d_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzYtMS0xLTEtMjI1NDU_16f8db61-d67a-4fd5-9fed-c205ceb7b193">14,586</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d2bddbdf568489b92aaf86fbd855a9d_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzYtMy0xLTEtMjI1NDU_fec43e73-d330-4513-a9c0-143a9452109d">6.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="shares" contextRef="i60ac161568b9493f9839384faf16222a_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzYtNS0xLTEtMjI1NDU_2ce81a6e-c25a-461c-bcc5-6c3b396d4811">43,875</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="i60ac161568b9493f9839384faf16222a_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzYtNy0xLTEtMjI1NDU_67766346-a292-4e3a-9e06-345b84d7eb73">8.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="shares" contextRef="i5d2bddbdf568489b92aaf86fbd855a9d_D20210101-20211231" sign="-" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzctMS0xLTEtMzI3OTY_f02732da-2b33-4826-8667-6291b26b258e"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="i5d2bddbdf568489b92aaf86fbd855a9d_D20210101-20211231" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzctMy0xLTEtMzI3OTY_18decbdb-0917-4ce7-8b74-d0336bd17d1e"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="shares" contextRef="i60ac161568b9493f9839384faf16222a_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzctNS0xLTEtMzI3Nzk_e6ce014e-3ff0-4b7e-9a44-ccf8f5fc7eb7">12,764</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="i60ac161568b9493f9839384faf16222a_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzctNy0xLTEtMzE5OTg_39f81939-3c26-4fee-8de9-8dde9ba90c94">6.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="id7f5c1532cac4e2b998ae309d92d8edd_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzctMS0xLTEtMjI1NDU_f857707e-3023-47aa-8823-c57b57e5bca9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="id7f5c1532cac4e2b998ae309d92d8edd_I20211231" xsi:nil="true" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzctMy0xLTEtMjI1NDU_0a121a68-1bfd-4fd8-866b-e78e5312bcb8"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="idc8909f8292a435ca08e7ea8957de0e8_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzctNS0xLTEtMjI1NDU_26b75904-d960-4683-b69e-1ae8153662dd">17,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="idc8909f8292a435ca08e7ea8957de0e8_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzctNy0xLTEtMjI1NDU_59285057-715a-45fa-bf1b-90f815ce45bd">9.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Vested as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="id7f5c1532cac4e2b998ae309d92d8edd_I20211231" decimals="INF" name="angn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzktMS0xLTEtMzI3OTk_926858b5-fffa-4a8d-a666-932065419e2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usdPerShare" contextRef="id7f5c1532cac4e2b998ae309d92d8edd_I20211231" xsi:nil="true" name="angn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzgtMy0xLTEtMjM2MTY_a53dcdd9-aa67-4c69-8fbd-4ba61bf26905"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="idc8909f8292a435ca08e7ea8957de0e8_I20211231" decimals="INF" name="angn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzgtNS0xLTEtMjI1NDU_ac1b95f2-8284-4be4-82c0-eeb7885b9ff4">43,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="idc8909f8292a435ca08e7ea8957de0e8_I20211231" decimals="2" name="angn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzgtNy0xLTEtMjI1NDU_9f271b4b-d0f0-4bff-b940-2a4a963824fa">8.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-based Restricted Stock Units</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had <ix:nonFraction unitRef="shares" contextRef="i7817467d29ec42488073e266808a1b4a_D20190601-20190630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzEwOTk1MTE2NDE1MDQ_caeaf16b-08f5-4916-92f7-b3dfe725c391">556,530</ix:nonFraction> PSUs outstanding that were granted in June 2019. Vesting of the PSUs is dependent upon the satisfaction of both a service condition and a performance condition, an initial public offering or a change of control, as defined in the 2015 Plan. As the IPO occurred in February 2021, the performance condition was met and <ix:nonFraction unitRef="shares" contextRef="idaadc88b9cdc4d3b9741cddf31c97c95_D20210209-20210209" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzEwOTk1MTE2NDE4MjU_d63521ae-9f72-4063-a952-6e613a2bc836">185,510</ix:nonFraction> PSUs vested and were released upon the closing of the IPO. Another <ix:nonFraction unitRef="shares" contextRef="if60e35a6de454aaba1b4e414c82f9bab_D20210601-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzEwOTk1MTE2NDE4OTY_6c7bce04-b44c-485a-be0c-25d8c3ddcbb7">185,510</ix:nonFraction> PSUs vested and released were in June 2021 upon the second anniversary of the grants. A</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company had <ix:nonFraction unitRef="shares" contextRef="ib6ed7c4e75a34a8e8f44a7115b92ba55_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzEwOTk1MTE2NDIwMTM_2d3fe598-9319-48bd-8cfe-ae37c67f216c">185,510</ix:nonFraction> PSUs outstanding.</span></div></ix:continuation><div style="margin-top:10pt;text-indent:22.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i752157219d324c4b8cdf9a6aacc8f8a6"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzMyOTg1MzQ4ODk4Nzc_7c4feedd-46e6-47fd-8f0c-97b73840333d" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total stock-based compensation expense for the stock options, RSUs, RSAs, PSUs compensation issued in shares recorded in the consolidated statements of operations (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i92b1ec8f60c4409cbb367354f0969366_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpmNDM5ZjJjMDZjYzM0NmYwYWJhODZiMGZkMWJkM2ZhNS90YWJsZXJhbmdlOmY0MzlmMmMwNmNjMzQ2ZjBhYmE4NmIwZmQxYmQzZmE1XzItMS0xLTEtMjI1NDU_660d47f6-bc36-4102-b5e9-382bad0cf6ce">5,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i92b73a2382864a80b71e3f51aef05903_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpmNDM5ZjJjMDZjYzM0NmYwYWJhODZiMGZkMWJkM2ZhNS90YWJsZXJhbmdlOmY0MzlmMmMwNmNjMzQ2ZjBhYmE4NmIwZmQxYmQzZmE1XzItMy0xLTEtMjI1NDU_a16ce785-e0e3-4d9a-9035-92229739d3c0">2,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ic47bf067546145a8a6fa9b871d43cefe_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpmNDM5ZjJjMDZjYzM0NmYwYWJhODZiMGZkMWJkM2ZhNS90YWJsZXJhbmdlOmY0MzlmMmMwNmNjMzQ2ZjBhYmE4NmIwZmQxYmQzZmE1XzMtMS0xLTEtMjI1NDU_3564ce7e-016b-4fb0-8505-057d0cee5cc3">6,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i6cfa5bf5e100430bbe5f169211eb27e2_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpmNDM5ZjJjMDZjYzM0NmYwYWJhODZiMGZkMWJkM2ZhNS90YWJsZXJhbmdlOmY0MzlmMmMwNmNjMzQ2ZjBhYmE4NmIwZmQxYmQzZmE1XzMtMy0xLTEtMjI1NDU_71fb8acf-b4f8-4600-a613-c564960ed1f8">2,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpmNDM5ZjJjMDZjYzM0NmYwYWJhODZiMGZkMWJkM2ZhNS90YWJsZXJhbmdlOmY0MzlmMmMwNmNjMzQ2ZjBhYmE4NmIwZmQxYmQzZmE1XzQtMS0xLTEtMjI1NDU_690de8c1-ff19-4566-9a7f-e0fbf426d11a">12,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpmNDM5ZjJjMDZjYzM0NmYwYWJhODZiMGZkMWJkM2ZhNS90YWJsZXJhbmdlOmY0MzlmMmMwNmNjMzQ2ZjBhYmE4NmIwZmQxYmQzZmE1XzQtMy0xLTEtMjI1NDU_222363bc-269d-4ea8-9e28-4fbd90a4155e">4,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the board of directors of the Company approved the Employee Stock Purchase Plan (the "ESPP"). The ESPP was effective on the date immediately prior to the effectiveness of the Company's registration statement relating to the IPO. A total of <ix:nonFraction unitRef="shares" contextRef="if41f90861d0545f185125b2fd6ebf84a_I20210131" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzEwOTk1MTE2NDI1OTc_d95dccb5-bb20-4d43-b708-bca8e028ac42">390,000</ix:nonFraction> shares of common stock were initially reserved for issuance under the ESPP. The offering period and purchase period will be determined by the Board of Directors. As of December&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="i6079bc9dc350474297feb207d4409628_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzIxOTkwMjMyNzU5OTQ_eb32d0b2-1b0f-43f6-8409-fd5774d667a4">390,000</ix:nonFraction> shares under the ESPP remain available for purchase and <ix:nonFraction unitRef="shares" contextRef="i6079bc9dc350474297feb207d4409628_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzEwOTk1MTE2NDI2MDk_e891770a-53ab-4d4e-89ad-fb6a7c38c9d5">no</ix:nonFraction> offerings had been authorized.</span></div></ix:continuation><div style="margin-top:3pt;text-indent:22.5pt"><span><br/></span></div><div id="idee3699378af4447a4091414c0adfaa7_130"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10&#8212;<ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="angn:WarrantsAndRightsOutstandingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90ZXh0cmVnaW9uOmExMzRiNmZjY2I1MTRkOWM5NzY3MzEyNWE0MTVhN2U2XzMyOTg1MzQ4ODQ1NDQ_964c9fcc-df24-4c5d-9ff3-3fce44fd8bf3" continuedAt="ia775d78dc4a74e8e9363b1923fb6e452" escape="true">Warrants</ix:nonNumeric></span></div><ix:continuation id="ia775d78dc4a74e8e9363b1923fb6e452" continuedAt="ic0f792ae07eb4ca296b139037f54a2be"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90ZXh0cmVnaW9uOmExMzRiNmZjY2I1MTRkOWM5NzY3MzEyNWE0MTVhN2U2XzMyOTg1MzQ4ODQ1NDU_d6f6db30-a382-4b38-8e5c-ea4b1fd69397" escape="true"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the outstanding warrants to purchase the Company's common stock were comprised of the following:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.549%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exercise <br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Expiration <br/>Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Warrants at December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Warrants issued with 2015 Notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="if16b69b23bb6477c809c732686e6c818_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzItMy0xLTEtMjI1NDU_7a8fed7a-e833-4d65-b877-19c4e1ffb5cd">6.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">7/5/28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="if16b69b23bb6477c809c732686e6c818_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzItNy0xLTEtMjI1NDU_bd327c26-a298-4abf-b20c-5f29976ae98c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i43c1a8313c78494992d014e2ea73ba94_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzItOS0xLTEtMjI1NDU_c7efb121-1961-4ffb-b5b5-74da1dfc1269">388,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Warrants issued with 2016 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="i27dc24aec76340a998ae99277f3efd2e_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzMtMy0xLTEtMjI1NDU_a6a636c9-510e-40dd-a5c7-a30de8b3645c">6.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">7/5/28</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i27dc24aec76340a998ae99277f3efd2e_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzMtNy0xLTEtMjI1NDU_e4311c1b-ba6e-49c9-9151-a03bf7a53cfa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i5280c6af39144c0097d2718db5b41580_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzMtOS0xLTEtMjI1NDU_e0982128-00ea-4209-9587-570cb7c95589">538,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Warrants issued with 2017 Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0fc4689e5cff46898c878ceef7ce56cd_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzQtMy0xLTEtMjI1NDU_b2635d47-29c8-4531-8e45-5f602900a4d4">6.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">7/5/28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i0fc4689e5cff46898c878ceef7ce56cd_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzQtNy0xLTEtMjI1NDU_1a417c5e-ff40-455f-b02d-97ce986872c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="id76d56a33e4f4a60bb37b2bc487fbad9_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzQtOS0xLTEtMjI1NDU_1330bd18-7dae-4ab7-aa6f-629a577548b5">79,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Warrants issued with 2018 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="i79898ce5c218453fb0a55a7cb08aee82_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzUtMy0xLTEtMjI1NDU_7bbbfbb5-58fa-4fb2-a839-b9644ebe5c7e">6.43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">7/5/28</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i79898ce5c218453fb0a55a7cb08aee82_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzUtNy0xLTEtMjI1NDU_106c679d-ff7e-43c6-9cb6-aed951590c5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="ib75e81811b1f43cb90f7a7a898c09ac1_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzUtOS0xLTEtMjI1NDU_71fe79f3-43c6-4130-ae65-44a2584a9451">498,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Warrants issued with Conversion of Notes to Common Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib18fedbfd53d471ca8ad9bda5ea20ac9_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzYtMy0xLTEtMjI1NDU_9591da8b-3c2b-4700-a3de-9d813c2649c6">8.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">8/31/28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="ib18fedbfd53d471ca8ad9bda5ea20ac9_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzYtNy0xLTEtMjI1NDU_84188d86-ec33-4f42-8b88-62a921b747ca">232,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i84612d7718b644af9a1cf862077b6bc7_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzYtOS0xLTEtMjI1NDU_fe78ff16-b0a7-4aa0-8ab6-71d30f984c73">238,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Warrants issued with Units in the Equity Offering</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibea121a245f649d6a99c181f5a14bd89_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzctMy0xLTEtMjI1NDU_ac089525-707e-46b7-bc32-0a5c349240ed">8.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">8/31/28</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="ibea121a245f649d6a99c181f5a14bd89_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzctNy0xLTEtMjI1NDU_c5fa316b-a1dc-41bf-bbb0-d2af5adc2d10">875,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i855a01903f014f53bf8b37778bc42c99_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzctOS0xLTEtMjI1NDU_c3f62237-c69c-420e-b4fe-e75ae21bcc00">907,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Broker Warrants issued with Equity Offering</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="i891c62a6c35b47e48378588b88bb112c_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzgtMy0xLTEtMjI1NDU_d6a59804-09b0-428a-986a-b20df0f10ff8">0.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">8/31/25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i891c62a6c35b47e48378588b88bb112c_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzgtNy0xLTEtMjI1NDU_1198185b-930a-4827-b308-9a5c0d2af1ad">1,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="ie0e5243bae824dccb7342c17c8cca4aa_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzgtOS0xLTEtMjI1NDU_aa7f68d8-0854-45ce-bf5f-88075ab1ade8">48,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Broker Warrants issued with 2019 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3a61ee941a9e4d32b5dd2e580ef7e639_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzktMy0xLTEtMjI1NDU_af07809f-bbf0-4085-943c-9dd880facb8f">0.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">1/30/20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i3a61ee941a9e4d32b5dd2e580ef7e639_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzktNy0xLTEtMjI1NDU_076f81bf-2569-4019-b19e-23fd042de99b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i3279c6cb0327462d84d652b4f17138c3_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzktOS0xLTEtMjI1NDU_7c86af2c-a2b9-482d-bb8f-90903a0db7b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Consultant Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="i92b4a25f21264eb2b06953b7ef40a96f_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzExLTMtMS0xLTIyNTQ1_2c2704b7-9f34-4d35-8364-6d81e4763198">7.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">8/31/28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i92b4a25f21264eb2b06953b7ef40a96f_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzExLTctMS0xLTIyNTQ1_6731a416-d592-45d8-8025-ab94b2563cb4">39,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="ia49fffc648cc4ba7bc5e1c58b7adb469_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzExLTktMS0xLTIyNTQ1_ec854efd-32db-4e28-980f-826686ff8b4a">39,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Total Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzEyLTctMS0xLTIyNTQ1_ab3bbce8-ec07-43e2-abde-21fb64b708d9">1,148,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzEyLTktMS0xLTIyNTQ1_a3709afe-f62b-48b3-b510-99491f0c8d9e">2,739,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 815, the warrants classified as liabilities are recorded at fair value at the issuance date, with changes in the fair value recognized in the consolidated statements of operations at the end of each reporting period. Refer to Note 4 for changes in the fair value recognized during the periods reported.  </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 815, the warrants classified as equity do not meet the definition of a derivative and are classified in stockholders' equity (deficit) in the consolidated balance sheets.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic0f792ae07eb4ca296b139037f54a2be"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="angn:WarrantsAndRightsOutstandingActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90ZXh0cmVnaW9uOmExMzRiNmZjY2I1MTRkOWM5NzY3MzEyNWE0MTVhN2U2XzMyOTg1MzQ4ODQ1NzQ_e9c2ea1d-645c-4bd0-b357-694ade42fa1a" escape="true"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's warrant activity for the year ended December&#160;31, 2021 was as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Warrants</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Average </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exercise </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Average </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Remaining </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Contractual </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Life (in years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Balance&#8212;December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpkYzA3ZDkzN2IyMzQ0OGYzOTc2OGIyNTExMGM1ZjY5MC90YWJsZXJhbmdlOmRjMDdkOTM3YjIzNDQ4ZjM5NzY4YjI1MTEwYzVmNjkwXzUtMS0xLTEtMjI1NDU_e58ae093-9f1b-45fa-a903-d724cf3396df">2,739,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="2" name="angn:ClassOfWarrantOrRightWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpkYzA3ZDkzN2IyMzQ0OGYzOTc2OGIyNTExMGM1ZjY5MC90YWJsZXJhbmdlOmRjMDdkOTM3YjIzNDQ4ZjM5NzY4YjI1MTEwYzVmNjkwXzUtMy0xLTEtMjI1NDU_48dc54de-7402-448c-bd02-3f23168c319b">7.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" name="angn:WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpkYzA3ZDkzN2IyMzQ0OGYzOTc2OGIyNTExMGM1ZjY5MC90YWJsZXJhbmdlOmRjMDdkOTM3YjIzNDQ4ZjM5NzY4YjI1MTEwYzVmNjkwXzUtNS0xLTEtMjI1NDU_98e580fb-2784-4a73-afe0-405acaddb089">4.9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exercised </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="shares" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="INF" name="angn:ClassOfWarrantOrRightExercisesInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpkYzA3ZDkzN2IyMzQ0OGYzOTc2OGIyNTExMGM1ZjY5MC90YWJsZXJhbmdlOmRjMDdkOTM3YjIzNDQ4ZjM5NzY4YjI1MTEwYzVmNjkwXzctMS0xLTEtMjI1NDU_adf90682-13f5-4170-b8a3-ce059f2b5c6d">1,588,756</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="2" name="angn:ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpkYzA3ZDkzN2IyMzQ0OGYzOTc2OGIyNTExMGM1ZjY5MC90YWJsZXJhbmdlOmRjMDdkOTM3YjIzNDQ4ZjM5NzY4YjI1MTEwYzVmNjkwXzctMy0xLTEtMjI1NDU_a09439c1-4611-4de7-b0d1-596d1064b05f">7.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expired</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="shares" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="INF" name="angn:ClassOfWarrantOrRightExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpkYzA3ZDkzN2IyMzQ0OGYzOTc2OGIyNTExMGM1ZjY5MC90YWJsZXJhbmdlOmRjMDdkOTM3YjIzNDQ4ZjM5NzY4YjI1MTEwYzVmNjkwXzgtMS0xLTEtMjI1NDU_9b8a1481-ca6d-4760-93cd-10b44c51a7ca">2,912</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="2" name="angn:ClassOfWarrantOrRightWeightedAverageExercisePriceExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpkYzA3ZDkzN2IyMzQ0OGYzOTc2OGIyNTExMGM1ZjY5MC90YWJsZXJhbmdlOmRjMDdkOTM3YjIzNDQ4ZjM5NzY4YjI1MTEwYzVmNjkwXzgtMy0xLTEtMjI1NDU_9e535be5-71f3-4c61-914a-5bcea67dbe46">8.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Balance&#8212;December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpkYzA3ZDkzN2IyMzQ0OGYzOTc2OGIyNTExMGM1ZjY5MC90YWJsZXJhbmdlOmRjMDdkOTM3YjIzNDQ4ZjM5NzY4YjI1MTEwYzVmNjkwXzktMS0xLTEtMjI1NDU_8cdd34c8-377a-4d1e-ba08-3d02e2b75b5d">1,148,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="2" name="angn:ClassOfWarrantOrRightWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpkYzA3ZDkzN2IyMzQ0OGYzOTc2OGIyNTExMGM1ZjY5MC90YWJsZXJhbmdlOmRjMDdkOTM3YjIzNDQ4ZjM5NzY4YjI1MTEwYzVmNjkwXzktMy0xLTEtMjI1NDU_edf567a3-f0a6-4afb-9d17-c33397bec0d9">8.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="angn:WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpkYzA3ZDkzN2IyMzQ0OGYzOTc2OGIyNTExMGM1ZjY5MC90YWJsZXJhbmdlOmRjMDdkOTM3YjIzNDQ4ZjM5NzY4YjI1MTEwYzVmNjkwXzktNS0xLTEtMjI1NDU_fda990e8-63c1-4674-bb66-c4027c7e0d4b">1.2</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________________________</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) <ix:nonFraction unitRef="shares" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="INF" name="angn:ClassOfWarrantOrRightExercisesInPeriodTendered" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90ZXh0cmVnaW9uOmExMzRiNmZjY2I1MTRkOWM5NzY3MzEyNWE0MTVhN2U2XzIxOTkwMjMyNjAzNjk_290875fa-5f5d-452b-af0d-9eda656f11fb">613,892</ix:nonFraction> shares from warrant exercised were tendered back to the Company to cover the exercise price of the warrant.</span></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion of Warrants</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, all warrants outstanding issued with 2015 Notes, 2016 Notes, 2017 Notes, and 2018 Notes   with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie75149bd389348ac91dd0c486618b376_I20210228" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90ZXh0cmVnaW9uOmExMzRiNmZjY2I1MTRkOWM5NzY3MzEyNWE0MTVhN2U2XzEwOTk1MTE2MzA1MTc_9b4e300a-8710-4b5e-9b22-3f146d51fe22">6.43</ix:nonFraction> per share were net exercised into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i3b02e038496248b1bb8753bc722a0bb7_D20210201-20210228" decimals="INF" name="angn:StockIssuedDuringPeriodSharesWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90ZXh0cmVnaW9uOmExMzRiNmZjY2I1MTRkOWM5NzY3MzEyNWE0MTVhN2U2XzEwOTk1MTE2MzA1MjU_0f5f314b-f60f-4af1-bccd-87ba12529ba1">844,335</ix:nonFraction> shares of common stock upon the IPO with a conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i59e2995c2115446d9af3ddecfb37c4fb_I20210228" decimals="2" name="angn:ClassOfWarrantOrRightConversionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90ZXh0cmVnaW9uOmExMzRiNmZjY2I1MTRkOWM5NzY3MzEyNWE0MTVhN2U2XzEwOTk1MTE2MzA1MjE_ea372a56-2b68-4875-9bae-185068b43078">11.57</ix:nonFraction> per share.</span></div></ix:continuation><div style="margin-top:3pt"><span><br/></span></div><div id="idee3699378af4447a4091414c0adfaa7_133"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11&#8212;<ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzMyOTg1MzQ4ODc4NTU_6275d35f-2a69-4b80-b305-fca1866002c4" continuedAt="i1fd87acf6c384b839b88b6334282bef8" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i1fd87acf6c384b839b88b6334282bef8" continuedAt="i4be55ca5e90242e1a70a036ae3002989"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office and laboratory space in Uniondale, New York from NovaPark, a related party, under an agreement classified as an operating lease that expires on June 20, 2026. The Company's lease does not require any contingent rental payments, impose any financial restrictions, or contain any residual value guarantees. Variable expenses generally represent the Company's share of the landlord's operating expenses, including management fees. The Company does not act as a lessor or have any leases classified as financing leases.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office space in Fort Lee, New Jersey, comprising approximately <ix:nonFraction unitRef="sqft" contextRef="i01849912679d402f8b851a0ea52911e4_I20211231" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzY4MQ_a1a5a767-fef0-4e3f-bd2c-e8098a3b1b63">2,105</ix:nonFraction> square feet for approximately $<ix:nonFraction unitRef="usd" contextRef="i444bffaeb5fd4c7dae715a0266b8d087_D20210101-20211231" decimals="-5" name="angn:LesseeOperatingLeaseAnnualRentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzcxNA_b928863a-1a8a-4d31-b27c-068f05072bbc">0.1</ix:nonFraction>&#160;million per year, under a non-cancelable operating lease through March 31, 2022. However, this arrangement is excluded from the calculation of lease liabilities and right of use assets as its term is less than one year. The lease is subject to charges for common area maintenance and other costs. The Company is not going to renew the New Jersey lease after March 31, 2022.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company entered into a lease for office furniture in San Francisco, California set to expire in July 2025, with an annual lease payment of approximately $<ix:nonFraction unitRef="usd" contextRef="i519304eebcb54dc99bfcc6afa7d63b44_D20200701-20200731" decimals="-3" name="angn:LesseeOperatingLeaseAnnualRentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzEwOTk1MTE2MzQ3OTk_3e44b853-2e05-42b5-9ff9-57db865548c8">13,000</ix:nonFraction>. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company entered into a lease for clinical and regulatory space in Newton, Massachusetts (the &#8220;Newton lease&#8221;), comprising approximately <ix:nonFraction unitRef="sqft" contextRef="i7dfcdb12bfb34eb6b5ec1d691edc1a6b_I20210228" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzEwOTk1MTE2MzQ3NjA_55cc8c6c-f25b-4c20-8d71-aa13374a6a01">6,157</ix:nonFraction> square feet for approximately $<ix:nonFraction unitRef="usd" contextRef="i7fa0c3e9d7c641a48770a0df7a146319_D20210201-20210228" decimals="-5" name="angn:LesseeOperatingLeaseAnnualRentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzEwOTk1MTE2MzQ3ODA_81ae0995-f97c-4122-8e99-b75b78c0d44a">0.2</ix:nonFraction>&#160;million per year, under a non-cancelable operating lease through June 30, 2024. Pursuant to the Newton lease, the Company had <ix:nonNumeric contextRef="i7fa0c3e9d7c641a48770a0df7a146319_D20210201-20210228" name="angn:LesseeOperatingLeaseFreeRentExpensePeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzYwNDczMTM5ODE5OTc_1ea94b26-2d6a-485f-a3c4-74a50986bed3">4</ix:nonNumeric> months of free rent starting from February 15, 2021 to June 14, 2021. The Company has <ix:nonFraction unitRef="option" contextRef="i7dfcdb12bfb34eb6b5ec1d691edc1a6b_I20210228" decimals="INF" name="angn:LesseeOperatingLeaseNumberOfOptionsToExtend" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzIxOTkwMjMyODQ3MTM_03a2ee58-3a6b-4198-b57f-59e5f6926293">one</ix:nonFraction> option to extend the term of the lease for <ix:nonNumeric contextRef="i7dfcdb12bfb34eb6b5ec1d691edc1a6b_I20210228" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzEwOTk1MTE2MzQ3NjY_ca1fbdaf-1b01-416d-a5c2-b782f963efa7">3</ix:nonNumeric> years with <ix:nonNumeric contextRef="i7fa0c3e9d7c641a48770a0df7a146319_D20210201-20210228" name="angn:LesseeOperatingLeaseNoticePeriodForOptionToExtend" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzIxOTkwMjMyODQ2OTk_4b88c557-007e-4ad8-b9d4-21b17ba39616">9</ix:nonNumeric> months&#8217; notice.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4be55ca5e90242e1a70a036ae3002989" continuedAt="ia5f76ae3114f4a79a33d9a6973121342"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzMyOTg1MzQ4ODc4NTY_2c655eef-40f5-44f4-abf3-8f25e0085523" escape="true"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the components of the Company's rent expense (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">For the Year Ended <br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease cost</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo1NDliYWNmNTIxNTM0NjM0YjQ1MjdkOWViNTljNWMxNC90YWJsZXJhbmdlOjU0OWJhY2Y1MjE1MzQ2MzRiNDUyN2Q5ZWI1OWM1YzE0XzMtMS0xLTEtMjM3MDE_d20ae555-7373-4a9d-a28d-366476957fd0">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo1NDliYWNmNTIxNTM0NjM0YjQ1MjdkOWViNTljNWMxNC90YWJsZXJhbmdlOjU0OWJhY2Y1MjE1MzQ2MzRiNDUyN2Q5ZWI1OWM1YzE0XzMtMy0xLTEtMjM3MDM_2b725a20-dadd-4432-b5f7-60b6a592a5de">1,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Variable cost</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo1NDliYWNmNTIxNTM0NjM0YjQ1MjdkOWViNTljNWMxNC90YWJsZXJhbmdlOjU0OWJhY2Y1MjE1MzQ2MzRiNDUyN2Q5ZWI1OWM1YzE0XzQtMS0xLTEtMjM3MDE_071ebe4c-c72b-479b-8996-ccfa44ef8218">473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo1NDliYWNmNTIxNTM0NjM0YjQ1MjdkOWViNTljNWMxNC90YWJsZXJhbmdlOjU0OWJhY2Y1MjE1MzQ2MzRiNDUyN2Q5ZWI1OWM1YzE0XzQtMy0xLTEtMjM3MDM_cf80f153-9fd4-47ee-b74b-d4de07562499">646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease expense</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo1NDliYWNmNTIxNTM0NjM0YjQ1MjdkOWViNTljNWMxNC90YWJsZXJhbmdlOjU0OWJhY2Y1MjE1MzQ2MzRiNDUyN2Q5ZWI1OWM1YzE0XzUtMS0xLTEtMjM3MDE_1efb37b4-b70d-4a8c-bac3-e634535965e4">1,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 13pt 0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo1NDliYWNmNTIxNTM0NjM0YjQ1MjdkOWViNTljNWMxNC90YWJsZXJhbmdlOjU0OWJhY2Y1MjE1MzQ2MzRiNDUyN2Q5ZWI1OWM1YzE0XzUtMy0xLTEtMjM3MDM_bbd8c2ca-8785-43bb-8db3-f58649268fe8">1,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Short-term lease rent expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo1NDliYWNmNTIxNTM0NjM0YjQ1MjdkOWViNTljNWMxNC90YWJsZXJhbmdlOjU0OWJhY2Y1MjE1MzQ2MzRiNDUyN2Q5ZWI1OWM1YzE0XzYtMS0xLTEtMjM3MDE_33a6dad4-8acb-4e33-8db6-fde5c6922de0">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo1NDliYWNmNTIxNTM0NjM0YjQ1MjdkOWViNTljNWMxNC90YWJsZXJhbmdlOjU0OWJhY2Y1MjE1MzQ2MzRiNDUyN2Q5ZWI1OWM1YzE0XzYtMy0xLTEtMjM3MDM_9f7dbb85-bd9c-480f-bb65-b5fc7e1378d5">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total rent expense</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo1NDliYWNmNTIxNTM0NjM0YjQ1MjdkOWViNTljNWMxNC90YWJsZXJhbmdlOjU0OWJhY2Y1MjE1MzQ2MzRiNDUyN2Q5ZWI1OWM1YzE0XzctMS0xLTEtMjM3MDE_6d30265d-dbaa-45bb-8c80-56f2fb267a3a">1,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo1NDliYWNmNTIxNTM0NjM0YjQ1MjdkOWViNTljNWMxNC90YWJsZXJhbmdlOjU0OWJhY2Y1MjE1MzQ2MzRiNDUyN2Q5ZWI1OWM1YzE0XzctMy0xLTEtMjM3MDM_c658abad-0fa8-479b-b150-0bf21da6e6fe">1,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="angn:ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzMyOTg1MzQ4ODc4NTc_52d16f45-98a5-4a9f-bc29-d719572c3b3b" escape="true"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes quantitative information about the Company's NovaPark operating leases (dollars in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">For the Year Ended <br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating cash flows from operating leases</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo5OGM4YWQ4MDIxMTU0M2Y1YmQzNjNlYTZmOTA0YmY5MC90YWJsZXJhbmdlOjk4YzhhZDgwMjExNTQzZjViZDM2M2VhNmY5MDRiZjkwXzItMS0xLTEtMjI1NDU_9f7c3ca6-88d5-4cea-8a72-4512940ae59c">1,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo5OGM4YWQ4MDIxMTU0M2Y1YmQzNjNlYTZmOTA0YmY5MC90YWJsZXJhbmdlOjk4YzhhZDgwMjExNTQzZjViZDM2M2VhNmY5MDRiZjkwXzItMy0xLTEtMjI1NDU_06fb5236-4352-407e-ba26-3dab8a82d720">1,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets exchanged for operating lease liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo5OGM4YWQ4MDIxMTU0M2Y1YmQzNjNlYTZmOTA0YmY5MC90YWJsZXJhbmdlOjk4YzhhZDgwMjExNTQzZjViZDM2M2VhNmY5MDRiZjkwXzMtMS0xLTEtMjI1NDU_638379be-a31d-4caa-b000-f4aef2a7393a">624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo5OGM4YWQ4MDIxMTU0M2Y1YmQzNjNlYTZmOTA0YmY5MC90YWJsZXJhbmdlOjk4YzhhZDgwMjExNTQzZjViZDM2M2VhNmY5MDRiZjkwXzMtMy0xLTEtMjI1NDU_5d3a2bcf-43f8-47df-9917-7919c0f97321">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average remaining lease term&#8212;operating leases (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo5OGM4YWQ4MDIxMTU0M2Y1YmQzNjNlYTZmOTA0YmY5MC90YWJsZXJhbmdlOjk4YzhhZDgwMjExNTQzZjViZDM2M2VhNmY5MDRiZjkwXzQtMS0xLTEtMjI1NDU_eef48d2a-9f2f-42cd-93ba-f443001e6fab">3.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo5OGM4YWQ4MDIxMTU0M2Y1YmQzNjNlYTZmOTA0YmY5MC90YWJsZXJhbmdlOjk4YzhhZDgwMjExNTQzZjViZDM2M2VhNmY5MDRiZjkwXzQtMy0xLTEtMjI1NDU_10b2ac3d-1a4c-42ab-8c82-887a50ed0092">5.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average discount rate&#8212;operating leases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo5OGM4YWQ4MDIxMTU0M2Y1YmQzNjNlYTZmOTA0YmY5MC90YWJsZXJhbmdlOjk4YzhhZDgwMjExNTQzZjViZDM2M2VhNmY5MDRiZjkwXzUtMS0xLTEtMjI1NDU_36d86888-cf5b-4108-92b4-c078a7e72e39">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo5OGM4YWQ4MDIxMTU0M2Y1YmQzNjNlYTZmOTA0YmY5MC90YWJsZXJhbmdlOjk4YzhhZDgwMjExNTQzZjViZDM2M2VhNmY5MDRiZjkwXzUtMy0xLTEtMjI1NDU_851cb7a4-f9c2-47fc-af0f-b4265f9c0c9b">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzMyOTg1MzQ4ODc4NTg_5cb09c30-b64c-4396-b105-02a8f80ceed9" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, maturities of lease liabilities were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpmODU1MzNkZDgxNzI0YjczOTI4ZGViMzE3MTBkMjI1MC90YWJsZXJhbmdlOmY4NTUzM2RkODE3MjRiNzM5MjhkZWIzMTcxMGQyMjUwXzEtMi0xLTEtMjI1NDU_a08867f0-fd38-499e-b846-b771f0a16ab7">1,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpmODU1MzNkZDgxNzI0YjczOTI4ZGViMzE3MTBkMjI1MC90YWJsZXJhbmdlOmY4NTUzM2RkODE3MjRiNzM5MjhkZWIzMTcxMGQyMjUwXzItMi0xLTEtMjI1NDU_5836f887-6b2e-4b38-9fa4-caa3768c3ebd">1,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpmODU1MzNkZDgxNzI0YjczOTI4ZGViMzE3MTBkMjI1MC90YWJsZXJhbmdlOmY4NTUzM2RkODE3MjRiNzM5MjhkZWIzMTcxMGQyMjUwXzMtMi0xLTEtMjI1NDU_bfacbce1-3bd0-477a-a12e-b3a1683b3c69">1,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpmODU1MzNkZDgxNzI0YjczOTI4ZGViMzE3MTBkMjI1MC90YWJsZXJhbmdlOmY4NTUzM2RkODE3MjRiNzM5MjhkZWIzMTcxMGQyMjUwXzQtMi0xLTEtMjI1NDU_1f794a00-e8fa-401a-8ff7-2aa915a9bb77">1,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpmODU1MzNkZDgxNzI0YjczOTI4ZGViMzE3MTBkMjI1MC90YWJsZXJhbmdlOmY4NTUzM2RkODE3MjRiNzM5MjhkZWIzMTcxMGQyMjUwXzUtMi0xLTEtMjI1NDU_db686f8e-d833-4740-b68a-36f379bfdabc">516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpmODU1MzNkZDgxNzI0YjczOTI4ZGViMzE3MTBkMjI1MC90YWJsZXJhbmdlOmY4NTUzM2RkODE3MjRiNzM5MjhkZWIzMTcxMGQyMjUwXzYtMi0xLTEtMjI1NDU_4034ad4c-7801-436c-8c90-c871860a96e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpmODU1MzNkZDgxNzI0YjczOTI4ZGViMzE3MTBkMjI1MC90YWJsZXJhbmdlOmY4NTUzM2RkODE3MjRiNzM5MjhkZWIzMTcxMGQyMjUwXzctMi0xLTEtMjI1NDU_36b39712-90b8-4bda-88d4-b1ba0c38e5f4">5,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less present value discount</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpmODU1MzNkZDgxNzI0YjczOTI4ZGViMzE3MTBkMjI1MC90YWJsZXJhbmdlOmY4NTUzM2RkODE3MjRiNzM5MjhkZWIzMTcxMGQyMjUwXzgtMi0xLTEtMjI1NDU_ef8eca64-ba08-4cdf-8fa2-f508e7f1c3bd">1,054</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpmODU1MzNkZDgxNzI0YjczOTI4ZGViMzE3MTBkMjI1MC90YWJsZXJhbmdlOmY4NTUzM2RkODE3MjRiNzM5MjhkZWIzMTcxMGQyMjUwXzktMi0xLTEtMjI1NDU_4053fa00-d197-46c9-ac39-6799aa114ee9">4,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing obligation</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Company entered into a sale and leaseback arrangement with a third-party financing institution as a financing mechanism to fund certain of its capital expenditures primarily related to operating equipment, whereby the physical asset is sold concurrent with an agreement to lease the asset back. The initial leaseback term is <ix:nonNumeric contextRef="i0bf681e0236d4273af7ed9eb86410720_I20211130" name="us-gaap:LesseeFinanceLeaseTermOfContract1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzIxOTkwMjMyODc4NjA_25b038f6-1e62-4172-8bfe-8beee4c4c84a">42</ix:nonNumeric> months starting from November 2021. The arrangement includes a renewal option as well as a repurchase option at fair value with a cap at the end of the term. The arrangement does not qualify as an asset sale as control of the equipment did not transfer to the third party and is accounted for as a failed sale-leaseback. Therefore, the Company accounts for the arrangement as a financing transaction and records the proceeds received as a financing obligation. The leased assets are included in property and equipment, net on the consolidated balance sheets and are subject to depreciation. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, the Company received $<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-5" name="angn:ProceedsFromFinancingObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzEwOTk1MTE2NDc1ODY_11b7c78b-77cd-4407-8c72-02acff053e13">0.3</ix:nonFraction>&#160;million in connection with the sale and leaseback of certain equipment. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia5f76ae3114f4a79a33d9a6973121342" continuedAt="i2234a97292ad4c468ed69f5fd88eafc2"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="angn:ScheduleOfQuantitativeInformationAboutTheFinancingObligationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzIxOTkwMjMyODQ3NTA_802f8aa1-62ab-43bd-8026-9c3fef33f6af" escape="true"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes quantitative information about the Company's financing obligation (dollars in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.760%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">For the Year Ended December 31, </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Proceeds from sale and leaseback arrangement</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="angn:ProceedsFromFinancingObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkMjY3ZTg1ODM1ZTM0N2UwOTFlNjA1MjI3YWEzOTQ0My90YWJsZXJhbmdlOmQyNjdlODU4MzVlMzQ3ZTA5MWU2MDUyMjdhYTM5NDQzXzItMS0xLTEtMjk2ODA_20aac462-4ee6-4725-9dae-b82e75ec09d0">302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Payments of financing obligation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating cash flows from financing obligation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkMjY3ZTg1ODM1ZTM0N2UwOTFlNjA1MjI3YWEzOTQ0My90YWJsZXJhbmdlOmQyNjdlODU4MzVlMzQ3ZTA5MWU2MDUyMjdhYTM5NDQzXzQtMS0xLTEtMjk5MzA_2c5663b7-4554-451b-bde6-e820a222b588">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from financing obligation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkMjY3ZTg1ODM1ZTM0N2UwOTFlNjA1MjI3YWEzOTQ0My90YWJsZXJhbmdlOmQyNjdlODU4MzVlMzQ3ZTA5MWU2MDUyMjdhYTM5NDQzXzUtMS0xLTEtMjk5MzA_ef456c58-d7c6-4976-91e8-d691840472ed">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Other information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average remaining lease term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkMjY3ZTg1ODM1ZTM0N2UwOTFlNjA1MjI3YWEzOTQ0My90YWJsZXJhbmdlOmQyNjdlODU4MzVlMzQ3ZTA5MWU2MDUyMjdhYTM5NDQzXzQtMS0xLTEtMjk2ODA_ce695521-ea50-4904-b365-220d34f084b2">3.0</ix:nonNumeric> years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average discount rate (in percent)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkMjY3ZTg1ODM1ZTM0N2UwOTFlNjA1MjI3YWEzOTQ0My90YWJsZXJhbmdlOmQyNjdlODU4MzVlMzQ3ZTA5MWU2MDUyMjdhYTM5NDQzXzUtMS0xLTEtMjk2ODA_8e2dc0cb-aba9-4968-b94b-6d9d35defda9">1.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Carrying value of leased asset included in Property and Equipment, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i2f1573b2c4114052bab5a6fe444a4633_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkMjY3ZTg1ODM1ZTM0N2UwOTFlNjA1MjI3YWEzOTQ0My90YWJsZXJhbmdlOmQyNjdlODU4MzVlMzQ3ZTA5MWU2MDUyMjdhYTM5NDQzXzEwLTEtMS0xLTMwMDc5_f37d10af-3bf8-4a30-bae4-74eef52c8bb1">270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation associated with the leased asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="idfd7384fca0f46b6adea2d3695af1f7e_D20210101-20211231" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkMjY3ZTg1ODM1ZTM0N2UwOTFlNjA1MjI3YWEzOTQ0My90YWJsZXJhbmdlOmQyNjdlODU4MzVlMzQ3ZTA5MWU2MDUyMjdhYTM5NDQzXzExLTEtMS0xLTMwMDc5_b18caf27-bb0a-46b6-a5cd-0b9b7744dbab">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzIxOTkwMjMyODQ3NTM_17b19e00-9d39-4b32-9d9d-0b0a56d09fdf" escape="true"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, maturities of financing obligation were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkNGZmNzNjNWU0NGE0NDM1YWE0NTAwZGM1ZDk2MzBhMS90YWJsZXJhbmdlOmQ0ZmY3M2M1ZTQ0YTQ0MzVhYTQ1MDBkYzVkOTYzMGExXzEtMi0xLTEtMjk2NzE_95c9fd50-3e5d-4cba-9809-025a88c8316a">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkNGZmNzNjNWU0NGE0NDM1YWE0NTAwZGM1ZDk2MzBhMS90YWJsZXJhbmdlOmQ0ZmY3M2M1ZTQ0YTQ0MzVhYTQ1MDBkYzVkOTYzMGExXzItMi0xLTEtMjk2NzE_dc10c70c-ea76-4a3d-ab73-012830406608">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkNGZmNzNjNWU0NGE0NDM1YWE0NTAwZGM1ZDk2MzBhMS90YWJsZXJhbmdlOmQ0ZmY3M2M1ZTQ0YTQ0MzVhYTQ1MDBkYzVkOTYzMGExXzMtMi0xLTEtMjk2NzE_609db37f-a568-455e-a548-7efbabcb0f1f">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkNGZmNzNjNWU0NGE0NDM1YWE0NTAwZGM1ZDk2MzBhMS90YWJsZXJhbmdlOmQ0ZmY3M2M1ZTQ0YTQ0MzVhYTQ1MDBkYzVkOTYzMGExXzQtMi0xLTEtMjk2NzE_89417f6a-ed49-4c46-ada5-1b21fb71dca6">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkNGZmNzNjNWU0NGE0NDM1YWE0NTAwZGM1ZDk2MzBhMS90YWJsZXJhbmdlOmQ0ZmY3M2M1ZTQ0YTQ0MzVhYTQ1MDBkYzVkOTYzMGExXzUtMi0xLTEtMjk2NzE_cf9ce593-8fd8-4459-a504-b0b95af399be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkNGZmNzNjNWU0NGE0NDM1YWE0NTAwZGM1ZDk2MzBhMS90YWJsZXJhbmdlOmQ0ZmY3M2M1ZTQ0YTQ0MzVhYTQ1MDBkYzVkOTYzMGExXzYtMi0xLTEtMjk2NzE_b45f2489-783a-48fc-9511-9f91c2c9bf0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkNGZmNzNjNWU0NGE0NDM1YWE0NTAwZGM1ZDk2MzBhMS90YWJsZXJhbmdlOmQ0ZmY3M2M1ZTQ0YTQ0MzVhYTQ1MDBkYzVkOTYzMGExXzctMi0xLTEtMjk2NzE_3b54b54e-7592-4074-bc25-7f6270eaf463">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less present value discount</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkNGZmNzNjNWU0NGE0NDM1YWE0NTAwZGM1ZDk2MzBhMS90YWJsZXJhbmdlOmQ0ZmY3M2M1ZTQ0YTQ0MzVhYTQ1MDBkYzVkOTYzMGExXzgtMi0xLTEtMjk2NzE_998def4a-fa81-4fb6-b5c5-67222c792e8e">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financing obligation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkNGZmNzNjNWU0NGE0NDM1YWE0NTAwZGM1ZDk2MzBhMS90YWJsZXJhbmdlOmQ0ZmY3M2M1ZTQ0YTQ0MzVhYTQ1MDBkYzVkOTYzMGExXzktMi0xLTEtMjk2NzE_afcf1830-c858-4a90-952a-7684dd0a7476">293</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the fair value of these agreements is minimal.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Paycheck Protection Program</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company received funds in the amount of $<ix:nonFraction unitRef="usd" contextRef="i0c20e7a2f2df45a3b8f60672c1031439_D20200401-20200430" decimals="-5" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzM2NTU_7f39ba5d-7762-40d3-995b-bacfbf3200df">0.9</ix:nonFraction>&#160;million pursuant to a loan under the Paycheck Protection Program of the 2020 CARES Act ("PPP") administered by the Small Business Association. The loan has an interest rate of 1.0% and a term of 24 months. No payments were due for the first 16 months, although interest accrued, and monthly payments were due over the next 8 months to retire the loan plus accrued interest. Funds </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2234a97292ad4c468ed69f5fd88eafc2" continuedAt="ic1c3d0588a674711bd6a6e0b4824450d"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from the loan could only be used for certain purposes, including payroll, benefits, rent and utilities, and a portion of the loan used to pay certain costs were forgivable, all as provided by the terms of the PPP. The loan was evidenced by a promissory note, which contained customary events of default relating to, among other things, payment defaults and breaches of representations and warranties. The SBA approved the Company's PPP Loan forgiveness application on May 26, 2021 for the entire principal amount of the PPP Loan and accrued interest. As a result, the Company recorded a gain on the forgiveness of the loan in the amount of $<ix:nonFraction unitRef="usd" contextRef="i17fa801811ba45e3a75870ab1d78e1e1_D20210526-20210526" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzIxOTkwMjMyODQ3Njg_20fdb05f-f354-481f-8517-6ecbcb3b6ee5">0.9</ix:nonFraction>&#160;million. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Retention Credit ("ERC")</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Employee Retention Credit ("ERC") under the CARES Act is a refundable tax credit which encourages businesses to keep employees on the payroll during the COVID-19 pandemic. Eligible employers could qualify for up to $5,000 of credit for each employee based on qualified wages paid after March 12, 2020 and before January 1, 2021. The Internal Revenue Service ("IRS") subsequently issued Notice 2021-23 and Notice 2021-49 which collectively extended the ERC eligibility to cover qualified wages paid after December 31, 2020 and before January 1, 2022. Qualified wages are the wages paid to an employee for the time that the employee is not providing services due to an economic hardship, specifically, either (1) a full or partial suspension of operations by order of a governmental authority due to COVID-19, or (2) a significant decline in gross receipts. </span></div></ix:continuation><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic1c3d0588a674711bd6a6e0b4824450d">During the years ended December 31, 2021 and 2020, the Company received $<ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-5" name="angn:CARESActEmployeeRetentionCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzEwOTk1MTE2NTc0ODE_19df29f1-d806-40f7-ba1c-d4b57ae07f5a">1.5</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="INF" name="angn:CARESActEmployeeRetentionCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzEwOTk1MTE2NTc0OTI_81632589-409d-4d68-bd97-8398a6c47a5a">zero</ix:nonFraction>, respectively for ERC and applied the benefit as a reduction to the payroll expenses in the consolidated statement of operations.</ix:continuation> </span></div><div style="margin-top:3pt"><span><br/></span></div><div id="idee3699378af4447a4091414c0adfaa7_139"></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12&#8212;<ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90ZXh0cmVnaW9uOmVlODU5MWQ5MmNkOTQ4YTFiOTM0MDIxY2M3ZjE2MGQ3XzMyOTg1MzQ4ODg1MjE_053f306b-89ea-47b3-bea0-ddb78a41255e" continuedAt="i88c0fe77f629495dafe32a706c94c637" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="i88c0fe77f629495dafe32a706c94c637" continuedAt="i833b90192d534d188f9c919b91efd426"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized <ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90ZXh0cmVnaW9uOmVlODU5MWQ5MmNkOTQ4YTFiOTM0MDIxY2M3ZjE2MGQ3XzIxOTkwMjMyODQyMjc_5668eaee-1a32-4af0-8303-0645c3dd1943"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90ZXh0cmVnaW9uOmVlODU5MWQ5MmNkOTQ4YTFiOTM0MDIxY2M3ZjE2MGQ3XzIxOTkwMjMyODQyMjc_c43af010-5209-43ae-93e7-8c631d01f7ca">no</ix:nonFraction></ix:nonFraction> tax provision for the year ended December 31, 2021 and December 31, 2020. The difference between the Company's effective tax rate of <ix:nonFraction unitRef="number" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90ZXh0cmVnaW9uOmVlODU5MWQ5MmNkOTQ4YTFiOTM0MDIxY2M3ZjE2MGQ3XzIxOTkwMjMyODQyMjk_8e2fbc4d-f1f0-4aa8-b721-467440bc4164"><ix:nonFraction unitRef="number" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90ZXh0cmVnaW9uOmVlODU5MWQ5MmNkOTQ4YTFiOTM0MDIxY2M3ZjE2MGQ3XzIxOTkwMjMyODQyMjk_97f81ee1-66e0-43fe-b48a-738d5d055710">0</ix:nonFraction></ix:nonFraction>% and the U.S. federal statutory tax rate of 21% is largely due to the Company's net operating losses, which are offset by the corresponding valuation allowance. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company has established a valuation allowance against net deferred tax assets due to the uncertainty that such assets will be realized. The Company periodically evaluates the recoverability of the deferred assets. At such time as it is determined that it is more likely than not that the deferred tax asset will be realized, the valuation allowance will be reduced.</span></div><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90ZXh0cmVnaW9uOmVlODU5MWQ5MmNkOTQ4YTFiOTM0MDIxY2M3ZjE2MGQ3XzIxOTkwMjMyNzg5ODU_366c06b8-5f6d-4ff0-9681-d15907243c5b" escape="true"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Losses before income taxes includes the following components:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:72.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.828%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo2M2M0NzgzYmQ0MTc0ZGY5YTc5ZGJjNzE1NzQxMzZjMy90YWJsZXJhbmdlOjYzYzQ3ODNiZDQxNzRkZjlhNzlkYmM3MTU3NDEzNmMzXzItMS0xLTEtMzc4MDY_8d0da61a-25a4-4e6a-91f0-c7e6da586b95">53,547</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo2M2M0NzgzYmQ0MTc0ZGY5YTc5ZGJjNzE1NzQxMzZjMy90YWJsZXJhbmdlOjYzYzQ3ODNiZDQxNzRkZjlhNzlkYmM3MTU3NDEzNmMzXzItMy0xLTEtMzc4MDg_7fba45bb-b628-4dbf-a1d0-6242a12cd580">78,164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo2M2M0NzgzYmQ0MTc0ZGY5YTc5ZGJjNzE1NzQxMzZjMy90YWJsZXJhbmdlOjYzYzQ3ODNiZDQxNzRkZjlhNzlkYmM3MTU3NDEzNmMzXzMtMS0xLTEtMzc4MDY_a23c2921-e8c7-4b0e-ab27-7f5f2459f5d7">1,026</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo2M2M0NzgzYmQ0MTc0ZGY5YTc5ZGJjNzE1NzQxMzZjMy90YWJsZXJhbmdlOjYzYzQ3ODNiZDQxNzRkZjlhNzlkYmM3MTU3NDEzNmMzXzMtMy0xLTEtMzc4MDg_2350e8d6-673d-48a7-a133-6b5b9df4c990">1,943</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo2M2M0NzgzYmQ0MTc0ZGY5YTc5ZGJjNzE1NzQxMzZjMy90YWJsZXJhbmdlOjYzYzQ3ODNiZDQxNzRkZjlhNzlkYmM3MTU3NDEzNmMzXzQtMS0xLTEtMzc4MDY_e8e0da4f-4e94-4d6c-b047-206caae6fed1">54,573</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo2M2M0NzgzYmQ0MTc0ZGY5YTc5ZGJjNzE1NzQxMzZjMy90YWJsZXJhbmdlOjYzYzQ3ODNiZDQxNzRkZjlhNzlkYmM3MTU3NDEzNmMzXzQtMy0xLTEtMzc4MDg_4ca36ff2-fd20-47b9-8f1c-764a29db165a">80,107</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i833b90192d534d188f9c919b91efd426" continuedAt="i567b12f48bcf4fde80bd841f4e11e228"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90ZXh0cmVnaW9uOmVlODU5MWQ5MmNkOTQ4YTFiOTM0MDIxY2M3ZjE2MGQ3XzY1OTcwNjk3NzE4NTA_9e1b4f93-2397-4851-a714-7b246c439f22" escape="true"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes provision (benefit) for the years ended December&#160;31, 2021 and 2020 consists of the following (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:72.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.828%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzMtMS0xLTEtMjI1NDU_1a3047fe-c703-49a1-86d5-348f7b08ae6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzMtMy0xLTEtMjI1NDU_4dca68fd-15b8-4b06-9de9-08d467be97d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">United States</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzQtMS0xLTEtMjI1NDU_366b76ec-801d-455a-8c97-9a93a4ef4839">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzQtMy0xLTEtMjI1NDU_29eb2974-9d54-46ed-b6ad-b675c4b8398c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzUtMS0xLTEtMjI1NDU_1c8a1d2f-e610-4269-b45a-cb257141599c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzUtMy0xLTEtMjI1NDU_cfac148f-69ba-4bd1-96a0-455e0ea40da8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Current</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzYtMS0xLTEtMjQ0NjI_a35344d9-f707-4cf7-9ebe-2a3fa01d1eca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzYtMy0xLTEtMjQ0NjI_e82e2d56-7f45-4ce4-9a84-1aac3a979e74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzktMS0xLTEtMjI1NDU_c6ac5b04-8cd1-4d42-9fda-ab18f1a7246b">5,460</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzktMy0xLTEtMjI1NDU_26733c44-c124-4931-a820-89e2f1f69e80">12,129</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzEwLTEtMS0xLTIyNTQ1_25b0e87c-d9b2-4e6f-8707-82607f83b24b">4,779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzEwLTMtMS0xLTIyNTQ1_ec8f0519-cf3d-4af4-85ca-f2df566634b0">522</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzExLTEtMS0xLTIyNTQ1_c5caf402-baeb-42ee-910a-1be295c12c61">10,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzExLTMtMS0xLTIyNTQ1_1adfad6a-dc67-49e9-a355-e251f9f93d92">12,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Deferred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzEyLTEtMS0xLTI0NDY2_93050bb9-b847-4a89-b1d4-64b5a2960302">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzEyLTMtMS0xLTI0NDY2_6bc5ac6f-6a82-489e-9b7a-1ed6263a44ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total tax provision</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzEzLTEtMS0xLTIyNTQ1_41d1c631-e48b-41bb-a94a-920b6e75783c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzEzLTMtMS0xLTIyNTQ1_4a42dadf-851f-4360-9758-84310ce95060">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90ZXh0cmVnaW9uOmVlODU5MWQ5MmNkOTQ4YTFiOTM0MDIxY2M3ZjE2MGQ3XzIxOTkwMjMyNjA3NDc_2448ff3c-8d75-44b2-a44a-d86a88eda0af" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations between the federal statutory income tax rate and the Company's effective income tax rate were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:72.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.828%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Federal statutory income tax rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzItMS0xLTEtMjI1NDU_334845d7-553d-4d72-9d9d-02218f123d03">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzItMy0xLTEtMjI1NDU_83c2c5c8-9dae-4f68-9ea9-7bc6deec3312">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">State taxes, net of federal tax benefit</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzMtMS0xLTEtMjI1NDU_58d373da-6e69-4f38-b998-68d530c3f692">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzMtMy0xLTEtMjI1NDU_366ca1cf-e21b-4aa1-b8b7-785af130c002">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="number" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzQtMS0xLTEtMjI1NDU_5d63737a-bbd0-4f00-ae0a-3e90b02caaac">2.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="number" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzQtMy0xLTEtMjI1NDU_d8d68420-4c9e-4f74-bc52-4ea25df8f101">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="number" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzUtMS0xLTEtMjI1NDU_486008a3-bd00-4b95-bff8-fdcd6330735a">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="number" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzUtMy0xLTEtMjI1NDU_a10bb89a-65de-468b-a6eb-602d3fc99a45">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="number" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="3" sign="-" name="angn:EffectiveIncomeTaxRateReconciliationInterestPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzYtMS0xLTEtMzYwNDY_4d106bec-6703-4a82-9598-713166011108">4.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="3" name="angn:EffectiveIncomeTaxRateReconciliationInterestPercent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzYtMy0xLTEtMzYwNDY_5280812a-748a-498a-97f6-bd71d49645b9">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">R&amp;D and other tax credit changes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzYtMS0xLTEtMjI1NDU_943b3a7f-dcce-4f6f-adc9-9b2b8238ab79">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="number" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzYtMy0xLTEtMjI1NDU_acab58c0-373e-4f64-a7b5-1816993b9e95">1.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Permanent items</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="number" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="3" sign="-" name="angn:EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzctMS0xLTEtMjI1NDU_7c7a7faa-7f76-45c3-aaca-1a90bf638d65">7.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="number" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="3" sign="-" name="angn:EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzctMy0xLTEtMjI1NDU_de37894b-fbca-4c38-82ad-a17046c4de80">4.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Nontaxable Income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzktMS0xLTEtMzYwNTU_7b47ae0e-3fc8-4543-8db6-b90ed570fa9e">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzktMy0xLTEtMzYwNTU_49211689-85a9-4a03-8a35-a5db61eaf35b">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzgtMS0xLTEtMjI1NDU_59548f63-fd28-4dac-a1e3-2e511e9b4048">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzgtMy0xLTEtMjI1NDU_4141109e-a258-446a-8b6a-463fb8bcd13c">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="number" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzktMS0xLTEtMjI1NDU_0c8717df-aa65-416e-a1b9-ffcdedbea25e">10.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="number" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzktMy0xLTEtMjI1NDU_d10c2f22-5d44-4dc9-9c9d-cad21f22111c">15.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Effective income tax rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzEwLTEtMS0xLTIyNTQ1_8751da35-dc8d-49a6-8023-6ed37bdcaf9d">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzEwLTMtMS0xLTIyNTQ1_72bf1ebf-fc82-4078-b584-4fb084ea5486">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i567b12f48bcf4fde80bd841f4e11e228" continuedAt="i434af58ac3914ffabb113562840ce257"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90ZXh0cmVnaW9uOmVlODU5MWQ5MmNkOTQ4YTFiOTM0MDIxY2M3ZjE2MGQ3XzIxOTkwMjMyNjA3NDg_3424dc38-b5f6-446b-a555-0ee67095dd5c" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company's deferred tax asset at December&#160;31, 2021 and 2020 were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net operating loss carryforwards</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzMtMS0xLTEtMjI1NDU_c01baa60-4e46-4d7f-b33f-ecd6ad4794ac">29,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzMtMy0xLTEtMjI1NDU_7ef052a5-b0b8-47dd-a7d4-b9f5125292f4">22,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">R&amp;D and other tax credit carryovers</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzQtMS0xLTEtMjI1NDU_96535dfc-3c53-460d-afd9-188146634120">6,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzQtMy0xLTEtMjI1NDU_44bd9a56-ff76-4cdd-bdd5-ed3bdcf62c6d">4,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liability</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="angn:DeferredTaxAssetsOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzUtMS0xLTEtMjI1NDU_80fc24ef-70b1-4df3-bfc7-ad758c242396">1,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="angn:DeferredTaxAssetsOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzUtMy0xLTEtMjI1NDU_d88e9bed-215b-4704-ac5a-b09cff9180b9">956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzYtMS0xLTEtMjI1NDU_cbb26af4-92b0-4e3b-9436-7af44ab49ad2">3,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzYtMy0xLTEtMjI1NDU_30830830-1ab8-4691-8ae9-6a4703ebe994">1,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued compensation and other expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzctMS0xLTEtMjI1NDU_568de8b5-5177-4cbb-a922-fbabf749f520">536</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzctMy0xLTEtMjI1NDU_d85c6e7d-3057-4229-9d30-f70b7d8b7be8">658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fixed assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzgtMS0xLTEtMjI1NDU_0db9815d-15e9-4927-8b7e-7decfbdf56ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzgtMy0xLTEtMjI1NDU_ccb46fd1-022b-445d-b7ba-59afe732cd48">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total deferred tax assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzktMS0xLTEtMjI1NDU_8f1d236e-af2e-4eae-9bd8-7b5cd8e48374">40,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzktMy0xLTEtMjI1NDU_56875c76-2957-473e-b21f-eea71a793782">30,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fixed assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzExLTEtMS0xLTM2MDY2_cf9ab297-d7a1-4f1e-9811-ca9b7c76863b">37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzExLTMtMS0xLTM2MDY2_9d11c2cf-a4a8-4e5e-9c0c-2a2283e3d112">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right of use assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzExLTEtMS0xLTIyNTQ1_936e1a03-f504-47e8-afcb-6982134a587b">1,046</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzExLTMtMS0xLTIyNTQ1_296e0fc6-3edc-4c5f-8ba3-baa03b5ca297">874</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Valuation allowance</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzEyLTEtMS0xLTIyNTQ1_9f371ec8-7df2-489f-b02f-8b4a2243fb3a">39,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzEyLTMtMS0xLTIyNTQ1_47d0af02-4a0f-43b4-b33c-db7b0fd99e57">29,470</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax assets, net of allowance</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzEzLTEtMS0xLTIyNTQ1_21cd3a5a-af1d-4fee-aa0a-808098d488eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzEzLTMtMS0xLTIyNTQ1_bb021264-e1da-4161-af29-0eca36d2916c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company has federal net operating loss carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90ZXh0cmVnaW9uOmVlODU5MWQ5MmNkOTQ4YTFiOTM0MDIxY2M3ZjE2MGQ3XzEwOTk1MTE2NDkwNTA_c926726f-4859-454f-95bf-e48e93a730e9">118.5</ix:nonFraction>&#160;million available to reduce future taxable income, if any, for federal income tax purposes. Approximately $<ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-5" name="angn:OperatingLossCarryforwardSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90ZXh0cmVnaW9uOmVlODU5MWQ5MmNkOTQ4YTFiOTM0MDIxY2M3ZjE2MGQ3XzE2NDkyNjc0NTM2ODM_aa4259bf-a9f3-4595-a632-dc2893fde318">9.6</ix:nonFraction>&#160;million of federal net operating losses can be carried forward to future tax years and begin to expire in 2035. The federal net operating losses generated for the years beginning after December 31, 2017, approximately $<ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-5" name="angn:OperatingLossCarryforwardNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90ZXh0cmVnaW9uOmVlODU5MWQ5MmNkOTQ4YTFiOTM0MDIxY2M3ZjE2MGQ3XzE2NDkyNjc0NTM2Njk_d6c5f6a7-2934-4898-be0c-ec090b4d1c0d">108.9</ix:nonFraction>&#160;million in total, can be carried forward indefinitely. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NOL carryforward may be subject to an annual limitation under Section 382 and 383 of the Internal Revenue Code of 1986, and similar state provisions if the Company experienced one or more ownership changes which would limit the amount of NOL and tax credit carryforwards that can be utilized to offset future taxable income and tax respectively. In general, an ownership change as defined by Section 382 and 383, results from the transactions increasing ownership of certain stockholders or public groups in the stock of the corporation of more than 50 percentage points over a three-year period. The Company has not completed a Section 382 and 383 analysis to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company's formation due to the complexity and cost associated with such study and the fact there may be additional such ownership changes in the future. If a change in ownership were to have occurred or occurs in the future, the NOL and tax credits carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company's effective tax rate.</span></div><div style="margin-top:1pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:1pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the United States, California, Massachusetts, New York and New Jersey. Due to the Company's losses incurred, the Company is subject to the income tax examination by authorities since inception. The Company's policy is to recognize interest expense and penalties related to income tax matters as tax expense. As of December&#160;31, 2021 and 2020, there were no significant accruals for interest related to unrecognized tax benefits or tax penalties.</span></div><div style="margin-top:1pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:1pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, the Company's reserve for unrecognized tax benefits is approximately $<ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90ZXh0cmVnaW9uOmVlODU5MWQ5MmNkOTQ4YTFiOTM0MDIxY2M3ZjE2MGQ3XzE2NDkyNjc0NTg1NjU_a4f93a3a-2381-478a-b6fc-9f01fdff110a">3.7</ix:nonFraction>&#160;million. Due to the full valuation allowance at December 31, 2021, current adjustments to the unrecognized benefits will have no impact to the Company's effective income tax rate.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i434af58ac3914ffabb113562840ce257"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90ZXh0cmVnaW9uOmVlODU5MWQ5MmNkOTQ4YTFiOTM0MDIxY2M3ZjE2MGQ3XzYwNDczMTM5NTgwMzk_452e7b16-92d9-46ec-ae66-597734fef960" escape="true"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reconciliation of uncertain tax positions as of December 31, 2021 and 2020 was as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning Balance </span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNWRmYjkwMzFiODI0NGY4YWJkZTk4ZDFjYWJkM2Q2OS90YWJsZXJhbmdlOjA1ZGZiOTAzMWI4MjQ0ZjhhYmRlOThkMWNhYmQzZDY5XzItMS0xLTEtMjQ1Njk_a9159197-bbd0-4f91-8701-cca2405ab8c6">2,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i08c03f72f0b941539e5cdcb6bd71e375_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNWRmYjkwMzFiODI0NGY4YWJkZTk4ZDFjYWJkM2Q2OS90YWJsZXJhbmdlOjA1ZGZiOTAzMWI4MjQ0ZjhhYmRlOThkMWNhYmQzZDY5XzItMy0xLTEtMjQ1NzU_17d6e47d-9879-4f88-bbf8-aa1e9c3b165d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions for current year</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNWRmYjkwMzFiODI0NGY4YWJkZTk4ZDFjYWJkM2Q2OS90YWJsZXJhbmdlOjA1ZGZiOTAzMWI4MjQ0ZjhhYmRlOThkMWNhYmQzZDY5XzQtMS0xLTEtMjQ1NzE_46037ace-1ef2-43c5-bb64-5308625cbb7c">1,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNWRmYjkwMzFiODI0NGY4YWJkZTk4ZDFjYWJkM2Q2OS90YWJsZXJhbmdlOjA1ZGZiOTAzMWI4MjQ0ZjhhYmRlOThkMWNhYmQzZDY5XzQtMy0xLTEtMjQ1Nzc_029ffe23-1a6f-4014-8b2a-7926ff1cceb2">633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions for prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNWRmYjkwMzFiODI0NGY4YWJkZTk4ZDFjYWJkM2Q2OS90YWJsZXJhbmdlOjA1ZGZiOTAzMWI4MjQ0ZjhhYmRlOThkMWNhYmQzZDY5XzUtMS0xLTEtMjQ1NzE_bfa2b411-1c83-44da-8222-fc9f5f40c75b">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNWRmYjkwMzFiODI0NGY4YWJkZTk4ZDFjYWJkM2Q2OS90YWJsZXJhbmdlOjA1ZGZiOTAzMWI4MjQ0ZjhhYmRlOThkMWNhYmQzZDY5XzUtMy0xLTEtMjQ1Nzc_b7232014-2cdb-4584-a63f-81067e28af08">1,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ending Balance</span></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNWRmYjkwMzFiODI0NGY4YWJkZTk4ZDFjYWJkM2Q2OS90YWJsZXJhbmdlOjA1ZGZiOTAzMWI4MjQ0ZjhhYmRlOThkMWNhYmQzZDY5XzEwLTEtMS0xLTI0NTcz_2d57040e-bc77-4db3-a17d-0ac21c77ad05">3,675</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNWRmYjkwMzFiODI0NGY4YWJkZTk4ZDFjYWJkM2Q2OS90YWJsZXJhbmdlOjA1ZGZiOTAzMWI4MjQ0ZjhhYmRlOThkMWNhYmQzZDY5XzEwLTMtMS0xLTI0NTc5_452576b4-02e6-4d18-b0ea-74bead2935d0">2,579</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="angn:UnrecognizedTaxBenefitsIfRecognizedWouldAffectTheEffectiveTaxRateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90ZXh0cmVnaW9uOmVlODU5MWQ5MmNkOTQ4YTFiOTM0MDIxY2M3ZjE2MGQ3XzYwNDczMTM5NTgwNDA_a0e081a1-2649-4791-92bf-1a0e8f11f21f" escape="true"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amount of unrecognized tax benefits, if recognized, would affect the effective tax rate was as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unrecognized benefits that would affect the effective tax rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo1MjhhMjA1ZWIzYjE0MTNiYWI3ZDU2MjQwZDc0MTQ1ZS90YWJsZXJhbmdlOjUyOGEyMDVlYjNiMTQxM2JhYjdkNTYyNDBkNzQxNDVlXzEtMS0xLTEtMjQ1ODE_b642b47f-21c7-4c53-8f2a-073b86044279">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo1MjhhMjA1ZWIzYjE0MTNiYWI3ZDU2MjQwZDc0MTQ1ZS90YWJsZXJhbmdlOjUyOGEyMDVlYjNiMTQxM2JhYjdkNTYyNDBkNzQxNDVlXzItMy0xLTEtNDAzMTE_abf28a0c-d0e8-4739-9136-5b737942205e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unrecognized benefits that would not affect the effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="angn:UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo1MjhhMjA1ZWIzYjE0MTNiYWI3ZDU2MjQwZDc0MTQ1ZS90YWJsZXJhbmdlOjUyOGEyMDVlYjNiMTQxM2JhYjdkNTYyNDBkNzQxNDVlXzItMS0xLTEtMjQ1ODE_f6af49e0-0fca-497a-9a7d-174d75f8acde">3,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="angn:UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo1MjhhMjA1ZWIzYjE0MTNiYWI3ZDU2MjQwZDc0MTQ1ZS90YWJsZXJhbmdlOjUyOGEyMDVlYjNiMTQxM2JhYjdkNTYyNDBkNzQxNDVlXzMtMy0xLTEtNDAzMTE_ebc20c85-b68f-4881-9d23-655450c623fa">2,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total unrecognized benefits</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo1MjhhMjA1ZWIzYjE0MTNiYWI3ZDU2MjQwZDc0MTQ1ZS90YWJsZXJhbmdlOjUyOGEyMDVlYjNiMTQxM2JhYjdkNTYyNDBkNzQxNDVlXzMtMS0xLTEtMjQ1ODE_6433b2b1-ecd5-4c71-8f26-888363a3ba5a">3,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo1MjhhMjA1ZWIzYjE0MTNiYWI3ZDU2MjQwZDc0MTQ1ZS90YWJsZXJhbmdlOjUyOGEyMDVlYjNiMTQxM2JhYjdkNTYyNDBkNzQxNDVlXzQtMy0xLTEtNDAzMTE_7cf9bfcd-2030-40fd-ad0f-154e8d50bc62">2,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not anticipate material changes to its uncertain tax positions for the next twelve months.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the 2018 Act that amends the Internal Revenue Code that reduced the U.S. corporate tax rate from 35% to 21% effective January 1, 2018 and modified policies, credits, and deductions (the "Tax Act"), the SEC staff issued Staff Accounting Bulletin No. 118 ("SAB 118") to address the application of GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. The Company has completed its evaluation and determined that there was no net impact on the Company's consolidated financial statements for the years ended December&#160;31, 2021 and 2020 as the corresponding adjustment was made to the valuation allowance.</span></div></ix:continuation><div style="margin-top:3pt;text-indent:22.5pt"><span><br/></span></div><div id="idee3699378af4447a4091414c0adfaa7_142"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13&#8212;<ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:DefinedContributionPlanTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDIvZnJhZzpiZTM0MWU3YWEyZTQ0YWMyOTI5NGUyZjNkZTQxNWNhZS90ZXh0cmVnaW9uOmJlMzQxZTdhYTJlNDRhYzI5Mjk0ZTJmM2RlNDE1Y2FlXzMyOTg1MzQ4ODM5NjI_a818167c-7569-4246-af32-712a0fb01dfa" continuedAt="i22400c072ca14a6fbc05ed1f4947e00a" escape="true">Employee Benefit Plan</ix:nonNumeric></span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="i22400c072ca14a6fbc05ed1f4947e00a" continuedAt="i7dae3d4e2a924db78602e3b78c3018c3">Employee Benefit Plan</ix:continuation></span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7dae3d4e2a924db78602e3b78c3018c3">The Company sponsors a retirement savings plan that is intended to qualify for favorable tax treatment under Section 401(a) of the Code, and contains a cash or deferred feature that is intended to meet the requirements of Section 401(k) of the Code. Participants may make pre-tax and certain after-tax (Roth) salary deferral contributions to the plan from their eligible earnings up to the statutorily prescribed annual limit under the Code. Participants who are 50 years of age or older may contribute additional amounts based on the statutory limits for catch-up contributions. Participant contributions are held in trust as required by law. No minimum benefit is provided under the plan. An employee&#8217;s interest in his or her salary deferral contributions is <ix:nonFraction unitRef="number" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDIvZnJhZzpiZTM0MWU3YWEyZTQ0YWMyOTI5NGUyZjNkZTQxNWNhZS90ZXh0cmVnaW9uOmJlMzQxZTdhYTJlNDRhYzI5Mjk0ZTJmM2RlNDE1Y2FlXzEwOTk1MTE2MzAwMTk_bd48ca73-ebff-46e7-9722-ee7d7643901b">100</ix:nonFraction>% vested when contributed. Contributions, subject to established limits, are matched at a dollar for dollar rate up to <ix:nonFraction unitRef="number" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="INF" name="angn:DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayOneHundredPercentEmployerMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDIvZnJhZzpiZTM0MWU3YWEyZTQ0YWMyOTI5NGUyZjNkZTQxNWNhZS90ZXh0cmVnaW9uOmJlMzQxZTdhYTJlNDRhYzI5Mjk0ZTJmM2RlNDE1Y2FlXzEwOTk1MTE2MzAwMjM_58930adf-3e01-41e0-894a-004d1bde65ad">3</ix:nonFraction>% of an individual&#8217;s earnings and fifty cents on the dollar on the next <ix:nonFraction unitRef="number" contextRef="i1461dc15821341d7a6cca5de3d10b493_D20210101-20211231" decimals="INF" name="angn:DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayFiftyPercentEmployerMatch" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDIvZnJhZzpiZTM0MWU3YWEyZTQ0YWMyOTI5NGUyZjNkZTQxNWNhZS90ZXh0cmVnaW9uOmJlMzQxZTdhYTJlNDRhYzI5Mjk0ZTJmM2RlNDE1Y2FlXzEwOTk1MTE2MzAwMjc_303c31ba-c9da-4cc7-a16f-0740ee425d51">4</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="i49372af6f1524e94bc325a0b4866deb5_D20210101-20211231" decimals="INF" name="angn:DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayFiftyPercentEmployerMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDIvZnJhZzpiZTM0MWU3YWEyZTQ0YWMyOTI5NGUyZjNkZTQxNWNhZS90ZXh0cmVnaW9uOmJlMzQxZTdhYTJlNDRhYzI5Mjk0ZTJmM2RlNDE1Y2FlXzEwOTk1MTE2MzAwMzE_3e959a86-bb9e-4187-8cac-2f82913da224">5</ix:nonFraction>% of earnings.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><div id="idee3699378af4447a4091414c0adfaa7_145"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14&#8212;<ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90ZXh0cmVnaW9uOmUxZTJkOGE4MjNlMDQxZmJhMjQwMzg3NjJlMmUzYzQ3XzMyOTg1MzQ4ODQyOTk_87f3e6db-d62d-48e2-a082-dd8b51c47317" continuedAt="i1a25254832714a4eb655f9452f1a208e" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><ix:continuation id="i1a25254832714a4eb655f9452f1a208e"><ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90ZXh0cmVnaW9uOmUxZTJkOGE4MjNlMDQxZmJhMjQwMzg3NjJlMmUzYzQ3XzMyOTg1MzQ4ODQzMDA_56b7b9e6-80f6-4d19-8d69-dd9548cbfb4c" escape="true"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of the Company&#8217;s basic and diluted net loss per share attributable to common stockholders, which excludes shares which are legally outstanding but subject to repurchase by the Company (in thousands, except share and per share data):</span></div><div style="margin-top:10pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:72.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.022%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Numerator</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net loss attributable to common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTo3YTZkODZiOTY4YmI0NjY4ODJjMTllNmEyOGQ2ZGEyZS90YWJsZXJhbmdlOjdhNmQ4NmI5NjhiYjQ2Njg4MmMxOWU2YTI4ZDZkYTJlXzMtMS0xLTEtMjI1NDU_811dc8e2-78ce-4d50-9048-f8960f79f901">54,573</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTo3YTZkODZiOTY4YmI0NjY4ODJjMTllNmEyOGQ2ZGEyZS90YWJsZXJhbmdlOjdhNmQ4NmI5NjhiYjQ2Njg4MmMxOWU2YTI4ZDZkYTJlXzMtMy0xLTEtMjI1NDU_f024e993-06db-4a34-84dd-a47f4722ad41">80,107</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTo3YTZkODZiOTY4YmI0NjY4ODJjMTllNmEyOGQ2ZGEyZS90YWJsZXJhbmdlOjdhNmQ4NmI5NjhiYjQ2Njg4MmMxOWU2YTI4ZDZkYTJlXzctMS0xLTEtMjI1NDU_b053e388-2420-4d58-a1be-ff9207ce26ba"><ix:nonFraction unitRef="shares" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTo3YTZkODZiOTY4YmI0NjY4ODJjMTllNmEyOGQ2ZGEyZS90YWJsZXJhbmdlOjdhNmQ4NmI5NjhiYjQ2Njg4MmMxOWU2YTI4ZDZkYTJlXzctMS0xLTEtMjI1NDU_bdf11b30-ebc3-40e0-949d-5b1cb2f1b261">28,244,825</ix:nonFraction></ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTo3YTZkODZiOTY4YmI0NjY4ODJjMTllNmEyOGQ2ZGEyZS90YWJsZXJhbmdlOjdhNmQ4NmI5NjhiYjQ2Njg4MmMxOWU2YTI4ZDZkYTJlXzctMy0xLTEtMjI1NDU_5f821b47-2b55-4bc3-877a-b2986a15d002"><ix:nonFraction unitRef="shares" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTo3YTZkODZiOTY4YmI0NjY4ODJjMTllNmEyOGQ2ZGEyZS90YWJsZXJhbmdlOjdhNmQ4NmI5NjhiYjQ2Njg4MmMxOWU2YTI4ZDZkYTJlXzctMy0xLTEtMjI1NDU_edeeb49c-5410-4c91-9ba0-5d6a115ab741">14,762,120</ix:nonFraction></ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net loss per share attributable to common stockholders, basic and diluted</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTo3YTZkODZiOTY4YmI0NjY4ODJjMTllNmEyOGQ2ZGEyZS90YWJsZXJhbmdlOjdhNmQ4NmI5NjhiYjQ2Njg4MmMxOWU2YTI4ZDZkYTJlXzgtMS0xLTEtMjI1NDU_9e94d9e0-8cc1-4e4b-9043-c564cc4b0293"><ix:nonFraction unitRef="usdPerShare" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTo3YTZkODZiOTY4YmI0NjY4ODJjMTllNmEyOGQ2ZGEyZS90YWJsZXJhbmdlOjdhNmQ4NmI5NjhiYjQ2Njg4MmMxOWU2YTI4ZDZkYTJlXzgtMS0xLTEtMjI1NDU_fd7589f0-1789-4405-ac95-721e3c267785">1.93</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTo3YTZkODZiOTY4YmI0NjY4ODJjMTllNmEyOGQ2ZGEyZS90YWJsZXJhbmdlOjdhNmQ4NmI5NjhiYjQ2Njg4MmMxOWU2YTI4ZDZkYTJlXzgtMy0xLTEtMjI1NDU_4ee713f8-e894-4925-928f-40f6a83ed182"><ix:nonFraction unitRef="usdPerShare" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTo3YTZkODZiOTY4YmI0NjY4ODJjMTllNmEyOGQ2ZGEyZS90YWJsZXJhbmdlOjdhNmQ4NmI5NjhiYjQ2Njg4MmMxOWU2YTI4ZDZkYTJlXzgtMy0xLTEtMjI1NDU_f5120ec4-9911-4b90-8cfe-8c3eb5a7a888">5.43</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90ZXh0cmVnaW9uOmUxZTJkOGE4MjNlMDQxZmJhMjQwMzg3NjJlMmUzYzQ3XzMyOTg1MzQ4ODQzMDE_7a10b93c-e893-4938-8ec8-32575162a78a" continuedAt="i84e45db8ff7f473eb2e01c7db53f7cf4" escape="true">The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share because to do so would be anti-dilutive:</ix:nonNumeric></span></div><ix:continuation id="i84e45db8ff7f473eb2e01c7db53f7cf4"><div style="margin-top:10pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:71.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Shares issuable upon exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief165a389cc44da0a2f2c5c214517d94_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTpjMjkzNWE5OWEwOWI0MWEyOGU4ZWRiNWEyNTg2OTQ0YS90YWJsZXJhbmdlOmMyOTM1YTk5YTA5YjQxYTI4ZThlZGI1YTI1ODY5NDRhXzItMS0xLTEtMjI1NDU_43ec91a0-1d1f-4202-b02d-f346bbfa0ea5">4,230,162</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iad85a45e0dbd4ab7a6756cc10a24ecbd_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTpjMjkzNWE5OWEwOWI0MWEyOGU4ZWRiNWEyNTg2OTQ0YS90YWJsZXJhbmdlOmMyOTM1YTk5YTA5YjQxYTI4ZThlZGI1YTI1ODY5NDRhXzItMy0xLTEtMjI1NDU_0bb16426-72b2-42bf-8166-0d43604bc621">3,479,731</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Shares issuable upon the exercise of warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i43a2b3ab97bd48fbbe083e2b87ed4fa9_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTpjMjkzNWE5OWEwOWI0MWEyOGU4ZWRiNWEyNTg2OTQ0YS90YWJsZXJhbmdlOmMyOTM1YTk5YTA5YjQxYTI4ZThlZGI1YTI1ODY5NDRhXzMtMS0xLTEtMjI1NDU_5755b671-f512-4e5a-bf1b-3c1e69fb4c91">1,148,123</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iac1a9fb579254c0480b5589b1c009eb5_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTpjMjkzNWE5OWEwOWI0MWEyOGU4ZWRiNWEyNTg2OTQ0YS90YWJsZXJhbmdlOmMyOTM1YTk5YTA5YjQxYTI4ZThlZGI1YTI1ODY5NDRhXzMtMy0xLTEtMjI1NDU_7945944b-c53c-4c04-8c09-dae0a3ec5cc3">2,739,791</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Shares issuable upon conversion of the convertible notes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i61bbd5c3b1454d27b052909fc297f17e_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTpjMjkzNWE5OWEwOWI0MWEyOGU4ZWRiNWEyNTg2OTQ0YS90YWJsZXJhbmdlOmMyOTM1YTk5YTA5YjQxYTI4ZThlZGI1YTI1ODY5NDRhXzQtMS0xLTEtMjI1NDU_efa374d7-cc96-4ba0-abeb-b9c65d63558d">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="ieed9eb60e9b8413cacd41a553ad6bd3f_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTpjMjkzNWE5OWEwOWI0MWEyOGU4ZWRiNWEyNTg2OTQ0YS90YWJsZXJhbmdlOmMyOTM1YTk5YTA5YjQxYTI4ZThlZGI1YTI1ODY5NDRhXzQtMy0xLTEtMjI1NDU_92e7e033-9b31-41aa-ab6c-187179e94319">5,603,388</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Shares issuable upon conversion of the Series C preferred stock</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i02a82bc7014f4eb19de71fe9d69bdca3_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTpjMjkzNWE5OWEwOWI0MWEyOGU4ZWRiNWEyNTg2OTQ0YS90YWJsZXJhbmdlOmMyOTM1YTk5YTA5YjQxYTI4ZThlZGI1YTI1ODY5NDRhXzUtMS0xLTEtMjI1NDU_245ae6f2-5419-4d4e-bf99-cf09de7cfa6e">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i49f753c217c344e0805c4e8e7c263cd5_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTpjMjkzNWE5OWEwOWI0MWEyOGU4ZWRiNWEyNTg2OTQ0YS90YWJsZXJhbmdlOmMyOTM1YTk5YTA5YjQxYTI4ZThlZGI1YTI1ODY5NDRhXzUtMy0xLTEtMjI1NDU_5a44ee79-7d5a-46ae-9585-fb5d107fbcef">3,920,172</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Non-vested shares under restricted stock unit grants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i53245befe1874188ac185852fef3d5a1_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTpjMjkzNWE5OWEwOWI0MWEyOGU4ZWRiNWEyNTg2OTQ0YS90YWJsZXJhbmdlOmMyOTM1YTk5YTA5YjQxYTI4ZThlZGI1YTI1ODY5NDRhXzYtMS0xLTEtMjI1NDU_bcb8a369-e4ae-41a3-939a-d5596d9481e6">203,015</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i83977ab456f040ddb39978debda8bbe4_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTpjMjkzNWE5OWEwOWI0MWEyOGU4ZWRiNWEyNTg2OTQ0YS90YWJsZXJhbmdlOmMyOTM1YTk5YTA5YjQxYTI4ZThlZGI1YTI1ODY5NDRhXzYtMy0xLTEtMjI1NDU_5700b70a-0416-47ad-9735-57db00d3393d">58,951</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Non-vested shares under restricted stock grants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="ia0f25cf926ad4d1cb71681e8f131863c_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTpjMjkzNWE5OWEwOWI0MWEyOGU4ZWRiNWEyNTg2OTQ0YS90YWJsZXJhbmdlOmMyOTM1YTk5YTA5YjQxYTI4ZThlZGI1YTI1ODY5NDRhXzctMS0xLTEtMjI1NDU_ae5d2b45-fafe-4364-9b6e-6d8fd6fdc3e5">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="if8ec568c6dc54174abe4f2ad93aeceac_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTpjMjkzNWE5OWEwOWI0MWEyOGU4ZWRiNWEyNTg2OTQ0YS90YWJsZXJhbmdlOmMyOTM1YTk5YTA5YjQxYTI4ZThlZGI1YTI1ODY5NDRhXzctMy0xLTEtMjI1NDU_3208c114-b6f6-48c4-87da-30a8ecfa024b">14,585</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total </span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTpjMjkzNWE5OWEwOWI0MWEyOGU4ZWRiNWEyNTg2OTQ0YS90YWJsZXJhbmdlOmMyOTM1YTk5YTA5YjQxYTI4ZThlZGI1YTI1ODY5NDRhXzgtMS0xLTEtMjI1NDU_8cd6687f-62c7-490e-80ed-a491e4d7e5bf">5,581,300</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTpjMjkzNWE5OWEwOWI0MWEyOGU4ZWRiNWEyNTg2OTQ0YS90YWJsZXJhbmdlOmMyOTM1YTk5YTA5YjQxYTI4ZThlZGI1YTI1ODY5NDRhXzgtMy0xLTEtMjI1NDU_d5598455-b759-4557-b63c-3c912d910237">15,816,618</ix:nonFraction></span></td></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">___________________________________</span></div><div style="margin-top:10pt;padding-left:49.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.24pt">The number of shares issuable upon conversion of the 2019 Notes, 2020 Notes and Series C preferred stock has been estimated using the Company's common stock fair value at December 31, 2020, discounted by <ix:nonFraction unitRef="number" contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231" decimals="2" name="angn:SharesIssuableUponConversionOfConvertibleNotesDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90ZXh0cmVnaW9uOmUxZTJkOGE4MjNlMDQxZmJhMjQwMzg3NjJlMmUzYzQ3XzMyOTg1MzQ4ODQzMDM_d57ca0c4-d687-474c-ae9e-91da591d4bd8">20</ix:nonFraction>%.</span></div></ix:continuation></ix:continuation><div style="margin-top:3pt;text-indent:22.5pt"><span><br/></span></div><div id="idee3699378af4447a4091414c0adfaa7_148"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 15&#8212;<ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzMyOTg1MzQ4ODgwNDU_8c6adae9-8764-465b-85ea-0e361633261b" continuedAt="ib226a179d5374d2eb50043f7219789c8" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="ib226a179d5374d2eb50043f7219789c8" continuedAt="i4da59cb4545f40d395324fd1efe6b163"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ohr Investment</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a series of investments in November 2013 and July 2017, the Company invested a total of $<ix:nonFraction unitRef="usd" contextRef="ibcf59fe47e7a4763a6e2bceeb52dd3ad_I20170731" decimals="-4" name="us-gaap:OtherInvestmentsAndSecuritiesAtCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzE0Ng_52f56f12-9ec4-441d-bf64-0d7b4f85ce17">150,000</ix:nonFraction> to acquire a membership interest in Ohr Cosmetics, LLC ("Ohr"), an affiliated company.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owns and the family of the Company's director and Chairman Emeritus owns approximately <ix:nonFraction unitRef="number" contextRef="i2aaa47df28a24e29abd67cbe8873e02c_I20211231" decimals="3" name="angn:OtherInvestmentAndSecuritiesAtCostOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzMyMw_79deab4a-3f59-49f8-bf53-cdde38313fb1">2.4</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ie1f1c87d61094a8385e1928cbcdef76b_D20210101-20211231" decimals="3" name="us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzE2NDkyNjc0NDg4MDM_ba323867-387b-4e03-9b6c-2ae9096c521d">80.6</ix:nonFraction>%, respectively, of the membership interests in Ohr. Our Chief Executive Officer is also owns approximately <ix:nonFraction unitRef="number" contextRef="i334eff8b0f0f4134b32ad37b7a4d1913_D20210101-20211231" decimals="3" name="us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzE2NDkyNjc0NDk0Njc_65e683ed-32ae-4c7f-8ddf-d60ebe1087e2">0.80</ix:nonFraction>% of the membership interests in Ohr. The Chairman Emeritus&#8217;s son is the manager of Ohr.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2013, the Company granted Ohr an exclusive worldwide license, with the right to sublicense, under the Company's patent rights covering one of the Company's CYP26 inhibitors, ANG-3522, for the use in treating conditions of the skin or hair. Sublicensees may not grant further sublicenses under the Company's patent rights other than to affiliates of such sublicensees and entities with which sublicensees are collaborating for the research, development, manufacture and commercialization of the products. Ohr will pay the Company a royalty at a rate in the low single digits on gross revenue of products incorporating ANG-3522, and milestone payments potentially totaling up to $<ix:nonFraction unitRef="usd" contextRef="i8d2bf22513e944e391d7fad6085a8765_I20131130" decimals="-5" name="angn:RelatedPartyTransactionPotentialMaximumMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzExMjU_3035cdc9-5c12-4cf8-8ff8-e886b48d434d">9.0</ix:nonFraction>&#160;million based on achievement of sales milestones. Royalties and milestone payments will be paid until the later of <ix:nonNumeric contextRef="i65008406702b49f183286b36f4fbea14_D20131101-20131130" name="angn:RelatedPartyTransactionRoyaltiesAndMilestonePaymentsPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzEyMzU_5b109854-7b9a-423f-a3ff-200cfa06c86f">15</ix:nonNumeric> years from the first commercial sale of a licensed product or the last to expire licensed patent rights. The royalty rate is subject to adjustments under certain circumstances. The Company believes that the Ohr License was made on terms no less favorable to the Company than those that the Company could obtain from unaffiliated third parties.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i84aca19f2bf6464d955946950b093dca_D20210101-20211231" decimals="INF" name="us-gaap:RevenueFromRelatedParties" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzE1NzY_60024328-76d7-46b9-a9ac-8abe60d2e570"><ix:nonFraction unitRef="usd" contextRef="i2e21962d26f9431d9076d02be4f4d666_D20200101-20201231" decimals="INF" name="us-gaap:RevenueFromRelatedParties" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzE1NzY_e9e8927e-ed9a-4f6d-b4cc-27274b3ed0ea">No</ix:nonFraction></ix:nonFraction> revenue from this license agreement was recognized for the years presented. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4da59cb4545f40d395324fd1efe6b163"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NovaPark Investment and Lease</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had a <ix:nonFraction unitRef="number" contextRef="i22b6851c4c8c4d8e9f955da168470856_I20211231" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzE3MTQ_9cf37f56-a18d-4b81-8887-9089f6833c52">10</ix:nonFraction>% interest in NovaPark. Members of the Company's director and Chairman Emeritus&#8217;s 's immediate family own a majority of the membership interests of NovaPark. The Company accounts for its aggregate <ix:nonFraction unitRef="number" contextRef="i22b6851c4c8c4d8e9f955da168470856_I20211231" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzE4OTc_87e6a8ec-10d3-49ca-a9a3-c580431f5292">10</ix:nonFraction>% investment in NovaPark under the equity method. <ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:EquityMethodInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzMyOTg1MzQ4ODgwNDY_63abfaaa-139c-419a-a9db-759a17903dec" continuedAt="i3cd5033d66f5404a8eead22e845a6bcc" escape="true">The following table provides the activity for the NovaPark investment for the years ended December&#160;31, 2021 and 2020 (in thousands):</ix:nonNumeric></span></div><div style="margin-top:10pt"><ix:continuation id="i3cd5033d66f5404a8eead22e845a6bcc"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning balance</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i2f9aa6708d66419390b7f00e52079f31_I20201231" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90YWJsZTpjMWFhYmY0MjQ1ZjM0MmFmYTgyYjBhN2NmYTZiNTJiYi90YWJsZXJhbmdlOmMxYWFiZjQyNDVmMzQyYWZhODJiMGE3Y2ZhNmI1MmJiXzItMS0xLTEtMjI1NDU_87bc48ba-2a95-42c4-a9bf-d026347b27f3">672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i4da1e16a428f4e4aa7b45ff38eee1854_I20191231" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90YWJsZTpjMWFhYmY0MjQ1ZjM0MmFmYTgyYjBhN2NmYTZiNTJiYi90YWJsZXJhbmdlOmMxYWFiZjQyNDVmMzQyYWZhODJiMGE3Y2ZhNmI1MmJiXzItMy0xLTEtMjI1NDU_62395aca-2fcc-461d-80a7-81592c90e41d">849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Losses of equity method investment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i19d9a4a649894b55b85b7b8ebaac451b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90YWJsZTpjMWFhYmY0MjQ1ZjM0MmFmYTgyYjBhN2NmYTZiNTJiYi90YWJsZXJhbmdlOmMxYWFiZjQyNDVmMzQyYWZhODJiMGE3Y2ZhNmI1MmJiXzMtMS0xLTEtMjI1NDU_382286e2-2b38-4158-9e01-eeda416d4665">96</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i7ed3c6aeb1c1419881dbc5be2cf6ddfe_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90YWJsZTpjMWFhYmY0MjQ1ZjM0MmFmYTgyYjBhN2NmYTZiNTJiYi90YWJsZXJhbmdlOmMxYWFiZjQyNDVmMzQyYWZhODJiMGE3Y2ZhNmI1MmJiXzMtMy0xLTEtMjI1NDU_f941beca-a276-4f95-9ecc-58e2389f5455">71</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Distribution from NovaPark</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i19d9a4a649894b55b85b7b8ebaac451b_D20210101-20211231" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90YWJsZTpjMWFhYmY0MjQ1ZjM0MmFmYTgyYjBhN2NmYTZiNTJiYi90YWJsZXJhbmdlOmMxYWFiZjQyNDVmMzQyYWZhODJiMGE3Y2ZhNmI1MmJiXzQtMS0xLTEtMjI1NDU_f875b71b-24b2-4468-bd05-cfe8965ef084">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i7ed3c6aeb1c1419881dbc5be2cf6ddfe_D20200101-20201231" decimals="-3" name="us-gaap:EquityMethodInvestmentDividendsOrDistributions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90YWJsZTpjMWFhYmY0MjQ1ZjM0MmFmYTgyYjBhN2NmYTZiNTJiYi90YWJsZXJhbmdlOmMxYWFiZjQyNDVmMzQyYWZhODJiMGE3Y2ZhNmI1MmJiXzQtMy0xLTEtMjI1NDU_50d930b8-b3bb-4472-bab2-5ae8b40b3d42">106</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ending balance</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i22b6851c4c8c4d8e9f955da168470856_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90YWJsZTpjMWFhYmY0MjQ1ZjM0MmFmYTgyYjBhN2NmYTZiNTJiYi90YWJsZXJhbmdlOmMxYWFiZjQyNDVmMzQyYWZhODJiMGE3Y2ZhNmI1MmJiXzUtMS0xLTEtMjI1NDU_032895f5-677f-4abb-aa87-0d33e8f91f6a">573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i2f9aa6708d66419390b7f00e52079f31_I20201231" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90YWJsZTpjMWFhYmY0MjQ1ZjM0MmFmYTgyYjBhN2NmYTZiNTJiYi90YWJsZXJhbmdlOmMxYWFiZjQyNDVmMzQyYWZhODJiMGE3Y2ZhNmI1MmJiXzUtMy0xLTEtMjI1NDU_619423e2-80b4-474f-a810-6f080694d028">672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></ix:continuation></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company rents office and laboratory space in Uniondale, New York from NovaPark under a lease that expires June 20, 2026. The Company recorded rent expense for fixed lease payments of $<ix:nonFraction unitRef="usd" contextRef="i35fe645b7bfa4fde8dbbbdd2b80db240_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzEwOTk1MTE2MzI1NjE_ec4dfe1a-87cd-4d05-9b00-6c5162469445">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8f44decd2d424510858c214c0073163a_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzIyNTM_7e935d79-1699-43cd-9a31-e5c53cca7d74">1.0</ix:nonFraction> million for the years ended December&#160;31, 2021 and 2020, respectively. The Company recorded rent expense for variable expenses related to the lease of $<ix:nonFraction unitRef="usd" contextRef="i35fe645b7bfa4fde8dbbbdd2b80db240_D20210101-20211231" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzIzNzQ_10e8d658-feeb-49f3-ba17-97ac1b9c84e7">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8f44decd2d424510858c214c0073163a_D20200101-20201231" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzIzODE_6c6110b7-f265-481c-8f37-0267aa040b3e">0.6</ix:nonFraction> million for the years ended December&#160;31, 2021 and 2020, respectively. See Note 11. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the IPO in February 2021, Victor Ganzi, Gilbert Omenn and Karen Wilson, directors of the Company, and Raj Venkatesan, brother of the Chief Executive Officer and director of the Company, converted all their outstanding convertible notes into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i917e433688284eaa953fc3c2fc1e1b85_D20210209-20210209" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzEwOTk1MTE2MzMxMjA_a2c8d186-57ba-4ae9-a202-25c6e15b0a74">149,500</ix:nonFraction> shares of common stock with a conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2962b55847164c55acf82150946c5fd6_I20210209" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzIxOTkwMjMyNjIzOTI_3fbcec91-6d55-47e4-a0ec-e5488047d0b4">11.57</ix:nonFraction>. As of December&#160;31, 2021, there were <ix:nonFraction unitRef="usd" contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231" decimals="INF" name="us-gaap:ConvertibleNotesPayableCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzIxOTkwMjMyNjIzNzY_1787f49a-fb01-4559-8176-c7acdb1ccbe5">no</ix:nonFraction> convertible notes outstanding.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series C Convertible Preferred Stock</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the IPO in February 2021, Jay Venkatesan, M.D., the President and Chief Executive Officer and director of the Company converted all his outstanding preferred stock into an aggregate of <ix:nonFraction unitRef="shares" contextRef="id1f12f1c81f2458db6d959e118e59154_I20210209" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzEwOTk1MTE2MzQ0OTA_b187e35d-d48d-4354-8b5b-44b0580b31b3">165,094</ix:nonFraction> shares of common stock with a conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iac7d715402754b8caf32b6a9c1cee1f7_I20210209" decimals="2" name="angn:ConvertiblePreferredStockConversionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzEwOTk1MTE2MzQ1MDA_9831a249-f149-44f2-b5f1-a8b56e44a49c">11.57</ix:nonFraction> per share. As of December&#160;31, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i60078b3a55804ab1887cc07c853ff6f7_I20211231" decimals="INF" name="us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzEwOTk1MTE2MzQ1MDQ_7845b10b-d38b-40e5-bd26-e4614ff0d940">no</ix:nonFraction> shares of convertible preferred stock outstanding.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consultant Fees</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Angion paid consulting fees under an agreement with the wife of the director and Chairman Emeritus of the Company for Company management services. Consultant fees paid to the wife were approximately <ix:nonFraction unitRef="usd" contextRef="i4f17b2c4422d42688d50097720558178_D20210101-20211231" decimals="INF" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzEwOTk1MTE2MzQ1MTU_419a4233-cfc5-443a-9ecc-8cbfd46b6e57">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ia5c69981108b4d979649ac7fc1b0e400_D20200101-20201231" decimals="-5" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzM4Mjk_83ad339b-e5ee-4add-8189-d95597fae025">0.1</ix:nonFraction> million in the years ended December&#160;31, 2021 and 2020, respectively. This consultant agreement was terminated in February 2022.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Dr. Michael Yamin, a former member of the Board of Directors of the Company, is a Scientific Advisor for Pearl Cohen Zedek Latzer Baratz LLP (Pearl Cohen). In the years ended December&#160;31, 2021 and 2020, the Company paid Pearl Cohen $<ix:nonFraction unitRef="usd" contextRef="ie9131c9ee7eb4cf68ebd482f734ab577_D20210101-20211231" decimals="-2" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzIxOTkwMjMyNjIzNjY_404bb027-a2f0-4038-a3a5-bea68d2f33fc">3.9</ix:nonFraction>&#160;thousand and $<ix:nonFraction unitRef="usd" contextRef="id853bebfd0c74da580bb31ede0e8af3e_D20200101-20201231" decimals="-5" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzMyOTg1MzQ4ODgwODg_acedfc5c-9c1a-4f51-a8c1-c3b7d80a23a5">0.1</ix:nonFraction>&#160;million in legal fees, respectively.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, the Company also entered into a consulting agreement with Dr. Yamin pursuant to which he agreed to provide consulting services to the Company in the areas of biomedical research and development. Pursuant to the terms of the consulting agreement, Dr. Yamin, in his capacity as a consultant, received $<ix:nonFraction unitRef="usd" contextRef="i30dc8694797e467d9c9068c898bcc9f8_D20200101-20201231" decimals="-5" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzQ0ODQ_2329ee74-de6c-49bd-be0b-baddd0acb84b"><ix:nonFraction unitRef="usd" contextRef="i5b7efeca53e04af18bee4dc3749aeaa9_D20210101-20211231" decimals="-5" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzQ0ODQ_a893c9d3-bf4e-45e2-92d5-e2ac98f6b9ed">0.1</ix:nonFraction></ix:nonFraction> million during each of the years ended December&#160;31, 2021 and 2020. Dr. Yamin resigned from the Company's Board of Directors in March 2020. Dr. Yamin's resignation was not due to any disagreement with the Company, the Board or management of the Company.</span></div></ix:continuation><div style="margin-top:3pt;text-indent:22.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><div id="idee3699378af4447a4091414c0adfaa7_154"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 16&#8212;<ix:nonNumeric contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNTQvZnJhZzoyYjM1NzUxNDc0MjQ0ZmY3OGNjNWEwOWI0ZWJjN2Q2Yy90ZXh0cmVnaW9uOjJiMzU3NTE0NzQyNDRmZjc4Y2M1YTA5YjRlYmM3ZDZjXzMyOTg1MzQ4ODk5MzE_f3c65b7d-688f-4ce6-8682-40ab266509da" continuedAt="i78dc109be91b4d8e9446e16f9f2f8c97" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="i78dc109be91b4d8e9446e16f9f2f8c97"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 4, 2022, the Company announced a reduction in force impacting somewhat less than half of its current employees. The Company&#8217;s decision to engage in this reduction resulted from an assessment of its internal resources needs, given the results of the Phase 3 study of ANG-3777 in patients at risk for DGF would likely not support a regulatory approval in that population and the Phase 2 study in CSA-AKI would not support a Phase 3 trial in that indication. This reduction was a cost-cutting measure across the organization to support the Company&#8217;s 2022 primary focus on the clinical development of its investigational asset ANG-3070, a highly selective, oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, particularly in the kidney and lung, as well as advancing preclinical assets to IND-enabling studies.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 25, 2022, the Company entered into a Separation Agreement with Itzhak D. Goldberg, M.D., who formerly served as Executive Chairman and Chief Scientific Officer and currently serves as a director and Chairman Emeritus on our Board.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the terms of the Separation Agreement, Dr. Goldberg will receive severance benefits of approximately $<ix:nonFraction unitRef="usd" contextRef="i8f608066967d490d9002d2bb0340bdf8_I20220225" decimals="-5" name="us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNTQvZnJhZzoyYjM1NzUxNDc0MjQ0ZmY3OGNjNWEwOWI0ZWJjN2Q2Yy90ZXh0cmVnaW9uOjJiMzU3NTE0NzQyNDRmZjc4Y2M1YTA5YjRlYmM3ZDZjXzIxOTkwMjMyOTA2ODQ_3a49017c-1258-49d9-ac73-38be240e68ca">1.1</ix:nonFraction>&#160;million. Under our Amended and Second Restated 2015 Equity Incentive Plan and our 2021 Incentive Award Plan, Dr. Goldberg will continue to vest his PSUs and stock options and exercisability of his options, so long as he remains in continuous service with the Company as a director on the Board or otherwise. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 1, 2022, the Company entered into a Separation Agreement with Elisha Goldberg, former employee and son of Itzhak D. Goldberg, M.D., who currently serves as a director and Chairman Emeritus on the Company&#8217;s Board.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the terms of the Separation Agreement, Mr. Goldberg will receive severance benefits of approximately $<ix:nonFraction unitRef="usd" contextRef="ie6b23068ffab46b0a0c550ea36e51385_I20220301" decimals="-5" name="us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNTQvZnJhZzoyYjM1NzUxNDc0MjQ0ZmY3OGNjNWEwOWI0ZWJjN2Q2Yy90ZXh0cmVnaW9uOjJiMzU3NTE0NzQyNDRmZjc4Y2M1YTA5YjRlYmM3ZDZjXzIxOTkwMjMyOTA2NTY_189b2981-0bae-4d02-bbbe-d01beac98f33">0.5</ix:nonFraction>&#160;million. Mr. Goldberg will also have the right to exercise any vested stock options he may have received under our Amended and Second Restated 2015 Equity Incentive Plan or our 2021 Incentive Award Plan until December 31, 2022, which extended the exercise period by <ix:nonNumeric contextRef="i405a2449e3304874876b5c7f79fa0336_D20220301-20220301" name="angn:ShareBasedPaymentArrangementPlanModificationExtendedExercisePeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNTQvZnJhZzoyYjM1NzUxNDc0MjQ0ZmY3OGNjNWEwOWI0ZWJjN2Q2Yy90ZXh0cmVnaW9uOjJiMzU3NTE0NzQyNDRmZjc4Y2M1YTA5YjRlYmM3ZDZjXzIxOTkwMjMyOTA2Njk_94b4945b-ee05-465a-b3f4-bc4d377468e9">11</ix:nonNumeric> months.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><div id="idee3699378af4447a4091414c0adfaa7_157"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="idee3699378af4447a4091414c0adfaa7_160"></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our President and Chief Executive Officer and our Chief Financial Officer, our principal executive officer and principal accounting and financial officer, respectively, have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of December 31, 2021.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our President and Chief Executive Officer and our Chief Financial Officer, to allow timely decisions regarding required disclosure. Based on the evaluation of our disclosure controls and procedures, our President and Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of December 31, 2021 due to the material weaknesses in our internal control over financial reporting described below. In light of this fact, our management has performed additional analyses, reconciliations, and other post-closing procedures and has concluded that, notwithstanding the material weaknesses in our internal control over financial reporting, the consolidated financial statements for the periods covered by and included in this Annual Report on Form 10-K fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented in conformity with U.S. GAAP.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the changes in connection with the ongoing remediation of the previously identified material weakness discussed below, there has been no change in our internal control over financial reporting during the year ended December 31, 2021, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the preparation of our consolidated financial statements, we identified control deficiencies in the design and operation of our internal control over financial reporting that constituted material weaknesses. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The material weaknesses identified in our internal control over financial reporting related to (i) insufficient resources with knowledge and expertise in U.S. GAAP to properly evaluate certain complex transactions, including debt instruments and equity instruments; and (ii) insufficient financial reporting and close controls to ensure that incurred expenses are accrued at period end and deliverables from third party contractors are reviewed for accuracy. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, we took a number of actions to remediate these material weaknesses, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">engaging SEC compliance and technical accounting consultants to assist in evaluating transactions for conformity with U.S. GAAP;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hiring additional finance and accounting personnel to augment accounting staff and to provide more resources for complex accounting matters and financial reporting; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strengthening our financial reporting and close relating to incurred expenses by ensuring our data capture procedures are clearly defined and that responsible personnel, including supervisory personnel, have adequate training regarding the process and expectation.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are still in the process of implementing these controls. We intend to continue to take steps to remediate the material weaknesses through formalizing documentation of policies and procedures and further evolving our accounting processes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe that these efforts will improve our internal control over financial reporting, the design and implementation of our remediation is ongoing and will require validation and testing of the design and operating effectiveness of our internal controls over a sustained period of financial reporting cycles. The actions that we are taking are subject to ongoing senior management review, as well as audit committee oversight. We will not be able to conclude whether the steps we are taking will fully remediate the material weaknesses in our internal control over financial reporting until we have completed our remediation efforts and subsequent evaluation of their effectiveness.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2021. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013 framework). Based on our assessment, management concluded our internal control over financial reporting was not effective as of December 31, 2021, based on the COSO criteria, due to the existence of the material weaknesses.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitation on the Effectiveness Over Financial Reporting</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of any system of internal control over financial reporting, including ours, is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct completely. Accordingly, any system of internal control over financial reporting, including ours, no matter how well designed and operated, can only provide reasonable, not absolute assurances. In addition, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. We intend to continue to monitor and upgrade our internal controls as necessary or appropriate for our business, but there can be no assurance that such improvements will be sufficient to provide us with effective internal control over financial reporting.</span></div><div id="idee3699378af4447a4091414c0adfaa7_163"></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span><br/></span></div><div id="idee3699378af4447a4091414c0adfaa7_525"></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><div id="idee3699378af4447a4091414c0adfaa7_166"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part III</span></div><div id="idee3699378af4447a4091414c0adfaa7_169"></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance </span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Officers</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information regarding our executive officers and directors as of March 1, 2022:</span></div><div style="margin-top:10pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.251%"><tr><td style="width:1.0%"></td><td style="width:45.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.774%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.851%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Age</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Position(s)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Executive Officers and Employee Directors:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jay R. Venkatesan, M.D. </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">President and Chief Executive Officer and Chairman of the Board </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">John F. Neylan, M.D. </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Executive Vice President, Chief Medical Officer and Head of Research</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jennifer J. Rhodes, J.D. </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Executive Vice President, Chief Business Officer, General Counsel, Chief Compliance Officer and Corporate Secretary</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gregory S. Curhan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Employee Directors:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Victor F. Ganzi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)(2)(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Director, Lead Independent Director</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Itzhak D. Goldberg, M.D.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director and Chairman Emeritus</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allen R. Nissenson, M.D.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)(2)(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gilbert S. Omenn, M.D., Ph.D.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)(2)(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Karen J. Wilson</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)(2)(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">________________________</span></div><div style="margin-top:1pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Member of the audit committee.</span></div><div style="margin-top:1pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Member of the compensation committee.</span></div><div style="margin-top:1pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Member of the nominating and corporate governance committee.</span></div><div style="padding-left:31.5pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">          (4) Dr. Goldberg resigned his employment  in February 2022 and no longer serves as an Executive Officer of Angion. Dr. Goldberg continues to serve as a Director and Chairman Emeritus.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Executive Officers and Employee Directors</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Jay R. Venkatesan, M.D., President, Chief Executive Officer and Chairman</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.    Dr. Venkatesan was appointed Chairman of the Board in January 2022, and he has been our President and Chief Executive Officer and director since May 2018. Dr. Venkatesan has served as a Managing Partner of Alpine BioVentures, an investment firm, since July 2015. From July 2015 to August 2018, Dr. Venkatesan served as President of Alpine Immune Sciences, an immunotherapy company that he co-founded as a Managing Partner of Alpine BioVentures, and also served as its Chief Executive Officer from July 2015 to June 2016. Additionally, as Managing Partner of Alpine BioVentures, from January 2014 to August 2014, Dr. Venkatesan served as Founder and Chief Executive Officer of Alpine BioSciences, a biotechnology company, which was acquired by Cascadian Therapeutics, where he then served as Executive Vice President and General Manager from August 2014 to May 2015 (subsequently acquired by Seagen, Inc.). Since January 2008, Dr. Venkatesan has served as the founder and managing member of Ayer Capital, a global healthcare fund. Prior to that, he served as a director at Brookside Capital, part of Bain Capital, where he co-managed healthcare investments. He was also a consultant at McKinsey &amp; Co., a consulting firm, and a venture investor with Patricof &amp; Co. Ventures (now Apax Partners), an investment firm. Dr. Venkatesan has served on the board, of Alpine Immune Sciences, Inc. (Nasdaq: ALPN) since June 2015. Dr. Venkatesan previously served on the board of Exicure Inc. (Nasdaq: XCUR) from March 2014 to December 2020 and Iovance Biotherapeutics Inc. (Nasdaq: IOVA) from September 2013 to March 2018. He has an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School of the University of Pennsylvania, and a B.A. from Williams College. We believe that Dr. Venkatesan's leadership experience and investment experience in the biopharmaceutical industry qualify him to serve as a member of our board of directors.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">      </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">  John F. Neylan, M.D.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">    Dr. Neylan was appointed Executive Vice President and Head of Research in March 2022, and he has served as our Chief Medical Officer since December 2018. From April 2015 to December 2018, Dr. Neylan served as Chief Medical Officer of Keryx, a biopharmaceutical company focused on nephrology. From May 2008 to April 2015, Dr. Neylan served as Senior Vice President, Clinical Development, at Genzyme </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Corporation, a biopharmaceutical company focusing on specialty metabolic diseases. From 2000 to 2008, Dr. Neylan served as Vice President, Research and Development for Wyeth Research, a pharmaceutical company, overseeing the clinical development of transplantation therapeutics and providing medical affairs support to the transplant franchise. Dr. Neylan has also held prestigious positions in academia, including Professor of Medicine at Emory University and Assistant Professor of Medicine at University of California, Davis, serving at both institutions as Medical Director of the respective Renal Transplant Programs, with oversight of the clinical research programs. Dr. Neylan has a B.S. from Duke University and an M.D. from Rush Medical School in Chicago. He completed his Internal Medicine residency at Vanderbilt University and fellowships in Nephrology and in Transplantation and Immunogenetics at Brigham and Women's Hospital, Harvard University. He was formerly the President of the American Society of Transplantation, past Board Member of the National Kidney Foundation and a past Industry Representative on the FDA Cardiovascular and Renal Drugs Advisory Committee.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">        </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Jennifer J. Rhodes, J.D. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">   Ms. Rhodes was appointed Executive Vice President and Chief Business Officer in March 2022 and she has served as, General Counsel, Chief Compliance Officer and Corporate Secretary since January 2020. In February 2019, Ms. Rhodes also became a director of Legal Aid at Work, a non-profit legal services organization. Ms. Rhodes previously served as General Counsel and Corporate Secretary at Adamas Pharmaceuticals, Inc., a public pharmaceutical company, from April 2016 until January 2020, during which time she also served as Chief Compliance Officer since August 2016 and Chief Business Officer since January 2017. Prior to that, Ms. Rhodes served as General Counsel at Medivation, Inc., a biopharmaceutical company, from June 2012 to September 2015, where she was responsible for Medivation's legal matters, and also served as Corporate Secretary from April 2013 to September 2015 and as Chief Compliance Officer from July 2012 to October 2014. From May 2006 to June 2012, Ms. Rhodes was an Assistant General Counsel at Pfizer Inc., a biopharmaceutical company, where she supported the U.S. Primary Care Business and its Primary Care Medicines Development Group and served as a global product lead for Pfizer Inc.'s primary care medicines. Prior to joining Pfizer Inc., she was an associate in the regulatory law and international trade practice areas at Weil, Gotshal &amp; Manges, LLP from October 2000 to April 2006. Ms. Rhodes has a J.D. from Wake Forest University School of Law and a B.A. in Economics from Newcomb College of Tulane University.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gregory S. Curhan. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Mr. Curhan has served as our Chief Financial Officer since June 2020 through his capacity as a partner at FLG Partners, LLC (FLG Partners), a Silicon Valley chief financial officer services firm. Prior to joining FLG Partners, LLC, Mr. Curhan was Chief Financial Officer and Senior Vice President Corporate Development of Providence Medical Technology, a venture-backed medical device manufacturer, December 2016 until January 2020. Prior to that, Mr. Curhan was a Business Development Officer at Brighton Jones, a financial planning company, from December 2012 to December 2016. Mr. Curhan has a B.A. in Economics from Dartmouth College.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Employee Directors</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">     </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">  </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">   Victor F. Ganzi.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Mr. Ganzi has been a member of our board of directors since April 2018, and lead independent director since February 2021. He has served as Non-Executive Chairman of the board of directors of Willis Towers Watson (Nasdaq: WTW), a global advisory, broking and solutions company, since January 2019 and as a director since January 2016. Previously, he served as a director of Towers Watson beginning on January 1, 2010, as Chairman of Towers Watson's Audit Committee, and a member of its Nominating and Governance Committee. Mr. Ganzi is presently a consultant and corporate director, serving on the public company board of Aveanna Healthcare Holdings Inc., a provider of pediatric and adult home healthcare and hospice care since 2016, and serving on the boards of numerous private and not-for-profit organizations, including PGA Tour, Inc., the Partnership to End Addiction, the Whitney Museum of American Art and the Madison Square Boys and Girls Club. Mr. Ganzi was the President and Chief Executive Officer of The Hearst Corporation, a private diversified communications company, from 2002 to 2008. He served as Hearst's Executive Vice President from 1997 to 2002 and as its Chief Operating Officer from 1998 to 2002. Prior to joining Hearst in 1990, Mr. Ganzi was the managing partner at the international law firm of Rogers &amp; Wells (now part of Clifford Chance). Mr. Ganzi previously served as a director of Gentiva Health Services, Inc., Wyeth and Hearst-Argyle Television, Inc. Mr. Ganzi has a B.S. in Accounting summa cum laude, from Fordham University, a J.D. from Harvard Law School and an L.L.M. in Taxation from New York University. We believe that Mr. Ganzi's years of experience serving on boards and legal expertise qualify him to serve as a member of our board of directors.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">     </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">   Itzhak D. Goldberg, M.D., </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Goldberg was appointed Chairman Emeritus in January 2022, after having been a director and Chairman of the Board since March 2018.  Dr. Goldberg also served as Executive Chairman and Chief Scientific Officer between March 2018 and March 2022,  after serving as our Chairman, President, Chief Executive Officer and Scientific Director since our founding in April 1998. Dr. Goldberg was formerly a faculty </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">member at Harvard Medical School, Radiation Oncologist-in-Chief for the North Shore-LIJ (Northwell) Health System, and Professor at the Albert Einstein College of Medicine. He is a Fellow of the American College of Radiology. Dr. Goldberg has an M.D. from Albert Einstein College of Medicine, was a postdoctoral research fellow at Harvard Medical School and was subsequently trained as a radiation oncologist at the Harvard Joint Center for Radiation Therapy. We believe that Dr. Goldberg's extensive experience in the biopharmaceutical industry qualifies him to serve as a member of our board of directors.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allen R. Nissenson, M.D. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Dr. Nissenson has been a member of our board of directors since January 2020. He completed serving as the Emeritus</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Medical Officer of DaVita Kidney Care in January 2022, where he has served since January 2020 and where he previously served as Chief Medical Officer from August 2008 to January 2020. He is currently an Emeritus Professor of Medicine at the David Geffen School of Medicine at UCLA, where he has served since August 2008 and where he previously served as Director of the Dialysis Program from July 1977 to August 2008 and Associate Dean from July 2005 to August 2008. Dr. Nissenson is also currently on the board of directors of Rockwell Medical Inc., a public biopharmaceutical company, which he joined in June 2020 and Diality, a private technology development company. Dr. Nissenson is a past chair of Kidney Care Partners and past co-chair of the Kidney Care Quality Alliance. He is a former president of the Renal Physicians Association (RPA) and current member of the Government Affairs Committee. Dr. Nissenson also previously served as president of the Southern California End-Stage Renal Disease Network, as well as chair of the Medical Review Board. He served as a Robert Wood Johnson Health Policy Fellow of the National Academy of Medicine from 1994 to 1995 and worked in the office of the late Senator Paul Wellstone. Dr. Nissenson has an M.D. from Northwestern University Medical School and is the recipient of various awards, including the President's Award of the National Kidney Foundation, the Lifetime Achievement Award in Hemodialysis, the American Association of Kidney Patients' (AAKP) Medal of Excellence Award and, in 2017, the RPA Distinguished Nephrology Service Award. We believe that Dr. Nissenson's years of experience in the healthcare industry qualify him to serve as a member of our board of directors</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">        Gilbert S. Omenn, M.D., Ph.D.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    Dr. Omenn has been a member of our board of directors since January 2020. Since 1997, Dr. Omenn has</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">been a faculty member at the University of Michigan, where he is currently the Harold T. Shapiro Distinguished University Professor of Computational Medicine &amp; Bioinformatics, Internal Medicine, Human Genetics, and Public Health. Earlier, he was the dean of the School of Public Health and Community Medicine and professor of medicine at the University of Washington. Dr. Omenn served as Executive Vice President for Medical Affairs of the University of Michigan and as Chief Executive Officer of the University of Michigan Health System from 1997 to 2002.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From 1977 to 1981 he was associate director of the White House Office of Science &amp; Technology Policy and then the Office of Management &amp; Budget. Dr. Omenn is a member of the National Academy of Medicine and the American Academy of Arts and Sciences. He chaired the Presidential/Congressional Commission on Risk Assessment and Risk Management, the NAS/NAE/IOM Committee on Science, Engineering, and Public Policy, and the Advisory Committee for the Agency for Toxic Substances and Disease Registry. He served on the National Commission on the Environment, the NIH Scientific Management Review Board, and the CDC Director's Advisory Committee. He is a past president of the American Association for the Advancement of Science.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2014, Dr. Omenn has served as a director of Galectin Therapeutics Inc., a biotechnology company (Nasdaq: GALT), and since 2020 as a director of Amesite Inc, an AI-based educational technology company (Nasdaq: AMST). Dr. Omenn previously served as a director of Amgen, Inc. for 27 years and Rohm &amp; Haas Company for 22 years. Dr. Omenn was a director of Esperion Therapeutics (Nasdaq: ESPR) from August 2014 to May 2018. He is a director of the Hastings Center for Bioethics and the Center for Public Integrity. Dr. Omenn has a B.A. summa cum laude from Princeton University, M.D. magna cum laude from Harvard Medical School and Ph.D. in genetics from the University of Washington. We believe that Dr. Omenn's years of experience in the healthcare industry qualify him to serve as a member of our board of directors. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Karen J. Wilson</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.    Ms. Wilson has been a member of our board of directors since April 2020. Ms. Wilson is also currently a member of the boards of directors of Connect Biopharma, LAVA Therapeutics and Vaxart, Inc. Ms. Wilson previously served as Senior Vice President of Finance at Jazz Pharmaceuticals plc, a biopharmaceutical company, until September 2020 after serving as Principal Accounting Officer and Vice President of Finance. Prior to joining the Jazz Pharmaceuticals organization in February 2011, she served as Principal Accounting Officer and Vice President of Finance at PDL BioPharma, Inc., a life sciences company. She also previously served as a Principal at the consulting firm of Wilson Crisler LLC, Chief Financial Officer of ViroLogic, Inc., a biosciences company, Chief Financial Officer and Vice President of Operations for Novare Surgical Systems, Inc., a medical device manufacturer, and as a consultant and auditor for Deloitte &amp; Touche LLP, a professional services firm. Ms. Wilson is a Certified Public Accountant and received a B.S. in Business from the University of California, Berkeley. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that Ms. Wilson is qualified to serve on our Board due to her extensive background in financial and accounting matters for public companies and her leadership experience in the life science industry.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Delinquent Section 16(a) Reports </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 16(a) of the Exchange Act requires our directors, executive officers, and persons holding more than 10% of our common stock to report their initial ownership of the common stock and other equity securities and any changes in that ownership in reports that must be filed with the SEC. The SEC has designated specific deadlines for these reports, and we must identify in our Annual Report on Form 10-K those persons who did not file these reports when due.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We filed reports on behalf of our directors, executive officers and 10% holders during the year ended December 31, 2021. Such reports were filed consistent with the reporting obligations of Section 16(a) of the Exchange Act, except that untimely reports were filed on behalf of Dr. Goldberg and Dr. Venkatesan on November 17, 2021 and December 17, 2021, respectively, reporting the shares that were withheld to satisfy tax or other government withholding obligations in connection with the vesting of PSUs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Audit Committee</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit committee oversees our corporate accounting and financial reporting process. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The members of our audit committee are Karen Wilson, Victor Ganzi, Allen Nissenson and Gilbert Omenn. Ms. Wilson serves as the chairperson of the committee. All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and The Nasdaq Stock Market. Our board of directors has determined that Ms. Wilson is an audit committee financial expert as defined under the applicable rules of the SEC and has the requisite financial sophistication as defined under the applicable rules and regulations of The Nasdaq Stock Market. Under the rules of the SEC, members of the audit committee must also meet heightened independence standards. Our board of directors has determined that each of Ms. Wilson, Mr. Ganzi, Dr. Nissenson and Dr. Omenn are independent under the applicable rules of the SEC and The Nasdaq Stock Market. The audit committee operates under a written charter that satisfies the applicable standards of the SEC and The Nasdaq Stock Market.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Procedures by Which Security holders May Recommend Nominees to the Board of Directors</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Nominating and Corporate Governance Committee of the Board has adopted procedures for considering director candidates recommended by stockholders. Stockholders who wish to recommend individuals for consideration by the Committee as candidates for potential election by the Board as directors, can deliver a written recommendation to the Corporate at Angion Biomedica Corp., 51 Charles Lindbergh Boulevard, Uniondale, New York 11553, at least 120 days prior to the anniversary date of the mailing of the proxy statement for the last annual meeting of stockholders and must include the following information:  name and address of the nominating stockholder;  a representation that the nominating stockholder is a record holder; a representation that the nominating stockholder intends to appear in person or by proxy at the annual meeting to nominate the person or persons specified; information regarding each nominee that would be required to be included in a proxy statement; a description of any arrangements or understandings between the nominating stockholder and the nominee; and the consent of each nominee to serve as a director, if elected.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Nominating and Corporate Governance Committee will evaluate candidates recommended by a stockholder in the same manner as candidates identified any other person, including members of the Board. </span></div><div><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Business Conduct and Ethics</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of directors has adopted a code of business conduct and ethics that applies to all of our employees, officers and directors, including those officers responsible for financial reporting. The code of business conduct and ethics is available on our website. We intend that any amendments to the code, or any waivers of its requirements, will be disclosed on our website.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><div id="idee3699378af4447a4091414c0adfaa7_172"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a discussion and analysis of compensation arrangements of our named executive officers (NEOs). This discussion contains forward looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. Actual compensation programs that we adopt may differ materially from currently planned programs as summarized in this discussion. As an &#8220;emerging growth company&#8221; as defined in the JOBS Act, we are not required to include a Compensation Discussion and Analysis section and have elected to comply with the scaled disclosure requirements applicable to emerging growth companies.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to ensure that the total compensation paid to our executive officers is reasonable and competitive. Compensation of our executives is structured around the achievement of individual performance and near-term corporate targets as well as long-term business objectives.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our NEOs for fiscal year 2021 were as follows:</span></div><div style="margin-top:10pt;padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.88pt">Jay R. Venkatesan, M.D., President and Chief Executive Officer and Chairman of the Board</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.88pt">Itzhak Goldberg, Director and Chairman Emeritus</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">(2) </span></div><div style="padding-left:63pt;text-indent:-28.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.26pt">John Neylan, Executive  Vice President, Chief Medical Officer and Head of Research</span></div><div style="padding-left:27pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________</span></div><div style="padding-left:27pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(1) Dr. Venkatesan was appointed Chairman of the Board in January 2022.</span></div><div style="padding-left:27pt;text-indent:-10.8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(2) After serving as Executive Chairman and Chief Scientific Officer for Angion during the year ended December 31, 2021. Dr. Goldberg </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:112%;position:relative;top:-4.2pt;vertical-align:baseline">resigned his employment in February 2022, and no longer serves as an Executive Officer of Angion.</span></div><div><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 Summary Compensation Table</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth total compensation paid to our NEOs for the fiscal year ending on December 31, 2021 and, with respect to Dr. Venkatesan, 2020. Neither Dr. Goldberg or Dr. Neylan were named executive officers in 2020 and, accordingly, their compensation for 2020 is omitted.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.046%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Name and Principal Position</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Year</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Salary </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">($)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Bonus</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">($)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Option Awards</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"> ($)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">($)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Jay R. Venkatesan, M.D., President and Chief Executive Officer and Chairman of the Board</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(4) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">587,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">1,952,099&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">2,539,199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">570,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">194,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">629,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">1,394,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Itzhak D. Goldberg, M.D.,</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Executive Chairman and Chief Scientific Officer</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(5) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">484,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">763,863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">1,247,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">John F. Neylan, M.D., </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Executive Vice President, Chief Medical Officer and Head of Research </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(6) </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">468,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">763,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">1,232,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">___________________________________</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.24pt">The bonus column includes discretionary annual bonuses paid to each of our NEOs in connection with their service in the applicable fiscal year. For fiscal year 2020, the bonuses were paid in March 2021. Please see the descriptions of the bonuses paid to our NEOs under "2021 Bonuses" below, including target amounts for the discretionary annual bonuses. </span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.24pt">Amounts shown represents the grant date fair value of options granted as calculated in accordance with ASC Topic 718. See Note 2 of the financial statements included in this Annual Report on Form 10-K for the assumptions used in calculating this amount. </span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.24pt">NEOs received no compensation other than salaries, bonuses, and stock option awards. </span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.24pt">Dr. Venkatesan was appointed Chairman of the Board in January 2022.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.24pt">After serving as Executive Chairman and Chief Scientific Officer for Angion during the year ended December 31, 2021, Dr. Goldberg resigned his employment in February 2022, and no longer serves as an Executive Officer of Angion. Dr. Goldberg continues to serve as a Director and Chairman Emeritus. </span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.24pt">Dr. Neylan was appointed Executive Vice President and Head of Research in March 2022, and continues to serve as Chief Medical Officer.</span></div><div style="text-indent:-9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Narrative to Summary Compensation Table</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Salaries</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our NEOs each receive a base salary to compensate them for services rendered to our company. The base salary payable to each named executive officer is intended to provide a fixed component of compensation reflecting the executive's skill set, experience, role and responsibilities. Dr. Venkatesan's base salary in 2020 was $570,000 and was increased to $587,100, effective as of January 1, 2021. Dr. Venkatesan current annual salary, effective January 1, 2022 is $608,000. Dr. Goldberg's base salary in 2020 was $469,920 and was increased in 2021 to $484,018, effective as of January 1, 2021. Dr. Goldberg is no longer employed by Angion. Dr. Neylan's base salary in 2020 was $455,000 and was increased to $468,650, effective as of January 1, 2021. Dr. Neylan&#8217;s current annual salary, effective January 1, 2022, is $485,100. Our board of directors and compensation committee may adjust base salaries from time to time in their discretion.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Bonuses</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our NEOs did not receive a 2021 discretionary cash bonus. We paid each of our NEOs a discretionary cash bonus in 2021 in connection with their contributions to Angion in 2020, based upon their bonus targets, or 50%, 40% and 40% of Dr. Venkatesan's, Dr. Goldberg&#8217;s and Dr. Neylan's base salary, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity-Based Compensation</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we granted each of Dr. Venkatesan, Dr. Goldberg and Dr. Neylan an option to purchase 178,920, 70,012 and 70,012 shares of our common stock, respectively, under our 2021 Incentive Award Plan (the &#8220;2021 Plan&#8221;). Each of Dr. Venkatesan's, Dr. Goldberg&#8217;s and Dr. Neylan&#8217;s options vest as to 1/48th of the shares subject to the option on each monthly anniversary of February 5, 2021, subject to the applicable NEO being employed or in continuous service to us as defined in the 2021 Plan through such vesting date. Upon our IPO in February 2021, Dr. Venkatesan&#8217;s and Dr. Goldberg&#8217;s performance-based restricted stock units (PSUs) met the performance condition, an initial public offering as defined in the Amended and Second Restated 2015 Equity Award Plan (the &#8220;2015 Plan&#8221;). Accordingly, the vesting of such PSUs in three equal parts, with the first part vesting commenced upon the IPO in February 2021, the second part vesting for each Dr. Venkatesan and Dr. Goldberg on June 24, 2021, and the third part to vest for each on June 24, 2022. As of December 31, 2021, 371,020 PSUs have been vested. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Elements of Compensation</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Retirement Savings and Health and Welfare Benefits</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, we implemented a 401(k) Retirement Savings Program through a third-party provider. Our NEOs are eligible to participate our 401(k) Program on the same terms as other full-time employees. We match 100% of the first 3% of a participant's annual eligible contributions to their 401(k) plan, and 50% of annual eligible contribution between 3% and 5%.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We terminated our simple IRA plan for our employees, including our named executive officers, who satisfy certain eligibility requirements on December 31, 2020.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that providing a vehicle for tax-deferred retirement savings though 401(k) Plan and our former simple IRA plan adds to the overall desirability of our executive compensation package and further incentivizes our employees, including our NEOs, in accordance with our compensation policies.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our full-time employees, including our NEOs, are eligible to participate in our health and welfare plans, including medical, dental and vision benefits; short-term and long-term disability insurance; and life and AD&amp;D insurance.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Perquisites and Other Personal Benefits</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine perquisites on a case-by-case basis and will provide a perquisite to an NEO when we believe it is necessary to attract or retain the NEO. In 2021 and 2020, we did not provide any perquisites or personal benefits to our NEOs not otherwise made available to our other employees.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding Equity Awards at 2021 Fiscal Year End</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table lists all outstanding equity awards held by our NEOs as of December 31, 2021.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Option Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Stock Awards</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Vesting</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Commencement Date</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Number <br/>of <br/>Securities <br/>Underlying Unexercised <br/>Options <br/>Exercisable <br/>(#)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Number <br/>of <br/>Securities <br/>Underlying Unexercised <br/>Options Unexercisable <br/>(#)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Option <br/>Exercise <br/>Price <br/>($)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Option <br/>Expiration <br/>Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Number <br/>of Shares <br/>that <br/>Have Not <br/>Vested <br/>(#)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Market </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Value of </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Shares or </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Units of </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Shares </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">that Have </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Not Vested </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">($)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:4.55pt;font-weight:700;line-height:115%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Jay R. Venkatesan, M.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">5/1/2018 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">934,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">5.89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">5/1/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">6/24/2019 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">6/24/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">92,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">268,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">6/18/2020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">46,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">77,792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">7.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">6/17/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">2/5/2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">37,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">141,645&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">16.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">2/4/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Itzhak Goldberg</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">12/19/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">40,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">6.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">1/21/2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">6/24/2019 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">6/24/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">92,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">268,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">6/18/2020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">23,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">38,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">7.77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">6/17/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">2/5/2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">14,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">55,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">16.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">2/4/2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">John Neylan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">12/17/2018 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">116,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">6.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">12/18/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">6/18/2020</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">35,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">58,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">7.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">8/30/2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">2/5/2021</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">14,585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">55,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">16.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">12/8/2030</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">___________________________________</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.24pt">Except as otherwise noted, options and stock awards vest as to 1/48th of the shares subject to the award on each monthly anniversary of the vesting commencement date, subject to the holder's continued service to Angion through each vesting date.</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.24pt">The market value of shares that have not vested is calculated based on the fair market value of our common stock as of December 31, 2021.</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.24pt">The stock option vests as to 25% of the shares on the vesting commencement date and thereafter 10% of the shares vest on each quarterly anniversary, subject to Dr. Venkatesan's continued service to us through such vesting date; provided that an additional 25% of the shares can vest if certain financing goals are achieved.</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.24pt">The non-market performance and service conditions based restricted stock units (PSUs) vest upon the occurrence of two vesting conditions, which must be achieved within seven years from the date of grant, a service vesting condition (the Service-Based Requirement) and a liquidity event requirement (the Liquidity Event Requirement). The Liquidity Event Requirement will be satisfied as to any then-outstanding RSUs that have not terminated earlier on the first to occur of (i) a change in control of Angion or (ii) the six month anniversary of or, if earlier, March 15 of the year following an initial public offering of Angion. The PSUs condition was met upon the closing of our IPO in February 2021. Accordingly, the PSUs vest in three equal parts, with the first part vesting commenced upon the IPO in February 2021, the second part vested on June 24, 2021, and the third part to vest on June 24, 2022. As of December 31, 2021, 371,020 PSUs have been vested. </span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.24pt">The stock option shall vest as to 25% of the shares on the first anniversary of the vesting commencement date and vest as to the remaining 75% of the shares in 24 substantially equal monthly installments thereafter, such that all awards will be vested on the third year anniversary of the vesting commencement date, subject to the holder's continued service to Angion through such vesting date.</span></div><div style="text-indent:-9pt"><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Compensation Arrangements</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously entered into offer letter agreements with each of our named executive officers in connection with his or her employment with us. These agreements set forth the terms and conditions of employment of each named executive officer, including initial base salary, equity grants and employee benefits eligibility.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Severance Plan</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our IPO, we entered into new severance and change in control plan that covers all of our NEOs that supersedes and replaces the severance benefits they would otherwise be entitled to receive. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our severance plan that encompasses each of our NEOs, if such NEO's employment with us is terminated without "cause" or such NEO resigns for "good reason" (as each is defined in the severance plan), the applicable NEO will be entitled to receive: (i) nine months of continued base salary (or 12 months for Dr. Venkatesan) and (ii) payment or reimbursement of the cost of continued healthcare coverage for nine months (or 12 months for Dr. Venkatesan). In lieu of the foregoing benefits, if each NEO's employment with us is terminated without "cause" or such NEO resigns for "good reason" during the 12-month period following a Change in Control (as defined in the 2021 Plan), the applicable NEO will be entitled to receive: (i) 12 months of continued base salary (or 18 months for Dr. Venkatesan), (ii) payment or reimbursement of the cost of continued healthcare coverage for 12 months (or 18 months for Dr. Venkatesan), (iii) an amount equal to 12 months of such NEO's annual bonus for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the year of termination assuming 100% of target performance (or 18 months for Dr. Venkatesan) and (iv) full accelerated vesting of any of unvested equity awards (except for any performance awards). The foregoing severance benefits are subject to the applicable NEO's delivery of an executed release of claims against us and continued compliance with the NEO's confidentiality obligations under the severance plan.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until February 28, 2022, Dr. Goldberg had separate severance arrangements with us set forth in his Employment Agreement with us dated May 1, 2018, providing him severance pay, annual bonus payments and COBRA reimbursements for eighteen (18) months for any termination without &#8220;cause&#8221;, resignation for &#8220;good reason&#8221;, or &#8220;change of control&#8221; as defined by his Employment Agreement. On February 25, 2022, we and Dr. Goldberg entered into a Separation Agreement on such terms.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Director</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Compensation</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We approved a compensation policy for our non-employee directors (Director Compensation Program) that became effective in connection with the consummation of the IPO in February 2021 and is subject to amendment by the board of directors as appropriate. Pursuant to the Director Compensation Program, our non-employee directors receive cash compensation as follows:</span></div><div><span><br/></span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Each non-employee director will receive an annual cash retainer in the amount of $40,000 per year.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Non-Executive Chairperson will receive an additional annual cash retainer in the amount of $35,000 per year.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The lead non-employee director will receive an additional annual cash retained in the amount of $20,000 per year.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The chairperson of the audit committee will receive additional annual cash compensation in the amount of $15,000 per year for such chairperson's service on the audit committee. Each non-chairperson member of the audit committee will receive additional annual cash compensation in the amount of $7,500 per year for such member's service on the audit committee.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The chairperson of the compensation committee will receive additional annual cash compensation in the amount of $10,000 per year for such chairperson's service on the compensation committee. Each non-chairperson member of the compensation committee will receive additional annual cash compensation in the amount of $5,000 per year for such member's service on the compensation committee.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The chairperson of the nominating and corporate governance committee will receive additional annual cash compensation in the amount of $8,000 per year for such chairperson's service on the nominating and corporate governance committee. Each non-chairperson member of the nominating and corporate governance committee will receive additional annual cash compensation in the amount of $5,000 per year for such member's service on the nominating and corporate governance committee.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Under the Director Compensation Program, as amended by the board of directors on March 8, 2021, each non-employee director will automatically be granted an option to purchase 30,000 shares of our common stock upon the director's initial appointment or election to our board of directors (Initial Grant) and an option to purchase 15,000 shares of our common stock automatically on the date of each annual stockholder's meeting thereafter, (Annual Grant), unless otherwise approved by the Board. The Initial Grant will vest as to 1/36th of the underlying shares on a monthly basis over three years, subject to continued service through each applicable vesting date. The Annual Grant will vest on the earlier of the first anniversary of the date of grant or the date of the next annual stockholder's meeting to the extent unvested as of such date, subject to continued service through each applicable vesting date. The exercise price per share of director options is equal to the fair market value of a share of our common stock on the grant date, and the director options will vest in full upon (i) a termination of service due to the director's death or Disability (as defined in the 2021 Plan) and (ii) the consummation of a Change in Control (as defined in the 2021 Plan).</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information concerning the compensation earned by our non-employee directors during the year ended December 31, 2021.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Name</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Fees Earned or Paid in Cash ($)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Option Awards</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">($)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Total</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#160;($)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Victor Ganzi</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">77,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">138,029&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">215,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Allen Nissenson</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">62,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">138,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">200,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gilbert Omenn</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">60,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">138,029&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">198,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Karen Wilson</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">65,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">138,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">203,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________________</span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Amounts shown represents the grant date fair value of options granted during fiscal year 2021 as calculated in accordance with ASC Topic 718. See note 2 of the financial statements included in this Annual Report on Form 10-K for the assumptions used in calculating this amount. As of December 31, 2021, Messrs. Ganzi, Nissenson and Omenn and Ms. Wilson each held options to purchase an aggregate of 53,895 shares of our common stock.</span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Non-employee directors only received cash fees and stock awards as compensation for their service on the Board of Directors. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee of the Board has reviewed and assessed Angion&#8217;s compensation policies and practices as they related to risk management are not reasonably likely to have a material adverse effect on Angion.</span></div><div style="padding-left:18pt"><span><br/></span></div><div id="idee3699378af4447a4091414c0adfaa7_175"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 12. Security ownership of certain beneficial owners and management and related stockholder matters.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  The following table sets forth certain information regarding the beneficial ownership of our common stock as of March 1, 2022 by:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our outstanding shares of our common stock;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each of our directors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each of our named executive officers; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all directors and executive officers as a group.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares beneficially owned by each entity, person, director or executive officer is determined in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares over which the individual has sole or shared voting power or investment power as well as any shares that the individual has the right to acquire within 60 days after March&#160;1, 2022 through the exercise of any stock option, warrants or other rights. Except as otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all shares of our common stock held by that person.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of shares beneficially owned is computed on the basis of 29,957,509 shares of our common stock outstanding as of March&#160;1, 2022. Shares of our common stock that a person has the right to acquire within 60 days after March&#160;1, 2022 are deemed outstanding for purposes of computing the percentage ownership of the person holding such rights, but are not deemed outstanding for purposes of computing the percentage ownership of any other person, except with respect to the percentage ownership of all directors and executive officers as a group.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated below, the address for each beneficial owner listed is c/o Angion Biomedica Corp., 51 Charles Lindbergh Boulevard, Uniondale, New York 11553.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Beneficiary Ownership Table <br/>as of March 1, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Number </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Percentage</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">5% and Greater Stockholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Jay R. Venkatesan </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,880,898</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Itzhak D. Goldberg </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,995,121</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Vifor International, Ltd</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,995,643</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">EISA-ABC, LLC </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,722,237</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Named Executive Officers and Directors:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Jay R. Venkatesan </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,880,898</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Itzhak D. Goldberg </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,995,121</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Victor F. Ganzi </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,019,628</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">John Neylan</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">257,567</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gilbert S. Omenn </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">121,256</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Allen R. Nissenson </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,930</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Karen J. Wilson </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">59,648</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">All directors and executive officers as a group (9&#160;persons) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(11)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">6,671,978</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">20.8</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________________________________</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> * &#160;&#160;&#160;&#160;Represents beneficial ownership of less than 1% of the shares of our common stock.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) &#160;&#160;&#160;&#160;Consists of (i) 1,639,257 shares of our common stock held directly by Jay R. Venkatesan and (ii) 1,241,641 shares of our common stock that may be acquired pursuant to the exercise of stock options within 60 days of March&#160;1, 2022.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Consists of (i) 1,720,068 shares of our common stock held directly by Dr. Goldberg; (ii) 233,374 shares of our common stock held by Itzhak D.  Goldberg's Grandchildren's Trust #1 and 116,687 shares of our common stock held by the Itzhak D. Goldberg's Grandchildren's Trust #2, both in which Dr. Goldberg disclaims any pecuniary interest and (iii) 273,053 shares of our common stock that may be acquired pursuant to the exercise of stock options within 60 days of March&#160;1, 2022.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Based on a Schedule 13G filed on February 14, 2022. The address of EISA-ABC, LLC is 41 Brayton Street, Englewood, NJ 07631.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) &#160;&#160;&#160;&#160;Consists of the shares described in footnote 1 above.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5) &#160;&#160;&#160;&#160;Consists of the shares described in footnote 2 above.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6) &#160;&#160;&#160;&#160;Consists of (i) 823,117 shares of our common stock held directly by Victor F. Ganzi and 155,581 shares of our common stock held by Victor F Ganzi 2012 GST Family Trust held by Victor Ganzi; (ii) 40,930 shares of our common stock that may be acquired pursuant to the exercise of stock options within 60 days of March&#160;1, 2022.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7) &#160;&#160;&#160;&#160;Consists of (i) 35,136 shares of our common stock held directly by John Neylan and  (ii)222,431 shares of our common stock that may be acquired pursuant to the exercise of stock options within 60 days of March&#160;1, 2022.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(8) &#160;&#160;&#160;&#160;Consists of (i) 80,326 shares of our common stock held by the Gilbert S. Omenn Revocable Trust and (ii) 40,930 shares of common stock that may be acquired pursuant to the exercise of stock options within 60 days of March&#160;1, 2022.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(9) &#160;&#160;&#160;&#160;Consists of 40,930 shares of our common stock that may be acquired pursuant to the exercise of stock options within 60 days of March&#160;1, 2022.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(10) &#160;&#160;&#160;&#160;Consists of (i)18,718 shares of our common stock held directly by Karen Wilson and (ii) 40,930 shares of our common stock that may be acquired pursuant to the exercise of stock options within 60 days of March&#160;1, 2022.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(11) &#160;&#160;&#160;&#160;Consists of (i) the shares described in footnotes 3 through 9 above, (ii) 34,399 shares of our common stock held by two other  executive officers who are not in the table above, and (iii) 262,531 shares of our common stock that may be acquired pursuant to the exercise of stock options held by the two other executive officers who are not in the table above within 60 days of  March&#160;1, 2022.</span></div><div><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes our equity compensation plan information as of December 31, 2021.  Information is included for equity compensation plans approved by our stockholders. As of December 31, 2021, we did not have any equity compensation plans that were not approved by our stockholders.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.226%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Securities to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">be Issued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Upon Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">of Outstanding</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Options,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Warrants</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">and Rights</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Price of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Outstanding</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Options,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Warrants</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">and Rights</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Securities</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Available for</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Future</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Issuance</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Under Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Compensation</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Plans</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Equity compensation plans approved by    stockholders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">4,433,177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">8.51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">4,168,609&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Equity compensation plans not approved by    stockholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,433,177</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8.51</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,168,609</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">(1) Consists of shares subject to our 2015 Equity Incentive Plan (the &#8220;2015 Plan&#8221;), our 2021 Incentive Award Plan. (the &#8220;2021 Plan&#8221;), and 2021 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;).  The 2021 Plan contains an &#8220;evergreen&#8221; provision, pursuant to which the number of shares of common stock reserved for issuance pursuant to awards under such plan shall be increased on the first day of each year equal to the lesser of (i) 5% of the number of shares of common stock outstanding (on an as converted basis) on the last day of the immediately preceding fiscal year, or (ii) if our Board acts prior to the first day of the fiscal year, such lesser amount that our Board determines for purposes of the annual increase of the fiscal year. As of January 1, 2022, the 2021 Plan was increased by 1,497,818 pursuant to such evergreen provision. The ESPP contains an &#8220;evergreen&#8221; provision, pursuant to which the number of shares of common stock reserved for issuance pursuant to awards under such plan shall be increased on the first day of each year equal to the lesser of (i) 299,564 (on an as converted basis) on the last day of the immediately preceding fiscal year, or (ii) if our Board acts prior to the first day of the fiscal year, such lesser amount that our Board determines for purposes of the annual increase of the fiscal year. As of January 1, 2022, the ESPP was increased by 1% of share outstanding shares as of January 1, 2022 pursuant to such evergreen provision.  No shares are reflected as being subject to rights as of December 31, 2021 as we have not started any offering periods under the ESPP and, even if we did, such number of shares could not be calculated.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Shares subject to RSUs and PSUs do not have an exercise price. The weighted average exercise price for just the stock options outstanding was $8.92.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="padding-left:36pt"><span><br/></span></div><div id="idee3699378af4447a4091414c0adfaa7_178"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a description of transactions since January 1, 2020 to which we have been a party, in which the amount involved exceeds or will exceed $120,000, and in which any of our directors, executive officers or beneficial owners of more than 5% of our capital stock, or an affiliate or immediate family member thereof, had or will have a direct or indirect material interest, other than compensation, termination and change-in-control arrangements, which are described under "Executive Compensation." We also describe below certain other transactions with our directors, executive officers and stockholders.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the transactions set forth below were approved by a majority of our board of directors. We believe that we have executed all of the transactions set forth below on terms no less favorable to us than we could have obtained from unaffiliated third parties. It is our intention to ensure that all future transactions between us and our officers, directors and principal stockholders and their affiliates are approved by our audit committee, once it is constituted, and a majority of the members of our board of directors, including a majority of the independent and disinterested members of our board of directors, and are on terms no less favorable to us than those that we could obtain from unaffiliated third parties.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Note Financings</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our issued convertible promissory notes were converted to common stock in February 2021 upon our IPO. During 2020, $1.8 million convertible notes from Dr. Venkatesan were exchanged into convertible preferred stock in August 2020 which were then converted into common stock upon IPO. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first nine months of 2020, we issued convertible promissory notes (the Convertible Notes) to certain investors in aggregate principal amount of $34.8 million. The Convertible Notes accrued interest at a rate of 12% per annum, and convert into shares of our common stock upon the consummation of our IPO. In December 2020, we issued Vifor Pharma a convertible promissory note in aggregate principal amount of $5.0 million as part of the equity investment with a maturity date of three years, 2% interest and a conversion price of $11.57 per share, which was automatically converted into shares of our common stock upon our IPO.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below sets forth the principal amount, and number of shares of issuable upon conversion of the Convertible Notes issued in 2020 to our directors, executive officers or owners of more than 5% of a class of our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capital stock, or an affiliate or immediate family member thereof:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Name</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Convertible Note Issued and Outstanding as of December 31, 2020 ( Principal Amount)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Shares of Our</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Common Stock</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Issuable Upon</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Conversion</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:115%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gilbert S. Omenn, M.D., Ph.D.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661,540&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,657</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Jay R. Venkatesan, M.D.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">(3)(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Victor F. Ganzi</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">(3)(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747,671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,863</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Karen Wilson</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,718</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Vifor (International) Ltd.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433,143</span></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.24pt">The terms of the Convertible Notes provide that the notes and accrued dividends will convert at a price that is equal to a 20% discount to the price of the common stock offered in our IPO. The number of shares reflected are based on an initial public offering price of $16.00 per share and assumed the conversion occurs on February 9, 2021.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.24pt">Dr. Omenn is a member of our board of directors. Amount shown includes Convertible Notes held by the Gilbert S. Omenn Revocable Trust, an estate planning instrument for which Mr. Omenn is trustee.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.24pt">Consists of common stock converted from both convertible notes outstanding and convertible preferred stock outstanding.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.24pt">Dr. Venkatesan is our chief executive officer and a member of our board of directors.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.24pt">Mr. Ganzi is a member of our board of directors.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.24pt">Ms. Wilson is a member of our board of directors.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.24pt">Vifor (International) Ltd. is our licensing partner.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transactions with NovaPark LLC</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rent office and laboratory space in Uniondale, New York from NovaPark LLC (NovaPark), an affiliated company, under a lease that expires on June 20, 2026. The space that we rent is part of a 110,000-square-foot general laboratory and development facility (the NovaPark Facility) for biological and chemistry research owned by NovaPark. We recorded rent expense for fixed lease payments of $1.1&#160;million and $1.0&#160;million for years ended December&#160;31, 2021 and 2020, respectively. We recorded rent expense for variable expenses related to the lease of $0.5&#160;million and $0.6&#160;million for the years ended December&#160;31, 2021 and 2020. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, Dr. Goldberg and Rina Kurz, Dr. Goldberg's spouse, own 10%, 45% and 45%, respectively, of the membership interests in NovaPark LLC.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NovaPark Facility has been financed by a mortgage pursuant to which NovaPark's payment obligations are guaranteed by Dr. Goldberg, including a limited personal guarantee up to an amount of $2.1 million. In 2016, in connection with the refinancing of the mortgage, we entered into an indemnification agreement with Dr. Goldberg, pursuant to which we agreed to indemnify Dr. Goldberg from any loss arising out of any claim or action asserted by the mortgage lender against Dr. Goldberg related to Dr. Goldberg's personal limited guarantee of the mortgage. In February 2020, we and Dr. Goldberg terminated the indemnification agreement.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consultant Fees and Employment of Immediate Family</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have paid consulting fees under an agreement with Rina Kurz, Dr. Goldberg's spouse, for management and administrative services relating to our U.S. government grants and contracts. For the year ended December 31, 2021, consultant fees paid to Ms. Kurz were approximately $0.1 million. We believe the consulting arrangement with Ms. Kurz was made on terms no less favorable to us than those that we could obtain from unaffiliated third parties. Angion terminated Ms. Kurz&#8217;s consultant agreement in February 2022.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elisha Goldberg, Dr. Goldberg's son, who formerly served as our Vice President and Director of Strategy, was separated from his employment with us on January 31, 2022 as part of our reduction in force announced in January 2022.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2021, Elisha Goldberg was paid $0.3 million in salary and total award of options during 2021 representing less than 0.1% of our fully diluted capitalization.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Policies and Procedures for Related Party Transactions</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors has adopted a related party transaction policy setting forth the policies and procedures for the identification, review and approval or ratification of related party transactions. This policy covers, with certain exceptions set forth in Item 404 of Regulation S-K under the Securities Act, any transaction, arrangement or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">relationship, or any series of similar transactions, arrangements or relationships, in which we and a related party were or will be participants and the amount involved exceeds $120,000, including purchases of goods or services by or from the related party or entities in which the related party has a material interest, indebtedness and guarantees of indebtedness. In reviewing and approving any such transactions, our audit committee will consider all relevant facts and circumstances as appropriate, such as the purpose of the transaction, the availability of other sources of comparable products or services, whether the transaction is on terms comparable to those that could be obtained in an arm's length transaction, management's recommendation with respect to the proposed related party transaction, and the extent of the related party's interest in the transaction.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Independence</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors currently consists of six members. Our board of directors has determined that all of our directors, other than Dr. Venkatesan and Dr. Goldberg, qualify as "independent" directors in accordance with The Nasdaq Stock Market listing requirements. Dr. Venkatesan and Dr. Goldberg are not considered independent because they were employees of Angion Biomedica Corp. in 2021. As of March 2022, Dr. Goldberg was no longer an employee of Angion. In addition, as required by The Nasdaq Stock Market rules, our board of directors has made a subjective determination as to each independent director that no relationships exist that, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In making these determinations, our board of directors reviewed and discussed information provided by the directors and us with regard to each director's business and personal activities and relationships as they may relate to us and our management. There are no family relationships among any of our directors or executive officers.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div id="idee3699378af4447a4091414c0adfaa7_181"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accountant Fees</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth all fees billed for professional audit, tax and other services rendered by Moss Adams LLP (in thousands):</span></div><div style="margin-top:10pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:71.641%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Audit Fees </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tax Fees </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total Fees</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">461&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,028&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________</span></div><div style="margin-top:10pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Audit fees are for professional services for the audit of our financial statements, the review of quarterly interim financial statements, and for services that are normally provided by the accountant in connection with other regulatory filings or engagements. Fees for the year ended December 31, 2021 include services associated with our IPO and services rendered for the 2021 audit. Fees for the year ended December 31, 2020 include services associated with our IPO. </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  (2) Tax fees are for compliance and consultation.</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  (3) Other fees are for grant compliance audit fee in 2021 and 2020.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><div id="idee3699378af4447a4091414c0adfaa7_184"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part IV</span></div><div id="idee3699378af4447a4091414c0adfaa7_187"></div><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibits and Financial Statement Schedules</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.73pt">Financial Statements: See &#8220;Index to Consolidated Financial Statements&#8221; in Part II, Item 8 of this Annual Report on Form 10-K</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(b)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.26pt">Exhibits.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Exhibit <br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Exhibit <br/>Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Incorporated by <br/>Reference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Filed Herewith</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Date</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000110465921016652/tm215755d1_ex3-1.htm">Amended and Restated Certificate of Incorporation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/9/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000110465921016652/tm215755d1_ex3-2.htm">Amended and Restated Bylaws</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/9/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Reference is made to exhibits 3.1 through 3.2.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000234/a2242860zex-4_2.htm">Form of Common Stock Certificate.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/1/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000107/a2242765zex-4_3.htm">Form of Warrant to Purchase Common Stock.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1/15/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000107/a2242765zex-4_6.htm">Registration Rights Agreement, dated as of March 31, 2020, by and among Angion Biomedica Corp. and the investors party thereto.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1/15/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="angion-descriptionofsecuri.htm">Description of Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">X</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000107/a2242765zex-10_1.htm">Agreement of Lease, dated June 21, 2011, by and between Angion Biomedica Corp. and NovaPark LLC, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1/15/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">10.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000107/a2242765zex-10_4.htm">Licensing Agreement, dated November 6, 2020, by and between Angion Biomedica Corp. and Vifor (International) Ltd.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1/15/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">10.2(a)&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="licenseagreementangionvit2.htm">Amendment &#8211; First Amendment dated July 1, 2021 to Licensing Agreement, dated November 6, 2020, by and between Angion Biomedica Corp. and Vifor (International) Ltd.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">X</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">10.3(a)#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000107/a2242765zex-10_5a.htm">Second Amended and Restated 2015 Equity Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1/15/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">10.5(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">10.3(b)#</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000107/a2242765zex-10_5b.htm">Form of Incentive Stock Option Grant under 2015 Equity Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1/15/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">10.5(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3(c)#</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000107/a2242765zex-10_5c.htm">Form of Non-Qualified Stock Option Grant under 2015 Equity Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1/15/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3(d)#</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000107/a2242765zex-10_5d.htm">Form of Stock Option Exercise under 2015 Equity Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1/15/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4(a)#</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000234/a2242860zex-10_6a.htm">2021 Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/1/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;10.6(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4(b)#</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000234/a2242860zex-10_6b.htm">Form of Stock Option Grant Notice and Stock Option Agreement under the 2021 Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/1/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6(b)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4(c)#</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000234/a2242860zex-10_6c.htm">Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2021 Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/1/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6(c)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4(d)#</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000234/a2242860zex-10_6d.htm">Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2021 Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/1/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6(d)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000234/a2242860zex-10_7.htm">2021 Employee Stock Purchase Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/1/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000107/a2242765zex-10_8.htm">Amended and Restated Employment Agreement, dated March 29, 2019, by and between Angion Biomedica Corp. and Jay R. Venkatesan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1/15/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.7#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000107/a2242765zex-10_9.htm">Executive Employment Agreement, dated May 1, 2018, by and between Angion Biomedica Corp. and Itzhak D. Goldberg.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1/15/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.7(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="igseparationagreement-fina.htm">Separation Agreement, dated February 25, 2022, by and between Angion Biomedica Corp. and Itzhak D. Goldberg</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">X</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.8(b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="egoldberg-angionxformsepar.htm">Separation Agreement, dated March 1, 2022, by and between Angion Biomedica Corp. and Elisha Goldberg</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">X</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000107/a2242765zex-10_10.htm">Executive Employment Agreement, dated December 17, 2018, by and between Angion Biomedica Corp. and John F. Neylan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1/15/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.10#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000107/a2242765zex-10_11.htm">Offer Letter, dated November 27, 2019, as amended, by and between Angion Biomedica Corp. and Jennifer J. Rhodes.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1/15/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.532%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Exhibit <br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Exhibit <br/>Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Incorporated by <br/>Reference</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Filed Herewith</span></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Date</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.11#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000107/a2242765zex-10_12.htm">Consulting Agreement, dated June 3, 2020, as amended, by and between Angion Biomedica Corp. and Gregory S. Curhan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1/15/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.11(a)#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="a200909flg-angionfirstamen.htm">First Amendment dated September 9, 2022 to Consulting Agreement, dated June 3, 2020, as amended, by and between Angion Biomedica Corp. and Gregory S. Curhan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">X</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.11(b)#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="a201210flg-angionsecondame.htm">Second Amendment dated December 1, 2021 to Consulting Agreement, dated June 3, 2020, as amended, by and between Angion Biomedica Corp. and Gregory S. Curhan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">X</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.11(c)#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="a220311flg-angionthirdamen.htm">Third Amendment dated March 17, 2022 to Consulting Agreement, dated June 3, 2020, as amended, by and between Angion Biomedica Corp. and Gregory S. Curhan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">X</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.12#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="non-employeedirectorcompen.htm">Non-Employee Director Compensation Program.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">X</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000107/a2242765zex-10_14.htm">Form of Indemnification Agreement for directors and officers.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1/15/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.14#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="angion-executiveseparation.htm">Amended and Restated Executive Separation Benefits Plan dated November 19, 2021</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="angion-executiveseparation.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">X</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.15#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="solara-angionxredactedclin.htm">Supply Agreement, dated December 10, 2022, by and between Angion Biomedica Corp. and Solara Active Pharma Sciences, Ltd.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">X</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001601485/000110465921016652/tm215755d1_ex10-1.htm">Stock Purchase Agreement, dated February 4, 2021, by and among Angion Biomedica Corp. and the purchasers named therein.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/09/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2016#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/ix?doc=/Archives/edgar/data/0001601485/000160148522000010/angn-20220302.htm">2022 Compensation Decisions with Executive Officers</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3/04/2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 5.02</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1601485/000104746921000107/a2242765zex-21_1.htm">Subsidiaries of the registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1/15/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex231_angnx123121-10k.htm">Consent of independent registered public accounting firm.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">X</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#idee3699378af4447a4091414c0adfaa7_193">Power of Attorney (reference is made to the signature page hereto)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">X</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex311_angnx123121-revisedv.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">X</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex312_angnx123121xrevisedc.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">X</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex321angn-12312021x10k.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">X</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.2&#94;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex322_angnx123121x10k.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.&#160;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">X</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________________________</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8224;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:22.56pt">Portions of this exhibit have been omitted in accordance with Item 601(b)(10) of Regulation S-K.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#94;          The certification that accompanies this Annual Report on Form 10-K pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, is not deemed &#8220;filed&#8221; by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.</span></div><div id="idee3699378af4447a4091414c0adfaa7_190"></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><div id="idee3699378af4447a4091414c0adfaa7_193"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:10pt;text-align:right;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.485%"><tr><td style="width:1.0%"></td><td style="width:7.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.914%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ANGION BIOMEDICA CORP.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ JAY R. VENKATESAN, M.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Jay R. Venkatesan, M.D.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">President and Chief Executive Officer and Chairman</span></div></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Power of Attorney</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Jay R. Venkatesan, M.D. and Jennifer J. Rhodes, and each of them acting individually, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Registration Statement on Form 10-K and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Date</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ JAY R. VENKATESAN, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">President and Chief Executive Officer and Chairman of the Board (Principal Executive Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;30, 2022</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Jay R. Venkatesan, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ GREGORY S. CURHAN</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Financial Officer (Principal Financial and Accounting Officer)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;30, 2022</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gregory S. Curhan</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ ITZHAK D. GOLDBERG, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Director and Chairman Emeritus</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;30, 2022</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Itzhak D. Goldberg, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ VICTOR F. GANZI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Lead Independent Director</span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;30, 2022</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Victor F. Ganzi</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ ALLEN R. NISSENSON, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;30, 2022</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Allen R. Nissenson, M.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ GILBERT S. OMENN, M.D., PH.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;30, 2022</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gilbert S. Omenn, M.D., Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ KAREN J. WILSON</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;30, 2022</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Karen J. Wilson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>2
<FILENAME>angion-descriptionofsecuri.htm
<DESCRIPTION>EX-4.5
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="iaf2ebef99ed64303850bd7580a077d66_1"></div><div style="min-height:72.72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:139%">Exhibit 4.5</font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">DESCRIPTION OF REGISTRANT&#8217;S SECURITIES</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">REGISTERED PURSUANT TO SECTION 12 OF THE</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECURITIES EXCHANGE ACT OF 1934</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;Angion Biomedica Corp. has common stock, $0.01 par value per share, registered under Section 12 of the Securities Exchange Act of 1934, as amended (the Exchange Act), and listed on The Nasdaq Global Select Market under the trading symbol &#8220;ANGN.&#8221;  </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">DESCRIPTION OF COMMON STOCK</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;The following summary describes our common stock, our only class of securities registered pursuant to the Exchange Act, and the material provisions of our amended and restated certificate of incorporation, our amended and restated bylaws, and of the Delaware General Corporation Law. Because the following is only a summary, it does not contain all of the information that may be important to you. For a complete description, you should refer to our amended and restated certificate of incorporation, and amended and restated bylaws, copies of which are incorporated by reference as Exhibits 3.1 and 3.2, respectively, to our Annual Report on Form 10-K to which this is an exhibit.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">General</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Our authorized capital stock consists of 300,000,000 shares of common stock, $0.01 par value per share, and 10,000,000 shares of preferred stock, $0.01 par value per share. </font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Common Stock</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Voting Rights</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Our stockholders do not have cumulative voting rights in the election of directors. Accordingly, holders of a majority of the voting shares are able to elect all of the directors. In addition, the affirmative vote of holders of 66</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:139%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#47;3% of the voting power of all of the then outstanding voting stock is required to take certain actions, including amending certain provisions of our amended and restated certificate of incorporation, such as the provisions relating to amending our amended and restated bylaws, the classified board and director liability.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Dividends</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to preferences that may be applicable to any then outstanding preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Liquidation</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of preferred stock.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Rights and Preferences</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Holders of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate in the future.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72.72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:139%">Fully Paid and Nonassessable</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All of our outstanding shares of common stock are fully paid and nonassessable.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Anti-Takeover Effects of Provisions of our Amended and Restated Certificate of Incorporation, our Amended and Restated Bylaws and Delaware Law</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Certain provisions of Delaware law and our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that could make the following transactions more difficult&#58; acquisition of us by means of a tender offer&#59; acquisition of us by means of a proxy contest or otherwise&#59; or removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions that might result in a premium over the market price for our shares.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;These provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Delaware Anti-Takeover Statute</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;We are subject to Section&#160;203 of the Delaware General Corporation Law, which prohibits persons deemed &#34;interested stockholders&#34; from engaging in a &#34;business combination&#34; with a publicly-held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#34;interested stockholder&#34; is a person who, together with affiliates and associates, owns or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation's voting stock. Generally, a &#34;business combination&#34; includes a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors, such as discouraging takeover attempts that might result in a premium over the market price of our common stock.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Undesignated Preferred Stock</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The ability to authorize undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of us. These and other provisions may have the effect of deterring hostile takeovers or delaying changes in control or management of our company.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Special Stockholder Meetings</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Our amended and restated bylaws provide that a special meeting of stockholders may be called at any time by our board of directors or the chairperson of the Board of Directors or our President or Chief Executive Officer, but such special meetings may not be called by the stockholders or any other person or persons.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Requirements for Advance Notification of Stockholder Nominations and Proposals</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72.72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Elimination of Stockholder Action by Written Consent</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Our amended and restated certificate of incorporation and our amended and restated bylaws eliminated the right of stockholders to act by written consent without a meeting.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Classified Board&#59; Election and Removal of Directors&#59; Filling Vacancies</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders, with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Because our stockholders do not have cumulative voting rights, our stockholders holding a majority of the shares of our common stock outstanding will be able to elect all of our directors. Our amended and restated certificate of incorporation provides for the removal of any of our directors only for cause and requires a stockholder vote by the holders of at least a 66</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:139%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#47;3% of the voting power of the then outstanding voting stock. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of the board, may only be filled by a resolution of the board of directors unless the board of directors determines that such vacancies shall be filled by the stockholders. This system of electing and removing directors and filling vacancies may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Choice of Forum</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Our amended and restated certificate of incorporation and amended and restated bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law&#58; any derivative action or proceeding brought on our behalf&#59; any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers or stockholders to us or to our stockholders&#59; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws (as either may be amended from time to time)&#59; or any action asserting a claim against us that is governed by the internal affairs doctrine. As a result, any action brought by any of our stockholders with regard to any of these matters will need to be filed in the Court of Chancery of the State of Delaware and cannot be filed in any other jurisdiction&#59; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction&#59; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our amended and restated certificate of incorporation and amended and restated bylaws also provide that the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action against us or any of our directors, officers, employees or agents and arising under the Securities Act. Nothing in our amended and restated certificate of incorporation and amended and restated bylaws preclude stockholders that assert claims under the Exchange Act from bringing such claims in state or federal court, subject to applicable law.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72.72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If any action the subject matter of which is within the scope described above is filed in a court other than a court located within the State of Delaware, or a Foreign Action, in the name of any stockholder, such stockholder shall be deemed to have consented to the personal jurisdiction of the state and federal courts located within the State of Delaware in connection with any action brought in any such court to enforce the applicable provisions of our amended and restated certificate of incorporation and amended and restated bylaws and having service of process made upon such stockholder in any such action by service upon such stockholder's counsel in the Foreign Action as agent for such stockholder. Although our amended and restated certificate of incorporation and amended and restated bylaws contain the choice of forum provision described above, it is possible that a court could find that such a provision is inapplicable for a particular claim or action or that such provision is unenforceable.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;&#160;This choice of forum provision may limit a stockholder's ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Amendment of Charter Provisions</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The amendment of any of the above provisions in our amended and restated certificate of incorporation, except for the provision making it possible for our board of directors to issue undesignated preferred stock, would require approval by a stockholder vote by the holders of at least a 66</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:139%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#47;3% of the voting power of the then outstanding voting stock.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The provisions of the Delaware General Corporation Law, our amended and restated certificate of incorporation and our amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Limitation of Liability and Indemnification Matters</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">        Our amended and restated certificate of incorporation contains provisions that limit the liability of our directors for monetary damages to the fullest extent permitted by Delaware law. Consequently, our directors will not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">any breach of the director's duty of loyalty to us or our stockholders&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the Delaware General Corporation Law&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:14.5pt">any transaction from which the director derived an improper personal benefit.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Each of our amended and restated certificate of incorporation and amended and restated bylaws provide that we are required to indemnify our directors and officers, in each case to the fullest extent </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72.72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">permitted by Delaware law. Our amended and restated bylaws also obligate us to advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding, and permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under Delaware law. We have entered and expect to continue to enter into agreements to indemnify our directors, executive officers and other employees as determined by our board of directors. With specified exceptions, these agreements provide for indemnification for related expenses including, among other things, attorneys' fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding. We believe that these bylaw provisions and indemnification agreements are necessary to attract and retain qualified persons as directors and officers. We also maintain directors' and officers' liability insurance.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and our stockholders. Further, a stockholder's investment may be adversely affected to the extent that we pay the costs of settlement and damages.</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Transfer Agent and Registrar</font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The transfer agent and registrar for our common stock is Continental Stock Transfer &#38; Trust Company. The transfer agent and registrar's address is 1 State Street, 30</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:139%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> Floor, New York, New York  10004. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2(A)
<SEQUENCE>3
<FILENAME>licenseagreementangionvit2.htm
<DESCRIPTION>EX-10.2(A)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib29aa9d211264ce4b4a3e09af618a1bf_1"></div><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Angion July 1, 2021</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agreement Number&#58; 115888&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   </font><img alt="image_03.jpg" src="image_03.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:102px"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:16pt"><td colspan="3" style="border-bottom:2pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FIRST AMENDMENT AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(hereinafter referred to as the &#8220;Amendment Agreement&#8221;)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Between</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Vifor (International) AG, Rechenstrasse 37, 9014 St. Gallen, Switzerland</font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(&#8220;LICENSEE&#8221;)</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">And</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Angion Biomedica Corp, 51 Charles Lindbergh Blvd., NY 11553 Uniondale, the United States of America</font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(&#8220;LICENSOR&#8221;)</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">LICENSEE and LICENSOR may hereinafter be referred to individually as a &#8220;Party&#8221; or jointly as the &#8220;Parties&#8221;.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">PREAMBLE&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Parties concluded a License Agreement with effective date as of 06 November 2020</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(hereinafter the &#8220;Agreement&#8221;)&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">pursuant to section 13, each Party may not share other Party&#8217;s confidential information to</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">any Third Party without the prior written consent of the Disclosing Party, knowing that the Third Party definition is very broad and then includes also vendors which will be used by each Party in the performance of its obligations&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, this restriction creates major operational hurdle and then the Parties wish to make certain changes regarding Confidentiality and Public Announcements </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOW, THEREFORE,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> in consideration of the mutual covenants expressed herein and for good and valuable consideration, the Parties hereto agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Article 1 </font></div><div style="padding-left:35.25pt;text-indent:-35.25pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Parties wish to amend Section 13 (</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Confidentiality and Public Announcements</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) of the Agreement by replacing it in its entirety with the new Section 13 (</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Confidentiality and Public Announcements</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) below&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:42.55pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">13. Confidentiality and Public Announcements</font></div><div style="padding-left:42.55pt"><font><br></font></div><div style="padding-left:42.55pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a) Each Party shall keep strictly confidential all Confidential Information obtained from or</font></div><div style="padding-left:42.55pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">about the other Party, and it shall have its officers and employees adhere to such duty.</font></div><div style="padding-left:42.55pt;text-align:justify"><font><br></font></div><div style="padding-left:42.55pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b) Each Party agrees (i) to keep and maintain Confidential Information received from the other in strict trust and confidence&#59; (ii) to not disclose Confidential Information of the Disclosing</font></div><div style="padding-left:42.55pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Party to any Third Party without the prior written consent of the Disclosing Party except as is required by mandatory statutes, a court or governmental order or the rules of any stock exchange on which a Party&#8217;s shares are listed or are to be listed. Notwithstanding the foregoing, each Party may disclose the terms of this Agreement and any reports delivered </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agreement Number&#58; 115888</font></div></div><div style="padding-left:42.55pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">hereunder to its investors, potential investors and shareholders, and actual and potential contracting parties including Affiliates and sub-licensees under and subject to the terms of a non-disclosure agreement no less stringent than the terms of this Article 13, provided that the length of confidentiality obligations shall be based on commercially reasonable industry standards for such disclosures.</font><font style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Furthermore, each Party may use the other Party's Confidential Information and disclose such Confidential Information to Third Parties only to the extent required to accomplish the purposes of this Agreement, including exercising its rights or performing its obligations with or without support of such Third Parties. Each Party will use at least the same standard of care as it uses to protect proprietary or confidential information of its own (but no less than reasonable care) to ensure that its employees, Affiliates&#8217; employees or sublicensee&#8217;s employees and other Third Parties do not disclose or make any unauthorized use of the Confidential Information of the other Party.</font></div><div style="padding-left:42.55pt;text-align:justify"><font><br></font></div><div style="padding-left:42.55pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c) In the event that a disclosure of Confidential Information becomes necessary or required under applicable laws or court or governmental orders, and such disclosure is not otherwise permitted under this Agreement, the Receiving Party requested to disclose shall give to the Disclosing Party the greatest practical prior written notice so as to permit the latter to take all possible action to safeguard its rights in Confidential Information.</font></div><div style="padding-left:42.55pt;text-align:justify"><font><br></font></div><div style="padding-left:42.55pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d) The obligations of the Parties relating to Confidential Information shall expire five (5) years after termination or expiry of this Agreement, except that obligations of the Parties relating to Confidential Information deemed trade secrets shall survive termination or expiry of this Agreement for an unlimited period of time for as long as they remain trade secrets.</font></div><div style="padding-left:42.55pt;text-align:justify"><font><br></font></div><div style="padding-left:42.55pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e) Each Party shall be as careful to preserve the confidential nature of the other Party's Confidential Information as it is with its own proprietary information.</font></div><div style="padding-left:42.55pt;text-align:justify"><font><br></font></div><div style="padding-left:42.55pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f) Subject to any statutory disclosure requirements and paragraphs (g) and (h) below, neither</font></div><div style="padding-left:42.55pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Party shall make any public announcement concerning the transactions contemplated herein or make any public statement which includes the name of the other Party or any of its Affiliates, or otherwise use the name of the other Party or any of its Affiliates in any public statement or document without the written consent of the other Party. Notwithstanding the foregoing, the Parties will issue joint or unilateral press releases upon the execution of this Agreement, which have been agreed to in advance and the Parties shall have the right to repeat any information disclosed in such press releases in any subsequent press release or other public disclosure so long as such information remains accurate at the time of such disclosure.</font></div><div style="padding-left:42.55pt;text-align:justify"><font><br></font></div><div style="padding-left:42.55pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g) The Parties acknowledge that either or both Parties or their Affiliates may be obligated to file under applicable laws a copy of this Agreement with governmental authorities, including, without limitation, the U.S. Securities and Exchange Commission. Each Party and its</font></div><div style="padding-left:42.55pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Affiliates shall be entitled to make such a required filing, provided that it requests confidential treatment of the commercial terms and sensitive technical terms hereof to the extent such confidential treatment is reasonably available. In the event of any such filing, each Party will provide the other Party with a copy of this Agreement marked to show provisions for which such Party or its Affiliate intends to seek confidential treatment and shall reasonably consider and incorporate the other Party&#8217;s timely comments thereon to the extent consistent with the applicable legal requirements, with respect to the filing Party or Affiliate, governing disclosure of material agreements and material information that must be publicly filed.</font></div><div style="padding-left:42.55pt;text-align:justify"><font><br></font></div><div style="padding-left:42.55pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h) Each Party acknowledges that the other Party or its Affiliates may be legally required to make public disclosures (including in filings with the governmental authorities) of certain terms of or material developments or material information generated under this Agreement and agrees that each Party and its Affiliates may make such disclosures as required by applicable law, provided that the Party seeking such disclosure first provides the other Party a copy of the proposed disclosure, and shall reasonably consider the other Party&#8217;s timely comments thereon to the extent consistent with the applicable legal requirements with respect to the disclosing Party or its Affiliate.</font></div><div style="padding-left:42.55pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 2 &#47; #NUM_PAGES#</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agreement Number&#58; 115888</font></div></div><div style="padding-left:42.55pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i) The Parties acknowledge and agree that LICENSOR shall have the right to disclose publicly (including on its website)&#58; (i) the commencement, progress, status, completion and key results of each clinical trial conducted under this Agreement&#59; (ii) the receipt of any Milestone Payments under this Agreement&#59; and (iii) regulatory approval of any Licensed Product. For each such disclosure, unless LICENSOR otherwise has the right to make such disclosure under this Article 13, LICENSOR shall provide LICENSEE with a draft of such disclosure at least seven (7) days prior to its intended release for LICENSEE&#8217;s review and comment, and shall consider LICENSEE&#8217;s comments in good faith. If LICENSOR does not receive comments from LICENSEE within seven (7) days, LICENSOR shall have the right to make such disclosure without further delay.</font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Article 2 </font></div><div style="padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All other provisions of the Agreement remain in full force and effect and shall not be affected by this Amendment Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:35.25pt;text-align:justify;text-indent:-35.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Article 3</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Amendment Agreement shall become effective as of the date of the last signature with retroactive effect to the original Effective Date of the License and shall be incorporated into the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Article 4</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any capitalized term not herein defined has the meaning given to it in the Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the Parties have caused this Amendment Agreement to be executed in 2 (two) copies.</font></div><div style="text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Signed for and on behalf of&#58; Angion Biomedica Corp<br></font><font style="font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"><br><br><br></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">________________________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;_______________________________<br>Print name&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Print name&#58;&#160;&#160;&#160;&#160;<br>Title&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>Date&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Date&#58;</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">Signed for and on behalf of&#58; Vifor (International) AG</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.75pt"><font><br></font></div><div style="padding-right:2.75pt"><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#92;si2&#92;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#92;si3&#92;</font></div><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:174%">________________________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;_______________________________</font></div><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Print name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#92;na2&#92;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Print name&#58;   &#160;&#160;&#160;&#160;</font><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#92;na3&#92;</font></div><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Title&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#92;ti2&#92;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#92;ti3&#92;</font></div><div style="padding-right:2.75pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Date&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#92;ds2&#92;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Date&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#92;ds3&#92;</font></div><div style="padding-right:2.75pt"><font><br></font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Approved by Legal&#58; </font><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#92;si1&#92;  </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Date&#58; </font><font style="color:#ffffff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#92;ds1&#92;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Page 3 &#47; #NUM_PAGES#</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>4
<FILENAME>igseparationagreement-fina.htm
<DESCRIPTION>EX-10.7
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="if25bb59d937645c6be662a70077e8271_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:24pt;text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:62px;margin-bottom:5pt;vertical-align:text-bottom;width:124px"></div><div style="margin-bottom:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Via Email</font></div><div style="margin-bottom:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">February 25, 2022 </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Itzhak D. Goldberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">41 Brayton Street</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Englewood, NJ  07631</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">itzhakgoldbergmd&#64;gmail.com</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Separation Agreement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear Itzhak&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This letter sets forth the substance of the separation agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) that Angion Biomedica Corp. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is offering to you pursuant to the terms of your employment agreement with the Company dated May 1, 2018 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2018 Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Separation Date.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Your last day of work with the Company and your employment termination date will be February 28, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Separation Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  On the Separation Date, the Company will pay you all accrued salary, and all accrued and unused vacation earned through the Separation Date, subject to standard payroll deductions and withholdings.  The Company shall also provide you with all accrued and vested benefits you are entitled to under the terms of  the Company&#8217;s employee benefit plans. You are entitled to these payments regardless of whether or not you sign this Agreement.  For the avoidance of doubt, this Agreement does not terminate your service on the Company&#8217;s Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and you shall continue to serve as Chairman Emeritus of the Board. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Severance Benefits.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If you timely return this fully-signed Agreement to the Company, allow the releases set forth herein to become effective, and remain in compliance in all material respects with all obligations contained in this Agreement (provided, that, the Company shall provide you with written notice of any noncompliance and not less than thirty (30) days to cure, if curable), then, pursuant to and in full satisfaction of any obligations for the Company to provide you with any severance benefits under Section 6 of the 2018 Agreement, the Company will provide you with the following severance benefits&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Severance Pay</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company will pay you the equivalent of eighteen (18) months of your base salary in effect as of the Separation Date ($726,028.00), subject to standard payroll deductions and withholdings (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Severance Pay</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Severance Pay will be paid to you in the form of salary continuation payments made in accordance with the Company&#8217;s regularly scheduled payroll paydays, beginning sixty (60) days after the Separation Date.  The first installment payment shall contain all of the payments that would have been made had the payments commenced on the first payroll date following the Separation Date.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;1</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Annual Bonus Payments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You will receive a single lump-sum bonus amount of $363,014.00, less required deductions and withholdings, which is equal to 18 months of your Annual Bonus (as defined in the 2018 Agreement) at target.  This amount shall be paid to you on December 31, 2022. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;Health Insurance Payment.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Your participation in the Company&#8217;s group health insurance plan will end on the last day of the month in which your employment termination occurs. To the extent provided by the federal COBRA law or, if applicable, state insurance laws, and by the Company&#8217;s current group health insurance policies, you may be eligible to continue your group health insurance benefits at your own expense following the Separation Date.  Later, you may be able to convert to an individual policy through the provider of the Company&#8217;s health insurance, if you wish.  You will be provided with a separate notice describing your rights and obligations under COBRA.  As an additional severance benefit, the Company will pay you a lump sum cash payment in the total amount of $2,219.76, less applicable deductions and withholdings, for your use in covering COBRA premiums to continue your health insurance coverage (including coverage for your spouse and eligible dependents, if applicable) for a period of eighteen (18) months (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COBRA Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  However, you are not obligated to use such COBRA Payment toward the cost of COBRA premiums.  The COBRA Payment will be paid to you on the first payroll date following the Effective Date (as defined in the Release).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Equity.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You were previously granted restricted stock units (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and options to purchase shares of the Company&#8217;s common stock, pursuant to the Company&#8217;s Amended and Second Restated 2015 Equity Incentive Plan and&#47;or 2021 Incentive Award Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Notwithstanding the termination of your employment with the Company and based upon the terms of the Plans and your equity grants, vesting of your RSUs and options and exercisability of your options will continue beyond your Separation Date so long as you remain in continuous service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with the Company as a director on the Board or otherwise.  You shall be permitted to exercise any of your outstanding options at any time during the original term thereof, and you shall be permitted to exercise your options through a cashless &#8220;net&#8221; exercise and to satisfy tax withholding obligations through a net settlement of shares underlying the award, provided that while you continue to serve as a director on the Board you will be subject to and must comply with the Company&#8217;s Code of Conduct and Ethics, Insider Trading Compliance Policy and Section 16 Compliance Program.  Your RSUs and options shall continue to be governed by the terms of the applicable grant notices, stock option agreements and the Plans.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Other Compensation or Benefits.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You acknowledge and agree that, except as expressly provided in this Agreement, you will not receive any additional compensation, severance or benefits after the Separation Date, with the exception of any vested right you may have under the express terms of a written ERISA-qualified benefit plan (e.g., 401(k) account). You further acknowledge and agree that the benefits set forth herein fulfill and exceed all of the Company&#8217;s obligations to pay you severance benefits in connection with your employment termination, pursuant to the 2018 Agreement, any severance plan, other agreement, or policy.  You further acknowledge and agree that as of the Separation Date, you will not have earned and will not be entitled to any amount of a 2021 Annual Bonus, as the Compensation Committee of the Board has determined, as reflected in the Board approved 2022 budget, that no Company executive officer shall be entitled to a discretionary cash bonus based upon the Company&#8217;s 2021 performance or any amount in lieu thereof. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Expense Reimbursements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You agree that, within ten (10) days after the Separation Date, you will submit your final documented expense reimbursement statement reflecting all business expenses you incurred through the Separation Date, if any, for which you seek reimbursement.  The Company will reimburse you for these expenses pursuant to its regular business practice. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Return of Company Property.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  At a time and place specified by the Company and by no later than the close of business on the Separation Date, you shall return to the Company all Company documents (and all copies thereof) and other Company property in your possession or control, other than such documents that are reasonably needed by you in connection with your continuing role as a member of the Board.  You agree that you will make a diligent search to locate any such documents, property and information within the timeframe referenced above.  In addition, if you have used any personally owned computer, server, or e-mail system to receive, store, review, prepare or transmit any confidential or proprietary data, materials or information of the Company, then within five (5) business days after the Separation Date, you must provide the Company with a computer-useable copy of such information and then permanently delete and expunge such confidential or proprietary information from those systems without retaining any reproductions (in whole or in part)&#59; and you agree to provide the Company access to your system, as requested, to verify that the necessary copying and deletion is done.  Your timely compliance with the provisions of this paragraph is a precondition to your receipt of the severance benefits provided hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to your compliance with Section 6 of this Agreement, while you are serving as a director on the Board, you will be permitted to retain your Angion email address and computer&#59; provided, however, that you hereby  agree that&#58; (i) </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">you will have no authority to bind the Company to any contractual obligations, whether written, oral or implied, except with the prior written authorization of the Board or an officer of the Company&#59; (ii) you will not represent or purport to represent the Company in any manner whatsoever to any third party unless authorized in advance by the Board or an officer of the Company, in writing, other than </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to identify yourself as a director on the Board&#59; and (iii) you will comply with all Company Information Technology policies and procedures.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Proprietary Information Obligations. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Both during and after your employment you acknowledge your continuing obligations under your Confidential Information and Invention Assignment Agreement, including your obligations not to use or disclose any confidential or proprietary information of the Company.  You hereby agree to timely execute the Confidential Information and Invention Assignment Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in exchange for the consideration provided to you in this Agreement. Notwithstanding the terms of the CDA or any other agreement, you shall be permitted to disclose confidential or proprietary information if required by applicable law, court order or subpoena, or governmental or regulatory investigation or in connection with a dispute under this Agreement or otherwise.  In addition, you shall not be in violation of the non-solicitation restrictions therein merely as a result of general marketing and recruiting activities that are not directed to employees and consultants of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Nondisparagement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You agree not to disparage the Company and its officers, directors and  employees, in any manner likely to be harmful to them or their business, business reputations or personal reputations&#59; provided that&#58; (a) you may respond accurately and fully to any question, inquiry or request for information when required by legal process (e.g., a valid subpoena or other similar compulsion of law) or as part of a government investigation, (b) you may make critical or negative statements to the Company&#8217;s board pursuant to your continuing role as a member of the Board and (c) nothing in this provision or this Agreement is intended to prohibit or restrain you in any manner from making disclosures that are protected under the whistleblower provisions of federal or state law or regulation or limit your rights under Section 7 of the National Labor Relations Act, which include your right to engage in protected concerted activities with other employees to improve or discuss terms and conditions of employment. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company agrees to direct its officers and directors not to disparage you, in any manner likely to be harmful to your business, business reputation or personal reputation&#59; provided, however, that both you and the Company may respond accurately and truthfully to any question, inquiry or request for information when required by legal process (e.g., a valid subpoena or other similar </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">compulsion of law) or as part of a government investigation or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a dispute under this Agreement or otherwise</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">No Admissions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You understand and agree that the promises and payments in consideration of this Agreement shall not be construed to be an admission of any liability or obligation by the Company to you or to any other person, and that the Company makes no such admission</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Release of Claims.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;General Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In exchange for the consideration provided to you under this Agreement to which you would not otherwise be entitled, you hereby generally and completely release the Company, TriNet Group Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TriNet</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), or their parent and subsidiary entities, and their current and former directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, insurers, affiliates, and assigns, each in their respective capacities as such (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Released Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to or on the date you sign this Agreement (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Released Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;Scope of Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as set forth herein and subject to 10(e) below, the Released Claims include, but are not limited to&#58;  (i) all claims arising out of or in any way related to your employment with the Company, or the termination of that employment&#59; (ii) all claims related to your compensation or benefits from the Company, including salary, bonuses, commissions, vacation, expense reimbursements, severance pay fringe benefits, stock, stock options, or any other ownership, equity, or profits interests in the Company&#59; (iii)&#160;all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing&#59; (iv) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy&#59; and (v) all federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys&#8217; fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of 1967 (as amended) (the &#8220;ADEA&#8221;), the New Jersey Law Against Discrimination, the New Jersey Conscientious Employee Protection Act, the New Jersey Family Leave Act, the New Jersey Wage Payment Law, the New Jersey Wage and Hour Law, and the employment and civil rights laws of New Jersey.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;ADEA Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that you are knowingly and voluntarily waiving and releasing any rights you may have under the ADEA (the &#8220;ADEA Waiver&#8221;), and that the consideration given for the ADEA Waiver is in addition to anything of value to which you are already entitled.  You further acknowledge that you have been advised, as required by the ADEA, that&#58;  (i) your ADEA Waiver does not apply to any rights or claims that may arise after the date that you sign this Agreement&#59; (ii) you should consult with an attorney prior to signing this Agreement (although you may choose voluntarily not to do so)&#59; (iii) you have twenty-one (21) days to consider this Agreement (although you may choose voluntarily to sign it earlier)&#59; (iv) you have seven (7) days following the date you sign this Agreement to revoke the ADEA Waiver&#59; and (v) this Agreement will not be effective until the date upon which the revocation period has expired, which will be the eighth day after the date that this Agreement is signed by you provided that you do not revoke it (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)&#160;&#160;&#160;&#160;Section 1542 Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  YOU UNDERSTAND THAT THIS AGREEMENT INCLUDES A RELEASE OF ALL KNOWN AND UNKNOWN CLAIMS.  In giving the release herein, which includes claims which may be unknown to you at present, you </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">acknowledge that you have read and understand Section 1542 of the California Civil Code, which reads as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.&#8221; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You hereby expressly waive and relinquish all rights and benefits under that section and any law of any other jurisdiction of similar effect with respect to your release of any unknown or unsuspected claims herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)&#160;&#160;&#160;&#160;Excluded Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding the foregoing, the following are not included in the Released Claims (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Excluded Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#58; (i) any rights or claims for indemnification you may have pursuant to any written indemnification agreement with the Company to which you are a party or under applicable law or the Company&#8217;s Bylaws&#59; (ii) coverage under any applicable directors&#8217; and officers&#8217; or other third-party liability insurance&#59; (iii) Employee&#8217;s vested accrued benefits under the Company or TriNet&#8217;s respective benefits and compensation plans&#59; (v) any rights which are not waivable as a matter of law&#59; and (vi) any claims for breach of this Agreement.  You hereby represent and warrant that, other than the Excluded Claims, you are not aware of any claims you have or might have against any of the Released Parties that are not included in the Released Claims.  You understand that nothing in this Agreement limits your ability to file a charge or complaint with the Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Government Agencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  You further understand this Agreement does not limit your ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company.  While this Agreement does not limit your right to receive an award for information provided to the Securities and Exchange Commission, you understand and agree that, to maximum extent permitted by law, you are otherwise waiving any and all rights you may have to individual relief based on any claims that you have released and any rights you have waived by signing this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)  Company Acknowledgement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company hereby acknowledges and agrees that you</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">shall have no obligation to seek other employment or otherwise mitigate any payments hereunder, and no such payments shall be subject to set-off or be reduced by any compensation earned by you following your termination of employment. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.&#160;&#160;&#160;&#160;Representations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You hereby represent that you have been paid all compensation owed and for all hours worked, have received all the leave and leave benefits and protections for which you are eligible, pursuant to the Family and Medical Leave Act or otherwise, and have not suffered any on-the-job injury for which you have not already filed a claim.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12. &#160;&#160;&#160;&#160;Miscellaneous.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This Agreement, including its exhibits, constitutes the complete, final and exclusive embodiment of the entire agreement between you and the Company with regard to the subject matter hereof (other than existing equity awards and benefit plans).  It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other agreements, promises, warranties or representations concerning its subject matter.  This Agreement may not be modified or amended except in a writing signed by both you and a duly authorized officer of the Company.  This Agreement will bind the heirs, personal representatives, successors and assigns of both you and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;5</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Company, and inure to the benefit of both you and the Company and each of your heirs, successors and assigns.  If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any other provision of this Agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties insofar as possible under applicable law.  This Agreement shall be construed and enforced in accordance with the laws of the State of New Jersey without regard to conflicts of law principles. Any ambiguity in this Agreement shall not be construed against either party as the drafter.  Any waiver of a breach of this Agreement, or rights hereunder, shall be in writing and shall not be deemed to be a waiver of any successive breach or rights hereunder.  This Agreement may be executed in counterparts which shall be deemed to be part of one original, and facsimile and signatures transmitted by PDF shall be equivalent to original signatures.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If this Agreement is acceptable to you, please sign below and return the original to me on or within twenty-one (21) days after the Separation Date.  The Company&#8217;s offer contained herein will automatically expire if we do not receive the fully signed Agreement within this timeframe.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I wish you good luck in your future endeavors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sincerely,</font></div><div style="margin-bottom:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Angion Biomedica Corp.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Jay Venkatesan</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit A &#8211; Confidential Information and Inventions Assignment Agreement</font></div><div style="margin-bottom:24pt;text-align:justify"><font><br></font></div><div style="margin-bottom:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted and Agreed&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Itzhak D. Goldberg</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date</font></div><div id="if25bb59d937645c6be662a70077e8271_4"></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;7</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONFIDENTIAL INFORMATION AND INVENTIONS ASSIGNMENT AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Confidential Information and Invention Assignment Agreement</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;This Confidential Information and Invention Disclosure Agreement (the &#8220;Agreement&#8221;), dated August 25, 2006 (the &#8220;Effective Date&#8221;) is between Angion Biomedica Corp. and its affiliates (collectively, the &#8220;Company&#8221;) and Itzhak Goldberg (&#8220;Employee&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Employee enters this Agreement in consideration of Employee&#8217;s employment or continued employment and the compensation now and later paid to Employee during his or her employment with the Company, and the Company&#8217;s agreement to provide Employee with access to its Confidential Information.  Accordingly, the parties agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Employee shall, throughout the term of employment with the Company and thereafter, maintain the confidentiality of all Confidential Information of the Company, as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.  &#160;&#160;&#160;&#160;The term &#8220;Confidential Information&#8221; shall mean any and all confidential, proprietary and trade secret information of the Company, whether in written, oral, electronic or other form, including but not limited to&#58; (i) any and all Inventions (as defined herein)&#59; (ii) information and facts concerning Company employees and service providers, business plans, customers, future customers, suppliers, licensors, licensees, partners, investors, affiliates or others&#59; (iii) training methods and materials, financial information, sales prospects, client lists, customer lists, inventions&#59; (iv) information regarding research, development, new products, business and operational plans, budgets, unpublished financial statements and projections, costs, margins, discounts, credit terms, pricing, quoting procedures, future plans and strategies, capital-raising plans, internal services, suppliers and supplier information&#59; (v) any other scientific, technical or trade secrets of the Company or of any third party provided to Employee or the Company under a condition of confidentiality&#59; and (vi) any other non-public information that a competitor of Company could use to the Company&#8217;s competitive disadvantage.  The term &#8220;trade secrets,&#8221; as used in this Agreement, shall be given its broadest possible interpretation under California law and shall include, without limitation, anything tangible or intangible or electronically kept or stored, which constitutes, represents, evidences or records any secret scientific, technical, merchandising, production or management information, or any design, process, procedure, formula, invention, improvement or other confidential or proprietary information or documents.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.2.  &#160;&#160;&#160;&#160;This Agreement covers all Confidential Information disclosed to Employee during his or her employment with the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.3. &#160;&#160;&#160;&#160;Employee&#8217;s obligations regarding Confidential Information continue following termination of employment.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.4.  &#160;&#160;&#160;&#160;Employee shall&#58; (a) use Confidential Information only within the scope of his or her employment with the Company&#59; (b) hold in confidence and will not disclose, use, lecture upon, or publish any of the Company&#8217;s Confidential Information to any third party without the prior written approval of the Company&#59; (c) restrict dissemination of Confidential Information only to those Company employees who have a need to know&#59; (d) follow all Company policies in preventing disclosure of Confidential Information to third parties&#59;  (e) not use Confidential Information to solicit or induce any vendor, supplier or strategic partner of the Company to cease doing business with the Company&#59; and (f) not disclose to the Company any confidential information belonging to a third party.  Employee shall promptly notify the Company of any loss of Confidential Information or breach of these obligations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.5.  Confidential Information shall not include any information that&#58; (a) is or becomes publicly known through no wrongful act of Employee or was known to Employee prior to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">employment with the Company or generally known in the trade or industry&#59; (b) is furnished to a third party by the Company without a duty of confidentiality&#59; (c) is explicitly approved for release by written authorization of the Company&#59; or (d) is ordered to be disclosed by a court of competent jurisdiction, provided Employee gives timely written notice of such order to the Company to enable it to seek a protective order.   </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;1.6.&#160;&#160;&#160;&#160;Employee will obtain the Company's written approval before publishing or submitting for publication any material (written, verbal, or otherwise) that discloses and&#47;or incorporates any Confidential Information.  Employee hereby assigns to the Company any rights Employee may have or acquire in such Confidential Information and recognize that all Confidential Information will be the sole property of the Company and its assigns.  Employee will take all reasonable precautions to prevent the inadvertent or accidental disclosure of Confidential Information.  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.7.&#160;&#160;&#160;&#160;During Employee&#8217;s employment by the Company, Employee will not improperly use or disclose any confidential information or trade secrets, if any, of any former employer or any other person to whom Employee has an obligation of confidentiality, and Employee will not bring onto the premises of the Company, or upload to, transmit to, or store on any Company computer systems any unpublished documents or any property belonging to any former employer or any other person to whom Employee has an obligation of confidentiality unless consented to in writing by that former employer or person.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.8&#160;&#160;&#160;&#160;Notwithstanding the foregoing, pursuant to 18 U.S.C. Section 1833(b), Employee will not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that&#58; (1) is made in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law&#59; or (2) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.  Additionally, nothing in this Agreement shall limit&#58; (i) Employee&#8217;s right to discuss his or her employment or unlawful acts in the Company&#8217;s workplace, including but not limited to sexual harassment&#59; (ii) Employee&#8217;s right to report possible violations of law or regulation with any federal, state or local government agency&#59; or (iii) Employee&#8217;s right to discuss the terms and conditions of their employment with others to the extent expressly permitted by Section 7 of the National Labor Relations Act or to the extent that such disclosure is protected under applicable &#8220;whistleblower&#8221; statutes or other provisions of law or regulation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the period in which Employee performs services for or at the request of the Company and for a period of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">one (1) year </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">following the termination of Employee&#8217;s employment with the Company for any reason, including voluntary or involuntary termination, Employee shall not, either individually or on behalf of or through any third party, directly or indirectly, without the prior written consent of the Company&#58; (i) solicit, induce, encourage, or participate in soliciting, inducing or encouraging any employee of or consultant to the Company to terminate his or her relationship with the Company or any such parent, subsidiary or affiliate for any reason&#59; or (ii) solicit the employment or engagement of any employee of or consultant to the Company while any such person is providing services to the Company.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Ownership of Ideas, Copyrights and Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Property of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All ideas, discoveries, creations, manuscripts and properties, innovations, improvements, know-how, inventions, designs, developments, apparatus, techniques, methods, biological processes, cell lines, laboratory notebooks, formulae and other similar material (collectively the &#8220;Inventions&#8221;) which may be used in the business of the Company, whether patentable, copyrightable or not, which Employee may conceive, reduce to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">practice or develop while employed by the Company, alone or in conjunction with another or others, whether during or outside of regular business hours, whether or not on the Company&#8217;s premises or with the use of its equipment, and whether at the request or upon the suggestion of the Company or otherwise, shall be the sole and exclusive property of the Company, and Employee shall not publish any of the Inventions without the prior written consent of the Company.  Without limiting the foregoing, Employee also acknowledges that all original works of authorship which are made by Employee (solely or jointly with others) within the scope of Employee&#8217;s employment or which relate to the business of the Company or a Company affiliate and which are protectable by copyright are &#8220;works made for hire&#8221; pursuant to the United States Copyright Act (17 U.S.C. Section 101).  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Assignment of Company Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Employee hereby assigns, grants, and conveys to the Company or its designee all of Employee&#8217;s right, title and interest in and to all of the Inventions whether or not patentable or registrable under copyright or similar statute.   Employee further agrees that all Inventions includes an assignment of all Moral Rights.  To the extent such Moral Rights cannot be assigned to Company and to the extent the following is allowed by the laws in any country where Moral Rights exist, Employee hereby unconditionally and irrevocably waives the enforcement of such Moral Rights, and all claims and causes of action of any kind against Company or related to Company&#8217;s customers, with respect to such rights.  Employee further agrees that neither Employee&#8217;s successors-in-interest nor legal heirs retain any Moral Rights in any Company Inventions.  Nothing contained in this Agreement may be construed to reduce or limit Company&#8217;s rights, title, or interest in any Company Inventions so as to be less in any respect than that Company would have had in the absence of this Agreement. &#8220;Moral Rights&#8221; means all paternity, integrity, disclosure, withdrawal, special and similar rights recognized by the laws of any jurisdiction in the world. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.3  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  At any time during or after the period of employment with the Company, Employee shall comply with all Company policies concerning Inventions and shall fully cooperate with the Company and its attorneys and agents in the preparation and filing of all papers and other documents as may be required to perfect the Company&#8217;s rights in and to any of such Inventions, including, but not limited to, joining in any proceeding to obtain letters patent, copyrights, trademarks or other legal rights with respect to any such Inventions in the United States and in any and all other countries, provided that the Company shall bear the expense of such proceedings, and that any patent or other legal right so issued to Employee personally shall be assigned by Employee to the Company or its designee without any further compensation to Employee.  Employee designates the Company as his or her agent, and grants to the Company a power of attorney with full power of substitution (which power of attorney shall be deemed coupled with an interest), for the purpose of effecting the foregoing assignments to the Company with the same legal force and effect as if executed by Employee.  Employee hereby waives and quitclaims to the Company any and all claims, of any nature whatsoever, which Employee now or may hereafter have for infringement of any Inventions assigned under this Agreement to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.4 &#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Licensing and Use of Innovations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  With respect to any Inventions and work of any similar nature (from any source), whenever created, which Employee has not prepared or originated in the performance of employment (including Prior Inventions, as defined herein), but which Employee provides to the Company or incorporates in any Company product or system, Employee hereby grants to the Company a royalty-free, fully paid-up, non-exclusive, perpetual and irrevocable license throughout the world to use, modify, create derivative works from, disclose, publish, translate, reproduce, deliver, perform, dispose of, and to authorize others so to do, all such Inventions.  Employee shall not include in any Inventions delivered to the Company or used on its behalf, without the prior written approval of the Company, any material which is or shall be patented, copyrighted or trademarked by Employee or others unless Employee provides the Company with the written permission of the holder of any patent, copyright or trademark </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">owner for the Company to use such material in a manner consistent with then-current Company policy. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.5  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Prior Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to this Agreement are any and all Inventions in which Employee claims or intends to claim any right, title and interest, including, without limitation, patent, copyright and trademark interests,  that Employee has, alone or jointly with others, made prior to the commencement of employment with the Company that Employee considers to be his or her property or the property of third parties and that shall be excluded from the scope of this Agreement (collectively, &#8220;Prior Inventions&#8221;).  If no such disclosure is provided in Exhibit A, Employee represents that there are no Prior Inventions.  If disclosure of any such Prior Inventions would cause Employee to violate any prior confidentiality agreement, Employee understands that Employee is not to list such Prior Inventions in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit&#160;A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> but is only to disclose a cursory name for each such invention, a listing of the party(ies) to whom it belongs and the fact that full disclosure as to such inventions has not been made for that reason.  A space is provided on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for such purpose.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Incorporation of Software Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Employee agrees not to incorporate into any Inventions, including any Company software, or otherwise deliver to Company, any software code licensed under the GNU General Public License, Lesser General Public License, or any other license that, by its terms, requires or conditions the use or distribution of such code on the disclosure, licensing, or distribution of any source code owned or licensed by Company, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">except</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in strict compliance with Company&#8217;s policies regarding the use of such software or as directed by the Company.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.7  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Obligation to Keep Company Informed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the period of Employee&#8217;s employment and for a period of six (6) months after termination of Employee&#8217;s employment with the Company, Employee will promptly disclose to the Company fully and in writing all Inventions authored, conceived or reduced to practice by Employee, either alone or jointly with others.  In addition, Employee will promptly disclose to the Company all patent applications filed by Employee or on Employee&#8217;s behalf within a year after termination of employment.  At the time of each such disclosure, Employee will advise the Company in writing of any Inventions that Employee believes fully qualify for protection under the provisions in Section 3.9&#59; and Employee will at that time provide to the Company in writing all evidence necessary to substantiate that belief.  The Company will keep in confidence and will not use for any purpose or disclose to third parties without Employee&#8217;s consent any confidential information disclosed in writing to the Company pursuant to this Agreement relating to Inventions that qualify fully for protection under Section 3.9.  Employee will preserve the confidentiality of any Invention that does not fully qualify for protection under Section 3.9.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.8  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Employee agrees to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that may be required by the Company) of all Confidential Information developed by Employee and all Company Inventions made by Employee during the period of Employee&#8217;s employment at the Company, which records will be available to and remain the sole property of the Company at all times.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.9 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exception to Assignments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company and Employee acknowledge that this Agreement does not require assignment of any Invention which qualifies fully for protection under Section 2870 of the California Labor Code (hereinafter &#8220;Section 2870&#8221;), which provides as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">using the employer&#8217;s equipment, supplies, facilities, or trade secret information except for those inventions that either&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;Relate at the time of conception or reduction to practice of &#160;&#160;&#160;&#160;the invention to the employer&#8217;s business, or actual or demonstrably anticipated research or development of the employer&#59; or</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;Result from any work performed by the employee for the employer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;To the extent a provision in this Agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under subdivision (a), the provision is against the public policy of this state and is unenforceable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Reasonableness of Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Employee acknowledges that the types of conduct which are prohibited by Sections 1 and 2 are narrow and reasonable in relation to the skills which represent Employee&#8217;s principal marketable asset both to the Company and to other prospective employers. Employee has read this entire Agreement and understands it.  Employee agrees that this Agreement does not prevent Employee from earning a living or pursuing Employee&#8217;s career.  Employee agrees that the restrictions contained in this Agreement are reasonable, proper, and necessitated by the Company&#8217;s legitimate business interests.  Employee represents and agrees that Employee is entering into this Agreement freely and with knowledge of its contents with the intent to be bound by the Agreement and the restrictions contained in it.  In the event that a court finds this Agreement, or any of its restrictions, to be ambiguous, unenforceable, or invalid, Employee and the Company agree that the court will read the Agreement as a whole and interpret the restriction(s) at issue to be enforceable and valid to the maximum extent allowed by law.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Conflicting Obligations&#47;Duty of Loyalty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Employee represents that he or she has no commitments or obligations inconsistent with this Agreement, and Employee shall not enter into any such conflicting agreement during his or her employment with the Company.  Employee agrees that during the period of Employee&#8217;s employment by the Company, Employee will not, without the Company's express written consent, directly or indirectly engage in any employment or business activity which is directly or indirectly competitive with, or would otherwise conflict with, Employee&#8217;s employment by the Company.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon termination of Employee&#8217;s employment with the Company, Employee agrees to deliver to Company any and all materials, together with all copies thereof, containing or disclosing any Company Inventions or Confidential Information.  Employee will not copy, delete, or alter any information contained upon my Company computer or Company equipment before Employee returns it to Company.  In addition, if Employee has used any personal computer, server, or e-mail system to receive, store, review, prepare or transmit any Company information, including but not limited to, Confidential Information, Employee agrees to provide Company with a computer-useable copy of all such information and then permanently delete such information from those systems&#59; and Employee agrees to provide Company access to his or her system as reasonably requested to verify that the necessary copying and&#47;or deletion is completed.  Employee further agrees that any property situated on Company&#8217;s premises and owned by Company, including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company&#8217;s personnel at any time during Employee&#8217;s employment, with or without notice.  Prior to leaving, Employee hereby agrees to&#58; provide Company any and all information needed to access any Company property or information returned or required to be returned pursuant to this paragraph, including without limitation any login, password, and account information&#59; cooperate with Company in attending an exit interview&#59; and complete and sign Company&#8217;s termination statement if required to do so by Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Publication of This Agreement to Subsequent Employer or Business Associates of Employee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If Employee is offered employment, or the opportunity to enter into any business venture as owner, partner, consultant or other capacity, while the restrictions in Section 2 of this Agreement are in effect, Employee agrees to inform his or her potential employer, partner, co-owner and&#47;or others involved in managing the business Employee has an opportunity to be associated with, of his or her obligations under this Agreement and to provide such person or persons with a copy of this Agreement.  Employee agrees to inform Company of all employment and business ventures which Employees enters into while the restrictions described in Section 2 of this Agreement are in effect and Employee authorizes Company to provide copies of this Agreement to Employee&#8217;s employer, partner, co-owner and&#47;or others involved in managing the business Employee has an opportunity to be associated with and to make such persons aware of his or her obligations under this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.1  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company may assign its rights and obligations to any person or entity that succeeds it to all or substantially all of the Company&#8217;s business or that aspect of the Company&#8217;s business in which Employee is principally involved.  Employee&#8217;s rights and obligations under this Agreement may not be assigned by Employee, but will be binding upon Employee&#8217;s heirs, executors, administrators and other legal representatives.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.2  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law, Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The laws of the state of California shall govern the provisions of this Agreement, and the parties agree to submit to the exclusive jurisdiction of the courts of Alameda County, California.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.3  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All notices required or permitted to be given under this Agreement to any party shall be in writing and shall be deemed given upon&#58; (i) personal delivery&#59; (ii) acknowledgment of facsimile transmission&#59; or (iii) if delivered by certified mail with return receipt requested, three (3) days after mailing or when received (whichever is earlier).  All postage and registration or certification fees must be prepaid and addressed as set forth on the signature page of this Agreement.  Any notices required or permitted under this Agreement will be given to the Company at its headquarters location at the time notice is given, labeled &#8220;Attention Chief Executive Officer,&#8221; and to Employee at Employee address as listed on the Company payroll, or at such other address as the Company or Employee may designate by written notice to the other.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.4  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Injunctive Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Employee expressly acknowledges that any breach or threatened breach of any of the terms and&#47;or conditions of this Agreement may result in substantial, continuing, immediate, and irreparable injury to the Company, and Employee agrees that it may be impossible to assess the damages caused by Employee&#8217;s violation of this Agreement.  Therefore, in addition to any other remedy that may be available to the Company, the Company shall be entitled to seek injunctive or other equitable relief, without bond, by a court of appropriate jurisdiction in the event of any breach or threatened breach of the terms of this Agreement.   In the event the Company enforces this Agreement through a court order, Employee agrees that the restrictions of Section 2 will remain in effect for a period of twelve (12) months from the effective date of the order enforcing the Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.5  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Opportunity to Review</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Employee hereby acknowledges that he or she has had adequate opportunity to review these terms and conditions and to reflect upon and consider the terms and conditions of this Agreement, and has had the opportunity to consult with his&#47;her own counsel regarding such terms.  Employee further acknowledges that he or she fully understands the terms of this Agreement and has voluntarily executed this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.6  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">At-Will Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  Employee acknowledges that nothing in this Agreement shall confer any right with respect to continuation of employment by the Company, nor shall it interfere in any way with Employee&#8217;s right or the Company&#8217;s right to terminate his or her employment at any time with or without cause or advance notice, except as otherwise expressly provided in any written employment agreement he or she has with the Company.  This Agreement will not be construed against any party by reason of the drafting or preparation of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.7  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In case any one or more of the provisions, subsections, or sentences contained in this Agreement will, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect the other provisions of this Agreement, and this Agreement will be construed as if such invalid, illegal or unenforceable provision had never been contained in this Agreement.  Moreover, if any one or more of the provisions contained in this Agreement will for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, it will be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it will then appear.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.8  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No waiver by the Company of any breach of this Agreement will be a waiver of any preceding or succeeding breach.  No waiver by the Company of any right under this Agreement will be construed as a waiver of any other right.  The Company will not be required to give notice to enforce strict adherence to all terms of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.9  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The provision of this Agreement, shall survive the termination of Employee&#8217;s employment with the Company for any reason, and the assignment of this Agreement by the Company to any successor in interest or other assignee.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.10   &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may be executed in two or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.  Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.11  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement, together with Employee&#8217;s offer letter, constitutes the entire agreement of the parties with respect to its subject matter, and supersedes any and all prior discussions, correspondence, agreements or understanding between the parties with respect to such matters.  No amendment or waiver of any of the provisions of this Agreement shall be effective unless in writing and signed by both parties.  Any subsequent change or changes in Employee&#8217;s duties, salary or compensation will not affect the validity or scope of this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#91;Rest of Page Intentionally Left Blank&#93;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Authorized representatives of the parties have executed this Agreement as of the Effective Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">Angion Biomedica Corp</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;   &#160;&#160;&#160;&#160;&#47;s&#47; Jay Venkatesan&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#47;s&#47; Itzhak D. Goldberg</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> _________________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">         Name&#58;&#160;&#160;&#160;&#160;Jay Venkatesan&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58; Itzhak D. Goldberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">         Title&#58; &#160;&#160;&#160;&#160;CEO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;    February 28, 2022&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;February 25, 2022</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">________________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Date&#58; _________________________</font></div><div style="padding-left:216pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">EXHIBIT A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">PRIOR INVENTIONS</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TO&#58;&#160;&#160;&#160;&#160;ANGION BIOMEDICA CORP.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FROM&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">_________________________</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DATE&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:57.6pt;text-align:justify;text-indent:-57.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SUBJECT&#58;&#160;&#160;&#160;&#160;Prior Inventions </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Except as listed in Section 2 below, the following is a complete list of all inventions or improvements relevant to the subject matter of my employment by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Angion Biomedica Corp.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) that have been made or conceived or first reduced to practice by me alone or jointly with others prior to my engagement by the Company&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;&#160;&#160;&#160;&#160;No inventions or improvements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;&#160;&#160;&#160;&#160;See below&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:28.8pt;text-align:justify;text-indent:-28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;&#160;&#160;&#160;&#160;Additional sheets attached.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due to a prior confidentiality agreement, I cannot complete the disclosure under Section&#160;1 above with respect to inventions or improvements generally listed below, the proprietary rights and duty of confidentiality with respect to which I owe to the following party(ies)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Invention or Improvement&#160;&#160;&#160;&#160;Party(ies)&#160;&#160;&#160;&#160; Relationship</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;_________________________</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">                  _________________________</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;_________________________</font></div><div style="margin-bottom:12pt;padding-left:28.8pt;text-align:justify;text-indent:-28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;&#160;&#160;&#160;&#160;Additional sheets attached.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>5
<FILENAME>egoldberg-angionxformsepar.htm
<DESCRIPTION>EX-10.8
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i9e9570ee6e7f4ee8b1c167cc5cb1f91a_1"></div><div style="min-height:78.48pt;width:100%"><div style="text-align:justify"><img alt="image_01.jpg" src="image_01.jpg" style="height:57px;margin-bottom:5pt;vertical-align:text-bottom;width:117px"></div></div><div style="margin-bottom:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Via Email</font></div><div style="margin-bottom:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2022</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Elisha Goldberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7 Essex Street, Apt. 4A, </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">New York, NY 10002</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">elisha.goldberg&#64;gmail.com</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Separation Agreement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear Elisha&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This letter sets forth the substance of the separation agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) that Angion Biomedica Corp. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is offering to you to aid in the transition of your employment. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Separation Date.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Your last day of work with the Company and your employment termination date was January 31, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Separation Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  On the Separation Date, the Company paid you all accrued salary, and all accrued and unused vacation earned through the Separation Date, subject to standard payroll deductions and withholdings.  You are entitled to these payments regardless of whether or not you sign this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Severance Benefits.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If you timely return this fully-signed Agreement to the Company, allow the releases set forth herein to become effective, and remain in compliance with all obligations contained in this Agreement, then, in full satisfaction of any obligations the Company may have to provide you with severance benefits the Company will provide you with the following severance benefits&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Severance Pay</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company will pay you the equivalent of 13 months of your base salary in effect as of the Separation Date ($334,750.00), subject to standard payroll deductions and withholdings (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Severance Pay</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Severance Pay will be paid to you in the form of salary continuation payments made in accordance with the Company&#8217;s regularly scheduled payroll paydays, beginning on the first such payroll date following the Effective Date (as defined in the Release). The first installment payment shall contain all of the payments that would have been made had the payments commenced on the first payroll date following the Separation Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.35pt">Health Insurance Payment.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Your participation in the Company&#8217;s group health insurance plan will end on the last day of the month in which your employment termination occurs. To the extent provided by the federal COBRA law or, if applicable, state insurance laws, and by the Company&#8217;s current group health insurance policies, you may be eligible to continue your group health insurance benefits at your own expense following the Separation Date.  Later, you may be able to convert to an individual policy through the provider of the Company&#8217;s health insurance, if you wish.  You will be provided with a separate notice describing your rights and obligations under COBRA.  As an additional severance benefit, the Company will pay you a lump sum cash payment in the total amount of $11,338.00, less applicable deductions and withholdings, for your use in covering COBRA premiums to continue your health insurance coverage (including coverage for your spouse and eligible dependents, if applicable) for the period of 13 months from your Separation Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COBRA Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;1</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:78.48pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Elisha Goldberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2022</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">However, you are not obligated to use such COBRA Payment toward the cost of COBRA premiums.  The COBRA Payment will be paid to you on the first payroll date following the Effective Date (as defined in the Release).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Equity.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You were previously granted options to purchase shares of the Company&#8217;s common stock, pursuant to the Company&#8217;s Amended and Second Restated 2015 Equity Incentive Plan and&#47;or 2021 Incentive Award Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Under the terms of the Plans, and your equity grant, vesting ceased as of the Separation Date.  Your vested options shall continue to be governed by the terms of the applicable grant notices, stock option agreements and the Plans, but notwithstanding the foregoing and for the avoidance of doubt your rights to exercise any vested options shall not expire until December 31, 2022. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Other Compensation or Benefits.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You acknowledge and agree that, except as expressly provided in this Agreement, you will not receive any additional compensation, severance or benefits after the Separation Date, with the exception of any vested right you may have under the express terms of a written ERISA-qualified benefit plan (e.g., 401(k) account).  You further acknowledge and agree that the benefits set forth herein fulfill and exceed all of the Company&#8217;s obligations to pay you severance benefits in connection with your employment termination. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Expense Reimbursements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You agree that you have submitted your final documented expense reimbursement statement reflecting all business expenses you incurred through the Separation Date, if any, for which you seek reimbursement.  The Company will reimburse you for these expenses pursuant to its regular business practice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Return of Company Property.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  At a time and place specified by the Company and by no later than the close of business on the Effective Date, you shall return to the Company all Company documents (and all copies thereof) and other Company property in your possession or control.  You agree that you will make a diligent search to locate any such documents, property and information within the timeframe referenced above.  In addition, if you have used any personally owned computer, server, or e-mail system to receive, store, review, prepare or transmit any confidential or proprietary data, materials or information of the Company, then within five (5) business days after the Separation Date, you must provide the Company with a computer-useable copy of such information and then permanently delete and expunge such confidential or proprietary information from those systems without retaining any reproductions (in whole or in part)&#59; and you agree to provide the Company access to your system, as requested, to verify that the necessary copying and deletion is done.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Your timely compliance with the provisions of this paragraph is a precondition to your receipt of the severance benefits provided hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Proprietary Information Obligations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  Both during and after your employment you acknowledge your continuing obligations under your Confidential Information and Invention Assignment Agreement, including your obligations not to use or disclose any confidential or proprietary information of the Company.  You hereby agree to timely execute the Confidential Information and Invention Assignment Agreement (&#8220;CDA&#8221;) set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in exchange for the consideration provided to you in this Agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Nondisparagement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You agree not to disparage the Company and its officers, directors, employees, shareholders and agents, in any manner likely to be harmful to them or their business, business reputations or personal reputations&#59; provided that&#58; (a) you may respond accurately and fully to any question, inquiry or request for information when required by legal process (e.g., a valid subpoena or other similar compulsion of law) or as part of a government investigation and (b) nothing in this provision or this Agreement is intended to prohibit or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;2</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">261503589 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:78.48pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Elisha Goldberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2022</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">restrain you in any manner from making disclosures that are protected under the whistleblower provisions of federal or state law or regulation or limit your rights under Section 7 of the National Labor Relations Act, which include your right to engage in protected concerted activities with other employees to improve or discuss terms and conditions of employment. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company agrees to direct its officers and directors not to disparage you in any manner likely to be harmful to your business, business reputation or personal reputation&#59; provided, however, that both you and the Company must respond accurately and truthfully to any question, inquiry or request for information when required by legal process (e.g., a valid subpoena or other similar compulsion of law) or as part of a government investigation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">No Admissions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You understand and agree that the promises and payments in consideration of this Agreement shall not be construed to be an admission of any liability or obligation by the Company to you or to any other person, and that the Company makes no such admission</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Release of Claims.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;General Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In exchange for the consideration provided to you under this Agreement to which you would not otherwise be entitled, you hereby generally and completely release the Company, TriNet Group Inc. (&#8220;TriNet&#8221;), or their parent and subsidiary entities, and their current and former directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, insurers, affiliates, and assigns (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Released Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) from any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to or on the date you sign this Agreement (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Released Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;Scope of Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Released Claims include, but are not limited to&#58;  (i) all claims arising out of or in any way related to your employment with the Company, or the termination of that employment&#59; (ii) all claims related to your compensation or benefits from the Company, including salary, bonuses, commissions, vacation, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership, equity, or profits interests in the Company&#59; (iii) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing&#59; (iv) all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy&#59; and (v) all federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys&#8217; fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of 1967 (as amended) (the &#8220;ADEA&#8221;), the New York State Human Rights Law, the New York Equal Opportunity for Disabled Persons Act&#59; the New York City Human Rights Law, the employment and civil rights laws of New York.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;ADEA Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You acknowledge that you are knowingly and voluntarily waiving and releasing any rights you may have under the ADEA (the &#8220;ADEA Waiver&#8221;), and that the consideration given for the ADEA Waiver is in addition to anything of value to which you are already entitled.  You further acknowledge that you have been advised, as required by the ADEA, that&#58;  (i) your ADEA Waiver does not apply to any rights or claims that may arise after the date that you sign this Agreement&#59; (ii) you should consult with an attorney prior to signing this Agreement (although you may choose voluntarily not to do so)&#59; (iii) you have twenty-one (21) days to consider this Agreement (although you may choose voluntarily to sign it earlier)&#59; (iv) you have seven (7) days following the date you sign this Agreement to revoke the ADEA Waiver&#59; and (v) this Agreement will not be effective until the date upon which the revocation period has expired, which will be the eighth day after the date that this Agreement is signed by you provided that you do not revoke it (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;3</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">261503589 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:78.48pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Elisha Goldberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2022</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)&#160;&#160;&#160;&#160;Section 1542 Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  YOU UNDERSTAND THAT THIS AGREEMENT INCLUDES A RELEASE OF ALL KNOWN AND UNKNOWN CLAIMS.  In giving the release herein, which includes claims which may be unknown to you at present, you acknowledge that you have read and understand Section 1542 of the California Civil Code, which reads as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.&#8221; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You hereby expressly waive and relinquish all rights and benefits under that section and any law of any other jurisdiction of siilar effect with respect to your release of any unknown or unsuspected claims herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)&#160;&#160;&#160;&#160;Excluded Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding the foregoing, the following are not included in the Released Claims (the &#8220;Excluded Claims&#8221;)&#58; (i) any rights or claims for indemnification you may have pursuant to any written indemnification agreement with the Company to which you are a party or under applicable law&#59; (ii)&#160;any rights which are not waivable as a matter of law&#59; and (iii) any claims for breach of this Agreement.  You hereby represent and warrant that, other than the Excluded Claims, you are not aware of any claims you have or might have against any of the Released Parties that are not included in the Released Claims.  You understand that nothing in this Agreement limits your ability to file a charge or complaint with the Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission (&#8220;Government Agencies&#8221;).  You further understand this Agreement does not limit your ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company.  While this Agreement does not limit your right to receive an award for information provided to the Securities and Exchange Commission, you understand and agree that, to maximum extent permitted by law, you are otherwise waiving any and all rights you may have to individual relief based on any claims that you have released and any rights you have waived by signing this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.&#160;&#160;&#160;&#160;Representations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  You hereby represent that you have been paid all compensation owed and for all hours worked, have received all the leave and leave benefits and protections for which you are eligible, pursuant to the Family and Medical Leave Act or otherwise, and have not suffered any on-the-job injury for which you have not already filed a claim.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12. &#160;&#160;&#160;&#160;Miscellaneous.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  This Agreement, including its exhibits, constitutes the complete, final and exclusive embodiment of the entire agreement between you and the Company with regard to the subject matter hereof.  It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other agreements, promises, warranties or representations concerning its subject matter.  This Agreement may not be modified or amended except in a writing signed by both you and a duly authorized officer of the Company.  This Agreement will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit of both you and the Company, their heirs, successors and assigns.  If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any other provision of this Agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties insofar as possible </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;4</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">261503589 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:78.48pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Elisha Goldberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2022</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">under applicable law.  This Agreement shall be construed and enforced in accordance with the laws of the State of New York without regard to conflicts of law principles.  Any ambiguity in this Agreement shall not be construed against either party as the drafter.  Any waiver of a breach of this Agreement, or rights hereunder, shall be in writing and shall not be deemed to be a waiver of any successive breach or rights hereunder.  This Agreement may be executed in counterparts which shall be deemed to be part of one original, and facsimile and signatures transmitted by PDF shall be equivalent to original signatures.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#91;The rest of page intentionally left blank&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;5</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">261503589 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:78.48pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Elisha Goldberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2022</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If this Agreement is acceptable to you, please sign below and return the original to me on or within twenty-one (21) days after the Separation Date.  The Company&#8217;s offer contained herein will automatically expire if we do not receive the fully signed Agreement within this timeframe.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I wish you good luck in your future endeavors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Sincerely,</font></div><div style="margin-bottom:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Angion Biomedica Corp.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;  &#47;s&#47; Jay Venkatesan</font></div><div style="padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Jay Venkatesan</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit A &#8211; Confidential Information and Inventions Assignment Agreement</font></div><div style="margin-bottom:24pt;text-align:justify"><font><br></font></div><div style="margin-bottom:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Accepted and Agreed&#58;</font></div><div style="margin-bottom:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Elisha Goldberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Elisha Goldberg</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2022</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;6</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.948%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">261503589 v3</font></div><div><font><br></font></div></td></tr></table></div></div></div><div id="i9e9570ee6e7f4ee8b1c167cc5cb1f91a_4"></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:justify"><img alt="image_01.jpg" src="image_01.jpg" style="height:57px;margin-bottom:5pt;vertical-align:text-bottom;width:117px"></div></div><div style="margin-bottom:6pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;1</font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Elisha Goldberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2022</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONFIDENTIAL INFORMATION AND INVENTIONS ASSIGNMENT AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Confidential Information and Invention Assignment Agreement</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;This Confidential Information and Invention Disclosure Agreement (the &#8220;Agreement&#8221;), dated May 1, 2018 (the &#8220;Effective Date&#8221;) is between Angion Biomedica Corp. and its affiliates (collectively, the &#8220;Company&#8221;) and Elisha Goldberg (&#8220;Employee&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Employee enters this Agreement in consideration of Employee&#8217;s employment or continued employment and the compensation now and later paid to Employee during his or her employment with the Company, and the Company&#8217;s agreement to provide Employee with access to its Confidential Information.  Accordingly, the parties agree as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Employee shall, throughout the term of employment with the Company and thereafter, maintain the confidentiality of all Confidential Information of the Company, as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.1.  &#160;&#160;&#160;&#160;The term &#8220;Confidential Information&#8221; shall mean any and all confidential, proprietary and trade secret information of the Company, whether in written, oral, electronic or other form, including but not limited to&#58; (i) any and all Inventions (as defined herein)&#59; (ii) information and facts concerning Company employees and service providers, business plans, customers, future customers, suppliers, licensors, licensees, partners, investors, affiliates or others&#59; (iii) training methods and materials, financial information, sales prospects, client lists, customer lists, inventions&#59; (iv) information regarding research, development, new products, business and operational plans, budgets, unpublished financial statements and projections, costs, margins, discounts, credit terms, pricing, quoting procedures, future plans and strategies, capital-raising plans, internal services, suppliers and supplier information&#59; (v) any other scientific, technical or trade secrets of the Company or of any third party provided to Employee or the Company under a condition of confidentiality&#59; and (vi) any other non-public information that a competitor of Company could use to the Company&#8217;s competitive disadvantage.  The term &#8220;trade secrets,&#8221; as used in this Agreement, shall be given its broadest possible interpretation under California law and shall include, without limitation, anything tangible or intangible or electronically kept or stored, which constitutes, represents, evidences or records any secret scientific, technical, merchandising, production or management information, or any design, process, procedure, formula, invention, improvement or other confidential or proprietary information or documents.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.2.  &#160;&#160;&#160;&#160;This Agreement covers all Confidential Information disclosed to Employee during his or her employment with the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.3. &#160;&#160;&#160;&#160;Employee&#8217;s obligations regarding Confidential Information continue following termination of employment.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.4.  &#160;&#160;&#160;&#160;Employee shall&#58; (a) use Confidential Information only within the scope of his or her employment with the Company&#59; (b) hold in confidence and will not disclose, use, lecture upon, or publish any of the Company&#8217;s Confidential Information to any third party without the prior written approval of the Company&#59; (c) restrict dissemination of Confidential Information only to those Company employees who have a need to know&#59; (d) follow all Company policies in preventing disclosure of Confidential Information to third parties&#59;  (e) not use Confidential Information to solicit or induce any vendor, supplier or strategic partner of the Company to cease doing business with the Company&#59; and (f) not disclose to the Company any confidential </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Elisha Goldberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2022</font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">information belonging to a third party.  Employee shall promptly notify the Company of any loss of Confidential Information or breach of these obligations.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.5.  Confidential Information shall not include any information that&#58; (a) is or becomes publicly known through no wrongful act of Employee or was known to Employee prior to employment with the Company or generally known in the trade or industry&#59; (b) is furnished to a third party by the Company without a duty of confidentiality&#59; (c) is explicitly approved for release by written authorization of the Company&#59; or (d) is ordered to be disclosed by a court of competent jurisdiction, provided Employee gives timely written notice of such order to the Company to enable it to seek a protective order.   </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;1.6.&#160;&#160;&#160;&#160;Employee will obtain the Company's written approval before publishing or submitting for publication any material (written, verbal, or otherwise) that discloses and&#47;or incorporates any Confidential Information.  Employee hereby assigns to the Company any rights Employee may have or acquire in such Confidential Information and recognize that all Confidential Information will be the sole property of the Company and its assigns.  Employee will take all reasonable precautions to prevent the inadvertent or accidental disclosure of Confidential Information.  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.7.&#160;&#160;&#160;&#160;During Employee&#8217;s employment by the Company, Employee will not improperly use or disclose any confidential information or trade secrets, if any, of any former employer or any other person to whom Employee has an obligation of confidentiality, and Employee will not bring onto the premises of the Company, or upload to, transmit to, or store on any Company computer systems any unpublished documents or any property belonging to any former employer or any other person to whom Employee has an obligation of confidentiality unless consented to in writing by that former employer or person.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.8&#160;&#160;&#160;&#160;Notwithstanding the foregoing, pursuant to 18 U.S.C. Section 1833(b), Employee will not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that&#58; (1) is made in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law&#59; or (2) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.  Additionally, nothing in this Agreement shall limit&#58; (i) Employee&#8217;s right to discuss his or her employment or unlawful acts in the Company&#8217;s workplace, including but not limited to sexual harassment&#59; (ii) Employee&#8217;s right to report possible violations of law or regulation with any federal, state or local government agency&#59; or (iii) Employee&#8217;s right to discuss the terms and conditions of their employment with others to the extent expressly permitted by Section 7 of the National Labor Relations Act or to the extent that such disclosure is protected under applicable &#8220;whistleblower&#8221; statutes or other provisions of law or regulation.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the period in which Employee performs services for or at the request of the Company and for a period of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">one (1) year </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">following the termination of Employee&#8217;s employment with the Company for any reason, including voluntary or involuntary termination, Employee shall not, either individually or on behalf of or through any third party, directly or indirectly, without the prior written consent of the Company&#58; (i) solicit, induce, encourage, or participate in soliciting, inducing or encouraging any employee of or consultant to the Company to terminate his or her relationship with the Company or any such parent, subsidiary or affiliate for any reason&#59; or (ii) solicit the employment or engagement of any employee of or consultant to the Company while any such person is providing services to the Company.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Ownership of Ideas, Copyrights and Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Elisha Goldberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2022</font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.1  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Property of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All ideas, discoveries, creations, manuscripts and properties, innovations, improvements, know-how, inventions, designs, developments, apparatus, techniques, methods, biological processes, cell lines, laboratory notebooks, formulae and other similar material (collectively the &#8220;Inventions&#8221;) which may be used in the business of the Company, whether patentable, copyrightable or not, which Employee may conceive, reduce to practice or develop while employed by the Company, alone or in conjunction with another or others, whether during or outside of regular business hours, whether or not on the Company&#8217;s premises or with the use of its equipment, and whether at the request or upon the suggestion of the Company or otherwise, shall be the sole and exclusive property of the Company, and Employee shall not publish any of the Inventions without the prior written consent of the Company.  Without limiting the foregoing, Employee also acknowledges that all original works of authorship which are made by Employee (solely or jointly with others) within the scope of Employee&#8217;s employment or which relate to the business of the Company or a Company affiliate and which are protectable by copyright are &#8220;works made for hire&#8221; pursuant to the United States Copyright Act (17 U.S.C. Section 101).  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Assignment of Company Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Employee hereby assigns, grants, and conveys to the Company or its designee all of Employee&#8217;s right, title and interest in and to all of the Inventions whether or not patentable or registrable under copyright or similar statute.   Employee further agrees that all Inventions includes an assignment of all Moral Rights.  To the extent such Moral Rights cannot be assigned to Company and to the extent the following is allowed by the laws in any country where Moral Rights exist, Employee hereby unconditionally and irrevocably waives the enforcement of such Moral Rights, and all claims and causes of action of any kind against Company or related to Company&#8217;s customers, with respect to such rights.  Employee further agrees that neither Employee&#8217;s successors-in-interest nor legal heirs retain any Moral Rights in any Company Inventions.  Nothing contained in this Agreement may be construed to reduce or limit Company&#8217;s rights, title, or interest in any Company Inventions so as to be less in any respect than that Company would have had in the absence of this Agreement. &#8220;Moral Rights&#8221; means all paternity, integrity, disclosure, withdrawal, special and similar rights recognized by the laws of any jurisdiction in the world. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.3  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  At any time during or after the period of employment with the Company, Employee shall comply with all Company policies concerning Inventions and shall fully cooperate with the Company and its attorneys and agents in the preparation and filing of all papers and other documents as may be required to perfect the Company&#8217;s rights in and to any of such Inventions, including, but not limited to, joining in any proceeding to obtain letters patent, copyrights, trademarks or other legal rights with respect to any such Inventions in the United States and in any and all other countries, provided that the Company shall bear the expense of such proceedings, and that any patent or other legal right so issued to Employee personally shall be assigned by Employee to the Company or its designee without any further compensation to Employee.  Employee designates the Company as his or her agent, and grants to the Company a power of attorney with full power of substitution (which power of attorney shall be deemed coupled with an interest), for the purpose of effecting the foregoing assignments to the Company with the same legal force and effect as if executed by Employee.  Employee hereby waives and quitclaims to the Company any and all claims, of any nature whatsoever, which Employee now or may hereafter have for infringement of any Inventions assigned under this Agreement to the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.4 &#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Licensing and Use of Innovations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  With respect to any Inventions and work of any similar nature (from any source), whenever created, which Employee has not prepared or originated in the performance of employment (including Prior Inventions, as defined herein), but which Employee provides to the Company or incorporates in any Company product or system, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Elisha Goldberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2022</font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee hereby grants to the Company a royalty-free, fully paid-up, non-exclusive, perpetual and irrevocable license throughout the world to use, modify, create derivative works from, disclose, publish, translate, reproduce, deliver, perform, dispose of, and to authorize others so to do, all such Inventions.  Employee shall not include in any Inventions delivered to the Company or used on its behalf, without the prior written approval of the Company, any material which is or shall be patented, copyrighted or trademarked by Employee or others unless Employee provides the Company with the written permission of the holder of any patent, copyright or trademark owner for the Company to use such material in a manner consistent with then-current Company policy. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.5  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Prior Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to this Agreement are any and all Inventions in which Employee claims or intends to claim any right, title and interest, including, without limitation, patent, copyright and trademark interests,  that Employee has, alone or jointly with others, made prior to the commencement of employment with the Company that Employee considers to be his or her property or the property of third parties and that shall be excluded from the scope of this Agreement (collectively, &#8220;Prior Inventions&#8221;).  If no such disclosure is provided in Exhibit A, Employee represents that there are no Prior Inventions.  If disclosure of any such Prior Inventions would cause Employee to violate any prior confidentiality agreement, Employee understands that Employee is not to list such Prior Inventions in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit&#160;A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> but is only to disclose a cursory name for each such invention, a listing of the party(ies) to whom it belongs and the fact that full disclosure as to such inventions has not been made for that reason.  A space is provided on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">for such purpose.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Incorporation of Software Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Employee agrees not to incorporate into any Inventions, including any Company software, or otherwise deliver to Company, any software code licensed under the GNU General Public License, Lesser General Public License, or any other license that, by its terms, requires or conditions the use or distribution of such code on the disclosure, licensing, or distribution of any source code owned or licensed by Company, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">except</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in strict compliance with Company&#8217;s policies regarding the use of such software or as directed by the Company.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.7  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Obligation to Keep Company Informed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During the period of Employee&#8217;s employment and for a period of six (6) months after termination of Employee&#8217;s employment with the Company, Employee will promptly disclose to the Company fully and in writing all Inventions authored, conceived or reduced to practice by Employee, either alone or jointly with others.  In addition, Employee will promptly disclose to the Company all patent applications filed by Employee or on Employee&#8217;s behalf within a year after termination of employment.  At the time of each such disclosure, Employee will advise the Company in writing of any Inventions that Employee believes fully qualify for protection under the provisions in Section 3.9&#59; and Employee will at that time provide to the Company in writing all evidence necessary to substantiate that belief.  The Company will keep in confidence and will not use for any purpose or disclose to third parties without Employee&#8217;s consent any confidential information disclosed in writing to the Company pursuant to this Agreement relating to Inventions that qualify fully for protection under Section 3.9.  Employee will preserve the confidentiality of any Invention that does not fully qualify for protection under Section 3.9.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.8  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Employee agrees to keep and maintain adequate and current records (in the form of notes, sketches, drawings and in any other form that may be required by the Company) of all Confidential Information developed by Employee and all Company Inventions made by Employee during the period of Employee&#8217;s employment at the Company, which records will be available to and remain the sole property of the Company at all times.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Elisha Goldberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2022</font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.9 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exception to Assignments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company and Employee acknowledge that this Agreement does not require assignment of any Invention which qualifies fully for protection under Section 2870 of the California Labor Code (hereinafter &#8220;Section 2870&#8221;), which provides as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer&#8217;s equipment, supplies, facilities, or trade secret information except for those inventions that either&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(1)&#160;&#160;&#160;&#160;Relate at the time of conception or reduction to practice of &#160;&#160;&#160;&#160;the invention to the employer&#8217;s business, or actual or demonstrably anticipated research or development of the employer&#59; or</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(2)&#160;&#160;&#160;&#160;Result from any work performed by the employee for the employer.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;To the extent a provision in this Agreement purports to require an employee to assign an invention otherwise excluded from being required to be assigned under subdivision (a), the provision is against the public policy of this state and is unenforceable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Reasonableness of Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Employee acknowledges that the types of conduct which are prohibited by Sections 1 and 2 are narrow and reasonable in relation to the skills which represent Employee&#8217;s principal marketable asset both to the Company and to other prospective employers. Employee has read this entire Agreement and understands it.  Employee agrees that this Agreement does not prevent Employee from earning a living or pursuing Employee&#8217;s career.  Employee agrees that the restrictions contained in this Agreement are reasonable, proper, and necessitated by the Company&#8217;s legitimate business interests.  Employee represents and agrees that Employee is entering into this Agreement freely and with knowledge of its contents with the intent to be bound by the Agreement and the restrictions contained in it.  In the event that a court finds this Agreement, or any of its restrictions, to be ambiguous, unenforceable, or invalid, Employee and the Company agree that the court will read the Agreement as a whole and interpret the restriction(s) at issue to be enforceable and valid to the maximum extent allowed by law.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">No Conflicting Obligations&#47;Duty of Loyalty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Employee represents that he or she has no commitments or obligations inconsistent with this Agreement, and Employee shall not enter into any such conflicting agreement during his or her employment with the Company.  Employee agrees that during the period of Employee&#8217;s employment by the Company, Employee will not, without the Company's express written consent, directly or indirectly engage in any employment or business activity which is directly or indirectly competitive with, or would otherwise conflict with, Employee&#8217;s employment by the Company.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Return of Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon termination of Employee&#8217;s employment with the Company, Employee agrees to deliver to Company any and all materials, together with all copies thereof, containing or disclosing any Company Inventions or Confidential Information.  Employee will not copy, delete, or alter any information contained upon my Company computer or Company equipment before Employee returns it to Company.  In addition, if Employee has used any personal computer, server, or e-mail system to receive, store, review, prepare or transmit any Company information, including but not limited to, Confidential Information, Employee agrees to provide Company with a computer-useable copy of all such information and then permanently delete such information from those systems&#59; and Employee agrees to provide Company access to his or her system as reasonably requested to verify that the necessary copying and&#47;or deletion is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Elisha Goldberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2022</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">completed.  Employee further agrees that any property situated on Company&#8217;s premises and owned by Company, including disks and other storage media, filing cabinets or other work areas, is subject to inspection by Company&#8217;s personnel at any time during Employee&#8217;s employment, with or without notice.  Prior to leaving, Employee hereby agrees to&#58; provide Company any and all information needed to access any Company property or information returned or required to be returned pursuant to this paragraph, including without limitation any login, password, and account information&#59; cooperate with Company in attending an exit interview&#59; and complete and sign Company&#8217;s termination statement if required to do so by Company.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">   </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Publication of This Agreement to Subsequent Employer or Business Associates of Employee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  If Employee is offered employment, or the opportunity to enter into any business venture as owner, partner, consultant or other capacity, while the restrictions in Section 2 of this Agreement are in effect, Employee agrees to inform his or her potential employer, partner, co-owner and&#47;or others involved in managing the business Employee has an opportunity to be associated with, of his or her obligations under this Agreement and to provide such person or persons with a copy of this Agreement.  Employee agrees to inform Company of all employment and business ventures which Employees enters into while the restrictions described in Section 2 of this Agreement are in effect and Employee authorizes Company to provide copies of this Agreement to Employee&#8217;s employer, partner, co-owner and&#47;or others involved in managing the business Employee has an opportunity to be associated with and to make such persons aware of his or her obligations under this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.1  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company may assign its rights and obligations to any person or entity that succeeds it to all or substantially all of the Company&#8217;s business or that aspect of the Company&#8217;s business in which Employee is principally involved.  Employee&#8217;s rights and obligations under this Agreement may not be assigned by Employee, but will be binding upon Employee&#8217;s heirs, executors, administrators and other legal representatives.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.2  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law, Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The laws of the state of California shall govern the provisions of this Agreement, and the parties agree to submit to the exclusive jurisdiction of the courts of Alameda County, California.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.3  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All notices required or permitted to be given under this Agreement to any party shall be in writing and shall be deemed given upon&#58; (i) personal delivery&#59; (ii) acknowledgment of facsimile transmission&#59; or (iii) if delivered by certified mail with return receipt requested, three (3) days after mailing or when received (whichever is earlier).  All postage and registration or certification fees must be prepaid and addressed as set forth on the signature page of this Agreement.  Any notices required or permitted under this Agreement will be given to the Company at its headquarters location at the time notice is given, labeled &#8220;Attention Chief Executive Officer,&#8221; and to Employee at Employee address as listed on the Company payroll, or at such other address as the Company or Employee may designate by written notice to the other.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.4  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Injunctive Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Employee expressly acknowledges that any breach or threatened breach of any of the terms and&#47;or conditions of this Agreement may result in substantial, continuing, immediate, and irreparable injury to the Company, and Employee agrees that it may be impossible to assess the damages caused by Employee&#8217;s violation of this Agreement.  Therefore, in addition to any other remedy that may be available to the Company, the Company shall be entitled to seek injunctive or other equitable relief, without bond, by a court of appropriate jurisdiction in the event of any breach or threatened breach of the terms of this Agreement.   In the event the Company enforces this Agreement through a court order, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Elisha Goldberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2022</font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee agrees that the restrictions of Section 2 will remain in effect for a period of twelve (12) months from the effective date of the order enforcing the Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.5  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Opportunity to Review</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Employee hereby acknowledges that he or she has had adequate opportunity to review these terms and conditions and to reflect upon and consider the terms and conditions of this Agreement, and has had the opportunity to consult with his&#47;her own counsel regarding such terms.  Employee further acknowledges that he or she fully understands the terms of this Agreement and has voluntarily executed this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.6  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">At-Will Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">.  Employee acknowledges that nothing in this Agreement shall confer any right with respect to continuation of employment by the Company, nor shall it interfere in any way with Employee&#8217;s right or the Company&#8217;s right to terminate his or her employment at any time with or without cause or advance notice, except as otherwise expressly provided in any written employment agreement he or she has with the Company.  This Agreement will not be construed against any party by reason of the drafting or preparation of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.7  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In case any one or more of the provisions, subsections, or sentences contained in this Agreement will, for any reason, be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect the other provisions of this Agreement, and this Agreement will be construed as if such invalid, illegal or unenforceable provision had never been contained in this Agreement.  Moreover, if any one or more of the provisions contained in this Agreement will for any reason be held to be excessively broad as to duration, geographical scope, activity or subject, it will be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it will then appear.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.8  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No waiver by the Company of any breach of this Agreement will be a waiver of any preceding or succeeding breach.  No waiver by the Company of any right under this Agreement will be construed as a waiver of any other right.  The Company will not be required to give notice to enforce strict adherence to all terms of this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.9  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The provision of this Agreement, shall survive the termination of Employee&#8217;s employment with the Company for any reason, and the assignment of this Agreement by the Company to any successor in interest or other assignee.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.10   &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may be executed in two or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.  Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and any counterpart so delivered will be deemed to have been duly and validly delivered and be valid and effective for all purposes.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.11  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement, together with Employee&#8217;s offer letter, constitutes the entire agreement of the parties with respect to its subject matter, and supersedes any and all prior discussions, correspondence, agreements or understanding between the parties with respect to such matters.  No amendment or waiver of any of the provisions of this Agreement shall be effective unless in writing and signed by both parties.  Any subsequent change or changes in Employee&#8217;s duties, salary or compensation will not affect the validity or scope of this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">&#91;Rest of Page Intentionally Left Blank&#93;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Elisha Goldberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2022</font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Authorized representatives of the parties have executed this Agreement as of the Effective Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">Angion Biomedica Corp</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;   &#47;s&#47; Jay Venkatesan&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#47;s&#47; Elisha Goldberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">        _________________________&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">         Name&#58; Jay Venkatesan&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58; Elisha Goldberg </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">         Title&#58;   President and CEO </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:77.76pt;width:100%"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Elisha Goldberg</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 1, 2022</font></div><div style="text-align:justify"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">EXHIBIT A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">PRIOR INVENTIONS</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TO&#58;&#160;&#160;&#160;&#160;ANGION BIOMEDICA CORP.</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FROM&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">_________________________</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DATE&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:57.6pt;text-align:justify;text-indent:-57.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SUBJECT&#58;&#160;&#160;&#160;&#160;Prior Inventions </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Except as listed in Section 2 below, the following is a complete list of all inventions or improvements relevant to the subject matter of my employment by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Angion Biomedica Corp.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) that have been made or conceived or first reduced to practice by me alone or jointly with others prior to my engagement by the Company&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;&#160;&#160;&#160;&#160;No inventions or improvements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;&#160;&#160;&#160;&#160;See below&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:28.8pt;text-align:justify;text-indent:-28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;&#160;&#160;&#160;&#160;Additional sheets attached.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due to a prior confidentiality agreement, I cannot complete the disclosure under Section&#160;1 above with respect to inventions or improvements generally listed below, the proprietary rights and duty of confidentiality with respect to which I owe to the following party(ies)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Invention or Improvement&#160;&#160;&#160;&#160;Party(ies)&#160;&#160;&#160;&#160; Relationship</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;_________________________</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">                  _________________________</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;_________________________</font></div><div style="margin-bottom:12pt;padding-left:28.8pt;text-align:justify;text-indent:-28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;&#160;&#160;&#160;&#160;Additional sheets attached.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11(A)
<SEQUENCE>6
<FILENAME>a200909flg-angionfirstamen.htm
<DESCRIPTION>EX-10.11(A)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="idfb3fc81eddb4c7eb5de3ad8573ae86f_1"></div><div style="min-height:95.76pt;width:100%"><div style="text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:46px;margin-bottom:5pt;vertical-align:text-bottom;width:196px"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FIRST AMENDMENT TO CONFIDENTIAL CONSULTING AGREEMENT</font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This first amendment (the &#8220;First Amendment&#8221;) to the Confidential Consulting Agreement dated June 3, 2020 (the &#8220;Agreement&#8221;) by and between the parties hereto, is executed as of the date shown on the signature page (the &#8220;Effective Date&#8221;), by and between FLG Partners, LLC, a California limited liability company (&#8220;FLG&#8221;), and Angion Biomedica Corp. (&#8220;Client&#8221;).</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RECITALS</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, FLG is in the business of providing certain financial services&#59; and</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Client wishes to retain FLG to provide and FLG wishes to provide such services to Client on the terms set forth herein&#59; and</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, FLG has been continuously retained by Client since June 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> and</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the parties hereto wish to extend the term of the Agreement&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, in consideration of the mutual covenants set forth herein, the parties hereto agree as follows&#58;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-0.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 1 of #NUM_PAGES#&#160;&#160;&#160;&#160;200909 FLG-Angion First Amendment to Agreement.docx</font></div></div></div><div id="idfb3fc81eddb4c7eb5de3ad8573ae86f_4"></div><hr style="page-break-after:always"><div style="min-height:89.28pt;width:100%"><div style="text-align:center"><img alt="image_1.jpg" src="image_1.jpg" style="height:46px;margin-bottom:5pt;vertical-align:text-bottom;width:196px"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">FIRST AMENDMENT TO CONFIDENTIAL CONSULTING AGREEMENT</font></div></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt;text-decoration:underline">Additional Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  &#160;&#160;&#160;&#160;Exhibit A of the Agreement is amended to add &#8220;7. Additional Compensation&#58; Non-qualified Common stock purchase options (the &#8220;Options&#8221;) equal to 36,000 shares. The exercise price per share of the Options (as determined by Client&#8217;s Board of Directors) shall be computed pursuant to and consistent with Client&#8217;s IRC &#167;409A per share common stock valuation (the &#8220;Common Stock Value&#8221;) as of the grant date of the Options. 9,000 of the Options shall be vested upon grant, with the balance vesting ratably over the subsequent nine (9) months. Vesting of the Options shall cease upon termination of the Agreement, and the Options shall be exercisable for one (1) year after termination of the Agreement. Subject to compliance with applicable federal and state securities laws and regulations, the Options shall be issued 95% in the name of FLG Member and 5% in the name of FLG, each rounded to the nearest whole number of shares subject to the Options. </font></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;All other terms and conditions of the Agreement remain unchanged.  This First Amendment shall be incorporated in the Agreement as Exhibit B.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the parties hereto have executed this Amendment as of the Effective Date.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.521%"><tr><td style="width:1.0%"></td><td style="width:51.961%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.839%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CLIENT&#58;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Angion Biomedica Corp.,</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware corporation.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;Jay Venkatesan</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signed&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Chief Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Address&#58;&#160;&#160;&#160;&#160;51 Charles Lindbergh Boulevard<br>&#160;&#160;&#160;&#160;Uniondale, NY 11553</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tel&#58;&#160;&#160;&#160;&#160;(415) 655-4899</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Email&#58;&#160;&#160;&#160;&#160;jrv&#64;angion.com</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">FLG&#58;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">FLG Partners, LLC, </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a California limited liability company.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;Jeffrey S. Kuhn</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signed&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Administrative Partner</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Effective Date&#58;&#160;&#160;&#160;&#160;September 9, 2020</font></div></td></tr></table></div><div><font><br></font></div><div style="height:54.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-0.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 2 of #NUM_PAGES#&#160;&#160;&#160;&#160;200909 FLG-Angion First Amendment to Agreement.docx</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11(B)
<SEQUENCE>7
<FILENAME>a201210flg-angionsecondame.htm
<DESCRIPTION>EX-10.11(B)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie77e47a78a6e47d9a5d1c9e82195ff6e_1"></div><div style="min-height:95.76pt;width:100%"><div style="text-align:center"><img alt="image_04.jpg" src="image_04.jpg" style="height:46px;margin-bottom:5pt;vertical-align:text-bottom;width:196px"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SECOND AMENDMENT TO CONFIDENTIAL CONSULTING AGREEMENT</font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This second amendment (the &#8220;Second Amendment&#8221;) to the Confidential Consulting Agreement dated June 3, 2020 (the &#8220;Agreement&#8221;) by and between the parties hereto, is executed as of the date shown on the signature page (the &#8220;Effective Date&#8221;), by and between FLG Partners, LLC, a California limited liability company (&#8220;FLG&#8221;), and Angion Biomedica Corp. (&#8220;Client&#8221;).</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RECITALS</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, FLG is in the business of providing certain financial services&#59; and</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Client wishes to retain FLG to provide and FLG wishes to provide such services to Client on the terms set forth herein&#59; and</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, FLG has been continuously retained by Client since June 3, 2020&#59; and</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the parties hereto wish to extend the term of the Agreement&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, in consideration of the mutual covenants set forth herein, the parties hereto agree as follows&#58;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-0.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 1 of #NUM_PAGES#&#160;&#160;&#160;&#160;201210 FLG-Angion Second Amendment to Agreement (FLG redline).doc</font></div></div></div><div id="ie77e47a78a6e47d9a5d1c9e82195ff6e_4"></div><hr style="page-break-after:always"><div style="min-height:89.28pt;width:100%"><div style="text-align:center"><img alt="image_13.jpg" src="image_13.jpg" style="height:46px;margin-bottom:5pt;vertical-align:text-bottom;width:196px"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">SECOND AMENDMENT TO CONFIDENTIAL CONSULTING AGREEMENT</font></div></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt;text-decoration:underline">Additional Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  &#160;&#160;&#160;&#160;Exhibit A of the Agreement is amended to delete paragraph 7 in its entirety and replace it with the following language&#58; </font></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;7. Additional Compensation&#58; Additional Compensation shall consistent of two non-qualified common stock purchase option grants (the &#8220;Options&#8221;)&#58; one granted as of August 31, 2020 in an amount equal to 36,000 shares (the &#8220;First Options&#8221;), and a second granted as of December 9, 2020 in an amount equal to 108,000 shares (the &#8220;Second Options&#8221;). The exercise price per share all of the Options (as determined by Client&#8217;s Board of Directors) shall be computed pursuant to and consistent with Client&#8217;s IRC &#167;409A per share common stock valuation (the &#8220;Common Stock Value&#8221;) applicable the grant date for each Option. With respect to the First Options, nine thousand (9,000) of such First Options shall be vested upon grant, with the balance vesting ratably over the subsequent nine (9) months. Vesting of the First Options shall cease upon termination of the Agreement, and the First Options shall be exercisable for one (1) year after termination of the Agreement.  With respect to the Second Options, all the Second Options shall commence vesting on June 1, 2021, at a rate of three thousand (3,000) per month, and shall cease vesting upon the earlier of (i) the termination of the Agreement, or (ii) the first month anniversary after the Client&#8217;s employment of a full time Chief Financial Officer.  Vested Second Options shall be exercisable for ninety (90) days after termination of the Agreement.  </font></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to compliance with applicable federal and state securities laws and regulations, all Options shall be issued 95% in the name of FLG Member and 5% in the name of FLG, each rounded to the nearest whole number of shares subject to the Options.&#8221;</font></div><div style="margin-bottom:6pt;padding-left:22.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;All other terms and conditions of the Agreement remain unchanged.  This Second Amendment shall be incorporated in the Agreement as Exhibit C.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the parties hereto have executed this Amendment as of the Effective Date.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.521%"><tr><td style="width:1.0%"></td><td style="width:51.961%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.839%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CLIENT&#58;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Angion Biomedica Corp.,</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware corporation.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Jay Venkatesan</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signed&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Executive Officer </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Address&#58; 51 Charles Lindbergh Boulevard, </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Uniondale, New York  11553</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tel&#58;&#160;&#160;&#160;&#160;(415) 655-4899</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Email&#58;&#160;&#160;&#160;&#160;jrv&#64;angion.com</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">FLG&#58;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">FLG Partners, LLC, </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a California limited liability company.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;Jeffrey S. Kuhn</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signed&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Managing Partner</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Effective Date&#58;&#160;&#160;&#160;&#160;_____________________.</font></div></td></tr></table></div><div><font><br></font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-0.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 2 of #NUM_PAGES#&#160;&#160;&#160;&#160;201210 FLG-Angion Second Amendment to Agreement (FLG redline).doc</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11(C)
<SEQUENCE>8
<FILENAME>a220311flg-angionthirdamen.htm
<DESCRIPTION>EX-10.11(C)
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i0d6b45cb5c014ebba8bf04cbe97dd923_1"></div><div style="min-height:125.28pt;width:100%"><div style="text-align:center"><img alt="image_12.jpg" src="image_12.jpg" style="height:67px;margin-bottom:5pt;vertical-align:text-bottom;width:281px"></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">THIRD AMENDMENT TO CONFIDENTIAL CONSULTING AGREEMENT</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This third amendment (the &#8220;Third Amendment&#8221;) to the Confidential Consulting Agreement dated June 3, 2020 (the &#8220;Agreement&#8221;) by and between the parties hereto, is executed as of the date shown on the signature page (the &#8220;Effective Date&#8221;), by and between FLG Partners, LLC, a California limited liability company (&#8220;FLG&#8221;), and Angion Biomedica Corporation (&#8220;Client&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Capitalized terms used herein without definition shall have the meanings ascribed to them in the Agreement</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RECITALS</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the parties hereto wish to amend the Agreement&#59;</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, Client wishes to retain FLG to provide and FLG wishes to provide such services to Client on the terms set forth herein&#59; and</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, FLG has been continuously retained by Client since June 3, 2020&#59; and</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the parties hereto wish to extend the term of the Agreement&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, in consideration of the mutual covenants set forth herein, the parties hereto agree as follows&#58;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-0.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 1 of #NUM_PAGES#&#160;&#160;&#160;&#160;220311 FLG-Angion Third Amendment.docx</font></div></div></div><div id="i0d6b45cb5c014ebba8bf04cbe97dd923_4"></div><hr style="page-break-after:always"><div style="min-height:105.12pt;width:100%"><div style="text-align:center"><img alt="image_2.jpg" src="image_2.jpg" style="height:67px;margin-bottom:5pt;vertical-align:text-bottom;width:281px"></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">THIRD AMENDMENT TO CONFIDENTIAL CONSULTING AGREEMENT</font></div></div><div style="margin-bottom:6pt;padding-left:112.5pt;text-align:justify;text-indent:-112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:104.25pt;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  &#160;&#160;&#160;&#160;The term of the Agreement is hereby extended until terminated by either party upon 15 days&#8217; written notice to the other.</font></div><div style="margin-bottom:6pt;padding-left:112.5pt;text-align:justify;text-indent:-112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:104.25pt;text-decoration:underline">Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  &#160;&#160;&#160;&#160;$550 per hour, effective March 14, 2022.</font></div><div style="margin-bottom:6pt;padding-left:112.5pt;text-align:justify;text-indent:-112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:104.25pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;All other terms and conditions of the Agreement remain unchanged.  This Third Amendment shall be incorporated in the Agreement as Exhibit D.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, the parties hereto have executed this Amendment as of the Effective Date.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.521%"><tr><td style="width:1.0%"></td><td style="width:51.961%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.839%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CLIENT&#58;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Angion Biomedica Corp.,</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a Delaware corporation.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Jay Venkatesan</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signed&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Executive Officer </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Address&#58; 51 Charles Lindbergh Boulevard, </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Uniondale, New York  11553</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Tel&#58;&#160;&#160;&#160;&#160;(415) 655-4899</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Email&#58;&#160;&#160;&#160;&#160;jrv&#64;angion.com</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">FLG&#58;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">FLG Partners, LLC, </font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a California limited liability company.</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;&#160;&#160;&#160;&#160;U. Heather Ogan</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signed&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;&#160;&#160;Administrative Partner</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Effective Date&#58;&#160;&#160;&#160;&#160;March 17, 2022.</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-right:-0.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Page 2 of #NUM_PAGES#&#160;&#160;&#160;&#160;220311 FLG-Angion Third Amendment.docx</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>9
<FILENAME>non-employeedirectorcompen.htm
<DESCRIPTION>EX-10.12
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3c2311dbdd7e4b0ba49f62a69a1eb88f_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revised March 2021</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ANGION BIOMEDICA CORP.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non-employee members of the board of directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) of Angion Biomedica Corp. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), which is being adopted pursuant to the Board&#8217;s resolutions on January 25, 2021 and March 8, 2021.  The cash and equity compensation described in this Program shall be paid or be made, as applicable, automatically and without further action of the Board, to each member of the Board who is not an employee of the Company or any parent or subsidiary of the Company (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Non-Employee Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) who may be eligible to receive such cash or equity compensation, unless such Non-Employee Director declines the receipt of such cash or equity compensation by written notice to the Company.  This Program shall remain in effect until it is revised or rescinded by further action of the Board.  This Program may be amended, modified or terminated by the Board at any time, without advance notice, in its sole discretion.  The terms and conditions of this Program shall supersede any prior cash and&#47;or equity compensation arrangements for service as a member of the Board between the Company and any of its Non-Employee Directors.  This Program shall be effective upon the effectiveness of the registration statement for the Company&#8217;s initial public offering (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-right:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cash Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Annual Retainers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Non-Employee Director shall be eligible to receive an annual retainer of $40,000 for service on the Board.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Annual Retainers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In addition, a Non-Employee Director shall receive the following annual retainers&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Executive Chairman of the Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  A Non-Employee Director serving as the Non-Executive Chairman of the Board shall receive an additional annual retainer of $35,000 for such service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Lead Director of the Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  A Non-Employee Director serving as the Lead Director of the Board shall receive an additional annual retainer of $20,000 for such service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Audit Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  A Non-Employee Director serving as Chairperson of the Audit Committee shall receive an additional annual retainer of $15,000 for such service.  A Non-Employee Director serving as a member of the Audit Committee (other than the Chairperson) shall receive an additional annual retainer of $7,500 for such service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  A Non-Employee Director serving as Chairperson of the Compensation Committee shall receive an additional annual retainer of $10,000 for such service.  A Non-Employee Director serving as a member of the Compensation Committee (other than the Chairperson) shall receive an additional annual retainer of $5,000 for such service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v) &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Nominating and Corporate Governance Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  A Non-Employee Director serving as Chairperson of the Nominating and Corporate Governance Committee shall receive an additional annual retainer of $8,000 for such service.  A Non-Employee Director serving as a member of the Nominating and Corporate Governance Committee (other than the Chairperson) shall receive an additional annual retainer of $5,000 for such service.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Payment of Retainers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The annual retainers described in Sections 1(a) and 1(b) shall be earned on a quarterly basis based on a calendar quarter and shall be paid by the Company in arrears not later than the fifteenth (15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) day following the end of each calendar quarter.  In the event a Non-Employee Director does not serve as a Non-Employee Director, or in the applicable positions described in Section 1(b), for an entire calendar quarter, the retainer paid to such Non-Employee Director shall be prorated for the portion of such calendar quarter actually served as a Non-Employee Director, or in such position, as applicable.</font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#124;US-DOCS&#92;116488861.4&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Equity Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Non-Employee Directors shall be granted the equity awards described below.  The awards described below shall be granted under and shall be subject to the terms and provisions of the Company&#8217;s 2021 Equity Incentive Award Plan, as amended from time to time, or any other applicable Company equity incentive plan then-maintained by the Company (in any case, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Equity Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and shall be evidenced by the execution and delivery of award agreements in substantially the forms approved by the Board from time to time.  All applicable terms of the Equity Plan apply to this Program as if fully set forth herein, and all grants of stock options hereby are subject in all respects to the terms of the Equity Plan.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each Non-Employee Director who is initially elected or appointed to the Board after the Effective Date shall automatically be granted, on the date of such initial election or appointment, an option (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Initial Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to purchase 30,000 shares of the Company&#8217;s common stock (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  No Non-Employee Director shall be granted more than one Initial Award.  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Subsequent Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  A Non-Employee Director who (i) has been serving on the Board immediately prior to any annual meeting of the Company&#8217;s stockholders after the Effective Date and (ii) will continue to serve as a Non-Employee Director immediately following such meeting, shall be automatically granted, on the date of such annual meeting, an option (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Subsequent Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to purchase 15,000 Shares.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Termination of Service of Employee Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Members of the Board who are employees of the Company or any parent or subsidiary of the Company who subsequently terminate their service with the Company and any parent or subsidiary of the Company and remain on the Board will not receive an Initial Award pursuant to Section 2(a) above, but to the extent that they are otherwise eligible, will be eligible to receive, after termination from service with the Company and any parent or subsidiary of the Company, Subsequent Awards as described in Section 2(b) above.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Terms of Awards Granted to Non-Employee Directors</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The per Share exercise price of each option granted to a Non-Employee Director shall equal the Fair Market Value (as defined in the Equity Plan) of a Share on the date the option is granted.  Without limiting the foregoing, Fair Market Value as of the Effective Date shall be equal to the price per Share to the public in the Company&#8217;s initial public offering, as set forth on the cover of the final prospectus of the initial public offering of Company common stock. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to Section 2(d)(iii) below, each Initial Award shall vest and become exercisable in thirty-six (36) substantially equal installments on each monthly anniversary of the date of grant, subject to the Non-Employee Director continuing to provide services to the Company through each such vesting date.  Subject to Section 2(d)(iii) below, each Subsequent Award shall vest and become exercisable in full on the earlier of the one year anniversary of the date of grant and the next annual meeting of the Company&#8217;s stockholders after the grant date, subject to the Non-Employee Director continuing to provide services to the Company through such vesting date.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Accelerated Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.74pt"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Termination Due to Death or Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event that any Non-Employee Director incurs a Termination of Service (as defined in the Equity Plan) due to such Non-Employee Director&#8217;s death or Disability (as defined the Equity Plan), each of such Non-Employee Director&#8217;s Initial Award and Subsequent Award(s), along with any other stock options or other equity-based awards held by such Non-Employee Director, shall vest and, if applicable, become exercisable with respect to one hundred percent (100%) of the Shares subject thereto upon such Termination of Service.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(B)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event that a Change in Control (as defined in the Equity Plan) occurs, each Initial Award and Subsequent Award, along with any other stock options or other equity-based awards held by any Non-Employee Director, shall vest </font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#124;US-DOCS&#92;116488861.4&#124;&#124;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and, if applicable, become exercisable with respect to one hundred percent (100%) of the Shares subject thereto as of immediately prior to such Change in Control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The term of each stock option granted to a Non-Employee Director shall be ten (10) years from the date the option is granted. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Reimbursements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company shall reimburse each Non-Employee Director for all reasonable, documented, out-of-pocket travel and other business expenses incurred by such Non-Employee Director in the performance of his or her duties to the Company in accordance with the Company&#8217;s applicable expense reimbursement policies and procedures as in effect from time to time. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">* * * * *</font></div><div style="height:73.44pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#124;US-DOCS&#92;116488861.4&#124;&#124;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>10
<FILENAME>angion-executiveseparation.htm
<DESCRIPTION>EX-10.14
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i755f0c5658fa43aa915c5c560940de7f_1"></div><div style="min-height:40.32pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Angion Biomedica Corp.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Executive Separation Benefits Plan</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">(and Summary Plan Description)</font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Amended and Restated as of November 19, 2021</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Angion Biomedica Corp. Executive Separation Benefits Plan, as amended and restated (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is effective as of November 19, 2021 (the &#8220;E</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ffective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  The purpose of this Plan is to provide severance benefits to certain employees of Angion Biomedica Corp. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) whose employment with the Company is terminated both in connection with and outside of a Change in Control (as defined below). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Plan is an employee welfare benefit plan subject to the Employee Retirement Income Security Act of 1974, as amended (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ERISA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  This Plan document is also the summary plan description of this Plan.  References in this Plan to &#8220;You&#8221; or &#8220;Your&#8221; are references to a Covered Employee (as defined below).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">General Eligibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The eligible employees in this Plan shall be employees of the Company who (i) are full time&#59; (ii) are at the level of Vice President and above and (iii) provide services to the Company within the United States of America (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Covered Employees&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">). Notwithstanding the foregoing, in the event that a Covered Employee is eligible to receive severance benefits pursuant to an individual agreement with the Company (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Individual Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) that are more favorable than the severance benefits provided hereunder, such Covered Employee shall receive the severance benefits under his or her Individual Agreement in lieu of the severance benefits provided hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Involuntary Termination Outside of a Change in Control Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If you are a Covered Employee and you experience an Involuntary Termination other than during a Change in Control Period, then, subject to (i) your execution and delivery of a release of claims agreement in substantially the form attached as Appendix A hereto (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) that becomes effective and irrevocable on or before the Release Expiration Date (as defined below), (ii) your continued compliance with Section 16 below, (iii) if requested, your execution of a proprietary information and invention assignment agreement that assigns all intellectual property created by you during your employment to the Company, (iv) your  assistance in fully transitioning your duties prior to the date of your termination and (v) your full cooperation in responding to other Company requests for information or actions during the remainder of your employment and during the Severance Period, then you shall be entitled to receive the following severance payments and benefits&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:28.37pt;text-decoration:underline">Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  During the Severance Period, the Company shall continue to pay you your base salary at the rate in effect immediately prior to your date of termination.  Such payments shall be made in accordance with the Company&#8217;s standard payroll practices, less applicable withholdings, beginning on the first payroll date following the date the Release becomes effective and irrevocable in accordance with Section 18 below, and with the first installment including any amounts that would have been paid had the Release been effective and irrevocable on your date of termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">COBRA Premium Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If you timely elect to receive continued healthcare coverage under Section 4980B of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and the regulations thereunder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">COBRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), the Company shall directly pay, or reimburse you for, the Company&#8217;s portion of the premium (at the same rates in effect on the date of termination) for you and your covered dependents through the earlier of (i) the end of the Severance Period and (ii) the date you and your covered dependents, if any, become eligible for healthcare coverage under another employer&#8217;s plan(s).  Notwithstanding the foregoing, (i) if any plan pursuant to which such benefits are provided is not, or ceases prior to the expiration of the period of continuation coverage to be, exempt from the application of Section 409A of the Code under Treasury Regulation Section 1.409A-1(a)(5), or (ii) the Company is otherwise unable to continue to cover you under its group health plans without penalty under applicable law (including without limitation, Section 2716 of the Public Health Service Act), then, in either case, an amount equal to each remaining Company subsidy shall thereafter be paid to you in substantially equal monthly installments. After the Company ceases to pay premiums pursuant to this Section 2(b), you may, if eligible, elect to continue healthcare coverage at your expense in accordance with the provisions of COBRA. You shall notify the Company immediately if you become covered by a group health plan of a subsequent employer.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.32pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Covered Termination During a Change in Control Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If you experience a Covered Termination during a Change in Control Period, then subject to (i) your execution and delivery of a Release that becomes effective and irrevocable on or before the Release Expiration Date, (ii) your continued compliance with Section 16 below, (iii) if requested, your execution of a proprietary information and invention assignment agreement that assigns all intellectual property created by you during your employment to the Company and (iv) your  assistance in fully transitioning your duties prior to the date of your termination, you shall be entitled to receive the following severance payments and benefits applicable to your position or designation&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:28.37pt;text-decoration:underline">Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  During the Severance Period, the Company shall continue to pay you your base salary at the rate in effect immediately prior to your date of termination.  Such payments shall be made in accordance with the Company&#8217;s standard payroll practices, less applicable withholdings, beginning on the first payroll date following the date the Release becomes effective and irrevocable in accordance with Section 18 below, and with the first installment including any amounts that would have been paid had the Release been effective and irrevocable on your date of termination.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Target Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  You shall be entitled to receive a bonus payment equal to your target annual bonus as of the date of the Covered Termination, multiplied by a fraction, the numerator of which is the number of months in the Severance Period and the denominator of which is 12, assuming achievement of performance goals at one hundred percent (100%) of target at the rate in effect immediately prior to your date of termination, payable in a cash lump sum, less applicable withholdings, on the first payroll date following the date the Release becomes effective and irrevocable becomes effective and irrevocable in accordance with Section 18 below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:28.37pt;text-decoration:underline">COBRA Premium Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. If you timely elect to receive continued healthcare coverage pursuant to the provisions of COBRA, the Company shall directly pay, or reimburse you for, the Company&#8217;s portion of the premium (at the same rates in effect on the date of termination) for you and your covered dependents through the earlier of (i) the end of the Severance Period and (ii) the date you and your covered dependents, if any, become eligible for healthcare coverage under another employer&#8217;s plan(s).  Notwithstanding the foregoing, (i) if any plan pursuant to which such benefits are provided is not, or ceases prior to the expiration of the period of continuation coverage to be, exempt from the application of Section 409A of the Code under Treasury Regulation Section 1.409A-1(a)(5), or (ii) the Company is otherwise unable to continue to cover you under its group health plans without penalty under applicable law (including without limitation, Section 2716 of the Public Health Service Act), then, in either case, an amount equal to each remaining Company subsidy shall thereafter be paid to you in substantially equal monthly installments. After the Company ceases to pay premiums pursuant to this Section 3(c), you may, if eligible, elect to continue healthcare coverage at your expense in accordance with the provisions of COBRA. You shall notify the Company immediately if you become covered by a group health plan of a subsequent employer.  </font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Vesting Acceleration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each outstanding and unvested equity award (excluding any such awards that vest in whole or in part based on the attainment of performance-vesting conditions), including, without limitation, each restricted stock award, stock option, restricted stock unit award and stock appreciation right, held by you shall automatically become vested and, if applicable, exercisable and any forfeiture restrictions or rights of repurchase thereon shall immediately lapse with respect to one hundred percent (100%) of the shares subject thereto (excluding any such awards that vest in whole or in part based on the attainment of performance-vesting conditions, which shall be governed by the terms of the applicable award agreement), as of immediately prior to your date of termination.  <br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For the purposes of this Plan, the following terms shall have the following meanings&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:28.37pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean any of the following&#58; (i) your commission of any act or involvement in any situation, or occurrence, which brings you into widespread public disrepute, contempt, scandal or ridicule, or which justifiably shocks, insults or offends a significant portion of the community, or you being subject to publicity for any such conduct or involvement in such conduct&#59; (ii) your failure to attempt in good faith to implement a clear and reasonable directive from the Company or to comply with any of the Company&#8217;s policies and procedures which failure is either material or occurs after written notice from the Company&#59; (iii) your commission of any felony or any crime involving fraud, dishonesty or moral turpitude under the laws of the United States or any state thereof&#59; (iv) your attempted </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.32pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">commission of, or participation in, a fraud or act of dishonesty against the Company&#59; (v)  intentional, material violation of any contract or agreement between you and the Company (or any subsidiary thereof) or of any statutory duty owed to the Company&#59; (vi) your unauthorized use or disclosure of the Company&#8217;s confidential information or trade secrets&#59; (vii)  an act by you which constitutes gross negligence, willful misconduct or insubordination in the course of employment&#59; or (viii) your continued failure to perform the essential duties and responsibilities of your position, after having received notice of the deficiencies and having had 30 days to cure such defects in performance. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in the Company&#8217;s 2021 Incentive Award Plan, as amended from time to time.  Notwithstanding the foregoing, a &#8220;Change in Control&#8221; must also constitute a &#8220;change in control event&#8221; as defined in Treasury Regulation &#167;1.409A-3(i)(5). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:28.37pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Change in Control Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;  means the period of time commencing on the closing of a Change in Control and ending on the twelve (12)-month anniversary of the Change in Control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;, for each Covered Employee, means (i) a decrease in your base salary by more than 10%, (ii) a relocation of your primary work location by more than fifty (50) miles, (iii) a material decrease in your duties or responsibilities (but excluding a change in title or reporting relationship), or (iv) the Company&#8217;s failure to obtain an agreement from a successor to continue the Plan or to substitute for it a plan or other compensation arrangement that provides equivalent or greater benefits&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that to resign for Good Reason, you must (1) provide written notice to the Company&#8217;s General Counsel within thirty (30) days after the first occurrence of the event giving rise to Good Reason setting forth the basis for your resignation for Good Reason, (2) allow the Company at least thirty (30) days from receipt of such written notice to cure such event, and (3) if such event is not reasonably cured within such period, your resignation from all positions you then hold with the Company is effective not later than thirty (30) days after the expiration of the cure period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:28.37pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Involuntary Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Covered Employee&#8217;s termination by the Company without Cause or by the Covered Employee for Good Reason, and shall not include a termination for death or disability.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:29.59pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Plan Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Board of Directors of the Company (the &#8220;Board&#8221;), the Compensation Committee of the Board or any officer or group of officers designated by the Board to administer the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Severance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall, with respect to any Covered Employee, mean a duration equal to the period calculated by from the date of termination through (i) if such Involuntary Termination occurs outside a Change in Control Period, such anniversary of such termination date calculated as follows&#58; twelve (12) months if the Covered Employee is the Company&#8217;s Chief Executive Officer, nine (9) months if the Covered Employee is a C-suite executive and reports directly to the Company&#8217;s Chief Executive Officer, and six (6) months for all other Covered Employees&#59; and (ii) if such Involuntary Termination occurs during a Change in Control Period, such anniversary of such termination date calculated as follows&#58; eighteen (18) months if the Covered Employee is the Company&#8217;s Chief Executive Officer, twelve (12) months if the Covered Employee is a C-suite executive and reports directly to the Company&#8217;s Chief Executive Officer, and nine (9) months for all other Covered Employees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All payments to be made under this Plan will be subject to appropriate tax withholding and other deductions.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Amendment of Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Prior to the consummation of a Change in Control, the Plan Administrator shall have the power to amend or terminate this Plan from time to time in its discretion and for any reason (or no reason).  On or following the consummation of a Change in Control, the Plan may not be terminated or amended until the later of the first anniversary of the consummation of the Change in Control or the date all payments and benefits eligible to be received hereunder shall have been paid.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Claims Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.32pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:28.37pt">Normally, you do not need to present a formal claim to receive benefits payable under this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt">If any person (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Claimant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) believes that benefits are being denied improperly, that this Plan is not being operated properly, that fiduciaries of this Plan have breached their duties, or that the Claimant&#8217;s legal rights are being violated with respect to this Plan, the Claimant must file a formal claim, in writing, with the Plan Administrator.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This requirement applies to all claims that any Claimant has with respect to this Plan, including claims against fiduciaries and former fiduciaries, except to the extent the Plan Administrator determines, in its sole discretion that it does not have the power to grant all relief reasonably being sought by the Claimant.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:28.37pt">A formal claim must be filed within ninety (90) days after the date the Claimant first knew or should have known of the facts on which the claim is based, unless the Plan Administrator in writing consents otherwise.  The Plan Administrator shall provide a Claimant, on request, with a copy of the claims procedures established under subsection (d).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt">The Plan Administrator has adopted procedures for considering claims (which are set forth in Appendix B), which it may amend from time to time, as it sees fit.  These procedures shall comply with all applicable legal requirements.  These procedures may provide that final and binding arbitration shall be the ultimate means of contesting a denied claim (even if the Plan Administrator or its delegates have failed to follow the prescribed procedures with respect to the claim such that the claim was deemed denied).  The right to receive benefits under this Plan is contingent on a Claimant using the prescribed claims and arbitration procedures to resolve any claim.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Plan Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:28.37pt">The Plan Administrator is responsible for the general administration and management of this Plan and shall have all powers and duties necessary to fulfill its responsibilities, including, but not limited to, the discretion to interpret and apply this Plan and to determine all questions relating to eligibility for benefits.  This Plan shall be interpreted in accordance with its terms and their intended meanings.  However, the Plan Administrator and all Plan fiduciaries shall have the discretion to interpret or construe ambiguous, unclear, or implied (but omitted) terms in any fashion they deem to be appropriate in their sole discretion, and to make any findings of fact needed in the administration of this Plan.  The validity of any such interpretation, construction, decision, or finding of fact shall not be given de novo review if challenged in court, by arbitration, or in any other forum, and shall be upheld unless clearly arbitrary or capricious.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt">All actions taken and all determinations made in good faith by the Plan Administrator or by Plan fiduciaries will be final and binding on all persons claiming any interest in or under this Plan.  To the extent the Plan Administrator or any Plan fiduciary has been granted discretionary authority under this Plan, the Plan Administrator&#8217;s or Plan fiduciary&#8217;s prior exercise of such authority shall not obligate it to exercise its authority in a like fashion thereafter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:28.37pt">If, due to errors in drafting, any Plan provision does not accurately reflect its intended meaning, as demonstrated by consistent interpretations or other evidence of intent, or as determined by the Plan Administrator in its sole discretion, the provision shall be considered ambiguous and shall be interpreted by the Plan Administrator and all Plan fiduciaries in a fashion consistent with its intent, as determined in the sole discretion of the Plan Administrator.  The Plan Administrator may amend this Plan retroactively to cure any such ambiguity.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt">No Plan fiduciary shall have the authority to answer questions about any pending or final business decision of the Company or any affiliate that has not been officially announced, to make disclosures about such matters, or even to discuss them, and no person shall rely on any unauthorized, unofficial disclosure.  Thus, before a decision is officially announced, no fiduciary is authorized to tell any employee, for example, that the employee will or will not be laid off or that the Company will or will not offer exit incentives in the future.  Nothing in this subsection shall preclude any fiduciary from fully participating in the consideration, making, or official announcement of any business decision.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.32pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:28.37pt">This Section may not be invoked by any person to require this Plan to be interpreted in a manner inconsistent with its interpretation by the Plan Administrator or other Plan fiduciaries.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Funding and Payment of Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Plan shall be maintained in a manner to be considered &#8220;unfunded&#8221; for purposes of ERISA.  The Company shall be required to make payments only as benefits become due and payable.  No person shall have any right, other than the right of an unsecured general creditor against the Company, with respect to the benefits payable hereunder, or which may be payable hereunder, to any Covered Employee, surviving spouse or beneficiary hereunder.  If the Company, acting in its sole discretion, establishes a reserve or other fund associated with this Plan, no person shall have any right to or interest in any specific amount or asset of such reserve or fund by reason of amounts which may be payable to such person under this Plan, nor shall such person have any right to receive any payment under this Plan except as and to the extent expressly provided in this Plan.  The assets in any such reserve or fund shall be part of the general assets of the Company, subject to the control of the Company.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Plan Application</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Unless you are eligible to receive severance benefits in connection with a Change in Control pursuant to an Individual Agreement that are more favorable than the severance benefits provided hereunder, this Plan shall be the only plan, agreement or arrangement with respect to which benefits may be provided to you upon a termination of your employment and supersedes all prior agreements, arrangements or related communications of the Company relating to separation benefits or accelerated vesting benefits on a Change in Control for the Covered Employees, whether formal or informal, or written or unwritten.  However, if a prior plan or agreement requires the consent of the employee in order for such prior plan or agreement to be modified or amended or superseded by this Plan, such consent must be obtained from such employee in order for this Plan to supersede such prior plan or agreement.  Subject to the foregoing, any benefits under this Plan will be provided to Covered Employees in lieu of benefits under any other separation plan or agreement.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any successor to the Company (whether direct or indirect and whether by purchase, lease, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company&#8217;s business and&#47;or assets shall assume the obligations under this Plan and agree expressly to perform any of the Company&#8217;s obligations under this Plan.  For the avoidance of doubt, any successor to any affiliate of the Company, including without limitation, a successor to a subsidiary of the Company (whether direct or indirect and whether by purchase, lease, merger, consolidation, liquidation or otherwise), to all or substantially all of such affiliate&#8217;s business and&#47;or assets shall assume the obligations under this Plan and agree expressly to perform any of the Company&#8217;s obligations under this Plan as such obligations relate to the Covered Employees employed by the affiliate of the Company.  For all purposes under this Plan, the term &#8220;Company&#8221; shall include any successor to the Company&#8217;s and&#47;or Company&#8217;s affiliate&#8217;s business and&#47;or assets which executes and delivers an assumption agreement or which becomes bound by the terms of the Plan by operation of law.  All of your rights hereunder shall inure to the benefit of, and be enforceable by, your personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Limitation On Employee Rights&#59; At-Will Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Plan shall not give any employee the right to be retained in the service of the Company or interfere with or restrict the right of the Company to discharge or retire the employee.  All employees of the Company are employed at will.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">No Third-Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Plan shall not give any rights or remedies to any person other than Covered Employees (or their estates or beneficiaries, in the event of a Covered Employee&#8217;s death) and the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Plan is a welfare plan subject to ERISA and it shall be interpreted, administered, and enforced in accordance with that law.  To the extent that state law is applicable, the laws of the state of California shall apply, excluding any that mandate the use of another jurisdiction&#8217;s laws.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.32pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">No Assignment of Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The rights of any person to payments or benefits under this Plan shall not be made subject to option or assignment, either by voluntary or involuntary assignment or by operation of law, including (without limitation) bankruptcy, garnishment, attachment or other creditor&#8217;s process, and any action in violation of this subsection shall be void.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:28.37pt">You hereby expressly confirm your continuing obligations to the Company pursuant to the confidentiality provisions of the Company&#8217;s Code of Conduct, the confidential information and inventions assignment agreement and&#47;or other agreements regarding non-competition, non-solicitation, non-disparagement, confidentiality, assignment of inventions or other similar covenants between you and the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  In addition, without limiting the foregoing, you agree that you shall not disparage, criticize or defame the Company, its affiliates and their respective affiliates, directors, officers, agents, partners, stockholders, employees, products, services, technology or business, either publicly or privately.  Nothing in this subsection (a) shall have application to any evidence or testimony required by any court, arbitrator or government agency.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Whistleblower Protections and Trade Secrets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary contained herein, nothing in this Plan or the Restrictive Covenants prohibits you from reporting possible violations of federal law or regulation to any United States governmental agency or entity in accordance with the provisions of and rules promulgated under Section 21F of the Securities Exchange Act of 1934 or Section 806 of the Sarbanes-Oxley Act of 2002, or any other whistleblower protection provisions of state or federal law or regulation (including the right to receive an award for information provided to any such government agencies).  Furthermore, in accordance with 18 U.S.C. &#167; 1833, notwithstanding anything to the contrary in this Agreement&#58; (i) you shall not be in breach of this Plan, and shall not be held criminally or civilly liable under any federal or state trade secret law (A) for the disclosure of a trade secret that is made in confidence to a federal, state, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, or (B) for the disclosure of a trade secret that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal&#59; and (ii) if you file a lawsuit for retaliation by the Company for reporting a suspected violation of law, you may disclose the trade secret to your attorney, and may use the trade secret information in the court proceeding, if you file any document containing the trade secret under seal, and does not disclose the trade secret, except pursuant to court order.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Where the context so indicates, the singular will include the plural and vice versa.  Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Plan.  Unless the context clearly indicates to the contrary, a reference to a statute or document shall be construed as referring to any subsequently enacted, adopted, or executed counterpart.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:28.37pt;text-decoration:underline">Separation from Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding any provision to the contrary in this Plan, no amount constituting deferred compensation subject to Section 409A of the Code shall be payable hereunder unless your termination of employment constitutes a &#8220;separation from service&#8221; with the Company within the meaning of Section 409A of the Code and the Department of Treasury regulations and other guidance promulgated thereunder (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Separation from Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Specified Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding any provision to the contrary in this Plan, if you are deemed at the time of your Separation from Service to be a &#8220;specified employee&#8221; for purposes of Section 409A(a)(2)(B)(i) of the Code, to the extent delayed commencement of any portion of the benefits to which you are entitled under this Agreement is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, such portion of your benefits shall not be provided to you prior to the earlier of (A) the expiration of the six-month period measured from the date of your Separation from Service or (B) the date of your death.  Upon the first business day following the expiration of the applicable Code Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this Section 18(b) shall be paid in a lump sum to you, and any remaining payments due under this Plan shall be paid as otherwise provided herein.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.32pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:28.37pt;text-decoration:underline">Expense Reimbursements and In-Kind Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  To the extent that any reimbursements or in-kind benefits provided pursuant to this Plan are subject to the provisions of Section 409A of the Code, any such reimbursements payable to you pursuant to this Agreement shall be paid to you no later than December 31 of the year following the year in which the expense was incurred, the amount of expenses reimbursed or in-kind benefits provided in one year shall not affect the amount eligible for reimbursement  or in-kind benefits to be provided in any subsequent year, and your right to reimbursement or in-kind benefits under this Plan will not be subject to liquidation or exchange for another benefit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Installments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For purposes of Section 409A of the Code (including, without limitation, for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii)), your right to receive any installment payments under this Agreement shall be treated as a right to receive a series of separate payments and, accordingly, each such installment payment shall at all times be considered a separate and distinct payment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:28.37pt;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary in this Plan, to the extent that any payments due under this Plan as a result of your termination of employment are subject to your execution and delivery of a Release, (i) if you fail to execute the Release on or prior to the Release Expiration Date (as defined below) or timely revoke your acceptance of the Release thereafter, you shall not be entitled to any payments or benefits otherwise conditioned on the Release, and (ii) in any case where your date of termination and the last day the Release may be considered or, if applicable, revoked fall in two separate taxable years, any payments required to be made to you that are conditioned on the Release and are treated as nonqualified deferred compensation for purposes of Section 409A of the Code shall be made in the later taxable year.  For purposes hereof, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Release Expiration Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean (1) if you are under 40 years old as of the date of termination, the date that is seven (7) days following the date upon which the Company timely delivers the Release to you, or such shorter time prescribed by the Company, and (2) if you are 40 years or older as of the date of termination, the date that is twenty one (21) days following the date upon which the Company timely delivers the Release to you, or, if your termination of employment is &#8220;in connection with an exit incentive or other employment termination program&#8221; (as such phrase is defined in the Age Discrimination in Employment Act of 1967), the date that is forty five (45) days following such delivery date.  To the extent that any payments of nonqualified deferred compensation (within the meaning of Section 409A) due under this Agreement as a result of your termination of employment are delayed pursuant to this Section 18(e), such amounts shall be paid in a lump sum on the first payroll date following the date the Release becomes effective and irrevocable or, in the case of any payments subject to Section 18(e)(ii), on the first payroll date to occur in the subsequent taxable year, if later.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Limitation on Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding anything in this Plan to the contrary, if any payment or distribution you would receive pursuant to this Plan or otherwise (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) would (a) constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code and (b) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Excise Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), then such Payment shall either be (i) delivered in full, or (ii) delivered as to such lesser extent which would result in no portion of such Payment being subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the Excise Tax, results in the receipt by you on an after-tax basis, of the largest payment, notwithstanding that all or some portion the Payment may be taxable under Section 4999 of the Code.  The Company will select an adviser with experience in performing calculations regarding the applicability of Section 280G of the Code and the Excise Tax, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the adviser&#8217;s determination shall be made based upon &#8220;substantial authority&#8221; within the meaning of Section 6662 of the Code to perform the foregoing calculations.  The Company shall bear all expenses with respect to the determinations by such adviser required to be made hereunder.  The adviser shall provide its calculations to you and the Company within fifteen (15) calendar days after the date on which your right to a Payment is triggered (if requested at that time by you or the Company) or such other time as requested by the Company.  Any good faith determinations of the adviser made hereunder shall be final, binding and conclusive upon you and the Company.  Any reduction in payments or benefits pursuant to this Section 19 will occur in the following order&#58; (1) reduction of cash payments&#59; (2) cancellation of accelerated vesting of equity awards other than stock options&#59; (3) cancellation of accelerated vesting of stock options&#59; and (4) reduction of other benefits payable to you.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.32pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Forfeiture and Repayment of Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event that, within one year following your date of termination, the Company determines that during your employment with the Company, you engaged in conduct that would have constituted Cause for termination, (i) the Company shall have no further obligations under Sections 2 or 3 and you shall repay the Company any amounts previously paid by the Company pursuant to Sections 2 or 3&#59; and (ii) all shares held by you that were subject to equity awards that became vested pursuant to Section 3 shall be automatically forfeited, and you shall pay the Company an amount equal to all proceeds received in connection with any sale or other disposition of any such shares. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="i755f0c5658fa43aa915c5c560940de7f_4"></div><hr style="page-break-after:always"><div style="min-height:40.32pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">APPENDIX A</font></div><div style="margin-top:14.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Release of Claims (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) is entered into as of _________________, 20__, between &#91;__________&#93; (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and Angion Biomedica Corp., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and, together with Employee, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), effective &#91;eight days after&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> &#91;as of&#93; Employee&#8217;s signature hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#91;, unless Employee revokes Employee&#8217;s acceptance of this Release as provided in Paragraph 1(c), below.&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">2</font></div><div style="margin-top:14.4pt;padding-left:13.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.25pt;text-decoration:underline">Employee&#8217;s Release of the Company Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Employee agrees not to sue, or otherwise file any claim against, the Company, TriNet Group, Inc. (&#8220;TriNet&#8221;), or their parent companies, subsidiaries or affiliates, and any of their respective successors, assigns, directors, officers, managers, employees, attorneys, insurers, or agents, each in their respective capacities as such (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Company Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), for any reason whatsoever based on anything that has occurred at any time up to and including the  execution date of this Release as follows&#58;</font></div><div style="margin-top:14.4pt;padding-left:42pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.8pt">On behalf of Employee and Employee&#8217;s executors, administrators, heirs and assigns, Employee hereby releases and forever discharges the Company Parties, and all persons acting by, through, under or in concert with them, or any of them, of and from any and all manner of action or actions, cause or causes of action, in law or in equity, suits, debts, liens, contracts, agreements, promises, liability, claims, demands, damages, loss, cost or expense, of any nature whatsoever, known or unknown, fixed or contingent (hereinafter called &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), which Employee now have or may hereafter have against any of the Company Parties by reason of any matter, cause, or thing whatsoever from the beginning of time through and including the execution date of this Release, including, without limiting the generality of the foregoing&#58; any Claims arising directly or indirectly out of, relating to, or in any other way involving in any manner whatsoever Employee&#8217;s employment by the Company or the separation thereof, including without limitation any and all Claims arising under federal, state, or local laws relating to employment&#59; any Claims of any kind that may be brought in any court or administrative agency&#59; any Claims arising under the Age Discrimination in Employment Act (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ADEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), the Older Workers Benefits Protection Act, the Title VII of the Civil Rights Act of 1964, the Civil Rights Act of 1991, the Equal Pay Act, the Civil Rights Act of 1866, Section 1981, 42 U.S.C. &#167; 1981, the Family and Medical Leave Act of 1993, the Americans with Disabilities Act of 1990, the False Claims Act, the Employee Retirement Income Security Act, the Worker Adjustment and Retraining Notification Act, the Fair Labor Standards Act, the Sarbanes-Oxley Act of 2002, the National Labor Relations Act of 1935, the Uniformed Services Employment and Reemployment Rights Act of 1994, Fair Credit Reporting Act, the California Fair Employment and Housing Act, as amended, Cal. Lab. Code &#167; 12940 et seq., the California Equal Pay Law, as amended, Cal. Lab. Code &#167;&#167; 1197.5(a),199.5, the Moore-Brown-Roberti Family Rights Act of 1991, as amended, Cal. Gov&#8217;t Code &#167;&#167;12945.2, 19702.3, California Labor Code &#167;&#167; 1101, 1102&#59; the California WARN Act, California Labor Code &#167;&#167; 1400 et. seq., California Labor Code &#167;&#167; 1102.5(a),(b), Claims for wages under the California Labor Code and any other federal, state or local laws of similar effect, the employment and civil rights laws of California</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, each of the foregoing as may have been amended, and any other federal, state, or local statute, regulation, ordinance, constitution, or order concerning labor or employment, termination of labor or employment, wages and benefits, retaliation, leaves of absence, or any other term or condition of employment&#59; Claims for breach of contract&#59; Claims for unfair business practices&#59; Claims arising in tort, including, without limitation, Claims of wrongful dismissal or discharge, discrimination, harassment, retaliation, fraud, misrepresentation, defamation, libel, infliction of emotional distress, violation of public policy, and&#47;or breach of the implied covenant of good faith and fair dealing&#59; and Claims for damages or other remedies of any sort, including, without limitation, compensatory damages, punitive damages, injunctive relief and attorney&#8217;s fees. </font></div><div style="margin-top:14.4pt;padding-left:42pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.18pt">Notwithstanding the generality of the foregoing, Employee does not release any Claims that cannot be released as a matter of law including, without limitation, (i) Employee&#8217;s right to file for unemployment insurance benefits&#59; (ii) Employee&#8217;s right to file a charge of discrimination, harassment, interference with leave rights, failure to accommodate, or </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> NTD&#58; Include if Employee is 40 or over.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> NTD&#58; Include if Employee is 40 or over.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> NTD&#58; To include applicable state statutes based on participant&#8217;s state of employment.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Appendix A-1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.32pt;width:100%"><div><font><br></font></div></div><div style="margin-top:14.4pt;padding-left:42pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">retaliation with the Equal Employment Opportunity Commission, the California Department of Fair Employment and Housing  or similar local agency, or to cooperate with or participate in any investigation conducted by such agency&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that Employee hereby releases Employee&#8217;s right to receive damages in any such proceeding brought by Employee or on Employee&#8217;s behalf, (iii) Employee&#8217;s right to communicate directly with the U.S. Securities and Exchange Commission, the U.S. Commodity Futures Trading Commission, the U.S. Department of Justice or similar agency, or to cooperate with or participate in any investigation by such agency&#59; or (iv) Employee&#8217;s right to make any disclosure that are protected under the whistleblower provisions of applicable law.  For the avoidance of doubt, Employee does not need to notify or obtain the prior authorization of the Company to exercise any of the foregoing rights.  Furthermore, Employee does not release hereby any rights that he&#47;she may have relating to (i) indemnification by the Company or its affiliates under any indemnification agreement with the Company, the Company&#8217;s Bylaws or any applicable law&#59; (ii) coverage under any applicable directors&#8217; and officers&#8217; or other third-party liability insurance&#59; (iii) Employee&#8217;s vested accrued benefits under the Company or TriNet&#8217;s respective benefits and compensation plans&#59; and (iv) any severance payment entitlements to which Employee is specifically entitled to as of the date of termination pursuant to the Company&#8217;s Executive Change in Control Separation Benefits Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Severance Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:14.4pt;padding-left:42pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.8pt">Employee acknowledges that Employee has been advised of and is familiar with the provisions of California Civil Code Section 1542, which provides as follows&#58;</font></div><div style="margin-top:14.4pt;padding-left:76.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.&#8221;</font></div><div style="margin-top:14.4pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Being aware of said section, Employee hereby expressly waives any rights Employee may have thereunder, as well as under any other statutes or common law principles of similar effect.</font></div><div style="margin-top:14.4pt;padding-left:42pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.18pt">&#91;Employee acknowledges that the General Release of Claims set forth in Section 1(a) above includes a release of Claims under the Age Discrimination in Employment Act (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ADEA Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;). In accordance with the Older Workers Benefit Protection Act, Employee acknowledge as follows&#58;</font></div><div style="margin-top:14.4pt;padding-left:45pt;text-align:justify;text-indent:135pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;Employee has been advised to consult an attorney of Employee&#8217;s choice before signing this Release and Employee either has so consulted with counsel or voluntarily decided not to consult with counsel&#59;</font></div><div style="margin-top:14.4pt;padding-left:45pt;text-align:justify;text-indent:135pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;Employee has been granted &#91;twenty-one (21)&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> days after Employee is presented with this Release to decide whether or not to sign it. Employee agrees that such period shall not be extended due to any material or immaterial changes to the Release. If Employee executes this Release prior to the expiration of such period, Employee does so voluntarily and after having had the opportunity to consult with an attorney, and hereby waives the remainder of the &#91;twenty-one (21)&#93; day period&#59;</font></div><div style="margin-top:14.4pt;padding-left:45pt;text-align:justify;text-indent:135pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;Employee has carefully reviewed and considered and fully understand the terms set forth in this Release, including all exhibits hereto&#59; and</font></div><div style="margin-top:14.4pt;padding-left:45pt;text-align:justify;text-indent:99pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;(iv)&#160;&#160;&#160;&#160;Employee has the right to revoke Employee&#8217;s ADEA Release within seven (7) calendar days of signing this Release. If Employee wishes to revoke Employee&#8217;s ADEA Release, Employee must deliver written notice stating Employee&#8217;s intent to so revoke to &#91;Insert Name&#93;, &#91;Insert Address&#93;, on or before 11&#58;59 p.m. P.T. on the seventh (7th) day after the date on which Employee signs this Release.&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="margin-top:14.4pt;padding-left:13.5pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.25pt;text-decoration:underline">Employee Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Employee represents and warrants that&#58;</font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> NTD&#58; To be updated to 45 days for a group termination.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> NTD&#58; Include if Employee is 40 or over.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.32pt;width:100%"><div><font><br></font></div></div><div style="margin-top:14.4pt;padding-left:42pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.8pt">Employee has returned to the Company all Company property in Employee&#8217;s possession (other than any property that the Company has specifically permitted the Employee to keep following his termination date in writing), including without limitation, any cell phone, laptop computer or tablet&#59;</font></div><div style="margin-top:14.4pt;padding-left:42pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.18pt">Employee is not owed wages, commissions, bonuses or other compensation, other than wages through the date of the termination of Employee&#8217;s employment and any accrued, unused vacation earned through such date, other than as set forth in the Severance Plan&#59;</font></div><div style="margin-top:14.4pt;padding-left:42pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.8pt">During the course of Employee&#8217;s employment Employee did not sustain any injuries for which Employee might be entitled to compensation pursuant to worker&#8217;s compensation law or Employee has disclosed any injuries of which Employee is currently, reasonably aware for which Employee might be entitled to compensation pursuant to worker&#8217;s compensation law&#59; and</font></div><div style="margin-top:14.4pt;padding-left:42pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:17.18pt">Employee has not initiated any adversarial proceedings of any kind against the Company or, in their capacities as such, against any other person or entity released herein, nor will Employee do so in the future, except as specifically allowed by this Release.</font></div><div style="margin-top:14.4pt;padding-left:13.5pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.25pt;text-decoration:underline">Restrictive Covenants&#59; Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Employee reaffirms Employee&#8217;s continuing obligations under Section 16 of the Severance Plan.  In addition, Employee shall cooperate with the Company and its affiliates, upon the Company&#8217;s reasonable request, with respect to any internal investigation or administrative, regulatory or judicial proceeding involving matters within the scope of Employee&#8217;s duties and responsibilities to the Company or its affiliates during Employee&#8217;s employment with the Company (including, without limitation, Employee being available to the Company upon reasonable notice for interviews and factual investigations, appearing at the Company&#8217;s reasonable request to give testimony without requiring service of a subpoena or other legal process, and turning over to the Company all relevant Company documents which are or may have come into Employee&#8217;s possession during his employment)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that any such request by the Company shall not be unduly burdensome or interfere with Employee&#8217;s personal schedule&#160;or ability to engage in gainful employment.</font></div><div style="margin-top:14.4pt;padding-left:13.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.25pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The provisions of this Release are severable.  If any provision is held to be invalid or unenforceable, it shall not affect the validity or enforceability of any other provision.</font></div><div style="margin-top:14.4pt;padding-left:13.5pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.25pt;text-decoration:underline">Choice of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Release shall in all respects be governed and construed in accordance with the laws of the State of &#91;California&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, including all matters of construction, validity and performance, without regard to conflicts of law principles.</font></div><div style="margin-top:14.4pt;padding-left:13.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.25pt;text-decoration:underline">Integration Clause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Release, and the Severance Plan contain the Parties&#8217; entire agreement with regard to the separation of Employee&#8217;s employment, and supersede and replace any prior agreements as to those matters, whether oral or written. This Release may not be changed or modified, in whole or in part, except by an instrument in writing signed by Employee and a duly authorized officer or director of the Company.</font></div><div style="margin-top:14.4pt;padding-left:13.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.25pt;text-decoration:underline">Execution in Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Release may be executed in counterparts with the same force and effectiveness as though executed in a single document.  Facsimile signatures shall have the same force and effectiveness as original signatures.</font></div><div style="margin-top:14.4pt;padding-left:13.5pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14.25pt;text-decoration:underline">Intent to be Bound</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Parties have carefully read this Release in its entirety&#59; fully understand and agree to its terms and provisions&#59; and intend and agree that it is final and binding on all Parties.</font></div><div style="margin-top:14.4pt"><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> NTD&#58; To be Employee&#8217;s state of employment.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.32pt;width:100%"><div><font><br></font></div></div><div style="margin-top:14.4pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.32pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;IN WITNESS WHEREOF, and intending to be legally bound, the Parties have executed the foregoing on the dates shown below.</font></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EMPLOYEE</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ANGION BIOMEDICA CORP.</font></td></tr><tr style="height:65pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:8pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:8pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:8pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:8pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:8pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58;</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="i755f0c5658fa43aa915c5c560940de7f_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">APPENDIX B</font></div><div style="margin-bottom:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Detailed Claims And Arbitration Procedures</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:9pt">Claims Procedure</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Claims for benefits under the Plan shall be administered in accordance with Section 503 of ERISA and the Department of Labor Regulations thereunder. The Plan Administrator shall make all determinations as to the rights of any Claimant.  A Claimant may authorize a representative to act on his or her behalf with respect to any claim under the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Initial Claims</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">All claims shall be presented to the Plan Administrator in writing.  Within ninety (90) days after receiving a claim, a claims official appointed by the Plan Administrator shall consider the claim and issue his or her determination thereon in writing.  If the Plan Administrator or claims official determines that an extension of time is necessary, the claims official may extend the determination period for up to an additional ninety (90) days by giving the Claimant written notice indicating the special circumstances requiring the extension of time prior to the termination of the initial ninety (90) day period.  Any claims that the Claimant does not pursue in good faith through the initial claims stage shall be treated as having been irrevocably waived.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Claims Decisions</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If the claim is granted, the benefits or relief the Claimant seeks shall be provided.  If the claim is wholly or partially denied, the claims official shall, within ninety (90) days (or a longer period, as described above), provide the Claimant with written notice of the denial, setting forth, in a manner calculated to be understood by the Claimant&#58; (1) the specific reason or reasons for the denial&#59; (2) specific references to the provisions on which the denial is based&#59; (3) a description of any additional material or information necessary for the Claimant to perfect the claim, together with an explanation of why the material or information is necessary&#59; and (4) an explanation of the procedures for appealing denied claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and time limits applicable to such procedures, including a statement of the Claimant&#8217;s right to submit a request for arbitration after the appeal is denied or deemed denied.  If the Claimant can establish that the claims official has failed to respond to the claim in a timely manner, the Claimant may treat the claim as having been denied by the claims official.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Appeals of Denied Claims</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Each Claimant shall have the opportunity to appeal the claims official&#8217;s denial of a claim in writing to an appeals official appointed by the Plan Administrator (which may be a person, committee, or other entity).  A Claimant must appeal a denied claim within sixty (60) days after receipt of written notice of denial of the claim, or within sixty (60) days after it was due if the Claimant did not receive it by its due date.  The Claimant shall have the opportunity to submit written comments, documents, records and other information relating to the Claimant&#8217;s claim.  The Claimant (or the Claimant&#8217;s duly authorized representative) shall be provided upon request and free of charge, reasonable access to, and copies of, all documents, records and other information relevant to the Claimant&#8217;s claim.  The appeals official shall take into account during its review all comments, documents, records and other information submitted by the Clamant relating to the claim, without regard to whether such information was submitted or considered in the initial benefits review.  Any claims that the Claimant does not pursue in good faith through the appeals stage, such as by failing to file a timely appeal request, shall be treated as having been irrevocably waived.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Appeals Decisions</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The decision by the appeals official shall be made not later than sixty (60) days after the written appeal is received by the Plan Administrator, however, if the appeals official determines that an extension of time is necessary, the appeals official may extend the determination period for up to an </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Appendix B-1</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">additional sixty (60) days by giving the Claimant written notice indicating the special circumstances requiring the extension of time prior to the termination of the initial sixty (60) day period.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">However, if the appeals official is a committee that meets at least quarterly, then the decision by the appeals official shall be made not later than the date of the meeting that immediately follows the Plan&#8217;s receipt of an appeal request, unless the appeal request is filed within thirty (30) days preceding the date of such meeting. In such case, a benefit determination may be made by no later than the date of the second meeting following the Plan&#8217;s receipt of the appeal request.  If special circumstances require a further extension of time for processing, a benefit determination shall be rendered no later than the third meeting of the appeals official following the Plan&#8217;s receipt of the appeal request.  If such an extension of time for review is required, the appeals official shall provide the Claimant with written notice of the extension, describing the special circumstances and the date as of which the benefit determination will be made, prior to the commencement of the extension. The appeals official shall notify the Claimant of the benefit determination as soon as possible but not later than five (5) days after it has been made.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The appeal decision shall be in writing, shall be set forth in a manner calculated to be understood by the Claimant and shall include the following&#58; (1) the specific reason or reasons for the denial&#59; (2) specific references to the provisions on which the denial is based&#59; (3) a statement that the Claimant is entitled to receive, upon request and free of charge, reasonable access to, and copies of, all documents, records and other information relevant to the Claimant&#8217;s claim&#59; and (4) a statement of the Claimant&#8217;s right to submit a request for arbitration and the deadline for doing so.  If a Claimant does not receive the appeal decision by the date it is due, the Claimant may deem the appeal to have been denied.    Subject to applicable law, any decision made in accordance with the claims procedures in this Appendix B is final and binding on all parties and shall be given the maximum possible deference allowed by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Procedures</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Plan Administrator shall adopt procedures by which initial claims shall be considered and appeals shall be resolved&#59; different procedures may be established for different claims.  All procedures shall be designed to afford a Claimant full and fair consideration of his or her claim and appeal.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Arbitration of Rejected Appeals</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If a Claimant has pursued a claim through the appeal stage of these claims procedures, the Claimant may contest the actual or deemed denial of that claim through arbitration, as described below.  In no event shall any denied claim be subject to resolution by any means (such as in a court of law) other than arbitration in accordance with the following provisions.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27pt">Arbitration Procedure</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Request for Arbitration</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A Claimant must submit a request for arbitration to the Plan Administrator within 60 days after receipt of the written denial of an appeal (or within sixty (60) days after he or she should have received the determination). The Claimant or the Plan Administrator may bring an action in any court of appropriate jurisdiction to compel arbitration in accordance with these procedures.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Applicable Arbitration Rules</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If the Claimant has entered into a valid arbitration agreement with the Company, the arbitration shall be conducted in accordance with that agreement.  If not, the rules set forth in the balance of this Appendix shall apply&#58; The arbitration shall be held under the auspices of the Judicial Arbitration and Mediation Service (&#8220;JAMS&#8221;), whichever is chosen by the party who did not initiate the arbitration.  Except as provided below, the arbitration shall be in accordance with JAMS&#8217; then-current employment dispute resolution rules.  The Arbitrator shall apply the Federal Rules of Evidence and shall have the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Appendix B-2</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">authority to entertain a motion to dismiss or a motion for summary judgment by any party and shall apply the standards governing such motions under the Federal Rules of Civil Procedure.  The Federal Arbitration Act shall govern all arbitrations that take place under these Detailed Claims and Arbitration Procedures (or that are required to take place under them), and shall govern the interpretation or enforcement of these Procedures or any arbitration award.  To the extent that the Federal Arbitration Act is inapplicable, California law pertaining to arbitration agreements shall apply.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Arbitrator</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The arbitrator (the &#8220;Arbitrator&#8221;) shall be an attorney familiar with employee benefit matters who is licensed to practice law in the state in which the arbitration is convened.  The Arbitrator shall be selected in the following manner from a list of eleven arbitrators drawn by the sponsoring organization under whose auspices the arbitration is being conducted and taken from its panel of labor and employment arbitrators.  Each party shall designate all arbitrators on the list whom they find acceptable&#59; the parties shall then alternately strike arbitrators from the list of arbitrators acceptable to both parties, with the party who did not initiate the arbitration striking first.  If only one arbitrator is acceptable to both parties, he or she will be the Arbitrator.  If none of the arbitrators is acceptable to both parties, a new panel of arbitrators shall be obtained from the sponsoring organization and the selection process shall be repeated.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Location</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The arbitration will take place in or near the city in which the Claimant is or was last employed by the Company or in which the Plan is principally administered, whichever is specified by the Plan Administrator, or in such other location as may be acceptable to both the Claimant and the Plan Administrator.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Authority of Arbitrator</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Arbitrator shall have the authority to resolve any factual or legal claim relating to the Plan or relating to the interpretation, applicability, or enforceability of these arbitration procedures, including, but not limited to, any claim that these procedures are void or voidable.  The Arbitrator may grant a Claimant&#8217;s claim only if the Arbitrator determines that it is justified because&#58; (1) the appeals official erred on an issue of law&#59; or (2) the appeals official&#8217;s findings of fact, if applicable, were not supported by substantial evidence.  The arbitration shall be final and binding on all parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Limitation on Scope of Arbitration</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Claimant may not present any evidence, facts, arguments, or theories at the arbitration that the Claimant did not pursue in his or her appeal, except in response to new evidence, facts, arguments, or theories presented on behalf of the other parties to the arbitration.  However, an arbitrator may permit a Claimant to present additional evidence or theories if the Arbitrator determines that the Claimant was precluded from presenting them during the claim and appeal procedures due to procedural errors of the Plan Administrator or its delegates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Administrative Record</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Plan Administrator shall submit to the Arbitrator a certified copy of the record on which the appeals official&#8217;s decision was made.  Each Claimant may only submit individual claims to the Arbitrator, and the Arbitrator may only review individual, not class, claims.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Experts, Depositions, and Discovery</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Except as otherwise permitted by the Arbitrator on a showing of substantial need, either party may&#58; (1) designate one expert witness&#59; (2) take the deposition of one individual and the other party&#8217;s expert witness&#59; (3) propound requests for production of documents&#59; and (4) subpoena witnesses and documents relating to the discovery permitted in this paragraph.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Appendix B-3</font></div><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Pre-Hearing Procedures</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">At least thirty (30) days before the arbitration hearing, the parties must exchange lists of witnesses, including any expert witnesses, and copies of all exhibits intended to be used at the hearing.  The Arbitrator shall have jurisdiction to hear and rule on pre-hearing disputes and is authorized to hold pre-hearing conferences by telephone or in person, as the Arbitrator deems necessary.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Transcripts</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Either party may arrange for a court reporter to provide a stenographic record of the proceedings at the party&#8217;s own cost.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Post-Hearing Procedures</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Either party, on request at the close of the hearing, may be given leave to file a post-hearing brief within the time limits established by the Arbitrator.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Costs and Attorneys&#8217; Fees</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Claimant and the Company shall equally share the fees and costs of the Arbitrator, except that the Claimant shall not be required to pay any of the Arbitrator&#8217;s fees and costs if such a requirement would make mandatory arbitration under these procedures unenforceable.  On a showing of material hardship, the Company, in its discretion, may advance all or part of the Claimant&#8217;s share of the fees and costs, in which case the Claimant shall reimburse the Company out of the proceeds of the arbitration award, if any, that the Claimant receives.  Each party shall pay its own costs and attorneys&#8217; fees, except as required by applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Procedure for Collecting Costs From Claimant</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Before the arbitration commences, the Claimant must deposit with the Plan Administrator his or her share of the anticipated fees and costs of the Arbitrator, as reasonably determined by the Plan Administrator.  At least two weeks before delivering his or her decision, the Arbitrator shall send his or her final bill for fees and costs to the Plan Administrator for payment.  The Plan Administrator shall apply the amount deposited by the Claimant to pay the Claimant&#8217;s share of the Arbitrator&#8217;s fees and costs and return any surplus deposit.  If the Claimant&#8217;s deposit is insufficient, the Claimant will be billed for any remaining amount due.  Failure to pay any amount within 10 days after it is billed shall constitute the Claimant&#8217;s irrevocable election to withdraw his or her arbitration request and abandon his or her claim.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Arbitration Award</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Arbitrator shall render an award and opinion in the form typically rendered in labor arbitrations.  Within twenty (20) days after issuance of the Arbitrator&#8217;s award and opinion, either party may file with the Arbitrator a motion to reconsider, which shall be accompanied by a supporting brief.  If such a motion is filed, the other party shall have twenty (20) days from the date of the motion to respond, after which the Arbitrator shall reconsider the issues raised by the motion and either promptly confirm or promptly change his or her decision.  The decision shall then be final and conclusive on the parties.  Arbitrator fees and other costs of a motion for reconsideration shall be borne by the losing party, unless the Arbitrator orders otherwise.  Either party may bring an action in any court of appropriate jurisdiction to enforce an arbitration award.  A party opposing enforcement of an arbitration award may not do so in an enforcement proceeding, but must bring a separate action in a court of competent jurisdiction to set aside the award.  In any such action, the standard of review shall be the same as that applied by an appellate court reviewing the decision of a trial court in a nonjury trial.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Severability</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The invalidity or unenforceability of any part of these arbitration procedures shall not affect the validity of the rest of the procedures.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Appendix B-4</font></div><div><font><br></font></div><div><font><br></font></div></div></div><div id="i755f0c5658fa43aa915c5c560940de7f_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">APPENDIX C</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ADDITIONAL INFORMATION</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RIGHTS UNDER ERISA</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As a participant in the Plan, you are entitled to certain rights and protections under ERISA.  ERISA provides that all Plan participants will be entitled to&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Receive Information About Your Plan and Benefits</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9pt">Examine, without charge, at the Company&#8217;s headquarters, all documents governing the Plan, if any, and a copy of the latest annual report (Form 5500 Series) filed by the Plan with U.S. Department of Labor and available at the Public Disclosure Room of the Pension and Welfare Benefit Administration.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt">Obtain, upon written request to the Plan Administrator, copies of documents governing the operation of the Plan, including copies of the latest annual report (Form 5500 Series) and updated summary plan description.  The Plan Administrator may make a reasonable charge for the copies.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27pt">Receive a summary of the Plan&#8217;s annual financial report, if any.  The Plan Administrator is required by law to furnish each participant with a copy of this summary annual report.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Prudent Actions by Plan Fiduciaries</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition to creating rights for Plan participants, ERISA imposes duties upon the people who are responsible for the operation of the employee benefit plan. The people who operate your Plan, called &#8220;fiduciaries&#8221; of the Plan, have a duty to do so prudently and in the interest of you and other Plan participants and beneficiaries.  No one, including the Company, your union, or any other person, may fire you or otherwise discriminate against you in any way to prevent you from obtaining a welfare benefit or exercising your right under ERISA.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Enforce Your Rights</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If your claim for a welfare benefit is denied or ignored, in whole or in part, you have a right to know why this was done, to obtain copies of documents relating to the decision without charge, and to appeal any denial, all within certain time schedules.  Under ERISA, there are steps you can take to enforce the above rights.  For instance, if you request a copy of plan documents or the latest annual report from the Plan and do not receive them within thirty (30) days, you may file suit in a Federal court.  In such a case, the court may require the Plan Administrator to provide the materials and pay you up to $110 a day until you receive the materials, unless the materials were not sent because of reasons beyond the control of the Plan Administrator.  If you have a claim for benefits, which is denied or ignored, in whole or in part, you may file suit in a state or Federal court.  In addition, if you disagree with the Plan&#8217;s decision or lack thereof concerning the qualified status of a domestic relations order or a medical child support order, you may file suit in Federal court.  If it should happen that Plan fiduciaries misuse the Plan&#8217;s money, or if you are discriminated against for asserting your rights, you may seek assistance from the U.S. Department of Labor, or you may file suit in a federal court.  The court will decide who should pay court costs and legal fees.  If you are successful, the court may order the person you have sued to pay these costs and fees.  If you lose, the court may order you to pay these costs and fees, for example, if it finds your claim is frivolous.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Appendix C-1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Assistance with Your Questions</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If you have any questions about your Plan, you should contact the Plan Administrator.  If you should have any questions about this statement or about your rights under ERISA, or if you need assistance in obtaining documents from the Plan Administrator, you should contact the nearest office of the Employee Benefits Security Administration, U.S.&#160;Department of Labor, listed in your telephone directory or the Division of Technical Assistance and Inquiries, Employee Benefits Security Administration, U.S. Department of Labor, 200 Constitution Avenue N. W., Washington, D. C. 20210.  You may also obtain certain publications about your rights and responsibilities under ERISA by calling the publications hotline of the Employee Benefits Security Administration.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.618%"><tr><td style="width:1.0%"></td><td style="width:36.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.088%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">ADMINISTRATIVE INFORMATION</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name of Plan&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Angion Biomedica Corp. Executive Separation Benefits Plan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Plan Administrator and Sponsor&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Board of Directors<br>Angion Biomedica Corp.<br>51 Charles Lindbergh Boulevard</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Uniondale, NY 1553<br>Tel&#58; (&#91;__&#93;) &#91;__&#93;-&#91;____&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Type of Administration&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Self-Administered</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Type of Plan&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Severance Pay Employee Welfare Benefit Plan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Employer Identification Number&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;_____________&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Direct Questions Regarding the Plan to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Board of Directors<br>Angion Biomedica Corp.<br>51 Charles Lindbergh Boulevard</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Uniondale, NY 1553<br>Tel&#58; (&#91;__&#93;) &#91;__&#93;-&#91;____&#93;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Agent for Service of Legal Process&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Human Resources<br>Angion Biomedica Corp.<br>51 Charles Lindbergh Boulevard</font></div><div style="margin-bottom:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Uniondale, NY 1553<br>Tel&#58; (&#91;__&#93;) &#91;__&#93;-&#91;____&#93;<br>Service of Legal Process may also be made upon the Plan Administrator.</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Plan Year End&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">December 31</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Plan Number&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;502&#93;</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Appendix C-2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>11
<FILENAME>solara-angionxredactedclin.htm
<DESCRIPTION>EX-10.15
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i03c3d23ba205432199b00dc6108e1e13_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:justify"><font><br></font></div></div><div style="padding-right:55.5pt;text-align:justify"><font><br></font></div><div style="padding-right:55.5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit 10.15</font></div><div style="padding-right:55.5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Certain confidential information contained in this document,</font></div><div style="padding-right:55.5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">marked by brackets, has been omitted because it is both</font></div><div style="padding-right:55.5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(i) not material and (ii) is the type of information that Angion treats as confidential.</font></div><div style="padding-right:55.5pt;text-align:justify"><font><br></font></div><div style="padding-right:55.5pt;text-align:justify"><font><br></font></div><div style="padding-right:55.5pt;text-align:justify"><font><br></font></div><div style="padding-left:0.75pt;padding-right:0.75pt;text-align:center"><font style="color:#0070c0;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:100%">SUPPLY AGREEMENT </font></div><div style="padding-right:55.5pt;text-align:justify"><font><br></font></div><div style="padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">THIS SUPPLY AGREEMENT (this &#8220;Agreement&#8221;) is made and entered into as of the date of last signature (the &#8220;Effective Date&#8221;) by and between Angion Biomedica Corp, a company organized under the laws of USA located at 51 Charles Lindbergh Blvd, Uniondale, NY 11553 (&#8220;ANGION&#8221;) and Solara Active Pharma Sciences Ltd., a company organized under the laws of India located at Batra Centre, No.28, Sardar Patel Road, Guindy, Chennai - 600 032, Tamilnadu, India (&#8220;SOLARA&#8221;).</font></div><div style="padding-right:1.5pt;text-align:justify"><font><br></font></div><div style="padding-left:0.75pt;padding-right:0.75pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">WITNESSETH</font></div><div style="padding-right:1.5pt;text-align:justify"><font><br></font></div><div style="padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">WHEREAS, ANGION and SOLARA have entered into the certain Supply Agreement dated as of the 20 October 2021 for manufacture and supply of pharmaceutical intermediates and active pharmaceutical ingredients, including ANG-3070. </font></div><div style="padding-right:1.5pt;text-align:justify"><font><br></font></div><div style="padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the above premises and mutual agreements contained herein below, the Parties have agreed as follows&#58;</font></div><div style="padding-right:1.5pt;text-align:justify"><font><br></font></div><div style="padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;&#160;Supply and Purchase</font></div><div style="padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to the terms and conditions of this Agreement, SOLARA agrees to </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">manufacture and supply the required amount of ANG-3070 at its facility.  If a specific SOLARA facility(ies) is identified in a purchase order, the services under such purchase order shall only be performed at such specific SOLARA facility(ies).  SOLARA shall store all Angion-provided- materials and the Compound in accordance with applicable laws (including cGMP, if applicable) and the explicit handling, production, packaging (if applicable), specifications, storage and shipping procedures and instructions provided by Angion. </font></div><div style="padding-right:1.5pt;text-align:justify"><font><br></font></div><div style="padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.&#160;&#160;&#160;&#160;Quality</font></div><div style="padding-left:42.55pt;padding-right:1.5pt;text-align:justify;text-indent:-42.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1&#160;&#160;&#160;&#160;SOLARA warrants that the Compound shall, at the point and time of delivery to ANGION (a) be of the agreed quantity&#59; and (b) have been manufactured in accordance with applicable laws (including cGMP, if applicable), the applicable specifications, batch record and&#47;or other protocols as agreed to among the Parties in a timely manner.</font></div><div style="padding-left:42.55pt;padding-right:1.5pt;text-align:justify;text-indent:-42.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2&#160;&#160;&#160;&#160;SOLARA further warrants that&#58;</font></div><div style="padding-left:42.55pt;padding-right:1.5pt;text-align:justify;text-indent:-0.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;the Compounds shall not be adulterated, misbranded, or mislabeled within the meaning of applicable laws, and shall have a shelf life or retest dating no less than the shelf life or retest dating set forth in the specifications.  </font></div><div style="padding-left:42.55pt;padding-right:1.5pt;text-align:justify;text-indent:-0.55pt"><font><br></font></div><div style="padding-left:42.55pt;padding-right:1.5pt;text-align:justify;text-indent:-0.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;SOLARA&#8217;s performance of the services shall comply with applicable laws (including cGMP, if applicable)&#59;</font></div><div style="padding-left:42.55pt;padding-right:1.5pt;text-align:justify;text-indent:-0.55pt"><font><br></font></div><div style="padding-left:42.55pt;padding-right:1.5pt;text-align:justify;text-indent:-0.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;all work under this Agreement shall be SOLARA&#8217;s original work and none of the services infringe, misappropriate, or violate any proprietary rights of any third party.</font></div><div style="padding-right:1.5pt;text-align:justify"><font><br></font></div><div style="padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.&#160;&#160;&#160;&#160;Forecast&#47;Order</font></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify;text-indent:-45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1&#160;&#160;&#160;&#160;ANGION shall place firm purchase orders to SOLARA at least &#91;***&#93; months prior to the requested delivery date.  Such purchase order shall specify the quantity and the date and place of delivery in writing. Each purchase order shall be made on kilogram basis.</font></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify;text-indent:-45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.3&#160;&#160;&#160;&#160;SOLARA shall be deemed to accept the purchase order unless it expresses its intention to refuse the purchase order within &#91;***&#93; days from receipt of such purchase order. </font></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify;text-indent:-45pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div><div style="padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.&#160;&#160;&#160;&#160;Price and payment</font></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify;text-indent:-45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1&#160;&#160;&#160;&#160;The price and quantity of the Compound shall be provided in the appendix A, which may be updated to reflect individual projects and quantities. ANGION shall pay the Price in accordance with the terms provided in proposal submitted by Solara.</font></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify;text-indent:-45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2&#160;&#160;&#160;&#160;SOLARA shall issue an invoice for the Compound purchased by ANGION or its Affiliates by the last day of the calendar month following the month of receipt by ANGION, its Affiliates or its toll-manufacturers of the Compound. </font></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify;text-indent:-45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.3&#160;&#160;&#160;&#160;In the event ANGION fails to pay any undisputed invoiced amount by any due date ANGION shall pay interest on such outstanding amount at an annual rate equal to &#91;***&#93; per annum, accruing from such due date until full payment of the outstanding amount is received by SOLARA. </font></div><div style="padding-right:1.5pt;text-align:justify"><font><br></font></div><div style="padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.&#160;&#160;&#160;&#160;Delivery, Inspection and Recall</font></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify;text-indent:-45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1&#160;&#160;&#160;&#160;SOLARA shall deliver the Compound to ANGION with the applicable certificate of analysis and batch records. The delivery shall be done under the instruction of ANGION. </font></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify;text-indent:-45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.2&#160;&#160;&#160;&#160;Subject to the foregoing, in the event that any of the Compound is short delivered or otherwise found not to meet the warranty set forth in Section 2.2 shall be deemed to be a defective product (&#8220;Defective Product&#8221;). Within thirty &#91;***&#93; after tender of delivery of the Compound, ANGION, or its designee, shall notify SOLARA in writing that the COMPOUND is allegedly a Defective Product (an &#8220;Exception Notice&#8221;), except in the case of Latent Defects (as such term is defined below), for which ANGION will have &#91;***&#93; from ANGION&#8217;s confirmation of such Latent Defect.  Upon receipt of an Exception Notice from ANGION, SOLARA shall conduct and document an investigation in its discretion to determine whether or not it agrees with ANGION that such delivered Compound is a Defective Product and to determine the cause of any nonconformity. If SOLARA agrees that such Deliverable is Defective Product, and determines the cause of the nonconformity is attributable to SOLARA&#8217;s negligence, willful misconduct, or failure to perform the Services in accordance with the terms of this Agreement (&#8220;SOLARA Defective Processing&#8221;), then SOLARA shall, within a reasonable time (&#91;***&#93; days and to the extent SOLARA has stock), deliver any such missing quantities or re-deliver the Compound that comply with the Specifications (as the case may be).  </font></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify;text-indent:-45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3&#160;&#160;&#160;&#160;If SOLARA fails to make delivery or re-delivery in accordance, ANGION shall have the option to (a) cancel its purchase order for the Compound for which delivery or re-delivery failed, to which SOLARA will credit any payments made by ANGION for such Defective Product, or (b) reduce the purchase price by a mutually agreed amount.</font></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify;text-indent:-45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.4&#160;&#160;&#160;&#160;&#8220;Latent Defect&#8221; shall mean any defects in the Compound that existed at the time of delivery to ANGION but could not be reasonably detected upon review of records or the initial testing and inspection of the Compound in accordance with the specifications.</font></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify;text-indent:-45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.6&#160;&#160;&#160;&#160;If the Parties disagree as to whether the Compound is Defective Product, and such disagreement is not resolved within &#91;***&#93; days of the Exception Notice date, the Parties shall cause a mutually acceptable independent third party to review records, test data and to perform comparative tests and&#47;or analyses on samples of the alleged Defective Product and its components.  The independent party&#8217;s results as to whether or not product is Defective Product and the cause of any nonconformity shall be final and binding.  Unless otherwise agreed to by the Parties in writing, the costs associated with such testing and review shall be borne by SOLARA if the Compound is Defective Product attributable to SOLARA Defective Processing, and by ANGION in all other circumstances. For avoidance of doubt, where the cause of nonconformity cannot be determined or assigned, it shall not be deemed SOLARA Defective Processing.</font></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify;text-indent:-45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.7&#160;&#160;&#160;&#160;The Parties will maintain traceability records necessary to permit a recall, field correction or other notification to the field of the Compound.  Each Party will give notice via telephone or e-mail 24-hours within receipt of any information which indicates that a recall, field correction or other notification to the field may be necessary.  The decision to conduct and the control of a recall, field correction or other notification will solely be that of ANGION.  Each Party will cooperate fully with the other in connection with any such efforts. If any recall, field correction or other notification is due to a breach by SOLARA of its obligations under this Agreement, or any act by a SOLARA Indemnitee (as defined below) outside the scope of this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Agreement, including, without limitation, the negligence or willful misconduct of any SOLARA Indemnitee, SOLARA will replace recalled or field corrected Compound with conforming Compound and will reimburse ANGION for the direct costs and expenses of recalling and returning Compound from the clinical sites and study subjects. </font></div><div style="padding-right:1.5pt;text-align:justify"><font><br></font></div><div style="padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> 6.&#160;&#160;&#160;&#160;Transfer of Title and Risk of Loss</font></div><div style="padding-left:44.95pt;padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title and risk of loss in and to the Compound shall pass through ANGION when the Compound is received by ANGION, its Affiliates or its toll-manufacturers. </font></div><div style="padding-left:44.95pt;padding-right:1.5pt;text-align:justify"><font><br></font></div><div style="padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.&#160;&#160;&#160;&#160;Results and Records Keeping&#59; Regulatory Inspection and Audit </font></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify;text-indent:-40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1&#160;&#160;&#160;&#160;SOLARA shall create and maintain written records of the batch, results, laboratory data and other technical records, reports or deliverables generated or recorded in the performance of the Services (collectively, the &#8220;Results&#8221;) in a timely and accurate manner.  The Results shall be owned by Angion.  SOLARA shall maintain the Results in compliance with the terms and conditions of this Agreement, the applicable purchase order and all applicable laws.  Promptly upon completion or termination of Services, or promptly upon request by Angion, SOLARA shall transfer the Results to Angion.  Company shall store the Results for &#91;***&#93; years following termination of this Agreement and, at least &#91;***&#93; months prior to the expiration of such &#91;***&#93; year period, SOLARA shall contact Angion to determine whether Angion chooses, at Angion&#8217;s sole option, to&#58; (1) request return of the Results at Angion&#8217;s reasonable expense&#59; (2) request extended storage of such raw data at reasonable storage rates to be charged to Angion&#59; or (3) request disposal (in accordance with all applicable guidelines) of such data at Angion&#8217;s reasonable expense. </font></div><div style="padding-right:1.5pt;text-align:justify"><font><br></font></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If any governmental or regulatory authority conducts or gives notice to SOLARA of its intent to conduct an inspection at SOLARA&#8217;s facilities or take any other regulatory action, SOLARA will promptly give Angion notice thereof, including all information pertinent thereto.</font></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify"><font><br></font></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify;text-indent:-40.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.2&#160;&#160;&#160;&#160;During the Term and for &#91;***&#93; year thereafter, or such longer period as may be required by applicable laws, Angion shall have access to books and records maintained by SOLARA in connection with this Agreement as reasonably necessary for Angion to audit or inspect SOLARA&#8217;s performance and compliance with this Agreement and to verify the accuracy of amounts invoiced and paid hereunder.  Angion, or its designated agent, shall have the right to inspect such records during normal business hours at SOLARA&#8217;s offices upon giving SOLARA written notice of at least &#91;***&#93; days before the intended date of such audit or inspection.  Angion shall be responsible for all expenses it incurs in connection with any audit or inspection.  During the Term, SOLARA will permit Angion&#8217;s representative(s) to examine the work performed hereunder and to inspect SOLARA&#8217;s and its permitted subcontractors&#8217; facilities, upon reasonable advance notice and during regular business hours.</font></div><div style="padding-right:1.5pt;text-align:justify"><font><br></font></div><div style="padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.&#160;&#160;&#160;&#160;Liability</font></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify;text-indent:-45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary hereunder, each Party shall indemnify and hold harmless the other Parties, their Affiliates and their respective officers, employees, and agents against all allegations, claims (including those related to product liability), or demands (whether threatened or pending), costs, fees and charges (including reasonable attorneys&#8217; fees and the fees of other consulting professionals) and losses, damages, judgments and liabilities of any kind whatsoever (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Claims</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), which such Party may hereafter incur, become responsible for, or pay out, as a result of and to the extent that such Claims are due to (a) any breach of, or inaccuracy in, any representation or warranty made by indemnifying Party in this Agreement, or in the performance of, this Agreement, (b) the negligence or willful misconduct of the indemnifying Party in the performance of such Party&#8217;s obligations under this Agreement.</font></div><div style="padding-right:1.5pt;text-align:justify"><font><br></font></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Each Party shall, during the term of this Agreement and for &#91;***&#93; years thereafter, obtain and maintain at its own cost and expense from a qualified insurance company, comprehensive general liability insurance of at least $&#91;***&#93; per claim and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">$&#91;***&#93; in the aggregate, and product liability coverage in the amount of at least US$&#91;***&#93; per claim and $&#91;***&#93; in the aggregate.  Each Party shall provide the respective other Party with a certificate of such insurance upon reasonable request.</font></div><div style="padding-right:1.5pt;text-align:justify"><font><br></font></div><div style="padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.&#160;&#160;&#160;&#160;Force Majeure</font></div><div style="padding-left:44.95pt;padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any and all circumstances beyond the reasonable control of the Parties including, but not limited to, acts of God, war, riots, pandemic, unavoidable break-downs and acts of authorities, release the Parties hereto from their respective obligations under or pursuant to this Agreement - insofar as the circumstances prevent the deliveries of SOLARA or the takings of further processing of the Compound by ANGION or its toll-manufacturer - for the duration of that contingencies and to the extent of the effects resulting therefrom. If any such case occurs, the Party affected shall inform the other Parties immediately indicating the presumable duration and extent of such contingency. Moreover, the Party affected shall promptly take care to settle such contingencies so that the performance of its obligations under this Agreement can be resumed as soon as possible.</font></div><div style="padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div style="padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.&#160;&#160;&#160;&#160;Assignment</font></div><div style="padding-left:44.95pt;padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Non of the Parties shall assign or transfer this Agreement or any right or interest under this Agreement to any third party without the other Parties&#8217; prior written consent, provided however, that either party  shall be entitled to assign right under this Agreement in whole or in part to its Affiliates or in connection with a merger, acquisition, or sale of all or substantially all of its assets pertaining to this Agreement with prior consent from other party. Assigning party shall inform the other party immediately upon such assignment. &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Affiliates</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean with respect to a Party, any entity, which, directly or indirectly, Controls, is Controlled by or is under the common Control with the Party. A person shall be deemed to &#8220;Control&#8221; another person if the controlling person possesses, directly or indirectly, ownership of at least fifty percent (50%) of the equity shares of such an entity and&#47;or the power to direct the management of such an entity. </font></div><div style="padding-right:1.5pt;text-align:justify"><font><br></font></div><div style="padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.&#160;&#160;&#160;&#160;Modifications</font></div><div style="padding-left:44.95pt;padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any modification or amendment of this Agreement, including this clause, shall only be valid if made in writing executed by duly authorized representatives of the Parties.</font></div><div style="padding-right:1.5pt;text-align:justify"><font><br></font></div><div style="padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.&#160;&#160;&#160;&#160;Severability</font></div><div style="padding-left:44.95pt;padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In the event that any of the provisions of this Agreement are invalid because they are inconsistent with the applicable law, this shall in no manner affect the validity of the other provisions of this Agreement. The Parties hereto shall be obliged to replace such invalid provisions by new provisions having similar economic effects.</font></div><div style="padding-right:1.5pt;text-align:justify"><font><br></font></div><div style="padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.&#160;&#160;&#160;&#160;Confidentiality</font></div><div style="padding-left:42pt;padding-right:1.5pt;text-align:justify;text-indent:-42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.1&#160;&#160;&#160;&#160;Each Party shall keep confidential the terms and conditions of this Agreement, the contents of prior negotiations and any other information received from the other Parties in connection with this Agreement as well as the Confidentiality Agreement between the Parties (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Proprietary Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), except for such disclosure as may be agreed to by the other Parties or made to their respective professional advisors, as required by law or by an order of a court or tribunal of relevant jurisdiction from time to time. If Proprietary Information is required to be disclosed by law or by an order of a court or tribunal of relevant jurisdiction, an appropriate and timely notice thereof shall be given by the receiving Party, so as to allow the disclosing Party the opportunity to obtain an appropriate protection from the relevant court or jurisdiction.</font></div><div style="padding-left:42pt;padding-right:1.5pt;text-align:justify;text-indent:-42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.2&#160;&#160;&#160;&#160;The foregoing confidentiality obligations shall not apply with respect to any information which the receiving Party can establish competent proof that&#58;</font></div><div style="padding-left:70.9pt;padding-right:1.5pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.82pt">the information is publicly known at the time of disclosure or becomes publicly known without any breach of this Agreement by the receiving Party&#59;</font></div><div style="padding-left:70.9pt;padding-right:1.5pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.82pt">the information was in the receiving Party&#8217;s possession at or before the time of disclosure by the disclosing Party and was not acquired, directly or indirectly, from the disclosing Party under obligation of confidentiality with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div><div style="padding-left:70.9pt;padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">respect to thereto, as proven by receiving Party&#8217;s contemporaneous written records&#59;</font></div><div style="padding-left:70.9pt;padding-right:1.5pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.43pt">the information is received from a third party&#59; provided, however, that such information was not obtained by said third party, directly or indirectly, from the disclosing Party&#59; </font></div><div style="padding-left:70.9pt;padding-right:1.5pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.82pt">the information is disclosed upon approval for release by written authorization of the disclosing Party&#59; and</font></div><div style="padding-left:70.9pt;padding-right:1.5pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:7.82pt">the information is independently developed by the receiving Party without use or reliance on the disclosing Party&#8217;s Proprietary Information.</font></div><div style="padding-left:42pt;padding-right:1.5pt;text-align:justify;text-indent:-42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.3&#160;&#160;&#160;&#160;Each Party shall make the Proprietary Information available only to such of its employees and employees of its Affiliates who need to have access to such Proprietary Information for the purposes of performing this Agreement and who are contractually or otherwise obligated to keep it confidential and instructed to neither use nor disclose such Proprietary Information in a manner other than as permitted herein. </font></div><div style="padding-left:42pt;padding-right:1.5pt;text-align:justify;text-indent:-42pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.4&#160;&#160;&#160;&#160;This Article shall survive any termination of this Agreement for a period of &#91;***&#93; years. </font></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify"><font><br></font></div><div style="padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">13.&#160;&#160;&#160;&#160;Term and Termination</font></div><div style="padding-left:41.95pt;padding-right:1.5pt;text-align:justify;text-indent:-41.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.1&#160;&#160;&#160;&#160;This Agreement shall take effect as of the date last signed (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and shall be valid for eight (8) years. Thereafter, the Agreement shall automatically be renewed for successive periods of two (2) years each, unless any Party proposes the termination to the other Parties otherwise no later than six (6) months prior to the end of then-current term.</font></div><div style="padding-left:41.95pt;padding-right:1.5pt;text-align:justify;text-indent:-41.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.2&#160;&#160;&#160;&#160;A Party may terminate this Agreement at any time by written notice to the other Parties&#58; </font></div><div style="padding-left:85.1pt;padding-right:1.5pt;text-align:justify;text-indent:-43.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;if any Party materially breaches any of its obligations under this Agreement, and such breach is not remedied within &#91;***&#93; days of the non-breaching Parties giving written notice to the breaching party (which notice shall refer to this Article) clearly stating the details of the breach and requiring such breach to be remedied&#59; </font></div><div style="padding-left:85.1pt;padding-right:1.5pt;text-align:justify;text-indent:-43.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;if any Party becomes bankrupt, is unable to pay its debts as they fall due, is subject to any insolvency or liquidation proceedings, or ceases to carry on business&#59; or </font></div><div style="padding-left:85.1pt;padding-right:1.5pt;text-align:justify;text-indent:-43.15pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;if any Party fails to pay any amount due under this Agreement within &#91;***&#93; days of such amount falling due for payment. &#160;&#160;&#160;&#160;</font></div><div style="padding-left:41.95pt;padding-right:1.5pt;text-align:justify;text-indent:-41.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.3&#160;&#160;&#160;&#160;ANGION may terminate this Agreement for any reason upon &#91;***&#93; days notice to SOLARA.</font></div><div style="padding-left:41.95pt;padding-right:1.5pt;text-align:justify;text-indent:-41.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.4&#160;&#160;&#160;&#160;Upon termination of this Agreement under Section 13.2 all monies to be paid by one Party to the other (irrespective of whether the same has fallen due for payment) shall become immediately due and payable. </font></div><div style="padding-right:1.5pt;text-align:justify"><font><br></font></div><div style="padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">14.&#160;&#160;&#160;&#160;Intellectual Property</font></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify;text-indent:-45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.1&#160;&#160;&#160;&#160;&#8220;Intellectual Property&#8221; shall mean any and all ideas, concepts, discoveries, inventions, developments, formulae, processes, know-how, trade secrets, techniques, methodologies, modifications, innovations, inventions, improvements, processes, writings, documentation, electronic code, data and rights (whether or not protectable under state, federal or foreign patent, trademark, copyright or similar laws) or the like, whether or not written or otherwise fixed in any form or medium, regardless of the media on which contained and whether or not patentable or copyrightable, and all intellectual property rights therein.</font></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify;text-indent:-45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.2&#160;&#160;&#160;&#160;SOLARA Intellectual Property.  Subject to the license set forth in Section 14.4, the Parties acknowledge and agree that all Intellectual Property owned by or licensed to SOLARA prior to the effective date of this Agreement, or made by SOLARA during the term independent of this Agreement and not incorporating or resulting from access to any ANGION materials, Intellectual Property or Confidential Information belonging to ANGION, shall remain the owned or licensed property of SOLARA (&#8220;SOLARA IP&#8221;).  For clarity, SOLARA Intellectual Property shall not include any Project Technology (as defined below).</font></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify;text-indent:-45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.3&#160;&#160;&#160;&#160;ANGION shall own all right, title and interest in and to&#58; (i) the Compound, Results and all Intellectual Property therein&#59; (ii) all Intellectual Property arising from SOLARA&#8217;s performance of the services that covers the composition of matter&#59; formulation, dosage or administration, method of use, or method of manufacture of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the Compound, and (iii) all Intellectual Property arising from SOLARA&#8217;s performance of the services that incorporates or results from access to any Intellectual Property or Confidential Information owned or controlled by ANGION, and in each case of (i) and (ii), whether made solely by either Party or jointly by the Parties (collectively, &#8220;Project Technology&#8221;).  SOLARA hereby assigns to ANGION all right, title, and interest in the Project Technology.  SOLARA shall promptly notify Angion in writing of any inventions within the Project Technology conceived of or reduced to practice by SOLARA, together with a reasonable description of any such invention.  Upon the written request of ANGION, SOLARA agrees to execute such documents and take such action as ANGION may reasonably request (at ANGION&#8217;s reasonable expense) to memorialize, secure and perfect ANGION&#8217;s interest in such Project Technology.  </font></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify;text-indent:-45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.4&#160;&#160;&#160;&#160;SOLARA hereby grants to ANGION a non-exclusive, perpetual, worldwide, royalty-free, sublicensable (through multiple tiers) license under all SOLARA IP pertaining to, embodied within, or covering the Compound&#58; (i) to fully exploit the Project Technology or the Compound, and (ii) to exercise any and all other present or future rights in the Results for any and all purposes.  </font></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify;text-indent:-45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.5&#160;&#160;&#160;&#160;Except as set forth in this Agreement, neither Party shall acquire any license or other Intellectual Property interest, by implication or otherwise, under or to any Intellectual Property owned or controlled by the other Party.  </font></div><div style="padding-right:1.5pt;text-align:justify"><font><br></font></div><div style="padding-right:1.5pt;text-align:justify"><font><br></font></div><div style="padding-right:1.5pt;text-align:justify"><font><br></font></div><div style="padding-right:1.5pt;text-align:justify"><font><br></font></div><div style="padding-right:1.5pt;text-align:justify"><font><br></font></div><div style="padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">15.</font><font style="color:#000000;font-family:'Century',serif;font-size:10.5pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Governing Law&#47;Dispute Resolution</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58; </font></div><div style="padding-right:1.5pt;text-align:justify"><font><br></font></div><div style="padding-left:28.35pt;padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Agreement and any disputes or claims arising out of, or in connection with, its subject matter shall be governed by and construed in accordance with the laws of State of New York, USA. Any dispute that may arise between the Parties as a result of this Agreement, after execution of these presents, shall be solved through mutual discussion and in an amicable manner. If the mutual discussion fails, then the dispute shall be referred to arbitration.  All arbitration proceedings shall be conducted in accordance with the arbitration rules of International Chamber of Commerce (ICC rules) before sole Arbitrator Appointed by the parties. The venue of arbitration proceedings shall be the state of New York, USA and the arbitration proceedings shall be conducted in English language. </font></div><div style="padding-right:1.5pt;text-align:justify"><font><br></font></div><div style="padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">15.&#160;&#160;&#160;&#160;Miscellaneous </font></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify;text-indent:-45pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.1&#160;&#160;&#160;&#160;The terms and conditions of this Agreement and the quality agreement (to the extent applicable) constitute the entire agreement between the Parties with regard to the subject matter hereof, and supersede all prior negotiations, agreements, statements, communications, either oral or written, including any letter of intent, memorandum of understanding or any similar document with regard to the subject matter hereof.</font></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.2&#160;&#160;&#160;&#160;This Agreement may be executed in one or more counterparts, each of which may be signed and transmitted via electronic means or facsimile with the same validity as if it were an ink signed document, all of which taken together shall constitute one and the same Agreement.</font></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.3&#160;&#160;&#160;&#160;No waiver of any term or condition of this Agreement will be construed as a waiver of any other term or condition.  No failure to exercise any right or demand performance of any obligation under this Agreement will be deemed a waiver of such right or obligation.  </font></div><div style="padding-left:45pt;padding-right:1.5pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-right:1.5pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In witness whereof, the Parties hereby execute this Agreement by their duly authorized representatives and keep one original copy each.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:209%">Angion Biomedica Corp&#160;&#160;&#160;&#160;                         Solara Active Pharma Sciences Ltd&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.85pt;padding-right:0.85pt;text-align:justify"><font><br></font></div><div style="padding-left:0.85pt;padding-right:0.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:190%">&#47;s&#47; Jay Venkatesan</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.85pt;padding-right:0.85pt;text-align:justify"><font><br></font></div><div style="padding-left:0.85pt;padding-right:0.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:190%">&#47;s&#47; B. Ananda Ganesh</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.85pt;padding-right:0.85pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:190%">Name&#58; Jay Venkatesan                                                                Title&#58; President &#38; CEO                                            </font></div><div style="padding-left:0.85pt;padding-right:0.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:190%">Date&#58;12&#47;10&#47;21 </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.85pt;padding-right:0.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:190%">Name&#58; B. Ananda Ganesh</font></div><div style="padding-left:0.85pt;padding-right:0.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:190%">Title&#58; Deputy General Manager</font></div><div style="padding-left:0.85pt;padding-right:0.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:190%">Date&#58; 09&#47;Dec&#47;2021</font></div></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:54.160%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Century',serif;font-size:10.5pt;font-weight:400;line-height:100%">Appendix A-1</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Century',serif;font-size:10.5pt;font-weight:400;line-height:100%">For the supply of ANG-3070 active ingredient, pursuant to proposal SOL-290, Revison 2&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The price of the COMPOUND is </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;&#47;KG </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">for manufacture and supply of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#91;***&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> quantity.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The timeline is proposed as follows&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div></div></div><div id="i03c3d23ba205432199b00dc6108e1e13_4"></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><img alt="image_0c.jpg" src="image_0c.jpg" style="height:42px;margin-bottom:5pt;vertical-align:text-bottom;width:130px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.283%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-top:0.7pt;padding-left:1pt;text-align:justify"><font><br></font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.984%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt;text-align:justify"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:109%">Solara Active Pharma Sciences Limited</font></div><div style="padding-left:25.85pt;padding-right:35.4pt;text-align:justify;text-indent:31.05pt"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product &#58; ANG 3070 Customer &#58; Angion Biomedia Corp</font></div><div style="padding-left:54.3pt;text-align:justify"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Solara Ref. No SOL-290</font></div></td></tr></table></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:9.6pt;padding-left:54.45pt;padding-right:54.45pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:20pt;font-weight:700;line-height:100%">Proposal for Manufacture of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:18pt;font-weight:700;line-height:100%">ANG 3070</font></div><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:191.75pt;padding-right:214.7pt;text-indent:-25.8pt"><font style="color:#3333ff;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:400;line-height:100%">(</font><font style="color:#006fc0;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">Solara Ref.No SOL-290</font><font style="color:#3333ff;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">) Revision # 02</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:164.4pt;padding-right:214.7pt;text-indent:26.85pt"><font style="color:#3333ff;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:215%">Prepared for&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:215%">Angion Biomedica Corp</font></div><div style="margin-top:10pt;padding-left:163.05pt"><font style="color:#3333ff;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">Contact Person details&#58;</font></div><div><font><br></font></div><div style="margin-top:12.25pt;padding-left:198.72pt;padding-right:198.72pt;text-align:center;text-indent:0.15pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Ananda Ganesh. B Deputy General Manager Business Development</font></div><div style="padding-left:164.77pt;padding-right:164.77pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Solara Active Pharma Sciences Ltd Contact&#58; 9500037768</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:149.65pt;padding-right:197.85pt;text-indent:21.95pt"><font style="color:#3333ff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Issue Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:174%">&#58; 12 Oct 2021 </font><font style="color:#3333ff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:174%">Validity of the proposal</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:174%">&#58; &#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="height:124.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:22.72pt;padding-right:22.72pt;text-align:center"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:121%">Page 1 of 5</font></div><div style="margin-top:2.95pt;padding-left:65.75pt;padding-right:65.75pt;text-align:center"><font><br></font></div><div style="margin-top:2.95pt;padding-left:65.75pt;padding-right:65.75pt;text-align:center"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate Office &#8211;</font></div><div style="margin-top:0.05pt;padding-left:175.85pt;padding-right:175.85pt;text-align:center"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Solara Active Pharma Sciences Limited No. 28, Sardar Patel Road, Post Box 2630, Guindy, Chennai &#8211; 600032, India</font></div><div style="margin-top:6.1pt;padding-left:65.65pt;padding-right:65.65pt;text-align:center"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:152%">Reach us &#64; https&#58;&#47;&#47;solaracrams.com&#47;</font></div><div style="padding-left:65.75pt;padding-right:65.75pt;text-align:center"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Visit our LinkedIn page &#58; https&#58;&#47;&#47;www.linkedin.com&#47;company&#47;solara-active-pharma-sciences- cdmo-services&#47;&#63;viewAsMember&#61;true</font></div><div style="text-align:justify"><font><br></font></div></div></div><div id="i03c3d23ba205432199b00dc6108e1e13_7"></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><img alt="image_0c.jpg" src="image_0c.jpg" style="height:42px;margin-bottom:5pt;vertical-align:text-bottom;width:130px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.283%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-top:0.7pt;padding-left:1pt;text-align:justify"><font><br></font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.984%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt;text-align:justify"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:109%">Solara Active Pharma Sciences Limited</font></div><div style="padding-left:25.85pt;padding-right:35.4pt;text-align:justify;text-indent:31.05pt"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product &#58; ANG 3070 Customer &#58; Angion Biomedia Corp</font></div><div style="padding-left:54.3pt;text-align:justify"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Solara Ref. No SOL-290</font></div></td></tr></table></div></div><div><font><br></font></div><div style="margin-top:1.75pt;padding-left:62.65pt;padding-right:62.65pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:100%;text-decoration:underline">CONTENTS</font></div><div style="margin-top:0.6pt"><font><br></font></div><div style="padding-left:19.89pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.545%"><tr><td style="width:1.0%"></td><td style="width:85.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.157%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.8pt;padding-right:15.8pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:122%">PAGE</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.95pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.  Executive Summary</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10.95pt;padding-right:10.95pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:122%">3</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.95pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.  Structure of the compound</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10.95pt;padding-right:10.95pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:122%">3</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3.05pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.  Synthetic route</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.05pt;padding-left:10.95pt;padding-right:10.95pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.95pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.  Project Execution Proposal</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10.95pt;padding-right:10.95pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:122%">4</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.95pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.  Timeline</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10.95pt;padding-right:10.95pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:122%">4</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.95pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.  Pricing Summary</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10.95pt;padding-right:10.95pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:122%">5</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.95pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.  Payment schedule</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10.95pt;padding-right:10.95pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:122%">5</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.95pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.  Shipping details</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10.95pt;padding-right:10.95pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:122%">5</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.95pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.  Acceptance</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10.95pt;padding-right:10.95pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:122%">5</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:124.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:22.72pt;padding-right:22.72pt;text-align:center"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:121%">Page 2 of 5</font></div><div style="margin-top:2.95pt;padding-left:65.75pt;padding-right:65.75pt;text-align:center"><font><br></font></div><div style="margin-top:2.95pt;padding-left:65.75pt;padding-right:65.75pt;text-align:center"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate Office &#8211;</font></div><div style="margin-top:0.05pt;padding-left:175.85pt;padding-right:175.85pt;text-align:center"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Solara Active Pharma Sciences Limited No. 28, Sardar Patel Road, Post Box 2630, Guindy, Chennai &#8211; 600032, India</font></div><div style="margin-top:6.1pt;padding-left:65.65pt;padding-right:65.65pt;text-align:center"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:152%">Reach us &#64; https&#58;&#47;&#47;solaracrams.com&#47;</font></div><div style="padding-left:65.75pt;padding-right:65.75pt;text-align:center"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Visit our LinkedIn page &#58; https&#58;&#47;&#47;www.linkedin.com&#47;company&#47;solara-active-pharma-sciences- cdmo-services&#47;&#63;viewAsMember&#61;true</font></div><div style="text-align:justify"><font><br></font></div></div></div><div id="i03c3d23ba205432199b00dc6108e1e13_10"></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><img alt="image_0c.jpg" src="image_0c.jpg" style="height:42px;margin-bottom:5pt;vertical-align:text-bottom;width:130px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.283%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-top:0.7pt;padding-left:1pt;text-align:justify"><font><br></font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.984%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt;text-align:justify"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:109%">Solara Active Pharma Sciences Limited</font></div><div style="padding-left:25.85pt;padding-right:35.4pt;text-align:justify;text-indent:31.05pt"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product &#58; ANG 3070 Customer &#58; Angion Biomedia Corp</font></div><div style="padding-left:54.3pt;text-align:justify"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Solara Ref. No SOL-290</font></div></td></tr></table></div></div><div><font><br></font></div><div style="margin-top:9.4pt"><font style="color:#3333ff;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">1.0&#58; Executive Summary&#58;</font></div><div style="margin-top:8.45pt;padding-left:5pt;padding-right:47.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Angion has requested a proposal for manufacture of 100 Kg of ANG-3070 in GMP conditions from Solara Active Pharma Sciences Limited.</font></div><div><font><br></font></div><div style="margin-top:7.45pt"><font style="color:#3333ff;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">2.0&#58; Structure of the compound&#58;</font></div><div style="margin-top:0.55pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-top:0.55pt;text-align:center"><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:2.2pt"><font style="color:#3333ff;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">3.0&#58; Synthetic route&#58;</font></div><div><font><br></font></div><div style="margin-top:0.55pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-right:45.45pt;text-align:right"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:121%">Page 3 of 5</font></div><div style="height:124.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:22.72pt;padding-right:22.72pt;text-align:center"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:121%">Page 3 of 5</font></div><div style="margin-top:2.95pt;padding-left:65.75pt;padding-right:65.75pt;text-align:center"><font><br></font></div><div style="margin-top:2.95pt;padding-left:65.75pt;padding-right:65.75pt;text-align:center"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate Office &#8211;</font></div><div style="margin-top:0.05pt;padding-left:175.85pt;padding-right:175.85pt;text-align:center"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Solara Active Pharma Sciences Limited No. 28, Sardar Patel Road, Post Box 2630, Guindy, Chennai &#8211; 600032, India</font></div><div style="margin-top:6.1pt;padding-left:65.65pt;padding-right:65.65pt;text-align:center"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:152%">Reach us &#64; https&#58;&#47;&#47;solaracrams.com&#47;</font></div><div style="padding-left:65.75pt;padding-right:65.75pt;text-align:center"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Visit our LinkedIn page &#58; https&#58;&#47;&#47;www.linkedin.com&#47;company&#47;solara-active-pharma-sciences- cdmo-services&#47;&#63;viewAsMember&#61;true</font></div><div style="text-align:justify"><font><br></font></div></div></div><div id="i03c3d23ba205432199b00dc6108e1e13_13"></div><hr style="page-break-after:always"><div style="min-height:92.16pt;width:100%"><div style="margin-bottom:6pt;text-align:justify"><img alt="image_0c.jpg" src="image_0c.jpg" style="height:42px;margin-bottom:5pt;vertical-align:text-bottom;width:130px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.283%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-top:0.7pt;padding-left:1pt;text-align:justify"><font><br></font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:42.984%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt;text-align:justify"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:109%">Solara Active Pharma Sciences Limited</font></div><div style="padding-left:25.85pt;padding-right:35.4pt;text-align:justify;text-indent:31.05pt"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product &#58; ANG 3070 Customer &#58; Angion Biomedia Corp</font></div><div style="padding-left:54.3pt;text-align:justify"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Solara Ref. No SOL-290</font></div></td></tr></table></div></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="margin-top:2.2pt;padding-left:22.95pt;text-indent:-18pt"><font style="color:#3333ff;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:700;line-height:100%">4.1</font><font style="color:#3333ff;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%;padding-left:1.37pt">&#58; Project Execution Proposal&#58;</font></div><div style="margin-top:8.35pt;padding-left:5pt;padding-right:67.95pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Solara has prepared this proposal based on certain key assumptions. If the following assumptions change, or are found to be invalid, the pricing and timeline of the project may vary.</font></div><div style="margin-top:0.05pt;padding-left:30.1pt;padding-right:68.15pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.9pt">&#91;***&#93;</font></div><div style="padding-left:30.1pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:122%;padding-left:13.95pt">&#91;***&#93;</font></div><div style="padding-left:30.1pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:122%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:122%;padding-left:13.95pt">Solara has not considered cost for stability studies in this proposal.</font></div><div style="margin-top:7.35pt;padding-left:32pt;padding-right:68.2pt;text-indent:-18pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%;padding-left:13.9pt">Solara will adopt the final specification and methods as followed in previous campaign. If there is any change in the analytical specification during the course of the project execution, a separate scope change sheet will be provided to Angion.</font></div><div style="margin-top:0.1pt;padding-left:30.1pt;text-indent:-18.05pt"><font style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:13.95pt">Pricing assumes process yields and norms as per the previous campaign.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">5</font><font style="color:#3333ff;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%;padding-left:10.91pt">5.0. Timeline</font></div><div style="padding-left:5pt"><font><br></font></div><div style="margin-top:0.55pt;padding-left:11.47pt;padding-right:11.47pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#91;***&#93;</font></div><div style="margin-top:0.6pt"><font><br></font></div><div style="padding-right:45.45pt;text-align:right"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:121%">Page 4 of 5</font></div><div style="height:124.56pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:22.72pt;padding-right:22.72pt;text-align:center"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:121%">Page 4 of 5</font></div><div style="margin-top:2.95pt;padding-left:65.75pt;padding-right:65.75pt;text-align:center"><font><br></font></div><div style="margin-top:2.95pt;padding-left:65.75pt;padding-right:65.75pt;text-align:center"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate Office &#8211;</font></div><div style="margin-top:0.05pt;padding-left:175.85pt;padding-right:175.85pt;text-align:center"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Solara Active Pharma Sciences Limited No. 28, Sardar Patel Road, Post Box 2630, Guindy, Chennai &#8211; 600032, India</font></div><div style="margin-top:6.1pt;padding-left:65.65pt;padding-right:65.65pt;text-align:center"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:152%">Reach us &#64; https&#58;&#47;&#47;solaracrams.com&#47;</font></div><div style="padding-left:65.75pt;padding-right:65.75pt;text-align:center"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Visit our LinkedIn page &#58; https&#58;&#47;&#47;www.linkedin.com&#47;company&#47;solara-active-pharma-sciences- cdmo-services&#47;&#63;viewAsMember&#61;true</font></div><div style="text-align:justify"><font><br></font></div></div></div><div id="i03c3d23ba205432199b00dc6108e1e13_16"></div><hr style="page-break-after:always"><div style="min-height:76.32pt;width:100%"><div style="text-align:justify"><img alt="image_0c.jpg" src="image_0c.jpg" style="height:42px;margin-bottom:5pt;vertical-align:text-bottom;width:130px"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.876%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1pt;text-align:justify"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:109%">Solara Active Pharma Sciences Limited</font></div><div style="padding-left:25.85pt;padding-right:35.4pt;text-align:justify;text-indent:31.05pt"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Product&#58; ANG 3070 Customer &#58; Angion Biomedia Corp</font></div><div style="padding-left:54.3pt;text-align:justify"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Solara Ref. No SOL-290</font></div></td></tr></table></div></div><div><font><br></font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="margin-top:2.2pt;padding-left:5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">6</font><font style="color:#3333ff;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%;padding-left:10.91pt">6.0&#58; Pricing Summary</font></div><div><font><br></font></div><div style="margin-top:0.55pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:9.95pt;padding-left:5pt"><font style="color:#006fc0;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">7.0&#58; Payment schedule&#58;</font></div><div style="margin-top:0.4pt"><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The project will be conducted on a &#8220;Milestone and Delivery&#8221; basis</font></div><div style="margin-bottom:0.05pt;margin-top:0.5pt"><font><br></font></div><div style="padding-left:32.4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.526%"><tr><td style="width:1.0%"></td><td style="width:22.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 42.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Milestone</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:137.7pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:122%">Payment Details</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:16.9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:122%">Milestone 1</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.55pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#91;***&#93; of project value upon receipt of PO</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:16.9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:122%">Milestone-2</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.55pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#91;***&#93; payable upon completion of project</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">7</font><font style="color:#3333ff;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%;padding-left:10.91pt">8</font><font style="color:#006fc0;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">.0. Shipping details&#58;</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Shipment&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Ex works</font></div><div><font><br></font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">8</font><font style="color:#006fc0;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%;padding-left:10.91pt">9.0&#58; Acceptance&#58;</font></div><div style="margin-top:8.3pt;padding-left:5pt;padding-right:47.85pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Please indicate Angion&#8217;s acceptance of this proposal by returning a signed copy of this proposal, or a purchase order.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:0.2pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="height:229.68pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:22.72pt;padding-right:22.72pt;text-align:center"><font style="color:#808080;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:121%">Page 5 of 5</font></div><div style="margin-top:2.95pt;padding-left:65.75pt;padding-right:65.75pt;text-align:center"><font><br></font></div><div style="margin-top:2.95pt;padding-left:65.75pt;padding-right:65.75pt;text-align:center"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Corporate Office &#8211;</font></div><div style="margin-top:0.05pt;padding-left:175.85pt;padding-right:175.85pt;text-align:center"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Solara Active Pharma Sciences Limited No. 28, Sardar Patel Road, Post Box 2630, Guindy, Chennai &#8211; 600032, India</font></div><div style="margin-top:6.1pt;padding-left:65.65pt;padding-right:65.65pt;text-align:center"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:152%">Reach us &#64; https&#58;&#47;&#47;solaracrams.com&#47;</font></div><div style="padding-left:65.75pt;padding-right:65.75pt;text-align:center"><font style="color:#003300;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Visit our LinkedIn page &#58; https&#58;&#47;&#47;www.linkedin.com&#47;company&#47;solara-active-pharma-sciences- cdmo-services&#47;&#63;viewAsMember&#61;true</font></div><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>12
<FILENAME>ex231_angnx123121-10k.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="idb3d97b03d794d42afd62b78e6c48962_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">         Exhibit 23.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Consent of Independent Registered Public Accounting Firm   </font></div><div><font><br></font></div><div style="text-indent:22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333- 252906) of our report dated March 30, 2022, relating to the consolidated financial statements of Angion Biomedica Corp., appearing in this Annual Report (Form 10-K) for the year ended December 31, 2021.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Moss Adams LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Seattle, Washington</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 30, 2022</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>13
<FILENAME>ex311_angnx123121-revisedv.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3bc56e338fdc49bfa78c5ef03c4ead72_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">                                                                                                       Exhibit 31.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">I, Jay R. Venkatesan, certify that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">1.&#160;&#160;&#160;&#160;I have reviewed this Form 10-K of Angion Biomedica Corp.&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:27.67pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:27.67pt">Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">c.         Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">d.          Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:27.67pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b. &#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:10pt;text-align:center"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">             </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.111%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.664%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANGION BIOMEDICA CORP.</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; JAY R. VENKATESAN, M.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March&#160;30, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.65pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Jay R. Venkatesan, M.D.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">President and Chief Executive Officer and Director (Principal Executive Officer)</font></div></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>14
<FILENAME>ex312_angnx123121xrevisedc.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3f1161d856e3409a84dba77fc96ecf1f_1"></div><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">                                             Exhibit 31.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">I, Gregory S. Curhan, certify that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">1.&#160;&#160;&#160;&#160;I have reviewed this on Form 10-K of Angion Biomedica Corp.&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:27.67pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:27.67pt">Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">c.&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%"> </font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">d.          Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:27.67pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div><font><br></font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b. &#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANGION BIOMEDICA CORP.</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.02pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Gregory S. Curhan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March&#160;30, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.65pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Gregory S. Curhan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:133%">Interim Chief Financial Officer                                            (Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>15
<FILENAME>ex321angn-12312021x10k.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie6961c8c135f4ab69ba310a8fa461fc4_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(18 U.S.C. SECTION 1350)</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The undersigned officers of Angion Biomedica Corp. (the Company) certifies, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;The Annual Report on Form 10-K of the Company for the period ended December 31, 2021 (the Annual Report), as filed with the Securities and Exchange Commission, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;The information contained in this Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div id="ie6961c8c135f4ab69ba310a8fa461fc4_4"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ANGION BIOMEDICA CORP.</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; JAY R. VENKATESAN, M.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58; March&#160;30, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Jay R. Venkatesan, M.D.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">President and Chief Executive Officer and Chairman (Principal Executive Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>16
<FILENAME>ex322_angnx123121x10k.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i99daeb0901b74a68a509a5ce653ca81d_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(18 U.S.C. SECTION 1350)</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The undersigned officers of Angion Biomedica Corp. (the Company) certifies, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;The Annual Report on Form 10-K of the Company for the period ended December 31, 2021 (the &#160;&#160;&#160;&#160;Annual Report), as filed with the Securities and Exchange Commission, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;The information contained in this Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div id="i99daeb0901b74a68a509a5ce653ca81d_4"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.125%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ANGION BIOMEDICA CORP.</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; Gregory S. Curhan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58; March&#160;30, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Gregory S. Curhan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Chief Financial Officer </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>17
<FILENAME>angn-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:808f0db7-14af-45c6-a88e-e152464defe4,g:f048552f-f790-4462-b881-32982147c095-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:angn="http://www.angn.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.angn.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="angn-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="angn-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="angn-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="angn-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.angn.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.angn.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.angn.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.angn.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1003005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityDeficit" roleURI="http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit">
        <link:definition>1004006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityDeficitParenthetical" roleURI="http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficitParenthetical">
        <link:definition>1005007 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.angn.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1006008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionoftheBusinessandFinancialCondition" roleURI="http://www.angn.com/role/DescriptionoftheBusinessandFinancialCondition">
        <link:definition>2101101 - Disclosure - Description of the Business and Financial Condition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionoftheBusinessandFinancialConditionDetails" roleURI="http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails">
        <link:definition>2402401 - Disclosure - Description of the Business and Financial Condition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.angn.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.angn.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueandDeferredRevenue" roleURI="http://www.angn.com/role/RevenueandDeferredRevenue">
        <link:definition>2107103 - Disclosure - Revenue and Deferred Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueandDeferredRevenueDetails" roleURI="http://www.angn.com/role/RevenueandDeferredRevenueDetails">
        <link:definition>2408403 - Disclosure - Revenue and Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueandDeferredRevenueDetails_1" roleURI="http://www.angn.com/role/RevenueandDeferredRevenueDetails_1">
        <link:definition>2408403 - Disclosure - Revenue and Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.angn.com/role/FairValueMeasurements">
        <link:definition>2109104 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.angn.com/role/FairValueMeasurementsTables">
        <link:definition>2310302 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" roleURI="http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails">
        <link:definition>2411404 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" roleURI="http://www.angn.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails">
        <link:definition>2412405 - Disclosure - Fair Value Measurements - Fair Value, Liabilities, Measured on Recurring Basis, Unobservable Input Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.angn.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2413406 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueMeasurementInputsandValuationTechniquesDetails" roleURI="http://www.angn.com/role/FairValueMeasurementsFairValueMeasurementInputsandValuationTechniquesDetails">
        <link:definition>2414407 - Disclosure - Fair Value Measurements - Fair Value Measurement Inputs and Valuation Techniques (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponents" roleURI="http://www.angn.com/role/BalanceSheetComponents">
        <link:definition>2115105 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://www.angn.com/role/BalanceSheetComponentsTables">
        <link:definition>2316303 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" roleURI="http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails">
        <link:definition>2417408 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsNarrativeDetails" roleURI="http://www.angn.com/role/BalanceSheetComponentsNarrativeDetails">
        <link:definition>2418409 - Disclosure - Balance Sheet Components - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails" roleURI="http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails">
        <link:definition>2419410 - Disclosure - Balance Sheet Components - Schedule of Prepaid and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofAccruedExpensesDetails" roleURI="http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails">
        <link:definition>2420411 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleNotesPayable" roleURI="http://www.angn.com/role/ConvertibleNotesPayable">
        <link:definition>2121106 - Disclosure - Convertible Notes Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleNotesPayableDetails" roleURI="http://www.angn.com/role/ConvertibleNotesPayableDetails">
        <link:definition>2422412 - Disclosure - Convertible Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SeriesCConvertiblePreferredStock" roleURI="http://www.angn.com/role/SeriesCConvertiblePreferredStock">
        <link:definition>2123107 - Disclosure - Series C Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SeriesCConvertiblePreferredStockTables" roleURI="http://www.angn.com/role/SeriesCConvertiblePreferredStockTables">
        <link:definition>2324304 - Disclosure - Series C Convertible Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SeriesCConvertiblePreferredStockSummaryofAggregateValuesRecordedDetails" roleURI="http://www.angn.com/role/SeriesCConvertiblePreferredStockSummaryofAggregateValuesRecordedDetails">
        <link:definition>2425413 - Disclosure - Series C Convertible Preferred Stock - Summary of Aggregate Values Recorded (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SeriesCConvertiblePreferredStockNarrativeDetails" roleURI="http://www.angn.com/role/SeriesCConvertiblePreferredStockNarrativeDetails">
        <link:definition>2426414 - Disclosure - Series C Convertible Preferred Stock - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.angn.com/role/StockholdersEquity">
        <link:definition>2127108 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.angn.com/role/StockholdersEquityDetails">
        <link:definition>2428415 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.angn.com/role/StockBasedCompensation">
        <link:definition>2129109 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.angn.com/role/StockBasedCompensationTables">
        <link:definition>2330305 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.angn.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2431416 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails" roleURI="http://www.angn.com/role/StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails">
        <link:definition>2432417 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofShareOptionActivityDetails" roleURI="http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails">
        <link:definition>2433418 - Disclosure - Stock-Based Compensation - Schedule of Share Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationScheduleofRSAandRSUActivityDetails" roleURI="http://www.angn.com/role/StockBasedCompensationScheduleofRSAandRSUActivityDetails">
        <link:definition>2434419 - Disclosure - Stock-Based Compensation - Schedule of RSA and RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails" roleURI="http://www.angn.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails">
        <link:definition>2435420 - Disclosure - Stock-Based Compensation - Components of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Warrants" roleURI="http://www.angn.com/role/Warrants">
        <link:definition>2136110 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsTables" roleURI="http://www.angn.com/role/WarrantsTables">
        <link:definition>2337306 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsOutstandingWarrantsDetails" roleURI="http://www.angn.com/role/WarrantsOutstandingWarrantsDetails">
        <link:definition>2438421 - Disclosure - Warrants - Outstanding Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsWarrantActivityDetails" roleURI="http://www.angn.com/role/WarrantsWarrantActivityDetails">
        <link:definition>2439422 - Disclosure - Warrants - Warrant Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsNarrativeDetails" roleURI="http://www.angn.com/role/WarrantsNarrativeDetails">
        <link:definition>2440423 - Disclosure - Warrants - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.angn.com/role/CommitmentsandContingencies">
        <link:definition>2141111 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.angn.com/role/CommitmentsandContingenciesTables">
        <link:definition>2342307 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>2443424 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofComponentsofRentExpenseDetails" roleURI="http://www.angn.com/role/CommitmentsandContingenciesScheduleofComponentsofRentExpenseDetails">
        <link:definition>2444425 - Disclosure - Commitments and Contingencies - Schedule of Components of Rent Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofQuantitativeInformationaboutOperatingLeasesDetails" roleURI="http://www.angn.com/role/CommitmentsandContingenciesScheduleofQuantitativeInformationaboutOperatingLeasesDetails">
        <link:definition>2445426 - Disclosure - Commitments and Contingencies - Schedule of Quantitative Information about Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails" roleURI="http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>2446427 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails_1" roleURI="http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails_1">
        <link:definition>2446427 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesScheduleOfQuantitativeInformationAboutTheFinancingObligationDetails" roleURI="http://www.angn.com/role/CommitmentsandContingenciesScheduleOfQuantitativeInformationAboutTheFinancingObligationDetails">
        <link:definition>2447428 - Disclosure - Commitments and Contingencies - Schedule Of Quantitative Information About The Financing Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails" roleURI="http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails">
        <link:definition>2448429 - Disclosure - Commitments and Contingencies - Finance Lease, Liability, Fiscal Year Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails_1" roleURI="http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails_1">
        <link:definition>2448429 - Disclosure - Commitments and Contingencies - Finance Lease, Liability, Fiscal Year Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.angn.com/role/IncomeTaxes">
        <link:definition>2149112 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.angn.com/role/IncomeTaxesTables">
        <link:definition>2350308 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.angn.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2451430 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofIncomebeforeIncomeTaxDomesticandForeignDetails" roleURI="http://www.angn.com/role/IncomeTaxesScheduleofIncomebeforeIncomeTaxDomesticandForeignDetails">
        <link:definition>2452431 - Disclosure - Income Taxes - Schedule of Income before Income Tax, Domestic and Foreign (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails" roleURI="http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails">
        <link:definition>2453432 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>2454433 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>2455434 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails" roleURI="http://www.angn.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails">
        <link:definition>2456435 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesUnrecognizedTaxBenefitsIfRecognizedWouldAffecttheEffectiveTaxRateDetails" roleURI="http://www.angn.com/role/IncomeTaxesUnrecognizedTaxBenefitsIfRecognizedWouldAffecttheEffectiveTaxRateDetails">
        <link:definition>2457436 - Disclosure - Income Taxes - Unrecognized Tax Benefits, If Recognized, Would Affect the Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://www.angn.com/role/EmployeeBenefitPlan">
        <link:definition>2158113 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlanNarrativeDetails" roleURI="http://www.angn.com/role/EmployeeBenefitPlanNarrativeDetails">
        <link:definition>2459437 - Disclosure - Employee Benefit Plan - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.angn.com/role/NetLossPerShare">
        <link:definition>2160114 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.angn.com/role/NetLossPerShareTables">
        <link:definition>2361309 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofnetlosspersharebasicanddilutedDetails" roleURI="http://www.angn.com/role/NetLossPerShareScheduleofnetlosspersharebasicanddilutedDetails">
        <link:definition>2462438 - Disclosure - Net Loss Per Share - Schedule of net loss per share, basic and diluted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofantidilutivesecuritiesexcludedfromcomputationofnetlosspershareDetails" roleURI="http://www.angn.com/role/NetLossPerShareScheduleofantidilutivesecuritiesexcludedfromcomputationofnetlosspershareDetails">
        <link:definition>2463439 - Disclosure - Net Loss Per Share - Schedule of antidilutive securities excluded from computation of net loss per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.angn.com/role/RelatedPartyTransactions">
        <link:definition>2164115 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsTables" roleURI="http://www.angn.com/role/RelatedPartyTransactionsTables">
        <link:definition>2365310 - Disclosure - Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsNarrativeDetails" roleURI="http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails">
        <link:definition>2466440 - Disclosure - Related Party Transactions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsNovaParkInvestmentDetails" roleURI="http://www.angn.com/role/RelatedPartyTransactionsNovaParkInvestmentDetails">
        <link:definition>2467441 - Disclosure - Related Party Transactions - Nova Park Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.angn.com/role/SubsequentEvents">
        <link:definition>2168116 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.angn.com/role/SubsequentEventsDetails">
        <link:definition>2469442 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="angn_WarrantsIssuedWith2015Notes2016Notes2017NotesAnd2018NotesMember" abstract="true" name="WarrantsIssuedWith2015Notes2016Notes2017NotesAnd2018NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_WarrantsIssuedWith2015NotesLiabilityMember" abstract="true" name="WarrantsIssuedWith2015NotesLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_AdditionalConvertibleNotesAndViforConvertibleNoteMember" abstract="true" name="AdditionalConvertibleNotesAndViforConvertibleNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_PresidentAndChiefExecutiveOfficerAndDirectorMember" abstract="true" name="PresidentAndChiefExecutiveOfficerAndDirectorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_EarningsPerShareBasicIncrease" abstract="false" name="EarningsPerShareBasicIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="angn_ClassOfWarrantOrRightExercisesInPeriodTendered" abstract="false" name="ClassOfWarrantOrRightExercisesInPeriodTendered" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="angn_LesseeOperatingLeaseAnnualRentExpense" abstract="false" name="LesseeOperatingLeaseAnnualRentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_ClassOfWarrantOrRightExpirationsInPeriod" abstract="false" name="ClassOfWarrantOrRightExpirationsInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="angn_PaymentsForForwardStockSplitFractionalShares" abstract="false" name="PaymentsForForwardStockSplitFractionalShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_LesseeOperatingLeaseNoticePeriodForOptionToExtend" abstract="false" name="LesseeOperatingLeaseNoticePeriodForOptionToExtend" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="angn_DeferredTaxAssetsOperatingLeaseLiability" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsConversionPrice" abstract="false" name="FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsConversionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountIssuedInConvertibleNoteExchange" abstract="false" name="FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountIssuedInConvertibleNoteExchange" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_OhrCosmeticsLLCMember" abstract="true" name="OhrCosmeticsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_A2021IncentiveAwardPlanMember" abstract="true" name="A2021IncentiveAwardPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountAccumulatedChangeInFairValue" abstract="false" name="FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountAccumulatedChangeInFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_ContractWithCustomerMilestonePaymentsEntitledToReceive" abstract="false" name="ContractWithCustomerMilestonePaymentsEntitledToReceive" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_WarrantsIssuedWith2016NotesLiabilityMember" abstract="true" name="WarrantsIssuedWith2016NotesLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock" abstract="false" name="StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="angn_ClassOfWarrantOrRightConversionPrice" abstract="false" name="ClassOfWarrantOrRightConversionPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="angn_PaymentsForBrokerWarrantExercises" abstract="false" name="PaymentsForBrokerWarrantExercises" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_PrepaidClinicalFeesCurrent" abstract="false" name="PrepaidClinicalFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_EffectiveIncomeTaxRateReconciliationInterestPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationInterestPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="angn_IncreaseDecreaseInGrantReceivables" abstract="false" name="IncreaseDecreaseInGrantReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_OperatingLossCarryforwardSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_ContractWithCustomerContractTerminationPeriodIncurableBreach" abstract="false" name="ContractWithCustomerContractTerminationPeriodIncurableBreach" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="angn_AccruedOperatingLiabilitiesCurrent" abstract="false" name="AccruedOperatingLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_WarrantLiabilityMember" abstract="true" name="WarrantLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_ConvertiblePreferredStockConversionPrice" abstract="false" name="ConvertiblePreferredStockConversionPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="angn_FinancialInstrumentsSubjectToMandatoryRedemptionFairValueAbstract" abstract="true" name="FinancialInstrumentsSubjectToMandatoryRedemptionFairValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="angn_StockIssuedDuringPeriodValueWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayOneHundredPercentEmployerMatch" abstract="false" name="DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayOneHundredPercentEmployerMatch" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="angn_SharesIssuableUponConversionOfConvertibleNotesDiscountRate" abstract="false" name="SharesIssuableUponConversionOfConvertibleNotesDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="angn_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsRollForward" abstract="true" name="ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="angn_NovaParkMember" abstract="true" name="NovaParkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_A2021PlanMember" abstract="true" name="A2021PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_ContractWithCustomerContractTerminationPeriodCurableBreach" abstract="false" name="ContractWithCustomerContractTerminationPeriodCurableBreach" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="angn_CARESActEmployeeRetentionCredit" abstract="false" name="CARESActEmployeeRetentionCredit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_NetIncomeLossAttributableToParentIncrease" abstract="false" name="NetIncomeLossAttributableToParentIncrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTermRollForward" abstract="true" name="WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTermRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="angn_ProceedsFromFinancingObligation" abstract="false" name="ProceedsFromFinancingObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="angn_PaycheckProtectionProgramCARESActMember" abstract="true" name="PaycheckProtectionProgramCARESActMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_StockRetired" abstract="false" name="StockRetired" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_InvestmentsInRelatedPartiesPolicyPolicyTextBlock" abstract="false" name="InvestmentsInRelatedPartiesPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="angn_BrokerWarrantsIssuedWith2019NotesLiabilityMember" abstract="true" name="BrokerWarrantsIssuedWith2019NotesLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_ConsultingAgreementMember" abstract="true" name="ConsultingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock" abstract="false" name="ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="angn_StockIssuedDuringPeriodValueBrokerWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueBrokerWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_ClassOfWarrantOrRightWeightedAverageExercisePrice" abstract="false" name="ClassOfWarrantOrRightWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium" abstract="false" name="FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_ScheduleOfQuantitativeInformationAboutTheFinancingObligationTableTextBlock" abstract="false" name="ScheduleOfQuantitativeInformationAboutTheFinancingObligationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="angn_ContractWithCustomerRoyaltyRatesMaximum" abstract="false" name="ContractWithCustomerRoyaltyRatesMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="angn_LesseeOperatingLeaseFreeRentExpensePeriod" abstract="false" name="LesseeOperatingLeaseFreeRentExpensePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="angn_WarrantsIssuedWithUnitsInTheEquityOfferingEquityMember" abstract="true" name="WarrantsIssuedWithUnitsInTheEquityOfferingEquityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_MeasurementInputStrikePriceMember" abstract="true" name="MeasurementInputStrikePriceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayFiftyPercentEmployerMatch" abstract="false" name="DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayFiftyPercentEmployerMatch" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="angn_WarrantsExercised" abstract="false" name="WarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_AccruedInterestPremiumForConvertiblePreferredStock" abstract="false" name="AccruedInterestPremiumForConvertiblePreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_LegalServicesMember" abstract="true" name="LegalServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees" abstract="false" name="FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent" abstract="false" name="FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_EarningsPerShareDilutedIncrease" abstract="false" name="EarningsPerShareDilutedIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="angn_A2020NotesMember" abstract="true" name="A2020NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_RelatedPartyTransactionPotentialMaximumMilestonePayment" abstract="false" name="RelatedPartyTransactionPotentialMaximumMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_DirectorsAndFamilyMemberOfChiefExecutiveOfficerDirectorMember" abstract="true" name="DirectorsAndFamilyMemberOfChiefExecutiveOfficerDirectorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="angn_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" abstract="false" name="UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_WarrantsAndRightsOutstandingAbstract" abstract="true" name="WarrantsAndRightsOutstandingAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross" abstract="false" name="FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_WarrantLiabilityCurrent" abstract="false" name="WarrantLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_LesseeOperatingLeaseNumberOfOptionsToExtend" abstract="false" name="LesseeOperatingLeaseNumberOfOptionsToExtend" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="angn_TemporaryEquityAmortizedCostAbstract" abstract="true" name="TemporaryEquityAmortizedCostAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="angn_WarrantsIssuedWithConversionOfNotesToCommonStockEquityMember" abstract="true" name="WarrantsIssuedWithConversionOfNotesToCommonStockEquityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss" abstract="false" name="FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExpirationsInPeriod" abstract="false" name="ClassOfWarrantOrRightWeightedAverageExercisePriceExpirationsInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="angn_NumberOfRelatedPartyEntities" abstract="false" name="NumberOfRelatedPartyEntities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="angn_OperatingLossCarryforwardNotSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardNotSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_ClassOfWarrantOrRightExercisesInPeriod" abstract="false" name="ClassOfWarrantOrRightExercisesInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="angn_WarrantsAndRightsOutstandingActivityTableTextBlock" abstract="false" name="WarrantsAndRightsOutstandingActivityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="angn_ContractWithCustomerLiabilityPercentOfUpfrontPayment" abstract="false" name="ContractWithCustomerLiabilityPercentOfUpfrontPayment" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="angn_WarrantsAndRightsOutstandingPolicyPolicyTextBlock" abstract="false" name="WarrantsAndRightsOutstandingPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="angn_AccruedDirectResearchCostsCurrent" abstract="false" name="AccruedDirectResearchCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_ContractWithCustomerSalesRelatedMilestonePaymentEntitledToReceive" abstract="false" name="ContractWithCustomerSalesRelatedMilestonePaymentEntitledToReceive" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_ConsultantWarrantsLiabilityMember" abstract="true" name="ConsultantWarrantsLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_FinancialInstrumentsSubjectToMandatoryRedemptionDisclosureTextBlock" abstract="false" name="FinancialInstrumentsSubjectToMandatoryRedemptionDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount" abstract="false" name="FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_ViforPharmaMember" abstract="true" name="ViforPharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_NonCashPlacementAgentFee" abstract="false" name="NonCashPlacementAgentFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_ImmediateFamilyOfDirectorAndChairmanMember" abstract="true" name="ImmediateFamilyOfDirectorAndChairmanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_OtherInvestmentAndSecuritiesAtCostOwnershipPercentage" abstract="false" name="OtherInvestmentAndSecuritiesAtCostOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="angn_BrokerWarrantsIssuedWithEquityOfferingEquityMember" abstract="true" name="BrokerWarrantsIssuedWithEquityOfferingEquityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_WarrantsIssuedWith2017NotesLiabilityMember" abstract="true" name="WarrantsIssuedWith2017NotesLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_FinancialInstrumentsSubjectToMandatoryRedemptionPolicyTextBlock" abstract="false" name="FinancialInstrumentsSubjectToMandatoryRedemptionPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="angn_UnrecognizedTaxBenefitsIfRecognizedWouldAffectTheEffectiveTaxRateTableTextBlock" abstract="false" name="UnrecognizedTaxBenefitsIfRecognizedWouldAffectTheEffectiveTaxRateTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="angn_IPOAndPrivatePlacementMember" abstract="true" name="IPOAndPrivatePlacementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_RevenueFromContractWithCustomerIncludingAssessedTaxIncrease" abstract="false" name="RevenueFromContractWithCustomerIncludingAssessedTaxIncrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_RelatedPartyTransactionRoyaltiesAndMilestonePaymentsPeriod" abstract="false" name="RelatedPartyTransactionRoyaltiesAndMilestonePaymentsPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="angn_ContractWithCustomerUpfrontAndNearTermMilestonePaymentEntitledToReceive" abstract="false" name="ContractWithCustomerUpfrontAndNearTermMilestonePaymentEntitledToReceive" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_IssuanceOfBrokerWarrants" abstract="false" name="IssuanceOfBrokerWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_StockIssuedDuringPeriodSharesBrokerWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesBrokerWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="angn_WarrantsAndRightsOutstandingTextBlock" abstract="false" name="WarrantsAndRightsOutstandingTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="angn_EquityMethodInvestmentsRollForward" abstract="true" name="EquityMethodInvestmentsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="angn_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock" abstract="false" name="StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="angn_WarrantsFairValueDisclosure" abstract="false" name="WarrantsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_FormerMemberOfTheBoardOfDirectorsMember" abstract="true" name="FormerMemberOfTheBoardOfDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm" abstract="false" name="WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="angn_ShareBasedPaymentArrangementPlanModificationExtendedExercisePeriod" abstract="false" name="ShareBasedPaymentArrangementPlanModificationExtendedExercisePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="angn_ContractWithCustomerPostApprovalMilestonePaymentEntitledToReceive" abstract="false" name="ContractWithCustomerPostApprovalMilestonePaymentEntitledToReceive" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="angn_NonIPORelatedStockTransactionsMember" abstract="true" name="NonIPORelatedStockTransactionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_WarrantsIssuedWith2018NotesLiabilityMember" abstract="true" name="WarrantsIssuedWith2018NotesLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod" abstract="false" name="ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="angn_ClassOfWarrantOrRightOutstandingRollForward" abstract="true" name="ClassOfWarrantOrRightOutstandingRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>18
<FILENAME>angn-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:808f0db7-14af-45c6-a88e-e152464defe4,g:f048552f-f790-4462-b881-32982147c095-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.angn.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="angn-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8dcd9b38-55e5-423e-a898-190011ecc342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_43215f00-124c-4b2a-a6e4-ae074acb89bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8dcd9b38-55e5-423e-a898-190011ecc342" xlink:to="loc_us-gaap_CommitmentsAndContingencies_43215f00-124c-4b2a-a6e4-ae074acb89bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f5abfcd1-9962-412c-b4b6-9e503de73127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8dcd9b38-55e5-423e-a898-190011ecc342" xlink:to="loc_us-gaap_StockholdersEquity_f5abfcd1-9962-412c-b4b6-9e503de73127" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_685b3e89-2475-4479-a0a9-0093ce08e184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8dcd9b38-55e5-423e-a898-190011ecc342" xlink:to="loc_us-gaap_Liabilities_685b3e89-2475-4479-a0a9-0093ce08e184" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b673762a-9c75-489f-89fb-539e2a148cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings_9a4d35ad-5e2c-4962-9094-11993bf0dc87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b673762a-9c75-489f-89fb-539e2a148cbd" xlink:to="loc_us-gaap_OtherShortTermBorrowings_9a4d35ad-5e2c-4962-9094-11993bf0dc87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_dd7a686f-afa8-499a-acdd-d50ab7204a49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b673762a-9c75-489f-89fb-539e2a148cbd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_dd7a686f-afa8-499a-acdd-d50ab7204a49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_65e6ed63-bcbf-464b-aece-2eba23ea44d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b673762a-9c75-489f-89fb-539e2a148cbd" xlink:to="loc_us-gaap_AccountsPayableCurrent_65e6ed63-bcbf-464b-aece-2eba23ea44d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermNonBankLoansAndNotesPayable_a62d6043-98e7-45af-a22b-786f980fae11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermNonBankLoansAndNotesPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b673762a-9c75-489f-89fb-539e2a148cbd" xlink:to="loc_us-gaap_ShortTermNonBankLoansAndNotesPayable_a62d6043-98e7-45af-a22b-786f980fae11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent_2449dabb-cfac-4bfb-8864-df6b1a23a638" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b673762a-9c75-489f-89fb-539e2a148cbd" xlink:to="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent_2449dabb-cfac-4bfb-8864-df6b1a23a638" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_51c78a76-186f-452c-b2af-5c464c8379ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b673762a-9c75-489f-89fb-539e2a148cbd" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_51c78a76-186f-452c-b2af-5c464c8379ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_cdf8f563-6b52-4490-8f63-dfebb8df5a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b673762a-9c75-489f-89fb-539e2a148cbd" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_cdf8f563-6b52-4490-8f63-dfebb8df5a1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_84577f8b-e291-4e96-8358-2f072ee9c1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b673762a-9c75-489f-89fb-539e2a148cbd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_84577f8b-e291-4e96-8358-2f072ee9c1d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3c32fdec-e474-4273-9386-d1ae1fee4e49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b673762a-9c75-489f-89fb-539e2a148cbd" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3c32fdec-e474-4273-9386-d1ae1fee4e49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantLiabilityCurrent_4bc6d3b5-62ce-4979-a007-c89a7a6e3624" xlink:href="angn-20211231.xsd#angn_WarrantLiabilityCurrent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b673762a-9c75-489f-89fb-539e2a148cbd" xlink:to="loc_angn_WarrantLiabilityCurrent_4bc6d3b5-62ce-4979-a007-c89a7a6e3624" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fcf52555-1a0f-4847-b337-16b871027ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_b8641ae9-58c6-4738-9795-7b483f427c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fcf52555-1a0f-4847-b337-16b871027ff3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_b8641ae9-58c6-4738-9795-7b483f427c2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_891e2410-48a0-4a27-8d43-c3bf426f0d81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fcf52555-1a0f-4847-b337-16b871027ff3" xlink:to="loc_us-gaap_CommonStockValue_891e2410-48a0-4a27-8d43-c3bf426f0d81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2bfdb7fe-b168-488d-a3e0-542bffe95d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fcf52555-1a0f-4847-b337-16b871027ff3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2bfdb7fe-b168-488d-a3e0-542bffe95d3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_45f74a37-a0ba-4c25-8a7e-ecfdae29205c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fcf52555-1a0f-4847-b337-16b871027ff3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_45f74a37-a0ba-4c25-8a7e-ecfdae29205c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_d3e71a0f-c364-4018-8acc-a33bd86ab7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fcf52555-1a0f-4847-b337-16b871027ff3" xlink:to="loc_us-gaap_TreasuryStockValue_d3e71a0f-c364-4018-8acc-a33bd86ab7ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_294ae201-4951-4899-a627-92eb5e92ee82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7d23413a-a8e7-4584-9257-c4afaaa98368" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_294ae201-4951-4899-a627-92eb5e92ee82" xlink:to="loc_us-gaap_LiabilitiesCurrent_7d23413a-a8e7-4584-9257-c4afaaa98368" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f13f6d70-04c7-4bc4-b0a4-60460c2225cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_294ae201-4951-4899-a627-92eb5e92ee82" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f13f6d70-04c7-4bc4-b0a4-60460c2225cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_6c6fb6bb-6fa6-446f-a1db-c75f071a1a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_294ae201-4951-4899-a627-92eb5e92ee82" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_6c6fb6bb-6fa6-446f-a1db-c75f071a1a9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_df1a160e-4c53-4567-9d82-0397028faeae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_294ae201-4951-4899-a627-92eb5e92ee82" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_df1a160e-4c53-4567-9d82-0397028faeae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1401a8cf-70d4-4796-8610-b0456b93f61d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_294ae201-4951-4899-a627-92eb5e92ee82" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1401a8cf-70d4-4796-8610-b0456b93f61d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5c1520e2-d844-49aa-830e-118935c354db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivableCurrent_3e284a26-737b-477c-80ce-0d9724efb367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5c1520e2-d844-49aa-830e-118935c354db" xlink:to="loc_us-gaap_GrantsReceivableCurrent_3e284a26-737b-477c-80ce-0d9724efb367" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_17065e31-5441-4d8b-b5f1-7c59cc25ec1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5c1520e2-d844-49aa-830e-118935c354db" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_17065e31-5441-4d8b-b5f1-7c59cc25ec1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dd8dbd0e-2bf7-4662-8577-fba86d7f0970" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5c1520e2-d844-49aa-830e-118935c354db" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_dd8dbd0e-2bf7-4662-8577-fba86d7f0970" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c65f7ec3-206b-45d0-b856-435b7e2049a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_53061942-7b87-429e-a7b5-d6bc5b715e46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c65f7ec3-206b-45d0-b856-435b7e2049a8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_53061942-7b87-429e-a7b5-d6bc5b715e46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9da45671-8983-4d97-a6a2-cf0fb275483b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c65f7ec3-206b-45d0-b856-435b7e2049a8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9da45671-8983-4d97-a6a2-cf0fb275483b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bc22140a-1c9f-4d2a-9271-97a358b8472f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c65f7ec3-206b-45d0-b856-435b7e2049a8" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bc22140a-1c9f-4d2a-9271-97a358b8472f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4a1911c4-c2f8-421e-9ebd-e4476b18ba06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c65f7ec3-206b-45d0-b856-435b7e2049a8" xlink:to="loc_us-gaap_AssetsCurrent_4a1911c4-c2f8-421e-9ebd-e4476b18ba06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_e6369547-8574-487e-972d-15eab2c0715d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c65f7ec3-206b-45d0-b856-435b7e2049a8" xlink:to="loc_us-gaap_Investments_e6369547-8574-487e-972d-15eab2c0715d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="angn-20211231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1bfc614c-1506-4da5-9583-701b70c40e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ee77d3ba-4d37-48ec-96ec-ab82ef6bfac7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_1bfc614c-1506-4da5-9583-701b70c40e2e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ee77d3ba-4d37-48ec-96ec-ab82ef6bfac7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_c7e0366c-3cdb-4ae6-ae11-01b5c41ed96f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_1bfc614c-1506-4da5-9583-701b70c40e2e" xlink:to="loc_us-gaap_CostOfRevenue_c7e0366c-3cdb-4ae6-ae11-01b5c41ed96f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2fce0dcc-760e-412c-b442-393e9eccc5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_1bfc614c-1506-4da5-9583-701b70c40e2e" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2fce0dcc-760e-412c-b442-393e9eccc5c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c1b5a52c-c8dd-4dfb-a43e-2b0522bf01f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4ab7fe7b-42fa-4109-9ca0-2d6b14d2dd83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c1b5a52c-c8dd-4dfb-a43e-2b0522bf01f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4ab7fe7b-42fa-4109-9ca0-2d6b14d2dd83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_adbfdb24-c1ad-45d6-8dca-648b0c2bb750" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c1b5a52c-c8dd-4dfb-a43e-2b0522bf01f7" xlink:to="loc_us-gaap_NetIncomeLoss_adbfdb24-c1ad-45d6-8dca-648b0c2bb750" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_18b32c7d-a610-4d05-9197-28c3468e2870" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_801d8a5e-3be0-490e-be68-25250d85163d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_18b32c7d-a610-4d05-9197-28c3468e2870" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_801d8a5e-3be0-490e-be68-25250d85163d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_a7dd6727-593d-4661-9afc-54dd651d8218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_18b32c7d-a610-4d05-9197-28c3468e2870" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_a7dd6727-593d-4661-9afc-54dd651d8218" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_46fe15c4-7f11-43f6-8132-00535bfc4d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cc6f3eb0-b4ba-469a-ab4c-ab8e59c5de2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_46fe15c4-7f11-43f6-8132-00535bfc4d40" xlink:to="loc_us-gaap_Revenues_cc6f3eb0-b4ba-469a-ab4c-ab8e59c5de2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_82db7abe-5860-4265-9f3e-99bfce575bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_46fe15c4-7f11-43f6-8132-00535bfc4d40" xlink:to="loc_us-gaap_CostsAndExpenses_82db7abe-5860-4265-9f3e-99bfce575bbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_1dfff67b-a12e-477f-81a2-5400b167e584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_a19400e7-34b3-4c60-87f1-dd2970db4d37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1dfff67b-a12e-477f-81a2-5400b167e584" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_a19400e7-34b3-4c60-87f1-dd2970db4d37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_41c23c35-d722-4825-b03c-f72138fb3797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1dfff67b-a12e-477f-81a2-5400b167e584" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_41c23c35-d722-4825-b03c-f72138fb3797" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_24dc7bd3-80fd-4b9a-81a4-c87c6fb89242" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1dfff67b-a12e-477f-81a2-5400b167e584" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_24dc7bd3-80fd-4b9a-81a4-c87c6fb89242" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_33b5a2da-63c6-46c9-8d14-940410f0278e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1dfff67b-a12e-477f-81a2-5400b167e584" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_33b5a2da-63c6-46c9-8d14-940410f0278e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_bb42e0fb-666e-4e3e-a20b-a1917a15f747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1dfff67b-a12e-477f-81a2-5400b167e584" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_bb42e0fb-666e-4e3e-a20b-a1917a15f747" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_f5bc4ab8-ecaf-457b-826f-19dfdaf6954a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1dfff67b-a12e-477f-81a2-5400b167e584" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_f5bc4ab8-ecaf-457b-826f-19dfdaf6954a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6da1d0b3-8d96-4050-9df3-474a935f18bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1dfff67b-a12e-477f-81a2-5400b167e584" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6da1d0b3-8d96-4050-9df3-474a935f18bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss_512650a8-fcc5-48b2-8ef3-6ec547d54945" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_1dfff67b-a12e-477f-81a2-5400b167e584" xlink:to="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss_512650a8-fcc5-48b2-8ef3-6ec547d54945" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6d3ecbed-ab61-4880-bb57-812065fb8c29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_737ec422-d83e-4799-8df3-9839f8624637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6d3ecbed-ab61-4880-bb57-812065fb8c29" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_737ec422-d83e-4799-8df3-9839f8624637" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_64d08541-0d42-4ecb-807c-a91d1437583e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_6d3ecbed-ab61-4880-bb57-812065fb8c29" xlink:to="loc_us-gaap_OperatingIncomeLoss_64d08541-0d42-4ecb-807c-a91d1437583e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angn.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="angn-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9d51a0f3-10c0-4114-b782-08c2a37d19f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_84c5c4d9-4e40-4b6b-b232-745b8cfb043c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9d51a0f3-10c0-4114-b782-08c2a37d19f5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_84c5c4d9-4e40-4b6b-b232-745b8cfb043c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d428f365-9f83-46ce-aeb4-a18e71e7db34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9d51a0f3-10c0-4114-b782-08c2a37d19f5" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d428f365-9f83-46ce-aeb4-a18e71e7db34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fe6d3bde-9d01-4964-8c2d-004e2fd8ffc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9d51a0f3-10c0-4114-b782-08c2a37d19f5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fe6d3bde-9d01-4964-8c2d-004e2fd8ffc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b6816d69-a091-43f1-bd65-63962aeea339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9d51a0f3-10c0-4114-b782-08c2a37d19f5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b6816d69-a091-43f1-bd65-63962aeea339" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c577dceb-c855-4b83-8320-0f9ca7646ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_e6627e8c-57d6-4c2c-8666-5680e8b523a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c577dceb-c855-4b83-8320-0f9ca7646ec8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_e6627e8c-57d6-4c2c-8666-5680e8b523a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_db8c3044-856d-4c8b-a4b2-689d6511eef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c577dceb-c855-4b83-8320-0f9ca7646ec8" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_db8c3044-856d-4c8b-a4b2-689d6511eef4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_4f0b90a5-2954-4b6a-b97d-95dca5493e53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c577dceb-c855-4b83-8320-0f9ca7646ec8" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_4f0b90a5-2954-4b6a-b97d-95dca5493e53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_cb9de6e1-2c46-4d28-92f8-67131edee387" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c577dceb-c855-4b83-8320-0f9ca7646ec8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_cb9de6e1-2c46-4d28-92f8-67131edee387" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NonCashPlacementAgentFee_757d6e4e-f748-4910-bc74-8dec7f8b8ea4" xlink:href="angn-20211231.xsd#angn_NonCashPlacementAgentFee"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c577dceb-c855-4b83-8320-0f9ca7646ec8" xlink:to="loc_angn_NonCashPlacementAgentFee_757d6e4e-f748-4910-bc74-8dec7f8b8ea4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_eefdd31c-adc7-48b5-8ede-7eea57d97c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c577dceb-c855-4b83-8320-0f9ca7646ec8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_eefdd31c-adc7-48b5-8ede-7eea57d97c2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1c1979b1-f2c2-44ee-bca8-39c270016a94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c577dceb-c855-4b83-8320-0f9ca7646ec8" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_1c1979b1-f2c2-44ee-bca8-39c270016a94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e0c0eeb4-3653-4659-9779-4f946447faf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c577dceb-c855-4b83-8320-0f9ca7646ec8" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e0c0eeb4-3653-4659-9779-4f946447faf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a6b96688-3a4b-49e0-86ae-551f6d889373" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c577dceb-c855-4b83-8320-0f9ca7646ec8" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a6b96688-3a4b-49e0-86ae-551f6d889373" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_47184ade-1175-41c5-9fed-0e60398d41b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c577dceb-c855-4b83-8320-0f9ca7646ec8" xlink:to="loc_us-gaap_NetIncomeLoss_47184ade-1175-41c5-9fed-0e60398d41b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_83f71061-0cdb-45fc-836b-0ffd83daa76b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c577dceb-c855-4b83-8320-0f9ca7646ec8" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_83f71061-0cdb-45fc-836b-0ffd83daa76b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_IncreaseDecreaseInGrantReceivables_11ec7f6d-9ba9-46db-a006-200a3505418d" xlink:href="angn-20211231.xsd#angn_IncreaseDecreaseInGrantReceivables"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c577dceb-c855-4b83-8320-0f9ca7646ec8" xlink:to="loc_angn_IncreaseDecreaseInGrantReceivables_11ec7f6d-9ba9-46db-a006-200a3505418d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2868c1b1-d7eb-46f5-a487-aae48db2fb75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c577dceb-c855-4b83-8320-0f9ca7646ec8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2868c1b1-d7eb-46f5-a487-aae48db2fb75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_5a298093-17a8-4c02-8f4c-2da7c8d94c02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c577dceb-c855-4b83-8320-0f9ca7646ec8" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_5a298093-17a8-4c02-8f4c-2da7c8d94c02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_7e1676b6-d770-4863-b528-d0d2588b7517" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c577dceb-c855-4b83-8320-0f9ca7646ec8" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_7e1676b6-d770-4863-b528-d0d2588b7517" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_d93cb9fd-7bb8-400c-ac78-5b2b5371c467" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c577dceb-c855-4b83-8320-0f9ca7646ec8" xlink:to="loc_us-gaap_Depreciation_d93cb9fd-7bb8-400c-ac78-5b2b5371c467" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e1c9738d-bea0-468d-ba80-087ecdc0c133" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c577dceb-c855-4b83-8320-0f9ca7646ec8" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e1c9738d-bea0-468d-ba80-087ecdc0c133" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_11bffa06-e2d3-42e1-b18a-bdf08da5c237" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c577dceb-c855-4b83-8320-0f9ca7646ec8" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_11bffa06-e2d3-42e1-b18a-bdf08da5c237" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss_8e116cbc-b341-4603-93ad-e40ddc08da75" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c577dceb-c855-4b83-8320-0f9ca7646ec8" xlink:to="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss_8e116cbc-b341-4603-93ad-e40ddc08da75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_caed41b1-718a-4ad4-808c-1b390e439052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c577dceb-c855-4b83-8320-0f9ca7646ec8" xlink:to="loc_us-gaap_ShareBasedCompensation_caed41b1-718a-4ad4-808c-1b390e439052" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_35d64b05-b0d4-4384-9c16-e425d9d9bfde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ProceedsFromFinancingObligation_8efb676c-f196-4f5f-bff3-48b50f37c1ac" xlink:href="angn-20211231.xsd#angn_ProceedsFromFinancingObligation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_35d64b05-b0d4-4384-9c16-e425d9d9bfde" xlink:to="loc_angn_ProceedsFromFinancingObligation_8efb676c-f196-4f5f-bff3-48b50f37c1ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_0a39eeb2-e979-4b7c-a2db-a0cb81deb695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_35d64b05-b0d4-4384-9c16-e425d9d9bfde" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_0a39eeb2-e979-4b7c-a2db-a0cb81deb695" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_3444e071-fc71-4f07-8f80-f903cc4d0eae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_35d64b05-b0d4-4384-9c16-e425d9d9bfde" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_3444e071-fc71-4f07-8f80-f903cc4d0eae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PaymentsForBrokerWarrantExercises_ff5350bd-9a7b-40de-b8c9-b44f18ac2eb4" xlink:href="angn-20211231.xsd#angn_PaymentsForBrokerWarrantExercises"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_35d64b05-b0d4-4384-9c16-e425d9d9bfde" xlink:to="loc_angn_PaymentsForBrokerWarrantExercises_ff5350bd-9a7b-40de-b8c9-b44f18ac2eb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_111fe678-19a4-4fd1-83e7-61e45d94bac7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_35d64b05-b0d4-4384-9c16-e425d9d9bfde" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_111fe678-19a4-4fd1-83e7-61e45d94bac7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_cfd3b235-60b4-4122-90fc-9c07b4a2aadb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_35d64b05-b0d4-4384-9c16-e425d9d9bfde" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_cfd3b235-60b4-4122-90fc-9c07b4a2aadb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_7464b6c4-aeb5-4247-897a-640856934f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_35d64b05-b0d4-4384-9c16-e425d9d9bfde" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_7464b6c4-aeb5-4247-897a-640856934f4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PaymentsForForwardStockSplitFractionalShares_69a8a543-f229-4652-8a4e-5ac7be0a830d" xlink:href="angn-20211231.xsd#angn_PaymentsForForwardStockSplitFractionalShares"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_35d64b05-b0d4-4384-9c16-e425d9d9bfde" xlink:to="loc_angn_PaymentsForForwardStockSplitFractionalShares_69a8a543-f229-4652-8a4e-5ac7be0a830d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_e49c4d73-b9af-4206-bf23-42c9cf8edc0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_35d64b05-b0d4-4384-9c16-e425d9d9bfde" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_e49c4d73-b9af-4206-bf23-42c9cf8edc0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_36032f05-6642-4f8d-8537-c5beb1770efa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_35d64b05-b0d4-4384-9c16-e425d9d9bfde" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_36032f05-6642-4f8d-8537-c5beb1770efa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_ad41a752-18f9-460e-ba07-6b72a79a57d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_35d64b05-b0d4-4384-9c16-e425d9d9bfde" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_ad41a752-18f9-460e-ba07-6b72a79a57d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_9d1bd0e9-1e25-4ab0-b073-f445756b4fab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_35d64b05-b0d4-4384-9c16-e425d9d9bfde" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_9d1bd0e9-1e25-4ab0-b073-f445756b4fab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3da65558-2869-4a4f-8864-d99c620b6095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_08ce3928-c9fd-4a42-9034-8a11af619d68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3da65558-2869-4a4f-8864-d99c620b6095" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_08ce3928-c9fd-4a42-9034-8a11af619d68" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2b7ea5b8-c6e4-4618-b2d5-516e7bf1de1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f57814bd-0581-4ac5-b43d-e7250915ffb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_2b7ea5b8-c6e4-4618-b2d5-516e7bf1de1d" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f57814bd-0581-4ac5-b43d-e7250915ffb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_e8ba0fe1-8cac-4d83-9382-833f7241168e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_d2dddc88-a72f-4226-b400-d1d0599fb4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_e8ba0fe1-8cac-4d83-9382-833f7241168e" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_d2dddc88-a72f-4226-b400-d1d0599fb4ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsFairValueDisclosure_2aa87e7a-10d9-4601-ba1a-579ef1670eef" xlink:href="angn-20211231.xsd#angn_WarrantsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_e8ba0fe1-8cac-4d83-9382-833f7241168e" xlink:to="loc_angn_WarrantsFairValueDisclosure_2aa87e7a-10d9-4601-ba1a-579ef1670eef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent_8b1b9dbc-95a1-4afd-ba27-42473830c240" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_e8ba0fe1-8cac-4d83-9382-833f7241168e" xlink:to="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent_8b1b9dbc-95a1-4afd-ba27-42473830c240" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_eda9502d-9214-44f1-bd11-6b13729feb57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_225abc2f-73d0-4701-a871-9b7c059d115d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_eda9502d-9214-44f1-bd11-6b13729feb57" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_225abc2f-73d0-4701-a871-9b7c059d115d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_40c19fda-62b8-4fe2-9893-fec58f773a96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_eda9502d-9214-44f1-bd11-6b13729feb57" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_40c19fda-62b8-4fe2-9893-fec58f773a96" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_06cc8b84-44ac-485b-a490-8e53a493ec46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_a4772624-c4f1-4446-a5ae-8526d22aa6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidTaxes"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_06cc8b84-44ac-485b-a490-8e53a493ec46" xlink:to="loc_us-gaap_PrepaidTaxes_a4772624-c4f1-4446-a5ae-8526d22aa6b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_ab423063-f6e0-4601-9de0-9cb3851dc112" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_06cc8b84-44ac-485b-a490-8e53a493ec46" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_ab423063-f6e0-4601-9de0-9cb3851dc112" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_052e48c5-f202-434d-91af-23ed41feff93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_06cc8b84-44ac-485b-a490-8e53a493ec46" xlink:to="loc_us-gaap_DeferredOfferingCosts_052e48c5-f202-434d-91af-23ed41feff93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_02ddeda4-0e1b-46e4-ac3f-89f8081d42e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_06cc8b84-44ac-485b-a490-8e53a493ec46" xlink:to="loc_us-gaap_PrepaidInsurance_02ddeda4-0e1b-46e4-ac3f-89f8081d42e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent_1095b3fd-80c4-4ffe-bae3-3318366e9983" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_06cc8b84-44ac-485b-a490-8e53a493ec46" xlink:to="loc_us-gaap_DepositsAssetsCurrent_1095b3fd-80c4-4ffe-bae3-3318366e9983" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PrepaidClinicalFeesCurrent_4bd57a2d-a4f8-4ee5-b711-083f2d811296" xlink:href="angn-20211231.xsd#angn_PrepaidClinicalFeesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_06cc8b84-44ac-485b-a490-8e53a493ec46" xlink:to="loc_angn_PrepaidClinicalFeesCurrent_4bd57a2d-a4f8-4ee5-b711-083f2d811296" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_40ae2fcf-b110-45cf-b3f6-c66bbd2b0db5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_06cc8b84-44ac-485b-a490-8e53a493ec46" xlink:to="loc_us-gaap_OtherAssetsCurrent_40ae2fcf-b110-45cf-b3f6-c66bbd2b0db5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#BalanceSheetComponentsScheduleofAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_00974e5c-e429-4f61-b815-0f41e4d0a1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0f01d086-a2dd-4d07-b3cb-01f4952a75fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_00974e5c-e429-4f61-b815-0f41e4d0a1cd" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0f01d086-a2dd-4d07-b3cb-01f4952a75fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AccruedDirectResearchCostsCurrent_96bd13c2-aab0-45db-8f71-c745a5c362b0" xlink:href="angn-20211231.xsd#angn_AccruedDirectResearchCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_00974e5c-e429-4f61-b815-0f41e4d0a1cd" xlink:to="loc_angn_AccruedDirectResearchCostsCurrent_96bd13c2-aab0-45db-8f71-c745a5c362b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AccruedOperatingLiabilitiesCurrent_b521282a-673f-449a-9b4a-5f5962fb957a" xlink:href="angn-20211231.xsd#angn_AccruedOperatingLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_00974e5c-e429-4f61-b815-0f41e4d0a1cd" xlink:to="loc_angn_AccruedOperatingLiabilitiesCurrent_b521282a-673f-449a-9b4a-5f5962fb957a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_18619fe3-01af-4ae6-b29b-08da0a8be257" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_00974e5c-e429-4f61-b815-0f41e4d0a1cd" xlink:to="loc_us-gaap_InterestPayableCurrent_18619fe3-01af-4ae6-b29b-08da0a8be257" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angn.com/role/SeriesCConvertiblePreferredStockSummaryofAggregateValuesRecordedDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#SeriesCConvertiblePreferredStockSummaryofAggregateValuesRecordedDetails"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/SeriesCConvertiblePreferredStockSummaryofAggregateValuesRecordedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount_aa603e28-8de5-4fb0-98ab-5e50b2858a7b" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_d4411d48-f7ca-43db-8398-6df79a6fa498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount_aa603e28-8de5-4fb0-98ab-5e50b2858a7b" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_d4411d48-f7ca-43db-8398-6df79a6fa498" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountAccumulatedChangeInFairValue_8d7a551d-9cc1-4fca-a7dd-7c2bb0a19f18" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountAccumulatedChangeInFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount_aa603e28-8de5-4fb0-98ab-5e50b2858a7b" xlink:to="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountAccumulatedChangeInFairValue_8d7a551d-9cc1-4fca-a7dd-7c2bb0a19f18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountIssuedInConvertibleNoteExchange_3b8e2d84-8ffa-4abc-a495-be9f28880db8" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountIssuedInConvertibleNoteExchange"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount_aa603e28-8de5-4fb0-98ab-5e50b2858a7b" xlink:to="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountIssuedInConvertibleNoteExchange_3b8e2d84-8ffa-4abc-a495-be9f28880db8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_80654877-298f-4e5a-9ed3-aa3bc2a1eaea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross_ca81aeaa-2e2f-48c8-951b-d9a57dfb3df2" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_80654877-298f-4e5a-9ed3-aa3bc2a1eaea" xlink:to="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross_ca81aeaa-2e2f-48c8-951b-d9a57dfb3df2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium_056f6698-0b04-4c3d-b6f2-fd8fe09ad450" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_80654877-298f-4e5a-9ed3-aa3bc2a1eaea" xlink:to="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium_056f6698-0b04-4c3d-b6f2-fd8fe09ad450" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees_efee6f62-b3ff-4901-9211-bb8b9646e22d" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_80654877-298f-4e5a-9ed3-aa3bc2a1eaea" xlink:to="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees_efee6f62-b3ff-4901-9211-bb8b9646e22d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angn.com/role/CommitmentsandContingenciesScheduleofComponentsofRentExpenseDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#CommitmentsandContingenciesScheduleofComponentsofRentExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/CommitmentsandContingenciesScheduleofComponentsofRentExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_34e3a39e-74a8-44c9-9ab2-3b76fb21f79f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_bd98986d-cd99-475c-8147-8356e7fcbbae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_34e3a39e-74a8-44c9-9ab2-3b76fb21f79f" xlink:to="loc_us-gaap_OperatingLeaseExpense_bd98986d-cd99-475c-8147-8356e7fcbbae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_9cabd8f4-7e41-40d1-92ac-38de624c100e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_34e3a39e-74a8-44c9-9ab2-3b76fb21f79f" xlink:to="loc_us-gaap_ShortTermLeaseCost_9cabd8f4-7e41-40d1-92ac-38de624c100e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_8d87a2d7-cbb9-4e44-b722-fc1d96c95374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_0745ba16-3ed6-4465-9e2c-66377272c1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseExpense_8d87a2d7-cbb9-4e44-b722-fc1d96c95374" xlink:to="loc_us-gaap_VariableLeaseCost_0745ba16-3ed6-4465-9e2c-66377272c1f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_4625d00f-0255-4ffe-991a-142deb4a3083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseExpense_8d87a2d7-cbb9-4e44-b722-fc1d96c95374" xlink:to="loc_us-gaap_OperatingLeaseCost_4625d00f-0255-4ffe-991a-142deb4a3083" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f569571a-9090-46f0-bb5e-e54f73a544b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b9b70827-c4f3-4d19-9f59-737480d8e7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f569571a-9090-46f0-bb5e-e54f73a544b0" xlink:to="loc_us-gaap_OperatingLeaseLiability_b9b70827-c4f3-4d19-9f59-737480d8e7e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ebcb9c73-7b7e-457c-a83d-a966daf5e876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f569571a-9090-46f0-bb5e-e54f73a544b0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ebcb9c73-7b7e-457c-a83d-a966daf5e876" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="angn-20211231.xsd#CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_420029d2-23c3-44dd-bc62-3f98b4bdfb9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d9ce82c5-ac08-4956-b225-feaf03b5d4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_420029d2-23c3-44dd-bc62-3f98b4bdfb9e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d9ce82c5-ac08-4956-b225-feaf03b5d4c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_54846a0a-2a9f-4418-a78e-cba3eb86f6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_420029d2-23c3-44dd-bc62-3f98b4bdfb9e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_54846a0a-2a9f-4418-a78e-cba3eb86f6a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f275f0a3-8e21-4f87-b764-ad5836cb5e55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_420029d2-23c3-44dd-bc62-3f98b4bdfb9e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f275f0a3-8e21-4f87-b764-ad5836cb5e55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4cd67153-b436-4eca-9182-cc442c89466a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_420029d2-23c3-44dd-bc62-3f98b4bdfb9e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4cd67153-b436-4eca-9182-cc442c89466a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0777f05b-8315-4268-a935-3748ee9183bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_420029d2-23c3-44dd-bc62-3f98b4bdfb9e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0777f05b-8315-4268-a935-3748ee9183bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_98c2a932-d9bb-418d-8a5c-5f99ee3636cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_420029d2-23c3-44dd-bc62-3f98b4bdfb9e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_98c2a932-d9bb-418d-8a5c-5f99ee3636cd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_7171e156-ec91-4bcb-a1d4-b5cbbc709971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_597a3fd2-2366-4d83-9f05-f06db58e8050" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_7171e156-ec91-4bcb-a1d4-b5cbbc709971" xlink:to="loc_us-gaap_FinanceLeaseLiability_597a3fd2-2366-4d83-9f05-f06db58e8050" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_89738ede-cade-4e9d-95d2-3ac044d0fe13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_7171e156-ec91-4bcb-a1d4-b5cbbc709971" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_89738ede-cade-4e9d-95d2-3ac044d0fe13" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails_1" xlink:type="simple" xlink:href="angn-20211231.xsd#CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails_1"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_268c48e5-02e5-4813-b3a6-d7ae03f70f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2ff8e046-05c7-446f-b78b-ba29fb945207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_268c48e5-02e5-4813-b3a6-d7ae03f70f1f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_2ff8e046-05c7-446f-b78b-ba29fb945207" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_7f47cd6a-3432-46dc-95d8-351a54f89c38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_268c48e5-02e5-4813-b3a6-d7ae03f70f1f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_7f47cd6a-3432-46dc-95d8-351a54f89c38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_319f6790-3318-4838-962f-1afffbdb0c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_268c48e5-02e5-4813-b3a6-d7ae03f70f1f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_319f6790-3318-4838-962f-1afffbdb0c3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_62ff322e-f066-45b0-9661-b4a4315cd4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_268c48e5-02e5-4813-b3a6-d7ae03f70f1f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_62ff322e-f066-45b0-9661-b4a4315cd4c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_1a53115b-7f03-4eb7-86a9-bdc75da40366" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_268c48e5-02e5-4813-b3a6-d7ae03f70f1f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_1a53115b-7f03-4eb7-86a9-bdc75da40366" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_016d2533-100c-4929-b807-57a9624ebc99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_268c48e5-02e5-4813-b3a6-d7ae03f70f1f" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_016d2533-100c-4929-b807-57a9624ebc99" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angn.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_38bbf475-0108-4a2b-9e84-9bf992c4c2ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OperatingLossCarryforwardSubjectToExpiration_a268551d-5757-4a02-b117-0b2f06fc7422" xlink:href="angn-20211231.xsd#angn_OperatingLossCarryforwardSubjectToExpiration"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_38bbf475-0108-4a2b-9e84-9bf992c4c2ab" xlink:to="loc_angn_OperatingLossCarryforwardSubjectToExpiration_a268551d-5757-4a02-b117-0b2f06fc7422" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OperatingLossCarryforwardNotSubjectToExpiration_a0c079c9-c729-40e7-a892-f82492f93132" xlink:href="angn-20211231.xsd#angn_OperatingLossCarryforwardNotSubjectToExpiration"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_38bbf475-0108-4a2b-9e84-9bf992c4c2ab" xlink:to="loc_angn_OperatingLossCarryforwardNotSubjectToExpiration_a0c079c9-c729-40e7-a892-f82492f93132" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angn.com/role/IncomeTaxesScheduleofIncomebeforeIncomeTaxDomesticandForeignDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#IncomeTaxesScheduleofIncomebeforeIncomeTaxDomesticandForeignDetails"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/IncomeTaxesScheduleofIncomebeforeIncomeTaxDomesticandForeignDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8baaff46-7e18-47f6-9327-10eb633b8e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_f41ae307-271c-4901-b2d0-6a5a7700ad2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8baaff46-7e18-47f6-9327-10eb633b8e7c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_f41ae307-271c-4901-b2d0-6a5a7700ad2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_bbae2e82-4d55-4c8a-a514-e079bb8b943d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8baaff46-7e18-47f6-9327-10eb633b8e7c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_bbae2e82-4d55-4c8a-a514-e079bb8b943d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e04bbbc7-b215-4482-beae-0201bc0540a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0280ea96-a261-4719-a51e-0a910e96d71f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e04bbbc7-b215-4482-beae-0201bc0540a3" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0280ea96-a261-4719-a51e-0a910e96d71f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_c077090f-e316-46c4-b4c2-5cdf0426af8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e04bbbc7-b215-4482-beae-0201bc0540a3" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_c077090f-e316-46c4-b4c2-5cdf0426af8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_debb246e-cb5e-496d-94b5-ef1d52ac541b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e04bbbc7-b215-4482-beae-0201bc0540a3" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_debb246e-cb5e-496d-94b5-ef1d52ac541b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_437d40e1-b6ea-4685-b29e-5371f4fe02c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7238e1d3-cc7d-440e-9599-e8006a8bcb41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_437d40e1-b6ea-4685-b29e-5371f4fe02c2" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7238e1d3-cc7d-440e-9599-e8006a8bcb41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f9914730-aa60-4461-a8e4-83c8f67b9ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_437d40e1-b6ea-4685-b29e-5371f4fe02c2" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f9914730-aa60-4461-a8e4-83c8f67b9ace" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_961d5e53-edeb-4ba5-8221-36c503f70db2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_a2a8558e-f16e-4faf-8140-06ee3bd19488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_961d5e53-edeb-4ba5-8221-36c503f70db2" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_a2a8558e-f16e-4faf-8140-06ee3bd19488" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_32459060-92a7-48f1-ab73-e39d8334b3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_961d5e53-edeb-4ba5-8221-36c503f70db2" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_32459060-92a7-48f1-ab73-e39d8334b3bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_c3b7fbf4-da8a-4237-9fc5-f62a64920bea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_961d5e53-edeb-4ba5-8221-36c503f70db2" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_c3b7fbf4-da8a-4237-9fc5-f62a64920bea" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e3c760cb-9fc5-4dc1-bcd5-49ec891b9383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent_9f681c57-e540-4b8d-a5e5-e6938c66088e" xlink:href="angn-20211231.xsd#angn_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e3c760cb-9fc5-4dc1-bcd5-49ec891b9383" xlink:to="loc_angn_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent_9f681c57-e540-4b8d-a5e5-e6938c66088e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_72baf2ec-5874-43c7-a4a2-7396042b9c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e3c760cb-9fc5-4dc1-bcd5-49ec891b9383" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_72baf2ec-5874-43c7-a4a2-7396042b9c7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_d1f1f306-23d3-438d-ba77-73b083ae094e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e3c760cb-9fc5-4dc1-bcd5-49ec891b9383" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_d1f1f306-23d3-438d-ba77-73b083ae094e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EffectiveIncomeTaxRateReconciliationInterestPercent_aaaad60c-2c0d-4c6f-a1dd-6617e6dc40eb" xlink:href="angn-20211231.xsd#angn_EffectiveIncomeTaxRateReconciliationInterestPercent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e3c760cb-9fc5-4dc1-bcd5-49ec891b9383" xlink:to="loc_angn_EffectiveIncomeTaxRateReconciliationInterestPercent_aaaad60c-2c0d-4c6f-a1dd-6617e6dc40eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_6a8be431-994b-467b-abfd-cd574a87c7db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e3c760cb-9fc5-4dc1-bcd5-49ec891b9383" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_6a8be431-994b-467b-abfd-cd574a87c7db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1ecfe47d-305b-4a88-bf8d-774dff7cedc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e3c760cb-9fc5-4dc1-bcd5-49ec891b9383" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1ecfe47d-305b-4a88-bf8d-774dff7cedc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_8ddb7731-9c1e-4d88-8a88-92ab4cbb9b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e3c760cb-9fc5-4dc1-bcd5-49ec891b9383" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_8ddb7731-9c1e-4d88-8a88-92ab4cbb9b3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_3231174f-8094-4345-9692-6e9af3bfc4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e3c760cb-9fc5-4dc1-bcd5-49ec891b9383" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_3231174f-8094-4345-9692-6e9af3bfc4b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_4f4f83eb-c793-4271-a741-037345405e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e3c760cb-9fc5-4dc1-bcd5-49ec891b9383" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_4f4f83eb-c793-4271-a741-037345405e8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_89f21555-9484-49bc-8887-63e6258a10d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e3c760cb-9fc5-4dc1-bcd5-49ec891b9383" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_89f21555-9484-49bc-8887-63e6258a10d2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_19541ea2-1cc1-46fb-b274-6359fb33e9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_971f4548-a1db-4851-b133-da6dd1a573d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_19541ea2-1cc1-46fb-b274-6359fb33e9c3" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_971f4548-a1db-4851-b133-da6dd1a573d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_e30fd9c7-ffad-4e81-abd2-5969d6d8c752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_19541ea2-1cc1-46fb-b274-6359fb33e9c3" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_e30fd9c7-ffad-4e81-abd2-5969d6d8c752" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_3218a363-929f-48dc-b6ae-63d964394f24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_19541ea2-1cc1-46fb-b274-6359fb33e9c3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_3218a363-929f-48dc-b6ae-63d964394f24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_61286467-e74d-4c4f-b85d-2c4f77f7ea84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_19541ea2-1cc1-46fb-b274-6359fb33e9c3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_61286467-e74d-4c4f-b85d-2c4f77f7ea84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_72e9e59a-1e68-4744-ac55-2e82bb0ea2de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_dd3611b4-d39f-4dc4-8a61-42170e98fb78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_72e9e59a-1e68-4744-ac55-2e82bb0ea2de" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_dd3611b4-d39f-4dc4-8a61-42170e98fb78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_19a28640-0550-41dd-aaa7-021fd1ed0e25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_72e9e59a-1e68-4744-ac55-2e82bb0ea2de" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_19a28640-0550-41dd-aaa7-021fd1ed0e25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_DeferredTaxAssetsOperatingLeaseLiability_53a46b15-c678-4467-be97-5cb9c54a4149" xlink:href="angn-20211231.xsd#angn_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_72e9e59a-1e68-4744-ac55-2e82bb0ea2de" xlink:to="loc_angn_DeferredTaxAssetsOperatingLeaseLiability_53a46b15-c678-4467-be97-5cb9c54a4149" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_e6465d57-2406-484b-b5e0-05bebadeb7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_72e9e59a-1e68-4744-ac55-2e82bb0ea2de" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_e6465d57-2406-484b-b5e0-05bebadeb7a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_80507cc2-c91d-48ad-88de-893ebc751e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_72e9e59a-1e68-4744-ac55-2e82bb0ea2de" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_80507cc2-c91d-48ad-88de-893ebc751e7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_85ee1b08-f593-4bc5-aeee-454d83733f01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_72e9e59a-1e68-4744-ac55-2e82bb0ea2de" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_85ee1b08-f593-4bc5-aeee-454d83733f01" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.angn.com/role/IncomeTaxesUnrecognizedTaxBenefitsIfRecognizedWouldAffecttheEffectiveTaxRateDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#IncomeTaxesUnrecognizedTaxBenefitsIfRecognizedWouldAffecttheEffectiveTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.angn.com/role/IncomeTaxesUnrecognizedTaxBenefitsIfRecognizedWouldAffecttheEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_f610ad0c-c16d-4458-a238-7ff7a884486c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_b502905c-eb71-47c2-a19e-cf289e3d2ac4" xlink:href="angn-20211231.xsd#angn_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_f610ad0c-c16d-4458-a238-7ff7a884486c" xlink:to="loc_angn_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_b502905c-eb71-47c2-a19e-cf289e3d2ac4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_c4de13df-ed4a-4c27-aa09-f79ddfcaa181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_f610ad0c-c16d-4458-a238-7ff7a884486c" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_c4de13df-ed4a-4c27-aa09-f79ddfcaa181" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>19
<FILENAME>angn-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:808f0db7-14af-45c6-a88e-e152464defe4,g:f048552f-f790-4462-b881-32982147c095-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" xlink:type="simple" xlink:href="angn-20211231.xsd#ConsolidatedStatementsofStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" xlink:type="extended" id="idb4ffd7fad1e4c3a9b83282fc6d80022_ConsolidatedStatementsofStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_cd0e2551-0d94-46c9-84bb-16e1a37ff206" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cd0e2551-0d94-46c9-84bb-16e1a37ff206" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e4af4ee0-def6-42fa-ab7d-2d773611fcde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_SharesOutstanding_e4af4ee0-def6-42fa-ab7d-2d773611fcde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b82aabb5-ef6b-41d4-ad32-0b2ce276eb82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_StockholdersEquity_b82aabb5-ef6b-41d4-ad32-0b2ce276eb82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f847a516-dc72-496a-bc5c-68d7f31fe5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f847a516-dc72-496a-bc5c-68d7f31fe5a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_66955015-bf0e-42f9-acc7-3afc03a97e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_66955015-bf0e-42f9-acc7-3afc03a97e2c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock_bfda37b4-3dfb-4542-a346-4614face9f98" xlink:href="angn-20211231.xsd#angn_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_angn_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock_bfda37b4-3dfb-4542-a346-4614face9f98" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock_e0c6faa9-6b02-4c56-9f2c-5af161a2b073" xlink:href="angn-20211231.xsd#angn_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_angn_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock_e0c6faa9-6b02-4c56-9f2c-5af161a2b073" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8d9ecb1b-036a-442a-8bd2-0ebbf3498dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8d9ecb1b-036a-442a-8bd2-0ebbf3498dd4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_758ad216-e2a5-4acd-8c22-4f46abfa9abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_758ad216-e2a5-4acd-8c22-4f46abfa9abe" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_19dcb0d8-349d-4989-bfa0-8ba0333592b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_19dcb0d8-349d-4989-bfa0-8ba0333592b6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodSharesBrokerWarrantsExercised_14d8759e-0df2-447f-9444-3d8d2bec67cb" xlink:href="angn-20211231.xsd#angn_StockIssuedDuringPeriodSharesBrokerWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_angn_StockIssuedDuringPeriodSharesBrokerWarrantsExercised_14d8759e-0df2-447f-9444-3d8d2bec67cb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodValueBrokerWarrantsExercised_f9dd1d2d-ce82-4ee3-b52d-67da319e33ac" xlink:href="angn-20211231.xsd#angn_StockIssuedDuringPeriodValueBrokerWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_angn_StockIssuedDuringPeriodValueBrokerWarrantsExercised_f9dd1d2d-ce82-4ee3-b52d-67da319e33ac" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodSharesWarrantsExercised_ada83579-34eb-497f-a41d-263de685ee46" xlink:href="angn-20211231.xsd#angn_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_angn_StockIssuedDuringPeriodSharesWarrantsExercised_ada83579-34eb-497f-a41d-263de685ee46" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodValueWarrantsExercised_c0b289d6-fc2c-4698-8416-54c56095fe99" xlink:href="angn-20211231.xsd#angn_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_angn_StockIssuedDuringPeriodValueWarrantsExercised_c0b289d6-fc2c-4698-8416-54c56095fe99" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_020e18c3-537e-4895-aece-ecadd25eef70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_020e18c3-537e-4895-aece-ecadd25eef70" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1282108e-286d-4aae-a895-f0d33a68b2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1282108e-286d-4aae-a895-f0d33a68b2dc" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_32f3ed96-497a-41a2-83fa-fc07ad8ba193" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_32f3ed96-497a-41a2-83fa-fc07ad8ba193" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_0de4181e-9572-417a-b49d-1dd8e0c91613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_0de4181e-9572-417a-b49d-1dd8e0c91613" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_c718db91-dfb7-4b91-828c-976632470791" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_c718db91-dfb7-4b91-828c-976632470791" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_5d7ff4ca-a0d5-46b2-b879-2de09c30acb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_5d7ff4ca-a0d5-46b2-b879-2de09c30acb8" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_82a245d1-fcd5-4e05-9073-5afe37d2501a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_82a245d1-fcd5-4e05-9073-5afe37d2501a" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_a445a925-3a29-4cbc-a482-e24c8930a54c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_a445a925-3a29-4cbc-a482-e24c8930a54c" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_22b4e014-68df-46bd-8a7c-bd836a52c380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_22b4e014-68df-46bd-8a7c-bd836a52c380" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d837f80f-0641-48cb-8a0c-600c583b8044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d837f80f-0641-48cb-8a0c-600c583b8044" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_09a5f2c2-065d-4eba-864d-5a66e3169f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_09a5f2c2-065d-4eba-864d-5a66e3169f4d" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f6820266-2d3d-4c6e-b610-b5c078c8a523" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_NetIncomeLoss_f6820266-2d3d-4c6e-b610-b5c078c8a523" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_beebe5d6-0f90-471d-b3e1-3d0ded7963c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_268e221d-d57f-45a2-8fae-1f033e8dd32f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9af511a0-0718-4d58-bd24-77fa1fed0cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_cd0e2551-0d94-46c9-84bb-16e1a37ff206" xlink:to="loc_us-gaap_StatementTable_9af511a0-0718-4d58-bd24-77fa1fed0cb0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7274e657-f978-4cbc-b179-5e1adcae8f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9af511a0-0718-4d58-bd24-77fa1fed0cb0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7274e657-f978-4cbc-b179-5e1adcae8f5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7274e657-f978-4cbc-b179-5e1adcae8f5a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7274e657-f978-4cbc-b179-5e1adcae8f5a" xlink:to="loc_us-gaap_EquityComponentDomain_7274e657-f978-4cbc-b179-5e1adcae8f5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a4cb0fed-1d32-4587-bb0a-921c983aca0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7274e657-f978-4cbc-b179-5e1adcae8f5a" xlink:to="loc_us-gaap_EquityComponentDomain_a4cb0fed-1d32-4587-bb0a-921c983aca0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ffe3d9f9-1d65-48a8-8411-6a59ae0ca351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a4cb0fed-1d32-4587-bb0a-921c983aca0e" xlink:to="loc_us-gaap_CommonStockMember_ffe3d9f9-1d65-48a8-8411-6a59ae0ca351" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_5f4088ef-d5a4-4f74-8d74-958deb05f060" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a4cb0fed-1d32-4587-bb0a-921c983aca0e" xlink:to="loc_us-gaap_TreasuryStockMember_5f4088ef-d5a4-4f74-8d74-958deb05f060" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_eb058017-13f4-4006-8849-e47faaf5ee5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a4cb0fed-1d32-4587-bb0a-921c983aca0e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_eb058017-13f4-4006-8849-e47faaf5ee5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e17098d3-529c-41a0-9ea4-47ad49b96f87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a4cb0fed-1d32-4587-bb0a-921c983aca0e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e17098d3-529c-41a0-9ea4-47ad49b96f87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4bb19492-8a4b-4086-b62b-4bbcf862af91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a4cb0fed-1d32-4587-bb0a-921c983aca0e" xlink:to="loc_us-gaap_RetainedEarningsMember_4bb19492-8a4b-4086-b62b-4bbcf862af91" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_90abd5a7-ed6f-479b-ac6b-5e7d69dc2d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9af511a0-0718-4d58-bd24-77fa1fed0cb0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_90abd5a7-ed6f-479b-ac6b-5e7d69dc2d2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_90abd5a7-ed6f-479b-ac6b-5e7d69dc2d2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_90abd5a7-ed6f-479b-ac6b-5e7d69dc2d2e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_90abd5a7-ed6f-479b-ac6b-5e7d69dc2d2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e13ce273-a2d6-4976-883b-775d973792b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_90abd5a7-ed6f-479b-ac6b-5e7d69dc2d2e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e13ce273-a2d6-4976-883b-775d973792b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_cc5a61e7-70b2-47ac-bc3c-12b944144c37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e13ce273-a2d6-4976-883b-775d973792b4" xlink:to="loc_us-gaap_IPOMember_cc5a61e7-70b2-47ac-bc3c-12b944144c37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_e9166724-9f29-4f2d-8392-9aaff88dc9b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e13ce273-a2d6-4976-883b-775d973792b4" xlink:to="loc_us-gaap_PrivatePlacementMember_e9166724-9f29-4f2d-8392-9aaff88dc9b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NonIPORelatedStockTransactionsMember_b8bb5f9a-d323-49c2-919e-b1ba7d1ac1bf" xlink:href="angn-20211231.xsd#angn_NonIPORelatedStockTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e13ce273-a2d6-4976-883b-775d973792b4" xlink:to="loc_angn_NonIPORelatedStockTransactionsMember_b8bb5f9a-d323-49c2-919e-b1ba7d1ac1bf" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficitParenthetical" xlink:type="simple" xlink:href="angn-20211231.xsd#ConsolidatedStatementsofStockholdersEquityDeficitParenthetical"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficitParenthetical" xlink:type="extended" id="ie6ee75af55ba4050b36005724340839c_ConsolidatedStatementsofStockholdersEquityDeficitParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8dce34c8-cae3-4c95-a567-faf1e2a2d26d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_5c03a71c-8af8-4b10-a9f5-48700e791c92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8dce34c8-cae3-4c95-a567-faf1e2a2d26d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_5c03a71c-8af8-4b10-a9f5-48700e791c92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d75a5819-7f13-4348-899b-6ae92c8f62e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8dce34c8-cae3-4c95-a567-faf1e2a2d26d" xlink:to="loc_us-gaap_StatementTable_d75a5819-7f13-4348-899b-6ae92c8f62e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b45c114f-396f-4caa-a244-1feb0c4466e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d75a5819-7f13-4348-899b-6ae92c8f62e3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b45c114f-396f-4caa-a244-1feb0c4466e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b45c114f-396f-4caa-a244-1feb0c4466e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b45c114f-396f-4caa-a244-1feb0c4466e7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b45c114f-396f-4caa-a244-1feb0c4466e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_41261eed-d75e-41b8-9151-6ac37c27f8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b45c114f-396f-4caa-a244-1feb0c4466e7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_41261eed-d75e-41b8-9151-6ac37c27f8fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_26f6d904-2d41-46b5-99f1-d5c1c00891f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_41261eed-d75e-41b8-9151-6ac37c27f8fa" xlink:to="loc_us-gaap_IPOMember_26f6d904-2d41-46b5-99f1-d5c1c00891f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_46fc7dee-0906-4979-86a7-c816acd5af17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_41261eed-d75e-41b8-9151-6ac37c27f8fa" xlink:to="loc_us-gaap_PrivatePlacementMember_46fc7dee-0906-4979-86a7-c816acd5af17" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="angn-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i9972bfa3c7ac49e6aadfe966d0b85db3_ConsolidatedStatementsofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1f20e4ef-9a76-4be4-ad0a-588211b531d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockRetired_26ac28a6-6b8c-43b2-8049-a597a60c1156" xlink:href="angn-20211231.xsd#angn_StockRetired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1f20e4ef-9a76-4be4-ad0a-588211b531d6" xlink:to="loc_angn_StockRetired_26ac28a6-6b8c-43b2-8049-a597a60c1156" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_cfcc8235-1d3c-4316-90c6-ff67b9b2505e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1f20e4ef-9a76-4be4-ad0a-588211b531d6" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_cfcc8235-1d3c-4316-90c6-ff67b9b2505e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_69f24de2-bad1-4ec6-83c1-3cefc2be5632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1f20e4ef-9a76-4be4-ad0a-588211b531d6" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_69f24de2-bad1-4ec6-83c1-3cefc2be5632" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsExercised_eda17360-969a-4f2a-9299-35ce9ff92267" xlink:href="angn-20211231.xsd#angn_WarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1f20e4ef-9a76-4be4-ad0a-588211b531d6" xlink:to="loc_angn_WarrantsExercised_eda17360-969a-4f2a-9299-35ce9ff92267" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_IssuanceOfBrokerWarrants_4927b69e-04fb-4d0d-ad88-7ac1ffcb7902" xlink:href="angn-20211231.xsd#angn_IssuanceOfBrokerWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1f20e4ef-9a76-4be4-ad0a-588211b531d6" xlink:to="loc_angn_IssuanceOfBrokerWarrants_4927b69e-04fb-4d0d-ad88-7ac1ffcb7902" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AccruedInterestPremiumForConvertiblePreferredStock_46ae1244-d1bf-4417-9576-06b5d882fb65" xlink:href="angn-20211231.xsd#angn_AccruedInterestPremiumForConvertiblePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1f20e4ef-9a76-4be4-ad0a-588211b531d6" xlink:to="loc_angn_AccruedInterestPremiumForConvertiblePreferredStock_46ae1244-d1bf-4417-9576-06b5d882fb65" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_cbb6b51b-a861-4f00-8656-d4a8080f90b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1f20e4ef-9a76-4be4-ad0a-588211b531d6" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_cbb6b51b-a861-4f00-8656-d4a8080f90b0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesIssued1_34682de0-54c4-47e0-95fe-d148a76e4965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1f20e4ef-9a76-4be4-ad0a-588211b531d6" xlink:to="loc_us-gaap_NotesIssued1_34682de0-54c4-47e0-95fe-d148a76e4965" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_0717bcfd-7eb7-46ad-9401-9ed4c5c53859" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1f20e4ef-9a76-4be4-ad0a-588211b531d6" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_0717bcfd-7eb7-46ad-9401-9ed4c5c53859" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_e63b0edb-668f-48a2-aed8-364fcd97b007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1f20e4ef-9a76-4be4-ad0a-588211b531d6" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_e63b0edb-668f-48a2-aed8-364fcd97b007" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e3ba295f-a6a1-46f4-a700-b1996d26a54c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1f20e4ef-9a76-4be4-ad0a-588211b531d6" xlink:to="loc_us-gaap_StatementTable_e3ba295f-a6a1-46f4-a700-b1996d26a54c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_91b70b6c-a3fd-46d9-bf28-01d12b7a060b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e3ba295f-a6a1-46f4-a700-b1996d26a54c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_91b70b6c-a3fd-46d9-bf28-01d12b7a060b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_91b70b6c-a3fd-46d9-bf28-01d12b7a060b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_91b70b6c-a3fd-46d9-bf28-01d12b7a060b" xlink:to="loc_us-gaap_ClassOfStockDomain_91b70b6c-a3fd-46d9-bf28-01d12b7a060b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b84e9c6d-4ed5-46f4-a66a-e44a833e90c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_91b70b6c-a3fd-46d9-bf28-01d12b7a060b" xlink:to="loc_us-gaap_ClassOfStockDomain_b84e9c6d-4ed5-46f4-a66a-e44a833e90c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3cb86f8b-54fa-4317-83eb-a46f2238fdcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b84e9c6d-4ed5-46f4-a66a-e44a833e90c8" xlink:to="loc_us-gaap_CommonStockMember_3cb86f8b-54fa-4317-83eb-a46f2238fdcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_e7e6ca12-fafa-401b-9d9f-201da472e271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_b84e9c6d-4ed5-46f4-a66a-e44a833e90c8" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_e7e6ca12-fafa-401b-9d9f-201da472e271" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2d4d2980-7f5d-4c72-ac8c-27dfbb0fac3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e3ba295f-a6a1-46f4-a700-b1996d26a54c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2d4d2980-7f5d-4c72-ac8c-27dfbb0fac3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2d4d2980-7f5d-4c72-ac8c-27dfbb0fac3b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2d4d2980-7f5d-4c72-ac8c-27dfbb0fac3b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2d4d2980-7f5d-4c72-ac8c-27dfbb0fac3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1c229568-11cc-4069-968c-4854bbe054dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2d4d2980-7f5d-4c72-ac8c-27dfbb0fac3b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1c229568-11cc-4069-968c-4854bbe054dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NonIPORelatedStockTransactionsMember_9e446231-4dab-455b-aea0-8b8973a31cbb" xlink:href="angn-20211231.xsd#angn_NonIPORelatedStockTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1c229568-11cc-4069-968c-4854bbe054dd" xlink:to="loc_angn_NonIPORelatedStockTransactionsMember_9e446231-4dab-455b-aea0-8b8973a31cbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_5a0b3331-1743-4939-b326-e2788554ec9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1c229568-11cc-4069-968c-4854bbe054dd" xlink:to="loc_us-gaap_IPOMember_5a0b3331-1743-4939-b326-e2788554ec9d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#DescriptionoftheBusinessandFinancialConditionDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails" xlink:type="extended" id="i828c0915a1ce4ab0848ea94c81a3691e_DescriptionoftheBusinessandFinancialConditionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_43b65d80-24ed-4a69-a330-7f5d195506dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_69940247-cc6a-43ed-91ef-6723afaae0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_43b65d80-24ed-4a69-a330-7f5d195506dd" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_69940247-cc6a-43ed-91ef-6723afaae0f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_352f6a09-6578-46be-96cf-341f74f2bf85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_43b65d80-24ed-4a69-a330-7f5d195506dd" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_352f6a09-6578-46be-96cf-341f74f2bf85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_7b1957e5-f3c4-48c2-973b-71e2f462b5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_43b65d80-24ed-4a69-a330-7f5d195506dd" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_7b1957e5-f3c4-48c2-973b-71e2f462b5d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6fc26c0e-e1b9-422a-b76e-e3342c553ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_43b65d80-24ed-4a69-a330-7f5d195506dd" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6fc26c0e-e1b9-422a-b76e-e3342c553ba7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_cf45d1b8-b800-4200-8535-48ceac6c65c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_43b65d80-24ed-4a69-a330-7f5d195506dd" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_cf45d1b8-b800-4200-8535-48ceac6c65c9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_ac54bf03-0f2c-4e76-8b70-85d5d313c61b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_43b65d80-24ed-4a69-a330-7f5d195506dd" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_ac54bf03-0f2c-4e76-8b70-85d5d313c61b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_374580d4-6733-4880-ba87-c1d87632de0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_43b65d80-24ed-4a69-a330-7f5d195506dd" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_374580d4-6733-4880-ba87-c1d87632de0b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a206c4ff-0333-4fe4-a1a1-d5221e17e3be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_43b65d80-24ed-4a69-a330-7f5d195506dd" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a206c4ff-0333-4fe4-a1a1-d5221e17e3be" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_29003467-dba3-4789-a7d2-8cbc7d2b90b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_43b65d80-24ed-4a69-a330-7f5d195506dd" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_29003467-dba3-4789-a7d2-8cbc7d2b90b8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e0aabe29-e964-4f70-aec6-1893ece94e37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_43b65d80-24ed-4a69-a330-7f5d195506dd" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e0aabe29-e964-4f70-aec6-1893ece94e37" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f61b769f-2808-444f-8cc0-2ba4fd804a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_43b65d80-24ed-4a69-a330-7f5d195506dd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f61b769f-2808-444f-8cc0-2ba4fd804a5d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a0058d57-704a-4da3-9477-411e13ab1b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_43b65d80-24ed-4a69-a330-7f5d195506dd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a0058d57-704a-4da3-9477-411e13ab1b2c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_f79c6593-1fda-472d-901a-388a6acd3e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_43b65d80-24ed-4a69-a330-7f5d195506dd" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_f79c6593-1fda-472d-901a-388a6acd3e8c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_20994b65-a3d8-4c68-9061-c6193c5787d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_f79c6593-1fda-472d-901a-388a6acd3e8c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_20994b65-a3d8-4c68-9061-c6193c5787d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20994b65-a3d8-4c68-9061-c6193c5787d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_20994b65-a3d8-4c68-9061-c6193c5787d0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_20994b65-a3d8-4c68-9061-c6193c5787d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f199b9c0-4e19-4dbc-8737-822937d207fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_20994b65-a3d8-4c68-9061-c6193c5787d0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f199b9c0-4e19-4dbc-8737-822937d207fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_641b4825-cf02-4f3b-abd7-fc4e7b44510c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f199b9c0-4e19-4dbc-8737-822937d207fa" xlink:to="loc_us-gaap_IPOMember_641b4825-cf02-4f3b-abd7-fc4e7b44510c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_e21d2672-3cd8-4acc-9e3d-b6c58ada4ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f199b9c0-4e19-4dbc-8737-822937d207fa" xlink:to="loc_us-gaap_OverAllotmentOptionMember_e21d2672-3cd8-4acc-9e3d-b6c58ada4ed4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_d0488fed-4396-4b02-a428-3843643b7afb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f199b9c0-4e19-4dbc-8737-822937d207fa" xlink:to="loc_us-gaap_PrivatePlacementMember_d0488fed-4396-4b02-a428-3843643b7afb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_IPOAndPrivatePlacementMember_936cc4e6-a217-4711-bc6a-d1b6ad36255e" xlink:href="angn-20211231.xsd#angn_IPOAndPrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f199b9c0-4e19-4dbc-8737-822937d207fa" xlink:to="loc_angn_IPOAndPrivatePlacementMember_936cc4e6-a217-4711-bc6a-d1b6ad36255e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7f69edd5-0071-4e6d-bca1-f2c464470de3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_f79c6593-1fda-472d-901a-388a6acd3e8c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7f69edd5-0071-4e6d-bca1-f2c464470de3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7f69edd5-0071-4e6d-bca1-f2c464470de3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7f69edd5-0071-4e6d-bca1-f2c464470de3" xlink:to="loc_us-gaap_ClassOfStockDomain_7f69edd5-0071-4e6d-bca1-f2c464470de3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4704118c-9b85-4d49-b64a-e41a45f53731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7f69edd5-0071-4e6d-bca1-f2c464470de3" xlink:to="loc_us-gaap_ClassOfStockDomain_4704118c-9b85-4d49-b64a-e41a45f53731" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_3d19e61a-5b5b-45ee-9831-8ab10fa3e45e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4704118c-9b85-4d49-b64a-e41a45f53731" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_3d19e61a-5b5b-45ee-9831-8ab10fa3e45e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="iea86e6e43728405d981a70f221641661_SummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dbfad555-2274-4f06-93c0-6dbd103020e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_e99b449a-8dac-4192-87c3-42ae898aa350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dbfad555-2274-4f06-93c0-6dbd103020e2" xlink:to="loc_us-gaap_NumberOfOperatingSegments_e99b449a-8dac-4192-87c3-42ae898aa350" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_13ad08bd-2619-4e0d-b914-3d96ad2efa33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dbfad555-2274-4f06-93c0-6dbd103020e2" xlink:to="loc_us-gaap_DeferredOfferingCosts_13ad08bd-2619-4e0d-b914-3d96ad2efa33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d250cd7a-5550-45c0-a28b-01a7473c1123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dbfad555-2274-4f06-93c0-6dbd103020e2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d250cd7a-5550-45c0-a28b-01a7473c1123" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_469b58f4-fd38-4754-a284-9368784db1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dbfad555-2274-4f06-93c0-6dbd103020e2" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_469b58f4-fd38-4754-a284-9368784db1fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_83f135a9-aa2d-4a4d-b40a-670336354117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dbfad555-2274-4f06-93c0-6dbd103020e2" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_83f135a9-aa2d-4a4d-b40a-670336354117" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OtherInvestmentAndSecuritiesAtCostOwnershipPercentage_eee1883c-3338-4ae5-8605-af8401d9904d" xlink:href="angn-20211231.xsd#angn_OtherInvestmentAndSecuritiesAtCostOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dbfad555-2274-4f06-93c0-6dbd103020e2" xlink:to="loc_angn_OtherInvestmentAndSecuritiesAtCostOwnershipPercentage_eee1883c-3338-4ae5-8605-af8401d9904d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NumberOfRelatedPartyEntities_362d9482-ee59-424f-af9c-0e0ae06fb147" xlink:href="angn-20211231.xsd#angn_NumberOfRelatedPartyEntities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dbfad555-2274-4f06-93c0-6dbd103020e2" xlink:to="loc_angn_NumberOfRelatedPartyEntities_362d9482-ee59-424f-af9c-0e0ae06fb147" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_f62a6b7b-0ed2-4867-ac6b-397cccfeba5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dbfad555-2274-4f06-93c0-6dbd103020e2" xlink:to="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_f62a6b7b-0ed2-4867-ac6b-397cccfeba5b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_034d19c5-2188-49fd-98c5-d57f770b3198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dbfad555-2274-4f06-93c0-6dbd103020e2" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_034d19c5-2188-49fd-98c5-d57f770b3198" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_fea3ec98-d0f9-4f0f-8529-594f013f5cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dbfad555-2274-4f06-93c0-6dbd103020e2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_fea3ec98-d0f9-4f0f-8529-594f013f5cc2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b091fa12-93fb-426e-b625-b68a52fa7b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dbfad555-2274-4f06-93c0-6dbd103020e2" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b091fa12-93fb-426e-b625-b68a52fa7b6a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ae99c02d-812f-4bdd-af68-1acbf8ee992d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b091fa12-93fb-426e-b625-b68a52fa7b6a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ae99c02d-812f-4bdd-af68-1acbf8ee992d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ae99c02d-812f-4bdd-af68-1acbf8ee992d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ae99c02d-812f-4bdd-af68-1acbf8ee992d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ae99c02d-812f-4bdd-af68-1acbf8ee992d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d3f06325-07ed-43c4-8750-04daddab040b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ae99c02d-812f-4bdd-af68-1acbf8ee992d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d3f06325-07ed-43c4-8750-04daddab040b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_c89e1d2d-fbb8-4795-affb-61b28ce74a29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d3f06325-07ed-43c4-8750-04daddab040b" xlink:to="loc_us-gaap_EquipmentMember_c89e1d2d-fbb8-4795-affb-61b28ce74a29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_a7245195-0238-45ab-a37c-3f56e6d96774" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d3f06325-07ed-43c4-8750-04daddab040b" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_a7245195-0238-45ab-a37c-3f56e6d96774" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0b8a6739-cbf6-4fae-9c0d-5c43c719598b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b091fa12-93fb-426e-b625-b68a52fa7b6a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0b8a6739-cbf6-4fae-9c0d-5c43c719598b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_0b8a6739-cbf6-4fae-9c0d-5c43c719598b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0b8a6739-cbf6-4fae-9c0d-5c43c719598b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_0b8a6739-cbf6-4fae-9c0d-5c43c719598b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b27513ae-cb5e-427a-8d1d-3c5f6993ee31" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0b8a6739-cbf6-4fae-9c0d-5c43c719598b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b27513ae-cb5e-427a-8d1d-3c5f6993ee31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NovaParkMember_27018dc7-97f5-4e3f-ab20-2433c64d7e6c" xlink:href="angn-20211231.xsd#angn_NovaParkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b27513ae-cb5e-427a-8d1d-3c5f6993ee31" xlink:to="loc_angn_NovaParkMember_27018dc7-97f5-4e3f-ab20-2433c64d7e6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OhrCosmeticsLLCMember_7211ee7a-c21f-4690-9164-c227f15c8457" xlink:href="angn-20211231.xsd#angn_OhrCosmeticsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b27513ae-cb5e-427a-8d1d-3c5f6993ee31" xlink:to="loc_angn_OhrCosmeticsLLCMember_7211ee7a-c21f-4690-9164-c227f15c8457" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fd083d42-4b03-411e-a67a-20aed33caa93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b091fa12-93fb-426e-b625-b68a52fa7b6a" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fd083d42-4b03-411e-a67a-20aed33caa93" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_fd083d42-4b03-411e-a67a-20aed33caa93_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fd083d42-4b03-411e-a67a-20aed33caa93" xlink:to="loc_us-gaap_RelatedPartyDomain_fd083d42-4b03-411e-a67a-20aed33caa93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a9702342-b151-4423-8e4d-36b3691e3736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fd083d42-4b03-411e-a67a-20aed33caa93" xlink:to="loc_us-gaap_RelatedPartyDomain_a9702342-b151-4423-8e4d-36b3691e3736" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember_0a4790a4-e8bd-4e82-bcea-da98d6361467" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_a9702342-b151-4423-8e4d-36b3691e3736" xlink:to="loc_us-gaap_EquityMethodInvesteeMember_0a4790a4-e8bd-4e82-bcea-da98d6361467" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_78a16a16-5dae-43ba-b80e-45f5e065c153" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b091fa12-93fb-426e-b625-b68a52fa7b6a" xlink:to="loc_srt_OwnershipAxis_78a16a16-5dae-43ba-b80e-45f5e065c153" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_78a16a16-5dae-43ba-b80e-45f5e065c153_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_78a16a16-5dae-43ba-b80e-45f5e065c153" xlink:to="loc_srt_OwnershipDomain_78a16a16-5dae-43ba-b80e-45f5e065c153_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_18de9098-988b-4666-840e-4e8d635a76e6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_78a16a16-5dae-43ba-b80e-45f5e065c153" xlink:to="loc_srt_OwnershipDomain_18de9098-988b-4666-840e-4e8d635a76e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OhrCosmeticsLLCMember_096e93e0-296d-442b-b3e7-c8cf1585e4b8" xlink:href="angn-20211231.xsd#angn_OhrCosmeticsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_18de9098-988b-4666-840e-4e8d635a76e6" xlink:to="loc_angn_OhrCosmeticsLLCMember_096e93e0-296d-442b-b3e7-c8cf1585e4b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_e32aa65a-c3e9-4c44-b559-19cb1bb20022" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b091fa12-93fb-426e-b625-b68a52fa7b6a" xlink:to="loc_srt_TitleOfIndividualAxis_e32aa65a-c3e9-4c44-b559-19cb1bb20022" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e32aa65a-c3e9-4c44-b559-19cb1bb20022_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_e32aa65a-c3e9-4c44-b559-19cb1bb20022" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e32aa65a-c3e9-4c44-b559-19cb1bb20022_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_97a65700-63c7-4c66-b58d-935811e5c758" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_e32aa65a-c3e9-4c44-b559-19cb1bb20022" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_97a65700-63c7-4c66-b58d-935811e5c758" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_ed8de4c4-b545-48ff-b8a3-b1142ceedf06" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_97a65700-63c7-4c66-b58d-935811e5c758" xlink:to="loc_srt_ChiefExecutiveOfficerMember_ed8de4c4-b545-48ff-b8a3-b1142ceedf06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1f59dd55-0ffe-4448-be32-6ef47a3226b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b091fa12-93fb-426e-b625-b68a52fa7b6a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1f59dd55-0ffe-4448-be32-6ef47a3226b9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1f59dd55-0ffe-4448-be32-6ef47a3226b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1f59dd55-0ffe-4448-be32-6ef47a3226b9" xlink:to="loc_us-gaap_ClassOfStockDomain_1f59dd55-0ffe-4448-be32-6ef47a3226b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_98ec570a-cba8-49ff-b9ab-b376d691065e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1f59dd55-0ffe-4448-be32-6ef47a3226b9" xlink:to="loc_us-gaap_ClassOfStockDomain_98ec570a-cba8-49ff-b9ab-b376d691065e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_c1f20ea4-5f43-40e4-bb42-60b88d4ebda2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_98ec570a-cba8-49ff-b9ab-b376d691065e" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_c1f20ea4-5f43-40e4-bb42-60b88d4ebda2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/RevenueandDeferredRevenueDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#RevenueandDeferredRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/RevenueandDeferredRevenueDetails" xlink:type="extended" id="ib9781a9e137d41f6aae98461c868ee32_RevenueandDeferredRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_84488bb0-2850-469a-8652-7d6c092f44bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_84488bb0-2850-469a-8652-7d6c092f44bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerUpfrontAndNearTermMilestonePaymentEntitledToReceive_764c3ecb-93f5-41bc-b6f9-420bc687ed52" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerUpfrontAndNearTermMilestonePaymentEntitledToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_ContractWithCustomerUpfrontAndNearTermMilestonePaymentEntitledToReceive_764c3ecb-93f5-41bc-b6f9-420bc687ed52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_c355edb8-9f72-4284-8890-e6b10c442c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_c355edb8-9f72-4284-8890-e6b10c442c15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_9728e159-0e84-4772-ab82-d6ace6595acf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_9728e159-0e84-4772-ab82-d6ace6595acf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_687534ff-580f-49db-b2a8-d8d9903fece5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_687534ff-580f-49db-b2a8-d8d9903fece5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerPostApprovalMilestonePaymentEntitledToReceive_d54c53b4-6f02-4d83-b0cf-3dbb1c0aee04" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerPostApprovalMilestonePaymentEntitledToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_ContractWithCustomerPostApprovalMilestonePaymentEntitledToReceive_d54c53b4-6f02-4d83-b0cf-3dbb1c0aee04" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerSalesRelatedMilestonePaymentEntitledToReceive_c4b0b4a0-82f0-44e1-9ed3-e8fc15209a2a" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerSalesRelatedMilestonePaymentEntitledToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_ContractWithCustomerSalesRelatedMilestonePaymentEntitledToReceive_c4b0b4a0-82f0-44e1-9ed3-e8fc15209a2a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerMilestonePaymentsEntitledToReceive_f6ca7d66-2ffa-4c63-aff7-f0635addca82" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerMilestonePaymentsEntitledToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_ContractWithCustomerMilestonePaymentsEntitledToReceive_f6ca7d66-2ffa-4c63-aff7-f0635addca82" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerRoyaltyRatesMaximum_98ace0e9-4641-4179-a06d-1205c81bba56" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerRoyaltyRatesMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_ContractWithCustomerRoyaltyRatesMaximum_98ace0e9-4641-4179-a06d-1205c81bba56" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerContractTerminationPeriodCurableBreach_ab9a0830-20d3-48ff-8b25-7f7890e30b90" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerContractTerminationPeriodCurableBreach"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_ContractWithCustomerContractTerminationPeriodCurableBreach_ab9a0830-20d3-48ff-8b25-7f7890e30b90" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerContractTerminationPeriodIncurableBreach_7a79e74d-f764-4039-957b-bbfc8511360a" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerContractTerminationPeriodIncurableBreach"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_ContractWithCustomerContractTerminationPeriodIncurableBreach_7a79e74d-f764-4039-957b-bbfc8511360a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_f2d2be3c-08aa-485d-a69c-00acd2a3a0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_f2d2be3c-08aa-485d-a69c-00acd2a3a0f7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerLiabilityPercentOfUpfrontPayment_43c78379-0049-4dd9-9ff2-0884fe4f025d" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerLiabilityPercentOfUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_ContractWithCustomerLiabilityPercentOfUpfrontPayment_43c78379-0049-4dd9-9ff2-0884fe4f025d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_9a9d75ab-5048-45d2-a1bf-b60bed5133df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_9a9d75ab-5048-45d2-a1bf-b60bed5133df" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_RevenueFromContractWithCustomerIncludingAssessedTaxIncrease_a0893fc4-f94a-4ce3-8d08-9e0655f49386" xlink:href="angn-20211231.xsd#angn_RevenueFromContractWithCustomerIncludingAssessedTaxIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_RevenueFromContractWithCustomerIncludingAssessedTaxIncrease_a0893fc4-f94a-4ce3-8d08-9e0655f49386" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NetIncomeLossAttributableToParentIncrease_c6ccbae8-a239-48f2-bd55-4bfa2981cabc" xlink:href="angn-20211231.xsd#angn_NetIncomeLossAttributableToParentIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_NetIncomeLossAttributableToParentIncrease_c6ccbae8-a239-48f2-bd55-4bfa2981cabc" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EarningsPerShareBasicIncrease_d165f298-fa5d-403d-9bff-1f8bba9225d7" xlink:href="angn-20211231.xsd#angn_EarningsPerShareBasicIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_EarningsPerShareBasicIncrease_d165f298-fa5d-403d-9bff-1f8bba9225d7" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EarningsPerShareDilutedIncrease_a601842f-4363-441e-96ef-63c96f750835" xlink:href="angn-20211231.xsd#angn_EarningsPerShareDilutedIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_EarningsPerShareDilutedIncrease_a601842f-4363-441e-96ef-63c96f750835" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_95e08fcf-3307-421c-9ed1-20409d447eff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_95e08fcf-3307-421c-9ed1-20409d447eff" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_17faf22c-4792-424a-837b-0f6902a7e316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_17faf22c-4792-424a-837b-0f6902a7e316" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_005fa8a2-6086-4729-8155-91570456c3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_005fa8a2-6086-4729-8155-91570456c3c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_194ecea8-1e83-42b7-a6da-81dc431063e1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_005fa8a2-6086-4729-8155-91570456c3c9" xlink:to="loc_srt_CounterpartyNameAxis_194ecea8-1e83-42b7-a6da-81dc431063e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_194ecea8-1e83-42b7-a6da-81dc431063e1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_194ecea8-1e83-42b7-a6da-81dc431063e1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_194ecea8-1e83-42b7-a6da-81dc431063e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6a97f2cb-e477-4080-99fd-1f74e4bbe171" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_194ecea8-1e83-42b7-a6da-81dc431063e1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6a97f2cb-e477-4080-99fd-1f74e4bbe171" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ViforPharmaMember_4be88839-5049-40eb-87b6-0209bf0eb8e3" xlink:href="angn-20211231.xsd#angn_ViforPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6a97f2cb-e477-4080-99fd-1f74e4bbe171" xlink:to="loc_angn_ViforPharmaMember_4be88839-5049-40eb-87b6-0209bf0eb8e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dcf0a555-5f55-4136-b4ed-ba7e387bd13e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_005fa8a2-6086-4729-8155-91570456c3c9" xlink:to="loc_srt_ProductOrServiceAxis_dcf0a555-5f55-4136-b4ed-ba7e387bd13e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dcf0a555-5f55-4136-b4ed-ba7e387bd13e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_dcf0a555-5f55-4136-b4ed-ba7e387bd13e" xlink:to="loc_srt_ProductsAndServicesDomain_dcf0a555-5f55-4136-b4ed-ba7e387bd13e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_abf9ba6d-22ed-44bd-bf3a-b00a8eefbc7a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_dcf0a555-5f55-4136-b4ed-ba7e387bd13e" xlink:to="loc_srt_ProductsAndServicesDomain_abf9ba6d-22ed-44bd-bf3a-b00a8eefbc7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_91f064cf-30f3-4c05-82e4-6bd2b7b73a90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_abf9ba6d-22ed-44bd-bf3a-b00a8eefbc7a" xlink:to="loc_us-gaap_LicenseMember_91f064cf-30f3-4c05-82e4-6bd2b7b73a90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e095e1b2-7893-4615-be99-4393c31ab5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_005fa8a2-6086-4729-8155-91570456c3c9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e095e1b2-7893-4615-be99-4393c31ab5fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e095e1b2-7893-4615-be99-4393c31ab5fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e095e1b2-7893-4615-be99-4393c31ab5fb" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e095e1b2-7893-4615-be99-4393c31ab5fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_588f2f54-f2ff-4242-8b06-7cdf74d2db6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e095e1b2-7893-4615-be99-4393c31ab5fb" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_588f2f54-f2ff-4242-8b06-7cdf74d2db6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_29a45761-3989-429a-9919-6b1f73afc7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_588f2f54-f2ff-4242-8b06-7cdf74d2db6f" xlink:to="loc_us-gaap_IPOMember_29a45761-3989-429a-9919-6b1f73afc7b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_59ba48f6-b399-4d18-b678-b1300d9b197e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_588f2f54-f2ff-4242-8b06-7cdf74d2db6f" xlink:to="loc_us-gaap_PrivatePlacementMember_59ba48f6-b399-4d18-b678-b1300d9b197e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_98d139aa-bebc-4737-b613-d1a035688020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_005fa8a2-6086-4729-8155-91570456c3c9" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_98d139aa-bebc-4737-b613-d1a035688020" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/RevenueandDeferredRevenueDetails_1" xlink:type="simple" xlink:href="angn-20211231.xsd#RevenueandDeferredRevenueDetails_1"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/RevenueandDeferredRevenueDetails_1" xlink:type="extended" id="i26d19dec940d4fdb829d4dfb3f9ba082_RevenueandDeferredRevenueDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_84488bb0-2850-469a-8652-7d6c092f44bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_84488bb0-2850-469a-8652-7d6c092f44bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerUpfrontAndNearTermMilestonePaymentEntitledToReceive_764c3ecb-93f5-41bc-b6f9-420bc687ed52" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerUpfrontAndNearTermMilestonePaymentEntitledToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_ContractWithCustomerUpfrontAndNearTermMilestonePaymentEntitledToReceive_764c3ecb-93f5-41bc-b6f9-420bc687ed52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_c355edb8-9f72-4284-8890-e6b10c442c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_c355edb8-9f72-4284-8890-e6b10c442c15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_9728e159-0e84-4772-ab82-d6ace6595acf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_9728e159-0e84-4772-ab82-d6ace6595acf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_687534ff-580f-49db-b2a8-d8d9903fece5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_687534ff-580f-49db-b2a8-d8d9903fece5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerPostApprovalMilestonePaymentEntitledToReceive_d54c53b4-6f02-4d83-b0cf-3dbb1c0aee04" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerPostApprovalMilestonePaymentEntitledToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_ContractWithCustomerPostApprovalMilestonePaymentEntitledToReceive_d54c53b4-6f02-4d83-b0cf-3dbb1c0aee04" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerSalesRelatedMilestonePaymentEntitledToReceive_c4b0b4a0-82f0-44e1-9ed3-e8fc15209a2a" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerSalesRelatedMilestonePaymentEntitledToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_ContractWithCustomerSalesRelatedMilestonePaymentEntitledToReceive_c4b0b4a0-82f0-44e1-9ed3-e8fc15209a2a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerMilestonePaymentsEntitledToReceive_f6ca7d66-2ffa-4c63-aff7-f0635addca82" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerMilestonePaymentsEntitledToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_ContractWithCustomerMilestonePaymentsEntitledToReceive_f6ca7d66-2ffa-4c63-aff7-f0635addca82" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerRoyaltyRatesMaximum_98ace0e9-4641-4179-a06d-1205c81bba56" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerRoyaltyRatesMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_ContractWithCustomerRoyaltyRatesMaximum_98ace0e9-4641-4179-a06d-1205c81bba56" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerContractTerminationPeriodCurableBreach_ab9a0830-20d3-48ff-8b25-7f7890e30b90" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerContractTerminationPeriodCurableBreach"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_ContractWithCustomerContractTerminationPeriodCurableBreach_ab9a0830-20d3-48ff-8b25-7f7890e30b90" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerContractTerminationPeriodIncurableBreach_7a79e74d-f764-4039-957b-bbfc8511360a" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerContractTerminationPeriodIncurableBreach"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_ContractWithCustomerContractTerminationPeriodIncurableBreach_7a79e74d-f764-4039-957b-bbfc8511360a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_f2d2be3c-08aa-485d-a69c-00acd2a3a0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_f2d2be3c-08aa-485d-a69c-00acd2a3a0f7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerLiabilityPercentOfUpfrontPayment_43c78379-0049-4dd9-9ff2-0884fe4f025d" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerLiabilityPercentOfUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_ContractWithCustomerLiabilityPercentOfUpfrontPayment_43c78379-0049-4dd9-9ff2-0884fe4f025d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_9a9d75ab-5048-45d2-a1bf-b60bed5133df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_9a9d75ab-5048-45d2-a1bf-b60bed5133df" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_RevenueFromContractWithCustomerIncludingAssessedTaxIncrease_a0893fc4-f94a-4ce3-8d08-9e0655f49386" xlink:href="angn-20211231.xsd#angn_RevenueFromContractWithCustomerIncludingAssessedTaxIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_RevenueFromContractWithCustomerIncludingAssessedTaxIncrease_a0893fc4-f94a-4ce3-8d08-9e0655f49386" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NetIncomeLossAttributableToParentIncrease_c6ccbae8-a239-48f2-bd55-4bfa2981cabc" xlink:href="angn-20211231.xsd#angn_NetIncomeLossAttributableToParentIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_NetIncomeLossAttributableToParentIncrease_c6ccbae8-a239-48f2-bd55-4bfa2981cabc" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EarningsPerShareBasicIncrease_d165f298-fa5d-403d-9bff-1f8bba9225d7" xlink:href="angn-20211231.xsd#angn_EarningsPerShareBasicIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_EarningsPerShareBasicIncrease_d165f298-fa5d-403d-9bff-1f8bba9225d7" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EarningsPerShareDilutedIncrease_a601842f-4363-441e-96ef-63c96f750835" xlink:href="angn-20211231.xsd#angn_EarningsPerShareDilutedIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_EarningsPerShareDilutedIncrease_a601842f-4363-441e-96ef-63c96f750835" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_95e08fcf-3307-421c-9ed1-20409d447eff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_95e08fcf-3307-421c-9ed1-20409d447eff" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_17faf22c-4792-424a-837b-0f6902a7e316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_17faf22c-4792-424a-837b-0f6902a7e316" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_005fa8a2-6086-4729-8155-91570456c3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_005fa8a2-6086-4729-8155-91570456c3c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_194ecea8-1e83-42b7-a6da-81dc431063e1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_005fa8a2-6086-4729-8155-91570456c3c9" xlink:to="loc_srt_CounterpartyNameAxis_194ecea8-1e83-42b7-a6da-81dc431063e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_194ecea8-1e83-42b7-a6da-81dc431063e1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_194ecea8-1e83-42b7-a6da-81dc431063e1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_194ecea8-1e83-42b7-a6da-81dc431063e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6a97f2cb-e477-4080-99fd-1f74e4bbe171" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_194ecea8-1e83-42b7-a6da-81dc431063e1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6a97f2cb-e477-4080-99fd-1f74e4bbe171" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ViforPharmaMember_4be88839-5049-40eb-87b6-0209bf0eb8e3" xlink:href="angn-20211231.xsd#angn_ViforPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6a97f2cb-e477-4080-99fd-1f74e4bbe171" xlink:to="loc_angn_ViforPharmaMember_4be88839-5049-40eb-87b6-0209bf0eb8e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dcf0a555-5f55-4136-b4ed-ba7e387bd13e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_005fa8a2-6086-4729-8155-91570456c3c9" xlink:to="loc_srt_ProductOrServiceAxis_dcf0a555-5f55-4136-b4ed-ba7e387bd13e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dcf0a555-5f55-4136-b4ed-ba7e387bd13e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_dcf0a555-5f55-4136-b4ed-ba7e387bd13e" xlink:to="loc_srt_ProductsAndServicesDomain_dcf0a555-5f55-4136-b4ed-ba7e387bd13e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_abf9ba6d-22ed-44bd-bf3a-b00a8eefbc7a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_dcf0a555-5f55-4136-b4ed-ba7e387bd13e" xlink:to="loc_srt_ProductsAndServicesDomain_abf9ba6d-22ed-44bd-bf3a-b00a8eefbc7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_91f064cf-30f3-4c05-82e4-6bd2b7b73a90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_abf9ba6d-22ed-44bd-bf3a-b00a8eefbc7a" xlink:to="loc_us-gaap_LicenseMember_91f064cf-30f3-4c05-82e4-6bd2b7b73a90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e095e1b2-7893-4615-be99-4393c31ab5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_005fa8a2-6086-4729-8155-91570456c3c9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e095e1b2-7893-4615-be99-4393c31ab5fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e095e1b2-7893-4615-be99-4393c31ab5fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e095e1b2-7893-4615-be99-4393c31ab5fb" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e095e1b2-7893-4615-be99-4393c31ab5fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_588f2f54-f2ff-4242-8b06-7cdf74d2db6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e095e1b2-7893-4615-be99-4393c31ab5fb" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_588f2f54-f2ff-4242-8b06-7cdf74d2db6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_29a45761-3989-429a-9919-6b1f73afc7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_588f2f54-f2ff-4242-8b06-7cdf74d2db6f" xlink:to="loc_us-gaap_IPOMember_29a45761-3989-429a-9919-6b1f73afc7b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_59ba48f6-b399-4d18-b678-b1300d9b197e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_588f2f54-f2ff-4242-8b06-7cdf74d2db6f" xlink:to="loc_us-gaap_PrivatePlacementMember_59ba48f6-b399-4d18-b678-b1300d9b197e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended" id="i71f365daa2a44c719634221854ca775e_FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_eedfa85c-4229-4584-82d5-4d04243cad35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_d7095338-51ca-4cee-9dee-42ad9ba59ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_eedfa85c-4229-4584-82d5-4d04243cad35" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_d7095338-51ca-4cee-9dee-42ad9ba59ee4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3708986b-7212-4327-be26-19ed48dfc9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d7095338-51ca-4cee-9dee-42ad9ba59ee4" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3708986b-7212-4327-be26-19ed48dfc9ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4e284174-61ec-4b4f-8cd6-0722b59ada16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d7095338-51ca-4cee-9dee-42ad9ba59ee4" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_4e284174-61ec-4b4f-8cd6-0722b59ada16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_62afe0f8-728e-453b-8e2b-344215e88556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_eedfa85c-4229-4584-82d5-4d04243cad35" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_62afe0f8-728e-453b-8e2b-344215e88556" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_606fca8c-8769-4cd7-accc-9543fff5a4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_62afe0f8-728e-453b-8e2b-344215e88556" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_606fca8c-8769-4cd7-accc-9543fff5a4b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsFairValueDisclosure_9fc80ad5-655a-400c-8a97-f9dea70a2ecf" xlink:href="angn-20211231.xsd#angn_WarrantsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_62afe0f8-728e-453b-8e2b-344215e88556" xlink:to="loc_angn_WarrantsFairValueDisclosure_9fc80ad5-655a-400c-8a97-f9dea70a2ecf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent_39f01bef-86cb-4385-86a6-db5509e7e1b9" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_62afe0f8-728e-453b-8e2b-344215e88556" xlink:to="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent_39f01bef-86cb-4385-86a6-db5509e7e1b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_7a9e51b8-fff2-4986-a714-63b035c9618d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_62afe0f8-728e-453b-8e2b-344215e88556" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_7a9e51b8-fff2-4986-a714-63b035c9618d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a7f00ab3-b044-44d4-bb74-2dfaa0778d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_eedfa85c-4229-4584-82d5-4d04243cad35" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a7f00ab3-b044-44d4-bb74-2dfaa0778d4e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_627893d9-8b3b-49bb-9d9b-9e9e8010daab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a7f00ab3-b044-44d4-bb74-2dfaa0778d4e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_627893d9-8b3b-49bb-9d9b-9e9e8010daab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_627893d9-8b3b-49bb-9d9b-9e9e8010daab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_627893d9-8b3b-49bb-9d9b-9e9e8010daab" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_627893d9-8b3b-49bb-9d9b-9e9e8010daab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_79b6cd7b-ae44-4d69-93a5-ad28fefb022d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_627893d9-8b3b-49bb-9d9b-9e9e8010daab" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_79b6cd7b-ae44-4d69-93a5-ad28fefb022d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d929fa02-54e5-4109-a7ad-f0e6313f58c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_79b6cd7b-ae44-4d69-93a5-ad28fefb022d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d929fa02-54e5-4109-a7ad-f0e6313f58c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5459f5be-1f11-4f0a-8fd6-8f145197f3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_79b6cd7b-ae44-4d69-93a5-ad28fefb022d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5459f5be-1f11-4f0a-8fd6-8f145197f3ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c70aeff9-c999-440b-8180-adaaa280f318" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_79b6cd7b-ae44-4d69-93a5-ad28fefb022d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c70aeff9-c999-440b-8180-adaaa280f318" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_169c5ecf-8179-4abe-919b-4992e919a1a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a7f00ab3-b044-44d4-bb74-2dfaa0778d4e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_169c5ecf-8179-4abe-919b-4992e919a1a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_169c5ecf-8179-4abe-919b-4992e919a1a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_169c5ecf-8179-4abe-919b-4992e919a1a5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_169c5ecf-8179-4abe-919b-4992e919a1a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_26ad9fe0-b8af-4195-963a-7b0f59fbb0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_169c5ecf-8179-4abe-919b-4992e919a1a5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_26ad9fe0-b8af-4195-963a-7b0f59fbb0c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_8caabdda-878c-44b8-98c5-3f7b862e607b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_26ad9fe0-b8af-4195-963a-7b0f59fbb0c4" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_8caabdda-878c-44b8-98c5-3f7b862e607b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" xlink:type="extended" id="i79d23dc116b843a0b1f6f25f1f2c1e38_FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8b9a91fd-2a09-4f17-91e2-faaf96c77eae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0e48f61e-1799-48bc-be3c-51f577be383e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8b9a91fd-2a09-4f17-91e2-faaf96c77eae" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0e48f61e-1799-48bc-be3c-51f577be383e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_eecf4f08-4fd8-4cd7-8e96-b69a9edcd277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0e48f61e-1799-48bc-be3c-51f577be383e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_eecf4f08-4fd8-4cd7-8e96-b69a9edcd277" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0a80d8a4-3df5-4202-9a77-f84eb10c3e97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0e48f61e-1799-48bc-be3c-51f577be383e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0a80d8a4-3df5-4202-9a77-f84eb10c3e97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_56b20c84-7013-4bf4-a885-9992d0450bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0e48f61e-1799-48bc-be3c-51f577be383e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_56b20c84-7013-4bf4-a885-9992d0450bb3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_fb03d3c1-8814-4ad0-af8c-939324811cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_78d7afe9-635a-4373-839e-19b00b3478d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8b9a91fd-2a09-4f17-91e2-faaf96c77eae" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_78d7afe9-635a-4373-839e-19b00b3478d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_4f1dba6c-494c-4a49-8131-8e4a507cad19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_78d7afe9-635a-4373-839e-19b00b3478d1" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_4f1dba6c-494c-4a49-8131-8e4a507cad19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4f1dba6c-494c-4a49-8131-8e4a507cad19_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_4f1dba6c-494c-4a49-8131-8e4a507cad19" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_4f1dba6c-494c-4a49-8131-8e4a507cad19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_35cc85d6-08f2-4a58-be4d-805cd0e24d65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_4f1dba6c-494c-4a49-8131-8e4a507cad19" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_35cc85d6-08f2-4a58-be4d-805cd0e24d65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantLiabilityMember_e829bd42-1f7f-4166-989d-8e4885a63049" xlink:href="angn-20211231.xsd#angn_WarrantLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_35cc85d6-08f2-4a58-be4d-805cd0e24d65" xlink:to="loc_angn_WarrantLiabilityMember_e829bd42-1f7f-4166-989d-8e4885a63049" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_c84678e3-e529-455c-bfb3-324756fb87f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_35cc85d6-08f2-4a58-be4d-805cd0e24d65" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_c84678e3-e529-455c-bfb3-324756fb87f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_e630ca17-a933-4bb6-a47b-2904b9af0352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_35cc85d6-08f2-4a58-be4d-805cd0e24d65" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_e630ca17-a933-4bb6-a47b-2904b9af0352" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i658ba98da37a4828b1b9aac3c807b927_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_5a83ece4-417b-4b7f-86f8-b4879d8d505b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_cdfbf638-d230-426a-a7c5-38646ac94479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_5a83ece4-417b-4b7f-86f8-b4879d8d505b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_cdfbf638-d230-426a-a7c5-38646ac94479" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_57c88cda-9c6f-40c9-b175-39bef949efc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_5a83ece4-417b-4b7f-86f8-b4879d8d505b" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_57c88cda-9c6f-40c9-b175-39bef949efc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsConversionPrice_eef7e639-e1ea-475a-a7e6-01b88eb985bb" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_5a83ece4-417b-4b7f-86f8-b4879d8d505b" xlink:to="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsConversionPrice_eef7e639-e1ea-475a-a7e6-01b88eb985bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ca1cd2e1-f147-4ee9-a935-e0cecdcc28ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_5a83ece4-417b-4b7f-86f8-b4879d8d505b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_ca1cd2e1-f147-4ee9-a935-e0cecdcc28ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_20a9039c-0cf6-4583-8bc9-80d8d811eef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_5a83ece4-417b-4b7f-86f8-b4879d8d505b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_20a9039c-0cf6-4583-8bc9-80d8d811eef7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_1067ad5a-82bd-485d-afc4-bf034615456c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_5a83ece4-417b-4b7f-86f8-b4879d8d505b" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_1067ad5a-82bd-485d-afc4-bf034615456c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_bb93058b-58ee-483f-8620-923b8c31e043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_5a83ece4-417b-4b7f-86f8-b4879d8d505b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_bb93058b-58ee-483f-8620-923b8c31e043" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_9bdbce39-d043-4d6a-a3e9-fe814f92d74d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_bb93058b-58ee-483f-8620-923b8c31e043" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_9bdbce39-d043-4d6a-a3e9-fe814f92d74d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_9bdbce39-d043-4d6a-a3e9-fe814f92d74d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_9bdbce39-d043-4d6a-a3e9-fe814f92d74d" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_9bdbce39-d043-4d6a-a3e9-fe814f92d74d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_14ccd30e-d36c-45a5-9fcb-89b883dfd98e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_9bdbce39-d043-4d6a-a3e9-fe814f92d74d" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_14ccd30e-d36c-45a5-9fcb-89b883dfd98e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_1feb665f-cf26-49ad-9b1a-d91a43e4400c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_14ccd30e-d36c-45a5-9fcb-89b883dfd98e" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_1feb665f-cf26-49ad-9b1a-d91a43e4400c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_b8083040-9172-4739-8521-eeba3528d1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_bb93058b-58ee-483f-8620-923b8c31e043" xlink:to="loc_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_b8083040-9172-4739-8521-eeba3528d1ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_b8083040-9172-4739-8521-eeba3528d1ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_b8083040-9172-4739-8521-eeba3528d1ce" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_b8083040-9172-4739-8521-eeba3528d1ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_bf32b464-b399-4362-8ba5-139e74a0b641" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_b8083040-9172-4739-8521-eeba3528d1ce" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_bf32b464-b399-4362-8ba5-139e74a0b641" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSubjectToMandatoryRedemptionMember_0c15d2d4-4dbf-4ba7-8d3d-c50d2e8a2962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSubjectToMandatoryRedemptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_bf32b464-b399-4362-8ba5-139e74a0b641" xlink:to="loc_us-gaap_ConvertiblePreferredStockSubjectToMandatoryRedemptionMember_0c15d2d4-4dbf-4ba7-8d3d-c50d2e8a2962" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0c29dc56-2edd-4e78-b601-38d5e54372c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_bb93058b-58ee-483f-8620-923b8c31e043" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0c29dc56-2edd-4e78-b601-38d5e54372c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0c29dc56-2edd-4e78-b601-38d5e54372c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0c29dc56-2edd-4e78-b601-38d5e54372c3" xlink:to="loc_us-gaap_ClassOfStockDomain_0c29dc56-2edd-4e78-b601-38d5e54372c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_45545427-912c-4927-afb4-b70c6b89be61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0c29dc56-2edd-4e78-b601-38d5e54372c3" xlink:to="loc_us-gaap_ClassOfStockDomain_45545427-912c-4927-afb4-b70c6b89be61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_ed7b8545-68f2-4457-bc09-daf61c8d2ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_45545427-912c-4927-afb4-b70c6b89be61" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_ed7b8545-68f2-4457-bc09-daf61c8d2ee3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/FairValueMeasurementsFairValueMeasurementInputsandValuationTechniquesDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#FairValueMeasurementsFairValueMeasurementInputsandValuationTechniquesDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/FairValueMeasurementsFairValueMeasurementInputsandValuationTechniquesDetails" xlink:type="extended" id="i53a837a39ad948be895328a922660ff7_FairValueMeasurementsFairValueMeasurementInputsandValuationTechniquesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_fb79acd9-3021-4217-96a1-3d295b829130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_d0b894ae-d0a6-48d3-bb23-f91e84ebcb7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_fb79acd9-3021-4217-96a1-3d295b829130" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_d0b894ae-d0a6-48d3-bb23-f91e84ebcb7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_bbf5c966-7d3f-4d18-ae4e-5eba4a08fcc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_fb79acd9-3021-4217-96a1-3d295b829130" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_bbf5c966-7d3f-4d18-ae4e-5eba4a08fcc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_ee56e0ab-33e6-4a02-8865-5cdb6aff240f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_fb79acd9-3021-4217-96a1-3d295b829130" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_ee56e0ab-33e6-4a02-8865-5cdb6aff240f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5203aac1-c4be-4c45-b855-96e20cc9220f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_ee56e0ab-33e6-4a02-8865-5cdb6aff240f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5203aac1-c4be-4c45-b855-96e20cc9220f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5203aac1-c4be-4c45-b855-96e20cc9220f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5203aac1-c4be-4c45-b855-96e20cc9220f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5203aac1-c4be-4c45-b855-96e20cc9220f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_75d6e13c-02e3-4358-8b21-cc5738bd7952" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5203aac1-c4be-4c45-b855-96e20cc9220f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_75d6e13c-02e3-4358-8b21-cc5738bd7952" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_61260cec-a8dc-4660-a59f-38c21834ab59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_75d6e13c-02e3-4358-8b21-cc5738bd7952" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_61260cec-a8dc-4660-a59f-38c21834ab59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_b1a1ecc4-e581-4176-a331-4a6d9f19f659" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_ee56e0ab-33e6-4a02-8865-5cdb6aff240f" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_b1a1ecc4-e581-4176-a331-4a6d9f19f659" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_b1a1ecc4-e581-4176-a331-4a6d9f19f659_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_b1a1ecc4-e581-4176-a331-4a6d9f19f659" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_b1a1ecc4-e581-4176-a331-4a6d9f19f659_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_ddb60a47-622f-447d-9c13-89f0e0688b88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_b1a1ecc4-e581-4176-a331-4a6d9f19f659" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_ddb60a47-622f-447d-9c13-89f0e0688b88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_MeasurementInputStrikePriceMember_6acf5973-cfc6-4223-a07d-56e42351ba72" xlink:href="angn-20211231.xsd#angn_MeasurementInputStrikePriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_ddb60a47-622f-447d-9c13-89f0e0688b88" xlink:to="loc_angn_MeasurementInputStrikePriceMember_6acf5973-cfc6-4223-a07d-56e42351ba72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_9edd4950-ce27-4b1f-a59a-4b7854c40dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_ddb60a47-622f-447d-9c13-89f0e0688b88" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_9edd4950-ce27-4b1f-a59a-4b7854c40dd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1c4ec3a7-85e8-4801-9637-ec13bc6dc1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_ddb60a47-622f-447d-9c13-89f0e0688b88" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1c4ec3a7-85e8-4801-9637-ec13bc6dc1bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_35d9598d-e223-4d2f-a0df-fbc3a9091021" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_ddb60a47-622f-447d-9c13-89f0e0688b88" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_35d9598d-e223-4d2f-a0df-fbc3a9091021" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="extended" id="i9b238d5b212e4e0581122ba603f52e22_BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cfb9cee9-c813-4e94-95b6-17f43c163bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1f60f23c-820b-49cd-b0ab-3e3147d2490d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cfb9cee9-c813-4e94-95b6-17f43c163bb7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1f60f23c-820b-49cd-b0ab-3e3147d2490d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9c1a7a4b-017e-4472-a037-c3dd08b9262c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cfb9cee9-c813-4e94-95b6-17f43c163bb7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9c1a7a4b-017e-4472-a037-c3dd08b9262c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8bed89f9-49e8-4a98-9ffd-ed83f6ff6ade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cfb9cee9-c813-4e94-95b6-17f43c163bb7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8bed89f9-49e8-4a98-9ffd-ed83f6ff6ade" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_489dd03c-01db-4784-bb7c-c992eb9e7cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cfb9cee9-c813-4e94-95b6-17f43c163bb7" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_489dd03c-01db-4784-bb7c-c992eb9e7cf0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6e27ba6b-d559-485b-9f85-92f66d296019" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_489dd03c-01db-4784-bb7c-c992eb9e7cf0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6e27ba6b-d559-485b-9f85-92f66d296019" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6e27ba6b-d559-485b-9f85-92f66d296019_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6e27ba6b-d559-485b-9f85-92f66d296019" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6e27ba6b-d559-485b-9f85-92f66d296019_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_35e04578-de52-4e2e-aef6-7992141847dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6e27ba6b-d559-485b-9f85-92f66d296019" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_35e04578-de52-4e2e-aef6-7992141847dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_2cb49b7e-a35b-4a02-a9e1-044a2f52bf93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_35e04578-de52-4e2e-aef6-7992141847dd" xlink:to="loc_us-gaap_EquipmentMember_2cb49b7e-a35b-4a02-a9e1-044a2f52bf93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_21983ce5-e3b2-44c4-8fb8-801212ad20a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_35e04578-de52-4e2e-aef6-7992141847dd" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_21983ce5-e3b2-44c4-8fb8-801212ad20a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_99e4e4ea-17fe-4f45-aec1-4a80930b2067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_35e04578-de52-4e2e-aef6-7992141847dd" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_99e4e4ea-17fe-4f45-aec1-4a80930b2067" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/BalanceSheetComponentsNarrativeDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#BalanceSheetComponentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/BalanceSheetComponentsNarrativeDetails" xlink:type="extended" id="i8042c9581d29412396e8b41183481fcb_BalanceSheetComponentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_2aa08fc1-2419-40e8-bf4e-7db0bd8bb62c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_a61adf5d-fd06-46aa-9b82-84367e02a3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_2aa08fc1-2419-40e8-bf4e-7db0bd8bb62c" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_a61adf5d-fd06-46aa-9b82-84367e02a3dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_317dc802-541d-404c-a55b-9ede832999db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_2aa08fc1-2419-40e8-bf4e-7db0bd8bb62c" xlink:to="loc_us-gaap_Depreciation_317dc802-541d-404c-a55b-9ede832999db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_d15c8e05-d1e5-4b33-8281-32a884ff5f25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_2aa08fc1-2419-40e8-bf4e-7db0bd8bb62c" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_d15c8e05-d1e5-4b33-8281-32a884ff5f25" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_0cc7c0bc-1f65-4c18-af63-8f881cebf739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d15c8e05-d1e5-4b33-8281-32a884ff5f25" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_0cc7c0bc-1f65-4c18-af63-8f881cebf739" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_0cc7c0bc-1f65-4c18-af63-8f881cebf739_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_0cc7c0bc-1f65-4c18-af63-8f881cebf739" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_0cc7c0bc-1f65-4c18-af63-8f881cebf739_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_eff620df-0fc8-450f-af5f-77e62b8fac20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_0cc7c0bc-1f65-4c18-af63-8f881cebf739" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_eff620df-0fc8-450f-af5f-77e62b8fac20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AustralianTaxationOfficeMember_cd4a7efe-4675-46a4-8588-24e3c8b8660e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AustralianTaxationOfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_eff620df-0fc8-450f-af5f-77e62b8fac20" xlink:to="loc_us-gaap_AustralianTaxationOfficeMember_cd4a7efe-4675-46a4-8588-24e3c8b8660e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_c744988d-56a8-40e8-9ac1-9c2d91be6ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d15c8e05-d1e5-4b33-8281-32a884ff5f25" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_c744988d-56a8-40e8-9ac1-9c2d91be6ecf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_c744988d-56a8-40e8-9ac1-9c2d91be6ecf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_c744988d-56a8-40e8-9ac1-9c2d91be6ecf" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_c744988d-56a8-40e8-9ac1-9c2d91be6ecf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_16f0f4a3-ab8a-4f0b-8bc7-3a27bec2f599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_c744988d-56a8-40e8-9ac1-9c2d91be6ecf" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_16f0f4a3-ab8a-4f0b-8bc7-3a27bec2f599" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_6738b0b2-caa2-4b00-a26c-39e4b65ba70d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_16f0f4a3-ab8a-4f0b-8bc7-3a27bec2f599" xlink:to="loc_us-gaap_ResearchMember_6738b0b2-caa2-4b00-a26c-39e4b65ba70d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/ConvertibleNotesPayableDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#ConvertibleNotesPayableDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/ConvertibleNotesPayableDetails" xlink:type="extended" id="i10863287337946a88d031de2db422870_ConvertibleNotesPayableDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionLineItems_f9c596bc-f59b-4952-80da-d977a29015a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d784bbda-a321-4c96-b90d-5cdb3dff6670" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_f9c596bc-f59b-4952-80da-d977a29015a6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d784bbda-a321-4c96-b90d-5cdb3dff6670" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentIncreaseAccruedInterest_2771dfad-1a37-4a88-9320-6d81b25df620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_f9c596bc-f59b-4952-80da-d977a29015a6" xlink:to="loc_us-gaap_DebtInstrumentIncreaseAccruedInterest_2771dfad-1a37-4a88-9320-6d81b25df620" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c7748098-3653-4e89-b37a-38180ea5410b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_f9c596bc-f59b-4952-80da-d977a29015a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c7748098-3653-4e89-b37a-38180ea5410b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_50ef3d90-6240-4bbc-a580-293044791819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_f9c596bc-f59b-4952-80da-d977a29015a6" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_50ef3d90-6240-4bbc-a580-293044791819" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_07658f7a-cba5-4689-a161-1dea07051e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_f9c596bc-f59b-4952-80da-d977a29015a6" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_07658f7a-cba5-4689-a161-1dea07051e9a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable_2a8edc61-f173-4baa-982b-bd267ac62458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionLineItems_f9c596bc-f59b-4952-80da-d977a29015a6" xlink:to="loc_us-gaap_ConvertibleNotesPayable_2a8edc61-f173-4baa-982b-bd267ac62458" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionTable_3778617d-cff6-498e-80a9-840c7c9092af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtConversionLineItems_f9c596bc-f59b-4952-80da-d977a29015a6" xlink:to="loc_us-gaap_DebtConversionTable_3778617d-cff6-498e-80a9-840c7c9092af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_cb3992a0-fd5a-4473-b9a0-cb978e3cd00c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtConversionTable_3778617d-cff6-498e-80a9-840c7c9092af" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_cb3992a0-fd5a-4473-b9a0-cb978e3cd00c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_cb3992a0-fd5a-4473-b9a0-cb978e3cd00c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_cb3992a0-fd5a-4473-b9a0-cb978e3cd00c" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_cb3992a0-fd5a-4473-b9a0-cb978e3cd00c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_8b0e56ce-6c69-4beb-90b5-1694f0363522" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_cb3992a0-fd5a-4473-b9a0-cb978e3cd00c" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_8b0e56ce-6c69-4beb-90b5-1694f0363522" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_66b780cd-790f-45ed-9c53-b11a6d54fc76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_8b0e56ce-6c69-4beb-90b5-1694f0363522" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_66b780cd-790f-45ed-9c53-b11a6d54fc76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5f0cc6da-508d-4a08-9ce2-bc5fa780915f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtConversionTable_3778617d-cff6-498e-80a9-840c7c9092af" xlink:to="loc_us-gaap_DebtInstrumentAxis_5f0cc6da-508d-4a08-9ce2-bc5fa780915f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5f0cc6da-508d-4a08-9ce2-bc5fa780915f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5f0cc6da-508d-4a08-9ce2-bc5fa780915f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5f0cc6da-508d-4a08-9ce2-bc5fa780915f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c4b46ae9-8dae-401a-bfad-0772fe0f2d20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5f0cc6da-508d-4a08-9ce2-bc5fa780915f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c4b46ae9-8dae-401a-bfad-0772fe0f2d20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_A2020NotesMember_2f722668-d698-4d4e-9bce-593bbfaf19e6" xlink:href="angn-20211231.xsd#angn_A2020NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c4b46ae9-8dae-401a-bfad-0772fe0f2d20" xlink:to="loc_angn_A2020NotesMember_2f722668-d698-4d4e-9bce-593bbfaf19e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AdditionalConvertibleNotesAndViforConvertibleNoteMember_bdd62232-eb27-44a3-affd-ef3640cf0c9f" xlink:href="angn-20211231.xsd#angn_AdditionalConvertibleNotesAndViforConvertibleNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c4b46ae9-8dae-401a-bfad-0772fe0f2d20" xlink:to="loc_angn_AdditionalConvertibleNotesAndViforConvertibleNoteMember_bdd62232-eb27-44a3-affd-ef3640cf0c9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_afd976e6-8840-4bcc-aaed-96368506d359" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtConversionTable_3778617d-cff6-498e-80a9-840c7c9092af" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_afd976e6-8840-4bcc-aaed-96368506d359" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_afd976e6-8840-4bcc-aaed-96368506d359_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_afd976e6-8840-4bcc-aaed-96368506d359" xlink:to="loc_us-gaap_EquityComponentDomain_afd976e6-8840-4bcc-aaed-96368506d359_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d920e5a1-cead-438a-b745-52d45cccbca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_afd976e6-8840-4bcc-aaed-96368506d359" xlink:to="loc_us-gaap_EquityComponentDomain_d920e5a1-cead-438a-b745-52d45cccbca6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_be99f784-4ea2-4c70-8876-596463e2b88c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d920e5a1-cead-438a-b745-52d45cccbca6" xlink:to="loc_us-gaap_CommonStockMember_be99f784-4ea2-4c70-8876-596463e2b88c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_dd96caa2-0a6e-4c0e-9903-e05a00e2e2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtConversionTable_3778617d-cff6-498e-80a9-840c7c9092af" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_dd96caa2-0a6e-4c0e-9903-e05a00e2e2aa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dd96caa2-0a6e-4c0e-9903-e05a00e2e2aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_dd96caa2-0a6e-4c0e-9903-e05a00e2e2aa" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dd96caa2-0a6e-4c0e-9903-e05a00e2e2aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4abfa282-5d74-4aac-a3d0-b9fa77eb759b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_dd96caa2-0a6e-4c0e-9903-e05a00e2e2aa" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4abfa282-5d74-4aac-a3d0-b9fa77eb759b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_4b853106-484f-4ac6-912d-0ddedbc498c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4abfa282-5d74-4aac-a3d0-b9fa77eb759b" xlink:to="loc_us-gaap_IPOMember_4b853106-484f-4ac6-912d-0ddedbc498c9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/SeriesCConvertiblePreferredStockNarrativeDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#SeriesCConvertiblePreferredStockNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/SeriesCConvertiblePreferredStockNarrativeDetails" xlink:type="extended" id="i7979b23fe953452bbe8aa9d501b22a07_SeriesCConvertiblePreferredStockNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_3810ad94-5a57-4fbc-9299-5cf916f812f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_fddbb210-c925-4030-8b64-acb985f052ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3810ad94-5a57-4fbc-9299-5cf916f812f8" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_fddbb210-c925-4030-8b64-acb985f052ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_43ea5e47-40e7-442d-8a63-4a88c21cd54e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3810ad94-5a57-4fbc-9299-5cf916f812f8" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_43ea5e47-40e7-442d-8a63-4a88c21cd54e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ConvertiblePreferredStockConversionPrice_6db87ddf-1cfb-45d5-ba62-f4ae124a1a11" xlink:href="angn-20211231.xsd#angn_ConvertiblePreferredStockConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3810ad94-5a57-4fbc-9299-5cf916f812f8" xlink:to="loc_angn_ConvertiblePreferredStockConversionPrice_6db87ddf-1cfb-45d5-ba62-f4ae124a1a11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_e17589f5-9364-48e4-b888-78c1573dfd00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3810ad94-5a57-4fbc-9299-5cf916f812f8" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_e17589f5-9364-48e4-b888-78c1573dfd00" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_6d6ad984-1526-4b71-a8a5-35cf4a7d4971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_3810ad94-5a57-4fbc-9299-5cf916f812f8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_6d6ad984-1526-4b71-a8a5-35cf4a7d4971" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c5e97b0c-f770-40a1-8c1f-5333031bcce1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6d6ad984-1526-4b71-a8a5-35cf4a7d4971" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c5e97b0c-f770-40a1-8c1f-5333031bcce1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c5e97b0c-f770-40a1-8c1f-5333031bcce1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c5e97b0c-f770-40a1-8c1f-5333031bcce1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c5e97b0c-f770-40a1-8c1f-5333031bcce1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70fa4e68-baee-4523-89af-6a8444b8319c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c5e97b0c-f770-40a1-8c1f-5333031bcce1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70fa4e68-baee-4523-89af-6a8444b8319c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_a3a6062d-8ec9-4b40-80b2-dfbb177aecab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70fa4e68-baee-4523-89af-6a8444b8319c" xlink:to="loc_us-gaap_IPOMember_a3a6062d-8ec9-4b40-80b2-dfbb177aecab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3f105992-b562-4be5-a7eb-ff79a20e19e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6d6ad984-1526-4b71-a8a5-35cf4a7d4971" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3f105992-b562-4be5-a7eb-ff79a20e19e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3f105992-b562-4be5-a7eb-ff79a20e19e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3f105992-b562-4be5-a7eb-ff79a20e19e6" xlink:to="loc_us-gaap_ClassOfStockDomain_3f105992-b562-4be5-a7eb-ff79a20e19e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_834c7660-1647-4b0e-8742-de81a05d8d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3f105992-b562-4be5-a7eb-ff79a20e19e6" xlink:to="loc_us-gaap_ClassOfStockDomain_834c7660-1647-4b0e-8742-de81a05d8d7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_8ff9ff21-17d8-4da8-af5a-b2f6e321c58a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_834c7660-1647-4b0e-8742-de81a05d8d7b" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_8ff9ff21-17d8-4da8-af5a-b2f6e321c58a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="i2d240a873fdb4894ac320445a2bcb509_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9f8c2e5-16c4-41ad-a410-412d01aa7724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_54419285-116a-4d81-8e89-2f54a3925ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9f8c2e5-16c4-41ad-a410-412d01aa7724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_54419285-116a-4d81-8e89-2f54a3925ba8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7dc538e0-ebcb-4a9e-a38a-e88671f9a8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9f8c2e5-16c4-41ad-a410-412d01aa7724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7dc538e0-ebcb-4a9e-a38a-e88671f9a8a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f4842ac8-0f95-4e92-8006-5b046c263037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9f8c2e5-16c4-41ad-a410-412d01aa7724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f4842ac8-0f95-4e92-8006-5b046c263037" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_038a3801-1697-4bf9-93da-447f0c27cc78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9f8c2e5-16c4-41ad-a410-412d01aa7724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_038a3801-1697-4bf9-93da-447f0c27cc78" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_8ab61563-0d1d-4c97-9909-937a07f80d61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9f8c2e5-16c4-41ad-a410-412d01aa7724" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_8ab61563-0d1d-4c97-9909-937a07f80d61" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c6724c04-7ce6-492e-8e03-29505b5aadb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9f8c2e5-16c4-41ad-a410-412d01aa7724" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c6724c04-7ce6-492e-8e03-29505b5aadb5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2eafb998-79d7-4131-ac6d-75c51a9bdfde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9f8c2e5-16c4-41ad-a410-412d01aa7724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2eafb998-79d7-4131-ac6d-75c51a9bdfde" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6115705a-8f1c-4781-b3f1-20c1a1b7a389" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9f8c2e5-16c4-41ad-a410-412d01aa7724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6115705a-8f1c-4781-b3f1-20c1a1b7a389" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_b87d2bfe-b3a4-4217-8cb4-2af333cc7417" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9f8c2e5-16c4-41ad-a410-412d01aa7724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_b87d2bfe-b3a4-4217-8cb4-2af333cc7417" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_193d1f18-a02e-4e85-ade5-3e134e9e64de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9f8c2e5-16c4-41ad-a410-412d01aa7724" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_193d1f18-a02e-4e85-ade5-3e134e9e64de" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_02d96138-757f-4494-944e-8f71ad4ae1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9f8c2e5-16c4-41ad-a410-412d01aa7724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_02d96138-757f-4494-944e-8f71ad4ae1cf" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_beaf7f28-9c32-479a-80f5-589f7d0f5a47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9f8c2e5-16c4-41ad-a410-412d01aa7724" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_beaf7f28-9c32-479a-80f5-589f7d0f5a47" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6b963dc2-c51b-48d6-9f98-86539e250ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_beaf7f28-9c32-479a-80f5-589f7d0f5a47" xlink:to="loc_us-gaap_PlanNameAxis_6b963dc2-c51b-48d6-9f98-86539e250ff1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6b963dc2-c51b-48d6-9f98-86539e250ff1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6b963dc2-c51b-48d6-9f98-86539e250ff1" xlink:to="loc_us-gaap_PlanNameDomain_6b963dc2-c51b-48d6-9f98-86539e250ff1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_73ed6c47-c4f7-4ffb-bf6f-88e32e5490bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6b963dc2-c51b-48d6-9f98-86539e250ff1" xlink:to="loc_us-gaap_PlanNameDomain_73ed6c47-c4f7-4ffb-bf6f-88e32e5490bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_A2021PlanMember_a15e23b4-70a7-4d4a-9e14-65ad39bba1ab" xlink:href="angn-20211231.xsd#angn_A2021PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_73ed6c47-c4f7-4ffb-bf6f-88e32e5490bc" xlink:to="loc_angn_A2021PlanMember_a15e23b4-70a7-4d4a-9e14-65ad39bba1ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_890a0857-cd73-470f-8353-4ee9b208862a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_beaf7f28-9c32-479a-80f5-589f7d0f5a47" xlink:to="loc_us-gaap_AwardTypeAxis_890a0857-cd73-470f-8353-4ee9b208862a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_890a0857-cd73-470f-8353-4ee9b208862a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_890a0857-cd73-470f-8353-4ee9b208862a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_890a0857-cd73-470f-8353-4ee9b208862a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bf4ee80-953d-4efd-b730-4c44f7925f72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_890a0857-cd73-470f-8353-4ee9b208862a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bf4ee80-953d-4efd-b730-4c44f7925f72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e3fa46b7-1cb0-4ae3-9331-6e3bfe1359ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bf4ee80-953d-4efd-b730-4c44f7925f72" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e3fa46b7-1cb0-4ae3-9331-6e3bfe1359ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_4876e7fb-88fb-4cfe-a015-6b38950b256a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bf4ee80-953d-4efd-b730-4c44f7925f72" xlink:to="loc_us-gaap_PerformanceSharesMember_4876e7fb-88fb-4cfe-a015-6b38950b256a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_9029ac1e-979a-49ef-ac1d-b2a0da47dd95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bf4ee80-953d-4efd-b730-4c44f7925f72" xlink:to="loc_us-gaap_EmployeeStockMember_9029ac1e-979a-49ef-ac1d-b2a0da47dd95" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails" xlink:type="extended" id="i1aabaa273455446f9d93d7db4752322b_StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59e21eb0-00de-454e-bd8d-2d63fb9c760d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a7cb7a75-68bf-4c7f-bbe3-1eb4cf5d0015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59e21eb0-00de-454e-bd8d-2d63fb9c760d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a7cb7a75-68bf-4c7f-bbe3-1eb4cf5d0015" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ded8fba8-d9d8-48ea-a3b6-abfa772e6e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59e21eb0-00de-454e-bd8d-2d63fb9c760d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ded8fba8-d9d8-48ea-a3b6-abfa772e6e2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4ae6dd0a-3de4-46c3-843f-478aa3ac8953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59e21eb0-00de-454e-bd8d-2d63fb9c760d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4ae6dd0a-3de4-46c3-843f-478aa3ac8953" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2316fa99-fb3d-496d-89f9-297495c60b67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59e21eb0-00de-454e-bd8d-2d63fb9c760d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2316fa99-fb3d-496d-89f9-297495c60b67" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_199f6b31-7bd6-4db4-81f7-49d91a10b371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59e21eb0-00de-454e-bd8d-2d63fb9c760d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_199f6b31-7bd6-4db4-81f7-49d91a10b371" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_964c381c-042d-4305-b92b-2b2e87c5f507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59e21eb0-00de-454e-bd8d-2d63fb9c760d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_964c381c-042d-4305-b92b-2b2e87c5f507" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cc9356d5-ee4b-4c4d-8197-8e2c97c56c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_964c381c-042d-4305-b92b-2b2e87c5f507" xlink:to="loc_us-gaap_AwardTypeAxis_cc9356d5-ee4b-4c4d-8197-8e2c97c56c9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc9356d5-ee4b-4c4d-8197-8e2c97c56c9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_cc9356d5-ee4b-4c4d-8197-8e2c97c56c9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc9356d5-ee4b-4c4d-8197-8e2c97c56c9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aad93a08-a573-4b47-b997-6b4af6b0c856" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_cc9356d5-ee4b-4c4d-8197-8e2c97c56c9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aad93a08-a573-4b47-b997-6b4af6b0c856" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0eeb5d8a-b623-486b-82fc-a61078fb2f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aad93a08-a573-4b47-b997-6b4af6b0c856" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0eeb5d8a-b623-486b-82fc-a61078fb2f4d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/StockBasedCompensationScheduleofRSAandRSUActivityDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#StockBasedCompensationScheduleofRSAandRSUActivityDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/StockBasedCompensationScheduleofRSAandRSUActivityDetails" xlink:type="extended" id="i271c28c525b94ddf881e970a1c41c3fe_StockBasedCompensationScheduleofRSAandRSUActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54a0e04e-3bb0-417d-bed3-ae1526a5fefd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_1c0dff56-ecc4-4b4b-9ba0-c77afc908414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54a0e04e-3bb0-417d-bed3-ae1526a5fefd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_1c0dff56-ecc4-4b4b-9ba0-c77afc908414" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_608e6134-b3cd-4397-8c99-8969b0dcedef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_1c0dff56-ecc4-4b4b-9ba0-c77afc908414" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_608e6134-b3cd-4397-8c99-8969b0dcedef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cff12ead-e03a-4a8b-95cd-13ba408f843a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_1c0dff56-ecc4-4b4b-9ba0-c77afc908414" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cff12ead-e03a-4a8b-95cd-13ba408f843a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3115df86-f580-4008-9997-d70f9d56b9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_1c0dff56-ecc4-4b4b-9ba0-c77afc908414" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3115df86-f580-4008-9997-d70f9d56b9c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_267c2669-b456-4c4d-a5be-94109f8821c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber_4b2c4c03-06a2-42c5-8242-d4a48e2b9b34" xlink:href="angn-20211231.xsd#angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54a0e04e-3bb0-417d-bed3-ae1526a5fefd" xlink:to="loc_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber_4b2c4c03-06a2-42c5-8242-d4a48e2b9b34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7df615b0-255b-430c-a6a0-f0707f5f2777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54a0e04e-3bb0-417d-bed3-ae1526a5fefd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7df615b0-255b-430c-a6a0-f0707f5f2777" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2ee05882-2950-4f23-816f-e41d2a8c5373" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7df615b0-255b-430c-a6a0-f0707f5f2777" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2ee05882-2950-4f23-816f-e41d2a8c5373" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d3bce1a7-5c27-4b2c-aa30-3f40fab6018d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7df615b0-255b-430c-a6a0-f0707f5f2777" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d3bce1a7-5c27-4b2c-aa30-3f40fab6018d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_70ada81a-0965-42c3-a63d-4ddda797b14a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7df615b0-255b-430c-a6a0-f0707f5f2777" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_70ada81a-0965-42c3-a63d-4ddda797b14a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_459ad485-4186-473e-bda6-5294509507d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageExercisePrice_dfbedd34-e709-4cbe-8f02-08eadcc35c0a" xlink:href="angn-20211231.xsd#angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54a0e04e-3bb0-417d-bed3-ae1526a5fefd" xlink:to="loc_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageExercisePrice_dfbedd34-e709-4cbe-8f02-08eadcc35c0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ac83033-8707-4d6c-98f3-c255fe3f5fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54a0e04e-3bb0-417d-bed3-ae1526a5fefd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ac83033-8707-4d6c-98f3-c255fe3f5fd1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fe769ff9-d449-49d9-a684-28fd0a2cd86f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ac83033-8707-4d6c-98f3-c255fe3f5fd1" xlink:to="loc_us-gaap_AwardTypeAxis_fe769ff9-d449-49d9-a684-28fd0a2cd86f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe769ff9-d449-49d9-a684-28fd0a2cd86f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_fe769ff9-d449-49d9-a684-28fd0a2cd86f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fe769ff9-d449-49d9-a684-28fd0a2cd86f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f3bd5a27-03d5-4df8-a444-f2f66fac7458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_fe769ff9-d449-49d9-a684-28fd0a2cd86f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f3bd5a27-03d5-4df8-a444-f2f66fac7458" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_2799686f-c20c-447a-94c4-e0546ed279ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f3bd5a27-03d5-4df8-a444-f2f66fac7458" xlink:to="loc_us-gaap_RestrictedStockMember_2799686f-c20c-447a-94c4-e0546ed279ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a984b14f-aeb7-4767-8d5d-596843f8bdb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f3bd5a27-03d5-4df8-a444-f2f66fac7458" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a984b14f-aeb7-4767-8d5d-596843f8bdb9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails" xlink:type="extended" id="ibbf767b7356d448d9fcea8c92ad46d39_StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d74a1dc4-26e3-4684-8ca8-b892c20b14db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_912f3ece-d529-4456-b2ff-e99db2e219a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d74a1dc4-26e3-4684-8ca8-b892c20b14db" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_912f3ece-d529-4456-b2ff-e99db2e219a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_93cf0f6f-348f-4c97-b18b-f15e8aa59b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d74a1dc4-26e3-4684-8ca8-b892c20b14db" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_93cf0f6f-348f-4c97-b18b-f15e8aa59b75" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bc75770f-92a1-4c98-bb39-8fae5ac7a455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_93cf0f6f-348f-4c97-b18b-f15e8aa59b75" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bc75770f-92a1-4c98-bb39-8fae5ac7a455" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bc75770f-92a1-4c98-bb39-8fae5ac7a455_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bc75770f-92a1-4c98-bb39-8fae5ac7a455" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bc75770f-92a1-4c98-bb39-8fae5ac7a455_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1988b3fa-f23f-4e4b-a8e4-195759af7b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bc75770f-92a1-4c98-bb39-8fae5ac7a455" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1988b3fa-f23f-4e4b-a8e4-195759af7b87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cff9f61b-1f81-46a1-aa26-deaa7276808f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1988b3fa-f23f-4e4b-a8e4-195759af7b87" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cff9f61b-1f81-46a1-aa26-deaa7276808f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4c72df5a-d05e-4278-a051-2d59aaf3604a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1988b3fa-f23f-4e4b-a8e4-195759af7b87" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4c72df5a-d05e-4278-a051-2d59aaf3604a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/WarrantsOutstandingWarrantsDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#WarrantsOutstandingWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/WarrantsOutstandingWarrantsDetails" xlink:type="extended" id="i2280dcd2a1d44683887de7b205bc5238_WarrantsOutstandingWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_8ef2349a-ae32-48e3-bfee-85a82c7f76ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_48b3707f-6069-4acd-bc5a-0045b044447a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8ef2349a-ae32-48e3-bfee-85a82c7f76ef" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_48b3707f-6069-4acd-bc5a-0045b044447a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7dcd632e-2aee-40de-a114-51042d2c788e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8ef2349a-ae32-48e3-bfee-85a82c7f76ef" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7dcd632e-2aee-40de-a114-51042d2c788e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_48987641-1228-4e6e-ba12-26b577fb799d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8ef2349a-ae32-48e3-bfee-85a82c7f76ef" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_48987641-1228-4e6e-ba12-26b577fb799d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2459cf7f-2729-4e7c-8fa8-f65c71575ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_48987641-1228-4e6e-ba12-26b577fb799d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2459cf7f-2729-4e7c-8fa8-f65c71575ef0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2459cf7f-2729-4e7c-8fa8-f65c71575ef0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2459cf7f-2729-4e7c-8fa8-f65c71575ef0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2459cf7f-2729-4e7c-8fa8-f65c71575ef0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ebf8f319-7d6b-42d8-910b-4f30507a4e46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2459cf7f-2729-4e7c-8fa8-f65c71575ef0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ebf8f319-7d6b-42d8-910b-4f30507a4e46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsIssuedWith2015NotesLiabilityMember_26aedc5f-6ad7-4b5f-b107-8b2f5fabad44" xlink:href="angn-20211231.xsd#angn_WarrantsIssuedWith2015NotesLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ebf8f319-7d6b-42d8-910b-4f30507a4e46" xlink:to="loc_angn_WarrantsIssuedWith2015NotesLiabilityMember_26aedc5f-6ad7-4b5f-b107-8b2f5fabad44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsIssuedWith2016NotesLiabilityMember_8e5ce30f-63a1-4d6b-bc9b-71ddf5e07149" xlink:href="angn-20211231.xsd#angn_WarrantsIssuedWith2016NotesLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ebf8f319-7d6b-42d8-910b-4f30507a4e46" xlink:to="loc_angn_WarrantsIssuedWith2016NotesLiabilityMember_8e5ce30f-63a1-4d6b-bc9b-71ddf5e07149" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsIssuedWith2017NotesLiabilityMember_6acb2c32-374c-4ff4-b51d-3979c58d3502" xlink:href="angn-20211231.xsd#angn_WarrantsIssuedWith2017NotesLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ebf8f319-7d6b-42d8-910b-4f30507a4e46" xlink:to="loc_angn_WarrantsIssuedWith2017NotesLiabilityMember_6acb2c32-374c-4ff4-b51d-3979c58d3502" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsIssuedWith2018NotesLiabilityMember_4f0ad139-ae91-4742-9f41-0bc9cbff0e93" xlink:href="angn-20211231.xsd#angn_WarrantsIssuedWith2018NotesLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ebf8f319-7d6b-42d8-910b-4f30507a4e46" xlink:to="loc_angn_WarrantsIssuedWith2018NotesLiabilityMember_4f0ad139-ae91-4742-9f41-0bc9cbff0e93" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsIssuedWithConversionOfNotesToCommonStockEquityMember_9e8b17a5-9503-4aa8-8be6-db898e1c2869" xlink:href="angn-20211231.xsd#angn_WarrantsIssuedWithConversionOfNotesToCommonStockEquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ebf8f319-7d6b-42d8-910b-4f30507a4e46" xlink:to="loc_angn_WarrantsIssuedWithConversionOfNotesToCommonStockEquityMember_9e8b17a5-9503-4aa8-8be6-db898e1c2869" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsIssuedWithUnitsInTheEquityOfferingEquityMember_8ca7963e-c541-4ca8-a141-60f4874968de" xlink:href="angn-20211231.xsd#angn_WarrantsIssuedWithUnitsInTheEquityOfferingEquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ebf8f319-7d6b-42d8-910b-4f30507a4e46" xlink:to="loc_angn_WarrantsIssuedWithUnitsInTheEquityOfferingEquityMember_8ca7963e-c541-4ca8-a141-60f4874968de" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BrokerWarrantsIssuedWithEquityOfferingEquityMember_a4bbe2ea-4e40-4ed4-af63-3cae5d4b06d5" xlink:href="angn-20211231.xsd#angn_BrokerWarrantsIssuedWithEquityOfferingEquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ebf8f319-7d6b-42d8-910b-4f30507a4e46" xlink:to="loc_angn_BrokerWarrantsIssuedWithEquityOfferingEquityMember_a4bbe2ea-4e40-4ed4-af63-3cae5d4b06d5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BrokerWarrantsIssuedWith2019NotesLiabilityMember_61a4c07a-0bfe-4e15-a1e3-e7e5f6bf6e59" xlink:href="angn-20211231.xsd#angn_BrokerWarrantsIssuedWith2019NotesLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ebf8f319-7d6b-42d8-910b-4f30507a4e46" xlink:to="loc_angn_BrokerWarrantsIssuedWith2019NotesLiabilityMember_61a4c07a-0bfe-4e15-a1e3-e7e5f6bf6e59" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ConsultantWarrantsLiabilityMember_25dd3a04-a976-4cf8-a0dd-4abed712d307" xlink:href="angn-20211231.xsd#angn_ConsultantWarrantsLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ebf8f319-7d6b-42d8-910b-4f30507a4e46" xlink:to="loc_angn_ConsultantWarrantsLiabilityMember_25dd3a04-a976-4cf8-a0dd-4abed712d307" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/WarrantsNarrativeDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#WarrantsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/WarrantsNarrativeDetails" xlink:type="extended" id="iebfd35192ab64dd68a2e01e249d5a035_WarrantsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_d74a98b2-9a76-4b1d-bb4c-be0abd059fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5240b167-92bb-4886-865c-8f81d1724760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d74a98b2-9a76-4b1d-bb4c-be0abd059fc5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5240b167-92bb-4886-865c-8f81d1724760" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodSharesWarrantsExercised_c267cff9-c6fb-470b-bc02-6b1ab55dbef4" xlink:href="angn-20211231.xsd#angn_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d74a98b2-9a76-4b1d-bb4c-be0abd059fc5" xlink:to="loc_angn_StockIssuedDuringPeriodSharesWarrantsExercised_c267cff9-c6fb-470b-bc02-6b1ab55dbef4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightConversionPrice_7760c689-603c-46e0-a3ff-5be2c0bf7503" xlink:href="angn-20211231.xsd#angn_ClassOfWarrantOrRightConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d74a98b2-9a76-4b1d-bb4c-be0abd059fc5" xlink:to="loc_angn_ClassOfWarrantOrRightConversionPrice_7760c689-603c-46e0-a3ff-5be2c0bf7503" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_571f3f25-1b98-42e4-ab30-289601dd4dea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d74a98b2-9a76-4b1d-bb4c-be0abd059fc5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_571f3f25-1b98-42e4-ab30-289601dd4dea" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_23d19758-e254-42fd-8657-43c6d7974188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_571f3f25-1b98-42e4-ab30-289601dd4dea" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_23d19758-e254-42fd-8657-43c6d7974188" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_23d19758-e254-42fd-8657-43c6d7974188_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_23d19758-e254-42fd-8657-43c6d7974188" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_23d19758-e254-42fd-8657-43c6d7974188_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_b3a202a8-06cd-48c5-a549-e208afc41387" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_23d19758-e254-42fd-8657-43c6d7974188" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_b3a202a8-06cd-48c5-a549-e208afc41387" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsIssuedWith2015Notes2016Notes2017NotesAnd2018NotesMember_1eb0f06e-c0e4-4b2d-9c7a-0393f0bd5647" xlink:href="angn-20211231.xsd#angn_WarrantsIssuedWith2015Notes2016Notes2017NotesAnd2018NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_b3a202a8-06cd-48c5-a549-e208afc41387" xlink:to="loc_angn_WarrantsIssuedWith2015Notes2016Notes2017NotesAnd2018NotesMember_1eb0f06e-c0e4-4b2d-9c7a-0393f0bd5647" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0f928664-7f5e-4e80-ac75-d55906874e20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_571f3f25-1b98-42e4-ab30-289601dd4dea" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0f928664-7f5e-4e80-ac75-d55906874e20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0f928664-7f5e-4e80-ac75-d55906874e20_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0f928664-7f5e-4e80-ac75-d55906874e20" xlink:to="loc_us-gaap_EquityComponentDomain_0f928664-7f5e-4e80-ac75-d55906874e20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1839c263-2bcb-4fab-8793-ab903ea64c73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0f928664-7f5e-4e80-ac75-d55906874e20" xlink:to="loc_us-gaap_EquityComponentDomain_1839c263-2bcb-4fab-8793-ab903ea64c73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4a605725-be8f-48f4-aa81-9b73ed281e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1839c263-2bcb-4fab-8793-ab903ea64c73" xlink:to="loc_us-gaap_CommonStockMember_4a605725-be8f-48f4-aa81-9b73ed281e64" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="i5722450588194c9d8069ddb3afb9bc4b_CommitmentsandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_0f13ceaa-318d-4a04-bf4d-2a135c891666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_b0c18d34-c07e-4ce8-b07b-1a883936bb6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0f13ceaa-318d-4a04-bf4d-2a135c891666" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_b0c18d34-c07e-4ce8-b07b-1a883936bb6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_LesseeOperatingLeaseAnnualRentExpense_bdb4397b-665b-46f1-98d2-fc9468990fc2" xlink:href="angn-20211231.xsd#angn_LesseeOperatingLeaseAnnualRentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0f13ceaa-318d-4a04-bf4d-2a135c891666" xlink:to="loc_angn_LesseeOperatingLeaseAnnualRentExpense_bdb4397b-665b-46f1-98d2-fc9468990fc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_LesseeOperatingLeaseFreeRentExpensePeriod_f0e4fb4d-4c94-4f72-8801-633fd2e66819" xlink:href="angn-20211231.xsd#angn_LesseeOperatingLeaseFreeRentExpensePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0f13ceaa-318d-4a04-bf4d-2a135c891666" xlink:to="loc_angn_LesseeOperatingLeaseFreeRentExpensePeriod_f0e4fb4d-4c94-4f72-8801-633fd2e66819" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_LesseeOperatingLeaseNumberOfOptionsToExtend_1283cc32-1ca3-4a2a-9c86-f4bb290ac0b3" xlink:href="angn-20211231.xsd#angn_LesseeOperatingLeaseNumberOfOptionsToExtend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0f13ceaa-318d-4a04-bf4d-2a135c891666" xlink:to="loc_angn_LesseeOperatingLeaseNumberOfOptionsToExtend_1283cc32-1ca3-4a2a-9c86-f4bb290ac0b3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b7276536-aab6-423f-a4a0-e7d7b11d3c29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0f13ceaa-318d-4a04-bf4d-2a135c891666" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b7276536-aab6-423f-a4a0-e7d7b11d3c29" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_LesseeOperatingLeaseNoticePeriodForOptionToExtend_5789f2da-ad2c-4607-92d4-e06101252bf6" xlink:href="angn-20211231.xsd#angn_LesseeOperatingLeaseNoticePeriodForOptionToExtend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0f13ceaa-318d-4a04-bf4d-2a135c891666" xlink:to="loc_angn_LesseeOperatingLeaseNoticePeriodForOptionToExtend_5789f2da-ad2c-4607-92d4-e06101252bf6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_8f583ca8-66ee-44b0-bf11-654f3a6203a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0f13ceaa-318d-4a04-bf4d-2a135c891666" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_8f583ca8-66ee-44b0-bf11-654f3a6203a3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ProceedsFromFinancingObligation_6015c4cf-5350-43ff-80ae-be4393c3ca11" xlink:href="angn-20211231.xsd#angn_ProceedsFromFinancingObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0f13ceaa-318d-4a04-bf4d-2a135c891666" xlink:to="loc_angn_ProceedsFromFinancingObligation_6015c4cf-5350-43ff-80ae-be4393c3ca11" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_6ae06101-4a6d-42fa-abf6-63678b7d2067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0f13ceaa-318d-4a04-bf4d-2a135c891666" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_6ae06101-4a6d-42fa-abf6-63678b7d2067" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4c7b92e7-1f8d-40de-be55-ccce5ea93eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0f13ceaa-318d-4a04-bf4d-2a135c891666" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4c7b92e7-1f8d-40de-be55-ccce5ea93eb9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_CARESActEmployeeRetentionCredit_f8502044-f759-4b22-949c-2f5c93410c3a" xlink:href="angn-20211231.xsd#angn_CARESActEmployeeRetentionCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0f13ceaa-318d-4a04-bf4d-2a135c891666" xlink:to="loc_angn_CARESActEmployeeRetentionCredit_f8502044-f759-4b22-949c-2f5c93410c3a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_65dd333c-cee9-42b4-af8b-d088683887a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0f13ceaa-318d-4a04-bf4d-2a135c891666" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_65dd333c-cee9-42b4-af8b-d088683887a2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e82ebc95-1f02-44ea-a288-318843bdc2ef" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_65dd333c-cee9-42b4-af8b-d088683887a2" xlink:to="loc_srt_StatementGeographicalAxis_e82ebc95-1f02-44ea-a288-318843bdc2ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e82ebc95-1f02-44ea-a288-318843bdc2ef_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_e82ebc95-1f02-44ea-a288-318843bdc2ef" xlink:to="loc_srt_SegmentGeographicalDomain_e82ebc95-1f02-44ea-a288-318843bdc2ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ec14f5d9-87aa-454d-9573-80adee3b3110" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_e82ebc95-1f02-44ea-a288-318843bdc2ef" xlink:to="loc_srt_SegmentGeographicalDomain_ec14f5d9-87aa-454d-9573-80adee3b3110" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_936dc813-5bbf-4e76-8276-3bfbfacb7fa1" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ec14f5d9-87aa-454d-9573-80adee3b3110" xlink:to="loc_stpr_NJ_936dc813-5bbf-4e76-8276-3bfbfacb7fa1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_b1c44ae1-7026-4720-8bd9-d455aa43f62f" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ec14f5d9-87aa-454d-9573-80adee3b3110" xlink:to="loc_stpr_CA_b1c44ae1-7026-4720-8bd9-d455aa43f62f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_43922eb2-f0f0-4a04-8090-74f94d1c4381" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_MA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ec14f5d9-87aa-454d-9573-80adee3b3110" xlink:to="loc_stpr_MA_43922eb2-f0f0-4a04-8090-74f94d1c4381" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_37cd0afa-8403-47f5-ac82-6ad06a1ea982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_65dd333c-cee9-42b4-af8b-d088683887a2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_37cd0afa-8403-47f5-ac82-6ad06a1ea982" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_37cd0afa-8403-47f5-ac82-6ad06a1ea982_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_37cd0afa-8403-47f5-ac82-6ad06a1ea982" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_37cd0afa-8403-47f5-ac82-6ad06a1ea982_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5fba7e2f-355b-4e44-a626-649cab33bad1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_37cd0afa-8403-47f5-ac82-6ad06a1ea982" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5fba7e2f-355b-4e44-a626-649cab33bad1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_e10544bd-9de2-410a-98b3-03bb78da0b47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5fba7e2f-355b-4e44-a626-649cab33bad1" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_e10544bd-9de2-410a-98b3-03bb78da0b47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_66b0a2b9-a588-41fc-b5e5-4e74336ac2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_65dd333c-cee9-42b4-af8b-d088683887a2" xlink:to="loc_us-gaap_DebtInstrumentAxis_66b0a2b9-a588-41fc-b5e5-4e74336ac2d8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_66b0a2b9-a588-41fc-b5e5-4e74336ac2d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_66b0a2b9-a588-41fc-b5e5-4e74336ac2d8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_66b0a2b9-a588-41fc-b5e5-4e74336ac2d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3c268186-1023-4ccb-b8b2-ec8bad00efc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_66b0a2b9-a588-41fc-b5e5-4e74336ac2d8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3c268186-1023-4ccb-b8b2-ec8bad00efc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PaycheckProtectionProgramCARESActMember_c7f3d142-35de-4a55-ab5c-b5a373198d9e" xlink:href="angn-20211231.xsd#angn_PaycheckProtectionProgramCARESActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3c268186-1023-4ccb-b8b2-ec8bad00efc5" xlink:to="loc_angn_PaycheckProtectionProgramCARESActMember_c7f3d142-35de-4a55-ab5c-b5a373198d9e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/CommitmentsandContingenciesScheduleOfQuantitativeInformationAboutTheFinancingObligationDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#CommitmentsandContingenciesScheduleOfQuantitativeInformationAboutTheFinancingObligationDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/CommitmentsandContingenciesScheduleOfQuantitativeInformationAboutTheFinancingObligationDetails" xlink:type="extended" id="i215a9783a9e64ea384768259dd1ec7af_CommitmentsandContingenciesScheduleOfQuantitativeInformationAboutTheFinancingObligationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a92fad84-dc04-4e16-bdd1-89d47903ce13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ProceedsFromFinancingObligation_eeb07618-a263-4521-ab90-d0fe86e60dd8" xlink:href="angn-20211231.xsd#angn_ProceedsFromFinancingObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a92fad84-dc04-4e16-bdd1-89d47903ce13" xlink:to="loc_angn_ProceedsFromFinancingObligation_eeb07618-a263-4521-ab90-d0fe86e60dd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_c3b4fc0a-81f3-4bb5-bbb1-3b38a95de070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a92fad84-dc04-4e16-bdd1-89d47903ce13" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_c3b4fc0a-81f3-4bb5-bbb1-3b38a95de070" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_210e246d-08a3-45e9-90ac-6d34db2a467e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a92fad84-dc04-4e16-bdd1-89d47903ce13" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_210e246d-08a3-45e9-90ac-6d34db2a467e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_f87cfcce-5a23-4a5f-bf1c-cb7fe5f8379b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a92fad84-dc04-4e16-bdd1-89d47903ce13" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_f87cfcce-5a23-4a5f-bf1c-cb7fe5f8379b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_feaf42ab-b929-41c6-877f-655256570519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a92fad84-dc04-4e16-bdd1-89d47903ce13" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_feaf42ab-b929-41c6-877f-655256570519" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_509970e5-9961-4325-8daf-5815f5201240" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a92fad84-dc04-4e16-bdd1-89d47903ce13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_509970e5-9961-4325-8daf-5815f5201240" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_e891c38f-2cfb-40a6-93e1-478260975ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a92fad84-dc04-4e16-bdd1-89d47903ce13" xlink:to="loc_us-gaap_Depreciation_e891c38f-2cfb-40a6-93e1-478260975ec6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_3bae2f82-024f-4741-a366-3d783c84231a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a92fad84-dc04-4e16-bdd1-89d47903ce13" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_3bae2f82-024f-4741-a366-3d783c84231a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2dc9ecd2-616d-40c2-8432-0c4cde79d6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3bae2f82-024f-4741-a366-3d783c84231a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2dc9ecd2-616d-40c2-8432-0c4cde79d6a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2dc9ecd2-616d-40c2-8432-0c4cde79d6a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2dc9ecd2-616d-40c2-8432-0c4cde79d6a9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2dc9ecd2-616d-40c2-8432-0c4cde79d6a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dc5cc2a3-4662-41a4-b56e-ad44376da425" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2dc9ecd2-616d-40c2-8432-0c4cde79d6a9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dc5cc2a3-4662-41a4-b56e-ad44376da425" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_f66d9cc6-16d5-465a-92dc-e64fb2a4150c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dc5cc2a3-4662-41a4-b56e-ad44376da425" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_f66d9cc6-16d5-465a-92dc-e64fb2a4150c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/EmployeeBenefitPlanNarrativeDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#EmployeeBenefitPlanNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/EmployeeBenefitPlanNarrativeDetails" xlink:type="extended" id="i93d27af1a0144ab6b356aeb60cc054e0_EmployeeBenefitPlanNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_974ad4a5-7e89-4973-a863-7aa8b63dce35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_af2ecaa2-82b5-433b-93af-397a9ac25bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_974ad4a5-7e89-4973-a863-7aa8b63dce35" xlink:to="loc_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_af2ecaa2-82b5-433b-93af-397a9ac25bb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayOneHundredPercentEmployerMatch_16b190c2-3088-42cc-84f9-1fa851b6e959" xlink:href="angn-20211231.xsd#angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayOneHundredPercentEmployerMatch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_974ad4a5-7e89-4973-a863-7aa8b63dce35" xlink:to="loc_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayOneHundredPercentEmployerMatch_16b190c2-3088-42cc-84f9-1fa851b6e959" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayFiftyPercentEmployerMatch_107d9d80-d155-4a91-b521-76a020bb148f" xlink:href="angn-20211231.xsd#angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayFiftyPercentEmployerMatch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_974ad4a5-7e89-4973-a863-7aa8b63dce35" xlink:to="loc_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayFiftyPercentEmployerMatch_107d9d80-d155-4a91-b521-76a020bb148f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable_cdaa379a-b34e-4e53-809b-dab3153cb879" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_974ad4a5-7e89-4973-a863-7aa8b63dce35" xlink:to="loc_us-gaap_DefinedContributionPlanTable_cdaa379a-b34e-4e53-809b-dab3153cb879" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9732361b-c052-4646-b14a-8da0837aed6e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedContributionPlanTable_cdaa379a-b34e-4e53-809b-dab3153cb879" xlink:to="loc_srt_RangeAxis_9732361b-c052-4646-b14a-8da0837aed6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9732361b-c052-4646-b14a-8da0837aed6e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9732361b-c052-4646-b14a-8da0837aed6e" xlink:to="loc_srt_RangeMember_9732361b-c052-4646-b14a-8da0837aed6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c15c7268-ff91-439c-8008-81a0ffd38d1e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9732361b-c052-4646-b14a-8da0837aed6e" xlink:to="loc_srt_RangeMember_c15c7268-ff91-439c-8008-81a0ffd38d1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5055de20-a75d-4583-9e73-9761b1199325" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c15c7268-ff91-439c-8008-81a0ffd38d1e" xlink:to="loc_srt_MinimumMember_5055de20-a75d-4583-9e73-9761b1199325" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0811ecd2-f90b-4a2b-b042-bfcda5506309" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c15c7268-ff91-439c-8008-81a0ffd38d1e" xlink:to="loc_srt_MaximumMember_0811ecd2-f90b-4a2b-b042-bfcda5506309" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/NetLossPerShareScheduleofantidilutivesecuritiesexcludedfromcomputationofnetlosspershareDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#NetLossPerShareScheduleofantidilutivesecuritiesexcludedfromcomputationofnetlosspershareDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/NetLossPerShareScheduleofantidilutivesecuritiesexcludedfromcomputationofnetlosspershareDetails" xlink:type="extended" id="i49e1b12cf8994d9db8afb146ba74f639_NetLossPerShareScheduleofantidilutivesecuritiesexcludedfromcomputationofnetlosspershareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_03750ea6-0cf9-4c3a-9742-cdc72d1ffd66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_addb9456-e804-4c19-b65e-34f9377e612f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_03750ea6-0cf9-4c3a-9742-cdc72d1ffd66" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_addb9456-e804-4c19-b65e-34f9377e612f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_SharesIssuableUponConversionOfConvertibleNotesDiscountRate_95b4084a-22e2-4c9c-8b8e-c384d43dd626" xlink:href="angn-20211231.xsd#angn_SharesIssuableUponConversionOfConvertibleNotesDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_03750ea6-0cf9-4c3a-9742-cdc72d1ffd66" xlink:to="loc_angn_SharesIssuableUponConversionOfConvertibleNotesDiscountRate_95b4084a-22e2-4c9c-8b8e-c384d43dd626" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8a7a98f2-c5b0-460a-b718-20ccd69bea19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_03750ea6-0cf9-4c3a-9742-cdc72d1ffd66" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8a7a98f2-c5b0-460a-b718-20ccd69bea19" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7fe47d35-5aae-4a5d-90bb-0063a269563c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8a7a98f2-c5b0-460a-b718-20ccd69bea19" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7fe47d35-5aae-4a5d-90bb-0063a269563c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7fe47d35-5aae-4a5d-90bb-0063a269563c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7fe47d35-5aae-4a5d-90bb-0063a269563c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_7fe47d35-5aae-4a5d-90bb-0063a269563c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23aa28bc-53b5-4fd0-b168-e314a8be6623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7fe47d35-5aae-4a5d-90bb-0063a269563c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23aa28bc-53b5-4fd0-b168-e314a8be6623" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d2a2fc87-6193-494c-8a35-6d9656cc7193" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23aa28bc-53b5-4fd0-b168-e314a8be6623" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d2a2fc87-6193-494c-8a35-6d9656cc7193" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_2572d32e-f8b2-4595-86ab-3737301af8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23aa28bc-53b5-4fd0-b168-e314a8be6623" xlink:to="loc_us-gaap_WarrantMember_2572d32e-f8b2-4595-86ab-3737301af8f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_1a5fee0e-5b70-4ff0-a2f6-7b5ec4006ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23aa28bc-53b5-4fd0-b168-e314a8be6623" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_1a5fee0e-5b70-4ff0-a2f6-7b5ec4006ca2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_1eb0524b-a807-436d-8dd1-704ab3c97ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23aa28bc-53b5-4fd0-b168-e314a8be6623" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_1eb0524b-a807-436d-8dd1-704ab3c97ab0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d93d6ca2-c303-4656-b11c-cc1ef19ba781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23aa28bc-53b5-4fd0-b168-e314a8be6623" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d93d6ca2-c303-4656-b11c-cc1ef19ba781" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_853d3efc-08b1-4d84-b38e-e14993d8df6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23aa28bc-53b5-4fd0-b168-e314a8be6623" xlink:to="loc_us-gaap_RestrictedStockMember_853d3efc-08b1-4d84-b38e-e14993d8df6f" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#RelatedPartyTransactionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended" id="i09105268b96a4a68a85249d7729c4dd0_RelatedPartyTransactionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsAndSecuritiesAtCost_7e71c191-e248-4766-9e66-5d40f487106f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentsAndSecuritiesAtCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_us-gaap_OtherInvestmentsAndSecuritiesAtCost_7e71c191-e248-4766-9e66-5d40f487106f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OtherInvestmentAndSecuritiesAtCostOwnershipPercentage_70de4631-15c9-41b9-ad15-7f3967376521" xlink:href="angn-20211231.xsd#angn_OtherInvestmentAndSecuritiesAtCostOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_angn_OtherInvestmentAndSecuritiesAtCostOwnershipPercentage_70de4631-15c9-41b9-ad15-7f3967376521" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_1a2a8ca9-d8a2-44a3-b318-e4442ba1a09e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_1a2a8ca9-d8a2-44a3-b318-e4442ba1a09e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_RelatedPartyTransactionPotentialMaximumMilestonePayment_14d12ba7-5994-4ad5-a486-ef3ed3c22a2c" xlink:href="angn-20211231.xsd#angn_RelatedPartyTransactionPotentialMaximumMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_angn_RelatedPartyTransactionPotentialMaximumMilestonePayment_14d12ba7-5994-4ad5-a486-ef3ed3c22a2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_RelatedPartyTransactionRoyaltiesAndMilestonePaymentsPeriod_a41fb340-4b5b-4524-b102-9b29a6598d7a" xlink:href="angn-20211231.xsd#angn_RelatedPartyTransactionRoyaltiesAndMilestonePaymentsPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_angn_RelatedPartyTransactionRoyaltiesAndMilestonePaymentsPeriod_a41fb340-4b5b-4524-b102-9b29a6598d7a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_a085d2a0-fb4d-432a-84c5-df62a64be2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_us-gaap_RevenueFromRelatedParties_a085d2a0-fb4d-432a-84c5-df62a64be2ee" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_fab0840b-8f54-4deb-a64d-fd746edc9886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_fab0840b-8f54-4deb-a64d-fd746edc9886" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_af941c8f-1bc5-4faf-ac59-bb03a3f382bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_us-gaap_OperatingLeaseCost_af941c8f-1bc5-4faf-ac59-bb03a3f382bd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_24135142-8016-47a8-aae1-d52462c132c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_us-gaap_VariableLeaseCost_24135142-8016-47a8-aae1-d52462c132c5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a445ea3d-e1e1-44f9-948f-1747d60cb0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a445ea3d-e1e1-44f9-948f-1747d60cb0f2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_f78aee50-859e-4993-a847-3bdd313168d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_f78aee50-859e-4993-a847-3bdd313168d0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_b5f26fb3-f17e-4bc7-a350-8fe33771086e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_b5f26fb3-f17e-4bc7-a350-8fe33771086e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_505fd5a7-2c44-4960-88e3-d66ffd24872b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_505fd5a7-2c44-4960-88e3-d66ffd24872b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ConvertiblePreferredStockConversionPrice_3c7d7973-f3c6-454f-a4c0-a7118dd36aff" xlink:href="angn-20211231.xsd#angn_ConvertiblePreferredStockConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_angn_ConvertiblePreferredStockConversionPrice_3c7d7973-f3c6-454f-a4c0-a7118dd36aff" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_0b24952e-c415-42f8-9a4e-4f1e38b5593c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_0b24952e-c415-42f8-9a4e-4f1e38b5593c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_873e6115-bc40-480d-8fe0-60b9e89c5a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_873e6115-bc40-480d-8fe0-60b9e89c5a3c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f26d506d-f89f-4b29-8987-de66cff245b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f26d506d-f89f-4b29-8987-de66cff245b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fae1a148-ed31-4a64-bd0d-9429c342c8e3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f26d506d-f89f-4b29-8987-de66cff245b8" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fae1a148-ed31-4a64-bd0d-9429c342c8e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_fae1a148-ed31-4a64-bd0d-9429c342c8e3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fae1a148-ed31-4a64-bd0d-9429c342c8e3" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_fae1a148-ed31-4a64-bd0d-9429c342c8e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_3ccd8773-f8f0-48fc-8040-150e3d8f23b8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fae1a148-ed31-4a64-bd0d-9429c342c8e3" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_3ccd8773-f8f0-48fc-8040-150e3d8f23b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OhrCosmeticsLLCMember_c222fbfe-10bf-40d0-8a23-49f3f8746d10" xlink:href="angn-20211231.xsd#angn_OhrCosmeticsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_3ccd8773-f8f0-48fc-8040-150e3d8f23b8" xlink:to="loc_angn_OhrCosmeticsLLCMember_c222fbfe-10bf-40d0-8a23-49f3f8746d10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NovaParkMember_bfc034a8-2e58-46f8-9bb5-abebdf4dfa2c" xlink:href="angn-20211231.xsd#angn_NovaParkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_3ccd8773-f8f0-48fc-8040-150e3d8f23b8" xlink:to="loc_angn_NovaParkMember_bfc034a8-2e58-46f8-9bb5-abebdf4dfa2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_54ffe575-ea9b-414a-966a-0677571ecee3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f26d506d-f89f-4b29-8987-de66cff245b8" xlink:to="loc_srt_OwnershipAxis_54ffe575-ea9b-414a-966a-0677571ecee3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_54ffe575-ea9b-414a-966a-0677571ecee3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_54ffe575-ea9b-414a-966a-0677571ecee3" xlink:to="loc_srt_OwnershipDomain_54ffe575-ea9b-414a-966a-0677571ecee3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_31dc0be8-fc91-4f50-8b38-2c2557b735f9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_54ffe575-ea9b-414a-966a-0677571ecee3" xlink:to="loc_srt_OwnershipDomain_31dc0be8-fc91-4f50-8b38-2c2557b735f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OhrCosmeticsLLCMember_2acfcef1-1b00-44b1-b137-f2f5eaa899b7" xlink:href="angn-20211231.xsd#angn_OhrCosmeticsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_31dc0be8-fc91-4f50-8b38-2c2557b735f9" xlink:to="loc_angn_OhrCosmeticsLLCMember_2acfcef1-1b00-44b1-b137-f2f5eaa899b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3234f323-fb3b-4a7b-9c2f-2f3576014fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f26d506d-f89f-4b29-8987-de66cff245b8" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3234f323-fb3b-4a7b-9c2f-2f3576014fb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3234f323-fb3b-4a7b-9c2f-2f3576014fb1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3234f323-fb3b-4a7b-9c2f-2f3576014fb1" xlink:to="loc_us-gaap_RelatedPartyDomain_3234f323-fb3b-4a7b-9c2f-2f3576014fb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9488da80-d810-45b9-bd9c-9abc6549d535" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3234f323-fb3b-4a7b-9c2f-2f3576014fb1" xlink:to="loc_us-gaap_RelatedPartyDomain_9488da80-d810-45b9-bd9c-9abc6549d535" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_4183eb81-ede4-4278-8b0c-d16d6a50c2e7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9488da80-d810-45b9-bd9c-9abc6549d535" xlink:to="loc_srt_AffiliatedEntityMember_4183eb81-ede4-4278-8b0c-d16d6a50c2e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember_0e21b74d-37b1-4619-a353-4ac093b9c066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9488da80-d810-45b9-bd9c-9abc6549d535" xlink:to="loc_us-gaap_EquityMethodInvesteeMember_0e21b74d-37b1-4619-a353-4ac093b9c066" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_DirectorsAndFamilyMemberOfChiefExecutiveOfficerDirectorMember_7fbcb653-1b21-42b1-8ef9-06983ba4c351" xlink:href="angn-20211231.xsd#angn_DirectorsAndFamilyMemberOfChiefExecutiveOfficerDirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9488da80-d810-45b9-bd9c-9abc6549d535" xlink:to="loc_angn_DirectorsAndFamilyMemberOfChiefExecutiveOfficerDirectorMember_7fbcb653-1b21-42b1-8ef9-06983ba4c351" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PresidentAndChiefExecutiveOfficerAndDirectorMember_b78bc384-f8a0-45cf-80a7-2101cede95d4" xlink:href="angn-20211231.xsd#angn_PresidentAndChiefExecutiveOfficerAndDirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9488da80-d810-45b9-bd9c-9abc6549d535" xlink:to="loc_angn_PresidentAndChiefExecutiveOfficerAndDirectorMember_b78bc384-f8a0-45cf-80a7-2101cede95d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_b8f63c43-bc8e-4593-9a8f-efac4cb3e5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9488da80-d810-45b9-bd9c-9abc6549d535" xlink:to="loc_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_b8f63c43-bc8e-4593-9a8f-efac4cb3e5cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FormerMemberOfTheBoardOfDirectorsMember_c4180c75-c3e8-4683-b202-7d09d5dd50a3" xlink:href="angn-20211231.xsd#angn_FormerMemberOfTheBoardOfDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9488da80-d810-45b9-bd9c-9abc6549d535" xlink:to="loc_angn_FormerMemberOfTheBoardOfDirectorsMember_c4180c75-c3e8-4683-b202-7d09d5dd50a3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_12e0215f-9cc8-4d64-857d-5a875e251bbb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f26d506d-f89f-4b29-8987-de66cff245b8" xlink:to="loc_dei_LegalEntityAxis_12e0215f-9cc8-4d64-857d-5a875e251bbb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_12e0215f-9cc8-4d64-857d-5a875e251bbb_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_12e0215f-9cc8-4d64-857d-5a875e251bbb" xlink:to="loc_dei_EntityDomain_12e0215f-9cc8-4d64-857d-5a875e251bbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_155b1105-278b-4bb3-acae-0d9e66c04d56" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_12e0215f-9cc8-4d64-857d-5a875e251bbb" xlink:to="loc_dei_EntityDomain_155b1105-278b-4bb3-acae-0d9e66c04d56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ImmediateFamilyOfDirectorAndChairmanMember_2f5bb385-ae33-4176-b28d-b35cb0b67f4d" xlink:href="angn-20211231.xsd#angn_ImmediateFamilyOfDirectorAndChairmanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_155b1105-278b-4bb3-acae-0d9e66c04d56" xlink:to="loc_angn_ImmediateFamilyOfDirectorAndChairmanMember_2f5bb385-ae33-4176-b28d-b35cb0b67f4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NovaParkMember_8fe7dbb5-8684-47d1-bf76-2e40014d514a" xlink:href="angn-20211231.xsd#angn_NovaParkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_155b1105-278b-4bb3-acae-0d9e66c04d56" xlink:to="loc_angn_NovaParkMember_8fe7dbb5-8684-47d1-bf76-2e40014d514a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_d755ef3c-7b13-43a6-88ff-8cc0aeb7ded0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f26d506d-f89f-4b29-8987-de66cff245b8" xlink:to="loc_srt_TitleOfIndividualAxis_d755ef3c-7b13-43a6-88ff-8cc0aeb7ded0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d755ef3c-7b13-43a6-88ff-8cc0aeb7ded0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_d755ef3c-7b13-43a6-88ff-8cc0aeb7ded0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d755ef3c-7b13-43a6-88ff-8cc0aeb7ded0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7d0f2800-17a3-4d01-83c3-5245feade08e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_d755ef3c-7b13-43a6-88ff-8cc0aeb7ded0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7d0f2800-17a3-4d01-83c3-5245feade08e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_95d894b9-a4f3-44a5-89f5-73807c8c18c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7d0f2800-17a3-4d01-83c3-5245feade08e" xlink:to="loc_srt_ChiefExecutiveOfficerMember_95d894b9-a4f3-44a5-89f5-73807c8c18c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c64d3623-92d3-4818-979c-bb71b70e36dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f26d506d-f89f-4b29-8987-de66cff245b8" xlink:to="loc_srt_CounterpartyNameAxis_c64d3623-92d3-4818-979c-bb71b70e36dd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c64d3623-92d3-4818-979c-bb71b70e36dd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c64d3623-92d3-4818-979c-bb71b70e36dd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c64d3623-92d3-4818-979c-bb71b70e36dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8bb50d2d-daa5-4759-aab9-114b3f1203ef" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c64d3623-92d3-4818-979c-bb71b70e36dd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8bb50d2d-daa5-4759-aab9-114b3f1203ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OhrCosmeticsLLCMember_48a4f66d-503c-491b-9877-efb50bad007e" xlink:href="angn-20211231.xsd#angn_OhrCosmeticsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8bb50d2d-daa5-4759-aab9-114b3f1203ef" xlink:to="loc_angn_OhrCosmeticsLLCMember_48a4f66d-503c-491b-9877-efb50bad007e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NovaParkMember_4700d4b3-dede-4b91-86f9-45c2c2359ea6" xlink:href="angn-20211231.xsd#angn_NovaParkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8bb50d2d-daa5-4759-aab9-114b3f1203ef" xlink:to="loc_angn_NovaParkMember_4700d4b3-dede-4b91-86f9-45c2c2359ea6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_67b7be91-d7c3-4f6b-8d64-4664caefd886" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f26d506d-f89f-4b29-8987-de66cff245b8" xlink:to="loc_srt_ProductOrServiceAxis_67b7be91-d7c3-4f6b-8d64-4664caefd886" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_67b7be91-d7c3-4f6b-8d64-4664caefd886_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_67b7be91-d7c3-4f6b-8d64-4664caefd886" xlink:to="loc_srt_ProductsAndServicesDomain_67b7be91-d7c3-4f6b-8d64-4664caefd886_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1affab63-4904-4d47-a56a-fbced79d94ad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_67b7be91-d7c3-4f6b-8d64-4664caefd886" xlink:to="loc_srt_ProductsAndServicesDomain_1affab63-4904-4d47-a56a-fbced79d94ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_684c261d-462e-4b5d-9389-41ea314b5c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1affab63-4904-4d47-a56a-fbced79d94ad" xlink:to="loc_us-gaap_LicenseMember_684c261d-462e-4b5d-9389-41ea314b5c0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4c77f080-7140-4340-8a2d-0354b1886818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f26d506d-f89f-4b29-8987-de66cff245b8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4c77f080-7140-4340-8a2d-0354b1886818" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4c77f080-7140-4340-8a2d-0354b1886818_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4c77f080-7140-4340-8a2d-0354b1886818" xlink:to="loc_us-gaap_EquityComponentDomain_4c77f080-7140-4340-8a2d-0354b1886818_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6c1ada06-7ba9-4e9c-927e-2746debb66c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4c77f080-7140-4340-8a2d-0354b1886818" xlink:to="loc_us-gaap_EquityComponentDomain_6c1ada06-7ba9-4e9c-927e-2746debb66c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cc93682f-cb0a-4d96-bc50-8798a7ac08ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6c1ada06-7ba9-4e9c-927e-2746debb66c3" xlink:to="loc_us-gaap_CommonStockMember_cc93682f-cb0a-4d96-bc50-8798a7ac08ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1e080985-c532-40f6-8c89-b2d6a82ab2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f26d506d-f89f-4b29-8987-de66cff245b8" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1e080985-c532-40f6-8c89-b2d6a82ab2e3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1e080985-c532-40f6-8c89-b2d6a82ab2e3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1e080985-c532-40f6-8c89-b2d6a82ab2e3" xlink:to="loc_us-gaap_ClassOfStockDomain_1e080985-c532-40f6-8c89-b2d6a82ab2e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_37d52eba-7944-4895-91d3-0ec8acda7498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1e080985-c532-40f6-8c89-b2d6a82ab2e3" xlink:to="loc_us-gaap_ClassOfStockDomain_37d52eba-7944-4895-91d3-0ec8acda7498" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_845f290f-907a-44f4-a3b9-7d33284c3a04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_37d52eba-7944-4895-91d3-0ec8acda7498" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_845f290f-907a-44f4-a3b9-7d33284c3a04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_428fc69b-36d7-47a2-88a9-01e467738076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f26d506d-f89f-4b29-8987-de66cff245b8" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_428fc69b-36d7-47a2-88a9-01e467738076" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_428fc69b-36d7-47a2-88a9-01e467738076_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_428fc69b-36d7-47a2-88a9-01e467738076" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_428fc69b-36d7-47a2-88a9-01e467738076_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2e48d408-cd23-4fdc-b608-65c22d4d5e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_428fc69b-36d7-47a2-88a9-01e467738076" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2e48d408-cd23-4fdc-b608-65c22d4d5e02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ConsultingAgreementMember_aa9a8caa-32df-4148-8468-7c64f8373660" xlink:href="angn-20211231.xsd#angn_ConsultingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2e48d408-cd23-4fdc-b608-65c22d4d5e02" xlink:to="loc_angn_ConsultingAgreementMember_aa9a8caa-32df-4148-8468-7c64f8373660" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_LegalServicesMember_32628e28-31a7-4e64-bce3-dcd216a15acb" xlink:href="angn-20211231.xsd#angn_LegalServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2e48d408-cd23-4fdc-b608-65c22d4d5e02" xlink:to="loc_angn_LegalServicesMember_32628e28-31a7-4e64-bce3-dcd216a15acb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/RelatedPartyTransactionsNovaParkInvestmentDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#RelatedPartyTransactionsNovaParkInvestmentDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/RelatedPartyTransactionsNovaParkInvestmentDetails" xlink:type="extended" id="i73355bd2d1ff42038e2a3ce89c73064e_RelatedPartyTransactionsNovaParkInvestmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_81acf954-fb0a-4530-ba56-fec9191ca5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EquityMethodInvestmentsRollForward_298b4153-af5e-4002-9c83-15b6e7de0550" xlink:href="angn-20211231.xsd#angn_EquityMethodInvestmentsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_81acf954-fb0a-4530-ba56-fec9191ca5e7" xlink:to="loc_angn_EquityMethodInvestmentsRollForward_298b4153-af5e-4002-9c83-15b6e7de0550" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_bc034c0a-d609-4920-b1f9-1824da545d35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_angn_EquityMethodInvestmentsRollForward_298b4153-af5e-4002-9c83-15b6e7de0550" xlink:to="loc_us-gaap_EquityMethodInvestments_bc034c0a-d609-4920-b1f9-1824da545d35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ef7a9fcb-b70d-4979-86a8-a39c31a7698a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_angn_EquityMethodInvestmentsRollForward_298b4153-af5e-4002-9c83-15b6e7de0550" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ef7a9fcb-b70d-4979-86a8-a39c31a7698a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_dacd3bc5-0406-4d3f-92bb-801ea90b022a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_angn_EquityMethodInvestmentsRollForward_298b4153-af5e-4002-9c83-15b6e7de0550" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_dacd3bc5-0406-4d3f-92bb-801ea90b022a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_2dce7807-5065-4170-87a3-444903658196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_94d6fe39-2b75-47c6-9291-f2e10b7dcb85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_81acf954-fb0a-4530-ba56-fec9191ca5e7" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_94d6fe39-2b75-47c6-9291-f2e10b7dcb85" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_938fccb9-adba-4d6a-8323-57943907f723" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_94d6fe39-2b75-47c6-9291-f2e10b7dcb85" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_938fccb9-adba-4d6a-8323-57943907f723" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_938fccb9-adba-4d6a-8323-57943907f723_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_938fccb9-adba-4d6a-8323-57943907f723" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_938fccb9-adba-4d6a-8323-57943907f723_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6186a7e8-a08e-488d-8f1c-b197df12a33a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_938fccb9-adba-4d6a-8323-57943907f723" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6186a7e8-a08e-488d-8f1c-b197df12a33a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NovaParkMember_83b903be-3986-435e-a808-7299adf74cd8" xlink:href="angn-20211231.xsd#angn_NovaParkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6186a7e8-a08e-488d-8f1c-b197df12a33a" xlink:to="loc_angn_NovaParkMember_83b903be-3986-435e-a808-7299adf74cd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c0e26741-5426-4fc9-af8a-90642fbd45bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_94d6fe39-2b75-47c6-9291-f2e10b7dcb85" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c0e26741-5426-4fc9-af8a-90642fbd45bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c0e26741-5426-4fc9-af8a-90642fbd45bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c0e26741-5426-4fc9-af8a-90642fbd45bf" xlink:to="loc_us-gaap_RelatedPartyDomain_c0e26741-5426-4fc9-af8a-90642fbd45bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_df71db64-fd27-4f68-a1e5-8fb88329bab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c0e26741-5426-4fc9-af8a-90642fbd45bf" xlink:to="loc_us-gaap_RelatedPartyDomain_df71db64-fd27-4f68-a1e5-8fb88329bab7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember_fd864742-6374-4f86-b38c-f98f0e2c26d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_df71db64-fd27-4f68-a1e5-8fb88329bab7" xlink:to="loc_us-gaap_EquityMethodInvesteeMember_fd864742-6374-4f86-b38c-f98f0e2c26d6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.angn.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.angn.com/role/SubsequentEventsDetails" xlink:type="extended" id="ia320e6a3818b416fb65cb517ffbf7664_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_9ea47d1b-4cdc-4838-8805-2a35bbb71068" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_d2d487a4-9127-46b2-adbb-56c4e5b6a212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9ea47d1b-4cdc-4838-8805-2a35bbb71068" xlink:to="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_d2d487a4-9127-46b2-adbb-56c4e5b6a212" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ShareBasedPaymentArrangementPlanModificationExtendedExercisePeriod_bab91028-4701-462f-937b-a31b37a54b73" xlink:href="angn-20211231.xsd#angn_ShareBasedPaymentArrangementPlanModificationExtendedExercisePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_9ea47d1b-4cdc-4838-8805-2a35bbb71068" xlink:to="loc_angn_ShareBasedPaymentArrangementPlanModificationExtendedExercisePeriod_bab91028-4701-462f-937b-a31b37a54b73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_efa02fd2-b7a4-4a0f-9031-78247d5bd63b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_9ea47d1b-4cdc-4838-8805-2a35bbb71068" xlink:to="loc_us-gaap_SubsequentEventTable_efa02fd2-b7a4-4a0f-9031-78247d5bd63b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f672fa62-404c-48c2-adc4-32dfd646750e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_efa02fd2-b7a4-4a0f-9031-78247d5bd63b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f672fa62-404c-48c2-adc4-32dfd646750e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f672fa62-404c-48c2-adc4-32dfd646750e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f672fa62-404c-48c2-adc4-32dfd646750e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f672fa62-404c-48c2-adc4-32dfd646750e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_755fb46d-2d4b-46f6-b930-8b7e6a02f2df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f672fa62-404c-48c2-adc4-32dfd646750e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_755fb46d-2d4b-46f6-b930-8b7e6a02f2df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_87376d60-bac6-4818-951c-7f5404075a50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_755fb46d-2d4b-46f6-b930-8b7e6a02f2df" xlink:to="loc_us-gaap_SubsequentEventMember_87376d60-bac6-4818-951c-7f5404075a50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_5f708c3d-658e-4f33-bdd3-2ec274be53b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_efa02fd2-b7a4-4a0f-9031-78247d5bd63b" xlink:to="loc_us-gaap_PlanNameAxis_5f708c3d-658e-4f33-bdd3-2ec274be53b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5f708c3d-658e-4f33-bdd3-2ec274be53b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_5f708c3d-658e-4f33-bdd3-2ec274be53b3" xlink:to="loc_us-gaap_PlanNameDomain_5f708c3d-658e-4f33-bdd3-2ec274be53b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5364fc9e-70f0-4b9b-9463-1d519b22ec38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_5f708c3d-658e-4f33-bdd3-2ec274be53b3" xlink:to="loc_us-gaap_PlanNameDomain_5364fc9e-70f0-4b9b-9463-1d519b22ec38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_A2021IncentiveAwardPlanMember_f0e1ba05-4aa9-40b1-9032-779a32ca3899" xlink:href="angn-20211231.xsd#angn_A2021IncentiveAwardPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_5364fc9e-70f0-4b9b-9463-1d519b22ec38" xlink:to="loc_angn_A2021IncentiveAwardPlanMember_f0e1ba05-4aa9-40b1-9032-779a32ca3899" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>20
<FILENAME>angn-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:808f0db7-14af-45c6-a88e-e152464defe4,g:f048552f-f790-4462-b881-32982147c095-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_3850b6fc-3e87-4f5c-9044-87d67a88af2c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AustralianTaxationOfficeMember_867c078d-ff81-4e40-8c2e-6bb324a0675e_terseLabel_en-US" xlink:label="lab_us-gaap_AustralianTaxationOfficeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australian Taxation Office</link:label>
    <link:label id="lab_us-gaap_AustralianTaxationOfficeMember_label_en-US" xlink:label="lab_us-gaap_AustralianTaxationOfficeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australian Taxation Office [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AustralianTaxationOfficeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AustralianTaxationOfficeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AustralianTaxationOfficeMember" xlink:to="lab_us-gaap_AustralianTaxationOfficeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_6e46cff8-d7de-48f3-95fe-b9d7f316a126_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9e5babb2-3b7a-4c08-a0c7-72e72298879a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal statutory income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_2e702773-69cc-425a-bed7-29825daf5b44_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_64c1a7de-442f-4dce-9964-f77da760b447_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b7964564-3a2b-4569-b284-a0ceb0596880_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs vested and released (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2dc3bb6d-ca74-4d63-bd71-e646a231c349_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_4a79d9ba-7c64-4fae-96d4-279d29dbf806_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fd4c362f-9405-41b4-b367-a1f13d0e6b4d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_20d2459a-91e8-4e68-8f45-93964d056b04_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_400820eb-56a7-48f8-8b7d-1191b257b93e_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_c7648d7e-c69f-4f5c-bb5e-203a2e4ec0f7_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_c821c936-f610-40ef-8b2b-8ceeabbb732b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_05834dea-f619-4ad3-acc1-46f632e46888_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_d6a050a5-61c8-4136-a252-067760bfdb0b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stocks outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_c9067221-5bf5-4e9d-a767-f69741070194_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_d3fe7836-a09e-4865-8176-fc8270a61935_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_a737b604-050c-436e-bc94-0d632af9eb45_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering costs</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_label_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts" xlink:to="lab_us-gaap_DeferredOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_8ce78408-ac32-4df1-be2c-ef9d871a8fc8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_4db095fa-5787-47c6-bce8-5f06f5262b5e_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_3e0a3e0e-a259-4b16-9ba0-1cc70d695f1b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nontaxable Income</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_fb4e35a9-42f7-45e2-8421-eb76f0ccc99d_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_d8b67d6f-e671-4266-ad9b-5008a5d91de7_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_3d1d12d5-7243-4259-b8b1-84fbf1e025e8_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_abc705c8-23d3-4d04-9aef-a393c2343778_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_296b9873-f49a-4f7a-8447-597edf21a89b_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price of convertible notes (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_9d86372b-572f-4cf1-a92f-df6f7a79d3b5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5d2ed282-ebae-4e91-b3e5-b476bcf067ad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f7115566-560b-4989-95f9-6f2c4636a3cb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c169ede0-bf86-444f-aab2-d9f2156fed3a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term&#8212;operating leases (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_bd0ad937-7a16-47d2-be3f-a7b1032f87c7_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation and Transactions</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1930dfda-aa37-4ff3-b456-e4aed02469f7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_5ee0aae5-6053-47d2-b6bf-87bf833de487_terseLabel_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible note receivable</link:label>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_52079071-a7d4-4132-bd33-f859dae35a2a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4f9223d0-f489-48ff-96bf-ef3a86236be9_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_BrokerWarrantsIssuedWith2019NotesLiabilityMember_2614ad92-c05d-438f-ac79-a0e642a5e46f_terseLabel_en-US" xlink:label="lab_angn_BrokerWarrantsIssuedWith2019NotesLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Broker Warrants issued with 2019 Notes</link:label>
    <link:label id="lab_angn_BrokerWarrantsIssuedWith2019NotesLiabilityMember_label_en-US" xlink:label="lab_angn_BrokerWarrantsIssuedWith2019NotesLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Broker Warrants Issued with2019 Notes, Liability [Member]</link:label>
    <link:label id="lab_angn_BrokerWarrantsIssuedWith2019NotesLiabilityMember_documentation_en-US" xlink:label="lab_angn_BrokerWarrantsIssuedWith2019NotesLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Broker Warrants Issued with2019 Notes, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BrokerWarrantsIssuedWith2019NotesLiabilityMember" xlink:href="angn-20211231.xsd#angn_BrokerWarrantsIssuedWith2019NotesLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_BrokerWarrantsIssuedWith2019NotesLiabilityMember" xlink:to="lab_angn_BrokerWarrantsIssuedWith2019NotesLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_84601cd3-d374-479d-a2b5-bbe8107ad66c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for purchase under the ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c2d92faa-079a-40aa-920e-1b53b2439782_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_978b9497-121f-4c5d-ad23-5c20926e1781_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_e1e8bab9-11a8-46ca-8636-8cf02d142e3a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_60264d0b-53eb-47f9-b192-9006091b67d4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_642891eb-3b71-4181-b9d0-0728a6d830b7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_c914a597-18f4-4b9a-8a56-e0c650fc7db2_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses from transactions with related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePrice_f583c0be-4a44-46eb-88ac-8adee5b26ed8_periodStartLabel_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning (in dollars per share)</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePrice_e9bc861c-26f2-487b-bc03-360a9c39ba14_periodEndLabel_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, ending (in dollars per share)</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePrice_label_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Weighted Average Exercise Price</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:href="angn-20211231.xsd#angn_ClassOfWarrantOrRightWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:to="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_be6ae7c3-2c5d-47e4-b18a-b4b8444356fd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_19718151-3f6b-4087-9bee-818d7250a37d_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_61876446-c205-4d87-a874-50064a77b563_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_82dcb223-36df-4ced-a5e2-e5bd1174e983_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_91e7a786-4dd6-467d-a9af-a1ea89d677fb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_7ae877db-e2d6-4c8b-81b9-e47b3b56e6c5_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_fefcbf89-cac7-463d-982c-4ef676a545cb_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_cf334e28-691a-4d1c-b714-75cc5a60f579_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net of allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3822a835-c1ca-4719-84bf-5f9b85025513_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d35ad8e9-d873-4259-986b-18ac5ee54492_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate&#8212;operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_7562a904-98f6-4cf5-88a1-35ed9afc77f0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_b1b8894a-dcca-4df1-965e-8a94d6e6fc44_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_fc48fcfd-b65c-43d0-ab99-af025cb0ccf4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidTaxes_00525e33-1edb-4cba-9cfc-de5f50ec3504_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Angion Pty tax</link:label>
    <link:label id="lab_us-gaap_PrepaidTaxes_label_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidTaxes" xlink:to="lab_us-gaap_PrepaidTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_WarrantsIssuedWith2017NotesLiabilityMember_dbced573-8e08-4bf4-b887-fbc77dbccd72_terseLabel_en-US" xlink:label="lab_angn_WarrantsIssuedWith2017NotesLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued with 2017 Notes</link:label>
    <link:label id="lab_angn_WarrantsIssuedWith2017NotesLiabilityMember_label_en-US" xlink:label="lab_angn_WarrantsIssuedWith2017NotesLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued with 2017 Notes, Liability [Member]</link:label>
    <link:label id="lab_angn_WarrantsIssuedWith2017NotesLiabilityMember_documentation_en-US" xlink:label="lab_angn_WarrantsIssuedWith2017NotesLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued with 2017 Notes, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsIssuedWith2017NotesLiabilityMember" xlink:href="angn-20211231.xsd#angn_WarrantsIssuedWith2017NotesLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_WarrantsIssuedWith2017NotesLiabilityMember" xlink:to="lab_angn_WarrantsIssuedWith2017NotesLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_7a8a7b7a-f6c3-4eb1-96e8-3d8d43daef17_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock split, conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_8e8ce823-fd3c-4a00-b3b3-ad0670cbdb52_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_967fce27-581d-48f9-9f13-7ea415b28d23_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_PaymentsForBrokerWarrantExercises_50457272-ec7c-4178-8e32-32854074bdeb_negatedTerseLabel_en-US" xlink:label="lab_angn_PaymentsForBrokerWarrantExercises" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of broker warrants</link:label>
    <link:label id="lab_angn_PaymentsForBrokerWarrantExercises_label_en-US" xlink:label="lab_angn_PaymentsForBrokerWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Broker Warrant Exercises</link:label>
    <link:label id="lab_angn_PaymentsForBrokerWarrantExercises_documentation_en-US" xlink:label="lab_angn_PaymentsForBrokerWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Broker Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PaymentsForBrokerWarrantExercises" xlink:href="angn-20211231.xsd#angn_PaymentsForBrokerWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_PaymentsForBrokerWarrantExercises" xlink:to="lab_angn_PaymentsForBrokerWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_943c139d-167e-48d3-85b7-81e735bd79ee_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_933baad5-12a7-469c-9141-a03cee8a0a8b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_b09a1185-162a-49a4-8571-02f3cd9fe862_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_1506182b-7161-40e5-a8e7-db4359e2c86f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_711b16ea-1c18-4c9b-8e45-0861dfb1877b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Activity, Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d6cf550a-b9b0-4cb6-af0d-79e76fe910bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_CARESActEmployeeRetentionCredit_b1e53056-4241-4aaf-a156-a308e430a525_terseLabel_en-US" xlink:label="lab_angn_CARESActEmployeeRetentionCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act, Employee Retention Credit</link:label>
    <link:label id="lab_angn_CARESActEmployeeRetentionCredit_label_en-US" xlink:label="lab_angn_CARESActEmployeeRetentionCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act, Employee Retention Credit</link:label>
    <link:label id="lab_angn_CARESActEmployeeRetentionCredit_documentation_en-US" xlink:label="lab_angn_CARESActEmployeeRetentionCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act, Employee Retention Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_CARESActEmployeeRetentionCredit" xlink:href="angn-20211231.xsd#angn_CARESActEmployeeRetentionCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_CARESActEmployeeRetentionCredit" xlink:to="lab_angn_CARESActEmployeeRetentionCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_ad2aac30-0041-4c66-8561-d72bca00f010_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_DeferredTaxAssetsOperatingLeaseLiability_d066a9ef-fd4d-4bb1-bc37-ed11cd893ea2_terseLabel_en-US" xlink:label="lab_angn_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_angn_DeferredTaxAssetsOperatingLeaseLiability_label_en-US" xlink:label="lab_angn_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Liability</link:label>
    <link:label id="lab_angn_DeferredTaxAssetsOperatingLeaseLiability_documentation_en-US" xlink:label="lab_angn_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_DeferredTaxAssetsOperatingLeaseLiability" xlink:href="angn-20211231.xsd#angn_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="lab_angn_DeferredTaxAssetsOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9e976423-74c4-4baa-a9e8-a8b57c41599e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_680e1b1e-83e4-4b3c-9b24-3d54bf55822a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_WarrantsAndRightsOutstandingAbstract_label_en-US" xlink:label="lab_angn_WarrantsAndRightsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding [Abstract]</link:label>
    <link:label id="lab_angn_WarrantsAndRightsOutstandingAbstract_documentation_en-US" xlink:label="lab_angn_WarrantsAndRightsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsAndRightsOutstandingAbstract" xlink:href="angn-20211231.xsd#angn_WarrantsAndRightsOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_WarrantsAndRightsOutstandingAbstract" xlink:to="lab_angn_WarrantsAndRightsOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_4f60ae0f-5ece-499b-972a-e5de4389ec35_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_caccaf6f-067b-46db-a1fd-19157fa1e02c_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_96119e92-e6ba-4fcd-8ee7-6a127110cac7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8003eed8-cace-4b03-b591-e41f10fd9896_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_1b9166f0-5c9b-4fbe-99ea-699d80cbaed9_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of office space (in sqft)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_1f29e2e5-9d18-4c21-9d85-52c6dc297a5d_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_b18e6441-0215-492f-9aea-2a6b86b3b839_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_84745d90-df01-4168-a7d4-54aca36babe9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1d672748-33e1-4813-ac48-904faba3134d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible notes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_WarrantsIssuedWithConversionOfNotesToCommonStockEquityMember_5b2b6816-c464-4636-ab5f-96bf2067a930_terseLabel_en-US" xlink:label="lab_angn_WarrantsIssuedWithConversionOfNotesToCommonStockEquityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued with Conversion of Notes to Common Stock</link:label>
    <link:label id="lab_angn_WarrantsIssuedWithConversionOfNotesToCommonStockEquityMember_label_en-US" xlink:label="lab_angn_WarrantsIssuedWithConversionOfNotesToCommonStockEquityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued with Conversion Of Notes To Common Stock, Equity [Member]</link:label>
    <link:label id="lab_angn_WarrantsIssuedWithConversionOfNotesToCommonStockEquityMember_documentation_en-US" xlink:label="lab_angn_WarrantsIssuedWithConversionOfNotesToCommonStockEquityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued with Conversion Of Notes To Common Stock, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsIssuedWithConversionOfNotesToCommonStockEquityMember" xlink:href="angn-20211231.xsd#angn_WarrantsIssuedWithConversionOfNotesToCommonStockEquityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_WarrantsIssuedWithConversionOfNotesToCommonStockEquityMember" xlink:to="lab_angn_WarrantsIssuedWithConversionOfNotesToCommonStockEquityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c1a1c414-8adb-4e57-a6ca-664a88e97732_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesOperatingAbstract_e6f1ca73-1580-49e0-800e-1cc77fc9934b_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesOperatingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_LeasesOperatingAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesOperatingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases, Operating [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesOperatingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesOperatingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesOperatingAbstract" xlink:to="lab_us-gaap_LeasesOperatingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ContractWithCustomerContractTerminationPeriodCurableBreach_2aaf574f-4b5b-481c-a885-9e45f94013a4_terseLabel_en-US" xlink:label="lab_angn_ContractWithCustomerContractTerminationPeriodCurableBreach" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract termination period, curable breach</link:label>
    <link:label id="lab_angn_ContractWithCustomerContractTerminationPeriodCurableBreach_label_en-US" xlink:label="lab_angn_ContractWithCustomerContractTerminationPeriodCurableBreach" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Termination Period, Curable Breach</link:label>
    <link:label id="lab_angn_ContractWithCustomerContractTerminationPeriodCurableBreach_documentation_en-US" xlink:label="lab_angn_ContractWithCustomerContractTerminationPeriodCurableBreach" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Termination Period, Curable Breach</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerContractTerminationPeriodCurableBreach" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerContractTerminationPeriodCurableBreach"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ContractWithCustomerContractTerminationPeriodCurableBreach" xlink:to="lab_angn_ContractWithCustomerContractTerminationPeriodCurableBreach" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ContractWithCustomerMilestonePaymentsEntitledToReceive_eeaab66f-dfc5-40a1-9f8b-60773e70e276_terseLabel_en-US" xlink:label="lab_angn_ContractWithCustomerMilestonePaymentsEntitledToReceive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total milestone payment, entitled to receive</link:label>
    <link:label id="lab_angn_ContractWithCustomerMilestonePaymentsEntitledToReceive_label_en-US" xlink:label="lab_angn_ContractWithCustomerMilestonePaymentsEntitledToReceive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Milestone Payments, Entitled To Receive</link:label>
    <link:label id="lab_angn_ContractWithCustomerMilestonePaymentsEntitledToReceive_documentation_en-US" xlink:label="lab_angn_ContractWithCustomerMilestonePaymentsEntitledToReceive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Milestone Payments, Entitled To Receive</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerMilestonePaymentsEntitledToReceive" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerMilestonePaymentsEntitledToReceive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ContractWithCustomerMilestonePaymentsEntitledToReceive" xlink:to="lab_angn_ContractWithCustomerMilestonePaymentsEntitledToReceive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3f7596c6-4ca1-4d6f-8662-0edf58eb888a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_9739b8f5-3b1d-47a1-b596-eef2524cd55a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_843e3d95-8e73-4a34-ab22-5430dfb592f5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution from equity investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_d5f83751-9462-4e4e-afa9-4baa9bff5a1d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution from NovaPark</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:to="lab_us-gaap_EquityMethodInvestmentDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_db9848f9-8742-48d6-86ed-d869c774dda1_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets purchased in accrued expenses or accounts payable</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c4f84387-8be6-4433-8c51-7bf6972b0ae9_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use assets exchanged for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b0c970bc-b29e-4691-a6ae-5253067a268c_verboseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets exchanged for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_FormerMemberOfTheBoardOfDirectorsMember_bd13b574-cd26-403f-b4a0-037a7580c0e2_terseLabel_en-US" xlink:label="lab_angn_FormerMemberOfTheBoardOfDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Member of the Board of Directors</link:label>
    <link:label id="lab_angn_FormerMemberOfTheBoardOfDirectorsMember_label_en-US" xlink:label="lab_angn_FormerMemberOfTheBoardOfDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Member Of The Board Of Directors [Member]</link:label>
    <link:label id="lab_angn_FormerMemberOfTheBoardOfDirectorsMember_documentation_en-US" xlink:label="lab_angn_FormerMemberOfTheBoardOfDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Member Of The Board Of Directors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FormerMemberOfTheBoardOfDirectorsMember" xlink:href="angn-20211231.xsd#angn_FormerMemberOfTheBoardOfDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_FormerMemberOfTheBoardOfDirectorsMember" xlink:to="lab_angn_FormerMemberOfTheBoardOfDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentIncreaseAccruedInterest_ae3c662a-95bc-4252-89f5-daaa76f74e28_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase due to accrued interest balance</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentIncreaseAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Increase, Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="lab_us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_ea33120a-3843-4831-ad12-634a6aaabbe7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_AccruedDirectResearchCostsCurrent_2f008206-7cb8-4033-81b8-bd81dcf3ac8d_terseLabel_en-US" xlink:label="lab_angn_AccruedDirectResearchCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued direct research costs</link:label>
    <link:label id="lab_angn_AccruedDirectResearchCostsCurrent_label_en-US" xlink:label="lab_angn_AccruedDirectResearchCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Direct Research Costs, Current</link:label>
    <link:label id="lab_angn_AccruedDirectResearchCostsCurrent_documentation_en-US" xlink:label="lab_angn_AccruedDirectResearchCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Direct Research Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AccruedDirectResearchCostsCurrent" xlink:href="angn-20211231.xsd#angn_AccruedDirectResearchCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_AccruedDirectResearchCostsCurrent" xlink:to="lab_angn_AccruedDirectResearchCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_c09d7678-f4d1-4206-b63c-0998bb5f843d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_93892f99-302c-4b79-a256-83d589aeffb0_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_8335f4cc-cf65-44ae-b9ec-49c8e9a1d5cb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ContractWithCustomerPostApprovalMilestonePaymentEntitledToReceive_48c03559-56d1-44e6-bd37-654a4567d5a5_terseLabel_en-US" xlink:label="lab_angn_ContractWithCustomerPostApprovalMilestonePaymentEntitledToReceive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-approval milestone payment, entitled to receive</link:label>
    <link:label id="lab_angn_ContractWithCustomerPostApprovalMilestonePaymentEntitledToReceive_label_en-US" xlink:label="lab_angn_ContractWithCustomerPostApprovalMilestonePaymentEntitledToReceive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Post-Approval Milestone Payment, Entitled To Receive</link:label>
    <link:label id="lab_angn_ContractWithCustomerPostApprovalMilestonePaymentEntitledToReceive_documentation_en-US" xlink:label="lab_angn_ContractWithCustomerPostApprovalMilestonePaymentEntitledToReceive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Post-Approval Milestone Payment, Entitled To Receive</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerPostApprovalMilestonePaymentEntitledToReceive" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerPostApprovalMilestonePaymentEntitledToReceive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ContractWithCustomerPostApprovalMilestonePaymentEntitledToReceive" xlink:to="lab_angn_ContractWithCustomerPostApprovalMilestonePaymentEntitledToReceive" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_WarrantLiabilityCurrent_dc86badb-27a6-4a99-a41b-eea1203bc5d6_terseLabel_en-US" xlink:label="lab_angn_WarrantLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant liability</link:label>
    <link:label id="lab_angn_WarrantLiabilityCurrent_label_en-US" xlink:label="lab_angn_WarrantLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability, Current</link:label>
    <link:label id="lab_angn_WarrantLiabilityCurrent_documentation_en-US" xlink:label="lab_angn_WarrantLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantLiabilityCurrent" xlink:href="angn-20211231.xsd#angn_WarrantLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_WarrantLiabilityCurrent" xlink:to="lab_angn_WarrantLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ClassOfWarrantOrRightExercisesInPeriod_4dea492a-b23d-4429-819c-b024a7f53a43_negatedTerseLabel_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightExercisesInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightExercisesInPeriod_label_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercises in Period</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightExercisesInPeriod_documentation_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightExercisesInPeriod" xlink:href="angn-20211231.xsd#angn_ClassOfWarrantOrRightExercisesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ClassOfWarrantOrRightExercisesInPeriod" xlink:to="lab_angn_ClassOfWarrantOrRightExercisesInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_93f36cc0-da13-4c03-8476-373c2e036521_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_ef5c5916-220f-4938-8a52-2d5e86907dab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of financing obligation</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_5569f572-21c9-4731-bb24-26bd5033eacb_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash flows from financing obligation</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherShortTermBorrowings_aba5b151-8818-4583-ad8d-ef4b976362d3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other short-term debt</link:label>
    <link:label id="lab_us-gaap_OtherShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_OtherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short-term Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermBorrowings" xlink:to="lab_us-gaap_OtherShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_ccacb82c-c77e-4a72-9200-7ef6959ec014_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_13d428a0-4583-4714-a3ef-92df25708781_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c0a6f1cb-163c-4bd8-8d3c-258eba5673c7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_18bf61c2-ed5f-4e17-9ef5-37fa26da35f7_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_bececea0-7c29-4941-8054-14663c3c0cbb_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to common stockholders, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_99ba2c66-b1c7-40c8-9892-d17f1a7a4280_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_a8cae06f-231a-4151-ac0f-e2525e7fb0d9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from RSU settlement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2d888238-5bcc-4c76-aa88-568bf48bee56_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_b1a5273e-5848-44c5-b500-63368f835de0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue and Deferred Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_AccruedOperatingLiabilitiesCurrent_e60458d0-c3bb-48a7-ac28-0b63d4db9adc_terseLabel_en-US" xlink:label="lab_angn_AccruedOperatingLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued operating expenses</link:label>
    <link:label id="lab_angn_AccruedOperatingLiabilitiesCurrent_label_en-US" xlink:label="lab_angn_AccruedOperatingLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Operating Liabilities, Current</link:label>
    <link:label id="lab_angn_AccruedOperatingLiabilitiesCurrent_documentation_en-US" xlink:label="lab_angn_AccruedOperatingLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Operating Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AccruedOperatingLiabilitiesCurrent" xlink:href="angn-20211231.xsd#angn_AccruedOperatingLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_AccruedOperatingLiabilitiesCurrent" xlink:to="lab_angn_AccruedOperatingLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_f94fc275-99a1-47f4-8fde-c488a3a4d071_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of Series C convertible preferred stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3dddd68b-2aae-4de3-bd74-327b5a2456a6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_59ccb5ad-c36f-46fe-abfa-635777a2bf4d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3aad423f-5524-4500-b281-45fae8fa5754_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_aa58bd76-0ac5-4343-84e3-812ae14e8eae_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_EquityMethodInvestmentsRollForward_d77da39b-327a-4e49-afbd-48b5fd1ef3e8_terseLabel_en-US" xlink:label="lab_angn_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Roll Forward]</link:label>
    <link:label id="lab_angn_EquityMethodInvestmentsRollForward_label_en-US" xlink:label="lab_angn_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Roll Forward]</link:label>
    <link:label id="lab_angn_EquityMethodInvestmentsRollForward_documentation_en-US" xlink:label="lab_angn_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EquityMethodInvestmentsRollForward" xlink:href="angn-20211231.xsd#angn_EquityMethodInvestmentsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_EquityMethodInvestmentsRollForward" xlink:to="lab_angn_EquityMethodInvestmentsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayFiftyPercentEmployerMatch_43915389-7865-46ae-bc08-ee6cf4738747_terseLabel_en-US" xlink:label="lab_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayFiftyPercentEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contribution, percent of employees' gross pay, 50% employer match</link:label>
    <link:label id="lab_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayFiftyPercentEmployerMatch_label_en-US" xlink:label="lab_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayFiftyPercentEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay, Fifty Percent Employer Match</link:label>
    <link:label id="lab_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayFiftyPercentEmployerMatch_documentation_en-US" xlink:label="lab_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayFiftyPercentEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay, Fifty Percent Employer Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayFiftyPercentEmployerMatch" xlink:href="angn-20211231.xsd#angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayFiftyPercentEmployerMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayFiftyPercentEmployerMatch" xlink:to="lab_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayFiftyPercentEmployerMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1a4bed29-99fc-4e63-adee-ce2b53575d72_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D and other tax credit carryovers</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_0f7a764a-4a90-46ef-b35c-f2116a6b94b2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return of common stock to pay withholding taxes on restricted stock</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_fe2a287c-4e0b-4780-a9c9-01a56320578f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1c004c29-1965-4387-b131-8dea8631b2fa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_IncreaseDecreaseInGrantReceivables_f432c880-6379-4541-ad02-b4f38d48db13_negatedTerseLabel_en-US" xlink:label="lab_angn_IncreaseDecreaseInGrantReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants receivable</link:label>
    <link:label id="lab_angn_IncreaseDecreaseInGrantReceivables_label_en-US" xlink:label="lab_angn_IncreaseDecreaseInGrantReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Grant Receivables</link:label>
    <link:label id="lab_angn_IncreaseDecreaseInGrantReceivables_documentation_en-US" xlink:label="lab_angn_IncreaseDecreaseInGrantReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Grant Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_IncreaseDecreaseInGrantReceivables" xlink:href="angn-20211231.xsd#angn_IncreaseDecreaseInGrantReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_IncreaseDecreaseInGrantReceivables" xlink:to="lab_angn_IncreaseDecreaseInGrantReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1493243f-3c0c-41d1-805d-51eb00261217_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_e3a04749-1e85-4013-9918-89f202a7fcb4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_MeasurementInputStrikePriceMember_3e231bfc-a3ab-47f1-b760-e36d3c0801cd_terseLabel_en-US" xlink:label="lab_angn_MeasurementInputStrikePriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average strike price</link:label>
    <link:label id="lab_angn_MeasurementInputStrikePriceMember_label_en-US" xlink:label="lab_angn_MeasurementInputStrikePriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Strike Price [Member]</link:label>
    <link:label id="lab_angn_MeasurementInputStrikePriceMember_documentation_en-US" xlink:label="lab_angn_MeasurementInputStrikePriceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Strike Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_MeasurementInputStrikePriceMember" xlink:href="angn-20211231.xsd#angn_MeasurementInputStrikePriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_MeasurementInputStrikePriceMember" xlink:to="lab_angn_MeasurementInputStrikePriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_4c15f1a7-16fd-4c27-9593-4fee8ad49651_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_9258a0e0-d507-4d3a-b671-abb81104c94e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_3c9a6bd5-25f3-4b42-8590-0bffd81fb170_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets included in:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_ff718c82-406f-4338-980c-a662a8b1bfc8_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_IssuanceOfBrokerWarrants_3cd5a5b8-b8d4-4f8e-bca1-076b824f50bd_terseLabel_en-US" xlink:label="lab_angn_IssuanceOfBrokerWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of broker warrants with Series C convertible preferred stock</link:label>
    <link:label id="lab_angn_IssuanceOfBrokerWarrants_label_en-US" xlink:label="lab_angn_IssuanceOfBrokerWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Broker Warrants</link:label>
    <link:label id="lab_angn_IssuanceOfBrokerWarrants_documentation_en-US" xlink:label="lab_angn_IssuanceOfBrokerWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Broker Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_IssuanceOfBrokerWarrants" xlink:href="angn-20211231.xsd#angn_IssuanceOfBrokerWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_IssuanceOfBrokerWarrants" xlink:to="lab_angn_IssuanceOfBrokerWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_96739aa5-9e56-48f2-8c17-3e736bb7b581_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9d870055-263f-4976-853f-8f56be104915_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_9f4c5096-7cd7-4fae-8e6d-4caafcb7af4c_terseLabel_en-US" xlink:label="lab_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immediate Family Member of Management or Principal Owner</link:label>
    <link:label id="lab_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_label_en-US" xlink:label="lab_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immediate Family Member of Management or Principal Owner [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" xlink:to="lab_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_81237e82-3e05-469d-ac19-4ae0bb0d11d7_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_ff8f3677-5aa8-4658-ad8e-2ad5981d9d22_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_1ab92ab8-7afe-470a-82af-5b2d52423aee_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ContractWithCustomerSalesRelatedMilestonePaymentEntitledToReceive_124102ad-1f6a-4825-91c9-ced30e8cd864_terseLabel_en-US" xlink:label="lab_angn_ContractWithCustomerSalesRelatedMilestonePaymentEntitledToReceive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-related milestone payment, entitled to receive</link:label>
    <link:label id="lab_angn_ContractWithCustomerSalesRelatedMilestonePaymentEntitledToReceive_label_en-US" xlink:label="lab_angn_ContractWithCustomerSalesRelatedMilestonePaymentEntitledToReceive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Sales-Related Milestone Payment, Entitled To Receive</link:label>
    <link:label id="lab_angn_ContractWithCustomerSalesRelatedMilestonePaymentEntitledToReceive_documentation_en-US" xlink:label="lab_angn_ContractWithCustomerSalesRelatedMilestonePaymentEntitledToReceive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Sales-Related Milestone Payment, Entitled To Receive</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerSalesRelatedMilestonePaymentEntitledToReceive" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerSalesRelatedMilestonePaymentEntitledToReceive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ContractWithCustomerSalesRelatedMilestonePaymentEntitledToReceive" xlink:to="lab_angn_ContractWithCustomerSalesRelatedMilestonePaymentEntitledToReceive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_034ccd91-b1b6-481e-9d33-d3bc88e45341_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_f748a5d7-dedf-4e2b-b547-2f7109450ac9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_c3a4f454-407f-49c3-9eda-b6a5478533c6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_8c4b00bf-e04b-4845-b72a-09d36891cd1f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue&#8212;current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f60be946-f4a7-49da-9c27-bd06b0ac8e0c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentsAndSecuritiesAtCost_509c7ecf-f1ca-445b-9358-d41e73f232b7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentsAndSecuritiesAtCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, at cost</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentsAndSecuritiesAtCost_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentsAndSecuritiesAtCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investments and Securities, at Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsAndSecuritiesAtCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentsAndSecuritiesAtCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentsAndSecuritiesAtCost" xlink:to="lab_us-gaap_OtherInvestmentsAndSecuritiesAtCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d3febdf4-d23d-47d7-996e-4e8f12b954c3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_NumberOfRelatedPartyEntities_f2ad7d60-d4fb-4a69-ab96-33ff80573d6e_terseLabel_en-US" xlink:label="lab_angn_NumberOfRelatedPartyEntities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of related party entities</link:label>
    <link:label id="lab_angn_NumberOfRelatedPartyEntities_label_en-US" xlink:label="lab_angn_NumberOfRelatedPartyEntities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Related Party Entities</link:label>
    <link:label id="lab_angn_NumberOfRelatedPartyEntities_documentation_en-US" xlink:label="lab_angn_NumberOfRelatedPartyEntities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Related Party Entities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NumberOfRelatedPartyEntities" xlink:href="angn-20211231.xsd#angn_NumberOfRelatedPartyEntities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_NumberOfRelatedPartyEntities" xlink:to="lab_angn_NumberOfRelatedPartyEntities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_467c8fdc-f04e-4ab2-8186-d5de7d0db600_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_9d164d7b-b9e1-499d-92dc-f1a970dc4a24_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_8cb72674-aba5-4b27-8eac-0b4f302e8209_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_RelatedPartyTransactionPotentialMaximumMilestonePayment_e4b6e5db-c701-4f6a-b1ce-e0163b184a5a_terseLabel_en-US" xlink:label="lab_angn_RelatedPartyTransactionPotentialMaximumMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential maximum milestone payment</link:label>
    <link:label id="lab_angn_RelatedPartyTransactionPotentialMaximumMilestonePayment_label_en-US" xlink:label="lab_angn_RelatedPartyTransactionPotentialMaximumMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Potential Maximum Milestone Payment</link:label>
    <link:label id="lab_angn_RelatedPartyTransactionPotentialMaximumMilestonePayment_documentation_en-US" xlink:label="lab_angn_RelatedPartyTransactionPotentialMaximumMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Potential Maximum Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_RelatedPartyTransactionPotentialMaximumMilestonePayment" xlink:href="angn-20211231.xsd#angn_RelatedPartyTransactionPotentialMaximumMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_RelatedPartyTransactionPotentialMaximumMilestonePayment" xlink:to="lab_angn_RelatedPartyTransactionPotentialMaximumMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c046e8e0-7f5c-4548-a879-0662d68c5241_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1eb0a481-b6bf-4410-9b22-515e279f6ab1_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized benefits that would affect the effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_aa10e22d-71b4-4b02-b88b-144783d9fd22_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_04066086-7be3-44b0-9e26-75e2dac55371_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fractional shares paid out related to the forward stock split</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Split</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross_78a0d75d-ff35-4dac-8ff3-57a71c8be146_terseLabel_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal</link:label>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross_label_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Gross</link:label>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross_documentation_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross" xlink:to="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_0571eecf-c4e3-4de5-a42c-829476884d02_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_cfe0e156-6520-4fb6-988b-1090267d63e6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_89ff5e23-abfe-4592-a4e4-50e8b36d9fa6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of leased assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_f49dcc9d-be09-41e1-8de1-43eb4bd64282_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment, ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_c9bec3e2-c7e8-4aa3-89e6-5a190023021a_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_470a210f-3d6a-4dbd-8090-e2d54828ec7b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_c7d273d7-ed2d-485f-9c62-5672deececae_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionTable_22646a49-78e9-447f-8a8c-0696900c5b2c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion [Table]</link:label>
    <link:label id="lab_us-gaap_DebtConversionTable_label_en-US" xlink:label="lab_us-gaap_DebtConversionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionTable" xlink:to="lab_us-gaap_DebtConversionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_916d1962-3b5b-4c10-a3f2-a0b2ca53f660_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of the Business and Financial Condition</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_d0a869fa-e0e9-4626-aeef-1d3ef150aa54_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1f8f03af-5673-42c1-a8ca-6a62e5bd6228_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_66154d2c-5938-492d-9d32-9b90f23ece44_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of foreign currency on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_f11cac83-f90f-41f7-aa94-567f28274cf6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and other expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_UnrecognizedTaxBenefitsIfRecognizedWouldAffectTheEffectiveTaxRateTableTextBlock_ec844657-a330-4f1a-9fee-95f9add8ad6f_terseLabel_en-US" xlink:label="lab_angn_UnrecognizedTaxBenefitsIfRecognizedWouldAffectTheEffectiveTaxRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, If Recognized, Would Affect the Effective Tax Rate</link:label>
    <link:label id="lab_angn_UnrecognizedTaxBenefitsIfRecognizedWouldAffectTheEffectiveTaxRateTableTextBlock_label_en-US" xlink:label="lab_angn_UnrecognizedTaxBenefitsIfRecognizedWouldAffectTheEffectiveTaxRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, If Recognized, Would Affect the Effective Tax Rate [Table Text Block]</link:label>
    <link:label id="lab_angn_UnrecognizedTaxBenefitsIfRecognizedWouldAffectTheEffectiveTaxRateTableTextBlock_documentation_en-US" xlink:label="lab_angn_UnrecognizedTaxBenefitsIfRecognizedWouldAffectTheEffectiveTaxRateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, If Recognized, Would Affect the Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_UnrecognizedTaxBenefitsIfRecognizedWouldAffectTheEffectiveTaxRateTableTextBlock" xlink:href="angn-20211231.xsd#angn_UnrecognizedTaxBenefitsIfRecognizedWouldAffectTheEffectiveTaxRateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_UnrecognizedTaxBenefitsIfRecognizedWouldAffectTheEffectiveTaxRateTableTextBlock" xlink:to="lab_angn_UnrecognizedTaxBenefitsIfRecognizedWouldAffectTheEffectiveTaxRateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_a1072a1e-9a12-460a-8abc-059c0065941f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_d17599c5-ff95-435b-8779-b59de37ec17d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_6962f773-41d1-4db6-be76-f6da6e253afe_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of convertible notes and warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_cc79ff48-c397-4a36-9d05-6c906ab2398b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_1d26e071-eae0-400a-a15a-455d9868361e_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_45d537b2-4021-47bb-953d-2428626343c1_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_11b560d7-a5b4-498b-ac65-24aeaac62b20_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_d3221fe3-8c13-43b2-b77a-3c968679f757_totalLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_2996766b-449d-4d7f-bae8-7de19f2f4cea_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_4889d2cc-cd4a-47e8-bad9-30b114baa066_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_6646a5a1-f30f-4100-8768-cd531cd7319b_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_NetIncomeLossAttributableToParentIncrease_23513954-d98c-4d0e-b220-52d220495d36_terseLabel_en-US" xlink:label="lab_angn_NetIncomeLossAttributableToParentIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in net loss</link:label>
    <link:label id="lab_angn_NetIncomeLossAttributableToParentIncrease_label_en-US" xlink:label="lab_angn_NetIncomeLossAttributableToParentIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Increase</link:label>
    <link:label id="lab_angn_NetIncomeLossAttributableToParentIncrease_documentation_en-US" xlink:label="lab_angn_NetIncomeLossAttributableToParentIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NetIncomeLossAttributableToParentIncrease" xlink:href="angn-20211231.xsd#angn_NetIncomeLossAttributableToParentIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_NetIncomeLossAttributableToParentIncrease" xlink:to="lab_angn_NetIncomeLossAttributableToParentIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm_0c2c419b-dcbc-424e-9bd4-4bb518add7e4_terseLabel_en-US" xlink:label="lab_angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, weighted average remaining contractual life (in years)</link:label>
    <link:label id="lab_angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="angn-20211231.xsd#angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="lab_angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_4fcf5e53-8387-49e4-934c-a58df1e4c35a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_A2020NotesMember_2d6697b5-0a92-4212-b37b-02cc1ec508ec_terseLabel_en-US" xlink:label="lab_angn_A2020NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Notes</link:label>
    <link:label id="lab_angn_A2020NotesMember_label_en-US" xlink:label="lab_angn_A2020NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Notes [Member]</link:label>
    <link:label id="lab_angn_A2020NotesMember_documentation_en-US" xlink:label="lab_angn_A2020NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_A2020NotesMember" xlink:href="angn-20211231.xsd#angn_A2020NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_A2020NotesMember" xlink:to="lab_angn_A2020NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ConvertiblePreferredStockConversionPrice_fdf94e83-2e8f-4b08-816f-1d595239ef1f_terseLabel_en-US" xlink:label="lab_angn_ConvertiblePreferredStockConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, conversion price (in dollars per share)</link:label>
    <link:label id="lab_angn_ConvertiblePreferredStockConversionPrice_label_en-US" xlink:label="lab_angn_ConvertiblePreferredStockConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Conversion Price</link:label>
    <link:label id="lab_angn_ConvertiblePreferredStockConversionPrice_documentation_en-US" xlink:label="lab_angn_ConvertiblePreferredStockConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ConvertiblePreferredStockConversionPrice" xlink:href="angn-20211231.xsd#angn_ConvertiblePreferredStockConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ConvertiblePreferredStockConversionPrice" xlink:to="lab_angn_ConvertiblePreferredStockConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_afd79454-3017-49e9-ab9a-3aafbb243b66_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_7dc887a1-2502-47de-bb15-803abb3d9e77_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsConversionPrice_e94f87f9-f733-4056-b23a-1e173ebea42f_terseLabel_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price of series C preferred stock (in dollars per share)</link:label>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsConversionPrice_label_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption by Settlement Terms, Conversion Price</link:label>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsConversionPrice_documentation_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption by Settlement Terms, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsConversionPrice" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsConversionPrice" xlink:to="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_176c36c3-e1e4-4bc4-8e17-cbf1890a7f42_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_db92f221-c28c-470e-976d-07d7e6b28d78_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e0bce382-648f-47bc-a169-9fa910403816_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsRollForward_68ea5720-988a-4f56-b0f7-fe05fc2c1c16_terseLabel_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsRollForward_label_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Weighted Average Exercise Price of Warrants or Rights [Roll Forward]</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsRollForward_documentation_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Weighted Average Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsRollForward" xlink:href="angn-20211231.xsd#angn_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsRollForward" xlink:to="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_d3517bcd-4191-4812-9685-44080d3ce0cc_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium_6968d343-7dcf-4bbe-8a3a-cd53f703d20b_terseLabel_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement premium</link:label>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium_label_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Settlement Premium</link:label>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium_documentation_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Settlement Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium" xlink:to="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_fc9be990-b394-4273-ad2d-04e5de66675b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_2ef787c8-276c-44d4-8346-00ce3bb9d326_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_ffabe1a2-0a9d-48ba-acf5-97c8d402792f_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_8d9e256b-452b-415d-b3fb-c5884bfbf7a7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7a21e236-8913-42cf-a2ee-f2bb26dbf120_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_LesseeOperatingLeaseNumberOfOptionsToExtend_a80a7880-f383-4520-92b2-4de9fc524bc6_terseLabel_en-US" xlink:label="lab_angn_LesseeOperatingLeaseNumberOfOptionsToExtend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to extend</link:label>
    <link:label id="lab_angn_LesseeOperatingLeaseNumberOfOptionsToExtend_label_en-US" xlink:label="lab_angn_LesseeOperatingLeaseNumberOfOptionsToExtend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number of Options to Extend</link:label>
    <link:label id="lab_angn_LesseeOperatingLeaseNumberOfOptionsToExtend_documentation_en-US" xlink:label="lab_angn_LesseeOperatingLeaseNumberOfOptionsToExtend" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number of Options to Extend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_LesseeOperatingLeaseNumberOfOptionsToExtend" xlink:href="angn-20211231.xsd#angn_LesseeOperatingLeaseNumberOfOptionsToExtend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_LesseeOperatingLeaseNumberOfOptionsToExtend" xlink:to="lab_angn_LesseeOperatingLeaseNumberOfOptionsToExtend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_b2dca78e-9ae5-4bc2-af62-716847ff30be_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_ed26b604-0cb6-4755-8fd5-c69fbb5acaea_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_eba3e23c-6020-4cc9-9980-860e1a2cc546_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_WarrantsIssuedWith2018NotesLiabilityMember_6ba8383b-2ea1-4f76-9fb0-112fb25509c7_terseLabel_en-US" xlink:label="lab_angn_WarrantsIssuedWith2018NotesLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued with 2018 Notes</link:label>
    <link:label id="lab_angn_WarrantsIssuedWith2018NotesLiabilityMember_label_en-US" xlink:label="lab_angn_WarrantsIssuedWith2018NotesLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued with 2018 Notes, Liability [Member]</link:label>
    <link:label id="lab_angn_WarrantsIssuedWith2018NotesLiabilityMember_documentation_en-US" xlink:label="lab_angn_WarrantsIssuedWith2018NotesLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued with 2018 Notes, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsIssuedWith2018NotesLiabilityMember" xlink:href="angn-20211231.xsd#angn_WarrantsIssuedWith2018NotesLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_WarrantsIssuedWith2018NotesLiabilityMember" xlink:to="lab_angn_WarrantsIssuedWith2018NotesLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_bc6bd618-b014-4443-a5db-e2ec97cacbcc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ContractWithCustomerRoyaltyRatesMaximum_c4d7293d-ac31-4cb7-92a5-441b1ba4bebb_terseLabel_en-US" xlink:label="lab_angn_ContractWithCustomerRoyaltyRatesMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty rates (up to)</link:label>
    <link:label id="lab_angn_ContractWithCustomerRoyaltyRatesMaximum_label_en-US" xlink:label="lab_angn_ContractWithCustomerRoyaltyRatesMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Royalty Rates, Maximum</link:label>
    <link:label id="lab_angn_ContractWithCustomerRoyaltyRatesMaximum_documentation_en-US" xlink:label="lab_angn_ContractWithCustomerRoyaltyRatesMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Royalty Rates, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerRoyaltyRatesMaximum" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerRoyaltyRatesMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ContractWithCustomerRoyaltyRatesMaximum" xlink:to="lab_angn_ContractWithCustomerRoyaltyRatesMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_117a908a-6b5c-4343-9d24-fc71ba3b49ab_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs in accrued expenses or accounts payable</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1df62364-9347-4ef2-9c81-c558548ed52b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, weighted average remaining contractual life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayOneHundredPercentEmployerMatch_529c4184-2488-4fd1-b5c2-e276d32f6651_terseLabel_en-US" xlink:label="lab_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayOneHundredPercentEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contribution, percent of employees' gross pay, 100% employer match</link:label>
    <link:label id="lab_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayOneHundredPercentEmployerMatch_label_en-US" xlink:label="lab_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayOneHundredPercentEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay, One Hundred Percent Employer Match</link:label>
    <link:label id="lab_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayOneHundredPercentEmployerMatch_documentation_en-US" xlink:label="lab_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayOneHundredPercentEmployerMatch" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay, One Hundred Percent Employer Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayOneHundredPercentEmployerMatch" xlink:href="angn-20211231.xsd#angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayOneHundredPercentEmployerMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayOneHundredPercentEmployerMatch" xlink:to="lab_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayOneHundredPercentEmployerMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_67ae4643-38c0-411f-ab28-f137ffab25c9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_46824566-4759-40bc-bec2-2abc8f621e45_terseLabel_en-US" xlink:label="lab_angn_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized benefits that would not affect the effective tax rate</link:label>
    <link:label id="lab_angn_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_label_en-US" xlink:label="lab_angn_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Not Impact Effective Tax Rate</link:label>
    <link:label id="lab_angn_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_documentation_en-US" xlink:label="lab_angn_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Not Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:href="angn-20211231.xsd#angn_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:to="lab_angn_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_ca05fe4f-8f5d-4d7d-9ca0-d4eadac755ec_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_232e4336-515c-4c15-8c20-8eea33a70c59_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_IPOAndPrivatePlacementMember_3f0f7fa2-8793-4276-b70b-80b0e35279d1_terseLabel_en-US" xlink:label="lab_angn_IPOAndPrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO and Private placement</link:label>
    <link:label id="lab_angn_IPOAndPrivatePlacementMember_label_en-US" xlink:label="lab_angn_IPOAndPrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO and Private Placement [Member]</link:label>
    <link:label id="lab_angn_IPOAndPrivatePlacementMember_documentation_en-US" xlink:label="lab_angn_IPOAndPrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO and Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_IPOAndPrivatePlacementMember" xlink:href="angn-20211231.xsd#angn_IPOAndPrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_IPOAndPrivatePlacementMember" xlink:to="lab_angn_IPOAndPrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_9e5f94b6-ae6e-4625-8eb2-a5e11349c476_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_a14e59c2-1208-45e7-aef2-fec815f6faa0_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange transaction gain (loss)</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_1f596d7b-f5fe-4292-abd4-df8dbbdd73c2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value per share; 30,000,000 authorized shares; 29,959,060 and 15,632,809 shares issued as of December 31, 2021 and 2020, respectively; 29,959,060 and 15,316,721 shares outstanding as of December 31, 2021 and 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_75e65a8f-6152-4629-b7e4-6a4dba038de9_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate (in percent)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_1c8ad8e0-e385-42f6-bd9a-568ddc7a962e_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_57029fda-45c6-427b-a7ec-b23e938bb6b0_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_960abbf7-afdb-44ea-b6a1-d3a2027378f8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation related to unvested stock option awards, period for recognition (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6736e4d8-b368-4001-bb96-4cc081a1eb10_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e3e235e0-4a98-4535-9ce8-f5f3a36b99c7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d872253f-e59c-4eac-8e68-0ae6f4385274_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_5d3dfa53-7cc9-489a-b66c-36d614736d1e_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based Restricted Stock Units (PSUs)</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_b2c1831b-b840-4813-83a7-5ecdfa709955_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies&#8212;Note 11</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_b95b41c1-4444-4782-8277-2276c3747abb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesSubjectToMandatoryRedemptionDisclosureTextBlock_35c9a15f-0b33-4bb2-ab88-c8d6ea5ea3d5_terseLabel_en-US" xlink:label="lab_us-gaap_SharesSubjectToMandatoryRedemptionDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption Disclosure</link:label>
    <link:label id="lab_us-gaap_SharesSubjectToMandatoryRedemptionDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SharesSubjectToMandatoryRedemptionDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesSubjectToMandatoryRedemptionDisclosureTextBlock" xlink:to="lab_us-gaap_SharesSubjectToMandatoryRedemptionDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionLineItems_0f400ffb-2c60-4ada-beac-e1225efc8cdf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtConversionLineItems_label_en-US" xlink:label="lab_us-gaap_DebtConversionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionLineItems" xlink:to="lab_us-gaap_DebtConversionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8561268e-97f4-4543-9aa2-58fa4bb6b07d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_82cef426-5ce0-4cc3-a7cd-0acf94ed5751_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ClassOfWarrantOrRightOutstandingRollForward_340cd8b8-eac5-42df-8cee-e0baf40021f4_terseLabel_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightOutstandingRollForward_label_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightOutstandingRollForward_documentation_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightOutstandingRollForward" xlink:href="angn-20211231.xsd#angn_ClassOfWarrantOrRightOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ClassOfWarrantOrRightOutstandingRollForward" xlink:to="lab_angn_ClassOfWarrantOrRightOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_fc6ddf8a-7496-404c-82ab-a00806cb828c_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_40595ac9-8752-41f4-866e-2f170df70619_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested shares under restricted stock grants</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionPolicyTextBlock_557b249c-0797-4604-97c8-027a35f34894_terseLabel_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionPolicyTextBlock_label_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption [Policy Text Block]</link:label>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionPolicyTextBlock_documentation_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionPolicyTextBlock" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionPolicyTextBlock" xlink:to="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_d7a795f4-6dbf-4fb3-bead-d6150e34c2dd_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f548dbed-601b-4ce2-93ef-325a6dddc09b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions Used to Estimate Fair Value of Stock Option Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract_22060408-ea9d-4634-9575-8211fb7c1509_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_c871a52b-3bb2-408e-9918-dc63e070cb68_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_71363d4c-6e73-4b49-85e4-abc35ee1ee66_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_bcd42233-0d0d-4c7b-a560-fc423f8197c9_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_RevenueFromContractWithCustomerIncludingAssessedTaxIncrease_10f3380f-6c66-4306-9ba8-294ef8c58af2_terseLabel_en-US" xlink:label="lab_angn_RevenueFromContractWithCustomerIncludingAssessedTaxIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in contract revenue</link:label>
    <link:label id="lab_angn_RevenueFromContractWithCustomerIncludingAssessedTaxIncrease_label_en-US" xlink:label="lab_angn_RevenueFromContractWithCustomerIncludingAssessedTaxIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Including Assessed Tax, Increase</link:label>
    <link:label id="lab_angn_RevenueFromContractWithCustomerIncludingAssessedTaxIncrease_documentation_en-US" xlink:label="lab_angn_RevenueFromContractWithCustomerIncludingAssessedTaxIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Including Assessed Tax, Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_RevenueFromContractWithCustomerIncludingAssessedTaxIncrease" xlink:href="angn-20211231.xsd#angn_RevenueFromContractWithCustomerIncludingAssessedTaxIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_RevenueFromContractWithCustomerIncludingAssessedTaxIncrease" xlink:to="lab_angn_RevenueFromContractWithCustomerIncludingAssessedTaxIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_0fcf81ef-8f01-4791-a28d-9459a7d85104_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock_1a49c789-4127-4e22-ae4e-15ec3d15800f_terseLabel_en-US" xlink:label="lab_angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of quantitative information regarding NovaPark operating leases</link:label>
    <link:label id="lab_angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Quantitative Information On Operating Leases [Table Text Block]</link:label>
    <link:label id="lab_angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock_documentation_en-US" xlink:label="lab_angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Quantitative Information On Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock" xlink:href="angn-20211231.xsd#angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock" xlink:to="lab_angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_28c99b8f-daaa-4e04-98e1-4ef3d105427e_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_3835425b-b404-48d5-981f-d62c396dd4af_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_025d7b57-5593-4997-bfa9-dde5700f39b7_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_a265b28c-58d9-4ddd-abda-624998483251_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_bb18c78a-ed01-4d1e-91a3-284bf72d40ce_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_561d459a-b7c4-4e21-8eb6-abc830cedaaa_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income (expense), net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_94e47818-f371-4f6c-aa10-ca086a2ab8fc_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_37df05aa-4c1d-454c-8285-b85b8a625804_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_c68ea147-af36-4023-85f5-818672bf3baf_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, ending (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d464a178-f825-4fa1-a030-6cab01efc39a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less present value discount</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_8feaab6b-0ceb-4a20-a41b-3ed96f68034b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_SharesIssuableUponConversionOfConvertibleNotesDiscountRate_602095eb-c226-42e2-991d-ac5a1a24c6e6_terseLabel_en-US" xlink:label="lab_angn_SharesIssuableUponConversionOfConvertibleNotesDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_angn_SharesIssuableUponConversionOfConvertibleNotesDiscountRate_label_en-US" xlink:label="lab_angn_SharesIssuableUponConversionOfConvertibleNotesDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issuable Upon Conversion Of Convertible Notes, Discount Rate</link:label>
    <link:label id="lab_angn_SharesIssuableUponConversionOfConvertibleNotesDiscountRate_documentation_en-US" xlink:label="lab_angn_SharesIssuableUponConversionOfConvertibleNotesDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issuable Upon Conversion Of Convertible Notes, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_SharesIssuableUponConversionOfConvertibleNotesDiscountRate" xlink:href="angn-20211231.xsd#angn_SharesIssuableUponConversionOfConvertibleNotesDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_SharesIssuableUponConversionOfConvertibleNotesDiscountRate" xlink:to="lab_angn_SharesIssuableUponConversionOfConvertibleNotesDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_f3d5efd0-ba1f-4593-adf1-7d320b470da4_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Francisco, California</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_de75d874-b493-42ac-9198-62333632294e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_524a54df-5d3c-46bc-9519-40d5abc3556c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod_26e75440-59a3-4e0d-8924-4ce9e3b73ac2_terseLabel_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod_label_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Weighted Average Exercise Price, Exercises in Period</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod_documentation_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Weighted Average Exercise Price, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod" xlink:href="angn-20211231.xsd#angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod" xlink:to="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_StockRetired_38cd5e0c-e1ff-4faa-9df6-1d969f43a734_terseLabel_en-US" xlink:label="lab_angn_StockRetired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury stock</link:label>
    <link:label id="lab_angn_StockRetired_label_en-US" xlink:label="lab_angn_StockRetired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Retired</link:label>
    <link:label id="lab_angn_StockRetired_documentation_en-US" xlink:label="lab_angn_StockRetired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Retired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockRetired" xlink:href="angn-20211231.xsd#angn_StockRetired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_StockRetired" xlink:to="lab_angn_StockRetired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_248c3b98-582a-4d3a-8e75-72691d9eab30_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_434b1c73-aec2-44e0-8697-f8b235b17c69_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total prepaid and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_438ba681-1480-43fd-8f51-b93fc67cb860_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment received</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:to="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_618c4724-88bc-4992-8eb5-a467a4d7c6e0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from license agreement</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties" xlink:to="lab_us-gaap_RevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_e68207bf-9677-469e-b073-10f7ecc8eefc_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_3c72ec0d-49d1-4770-898b-0887816e965d_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_7ab0b827-cae6-44d9-9230-ed61c81b528e_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_efd3f2a4-41f6-4407-8ef6-6e2604e5bc5f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_db5d7df0-c21e-4d90-9f77-259b461b234b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less present value discount</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_f31d22cb-ae73-45f5-8a8d-991f84268ae7_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_WarrantsAndRightsOutstandingTextBlock_2c99c737-9c45-4196-9683-2b418c9f742e_terseLabel_en-US" xlink:label="lab_angn_WarrantsAndRightsOutstandingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_angn_WarrantsAndRightsOutstandingTextBlock_label_en-US" xlink:label="lab_angn_WarrantsAndRightsOutstandingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants And Rights Outstanding [Text Block]</link:label>
    <link:label id="lab_angn_WarrantsAndRightsOutstandingTextBlock_documentation_en-US" xlink:label="lab_angn_WarrantsAndRightsOutstandingTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants And Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsAndRightsOutstandingTextBlock" xlink:href="angn-20211231.xsd#angn_WarrantsAndRightsOutstandingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_WarrantsAndRightsOutstandingTextBlock" xlink:to="lab_angn_WarrantsAndRightsOutstandingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_80789209-c799-4662-844e-badc0e6aa7b7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_b7239e25-eb88-47fb-b343-630a2fa465b5_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issuable upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueNotFromContractWithCustomer_e0a7e61b-9509-4ab5-9ebf-513c3807fcba_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueNotFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant revenue</link:label>
    <link:label id="lab_us-gaap_RevenueNotFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueNotFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Not from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueNotFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueNotFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_13218bb9-dd02-4975-96f6-c5086a125ada_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_9070f4b1-c6b1-4624-b20a-ed4301862622_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_aa4a34e7-280c-4d55-a1ca-747fe304c132_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_bf946b60-aecb-46df-8d56-a535014af242_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_32e2aabe-1fe9-4903-824b-77fae3c7d13e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D and other tax credit changes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayable_63a03f72-879d-4021-b2cb-e1263c190b9c_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayable_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayable" xlink:to="lab_us-gaap_ConvertibleNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_6a9b76b2-fac4-45b1-a656-7273c314009b_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_ffbf9f96-8926-495e-9b9b-a28a618b0c0f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_70a42eca-8ca7-482f-a904-060b5811eede_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_ebf1f017-164d-4500-b078-8e3fc36b7f66_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_0bbb78a2-e50b-4880-9304-ddc13cd5f391_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_2522a4dc-35c4-41bf-a485-71d569c6b5f7_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_WarrantsAndRightsOutstandingActivityTableTextBlock_f20f9002-6906-437c-b1c9-b5f6ce8b86f5_terseLabel_en-US" xlink:label="lab_angn_WarrantsAndRightsOutstandingActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Warrant Activity</link:label>
    <link:label id="lab_angn_WarrantsAndRightsOutstandingActivityTableTextBlock_label_en-US" xlink:label="lab_angn_WarrantsAndRightsOutstandingActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Activity [Table Text Block]</link:label>
    <link:label id="lab_angn_WarrantsAndRightsOutstandingActivityTableTextBlock_documentation_en-US" xlink:label="lab_angn_WarrantsAndRightsOutstandingActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsAndRightsOutstandingActivityTableTextBlock" xlink:href="angn-20211231.xsd#angn_WarrantsAndRightsOutstandingActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_WarrantsAndRightsOutstandingActivityTableTextBlock" xlink:to="lab_angn_WarrantsAndRightsOutstandingActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_c5b4cf8b-8c1a-4205-bf2a-1ea8a078e823_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_596c2bdc-7e78-4f25-b488-43692a6eee55_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_5330c8d9-ae31-40d0-b4db-2f493e4d2102_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_92806cc6-1da7-4d74-901c-1705c8b23c79_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_BrokerWarrantsIssuedWithEquityOfferingEquityMember_02b882b5-af49-48bb-9d26-67204c704806_terseLabel_en-US" xlink:label="lab_angn_BrokerWarrantsIssuedWithEquityOfferingEquityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Broker Warrants issued with Equity Offering</link:label>
    <link:label id="lab_angn_BrokerWarrantsIssuedWithEquityOfferingEquityMember_label_en-US" xlink:label="lab_angn_BrokerWarrantsIssuedWithEquityOfferingEquityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Broker Warrants Issued with Equity Offering, Equity [Member]</link:label>
    <link:label id="lab_angn_BrokerWarrantsIssuedWithEquityOfferingEquityMember_documentation_en-US" xlink:label="lab_angn_BrokerWarrantsIssuedWithEquityOfferingEquityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Broker Warrants Issued with Equity Offering, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BrokerWarrantsIssuedWithEquityOfferingEquityMember" xlink:href="angn-20211231.xsd#angn_BrokerWarrantsIssuedWithEquityOfferingEquityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_BrokerWarrantsIssuedWithEquityOfferingEquityMember" xlink:to="lab_angn_BrokerWarrantsIssuedWithEquityOfferingEquityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6ca0ffb3-fd69-432a-b4ce-369b38bd6f9f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_83be53b2-c883-43a3-98eb-4a3b5cff528d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability&#8212;current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e9bf9fa1-39f2-448f-b87e-7904e3e1ce51_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_30736806-ecd0-4f05-bb30-b9a0a531b363_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_WarrantsIssuedWith2016NotesLiabilityMember_c2fdcf2a-608d-4cb0-b066-7d432df0b804_terseLabel_en-US" xlink:label="lab_angn_WarrantsIssuedWith2016NotesLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued with 2016 Notes</link:label>
    <link:label id="lab_angn_WarrantsIssuedWith2016NotesLiabilityMember_label_en-US" xlink:label="lab_angn_WarrantsIssuedWith2016NotesLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued with 2016 Notes, Liability [Member]</link:label>
    <link:label id="lab_angn_WarrantsIssuedWith2016NotesLiabilityMember_documentation_en-US" xlink:label="lab_angn_WarrantsIssuedWith2016NotesLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued with 2016 Notes, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsIssuedWith2016NotesLiabilityMember" xlink:href="angn-20211231.xsd#angn_WarrantsIssuedWith2016NotesLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_WarrantsIssuedWith2016NotesLiabilityMember" xlink:to="lab_angn_WarrantsIssuedWith2016NotesLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_b7bc83c9-e303-4357-8032-5d05f3330a12_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionDisclosureTextBlock_e5a060b6-6b39-4df5-99d8-0a416a207464_terseLabel_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Convertible Preferred Stock</link:label>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionDisclosureTextBlock_label_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption Disclosure [Text Block]</link:label>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionDisclosureTextBlock_documentation_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionDisclosureTextBlock" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionDisclosureTextBlock" xlink:to="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_33e5add0-8e4a-41b0-8ea6-f6efebd7ea04_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c7debb0d-dfed-4e0b-a889-6023b6388b85_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_6c766e43-a875-4240-a58f-254c287f33a9_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_61721c73-bba8-407a-89dc-904ae4fae40b_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_9d89d5f4-6046-482a-b09c-9f1e2db4448c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_ca711b11-50a5-4f5b-ac29-4eea1e9240d4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_TemporaryEquityAmortizedCostAbstract_26bde6db-e1ad-400d-90ab-5c449b1c8ee4_terseLabel_en-US" xlink:label="lab_angn_TemporaryEquityAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C convertible preferred stock recorded at amortized cost</link:label>
    <link:label id="lab_angn_TemporaryEquityAmortizedCostAbstract_label_en-US" xlink:label="lab_angn_TemporaryEquityAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Amortized Cost [Abstract]</link:label>
    <link:label id="lab_angn_TemporaryEquityAmortizedCostAbstract_documentation_en-US" xlink:label="lab_angn_TemporaryEquityAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_TemporaryEquityAmortizedCostAbstract" xlink:href="angn-20211231.xsd#angn_TemporaryEquityAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_TemporaryEquityAmortizedCostAbstract" xlink:to="lab_angn_TemporaryEquityAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_AdditionalConvertibleNotesAndViforConvertibleNoteMember_fdec7065-5bd0-4d3b-bccb-7763b0b92188_terseLabel_en-US" xlink:label="lab_angn_AdditionalConvertibleNotesAndViforConvertibleNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Convertible Notes and Vifor Convertible Note</link:label>
    <link:label id="lab_angn_AdditionalConvertibleNotesAndViforConvertibleNoteMember_label_en-US" xlink:label="lab_angn_AdditionalConvertibleNotesAndViforConvertibleNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Convertible Notes And Vifor Convertible Note [Member]</link:label>
    <link:label id="lab_angn_AdditionalConvertibleNotesAndViforConvertibleNoteMember_documentation_en-US" xlink:label="lab_angn_AdditionalConvertibleNotesAndViforConvertibleNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Convertible Notes And Vifor Convertible Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AdditionalConvertibleNotesAndViforConvertibleNoteMember" xlink:href="angn-20211231.xsd#angn_AdditionalConvertibleNotesAndViforConvertibleNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_AdditionalConvertibleNotesAndViforConvertibleNoteMember" xlink:to="lab_angn_AdditionalConvertibleNotesAndViforConvertibleNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss_527c69b1-4f0e-42ac-8c12-e1f703aaa8b7_terseLabel_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of Series C convertible preferred stock</link:label>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss_576f93a0-fa1e-4a85-bba0-c356e3f89f10_negatedTerseLabel_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of Series C convertible preferred stock</link:label>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss_label_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption by Settlement Terms, Change in Fair Value, Gain (Loss)</link:label>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss_documentation_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption by Settlement Terms, Change in Fair Value, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss" xlink:to="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_323fca26-50cf-49ce-8021-68020600f8c3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs outstanding that were granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_EffectiveIncomeTaxRateReconciliationInterestPercent_3ed1224f-8cf3-46fe-a671-44c01a326546_terseLabel_en-US" xlink:label="lab_angn_EffectiveIncomeTaxRateReconciliationInterestPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_angn_EffectiveIncomeTaxRateReconciliationInterestPercent_label_en-US" xlink:label="lab_angn_EffectiveIncomeTaxRateReconciliationInterestPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Interest, Percent</link:label>
    <link:label id="lab_angn_EffectiveIncomeTaxRateReconciliationInterestPercent_documentation_en-US" xlink:label="lab_angn_EffectiveIncomeTaxRateReconciliationInterestPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Interest, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EffectiveIncomeTaxRateReconciliationInterestPercent" xlink:href="angn-20211231.xsd#angn_EffectiveIncomeTaxRateReconciliationInterestPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_EffectiveIncomeTaxRateReconciliationInterestPercent" xlink:to="lab_angn_EffectiveIncomeTaxRateReconciliationInterestPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ContractWithCustomerUpfrontAndNearTermMilestonePaymentEntitledToReceive_bacfde0b-fc22-4c80-b597-622fcf009a30_terseLabel_en-US" xlink:label="lab_angn_ContractWithCustomerUpfrontAndNearTermMilestonePaymentEntitledToReceive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and near-term milestone payment, entitled to receive</link:label>
    <link:label id="lab_angn_ContractWithCustomerUpfrontAndNearTermMilestonePaymentEntitledToReceive_label_en-US" xlink:label="lab_angn_ContractWithCustomerUpfrontAndNearTermMilestonePaymentEntitledToReceive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Upfront and Near-term Milestone Payment, Entitled To Receive</link:label>
    <link:label id="lab_angn_ContractWithCustomerUpfrontAndNearTermMilestonePaymentEntitledToReceive_documentation_en-US" xlink:label="lab_angn_ContractWithCustomerUpfrontAndNearTermMilestonePaymentEntitledToReceive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Upfront and Near-term Milestone Payment, Entitled To Receive</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerUpfrontAndNearTermMilestonePaymentEntitledToReceive" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerUpfrontAndNearTermMilestonePaymentEntitledToReceive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ContractWithCustomerUpfrontAndNearTermMilestonePaymentEntitledToReceive" xlink:to="lab_angn_ContractWithCustomerUpfrontAndNearTermMilestonePaymentEntitledToReceive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_629b3d7e-69bc-498f-a71d-6937c3e5e040_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_NovaParkMember_18ace4f5-dfa7-434e-9ba4-4d0c1772a9c2_terseLabel_en-US" xlink:label="lab_angn_NovaParkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NovaPark</link:label>
    <link:label id="lab_angn_NovaParkMember_label_en-US" xlink:label="lab_angn_NovaParkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NovaPark [Member]</link:label>
    <link:label id="lab_angn_NovaParkMember_documentation_en-US" xlink:label="lab_angn_NovaParkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NovaPark</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NovaParkMember" xlink:href="angn-20211231.xsd#angn_NovaParkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_NovaParkMember" xlink:to="lab_angn_NovaParkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ecd14715-e361-466d-b3be-912d7b583859_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of fixed assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ConsultingAgreementMember_6bace15a-60fe-4d6e-b2f9-d0c04ed89fc6_terseLabel_en-US" xlink:label="lab_angn_ConsultingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Agreement</link:label>
    <link:label id="lab_angn_ConsultingAgreementMember_label_en-US" xlink:label="lab_angn_ConsultingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Agreement [Member]</link:label>
    <link:label id="lab_angn_ConsultingAgreementMember_documentation_en-US" xlink:label="lab_angn_ConsultingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ConsultingAgreementMember" xlink:href="angn-20211231.xsd#angn_ConsultingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ConsultingAgreementMember" xlink:to="lab_angn_ConsultingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_19f193c0-9427-4224-88b9-192b5b20e6f3_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_a97ae640-cc38-4801-bd00-c1688654b864_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4b3c6a93-0a5f-435e-a2ff-3399b3aa34ab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_f104f2bd-d2a7-4db3-b401-2fe7e5d2c610_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_302e5934-d17e-47c5-9a51-a9022ba50119_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2903ca2a-1937-4cbb-b83a-2b4ffabb76b6_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b00901cc-ea4b-430b-a90d-cf37deb5adfe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, total intrinsic value (in thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_f26ed296-57b2-4e14-a9be-0cb7ca3705b0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_7fee0d33-c671-4dd3-ae53-8288680c6d20_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of maturities of lease liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_a5df90de-1c2d-40a3-b272-e5477d9e1c71_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesIssued1_4f3cb93e-b733-4dfe-ae7b-eaa62086d850_terseLabel_en-US" xlink:label="lab_us-gaap_NotesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes issued in receivable</link:label>
    <link:label id="lab_us-gaap_NotesIssued1_label_en-US" xlink:label="lab_us-gaap_NotesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesIssued1" xlink:to="lab_us-gaap_NotesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_8cbd040f-3785-48db-b778-a33c79c75c3a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_da4e3b49-be37-435b-be98-17c73ae61bdb_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_7770e8a8-b568-4065-b2dd-d2a86bbb2046_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_49b13873-74b6-4b23-83b5-17483f354f99_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_416d5cf2-e311-4100-b2a1-419146706fbb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_ff46e368-0bc2-48fe-92db-a8f4c0eb6c5d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_d57df8cc-1d89-4b45-b2d0-6b5aff142054_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_dee1e1b3-976f-49cf-9435-25a7ab0a94b5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and exercisable, total intrinsic value (in thousands)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_A2021IncentiveAwardPlanMember_a0af14ca-abda-495b-96fe-f187158fb2f6_terseLabel_en-US" xlink:label="lab_angn_A2021IncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Incentive Award Plan</link:label>
    <link:label id="lab_angn_A2021IncentiveAwardPlanMember_label_en-US" xlink:label="lab_angn_A2021IncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Incentive Award Plan [Member]</link:label>
    <link:label id="lab_angn_A2021IncentiveAwardPlanMember_documentation_en-US" xlink:label="lab_angn_A2021IncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Incentive Award Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_A2021IncentiveAwardPlanMember" xlink:href="angn-20211231.xsd#angn_A2021IncentiveAwardPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_A2021IncentiveAwardPlanMember" xlink:to="lab_angn_A2021IncentiveAwardPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTermRollForward_6bcacfe6-90d3-4a8b-bc9a-f09618935032_terseLabel_en-US" xlink:label="lab_angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTermRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life (in years)</link:label>
    <link:label id="lab_angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTermRollForward_label_en-US" xlink:label="lab_angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTermRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Weighted Average Remaining Contractual Term [Roll Forward]</link:label>
    <link:label id="lab_angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTermRollForward_documentation_en-US" xlink:label="lab_angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTermRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTermRollForward" xlink:href="angn-20211231.xsd#angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTermRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTermRollForward" xlink:to="lab_angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTermRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock_55e81ea7-5069-4583-af18-1ea751b16122_terseLabel_en-US" xlink:label="lab_angn_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible preferred stock into common stock upon IPO</link:label>
    <link:label id="lab_angn_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock_label_en-US" xlink:label="lab_angn_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Preferred Stock</link:label>
    <link:label id="lab_angn_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock_documentation_en-US" xlink:label="lab_angn_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock" xlink:href="angn-20211231.xsd#angn_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock" xlink:to="lab_angn_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_ad9328ae-f9d3-4ed0-9d42-c89eda6e8f0f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_a5599bf7-c0d8-4bae-a2a0-5e360509f4df_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible notes</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_4cbcf3a8-e99c-47a6-9eec-58191330a017_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain upon debt extinguishment</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_937f7ea8-8f90-44ae-a691-691fd4337c22_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PPP Loan forgiveness</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_57432893-90ae-442e-b417-0a238dbf841a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, estimated useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_StockIssuedDuringPeriodValueBrokerWarrantsExercised_1790cb3e-45b6-4b00-91cf-5d04797131b3_terseLabel_en-US" xlink:label="lab_angn_StockIssuedDuringPeriodValueBrokerWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of broker warrants</link:label>
    <link:label id="lab_angn_StockIssuedDuringPeriodValueBrokerWarrantsExercised_label_en-US" xlink:label="lab_angn_StockIssuedDuringPeriodValueBrokerWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Broker Warrants Exercised</link:label>
    <link:label id="lab_angn_StockIssuedDuringPeriodValueBrokerWarrantsExercised_documentation_en-US" xlink:label="lab_angn_StockIssuedDuringPeriodValueBrokerWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Broker Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodValueBrokerWarrantsExercised" xlink:href="angn-20211231.xsd#angn_StockIssuedDuringPeriodValueBrokerWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_StockIssuedDuringPeriodValueBrokerWarrantsExercised" xlink:to="lab_angn_StockIssuedDuringPeriodValueBrokerWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_StockIssuedDuringPeriodValueWarrantsExercised_b1824cee-c4e5-42b3-a9b6-22980ae999f7_terseLabel_en-US" xlink:label="lab_angn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of warrants</link:label>
    <link:label id="lab_angn_StockIssuedDuringPeriodValueWarrantsExercised_label_en-US" xlink:label="lab_angn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:label id="lab_angn_StockIssuedDuringPeriodValueWarrantsExercised_documentation_en-US" xlink:label="lab_angn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:href="angn-20211231.xsd#angn_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="lab_angn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_4e3d3396-7b23-4eee-ab4b-e71f7a78fda1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_WarrantsAndRightsOutstandingPolicyPolicyTextBlock_e40f0d8e-eeae-405d-b602-973190d5f0b4_terseLabel_en-US" xlink:label="lab_angn_WarrantsAndRightsOutstandingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability</link:label>
    <link:label id="lab_angn_WarrantsAndRightsOutstandingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_angn_WarrantsAndRightsOutstandingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Policy [Policy Text Block]</link:label>
    <link:label id="lab_angn_WarrantsAndRightsOutstandingPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_angn_WarrantsAndRightsOutstandingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsAndRightsOutstandingPolicyPolicyTextBlock" xlink:href="angn-20211231.xsd#angn_WarrantsAndRightsOutstandingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_WarrantsAndRightsOutstandingPolicyPolicyTextBlock" xlink:to="lab_angn_WarrantsAndRightsOutstandingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_66659376-b424-4d11-8aad-044e9b37e890_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_47ea8dfd-4de5-469a-b1ef-ba3e3f72496e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk and Off-Balance Sheet Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MA_770e18e8-cad5-4204-9f70-aa12056cad21_terseLabel_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Massachusetts</link:label>
    <link:label id="lab_stpr_MA_label_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MASSACHUSETTS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_MA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MA" xlink:to="lab_stpr_MA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_59c2384f-7471-45e2-993c-0ab14cdf8edd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability&#8212;noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_cbbb6b23-4c6a-4440-9229-6dba8d617ebd_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_80ca332e-45ae-4b45-9388-3cd03795be32_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_1fd163e7-c641-4123-878c-5c58d7473b5b_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_858eac05-00fa-4c57-b503-032061c6c771_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount of convertible notes issued</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_cce14718-156f-40df-92f4-8c6283c7583d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_2c903855-28cf-4e38-99b0-a961fa3025c3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_WarrantLiabilityMember_bd3588d8-662d-43cf-95b7-080edd64f27f_terseLabel_en-US" xlink:label="lab_angn_WarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability</link:label>
    <link:label id="lab_angn_WarrantLiabilityMember_label_en-US" xlink:label="lab_angn_WarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability [Member]</link:label>
    <link:label id="lab_angn_WarrantLiabilityMember_documentation_en-US" xlink:label="lab_angn_WarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantLiabilityMember" xlink:href="angn-20211231.xsd#angn_WarrantLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_WarrantLiabilityMember" xlink:to="lab_angn_WarrantLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_7a061d71-4028-4ef0-83a4-54fe0b5ecaa6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanTextBlock_68727c39-59d0-41e6-87c7-cfb265385448_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanTextBlock_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTextBlock" xlink:to="lab_us-gaap_DefinedContributionPlanTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_54d85ab8-cb7b-4c00-aa1b-f8e4b78af3fe_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_c21360ce-6c19-4553-8f5c-5db43902e829_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_210ab402-7a59-4584-a23c-442aa7ba37fb_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_b6544d98-4d7b-458b-9aca-71b9422b4438_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested shares under restricted stock unit grants</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_45be327f-4d42-4f70-8f5a-40c4c2c26dd7_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Series C preferred stock to common stock upon IPO</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Amount Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_0b1b4f34-7099-4098-8ae2-02f311d55e2b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_fae29e1b-5cec-4e91-9363-47c79581c70d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_b309c8d3-285a-4253-a9e7-505d87c8b33b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_858f57e7-793b-45ac-bfc2-76b90a19f759_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing obligation</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_WarrantsIssuedWith2015Notes2016Notes2017NotesAnd2018NotesMember_68d1b29c-462c-4fa5-9a89-c1b423b94b9e_terseLabel_en-US" xlink:label="lab_angn_WarrantsIssuedWith2015Notes2016Notes2017NotesAnd2018NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued with 2015 Notes, 2016 Notes, 2017 Notes, and 2018 Notes</link:label>
    <link:label id="lab_angn_WarrantsIssuedWith2015Notes2016Notes2017NotesAnd2018NotesMember_label_en-US" xlink:label="lab_angn_WarrantsIssuedWith2015Notes2016Notes2017NotesAnd2018NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued with 2015 Notes, 2016 Notes, 2017 Notes, and 2018 Notes [Member]</link:label>
    <link:label id="lab_angn_WarrantsIssuedWith2015Notes2016Notes2017NotesAnd2018NotesMember_documentation_en-US" xlink:label="lab_angn_WarrantsIssuedWith2015Notes2016Notes2017NotesAnd2018NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued with 2015 Notes, 2016 Notes, 2017 Notes, and 2018 Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsIssuedWith2015Notes2016Notes2017NotesAnd2018NotesMember" xlink:href="angn-20211231.xsd#angn_WarrantsIssuedWith2015Notes2016Notes2017NotesAnd2018NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_WarrantsIssuedWith2015Notes2016Notes2017NotesAnd2018NotesMember" xlink:to="lab_angn_WarrantsIssuedWith2015Notes2016Notes2017NotesAnd2018NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4f327649-4d79-4bed-a06c-3af465475da8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ViforPharmaMember_d9e5537d-9223-47b0-8e62-ba26c7418ef0_terseLabel_en-US" xlink:label="lab_angn_ViforPharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vifor Pharma</link:label>
    <link:label id="lab_angn_ViforPharmaMember_label_en-US" xlink:label="lab_angn_ViforPharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vifor Pharma [Member]</link:label>
    <link:label id="lab_angn_ViforPharmaMember_documentation_en-US" xlink:label="lab_angn_ViforPharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vifor Pharma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ViforPharmaMember" xlink:href="angn-20211231.xsd#angn_ViforPharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ViforPharmaMember" xlink:to="lab_angn_ViforPharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_18a496d4-8ee7-41ef-aac8-4b20d4e18c24_periodStartLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_ca5df7c7-636e-4616-8e79-6725f457eee3_periodEndLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_072a11e7-051e-428e-b358-159b561502bb_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ClassOfWarrantOrRightConversionPrice_e6bc08d0-8463-4a90-ab33-0180e0e28781_terseLabel_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant conversion price (in dollars per share)</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightConversionPrice_label_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Conversion Price</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightConversionPrice_documentation_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightConversionPrice" xlink:href="angn-20211231.xsd#angn_ClassOfWarrantOrRightConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ClassOfWarrantOrRightConversionPrice" xlink:to="lab_angn_ClassOfWarrantOrRightConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_47c617ee-c1b0-4efd-af4d-062b80d32940_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_5d996a5c-c4fe-49b9-9de3-d2a16a6b94a9_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_InvestmentsInRelatedPartiesPolicyPolicyTextBlock_ce90fcaf-7fa0-444d-b716-2e2bdcaa4d4c_terseLabel_en-US" xlink:label="lab_angn_InvestmentsInRelatedPartiesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Related Party Entities</link:label>
    <link:label id="lab_angn_InvestmentsInRelatedPartiesPolicyPolicyTextBlock_label_en-US" xlink:label="lab_angn_InvestmentsInRelatedPartiesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Related Parties, Policy [Policy Text Block]</link:label>
    <link:label id="lab_angn_InvestmentsInRelatedPartiesPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_angn_InvestmentsInRelatedPartiesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Related Parties, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_InvestmentsInRelatedPartiesPolicyPolicyTextBlock" xlink:href="angn-20211231.xsd#angn_InvestmentsInRelatedPartiesPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_InvestmentsInRelatedPartiesPolicyPolicyTextBlock" xlink:to="lab_angn_InvestmentsInRelatedPartiesPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_50ee8152-d3f0-4a6f-ae98-d26856ba5b8b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_429fe7cd-635f-4ff5-80df-0b40054c16ff_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_4a0bd374-eec0-474a-9d7e-d5d47cf739b3_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_f9a9e001-c71b-4c4c-9224-5e53bde4dfdc_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_0d694c9e-8491-4a01-b297-2362fbc3aa50_terseLabel_en-US" xlink:label="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of convertible preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" xlink:to="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_68600856-5788-4612-b2b0-429d3d46996e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_db51b732-99f2-415b-adca-c9d265aad716_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7d6dd92e-e067-4b19-a42b-238ec4e986e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a765619d-1db0-46fb-b700-822a414762a0_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_e4335374-9d91-4bac-abc9-c31791b8ff20_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6cb49a1a-8c75-4532-bcdb-15d47d409a48_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7d49c1e7-b76f-4594-80e8-4ecd2ba6c521_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_e3adc376-cb13-4a4d-91f9-659d0dc352c1_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_bf589366-7c88-4309-af4b-87697ae935bc_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f391547e-fd0e-4570-aa19-d47f0a4953c5_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_98c41465-ec18-4152-adb3-b6b7d79148a0_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_a747e91b-a957-45a3-b6a7-215727d9defd_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_47f75e1b-18d1-4893-bd5a-96241d9a7913_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c8fe8aac-4765-40ae-98d2-fb36d3a192e0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_PaymentsForForwardStockSplitFractionalShares_0c783f7c-8298-423b-ad20-753342d4c16b_negatedTerseLabel_en-US" xlink:label="lab_angn_PaymentsForForwardStockSplitFractionalShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fractional share payments related to the forward stock split</link:label>
    <link:label id="lab_angn_PaymentsForForwardStockSplitFractionalShares_label_en-US" xlink:label="lab_angn_PaymentsForForwardStockSplitFractionalShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Forward Stock Split Fractional Shares</link:label>
    <link:label id="lab_angn_PaymentsForForwardStockSplitFractionalShares_documentation_en-US" xlink:label="lab_angn_PaymentsForForwardStockSplitFractionalShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Forward Stock Split Fractional Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PaymentsForForwardStockSplitFractionalShares" xlink:href="angn-20211231.xsd#angn_PaymentsForForwardStockSplitFractionalShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_PaymentsForForwardStockSplitFractionalShares" xlink:to="lab_angn_PaymentsForForwardStockSplitFractionalShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_4a349655-999e-4848-933f-3dc33b3d02b5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount_b9acb0e5-ad26-4a6d-8e67-4ac8ea23f640_totalLabel_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Series C convertible preferred stock</link:label>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount_label_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption Carried At Amortized Cost And Fair Value, Settlement Terms, Share Value, Amount,</link:label>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount_documentation_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption Carried At Amortized Cost And Fair Value, Settlement Terms, Share Value, Amount,</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount" xlink:to="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8d9caead-ba02-4837-a560-63de34a56e07_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2b68ed7f-c1cf-42e1-bd88-565a0a031488_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of broker warrants</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantsReceivableCurrent_0901b778-2817-4c20-b5ea-a72f8c11e044_terseLabel_en-US" xlink:label="lab_us-gaap_GrantsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants receivable</link:label>
    <link:label id="lab_us-gaap_GrantsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_GrantsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantsReceivableCurrent" xlink:to="lab_us-gaap_GrantsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6a912fc9-eb4c-45a9-8f49-c7fe8d1624f4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_bc991b02-96e4-4b4a-bc3f-e85e84e633e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8fb0de56-0885-4f23-914f-3cdaf01c17f5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageExercisePrice_c7666d0a-5096-4bce-9122-5ddb1e2338d4_terseLabel_en-US" xlink:label="lab_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested at end of period (in dollars per share)</link:label>
    <link:label id="lab_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label id="lab_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageExercisePrice" xlink:href="angn-20211231.xsd#angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageExercisePrice" xlink:to="lab_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountAccumulatedChangeInFairValue_48558a99-351a-45f7-8eb2-dab3e9d2aa12_terseLabel_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountAccumulatedChangeInFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of Series C convertible preferred stock exchanged for convertible notes</link:label>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountAccumulatedChangeInFairValue_label_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountAccumulatedChangeInFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption Carried At Fair Value, Settlement Terms, Share Value, Amount, Accumulated Change In Fair Value</link:label>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountAccumulatedChangeInFairValue_documentation_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountAccumulatedChangeInFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption Carried At Fair Value, Settlement Terms, Share Value, Amount, Accumulated Change In Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountAccumulatedChangeInFairValue" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountAccumulatedChangeInFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountAccumulatedChangeInFairValue" xlink:to="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountAccumulatedChangeInFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_c7b96570-2287-4107-817c-f81ae11e707e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_f62607f9-301a-4bf3-95c0-c079a523c8ac_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation related to unvested stock option awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_fb1dc993-aea7-4fc7-93ca-365de0d9e1be_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_bdb702ef-5b14-4770-8613-78ddead58546_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Outstanding Warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_dbcde16d-5330-4e89-8ad6-e28d6b525c1d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_dafd3962-68f2-46ca-b087-a08831bbe96b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_175499c9-eec1-467b-b124-cbecc52cf601_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_769cea0e-f9ec-42aa-bd39-110014afaf97_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_ddc0e02c-e671-4f00-bfbb-580b07174d7e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_f0a76577-6f42-408b-b47b-fcb3c2fb486e_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_ec2b9317-6ff2-4df0-bb04-e21a8f6a72f0_terseLabel_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer</link:label>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember" xlink:to="lab_srt_ChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_08461f63-9858-4ffc-a6b9-9933f33c3e87_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value per share for stock option grants (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_1181d31d-a8cb-48df-b51d-9cc61a2a927a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_4a6cc25d-775c-4ef8-93ce-9a7562f589dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-option equity instruments outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_9fb4220b-5b85-484a-84e4-fa7ed637b871_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease rent expense</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ClassOfWarrantOrRightExpirationsInPeriod_edbe14c4-4921-4d3f-88d4-7e7bedebd348_negatedLabel_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightExpirationsInPeriod_label_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Expirations in Period</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightExpirationsInPeriod_documentation_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightExpirationsInPeriod" xlink:href="angn-20211231.xsd#angn_ClassOfWarrantOrRightExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ClassOfWarrantOrRightExpirationsInPeriod" xlink:to="lab_angn_ClassOfWarrantOrRightExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_51eecb64-d13d-4180-9a35-96cf358d240e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employers matching contribution annual vesting (in percentage)</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:to="lab_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5d2655a3-28c4-45b8-a91b-c22a0889f564_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_45b6b772-0d33-4127-825e-1a566daaf09d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_21939366-b028-4b60-bdc9-3e0d5c36e82d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_d68ce0ee-639f-4417-b16c-e93fae3db06b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_df42905d-3aec-46ae-a854-e9350ac5a9a9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9053c45c-cbd2-423a-8a64-083dab003a34_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_2eb97370-8324-4ee8-8fc2-c66c3a819c79_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price at inception of license agreement</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_53784258-ee55-41d9-9d43-46b9269e5987_terseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in related parties</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_a9337b46-5836-453e-b0c4-9312997dee42_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_e0cc88f3-7446-45b2-b3e5-d6cc42dda21a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units releases</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_29637550-638e-4628-ab92-40459259c87d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_c438fd7d-38fc-4e4c-a461-5e692a7e9d1a_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_0b7fc955-569d-4505-a45c-4b32d0bcab29_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_NonCashPlacementAgentFee_8c42a137-eb22-422e-bf92-cd244213edf3_terseLabel_en-US" xlink:label="lab_angn_NonCashPlacementAgentFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash placement agent fee</link:label>
    <link:label id="lab_angn_NonCashPlacementAgentFee_label_en-US" xlink:label="lab_angn_NonCashPlacementAgentFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Placement Agent Fee</link:label>
    <link:label id="lab_angn_NonCashPlacementAgentFee_documentation_en-US" xlink:label="lab_angn_NonCashPlacementAgentFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Placement Agent Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NonCashPlacementAgentFee" xlink:href="angn-20211231.xsd#angn_NonCashPlacementAgentFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_NonCashPlacementAgentFee" xlink:to="lab_angn_NonCashPlacementAgentFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_a7742355-9d23-4619-b89e-b863c4eb3d75_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_8b324e1a-a7b7-4bf2-975a-5f84e10afd96_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance benefits</link:label>
    <link:label id="lab_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_label_en-US" xlink:label="lab_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Unemployment Benefits, Severance Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:to="lab_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_fa90334d-fefd-41f6-a021-c8c351fee3f4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountIssuedInConvertibleNoteExchange_802bfd4c-f053-4d1e-9c41-ba7af51b2086_terseLabel_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountIssuedInConvertibleNoteExchange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C convertible preferred stock issued in exchange for convertible notes</link:label>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountIssuedInConvertibleNoteExchange_label_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountIssuedInConvertibleNoteExchange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption Carried At Fair Value, Settlement Terms, Share Value, Amount, Issued In Convertible Note Exchange</link:label>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountIssuedInConvertibleNoteExchange_documentation_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountIssuedInConvertibleNoteExchange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption Carried At Fair Value, Settlement Terms, Share Value, Amount, Issued In Convertible Note Exchange</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountIssuedInConvertibleNoteExchange" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountIssuedInConvertibleNoteExchange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountIssuedInConvertibleNoteExchange" xlink:to="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountIssuedInConvertibleNoteExchange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_61cd4371-ad43-4ade-9ab8-2e9a38df7a3d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ContractWithCustomerContractTerminationPeriodIncurableBreach_d320c318-c4cd-4aeb-ae91-ff89e5281c0e_terseLabel_en-US" xlink:label="lab_angn_ContractWithCustomerContractTerminationPeriodIncurableBreach" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract termination period, incurable breach</link:label>
    <link:label id="lab_angn_ContractWithCustomerContractTerminationPeriodIncurableBreach_label_en-US" xlink:label="lab_angn_ContractWithCustomerContractTerminationPeriodIncurableBreach" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Termination Period, Incurable Breach</link:label>
    <link:label id="lab_angn_ContractWithCustomerContractTerminationPeriodIncurableBreach_documentation_en-US" xlink:label="lab_angn_ContractWithCustomerContractTerminationPeriodIncurableBreach" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Termination Period, Incurable Breach</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerContractTerminationPeriodIncurableBreach" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerContractTerminationPeriodIncurableBreach"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ContractWithCustomerContractTerminationPeriodIncurableBreach" xlink:to="lab_angn_ContractWithCustomerContractTerminationPeriodIncurableBreach" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_594ad6ed-8c0a-4d56-9c68-b88af44c7931_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing obligation&#8212;current</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8ccf747c-7172-4397-b0b0-94f1d53f99c5_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_493ebf01-2694-48d2-aaca-918c3063c3d6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionFairValueAbstract_e2cbc89f-a1e4-4ae5-a8c4-f5e8327e946b_terseLabel_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C convertible preferred stock recorded at fair value</link:label>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionFairValueAbstract_label_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption, Fair Value [Abstract]</link:label>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionFairValueAbstract_documentation_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionFairValueAbstract" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionFairValueAbstract" xlink:to="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2b33a5cb-e80b-4fb6-879a-8887a3c70593_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_a1d31cb3-d4c4-4a38-a70a-a80275275cea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_a1f6424a-08b5-4540-90aa-e21d46e5a06c_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield (per share)</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_e9bf9e95-388b-4055-9a8b-13061f9c96cd_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_cb935746-e412-4827-a1f6-7999650f869d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue&#8212;noncurrent</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_b7a7983d-348b-42c9-8fbc-3020a663a1a8_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableCurrent_35085f9a-c2d5-4b4c-bc17-062b5ec46fab_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes payable</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableCurrent" xlink:to="lab_us-gaap_ConvertibleNotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_3a12699a-fa45-402e-b65f-32032cf82e0f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, term</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_dfcbbba5-574a-4fe9-ae2c-214a5ce88b4c_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b08a4307-24e0-4451-b592-071c5041e5d2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of net loss per share, basic and diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4e362fe1-1998-46d1-802d-560f475e7d1f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees_b508a3fb-e9f5-4c6c-be9c-bb56e116a4a6_negatedTerseLabel_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized discounts and fees</link:label>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees_label_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Unamortized Discount and Fees</link:label>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees_documentation_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Unamortized Discount and Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees" xlink:to="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ScheduleOfQuantitativeInformationAboutTheFinancingObligationTableTextBlock_77944b98-b4d3-46ec-b4b0-543a0b18fb40_terseLabel_en-US" xlink:label="lab_angn_ScheduleOfQuantitativeInformationAboutTheFinancingObligationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Quantitative Information About The Financing Obligation</link:label>
    <link:label id="lab_angn_ScheduleOfQuantitativeInformationAboutTheFinancingObligationTableTextBlock_label_en-US" xlink:label="lab_angn_ScheduleOfQuantitativeInformationAboutTheFinancingObligationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Quantitative Information About The Financing Obligation [Table Text Block]</link:label>
    <link:label id="lab_angn_ScheduleOfQuantitativeInformationAboutTheFinancingObligationTableTextBlock_documentation_en-US" xlink:label="lab_angn_ScheduleOfQuantitativeInformationAboutTheFinancingObligationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Quantitative Information About The Financing Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ScheduleOfQuantitativeInformationAboutTheFinancingObligationTableTextBlock" xlink:href="angn-20211231.xsd#angn_ScheduleOfQuantitativeInformationAboutTheFinancingObligationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ScheduleOfQuantitativeInformationAboutTheFinancingObligationTableTextBlock" xlink:to="lab_angn_ScheduleOfQuantitativeInformationAboutTheFinancingObligationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_527babcb-60de-4963-8336-c7d14ce28458_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_30cea2bd-8d02-4752-9dec-010a83f880b0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_6b93a504-c00a-49de-9ef1-9abcacafabee_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_229d4973-d4c1-42cd-a06d-e706cd2c44b0_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ProceedsFromFinancingObligation_3e2c5501-94ff-414b-a2f3-e3258bc1e6c0_terseLabel_en-US" xlink:label="lab_angn_ProceedsFromFinancingObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from financing obligation</link:label>
    <link:label id="lab_angn_ProceedsFromFinancingObligation_label_en-US" xlink:label="lab_angn_ProceedsFromFinancingObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Financing Obligation</link:label>
    <link:label id="lab_angn_ProceedsFromFinancingObligation_documentation_en-US" xlink:label="lab_angn_ProceedsFromFinancingObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Financing Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ProceedsFromFinancingObligation" xlink:href="angn-20211231.xsd#angn_ProceedsFromFinancingObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ProceedsFromFinancingObligation" xlink:to="lab_angn_ProceedsFromFinancingObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_EarningsPerShareDilutedIncrease_b10be692-2e83-4846-9025-4700d40f43d1_negatedTerseLabel_en-US" xlink:label="lab_angn_EarningsPerShareDilutedIncrease" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share increase (in dollars per share)</link:label>
    <link:label id="lab_angn_EarningsPerShareDilutedIncrease_label_en-US" xlink:label="lab_angn_EarningsPerShareDilutedIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, Increase</link:label>
    <link:label id="lab_angn_EarningsPerShareDilutedIncrease_documentation_en-US" xlink:label="lab_angn_EarningsPerShareDilutedIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EarningsPerShareDilutedIncrease" xlink:href="angn-20211231.xsd#angn_EarningsPerShareDilutedIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_EarningsPerShareDilutedIncrease" xlink:to="lab_angn_EarningsPerShareDilutedIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_bb428fb1-cda4-4483-b198-b723aa3aa3fb_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_OperatingLossCarryforwardSubjectToExpiration_7b8ad9c3-5ea1-48ab-a6f5-84d43c804124_terseLabel_en-US" xlink:label="lab_angn_OperatingLossCarryforwardSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforward, subject to expiration</link:label>
    <link:label id="lab_angn_OperatingLossCarryforwardSubjectToExpiration_label_en-US" xlink:label="lab_angn_OperatingLossCarryforwardSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforward, Subject to Expiration</link:label>
    <link:label id="lab_angn_OperatingLossCarryforwardSubjectToExpiration_documentation_en-US" xlink:label="lab_angn_OperatingLossCarryforwardSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforward, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OperatingLossCarryforwardSubjectToExpiration" xlink:href="angn-20211231.xsd#angn_OperatingLossCarryforwardSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_OperatingLossCarryforwardSubjectToExpiration" xlink:to="lab_angn_OperatingLossCarryforwardSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_090e0795-6208-41ac-bced-ac5dfa88a840_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of common stock upon IPO and Concurrent Private Placement, net of discount, commissions and offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermNonBankLoansAndNotesPayable_f1daed72-1056-4a40-9cb8-8895cb2f7920_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermNonBankLoansAndNotesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible promissory notes payable at fair value</link:label>
    <link:label id="lab_us-gaap_ShortTermNonBankLoansAndNotesPayable_label_en-US" xlink:label="lab_us-gaap_ShortTermNonBankLoansAndNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Non-bank Loans and Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermNonBankLoansAndNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermNonBankLoansAndNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermNonBankLoansAndNotesPayable" xlink:to="lab_us-gaap_ShortTermNonBankLoansAndNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_cd34e5b5-3223-4b61-a79f-1a8f54298aff_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_2669e071-61ae-40c8-ab62-c73666ea4d67_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExpirationsInPeriod_3e785bb3-3146-4c5e-847c-72213f25c3b7_terseLabel_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExpirationsInPeriod_label_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Weighted Average Exercise Price, Expirations in Period</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExpirationsInPeriod_documentation_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Weighted Average Exercise Price, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExpirationsInPeriod" xlink:href="angn-20211231.xsd#angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExpirationsInPeriod" xlink:to="lab_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_222d3050-3cde-4a8b-9648-950fe735dae1_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_9fff6102-f577-4bb3-8d68-c2ccfab7aab9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_0d49b887-4d4c-4024-85ef-91eac19d79cd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of convertible notes</link:label>
    <link:label id="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_2849d87c-0ddb-487d-880f-287cea08377a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of convertible notes</link:label>
    <link:label id="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_label_en-US" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Option, Changes in Fair Value, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:to="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_75ae9e4f-7f7e-4068-8c47-01aad7515d38_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_2f49e30e-4d5e-4d78-8161-0b4bdad28c07_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_c94c3f60-465d-446e-a5a6-72492428b5a3_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_6b935269-7b7c-455c-b8a2-31e824d7f8f1_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_11b076b6-1fc5-4472-93c8-550c003a7128_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_a682ebb1-2daa-40fe-963a-20631c0d9d2e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_17efc9c1-9663-423d-8292-8a4887b8669d_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_cb62d00d-c8a1-4c96-b24c-bb4a6e114d36_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e1f3604-fe31-4a41-9d16-478c2d2e7950_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_b57851b7-8c4a-4ea0-b3f5-d48d06a9115a_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_PaycheckProtectionProgramCARESActMember_ef1193af-c303-4edd-85b7-034deccf8fd3_terseLabel_en-US" xlink:label="lab_angn_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program, CARES Act</link:label>
    <link:label id="lab_angn_PaycheckProtectionProgramCARESActMember_label_en-US" xlink:label="lab_angn_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program, CARES Act [Member]</link:label>
    <link:label id="lab_angn_PaycheckProtectionProgramCARESActMember_documentation_en-US" xlink:label="lab_angn_PaycheckProtectionProgramCARESActMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paycheck Protection Program, CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PaycheckProtectionProgramCARESActMember" xlink:href="angn-20211231.xsd#angn_PaycheckProtectionProgramCARESActMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_PaycheckProtectionProgramCARESActMember" xlink:to="lab_angn_PaycheckProtectionProgramCARESActMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_6b5d3dd1-4864-4e58-97e3-c82a44e6ec65_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_2f092205-1976-4be8-ba52-952d543190ad_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f5c4913-6230-4c19-82ff-7e8bfd34327a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_f05cc645-5f99-4ec6-ae52-ad7a878b9d95_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward, amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_da0dc45d-62db-4754-a607-3099c650f2ba_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_766ce3ce-8a44-4489-8b6d-1e40589d9d0f_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_a0b8fa4f-64be-45c6-b155-1ebc9ab155d5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_6c3296e7-f16a-4213-903d-379b81c692ab_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_c5bf74ac-a2ff-4734-8866-76f70eeb8f5a_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_6c40bcb4-581d-4647-9472-223fb61259d2_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_aeee0da3-a8fc-49af-aefd-62ac2c765a4c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Instruments Subject to Mandatory Redemption by Settlement Terms [Axis]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Instruments Subject to Mandatory Redemption by Settlement Terms [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:to="lab_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5cdaf502-6dc4-4dfd-9b3f-a4f36d3471c3_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a0f7fcac-a132-4b15-8bc5-e1c35a91fe30_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_91b32d44-e5d6-41ee-ac62-0f49872d350d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_68e45c9a-06b5-4288-86d4-d3bc0b1f3027_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to common stockholders, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_LesseeOperatingLeaseFreeRentExpensePeriod_080b6654-9270-4c64-a00f-30801c90b195_terseLabel_en-US" xlink:label="lab_angn_LesseeOperatingLeaseFreeRentExpensePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free rent expense period</link:label>
    <link:label id="lab_angn_LesseeOperatingLeaseFreeRentExpensePeriod_label_en-US" xlink:label="lab_angn_LesseeOperatingLeaseFreeRentExpensePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Free Rent Expense Period</link:label>
    <link:label id="lab_angn_LesseeOperatingLeaseFreeRentExpensePeriod_documentation_en-US" xlink:label="lab_angn_LesseeOperatingLeaseFreeRentExpensePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Free Rent Expense Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_LesseeOperatingLeaseFreeRentExpensePeriod" xlink:href="angn-20211231.xsd#angn_LesseeOperatingLeaseFreeRentExpensePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_LesseeOperatingLeaseFreeRentExpensePeriod" xlink:to="lab_angn_LesseeOperatingLeaseFreeRentExpensePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_9f6ec158-722d-4edb-9007-afbee4557a8e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_da10e3a3-a347-4b70-8e56-527a3b637887_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right of use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_32cc5a7e-6450-4ba6-a601-4667f62a89dc_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leaseholds and Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leaseholds and Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_WarrantsIssuedWithUnitsInTheEquityOfferingEquityMember_c4f28aca-6811-4fec-bc26-a3330b05af30_terseLabel_en-US" xlink:label="lab_angn_WarrantsIssuedWithUnitsInTheEquityOfferingEquityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued with Units in the Equity Offering</link:label>
    <link:label id="lab_angn_WarrantsIssuedWithUnitsInTheEquityOfferingEquityMember_label_en-US" xlink:label="lab_angn_WarrantsIssuedWithUnitsInTheEquityOfferingEquityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued with Units In The Equity Offering, Equity [Member]</link:label>
    <link:label id="lab_angn_WarrantsIssuedWithUnitsInTheEquityOfferingEquityMember_documentation_en-US" xlink:label="lab_angn_WarrantsIssuedWithUnitsInTheEquityOfferingEquityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued with Units In The Equity Offering, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsIssuedWithUnitsInTheEquityOfferingEquityMember" xlink:href="angn-20211231.xsd#angn_WarrantsIssuedWithUnitsInTheEquityOfferingEquityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_WarrantsIssuedWithUnitsInTheEquityOfferingEquityMember" xlink:to="lab_angn_WarrantsIssuedWithUnitsInTheEquityOfferingEquityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_426830e5-e5a2-45a7-8b17-c819bc2eebe6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NJ_aa0f4172-ecae-4a8d-aad7-46f91b2bb35e_terseLabel_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fort Lee, New Jersey</link:label>
    <link:label id="lab_stpr_NJ_label_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW JERSEY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NJ" xlink:to="lab_stpr_NJ" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_4aa9d002-7694-418f-9042-a35b89e724f7_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_21b6263e-a811-4712-bea0-db26e0fea37f_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of grant revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_EarningsPerShareBasicIncrease_ffd8e6f1-4e4b-4525-b7ac-4994c22ad13f_negatedTerseLabel_en-US" xlink:label="lab_angn_EarningsPerShareBasicIncrease" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share increase (in dollars per share)</link:label>
    <link:label id="lab_angn_EarningsPerShareBasicIncrease_label_en-US" xlink:label="lab_angn_EarningsPerShareBasicIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, Increase</link:label>
    <link:label id="lab_angn_EarningsPerShareBasicIncrease_documentation_en-US" xlink:label="lab_angn_EarningsPerShareBasicIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EarningsPerShareBasicIncrease" xlink:href="angn-20211231.xsd#angn_EarningsPerShareBasicIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_EarningsPerShareBasicIncrease" xlink:to="lab_angn_EarningsPerShareBasicIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_9989944e-6d9b-4184-95de-feefbced39c6_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_StockIssuedDuringPeriodSharesWarrantsExercised_3f35b807-c0e7-4fd1-aa0a-d5367de788e3_terseLabel_en-US" xlink:label="lab_angn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of warrants (in shares)</link:label>
    <link:label id="lab_angn_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_angn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:label id="lab_angn_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_angn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="angn-20211231.xsd#angn_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_angn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_bb9e3609-7bd7-4fd1-bf4f-42d9f7796ade_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_104d4268-2c4a-4312-879d-ce6a19a3e24c_terseLabel_en-US" xlink:label="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C convertible preferred stock at amortized cost</link:label>
    <link:label id="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_d905770b-82f0-40db-a9d8-c17a31ac9a84_totalLabel_en-US" xlink:label="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying amount</link:label>
    <link:label id="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_label_en-US" xlink:label="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" xlink:to="lab_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_4ff17b8d-81ae-465b-b4aa-3af99fbe33db_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, zero and 316,088 shares outstanding as of December 31, 2021 and 2020, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_0be7b14c-94e5-4dcd-8cc4-8f8480bd4071_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_4f8c01d4-4344-4843-91ab-e4be9bc455f5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable at Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_b13e0105-15e9-4fea-98c0-0f3d23185a21_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSubjectToMandatoryRedemptionMember_cd939dfb-817e-4618-b00f-ca69c38a912e_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSubjectToMandatoryRedemptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock Subject to Mandatory Redemption</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSubjectToMandatoryRedemptionMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSubjectToMandatoryRedemptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock Subject to Mandatory Redemption [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSubjectToMandatoryRedemptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSubjectToMandatoryRedemptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSubjectToMandatoryRedemptionMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockSubjectToMandatoryRedemptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_90caf7d3-10a0-4dc3-bcb6-af37b0688346_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses from equity investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_76eb6edf-24b7-473d-9995-5e15bdeca049_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses of equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_5d45582c-d534-4883-b390-aac60e1432b6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible notes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_RelatedPartyTransactionRoyaltiesAndMilestonePaymentsPeriod_25214355-09e7-4376-8dbe-3a1794ed92f7_terseLabel_en-US" xlink:label="lab_angn_RelatedPartyTransactionRoyaltiesAndMilestonePaymentsPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and milestone payments, period</link:label>
    <link:label id="lab_angn_RelatedPartyTransactionRoyaltiesAndMilestonePaymentsPeriod_label_en-US" xlink:label="lab_angn_RelatedPartyTransactionRoyaltiesAndMilestonePaymentsPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Royalties And Milestone Payments, Period</link:label>
    <link:label id="lab_angn_RelatedPartyTransactionRoyaltiesAndMilestonePaymentsPeriod_documentation_en-US" xlink:label="lab_angn_RelatedPartyTransactionRoyaltiesAndMilestonePaymentsPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Royalties And Milestone Payments, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_RelatedPartyTransactionRoyaltiesAndMilestonePaymentsPeriod" xlink:href="angn-20211231.xsd#angn_RelatedPartyTransactionRoyaltiesAndMilestonePaymentsPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_RelatedPartyTransactionRoyaltiesAndMilestonePaymentsPeriod" xlink:to="lab_angn_RelatedPartyTransactionRoyaltiesAndMilestonePaymentsPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_e74aebca-36ba-4550-8cb7-92c155b6e2a5_terseLabel_en-US" xlink:label="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Family of the Executive Chairman investment, ownership percentage</link:label>
    <link:label id="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_label_en-US" xlink:label="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited Liability Company or Limited Partnership, Members or Limited Partners, Ownership Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:to="lab_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent_1794703a-cf11-444d-95ea-b924aea29083_terseLabel_en-US" xlink:label="lab_angn_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Permanent items</link:label>
    <link:label id="lab_angn_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent_label_en-US" xlink:label="lab_angn_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Permanent Items, Percent</link:label>
    <link:label id="lab_angn_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent_documentation_en-US" xlink:label="lab_angn_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Permanent Items, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" xlink:href="angn-20211231.xsd#angn_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" xlink:to="lab_angn_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_e916fc16-84c6-4a18-a54d-44e3ae96a559_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of RSA and RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock_679b9300-0f39-49e1-aa4b-38f35baa2625_terseLabel_en-US" xlink:label="lab_angn_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible preferred stock into common stock upon IPO (in shares)</link:label>
    <link:label id="lab_angn_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock_label_en-US" xlink:label="lab_angn_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Preferred Stock</link:label>
    <link:label id="lab_angn_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock_documentation_en-US" xlink:label="lab_angn_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock" xlink:href="angn-20211231.xsd#angn_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock" xlink:to="lab_angn_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_WarrantsFairValueDisclosure_04f0f762-4889-4733-b012-b01c23799361_terseLabel_en-US" xlink:label="lab_angn_WarrantsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_angn_WarrantsFairValueDisclosure_label_en-US" xlink:label="lab_angn_WarrantsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Fair Value Disclosure</link:label>
    <link:label id="lab_angn_WarrantsFairValueDisclosure_documentation_en-US" xlink:label="lab_angn_WarrantsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsFairValueDisclosure" xlink:href="angn-20211231.xsd#angn_WarrantsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_WarrantsFairValueDisclosure" xlink:to="lab_angn_WarrantsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_b069a9a5-0b37-48dd-affa-4d93aaeb3473_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_9082060d-5ba4-4415-9a7c-db9836fbc620_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_6782d2af-3b66-4904-9ff1-de3e1223e70c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_LegalServicesMember_892a60cd-e201-4303-996d-525d26fc7e91_terseLabel_en-US" xlink:label="lab_angn_LegalServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Services</link:label>
    <link:label id="lab_angn_LegalServicesMember_label_en-US" xlink:label="lab_angn_LegalServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Services [Member]</link:label>
    <link:label id="lab_angn_LegalServicesMember_documentation_en-US" xlink:label="lab_angn_LegalServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_LegalServicesMember" xlink:href="angn-20211231.xsd#angn_LegalServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_LegalServicesMember" xlink:to="lab_angn_LegalServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_a7172d58-cbe8-44ef-aeac-6450a4520722_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_4b8acd0c-119c-40a8-911a-643a56679cdb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_5c03b8e9-7d9c-411d-9a96-69c0a68c541b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from loan from PPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Long-term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_81ee0eb7-2778-48e0-a34a-830513666e89_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_19ef1344-6066-4320-ba87-9b3673151693_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_StockIssuedDuringPeriodSharesBrokerWarrantsExercised_97987234-2bae-42ba-bf53-ab9d55fb8593_terseLabel_en-US" xlink:label="lab_angn_StockIssuedDuringPeriodSharesBrokerWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of broker warrants (in shares)</link:label>
    <link:label id="lab_angn_StockIssuedDuringPeriodSharesBrokerWarrantsExercised_label_en-US" xlink:label="lab_angn_StockIssuedDuringPeriodSharesBrokerWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Broker Warrants Exercised</link:label>
    <link:label id="lab_angn_StockIssuedDuringPeriodSharesBrokerWarrantsExercised_documentation_en-US" xlink:label="lab_angn_StockIssuedDuringPeriodSharesBrokerWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Broker Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodSharesBrokerWarrantsExercised" xlink:href="angn-20211231.xsd#angn_StockIssuedDuringPeriodSharesBrokerWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_StockIssuedDuringPeriodSharesBrokerWarrantsExercised" xlink:to="lab_angn_StockIssuedDuringPeriodSharesBrokerWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_a42dd551-4a49-46ee-986b-66fce1627b9e_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Convertible Preferred Stock at Fair Value</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d3027fa1-f9ea-43de-b849-052bb2535140_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_OtherInvestmentAndSecuritiesAtCostOwnershipPercentage_b8fccbb5-ac6b-4ab4-871c-6b7e6bb3dbd3_terseLabel_en-US" xlink:label="lab_angn_OtherInvestmentAndSecuritiesAtCostOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, ownership percentage</link:label>
    <link:label id="lab_angn_OtherInvestmentAndSecuritiesAtCostOwnershipPercentage_label_en-US" xlink:label="lab_angn_OtherInvestmentAndSecuritiesAtCostOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment and Securities, at Cost, Ownership Percentage</link:label>
    <link:label id="lab_angn_OtherInvestmentAndSecuritiesAtCostOwnershipPercentage_documentation_en-US" xlink:label="lab_angn_OtherInvestmentAndSecuritiesAtCostOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment and Securities, at Cost, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OtherInvestmentAndSecuritiesAtCostOwnershipPercentage" xlink:href="angn-20211231.xsd#angn_OtherInvestmentAndSecuritiesAtCostOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_OtherInvestmentAndSecuritiesAtCostOwnershipPercentage" xlink:to="lab_angn_OtherInvestmentAndSecuritiesAtCostOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_45c3060b-cfe2-4592-95d5-3a583f06ccb8_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Retired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesRetired" xlink:to="lab_us-gaap_TreasuryStockSharesRetired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_fcc35c86-cfcf-429a-b20d-5087baa0fb85_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_dca5d776-dbfe-4b78-89d3-aa3f46e85ab7_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_efa5b3f6-96a1-4221-a1a0-ae2b32cf2552_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units releases (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_4cd12b5a-3f48-4666-862d-9f3be9850a70_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_72cb5693-e9ec-49f5-bda1-b4ee89dbcf7a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_af88a8f0-afe8-4270-8cc3-9fe47427f58c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_c545c37d-23e7-49d0-8e4f-4699d4c465f7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_ba706942-58d0-4986-a1d5-6269218f4ea6_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes, net of federal tax benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_92405e9b-3d53-4894-ae2b-e5e8c37fe8e1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_17467a90-e390-447d-9a85-a716f3d76aa4_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ContractWithCustomerLiabilityPercentOfUpfrontPayment_1e52b1b4-eecd-47ff-ae13-f37a134a30c9_terseLabel_en-US" xlink:label="lab_angn_ContractWithCustomerLiabilityPercentOfUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price, percent of upfront payment</link:label>
    <link:label id="lab_angn_ContractWithCustomerLiabilityPercentOfUpfrontPayment_label_en-US" xlink:label="lab_angn_ContractWithCustomerLiabilityPercentOfUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Percent Of Upfront Payment</link:label>
    <link:label id="lab_angn_ContractWithCustomerLiabilityPercentOfUpfrontPayment_documentation_en-US" xlink:label="lab_angn_ContractWithCustomerLiabilityPercentOfUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Percent Of Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerLiabilityPercentOfUpfrontPayment" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerLiabilityPercentOfUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ContractWithCustomerLiabilityPercentOfUpfrontPayment" xlink:to="lab_angn_ContractWithCustomerLiabilityPercentOfUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_732842b7-a607-4fab-a88f-1beb4b1e8c07_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a780effe-c399-4b66-96c9-9031a7ed8c39_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_27b8ea6c-b605-46d8-b8a1-29c1a353e949_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of noncash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber_81dfcb2e-b4d1-4346-ad4c-eec4ed740af4_terseLabel_en-US" xlink:label="lab_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested at end of period (in shares)</link:label>
    <link:label id="lab_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber_label_en-US" xlink:label="lab_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Outstanding, Number</link:label>
    <link:label id="lab_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber_documentation_en-US" xlink:label="lab_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber" xlink:href="angn-20211231.xsd#angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber" xlink:to="lab_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_55fd6862-a4e4-4dfe-9b93-d5031e0233c3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c6e43ed5-5e75-418d-a71f-7bf63b317758_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_A2021PlanMember_415e66db-e64f-4ee1-b8c5-0b9d85f322b5_terseLabel_en-US" xlink:label="lab_angn_A2021PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Plan</link:label>
    <link:label id="lab_angn_A2021PlanMember_label_en-US" xlink:label="lab_angn_A2021PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Plan [Member]</link:label>
    <link:label id="lab_angn_A2021PlanMember_documentation_en-US" xlink:label="lab_angn_A2021PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_A2021PlanMember" xlink:href="angn-20211231.xsd#angn_A2021PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_A2021PlanMember" xlink:to="lab_angn_A2021PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c5cc6ea9-b5f0-4465-a72b-68b7f1765a0e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_bb9b038f-d7f8-4d38-8cf2-7139c57a3d01_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvesteeMember_cf22fb3e-3b97-492f-8679-220c06efb850_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investee</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvesteeMember_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvesteeMember" xlink:to="lab_us-gaap_EquityMethodInvesteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_e7421019-f1ef-4e9e-b4f5-1db97f68755e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_92523398-5312-4e29-8cd7-eb22fb9b83f4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_506485b4-4e9b-48a1-9104-37d17bb47111_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_bbe6eeba-6294-4c2f-b984-06bb1bcd5c1c_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_OhrCosmeticsLLCMember_890571bf-e47f-4242-a961-5d939dfb4845_terseLabel_en-US" xlink:label="lab_angn_OhrCosmeticsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ohr Cosmetics, LLC</link:label>
    <link:label id="lab_angn_OhrCosmeticsLLCMember_label_en-US" xlink:label="lab_angn_OhrCosmeticsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ohr Cosmetics, LLC [Member]</link:label>
    <link:label id="lab_angn_OhrCosmeticsLLCMember_documentation_en-US" xlink:label="lab_angn_OhrCosmeticsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ohr Cosmetics, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OhrCosmeticsLLCMember" xlink:href="angn-20211231.xsd#angn_OhrCosmeticsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_OhrCosmeticsLLCMember" xlink:to="lab_angn_OhrCosmeticsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_289bc5e0-c62d-43c6-9f0e-33018b50be09_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of equity-classified broker warrants (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_333390ab-e3cd-4a2d-a3e3-e815722aa2c9_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_3d124621-3bee-43af-a941-8cca76abe376_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_NonIPORelatedStockTransactionsMember_dcea3c32-5631-4f67-8e34-4896243d4f8d_terseLabel_en-US" xlink:label="lab_angn_NonIPORelatedStockTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-IPO Related Stock Transactions</link:label>
    <link:label id="lab_angn_NonIPORelatedStockTransactionsMember_label_en-US" xlink:label="lab_angn_NonIPORelatedStockTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-IPO Related Stock Transactions [Member]</link:label>
    <link:label id="lab_angn_NonIPORelatedStockTransactionsMember_documentation_en-US" xlink:label="lab_angn_NonIPORelatedStockTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-IPO Related Stock Transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NonIPORelatedStockTransactionsMember" xlink:href="angn-20211231.xsd#angn_NonIPORelatedStockTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_NonIPORelatedStockTransactionsMember" xlink:to="lab_angn_NonIPORelatedStockTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ImmediateFamilyOfDirectorAndChairmanMember_4cfe9264-5746-4e9d-a4a2-220ddc22b9d4_terseLabel_en-US" xlink:label="lab_angn_ImmediateFamilyOfDirectorAndChairmanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immediate Family of Director and Chairman</link:label>
    <link:label id="lab_angn_ImmediateFamilyOfDirectorAndChairmanMember_label_en-US" xlink:label="lab_angn_ImmediateFamilyOfDirectorAndChairmanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immediate Family of Director and Chairman [Member]</link:label>
    <link:label id="lab_angn_ImmediateFamilyOfDirectorAndChairmanMember_documentation_en-US" xlink:label="lab_angn_ImmediateFamilyOfDirectorAndChairmanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immediate Family of Director and Chairman</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ImmediateFamilyOfDirectorAndChairmanMember" xlink:href="angn-20211231.xsd#angn_ImmediateFamilyOfDirectorAndChairmanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ImmediateFamilyOfDirectorAndChairmanMember" xlink:to="lab_angn_ImmediateFamilyOfDirectorAndChairmanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent_731006a9-e660-488b-90f3-b69e4a3dec5c_terseLabel_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C convertible preferred stock at fair value</link:label>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent_label_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption Carried At Fair Value, Settlement Terms, Share Value, Amount, Current</link:label>
    <link:label id="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent_documentation_en-US" xlink:label="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption Carried At Fair Value, Settlement Terms, Share Value, Amount, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent" xlink:to="lab_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_1ab466e8-8705-4862-a7ce-ce06cf5f0485_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issuable upon the exercise of warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3ffaddda-b957-4b08-9121-54c61f79204b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bfe77ec4-262c-485b-825c-a2efa97107ca_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_dead80e9-3f0f-4265-9a28-26b916b4b123_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C preferred stock</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_66c185e6-987d-4b60-93d5-fe145a6ed23b_verboseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issuable upon conversion of the Series C preferred stock</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_us-gaap_SeriesCPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_15d94cd5-890f-40b6-ad5d-53bf4fb2418c_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, contractual term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_3216dcfb-8cb0-45c3-a0d9-ed7960fd12f4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_b06da7ff-63b7-41ad-a590-daa43ce13f48_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities included in:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_a44b7af4-1c04-459d-8d7f-92ead9f6a720_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_e59f37e9-c6d6-4121-b107-008a01d5a9b2_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_94f9de6a-f701-4673-95fc-a1d58d3f0e89_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issuable upon conversion of the convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_61de612d-b74c-4d62-9f19-d1704569a7d1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and exercisable, weighted average remaining contractual life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_b3fcb148-e18d-4f1c-9c88-e45cef7b1cce_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_166beacb-0d46-4141-a269-f5dd019d4ae5_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_6d2eb194-5a30-43bc-88ea-5fdfe1e0bb2f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_17363ba0-49a1-4ede-9172-40283a78c486_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8ec0f5b4-96c8-4f72-91a0-716fc5bb9ba6_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_63a121f3-6af0-47cb-a4bc-39b5fe9c737e_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_AccruedInterestPremiumForConvertiblePreferredStock_a6cbf1aa-2c18-467e-a335-b4df4ec3a15c_terseLabel_en-US" xlink:label="lab_angn_AccruedInterestPremiumForConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest premium for Series C convertible preferred stock</link:label>
    <link:label id="lab_angn_AccruedInterestPremiumForConvertiblePreferredStock_label_en-US" xlink:label="lab_angn_AccruedInterestPremiumForConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Interest Premium For Convertible Preferred Stock</link:label>
    <link:label id="lab_angn_AccruedInterestPremiumForConvertiblePreferredStock_documentation_en-US" xlink:label="lab_angn_AccruedInterestPremiumForConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Interest Premium For Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AccruedInterestPremiumForConvertiblePreferredStock" xlink:href="angn-20211231.xsd#angn_AccruedInterestPremiumForConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_AccruedInterestPremiumForConvertiblePreferredStock" xlink:to="lab_angn_AccruedInterestPremiumForConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_447bafab-7d52-4c8e-ab63-9a8b6fd8f29d_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock into which all convertible preferred stock outstanding were automatically converted into (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2162d598-18d3-405c-8b7d-e99d10b2091b_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of convertible preferred stock into common stock upon IPO (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_7a17f89a-8ca8-48d7-a980-e82b774fcfaf_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_LesseeOperatingLeaseNoticePeriodForOptionToExtend_b6f26423-6080-4c06-bdc9-aba1e3a82921_terseLabel_en-US" xlink:label="lab_angn_LesseeOperatingLeaseNoticePeriodForOptionToExtend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notice period for option to extend</link:label>
    <link:label id="lab_angn_LesseeOperatingLeaseNoticePeriodForOptionToExtend_label_en-US" xlink:label="lab_angn_LesseeOperatingLeaseNoticePeriodForOptionToExtend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Notice Period for Option to Extend</link:label>
    <link:label id="lab_angn_LesseeOperatingLeaseNoticePeriodForOptionToExtend_documentation_en-US" xlink:label="lab_angn_LesseeOperatingLeaseNoticePeriodForOptionToExtend" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Notice Period for Option to Extend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_LesseeOperatingLeaseNoticePeriodForOptionToExtend" xlink:href="angn-20211231.xsd#angn_LesseeOperatingLeaseNoticePeriodForOptionToExtend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_LesseeOperatingLeaseNoticePeriodForOptionToExtend" xlink:to="lab_angn_LesseeOperatingLeaseNoticePeriodForOptionToExtend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_b420e9b7-fe50-44c7-ac39-dfce67387d02_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_84af1268-a46d-40b1-8bb2-d0d9cb35d33c_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_68d95d21-c0ea-46b7-ae62-94ad4d52a617_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_26895197-f788-4842-b8bb-a70949458c7a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_LesseeOperatingLeaseAnnualRentExpense_f0e52f18-9758-4d8e-936a-0717b0ac18be_terseLabel_en-US" xlink:label="lab_angn_LesseeOperatingLeaseAnnualRentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, payment per year</link:label>
    <link:label id="lab_angn_LesseeOperatingLeaseAnnualRentExpense_label_en-US" xlink:label="lab_angn_LesseeOperatingLeaseAnnualRentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Annual Rent Expense</link:label>
    <link:label id="lab_angn_LesseeOperatingLeaseAnnualRentExpense_documentation_en-US" xlink:label="lab_angn_LesseeOperatingLeaseAnnualRentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Annual Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_LesseeOperatingLeaseAnnualRentExpense" xlink:href="angn-20211231.xsd#angn_LesseeOperatingLeaseAnnualRentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_LesseeOperatingLeaseAnnualRentExpense" xlink:to="lab_angn_LesseeOperatingLeaseAnnualRentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44c208d3-ca66-45c1-ae00-2f2ddc8e50ad_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0c3926fa-29a6-4cbb-a2fc-48830f216930_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at the end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_0a1cede5-82fc-466e-8c50-c14e7d27d974_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0d02fa7b-c90e-4b88-b78c-f89794929fb7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in offering (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_16fa32de-e314-41bc-9787-8c4a86445f50_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_72fa4e95-3883-4ba0-840d-10d4b9165c51_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_95329f88-5b15-42ff-a352-3291b507f42b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_DirectorsAndFamilyMemberOfChiefExecutiveOfficerDirectorMember_365d1264-0b21-45f6-963e-d7091c491af5_terseLabel_en-US" xlink:label="lab_angn_DirectorsAndFamilyMemberOfChiefExecutiveOfficerDirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Directors and Family Member of Chief Executive Officer/Director</link:label>
    <link:label id="lab_angn_DirectorsAndFamilyMemberOfChiefExecutiveOfficerDirectorMember_label_en-US" xlink:label="lab_angn_DirectorsAndFamilyMemberOfChiefExecutiveOfficerDirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Directors and Family Member of Chief Executive Officer/Director [Member]</link:label>
    <link:label id="lab_angn_DirectorsAndFamilyMemberOfChiefExecutiveOfficerDirectorMember_documentation_en-US" xlink:label="lab_angn_DirectorsAndFamilyMemberOfChiefExecutiveOfficerDirectorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Directors and Family Member of Chief Executive Officer/Director</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_DirectorsAndFamilyMemberOfChiefExecutiveOfficerDirectorMember" xlink:href="angn-20211231.xsd#angn_DirectorsAndFamilyMemberOfChiefExecutiveOfficerDirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_DirectorsAndFamilyMemberOfChiefExecutiveOfficerDirectorMember" xlink:to="lab_angn_DirectorsAndFamilyMemberOfChiefExecutiveOfficerDirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_1bb3b7b5-6c2b-4ec5-99d6-1c0b0baf5993_terseLabel_en-US" xlink:label="lab_us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption, Financial Instrument [Domain]</link:label>
    <link:label id="lab_us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_label_en-US" xlink:label="lab_us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Subject to Mandatory Redemption, Financial Instrument [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:to="lab_us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_eefc4e9e-9e23-40e4-83c4-5c1a1ed409c4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_PrepaidClinicalFeesCurrent_510664e2-465b-4343-8abc-5752213f72b9_terseLabel_en-US" xlink:label="lab_angn_PrepaidClinicalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid clinical fees</link:label>
    <link:label id="lab_angn_PrepaidClinicalFeesCurrent_label_en-US" xlink:label="lab_angn_PrepaidClinicalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Clinical Fees, Current</link:label>
    <link:label id="lab_angn_PrepaidClinicalFeesCurrent_documentation_en-US" xlink:label="lab_angn_PrepaidClinicalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Clinical Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PrepaidClinicalFeesCurrent" xlink:href="angn-20211231.xsd#angn_PrepaidClinicalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_PrepaidClinicalFeesCurrent" xlink:to="lab_angn_PrepaidClinicalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_af941e14-f9b5-4d78-ba93-22ce4337d277_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1e1bb278-5934-43fd-a931-15af9b941325_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents - Money market securities</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_5195cf63-d27f-448d-8bde-5a66fc2331d7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7ebbe986-07cb-4e86-9e99-5da5f0958e53_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fd8ad4b4-181e-49b5-acb1-9fc55ce15a64_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_fefc9664-91f2-457f-bf8b-0e4749c23782_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1aed87f6-261f-4392-a042-7a261aadea89_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_00eba7fc-9cc2-466c-8a35-c8f6f3160e2e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_4b7d5084-01e8-4f28-a568-a0175f2e9648_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements, recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_c6c624e7-26f2-46a0-b41b-979d580b45a0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_8231a064-8166-442c-8d27-6ac30a266203_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_348fa450-b2ef-4547-b3b3-3dbcfe500311_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-allotment option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_bf1616c6-8837-4ed0-9f97-fd6d25d0a315_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ba8c0bc2-d6ea-411f-8609-5a08c33361f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ClassOfWarrantOrRightExercisesInPeriodTendered_9edad47a-b761-4aaf-bc5b-5f589bf34d35_terseLabel_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightExercisesInPeriodTendered" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants tendered back to the Company (in shares)</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightExercisesInPeriodTendered_label_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightExercisesInPeriodTendered" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercises in Period, Tendered</link:label>
    <link:label id="lab_angn_ClassOfWarrantOrRightExercisesInPeriodTendered_documentation_en-US" xlink:label="lab_angn_ClassOfWarrantOrRightExercisesInPeriodTendered" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercises in Period, Tendered</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightExercisesInPeriodTendered" xlink:href="angn-20211231.xsd#angn_ClassOfWarrantOrRightExercisesInPeriodTendered"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ClassOfWarrantOrRightExercisesInPeriodTendered" xlink:to="lab_angn_ClassOfWarrantOrRightExercisesInPeriodTendered" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_af852e94-de72-4683-862e-3e1310c22437_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_AuditInformationAbstract_label_en-US" xlink:label="lab_angn_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_angn_AuditInformationAbstract_documentation_en-US" xlink:label="lab_angn_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AuditInformationAbstract" xlink:href="angn-20211231.xsd#angn_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_AuditInformationAbstract" xlink:to="lab_angn_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_e8a98825-c789-41e2-a98b-67e8f01c885a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of antidilutive securities excluded from computation of net loss per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_WarrantsIssuedWith2015NotesLiabilityMember_f886a77a-53c3-4f7c-8f1c-9085cd776674_terseLabel_en-US" xlink:label="lab_angn_WarrantsIssuedWith2015NotesLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued with 2015 Notes</link:label>
    <link:label id="lab_angn_WarrantsIssuedWith2015NotesLiabilityMember_label_en-US" xlink:label="lab_angn_WarrantsIssuedWith2015NotesLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued with 2015 Notes, Liability [Member]</link:label>
    <link:label id="lab_angn_WarrantsIssuedWith2015NotesLiabilityMember_documentation_en-US" xlink:label="lab_angn_WarrantsIssuedWith2015NotesLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued with 2015 Notes, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsIssuedWith2015NotesLiabilityMember" xlink:href="angn-20211231.xsd#angn_WarrantsIssuedWith2015NotesLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_WarrantsIssuedWith2015NotesLiabilityMember" xlink:to="lab_angn_WarrantsIssuedWith2015NotesLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ConsultantWarrantsLiabilityMember_a634b710-8518-4dba-b002-250ef5da868f_terseLabel_en-US" xlink:label="lab_angn_ConsultantWarrantsLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consultant Warrants</link:label>
    <link:label id="lab_angn_ConsultantWarrantsLiabilityMember_label_en-US" xlink:label="lab_angn_ConsultantWarrantsLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consultant Warrants, Liability [Member]</link:label>
    <link:label id="lab_angn_ConsultantWarrantsLiabilityMember_documentation_en-US" xlink:label="lab_angn_ConsultantWarrantsLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consultant Warrants, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ConsultantWarrantsLiabilityMember" xlink:href="angn-20211231.xsd#angn_ConsultantWarrantsLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ConsultantWarrantsLiabilityMember" xlink:to="lab_angn_ConsultantWarrantsLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_d00fe203-1bc5-4251-951d-69dc04fea7c5_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_7bac52cb-c7dc-4aef-aa5f-5d5d1d28096d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_f68dea23-237c-4c0b-bf97-d0c2c26dcd06_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6353b4b8-bf48-444f-aa60-1edcd816722c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0e34a186-09ea-4355-ac04-aaa3500baf1b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_308cd66a-d7c1-4f3c-ac6b-2e2be0e2b66d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_0608af24-1b8b-46a2-a1db-41fcafa8a591_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Prepaid and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d8021e1d-af23-48f5-8ce5-22d6d96139bd_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2b4b175a-45b4-45d5-a480-dd30880e3744_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_6f5031cf-8e69-480a-a2eb-b3783e1eac5e_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_d5a6abab-1d90-4f9c-b422-7f7694caa07e_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1c7be028-1f36-486a-a854-9cc0975ca4d7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_7168ee26-97a2-4950-b881-4bea81386a2c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_97c36535-ead1-4358-8dbb-989d29c9d06e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_a53d2513-61bf-47be-9ec3-f1f2d635e344_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e945767f-2096-44e6-ba40-c3736ed420ec_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement upon vesting of restricted stock awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_a35ddd40-4798-4c18-adaa-06f973b429bd_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTable" xlink:to="lab_us-gaap_DefinedContributionPlanTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_8f86e867-8be3-44b2-9a3b-2e2c8f292d3a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from financing obligation</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_df435619-583e-4a19-9820-b6787312b1d7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_d4ec778e-8881-4d9e-a9f8-a37377273c66_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_0b26c7e2-bae9-4491-876f-2ccf1e3a32cd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Post-IPO capitalization rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_6663d79f-7359-4692-bd30-0408d7c392f4_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_62c9a001-b2c3-4ba8-81a0-0dfc8f5c9baa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_599e4a11-2c3c-4ca9-a98f-e3176a39b5d1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_cf8dece4-5ecf-4924-b0b1-cb6bce10052d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_b0cc3488-6f1e-46d7-815d-e942838026af_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of Restricted Stock and Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4650a24e-1a41-4e23-a295-aa99320f5c97_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_d1b22271-1615-46b0-adbb-9a5795dee920_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepositsAssetsCurrent_240fcbd1-a764-46a3-aa37-e10a2ce98cd9_terseLabel_en-US" xlink:label="lab_us-gaap_DepositsAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security deposit</link:label>
    <link:label id="lab_us-gaap_DepositsAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DepositsAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsCurrent" xlink:to="lab_us-gaap_DepositsAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_b6a88ffc-e3b4-482f-9058-b28b8493beaa_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_OperatingLossCarryforwardNotSubjectToExpiration_fa01d4f4-6e3e-4ef5-b75f-80a731297d7f_terseLabel_en-US" xlink:label="lab_angn_OperatingLossCarryforwardNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforward, not subject to expiration</link:label>
    <link:label id="lab_angn_OperatingLossCarryforwardNotSubjectToExpiration_label_en-US" xlink:label="lab_angn_OperatingLossCarryforwardNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforward, Not Subject to Expiration</link:label>
    <link:label id="lab_angn_OperatingLossCarryforwardNotSubjectToExpiration_documentation_en-US" xlink:label="lab_angn_OperatingLossCarryforwardNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforward, Not Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OperatingLossCarryforwardNotSubjectToExpiration" xlink:href="angn-20211231.xsd#angn_OperatingLossCarryforwardNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_OperatingLossCarryforwardNotSubjectToExpiration" xlink:to="lab_angn_OperatingLossCarryforwardNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_b98582f0-1644-463a-8190-e5d507bc4a71_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_1f92969d-8ca5-4825-94fd-d6c289ab3f5a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing obligation&#8212;noncurrent</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_ShareBasedPaymentArrangementPlanModificationExtendedExercisePeriod_8005665e-bead-4849-b8ee-cbfd29d7bdbc_terseLabel_en-US" xlink:label="lab_angn_ShareBasedPaymentArrangementPlanModificationExtendedExercisePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan modification, extended exercise period</link:label>
    <link:label id="lab_angn_ShareBasedPaymentArrangementPlanModificationExtendedExercisePeriod_label_en-US" xlink:label="lab_angn_ShareBasedPaymentArrangementPlanModificationExtendedExercisePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Plan Modification, Extended Exercise Period</link:label>
    <link:label id="lab_angn_ShareBasedPaymentArrangementPlanModificationExtendedExercisePeriod_documentation_en-US" xlink:label="lab_angn_ShareBasedPaymentArrangementPlanModificationExtendedExercisePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Plan Modification, Extended Exercise Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ShareBasedPaymentArrangementPlanModificationExtendedExercisePeriod" xlink:href="angn-20211231.xsd#angn_ShareBasedPaymentArrangementPlanModificationExtendedExercisePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_ShareBasedPaymentArrangementPlanModificationExtendedExercisePeriod" xlink:to="lab_angn_ShareBasedPaymentArrangementPlanModificationExtendedExercisePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_70905d0d-05b7-4157-b2b3-fc039fed3088_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign rate differential</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_1408fb3d-a334-4fef-917c-1cb7b577d82c_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility (annual)</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_909008d5-1b34-4f0f-af80-d0e2099e381b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_0abea0d1-e048-4136-8ac6-f8659776089d_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, measurement input</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_8507d44a-3f64-4952-96b2-2e32b253e491_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_c51d8aa9-3c29-410b-8833-9fe815320815_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0c2005d9-4982-41d3-afc1-70df5ac822df_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_7822bf1e-2fab-4f55-927d-0c827e780b9b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_51cc24d5-f652-4857-899b-ff670256f94e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_a5f88575-2392-46f1-9c8d-f90b16e7f809_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses in equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Dividends or Distributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_519b6bc9-9906-4f14-95ed-0970072e5eb5_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_WarrantsExercised_e2126ad3-928c-49c6-bc21-7b1195fd388c_terseLabel_en-US" xlink:label="lab_angn_WarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net exercise of warrants upon IPO</link:label>
    <link:label id="lab_angn_WarrantsExercised_label_en-US" xlink:label="lab_angn_WarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exercised</link:label>
    <link:label id="lab_angn_WarrantsExercised_documentation_en-US" xlink:label="lab_angn_WarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsExercised" xlink:href="angn-20211231.xsd#angn_WarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_WarrantsExercised" xlink:to="lab_angn_WarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_angn_PresidentAndChiefExecutiveOfficerAndDirectorMember_7c4c0ef5-b3c7-423e-8c57-6ef2231619d8_terseLabel_en-US" xlink:label="lab_angn_PresidentAndChiefExecutiveOfficerAndDirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">President and Chief Executive Officer and Director</link:label>
    <link:label id="lab_angn_PresidentAndChiefExecutiveOfficerAndDirectorMember_label_en-US" xlink:label="lab_angn_PresidentAndChiefExecutiveOfficerAndDirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">President And Chief Executive Officer And Director [Member]</link:label>
    <link:label id="lab_angn_PresidentAndChiefExecutiveOfficerAndDirectorMember_documentation_en-US" xlink:label="lab_angn_PresidentAndChiefExecutiveOfficerAndDirectorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">President And Chief Executive Officer And Director</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PresidentAndChiefExecutiveOfficerAndDirectorMember" xlink:href="angn-20211231.xsd#angn_PresidentAndChiefExecutiveOfficerAndDirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_angn_PresidentAndChiefExecutiveOfficerAndDirectorMember" xlink:to="lab_angn_PresidentAndChiefExecutiveOfficerAndDirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_4503b01d-bf13-4242-b9c2-2971b36767f7_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>21
<FILENAME>angn-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:808f0db7-14af-45c6-a88e-e152464defe4,g:f048552f-f790-4462-b881-32982147c095-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.angn.com/role/Cover" xlink:type="simple" xlink:href="angn-20211231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f20306e7-47d1-4a41-afae-2ecc91f867a1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_DocumentType_f20306e7-47d1-4a41-afae-2ecc91f867a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_b37ca272-e1a9-415c-adad-0025e1769212" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_DocumentAnnualReport_b37ca272-e1a9-415c-adad-0025e1769212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_50e56b13-74de-4825-93eb-a95624d9596c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_DocumentPeriodEndDate_50e56b13-74de-4825-93eb-a95624d9596c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_1ddc7aa3-da22-4967-81af-0e674e6874f0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_CurrentFiscalYearEndDate_1ddc7aa3-da22-4967-81af-0e674e6874f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_116f7f8c-af6f-43de-b7ea-cb43680b5381" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_DocumentTransitionReport_116f7f8c-af6f-43de-b7ea-cb43680b5381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_23e38bcd-c72c-4cff-970c-bf79d01c322d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_EntityFileNumber_23e38bcd-c72c-4cff-970c-bf79d01c322d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e2cd225a-9bd0-4b9b-9b11-a2535735e5df" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_EntityRegistrantName_e2cd225a-9bd0-4b9b-9b11-a2535735e5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5cbe8a5b-e8eb-4489-8a9e-876a47ac1467" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5cbe8a5b-e8eb-4489-8a9e-876a47ac1467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_7da49b51-b1e4-45e9-addc-55dff02d022d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_EntityTaxIdentificationNumber_7da49b51-b1e4-45e9-addc-55dff02d022d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f6fa421e-b6df-47ad-ae3b-28e3dad1f28c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_EntityAddressAddressLine1_f6fa421e-b6df-47ad-ae3b-28e3dad1f28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_3631710c-c63d-46da-a816-cc3101f48236" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_EntityAddressCityOrTown_3631710c-c63d-46da-a816-cc3101f48236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_4b52ac4d-0fb7-4fb7-8ca7-6f3c778d57b3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_EntityAddressStateOrProvince_4b52ac4d-0fb7-4fb7-8ca7-6f3c778d57b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_dddf9264-ee13-44e1-973e-85002f7e06d0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_EntityAddressPostalZipCode_dddf9264-ee13-44e1-973e-85002f7e06d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_33cde557-6fc3-49dd-a7cf-67dcc58c5d1f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_CityAreaCode_33cde557-6fc3-49dd-a7cf-67dcc58c5d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_6168ad3c-bc28-4f29-84ab-f0b3e1e296ef" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_LocalPhoneNumber_6168ad3c-bc28-4f29-84ab-f0b3e1e296ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_95b68991-4563-4fa2-8932-ff1e7cf35ae1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_Security12bTitle_95b68991-4563-4fa2-8932-ff1e7cf35ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3ea50c72-cbd0-4fa2-b749-25cfc8caf694" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_TradingSymbol_3ea50c72-cbd0-4fa2-b749-25cfc8caf694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2e034ae8-b414-43c9-b9a2-32e49239a7a3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_SecurityExchangeName_2e034ae8-b414-43c9-b9a2-32e49239a7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_5bd4ea18-941e-4997-8e6b-9497458f7ec2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_5bd4ea18-941e-4997-8e6b-9497458f7ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_f116cb74-50bc-4977-9707-b1c05c90fc48" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_EntityVoluntaryFilers_f116cb74-50bc-4977-9707-b1c05c90fc48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_5f1c4a13-b33c-4e10-bf83-ffe069c3ef3a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_EntityCurrentReportingStatus_5f1c4a13-b33c-4e10-bf83-ffe069c3ef3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_58987310-1e54-431b-bd1a-7ee3e8828a09" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_EntityInteractiveDataCurrent_58987310-1e54-431b-bd1a-7ee3e8828a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_62e1d3cf-b793-4498-a7c8-af1a6eabe33d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_EntityFilerCategory_62e1d3cf-b793-4498-a7c8-af1a6eabe33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_23e2abeb-b320-4f15-8e93-a6096604d276" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_EntitySmallBusiness_23e2abeb-b320-4f15-8e93-a6096604d276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_596fcd5b-ab7d-41cd-90a5-1ebf0a46a6b2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_EntityEmergingGrowthCompany_596fcd5b-ab7d-41cd-90a5-1ebf0a46a6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_a8a9fe1f-d999-4dc1-98e4-633bd096293c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_EntityExTransitionPeriod_a8a9fe1f-d999-4dc1-98e4-633bd096293c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_5cd83a46-8efd-4f77-8e6d-9369dac02851" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_IcfrAuditorAttestationFlag_5cd83a46-8efd-4f77-8e6d-9369dac02851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_0ed9337b-f6b2-4410-87ce-cfc1d10678ed" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_EntityShellCompany_0ed9337b-f6b2-4410-87ce-cfc1d10678ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_977636d2-78a7-4f84-b158-40ef1359e139" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_EntityPublicFloat_977636d2-78a7-4f84-b158-40ef1359e139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_c517ba93-ec62-476a-94e4-589cc8efa8e8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_c517ba93-ec62-476a-94e4-589cc8efa8e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_b6e82d2b-7549-4a80-ad84-554e11f14447" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_b6e82d2b-7549-4a80-ad84-554e11f14447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_3a25bce1-acf0-49c2-afd5-86d98321b48c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_DocumentFiscalYearFocus_3a25bce1-acf0-49c2-afd5-86d98321b48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_570e97e4-fc20-4e9a-bd73-5a0bc5db7a7d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_DocumentFiscalPeriodFocus_570e97e4-fc20-4e9a-bd73-5a0bc5db7a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_972da2da-9dd7-4d26-91b8-c083a6f16ff5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_EntityCentralIndexKey_972da2da-9dd7-4d26-91b8-c083a6f16ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_eabcdc9e-45ec-47c0-b96a-d52cb7f36d2e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c7f975a5-5d5d-483e-abb8-7fe696635041" xlink:to="loc_dei_AmendmentFlag_eabcdc9e-45ec-47c0-b96a-d52cb7f36d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/AuditInformation" xlink:type="simple" xlink:href="angn-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_angn_AuditInformationAbstract_6f159cd1-20f2-4b10-93cb-5877e126d613" xlink:href="angn-20211231.xsd#angn_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_5ca8070b-e1b4-40f5-94ab-2984284a1f29" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_AuditInformationAbstract_6f159cd1-20f2-4b10-93cb-5877e126d613" xlink:to="loc_dei_AuditorName_5ca8070b-e1b4-40f5-94ab-2984284a1f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_402b3327-68bb-423d-b5b5-48bb495cc35d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_AuditInformationAbstract_6f159cd1-20f2-4b10-93cb-5877e126d613" xlink:to="loc_dei_AuditorLocation_402b3327-68bb-423d-b5b5-48bb495cc35d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_dc6d264a-6319-49ec-ac69-b23891d3e8fe" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_AuditInformationAbstract_6f159cd1-20f2-4b10-93cb-5877e126d613" xlink:to="loc_dei_AuditorFirmId_dc6d264a-6319-49ec-ac69-b23891d3e8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="angn-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_48f00be9-e44f-41e0-bde5-b035e1214b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_3d8e753a-88a2-4b00-8876-9819d0498218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_48f00be9-e44f-41e0-bde5-b035e1214b0b" xlink:to="loc_us-gaap_AssetsAbstract_3d8e753a-88a2-4b00-8876-9819d0498218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2fff4977-75e2-4376-8d48-f13f287c156e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3d8e753a-88a2-4b00-8876-9819d0498218" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2fff4977-75e2-4376-8d48-f13f287c156e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_474e790f-7c63-4af6-9f8d-08cbdde24c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2fff4977-75e2-4376-8d48-f13f287c156e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_474e790f-7c63-4af6-9f8d-08cbdde24c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivableCurrent_55ca9abf-1f09-469c-b3f8-e2e926514c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2fff4977-75e2-4376-8d48-f13f287c156e" xlink:to="loc_us-gaap_GrantsReceivableCurrent_55ca9abf-1f09-469c-b3f8-e2e926514c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2a4ebc5e-37f9-43f9-ae3e-681628bed879" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2fff4977-75e2-4376-8d48-f13f287c156e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2a4ebc5e-37f9-43f9-ae3e-681628bed879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_897075e4-dfa7-4012-8913-01716be65cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2fff4977-75e2-4376-8d48-f13f287c156e" xlink:to="loc_us-gaap_AssetsCurrent_897075e4-dfa7-4012-8913-01716be65cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_693340ce-993d-498e-b672-70d7beea6902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3d8e753a-88a2-4b00-8876-9819d0498218" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_693340ce-993d-498e-b672-70d7beea6902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_284b6403-c291-4807-be37-6b82d6b67d54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3d8e753a-88a2-4b00-8876-9819d0498218" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_284b6403-c291-4807-be37-6b82d6b67d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_35600b23-cda1-4c34-adc5-a59324c2c9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Investments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3d8e753a-88a2-4b00-8876-9819d0498218" xlink:to="loc_us-gaap_Investments_35600b23-cda1-4c34-adc5-a59324c2c9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_fa63fef1-ebad-44f2-ac1a-48fc6d9358c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3d8e753a-88a2-4b00-8876-9819d0498218" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_fa63fef1-ebad-44f2-ac1a-48fc6d9358c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c69e6c09-6e07-4735-8fee-53ed0f76511e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3d8e753a-88a2-4b00-8876-9819d0498218" xlink:to="loc_us-gaap_Assets_c69e6c09-6e07-4735-8fee-53ed0f76511e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31c7e6da-a4b9-4b16-ba7b-9bed2b4cf7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_48f00be9-e44f-41e0-bde5-b035e1214b0b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31c7e6da-a4b9-4b16-ba7b-9bed2b4cf7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_699a5130-d7de-4521-b403-405438620dba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31c7e6da-a4b9-4b16-ba7b-9bed2b4cf7c7" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_699a5130-d7de-4521-b403-405438620dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a166c46b-e89c-48bb-8d6e-534615332d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_699a5130-d7de-4521-b403-405438620dba" xlink:to="loc_us-gaap_AccountsPayableCurrent_a166c46b-e89c-48bb-8d6e-534615332d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_22b94587-490e-4627-bdbe-945ae6721390" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_699a5130-d7de-4521-b403-405438620dba" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_22b94587-490e-4627-bdbe-945ae6721390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8262bb53-50d6-4035-a875-555b543e44b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_699a5130-d7de-4521-b403-405438620dba" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8262bb53-50d6-4035-a875-555b543e44b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_d3538cde-6b4a-462a-9dfd-77bf71e10877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_699a5130-d7de-4521-b403-405438620dba" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_d3538cde-6b4a-462a-9dfd-77bf71e10877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f12152e5-629e-4937-bd9c-5a364ce13532" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_699a5130-d7de-4521-b403-405438620dba" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f12152e5-629e-4937-bd9c-5a364ce13532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantLiabilityCurrent_4b3337fe-0eb6-412c-b124-6936d3fe9199" xlink:href="angn-20211231.xsd#angn_WarrantLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_699a5130-d7de-4521-b403-405438620dba" xlink:to="loc_angn_WarrantLiabilityCurrent_4b3337fe-0eb6-412c-b124-6936d3fe9199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermNonBankLoansAndNotesPayable_78690ea4-c7f3-4f9e-8afa-2060a5a0d394" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermNonBankLoansAndNotesPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_699a5130-d7de-4521-b403-405438620dba" xlink:to="loc_us-gaap_ShortTermNonBankLoansAndNotesPayable_78690ea4-c7f3-4f9e-8afa-2060a5a0d394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_2484fd96-00ab-49d6-8f9b-634ce1b3318f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_699a5130-d7de-4521-b403-405438620dba" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_2484fd96-00ab-49d6-8f9b-634ce1b3318f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent_525c38db-1552-4637-baa3-172bad67e073" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_699a5130-d7de-4521-b403-405438620dba" xlink:to="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent_525c38db-1552-4637-baa3-172bad67e073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermBorrowings_bbef7dfa-1589-40eb-994b-aab04d938b42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherShortTermBorrowings"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_699a5130-d7de-4521-b403-405438620dba" xlink:to="loc_us-gaap_OtherShortTermBorrowings_bbef7dfa-1589-40eb-994b-aab04d938b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4af99bbe-4836-4c89-911d-30e1b5f2cc9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_699a5130-d7de-4521-b403-405438620dba" xlink:to="loc_us-gaap_LiabilitiesCurrent_4af99bbe-4836-4c89-911d-30e1b5f2cc9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6e688abb-cdda-450e-9e27-2fb399bbf66c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31c7e6da-a4b9-4b16-ba7b-9bed2b4cf7c7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6e688abb-cdda-450e-9e27-2fb399bbf66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1a66622f-4bf6-475a-a598-d40c471dcff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31c7e6da-a4b9-4b16-ba7b-9bed2b4cf7c7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1a66622f-4bf6-475a-a598-d40c471dcff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_364dd383-d455-43bd-95ce-5ffe90de68fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31c7e6da-a4b9-4b16-ba7b-9bed2b4cf7c7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_364dd383-d455-43bd-95ce-5ffe90de68fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_4c3362dc-9fa0-4a6c-a5e9-08ce558b5fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31c7e6da-a4b9-4b16-ba7b-9bed2b4cf7c7" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_4c3362dc-9fa0-4a6c-a5e9-08ce558b5fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fb659083-c392-40f8-adc2-1d1b290cd909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31c7e6da-a4b9-4b16-ba7b-9bed2b4cf7c7" xlink:to="loc_us-gaap_Liabilities_fb659083-c392-40f8-adc2-1d1b290cd909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_08380966-1561-4669-9f23-bf0c40654ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31c7e6da-a4b9-4b16-ba7b-9bed2b4cf7c7" xlink:to="loc_us-gaap_CommitmentsAndContingencies_08380966-1561-4669-9f23-bf0c40654ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_c09ee060-2d61-4fc5-9e30-6bce805f4204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31c7e6da-a4b9-4b16-ba7b-9bed2b4cf7c7" xlink:to="loc_us-gaap_StatementOfStockholdersEquityAbstract_c09ee060-2d61-4fc5-9e30-6bce805f4204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_cac5907f-3430-4141-a234-be29340c39c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c09ee060-2d61-4fc5-9e30-6bce805f4204" xlink:to="loc_us-gaap_CommonStockValue_cac5907f-3430-4141-a234-be29340c39c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_dac978e2-9d8f-4d2e-91b5-6096546470dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c09ee060-2d61-4fc5-9e30-6bce805f4204" xlink:to="loc_us-gaap_TreasuryStockValue_dac978e2-9d8f-4d2e-91b5-6096546470dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1c906eb1-ed62-4d28-9cd4-056c83b9a472" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c09ee060-2d61-4fc5-9e30-6bce805f4204" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1c906eb1-ed62-4d28-9cd4-056c83b9a472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aa2567ee-16ec-4594-990a-3ce46326fbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c09ee060-2d61-4fc5-9e30-6bce805f4204" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aa2567ee-16ec-4594-990a-3ce46326fbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5963e5e1-1715-46a4-8898-7b63275fc35a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c09ee060-2d61-4fc5-9e30-6bce805f4204" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5963e5e1-1715-46a4-8898-7b63275fc35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1c1a036d-3aed-40af-88f2-39b05f8844bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c09ee060-2d61-4fc5-9e30-6bce805f4204" xlink:to="loc_us-gaap_StockholdersEquity_1c1a036d-3aed-40af-88f2-39b05f8844bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_eb6dc47d-ae6c-4707-bd4b-fd5253dcabb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_31c7e6da-a4b9-4b16-ba7b-9bed2b4cf7c7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_eb6dc47d-ae6c-4707-bd4b-fd5253dcabb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="angn-20211231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_caf347dc-618d-4f6c-b6c7-3026d98bf1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7e22165b-7149-4397-a9b1-27d048fa37b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_caf347dc-618d-4f6c-b6c7-3026d98bf1c1" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7e22165b-7149-4397-a9b1-27d048fa37b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a51bbd80-0446-49a1-8b20-82bef13af09a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_caf347dc-618d-4f6c-b6c7-3026d98bf1c1" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a51bbd80-0446-49a1-8b20-82bef13af09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c726a314-d86b-4cb4-b5b1-754f9bc92ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_caf347dc-618d-4f6c-b6c7-3026d98bf1c1" xlink:to="loc_us-gaap_CommonStockSharesIssued_c726a314-d86b-4cb4-b5b1-754f9bc92ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_e03da815-c717-44c6-b4eb-65dbbde1b8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_caf347dc-618d-4f6c-b6c7-3026d98bf1c1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_e03da815-c717-44c6-b4eb-65dbbde1b8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_4dfd0d4c-8f5d-4f7f-8600-d4851049ceef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_caf347dc-618d-4f6c-b6c7-3026d98bf1c1" xlink:to="loc_us-gaap_TreasuryStockShares_4dfd0d4c-8f5d-4f7f-8600-d4851049ceef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_009402a8-46ea-4e86-a57e-a6154b98de16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_caf347dc-618d-4f6c-b6c7-3026d98bf1c1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_009402a8-46ea-4e86-a57e-a6154b98de16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4494b7e2-b61c-472a-a63b-a2b809068f68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_caf347dc-618d-4f6c-b6c7-3026d98bf1c1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4494b7e2-b61c-472a-a63b-a2b809068f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="angn-20211231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_a9d09c21-d261-4879-914c-a10dbf48db25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_d9b2dd21-a093-4d01-863a-9fd415f98b96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a9d09c21-d261-4879-914c-a10dbf48db25" xlink:to="loc_us-gaap_RevenuesAbstract_d9b2dd21-a093-4d01-863a-9fd415f98b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_7f8b6dde-25ea-4995-aaea-5000cd1bc1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_d9b2dd21-a093-4d01-863a-9fd415f98b96" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_7f8b6dde-25ea-4995-aaea-5000cd1bc1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_da39af1e-094b-4ef0-9636-a86c64104b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_d9b2dd21-a093-4d01-863a-9fd415f98b96" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_da39af1e-094b-4ef0-9636-a86c64104b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7925f3d2-0923-4f01-bc07-36362d5d8771" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_d9b2dd21-a093-4d01-863a-9fd415f98b96" xlink:to="loc_us-gaap_Revenues_7925f3d2-0923-4f01-bc07-36362d5d8771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_0684cb15-1ccd-4808-b89a-d759344865af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a9d09c21-d261-4879-914c-a10dbf48db25" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_0684cb15-1ccd-4808-b89a-d759344865af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_4d60ff95-c994-4262-bc34-8d28cf648c83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_0684cb15-1ccd-4808-b89a-d759344865af" xlink:to="loc_us-gaap_CostOfRevenue_4d60ff95-c994-4262-bc34-8d28cf648c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_61242013-2cc5-4bc2-8bd7-b48959253e57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_0684cb15-1ccd-4808-b89a-d759344865af" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_61242013-2cc5-4bc2-8bd7-b48959253e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7b498192-13c1-4d20-a0e2-b000e431f224" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_0684cb15-1ccd-4808-b89a-d759344865af" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7b498192-13c1-4d20-a0e2-b000e431f224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b7c6732c-6ae3-40a5-90bb-7993cf6b4934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_0684cb15-1ccd-4808-b89a-d759344865af" xlink:to="loc_us-gaap_CostsAndExpenses_b7c6732c-6ae3-40a5-90bb-7993cf6b4934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b803cdfb-5d24-4ebd-bfec-15c4ec0e0700" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a9d09c21-d261-4879-914c-a10dbf48db25" xlink:to="loc_us-gaap_OperatingIncomeLoss_b803cdfb-5d24-4ebd-bfec-15c4ec0e0700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_379fcbbd-388b-4a9f-b7d3-f49a80ac588b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a9d09c21-d261-4879-914c-a10dbf48db25" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_379fcbbd-388b-4a9f-b7d3-f49a80ac588b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_cca15244-847e-4ec9-8d6e-f8d05bc48e19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_379fcbbd-388b-4a9f-b7d3-f49a80ac588b" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_cca15244-847e-4ec9-8d6e-f8d05bc48e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_3048f49d-9b8a-46ae-b117-7a0e17930d28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_379fcbbd-388b-4a9f-b7d3-f49a80ac588b" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_3048f49d-9b8a-46ae-b117-7a0e17930d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss_dd8b9a95-9223-4abc-9b3e-f2c0bbb6b9b8" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_379fcbbd-388b-4a9f-b7d3-f49a80ac588b" xlink:to="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss_dd8b9a95-9223-4abc-9b3e-f2c0bbb6b9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_b3b5ccde-16da-4785-acd4-b58329414f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_379fcbbd-388b-4a9f-b7d3-f49a80ac588b" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_b3b5ccde-16da-4785-acd4-b58329414f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_a59b6acc-ec8c-4b09-921b-a2362c0f350d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_379fcbbd-388b-4a9f-b7d3-f49a80ac588b" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_a59b6acc-ec8c-4b09-921b-a2362c0f350d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_dad912ca-bd40-4a52-9cca-fa557a21c587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_379fcbbd-388b-4a9f-b7d3-f49a80ac588b" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_dad912ca-bd40-4a52-9cca-fa557a21c587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_9ab4b3ba-adea-498f-9782-b5bf3ec0c90a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_379fcbbd-388b-4a9f-b7d3-f49a80ac588b" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_9ab4b3ba-adea-498f-9782-b5bf3ec0c90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_aed5b07a-4374-49e8-be56-ac2a92744a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_379fcbbd-388b-4a9f-b7d3-f49a80ac588b" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_aed5b07a-4374-49e8-be56-ac2a92744a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_913adf37-c246-4596-9ba9-32ff2203001a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_379fcbbd-388b-4a9f-b7d3-f49a80ac588b" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_913adf37-c246-4596-9ba9-32ff2203001a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f5d892ad-b85d-4505-8332-1eebafe64fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a9d09c21-d261-4879-914c-a10dbf48db25" xlink:to="loc_us-gaap_NetIncomeLoss_f5d892ad-b85d-4505-8332-1eebafe64fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract_fa54c074-ebd1-4b81-887d-7d7d37c2bcbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a9d09c21-d261-4879-914c-a10dbf48db25" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract_fa54c074-ebd1-4b81-887d-7d7d37c2bcbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4e8fa3cc-f895-4abb-9fc7-452a1c270ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract_fa54c074-ebd1-4b81-887d-7d7d37c2bcbb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_4e8fa3cc-f895-4abb-9fc7-452a1c270ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_25e405a7-9c61-4cc8-b5ef-9c80df7519a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract_fa54c074-ebd1-4b81-887d-7d7d37c2bcbb" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_25e405a7-9c61-4cc8-b5ef-9c80df7519a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_19e06e59-8a80-4aae-82a4-f544bfca2f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a9d09c21-d261-4879-914c-a10dbf48db25" xlink:to="loc_us-gaap_EarningsPerShareBasic_19e06e59-8a80-4aae-82a4-f544bfca2f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d920158d-61ef-4e31-bb73-6644dd761e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a9d09c21-d261-4879-914c-a10dbf48db25" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d920158d-61ef-4e31-bb73-6644dd761e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1ebc6d13-aa7b-41f1-a8a8-383522966439" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a9d09c21-d261-4879-914c-a10dbf48db25" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1ebc6d13-aa7b-41f1-a8a8-383522966439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cff03a03-46eb-4b7d-b9db-e015830c2fab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a9d09c21-d261-4879-914c-a10dbf48db25" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cff03a03-46eb-4b7d-b9db-e015830c2fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" xlink:type="simple" xlink:href="angn-20211231.xsd#ConsolidatedStatementsofStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_e8b2363d-2181-47f1-8c3e-556a4ce5e705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9af511a0-0718-4d58-bd24-77fa1fed0cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_e8b2363d-2181-47f1-8c3e-556a4ce5e705" xlink:to="loc_us-gaap_StatementTable_9af511a0-0718-4d58-bd24-77fa1fed0cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7274e657-f978-4cbc-b179-5e1adcae8f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9af511a0-0718-4d58-bd24-77fa1fed0cb0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7274e657-f978-4cbc-b179-5e1adcae8f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a4cb0fed-1d32-4587-bb0a-921c983aca0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7274e657-f978-4cbc-b179-5e1adcae8f5a" xlink:to="loc_us-gaap_EquityComponentDomain_a4cb0fed-1d32-4587-bb0a-921c983aca0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_ffe3d9f9-1d65-48a8-8411-6a59ae0ca351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a4cb0fed-1d32-4587-bb0a-921c983aca0e" xlink:to="loc_us-gaap_CommonStockMember_ffe3d9f9-1d65-48a8-8411-6a59ae0ca351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_5f4088ef-d5a4-4f74-8d74-958deb05f060" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a4cb0fed-1d32-4587-bb0a-921c983aca0e" xlink:to="loc_us-gaap_TreasuryStockMember_5f4088ef-d5a4-4f74-8d74-958deb05f060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_eb058017-13f4-4006-8849-e47faaf5ee5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a4cb0fed-1d32-4587-bb0a-921c983aca0e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_eb058017-13f4-4006-8849-e47faaf5ee5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e17098d3-529c-41a0-9ea4-47ad49b96f87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a4cb0fed-1d32-4587-bb0a-921c983aca0e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e17098d3-529c-41a0-9ea4-47ad49b96f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4bb19492-8a4b-4086-b62b-4bbcf862af91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a4cb0fed-1d32-4587-bb0a-921c983aca0e" xlink:to="loc_us-gaap_RetainedEarningsMember_4bb19492-8a4b-4086-b62b-4bbcf862af91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_90abd5a7-ed6f-479b-ac6b-5e7d69dc2d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9af511a0-0718-4d58-bd24-77fa1fed0cb0" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_90abd5a7-ed6f-479b-ac6b-5e7d69dc2d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e13ce273-a2d6-4976-883b-775d973792b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_90abd5a7-ed6f-479b-ac6b-5e7d69dc2d2e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e13ce273-a2d6-4976-883b-775d973792b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_cc5a61e7-70b2-47ac-bc3c-12b944144c37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e13ce273-a2d6-4976-883b-775d973792b4" xlink:to="loc_us-gaap_IPOMember_cc5a61e7-70b2-47ac-bc3c-12b944144c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_e9166724-9f29-4f2d-8392-9aaff88dc9b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e13ce273-a2d6-4976-883b-775d973792b4" xlink:to="loc_us-gaap_PrivatePlacementMember_e9166724-9f29-4f2d-8392-9aaff88dc9b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NonIPORelatedStockTransactionsMember_b8bb5f9a-d323-49c2-919e-b1ba7d1ac1bf" xlink:href="angn-20211231.xsd#angn_NonIPORelatedStockTransactionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e13ce273-a2d6-4976-883b-775d973792b4" xlink:to="loc_angn_NonIPORelatedStockTransactionsMember_b8bb5f9a-d323-49c2-919e-b1ba7d1ac1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_cd0e2551-0d94-46c9-84bb-16e1a37ff206" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9af511a0-0718-4d58-bd24-77fa1fed0cb0" xlink:to="loc_us-gaap_StatementLineItems_cd0e2551-0d94-46c9-84bb-16e1a37ff206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cd0e2551-0d94-46c9-84bb-16e1a37ff206" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e4af4ee0-def6-42fa-ab7d-2d773611fcde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_SharesOutstanding_e4af4ee0-def6-42fa-ab7d-2d773611fcde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b82aabb5-ef6b-41d4-ad32-0b2ce276eb82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_StockholdersEquity_b82aabb5-ef6b-41d4-ad32-0b2ce276eb82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f847a516-dc72-496a-bc5c-68d7f31fe5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f847a516-dc72-496a-bc5c-68d7f31fe5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_66955015-bf0e-42f9-acc7-3afc03a97e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_66955015-bf0e-42f9-acc7-3afc03a97e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock_bfda37b4-3dfb-4542-a346-4614face9f98" xlink:href="angn-20211231.xsd#angn_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_angn_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock_bfda37b4-3dfb-4542-a346-4614face9f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock_e0c6faa9-6b02-4c56-9f2c-5af161a2b073" xlink:href="angn-20211231.xsd#angn_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_angn_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock_e0c6faa9-6b02-4c56-9f2c-5af161a2b073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8d9ecb1b-036a-442a-8bd2-0ebbf3498dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8d9ecb1b-036a-442a-8bd2-0ebbf3498dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_758ad216-e2a5-4acd-8c22-4f46abfa9abe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_758ad216-e2a5-4acd-8c22-4f46abfa9abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_19dcb0d8-349d-4989-bfa0-8ba0333592b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_19dcb0d8-349d-4989-bfa0-8ba0333592b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodSharesBrokerWarrantsExercised_14d8759e-0df2-447f-9444-3d8d2bec67cb" xlink:href="angn-20211231.xsd#angn_StockIssuedDuringPeriodSharesBrokerWarrantsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_angn_StockIssuedDuringPeriodSharesBrokerWarrantsExercised_14d8759e-0df2-447f-9444-3d8d2bec67cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodValueBrokerWarrantsExercised_f9dd1d2d-ce82-4ee3-b52d-67da319e33ac" xlink:href="angn-20211231.xsd#angn_StockIssuedDuringPeriodValueBrokerWarrantsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_angn_StockIssuedDuringPeriodValueBrokerWarrantsExercised_f9dd1d2d-ce82-4ee3-b52d-67da319e33ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodSharesWarrantsExercised_ada83579-34eb-497f-a41d-263de685ee46" xlink:href="angn-20211231.xsd#angn_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_angn_StockIssuedDuringPeriodSharesWarrantsExercised_ada83579-34eb-497f-a41d-263de685ee46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodValueWarrantsExercised_c0b289d6-fc2c-4698-8416-54c56095fe99" xlink:href="angn-20211231.xsd#angn_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_angn_StockIssuedDuringPeriodValueWarrantsExercised_c0b289d6-fc2c-4698-8416-54c56095fe99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_020e18c3-537e-4895-aece-ecadd25eef70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_020e18c3-537e-4895-aece-ecadd25eef70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1282108e-286d-4aae-a895-f0d33a68b2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1282108e-286d-4aae-a895-f0d33a68b2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_32f3ed96-497a-41a2-83fa-fc07ad8ba193" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_32f3ed96-497a-41a2-83fa-fc07ad8ba193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_0de4181e-9572-417a-b49d-1dd8e0c91613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_0de4181e-9572-417a-b49d-1dd8e0c91613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_c718db91-dfb7-4b91-828c-976632470791" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_c718db91-dfb7-4b91-828c-976632470791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_5d7ff4ca-a0d5-46b2-b879-2de09c30acb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_5d7ff4ca-a0d5-46b2-b879-2de09c30acb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_82a245d1-fcd5-4e05-9073-5afe37d2501a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_82a245d1-fcd5-4e05-9073-5afe37d2501a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_a445a925-3a29-4cbc-a482-e24c8930a54c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_a445a925-3a29-4cbc-a482-e24c8930a54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_22b4e014-68df-46bd-8a7c-bd836a52c380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_22b4e014-68df-46bd-8a7c-bd836a52c380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d837f80f-0641-48cb-8a0c-600c583b8044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d837f80f-0641-48cb-8a0c-600c583b8044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_09a5f2c2-065d-4eba-864d-5a66e3169f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_09a5f2c2-065d-4eba-864d-5a66e3169f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f6820266-2d3d-4c6e-b610-b5c078c8a523" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_NetIncomeLoss_f6820266-2d3d-4c6e-b610-b5c078c8a523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_beebe5d6-0f90-471d-b3e1-3d0ded7963c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_SharesOutstanding_beebe5d6-0f90-471d-b3e1-3d0ded7963c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_268e221d-d57f-45a2-8fae-1f033e8dd32f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d10f6d8-664a-4e9e-945b-3fa32b657d13" xlink:to="loc_us-gaap_StockholdersEquity_268e221d-d57f-45a2-8fae-1f033e8dd32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficitParenthetical" xlink:type="simple" xlink:href="angn-20211231.xsd#ConsolidatedStatementsofStockholdersEquityDeficitParenthetical"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficitParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_fb3bfb05-3742-453c-8b8a-d149c56d5f48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d75a5819-7f13-4348-899b-6ae92c8f62e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_fb3bfb05-3742-453c-8b8a-d149c56d5f48" xlink:to="loc_us-gaap_StatementTable_d75a5819-7f13-4348-899b-6ae92c8f62e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b45c114f-396f-4caa-a244-1feb0c4466e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d75a5819-7f13-4348-899b-6ae92c8f62e3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b45c114f-396f-4caa-a244-1feb0c4466e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_41261eed-d75e-41b8-9151-6ac37c27f8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b45c114f-396f-4caa-a244-1feb0c4466e7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_41261eed-d75e-41b8-9151-6ac37c27f8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_26f6d904-2d41-46b5-99f1-d5c1c00891f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_41261eed-d75e-41b8-9151-6ac37c27f8fa" xlink:to="loc_us-gaap_IPOMember_26f6d904-2d41-46b5-99f1-d5c1c00891f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_46fc7dee-0906-4979-86a7-c816acd5af17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_41261eed-d75e-41b8-9151-6ac37c27f8fa" xlink:to="loc_us-gaap_PrivatePlacementMember_46fc7dee-0906-4979-86a7-c816acd5af17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8dce34c8-cae3-4c95-a567-faf1e2a2d26d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d75a5819-7f13-4348-899b-6ae92c8f62e3" xlink:to="loc_us-gaap_StatementLineItems_8dce34c8-cae3-4c95-a567-faf1e2a2d26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_5c03a71c-8af8-4b10-a9f5-48700e791c92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8dce34c8-cae3-4c95-a567-faf1e2a2d26d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_5c03a71c-8af8-4b10-a9f5-48700e791c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="angn-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_03fc5b4d-7c21-4e81-a0fb-bee7567f7b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_547b7596-3f04-4ec8-b753-e08c6ff7a890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_03fc5b4d-7c21-4e81-a0fb-bee7567f7b2e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_547b7596-3f04-4ec8-b753-e08c6ff7a890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ac8680b6-4d98-4327-9f5b-bb9a30b35671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_547b7596-3f04-4ec8-b753-e08c6ff7a890" xlink:to="loc_us-gaap_NetIncomeLoss_ac8680b6-4d98-4327-9f5b-bb9a30b35671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e5bb7a80-8286-4099-9f6d-e36eb078121e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_547b7596-3f04-4ec8-b753-e08c6ff7a890" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e5bb7a80-8286-4099-9f6d-e36eb078121e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_1387ddc7-14fc-4518-bf6c-d8db52e34558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e5bb7a80-8286-4099-9f6d-e36eb078121e" xlink:to="loc_us-gaap_Depreciation_1387ddc7-14fc-4518-bf6c-d8db52e34558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_5808961f-b8f5-4f25-9f2f-b11d65dbda40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e5bb7a80-8286-4099-9f6d-e36eb078121e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_5808961f-b8f5-4f25-9f2f-b11d65dbda40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_0d6365b7-61ac-4997-a32b-34970d434a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e5bb7a80-8286-4099-9f6d-e36eb078121e" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_0d6365b7-61ac-4997-a32b-34970d434a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NonCashPlacementAgentFee_f15513cb-32f4-4537-9e91-540cd0f1c1c8" xlink:href="angn-20211231.xsd#angn_NonCashPlacementAgentFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e5bb7a80-8286-4099-9f6d-e36eb078121e" xlink:to="loc_angn_NonCashPlacementAgentFee_f15513cb-32f4-4537-9e91-540cd0f1c1c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_48cbdb40-e998-420a-ac8d-46144e6494fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e5bb7a80-8286-4099-9f6d-e36eb078121e" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_48cbdb40-e998-420a-ac8d-46144e6494fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_eaa0538f-f8a2-4b13-b9d0-c490e8790705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e5bb7a80-8286-4099-9f6d-e36eb078121e" xlink:to="loc_us-gaap_ShareBasedCompensation_eaa0538f-f8a2-4b13-b9d0-c490e8790705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_9979cc42-5780-45e9-9a49-f30a1a349263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e5bb7a80-8286-4099-9f6d-e36eb078121e" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_9979cc42-5780-45e9-9a49-f30a1a349263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss_18d96440-6b6c-47ec-bf49-fbe3542628ad" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e5bb7a80-8286-4099-9f6d-e36eb078121e" xlink:to="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss_18d96440-6b6c-47ec-bf49-fbe3542628ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_53a57701-8f39-4697-a941-7bd1e94591e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e5bb7a80-8286-4099-9f6d-e36eb078121e" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_53a57701-8f39-4697-a941-7bd1e94591e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_3cc3a43f-fd40-4ef2-ba43-5ffb59d8229c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e5bb7a80-8286-4099-9f6d-e36eb078121e" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_3cc3a43f-fd40-4ef2-ba43-5ffb59d8229c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ea708fe7-7238-46cd-930d-c56777baa519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e5bb7a80-8286-4099-9f6d-e36eb078121e" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ea708fe7-7238-46cd-930d-c56777baa519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_bc3b2657-d886-4b15-9cde-62010131d38b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e5bb7a80-8286-4099-9f6d-e36eb078121e" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_bc3b2657-d886-4b15-9cde-62010131d38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e6a70bdd-2235-4c37-84b1-3785c648effc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_547b7596-3f04-4ec8-b753-e08c6ff7a890" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e6a70bdd-2235-4c37-84b1-3785c648effc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_IncreaseDecreaseInGrantReceivables_449207cc-ffab-47b4-9393-c2b6bbdae70a" xlink:href="angn-20211231.xsd#angn_IncreaseDecreaseInGrantReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e6a70bdd-2235-4c37-84b1-3785c648effc" xlink:to="loc_angn_IncreaseDecreaseInGrantReceivables_449207cc-ffab-47b4-9393-c2b6bbdae70a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e9c72e34-4c6f-4046-ae73-76c39cdee16c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e6a70bdd-2235-4c37-84b1-3785c648effc" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e9c72e34-4c6f-4046-ae73-76c39cdee16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_e18eef28-538f-4544-8833-967b539f82ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e6a70bdd-2235-4c37-84b1-3785c648effc" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_e18eef28-538f-4544-8833-967b539f82ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_fdd342d1-8b02-4e22-b1e9-70f3d77bdebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e6a70bdd-2235-4c37-84b1-3785c648effc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_fdd342d1-8b02-4e22-b1e9-70f3d77bdebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ff1a6b5c-1573-4a0e-aabc-0b0de5b8fcf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e6a70bdd-2235-4c37-84b1-3785c648effc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ff1a6b5c-1573-4a0e-aabc-0b0de5b8fcf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_cc2b6b71-676e-4c22-bdd8-10f134585b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e6a70bdd-2235-4c37-84b1-3785c648effc" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_cc2b6b71-676e-4c22-bdd8-10f134585b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b9f82739-23b2-4b7e-b673-c3750a765cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e6a70bdd-2235-4c37-84b1-3785c648effc" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b9f82739-23b2-4b7e-b673-c3750a765cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94f3fb8d-2120-441e-ae49-3d2eb9b231bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_547b7596-3f04-4ec8-b753-e08c6ff7a890" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_94f3fb8d-2120-441e-ae49-3d2eb9b231bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3129f1c0-4767-4f87-a383-8556b2950efa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_03fc5b4d-7c21-4e81-a0fb-bee7567f7b2e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3129f1c0-4767-4f87-a383-8556b2950efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ad2a6608-d03a-485e-9908-510caff002a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3129f1c0-4767-4f87-a383-8556b2950efa" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ad2a6608-d03a-485e-9908-510caff002a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_71d47034-dbfd-4c1b-82e1-0f5529eca51d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3129f1c0-4767-4f87-a383-8556b2950efa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_71d47034-dbfd-4c1b-82e1-0f5529eca51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7b0531b7-475d-4077-a4bf-dbea5b0f0c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_03fc5b4d-7c21-4e81-a0fb-bee7567f7b2e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7b0531b7-475d-4077-a4bf-dbea5b0f0c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_72544122-8367-4734-8453-83df732f1348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7b0531b7-475d-4077-a4bf-dbea5b0f0c3d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_72544122-8367-4734-8453-83df732f1348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_e8a66e39-fca0-4f9c-a697-0d1aace16604" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7b0531b7-475d-4077-a4bf-dbea5b0f0c3d" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_e8a66e39-fca0-4f9c-a697-0d1aace16604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_c13bc0c2-6e0e-492f-b713-332fa103a1af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7b0531b7-475d-4077-a4bf-dbea5b0f0c3d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_c13bc0c2-6e0e-492f-b713-332fa103a1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_fda1dcda-e8fb-4001-b7d0-358743cd0f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7b0531b7-475d-4077-a4bf-dbea5b0f0c3d" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_fda1dcda-e8fb-4001-b7d0-358743cd0f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ProceedsFromFinancingObligation_a588c304-e301-463a-ac7d-6b1e409e83a0" xlink:href="angn-20211231.xsd#angn_ProceedsFromFinancingObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7b0531b7-475d-4077-a4bf-dbea5b0f0c3d" xlink:to="loc_angn_ProceedsFromFinancingObligation_a588c304-e301-463a-ac7d-6b1e409e83a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_f1c535c2-effa-4f5e-a232-be7ccf6932c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7b0531b7-475d-4077-a4bf-dbea5b0f0c3d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_f1c535c2-effa-4f5e-a232-be7ccf6932c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_b3359382-0d1b-4328-8fbd-9802a26c4fae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7b0531b7-475d-4077-a4bf-dbea5b0f0c3d" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_b3359382-0d1b-4328-8fbd-9802a26c4fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PaymentsForForwardStockSplitFractionalShares_8ab0f67a-242a-4e09-85ed-2b09519ca72b" xlink:href="angn-20211231.xsd#angn_PaymentsForForwardStockSplitFractionalShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7b0531b7-475d-4077-a4bf-dbea5b0f0c3d" xlink:to="loc_angn_PaymentsForForwardStockSplitFractionalShares_8ab0f67a-242a-4e09-85ed-2b09519ca72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_796ca972-effa-4a1a-996c-7c26982f3d37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7b0531b7-475d-4077-a4bf-dbea5b0f0c3d" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_796ca972-effa-4a1a-996c-7c26982f3d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PaymentsForBrokerWarrantExercises_69d463b4-9e9c-4608-ad3e-fcbbd225a5bb" xlink:href="angn-20211231.xsd#angn_PaymentsForBrokerWarrantExercises"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7b0531b7-475d-4077-a4bf-dbea5b0f0c3d" xlink:to="loc_angn_PaymentsForBrokerWarrantExercises_69d463b4-9e9c-4608-ad3e-fcbbd225a5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_a5f52887-fb93-44a0-9902-02c07308a4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7b0531b7-475d-4077-a4bf-dbea5b0f0c3d" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_a5f52887-fb93-44a0-9902-02c07308a4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_8cb0a76d-866b-46de-b9c4-3ef2f2062e97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7b0531b7-475d-4077-a4bf-dbea5b0f0c3d" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_8cb0a76d-866b-46de-b9c4-3ef2f2062e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a9c10fe8-abd6-40f8-9fbd-c4d72511f17e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7b0531b7-475d-4077-a4bf-dbea5b0f0c3d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a9c10fe8-abd6-40f8-9fbd-c4d72511f17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d20a22d8-ad8c-4a35-9cf3-5c745741f03b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_03fc5b4d-7c21-4e81-a0fb-bee7567f7b2e" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d20a22d8-ad8c-4a35-9cf3-5c745741f03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bf6dc8c6-6bd5-4e52-bcc8-7f030b00925f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_03fc5b4d-7c21-4e81-a0fb-bee7567f7b2e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bf6dc8c6-6bd5-4e52-bcc8-7f030b00925f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22c85395-a5de-4758-9803-6a9d03c5220c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_03fc5b4d-7c21-4e81-a0fb-bee7567f7b2e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22c85395-a5de-4758-9803-6a9d03c5220c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fb3e2aa8-1a76-4f7e-8b14-e6e062b18a82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_03fc5b4d-7c21-4e81-a0fb-bee7567f7b2e" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fb3e2aa8-1a76-4f7e-8b14-e6e062b18a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_d5109efe-844b-44ff-9bde-878ea523c6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_03fc5b4d-7c21-4e81-a0fb-bee7567f7b2e" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_d5109efe-844b-44ff-9bde-878ea523c6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_f03ffb74-1b35-4b69-a088-40d44d686576" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_d5109efe-844b-44ff-9bde-878ea523c6ec" xlink:to="loc_us-gaap_InterestPaidNet_f03ffb74-1b35-4b69-a088-40d44d686576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_33ffd65b-ea8a-49a5-9d33-61116cbc0a26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_03fc5b4d-7c21-4e81-a0fb-bee7567f7b2e" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_33ffd65b-ea8a-49a5-9d33-61116cbc0a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e3ba295f-a6a1-46f4-a700-b1996d26a54c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_33ffd65b-ea8a-49a5-9d33-61116cbc0a26" xlink:to="loc_us-gaap_StatementTable_e3ba295f-a6a1-46f4-a700-b1996d26a54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_91b70b6c-a3fd-46d9-bf28-01d12b7a060b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e3ba295f-a6a1-46f4-a700-b1996d26a54c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_91b70b6c-a3fd-46d9-bf28-01d12b7a060b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b84e9c6d-4ed5-46f4-a66a-e44a833e90c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_91b70b6c-a3fd-46d9-bf28-01d12b7a060b" xlink:to="loc_us-gaap_ClassOfStockDomain_b84e9c6d-4ed5-46f4-a66a-e44a833e90c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3cb86f8b-54fa-4317-83eb-a46f2238fdcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b84e9c6d-4ed5-46f4-a66a-e44a833e90c8" xlink:to="loc_us-gaap_CommonStockMember_3cb86f8b-54fa-4317-83eb-a46f2238fdcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_e7e6ca12-fafa-401b-9d9f-201da472e271" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_b84e9c6d-4ed5-46f4-a66a-e44a833e90c8" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_e7e6ca12-fafa-401b-9d9f-201da472e271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2d4d2980-7f5d-4c72-ac8c-27dfbb0fac3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e3ba295f-a6a1-46f4-a700-b1996d26a54c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2d4d2980-7f5d-4c72-ac8c-27dfbb0fac3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1c229568-11cc-4069-968c-4854bbe054dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2d4d2980-7f5d-4c72-ac8c-27dfbb0fac3b" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1c229568-11cc-4069-968c-4854bbe054dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NonIPORelatedStockTransactionsMember_9e446231-4dab-455b-aea0-8b8973a31cbb" xlink:href="angn-20211231.xsd#angn_NonIPORelatedStockTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1c229568-11cc-4069-968c-4854bbe054dd" xlink:to="loc_angn_NonIPORelatedStockTransactionsMember_9e446231-4dab-455b-aea0-8b8973a31cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_5a0b3331-1743-4939-b326-e2788554ec9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1c229568-11cc-4069-968c-4854bbe054dd" xlink:to="loc_us-gaap_IPOMember_5a0b3331-1743-4939-b326-e2788554ec9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1f20e4ef-9a76-4be4-ad0a-588211b531d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e3ba295f-a6a1-46f4-a700-b1996d26a54c" xlink:to="loc_us-gaap_StatementLineItems_1f20e4ef-9a76-4be4-ad0a-588211b531d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockRetired_26ac28a6-6b8c-43b2-8049-a597a60c1156" xlink:href="angn-20211231.xsd#angn_StockRetired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1f20e4ef-9a76-4be4-ad0a-588211b531d6" xlink:to="loc_angn_StockRetired_26ac28a6-6b8c-43b2-8049-a597a60c1156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_cfcc8235-1d3c-4316-90c6-ff67b9b2505e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1f20e4ef-9a76-4be4-ad0a-588211b531d6" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_cfcc8235-1d3c-4316-90c6-ff67b9b2505e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_69f24de2-bad1-4ec6-83c1-3cefc2be5632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1f20e4ef-9a76-4be4-ad0a-588211b531d6" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_69f24de2-bad1-4ec6-83c1-3cefc2be5632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsExercised_eda17360-969a-4f2a-9299-35ce9ff92267" xlink:href="angn-20211231.xsd#angn_WarrantsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1f20e4ef-9a76-4be4-ad0a-588211b531d6" xlink:to="loc_angn_WarrantsExercised_eda17360-969a-4f2a-9299-35ce9ff92267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_IssuanceOfBrokerWarrants_4927b69e-04fb-4d0d-ad88-7ac1ffcb7902" xlink:href="angn-20211231.xsd#angn_IssuanceOfBrokerWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1f20e4ef-9a76-4be4-ad0a-588211b531d6" xlink:to="loc_angn_IssuanceOfBrokerWarrants_4927b69e-04fb-4d0d-ad88-7ac1ffcb7902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AccruedInterestPremiumForConvertiblePreferredStock_46ae1244-d1bf-4417-9576-06b5d882fb65" xlink:href="angn-20211231.xsd#angn_AccruedInterestPremiumForConvertiblePreferredStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1f20e4ef-9a76-4be4-ad0a-588211b531d6" xlink:to="loc_angn_AccruedInterestPremiumForConvertiblePreferredStock_46ae1244-d1bf-4417-9576-06b5d882fb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_cbb6b51b-a861-4f00-8656-d4a8080f90b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1f20e4ef-9a76-4be4-ad0a-588211b531d6" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_cbb6b51b-a861-4f00-8656-d4a8080f90b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesIssued1_34682de0-54c4-47e0-95fe-d148a76e4965" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesIssued1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1f20e4ef-9a76-4be4-ad0a-588211b531d6" xlink:to="loc_us-gaap_NotesIssued1_34682de0-54c4-47e0-95fe-d148a76e4965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_0717bcfd-7eb7-46ad-9401-9ed4c5c53859" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1f20e4ef-9a76-4be4-ad0a-588211b531d6" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_0717bcfd-7eb7-46ad-9401-9ed4c5c53859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_e63b0edb-668f-48a2-aed8-364fcd97b007" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1f20e4ef-9a76-4be4-ad0a-588211b531d6" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_e63b0edb-668f-48a2-aed8-364fcd97b007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/DescriptionoftheBusinessandFinancialCondition" xlink:type="simple" xlink:href="angn-20211231.xsd#DescriptionoftheBusinessandFinancialCondition"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/DescriptionoftheBusinessandFinancialCondition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bf92f233-58c1-4525-85d3-70bfbe59ed91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_4a83da33-a556-43ca-b035-b5ed723ef9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bf92f233-58c1-4525-85d3-70bfbe59ed91" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_4a83da33-a556-43ca-b035-b5ed723ef9dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#DescriptionoftheBusinessandFinancialConditionDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_51b28d82-d8e6-4078-8157-cc79995bc0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_f79c6593-1fda-472d-901a-388a6acd3e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_51b28d82-d8e6-4078-8157-cc79995bc0f8" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_f79c6593-1fda-472d-901a-388a6acd3e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_20994b65-a3d8-4c68-9061-c6193c5787d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_f79c6593-1fda-472d-901a-388a6acd3e8c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_20994b65-a3d8-4c68-9061-c6193c5787d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f199b9c0-4e19-4dbc-8737-822937d207fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_20994b65-a3d8-4c68-9061-c6193c5787d0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f199b9c0-4e19-4dbc-8737-822937d207fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_641b4825-cf02-4f3b-abd7-fc4e7b44510c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f199b9c0-4e19-4dbc-8737-822937d207fa" xlink:to="loc_us-gaap_IPOMember_641b4825-cf02-4f3b-abd7-fc4e7b44510c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_e21d2672-3cd8-4acc-9e3d-b6c58ada4ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f199b9c0-4e19-4dbc-8737-822937d207fa" xlink:to="loc_us-gaap_OverAllotmentOptionMember_e21d2672-3cd8-4acc-9e3d-b6c58ada4ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_d0488fed-4396-4b02-a428-3843643b7afb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f199b9c0-4e19-4dbc-8737-822937d207fa" xlink:to="loc_us-gaap_PrivatePlacementMember_d0488fed-4396-4b02-a428-3843643b7afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_IPOAndPrivatePlacementMember_936cc4e6-a217-4711-bc6a-d1b6ad36255e" xlink:href="angn-20211231.xsd#angn_IPOAndPrivatePlacementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_f199b9c0-4e19-4dbc-8737-822937d207fa" xlink:to="loc_angn_IPOAndPrivatePlacementMember_936cc4e6-a217-4711-bc6a-d1b6ad36255e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7f69edd5-0071-4e6d-bca1-f2c464470de3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_f79c6593-1fda-472d-901a-388a6acd3e8c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7f69edd5-0071-4e6d-bca1-f2c464470de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4704118c-9b85-4d49-b64a-e41a45f53731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7f69edd5-0071-4e6d-bca1-f2c464470de3" xlink:to="loc_us-gaap_ClassOfStockDomain_4704118c-9b85-4d49-b64a-e41a45f53731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_3d19e61a-5b5b-45ee-9831-8ab10fa3e45e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4704118c-9b85-4d49-b64a-e41a45f53731" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_3d19e61a-5b5b-45ee-9831-8ab10fa3e45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_43b65d80-24ed-4a69-a330-7f5d195506dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_f79c6593-1fda-472d-901a-388a6acd3e8c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_43b65d80-24ed-4a69-a330-7f5d195506dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_69940247-cc6a-43ed-91ef-6723afaae0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_43b65d80-24ed-4a69-a330-7f5d195506dd" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_69940247-cc6a-43ed-91ef-6723afaae0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_352f6a09-6578-46be-96cf-341f74f2bf85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_43b65d80-24ed-4a69-a330-7f5d195506dd" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_352f6a09-6578-46be-96cf-341f74f2bf85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_7b1957e5-f3c4-48c2-973b-71e2f462b5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_43b65d80-24ed-4a69-a330-7f5d195506dd" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_7b1957e5-f3c4-48c2-973b-71e2f462b5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6fc26c0e-e1b9-422a-b76e-e3342c553ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_43b65d80-24ed-4a69-a330-7f5d195506dd" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6fc26c0e-e1b9-422a-b76e-e3342c553ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_cf45d1b8-b800-4200-8535-48ceac6c65c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_43b65d80-24ed-4a69-a330-7f5d195506dd" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_cf45d1b8-b800-4200-8535-48ceac6c65c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_ac54bf03-0f2c-4e76-8b70-85d5d313c61b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_43b65d80-24ed-4a69-a330-7f5d195506dd" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_ac54bf03-0f2c-4e76-8b70-85d5d313c61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_374580d4-6733-4880-ba87-c1d87632de0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_43b65d80-24ed-4a69-a330-7f5d195506dd" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_374580d4-6733-4880-ba87-c1d87632de0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a206c4ff-0333-4fe4-a1a1-d5221e17e3be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_43b65d80-24ed-4a69-a330-7f5d195506dd" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a206c4ff-0333-4fe4-a1a1-d5221e17e3be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_29003467-dba3-4789-a7d2-8cbc7d2b90b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_43b65d80-24ed-4a69-a330-7f5d195506dd" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_29003467-dba3-4789-a7d2-8cbc7d2b90b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e0aabe29-e964-4f70-aec6-1893ece94e37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_43b65d80-24ed-4a69-a330-7f5d195506dd" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e0aabe29-e964-4f70-aec6-1893ece94e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f61b769f-2808-444f-8cc0-2ba4fd804a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_43b65d80-24ed-4a69-a330-7f5d195506dd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f61b769f-2808-444f-8cc0-2ba4fd804a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a0058d57-704a-4da3-9477-411e13ab1b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_43b65d80-24ed-4a69-a330-7f5d195506dd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a0058d57-704a-4da3-9477-411e13ab1b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="angn-20211231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4e0da248-7600-49f2-a3b0-1f4cd39a71c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_126439e2-e960-468d-8827-b94974262aff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4e0da248-7600-49f2-a3b0-1f4cd39a71c1" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_126439e2-e960-468d-8827-b94974262aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="angn-20211231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_59222d26-7c69-4694-b564-7cf1841bcaa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7fdef2e9-80ec-4cc2-9bc0-fcbf3e6554db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59222d26-7c69-4694-b564-7cf1841bcaa7" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7fdef2e9-80ec-4cc2-9bc0-fcbf3e6554db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_b64d349e-ce20-4750-8f39-7afed932acc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59222d26-7c69-4694-b564-7cf1841bcaa7" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_b64d349e-ce20-4750-8f39-7afed932acc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_47cc0e6f-e075-40b6-b92e-fbf92f1113e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59222d26-7c69-4694-b564-7cf1841bcaa7" xlink:to="loc_us-gaap_UseOfEstimates_47cc0e6f-e075-40b6-b92e-fbf92f1113e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_466a6f57-07e3-4f80-a93f-582fc6e27a53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59222d26-7c69-4694-b564-7cf1841bcaa7" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_466a6f57-07e3-4f80-a93f-582fc6e27a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_e1d36d70-8b39-46e6-96be-49c6ac44ac11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59222d26-7c69-4694-b564-7cf1841bcaa7" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_e1d36d70-8b39-46e6-96be-49c6ac44ac11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_5f28c11b-3dcb-4aa6-9ef6-8f5f071d5f39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59222d26-7c69-4694-b564-7cf1841bcaa7" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_5f28c11b-3dcb-4aa6-9ef6-8f5f071d5f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_847a427f-ccaa-481e-a97d-93788d813d18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59222d26-7c69-4694-b564-7cf1841bcaa7" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_847a427f-ccaa-481e-a97d-93788d813d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_857df3cb-c420-488f-819d-24e2d59b8b96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59222d26-7c69-4694-b564-7cf1841bcaa7" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_857df3cb-c420-488f-819d-24e2d59b8b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_225291ea-db76-4bcc-83c9-e25f51888cba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59222d26-7c69-4694-b564-7cf1841bcaa7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_225291ea-db76-4bcc-83c9-e25f51888cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_724a9276-22d3-4a8d-a869-b6bf3e8e4101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59222d26-7c69-4694-b564-7cf1841bcaa7" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_724a9276-22d3-4a8d-a869-b6bf3e8e4101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_a4fafdb3-d8af-4eb6-93a7-d47b0983ec86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59222d26-7c69-4694-b564-7cf1841bcaa7" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_a4fafdb3-d8af-4eb6-93a7-d47b0983ec86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_b6827571-7e6a-4af4-b8e6-29bb5877768e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59222d26-7c69-4694-b564-7cf1841bcaa7" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_b6827571-7e6a-4af4-b8e6-29bb5877768e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_InvestmentsInRelatedPartiesPolicyPolicyTextBlock_3b7a320b-b9a9-49d7-987d-b1e470cc82e0" xlink:href="angn-20211231.xsd#angn_InvestmentsInRelatedPartiesPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59222d26-7c69-4694-b564-7cf1841bcaa7" xlink:to="loc_angn_InvestmentsInRelatedPartiesPolicyPolicyTextBlock_3b7a320b-b9a9-49d7-987d-b1e470cc82e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsAndRightsOutstandingPolicyPolicyTextBlock_a99bfc1a-44ef-41cc-acbe-cb2712ef7d39" xlink:href="angn-20211231.xsd#angn_WarrantsAndRightsOutstandingPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59222d26-7c69-4694-b564-7cf1841bcaa7" xlink:to="loc_angn_WarrantsAndRightsOutstandingPolicyPolicyTextBlock_a99bfc1a-44ef-41cc-acbe-cb2712ef7d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock_7cdd4e76-3141-40ac-8b21-7a592f5e8d15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59222d26-7c69-4694-b564-7cf1841bcaa7" xlink:to="loc_us-gaap_DebtPolicyTextBlock_7cdd4e76-3141-40ac-8b21-7a592f5e8d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionPolicyTextBlock_8601ff5c-e777-473d-86bd-61a5312bbc4f" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59222d26-7c69-4694-b564-7cf1841bcaa7" xlink:to="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionPolicyTextBlock_8601ff5c-e777-473d-86bd-61a5312bbc4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_ec44566d-8aef-478b-b64e-bd48ec6573ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59222d26-7c69-4694-b564-7cf1841bcaa7" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_ec44566d-8aef-478b-b64e-bd48ec6573ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_1fee98c6-9f82-4640-902c-b11c37fa53b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59222d26-7c69-4694-b564-7cf1841bcaa7" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_1fee98c6-9f82-4640-902c-b11c37fa53b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_ee813303-fc08-48af-8b89-1c00c86c41db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59222d26-7c69-4694-b564-7cf1841bcaa7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_ee813303-fc08-48af-8b89-1c00c86c41db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_ef05837c-ceee-4b17-9a7f-47d9bd9e8cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59222d26-7c69-4694-b564-7cf1841bcaa7" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_ef05837c-ceee-4b17-9a7f-47d9bd9e8cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ad613fe3-8f4b-4a28-afbb-45edec230545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59222d26-7c69-4694-b564-7cf1841bcaa7" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ad613fe3-8f4b-4a28-afbb-45edec230545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_521431d7-87a3-4e69-a12f-a9b9f839410b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59222d26-7c69-4694-b564-7cf1841bcaa7" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_521431d7-87a3-4e69-a12f-a9b9f839410b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_56b2641b-c243-4c79-b180-07e6827f6a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59222d26-7c69-4694-b564-7cf1841bcaa7" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_56b2641b-c243-4c79-b180-07e6827f6a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_c8bfd9c9-983d-4700-b387-2cf086fc4d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59222d26-7c69-4694-b564-7cf1841bcaa7" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_c8bfd9c9-983d-4700-b387-2cf086fc4d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4013e369-e679-47b9-a452-53e1b5339a04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_59222d26-7c69-4694-b564-7cf1841bcaa7" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4013e369-e679-47b9-a452-53e1b5339a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="angn-20211231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1a65c02a-4662-4a5e-b9e6-fd42c1591dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_8c6282ae-abe8-41d0-88ed-4fa43ec63431" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1a65c02a-4662-4a5e-b9e6-fd42c1591dfe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_8c6282ae-abe8-41d0-88ed-4fa43ec63431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8817e29a-5094-4094-802c-8e6a7447cbb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b091fa12-93fb-426e-b625-b68a52fa7b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8817e29a-5094-4094-802c-8e6a7447cbb8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b091fa12-93fb-426e-b625-b68a52fa7b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ae99c02d-812f-4bdd-af68-1acbf8ee992d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b091fa12-93fb-426e-b625-b68a52fa7b6a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ae99c02d-812f-4bdd-af68-1acbf8ee992d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d3f06325-07ed-43c4-8750-04daddab040b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ae99c02d-812f-4bdd-af68-1acbf8ee992d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d3f06325-07ed-43c4-8750-04daddab040b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_c89e1d2d-fbb8-4795-affb-61b28ce74a29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d3f06325-07ed-43c4-8750-04daddab040b" xlink:to="loc_us-gaap_EquipmentMember_c89e1d2d-fbb8-4795-affb-61b28ce74a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_a7245195-0238-45ab-a37c-3f56e6d96774" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d3f06325-07ed-43c4-8750-04daddab040b" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_a7245195-0238-45ab-a37c-3f56e6d96774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0b8a6739-cbf6-4fae-9c0d-5c43c719598b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b091fa12-93fb-426e-b625-b68a52fa7b6a" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0b8a6739-cbf6-4fae-9c0d-5c43c719598b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b27513ae-cb5e-427a-8d1d-3c5f6993ee31" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0b8a6739-cbf6-4fae-9c0d-5c43c719598b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b27513ae-cb5e-427a-8d1d-3c5f6993ee31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NovaParkMember_27018dc7-97f5-4e3f-ab20-2433c64d7e6c" xlink:href="angn-20211231.xsd#angn_NovaParkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b27513ae-cb5e-427a-8d1d-3c5f6993ee31" xlink:to="loc_angn_NovaParkMember_27018dc7-97f5-4e3f-ab20-2433c64d7e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OhrCosmeticsLLCMember_7211ee7a-c21f-4690-9164-c227f15c8457" xlink:href="angn-20211231.xsd#angn_OhrCosmeticsLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_b27513ae-cb5e-427a-8d1d-3c5f6993ee31" xlink:to="loc_angn_OhrCosmeticsLLCMember_7211ee7a-c21f-4690-9164-c227f15c8457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fd083d42-4b03-411e-a67a-20aed33caa93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b091fa12-93fb-426e-b625-b68a52fa7b6a" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fd083d42-4b03-411e-a67a-20aed33caa93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a9702342-b151-4423-8e4d-36b3691e3736" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fd083d42-4b03-411e-a67a-20aed33caa93" xlink:to="loc_us-gaap_RelatedPartyDomain_a9702342-b151-4423-8e4d-36b3691e3736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember_0a4790a4-e8bd-4e82-bcea-da98d6361467" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_a9702342-b151-4423-8e4d-36b3691e3736" xlink:to="loc_us-gaap_EquityMethodInvesteeMember_0a4790a4-e8bd-4e82-bcea-da98d6361467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_78a16a16-5dae-43ba-b80e-45f5e065c153" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b091fa12-93fb-426e-b625-b68a52fa7b6a" xlink:to="loc_srt_OwnershipAxis_78a16a16-5dae-43ba-b80e-45f5e065c153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_18de9098-988b-4666-840e-4e8d635a76e6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_78a16a16-5dae-43ba-b80e-45f5e065c153" xlink:to="loc_srt_OwnershipDomain_18de9098-988b-4666-840e-4e8d635a76e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OhrCosmeticsLLCMember_096e93e0-296d-442b-b3e7-c8cf1585e4b8" xlink:href="angn-20211231.xsd#angn_OhrCosmeticsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_18de9098-988b-4666-840e-4e8d635a76e6" xlink:to="loc_angn_OhrCosmeticsLLCMember_096e93e0-296d-442b-b3e7-c8cf1585e4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_e32aa65a-c3e9-4c44-b559-19cb1bb20022" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b091fa12-93fb-426e-b625-b68a52fa7b6a" xlink:to="loc_srt_TitleOfIndividualAxis_e32aa65a-c3e9-4c44-b559-19cb1bb20022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_97a65700-63c7-4c66-b58d-935811e5c758" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_e32aa65a-c3e9-4c44-b559-19cb1bb20022" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_97a65700-63c7-4c66-b58d-935811e5c758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_ed8de4c4-b545-48ff-b8a3-b1142ceedf06" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_97a65700-63c7-4c66-b58d-935811e5c758" xlink:to="loc_srt_ChiefExecutiveOfficerMember_ed8de4c4-b545-48ff-b8a3-b1142ceedf06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1f59dd55-0ffe-4448-be32-6ef47a3226b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b091fa12-93fb-426e-b625-b68a52fa7b6a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1f59dd55-0ffe-4448-be32-6ef47a3226b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_98ec570a-cba8-49ff-b9ab-b376d691065e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1f59dd55-0ffe-4448-be32-6ef47a3226b9" xlink:to="loc_us-gaap_ClassOfStockDomain_98ec570a-cba8-49ff-b9ab-b376d691065e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_c1f20ea4-5f43-40e4-bb42-60b88d4ebda2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_98ec570a-cba8-49ff-b9ab-b376d691065e" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_c1f20ea4-5f43-40e4-bb42-60b88d4ebda2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dbfad555-2274-4f06-93c0-6dbd103020e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b091fa12-93fb-426e-b625-b68a52fa7b6a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dbfad555-2274-4f06-93c0-6dbd103020e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_e99b449a-8dac-4192-87c3-42ae898aa350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dbfad555-2274-4f06-93c0-6dbd103020e2" xlink:to="loc_us-gaap_NumberOfOperatingSegments_e99b449a-8dac-4192-87c3-42ae898aa350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_13ad08bd-2619-4e0d-b914-3d96ad2efa33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dbfad555-2274-4f06-93c0-6dbd103020e2" xlink:to="loc_us-gaap_DeferredOfferingCosts_13ad08bd-2619-4e0d-b914-3d96ad2efa33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d250cd7a-5550-45c0-a28b-01a7473c1123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dbfad555-2274-4f06-93c0-6dbd103020e2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d250cd7a-5550-45c0-a28b-01a7473c1123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_469b58f4-fd38-4754-a284-9368784db1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dbfad555-2274-4f06-93c0-6dbd103020e2" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_469b58f4-fd38-4754-a284-9368784db1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_83f135a9-aa2d-4a4d-b40a-670336354117" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dbfad555-2274-4f06-93c0-6dbd103020e2" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_83f135a9-aa2d-4a4d-b40a-670336354117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OtherInvestmentAndSecuritiesAtCostOwnershipPercentage_eee1883c-3338-4ae5-8605-af8401d9904d" xlink:href="angn-20211231.xsd#angn_OtherInvestmentAndSecuritiesAtCostOwnershipPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dbfad555-2274-4f06-93c0-6dbd103020e2" xlink:to="loc_angn_OtherInvestmentAndSecuritiesAtCostOwnershipPercentage_eee1883c-3338-4ae5-8605-af8401d9904d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NumberOfRelatedPartyEntities_362d9482-ee59-424f-af9c-0e0ae06fb147" xlink:href="angn-20211231.xsd#angn_NumberOfRelatedPartyEntities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dbfad555-2274-4f06-93c0-6dbd103020e2" xlink:to="loc_angn_NumberOfRelatedPartyEntities_362d9482-ee59-424f-af9c-0e0ae06fb147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_f62a6b7b-0ed2-4867-ac6b-397cccfeba5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dbfad555-2274-4f06-93c0-6dbd103020e2" xlink:to="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_f62a6b7b-0ed2-4867-ac6b-397cccfeba5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_034d19c5-2188-49fd-98c5-d57f770b3198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dbfad555-2274-4f06-93c0-6dbd103020e2" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_034d19c5-2188-49fd-98c5-d57f770b3198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_fea3ec98-d0f9-4f0f-8529-594f013f5cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_dbfad555-2274-4f06-93c0-6dbd103020e2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_fea3ec98-d0f9-4f0f-8529-594f013f5cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/RevenueandDeferredRevenue" xlink:type="simple" xlink:href="angn-20211231.xsd#RevenueandDeferredRevenue"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/RevenueandDeferredRevenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5a61ac52-83fe-4344-9f0b-a0e2647cf23c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_b2005729-10e9-4cc9-93dd-73b7d81becbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5a61ac52-83fe-4344-9f0b-a0e2647cf23c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_b2005729-10e9-4cc9-93dd-73b7d81becbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/RevenueandDeferredRevenueDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#RevenueandDeferredRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/RevenueandDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9bf146a9-d405-46ec-8bc5-91bcd4dd28d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_005fa8a2-6086-4729-8155-91570456c3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9bf146a9-d405-46ec-8bc5-91bcd4dd28d5" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_005fa8a2-6086-4729-8155-91570456c3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_194ecea8-1e83-42b7-a6da-81dc431063e1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_005fa8a2-6086-4729-8155-91570456c3c9" xlink:to="loc_srt_CounterpartyNameAxis_194ecea8-1e83-42b7-a6da-81dc431063e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6a97f2cb-e477-4080-99fd-1f74e4bbe171" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_194ecea8-1e83-42b7-a6da-81dc431063e1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6a97f2cb-e477-4080-99fd-1f74e4bbe171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ViforPharmaMember_4be88839-5049-40eb-87b6-0209bf0eb8e3" xlink:href="angn-20211231.xsd#angn_ViforPharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6a97f2cb-e477-4080-99fd-1f74e4bbe171" xlink:to="loc_angn_ViforPharmaMember_4be88839-5049-40eb-87b6-0209bf0eb8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dcf0a555-5f55-4136-b4ed-ba7e387bd13e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_005fa8a2-6086-4729-8155-91570456c3c9" xlink:to="loc_srt_ProductOrServiceAxis_dcf0a555-5f55-4136-b4ed-ba7e387bd13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_abf9ba6d-22ed-44bd-bf3a-b00a8eefbc7a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_dcf0a555-5f55-4136-b4ed-ba7e387bd13e" xlink:to="loc_srt_ProductsAndServicesDomain_abf9ba6d-22ed-44bd-bf3a-b00a8eefbc7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_91f064cf-30f3-4c05-82e4-6bd2b7b73a90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_abf9ba6d-22ed-44bd-bf3a-b00a8eefbc7a" xlink:to="loc_us-gaap_LicenseMember_91f064cf-30f3-4c05-82e4-6bd2b7b73a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e095e1b2-7893-4615-be99-4393c31ab5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_005fa8a2-6086-4729-8155-91570456c3c9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e095e1b2-7893-4615-be99-4393c31ab5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_588f2f54-f2ff-4242-8b06-7cdf74d2db6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e095e1b2-7893-4615-be99-4393c31ab5fb" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_588f2f54-f2ff-4242-8b06-7cdf74d2db6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_29a45761-3989-429a-9919-6b1f73afc7b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_588f2f54-f2ff-4242-8b06-7cdf74d2db6f" xlink:to="loc_us-gaap_IPOMember_29a45761-3989-429a-9919-6b1f73afc7b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_59ba48f6-b399-4d18-b678-b1300d9b197e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_588f2f54-f2ff-4242-8b06-7cdf74d2db6f" xlink:to="loc_us-gaap_PrivatePlacementMember_59ba48f6-b399-4d18-b678-b1300d9b197e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_98d139aa-bebc-4737-b613-d1a035688020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_005fa8a2-6086-4729-8155-91570456c3c9" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_98d139aa-bebc-4737-b613-d1a035688020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_005fa8a2-6086-4729-8155-91570456c3c9" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_84488bb0-2850-469a-8652-7d6c092f44bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_84488bb0-2850-469a-8652-7d6c092f44bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerUpfrontAndNearTermMilestonePaymentEntitledToReceive_764c3ecb-93f5-41bc-b6f9-420bc687ed52" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerUpfrontAndNearTermMilestonePaymentEntitledToReceive"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_ContractWithCustomerUpfrontAndNearTermMilestonePaymentEntitledToReceive_764c3ecb-93f5-41bc-b6f9-420bc687ed52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_c355edb8-9f72-4284-8890-e6b10c442c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_c355edb8-9f72-4284-8890-e6b10c442c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_9728e159-0e84-4772-ab82-d6ace6595acf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_9728e159-0e84-4772-ab82-d6ace6595acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_687534ff-580f-49db-b2a8-d8d9903fece5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_687534ff-580f-49db-b2a8-d8d9903fece5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerPostApprovalMilestonePaymentEntitledToReceive_d54c53b4-6f02-4d83-b0cf-3dbb1c0aee04" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerPostApprovalMilestonePaymentEntitledToReceive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_ContractWithCustomerPostApprovalMilestonePaymentEntitledToReceive_d54c53b4-6f02-4d83-b0cf-3dbb1c0aee04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerSalesRelatedMilestonePaymentEntitledToReceive_c4b0b4a0-82f0-44e1-9ed3-e8fc15209a2a" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerSalesRelatedMilestonePaymentEntitledToReceive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_ContractWithCustomerSalesRelatedMilestonePaymentEntitledToReceive_c4b0b4a0-82f0-44e1-9ed3-e8fc15209a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerMilestonePaymentsEntitledToReceive_f6ca7d66-2ffa-4c63-aff7-f0635addca82" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerMilestonePaymentsEntitledToReceive"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_ContractWithCustomerMilestonePaymentsEntitledToReceive_f6ca7d66-2ffa-4c63-aff7-f0635addca82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerRoyaltyRatesMaximum_98ace0e9-4641-4179-a06d-1205c81bba56" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerRoyaltyRatesMaximum"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_ContractWithCustomerRoyaltyRatesMaximum_98ace0e9-4641-4179-a06d-1205c81bba56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerContractTerminationPeriodCurableBreach_ab9a0830-20d3-48ff-8b25-7f7890e30b90" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerContractTerminationPeriodCurableBreach"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_ContractWithCustomerContractTerminationPeriodCurableBreach_ab9a0830-20d3-48ff-8b25-7f7890e30b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerContractTerminationPeriodIncurableBreach_7a79e74d-f764-4039-957b-bbfc8511360a" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerContractTerminationPeriodIncurableBreach"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_ContractWithCustomerContractTerminationPeriodIncurableBreach_7a79e74d-f764-4039-957b-bbfc8511360a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_f2d2be3c-08aa-485d-a69c-00acd2a3a0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_f2d2be3c-08aa-485d-a69c-00acd2a3a0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ContractWithCustomerLiabilityPercentOfUpfrontPayment_43c78379-0049-4dd9-9ff2-0884fe4f025d" xlink:href="angn-20211231.xsd#angn_ContractWithCustomerLiabilityPercentOfUpfrontPayment"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_ContractWithCustomerLiabilityPercentOfUpfrontPayment_43c78379-0049-4dd9-9ff2-0884fe4f025d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_9a9d75ab-5048-45d2-a1bf-b60bed5133df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_9a9d75ab-5048-45d2-a1bf-b60bed5133df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_RevenueFromContractWithCustomerIncludingAssessedTaxIncrease_a0893fc4-f94a-4ce3-8d08-9e0655f49386" xlink:href="angn-20211231.xsd#angn_RevenueFromContractWithCustomerIncludingAssessedTaxIncrease"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_RevenueFromContractWithCustomerIncludingAssessedTaxIncrease_a0893fc4-f94a-4ce3-8d08-9e0655f49386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NetIncomeLossAttributableToParentIncrease_c6ccbae8-a239-48f2-bd55-4bfa2981cabc" xlink:href="angn-20211231.xsd#angn_NetIncomeLossAttributableToParentIncrease"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_NetIncomeLossAttributableToParentIncrease_c6ccbae8-a239-48f2-bd55-4bfa2981cabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EarningsPerShareBasicIncrease_d165f298-fa5d-403d-9bff-1f8bba9225d7" xlink:href="angn-20211231.xsd#angn_EarningsPerShareBasicIncrease"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_EarningsPerShareBasicIncrease_d165f298-fa5d-403d-9bff-1f8bba9225d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EarningsPerShareDilutedIncrease_a601842f-4363-441e-96ef-63c96f750835" xlink:href="angn-20211231.xsd#angn_EarningsPerShareDilutedIncrease"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_angn_EarningsPerShareDilutedIncrease_a601842f-4363-441e-96ef-63c96f750835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_95e08fcf-3307-421c-9ed1-20409d447eff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_95e08fcf-3307-421c-9ed1-20409d447eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_17faf22c-4792-424a-837b-0f6902a7e316" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_853c8ec2-5485-4342-a97d-e349c7abe89b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_17faf22c-4792-424a-837b-0f6902a7e316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/RevenueandDeferredRevenueDetails_1" xlink:type="simple" xlink:href="angn-20211231.xsd#RevenueandDeferredRevenueDetails_1"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/RevenueandDeferredRevenueDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.angn.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="angn-20211231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5ae6a966-02a5-4dd0-b1fb-8fcb3d318571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_b8815977-f14b-4b14-8d78-b85fb3eccecc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5ae6a966-02a5-4dd0-b1fb-8fcb3d318571" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_b8815977-f14b-4b14-8d78-b85fb3eccecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="angn-20211231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_37e41fc4-6ec6-4a95-9a4e-706414c9db0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_5bb7c731-5db1-4320-89ee-361a73f4f7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_37e41fc4-6ec6-4a95-9a4e-706414c9db0d" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_5bb7c731-5db1-4320-89ee-361a73f4f7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7d0b2e76-025d-4750-9f4a-8c2eca11a287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_37e41fc4-6ec6-4a95-9a4e-706414c9db0d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7d0b2e76-025d-4750-9f4a-8c2eca11a287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_e6073bc0-3acc-46b9-950b-a2033f3b862c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_37e41fc4-6ec6-4a95-9a4e-706414c9db0d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_e6073bc0-3acc-46b9-950b-a2033f3b862c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f98af250-a827-4628-abe0-180a84a331fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a7f00ab3-b044-44d4-bb74-2dfaa0778d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f98af250-a827-4628-abe0-180a84a331fc" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a7f00ab3-b044-44d4-bb74-2dfaa0778d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_627893d9-8b3b-49bb-9d9b-9e9e8010daab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a7f00ab3-b044-44d4-bb74-2dfaa0778d4e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_627893d9-8b3b-49bb-9d9b-9e9e8010daab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_79b6cd7b-ae44-4d69-93a5-ad28fefb022d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_627893d9-8b3b-49bb-9d9b-9e9e8010daab" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_79b6cd7b-ae44-4d69-93a5-ad28fefb022d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_d929fa02-54e5-4109-a7ad-f0e6313f58c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_79b6cd7b-ae44-4d69-93a5-ad28fefb022d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_d929fa02-54e5-4109-a7ad-f0e6313f58c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5459f5be-1f11-4f0a-8fd6-8f145197f3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_79b6cd7b-ae44-4d69-93a5-ad28fefb022d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5459f5be-1f11-4f0a-8fd6-8f145197f3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c70aeff9-c999-440b-8180-adaaa280f318" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_79b6cd7b-ae44-4d69-93a5-ad28fefb022d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c70aeff9-c999-440b-8180-adaaa280f318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_169c5ecf-8179-4abe-919b-4992e919a1a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a7f00ab3-b044-44d4-bb74-2dfaa0778d4e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_169c5ecf-8179-4abe-919b-4992e919a1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_26ad9fe0-b8af-4195-963a-7b0f59fbb0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_169c5ecf-8179-4abe-919b-4992e919a1a5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_26ad9fe0-b8af-4195-963a-7b0f59fbb0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_8caabdda-878c-44b8-98c5-3f7b862e607b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_26ad9fe0-b8af-4195-963a-7b0f59fbb0c4" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_8caabdda-878c-44b8-98c5-3f7b862e607b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_eedfa85c-4229-4584-82d5-4d04243cad35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_a7f00ab3-b044-44d4-bb74-2dfaa0778d4e" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_eedfa85c-4229-4584-82d5-4d04243cad35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_d7095338-51ca-4cee-9dee-42ad9ba59ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_eedfa85c-4229-4584-82d5-4d04243cad35" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_d7095338-51ca-4cee-9dee-42ad9ba59ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3708986b-7212-4327-be26-19ed48dfc9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d7095338-51ca-4cee-9dee-42ad9ba59ee4" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3708986b-7212-4327-be26-19ed48dfc9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4e284174-61ec-4b4f-8cd6-0722b59ada16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d7095338-51ca-4cee-9dee-42ad9ba59ee4" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_4e284174-61ec-4b4f-8cd6-0722b59ada16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_62afe0f8-728e-453b-8e2b-344215e88556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_eedfa85c-4229-4584-82d5-4d04243cad35" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_62afe0f8-728e-453b-8e2b-344215e88556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_606fca8c-8769-4cd7-accc-9543fff5a4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_62afe0f8-728e-453b-8e2b-344215e88556" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_606fca8c-8769-4cd7-accc-9543fff5a4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsFairValueDisclosure_9fc80ad5-655a-400c-8a97-f9dea70a2ecf" xlink:href="angn-20211231.xsd#angn_WarrantsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_62afe0f8-728e-453b-8e2b-344215e88556" xlink:to="loc_angn_WarrantsFairValueDisclosure_9fc80ad5-655a-400c-8a97-f9dea70a2ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent_39f01bef-86cb-4385-86a6-db5509e7e1b9" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_62afe0f8-728e-453b-8e2b-344215e88556" xlink:to="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent_39f01bef-86cb-4385-86a6-db5509e7e1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_7a9e51b8-fff2-4986-a714-63b035c9618d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_62afe0f8-728e-453b-8e2b-344215e88556" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_7a9e51b8-fff2-4986-a714-63b035c9618d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_191c7c1c-9555-414c-b4bd-62a11c6c91e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_78d7afe9-635a-4373-839e-19b00b3478d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_191c7c1c-9555-414c-b4bd-62a11c6c91e6" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_78d7afe9-635a-4373-839e-19b00b3478d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_4f1dba6c-494c-4a49-8131-8e4a507cad19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_78d7afe9-635a-4373-839e-19b00b3478d1" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_4f1dba6c-494c-4a49-8131-8e4a507cad19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_35cc85d6-08f2-4a58-be4d-805cd0e24d65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_4f1dba6c-494c-4a49-8131-8e4a507cad19" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_35cc85d6-08f2-4a58-be4d-805cd0e24d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantLiabilityMember_e829bd42-1f7f-4166-989d-8e4885a63049" xlink:href="angn-20211231.xsd#angn_WarrantLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_35cc85d6-08f2-4a58-be4d-805cd0e24d65" xlink:to="loc_angn_WarrantLiabilityMember_e829bd42-1f7f-4166-989d-8e4885a63049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_c84678e3-e529-455c-bfb3-324756fb87f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_35cc85d6-08f2-4a58-be4d-805cd0e24d65" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_c84678e3-e529-455c-bfb3-324756fb87f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_e630ca17-a933-4bb6-a47b-2904b9af0352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_35cc85d6-08f2-4a58-be4d-805cd0e24d65" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_e630ca17-a933-4bb6-a47b-2904b9af0352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8b9a91fd-2a09-4f17-91e2-faaf96c77eae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_78d7afe9-635a-4373-839e-19b00b3478d1" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8b9a91fd-2a09-4f17-91e2-faaf96c77eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0e48f61e-1799-48bc-be3c-51f577be383e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_8b9a91fd-2a09-4f17-91e2-faaf96c77eae" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0e48f61e-1799-48bc-be3c-51f577be383e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_eecf4f08-4fd8-4cd7-8e96-b69a9edcd277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0e48f61e-1799-48bc-be3c-51f577be383e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_eecf4f08-4fd8-4cd7-8e96-b69a9edcd277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0a80d8a4-3df5-4202-9a77-f84eb10c3e97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0e48f61e-1799-48bc-be3c-51f577be383e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0a80d8a4-3df5-4202-9a77-f84eb10c3e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_56b20c84-7013-4bf4-a885-9992d0450bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0e48f61e-1799-48bc-be3c-51f577be383e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_56b20c84-7013-4bf4-a885-9992d0450bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_fb03d3c1-8814-4ad0-af8c-939324811cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0e48f61e-1799-48bc-be3c-51f577be383e" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_fb03d3c1-8814-4ad0-af8c-939324811cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a23e3ffb-763a-4534-b627-ee3d4c276c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_bb93058b-58ee-483f-8620-923b8c31e043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a23e3ffb-763a-4534-b627-ee3d4c276c5a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_bb93058b-58ee-483f-8620-923b8c31e043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_9bdbce39-d043-4d6a-a3e9-fe814f92d74d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_bb93058b-58ee-483f-8620-923b8c31e043" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_9bdbce39-d043-4d6a-a3e9-fe814f92d74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_14ccd30e-d36c-45a5-9fcb-89b883dfd98e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_9bdbce39-d043-4d6a-a3e9-fe814f92d74d" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_14ccd30e-d36c-45a5-9fcb-89b883dfd98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_1feb665f-cf26-49ad-9b1a-d91a43e4400c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_14ccd30e-d36c-45a5-9fcb-89b883dfd98e" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_1feb665f-cf26-49ad-9b1a-d91a43e4400c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_b8083040-9172-4739-8521-eeba3528d1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_bb93058b-58ee-483f-8620-923b8c31e043" xlink:to="loc_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_b8083040-9172-4739-8521-eeba3528d1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_bf32b464-b399-4362-8ba5-139e74a0b641" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis_b8083040-9172-4739-8521-eeba3528d1ce" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_bf32b464-b399-4362-8ba5-139e74a0b641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSubjectToMandatoryRedemptionMember_0c15d2d4-4dbf-4ba7-8d3d-c50d2e8a2962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSubjectToMandatoryRedemptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain_bf32b464-b399-4362-8ba5-139e74a0b641" xlink:to="loc_us-gaap_ConvertiblePreferredStockSubjectToMandatoryRedemptionMember_0c15d2d4-4dbf-4ba7-8d3d-c50d2e8a2962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0c29dc56-2edd-4e78-b601-38d5e54372c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_bb93058b-58ee-483f-8620-923b8c31e043" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0c29dc56-2edd-4e78-b601-38d5e54372c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_45545427-912c-4927-afb4-b70c6b89be61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0c29dc56-2edd-4e78-b601-38d5e54372c3" xlink:to="loc_us-gaap_ClassOfStockDomain_45545427-912c-4927-afb4-b70c6b89be61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_ed7b8545-68f2-4457-bc09-daf61c8d2ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_45545427-912c-4927-afb4-b70c6b89be61" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_ed7b8545-68f2-4457-bc09-daf61c8d2ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_5a83ece4-417b-4b7f-86f8-b4879d8d505b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_bb93058b-58ee-483f-8620-923b8c31e043" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_5a83ece4-417b-4b7f-86f8-b4879d8d505b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_cdfbf638-d230-426a-a7c5-38646ac94479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_5a83ece4-417b-4b7f-86f8-b4879d8d505b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_cdfbf638-d230-426a-a7c5-38646ac94479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_57c88cda-9c6f-40c9-b175-39bef949efc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_5a83ece4-417b-4b7f-86f8-b4879d8d505b" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_57c88cda-9c6f-40c9-b175-39bef949efc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsConversionPrice_eef7e639-e1ea-475a-a7e6-01b88eb985bb" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsConversionPrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_5a83ece4-417b-4b7f-86f8-b4879d8d505b" xlink:to="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsConversionPrice_eef7e639-e1ea-475a-a7e6-01b88eb985bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ca1cd2e1-f147-4ee9-a935-e0cecdcc28ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_5a83ece4-417b-4b7f-86f8-b4879d8d505b" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_ca1cd2e1-f147-4ee9-a935-e0cecdcc28ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_20a9039c-0cf6-4583-8bc9-80d8d811eef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_5a83ece4-417b-4b7f-86f8-b4879d8d505b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_20a9039c-0cf6-4583-8bc9-80d8d811eef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_1067ad5a-82bd-485d-afc4-bf034615456c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_5a83ece4-417b-4b7f-86f8-b4879d8d505b" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_1067ad5a-82bd-485d-afc4-bf034615456c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/FairValueMeasurementsFairValueMeasurementInputsandValuationTechniquesDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#FairValueMeasurementsFairValueMeasurementInputsandValuationTechniquesDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/FairValueMeasurementsFairValueMeasurementInputsandValuationTechniquesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2bb2e05c-f386-4157-a77e-a0eb8688e355" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_ee56e0ab-33e6-4a02-8865-5cdb6aff240f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2bb2e05c-f386-4157-a77e-a0eb8688e355" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_ee56e0ab-33e6-4a02-8865-5cdb6aff240f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5203aac1-c4be-4c45-b855-96e20cc9220f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_ee56e0ab-33e6-4a02-8865-5cdb6aff240f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5203aac1-c4be-4c45-b855-96e20cc9220f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_75d6e13c-02e3-4358-8b21-cc5738bd7952" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5203aac1-c4be-4c45-b855-96e20cc9220f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_75d6e13c-02e3-4358-8b21-cc5738bd7952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_61260cec-a8dc-4660-a59f-38c21834ab59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_75d6e13c-02e3-4358-8b21-cc5738bd7952" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_61260cec-a8dc-4660-a59f-38c21834ab59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_b1a1ecc4-e581-4176-a331-4a6d9f19f659" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_ee56e0ab-33e6-4a02-8865-5cdb6aff240f" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_b1a1ecc4-e581-4176-a331-4a6d9f19f659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_ddb60a47-622f-447d-9c13-89f0e0688b88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_b1a1ecc4-e581-4176-a331-4a6d9f19f659" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_ddb60a47-622f-447d-9c13-89f0e0688b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_MeasurementInputStrikePriceMember_6acf5973-cfc6-4223-a07d-56e42351ba72" xlink:href="angn-20211231.xsd#angn_MeasurementInputStrikePriceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_ddb60a47-622f-447d-9c13-89f0e0688b88" xlink:to="loc_angn_MeasurementInputStrikePriceMember_6acf5973-cfc6-4223-a07d-56e42351ba72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_9edd4950-ce27-4b1f-a59a-4b7854c40dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_ddb60a47-622f-447d-9c13-89f0e0688b88" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_9edd4950-ce27-4b1f-a59a-4b7854c40dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1c4ec3a7-85e8-4801-9637-ec13bc6dc1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_ddb60a47-622f-447d-9c13-89f0e0688b88" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1c4ec3a7-85e8-4801-9637-ec13bc6dc1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_35d9598d-e223-4d2f-a0df-fbc3a9091021" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_ddb60a47-622f-447d-9c13-89f0e0688b88" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_35d9598d-e223-4d2f-a0df-fbc3a9091021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_fb79acd9-3021-4217-96a1-3d295b829130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_ee56e0ab-33e6-4a02-8865-5cdb6aff240f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_fb79acd9-3021-4217-96a1-3d295b829130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_d0b894ae-d0a6-48d3-bb23-f91e84ebcb7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_fb79acd9-3021-4217-96a1-3d295b829130" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_d0b894ae-d0a6-48d3-bb23-f91e84ebcb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_bbf5c966-7d3f-4d18-ae4e-5eba4a08fcc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_fb79acd9-3021-4217-96a1-3d295b829130" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_bbf5c966-7d3f-4d18-ae4e-5eba4a08fcc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="angn-20211231.xsd#BalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_494ef0d7-fe15-421e-a923-0e13fb7becc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_af494c5d-06c4-49da-a918-87c2102302b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_494ef0d7-fe15-421e-a923-0e13fb7becc9" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_af494c5d-06c4-49da-a918-87c2102302b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="angn-20211231.xsd#BalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f817e0f3-62fc-4495-ada5-cf7fa4231b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_4d702e0b-36c5-4951-bea0-610e716378f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f817e0f3-62fc-4495-ada5-cf7fa4231b2c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_4d702e0b-36c5-4951-bea0-610e716378f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_c6d286ec-0ec8-4fd4-9cb4-4a93d9be3add" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f817e0f3-62fc-4495-ada5-cf7fa4231b2c" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_c6d286ec-0ec8-4fd4-9cb4-4a93d9be3add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7f07d646-7a61-4076-9cbd-0c79e11d33f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f817e0f3-62fc-4495-ada5-cf7fa4231b2c" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_7f07d646-7a61-4076-9cbd-0c79e11d33f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aca73d8f-e23b-4b6f-8360-f24d51b686e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_489dd03c-01db-4784-bb7c-c992eb9e7cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aca73d8f-e23b-4b6f-8360-f24d51b686e9" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_489dd03c-01db-4784-bb7c-c992eb9e7cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6e27ba6b-d559-485b-9f85-92f66d296019" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_489dd03c-01db-4784-bb7c-c992eb9e7cf0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6e27ba6b-d559-485b-9f85-92f66d296019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_35e04578-de52-4e2e-aef6-7992141847dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6e27ba6b-d559-485b-9f85-92f66d296019" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_35e04578-de52-4e2e-aef6-7992141847dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_2cb49b7e-a35b-4a02-a9e1-044a2f52bf93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_35e04578-de52-4e2e-aef6-7992141847dd" xlink:to="loc_us-gaap_EquipmentMember_2cb49b7e-a35b-4a02-a9e1-044a2f52bf93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_21983ce5-e3b2-44c4-8fb8-801212ad20a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_35e04578-de52-4e2e-aef6-7992141847dd" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_21983ce5-e3b2-44c4-8fb8-801212ad20a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_99e4e4ea-17fe-4f45-aec1-4a80930b2067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_35e04578-de52-4e2e-aef6-7992141847dd" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_99e4e4ea-17fe-4f45-aec1-4a80930b2067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cfb9cee9-c813-4e94-95b6-17f43c163bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_489dd03c-01db-4784-bb7c-c992eb9e7cf0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cfb9cee9-c813-4e94-95b6-17f43c163bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1f60f23c-820b-49cd-b0ab-3e3147d2490d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cfb9cee9-c813-4e94-95b6-17f43c163bb7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1f60f23c-820b-49cd-b0ab-3e3147d2490d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9c1a7a4b-017e-4472-a037-c3dd08b9262c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cfb9cee9-c813-4e94-95b6-17f43c163bb7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9c1a7a4b-017e-4472-a037-c3dd08b9262c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8bed89f9-49e8-4a98-9ffd-ed83f6ff6ade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cfb9cee9-c813-4e94-95b6-17f43c163bb7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8bed89f9-49e8-4a98-9ffd-ed83f6ff6ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/BalanceSheetComponentsNarrativeDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#BalanceSheetComponentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/BalanceSheetComponentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bb974000-a54f-4345-ab02-7703903ce323" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_d15c8e05-d1e5-4b33-8281-32a884ff5f25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bb974000-a54f-4345-ab02-7703903ce323" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_d15c8e05-d1e5-4b33-8281-32a884ff5f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_0cc7c0bc-1f65-4c18-af63-8f881cebf739" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d15c8e05-d1e5-4b33-8281-32a884ff5f25" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_0cc7c0bc-1f65-4c18-af63-8f881cebf739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_eff620df-0fc8-450f-af5f-77e62b8fac20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_0cc7c0bc-1f65-4c18-af63-8f881cebf739" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_eff620df-0fc8-450f-af5f-77e62b8fac20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AustralianTaxationOfficeMember_cd4a7efe-4675-46a4-8588-24e3c8b8660e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AustralianTaxationOfficeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_eff620df-0fc8-450f-af5f-77e62b8fac20" xlink:to="loc_us-gaap_AustralianTaxationOfficeMember_cd4a7efe-4675-46a4-8588-24e3c8b8660e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_c744988d-56a8-40e8-9ac1-9c2d91be6ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d15c8e05-d1e5-4b33-8281-32a884ff5f25" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_c744988d-56a8-40e8-9ac1-9c2d91be6ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_16f0f4a3-ab8a-4f0b-8bc7-3a27bec2f599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_c744988d-56a8-40e8-9ac1-9c2d91be6ecf" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_16f0f4a3-ab8a-4f0b-8bc7-3a27bec2f599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_6738b0b2-caa2-4b00-a26c-39e4b65ba70d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_16f0f4a3-ab8a-4f0b-8bc7-3a27bec2f599" xlink:to="loc_us-gaap_ResearchMember_6738b0b2-caa2-4b00-a26c-39e4b65ba70d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_2aa08fc1-2419-40e8-bf4e-7db0bd8bb62c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_d15c8e05-d1e5-4b33-8281-32a884ff5f25" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_2aa08fc1-2419-40e8-bf4e-7db0bd8bb62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_a61adf5d-fd06-46aa-9b82-84367e02a3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_2aa08fc1-2419-40e8-bf4e-7db0bd8bb62c" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_a61adf5d-fd06-46aa-9b82-84367e02a3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_317dc802-541d-404c-a55b-9ede832999db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_2aa08fc1-2419-40e8-bf4e-7db0bd8bb62c" xlink:to="loc_us-gaap_Depreciation_317dc802-541d-404c-a55b-9ede832999db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8d319580-09c3-44db-a87e-fc78d1ccd563" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_6ad59fe0-55f3-40ab-b88e-9d4009d75c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8d319580-09c3-44db-a87e-fc78d1ccd563" xlink:to="loc_us-gaap_DeferredOfferingCosts_6ad59fe0-55f3-40ab-b88e-9d4009d75c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PrepaidClinicalFeesCurrent_71cd8ae7-7cec-4603-b0b1-468528d0d633" xlink:href="angn-20211231.xsd#angn_PrepaidClinicalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8d319580-09c3-44db-a87e-fc78d1ccd563" xlink:to="loc_angn_PrepaidClinicalFeesCurrent_71cd8ae7-7cec-4603-b0b1-468528d0d633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_5304dc1e-78ce-440d-ab98-608836323fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8d319580-09c3-44db-a87e-fc78d1ccd563" xlink:to="loc_us-gaap_PrepaidInsurance_5304dc1e-78ce-440d-ab98-608836323fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent_58809ab3-42ab-42ee-baae-8fc3617accbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8d319580-09c3-44db-a87e-fc78d1ccd563" xlink:to="loc_us-gaap_DepositsAssetsCurrent_58809ab3-42ab-42ee-baae-8fc3617accbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_d463ad9f-a442-429d-b692-f09e1fd994b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8d319580-09c3-44db-a87e-fc78d1ccd563" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_d463ad9f-a442-429d-b692-f09e1fd994b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_f44dd6f1-4878-41c3-ab8d-2ae102f03290" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidTaxes"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8d319580-09c3-44db-a87e-fc78d1ccd563" xlink:to="loc_us-gaap_PrepaidTaxes_f44dd6f1-4878-41c3-ab8d-2ae102f03290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_c88ae295-d6fe-4cfc-9699-75b504545eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8d319580-09c3-44db-a87e-fc78d1ccd563" xlink:to="loc_us-gaap_OtherAssetsCurrent_c88ae295-d6fe-4cfc-9699-75b504545eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b28d5feb-10cb-490f-b18b-a840385cdaaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8d319580-09c3-44db-a87e-fc78d1ccd563" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b28d5feb-10cb-490f-b18b-a840385cdaaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#BalanceSheetComponentsScheduleofAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1ee18327-74ce-4f88-9e45-724483cfe2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_fa758925-8a75-4d4d-bb64-aeac6b5448f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1ee18327-74ce-4f88-9e45-724483cfe2d1" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_fa758925-8a75-4d4d-bb64-aeac6b5448f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AccruedDirectResearchCostsCurrent_9874b2a7-7b12-4c25-aada-24f824d744f0" xlink:href="angn-20211231.xsd#angn_AccruedDirectResearchCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1ee18327-74ce-4f88-9e45-724483cfe2d1" xlink:to="loc_angn_AccruedDirectResearchCostsCurrent_9874b2a7-7b12-4c25-aada-24f824d744f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AccruedOperatingLiabilitiesCurrent_0eb4fd2b-58c1-45e5-a631-325ede72c853" xlink:href="angn-20211231.xsd#angn_AccruedOperatingLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1ee18327-74ce-4f88-9e45-724483cfe2d1" xlink:to="loc_angn_AccruedOperatingLiabilitiesCurrent_0eb4fd2b-58c1-45e5-a631-325ede72c853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_c3a8a9d4-5a91-47dd-9fa1-211c4768affd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1ee18327-74ce-4f88-9e45-724483cfe2d1" xlink:to="loc_us-gaap_InterestPayableCurrent_c3a8a9d4-5a91-47dd-9fa1-211c4768affd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2b26469b-820d-47a7-85cb-299ccd020582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1ee18327-74ce-4f88-9e45-724483cfe2d1" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2b26469b-820d-47a7-85cb-299ccd020582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/ConvertibleNotesPayable" xlink:type="simple" xlink:href="angn-20211231.xsd#ConvertibleNotesPayable"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/ConvertibleNotesPayable" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0598febb-81ea-49b9-a9d1-33db07703ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_7c5a2b48-8ecc-43e4-9484-28383f3efc76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0598febb-81ea-49b9-a9d1-33db07703ece" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_7c5a2b48-8ecc-43e4-9484-28383f3efc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/ConvertibleNotesPayableDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#ConvertibleNotesPayableDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/ConvertibleNotesPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5a413675-79aa-40fc-8fe2-18a56520ad60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionTable_3778617d-cff6-498e-80a9-840c7c9092af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5a413675-79aa-40fc-8fe2-18a56520ad60" xlink:to="loc_us-gaap_DebtConversionTable_3778617d-cff6-498e-80a9-840c7c9092af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_cb3992a0-fd5a-4473-b9a0-cb978e3cd00c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionTable_3778617d-cff6-498e-80a9-840c7c9092af" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_cb3992a0-fd5a-4473-b9a0-cb978e3cd00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_8b0e56ce-6c69-4beb-90b5-1694f0363522" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_cb3992a0-fd5a-4473-b9a0-cb978e3cd00c" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_8b0e56ce-6c69-4beb-90b5-1694f0363522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_66b780cd-790f-45ed-9c53-b11a6d54fc76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_8b0e56ce-6c69-4beb-90b5-1694f0363522" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_66b780cd-790f-45ed-9c53-b11a6d54fc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5f0cc6da-508d-4a08-9ce2-bc5fa780915f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionTable_3778617d-cff6-498e-80a9-840c7c9092af" xlink:to="loc_us-gaap_DebtInstrumentAxis_5f0cc6da-508d-4a08-9ce2-bc5fa780915f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c4b46ae9-8dae-401a-bfad-0772fe0f2d20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_5f0cc6da-508d-4a08-9ce2-bc5fa780915f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c4b46ae9-8dae-401a-bfad-0772fe0f2d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_A2020NotesMember_2f722668-d698-4d4e-9bce-593bbfaf19e6" xlink:href="angn-20211231.xsd#angn_A2020NotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c4b46ae9-8dae-401a-bfad-0772fe0f2d20" xlink:to="loc_angn_A2020NotesMember_2f722668-d698-4d4e-9bce-593bbfaf19e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_AdditionalConvertibleNotesAndViforConvertibleNoteMember_bdd62232-eb27-44a3-affd-ef3640cf0c9f" xlink:href="angn-20211231.xsd#angn_AdditionalConvertibleNotesAndViforConvertibleNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c4b46ae9-8dae-401a-bfad-0772fe0f2d20" xlink:to="loc_angn_AdditionalConvertibleNotesAndViforConvertibleNoteMember_bdd62232-eb27-44a3-affd-ef3640cf0c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_afd976e6-8840-4bcc-aaed-96368506d359" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionTable_3778617d-cff6-498e-80a9-840c7c9092af" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_afd976e6-8840-4bcc-aaed-96368506d359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d920e5a1-cead-438a-b745-52d45cccbca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_afd976e6-8840-4bcc-aaed-96368506d359" xlink:to="loc_us-gaap_EquityComponentDomain_d920e5a1-cead-438a-b745-52d45cccbca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_be99f784-4ea2-4c70-8876-596463e2b88c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d920e5a1-cead-438a-b745-52d45cccbca6" xlink:to="loc_us-gaap_CommonStockMember_be99f784-4ea2-4c70-8876-596463e2b88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_dd96caa2-0a6e-4c0e-9903-e05a00e2e2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionTable_3778617d-cff6-498e-80a9-840c7c9092af" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_dd96caa2-0a6e-4c0e-9903-e05a00e2e2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4abfa282-5d74-4aac-a3d0-b9fa77eb759b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_dd96caa2-0a6e-4c0e-9903-e05a00e2e2aa" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4abfa282-5d74-4aac-a3d0-b9fa77eb759b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_4b853106-484f-4ac6-912d-0ddedbc498c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4abfa282-5d74-4aac-a3d0-b9fa77eb759b" xlink:to="loc_us-gaap_IPOMember_4b853106-484f-4ac6-912d-0ddedbc498c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionLineItems_f9c596bc-f59b-4952-80da-d977a29015a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionTable_3778617d-cff6-498e-80a9-840c7c9092af" xlink:to="loc_us-gaap_DebtConversionLineItems_f9c596bc-f59b-4952-80da-d977a29015a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d784bbda-a321-4c96-b90d-5cdb3dff6670" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_f9c596bc-f59b-4952-80da-d977a29015a6" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d784bbda-a321-4c96-b90d-5cdb3dff6670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentIncreaseAccruedInterest_2771dfad-1a37-4a88-9320-6d81b25df620" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_f9c596bc-f59b-4952-80da-d977a29015a6" xlink:to="loc_us-gaap_DebtInstrumentIncreaseAccruedInterest_2771dfad-1a37-4a88-9320-6d81b25df620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c7748098-3653-4e89-b37a-38180ea5410b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_f9c596bc-f59b-4952-80da-d977a29015a6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c7748098-3653-4e89-b37a-38180ea5410b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_50ef3d90-6240-4bbc-a580-293044791819" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_f9c596bc-f59b-4952-80da-d977a29015a6" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_50ef3d90-6240-4bbc-a580-293044791819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_07658f7a-cba5-4689-a161-1dea07051e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_f9c596bc-f59b-4952-80da-d977a29015a6" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_07658f7a-cba5-4689-a161-1dea07051e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayable_2a8edc61-f173-4baa-982b-bd267ac62458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionLineItems_f9c596bc-f59b-4952-80da-d977a29015a6" xlink:to="loc_us-gaap_ConvertibleNotesPayable_2a8edc61-f173-4baa-982b-bd267ac62458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/SeriesCConvertiblePreferredStock" xlink:type="simple" xlink:href="angn-20211231.xsd#SeriesCConvertiblePreferredStock"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/SeriesCConvertiblePreferredStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_19a411ac-e188-4a1b-b5e9-459dfffe2581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionDisclosureTextBlock_e5dbadf1-2fcf-4576-99cf-3c346e783181" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_19a411ac-e188-4a1b-b5e9-459dfffe2581" xlink:to="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionDisclosureTextBlock_e5dbadf1-2fcf-4576-99cf-3c346e783181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/SeriesCConvertiblePreferredStockTables" xlink:type="simple" xlink:href="angn-20211231.xsd#SeriesCConvertiblePreferredStockTables"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/SeriesCConvertiblePreferredStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_7d761908-1283-4229-965e-5a05c9dc77d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionDisclosureTextBlock_8cd599e5-52f6-4371-83c3-541f16a23d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_7d761908-1283-4229-965e-5a05c9dc77d0" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionDisclosureTextBlock_8cd599e5-52f6-4371-83c3-541f16a23d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/SeriesCConvertiblePreferredStockSummaryofAggregateValuesRecordedDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#SeriesCConvertiblePreferredStockSummaryofAggregateValuesRecordedDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/SeriesCConvertiblePreferredStockSummaryofAggregateValuesRecordedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b462cbf7-0e76-42b7-aeda-f0c3e14fbd38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_TemporaryEquityAmortizedCostAbstract_cc296ab1-e03b-41ce-b6f3-11244affe196" xlink:href="angn-20211231.xsd#angn_TemporaryEquityAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b462cbf7-0e76-42b7-aeda-f0c3e14fbd38" xlink:to="loc_angn_TemporaryEquityAmortizedCostAbstract_cc296ab1-e03b-41ce-b6f3-11244affe196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross_df440379-5eeb-47fb-9f31-70c32ceeaa42" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_TemporaryEquityAmortizedCostAbstract_cc296ab1-e03b-41ce-b6f3-11244affe196" xlink:to="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross_df440379-5eeb-47fb-9f31-70c32ceeaa42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium_0ae8bf08-ecfb-449c-9013-3b3f7762d586" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_TemporaryEquityAmortizedCostAbstract_cc296ab1-e03b-41ce-b6f3-11244affe196" xlink:to="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium_0ae8bf08-ecfb-449c-9013-3b3f7762d586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees_6b56d8e3-1bbc-4d78-9fcf-3fa8f40d1e5d" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_TemporaryEquityAmortizedCostAbstract_cc296ab1-e03b-41ce-b6f3-11244affe196" xlink:to="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees_6b56d8e3-1bbc-4d78-9fcf-3fa8f40d1e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_e59fc3fd-3d04-41ac-adfc-23c7b0dd2259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_TemporaryEquityAmortizedCostAbstract_cc296ab1-e03b-41ce-b6f3-11244affe196" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent_e59fc3fd-3d04-41ac-adfc-23c7b0dd2259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionFairValueAbstract_f877e393-a7ab-4ef7-be7a-a47e0953d17f" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b462cbf7-0e76-42b7-aeda-f0c3e14fbd38" xlink:to="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionFairValueAbstract_f877e393-a7ab-4ef7-be7a-a47e0953d17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountIssuedInConvertibleNoteExchange_37668c1e-184d-47f3-b381-ec6edb3cc518" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountIssuedInConvertibleNoteExchange"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionFairValueAbstract_f877e393-a7ab-4ef7-be7a-a47e0953d17f" xlink:to="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountIssuedInConvertibleNoteExchange_37668c1e-184d-47f3-b381-ec6edb3cc518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountAccumulatedChangeInFairValue_4b7e9f32-9952-4801-a201-942ec94eb8c6" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountAccumulatedChangeInFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionFairValueAbstract_f877e393-a7ab-4ef7-be7a-a47e0953d17f" xlink:to="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountAccumulatedChangeInFairValue_4b7e9f32-9952-4801-a201-942ec94eb8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount_f0569ee4-a9c4-40f9-8fb9-745cd65a89c8" xlink:href="angn-20211231.xsd#angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b462cbf7-0e76-42b7-aeda-f0c3e14fbd38" xlink:to="loc_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount_f0569ee4-a9c4-40f9-8fb9-745cd65a89c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/SeriesCConvertiblePreferredStockNarrativeDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#SeriesCConvertiblePreferredStockNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/SeriesCConvertiblePreferredStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c8f01401-92d5-4e4f-b810-43856bca3a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_6d6ad984-1526-4b71-a8a5-35cf4a7d4971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c8f01401-92d5-4e4f-b810-43856bca3a4a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_6d6ad984-1526-4b71-a8a5-35cf4a7d4971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c5e97b0c-f770-40a1-8c1f-5333031bcce1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6d6ad984-1526-4b71-a8a5-35cf4a7d4971" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c5e97b0c-f770-40a1-8c1f-5333031bcce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70fa4e68-baee-4523-89af-6a8444b8319c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c5e97b0c-f770-40a1-8c1f-5333031bcce1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70fa4e68-baee-4523-89af-6a8444b8319c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_a3a6062d-8ec9-4b40-80b2-dfbb177aecab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70fa4e68-baee-4523-89af-6a8444b8319c" xlink:to="loc_us-gaap_IPOMember_a3a6062d-8ec9-4b40-80b2-dfbb177aecab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3f105992-b562-4be5-a7eb-ff79a20e19e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6d6ad984-1526-4b71-a8a5-35cf4a7d4971" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3f105992-b562-4be5-a7eb-ff79a20e19e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_834c7660-1647-4b0e-8742-de81a05d8d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3f105992-b562-4be5-a7eb-ff79a20e19e6" xlink:to="loc_us-gaap_ClassOfStockDomain_834c7660-1647-4b0e-8742-de81a05d8d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_8ff9ff21-17d8-4da8-af5a-b2f6e321c58a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_834c7660-1647-4b0e-8742-de81a05d8d7b" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_8ff9ff21-17d8-4da8-af5a-b2f6e321c58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_3810ad94-5a57-4fbc-9299-5cf916f812f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6d6ad984-1526-4b71-a8a5-35cf4a7d4971" xlink:to="loc_us-gaap_ClassOfStockLineItems_3810ad94-5a57-4fbc-9299-5cf916f812f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_fddbb210-c925-4030-8b64-acb985f052ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3810ad94-5a57-4fbc-9299-5cf916f812f8" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_fddbb210-c925-4030-8b64-acb985f052ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_43ea5e47-40e7-442d-8a63-4a88c21cd54e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3810ad94-5a57-4fbc-9299-5cf916f812f8" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_43ea5e47-40e7-442d-8a63-4a88c21cd54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ConvertiblePreferredStockConversionPrice_6db87ddf-1cfb-45d5-ba62-f4ae124a1a11" xlink:href="angn-20211231.xsd#angn_ConvertiblePreferredStockConversionPrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3810ad94-5a57-4fbc-9299-5cf916f812f8" xlink:to="loc_angn_ConvertiblePreferredStockConversionPrice_6db87ddf-1cfb-45d5-ba62-f4ae124a1a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_e17589f5-9364-48e4-b888-78c1573dfd00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3810ad94-5a57-4fbc-9299-5cf916f812f8" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_e17589f5-9364-48e4-b888-78c1573dfd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/StockholdersEquity" xlink:type="simple" xlink:href="angn-20211231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_867c8ac8-5aef-4358-b204-efbb74143a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d23025bf-d425-4f1f-a36e-b9919659d99c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_867c8ac8-5aef-4358-b204-efbb74143a2f" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d23025bf-d425-4f1f-a36e-b9919659d99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_158e685b-0f1b-432f-86f7-41768b7ad0d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_97a9d7fd-8afd-427e-9985-2155a886a506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_158e685b-0f1b-432f-86f7-41768b7ad0d0" xlink:to="loc_us-gaap_TreasuryStockValue_97a9d7fd-8afd-427e-9985-2155a886a506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="angn-20211231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af7dcd62-651d-4e77-97ef-a57a9fc072f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6af7b322-8232-463f-8fd4-334e26fd4cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af7dcd62-651d-4e77-97ef-a57a9fc072f2" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6af7b322-8232-463f-8fd4-334e26fd4cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="angn-20211231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a64d9785-2428-49bc-89a9-3fde46e6de6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_48739e04-ddbc-44de-9695-d62b6b2e0e42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a64d9785-2428-49bc-89a9-3fde46e6de6c" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_48739e04-ddbc-44de-9695-d62b6b2e0e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5fe5efac-fd2e-46d9-84bd-65bcd7d7eadf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a64d9785-2428-49bc-89a9-3fde46e6de6c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_5fe5efac-fd2e-46d9-84bd-65bcd7d7eadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_038a0848-246d-425a-b22e-69c30e7404a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a64d9785-2428-49bc-89a9-3fde46e6de6c" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_038a0848-246d-425a-b22e-69c30e7404a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0dcfce65-85d5-4806-bf0c-6ca2f4faa3e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a64d9785-2428-49bc-89a9-3fde46e6de6c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0dcfce65-85d5-4806-bf0c-6ca2f4faa3e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9f714d0e-ffae-4742-abb3-13eb26d1ee18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_beaf7f28-9c32-479a-80f5-589f7d0f5a47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9f714d0e-ffae-4742-abb3-13eb26d1ee18" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_beaf7f28-9c32-479a-80f5-589f7d0f5a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6b963dc2-c51b-48d6-9f98-86539e250ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_beaf7f28-9c32-479a-80f5-589f7d0f5a47" xlink:to="loc_us-gaap_PlanNameAxis_6b963dc2-c51b-48d6-9f98-86539e250ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_73ed6c47-c4f7-4ffb-bf6f-88e32e5490bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_6b963dc2-c51b-48d6-9f98-86539e250ff1" xlink:to="loc_us-gaap_PlanNameDomain_73ed6c47-c4f7-4ffb-bf6f-88e32e5490bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_A2021PlanMember_a15e23b4-70a7-4d4a-9e14-65ad39bba1ab" xlink:href="angn-20211231.xsd#angn_A2021PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_73ed6c47-c4f7-4ffb-bf6f-88e32e5490bc" xlink:to="loc_angn_A2021PlanMember_a15e23b4-70a7-4d4a-9e14-65ad39bba1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_890a0857-cd73-470f-8353-4ee9b208862a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_beaf7f28-9c32-479a-80f5-589f7d0f5a47" xlink:to="loc_us-gaap_AwardTypeAxis_890a0857-cd73-470f-8353-4ee9b208862a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bf4ee80-953d-4efd-b730-4c44f7925f72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_890a0857-cd73-470f-8353-4ee9b208862a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bf4ee80-953d-4efd-b730-4c44f7925f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e3fa46b7-1cb0-4ae3-9331-6e3bfe1359ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bf4ee80-953d-4efd-b730-4c44f7925f72" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e3fa46b7-1cb0-4ae3-9331-6e3bfe1359ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_4876e7fb-88fb-4cfe-a015-6b38950b256a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bf4ee80-953d-4efd-b730-4c44f7925f72" xlink:to="loc_us-gaap_PerformanceSharesMember_4876e7fb-88fb-4cfe-a015-6b38950b256a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_9029ac1e-979a-49ef-ac1d-b2a0da47dd95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1bf4ee80-953d-4efd-b730-4c44f7925f72" xlink:to="loc_us-gaap_EmployeeStockMember_9029ac1e-979a-49ef-ac1d-b2a0da47dd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9f8c2e5-16c4-41ad-a410-412d01aa7724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_beaf7f28-9c32-479a-80f5-589f7d0f5a47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9f8c2e5-16c4-41ad-a410-412d01aa7724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_54419285-116a-4d81-8e89-2f54a3925ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9f8c2e5-16c4-41ad-a410-412d01aa7724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_54419285-116a-4d81-8e89-2f54a3925ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7dc538e0-ebcb-4a9e-a38a-e88671f9a8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9f8c2e5-16c4-41ad-a410-412d01aa7724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7dc538e0-ebcb-4a9e-a38a-e88671f9a8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f4842ac8-0f95-4e92-8006-5b046c263037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9f8c2e5-16c4-41ad-a410-412d01aa7724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f4842ac8-0f95-4e92-8006-5b046c263037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_038a3801-1697-4bf9-93da-447f0c27cc78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9f8c2e5-16c4-41ad-a410-412d01aa7724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_038a3801-1697-4bf9-93da-447f0c27cc78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_8ab61563-0d1d-4c97-9909-937a07f80d61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9f8c2e5-16c4-41ad-a410-412d01aa7724" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_8ab61563-0d1d-4c97-9909-937a07f80d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c6724c04-7ce6-492e-8e03-29505b5aadb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9f8c2e5-16c4-41ad-a410-412d01aa7724" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c6724c04-7ce6-492e-8e03-29505b5aadb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2eafb998-79d7-4131-ac6d-75c51a9bdfde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9f8c2e5-16c4-41ad-a410-412d01aa7724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2eafb998-79d7-4131-ac6d-75c51a9bdfde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6115705a-8f1c-4781-b3f1-20c1a1b7a389" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9f8c2e5-16c4-41ad-a410-412d01aa7724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6115705a-8f1c-4781-b3f1-20c1a1b7a389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_b87d2bfe-b3a4-4217-8cb4-2af333cc7417" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9f8c2e5-16c4-41ad-a410-412d01aa7724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_b87d2bfe-b3a4-4217-8cb4-2af333cc7417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_193d1f18-a02e-4e85-ade5-3e134e9e64de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9f8c2e5-16c4-41ad-a410-412d01aa7724" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_193d1f18-a02e-4e85-ade5-3e134e9e64de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_02d96138-757f-4494-944e-8f71ad4ae1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_c9f8c2e5-16c4-41ad-a410-412d01aa7724" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_02d96138-757f-4494-944e-8f71ad4ae1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_68ab4f9e-9f53-44df-914e-a54e61c8b577" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_964c381c-042d-4305-b92b-2b2e87c5f507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_68ab4f9e-9f53-44df-914e-a54e61c8b577" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_964c381c-042d-4305-b92b-2b2e87c5f507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cc9356d5-ee4b-4c4d-8197-8e2c97c56c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_964c381c-042d-4305-b92b-2b2e87c5f507" xlink:to="loc_us-gaap_AwardTypeAxis_cc9356d5-ee4b-4c4d-8197-8e2c97c56c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aad93a08-a573-4b47-b997-6b4af6b0c856" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_cc9356d5-ee4b-4c4d-8197-8e2c97c56c9c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aad93a08-a573-4b47-b997-6b4af6b0c856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0eeb5d8a-b623-486b-82fc-a61078fb2f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aad93a08-a573-4b47-b997-6b4af6b0c856" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0eeb5d8a-b623-486b-82fc-a61078fb2f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59e21eb0-00de-454e-bd8d-2d63fb9c760d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_964c381c-042d-4305-b92b-2b2e87c5f507" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59e21eb0-00de-454e-bd8d-2d63fb9c760d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a7cb7a75-68bf-4c7f-bbe3-1eb4cf5d0015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59e21eb0-00de-454e-bd8d-2d63fb9c760d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a7cb7a75-68bf-4c7f-bbe3-1eb4cf5d0015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ded8fba8-d9d8-48ea-a3b6-abfa772e6e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59e21eb0-00de-454e-bd8d-2d63fb9c760d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ded8fba8-d9d8-48ea-a3b6-abfa772e6e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4ae6dd0a-3de4-46c3-843f-478aa3ac8953" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59e21eb0-00de-454e-bd8d-2d63fb9c760d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_4ae6dd0a-3de4-46c3-843f-478aa3ac8953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2316fa99-fb3d-496d-89f9-297495c60b67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59e21eb0-00de-454e-bd8d-2d63fb9c760d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2316fa99-fb3d-496d-89f9-297495c60b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_199f6b31-7bd6-4db4-81f7-49d91a10b371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_59e21eb0-00de-454e-bd8d-2d63fb9c760d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_199f6b31-7bd6-4db4-81f7-49d91a10b371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#StockBasedCompensationScheduleofShareOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dde14a99-d13b-4e8c-b269-6eb66a4b841e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5d5c480d-8561-4263-a2cf-973454662bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dde14a99-d13b-4e8c-b269-6eb66a4b841e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5d5c480d-8561-4263-a2cf-973454662bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_20c4028f-d974-4fc8-bb7e-cd2ac5cd8a47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5d5c480d-8561-4263-a2cf-973454662bf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_20c4028f-d974-4fc8-bb7e-cd2ac5cd8a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cf51beb5-f799-40d0-93b3-bf6bb8389ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5d5c480d-8561-4263-a2cf-973454662bf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cf51beb5-f799-40d0-93b3-bf6bb8389ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ee9e3f64-41b4-4b0d-865d-0808262bfa97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5d5c480d-8561-4263-a2cf-973454662bf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ee9e3f64-41b4-4b0d-865d-0808262bfa97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2b1b4e8d-b5b1-4639-859e-d839725ae32f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5d5c480d-8561-4263-a2cf-973454662bf3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2b1b4e8d-b5b1-4639-859e-d839725ae32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_4b06d53a-18e2-4f95-b376-f7a42a2aa523" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5d5c480d-8561-4263-a2cf-973454662bf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_4b06d53a-18e2-4f95-b376-f7a42a2aa523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4d15d7a6-5a36-4c0b-a2a3-af0987e43e72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5d5c480d-8561-4263-a2cf-973454662bf3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4d15d7a6-5a36-4c0b-a2a3-af0987e43e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_05d394e3-bf6f-4567-8d46-02ec06c1f645" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dde14a99-d13b-4e8c-b269-6eb66a4b841e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_05d394e3-bf6f-4567-8d46-02ec06c1f645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6318f1b4-ba63-436f-a8cf-cb116330ace9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dde14a99-d13b-4e8c-b269-6eb66a4b841e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6318f1b4-ba63-436f-a8cf-cb116330ace9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c1025c15-df1a-42ac-9aed-c05567ee7c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6318f1b4-ba63-436f-a8cf-cb116330ace9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c1025c15-df1a-42ac-9aed-c05567ee7c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1c66ea28-7ec1-4be1-aa14-bbd8c4f95dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6318f1b4-ba63-436f-a8cf-cb116330ace9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1c66ea28-7ec1-4be1-aa14-bbd8c4f95dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_31629afe-edec-4e67-9155-102d84cedf4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6318f1b4-ba63-436f-a8cf-cb116330ace9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_31629afe-edec-4e67-9155-102d84cedf4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6a52b903-b162-47f4-b643-374b39ab3cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6318f1b4-ba63-436f-a8cf-cb116330ace9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6a52b903-b162-47f4-b643-374b39ab3cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4d4e51a9-30e1-462b-8f53-9b8ccac715b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6318f1b4-ba63-436f-a8cf-cb116330ace9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_4d4e51a9-30e1-462b-8f53-9b8ccac715b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10299ba2-7236-4633-8088-de29448dbbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6318f1b4-ba63-436f-a8cf-cb116330ace9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10299ba2-7236-4633-8088-de29448dbbd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_33788395-0967-4c36-abc7-9027d7708c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dde14a99-d13b-4e8c-b269-6eb66a4b841e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_33788395-0967-4c36-abc7-9027d7708c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_6d56ede4-e291-4a15-8083-f6a8abcc960e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dde14a99-d13b-4e8c-b269-6eb66a4b841e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_6d56ede4-e291-4a15-8083-f6a8abcc960e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_de45da74-9a01-45fe-9c22-a526b65864a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_6d56ede4-e291-4a15-8083-f6a8abcc960e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_de45da74-9a01-45fe-9c22-a526b65864a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5f387f75-3172-44c4-a718-9c19e9ff4968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_6d56ede4-e291-4a15-8083-f6a8abcc960e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5f387f75-3172-44c4-a718-9c19e9ff4968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_062c02dd-5f13-41d5-9422-c1b91a154b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_6d56ede4-e291-4a15-8083-f6a8abcc960e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_062c02dd-5f13-41d5-9422-c1b91a154b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_cf5f56ed-9de6-441e-a692-4419d99779ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_6d56ede4-e291-4a15-8083-f6a8abcc960e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_cf5f56ed-9de6-441e-a692-4419d99779ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/StockBasedCompensationScheduleofRSAandRSUActivityDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#StockBasedCompensationScheduleofRSAandRSUActivityDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/StockBasedCompensationScheduleofRSAandRSUActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_58fbed64-85f9-41b8-a59e-f323b370e6ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ac83033-8707-4d6c-98f3-c255fe3f5fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_58fbed64-85f9-41b8-a59e-f323b370e6ff" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ac83033-8707-4d6c-98f3-c255fe3f5fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fe769ff9-d449-49d9-a684-28fd0a2cd86f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ac83033-8707-4d6c-98f3-c255fe3f5fd1" xlink:to="loc_us-gaap_AwardTypeAxis_fe769ff9-d449-49d9-a684-28fd0a2cd86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f3bd5a27-03d5-4df8-a444-f2f66fac7458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_fe769ff9-d449-49d9-a684-28fd0a2cd86f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f3bd5a27-03d5-4df8-a444-f2f66fac7458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_2799686f-c20c-447a-94c4-e0546ed279ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f3bd5a27-03d5-4df8-a444-f2f66fac7458" xlink:to="loc_us-gaap_RestrictedStockMember_2799686f-c20c-447a-94c4-e0546ed279ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a984b14f-aeb7-4767-8d5d-596843f8bdb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f3bd5a27-03d5-4df8-a444-f2f66fac7458" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a984b14f-aeb7-4767-8d5d-596843f8bdb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54a0e04e-3bb0-417d-bed3-ae1526a5fefd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8ac83033-8707-4d6c-98f3-c255fe3f5fd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54a0e04e-3bb0-417d-bed3-ae1526a5fefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_1c0dff56-ecc4-4b4b-9ba0-c77afc908414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54a0e04e-3bb0-417d-bed3-ae1526a5fefd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_1c0dff56-ecc4-4b4b-9ba0-c77afc908414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_608e6134-b3cd-4397-8c99-8969b0dcedef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_1c0dff56-ecc4-4b4b-9ba0-c77afc908414" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_608e6134-b3cd-4397-8c99-8969b0dcedef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cff12ead-e03a-4a8b-95cd-13ba408f843a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_1c0dff56-ecc4-4b4b-9ba0-c77afc908414" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cff12ead-e03a-4a8b-95cd-13ba408f843a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3115df86-f580-4008-9997-d70f9d56b9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_1c0dff56-ecc4-4b4b-9ba0-c77afc908414" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3115df86-f580-4008-9997-d70f9d56b9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_267c2669-b456-4c4d-a5be-94109f8821c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_1c0dff56-ecc4-4b4b-9ba0-c77afc908414" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_267c2669-b456-4c4d-a5be-94109f8821c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber_4b2c4c03-06a2-42c5-8242-d4a48e2b9b34" xlink:href="angn-20211231.xsd#angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54a0e04e-3bb0-417d-bed3-ae1526a5fefd" xlink:to="loc_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber_4b2c4c03-06a2-42c5-8242-d4a48e2b9b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7df615b0-255b-430c-a6a0-f0707f5f2777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54a0e04e-3bb0-417d-bed3-ae1526a5fefd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7df615b0-255b-430c-a6a0-f0707f5f2777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2ee05882-2950-4f23-816f-e41d2a8c5373" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7df615b0-255b-430c-a6a0-f0707f5f2777" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2ee05882-2950-4f23-816f-e41d2a8c5373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d3bce1a7-5c27-4b2c-aa30-3f40fab6018d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7df615b0-255b-430c-a6a0-f0707f5f2777" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_d3bce1a7-5c27-4b2c-aa30-3f40fab6018d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_70ada81a-0965-42c3-a63d-4ddda797b14a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7df615b0-255b-430c-a6a0-f0707f5f2777" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_70ada81a-0965-42c3-a63d-4ddda797b14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_459ad485-4186-473e-bda6-5294509507d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_7df615b0-255b-430c-a6a0-f0707f5f2777" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_459ad485-4186-473e-bda6-5294509507d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageExercisePrice_dfbedd34-e709-4cbe-8f02-08eadcc35c0a" xlink:href="angn-20211231.xsd#angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_54a0e04e-3bb0-417d-bed3-ae1526a5fefd" xlink:to="loc_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageExercisePrice_dfbedd34-e709-4cbe-8f02-08eadcc35c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9d2c6379-5851-4dd5-8b7f-92fc1b77d25d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_93cf0f6f-348f-4c97-b18b-f15e8aa59b75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9d2c6379-5851-4dd5-8b7f-92fc1b77d25d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_93cf0f6f-348f-4c97-b18b-f15e8aa59b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bc75770f-92a1-4c98-bb39-8fae5ac7a455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_93cf0f6f-348f-4c97-b18b-f15e8aa59b75" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bc75770f-92a1-4c98-bb39-8fae5ac7a455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1988b3fa-f23f-4e4b-a8e4-195759af7b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bc75770f-92a1-4c98-bb39-8fae5ac7a455" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1988b3fa-f23f-4e4b-a8e4-195759af7b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cff9f61b-1f81-46a1-aa26-deaa7276808f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1988b3fa-f23f-4e4b-a8e4-195759af7b87" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cff9f61b-1f81-46a1-aa26-deaa7276808f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4c72df5a-d05e-4278-a051-2d59aaf3604a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1988b3fa-f23f-4e4b-a8e4-195759af7b87" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4c72df5a-d05e-4278-a051-2d59aaf3604a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d74a1dc4-26e3-4684-8ca8-b892c20b14db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_93cf0f6f-348f-4c97-b18b-f15e8aa59b75" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d74a1dc4-26e3-4684-8ca8-b892c20b14db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_912f3ece-d529-4456-b2ff-e99db2e219a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d74a1dc4-26e3-4684-8ca8-b892c20b14db" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_912f3ece-d529-4456-b2ff-e99db2e219a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/Warrants" xlink:type="simple" xlink:href="angn-20211231.xsd#Warrants"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/Warrants" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsAndRightsOutstandingAbstract_d6ccbc5a-e39a-4ccc-bca1-12b7d1be4402" xlink:href="angn-20211231.xsd#angn_WarrantsAndRightsOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsAndRightsOutstandingTextBlock_373ef6c9-1e33-440b-90d7-1aa14ca2e7a1" xlink:href="angn-20211231.xsd#angn_WarrantsAndRightsOutstandingTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_WarrantsAndRightsOutstandingAbstract_d6ccbc5a-e39a-4ccc-bca1-12b7d1be4402" xlink:to="loc_angn_WarrantsAndRightsOutstandingTextBlock_373ef6c9-1e33-440b-90d7-1aa14ca2e7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/WarrantsTables" xlink:type="simple" xlink:href="angn-20211231.xsd#WarrantsTables"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/WarrantsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsAndRightsOutstandingAbstract_0847dd04-643c-483b-bb53-7b7a5af31a2c" xlink:href="angn-20211231.xsd#angn_WarrantsAndRightsOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_0e4d7294-b7f2-4333-a34f-ecbda824466f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_WarrantsAndRightsOutstandingAbstract_0847dd04-643c-483b-bb53-7b7a5af31a2c" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_0e4d7294-b7f2-4333-a34f-ecbda824466f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsAndRightsOutstandingActivityTableTextBlock_5b4cb8ca-a9d3-4d1e-af65-e4f8cf2c4088" xlink:href="angn-20211231.xsd#angn_WarrantsAndRightsOutstandingActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_WarrantsAndRightsOutstandingAbstract_0847dd04-643c-483b-bb53-7b7a5af31a2c" xlink:to="loc_angn_WarrantsAndRightsOutstandingActivityTableTextBlock_5b4cb8ca-a9d3-4d1e-af65-e4f8cf2c4088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/WarrantsOutstandingWarrantsDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#WarrantsOutstandingWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/WarrantsOutstandingWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsAndRightsOutstandingAbstract_9f24a3fe-706e-47c3-a252-8c3a5c7c6e72" xlink:href="angn-20211231.xsd#angn_WarrantsAndRightsOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_48987641-1228-4e6e-ba12-26b577fb799d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_WarrantsAndRightsOutstandingAbstract_9f24a3fe-706e-47c3-a252-8c3a5c7c6e72" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_48987641-1228-4e6e-ba12-26b577fb799d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_2459cf7f-2729-4e7c-8fa8-f65c71575ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_48987641-1228-4e6e-ba12-26b577fb799d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_2459cf7f-2729-4e7c-8fa8-f65c71575ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ebf8f319-7d6b-42d8-910b-4f30507a4e46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_2459cf7f-2729-4e7c-8fa8-f65c71575ef0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ebf8f319-7d6b-42d8-910b-4f30507a4e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsIssuedWith2015NotesLiabilityMember_26aedc5f-6ad7-4b5f-b107-8b2f5fabad44" xlink:href="angn-20211231.xsd#angn_WarrantsIssuedWith2015NotesLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ebf8f319-7d6b-42d8-910b-4f30507a4e46" xlink:to="loc_angn_WarrantsIssuedWith2015NotesLiabilityMember_26aedc5f-6ad7-4b5f-b107-8b2f5fabad44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsIssuedWith2016NotesLiabilityMember_8e5ce30f-63a1-4d6b-bc9b-71ddf5e07149" xlink:href="angn-20211231.xsd#angn_WarrantsIssuedWith2016NotesLiabilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ebf8f319-7d6b-42d8-910b-4f30507a4e46" xlink:to="loc_angn_WarrantsIssuedWith2016NotesLiabilityMember_8e5ce30f-63a1-4d6b-bc9b-71ddf5e07149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsIssuedWith2017NotesLiabilityMember_6acb2c32-374c-4ff4-b51d-3979c58d3502" xlink:href="angn-20211231.xsd#angn_WarrantsIssuedWith2017NotesLiabilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ebf8f319-7d6b-42d8-910b-4f30507a4e46" xlink:to="loc_angn_WarrantsIssuedWith2017NotesLiabilityMember_6acb2c32-374c-4ff4-b51d-3979c58d3502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsIssuedWith2018NotesLiabilityMember_4f0ad139-ae91-4742-9f41-0bc9cbff0e93" xlink:href="angn-20211231.xsd#angn_WarrantsIssuedWith2018NotesLiabilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ebf8f319-7d6b-42d8-910b-4f30507a4e46" xlink:to="loc_angn_WarrantsIssuedWith2018NotesLiabilityMember_4f0ad139-ae91-4742-9f41-0bc9cbff0e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsIssuedWithConversionOfNotesToCommonStockEquityMember_9e8b17a5-9503-4aa8-8be6-db898e1c2869" xlink:href="angn-20211231.xsd#angn_WarrantsIssuedWithConversionOfNotesToCommonStockEquityMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ebf8f319-7d6b-42d8-910b-4f30507a4e46" xlink:to="loc_angn_WarrantsIssuedWithConversionOfNotesToCommonStockEquityMember_9e8b17a5-9503-4aa8-8be6-db898e1c2869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsIssuedWithUnitsInTheEquityOfferingEquityMember_8ca7963e-c541-4ca8-a141-60f4874968de" xlink:href="angn-20211231.xsd#angn_WarrantsIssuedWithUnitsInTheEquityOfferingEquityMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ebf8f319-7d6b-42d8-910b-4f30507a4e46" xlink:to="loc_angn_WarrantsIssuedWithUnitsInTheEquityOfferingEquityMember_8ca7963e-c541-4ca8-a141-60f4874968de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BrokerWarrantsIssuedWithEquityOfferingEquityMember_a4bbe2ea-4e40-4ed4-af63-3cae5d4b06d5" xlink:href="angn-20211231.xsd#angn_BrokerWarrantsIssuedWithEquityOfferingEquityMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ebf8f319-7d6b-42d8-910b-4f30507a4e46" xlink:to="loc_angn_BrokerWarrantsIssuedWithEquityOfferingEquityMember_a4bbe2ea-4e40-4ed4-af63-3cae5d4b06d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_BrokerWarrantsIssuedWith2019NotesLiabilityMember_61a4c07a-0bfe-4e15-a1e3-e7e5f6bf6e59" xlink:href="angn-20211231.xsd#angn_BrokerWarrantsIssuedWith2019NotesLiabilityMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ebf8f319-7d6b-42d8-910b-4f30507a4e46" xlink:to="loc_angn_BrokerWarrantsIssuedWith2019NotesLiabilityMember_61a4c07a-0bfe-4e15-a1e3-e7e5f6bf6e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ConsultantWarrantsLiabilityMember_25dd3a04-a976-4cf8-a0dd-4abed712d307" xlink:href="angn-20211231.xsd#angn_ConsultantWarrantsLiabilityMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ebf8f319-7d6b-42d8-910b-4f30507a4e46" xlink:to="loc_angn_ConsultantWarrantsLiabilityMember_25dd3a04-a976-4cf8-a0dd-4abed712d307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_8ef2349a-ae32-48e3-bfee-85a82c7f76ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_48987641-1228-4e6e-ba12-26b577fb799d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_8ef2349a-ae32-48e3-bfee-85a82c7f76ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_48b3707f-6069-4acd-bc5a-0045b044447a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8ef2349a-ae32-48e3-bfee-85a82c7f76ef" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_48b3707f-6069-4acd-bc5a-0045b044447a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7dcd632e-2aee-40de-a114-51042d2c788e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_8ef2349a-ae32-48e3-bfee-85a82c7f76ef" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7dcd632e-2aee-40de-a114-51042d2c788e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/WarrantsWarrantActivityDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#WarrantsWarrantActivityDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/WarrantsWarrantActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsAndRightsOutstandingAbstract_9ac1842b-4674-44e5-a990-4b33755f7d17" xlink:href="angn-20211231.xsd#angn_WarrantsAndRightsOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightOutstandingRollForward_4a176606-f33f-483e-a2d4-6e46d508e0da" xlink:href="angn-20211231.xsd#angn_ClassOfWarrantOrRightOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_WarrantsAndRightsOutstandingAbstract_9ac1842b-4674-44e5-a990-4b33755f7d17" xlink:to="loc_angn_ClassOfWarrantOrRightOutstandingRollForward_4a176606-f33f-483e-a2d4-6e46d508e0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_052e92da-e094-4f68-af2f-1e7c55c99313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ClassOfWarrantOrRightOutstandingRollForward_4a176606-f33f-483e-a2d4-6e46d508e0da" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_052e92da-e094-4f68-af2f-1e7c55c99313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightExercisesInPeriod_4065c010-45a6-4e0a-993c-f08298008f51" xlink:href="angn-20211231.xsd#angn_ClassOfWarrantOrRightExercisesInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ClassOfWarrantOrRightOutstandingRollForward_4a176606-f33f-483e-a2d4-6e46d508e0da" xlink:to="loc_angn_ClassOfWarrantOrRightExercisesInPeriod_4065c010-45a6-4e0a-993c-f08298008f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightExpirationsInPeriod_dd719c3f-308a-42ff-a670-73644a2b0c18" xlink:href="angn-20211231.xsd#angn_ClassOfWarrantOrRightExpirationsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ClassOfWarrantOrRightOutstandingRollForward_4a176606-f33f-483e-a2d4-6e46d508e0da" xlink:to="loc_angn_ClassOfWarrantOrRightExpirationsInPeriod_dd719c3f-308a-42ff-a670-73644a2b0c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5c7ee7b9-e949-4ece-a372-bddaea3869ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ClassOfWarrantOrRightOutstandingRollForward_4a176606-f33f-483e-a2d4-6e46d508e0da" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5c7ee7b9-e949-4ece-a372-bddaea3869ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsRollForward_ad3e3f1e-3d84-4352-9ddf-934aedc3ea4f" xlink:href="angn-20211231.xsd#angn_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_WarrantsAndRightsOutstandingAbstract_9ac1842b-4674-44e5-a990-4b33755f7d17" xlink:to="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsRollForward_ad3e3f1e-3d84-4352-9ddf-934aedc3ea4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePrice_5726be34-d040-44f6-8d4e-0fba9a584524" xlink:href="angn-20211231.xsd#angn_ClassOfWarrantOrRightWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsRollForward_ad3e3f1e-3d84-4352-9ddf-934aedc3ea4f" xlink:to="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePrice_5726be34-d040-44f6-8d4e-0fba9a584524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod_2d3ef6ee-dbb5-4a2b-af93-11feb283fdb4" xlink:href="angn-20211231.xsd#angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsRollForward_ad3e3f1e-3d84-4352-9ddf-934aedc3ea4f" xlink:to="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod_2d3ef6ee-dbb5-4a2b-af93-11feb283fdb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExpirationsInPeriod_93bb7bc4-7ff3-407f-aa8c-7822a58de5b7" xlink:href="angn-20211231.xsd#angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExpirationsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsRollForward_ad3e3f1e-3d84-4352-9ddf-934aedc3ea4f" xlink:to="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExpirationsInPeriod_93bb7bc4-7ff3-407f-aa8c-7822a58de5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePrice_b3daa640-1ff2-4f44-8504-ff55e441ea4c" xlink:href="angn-20211231.xsd#angn_ClassOfWarrantOrRightWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsRollForward_ad3e3f1e-3d84-4352-9ddf-934aedc3ea4f" xlink:to="loc_angn_ClassOfWarrantOrRightWeightedAverageExercisePrice_b3daa640-1ff2-4f44-8504-ff55e441ea4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTermRollForward_bee1dc63-954c-4983-a47b-8a5362f00fb7" xlink:href="angn-20211231.xsd#angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTermRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_WarrantsAndRightsOutstandingAbstract_9ac1842b-4674-44e5-a990-4b33755f7d17" xlink:to="loc_angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTermRollForward_bee1dc63-954c-4983-a47b-8a5362f00fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm_f8a5f451-4276-422e-bd5b-f66bffaac3b2" xlink:href="angn-20211231.xsd#angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTermRollForward_bee1dc63-954c-4983-a47b-8a5362f00fb7" xlink:to="loc_angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm_f8a5f451-4276-422e-bd5b-f66bffaac3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightExercisesInPeriodTendered_e41e90a0-ce8c-4e8d-9085-8f866c0e4580" xlink:href="angn-20211231.xsd#angn_ClassOfWarrantOrRightExercisesInPeriodTendered"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_WarrantsAndRightsOutstandingAbstract_9ac1842b-4674-44e5-a990-4b33755f7d17" xlink:to="loc_angn_ClassOfWarrantOrRightExercisesInPeriodTendered_e41e90a0-ce8c-4e8d-9085-8f866c0e4580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/WarrantsNarrativeDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#WarrantsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/WarrantsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsAndRightsOutstandingAbstract_ddda96d9-6d64-4702-b5e2-bbd88bf5d023" xlink:href="angn-20211231.xsd#angn_WarrantsAndRightsOutstandingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_571f3f25-1b98-42e4-ab30-289601dd4dea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_WarrantsAndRightsOutstandingAbstract_ddda96d9-6d64-4702-b5e2-bbd88bf5d023" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_571f3f25-1b98-42e4-ab30-289601dd4dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_23d19758-e254-42fd-8657-43c6d7974188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_571f3f25-1b98-42e4-ab30-289601dd4dea" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_23d19758-e254-42fd-8657-43c6d7974188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_b3a202a8-06cd-48c5-a549-e208afc41387" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_23d19758-e254-42fd-8657-43c6d7974188" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_b3a202a8-06cd-48c5-a549-e208afc41387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_WarrantsIssuedWith2015Notes2016Notes2017NotesAnd2018NotesMember_1eb0f06e-c0e4-4b2d-9c7a-0393f0bd5647" xlink:href="angn-20211231.xsd#angn_WarrantsIssuedWith2015Notes2016Notes2017NotesAnd2018NotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_b3a202a8-06cd-48c5-a549-e208afc41387" xlink:to="loc_angn_WarrantsIssuedWith2015Notes2016Notes2017NotesAnd2018NotesMember_1eb0f06e-c0e4-4b2d-9c7a-0393f0bd5647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0f928664-7f5e-4e80-ac75-d55906874e20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_571f3f25-1b98-42e4-ab30-289601dd4dea" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0f928664-7f5e-4e80-ac75-d55906874e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1839c263-2bcb-4fab-8793-ab903ea64c73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0f928664-7f5e-4e80-ac75-d55906874e20" xlink:to="loc_us-gaap_EquityComponentDomain_1839c263-2bcb-4fab-8793-ab903ea64c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4a605725-be8f-48f4-aa81-9b73ed281e64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1839c263-2bcb-4fab-8793-ab903ea64c73" xlink:to="loc_us-gaap_CommonStockMember_4a605725-be8f-48f4-aa81-9b73ed281e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_d74a98b2-9a76-4b1d-bb4c-be0abd059fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_571f3f25-1b98-42e4-ab30-289601dd4dea" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_d74a98b2-9a76-4b1d-bb4c-be0abd059fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5240b167-92bb-4886-865c-8f81d1724760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d74a98b2-9a76-4b1d-bb4c-be0abd059fc5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5240b167-92bb-4886-865c-8f81d1724760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_StockIssuedDuringPeriodSharesWarrantsExercised_c267cff9-c6fb-470b-bc02-6b1ab55dbef4" xlink:href="angn-20211231.xsd#angn_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d74a98b2-9a76-4b1d-bb4c-be0abd059fc5" xlink:to="loc_angn_StockIssuedDuringPeriodSharesWarrantsExercised_c267cff9-c6fb-470b-bc02-6b1ab55dbef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ClassOfWarrantOrRightConversionPrice_7760c689-603c-46e0-a3ff-5be2c0bf7503" xlink:href="angn-20211231.xsd#angn_ClassOfWarrantOrRightConversionPrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_d74a98b2-9a76-4b1d-bb4c-be0abd059fc5" xlink:to="loc_angn_ClassOfWarrantOrRightConversionPrice_7760c689-603c-46e0-a3ff-5be2c0bf7503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="angn-20211231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ffd1ae7f-cd27-43e3-b762-826796bd8d26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6f4deaf6-0dda-4006-949e-fee06fa4c7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ffd1ae7f-cd27-43e3-b762-826796bd8d26" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6f4deaf6-0dda-4006-949e-fee06fa4c7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="angn-20211231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8bc0f033-c466-455f-be16-f1443c5af853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_ed7aea4c-fc06-446e-934b-6e52072d2264" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8bc0f033-c466-455f-be16-f1443c5af853" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_ed7aea4c-fc06-446e-934b-6e52072d2264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock_44e698d7-6369-4252-bf38-2437178c1fe0" xlink:href="angn-20211231.xsd#angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8bc0f033-c466-455f-be16-f1443c5af853" xlink:to="loc_angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock_44e698d7-6369-4252-bf38-2437178c1fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_fff41760-45b3-4215-9b73-a405376ca642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8bc0f033-c466-455f-be16-f1443c5af853" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_fff41760-45b3-4215-9b73-a405376ca642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ScheduleOfQuantitativeInformationAboutTheFinancingObligationTableTextBlock_95455b20-8a08-4e38-bd65-fba2ceaf2780" xlink:href="angn-20211231.xsd#angn_ScheduleOfQuantitativeInformationAboutTheFinancingObligationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8bc0f033-c466-455f-be16-f1443c5af853" xlink:to="loc_angn_ScheduleOfQuantitativeInformationAboutTheFinancingObligationTableTextBlock_95455b20-8a08-4e38-bd65-fba2ceaf2780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_93c34a3d-b1bb-44f8-85dd-e565a7ba68eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8bc0f033-c466-455f-be16-f1443c5af853" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_93c34a3d-b1bb-44f8-85dd-e565a7ba68eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1ecd8f04-0cab-4408-8e39-a33706e29492" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_65dd333c-cee9-42b4-af8b-d088683887a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1ecd8f04-0cab-4408-8e39-a33706e29492" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_65dd333c-cee9-42b4-af8b-d088683887a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_e82ebc95-1f02-44ea-a288-318843bdc2ef" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_65dd333c-cee9-42b4-af8b-d088683887a2" xlink:to="loc_srt_StatementGeographicalAxis_e82ebc95-1f02-44ea-a288-318843bdc2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ec14f5d9-87aa-454d-9573-80adee3b3110" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_e82ebc95-1f02-44ea-a288-318843bdc2ef" xlink:to="loc_srt_SegmentGeographicalDomain_ec14f5d9-87aa-454d-9573-80adee3b3110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_936dc813-5bbf-4e76-8276-3bfbfacb7fa1" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ec14f5d9-87aa-454d-9573-80adee3b3110" xlink:to="loc_stpr_NJ_936dc813-5bbf-4e76-8276-3bfbfacb7fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_b1c44ae1-7026-4720-8bd9-d455aa43f62f" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ec14f5d9-87aa-454d-9573-80adee3b3110" xlink:to="loc_stpr_CA_b1c44ae1-7026-4720-8bd9-d455aa43f62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_43922eb2-f0f0-4a04-8090-74f94d1c4381" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_MA"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ec14f5d9-87aa-454d-9573-80adee3b3110" xlink:to="loc_stpr_MA_43922eb2-f0f0-4a04-8090-74f94d1c4381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_37cd0afa-8403-47f5-ac82-6ad06a1ea982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_65dd333c-cee9-42b4-af8b-d088683887a2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_37cd0afa-8403-47f5-ac82-6ad06a1ea982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5fba7e2f-355b-4e44-a626-649cab33bad1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_37cd0afa-8403-47f5-ac82-6ad06a1ea982" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5fba7e2f-355b-4e44-a626-649cab33bad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_e10544bd-9de2-410a-98b3-03bb78da0b47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5fba7e2f-355b-4e44-a626-649cab33bad1" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_e10544bd-9de2-410a-98b3-03bb78da0b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_66b0a2b9-a588-41fc-b5e5-4e74336ac2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_65dd333c-cee9-42b4-af8b-d088683887a2" xlink:to="loc_us-gaap_DebtInstrumentAxis_66b0a2b9-a588-41fc-b5e5-4e74336ac2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3c268186-1023-4ccb-b8b2-ec8bad00efc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_66b0a2b9-a588-41fc-b5e5-4e74336ac2d8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3c268186-1023-4ccb-b8b2-ec8bad00efc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PaycheckProtectionProgramCARESActMember_c7f3d142-35de-4a55-ab5c-b5a373198d9e" xlink:href="angn-20211231.xsd#angn_PaycheckProtectionProgramCARESActMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3c268186-1023-4ccb-b8b2-ec8bad00efc5" xlink:to="loc_angn_PaycheckProtectionProgramCARESActMember_c7f3d142-35de-4a55-ab5c-b5a373198d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_0f13ceaa-318d-4a04-bf4d-2a135c891666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_65dd333c-cee9-42b4-af8b-d088683887a2" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_0f13ceaa-318d-4a04-bf4d-2a135c891666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_b0c18d34-c07e-4ce8-b07b-1a883936bb6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0f13ceaa-318d-4a04-bf4d-2a135c891666" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_b0c18d34-c07e-4ce8-b07b-1a883936bb6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_LesseeOperatingLeaseAnnualRentExpense_bdb4397b-665b-46f1-98d2-fc9468990fc2" xlink:href="angn-20211231.xsd#angn_LesseeOperatingLeaseAnnualRentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0f13ceaa-318d-4a04-bf4d-2a135c891666" xlink:to="loc_angn_LesseeOperatingLeaseAnnualRentExpense_bdb4397b-665b-46f1-98d2-fc9468990fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_LesseeOperatingLeaseFreeRentExpensePeriod_f0e4fb4d-4c94-4f72-8801-633fd2e66819" xlink:href="angn-20211231.xsd#angn_LesseeOperatingLeaseFreeRentExpensePeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0f13ceaa-318d-4a04-bf4d-2a135c891666" xlink:to="loc_angn_LesseeOperatingLeaseFreeRentExpensePeriod_f0e4fb4d-4c94-4f72-8801-633fd2e66819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_LesseeOperatingLeaseNumberOfOptionsToExtend_1283cc32-1ca3-4a2a-9c86-f4bb290ac0b3" xlink:href="angn-20211231.xsd#angn_LesseeOperatingLeaseNumberOfOptionsToExtend"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0f13ceaa-318d-4a04-bf4d-2a135c891666" xlink:to="loc_angn_LesseeOperatingLeaseNumberOfOptionsToExtend_1283cc32-1ca3-4a2a-9c86-f4bb290ac0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b7276536-aab6-423f-a4a0-e7d7b11d3c29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0f13ceaa-318d-4a04-bf4d-2a135c891666" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_b7276536-aab6-423f-a4a0-e7d7b11d3c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_LesseeOperatingLeaseNoticePeriodForOptionToExtend_5789f2da-ad2c-4607-92d4-e06101252bf6" xlink:href="angn-20211231.xsd#angn_LesseeOperatingLeaseNoticePeriodForOptionToExtend"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0f13ceaa-318d-4a04-bf4d-2a135c891666" xlink:to="loc_angn_LesseeOperatingLeaseNoticePeriodForOptionToExtend_5789f2da-ad2c-4607-92d4-e06101252bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_8f583ca8-66ee-44b0-bf11-654f3a6203a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0f13ceaa-318d-4a04-bf4d-2a135c891666" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_8f583ca8-66ee-44b0-bf11-654f3a6203a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ProceedsFromFinancingObligation_6015c4cf-5350-43ff-80ae-be4393c3ca11" xlink:href="angn-20211231.xsd#angn_ProceedsFromFinancingObligation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0f13ceaa-318d-4a04-bf4d-2a135c891666" xlink:to="loc_angn_ProceedsFromFinancingObligation_6015c4cf-5350-43ff-80ae-be4393c3ca11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_6ae06101-4a6d-42fa-abf6-63678b7d2067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0f13ceaa-318d-4a04-bf4d-2a135c891666" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_6ae06101-4a6d-42fa-abf6-63678b7d2067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4c7b92e7-1f8d-40de-be55-ccce5ea93eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0f13ceaa-318d-4a04-bf4d-2a135c891666" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_4c7b92e7-1f8d-40de-be55-ccce5ea93eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_CARESActEmployeeRetentionCredit_f8502044-f759-4b22-949c-2f5c93410c3a" xlink:href="angn-20211231.xsd#angn_CARESActEmployeeRetentionCredit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0f13ceaa-318d-4a04-bf4d-2a135c891666" xlink:to="loc_angn_CARESActEmployeeRetentionCredit_f8502044-f759-4b22-949c-2f5c93410c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/CommitmentsandContingenciesScheduleofComponentsofRentExpenseDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#CommitmentsandContingenciesScheduleofComponentsofRentExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/CommitmentsandContingenciesScheduleofComponentsofRentExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e6c7279c-67bd-45aa-90a3-3400c2927c38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesOperatingAbstract_dcbe7dc4-ccd1-4805-b637-94f0de5072e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesOperatingAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e6c7279c-67bd-45aa-90a3-3400c2927c38" xlink:to="loc_us-gaap_LeasesOperatingAbstract_dcbe7dc4-ccd1-4805-b637-94f0de5072e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_f959f581-0348-4f35-b744-10de238f6a45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_dcbe7dc4-ccd1-4805-b637-94f0de5072e3" xlink:to="loc_us-gaap_OperatingLeaseCost_f959f581-0348-4f35-b744-10de238f6a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_3a10eb8d-a8f2-4988-acd1-bb3157b922e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_dcbe7dc4-ccd1-4805-b637-94f0de5072e3" xlink:to="loc_us-gaap_VariableLeaseCost_3a10eb8d-a8f2-4988-acd1-bb3157b922e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_f7fc3a0c-c36c-4208-8042-2a4d440d96e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e6c7279c-67bd-45aa-90a3-3400c2927c38" xlink:to="loc_us-gaap_OperatingLeaseExpense_f7fc3a0c-c36c-4208-8042-2a4d440d96e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_97353df8-cbfb-4f56-b7b8-3294f757d35c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e6c7279c-67bd-45aa-90a3-3400c2927c38" xlink:to="loc_us-gaap_ShortTermLeaseCost_97353df8-cbfb-4f56-b7b8-3294f757d35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_772d5a37-00be-41f3-b133-718457a2d303" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e6c7279c-67bd-45aa-90a3-3400c2927c38" xlink:to="loc_us-gaap_LeaseCost_772d5a37-00be-41f3-b133-718457a2d303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/CommitmentsandContingenciesScheduleofQuantitativeInformationaboutOperatingLeasesDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#CommitmentsandContingenciesScheduleofQuantitativeInformationaboutOperatingLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/CommitmentsandContingenciesScheduleofQuantitativeInformationaboutOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ef630638-b63e-48d4-aab3-0b35aba7b99d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_87758874-0b91-4c5d-8c14-b7fb9aba404d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ef630638-b63e-48d4-aab3-0b35aba7b99d" xlink:to="loc_us-gaap_OperatingLeasePayments_87758874-0b91-4c5d-8c14-b7fb9aba404d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_051b7b3a-0dc4-4e20-8ff9-cff8b64bca34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ef630638-b63e-48d4-aab3-0b35aba7b99d" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_051b7b3a-0dc4-4e20-8ff9-cff8b64bca34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5f0e7dd0-f7d3-4acf-9373-84deeb5ec5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ef630638-b63e-48d4-aab3-0b35aba7b99d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5f0e7dd0-f7d3-4acf-9373-84deeb5ec5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9d920eca-1f53-4d07-a085-40225a8f20a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ef630638-b63e-48d4-aab3-0b35aba7b99d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9d920eca-1f53-4d07-a085-40225a8f20a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c97ef2b7-64a0-4e9a-a729-c0866d5d55a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d648235c-e559-470f-9a26-f68690e01865" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c97ef2b7-64a0-4e9a-a729-c0866d5d55a9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d648235c-e559-470f-9a26-f68690e01865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b86893b4-f92e-4ac9-bd8a-ab9776580a17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c97ef2b7-64a0-4e9a-a729-c0866d5d55a9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b86893b4-f92e-4ac9-bd8a-ab9776580a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2dd2cb97-929c-4799-b915-b3e389ac1ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c97ef2b7-64a0-4e9a-a729-c0866d5d55a9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2dd2cb97-929c-4799-b915-b3e389ac1ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_981c7f19-3829-473c-a9ea-b5863b4930a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c97ef2b7-64a0-4e9a-a729-c0866d5d55a9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_981c7f19-3829-473c-a9ea-b5863b4930a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2a52e690-fde1-4425-b9a6-67925024f627" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c97ef2b7-64a0-4e9a-a729-c0866d5d55a9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2a52e690-fde1-4425-b9a6-67925024f627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_bac1a465-bc30-41c4-bdaa-158f2b38e062" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c97ef2b7-64a0-4e9a-a729-c0866d5d55a9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_bac1a465-bc30-41c4-bdaa-158f2b38e062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7f5b626e-876c-4c79-a6a3-1e02ad0b35ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c97ef2b7-64a0-4e9a-a729-c0866d5d55a9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7f5b626e-876c-4c79-a6a3-1e02ad0b35ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ca9c3f49-5585-4470-ae23-dd042b8bf463" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c97ef2b7-64a0-4e9a-a729-c0866d5d55a9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ca9c3f49-5585-4470-ae23-dd042b8bf463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0fd8b75c-d624-4e7f-9e8c-532618f0b5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c97ef2b7-64a0-4e9a-a729-c0866d5d55a9" xlink:to="loc_us-gaap_OperatingLeaseLiability_0fd8b75c-d624-4e7f-9e8c-532618f0b5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="angn-20211231.xsd#CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.angn.com/role/CommitmentsandContingenciesScheduleOfQuantitativeInformationAboutTheFinancingObligationDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#CommitmentsandContingenciesScheduleOfQuantitativeInformationAboutTheFinancingObligationDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/CommitmentsandContingenciesScheduleOfQuantitativeInformationAboutTheFinancingObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3cf1f686-4f48-4769-ba34-3e3c609db47f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_3bae2f82-024f-4741-a366-3d783c84231a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3cf1f686-4f48-4769-ba34-3e3c609db47f" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_3bae2f82-024f-4741-a366-3d783c84231a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2dc9ecd2-616d-40c2-8432-0c4cde79d6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3bae2f82-024f-4741-a366-3d783c84231a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2dc9ecd2-616d-40c2-8432-0c4cde79d6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dc5cc2a3-4662-41a4-b56e-ad44376da425" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2dc9ecd2-616d-40c2-8432-0c4cde79d6a9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dc5cc2a3-4662-41a4-b56e-ad44376da425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_f66d9cc6-16d5-465a-92dc-e64fb2a4150c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dc5cc2a3-4662-41a4-b56e-ad44376da425" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_f66d9cc6-16d5-465a-92dc-e64fb2a4150c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a92fad84-dc04-4e16-bdd1-89d47903ce13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_3bae2f82-024f-4741-a366-3d783c84231a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_a92fad84-dc04-4e16-bdd1-89d47903ce13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ProceedsFromFinancingObligation_eeb07618-a263-4521-ab90-d0fe86e60dd8" xlink:href="angn-20211231.xsd#angn_ProceedsFromFinancingObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a92fad84-dc04-4e16-bdd1-89d47903ce13" xlink:to="loc_angn_ProceedsFromFinancingObligation_eeb07618-a263-4521-ab90-d0fe86e60dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_c3b4fc0a-81f3-4bb5-bbb1-3b38a95de070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a92fad84-dc04-4e16-bdd1-89d47903ce13" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_c3b4fc0a-81f3-4bb5-bbb1-3b38a95de070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_210e246d-08a3-45e9-90ac-6d34db2a467e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a92fad84-dc04-4e16-bdd1-89d47903ce13" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_210e246d-08a3-45e9-90ac-6d34db2a467e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_f87cfcce-5a23-4a5f-bf1c-cb7fe5f8379b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a92fad84-dc04-4e16-bdd1-89d47903ce13" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_f87cfcce-5a23-4a5f-bf1c-cb7fe5f8379b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_feaf42ab-b929-41c6-877f-655256570519" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a92fad84-dc04-4e16-bdd1-89d47903ce13" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_feaf42ab-b929-41c6-877f-655256570519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_509970e5-9961-4325-8daf-5815f5201240" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a92fad84-dc04-4e16-bdd1-89d47903ce13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_509970e5-9961-4325-8daf-5815f5201240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_e891c38f-2cfb-40a6-93e1-478260975ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a92fad84-dc04-4e16-bdd1-89d47903ce13" xlink:to="loc_us-gaap_Depreciation_e891c38f-2cfb-40a6-93e1-478260975ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8a230290-45a5-45f0-9cc6-7316075f96b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_7f5016ac-7b4c-447e-94bf-9631f8cbe089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8a230290-45a5-45f0-9cc6-7316075f96b5" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_7f5016ac-7b4c-447e-94bf-9631f8cbe089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_0ca41e82-9997-45d9-ae00-a170d813e12f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8a230290-45a5-45f0-9cc6-7316075f96b5" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_0ca41e82-9997-45d9-ae00-a170d813e12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_c138bce2-566d-4b14-89d5-940a8a6fd133" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8a230290-45a5-45f0-9cc6-7316075f96b5" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_c138bce2-566d-4b14-89d5-940a8a6fd133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_cf474fda-8b57-4cc5-99df-4b5eb27d74b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8a230290-45a5-45f0-9cc6-7316075f96b5" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_cf474fda-8b57-4cc5-99df-4b5eb27d74b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_1aa2b1ed-d3e5-4871-a4a4-afeeb6fd2026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8a230290-45a5-45f0-9cc6-7316075f96b5" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_1aa2b1ed-d3e5-4871-a4a4-afeeb6fd2026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_4d0dc890-04f7-4494-99fd-28198e0ce26d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8a230290-45a5-45f0-9cc6-7316075f96b5" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_4d0dc890-04f7-4494-99fd-28198e0ce26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_1ce278b9-4421-42c7-9d56-d2d87912222f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8a230290-45a5-45f0-9cc6-7316075f96b5" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_1ce278b9-4421-42c7-9d56-d2d87912222f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_a072462a-4849-49ae-aa28-703ae210ac9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8a230290-45a5-45f0-9cc6-7316075f96b5" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_a072462a-4849-49ae-aa28-703ae210ac9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_08f46bae-e146-4c0a-bd31-d61c9f70fe39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8a230290-45a5-45f0-9cc6-7316075f96b5" xlink:to="loc_us-gaap_FinanceLeaseLiability_08f46bae-e146-4c0a-bd31-d61c9f70fe39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails_1" xlink:type="simple" xlink:href="angn-20211231.xsd#CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails_1"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.angn.com/role/IncomeTaxes" xlink:type="simple" xlink:href="angn-20211231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7abd5330-c445-4dff-a0b3-7388a110f369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_3b3e622b-e341-40f2-87d1-1a6cd1e8d053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7abd5330-c445-4dff-a0b3-7388a110f369" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_3b3e622b-e341-40f2-87d1-1a6cd1e8d053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="angn-20211231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_179e7d9f-a907-401e-8ecf-754caa34f1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_3f32c312-f8b1-4394-9774-d208e4f7b77f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_179e7d9f-a907-401e-8ecf-754caa34f1bb" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_3f32c312-f8b1-4394-9774-d208e4f7b77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_52a4acd8-ee42-4f1c-bfd6-b78cb027e60b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_179e7d9f-a907-401e-8ecf-754caa34f1bb" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_52a4acd8-ee42-4f1c-bfd6-b78cb027e60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_a09f98cc-87b9-4ce4-be75-99a44b094288" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_179e7d9f-a907-401e-8ecf-754caa34f1bb" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_a09f98cc-87b9-4ce4-be75-99a44b094288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_d0bc8ac5-d100-4c19-935f-148c569bd742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_179e7d9f-a907-401e-8ecf-754caa34f1bb" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_d0bc8ac5-d100-4c19-935f-148c569bd742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_59c3bab8-e16a-45da-aefd-f97cc212776d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_179e7d9f-a907-401e-8ecf-754caa34f1bb" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_59c3bab8-e16a-45da-aefd-f97cc212776d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_UnrecognizedTaxBenefitsIfRecognizedWouldAffectTheEffectiveTaxRateTableTextBlock_2ac42ce1-cd16-43ab-bd9e-0277943e92f4" xlink:href="angn-20211231.xsd#angn_UnrecognizedTaxBenefitsIfRecognizedWouldAffectTheEffectiveTaxRateTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_179e7d9f-a907-401e-8ecf-754caa34f1bb" xlink:to="loc_angn_UnrecognizedTaxBenefitsIfRecognizedWouldAffectTheEffectiveTaxRateTableTextBlock_2ac42ce1-cd16-43ab-bd9e-0277943e92f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_07d07e4c-744b-426a-8179-efa3a5b36ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_989ea9fd-312e-4595-b126-baa44f121ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_07d07e4c-744b-426a-8179-efa3a5b36ed1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_989ea9fd-312e-4595-b126-baa44f121ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_fb79637b-4adc-4206-996f-9abb95a6b230" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_07d07e4c-744b-426a-8179-efa3a5b36ed1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_fb79637b-4adc-4206-996f-9abb95a6b230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_7c3ef99d-51e6-43bd-9982-4bee1dfec685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_07d07e4c-744b-426a-8179-efa3a5b36ed1" xlink:to="loc_us-gaap_OperatingLossCarryforwards_7c3ef99d-51e6-43bd-9982-4bee1dfec685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OperatingLossCarryforwardSubjectToExpiration_31823f47-2439-41dc-8358-60be61ea1455" xlink:href="angn-20211231.xsd#angn_OperatingLossCarryforwardSubjectToExpiration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_07d07e4c-744b-426a-8179-efa3a5b36ed1" xlink:to="loc_angn_OperatingLossCarryforwardSubjectToExpiration_31823f47-2439-41dc-8358-60be61ea1455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OperatingLossCarryforwardNotSubjectToExpiration_eedc1bcb-d381-4dc9-8ac3-2b79c77fcc31" xlink:href="angn-20211231.xsd#angn_OperatingLossCarryforwardNotSubjectToExpiration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_07d07e4c-744b-426a-8179-efa3a5b36ed1" xlink:to="loc_angn_OperatingLossCarryforwardNotSubjectToExpiration_eedc1bcb-d381-4dc9-8ac3-2b79c77fcc31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_bc571d8c-61c9-4062-9a8f-6b43b9243518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_07d07e4c-744b-426a-8179-efa3a5b36ed1" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_bc571d8c-61c9-4062-9a8f-6b43b9243518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/IncomeTaxesScheduleofIncomebeforeIncomeTaxDomesticandForeignDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#IncomeTaxesScheduleofIncomebeforeIncomeTaxDomesticandForeignDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/IncomeTaxesScheduleofIncomebeforeIncomeTaxDomesticandForeignDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_49a651a6-267d-42ca-8a4b-15194c8cd2e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_48b638dd-0817-4176-bcda-f436e7af7cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_49a651a6-267d-42ca-8a4b-15194c8cd2e7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_48b638dd-0817-4176-bcda-f436e7af7cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_11cd66e6-58d1-4bc0-add1-08fb9bc88ede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_49a651a6-267d-42ca-8a4b-15194c8cd2e7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_11cd66e6-58d1-4bc0-add1-08fb9bc88ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5bc8071f-5a58-4332-a646-92f30843f703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_49a651a6-267d-42ca-8a4b-15194c8cd2e7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5bc8071f-5a58-4332-a646-92f30843f703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_24e78517-b53c-45df-95da-25f143aaf711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_daf0e97f-72a5-4de4-ab2e-78835cef8ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_24e78517-b53c-45df-95da-25f143aaf711" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_daf0e97f-72a5-4de4-ab2e-78835cef8ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_87d4928b-c8bb-48e5-85d1-a0491a44e6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_daf0e97f-72a5-4de4-ab2e-78835cef8ccb" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_87d4928b-c8bb-48e5-85d1-a0491a44e6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b7ce3ff9-717d-4836-baca-787b059833ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_daf0e97f-72a5-4de4-ab2e-78835cef8ccb" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_b7ce3ff9-717d-4836-baca-787b059833ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_325d2b9e-5c8b-499e-856b-d46d9eaf12ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_daf0e97f-72a5-4de4-ab2e-78835cef8ccb" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_325d2b9e-5c8b-499e-856b-d46d9eaf12ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_21ddd09d-5a90-44c5-9c81-2af19ce01a14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_daf0e97f-72a5-4de4-ab2e-78835cef8ccb" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_21ddd09d-5a90-44c5-9c81-2af19ce01a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_d59c8686-bb6e-4ab0-951d-6cd39418cdac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_24e78517-b53c-45df-95da-25f143aaf711" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_d59c8686-bb6e-4ab0-951d-6cd39418cdac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_952e58d5-2880-4cf4-8792-7c32385e7fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_d59c8686-bb6e-4ab0-951d-6cd39418cdac" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_952e58d5-2880-4cf4-8792-7c32385e7fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_f8294753-ffb3-44bb-85bd-22e385ec3029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_d59c8686-bb6e-4ab0-951d-6cd39418cdac" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_f8294753-ffb3-44bb-85bd-22e385ec3029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_862c423e-4d56-4170-b311-dcda8a99daf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_d59c8686-bb6e-4ab0-951d-6cd39418cdac" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_862c423e-4d56-4170-b311-dcda8a99daf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b5fa1d38-42ad-483e-8cf6-ad3f522a908d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_d59c8686-bb6e-4ab0-951d-6cd39418cdac" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b5fa1d38-42ad-483e-8cf6-ad3f522a908d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f2c7a692-40b0-4b2f-b5c8-9ccb1ade12e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_24e78517-b53c-45df-95da-25f143aaf711" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f2c7a692-40b0-4b2f-b5c8-9ccb1ade12e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2ec14d05-7a43-4542-9a75-d6ba065df554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2236299d-6254-4a9a-9b54-42c61040ddd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2ec14d05-7a43-4542-9a75-d6ba065df554" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2236299d-6254-4a9a-9b54-42c61040ddd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_6d7153c5-33ad-4f79-9cc6-9a5b2fb185de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2ec14d05-7a43-4542-9a75-d6ba065df554" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_6d7153c5-33ad-4f79-9cc6-9a5b2fb185de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_f5703186-c4aa-4a6b-8278-f0d7c495bef5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2ec14d05-7a43-4542-9a75-d6ba065df554" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_f5703186-c4aa-4a6b-8278-f0d7c495bef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_dcfba415-af28-4834-9ff4-45c68ce03781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2ec14d05-7a43-4542-9a75-d6ba065df554" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_dcfba415-af28-4834-9ff4-45c68ce03781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EffectiveIncomeTaxRateReconciliationInterestPercent_1df12b5c-ff0d-450d-bda9-7766c3440c0c" xlink:href="angn-20211231.xsd#angn_EffectiveIncomeTaxRateReconciliationInterestPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2ec14d05-7a43-4542-9a75-d6ba065df554" xlink:to="loc_angn_EffectiveIncomeTaxRateReconciliationInterestPercent_1df12b5c-ff0d-450d-bda9-7766c3440c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_c589a67b-142d-45a2-be3d-77f19f4a7f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2ec14d05-7a43-4542-9a75-d6ba065df554" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_c589a67b-142d-45a2-be3d-77f19f4a7f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent_dec7f51e-8f78-4a10-b428-9229200f89ff" xlink:href="angn-20211231.xsd#angn_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2ec14d05-7a43-4542-9a75-d6ba065df554" xlink:to="loc_angn_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent_dec7f51e-8f78-4a10-b428-9229200f89ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_4a031bd8-90e6-4b46-9f7f-8d44d5d95502" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2ec14d05-7a43-4542-9a75-d6ba065df554" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome_4a031bd8-90e6-4b46-9f7f-8d44d5d95502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_8a8e2ec2-a0ca-4208-b038-fc96d84f8742" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2ec14d05-7a43-4542-9a75-d6ba065df554" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_8a8e2ec2-a0ca-4208-b038-fc96d84f8742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_da5b46e5-c26d-4cd5-8d1d-24b29f0be7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2ec14d05-7a43-4542-9a75-d6ba065df554" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_da5b46e5-c26d-4cd5-8d1d-24b29f0be7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3b46804f-8749-402e-b61b-0a709a5ae4ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2ec14d05-7a43-4542-9a75-d6ba065df554" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3b46804f-8749-402e-b61b-0a709a5ae4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_afc15cb0-1195-4a48-8b6a-061fec3a4691" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_16c207ce-7c29-4de9-a437-a85d12f6d5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_afc15cb0-1195-4a48-8b6a-061fec3a4691" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_16c207ce-7c29-4de9-a437-a85d12f6d5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_48512469-a351-4835-92b6-bbb30f219db7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_16c207ce-7c29-4de9-a437-a85d12f6d5ff" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_48512469-a351-4835-92b6-bbb30f219db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_295bd9cd-2d4d-4e99-9ce7-afc27cab4e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_16c207ce-7c29-4de9-a437-a85d12f6d5ff" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_295bd9cd-2d4d-4e99-9ce7-afc27cab4e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_DeferredTaxAssetsOperatingLeaseLiability_537fc5f3-5585-4c8e-8a94-92a301da60f9" xlink:href="angn-20211231.xsd#angn_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_16c207ce-7c29-4de9-a437-a85d12f6d5ff" xlink:to="loc_angn_DeferredTaxAssetsOperatingLeaseLiability_537fc5f3-5585-4c8e-8a94-92a301da60f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_69fa92a2-206b-475c-bb13-53af37966dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_16c207ce-7c29-4de9-a437-a85d12f6d5ff" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_69fa92a2-206b-475c-bb13-53af37966dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_21f3f07e-47d3-4cf4-928e-f0953d727511" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_16c207ce-7c29-4de9-a437-a85d12f6d5ff" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_21f3f07e-47d3-4cf4-928e-f0953d727511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_4d797cfa-cb72-4140-8f66-683a38c1da7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_16c207ce-7c29-4de9-a437-a85d12f6d5ff" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_4d797cfa-cb72-4140-8f66-683a38c1da7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_ab8742a5-c48a-488b-b750-588259d5a046" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_16c207ce-7c29-4de9-a437-a85d12f6d5ff" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_ab8742a5-c48a-488b-b750-588259d5a046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_3dd0a011-06d3-4178-a12f-4478c0d276d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_afc15cb0-1195-4a48-8b6a-061fec3a4691" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_3dd0a011-06d3-4178-a12f-4478c0d276d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_cb57d106-94e7-424b-bb5d-b365be9cec4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_3dd0a011-06d3-4178-a12f-4478c0d276d0" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_cb57d106-94e7-424b-bb5d-b365be9cec4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_8f9010a2-e003-47c3-9e70-9b2c931c7c81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_3dd0a011-06d3-4178-a12f-4478c0d276d0" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_8f9010a2-e003-47c3-9e70-9b2c931c7c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_bdec2947-670f-4e23-a442-a75f51818c02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_afc15cb0-1195-4a48-8b6a-061fec3a4691" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_bdec2947-670f-4e23-a442-a75f51818c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_aa7bc56e-8338-4d3e-b84c-4a1487b97df3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_afc15cb0-1195-4a48-8b6a-061fec3a4691" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_aa7bc56e-8338-4d3e-b84c-4a1487b97df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3aeb5908-5bba-49c9-912a-985216c16326" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_64c5af27-70f7-4321-b45e-fd86f7b64309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3aeb5908-5bba-49c9-912a-985216c16326" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_64c5af27-70f7-4321-b45e-fd86f7b64309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_a67210de-9393-4e97-b352-7a5a3134464e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_64c5af27-70f7-4321-b45e-fd86f7b64309" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_a67210de-9393-4e97-b352-7a5a3134464e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_c86827d3-0382-4e9d-8222-d75e7887ef4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_64c5af27-70f7-4321-b45e-fd86f7b64309" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_c86827d3-0382-4e9d-8222-d75e7887ef4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_3869fcd9-55dd-4166-ae11-e1750e0d5511" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_64c5af27-70f7-4321-b45e-fd86f7b64309" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_3869fcd9-55dd-4166-ae11-e1750e0d5511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_b6b5c383-09f1-4176-b6b9-a308d2aee0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_64c5af27-70f7-4321-b45e-fd86f7b64309" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_b6b5c383-09f1-4176-b6b9-a308d2aee0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/IncomeTaxesUnrecognizedTaxBenefitsIfRecognizedWouldAffecttheEffectiveTaxRateDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#IncomeTaxesUnrecognizedTaxBenefitsIfRecognizedWouldAffecttheEffectiveTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/IncomeTaxesUnrecognizedTaxBenefitsIfRecognizedWouldAffecttheEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_16b722df-5116-435b-9a53-d743d9db6e92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_876b79a8-cf81-4482-8774-d08b5e1c17d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_16b722df-5116-435b-9a53-d743d9db6e92" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_876b79a8-cf81-4482-8774-d08b5e1c17d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_032dd564-31da-4d04-bc49-c8eb94845bd5" xlink:href="angn-20211231.xsd#angn_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_16b722df-5116-435b-9a53-d743d9db6e92" xlink:to="loc_angn_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate_032dd564-31da-4d04-bc49-c8eb94845bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_7c800f24-de4e-4fdf-bdd4-e613abb5a28c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_16b722df-5116-435b-9a53-d743d9db6e92" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_7c800f24-de4e-4fdf-bdd4-e613abb5a28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="angn-20211231.xsd#EmployeeBenefitPlan"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e91a3d1b-2adf-4c06-8d27-cad6175692cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTextBlock_f8d9d0e2-fbd7-45df-9970-5605f70cc522" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e91a3d1b-2adf-4c06-8d27-cad6175692cf" xlink:to="loc_us-gaap_DefinedContributionPlanTextBlock_f8d9d0e2-fbd7-45df-9970-5605f70cc522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/EmployeeBenefitPlanNarrativeDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#EmployeeBenefitPlanNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/EmployeeBenefitPlanNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_7c9b0b07-3c89-4bad-9745-f4dc0d06df60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable_cdaa379a-b34e-4e53-809b-dab3153cb879" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_7c9b0b07-3c89-4bad-9745-f4dc0d06df60" xlink:to="loc_us-gaap_DefinedContributionPlanTable_cdaa379a-b34e-4e53-809b-dab3153cb879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9732361b-c052-4646-b14a-8da0837aed6e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_cdaa379a-b34e-4e53-809b-dab3153cb879" xlink:to="loc_srt_RangeAxis_9732361b-c052-4646-b14a-8da0837aed6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c15c7268-ff91-439c-8008-81a0ffd38d1e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9732361b-c052-4646-b14a-8da0837aed6e" xlink:to="loc_srt_RangeMember_c15c7268-ff91-439c-8008-81a0ffd38d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5055de20-a75d-4583-9e73-9761b1199325" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c15c7268-ff91-439c-8008-81a0ffd38d1e" xlink:to="loc_srt_MinimumMember_5055de20-a75d-4583-9e73-9761b1199325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0811ecd2-f90b-4a2b-b042-bfcda5506309" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c15c7268-ff91-439c-8008-81a0ffd38d1e" xlink:to="loc_srt_MaximumMember_0811ecd2-f90b-4a2b-b042-bfcda5506309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_974ad4a5-7e89-4973-a863-7aa8b63dce35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_cdaa379a-b34e-4e53-809b-dab3153cb879" xlink:to="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_974ad4a5-7e89-4973-a863-7aa8b63dce35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_af2ecaa2-82b5-433b-93af-397a9ac25bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_974ad4a5-7e89-4973-a863-7aa8b63dce35" xlink:to="loc_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_af2ecaa2-82b5-433b-93af-397a9ac25bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayOneHundredPercentEmployerMatch_16b190c2-3088-42cc-84f9-1fa851b6e959" xlink:href="angn-20211231.xsd#angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayOneHundredPercentEmployerMatch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_974ad4a5-7e89-4973-a863-7aa8b63dce35" xlink:to="loc_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayOneHundredPercentEmployerMatch_16b190c2-3088-42cc-84f9-1fa851b6e959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayFiftyPercentEmployerMatch_107d9d80-d155-4a91-b521-76a020bb148f" xlink:href="angn-20211231.xsd#angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayFiftyPercentEmployerMatch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_974ad4a5-7e89-4973-a863-7aa8b63dce35" xlink:to="loc_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayFiftyPercentEmployerMatch_107d9d80-d155-4a91-b521-76a020bb148f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/NetLossPerShare" xlink:type="simple" xlink:href="angn-20211231.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_43b58012-5677-4eaa-83d8-31ae24b959b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_c9c059ff-5cbf-4244-9524-c263db7455c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_43b58012-5677-4eaa-83d8-31ae24b959b2" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_c9c059ff-5cbf-4244-9524-c263db7455c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="angn-20211231.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_42cc9e27-3a6c-4545-b1f6-735fcca0f263" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2cba6258-03c3-4465-8b4c-b9a81e77aede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_42cc9e27-3a6c-4545-b1f6-735fcca0f263" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2cba6258-03c3-4465-8b4c-b9a81e77aede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ea843a3b-a944-4a89-9c5c-975cf9daef72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_42cc9e27-3a6c-4545-b1f6-735fcca0f263" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ea843a3b-a944-4a89-9c5c-975cf9daef72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/NetLossPerShareScheduleofnetlosspersharebasicanddilutedDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#NetLossPerShareScheduleofnetlosspersharebasicanddilutedDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/NetLossPerShareScheduleofnetlosspersharebasicanddilutedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_56026e43-b619-43bb-b1fa-96625402a4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_447609bd-ddb2-464f-9872-61deb9989a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_56026e43-b619-43bb-b1fa-96625402a4a0" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_447609bd-ddb2-464f-9872-61deb9989a2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d02bc3ee-af22-403a-a466-5c716236bdf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_447609bd-ddb2-464f-9872-61deb9989a2b" xlink:to="loc_us-gaap_NetIncomeLoss_d02bc3ee-af22-403a-a466-5c716236bdf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_f97ffa12-841c-414e-a60d-93a0b544efe8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_56026e43-b619-43bb-b1fa-96625402a4a0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_f97ffa12-841c-414e-a60d-93a0b544efe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_860ee301-392e-450c-8ea0-52097846848c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_f97ffa12-841c-414e-a60d-93a0b544efe8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_860ee301-392e-450c-8ea0-52097846848c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ac50a499-186b-4300-ae12-b3615916e745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_f97ffa12-841c-414e-a60d-93a0b544efe8" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ac50a499-186b-4300-ae12-b3615916e745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_892178d7-7f45-4b3f-992a-ab7d6602e1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_f97ffa12-841c-414e-a60d-93a0b544efe8" xlink:to="loc_us-gaap_EarningsPerShareBasic_892178d7-7f45-4b3f-992a-ab7d6602e1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9a5c31ff-0922-48b8-bf44-4965c1ecb82d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_f97ffa12-841c-414e-a60d-93a0b544efe8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9a5c31ff-0922-48b8-bf44-4965c1ecb82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/NetLossPerShareScheduleofantidilutivesecuritiesexcludedfromcomputationofnetlosspershareDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#NetLossPerShareScheduleofantidilutivesecuritiesexcludedfromcomputationofnetlosspershareDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/NetLossPerShareScheduleofantidilutivesecuritiesexcludedfromcomputationofnetlosspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8071c82e-b0d6-479d-be4c-fcef946b2ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8a7a98f2-c5b0-460a-b718-20ccd69bea19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8071c82e-b0d6-479d-be4c-fcef946b2ff6" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8a7a98f2-c5b0-460a-b718-20ccd69bea19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7fe47d35-5aae-4a5d-90bb-0063a269563c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8a7a98f2-c5b0-460a-b718-20ccd69bea19" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7fe47d35-5aae-4a5d-90bb-0063a269563c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23aa28bc-53b5-4fd0-b168-e314a8be6623" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7fe47d35-5aae-4a5d-90bb-0063a269563c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23aa28bc-53b5-4fd0-b168-e314a8be6623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d2a2fc87-6193-494c-8a35-6d9656cc7193" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23aa28bc-53b5-4fd0-b168-e314a8be6623" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d2a2fc87-6193-494c-8a35-6d9656cc7193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_2572d32e-f8b2-4595-86ab-3737301af8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23aa28bc-53b5-4fd0-b168-e314a8be6623" xlink:to="loc_us-gaap_WarrantMember_2572d32e-f8b2-4595-86ab-3737301af8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_1a5fee0e-5b70-4ff0-a2f6-7b5ec4006ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23aa28bc-53b5-4fd0-b168-e314a8be6623" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_1a5fee0e-5b70-4ff0-a2f6-7b5ec4006ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_1eb0524b-a807-436d-8dd1-704ab3c97ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23aa28bc-53b5-4fd0-b168-e314a8be6623" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_1eb0524b-a807-436d-8dd1-704ab3c97ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d93d6ca2-c303-4656-b11c-cc1ef19ba781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23aa28bc-53b5-4fd0-b168-e314a8be6623" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d93d6ca2-c303-4656-b11c-cc1ef19ba781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_853d3efc-08b1-4d84-b38e-e14993d8df6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_23aa28bc-53b5-4fd0-b168-e314a8be6623" xlink:to="loc_us-gaap_RestrictedStockMember_853d3efc-08b1-4d84-b38e-e14993d8df6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_03750ea6-0cf9-4c3a-9742-cdc72d1ffd66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8a7a98f2-c5b0-460a-b718-20ccd69bea19" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_03750ea6-0cf9-4c3a-9742-cdc72d1ffd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_addb9456-e804-4c19-b65e-34f9377e612f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_03750ea6-0cf9-4c3a-9742-cdc72d1ffd66" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_addb9456-e804-4c19-b65e-34f9377e612f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_SharesIssuableUponConversionOfConvertibleNotesDiscountRate_95b4084a-22e2-4c9c-8b8e-c384d43dd626" xlink:href="angn-20211231.xsd#angn_SharesIssuableUponConversionOfConvertibleNotesDiscountRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_03750ea6-0cf9-4c3a-9742-cdc72d1ffd66" xlink:to="loc_angn_SharesIssuableUponConversionOfConvertibleNotesDiscountRate_95b4084a-22e2-4c9c-8b8e-c384d43dd626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="angn-20211231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_4601efb3-c16b-408e-9ff0-45a3ac2f62a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_c55dcb38-74ea-4441-83e8-879ec2b7fb6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_4601efb3-c16b-408e-9ff0-45a3ac2f62a5" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_c55dcb38-74ea-4441-83e8-879ec2b7fb6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/RelatedPartyTransactionsTables" xlink:type="simple" xlink:href="angn-20211231.xsd#RelatedPartyTransactionsTables"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_9164ec74-d16a-431e-bb77-f844076a3401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_d6020e5e-92c0-4281-ae51-2992f1cf4419" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_9164ec74-d16a-431e-bb77-f844076a3401" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_d6020e5e-92c0-4281-ae51-2992f1cf4419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#RelatedPartyTransactionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_6572ac2c-f742-4cce-8380-54e5b70405af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f26d506d-f89f-4b29-8987-de66cff245b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_6572ac2c-f742-4cce-8380-54e5b70405af" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f26d506d-f89f-4b29-8987-de66cff245b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fae1a148-ed31-4a64-bd0d-9429c342c8e3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f26d506d-f89f-4b29-8987-de66cff245b8" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fae1a148-ed31-4a64-bd0d-9429c342c8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_3ccd8773-f8f0-48fc-8040-150e3d8f23b8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_fae1a148-ed31-4a64-bd0d-9429c342c8e3" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_3ccd8773-f8f0-48fc-8040-150e3d8f23b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OhrCosmeticsLLCMember_c222fbfe-10bf-40d0-8a23-49f3f8746d10" xlink:href="angn-20211231.xsd#angn_OhrCosmeticsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_3ccd8773-f8f0-48fc-8040-150e3d8f23b8" xlink:to="loc_angn_OhrCosmeticsLLCMember_c222fbfe-10bf-40d0-8a23-49f3f8746d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NovaParkMember_bfc034a8-2e58-46f8-9bb5-abebdf4dfa2c" xlink:href="angn-20211231.xsd#angn_NovaParkMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_3ccd8773-f8f0-48fc-8040-150e3d8f23b8" xlink:to="loc_angn_NovaParkMember_bfc034a8-2e58-46f8-9bb5-abebdf4dfa2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_54ffe575-ea9b-414a-966a-0677571ecee3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f26d506d-f89f-4b29-8987-de66cff245b8" xlink:to="loc_srt_OwnershipAxis_54ffe575-ea9b-414a-966a-0677571ecee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_31dc0be8-fc91-4f50-8b38-2c2557b735f9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_54ffe575-ea9b-414a-966a-0677571ecee3" xlink:to="loc_srt_OwnershipDomain_31dc0be8-fc91-4f50-8b38-2c2557b735f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OhrCosmeticsLLCMember_2acfcef1-1b00-44b1-b137-f2f5eaa899b7" xlink:href="angn-20211231.xsd#angn_OhrCosmeticsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_31dc0be8-fc91-4f50-8b38-2c2557b735f9" xlink:to="loc_angn_OhrCosmeticsLLCMember_2acfcef1-1b00-44b1-b137-f2f5eaa899b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3234f323-fb3b-4a7b-9c2f-2f3576014fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f26d506d-f89f-4b29-8987-de66cff245b8" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3234f323-fb3b-4a7b-9c2f-2f3576014fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9488da80-d810-45b9-bd9c-9abc6549d535" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3234f323-fb3b-4a7b-9c2f-2f3576014fb1" xlink:to="loc_us-gaap_RelatedPartyDomain_9488da80-d810-45b9-bd9c-9abc6549d535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_4183eb81-ede4-4278-8b0c-d16d6a50c2e7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9488da80-d810-45b9-bd9c-9abc6549d535" xlink:to="loc_srt_AffiliatedEntityMember_4183eb81-ede4-4278-8b0c-d16d6a50c2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember_0e21b74d-37b1-4619-a353-4ac093b9c066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9488da80-d810-45b9-bd9c-9abc6549d535" xlink:to="loc_us-gaap_EquityMethodInvesteeMember_0e21b74d-37b1-4619-a353-4ac093b9c066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_DirectorsAndFamilyMemberOfChiefExecutiveOfficerDirectorMember_7fbcb653-1b21-42b1-8ef9-06983ba4c351" xlink:href="angn-20211231.xsd#angn_DirectorsAndFamilyMemberOfChiefExecutiveOfficerDirectorMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9488da80-d810-45b9-bd9c-9abc6549d535" xlink:to="loc_angn_DirectorsAndFamilyMemberOfChiefExecutiveOfficerDirectorMember_7fbcb653-1b21-42b1-8ef9-06983ba4c351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_PresidentAndChiefExecutiveOfficerAndDirectorMember_b78bc384-f8a0-45cf-80a7-2101cede95d4" xlink:href="angn-20211231.xsd#angn_PresidentAndChiefExecutiveOfficerAndDirectorMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9488da80-d810-45b9-bd9c-9abc6549d535" xlink:to="loc_angn_PresidentAndChiefExecutiveOfficerAndDirectorMember_b78bc384-f8a0-45cf-80a7-2101cede95d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_b8f63c43-bc8e-4593-9a8f-efac4cb3e5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9488da80-d810-45b9-bd9c-9abc6549d535" xlink:to="loc_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_b8f63c43-bc8e-4593-9a8f-efac4cb3e5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_FormerMemberOfTheBoardOfDirectorsMember_c4180c75-c3e8-4683-b202-7d09d5dd50a3" xlink:href="angn-20211231.xsd#angn_FormerMemberOfTheBoardOfDirectorsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9488da80-d810-45b9-bd9c-9abc6549d535" xlink:to="loc_angn_FormerMemberOfTheBoardOfDirectorsMember_c4180c75-c3e8-4683-b202-7d09d5dd50a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_12e0215f-9cc8-4d64-857d-5a875e251bbb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f26d506d-f89f-4b29-8987-de66cff245b8" xlink:to="loc_dei_LegalEntityAxis_12e0215f-9cc8-4d64-857d-5a875e251bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_155b1105-278b-4bb3-acae-0d9e66c04d56" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_12e0215f-9cc8-4d64-857d-5a875e251bbb" xlink:to="loc_dei_EntityDomain_155b1105-278b-4bb3-acae-0d9e66c04d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ImmediateFamilyOfDirectorAndChairmanMember_2f5bb385-ae33-4176-b28d-b35cb0b67f4d" xlink:href="angn-20211231.xsd#angn_ImmediateFamilyOfDirectorAndChairmanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_155b1105-278b-4bb3-acae-0d9e66c04d56" xlink:to="loc_angn_ImmediateFamilyOfDirectorAndChairmanMember_2f5bb385-ae33-4176-b28d-b35cb0b67f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NovaParkMember_8fe7dbb5-8684-47d1-bf76-2e40014d514a" xlink:href="angn-20211231.xsd#angn_NovaParkMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_155b1105-278b-4bb3-acae-0d9e66c04d56" xlink:to="loc_angn_NovaParkMember_8fe7dbb5-8684-47d1-bf76-2e40014d514a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_d755ef3c-7b13-43a6-88ff-8cc0aeb7ded0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f26d506d-f89f-4b29-8987-de66cff245b8" xlink:to="loc_srt_TitleOfIndividualAxis_d755ef3c-7b13-43a6-88ff-8cc0aeb7ded0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7d0f2800-17a3-4d01-83c3-5245feade08e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_d755ef3c-7b13-43a6-88ff-8cc0aeb7ded0" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7d0f2800-17a3-4d01-83c3-5245feade08e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_95d894b9-a4f3-44a5-89f5-73807c8c18c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7d0f2800-17a3-4d01-83c3-5245feade08e" xlink:to="loc_srt_ChiefExecutiveOfficerMember_95d894b9-a4f3-44a5-89f5-73807c8c18c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c64d3623-92d3-4818-979c-bb71b70e36dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f26d506d-f89f-4b29-8987-de66cff245b8" xlink:to="loc_srt_CounterpartyNameAxis_c64d3623-92d3-4818-979c-bb71b70e36dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8bb50d2d-daa5-4759-aab9-114b3f1203ef" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c64d3623-92d3-4818-979c-bb71b70e36dd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8bb50d2d-daa5-4759-aab9-114b3f1203ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OhrCosmeticsLLCMember_48a4f66d-503c-491b-9877-efb50bad007e" xlink:href="angn-20211231.xsd#angn_OhrCosmeticsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8bb50d2d-daa5-4759-aab9-114b3f1203ef" xlink:to="loc_angn_OhrCosmeticsLLCMember_48a4f66d-503c-491b-9877-efb50bad007e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NovaParkMember_4700d4b3-dede-4b91-86f9-45c2c2359ea6" xlink:href="angn-20211231.xsd#angn_NovaParkMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8bb50d2d-daa5-4759-aab9-114b3f1203ef" xlink:to="loc_angn_NovaParkMember_4700d4b3-dede-4b91-86f9-45c2c2359ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_67b7be91-d7c3-4f6b-8d64-4664caefd886" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f26d506d-f89f-4b29-8987-de66cff245b8" xlink:to="loc_srt_ProductOrServiceAxis_67b7be91-d7c3-4f6b-8d64-4664caefd886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1affab63-4904-4d47-a56a-fbced79d94ad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_67b7be91-d7c3-4f6b-8d64-4664caefd886" xlink:to="loc_srt_ProductsAndServicesDomain_1affab63-4904-4d47-a56a-fbced79d94ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_684c261d-462e-4b5d-9389-41ea314b5c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1affab63-4904-4d47-a56a-fbced79d94ad" xlink:to="loc_us-gaap_LicenseMember_684c261d-462e-4b5d-9389-41ea314b5c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_4c77f080-7140-4340-8a2d-0354b1886818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f26d506d-f89f-4b29-8987-de66cff245b8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_4c77f080-7140-4340-8a2d-0354b1886818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6c1ada06-7ba9-4e9c-927e-2746debb66c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_4c77f080-7140-4340-8a2d-0354b1886818" xlink:to="loc_us-gaap_EquityComponentDomain_6c1ada06-7ba9-4e9c-927e-2746debb66c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cc93682f-cb0a-4d96-bc50-8798a7ac08ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6c1ada06-7ba9-4e9c-927e-2746debb66c3" xlink:to="loc_us-gaap_CommonStockMember_cc93682f-cb0a-4d96-bc50-8798a7ac08ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1e080985-c532-40f6-8c89-b2d6a82ab2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f26d506d-f89f-4b29-8987-de66cff245b8" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1e080985-c532-40f6-8c89-b2d6a82ab2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_37d52eba-7944-4895-91d3-0ec8acda7498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1e080985-c532-40f6-8c89-b2d6a82ab2e3" xlink:to="loc_us-gaap_ClassOfStockDomain_37d52eba-7944-4895-91d3-0ec8acda7498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_845f290f-907a-44f4-a3b9-7d33284c3a04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_37d52eba-7944-4895-91d3-0ec8acda7498" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_845f290f-907a-44f4-a3b9-7d33284c3a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_428fc69b-36d7-47a2-88a9-01e467738076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f26d506d-f89f-4b29-8987-de66cff245b8" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_428fc69b-36d7-47a2-88a9-01e467738076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_2e48d408-cd23-4fdc-b608-65c22d4d5e02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_428fc69b-36d7-47a2-88a9-01e467738076" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_2e48d408-cd23-4fdc-b608-65c22d4d5e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ConsultingAgreementMember_aa9a8caa-32df-4148-8468-7c64f8373660" xlink:href="angn-20211231.xsd#angn_ConsultingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2e48d408-cd23-4fdc-b608-65c22d4d5e02" xlink:to="loc_angn_ConsultingAgreementMember_aa9a8caa-32df-4148-8468-7c64f8373660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_LegalServicesMember_32628e28-31a7-4e64-bce3-dcd216a15acb" xlink:href="angn-20211231.xsd#angn_LegalServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_2e48d408-cd23-4fdc-b608-65c22d4d5e02" xlink:to="loc_angn_LegalServicesMember_32628e28-31a7-4e64-bce3-dcd216a15acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_f26d506d-f89f-4b29-8987-de66cff245b8" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentsAndSecuritiesAtCost_7e71c191-e248-4766-9e66-5d40f487106f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentsAndSecuritiesAtCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_us-gaap_OtherInvestmentsAndSecuritiesAtCost_7e71c191-e248-4766-9e66-5d40f487106f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_OtherInvestmentAndSecuritiesAtCostOwnershipPercentage_70de4631-15c9-41b9-ad15-7f3967376521" xlink:href="angn-20211231.xsd#angn_OtherInvestmentAndSecuritiesAtCostOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_angn_OtherInvestmentAndSecuritiesAtCostOwnershipPercentage_70de4631-15c9-41b9-ad15-7f3967376521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_1a2a8ca9-d8a2-44a3-b318-e4442ba1a09e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest_1a2a8ca9-d8a2-44a3-b318-e4442ba1a09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_RelatedPartyTransactionPotentialMaximumMilestonePayment_14d12ba7-5994-4ad5-a486-ef3ed3c22a2c" xlink:href="angn-20211231.xsd#angn_RelatedPartyTransactionPotentialMaximumMilestonePayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_angn_RelatedPartyTransactionPotentialMaximumMilestonePayment_14d12ba7-5994-4ad5-a486-ef3ed3c22a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_RelatedPartyTransactionRoyaltiesAndMilestonePaymentsPeriod_a41fb340-4b5b-4524-b102-9b29a6598d7a" xlink:href="angn-20211231.xsd#angn_RelatedPartyTransactionRoyaltiesAndMilestonePaymentsPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_angn_RelatedPartyTransactionRoyaltiesAndMilestonePaymentsPeriod_a41fb340-4b5b-4524-b102-9b29a6598d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_a085d2a0-fb4d-432a-84c5-df62a64be2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_us-gaap_RevenueFromRelatedParties_a085d2a0-fb4d-432a-84c5-df62a64be2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_fab0840b-8f54-4deb-a64d-fd746edc9886" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_fab0840b-8f54-4deb-a64d-fd746edc9886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_af941c8f-1bc5-4faf-ac59-bb03a3f382bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_us-gaap_OperatingLeaseCost_af941c8f-1bc5-4faf-ac59-bb03a3f382bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_24135142-8016-47a8-aae1-d52462c132c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_us-gaap_VariableLeaseCost_24135142-8016-47a8-aae1-d52462c132c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a445ea3d-e1e1-44f9-948f-1747d60cb0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_a445ea3d-e1e1-44f9-948f-1747d60cb0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_f78aee50-859e-4993-a847-3bdd313168d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_f78aee50-859e-4993-a847-3bdd313168d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_b5f26fb3-f17e-4bc7-a350-8fe33771086e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_b5f26fb3-f17e-4bc7-a350-8fe33771086e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_505fd5a7-2c44-4960-88e3-d66ffd24872b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_505fd5a7-2c44-4960-88e3-d66ffd24872b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ConvertiblePreferredStockConversionPrice_3c7d7973-f3c6-454f-a4c0-a7118dd36aff" xlink:href="angn-20211231.xsd#angn_ConvertiblePreferredStockConversionPrice"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_angn_ConvertiblePreferredStockConversionPrice_3c7d7973-f3c6-454f-a4c0-a7118dd36aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_0b24952e-c415-42f8-9a4e-4f1e38b5593c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares_0b24952e-c415-42f8-9a4e-4f1e38b5593c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_873e6115-bc40-480d-8fe0-60b9e89c5a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_070171df-9d67-49fe-8cd2-db6c4832d50f" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_873e6115-bc40-480d-8fe0-60b9e89c5a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/RelatedPartyTransactionsNovaParkInvestmentDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#RelatedPartyTransactionsNovaParkInvestmentDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/RelatedPartyTransactionsNovaParkInvestmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_c8f9b9a4-546c-4317-9c41-4c770c5d2a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_94d6fe39-2b75-47c6-9291-f2e10b7dcb85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_c8f9b9a4-546c-4317-9c41-4c770c5d2a2f" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_94d6fe39-2b75-47c6-9291-f2e10b7dcb85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_938fccb9-adba-4d6a-8323-57943907f723" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_94d6fe39-2b75-47c6-9291-f2e10b7dcb85" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_938fccb9-adba-4d6a-8323-57943907f723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6186a7e8-a08e-488d-8f1c-b197df12a33a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_938fccb9-adba-4d6a-8323-57943907f723" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6186a7e8-a08e-488d-8f1c-b197df12a33a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_NovaParkMember_83b903be-3986-435e-a808-7299adf74cd8" xlink:href="angn-20211231.xsd#angn_NovaParkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6186a7e8-a08e-488d-8f1c-b197df12a33a" xlink:to="loc_angn_NovaParkMember_83b903be-3986-435e-a808-7299adf74cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c0e26741-5426-4fc9-af8a-90642fbd45bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_94d6fe39-2b75-47c6-9291-f2e10b7dcb85" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c0e26741-5426-4fc9-af8a-90642fbd45bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_df71db64-fd27-4f68-a1e5-8fb88329bab7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c0e26741-5426-4fc9-af8a-90642fbd45bf" xlink:to="loc_us-gaap_RelatedPartyDomain_df71db64-fd27-4f68-a1e5-8fb88329bab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember_fd864742-6374-4f86-b38c-f98f0e2c26d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_df71db64-fd27-4f68-a1e5-8fb88329bab7" xlink:to="loc_us-gaap_EquityMethodInvesteeMember_fd864742-6374-4f86-b38c-f98f0e2c26d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_81acf954-fb0a-4530-ba56-fec9191ca5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_94d6fe39-2b75-47c6-9291-f2e10b7dcb85" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_81acf954-fb0a-4530-ba56-fec9191ca5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_EquityMethodInvestmentsRollForward_298b4153-af5e-4002-9c83-15b6e7de0550" xlink:href="angn-20211231.xsd#angn_EquityMethodInvestmentsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_81acf954-fb0a-4530-ba56-fec9191ca5e7" xlink:to="loc_angn_EquityMethodInvestmentsRollForward_298b4153-af5e-4002-9c83-15b6e7de0550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_bc034c0a-d609-4920-b1f9-1824da545d35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_EquityMethodInvestmentsRollForward_298b4153-af5e-4002-9c83-15b6e7de0550" xlink:to="loc_us-gaap_EquityMethodInvestments_bc034c0a-d609-4920-b1f9-1824da545d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ef7a9fcb-b70d-4979-86a8-a39c31a7698a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_EquityMethodInvestmentsRollForward_298b4153-af5e-4002-9c83-15b6e7de0550" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ef7a9fcb-b70d-4979-86a8-a39c31a7698a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_dacd3bc5-0406-4d3f-92bb-801ea90b022a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDividendsOrDistributions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_EquityMethodInvestmentsRollForward_298b4153-af5e-4002-9c83-15b6e7de0550" xlink:to="loc_us-gaap_EquityMethodInvestmentDividendsOrDistributions_dacd3bc5-0406-4d3f-92bb-801ea90b022a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_2dce7807-5065-4170-87a3-444903658196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_angn_EquityMethodInvestmentsRollForward_298b4153-af5e-4002-9c83-15b6e7de0550" xlink:to="loc_us-gaap_EquityMethodInvestments_2dce7807-5065-4170-87a3-444903658196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/SubsequentEvents" xlink:type="simple" xlink:href="angn-20211231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_7f6e4016-a309-4942-b1a8-c12ad24613ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_c2011e8a-8c59-4c19-856b-f8870f857b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_7f6e4016-a309-4942-b1a8-c12ad24613ca" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_c2011e8a-8c59-4c19-856b-f8870f857b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.angn.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="angn-20211231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.angn.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_41b74e8a-5a65-408e-83fa-a8dec4c1ec69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_efa02fd2-b7a4-4a0f-9031-78247d5bd63b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_41b74e8a-5a65-408e-83fa-a8dec4c1ec69" xlink:to="loc_us-gaap_SubsequentEventTable_efa02fd2-b7a4-4a0f-9031-78247d5bd63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f672fa62-404c-48c2-adc4-32dfd646750e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_efa02fd2-b7a4-4a0f-9031-78247d5bd63b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f672fa62-404c-48c2-adc4-32dfd646750e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_755fb46d-2d4b-46f6-b930-8b7e6a02f2df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f672fa62-404c-48c2-adc4-32dfd646750e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_755fb46d-2d4b-46f6-b930-8b7e6a02f2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_87376d60-bac6-4818-951c-7f5404075a50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_755fb46d-2d4b-46f6-b930-8b7e6a02f2df" xlink:to="loc_us-gaap_SubsequentEventMember_87376d60-bac6-4818-951c-7f5404075a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_5f708c3d-658e-4f33-bdd3-2ec274be53b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_efa02fd2-b7a4-4a0f-9031-78247d5bd63b" xlink:to="loc_us-gaap_PlanNameAxis_5f708c3d-658e-4f33-bdd3-2ec274be53b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5364fc9e-70f0-4b9b-9463-1d519b22ec38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_5f708c3d-658e-4f33-bdd3-2ec274be53b3" xlink:to="loc_us-gaap_PlanNameDomain_5364fc9e-70f0-4b9b-9463-1d519b22ec38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_A2021IncentiveAwardPlanMember_f0e1ba05-4aa9-40b1-9032-779a32ca3899" xlink:href="angn-20211231.xsd#angn_A2021IncentiveAwardPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_5364fc9e-70f0-4b9b-9463-1d519b22ec38" xlink:to="loc_angn_A2021IncentiveAwardPlanMember_f0e1ba05-4aa9-40b1-9032-779a32ca3899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_9ea47d1b-4cdc-4838-8805-2a35bbb71068" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_efa02fd2-b7a4-4a0f-9031-78247d5bd63b" xlink:to="loc_us-gaap_SubsequentEventLineItems_9ea47d1b-4cdc-4838-8805-2a35bbb71068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_d2d487a4-9127-46b2-adbb-56c4e5b6a212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9ea47d1b-4cdc-4838-8805-2a35bbb71068" xlink:to="loc_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits_d2d487a4-9127-46b2-adbb-56c4e5b6a212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_angn_ShareBasedPaymentArrangementPlanModificationExtendedExercisePeriod_bab91028-4701-462f-937b-a31b37a54b73" xlink:href="angn-20211231.xsd#angn_ShareBasedPaymentArrangementPlanModificationExtendedExercisePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_9ea47d1b-4cdc-4838-8805-2a35bbb71068" xlink:to="loc_angn_ShareBasedPaymentArrangementPlanModificationExtendedExercisePeriod_bab91028-4701-462f-937b-a31b37a54b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>angn-20211231_g1.jpg
<TEXT>
begin 644 angn-20211231_g1.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1/#]0# 2(  A$! Q$!_\0
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M7_)3O&?_ &'+S_T>]<%7[!0HTYTXMH_-<5BJM*JXQ>AVO_"V_%?_ $-.N_\
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MG_H]ZX*N]^-7_)3O&?\ V'+S_P!'O7!5^O8;^%$_+\?_ !V%%%%=1YX4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!ZG^S!_P EQ\-_2Y_])I:QOCI_R5[Q9_U_/_2MG]F#
M_DN/AOZ7/_I-+6-\=/\ DKWBS_K^?^E>.O\ D9O_ *]K_P!*9ZK_ .1<O\;_
M /24<+1117L'E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M )&;5_\ K\F_]#-9=>E3^!'!/XF%%%%60%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% 'T;J'_ "9?IG_7\?\ TJDKYRKZ-U#_ ),OTS_K^/\ Z525
M\Y5X^6[5O^ODCU<PWH_X(A1117L'E!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*=XS_P"PY>?^CWK@J_7L-_"B?E^/_CL****ZCSPHHHH **** "BBB@ HHHH
M**** "BBB@ K]HOV7?\ DW;X=_\ 8$MO_0!7XNU^T7[+O_)NWP[_ .P);?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% "K]X?6OHO]M7_D;_#W_7BW
M_HPU\Z+]X?6OHO\ ;5_Y&_P]_P!>+?\ HPUX^)_W[#^D_P D>MA_]RK^L/S9
M\YT445[!Y(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>\_L9_\
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MKS_DKK?]>$'\VKS;X<_\E"\+_P#84M?_ $<M>D_M>?\ )76_Z\(/YM7CU/\
MD8T_\,OS1ZU/_<*G^)?DSQ2BBBO8/)"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ KZ-_8_\ ]5X[_P"O&+_VK7SE7T;^Q_\ ZKQW_P!>,7_M6O'S
M?_<I_+\T>KE7^^0^?Y,^<J***]@\H**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *MZ=_K&^E5*MZ=_K&^E1/X6=&'_ (L3]G?V:?\
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MU+2[BVUO0-5MS'+&<,"K+AXI%[, 2&4\BOPWK;\,^-_$?@F>6;P[K^J:#-*
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M (;'FXJK3K5G.C'ECII\@HHHKL.0**** "BBB@ HHHH **** "BBB@ HHHH
M]3_9@_Y+CX;^ES_Z32UC?'3_ )*]XL_Z_G_I6S^S!_R7'PW]+G_TFEK&^.G_
M "5[Q9_U_/\ TKQU_P C-_\ 7M?^E,]5_P#(N7^-_P#I*.%HHHKV#R@HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M($ NY'/4@!1R2?3)'T<:]*=+VRE[MKW/FIT:E.I[&4?>VL>?T5^DN@?\$O\
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ML6=2V-Q. 3P !VK\FOBI9V^G_%#QA:VL$=M:P:Q>1100H$2-%G<*JJ.
M.F*_;;POX@@\6>&=)UNU22.UU*TBO(DE #JDB!@&P2,X([U^)WQ@_P"2M^-O
M^PY??^E#U\_D=6M4Q=7VS;=G?UN>YG%*C3PE+V*TTMZ6.1HHHK[D^-"BBB@
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M'_T8M7'XD88C2C-KL_R/V>_X9]^%W_1-O"'_ ((K7_XW1_PS[\+O^B;>$/\
MP16O_P ;KMM2_P"0==?]<F_D:_!4$CD<&OR[+,)5S)S7MG'EMW>]_-=C].S+
M%4LO4'[)2YK^6UO)]S]HM<_9>^$GB"QEM+GX=^'H8I!@M8V"6D@^CQ!67\#7
MYY?MB_LEG]G_ %2UUK09IKWP=J4IBB\\[I;*;!;RG;^)2 2K=?E(/(RW9?\
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M(,96Q-.=.J[\MK-^=]/E;\3#/<)2P\X5*2MS7NO2VOSO^ 4445]6?+A1110
M4444 %?1O['_ /JO'?\ UXQ?^U:^<J^C?V/_ /5>._\ KQB_]JUX^;_[E/Y?
MFCU<J_WR'S_)GSE1117L'E!1110 4444 %%%% !1110 4444 %%%% !1110
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MKOO@O\$_$_QV\7)H/AJV5F5?,NKR<E8+6/.-\C 'KT  ))Z#KC[F\._\$O\
MP/;Z;$NN^+/$%_J&/WDNG>1:Q$^R/'(?_'JK%YCAL$U&M+5]-V1A<!B,9=TH
MZ+KT/S;HK[G^,?\ P30NM%TF?4_AWKMQK$D";SH^K*@GE !)\N5 JENF%95[
M_-VKX=NK6:QNIK:YADM[B%S')#*I5T8'!4@\@@C&#5X7'4,:FZ,KVW74G%8*
MO@VE6C:_7H145]7_ +-_[!.M?&+P_:^*/$NJ/X9\.W6'M(8X1)=W<?\ ?&3B
M-3_"Q#$]=N""?H<?\$Q?AALP?$'BW?Z_:[7'Y?9ZY,1G&$PTW3G*[6]E<Z</
ME6*Q$%4A'1]S\R:*^Q/V@O\ @GGJOPU\.WWB7P=K$OB32[)&FN=/NH0EW#$H
MR75E.V7 R2 %( X!KX[KNPN,H8R//1E>QR8G!UL')1K1M<****[#C"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K>G?ZQOI52K>G?ZQOI
M43^%G1A_XL3]G?V:?^3?_A]_V!;;_P!%BBC]FG_DW_X??]@6V_\ 18HK\:Q'
M\:?J_P S]8I?PX^B/R4^-7_)3O&?_8<O/_1[UP5=[\:O^2G>,_\ L.7G_H]Z
MX*OU[#?PHGY?C_X["BBBNH\\**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ]3_9@_Y+CX;^
MES_Z32UC?'3_ )*]XL_Z_G_I6S^S!_R7'PW]+G_TFEK&^.G_ "5[Q9_U_/\
MTKQU_P C-_\ 7M?^E,]5_P#(N7^-_P#I*.%HHHKV#R@HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KWK]A7_DZ
MCP1_O7?_ *1S5X+7O7["O_)U'@C_ 'KO_P!(YJY\3_N]7_!/_P!)9T8;^/3]
M5^9^IWQ2^'&F_%SP'JWA+6)[JVTW4D1)I;%U290KJXVEE8#E1U!XS7SI;?\
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M%9>JKSC/%?%__!.?_DY"W_[!5U_):^I/^"E7_)OMC_V';?\ ]%35Z69TJ?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ^9_^"<$;P_M&W$<B-'(FC72LK#!!#Q9!'K7TQ_P4J_Y-]L?^P[;_P#HJ:O
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M7)( R2.20*]$\:?LN?%7X?:;<:CKG@G4;:PMD,L]U!LN8XD R6=HF8* .I/
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MW_DZ+Q/_ -<+/_TFCKKP/_(ZJ^DOS1A6_P"1*OE^9\[T445]P?$A7O/[&?\
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M8N$79/?S/V_^"O\ R1WP-_V [+_T0E?C=\8/^2M^-O\ L.7W_I0]?LC\%?\
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M_6+^U:2YN?*2/>PD=<[4 4< = *^!OVK/VG_ (FP_$KXA>!$\2X\*&YFT_\
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M_P!'O7Q'^W[_ ,G1>)_^N%G_ .DT=?;G_!/K_DV'0/\ K[O/_1[U\1_M^_\
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MQ^R_XTBM%9Y(8[>Y=5Z^7'<1NY^@52?PK\@ZY^'J%*M"I6J+FE>VNO2_XW_
MZ<^K5*/LZ--VC;IIY6^7ZGZ_?L>_'RZ^/WPL.H:LD:>(-,N/L5^T2A4F;:&2
M4*.FY3R.FY6QQBOA+]O;X46?PS^.<]UID M],\06XU-(D&%CF+,LRK[%AO\
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M_K^?^E>.O^1F_P#KVO\ TIGJO_D7+_&__24<+1117L'E!1110 4444 %%%%
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M&A)W:O\ BV_U,\?B5C,1*O%63M^"2_0****]$\\**** "BBB@ HHHH ****
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MI?\ \G Z;_V+]O\ ^C[BOG3PQ\4/&?@FQDLO#OBW7= LY)#,]OI>I36T;.0
M7*HP!;"@9ZX ]*SO$WB[7?&FH+?^(=:U'7KY8Q"MUJ=U)<2A 20H9R3@$DXZ
M<FO"CETXY@\;S:/I\K'N2S",L L'RZ]_G<K:+K%UX?UBPU2QE\F]L9X[F"3&
M=LB,&4_@0*_93X._%CPQ^TI\+%O8A;W27EL;76-(D8,T#LI62)UZ[3S@]QS7
MXO5M^$?&VO\ @'5TU3PYK-[HFH+Q]HL9VB9AD':V#\RY RIR#W%:YEET<PIJ
M-[26S.?+\?/ 57-*Z>Z_KJC]!9O^"8/A)O&0OH_%NI1^&O,WG1S;*9MN<[!<
M;ON]O]63COGFO=?CYXR\!_!?X4S7OB'2=+O+6VMQ:Z9H]S!')]ID5<1PHK _
M*.,G'RJ":_.-?VZ/CBL/E?\ "<OMQC)TRR+?]]>3G]:\D\9>//$7Q#UAM4\3
M:U>ZY?D8$U[,TA5<YVJ#PJY/W5P!Z5XSRG'8F4%C*UXQ[;_DM?/4]E9I@L.I
M3PM&TGWV_-Z>2L:GPW^)U_\ #?XI:1XVLX(?M5C>_:FMH4$4;HQ(DC4 812K
M,HP,#/'2OU_TW5?!7[3'PGF\B6+6_#.MV_DSQ!L21,0"48#E)$.#Z@@$=C7X
MG5T_@/XG>*_A?J;7_A37[[0[E\>9]EE(27&<"1#\K@9/# CFO5S++(XZ,7!\
MLH[/]/\ +L>5E^92P523DKQENOU/OWPO_P $R?"FB^-8=3U#Q7?:SH,$PE31
MY+1(W?!R$EF#$,I[X1<CN*]B_:L^/VF? ;X8WLB7,0\2ZA ]MI%BI&\N1CS2
MO9$SDGID!>IK\\9OVY_CC<0&)O',@4C&4TVS1O\ OH0@_K7C/B+Q-J_B[5IM
M4US4[S6-2FQYEW?3M-*V.@+,2<#T[5Y?]D8O%5(O'U5*,>B_X9;]7N>HLUPF
M%C)X*DU*75_\._NT1],?\$W6+?M%3,Q)8Z+=$D]3\\5?3/\ P4J_Y-]L?^P[
M;_\ HJ:OS1\-^+-<\&ZB=0\/ZSJ&A7Y0Q&ZTVZ>WEV'&5W(0<' X]A6GXF^*
MGC7QIIZV'B'Q?KVNV*R"46NIZG/<1!P" VUV(R 3S[FO0Q66SQ&-IXI224;:
M>CN<6"S*.%PM6A*+;ES:^L;'T]_P3#_Y+%XF_P"P&W_H^*O8O^"H'_))/"G_
M &'/_;>6OSP\+^-/$'@B\EN_#NNZEH%W*GE23Z7>26SNF0=I9""1D X]A5SQ
M1\3?&'CBSBM?$?BO7-?M87\V.#5-1FN41\$;@KL0#@D9'K3Q&6SKXZ&+4K*-
MM/0RPV/C0P=3#.-W*^OJDOT/L+_@EG_R,GQ!_P"O2S_]#EK>_P""IO\ R"/A
MU_UWOO\ T&"OA?PKX\\3>!9+B3PWXBU;P_)<!5F;2KZ6V,H&<!BC#(&3C/K4
MGBKXB>*_'26R>)/$VL>(5MBQ@75;^6Y$1;&XKO8[<X&<=<"E4RV<\PCC>967
M3Y6-,/F4*."EA7'5WU]3L_V5_P#DXSX>?]AB#_T*OU'_ &KO^3<?B%_V"9?Z
M5^-^E:M?:%J5OJ&FWEQI]_;.)(+JUE:*6)AT964@J?<&NHU;XU_$/7M-N-/U
M/QYXFU'3[E#'/:W>L7$L4JGJK(SD,/8BC,\LGCYPG&27*9Y;CXX%5.:-^:WX
M7_S/1_V%?^3J/!'^]=_^D<U?>?[?7_)K/BS_ *ZV7_I7%7Y0Z%X@U3POJL&I
MZ-J5YI&I09\J\L9W@FCRI4[74@C()'!Z$BM_7_B_X\\6:7-IFM^-O$6L:;,5
M,EGJ&JSSPOM(9=R.Y!P0",CJ!5X_+IXS%4<1&5E"WSM)R'@LPCA<-5H.-W._
MXJQW_P"R'\=(O@/\7+;4]1+?\(_J,1L-2V@L8XV8%90!UV, 3WV[L<D5^G7Q
M:^$_A']ICX;P:=?W7VK3+@I>Z?JNFRJS1MCY9(VY5@5)!'((/K@C\6*[[X<_
M'KX@_"6-HO"?BJ_TFV8DFT#++;Y/5O*D#)GWQFHS+*WC)QKT9<M2/](,NS)8
M.,J52/-"7_#/\.A^A?P$_8#\/?!GQS!XJU#Q%/XHU"R8O81-9BVB@8@C>PWN
M78 \'( /.,XQ@?\ !0S]H/3_  UX%G^'.DWBS^(-8V?V@L+Y-I:@ABKXZ-(0
M!M_NEB>HS\AZU^VM\:]>T^6SNO'EW'#*NUFL[2VM9,>TD4:LI]P17BUU=3WU
MU-<W,TEQ<S.9))I6+.[$Y+,3R23W-<E+*<36Q$:^/J*7+LEY?)?EJ=L\TPU"
MC*E@:;BY=7_P[^78_5'_ ()[_$72_%7P#T_0(9XQJ_A^26WNK7/SA'E>2.3'
M7:0V,^JM5'X\?L!Z%\9OB'/XMM?$UUX<NKXJVH6XM!<I,RJ%W)EU\LD*,_>&
M><5^:'A'QGKO@'6X=8\.ZM=Z+J<7"W-G*8VQD$J<?>4X&5.0>XKUC4OVVOC;
MJNG2V,_CNY2&12C-;V5K!* ?21(@ZGW!!I8C*<5'%RQ>#J*+E>]_/?HTU?4G
M#YGAGA5A<73;4=K>6W56ML?IC\#? O@7X-:;=?#SPE>K<7^GA+[48YI1)<LT
MN0LDN  "1'@  8 ''()^*?\ @IYX=GM/BMX7ULQ_Z-?:1]E63GEXIG9A^4J_
MG7RIHGQ$\5^&=6O-4T?Q-K&E:G>Y^U7MC?RPS3Y.X[W5@6R>>3UIWBGXD>+O
M'%O!!XD\4ZUX@A@8O%'JFH37*QL1@E0['!QW%:8?*:U#%QQ4JG-WOUNK?\,*
MMFM&KA986-+E73RLT_Z]3]0?^"?7_)L.@?\ 7W>?^CWKXC_;]_Y.B\3_ /7"
MS_\ 2:.O)/#_ ,7/'7A+2X]-T/QIXBT73HRS)9Z?JL\$*DG)(1' !).3Q6'X
M@\2:MXLU274]<U2]UG4I0HDO-0N'GF<   %W))P  .>@KHP^6SHX^>+<M)7T
M];?Y&%3,H3P"PG+KIK\[F=1117T!X(5[S^QG_P E2U'_ +!$O_HZ&O!J]Y_8
MS_Y*EJ/_ &")?_1T->5FG^Y5?0]++?\ ?*?J>->*?^1FU?\ Z_)O_0S676IX
MI_Y&;5_^OR;_ -#-9=>E3^!'!/XF%%%%60%%%% !1110!])?\$]O^3F]%_Z\
MKS_T2U?;?[?7_)K/BS_KK9?^E<5?E)X>\3:QX1U1-2T+5;[1=1C5E2\T^Y>"
M901@@.A! (X/-;FO_%_QYXLTN;3-;\;>(M8TV8J9+/4-5GGA?:0R[D=R#@@$
M9'4"OG\=EL\5BZ6)C*RARZ>DKGM8''QPF&K4)1NYW^5XJ/Z'(T445] >*%?K
M)_P3Z_Y-AT#_ *^[S_T>]?DW76^'_BYXZ\):7'INA^-/$6BZ=&69+/3]5G@A
M4DY)"(X ))R>*\K,L'+'4/91=M;GHY?BHX.NJLE<];_;]_Y.B\3_ /7"S_\
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MA\"O"?[3'@>SL]1N6 3_ $K3-8T]U=HBRCYE/*NC#&1T. 000"///V<?V'-
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MK_XY1_PT%\4?^BD^+_\ P>W7_P <KYF/#^)@K1K6^\^EEGN'D[RI7^X^CO\
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M1EF2ST_59X(5).20B. "2<GBL/Q!XDU;Q9JDNIZYJE[K.I2A1)>:A<//,X
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ML>K,[$DGW)I8/+)X;&U,4Y)J5]/5IBQ&8QK8"GA%'6/+KZ)K]3[Y_P""6?\
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MF-KUU^^S..5C!^7Y<$D'D;>?L+5&_9__ &8_LXO+;POX5OXX@T8%LL^HF,G
M;A7G8$@_,<]#S7S6/J8*&.<G!U*G;=;?UW7S/H,!#&2P?+&2IT_YNN_]?\,5
M/V+_ (Q>,OC)\-+O4O&EB8KVWN_*M[];0VZ7L)12' QM)#;@2F!TXKY#_P""
MF&C6^G_'72KV&-4DO]$ADF*C&]EEE0,??:%'T45]]_"'XZ>$_CC::K=^$;FX
MO;+39UMY+B:W:%78KN^4-AL8]0*^$?\ @IW*K?&;PV@^\F@IG\;B:O.R]O\
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MQ])?M7?\FX_$+_L$R_TK\N/V5X;F;]HOX>K:9\[^UX6./[@.7_\ '0U?J/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!5^\/K7T7^VK_R-_A[_
M *\6_P#1AKYT7[P^M?1?[:O_ "-_A[_KQ;_T8:\?$_[]A_2?Y(];#_[E7]8?
MFSYSHHHKV#R0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]Y_8S_
M .2I:C_V")?_ $=#7@U>\_L9_P#)4M1_[!$O_HZ&O*S3_<JOH>EEO^^4_4\:
M\4_\C-J__7Y-_P"AFLNM3Q3_ ,C-J_\ U^3?^AFLNO2I_ C@G\3"BBBK("BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Z-U#_ ),OTS_K^/\ Z525
M\Y5]&ZA_R9?IG_7\?_2J2OG*O'RW:M_U\D>KF&]'_!$****]@\H**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** .B^'/_)0O"__ &%+7_T<M>D_M>?\
ME=;_ *\(/YM7FWPY_P"2A>%_^PI:_P#HY:])_:\_Y*ZW_7A!_-J\>I_R,:?^
M&7YH]:G_ +A4_P 2_)GBE%%%>P>2%%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY*]XL_Z_G_I7CK_D9O\ Z]K_ -*9ZK_Y%R_QO_TE'"T445[!Y04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "K]X?6OH
MO]M7_D;_  ]_UXM_Z,-?.B_>'UKZ+_;5_P"1O\/?]>+?^C#7CXG_ '[#^D_R
M1ZV'_P!RK^L/S9\YT445[!Y(4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^1C3_P ,OS1ZU/\ W"I_B7Y,\4HHHKV#R0HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *^C?V/_\ 5>._^O&+_P!JU\Y5]&_L?_ZKQW_UXQ?^U:\?
M-_\ <I_+\T>KE7^^0^?Y,^<J***]@\H**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** %7[P^M?1?[:O_(W^'O\ KQ;_ -&&OG1?
MO#ZU]%_MJ_\ (W^'O^O%O_1AKQ\3_OV'])_DCUL/_N5?UA^;/G.BBBO8/)"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KWG]C/\ Y*EJ/_8(E_\
M1T->#5[S^QG_ ,E2U'_L$2_^CH:\K-/]RJ^AZ66_[Y3]3QKQ3_R,VK_]?DW_
M *&:RZU/%/\ R,VK_P#7Y-_Z&:RZ]*G\"."?Q,****L@**** "BBB@ HHHH
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M\F?.5%%%>P>4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^55%?JK11_Q,7_U*?_*W_P!R#_B&_P#U%_\ DG_VY^55%?JK11_Q,7_U*?\
MRM_]R#_B&_\ U%_^2?\ VY^55%?JK11_Q,7_ -2G_P K?_<@_P"(;_\ 47_Y
M)_\ ;GY545^JM%'_ !,7_P!2G_RM_P#<@_XAO_U%_P#DG_VY^55%?JK11_Q,
M7_U*?_*W_P!R#_B&_P#U%_\ DG_VY^55%?JK11_Q,7_U*?\ RM_]R#_B&_\
MU%_^2?\ VY^55%?JK11_Q,7_ -2G_P K?_<@_P"(;_\ 47_Y)_\ ;GY545^J
MM%'_ !,7_P!2G_RM_P#<@_XAO_U%_P#DG_VY^55%?JK11_Q,7_U*?_*W_P!R
M#_B&_P#U%_\ DG_VY^55%?JK11_Q,7_U*?\ RM_]R#_B&_\ U%_^2?\ VY^5
M5%?JK11_Q,7_ -2G_P K?_<@_P"(;_\ 47_Y)_\ ;GY545^JM%'_ !,7_P!2
MG_RM_P#<@_XAO_U%_P#DG_VY^55%?JK11_Q,7_U*?_*W_P!R#_B&_P#U%_\
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M^55%?JK11_Q,7_U*?_*W_P!R#_B&_P#U%_\ DG_VY^55%?JK11_Q,7_U*?\
MRM_]R#_B&_\ U%_^2?\ VY^55%?JK11_Q,7_ -2G_P K?_<@_P"(;_\ 47_Y
M)_\ ;GY545^JM%'_ !,7_P!2G_RM_P#<@_XAO_U%_P#DG_VY^55%?JK11_Q,
M7_U*?_*W_P!R#_B&_P#U%_\ DG_VY^55%?JK11_Q,7_U*?\ RM_]R#_B&_\
MU%_^2?\ VY^?G[,;!/CAX<+$*,7/)_Z]I:QOCDP?XN>*RI##[<_(K]'**X_^
M)@O]I>)_LO[/+;VWG>_\(Z_^(??[/]7^M?:O?D\K?SGY545^JM%=G_$Q?_4I
M_P#*W_W(Y/\ B&__ %%_^2?_ &Y^55%?JK11_P 3%_\ 4I_\K?\ W(/^(;_]
M1?\ Y)_]N?E517ZJT4?\3%_]2G_RM_\ <@_XAO\ ]1?_ ))_]N?E517ZJT4?
M\3%_]2G_ ,K?_<@_XAO_ -1?_DG_ -N?E517ZJT4?\3%_P#4I_\ *W_W(/\
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M\3%_]2G_ ,K?_<@_XAO_ -1?_DG_ -N?E517ZJT4?\3%_P#4I_\ *W_W(/\
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M\3%_]2G_ ,K?_<@_XAO_ -1?_DG_ -N?E517ZJT4?\3%_P#4I_\ *W_W(/\
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M\3%_]2G_ ,K?_<@_XAO_ -1?_DG_ -N?E517ZJT4?\3%_P#4I_\ *W_W(/\
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M#=S?^AFLROU5HKHC](KE27]E?^5O_N1SR\-^9M_6_P#R3_[<_*JBOU5HJO\
MB8O_ *E/_E;_ .Y$_P#$-_\ J+_\D_\ MS\JJ*_56BC_ (F+_P"I3_Y6_P#N
M0?\ $-_^HO\ \D_^W/RJHK]5:*/^)B_^I3_Y6_\ N0?\0W_ZB_\ R3_[<_*J
MBOU5HH_XF+_ZE/\ Y6_^Y!_Q#?\ ZB__ "3_ .W/RJHK]5:*/^)B_P#J4_\
ME;_[D'_$-_\ J+_\D_\ MS\JJ*_56BC_ (F+_P"I3_Y6_P#N0?\ $-_^HO\
M\D_^W/RJHK]5:*/^)B_^I3_Y6_\ N0?\0W_ZB_\ R3_[<_*JBOU5HH_XF+_Z
ME/\ Y6_^Y!_Q#?\ ZB__ "3_ .W/RJHK]5:*/^)B_P#J4_\ E;_[D'_$-_\
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M*?\ RM_]R#_B&_\ U%_^2?\ VY^55%?JK11_Q,7_ -2G_P K?_<@_P"(;_\
M47_Y)_\ ;GY545^JM%'_ !,7_P!2G_RM_P#<@_XAO_U%_P#DG_VY^55%?JK1
M1_Q,7_U*?_*W_P!R#_B&_P#U%_\ DG_VY^55%?JK11_Q,7_U*?\ RM_]R#_B
M&_\ U%_^2?\ VY^55%?JK11_Q,7_ -2G_P K?_<@_P"(;_\ 47_Y)_\ ;GY5
M45^JM%'_ !,7_P!2G_RM_P#<@_XAO_U%_P#DG_VY^55%?JK11_Q,7_U*?_*W
M_P!R#_B&_P#U%_\ DG_VY^55%?JK11_Q,7_U*?\ RM_]R#_B&_\ U%_^2?\
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MG_RM_P#<@_XAO_U%_P#DG_VY^55%?JK11_Q,7_U*?_*W_P!R#_B&_P#U%_\
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M^55%?JK11_Q,7_U*?_*W_P!R#_B&_P#U%_\ DG_VY^55%?JK11_Q,7_U*?\
MRM_]R#_B&_\ U%_^2?\ VY^55%?JK11_Q,7_ -2G_P K?_<@_P"(;_\ 47_Y
M)_\ ;GY545^JM%'_ !,7_P!2G_RM_P#<@_XAO_U%_P#DG_VY^55%?JK11_Q,
M7_U*?_*W_P!R#_B&_P#U%_\ DG_VY^55%?JK11_Q,7_U*?\ RM_]R#_B&_\
MU%_^2?\ VY^55%?JK11_Q,7_ -2G_P K?_<@_P"(;_\ 47_Y)_\ ;GY545^J
MM%'_ !,7_P!2G_RM_P#<@_XAO_U%_P#DG_VY^55%?JK11_Q,7_U*?_*W_P!R
M#_B&_P#U%_\ DG_VY^55%?JK11_Q,7_U*?\ RM_]R#_B&_\ U%_^2?\ VY^5
M5%?JK11_Q,7_ -2G_P K?_<@_P"(;_\ 47_Y)_\ ;GY545^JM%'_ !,7_P!2
MG_RM_P#<@_XAO_U%_P#DG_VY^55%?JK11_Q,7_U*?_*W_P!R#_B&_P#U%_\
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M^55%?JK11_Q,7_U*?_*W_P!R#_B&_P#U%_\ DG_VY^55%?JK11_Q,7_U*?\
MRM_]R#_B&_\ U%_^2?\ VY^55%?JK11_Q,7_ -2G_P K?_<@_P"(;_\ 47_Y
M)_\ ;GY545^JM%'_ !,7_P!2G_RM_P#<@_XAO_U%_P#DG_VY^55%?JK11_Q,
M7_U*?_*W_P!R#_B&_P#U%_\ DG_VY^55%?JK11_Q,7_U*?\ RM_]R#_B&_\
MU%_^2?\ VY^55%?JK11_Q,7_ -2G_P K?_<@_P"(;_\ 47_Y)_\ ;GY545^J
MM%'_ !,7_P!2G_RM_P#<@_XAO_U%_P#DG_VY^55%?JK11_Q,7_U*?_*W_P!R
M#_B&_P#U%_\ DG_VY^55%?JK11_Q,7_U*?\ RM_]R#_B&_\ U%_^2?\ VY^5
M5%?JK11_Q,7_ -2G_P K?_<@_P"(;_\ 47_Y)_\ ;GY545^JM%'_ !,7_P!2
MG_RM_P#<@_XAO_U%_P#DG_VY^55%?JK11_Q,7_U*?_*W_P!R#_B&_P#U%_\
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M^55%?JK11_Q,7_U*?_*W_P!R#_B&_P#U%_\ DG_VY^55%?JK11_Q,7_U*?\
MRM_]R#_B&_\ U%_^2?\ VY^55%?JK11_Q,7_ -2G_P K?_<@_P"(;_\ 47_Y
M)_\ ;GY545^JM%'_ !,7_P!2G_RM_P#<@_XAO_U%_P#DG_VY^55%?JK11_Q,
M7_U*?_*W_P!R#_B&_P#U%_\ DG_VY^55%?JK11_Q,7_U*?\ RM_]R#_B&_\
MU%_^2?\ VY^55%?JK11_Q,7_ -2G_P K?_<@_P"(;_\ 47_Y)_\ ;GY545^J
MM%'_ !,7_P!2G_RM_P#<@_XAO_U%_P#DG_VY^55%?JK11_Q,7_U*?_*W_P!R
M#_B&_P#U%_\ DG_VY^55%?JK11_Q,7_U*?\ RM_]R#_B&_\ U%_^2?\ VY^5
M5%?JK11_Q,7_ -2G_P K?_<@_P"(;_\ 47_Y)_\ ;GY545^JM%'_ !,7_P!2
MG_RM_P#<@_XAO_U%_P#DG_VY^55%?JK11_Q,7_U*?_*W_P!R#_B&_P#U%_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/#6H7PB\2>!=2T6V8@"?3[Y+TCW962+CZ9/M7%_ 7_@F>WBKPS::Y\1]9O\
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M-MOH<WB:PUB^76&F2 :3#%(5,00MO\R1,?ZP8QGH>E>O5\"_\%7O^03\-/\
MKOJ'_H-O7TW"&5X?.<[P^ Q:;ISYKV=GI&3W]4<V-JRH8:=6&Z1]/_L^_M,^
M%_VDK+6KKPS8:O8QZ3)%'.-6ABC+&0,5V^7(^1\ASG':O6Z^#/\ @E'_ ,B[
M\1?^ONR_] FK[SJ>+LLP^39WB,!A$U3ARVN[O6,7OZLY,IQ53&8.-:K\3<OP
MDU^2"O"?C[^V-X+_ &=/%%AH/B33->O;R]LQ?1OI5O#)&$+NF"7F0YRA[8QC
MFO=J_,3_ (*F?\EJ\+_]B\G_ *4SUW<$9-A,^SF&"QJ;@XR>CL]%H;9E7GA<
M)4K4]U;\TOU/=_\ AZ1\*O\ H7_&/_@%:?\ R34]G_P5 ^$US.L<FD>++1">
M99K&W*CZ[;AC^E?*7[+/[$O_  TMX%U+Q'_PF?\ PCGV/4GT_P"S?V7]JW[8
MHY-^[SDQ_K,8QVZ\UZAXB_X)2ZU::;+)H?Q"L=3OE&4M[[3'M(V]BZRR$?\
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M?^"D?PS\:>+-%\/V6A^+(KW5KV&P@DN+2V$:R2R*BEB+@D+EAG )QV->4?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPI^"OQ%_:U\9ZO/I]T-1OHP)]1UK6[E_+0MD('?#,2=IPJ@\+V J]\>OV/\
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M#PN55JT=TW;U?*E^9\UVL/Q2_;$^)WD>?=>)]=FW2GSI-EM8PY&2 ?EBC''
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M_*I*^O0Y/RW]E6_\5?9G.$FO?+)]C)C^M?OA9VL=C:06T**D4*+&BJ, *!@
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M]K36OB=XUU3P5X<U"6R\%Z9,UI(MJY4ZE*IVN\A'WHPP(5>AQN.21C+\._\
M!.;XO^(O!\.O"'1]/EFA\^/2+Z\>.]8$94%1&45B,<,X(SSCFOGOP1XDA\*>
M-M"UZ[L?[6ATV_AO9+)Y-@N!'('*%MK8W8QG!Z]*^Z?^'L?_ %2S_P N'_[E
MK[G,<%GG#V$PV7\)X6,HQ7OR;BKO3>\HW;U;>O1*QY-.OA<=B*E;,)M+[*U_
M1/;\3Y]_9U_:.\8?LM_$3^QM7>\'AR.[-KK/A^Z+'R"&VO)&A^Y*O)X^]C![
M$?KO<7D&H^'Y;NVE6:VGM3+%(AR'5DR"/8@U^)'Q_P#BQ!\;OBIJ_C.#0_\
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MJ\?<38S 9+AXTHQ?UJ$E.Z>B<5?EU5OB>]SFP&74JF85*+;M3=UM]F6E]/\
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MRIJI:]U?>"6U]V>KAZF<.K%5H+EOK\.WWFE^WO\ \FI^-?\ MT_]*X:^%_\
M@G#_ ,G.:=_V#;S_ - %?='[>_\ R:GXU_[=/_2N&OA?_@G#_P G.:=_V#;S
M_P! %?2\(_\ )!YGZU/_ $W X\Z_Y&&%]8_^EGUC_P %._\ DW;3O^QAMO\
MT3<5^=WP:\0>/+/7KOP[\/)+M-<\30C3&6P^6X>/<'95?(\L?)EFR,*#D@9K
M]$?^"G?_ ";MIW_8PVW_ *)N*^?_ /@EMH5M??&#Q/JDR![BPT;9!D9VF25
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MOPZZZ;'Z5A;>PA:?/IOW"BBBO..H**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXJZ[\TM/Q1IP_AJV%H5(UH\K<K_+EBOT/P9^)G_)2/%?_86N_P#T<]?NVO\
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MOL433W6CS1:LL:]2D9(D/X1O(W_ :]R\&^%;'P/X3T?P]ID?E6&EVD=I O\
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MMM?%_3/C-\>M2U/1)UN]%T^WCTRTND)VSK&69I![%W?![@ ]Z_1[]B?P/=>
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M%W[='P!^&GP/U/14\$ZM(FIWKR?;-!DNQ<FUC &R0'[Z DD8<G/;H:S?$?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M *&S3/\ P=77_P ;H_X@6O\ H;T__ '_ /)!_KK5_P"@&7_@2_R/HRBOG/\
MX8)^//\ T-FF?^#JZ_\ C='_  P3\>?^ALTS_P '5U_\;H_X@6O^AO3_ / '
M_P#)!_KK5_Z 9?\ @2_R/HRBOG/_ (8)^//_ $-FF?\ @ZNO_C='_#!/QY_Z
M&S3/_!U=?_&Z/^(%K_H;T_\ P!__ "0?ZZU?^@&7_@2_R/HRBOG/_A@GX\_]
M#9IG_@ZNO_C='_#!/QY_Z&S3/_!U=?\ QNC_ (@6O^AO3_\  '_\D'^NM7_H
M!E_X$O\ (^C**^<_^&"?CS_T-FF?^#JZ_P#C='_#!/QY_P"ALTS_ ,'5U_\
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MY_Z&S3/_  =77_QNC_B!:_Z&]/\ \ ?_ ,D'^NM7_H!E_P"!+_(^C**^<_\
MA@GX\_\ 0V:9_P"#JZ_^-T?\,$_'G_H;-,_\'5U_\;H_X@6O^AO3_P# '_\
M)!_KK5_Z 9?^!+_(^C**^<_^&"?CS_T-FF?^#JZ_^-T?\,$_'G_H;-,_\'5U
M_P#&Z/\ B!:_Z&]/_P  ?_R0?ZZU?^@&7_@2_P CZ,HKYS_X8)^//_0V:9_X
M.KK_ .-T?\,$_'G_ *&S3/\ P=77_P ;H_X@6O\ H;T__ '_ /)!_KK5_P"@
M&7_@2_R/HRBOG/\ X8)^//\ T-FF?^#JZ_\ C='_  P3\>?^ALTS_P '5U_\
M;H_X@6O^AO3_ / '_P#)!_KK5_Z 9?\ @2_R/HRBOG/_ (8)^//_ $-FF?\
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MO_C='_#!/QY_Z&S3/_!U=?\ QNC_ (@6O^AO3_\  '_\D'^NM7_H!E_X$O\
M(^C**^<_^&"?CS_T-FF?^#JZ_P#C='_#!/QY_P"ALTS_ ,'5U_\ &Z/^(%K_
M *&]/_P!_P#R0?ZZU?\ H!E_X$O\CZ,HKYS_ .&"?CS_ -#9IG_@ZNO_ (W1
M_P ,$_'G_H;-,_\ !U=?_&Z/^(%K_H;T_P#P!_\ R0?ZZU?^@&7_ ($O\CZ,
MHKYS_P"&"?CS_P!#9IG_ (.KK_XW1_PP3\>?^ALTS_P=77_QNC_B!:_Z&]/_
M , ?_P D'^NM7_H!E_X$O\CZ,HKYS_X8)^//_0V:9_X.KK_XW1_PP3\>?^AL
MTS_P=77_ ,;H_P"(%K_H;T__  !__)!_KK5_Z 9?^!+_ "/HRBOG/_A@GX\_
M]#9IG_@ZNO\ XW1_PP3\>?\ H;-,_P#!U=?_ !NC_B!:_P"AO3_\ ?\ \D'^
MNM7_ * 9?^!+_(^C**^<_P#A@GX\_P#0V:9_X.KK_P"-T?\ #!/QY_Z&S3/_
M  =77_QNC_B!:_Z&]/\ \ ?_ ,D'^NM7_H!E_P"!+_(^C**^<_\ A@GX\_\
M0V:9_P"#JZ_^-T?\,$_'G_H;-,_\'5U_\;H_X@6O^AO3_P# '_\ )!_KK5_Z
M 9?^!+_(^C**^<_^&"?CS_T-FF?^#JZ_^-T?\,$_'G_H;-,_\'5U_P#&Z/\
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M6O\ H;T__ '_ /)!_KK5_P"@&7_@2_R/HRBOG/\ X8)^//\ T-FF?^#JZ_\
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M_P"(%K_H;T__  !__)!_KK5_Z 9?^!+_ "/HRBOG/_A@GX\_]#9IG_@ZNO\
MXW1_PP3\>?\ H;-,_P#!U=?_ !NC_B!:_P"AO3_\ ?\ \D'^NM7_ * 9?^!+
M_(^C**^<_P#A@GX\_P#0V:9_X.KK_P"-T?\ #!/QY_Z&S3/_  =77_QNC_B!
M:_Z&]/\ \ ?_ ,D'^NM7_H!E_P"!+_(^C**^<_\ A@GX\_\ 0V:9_P"#JZ_^
M-T?\,$_'G_H;-,_\'5U_\;H_X@6O^AO3_P# '_\ )!_KK5_Z 9?^!+_(^C**
M^<_^&"?CS_T-FF?^#JZ_^-T?\,$_'G_H;-,_\'5U_P#&Z/\ B!:_Z&]/_P
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MGX\_]#9IG_@ZNO\ XW1_PP3\>?\ H;-,_P#!U=?_ !NC_B!:_P"AO3_\ ?\
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MBOG/_A@GX\_]#9IG_@ZNO_C='_#!/QY_Z&S3/_!U=?\ QNC_ (@6O^AO3_\
M '_\D'^NM7_H!E_X$O\ (^C**^<_^&"?CS_T-FF?^#JZ_P#C='_#!/QY_P"A
MLTS_ ,'5U_\ &Z/^(%K_ *&]/_P!_P#R0?ZZU?\ H!E_X$O\CZ,HKYS_ .&"
M?CS_ -#9IG_@ZNO_ (W1_P ,$_'G_H;-,_\ !U=?_&Z/^(%K_H;T_P#P!_\
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M^#JZ_P#C='_#!/QY_P"ALTS_ ,'5U_\ &Z/^(%K_ *&]/_P!_P#R0?ZZU?\
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M_P#A@GX\_P#0V:9_X.KK_P"-T?\ #!/QY_Z&S3/_  =77_QNC_B!:_Z&]/\
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M?^#JZ_\ C='_  P3\>?^ALTS_P '5U_\;H_X@6O^AO3_ / '_P#)!_KK5_Z
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M ! M?]#>G_X _P#Y(/\ 76K_ - ,O_ E_D?1E%?.?_#!/QY_Z&S3/_!U=?\
MQNC_ (8)^//_ $-FF?\ @ZNO_C='_$"U_P!#>G_X _\ Y(/]=:O_ $ R_P#
ME_D?1E%?.?\ PP3\>?\ H;-,_P#!U=?_ !NC_A@GX\_]#9IG_@ZNO_C='_$"
MU_T-Z?\ X __ )(/]=:O_0#+_P "7^1]&45\Y_\ #!/QY_Z&S3/_  =77_QN
MC_A@GX\_]#9IG_@ZNO\ XW1_Q M?]#>G_P" /_Y(/]=:O_0#+_P)?Y'T917S
MG_PP3\>?^ALTS_P=77_QNC_A@GX\_P#0V:9_X.KK_P"-T?\ $"U_T-Z?_@#_
M /D@_P!=:O\ T R_\"7^1]&45\Y_\,$_'G_H;-,_\'5U_P#&Z/\ A@GX\_\
M0V:9_P"#JZ_^-T?\0+7_ $-Z?_@#_P#D@_UUJ_\ 0#+_ ,"7^1]&45\Y_P##
M!/QY_P"ALTS_ ,'5U_\ &Z/^&"?CS_T-FF?^#JZ_^-T?\0+7_0WI_P#@#_\
MD@_UUJ_] ,O_  )?Y'T917SG_P ,$_'G_H;-,_\ !U=?_&Z/^&"?CS_T-FF?
M^#JZ_P#C='_$"U_T-Z?_ ( __D@_UUJ_] ,O_ E_D?1E%?.?_#!/QY_Z&S3/
M_!U=?_&Z/^&"?CS_ -#9IG_@ZNO_ (W1_P 0+7_0WI_^ /\ ^2#_ %UJ_P#0
M#+_P)?Y'T917SG_PP3\>?^ALTS_P=77_ ,;H_P"&"?CS_P!#9IG_ (.KK_XW
M1_Q M?\ 0WI_^ /_ .2#_76K_P! ,O\ P)?Y'T917SG_ ,,$_'G_ *&S3/\
MP=77_P ;H_X8)^//_0V:9_X.KK_XW1_Q M?]#>G_ . /_P"2#_76K_T R_\
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MT-Z?_@#_ /D@_P!=:O\ T R_\"7^1]&45\Y_\,$_'G_H;-,_\'5U_P#&Z/\
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MG_H;-,_\'5U_\;H_X8)^//\ T-FF?^#JZ_\ C='_ ! M?]#>G_X _P#Y(/\
M76K_ - ,O_ E_D?1E%?.?_#!/QY_Z&S3/_!U=?\ QNC_ (8)^//_ $-FF?\
M@ZNO_C='_$"U_P!#>G_X _\ Y(/]=:O_ $ R_P# E_D?1E%?.?\ PP3\>?\
MH;-,_P#!U=?_ !NC_A@GX\_]#9IG_@ZNO_C='_$"U_T-Z?\ X __ )(/]=:O
M_0#+_P "7^1]&45\Y_\ #!/QY_Z&S3/_  =77_QNC_A@GX\_]#9IG_@ZNO\
MXW1_Q M?]#>G_P" /_Y(/]=:O_0#+_P)?Y'T917SG_PP3\>?^ALTS_P=77_Q
MNC_A@GX\_P#0V:9_X.KK_P"-T?\ $"U_T-Z?_@#_ /D@_P!=:O\ T R_\"7^
M1]&45\Y_\,$_'G_H;-,_\'5U_P#&Z/\ A@GX\_\ 0V:9_P"#JZ_^-T?\0+7_
M $-Z?_@#_P#D@_UUJ_\ 0#+_ ,"7^1]&45\Y_P##!/QY_P"ALTS_ ,'5U_\
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M ! M?]#>G_X _P#Y(/\ 76K_ - ,O_ E_D?1E%?.?_#!/QY_Z&S3/_!U=?\
MQNC_ (8)^//_ $-FF?\ @ZNO_C='_$"U_P!#>G_X _\ Y(/]=:O_ $ R_P#
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M6K_T R_\"7^1]&45\Y_\,$_'G_H;-,_\'5U_\;H_X8)^//\ T-FF?^#JZ_\
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M3/\ P=77_P ;H_X8)^//_0V:9_X.KK_XW1_Q M?]#>G_ . /_P"2#_76K_T
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MY_\ #!/QY_Z&S3/_  =77_QNC_A@GX\_]#9IG_@ZNO\ XW1_Q M?]#>G_P"
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M6K_T R_\"7^1]&45\Y_\,$_'G_H;-,_\'5U_\;H_X8)^//\ T-FF?^#JZ_\
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M3/\ P=77_P ;H_X8)^//_0V:9_X.KK_XW1_Q M?]#>G_ . /_P"2#_76K_T
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MY_\ #!/QY_Z&S3/_  =77_QNC_A@GX\_]#9IG_@ZNO\ XW1_Q M?]#>G_P"
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!SGQ)_P"2=^*?^P5=?^B6KXV_X)?_ '?B7_W#
M?_;JOLGXD_\ )._%/_8*NO\ T2U?&W_!+_[OQ+_[AO\ [=5[F&_Y%^(]8_F>
M=6_WJE\_R/NRBBBO#/1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M KXO_P""FO\ R)'@K_L(S?\ HH5]H5\7_P#!37_D2/!7_81F_P#10KU<K_WR
MG_71G%C?]WD?27[/_P#R0GX=?]B[I_\ Z3QUWU<#^S__ ,D)^'7_ &+NG_\
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M(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNN*^@E_R)X_]?/T9X4?^1K+_  ?JCWVBBBOGSW0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV"BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\=_\
M!3#_ ))CX3_[#!_]$/7V)7QW_P %,/\ DF/A/_L,'_T0]>IE?^^4_7]#CQG\
M"1[S^S3_ ,F__#[_ + MM_Z+%%'[-/\ R;_\/O\ L"VW_HL45QXC^-/U?YF]
M+^''T1\=_LD?\GL>-O\ >U;_ -*17Z'U^>'[)'_)['C;_>U;_P!*17Z'UZF;
M_P >/^%''@?X;]6%%%%>&>B%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?+?\ P4>_Y-OE
M_P"PM:_^SUT_[!__ ":CX&^E]_Z77%<Q_P %'O\ DV^7_L+6O_L]=/\ L'_\
MFH^!OI??^EUQ7T$O^1/'_KY^C/"C_P C67^#]4>^T445\^>Z%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!SGQ)_Y)WX
MI_[!5U_Z):OC;_@E_P#=^)?_ '#?_;JOLGXD_P#)._%/_8*NO_1+5^=_[&'Q
MB_X4SIGBJ[_LC^V/[6FMXMGVGR/*\E9#G.QMV[S_ &QM[YX^FRS"UL;A*]"A
M&\GRZ:+KYGB8[%4L'5IUJ[M%7[O\C],Z*^7?^&V_^I,_\JO_ -IH_P"&V_\
MJ3/_ "J__::?^K6:_P#/G_R:/^9S_P"L.6?\_?\ R67^1]145\N_\-M_]29_
MY5?_ +31_P -M_\ 4F?^57_[31_JUFO_ #Y_\FC_ )A_K#EG_/W_ ,EE_D?4
M5%?+O_#;?_4F?^57_P"TT?\ #;?_ %)G_E5_^TT?ZM9K_P ^?_)H_P"8?ZPY
M9_S]_P#)9?Y'U%17R[_PVW_U)G_E5_\ M-'_  VW_P!29_Y5?_M-'^K6:_\
M/G_R:/\ F'^L.6?\_?\ R67^1]145\N_\-M_]29_Y5?_ +31_P -M_\ 4F?^
M57_[31_JUFO_ #Y_\FC_ )A_K#EG_/W_ ,EE_D?45%?+O_#;?_4F?^57_P"T
MT?\ #;?_ %)G_E5_^TT?ZM9K_P ^?_)H_P"8?ZPY9_S]_P#)9?Y'U%17R[_P
MVW_U)G_E5_\ M-'_  VW_P!29_Y5?_M-'^K6:_\ /G_R:/\ F'^L.6?\_?\
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M9_S]_P#)9?Y'U%17R[_PVW_U)G_E5_\ M-'_  VW_P!29_Y5?_M-'^K6:_\
M/G_R:/\ F'^L.6?\_?\ R67^1]145\N_\-M_]29_Y5?_ +31_P -M_\ 4F?^
M57_[31_JUFO_ #Y_\FC_ )A_K#EG_/W_ ,EE_D?45%?+O_#;?_4F?^57_P"T
MT?\ #;?_ %)G_E5_^TT?ZM9K_P ^?_)H_P"8?ZPY9_S]_P#)9?Y'U%17R[_P
MVW_U)G_E5_\ M-'_  VW_P!29_Y5?_M-'^K6:_\ /G_R:/\ F'^L.6?\_?\
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M491C5U?E+_(^S/V?_P#DA/PZ_P"Q=T__ -)XZ[ZOC[X?_M8_\(+X$\.^&_\
MA%OMW]D:=;V'VK^T?+\WRHU3?M\H[<[<XR<9ZFM__AMO_J3/_*K_ /::Y*O#
M>:RJ2DJ.C;^U'_,VAQ!EBBDZO_DLO\CZBHKY=_X;;_ZDS_RJ_P#VFC_AMO\
MZDS_ ,JO_P!IK/\ U:S7_GS_ .31_P R_P#6'+/^?O\ Y++_ "/J*BOEW_AM
MO_J3/_*K_P#::/\ AMO_ *DS_P JO_VFC_5K-?\ GS_Y-'_,/]8<L_Y^_P#D
MLO\ (^HJ*^7?^&V_^I,_\JO_ -IH_P"&V_\ J3/_ "J__::/]6LU_P"?/_DT
M?\P_UARS_G[_ .2R_P CZBHKY=_X;;_ZDS_RJ_\ VFC_ (;;_P"I,_\ *K_]
MIH_U:S7_ )\_^31_S#_6'+/^?O\ Y++_ "/J*BOEW_AMO_J3/_*K_P#::/\
MAMO_ *DS_P JO_VFC_5K-?\ GS_Y-'_,/]8<L_Y^_P#DLO\ (^HJ*^7?^&V_
M^I,_\JO_ -IH_P"&V_\ J3/_ "J__::/]6LU_P"?/_DT?\P_UARS_G[_ .2R
M_P CZBHKY=_X;;_ZDS_RJ_\ VFC_ (;;_P"I,_\ *K_]IH_U:S7_ )\_^31_
MS#_6'+/^?O\ Y++_ "/J*BOEW_AMO_J3/_*K_P#::/\ AMO_ *DS_P JO_VF
MC_5K-?\ GS_Y-'_,/]8<L_Y^_P#DLO\ (^HJ*^7?^&V_^I,_\JO_ -IH_P"&
MV_\ J3/_ "J__::/]6LU_P"?/_DT?\P_UARS_G[_ .2R_P CZBHKY=_X;;_Z
MDS_RJ_\ VFC_ (;;_P"I,_\ *K_]IH_U:S7_ )\_^31_S#_6'+/^?O\ Y++_
M "/J*BOEW_AMO_J3/_*K_P#::/\ AMO_ *DS_P JO_VFC_5K-?\ GS_Y-'_,
M/]8<L_Y^_P#DLO\ (^HJ*^7?^&V_^I,_\JO_ -IH_P"&V_\ J3/_ "J__::/
M]6LU_P"?/_DT?\P_UARS_G[_ .2R_P CZBHKY=_X;;_ZDS_RJ_\ VFC_ (;;
M_P"I,_\ *K_]IH_U:S7_ )\_^31_S#_6'+/^?O\ Y++_ "/J*BOEW_AMO_J3
M/_*K_P#::/\ AMO_ *DS_P JO_VFC_5K-?\ GS_Y-'_,/]8<L_Y^_P#DLO\
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M?;9_BKH]3"8_#8Z+EAY\UO5?@Q]%%%><=X4444 %%%% !1110 4444 %%%%
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M %:%>/+=G>M@HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\M_\
M!1[_ )-OE_["UK_[/73_ +!__)J/@;Z7W_I=<5S'_!1[_DV^7_L+6O\ [/73
M_L'_ /)J/@;Z7W_I=<5]!+_D3Q_Z^?HSPH_\C67^#]4>^T445\^>Z%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %?'?_  4P_P"28^$_^PP?_1#U]B5\=_\ !3#_
M ))CX3_[#!_]$/7J97_OE/U_0X\9_ D>\_LT_P#)O_P^_P"P+;?^BQ11^S3_
M ,F__#[_ + MM_Z+%%<>(_C3]7^9O2_AQ]$?'?[)'_)['C;_ 'M6_P#2D5^A
M]?GA^R1_R>QXV_WM6_\ 2D5^A]>IF_\ 'C_A1QX'^&_5A1117AGHA1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'RW_ ,%'O^3;Y?\ L+6O_L]=/^P?_P FH^!OI??^EUQ7
M,?\ !1[_ )-OE_["UK_[/73_ +!__)J/@;Z7W_I=<5]!+_D3Q_Z^?HSPH_\
M(UE_@_5'OM%%%?/GNA1110!\\?$3_@H)\ OA/XTU7PEXJ\>_V7X@TN40WEG_
M &/J$WE.5# ;XX&4\,.A/6N<_P"'HW[,7_13/_*!JG_R-7PS=?"WPM\9O^"O
M?BSPIXRTE=;\/WEY<O/9/+)$'*:>'0[HV5AAE!X/:OO/_AV?^S3_ -$OM?\
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M?WKQ+&VUV ^5CG.1D5ZO7RE\$_@!\#O!7[5OCGQSX0^)']O?$O56OSJWAO\
MMVQN?L9EN%>?_1HHQ-'LD"K\[';G!R:^K*E?PX-[M:]K^7D5+2I-+9/3O;S\
MQ:\I\4?M2?##P7\8-(^%VL^)OL?CO5O)^Q:3]@NG\WS21'^]6(Q+DJ?O.,8Y
MQ6RWQ^^&"^(O^$?/Q'\(C7O,\G^RSKMK]JWYQM\KS-V[VQFOSF_:B_Y2_?"3
MZZ/_ .C):(>]6I0Z3E;\'L14?)1JS6\8MGZK45S?C;XE>$?AG9VUYXO\5:+X
M4M+F3R8+C6]1ALXY9,9V*TK*&; )P.<"CQ=\2O"/P^TV#4?%/BK1?#6GSG$5
MUJ^HPVL4AQGY7D8 \>AI>99TE%8/@_Q[X9^(6FG4?"OB+2?$VGAMAN]'OHKN
M(-Z;XV(S^-;U5MN(**Y?QK\4O!GPUCAD\7>+M!\+1S?ZI]:U.&S#_P"Z9&7/
MX5:\'^/O#'Q"TXZAX6\1Z3XEL%;:;K1[Z*[B!]-T;$9I+78-MS>HKGO&WQ%\
M*?#738=1\7^)]&\*Z?-*((KK6]0BLXGD()"*\C*"V%)P#G /I6KH^LZ?XBTF
MSU32KZVU/3+R)9[:\LYEEAGC895T=20RD$$$'!H N45F^(O$FD>#]%NM8U[5
M;+1-(M%WW&H:C<);P0KD#+R.0JC) R3WJ'PGXRT#QYHD.L^&=<TWQ%H\Q98M
M0TF[CNK=RI*L%DC)4D$$'!X(H V*\3^-'[9WP<_9Y\4V_ASX@>,/[ UFXM5O
M8[;^S+RYW0LS*&W0PNHY1A@G/'2O;*_(?_@IAX?T_P 6?\%#/A%HFK6XN]+U
M*TTBSN[=F91+#)J,R.N5((RI(R"#S27-*K3IQ^T[?@RTDJ=2<OLJ_P"*_P S
M[._X>C?LQ?\ 13/_ "@:I_\ (U=S\-?VWO@5\7-2AT[PQ\2]&NM1F<1PV=Z9
M+&:9CT6-+A8V=CZ*":Y/_AV?^S3_ -$OM?\ P:7W_P ?KQ[]HK_@D3\+?%G@
MF_G^%EC/X+\76\;36D1OI[FSO' R(I1,[LF[H&0@*3DAAQ0Y*"YI*Z\B5%R=
MD['W]7E7QH_:D^&'[/.I:%8?$#Q-_8%WKGF?V?']@NKGSMA16YAB<+@R)]['
M7ZU\D_\ !*G]JOQ'X_L_$'P>^(%S/<>*_"B%[*XOF)NI+9'\N6&4GDM"Y4 G
MG:P'\.:]@_;2^ /P0^,WB+P-=_%OXC_\(+?Z5Y_]DP?VY8Z=]LW/$7^6YC8R
M8*1CY,8W<]16KBE4IZWA*VOEY>?W]3.,FX3NK2CT\_/R/JI6#*".0>12TV,!
M8U"G( X-<1XN^.WPU^'^I_V;XH^(7A7PWJ.-WV35];MK67'KLD<']*STN5&[
M5SN:*S?#_B32/%FEQ:EH>J66LZ=,,QWFGW"3PO\ 1T)!_ UI4]MQA17'>-/C
M)X ^&]U%;>+?'/AOPM<2C='#K6KV]F[CU D=216YX:\6:)XTTF/5/#^L:?KN
MF2?<O--NDN(7^CH2#^=):ZH'IN:M%%<QXT^*/@SX;QQ2>+?%VA>%XY?]6VM:
ME#9A_H9&7-*XSIZ*Y/P7\6_ WQ(>5/"/C/P]XI:(;I%T758+PH.F3Y;MBNLJ
MB0HKE/&WQ8\$?#7R?^$N\9>'_"OG<Q?VWJD%GYG^[YCKG\*N>#_B#X6^(5BU
M[X5\2Z1XELU.&N-'OXKN,'T+1L126NPWIN;]%%<[XR^(_A/X<V<=WXL\4:+X
M7M9#M2?6=0AM$8^@:1E!I7MN/<Z*BN<\%_$CPC\1[26Z\)>*=%\46L1VR3:+
MJ$-XB'T+1LP!KHZK;<045RGC;XL>"/AKY/\ PEWC+P_X5\[F+^V]4@L_,_W?
M,=<_A5SP?\0?"WQ"L6O?"OB72/$MFIPUQH]_%=Q@^A:-B*2UV!Z;F_1110 5
MP.E_';P-K7Q;U/X9:?KHO?&^F6@O;[3;>UG=;:([<&28)Y2L=Z_*7W?,.*YO
M]K;X_6G[-/P&\2^-Y@DNH01"VTNV?I/>2?+$I'< Y=O]E&KR?_@FK\%[KP+\
M#V\?>)7DOO'GQ%F_M_5;^XYF:*0EH$)]"K&0CUE(["BG[\I/[,=_5[+]7Y>H
M3]V,>\GIZ+=_HO/T/5OC;^V!\(_V<]<L-&^(?BW_ (1[4KZW^UV\/]FWESOB
MW%=VZ&)P/F4C!(/%><_\/1OV8O\ HIG_ )0-4_\ D:OCS_@K=I=KKG[6WP:T
MV^B\^RO+*VMYXB2-\;W[*RY!R,@GI7VA_P .S_V:?^B7VO\ X-+[_P"/U%)R
MG2]H^\E]SL74Y85?9KM%_>BE_P /1OV8O^BF?^4#5/\ Y&KZ.\#^-M%^)'A#
M2/%'AR]_M'0M6MDN[*Z\IXO-B895MCJK+D=F -?/W_#L_P#9I_Z)?:_^#2^_
M^/UZOXFFT7]F_P" .LW'A_2UM]$\&Z#<3V6FK([@1P0LZ1[F)8CY0,DDU4Y1
MITY3ET_+J3&,ZE2,(]?SZ%GXJ?'KX=_!&SCN/'7C+2/#(E0O##?7*B>91U,<
M0R[X_P!E37D>A_\ !2C]FSQ!JD=A:_%&RBG=MH>^T^]M(?QEFA5 /<MBOA;]
M@S]E'2_V[-8\:?&+XTZO?^*#_:K68TQ+MX?/F\M9&,CH0ZQ*LB*B(5 VXS@8
MK[3UO_@EO^S7K&DS6</@!]*E9"L=Y8ZQ>B:(XP&&^9E)'^TK#U!JG&=-+VF[
M5[+SUW]!<T9-J&VUW_D?3WA_Q%I7BS1[75M#U.SUG2KI-]O?:?.D\$J^JNI*
ML/H:T:_(_P#9G7Q9^P;^WU)\%&U:\UKX?^))HXXQ(#L(G0FUN=HX24.OE.1@
M, W'"X_2W]H#XSZ3^S[\'_$OCW6AYMKI%MOCMU;#7$[$)%$#V+.RKGMDGM2G
M*"I*O%^Z_O36Z]?ZW",9.HZ+^+3[GLSH_&WQ"\+_  UT5M7\6^(M+\,Z6&V?
M;-6O([:(L>BAG(!8]@.37@%]_P %,_V:-/U!K.7XH6[S*VTM!I5_+'G..)$@
M*$>X.*^%?V<_V8?'/_!2[Q?J7Q=^,OB?4+3P;'=/;V5K8D(TV#\T%J&RL,"<
M MM8L01RVYA]PVW_  2__9GM['[,?ALLW&#-)K.H&0G'7/G\'Z8%/EG%)ST;
MZ!S0DVH:VZGNGPS^-'@3XR:;)?>!_%ND>*+>(*9O[-NTE>'/02(#NC)]& -=
MI7Y!_MC?L5ZG^PK?:9\;_@;X@U33-+L+Q([RSFF\R2PWMA,/C][;L<1LDF3E
MER6#';^F7[-_QFM?V@?@AX1\>VL:P-K%F'N+=#D0W"DI-&#Z+(K@>P%5'EJ0
M<X='9KMU1,N:$E&7573.M\:>//#?PYT.76O%6O:;X<TB,A7OM4NDMX@QZ+N<
M@9/8=37S[<?\%,OV:+;46L7^*%N9E?86CTJ_>+/_ %T6 H1[YQ7PU=>%[[_@
MI!_P4)\7^%?%VO7FG>!O!K7D<&FVLH5A;VTZVY6('(5Y9"'=\$XX[+C[=A_X
M)@?LSPV7V8_#59!C!E?6=0,A]]WVC@_2LH<TJ<:KVDKI=;&D^6,Y4UO'1]KG
MOGP\^*W@WXM:0VJ>"_%&D^*+!"%DFTN[2?RF(R%<*<HV/X6 -=77XV_M._ W
M5?\ @FA\>_!'Q'^$>I:D_AG5YI(WTF>4R'Y"K36<A'^LA=#E=P+*5)SN4-7[
M!Z#K$'B+0].U6UW?9KZVCNHMPYV.H9<_@16D>6</:0[V:ZI_\'I_5\Y7A/DE
MU5T^Z_X!?HHHJ2@KR;0_VJOA;XD^,][\)].\4?:/']FTJ3Z1_9]TNPQIO<><
MT0B.%YX?GM7K-?DY\#_^4SGC3_KYU3_TEI4WS8A4GLXS?_@*5OS%5?)1=1;\
MT5][LS]8Z**X;Q+\=OAKX,UO^QO$'Q"\*Z%J^0/[/U+6[:WN.>G[MW#<_2GU
ML/S.YHKEO%WQ5\%?#_3[&_\ %'C#0?#=C?MMM+K5]3@M8K@XSB-I& <X.>,\
M5U"L&4$'(/((H RO%GBK2? OA?5O$6NWJ:=HNE6LE[>7<@)6*&-2SMA02< '
M@ D]@:\Y^!_[67PI_:0OM5L_AUXL3Q#=:7&DUW";&YM6C1R0K 3Q)N&5(.W.
M.,XR,_,W_!7_ .-$G@OX#:9\/M,D8ZUXVO1"T46=YLX65Y ,?WI#"F.X9A7S
M'X<\%W7_  3=_;1^$=S<NUMX8\6:%96.L2R,?+\V1$BO,DGHEPL<WL& Z44/
MWM3EELWRKSE9O[NC[/<*W[NGS+=+F?\ ANE]^[/V1KSKXV?M!^ /V=/#UCKG
MQ#U__A'M+O;H65O<?8[BYWS%&?;MAC=A\J,<D <=:]$SGD<BOSO_ ."V7_)O
M?@?_ +&A?_22XK*K)PC==TOO:1I3BI.S[/\ !7/NKX;?$OPS\7_!>F^+?!^K
MPZYX>U%2]M>PJR!L,58%7 96!!!5@"".173U^-O_  3G_: UW]DWXOVWPF^(
MI;3_  GXSAM=0TZ:9OW-M<7,2-;SHQX\N92J,>S*N<;6K]DJZZD%&TH[/\&M
MT_-'-3FY74M_T>S^9Y3XH_:D^&'@OXP:1\+M9\3?8_'>K>3]BTG[!=/YOFDB
M/]ZL1B7)4_><8QSBNH^*GQ8\+_!/P7>>+?&6H2:5X>LV1;B\CLY[H1;V"J66
M%'8#<0,XP,C)K\U_VH_^4OWPD^NC_P#HR6OT_P#%WA32_'?A75_#FMVB7VCZ
MK:R6=W;2#B2)U*L/R/7M7,N:6&]K'XN:2\O=:M]_](UNEB'2E\-HOSUO?\B?
MP_X@TWQ7H>GZSH][#J6E:A ES:WENX>.:)P&5U(Z@@BM"OSY_P"">'Q"U7X,
M?%[XA?LL^++R2YE\-W4U[X:N9SS+:$AS&/JDB3 #IND]!7Z#5M+E:C.'PR5U
MZ/\ RV)7,FX3^*+L_P"O-:A1114%!1110!SGQ)_Y)WXI_P"P5=?^B6K\I_A#
M_P BW<_]?;?^@)7ZL?$G_DG?BG_L%77_ *):ORG^$/\ R+=S_P!?;?\ H"5^
MC<'_ ,2H?#\5?[O$[BBBBOU4_+ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV=H6DV[75[=^4\OE1+RS;$5F;Z*":^*_^",__)J.J?\ 8SW?_HBWKWW]N?\
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M\,@]5=20?P-:%/;<-PK(\6>,-"\!Z#<ZWXDUFQT'1[4 S7^I7"00QY.!EW(
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M-9M.,C$X"K]I2/<2>PYZ5ST/_!-']FIHD)^%]J25!/\ Q-+[_P"/UYY\:/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXUNPRT<>K,O/0FY@'\B:WJQ4L?!/_GV__2(&<6U@Y\N_.O\ TJ6OJNGF=O\
M'#_@D?\ "/1?@9X@N?"$FM6?BW1].FO;;4KV_P#-%V\2,^R9-H0!L8RBK@X/
M."#X'^P[\,_&_P"WMX)B\%_$3QMK,/PA\ [(X]/L)0L^H3R%FCBDE;=E(E7
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M7PX\>_%7X!>)',6I:3>2:A;0MD 21.+>Z"Y['$+#VW&OT[K\K_VT+-_V2?\
M@H7\-OC;9H;?P[XFD1-59,A=R@6]WG'K!)&X]6!/:N:E)K$1BWI-<GSNY1^5
M[G34C>C)I:Q?-^C^;7Y'U/\ \%+_ (U?\*9_9/\ $YM9_)UGQ)C0+':2&'G
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M_@K)_P G*?L[?]?'_MY;U]:_\%&M/O=2_8J^*45@"9DL(IGQ_P \DN8GE_\
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MK_DS>_\ ^PU8?^A-7LG[#B+'^R#\(PJA1_PCMJ< 8Y*9)_.L\.ERXAO^9?\
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M59PH)VA]H<#L'QVKT2N4^&7Q3\*_&3PE;^)_!FLPZ]H-P[1Q7L"NJLRG###
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M'\,!^S=X3F^$MJMKX7G@WR+)@W1N\ 3_ &E@/FF##!/3 &WY=M>[U^-7P/\
MB#XE_P""7?[5VK?#CQO/-<_#/7IE<WF#Y9A8[8-008^\H!251Z-UV+7['VEW
M!J%K#=6TT=Q;3(LD4T3!D=2,A@1P00<YKJJ259*O#:7X/JOE_6MSDA%T6Z,M
MU^*[_/\ K='Y5_L3?\I6OCE_OZ]_Z<(J['_@I=\:?&OQ!^,7@W]F;X>7\FF3
M^(O).L7$,C(91.S*D+LIR(E16DD'\0*CH"#QW[$W_*5KXY?[^O?^G"*G>/\
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M%^ .B>#M*\96OCW3K6>YFAUNSB6.*42RLY5566084L1PYS[5\/?!NW/[&_\
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MC*9?&GP&^*BZ7:S.\]A%)*+VU60.1B"]@?>BJP*\K(PP<L2*\\\7>-?VT?\
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M&,H->XU;T[?CV)Y9-23]^]_7^D?KQI<EU-IMI)?0K;WKPHT\*-N5)"HW*#W
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M_5LPHQ=7"TY1^.$5\U;5?+I_DC7_ &H_^4OWPD^NC_\ HR6OU6K\=_B%\6-
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M_P#0XZ^_Z^ /^"G/_(R^ _\ KTNO_0XZ]K)_]]A\_P F>?C_ /=Y?+\S[O\
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M D4GCJ#D@@@D%2BZN$C%._O27R37N_FO/YBA)0Q<FU;W8OYM/7\F?)'[/O\
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MW?K3H>LVGB+1=/U:PE$]C?6\=U;RCH\;J&4_B"*_,#XI?\$N[J/3].M_B/\
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M4W\>C?9WT7IT_P VSAA%U:$>3[-FEW5M_7K_ )6/U]K\G?\ @L]_R5[X+_\
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MS:^YM'YP_P#!;C_DBOP^_P"QA?\ ])I*^G/C)_R8;XK_ .R?3?\ I :^8_\
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MWO%'B33?!OAO5M?UBY^QZ1I5I+?7EQL9_*AC0N[;5!8X52< $G' KPKX>_\
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MR"*]-_8#_86U[X&^(-:^*7Q2U%-7^*&O+('C6;SQ9+*P>8O)T>9VQN*Y4 $
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M^SM>Z[XPA MH_$3:;<K9NP&/,E:/]PY[EDE1/85XUX1_9E^/N@_MU?"OQO\
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M1,UNS<;E=&3=G;DDL?U>HH;E[251/66_G_7]= 2BJ:IVT6WD?E)\4KK]KO\
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MO':>3[+WS7TA57]R">]E?U>OX7M\A/\ B3:VOI^7W7U7D%?F1\'?A'XZTO\
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M@BGL[9U2.24#D[)@DD63_#AR,]344VESI.UWJN_FOZ_4UJ7:@VKV6C[:[/\
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MBBB@ HHHH **** "O@#_ (*<_P#(R^ _^O2Z_P#0XZ^_Z^ /^"G/_(R^ _\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX[_X*8?\DQ\)_P#88/\
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M\R^S+=0L#^8K\T?^".^L0:;^UX;:9E5]0\/WMO#N.-SAHI,#U^6-C^%?I/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P!!$/\ P*/^8?V;CO\ GQ/_ ,!?^1Y=17J/_#,GQ+_Z%O\ \G[;_P".4?\
M#,GQ+_Z%O_R?MO\ XY1_:F _Z"(?^!1_S#^S<=_SXG_X"_\ (\NHKU'_ (9D
M^)?_ $+?_D_;?_'*/^&9/B7_ -"W_P"3]M_\<H_M3 ?]!$/_  */^8?V;CO^
M?$__  %_Y'EU%>H_\,R?$O\ Z%O_ ,G[;_XY1_PS)\2_^A;_ /)^V_\ CE']
MJ8#_ *"(?^!1_P P_LW'?\^)_P#@+_R/+J*]1_X9D^)?_0M_^3]M_P#'*/\
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MCO\ GQ/_ ,!?^1Y=17J/_#,GQ+_Z%O\ \G[;_P".4?\ #,GQ+_Z%O_R?MO\
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M )A_9N._Y\3_ / 7_D>745ZC_P ,R?$O_H6__)^V_P#CE'_#,GQ+_P"A;_\
M)^V_^.4?VI@/^@B'_@4?\P_LW'?\^)_^ O\ R/+J*]1_X9D^)?\ T+?_ )/V
MW_QRC_AF3XE_]"W_ .3]M_\ '*/[4P'_ $$0_P# H_YA_9N._P"?$_\ P%_Y
M'EU%>H_\,R?$O_H6_P#R?MO_ (Y1_P ,R?$O_H6__)^V_P#CE']J8#_H(A_X
M%'_,/[-QW_/B?_@+_P CRZBO4?\ AF3XE_\ 0M_^3]M_\<H_X9D^)?\ T+?_
M )/VW_QRC^U,!_T$0_\  H_YA_9N._Y\3_\  7_D>745ZC_PS)\2_P#H6_\
MR?MO_CE'_#,GQ+_Z%O\ \G[;_P".4?VI@/\ H(A_X%'_ ##^S<=_SXG_ . O
M_(\NHKU'_AF3XE_]"W_Y/VW_ ,<H_P"&9/B7_P!"W_Y/VW_QRC^U,!_T$0_\
M"C_F']FX[_GQ/_P%_P"1Y=17J/\ PS)\2_\ H6__ "?MO_CE'_#,GQ+_ .A;
M_P#)^V_^.4?VI@/^@B'_ (%'_,/[-QW_ #XG_P" O_(\NHKU'_AF3XE_]"W_
M .3]M_\ '*/^&9/B7_T+?_D_;?\ QRC^U,!_T$0_\"C_ )A_9N._Y\3_ / 7
M_D>745ZC_P ,R?$O_H6__)^V_P#CE'_#,GQ+_P"A;_\ )^V_^.4?VI@/^@B'
M_@4?\P_LW'?\^)_^ O\ R/+J*]1_X9D^)?\ T+?_ )/VW_QRC_AF3XE_]"W_
M .3]M_\ '*/[4P'_ $$0_P# H_YA_9N._P"?$_\ P%_Y'EU%>H_\,R?$O_H6
M_P#R?MO_ (Y1_P ,R?$O_H6__)^V_P#CE']J8#_H(A_X%'_,/[-QW_/B?_@+
M_P CRZBKMMHUY>?$H_#^*'?XN$KP'3MRCYU0R,/,)\OA03][]:]$_P"&9/B7
M_P!"W_Y/VW_QRM)9A@Z=N>M%7U^)?YDQR_&2^&C)_P#;K_R/+J*]1_X9D^)?
M_0M_^3]M_P#'*/\ AF3XE_\ 0M_^3]M_\<K/^U,!_P!!$/\ P*/^97]FX[_G
MQ/\ \!?^1Y=17J/_  S)\2_^A;_\G[;_ ..4?\,R?$O_ *%O_P G[;_XY1_:
MF _Z"(?^!1_S#^S<=_SXG_X"_P#(\NHKU'_AF3XE_P#0M_\ D_;?_'*/^&9/
MB7_T+?\ Y/VW_P <H_M3 ?\ 01#_ ,"C_F']FX[_ )\3_P# 7_D>745ZC_PS
M)\2_^A;_ /)^V_\ CE'_  S)\2_^A;_\G[;_ ..4?VI@/^@B'_@4?\P_LW'?
M\^)_^ O_ "/+J*]1_P"&9/B7_P!"W_Y/VW_QRC_AF3XE_P#0M_\ D_;?_'*/
M[4P'_01#_P "C_F']FX[_GQ/_P !?^1Y=17J/_#,GQ+_ .A;_P#)^V_^.4?\
M,R?$O_H6_P#R?MO_ (Y1_:F _P"@B'_@4?\ ,/[-QW_/B?\ X"_\CRZBO4?^
M&9/B7_T+?_D_;?\ QRC_ (9D^)?_ $+?_D_;?_'*/[4P'_01#_P*/^8?V;CO
M^?$__ 7_ )'EU%>H_P##,GQ+_P"A;_\ )^V_^.4?\,R?$O\ Z%O_ ,G[;_XY
M1_:F _Z"(?\ @4?\P_LW'?\ /B?_ ("_\CRZN_\ A!\(-3^+&N^1!NM=*MV!
MO+XKQ&/[J^KGL/Q-=1X5_93\;ZIKMM;ZU8+HNF%LSW9N892JCJ%5')+'MGCU
MK[%\*^%=,\%:%;:1I%LMK96XPJCJQ[LQ[L>YKYO.N(Z.%I^SP<E.;ZIII>?K
MV7W^?T&4</U<34]IBXN,%T>C?_ \_N\CPKX5TSP5H5MI&D6RVME;C"J.K'NS
M'NQ[FM>BBOQ^<Y5).<W=L_5XQC3BHQ5D@HHHJ"@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#RW]J3_DWGQ_\ ]@F7^5>*?\$TO^20^)O^
MPZW_ *3PU[7^U)_R;SX__P"P3+_*O%/^":7_ "2'Q-_V'6_])X:]RE_R+:G^
M)?H>=/\ WN'HSZ]HHHKPST0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "OCO\ X*8?\DQ\)_\ 88/_ *(>OL2OCO\ X*8?\DQ\)_\ 88/_ *(>
MO4RO_?*?K^AQXS^!(]Y_9I_Y-_\ A]_V!;;_ -%BBC]FG_DW_P"'W_8%MO\
MT6**X\1_&GZO\S>E_#CZ(^._V2/^3V/&W^]JW_I2*_0^OSP_9(_Y/8\;?[VK
M?^E(K]#Z]3-_X\?\*./ _P -^K"BBBO#/1"BBB@ HHHH **** "BBB@ HHHH
M _"/_@J[\:#\4OVJ-1T2TG,ND>#[=='A4-E3<??N&'OO8(?^N0K])/V/_P!B
MCX:^%?V;O EMXQ^&OA77_%-SIZW^H7FM:':W5SYLY,OEL\B%OW8<)C/&RO;-
M0_9A^#FK:E<ZA??";P->7]S*T\]U<>&[.2661B69V<Q99B2223DDUZ6JA5"J
M % P .@HHVI4?9O=N[?WM_>W^ ZO[RJIK9=/N2_!'E?_  R=\$/^B-_#_P#\
M)>Q_^-5^'G[?_P %X_V??VK/%6DZ1:)I6BWDB:SI$=JHCCAAF^;;&%P%5)!(
M@ Z!!7]#%<9XV^"WP]^)FH07WB_P)X9\5WMO'Y,-SK>CV]Y)''DG8K2HQ"Y)
M.!QDFLW&7/&<7:W]??=(M27)*$EO_7Y7/#+#XQ1_'G_@G1X@\:B17N[_ ,":
MDE\$/W;N.TECG'M^\1B/8BOS3_X)!_\ )Y%A_P!@2^_]!6OVLT/X8^#O"_A6
MZ\,:-X3T/2?#5TLBW&C6.FPPV<PD7;('A50C!APV1R.M9?@_X#?#/X>ZRNK^
M%OAWX3\-:LJ-$+_1]$MK2<(WWE\R- V#W&>:Z.9+$3K):25K??\ YF$HN6&A
M0ZQ=[_./XZ&K\2?A[HOQ8\!Z[X0\16HO-%UBU>TN8^^UAPRGLRG# ]B :_G
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M'?;D<L0HW8 RV?W]\6>"/#GC[2SIOB?0-+\1Z<3N-GJUE'=0D^NR12/TK/\
M!7PG\$?#7SO^$1\&^'_"OG#$O]BZ7!9^9_O>6BY_&JC[RBJNMOZ_KSU)?NMN
MEHW_ %_7EH?/_P#P3I_9-O/V5_@K+;^(!'_PF?B&=;_58XV#K:@+MBMPPX8H
M"Q)'&YV ) !/Q5_P5L_9 \0:;\1+KXS^&=,FU+PYJL,?]N?98R[6%Q&@3SG
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MD;!11169H%%%% !1110 4444 %%%% !1110 4444 ?+?_!1[_DV^7_L+6O\
M[/73_L'_ /)J/@;Z7W_I=<5S'_!1[_DV^7_L+6O_ +/73_L'_P#)J/@;Z7W_
M *77%?02_P"1/'_KY^C/"C_R-9?X/U1[[1117SY[H4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '.?$G_DG?BG_L%77_
M *):OC;_ ()?_=^)?_<-_P#;JOLGXD_\D[\4_P#8*NO_ $2U?&W_  2_^[\2
M_P#N&_\ MU7N8;_D7XCUC^9YU;_>J7S_ "/NRBBBO#/1"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KXO_X*:_\ (D>"O^PC-_Z*%?:%?%__  4U
M_P"1(\%?]A&;_P!%"O5RO_?*?]=&<6-_W>1])?L__P#)"?AU_P!B[I__ *3Q
MUWU<#^S_ /\ )"?AU_V+NG_^D\==]7!6_BR]6=-/X(^@4445B:!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ]K)_P#?8?/\F>?C_P#=Y?+\S[O\/_\ (!TW_KVC_P#0!6A6?X?_ .0#IO\
MU[1_^@"M"O'ENSO6P4445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y
M;_X*/?\ )M\O_86M?_9ZZ?\ 8/\ ^34? WTOO_2ZXKF/^"CW_)M\O_86M?\
MV>NG_8/_ .34? WTOO\ TNN*^@E_R)X_]?/T9X4?^1K+_!^J/?:***^?/="B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M YSXD_\ )._%/_8*NO\ T2U?&W_!+_[OQ+_[AO\ [=5]D_$G_DG?BG_L%77_
M *):OC;_ ()?_=^)?_<-_P#;JO<PW_(OQ'K'\SSJW^]4OG^1]V4445X9Z(44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %?%__  4U_P"1(\%?]A&;
M_P!%"OM"OB__ (*:_P#(D>"O^PC-_P"BA7JY7_OE/^NC.+&_[O(^DOV?_P#D
MA/PZ_P"Q=T__ -)XZ[ZN!_9__P"2$_#K_L7=/_\ 2>.N^K@K?Q9>K.FG\$?0
M****Q- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5\ ?\ !3G_ )&7P'_UZ77_ *''7W_7P!_P4Y_Y
M&7P'_P!>EU_Z''7M9/\ [[#Y_DSS\?\ [O+Y?F?=_A__ ) .F_\ 7M'_ .@"
MM"L_P_\ \@'3?^O:/_T 5H5X\MV=ZV"BBBI&%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5\=_\%,/^28^$_P#L,'_T0]?8E?'?_!3#_DF/
MA/\ [#!_]$/7J97_ +Y3]?T./&?P)'O/[-/_ ";_ /#[_L"VW_HL44?LT_\
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M"0>QK\C?^"G'Q^^)_@']KKQ%HWACXC^+O#FD165B\>GZ3KMU:VZ,T"EB(XY
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M(5555&  ,(B\+G:"5&2/Z#_@7\#?"G[._P .--\&>#['[)IMHNZ6:3#3W<Q
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M'?\ KYK[S.4G!I26CV/JRBBBH+"BBB@#Y;_X*/?\FWR_]A:U_P#9ZZ?]@_\
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MH]PHKP__ (;8^"O_ $.\7_@ON_\ XU1_PVQ\%?\ H=XO_!?=_P#QJCZGB?\
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MQ?\ @ON__C5'U/$_\^I?<P]O2_G7WH]PHKP__AMCX*_]#O%_X+[O_P"-4?\
M#;'P5_Z'>+_P7W?_ ,:H^IXG_GU+[F'MZ7\Z^]'N%%>'_P##;'P5_P"AWB_\
M%]W_ /&J/^&V/@K_ -#O%_X+[O\ ^-4?4\3_ ,^I?<P]O2_G7WH]PHKP_P#X
M;8^"O_0[Q?\ @ON__C5'_#;'P5_Z'>+_ ,%]W_\ &J/J>)_Y]2^YA[>E_.OO
M1[A17A__  VQ\%?^AWB_\%]W_P#&J/\ AMCX*_\ 0[Q?^"^[_P#C5'U/$_\
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MT>X45X?_ ,-L?!7_ *'>+_P7W?\ \:H_X;8^"O\ T.\7_@ON_P#XU1]3Q/\
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M^"^[_P#C5'_#;'P5_P"AWB_\%]W_ /&J/J>)_P"?4ON8>WI?SK[T>X45X?\
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M?<P]O2_G7WH]PHKP_P#X;8^"O_0[Q?\ @ON__C5'_#;'P5_Z'>+_ ,%]W_\
M&J/J>)_Y]2^YA[>E_.OO1[A17A__  VQ\%?^AWB_\%]W_P#&J/\ AMCX*_\
M0[Q?^"^[_P#C5'U/$_\ /J7W,/;TOYU]Z/<**\/_ .&V/@K_ -#O%_X+[O\
M^-4?\-L?!7_H=XO_  7W?_QJCZGB?^?4ON8>WI?SK[T>X45X?_PVQ\%?^AWB
M_P#!?=__ !JC_AMCX*_]#O%_X+[O_P"-4?4\3_SZE]S#V]+^=?>CW"BO#_\
MAMCX*_\ 0[Q?^"^[_P#C5'_#;'P5_P"AWB_\%]W_ /&J/J>)_P"?4ON8>WI?
MSK[T>X45X?\ \-L?!7_H=XO_  7W?_QJC_AMCX*_]#O%_P""^[_^-4?4\3_S
MZE]S#V]+^=?>CW"BO#_^&V/@K_T.\7_@ON__ (U1_P -L?!7_H=XO_!?=_\
MQJCZGB?^?4ON8>WI?SK[T>X45X?_ ,-L?!7_ *'>+_P7W?\ \:H_X;8^"O\
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M/@K_ -#O%_X+[O\ ^-4?4\3_ ,^I?<P]O2_G7WH]PHKP_P#X;8^"O_0[Q?\
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M?^AWB_\ !?=__&J/J>)_Y]2^YA[>E_.OO1[A17A__#;'P5_Z'>+_ ,%]W_\
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MQ?\ @ON__C5'U/$_\^I?<P]O2_G7WH]PHKP__AMCX*_]#O%_X+[O_P"-4?\
M#;'P5_Z'>+_P7W?_ ,:H^IXG_GU+[F'MZ7\Z^]'N%%>'_P##;'P5_P"AWB_\
M%]W_ /&J/^&V/@K_ -#O%_X+[O\ ^-4?4\3_ ,^I?<P]O2_G7WH]PHKP_P#X
M;8^"O_0[Q?\ @ON__C5'_#;'P5_Z'>+_ ,%]W_\ &J/J>)_Y]2^YA[>E_.OO
M1[A17A__  VQ\%?^AWB_\%]W_P#&J/\ AMCX*_\ 0[Q?^"^[_P#C5'U/$_\
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MT>X45X?_ ,-L?!7_ *'>+_P7W?\ \:H_X;8^"O\ T.\7_@ON_P#XU1]3Q/\
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M^O:/_P! %:%>!Z/^VA\&;72+&&7QK&LD<$:,OV"[."% (_U57/\ AMCX*_\
M0[Q?^"^[_P#C5>5+!XF[_=R^YG:J]*WQK[T>X45X?_PVQ\%?^AWB_P#!?=__
M !JC_AMCX*_]#O%_X+[O_P"-4OJ>)_Y]2^YC]O2_G7WH]PHKP_\ X;8^"O\
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M7W?_ ,:H_P"&V/@K_P!#O%_X+[O_ .-4?4\3_P ^I?<P]O2_G7WH]PHKP_\
MX;8^"O\ T.\7_@ON_P#XU1_PVQ\%?^AWB_\ !?=__&J/J>)_Y]2^YA[>E_.O
MO1[A17A__#;'P5_Z'>+_ ,%]W_\ &J/^&V/@K_T.\7_@ON__ (U1]3Q/_/J7
MW,/;TOYU]Z/<**\/_P"&V/@K_P!#O%_X+[O_ .-4?\-L?!7_ *'>+_P7W?\
M\:H^IXG_ )]2^YA[>E_.OO1[A17A_P#PVQ\%?^AWB_\ !?=__&J/^&V/@K_T
M.\7_ (+[O_XU1]3Q/_/J7W,/;TOYU]Z/<**\/_X;8^"O_0[Q?^"^[_\ C5'_
M  VQ\%?^AWB_\%]W_P#&J/J>)_Y]2^YA[>E_.OO1[A17A_\ PVQ\%?\ H=XO
M_!?=_P#QJC_AMCX*_P#0[Q?^"^[_ /C5'U/$_P#/J7W,/;TOYU]Z/<**\/\
M^&V/@K_T.\7_ (+[O_XU1_PVQ\%?^AWB_P#!?=__ !JCZGB?^?4ON8>WI?SK
M[T>X45X?_P -L?!7_H=XO_!?=_\ QJC_ (;8^"O_ $.\7_@ON_\ XU1]3Q/_
M #ZE]S#V]+^=?>CW"BO#_P#AMCX*_P#0[Q?^"^[_ /C5'_#;'P5_Z'>+_P %
M]W_\:H^IXG_GU+[F'MZ7\Z^]'N%%>'_\-L?!7_H=XO\ P7W?_P :H_X;8^"O
M_0[Q?^"^[_\ C5'U/$_\^I?<P]O2_G7WH]PHKP__ (;8^"O_ $.\7_@ON_\
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MN8>WI?SK[T>X45X?_P -L?!7_H=XO_!?=_\ QJC_ (;8^"O_ $.\7_@ON_\
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M[F'MZ7\Z^]'N%%>'_P##;'P5_P"AWB_\%]W_ /&J/^&V/@K_ -#O%_X+[O\
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MKRUMM/$@(\XVXE\V1?5=TH3([HP[55%^UA4YU;EV_#_/[T357LW#E=[]/O\
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MJ'@6UT=/!NJPFWEU:XT]KBXM+T$G8S%_+"LF"N4Y*/R<5V8OE]E1O\O6\O\
MAOG;J<N'YO:U+=OPM_3^5^A^7OA?XT_M"?L=ZF=!LM:\5?#^12SC1-5MV^S\
MMRZVUPC1G)_C5>?6OJWX'_\ !:+QGHNI6EE\4O#.G^(](.U)=4T1#:WR#O(8
MRQBD/^R!']>U>Q_L[?\ !4CX3?$+X/P:'^T#?10>)H T-\]]H3WEEJ:ECMD6
M.")U4[2 RLBC(XR#Q\!?MS>.?@W\1/C/%>_ _P /1Z+X=2R2&Y:TLC96]Y<[
MF)DAM\#RUVE%^ZN2#\O<IRG":B_>O_7R_,<8PG%R7NV_KY]^Q^M?[>GQ*L_$
M7_!/WQOXK\*WHO\ 2M;TNS-M>0Y >WN+B%&..",HY!!Y&<&OR1_8G^+GQ6^#
M/Q!UK6_A%\/U\?Z_-IIM;FW.CWFI&VMVE1BX6V=67+(@R3CM7ZR_"_\ 9GUG
MQ!_P3=T[X1>(5^QZ_J'AN11'<9S:W$DC7$"/Z%',8([;37Y9_L5_M!W'[$G[
M25Y<>,-*O8=.:.;0M?L43_2+;$BG>$)&622,9&>5+8YQ1&,:>-JTU*V]GY:J
MWW[_ .(3DZF"ISM=WN__ "5W_!V7D>^?&K]IS]L+X\_"_7O ?B3]G2ZBT;68
MEBGEL?!.LK/'M=75D+RLH8,H()4UTO\ P2%^%?Q.^%OQR\7)XK\!>*O"NAZA
MX?;-UK6CW-G \\=Q%Y:!I$52VUY"!G. WO7KW[1O_!7WX=^$O!ULWP?NHO&_
MBBXG3<FI:;=V]G:PCES)O$3,Y'"A,C.23Q@^T?L)_M9>+?VM_!^L^(M<\ P^
M$])LIDM;74H;YY8]0FP3*$C:,%53Y<MN;EL=0:JA[LISBMDT_NM?\15M8QA)
MZ737K>_Z?<?4%%%%9EA1110!\Q?\%$(1)^SWN)8&/5[9A@XSQ(.?7K7E_P"S
M3^QC\/OBQ\$_#GBK7&U<:IJ'VGSOLMVJ1_)<RQKA2AQ\J#OUS7JG_!0S_DWB
M7_L*VO\ [/71_L._\FN>"O\ M]_]+9Z^BA6J4,M4J<K/G_0\J5.-3%M35_=_
M4Y;_ (=V_"C^_KW_ ('K_P#&Z/\ AW;\*/[^O?\ @>O_ ,;KZ?HKS?[0Q?\
MS\?WG7]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[
M0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^G
MZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\
M&Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'
MK_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ
M]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OP
MH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^
M'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\
M&Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'
MK_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ
M]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OP
MH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^
M'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(
M^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5
MH?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?
MWA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_
M #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[
M0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^G
MZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\
M&Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'
MK_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ
M]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OP
MH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^
M'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\
M&Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'
MK_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ
M]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OP
MH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^
M'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(
M^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5
MH?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?
MWA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_
M #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[
M0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^G
MZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\
M&Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'
MK_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ
M]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OP
MH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^
M'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\
M&Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'
MK_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ
M]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OP
MH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^
M'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(
M^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5
MH?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?
MWA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_
M #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[
M0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^G
MZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\
M&Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'
MK_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ
M]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OP
MH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^
M'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\
M&Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'
MK_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ
M]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OP
MH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^
M'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(
M^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5
MH?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?
MWA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_
M #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^GZ*/[
M0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\ &Z^G
MZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'K_\
M&Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ]_X'
MK_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OPH_OZ
M]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^'=OP
MH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\ &Z/^
M'=OPH_OZ]_X'K_\ &Z^GZ*/[0Q?_ #\?WA]5H?R(^8/^'=OPH_OZ]_X'K_\
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M&]_X1I;Z>W!68"?:EL\@^?;C.Y1VZ5]:?\.[?A1_?U[_ ,#U_P#C=>'^&_\
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M/^'=OPH_OZ]_X'K_ /&Z^GZ*\C^T,7_S\?WG=]5H?R(^8/\ AW;\*/[^O?\
M@>O_ ,;H_P"'=OPH_OZ]_P"!Z_\ QNOI^BC^T,7_ ,_']X?5:'\B/F#_ (=V
M_"C^_KW_ ('K_P#&Z/\ AW;\*/[^O?\ @>O_ ,;KZ?HH_M#%_P#/Q_>'U6A_
M(CY@_P"'=OPH_OZ]_P"!Z_\ QNC_ (=V_"C^_KW_ ('K_P#&Z^GZ*/[0Q?\
MS\?WA]5H?R(^8/\ AW;\*/[^O?\ @>O_ ,;H_P"'=OPH_OZ]_P"!Z_\ QNOI
M^BC^T,7_ ,_']X?5:'\B/F#_ (=V_"C^_KW_ ('K_P#&Z/\ AW;\*/[^O?\
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M<2/KOF2PI(V+Y<9*@G_EG5K_ (=V_"C^_KW_ ('K_P#&Z^C_  __ ,@'3?\
MKVC_ /0!6A7ERS#%W?[Q_>=BPM&WP(^8/^'=OPH_OZ]_X'K_ /&Z/^'=OPH_
MOZ]_X'K_ /&Z^GZ*G^T,7_S\?WC^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-T?\.[?A
M1_?U[_P/7_XW7T_11_:&+_Y^/[P^JT/Y$?,'_#NWX4?W]>_\#U_^-U\^_ME?
MLO\ @SX$^"]"U3PTVI&ZO=0-M+]MN1(NSRV;@!1@Y K](:^._P#@IA_R3'PG
M_P!A@_\ HAZ]'+\;B:F*A"<VTSEQ6'I0HRE&*N>[_LR0I#^S[\/U08!T>W;\
M2@)_4FBG?LT_\F__  ^_[ MM_P"BQ17C8C^-/U?YG?2_AQ]$?'?[)'_)['C;
M_>U;_P!*17Z'U^>'[)'_ ">QXV_WM6_]*17Z'UZF;_QX_P"%''@?X;]6%%%%
M>&>B%5=4TVVUK3+O3[V%;BSNX7@FB<95T92K*?8@FK5%3**DG&6S&FXNZ/PR
M_9AAN_V,?^"DEKX1UEVMK$:I-X=DED_Y:VUR,6LI/HQ:W?VYK]S:^(/^"@G_
M  3\U7]J77O#7C#P'JFE:!XUTY?LEW-JLLL,5Q;J2\3!XHY&$D;DX^7D.>1M
M%?7OP[M_$EGX$T"W\826,_BF&RBCU.;3)'>VDN%4!WC+JK;6(SRHQG%:4Y.6
M'C&?Q1T]5T?YW];$U$E7<H;25_1]?^!Y(UM8TR+6M)OM.G9T@NX'MY&C(#!7
M4J2,@\X/I7R#\%_^"5WPG^!7Q0T#QYH/B'QE=ZOHLS3V\.I7MH]NS%&0AU2U
M1B,.>C#G%?95%3'W9\\=_P#(<O>CR/8*BFNH;>.5Y9HXDB7?(SL $7U/H*EK
MX _X*&?\$\_&W[6'Q0T'Q;X-UOP]IOV/25TVZ@UR>>(L5EDD5E,4,F>),<XZ
M5$FTTDM_PT+BDTVWM^.I^<W_  4#\>>%_BQ^UUXTUCP.([W39IH+3[9:-O2^
MN(XDCDECQU!9=H(X;;N'WJ_;W]D_X/I\"?V=_ W@SREBO+'3DDOMO>[D_>3G
MW_>.P^@%?'G[)/\ P2-@^$?CS2?&OQ*\26/B74=)E%S9Z)I,+FS6=3E)))9
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >6_M2?\F\^/_\
ML$R_RKQ3_@FE_P DA\3?]AUO_2>&O:_VI/\ DWGQ_P#]@F7^5>*?\$TO^20^
M)O\ L.M_Z3PU[E+_ )%M3_$OT/.G_O</1GU[1117AGHA1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5\ ?\%.?^1E\!_]>EU_Z''7W_7P!_P4Y_Y&
M7P'_ ->EU_Z''7M9/_OL/G^3//Q_^[R^7YGW?X?_ .0#IO\ U[1_^@"M"L_P
M_P#\@'3?^O:/_P! %:%>/+=G>M@HHHJ1A1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXO_X*:_\
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M_P 3"BBBO#/1"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RW]J3_
M )-Y\?\ _8)E_E7BG_!-+_DD/B;_ +#K?^D\->U_M2?\F\^/_P#L$R_RKQ3_
M ()I?\DA\3?]AUO_ $GAKW*7_(MJ?XE^AYT_][AZ,^O:***\,]$**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "O@#_@IS_P C+X#_ .O2Z_\ 0XZ^
M_P"O@#_@IS_R,O@/_KTNO_0XZ]K)_P#?8?/\F>?C_P#=Y?+\S[O\/_\ (!TW
M_KVC_P#0!6A6?X?_ .0#IO\ U[1_^@"M"O'ENSO6P4445(PHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[&T]MMJ+TQ"/>;?>?DXW%MW?.>:^V/\ @K7_ ,F6^(O^PEI__I0M?D[\2/\
MD^[Q#_V42;_TXFOUB_X*U_\ )EOB+_L):?\ ^E"UQ3UP-&3W<H_G ZML=6BM
MDG_[>?EG^QO^T-\2_A#)XK\)?"/0FU;QWXV-I:65S'"+B2T$7G%F2(@J6Q)G
M<_R(%8L".1WGQ8\0_MN?LTWEGXP\<^)_'&BP74_[NXEUM-0T\2'D(\,<DD"9
MYPC*,X.!Q7LG_!$/PGI]]X]^)WB*:&.34M.T^SL[:1OO1I/)*TFT>_D("?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW_KVC_\ 0!6A6?X?_P"0#IO_ %[1_P#H K0KQY;L[UL%%%%2,**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPST0HHHH **** "BBB@ HHHH **** "BBB@ K^;G]K;_ ).T^+/_ &-VH_\
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MUXU_X6-_PE?GZ7-IOV'^P_L>W>\;[]_VF3IY>,;>_7BEA_<Q$YRV<;?.TO\
M-%UO>HQBMT[_ (Q_R/FC_@N%_P CY\*_^P;??^C8J^NO^"5/_)D?@G_KYU#_
M -+)J3]N#]@/_ALS7O"NI?\ "=_\(?\ V';3V_E?V/\ ;O/\QU;=GSX]N-O3
M!SFO7OV5/@%_PS)\$=$^'G]N_P#"2?V;)<2?VE]C^R^9YLSRX\OS'QC?C[QS
MC/'2C#?NZ,X2W;?_ *4W^05_?J0E'I;_ -)M^9^>O_!<;_D9/A#_ ->FI_\
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M_J\8P.N<\5,I**N_ZN7&+D[(^B:*\NU+XV_V?^S3-\6O[%\SR_"__"2?V/\
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M^V/[ T^2_P#L'G^1Y^P9V>9M;;GUVGZ5Q'['?[37_#67P@/CG_A&_P#A%?\
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M.*?VMOR_-6_X=$J2ES-?9W_/\G?0^@**16#J&4AE89!'(-+4E!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!SGQ)_Y)WXI_[!
M5U_Z):ORG^$/_(MW/_7VW_H"5^K'Q)_Y)WXI_P"P5=?^B6K\I_A#_P BW<_]
M?;?^@)7Z-P?_ !*A\/Q5_N\3N****_53\L"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M**** "BBB@ HHHH **** "BBB@ HI&.%)KY6_8Y_;G_X:S\:^._#_P#PA/\
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M4XD"CJ"%; )VX&:^B/&?C30_AWX6U+Q)XDU.WT?0]-A,]U>W3;4B0=SZDG
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M-WF>7)TQTV\^HI5/W23GHG;\7;\] A^\;4>G_#_D>UT5^6L/_!;F]N(UDB^
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M@ HHHH ^9O\ @H9_R;Q+_P!A6U_]GKH_V'?^37/!7_;[_P"EL]<Y_P %#/\
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M^U)\-_\ A-?"ECJNGZ5]MEL?)UB&**??&%+'$<DB[?G&/FSUXK3^/GQNT/\
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MNIY+>PUIM,M[QH7*,;86RO,H/J41@/<BOU'_ .&:_A8OP\F\#1^ ?#\/A>:
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MY':_!7_@I_\  KXU:];:)!K&H>$M7NY1#:VOBBU6V6=CT"RQO)$"3P S@DX
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M4_GL_O:O\S)0]C.I16T&TO3=?G8****S+"BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOU=K+.L%2P.(C3H[.-_Q?^1>38RKCL/*I6W3M^"_S"BBBOGSW@HHHH ^"/\
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M .!H?J+_ &'IQT7^QS86ITGR/LOV'R5\CR=NWR]F-NW;QMQC'%?EI\"[6/\
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MMX(BYE#E=GE329QY9SG'4=:]GU7PSIFM>&;SP]=VBOHUW:/836J,8U,#(49
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5\=_\%,/^28^$_\ L,'_ -$/7V)7
MQW_P4P_Y)CX3_P"PP?\ T0]>IE?^^4_7]#CQG\"1[S^S3_R;_P##[_L"VW_H
ML44?LT_\F_\ P^_[ MM_Z+%%<>(_C3]7^9O2_AQ]$?'?[)'_ ">QXV_WM6_]
M*17Z'U^>'[)'_)['C;_>U;_TI%?H?7J9O_'C_A1QX'^&_5A1117AGHA1110
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M8P3WK&C[N(<GMRM?@S:IKAG!;\T7\E>Y]OT444R3\J_^"K__ "==\ ?^V/\
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MO?\ !*_6O&'B!<:WJG@J62[<)L$LB@H9=H  W[=^!Q\W'%<__P $C]4AT/\
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M*\C;[RK&=T!QZ>4R+]4;TK##JT:T.MXR^5K?F;5OBHSZ6E'YWYOR.!_X+/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <Y\2?^2=^*?^
MP5=?^B6K\I_A#_R+=S_U]M_Z E?JQ\2?^2=^*?\ L%77_HEJ_*?X0_\ (MW/
M_7VW_H"5^C<'_P 2H?#\5?[O$[BBBBOU4_+ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTW_KVC_] %:%9_A__D Z;_U[1_\ H K0KQY;L[UL%%%%2,1AN4CUXKY#N?\
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MHJ-7VTGM&22[\VGX&-1N5+V26[3OZ%C]NKX(CX^?LP^,O#D$'GZQ;6_]J:6
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M6?LE_"KQ!X9\7ZAHVI7^H:RVHQ2:)/-+$(S#%'AC)%&=V8ST!&".:YK]KO\
MX)RZ=\>O&D7Q'\">)IOAW\3(2CMJ-N&$-VZ+A'8QD/%*,*/-0G@<J3@C6I4Y
M:_.M8RBHOY)6?R?WF<8<U'D>C4FU][NOFCZ^\0^(-/\ "N@ZAK6K7<5AI>GV
M[W5U=3L%2*-%+,S$]  #7Y?_ /!'[Q%%XN^.?Q\UV!&B@U1X;V-&ZJLEU<.
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MBK7_ ,*[5_\ Y&IT;TX\S^-[OMY+R_/[[E7WY<J^!;+OYO\ RZ?E^H]?E/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5\=_\%,/^28^$_\ L,'_ -$/7V)7
MQW_P4P_Y)CX3_P"PP?\ T0]>IE?^^4_7]#CQG\"1[S^S3_R;_P##[_L"VW_H
ML44?LT_\F_\ P^_[ MM_Z+%%<>(_C3]7^9O2_AQ]$?'?[)'_ ">QXV_WM6_]
M*17Z'U^>'[)'_)['C;_>U;_TI%?H?7J9O_'C_A1QX'^&_5A1117AGHA1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7_#$G_4Y_P#E*_\ MU'_  Q)_P!3G_Y2O_MU?45%/_67-?\ G]_Y+'_(Y_\
M5[+/^?7_ )-+_,^7?^&)/^IS_P#*5_\ ;J/^&)/^IS_\I7_VZOJ*BC_67-?^
M?W_DL?\ (/\ 5[+/^?7_ )-+_,^7?^&)/^IS_P#*5_\ ;J/^&)/^IS_\I7_V
MZOJ*BC_67-?^?W_DL?\ (/\ 5[+/^?7_ )-+_,^7?^&)/^IS_P#*5_\ ;J/^
M&)/^IS_\I7_VZOJ*BC_67-?^?W_DL?\ (/\ 5[+/^?7_ )-+_,^7?^&)/^IS
M_P#*5_\ ;J/^&)/^IS_\I7_VZOJ*BC_67-?^?W_DL?\ (/\ 5[+/^?7_ )-+
M_,^7?^&)/^IS_P#*5_\ ;J/^&)/^IS_\I7_VZOJ*BC_67-?^?W_DL?\ (/\
M5[+/^?7_ )-+_,^7?^&)/^IS_P#*5_\ ;J/^&)/^IS_\I7_VZOJ*BC_67-?^
M?W_DL?\ (/\ 5[+/^?7_ )-+_,^7?^&)/^IS_P#*5_\ ;J/^&)/^IS_\I7_V
MZOJ*BC_67-?^?W_DL?\ (/\ 5[+/^?7_ )-+_,^7?^&)/^IS_P#*5_\ ;J/^
M&)/^IS_\I7_VZOJ*BC_67-?^?W_DL?\ (/\ 5[+/^?7_ )-+_,^7?^&)/^IS
M_P#*5_\ ;J/^&)/^IS_\I7_VZOJ*BC_67-?^?W_DL?\ (/\ 5[+/^?7_ )-+
M_,^7?^&)/^IS_P#*5_\ ;J/^&)/^IS_\I7_VZOJ*BC_67-?^?W_DL?\ (/\
M5[+/^?7_ )-+_,^7?^&)/^IS_P#*5_\ ;J/^&)/^IS_\I7_VZOJ*BC_67-?^
M?W_DL?\ (/\ 5[+/^?7_ )-+_,^7?^&)/^IS_P#*5_\ ;J/^&)/^IS_\I7_V
MZOJ*BC_67-?^?W_DL?\ (/\ 5[+/^?7_ )-+_,^7?^&)/^IS_P#*5_\ ;J/^
M&)/^IS_\I7_VZOJ*BC_67-?^?W_DL?\ (/\ 5[+/^?7_ )-+_,^7?^&)/^IS
M_P#*5_\ ;J/^&)/^IS_\I7_VZOJ*BC_67-?^?W_DL?\ (/\ 5[+/^?7_ )-+
M_,^7?^&)/^IS_P#*5_\ ;J/^&)/^IS_\I7_VZOJ*BC_67-?^?W_DL?\ (/\
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MV-7V;O-&[&[&<#..@K?_ .&)/^IS_P#*5_\ ;J]D_9__ .2$_#K_ +%W3_\
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M3_J<_P#RE?\ VZOJ*BC_ %ES7_G]_P"2Q_R#_5[+/^?7_DTO\SY=_P"&)/\
MJ<__ "E?_;J/^&)/^IS_ /*5_P#;J^HJ*/\ 67-?^?W_ )+'_(/]7LL_Y]?^
M32_S/EW_ (8D_P"IS_\ *5_]NH_X8D_ZG/\ \I7_ -NKZBHH_P!9<U_Y_?\
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MK*KQ#F=:#ISK:/RBOQ2N:T\BRZE-5(4M5YM_@W8****^=/>"BBB@#\\/#?\
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M %%%% !1110 4444 %%%% !1110 5\ ?\%.?^1E\!_\ 7I=?^AQU]_U\ ?\
M!3G_ )&7P'_UZ77_ *''7M9/_OL/G^3//Q_^[R^7YGW?X?\ ^0#IO_7M'_Z
M*T*S_#__ " =-_Z]H_\ T 5H5X\MV=ZV"BBBI&%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5\=_P#!3#_DF/A/_L,'_P!$/7V)7QW_ ,%,
M/^28^$_^PP?_ $0]>IE?^^4_7]#CQG\"1[S^S3_R;_\ #[_L"VW_ *+%%'[-
M/_)O_P /O^P+;?\ HL45QXC^-/U?YF]+^''T1\=_LD?\GL>-O][5O_2D5^A]
M?GA^R1_R>QXV_P![5O\ TI%?H?7J9O\ QX_X4<>!_AOU84445X9Z(4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!\S?\%#/^3>)?^PK:_\ L]='^P[_ ,FN>"O^WW_TMGKG
M/^"AG_)O$O\ V%;7_P!GKH_V'?\ DUSP5_V^_P#I;/7N2_Y%<?\ '^C/.7^^
M/_#^I[M1117AGHA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 <Y\2?\ DG?BG_L%77_HEJ^-O^"7_P!WXE_]PW_VZK[)
M^)/_ "3OQ3_V"KK_ -$M7QM_P2_^[\2_^X;_ .W5>YAO^1?B/6/YGG5O]ZI?
M/\C[LHHHKPST0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^+_\
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M_P#0XZ^_Z^ /^"G/_(R^ _\ KTNO_0XZ]K)_]]A\_P F>?C_ /=Y?+\S[O\
M#_\ R =-_P"O:/\ ] %:%9_A_P#Y .F_]>T?_H K0KQY;L[UL%%%%2,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /F;_ (*&?\F\2_\ 85M?_9ZZ/]AW
M_DUSP5_V^_\ I;/7.?\ !0S_ )-XE_["MK_[/71_L._\FN>"O^WW_P!+9Z]R
M7_(KC_C_ $9YR_WQ_P"']3W:BBBO#/1"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH YSXD_\D[\4_P#8*NO_ $2U?&W_
M  2_^[\2_P#N&_\ MU7V3\2?^2=^*?\ L%77_HEJ^-O^"7_W?B7_ -PW_P!N
MJ]S#?\B_$>L?S/.K?[U2^?Y'W91117AGHA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5\7_\%-?^1(\%?]A&;_T4*^T*^+_^"FO_ ")'@K_L(S?^
MBA7JY7_OE/\ KHSBQO\ N\CZ2_9__P"2$_#K_L7=/_\ 2>.N^K@?V?\ _DA/
MPZ_[%W3_ /TGCKOJX*W\67JSII_!'T"BBBL30**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /SP\-_\I*YO^PK=?\ I#)7Z'U^>'AO_E)7-_V%;K_T
MADK]#Z]S-=Z/^!?J>=@]I_XF%%%%>&>B%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% 'EO[4G_ ";SX_\ ^P3+_*O%/^":7_)(?$W_ &'6_P#2>&O:
M_P!J3_DWGQ__ -@F7^5>*?\ !-+_ ))#XF_[#K?^D\->Y2_Y%M3_ !+]#SI_
M[W#T9]>T445X9Z(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %? '
M_!3G_D9? ?\ UZ77_H<=??\ 7P!_P4Y_Y&7P'_UZ77_H<=>UD_\ OL/G^3//
MQ_\ N\OE^9]W^'_^0#IO_7M'_P"@"M"L_P /_P#(!TW_ *]H_P#T 5H5X\MV
M=ZV"BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=)_\37IGV&V_Y]XO^^!1]AMO^?>+_O@4?\1LR_\ Z%'_ )6?_P K#_4[$_\
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M=)_\37IGV&V_Y]XO^^!1]AMO^?>+_O@4?\1LR_\ Z%'_ )6?_P K#_4[$_\
M09_Y)_\ ;'F?_#SC7O\ H1M._P# Z3_XFC_AYQKW_0C:=_X'2?\ Q->F?8;;
M_GWB_P"^!1]AMO\ GWB_[X%'_$;,O_Z%'_E9_P#RL/\ 4[$_]!G_ ))_]L>9
M_P##SC7O^A&T[_P.D_\ B:/^'G&O?]"-IW_@=)_\37IGV&V_Y]XO^^!1]AMO
M^?>+_O@4?\1LR_\ Z%'_ )6?_P K#_4[$_\ 09_Y)_\ ;'F?_#SC7O\ H1M.
M_P# Z3_XFC_AYQKW_0C:=_X'2?\ Q->F?8;;_GWB_P"^!1]AMO\ GWB_[X%'
M_$;,O_Z%'_E9_P#RL/\ 4[$_]!G_ ))_]L>9_P##SC7O^A&T[_P.D_\ B:/^
M'G&O?]"-IW_@=)_\37IGV&V_Y]XO^^!1]AMO^?>+_O@4?\1LR_\ Z%'_ )6?
M_P K#_4[$_\ 09_Y)_\ ;'F?_#SC7O\ H1M._P# Z3_XFC_AYQKW_0C:=_X'
M2?\ Q->F?8;;_GWB_P"^!1]AMO\ GWB_[X%'_$;,O_Z%'_E9_P#RL/\ 4[$_
M]!G_ ))_]L>9_P##SC7O^A&T[_P.D_\ B:/^'G&O?]"-IW_@=)_\37IGV&V_
MY]XO^^!1]AMO^?>+_O@4?\1LR_\ Z%'_ )6?_P K#_4[$_\ 09_Y)_\ ;'F?
M_#SC7O\ H1M._P# Z3_XFC_AYQKW_0C:=_X'2?\ Q->F?8;;_GWB_P"^!1]A
MMO\ GWB_[X%'_$;,O_Z%'_E9_P#RL/\ 4[$_]!G_ ))_]L>9_P##SC7O^A&T
M[_P.D_\ B:/^'G&O?]"-IW_@=)_\37IGV&V_Y]XO^^!1]AMO^?>+_O@4?\1L
MR_\ Z%'_ )6?_P K#_4[$_\ 09_Y)_\ ;'F?_#SC7O\ H1M._P# Z3_XFC_A
MYQKW_0C:=_X'2?\ Q->F?8;;_GWB_P"^!1]AMO\ GWB_[X%'_$;,O_Z%'_E9
M_P#RL/\ 4[$_]!G_ ))_]L>9_P##SC7O^A&T[_P.D_\ B:/^'G&O?]"-IW_@
M=)_\37IGV&V_Y]XO^^!1]AMO^?>+_O@4?\1LR_\ Z%'_ )6?_P K#_4[$_\
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M[_H1M._\#I/_ (FO3/L-M_S[Q?\ ? H^PVW_ #[Q?]\"C_B-F7_]"C_RL_\
MY6'^IV)_Z#/_ "3_ .V/,_\ AYQKW_0C:=_X'2?_ !-'_#SC7O\ H1M._P#
MZ3_XFO3/L-M_S[Q?]\"C[#;?\^\7_? H_P"(V9?_ -"C_P K/_Y6'^IV)_Z#
M/_)/_MCS/_AYQKW_ $(VG?\ @=)_\31_P\XU[_H1M._\#I/_ (FO3/L-M_S[
MQ?\ ? H^PVW_ #[Q?]\"C_B-F7_]"C_RL_\ Y6'^IV)_Z#/_ "3_ .V/,_\
MAYQKW_0C:=_X'2?_ !-'_#SC7O\ H1M._P# Z3_XFO3/L-M_S[Q?]\"C[#;?
M\^\7_? H_P"(V9?_ -"C_P K/_Y6'^IV)_Z#/_)/_MCS/_AYQKW_ $(VG?\
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M[_H1M._\#I/_ (FO3/L-M_S[Q?\ ? H^PVW_ #[Q?]\"C_B-F7_]"C_RL_\
MY6'^IV)_Z#/_ "3_ .V/,_\ AYQKW_0C:=_X'2?_ !-'_#SC7O\ H1M._P#
MZ3_XFO3/L-M_S[Q?]\"C[#;?\^\7_? H_P"(V9?_ -"C_P K/_Y6'^IV)_Z#
M/_)/_MCS/_AYQKW_ $(VG?\ @=)_\31_P\XU[_H1M._\#I/_ (FO3/L-M_S[
MQ?\ ? H^PVW_ #[Q?]\"C_B-F7_]"C_RL_\ Y6'^IV)_Z#/_ "3_ .V/,_\
MAYQKW_0C:=_X'2?_ !-'_#SC7O\ H1M._P# Z3_XFO3/L-M_S[Q?]\"C[#;?
M\^\7_? H_P"(V9?_ -"C_P K/_Y6'^IV)_Z#/_)/_MCS/_AYQKW_ $(VG?\
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M[_H1M._\#I/_ (FO3/L-M_S[Q?\ ? H^PVW_ #[Q?]\"C_B-F7_]"C_RL_\
MY6'^IV)_Z#/_ "3_ .V/,_\ AYQKW_0C:=_X'2?_ !-'_#SC7O\ H1M._P#
MZ3_XFO3/L-M_S[Q?]\"C[#;?\^\7_? H_P"(V9?_ -"C_P K/_Y6'^IV)_Z#
M/_)/_MCS/_AYQKW_ $(VG?\ @=)_\31_P\XU[_H1M._\#I/_ (FO3/L-M_S[
MQ?\ ? H^PVW_ #[Q?]\"C_B-F7_]"C_RL_\ Y6'^IV)_Z#/_ "3_ .V/,_\
MAYQKW_0C:=_X'2?_ !-'_#SC7O\ H1M._P# Z3_XFO3/L-M_S[Q?]\"C[#;?
M\^\7_? H_P"(V9?_ -"C_P K/_Y6'^IV)_Z#/_)/_MCS/_AYQKW_ $(VG?\
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M[_H1M._\#I/_ (FO3/L-M_S[Q?\ ? H^PVW_ #[Q?]\"C_B-F7_]"C_RL_\
MY6'^IV)_Z#/_ "3_ .V/,_\ AYQKW_0C:=_X'2?_ !-'_#SC7O\ H1M._P#
MZ3_XFO3/L-M_S[Q?]\"C[#;?\^\7_? H_P"(V9?_ -"C_P K/_Y6'^IV)_Z#
M/_)/_MCS/_AYQKW_ $(VG?\ @=)_\31_P\XU[_H1M._\#I/_ (FO3/L-M_S[
MQ?\ ? H^PVW_ #[Q?]\"C_B-F7_]"C_RL_\ Y6'^IV)_Z#/_ "3_ .V/,_\
MAYQKW_0C:=_X'2?_ !-'_#SC7O\ H1M._P# Z3_XFO3/L-M_S[Q?]\"C[#;?
M\^\7_? H_P"(V9?_ -"C_P K/_Y6'^IV)_Z#/_)/_MCS/_AYQKW_ $(VG?\
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M[_H1M._\#I/_ (FO3/L-M_S[Q?\ ? H^PVW_ #[Q?]\"C_B-F7_]"C_RL_\
MY6'^IV)_Z#/_ "3_ .V/,_\ AYQKW_0C:=_X'2?_ !-'_#SC7O\ H1M._P#
MZ3_XFO3/L-M_S[Q?]\"C[#;?\^\7_? H_P"(V9?_ -"C_P K/_Y6'^IV)_Z#
M/_)/_MCS/_AYQKW_ $(VG?\ @=)_\31_P\XU[_H1M._\#I/_ (FO3/L-M_S[
MQ?\ ? H^PVW_ #[Q?]\"C_B-F7_]"C_RL_\ Y6'^IV)_Z#/_ "3_ .V/,_\
MAYQKW_0C:=_X'2?_ !-'_#SC7O\ H1M._P# Z3_XFO3/L-M_S[Q?]\"C[#;?
M\^\7_? H_P"(V9?_ -"C_P K/_Y6'^IV)_Z#/_)/_MCS/_AYQKW_ $(VG?\
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M[_H1M._\#I/_ (FO3/L-M_S[Q?\ ? H^PVW_ #[Q?]\"C_B-F7_]"C_RL_\
MY6'^IV)_Z#/_ "3_ .V/,_\ AYQKW_0C:=_X'2?_ !-'_#SC7O\ H1M._P#
MZ3_XFO3/L-M_S[Q?]\"C[#;?\^\7_? H_P"(V9?_ -"C_P K/_Y6'^IV)_Z#
M/_)/_MCS/_AYQKW_ $(VG?\ @=)_\31_P\XU[_H1M._\#I/_ (FO3/L-M_S[
MQ?\ ? H^PVW_ #[Q?]\"C_B-F7_]"C_RL_\ Y6'^IV)_Z#/_ "3_ .V/,_\
MAYQKW_0C:=_X'2?_ !-'_#SC7O\ H1M._P# Z3_XFO3/L-M_S[Q?]\"C[#;?
M\^\7_? H_P"(V9?_ -"C_P K/_Y6'^IV)_Z#/_)/_MCS/_AYQKW_ $(VG?\
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M[_H1M._\#I/_ (FO3/L-M_S[Q?\ ? H^PVW_ #[Q?]\"C_B-F7_]"C_RL_\
MY6'^IV)_Z#/_ "3_ .V/,_\ AYQKW_0C:=_X'2?_ !-'_#SC7O\ H1M._P#
MZ3_XFO3/L-M_S[Q?]\"C[#;?\^\7_? H_P"(V9?_ -"C_P K/_Y6'^IV)_Z#
M/_)/_MCS/_AYQKW_ $(VG?\ @=)_\31_P\XU[_H1M._\#I/_ (FO3/L-M_S[
MQ?\ ? H^PVW_ #[Q?]\"C_B-F7_]"C_RL_\ Y6'^IV)_Z#/_ "3_ .V/,_\
MAYQKW_0C:=_X'2?_ !-'_#SC7O\ H1M._P# Z3_XFO3/L-M_S[Q?]\"C[#;?
M\^\7_? H_P"(V9?_ -"C_P K/_Y6'^IV)_Z#/_)/_MCS/_AYQKW_ $(VG?\
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M_MCS/_AYQKW_ $(VG?\ @=)_\31_P\XU[_H1M._\#I/_ (FO3/L-M_S[Q?\
M? H^PVW_ #[Q?]\"C_B-F7_]"C_RL_\ Y6'^IV)_Z#/_ "3_ .V/,_\ AYQK
MW_0C:=_X'2?_ !-'_#SC7O\ H1M._P# Z3_XFO3/L-M_S[Q?]\"C[#;?\^\7
M_? H_P"(V9?_ -"C_P K/_Y6'^IV)_Z#/_)/_MCS/_AYQKW_ $(VG?\ @=)_
M\31_P\XU[_H1M._\#I/_ (FO3/L-M_S[Q?\ ? H^PVW_ #[Q?]\"C_B-F7_]
M"C_RL_\ Y6'^IV)_Z#/_ "3_ .V/,_\ AYQKW_0C:=_X'2?_ !-'_#SC7O\
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M_MCS/_AYQKW_ $(VG?\ @=)_\31_P\XU[_H1M._\#I/_ (FO3/L-M_S[Q?\
M? H^PVW_ #[Q?]\"C_B-F7_]"C_RL_\ Y6'^IV)_Z#/_ "3_ .V/,_\ AYQK
MW_0C:=_X'2?_ !-'_#SC7O\ H1M._P# Z3_XFO3/L-M_S[Q?]\"C[#;?\^\7
M_? H_P"(V9?_ -"C_P K/_Y6'^IV)_Z#/_)/_MCS/_AYQKW_ $(VG?\ @=)_
M\31_P\XU[_H1M._\#I/_ (FO3/L-M_S[Q?\ ? H^PVW_ #[Q?]\"C_B-F7_]
M"C_RL_\ Y6'^IV)_Z#/_ "3_ .V/,_\ AYQKW_0C:=_X'2?_ !-'_#SC7O\
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M+_O@4?\ $;,O_P"A1_Y6?_RL/]3L3_T&?^2?_;'F?_#SC7O^A&T[_P #I/\
MXFC_ (><:]_T(VG?^!TG_P 37IGV&V_Y]XO^^!1]AMO^?>+_ +X%'_$;,O\
M^A1_Y6?_ ,K#_4[$_P#09_Y)_P#;'F?_  \XU[_H1M._\#I/_B:/^'G&O?\
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M+_O@4?\ $;,O_P"A1_Y6?_RL/]3L3_T&?^2?_;'F?_#SC7O^A&T[_P #I/\
MXFC_ (><:]_T(VG?^!TG_P 37IGV&V_Y]XO^^!1]AMO^?>+_ +X%'_$;,O\
M^A1_Y6?_ ,K#_4[$_P#09_Y)_P#;'F?_  \XU[_H1M._\#I/_B:/^'G&O?\
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M=)_\37IGV&V_Y]XO^^!1]AMO^?>+_O@4?\1LR_\ Z%'_ )6?_P K#_4[$_\
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M=)_\37IGV&V_Y]XO^^!1]AMO^?>+_O@4?\1LR_\ Z%'_ )6?_P K#_4[$_\
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M_0C:=_X'2?\ Q-'_  \XU[_H1M._\#I/_B:],^PVW_/O%_WP*/L-M_S[Q?\
M? H_XC9E_P#T*/\ RL__ )6'^IV)_P"@S_R3_P"V/,_^'G&O?]"-IW_@=)_\
M31_P\XU[_H1M._\  Z3_ .)KTS[#;?\ /O%_WP*/L-M_S[Q?]\"C_B-F7_\
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M]\"C_B-F7_\ 0H_\K/\ ^5A_J=B?^@S_ ,D_^V/,_P#AYQKW_0C:=_X'2?\
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M_0C:=_X'2?\ Q-'_  \XU[_H1M._\#I/_B:],^PVW_/O%_WP*/L-M_S[Q?\
M? H_XC9E_P#T*/\ RL__ )6'^IV)_P"@S_R3_P"V/,_^'G&O?]"-IW_@=)_\
M31_P\XU[_H1M._\  Z3_ .)KTS[#;?\ /O%_WP*/L-M_S[Q?]\"C_B-F7_\
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M]\"C_B-F7_\ 0H_\K/\ ^5A_J=B?^@S_ ,D_^V/,_P#AYQKW_0C:=_X'2?\
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M_0C:=_X'2?\ Q-'_  \XU[_H1M._\#I/_B:],^PVW_/O%_WP*/L-M_S[Q?\
M? H_XC9E_P#T*/\ RL__ )6'^IV)_P"@S_R3_P"V/,_^'G&O?]"-IW_@=)_\
M31_P\XU[_H1M._\  Z3_ .)KTS[#;?\ /O%_WP*/L-M_S[Q?]\"C_B-F7_\
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M]\"C_B-F7_\ 0H_\K/\ ^5A_J=B?^@S_ ,D_^V/,_P#AYQKW_0C:=_X'2?\
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M_0C:=_X'2?\ Q-'_  \XU[_H1M._\#I/_B:],^PVW_/O%_WP*/L-M_S[Q?\
M? H_XC9E_P#T*/\ RL__ )6'^IV)_P"@S_R3_P"V/,_^'G&O?]"-IW_@=)_\
M31_P\XU[_H1M._\  Z3_ .)KTS[#;?\ /O%_WP*/L-M_S[Q?]\"C_B-F7_\
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M]\"C_B-F7_\ 0H_\K/\ ^5A_J=B?^@S_ ,D_^V/,_P#AYQKW_0C:=_X'2?\
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M_0C:=_X'2?\ Q-'_  \XU[_H1M._\#I/_B:],^PVW_/O%_WP*/L-M_S[Q?\
M? H_XC9E_P#T*/\ RL__ )6'^IV)_P"@S_R3_P"V/,_^'G&O?]"-IW_@=)_\
M31_P\XU[_H1M._\  Z3_ .)KTS[#;?\ /O%_WP*/L-M_S[Q?]\"C_B-F7_\
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M]\"C_B-F7_\ 0H_\K/\ ^5A_J=B?^@S_ ,D_^V/,_P#AYQKW_0C:=_X'2?\
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M_0C:=_X'2?\ Q-'_  \XU[_H1M._\#I/_B:],^PVW_/O%_WP*/L-M_S[Q?\
M? H_XC9E_P#T*/\ RL__ )6'^IV)_P"@S_R3_P"V/,_^'G&O?]"-IW_@=)_\
M31_P\XU[_H1M._\  Z3_ .)KTS[#;?\ /O%_WP*/L-M_S[Q?]\"C_B-F7_\
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M]\"C_B-F7_\ 0H_\K/\ ^5A_J=B?^@S_ ,D_^V/,_P#AYQKW_0C:=_X'2?\
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M_0C:=_X'2?\ Q-'_  \XU[_H1M._\#I/_B:],^PVW_/O%_WP*/L-M_S[Q?\
M? H_XC9E_P#T*/\ RL__ )6'^IV)_P"@S_R3_P"V/,_^'G&O?]"-IW_@=)_\
M31_P\XU[_H1M._\  Z3_ .)KTS[#;?\ /O%_WP*/L-M_S[Q?]\"C_B-F7_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+$X+'@$U^I>G_MP_ '2=/MK&R\8QVEG;1K##;PZ-?*D:*,*J@0<  8Q7NXS
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M"UN(\#EN"I1I1JI)\L5'[3N[)*[2.;(L;5^K8BM7FY<FNK;Z-VU[GR[\</\
M@H'X\\?:]<6'@6ZE\*>'=YB@^SQJ;VY!. [N02A/98\$9P2W6O/[WXE?M%_#
MN.'7=5UGXA:3:%QLN=:-Y]F9CR!B<&,Y],5Z5_P35\ Z=XH^,&KZYJ$$=RV@
MV EM$D4$)/(^T2 >JJKX]"V>U?I/XJ\,Z?XS\-ZGH6K0+<Z;J-N]M<1, <HP
M(.,]".H/8@&O6SO/\GX0QL<FPV7PG"*7.VE=WUZIW=M;MZ[:&&"PF*SF$L56
MKN.MDEM^>W]7/D_]C+]M2]^,&K#P5XW%NOB4Q&2QU*!!$M\%&71T'"R  M\N
M 0#P,<^T_M-?M 67[/'PYDUR2!+_ %>ZD^RZ;8NQ42S$9+-CG8HY..O R"P-
M<U\-_P!AGX6?#'7--UK3[+5+W6-.F6XMKV\U&3>C@Y!VQ[%/T*X(Z@UVOQH_
M9_\  OQOM;-_&EE-<#3$E-O<1WLD @#[2[85@I^XO+ ]*_+\PQ7#&(SZGB</
M3FL*]9Q22UUTBN;X7I=:-:VZ'T>#IYC2PDJ=62=3[+;O]^G3YWV9^9UW^T1^
MT!\;-:N/[&USQ1>3QYD-AX2BFB6%">!MMQNP.F6)/N:J0?M%?'GX0ZZD.J>)
M_%-A? +(;'Q,)9BRY/6.Y!.#R,C'UK[7\"_%O]G3]DO0+WP]H7C!=2>>=KN9
MK4'4)I7P %,L*>7A0,!21CGU)KY5_;0_:D\+_M&-X<@\/:'J%D-(>8F^U(1I
M)(L@0; B,V!E <EOPK]RRG&+-,<L'3R51P3NN>4%'2V]FK.[TLKOK<^/Q-%T
M*+JU<7^^[)WZ[:.Y]Z_LJ?M #]HCX9C6[FTBT_6K*X-EJ%O 3Y7F!58.F>0K
M*P."3@Y&3C)^-?\ @J#_ ,EF\,?]@!/_ $HGKT?_ ()8RNWAKX@QEOD6[LV"
M^A*2Y/Z#\J\X_P""H/\ R6;PQ_V $_\ 2B>OC<@R^AE7']7!X96A%2LNUX*5
MOE<]:IB:F+X?E6JN\GI]U2WZ'T'_ ,$UO^3=[C_L.7/_ *+AKZMKY2_X)K?\
MF[W'_8<N?_1<-?5M?E?&/_)08W_&SV\C_P"1=2^?YL****^./="BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ KP3]K_\ Y$[1/^O\_P#HMJ][KP3]K_\
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MW,P (.%R3D?=?[5NAZAX@_9U\;:9I&GW.I:A/9*D%G90M++(?,0X5%!). >
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MLVC^5'/JFFS6R._GQG:&=0"< G ]*^[?&4$MUX/UR&&-III+"=$CC4LS,8V
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "O!/VO_P#D3M$_Z_S_ .BVKWNO!/VO_P#D3M$_Z_S_ .BVK]/\
M,?\ DL,O_P 3_P#29'S/$W_(HQ'I^J/N#]FG_DW_ .'W_8%MO_18HH_9I_Y-
M_P#A]_V!;;_T6**_M;$?QI^K_,_(Z7\./HCX ^%W_)U'C7_K[U/_ -**^FJ^
M.M)^(UAX ^/_ (OUV]M[FXM9+^_C$< 7?EYR1G) [>M>G_\ #7GA?_H$:O\
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M_P!9,I_Z"%^/^1[M17A/_#7GA?\ Z!&K_P#?$7_Q='_#7GA?_H$:O_WQ%_\
M%T?\0UXO_P"A?/\ \E_S#_63*?\ H(7X_P"1[M17A/\ PUYX7_Z!&K_]\1?_
M !='_#7GA?\ Z!&K_P#?$7_Q='_$->+_ /H7S_\ )?\ ,/\ 63*?^@A?C_D>
M[45X3_PUYX7_ .@1J_\ WQ%_\71_PUYX7_Z!&K_]\1?_ !='_$->+_\ H7S_
M /)?\P_UDRG_ *"%^/\ D>[45X3_ ,->>%_^@1J__?$7_P 71_PUYX7_ .@1
MJ_\ WQ%_\71_Q#7B_P#Z%\__ "7_ ##_ %DRG_H(7X_Y'NU%>$_\->>%_P#H
M$:O_ -\1?_%T?\->>%_^@1J__?$7_P 71_Q#7B__ *%\_P#R7_,/]9,I_P"@
MA?C_ )'NU%>$_P##7GA?_H$:O_WQ%_\ %T?\->>%_P#H$:O_ -\1?_%T?\0U
MXO\ ^A?/_P E_P P_P!9,I_Z"%^/^1[M17A/_#7GA?\ Z!&K_P#?$7_Q='_#
M7GA?_H$:O_WQ%_\ %T?\0UXO_P"A?/\ \E_S#_63*?\ H(7X_P"1[M17A/\
MPUYX7_Z!&K_]\1?_ !='_#7GA?\ Z!&K_P#?$7_Q='_$->+_ /H7S_\ )?\
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M$:O_ -\1?_%T?\0UXO\ ^A?/_P E_P P_P!9,I_Z"%^/^1[M17A/_#7GA?\
MZ!&K_P#?$7_Q='_#7GA?_H$:O_WQ%_\ %T?\0UXO_P"A?/\ \E_S#_63*?\
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M?/\ \E_S#_63*?\ H(7X_P"1[M17A/\ PUYX7_Z!&K_]\1?_ !='_#7GA?\
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MX:\\+_\ 0(U?_OB+_P"+H_X:\\+_ /0(U?\ [XB_^+H_XAKQ?_T+Y_\ DO\
MF'^LF4_]!"_'_(]VHKPG_AKSPO\ ] C5_P#OB+_XNC_AKSPO_P! C5_^^(O_
M (NC_B&O%_\ T+Y_^2_YA_K)E/\ T$+\?\CW:BO"?^&O/"__ $"-7_[XB_\
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M*\)_X:\\+_\ 0(U?_OB+_P"+H_X:\\+_ /0(U?\ [XB_^+H_XAKQ?_T+Y_\
MDO\ F'^LF4_]!"_'_(]VHKPG_AKSPO\ ] C5_P#OB+_XNC_AKSPO_P! C5_^
M^(O_ (NC_B&O%_\ T+Y_^2_YA_K)E/\ T$+\?\CW:BO"?^&O/"__ $"-7_[X
MB_\ BZ/^&O/"_P#T"-7_ .^(O_BZ/^(:\7_]"^?_ )+_ )A_K)E/_00OQ_R/
M=J*\)_X:\\+_ /0(U?\ [XB_^+H_X:\\+_\ 0(U?_OB+_P"+H_XAKQ?_ -"^
M?_DO^8?ZR93_ -!"_'_(]VHKPG_AKSPO_P! C5_^^(O_ (NC_AKSPO\ ] C5
M_P#OB+_XNC_B&O%__0OG_P"2_P"8?ZR93_T$+\?\CW:BO"?^&O/"_P#T"-7_
M .^(O_BZ/^&O/"__ $"-7_[XB_\ BZ/^(:\7_P#0OG_Y+_F'^LF4_P#00OQ_
MR/=J*\)_X:\\+_\ 0(U?_OB+_P"+H_X:\\+_ /0(U?\ [XB_^+H_XAKQ?_T+
MY_\ DO\ F'^LF4_]!"_'_(]VHKPG_AKSPO\ ] C5_P#OB+_XNC_AKSPO_P!
MC5_^^(O_ (NC_B&O%_\ T+Y_^2_YA_K)E/\ T$+\?\CW:BO"?^&O/"__ $"-
M7_[XB_\ BZ/^&O/"_P#T"-7_ .^(O_BZ/^(:\7_]"^?_ )+_ )A_K)E/_00O
MQ_R/=J*\)_X:\\+_ /0(U?\ [XB_^+H_X:\\+_\ 0(U?_OB+_P"+H_XAKQ?_
M -"^?_DO^8?ZR93_ -!"_'_(]VHKPG_AKSPO_P! C5_^^(O_ (NC_AKSPO\
M] C5_P#OB+_XNC_B&O%__0OG_P"2_P"8?ZR93_T$+\?\CW:BO"?^&O/"_P#T
M"-7_ .^(O_BZ/^&O/"__ $"-7_[XB_\ BZ/^(:\7_P#0OG_Y+_F'^LF4_P#0
M0OQ_R/=J*\)_X:\\+_\ 0(U?_OB+_P"+H_X:\\+_ /0(U?\ [XB_^+H_XAKQ
M?_T+Y_\ DO\ F'^LF4_]!"_'_(]VHKPG_AKSPO\ ] C5_P#OB+_XNC_AKSPO
M_P! C5_^^(O_ (NC_B&O%_\ T+Y_^2_YA_K)E/\ T$+\?\CW:BO"?^&O/"__
M $"-7_[XB_\ BZ/^&O/"_P#T"-7_ .^(O_BZ/^(:\7_]"^?_ )+_ )A_K)E/
M_00OQ_R/=J*\)_X:\\+_ /0(U?\ [XB_^+H_X:\\+_\ 0(U?_OB+_P"+H_XA
MKQ?_ -"^?_DO^8?ZR93_ -!"_'_(]VHKPG_AKSPO_P! C5_^^(O_ (NC_AKS
MPO\ ] C5_P#OB+_XNC_B&O%__0OG_P"2_P"8?ZR93_T$+\?\CW:BO"?^&O/"
M_P#T"-7_ .^(O_BZ/^&O/"__ $"-7_[XB_\ BZ/^(:\7_P#0OG_Y+_F'^LF4
M_P#00OQ_R/=J*\)_X:\\+_\ 0(U?_OB+_P"+H_X:\\+_ /0(U?\ [XB_^+H_
MXAKQ?_T+Y_\ DO\ F'^LF4_]!"_'_(]VHKPG_AKSPO\ ] C5_P#OB+_XNC_A
MKSPO_P! C5_^^(O_ (NC_B&O%_\ T+Y_^2_YA_K)E/\ T$+\?\CW:BO"?^&O
M/"__ $"-7_[XB_\ BZ/^&O/"_P#T"-7_ .^(O_BZ/^(:\7_]"^?_ )+_ )A_
MK)E/_00OQ_R/=J*\)_X:\\+_ /0(U?\ [XB_^+H_X:\\+_\ 0(U?_OB+_P"+
MH_XAKQ?_ -"^?_DO^8?ZR93_ -!"_'_(]VHKPG_AKSPO_P! C5_^^(O_ (NC
M_AKSPO\ ] C5_P#OB+_XNC_B&O%__0OG_P"2_P"8?ZR93_T$+\?\CW:BO"?^
M&O/"_P#T"-7_ .^(O_BZ/^&O/"__ $"-7_[XB_\ BZ/^(:\7_P#0OG_Y+_F'
M^LF4_P#00OQ_R/=J*\)_X:\\+_\ 0(U?_OB+_P"+H_X:\\+_ /0(U?\ [XB_
M^+H_XAKQ?_T+Y_\ DO\ F'^LF4_]!"_'_(]VHKPG_AKSPO\ ] C5_P#OB+_X
MNC_AKSPO_P! C5_^^(O_ (NC_B&O%_\ T+Y_^2_YA_K)E/\ T$+\?\CW:BO"
M?^&O/"__ $"-7_[XB_\ BZ/^&O/"_P#T"-7_ .^(O_BZ/^(:\7_]"^?_ )+_
M )A_K)E/_00OQ_R/=J*\)_X:\\+_ /0(U?\ [XB_^+H_X:\\+_\ 0(U?_OB+
M_P"+H_XAKQ?_ -"^?_DO^8?ZR93_ -!"_'_(]VHKPG_AKSPO_P! C5_^^(O_
M (NC_AKSPO\ ] C5_P#OB+_XNC_B&O%__0OG_P"2_P"8?ZR93_T$+\?\CW:B
MO"?^&O/"_P#T"-7_ .^(O_BZ/^&O/"__ $"-7_[XB_\ BZ/^(:\7_P#0OG_Y
M+_F'^LF4_P#00OQ_R/=J*\)_X:\\+_\ 0(U?_OB+_P"+H_X:\\+_ /0(U?\
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M"^?_ )+_ )A_K)E/_00OQ_R/=J*\)_X:\\+_ /0(U?\ [XB_^+H_X:\\+_\
M0(U?_OB+_P"+H_XAKQ?_ -"^?_DO^8?ZR93_ -!"_'_(]VHKPG_AKSPO_P!
MC5_^^(O_ (NC_AKSPO\ ] C5_P#OB+_XNC_B&O%__0OG_P"2_P"8?ZR93_T$
M+\?\CW:BO"?^&O/"_P#T"-7_ .^(O_BZ/^&O/"__ $"-7_[XB_\ BZ/^(:\7
M_P#0OG_Y+_F'^LF4_P#00OQ_R/=J*\)_X:\\+_\ 0(U?_OB+_P"+H_X:\\+_
M /0(U?\ [XB_^+H_XAKQ?_T+Y_\ DO\ F'^LF4_]!"_'_(]VHKPG_AKSPO\
M] C5_P#OB+_XNC_AKSPO_P! C5_^^(O_ (NC_B&O%_\ T+Y_^2_YA_K)E/\
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M?ZR93_T$+\?\CW:BO"?^&O/"_P#T"-7_ .^(O_BZ/^&O/"__ $"-7_[XB_\
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M+_F'^LF4_P#00OQ_R/=J*\)_X:\\+_\ 0(U?_OB+_P"+H_X:\\+_ /0(U?\
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M"^?_ )+_ )A_K)E/_00OQ_R/=J*\)_X:\\+_ /0(U?\ [XB_^+H_X:\\+_\
M0(U?_OB+_P"+H_XAKQ?_ -"^?_DO^8?ZR93_ -!"_'_(]VHKPG_AKSPO_P!
MC5_^^(O_ (NC_AKSPO\ ] C5_P#OB+_XNC_B&O%__0OG_P"2_P"8?ZR93_T$
M+\?\CW:BO"?^&O/"_P#T"-7_ .^(O_BZ/^&O/"__ $"-7_[XB_\ BZ/^(:\7
M_P#0OG_Y+_F'^LF4_P#00OQ_R/=J*\)_X:\\+_\ 0(U?_OB+_P"+H_X:\\+_
M /0(U?\ [XB_^+H_XAKQ?_T+Y_\ DO\ F'^LF4_]!"_'_(]VHKPG_AKSPO\
M] C5_P#OB+_XNC_AKSPO_P! C5_^^(O_ (NC_B&O%_\ T+Y_^2_YA_K)E/\
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MUDRG_H(7X_Y'NU%>$_\ #7GA?_H$:O\ ]\1?_%T?\->>%_\ H$:O_P!\1?\
MQ='_ !#7B_\ Z%\__)?\P_UDRG_H(7X_Y'NU%>$_\->>%_\ H$:O_P!\1?\
MQ='_  UYX7_Z!&K_ /?$7_Q='_$->+_^A?/_ ,E_S#_63*?^@A?C_D>[45X3
M_P ->>%_^@1J_P#WQ%_\71_PUYX7_P"@1J__ 'Q%_P#%T?\ $->+_P#H7S_\
ME_S#_63*?^@A?C_D>[45X3_PUYX7_P"@1J__ 'Q%_P#%T?\ #7GA?_H$:O\
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M(U?_ +XB_P#BZ/\ B&O%_P#T+Y_^2_YC_P!9,I_Z"%^/^1[M17A/_#7GA?\
MZ!&K_P#?$7_Q='_#7GA?_H$:O_WQ%_\ %T?\0UXO_P"A?/\ \E_S#_63*?\
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M?/\ \E_S#_63*?\ H(7X_P"1[M17A/\ PUYX7_Z!&K_]\1?_ !='_#7GA?\
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MC_D>[45X3_PUYX7_ .@1J_\ WQ%_\71_PUYX7_Z!&K_]\1?_ !='_$->+_\
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M .^(O_BZ/^(:\7_]"^?_ )+_ )A_K)E/_00OQ_R/=J*\)_X:\\+_ /0(U?\
M[XB_^+H_X:\\+_\ 0(U?_OB+_P"+H_XAKQ?_ -"^?_DO^8?ZR93_ -!"_'_(
M]VHKPG_AKSPO_P! C5_^^(O_ (NC_AKSPO\ ] C5_P#OB+_XNC_B&O%__0OG
M_P"2_P"8?ZR93_T$+\?\CW:BO"?^&O/"_P#T"-7_ .^(O_BZ/^&O/"__ $"-
M7_[XB_\ BZ/^(:\7_P#0OG_Y+_F'^LF4_P#00OQ_R/=J*\)_X:\\+_\ 0(U?
M_OB+_P"+H_X:\\+_ /0(U?\ [XB_^+H_XAKQ?_T+Y_\ DO\ F'^LF4_]!"_'
M_(]VHKPG_AKSPO\ ] C5_P#OB+_XNC_AKSPO_P! C5_^^(O_ (NC_B&O%_\
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M $"-7_[XB_\ BZ/^(:\7_P#0OG_Y+_F'^LF4_P#00OQ_R/=J*\)_X:\\+_\
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MO#3B]NW]GS_\E_S%_K)E'_00OQ_R/>:*\)_X:\\+_P#0(U?_ +XB_P#BZ/\
MAKSPO_T"-7_[XB_^+H_XAKQ?_P!"^?\ Y+_F/_63*?\ H(7X_P"1[M17A/\
MPUYX7_Z!&K_]\1?_ !='_#7GA?\ Z!&K_P#?$7_Q='_$->+_ /H7S_\ )?\
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M$:O_ -\1?_%T?\0UXO\ ^A?/_P E_P P_P!9,I_Z"%^/^1[M17A/_#7GA?\
MZ!&K_P#?$7_Q='_#7GA?_H$:O_WQ%_\ %T?\0UXO_P"A?/\ \E_S#_63*?\
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M?/\ \E_S#_63*?\ H(7X_P"1[M17A/\ PUYX7_Z!&K_]\1?_ !='_#7GA?\
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MC_D>[45X3_PUYX7_ .@1J_\ WQ%_\71_PUYX7_Z!&K_]\1?_ !='_$->+_\
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MA/\ PUYX7_Z!&K_]\1?_ !='_#7GA?\ Z!&K_P#?$7_Q='_$->+_ /H7S_\
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M$7_Q='_$->+_ /H7S_\ )?\ ,/\ 63*?^@A?C_D>[45X3_PUYX7_ .@1J_\
MWQ%_\71_PUYX7_Z!&K_]\1?_ !='_$->+_\ H7S_ /)?\P_UDRG_ *"%^/\
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M\P_UDRG_ *"%^/\ D>[45X3_ ,->>%_^@1J__?$7_P 71_PUYX7_ .@1J_\
MWQ%_\71_Q#7B_P#Z%\__ "7_ ##_ %DRG_H(7X_Y'NU%>$_\->>%_P#H$:O_
M -\1?_%T?\->>%_^@1J__?$7_P 71_Q#7B__ *%\_P#R7_,/]9,I_P"@A?C_
M )'NU%>$_P##7GA?_H$:O_WQ%_\ %T?\->>%_P#H$:O_ -\1?_%T?\0UXO\
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MWL/94_Y5]QY9_P ,M_"7_H0-$_\  >C_ (9;^$O_ $(&B?\ @/7J=%'UFO\
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MA+_T(&B?^ ]'_#+?PE_Z$#1/_ >O4Z*/K-?^=_>P]E3_ )5]QY9_PRW\)?\
MH0-$_P# >C_AEOX2_P#0@:)_X#UZG11]9K_SO[V'LJ?\J^X\L_X9;^$O_0@:
M)_X#T?\ #+?PE_Z$#1/_  'KU.BCZS7_ )W][#V5/^5?<>6?\,M_"7_H0-$_
M\!Z/^&6_A+_T(&B?^ ]>IT4?6:_\[^]A[*G_ "K[CRS_ (9;^$O_ $(&B?\
M@/1_PRW\)?\ H0-$_P# >O4Z*/K-?^=_>P]E3_E7W'EG_#+?PE_Z$#1/_ >C
M_AEOX2_]"!HG_@/7J=%'UFO_ #O[V'LJ?\J^X\L_X9;^$O\ T(&B?^ ]'_#+
M?PE_Z$#1/_ >O4Z*/K-?^=_>P]E3_E7W'EG_  RW\)?^A T3_P !Z/\ AEOX
M2_\ 0@:)_P" ]>IT4?6:_P#._O8>RI_RK[CRS_AEOX2_]"!HG_@/1_PRW\)?
M^A T3_P'KU.BCZS7_G?WL/94_P"5?<>6?\,M_"7_ *$#1/\ P'H_X9;^$O\
MT(&B?^ ]>IT4?6:_\[^]A[*G_*ON/+/^&6_A+_T(&B?^ ]'_  RW\)?^A T3
M_P !Z]3HH^LU_P"=_>P]E3_E7W'EG_#+?PE_Z$#1/_ >C_AEOX2_]"!HG_@/
M7J=%'UFO_._O8>RI_P J^X\L_P"&6_A+_P!"!HG_ (#T?\,M_"7_ *$#1/\
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M'KU.BCZS7_G?WL/94_Y5]QY9_P ,M_"7_H0-$_\  >C_ (9;^$O_ $(&B?\
M@/7J=%'UFO\ SO[V'LJ?\J^X\L_X9;^$O_0@:)_X#T?\,M_"7_H0-$_\!Z]3
MHH^LU_YW][#V5/\ E7W'EG_#+?PE_P"A T3_ ,!Z/^&6_A+_ -"!HG_@/7J=
M%'UFO_._O8>RI_RK[CRS_AEOX2_]"!HG_@/1_P ,M_"7_H0-$_\  >O4Z*/K
M-?\ G?WL/94_Y5]QY9_PRW\)?^A T3_P'H_X9;^$O_0@:)_X#UZG11]9K_SO
M[V'LJ?\ *ON/+/\ AEOX2_\ 0@:)_P" ]'_#+?PE_P"A T3_ ,!Z]3HH^LU_
MYW][#V5/^5?<>6?\,M_"7_H0-$_\!Z/^&6_A+_T(&B?^ ]>IT4?6:_\ ._O8
M>RI_RK[CRS_AEOX2_P#0@:)_X#T?\,M_"7_H0-$_\!Z]3HH^LU_YW][#V5/^
M5?<>6?\ #+?PE_Z$#1/_  'H_P"&6_A+_P!"!HG_ (#UZG11]9K_ ,[^]A[*
MG_*ON/+/^&6_A+_T(&B?^ ]'_#+?PE_Z$#1/_ >O4Z*/K-?^=_>P]E3_ )5]
MQY9_PRW\)?\ H0-$_P# >C_AEOX2_P#0@:)_X#UZG11]9K_SO[V'LJ?\J^X\
ML_X9;^$O_0@:)_X#T?\ #+?PE_Z$#1/_  'KU.BCZS7_ )W][#V5/^5?<>6?
M\,M_"7_H0-$_\!Z/^&6_A+_T(&B?^ ]>IT4?6:_\[^]A[*G_ "K[CRS_ (9;
M^$O_ $(&B?\ @/1_PRW\)?\ H0-$_P# >O4Z*/K-?^=_>P]E3_E7W'EG_#+?
MPE_Z$#1/_ >C_AEOX2_]"!HG_@/7J=%'UFO_ #O[V'LJ?\J^X\L_X9;^$O\
MT(&B?^ ]'_#+?PE_Z$#1/_ >O4Z*/K-?^=_>P]E3_E7W'EG_  RW\)?^A T3
M_P !Z/\ AEOX2_\ 0@:)_P" ]>IT4?6:_P#._O8>RI_RK[CRS_AEOX2_]"!H
MG_@/1_PRW\)?^A T3_P'KU.BCZS7_G?WL/94_P"5?<>6?\,M_"7_ *$#1/\
MP'H_X9;^$O\ T(&B?^ ]>IT4?6:_\[^]A[*G_*ON/+/^&6_A+_T(&B?^ ]'_
M  RW\)?^A T3_P !Z]3HH^LU_P"=_>P]E3_E7W'EG_#+?PE_Z$#1/_ >C_AE
MOX2_]"!HG_@/7J=%'UFO_._O8>RI_P J^X\L_P"&6_A+_P!"!HG_ (#T?\,M
M_"7_ *$#1/\ P'KU.BCZS7_G?WL/94_Y5]QY9_PRW\)?^A T3_P'H_X9;^$O
M_0@:)_X#UZG11]9K_P [^]A[*G_*ON/+/^&6_A+_ -"!HG_@/1_PRW\)?^A
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M^LU_YW][#V5/^5?<>6?\,M_"7_H0-$_\!Z/^&6_A+_T(&B?^ ]>IT4?6:_\
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M'LJ?\J^X\L_X9;^$O_0@:)_X#T?\,M_"7_H0-$_\!Z]3HH^LU_YW][#V5/\
ME7W'EG_#+?PE_P"A T3_ ,!Z/^&6_A+_ -"!HG_@/7J=%'UFO_._O8>RI_RK
M[CRS_AEOX2_]"!HG_@/1_P ,M_"7_H0-$_\  >O4Z*/K-?\ G?WL/94_Y5]Q
MY9_PRW\)?^A T3_P'H_X9;^$O_0@:)_X#UZG11]9K_SO[V'LJ?\ *ON/+/\
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MZ$#1/_ >O4Z*/K-?^=_>P]E3_E7W'EG_  RW\)?^A T3_P !Z/\ AEOX2_\
M0@:)_P" ]>IT4?6:_P#._O8>RI_RK[CRS_AEOX2_]"!HG_@/7RI^W_\ "/P;
M\-_"/A.X\,>'+#1)[F^ECFDLXMA=1&" ?QK[^KXO_P""FO\ R)'@K_L(S?\
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M'KU.BCZS7_G?WL/94_Y5]QY9_P ,M_"7_H0-$_\  >C_ (9;^$O_ $(&B?\
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MPE_Z$#1/_ >C_AEOX2_]"!HG_@/7J=%'UFO_ #O[V'LJ?\J^X\L_X9;^$O\
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M\L_X9;^$O_0@:)_X#U\6_P#!0+X9^%OAOK_@V'POH5GH<5U;7+SK9Q[!(5=
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M?^A T3_P'H_X9;^$O_0@:)_X#UZG11]9K_SO[V'LJ?\ *ON/+/\ AEOX2_\
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M(&B?^ ]>IT4?6:_\[^]A[*G_ "K[CRS_ (9;^$O_ $(&B?\ @/1_PRW\)?\
MH0-$_P# >O4Z*/K-?^=_>P]E3_E7W'EG_#+?PE_Z$#1/_ >C_AEOX2_]"!HG
M_@/7J=%'UFO_ #O[V'LJ?\J^X\L_X9;^$O\ T(&B?^ ]'_#+?PE_Z$#1/_ >
MO4Z*/K-?^=_>P]E3_E7W'EG_  RW\)?^A T3_P !Z/\ AEOX2_\ 0@:)_P"
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M^ ]'_#+?PE_Z$#1/_ >O4Z*/K-?^=_>P]E3_ )5]QY9_PRW\)?\ H0-$_P#
M>C_AEOX2_P#0@:)_X#UZG11]9K_SO[V'LJ?\J^X\L_X9;^$O_0@:)_X#T?\
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MZ4BOT/KU,W_CQ_PHX\#_  WZL****\,]$**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^9O
M^"AG_)O$O_85M?\ V>NC_8=_Y-<\%?\ ;[_Z6SUSG_!0S_DWB7_L*VO_ +/7
M1_L._P#)KG@K_M]_]+9Z]R7_ "*X_P"/]&><O]\?^']3W:BBBO#/1"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB_\ X*:_\B1X*_[",W_HH5ZN5_[Y3_KHSBQO^[R/I+]G_P#Y(3\.O^Q=T_\
M])XZ[ZN!_9__ .2$_#K_ +%W3_\ TGCKOJX*W\67JSII_!'T"BBBL30****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#_@IS_R,O@/_ *]+K_T..O:R?_?8?/\ )GGX_P#W>7R_,^[_  __ ,@'3?\
MKVC_ /0!6A6?X?\ ^0#IO_7M'_Z *T*\>6[.];!1114C"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO=M1B6D.0.7;/.17[;45DUS554GK;\;_ *_YLN+Y:;IQTO\ I^G^2/BC1?\
M@D=\ K7X>PZ+J.C:E>^(C:>7-XD75;A+CSBO,J1!_)&#T4QD8 SGK7Y/_!V3
M6/@/^V5X<L=(OGEU+0/&*:09X1M^THMW]GE7!/W9$W @GHU?L5^W=^W-H/[*
M/@V73=.EAU3XD:I W]F:6&#"U4Y NK@=D!SM7JY&!P&9?S[_ ."7G[+.N?'#
MXW1?%GQ/!-)X6\.WIOQ>70/_ !,M3R60*2/FV.?,<^H4?Q'&N'DYXI5%\,=^
MV_3\O-M+TSKQ4,,Z;^*6B[[=?S]$WZ_MC1114%A1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!SGQ)_Y)WXI_[!5U_Z):ORY^ OB;5_"_A_49-&U6^T
MF2XNMLS6-P\)E"H-H8J1D#>V,]-Q]37ZC?$G_DG?BG_L%77_ *):ORG^$/\
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M:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *^._^"F'_ "3'PG_V&#_Z(>OL2OCO_@IA_P D
MQ\)_]A@_^B'KU,K_ -\I^OZ''C/X$CWG]FG_ )-_^'W_ &!;;_T6**/V:?\
MDW_X??\ 8%MO_18HKCQ'\:?J_P S>E_#CZ(^._V2/^3V/&W^]JW_ *4BOT/K
M\\/V2/\ D]CQM_O:M_Z4BOT/KU,W_CQ_PHX\#_#?JPHHHKPST0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *_-3_ (+>_P#)+_AG_P!AFY_]$"OTKK\^
M?^"PWPQ\8_$WX<_#VV\'^$]<\67-KJUQ)/#H>FS7CQ*80 SB)6*@GC)KDQ2;
MIJW\T?\ TI'11^)^DOR9D_\ !$Q%D^!?Q 1U#JWB( JPR#_HL5>5_P#!63]B
MC3_!JQ_&3P)I$6GZ7/*L'B/3[*()%#*Q CNU0#"AV.U\<;BIZLQKWG_@C_\
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M69",,.#N7(&"*_:7]E?XG>)OBQ\%-!UGQKX7UCPCXOCC^R:KI^L:=-9.UP@
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M'8@CM7SO^WM^V]IO[)/@>.TTP0:G\0]9B;^R]/D.4MTY!NI@/X%/"KQO88'
M8CYN_P""4?B#XO?"?5M0^%_CWX;^-M(\(:@7O=+U+4_#]Y#;V%T!F2-I'C"H
MD@&1D@!U]7KY&_:T^&/QZ^._[0WC;Q=/\)OB!=VEQJ$EOIQ7PU?,B6<3%( G
M[K&"BAN."6)[U>)7OQA3^&6OHNWK?KVU5M",._<E*>\=/5]_3]=.YZ5^Q?\
ML-^*/VV/%EW\6_BUJM_)X2NKUI9IYG(N]=F4X94;^"$$;2R]-NQ,8RO[+^%O
M"NC^"/#NGZ#H&FVVD:-I\*P6MC:1A(HD'0 #_)ZU_.#_ ,,G?&__ *(W\0/_
M  E[[_XU73_"W]EKXT:?\3/"-U=?"+QY;6L&KV<LLTWAJ]1(T69"S,QBP  "
M2373"TW&C'W8Z+_@_P!;'/-N"E5E[TM?^&/Z+****P-PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /F;_@H9_R;Q+_V%;7_ -GKH_V'?^37/!7_
M &^_^EL]<Y_P4,_Y-XE_["MK_P"SUT?[#O\ R:YX*_[??_2V>O<E_P BN/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M -)XZ[ZN"M_%EZLZ:?P1] HHHK$T"BBB@ HHHH **** "BBB@ HHHH ****
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MA_\ Y .F_P#7M'_Z *T*S_#_ /R =-_Z]H__ $ 5H5X\MV=ZV"BBBI&%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7Q'^)M[&K_V7:E_+M=ZEHPRQJSRN0-WEKC"\EAQGYM_X(Z?\EJ^._P#VP_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(?,-NQ'W(_ZGN:_+^+<%A*=L3%\M673^;S\K=^I^D<+XO%5+X>2O377MY?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7P!_P4Y_Y&7P'_ ->EU_Z'
M'7W_ %\ ?\%.?^1E\!_]>EU_Z''7M9/_ +[#Y_DSS\?_ +O+Y?F?=_A__D Z
M;_U[1_\ H K0K/\ #_\ R =-_P"O:/\ ] %:%>/+=G>M@HHHJ1A1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#DA/PZ_P"Q=T__ -)XZ[ZN"M_%EZLZ:?P1] HHHK$T"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#\\/#?_ "DKF_["MU_Z0R5^A]?GAX;_ .4E
M<W_85NO_ $ADK]#Z]S-=Z/\ @7ZGG8/:?^)A1117AGHA1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!Y;^U)_R;SX__P"P3+_*O%/^":7_ "2'Q-_V
M'6_])X:]K_:D_P"3>?'_ /V"9?Y5XI_P32_Y)#XF_P"PZW_I/#7N4O\ D6U/
M\2_0\Z?^]P]&?7M%%%>&>B%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7P!_P4Y_Y&7P'_UZ77_H<=??]? '_!3G_D9? ?\ UZ77_H<=>UD_^^P^
M?Y,\_'_[O+Y?F?=_A_\ Y .F_P#7M'_Z *T*S_#_ /R =-_Z]H__ $ 5H5X\
MMV=ZV"BBBI&%%%% !1110 4444 %%%% !129QR>!7SYX]_X*!?L]_#769-*U
MSXGZ7]OB8I)'ID-QJ(C8'!5FMHY%5@0003D4KJ]AV=KGT)17G7PB_:(^&WQX
MLY;CP#XRTOQ)Y*AYK>VE*7,*DX#20.%D0$]"RC->BU336Y*:>P45XY\8/VPO
M@U\!=2_LWQQX^TW1]4&-VGQ++=W48(R"\,".Z CD%@ :U/@Y^TY\+?V@(Y3X
M \:Z;XAGA7S)+.,M#=(F0-[02JL@7) W%<<]:4?>^'4<O=^+0]/HHKRSXP?M
M1_"CX".L7CSQSI>@7C()%L'=I[LH<X<6\0:3:<'YMN.#2;2W&DWL>IT5X1\,
M?VZ/@1\8M;BT?PM\2-+NM5F81PV=]'-823L>BQK<1Q^8Q]%R:]WJK-:LFZ>@
M45Q'Q2^-W@+X):3'J7CKQ9I?ABUEW>3]ON LD^W[PBC&7D(R.%!/->3>$_\
M@HO^SCXTUF/2].^*6FQ74APK:G:W6GPD^GFW$2)_X]2C[SM'5C?NJ[/I"BF0
MS)<1)+$ZR1.H970Y# \@@]Q3Z "BBB@ HKQSXU?M??"/]G;7].T7XA>+1X>U
M/4+?[5;0G3KNX#Q;BF[=#$ZK\P(Y(/%>MZ?J%MJUA;7UE/'=6=S&LT,\+!DD
M1@"K*1U!!!!]Z%[RYEL#]U\KW+%%%>4>"?VIOA?\1OBMKOPU\/>)_P"T/&NA
MF<:AI?\ 9]U%Y/DR".7]Z\2QMM=@/E8YSD9%"U?*M_\ +<-ES=/\SU>BBB@
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MSN(KJVD&4F@<.C<XX(X/->7^"?VIOA?\1OBMKOPU\/>)_P"T/&NAF<:AI?\
M9]U%Y/DR".7]Z\2QMM=@/E8YSD9%"U?*M_\ +<.G-T_SV/5Z*** "BBDSCD\
M"@!:*@L;ZVU*UCN;.XBNK:092:!PZ-SC@C@\U/0 4444 %%%% !1110 4444
M %%%% !1110 4444 %?'?_!3#_DF/A/_ +#!_P#1#U]B5\=_\%,/^28^$_\
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M]<CM9))&TK["+5;<3$D_OY=V1+[8V]\\?D+\2/\ D^[Q#_V42;_TXFOWM_:
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M[M:_-?\ R-D<$?WMT]D]/EK^=PHHHKE.@**** "BBB@ HHHH **** "BBB@
MHHHH **** /F;_@H9_R;Q+_V%;7_ -GKH_V'?^37/!7_ &^_^EL]<Y_P4,_Y
M-XE_["MK_P"SUT?[#O\ R:YX*_[??_2V>O<E_P BN/\ C_1GG+_?'_A_4]VH
MHHKPST0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS9QZJ)'7/X5L>%_%^A>-M*35/#NM:=K^FR'"7FEW<=S"WT="0?SK\]?V<_\
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MY'QI\7_ GPVDAC\7>-?#OA:289C36M5@LR_^Z)'7/X5X#_P4@_:>U/\ 9E^
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MGDTZT?:4XTH:*+3^YI_I85&3A4E5GJVFOO37ZW/S6_X(<_\ (#^+G_7QIO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#G/B3_ ,D[\4_]@JZ_]$M7P#^PG\)=(^+]CXRM=9N;ZVCTN2TEA-BZ
M(6,PE#;MR-D#R5QC'4]>,??WQ)_Y)WXI_P"P5=?^B6KXV_X)?_=^)?\ W#?_
M &ZKZ3+\15PN#KU:,N62Y=?F>/C*%+$UJ=.M&\7?0]S_ .&-?!7_ $%->_\
M B#_ .,T?\,:^"O^@IKW_@1!_P#&:]YHK#^W<R_Y_LG^Q<O_ .?*/!O^&-?!
M7_04U[_P(@_^,T?\,:^"O^@IKW_@1!_\9KWFBC^W<R_Y_L/[%R__ )\H\&_X
M8U\%?]!37O\ P(@_^,T?\,:^"O\ H*:]_P"!$'_QFO>:*/[=S+_G^P_L7+_^
M?*/!O^&-?!7_ $%->_\  B#_ .,T?\,:^"O^@IKW_@1!_P#&:]YHH_MW,O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)7PC\5^%M,EMX-0U:PDM8)+MF6)68<%BJL0/H#7YZ_\ #KSXJ?\ 0?\ !_\
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M:PT]W,?OS3,&&YV^@       SI\M1N539;+N^[\O+Y]K:3YJ:2AN]WV]//\
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MV\C+RH)56# ':1TP37SEX0_:N_;,^!^BQ>$/&7P!U7X@ZA91""VUNRL[B=G
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MWJ+_ +D_R1K6_P!W:_O0_,X?_@L+_P EU^!/TE_]*H*^I_\ @J3_ ,F0^/\
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M64,"YR0.!I4Y98FKS]_=[;Z_/_@&=--8:ER?/OM_7X^1%^U%^PK\2_"/[/\
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M4MC) R "17*XMX&"[3;^2E%_D;W7UMOO"*^?*T=#^P__ ,FA_"+_ +%RT_\
M0!7PK^Q-_P I6OCE_OZ]_P"G"*O1?^">OQE_:#T?7O"?P?\ B#\(]3T#P3I.
MFS6<'B*Z\/WULR&)"T2R3L?)(."H( S\O?KB_L@_"7QSX9_X*7_&3Q1K'@SQ
M!I7AF_?6C::U?:7/#9W&^^C:/RYF0(^Y06&"<@9%>KH\;[1;2C4:^9Q0]W!N
MF]XRIK\SO_VWOVY_&_P_^+6C_!#X+:-;ZK\1M46(2WURBR_97F!,444;$)OV
MXD+R915(R#DE>4C_ &1_VUOB8T1\;_M&6_AFUD 9U\.SRQS)_LE+>*W0]^CD
M55_;L_9-^+6D_M):/^T/\%K(:]K-J()+S3(PKSQS0IY8=8V(\V-X@J,J_..<
M#G(MZ5^VI^V#X\LX]%T#]F2?1_$;)M?5-;M+NUL@>A91<&)1[ RM^-<=*SIW
MDKSN[KRZ6_K]3HJW4URNT;+7SZW^9\SM\"6_9W_X*7?"3PK<^,K[QYJKW^FW
M^H:SJ*%)9)Y)'R,%W;&Q4/S,3S]*^W/^"O7_ "9O?_\ 8:L/_0FKY!\0_LJ_
M';X/?M=?"GXE^,;76?B=JVJ:M:ZQXAU3PUI-Q>Q:>RW 1XF:.,C"P["/E08!
M51A,G] _^"@WP-\1?M"?LQ:_X7\)PI=^(([BWU"TLWD6/[28GRT89L ,5+8R
M0,@ D5-92E@H)ZM3;=NEI1_!6WZV)IV6+DULX)?A+\[_ "-O]BE'D_8X^%*Q
M';(WAFV"GT/E\5^2?["_[,/B/X_?$+XAZ!I?Q9U7X4:]HP1[B+38)))+U?-D
M20-LN(<"-PO7=_K.W?[-_P"">OQE_:#T?7O"?P?^(/PCU/0/!.DZ;-9P>(KK
MP_?6S(8D+1+).Q\D@X*@@#/R]^N;^TO^Q/\ %CX2_M"3?'G]F]X[G4;R=[G4
M_#H=$;S'YGVHY59H93EFCR'#'*YX*=-5Q6)]L_AFGKVU=G^=S*ES?5G06DHN
M/SLM?^!\S0_X=8_%'_H[7Q=_X W7_P L:M_LK_L)Z+\'?VHHO&3_ +1%A\1/
M%VEBY@U'1&MD%^[O T9$S?;)9%*@YPR'[O;K7.ZA^V[^V)XKT8>'M$_9KU+0
MO%,ZF%M;N-)O1:QL1@O&)@L:$=07D=>.017IW_!/C]ASQ!\"M6UWXG_%"\34
M/B=XB1P\*S"?["DCB28O(/E>9W W%<J , G<:=/FC-RV23U[WTLOU%4Y7!1>
MK;6G:W5_H?<%%%%9F@4444 %%%% !1110 4444 %%%% !7QW_P %,/\ DF/A
M/_L,'_T0]?8E?'?_  4P_P"28^$_^PP?_1#UZF5_[Y3]?T./&?P)'O/[-/\
MR;_\/O\ L"VW_HL44?LT_P#)O_P^_P"P+;?^BQ17'B/XT_5_F;TOX<?1'QW^
MR1_R>QXV_P![5O\ TI%?H?7YX?LD?\GL>-O][5O_ $I%?H?7J9O_ !X_X4<>
M!_AOU84445X9Z(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!\S?\%#/^3>)?\ L*VO_L]=
M'^P[_P FN>"O^WW_ -+9ZYS_ (*&?\F\2_\ 85M?_9ZZ/]AW_DUSP5_V^_\
MI;/7N2_Y%<?\?Z,\Y?[X_P##^I[M1117AGHA1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 <Y\2?^2=^*?^P5=?\ HEJ^
M-O\ @E_]WXE_]PW_ -NJ^R?B3_R3OQ3_ -@JZ_\ 1+5\;?\ !+_[OQ+_ .X;
M_P"W5>YAO^1?B/6/YGG5O]ZI?/\ (^[****\,]$**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "OB__@IK_P B1X*_[",W_HH5]H5\7_\ !37_ )$C
MP5_V$9O_ $4*]7*_]\I_UT9Q8W_=Y'TE^S__ ,D)^'7_ &+NG_\ I/'7?5P/
M[/\ _P D)^'7_8NZ?_Z3QUWU<%;^++U9TT_@CZ!1116)H%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'YX>&_^4E<W_85NO\ TADK]#Z_/#PW_P I
M*YO^PK=?^D,E?H?7N9KO1_P+]3SL'M/_ !,****\,]$**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** /+?VI/\ DWGQ_P#]@F7^5>*?\$TO^20^)O\
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M *T*\>6[.];!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "ORV_X+%?\ )7/V?_\ KO=_^E%I7ZDT
M4X^[5IU?Y7?UW)J+GI5*7\RL%%%%(H**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^._\
M@IA_R3'PG_V&#_Z(>OL2OCO_ (*8?\DQ\)_]A@_^B'KU,K_WRGZ_H<>,_@2/
M>?V:?^3?_A]_V!;;_P!%BBC]FG_DW_X??]@6V_\ 18HKCQ'\:?J_S-Z7\./H
MCX[_ &2/^3V/&W^]JW_I2*_0^OSP_9(_Y/8\;?[VK?\ I2*_0^O4S?\ CQ_P
MHX\#_#?JPHHHKPST0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YF_X*&?\F\2_P#85M?_
M &>NC_8=_P"37/!7_;[_ .EL]<Y_P4,_Y-XE_P"PK:_^SUT?[#O_ ":YX*_[
M??\ TMGKW)?\BN/^/]&><O\ ?'_A_4]VHHHKPST0HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .<^)/_ "3OQ3_V"KK_
M -$M7QM_P2_^[\2_^X;_ .W5?9/Q)_Y)WXI_[!5U_P"B6KXV_P""7_W?B7_W
M#?\ VZKW,-_R+\1ZQ_,\ZM_O5+Y_D?=E%%%>&>B%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7Q?_P %-?\ D2/!7_81F_\ 10K[0KXO_P""FO\
MR)'@K_L(S?\ HH5ZN5_[Y3_KHSBQO^[R/I+]G_\ Y(3\.O\ L7=/_P#2>.N^
MK@?V?_\ DA/PZ_[%W3__ $GCKOJX*W\67JSII_!'T"BBBL30**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /SP\-_\I*YO^PK=?^D,E?H?7YX>&_\
ME)7-_P!A6Z_](9*_0^O<S7>C_@7ZGG8/:?\ B84445X9Z(4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M OC"V+![Y[> :>=ML+@X?SO,^X<?ZOK[<U] U\IZ1_PS!_PVY??8?^3A\O\
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MP#XOTWQ+'" T\-K(5N( 20#)"X62,'!QN49P<5Z%5--;DII[!17A'Q._;I^
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M7OASJGCRU^(-FGA73;L6%Q?75I<VQ-P4\P11Q2Q+)*Y3YL1JW /H:5UKY?\
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M8****0PHHHH **** "OCO_@IA_R3'PG_ -A@_P#HAZ^Q*^._^"F'_),?"?\
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ML8VYK6Z;;^IQK#R^LN'.]M^I\S_\+S_:S_Z%?6O_  EC_P#&Z/\ A>?[6?\
MT*^M?^$L?_C=?H=17F?VC2_Z!X_<=GU6?_/V1^>/_"\_VL_^A7UK_P )8_\
MQNC_ (7G^UG_ -"OK7_A+'_XW7Z'44?VC2_Z!X_<'U6?_/V1^>/_  O/]K/_
M *%?6O\ PEC_ /&Z/^%Y_M9_]"OK7_A+'_XW7Z'44?VC2_Z!X_<'U6?_ #]D
M?GC_ ,+S_:S_ .A7UK_PEC_\;H_X7G^UG_T*^M?^$L?_ (W7Z'44?VC2_P"@
M>/W!]5G_ ,_9'YX_\+S_ &L_^A7UK_PEC_\ &Z/^%Y_M9_\ 0KZU_P"$L?\
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M^M?^$L?_ (W7Z'44?VC2_P"@>/W!]5G_ ,_9'YX_\+S_ &L_^A7UK_PEC_\
M&Z/^%Y_M9_\ 0KZU_P"$L?\ XW7Z'44?VC2_Z!X_<'U6?_/V1^>/_"\_VL_^
MA7UK_P )8_\ QNC_ (7G^UG_ -"OK7_A+'_XW7Z'44?VC2_Z!X_<'U6?_/V1
M^>/_  O/]K/_ *%?6O\ PEC_ /&Z/^%Y_M9_]"OK7_A+'_XW7Z'44?VC2_Z!
MX_<'U6?_ #]D?GC_ ,+S_:S_ .A7UK_PEC_\;H_X7G^UG_T*^M?^$L?_ (W7
MZ'44?VC2_P"@>/W!]5G_ ,_9'YX_\+S_ &L_^A7UK_PEC_\ &Z/^%Y_M9_\
M0KZU_P"$L?\ XW7Z'44?VC2_Z!X_<'U6?_/V1^>/_"\_VL_^A7UK_P )8_\
MQNC_ (7G^UG_ -"OK7_A+'_XW7Z'44?VC2_Z!X_<'U6?_/V1^>/_  O/]K/_
M *%?6O\ PEC_ /&Z/^%Y_M9_]"OK7_A+'_XW7Z'44?VC2_Z!X_<'U6?_ #]D
M?GC_ ,+S_:S_ .A7UK_PEC_\;H_X7G^UG_T*^M?^$L?_ (W7Z'44?VC2_P"@
M>/W!]5G_ ,_9'YX_\+S_ &L_^A7UK_PEC_\ &Z/^%Y_M9_\ 0KZU_P"$L?\
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M^M?^$L?_ (W7Z'44?VC2_P"@>/W!]5G_ ,_9'YX_\+S_ &L_^A7UK_PEC_\
M&Z/^%Y_M9_\ 0KZU_P"$L?\ XW7Z'44?VC2_Z!X_<'U6?_/V1^>/_"\_VL_^
MA7UK_P )8_\ QNC_ (7G^UG_ -"OK7_A+'_XW7Z'44?VC2_Z!X_<'U6?_/V1
M^>/_  O/]K/_ *%?6O\ PEC_ /&Z/^%Y_M9_]"OK7_A+'_XW7Z'44?VC2_Z!
MX_<'U6?_ #]D?GC_ ,+S_:S_ .A7UK_PEC_\;H_X7G^UG_T*^M?^$L?_ (W7
MZ'44?VC2_P"@>/W!]5G_ ,_9'YX_\+S_ &L_^A7UK_PEC_\ &Z/^%Y_M9_\
M0KZU_P"$L?\ XW7Z'44?VC2_Z!X_<'U6?_/V1^>/_"\_VL_^A7UK_P )8_\
MQNC_ (7G^UG_ -"OK7_A+'_XW7Z'44?VC2_Z!X_<'U6?_/V1^>/_  O/]K/_
M *%?6O\ PEC_ /&Z/^%Y_M9_]"OK7_A+'_XW7Z'44?VC2_Z!X_<'U6?_ #]D
M?GC_ ,+S_:S_ .A7UK_PEC_\;H_X7G^UG_T*^M?^$L?_ (W7Z'44?VC2_P"@
M>/W!]5G_ ,_9'YX_\+S_ &L_^A7UK_PEC_\ &Z/^%Y_M9_\ 0KZU_P"$L?\
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M^M?^$L?_ (W7Z'44?VC2_P"@>/W!]5G_ ,_9'YX_\+S_ &L_^A7UK_PEC_\
M&Z/^%Y_M9_\ 0KZU_P"$L?\ XW7Z'44?VC2_Z!X_<'U6?_/V1^>/_"\_VL_^
MA7UK_P )8_\ QNC_ (7G^UG_ -"OK7_A+'_XW7Z'44?VC2_Z!X_<'U6?_/V1
M^>/_  O/]K/_ *%?6O\ PEC_ /&Z/^%Y_M9_]"OK7_A+'_XW7Z'44?VC2_Z!
MX_<'U6?_ #]D?GC_ ,+S_:S_ .A7UK_PEC_\;H_X7G^UG_T*^M?^$L?_ (W7
MZ'44?VC2_P"@>/W!]5G_ ,_9'YX_\+S_ &L_^A7UK_PEC_\ &Z/^%Y_M9_\
M0KZU_P"$L?\ XW7Z'44?VC2_Z!X_<'U6?_/V1^>/_"\_VL_^A7UK_P )8_\
MQNC_ (7G^UG_ -"OK7_A+'_XW7Z'44?VC2_Z!X_<'U6?_/V1^>/_  O/]K/_
M *%?6O\ PEC_ /&Z/^%Y_M9_]"OK7_A+'_XW7Z'44?VC2_Z!X_<'U6?_ #]D
M?GC_ ,+S_:S_ .A7UK_PEC_\;H_X7G^UG_T*^M?^$L?_ (W7Z'44?VC2_P"@
M>/W!]5G_ ,_9'YX_\+S_ &L_^A7UK_PEC_\ &Z/^%Y_M9_\ 0KZU_P"$L?\
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M/_QNC_A>?[6?_0KZU_X2Q_\ C=?H=11_:-+_ *!X_<'U6?\ S]D?GC_PO/\
M:S_Z%?6O_"6/_P ;H_X7G^UG_P!"OK7_ (2Q_P#C=?H=11_:-+_H'C]P?59_
M\_9'YX_\+S_:S_Z%?6O_  EC_P#&Z/\ A>?[6?\ T*^M?^$L?_C=?H=11_:-
M+_H'C]P?59_\_9'YX_\ "\_VL_\ H5]:_P#"6/\ \;H_X7G^UG_T*^M?^$L?
M_C=?H=11_:-+_H'C]P?59_\ /V1^>/\ PO/]K/\ Z%?6O_"6/_QNC_A>?[6?
M_0KZU_X2Q_\ C=?H=11_:-+_ *!X_<'U6?\ S]D?GC_PO/\ :S_Z%?6O_"6/
M_P ;H_X7G^UG_P!"OK7_ (2Q_P#C=?H=11_:-+_H'C]P?59_\_9'YX_\+S_:
MS_Z%?6O_  EC_P#&Z/\ A>?[6?\ T*^M?^$L?_C=?H=11_:-+_H'C]P?59_\
M_9'YX_\ "\_VL_\ H5]:_P#"6/\ \;H_X7G^UG_T*^M?^$L?_C=?H=11_:-+
M_H'C]P?59_\ /V1^>/\ PO/]K/\ Z%?6O_"6/_QNC_A>?[6?_0KZU_X2Q_\
MC=?H=11_:-+_ *!X_<'U6?\ S]D?GC_PO/\ :S_Z%?6O_"6/_P ;H_X7G^UG
M_P!"OK7_ (2Q_P#C=?H=11_:-+_H'C]P?59_\_9'YX_\+S_:S_Z%?6O_  EC
M_P#&Z/\ A>?[6?\ T*^M?^$L?_C=?H=11_:-+_H'C]P?59_\_9'YX_\ "\_V
ML_\ H5]:_P#"6/\ \;H_X7G^UG_T*^M?^$L?_C=?H=11_:-+_H'C]P?59_\
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MK/\ Z%?6O_"6/_QNC_A>?[6?_0KZU_X2Q_\ C=?H=11_:-+_ *!X_<'U6?\
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M_P! \?N#ZK/_ )^R/SQ_X7G^UG_T*^M?^$L?_C='_"\_VL_^A7UK_P )8_\
MQNOT.HH_M&E_T#Q^X/JL_P#G[(_/'_A>?[6?_0KZU_X2Q_\ C='_  O/]K/_
M *%?6O\ PEC_ /&Z_0ZBC^T:7_0/'[@^JS_Y^R/SQ_X7G^UG_P!"OK7_ (2Q
M_P#C='_"\_VL_P#H5]:_\)8__&Z_0ZBC^T:7_0/'[@^JS_Y^R/SQ_P"%Y_M9
M_P#0KZU_X2Q_^-T?\+S_ &L_^A7UK_PEC_\ &Z_0ZBC^T:7_ $#Q^X/JL_\
MG[(_/'_A>?[6?_0KZU_X2Q_^-T?\+S_:S_Z%?6O_  EC_P#&Z_0ZBC^T:7_0
M/'[@^JS_ .?LC\\?^%Y_M9_]"OK7_A+'_P"-T?\ "\_VL_\ H5]:_P#"6/\
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M  EC_P#&Z_0ZBC^T:7_0/'[@^JS_ .?LC\\?^%Y_M9_]"OK7_A+'_P"-T?\
M"\_VL_\ H5]:_P#"6/\ \;K]#J*/[1I?] \?N#ZK/_G[(_/'_A>?[6?_ $*^
MM?\ A+'_ .-T?\+S_:S_ .A7UK_PEC_\;K]#J*/[1I?] \?N#ZK/_G[(_/'_
M (7G^UG_ -"OK7_A+'_XW1_PO/\ :S_Z%?6O_"6/_P ;K]#J*/[1I?\ 0/'[
M@^JS_P"?LC\\?^%Y_M9_]"OK7_A+'_XW1_PO/]K/_H5]:_\ "6/_ ,;K]#J*
M/[1I?] \?N#ZK/\ Y^R/SQ_X7G^UG_T*^M?^$L?_ (W1_P +S_:S_P"A7UK_
M ,)8_P#QNOT.HH_M&E_T#Q^X/JL_^?LC\\?^%Y_M9_\ 0KZU_P"$L?\ XW1_
MPO/]K/\ Z%?6O_"6/_QNOT.HH_M&E_T#Q^X/JL_^?LC\\?\ A>?[6?\ T*^M
M?^$L?_C='_"\_P!K/_H5]:_\)8__ !NOT.HH_M&E_P! \?N#ZK/_ )^R/SQ_
MX7G^UG_T*^M?^$L?_C='_"\_VL_^A7UK_P )8_\ QNOT.HH_M&E_T#Q^X/JL
M_P#G[(_/'_A>?[6?_0KZU_X2Q_\ C='_  O/]K/_ *%?6O\ PEC_ /&Z_0ZB
MC^T:7_0/'[@^JS_Y^R/SQ_X7G^UG_P!"OK7_ (2Q_P#C='_"\_VL_P#H5]:_
M\)8__&Z_0ZBC^T:7_0/'[@^JS_Y^R/SQ_P"%Y_M9_P#0KZU_X2Q_^-T?\+S_
M &L_^A7UK_PEC_\ &Z_0ZBC^T:7_ $#Q^X/JL_\ G[(_/'_A>?[6?_0KZU_X
M2Q_^-T?\+S_:S_Z%?6O_  EC_P#&Z_0ZBC^T:7_0/'[@^JS_ .?LC\\?^%Y_
MM9_]"OK7_A+'_P"-T?\ "\_VL_\ H5]:_P#"6/\ \;K]#J*/[1I?] \?N#ZK
M/_G[(_/'_A>?[6?_ $*^M?\ A+'_ .-T?\+S_:S_ .A7UK_PEC_\;K]#J*/[
M1I?] \?N#ZK/_G[(_/'_ (7G^UG_ -"OK7_A+'_XW1_PO/\ :S_Z%?6O_"6/
M_P ;K]#J*/[1I?\ 0/'[@^JS_P"?LC\\?^%Y_M9_]"OK7_A+'_XW1_PO/]K/
M_H5]:_\ "6/_ ,;K]#J*/[1I?] \?N#ZK/\ Y^R/S.^(WQ?_ &E-:\"ZW8>*
M?#VJVWAVXMF2^FF\.F!$B/WB9-@VCWS7(_L_?$7XV>#O"^H6OPST>_U'1Y+P
MRW,EIHQO%6?8@(+;#@[0O'O[U^AO[4G_ ";SX_\ ^P3+_*O%/^":7_)(?$W_
M &'6_P#2>&O3IXR#P4ZGL8V36G0XY8>2Q$8<[VW/+O\ A>?[6?\ T*^M?^$L
M?_C='_"\_P!K/_H5]:_\)8__ !NOT.HKS/[1I?\ 0/'[CL^JS_Y^R/SQ_P"%
MY_M9_P#0KZU_X2Q_^-T?\+S_ &L_^A7UK_PEC_\ &Z_0ZBC^T:7_ $#Q^X/J
ML_\ G[(_/'_A>?[6?_0KZU_X2Q_^-T?\+S_:S_Z%?6O_  EC_P#&Z_0ZBC^T
M:7_0/'[@^JS_ .?LC\\?^%Y_M9_]"OK7_A+'_P"-T?\ "\_VL_\ H5]:_P#"
M6/\ \;K]#J*/[1I?] \?N#ZK/_G[(_/'_A>?[6?_ $*^M?\ A+'_ .-T?\+S
M_:S_ .A7UK_PEC_\;K]#J*/[1I?] \?N#ZK/_G[(_/'_ (7G^UG_ -"OK7_A
M+'_XW1_PO/\ :S_Z%?6O_"6/_P ;K]#J*/[1I?\ 0/'[@^JS_P"?LC\\?^%Y
M_M9_]"OK7_A+'_XW1_PO/]K/_H5]:_\ "6/_ ,;K]#J*/[1I?] \?N#ZK/\
MY^R/SQ_X7G^UG_T*^M?^$L?_ (W1_P +S_:S_P"A7UK_ ,)8_P#QNOT.HH_M
M&E_T#Q^X/JL_^?LC\\?^%Y_M9_\ 0KZU_P"$L?\ XW1_PO/]K/\ Z%?6O_"6
M/_QNOT.HH_M&E_T#Q^X/JL_^?LC\\?\ A>?[6?\ T*^M?^$L?_C='_"\_P!K
M/_H5]:_\)8__ !NOT.HH_M&E_P! \?N#ZK/_ )^R/SQ_X7G^UG_T*^M?^$L?
M_C='_"\_VL_^A7UK_P )8_\ QNOT.HH_M&E_T#Q^X/JL_P#G[(_/'_A>?[6?
M_0KZU_X2Q_\ C='_  O/]K/_ *%?6O\ PEC_ /&Z_0ZBC^T:7_0/'[@^JS_Y
M^R/SQ_X7G^UG_P!"OK7_ (2Q_P#C='_"\_VL_P#H5]:_\)8__&Z_0ZBC^T:7
M_0/'[@^JS_Y^R/SQ_P"%Y_M9_P#0KZU_X2Q_^-T?\+S_ &L_^A7UK_PEC_\
M&Z_0ZBC^T:7_ $#Q^X/JL_\ G[(_/'_A>?[6?_0KZU_X2Q_^-T?\+S_:S_Z%
M?6O_  EC_P#&Z_0ZBC^T:7_0/'[@^JS_ .?LC\\?^%Y_M9_]"OK7_A+'_P"-
MT?\ "\_VL_\ H5]:_P#"6/\ \;K]#J*/[1I?] \?N#ZK/_G[(_/'_A>?[6?_
M $*^M?\ A+'_ .-T?\+S_:S_ .A7UK_PEC_\;K]#J*/[1I?] \?N#ZK/_G[(
M_/'_ (7G^UG_ -"OK7_A+'_XW1_PO/\ :S_Z%?6O_"6/_P ;K]#J*/[1I?\
M0/'[@^JS_P"?LC\\?^%Y_M9_]"OK7_A+'_XW1_PO/]K/_H5]:_\ "6/_ ,;K
M]#J*/[1I?] \?N#ZK/\ Y^R/SQ_X7G^UG_T*^M?^$L?_ (W1_P +S_:S_P"A
M7UK_ ,)8_P#QNOT.HH_M&E_T#Q^X/JL_^?LC\\?^%Y_M9_\ 0KZU_P"$L?\
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M@M(<_,QC8RN<>@5.OJP]:]P_8?\ ^30_A%_V+EI_Z *G#M^SJQZ*2M_X#?\
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M['\E-?-?[%/P)A_X*&?&#Q[\9OC(]QK>CV=ZMM:Z.)WCADD(++"2I#"&&,H
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MJ%^6I.VO-;TTT7SW_P"'.NM:]*-^C=N[OO\ +8\Y_;W_ &9_!W[,5OH/QQ^
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M/_L,'_T0]?8E?'?_  4P_P"28^$_^PP?_1#UZF5_[Y3]?T./&?P)'O/[-/\
MR;_\/O\ L"VW_HL44?LT_P#)O_P^_P"P+;?^BQ17'B/XT_5_F;TOX<?1'QW^
MR1_R>QXV_P![5O\ TI%?H?7YX?LD?\GL>-O][5O_ $I%?H?7J9O_ !X_X4<>
M!_AOU84445X9Z(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!\S?\%#/^3>)?\ L*VO_L]=
M'^P[_P FN>"O^WW_ -+9ZYS_ (*&?\F\2_\ 85M?_9ZZ/]AW_DUSP5_V^_\
MI;/7N2_Y%<?\?Z,\Y?[X_P##^I[M1117AGHA1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 <Y\2?^2=^*?^P5=?\ HEJ^
M-O\ @E_]WXE_]PW_ -NJ^R?B3_R3OQ3_ -@JZ_\ 1+5\;?\ !+_[OQ+_ .X;
M_P"W5>YAO^1?B/6/YGG5O]ZI?/\ (^[****\,]$**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "OB__@IK_P B1X*_[",W_HH5]H5\7_\ !37_ )$C
MP5_V$9O_ $4*]7*_]\I_UT9Q8W_=Y'TE^S__ ,D)^'7_ &+NG_\ I/'7?5P/
M[/\ _P D)^'7_8NZ?_Z3QUWU<%;^++U9TT_@CZ!1116)H%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'YX>&_^4E<W_85NO\ TADK]#Z_/#PW_P I
M*YO^PK=?^D,E?H?7N9KO1_P+]3SL'M/_ !,****\,]$**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** /+?VI/\ DWGQ_P#]@F7^5>*?\$TO^20^)O\
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M:C'HWB'3+A;_ $J^F4M$LP0HT<H'.QU8@D9((4X.,'Y+^&_AO_@H1\%- MO
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MS*T?]@;X[?M6?$;2/%O[4'BNVM="TYB8?"^ES(T@3=DPJ(1Y,*M@!I SR,%
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MO- (9'E@M)'!5I6D< R2;3M4!0J#.-WRE:'_  50_9B^)G[2$/PR7X=>&O\
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M_2D5^A]>IF_\>/\ A1QX'^&_5A1117AGHA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S-
M_P %#/\ DWB7_L*VO_L]='^P[_R:YX*_[??_ $MGKG/^"AG_ ";Q+_V%;7_V
M>NC_ &'?^37/!7_;[_Z6SU[DO^17'_'^C/.7^^/_  _J>[4445X9Z(4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"0#IO_ %[1_P#H K0KQY;L[UL%%%%2,**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KX[_ ."F'_),?"?_ &&#_P"B'K[$KX[_ ."F'_),
M?"?_ &&#_P"B'KU,K_WRGZ_H<>,_@2/>?V:?^3?_ (??]@6V_P#18HH_9I_Y
M-_\ A]_V!;;_ -%BBN/$?QI^K_,WI?PX^B/CO]DC_D]CQM_O:M_Z4BOT/K\\
M/V2/^3V/&W^]JW_I2*_0^O4S?^/'_"CCP/\ #?JPHHHKPST0HHHH **** "B
MBB@ HHHH **** "BBB@"OJ&H6VE6-S>WMQ':6=M&TTUQ,P5(T4$LS$\   DD
M^E?D+^UE_P %>/%FN>(K[P_\%I(_#WAZVD,7_"1W%LDUY?8."T22 I%&>V5+
MD8.4/RU]2?\ !77XN7GPY_9;_L/39VM[OQ=J,>ERO&VUOLJJTLP'LVQ$/J'-
M?)G_  1U_9RT/XC>.O$OQ&\1V$6I0^%F@M]*M[A \8O)-S&8J>K1JJ[<]"^>
MJ@UG2BZ]22;M&&_X?YI)=]]"ZDE1IQ=KREM_7R;?DCP>7X@_MD2:>?%C:M\9
MQI&S[4=14ZHMCY>,[^!Y6S'/IBOH3]D/_@K=XNT/Q3I_AOXSW4?B+PY>2K /
M$2P)#=Z>3@!I0@"RQ#N<!P"3EL;:_86OSB_:Q_X).R_'#XY3>+_!&M:'X*T3
M5(%DU2VD@D=S>;COECB0!,.NTGYE^8,?XB:UC-PFERWB_P"OZ?<SE!3@VW:2
M_K^D?8O[2EI\0]:^"6M7?P@\2'1?&EO +_39H;6VNDO@H+&#$R.N)%^ZPP0V
MWG&0?RY_9;_X*F?%;3_CIHFG?&+Q6NK^#+V4Z??+/I=G9M82,0JSEH84;",
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M+&:TO_GO_76YQTV^:4-[?U;^NC04445SFP4444 %%%% !1110 4444 %%%%
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M[Q:WZ(CR+W9-K,"!WYS[5Z)7YC:7JEWHFHV]_87$EI>6[B2*:(X9&'<5]O?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#RW]J3_DWGQ_\ ]@F7^5>*?\$TO^20^)O^
MPZW_ *3PU[7^U)_R;SX__P"P3+_*O%/^":7_ "2'Q-_V'6_])X:]RE_R+:G^
M)?H>=/\ WN'HSZ]HHHKPST0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?\%5/@EJ7PHU#Q[<_P#"0:196VHG2X-*OK.$W]],(ED;R8XYG4J%=<N[*H)
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M5%#-N8#!;&,GUIU9&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5\=_\ !3#_ ))CX3_[#!_]$/7V
M)7QW_P %,/\ DF/A/_L,'_T0]>IE?^^4_7]#CQG\"1[S^S3_ ,F__#[_ + M
MM_Z+%%'[-/\ R;_\/O\ L"VW_HL45QXC^-/U?YF]+^''T1\=_LD?\GL>-O\
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MA6-7D=BSN0H&69B23U).35VBJE)SDY/=DQBH144?SL_MX?\ )Z'Q4_[#K?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M  /R/U7(\\6+2PV)?[SH_P";_@_F>MT445\(?:A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7Q?\ \%-?^1(\%?\ 81F_]%"OM"OB_P#X
M*:_\B1X*_P"PC-_Z*%>KE?\ OE/^NC.+&_[O(^DOV?\ _DA/PZ_[%W3_ /TG
MCKOJX']G_P#Y(3\.O^Q=T_\ ])XZ[ZN"M_%EZLZ:?P1] HHHK$T"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#\\/#?\ RDKF_P"PK=?^D,E?H?7Y
MX>&_^4E<W_85NO\ TADK]#Z]S-=Z/^!?J>=@]I_XF%%%%>&>B%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% 'EO[4G_)O/C_\ [!,O\J\4_P"":7_)
M(?$W_8=;_P!)X:]K_:D_Y-Y\?_\ 8)E_E7BG_!-+_DD/B;_L.M_Z3PU[E+_D
M6U/\2_0\Z?\ O</1GU[1117AGHA1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5\ ?\%.?^1E\!_\ 7I=?^AQU]_U\ ?\ !3G_ )&7P'_UZ77_ *''
M7M9/_OL/G^3//Q_^[R^7YGW?X?\ ^0#IO_7M'_Z *T*S_#__ " =-_Z]H_\
MT 5H5X\MV=ZV"BBBI&%%%% !1110 4444 %%%% 'YW?\%LO^3>_ _P#V-"_^
MDEQ7V/\ LW?$C2_BU\"? _BG2)XY[:^TJW\P(P/E3*@26)L=&1U92/:OCC_@
MME_R;WX'_P"QH7_TDN*Y[P?^P/\ %_P'X3\.^)_V<OC W@RS\1:39W^H>'M;
MGE^RI/);H9)$98Y5;)/&Z/<HXWD=%1=H5KK3FC]_+^0JOQTM=>5_=S:_/8ZC
M_@LW\2M-TCX#^'O R7"R:]KVL172V:$%_LT*ON<CJ 9&C4>ISCH:N_M6>";W
MX<?\$F+?PSJ:&/4M,T/1+>ZC/5)1<6Y=?P8D?A5C]G__ ()F7ND?%"V^*'QU
M\<R?$_QI;R)<6]J7EDM8ID.4=Y9</*%."J;452.A' ^B/VSO@CKO[17[.GBC
MP#X;N]/LM8U1K8PSZI))';KY=Q'*VYD1V'RH<84\X^M9SAR4)16LI24GY6LE
M^&YO3FI8B$GI&*:];N[.0_X)I_\ )DGPR_Z][K_TKFKYJ_X+;>";Z^\"_#7Q
M?;Q-)9:3J%U8W+*"=AG2-XR?09@89]2*^S_V0_@[K7P!_9V\'^ O$-S8WFL:
M/%-'<3Z9([V[%YY)!L9T1CPXZJ.<UW?Q,^&OASXP>!M6\(>+--CU70=4B\JY
MMI"1GD%65ARK*P#!AR" :Z<8W*M*I2>JE=??^J.?!OV4$I]FG\T4/@I\3-(^
M,'PI\+^,-$NH[NPU6PBG#1D'9)M DC;'1E<,I'8@U\R_\%:/B9I'@W]D?6O#
MMW<Q#5_%%S;6=C:%OWCB.>.:5P.NU5CP3TRZCN*\CM/^";/QX^ >M7K?L_\
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M%%'RL!\K-SGZUT2:^MQFMN1KY\L5;[SD47]6<.O.G\N9O\CV7]M#_DTKXO\
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MI*,IRE%63>QE3BXP49.[2"BBBLS0**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX[_X*8?\DQ\)_P#88/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!SGQ)_Y)WXI_[!5U_Z):ORG^$/_(MW/_7V
MW_H"5^K'Q)_Y)WXI_P"P5=?^B6K\I_A#_P BW<_]?;?^@)7Z-P?_ !*A\/Q5
M_N\3N****_53\L"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *M:
M7JEWHFHV]_87$EI>6[B2*:(X9&'<55HJ6E)6>PTW%W6Y]T? GX[6GQ0TX6%^
M8[3Q+;IF6$<+<*/^6D?]5[?2O6Z_,;2]4N]$U&WO["XDM+RW<2131'#(P[BO
MO+X$_$Z[^*'@T7]_826EY;OY$LP3$-PP'WX_ZCL:_'^(LB6 ?UK#_P -O5=G
M_E^1^KY#G3QJ^K5_XBZ]U_G^9Z/1117PQ]F%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5\7_\ !37_ )$CP5_V$9O_ $4*^T*^+_\ @IK_ ,B1
MX*_[",W_ **%>KE?^^4_ZZ,XL;_N\CZ2_9__ .2$_#K_ +%W3_\ TGCKOJX'
M]G__ )(3\.O^Q=T__P!)XZ[ZN"M_%EZLZ:?P1] HHHK$T"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MWW_TMGKG/^"AG_)O$O\ V%;7_P!GKH_V'?\ DUSP5_V^_P#I;/7N2_Y%<?\
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MK*2ZSA^;_/<_0']IC4KS1_V=?B??6#,E[;^&=2EA=#AE86TA##W'7\*^-?\
M@B;I5C#\ _'&HQJG]HW'B0P3,!\WEQVT)C!/IF23'U-?H-KFCVGB+1;_ $J_
MB$]C?6\EK/$W1XW4JP_$$U^0_P )_B!XO_X)-_&[Q-X4\=>'=2USX5^(KCS+
M/5+%03($+".>$L0ADV$+)$64C"G. N[DHR4*M12TYXI)^:E>W^1TU$YTH<JO
MRR;?HU;\.I^PU?E#^P#$GAW_ (*:_'/1M)_=:./[:3R8^4"IJ,6SIQQD@?6O
M7?BY_P %A_A;I'@^<?#FSU;Q9XMNHBEE;W%BUO;V\S#"F8L0S8)SMC#;L8RN
M<T__ ();?LL^+OAO#XK^+7Q'M9['Q=XPX@L[Q-ES% TAEEEF7^!Y9-IV$ @(
M,XW8%T4U6=5K2,9+YR5DE^OD9U9+V/L]W*47\EO_ %W/*_A'I<&H_P#!:+QO
M-,JLUD+RXBR,X;[%&F1Z<.:_5*ORY^"O_*9KXC?]>]W_ .DL%?J-44?]TP_^
M!?FQ2_WBO_B_1'Y3_P#!/N5H?^"F7Q]@0A8776F90!C(U2''\S^=>4_$K5/B
MK??\%4/&FH_"_1++Q'X^TZ\E&GV.K21+%Y,=DL18>;)&N1&21\P/<9KU/_@G
M_P#\I.OCU_USUS_TZ05L_M_?!SQ[^S]^TQHO[47PWTN35[.$QRZW!%&T@MY(
MXO)=I57D0RP#:7'W2"21E:4&H0PE23M'D:OVNW9ORTM\S>JG*>*A!7?->W>U
MKK^NQU?_  LC_@HS_P!$I\(_^!5A_P#+"O(]?_9Y_;#^,?[3WPZ^*/CGX;:;
MI=YH%]IZ2W6DZII\:+;0W7FLS(+MV8@._3J.,5]$^'?^"Q7P+U+PB-2U6'Q%
MH^LI'F31/[/\^1GQRL<JMY;#/0N4SW Z5Y;^SK\6_C?^W!^ULOCW1=0\1^!/
M@CHTB++8QWCI:74<62L!7[DL\K',A4?(G&[A-V]--5XV6L7>_16Z_P##'/4:
M=&5WNK6ZOR/4?VO/VK/VF?A'\9;KP]\+?@[_ ,)IX3CL[>:/5?\ A&-3O]TK
M*3(GFV\JH<'MC([UQ_P-_;0_:Y\<?%_PCH'C+X$_\(_X6U'48K?4M4_X1#5[
M;[- QPTGFRS%$P.[ @5^C=%94OW;3EKK?\;V_0JI[Z:CII^F_P"I^6?_  7(
M_P"0=\'?^NNJ_P K2O2/#G_!'/X':QX;TN]FUCQHL]U:13/Y>I6P 9D!. ;;
MU->;_P#!<C_D'?!W_KKJO\K2OTQ\#_\ (E>'_P#L'V__ *+6IP\5[&H^O-_F
M:XB3YJ*_NO\ ]*/Q6_:J_8BMOV'?'VA^+KK0A\6/A'>3B"2UU2XFM)X).ODR
MRVS)ABH)20#:2"&3@;OUB_9-\5?##QI\#]"U?X2:58Z'X2N W_$ML[=8&MK@
M8$L<RKUE!ZL2=W#9((-=O\5/ACH'QD^'NN>#/$UFM[HNKVS6\Z$#<F>5D0]G
M5@&4]BH-?DA^RO\ $O7_ /@G'^UOKGPF\?W)3P3K-TD$UY)E8%W'%KJ"9X"L
M"%?T&<\QXK2A)MO#2Z_"^_D^_E\O-F5:*Y57CTW7ZK]?^"CK?^"RL^KZQ\>/
MA#H5C MV38LUE;3E1%+<2W2IM8L0N#LC!R0,'G%>JI\1O^"B\:*B_"CP@JJ,
M!1=6& /_  85VW_!4C]E/7OV@/AOH/B[P/;2ZCXN\(O)-'8VIS+>6DFTN(L?
M>D1HT90.2-X&20*XSX!?\%>O K>$+71OC#9ZMX7\::9']FOKF&P::WNI$^4M
MM7]Y'(2#N1EP#T;L,:&E*5-OWE*3MY-WNOR?X=32M=SC42T:2OV:TL_7?\SR
M']I3X3_MR_M5>$]-\/>-?A3H*V6GWHOX)-,U'3H91)L9,%C>M\I#G(QU ]*^
MA?VR-$\0>&?^"5O]C^*X#;>)-/T70[3486E24I/'/;(X+HS*QRO520>U>&?%
MK]LSXG?MS?%WPQX#_9M'B;PGH]A<>??Z]'*UJ[!OE,MQY;$);H-Q"LQ+DCY=
MP45]0_\ !2;2Y=#_ & ?%NG3WUQJD]I#ID$E]=-NEN&6[MU,CGNS$9/N:*EU
MAI.UE*47YNVE_3I_PS+HV>*@KW:3^5];?K_2.@_X)MM$G[#GPW:<H(!:79D,
MF-H7[7/G.>V*\"U?_@I-X+\*>/-9\+?LZ? N;Q_?22%[Z^\.V0LTNW3@2K';
MP223*,D;W"=>,@Y/IW['GA/4?'G_  3$TGPUI$_V75-7\.:M86LQ;:%EDEN4
M0D]ADCFOC;_@GM^UQX2_8GN/''P]^+/AS5?#>KW&I+-+J4=EYDL+)'L,$\?#
MA1C<I4,#YC< <GLQ'O8VK%NUKOUUV^6_](XZ*Y<+3DE?6WIIO\]CVOQ-\>?V
MYOBYX5UA-+^$.C?#OP_):R_:-0U2(17-O#L.\E;F;)^7/2 FI?\ @B'_ ,DG
M^)/_ &&X/_1%:/QK_P""CD?[0'AW6/AA^SGX1\0^-/%VNVLEF^J/9^1;65O(
M"DDHW'<" 2 T@1%+ DG&TX7_  1%U../P7\5=$D*I?6NJ6EP\1/S!6CD3D?6
M,UC03O5:6G*O5VDK_)?YE5MJ6M[2=^RO%V^__(RO''_*;'PS_P!<(O\ TU25
MW7_!:[5+NU_9[\&64+.MI=^)5,^WHVRVF*J?Q)/_  &O&OVP/'R?LT_\%2?#
MOQ/\3:5?W/AM;*WN4-C&#)/']E>V<Q[RJLRN3E=P[<C(KZG^->DZ#_P4T_8O
MO+_P MU;WBWC7FC1ZNB02?;+9F0Q/M=E42(SJ#NP-ZD]*X[.>"CRZ\LFW\IG
M:Y*.+U=KQBEZ\C/ _@QXN_;T\-_"/P;IG@WX7^$[GPI;:1:II4\EU8AY;;RE
M,;MF^4[F7#'*@Y)X%1_&C2?V^?CU\-=9\#>*/A1X9;1-56-9S:7VGQRKLD61
M2C&^(!#(.U1_LC?\%(+;]G3PK;_!WX]:!KGA[5?"^+&UU!;(N\=NH^2*XBR'
M!48"N@8,NW@8W-)^U)_P4FU']H""Q^%O[-5EXGG\1:K=1^9KUDCVER41@VRV
M"MO4$CYY'V!5# @AB1VU[5)OD]]2>G7?O_7H<M&]-+G]UQWZ;=OT_$U/%WP]
M^(?P%_X)"^*?"7C737T/7[.Y\EK5;J&X*6DVHQM]^)W7!$C# /0U]#?\$L=.
ML[#]B/P*]IL+W4M_/<,HP6E^V3*<^X55'T KM=(_9XUSQ=^Q_)\*OB3XFNO$
MGB75M&>WU/6KJ0SLET^75E)^\L3[ I/)\L$\FO@W]E+]K+6/^">6J:O\$?CI
MX<U2ST:"\DNM,U:RA\T1!S\S(#CS;=R"X9,LK%@5))"WSI5:U.35Y<MGWY=&
MO_;O-D<MZ%.44]&VUVYMG^GDC[\_;FTFTUG]D'XMP7L2S11^'KJY56 P)(E\
MR-OJ'13^%>0?\$B?^3--*_[#%_\ ^C!7SQ^VO_P40T_]HSX7^(OAO\%=$UG6
MK2>S>]\0:_-:F&.WT^'$LFU3\P!V@,SA1CY0&+C'T/\ \$B?^3--*_[#%_\
M^C!66'B^:M*UDXK\);_I\F57:M1C?[3_ /27^/\ P#[3KXV_X*U_\F6^(O\
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M- X"D[2&1@>"Q*CV?]H;_@KEX(N? ][H'P<M]:\1>-=7A-I97ALGMXK.23Y
MX#?O))02"JJN"<?-V.E=QJ0O'WTTE;Y6M^A%*,J<N67NM-_G>_ZG2_\ !*S]
MG'XL?LXZ3\1=,^)/AS_A'K+4IK*YTY#J%K="215F68_N)7VX'E?>QGWQQB>.
MO^"B_P /?AO\5-:\+? ;X+GXB>+)I##J=]X=LUM%NGB)'RF&"26Y",6&X@+R
M2K$')]>_8G^%_P 7]-_9JU9/BQXLUO4/&/B2&8VEOK=V\\^DPM$5B5F8EA(2
MQ=@3D953@J17P/\ L'_M&:)^P'\2?B#X*^,'AC4M&U&^F@ADU*"U\V6U,)?Y
M77(9H7#[E=-V>" 0<C2HW+$.$G:T5\^EOE;7OT,X6C0YX1O>7W>=O/I_5OHY
MOVBOVZ?BY#-%X5^"FE> ;"<%1?ZY"8;BU4\;R+J9 V.O^I;Z&N+_ ."(7F?V
MA\:_.8-+NTK>R]"V;S)_.O3?BE_P5"TCXE:?=>!?V?/"_B'Q[X_UB%K:SN18
M&&VM-X*F8ACO)3(/S*J#JS@#!\L_X(JK/X:\<?&SPQJB?9M:MQ8B>V=@75H9
M;F.4<==K. 2#W'K3P_Q5%:UXZ=W9INWDE^9=9VI)-Z\T?EVOYOIZ/N=;^TW^
MP;\9/!_Q^U?XV?LY:^MMK&JR/<WFDBZCM[D32$&4)YH\F:)V&\I*1AN@;C'"
MVW_!1S]J+]G9T@^-/PC;5=,@;RI-2N=.ETQYGSP5NHU:V;_@$?/K6UXF_:B^
M*W["?[7WB9?B]<^)?&_PK\0&0Z1<+)O2& N7B:V5BL7F1@^7)'E21ALXV[O4
M?BO_ ,%</@3_ ,*]U.'1;;5O&.IWUI) FC3::8869T(VSO+A=G.#M#GV-<D)
M.%",J>JM\/5?W?+^NQO**E6:J:.^_?S\SW3X,_M<>&/VG/@'XH\9^"EN[/4=
M+LKA+O2KQ0+BSN5A9T'RY#*V,JPZ^@(*C\KO^"?&K_M)Z%9^-M2^ W@_1?%"
M74UM%J]SJTULLD3*)&C5?-N(FP=[DX!&17V?_P $A_V=_$WPQ^%OC'Q1XMTV
M?2!XQEMQ9Z7>1F.3[+"LF)60\J',S  \E4!Z$$_/VAZEXP_X),_M+>(Y-2\.
M7VO?!SQ1+LBN[11^\A#.\!1S\HN(@SJ8V*[AD\ JPZ91C2Q4DW92BEY*2U:?
MK>WRUV.9.52AIKRROZK:_P OQZ;GN'_"R/\ @HS_ -$I\(_^!5A_\L*R?V!?
MV9_C[\-?VM/%OQ%^)/@N#PSI?B6QOGO9+34K.6'[3-<1S!5BBGD8#<&QD' [
M\UW?CS_@L9\%M%\'27WABWUSQ)X@DB/V?2I+(VJQR8^432L=H7/4IO/M4_\
MP34TOXZ>,/\ A)_B=\6_$FOG1M<9CHGAW5+B3RP'D\Q[A(7),40&$C7@;2Q
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M4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?5P/[/\ _P D)^'7_8NZ?_Z3QUWU<%;^++U9TT_@CZ!1116)H%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^E(K]#Z]3-_X\?\ "CCP/\-^K"BBBO#/1"BBB@ HHHH **** "BBB@ HHHH
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MX"T+PMKWAJV74+2^T33X[61E1U$B2F-1YH*%OOYP<&M*W[B"K2VM>WE=W?\
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M>!6[1157;W)VV&30QW$+Q2HLL4BE71QE6!&"".XKC/"?P0^'/@+^T/\ A&?
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M744;.Z#=69E>)/"NB>,M+DTSQ!H]AKFFR??L]2M4N(6^J."#^5<]X/\ @?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7P!_P4Y_Y&7P'_ ->EU_Z'
M'7W_ %\ ?\%.?^1E\!_]>EU_Z''7M9/_ +[#Y_DSS\?_ +O+Y?F?=_A__D Z
M;_U[1_\ H K0K/\ #_\ R =-_P"O:/\ ] %:%>/+=G>M@HHHJ1A1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHHHKE.@**** "BBB@ HHHH **** "BBB@ HHHH **** /F;_ (*&?\F\2_\
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M_P#$U^C=%>M_KEB/^?*^]GB?ZHT/^?K^Y'YR?\*K\:_]"AKW_@LG_P#B:/\
MA5?C7_H4->_\%D__ ,37Z-T4?ZY8C_GROO8?ZHT/^?K^Y'YR?\*K\:_]"AKW
M_@LG_P#B:/\ A5?C7_H4->_\%D__ ,37Z-T4?ZY8C_GROO8?ZHT/^?K^Y'YR
M?\*K\:_]"AKW_@LG_P#B:/\ A5?C7_H4->_\%D__ ,37Z-T4?ZY8C_GROO8?
MZHT/^?K^Y'YR?\*K\:_]"AKW_@LG_P#B:/\ A5?C7_H4->_\%D__ ,37Z-T4
M?ZY8C_GROO8?ZHT/^?K^Y'YR?\*K\:_]"AKW_@LG_P#B:/\ A5?C7_H4->_\
M%D__ ,37Z-T4?ZY8C_GROO8?ZHT/^?K^Y'YR?\*K\:_]"AKW_@LG_P#B:/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH _/#PW_RDKF_["MU_P"D,E?H?7YX>&_^4E<W_85NO_2&2OT/KW,UWH_X
M%^IYV#VG_B84445X9Z(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M>6_M2?\ )O/C_P#[!,O\J\4_X)I?\DA\3?\ 8=;_ -)X:]K_ &I/^3>?'_\
MV"9?Y5XI_P $TO\ DD/B;_L.M_Z3PU[E+_D6U/\ $OT/.G_O</1GU[1117AG
MHA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\ ?\%.?^1E\!_P#7
MI=?^AQU]_P!? '_!3G_D9? ?_7I=?^AQU[63_P"^P^?Y,\_'_P"[R^7YGW?X
M?_Y .F_]>T?_ * *T*S_  __ ,@'3?\ KVC_ /0!6A7CRW9WK8****D84444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7QW_P4P_Y)CX3_P"P
MP?\ T0]?8E?'?_!3#_DF/A/_ +#!_P#1#UZF5_[Y3]?T./&?P)'O/[-/_)O_
M ,/O^P+;?^BQ11^S3_R;_P##[_L"VW_HL45QXC^-/U?YF]+^''T1\=_LD?\
M)['C;_>U;_TI%?H?7YX?LD?\GL>-O][5O_2D5^A]>IF_\>/^%''@?X;]6%%%
M%>&>B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 ?,W_!0S_DWB7_L*VO\ [/71_L._\FN>
M"O\ M]_]+9ZYS_@H9_R;Q+_V%;7_ -GKH_V'?^37/!7_ &^_^EL]>Y+_ )%<
M?\?Z,\Y?[X_\/ZGNU%%%>&>B%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** .<^)/_ "3OQ3_V"KK_ -$M7QM_P2_^[\2_
M^X;_ .W5?9/Q)_Y)WXI_[!5U_P"B6KXV_P""7_W?B7_W#?\ VZKW,-_R+\1Z
MQ_,\ZM_O5+Y_D?=E%%%>&>B%%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?'?_!3#_DF/
MA/\ [#!_]$/7V)7QW_P4P_Y)CX3_ .PP?_1#UZF5_P"^4_7]#CQG\"1[S^S3
M_P F_P#P^_[ MM_Z+%%'[-/_ ";_ /#[_L"VW_HL45QXC^-/U?YF]+^''T1\
M<?LGW$5M^VMXV>:1(DWZL-SL /\ CY'K7Z#_ -KV/_/[;_\ ?U?\:^$O$7_!
M-_Q)KWBS6=1'C#2H+2\NYKB+_1I6DP\A90PX .#S@GGUJG_P[(U__H>=-_\
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M_ &3_P"*H_X=D:__ -#SIO\ X R?_%4?5,%_T$_^2L/;XC_GU^)]\_VO8_\
M/[;_ /?U?\:/[7L?^?VW_P"_J_XU\#?\.R-?_P"AYTW_ , 9/_BJ/^'9&O\
M_0\Z;_X R?\ Q5'U3!?]!/\ Y*P]OB/^?7XGWS_:]C_S^V__ ']7_&C^U['_
M )_;?_OZO^-? W_#LC7_ /H>=-_\ 9/_ (JC_AV1K_\ T/.F_P#@#)_\51]4
MP7_03_Y*P]OB/^?7XGWS_:]C_P _MO\ ]_5_QH_M>Q_Y_;?_ +^K_C7P-_P[
M(U__ *'G3?\ P!D_^*H_X=D:_P#]#SIO_@#)_P#%4?5,%_T$_P#DK#V^(_Y]
M?B??/]KV/_/[;_\ ?U?\:/[7L?\ G]M_^_J_XU\#?\.R-?\ ^AYTW_P!D_\
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MY]?B??/]KV/_ #^V_P#W]7_&C^U['_G]M_\ OZO^-? W_#LC7_\ H>=-_P#
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M_ &3_P"*H_X=D:__ -#SIO\ X R?_%4?5,%_T$_^2L/;XC_GU^)]\_VO8_\
M/[;_ /?U?\:/[7L?^?VW_P"_J_XU\#?\.R-?_P"AYTW_ , 9/_BJ/^'9&O\
M_0\Z;_X R?\ Q5'U3!?]!/\ Y*P]OB/^?7XGWS_:]C_S^V__ ']7_&C^U['_
M )_;?_OZO^-? W_#LC7_ /H>=-_\ 9/_ (JC_AV1K_\ T/.F_P#@#)_\51]4
MP7_03_Y*P]OB/^?7XGWS_:]C_P _MO\ ]_5_QH_M>Q_Y_;?_ +^K_C7P-_P[
M(U__ *'G3?\ P!D_^*H_X=D:_P#]#SIO_@#)_P#%4?5,%_T$_P#DK#V^(_Y]
M?B??/]KV/_/[;_\ ?U?\:/[7L?\ G]M_^_J_XU\#?\.R-?\ ^AYTW_P!D_\
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MYTW_ , 9/_BJ/^'9&O\ _0\Z;_X R?\ Q5'U3!?]!/\ Y*P]OB/^?7XGL?\
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M/^?7XGWS_:]C_P _MO\ ]_5_QH_M>Q_Y_;?_ +^K_C7P-_P[(U__ *'G3?\
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M (JC_AV1K_\ T/.F_P#@#)_\51]4P7_03_Y*P]OB/^?7XGWS_:]C_P _MO\
M]_5_QH_M>Q_Y_;?_ +^K_C7P-_P[(U__ *'G3?\ P!D_^*H_X=D:_P#]#SIO
M_@#)_P#%4?5,%_T$_P#DK#V^(_Y]?B??/]KV/_/[;_\ ?U?\:/[7L?\ G]M_
M^_J_XU\#?\.R-?\ ^AYTW_P!D_\ BJ/^'9&O_P#0\Z;_ . ,G_Q5'U3!?]!/
M_DK#V^(_Y]?B??/]KV/_ #^V_P#W]7_&C^U['_G]M_\ OZO^-? W_#LC7_\
MH>=-_P# &3_XJC_AV1K_ /T/.F_^ ,G_ ,51]4P7_03_ .2L/;XC_GU^)]\_
MVO8_\_MO_P!_5_QH_M>Q_P"?VW_[^K_C7P-_P[(U_P#Z'G3?_ &3_P"*H_X=
MD:__ -#SIO\ X R?_%4?5,%_T$_^2L/;XC_GU^)]\_VO8_\ /[;_ /?U?\:/
M[7L?^?VW_P"_J_XU\#?\.R-?_P"AYTW_ , 9/_BJ/^'9&O\ _0\Z;_X R?\
MQ5'U3!?]!/\ Y*P]OB/^?7XGWS_:]C_S^V__ ']7_&C^U['_ )_;?_OZO^-?
M W_#LC7_ /H>=-_\ 9/_ (JC_AV1K_\ T/.F_P#@#)_\51]4P7_03_Y*P]OB
M/^?7XGWS_:]C_P _MO\ ]_5_QH_M>Q_Y_;?_ +^K_C7P-_P[(U__ *'G3?\
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M (JC_AV1K_\ T/.F_P#@#)_\51]4P7_03_Y*P]OB/^?7XGWS_:]C_P _MO\
M]_5_QH_M>Q_Y_;?_ +^K_C7P-_P[(U__ *'G3?\ P!D_^*H_X=D:_P#]#SIO
M_@#)_P#%4?5,%_T$_P#DK#V^(_Y]?B??/]KV/_/[;_\ ?U?\:/[7L?\ G]M_
M^_J_XU\#?\.R-?\ ^AYTW_P!D_\ BJ/^'9&O_P#0\Z;_ . ,G_Q5'U3!?]!/
M_DK#V^(_Y]?B??/]KV/_ #^V_P#W]7_&C^U['_G]M_\ OZO^-? W_#LC7_\
MH>=-_P# &3_XJC_AV1K_ /T/.F_^ ,G_ ,51]4P7_03_ .2L/;XC_GU^)]\_
MVO8_\_MO_P!_5_QH_M>Q_P"?VW_[^K_C7P-_P[(U_P#Z'G3?_ &3_P"*H_X=
MD:__ -#SIO\ X R?_%4?5,%_T$_^2L/;XC_GU^)]\_VO8_\ /[;_ /?U?\:/
M[7L?^?VW_P"_J_XU\#?\.R-?_P"AYTW_ , 9/_BJ/^'9&O\ _0\Z;_X R?\
MQ5'U3!?]!/\ Y*P]OB/^?7XGWS_:]C_S^V__ ']7_&C^U['_ )_;?_OZO^-?
M W_#LC7_ /H>=-_\ 9/_ (JC_AV1K_\ T/.F_P#@#)_\51]4P7_03_Y*P]OB
M/^?7XGWS_:]C_P _MO\ ]_5_QH_M>Q_Y_;?_ +^K_C7P-_P[(U__ *'G3?\
MP!D_^*H_X=D:_P#]#SIO_@#)_P#%4?5,%_T$_P#DK#V^(_Y]?B??/]KV/_/[
M;_\ ?U?\:/[7L?\ G]M_^_J_XU\#?\.R-?\ ^AYTW_P!D_\ BJ/^'9&O_P#0
M\Z;_ . ,G_Q5'U3!?]!/_DK#V^(_Y]?B??/]KV/_ #^V_P#W]7_&C^U['_G]
MM_\ OZO^-? W_#LC7_\ H>=-_P# &3_XJC_AV1K_ /T/.F_^ ,G_ ,51]4P7
M_03_ .2L/;XC_GU^)]\_VO8_\_MO_P!_5_QH_M>Q_P"?VW_[^K_C7P-_P[(U
M_P#Z'G3?_ &3_P"*H_X=D:__ -#SIO\ X R?_%4?5,%_T$_^2L/;XC_GU^)]
M\_VO8_\ /[;_ /?U?\:/[7L?^?VW_P"_J_XU\#?\.R-?_P"AYTW_ , 9/_BJ
M/^'9&O\ _0\Z;_X R?\ Q5'U3!?]!/\ Y*P]OB/^?7XGWS_:]C_S^V__ ']7
M_&C^U['_ )_;?_OZO^-? W_#LC7_ /H>=-_\ 9/_ (JC_AV1K_\ T/.F_P#@
M#)_\51]4P7_03_Y*P]OB/^?7XGWS_:]C_P _MO\ ]_5_QH_M>Q_Y_;?_ +^K
M_C7P-_P[(U__ *'G3?\ P!D_^*H_X=D:_P#]#SIO_@#)_P#%4?5,%_T$_P#D
MK#V^(_Y]?B??/]KV/_/[;_\ ?U?\:/[7L?\ G]M_^_J_XU\#?\.R-?\ ^AYT
MW_P!D_\ BJ/^'9&O_P#0\Z;_ . ,G_Q5'U3!?]!/_DK#V^(_Y]?B??/]KV/_
M #^V_P#W]7_&C^U['_G]M_\ OZO^-? W_#LC7_\ H>=-_P# &3_XJC_AV1K_
M /T/.F_^ ,G_ ,51]4P7_03_ .2L/;XC_GU^)]\_VO8_\_MO_P!_5_QH_M>Q
M_P"?VW_[^K_C7P-_P[(U_P#Z'G3?_ &3_P"*H_X=D:__ -#SIO\ X R?_%4?
M5,%_T$_^2L/;XC_GU^)]\_VO8_\ /[;_ /?U?\:/[7L?^?VW_P"_J_XU\#?\
M.R-?_P"AYTW_ , 9/_BJ/^'9&O\ _0\Z;_X R?\ Q5'U3!?]!/\ Y*P]OB/^
M?7XGWS_:]C_S^V__ ']7_&C^U['_ )_;?_OZO^-? W_#LC7_ /H>=-_\ 9/_
M (JC_AV1K_\ T/.F_P#@#)_\51]4P7_03_Y*P]OB/^?7XGWS_:]C_P _MO\
M]_5_QH_M>Q_Y_;?_ +^K_C7P-_P[(U__ *'G3?\ P!D_^*H_X=D:_P#]#SIO
M_@#)_P#%4?5,%_T$_P#DK#V^(_Y]?B??/]KV/_/[;_\ ?U?\:/[7L?\ G]M_
M^_J_XU\#?\.R-?\ ^AYTW_P!D_\ BJ/^'9&O_P#0\Z;_ . ,G_Q5'U3!?]!/
M_DK#V^(_Y]?B??/]KV/_ #^V_P#W]7_&C^U['_G]M_\ OZO^-? W_#LC7_\
MH>=-_P# &3_XJC_AV1K_ /T/.F_^ ,G_ ,51]4P7_03_ .2L/;XC_GU^)]\_
MVO8_\_MO_P!_5_QH_M>Q_P"?VW_[^K_C7P-_P[(U_P#Z'G3?_ &3_P"*H_X=
MD:__ -#SIO\ X R?_%4?5,%_T$_^2L/;XC_GU^)]\_VO8_\ /[;_ /?U?\:/
M[7L?^?VW_P"_J_XU\#?\.R-?_P"AYTW_ , 9/_BJ/^'9&O\ _0\Z;_X R?\
MQ5'U3!?]!/\ Y*P]OB/^?7XGWS_:]C_S^V__ ']7_&C^U['_ )_;?_OZO^-?
M W_#LC7_ /H>=-_\ 9/_ (JC_AV1K_\ T/.F_P#@#)_\51]4P7_03_Y*P]OB
M/^?7XGWS_:]C_P _MO\ ]_5_QH_M>Q_Y_;?_ +^K_C7P-_P[(U__ *'G3?\
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M (JC_AV1K_\ T/.F_P#@#)_\51]4P7_03_Y*P]OB/^?7XGWS_:]C_P _MO\
M]_5_QH_M>Q_Y_;?_ +^K_C7P-_P[(U__ *'G3?\ P!D_^*H_X=D:_P#]#SIO
M_@#)_P#%4?5,%_T$_P#DK#V^(_Y]?B?:_P 1]5LF^'GBA5O+<DZ7=  2K_SQ
M;WKX[_X)C7D%JOQ)\^:.'=_9N/,<+G_CZ]:S/^'9&O\ _0\Z;_X R?\ Q506
MO_!,OQ0V[[1XSTB+^[Y5M*^?7.<8KMIQP5/#U*'M_BMK9]&<\Y8B56-3V>U^
MO<_0#^U['_G]M_\ OZO^-']KV/\ S^V__?U?\:^!O^'9&O\ _0\Z;_X R?\
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M_BJ/JF"_Z"?_ "5A[?$?\^OQ/OG^U['_ )_;?_OZO^-']KV/_/[;_P#?U?\
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MF?8/P"U2SC^!?P\1[N!67P]IX*M(H(/V=..M=[_:]C_S^V__ ']7_&O@6/\
MX)D^(3&I?QOIBOCY@MG(0#WP=PS^5+_P[(U__H>=-_\  &3_ .*K">&P4Y.7
MUC?^ZS2-;$1BE[+\3[Y_M>Q_Y_;?_OZO^-']KV/_ #^V_P#W]7_&O@;_ (=D
M:_\ ]#SIO_@#)_\ %4?\.R-?_P"AYTW_ , 9/_BJCZI@O^@G_P E97M\1_SZ
M_$^^?[7L?^?VW_[^K_C1_:]C_P _MO\ ]_5_QKX&_P"'9&O_ /0\Z;_X R?_
M !5'_#LC7_\ H>=-_P# &3_XJCZI@O\ H)_\E8>WQ'_/K\3[Y_M>Q_Y_;?\
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M3[Y_M>Q_Y_;?_OZO^-']KV/_ #^V_P#W]7_&O@;_ (=D:_\ ]#SIO_@#)_\
M%4?\.R-?_P"AYTW_ , 9/_BJ/JF"_P"@G_R5A[?$?\^OQ/OG^U['_G]M_P#O
MZO\ C1_:]C_S^V__ ']7_&O@;_AV1K__ $/.F_\ @#)_\51_P[(U_P#Z'G3?
M_ &3_P"*H^J8+_H)_P#)6'M\1_SZ_$^^?[7L?^?VW_[^K_C1_:]C_P _MO\
M]_5_QKX&_P"'9&O_ /0\Z;_X R?_ !5'_#LC7_\ H>=-_P# &3_XJCZI@O\
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M_)6'M\1_SZ_$^^?[7L?^?VW_ ._J_P"-']KV/_/[;_\ ?U?\:^!O^'9&O_\
M0\Z;_P" ,G_Q5'_#LC7_ /H>=-_\ 9/_ (JCZI@O^@G_ ,E8>WQ'_/K\3[Y_
MM>Q_Y_;?_OZO^-']KV/_ #^V_P#W]7_&O@;_ (=D:_\ ]#SIO_@#)_\ %4?\
M.R-?_P"AYTW_ , 9/_BJ/JF"_P"@G_R5A[?$?\^OQ/OG^U['_G]M_P#OZO\
MC1_:]C_S^V__ ']7_&O@;_AV1K__ $/.F_\ @#)_\51_P[(U_P#Z'G3?_ &3
M_P"*H^J8+_H)_P#)6'M\1_SZ_$^^?[7L?^?VW_[^K_C1_:]C_P _MO\ ]_5_
MQKX&_P"'9&O_ /0\Z;_X R?_ !5'_#LC7_\ H>=-_P# &3_XJCZI@O\ H)_\
ME8>WQ'_/K\3/\.W4(_X*22S&6,0_VI='S-PV_P#'E)WK]"?[7L?^?VW_ ._J
M_P"-?G__ ,.R_%'VK;_PF>D?9O\ GI]FEW]/[O3K[_X5/_P[(U__ *'G3?\
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ML/;XC_GU^)]\_P!KV/\ S^V__?U?\:/[7L?^?VW_ ._J_P"-? W_  [(U_\
MZ'G3?_ &3_XJC_AV1K__ $/.F_\ @#)_\51]4P7_ $$_^2L/;XC_ )]?B??/
M]KV/_/[;_P#?U?\ &C^U['_G]M_^_J_XU\#?\.R-?_Z'G3?_  !D_P#BJ/\
MAV1K_P#T/.F_^ ,G_P 51]4P7_03_P"2L/;XC_GU^)]\_P!KV/\ S^V__?U?
M\:/[7L?^?VW_ ._J_P"-? W_  [(U_\ Z'G3?_ &3_XJC_AV1K__ $/.F_\
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M?\:/[7L?^?VW_P"_J_XU\#?\.R-?_P"AYTW_ , 9/_BJ/^'9&O\ _0\Z;_X
MR?\ Q5<7U3!?]!/_ )*SH]OB/^?7XGWS_:]C_P _MO\ ]_5_QH_M>Q_Y_;?_
M +^K_C7P-_P[(U__ *'G3?\ P!D_^*H_X=D:_P#]#SIO_@#)_P#%4?5,%_T$
M_P#DK#V^(_Y]?B??/]KV/_/[;_\ ?U?\:/[7L?\ G]M_^_J_XU\#?\.R-?\
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M#SIO_@#)_P#%4?5,%_T$_P#DK#V^(_Y]?B??/]KV/_/[;_\ ?U?\:/[7L?\
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M?\:/[7L?^?VW_P"_J_XU\#?\.R-?_P"AYTW_ , 9/_BJ/^'9&O\ _0\Z;_X
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M@X8+"UE5]O>WDT<^(EB*U-P]E:_F?>.@:M8C0M-!O+<'[-'_ ,M5_NCWJ_\
MVO8_\_MO_P!_5_QKX&_X=D:__P!#SIO_ ( R?_%4?\.R-?\ ^AYTW_P!D_\
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ML/;XC_GU^)]\_P!KV/\ S^V__?U?\:/[7L?^?VW_ ._J_P"-? W_  [(U_\
MZ'G3?_ &3_XJC_AV1K__ $/.F_\ @#)_\51]4P7_ $$_^2L/;XC_ )]?B??/
M]KV/_/[;_P#?U?\ &C^U['_G]M_^_J_XU\#?\.R-?_Z'G3?_  !D_P#BJ/\
MAV1K_P#T/.F_^ ,G_P 51]4P7_03_P"2L/;XC_GU^)]\_P!KV/\ S^V__?U?
M\:/[7L?^?VW_ ._J_P"-? W_  [(U_\ Z'G3?_ &3_XJC_AV1K__ $/.F_\
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M_P#BJ/\ AV1K_P#T/.F_^ ,G_P 51]4P7_03_P"2L/;XC_GU^)]\_P!KV/\
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M1K__ $/.F_\ @#)_\51]4P7_ $$_^2L/;XC_ )]?B??/]KV/_/[;_P#?U?\
M&C^U['_G]M_^_J_XU\#?\.R-?_Z'G3?_  !D_P#BJ/\ AV1K_P#T/.F_^ ,G
M_P 51]4P7_03_P"2L/;XC_GU^)]\_P!KV/\ S^V__?U?\:/[7L?^?VW_ ._J
M_P"-? W_  [(U_\ Z'G3?_ &3_XJC_AV1K__ $/.F_\ @#)_\51]4P7_ $$_
M^2L/;XC_ )]?B??/]KV/_/[;_P#?U?\ &C^U['_G]M_^_J_XU\#?\.R-?_Z'
MG3?_  !D_P#BJ/\ AV1K_P#T/.F_^ ,G_P 51]4P7_03_P"2L/;XC_GU^)]\
M_P!KV/\ S^V__?U?\:/[7L?^?VW_ ._J_P"-? W_  [(U_\ Z'G3?_ &3_XJ
MC_AV1K__ $/.F_\ @#)_\51]4P7_ $$_^2L/;XC_ )]?B??/]KV/_/[;_P#?
MU?\ &C^U['_G]M_^_J_XU\#?\.R-?_Z'G3?_  !D_P#BJ/\ AV1K_P#T/.F_
M^ ,G_P 51]4P7_03_P"2L/;XC_GU^)]\_P!KV/\ S^V__?U?\:/[7L?^?VW_
M ._J_P"-? W_  [(U_\ Z'G3?_ &3_XJC_AV1K__ $/.F_\ @#)_\51]4P7_
M $$_^2L/;XC_ )]?B??/]KV/_/[;_P#?U?\ &C^U['_G]M_^_J_XU\#?\.R-
M?_Z'G3?_  !D_P#BJ/\ AV1K_P#T/.F_^ ,G_P 51]4P7_03_P"2L/;XC_GU
M^)]\_P!KV/\ S^V__?U?\:/[7L?^?VW_ ._J_P"-? W_  [(U_\ Z'G3?_ &
M3_XJC_AV1K__ $/.F_\ @#)_\51]4P7_ $$_^2L/;XC_ )]?B??/]KV/_/[;
M_P#?U?\ &C^U['_G]M_^_J_XU\#?\.R-?_Z'G3?_  !D_P#BJ/\ AV1K_P#T
M/.F_^ ,G_P 51]4P7_03_P"2L/;XC_GU^)]\_P!KV/\ S^V__?U?\:/[7L?^
M?VW_ ._J_P"-? W_  [(U_\ Z'G3?_ &3_XJC_AV1K__ $/.F_\ @#)_\51]
M4P7_ $$_^2L/;XC_ )]?B??/]KV/_/[;_P#?U?\ &C^U['_G]M_^_J_XU\#?
M\.R-?_Z'G3?_  !D_P#BJ/\ AV1K_P#T/.F_^ ,G_P 51]4P7_03_P"2L/;X
MC_GU^)]\_P!KV/\ S^V__?U?\:/[7L?^?VW_ ._J_P"-? W_  [(U_\ Z'G3
M?_ &3_XJC_AV1K__ $/.F_\ @#)_\51]4P7_ $$_^2L/;XC_ )]?B??/]KV/
M_/[;_P#?U?\ &C^U['_G]M_^_J_XU\#?\.R-?_Z'G3?_  !D_P#BJ/\ AV1K
M_P#T/.F_^ ,G_P 51]4P7_03_P"2L/;XC_GU^)]\_P!KV/\ S^V__?U?\:/[
M7L?^?VW_ ._J_P"-? W_  [(U_\ Z'G3?_ &3_XJC_AV1K__ $/.F_\ @#)_
M\51]4P7_ $$_^2L/;XC_ )]?B??/]KV/_/[;_P#?U?\ &C^U['_G]M_^_J_X
MU\#?\.R-?_Z'G3?_  !D_P#BJ/\ AV1K_P#T/.F_^ ,G_P 51]4P7_03_P"2
ML/;XC_GU^)]\_P!KV/\ S^V__?U?\:/[7L?^?VW_ ._J_P"-? W_  [(U_\
MZ'G3?_ &3_XJC_AV1K__ $/.F_\ @#)_\51]4P7_ $$_^2L/;XC_ )]?B??/
M]KV/_/[;_P#?U?\ &C^U['_G]M_^_J_XU\#?\.R-?_Z'G3?_  !D_P#BJ/\
MAV1K_P#T/.F_^ ,G_P 51]4P7_03_P"2L/;XC_GU^)]\_P!KV/\ S^V__?U?
M\:/[7L?^?VW_ ._J_P"-? W_  [(U_\ Z'G3?_ &3_XJC_AV1K__ $/.F_\
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M_P#BJ/\ AV1K_P#T/.F_^ ,G_P 51]4P7_03_P"2L/;XC_GU^)]\_P!KV/\
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M1K__ $/.F_\ @#)_\51]4P7_ $$_^2L/;XC_ )]?B??/]KV/_/[;_P#?U?\
M&C^U['_G]M_^_J_XU\#?\.R-?_Z'G3?_  !D_P#BJ/\ AV1K_P#T/.F_^ ,G
M_P 51]4P7_03_P"2L/;XC_GU^)]\_P!KV/\ S^V__?U?\:/[7L?^?VW_ ._J
M_P"-? W_  [(U_\ Z'G3?_ &3_XJC_AV1K__ $/.F_\ @#)_\51]4P7_ $$_
M^2L/;XC_ )]?B??/]KV/_/[;_P#?U?\ &C^U['_G]M_^_J_XU\#?\.R-?_Z'
MG3?_  !D_P#BJ/\ AV1K_P#T/.F_^ ,G_P 51]4P7_03_P"2L/;XC_GU^)]\
M_P!KV/\ S^V__?U?\:/[7L?^?VW_ ._J_P"-? W_  [(U_\ Z'G3?_ &3_XJ
MC_AV1K__ $/.F_\ @#)_\51]4P7_ $$_^2L/;XC_ )]?B??/]KV/_/[;_P#?
MU?\ &C^U['_G]M_^_J_XU\#?\.R-?_Z'G3?_  !D_P#BJ/\ AV1K_P#T/.F_
M^ ,G_P 51]4P7_03_P"2L/;XC_GU^)]\_P!KV/\ S^V__?U?\:/[7L?^?VW_
M ._J_P"-? W_  [(U_\ Z'G3?_ &3_XJC_AV1K__ $/.F_\ @#)_\51]4P7_
M $$_^2L/;XC_ )]?B??/]KV/_/[;_P#?U?\ &C^U['_G]M_^_J_XU\#?\.R-
M?_Z'G3?_  !D_P#BJ/\ AV1K_P#T/.F_^ ,G_P 51]4P7_03_P"2L/;XC_GU
M^)]\_P!KV/\ S^V__?U?\:^/_P#@I3?6]U\,_"BPSQ3,-7)(C<,1^Y?TKAO^
M'9&O_P#0\Z;_ . ,G_Q517/_  3*\3+&#;^-=)E?/(DM94&/J"?Y5U86E@L/
M6C5^L7M_=9C6GB*M-P]E:_F?7W[-/_)O_P /O^P+;?\ HL45M_"'P/-\-?AC
LX:\+W-U'>W&EV26\D\2E4=AR=H/.,GO^G2BOGZTE*K*4=FV>G334(I]C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>angn-20211231_g2.jpg
<TEXT>
begin 644 angn-20211231_g2.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" :Q!GT# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **P/'WC?2OAKX(U
M[Q7KDK0:1HME+?W3H 6\N-"S!1D98XP!GDD5\/\ _#ZOX(?]"M\0/_!=8_\
MR94\ROR]2N5VYNA]_P!%?,W[+W_!03X:?M9>+M3\->%++7])U>QL_MWDZ];0
M0^?$'"L8_*FDR5++D''WAC/./IFM'%I)OJ9J2;:70****DH**^0_C]_P4[^%
MO[.?Q4U?P!XET#Q??:QI:PM-/I5G:R6[>;$DJ[6>Y1C\K@'*CG/7K6/\*?\
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /SY_X+(?'#_A"?@=H_P]L9]FI>+KO?
M=*O465N5=OINE,0]PK5^+M?3?_!1KXW_ /"\OVJO%5Y:S^=HNA,-"T['W3'
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MN_K_ ,'?[UT/-I^X_9/IMZ?\#;[NY\^_\%&/^3*_BE_UX1?^E$5?ST5_0O\
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MU+8&1SCO4?BKP;K_ (#UB32?$NAZEX>U6-0SV.JVDEK.H/0E) & /TK]W/\
M@F+\$],^$_[*?A?5([.)->\5PC6=0O-G[R19"3 A/7:L6S Z99CW-8?_  5<
M^!^G?$[]E_5O$ZV<;>(O![+J-K=!1YGV<LJ7$6[KM*'?CUC6NG%?[.WUMO\
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M_FSXG_X*6?\ !1._^&NH7GPH^%VH_9?$:ILUS7[<_/8;AG[/ W:4@Y9Q]S(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUJ2P_9E\-6"-M6_\3P!P.ZI;W#8_/'Y"OQ7K]B_^"W /_"D_A\<<?\)"_/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOA?HLJ&2W&L1WTRXX*6X-PP/L1%C\:_HTKTW[M!+^9_EM^;^X\_XJWHOS?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%E.2:SP?^^3CTY?S4D_P2-L3KA$WT;_#E:_$_H'HHHIB"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX'-?A'\4O%>I_M*?M"Z_KFEZ=*^I>+]==K'3UP9,S2[88N.-P!0$^M>VV?\
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MD+-C. =H)_B'6OU[_9B_9K\,?LL_"ZT\&^&O,N3O-S?ZG<*!-?7+ !I6 Z#
M"JH^ZH R3DG6A%4>>HWJ[_BK?@OQ\KVRK2=51II:+_._WM_@>M4445F:!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM'_#7_@W_H&ZY_WXA_\ CM'MJ?\ ,']J8+_GZCW*BO#?^&O_  ;_ - W7/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >&_M?_P#)-=,_["\7_HF:OD&OK[]K_P#Y)KIG_87B_P#1,U?(
M->/BOXA^;9]_OK]$%%%%<A\Z%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'W)^S;_ ,D5\._]O/\ Z4RUZ97F
M?[-O_)%?#O\ V\_^E,M>F5[]/X(^A^O8'_=:7^&/Y(****T.T**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _*WQ/\
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MD3_@EG\8M.^)G[)WAS1H[R.36_">_2;ZUW?O(T#LT#D==K1E0#T)1AV-7O\
M@IS\8-+^%O[)?BS3[B[C36/%$/\ 8VGVA?$DWF$"9@.NU8MY)Z9*C^(5XE\2
MO^"67BSP9\1[WQK^SE\2V^'EQ>,6?2+F>>VBA#-N:-)X0Q:+(&(GC(&.IX 9
M\/\ _@EGXT\??$2Q\8?M'_$]O'SV+ADTFRN)[F.90VX1M-,J%(LYS&D8SDX8
M5-;_ &O?W>;XOUM;O^%_(NE_LNWO6^']+^GXV/9/^"5OPQNOAM^Q_P"'YKZ
MV]YXCNI]<:-A@^7)M2$G_>BBC8>S"OKVHK6UAL;6&VMH8[>VA18XH8E"HB@8
M"J!P  ,8J6M:L_:3<EMT]%HOP,J<.2*3W_5ZL****R-0HHHH **** "BBB@
MK^5>OZJ*_E7H _?[_@EQ_P F)_#+_N)_^G2[KZJKY5_X)<?\F)_#+_N)_P#I
MTNZ^JJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BOG#]H_XN>+/ 7CBQT_0M5^PVDFG1SO']FADRYEE4G+H3T5>.G%>
M5?\ #27Q&_Z&+_R1MO\ XW7++$PA)Q:9\_B,[P^'JRI3C*Z\E_F?<E%?#?\
MPTE\1O\ H8O_ "1MO_C='_#27Q&_Z&+_ ,D;;_XW4?6X=F<_^L6%_EE]R_S/
MN2BOAO\ X:2^(W_0Q?\ DC;?_&Z/^&DOB-_T,7_DC;?_ !NCZW#LP_UBPO\
M++[E_F?<E%?#?_#27Q&_Z&+_ ,D;;_XW1_PTE\1O^AB_\D;;_P"-T?6X=F'^
ML6%_EE]R_P S[DHKX;_X:2^(W_0Q?^2-M_\ &Z/^&DOB-_T,7_DC;?\ QNCZ
MW#LP_P!8L+_++[E_F?<E%?#?_#27Q&_Z&+_R1MO_ (W1_P -)?$;_H8O_)&V
M_P#C='UN'9A_K%A?Y9?<O\S[DHKX;_X:2^(W_0Q?^2-M_P#&Z/\ AI+XC?\
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MSH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ?<G[-O_)%?#O_ &\_^E,M>F5YG^S;_P D5\._]O/_ *4RUZ97
MOT_@CZ'Z]@?]UI?X8_D@HHHK0[0HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "OY5Z_JHK^5>@#]_O\ @EQ_R8G\,O\ N)_^G2[KZJKY5_X)
M<?\ )B?PR_[B?_ITNZ^JJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** /D']K_ /Y*5IG_ &"(O_1TU>&U[E^U_P#\E*TS
M_L$1?^CIJ\-KPZW\1GY1FG^^U?4****P/+"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#],****^C/VL****
M"BBB@ HHHH **** /#?VO_\ DFNF?]A>+_T3-7R#7U]^U_\ \DUTS_L+Q?\
MHF:OD&O'Q7\0_-L^_P!]?H@HHHKD/G0HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^Y/V;?\ DBOAW_MY_P#2
MF6O3*\S_ &;?^2*^'?\ MY_]*9:],KWZ?P1]#]>P/^ZTO\,?R04445H=H444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7\J]?U45_*O0!^_W
M_!+C_DQ/X9?]Q/\ ].EW7U57RK_P2X_Y,3^&7_<3_P#3I=U]54 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?(/[7_P#R
M4K3/^P1%_P"CIJ\-KW+]K_\ Y*5IG_8(B_\ 1TU>&UX=;^(S\HS3_?:OJ%%%
M%8'EA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!^F%%%%?1G[6%%%% !1110 4444 %%%% 'AO[7_ /R373/^
MPO%_Z)FKY!KZ^_:__P"2:Z9_V%XO_1,U?(->/BOXA^;9]_OK]$%%%%<A\Z%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% 'W)^S;_R17P[_ -O/_I3+7IE>9_LV_P#)%?#O_;S_ .E,M>F5[]/X
M(^A^O8'_ '6E_AC^2"BBBM#M"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *_E7K^JBOY5Z /W^_X)<?\F)_#+_N)_\ ITNZ^JJ^5?\ @EQ_
MR8G\,O\ N)_^G2[KZJH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/]FW_DBOAW_MY_\ 2F6O3*]^G\$?0_7L#_NM+_#'\D%%%%:':%%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /N3]FW_ )(KX=_[>?\ TIEKTRO,_P!FW_DBOAW_ +>?_2F6O3*]^G\$
M?0_7L#_NM+_#'\D%%%%:':%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5_*O7]5%?RKT ?O]_P2X_Y,3^&7_<3_ /3I=U]55\J_\$N/^3$_
MAE_W$_\ TZ7=?55 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-O\ R17P[_V\_P#I3+7IE>_3^"/H?KV!_P!UI?X8_D@HHHK0[0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "OY5Z_JHK^5>@#]_O^"7'_)B
M?PR_[B?_ *=+NOJJOE7_ ()<?\F)_#+_ +B?_ITNZ^JJ "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX<^&+NPN=[.BZ5#&X9\EG1T4,CDL3O4ALDG-93C*6BVM_6O3J:1<5JUK_7_
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M $Z7=?55?*O_  2X_P"3$_AE_P!Q/_TZ7=?55 !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% 'R#^U__P E*TS_ +!$7_HZ
M:O#:]R_:_P#^2E:9_P!@B+_T=-7AM>'6_B,_*,T_WVKZA1116!Y84444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M ?IA1117T9^UA1110 4444 %%%% !1110!X;^U__ ,DUTS_L+Q?^B9J^0:^O
MOVO_ /DFNF?]A>+_ -$S5\@UX^*_B'YMGW^^OT04445R'SH4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?<G[
M-O\ R17P[_V\_P#I3+7IE>9_LV_\D5\._P#;S_Z4RUZ97OT_@CZ'Z]@?]UI?
MX8_D@HHHK0[0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/@+?>98T"!C[G&3[FNDHHIRDYR<I;L48J,5%;(****DH**** "BBB@ HHHH
M*_E7K^JBOY5Z /W^_P""7'_)B?PR_P"XG_Z=+NOJJOE7_@EQ_P F)_#+_N)_
M^G2[KZJH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVS[_ 'U^B"BBBN0^="BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#[D_9M_P"2*^'?^WG_ -*9:],KS/\ 9M_Y
M(KX=_P"WG_TIEKTRO?I_!'T/U[ _[K2_PQ_)!1116AVA1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %?RKU_517\J] '[_?\$N/^3$_AE_W$
M_P#TZ7=?55?*O_!+C_DQ/X9?]Q/_ -.EW7U50 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!\@_M?_ /)2M,_[!$7_ *.F
MKPVO<OVO_P#DI6F?]@B+_P!'35X;7AUOXC/RC-/]]J^H4445@>6%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+NOJJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]R?LV_\
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M $Z7=?55?*O_  2X_P"3$_AE_P!Q/_TZ7=?55 !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% 'R#^U__P E*TS_ +!$7_HZ
M:O#:]R_:_P#^2E:9_P!@B+_T=-7AM>'6_B,_*,T_WVKZA1116!Y84444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M ?IA1117T9^UA1110 4444 %%%% !1110!X;^U__ ,DUTS_L+Q?^B9J^0:^O
MOVO_ /DFNF?]A>+_ -$S5\@UX^*_B'YMGW^^OT04445R'SH4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?<G[
M-O\ R17P[_V\_P#I3+7IE>9_LV_\D5\._P#;S_Z4RUZ97OT_@CZ'Z]@?]UI?
MX8_D@HHHK0[0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWG_TIEKTRO?I_!'T/U[ _P"ZTO\ #'\D%%%%:':%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5_*O7]5%?RKT ?O]_P2X_Y,3^&7_<3_P#3
MI=U]55\J_P#!+C_DQ/X9?]Q/_P!.EW7U50 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!\@_M?_P#)2M,_[!$7_HZ:O#:]
MR_:__P"2E:9_V"(O_1TU>&UX=;^(S\HS3_?:OJ%%%%8'EA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^F%%%
M%?1G[6%%%% !1110 4444 %%%% 'AO[7_P#R373/^PO%_P"B9J^0:^OOVO\
M_DFNF?\ 87B_]$S5\@UX^*_B'YMGW^^OT04445R'SH4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?<G[-O_)%
M?#O_ &\_^E,M>F5YG^S;_P D5\._]O/_ *4RUZ97OT_@CZ'Z]@?]UI?X8_D@
MHHHK0[0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OY5Z_J
MHK^5>@#]_O\ @EQ_R8G\,O\ N)_^G2[KZJKY5_X)<?\ )B?PR_[B?_ITNZ^J
MJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHHH **** "BBB@ HHHH ^Y/V;?\ DBOAW_MY_P#2F6O3*\S_ &;?^2*^'?\
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MD>Q&^WNP@X+^1*J2;1D?-MQR*4?>^'4<O=^+0]5HHHH **** "BBB@ HHHH
M**** "OY5Z_JHK^5>@#]_O\ @EQ_R8G\,O\ N)_^G2[KZJKY5_X)<?\ )B?P
MR_[B?_ITNZ^JJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ7\0_-L^_P!]?H@HHHKD/G0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% 'R#^U__ ,E*TS_L$1?^CIJ\-KW+]K__ )*5IG_8(B_]'35X
M;7AUOXC/RC-/]]J^H4445@>6%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'Z84445]&?M84444 %%%% !1110
M 4444 >&_M?_ /)-=,_["\7_ *)FKY!KZ^_:_P#^2:Z9_P!A>+_T3-7R#7CX
MK^(?FV??[Z_1!1117(?.A1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!]R?LV_\D5\._\ ;S_Z4RUZ97F?[-O_
M "17P[_V\_\ I3+7IE>_3^"/H?KV!_W6E_AC^2"BBBM#M"BBB@ HHHH ****
M "BBB@ HHHH **** "L+QIX\\-_#G0Y-9\5:_IOAS28R%:]U6[2WB#'HNYR
M2>PZFMVOB+_@K)\,?%GQ:^!?A'0/!OAW4?$NKR>*(7^RZ=;M*R)]FN 7<CA$
M!(RS$*,C)K.I*45[JUNE][L:4XJ3M)VT;^Y7,KXS?\%AO@_X"$]IX+LM3^(N
MIH,+);(;&QW X(,TJ[_Q6)@?6OA'XT?\%6OCI\5/M%IH^JVOP^T>3<HM_#L9
M6Y*GINN7+2!A_>C,?TKTOX)_\$8_B'XK^SWWQ(\0Z?X'L6PS:=8XO[\\\JQ4
MB),CHP>3']VOOWX)_P#!.CX%_ W[/=6'A&/Q+K4."-7\3$7TVX'(94($4; ]
M&2-3P.:T]FOMO^OR^\S]H_L+^OZ['XP_#+]EOXY?M3:PVKZ+X8USQ%]N;?-X
MDUF1H[>3D L;J<@2$=PI9N.AK[N^"?\ P10LK;[/??%?QN][(,,^C>%T\N/(
M.<-<RKN8$<$+&I]&[U^HRJL:A54*JC 4#  IU6FHZ17]?D19R^)GEWP=_9A^
M%GP#MU3P+X)TO0[@(4;4%B\Z]=3U#7$A:0CV+8]JZ[QS\.?"OQ.T=M)\7>'-
M+\3::QS]EU6SCN$!_O .#@^XY%='142]_P"+4N/N_#H?A-_P4V_8]\/?LM_$
M30-1\&++:^$_$\,SPZ=-*TILIX2@D178EBA$B,-Q)!W#.,5^CW_!++XI:I\4
M/V1="_MB>2[O?#]W/HBW$ARSPQ!6B!/^S'(J?1!5K]N;]AV]_;.NO!J#QM#X
M0L/#ZW1(.EF]DF>8Q<_ZZ/: (O4]:]._9/\ V;]/_95^#MEX$L-6DUTQ74]Y
M<:E);B SR2-G.P,VW"A5^\?NT\.^2E.$^NWWZ?A="Q"4ITY0^?W/_@7\SV.B
MBBD,Y^?XA^%;7Q1;>&9O$VCQ>([DL(-'DOXEO)<(7.V$MO;"@L<#H,]*W^O!
MY%?E[_P4<^ WCSX2?'[0_P!ISX:6$NHBQ,$^L1V\32&UE@4)YLB+R8)(0$<C
M[NTY(W9KT7P[_P %G?@U>>$H[[6=#\4Z9KJQ+YVDV]I%.&DP,B*7S%5ESW?8
M>.E3"2G3N_B3::_)_,J<7&:2V:5G^:^1\X_\%0/A_IO[,?[37P[^)OP]A3PY
MJVK%]2F@L1Y4?VNWECW2A5X'F+( X'#88D98Y]]_X+,:5-KW[,/@S7(XFV6G
MB"!Y?]A9;:8<_P# @H_&O"_!_A?Q[_P5/_:BTOQ]KF@3^'/@_P"'9$CC\_)C
M:"-]YMHW( EFE;[Y7A%//10WZ6_M0? VU_:*^!/BKP#-)':SZC; V5Q(/E@N
MHV#PN<<[0ZJ#C^$FHG"4<%&#6O,Y6ZVNFOO2T7EV+C*,L6Y)Z<O*WYVM^#W[
MW(?V1==B\2?LN?"C4(65UD\,V",4Z!T@1''X,I'X5RO_  4&UR#P_P#L9_%6
MXN& 6;23:+D]7FD2)1^;BOA7]D?]NJ\_8AL+[X(_'3POK6GQZ+<R'3[RT@62
M2W1W+,C(S+OA+%G21"V0V ",$4_VI_VM]=_X**:UH?P4^"/AK5&T.XO$N=1O
M]0B$;3;&PKR!"PAMHR=Y9CN8[1@$ -MC/]KE+V6OM/R>_I;4RPO^SI>UTY/T
MV^_\#Z>_X(^:%/I/[($5W,,)J>NWMU%_N+Y<6?\ OJ)J^WJX3X%?"?3_ (&?
M"'PIX$TU_.MM$L4MFGV[?.E^]+*1V+NS-_P*N[K>O)2J.VJ5E]RM^AA1BXPU
MW=W][O\ J%%%%<YN%%%% !1110 4444 %?RKU_517\J] '[_ '_!+C_DQ/X9
M?]Q/_P!.EW7U57RK_P $N/\ DQ/X9?\ <3_].EW7U50 4444 %%%% !1110
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /TPHHHKZ,_:PHHHH
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MZ;X#_9ZLM)^+7PL\-MXQ74+J24ZMI]E?S^4S QYE <$8Z#=Q7T5_PS3\(?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK6.N:5<#=#?:=<I<02#U5T)!_ U;BUJ9J2>A^4__  X[U_\ Z*UIO_@DD_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?(/[7__ "4K3/\ L$1?^CIJ\-KW+]K_ /Y*5IG_
M &"(O_1TU>&UX=;^(S\HS3_?:OJ%%%%8'EA1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^F%%%%?1G[6%%%%
M!1110 4444 %%%% 'AO[7_\ R373/^PO%_Z)FKY!KZ^_:_\ ^2:Z9_V%XO\
MT3-7R#7CXK^(?FV??[Z_1!1117(?.A1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!]R?LV_P#)%?#O_;S_ .E,
MM>F5YG^S;_R17P[_ -O/_I3+7IE>_3^"/H?KV!_W6E_AC^2"BBBM#M"BBB@
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M /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM 'JM?RKU_2G_PUC\$/^BR?#_\
M\*BQ_P#CM?S64 ?O]_P2X_Y,3^&7_<3_ /3I=U]55\J_\$N/^3$_AE_W$_\
MTZ7=?55 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\@_M?_\ )2M,
M_P"P1%_Z.FKPVO<OVO\ _DI6F?\ 8(B_]'35X;7AUOXC/RC-/]]J^H4445@>
M6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'Z84445]&?M84444 %%%% !1110 4444 >&_M?_P#)-=,_["\7
M_HF:OD&OK[]K_P#Y)KIG_87B_P#1,U?(->/BOXA^;9]_OK]$%%%%<A\Z%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGDDUJJ;=-U.S2^^_^1FYVFH=TW]UO\SOZ***R- HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K^5>OZJ*_E7H _?[_ ()<?\F)_#+_ +B?
M_ITNZ^JJ^5?^"7'_ "8G\,O^XG_Z=+NOJJ@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M /)-=,_["\7_ *)FKY!KQ\5_$/S;/O\ ?7Z(****Y#YT**** "BBB@ HHHH
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M6/\ PVU\ _\ HKWA'_P:Q?XUT5(J+LGT7XJYSTY.2NU;5_@['MM%>)?\-M?
M/_HKWA'_ ,&L7^-,F_;?^ 4$+R-\7?"9506(34HV;\ #DGV%9FAU7Q&_:.^%
MOPBO'LO&7Q \.^'=12,3'3[W4(UNMASAA#GS"#@X(7G'%=AX3\5:3XY\,Z5X
MAT*]34=%U2VCO+.[C!"RQ.H96 (!&01P0".]?AC_ ,%0OV@O O[0GQXTK4O
M5V-6T[2=(33I]66%HTN91+(Y"!@&*J'QN(P23CC!/ZJ_\$Z5O5_8L^%HOM_F
M_P!GR%-_7ROM$OE_ALVX]L4Z*=2C*I+1IV^7O?Y(55JG5C3CK=7_ "_SL?1]
M%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_*O7]5
M%?RKT ?O]_P2X_Y,3^&7_<3_ /3I=U]55\J_\$N/^3$_AE_W$_\ TZ7=?55
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3+7IE>_3^"/H?KV!_P!UI?X8_D@HHHK0[0HHHH **** "BBB@ HHHH ****
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M;I<R:I:P$NAPPV22*W!]J[G_ (=4_M+?]"+:_P#@]L?_ (]7ZY?#?PK\+/V
M/@K;^'M1\;+I7AJ&ZGN8KSQ/>0K/-(YW,B!$3S",<*BEOK7JOPP^*'AGXR^!
M].\7^#]3&L>'=1\S[+>"&2+S-DC1M\DBJPPR,.0.E=$N5ZPV5K^MO^'L<\>9
M+W^M[??_ )'X<?\ #JG]I;_H1;7_ ,'MC_\ 'J/^'5/[2W_0BVO_ (/+'_X]
M7[XU\X:__P %!O@GX-^+VM_#?Q/XEF\,Z_I5REI)-J5HZV<CLBOE9TW*J@.
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MNZ^JJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /D']K_ /Y*5IG_ &"(O_1TU>&U[E^U_P#\E*TS_L$1?^CIJ\-KPZW\
M1GY1FG^^U?4****P/+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#],****^C/VL**** "BBB@ HHHH ****
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M1P0J6P,D+EN22W/[=?L$? WQC^SK^SKIG@GQM+ITFJVMY<7$2Z;.TR10RL)
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MOK[]K_\ Y)KIG_87B_\ 1,U?(->/BOXA^;9]_OK]$%%%%<A\Z%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'W
M)^S;_P D5\._]O/_ *4RUZ97F?[-O_)%?#O_ &\_^E,M>F5[]/X(^A^O8'_=
M:7^&/Y(****T.T**** "BBB@ HHHH **** "BBB@ HHHH *_.;_@M5\-KG7_
M (,^#/&=M 95\/:I):W3*/\ 5PW** Q]O,BC7ZN*_1FN9^)?P[T3XM> ==\'
M^([47FBZQ:O:W,70[2.&4]F4X8'L0#6%:+E'W=U9_=T^>QM1DHRUV=U]ZL?
MW_!'O]IC1-<^%\GP=U2\BL_$FBSS76EPRN%^VVDK&5Q'D\O&[2$J/X64C.&Q
M^C]?SQ?M._L?_$K]C?QR+J>.^FT"*Z$FC^,-,#I&Q!S'N=3F"88^Z2#D$J6
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#Y!_:_P#^2E:9_P!@B+_T=-7AM>Y?M?\ _)2M,_[!$7_H
MZ:O#:\.M_$9^49I_OM7U"BBBL#RPHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH _3"BBBOHS]K"BBB@ HHHH *
M*** "BBB@#PW]K__ ))KIG_87B_]$S5\@U]??M?_ /)-=,_["\7_ *)FKY!K
MQ\5_$/S;/O\ ?7Z(****Y#YT**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** /N3]FW_ )(KX=_[>?\ TIEKTRO,
M_P!FW_DBOAW_ +>?_2F6O3*]^G\$?0_7L#_NM+_#'\D%%%%:':%%%% !1110
M 4444 %%%% !1110 4444 %%%% $%]8VVJ6<UI>V\5W:3(8Y8)T#QR*>"K*>
M"#Z&OG'QQ_P3B_9T\?7SWE[\,]/TZZ88W:)//IR#_ME ZQY_X#7TK4<]Q%:P
MR332+##&I9Y)&"JH'4DGH*EI;L=WLCXWMO\ @DC^SI!>O.^@ZU<1,21;2:S,
M(UYZ J0W'3EJ]?\ A7^Q3\$/@O?17WA/X<Z1::E$_F1:A>J]]<Q-_>CEN&=D
M/^Z17FOQS_X*@? [X,>?9VFNMX\UR/@6'AC;<1*W.-]R2(@,C!VLS#^[7YT_
M';_@K5\9?BI]IL?"TEM\-=#DRHCT@^;?,A&,-=.,@^C1+&10JC^Q_7S&Z:^V
M?L5\7_VA/AS\!=)_M#Q[XOTWP[&REXK>XEWW,X!P?*@0&23K_"IQWKK?"?B:
MQ\:^%M'\0Z6[R:;JMG%?6KR(49HI$#H2#T.&'%?S+Z+X=\;?&KQ=-%I>GZYX
MW\37C&:;[/%-?7<IR 7<C<Q[98_B:_I&^!>A7_A?X*> =&U2V:SU/3] L;6Z
MMW(+12I;HKJ<'&001QZ5O&'[ISEO=6_&_KLC&4_WBA':SO\ A;]3N****R-
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MQO<3;6$62<QI&O7@CO\ H_11%N-GNUM?6PY>]?I?>VA#9V<&GVD%K:PQV]M
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M6O3*]^G\$?0_7L#_ +K2_P ,?R04445H=H4444 %%%% !1110 4444 %%%%
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MM_Y(KX=_[>?_ $IEKTRO,_V;?^2*^'?^WG_TIEKTRO?I_!'T/U[ _P"ZTO\
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M2@];,<>:G).2.;_X)O\ _)]'PX_Z_+S_ -))Z_H'K^=;]A7XA>'_ (:_M<>
M?%/BG4X=%T*UNYS<WLX8QP^9;RHI; ) W.HSC SDX&37]!_A+QIX?\?:+%J_
MAG7-.\0Z5+]R]TNZ2YA;U ="1GVKKE_!AY7,Y23Q$VNO_!-JBBBN<L**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OY5Z_JHK^5>@
M#]_O^"7'_)B?PR_[B?\ Z=+NOJJOE7_@EQ_R8G\,O^XG_P"G2[KZJH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^0?VO
M_P#DI6F?]@B+_P!'35X;7N7[7_\ R4K3/^P1%_Z.FKPVO#K?Q&?E&:?[[5]0
MHHHK \L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /TPHHHKZ,_:PHHHH **** "BBB@ HHHH \-_:_\ ^2:Z
M9_V%XO\ T3-7R#7U]^U__P DUTS_ +"\7_HF:OD&O'Q7\0_-L^_WU^B"BBBN
M0^="BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#[D_9M_Y(KX=_P"WG_TIEKTRO,_V;?\ DBOAW_MY_P#2F6O3
M*]^G\$?0_7L#_NM+_#'\D%%%%:':%%%% !1110 4444 %%%% !1110 4444
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MXG_Z=+NOJJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#Y!_:_P#^2E:9_P!@B+_T=-7AM>Y?M?\ _)2M,_[!$7_HZ:O#
M:\.M_$9^49I_OM7U"BBBL#RPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH _3"BBBOHS]K"BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#Y!_:_P#^2E:9_P!@B+_T=-7AM>Y?M?\ _)2M,_[!$7_HZ:O#:\.M_$9^
M49I_OM7U"BBBL#RPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH _3"BBBOHS]K"BBB@ HHHH **** "BBB@#PW
M]K__ ))KIG_87B_]$S5\@U]??M?_ /)-=,_["\7_ *)FKY!KQ\5_$/S;/O\
M?7Z(****Y#YT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4F^9/HW_ ,#[UK\PHHHKG-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "OY5Z_JHK^5>@#]_O\ @EQ_R8G\,O\ N)_^G2[K
MZJKY5_X)<?\ )B?PR_[B?_ITNZ^JJ "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** /D']K_ /Y*5IG_ &"(O_1TU>&U[E^U
M_P#\E*TS_L$1?^CIJ\-KPZW\1GY1FG^^U?4****P/+"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#],****^C
M/VL**** "BBB@ HHHH **** /#?VO_\ DFNF?]A>+_T3-7R#7U]^U_\ \DUT
MS_L+Q?\ HF:OD&O'Q7\0_-L^_P!]?H@HHHKD/G0HHHH **** "BBB@ HHHH
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M%>\>"?\ @IO^T;X(M;>TC^($FM6D*;%CUNQM[MSQC+3,GFL?<N:_6;_AV?\
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M)FKY!KZ^_:__ .2:Z9_V%XO_ $3-7R#7CXK^(?FV??[Z_1!1117(?.A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!]R?LV_\ )%?#O_;S_P"E,M>F5YG^S;_R17P[_P!O/_I3+7IE>_3^"/H?
MKV!_W6E_AC^2"BBBM#M"BBB@ HHHH **** "BBB@ HHHH **** "DI:^./\
M@JA\?-0^"?[,\]CH=U)9:[XLNAH\5S"VV2& HSW#J>H)1=F1R/,R.1652?LX
M\W]7>B-*<.>5OZTU+?QH_P""I7P+^#.OW&A_VEJ?C+5;60PW,7ABV2>*!QU!
MFDDCC;'0[&;!!!P17E%Q_P %L_A2LK"'P-XQDC[-(EHI/X"8_P Z_/#]D;]B
M/QQ^U]K%^- FM=$\.Z8RI?ZYJ 8QQNW(CC1>9),?-MR !C+#*Y]C_:X_X)<W
MW[+OP9N?B!!\0%\6QV=W!!=V(T7['Y4<K;!('^T29PY08VC[V<\8-R3I13J/
M>WX[:$QM4DU!;?H?5'_#[3X7?]"'XN_\E?\ X[1_P^T^%_\ T(?B[_R5_P#C
MM?'O[%O_  3MLOVQ/ASJWB2V^)O_  C&H:9J#6-QI;:%]KP-BNDGF?:4X8,1
M]W@J>M=9\:O^".?Q2^'FAW.K>#M<T[XAP6R;Y+&WA:SOV Z^7$S,CX'.!)N/
M0*3Q55/W?Q_U?4B'[SX?ZMH>M>.O^"X :PFA\&_"TI>LA\J\US5,QQMV+0Q(
M"XZ=)%K](_@[XIO?''PE\%^(]2\O^T=7T:SO[GR5VIYDL*.VT9.!EC@9K\,?
MV"_@3\)?CG\7KCP'\5;SQ%HFOLQ.EVMG<16T-W)'DRVLV^)G63 )&"N<,."!
MG]Z_#'AO3_!WAO2M!TF VVEZ7:Q65K"79RD4:!$7<Q).% Y))K?EC&E=ZN5F
MGY:W_3[O0RYI2J66B5[^NEOU-.BBBL#8**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *_E7K^JBOY5Z /W^_P""7'_)B?PR_P"XG_Z=+NOJ
MJOE7_@EQ_P F)_#+_N)_^G2[KZJH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#Y!_:_P#^2E:9_P!@B+_T=-7AM>Y?M?\ _)2M,_[!$7_HZ:O#:\.M_$9^
M49I_OM7U"BBBL#RPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH _3"BBBOHS]K"BBB@ HHHH **** "BBB@#PW
M]K__ ))KIG_87B_]$S5\@U]??M?_ /)-=,_["\7_ *)FKY!KQ\5_$/S;/O\
M?7Z(****Y#YT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#!.?EZ8(S[710!\J_P##T;]F+_HIG_E U3_Y&H_X>C?LQ?\ 13/_ "@:I_\
M(U?55% 'S%H?_!2S]F[Q)K6GZ1IWQ&^T:A?W$=K;0_V'J2^9*[!47+6P R2!
MDD"OY]*_JHK^5>@#]_O^"7'_ "8G\,O^XG_Z=+NOJJOE7_@EQ_R8G\,O^XG_
M .G2[KZJH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ^0?VO_ /DI6F?]@B+_ -'35X;7N7[7_P#R4K3/^P1%_P"CIJ\-
MKPZW\1GY1FG^^U?4****P/+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#],****^C/VL**** "BBB@ HHHH
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M ,%MW_\ )5?L'\(?%EYX\^%/@WQ+J*0QW^L:-9ZA<);J5C626%'8*"20N6.
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MGVS2M/47AC.5-U(3).0>X\QWQ[5ZK115U)NI-S>[)A%4XJ*Z!1116984444
M%%%% !1110 5_*O7]5%?RKT ?O\ ?\$N/^3$_AE_W$__ $Z7=?55?*O_  2X
M_P"3$_AE_P!Q/_TZ7=?55 !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"G2[KZJKY5_P""7'_)B?PR_P"XG_Z=+NOJJ@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y!_:__P"2E:9_V"(O_1TU
M>&U[E^U__P E*TS_ +!$7_HZ:O#:\.M_$9^49I_OM7U"BBBL#RPHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ?P1]#]>P/\ NM+_  Q_)!1116AVA1110 4444 %%%% !1110 4444 %%%%
M!6'XX\%Z/\1O!^L>&/$%FNH:+JUK)9W=L_1XW&#@]CW!'((!%;E%3**DG&6S
M'&3BTUNC^?/]KW]B'QY^R+XRFOX8+W5/!!N/,TKQ1:*<1?-E$G*_ZF8'')P&
M(RIZ@;'PQ_X*D?M!_#.QAL7\46WBVQA0)'%XFM!<N /692DSGW9S7[WW-M#>
M6\EO<1)/!*I1XI%#*ZG@@@\$5\[>.O\ @G;^SM\0KYKS4?ACIEE=$8W:++-I
MJ_7R[=T0GW*TH<\%RWNARY)/FM9GYO3_ /!:3XY30>6GA[P)"V,>;'IMX6Z=
M>;LC]*^??C9^VY\:?VA[633/%?C*ZDT69L'1=+C6TM7!((5TC ,HR!CS"V#7
MZY0_\$H?V;8Y%9O!]_,HZH^MWF#]<2 _K7K_ ,*?V0?@U\$;B&Z\&_#S1M+U
M"$EHM1FB:[O(R>#MGF+R+^#5?+&7Q$\TH_"?G;_P3?\ ^"<>N7WBK2OBI\5-
M'FTC2=.D6ZT70+Z,I/=SJ<I/-&>4C4_,JM@L0"1M'S_KE116LY\R45HE_7WF
M<8<K;>["BBBLC0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *_E7K^JBOY5Z /W^_X)<?\F)_#+_N)_P#ITNZ^JJ^5?^"7'_)B?PR_[B?_
M *=+NOJJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_AE_W$__ $Z7=?55 !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% 'R#^U__ ,E*TS_L$1?^CIJ\-KW+]K__ )*5IG_8(B_]
M'35X;7AUOXC/RC-/]]J^H4445@>6%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'Z84445]&?M84444 %%%% !
M1110 4444 >&_M?_ /)-=,_["\7_ *)FKY!KZ^_:_P#^2:Z9_P!A>+_T3-7R
M#7CXK^(?FV??[Z_1!1117(?.A1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!]R?LV_\D5\._\ ;S_Z4RUZ97F?
M[-O_ "17P[_V\_\ I3+7IE>_3^"/H?KV!_W6E_AC^2"BBBM#M"BBB@ HHHH
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]R?LV_\
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M/^AI^('_ (,;'_Y#H_X<J?!#_H:?B!_X,;'_ .0Z^_Z*YS8^ /\ ARI\$/\
MH:?B!_X,;'_Y#K[D\$>$[/P#X-T+PSI\D\UAHUC!I]O)<L&E:.*-44N5 !8A
M1G  SV%;=%5S/E<>G]?YD\JOS=0HHHJ2@HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ K^5>OZJ*_E7H _?[_@EQ_R8G\,O^XG_ .G2[KZJ
MKY5_X)<?\F)_#+_N)_\ ITNZ^JJ "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /D']K_\ Y*5IG_8(B_\ 1TU>&U[E^U__
M ,E*TS_L$1?^CIJ\-KPZW\1GY1FG^^U?4****P/+"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#],****^C/V
ML**** "BBB@ HHHH **** /#?VO_ /DFNF?]A>+_ -$S5\@U]??M?_\ )-=,
M_P"PO%_Z)FKY!KQ\5_$/S;/O]]?H@HHHKD/G0HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^Y/V;?^2*^'?\
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M 4444 %%%% !1110 4444 %%%% 'Z84445]&?M84444 %%%% !1110 4444
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MB?\ Z=+NOJJOE7_@EQ_R8G\,O^XG_P"G2[KZJH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^0?VO_P#DI6F?]@B+_P!'
M35X;7N7[7_\ R4K3/^P1%_Z.FKPVO#K?Q&?E&:?[[5]0HHHK \L**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB?PR_P"XG_Z=+NOJJ@ HHHH **** "BBB@ HHHH **** "BO,_\ AI+X<_\
M0Q?^2-S_ /&Z/^&DOAS_ -#%_P"2-S_\;K/VD/YD<7U["_\ /V/_ ($O\STR
MBO,_^&DOAS_T,7_DC<__ !NC_AI+X<_]#%_Y(W/_ ,;H]I#^9!]>PO\ S]C_
M .!+_,],HKS/_AI+X<_]#%_Y(W/_ ,;H_P"&DOAS_P!#%_Y(W/\ \;H]I#^9
M!]>PO_/V/_@2_P STRBO,_\ AI+X<_\ 0Q?^2-S_ /&Z/^&DOAS_ -#%_P"2
M-S_\;H]I#^9!]>PO_/V/_@2_S/3**\S_ .&DOAS_ -#%_P"2-S_\;H_X:2^'
M/_0Q?^2-S_\ &Z/:0_F0?7L+_P _8_\ @2_S/3**\S_X:2^'/_0Q?^2-S_\
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MZ/:0_F0?7L+_ ,_8_P#@2_S/3**\S_X:2^'/_0Q?^2-S_P#&Z/\ AI+X<_\
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MZ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/Q)IR3)I^L6,.H6ZW"A9!'*@=0P!(!PPR 3]:_*W_AQWK_\ T5K3?_!))_\
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M_$B>IE?^^TO4^OJ***]P_5PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@#\SZ***^</Q0**** "BBB@ HHHH **** "BBB@ HHHH ****
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M?\-0?&7_ **UXZ_\*2]_^.T?\-0?&7_HK7CK_P *2]_^.U_2G_9]K_S[0_\
M?L?X4?V?:_\ /M#_ -^Q_A3 _FL_X:@^,O\ T5KQU_X4E[_\=K^AS]GW4+K5
M_@/\.;Z^N9KV]N?#NGS3W-Q(9))9&MHRSLQ.68DDDGDDUV_]GVO_ #[0_P#?
ML?X5.JA5"J %'  [5JIVIN%MVG]U_P#,S<;S4[[)_C;_ "%HHHK(T"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OY5Z_JHK^5>@#]_O\
M@EQ_R8G\,O\ N)_^G2[KZJKY5_X)<?\ )B?PR_[B?_ITNZ^JJ "BBB@ HHHH
M **** "BBB@ HHHH _,^BBBOG#\4"BBB@ HHHH **** "BBB@ HHHH ****
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M/T(IOV\K07?\.GZ>IY1_P^K^-_\ T*WP_P#_  77W_R91_P^K^-__0K?#_\
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M_P"CH:WH_P 2)ZF5_P"^TO4^OJ***]P_5PHHHH **** "BBB@ HHHH ****
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M_P##SC]IG_HI\W_@GT__ .1Z/^'G'[3/_13YO_!/I_\ \CU^S/\ PQ+\ _\
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MS\HS3_?:OJ%%%%8'EA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!^F%%%%?1G[6%%%% !1110 4444 %%%% '
MAO[7_P#R373/^PO%_P"B9J^0:^OOVO\ _DFNF?\ 87B_]$S5\@UX^*_B'YMG
MW^^OT04445R'SH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 ?<G[-O_)%?#O_ &\_^E,M>F5YG^S;_P D5\._
M]O/_ *4RUZ97OT_@CZ'Z]@?]UI?X8_D@HHHK0[0HHHH **** "BBB@ HHHH
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M;VJ8+MC!>1SEI'..68DGN:ZVNA2C35J?W_Y=C!Q=1WJ?UZ]PHHHK(T"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^5>OZJ*_E7H
M _?[_@EQ_P F)_#+_N)_^G2[KZJKY5_X)<?\F)_#+_N)_P#ITNZ^JJ "BBB@
M HHHH **** "BBB@ HHHH _,^BBBOG#\4"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KW+]D#_DI6I_]@B7_
M -'0UX;7N7[('_)2M3_[!$O_ *.AK>C_ !(GJ97_ +[2]3Z^HHHKW#]7"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOM'\J[,RDXUJB6[E;[Y?Y'-E\5*G3OTC?[HW/+O@O^R%\6/^"BVCS?%+XO\
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MM>GAF_N17,BH/P3:/PKZJK2M%0J.,=NGIT_ SI2<H)RWZ^O4****Q-0HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /D']K_ /Y*5IG_ &"(O_1TU>&U[E^U_P#\E*TS_L$1?^CIJ\-K
MPZW\1GY1FG^^U?4****P/+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#],****^C/VL**** "BBB@ HHHH *
M*** /#?VO_\ DFNF?]A>+_T3-7R#7U]^U_\ \DUTS_L+Q?\ HF:OD&O'Q7\0
M_-L^_P!]?H@HHHKD/G0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH ^Y/V;?\ DBOAW_MY_P#2F6O3*\S_ &;?
M^2*^'?\ MY_]*9:],KWZ?P1]#]>P/^ZTO\,?R04445H=H4444 %%%% !1110
M 4444 %%%% !6;KGAO2/%%JEMK.E66K6Z/YBPWUNDR*V"-P# @'!//O6E10!
MR/\ PJ'P)_T)7AW_ ,%4'_Q%'_"H? G_ $)7AW_P50?_ !%==10!R/\ PJ'P
M)_T)7AW_ ,%4'_Q%'_"H? G_ $)7AW_P50?_ !%==10!R/\ PJ'P)_T)7AW_
M ,%4'_Q%'_"H? G_ $)7AW_P50?_ !%==10!R/\ PJ'P)_T)7AW_ ,%4'_Q%
M=3:VL-C:Q6UM#';V\*"..&)0J(H& H X  ["I:* "BBB@ HHHH *_.[_ (+9
M?\F]^!_^QH7_ -)+BOT1K\[O^"V7_)O?@?\ [&A?_22XKGK_  +UC_Z4C:C\
M3]'^3/LK]FW_ )-W^&'_ &+&F_\ I+'7P-_P7$TV63PO\)=0 _<PWFHP-Q_$
MZ0,/TC:OOG]FW_DW?X8?]BQIO_I+'7A__!3[X$ZA\</V7=2_L2TDOM=\-72:
MW:VT*[I)D1629% Y)\MV8 <DH!WKIS/2M.7:=_ES:_A<QRY_NX+O&WWQL?2G
MPWO8M2^'?A>[A.Z&XTJUE0Y!RK0J1T]C7SW_ ,%/KJ*U_8?^(XD8+YJV,:9[
ML;Z @?I7!_\ !.O]MKP'X\^!'AKP?XD\3Z;X>\:>&K2/2Y;35KM+<WD,2[8I
MH6<@2?NU4,!R"IR,$$^-?\%1OVJ-!^,.C:#\#/A=?Q>--<U758)-0?19!<Q;
ME)$-JKKE7=I&5CM/R[ #R3@QT7.JXPUYI*WFF_\ +_(,#+V48SGIR+7U2_S/
MHC_@D_:RV_[$_A)I$*K->ZA(A/=?M4@S^:G\J^P*\U_9M^% ^!WP)\$>!B4>
MXT;38H;EX_NO<$;YF'L9&<CV->E5O7:=1J.RT7HM#"BG[--]=?OU"BBBN<W"
MBBB@ KBO&WP1^'7Q*U6+4_%W@#POXJU*&$6T=YK>C6UY,D09F$8>1&(4,[G;
MG&6)[FNUHH \J_X9.^"'_1&_A_\ ^$O8_P#QJC_AD[X(?]$;^'__ (2]C_\
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M4S/^WL%W?W'U]17R#_PU_P",O^@;H?\ WXF_^.T?\-?^,O\ H&Z'_P!^)O\
MX[1]:IA_;V"[O[CZ^HKY!_X:_P#&7_0-T/\ [\3?_':/^&O_ !E_T#=#_P"_
M$W_QVCZU3#^WL%W?W'U]17R#_P -?^,O^@;H?_?B;_X[1_PU_P",O^@;H?\
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M6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'Z84445]&?M84444 %%%% !1110 4444 >&_M?_P#)-=,_["\7
M_HF:OD&OK[]K_P#Y)KIG_87B_P#1,U?(->/BOXA^;9]_OK]$%%%%<A\Z%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_1T->&U[E^R!_P E*U/_ +!$O_HZ&MZ/\2)ZF5_[[2]3Z^HHHKW#]7"BBB@
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M** "BBB@ HHHH **** "O<OV0/\ DI6I_P#8(E_]'0UX;7N7[('_ "4K4_\
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M *.FKPVO<OVO_P#DI6F?]@B+_P!'35X;7AUOXC/RC-/]]J^H4445@>6%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'Z84445]&?M84444 %%%% !1110 4444 >&_M?\ _)-=,_["\7_HF:OD
M&OK[]K__ ))KIG_87B_]$S5\@UX^*_B'YMGW^^OT04445R'SH4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?<
MG[-O_)%?#O\ V\_^E,M>F5YG^S;_ ,D5\._]O/\ Z4RUZ97OT_@CZ'Z]@?\
M=:7^&/Y(****T.T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ K^5>OZJ*_E7H _?[_@EQ_R8G\,O^XG_P"G2[KZJKY5_P""7'_)B?PR_P"X
MG_Z=+NOJJ@ HHHH **** "BBB@ HHHH **** /S/HHHKYP_% HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]
MR_9 _P"2E:G_ -@B7_T=#7AM>Y?L@?\ )2M3_P"P1+_Z.AK>C_$B>IE?^^TO
M4^OJ***]P_5PHHHH **** "BBB@ HHHH ^&_VDO^2U>(O^W;_P!)HJ\SKTS]
MI+_DM7B+_MV_])HJ\SKP:GQR]3\BQW^]5?\ %+\V%%%%9'"%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=-\,/^2E
M>$O^PO:?^CDKF:Z;X8?\E*\)?]A>T_\ 1R5<?B1O0_BP]5^9^A5%%%?0'[(%
M%%% !1110 4444 %%%% 'R#^U_\ \E*TS_L$1?\ HZ:O#:]R_:__ .2E:9_V
M"(O_ $=-7AM>'6_B,_*,T_WVKZA1116!Y84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?IA1117T9^UA1110
M4444 %%%% !1110!X;^U_P#\DUTS_L+Q?^B9J^0:^OOVO_\ DFNF?]A>+_T3
M-7R#7CXK^(?FV??[Z_1!1117(?.A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110!]R?LV_\D5\._P#;S_Z4RUZ9
M7F?[-O\ R17P[_V\_P#I3+7IE>_3^"/H?KV!_P!UI?X8_D@HHHK0[0HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OY5Z_JHK^5>@#]_O^"7
M'_)B?PR_[B?_ *=+NOJJOE7_ ()<?\F)_#+_ +B?_ITNZ^JJ "BBB@ HHHH
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M_?:OJ%%%%8'EA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-=,_["\7_HF:OD&O'Q7\0_-L^_WU^B"BBBN0^="BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#[D_9M_Y(KX=_
M[>?_ $IEKTRO,_V;?^2*^'?^WG_TIEKTRO?I_!'T/U[ _P"ZTO\ #'\D%%%%
M:':%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_*O7]5%?R
MKT ?O]_P2X_Y,3^&7_<3_P#3I=U]55\J_P#!+C_DQ/X9?]Q/_P!.EW7U50 4
M444 %%%% !1110 4444 %%%% 'YGT445\X?B@4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>Y?L@?\E*U/\
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MBOAW_MY_]*9:],KWZ?P1]#]>P/\ NM+_  Q_)!1116AVA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %?RKU_517\J] '[_?\$N/^3$_AE_W
M$_\ TZ7=?55?*O\ P2X_Y,3^&7_<3_\ 3I=U]54 %%%% !1110 4444 %%%%
M !1110!^9]%%%?.'XH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7N7[('_)2M3_ .P1+_Z.AKPVO<OV0/\
MDI6I_P#8(E_]'0UO1_B1/4RO_?:7J?7U%%%>X?JX4444 %%%% !1110 4444
M ?#?[27_ "6KQ%_V[?\ I-%7F=>F?M)?\EJ\1?\ ;M_Z315YG7@U/CEZGY%C
MO]ZJ_P"*7YL****R.$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *Z;X8?\E*\)?\ 87M/_1R5S-=-\,/^2E>$O^PO
M:?\ HY*N/Q(WH?Q8>J_,_0JBBBOH#]D"BBB@ HHHH **** "BBB@#Y!_:_\
M^2E:9_V"(O\ T=-7AM>Y?M?_ /)2M,_[!$7_ *.FKPVO#K?Q&?E&:?[[5]0H
MHHK \L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** /TPHHHKZ,_:PHHHH **** "BBB@ HHHH \-_:_P#^2:Z9
M_P!A>+_T3-7R#7U]^U__ ,DUTS_L+Q?^B9J^0:\?%?Q#\VS[_?7Z(****Y#Y
MT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%%%%:':%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[KZJH **** "BBB@ HHHH **** "BBB@#\SZ***^</Q0**** "BBB@ HHHH
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M=-7AM>'6_B,_*,T_WVKZA1116!Y84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ?IA1117T9^UA1110 4444 %
M%%% !1110!X;^U__ ,DUTS_L+Q?^B9J^0:^OOVO_ /DFNF?]A>+_ -$S5\@U
MX^*_B'YMGW^^OT04445R'SH4444 %%%% !1110 4444 %%%% !1110 4444
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M7AM>Y?M?_P#)2M,_[!$7_HZ:O#:\.M_$9^49I_OM7U"BBBL#RPHHHH ****
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M'_=:7^&/Y(****T.T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ K^5>OZJ*_E7H _?[_@EQ_P F)_#+_N)_^G2[KZJKY5_X)<?\F)_#+_N)
M_P#ITNZ^JJ "BBB@ HHHH **** "BBB@ HHHH _,^BBBOG#\4"BBB@ HHHH
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M110 4444 %%%% !1110!\@_M?_\ )2M,_P"P1%_Z.FKPVO<OVO\ _DI6F?\
M8(B_]'35X;7AUOXC/RC-/]]J^H4445@>6%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Z84445]&?M84444 %
M%%% !1110 4444 >&_M?_P#)-=,_["\7_HF:OD&OK[]K_P#Y)KIG_87B_P#1
M,U?(->/BOXA^;9]_OK]$%%%%<A\Z%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'W)^S;_ ,D5\._]O/\ Z4RU
MZ97F?[-O_)%?#O\ V\_^E,M>F5[]/X(^A^O8'_=:7^&/Y(****T.T**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^5>OZJ*_E7H _?[_@EQ
M_P F)_#+_N)_^G2[KZJKY5_X)<?\F)_#+_N)_P#ITNZ^JJ "BBB@ HHHH **
M** "BBB@ HHHH _,^BBBOG#\4"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KW+]D#_DI6I_]@B7_ -'0UX;7
MN7[('_)2M3_[!$O_ *.AK>C_ !(GJ97_ +[2]3Z^HHHKW#]7"BBB@ HHHH *
M*** "BBB@#X;_:2_Y+5XB_[=O_2:*O,Z],_:2_Y+5XB_[=O_ $FBKS.O!J?'
M+U/R+'?[U5_Q2_-A11161PA1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K^5>OZJ*_E7H _?[_@EQ_P F)_#+_N)_^G2[KZJKY5_X
M)<?\F)_#+_N)_P#ITNZ^JJ "BBB@ HHHH **** "BBB@ HHHH _,^BBBOG#\
M4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 4444 %%%% !1110 5TWPP_Y*5X2_P"PO:?^CDKF:Z;X8?\ )2O"7_87M/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M117T!^R!1110 4444 %%%% !1110!\@_M?\ _)2M,_[!$7_HZ:O#:]R_:_\
M^2E:9_V"(O\ T=-7AM>'6_B,_*,T_P!]J^H4445@>6%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Z84445]&
M?M84444 %%%% !1110 4444 >&_M?_\ )-=,_P"PO%_Z)FKY!KZ^_:__ .2:
MZ9_V%XO_ $3-7R#7CXK^(?FV??[Z_1!1117(?.A1110 4444 %%%% !1110
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MBOG#\4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOK[]K_\ Y)KIG_87B_\ 1,U?(->/BOXA^;9]_OK]$%%%%<A\Z%%%% !1110
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M/M?_  ^K^"'_ $*WQ _\%UC_ /)E 'W_ $5\ ?\ #ZOX(?\ 0K?$#_P76/\
M\F4?\/J_@A_T*WQ _P#!=8__ "90!]_T5\ ?\/J_@A_T*WQ _P#!=8__ "91
M_P /J_@A_P!"M\0/_!=8_P#R90!]_P!%? '_  ^K^"'_ $*WQ _\%UC_ /)E
M'_#ZOX(?]"M\0/\ P76/_P F4 ??]%? '_#ZOX(?]"M\0/\ P76/_P F4?\
M#ZOX(?\ 0K?$#_P76/\ \F4 ??\ 17P!_P /J_@A_P!"M\0/_!=8_P#R91_P
M^K^"'_0K?$#_ ,%UC_\ )E ''45R'_"XO 7_ $._AS_P;6__ ,71_P +B\!?
M]#OX<_\ !M;_ /Q=?/\ ++L?C?L*O\C^YG7T5R'_  N+P%_T._AS_P &UO\
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M+L'L*O\ (_N9U]%<A_PN+P%_T._AS_P;6_\ \71_PN+P%_T._AS_ ,&UO_\
M%T<LNP>PJ_R/[F=?17(?\+B\!?\ 0[^'/_!M;_\ Q='_  N+P%_T._AS_P &
MUO\ _%T<LNP>PJ_R/[F=?17(?\+B\!?]#OX<_P#!M;__ !='_"XO 7_0[^'/
M_!M;_P#Q='++L'L*O\C^YG7T5R'_  N+P%_T._AS_P &UO\ _%T?\+B\!?\
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M:ELV:=X@O+:VO8O+18CYD:RL%R8RP^8Y5E/?%8__  N+P%_T._AS_P &UO\
M_%UX=2,N>6G4_*,;1JO%56HOXGT\SKZ*Y#_A<7@+_H=_#G_@VM__ (NC_A<7
M@+_H=_#G_@VM_P#XNL^678XO85?Y']S.OHKD/^%Q> O^AW\.?^#:W_\ BZ/^
M%Q> O^AW\.?^#:W_ /BZ.678/85?Y']S.OHKD/\ A<7@+_H=_#G_ (-K?_XN
MC_A<7@+_ *'?PY_X-K?_ .+HY9=@]A5_D?W,Z^BN0_X7%X"_Z'?PY_X-K?\
M^+H_X7%X"_Z'?PY_X-K?_P"+HY9=@]A5_D?W,Z^BN0_X7%X"_P"AW\.?^#:W
M_P#BZ/\ A<7@+_H=_#G_ (-K?_XNCEEV#V%7^1_<SKZ*Y#_A<7@+_H=_#G_@
MVM__ (NC_A<7@+_H=_#G_@VM_P#XNCEEV#V%7^1_<SKZ*Y#_ (7%X"_Z'?PY
M_P"#:W_^+H_X7%X"_P"AW\.?^#:W_P#BZ.678/85?Y']S.OHKD/^%Q> O^AW
M\.?^#:W_ /BZ/^%Q> O^AW\.?^#:W_\ BZ.678/85?Y']S.OHKD/^%Q> O\
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M_P F4 ??]%? '_#ZOX(?]"M\0/\ P76/_P F4?\ #ZOX(?\ 0K?$#_P76/\
M\F4 ??\ 17P!_P /J_@A_P!"M\0/_!=8_P#R91_P^K^"'_0K?$#_ ,%UC_\
M)E 'H/[7_P#R4K3/^P1%_P"CIJ\-KSGX\?\ !33X7_%#Q=9ZKI6@^+K>WAL4
MM66\L[57W"21B0%N6&,.._K7G'_#=G@+_H$>(_\ P&M__C]>15I3E-M(_.<P
MR_%5<54G"FVFSZ-HKYR_X;L\!?\ 0(\1_P#@-;__ !^C_ANSP%_T"/$?_@-;
M_P#Q^LO8U/Y3SO[+QO\ SZ9]&T5\Y?\ #=G@+_H$>(__  &M_P#X_1_PW9X"
M_P"@1XC_ / :W_\ C]'L:G\H?V7C?^?3/HVBOG+_ (;L\!?] CQ'_P" UO\
M_'Z/^&[/ 7_0(\1_^ UO_P#'Z/8U/Y0_LO&_\^F?1M%?.7_#=G@+_H$>(_\
MP&M__C]'_#=G@+_H$>(__ :W_P#C]'L:G\H?V7C?^?3/HVBOG+_ANSP%_P!
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M?H_X;L\!?] CQ'_X#6__ ,?H]C4_E#^R\;_SZ9]&T5\Y?\-V> O^@1XC_P#
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M;X@?^"ZQ_P#DRC_A]7\$/^A6^('_ (+K'_Y,H ^_Z*^ /^'U?P0_Z%;X@?\
M@NL?_DRC_A]7\$/^A6^('_@NL?\ Y,H ^C?VO_\ DFNF?]A>+_T3-7R#61\>
M/^"LGPC^*'A&STK2O#OC6WN(;Y+IFO+&S5-HCD4@%;ICG+CMZUX3_P -V> O
M^@1XC_\  :W_ /C]>9B*<Y3ND?!YQ@<37Q3G2@VK(^C:*^<O^&[/ 7_0(\1_
M^ UO_P#'Z/\ ANSP%_T"/$?_ (#6_P#\?KF]C4_E/$_LO&_\^F?1M%?.7_#=
MG@+_ *!'B/\ \!K?_P"/T?\ #=G@+_H$>(__  &M_P#X_1[&I_*']EXW_GTS
MZ-HKYR_X;L\!?] CQ'_X#6__ ,?H_P"&[/ 7_0(\1_\ @-;_ /Q^CV-3^4/[
M+QO_ #Z9]&T5\Y?\-V> O^@1XC_\!K?_ ./T?\-V> O^@1XC_P# :W_^/T>Q
MJ?RA_9>-_P"?3/HVBOG+_ANSP%_T"/$?_@-;_P#Q^C_ANSP%_P! CQ'_ . U
MO_\ 'Z/8U/Y0_LO&_P#/IGT;17SE_P -V> O^@1XC_\  :W_ /C]'_#=G@+_
M *!'B/\ \!K?_P"/T>QJ?RA_9>-_Y],^C:*^<O\ ANSP%_T"/$?_ (#6_P#\
M?H_X;L\!?] CQ'_X#6__ ,?H]C4_E#^R\;_SZ9]&T5\Y?\-V> O^@1XC_P#
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M_P ?H]C4_E#^R\;_ ,^F?1M%?.7_  W9X"_Z!'B/_P !K?\ ^/T?\-V> O\
MH$>(_P#P&M__ (_1[&I_*']EXW_GTS]<?V;?^2*^'?\ MY_]*9:],K\T/A'_
M ,%>_@YX"^'NE:%J'AKQS-=VGF[WMK"S:,[IG<8+78/1AVZUV'_#ZOX(?]"M
M\0/_  76/_R97L4TU!)]C],PD94\/3A)6:BOR/O^BO@#_A]7\$/^A6^('_@N
ML?\ Y,H_X?5_!#_H5OB!_P""ZQ_^3*T.L^_Z*^ /^'U?P0_Z%;X@?^"ZQ_\
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MQOJ_Q@^-.MPJ?L;06XR?66XF=1^2&OU@KXV_X)<?LUZI^S_^S_)?^)+)M/\
M$_BRY74KBTE7;+;6X3;;Q..S8+.0>1YF#R#7V36U2*I*-&/V4E^K^YNQ$9>U
ME.LU\;;_ $_2X4445B:!1110 4444 %<IXZ^$_@CXH?8?^$R\&^'_%OV'?\
M9/[=TN"]^S[]N_R_-1MN[8F<8SM7/05U=% 'E7_#)WP0_P"B-_#_ /\ "7L?
M_C5'_#)WP0_Z(W\/_P#PE['_ .-5ZK10!Y5_PR=\$/\ HC?P_P#_  E['_XU
M7X _\,G?&_\ Z(W\0/\ PE[[_P"-5_2G10!_-9_PR=\;_P#HC?Q _P#"7OO_
M (U1_P ,G?&__HC?Q _\)>^_^-5_2G10!_-9_P ,G?&__HC?Q _\)>^_^-4?
M\,G?&_\ Z(W\0/\ PE[[_P"-5_2G10!_-9_PR=\;_P#HC?Q _P#"7OO_ (U1
M_P ,G?&__HC?Q _\)>^_^-5_2G10!_-9_P ,G?&__HC?Q _\)>^_^-4?\,G?
M&_\ Z(W\0/\ PE[[_P"-5_2G10!_-9_PR=\;_P#HC?Q _P#"7OO_ (U1_P ,
MG?&__HC?Q _\)>^_^-5_2G10!_-9_P ,G?&__HC?Q _\)>^_^-4?\,G?&_\
MZ(W\0/\ PE[[_P"-5_2G10!_-9_PR=\;_P#HC?Q _P#"7OO_ (U1_P ,G?&_
M_HC?Q _\)>^_^-5_2G10!_-9_P ,G?&__HC?Q _\)>^_^-4?\,G?&_\ Z(W\
M0/\ PE[[_P"-5_2G10!_-9_PR=\;_P#HC?Q _P#"7OO_ (U1_P ,G?&__HC?
MQ _\)>^_^-5_2G10!_-9_P ,G?&__HC?Q _\)>^_^-4?\,G?&_\ Z(W\0/\
MPE[[_P"-5_2G10!_-9_PR=\;_P#HC?Q _P#"7OO_ (U1_P ,G?&__HC?Q _\
M)>^_^-5_2G10!_-9_P ,G?&__HC?Q _\)>^_^-4?\,G?&_\ Z(W\0/\ PE[[
M_P"-5_2G10!_-9_PR=\;_P#HC?Q _P#"7OO_ (U1_P ,G?&__HC?Q _\)>^_
M^-5_2G10!_-9_P ,G?&__HC?Q _\)>^_^-4?\,G?&_\ Z(W\0/\ PE[[_P"-
M5_2G10!_-9_PR=\;_P#HC?Q _P#"7OO_ (U1_P ,G?&__HC?Q _\)>^_^-5_
M2G10!_-9_P ,G?&__HC?Q _\)>^_^-4?\,G?&_\ Z(W\0/\ PE[[_P"-5_2G
M10!_-9_PR=\;_P#HC?Q _P#"7OO_ (U1_P ,G?&__HC?Q _\)>^_^-5_2G10
M!_-9_P ,G?&__HC?Q _\)>^_^-4?\,G?&_\ Z(W\0/\ PE[[_P"-5_2G10!_
M-9_PR=\;_P#HC?Q _P#"7OO_ (U1_P ,G?&__HC?Q _\)>^_^-5_2G10!_-9
M_P ,G?&__HC?Q _\)>^_^-4?\,G?&_\ Z(W\0/\ PE[[_P"-5_2G10!_-9_P
MR=\;_P#HC?Q _P#"7OO_ (U1_P ,G?&__HC?Q _\)>^_^-5_2G10!_-9_P ,
MG?&__HC?Q _\)>^_^-4?\,G?&_\ Z(W\0/\ PE[[_P"-5_2G10!_-9_PR=\;
M_P#HC?Q _P#"7OO_ (U1_P ,G?&__HC?Q _\)>^_^-5_2G10!_-9_P ,G?&_
M_HC?Q _\)>^_^-4?\,G?&_\ Z(W\0/\ PE[[_P"-5_2G10!_-9_PR=\;_P#H
MC?Q _P#"7OO_ (U1_P ,G?&__HC?Q _\)>^_^-5_2G10!_-9_P ,G?&__HC?
MQ _\)>^_^-4?\,G?&_\ Z(W\0/\ PE[[_P"-5_2G10!_-9_PR=\;_P#HC?Q
M_P#"7OO_ (U1_P ,G?&__HC?Q _\)>^_^-5_2G10!_-9_P ,G?&__HC?Q _\
M)>^_^-4?\,G?&_\ Z(W\0/\ PE[[_P"-5_2G10!_-9_PR=\;_P#HC?Q _P#"
M7OO_ (U1_P ,G?&__HC?Q _\)>^_^-5_2G10!_-9_P ,G?&__HC?Q _\)>^_
M^-4?\,G?&_\ Z(W\0/\ PE[[_P"-5_2G10!_-9_PR=\;_P#HC?Q _P#"7OO_
M (U1_P ,G?&__HC?Q _\)>^_^-5_2G10!_-9_P ,G?&__HC?Q _\)>^_^-4?
M\,G?&_\ Z(W\0/\ PE[[_P"-5_2G10!_-9_PR=\;_P#HC?Q _P#"7OO_ (U1
M_P ,G?&__HC?Q _\)>^_^-5_2G10!_-9_P ,G?&__HC?Q _\)>^_^-4?\,G?
M&_\ Z(W\0/\ PE[[_P"-5_2G10!_-9_PR=\;_P#HC?Q _P#"7OO_ (U1_P ,
MG?&__HC?Q _\)>^_^-5_2G10!_-9_P ,G?&__HC?Q _\)>^_^-4?\,G?&_\
MZ(W\0/\ PE[[_P"-5_2G10!_-9_PR=\;_P#HC?Q _P#"7OO_ (U1_P ,G?&_
M_HC?Q _\)>^_^-5_2G10!_-9_P ,G?&__HC?Q _\)>^_^-4?\,G?&_\ Z(W\
M0/\ PE[[_P"-5_2G10!_-9_PR=\;_P#HC?Q _P#"7OO_ (U1_P ,G?&__HC?
MQ _\)>^_^-5_2G10!_-9_P ,G?&__HC?Q _\)>^_^-4?\,G?&_\ Z(W\0/\
MPE[[_P"-5_2G10!_-9_PR=\;_P#HC?Q _P#"7OO_ (U1_P ,G?&__HC?Q _\
M)>^_^-5_2G10!_-9_P ,G?&__HC?Q _\)>^_^-4?\,G?&_\ Z(W\0/\ PE[[
M_P"-5_2G10!_-9_PR=\;_P#HC?Q _P#"7OO_ (U1_P ,G?&__HC?Q _\)>^_
M^-5_2G10!_-9_P ,G?&__HC?Q _\)>^_^-4?\,G?&_\ Z(W\0/\ PE[[_P"-
M5_2G10!_-9_PR=\;_P#HC?Q _P#"7OO_ (U1_P ,G?&__HC?Q _\)>^_^-5_
M2G10!_-9_P ,G?&__HC?Q _\)>^_^-4?\,G?&_\ Z(W\0/\ PE[[_P"-5_2G
M10!_-9_PR=\;_P#HC?Q _P#"7OO_ (U1_P ,G?&__HC?Q _\)>^_^-5_2G10
M!_-9_P ,G?&__HC?Q _\)>^_^-4?\,G?&_\ Z(W\0/\ PE[[_P"-5_2G10!_
M-9_PR=\;_P#HC?Q _P#"7OO_ (U1_P ,G?&__HC?Q _\)>^_^-5_2G10!_-9
M_P ,G?&__HC?Q _\)>^_^-4?\,G?&_\ Z(W\0/\ PE[[_P"-5_2G10!_-9_P
MR=\;_P#HC?Q _P#"7OO_ (U1_P ,G?&__HC?Q _\)>^_^-5_2G10!_-9_P ,
MG?&__HC?Q _\)>^_^-4?\,G?&_\ Z(W\0/\ PE[[_P"-5_2G10!_-9_PR=\;
M_P#HC?Q _P#"7OO_ (U1_P ,G?&__HC?Q _\)>^_^-5_2G10!_-9_P ,G?&_
M_HC?Q _\)>^_^-4?\,G?&_\ Z(W\0/\ PE[[_P"-5_2G10!_-9_PR=\;_P#H
MC?Q _P#"7OO_ (U1_P ,G?&__HC?Q _\)>^_^-5_2G10!_-9_P ,G?&__HC?
MQ _\)>^_^-4?\,G?&_\ Z(W\0/\ PE[[_P"-5_2G10!_-9_PR=\;_P#HC?Q
M_P#"7OO_ (U1_P ,G?&__HC?Q _\)>^_^-5_2G10!_-9_P ,G?&__HC?Q _\
M)>^_^-4?\,G?&_\ Z(W\0/\ PE[[_P"-5_2G10!_-9_PR=\;_P#HC?Q _P#"
M7OO_ (U1_P ,G?&__HC?Q _\)>^_^-5_2G10!_-9_P ,G?&__HC?Q _\)>^_
M^-4?\,G?&_\ Z(W\0/\ PE[[_P"-5_2G10!_-9_PR=\;_P#HC?Q _P#"7OO_
M (U1_P ,G?&__HC?Q _\)>^_^-5_2G10!_-9_P ,G?&__HC?Q _\)>^_^-4?
M\,G?&_\ Z(W\0/\ PE[[_P"-5_2G10!_-9_PR=\;_P#HC?Q _P#"7OO_ (U1
M_P ,G?&__HC?Q _\)>^_^-5_2G10!_-9_P ,G?&__HC?Q _\)>^_^-4?\,G?
M&_\ Z(W\0/\ PE[[_P"-5_2G10!_-9_PR=\;_P#HC?Q _P#"7OO_ (U1_P ,
MG?&__HC?Q _\)>^_^-5_2G10!_-9_P ,G?&__HC?Q _\)>^_^-4?\,G?&_\
MZ(W\0/\ PE[[_P"-5_2G10!_-9_PR=\;_P#HC?Q _P#"7OO_ (U1_P ,G?&_
M_HC?Q _\)>^_^-5_2G10!_-9_P ,G?&__HC?Q _\)>^_^-4?\,G?&_\ Z(W\
M0/\ PE[[_P"-5_2G10!_-9_PR=\;_P#HC?Q _P#"7OO_ (U1_P ,G?&__HC?
MQ _\)>^_^-5_2G10!_-9_P ,G?&__HC?Q _\)>^_^-4?\,G?&_\ Z(W\0/\
MPE[[_P"-5_2G10!_-9_PR=\;_P#HC?Q _P#"7OO_ (U1_P ,G?&__HC?Q _\
M)>^_^-5_2G10!_-9_P ,G?&__HC?Q _\)>^_^-4?\,G?&_\ Z(W\0/\ PE[[
M_P"-5_2G10!_-9_PR=\;_P#HC?Q _P#"7OO_ (U1_P ,G?&__HC?Q _\)>^_
M^-5_2G10!_-9_P ,G?&__HC?Q _\)>^_^-4?\,G?&_\ Z(W\0/\ PE[[_P"-
M5_2G10!_-9_PR=\;_P#HC?Q _P#"7OO_ (U1_P ,G?&__HC?Q _\)>^_^-5_
M2G10!_-9_P ,G?&__HC?Q _\)>^_^-4?\,G?&_\ Z(W\0/\ PE[[_P"-5_2G
M10!_-9_PR=\;_P#HC?Q _P#"7OO_ (U1_P ,G?&__HC?Q _\)>^_^-5_2G10
M!_-9_P ,G?&__HC?Q _\)>^_^-4?\,G?&_\ Z(W\0/\ PE[[_P"-5_2G10!_
M-9_PR=\;_P#HC?Q _P#"7OO_ (U1_P ,G?&__HC?Q _\)>^_^-5_2G10!_-9
M_P ,G?&__HC?Q _\)>^_^-4?\,G?&_\ Z(W\0/\ PE[[_P"-5_2G10!_-9_P
MR=\;_P#HC?Q _P#"7OO_ (U1_P ,G?&__HC?Q _\)>^_^-5_2G10!_-9_P ,
MG?&__HC?Q _\)>^_^-4?\,G?&_\ Z(W\0/\ PE[[_P"-5_2G10!_-9_PR=\;
M_P#HC?Q _P#"7OO_ (U1_P ,G?&__HC?Q _\)>^_^-5_2G10!_-9_P ,G?&_
M_HC?Q _\)>^_^-4?\,G?&_\ Z(W\0/\ PE[[_P"-5_2G10!_-9_PR=\;_P#H
MC?Q _P#"7OO_ (U1_P ,G?&__HC?Q _\)>^_^-5_2G10!_.Q\(_V6_C/IOQ6
M\%W=W\(O'=K:6^M64LT\WAJ]2.-%G0LS,8L   DD],5_1/110 4444 %%%%
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M\6>-]:AT71[<A [@M)-(?NQQ(/F=S@_*!T!)P 2"I^[^/3_@["@_:?!K_P
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MQW-O;_V=]M^R;_-D";O,\N3&,YQMY]JFH_9_'IM^.B'#]Y\.O_ /9:*_*O\
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M3#PA_P!@>S_]$)74UZ.(_C3]7^9YN&_@4_1?D%%%%<YTA1110 4444 %%%%
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ME^*RT\M;?J:W_!4#]MKX??M,:;X2\,?#\W.JV>D74E_<:U<6KVZLS)L6*)9
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M[]LW]MSQ?^VQXZMOA3\)M/U"7P=/=""WL[6-A=Z[*#D22K_!",;@C8  WOC
M"<EY)*A16O1=%T_X9=?O.KEC)NM5>G?^OQ/"? NBO^T9^W#;+X4M9!:>(/&<
MFI0*JE##:&Z:=I#C&W;$"Q],5_1/7QQ_P3[_ &![/]E/09O$?B22#5/B1JT
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M^%O@;2]5^(WAVR\;>.KR!9KR/5D$]E9%@#Y$<!S&VWH78,20<;0<5Z9\;/\
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MQ=-:+?[K?B]?EZ'H-%%%9F@4444 %%%% !1110 4444 %%%% !1110 4444
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MYZ?;:3^S_P##6SLU"VL/AO3EC"XQC[-'7S+^V7_P4M_X9'^+5OX(_P"%<_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW_!'OX >%]06YOU\4>*XU.?LNL:HJQ?C]GBA8_G6E7]^WS]=R*?[K6)\$_\
M!+K]F#4_C9\>]-\::A92?\(;X/N5O[B[F0^7<WJ_-! IZ,P;;(W7"J,_>&?U
M$_X*,?\ )E?Q2_Z\(O\ THBKWCPCX-T+P#X=L]!\-:19:%HMFNRWL=/@6&&,
M9R<*H R3DD]222:POC5\)='^.WPOU_P)K]S?6FD:U"L-Q-IKHEPJAU<%&='4
M'*CJIXS48J]6BZ5/:WXOK_78K#?NZRJS[K[E_3/Q]_X(S_\ )V&J?]BO=_\
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M6,1G@TN]M8[=?+B2)=JO;.P^5!G+'G/TK"46ZD9=K_H=$9)0E%];'TQ\*_\
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ML.NZ3TY]%_X+9?\ )O?@?_L:%_\ 22XK]#+6UAL;6&VMH8[>WA01QPQ*%1%
MP%4#@ #L*\=_:C_93\)?M;>#M*\->+]1UK3;'3;\:C%)HD\,4K2"-X\,98I
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MEUXXGN((X 3@D/>,..Y"Y/'0UU8F^(E-PTYK_*YS8=+#PA&>O*E\['*_L5^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ=G')Z^6(I"GZL]?IK7162BH4ULDOQU_4QI2<W.H^K?X:?I<****YS<****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "FR?ZM_H:=3)?]6_T-95?X<O1C6Y_.M^Q\O]H?MJ
M_#,W&96D\5P2,6/);SMV?SK[E_;^_P""F7C#X>>-?'/P<\(>';71KJS"V,WB
M>6[::9HY;='8PQ!%$3@2;0Q9^F0 <8^"?V5-;A\._M??#2_N&5(8_%=HKLW0
M!K@)D_\ ?5?T)?$KX5^$OC!X7N_#WC'0+'Q!I5RA1H;R%7*$@C>C=4<9X92"
M#R#6LH.6$IK=>]IWT@:5)<N85GMMK\Y_\ _-+_@D'\ _A^/$5Y\16\=Z/XG\
M;VEJT5MX=L1*DNE)( LDTBS(C.Y#&/<BF,9;#L6&W]6*_G6-YJ7[%?[9UT-$
MOI6/@[Q(]NLA;FYLQ)M9'P.=\+;6XZDXK^B>.02QJZ_=8 C\:W<U6HTZT?A>
MB_/]3EY71JSI2W[]^GX6'4445@:A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %>:?M(?!6P_:&^"GBKP#?R+;C5
MK7;;W+#/V>X0AX9,=PKJI([C([UZ7143BJD7%]2XR<)*2Z'\^?P8^+WQ,_X)
MO_'W5H-4\.L+L1_8]6T&_9HHKZ#=E)(Y ".HRDH##!;@Y(KTWXU_M'?%?_@J
M-XN\.?#_ ,&>"%T31["0WKV$5TURB2;2IN;JY\M J*I8*-@Y=A\Q*@?LWXT^
M&WA'XD6<5IXM\+:+XIM86WQP:UIT-XB-ZA9%8 U9\)>!_#G@'2QIGACP_I?A
MS30=PL])LH[6$'UV1J!^E5\<5&KK;;^O76WY$_!)RI:7W_KTT/R-_P"",/Q
M/A'XZ>-O 6H%K:77--$T<,G!^TVDAW)C^]LED/\ P U^QM<+I/P'^&?A_P 5
M#Q/I?P[\*:;XE$LDXUFTT2VBO/,?(=_.5 ^YMS9.<G<<]:[JM93<XPYMTK/^
MOP^1FHJ,Y-;-W"BBBLRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *9+_JW^AI],E_U;
M_0UE6_AR]&-;G\QO@7P+K/Q-^+&F>%O#KQQZ]JNI?9K%I93$HF+'9\X^[R!S
MVK[_ -._X*Z?%;X+Z!=^!?B+\,H;_P"(&D(;1]2O[M[)PZKA7N+<1MYA/#%D
M= P.1C.:^2OV,O\ D]3X8?\ 8T0?^C#7] /C;X3^"/B7Y'_"7^#?#_BK[/GR
M?[;TN"\\O/7;YJ-C\*W49?5X-/1W3^2CMVW*Q$D\=536JU7S<M_N/P=_9<^"
MOC3]MK]IY=5U&&>\L9M6_MGQ/K/E$011F3S'3/0-)RB(.><XPIQ_06JA5  P
M!P*S?#OAC1_!^DPZ5H.DV.B:9#Q%9:=;);PQ_P"ZB */P%:=5S)4XTH*R7_
M_P D8V<IRJ3=V_Z_4****S+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ I&7<I![C%+12:4E9@?%_P ,O^"4?PD^%/Q0T'QWI/B+
MQI<:OHU^NHV\-[?6C6[2*VX!U6U5BN?1@?>OM"BBJN^50Z+^OT"7O3=1[O?^
MOF%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
=BB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>angn-20211231_g3.jpg
<TEXT>
begin 644 angn-20211231_g3.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 9?#Y$# 2(  A$! Q$!_\0
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M,_&@S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@ S1FBB@
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M_P!RU\!T4?V'E_\ S[_&7^8?VQCO^?GX+_(^_/\ AZM_U2__ ,N#_P"Y:/\
MAZM_U2__ ,N#_P"Y:^ Z*/[#R_\ Y]_C+_,/[8QW_/S\%_D??G_#U;_JE_\
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M/5O^J7_^7!_]RU\!T4?V'E__ #[_ !E_F']L8[_GY^"_R/OS_AZM_P!4O_\
M+@_^Y:/^'JW_ %2__P N#_[EKX#HH_L/+_\ GW^,O\P_MC'?\_/P7^1]^?\
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M"BCZO1_D7W(/;U?YG]YW_P#PT'\4O^BE>+__  ?77_QRC_AH/XI?]%*\7_\
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MZ/\ (ON0>WJ_S/[SO_\ AH/XI?\ 12O%_P#X/KK_ ..4?\-!_%+_ **5XO\
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M^&@_BE_T4KQ?_P"#ZZ_^.5P%%'U>C_(ON0>WJ_S/[SO_ /AH/XI?]%*\7_\
M@^NO_CE'_#0?Q2_Z*5XO_P#!]=?_ !RN HH^KT?Y%]R#V]7^9_>=_P#\-!_%
M+_HI7B__ ,'UU_\ '*/^&@_BE_T4KQ?_ .#ZZ_\ CE<!11]7H_R+[D'MZO\
M,_O._P#^&@_BE_T4KQ?_ .#ZZ_\ CE'_  T'\4O^BE>+_P#P?77_ ,<K@**/
MJ]'^1?<@]O5_F?WG?_\ #0?Q2_Z*5XO_ /!]=?\ QRC_ (:#^*7_ $4KQ?\
M^#ZZ_P#CE<!11]7H_P B^Y![>K_,_O.__P"&@_BE_P!%*\7_ /@^NO\ XY1_
MPT'\4O\ HI7B_P#\'UU_\<K@**/J]'^1?<@]O5_F?WG?_P##0?Q2_P"BE>+_
M /P?77_QRC_AH/XI?]%*\7_^#ZZ_^.5P%%'U>C_(ON0>WJ_S/[SO_P#AH/XI
M?]%*\7_^#ZZ_^.4?\-!_%+_HI7B__P 'UU_\<K@**/J]'^1?<@]O5_F?WG?_
M /#0?Q2_Z*5XO_\ !]=?_'*/^&@_BE_T4KQ?_P"#ZZ_^.5P%%'U>C_(ON0>W
MJ_S/[SO_ /AH/XI?]%*\7_\ @^NO_CE'_#0?Q2_Z*5XO_P#!]=?_ !RN HH^
MKT?Y%]R#V]7^9_>=_P#\-!_%+_HI7B__ ,'UU_\ '*/^&@_BE_T4KQ?_ .#Z
MZ_\ CE<!11]7H_R+[D'MZO\ ,_O._P#^&@_BE_T4KQ?_ .#ZZ_\ CE'_  T'
M\4O^BE>+_P#P?77_ ,<K@**/J]'^1?<@]O5_F?WG?_\ #0?Q2_Z*5XO_ /!]
M=?\ QRC_ (:#^*7_ $4KQ?\ ^#ZZ_P#CE<!11]7H_P B^Y![>K_,_O.__P"&
M@_BE_P!%*\7_ /@^NO\ XY1_PT'\4O\ HI7B_P#\'UU_\<K@**/J]'^1?<@]
MO5_F?WG?_P##0?Q2_P"BE>+_ /P?77_QRC_AH/XI?]%*\7_^#ZZ_^.5P%%'U
M>C_(ON0>WJ_S/[SO_P#AH/XI?]%*\7_^#ZZ_^.4?\-!_%+_HI7B__P 'UU_\
M<K@**/J]'^1?<@]O5_F?WG?_ /#0?Q2_Z*5XO_\ !]=?_'*/^&@_BE_T4KQ?
M_P"#ZZ_^.5P%%'U>C_(ON0>WJ_S/[SO_ /AH/XI?]%*\7_\ @^NO_CE'_#0?
MQ2_Z*5XO_P#!]=?_ !RN HH^KT?Y%]R#V]7^9_>=_P#\-!_%+_HI7B__ ,'U
MU_\ '*/^&@_BE_T4KQ?_ .#ZZ_\ CE<!11]7H_R+[D'MZO\ ,_O._P#^&@_B
ME_T4KQ?_ .#ZZ_\ CE'_  T'\4O^BE>+_P#P?77_ ,<K@**/J]'^1?<@]O5_
MF?WG?_\ #0?Q2_Z*5XO_ /!]=?\ QRC_ (:#^*7_ $4KQ?\ ^#ZZ_P#CE<!1
M1]7H_P B^Y![>K_,_O.__P"&@_BE_P!%*\7_ /@^NO\ XY1_PT'\4O\ HI7B
M_P#\'UU_\<K@**/J]'^1?<@]O5_F?WG?_P##0?Q2_P"BE>+_ /P?77_QRC_A
MH/XI?]%*\7_^#ZZ_^.5P%%'U>C_(ON0>WJ_S/[SO_P#AH/XI?]%*\7_^#ZZ_
M^.5[=^Q7\8O'WBK]IGP;I>M>./$FL:9/]L\ZRO\ 5KB>&3;93LNY'<J<,H(R
M." :^4J]^_8-_P"3KO W_;]_Z07%<..HTEA*K45\,NGDSLP=:H\323D_B77S
M/UZHHHK\A/U,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)\0/_"HOO_CM?T(44?5_,/;^1_/?_P -8_&__HLGQ _\*B^_^.T?\-8_&_\
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MO_Z+)\0/_"HOO_CM'_#6/QO_ .BR?$#_ ,*B^_\ CM?T(44?5_,/;^1_/?\
M\-8_&_\ Z+)\0/\ PJ+[_P".T?\ #6/QO_Z+)\0/_"HOO_CM?T(44?5_,/;^
M1_/?_P -8_&__HLGQ _\*B^_^.T?\-8_&_\ Z+)\0/\ PJ+[_P".U_0A11]7
M\P]OY'\]_P#PUC\;_P#HLGQ _P#"HOO_ ([1_P -8_&__HLGQ _\*B^_^.U_
M0A11]7\P]OY'\]__  UC\;_^BR?$#_PJ+[_X[1_PUC\;_P#HLGQ _P#"HOO_
M ([7]"%%'U?S#V_D?SW_ /#6/QO_ .BR?$#_ ,*B^_\ CM'_  UC\;_^BR?$
M#_PJ+[_X[7]"%%'U?S#V_D?SW_\ #6/QO_Z+)\0/_"HOO_CM'_#6/QO_ .BR
M?$#_ ,*B^_\ CM?T(44?5_,/;^1_/?\ \-8_&_\ Z+)\0/\ PJ+[_P".T?\
M#6/QO_Z+)\0/_"HOO_CM?T(44?5_,/;^1_/?_P -8_&__HLGQ _\*B^_^.T?
M\-8_&_\ Z+)\0/\ PJ+[_P".U_0A11]7\P]OY'\]_P#PUC\;_P#HLGQ _P#"
MHOO_ ([1_P -8_&__HLGQ _\*B^_^.U_0A11]7\P]OY'\]__  UC\;_^BR?$
M#_PJ+[_X[1_PUC\;_P#HLGQ _P#"HOO_ ([7]"%%'U?S#V_D?SW_ /#6/QO_
M .BR?$#_ ,*B^_\ CM'_  UC\;_^BR?$#_PJ+[_X[7]"%%'U?S#V_D?SW_\
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M^.T?\-8_&_\ Z+)\0/\ PJ+[_P".U_0A11]7\P]OY'\]_P#PUC\;_P#HLGQ
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M*B^_^.U_0A11]7\P]OY'\]__  UC\;_^BR?$#_PJ+[_X[1_PUC\;_P#HLGQ
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MT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX>TQ.?(L80F\_P!YVZNW^TQ)]ZZ:BBNHYPHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGPU_[%G3?_26.N_K\3K_ ,6?J_S/U^C_  H^B"BBBL#8**** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *]^_8-_Y.N\#?\ ;]_Z07%> U[]^P;_ ,G7>!O^W[_T@N*X,?\
M[I6_PR_)G9@O]ZI?XE^9^O5%%%?C9^LA1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7R%_P4\_Y('H'_8S6_\ Z2W=?7M?(7_!3S_D@>@?
M]C-;_P#I+=UZN5?[]2]3S,S_ -SJ>A^8E%%%?KQ^6A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<!^S[_R03X:_]BSIO_I+'7?U^)U_XL_5_F?K]'^%'T04445@;!1110 4444
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MH *]^_8-_P"3KO W_;]_Z07%> U[]^P;_P G7>!O^W[_ -(+BN#'_P"Z5O\
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MNO\ A[A6_I/P_P#%.OV*7NE^&M7U*S<D+<6EA++&Q!P0&52#@U@5]\?LE_\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /WXHHHK\,/V4****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^0O^"GG_ "0/0?\
ML9K?_P!);JOKVOD+_@IY_P D#T'_ +&:W_\ 26ZKU<J_WZEZGF9G_N=3T/S$
MHHHK]>/RT**** "BBB@ HHHH **** /L?]A[_D3?$?\ U_K_ .BQ7O.M>($T
MC7M L9#@:I-+;KG^\L32#]$->#?L/?\ (F^(_P#K_7_T6*ZC]ICQ&?"/_" Z
MQOV)9^((I)#_ -,]C!Q^*DC\:_SCXGRK^W/$?'Y>E=S]I;_$J$G'_P F2/Z1
MR7%_4>&*.)Z15WZ<^OX&3^VAX7_M;X:V.L(@,NDWJ[F[B*4;&_\ 'Q%7S1\
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M\.ZK8SHLD-U:2P.K="K(5/\ .OS,\)>'9_%OBC2M%MSB:_N8[<-C.W<P!;Z
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MDSYOA3):,\VQ&"S"FI^S3WVNI)7/&_"_['.D_P#">:R^IRWLOA:S>..QAEE
MFNR8D9V=U5<(&9E&T DCJ,<]'\1/V7?AO9^&Y[RWM;K0GA*A9;:[=][,P14(
ME+CEF XP>?PKH?V@OCQ_PINQL(+*RBU#6M0#M$D[$1Q1K@;V Y;).  1G#<\
M<_./Q _:IUSX@>#;;29M.M]-OXKV*[>\M&)C<1DLJ^6^<8;8W+$';TKX3AVA
MXE\78C!YVL5*EA966E3E7+%6<G#[7,UJVF[NZ7+:WTN8RX8R55\%*DI5;-V<
M;V;U4>;I9-6L]M]3ZQ^%/P>T;X/V-_:Z-<WUS'>R++(;Z1'(*C QM1>.:E^*
MGPETCXO:19Z=K%S>VT%K/]H1K%T1BVTK@[D;C!/:N!_94^)7B3XDZ'KUQXCU
M'^T9K6YCCA;R(XMJE22,(JYY]:L_M3_$3Q#\-_".D7OAW4/[.N;B^\F23R8Y
M=R>6QQAU8#D#I7Y+#)^)WQY_9JQD?[1YFO:W?+?V=[WY+_!I\'^9]52QF5RR
M!XF-%K#6?N65[<S3TO;?7<^6/C_\-=,^%7CQ=$TF>[N+4V<=QOO75GW,6!&5
M51CY1VKS:MWQGXXUOX@ZP-4U^]^WWXB6$2^4D?R D@810.Y[5A5_HSDF'QN%
MRS#T,RJ*I7C"*G):J4DO>:;2>K\EZ'\WYC5P];%U*F$CRTV]%V7WO\PHHHKV
MSS@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KW[]@W_DZ
M[P-_V_?^D%Q7@->_?L&_\G7>!O\ M^_](+BN#'_[I6_PR_)G9@O]ZI?XE^9^
MO5%%%?C9^LA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
M\]G_  40^-#?'3]K#Q??VLYN=(T>4:#IFTEAY5N2K%?4/,9G&.SBOW$_:>^)
MA^#O[/?Q!\8I+Y-UI>CW$EH^<8N679!S[RN@_&OPC_87^&*?%[]J;P3I=[&;
MG3[6Z;5KW=R&CMU,H#>H9U13_OTTKNPF[*Y^P_[(_P &8O@/^S_X3\+&W$&J
M"U6\U3CEKR4!Y<^NTD(/9%KV&BBO62LK'F-W=PHHHIB"BBB@ HHHH **** "
MBH[BXBM8))IY$AAC4L\DC!551R22>@KQ'QE^VA\*_!UQ);?VY)KES&<-'H\!
MG7\)#B,_@QK6G2J5GRTXMOR,YU(4US3=EYGN5%?,%O\ \%#?AK-,$?2_$T"D
MX\R2T@*CW^6<G]*]<^'?[07@#XJ3"W\.^([:YOB/^/&<-!<'C)PC@%L>JY%;
MU,'B*2YIP:1A#%T*CY8S5ST.BBBN,ZPHHJ&UO(+^!9[:>.XA8D"2)PRD@D'D
M>A!'X4 345SGCWXA>'_ACX?;6_$VH?V;I:R+"9_)DE^9ONC;&K-V]*XKPK^U
M1\+O&WB&QT/1?%'VW5+U_+M[?^S[J/>V"<;FB"C@'J16T*-6I%RA%M+LC&=:
MG3:C.23?=GK%%%%8FP4444 %%%% !1110 4444 %%%% !117C6H_MA?"+2=0
MNK&[\7>5=6TK0RQ_V;>':ZDAAD0X."#TK6G2J57:G%OT5S.=2%-7G))>9[+1
M7B7_  VE\&O^AQ_\I=[_ /&:/^&TO@U_T./_ )2[W_XS6WU/$_\ /N7W,Q^M
M8?\ Y^+[T>VT5XE_PVE\&O\ H<?_ "EWO_QFNJ^'?[07@'XL:Q/I?A77O[5O
MX(#<20_8[B'$88*6S)&HZL.,YYI2PN(BG*5-I+R8UB:$G935_5'H=%%%<ITA
M1110 4444 %%%% !1110 4444 %%17=Y!86TEQ=31VUO$I:2:9PJ(!U))X J
M4'(R.10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112,ZQJ68
MA549+$X % "T5%:W4-[;Q7%O+'/!*H>.6)@RNI&001P01WJ6@04444#"BBO(
M_$7[67PI\)Z[?:/JGBM;?4;&5H+B%;"ZD".IP5W)$5.#Z$UI3ISJOEIQ;?EJ
M9SJ0IKFF[+S/7**X_P"&_P 7?"7Q<LKR[\)ZPNK06<@BG/D2PLC$9&5D53@C
M/.,<'TKL*4X2IRY9JS\QQG&HN:#N@HHHJ"PHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ*\NHK&UFN9VV00HTDC
M8)PH&2<#V% ;Z(EHKQ+_ (;2^#7_ $./_E+O?_C->RZ=J$&K:?:WUK)YMK<Q
M+-%)@C<C %3@\C((ZUM4H5:2O4@UZIHQA6I5':$D_1EBBBBL38**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH _&S_@JG\%H_AS\?H/%>GVW
MDZ3XPMC=N5&%%[&0DX'U!B<^ID:OT6_X)8_&O_A;G[*.B:==W'G:SX1D;0;@
M,?F\E &MFQZ>2R)]8FKA?^"GWPNB^('[+>JZM'#YFI>%KF+58&4?-Y9813+]
M-DA<_P#7,5\K_P#!&'XG/X:_:"\1>#)IREGXFT=I8HMW#75LV]./^N3W'Y5Y
MM:/+,]"E+FB?M%1116)J?@/1117[F?C04444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !172?#WP'J'Q*\56N@:9-;07EPKLDE
MVS+&-BECDJK'H#VKU[_AB7QS_P!!7P__ .!$_P#\9KXW-^,<@R'$+"9IBXTJ
MC2E:5[V=TGMY,]C!9/C\QINKA*+G%.UUWLG;[FCY]HKZ"_X8E\<_]!7P_P#^
M!$__ ,9H_P"&)?'/_05\/_\ @1/_ /&:\3_B)G!W_0RI_>_\CT/]5\Y_Z!I'
MS[17K7Q'_9G\4?##PO+KVJW^D7%G'*D12SFE:3+' X:-1C\:\EK[3*<XR_/,
M-]<RVLJM.[7,MKK='BXS XG+ZBI8J#A)J]GV_I!17LGP]_95\9>.K.&_G2'0
M-.EPR2:AN$KK_>6,#/\ WUMSU&:]'7]A1MHW>-@&[@:5D?\ HZOB,R\3N#\I
MKO#8K,(\ZT:BISL^S<(R2??4]O"\+YQC*:JT<.^5]VH_^E-'RI17T+XN_8N\
M5:-;R3Z)J-GX@1!GR<&VG;_=#$J?Q<5X%J&GW6DWT]G>VTMI=P,4E@G0HZ,.
MH(/(-?59'Q-D_$E-U<IQ,:J6]GJO6+M)?-'F8_*<=E;2QE)POMV?HU=?B5Z*
M*5$:1U1%+NQP%49)/I7TNVK/)$HKVSP+^R3XU\76\5W?+!X=LY,$?;R3.5(Z
MB(#(^C%37H"_L*-M&[QL WH-*R/_ $=7Y;F'BAP=E=9X?$YA'F6_*IS7WPC)
M?B?58;A7.<7!5*6'=GW:C^$FF?*=%?1GB;]B?Q-IL#RZ+K-CK6U2?)E5K:1C
MZ+DLN?JPKP/7O#^I>%]5GTW5K*;3[Z$X>"==K#W]P>Q'![5]1D?%62<21<LI
MQ4:MMTG:2]8NTDO5'FX_)\?E=OKE%Q3Z[K[U=?B9]%%:GAKPOJWC'5X=+T6P
MFU&^E^[#",\=R3T4#N3@"OI*U:EAJ<JU>2C"*NVW9)=VWHD>3"$JDE""NWLD
M9=%?2?AW]B'7[ZV$FL^(++2I&Y$-O"UR5]F.4&?H2/>M:;]A658V,/C1'DQP
MKZ65!_$3'^5?E57Q9X*HU?8RS"-_*-1K_P "4''\3ZZGPAGE2'/'#NWFXI_<
MVF?*U%>F?$K]GGQA\+[=KV_M8K_2E(#7^GL9(TR>-X(#+VY(QD@9KS.OTC+<
MTP.<8>.+R^M&K3?VHM->FFS[IZH^;Q>#Q&!J>QQ4'"79H****]0XPHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /VY_9]_Y(
M)\-?^Q9TW_TECKOZX#]GW_D@GPU_[%G3?_26.N_K\3K_ ,6?J_S/U^C_  H^
MB"BBBL#8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K@/V@O^2"
M?$K_ +%G4O\ TEDKOZX#]H+_ )()\2O^Q9U+_P!)9*WH?Q8>J_,QK?PI>C/Q
M&HHHK]L/R **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** /WXHHHK\,/V4**** "BBB@ HHHH **** "BBB@ HHHH ****
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MB<1QEAUBXQC."<7RMM?!-[OKJ;G[;C'_ (5OHHSQ_:RG'_;&6OC*U_X^H?\
M?7^=?9G[;G_).-$_["R_^B9:^,[7_CZA_P!]?YU^G>#?_)"X?UJ_^ER/F>/?
M^1Q/_#'\C]4XO]6GT%?FE\6I&E^*?C%F.X_VQ>#/TF<5^EL7^K3Z"OS0^*W_
M "5'QC_V&;S_ -'O7XW]'?\ WS,O\-/\Y'V_B(_]BPZ_O/\ (^A_V%_]5XQ_
MWK3_ -JUTW[;7_)+M(_[#,?_ *(GKF?V%_\ 5>,?]ZT_]JUTW[;7_)+M(_[#
M,?\ Z(GK+$?\GK7^./\ ZCHG ?\ )$R_PS_]+9Y+^Q7_ ,E:OO\ L#S?^C8:
M^E/VD8Y9/@?XL$0);[/&3C^Z)HR?TS7S7^Q7_P E:OO^P/-_Z-AK[.\1:':^
M)]!U'2+T$VE];O;2[>NUE()'N,Y%>1XFYA3RGQ+P^85O@I>PD_1.[_ [N#:+
MQ'#U2C'>3FOO21^6M?2W[#N[_A+/$N,[/L,>?3/F<?UKS?QE^SGXZ\)Z[)8Q
M:%>:S;%R(+[3H&ECD7/#';G8?4-C'N.:^H_V8_@U>_"SPY?76LJL>M:HR-)
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MZW.MSK$=K&MY-']UY0HWD?CFOA#]J+6+76?C=X@>T972#R;9V4@@R)$JO^3
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M HHHH **** "BBB@ KW[]@W_ ).N\#?]OW_I!<5X#7OW[!O_ "==X&_[?O\
MT@N*X,?_ +I6_P ,OR9V8+_>J7^)?F?KU1117XV?K(4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!\%_P#!97QU+X<_9<TS0()-K^(M?MX)
MDS]Z"%))S^4B0U\S_P#!&_P)'=>*OB)XRE0;[*SM]*MV(_Y[.TLN/IY$7_?5
M=7_P7$\4/)K'PG\.(2(X8-0U"0=F+M#&GY>6_P#WU7?_ /!(SPR-)_9MU?5F
M7][JWB"=PW_3..*&-1_WT)/SK>BKS1C5=H'V_1117HG %%%% !1110 4444
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MYR[$L3ZDUVY+@E)?6:B33V\FFT_^ <V;8MT_]G@VGU]&C]@/@O\ \D?\$?\
M8%L__1*5V=?FM\"_VGOB9+XX\#>%&\2YT WMGIWV/[!;?\>^]4V;_*W?=XSG
M/O7Z4UY.8X2>&JN4VO>;:L=V78J%>DH13O%)/^OD%%%%>4>L<C\6_'D'PR^'
M&O\ B68KFQM6>)&.-\I^6-?Q8J*_'Z^O9]2O;B[N9&FN+B1I99&ZLS$DD_4F
MOMS_ (*)?$KR;/0? UK+\TQ_M*]53SM&5B4_4[S_ ,!%>)?LI_ F/XU:QXH%
MXN+*PTN1(I#T%U*K+"?^ X9OJHKZ_*8QPN%J8RIU_)?YO]#Y?-)/$8BGA(?T
MW_DM?FS1_8=^)8\"_&2#2KF;R]-\0Q_87!.%$V<PM]=V4_[:5^E]?BPRWWA?
M7"N7L]2T^YQQPT4L;?S##]*_7CX1^/H?B=\-] \30[0U];*TR+T28?+(OX.&
M%9YY03Y,3'9Z/]/Z\AY/6<7/#SW6OZ/]#KZ**^%?VK/VEOB1\-OC-J>A>'/$
M?]G:5#! Z6_V&VEP6C!8[GC9N2?6OGL-AYXJK[*#UWU/?Q%>.'INK/9'W517
MP+'^W=XBT?X/Z?;&YCUKQ[>2S&;4)[>-(K.$.0G[M%56<@<#& ,$YSBO![_]
MHCXG:EJ#7DOCW7TF8[BMO?R0Q?A&A" >V*]6GDN(FVI-)+\?0\RIFU"$4TFV
M_P /4_7*BOA+]G/]N+5H];M/#WQ%N8[[3[EQ%#K;($EMV/ \W: &3I\V 1U)
M(Z?=@(8 @Y!KS<5@ZN#ERU%OL^C.["XNGBH\U/IT%HK\[/C5^UA\5?"/Q9\5
MZ-I/BG[)IMCJ$L%O!_9]H^Q < ;FB)/XDUL>-OV[/$,'P]\/:1H%U'-XHDL8
MWU;798$^25ADI%& $W#C)Q@= ,\UUQRK$3IPJ1L^:WRNKZZ'/+,J$*DZ<[KE
MO^#MH??=%?D6O[0OQ-74/M@\>^(?.W;MIU&4QY_ZYYV8]L8KZS_9;_;.NO&F
MM6OA'QV\/]J7)\NQU>-!&)W[1RJ/E#'LR@ \#&>3M7R:O1@YIJ5NQC1S:A4G
MR--7[GV#12.2J,1UQ7Y?WW[9WQCAO;B-/&&$61E _LRSX )_Z8UP8/!U,;*4
M:;2M;?SO_D=^*Q4,)%3FGKV/U!HK\W?CI^V5XK\97T.F^%-:N]$T:VA1)+NR
M8P7%Y,%&^0NN&1<YPJXXY/7 ]'_85^)WQ#\=>--5T_6/$5YK/AVQLC-,-1;S
MY!,S 1@2M\XX#G&2/E/'>NR64UH4'6FTK=#C69T95E2@F[]3[;HKQS]HK]I+
M1_@+H\2/"-4\17B%K/35;:-O3S)#_"@/XDC [D?!OC3]K3XI^-+IY)/%5UH\
M!.4MM&8VB)[!D^<_\"8UAA,NK8Q<\=(]W^AOBL=1PCY9ZR[+]3]5:*_);P[^
MTQ\4O#-XMQ:^.-8N6!Y34;EKQ#[;9=PK[4_9E_; M/C!=IX<\1V\&D^*=I,#
MPDB"] &2$!.5<#G;DYP2#V'1B<HKX>#FO>2['/A\THUI*#T;[GTK117Q+^TM
M^VSJVB^);[PMX EAM5LG,%UK+1K*[2@X98@P*@ Y!8@Y.<8QD^9A\/4Q53V=
M-:GI5JT,/!U*CT/MJBOR'O/C]\2[^X::7Q]XD5V.2(=4FB7\%1@!^ KHO!O[
M6GQ3\&WD<T?BN[U>%6!>UUAOM:2#T)?YP/\ =8'WKW'D5:VDU?YGB_VU1OK%
MV^1^JU%><_ 7XS6/QR\ P:_;6YLKJ.0VU[9EMWDS* 2 >ZD,"#Z'U!K<^)GQ
M)T7X3^#[WQ'KLS1V=N %CC&9)I#]V-!W8G\N2>!7@5*4Z=1TI+WMK'N4ZD*L
M%4@]&=517YD?$S]M;XC>.KZ8:7J3>%-))(CM=,($N.Q:;&\M_N[1[5P%C^T#
M\3-/NEN(O'WB-W4Y GU.:9/Q5V*G\17N4\CQ$HWDTGV/&J9Q0C*T4WYGZ[5D
M^+?^15UG_KRF_P#1;5\B?LT_MM:AXB\067A7X@-!)->.(;36XT6+,AX5)E&%
M^8\!E P<9'.1]=^+?^15UG_KRF_]%M7CXS"5<(W"HO\ )GKX+%4\4U*GW1^,
M%?LK\._^2?\ AG_L&6O_ **6OQJKZ;^(_P"VSXENM$TKP[X(F.@Z;8V4-M+J
M 0&YN'6-58KN'[M<@XP-W&<CI7VN:86IBXPA377[CX[+<13PTY5*CTM^I^C5
M%?D=I?[17Q/TB_6\@\>:_)*IW!;J_DN(_P 8Y"RD>Q%?=7[)?[34WQPT^]T?
M78H;?Q1IL:RO) -L=W#G;Y@7^%@2 P''S C&<#YO%936PU-U+II;GOX?-*->
M:IV:;V/H>BH;Z]@TVSGN[J9+>U@1I99I#A451DL3V  KX!^.7[=GB+7M6N=,
M\ 3?V'HL3E!J1C5KJZ XW#<"(U/; W=\CI7GX7"U<7/DI+U[(]#$8BGA8<]1
M_P#!/T$HK\AX?C]\2X;H7"^/O$AD!SA]4F9/^^"VW]*^D/V>_P!NC5&UJUT'
MXCS0W5E<N(HM<6-8G@8G \X* I3H-P (ZG/4>M6R7$4X\T6I>74\NGG%"<N6
M2:\S[HHI%8,H(.0>017QM^U!^VAJ7A#Q)>>$? C0Q7EDWE7NKRQK*4D[QQ*V
M5RO0LP/.0!QFO&P^'J8FHJ=-:GK5JT*%-U*CT/LJBOR*U#]H+XFZI<M/-X^\
M1([')%OJ4L"?@J,%'X"M_P &_M:?%/P;=QRQ^*[K5X%8%[76#]K20>A9_G _
MW6!]Z]UY%7M=35_F>+_;5&_PNWR/U6HKS3X _'#3?CMX)76+2+[%J%N_D7]B
M6W&&7&<@]T8<@_4=0:]+KY^K3G1FZ<U9H]RG4A6@JD'=,****R-0HHHH ***
M* "BBB@#!\?>$K7Q]X'\0^&;T#[)K&GW&GRY&<++&R$_ANK\(/V3?%EW\)?V
MLOAOJ4C?9I;'Q);V5WSC;%)+]GG'_?$D@K]_:_GT_::T67X>_M0?$2UM#Y#6
M7B2ZN+8K_ K3&6/\@R_E7)B%LSJH/='])U%?,W_#;.B_\^'ZG_&BN(ZS\H**
M**_<S\:"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH ]?_9._Y+CHG_7*Y_\ 1+U]XZMJ,>CZ3?:A,K-#9P27$BQ@%BJ*6(&2
M.<"O@[]D[_DN.B?]<KG_ -$O7W'XR@ENO!OB""&-III=.N4CCC4LSL8F 4 =
M22<8K^!_&FC2Q''.$HU_@E3I)]-'4FGKTT/W_P /6UE-=K_GX_\ TB!XK_PV
MUX&_Z!7B#_P'@_\ CU'_  VUX&_Z!7B#_P !X/\ X]7RE_PJ7QS_ -"9X@_\
M%<__ ,11_P *E\<_]"9X@_\ !7/_ /$5^O?\0H\.O^?_ /Y71\A_K;Q)_)_Y
M(SVSX[?M,>&/B?\ #RXT'2K#5[>\DN(I0]Y#$L>%))Y61CG\*Y?]DOX=VGC;
MXA2W^HQ+<6.C1+<>2XRKS,<1Y'<##-]5%>.ZQHNH^'[Y[+5+"ZTV\4!FM[R%
MHI ",@E6 /(YKZ#_ &)?$EMIOC+7=&F=8YM2M8Y(-QQN:(L2H]]LA/T4U[W$
MV3T>#O#['8;AMRY>7F3YN9\LY14VGVY+N_3<\[!8^IG>?X:>:VNFE:UMKM)K
M_$SZL\<>-M)^'?ANYUS6IFALH,+^[7<\CG[J*.Y/Y=22 ":^>[O]N>Q2^*6O
MA&XFL\\337RQR8]=@1A_X]7N/Q:^&MI\5_!=SH-U<-9LSK/!<HN[RI5S@E<C
M(P2",C@U\=>*OV3?B#X=ED-K80Z[:J"PFT^9<X[91]K9]@#]:_GKPPR3P^S;
M RCQ%47UIR?NSJ2IQMTY6I13;ZW;=^EM_P!-XJQG$&%J1>5P_=VU<8J3O=[I
MIZ6MLOF?8/PK^+>A_%S19;[1VEBEMV"7-G< "6$GH2 2"#@X(/.#W!%>1_MD
M?#.UU+PM'XRM85CU'3W2&[95P9H6(52WJ58J ?1CZ"OGSP+XZ\7_ +/NO7<R
M:0;.ZO(/*DM-:M945E# A@N4.001GW-='XQ_:P\6^./"^I:#J&F:&EG?Q>5*
MT$$P<#((*DRD9R!U!K]"R?PQSGACC"EFW#LU+ \RWFKNG*W/%_S6UY?1/<^;
MK<58/,<HG@LVBU6::^'2_P!E^72_^1XM7V7^RM\"[30]%M/&6MVJS:O>+YMC
M'*,BVA/W7 _OL.<]@1C&37RM\.O#?_"8>/-!T5AF.]O(XI,?\\]P+G_OD&OT
MWAA6*-(HU"(H"JJ\  < 5Z'CMQ9BLNPU#(,%)Q==.4VM^2]E'TD[W[J-MFSS
M> LHIXS$3QU=75.RBNG,^OR7YWZ'*?$3XH^'OA;I*WVO7GDF3(@M8AOFG('(
M1?RY. ,C)&:\)O?VY[&.^*VGA"XGL\\2S7RQR8_W C#_ ,>KP'XV>.KCXA?$
MK6=2DE+VL<[6UFN>$@1B$ ^OWC[L:X6O6X6\$.'L/EU.>>4W6KR2<O>E&,6^
MD5!QVVNV[O738,ZXXQ[Q<Z6 DH0B[)V3;MUU3WZ:'Z-?"OXW>&_BY;RC299+
M?4(%WS:?=*%E5<XW#!(9<]P>,C.,UF_M!_".U^*'@NZ:&W3_ (2"PC::QG &
M]L<F$GNK<CGH<'UKX8^'_C2[^'OC#3-?L@9)+.4,\._:)8SPZ$X. RDC.#CK
MCBO9O$'[;'BV^9UTC2M-TB(CY6D#7$JGU#$A?S6OB\3X1Y[P[Q11S'A"25&-
MI7G.W+K[T';WI1:\MG9ZJ[]C"<98''Y;/#YTO>>EHKXEW[)KUWLUY?/%??'[
M+?P[M/!OPRT_4C"IU36HUO)Y\?-Y;<QH#Z!2#CU8U\%W5P]Y<RSRD&25R[%5
M"C).3@#@?05^BOP!\2VWBCX1>&KBW=6:WM$LYE!Y22(!"#Z9P#]"*^K\?L3C
M:7#^&I4;JE.I:=O*+<4_*]WZI'@< 4Z$\TG*6KC%\M_5)OUM^;,;XN_M(>'O
MA/J']E2V]QJVL^6)&M;<A%B!Y7>YZ$CD  G'7&1G@_#?[;VC:AJ$<.M>';G2
M+=V"_:;>Y%R$SW9=B' ]LGVK0^/O[+]S\2/$4OB30+^WMM3F1%N;6\R(Y2JA
M0RN <':%&",''45\U>(_@'\0/"V6O?"]])'S^\LU%RN!W)C+;1]<5\IP;PCX
M99_D]&E.LGBY17-S57"HIM:\L+J+2>WNR5K7;/HL^S7B? 8V<J,/W*>EHJ2:
M\W9M/OJO(_1)6L]:TT,/)OK"[BST#QS1L/R*D'\0:_/+X^?#N+X9_$O4=+M!
MC39@MW9@G)6)\_+_ ,!8,O\ P&NF\(_M8>,O _AO3]!MK'2+BWT^/R(Y+R"8
MR[03@,5E4<#CH. *XKXJ?%C5OB]K%GJ6L6MC:W%K;_9E%C&Z*R[F;)W.W.6/
M>OK/##@3B7@K.,1'%2B\'436DKW:?N2Y>C:O?U\CQN)N(<LSS+H1BFJ\;/;:
M_P 2OV_R1Q5%%%?U"?DX4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% '[<_L^_P#)!/AK_P!BSIO_ *2QUW]<!^S[_P D$^&O
M_8LZ;_Z2QUW]?B=?^+/U?YGZ_1_A1]$%%%%8&P4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7 ?M!?\D$^)7_8LZE_Z2R5W]<!^T%_R03XE?]BS
MJ7_I+)6]#^+#U7YF-;^%+T9^(U%%%?MA^0!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% 'Z(^ ?A=X,O/ GARXN/".A
M3SRZ;;222R:;"S.QB4EB2N22>]?)'[4FBZ=X?^,6I66EV%KIMFMO;,MO9PK%
M&"8E)(50!R>:^WOAO_R3OPO_ -@JU_\ 1*U\6_M=_P#)<-4_Z];7_P!$K7\0
M>"^88S%<78ZG7K2G%0G9.3:_B1Z-G[MQ3AZ-/AVC.$$G[FJ2OL>,T5H:!X?U
M'Q3J]MI>DV<M]?W#;8H(1DD^OL .23P ,FOHGP_^P]J]Y8I+K'B:UTRY;G[/
M;6IN0OL6+IS],CW-?U9Q!QED'"_*LXQ4:3ELM92:[\L4Y6\[6/R++\FQ^:W^
MITG*V[T2^]M*_E<^9J*]W^(W[(GB?P7ITNHZ3=Q>);*%=\J01&*X4#)+"/+;
M@/9B?:J_AG]D3QCXJ\.Z9K-IJ6AQVNH6T=U$DT\P<*ZA@& B(S@]B:X%X@\+
M/!PS#Z_#V4GRIW>Z5[-6NG;6S2.N7#F;1K/#O#RYDK]-O)[/Y,\0HK<\;>$;
MSP'XJU#0-0D@FO+)PDCVS,T9)4-P6 /0CJ!6'7W="M3Q-*%>B[QDDT^Z>J?W
M'S]6E.C4E2J*THMIKLUN>G_LX_#^/XA?%'3K:[@6XTRQ!O;N.10R.B$;48'@
MAF*@@]1FON#_ (5+X&_Z$SP__P""N#_XBO*OV-_ O_"/^ +G7[B/;=ZU-F,G
MJ((\JOYMO/N-M>RMXPTU?&:^&/.']JM8G4/+_P"F6_9^>:_SS\4^)\QSSB?%
M4LLJ35'"QY7R-I>Z_?D[/^=\M^R1_0W".58?!Y5"MBHKFJN^J772*5^^_P S
MX=_:@^',/P_^)DQL+9+72-3B%W;10H$CC/W9$4#@889P.@9:\BK[M_:V\!_\
M)9\+Y-3@BWWVAR?:U('S&$_+*/IC:_\ VSKX2K^N_"_B1\3<,8?$5)7JT_W<
M^_-'J_\ %&S]6?E7%^6++<UGR*T*GO+Y[K[[Z=K"5^DVE_"CP1)IEHS>#O#[
M,T*$LVEP$D[1S]ROS9K]4-(_Y!-E_P!<$_\ 017XQ](+&XK!K+/JU64+^UOR
MMJ_\/>Q]5X>4:5:>)]K!2LH[J_\ ,?('[6GP4MO"ES;>*_#]A#9Z1<;;>\M;
M6()';R@81PH&%5@,''\0_P!JOF^OU(\2>'K'Q9H-]H^IPB>QO8FAE3V/<>A!
MP0>Q -?FY\1O M]\-_&.HZ!?@L]L_P"ZFVX$T1Y20>Q'Y'([5]EX,\</B+*W
ME6.G?$X=;O>=/9/S<?A?R;U9P\<9"L#B%C\/&U.INETE_D]_6Y[1^QKX5T7Q
M1JGBE-9T>PU=88;<Q+?6J3!"6DR5W XS@=/2NW_:V\"^&O#?POMKO2/#VE:7
M='4X8S/9644+E3'(2NY5!QD#CV%<[^PQ_P A;Q?_ -<+;_T*2N^_;0_Y)':_
M]A:'_P!%RU^>9ACL7'QDAAE5E[/FA[O,^7^ GM>V^I]!EN'HRX/J5'!<W+/6
MRON^I\/T445_:!^'!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% '[\4445^&'[*%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %?(7_!3S_D@>@_\ 8S6__I+=5]>U\A?\%//^2!Z#
M_P!C-;_^DMU7JY5_OU+U/,S/_<ZGH?F)1117Z\?EH4444 %%%% !1110 444
M4 >^?LY_'WP_\(?#^K6.L6>IW,MW=+,C6,4;J%" 8.Z1><U#^TA\=] ^,.EZ
M#;:-9ZE;/83322F^BC0$.J ;=KM_=/7%>$T5^<T> <EH<0/B:$9?66V[\WNZ
MQY7IZ'TRXBQZR[^R[KV5K;:[WW/7/V<_C-8?!_7M6FU:WO+G3KZV5"EDBLXD
M5LJ<,RC&&?OW%>O>/?VP_"_B#P3KFEZ3I^M0:C>V<EM#)<0PJBEUVDDB4D8!
M/0&OD6BN3-/#?A_.,ZCG^+IR==.#TE9-PMRW7797[FN!XFS'+L)]2H27)KTU
MUWLS7\':Q#X>\7Z%JMRLCV]C?V]U(L0!<JDBL0H) S@'&2*^P&_;8\#LI']E
M>(.1C_CW@_\ CU?%%%=G$W 62\6XFCB\SC)SI*T>65NM]?F893Q!CLEC.&$:
M2E9NZOL%>V_ W]I>_P#A9;+H^J6TFK>'MQ9(XV FMB3D[,\%2<G:<<G((YSX
ME17TF>Y!EO$N"EE^:4E4IO7LT^C36J:[KTV;/*P./Q.6UUB<+/EDOZL^Z/ON
MP_:P^&=Y;I++K<UB[#)AN+&<LOL=B,/R)KG/''[97A/1[&1/#<5QK]^R_NV>
M)H+=3_M%@'..N O/3(ZU\3T5^,X/P*X2PN)6(G[6HD[\DIKE_P#)8QDU_P!O
M>I]S4X^S>I3<$H1?=)W_ !;7X&OXM\6:GXX\0WFM:Q<&YO[IMSMC   P%4=E
M   'M7K?[-WQRT'X/6FO1:S::C<M?O"T7V&.-P-@<'=N=?[PZ9KPVBOU_.^&
M\NS_ "J638N%J#Y=(^[91::2MLE9?(^+PF98G!XV.84Y7J)MW>NK33O][/H/
M]HK]H3P[\7/">G:7H]EJEM<6]\+EVOHHT0J(W7 *R,<Y8=J^?X7$<T;GHK G
M'UIE%5D'#V!X:RV.59>FJ4;VN[OWFV]?5AF>98C-L0\3BFN9JVBML?:Z?ML>
M!U10=*\0<#'_ ![P?_'J^0O&VM0>)/&6O:O;)(EM?ZA<742R@!PKR,P# $C.
M",X)K%HKP.%> LEX-J5JF51DG524N:7-M>WYGHYKQ#CLYIPI8MIJ+NK*Q[=^
MS;\;M"^#L>OC6;34+DZ@8#%]ACC?&S?G=N=?[PZ9[UL?M$?M#^'/BYX-L=(T
M>RU2VN8-02Z9KZ*-$*B.12 5D8YRX[>M?/-%3+@'))\0_P"M#C+ZU=._-[MU
M'D^'T%2X@QU'+GE<6O9.ZVUU=WKZL]-_9[^)VE_"?QQ<ZSJ]O>7-K)826H2R
M1&?<SQL#AF48PA[^E>R_$3]L?2=4\.&/PK;ZO8:W'/%+%+>01"$JK@LK;96)
M!7(QCOVZU\FT5GFWAWD&>9Q'.\?3<ZJLK-^ZTM+..S5M^Y>!XCS#+\'+!8>2
M4'?IKKV?3R/MWP/^V-X/UK3T_P"$B$_A[4%'[P>2\\+GU0H"WX$#&>IZTOC;
M]L;P=HNG/_PCWG^(=08'RU\EX(5/J[. V/90<XQD=:^(:*^)CX'<(1QOUODJ
M.-[^SY_<]-N>W_;Y[JX\SA4/8WC?^;E][\^7_P E-GQAXNU3QUXBO-:UBX-S
M?73;F;HJCH%4=E X KT_]FWXU:)\'9_$+ZS:ZA<C4%MQ%]@C1]NPR9W;G7^^
M,8SWKQ>BOUO.>'<OSW*IY+BH6H245:/NV46FDK;)-+Y'Q^%S+$X/&+'PE>HF
MW=ZZNZ=_O/I'X_?M)>&?BI\/_P"P])L=6M[O[;%<;[R&)8]JJX(RLC'/S#M7
MS=114\.<.8#A7 ++<M35--O5W=WOJ:9IFN)SBNL1BFG)*VBMHKO]3M/A+\4]
M2^$OBJ/5[%1<0.OE75FS;5GCSG&>Q!Y!['V)!^P=%_:X^'&IV*37>IW.D3'[
MUO=6<KLOXQJRG\Z^"J*^.XN\,>'^,L1'&8Z,H5DK.=-I-I;*5XR3MWM>VE[)
M'J9/Q/F&20=+#M2@];23:3\K--??8^R_B-^V9H.FV,MOX/@DU?4'7"7ES$T5
MO%GOM;#L1Z8 ]^U4?!/[9^@V'A73;;Q'9:U>:W%%LNKBV@A9)6!/S F1>HP3
MP.<U\A45XZ\&>$%@(X#V$M)<SGS>^W:VLK;>225];7/0EQMG$L1[=32TMRV]
MWIT[Z;ML[?XS>+-%\=?$/4M?T*&\M[2_V2O%>QHCK+M ?&UF!!(W9SG+&O?_
M (=?M<>#_"/@30=%O--UR2ZL+..WE>""$H650"5)E!Q]0*^2:*^LSS@/)^(L
MOPV69@I2IT+<MI6>D>75]=#R,'Q!C<#BZN-H64ZE[Z::N[T]3T;X^?$;3?BE
M\0)-=TJ"ZM[1K:*$)>(JR;E!!.%9ACGUKF?A[XAM_"?CK0=:O$EDM;"]BN94
M@ +E58$A02!GCN17/T5]31R?"T,J6303]BJ?L]]>7EY=^]NIY.(QM;%8J6,J
M?&W?YGVI<_MK>")K>6-=*\0 LA49MX.X_P"NU?%=%%?/\*<%91P;"M3RF,DJ
MK3ES2YMKV_,]+-\^QN=^S^MM/DO:RMO:_P"2/6O@O^T5K7PE_P! >+^U_#[O
MN-C(^UHB>K1-SC/4J1@^Q)-?3.B_M<_#C4[19;K4;O2)3U@N[.1V'XQ!Q^M?
M!E%?+\3>$_#/%&)EC<13E2JR^*5-J+EYM-2C?N^6[ZMGHY7Q;F>4TU1I24H+
M925[>EFG\KV/NGQ-^V%X"T>S9]+EO-?N2#LBM[=X5SVW-(%P/<!OI7R;\5OB
M[KGQ<UP7NJ.L-K#E;6PA)\J!3Z>K'C+'KCL  .(HKU.$_#?A[@ZH\1E]-RJM
M6YYOFE;LK))>=DF^IEFW%&99Q#V5>2C#^6*LGZZMO[[!7U?\&OVO+"QT6TT;
MQHD\<MLBQ1ZK"AE$B@8'FJ/FW8 &1G/<#O\ *%%>WQ5P?E/&.$6$S6FVHN\9
M)VE%];/SZIIIZ::(\O*LXQ>35_;X25F]&GJFO-?TS[XU3]K3X;:?9//;ZO<:
ME*HXMK:RF5V^AD55_,UY)H_[8IN?B1)JNM65W;^&8;.2"UTVP"R2>8SH1)(6
M90QPK#CIG '))^8J*_/\L\&.%,MH5J/).HZB<>:<DY)/?EM&*3\[7MI>S9]-
MBN-\WQ4H-.,%%WM%:.W>[;MY7L?2_P =OVF/#'Q/^'EQH.E6&KV]Y)<12A[R
M&)8\*23RLC'/X5\_^$_%FJ>"-?M-9T>Y:UOK9LJPY##NK#NI'!%9%%?HF1\)
MY5P_E<LFPE.]"7->,WS7YMT[[I]CYO,LXQ>:8F.+KR]^*236EK-M?.[/M+P/
M^V=X9U6UBB\36ESH=\!^\FAC,]NQ]1CYQGTVG'J:[!OVJ/A@JY'B4L?[HL+G
M/_HNOS]HK\FQG@1PEBJ[K4W5I)_9C-<O_DT)2_$^LH<?9O1IJ$E";75IW_!I
M?@?6'Q0_;.@ET^?3_!-I.MS("AU6\4*(_P#:CCR<GT+8QC[IKY1FF>XE>65V
MDD=BS.YR6)Y))[FFT5^L\,\)91PCA7A<II<JEK)MWE)^;?X+1+HCY3-<ZQN<
MU%4Q<[VV2T2]%^KU"BBBOL3PPHHHH **** "BBB@ KW[]@W_ ).N\#?]OW_I
M!<5X#7OW[!O_ "==X&_[?O\ T@N*X,?_ +I6_P ,OR9V8+_>J7^)?F?KU111
M7XV?K(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\A?\
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M HHHH **** "BBB@ HHHH **** /QI_X+9WWF?M ^!K+/^I\,+-C_?N[@?\
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ME2>WF19(Y8SE74C(8'N"#7O9]%\].?2UOZ^\\+)9+EG#KHR6N>^(L<<WP_\
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MG;?^C5K],/VQ/^3<?&/_ %SM_P#THBK\S_A[_P C]X:_["=M_P"C5K[/A_\
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M#_;[\$Z9X6^*VFW^F6D-D-6L//N(X4"*TJNRE\#N1MSZD9K]"?#ZA=!TT 8
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M\DZE917'EYQG;O4XS@=/05^.&H*$U"Y50%596  & .37[5R?ZMOH:_%74O\
MD)7?_75__0C7+D$G[2K&^EE^;.O.DO91=M;_ *'ZH?!7X5>"5^'/@C5U\'Z
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M%4<)CZDK^Y+JM?/[C>>&K8G 0A:TH]'IM=&#\#?VP/A+I'A'3-$N+)O!,]O
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MU^)U_P"+/U?YGZ_1_A1]$%%%%8&P4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7 ?M!?\D$^)7_ &+.I?\ I+)7?UP'[07_ "03XE?]BSJ7_I+)
M6]#^+#U7YF-;^%+T9^(U%%%?MA^0!1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %=;X%^+'BKX:QWD?AO5?[.2\*M./L\4N\KG;]]&QC<>GK7)45
MPXW X3,J#PV.I1JTW:\9Q4HNVJNFFM'JC:C6JX>HJM&3C);-.S731KRT.U\;
M?&?QE\1M+AT[Q%K']H6<,PN$C^RPQ8D"LH.413T9N,XYKBJ**6!P&$RV@L-@
M:,:5-;1A%1BKZO1)+4K$8FOBI^TQ$W.7=MM_>PHHHKO.<**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "O?OV#?^3KO W_ &_?^D%Q7@->_?L&_P#)UW@;_M^_](+BN#'_
M .Z5O\,OR9V8+_>J7^)?F?KU1117XV?K(4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!^*W_!:O_DZ;PM_V)EK_ .EU]7V;_P $V?\ DROX
M=?\ <1_].5U7QE_P6K_Y.F\+?]B9:_\ I=?5]F_\$V?^3*_AU_W$?_3E=5TX
M?XCGK_"?3-%%%=YQ!1110 4444 %%%% !69XH\.6/C#P[J6B:G%YUAJ$#V\R
M>JL,''N.H/J*TZ* /R$^,OPAUGX+^-;K0M6B8PY+V=X%/EW4.?E=3Z]B.QR*
M]5_9_P#VSM;^$.DP^']9L3XC\.P\6Z^;Y=Q:KGE48@AEZX4XQV('%??WQ#^&
M?AOXJ:"VC^)M,CU&TSN0ME9(6Q]Y''*GZ=>AR*^2O&G_  3C<W$DOA/Q:HA)
M^2UUB Y7ZRQ]?^^!7UU',L/BJ7L<:M>_1^>FS_KR/F*V7UL/5]M@W\NWEKNO
MZ\SK=2_X*,>"(K%WT_PWX@N;W;\L-RL$,9/H761R![[37R)\</CYXC^.VO1W
MNKE+33[;(L],MR?*@!ZG)^\QP,L?P '%>O0_\$Z_B"TP$VO>&8XL\LD]PS8^
MAA'\Z]>^&?\ P3[\,>&[R*^\6:M-XHEC(86447V:VSZ/\Q9QGW4>H-73GE>#
M?M8.\NF[_P" 9SCF6*C[.2LNNR_X)Y+^P_\ L_W?BKQ5;>/=8MC%H.E2%[$2
MKC[7<C@,OJJ'G/\ > '.&Q^A-06-C;:99P6EG;Q6MI @CB@A0(D:@8"JHX
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MR,XSTS7QI_P[7_ZJ+_Y0_P#[HJ<GQ='"RFZTK7MWZ7[&F:X:KB8TU25[7O\
M.W?T/LO0/^0#IO\ U[1_^@BOA;_@H[_R/7A#_L&R?^C:^\=/M?L-C;6V[?Y,
M:Q[L8S@ 9Q^%>%?M'?LK_P##0.N:1J/_  D_]@_V?;-;^7_9_P!I\S+;LY\U
M,?3!K@P5:%'&1JS=HIO\F=>)I3J8.5**]YI?FO\ (\2_X)N_\ASQS_U[6O\
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M[_\ )=O 7_89M?\ T8*_3GXU?#+_ (7!\.=3\*_VE_9'VTQG[7Y'G;-DBO\
M<W+G.W'7O7S_ /#O]@/_ (0'QUH/B/\ X3O[=_95[%=_9O['\OS=C!MN[SSC
M..N#4Y7C*&'H5(596;>FC[)!FF%K8F<'2C>R\NY];N,HP]J_%K7K62RUS4;>
M4;98;F2-QZ$,0:_:>OD3XZ_L(_\ "=>*K_Q'X/UFUTNYOY#/<:?J",(/,8Y9
MT= 2H)R=I4\D\]JYLIQ5/"UI>U=E);^G_#G5F>'GB**5/5IW.E^"?[67P\;P
M/X#\,OJ-R/$3P6>DFP6SDRLV%B!+XV;2><ALX/3/%?2U?"GP]_X)^^+]%\5:
M7JFL>)]%M(K&ZBNE^P+-<LQ1PP&'6,#..N:^ZZRS&.&4^;#RNW=OR_ >7O$<
MG)7C9))+^K^@5^<'[>7Q)_X2[XM)X?MI=]AX>A\@@=#</AI#^ V+_P !-?H[
M(&:-@C!7Q\K,,@'UQWKXSUK_ ()VW/B#6+[4[WXE&6\O)WN)I#H?WG=BQ/\
MQ\^IHRRI0HXCVM>5K+3?=^GE?[R\PA6J4'3HJ[>_IO\ G;\3SW]BO]G?0/BV
MOB+6O%VF-J6C6FRTM8?/EA#3GYG;=&RGY5VC&<?/[5]1_P##%OP:_P"A._\
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M?%6CV-KW;3DEN7/MAUC _.OKCX.? GPK\$-'DL_#]J[W4^/M6HW1#W$^.@)
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M4KM/L_U.++,'7P]64JL;*W='SE_P4)_Y(CI__8:@_P#14U?+'[%7_)Q_A?\
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MOKQ<QQBQE;GBM$K(]7+\*\)2Y9/5ZL****\L],**** "BBB@ HHHH *_#/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M?OQ1117X8?LH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+V%K>\MI6AFA?JCJ<$'Z$56KZJ_;&^$GER1^.],A^5ML&J(@Z'[L<WX\(?\
M@/J:^5:_IKA3B3#<5Y11S7"_;7O+^62^*+]'MW5GU/S?.\JJ9-C9X6>RUB^\
M7L_T?FF?1?P]_9!_X3SP7I/B#_A+/L/V^'S?L_\ 9OF;.2,;O-&>GH*\L^,7
MPS_X5+XS?0/[2_M7;;QS_:/(\G[X)QMW-TQZU]O_ +/7_)%_"?\ UZ?^SM7R
MQ^V-_P EFF_Z\+?^1K\&\/>-L_SSC/'Y3F&(YZ%+VO+'E@K<M116L8J3LG;5
MOSU/O,ZR++L)P]0QU&G:K)0N[RZJ[T;M^!X?116GHOA?6?$K.ND:1?:JT?WU
MLK9YBOUV@XK^HJM:G0@ZE62C%;MNR^]GY1"$JDE&"N_(S**W=8\!^)O#]J;G
M5/#NK:;;@X,UY8RQ)^;*!6%4T<11Q,/:4)J4>Z::^]%5*52D^6I%I^:L%%%%
M=!F%%6M,TF^UJ\6TTZSN+^Z;[L%K$TCGZ*H)K4U;X?\ BC0;1KK4_#>KZ=:K
M]Z:[L98D'U9E KDGB\/3JJA.I%3>R;5WZ+<VC1JSBYPBVEUMH8-=+\-?!G_"
MPO'&E>'?MG]G_;G9/M/E>9LPC-G;D9^[CJ.M<U7I?[-G_)</"O\ UWD_]$R5
MXO$V,KY?D6.QF&ERU*=*I*+LG:48-IV=T[-;--'5EU*%?&T:-17C*44_1M)G
MK.I_L/\ ]G:;>7?_  FGF?9X7FV?V5C=M4G&?.XZ5\MU^I'B;_D6M8_Z\I__
M $6U?F)I.BZCKUU]ETRPNM1N<;O)M(6E?'KM4$U^+^#O&&;\39?C<3GN(4_9
MRBDW&$$DTV_AC%?>?H'&F28+*YX:. I<KGS7UD[VY;;M]WL4J*W=7\ ^)_#]
MJ;K5/#FK:;; X,UY8RQ(,_[3*!6%7]"T,11Q,/:4)J4>Z::^]'YG4I5*+Y:D
M6GYJP4445T&845O:;X \4:U8+?:?X;U>_LFSBYMK&62,XZ_,JD5AR1M#(R.K
M(ZG:RL,$$=017-2Q-"O*4*4U)QT:33L^SML:RI5(14I1:3VTW]!M%%=+:_#'
MQC?0+-;>$]<N(6&5DBTV9E(]00M3B,7A\(E+$5(P3_F:7YA3HU*SM3BY>BN<
MU15W5M#U+P_=?9M4T^ZTVYQN\F[A:)\>N& -4JZ(3C4BIP=T^J(E&4&XR5F%
M%%%62%%:FA^%=;\3-(NCZ/?ZJ8_OBQM7FV_7:#BC7/"FM^&3&-8T?4-),GW/
MMUJ\.[Z;@,UR?6\/[;ZO[2/M/Y;J_P!VYM[&KR>UY7R][:?>9=%%%=9B%%:F
MB^%=;\2;_P"R-'O]4V'#?8K5YMOUV@XK5D^%7C6%"\G@_7XT'5FTR<#_ -!K
MSJF8X*C4]C5K1C+LY)/[KW.F&%KU(\\*;:[I,Y:BG30O;RO'*C1R(=K(XP01
MU!%-KT#FVT9L>%?!^M>-M433M#TV?4KMOX(5X4>K,>%'N2!2^,?"=]X'\27N
MAZD8C?6959?)8LH)4-@' SPU?HO\+_#>E^&? ^CP:5806$<MI#+)Y* &1RBD
MLQZL3ZGFOAG]I'_DMWBK_KNG_HI*_!N!_$FKQKG^+P-*@J="C"ZN[S;YDKOH
ME;HK^K/T'.>&89/E5+&3J<U2<DO))Q;]6]%K^!3^"OPK_P"%P>+I]$_M3^R?
M*LWN_/\ L_G9VNB[=NY?[^<Y[5Z9\1OV0_\ A7_@?5_$7_"6?;_[/B63[-_9
MOE^9EU7&[S3C[V>AZ51_8K_Y*U??]@>;_P!&PU],?M&?\D/\7_\ 7JG_ *.C
MKXWBSC?B#+?$+"9'A,3RX:<J*<>2#NIM<WO.+EKY/3H>[P]D.78[(ZN,Q%+F
MJ+GL[R6RTT32_ _.NBM/1/"^L^)7=-(TB^U5X_OK8VSS%<],[0<5)KG@_7O#
M*1OK&B:EI*2'"-?6DD(8^@W 9K^H?KF&]M]7]I'VG\MU?[MS\G5"JX>T4'R]
M[.WWF1111768A1110 4444 %%%% !1110 4444 %%%% !7OW[!O_ "==X&_[
M?O\ T@N*\!KW[]@W_DZ[P-_V_?\ I!<5P8__ '2M_AE^3.S!?[U2_P 2_,_7
MJBBBOQL_60HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY
M"_X*>?\ ) ] _P"QFM__ $ENZ^O:^0O^"GG_ "0/0/\ L9K?_P!);NO5RK_?
MJ7J>9F?^YU/0_,2BBBOUX_+0HHHH **** "BBB@ HHHH **** "BBB@ HZ\#
MDT5[)^RCX+MO%_Q8MY+V-9K;2H&O_+895I%953/T9@W_  &OG^(,YH\/Y5B,
MUKJ\:47*W=]%\W9?,[<#A)X_%4\+3T<VE]_7Y&[\,_V/]?\ %MC!J.OW@\.V
M<H#QVYB\RY=3SRN0$R/4D^JUZK'^Q+X)"CS-7U]F[E9X /R\DU[+X\\:6'P\
M\)ZAX@U(2-:6: F.$ N[,P55&>Y9A7RGJG[;_B>6]+:=H&DVMIGB*Z,LTF/]
M]60?^.U_&N6YYXH>(7M,?E%7V5"+LN5QA%/?E3=YR:35V[KTV/V[$Y=POPY&
M%'&QYYM7UNV_.RT2_K6QU/BC]AZQ>W9_#GB.XAG53MAU2-9%=NP+H%*CWVM7
MS-XV\"ZU\.]>ETC7+-K2[0;E.=R2H>CHPX93C^8.""*^WO@3^T'9_&+[78SV
M0TO6[5!*T"R;TECR 70X!&"0"#TR.3V;^U)X!MO&7PKU&]\M?[1T5&OK>7'(
M1?\ 6KGT* GZJM>]PGXC\3Y'Q'#AGC#WN>2A=J*E%R^%\T=)1=UKJ];WTL<>
M9<-93FN72S')M&DWI>SMNFGL^VWXW/@2BBBO[,/Q **** "BBB@ HHK:T7P1
MXC\26YGTG0-4U2 ':9+*RDF4'TRJFN>OB*.%A[2O-1CW;27WLTITYU9<M.+;
M\M3%HK0UKP[JWANX6#5M,O-+G8;ECO;=X6(]0& K/K2G4A5BITVFGLUJB90E
M3DXS5F@HHK;T;P-XD\16_P!HTGP_JFJ6^<>;9V4LRY],JI%9U\11PL/:5YJ$
M>[:2^]E4Z<ZLN6G%M^6IB5]2:;^P_P#VAIMK=?\ ":>7Y\22[/[*SMW '&?.
MYZU\U:QH&I^';H6VJZ;=Z9<$;A#>0-$Y'KA@#BOTZ\-?\B[I7_7I%_Z *_FW
MQDXTSGA>EE]3(L3[-5?:<S4833Y>2WQ1EW>V]S])X,R7!YI6Q%/,*7-R*-E>
M2M>_9K\3\V_B1X-_X5[XWU7P]]L^W_89%3[3Y7E[\HK9VY./O>IZ5S5>E?M(
M_P#);O%7_7=/_125YK7] 9)B*N,RO"XFN[SG3A)O:[<4V]--^Q\+FE&&'Q]>
MC25HQG))>2DT@HJQI^G7>K7D5I8VLUY=2G$<%O&9'<^@4#)K0USP;K_AF..3
M6-#U+28Y#M1[ZTDA#'T!8#->C+$T(550E-*;V5U=^BW.&-*I*+G&+:6[MH8]
M%%7=)T/4M?N?LVF:?=:E<8SY-I"TKX]<*":UJ5(4HN=1I);MZ(B,92:C%7;*
M5%=+=?#'QC8V[SW/A/7+>%!N:2739E50.Y)6N:K'#XK#XN//AZBFN\6G^1I4
MHU:.E2+CZJP4445U&(44L<;2.J(I=V. JC))]!73?\*O\9^1Y_\ PB.N^3C=
MYG]FS;<>N=M<E?%X?"N*KU(Q<MKM*_I?<VIT:M:_LXMV[*YS%%*RE6*L"&!P
M0>HK5T/PCKOB99#H^BZAJPC.'-C:R3;?KM!Q6E:O2P\'5K348KJW9?>R(4YU
M)<D%=]D9-%:>N>%]:\,O&FL:1?Z4\F=BWUL\);'7&X#-9E53JTZT%4I24HO9
MIW7WA.$J<N6:L_,***U]$\'Z]XF1WTC1-1U54.&:QM))@I]#M!Q4UJ]+#P=2
MM-1BNK=E]["%.=27+!7?D9%%;.M>"_$/AN%9M7T'4]*B8[1)>V<D*D^F645C
M44:U+$052C)2B^J=U]Z'4ISI2Y:D6GYZ!1116YF%%%% !1110 4444 %%%%
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M%%%>(>P%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^&?\
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MI2\L)G=4N(R#\J[B55@<8Z#D\]*^8/AE\5-=^%&N-J.C3*4E 2XM)@6AG4=
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M%)7VU\$?^20^#_\ L%P?^@"OB7]I'_DMWBK_ *[I_P"BDK[:^"/_ "2'P?\
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MHHH **** "BBB@#\5O\ @M7_ ,G3>%O^Q,M?_2Z^K[-_X)L_\F5_#K_N(_\
MIRNJ^,O^"U?_ "=-X6_[$RU_]+KZOLW_ ()L_P#)E?PZ_P"XC_Z<KJNG#_$<
M]?X3Z9HHHKO.(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_#/_@I-_R>
MI\1?^X=_Z;;6OW,K\,_^"DW_ ">I\1?^X=_Z;;6N;$?"=%#XCYFHHHK@.T^L
M****_<S\:"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7_7I<?\ H%?6GQ[_ .2,^,/^O!OYBOX@\1O^3HY9ZX?_ -.,_=^#?^2=Q/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OPS_X*3?\ )ZGQ%_[A
MW_IMM:_<ROPS_P""DW_)ZGQ%_P"X=_Z;;6N;$?"=%#XCYFHHHK@.T^L****_
M<S\:"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#]N?V??^2"?#7_L6=-_])8Z[^N _9]_Y()\-?\ L6=-_P#26.N_K\3K
M_P 6?J_S/U^C_"CZ(****P-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "N _:"_P"2"?$K_L6=2_\ 262N_K@/V@O^2"?$K_L6=2_])9*WH?Q8
M>J_,QK?PI>C/Q&HHHK]L/R **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO/?B)\:/%GQ095UO4B;)&W)8VR^5 I]=H^\?=B2,GFN'HKY/+>#>'<GQ/US
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M11;0Q!/W%7/0=:Y>BOL[]E+PYX9\6?"F+^U-$TK5+RSOIH@]Y:132*#M<8+
MD#YJ^(XKXBP?A[DL,71PEZ,9*"A3M!13YG=*UDKK\3W,KP%?B+'.C4K>_)7Y
MI7;=K:7WV_(SOV)?"&H:?I.N^(;CS(;&_,=O;1MP)=A8L_N 6V@_[U=M^UEX
MU_X17X3W-C$^V\UJ062 'GR_O2GZ;0%/^^*].U[Q1H7@G3?M&K:C9Z19QKA?
M.D5!@#[JKU)P. H)]J^#OV@_B\/BWXS%Q:!X]$L$,%DD@PS G+2$=BQ X[!5
M[YK^6^"\OQ_B+QS+BK&8=PP\)*>WNWBDJ<4[+F:LG)^3O:Z1^NYI6P_"V0_V
M;3J<U62:7?WG[TK=$KNWR/+Z***_NT_GX**** "BBB@ HHHH **** "O?OV#
M?^3KO W_ &_?^D%Q7@->_?L&_P#)UW@;_M^_](+BN#'_ .Z5O\,OR9V8+_>J
M7^)?F?KU1117XV?K(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5\A?\%//^2!Z!_V,UO_ .DMW7U[7R%_P4\_Y('H'_8S6_\ Z2W=>KE7
M^_4O4\S,_P#<ZGH?F)1117Z\?EH4444 %%%% !1110 4444 %%%% !1110 4
M444 =CX&^+WB[X<Y30M9FM;8MN:TD E@)[G8P(!/J,'WKTZ']M;QU&@5M.T&
M4_WGMILG\I17@%%?%YGP7PYG-9XC'X&G.;WDXI2?JU9OYGM87.LRP,/9X>O*
M,>U]/DNA[9KO[8'Q"UBW\JWGT_1\]9+&URQ'IF1GQ^'->/:MK%]KVH2WVI7D
M]_>RG,EQ<R&1V[<DG-5**]3*>'\HR*+CE>%A1OORQ2;]7N_FS#&9GC<PM]:K
M2G;N]/NV"M+PUX=OO%NO6.CZ;"T][>2K%&@'KU)] !DD]@#6[\()[>W^*/A8
MW:126K:A#%*LX!0JS!3D'C&#WK]$M%\)>'O#;RW&D:+IFEO(,2365K'"6'N5
M S7Y7XB^)?\ J/4C@X85U*E6#<)7M%2NUJK7=M'9;[:;GTO#G#+SY2J>UY8P
M:35KNWD7])L6TW2[.S:5[AH(4B,K\LY50-Q]SC-?GW^T;XU'CCXMZU<Q/YEG
M9L+"V(Z;(\@D>Q?>W_ J^HOCM^T3HO@;P[?:=HNI0ZAXFG1H(TM7$@M"009'
M(R 5[+USCC%?"))/)Y-?GG@7PCB\"L1Q!F-)PE47+34E9\M[RE;HF[)=[/H?
M7<>9O1E2IY7AI7L[RL[VMHE^K]$%=;X%^+'BKX:QWD?AO5?[.2\*M./L\4N\
MKG;]]&QC<>GK7)45_5.-P.$S*@\-CJ4:M-VO&<5*+MJKIIK1ZH_'Z-:KAZBJ
MT9.,ELT[-=-&O+0[7QM\9_&7Q&TN'3O$6L?VA9PS"X2/[+#%B0*R@Y1%/1FX
MSCFN*HHI8' 83+:"PV!HQI4UM&$5&*OJ]$DM2L1B:^*G[3$3<Y=VVW][/2=#
M_:,^(?AO1[/2].\0_9["SB6&"+[%;ML11@#+1DG\37'^+_&6L>/-<EUC7;S[
M=J,JJCS>4D>0JA5&U !P .U8U%<.#R'*<NKRQ6"PE.G4E>\HPC&3N[N[23=W
MJ[]3>KF&,KTE0K5I2@NCDVM-M&[:#[>XEM9XYX)'AFC8.DD;%65@<@@CH0:]
MI\.?M?>/_#^GI:S/I^L[!A9M2@9I,>A9'3/U.3[UXG166<<.Y1Q!",,UPT*R
MCMS)-KT>Z\[/4>#S'%Y?)RPE5P;WL]_4](^(G[0?C/XF6K6>I7\=GIK8W6&G
MH8HGQ_>))9A[%B.!Q2Z'^T9\0_#>CV>EZ=XA^SV%G$L,$7V*W;8BC &6C)/X
MFO-J*P_U5R#ZK# RP%)T8.ZBZ<'%-[M)IZOJ]V;RSC,95GB/K$^=Z74FG;MH
M]O(TO$GB34?%VN7>KZM<?:]1NF#33;%3<0 !\J@ < =!7;Z'^T9\0_#>CV>E
MZ=XA^SV%G$L,$7V*W;8BC &6C)/XFO-J*[L9D>59C1AA\;A:=2G#X8RA&2CI
M;W4TTM--.AS4L?BZ%25:C6E&<MVI--]=6G=ZFYXR\;:UX_UHZMKU[]OU!HUB
M,WE)'\J]!A% _2L.BBO4H4*6%I1H4(*$(I)))))+9)+1)=$CEJU:E:;J59.4
MGNV[M_,*]1\$_M*^/? ]O':P:JNIV,8VI;:FGG*H[ -D. .PW8'I7EU%>=F>
M3Y=G5'ZOF6'A5AVE%2MYJ^S\UJ=&%QF)P4_:8:HX2[IV/?+K]M+QY<6[QQV6
MAVKL,"6*VE++[C=*1^8KR#Q?XZU_Q[J7V[7]4GU.X PGFD!(QW"(,*HXZ*!6
M%17F91PKD60S=3+,'"E)]8Q7-;MS;V\KV.S&9QF&/A[/%5Y2CV;T^[8*])T/
M]HSXA^&]'L]+T[Q#]GL+.)88(OL5NVQ%& ,M&2?Q->;45ZF8Y1EV;PC3S'#0
MK1CJE.$9I/NE).QQ8?&8G!R<L-4E!O\ E;7Y&SXO\9:QX\UR76-=O/MVHRJJ
M/-Y21Y"J%4;4 '  [4_P=XVUKP!K(U70;W[!?B-HO.\I)/E;&1AU([#M6'17
M1/+\'4POU&=&+HVY>1Q7)R[<O+:UO*UB/K-?VWUCG?/>_-=WOWOO<]'U[]HG
MXA>*-%O-)U/Q!]IT^\C,4\/V*W3>I[96,$?@:\XHHK++\KP&4TG1R[#PHP;N
MU",8IOO:*2OIN7B,9B<8U+$U)3:_F;?YGH^@_M$_$+PQHUGI6F>(/LUA:1B*
M&'[%;OL4=!EHR3^)KE/&7C;6O'^M'5M>O?M^H-&L1F\I(_E7H,(H'Z5AT5S8
M/(<IR_$2Q>#PE.G5E>\HPC&3N[N\DDW=ZN[U9I5S#&5Z2H5:TI06R<FUIMI>
MVA);W$MG<13P2O#/$P>.2-BK(P.001T(/>O8_#/[6_Q!\.V:VTMU9ZTB@*KZ
MG 6< >K(REOJQ)]Z\8HJ,VX?RG/H*GFF&A62VYHIM>CW7R8\'F&+R^3GA:K@
MWV=K^O<]RUK]L?X@:I9M!;C2M)=O^6]E:L7'T\QW'Z5XOJFJ7FMZA/?:A=37
MM[.V^6XN'+NY]23R:JT5.4<.Y1D$91RO"PH\V_+%)OU>[^;+QF:8W,+?6ZLI
MVVN]/NV"BBBOHCS HHHH **** "BBB@ HHHH **** "BBB@ KW[]@W_DZ[P-
M_P!OW_I!<5X#7OW[!O\ R==X&_[?O_2"XK@Q_P#NE;_#+\F=F"_WJE_B7YGZ
M]4445^-GZR%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?B
MM_P6K_Y.F\+?]B9:_P#I=?5]F_\ !-G_ ),K^'7_ '$?_3E=5\9?\%J_^3IO
M"W_8F6O_ *77U?9O_!-G_DROX=?]Q'_TY75=.'^(YZ_PGTS1117><04444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5^&?\ P4F_Y/4^(O\ W#O_ $VVM?N9
M7X9_\%)O^3U/B+_W#O\ TVVM<V(^$Z*'Q'S-1117 =I]84445^YGXT%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '[<_L
M^_\ )!/AK_V+.F_^DL==_7 ?L^_\D$^&O_8LZ;_Z2QUW]?B=?^+/U?YGZ_1_
MA1]$%%%%8&P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7 ?M!?
M\D$^)7_8LZE_Z2R5W]<!^T%_R03XE?\ 8LZE_P"DLE;T/XL/5?F8UOX4O1GX
MC4445^V'Y %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% '[\4445^&'[*%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %?(7_  4\_P"2!Z#_ -C-;_\ I+=5]>U\A?\ !3S_ )('H/\
MV,UO_P"DMU7JY5_OU+U/,S/_ '.IZ'YB4445^O'Y:%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "O?OV#?^3KO W_;]_P"D%Q7@->_?L&_\G7>!O^W[_P!(+BN#'_[I6_PR
M_)G9@O\ >J7^)?F?KU1117XV?K(4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!^*W_!:O\ Y.F\+?\ 8F6O_I=?5]F_\$V?^3*_AU_W$?\
MTY75?&7_  6K_P"3IO"W_8F6O_I=?5]F_P#!-G_DROX=?]Q'_P!.5U73A_B.
M>O\ "?3-%%%=YQ!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7X9_\%)O^
M3U/B+_W#O_3;:U^YE?AG_P %)O\ D]3XB_\ <._]-MK7-B/A.BA\1\S4445P
M':?6%%%%?N9^-!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!^W/[/O_)!/AK_ -BSIO\ Z2QUW]<!^S[_ ,D$^&O_ &+.
MF_\ I+'7?U^)U_XL_5_F?K]'^%'T04445@;!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %<!^T%_P D$^)7_8LZE_Z2R5W]<!^T%_R03XE?]BSJ
M7_I+)6]#^+#U7YF-;^%+T9^(U%%%?MA^0!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!^_%%%%?AA^RA1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7R%_P4\_Y('H/_8S6_P#Z2W5?
M7M?(7_!3S_D@>@_]C-;_ /I+=5ZN5?[]2]3S,S_W.IZ'YB4445^O'Y:%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>_?L&_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7X9_P#!2;_D]3XB_P#<._\ 3;:U^YE?AG_P4F_Y/4^(O_<._P#3
M;:US8CX3HH?$?,U%%%<!VGW?_P ,^?%+_HFOB_\ \$-U_P#&Z/\ AGSXI?\
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M  0W7_QNOVYHH_UFK?\ /M?>P_U>I?\ /QGXC?\ #/GQ2_Z)KXO_ /!#=?\
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M7_\ @9:__(U'_#L/X6_]![Q?_P"!EK_\C4?ZP8+N_N#^P\9V7WGYB45^G?\
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M^_%%'^L__3G_ ,F_X ?ZN_\ 3W_R7_@GX#T5^_%%'^L__3G_ ,F_X ?ZN_\
M3W_R7_@GX#T5^_%%'^L__3G_ ,F_X ?ZN_\ 3W_R7_@GX#T5^_%%'^L__3G_
M ,F_X ?ZN_\ 3W_R7_@GX#T5^_%%'^L__3G_ ,F_X ?ZN_\ 3W_R7_@GX#T5
M^_%%'^L__3G_ ,F_X ?ZN_\ 3W_R7_@GX#T5^_%%'^L__3G_ ,F_X ?ZN_\
M3W_R7_@GX#T5^_%%'^L__3G_ ,F_X ?ZN_\ 3W_R7_@GX#T5^_%%'^L__3G_
M ,F_X ?ZN_\ 3W_R7_@GX#T5^_%%'^L__3G_ ,F_X ?ZN_\ 3W_R7_@GX#T5
M^_%%'^L__3G_ ,F_X ?ZN_\ 3W_R7_@GX#T5^_%%'^L__3G_ ,F_X ?ZN_\
M3W_R7_@GX#T5^_%%'^L__3G_ ,F_X ?ZN_\ 3W_R7_@GX#T5^_%%'^L__3G_
M ,F_X ?ZN_\ 3W_R7_@GX#T5^_%>5?M8_P#)K/QD_P"Q,UG_ -(9J/\ 6?\
MZ<_^3?\  #_5W_I[_P"2_P#!/Q<HKY/K[_\ ^"*G_)TWBG_L3+K_ -+K&C_6
M?_IS_P"3?\ /]7?^GO\ Y+_P3S"BOWXHH_UG_P"G/_DW_ #_ %=_Z>_^2_\
M!/P'HK]^**/]9_\ IS_Y-_P _P!7?^GO_DO_  3\!Z*_?BBC_6?_ *<_^3?\
M /\ 5W_I[_Y+_P $_ >BOWXHH_UG_P"G/_DW_ #_ %=_Z>_^2_\ !/P'HK]^
M**/]9_\ IS_Y-_P _P!7?^GO_DO_  3\!Z*_?BBC_6?_ *<_^3?\ /\ 5W_I
M[_Y+_P $_ >BOWXHH_UG_P"G/_DW_ #_ %=_Z>_^2_\ !/P'HK]^**/]9_\
MIS_Y-_P _P!7?^GO_DO_  3\!Z*_?BBC_6?_ *<_^3?\ /\ 5W_I[_Y+_P $
M_ >BOWXHH_UG_P"G/_DW_ #_ %=_Z>_^2_\ !/P'HK]^**/]9_\ IS_Y-_P
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MK_5:\:UK\KV.;%4?K%&5*]KGX#T5^_%%?7?ZS_\ 3G_R;_@'RO\ J[_T]_\
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MK]^**/\ 6?\ Z<_^3?\  #_5W_I[_P"2_P#!/P'HK]^**/\ 6?\ Z<_^3?\
M #_5W_I[_P"2_P#!/P'HK]^**/\ 6?\ Z<_^3?\  #_5W_I[_P"2_P#!/P'H
MK]^**/\ 6?\ Z<_^3?\  #_5W_I[_P"2_P#!/P'HK]^**/\ 6?\ Z<_^3?\
M #_5W_I[_P"2_P#!/P'HK]^**/\ 6?\ Z<_^3?\  #_5W_I[_P"2_P#!/P'H
MK]^**/\ 6?\ Z<_^3?\  #_5W_I[_P"2_P#!/P'HK]^**/\ 6?\ Z<_^3?\
M #_5W_I[_P"2_P#!/P'HK]^**/\ 6?\ Z<_^3?\  #_5W_I[_P"2_P#!/P'H
MK]^**/\ 6?\ Z<_^3?\  #_5W_I[_P"2_P#!/P'HK]^**/\ 6?\ Z<_^3?\
M #_5W_I[_P"2_P#!/P'HK]^**/\ 6?\ Z<_^3?\  #_5W_I[_P"2_P#!/P'H
MK]^**/\ 6?\ Z<_^3?\  #_5W_I[_P"2_P#!/P'HK]^**/\ 6?\ Z<_^3?\
M #_5W_I[_P"2_P#!/P'HK]^**/\ 6?\ Z<_^3?\  #_5W_I[_P"2_P#!/P'K
MW[]@W_DZ[P-_V_?^D%Q7Z]45AB.(O;T9TO96YDU\7=6[&]'(?8U8U/:WY6GM
MV^84445\:?6!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
MXK?\%J_^3IO"W_8F6O\ Z77U?9O_  39_P"3*_AU_P!Q'_TY75?&7_!:O_DZ
M;PM_V)EK_P"EU]7V;_P39_Y,K^'7_<1_].5U73A_B.>O\)],T445WG$%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %!..3P**^/_V\/CS>>&+.W\ Z%=-;
M7>H0^?J<\1(=8"2%B![;\$GV '\5;T*,\14C2ANS*K5C1INI/9'>_%#]MSX?
M_#N^GTZR>X\4:G"2DB:9M\B-AV:5C@_\ #5Y;#_P4G@:X42_#Z1(,\NFL!F
M]=OD ?K7@_[.O[,>L_'N\N+D70T?PY9OY=QJ+1[V:3&?+C7(W-@@DDX (Z\
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M:US8CX3HH?$?,U%%%<!VG]5%%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "N4^+'_)+/&7_8&O/_1#UU=<
MI\6/^26>,O\ L#7G_HAZ /Y@J^U/^"0W_)Y.G?\ 8%O_ /T!:^*Z^U/^"0W_
M ">3IW_8%O\ _P! 6@#]U**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M** "OE7_ (*C_P#)B?Q-_P"X9_Z=+2OJJOE7_@J/_P F)_$W_N&?^G2TH _
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M5T^=KN_N+=P\:R[2BQAAP2 6)QT) ZYKSO6OV&_BYI=XT-KH=IK$0/%Q9ZC
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M-4^L2Q$H<BZ+[BU1117S!]&%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M?AG_ ,%)O^3U/B+_ -P[_P!-MK7[F5^&?_!2;_D]3XB_]P[_ --MK7-B/A.B
MA\1\S4445P':?U44444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\X/[:W_)W'Q>_[
M&:^_]&M7*?L]_P#)??AI_P!C-IG_ *51UU?[:W_)W'Q>_P"QFOO_ $:U<I^S
MW_R7WX:?]C-IG_I5'0!_331110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %<I\6/\ DEGC+_L#7G_HAZZNN4^+'_)+/&7_ &!KS_T0
M] '\P5?:G_!(;_D\G3O^P+?_ /H"U\5U]J?\$AO^3R=._P"P+?\ _H"T ?NI
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>5?M8
M_P#)K/QD_P"Q,UG_ -(9J]5KRK]K'_DUGXR?]B9K/_I#-0!_-97W_P#\$5/^
M3IO%/_8F77_I=8U\ 5]__P#!%3_DZ;Q3_P!B9=?^EUC0!^U-%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\J_\ !4?_ ),3^)O_
M '#/_3I:5]55\J_\%1_^3$_B;_W#/_3I:4 ?@#7ZJ?\ !#'_ )K9_P!P3_V_
MK\JZ_53_ ((8_P#-;/\ N"?^W] 'ZJ4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^*W_!:
MO_DZ;PM_V)EK_P"EU]7V;_P39_Y,K^'7_<1_].5U7QE_P6K_ .3IO"W_ &)E
MK_Z77U?9O_!-G_DROX=?]Q'_ -.5U73A_B.>O\)],T445WG$%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %?AG_P %)O\ D]3XB_\ <._]-MK7[F5^&?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K@OC_-);_ ?XD2Q.T<
MJ>&M2970X*D6LA!![&N]KS_]H3_D@7Q+_P"Q9U/_ -)9* /YEZ^Y_P#@CC"D
MG[75PSHK-'X:O60L,E3YD R/0X)'XFOABONG_@C;_P G<7G_ &+-[_Z-MZ /
MV_HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O*O
MVL?^36?C)_V)FL_^D,U>JUY5^UC_ ,FL_&3_ +$S6?\ TAFH _FLK[__ ."*
MG_)TWBG_ +$RZ_\ 2ZQKX K[_P#^"*G_ "=-XI_[$RZ_]+K&@#]J:*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY5_X*C_\F)_$
MW_N&?^G2TKZJKY5_X*C_ /)B?Q-_[AG_ *=+2@#\ :_53_@AC_S6S_N"?^W]
M?E77ZJ?\$,?^:V?]P3_V_H _52BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Q6_P""U?\
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MK\,_^"DW_)ZGQ%_[AW_IMM:YL1\)T4/B/F:BBBN [3^JBBBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'VVN:THNCFM"<?9J,X[6_#\K-&5=5<LJPFIN49;W\K7_ #T9]R?MZ?\ )O\
M<_\ 82MOYM7SI_P3S_Y+;JG_ & I_P#T=!7T7^WI_P F_P!S_P!A*V_FU?.G
M_!//_DMNJ?\ 8"G_ /1T%8Y?_P BVOZO_P!)1KF/^_4/1?\ I3/M7XX?&72O
M@AX'GU[44-S<.WDV5BK;6N)B"0N>P &2>P'K@5^?.N_M(?&3XO>(&ATG5]9B
ME<EX=+\+K)$44=@(OG8#U8FN\_X*'>*)]0^*FC:'O;[+INFK*$SQYDKMN/\
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M2QIB:WM,7.E7J.$4[*WX?>M;_H>>?#3]LSXC_#K7H8/$%_<>)-*CD\NZL-4
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MW_)ZGQ%_[AW_ *;;6N;$?"=%#XCYFHHHK@.T_JHHHHH **** "BBB@ HHHH
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M?F62+(RE?=5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_8F6O_I=?5]F_P#!-G_DROX=?]Q'_P!.5U73A_B.>O\ "?3-%%%=YQ!1110
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MV_\ Z+:E_;_\"^)/&5QX,/A_P]JNNBW6Z\[^S;*6X\O)BQNV*<9P>OH:U_V
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M6J%Y1&^TAPHY(!4YQTSGIFOC_P"&OQ:^(GPYCO=%\':I>V!OY 9K.WM4F=G
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M^?L?O1[]17@/_#>7P+_Z'G_RDWW_ ,8H_P"&\O@7_P!#S_Y2;[_XQ1]0Q?\
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M^?L?O1[]17@/_#>7P+_Z'G_RDWW_ ,8H_P"&\O@7_P!#S_Y2;[_XQ1]0Q?\
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M^HKP'_AO+X%_]#S_ .4F^_\ C%'_  WE\"_^AY_\I-]_\8H^H8O_ )\R_P#
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M\"_^AY_\I-]_\8H^H8O_ )\R_P# 7_D'UW"_\_8_>CWZBO ?^&\O@7_T//\
MY2;[_P",4?\ #>7P+_Z'G_RDWW_QBCZAB_\ GS+_ ,!?^0?7<+_S]C]Z/?J*
M\!_X;R^!?_0\_P#E)OO_ (Q1_P -Y? O_H>?_*3??_&*/J&+_P"?,O\ P%_Y
M!]=PO_/V/WH]^HKP'_AO+X%_]#S_ .4F^_\ C%'_  WE\"_^AY_\I-]_\8H^
MH8O_ )\R_P# 7_D'UW"_\_8_>CWZBO ?^&\O@7_T//\ Y2;[_P",4?\ #>7P
M+_Z'G_RDWW_QBCZAB_\ GS+_ ,!?^0?7<+_S]C]Z/?J*\!_X;R^!?_0\_P#E
M)OO_ (Q1_P -Y? O_H>?_*3??_&*/J&+_P"?,O\ P%_Y!]=PO_/V/WH]^HKP
M'_AO+X%_]#S_ .4F^_\ C%'_  WE\"_^AY_\I-]_\8H^H8O_ )\R_P# 7_D'
MUW"_\_8_>CWZBO ?^&\O@7_T//\ Y2;[_P",4?\ #>7P+_Z'G_RDWW_QBCZA
MB_\ GS+_ ,!?^0?7<+_S]C]Z/?J*\!_X;R^!?_0\_P#E)OO_ (Q1_P -Y? O
M_H>?_*3??_&*/J&+_P"?,O\ P%_Y!]=PO_/V/WH]^HKP'_AO+X%_]#S_ .4F
M^_\ C%'_  WE\"_^AY_\I-]_\8H^H8O_ )\R_P# 7_D'UW"_\_8_>CWZBO ?
M^&\O@7_T//\ Y2;[_P",4?\ #>7P+_Z'G_RDWW_QBCZAB_\ GS+_ ,!?^0?7
M<+_S]C]Z/?J*\!_X;R^!?_0\_P#E)OO_ (Q1_P -Y? O_H>?_*3??_&*/J&+
M_P"?,O\ P%_Y!]=PO_/V/WH]^HKP'_AO+X%_]#S_ .4F^_\ C%'_  WE\"_^
MAY_\I-]_\8H^H8O_ )\R_P# 7_D'UW"_\_8_>CWZBO ?^&\O@7_T//\ Y2;[
M_P",4?\ #>7P+_Z'G_RDWW_QBCZAB_\ GS+_ ,!?^0?7<+_S]C]Z/?J*\!_X
M;R^!?_0\_P#E)OO_ (Q1_P -Y? O_H>?_*3??_&*/J&+_P"?,O\ P%_Y!]=P
MO_/V/WH]^HKP'_AO+X%_]#S_ .4F^_\ C%'_  WE\"_^AY_\I-]_\8H^H8O_
M )\R_P# 7_D'UW"_\_8_>CWZBO ?^&\O@7_T//\ Y2;[_P",4?\ #>7P+_Z'
MG_RDWW_QBCZAB_\ GS+_ ,!?^0?7<+_S]C]Z/?J*\!_X;R^!?_0\_P#E)OO_
M (Q1_P -Y? O_H>?_*3??_&*/J&+_P"?,O\ P%_Y!]=PO_/V/WH]^HKP'_AO
M+X%_]#S_ .4F^_\ C%'_  WE\"_^AY_\I-]_\8H^H8O_ )\R_P# 7_D'UW"_
M\_8_>CWZBO ?^&\O@7_T//\ Y2;[_P",4?\ #>7P+_Z'G_RDWW_QBCZAB_\
MGS+_ ,!?^0?7<+_S]C]Z/?J*\!_X;R^!?_0\_P#E)OO_ (Q1_P -Y? O_H>?
M_*3??_&*/J&+_P"?,O\ P%_Y!]=PO_/V/WH]^HKP'_AO+X%_]#S_ .4F^_\
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M/?J*\!_X;R^!?_0\_P#E)OO_ (Q1_P -Y? O_H>?_*3??_&*/J&+_P"?,O\
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M?DX R3C-)8+%-M*E+3R?^17US#))NI'[T?7U%> _\-Y? O\ Z'G_ ,I-]_\
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MY_\ *3??_&*/J&+_ .?,O_ 7_D'UW"_\_8_>CWZBO ?^&\O@7_T//_E)OO\
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MY_\ *3??_&*/J&+_ .?,O_ 7_D'UW"_\_8_>CWZBO ?^&\O@7_T//_E)OO\
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MY_\ *3??_&*/J&+_ .?,O_ 7_D'UW"_\_8_>CWZBO ?^&\O@7_T//_E)OO\
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MY_\ *3??_&*/J&+_ .?,O_ 7_D'UW"_\_8_>CWZBO ?^&\O@7_T//_E)OO\
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M_0\_^4F^_P#C%'U#%_\ /F7_ ("_\@^NX7_G['[T>_45X#_PWE\"_P#H>?\
MRDWW_P 8H_X;R^!?_0\_^4F^_P#C%'U#%_\ /F7_ ("_\@^NX7_G['[T>_45
MX#_PWE\"_P#H>?\ RDWW_P 8H_X;R^!?_0\_^4F^_P#C%'U#%_\ /F7_ ("_
M\@^NX7_G['[T>_45X#_PWE\"_P#H>?\ RDWW_P 8H_X;R^!?_0\_^4F^_P#C
M%'U#%_\ /F7_ ("_\@^NX7_G['[T>_45X#_PWE\"_P#H>?\ RDWW_P 8H_X;
MR^!?_0\_^4F^_P#C%'U#%_\ /F7_ ("_\@^NX7_G['[T>_45X#_PWE\"_P#H
M>?\ RDWW_P 8H_X;R^!?_0\_^4F^_P#C%'U#%_\ /F7_ ("_\@^NX7_G['[T
M>_45X#_PWE\"_P#H>?\ RDWW_P 8H_X;R^!?_0\_^4F^_P#C%'U#%_\ /F7_
M ("_\@^NX7_G['[T>_45X#_PWE\"_P#H>?\ RDWW_P 8H_X;R^!?_0\_^4F^
M_P#C%'U#%_\ /F7_ ("_\@^NX7_G['[T>_45X#_PWE\"_P#H>?\ RDWW_P 8
MH_X;R^!?_0\_^4F^_P#C%'U#%_\ /F7_ ("_\@^NX7_G['[T>_45X#_PWE\"
M_P#H>?\ RDWW_P 8H_X;R^!?_0\_^4F^_P#C%'U#%_\ /F7_ ("_\@^NX7_G
M['[T>_45X#_PWE\"_P#H>?\ RDWW_P 8H_X;R^!?_0\_^4F^_P#C%'U#%_\
M/F7_ ("_\@^NX7_G['[T>_45X#_PWE\"_P#H>?\ RDWW_P 8H_X;R^!?_0\_
M^4F^_P#C%'U#%_\ /F7_ ("_\@^NX7_G['[T>_45X#_PWE\"_P#H>?\ RDWW
M_P 8H_X;R^!?_0\_^4F^_P#C%'U#%_\ /F7_ ("_\@^NX7_G['[T>_45X#_P
MWE\"_P#H>?\ RDWW_P 8H_X;R^!?_0\_^4F^_P#C%'U#%_\ /F7_ ("_\@^N
MX7_G['[T>_45X#_PWE\"_P#H>?\ RDWW_P 8H_X;R^!?_0\_^4F^_P#C%'U#
M%_\ /F7_ ("_\@^NX7_G['[T>_45X#_PWE\"_P#H>?\ RDWW_P 8H_X;R^!?
M_0\_^4F^_P#C%'U#%_\ /F7_ ("_\@^NX7_G['[T>_45X#_PWE\"_P#H>?\
MRDWW_P 8H_X;R^!?_0\_^4F^_P#C%'U#%_\ /F7_ ("_\@^NX7_G['[T>_45
MX#_PWE\"_P#H>?\ RDWW_P 8H_X;R^!?_0\_^4F^_P#C%'U#%_\ /F7_ ("_
M\@^NX7_G['[T>_45X#_PWE\"_P#H>?\ RDWW_P 8H_X;R^!?_0\_^4F^_P#C
M%'U#%_\ /F7_ ("_\@^NX7_G['[T>_45X#_PWE\"_P#H>?\ RDWW_P 8H_X;
MR^!?_0\_^4F^_P#C%'U#%_\ /F7_ ("_\@^NX7_G['[T>_45X#_PWE\"_P#H
M>?\ RDWW_P 8H_X;R^!?_0\_^4F^_P#C%'U#%_\ /F7_ ("_\@^NX7_G['[T
M>_45X#_PWE\"_P#H>?\ RDWW_P 8H_X;R^!?_0\_^4F^_P#C%'U#%_\ /F7_
M ("_\@^NX7_G['[T>_45X#_PWE\"_P#H>?\ RDWW_P 8H_X;R^!?_0\_^4F^
M_P#C%'U#%_\ /F7_ ("_\@^NX7_G['[T>_45X#_PWE\"_P#H>?\ RDWW_P 8
MH_X;R^!?_0\_^4F^_P#C%'U#%_\ /F7_ ("_\@^NX7_G['[T>_45X#_PWE\"
M_P#H>?\ RDWW_P 8H_X;R^!?_0\_^4F^_P#C%'U#%_\ /F7_ ("_\@^NX7_G
M['[T>_45X#_PWE\"_P#H>?\ RDWW_P 8H_X;R^!?_0\_^4F^_P#C%'U#%_\
M/F7_ ("_\@^NX7_G['[T>_45X#_PWE\"_P#H>?\ RDWW_P 8H_X;R^!?_0\_
M^4F^_P#C%'U#%_\ /F7_ ("_\@^NX7_G['[T>_45X#_PWE\"_P#H>?\ RDWW
M_P 8H_X;R^!?_0\_^4F^_P#C%'U#%_\ /F7_ ("_\@^NX7_G['[T>_45X#_P
MWE\"_P#H>?\ RDWW_P 8H_X;R^!?_0\_^4F^_P#C%'U#%_\ /F7_ ("_\@^N
MX7_G['[T>_45X#_PWE\"_P#H>?\ RDWW_P 8H_X;R^!?_0\_^4F^_P#C%'U#
M%_\ /F7_ ("_\@^NX7_G['[T>_45X#_PWE\"_P#H>?\ RDWW_P 8H_X;R^!?
M_0\_^4F^_P#C%'U#%_\ /F7_ ("_\@^NX7_G['[T>_45X#_PWE\"_P#H>?\
MRDWW_P 8H_X;R^!?_0\_^4F^_P#C%'U#%_\ /F7_ ("_\@^NX7_G['[T>_45
MX#_PWE\"_P#H>?\ RDWW_P 8H_X;R^!?_0\_^4F^_P#C%'U#%_\ /F7_ ("_
M\@^NX7_G['[T>_45X#_PWE\"_P#H>?\ RDWW_P 8H_X;R^!?_0\_^4F^_P#C
M%'U#%_\ /F7_ ("_\@^NX7_G['[T>_45X#_PWE\"_P#H>?\ RDWW_P 8H_X;
MR^!?_0\_^4F^_P#C%'U#%_\ /F7_ ("_\@^NX7_G['[T>_45X#_PWE\"_P#H
M>?\ RDWW_P 8H_X;R^!?_0\_^4F^_P#C%'U#%_\ /F7_ ("_\@^NX7_G['[T
M>_45X#_PWE\"_P#H>?\ RDWW_P 8H_X;R^!?_0\_^4F^_P#C%'U#%_\ /F7_
M ("_\@^NX7_G['[T>_45X#_PWE\"_P#H>?\ RDWW_P 8H_X;R^!?_0\_^4F^
M_P#C%'U#%_\ /F7_ ("_\@^NX7_G['[T>_45X#_PWE\"_P#H>?\ RDWW_P 8
MH_X;R^!?_0\_^4F^_P#C%'U#%_\ /F7_ ("_\@^NX7_G['[T>_45X#_PWE\"
M_P#H>?\ RDWW_P 8H_X;R^!?_0\_^4F^_P#C%'U#%_\ /F7_ ("_\@^NX7_G
M['[T>_45X#_PWE\"_P#H>?\ RDWW_P 8H_X;R^!?_0\_^4F^_P#C%'U#%_\
M/F7_ ("_\@^NX7_G['[T>_5RGQ5^&^C_ !@^''B/P7KT7FZ3K=E)9S8 +)N'
MRR+_ +2-M93V*@UY9_PWE\"_^AY_\I-]_P#&*/\ AO+X%_\ 0\_^4F^_^,4?
M4,7_ ,^9?^ O_(/KN%_Y^Q^]'\__ ,5?AOK'P?\ B/XC\%Z]%Y6K:)>R6<V
M0K[3\LB_[+KM93W# U^W_P#P3 _9N_X4)^SC8ZKJ=KY'BSQGY>L:AO7#Q0%3
M]D@/?Y8V+D$95YY%/2OG']J33_V>/V@OVHOAI\0V\9VXT.!_+\76KZ3>@WD-
MN#);#;Y'S;R/(?N$*D?=K[/_ .&\O@7_ -#S_P"4F^_^,4?4,7_SYE_X"_\
M(/KN%_Y^Q^]'OU%> _\ #>7P+_Z'G_RDWW_QBC_AO+X%_P#0\_\ E)OO_C%'
MU#%_\^9?^ O_ "#Z[A?^?L?O1[]17@/_  WE\"_^AY_\I-]_\8H_X;R^!?\
MT//_ )2;[_XQ1]0Q?_/F7_@+_P @^NX7_G['[T>_45X#_P -Y? O_H>?_*3?
M?_&*/^&\O@7_ -#S_P"4F^_^,4?4,7_SYE_X"_\ (/KN%_Y^Q^]'OU%> _\
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M45X#_P -Y? O_H>?_*3??_&*/^&\O@7_ -#S_P"4F^_^,4?4,7_SYE_X"_\
M(/KN%_Y^Q^]'OU%> _\ #>7P+_Z'G_RDWW_QBC_AO+X%_P#0\_\ E)OO_C%'
MU#%_\^9?^ O_ "#Z[A?^?L?O1[]17@/_  WE\"_^AY_\I-]_\8H_X;R^!?\
MT//_ )2;[_XQ1]0Q?_/F7_@+_P @^NX7_G['[T>_45X#_P -Y? O_H>?_*3?
M?_&*/^&\O@7_ -#S_P"4F^_^,4?4,7_SYE_X"_\ (/KN%_Y^Q^]'OU%> _\
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M* "BBB@ HHHH **** /S^_X*,?\ )2O#'_8*/_HYZ]A_X)Y_\D5U/_L-3?\
MHF&O8/B-\ _ GQ:U*UU#Q7H7]JW=M%Y$4GVR>':F2V,1R*#R3UK8^'GPR\-?
M"G19=(\+:;_9>GR3M</#Y\LV9" "V9&8]%'&<<5[/UVG]06%L^;\-[GD2P=1
MX_ZU=<OX_#8ZBBBBO&/7"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M_#/_ (*3?\GJ?$7_ +AW_IMM:_<ROPS_ ."DW_)ZGQ%_[AW_ *;;6N;$?"=%
M#XCYFHHHK@.T^L****_<S\:"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0J#@D9
MQR*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF6O_ *77U?9O_!-G_DROX=?]Q'_TY75=.'^(YZ_PGTS1117><04444 %%%%
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M#K5%1I2JOH?8=%?*?[ ?C/Q!XR\,^+I=?UW4M<E@O(%B?4KR2X:,%&)"ER<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ_WEVM_P*O5Z_/C_ ()]_$O_ (1_X@:CX0NIMMGKD/FVZL>!<Q G _WDW?\
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MI?<F?K'\)_\ DEO@[_L#6?\ Z(2K'C_0_#VO>$M3@\46UI/HH@=KAKQ5*QJ
M27R?ND=01R"*_)VT^,_Q!L+6&UM?'7B6VMH46.*&'5[A4C0# 50'P    !5'
M7OB5XO\ %5G]DUKQ5K>L6N0?(O\ 49ITR.AVNQ%54R.I4FY>T2NS.CG$*5.,
M'!NR2(_">G3ZEX[TBRT?S);B;48HK0CAB3( A]CTK]EJ_-7]C'Q=\./"'CZ*
MY\6)<0>()'\K3=0G*FRMRPVY8=5<Y(W'*@'MUK]*JRSRHW.%.SLKZ][V_P C
M3)X*U2HFKNVG:U_\S\^/^"AGBHZM\3]#\/Q'<FEV'F,H/_+29LXQZ[43\Z^S
M/ /A,>!O@MI&@[ DECHRQ2@?\]/*RY_%BQ_&O@>^_P"+W?MG^7S/:7&OB/'7
M-M;GG\-D1_.OTEUW_D!ZA_U[R?\ H)KCS#]S@*-#NG)_/_AV=^!_?9C5K=FH
MKY:?HC\9-%_Y#-A_U\1_^A"OVIK\2XY&C=71BCJ<AE."#ZBNU_X7E\1_^B@>
M*?\ P=7/_P 77T^98&6.4%&5N6_XV_R/F,OQD<'*;DK\UOPO_F?J3\9/#_AG
M7OASKR^*K:UETN&SED>:Z5<PD*<.K'[K ]".<U^1^@&X77M--IN^U?:8_)V?
M>W[AMQ[YQ6^WB3QU\4]0M=$FUG7?%%U<2 065U>RW)=^V%=CSQ^E?5_[,/[%
MNL:!XHL/%OCV**S-@XGL]'6197,HY624J2H"G!"@DD@9QC!Y<+3AD\)RK5+W
MV7IV]3JQ526;.,*,+6OKZVW]#[73.Q=WWL<UYI^T=\2!\+?@_P"(-:CD"7S0
M_9++/4SR?*I'TR6_X#7IE?!/_!0SXDG4_%6C>"K67,&FQ_;;M1T,T@P@/T3)
M_P"!U\GA*'UJO&ET>_IU_P CZG$5OJU&57JEIZ[+\3Y]^"_PHO\ XT>-CH-E
M(T;_ &2>ZDGQG;L0E<_[TA1?^!4SX/\ CJZ^$'Q8T3771XSI]WY=Y"1\QB.4
MF7'KM+?B!7V!_P $\OAU_97@W6O&-S%B?59OLEJS#GR(C\Q'LSDC_MF*^>?V
MS/AQ_P *_P#C=J<T$7EZ=K8_M*# PH9R1*H^CAC]&%?:K&1J8V6$E\-K?/JO
MN?X'QWU1K!+%+XKW^6R?W[>I^GMM<Q7EO%<0.LL,J!T=3D,I&01^%25X#^Q/
M\2_^$^^"]G8W,WF:GH#_ -G2@GYC$!F%OIL^7_@!KWZOA\31>'K2I/H_^&/L
M<-66(HQJKK_3_$\B_:J^)7_"L?@MKE[#*(]2OD_L^SYPWF2 @L/]U-S?A7YS
M?!GX0ZE\9?$.HZ7IQ*/9Z;<7S,%SED7]VG_ G*+]":]N_P""@?Q*_P"$@^(6
MG>$K:;=::'#YMPJG@W$H!Y_W4V_]]&O8/^"?OP[_ .$?^&FH>*;B+;=:]<;8
M68<_9XB5'YN9/R%?182^!RZ>(VE/;\E^LCP\9;%XZ&'WC'?\W^B]3XX_9_\
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M_+:QG650?0E2<'V/-?*W[1_[%>L_$[XBR>(_"%SHFEP7D"F\AOI)8BUP"07
M2)ARNW/(Y!/>OA:SO]3\,ZGYMI<7>DZC V/,A=H98SW&1@@U[C\,_P!MGXC>
M!+B"+4[_ /X2S2E(#VVJ<S;>^V<#?N]VW#VKLCE5?"S]MA9IOS_K_(XY9G2Q
M$'2Q,++R/M/]EGX1^(_@K\/;KP[XCO=/O9/M[W-NVGRR2(D;(@*G>B$'<K'@
M=Z]CKD/A5\4-%^+_ (,M/$>AR,;:8E)8)<"2"48W1N/49'U!![UU]?,8F52=
M:3JJTNI]#AHTX4HJD[QZ!7YL?M\_\E\?_L%VW_L]?I/7YL?M\_\ )?'_ .P7
M;?\ L]>CD_\ O<?G^1QYI_ND_E^:/IG]@?\ Y(#'_P!A.Y_]DKV_QEX$T#Q_
MHMQI?B#2K74[.92I6>,%EX^\K=58=B.17YL?"+]KKQA\%_""^'-$TW0[JQ$[
MW'F:A!,\FY\9&4E48X]*U/&?[<WQ-\8:/<::LNEZ%%<(8Y)=)MG24J1@@,[N
M5^HP?>N_%Y7B:V(E4A:S?<\_!YEAZ-"-.=[KR/#_ !1IL&B^)M7T^UF^T6UI
M>30139SO57*JWX@ U^O7PQU*;4OAEX5O[US]HGTBUFF>0\[C"I8D_F:_+/X(
M_!O6?C7XVM-'TZ&1;%75]0O]IV6T.?F8GIN(!"CN?;)'ZD>.?!,_B+X;:EX5
MT;4?[!:XLOL,-VL1D\B/ 4X4,O\ #D=>,YK3.YQ4*=%N\OZU^9&40<JTZR5H
M_P#!_0^9_BU_P4$L_#^LW.E^"-&AUH6[F-M4OI&6!V!P?+C7#,O^T6&>PQS7
MG%K_ ,%%?B DRFYT#PW+#GE(H+A&/XF9OY5WOPO_ ."?Y\-^/8-0\7ZGIWB#
MPY;1M(+2$21O-+QM$BD8V#DGYN2 ,8)K>_:>\._ S3/AKKMK!#X5TGQ/#;LU
MA%I"0QW7G#E5*Q#.#T.X8YK*,LNIN-*G!U&]V;2CCZO-4G-4TME_P?U/0?V>
M?VJ-#^/#3Z=]BDT/Q';Q>=)822"1)8P<%XWP,XR,@@$9[CFOFW]M3]HC_A,+
MC5?AO_PC_P!D_L;5ED_M/[;O\[8C+CRO+&W._P#O'I7F7['5]+8_M&>$#&2!
M+)/$XSU5H)!C^1_"O?\ ]N[X/^$?#O@Q_&>GZ1]G\2ZEK$:75]]IF;S T<A8
M;&<H,E5Z*.E:5,-AL'CX)Q;C*UO*7-IUV^\SI8C$8O!5+-<RO=]X\KNMM_ZN
M?.W[./Q^_P"&?_$&K:G_ &#_ &]]OM5MO*^V?9MF'#;L^6^>G3 K]&OA;\2/
M^%M_":R\5_V=_97]H03G[)Y_G>7L=T^_M7.=N>@ZU\)_L5?"7PI\6_&'B&Q\
M6:5_:MK:V"S0Q_:)8=KF0 G,;J3QZU^@_A_P;H_P_P#!(T#0+/[!I-I#*(;?
MS7DV;BS'YG)8\L3R>]89]*AK%1?M._2UGY_H7DD:UU+F]R^W6^GE^I^0N@3)
M;^,--EE=8XDOXV9V. H$@))/I7V;\5O^"A2:7J\^G^ ]%MM2@A8I_:FJ%_*E
M(ZE(D*MM]&+#/I7Q']G>\U+R(ANDEFV*/4EL"OU)^'?[*?P[\%^$;72[SPOI
M>N7YB7[7?ZE:I/++(1\Q4N#L&>@7&.._->OF<L/35.>(3E:]E]V_I^IY^ 5>
M52K"@[7M=]M_S_0\%^&G_!1&XNM8@M/'.@6EO93.%.H:/O7R,_Q-$[,6'KAL
MXZ ]*^M?'GC23PI\/=6\4:98KKPLK,WT=M'<>6)XP-Q*N%;^')'!SBOS!_:6
M^'NG_"_XS^(-!TF-HM+C:.>VB9BVQ)(U?;D\D D@9["OT'_9<NO^$F_9O\(+
M>G[2CV#V<@;NB2/$%_[Y4"O&S##T%AJ>+P\;*5M/57^6UCU,#B*RQ,L)B'>W
M7T:_.]SSKX,_MR6_Q8^(NE^%;CPC_8?]H>8L=Y_:?G@.J%@NWR5Z[<=>I%?1
MWBSQ';^$/"^K:Y=C-MIUK+=2#.,A%+8S[XQ7Y/ZO:WGP.^.$T:!A<>'-9$D?
M/+I'(&3_ +Z3'YU]V_MI?$"#2_V=YS93J?\ A(G@MH&4_?B;]ZQ'L47'_ JG
M'8*ES49896C4LOOMKKY/\"\#BJEZT,2[N%W]U[K3T_$\\T'_ (*-0:KKFG65
MUX$^PVMS<1PRW7]L[_)5F +[?(&< YQD9QU%?9F1C/:OQ/:UFCMXKEHG6"1F
M1)2#M9EP6 /J-R_F*_3Z\^,2P_LCCQP9@;R30E0,3UNRODX_[^Y_*MLVP%*A
M"$L/&UW;=[O;?YF&5XVI7J2IUY=+[+3O^:/+-;_X*')8^*K[1].\!-JB0WCV
MEO<+K&PW&'*JP7R#C=P<9/6OICQ_\2](^%O@F7Q)XFD^Q6\**&AA/F.\K#B*
M/IN.<CMTR<#-?F_^R#X%/CSX\: DL9DM-,8ZI<'&1B+!3/UD*#\:^U_VH/V=
M]8^/UMHT-AXEATBVTWS'^QSV[.DTC8 <L&XP!@?*>I]:RQV%PN'JTJ/P_P S
MU>GX[V?3\#7!8G$8B-6MO;X5IOZZ;77X]3Y]\3?\%&O$TU\__".^%M)L[,'"
M?VFTMQ(P[$[&C ^G/U-'AK_@HUXFAO4_X2#PKI-[:$@/_9KRV\@'<C>T@/TX
M^HKV#X'_ +)/A/X2>&;R[^(%KH.OZO+*Q:ZOE66T@A'W543* #U)8C/.,X%?
M.'[9EE\+H->T2;X=SZ1]I9)4U&WT,J;=<%?+;Y/D!Y<87TYKLI?V?5K+#TZ5
MUWU[7]3EJ?7J=)UZE3E?;3_AOZ[GWSX#^)FE_%#P'%XG\,9OH9HWV6TQ\IUF
M4<Q2==K9P,\CD$9&*^7D_P""C0M]66RU#X>/9!)_)N&_MC>T.&PQV_9QDCGC
M(Z5I_P#!..^ED\">+;1F)AAU*.55SP"\6#_Z *\!_;4^&_\ P@/QKO[NWB\O
M3M=3^T8< !0Y.)5'_ P3_P "%<]#!X:./GA:JNNFK[7MIY/\#>IBJ\\!'$TW
M9K?1=[7U\_S/TVM[B.ZMXYX762*10Z.IR&4C((_"O(OVCOVBK7]GW2=(N6TC
M^W;W4IFCCM/M?V?:BKEGW;'Z$J,8[]>*J?L=_$#_ (3[X%Z(99?,OM)SI=QD
MY/[L#RS^,93\<U\>_MS>/?\ A+_C;<:;#)OL]!@6Q4#IYI^>0_FP7_@%<6'P
M/-COJT]E>_HO\]/O.RKC+8+ZQ'=I6]7_ ):_<?7G[-_[2EW^T'=:UCPE_8-A
MIB1[KHZC]H\R1R<(%\I.RDDY]..:]RKQ+]COX=_\*]^!NC>=%Y=_K&=4N,C!
M_> >6#](PG'J37MM<F.C2CB)0HJT5I_G^)O@I59T(SK.[>O^7X!7XU_$3_DH
M'B?_ +"EU_Z-:OV4K\:_B)_R4#Q/_P!A2Z_]&M7KY%_&GZ?J>=G/\"/K^C/U
MS^'IQ\/_  T?^H7;?^BEKYATO_@H*NH>-K30'\"BW2?4$L3=MK.0@,@3>5\@
M=,YQG\:^G?A__P D]\-_]@NV_P#1*U^/WB0;O$FJ ?\ /W+_ .AFIR_"TL5B
M:T:JO;;?N^P8O$5,/A*4J;L]/R/MWXO_ /!0*VT#6+C2_ FDVVLBW8HVJW[-
M]G=AU\N-2"R_[189[#'-<_\ #_\ X*+:DVK10^-/#EE_9\C!6N]%\Q'A']XQ
MR,^_Z!A^/2O=_A'^REX!\%^";"UU/PUINO:O-;H][>:G;I<,TI7+!-X(1020
M-N. ,Y/-?"?[4WPUTWX5_&;5M&T>-H=*D2.[MX6)/E+(N2@)Z@,&Q[5TX6GE
M]:H\*H-O^9];?EY&&)GCH4UBN=)=ET3_ #\S]4=+U2TUS3+34;"=+JRNHEG@
MGC.5D1@"K#V((K\R/VV?^3CO$O\ USM?_2>.OM/]C'5)-4_9S\+&5V=X/M%O
MEO[JSR!1^"X%?%G[;/\ R<=XE_ZYVO\ Z3QUSY;2]AF<J7927XHWQE5ULO51
M[NQZOX*_;%T?X,_ 7P=X?TJP_M_Q*EK*TT;2>7!:YFD*AV )9L$':,<'DBLK
M0_\ @HSXOAU)&UGPQHEWI^?FCL?.@EQ[.SN/_':[S]C#]F_PGJGPXMO&7B71
M[77M0U.23[-#J$8EA@A1RG^K;*EF*L<D'C&,<YX+]O'X,^&OA_<>'->\-Z7;
MZ,FHM+;W5K9H(X2RA65E0<*<%@< #@5V?[#+&2H3@Y2DW=^>KM^AQP6,6#C5
MA.T8Q5EW2TO^I]J?"_XF:+\7/!MGXDT*5VL[C*/%, )8)%^]&X!.&'Y$$$<&
MO//VDOVF/^&>Y-"3_A'/[?\ [4$QS]N^S>5LV?\ 3-\YW^W2O'O^";NJ2R:3
MXYTTR$PPSVMPL?8,ZR*Q_$(OY50_X*2?\?'@3_<N_P"<5>8\'3IYDL,]8M_^
MVW/2IXJ=3+Y8C:27ZV/??V;_ -H;_AH+2=:O?[ _L'^S9XX?+^V_:?,W*3G/
MEIC&/>OE?_@HI_R5O0/^P*G_ */EKT;_ ()O_P#(I^-/^OVW_P#1;5YS_P %
M%/\ DK>@?]@5/_1\M==.C"AFRITU9+_Y$YI5IU\JE4J.[?\ \F+\!?VJ-%^
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MKV]>IQ_QR_;8\-?"O5)]#T:S/BC78#LG6.81VUNW]UGP2S#NJCV)!XKP5?\
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MUBX5%>:G!]?Z_JWF>QT445X)[84444 %%%% !7X9_P#!2;_D]3XB_P#<._\
M3;:U^YE?AG_P4F_Y/4^(O_<._P#3;:US8CX3HH?$?,U%%%<!VGUA1117[F?C
M04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5[]^P;_ ,G7>!O^W[_T@N*\!KW[]@W_ ).N\#?]OW_I!<5P
M8_\ W2M_AE^3.S!?[U2_Q+\S]>J***_&S]9"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** /Q6_X+5_\G3>%O^Q,M?\ TNOJ^S?^";/_ "97
M\.O^XC_Z<KJOC+_@M7_R=-X6_P"Q,M?_ $NOJ^S?^";/_)E?PZ_[B/\ Z<KJ
MNG#_ !'/7^$^F:***[SB"BBB@ HHHH P/'WB^U\ ^"]:\17I M]-M9+@J?XB
M!\JCW)P/QK\=]>UJZ\2:YJ&JWTAEO+Z=[F9R<Y=V+']37W7_ ,%#/B1_9/A#
M1_!EM+BXU27[9=*/^>$9^4'ZOS_P"O,O^"?7PZ_M[XC:EXKN8MUKH=OY<#$<
M?:)05R/H@?\ [Z%?5Y5&.%PU3&3^7R_S>GR/FLTDZ]:GA(>K^?\ DM?F>!6'
MQB\?:58V]E9>./$EG9VZ+%#;V^K7"1QH!@*JA\  < "L7Q%XMUSQA=QW6O:S
MJ&MW,:>6DVHW4EPZKDG:&<D@9)./>OV@KG?B)X-MOB%X&USPY=@>3J5J\&X_
MP,1\K?4-@_A26=PB^;V/X_\  '_8\VN7VVGI_P $^%_^"?OQ,'AWXB:AX2NY
M=MIKL.^W#'@7,0) '^\F_P"I5:^D/VVO!<WC#X#ZG+;1^;<Z1-'J04#G8N5D
M_)'8_P# :_.33;[5?AEX[@NHP;;6=#OPVT_PRQ/RI]1E2/I7Z\^%?$&G_$'P
M9INL6ZK-IVK6:3"-\,-KKRC?3)!'L:,WA[.K3QE/R^]:K[U^0LJGS0J82KY_
M<]']WZGYB_LH_$NT^%OQITC4M2F6WTJ[5["[F8X6-),8<GT#A"?8&OU4CD2:
M-9(V5T8!E93D$'H0:_.']I/]C_7/ASJ]YK?A2QGUCPG,S2^7;H9)K'/)1U')
M0=G'0?>QU/FO@K]I+XF?#O2TTS0O%EW;6$8VQVUQ'%<I$!_"@E1M@]EP*Z<5
MAH9M&-?#R5TK-/\ 7L_S.?#UIY7*5&O&\7JFOT_K0_2/]H#XK6_P?^%^KZV;
MB.'4VB:#3HVP3)<L,)A3UQ]X^RFOFG]GS]L_Q]X\\?:%X2U71],UC[=*(GO(
M5:WF1 "SR-@E#M4$X"KG'6OE;Q%XN\:_&KQ);_VG>:EXIUB0^7;VZ(9&&>JQ
MQ(,+]% K[M_8^_9CN/A'8S>)O$T2KXIOHO*CM@0PLH3@E21QO8@9QT  ]:YY
M8/#Y?AI/$VE-[?\  Z^K-_K=?'5XQPUXQ6[_ ,^GHC6_;L_Y-YU/_K]M?_1@
MKY0_83_Y.&TW_KRNO_1=?5_[=G_)O.I_]?MK_P"C!7YW>!/B!KWPS\11:YX;
MO_[-U6-&C2X\F.7"L,,-KJR\CVK7*(.K@:U-;MM??%&>;24,71F]DD_NDV?L
MI17Y;_\ #:7QE_Z''_REV7_QFC_AM+XR_P#0X_\ E+LO_C-</]AXG^:/WO\
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MVM?SU.K)*].RHW]Z]_EH?E;X:_Y'72O^PA%_Z,%?LU7XR^&O^1UTK_L(1?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPM_V)EK_ .EU]7V;_P $V?\ DROX=?\ <1_].5U7QE_P6K_Y.F\+?]B9:_\
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M.GH*W**?/+FYKZBY8I<J6AC>&_!GA_P;#/%H&A:;H<4[!I4TVSCMUD(& 6"
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_3BO::*U&>'J.G/=$T:T:\%4ALPHHHK W"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "OPS_X*3?\ )ZGQ%_[AW_IMM:_<ROPS_P""DW_)ZGQ%_P"X=_Z;
M;6N;$?"=%#XCYFHHHK@.T^L****_<S\:"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@HHHK<P"BBB@ HKT/]GOX=Z;\6/C)X8\):O/=6VG:G.\4TMDZK,H$3N-I96
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ KW[]@W_DZ[P-_P!OW_I!<5X#7OW[!O\
MR==X&_[?O_2"XK@Q_P#NE;_#+\F=F"_WJE_B7YGZ]4445^-GZR%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 ?BM_P6K_Y.F\+?]B9:_P#I
M=?5]F_\ !-G_ ),K^'7_ '$?_3E=5\9?\%J_^3IO"W_8F6O_ *77U?9O_!-G
M_DROX=?]Q'_TY75=.'^(YZ_PGTS1117><04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\&_\
M!0[XD?VAXCT3P3;29AT^/[?>*.AE<8C!^B9/_ Z^Y]8U6VT+2;W4KR00VEG"
M\\TC=%15+$_D*_(7Q9KFI_&3XJ7VH)&TNHZ]J.V"'J1O<+$GX#:OX5[N38?V
MV)YWM#7YO;]7\CQ\UK^QPSBMY:?+K_E\S&U3PGJFC:%HVL7=LT6GZNLK6<I_
MY:"-]C_DU?HQ^P]\2QXZ^#5OI5Q-YFI>'I/L,@8Y8PGF%OIMRG_;.L']J;X%
MVL'[,>FV&EQ!Y_!L,<T3*.7C"A9S^.?,/NM?-O[$_P 3/^$!^-%G87$FS3?$
M"_V=+D\"4G,+?7?\OT<U[-2I'-,)44=XMV^6WWK3U/&A3EEN(I2EM)*_Z_<]
M?0_3:O.OB%^T-\/_ (5:U'I/BG7_ .R]0DA%PL/V*XFS&20#F.-AU4\9SQ7H
MM?G3_P %"O\ DM6F_P#8&A_]&RU\Q@</'%8B-*>SOMZ'TN+K2P]"56.ZM^:1
M]I:E^T'X TKP#9^,[CQ#$F@7I9;29HI%DN&5BK*D14.2"#_#QUZ<UY99_P#!
M0/X8W6I+;26^OVD);;]LFLHS$!_>PLK/C_@.?:OF_P#9M_9SU+]HRS%WKVMW
M5CX3T+_0;=(0#(S$F1HXLC:@!?<6(.2P&#V?^U5^RG9? O3=,US0-2O-0T6Z
MF^RRQZAL::&7:64[D505(5NP(QWSQ[,<#@:==X>K-N3>GEVN[;V^1Y'US&5:
M/MJ<$DEKYVWLNQ^AWA;Q9I'C;0[;6="U"#5-,N1F*XMVRI]0>X(/!!P0>M?#
M'[=7QA\(?$:WT#2O#NK_ -HW^DWERE[#]FFB\IL*N,NBAN5(^4GI6E_P3D\6
M7:^(/%?AII6:QDM4U".(GA)%<(Q ]2'7/^Z*\[_:S_9V_P"%-ZA;Z[_PD']K
M_P#"07]S+]G^Q>1Y'(?&[S&W??QT'2E0PE'"Y@J<Y/36/GZZ>O8=3%5<3@7.
M$5?52\EW7X=SI_V)/C?X*^$.F^+8O%NM?V3)?36S6Z_99YMX19 W^K1L8W#K
MCK7W#J>N>&_$WPVN]7O)_M/A*_TM[F:;9(F^S>(LS8 $@RA/  ;\:_.3]FW]
MF+_AH2SUZ?\ X27^P/[+DA3;]@^T^;Y@<Y_UJ8QL]^M?>OB;PO\ \(1^S;J_
MA[[3]M_LKPO-9?:?+\OS?+M67=MR<9QG&3CUK/.HT%5<HR?M-+KI:WIZ=2LE
M=9PC!K]WK9];\WKZ]#Q/X=_\,J?\)UH/_"*_\C)]MB_L[_D*_P"OW#9_K/DZ
MX^]QZU]<U^1O[.__ "7;P%_V&;7_ -&"OURK/-L/]7E!<\I7ON[E977]MS^X
MHVMLK=PHHHKP#WC\8_&G_(Y:]_U_W'_HQJ_87PAQX1T0_P#3C!_Z+6OQZ\:?
M\CEKW_7_ ''_ *,:OV$\)?\ (GZ-_P!>$/\ Z+6OJ\X=L'2?];'S67?[Y6^?
MYGG%G^UM\)[_ %R'1X/%?F:C-<K:1P_V==C,I;:%W&+'WN,YQ3OBK^U1\/OA
M#?OIVK:C-?ZO'S)IVEQ":6/_ 'B2$4^Q8'VK\P=3U"YTGQG=WUG*8+NVU!YH
M95 RCK(2I&?0@5]B_#']@>R\5>%;?7?'7B#55UO5(Q=FWL&0&$N-W[UY%<N_
M.3C&#D9/6HK9=A,/&%6K-\KZ=6_+3[S2&.Q%:I.C3BFT].R7GJ>N_#_]M;X9
M^/M6BTT7E[H%W,P2%=:@6))&/0!T=U7_ ($17M'B+Q#I_A/0;_6=5N/LNFV,
M+7%Q/L9]D:C).U02>.P!-?DG\:/A?<_!WXC:IX7N;@7BVQ5X+D+M\V)P&1B,
M\'!P1Z@U^@7P:CN_CE^R/8Z9?Z@T%WJ6F7&E27SIYK+L=X5<KN&X[54]1GUK
MGQV!H4Z,,30E[KM^)K@\96G7EAL0O>1\??MD_%#PY\5_B;8:KX7U0ZKIL.F1
MVYE\B6+:XDD8KMD53T8=L<UZW^Q_\>?A?\*?A;-IWB/6(]+UVYOI99U^P7$K
M/'A0F72-@1@'C/'/K7SW^T+\$_\ A0_C2V\/_P!L_P!N>=9I=_:/LOV?&YF7
M;MWO_=ZY[UZ)\ ?V-_\ A=_@%/$__"7_ -BYNI+?[+_9GG_<Q\V[SEZYZ8KW
M73P?U&,)3?LN_7?T[^1XW/BOKW-R+VG;IMZ]O,]<_P""C"QKX'\%"%52+[;-
ML51@ >4,8%8O_!-G_CX^('^Y8_SGK;_X*,Q^3X(\%)G.V^E7/TB%8G_!-G_C
MX^('^Y8_SGKS*/\ R**OK^J._$7_ +1I7WLOU/M+6M<T_P -Z5<ZGJM[!I^G
MVR>9-<W#A$1?4DU\]:]^WY\+]'O'@MEUO6D4X^T6%DHC/T\V1#^E<W^W'X1^
M)/Q!;1])\,^'[W4O#-K']JN7LV1C+<$D % V\A5_V<9?VKBO@9^P;;>+/!\>
ML>/;O6=$O;EF\G2[54@EA0$C,OF(QR<$A<# P<\\<&%PV%]C[?$S^2W^?];'
M?BL1B555##P^;V^7];GM/A#]N;X6^*[^*TFO-0\/R2,%1]7M@D>3ZO&SJH]V
M('O7O\,T=S#'+#(LL4BADD0@JP(R"".HK\L?VH/@-;_ 7QI9:=8:C-J6F7]M
M]I@>Y"B5,,596V@ ] <@#KTXK[*_82\377B#X"VT%W*TQTN^FLHF8Y(C 5U'
MT'F$#V K7%X&@L,L5AF[>?W?F8X?&5UB/JN(2OY>E_R.P\5_M4?"[P1XBOM"
MUKQ/]BU6R?R[BW_L^ZDV-@'&Y(BIX(Z$U8^(W[27@'X7Z997>L:QYDM[ MS:
MV-I&9+F6-AE6V<; 1W?;7YX?M6?\G#>-_P#K]'_HM*]E^ /[((^-_A=?&WCG
M7M2BCU E;2&R9!,\:?('9W5@!\N H7HHY[5K_9V&AAJ>)JS:32;]6MEH0\?7
MEB:F'IQ3:;2^3W>I[IX-_;H^&'B[5H]/EGU+P^\K!(YM8MT2%F)P 7C=PH]V
MP/>O3_B9\9O"/PCTF*_\2ZO':+.#]GMXP9)I\?W$7DCI\W09&37YF_M$_!Y?
M@A\2KGP[!>27]BT*75K/,H$AC;(PV.-P*L,CKC.!G%>C?LX_L]:A^TS)/K/B
MK7K^+0-'2/387C8-.^Q 5BC+ A%12IZ'[PXY)&M3+<(Z4<3";5/KW^7G<RAC
M\5"J\/."<^G_  ?*VI](Z'^WY\+]8U)+6X36]'C8X^UWUFAB'U\N1V'_ 'S7
MT3IVI6NL6%O?6-Q%>6=Q&LL-Q"X=)$(R&4C@@BOS"_:I_9ZM?@'XETJ+2[^Y
MU#1]4A>2%KP*9HV0@,K,H /WE(( Z].*^F_^">?BJ\UCX7:SH]S*TL.DZABV
MW'.R.1-Q0>VX,?\ @5<^*P.'>%^MX9NWGZV_,WP^,Q$<5]5Q"5WV]+_D>N>.
M?VEOAO\ #;Q%-H7B/Q'_ &=JL*J[V_V&YEP&&5.Y(V7D'UI_B[]HSX?^"?">
MF>(=1UU?L6J0"XL(HHG-Q<QD9#+$0& ]V  [FOA+]N3_ ).(UG_KUM?_ $4M
M=1^S?^RO+^T!H9\4>+]<O[;1H NGV,-H5\Z18E"\,X941?N@;3D[NF.73R_#
M_5(8FK-I.S?^2T_S"ICJRQ,L/3BGV_/7R/H+PW^WM\+]>U1+.X.L:&CG:+K4
MK1/)SVR8Y'(^I  [XKV#QQ\6?"?PY\,Q:_KVMVUKIDX!MI$;S3<Y&1Y2KDOD
M$'CC'/2OS<_:@^ L'P%\;6>GZ??3ZAI.H6WVBVDNMOG)ABK(Q4 $@X.0!UZ5
ML?LY_!'5_P!I;4Q:ZSKEW;^%_#<"PAE;>Z!V9EAA#<+D[R20<8'!XK>>782I
M1CB:<VH=?3;3SOI_6N$<?BJ59X>K!.?3UW^ZVO\ 6GU)I_\ P4"^&%YJ2VLL
M&O6,);;]LN+)#$!ZX21GQ_P'-?0OA_Q!IOBK1K35M(O8=1TVZ3S(;FW;<CK[
M'ZY!'4$$&OSA_:O_ &8M/^ RZ+J.AZE>7^D:@[P,FH%&FBE4;OO(J@@C/88Q
MWKV#_@G'XJO+K2_&'AZ:5I+.TD@O+=&.1&TF]7 ],[$/YUA7P.&GA7BL*WIW
M];&M+&8BGB5A\0EKV_KY'U[XB\1Z7X3T>YU76;^#3-.MUW2W-RX1%'U/<] .
MI-?/FM?\% /AAI=X\-M%KVKQJ<"XLK)%1OIYLB-^E<;^W%X,^)GQ$UC2[#P_
MX<OM2\*:?#YY:S9',UPQ(),8;>=JX ^7NU87P6_8&L/$O@NUU;QU?ZSI.IW@
M+IIEF$@>W3) $OF1L=Q'.,#&<5AA<-A%0]OB9_)?J=.)Q&)]M[##P^;V^7];
MGLW@O]M[X7>,M0BLI-0O/#\\K!8SK-N(HR3ZR(SJOU8@5Z_XR\=:'\/_  S<
M>(->OA8Z/;[/,NA$\H&Y@J_*BLQR2.@[U^8/[2WP2B^!/Q!CT2TOY=1T^ZM%
MO+>6=0) I9E*MC@D%#R .O2OJ[X*>%[K]H7]C>V\*WFKMI\JS-9+?/!YY1(9
M@Z#;N7.%VJ.> !6V)P.'5&&)HR?(VK^E]?N^9CA\97]M+#5TN9)V];77WGQS
M^T#XJTOQO\9/%.NZ+=?;=*O;H26]QY;Q[UV*,[7 8<@]0*^\/V>OVC/AYJ'@
M_P !^"X/$/F>)1IMK8FQ^Q7 _?)" R[S'LX*GG=CCK7Y]?%;P'_PK'XAZYX7
M^W?VE_9D_D_:_)\KS/E#9V;FQU]37UY^S;^QS_9-YX%^)/\ PEWF[H(=3_LS
M^S,?ZR+.SS?.[;NNWG'2O8Q<,(\%34YM027*^^FE].WH>3AYXGZ[4<8KG;?,
MNVNO7OYL^S:\8^(W[7GPT^&M]-87>KR:MJ4)VRVFCQ>>R'.""Y(0$=QNR/2N
M$_;H^-U[\/?"=EX7T2Y:TU;7%9I[B)L/#;+P0I'(+DXSZ!J^8/V9OV8+WX]W
M=Y?7=Z^D^&K%Q%-=1H&EFD(!\N// (!!+'.,C@YX\'!X"G4HO$XB5H+\?Z>A
M[F,QDZ518>A&\W^']+7T/K'P_P#M]?"[6KY;>Z_MK0T8X^T:A9*8Q]?*>0_I
M7T'HNN:?XDTNWU+2KVWU'3[A=\5S:R"2-QZAAP:^)_C1^P)9^&_"-YK/@C5]
M1O[FQB::73M2\N1YD49;RW1%PP&3M(.?45YA^QW\<K[X8_$:QT*[N7?PSKDZ
MVT]N[?)#,Q"I,OH<X#>JGGH*Z'@,-BJ4JF"D[QZ/^ON.;Z[B,+4C'%Q7++JO
MZZ=3]%?''CS0_AOX<GU[Q'??V=I,#(DEQY,DNTLP51M168Y)'05R'A/]I?X:
M^-UU1M'\41W":7:-?7DDUK/ D,*D N6DC4'D@8'//2N2_;B_Y-SU[_KXM/\
MT>E?F_X3L=;\0:DGAW0EFGN]8>.U^R0G'GG>&56]@P#<\#&3TK'+\OIXRA.<
MI--.WELG^O<VQ^.G@ZL(15TU=]]VM/N/T/T_]O3X77^O_P!FL^L6L!?8NI3V
M0^SMZ'"N9 #[H*O_ +1C? M]:T9OBM_R$#;,;'_C^_U.[G_CWXZ_WN:^?O /
M["/C?0/B!X4O=>;2;S1([V.>^6RNF=HD3Y]K*Z+G<5"_+N^]Z<U-_P %'?\
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M^$8U-/+C9"&;<TN!@$G)X&*\!_8M_P"3H/ /_7W+_P"B):_6CXE?\DY\4_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBBBN\X@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS_Z E>>?\$[?^2P:Y_V!9/\ T=#7H_\ P4@MY&\+^"YPO[I;RX0MZ$HI _\
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M,%?KE7HYU+V=>C-J]M?N:/.R>/-"M'NK?>FC\@/^%Y?$?_HH'BG_ ,'5S_\
M%U]9_L ^//$WC+6/&2>(/$6K:XEO;VQA74KZ6X$9+29*AV.,X'3TK[,HKBQ&
M:4ZU*5-44K];_P# .VCELZ-2-1U6[=+?\$_&/QI_R.6O?]?]Q_Z,:OV$\)?\
MB?HW_7A#_P"BUK\>_&G_ ".6O?\ 7_<?^C&K]A/"7_(GZ-_UX0_^BUKJSC_<
MJ7]=#GRW_?*WS_,_'G6%$GBZ^5AE6OI 1_VT-?LU;J%MX@!@!0!^5?C/JW_(
MXWG_ %_O_P"C#7[,P?ZF/_='\J>=?P:'S_*(99_O5?\ KJS\VOV^%"_'Z4@
M%M,MB??[U?5G[#O_ ";IH7_7S=?^CFKY4_;Y_P"2^/\ ]@NV_P#9Z^J_V'?^
M3=-"_P"OFZ_]'-17_P"11#U7ZCI_\C27I^B/F7_@H5_R6K3?^P-#_P"C9:^B
M/V!_^2 Q_P#83N?_ &2OG?\ X*%?\EJTW_L#0_\ HV6OHC]@?_D@,?\ V$[G
M_P!DJ:G_ "*(^OZL/^9L_1?^DHXS_@H]_P B;X-_Z_YO_18K!_X)L_\ 'Q\0
M/]RQ_G/6]_P4>_Y$WP;_ -?\W_HL5@_\$V?^/CX@?[EC_.>G0_Y%%7U_6(L5
M_P C*EZ+]3V']IC]JRQ^!+6^D:?8IK'B>YB\Y8)7*PVT9) >3'))(.%&,@$Y
M'&?DJZ_:>^.GQ7NI[70[O4"&'S6?AK3OFC!]&56D'XM57]MRPO;/]H?7I+M6
M\NYAMY;9FZ&+RE7CZ,K#Z@U[I^S+^U=\,_ OPCTW0-;F?P[J>GAQ*L=E+*MV
MQ8GS0T:M\Q! .['(],5>'P].A@H8B%+VDY6\[7\O+86(KU*N,EAY5/9Q7R_'
MS^X^1OB=X4\<^'=1L[KQW!J46HZA$98I-6G,L\B X).YBPY[-BON3_@GK&R_
M!/46(P&UJ;!]?W4-?)_[4_QTM?CKX\MK_3+2:TT?3K?[+:FX $LN6+,[ $XR
M3P,]![XKZO\ ^">MXD_P4U*!2-\&M3;AGGF*(BNG&RJ2RV]2/*]-.VNGX6.3
M#1IQS%*G+F7?_MW7\3Y _:L_Y.&\;_\ 7Z/_ $6E?HM^S?$D/P'\"*B[5_LF
M!L>Y7)_4FOSI_:L_Y.&\;_\ 7Z/_ $6E?HS^SI_R0GP)_P!@BW_] %<F._Y%
ME#_MW_TD[<+_ ,C.OZR_]*/B[_@H5_R6K3?^P-#_ .C9:^AOV X4C^ @95PT
MFJW+,?4X0?R KYY_X*%?\EJTW_L#0_\ HV6OHC]@?_D@,?\ V$[G_P!DI5/^
M11'U_5A_S-GZ?^VH\N_X*2?\?'@3_<N_YQ5M_P#!-_\ Y%/QI_U^V_\ Z+:L
M3_@I)_Q\>!/]R[_G%6W_ ,$W_P#D4_&G_7[;_P#HMJ5/_D2OU?\ Z6%;_D;P
M]/\ VQGA?[<G_)Q&L_\ 7K:_^BEK[,_8RB2+]F_PEL7&X7+'W)N9>:^,_P!N
M3_DXC6?^O6U_]%+7V?\ L;?\FX>$/]VX_P#2B6C$?\BBC\OR8J7_ "-9^G_R
M)\\?\%(/^1J\%?\ 7E<?^C%KN_\ @G-$B_#7Q1(%^=M6"EO4"%,?S/YUPG_!
M2#_D:O!7_7E<?^C%KOO^"<__ "3'Q+_V%_\ VC'51_Y$O]?SCJ?\C?Y+_P!(
M*_\ P4<_Y)_X3_["C_\ HIJY#_@F[_R'/'/_ %[6O_H4E=?_ ,%'/^2?^$_^
MPH__ **:N0_X)N_\ASQS_P!>UK_Z%)1AO^135_KL&*_Y&5+T7ZGL'[3'[6]K
M\$;R/0='L(]8\3R1"9UG8B"U0_=+XY9CUV@CCDD<9^5+C]I+X[_%JXN+?1+S
M59$/WK7PUIQ!BS_MQJ9!^+5A_M@Z?>V/[1'BTWJ,OGRQ30LW1HC$@4CVX(^H
M-?2?[/7[7'PP\'?"'1M$U::3P]J>FP>3-:QV4LJW+CK*K1J1E^IW$')/;FKH
MX>GA\'"O"E[2<K/O:^NWEL17KSK8R="53V<5?RO;S\]SXU^)GA7QGX7UJW;Q
MQ!?PZM?0"Z1M3G\V=XRQ4,Q+%ARIX;!XK[[_ &"8V3X 0%A@-J5R5]QE1_,&
MOC']IKXU0?'+XC?VU8V<MGI=K;+96BW&/,9%9F+-C(!)<\9.!BOLW]@F^2Z^
M ,,2D%K;4KF)QGN2K_R85OCW4EER=6/*]-%TUT_ Y\(J<<PM3ES+N^KMK^I\
M7?M6?\G#>-_^OT?^BTK](_@-_P D2\!?]@*R_P#1*5^<'[65O);_ +1'C59%
M*EKM'&>ZF)"#^5?8W[.G[3G@2^\$^ ?!O]IS'Q/]E@TPV/V20;9$3;DN1LP0
MN>&)YZ9XKGQ=.=7+:'(KZ1V_PF]"<:>95W-VUEO_ (CYT_X* R3M\=(5E)\I
M=(M_*STQODSC\<U]-_L)PP1?L]::T(4227MTTV.I?S,<_P# 0M>??\%!OA/>
MZUI>D^.=-MVN%TR-K34%C7+)"6W)(?\ 9#%@?3<*\F_9%_:DL?@PE[X=\2QS
MOX<O)OM,5U;IO:UF("L2O5D8!>G(*\ Y-%.+Q>5JG2UE%[?/_+4JM)8;,O:5
M/ADM_E;\]#]')%5XV5P"I&"#Z5^,NK;;3QE>?V?]V._?[/M]!(=N/TK[L^-7
M[='@ZU\'WUCX&O)];UN\A:&*Y^S200VNX8+GS%5BP!X &,]37S#^RG\'[WXM
M?%;37:!FT/29X[W4;AA\N%;<D>>Y=AC'IN/:GD]&>$]IB*ZY8V6^FW]:>I.;
M5H8F,*%%\TF^FO\ 7_ /L_\ ;<+-^S;K1?[QFL\_7STKY+_85TZ*^_:%TR60
M FTLKJ=,C/S>7L_DYKZX_;B_Y-SU[_KXM/\ T>E?*7[ _P#R7Z+_ +!ES_[+
M499_R+\1_P!O?^D(K,H_[9AT^T?_ $MGZ45\#_\ !1W_ )'KPA_V#9/_ $;7
MWQ7P/_P4=_Y'KPA_V#9/_1M>3E7^^T_G_P"DL];,?]SJ^B_]*1ZA_P $Z_\
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M]A^ ]<\?Z]\$XM8U2TTZU\;W5E)<V]F;=TA1B"84D0ONR1MW<C!..U?%]O\
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M-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO<>9J#H\FY\9&411CCTKM:*'B*KI^Q<O=[![&G[3VO+[W?\  \W^-GP%\/\
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M'Q'S-1117 =I]84445^YGXT%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5[]^P;_P G
M7>!O^W[_ -(+BO :]^_8-_Y.N\#?]OW_ *07%<&/_P!TK?X9?DSLP7^]4O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7OW[!O_)UW@;_M^_\
M2"XKP&O?OV#?^3KO W_;]_Z07%<&/_W2M_AE^3.S!?[U2_Q+\S]>J***_&S]
M9"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /R4_P""X7AR
M2'Q9\*=> S#<V-_8DXZ-%)"XS]1,?R->I_\ !)7Q&FK_ +,%YIV0)=)U^ZMR
MO?:\<4H/XF1A_P !-:G_  6C\%R:U^SCX9\0PQ>8^A^(8UF;'W(9X9$)_P"_
MBPC\:\(_X(U^-HTN_B3X0E?]](EKJMNF>JJ7BE/YO#^=;T7:9C67N'Z<4445
MZ)P!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4454U?5;;0]*O-1
MO91#:6D+SS2-T5%4LQ_(4; M79'PU_P4/^)/V_Q%H?@FUE_<V$?V^\53P97&
M(U/N%W'_ (&*\]_9-^.G@OX$W6O:EXAT_6+[5;Y([>W;3H(G6*$$LX)>5#EF
MV]OX!7DWCOQ1?_%;XD:KK+1M+>ZQ?$Q0KR?F;;'&/H-J_A7U9;?\$V99+>)I
M_B$L,S("\:Z+N"MCD _:!G![X%?=1AA\'@HT,2[<V_KN]NVWH?&U)5L9C)5<
M.K\NWILGKWW.+_:K_:2\!?'GPGIEOI&F:Y9ZYIUUYD,U];0+&8F7$B$K*Q&<
M*1Q_#6#^Q#\3#X$^,UMIEQ)LTWQ"GV"3)X$V<PM]=V5_[:&O5O\ AVM_U4;_
M ,H?_P!T5\E>,_#.I?"WX@:EHLTK1ZEHUZ42X0;22C921?3(VL/K5X7ZE5I2
MPE"5T[]_U\_Q,\4L9"<<56C9JRZ>;Z'[(5^-?Q$_Y*%XF_["EU_Z-:OUB^#W
MQ A^*'PT\/\ B6)E+WMLIG5>B3+\LJ_@X;\,5^3OQ$_Y*%XF_P"PI=?^CFKS
M,EINGBJE.6Z5OQ/3S6I&KA83CLVG^#/U\\&Z?#I/A#0[*W14@MK&"%%48 58
MU _E7Y^_\%!K=(OC?9RJ,-+H\!;\))1_*OT+T#_D Z;_ ->T?_H(K\^/^"A7
M_):M-_[ T/\ Z-EKBRUMY@GZ_DSKQJ2R^2\H_FCZ*_8)D9O@# "<A=2N0/89
M4_S)KXU_:Z_Y.,\:_P#7Q%_Z(CK[(_8'_P"2 Q_]A.Y_]DKXW_:Z!'[1GC7(
MQ_I$7_HB.O3PO_(VJ^C_ #B>;7_Y%-/_ !+\I'Z(_LZ?\D)\"?\ 8(M__0!7
MA7_!1S_DG_A/_L*/_P"BFKV?]F[7+&;X"^ W%W  =/AM1F5>95&TH.?O9&,=
M:\8_X*.?\D_\)_\ 84?_ -%-7DP_Y&?_ &^_S/4_YE__ &Y^AR'_  3=_P"0
MYXY_Z]K7_P!"DKTC]J_]J+Q5\"?%VCZ5H&GZ/=V]Y9&YD;4H97<-O9< I*@Q
M@>E>;_\ !-W_ )#GCG_KVM?_ $*2OJGXC? /P)\6M2M=0\5Z%_:MW;1>1%)]
MLGAVIDMC$<B@\D]:Z\PG2IYCS5E>*2NOE_F<N!C4G@'&D[2>S^:_0^+O^'B7
MQ'_Z GA;_P !+G_Y(KJ_VC_%VJ_&#]D3P9XSU.WMH+U]6+7$=DK+$HS/$" S
M,?X5ZMU->\_\,6_!K_H3O_*I>_\ QZMKQY\!]$U;X%ZE\.]!M%TZQ$#'3XWD
M>013!S*IW.2V"_7)Z$UG5QF"3A*A3<6I)O3HM^K+HX7&-RC6J)IQ:WZO;H?&
M7[ &LQ:;\=);61@IU#2IX(QZNK))_P"@HU?I!7XW:)JVN?"?Q[;7T*/I^O:)
M>9,4H^[(APR,.X/(/J":_2#X7?M@_#OXA:-!+?ZW:>%M6"#[18:M,(51N^R5
ML(ZYZ<YQU KKSG"SJ2CB*2NK6T_,Y,IQ$:2E0JZ._7[K?@>XU^:?[>6JP:E\
M?KF*%P[66G6]O)M.<-\SX_)Q7UQ\5?VQ/A[\/=%N)-,UJT\4ZR4/V:QTN83(
MS=B\JY15!Z\Y] :_.'4+[7?BQX\FN7234_$&N7F1'&.7E=L!5'8#@#T K')\
M)45;V\U:*77JSHS7%4U1]C%W;M\EN?>W_!/C39+/X(WUPZD+=ZS-(F>X$<29
M_-3^5=_^T_\ "'2_BU\+]0CO)8;'4-+C>]LM0G.U865<L&;LC 8/X'M75?!W
MX?1_"SX9^'_#",KR6-L!/(G1YF)>1A[%V;'MBOE?]N[]H [F^&^@W.!\LFLS
M1-]"MOD?@S?\!'K7%+GQF8-X=ZWT?9+K_7H=='DP>"7MUHEJO7I^GXGQ*>.*
M_2;]A_X6Z+X0^%=OXFM;F#4M7U]?,N+J+D0(I(%N/0J0=W^UZ@ U\0Z+\ _%
M&N_"#5/B);6^=(L9Q'Y14^9-&,B29?\ 90[0?^!?W37I?[%W[0 ^&'B[_A&=
M:N=GAG6I0HDD/RVER<!9/96X5O\ @)Z U]5F$7BL/.G0EK'=?C;^O0^8P36'
MK0JUH^Z]G^%_Z]>Q^BFN_P#(#U#_ *]Y/_037X[_  ]_Y'[PU_V$[;_T:M?L
M1KO_ " ]0_Z]Y/\ T$U^._P]_P"1^\-?]A.V_P#1JUX_#_QU?^W?_;CV,]_A
M4O67_MI^C7[<5]-9_L[ZVL3E!/<VL3X[J95)'Z"OE3]@?1;?5?CTEQ.JN^GZ
M9<74.[LY*1Y'OB1J^ROVL/!]QXV^ OBBRM(VENX(EO8XU&2WE.'('OM#5\!?
MLL_$ZR^%'QDTG5]4D\G29TDLKN;!/E)(.'X[!@I/L#1E7OX*O3A\6OXQ27Y,
M6:>[B:%27PZ?A*[_  :/U:K\H/VJ-#@\/_M >,[6VC6*%[L7 1!@ R(LC?\
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MI?VLH$M_VB?&R(,*;M'_ !:%&/ZDU^K5?E3^UU_R<9XU_P"OB+_T1'7%D?\
MO;_PO\XG?G'^Y_\ ;R_*1^A7[,[M)\ _ I8Y/]EQ#GVR!7Y?_%/_ )*CXO\
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M,Q_XY7UE7S.,H+#5Y4HNZ7_#GT.#K/$4(U9*S?\ G8****XCL"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ K^?K]K;7?^$R_:E^)EW;#S1)XANK6
M'9SO$<AA4CZ[!^=?OEXG\06GA/PWJVN7[;+'3+2:]N&](XT+L?R4U^!7[.^@
MW7QA_:H\!V,T?GRZUXHMI[L=?W9N!+.WX('/X5R8AZ)'506K9^O_ /PPO<_\
M_4'Z45]F45Q'6?@/1117[F?C04444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5[]^P;_ ,G7>!O^W[_T@N*\
M!KW[]@W_ ).N\#?]OW_I!<5P8_\ W2M_AE^3.S!?[U2_Q+\S]>J***_&S]9"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /&OVR/AI_PMW]
ME[XD^&$A\^ZN-'EN+2/&2UQ!B>$#ZR1(/QK\3O\ @G?\2X_AG^U?X0FNIQ!I
M^LM)HERS' _?KB('V\X0_E7]"U?SI?MJ?"&?]G7]JCQCH.GJ]C8QWPU71Y(_
MEV6\Q\V+81_SS),>?6,U47RM,35U8_>JBO./V=?BU;_'#X*>$?&D$D;SZE8H
M;Q(R,172C9.F.V)%;'M@]Z]'KU4[JZ/+>F@4444P"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^RP[YKNH3NN5G'6C9\R/7J***ZCF"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG44T>?.#@S0HHHK4S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ***^8?VT_P!MC0OV8?#,FF:=);ZM
M\0KZ$FQTLG<MJI! N)P.B ]%X+D<< D3*2BKL:3D[(Y#_@HI^V1'\"?!<G@O
MPIJ"#X@:W"59X6R^EVK @S'^[(PX0=1RW89^$O\ @GW^QW>?M7?%@7&KQS0^
M =!D2YUF[P?]);.4M$;^\^/F/\*9/4KGSWX+_!OXA_MK_&^33K.XGU/6M2F-
M[K.O7V6CM(BPWSRD=AT5!C)VJ,=OW\^ 7P-\-_LY_"W1_ WA:%ET^P0M+<R@
M>==SMS)/(0.68_@  !P *\VI-S=ST(0Y%8[ZUM8;&UAMK:&.WMX46.*&)0J(
MH& J@<  #  J6BBLS0**** /S$_X=A_%+_H/^$/_  ,NO_D:C_AV'\4O^@_X
M0_\  RZ_^1J_3NBOI/\ 6#'=U]Q\_P#V'@^S^\_,3_AV'\4O^@_X0_\  RZ_
M^1J/^'8?Q2_Z#_A#_P #+K_Y&K].Z*/]8,=W7W!_8>#[/[S\Q/\ AV'\4O\
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M[HH_U@QW=?<']AX/L_O/S$_X=A_%+_H/^$/_  ,NO_D:C_AV'\4O^@_X0_\
M RZ_^1J_3NBC_6#'=U]P?V'@^S^\_,3_ (=A_%+_ *#_ (0_\#+K_P"1J/\
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M_%+_ *#_ (0_\#+K_P"1J_3NBC_6#'=U]P?V'@^S^\_,3_AV'\4O^@_X0_\
M RZ_^1J/^'8?Q2_Z#_A#_P #+K_Y&K].Z*/]8,=W7W!_8>#[/[S\Q/\ AV'\
M4O\ H/\ A#_P,NO_ )&H_P"'8?Q2_P"@_P"$/_ RZ_\ D:OT[HH_U@QW=?<'
M]AX/L_O/S$_X=A_%+_H/^$/_  ,NO_D:C_AV'\4O^@_X0_\  RZ_^1J_3NBC
M_6#'=U]P?V'@^S^\_,3_ (=A_%+_ *#_ (0_\#+K_P"1J/\ AV'\4O\ H/\
MA#_P,NO_ )&K].Z*/]8,=W7W!_8>#[/[S\Q/^'8?Q2_Z#_A#_P #+K_Y&H_X
M=A_%+_H/^$/_  ,NO_D:OT[HH_U@QW=?<']AX/L_O/S$_P"'8?Q2_P"@_P"$
M/_ RZ_\ D:C_ (=A_%+_ *#_ (0_\#+K_P"1J_3NBC_6#'=U]P?V'@^S^\_,
M3_AV'\4O^@_X0_\  RZ_^1J/^'8?Q2_Z#_A#_P #+K_Y&K].Z*/]8,=W7W!_
M8>#[/[S\Q/\ AV'\4O\ H/\ A#_P,NO_ )&H_P"'8?Q2_P"@_P"$/_ RZ_\
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M0_\  RZ_^1J/^'8?Q2_Z#_A#_P #+K_Y&K].Z*/]8,=W7W!_8>#[/[S\Q/\
MAV'\4O\ H/\ A#_P,NO_ )&H_P"'8?Q2_P"@_P"$/_ RZ_\ D:OT[HH_U@QW
M=?<']AX/L_O/S$_X=A_%+_H/^$/_  ,NO_D:C_AV'\4O^@_X0_\  RZ_^1J_
M3NBC_6#'=U]P?V'@^S^\_,3_ (=A_%+_ *#_ (0_\#+K_P"1J/\ AV'\4O\
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M^'8?Q2_Z#_A#_P #+K_Y&K].Z*/]8,=W7W!_8>#[/[S\Q/\ AV'\4O\ H/\
MA#_P,NO_ )&H_P"'8?Q2_P"@_P"$/_ RZ_\ D:OT[HH_U@QW=?<']AX/L_O/
MS$_X=A_%+_H/^$/_  ,NO_D:C_AV'\4O^@_X0_\  RZ_^1J_3NBC_6#'=U]P
M?V'@^S^\_,3_ (=A_%+_ *#_ (0_\#+K_P"1J/\ AV'\4O\ H/\ A#_P,NO_
M )&K].Z*/]8,=W7W!_8>#[/[S\Q/^'8?Q2_Z#_A#_P #+K_Y&H_X=A_%+_H/
M^$/_  ,NO_D:OT[HH_U@QW=?<']AX/L_O/S$_P"'8?Q2_P"@_P"$/_ RZ_\
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M?_(U'_#L/XI?]!_PA_X&77_R-7Z=T4?ZP8[NON#^P\'V?WGYB?\ #L/XI?\
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M'_"'_@9=?_(U'_#L/XI?]!_PA_X&77_R-7Z=T4?ZP8[NON#^P\'V?WGYB?\
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M'_"'_@9=?_(U?IW11_K!CNZ^X/[#P?9_>?F)_P .P_BE_P!!_P (?^!EU_\
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MG=%'^L&.[K[@_L/!]G]Y^8G_  [#^*7_ $'_  A_X&77_P C4?\ #L/XI?\
M0?\ "'_@9=?_ "-7Z=T4?ZP8[NON#^P\'V?WGYB?\.P_BE_T'_"'_@9=?_(U
M'_#L/XI?]!_PA_X&77_R-7Z=T4?ZP8[NON#^P\'V?WGYB?\ #L/XI?\ 0?\
M"'_@9=?_ "-1_P .P_BE_P!!_P (?^!EU_\ (U?IW11_K!CNZ^X/[#P?9_>?
MF)_P[#^*7_0?\(?^!EU_\C4?\.P_BE_T'_"'_@9=?_(U?IW11_K!CNZ^X/[#
MP?9_>?F)_P .P_BE_P!!_P (?^!EU_\ (U'_  [#^*7_ $'_  A_X&77_P C
M5^G=%'^L&.[K[@_L/!]G]Y^8G_#L/XI?]!_PA_X&77_R-1_P[#^*7_0?\(?^
M!EU_\C5^G=%'^L&.[K[@_L/!]G]Y^8G_  [#^*7_ $'_  A_X&77_P C4?\
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MP\'V?WGYB?\ #L/XI?\ 0?\ "'_@9=?_ "-1_P .P_BE_P!!_P (?^!EU_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKRSXV?M/?#;]GVP,WC/Q
M+;65X5W1:5;GSKV;TVPK\V#_ 'FPOJ:_+7]I[_@I=X[^-)N]$\'F;P)X/D!C
M9+:7_3[M2"#YLR_<4C^!,=2"S"LIU(PW-(TY2/K_ /;$_P""DGA_X-+>^%/A
MZ]KXG\:A6BFO58266F/T^8CB64?W!P#]X\;3^<7P5^"/Q)_;6^,5Q9Z=)<:M
MJU[+]KUGQ!J+,T-HC'!EF?\ #"H.3C"C X]6_8W_ .";_CG]IJZM-=UR.Z\&
M_#PA93J]Q#B>_7/W;1&^]G_GH?D';<1MK]KO@W\$?!?P"\%VWA?P/HD&C:9"
M 9"@W37,F,&6:0_-(Y]3]!@ "N"=1S>IVQ@H+0YO]F/]F'P=^RM\.XO"_A2W
M:6>8K-J>KW"C[1J$X&-[D=%'(5!PH/<EF/KU%%9F@4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 ?RKU]5?\$N/^3[/AE_W$__ $UW=?*M
M?57_  2X_P"3[/AE_P!Q/_TUW= '[_4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!YU\;/V?? /[0_A=M!\>>';;6K90QM[AALN;1B,;X95
M^9#]#@XY!'%?E+^T;_P1Z\?> #=:M\+]07Q]HBY<:9/M@U2)?0#B.; SRI5C
MV0U^S]% '\VGP[^.WQ?_ &6_$%UINB:SK'A*ZMY<7F@ZC"?*#]Q);3+A6YZ[
M0W/45]I_"3_@L0R1Q6OQ+\%&1@ &U/PRX!/N;>5NO?(D_"OT_P#BE\#?A_\
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M\-0?&3_HK7CK_P *2]_^.T?6%V#V#[G]#-%?SS?\-0?&3_HK7CK_ ,*2]_\
MCM'_  U!\9/^BM>.O_"DO?\ X[1]878/8/N?T,T5_/-_PU!\9/\ HK7CK_PI
M+W_X[1_PU!\9/^BM>.O_  I+W_X[1]878/8/N?T,T5_/-_PU!\9/^BM>.O\
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M\-0?&3_HK7CK_P *2]_^.T?6%V#V#[G]#-%?SS?\-0?&3_HK7CK_ ,*2]_\
MCM'_  U!\9/^BM>.O_"DO?\ X[1]878/8/N?T,T5_/-_PU!\9/\ HK7CK_PI
M+W_X[1_PU!\9/^BM>.O_  I+W_X[1]878/8/N?T,T5_/-_PU!\9/^BM>.O\
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M\-0?&3_HK7CK_P *2]_^.T?6%V#V#[G]#-%?SS?\-0?&3_HK7CK_ ,*2]_\
MCM'_  U!\9/^BM>.O_"DO?\ X[1]878/8/N?T,T5_/-_PU!\9/\ HK7CK_PI
M+W_X[1_PU!\9/^BM>.O_  I+W_X[1]878/8/N?T,T5_/-_PU!\9/^BM>.O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Y5Z^JO^"7'_
M "?9\,O^XG_Z:[NOE6OJK_@EQ_R?9\,O^XG_ .FN[H _?ZBBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Y5Z^JO
M^"7'_)]GPR_[B?\ Z:[NOE6OJK_@EQ_R?9\,O^XG_P"FN[H _?ZBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M31_PLSPW_P!!+_R!+_\ $T?ZS9%_T'4O_!D/\P^HXO\ Y\R_\!?^1U%%<O\
M\+,\-_\ 02_\@2__ !-'_"S/#?\ T$O_ "!+_P#$T?ZS9%_T'4O_  9#_,/J
M.+_Y\R_\!?\ D=117+_\+,\-_P#02_\ ($O_ ,31_P +,\-_]!+_ ,@2_P#Q
M-'^LV1?]!U+_ ,&0_P P^HXO_GS+_P !?^1U%%<O_P +,\-_]!+_ ,@2_P#Q
M-'_"S/#?_02_\@2__$T?ZS9%_P!!U+_P9#_,/J.+_P"?,O\ P%_Y'445R_\
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M "!+_P#$T?\ "S/#?_02_P#($O\ \31_K-D7_0=2_P#!D/\ ,/J.+_Y\R_\
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M "!+_P#$T?ZS9%_T'4O_  9#_,/J.+_Y\R_\!?\ D=117+_\+,\-_P#02_\
M($O_ ,31_P +,\-_]!+_ ,@2_P#Q-'^LV1?]!U+_ ,&0_P P^HXO_GS+_P !
M?^1U%%<O_P +,\-_]!+_ ,@2_P#Q-'_"S/#?_02_\@2__$T?ZS9%_P!!U+_P
M9#_,/J.+_P"?,O\ P%_Y'445R_\ PLSPW_T$O_($O_Q-'_"S/#?_ $$O_($O
M_P 31_K-D7_0=2_\&0_S#ZCB_P#GS+_P%_Y'445R_P#PLSPW_P!!+_R!+_\
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M]!+_ ,@2_P#Q-'_"S/#?_02_\@2__$T?ZS9%_P!!U+_P9#_,/J.+_P"?,O\
MP%_Y'445R_\ PLSPW_T$O_($O_Q-'_"S/#?_ $$O_($O_P 31_K-D7_0=2_\
M&0_S#ZCB_P#GS+_P%_Y'445R_P#PLSPW_P!!+_R!+_\ $T?\+,\-_P#02_\
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M_"S/#?\ T$O_ "!+_P#$T?\ "S/#?_02_P#($O\ \31_K-D7_0=2_P#!D/\
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M$O\ R!+_ /$T?\+,\-_]!+_R!+_\31_K-D7_ $'4O_!D/\P^HXO_ )\R_P#
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MS#ZCB_\ GS+_ ,!?^1U%%<O_ ,+,\-_]!+_R!+_\31_PLSPW_P!!+_R!+_\
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M $'4O_!D/\P^HXO_ )\R_P# 7_D=117+_P#"S/#?_02_\@2__$T?\+,\-_\
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M -!+_P @2_\ Q-'^LV1?]!U+_P &0_S#ZCB_^?,O_ 7_ )'445R__"S/#?\
MT$O_ "!+_P#$T?\ "S/#?_02_P#($O\ \31_K-D7_0=2_P#!D/\ ,/J.+_Y\
MR_\  7_D=117+_\ "S/#?_02_P#($O\ \31_PLSPW_T$O_($O_Q-'^LV1?\
M0=2_\&0_S#ZCB_\ GS+_ ,!?^1U%%<O_ ,+,\-_]!+_R!+_\31_PLSPW_P!!
M+_R!+_\ $T?ZS9%_T'4O_!D/\P^HXO\ Y\R_\!?^1U%%<O\ \+,\-_\ 02_\
M@2__ !-'_"S/#?\ T$O_ "!+_P#$T?ZS9%_T'4O_  9#_,/J.+_Y\R_\!?\
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MLV1?]!U+_P &0_S#ZCB_^?,O_ 7_ )'445R__"S/#?\ T$O_ "!+_P#$T?\
M"S/#?_02_P#($O\ \31_K-D7_0=2_P#!D/\ ,/J.+_Y\R_\  7_D=117+_\
M"S/#?_02_P#($O\ \31_PLSPW_T$O_($O_Q-'^LV1?\ 0=2_\&0_S#ZCB_\
MGS+_ ,!?^1U%%<O_ ,+,\-_]!+_R!+_\31_PLSPW_P!!+_R!+_\ $T?ZS9%_
MT'4O_!D/\P^HXO\ Y\R_\!?^1U%%<O\ \+,\-_\ 02_\@2__ !-'_"S/#?\
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MU%%<O_PLSPW_ -!+_P @2_\ Q-'_  LSPW_T$O\ R!+_ /$T?ZS9%_T'4O\
MP9#_ ##ZCB_^?,O_  %_Y'445R__  LSPW_T$O\ R!+_ /$T?\+,\-_]!+_R
M!+_\31_K-D7_ $'4O_!D/\P^HXO_ )\R_P# 7_D=117+_P#"S/#?_02_\@2_
M_$T?\+,\-_\ 02_\@2__ !-'^LV1?]!U+_P9#_,/J.+_ .?,O_ 7_D=117+_
M /"S/#?_ $$O_($O_P 31_PLSPW_ -!+_P @2_\ Q-'^LV1?]!U+_P &0_S#
MZCB_^?,O_ 7_ )'445R__"S/#?\ T$O_ "!+_P#$T?\ "S/#?_02_P#($O\
M\31_K-D7_0=2_P#!D/\ ,/J.+_Y\R_\  7_D=117+_\ "S/#?_02_P#($O\
M\31_PLSPW_T$O_($O_Q-'^LV1?\ 0=2_\&0_S#ZCB_\ GS+_ ,!?^1U%%<O_
M ,+,\-_]!+_R!+_\31_PLSPW_P!!+_R!+_\ $T?ZS9%_T'4O_!D/\P^HXO\
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M31_PLSPW_P!!+_R!+_\ $T?ZS9%_T'4O_!D/\P^HXO\ Y\R_\!?^1U%%<O\
M\+,\-_\ 02_\@2__ !-'_"S/#?\ T$O_ "!+_P#$T?ZS9%_T'4O_  9#_,/J
M.+_Y\R_\!?\ D=117+_\+,\-_P#02_\ ($O_ ,31_P +,\-_]!+_ ,@2_P#Q
M-'^LV1?]!U+_ ,&0_P P^HXO_GS+_P !?^1U%%<O_P +,\-_]!+_ ,@2_P#Q
M-'_"S/#?_02_\@2__$T?ZS9%_P!!U+_P9#_,/J.+_P"?,O\ P%_Y'445R_\
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M "!+_P#$T?\ "S/#?_02_P#($O\ \31_K-D7_0=2_P#!D/\ ,/J.+_Y\R_\
M 7_D=117+_\ "S/#?_02_P#($O\ \31_PLSPW_T$O_($O_Q-'^LV1?\ 0=2_
M\&0_S#ZCB_\ GS+_ ,!?^1U%%<O_ ,+,\-_]!+_R!+_\31_PLSPW_P!!+_R!
M+_\ $T?ZS9%_T'4O_!D/\P^HXO\ Y\R_\!?^1U%%<O\ \+,\-_\ 02_\@2__
M !-'_"S/#?\ T$O_ "!+_P#$T?ZS9%_T'4O_  9#_,/J.+_Y\R_\!?\ D=11
M7+_\+,\-_P#02_\ ($O_ ,31_P +,\-_]!+_ ,@2_P#Q-'^LV1?]!U+_ ,&0
M_P P^HXO_GS+_P !?^1U%%<O_P +,\-_]!+_ ,@2_P#Q-'_"S/#?_02_\@2_
M_$T?ZS9%_P!!U+_P9#_,/J.+_P"?,O\ P%_Y'445R_\ PLSPW_T$O_($O_Q-
M'_"S/#?_ $$O_($O_P 31_K-D7_0=2_\&0_S#ZCB_P#GS+_P%_Y'445R_P#P
MLSPW_P!!+_R!+_\ $T?\+,\-_P#02_\ ($O_ ,31_K-D7_0=2_\ !D/\P^HX
MO_GS+_P%_P"1U%%<O_PLSPW_ -!+_P @2_\ Q-'_  LSPW_T$O\ R!+_ /$T
M?ZS9%_T'4O\ P9#_ ##ZCB_^?,O_  %_Y'445R__  LSPW_T$O\ R!+_ /$T
M?\+,\-_]!+_R!+_\31_K-D7_ $'4O_!D/\P^HXO_ )\R_P# 7_D=117+_P#"
MS/#?_02_\@2__$T?\+,\-_\ 02_\@2__ !-'^LV1?]!U+_P9#_,/J.+_ .?,
MO_ 7_D=117+_ /"S/#?_ $$O_($O_P 31_PLSPW_ -!+_P @2_\ Q-'^LV1?
M]!U+_P &0_S#ZCB_^?,O_ 7_ )'445R__"S/#?\ T$O_ "!+_P#$T?\ "S/#
M?_02_P#($O\ \31_K-D7_0=2_P#!D/\ ,/J.+_Y\R_\  7_D=117+_\ "S/#
M?_02_P#($O\ \31_PLSPW_T$O_($O_Q-'^LV1?\ 0=2_\&0_S#ZCB_\ GS+_
M ,!?^1U%%<O_ ,+,\-_]!+_R!+_\31_PLSPW_P!!+_R!+_\ $T?ZS9%_T'4O
M_!D/\P^HXO\ Y\R_\!?^1U%%<O\ \+,\-_\ 02_\@2__ !-'_"S/#?\ T$O_
M "!+_P#$T?ZS9%_T'4O_  9#_,/J.+_Y\R_\!?\ D=117+_\+,\-_P#02_\
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M (69X;_Z"7_D"7_XFC_A9GAO_H)?^0)?_B:/]9LB_P"@ZC_X,A_\D'U'%_\
M/F7_ ("_\CJ**Y?_ (69X;_Z"7_D"7_XFC_A9GAO_H)?^0)?_B:/]9LB_P"@
MZC_X,A_\D'U'%_\ /F7_ ("_\CJ**Y?_ (69X;_Z"7_D"7_XFC_A9GAO_H)?
M^0)?_B:/]9LB_P"@ZC_X,A_\D'U'%_\ /F7_ ("_\CJ**Y?_ (69X;_Z"7_D
M"7_XFC_A9GAO_H)?^0)?_B:/]9LB_P"@ZC_X,A_\D'U'%_\ /F7_ ("_\CJ*
M*Y?_ (69X;_Z"7_D"7_XFC_A9GAO_H)?^0)?_B:/]9LB_P"@ZC_X,A_\D'U'
M%_\ /F7_ ("_\CJ**Y?_ (69X;_Z"7_D"7_XFC_A9GAO_H)?^0)?_B:/]9LB
M_P"@ZC_X,A_\D'U'%_\ /F7_ ("_\CJ**Y?_ (69X;_Z"7_D"7_XFC_A9GAO
M_H)?^0)?_B:/]9LB_P"@ZC_X,A_\D'U'%_\ /F7_ ("_\CJ**Y?_ (69X;_Z
M"7_D"7_XFC_A9GAO_H)?^0)?_B:/]9LB_P"@ZC_X,A_\D'U'%_\ /F7_ ("_
M\CJ**Y?_ (69X;_Z"7_D"7_XFC_A9GAO_H)?^0)?_B:/]9LB_P"@ZC_X,A_\
MD'U'%_\ /F7_ ("_\CJ**Y?_ (69X;_Z"7_D"7_XFC_A9GAO_H)?^0)?_B:/
M]9LB_P"@ZC_X,A_\D'U'%_\ /F7_ ("_\CJ**Y?_ (69X;_Z"7_D"7_XFC_A
M9GAO_H)?^0)?_B:/]9LB_P"@ZC_X,A_\D'U'%_\ /F7_ ("_\CJ**Y?_ (69
MX;_Z"7_D"7_XFC_A9GAO_H)?^0)?_B:/]9LB_P"@ZC_X,A_\D'U'%_\ /F7_
M ("_\CJ**Y?_ (69X;_Z"7_D"7_XFC_A9GAO_H)?^0)?_B:/]9LB_P"@ZC_X
M,A_\D'U'%_\ /F7_ ("_\CJ**Y?_ (69X;_Z"7_D"7_XFC_A9GAO_H)?^0)?
M_B:/]9LB_P"@ZC_X,A_\D'U'%_\ /F7_ ("_\CJ**Y?_ (69X;_Z"7_D"7_X
MFC_A9GAO_H)?^0)?_B:/]9LB_P"@ZC_X,A_\D'U'%_\ /F7_ ("_\CJ**Y?_
M (69X;_Z"7_D"7_XFC_A9GAO_H)?^0)?_B:/]9LB_P"@ZC_X,A_\D'U'%_\
M/F7_ ("_\CJ**Y?_ (69X;_Z"7_D"7_XFC_A9GAO_H)?^0)?_B:/]9LB_P"@
MZC_X,A_\D'U'%_\ /F7_ ("_\CJ**Y?_ (69X;_Z"7_D"7_XFC_A9GAO_H)?
M^0)?_B:/]9LB_P"@ZC_X,A_\D'U'%_\ /F7_ ("_\CJ**Y?_ (69X;_Z"7_D
M"7_XFC_A9GAO_H)?^0)?_B:/]9LB_P"@ZC_X,A_\D'U'%_\ /F7_ ("_\CJ*
M*Y?_ (69X;_Z"7_D"7_XFC_A9GAO_H)?^0)?_B:/]9LB_P"@ZC_X,A_\D'U'
M%_\ /F7_ ("_\CJ**Y?_ (69X;_Z"7_D"7_XFC_A9GAO_H)?^0)?_B:/]9LB
M_P"@ZC_X,A_\D'U'%_\ /F7_ ("_\CJ**Y?_ (69X;_Z"7_D"7_XFC_A9GAO
M_H)?^0)?_B:/]9LB_P"@ZC_X,A_\D'U'%_\ /F7_ ("_\CJ**Y?_ (69X;_Z
M"7_D"7_XFC_A9GAO_H)?^0)?_B:/]9LB_P"@ZC_X,A_\D'U'%_\ /F7_ ("_
M\CJ**Y?_ (69X;_Z"7_D"7_XFC_A9GAO_H)?^0)?_B:/]9LB_P"@ZC_X,A_\
MD'U'%_\ /F7_ ("_\CJ**Y?_ (69X;_Z"7_D"7_XFC_A9GAO_H)?^0)?_B:/
M]9LB_P"@ZC_X,A_\D'U'%_\ /F7_ ("_\CJ**Y?_ (69X;_Z"7_D"7_XFC_A
M9GAO_H)?^0)?_B:/]9LB_P"@ZC_X,A_\D'U'%_\ /F7_ ("_\CJ**Y?_ (69
MX;_Z"7_D"7_XFC_A9GAO_H)?^0)?_B:/]9LB_P"@ZC_X,A_\D'U'%_\ /F7_
M ("_\CJ**Y?_ (69X;_Z"7_D"7_XFC_A9GAO_H)?^0)?_B:/]9LB_P"@ZC_X
M,A_\D'U'%_\ /F7_ ("_\CJ**Y?_ (69X;_Z"7_D"7_XFC_A9GAO_H)?^0)?
M_B:/]9LB_P"@ZC_X,A_\D'U'%_\ /F7_ ("_\CJ**Y?_ (69X;_Z"7_D"7_X
MFC_A9GAO_H)?^0)?_B:/]9LB_P"@ZC_X,A_\D'U'%_\ /F7_ ("_\CJ**Y?_
M (69X;_Z"7_D"7_XFC_A9GAO_H)?^0)?_B:/]9LB_P"@ZC_X,A_\D'U'%_\
M/F7_ ("_\CJ**Y?_ (69X;_Z"7_D"7_XFC_A9GAO_H)?^0)?_B:/]9LB_P"@
MZC_X,A_\D'U'%_\ /F7_ ("_\CJ**Y?_ (69X;_Z"7_D"7_XFC_A9GAO_H)?
M^0)?_B:/]9LB_P"@ZC_X,A_\D'U'%_\ /F7_ ("_\CJ**Y?_ (69X;_Z"7_D
M"7_XFC_A9GAO_H)?^0)?_B:/]9LB_P"@ZC_X,A_\D'U'%_\ /F7_ ("_\CJ*
M*Y?_ (69X;_Z"7_D"7_XFC_A9GAO_H)?^0)?_B:/]9LB_P"@ZC_X,A_\D'U'
M%_\ /F7_ ("_\CJ**Y?_ (69X;_Z"7_D"7_XFC_A9GAO_H)?^0)?_B:/]9LB
M_P"@ZC_X,A_\D'U'%_\ /F7_ ("_\CJ**Y?_ (69X;_Z"7_D"7_XFC_A9GAO
M_H)?^0)?_B:/]9LB_P"@ZC_X,A_\D'U'%_\ /F7_ ("_\CJ**Y?_ (69X;_Z
M"7_D"7_XFC_A9GAO_H)?^0)?_B:/]9LB_P"@ZC_X,A_\D'U'%_\ /F7_ ("_
M\CJ**Y?_ (69X;_Z"7_D"7_XFC_A9GAO_H)?^0)?_B:/]9LB_P"@ZC_X,A_\
MD'U'%_\ /F7_ ("_\CJ**Y?_ (69X;_Z"7_D"7_XFC_A9GAO_H)?^0)?_B:/
M]9LB_P"@ZC_X,A_\D'U'%_\ /F7_ ("_\CJ**Y?_ (69X;_Z"7_D"7_XFC_A
M9GAO_H)?^0)?_B:/]9LB_P"@ZC_X,A_\D'U'%_\ /F7_ ("_\CJ**Y?_ (69
MX;_Z"7_D"7_XFC_A9GAO_H)?^0)?_B:/]9LB_P"@ZC_X,A_\D'U'%_\ /F7_
M ("_\CJ**Y?_ (69X;_Z"7_D"7_XFC_A9GAO_H)?^0)?_B:/]9LB_P"@ZC_X
M,A_\D'U'%_\ /F7_ ("_\CJ**Y?_ (69X;_Z"7_D"7_XFC_A9GAO_H)?^0)?
M_B:/]9LB_P"@ZC_X,A_\D'U'%_\ /F7_ ("_\CJ**Y?_ (69X;_Z"7_D"7_X
MFC_A9GAO_H)?^0)?_B:/]9LB_P"@ZC_X,A_\D'U'%_\ /F7_ ("_\CJ**Y?_
M (69X;_Z"7_D"7_XFC_A9GAO_H)?^0)?_B:/]9LB_P"@ZC_X,A_\D'U'%_\
M/F7_ ("_\CJ**Y?_ (69X;_Z"7_D"7_XFK5MXZT"Z*A-4@7/3S"8^V?X@,5K
M3XBR:M+EIXVDWY5(/]298+%15Y4I+Y,WJ*9%,DT8>-UD0]&4Y!I]>^FI*ZV.
M,****8!1110!\PT445_FN?N 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** '1R-#(KHS(ZG<K*<$$="#7T'X1US_A(O
M#]K>''G$;)0.SC@_3/7Z$5\]5ZA\&-0.W4;$G@%9U7/_  %OY+7[+X6YM/!9
MW]2;]RNFK?WHIR3^ZZ^9\SG^'57"^UZP_)Z,].HHHK^PS\U/F&BBBO\ -<_<
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ KJ/AG_R.VF_]M/_ $4]<O74?#/_ )';3?\ MI_Z*>OI>&?^
M1[@/^OU/_P!+B<.._P!TJ_X9?DSW:BBBO] S\="BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** .9^)3%/!.I$'!Q&/SD45X/7NWQ,_Y$G4O^
MV?\ Z-2O":_D?Q=?_"[17_3J/_I=0_1N'/\ =)?XG^2"BBBOP\^J"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \^^-7Q>MO@YX9M]3ELO[3
MN;FX$$-GYWE%^"6;=M;   [=Q7B]M^W3%)<1+/X,:&%G >1=4WE5SR0ODC)
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MFG^H'^IU+ZA_R-.6GS?Q_BNN?XOW6U]M.QG1_P!8/[;?M/\ <[O^3;ET_O\
MQ?U8]/HHHK\,/N@KY[^)_P"UI_PK?QUJGAS_ (17^T?L+1C[3_:/E;]T:O\
M=\IL8W8ZGI7T)7Y[?M/?\ET\4?[\'_I/%7[YX.\+Y1Q5G&(PN<4?:PC2YDN:
M4;/FBKWC*+V;\CX3C+,\7E670KX.?+)S2O9/3ED^J:W2/7/^&[/^I(_\JW_V
MBC_ANS_J2/\ RK?_ &BO.O@A^SC_ ,+D\-WVK?\ "0_V/]EO#:^3]B\_=A$?
M=GS%Q]_&,=J]%_X83_ZG?_RD_P#V^OV3,\M\&,GQE3 8Z')5INTE?%NS]4VG
M\F?"83%\:XZA'$X>7-"6S_=+\[,/^&[/^I(_\JW_ -HKZ0\">*/^$V\':/KW
MV;['_:%LEQ]G\SS/+W#.-V!GZX%?-_\ PPG_ -3O_P"4G_[?7TAX$\+_ /"$
M^#M'T'[3]M_L^V2W^T>7Y?F;1C.W)Q],FOQ3Q#_XA]]4H?ZG?Q>9\_\ '^&V
MG\73?MJ?;\._ZQ_6)_VS\%M/X>]U_)KM??0\"\4?MI?\(WXFU?2/^$.^T?8+
MR:U\[^U-OF;'*[L>2<9QG&37NWPX\9?\+ \$Z5XA^Q_8/MT9D^S>;YFS#%<;
ML#/3T%>$^*/V+?\ A)/$VKZO_P )C]G^WWDUUY/]E[O+WN6VY\X9QG&<"O=O
MAQX-_P"%?^"=*\/?;/M_V&,Q_:?*\O?EBV=N3CKZFHXZ_P!0/[*PW^JG^\\R
M]I_'^'E=_P")[OQ6VU^1KDO^L']H5?[3_@6?+\&_,K?#KM??YZGD?Q5_:N_X
M5EXYU#P[_P (M_:7V01G[3_:'E;M\:O]WRFQC=CKVKO_ ()_%K_A<7A>ZUC^
MRO[(\B[:U\G[1Y^["(V[=L7'W\8QVKY _:J_Y+EX@_W;?_T1'7OO[$__ "2_
M5?\ L+2?^B8J^]XUX'X?RC@+!YU@L-RXF:H\TN>;OSQO+W7)QU?9:=#P,MSS
M,,1Q+5R^I4O23FDK1Z7MK:_XGT'17.W7Q&\)V-XUG<>*-%M[M3M-O+J$*R ^
MFTMG-=!#,EQ&LD3K)&PRKH<@CU!K^6Z^#Q.%495Z<HI[735_2^Y^J0K4ZC<8
M23:WLQU%%%<AJ%%5]0U"UTFSDNKVYAL[6,9>>XD"(H]2Q.!5/0_%6B^)ED;1
M]7L-56/[[6-RDP7Z[2<5TQPU>5)UU!N"T<K.R?KL9NI",E!R5WTZFI115/5=
M:T[0K?[1J5_:Z?;]/-NIEB7\V(%9TZ52M-4Z47*3V25W]Q4I**YI.R+E%8&E
M_$+PMK5TMMIWB71[^X;I#:W\4CG\%8FM^M,1A:^%ER8BFX/LTT_Q(IU:=9<U
M.2:\G<*@OK^VTNSFN[RXBM+6%=\D\[A$1?4L> *GKX;_ &O_ !+JMU\5;W19
M;^=M)M8;=X;+>1$K-$K%MO0G+'D\\XZ5^A^'_!DN.,V>7>V]E&,7.3M=V32L
MEW=^KLO/8\+/LXCDF#>*<.9W22VU?<^PO!/Q T3XA6=[=Z#=&]L[2Y-HUQL*
MJ[A58[<\D?,.<<]N.:M>,O$/_")>$]9UO[/]J_LZTENO(W[/,V(6V[L'&<=<
M&O%/V)_^27ZK_P!A:3_T3%7M?C+P]_PEOA/6=$^T?9/[1M);7S]F_P O>A7=
MMR,XSTR*Y,ZRG+LBXLJ995;>%I55&3=V^1-<U^5)WM?X5?L/*L=7S+*H8MI*
MI.+>FU];;_J?.-C^W%]MOK>W_P"$*V>=(L>[^U<XR0,X\FOJ:OEFQ_8=^Q7U
MO<?\)KO\F19-O]E8S@@XSYU?4U>_XB?ZE>UPW^IGPVE[3^+O=<O\7Y_#\^AY
MG#?]NVJ_VW_=Y?@\[_!\M_D%%%86K>//#.@7!M]4\1:3ILXZQ7=]%$WY,P-?
ME&'PM?%2Y,/3<WV2;?X'V%2I"DN:I))>>ANT5G:/XETCQ%&9-*U6RU.->K6=
MPDP'XJ36C6=6E4H3=.K%QDNC5G]PX3C47-!W7D%%%%9%A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5WOP;8_P#"27:YX-HQ/X.G^-<%7=_!S_D9
MKK_KS;_T-*^XX(=N(\%;^?\ 1GE9K_N57T/8Z***_O _)#YAHHHK_-<_< HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB/UW?+_P,U]Z5^5K+<Z/J!4A[:\M9<'LT<BG^8(_2OTI^%_C2/XA> M&UZ/
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M5&O^LQM^]QUZ\5L_L12,/B+K:9^5M*9B/<31X_F:^A_VD?\ DAOB[_KWB_\
M1\=?*_7:? OBG5PN74(^SQ3IPMLH^U<')Q2\[M+;6QZF%HRX@X52Q-1WIN3O
MNWRIV3^3M\C\\[2TGO[J&VMH9+BYF<1Q0PH6=V)P%4#DDGL*^E_V0_ _B3PU
M\2=0NM7\/ZII5LVER1K-?64D*%C+$0H+*!G /'L:\-^%/_)4/"/_ &%K7_T<
MM?IA7U_C=QEB,HP_^K\**E#$T[N3;O&TNBVZ'SO ^2T\?6>.E-IT9*R[GQ%^
MVI_R5FQ_[!$/_HV:N^_89_Y GBS_ *^+?_T%ZX']M3_DK-C_ -@B'_T;-7??
ML,_\@3Q9_P!?%O\ ^@O7%Q1_R9["_P#7NA_Z5$]#"?\ );R]9?\ IMGT_17(
M^.OBQX4^&LUG%XDU7^SGNU9H1]GEEWA2 ?N(V.HZUR__  U-\+_^AG_\I]U_
M\:K^0L)PKQ!CZ$<3A,OK5*<MI1I3E%^C46F?L%;-<OPU1TJ^(A&2W3E%-==F
MSU:OSV_:>_Y+IXH_WX/_ $GBK[5\$?&7P=\1M2FT_P .ZQ_:-W#"9Y(_LLT6
M$#!<Y=%'5A[\U\5?M/?\ET\4?[\'_I/%7]&>!.7XS+.)L9AL=1E2J*CK&<7&
M6LX6T:3U/SSCO$T,5DU.IAYJ<?:K5--?#/JCTO\ 99^,G@_X<>"=5L/$6L?V
M==SZBT\<?V::7*&*-<Y1&'53QUXKVC_AJ;X7_P#0S_\ E/NO_C5?%_@?X-^,
M/B/IL]_X=T?^T;2"8P22?:88L.%#8P[J>C#GIS71?\,L_%#_ *%C_P J%K_\
M=K[_ (FX!\/<RSC$XS-,W]E7G*\X^WH1Y7VY91<EZ-W/E<IS_B'"8*G0PF#Y
MZ:6CY)N^O=.S^1]@^&?V@/ /C'7;31M'U[[9J5T6$,/V.X3<0I8_,T8 X4GD
M]J]#KXW^!?[/_C[P;\5_#^LZQH/V/3;5Y3--]LMWV@PR*/E60D\L!P.]?9%?
MRQX@9'D.09I3PO#V+^L47!2<N>%2TG*2:O!);).V^OFC]7X=S#,<PP\ZF94?
M9R4K)<LHZ66MI-O<_,OXH?\ )2_%O_87N_\ T<]?=?[./_)$O"G_ %[O_P"C
M7KX4^*'_ "4OQ;_V%[O_ -'/7W7^SC_R1+PI_P!>[_\ HUZ_ICQT_P"26RW_
M !Q_]-R/S3@O_DH,7_AG_P"EQ/DC]JK_ )+EX@_W;?\ ]$1US?A?Q=XMOO#7
M_"">'1<M#?W;W$MO8JWG7!**NUB.=@"9(Z<G/ XZ3]JK_DN7B#_=M_\ T1'7
MLO[$?A2UB\.ZYXD>)6O9KK[#'(1RD:(KL >V2XS_ +HK[_-<_P -PSP#@<TQ
M%!5I0IT/9QEM[1P23_[=5WWTTL]3P_J-;,>)\1A:51PYISNUORW=_OV^?8^?
M/%'P)\>>#-);4]7\.7%O8(,O-')',(QZL(V8J/<X%7O@Q\;]9^$^MP[9Y;O0
M)7 N].9B5VD\O&/X7'7CKC!]OT.FACN(9(I466*12CQN,JRD8(([@BOS1^*G
MAF+P?\1O$6C6XQ;6M[(L(](R<H/^^2*\#@3C.EXK8+&9-Q!A8<T4G[M^5Q=U
M=*3DXRB[:I]4U8[>(,A?"LJ./RZK+>VMKI[]$DTTG=6^^Y^E.GW]OJEC;7MI
M*L]K<1K-%(O1T8 J1]017YM_&#_DJWB__L*W/_HUJ^T_V6]8?6/@GH/FL7DM
M3+:DDYX21MH_!2HKXL^,'_)5O%__ &%;G_T:U?'>".72RCB'.LND[NBU"_?E
MG)7^=CW.-,5]>R7!XJUN=I_?%C/%_P 2-4\7:%X?T25VATG1;2.W@M5;Y6<+
MAI6]6/;T''J3W_[(OAF77OB[;7H9TM]*MY+J0J2-Q(V*IQ[OG'?::]A_8T\
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M;?\ H:5]OP1_R4>"_P :_)GE9K_N57T/8Z***_O$_)#YAHHHK_-<_< HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KJ/AG_P CMIO_ &T_]%/7+UU'PS_Y';3?^VG_ **>OI>&?^1[@/\
MK]3_ /2XG#CO]TJ_X9?DSW:BBBO] S\="BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** .7^)G_(DZE_VS_\ 1J5X37NWQ,_Y$G4O^V?_ *-2
MO":_D;Q=_P"1[1_Z\Q_]+J'Z-PY_NDO\3_)!1117X@?5!1110 4444 %%%%
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M7PI\4/\ DI?BW_L+W?\ Z.>ONO\ 9Q_Y(EX4_P"O=_\ T:]?W)XZ?\DMEO\
MCC_Z;D?A7!?_ "4&+_PS_P#2XGR1^U5_R7+Q!_NV_P#Z(CKW3]B/6(;CP#K>
MF!A]HM=1\YD[[)(T"G\XV_*O"_VJO^2Y>(/]VW_]$1UA^ ?$_BOX.SZ9XOTR
M'&GZ@)(0906M[D(V'C?!X8$9'0]#TS7V^><-SXK\/<%E=":C6=.C*GS.RE*,
M$^7YQYO3=Z)GC4\P65\45\7.+<(SGS6Z)NU_DVC]'*_.#X[:E#JWQ@\67%NV
M^'[>\88=#LPA/YJ:]6\5?ML:WK&A2V>CZ##HE]*NPWQNC.4R.2B[% /H23BO
M#O _@O5?B-XIM-&TN)IKNY?+RMDK$F?FD<]@/UX'4BOE_"C@G'\"4\;G/$7+
M13C:W,G:,7S2E)Q;CVMJWN>KQ=G^%SRG1P.77F^:^S6MFDDFDV]7T['VS^R;
MI[V/P2TAW!4W,UQ. ?3S64?HM?&OQ@_Y*MXO_P"PK<_^C6K]&/#'A^U\)^'=
M-T:R&+6QMTMX\]2% &3[GJ?<U^<_Q@_Y*MXO_P"PK<_^C6KQ?!;,5F_$N>9C
M%655\Z])3FU^9V\8X66!R/!8:6\&D_51=_Q/M+]E9 GP+\/8&,M<$_\ @1)7
MK->3_LL?\D,\.?6X_P#2B2O6*_E7C#_DI,R_Z_U?_2Y'Z;P__P BC"_]>X?^
MDH_,[XJZ7+HOQ+\4V4R[6CU*XP/]DR$J?Q!!_&ON#]F768-8^"OAWR6!>U1[
M65>ZNKMP?J"I_$5Y%^UU\%[RZU ^.-%M6N8VB":G#$N63:,+-@=1M #>FT'I
MDCQ7X1?&S7?@_J$SZ>([W3KD@W&GW!.QR.C*1]UL<9_,' Q_9_$67?\ $6N"
M<)B,GG%UZ;C)Q;M[RCRS@^SUO%O1Z='<_'\-7_U2XAJO%Q?LIWL_[K=TUWML
M_F?HQ7YU_M$ZW#X@^,_BBYMY!+"EPMNK+TS&BQMC_@2FO1_&G[:6NZ]HLMEH
MFBQ>'YYE*/>&Y-Q(H/4I\BA3[G./KS7DGPO^&.L?%CQ1%INGQOY.X/>7K#*6
M\9/+,>Y/.!U)_$CS/"[@O%^'U+&<0<32C17)RVYD[1O=MN+:NVDHI-M^K2.K
MBO/J&?0HY;E=ZC<K[-:V:25[/JV]+'UY^Q_I,FF_!N":12HOKV>Y3/\ =R(\
M_P#D,U\Z?M<?\ERUC_KWM?\ T0E?<_A_0K/PQH=AI-A'Y5E90K!$O?:HQD^I
M/4GU-?$_[8VDS6/QADO'1A#?V4$L;D<':OED#Z%/UKXWPBSF&<\?YCF#]WV\
M*DDGV=2#2]4OR/:XHP,L!PS1PV[@X7]=;_BSV7]B?_DE^J_]A:3_ -$Q5ZG\
M8_\ DDWC+_L$77_HIJ^./@G^T=<_!WP_J&DC1(]7AN;C[3&S7)A,;E0IS\K;
MAA5].]?5'B3Q,WC+]F_5=<DC2*74/#DUP\<>=J,T!+*,]@<C\*^?XRX6S7*N
M.J6;XNG:A7Q4.25T[^]%[)W7S2\CNX9S7"8G)E@:<KU(0ES*STWZ[/?H? .A
M_P#(;T__ *^(_P#T(5^D7Q8TV35_ACXKM(5+32Z9<!%'=O+8@?I7YNZ'_P A
MO3_^OB/_ -"%?J:RAE*L RG@@C@U]SX[8QY=G.38U*_LW*7_ (#.F_T/GO#R
MFJU+&TY;/D7W\Y^5VEWG]GZE:77_ #PF27_OE@?Z5^IMK<QWEM%<0N)(94$B
M,O0J1D'\J_/7X]?"&\^%?C"Y5('.@WDC26%R!\NT\^63V9<XQW ![UUGPM_:
MVUKX?^'X-%U'2H_$%E:H([9VN#!+&@Z(6VL&4#@<9 []*^F\4.%,5XC9;@,Y
MX:<:O*GIS)<T9V>CDTDXM---K=]58\SAG,J?"^.Q&"S.\4[:V;LXWMHM;-/1
MKR/L;QAXWT3P#I*ZEK]^NG632K"LK(SY<@D#"@GHI[=JI>'/BIX0\77<=II'
MB/3KZ[DR4MHYU$K8&3A#AC@ GIVKX:^,WQWUCXR7%JES;1:9I=HQ>"RA<O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%4=>OI-+T+4KV(*TMM:RSHK@E2RH6
M/MD5OAZ,\36A0I_%)I+U;LA-V5V7J*^)_P#AMKQS_P! KP__ . \_P#\>H_X
M;:\<_P#0*\/_ /@//_\ 'J_>?^(&\8_\^Z?_ (,7^1^>_P"O>3?S2_\  3[8
MHKXG_P"&VO'/_0*\/_\ @//_ /'JW_ '[77C'Q5XXT#1KO3=#CM=0OH;:5X8
M)@X5W"DJ3*1G![@URXOP7XMP6'J8JM"'+"+D_?6R5WT[(TI\<9/4FH1E*[=O
MA/KFBN6^*7BJ[\$?#W7=>L8X9;RQM_-B2X4M&3N ^8 @XY[$5\S>$?VQ/&>O
M^+-$TNXTS0DM[Z^@M9&BMY@X5Y%4D$S$9P3C(-?(9!P!G?$N6ULVR^,72I.2
ME>5G[L5)V7HSV\SX@P.4UH4,2WS3VLK];'V%14%].UK8W$R %HXV<!NF0":^
M+O\ AMKQS_T"O#__ (#S_P#QZIX4X"SKC*G6J93&+5)I2YI<N][?D7F^?8+)
M/9_6VUSWM97VM?\ -'VQ16;X9U*76O#>DZA.J+-=VD,[K&"%#,@8@9)XR?6M
M*OSZI!TYN$MT['NTYJI!3CLU<****S- HHHH **** "BBB@ HHHH **** "B
MBB@ HKYQ_: _:/\ $OPI\=IHNDV.E7%JUG'<%[V&5GW,S C*R*,?*.U=?^SC
M\8-9^+^C:Q=ZS;6-M)9W"11BQC= 05).=SMS7Z/C^ ,[R[(:?$=>,?J\U%IJ
M5W:>VA\W3X@P-;,7E<6_:J_3317W/7Z***_.#Z0**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NH^&?\ R.VF_P#;3_T4
M]<O74?#/_D=M-_[:?^BGKZ7AG_D>X#_K]3_]+B<.._W2K_AE^3/=J***_P!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "N[^#G_(S77_7FW_H:5PE=W\'/^1FNO^O-O_0TK[?@C_DH\%_C
M7Y,\K-?]RJ^A['1117]XGY(?,-%%%?YKG[@%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5D^,/^11UW_L'W'_HIJUJR?&'_ "*.N_\
M8/N/_135[&3_ /(SPW_7R'_I2(J? S\NZ^QO#/[''@O6O#>DZA/J>O)-=VD,
M[K'<0A0S(&(&83QD^M?'-?8WAG]L?P7HOAO2=/GTS7GFM+2&!VCMX2I94"DC
M,PXR/2O]"O%;_6[V.#_U4]IS7GS\EMK1Y;W^=C^:.$_[)]M5_M;EY;*W-WN:
M7_#$O@;_ *"OB#_P(@_^,UI^&?V1?!WA7Q%INLVFI:Y)=:?<1W,233PE"R,&
M 8"('&1V(K,_X;:\#?\ 0*\0?^ \'_QZO1OA3\9-%^,%KJ,^C6M_;)8NB2"^
MC1"2P)&W:[>AZXK^6\[Q_B?EN J5LVJ5H4&N63E:UI:6?K>Q^K8/#\*8JO&E
MA8PE/HE>^FOZ&W\0M'TGQ!X*U?3M=OO[-TBXAV7-WYJ1>4NX'.]P5'(')'>O
M!?#/P-^#.F^)-)O-/^(/VK4+>\AFMK?^VK)_,E5P47:J9.6 &!R<\5ZS^T'_
M ,D5\7_]>?\ [.M?!7PU_P"2D>$_^PO9_P#H]*^M\-.'\PS/A/'8O#9E4H0C
M*I>$5'EE:G%MN^NJT?DCS>+<PP^$Q^'IUL-&HVM&[W6O2Q^EFL?\@F]_ZX/_
M .@FORPK]3]8_P"03>_]<'_]!-?EA7V/T=_]TS+_ !4_RD>5XD?\PG_;_P#[
M8?I)I/C+0_!?PW\.7FN:K:Z7;G3K<*UQ(%+GREX4=6/L :S-+_:0^&VL7@M;
M?Q5;)*QP#=12VZ?]]R(J_K7R)X1^%_C[]H";^T8Y$>SM(TM$OM0E,<$:HH"Q
M( ">!_=7'//)YR?B=\#?%/PF$$NLP036,S;$OK*0R0E\9VG(# X'<#/.,X->
M5@_"7A'$8N>5X[-[X]W;A"4$D]^7E<6Y-=5>+MK9%RXLS>GAHXC"X/\ V>*2
MYI)ZVTOHTDOO7F?HQ#,EQ$DL3K)&X#*Z'(8'H0>XJ*_U"UTJSFN[VYAL[2%=
M\L]Q($C1?5F/ 'UKXP_91^,U[X<\46OA'4KEIM$U)_+MED.?LTY^[M/96/&W
MU(/'.?IKX\?\D=\7?]@^2OP[.^ <3P]Q3A^'L;.\*TX*,TMX3ER\UGLUK=7W
M6[5F?>Y7Q!2S;+IXVE&TH)WB^C2O]SZ,U[/XG>#M2NX;6T\6:'=74SB.*&'4
M87>1B<!54-DDGL*H>,OC-X+\ 7RV6NZ_;V=X1DVZ(\TB@\C<L:L5S[XK\ZO#
M>O7'A?7].U>T"&ZL9TN8O,&5WJ01D=QD5H+X?\5>-Y+W6XM*U;6S)(TES?0V
MLDR[SR2S*" :_H5> 64X;%\^-Q\EA[+^2,G-MZ7::2M;HVV^EC\Z7B#BZM)Q
MHX=.K?3=JW716=S](/"WC/0_&U@;W0M4MM4MP0&:W<$H3V9>JGV(!K89@BEF
M(55&23P *\'_ &.O!Y\/_#.;5IH]ESK%RTF6&"(H\HH/_ A(?^!5X=^T9\?+
M_P"(&N7>AZ3=-;^&+20Q;86Q]M8'!=R.JY'RKTZ$\]/Q?+/#.?$/%.,R7*:S
M^K8:34JLE>UG:UE92DVFELFE?0^VJ<3+ Y/1S''0M4J+2*Z]M]E:S>]KVUT/
MJC7OV@_AWX;N3;WOBJS,H."MJKW.#Z$Q*P!JWX7^-G@;QE<K;:3XELY[ESM2
M"8M!(Y]%60*6/T%?%7PW_9T\8_$[3?[2T^"VL--8D1W>HR-&DI!P=@568@'O
MC'7G@UF_$SX)^*?A0T+ZU:QR64S;([ZS<R0LV,[<D J?9@,X.,X-?J\?"3@?
M$XF63X7.)/&JZMS4WJMUR**;:ZQ4[KJ?(_ZWY[&E]=E@E[#>]I;=[WV\^6Q^
MCU%?)O[+/[0%[-JEOX,\27;W:3_)IM[.V71@/]2S'J#_  D\@\=",>Y_';XA
M3?#/X:ZEK%H%-^Q6UM2PR%E?(#$=\ ,V/]FOY^S;@'-\IXCI\-5$G5J-*$OL
MRC)V4O)+7FZJSW/T/+\_PF89?+,8NT8)\RZQLKOUTV[FWXK^)'A?P/QKNNV6
MFR;=PAEE!E*^HC&6(^@KD(_VH?AC)((QXH4-G'S65R!^9CQ7P]X9\,^(?BUX
MO^Q66_4]8O"TTLUQ+V'+.[,>@_P ]*]2OOV,?'MI923Q7&BWDBKD6T%U()&]
MAOC5<_4U^]U_"C@;(I0P6?YQ*&(DD[*4(+7K:49M*^S<D? 0XMSS,.:KEF#3
MIIVU3;^]-*_DKGV7X<\7:)XPM6N-$U:SU6%<!VM9E?83V8 Y4^QK7K\Q_#?B
M37?A?XN2]L9)=-U6QE,<L+@C.#AXY%[@XP0?YU^CW@GQ5;>-_">E:[:#;!?P
M+,$)R48_>4^X8$?A7Y)XC^'%7@:K1K4*OM<-5NHR:LTUKRRMH[K5-;ZZ*VOU
M?#?$RSSGHU8<E6&ZZ-;7756>C3\CR?XS?"OX:^,O%Z7_ (L\7_V'J@M4B%K_
M &G;6_[L%BK;9%+<DGGIQ73? WP/X-\#Z7JD'@[Q!_PD%M/,KW$GVV&Y\M@N
M ,Q* ./6OF?]LS_DKT7_ &#(?_0Y*]+_ &'/^17\3_\ 7Y%_Z :_0>(^'\PP
MWAQALRJ9E4G2E&BU1:CR*]K)=?=Z'A83,,//BB>%6&BIWE[^O-\/W:['TR3@
M9/ KS_7OC]\/?#<YAO?%5B95.&6UW7)4]P?*#8/UKQ3]LCXJ:A875KX+TV=[
M6WFMQ<W[QG#2AB0L6?[N%)([Y'I7C'PQ^ 'BOXL6$U_I*6EMI\<AA^U7TQ1&
M< $JH568X!'.,<]:X>&/"G*:F14^(>*\<\/1J6<4G&+L_A;E)2UENHJ.VM]T
MNK..*\31Q[RW*J'M*D=[W>N^RMMU=S[)TO\ :/\ AMK%P(;?Q7:QN>ANHI;=
M?^^I$4?K7HEK=07UO'<6TT=Q;R*&26)@RL#T((X(K\__ (B?LT^,OAKHKZM>
MQV>HZ=%CSI].E9_)R< L&56QD]0"!WK?_97^+E[X/\:V?AR[N7DT'5I?($+G
M(@G;A'7TR<*?KGM79G_A'E%;)*N><(8YXB%)-N+<974=96<5&TDM>5QN_NOQ
MX+C#&T,;#!9SAU3<[6:NK7T3LV[J^[3T/N:BBBOY7/U@**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3_)!1117X@?5!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7=_!S_D9KK_
M *\V_P#0TKA*[OX.?\C-=?\ 7FW_ *&E?;\$?\E'@O\ &OR9Y6:_[E5]#V.B
MBBO[Q/R0^8:***_S7/W **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ]-1J*^J5G=;J2VOYJQX)^V9_P E>B_[!D/_ *')7I?[#G_(K^)_^OR+_P!
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %=1\,_P#D=M-_[:?^BGKEZZCX9_\ ([:;_P!M/_13U]+PS_R/
M<!_U^I_^EQ.''?[I5_PR_)GNU%%%?Z!GXZ%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 <O\3/^1)U+_MG_ .C4KPFO=OB9_P B3J7_ &S_
M /1J5X37\C>+O_(]H_\ 7F/_ *74/T;AS_=)?XG^2"BBBOQ ^J"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&\.[36\7NO/S7FOG8O445A>-_&FE_#[PU=ZYK$QAL[<=%&7D8_=11W8G_$X
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^1O%W_D>T?\ KS'_ -+J'Z-PY_NDO\3_ "04445^('U04444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5\A_ML>.OM>L:1X3MY,QV:?;;I1_ST<8C!^BY/\
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M)]*X3X$_"J7XL>.(+"0,FDVH%Q?S+QB,'A ?[S'@>V3VK^M,EXBS'"\,O/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNY [3)\K\=LD$CV(K\UJ^G_V)_'AM=6U;PC<2?NKI?MUH&/210%D4>Y7:?\
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M41.3' BY]<*!7Z-](I*^5OK^]_\ <9\9X;_Q,4O*/_MQ;HHHK^,S]P"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *[OX.?\C-=?]>;?^AI7"5W?P<_Y&:Z_Z\V_
M]#2OM^"/^2CP7^-?DSRLU_W*KZ'L=%%%?WB?DA\PT445_FN?N 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "NH^&?\ R.VF_P#;3_T4]<O7
M4?#/_D=M-_[:?^BGKZ7AG_D>X#_K]3_]+B<.._W2K_AE^3/=J***_P! S\="
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .7^)G_(DZE_VS
M_P#1J5X37NWQ,_Y$G4O^V?\ Z-2O":_D;Q=_Y'M'_KS'_P!+J'Z-PY_NDO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5U'PS_P"1VTW_ +:?^BGKEZZCX9_\CMIO_;3_ -%/7TO#/_(]
MP'_7ZG_Z7$X<=_NE7_#+\F>[4445_H&?CH4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!@^.K5KSPCJD:C<WE;\8S]TAOZ5\_U]-RQ)/$\<
MBAXW!5E/0@]17SEK>ER:+JUW8RYW0R%02/O+V/XC!_&OYB\8,OFJ^%S%+W6G
M!^33YE]]Y?<?=\-UER5*/7?]/\BC1117\Z'VH4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5Z+\&+8MJFHW&WB.%8]W'&YLX_\=_2O.J]N^%NCMI?AE)I$
M*RWC>=R?X>B_IS^-?JGAIE\\=Q%2JI>[24I/[K+\6ON9\_GE94L%*/65E^IV
M%%%%?VH?EY\PT445_FN?N 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6O\ GZL/^_C_ /Q%>QT4?\0MX<_DG_X&P_M_&]U]QXY_PIW6O^?JP_[^/_\
M$4?\*=UK_GZL/^_C_P#Q%>QT4?\ $+>'/Y)_^!L/[?QO=?<>.?\ "G=:_P"?
MJP_[^/\ _$4?\*=UK_GZL/\ OX__ ,17L=%'_$+>'/Y)_P#@;#^W\;W7W'CG
M_"G=:_Y^K#_OX_\ \11_PIW6O^?JP_[^/_\ $5['11_Q"WAS^2?_ (&P_M_&
M]U]QXY_PIW6O^?JP_P"_C_\ Q%'_  IW6O\ GZL/^_C_ /Q%>QT4?\0MX<_D
MG_X&P_M_&]U]QXY_PIW6O^?JP_[^/_\ $4?\*=UK_GZL/^_C_P#Q%>QT4?\
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M4?\ $+>'/Y)_^!L/[?QO=?<>.?\ "G=:_P"?JP_[^/\ _$4?\*=UK_GZL/\
MOX__ ,17L=%'_$+>'/Y)_P#@;#^W\;W7W'CG_"G=:_Y^K#_OX_\ \11_PIW6
MO^?JP_[^/_\ $5['11_Q"WAS^2?_ (&P_M_&]U]QXY_PIW6O^?JP_P"_C_\
MQ%'_  IW6O\ GZL/^_C_ /Q%>QT4?\0MX<_DG_X&P_M_&]U]QXY_PIW6O^?J
MP_[^/_\ $4?\*=UK_GZL/^_C_P#Q%>QT4?\ $+>'/Y)_^!L/[?QO=?<>.?\
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MK_GZL/\ OX__ ,17L=%'_$+>'/Y)_P#@;#^W\;W7W'CG_"G=:_Y^K#_OX_\
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M_GZL/^_C_P#Q%>QT4?\ $+>'/Y)_^!L/[?QO=?<>.?\ "G=:_P"?JP_[^/\
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M_$+>'/Y)_P#@;#^W\;W7W'CG_"G=:_Y^K#_OX_\ \11_PIW6O^?JP_[^/_\
M$5['11_Q"WAS^2?_ (&P_M_&]U]QXY_PIW6O^?JP_P"_C_\ Q%'_  IW6O\
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M6O\ GZL/^_C_ /Q%>QT4?\0MX<_DG_X&P_M_&]U]QXY_PIW6O^?JP_[^/_\
M$4?\*=UK_GZL/^_C_P#Q%>QT4?\ $+>'/Y)_^!L/[?QO=?<>.?\ "G=:_P"?
MJP_[^/\ _$4?\*=UK_GZL/\ OX__ ,17L=%'_$+>'/Y)_P#@;#^W\;W7W'CG
M_"G=:_Y^K#_OX_\ \11_PIW6O^?JP_[^/_\ $5['11_Q"WAS^2?_ (&P_M_&
M]U]QXY_PIW6O^?JP_P"_C_\ Q%'_  IW6O\ GZL/^_C_ /Q%>QT4?\0MX<_D
MG_X&P_M_&]U]QXY_PIW6O^?JP_[^/_\ $4?\*=UK_GZL/^_C_P#Q%>QT4?\
M$+>'/Y)_^!L/[?QO=?<>.?\ "G=:_P"?JP_[^/\ _$4?\*=UK_GZL/\ OX__
M ,17L=%'_$+>'/Y)_P#@;#^W\;W7W'CG_"G=:_Y^K#_OX_\ \11_PIW6O^?J
MP_[^/_\ $5['11_Q"WAS^2?_ (&P_M_&]U]QXY_PIW6O^?JP_P"_C_\ Q%'_
M  IW6O\ GZL/^_C_ /Q%>QT4?\0MX<_DG_X&P_M_&]U]QXY_PIW6O^?JP_[^
M/_\ $4?\*=UK_GZL/^_C_P#Q%>QT4?\ $+>'/Y)_^!L/[?QO=?<>.?\ "G=:
M_P"?JP_[^/\ _$4?\*=UK_GZL/\ OX__ ,17L=%'_$+>'/Y)_P#@;#^W\;W7
MW'CG_"G=:_Y^K#_OX_\ \11_PIW6O^?JP_[^/_\ $5['11_Q"WAS^2?_ (&P
M_M_&]U]QXY_PIW6O^?JP_P"_C_\ Q%'_  IW6O\ GZL/^_C_ /Q%>QT4?\0M
MX<_DG_X&P_M_&]U]QXY_PIW6O^?JP_[^/_\ $4?\*=UK_GZL/^_C_P#Q%>QT
M4?\ $+>'/Y)_^!L/[?QO=?<>.?\ "G=:_P"?JP_[^/\ _$4?\*=UK_GZL/\
MOX__ ,17L=%'_$+>'/Y)_P#@;#^W\;W7W'CG_"G=:_Y^K#_OX_\ \11_PIW6
MO^?JP_[^/_\ $5['11_Q"WAS^2?_ (&P_M_&]U]QXY_PIW6O^?JP_P"_C_\
MQ%'_  IW6O\ GZL/^_C_ /Q%>QT4?\0MX<_DG_X&P_M_&]U]QXY_PIW6O^?J
MP_[^/_\ $4?\*=UK_GZL/^_C_P#Q%>QT4?\ $+>'/Y)_^!L/[?QO=?<>.?\
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MU_S]6'_?Q_\ XBO8Z*/^(6\.?R3_ / V']OXWNON/'/^%.ZU_P _5A_W\?\
M^(H_X4[K7_/U8?\ ?Q__ (BO8Z*/^(6\.?R3_P# V']OXWNON/'/^%.ZU_S]
M6'_?Q_\ XBC_ (4[K7_/U8?]_'_^(KV.BC_B%O#G\D__  -A_;^-[K[CQS_A
M3NM?\_5A_P!_'_\ B*/^%.ZU_P _5A_W\?\ ^(KV.BC_ (A;PY_)/_P-A_;^
M-[K[CQS_ (4[K7_/U8?]_'_^(H_X4[K7_/U8?]_'_P#B*]CHH_XA;PY_)/\
M\#8?V_C>Z^X\<_X4[K7_ #]6'_?Q_P#XBC_A3NM?\_5A_P!_'_\ B*]CHH_X
MA;PY_)/_ ,#8?V_C>Z^X\<_X4[K7_/U8?]_'_P#B*/\ A3NM?\_5A_W\?_XB
MO8Z*/^(6\.?R3_\  V']OXWNON/'/^%.ZU_S]6'_ '\?_P"(H_X4[K7_ #]6
M'_?Q_P#XBO8Z*/\ B%O#G\D__ V']OXWNON/'/\ A3NM?\_5A_W\?_XBC_A3
MNM?\_5A_W\?_ .(KV.BC_B%O#G\D_P#P-A_;^-[K[CQS_A3NM?\ /U8?]_'_
M /B*/^%.ZU_S]6'_ '\?_P"(KV.BC_B%O#G\D_\ P-A_;^-[K[CQS_A3NM?\
M_5A_W\?_ .(H_P"%.ZU_S]6'_?Q__B*]CHH_XA;PY_)/_P #8?V_C>Z^X\<_
MX4[K7_/U8?\ ?Q__ (BC_A3NM?\ /U8?]_'_ /B*]CHH_P"(6\.?R3_\#8?V
M_C>Z^X\<_P"%.ZU_S]6'_?Q__B*/^%.ZU_S]6'_?Q_\ XBO8Z*/^(6\.?R3_
M / V']OXWNON/'/^%.ZU_P _5A_W\?\ ^(H_X4[K7_/U8?\ ?Q__ (BO8Z*/
M^(6\.?R3_P# V']OXWNON/'/^%.ZU_S]6'_?Q_\ XBC_ (4[K7_/U8?]_'_^
M(KV.BC_B%O#G\D__  -A_;^-[K[CQS_A3NM?\_5A_P!_'_\ B*/^%.ZU_P _
M5A_W\?\ ^(KV.BC_ (A;PY_)/_P-A_;^-[K[CQS_ (4[K7_/U8?]_'_^(H_X
M4[K7_/U8?]_'_P#B*]CHH_XA;PY_)/\ \#8?V_C>Z^X\<_X4[K7_ #]6'_?Q
M_P#XBC_A3NM?\_5A_P!_'_\ B*]CHH_XA;PY_)/_ ,#8?V_C>Z^X\<_X4[K7
M_/U8?]_'_P#B*/\ A3NM?\_5A_W\?_XBO8Z*/^(6\.?R3_\  V']OXWNON/'
M/^%.ZU_S]6'_ '\?_P"(H_X4[K7_ #]6'_?Q_P#XBO8Z*/\ B%O#G\D__ V'
M]OXWNON/'/\ A3NM?\_5A_W\?_XBC_A3NM?\_5A_W\?_ .(KV.BC_B%O#G\D
M_P#P-A_;^-[K[CQS_A3NM?\ /U8?]_'_ /B*/^%.ZU_S]6'_ '\?_P"(KV.B
MC_B%O#G\D_\ P-A_;^-[K[CQS_A3NM?\_5A_W\?_ .(H_P"%.ZU_S]6'_?Q_
M_B*]CHH_XA;PY_)/_P #8?V_C>Z^X\<_X4[K7_/U8?\ ?Q__ (BC_A3NM?\
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M;PY_)/\ \#8?V_C>Z^X\<_X4[K7_ #]6'_?Q_P#XBC_A3NM?\_5A_P!_'_\
MB*]CHH_XA;PY_)/_ ,#8?V_C>Z^X\<_X4[K7_/U8?]_'_P#B*/\ A3NM?\_5
MA_W\?_XBO8Z*/^(6\.?R3_\  V']OXWNON/'/^%.ZU_S]6'_ '\?_P"(H_X4
M[K7_ #]6'_?Q_P#XBO8Z*/\ B%O#G\D__ V']OXWNON/'/\ A3NM?\_5A_W\
M?_XBC_A3NM?\_5A_W\?_ .(KV.BC_B%O#G\D_P#P-A_;^-[K[CQS_A3NM?\
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M7XHSJ9WC*T)4Y-6:MMW"BBBOU$\ **** "BBB@ HHHH **** "BBB@ HHHH
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M>'/Y)_\ @;#^W\;W7W'CG_"G=:_Y^K#_ +^/_P#$4?\ "G=:_P"?JP_[^/\
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MMX<_DG_X&P_M_&]U]QXY_P *=UK_ )^K#_OX_P#\11_PIW6O^?JP_P"_C_\
MQ%>QT4?\0MX<_DG_ .!L/[?QO=?<>.?\*=UK_GZL/^_C_P#Q%'_"G=:_Y^K#
M_OX__P 17L=%'_$+>'/Y)_\ @;#^W\;W7W'CG_"G=:_Y^K#_ +^/_P#$4?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Y5Z^JO^"7'_)]
MGPR_[B?_ *:[NOE6OJK_ ()<?\GV?#+_ +B?_IKNZ /W^HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^5>OJK_
M ()<?\GV?#+_ +B?_IKNZ^5:^JO^"7'_ "?9\,O^XG_Z:[N@#]_J*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
ME7KZJ_X)<?\ )]GPR_[B?_IKNZ^5:^JO^"7'_)]GPR_[B?\ Z:[N@#]_J***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH _E7KZJ_X)<?\GV?#+_N)_P#IKNZ^5:^JO^"7'_)]GPR_[B?_ *:[N@#]
M_J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#XJ_;._X*):Q^Q[\1['P[>_"G_A(])U*R6\L-:7Q ;59\';+&8_LK[61L
M9&X\,AXW8'@'_#\[_JB?_EU__<5?57_!2+]F[_AHC]G'5/[-M?/\6>&=VL:3
ML7+R[%_?P#N?,C!P.[I'Z5^ - !7JO[+?QT_X9K^.WAGXC_V)_PD?]B_:O\
MB6?:_LOG>=:RP?ZW8^W'F[ONG.W'&<CRJB@#]5/^'YW_ %1/_P NO_[BK[4_
M8Q_:BU3]K3X<7WC*Z\#?\(7IJ7K6=E_Q-UO_ +7M'[QN(HRFUL##+SU%?@#\
M*OASJGQ<^(_ASP;HR;]2UJ]CLXN5&W<?F;YF4'"Y."PSC%?TI_"KX<Z7\(_A
MQX<\&Z,FS3=%LH[.+ECNVCYF^9F(RV3@L<9QF@#JZ*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,XS75T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYE_X"_\ (/KN%_Y^Q^]'OU%> _\ #>7P+_Z'G_RDWW_QBC_AO+X%_P#0\_\
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MYE_X"_\ (/KN%_Y^Q^]'OU%> _\ #>7P+_Z'G_RDWW_QBC_AO+X%_P#0\_\
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MYE_X"_\ (/KN%_Y^Q^]'OU%> _\ #>7P+_Z'G_RDWW_QBC_AO+X%_P#0\_\
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MYE_X"_\ (/KN%_Y^Q^]'OU%> _\ #>7P+_Z'G_RDWW_QBC_AO+X%_P#0\_\
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MYE_X"_\ (/KN%_Y^Q^]'OU%> _\ #>7P+_Z'G_RDWW_QBC_AO+X%_P#0\_\
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MYE_X"_\ (/KN%_Y^Q^]'OU%> _\ #>7P+_Z'G_RDWW_QBC_AO+X%_P#0\_\
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MYE_X"_\ (/KN%_Y^Q^]'OU%> _\ #>7P+_Z'G_RDWW_QBC_AO+X%_P#0\_\
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MYE_X"_\ (/KN%_Y^Q^]'OU%> _\ #>7P+_Z'G_RDWW_QBC_AO+X%_P#0\_\
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MYE_X"_\ (/KN%_Y^Q^]'OU%> _\ #>7P+_Z'G_RDWW_QBC_AO+X%_P#0\_\
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MJ&+_ .?,O_ 7_D'UW"_\_8_>CWZBO ?^&\O@7_T//_E)OO\ XQ1_PWE\"_\
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MJ&+_ .?,O_ 7_D'UW"_\_8_>CWZBO ?^&\O@7_T//_E)OO\ XQ1_PWE\"_\
MH>?_ "DWW_QBCZAB_P#GS+_P%_Y!]=PO_/V/WH]^HKP'_AO+X%_]#S_Y2;[_
M .,4?\-Y? O_ *'G_P I-]_\8H^H8O\ Y\R_\!?^0?7<+_S]C]Z/?J*\!_X;
MR^!?_0\_^4F^_P#C%'_#>7P+_P"AY_\ *3??_&*/J&+_ .?,O_ 7_D'UW"_\
M_8_>CWZBO ?^&\O@7_T//_E)OO\ XQ1_PWE\"_\ H>?_ "DWW_QBCZAB_P#G
MS+_P%_Y!]=PO_/V/WH]^HKP'_AO+X%_]#S_Y2;[_ .,4?\-Y? O_ *'G_P I
M-]_\8H^H8O\ Y\R_\!?^0?7<+_S]C]Z/?J*\!_X;R^!?_0\_^4F^_P#C%'_#
M>7P+_P"AY_\ *3??_&*/J&+_ .?,O_ 7_D'UW"_\_8_>CWZBO ?^&\O@7_T/
M/_E)OO\ XQ1_PWE\"_\ H>?_ "DWW_QBCZAB_P#GS+_P%_Y!]=PO_/V/WH]^
MHKP'_AO+X%_]#S_Y2;[_ .,4?\-Y? O_ *'G_P I-]_\8H^H8O\ Y\R_\!?^
M0?7<+_S]C]Z/?J*\!_X;R^!?_0\_^4F^_P#C%'_#>7P+_P"AY_\ *3??_&*/
MJ&+_ .?,O_ 7_D'UW"_\_8_>CWZBO ?^&\O@7_T//_E)OO\ XQ1_PWE\"_\
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MJ&+_ .?,O_ 7_D'UW"_\_8_>CWZBO ?^&\O@7_T//_E)OO\ XQ1_PWE\"_\
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MJ&+_ .?,O_ 7_D'UW"_\_8_>CWZBO ?^&\O@7_T//_E)OO\ XQ1_PWE\"_\
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MJ&+_ .?,O_ 7_D'UW"_\_8_>CWZBO ?^&\O@7_T//_E)OO\ XQ1_PWE\"_\
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MJ&+_ .?,O_ 7_D'UW"_\_8_>CWZBO ?^&\O@7_T//_E)OO\ XQ1_PWE\"_\
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MJ&+_ .?,O_ 7_D'UW"_\_8_>CWZBO ?^&\O@7_T//_E)OO\ XQ1_PWE\"_\
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MJ&+_ .?,O_ 7_D'UW"_\_8_>CWZBO ?^&\O@7_T//_E)OO\ XQ1_PWE\"_\
MH>?_ "DWW_QBCZAB_P#GS+_P%_Y!]=PO_/V/WH]^HKP'_AO+X%_]#S_Y2;[_
M .,4?\-Y? O_ *'G_P I-]_\8H^H8O\ Y\R_\!?^0?7<+_S]C]Z/?J*\!_X;
MR^!?_0\_^4F^_P#C%'_#>7P+_P"AY_\ *3??_&*/J&+_ .?,O_ 7_D'UW"_\
M_8_>CWZBO ?^&\O@7_T//_E)OO\ XQ1_PWE\"_\ H>?_ "DWW_QBCZAB_P#G
MS+_P%_Y!]=PO_/V/WH]^HKP'_AO+X%_]#S_Y2;[_ .,4?\-Y? O_ *'G_P I
M-]_\8H^H8O\ Y\R_\!?^0?7<+_S]C]Z/?J*\!_X;R^!?_0\_^4F^_P#C%'_#
M>7P+_P"AY_\ *3??_&*/J&+_ .?,O_ 7_D'UW"_\_8_>CWZBO ?^&\O@7_T/
M/_E)OO\ XQ1_PWE\"_\ H>?_ "DWW_QBCZAB_P#GS+_P%_Y!]=PO_/V/WH]^
MHKP'_AO+X%_]#S_Y2;[_ .,4?\-Y? O_ *'G_P I-]_\8H^H8O\ Y\R_\!?^
M0?7<+_S]C]Z/?J*\!_X;R^!?_0\_^4F^_P#C%'_#>7P+_P"AY_\ *3??_&*/
MJ&+_ .?,O_ 7_D'UW"_\_8_>CWZBO ?^&\O@7_T//_E)OO\ XQ1_PWE\"_\
MH>?_ "DWW_QBCZAB_P#GS+_P%_Y!]=PO_/V/WH]^HKP'_AO+X%_]#S_Y2;[_
M .,5O^ _VM?A1\3O%ECX:\->*_[2UN^\S[/:_P!G7<6_9&TC?-)$JC"HQY(Z
M>M3+!8J*<I4I)+R94<9AI-1C4BV_-'K]%%%<9UA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!^ ]%%%?N9^-!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7OW[!O\ R==X
M&_[?O_2"XKP&O?OV#?\ DZ[P-_V_?^D%Q7!C_P#=*W^&7Y,[,%_O5+_$OS/U
MZHHHK\;/UD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /P'HH
MHK]S/QH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!^ ]%%%?N9^-!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7OW[!O_)U
MW@;_ +?O_2"XKP&O?OV#?^3KO W_ &_?^D%Q7!C_ /=*W^&7Y,[,%_O5+_$O
MS/UZHHHK\;/UD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /P
M'HHHK]S/QH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *]^_8-_P"3KO W_;]_Z07%> U[]^P;_P G7>!O
M^W[_ -(+BN#'_P"Z5O\ #+\F=F"_WJE_B7YGZ]4445^-GZR%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'X#T445^YGXT%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>_?
ML&_\G7>!O^W[_P!(+BO :]^_8-_Y.N\#?]OW_I!<5P8__=*W^&7Y,[,%_O5+
M_$OS/UZHHHK\;/UD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /P'HHHK]S/QH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'/ ZL/F^#Q4U3A*S??0YZ^58O#P=24;I=M3PRBBBO:/("BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*^O_ -C?]C_P;^T-\/M7UWQ'J>NV5W9ZFUE&FESPQQE!%&^2'B<YRY[^G%8O
M[:7[+/A3]G*Q\*3^&M0UF^?5I;E)QJLT4@41B,KM\N),??.<Y[5Y;S+#K%?5
M+OG]/*YZ<,NKSP_UE)<MF]^Q\M4445ZAY@4444 %%%% !1110 4444 %%%%
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MZHJEL'LN/K7/@\?2Q[?L;Z=;:&V-P=3 0YZ]OOU,.BOT[_X=A_"W_H/^+_\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
M>BBBOW,_&@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "OK/_@F?_P G!:C_ -@"X_\
M1T%?)E?6?_!,_P#Y."U'_L 7'_HZ"O/S#_<ZO^%_D=N!_P!ZI?XE^9^B?QD\
M97OP]^%/BSQ-IT5O-?Z3ILUY!'=*S1,Z(2 P4@D<=B/K7Y[+_P %/?BCN&=
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ML;22RN3@*JJ"6)/85^V?Q\_Y(?\ $#_L WW_ *(>OR-_9H_Y."^'G_8<M/\
MT8*];*\SGCX5)2BERV_4\W-,NC@%!QE?FO\ A;_,S[KX"_$VRMY;BX^'7BR"
MWA0R22RZ'=*J*!DL24P !WK1^&O[-GQ+^+^F2:CX3\*76IZ<C;/M<DL5M"[
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M ;/Q/X4UB$C;(FZ.1<X(96&592.A 92.Q%>9_;F.I*-:M17(_5?CK^6IZ/\
M8^"J2=&G5?.O1_A_P=#\-:?;V\MW<1P01/--(P1(XU+,[$X  '4D]J]C_:N^
M ;_L_?%*?2+9I)]!OH_MFESR<MY1)!C8]V0@CW&T]\5]=?\ !./X$:1I_@4?
M$O4;6.\UO4II8=.DD4-]D@1C&Q3/1V8."?[H &,G/TE;,J-/!_7%K%[>;[?Y
M^C/GX9?6EB_JCTDM^UN_W;?(^1_#O[&?QH\46"7EEX!OXH7Z#4)H+)_^^)G1
MA^52:]^Q;\:O#MC)=W?@*]EBC&2MC<6]W)^"0R,Q_ 5^CWQN_; ^'OP%UI-&
MUZ;4+_6C$LS:?I=L)'C1L[69G9$&<=-V>AQR*?\ !+]K[X>?'C5&TG0KJ\T_
M6MC2+INK0"*61%ZE"K,C8ZX#9P"<8%?.?VQF4H>WC17)WL]OO_&Q[[RK+X35
M&=9\_JO\OU/QXO;*XTV\FM+N"6UNH7,<L$R%'C8'!5E/((/8U#7Z??\ !0/]
MGO3O&OPXO/'NF6<</B;04$US-&H#75H.'5_4H#N!/.%8=Z^%/V8_A+%\;/C1
MH'AB\+KI<C-<WS1G#>1&I9E![%L!<]MV:^AP.94\9AY5W[O+?F\K*_Y?Y'A8
M[+YX.M&DG?FV\[NUO6YA?#WX)^._BLY'A/PMJ.LQ*Q1KF&+;;JP .UIFP@/(
MX+9KT8_L(?',+N_X08X_["MCG\O/K]3O$'B#PE\#/AY)J%\;?P]X5T>%(PMO
M"=D2DA$540$DEB  !R37@%C_ ,%*/A)>:NMG+;^([*W+;3J$]A&8 /4A)6DQ
M_P  S[5X$<ZQV*;>$HWBO5_DU]Q[3RC!X>*6+JVD^UE^C^\_.#Q]\)O&7PMN
MEM_%?AK4=#9VV1R74!$4I R0D@RC_P# 2:Y.OW1UC1_"_P 8O ;6EY%:^(?#
M.LVRNI!WQRQL,JZ,.AZ$,.00",&OQJ^.GPMG^#/Q6\0^$9I&FCL9_P#1YVZR
MP. \3'WVL,^X->IE>;?7I2HU8\LU_3]+=C@S'*UA(*M2ES0?]+U7F>N_LO\
MQP^,GPQ\%ZGIWPY^'_\ PEFD3W[7$]W_ &+>7OES&-%*;X'51\JJ<$9Y]ZRO
MVJ/C#\5OBE9^'(_B3X(_X1"*RDG:Q;^R;NR\]F";QF=VW8VK]WIGGJ*^K?\
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M@U^F?_!.S_DV?3?^PC=_^C*]WF\(Z#I_B^[\;7,,,>K#3UL&O[A@!!;([R$
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M9^$[[Q!K][%IFCV$>Z25OR5%4=6)P HY)( K9L;&WTVS@M+2".UM8$6**"%
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MAA8XJC/F3M]SZ_UW/$[.SGU"[@M;6"2YNIW6**&%"[R.QPJJHY))(  KNO\
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M3J.FW,EI<(.@=&*G![@XR#W!%95?:1DIQ4HNZ9\C*,H2<)*S044451(4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %>_?L&_\G7>!O^W[_P!(+BO :]^_8-_Y.N\#?]OW_I!<
M5P8__=*W^&7Y,[,%_O5+_$OS/UZHHHK\;/UD**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /P'HHHK]S/QH**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKZS_ ."9_P#R<%J/_8 N/_1T%?)E?6?_  3/_P"3@M1_[ %Q_P"CH*\_,/\
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MAT^S@M;>-8K>"-8HXU& JJ, #Z 5^)OQ]\:WWQ!^,OC#6[^9IGFU*:.(,?\
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MOMMHON/JO_@F7\4/[;\ :YX'NI<W.B7'VNT5B,_9YB2P _V9 Q/_ %T%4_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7OW[!O_ "==
MX&_[?O\ T@N*\!KW[]@W_DZ[P-_V_?\ I!<5P8__ '2M_AE^3.S!?[U2_P 2
M_,_7JBBBOQL_60HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
M >BBBOW,_&@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO2S7+ZTE5K46Y>B?ZZ_<?H?^UO\ M&Z1\#?AWJ-O%>12>+]2MW@TVP1@9%+
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ME:^WRL.EFD*>!>$<7>S5_6YSU??W_!,/XJ;D\2?#V[EY7_B;V 8GI\J3*/\
MR&V!ZL:^ :T?#_B35_"6J1ZGH>JWNC:C&&"7FGW#P3*",$!T((R"0>:]?&89
M8S#SH/K^?0\;"UWA:\*RZ/\ #K^!^Z'B_P 3V7@KPKJ^OZB_EV&F6LEW,W^R
MBEB![\5^''C7Q9?>//%VL^(M2???:I=R7<O.0&=B=H]AG ]@*U]:^,WQ!\2Z
M7/INK^.O$NJZ=< +-9WNKW$T,@!! 9&<@\@'D=JXZO)RK*7E\ISG*[>GHO\
M@_H>MF>:+'0C3@K):OS[?=K]Y<T?5KO0-7L=3L)FM[ZRG2Y@F7JDB,&5A]"!
M7[)?LX_M#:#^T%X'M]2L9HK?7;>-4U322X\RVEZ%@.IC8Y*M^'4$#\8:OZ%X
M@U3POJD.I:-J5WI.HPY,=W8SM#*F1@X92"*[,RRZ&84U%NTEL_ZZ'#@,=/ U
M'.*NGNC]7/B-^P1\*?B/XHEUV6UU+0KNXD,US'HURD4-PY.261T<*3WV;<Y)
MZG->Q^'_  _X5^"O@*+3[!+7P[X8TB%G+2R[8XDY9G=V/))))8G))K\I[']N
M3XX:?;)!%X[F=$& 9]/M)7_%GA+'ZDUP?Q&^.GC[XM%1XL\5:AK$"D,MJ[B.
MW##HPA0*@;GKMS7SCR3'U8QHUJRY%YM_A9?GH?0K.,%3DZU.D^=^B_'_ (!W
MG[8G[0,?Q^^*37>F-)_PC.DQFSTP."IE7.7F*GD%SC@\[57/.:\)HHK['#X>
M&%I1HT]E_7XGRF(KSQ565:IN_P"OP"@$@Y'!HHKI.<_1C]DW]O32=5T>Q\)?
M$O4%TS5K=!#;:_=-B"Z4< 3N?N2 ?QM\K8Y(/7[+U#2]$\::.(;ZSL->TFX4
M.([B)+B"5>H.""I%?@Y70^&?B)XK\%QO'X>\3ZSH,<C;G73+^6V#'U(1ADU\
MGC<@IUZCJT)<C?3I_P  ^DP>=5,/!4JL>9+[_P#@G[<^%_ /ACP.LJ^'/#FD
MZ LO^L72[&*V#_78HS7D7[17[8'@[X%:5=VD5[!KOB_:5M]&M9 YC?'#3L.(
MU&0<'YCV'4C\M=4^-?Q#URSDM-2\>>)M0M9!M>"ZUBXE1AZ%6<@BN,KEH\.7
MGS8FIS+RZ_,[*F?J,.7#T[/S_P C7\7>+-4\=>)M3\0:U=->ZKJ,[7%Q,W\3
M$] .P P !P  .U?>'_!*_P#Y!'Q#_P"N]E_Z#-7Y\5T/A7XB>*_ J7">&O$^
ML^'EN2IG72M0EMA*5SM+;&&[&3C/J:^FQF%^L826%IZ722[*S3_0^<PV(='%
M0Q,];-M^=TU^I^CO_!3;_D@^C_\ 8>A_]$3U^8-=/XF^*?C3QM8)8^(O%^O:
M]9)()5MM3U.>YC5P" P5V(!P2,^YKF*PRS!2P%!TI.^MSIS+&QQU6-2*M96_
M%O\ 4_:?]ES_ )-U^'7_ &!+;_T 5^>/_!1+_DYC4O\ L'VG_HNO&]+^-WQ%
MT/3;;3]-\?>*-/L+9!%!:VNLW,442#@*JJX"@>@KG?$7BC6?&&IMJ6O:M?:W
MJ+*$:[U&Y>XE*C@ NY)P/K7GX7*9X?&RQ3FFG?3U.NMFD*N"6%47=)*_I8_4
MO_@G9_R;/IO_ &$;O_T97AO_  50_P"1@^'?_7K>_P#H<-?'WAWXM^.?!^F+
MIN@^,_$.B:<K%UM-.U6>WB#$Y)"(X&3]*H^*O'WB?QU);R>)?$>K>(7M@RP-
MJM]+<F(-C<%+L=N<#./04X93..8_7>96NW;U37ZD_P!I0_L]X/E=^_\ V]<P
MJ^A?V,_VE4_9]\>7$6L>9)X2UH)%?^6"S6[J3LG5>^W<0P')4\9( /SU17T%
M:C"O3E2J*Z9XE.I*C.-2#LUJC]S]0T_PE\:/ LEM<+8^*/"VK0\['$D,RYR"
MK*>&!&0005([$5X3H_\ P3I^$&D^)/[5>#6-1MU?>FE7E\&M5YR!\J+(P'HS
MG/?-?FGX!^+7C+X6W1G\*>)=1T,LV]XK6<B&1L8R\9RC\?W@:],E_;J^.4T)
MB;QTX4C&5TRR5O\ OH0Y_6OCEDN-PTFL)6M%^J_)/[SZS^V,)B(KZW1NUZ/\
M[?<?J-\2_BAX1^ _@=M6UVY@TO3+6/RK2R@"B29E'RPP1C&3@#@< <D@ FOQ
M[^-WQ<U/XW_$C5?%FJ+Y+73!+:U#;EMH%XCC!]AR3QEBQQS7.^+/&FO^.]5;
M4_$6LWVN7[#;]HO[AIG"Y)V@L3A>3P.!6-7K99E,<"W5F^:;Z]OZ[GFYAFDL
M9%4J:Y8+\?Z['Z<?\$P_^2%Z_P#]C%-_Z36]<?\ \%4/^0/\.O\ KO??^@P5
M\/>%_BEXS\$V,EEX=\7:[H%E)(9GM]+U*:VC9R "Y5& +84#/7 'I4/BKXB>
M*_'26R>)?$^L^(4MBQ@75=0EN1$6QN*^8QVYP,XZX%1+*IRS%8WF5NW_ &[8
MUIYK"G@7A'%WLU?UN<]7[N>!?^1)\/?]@ZW_ /12U^$==W!\?/B=:P1PP_$;
MQ;##&H1(X]<NE55 P  ). !6^:Y?+,(1C&5K,X\MQL<#4E.2O=6.I_;&_P"3
MFOB!_P!?X_\ 125^AG[ ?_)K7A7_ *[7G_I5+7Y-ZQK6H>(M4N-2U:_NM3U&
MX;?-=WDS332MC&6=B23@#J:Z+P_\8/'GA/2XM,T3QMXBT;382QCL]/U:X@A0
MDDG"(X R22<#J:G$9;.ME]/!J5G'EU]%8TH9A&ECIXMQTDY:>KN?3?\ P5 _
MY+'X7_[ 2_\ I1-7-?L*_M,67P3\6WN@>)+@V_A37'0M<D96SN1PLC>B,/E8
M]L*>@-?.GBCQIXA\<7D5WXCUW4]?NXH_*CGU2\DN9$3).T,[$@9)./<UC5T4
M,OC'!+!UM5K^=_P,L5CW6QOURDK/2WR27X_D?N3X\^'OA+XV>#?[)\065OKV
MAW6V>)TDZ'&5EBD0Y!P>&4\@D<@D5Y#\-OV"/A9\-/%5OX@@AU37+VUE$UK'
MK%RDD5O(#E65$C3<1VW[L$ ]1FOS6^'7[07Q%^$\'V?PKXMU#2[/G%GN6:W4
MDY)$4@9 2>X&:[/4/VX_CAJ5J]O-X[F2-P5)M]/M(7_!DB# ^X-?.K)<?A^:
M&&K6B_-K\DSVWG&#Q"C+$T;R7H_SL?I'^TM^T5HG[/O@6YOKBXAG\174;)I6
ME[@9)I",!V7J(U/+-[8') K\;]0U"YU;4+F^O)FN+NYE::::0Y9W8DLQ]R23
M4VN:]J?B;4YM2UC4;O5=0F.9;N^G::5\# R[$D\>]4:]W*\LCET'K>3W?Z+^
MM3Q\RS*6/DDE:*V7ZO\ K0****]P\8_:?]ES_DW7X=?]@2V_] %? O\ P4J_
MY.(M_P#L!VW_ *,FKP?2_C=\1=#TVVT_3?'WBC3["V0106MKK-S%%$@X"JJN
M H'H*Y_Q+XMUSQIJ(U#Q!K.H:[?B,1"ZU*ZDN)0@)(7<Y)P,GCW-?,87*)X?
M&O%.::;>GJ?0U\SA5P4<*HNZ25_2QE5^A_\ P3;^/G]IZ7=?##6+G-U9*]YH
M[2'[T).981[J3O ]&;LM?GA5W1=<U+PUJEOJ6D:A=:5J-N2T-Y93-#-&2""5
M=2"."1P>]>SC<+'&4)49==O)]'_70\C"XB6%K1K1Z?BNJ_KKJ?MG\:/A/I7Q
MJ^'.K>%-64*EU'NM[C;EK:=>8Y5]P?S!(Z&OQON/!VJ_#[XK1>'-;MS:ZIIN
MJ1V\\?;(D7# ]U(P0>X(-7_^&@_BE_T4KQ?_ .#ZZ_\ CE<KKGB[7/%&L#5M
M9UK4-6U4;<7U]=233_+]WYV);CMSQ7F93E]?+9-2FG%]//O_ )_(]'-\=1S*
MERQ@U+57\GT_7[^Y^\=?AM\8O^2N>-_^PY??^E#UH?\ #0?Q2_Z*5XO_ /!]
M=?\ QRN&O+RXU&\GN[N>2ZNIY&EEGF<N\CL<LS,>22222>N:RRK*9Y?4E.4D
M[JQMF6:0QU.,(Q:L[GZB_L*_M-:?\3/ NG^"]9O$A\7Z+ MO&DSX-];H,(Z9
M^\RJ &'7C=W./3?CA^RKX ^/TT%WXCLKFUU>%/*35=,E$-QY><[&RK*P]-RD
MC)QC)K\;;.\N-.O(;JTGDM;J!Q)%/"Y1XV!R&5AR"#SD5[7I?[;GQMT?3HK*
M#QY=20QKL5KJSM;B4CWDDB9R?<DFN;&9)5>(^LX.?*WKU6O6S7?M^FAO@\WI
MQH?5\7#FBM.FW2Z?;O\ KJ?H1H'@3X3_ +$O@^?4;<-!=7SI:BZO91-?ZA(3
M\D2< =3DA550!N;IFO>KK_CVE_W#_*OPN\8?$;Q1X_UX:UXBUZ_UC5%.8[BZ
MG9FBYR!&.B 'D!< =JW#^T%\4F!!^)/B\@]1_;MU_P#'*YJ_#];$14JE6\W>
M[?RM;TU_R.BCGE'#S<:=*U/2R6]];M^NG^9Q5[_R$I_^NK?^A5^\FD_\@JR_
MZXI_Z"*_!-F9F+$DL3DD]:[Q/V@/BC&JJOQ(\7*JC 5==N@ /3_65[6:9;/,
M*=.$96Y;_C;_ "/,P&8QP=6I4E&_,;O[6?\ R<E\0O\ L*R?R%=S_P $\_\
MDYW1/^O*\_\ 1+5\[ZMK%_K^I7&HZI>W&I:A</YDUW=RM++*Q_B9V))/N34_
MAWQ-K'A'5$U+0M6OM%U&-65+S3KE[>901@@.A! (X/-=T<,XX+ZK?7DY;_\
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M]&3JTJ+YO1+]7;[CU3]NC]H+3_C=\2K2ST"87/AOP_&]O;W2YVW,SD&61?\
M9^55![[2>AKNO^"??[3>F_#J]N_ /BF\2QT;4I_M.GW\[[8[>X("M&Y/"JX"
MX/ # Y^]D?&-%?2K+J*P?U+[-OG?>_K?7_@'ST\?6EBOK:TE^':WI;3_ ()^
MW7Q<^"'@WXZ:##IOBS3%ODA)>UNX7,<]NQ')C<>O&0<J<#(.!7'_  0_8_\
MA[\!=8EUC0H;_4=99&C34-6G662%&^\J!$15SZ[=V"1G!(K\P_ /[37Q1^&-
MBECX=\::C9V**%CM)REU#$!V1)E=4'^Z!6_KW[:GQK\1Z?+97?CV\BAD&&:Q
MMK>TD_"2&-6'X&OF?[$Q]*+HTJRY'YM?A9_GJ?1?VQ@JKC5K47SKT?XZ?EH?
M;/[=W[3.F_#OP'J/@C1;Z.X\7:U";:>.%\M8VSCYW?'1F4[5'!^;=V&?BW]C
M#XO:?\&OCIINIZQ*MOHVH02:9>7#=($D*LLA]@Z)GT&3VKQ"ZNIKZZEN;F:2
MXN)G,DDTK%G=B<EB3R23W-15]!@LKI83#2H-WYMW\K'AXW,JF*KQJQTY=E^.
MO];:'[R:YHFD^-O#EWI>I6\.J:-J5N8IH6.Z.:)AZCU!X(]B*^>/#O\ P3S^
M#WAGQ$VLS6NJ:K!&_FIIVJ7H>TBP<CA45F4>CLP(ZYK\\OA[^T[\4?A9I@T[
MPUXROK+3U&$M)UCNHHAZ(DRN$'LH%.^('[4/Q3^*&EMIOB/QE?7FGN,26MND
M=K%*/1UA5 X]FR*\"GD>.P\VJ%:T7ZI_=W^9[=3.,)B()UZ5Y+T:^_\ X!^O
MGP]^(_ACXCV.HR^%=1@U.PTN\;39)K7_ %0D15)"$<%0&&".#VXK\\/^"FGA
MFYTWXUZ+K10BTU/2$1)/62*1PX_ /'^=?,GA;XF>,/ ]K-;>&_%>M^'[>9_,
MEATO49K9)&QC<P1@"<<9-,\5?$;Q9XZCMX_$GB?6?$,=N6:%=5U":Y$1.,E0
M['&<#./2N[!Y++!XN->$[Q7??;_,Y,3G$,5A949PLWVV6MU^&A^I?['?[4&E
M?&WP18Z-J-['!XWTNW6&\M9F"M=JHP+B/^\" -P'W6)XP5)V_C1^QO\ #CXY
M:RVM:S:7NF:Y(%6;4M(G$,DP48&]65D8XP-VW=@ 9P!7X_6=[<:;>0W5I/+:
MW4+B2*>%RCQL#D,K#D$'N*]ET']M+XU>&[".SM/'M[+#&,!KZW@O)/QDFC=C
M^)K+$Y)5C7>(P-3E;Z:K\5T\K%8;.*?L50Q<.9+Y_@_SN?I+\$OV1_A[\!=2
M?5?#]I>7NM-&T(U+5+@2RJC8RJA55%SCJ%SVSBO)?^"@'[1VD>$_A_J'P\TB
M]CN_$VLH(;V.%@WV*V)!;?Z,X^4+UVL3QQGXP\2?MD_&?Q58/9WWCW4(X7^]
M_9\4-D__ 'W B-^M>-S327$SRRNTLLC%G=R2S$G))/<TJ&25JE=5\=4YK=-7
MMZVT\BZN<4*5%TL%3Y;^B^>E[OS/2?V<_C-<_ ?XK:5XICB>YLEW6U_:QD!I
MK9\;P,]P0K#W45^P6C:UX4^-/@,75E+9^)/#&KP%'4@21R(1AD=3T8="IY!'
M8U^&-=1X#^*/B[X87[7GA3Q%J&A3.09!:3E8Y<9QO3[K@9/# UZ6:95',+3B
M^6:_%>9YN6YE+ -Q:O%_GW1^FNG?\$[OA!IOBR/6A::M<6T<GF)HMQ>A[($<
M@$;?,89[-(0>AR.*]B^+GQ<\-? [P3<Z_P"(+J.UMX4*6MFA ENI /EBB7N3
M^0&2< $U^73?MV?'-HO+/CIMN,9&EV0/Y^3FO(O&'COQ%\0=6.I^)=;OM<OB
M"!-?3M*4!.=JY.%7/\(P!Z5XW]B8S$RBL96O%>;;_%+[]3U_[8PF'C)X6E:3
M\DE^#_ F^(WCK4?B9XZUOQ3JIS?:I<M<.H.0@/"H/95"J/917.445]K"$:<5
M""LEHCY&I.52;G-W;U844459 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>_?L&_P#)UW@;
M_M^_](+BO :]^_8-_P"3KO W_;]_Z07%<&/_ -TK?X9?DSLP7^]4O\2_,_7J
MBBBOQL_60HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _ >BBB
MOW,_&@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /US_9U_:!^'-O\#?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *]^_8-_Y.N\#?]OW_I!<5X#7OW[!O_)UW@;_
M +?O_2"XK@Q_^Z5O\,OR9V8+_>J7^)?F?KU1117XV?K(4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 ?@/1117[F?C04444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5[]^P;_
M ,G7>!O^W[_T@N*\!KW[]@W_ ).N\#?]OW_I!<5P8_\ W2M_AE^3.S!?[U2_
MQ+\S]>J***_&S]9"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#\!Z***_<S\:"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?@/1117[F?C04444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5[]^
MP;_R==X&_P"W[_T@N*\!KW[]@W_DZ[P-_P!OW_I!<5P8_P#W2M_AE^3.S!?[
MU2_Q+\S]>J***_&S]9"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#\!Z***_<S\:"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "O?OV#?\ DZ[P-_V_?^D%Q7@->_?L&_\
M)UW@;_M^_P#2"XK@Q_\ NE;_  R_)G9@O]ZI?XE^9^O5%%%?C9^LA1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!^8G_#L/XI?]!_PA_X&77_R
M-1_P[#^*7_0?\(?^!EU_\C5^G=%?2?ZP8[NON/G_ .P\'V?WGYB?\.P_BE_T
M'_"'_@9=?_(U'_#L/XI?]!_PA_X&77_R-7Z=T4?ZP8[NON#^P\'V?WGYB?\
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M'_"'_@9=?_(U?IW11_K!CNZ^X/[#P?9_>?F)_P .P_BE_P!!_P (?^!EU_\
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MG=%'^L&.[K[@_L/!]G]Y^8G_  [#^*7_ $'_  A_X&77_P C4?\ #L/XI?\
M0?\ "'_@9=?_ "-7Z=T4?ZP8[NON#^P\'V?WGYB?\.P_BE_T'_"'_@9=?_(U
M'_#L/XI?]!_PA_X&77_R-7Z=T4?ZP8[NON#^P\'V?WGYB?\ #L/XI?\ 0?\
M"'_@9=?_ "-1_P .P_BE_P!!_P (?^!EU_\ (U?IW11_K!CNZ^X/[#P?9_>?
MF)_P[#^*7_0?\(?^!EU_\C4?\.P_BE_T'_"'_@9=?_(U?IW11_K!CNZ^X/[#
MP?9_>?F)_P .P_BE_P!!_P (?^!EU_\ (U'_  [#^*7_ $'_  A_X&77_P C
M5^G=%'^L&.[K[@_L/!]G]Y^8G_#L/XI?]!_PA_X&77_R-1_P[#^*7_0?\(?^
M!EU_\C5^G=%'^L&.[K[@_L/!]G]Y^8G_  [#^*7_ $'_  A_X&77_P C4?\
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MP\'V?WGYB?\ #L/XI?\ 0?\ "'_@9=?_ "-1_P .P_BE_P!!_P (?^!EU_\
M(U?IW11_K!CNZ^X/[#P?9_>?F)_P[#^*7_0?\(?^!EU_\C4?\.P_BE_T'_"'
M_@9=?_(U?IW11_K!CNZ^X/[#P?9_>?F)_P .P_BE_P!!_P (?^!EU_\ (U'_
M  [#^*7_ $'_  A_X&77_P C5^G=%'^L&.[K[@_L/!]G]Y^8G_#L/XI?]!_P
MA_X&77_R-1_P[#^*7_0?\(?^!EU_\C5^G=%'^L&.[K[@_L/!]G]Y^8G_  [#
M^*7_ $'_  A_X&77_P C4?\ #L/XI?\ 0?\ "'_@9=?_ "-7Z=T4?ZP8[NON
M#^P\'V?WGYB?\.P_BE_T'_"'_@9=?_(U'_#L/XI?]!_PA_X&77_R-7Z=T4?Z
MP8[NON#^P\'V?WGYB?\ #L/XI?\ 0?\ "'_@9=?_ "-1_P .P_BE_P!!_P (
M?^!EU_\ (U?IW11_K!CNZ^X/[#P?9_>?F)_P[#^*7_0?\(?^!EU_\C4?\.P_
MBE_T'_"'_@9=?_(U?IW11_K!CNZ^X/[#P?9_>?F)_P .P_BE_P!!_P (?^!E
MU_\ (U'_  [#^*7_ $'_  A_X&77_P C5^G=%'^L&.[K[@_L/!]G]Y^8G_#L
M/XI?]!_PA_X&77_R-1_P[#^*7_0?\(?^!EU_\C5^G=%'^L&.[K[@_L/!]G]Y
M^8G_  [#^*7_ $'_  A_X&77_P C4?\ #L/XI?\ 0?\ "'_@9=?_ "-7Z=T4
M?ZP8[NON#^P\'V?WGYB?\.P_BE_T'_"'_@9=?_(U'_#L/XI?]!_PA_X&77_R
M-7Z=T4?ZP8[NON#^P\'V?WGYB?\ #L/XI?\ 0?\ "'_@9=?_ "-1_P .P_BE
M_P!!_P (?^!EU_\ (U?IW11_K!CNZ^X/[#P?9_>?F)_P[#^*7_0?\(?^!EU_
M\C4?\.P_BE_T'_"'_@9=?_(U?IW11_K!CNZ^X/[#P?9_>?F)_P .P_BE_P!!
M_P (?^!EU_\ (U'_  [#^*7_ $'_  A_X&77_P C5^G=%'^L&.[K[@_L/!]G
M]Y^8G_#L/XI?]!_PA_X&77_R-1_P[#^*7_0?\(?^!EU_\C5^G=%'^L&.[K[@
M_L/!]G]Y^8G_  [#^*7_ $'_  A_X&77_P C4?\ #L/XI?\ 0?\ "'_@9=?_
M "-7Z=T4?ZP8[NON#^P\'V?WGYB?\.P_BE_T'_"'_@9=?_(U'_#L/XI?]!_P
MA_X&77_R-7Z=T4?ZP8[NON#^P\'V?WGYB?\ #L/XI?\ 0?\ "'_@9=?_ "-1
M_P .P_BE_P!!_P (?^!EU_\ (U?IW11_K!CNZ^X/[#P?9_>?F)_P[#^*7_0?
M\(?^!EU_\C4?\.P_BE_T'_"'_@9=?_(U?IW11_K!CNZ^X/[#P?9_>?F)_P .
MP_BE_P!!_P (?^!EU_\ (U'_  [#^*7_ $'_  A_X&77_P C5^G=%'^L&.[K
M[@_L/!]G]Y^8G_#L/XI?]!_PA_X&77_R-1_P[#^*7_0?\(?^!EU_\C5^G=%'
M^L&.[K[@_L/!]G]Y^8G_  [#^*7_ $'_  A_X&77_P C4?\ #L/XI?\ 0?\
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M.Z*/]8,=W7W!_8>#[/[S\Q/^'8?Q2_Z#_A#_ ,#+K_Y&H_X=A_%+_H/^$/\
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MV'\4O^@_X0_\#+K_ .1J_3NBC_6#'=U]P?V'@^S^\_,3_AV'\4O^@_X0_P#
MRZ_^1J/^'8?Q2_Z#_A#_ ,#+K_Y&K].Z*/\ 6#'=U]P?V'@^S^\_,3_AV'\4
MO^@_X0_\#+K_ .1J/^'8?Q2_Z#_A#_P,NO\ Y&K].Z*/]8,=W7W!_8>#[/[S
M\Q/^'8?Q2_Z#_A#_ ,#+K_Y&H_X=A_%+_H/^$/\ P,NO_D:OT[HH_P!8,=W7
MW!_8>#[/[S\Q/^'8?Q2_Z#_A#_P,NO\ Y&H_X=A_%+_H/^$/_ RZ_P#D:OT[
MHH_U@QW=?<']AX/L_O/S$_X=A_%+_H/^$/\ P,NO_D:C_AV'\4O^@_X0_P#
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M_H/^$/\ P,NO_D:OT[HH_P!8,=W7W!_8>#[/[S\Q/^'8?Q2_Z#_A#_P,NO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Y5Z^JO^"7'_)]GPR_
M[B?_ *:[NOE6OJK_ ()<?\GV?#+_ +B?_IKNZ /W^HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^5>OJK_ ()<
M?\GV?#+_ +B?_IKNZ^5:^JO^"7'_ "?9\,O^XG_Z:[N@#]_J*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _E7KZ
MJ_X)<?\ )]GPR_[B?_IKNZ^5:^JO^"7'_)]GPR_[B?\ Z:[N@#]_J*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)IMJ#>W<8P+J\<[YY>><-(S;0>0H5?X17J%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/]6/^GW_ )+_ /;!_K%_TZ_\F_X!^_%%?@/11_JQ_P!/O_)?_M@_UB_Z=?\
MDW_ /WXHK\!Z*/\ 5C_I]_Y+_P#;!_K%_P!.O_)O^ ?OQ17X#T4?ZL?]/O\
MR7_[8/\ 6+_IU_Y-_P  _?BBOP'HH_U8_P"GW_DO_P!L'^L7_3K_ ,F_X!^_
M%%?@/11_JQ_T^_\ )?\ [8/]8O\ IU_Y-_P#]^**_ >BC_5C_I]_Y+_]L'^L
M7_3K_P F_P" ?OQ17X#T4?ZL?]/O_)?_ +8/]8O^G7_DW_ /WXHK\!Z*/]6/
M^GW_ )+_ /;!_K%_TZ_\F_X!^_%%?@/11_JQ_P!/O_)?_M@_UB_Z=?\ DW_
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MK\!Z*/\ 5C_I]_Y+_P#;!_K%_P!.O_)O^ ?OQ17X#T4?ZL?]/O\ R7_[8/\
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M^_\ )?\ [8/]8O\ IU_Y-_P#]^**_ >BC_5C_I]_Y+_]L'^L7_3K_P F_P"
M?OQ17X#T4?ZL?]/O_)?_ +8/]8O^G7_DW_ /WXHK\!Z*/]6/^GW_ )+_ /;!
M_K%_TZ_\F_X!^_%%?@/11_JQ_P!/O_)?_M@_UB_Z=?\ DW_ /WXHK\!Z*/\
M5C_I]_Y+_P#;!_K%_P!.O_)O^ ?OQ17X#T4?ZL?]/O\ R7_[8/\ 6+_IU_Y-
M_P  _?BBOP'HH_U8_P"GW_DO_P!L'^L7_3K_ ,F_X!^_%%?@/11_JQ_T^_\
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MT4?ZL?\ 3[_R7_[8/]8O^G7_ )-_P#]^**_ >BC_ %8_Z??^2_\ VP?ZQ?\
M3K_R;_@'[\45^ ]%'^K'_3[_ ,E_^V#_ %B_Z=?^3?\  /WXHK\!Z*/]6/\
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M_IU_Y-_P#]^**_ >BC_5C_I]_P"2_P#VP?ZQ?].O_)O^ ?OQ17X#T4?ZL?\
M3[_R7_[8/]8O^G7_ )-_P#]^**_ >BC_ %8_Z??^2_\ VP?ZQ?\ 3K_R;_@'
M[\45^ ]%'^K'_3[_ ,E_^V#_ %B_Z=?^3?\  /WXHK\!Z*/]6/\ I]_Y+_\
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M?ZL?]/O_ "7_ .V#_6+_ *=?^3?\ _?BBOP'HH_U8_Z??^2__;!_K%_TZ_\
M)O\ @'[\45^ ]%'^K'_3[_R7_P"V#_6+_IU_Y-_P#]^**_ >BC_5C_I]_P"2
M_P#VP?ZQ?].O_)O^ ?OQ17X#T4?ZL?\ 3[_R7_[8/]8O^G7_ )-_P#]^**_
M>BC_ %8_Z??^2_\ VP?ZQ?\ 3K_R;_@'[\45^ ]%'^K'_3[_ ,E_^V#_ %B_
MZ=?^3?\  /WXHK\!Z*/]6/\ I]_Y+_\ ;!_K%_TZ_P#)O^ ?OQ17X#T4?ZL?
M]/O_ "7_ .V#_6+_ *=?^3?\ _?BBOP'HH_U8_Z??^2__;!_K%_TZ_\ )O\
M@'[\45^ ]%'^K'_3[_R7_P"V#_6+_IU_Y-_P#]^**_ >BC_5C_I]_P"2_P#V
MP?ZQ?].O_)O^ ?OQ17X#T4?ZL?\ 3[_R7_[8/]8O^G7_ )-_P#]^**_ >BC_
M %8_Z??^2_\ VP?ZQ?\ 3K_R;_@'[\45^ ]%'^K'_3[_ ,E_^V#_ %B_Z=?^
M3?\  /WXHK\!Z]^_8-_Y.N\#?]OW_I!<5AB.'?849U?:WY4W\/97[F]'/O;5
M8T_96YFEOW^1^O5%%%?&GU@4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 ?@/1117[F?C04444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5[]^P;_R==X&_P"W[_T@N*\!KW[]
M@W_DZ[P-_P!OW_I!<5P8_P#W2M_AE^3.S!?[U2_Q+\S]>J***_&S]9"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\!Z***_<S\:"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "O?OV#?\ DZ[P-_V_?^D%Q7@->_?L&_\ )UW@;_M^_P#2"XK@Q_\ NE;_
M  R_)G9@O]ZI?XE^9^O5%%%?C9^LA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!^ ]%%%?N9^-!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7OW[!O_)UW@;_M^_\ 2"XK
MP&O?OV#?^3KO W_;]_Z07%<&/_W2M_AE^3.S!?[U2_Q+\S]>J***_&S]9"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\!Z***_<S\:"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "O?OV#?^3KO W_ &_?^D%Q7@->_?L&_P#)UW@;_M^_](+BN#'_ .Z5
MO\,OR9V8+_>J7^)?F?KU1117XV?K(4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 ?@/1117[F?C04444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5[]^P;_P G7>!O^W[_ -(+
MBO :]^_8-_Y.N\#?]OW_ *07%<&/_P!TK?X9?DSLP7^]4O\ $OS/UZHHHK\;
M/UD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX&_[?O\ T@N*X,?_ +I6_P ,OR9V8+_>J7^)?F?KU1117XV?K(4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 ?@/1117[F?C04444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+P]X1\+^&M5O#"D>K6NC01RVRB9&D92B!L[ P !&<XR :^"O^">?_)SNB?\
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M7]DGXH:I\+_CIX7GL;ATLM3O8=-O[?=\DT,KA/F'JI8,/=?<U^N/Q(\'VWQ
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M81:3I=I90((X+:%(40=%55  _(5\CQ)6<,/"FOM/\O\ AU]Q]-P_34\3*?\
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MR4NSO?3^MCXW,ZF&JU>;#Q:[Z6U_K<****]H\<**** "O8OV/?\ DYCX?_\
M81_]IO7CM>Q?L>_\G,?#_P#["/\ [3>N?$?P9^C_ "*A\2/V1NO^/:7_ '#_
M "K\$]0_X_[G_KJW\S7[V77_ ![2_P"X?Y5^">H?\?\ <_\ 75OYFOB>&/CK
M>D?U/N.(OX-/U?Y'J_[(^AZ;XD_:,\$Z;J^GVNJZ=<7,BS6=["LT,@$$A 9&
M!!&0#R.U?IYX^_9@^'OB;P1KND:3X'\*:-J=]92VUMJ,.B6ZO:R.A595*H""
MI.1@@\=:_-']BW_DZ#P#_P!?<O\ Z(EK]BI)%CC9V.%49)]!1Q%6G2Q%-PE;
M3]3'(:4*E*HI*^IQGPH^$'ACX,^$[70?#6G16L,: 3711?/NGQS)*X&68_D.
M@   KX _X*/1Z'=?&;P_H/A[1+2'7C:"2_FL8%26[FF<+$C[1\S (,9Y_>"O
M.?BO^V5\2O%_Q)O]8T7Q?JFAZ3!=.--T_3YS#"L(;">8@XE) !._=R3VP*\S
MU;XO>*M<^)D?C^_U%;GQ5'<0W2WLEO&5\R(*$;R]NSC8O&W'%=N795B:>)CC
M,1.[:;:UO=]'_6C.?,,RP[P\\'0A9+1/IH]U]WS3/TR_9O\ V*_!WPE\-V%[
MXBTBR\1^,I$6:YN[Z(316K\'RX$8;1M/&_&XG)R!@#V74/BMX"\.:K_8M]XQ
M\.:7J2$)_9]QJ=O#,I[#RRP(_*OSO\-_MS?'SQ[IUYX?T/1[7Q!J,ULT1NM,
MTB:2\A##;YJB)MJL"<@E< ]JY?PK^P#\:/&%P9+W1K70(Y!YANM:OT^8D\Y6
M/S'!^JBN&MEU2K5E4S*NH]M?R3V1UT<?3I4HT\OHN3ZZ?FUNS],?'WP=\#?%
MK2FMO$OAS3M8BD3$=RT2B:,'O',N'7MRI%?DE^TU\$V^ 7Q9U#PQ'<O>Z<T:
M7EA<2X\Q[=\[0^.-RLK*2.NW.!G%?JU^SO\ "W4?@S\)-%\(ZIJZZW=6'F9N
M8T944.[.$7<2=J[L#ITZ#I7PO_P5 4#XR>&6  8Z"N3Z_P"D35ADM:5''_5Z
M<^:#OZ::IVZ'3FE%5\ \14ARSC9^>K2M?YG>_P#!./X9>#_''PR\3W7B/PGH
M?B"ZAUCRHYM4TV&Y=$\F,[59U) R2<#UKVGXF?L2^ OB-XW\*WJ:'I?A[P[I
M<=PU]I^B6<=F^HR,T?EJ[1JOR*%?)Z_-@8R37G?_  2[_P"23^+?^PW_ .T(
MZ[#_ (*$_$_5OAU\$(;71;M[&\UV_73Y;B)MLBP>6[R!3U!.U5)]&-3C:F(_
MM9PH3LVTEV5XV_4C TZ#RM2K1NE=OOI)O]+'LW@C4_AOX<O#X0\)7_AFPO;;
M(;1=*N+=9TQU+1(=V?4D9]:Q/C7^S7X'^.6B7-OK6D6\&KM'BWUJUB5+N!@#
MM.\<NH)^XV0?K@C\9-+U2[T74K74+"XDM+VUE6:">%BKQNIRK CH017[J^"=
M9D\1>#=!U64 2WUA;W3XZ;GC5C^IK/,\OJ99R5X56V^NSN:9=F$,>Y8>5-))
M72W5ON]#\.O&GA.^\">+M9\.ZDH%]I=W):3;?NED8KD>QQD>QK] /V,?V*_#
M2>"M,\<^.]+AUW5-4B%S9:9>H'MK:!A\C/&>)'93N^;( (XR,U\K_MN0);_M
M2>/$08!N+=_Q:VA8_J37ZJ?!GQ%8>*_A-X0U7371K*XTJW*!""$(C563CNI!
M4CL0:]O,\=766T:L'9S2NUYJ]OF>/@,)1>95:4E=0YK)^3L2ZMXZ\!_#18-.
MU/Q!X=\*J%'E6MW>P68V]MJ,R\?04FN>#_ WQ@T%&U+2]%\6:5.I,5PT<=RG
M(QNCD&<'D_,I!]Z^1/CQ_P $Y=5\<>,M<\4^%?%\#W.JW;WDEAKB. C.Q9@L
MZ!B5!.%!3@ #)ZUYQX#\'_M)?L;KK<NB^$(]=TB^VB580VHV^Y>DR10R+(AQ
MP690,=1P,?/TL#AZU)3HXC][V>FO:_Z]3WJN,Q%&JX3H7I]UKIWM^AP_[9W[
M+L?[/OBNTO\ 0C-+X0U@M]E$I+-:2CEH&8_>&#E2>2,@Y*DFC^PKX9T?Q=^T
M5I&FZ[I-CK6G26ETSV>HVR7$+$1$@E'!!(/(XK!^-/[5GQ"^.6EIHWBFYL4T
MR&X%PMC:V*1A)5#*#N.7! 9AC=]:[#_@GG_R<[HG_7E>?^B6K[6$<32RZI'$
MN\U&6J]';YGQF(EAZF.IRPZM%SAI_P!O*_R_K8^\OC#^R;X'\>> +_0O#_A+
MPSX9U.\E@5=6L]'MXIK>,3(TC(R(#G8&&,C.<'BM3P7X)^$/[,.EV.E076@>
M&;N9 @OM7O((KV](ZEI)"&?D]!\HSP .*[WXB^+H_ /@'Q%XEE3S$TG3Y[WR
M_P"^8T+!?Q( _&OQ"\8>,-7\?>)M0U_7;V74-5OI3+-/*Q))/0#T4# "C@
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M,\8,?E ;=I!(*XQS7JG_  5(_P"2C>"_^P5)_P"CC7S'\ ?^2Z?#O_L8M/\
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MX P[9&X!A^8K\]/VU?V-K;X/0CQIX+CE_P"$3ED$=Y82.9&T^1CA65CR8F)
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MF"* 3CN:_,3_ (*.HJ_M(S$* 6TFU)P.I^<?T%>^_P#!+?\ Y)UXT_["L?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "O?OV#?^3KO W_;]_P"D%Q7@->_?L&_\G7>!O^W[_P!(+BN#'_[I6_PR
M_)G9@O\ >J7^)?F?KU1117XV?K(4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 ?@/1117[F?C04444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT7J_^!^IZ?$-2')3I_:NWZ+_ (/Z'[9_L\_\D%^'/_8NZ?\ ^DZ5^97[>?\
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M')"U^9]?O9I.K67B#2;34M/N([W3[R%9X+B([DEC8 JP/<$$5^5'[<O[//\
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MZ5\YE52=+*<3.E\2;M]T;_<KL^@S2%.IF5"%79I?^E2T^>Q]T^//'WA/X%^
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M+CHM]E^;/O,A5\)-+^9_DC\):='&\TBQQJSNQ"JJC))/0 5^G/\ P[#^%O\
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M &'!_P"D\M8O_!+'_D5?'_\ U^VO_HN2MK_@J'_R2/PI_P!AP?\ I/+1B_\
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MCYI-_I8^>/\ AYY\+?\ H >+_P#P#M?_ ))H_P"'GGPM_P"@!XO_ / .U_\
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M-SW:57,J==4JD%*-_BVT[_\  L0?M_?L]:%XH^&6J>/M.T^&S\4:,$GN+F!
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MM?\ O/[W<^4?^"H'_)8_"_\ V E_]*)J^6?AK_R47PK_ -A6U_\ 1RU]3?\
M!4#_ )+'X7_[ 2_^E$U?+/PU_P"2B^%?^PK:_P#HY:]O)?\ D7T_G^;/'X@_
MWVKZ1_\ 2$?NK7X6?$[_ )*5XL_["]W_ .CGK]TZ_"SXG?\ )2O%G_87N_\
MT<]?+\-?[Q/_  _JCZ+B#_=X>OZ,_6K]C/\ Y-B\ ?\ 7D__ *.DKX=_X*5?
M\G$6_P#V [;_ -&35]K?L0ZI#JG[+_@DPL#Y$,UNX!Z,L\@(/Z'\:\V_:R_8
MJ\0?M ?%+3/$VC:]IFF68L8[*\COED\Q-CNP>,*I#Y#]"5QMZG/$4:U/#9S5
MG5=ES3_4GV-2MDM*G35WRPT]$KGRI^PS\ M.^.'Q0N9M?@^U>'-!A6ZN;8G
MN)6;$43?[)VNQ]=F.]?IOX\\?>$_@7X#?6-:EAT70+%4@BAMH>YX2**-1U..
M .  2< $U\8_\$\[BT^&_P :?BC\/+VZ5]2\SRK>1E\O[1]DFE1\*2<$B0-C
M)X!]*^K_ -H_X&6G[0?PTN/#$]\VF723I=V=X$WB*9 0-RY&5*LP//?/:C.J
MRK8V$:DG[*T6O1[OUW7R-,FHJEAJDH+]Y=KYK9>FWWGS-XP_X*E:1 S1^%O
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M%W:^A)9CDD^8.37[PUOQ#3]C0PU/LI+[E$YLCJNOC,55?VN5_>YL_#WXX_\
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M2\3(13V'F!BN?[RH.]>'AZ,J^1.,%=ZO[I7_ "/=QE6-'-J4Y[6M]]T>B?\
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MG3=FCZ]_X>>?%+_H >$/_ .Z_P#DFC_AYY\4O^@!X0_\ [K_ .2:^0J*\_\
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MG!!]:2BE1HT\/!4Z2LAUJU3$2YJKNSZX^$?_  4?\;^ ]'ATOQ-I5OXVM[=
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MQK]T,4G4' P!@#@"OF2BHCEN#C3]DJ:Y=_Z>Y<LPQ4JGM74=]OZ6W0[3XO\
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MY:4[+[_S/JCXQ?\ !0WQ_P#$G2[G2=#M;?P7I=PNR5K*5I;QE((*^>0-H/\
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MD:[9I%+=Z9=PWL*3@F-GC<.H8 @D949P1]:^J?\ AYY\4O\ H >$/_ .Z_\
MDFOD*BM\1A*&*M[:"E8PHXJMA[^RE:Y:U;4I=8U2\OYE59KJ9YW6,$*&9BQ
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M"5=\%S'G)21.XX[$$=B*XFBO6E",HN$E==CRU*2ES)ZGWCIW_!5*^BL8DO\
MX;V]S>!0))K?66AC9NY"&!R![;C]:\/^/7[:WCSXYV<ND.T/AOPVY^?3--9M
MTX[":4\N!Z *OJ"0#7S]17F4LJP5&HJD*:NO5_F['I3S/&5(>SE4=OE^>Y];
M6'_!3+XIV-C;VQT;PI<&&-8_.FL[DN^ !N;%P!DXR< #VKYB\9>)Y?&OBS5]
M?N+.UL+C4[J2[EM[%66%'=BS; S,0,DG!)ZUC45TT<'A\/-SI02;.6IBJ]:"
MIU)-I'T%\$OVWOB+\%M-M]'CFM_$?A^'"Q:?JP9F@0?PQ2J0RC' !W*,<**]
MWC_X*K.(P'^&*L^.677L#\OLW]:^!J*YZ^5X/$2YZE-7^:_*QO1S'%8>/)3G
MI\G^9]:?%'_@I!\0?&NGSZ?X<L+/P7:S+M:XMW:XO .X65@%7([A P[$5\G7
M%Q+=3R332/--(Q=Y)&+,S$Y))/4DTRBNG#X.AA%:A!+^N^YCB,77Q33K2O\
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MLS(JD=0T9W#'4HM?DY7G9'66(P?L)[QO%KR_X;3Y'J9U1='%*O#:=FGYK?\
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M*6K_ $_"WS/*SC%+%8E\CO&.B_7\?PL%?4'PB_X*$?$;X:Z?;:7JR6OC+2H
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MR1H%4L1< $X S@#Z5\K45I7P]+$Q4:T;I&=&O4P\N>E*S.L^*OQ*U/XO^/\
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M+B^N)+F18@0@9V+$*"2<9/<FJ-%<]#!X?#2<J,$FS:MBZ^(2C5FVCW+]G/\
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MTH;127W'SM:K*O4E5GO)W"BBBMC$**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *]^_8-_Y.N\#?]OW_I!<5X#7
MOW[!O_)UW@;_ +?O_2"XK@Q_^Z5O\,OR9V8+_>J7^)?F?KU1117XV?K(4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 ?@/1117[F?C04444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% '9Z7\:OB'H=K':Z;X\\3:?;1C:D-K
MK%Q$BCT"JX J+6_C!X]\36,EEK'C;Q'JMG(-KV]]JUQ-&P]"K.0:Y&BL?8T[
MWY5?T-?:U$K*3MZA1116QD%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '5>'?
MBSXX\(:>MAH/C+Q!HEBI)6UT[5)[>($G)(5' Y/-4_$_C_Q/XV\K_A(O$>KZ
M_P"428_[4OI;G83UQO8XK!HK+V<.;FY5<OVD^7EN[!1116I 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7OW[!O_)UW@;_ +?O_2"XKP&O?OV#?^3K
MO W_ &_?^D%Q7!C_ /=*W^&7Y,[,%_O5+_$OS/UZHHHK\;/UD**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** /P'HHHK]S/QH**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]
M^_8-_P"3KO W_;]_Z07%> U[]^P;_P G7>!O^W[_ -(+BN#'_P"Z5O\ #+\F
M=F"_WJE_B7YGZ]4445^-GZR%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% 'X#T445^YGXT%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %>_?L&_\G7>!O^W[_P!(+BO :]^_
M8-_Y.N\#?]OW_I!<5P8__=*W^&7Y,[,%_O5+_$OS/UZHHHK\;/UD**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /P'HHHK]S/QH**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *]^_8-_Y.N\#?\ ;]_Z07%> U[]^P;_ ,G7>!O^W[_T@N*X,?\ [I6_PR_)
MG9@O]ZI?XE^9^O5%%%?C9^LA1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!^ ]%&TT;37[D?C044;31M- !11M-&TT %%&TT;30 44;31M- !1
M1M-&TT %%&TT;30 44;31M- !11M-&TT %%&TT;30 44;31M- !11M-&TT %
M%&TT;30 44;31M- !11M-&TT %%&TT;30 44;31M- !11M-&TT %%&TT;30
M44;31M- !11M-&TT %%&TT;30 44;31M- !11M-&TT %%&TT;30 44;31M-
M!11M-&TT %%&TT;30 44;31M- !11M-&TT %%&TT;30 44;31M- !11M-&TT
M %%&TT;30 44;31M- !11M-&TT %%&TT;30 44;31M- !11M-&TT %%&TT;3
M0 44;31M- !11M-&TT %%&TT;30 44;31M- !11M-&TT %%&TT;30 44;31M
M- !11M-&TT %%&TT;30 44;31M- !11M-&TT %%&TT;30 44;31M- !11M-&
MTT %%&TT;30 44;31M- !11M-&TT %%&TT;30 44;31M- !11M-&TT %%&TT
M;30 44;31M- !11M-&TT %%&TT;30 44;31M- !11M-&TT %%&TT;30 44;3
M1M- !11M-&TT %%&TT;30 44;31M- !11M-&TT %%&TT;30 44;31M- !11M
M-&TT %%&TT;30 44;31M- !11M-&TT %%&TT;30 44;31M- !11M-&TT %%&
MTT;30 44;31M- !11M-&TT %%&TT;30 44;31M- !11M-&TT %%&TT;30 44
M;31M- !11M-&TT %%&TT;30 44;31M- !11M-&TT %%&TT;30 44;31M- !1
M1M-&TT %%&TT;30 44;31M- !11M-&TT %%&TT;30 44;31M- !11M-&TT %
M%&TT;30 44;31M- !11M-&TT %%&TT;30 44;31M- !11M-&TT %%&TT;30
M44;31M- !11M-&TT %%&TT;30 44;31M- !11M-&TT %%&TT;30 44;31M-
M!11M-&TT %%&TT;30 44;31M- !11M-&TT %%&TT;30 44;31M- !11M-&TT
M %%&TT;30 44;31M- !11M-&TT %%&TT;30 44;31M- !11M-&TT %%&TT;3
M0 44;31M- !11M-&TT %%&TT;30 44;31M- !11M-&TT %%&TT;30 44;31M
M- !11M-&TT %%&TT;30 44;31M- !11M-&TT %%&TT;30 44;31M- !11M-&
MTT %%&TT;30 44;31M- !11M-&TT %%&TT;30 44;31M- !11M-&TT %%&TT
M;30 44;31M- !11M-&TT %%&TT;30 44;31M- !11M-&TT %%&TT;30 44;3
M1M- !11M-&TT %%&TT;30 44;31M- !11M-&TT %%&TT;30 44;31M- !11M
M-&TT %%&TT;30 44;31M- !11M-&TT %%&TT;30 44;31M- !11M-&TT %%&
MTT;30 5[]^P;_P G7>!O^W[_ -(+BO =IKW[]@T?\97>!O\ M^_](;BN''_[
MI6_PR_)G9@O]ZI?XE^9^O5%%%?C9^LA1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
..4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>angn-20211231_g4.jpg
<TEXT>
begin 644 angn-20211231_g4.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1%#!P# 2(  A$! Q$!_\0
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MS]ZA_P!_(_\ XBC_ (4CH7_/WJ'_ '\C_P#B*]"HKT?[*P/_ #Z1P?VGC/\
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MO0J*/[*P/_/I!_:>,_Y^,\]_X4CH7_/WJ'_?R/\ ^(H_X4CH7_/WJ'_?R/\
M^(KT*BC^RL#_ ,^D']IXS_GXSSW_ (4CH7_/WJ'_ '\C_P#B*/\ A2.A?\_>
MH?\ ?R/_ .(KT*BC^RL#_P ^D']IXS_GXSSW_A2.A?\ /WJ'_?R/_P"(H_X4
MCH7_ #]ZA_W\C_\ B*]"HH_LK _\^D']IXS_ )^,\]_X4CH7_/WJ'_?R/_XB
MC_A2.A?\_>H?]_(__B*]"HH_LK _\^D']IXS_GXSSW_A2.A?\_>H?]_(_P#X
MBC_A2.A?\_>H?]_(_P#XBO0J*/[*P/\ SZ0?VGC/^?C//?\ A2.A?\_>H?\
M?R/_ .(H_P"%(Z%_S]ZA_P!_(_\ XBO0J*/[*P/_ #Z0?VGC/^?C//?^%(Z%
M_P _>H?]_(__ (BC_A2.A?\ /WJ'_?R/_P"(KT*BC^RL#_SZ0?VGC/\ GXSS
MW_A2.A?\_>H?]_(__B*/^%(Z%_S]ZA_W\C_^(KT*BC^RL#_SZ0?VGC/^?C//
M?^%(Z%_S]ZA_W\C_ /B*/^%(Z%_S]ZA_W\C_ /B*]"HH_LK _P#/I!_:>,_Y
M^,\]_P"%(Z%_S]ZA_P!_(_\ XBC_ (4CH7_/WJ'_ '\C_P#B*]"HH_LK _\
M/I!_:>,_Y^,\]_X4CH7_ #]ZA_W\C_\ B*/^%(Z%_P _>H?]_(__ (BO0J*/
M[*P/_/I!_:>,_P"?C//?^%(Z%_S]ZA_W\C_^(H_X4CH7_/WJ'_?R/_XBO0J*
M/[*P/_/I!_:>,_Y^,\]_X4CH7_/WJ'_?R/\ ^(H_X4CH7_/WJ'_?R/\ ^(KT
M*BC^RL#_ ,^D']IXS_GXSSW_ (4CH7_/WJ'_ '\C_P#B*/\ A2.A?\_>H?\
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M^RL#_P ^D']IXS_GXSSW_A2.A?\ /WJ'_?R/_P"(H_X4CH7_ #]ZA_W\C_\
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M(_\ XBO0J*/[*P/_ #Z0?VGC/^?C//?^%(Z%_P _>H?]_(__ (BC_A2.A?\
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M$/\ W_UK_P"/5XO11_JYA?YI?>O\@_U@Q/\ +'\?\SVC_A _%W_1^'B'_O\
MZU_\>H_X0/Q=_P!'X>(?^_\ K7_QZO%Z*/\ 5S"_S2^]?Y!_K!B?Y8_C_F>T
M?\('XN_Z/P\0_P#?_6O_ (]1_P ('XN_Z/P\0_\ ?_6O_CU>+T4?ZN87^:7W
MK_(/]8,3_+'\?\SVC_A _%W_ $?AXA_[_P"M?_'J/^$#\7?]'X>(?^_^M?\
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M +_ZU_\ 'J/^$#\7?]'X>(?^_P#K7_QZO%Z*/]7,+_-+[U_D'^L&)_EC^/\
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M\TOO7^0?ZP8G^6/X_P"9[1_P@?B[_H_#Q#_W_P!:_P#CU'_"!^+O^C\/$/\
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M\>KQ>BC_ %<PO\TOO7^0?ZP8G^6/X_YGM'_"!^+O^C\/$/\ W_UK_P"/4?\
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M_P @_P!8,3_+'\?\SVC_ (0/Q=_T?AXA_P"_^M?_ !ZC_A _%W_1^'B'_O\
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MAXA_[_ZU_P#'J\7HH_U<PO\ -+[U_D'^L&)_EC^/^9[1_P ('XN_Z/P\0_\
M?_6O_CU'_"!^+O\ H_#Q#_W_ -:_^/5XO11_JYA?YI?>O\@_U@Q/\L?Q_P S
MVC_A _%W_1^'B'_O_K7_ ,>H_P"$#\7?]'X>(?\ O_K7_P >KQ>BC_5S"_S2
M^]?Y!_K!B?Y8_C_F>T?\('XN_P"C\/$/_?\ UK_X]1_P@?B[_H_#Q#_W_P!:
M_P#CU>+T4?ZN87^:7WK_ "#_ %@Q/\L?Q_S/:/\ A _%W_1^'B'_ +_ZU_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ??/
M_!%3_DUGQ3_V.=U_Z0V-??\ 7P!_P14_Y-9\4_\ 8YW7_I#8U]_U^&'[*%%%
M% !1110 4444 %%%% !1110!\J_\%1_^3$_B;_W#/_3I:5^2_@#_ )$G1?\
MKW']:_6C_@J/_P F)_$W_N&?^G2TK\E_ '_(DZ+_ ->X_K7U_#?^\5/\/ZH^
M5XA_@0]?T9OT445^@GP@4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% $&H?\ (.N_^N+_ /H)K[W_ ."+?_)MOB7_ +&.7_T1#7P1J'_(.N_^N+_^
M@FOO?_@BW_R;;XE_[&.7_P!$0U\+Q-\5+Y_H?:<._#5^7ZGZ!T445\2?8G\X
MOP1_Y%2[_P"OU_\ T7'7H5>>_!'_ )%2[_Z_7_\ 1<=>A5^NY5_N-+T/RW,_
M]\J>H4445ZQY@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 =+X7^&7C'QQ:377ASPGKGB
M"UA?RI)M+TV:Y1'P#M9D4@'!!P?6MK_AGSXI?]$U\7_^"&Z_^-U]U?\ !+O_
M ))/XM_[#?\ [0CKZ)^*?[0WP_\ @K>6%IXSU_\ L:XOHVEMT^Q7$^]5(#',
M4; <D=<5\AB\ZKT,7+"TJ?,UMO=Z7V/I\)E-&OA5B:M3E6M]K+6Q^13_ +/_
M ,4(URWPW\7*/5M"NA_[3KCM8T74?#U_)8ZK876F7L>-]M>0M%(N>F58 BOV
M'\*_MB?!OQEJD.G:9XZLOM<S!(TO8)[0,QZ --&BY.>!GFNG^,OP4\+_ !R\
M(W&B>(K&.5F1OLE^JCS[.0CB2-NHYQD=&'!!%8?V_7HS2Q-!Q3]4_P =SH62
M4*T6\/6NUZ-?@?B+16YXZ\'WWP_\9:UX;U( 7VE7<EI*5! 8HQ&X9[$8(]B*
MPZ^SA.-2*G%W3U/DYPE3DX35FM&%%%%60%%%% !117VI^P?^RKX+^,'AO4/&
M7BU+C5!8ZDUC#I/F>7;MMCCDWR%?F;F3&W(''.<\<N)Q$,)2E6J;(Z,/AYXJ
MJJ5/=GQ717U!_P %$M%T_P /?';3M.TNQM]-T^WT"U2&UM(EBBC423<*J@ #
MZ5\OTL)B%BJ,:R5KE8J@\+6E1;O8****ZSE+.EZ7>ZWJ%O8:=:3W]_<N(H+6
MUB:265R<!5502Q/H*Z^^^!/Q*TVSGO+SX>^*K2TMXVEFGGT2Y2.-%&69F*8
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MBV(H6_V2<D^H0CO7Z:?$SXM>"?@#X5M;WQ'?0Z+IO_'O9VEO"6>0J.$BC0=
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYEO 8_+?!.#DGL*\^.8865;V"G[VUM3NE@<3&E[9P]WOH>!4445Z!PA1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%;/@WPU)XR\4:=HD5PMK)
M>RB(3.N0F>Y%*4E%-L<4Y.R,:BOKKXC?\$Z-;^'/@76_$\_C>ROH=+MFN6MT
MLF4R 8X!SQ7S[\%_A7<?&CQ]:>%;74HM*FN%+"ZFC+JN#CH*XJ6-P]:G*K3E
M>,=WJ==3!UZ-2-*<;2>VQP]%?3GQX_86U?X#_#F]\77GBZSU>"UDCC-K%:-&
MS;VQD$D]*^8ZUP^(I8J'/1E=&=?#U<-+DJJS"BBBNDYPHHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2-0,M(Y[*J@L?IQD\5ZG^T)XY^/UBS^'?BGJ6N6EM=#_ (]9!'%:704JW!@
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M/\"'K^C-^BBBOT$^$"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%'18R]_X&U6U0)YA+H/N^O6OU!^)'[07PT_9_P#!MI<K+:RP,HBM+/2E21F
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M77ON?DTRE&*L,,#@BDJ?4)TNM0N9H\B.20LN1@X-05^D'Y\:WA'_ )&[0_\
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M6>J6-V')/&]4&P?F:_,\UI.MCZJ717^Y7/T3+*BI8&FWU=OO=CX4_;Y\$?\
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M"Q[5]+?\$VHDF^-&L"2-9!_9R\.H/\?O7OW_  4QM88?@CI1CACC;^V(>50
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M\OF5HW9'5D=3M96!!!%)7V[^WWHWPPUZPB\4^%=<T>7Q-%(L-S:Z=.C&=3@
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MC<R6&PT<337,I'G8/+GB,1+#U'9Q/RHA\-:M<:PVE1:=<2:FO6U5,N*ZN^^
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MB7^%3]6?6\/?Q*GHCXB^(/\ P4:^('A/QUKVBVOAW0);:PO);>.27SMS*K$
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ME4@^:#ZG"Z7I-]KE]'9:=:2WMW(<)%$I))KOE_9K^*LELUPO@/5C IVF38,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+62:UI;PO#<:U;QR1":(@JREP58;L$'!!%>%C?95HPJ8.@XP76V[_':W<]W
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M9315%WA>%O3E=OP/':***_0CX@_>;PS_ ,BWI7_7I%_Z *_#[XG?\E*\6?\
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M[(^#E)R;D]V%%%%42%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'WS_P14_Y-9\4_]CG=
M?^D-C7W_ %\ ?\$5/^36?%/_ &.=U_Z0V-??]?AA^RA1110 4444 %%%% !1
M110 4444 ?*O_!4?_DQ/XF_]PS_TZ6E?DOX _P"1)T7_ *]Q_6OUH_X*C_\
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M/]#['A_:K;R/SGU;_@HM\3+'5KRWC33_ "XI61<VR=!6MX*_X*7>*K+6(/\
MA)]+M[[36D E:W18FC7N>!S7-ZQ_P3Z^)EYJUY<1BVV2RLZ_0GZU:\+_ /!-
M[Q[JVM00:O?VFG:;G=-,5))7/*K@]:[91R;D][E^6YR1EFW/IS'W]XP\!>%_
MCS\/534;"WNK;4[198+AD!DB++E2&QD8R*_&_P"(OA%_ /CS7_#DA+_V;>26
MRN?XE4XS7[8V5O8_#KP+%$S)%8Z/8 ,YX&V-.2?KBOQ;^*?B0>/OBQXBU>&4
M/#J>J.T#]@CN OX<UQ<.RGSU8I^XOZ_([,^C#EIR:]]G&?9XO^>2?]\BI*^P
M8_\ @FCXNDT%=5'C;11$8//\O[-+G&,XSZU\AWEN;.]N;9F#-!*\18="58C/
MZ5]90Q=#%7]C*]MSY>OA:V&LZL;7(J***ZSE/O#_ ()>_P"O\6?]=!_Z"*U/
MV[O$TWA#X[?"K587\OR+GYS_ +&Y-P_*LO\ X)>_Z_Q9_P!=!_Z"*R/^"HA9
M?%G@\H=KB&8J1V.!7Q/*IYTXOJG_ .DGV*DXY.I+HU^9]=_M!>$%^-?P%U'3
M["/SGU**&6W/< NIS^6:OMY?P%_9]?A53P]I9..W'_US6=^R7XS3QM\!_#%R
MK;WM+=;*1L\EHU .?>N!_P""A7C8^$_@3+9(^&UFX%B5!ZJ5)/X<"OG:=.<J
M\<"]E/\ K\#WJE2$:,L:MW'^OQ.8_P"";=\VI^#/&EXS%C<:H)LDY^]O/]:^
M=O\ @HY_R<,__8.M_P#T$U[_ /\ !,0;?AKXD'I=PC_QUJ\ _P""CG_)PS_]
M@ZW_ /037TF%TSJJO+_(^>Q7_(HI^J_4T/\ @FO_ ,EJUC_L'+_Z'7T!_P %
M-O\ DA^D_P#88A_DU?,O_!/;7HM'^/4=O+)L;4(/(09^\02<5]L_MM?"'6/C
M'\&9-,T&'[3J=G=I>QP#AI0@;*#W.16>.DJ.<4YS=EH;8*+JY34A!7>I^4'A
M/_D;M!_Z_P"'_P!#%?MA=?\ )*Y_^P4W_HHU^8_P%_8]^(?BSXB:/-J^AS:%
MHUC<K<7-[<L-H,;!MF <Y."*_4CQ7#';^!]6BB_U26$JKCT$9K+/J].K5I0A
M*[78O(Z-2G3J2G&US\7O@K_R6+PK_P!A/_V8U^N_QV_Y('XO_P"P+-_Z+-?D
M1\%?^2Q>%?\ L)_^S&OUW^.W_) _%_\ V!9O_19K?/?]ZH?UU,<E_P!VK?UT
M/R1_9W_Y*WX2_P"OA/YBOU;_ &M/^3<?'G_8/_\ 9UK\GO@%=1V?Q5\)RRG:
MGVF-<_4@5^OG[0'A._\ '7P9\6:#ID1GO[ZS,4,8.-S;E./THSQJ.,H2>W_!
M09,G+"5XK?\ X!^),W^J?_/>OVM_9W_Y(OX9_P"O-?Y"OR)^)'P6\:?"BUMY
M/%FAS:,+HGR!*RMO&<9X-?KM^SO_ ,D7\,_]>:_R%:<0SC4H4Y0=U=D9#"5.
MO4C-6=C\D?BQ_P EZ\4_]C$__HT5^S?AF1H_!E@ZC++:*0/?;7XR?%C_ )+U
MXI_[&)__ $:*_9_PA_R*NEY_Y]D_E7+G_P#!P_I^B.C(_P"+7]?U9^'7BV]G
MU+Q=KES=2--.]].&=SDG$C "OL3_ ()@:Q=0>,/%^GJS-:2P0L4S\J$;CD#W
MKD/VCOV*O'>A_$;4+WPEH4FNZ%J$IFC:V*J8F8Y*MD]22:^G/V$_V;=8^"NA
MZMK/B6'[+K>K!$:S8@F%4)QT[G->GF6-PU3+WRR3<DK+K_2//R_!XBGCUS1:
M2;NSA?\ @J1I\*^#_!]Z"/M#:@T1'?;L)KU'_@G[_P F]Z5_O'^9KYQ_X*5?
M$NP\0>+M(\)V4PN'TP>?<,ARJ2<J4/OC%?1W_!/W_DWO2O\ >/\ ,UXV(A*&
M34U+O_F>M0G&>;5''M_D?&W[7ENMY^VE/;O]R:ZL(V^AP*_4/3])AM_!<&FB
M416ZV0@\S/"KLVYS7Y7?MM7YTG]K36K\*6-K]DG"CJ=JYQ7Z4_"?Q5I_Q6^#
MFEWMG.LB7FGB&89R8I"F&4^X)I9K&7U3"SZ67Y(,LE'ZUB8];O\ -GS _P#P
M3_\ A?)([OXTA=W8LS->*223G^_7T+\"_!/A/X&^#QX=T[Q/97=FK[T\R[3Y
M>I./F]Z_.7XD_LP_%?P3XYN=$L;#4=6M9)B+.[AD^692>O)X_'TKZ(\(?\$[
M[O4_ 5A<ZYXGU#3?$\B%KB+SB88^>!@=\5OC(0G2C[?%\T7MI<QPLY1JR]CA
M;27F?/O[=UK9V_[1^K-830W%M-9P2^9;L&7<02>1WKY^KK?BOX=@\(^/=4T6
MWU<:XEC(8&O 2074D,.?3%<E7V6%@J="$$[V2U/DL3)SK3DU:[8C-M7(!)]!
M7Z^_L8_"K_A5OP2TB"YB":G?K]JGD[LK?,F?HIK\T_V:/AM)\5/C-X>T<1>=
M9QSK<WBXS^X!PW\Z_6;XM?$"Q^"OPNU#7'51#I]N(;>-NA?;MC4_B!7R_$%:
M4W3PE/=Z_P"1]+D5%04\5/9:?YG@/[4'[''B7]H#XA)KD7B:+3M/AMUAAM&A
MW;2,Y;.>^:ZG]DK]FGQ#^SK)J]K>^((]4TJ^_>B!(MFV7(^;KZ"OF6/_ (*;
M>-F12VA:8#CG]VW_ ,54]M_P4V\7K=0FXT'3V@W@.(T;=C/;YJY98+-98?ZL
MTN3MH=,<9ED:_P!83?-\SW3_ (*'?"8^-OA5'XBLX3+J>BR Y Z0')D/Z"OA
M3]F+XU)\#OBEI_B&YA:YTMP8KJ)3@[6&-WX9SBOUTQI_Q2^'CQ^8LVGZS8E'
M9>1ATP1^&3^5?F5\*_V5=-\;_&SQ9X%U[4VT2XT^=FL8L[6N(=QP5_X"*O*<
M53^J5<-B=H_D]_Q(S3#U/K5+$8?>7YH_1W0_'GP\^-'A^"6&\TG7+&8;EMKT
M1LXR/^>;<@_A7G/CC]A?X6>-/,G&E2Z9>D[HY;.8QJK>NT5\Y?'+]A74?A!X
M=M?$'PKO=8O-3B?_ $U?/&\1X^\O3O4/[,?B[]HR;QYHMG=IJ6J>'_M*1ZA-
MJKEQ##GYB,D<BN*&%Y*;Q&!Q%DNCT9URQ/-45#&4+M]5JCSG]I3]B36_@982
M>(M.NQKN@;]LLRQA)("QX!&26^M>W?\ !+W2X(]/\5ZBI'VB;9$WKM5CC^=?
M2/[66N:=H/P)\2S:D5\J6$PH&[NP(7]:^+O^":OQ,L?"_C[5/#&I3^4^L0HM
MD"< R*2S#\J[5B<1F&557/5Q_%?\ XWAZ&!S.FH:)_@S7_X*@7T[>./"MD68
MVOV#SMN?EW^8PSCUQ7QAIFK7>AW\-_8W,EG=P,'CFC8JRD=\U^HG[<W[-VJ_
M&KPS8:IX9B^T^(--.!;$@>=%R=JYZ')[U\P?L\?L/>.-;^(&FWGC7P^VD:!9
MS+--%>%76YVGF,@'H>17H99CL-2P"YY+W;W77[O,XLQP6(J8Y\D7[UK,^9M<
M\?>(O$4<_P#:7B34M263+,EQ>/(I_ FOUL_8QTB'2?V>O"QA(/VFW6X?_>(&
M?Y5XC^VI\#_A3\,_A1J6LV6AV^FZW.ZI9P6@5-Q+#=@8Z &NX_X)[_$FR\6?
M!M-$\T)J6D2F%K=C\QC  #@>F:\_,\1''9>JM&+45([LNH2P>.=*K*\FC/\
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M4O+9F29+C:"G!P1@U]H_MW_LK^(OB1JEIXQ\'V9U2_1/*N[%"!(X  5E)XP
M*\S_ &/?V/\ QA#\2K'Q3XOTQM#TK2RSI%<,-UPQ& !@\8.#S7LX?&X:.6).
M2TC:W6_IYGD8C!XB68MJ+UE>_2Q]J?M0?\F]^.O^P8_\Q7YM?L,_\G%:1_UR
M?_T(5^DO[4/_ ";YX[_[!DG\Q7YM?L,_\G%:1_UR?_T(5Y64_P#(NQ'S_(]/
M-/\ ?Z'R_,^W_P#@H=_R;+K?_7S;_P#HP5\G?\$X_P#DM][_ ->8_F:^L?\
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MRK\0CU3_ 'U_F*_;WX*_\DL\-_\ 7HG\J^-XE_A4_5GUO#W\2IZ(_';XU?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2S,>22>I-05]+@,&L#AXT4[]WW9\_CL6\;7=6UET7D%%%%>B< 4444 %%%%
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ",,J17U]^S_\
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MAL;7PE_92M<^SOC9_P %$]2\7Z>VE>"K"31+*5P9;R4;;@IW4#D8(XK8M?\
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MM]<'.*K45KA\-2PU/V5)61C7Q%3$5/:U'=GW;;_\%(K"'PBNCGPU(6%D;7S
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M].56H[)&M*E.O45.FKMGS317[AZ3X9^'_P $?#^ZSLM!\&:3& 'N&$5JA(&
M7D;&YN.K$DU:T_Q!X'^+&G75K8ZEX?\ &5AC9<0V\\%]%@]G +#\Z^2?$F\H
M46X][_\  ?YGU$<@V4ZR4GTM_P %?D?AE17W]^VI^Q1H>B^%;_Q_\/[%=*-@
MOG:IHT'^H:'/S31+_ 5ZLH^7:"0 1\WPAX?T.[\3:]IVCZ?&);_4+F.TMXV8
M*&D=@J@D\#DCDU]'@<=2Q]/VE/INGT/!QF"JX&IR5-;[/N4**^ZIO^">VF_#
M7X+^,_%7C+5VUGQ%8:)=W5M9:>S1VEM*D3,K%CAY2" >BKV(:OA6KPV-HXMR
M5%WY>I&(PE;"J+JJW,%%%%=QQA1110 4444 %%>O?LCZ'IOB3]HSP3INKZ?:
MZKIUQ<R+-9WL*S0R 02$!D8$$9 /([5][_M@_!GX?^&?V</&FIZ/X&\-Z3J5
MO#"8;RQTBWAFC)N(@2KJ@(R"1P>A->+C,SA@Z].A*+;E;\78]C Y;/'0E.,K
M6/RJHHHKVCQPHHHH **** "BBB@ HHHH **[GX'?#M?BQ\6O"_A.25X;?4[Q
M8YY(_O+"H+R%??8K8]\5^Q6F:#X&^ ?@6>2SL]/\*^'--A\RXF2,* H &]VQ
MN=CQR<L2>YKP\RS2&7\L>7FE+IL>OE^73Q[E:7*EU/P\HK[G_;J_:$^&/Q<^
M&&DVW@S4K'6]8&JJTTYL)(;B&$1OG!EC5L%BG3KBOABNW!8F>*I<]2FX.^S_
M .&1S8S#PPU10IU%-6W7Y;L**LZ7IEUK6IVFG6,#7-[=S)!!"@RTDC,%51[D
MD"OU>_9X_8E\$_"70;*[U_2K/Q/XO=%DN;R^B$T-O)P=D",-JA3T?&X\G(!P
M,\?F%++Z:G4U;V7<>#P57'3<*?3=]C\F**_<B^^*W@'P_J7]C7OC'PWINH*0
MG]GSZI;Q2@]AY98']*P?BI^SG\//C3I<\>N^'[-[N>/$>L64:Q7<?'RLLJC)
M SG:V5/<&OGX\2)-.I1:B^M_^ OS/>?#]TU"LFUTM_P7^1^*M%>@_'CX-ZG\
M"?B5J/A34I!<K#B:TO%7:+FW;.R0#L>"".S*1SUKSZOKJ56%:"J4W=,^7JTI
MT9NG45F@HHHK4R"BBON#_@G/^S[X;\=0ZWXY\2Z=!K T^[6QT^SNT$D*2! [
MRLAX8@.@7/ Y/7!')BL3#"495Y[+_ACHP]">)JQHPW9\/T5^U_Q.^/?PW^"\
MUCIGC#7[;1I;R/=!:?9I9B8P<;BL2-M7((R<#@^E?E'^U!XJT'QG\=O%>K>&
M%M!H,TZ"U>RA$4<@6)%9PH Y9@Q)(R<\UY67YI4Q\[.BXQLW?=:-*VR/5QV6
MPP4+^U3E=:6UUUON>64445] >$%%%?4/[+_[#VJ?'G1K;Q3JVLQ:)X3>9XU^
MSCS;NXV-M<*#\L8R"-S9.1]TCFN>OB*6&@ZE:5D;4:-3$35.DKMGR]17K7[5
M/PYT7X3_ !PUWPMX>AEATJPCMA$LTID<EK>-F9F/<LQ/&!SP .*\EIT:T:]*
M-6&TE?[QUZ,L/4E2GN@HHHK<P"BBB@ HHHH **^Q/^";O@7PUXZ\8>,X?$GA
M[2O$$-O80/#'JME%<K&QD8$J'4X)'I7WK_PSY\+?^B:^$/\ P0VO_P ;KYS'
M9U3P-9T90;9[N"RF>-I>UC)+6Q^(U%?MS_PSY\+?^B:^$/\ P0VO_P ;H_X9
M\^%O_1-?"'_@AM?_ (W7!_K-1_Y]O[T=_P#J]5_Y^(_$:BOM7_@I1X \+^!+
M_P"'Z^&O#>D>'ENHKXSC2K&*U$NTP;=_EJ-V-QQGID^M?%5?28+%+&T(UXJR
M=_P;7Z'S^,PSP=>5"3NU;\4G^H4445W'&%%>\?L0>&])\6?M&^'M,US2[+6=
M-EANC)9ZA;I/"Y$#D$HX(." 1QVK[$_;D^$/@3PC^SCKVIZ'X*\.Z+J4=Q:*
MEYI^E003*#.@(#H@(R"0>>]>-B\RAA,33PTHMN=M?67*>IA,!+%4*E>,K*%_
MP5S\PZ***]D\L**** "BBB@ HHHH **** "BNU^".GVNK?&;P)97UM#>65SK
MMC#/;W$8DCE1KA R,IX92"00>"#7ZB_M ? _X<:+\#?']_I_P_\ "]C?6VA7
MDT%U;:-;1RQ.L+%65E0%2#R".17CX_,H8"4(RC?F_P"!_F>K@<OECHSE&5N4
M_(6BBBO8/*"BBOV ^!/P-^&^L?!/P%?7_P /O"U[>W.A6,T]S<:+;222NT"%
MG9BF68DDDGDYKR\PQT<OI*K*-[NWY_Y'HX'!2QU1TXNUE<_'^BNO^,=C;:7\
M7?'%G9V\5I9V^NWT,-O @2.)%N'"JJC@    #@ 5^N/@WX!_#&Z\'Z'--\.?
M"<TTEA [R2:':LS,8U)))CY)-88S-(8.C"M*+?-_E<UPN7SQ5>=",K.-_P '
M8_%^BMKQ=;Q6WC36H(8TBACU"9$C10%51(P  '0 =J_9.X_9_P#A>ND2./AO
MX1#^03N_L*USG;U_U=&/S2& HTZTHM\]_P $G^II@\LGC*TZ,9).+M^-C\4J
M*TO#/A^\\6^(M+T/3D634-2NHK.W1V"J9)'"*"3T&2.:^U]1_P""?>E_"[X(
M>,O%7B[5VUOQ+8Z/<7-M:V):*TMI5C)!+</*01QG:OJIKMQ6-HX-)U7OLNK.
M'#82MBVU26V[Z(^%J***[CC"BBB@ HHHH **** "BOT1_P""=?PN\&>-O@SK
M=[XB\(Z%K]['KLL*7&J:;#<R*@MX"$#.I(7+$XZ9)]:^J/\ AGSX6_\ 1-?"
M'_@AM?\ XW7S.,SRG@Z\J$H-M?Y7/HL+DU3%48UHS23/Q&HK]MY/V>?A9(N#
M\-?"('^SH=L/Y)7@?[1/_!/_ ,(>+_#U[JOP_P!/3PUXG@1I4L[=B+2\('^K
M*$XC8XP"F!D\@YR,*7$>&G)1G%Q7<VJ</XB,;PDF^VQ^8E%:^@6+1^+M.L[R
MWVLM]'#-;S)T/F ,K*?Q!!K]FM0_9_\ A<EA<LOPV\(JPB8@C0K4$<'_ *9U
MZ>99I#+8PE*/-S7V\K?YGF9?E\\PJ3I1?*XVW\[_ .1^)U%%?7O[$O['[?%/
M4(/&WC&S9?!]K)FTLIEQ_:<JGN".80>O]XC'0-7HXC$4\+2=6J[)?U8X*-&>
M(J*E35VSY"HK]=_C?I7P+^ _@F?Q!K_P\\'ECF.SL(]#M/.O)L<(@\O\VZ <
MFORF\=>+#XW\57^L_P!E:9HB7,FZ/3]'M([6V@3HJ(B #@=SR>I->=E^8_VA
M=QIM175]^QZ..R_ZBESU$Y/I^I@T445[1Y 4444 %%%% !1110 4444 %%%%
M !1110 45^QGPB^!/PUU+X4^#;N\^'GA6ZN[C1[.6:>?1+9WD=H4+,S%,DDD
MDDU^3GQ6L[?3OBAXPM+2".UM8-9O(HH(4")&BSN%55'     '3%>-A,RABZ\
MZ$8M.-_P=CU,1@)8?#T\0Y74K?BKG+445I^%X4N/$NDQ2HLD3W<*LCC*L"X!
M!'<5[25W8\>I+V<'-]#,HK]N?^&?/A;_ -$U\(?^"&U_^-T?\,^?"W_HFOA#
M_P $-K_\;KXS_6:C_P ^W]Z/L/\ 5ZK_ ,_$?B-17[<_\,^?"W_HFOA#_P $
M-K_\;K\X_P#@H9X0T+P5\<M/L/#VB:=H-BVA6\S6NF6D=M$7,TX+%4 &2% S
MUX%=V"SNGC:RHQ@TV<>,R>I@Z+K2FG8^8J***^D/GPHHHH **** "BBB@ HH
MHH **W_A_;0WGCSPW;W$23V\VIVT<D4BAE=3*H*D'@@CM7Z]?$'X"_#.R\!>
M)+BW^'7A."XATVYDCEBT.U5D81,0P(3((/>O%S+,X9;R\\6^:_X6_P SULNR
MZ>8SE"$K6M^-_P#(_&:BBBO:/)"BO7OV1]#TWQ)^T9X)TW5]/M=5TZXN9%FL
M[V%9H9 ()" R,"",@'D=J_5O_AGSX6_]$U\(?^"&U_\ C=>%F&;0R^<82BW=
M7/8P.6SQT92C)*Q^(U%?MS_PSY\+?^B:^$/_  0VO_QNC_AGSX6_]$U\(?\
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M!?L<_$7Q#\5/@/H_B+Q3J']J:S<7%RDESY$<.Y4F95&V-548 '05GF6*JX[
M4\0FE&]I+^]Y>7SZCP.%IX+,)T7J[7B_+6]_RVZ=#QW]I[]AG_A9GC#Q9\1_
M^$V_LW=:?:?[,_LGS?\ 4VX7;YOGK][R^NWC/>O$_@7^P+9?''X9:3XOLOB/
M]@%X'2:R.B>:;>5&*LA;[0,],@X&00<5L?MD_M1_$[P3\:O%W@W1?$WV+PVL
M$,(LOL%K)\DMLAD&]HB_)=OXN,\8K4_X)A_%+['K?B3P!=RXCO$&J6*M_P ]
M$ 291[E=A_X :ZJ']HT<M=:-162BXI):1ZIW7:SZ[&.*>!J9A&E.#NVU)W=F
MW;EM9]].F_W?+?[0'P8O/@+\3+_PE=WG]II#''/;W_D^2+B)U!#!-S;<-N7J
M>5-9'PB^&]Y\7OB3H'A"QF%K-JER(FN"F\0Q@%I)-N1NVHK-C(SC&17V_P#\
M%/OAI]LT#POX[M8<R64K:7>NJ\^6^7B8GT#!Q]9!7&_\$P_AR=2\:>)?&UQ%
MF#2[9=/M69>#-*=SD'U5% ^DE>IALR<\L>*F_>BFGZ[+[]'\SS,7EZIYA'#4
MU:,FK>G7[K/[C/\ B]_P3QLOA#\-]>\7W_Q+^T0Z7;F5;?\ L/RS/(2%CC#?
M:3C<Y5<X.,YQ7QG7Z'_\%/?B=]B\/^&? 5K-B6^E.J7JJW(B3*1*P]&8N?K&
M*_/"M,EK8G$8=UL1*]WIHEHO1=[DYO1P^'KJC0C:RUU>[]?*WWA1117OGAA2
MI]Y?K24J?>7ZU</B0C][-)_Y!-G_ -<$_P#017X6^.O^1V\0_P#81N/_ $:U
M?NEI/_()L_\ K@G_ *"*_"WQU_R.WB'_ +"-Q_Z-:OSWAW_>:OI^I]SG?^YT
MO5?D1^$?".L>//$5CH.@:?-JFK7LGEP6L RS'J3D\  9))P  22!7W;\-O\
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M+\L@ R2,*0!QNKAO /Q(_::\>>*H-<\-ZCXSUN2:;>"HE.F$_P!UD;%NJ_4
M5^K=Q"VI>'Y(;Z%5>>U*3P]0"R89?<<D5Y&+Q.897*,YUE/NO3O_ )GJ82A@
M<RYH1HN*[_UU\C\4_@#_ ,ET^'?_ &,6G_\ I3'7["_&_P /W_BSX.^-M$TJ
M#[5J>HZ/=6EM#N"[Y'B957).!DD<GBOQ_P#@7%Y'Q\\ 1@Y">)+!<_2Y2OV>
M\9^*+7P3X1UKQ#>@FTTJRFO957J5C0L0/<XKJXDE:5"2\_\ VTQR"#M6@_)?
MF?&7P_\ ^"7N@)HL;^-_%6ISZM(H9X="\N&&$XY7=+&YDY_BPOTKE/C=_P $
MT[CP_H=QJWPYUF[UM[9-[Z-J@3[1* "28I4"JS=,(5&>?FS@'P+QA^V-\6O%
M?C!]>C\9:EHP64O;Z=IL[0VD2YR$,0^60#UD#$]Z_23]D;XX7/QY^#UIK>IK
M&NN6<[Z?J!B4*LDJ!6$@ Z;E=20. 20.*,7+-L%!8J=1-=5T7_ Z?U<C"K*\
M54>%A3?D^]OR[[?Y'XYRQO#(\<B-'(A*LC#!4CJ"/6OMGX>?\$U?^$]\ ^'/
M$O\ PL;[#_;&G6]_]E_L/S/*\V-7V;OM W8W8S@9QT%>8_M]> +3P)^T5JDE
MC$(+76[:+5?+1<*LCEDDQ]7C9C[M7Z4_L\_\D%^'/_8NZ?\ ^DZ5VYAF56.
MI8K#OE<FNSZ.ZU\T<N!RZD\;4PU=<RBM-UU5GIY,_&3QQX:_X0OQKX@\/_:?
MMG]DZA<6'VC9L\WRI&3?MR=N=N<9.,]37[@^!O\ D2/#_P#V#K?_ -%+7XL_
M''_DM7Q _P"QAU#_ -*9*_:;P-_R)'A__L'6_P#Z*6N#/Y.>$H2EN_\ (Z,E
MBH8ZK&.RO^9^('C==WCC7QTSJ-P/_(K5]L2?\$L?+LFN/^%G9VQF3;_8'MG&
M?M5?%'C3_D>]>_["5Q_Z-:OW,N/^0++_ ->Y_P#0:Z\WQM? X3#RP\K-IWT3
MV4;;W[BRW!T,9C:T:\;I/NUU?8_,C]A_]E__ (6U?6?C[_A)O[*_X1G7K=_[
M/^P>=]I\HQS8\SS5V9^[]TXZ\]*_1WXH>"?^%D?#OQ'X6^V_V=_;%C+9?:_*
M\WRMZE=VS<N[&>F1]:_*;]E#XY>-_A_\0?"_A/0-;^P:!K?B"S74+/[)!)YP
M>6.-_G="RY3CY2/7K7ZB_'CQ-J7@SX,^--=T:Y^QZKIVE7%S:W'EJ_ER*A*M
MM8%3@]B"*\S/XXA8B#G)<K^'RVO?3OZG9D<J/U>:C'WE\7GO:VO;T/SM^*G[
M#]E\*?B%\/?#>H?$'S;;Q;=RV?\ :']C[!:.H0)E//.\,\BK]Y<=>:Z_XC?\
M$T+SP3X#U[Q!I_CO^W+K3+.2[73QHODF<(-S*'^T-@X!Q\IR>*^:?B9^T%X_
M^,4VDR^+O$#:I+I+M)9.EK!;M"S%22#$B9/R+USC'%?KG\"?B-!\9/@YX;\2
ML$D?4+,)>1XX$ZYCF7![;U;\"*]#,*V98##4ZLJB;NU*R5NZZ=M&<.!IY=C<
M3.G&FU&R:U=_/KZ6^9^)-?3'[,/[%%W^T9X/U'Q'+XH_X1FSM[PV<"G33=&<
MA%9VSYJ8 W*.^3GIBO)OCU\.7^%/QB\5>%O+*065ZWV4<\V[X>'Z_(R_CFOU
MK_9T^'Z?"+X%^%=!N +>>UL1<7I8_=FDS++D^@9B/H!7?FF9.A@HUZ#LYVMZ
M;O\ R^9P9?E_M<;*A65U"]_/HO\ /Y'Y<?M/? "R_9T\8:=X<A\4_P#"37UQ
M:?;+C_B7_91;J6*H/]:^XG:Q[8&.N:\<KT#X_?$A_BU\8O%/BC<6M[V\86O7
MBW3"1?3Y%4GW)KS^O7P?MOJ\'7=YM7?3?IIVV/-QGLEB)J@K13LOEI?7ON%%
M%%=IQGZ<?\$P_P#DA>O_ /8Q3?\ I-;UXA_P5 _Y+'X7_P"P$O\ Z435[?\
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ML[2%5']HS0PPQ+@#]Z0JJ!T[#%?;Y=FL,QG*G"#5CX_'Y9/ 4U4G)--V.^^
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MDZ7MN;W=[GE.C453V/+[VUCAZ]$_9YC23XS>%UD19$-TN5=00>1V-?=GA?\
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M&3G':O8_@=X+\#?"'2KKX=^$+U)[O2 EWJ4<DHDN?,FSMDF(  9A'P,# "\
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M9<?\@67_ *]S_P"@TN(O]RPWI+\H'3DG^_5_7]6?BC\ ?^2Z?#O_ +&+3_\
MTICK];?VH/\ DW?XC?\ 8#NO_19K\@OA'KEKX9^*W@S5[V016=AK-G=3R-T6
M-)T9C^ !K]J_'/A6T^(_@/6_#T]RT5EK5A+9M<6^&*I*A7>N>#@'(K?B1\LJ
M$GMK^AR\/VE&M!;Z?J?A17WW_P $P?BE\WB;X?7<O7&KV"M_P&.=1_Y"('^\
M:\4_:N_9*M_V:=!\+W4'B"?Q#-JD]Q%/,]LMO&FP(4"H&8Y(9LDL>@X%>6?
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M8FO57+4FVO-MFKX2_P"1JT;_ *_8?_1BU^[]Q,+>"24C(12Q ]AFOP@\)?\
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M/+MPJ(H)P.@R2<DDG\Y_VTOVC(?C[\1((]&9_P#A%=#5[>P9P5-P[$>9/CJ
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MAL:^_P"OPP_90HHHH **** "BBB@ HHHH **** /E7_@J/\ \F)_$W_N&?\
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M4D4%^0#[U^>_['LHN/VD-"E"[?,N_,V^F7SC]:^]_P!OI2W[->N #)^TV_\
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M:O\ ]@:3_P!$FOS!^/&O1>)OVS+K4(,>4^JVD8Q_L@+_ $K]/O&G_)'M7_[
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M,O\ Y*)KO_7'_P!EKU,3AJ4<ITBOA3^>AYF'Q%66::RZM?([7_@J=I\$.B^
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MZ_6OV2_:]_Y-N\=?]>0_]&)7XV^OUKFX;_W>?^+]$;\0?[Q#T_5A7J?[+O\
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M_P!\J>H4445ZQY@4444 %%%% 'KGA#]K;XO^!;%;+2?'>I"U7 2.^$=Z$ &
M%\]7VCCH.*VK[]N3XX:A;O!+X[F1'&"8-/M(6_!DA!'U!KPFBN.6#PTWS2I1
M;]$=4<5B(+EC4:7JS1\0>)=7\6:I)J6N:I>:QJ$@ >ZO[AYY6 Z LQ)K.HHK
MJ45%62T.9R<G=O4]9\!_M7?%CX9Z'%H_A[QG=VNF0C$5M<00W:Q+C 5/.1]B
M_P"RN![5A_$[X\>/OC(MM'XQ\2W6LP6S;X;=DCAA1L8W>7&JKNP2,XS@FN"H
MK#ZM0Y_:\BYN]E?[S;ZQ6Y/9\[Y>UW;[C5\+^+-:\$ZU!J^@:I=:/J<!S'=6
M<IC<>HR.H/<'@]Z]<U#]MSXW:EILEC-X\N4@D0HS6]E:PRXQCB1(@X/N#FO#
MJ*=3#T:S3JP4K=TF*G7JT;^SFXW[.QT.A_$3Q7X9U:]U31_$^LZ5J=[G[5>V
M-_+#-/EMQWNK!FR>>3UYIGBKX@>*/';6S>)?$FK^(6M0P@.JWTMT8MV-VSS&
M.W.T9QUP/2L&BM/9PNI65T1[2=FKZ,*]D\*?MB?&/P7H\.EZ7XYO!90C;&EY
M!!=LB]E#S1NP [#.!VKQNBE4I4ZRY:D5)>:N.G4G2?-3DT_+0ZSQ;\6/&7CK
MQ1!XCUWQ+J5_K=NZR6UXTY1K9E(93"%P(L$ C8!@\U)KGQF^('B;2Y],UCQS
MXDU;3;@ 36=]J]Q-#( 00&1G(." >1U KCZ*2HTTE%15EMIMZ#]M5;<G)W>^
MIT?A/X;^*_'T-[)X9\-ZKXA6R*"X&EV<ERT6_=MW*@)&=K=NU?H?_P $^?V<
M?$/PJL==\5^++";2-3U:..UM-/N.)8X =[/(N?E+-M&UL$;#G&:^7OV,/VFM
M _9QU;Q/+XAT_4[^SU>&!4_LM(W=&C9SDAW08(<]#VKZ-\7?\%1/"4&DR'PM
MX2UJ^U,C"#5S#;0J?[Q,<DA;'I@9]17SF;2Q]7FPV'IWA*VOYK[_ ,#W<LA@
MH<N(KU+2B]OR?]=3"_X*??%!5M_#'P_M)\NS'5K^-3R ,I"I^I,IQ_LJ:_/Z
MNB^(7C[6OBAXQU/Q/X@N?M6JZA)YDK*-JJ  %11V55  'H*YVO5RW!_4<-&D
M]]WZO_+;Y'!F6+^N8AU%\.R]/^#O\PHHHKU#S KU#P#^T]\4_ACIZV'AWQIJ
M%I8H L=K<!+J*)1T"),KA![*!7E]%9U*<*L>6I%->>I<*DZ<N:#L_(]@\7_M
M>?&'QUI;Z=JWCJ_-G)P\=C'#9EQT*L8$0D'N"<&O'Z**FG1I45:E%1]%8JI6
MJ5G>I)OU=R]H>O:GX8U2#4]'U&[TG4K<DPWEC.T,T9((.UU((R"1P>A-=#KW
MQC\?>*-+GTS6?''B35]-GQYMG?ZM<3PR8((W(SD'! /(Z@5R%%5*G"33DKM$
MQJ3BK1=@HHHK0@*Z#P7\0O$WPZU(W_AC7M0T&Z;&^2QN&B\P Y < X<>S BN
M?HJ6E)6:T&FT[H][B_;M^.<,81?'3$#CYM+LF/YF'-<;X^_:0^)OQ/M6M/$G
MC/4KZR==LEG&ZV\$@]'BB"JWX@UYM17+'!X:#YHTHI^B.F6+Q$ERRJ2:]6%;
MG@WQQX@^'NN1:QX:U>[T74XQM%Q9RE&*Y!*MV93@94Y!QR*PZ*ZVE)69RIM.
MZ/<=4_;;^-NL:;+8W'CRZC@E4HS6MG;6\H'M)'$KJ?<$&O+]!^(WBSPKJ-[J
M&B>)]9T>_OCFZNK#4)8);@Y+9D9&!;DD\YY-<]17/##4*::A!*_9(WGB*U2W
M/-NW=LZ'Q5\1O%GCJ.WC\2>)]9\0QVY9H5U74)KD1$XR5#L<9P,X]*F\+_%+
MQGX)L9++P[XNUW0+*20S/;Z7J4UM&SD %RJ, 6PH&>N /2N8HK7V<.7DY5;L
M1[2?-S<SN:WB;Q?KWC74%O\ Q#K6HZ]?+&(5NM3NY+F4("2%#.2< L3CIR:R
M:**J,5%6BK(AR<G=L]:\$_M8?%OX>:6FG:'XWOXK&,!8X+Q(KQ8U P%3SD?:
MH Z# IOCG]J[XL_$;2GTW7O&U_/82 K+;VJ16B2J1@JXA1-ZD=FR*\GHKG>%
MP[ESNFK][*YT1Q->,>2,VEVN[!73_#[XG>*OA5K7]J^$]=N]#O2-KM;L-DJ_
MW70@JXYZ,",\US%%=$HJ2<9*Z9SIN+NMSV_6OVV/C7X@TV:QN_'=TMO,I1S:
M6=M;28(P</%$K#\#7G'A7X6^,?'6GSWOAOPMK'B"U@E$,LFEV,ER(W(R VP'
M''K7+U]2?L7_ +5WAW]G.Q\467B33M6O[?5)8)H&TN.*0HR!PVX/(G4,O0GH
M:X*M-82C.>$I+FTT2M?7R\KG93J2Q5:$,34?+KJW>VGGYV/JG]@3]GO7/@SX
M-UK6/%%J^G:YKTD6+"1@6@MXPVS>!T=B[$CJ !G!R*\3_P""G7Q175/%'AWP
M'9S[XM,C.HWR*00)I!MB4^A5-Q^DHKM?'7_!4/P['H\J^#?">J7.J.I6.37/
M*@AB..&*QNY?!Q\N5SZBOS_\6>*M5\<>)=2U_6[M[[5=0F:>XN'ZLQ] . !P
M !P  !TKYW!8+%8G'/'8R/+;9>=K+[E^)]!BL7AL-@OJ>%ES-[OYW?W[6[$7
MANSU74/$.F6VAI<2:S+<QK9+9DB;SBPV;".0V[&".AK]&/$VI>(OV??V*=>L
M_B9XCO=7\;^)([BV@M]0U!KR:-IT$8B5V9LB- 7;!V@DXSD$_FY8WUQIM[;W
MEI,]O=6\BRQ31G#(ZG*L#V((!KH?B#\3?%/Q5US^U_%FMW6MW^W8LEPP"QK_
M '410%0=\* ,\U[V.P<L8X0NE%.[[Z6LEZ]?D>)@<5'".=2S<K::Z7UU?IT.
M8HHHKU3S0HHHH [U?V@/BC&JJOQ(\7*JC 4:[=  >G^LKA9[B6ZGDFFD:::1
MB[R2,69F)R22>I)IE%9QIP@[QBD7*I.2M)W"O2/AY^T=\2_A5:"T\,>,-0T^
MR482SD*W%NG.?EBE5E7D]@,UYO11.G"I'EFKKS%"<J<N:#L_(]G\3?MD_&;Q
M=ILEAJ'CR^2VD^]]@A@LG(]-\,:-CVSS7C+,TC%F)9F.22<DFDHJ*5"E1TI0
M4?16-*E:K6_B2<O5W-'P_P")-7\)ZI%J>AZI>Z-J4081WFGW#P3(",$!T((R
M"0>>];GB#XO>._%VER:9KGC7Q%K6FR%6>SU#59YX6(.02CN0<$ CCM7)45<J
M<)-2DKM$1G**:B[)A7IOP]_:8^)_PLT\6'AGQC?V-@HPEG,$N88QZ(DRNJ=?
MX0,UYE114IPJQY:D4UYZA"<J<N:#L_(]E\4?MC?&7QCIDEAJ7CN^6VD&'%C#
M#9LP]"\"(V/;.#7C1)8DDY-%%13HTJ*M2@H^BL74K5:W\23EZNYTOA?XG>,?
M ]I-:^'/%FN>'[69_-DATO49K9'? &YE1@"< #)]*I^*/&GB'QQ>17?B/7=3
MU^[BC\J.?5+R2YD1,D[0SL2!DDX]S6-15^SAS<]E?N1[2?+R7T[!7H_PU_:,
M^)'PAL7LO"?BR\TRQ8Y^QNL=Q I)R2L<JLJDD\D 9[UYQ11.G"I'EFKKS%"<
MJ<N:#L_(]*^)'[27Q+^+=@MAXJ\77NHV ZV<:QVT#\@@O'$J*^"!C<#CM6/H
MOQH^(/AS2[?3=)\=^)M+TZW7;#9V6L7$,,0SG"HK@ 9)Z#O7&T5G'#T81Y(P
M27:RL:2KU9RYY3;?>^IIW'BC6;KQ#_;TVKWTVN^>MS_:DER[7/FJ05D\TG=N
M! (;.>!6[KGQF^('B;2Y],UCQSXDU;3;@ 36=]J]Q-#( 00&1G(." >1U KC
MZ*T=.#M>*TV\B54FFVI/4]0^'?[3WQ1^%.D_V9X8\87ECIH^Y:31Q744?LBS
M(X0<]%Q63\2OCGX\^,#PGQ?XGO=9BA.Z.V<K% C<C<(HPJ!L$C=MS@]:X6BL
M_J]'G]KR+F[V5_O+]O5Y/9\[Y>UW;[@KM].^.7Q(T?3[:QL/B!XILK*VC6&"
MVM]:N8XXD485%4/A5    X&*XBBM90C-6DKF492@[Q=B:^OKG5+ZXO+RXEN[
MRXD:::XG<O)*[$EF9CR22223R2:[6#X^?$ZU@CAA^(WBV&&-0B1QZY=*JJ!@
M  2< "N$HI2IPDK2BFAQG*+NG9CYKB6YN))YI'EFD8N\CL2S,3DDD]23WKNC
M^T!\4&C*'XD>+BF,;?[=NL8]/]97!442IPFDI13L$:DXN\6TPKUSP+^UG\6_
MAOH<.C:!XTN[?3(0%AM[F""[$2@8"H9D<JH X4$ >E>1T4JE*G6CRU(IKS5Q
MTZDZ4N:FVGY:'=_$SXZ>//C(UJ/&'B2ZUJ.V8M# RI%$C$8+".-57=CC.,UT
MW@G]DGXJ^-/%5GH__"%ZQI,,SJ)=1U&R>"VAC)&9/,<!6P#G"DD]A7CU?I/X
M:_X*9?#JP\.:;;:AH'BDW\%K'%-Y%M;-&75 &(8SJ<9![#Z5YF+E6P=.*P-)
M/?3M\E8]##1I8NH_KE5KSW_,^K(_[)^%'PZC$T_D:)X=TP*TTIR5A@BQDGN=
MJU^)GQ"\97?Q#\<Z]XFOBQNM5O);ME8YV!F)5![*,*/8"OHK]J#]NK4_CAH,
MOA;P_I<GAWPQ,X:Y:>4/=7BJ055L<1KD9*@MG ^;&0?E6O.R7+ZN'<\1B5[\
MORW?WO\ (]'-L=2K1AAL._<C]W9?=^I[Y^R%\._B3X^\=)#X*U;5_#^A1W,!
MUW4=/OY+2-80Q8*VQAYC$;PJX/+<X&37H?\ P4H^)FF>+_BEHGAO3+A+L^&[
M61+N6-MRK<2LI://JJQIGT+$=0:^:_ OQ6\7?#*+5H_"NO7>AC58!;WC6C!6
MD0$D8;&5(R<,I!&3SR:Y:21YI&DD9G=B69F.22>I)KU)X.53&QQ,VK06EM[M
M6=_T/+IXJ-/"3H13YIVOVLG=67?O_5FT445ZIYQT_A?XI>,_!-C)9>'?%VNZ
M!922&9[?2]2FMHV<@ N51@"V% SUP!Z51\4>-/$/CB\BN_$>NZGK]W%'Y4<^
MJ7DES(B9)VAG8D#))Q[FL:BL_9PYN>ROW+]I/EY+NW8****T('0S26\R2Q.T
M<J,&5T)#*1R"#V-=XW[0/Q1=2K?$GQ<RD8(.NW1!_P#(E<#16<Z<*GQI/U+C
M.5-W@[!1116A!W5K\>?B98VL-M;?$3Q9;V\*"..&+6[E410,!5 ?  '&!5*/
MQ)XY^)7C/1F.M:YXC\4^='!ITT][+/=))OR@C=F++ACD8(P>:Y*K.FZE=:/J
M5K?V4[VU[:RK/!-&<-'(I#*P/J" :R5*G%\RBK^A;J5''EYG8_1WX@:MKWP"
M_8DU32/B/XANM9\=>)8YK5(+^_:\F4S85HU=F;*QQ9+$';N) )R,_FS72>/O
MB1XG^*6O/K/BO6KK6]19=@EN&&U%_NH@ 5%[X4 9)-<W7!@,)+#*<ZC3E-W=
MMEV2\D=^-Q4*_)"FGRQ5E?=]VPIT,TEO*DL3M'*C!E=#@J1R"#V--HKU#S#V
M[1?VUOC7X?TR&PM?'ET]O$NU6O+2VNI<>\DL;.?J37G/BCXI>+_&GBB'Q'K7
MB34K_7()!);WTEPPDMV#;E\K!'EX/("8 /2N7HKFAAJ%.7/""3[I*YT2Q%:<
M>24VUVN[':ZI\;_B-K>G7.GZCX_\47]A<QF*>UNM9N9(I4(P596<A@1V-8WA
M7QUXE\"SSS>&_$.J^'YKA0DTFE7LMLTB@Y 8HPR ?6L.BM%2IQ32BK/R(=2<
MFFY/0Z/Q5\2/%WCJ&"'Q)XIUKQ!#;L7ACU74)KE8V(P2H=C@D>E8NF:I>:+J
M%O?Z?=SV%];2"6"ZM9&CEB<'(964@J0>XJM151A&*M%61,I2F[R=SM=4^-WQ
M%US3KG3]1\?>*-0L+F,Q3VMUK-S)%*A&"K*SD,#Z&N*HHI1IPA\"L.4Y3^)W
M.]^&GQY\?_!_SE\(>*+S1X)CN>U&R:!FX^;RI%9-W ^;&:O?$C]I3XF?%O3E
MT_Q5XNO-1T\')LXTCMH7Y!!=(517P0"-P..U>:45G+#T93]I*"<N]E?[S2->
MK&'LXS:CVN['9Z3\;/B)H&FV^G:7X]\3Z;I]LGEP6EIK%Q%%$H_A5%<!1[ 5
MR5Y>7&HWD]W=SR75U/(TLL\SEWD=CEF9CR22223US4-%:1IPBW)*S9DYR:46
M]$%.AFDMYDEB=HY48,KH2&4CD$'L:;16A&YWS?M _%%U*M\2?%S*1@@Z[=$'
M_P B5P-%%9QIPI_ DC252<_B=PHHHK0@EM+R?3[J&YM9I+:YA<2130N4=&!R
M&4CD$'N*]HT']M3XU^'=/BLK3Q[>20QC"M?6UO=R?C)-&S'\37B5%8U*-*LK
M58J7JKFM.K4HN].33\G8[[XD?'OX@_%Q5C\6>*[_ %:V7!%H66&WR.C>3&%3
M=[[<UP-%%.G3A2CRTXI+RT%4J3JOFJ2;?GJ%>J^!?VJ/BQ\-].73]!\;:A!8
MH L=O=".[CB4# 5%F5P@]EP*\JHHJ4X55RU(IKSU%"I.F^:#L_(];\;?M9?%
MSXA:6^FZWXXOY;&0$20V:168D4C!5_(1-RD=CD5Y)112IT:=%6I145Y*Q52M
M4K.]23?J[A7J7P]_:A^*7PLTD:7X:\8WEEIJ_P"KM9XXKJ.(>B+,CA![+@5Y
M;155*<*L>6I%->>I,*DZ<N:#L_([;XE?&SQS\8+J&;Q?XDO-:\GF*&0K'!&>
M?F6) J!N?O!<FGS?'?XEW-G):S?$/Q7+:R(8G@?6[DHR$8*E2^",<8KAJ*A4
M**BH*"LNEE8MUZKESN;OWNPHHHK<Q+NBZYJ7AO5+?4M(U"ZTK4;<EH;RRF:&
M:,D$$JZD$'!(X/>NR_X:#^*7_12O%_\ X/KK_P".5P%%9RIPGK**9<:DX?"V
MCO\ _AH/XI?]%*\7_P#@^NO_ (Y1_P -!_%+_HI7B_\ \'UU_P#'*X"BH^KT
M?Y%]R+]O5_F?WG2>*?B9XO\ '%M#;>)/%>M^(+>%_,BAU349KE(VQC<H=B <
M<9%,\*_$3Q7X%2X3PUXGUGP\MR5,ZZ5J$ML)2N=I;8PW8R<9]37/45?LX*/(
MHJW8AU)N7,WJ;OBKQ]XG\=26\GB7Q'JWB%[8,L#:K?2W)B#8W!2[';G SCT%
M4-#U[4_#&J0:GH^HW>DZE;DF&\L9VAFC)!!VNI!&02.#T)JC1348QCRI:"<I
M2?,WJ=?KWQC\?>*-+GTS6?''B35]-GQYMG?ZM<3PR8((W(SD'! /(Z@5R%%%
M$81@K15ARG*?Q.YU/@'XI>+?A;J1OO"GB&_T*=B#(+64B.7&<>9&<JX&3PP-
M>GW'[='QQN;=H7\=2!&&"8]-LT;\&6$$?G7@]%8U,-0K/FJ04GYI,TIXBM15
MJ<VEY-HT?$'B35O%FK3ZIK>IW>KZE,<R7=].TTKXZ99B3Q6=116\8J*LE9&,
MI.3NW=G;_#GXV>.OA'+(WA'Q/?:+'(=SV\;AX'; &YHG!0M@#DKFN\U/]M_X
MWZM92VL_CRXCBD4JS6MC:V\@!]'CB5@?<$&O#**YZF%H59<U2FF_-)F]/$5J
M2Y:<VEY-HLZEJ=YK-_/?:A=SWU[<.9)KFYD:221CU9F8DD^YJSX=\2:KX1UF
MVU;1-1NM)U.V;=#=V<K1R(<8.&!SR,@CN"16;17196Y;:&%VW=[GO$G[='QQ
MDMC ?'4@3&W*Z;9A_P#OH0YS[YKQ36M;U#Q)JUWJFJWD^H:C=R&6>ZN7+R2.
M>I8GJ:I45A3P]&B[TH*+\DD;5,16JKEJ3;7FVPHHHKI, HHHH **** /OG_@
MBI_R:SXI_P"QSNO_ $AL:^_Z^ /^"*G_ ":SXI_['.Z_](;&OO\ K\,/V4**
M** "BBB@ HHHH **** "BBB@#Y5_X*C_ /)B?Q-_[AG_ *=+2OR7\ ?\B3HO
M_7N/ZU^M'_!4?_DQ/XF_]PS_ -.EI7Y+^ /^1)T7_KW']:^OX;_WBI_A_5'R
MO$/\"'K^C-^BBBOT$^$"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NM^%
M/Q*U7X1^/--\3Z1)LN;5\2+_ ,](B?F3\0*Y*BIE&,XN,E=,J,I0DI1=FC]D
MOA/^TIX ^.'AU&@U*TAN9(PMSINH,J-N(^90K'Y@#WJC??LC_![7K^75Y?#E
MM)(S^8TD4[*F?H#BOR L[RXTZY6XM)Y+6X7I-"VUA^-=##\4?&MO"T,7B_6X
MX6&#&MZX4_AFODI9#.G)O"UG%/\ KH?41SN%2*6)I*37]=3]C+OQ5\/O@CX7
M=&OM,T33K5,^1&Z"1L>BYRQK\OOVLOVB9?V@?'23VRM#H&FEH[&)NISPS'ZX
M!KQW5O$&JZ^P.J:G=ZD0<@W4ID_G5"N_+\HA@Y^VG+FGW.''9K/%P]E&/+$^
MQ/\ @G#\5-(\'>-=<T+6KR'3TU*%?LLT[A4:0-DJ2>!Q7V[\6O@I\.?C,MA>
M^,+6"_CLQ^YF^U&-<<G&01D<U^+\;M%(LB,4D4Y5EX(/M6_)\1?%LUL+=_%.
ML/;CI$UXY4?AFLL9E$L1B/K-&IR,UPF:QH8?ZO5I\R/08]?L/@?^TH+_ $HJ
M^CZ;?J#Y+[QY&[+ 'OP*_573?%G@CXX>#?(BO['5M-U* >9:><I< C.&7.01
M7XER2/,[/(S2.W)9CDFK^C^)=8\.MNTG5KW2VSG-I,8_Y5MCLJ6,4)*=IQZ]
MS+!9F\(YQ<+QET/TLNOV>_@)^S3=R>,M46(W.GOY]I:S7!=U/0!8RWS]>XKW
MWP7\4]#\:>";+6EOK.S6\A9U@>=04&2 "/IBOQ6UKQ-K/B217UC5KW577[K7
MDQD(^F:6'Q/K5O"L4.KWT42C"QI.0H_"N&KD<Z\4ZM9N7=]NQV4\ZA0DU2I)
M1[>9=\5WTUA\1]>O[.79<0:Q//!*O9A*2I'XXK]1?V7_ -JWPS\7O!MGIFKZ
ME#:>)K6!8KN*\81BX(&"RY/.>>*_)QF:1F9B69CDL>I/K3[6ZGL;A+BVFDMY
MTY66)MK+]#7KX[+J>.I*$G9K9GEX+,)X.HYQ5T]T?J_XS_9"^!]YXB?Q1J]E
M:V!F?SYMUX8H9#ZXW  ?2N[^%/QI\#^*I-:T;P[=V=KIF@/%:HX=4CDRI.4]
M0,=:_'O4?''B76+46U_XAU.^M@-HAN+EG3'I@U0T_6-0TE&2PO[FR1CEEMY"
M@/UQ7D2R.I5I\M:LY-;=D>K'.H4I\U&BDGOW9]*_\%$KZVU#X_F6UN(KF/\
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M#.[C.:_&Z1@J$GD 5^A'[-6DP_LS_"'6OB!XO\31W$VJV:'3M.\\.T7RG;@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]
M\_\ !%3_ )-9\4_]CG=?^D-C7W_7P!_P14_Y-9\4_P#8YW7_ *0V-??]?AA^
MRA1110 4444 %%%% !1110 4444 ?*O_  5'_P"3$_B;_P!PS_TZ6E?DOX _
MY$G1?^O<?UK]:/\ @J/_ ,F)_$W_ +AG_ITM*_)?P!_R).B_]>X_K7U_#?\
MO%3_  _JCY7B'^!#U_1F_1117Z"?"!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 .C<QRQN.J,&'
MU!S7V-X'_P""CFL^$O!UAHLGAZWN);&W6"*8!L-CNW/\J^-Z*Y,1A*.+25:-
M['5A\56PK;I2M<]N^._[7'C7X\0)8:@T.EZ+&VX65D6"R'U?)Y/6O$:**UHT
M:>'AR4HV1E5K5*\N>H[L****V,@HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH U/"^O3^%O$-AJ]L T]G*)%#=
M#@U]EO\ \%/-<_L]53PS:"]'4D-Y?3_>S7Q!17#B,%A\4TZT;V.S#XROA4U2
ME:YZ-\:/CYXL^.^MK?\ B.Y588LB"QMR1#$/8&O.:**ZJ=.%**A35DCFJ5)U
M9.<W=LM:;JU[H\S36%W+9RL-I>)L$CTJKZ\DDG)).:**NW4B[V"BBBF 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** (-0_Y!UW_P!<7_\ 037WO_P1;_Y-
MM\2_]C'+_P"B(:^"-0_Y!UW_ -<7_P#037WO_P $6_\ DVWQ+_V,<O\ Z(AK
MX7B;XJ7S_0^TX=^&K\OU/T#HHHKXD^Q/YQ?@C_R*EW_U^O\ ^BXZ]"KSWX(_
M\BI=_P#7Z_\ Z+CKT*OUW*O]QI>A^6YG_OE3U"BBBO6/,"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4O\ HFOB_P#\$5U_\;K]N:*/]9JW_/M?>P_U>I?\_&?B-_PSW\4O^B:^+_\
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M7J7_ #\9^(W_  SW\4O^B:^+_P#P177_ ,;H_P"&>_BE_P!$U\7_ /@BNO\
MXW7[<T4?ZS5O^?:^]A_J]2_Y^,_$;_AGOXI?]$U\7_\ @BNO_C='_#/?Q2_Z
M)KXO_P#!%=?_ !NOVYHH_P!9JW_/M?>P_P!7J7_/QGXC?\,]_%+_ *)KXO\
M_!%=?_&Z/^&>_BE_T37Q?_X(KK_XW7[<T4?ZS5O^?:^]A_J]2_Y^,_$;_AGO
MXI?]$U\7_P#@BNO_ (W1_P ,]_%+_HFOB_\ \$5U_P#&Z_;FBC_6:M_S[7WL
M/]7J7_/QGXC?\,]_%+_HFOB__P $5U_\;H_X9[^*7_1-?%__ ((KK_XW7[<T
M4?ZS5O\ GVOO8?ZO4O\ GXS\1O\ AGOXI?\ 1-?%_P#X(KK_ .-T?\,]_%+_
M *)KXO\ _!%=?_&Z_;FBC_6:M_S[7WL/]7J7_/QGXC?\,]_%+_HFOB__ ,$5
MU_\ &Z/^&>_BE_T37Q?_ ."*Z_\ C=?MS11_K-6_Y]K[V'^KU+_GXS\1O^&>
M_BE_T37Q?_X(KK_XW1_PSW\4O^B:^+__  177_QNOVYHH_UFK?\ /M?>P_U>
MI?\ /QGXC?\ #/?Q2_Z)KXO_ /!%=?\ QNC_ (9[^*7_ $37Q?\ ^"*Z_P#C
M=?MS11_K-6_Y]K[V'^KU+_GXS\1O^&>_BE_T37Q?_P""*Z_^-T?\,]_%+_HF
MOB__ ,$5U_\ &Z_;FBC_ %FK?\^U][#_ %>I?\_&?B-_PSW\4O\ HFOB_P#\
M$5U_\;H_X9[^*7_1-?%__@BNO_C=?MS11_K-6_Y]K[V'^KU+_GXS\1O^&>_B
ME_T37Q?_ ."*Z_\ C='_  SW\4O^B:^+_P#P177_ ,;K]N:*/]9JW_/M?>P_
MU>I?\_&?B-_PSW\4O^B:^+__  177_QNC_AGOXI?]$U\7_\ @BNO_C=?MS11
M_K-6_P"?:^]A_J]2_P"?C/Q&_P"&>_BE_P!$U\7_ /@BNO\ XW1_PSW\4O\
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MXO\ _!%=?_&Z_;FBC_6:M_S[7WL/]7J7_/QGXC?\,]_%+_HFOB__ ,$5U_\
M&Z/^&>_BE_T37Q?_ ."*Z_\ C=?MS11_K-6_Y]K[V'^KU+_GXS\1O^&>_BE_
MT37Q?_X(KK_XW1_PSW\4O^B:^+__  177_QNOVYHH_UFK?\ /M?>P_U>I?\
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M'^LU;_GVOO8?ZO4O^?C/Q&_X9[^*7_1-?%__ ((KK_XW1_PSW\4O^B:^+_\
MP177_P ;K]N:*/\ 6:M_S[7WL/\ 5ZE_S\9^(W_#/?Q2_P"B:^+_ /P177_Q
MNC_AGOXI?]$U\7_^"*Z_^-U^W-%'^LU;_GVOO8?ZO4O^?C/Q&_X9[^*7_1-?
M%_\ X(KK_P"-T?\ #/?Q2_Z)KXO_ /!%=?\ QNOVYHH_UFK?\^U][#_5ZE_S
M\9^(W_#/?Q2_Z)KXO_\ !%=?_&Z/^&>_BE_T37Q?_P""*Z_^-U^W-%'^LU;_
M )]K[V'^KU+_ )^,_$;_ (9[^*7_ $37Q?\ ^"*Z_P#C='_#/?Q2_P"B:^+_
M /P177_QNOVYHH_UFK?\^U][#_5ZE_S\9^(W_#/?Q2_Z)KXO_P#!%=?_ !NC
M_AGOXI?]$U\7_P#@BNO_ (W7[<T4?ZS5O^?:^]A_J]2_Y^,_$;_AGOXI?]$U
M\7_^"*Z_^-T?\,]_%+_HFOB__P $5U_\;K]N:*/]9JW_ #[7WL/]7J7_ #\9
M^(W_  SW\4O^B:^+_P#P177_ ,;H_P"&>_BE_P!$U\7_ /@BNO\ XW7[<T4?
MZS5O^?:^]A_J]2_Y^,_$;_AGOXI?]$U\7_\ @BNO_C='_#/?Q2_Z)KXO_P#!
M%=?_ !NOVYHH_P!9JW_/M?>P_P!7J7_/QGXC?\,]_%+_ *)KXO\ _!%=?_&Z
M/^&>_BE_T37Q?_X(KK_XW7[<T4?ZS5O^?:^]A_J]2_Y^,_$;_AGOXI?]$U\7
M_P#@BNO_ (W1_P ,]_%+_HFOB_\ \$5U_P#&Z_;FBC_6:M_S[7WL/]7J7_/Q
MGXC?\,]_%+_HFOB__P $5U_\;H_X9[^*7_1-?%__ ((KK_XW7[<T4?ZS5O\
MGVOO8?ZO4O\ GXS\1O\ AGOXI?\ 1-?%_P#X(KK_ .-T?\,]_%+_ *)KXO\
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M/_G['[P_L_%_\^G]Q\OT5]0?\.Y_B_\ \^VC?^#$?_$T?\.Y_B__ ,^VC?\
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MI8/_ )^Q^\/[/Q?_ #Z?W'R_17U!_P .Y_B__P ^VC?^#$?_ !-'_#N?XO\
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M_$T?VE@_^?L?O#^S\7_SZ?W'R_17U!_P[G^+_P#S[:-_X,1_\31_P[G^+_\
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MO#^S\7_SZ?W'R_17U!_P[G^+_P#S[:-_X,1_\31_P[G^+_\ S[:-_P"#$?\
MQ-']I8/_ )^Q^\/[/Q?_ #Z?W'R_17U!_P .Y_B__P ^VC?^#$?_ !-'_#N?
MXO\ _/MHW_@Q'_Q-']I8/_G['[P_L_%_\^G]Q\OT5]0?\.Y_B_\ \^VC?^#$
M?_$T?\.Y_B__ ,^VC?\ @Q'_ ,31_:6#_P"?L?O#^S\7_P ^G]Q\OT5]0?\
M#N?XO_\ /MHW_@Q'_P 31_P[G^+_ /S[:-_X,1_\31_:6#_Y^Q^\/[/Q?_/I
M_<?+]%?4'_#N?XO_ //MHW_@Q'_Q-'_#N?XO_P#/MHW_ (,1_P#$T?VE@_\
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M (,1_P#$T?VE@_\ G['[P_L_%_\ /I_<?+]%?4'_  [G^+__ #[:-_X,1_\
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M?XO_ //MHW_@Q'_Q-'_#N?XO_P#/MHW_ (,1_P#$T?VE@_\ G['[P_L_%_\
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M_B__ ,^VC?\ @Q'_ ,31_:6#_P"?L?O#^S\7_P ^G]Q\OT5]0?\ #N?XO_\
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M !-'_#N?XO\ _/MHW_@Q'_Q-']I8/_G['[P_L_%_\^G]Q\OT5]0?\.Y_B_\
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M/_G['[P_L_%_\^G]Q\OT5]0?\.Y_B_\ \^VC?^#$?_$T?\.Y_B__ ,^VC?\
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MI8/_ )^Q^\/[/Q?_ #Z?W'R_17U!_P .Y_B__P ^VC?^#$?_ !-'_#N?XO\
M_/MHW_@Q'_Q-']I8/_G['[P_L_%_\^G]Q\L:A_R#KO\ ZXO_ .@FOO?_ ((M
M_P#)MOB7_L8Y?_1$->0>(/\ @GK\6M-\/ZI=SV^CB&WM)I7VZ@"<*A)_A]J]
M?_X(M_\ )MOB7_L8Y?\ T1#7QO$&(HXB5+V4U*U]OD?69%AZM!5/:Q:O;?YG
MZ!T445\D?4GP!_P14_Y-9\4_]CG=?^D-C7W_ %\ ?\$5/^36?%/_ &.=U_Z0
MV-??] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!\ ?\$5/^36?%/_8YW7_I
M#8U]_P!? '_!%3_DUGQ3_P!CG=?^D-C7W_0 4444 %%%% !1110 4444 %%%
M% 'RK_P5'_Y,3^)O_<,_].EI78_L'_\ )G?PE_[ ,/\ 6N._X*C_ /)B?Q-_
M[AG_ *=+2NQ_8/\ ^3._A+_V 8?ZT >\T444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!SOQ&_P"2>^*/^P7=?^B6KX>_X(M_\FV^)?\ L8Y?
M_1$-?</Q&_Y)[XH_[!=U_P"B6KX>_P""+?\ R;;XE_[&.7_T1#0!^@=%%% '
MP!_P14_Y-9\4_P#8YW7_ *0V-??]? '_  14_P"36?%/_8YW7_I#8U]_T %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% 'P!_P14_Y-9\4_P#8YW7_ *0V-??]
M? '_  14_P"36?%/_8YW7_I#8U]_T %%%% !1110 4444 %%%% !1110!\J_
M\%1_^3$_B;_W#/\ TZ6E=C^P?_R9W\)?^P##_6N._P""H_\ R8G\3?\ N&?^
MG2TKL?V#_P#DSOX2_P#8!A_K0![S1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% '._$;_DGOBC_L%W7_ *):OA[_ ((M_P#)MOB7_L8Y?_1$
M-?</Q&_Y)[XH_P"P7=?^B6KX>_X(M_\ )MOB7_L8Y?\ T1#0!^@=%%% 'P!_
MP14_Y-9\4_\ 8YW7_I#8U]_U\ ?\$5/^36?%/_8YW7_I#8U]_P! !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!\ ?\$5/^36?%/_ &.=U_Z0V-??]? '_!%3
M_DUGQ3_V.=U_Z0V-??\ 0 4444 %%%% !1110 4444 %%%% 'RK_ ,%1_P#D
MQ/XF_P#<,_\ 3I:5V/[!_P#R9W\)?^P##_6N._X*C_\ )B?Q-_[AG_ITM*['
M]@__ ),[^$O_ & 8?ZT >\T444 %%%% !12$@=3BC</44 +12;AZBEH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ^ /^"*G_)K/BG_L<[K_ -(;&OO^O@#_ ((J?\FL^*?^QSNO
M_2&QK[_H **** "BBB@ HHHH **** "BBB@#Y5_X*C_\F)_$W_N&?^G2TKL?
MV#_^3._A+_V 8?ZUQW_!4?\ Y,3^)O\ W#/_ $Z6E=C^P?\ \F=_"7_L P_U
MH ]YHHHH **** /@O_@JQJ%]9^$?"*65_=6#37?EL]O,R=6 YP1FL;PA_P $
MR'\3>%-'U=_C)XDA>^M(KEHUB)"EU#8!,O.,UI_\%7O^17\$_P#7^O\ Z&M?
M9WPE_P"27^$_^P7;?^BUKZ+ZU5PV"I.D[7;['F>RA5Q$^=7V/B?5?^"</CKX
M?V[ZY\/OB[J]]XDM1OMK?41Y<4C#^%B78?F*[']C+]LC7?''BJ]^%WQ1M6T[
MQW8;MEQ(GE_:0N-P88 #<C '4<U]IU^:?[<VG1_"K]LCX8>,M- M;C4Y8Y+N
M1.LFV55Y_"EAZSS'FH8C65FT[:IKTZ#J4UA;5*>BZH_2RBO%?VD_CM>?!WX+
MR^*-'TFXUG6KJ*,65K;P-)\S@?.P /"YSS7R;X._9J_:&_:7\-V?C3Q7\5;S
MP-+?J)K?3+1)8_W9&0S*DB[2?[IZ5YU'"*I#VM6:A&]M?\D=-2MRRY(1NS]'
M**_*SXC7'QQ_X)]^+-(U:Z\:7/CSPO?R*LKWSNZN>2T8$CL58@=17VM^T5:Z
ME\7/V6-1U'0-2OM$U!].35HY=/G:&4%(RY0,N#CM[XJZF!]FX-33A/9_\ F&
M(YE).-FNA[[17R3_ ,$W/C+>_$_X(FPUO4)M0U_2;EXIY+F0O*8^ A8GG/!K
M9_X*%?&"?X3_ +/VH)I]W-8ZMK;_ -GVEQ;N4EC8_,64CD<#K63PDUB?JO6]
MO^"7[:/LO:]+'T[17BG['?A76_"OP!\,Q>)-1OM3URXA,]S-?SM,_P S$J,L
M2<;2*]KKFJ05.;@G>QM&7-%2:M<****R*"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZX_[^'_&C_A(M3_Y_KC_ +^'_&OE3PS^W1H&L:@+?5-!ET>$CBX\_P T9[#
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M>QA?D;]X]%9;A8S6$G4?M6OD?H)_PD6J#K?7'_?PT?\ "1:G_P _UQ_W\/\
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M *):OA[_ ((M_P#)MOB7_L8Y?_1$- 'Z!T444 ? '_!%3_DUGQ3_ -CG=?\
MI#8U]_U\ ?\ !%3_ )-9\4_]CG=?^D-C7W_0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 ? '_!%3_DUGQ3_ -CG=?\ I#8U]_U\ ?\ !%3_ )-9\4_]CG=?
M^D-C7W_0 4444 %%%% !1110 4444 %%%% 'RK_P5'_Y,3^)O_<,_P#3I:5V
M/[!__)G?PE_[ ,/]:X[_ (*C_P#)B?Q-_P"X9_Z=+2NQ_8/_ .3._A+_ -@&
M'^M 'O-%%% !1110!\"_\%7O^17\$_\ 7^O_ *&M?9WPE_Y)?X3_ .P7;?\
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M1#7W#\1O^2>^*/\ L%W7_HEJ^'O^"+?_ ";;XE_[&.7_ -$0T ?H'1110!\
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M31_PV'I/_0OW/_@0O_Q-'UBEW#^V,#_S\_!_Y'T+17SU_P -AZ3_ -"_<_\
M@0O_ ,31_P -AZ3_ -"_<_\ @0O_ ,31]8I=P_MC _\ /S\'_D?0M%?/7_#8
M>D_]"_<_^!"__$T?\-AZ3_T+]S_X$+_\31]8I=P_MC _\_/P?^1]"T5\]?\
M#8>D_P#0OW/_ ($+_P#$T?\ #8>D_P#0OW/_ ($+_P#$T?6*7</[8P/_ #\_
M!_Y'T+17SU_PV'I/_0OW/_@0O_Q-'_#8>D_]"_<_^!"__$T?6*7</[8P/_/S
M\'_D?0M%?/7_  V'I/\ T+]S_P"!"_\ Q-'_  V'I/\ T+]S_P"!"_\ Q-'U
MBEW#^V,#_P _/P?^1]"T5\]?\-AZ3_T+]S_X$+_\31_PV'I/_0OW/_@0O_Q-
M'UBEW#^V,#_S\_!_Y'T+17SU_P -AZ3_ -"_<_\ @0O_ ,31_P -AZ3_ -"_
M<_\ @0O_ ,31]8I=P_MC _\ /S\'_D?0M%?/7_#8>D_]"_<_^!"__$T?\-AZ
M3_T+]S_X$+_\31]8I=P_MC _\_/P?^1]"T5\]?\ #8>D_P#0OW/_ ($+_P#$
MTJ_MAZ1N&?#]UC/.+A3_ $H^L4NX?VQ@?^?GX/\ R/H2BN,^'OQ6T/XCPR?V
M=,4NHQNDMI/O*#W]Z[.MU)25T>G3J0K14Z;NF%%%><_%[XQ67PPL8E\K[7J,
M^?+A!P%''S-[4I245=BK5H8>#J5'9(]&HKXZG_:P\8M*QB6PC3/"FVW'\]PI
M@_:L\;-T-@?^W0__ !5<OUJF>#_;^#\_N/LBBOC;_AJ[QK_>T_\ \!/_ +.C
M_AJ[QK_>T_\ \!/_ +.CZU3#^W\'Y_<?9-%?&_\ PU7XW_Z</_ ,_P#Q5)_P
MU=XU_O:?_P" G_V='UJF']OX/S^X^R:*^-O^&KO&O][3_P#P$_\ LJ7_ (:K
M\;_].'_@&?\ XJCZU3#^W\'Y_<?9%%?&W_#5WC7^]I__ ("?_9T?\-7>-?[V
MG_\ @)_]G1]:IA_;^#\_N/LFBOC;_AJ[QK_>T_\ \!/_ +.C_AJ[QK_>T_\
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MY3=Z 4YU(TU>1>)Q5+"0YZSLCW^BOC?_ (:N\:D\'3__  $_^RI?^&J_&_\
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M1ZBBBOHC]H"BBB@ HHHH YWXC?\ )/?%'_8+NO\ T2U?#W_!%O\ Y-M\2_\
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M  DVJ?\ /_=?^!$G_P 51_PDVJ?\_P#=?^!$G_Q59=%%V'/+N:G_  DVJ?\
M/_=?^!$G_P 51_PDVJ?\_P#=?^!$G_Q59= YX%%V'/+N:G_"3:I_S_W7_@1)
M_P#%4?\ "3:I_P _]U_X$2?_ !5?/_QJ_::TOX77/]EZ>BZEK97<L(&Y!G@
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MR-\3@\5A$I5=GYW.Q_X2;5/^?^Z_\")/_BJ/^$FU3_G_ +K_ ,")/_BJ\O\
MBU\7](^$NB?:[]]URX_<PJ,ECVXKYS;]M[QBK"Z/A:W&E;O^/CRGQMSUW8Q3
MA2J35T5A\#B\5'GI[>;L?;G_  DVJ?\ /_=?^!$G_P 51_PDVJ?\_P#=?^!$
MG_Q5>:?"GXM:/\6-#%]IDA$R#]]"PPR'OQZ5V]9/FB[,X:BJTI.$[IHU/^$F
MU3_G_NO_  (D_P#BJ/\ A)M4_P"?^Z_\")/_ (JLNBE=F?/+N:G_  DVJ?\
M/_=?^!$G_P 51_PDVJ?\_P#=?^!$G_Q59=%%V'/+N:G_  DVJ?\ /_=?^!$G
M_P 51_PDVJ?\_P#=?^!$G_Q59=%%V'/+N:G_  DVJ?\ /_=?^!$G_P 51_PD
MVJ?\_P#=?^!$G_Q59=%%V'/+N:G_  DVJ?\ /_=?^!$G_P 51_PDVJ?\_P#=
M?^!$G_Q59=%%V'/+N:G_  DVJ?\ /_=?^!$G_P 51_PDVJ?\_P#=?^!$G_Q5
M9=%%V'/+N:G_  DVJ?\ /_=?^!$G_P 51_PDVJ?\_P#=?^!$G_Q59=%%V'/+
MN:G_  DVJ?\ /_=?^!$G_P 51_PDVJ?\_P#=?^!$G_Q59=%%V'/+N:G_  DV
MJ?\ /_=?^!$G_P 51_PDVJ?\_P#=?^!$G_Q59=%%V'/+N:G_  DVJ?\ /_=?
M^!$G_P 51_PDVJ?\_P#=?^!$G_Q59=%%V'/+N:G_  DVJ?\ /_=?^!$G_P 5
M1_PDVJ?\_P#=?^!$G_Q59=%%V'/+N:G_  DVJ?\ /_=?^!$G_P 51_PDVJ?\
M_P#=?^!$G_Q59=%%V'/+N:G_  DVJ?\ /_=?^!$G_P 51_PDVJ?\_P#=?^!$
MG_Q59=%%V'/+N:G_  DVJ?\ /_=?^!$G_P 51_PDVJ?\_P#=?^!$G_Q59=%%
MV'/+N:@\4:JO(U"Z!['[0_\ \574^'_C5XH\.NC0:@TA7M,-V?UK@J*:E*.S
M-(5ZM-WA)H^U_A!\=K+XA"/3[M?LVL!>5R )/=17K-?G'X;UNZ\/ZO;7MI,T
M,T+A@R_J*_0#P7X@'B?PW9:B,?O4&<>HZUZV'K.HK2W1^@9/F,L9!TZOQ1_%
M&Y11176?2!1110 4444 ? '_  14_P"36?%/_8YW7_I#8U]_U\ ?\$5/^36?
M%/\ V.=U_P"D-C7W_0 4444 %%%% !1110 4444 %%%% 'RK_P %1_\ DQ/X
MF_\ <,_].EI78_L'_P#)G?PE_P"P##_6N._X*C_\F)_$W_N&?^G2TKL?V#_^
M3._A+_V 8?ZT >\T444 %%%% !1110 4444 %<O>?$[PKI_C:V\'W&NV<7B>
MYB\^'2V?]\Z<_,!Z<'\J\<_:A_:R_P"%'W=CX:T'P]?>)O&FJJ196=O$6C'
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M=20RW47ZN!6#6YX)_P"1ITO_ *^H?_1BU4=T:4_CCZH_12BBBOH3]G"BBB@
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MY1(6N(PY ([9Z5\B_%71(+?XT:KIMG&8X&OEC"1\8!(!Q41ITIMP2V./#X/
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MW\)?^P##_6@#WFBBB@ HHHH **** "BBB@#/N/#^EW6J0ZE/IMI-J$/$5W)
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M;_R'-<_ZY_TKS#P7-''^T@6N^5_M20#S!GGS#BO4?V$X98-<USS(W3]W_$I
MZ5E?M-?!'7?"?C9_&7AR"273I&$[-;CY[:1>23]3Z5IS+VLHOJCN]I#^T*U&
M3MSQ21]G>)C&NB:I]H.(OL\FXD_[)KX%_93V_P#"[K?9]W<V/INK47X\?%?X
MM:*/"-C8K,\D01Y[:$I,ZCJ6<G'054_9AT6YT/XZ06=PCEX249]A SD>U1"F
MZ<))G-AL'/!86O"I)<S6R['Z!P_\?*?[U?H=X#_Y$G0/^O"#_P!%K7YXP_\
M'RG^]_6OT.\!_P#(DZ!_UX0?^BUJ<'NS#AO^)4]$;%U_Q[2_[A_E7YO:K_R$
M;C_>K](;K_CVE_W#_*OS=UB1(KZY>0[45B6/M58S[)MQ)_RZ^?Z'GWQ:^+&D
M?"7PW)J.HR![EP1;6H^](W;\,U\<:'X7\;?M9>.)=0O9'MM*B.6F8'RH(\\!
M!P">V17*?'7QWJOQ&^(E_>31SR6EK,T-O R,455.#@>^*['PQ^UIXX\'Z#:Z
M1I>@:/;6=NH556Q?YB!C<?FY)JH4I4XWC\3-\-E]7!X=3H).K+J^GH?;'@/P
M+I7PY\-6VBZ1%Y5M"OS,>6<XY8GN:XG_ (6M\*+CQE!I96QD\0O,(XV:P!<2
M9P/GQP<UR'[-W[0'BKXN>)-0T_7K&SMK>"V,J-;6[1DMD#!))KRG]HSX"Z]X
M1\;-XM\+6DUSI[R"Y+PXS;2 @\_4C/%<T:?ON-1ZGB4<&GBIT,7.TVKIWW?F
MSZN^,.DV6N?#G7+7555[98&;]YR%902,?C7R)^Q#-.GC[7(85W1S:>RN?09Z
MUC^(/C[\3?BQH*>$18*WF!8V:TMV2:3']YB>]?1O[+/P0N/A;X=GU#6H%AU[
M4!AX_P"**/CY#[YK3E]C2<9/5G:Z3RW U:5>2YI[)?F?-7P5C;P[^T9!:3X+
MF\:+DXY+ U]<_M/7BV/P=UQFQAF5>3CJ37S[^T?\&?$'@_XA#QUX9M9+FU>4
M73-",_9Y%Q@$?AVKA_%WQ>^(_P ?+*T\+OIB2[6'[JS@:-I".A<DXS6CC[5Q
MJ)Z=3LJ4%F%6CBX27*DN;7:QZ=^POILJ6/BN^/\ JGMS&OU&<UYC\+5#?M.V
M1(!(U(D>U?7/P%^%K?"GX9_V?=#_ (F=Q&\]SZHS+RGX8KY*^%MO,O[3-DYA
ME"_VD?F*''\J(R4I5&B:->.(JXNI%Z6_0][_ &XU!^&EJ2,G[8G/YU-^Q!;I
M'\+I)0OSR7<@8^H#<4S]M^-Y/AI:A$9S]L3[H)]:L_L3QO%\*=KHR'[9)PP(
M_BK'_F'^9YK?_"/_ -O'S?XN4+^U+?@# _MAJ[_]O(O_ ,)!X4'S;/L!^F<U
MPOBZVF/[45^XAD*?VNWS;#C^5?4/[3?P<N?BIX'@FTI ^M:>BO$AZRH%Y0>Y
M-;RDHS@WV/6JUX4,1A9S>G+;[T=)^SQ+#-\(- :V $6UA\HP-W&?UKY/_;(6
MV7XV0?9]NXVT/F8_O9/6LGX;_'#XD?"B&7POI]B+EO,V):WL#2-$V>0N",<U
MR7Q3T;Q/I_C:WN/%C,=8U!8[LQL<F-7.0OL!3ITG"JY-EX/ RP^.G5E)6=[:
MZNY^BOPY_P"1"T+_ *]EKHZY_P"'L;0^!M#1UVNMLH(KH*\R6[/A*O\ $EZL
M^+OV[O\ D9-$_P"N;?R%?1G[.ZVR_!OPQ]EQ@VB&3;_?QS^-?._[=%O+/XFT
M,)&[_NVY5">P]*Y'PG\4/B?\ ?#MM:Q6"3Z3J$8GM6O86D 4C'RX/'3O7?R.
MI1BDSZ]X66,RVC3IM*79]0_;+6'_ (6Z_D9-P8_WN.N[C%>\?M&;O^&6K7=G
M=Y5GG=UZ"O OA=\./%WQZ^)$7B'68YAI_G">YO)@0I (^1?<U]*?M;6OD_ :
M]MH$9UCFMXT502< X'2G)J,J<.P\1*-.MA,+>\H-7_ \\_8IS_P@OBO'7R9/
M_037DO[+TT4?QUM/M',K3,$WC)W;OYU[+^PS;M_PC>O131NBN2I#*1D'@UY=
M\<?A'XF^#_Q$F\4^'XYCI;3?:;>ZMQ_J#_<;W^GK5)IU)P[G1&<)8O$X9NSF
MM/N/LGXO>3_PK/Q3]H.V/[#-U]=IQ7R%^Q!_R4FZQT\G^AJGJWQ?^*?Q\T9_
M#\.GQI:1('N9;.!HSL Y+DGD8ZXK4_8NL)M/^*5_#+&X\M"A8H0#C<.]3&FZ
M=*2>YST\)+!X"O3J27,^B/TA^ G_ "5GPW_U]?\ M-Z^\*^#_@+_ ,E9\-_]
M?7_M-Z^\*O"? _4Z^'?]VG_B_1'YS>+,_P#"3ZGCK]JE_P#0VKQ+Q%\5_A18
M^*%TS6!8R:T)?+!EL1(P?./O8XYKVWQ8V/$^J$=KJ7_T,U\2?M3?L^ZO_P )
M)_PE_ABSEO(I"'NHXL;HG'._\37%3C&4[2=CY; TJ-;$.G6FXWO;IJ?5OC'3
M;36?">I6.HJKV$EN0ZORH7%?#7[)4TEA\?/*M%WQ^7<1\?W-P&?RJ.\_:-^)
MOBKPR?!OV17:6/[,TT=NPN6'NV>M>Y?LF_ ?4/A_#<>(_$=K]FUFY&V"!_OQ
M1GKN]SP:Z.7V-.2D]SV8T7EF#K1KR5YZ))_B?/\ Y+>&?VFI1/@[M49AD[>'
M<XK[<^-=TMC\+O$DSXVK;=SCN*^=OVKO@=K#>)X?&WANU>[7Y6N(H>L3)R&_
M$UYGXD^.OQ(^*V@Q>#9=/2028C86]NRRRX[,2<53C[;EDGMN;SH?VDJ&(IR5
MHVYO*QV7["NG2S>.M9OAQ"EL\9^IP:X;PO"WAG]I81W&"S:DW4[?OOQ_.OJC
M]E[X07/PJ\%.^J1&+6-082S1-]Z'C&W\L5Y#^U)\$=;L?&4?CCPU:O=1%EEF
M2$<P.F,'\<4*I&562ON.GC*5;'5H<VDE9/T/HCX_7:V/PG\22OC B Y..IKY
MP_8/TZ5O$6OWW_+$6K1?CP:X+Q1\;OB1\9='@\(2:<DH8A66VMV224C^^2<5
M]5_LS_".?X4^ S'J*;-7OCY]Q&W6([<;/TJ''V-)QENSCJ4GEN7SHU6N>;V7
M8^3-/4-^TY;9 .-50C/^\*^F?VT5#?"&X)&3]HCP?^!BOFK3[>;_ (:9MW\B
M7;_:J?-Y9Q]X>U?3'[9T;2?"&Y"(SG[1'PH)_C%74_B4SKQ7^^83T1S/["EO
M&O@G59@/WC73*3[8%>(_&Q0O[4.H8&/^)A'T^@KW7]AF)X? >J"1&0_;&^\I
M'\(KP_XUV\S?M/:@XAD9/[0C^8(2.@]JJ'\:9IAW_P *>(]'^AZ#^W,7_LGP
M*!NV?9GSZ=%KVG]EB2&7X,Z4;< *KE6VC'S8&?QJ'X^?".7XL?#&VM[':-7L
MX4EM]P^\  2GU/2OD[X=_&'XB_!*6Z\.V=AYC-)M^Q7T#2"-\\E<'K648^UI
M<L=T<=*G_:&7JA2:YX/9G5_MS+;#XE:28L><;$>;CUWGK7UE\&O^28:!_P!<
M*_/_ .,^F^+4\06NK>,=R:EJL7VI(&/^J0D@*!G@>U?H%\'XGA^&>@I(NUA!
MR**RY:44+-*:I8"A#FO;J=C7R#^WE][P_P#[Q_\ 037U]7R+^W9!)-)X?$<;
MO\Q^ZI/\)K'#_P 1'F9-_OL/G^1[#^RPMLOP1T V^-YC/G;?[VX]:^<?VX%A
M_P"%D6ACYN3#^\_(8K$\#_$3XE_ /P[;SV=@MSHNIKYL!O(6D0=N!D8J#P;X
M*\:_M&_$:+6-3CD%KYRO<7<BD1HJD'8H//(X%=<8<E1U&]#Z&AA?JN+J8V<U
MR:]>_0^B/B1N_P"&.X]X8-_9EKG=UZBN%_81_P!7XC_ZYM_Z"*]@_:0TY-/_
M &?=;L+96>.WAABC4#)P& '2O(_V$H9(?[?$D;ID8^92.PK&+O1D_,\VG+GR
MRO+O+_(\B^#$T<?[0UN;KDM?2!?,&3N\SBOOSQX8E\(Z_P#:#MB^R39)]=IQ
M7QA^T5\%_$/P[\>R^+_#L,KZ9)(+E)K<?-;.,<-]3D\53N?C;\5OC9HI\+6=
M@C+Y8\Z:TA,<C(HY+,3SQG-:5(>VY9Q>AVXO#?VBZ6)I32BDKW>Q6_8WQ_PM
M]-OW=AQ^9K],/@W_ ,E.\._]?L7_ *&*_-G]DG29]'^-+6LR/F$%"^P@9!/K
M7Z3?!O\ Y*=X=_Z_8O\ T,5G7_BKY''FS3S&FU_=_,^_*^-/VK/^2I2?]><'
M_L]?9=?*_P"UQX;DAUO3]:$9\N>/R"X'=>Q_.NK%*],]_/8.6#;71IGSO0#@
MYHHKQS\U/B+]H33W\!_M':5K,)\FWN98#N4;1U ?G\:SOB5J"?&G]IC3K&SE
M6>%9$ME;'&$RU>G?MS>&6NO#.C:Y&K;K*0H[CH-Q %>:_L4>&SKGQ)O=4G7?
M]@A$HD<9.XG'!]:]2,E[+VG5*Q][AZD?J*QC^*$7$N_M#Z7'\.?V@- UN,>1
M!,T=P61< ;2%(_2JGQ4OI?BE^TEH]G;NL]HAM9%"_P!W"L_->G?MR>&#?>#]
M,UN.-FDM9Q"Q'0*03FO+/V,?#\OB+XHR:Q=,9TL8&4^9SR1A?RQ1"2]G[3LK
M"P]2+P2QC?O0BX_Y'HO[=]NEGX0\)6\8Q'%/(BCV"BI/$&FV=U^QGIMS-9P3
M7,.F+Y<TD8+IS_">U)^WL?\ BE_"W_7S+_Z"*OZC:37G[%=H((VE*Z6&(49.
M,UE'^'#U.&BVL'A7?[?ZLA_8BT'2[WP5J%Y<Z99W%Y%=)Y=Q+"K2)P>C'D5X
MW\3_  ZGBK]IA]-E7?#-<1B1<]5SR/RKTK]C3XH>&/#7A^[T+5=5CL=4N[R-
M+>WD5B92<@ 8'')[UQ^O?\G;)_UW7^5:*\:LWY';3]I3Q^(D[KW7;\-CU+]K
M#X8^%]%^$\4^GZ/;6,]@P$4MM&$9N@^8@?-^-;W[&NK2ZE\)%@DSMLYO*3)[
M')JU^V)_R2"\_P!\?S%8_P"Q+_R2V]_Z^Q_*L+MT->YY#E*IE+<W=\Q]"5\<
M?MU*TFN^'U3[[9"_7 K['KX\_;B_Y&;PU_O?X5.'_B(Y\E_WV/S_ ".)T?X%
M?'*^TFTN;&?4!92QAH=NK[1M[8&_BOH[]F#P)XY\$:;K47C=[AYKB9&M_M%W
M]H.T#G!R<<UZ7\/O^1%T+_KU6NA5MK T5*TI)Q:#&9G5Q$9491BE?HM='ZGP
M;)YWQW_:<.FZP[M:07$D:P;_ )0L1Z =LXYKVK]J/X-^&S\*[O5=-TJWTZZT
MA Z/:QB,N,@8; YKQGQ;97G[/7[12Z]<02SZ;<3-,LZC@K)]\9]LUZ+^T;^T
M=X8\4?#R70?#%X=5N]4 2185.8AD'!R.3GCBNF7,Y0<-CW*D:TJ^&EAK^SLM
MMO.Y/^SK\4]5_P"&?/%-Y.S7%QX?1EMWD;)(V[N2?K7#_LE>"K+XH>-=>\3^
M(8O[4DM7#>7=?.K,^3R#UQBO4/@!\%K[3?@3KNDZCOM;SQ%&6\MNL0*X&?RK
MR+]GGQ]!\ _B!K>@>*EDTZRN'VO<2*<*5SM/'4$&IT:J<FY%XS6+6%^*_3MU
MM^)K_MA> =/^'NN:#XI\/P+I4]Q*5*6O[M04 (( Z=:Z?X[?$?4]2_9A\,:D
M6:*XUH+'<E3C(*D_TKB?VDOB/;?';Q5H?AGP@LFJP6\F5N(E.UV88/7I@#/-
M>H?&SX-WY_9QT;1+0M<76@1B9T7DR8&"!^=&RI\^X1:IPPBQ7QWZ[VZ7_ ?^
MRC\(_#,OPJM]6O\ 2K;4[K5=QD-W$)-@!*X7(XKP76?"-KX'_:8M]+LF)MEO
M(Y$!_A#'.T>PKU?]F7]H;PIX1^'O]A>);\Z3<Z:Q$:S*3YH))(4 <>G->077
MC ^.?VCK35_L[6T<UW&(E88+(#A6_$<U<5/GG?8WH0Q,<5B74ORV?IY6^1^A
M\G^L--ITG^L--KRSX,Z#P!_R.FB?]?L'_HU:_1"O@CX+^'9O$GQ"TF&)&?R9
MEN&QV"$'^E?>]>IA%[K9][PY%JE4D]FSY(_:\_Y'C3_^O)/_ $-Z\&KZ8_:\
M\.2/)I6M+&60+]G9@.GWB,U\SUQUU:HSYK-H.&-J7ZZ@..:^*/VL]*D\(_&;
M1?$-O^[298B608^8$Y.?7!K[7KYT_;:\+G5OA[9:I&C%]/G+NR]@0!S^=/#R
MM47F5E%54\7%/:6GWGCOQRUN+XP_'3P_I%E,L\:>59JP''.":TOVI/#:^ OB
M=X2UF)1#&5AWM&N,&+8#S^!KF_V/?#K>)OBVMW./,%C";C>XS\P(Q^->]?ML
M>%SK'PWAU6.-GFL9U'R]E8\FNMR4*D:?0^BG4CA<;1PB?NI6?S/&/COKDWQ0
M^,7A>PLY%GMWMK610/5N6Y^@KU/]MJQCTWX2^';2$;8H;T(H]/DKQ;]D;0)?
M%/Q>LKVY;SXM-CW,).>""%'X5[C^W7_R371O^PA_[)2E[M6$%T,ZMJ..PV%C
MM#]3-\/Z;9WO[&4<MS9P7$L-E.8I)8PS1G<W*D]*H?L-:#I>I:-K=Q>Z99WE
MQ#+&8YIX5=D.X\J3TK=\&VLUY^Q@T<$;2N+"X.U>N-S5Q'[&GQ.\,^"[35M-
MUW5(]-O+N:-+=)58^8Q;&!@<=1UJ'=PG;N8S4YX7%1A=OGZ>IR7[0VCCQ!^T
M2FG$96X:-",XR-QS7N/[2'PJ\*Z+\$Y#8Z-:VDU@@>*>"-4D)"_Q,!D]:\C^
M+C#_ (:HT_G_ ):1_P VKZ)_:D_Y(KJW_7+_ -E%.4FG305JDXRP<4[*R_0X
M_P#8AU26\^&]]9OGR[2;Y.?[Q)-?1=?,_P"PK_R).N?]=T_K7TQ7+6_B,\+-
M%;&U+=SY*_;PR;7P^!U\S_V4UYMX<^!_QMU;0[.\TJ?4!ITJ;H0FK;!M]EW\
M5Z5^W=_J/#O_ %U_]E-?0OPA_P"29Z!_UPKI51TZ46CVHXR>#RZC*"3NWNKG
MFW[+_P /?B!X'N-</C>2Y=+@1"V^T7OVCD$[L<G':O"O']Q<_&?]IR+PYJ4D
M@L(+QK-(0YVA4R<X]3BONY6VL#Z'-?#'Q@T>_P#@G^T);^+C!+<:?<7!O%D4
M<9;.Y?J :FC+GG)];&66XAXG$U:C24W'2W?R/;_VA?@GX8N/A+J$]AI-M876
MDVYGBFMXPC-M'1B!SUKC_P!DOXD:G+\)_%L5P[7']@P-+:M(V3RI;'/TJW\=
M?VF_"FM?#*ZTSP]??VEJ.J0^0\,:G,((YSD<\^E6OV6?A#?Z/\*O$ U)7M)_
M$4)C2)^"BX*@GZ@YHU5)\_<+3IY=)8O?F5K[^?ZGEG[,?AF#XR?%;6O$'B-/
M[1^RG[1Y,YWJ2[, "#V'I72?MF?#?2O",&C>*M#M8])NFG$#+9@1KP"0P Z'
M-<E\%?%*_LY_%S5])\21R6FGW#>2]PP. JEBK^X-;7[4'Q9T_P",=YHWA7P<
M7UE%F$OG0J<,Y!&T9K?WO;)KX3U)1KO,83A_"M\K6^X['XA?$S5=2_9%TO6F
M=DO=086DSJV"5Y7^E3?L=_"OPY??#N37]2TVWU.[OY7A87<0D5%5B/E!''6M
M3QU\%=0C_9=L_"\!,U_IB_;&4=7(RVT?G7%_LK_'CPUX#\(77ASQ1>G1Y;.5
MI(VF4D/N8DJ !P1[UCO2ER=SS]:F!JQPF_/TWMT/-_BIX+L? W[0UM8Z>-EK
M+-'<+'VCW,?E'L,5^@B?ZN+_ '%_]!%?GA\0O'*?$#X]VFJPPM#:&:..W9AC
MS(PQVO\ CFOT/3_5Q?[B_P#H(J<1>T;]CGSA35/#JIORZ_@+6EX;_P"0]8?]
M=T_]"%9M=5\,?#TWB;QMI=E"C.QF5R%]%Y/\JY(J[2/GJ47.I&,=VS]!J***
M^A/V8**** "BBB@#G?B-_P D]\4?]@NZ_P#1+5\/?\$6_P#DVWQ+_P!C'+_Z
M(AK[A^(W_)/?%'_8+NO_ $2U?#W_  1;_P"3;?$O_8QR_P#HB&@#] Z*** /
M@#_@BI_R:SXI_P"QSNO_ $AL:^_Z^ /^"*G_ ":SXI_['.Z_](;&OO\ H **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /A7]H#_DJFO\ _7Q_
M[(M><UZ-^T!_R537_P#KX_\ 9%KSFO J?&S\?QG^\U/\3_,****S.0***R/%
MGBG3_!7AZ[UG5)A!9VRY9CZ]A3WT148N348K5FPL;-T4GZ"AD9>JD?45\3W'
MQX^*/QE\1W%OX!CGLH;?+&.W8'*YP"2:/ O[3'C;P/XSCT7QR\MXKS".5IR
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M5ZQ^B!1110 4444 ? '_  14_P"36?%/_8YW7_I#8U]_U\ ?\$5/^36?%/\
MV.=U_P"D-C7W_0 4444 %%%% !1110 4444 %%%% 'RK_P %1_\ DQ/XF_\
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MD8$N.^,XKM!:[8A&(QY87:%.",>E?HY_PC.C_P#0)L?_  &3_"C_ (1G1_\
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MU'_P&?\ PIK?!7Q=(<OX6O)#ZO9%C^JU]_T5Q_5(]SYW_5VC_P _'^!\!?\
M"F_&0X'AS4 /06S#^E'_  IOQET/AS4"/0VS'^E??M%'U2/</]7*/_/Q_@?G
M^/@IXM5LCPK=!O46)!_]!I__  IOQG_T+NH_^ S_ .%??M%'U2/</]7:/_/Q
M_@? 7_"F_&1&#X<U CT-LQ'\J8/@IXM4Y'A6Z4^HL2#_ .@U^@%%'U2/</\
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MSU;P29)C;N!<V,2AC(O4G'I7ZY?\(SH__0)L?_ 9/\*/^$9T?!']DV.#P?\
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M )^/\#X#_P"%-^,_^A=U'_P&?_"D/P;\9,,'PWJ##T:U8C^5??M%'U2/</\
M5RC_ ,_'^!^?Z_!3Q:IROA6Z4^JV)!_]!J3_ (4WXS_Z%W4?_ 9_\*^_**/J
MD>X?ZNT?^?C_  /@#_A2OBW=N_X1:[W?WOL1S^>VE;X,^,9!A_#-](/1[1F'
MZBOOZN<^('C[1OACX3O?$>OW#6NE6:AII57<0"<=*/JD>X?ZNT?^?C_ ^)%^
M"_C"/A/#-]&/1+1E'Z"D/P5\7,VYO"UVS?WFLB3^>VOHOX-_MI?"OX\^)I-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9P["O@/X0_\ !(GX9?$#X8^&O$=YXGU^*ZU.RCN94B,8168<@9'2OI?]F/\
MX)^^"?V6_$USKGA_6-5U*[G7:1?%=H&",<#WH ^HZ\ _:^_Y%G0?^OJ3_P!%
MFO?Z\ _:^_Y%G0?^OJ3_ -%FL*_\-GD9O_N-3T_5'R=1117AGY6%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 !BO0XIWF.>
MK,?QIM% !0"1T.*** '>8_\ >;\Z;110 4[S'_O-^=-HH *579>C$?0TE%
M23R>:7S&QC<<?6DHH *4R,>"Q(^M)10!XG^TE\']9^(VEQWN@ZC)9WMK\S0K
M(R^:H'0 =Z^?_!>N?'KX9V<^GZ5I>H2P.^XM<0&8_@2:^[ 2.1P:D^T2_P!]
MOSKHC6<8\K5T>QA\RE1I>PG!3CYGPUX?^!GQ!^,_C"/6/%ZMIN) [_:(RF<'
M. .U?;&FV$.EZ?;V<"[8H4"@#V%6VD>3[S$_6FU-2HZFYAB\=4QEE))););!
M1116)YP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ,EH\3_]>,?_ +/7W?\ \%,?^32O$O\ UUC_ )-7PA_P1C_Y+/XG_P"O)/\
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MCX@\6:;HMFZSW%BQ$FPYY;I7O7@OX>W-K^SK/X>>#_2KJW+B/UW#(KCOA?\
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MG6--*4TF>;@Z<:N(A":NFT>4?\-_77?PA;?]_P _X4O_  W[=?\ 0HVW_?\
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M^8=V IR,8 KH=%.:BHZ=SUZF5TI8B-&%%QCUE?='I-G^W;?7UY%##X,C=))
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M4_\ 8YW7_I#8U]_U\ ?\$5/^36?%/_8YW7_I#8U]_P! !1110 4444 %%%%
M!1110 4444 ?*O\ P5'_ .3$_B;_ -PS_P!.EI78_L'_ /)G?PE_[ ,/]:X[
M_@J/_P F)_$W_N&?^G2TKL?V#_\ DSOX2_\ 8!A_K0![S1110 4444 %%%%
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M@ KP#]K[_D6=!_Z^I/\ T6:]_KP']KX'_A%]";L+J3)_[9XK"O\ PV>1F_\
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M3_%\A%'Q4+R&VZV4J5;5J6GWGA.EV4GQP^.*6M]/)B]N"&;/("]OTK[,\=?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MXKXV?\D=\;?]@:[_ /1+5^%/[ O_ ">AX2_Z^[C_ - :OW6^-G_)'?&W_8&N
M_P#T2U?A3^P+_P GH>$O^ONX_P#0&H _H+HHHH **** "BBB@ HHHH ****
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M_DT7P[_UTF_]&-7R#_P6N_Y*;X+_ .P9_P"U'KZ^_P""5?\ R:+X=_ZZ3?\
MHQJ /L&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,PPV,=:XK]HS]FA_'%X/$/AYQ!J2_-+$>3*V<Y%?2C13.<LCD^X-((95.0C
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MD'S,?4@BOJ=5$:A5&%48 KT,+3<;R9]ED.!G14J]16OHO0=1117>?7!1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYF_X*._\FB>-?\
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MO^"X7_(E?"O_ +"%]_Z+BH [/_@BS_R;CXH_[&.3_P!$15^@U?GS_P $6?\
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MWM_>/YT;V_O'\Z/K4P_U@Q?\L?N?^9]Q?\-&>!_^@C-_X#O_ (4?\-&>!_\
MH(S?^ [_ .%?#N]O[Q_.C>W]X_G1]:F'^L&+_EC]S_S/N+_AHSP/_P!!&;_P
M'?\ PH_X:,\#_P#01F_\!W_PKX=WM_>/YT;V_O'\Z/K4P_U@Q?\ +'[G_F?<
M7_#1G@?_ *",W_@._P#A1_PT9X'_ .@C-_X#O_A7P[O;^\?SHWM_>/YT?6IA
M_K!B_P"6/W/_ #/N+_AHSP/_ -!&;_P'?_"J.K?'#X<:["(;^X:YC'19+9Z^
M*][?WC^=&]O[Q_.E]:GV0GG^*DK.,?N?^9]53:_\#KB0O)IL+,>I-M)3/[:^
M!?\ T"X/_ 62OEC>W]X_G1O;^\?SJ?;O^5?<<W]K3_Y]0_\  3ZG_MKX%_\
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M]WH-K,Q[LI_QKKZ*32>Z,YTX5-)Q3]3A/^%&^!/^A:L_^^3_ (T?\*-\"?\
M0M6?_?)_QKNZ*GV<.QC]4P__ #[7W(X3_A1O@3_H6K/_ +Y/^-'_  HWP)_T
M+5G_ -\G_&N[HH]G#L'U3#_\^U]R.$_X4;X$_P"A:L_^^3_C1_PHWP)_T+5G
M_P!\G_&N[HH]G#L'U3#_ //M?<CA/^%&^!/^A:L_^^3_ (T?\*-\"?\ 0M6?
M_?)_QKNZ*/9P[!]4P_\ S[7W(X3_ (4;X$_Z%JS_ .^3_C1_PHWP)_T+5G_W
MR?\ &N[HH]G#L'U3#_\ /M?<CA/^%&^!/^A:L_\ OD_XT?\ "C? G_0M6?\
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M/_S[7W(X3_A1O@3_ *%JS_[Y/^-'_"C? G_0M6?_ 'R?\:[NBCV<.P?5,/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#KG_ %Y)_P"C#73AW:HCV\GFXXV"76Z_ ^IZ***]H_4 HHHH **** "BBB@
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M4 <#\?F*? WQ^RG##0KT@_\ ;%Z_#S_@FLHN/VTO!'FC?NDN"<^OE/7[A?M
M_P#)"_B!_P!@&]_]$/7X??\ !,__ )/2\#_[]Q_Z)>@#^@"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#XO\
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M /R9EX)^MQ_Z.>@#ZNHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.Z_](;&OO^O@#_@BI_R:SXI_['.Z_P#2&QK[_H **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% 'P!_P14_Y-9\4_\ 8YW7_I#8U]_U
M\ ?\$5/^36?%/_8YW7_I#8U]_P! !1110 4444 %%%% !1110 4444 ?*O\
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M'_I8* /Z.+/_ (\X/]Q?Y5-4-G_QYP?[B_RJ:@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** . _:!_Y
M(7\0/^P#>_\ HAZ_#[_@F?\ \GI>!_\ ?N/_ $2]?N#^T#_R0OX@?]@&]_\
M1#U^'W_!,_\ Y/2\#_[]Q_Z)>@#^@"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#XO_X*X?\ )G>I?]A>S_F]
M?+W_  1#_P"1U^)G_7C:?^AR5]0_\%</^3.]2_["]G_-Z^7O^"(?_(Z_$S_K
MQM/_ $.2@#]<:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "OE+_@J!_R9CXU_W[;_ -'+7U;7RE_P5 _Y,Q\:
M_P"_;?\ HY: /A?_ ((I_P#)<O&G_8$7_P!&BOV5K\:O^"*?_)<O&G_8$7_T
M:*_96@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#\;?\ @M9_R7'P9_V O_:SU]R?\$O_ /DS
M+P3];C_T<]?#?_!:S_DN/@S_ + 7_M9Z^Y/^"7__ "9EX)^MQ_Z.>@#ZNHHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M K\QO^"X7_(E?"O_ +"%]_Z+BK].:_,;_@N%_P B5\*_^PA??^BXJ .S_P""
M+/\ R;CXH_[&.3_T1%7Z#5^?/_!%G_DW'Q1_V,<G_HB*OT&H **** "BBB@
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M^3-I9-MN,=&<$$5Z!^PJH7P_K9'4[?YU\Y77P_O[SX:ZEXVU</Y]Q.A@D?\
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MB7H _H HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ^+_^"N'_ "9WJ7_87L_YO7R]_P $0_\ D=?B9_UXVG_H
M<E?4/_!7#_DSO4O^PO9_S>OE[_@B'_R.OQ,_Z\;3_P!#DH _7&BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MY2_X*@?\F8^-?]^V_P#1RU]6U\I?\%0/^3,?&O\ OVW_ *.6@#X7_P""*?\
MR7+QI_V!%_\ 1HK]E:_&K_@BG_R7+QI_V!%_]&BOV5H **** "BBB@ HHHH
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M&ON'XC?\D]\4?]@NZ_\ 1+5\/?\ !%O_ )-M\2_]C'+_ .B(: /T#HHHH ^
M/^"*G_)K/BG_ +'.Z_\ 2&QK[_KX _X(J?\ )K/BG_L<[K_TAL:^_P"@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y3XK?
M\DW\1_\ 7E)_*NKKE/BM_P DW\1_]>4G\JF7PLY\1_!GZ/\ (_/ZX_X^)/K4
M=27'_'Q)]:CKYX_'%L%%%% #)IDMX7FDXCC&YOI7PA\6O&!^.7QFATJXO8=,
MTBPE\EGN7V(55N3]<5]V7UJ+ZRGMF;:LR%"P[9KYOUC]AC0]8U:[OG\4WD;7
M$AD*"%3MSVS750E"#;DSW<JKX?#SE.L[.VCM<S?VEM0\)Z;\$[70/#VM6-ZE
MJ8U2*"4,Y&1GI4'[$GB/2-+T?5K:]U2UM+F;:(XII K/SV%<)\=OV6M*^$?@
M]M9M->N-0E#JOE2Q*HY..HIG[+/P)T_XC7$FMW.JS6DNFLKK#&H(8^YKIM#V
M+UT/=<,,\MG:HW&^]M;^AF?M<POI_P :I+B0;HC%$P9>A%?</P^N/,\!Z#,@
MQ_H49&?I7SC^V9\++S4-/LO$6GQO<_9U$<ZJ,D(HP#4/PY_:TT+0OA2^G:J\
M\>OVL7DV\*QDJ<#"Y/:LY1=6E'EZ''7ISQV H^Q5W'1GB/C"&;5?VB;M5 W_
M -K*?R<&O6/VZK":&^\,3%<IY!R1VZ5S/[.O@G4OBK\6+CQ/?0M#8+*TTDI'
M_+3@@"OH']J[X;7/CSP*;NQ4RWMBHV1#^(=ZUE-1JQ3Z'=6Q,*..P].3^%6?
MS-;]EFZ6\^"NC.H( +CGZU\L?MB--J'QHDBP-Y@C5:[']F_]H[1OAKX9NM \
M4FXM1; _9E6(L2Q)R".U<-I,.J?M$?'"/4([=OL*S+YDF#A803@_7VI0BX5)
M3>Q.%P\\+C:V(J*T5?7U/=OC=;O:_LR^'XG^\L,8/_?-<S^PC:1FUUJYQ^]6
M8*#[;17HG[5EFFE?!>WLD;,=NXC4GT K@?V$2/[+UP9Y^T+_ .@BLD_W$GYG
M#"7-E562ZR_4Q_V[^=6\.C_9>O;/V4;2.S^"^EB/^)I"2:\3_;N/_$V\._[K
M_P Z]R_9:.?@SI..>7HG_ B3BO\ D44?7_,^1/CZS+\<)""00Z8/XFO??VGI
M&'[-?AYMQ!)BR<]>*\ ^/S#_ (7?+R/OI_,U];?$'P"?B-\ ]/T^/F:&S6XC
M [L%X%:S:C[-L[\3.--8.<ME8\O_ &#;>(Z+XAF)_?"X0 >VVNX_;&MXIOA7
M<22']Y'MV?G7SK^SO\6T^!_BR\TWQ%;O;V$K'SW"DNC 8&!WKH_VEOC7#\6=
M'6/PO'/)H=G_ ,?-Q+&4SD\=:4J<G7YNA-7!UI9HJR7NW3OT.N_82_X]=;_Z
MY_UKZOKY0_82_P"/76_^N8_G7U?7-B/XC/!S?_?9_P!= HHHKF/&"OHG]CW_
M )&'7/\ KR3_ -&&OG:OHG]CW_D8=<_Z\D_]&&NBA_$1Z^4_[]3]?T9]3T44
M5[9^J!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ? '_  14_P"36?%/_8YW7_I#8U]_U\ ?\$5/^36?%/\
MV.=U_P"D-C7W_0 4444 %%%% !1110 4444 %%%% 'RK_P %1_\ DQ/XF_\
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M>L?_ &I7SM_P0]_Y&#XK?]>MA_Z'-0!^LM%%% !1110 4444 %%%% !1110
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M$NF#K^5=GM*2::OIT/I(XW 1E&:<_=VCNK_,Y_\ 8N\'SZ)X&EU>>-HS?%D
M88X!XKZ)J&TLX-/MDM[6&.W@086.-<*/PJ:N2<N>3D?.8JN\36E5?4****S.
M4*^B?V/?^1AUS_KR3_T8:^=J^B?V/?\ D8=<_P"O)/\ T8:Z*'\1'KY3_OU/
MU_1GU/1117MGZH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!\ ?\$5/^36?%/\ V.=U_P"D-C7W_7P!_P $
M5/\ DUGQ3_V.=U_Z0V-??] !1110 4444 %%%% !1110 4444 ?*O_!4?_DQ
M/XF_]PS_ -.EI78_L'_\F=_"7_L P_UKCO\ @J/_ ,F)_$W_ +AG_ITM*[']
M@_\ Y,[^$O\ V 8?ZT >\T444 %%%% !1110 4444 ?"/[?7COQEJWQ<^'/P
MZ\ >*[_PWJU^TANGL9WC 5@NUGV\D 9J@?V'?VCO^CC+O_O]=_\ Q5><?&[Q
M-XX\4?\ !06[C^'.G0:IKUI8I:V\ETK>5:9BVO*2.F.OX5UGC"S_ &OOV=8?
M^$XU?Q;;>/M'M&\R[TJ!VDC5.^1L4@#/K7U\(SI4J5.E*$6U?5)MM_(\63C.
M<Y33:OTZ'W%\%_!^O^ ?AGH>@^)]>;Q/KMG"4N=5<L3<-N)SEN>A Y]*[:O-
M_P!G_P"-6F_'OX9Z7XLTZ)K;[2F)K9\;HI!P5//M7I%?*U5-5)*:L[ZGKPMR
MKEV"BBBLBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH *_FYD_P"3P&_[
M'O\ ]R%?TC5_-S)_R> W_8]_^Y"@#^D:BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /-OVEO^3>
M?B7_ -BY?_\ I.]?BG_P2S_Y/6\$_P#7&]_])I*_:S]I;_DWGXE_]BY?_P#I
M.]?BG_P2S_Y/6\$_]<;W_P!)I* /WUHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^(_\ @L%_R9Y/_P!AZQ_]
MJ5\[?\$/?^1@^*W_ %ZV'_H<U?1/_!8+_DSR?_L/6/\ [4KYV_X(>_\ (P?%
M;_KUL/\ T.:@#]9:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "OD/_@JQ_P F5^+O^OJQ_P#2A*^O*^0_^"K'
M_)E?B[_KZL?_ $H2@#XU_P""(O\ R6#XB_\ 8!B_]*%K]AJ_'G_@B+_R6#XB
M_P#8!B_]*%K]AJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** /Q@_X+4_\G$>$O^Q<3_T?+7W_
M /\ !-#_ ),I^'/_ %QN/_2F6O@#_@M3_P G$>$O^Q<3_P!'RU]__P#!-#_D
MRGX<_P#7&X_]*9: /J"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "OS&_X+A?\B5\*_P#L(7W_ *+BK].:_,;_ (+A
M?\B5\*_^PA??^BXJ .S_ ."+/_)N/BC_ +&.3_T1%7Z#5^?/_!%G_DW'Q1_V
M,<G_ *(BK]!J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M .=^(W_)/?%'_8+NO_1+5\/?\$6_^3;?$O\ V,<O_HB&ON'XC?\ )/?%'_8+
MNO\ T2U?#W_!%O\ Y-M\2_\ 8QR_^B(: /T#HHHH ^ /^"*G_)K/BG_L<[K_
M -(;&OO^O@#_ ((J?\FL^*?^QSNO_2&QK[_H **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "N9^)ENUW\/]?A09=[1U'Y5TU5
MM0LUU"QGMGX25"A_&DU=6,ZD>>$H]T?F[=*R7#AQM;)R/2HJ[#XI>$[SPCXN
MOK6ZA,2M(TD1/\2$\&N/KY]KE=C\<J4W2FX26J"BBBI,PHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OHO]CV)_[<UR3'R?
M9$3/OO)_K7SJJEFP!DU]E?LT^!Y_#7A1K^[C,-Q>$_NV'(7.0:ZL/%NHGV/>
MR6E*IC(R6T=3V6BBBO9/TT**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#X _X(J?\FL^*?\ L<[K_P!(;&OO
M^O@#_@BI_P FL^*?^QSNO_2&QK[_ * "BBB@ HHHH **** "BBB@ HHHH ^5
M?^"H_P#R8G\3?^X9_P"G2TKL?V#_ /DSOX2_]@&'^M<=_P %1_\ DQ/XF_\
M<,_].EI78_L'_P#)G?PE_P"P##_6@#WFBBB@ HHHH **** "BBB@#QCX;_M"
M?#7XB?%;7_"6A0/#XNTK*W;3V A9P,YVR=6'!KO_ (H75A9?#OQ%-JCQQV"6
M4OFM,0% VG&?QQ7RM^TQ^Q[XPN/B:OQ;^#FJII7B^,*)M-/R)=8XSG(4=\YZ
MYKSKQ!\'_P!K;]I9K7PO\1[W3_"'A4OONKC3_*!D']UECD);IWX!KVHX6A4Y
M:L*J4=+IO5=[=_(X'5J1O"4+OI;8[O\ X)3Z;>6?P8\1W4S2?8;O5VDLU<8
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M_P"P]8_^U*^=O^"'O_(P?%;_ *];#_T.:OHG_@L%_P F>3_]AZQ_]J5\[?\
M!#W_ )&#XK?]>MA_Z'-0!^LM%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"&P-;_ .@/I_\ WW)_A753JT::M$^APN899@X<E)O[F?5M%?*7_#8&M_\
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M[F?5M%?*7_#8&M_] ?3_ /ON3_"C_AL#6_\ H#Z?_P!]R?X4?6:?</[<P/\
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M4BI1=TPHHHIEA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
M '_!%3_DUGQ3_P!CG=?^D-C7W_7P!_P14_Y-9\4_]CG=?^D-C7W_ $ %%%%
M!1110 4444 %%%% !1110!\J_P#!4?\ Y,3^)O\ W#/_ $Z6E=C^P?\ \F=_
M"7_L P_UKCO^"H__ "8G\3?^X9_Z=+2NQ_8/_P"3._A+_P!@&'^M 'O-%%%
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MQN_XI^]7'UA8?UK\8?\ @E9;^=^VAX1?./*M[QOK^X<?UH _>^BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X
MC_X+!?\ )GD__8>L?_:E?.W_  0]_P"1@^*W_7K8?^AS5[W_ ,%BV(_93A4'
M@ZW:Y'_?5>)?\$0%'G?%!L?,4LQG\7H _5>BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY#_ ."K'_)E?B[_
M *^K'_TH2OKROCC_ (*R,1^QKXB . ;ZRS_W^6@#Y _X(B_\E@^(O_8!B_\
M2A:_8:OR%_X(BJ/^%E?$9L?-_9$(S_VV%?KU0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^,
M'_!:G_DXCPE_V+B?^CY:^_\ _@FA_P F4_#G_KC<?^E,M?GO_P %GIVF_:2\
M/(Q^6/0(U7_O[(?ZU^B/_!-^%;?]C'X<(@X^RS'\3/(30!]+T444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^8W_!<+
M_D2OA7_V$+[_ -%Q5^G-?F-_P7"_Y$KX5_\ 80OO_1<5 '9_\$6?^3<?%'_8
MQR?^B(J_0:OSY_X(L_\ )N/BC_L8Y/\ T1%7Z#4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 <[\1O^2>^*/^P7=?^B6KX>_X(M_\FV^)
M?^QCE_\ 1$-?</Q&_P"2>^*/^P7=?^B6KX>_X(M_\FV^)?\ L8Y?_1$- 'Z!
MT444 ? '_!%3_DUGQ3_V.=U_Z0V-??\ 7P!_P14_Y-9\4_\ 8YW7_I#8U]_T
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /Q3_P""S7_)RVA_]@*+_P!&/7Z,_P#!.;_DS7X<
M?]>DG_HYZ_.;_@LU_P G+:'_ -@*+_T8]?HS_P $YO\ DS7X<?\ 7I)_Z.>@
M#Z3HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ K\QO^"X7_ ")7PK_["%]_Z+BK].:_,;_@N%_R)7PK_P"PA??^BXJ
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M "BBB@ HHHH **** /)_VK_^3:_B5_V ;O\ ]%M7XW?\$I?^3RO#'_7K>?\
MHEJ_9']J_P#Y-K^)7_8!N_\ T6U?C=_P2E_Y/*\,?]>MY_Z):@#]Z:*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* /A/_@L9_R:K!_V&[;_ -FKQ7_@B#_K/B?_ +MG_-Z]J_X+&?\ )JL'_8;M
MO_9J\5_X(@_ZSXG_ .[9_P WH _5:BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXW_X*R?\ )F_B#_K^L_\
MT<M?9%?&_P#P5D_Y,W\0?]?UG_Z.6@#Y._X(B_\ )2/B-_V"8?\ T<*_7FOR
M&_X(B_\ )2/B-_V"8?\ T<*_7F@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\4_^"S7_ "<M
MH?\ V HO_1CU^C/_  3F_P"3-?AQ_P!>DG_HYZ_.;_@LU_R<MH?_ & HO_1C
MU^C/_!.;_DS7X<?]>DG_ *.>@#Z3HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K\QO^"X7_(E?"O\ ["%]_P"BXJ_3
MFOS&_P""X7_(E?"O_L(7W_HN*@#L_P#@BS_R;CXH_P"QCD_]$15^@U?GS_P1
M9_Y-Q\4?]C')_P"B(J_0:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#G?B-_R3WQ1_V"[K_T2U?#W_!%O_DVWQ+_ -C'+_Z(AK[A^(W_
M "3WQ1_V"[K_ -$M7P]_P1;_ .3;?$O_ &,<O_HB&@#] Z*** /@#_@BI_R:
MSXI_['.Z_P#2&QK[_KX _P""*G_)K/BG_L<[K_TAL:^_Z "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /GO]L+_D >'O\ KXE_]%U\IU]6?MA?\@#P]_U\2_\ HNOE.O&Q/\1G
MYEG?^_3^7Y!1117*>"%'Z"BL/QM9:GJ7A;4;31V$>H31%(G+;=I]<TUN5%<T
MDF['G'Q$_:I\'_#R^:S8/K$ZMM=;-Q\I[@UA^&?VT_!OB+4H[.73[K2]YQYU
MRXVBN(^%/[(^N:?X\FU3QO;VMWIK!I,"3S#)(3GD5<_; ^%?A?0?!$>LZ1I5
MMI5Q'*D>RW3:&SZUVJ-'F4%KYGU$</EKJQPT;R;^TGI<^HM/U"VU:RAO+*=+
MFUF&Z.6,Y5A[5RGQ)^+7A_X6Z=]IU:X5I2/EM58!V^E>/?L5^,[O6/ ^KV-R
M[O'I:@1;N@&,\5X5XIO;GXW_ +0$&GW<Y^S37/E)&&^5 .N/KBHC1]]J6R.>
MCE:>*J4ZK]V&K/H+1/VWO!VL:I#9R:5>:>DK;?M,[KL7W->^Z9JEIK-C%>6,
MZ7-M(H99(SD$&OGK]HCX!^'(OA?]KTG3+?3;S2X?,DE@4*9<#'-8_P"P_P".
MKK4K&Z\-7,IF2,F6-G.2J@?='M1*G"4.>'05?"X:MA7BL*FN5ZIZGT3XR\;:
M1X#T>34=7NH[>)1PKM@M["O#E_;H\'M>B#^Q+\)NV^=O7;UZ_2O'_P!JSQA>
M>,?BA:^'_.*6=O*MOY:MP26 R??FO>M6_9L\,M\'1I2:;;QZM'!O_M!4'FDX
MSUJE3IPBG/J:PP>$PU&G/%W;GVZ(]=\*^+=*\::3%J.DW<=U;R#/[MLX]C6Q
M7P[^Q]XTN_#7Q O/#;RF2TNG,*QL>$8,<D5]._$KX_>$OA/JJZ=KS7?VEAN
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MJW4!@#C]:_&C_@HZK#]LC0LJ1F[3''NM?L9X7!7PSI (P?L</_H H U****
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MGBOI=?O"OB+]MO\ Y'/3L]/F_I6V'BI3LT>ED]*G6Q2A4C=6>Y@?\-M?$O\
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MHSW"BBBO8/TH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^EAK^CB\_P"/2;_</\J_G'\,_P#)XEM_V.C?^EAH _H^HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#R?\ :O\ ^3:_B5_V ;O_ -%M7XW?\$I?^3RO#'_7K>?^B6K]D?VK_P#D
MVOXE?]@&[_\ 1;5^-W_!*7_D\KPQ_P!>MY_Z):@#]Z:*** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /A/\ X+&?
M\FJP?]ANV_\ 9J\5_P""(/\ K/B?_NV?\WKV3_@L==(G[+]I;G_6/K-NP^@W
M5Y!_P1#MI(T^)DY7$<@M0I^A?- 'ZHT444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %?&__  5D_P"3-_$'_7]9
M_P#HY:^R*^,?^"M-TD/['^MPM]^6^M-OX2K0!\J?\$1?^2D?$;_L$P_^CA7Z
M\U^1?_!$:UD7Q_\ $6X*_NFTN% WOYPK]=* "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Q3_
M ."S7_)RVA_]@*+_ -&/7Z,_\$YO^3-?AQ_UZ2?^CGK\Y/\ @LM(LG[2VB!6
MR5T.('V/F/7Z.?\ !.=2O[&WPX##!^R2?^CGH ^DJ*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_,;_@N%_P B5\*_
M^PA??^BXJ_3FOS&_X+A?\B5\*_\ L(7W_HN*@#L_^"+/_)N/BC_L8Y/_ $1%
M7Z#5^?/_  19_P"3<?%'_8QR?^B(J_0:@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#G?B-_R3WQ1_P!@NZ_]$M7P]_P1;_Y-M\2_]C'+
M_P"B(:^X?B-_R3WQ1_V"[K_T2U?#W_!%O_DVWQ+_ -C'+_Z(AH _0.BBB@#X
M _X(J?\ )K/BG_L<[K_TAL:^_P"O@#_@BI_R:SXI_P"QSNO_ $AL:^_Z "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /GO]L+_ ) 'A[_KXE_]%U\IU]6?MA?\@#P]_P!?$O\
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M*E%L>9U)5<OH3GNST"BBBN ^0"E3[R_6DI4^\OUH ^X_V=?^24Z9_P!=)?\
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MJ>%WU#P%H][%"S+IR?.RCA> .:W;M.FF>Q.HJ>(PD);I?FCL/V2?^2.66/\
MGL_2OGC]N#R/^%G6?E?>^QKN_.O9?V)?$%K??#A](23-Y;322NA/12>#7A7[
M4&K6GC7XT6MKI["=DVVK!>?GW8Q6=--5V<6"A*.;56^ESV;Q5_R:#HW_ %PC
M_E7F'[%?A&SUKQE=:I<P+,]B0$+=!D>E>U_&#26T+]F:SL)$\N6"-$93V.*\
MV_82_P"/S7_]]/Y4HO\ =3:[DTZC_L_$2B]Y/\63_MX65O&N@7"0HDS.X9E
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MSVWMKL?37QN^+WPE\<?#K4+"UU6&XU"& BR00E3NZ#G%<7^PIXHG_P"$BO\
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M:J\5_8_'G?"7*?,%GYQ]*]JKEJ_&SPL?_O=3U"BBBLC@"OL#]DW_ )$?4?\
MK\_]D6OC^OL#]DW_ )$?4?\ K\_]D6NO"_Q#Z'(O]]7HSW"BBBO8/TH****
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M^U'FOZ(?$O\ R+^H_P#7!_Y&OYX?A/\ \GC6'_8U/_Z4F@#^C&BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M] T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5^8W_!<+_D2OA7_P!A"^_]%Q5^G-?F-_P7"_Y$KX5_]A"^_P#1<5 '
M9_\ !%G_ )-Q\4?]C')_Z(BK]!J_/G_@BS_R;CXH_P"QCD_]$15^@U !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '._$;_DGOBC_L%W7_
M *):OA[_ ((M_P#)MOB7_L8Y?_1$-?</Q&_Y)[XH_P"P7=?^B6KX>_X(M_\
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M% "AV'1B/QH\QC_$?SI** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH _$#_@K_\ \G/VG_8+C_\ 1C5^GW[!/_)I?P]_Z\V_]&/7Y@_\%?\
M_DY^T_[!<?\ Z,:OT^_8)_Y-+^'O_7FW_HQZ /H&BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OS&_X+A?\B5\*_\
ML(7W_HN*OTYK\QO^"X7_ ")7PK_["%]_Z+BH [/_ ((L_P#)N/BC_L8Y/_1$
M5?H-7Y\_\$6?^3<?%'_8QR?^B(J_0:@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#G?B-_P D]\4?]@NZ_P#1+5\/?\$6_P#DVWQ+_P!C
M'+_Z(AK[A^(W_)/?%'_8+NO_ $2U?#W_  1;_P"3;?$O_8QR_P#HB&@#] Z*
M** /@#_@BI_R:SXI_P"QSNO_ $AL:^_Z^ /^"*G_ ":SXI_['.Z_](;&OO\
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH P?''A2#QIX9O=*G.WSXRJOC[I]:^"?%_A6\\):
MW<V%Y&R/&Y 9OXQDX(K]%*Y/QW\,]%^(%B8=1MAYJ\I,GRL#VYKEKT?:*ZW/
M S3+/KT5.#M-?B?GW17TGJG[(5U),6L=8MXT[+,K-_*J?_#'^L?]!K3_ /OU
M)_C7G?5ZG8^+>48Y.WL_R_S/GBBOH?\ X8_UC_H-:?\ ]^I/\:/^&/\ 6/\
MH-:?_P!^I/\ &CV%3L+^R<=_SZ?X?YGSQ17T/_PQ_K'_ $&M/_[]2?XT?\,?
MZQ_T&M/_ ._4G^-'L*G8/[)QW_/I_A_F?/%%?0__  Q_K'_0:T__ +]2?XT?
M\,?ZQ_T&M/\ ^_4G^-'L*G8/[)QW_/I_A_F?/%%?0_\ PQ_K'_0:T_\ []2?
MXT?\,?ZQ_P!!K3_^_4G^-'L*G8/[)QW_ #Z?X?YGSQ17T/\ \,?ZQ_T&M/\
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MNK2R?,Q/?FNIKT:-'V:N]S[7*\M^HQ<IN\W^ 4445U'O!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 ? '_!%3_DUGQ3_P!CG=?^D-C7W_7P
M!_P14_Y-9\4_]CG=?^D-C7W_ $ %%%% !1110 4444 %%%% !1110!\J_P#!
M4?\ Y,3^)O\ W#/_ $Z6E=C^P?\ \F=_"7_L P_UKCO^"H__ "8G\3?^X9_Z
M=+2NQ_8/_P"3._A+_P!@&'^M 'O-%%% !1110 4444 %%%% 'YP_$:30='_X
M*56MY\38U.@/9QKILUVA-JLQB^3/'7=C'O7O'_!0+6_ <G[-^O0:W-8W5_-$
M%TB-"KS&;<O^JQT./TKP[XY2>(/VZ_CQ>_##0DM=(\)^%Y%:_P!68?Z0S'J!
MP1P5.!6?\5/^"9ES\,/#9\6^!/%VI^(=<T9OM:V&K(FR15Y(7:.OM7U:C1YJ
M#KU.6<4M/RUZ7ZGCWG:HJ<;IWU_K<^I/V#=/UO3/V8?!L.MI)%*+8F&.7.]8
M]QP#FOH.O"_V._V@C^T/\)X=9N;"/3=4L9/L=[;PC$:R+_=]L5[I7SV*YO;S
MYU9W9Z5&WLX\KNK!1117*;!1110 4444 %%%% !1110 4444 %%%% !1110!
ME>*I4A\-:G)(VU%MW+-Z#::_GF^#L3WW[8VG^0OFY\42.,>GVDG-?T'^/O\
MD2=<_P"O.7_T$U_/U^SM_P GD:5_V,$O_H\T ?T24444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
MXA^VK<1V_P"S#X_:5P@;3)E&>Y*-@5^3O_!)&WDD_:NT^14S'':3[V],QMBO
MU2_;N_Y-;\<?]>3_ /H#5^7G_!(7_DYL?]><G_H#4 ?N%1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^>?_!9
MJ\DC^!>B6P"^7)J,;D]\C-<K_P $4;-(_"/CBY!;S))8E8=N"U=%_P %G/\
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MY<?NH$Y8GMQZ5U6H7B:?937,GW(E+&O@KXK>,KSQGXNN[NZDWK&[11#^Z@)
MKFKU?9QTW/#S7,'@:2Y/B>QU/B;]H_Q+KDTGE2K91Y(58<@@=JXM_B9XED=F
M;6KXDG/%PP_3-<O17DNI*6[/SNIBZ]5WG-OYG3_\+*\1_P#08OO_  )?_&C_
M (65XC_Z#%]_X$O_ (US%%3S/N9>VJ?S/[V=/_PLKQ'_ -!B^_\  E_\:/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH ^ /\ @BI_R:SXI_['.Z_](;&OO^O@#_@BI_R:SXI_
M['.Z_P#2&QK[_H **** "BBB@ HHHH **** "BBB@#Y5_P""H_\ R8G\3?\
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M=O\ D\C2O^Q@E_\ 1YH _HDHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#P#]N[_DUOQQ_UY/\
M^@-7Y>?\$A?^3FQ_UYR?^@-7ZA_MW?\ )K?CC_KR?_T!J_+S_@D+_P G-C_K
MSD_] :@#]PJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** /SK_X+.?\D7T#_K_3^9K$_P""*O\ R(OC+_KM'_-J
MV_\ @LY_R1?0/^O]/YFL3_@BK_R(OC+_ *[1_P VH _2^BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'P!_P14_Y-
M9\4_]CG=?^D-C7W_ %\ ?\$5/^36?%/_ &.=U_Z0V-??] !1110 4444 %%%
M% !1110 4444 ?*O_!4?_DQ/XF_]PS_TZ6E=C^P?_P F=_"7_L P_P!:X[_@
MJ/\ \F)_$W_N&?\ ITM*[']@_P#Y,[^$O_8!A_K0![S1110 4444 %%%% !1
M110 45\T_M3?MM>'OV=[B'0+&R?Q+XVN@I@TF'HN2,>81R"<\#'->4>%_P#@
MHMXNT+5K:7XK_"74O!/AJX(1-6C@G958G'S>8JC'([UZ%/+\14I^TC'1[;7?
MHNIS2Q-*,N5O4^[:*H:#KNG^)M'M-5TJ[BOM/NXQ+#<0,&1U/<$5?K@>FC.D
M****0!1110 4444 %%%% !1110 4444 %%%% !1110!@>/O^1)US_KSE_P#0
M37\_7[.W_)Y&E?\ 8P2_^CS7] OC[_D2=<_Z\Y?_ $$U_/U^SM_R>1I7_8P2
M_P#H\T ?T24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!X!^W=_R:WXX_Z\G_\ 0&K\O/\ @D+_
M ,G-C_KSD_\ 0&K]0_V[O^36_''_ %Y/_P"@-7Y>?\$A?^3FQ_UYR?\ H#4
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M7_V$+[_T7%0!V?\ P19_Y-Q\4?\ 8QR?^B(J_0:OSY_X(L_\FX^*/^QCD_\
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M,1E=?#TW4=FEO9WMZGM=+M/H:YWQYXVT_P"'OAFZUG47"PPC 4G&6["ODO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#X _P""*G_)K/BG_L<[K_TAL:^_Z^ /^"*G_)K/BG_L<[K_
M -(;&OO^@ HHHH **** "BBB@ HHHH **** /E7_ (*C_P#)B?Q-_P"X9_Z=
M+2NQ_8/_ .3._A+_ -@&'^M<=_P5'_Y,3^)O_<,_].EI78_L'_\ )G?PE_[
M,/\ 6@#WFBBB@ HHHH **** "BBB@#\Z?V5_"FE_$+]MKXGZWXF6+4]3T>7;
M8Q7F'P"6&0K==H P>U?;OQL\(Z-XU^%_B'3-<M[>:P>SD8FX4%4(7(()Z'(K
MY5_:6_94\?\ AWXNQ_&#X*3K%KY %WI"G:)R  3U (/.03WK!U+3_P!J'X_>
M%=6TKXDV^G?#7PC;P/->2VB&.YNE"DA%99' &0.M?158QQ,H8B%1))+2^JMV
M74\R$G24J;BVW?T9W7_!+WQ5?ZY\![[3+R<SV^BZB]G:L3G$?)Q7V/7PW_P2
M<TTV/P;\4R!Y7AFU@^67/! 7&17W)7GYDDL742[G3A;NC&X4445YIU!1110
M4444 %%%% !1110 4444 %%%% !1110!@>/O^1)US_KSE_\ 037\_7[.W_)Y
M&E?]C!+_ .CS7[_?$RX-K\/?$4P&3'8S-CZ*:_ ?]EVW_M3]LC1\G9NUN63_
M ,BDT ?T/4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!X!^W=_R:WXX_P"O)_\ T!J_+S_@D+_R
M<V/^O.3_ - :OTY_;_O#8_LK^,V W;[<Q_FK5^:'_!'RS$_[1US/G!ALFX]<
MJXH _;BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#\Z_^"SA'_"F- &>?MZ<?B:Q/^"*H/_""^,CCCSX^?Q:K
M/_!:1F_X5OX57)VFYR1^-6?^"+Z@?"CQ,P'S&[Y/_ C0!^CM%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7PA
M_P %@B/^&:XAGG[;'_Z&M?=]?G]_P609E^ >DJ"0#>\CU^9* /+_ /@B:#_Q
M71QQY2<_\#6OU1K\O_\ @BBJ_P!@>-6Q\V\#/XK7Z@4 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 ?A;_ ,%9/^3J)O\ KT7_ -#:OUD_8K_Y-B\!_P#7E_[.U?D;_P %4+A[
MC]J_4U<Y$<2HOTW&OV _9%MTM?V<_!$<8P@L1@?B: /8**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_,;_@N%_P B
M5\*_^PA??^BXJ_3FOS&_X+A?\B5\*_\ L(7W_HN*@#L_^"+/_)N/BC_L8Y/_
M $1%7Z#5^?/_  19_P"3<?%'_8QR?^B(J_0:@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#G?B-_R3WQ1_P!@NZ_]$M7P]_P1;_Y-M\2_
M]C'+_P"B(:^X?B-_R3WQ1_V"[K_T2U?#W_!%O_DVWQ+_ -C'+_Z(AH _0.BB
MB@#X _X(J?\ )K/BG_L<[K_TAL:^_P"O@#_@BI_R:SXI_P"QSNO_ $AL:^_Z
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XWXQ?\DO\2_]>;_T
MKX%N/]?)_O&OOKXQ?\DO\2_]>;_TKX%N/]?)_O&O+Q?Q(^!XC_CT_3]2.BBB
MN ^2"E49.*2B@#Y'_:=^('C._P#&D7A'04E%O-&,M:JVXDG!R1T%?-GCCP#J
MW@'6;2WUAD-S<?O?E8DCD=?>OT\A\.Z7'JPU);*,7^-OGX^;'I7PO^V$<_%*
MV/\ LG_T(5Z>'J7:@D?<9/C5.<</3A9):]VSZ_\ @=_R2CP__P!<S_.ODC]M
M#7WU+XG#2A(SQVP4JF<@$CM7UO\  [_DD^@_]<C7Q=^TY\OQZNL\?ZKK6>'_
M (K.3*8IYC4;Z<WYGVI\/?#%C8_"FPTM(0MI<V:-+'C@EEYXKXA\(ZBO@G]H
M>:.R?[/#]O:W7:<?*6'%??O@\K_PB.CE^4^QQY_[YK\[O$9C;]H:;RA\G]LK
MC'^^*,/JYICRANI/$1EU3/=OV[/$;0PZ-I4<C>7<1>8R*>"01UKTG]DC0[?2
M_@_87<<7ESWJMYQQC=R:\0_;DX\3>'<\?Z.?YBOHW]F\@_!O0<'(V-T^M3/2
MA$RQ*Y,II)=7_F?'_P =8+?P+^T 9].'V98GCF&WC#'.3^M?5WQ6^*VJ?#WX
M2Z/XATE(;B[GB3=]H&0<KG-?*G[830M\:;SR1_RQCSCUQ7N'Q]_Y-N\-_P#7
M"/\ ] K624E3N=U>G&M#!NHKWT?W'/>%OVT-:U;PS>"XTI;WQ*)<6T%E"2I3
M'4CZUEV7[:'C;2=>MX/$^C06=DS?O$^SE) /49J?]AGPK:W-]?ZW+;J\\#&)
M)&ZC(!K/_;JMXE\4:'*D:K+)$V]@,9YI\M/VGL^4I4<$\<\&J2UZ]M.AW'C;
M]KR_O)1;_#W0[C5)HE!N))+<R(N1[53^$O[86I^(/%L.B>+[.&T:X<11/!'L
MV.?[V>@KO?V0_#%MH/PGM=0CMTBO;Y7\Z3 )8#.,U\I?%I(=)^/$C6\*JJS(
M^P="<G-3&-.3E!+;J8X?#X.O4JX2-/X4_>OJ?H?J6J6NDZ9<:A<2JMI#&96?
M/!4>E?)OBW]L[Q%=>)I-/\$Z9%?6ZY \R R.V.X [5W'[3OB2[T?X!Z-+:N8
MC>(D4FT_PE>17#?L+^$[.Y75->DMD>[MY?)CF8<J"!Q65.$8P=22N<.#PU&C
MA9XNO'FL[)%C4OVR]=TOP?)]LTC^S_%:,H\NZ@*1MSR0#STKTS]FOXT:Y\8K
M'49M:AMHFM@"GV==N>>]<A^VQX/LKKPK#KPM4%Y!A3,!@G)JC^PK_P @G6_]
MP?SJI1@Z+FEJ;5:6%J9=+$4Z=I7^[T/J:BBBN$^4"BBB@#Z/_8]_Y"VO?]>L
M?_H;5]0U\O?L>_\ (6U[_KUC_P#0VKZAKV<-_#1^G9)_N,/G^;"BBBNH]T**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** /@#_@BI_R:SXI_P"QSNO_ $AL:^_Z^ /^"*G_
M ":SXI_['.Z_](;&OO\ H **** "BBB@ HHHH **** "BBB@#Y5_X*C_ /)B
M?Q-_[AG_ *=+2NQ_8/\ ^3._A+_V 8?ZUQW_  5'_P"3$_B;_P!PS_TZ6E=C
M^P?_ ,F=_"7_ + ,/]: />:*** "BBB@ HHHH **** /AGXT_';XK_LN_M!7
M.N^(XM2\3_""]C4*EM$&%HVWG!P,')[G']>(^,W[<VJ?M/>&9OA]\%O"6M75
MYJV(+Z^N( 'MXR1RFQB/KGM7Z)ZAIEGJUN;>^M(+V ]8KB-9%/X$8JKI?A71
M=#D,FFZ/8:?(1@M:VR1$_BH%>O3QE"*C*5*\X];V6G5HXI4:CNE/W7]_WGGW
M[,_P3M_@'\)-'\+1R>?=Q1[[N?'^LE/)/ZXKU6BBO,J3E4DYRW9UQBHI16R"
MBBBLR@HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y3XK_ /),_$__ &#I
MO_0#7X)?LC_\GDZ+_P!A>;_T8:_>WXK_ /),_$__ &#IO_0#7X)?LC_\GDZ+
M_P!A>;_T8: /Z&**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH ^;?^"AW_)J?B__ *YC_P!!:OSB
M_P"".O\ R<'J7_7E_1Z_1W_@H=_R:GXO_P"N8_\ 06K\XO\ @CK_ ,G!ZE_U
MY?T>@#]KZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /S8_P""TG_).?"O_7S_ %JW_P $7_\ DDWB7_K[_P#9
MC53_ (+2?\DY\*_]?/\ 6K?_  1?_P"23>)?^OO_ -F- 'Z.4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?G
M[_P60_Y(+I'_ %^_U2OT"K\_?^"R'_)!=(_Z_?ZI0!P7_!%+_D7?&G^^/YK7
MZ?U^8'_!%+_D7?&G^^/YK7Z?T %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?@U_P5*_Y.RU?_
M '1_Z$:_8G]DW_DWGP3_ ->*_P S7X[?\%2O^3LM7_W1_P"A&OV)_9-_Y-Y\
M$_\ 7BO\S0!ZY1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M->SAOX:/T[)/]QA\_P V%%%%=1[H4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ? '_!%3
M_DUGQ3_V.=U_Z0V-??\ 7P!_P14_Y-9\4_\ 8YW7_I#8U]_T %%%% !1110
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MW_)J?B__ *YC_P!!:OSB_P"".O\ R<'J7_7E_1Z_1W_@H=_R:GXO_P"N8_\
M06K\XO\ @CK_ ,G!ZE_UY?T>@#]KZ*** "BBB@ HHHH **** "BBB@ HHHH
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M[)/]QA\_S84445U'NA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>W(KCP7P5[[<K_-6-J_Q4[=S[YHHHKRCL"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#E/BO_ ,DS\3_]@Z;_ - -?@E^R/\ \GDZ+_V%YO\ T8:_>WXK
M_P#),_$__8.F_P#0#7X)?LC_ /)Y.B_]A>;_ -&&@#^ABBBB@ HHHH ****
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MKP2&4J?L*\$8/4T >MT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YB?\
M!:W_ )%GP3_OR?\ H0KL_P#@C3_R0?5_^O\ D_\ 0C7&?\%K?^19\$_[\G_H
M0KL_^"-/_)!]7_Z_Y/\ T(T ?H11110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5^=7_!9[_DCWA;_K]D_]DK]%
M:_.K_@L]_P D>\+?]?LG_LE &1_P16_Y)WXN_P"OP_R2OTLK\T_^"*W_ "3O
MQ=_U^'^25^EE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'X#_P#!3#_D[KQ1_P!=OZU^U_[.
M/_)#_!__ %X1_P J_%#_ (*8?\G=>*/^NW]:_:_]G#_DA_@[_KPC_E0!Z311
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7YC?\ !<+_ )$KX5_]A"^_]%Q5^G-?F-_P7"_Y$KX5_P#80OO_ $7%0!V?
M_!%G_DW'Q1_V,<G_ *(BK]!J_/G_ ((L_P#)N/BC_L8Y/_1$5?H-0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!SOQ&_Y)[XH_P"P7=?^
MB6KX>_X(M_\ )MOB7_L8Y?\ T1#7W#\1O^2>^*/^P7=?^B6KX>_X(M_\FV^)
M?^QCE_\ 1$- 'Z!T444 ? '_  14_P"36?%/_8YW7_I#8U]_U\ ?\$5/^36?
M%/\ V.=U_P"D-C7W_0 5G:IX@T[15W7MW';C_:-><_&_XS+\.;%+6QV3:K.#
MM!Y$?^]7R!K7B_5->O)KF[O)I7D.2/,8 >P&:Y*N(5-V6K/G<PSBG@Y>S@N:
M7Y'V[<?&[P1:RF.7Q#:HXZC)_P *B_X7MX#_ .ACM?U_PKX0\Z3G#L,\GDT>
M=)_?;\S7+];GV/!_UBQ'2"_$^[_^%[> _P#H8[7]?\*/^%[> _\ H8[7]?\
M"OA#SI/[[?F:/.D_OM^9H^MS[!_K%B/Y(_C_ )GW?_PO;P'_ -#':_K_ (4?
M\+V\!_\ 0QVOZ_X5\(>=)_?;\S1YTG]]OS-'UN?8/]8L1_)'\?\ ,^[_ /A>
MW@/_ *&.U_7_  H_X7MX#_Z&.U_7_"OA#SI/[[?F:/.D_OM^9H^MS[!_K%B/
MY(_C_F?=_P#PO;P'_P!#':_K_A1_PO;P'_T,=K^O^%?"'G2?WV_,T>=)_?;\
MS1];GV#_ %BQ'\D?Q_S/N_\ X7MX#_Z&.U_7_"C_ (7MX#_Z&.U_7_"OA#SI
M/[[?F:/.D_OM^9H^MS[!_K%B/Y(_C_F?=_\ PO;P'_T,=K^O^%'_  O;P'_T
M,=K^O^%?"'G2?WV_,T>=)_?;\S1];GV#_6+$?R1_'_,^[_\ A>W@/_H8[7]?
M\*#\=O ;#!\16A'X_P"%?"'G2?WV_,T>=)_?;\S1];GV#_6+$?R1_'_,^P/$
M&N_!OQ-,\M_J%C*[G)*EE_D*Q/[-^!?_ #_P?]_Y*^6O.D_OM^9H\Z3^^WYF
MLWB+ZN*..6;<[O*A!OT/J7^S?@7_ ,_\'_?^2C^S?@7_ ,_\'_?^2OEKSI/[
M[?F:/.D_OM^9I>V7\B)_M2/_ $#P^X^I?[-^!?\ S_P?]_Y*/[-^!?\ S_P?
M]_Y*^6O.D_OM^9H\Z3^^WYFCVR_D0?VI'_H'A]Q]2_V;\"_^?^#_ +_R5?TW
MPC\&-68"TN(9CT^6X>ODOSI/^>C?F:=%=2PMN21E;U#$&G[9=8(<<TA?WL/#
M[C[<MO@!X!O(5EAT]I(VZ,MPQ_K4G_#._@;_ *!;_P#?]O\ &OEWX<?&;7/
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MY+7XE_Z\4_\ 9Z /V<HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH _,3_@M;_R+/@G_?D_]"%=G_P1I_Y(/J__
M %_R?^A&N,_X+6_\BSX)_P!^3_T(5V?_  1I_P"2#ZO_ -?\G_H1H _0BBBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M* "BBB@ HHHH **** "BBB@ HHHH **** "OI3]DOQ/)]LO=$,C&,J9@A/3
M%?-=>V_LH?\ )1OK:3?^RUO0=JB/6RJ;AC:=NKL?8=%%%>X?JH4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 ? '_!%3_DUGQ3_P!CG=?^D-C7W_7P!_P14_Y-9\4_]CG=?^D-C7W_ $ %
M%%% !1110 4444 %%%% !1110!\J_P#!4?\ Y,3^)O\ W#/_ $Z6E=C^P?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !7YC?\%PO^1*^%?_80OO\
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M4!9[D]%%%(04444 %%%% !1110 4444 %%%% !1110 5[9^RC_R4;_MTF_\
M9:\3KVS]E'_DHW_;I-_[+6U'^)$]++?]\I>I]B4445[I^LA1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M\ ?\$5/^36?%/_8YW7_I#8U]_P!? '_!%3_DUGQ3_P!CG=?^D-C7W_0 4444
M %%%% !1110 4444 %%%% 'RK_P5'_Y,3^)O_<,_].EI78_L'_\ )G?PE_[
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M-?B+_P $Y?\ D\SPS_OW/_H)H _?ZBBB@ HHHH **** "BBB@ HHHH ****
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MN/BC_L8Y/_1$5?H-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0HHHH *]L_91_P"2C?\ ;I-_[+7B=>V?LH_\E&_[=)O_ &6MJ/\ $B>EEO\
MOE+U/L2BBBO=/UD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /@#_ ((J?\FL^*?^QSNO_2&QK[_KX _X
M(J?\FL^*?^QSNO\ TAL:^_Z "BBB@ HHHH **** "BBB@ HHHH ^5?\ @J/_
M ,F)_$W_ +AG_ITM*[']@_\ Y,[^$O\ V 8?ZUQW_!4?_DQ/XF_]PS_TZ6E=
MC^P?_P F=_"7_L P_P!: />:*** "BBB@ HHHH BN;:&\MW@GB2:&0;7CD4,
MK#T(->%_M;:'I_AW]EGQ[9Z78V^G6@TV8B"UB6- 2IR< 8KWFO%/VSO^39_'
MW_8,F_\ 0375A6_;07FC*K\$O0YK_@GO_P FK>$OI)_.OI"OF_\ X)[_ /)J
MWA+Z2?SK9_:L_:ATW]G7PI%Y4:ZEXJU(^1IFFJ1EI#P&;GI6^(I3K8N=."NV
MV9TYJ%&,I;61H_M-?M+:#^SOX)GOKF5;SQ#<CRM,TF([I;B8CY1M&2![XKRC
M_@G[\#-9\&^']=\?^,+9H/%/BRX-WY,QR]O$2Q"Y]P16;^SC^RK?ZMXJ@^+?
MQKU--:\<W&)K/2IIE>#35)RO']\>QP,U]DPW4$QVQ31N1_"C UI6G##TGAZ3
MNW\3_1>7GU(A&52:JSTMLOU)J***\H[ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH \[_ &B?^2$^/O\ L"W7_HLU^(O_  3E_P"3S/#/^_<_^@FOVZ_:
M)_Y(3X^_[ MU_P"BS7XB_P#!.7_D\SPS_OW/_H)H _?ZBBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** /D;_@J9_R:%KW_7Y;_P#LU?%__!%7_DJGCC_KP@_]">OM#_@J9_R:%KW_
M %^6_P#[-7Q?_P $5?\ DJGCC_KP@_\ 0GH _8FBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\L/^"VW^K^'O
M^Y/_ .A"O6_^".G_ ";/<?\ 84N/_0J\D_X+;?ZOX>_[D_\ Z$*];_X(Z?\
M)L]Q_P!A2X_]"H ^]**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "OS7_X+7?\DW\"?]?EQ_)*_2BOS7_X+7?\
MDW\"?]?EQ_)* -#_ ((M_P#)%_%'_85;_P! 2OT8K\Y_^"+?_)%_%'_85;_T
M!*_1B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#^?7_@HM_R>)XY_P"O\_S%?NG\$_\ DD_A
M7_L'P_\ H K\+/\ @HM_R>)XY_Z_S_,5^Z?P3_Y)/X5_[!\/_H H [>BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
MS&_X+A?\B5\*_P#L(7W_ *+BK].:_,;_ (+A?\B5\*_^PA??^BXJ .S_ ."+
M/_)N/BC_ +&.3_T1%7Z#5^?/_!%G_DW'Q1_V,<G_ *(BK]!J "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** .=^(W_)/?%'_8+NO_1+5\/?
M\$6_^3;?$O\ V,<O_HB&ON'XC?\ )/?%'_8+NO\ T2U?#W_!%O\ Y-M\2_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% 'P!_P $5/\ DUGQ3_V.=U_Z0V-??]? '_!%3_DUGQ3_ -CG=?\
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M **** "BBB@ HHHH **** "BBB@ HHHH _+#_@ML1Y?P]&>=D_\ Z$M>M_\
M!'0'_AF>X../[4N/_0J\1_X+?,?[<^&0R<?9KKCM]]:^@?\ @CZH'[),+8&3
MK%WDX_VA0!]PT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %?FO_P6N(_X5QX$&>?MEQ_)*_2BOS%_X+>,1X0^
M&8!(!O+O(]?DCH Z/_@BV#_PI?Q0<<?VJW_H"5^B]?GU_P $7U'_  SKXC;
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M-3Z(HHHKVS]3"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>=X4_P"N%W_Z*- '[XT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB&1UBN90K%3!$ <>G!_*OT8T'Q#IOBC38M0TF]BO[*3[D\+;E;Z&@#1HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKX>_X(M_\FV^)?\ L8Y?_1$- 'Z!T444 ? '_!%3_DUGQ3_V.=U_Z0V-??\
M7P!_P14_Y-9\4_\ 8YW7_I#8U]_T %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% 'P!_P14_Y-9\4_]CG=?^D-C7W_ %\ ?\$5/^36?%/_ &.=U_Z0V-??] !1
M110 4444 %%%% !1110 4444 ?*O_!4?_DQ/XF_]PS_TZ6E=C^P?_P F=_"7
M_L P_P!:X[_@J/\ \F)_$W_N&?\ ITM*[']@_P#Y,[^$O_8!A_K0![S1110
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M HHHH **** "BBB@#GOB!X)T[XD>"=:\,:LGF:?JMK):S#&3M8$$CWK\YO\
M@GM^PSJ'PQ_:(\9>)/%.GM#;^'YG@T42C*3I(7 ?ZA0OXU^G5-554DA0">I
MH =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'B?[8GP+L_V@O@+XC\-31>9>I"UY8$#G[1&K%!
M]":^??\ @EC^RK=_!'P%K/B7Q+8FT\5:K<-:R02C)ABB8[2I[;LFONVA5"#"
M@*/84 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!Y3^TK^SWH?[2WPUF\(:X3% TZ7$<R?>1USC!_&NV\ ^#
MK+X?^"]$\.:?&D=KIEI%:IL&-VQ N[ZG&:Z"B@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\W_ &@O@CHW
M[0GPOU/P7KGRV=X4;S%^\C*P8$'MR*](HH X_P"$7PWL/A#\-_#_ (0TU5%K
MI-HELKJN"^T8W'U)KL*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHIDTT=O$TLKK'&HRS,< "@!]%<K-\5/!]M(8Y?$FFQN.JM<*#4?_"W/!?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI7@'XU>(O!NJ6[_;YKJTW@30SL9-R9Y ST-?<6DZ@FK:79WT8VQW,*S*/0,
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MM!H-X;/?M^W><,8_O;<9I1ISG\*%0P=?$INC"Z1],^=)_?;\S1YTG]]OS->
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M^*?^QSNO_2&QK[_KX _X(J?\FL^*?^QSNO\ TAL:^_Z "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#X _P""*G_)K/BG_L<[K_TAL:^_Z^ /^"*G_)K/BG_L
M<[K_ -(;&OO^@ HHHH **** "BBB@ HHHH **** /E7_ (*C_P#)B?Q-_P"X
M9_Z=+2NQ_8/_ .3._A+_ -@&'^M<=_P5'_Y,3^)O_<,_].EI78_L'_\ )G?P
ME_[ ,/\ 6@#WFBBB@ HHHH **** "O%/VSO^39_'W_8,F_\ 037M=>)_MH,$
M_9E\?EC@?V9-R?\ =-=.&_CP]5^9E5_AR]#F_P#@GO\ \FK>$OI)_.O"/^"@
MG[0\>M^,M,^"5MK5OX<TG4#&^N:U=.5B2$G/EDCGJGIW%>[?\$]6#?LJ^$B#
MD8D_G72_$7]C7X1_%;Q1/XA\3^%5U'5YE"R7'VJ:/<!G'"L!W->FJM&CCJE2
MLF[-VMW.5PG4P\8P[(^?_BQ\:O@/X8_9%\1?#WP3X\T6ZDCTA[:TM()"9)Y#
M^'4G-=;_ ,$[OC%X)OO@CX3\$6_B6QF\6Q1322:0KGSU4.221CT(/XUSG[3G
M[$'P6^'OP%\:>(=%\(K8ZKI^GR36]Q]MG;RW'0X9R#6A_P $Z?@'X"L?A+X4
M^)%KHJKXPFAGBDU+SY#E2Q4C9G:.!CI714>%E@I2BY/WNMM[?D91]JJZ32V\
M]C[2HHHKYL]0**** *^H?\@^Y_ZY-_(U^;U__P ?<GU_I7Z0ZA_R#[G_ *Y-
M_(U^;U__ ,?<GU_I7FXS[)\3Q)O2^?Z$%>2?M1ZY-HOP?U5;9"]Q<;44 $G&
M[D_E7K=<C\2/B1X<^&VEPWGB0%K68E440B3)'7@UQ0^):7/E,*VJ\&H\S3V[
MGP7\*8_BI#HMRW@*RU-('D_?76GIR>/NDGM7I/PM_:A\7>"?%XT#Q])/=PO*
M(IY+W_76Q.,'TQS7U;\,OB%X>^)&@2:IX84Q6*2^4Z^2(B&QGE17R#^W!9V%
MO\1["6U"K=36[-<[1_%D8S^%=T9JM-PE$^NHXB&8XB6&Q%%1O?U7JST/]N3Q
M$C>#_#5O;MYEMJ!:974\,HP0:[_]D/2X]-^#EH51%:XG:5BO?('6O&/VG-.N
M[_X+_#W4;@;3;6X0@>C*H%>U?LC:@FH?!NQV%3Y,QB.TYZ =:SEI02\S@Q$>
M3*HQCTD[_>SYD_:$4>&?VBI;ZW18V^TK-\G'/ KU3]M68W/@'PK-R#)$C'GU
M KRS]HS_ (J#]H:6R@*F3[0L(VG/.1UKU+]M2$V_P_\ "D1Y*1(I_ "MNM,]
M1?Q,%?>WZ'E7P^^%WQ$^.'@=UM=62V\.Z>I6*&ZD8)(RCD+@')XKG/A_\4/&
M_P *=6U#P]I$KRSSL;;[*Q)"29^\H]:^N/V0?^2(6P[>?-_2OEZQA2;]JL1N
MN4.LME?P-5&?-*<6M$:T<1[>KB*-2"<(7:5NPWXP_!CQO\/[2V\8^(-5BO+B
M\E1C-#(QDC<C(SD#%?4?[+?Q,O?&7PNDN-:E>>XTW=YEPW5HP>/R JA^VH!_
MPI:/CI?0C_QTUR'[)8+?!/Q@ "3]GFQC_=:L92]I1O+N>;6JO&Y:JM5*ZE;3
ML>3?%+XA>*_C]\2IO#VD22/IYF,%K90D[&52?G;W(Z_2MGQ%\*?B5^SSX5O+
MM=1M]1T:]B,-W;VLC,J*1DE@0,8Q6;^Q[<1V_P 9HHI@1-(&5-PYSSFOKW]H
M"2VB^#OBHW.T*;-PF[^]5SG[.2II:'5BL2\'B*>#IP7)ITW/FK]AES)XSU=R
M3\T1.,GT-?:M?%'["O\ R.&J_P#7'^AK[7KGQ/\ $9XF>?[[+T1A>.O^1-UC
M_KW:OS?^&-WXFC\<2VGA.1X=5O\ ?:"5.J(S8)_"OT@\=?\ (FZQ_P!>[5\0
M_L?RVT?QOD^T[<M;S+'N_O[ABM,.^6$F=V43]GA,1.U[="K\2_V=?'OPLLE\
M576HQ7\BN'DN+*1FDB8GJV0.]?2/[)_Q@N_B5X4FL=7G-QK.GGYI3U>/@ GW
MS79_M M!'\)=?-T,Q;,?\"YQ^M?-_P"P3%)_PEGB638WE?8XQNQQG?TH<O:T
M7*6Z*G6>89=4JUDN:#T9P_Q<)_X:CU$;FQ_::=SZ"OJ']I#XM7'PM^&]I_9D
MGEZS?1I'"_\ <7&&8>XKY>^+G_)TFH_]A)/Y"O1/VZE<P^"& ;8+1LGM_#6K
MBI2II]CLJ485ZN#A/;E_)'FOPW^ /CCXW0W/B.*^CMP9-PO-0D8&9P>=I Z@
MUS'QB7Q?I_B:WTGQE))<7^GQB&&>3G?$"<$'N*^XOV8;J*[^#.CM!]U69#@8
M^8 9KYI_;?FMY/BIIJQ$&1;%!)CL=QITZKE5<6C7"8^I7Q\J$HJRO;3:Q]>?
M"/\ Y)KH'_7"NNKD?A'_ ,DUT#_KA775YLOB9\-6_BR]6>C_ +/?_)6M _Z[
M-_Z+>ONFOA;]GO\ Y*UH'_79O_1;U]TUZ>$^!^I]UP[_ +M/_%^B"OC+]JG_
M )*G/_UZP?\ H)K[-KXR_:I_Y*G/_P!>L'_H)IXK^&:\0?[FO\2_4^,OB]^S
MC#\8/'UAK&HZ@UMI=O:K T,)_>,P8GOQBOEW]JKP7I'@/QE8:5HUJMK:16YX
M4<L<CD^]?H97P=^VU_R4ZV_ZX'^8KGP\Y.:BWH>+DN)JU,1&E*7NQ3LC[5^'
MO_(D^'/^O&#_ - %?!WBJ9]<_:<NH[AL!=4:,%?12<5]X_#_ (\$^'?^O&#_
M - %?"?Q>MO^$%_:.ENY T*27:W6['9V/-+#_%(G)]:]:*W:=OO/N+XEP+<?
M#G7HF.%:Q(X^@KY"_8GO);?XN7MHI_<R0REA].E?57Q<\26>F?"'6M3-RHMY
M;'$4JG(<X' ]37S)^PUHK7WCO5M:VL8[=#&6QQE\G^E*G_"G<SP/NY=B'+;]
M3A&F?7OVFIA<-C;JCH"OHK'%?<7Q@@6Z^&?B.)C@-:]OPKX@\=0#P!^TG)-+
MN@1KY9RV.SMU^E?9GQT\1VFD_!_7+\W"K#/:X@=>=Y..GK55M7"QT9DG.IA7
M#9I6_ ^9?V&;Z6'XD:K:*?W+VTC$>XQ7F?Q2L+K5?CCJ%A9R&*>ZO! ''&-S
M8S^M>M_L(Z(;CQ1K6L[6*1(8-W;+#->=>)/^3EE_["<?_H8KH3_>RMV/9A)+
M,*[CTBCK?C=^RK8_##X>PZ]:ZI=WM_'@7B3;?+!.!\N!GJ>]8O[/_P *[[X]
M*VGZYKMY#X=TF,K#%"P)1NH !&,<FOIC]KK_ )(OJWU3_P!"%>>_L'_\BSX@
MXY^U#_T 5DJDG1<GN>=3QU>66SKRE>2>C['S_P")O"LWP9^.,.EZ?=2N;&[A
M:.5SAF4D'!Q7U7^U)\4+[PC\)M/6SG:UU'6XU'G1G#*."X'U!-?/?[2W_)RU
MU_UWM_Y+7IW[:&GSW'PW\#W,:;H;=#YC?W<J *N5INFY&]5+$5<'*KJVM?NO
M^9P_[/O[+%O\5?#\VNZ]J-S863-L@6UVF1CUW'<.E<)\?/AQJ?PEU^'P_+J,
MU]H^TRV7F')"YYS[Y)Z5]7?L:Z]:ZO\ "M;&*6-KRTEVO K9<*!]XCTKQ+]N
M+Q-8:SXZTFQM)XYYM/MVCG\M@=K%L@'WQ1"I.59Q>P\-C,34S.5&?PJ^G;LS
MZC^ /_))-!_ZY_X5Z#7GWP!_Y))H/_7/_"O0:\V?Q,^+Q7\>?JSY1_;O_P"0
M1H7_ %T_H:X;]G_]FA/B]X9_M7Q#JUY9Z7&2EG':E2>IW<,,=:[G]N__ )!&
MA?\ 73^AKN?V-_$5EJ_PFM-*MY4>^L7<2PJ?G^9B0<?2NU2E"@G$^GC7JX?*
M83HZ.^_8^6?BAX O_P!G3XF69T_4))(HV6:"X4X<KG)5L#'2OKKXH>)%\8?L
MPZKK84+]NTQ9BHZ#+"OG_P#;<URTU;QYI^G6DL4\]O& _EL"0S #!KV?7-/F
MTO\ 8X>VN %ECT>,,!_O"G/WE3D]R\3)UJ6$K5?C;1YA^P<,ZYKG_7/^E>?_
M !H\0ZI\;OC8VD6LS&WCG%I;PD_)%@[7;^M>@_L&_P#(<US_ *YG^5>6Z/='
MP;^T4\VH!8%&IN6,AP K/P3^%:_\O9/K8]",4LPKU$O>C%6/9?$G[$MKX?\
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M/O'*>'=2O9+V"U*&U9SG]T3A?T%?<7[,OB"U\1?"/2?L\T;RVX9)HT;)CP<
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MX.SC>OT.:\E^ O[)MM\3/"S:[X@U*ZL()B5MH[3:7..[;ATKIOVXM/GF\/\
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MQ=C+'+%.<_C7Z8_!O_DIWAW_ *_8O_0Q7YG_ +&[;_B\C8QE,_J:_3#X-_\
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M0%&()(^F:48J,YQCV,J="G1Q6(H4?M1ND?9_QZC2;X4^(U=0R^6#@_6OF?\
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MI_R:SXI_['.Z_P#2&QK[_H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /@#_
M ((J?\FL^*?^QSNO_2&QK[_KX _X(J?\FL^*?^QSNO\ TAL:^_Z "BBB@ HH
MHH **** "BBB@ HHHH ^5?\ @J/_ ,F)_$W_ +AG_ITM*[']@_\ Y,[^$O\
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M)N=)D/EWBC?:R_W7'./QQBO??^%!^._^A<O/SC_^*H_X4'X[_P"A<O/SC_\
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M4?S52*)I"$/.>,[>?X:_6L? GQ\HP/#MYC_MG_\ %4B_ ?QZN<>';S_R'_\
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M"WMFOFCP'^SKX\T+XX6WB2\TF.+2$O3,TPN4)">N,YK]1?\ ACO6?^@Y8?\
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M_9I^ OB_X8^/[W4-:TQ+3364K%()U<D<XX!]Q7Z4_P##'>L_]!RP_P"^9/\
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M'_/UJ/\ WW'_ /$4?\,F^$/^?K4?^^X__B*4:=>"M%DT,#FV&AR4I)+U_P"
M?!_PY^&6A?"[1!INAVWE1L=TDKG<[MZDUA?&#X$Z!\8;.+[>#:ZE""(;R/@C
M/]X#K7Z&_P##)OA#_GZU'_ON/_XBC_ADWPA_S]:C_P!]Q_\ Q%0J%92YNIS1
MRG,HU?;)KF[W/R+T3]@NSM-4CEU/Q.+^Q4Y:WAMVC=AZ;LU]-^&?#.G>#]#M
M-(TF#[/8VJ!(UZG [D]S7VS_ ,,F^$/^?K4?^^X__B*/^&3?"'_/UJ/_ 'W'
M_P#$54Z->I\3-L1E^:XNRK23MY_\ _.SXQ? +0/C%#%+>9LM4A4K'>1^A_O
M?>KR#P_^P;966J1S:MXF&HV*GYK>&!HF8?[V:_7+_ADWPA_S]:C_ -]Q_P#Q
M%'_#)OA#_GZU'_ON/_XBG&G7BK)FE'!9O0I^RIS27K_P#XHT/P[8>&="@TC3
M(1;6-O#Y,:]3C&,D]S7@_AS]DF;0?BA#XO/B>*9([K[3]D%J0Q_V=V:_4_\
MX9-\(?\ /UJ/_?<?_P 11_PR;X0_Y^M1_P"^X_\ XBIC1K1O;J84LLS.CS<C
M7O;Z[_@?GK\<OA*_QD\*IHT>III1699?.>(R#@], BCX&?"5_@UX5?1Y-335
M2TS3><D1C R>F"37Z%?\,F^$/^?K4?\ ON/_ .(H_P"&3?"'_/UJ/_?<?_Q%
M'L*W+R=!?V5F7L?J]UR7O:__  #\L/$'[),VN?%2Y\8CQ/%"LUY]J^R&U)8?
M[.[/]*]-^*VM>#+/08M!\:3!+/4$$2;HR1G&W<&_A/O7Z!?\,F^$/^?K4?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /@#_ ((J?\FL^*?^QSNO_2&QK[_K
MX _X(J?\FL^*?^QSNO\ TAL:^_Z "BBB@ HHHH **** "BBB@ HHHH ^5?\
M@J/_ ,F)_$W_ +AG_ITM*[']@_\ Y,[^$O\ V 8?ZUQW_!4?_DQ/XF_]PS_T
MZ6E=C^P?_P F=_"7_L P_P!: />:*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH AN+6"Z4">&.8>
MDBAOYU"FCV$;!DL;9&'0K$H/\JN44 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!SOQ&_Y)
M[XH_[!=U_P"B6KX>_P""+?\ R;;XE_[&.7_T1#7W#\1O^2>^*/\ L%W7_HEJ
M^'O^"+?_ ";;XE_[&.7_ -$0T ?H'1110!\ ?\$5/^36?%/_ &.=U_Z0V-??
M]? '_!%3_DUGQ3_V.=U_Z0V-??\ 0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 ? '_!%3_DUGQ3_P!CG=?^D-C7W_7P!_P14_Y-9\4_]CG=?^D-C7W_ $ %
M%%% !1110 4444 %%%% !1110!\J_P#!4?\ Y,3^)O\ W#/_ $Z6E=C^P?\
M\F=_"7_L P_UKCO^"H__ "8G\3?^X9_Z=+2NQ_8/_P"3._A+_P!@&'^M 'O-
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <[\1O^2>^*/\
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M,_\ *!JG_P C4?\ #T;]F+_HIG_E U3_ .1J]5_X9.^"'_1&_A__ .$O8_\
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M[X(?]$;^'_\ X2]C_P#&J /*O^'HW[,7_13/_*!JG_R-1_P]&_9B_P"BF?\
ME U3_P"1J]5_X9.^"'_1&_A__P"$O8__ !JC_AD[X(?]$;^'_P#X2]C_ /&J
M /*O^'HW[,7_ $4S_P H&J?_ "-1_P /1OV8O^BF?^4#5/\ Y&KU7_AD[X(?
M]$;^'_\ X2]C_P#&J/\ AD[X(?\ 1&_A_P#^$O8__&J /*O^'HW[,7_13/\
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M[,7_ $4S_P H&J?_ "-1_P /1OV8O^BF?^4#5/\ Y&KU7_AD[X(?]$;^'_\
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M_P :H_X9.^"'_1&_A_\ ^$O8_P#QJ@#RK_AZ-^S%_P!%,_\ *!JG_P C4?\
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M?]%,_P#*!JG_ ,C4?\/1OV8O^BF?^4#5/_D:O5?^&3O@A_T1OX?_ /A+V/\
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M#5/_ )&KU7_AD[X(?]$;^'__ (2]C_\ &J/^&3O@A_T1OX?_ /A+V/\ \:H
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M(?\ 1&_A_P#^$O8__&J /*O^'HW[,7_13/\ R@:I_P#(U'_#T;]F+_HIG_E
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M_AZ-^S%_T4S_ ,H&J?\ R-1_P]&_9B_Z*9_Y0-4_^1J]5_X9.^"'_1&_A_\
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M:H_X9.^"'_1&_A__ .$O8_\ QJ@#RK_AZ-^S%_T4S_R@:I_\C4?\/1OV8O\
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M_AXE^TG_ -&O:C_W[O/_ (U7Z1T4 ?FY_P /$OVD_P#HU[4?^_=Y_P#&J/\
MAXE^TG_T:]J/_?N\_P#C5?I'10!^;G_#Q+]I/_HU[4?^_=Y_\:H_X>)?M)_]
M&O:C_P!^[S_XU7Z1T4 ?FY_P\2_:3_Z->U'_ +]WG_QJC_AXE^TG_P!&O:C_
M -^[S_XU7Z1T4 ?FY_P\2_:3_P"C7M1_[]WG_P :H_X>)?M)_P#1KVH_]^[S
M_P"-5^D=% 'YN?\ #Q+]I/\ Z->U'_OW>?\ QJC_ (>)?M)_]&O:C_W[O/\
MXU7Z1T4 ?FY_P\2_:3_Z->U'_OW>?_&J/^'B7[2?_1KVH_\ ?N\_^-5^D=%
M'YN?\/$OVD_^C7M1_P"_=Y_\:H_X>)?M)_\ 1KVH_P#?N\_^-5^D=% 'YN?\
M/$OVD_\ HU[4?^_=Y_\ &J/^'B7[2?\ T:]J/_?N\_\ C5?I'10!^;G_  \2
M_:3_ .C7M1_[]WG_ ,:H_P"'B7[2?_1KVH_]^[S_ .-5^D=% 'YN?\/$OVD_
M^C7M1_[]WG_QJC_AXE^TG_T:]J/_ '[O/_C5?I'10!^;G_#Q+]I/_HU[4?\
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M]&O:C_W[O/\ XU7Z1T4 ?FY_P\2_:3_Z->U'_OW>?_&J/^'B7[2?_1KVH_\
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MN\_^-5^D=% 'YN?\/$OVD_\ HU[4?^_=Y_\ &J/^'B7[2?\ T:]J/_?N\_\
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M_P :H_X>)?M)_P#1KVH_]^[S_P"-5^D=% 'YN?\ #Q+]I/\ Z->U'_OW>?\
MQJC_ (>)?M)_]&O:C_W[O/\ XU7Z1T4 ?FY_P\2_:3_Z->U'_OW>?_&J/^'B
M7[2?_1KVH_\ ?N\_^-5^D=% 'YN?\/$OVD_^C7M1_P"_=Y_\:H_X>)?M)_\
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M)?."!GL.IH ^X:**\X_: \.^._%7PPU;3?AOKD7AWQ9*F+34)CA8S]=K?R-
M'H]%<5\&]%\6^'OASHUAXXU6/6_%$,(6]OH?NROZC@?RKM: "BOB'4_C9X[A
M_P""C%CX#3Q)<KX.DT[S6TC:OEE_,QG.,]/>OMZ@ HHHH **** "BOF_]M[]
MJJ3]F'X>V4ND6"ZMXOUR?['I%FX)1I,C);'/ /'N*^7F^%/[>FL:/_PE<?Q*
ML=/\V/[6OA\28D0=1%M,/7';=0!^F-%?)_[#'[66M?'C3]<\+>.M*_L/Q]X;
MD6"]MV!4S#!._!_#\Z^L* "BBO*_VH?B5-\(_@+XT\4VEPMMJ-AI\DEFS?\
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MW9X+R$ M&=I.1D$=JO?L=^,]<^('[//A+7?$>HR:KK%W;!Y[N4 -(<#DX&*
M/::*** "BBB@ HK'\7V>J:AX8U.VT2Z6RU:2!EMKA^D<G8FO-/V7_!_Q3\%^
M YK+XM^*+?Q7XB:X9TO+8Y41Y.%^ZO;':@#V.BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *_'*TTWXC^+_VX/B?X,^'%]_8EYK[B.^UL(&^
MPP*7+$9XRRD@5^QM?G#^R7XLTK1?^"@WQ@TB]FCAO]4"?9!(P!?87+ 9[XH
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M1U^!5]IEEJ:RO]N;4C$ 4P-NWS 1GK7R]_PC/_!17_H/^%_^^[/_ .-U]/\
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M1/#]K\3]<^,FK:#X^O@-2@TN-6>V5B-T:M\X4 \9&W%<C^T5:S0_\$\_V?\
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MV@.#&4VDYW=,4 ?G-_P29U#5M5\=?%F\UZ+R=;FO6:\CQC;)E,BOTLK\\/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP<D@\^@KT7]E/]G76_@?=>/-6\3:O:ZWKOBK5!J$MQ:AMJ (%V_,,]J^@:*
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M^T?_ ,%.-)T_PR8KF#056]\02J-R.T;KE01QG!%?JA;P):V\4,2[8XU"*H[
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M-/M(;6VB6"WA01QQH,*J@8  J:@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>angn-20211231_g5.jpg
<TEXT>
begin 644 angn-20211231_g5.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 5A"JD# 2(  A$! Q$!_\0
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MT?\ #3_Q;_Z*-XC_ /!A)_C1_JU7_P"?B_$/]8:/\C_ _:FBOQ6_X:?^+?\
MT4;Q'_X,)/\ &C_AI_XM_P#11O$?_@PD_P :/]6J_P#S\7XA_K#1_D?X'[4T
M5^*W_#3_ ,6_^BC>(_\ P82?XT?\-/\ Q;_Z*-XC_P#!A)_C1_JU7_Y^+\0_
MUAH_R/\  _:FBOQ6_P"&G_BW_P!%&\1_^#"3_&C_ (:?^+?_ $4;Q'_X,)/\
M:/\ 5JO_ ,_%^(?ZPT?Y'^!^U-%?BM_PT_\ %O\ Z*-XC_\ !A)_C1_PT_\
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MP/VIHK\5O^&G_BW_ -%&\1_^#"3_ !H_X:?^+?\ T4;Q'_X,)/\ &C_5JO\
M\_%^(?ZPT?Y'^!^U-%?BM_PT_P#%O_HHWB/_ ,&$G^-'_#3_ ,6_^BC>(_\
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M_P"#"3_&C_5JO_S\7XA_K#1_D?X'[4T5^*W_  T_\6_^BC>(_P#P82?XT?\
M#3_Q;_Z*-XC_ /!A)_C1_JU7_P"?B_$/]8:/\C_ _:FBOQ6_X:?^+?\ T4;Q
M'_X,)/\ &C_AI_XM_P#11O$?_@PD_P :/]6J_P#S\7XA_K#1_D?X'[4T5^*W
M_#3_ ,6_^BC>(_\ P82?XT?\-/\ Q;_Z*-XC_P#!A)_C1_JU7_Y^+\0_UAH_
MR/\  _:FBOQ6_P"&G_BW_P!%&\1_^#"3_&C_ (:?^+?_ $4;Q'_X,)/\:/\
M5JO_ ,_%^(?ZPT?Y'^!^U-%?BM_PT_\ %O\ Z*-XC_\ !A)_C1_PT_\ %O\
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M ,6_^BC>(_\ P82?XT?\-/\ Q;_Z*-XC_P#!A)_C1_JU7_Y^+\0_UAH_R/\
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MP/VIHK\5O^&G_BW_ -%&\1_^#"3_ !H_X:?^+?\ T4;Q'_X,)/\ &C_5JO\
M\_%^(?ZPT?Y'^!^U-%?BM_PT_P#%O_HHWB/_ ,&$G^-'_#3_ ,6_^BC>(_\
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M_P"#"3_&C_5JO_S\7XA_K#1_D?X'[4T5^*W_  T_\6_^BC>(_P#P82?XT?\
M#3_Q;_Z*-XC_ /!A)_C1_JU7_P"?B_$/]8:/\C_ _:FBOQ6_X:?^+?\ T4;Q
M'_X,)/\ &C_AI_XM_P#11O$?_@PD_P :/]6J_P#S\7XA_K#1_D?X'[4T5^*W
M_#3_ ,6_^BC>(_\ P82?XT?\-/\ Q;_Z*-XC_P#!A)_C1_JU7_Y^+\0_UAH_
MR/\  _:FBOQ6_P"&G_BW_P!%&\1_^#"3_&C_ (:?^+?_ $4;Q'_X,)/\:/\
M5JO_ ,_%^(?ZPT?Y'^!^U-%?BM_PT_\ %O\ Z*-XC_\ !A)_C1_PT_\ %O\
MZ*-XC_\ !A)_C1_JU7_Y^+\0_P!8:/\ (_P/VIHK\5O^&G_BW_T4;Q'_ .#"
M3_&C_AI_XM_]%&\1_P#@PD_QH_U:K_\ /Q?B'^L-'^1_@?M317XK?\-/_%O_
M **-XC_\&$G^-'_#3_Q;_P"BC>(__!A)_C1_JU7_ .?B_$/]8:/\C_ _:FBO
MQ6_X:?\ BW_T4;Q'_P"#"3_&C_AI_P"+?_11O$?_ (,)/\:/]6J__/Q?B'^L
M-'^1_@?M317XK?\ #3_Q;_Z*-XC_ /!A)_C1_P -/_%O_HHWB/\ \&$G^-'^
MK5?_ )^+\0_UAH_R/\#]J:*_%;_AI_XM_P#11O$?_@PD_P :/^&G_BW_ -%&
M\1_^#"3_ !H_U:K_ //Q?B'^L-'^1_@?M317XK?\-/\ Q;_Z*-XC_P#!A)_C
M1_PT_P#%O_HHWB/_ ,&$G^-'^K5?_GXOQ#_6&C_(_P #]J:*_%;_ (:?^+?_
M $4;Q'_X,)/\:/\ AI_XM_\ 11O$?_@PD_QH_P!6J_\ S\7XA_K#1_D?X'[4
MT5^*W_#3_P 6_P#HHWB/_P &$G^-'_#3_P 6_P#HHWB/_P &$G^-'^K5?_GX
MOQ#_ %AH_P C_ _:FBOQ6_X:?^+?_11O$?\ X,)/\:/^&G_BW_T4;Q'_ .#"
M3_&C_5JO_P _%^(?ZPT?Y'^!^U-%?BM_PT_\6_\ HHWB/_P82?XT?\-/_%O_
M **-XC_\&$G^-'^K5?\ Y^+\0_UAH_R/\#]J:*_%;_AI_P"+?_11O$?_ (,)
M/\:/^&G_ (M_]%&\1_\ @PD_QH_U:K_\_%^(?ZPT?Y'^!^U-%?BM_P -/_%O
M_HHWB/\ \&$G^-'_  T_\6_^BC>(_P#P82?XT?ZM5_\ GXOQ#_6&C_(_P/VI
MHK\5O^&G_BW_ -%&\1_^#"3_ !H_X:?^+?\ T4;Q'_X,)/\ &C_5JO\ \_%^
M(?ZPT?Y'^!^U-%?BM_PT_P#%O_HHWB/_ ,&$G^-'_#3_ ,6_^BC>(_\ P82?
MXT?ZM5_^?B_$/]8:/\C_  /VIHK\5O\ AI_XM_\ 11O$?_@PD_QH_P"&G_BW
M_P!%&\1_^#"3_&C_ %:K_P#/Q?B'^L-'^1_@?M317XK?\-/_ !;_ .BC>(__
M  82?XT?\-/_ !;_ .BC>(__  82?XT?ZM5_^?B_$/\ 6&C_ "/\#]J:*_%;
M_AI_XM_]%&\1_P#@PD_QH_X:?^+?_11O$?\ X,)/\:/]6J__ #\7XA_K#1_D
M?X'[4T5^*W_#3_Q;_P"BC>(__!A)_C1_PT_\6_\ HHWB/_P82?XT?ZM5_P#G
MXOQ#_6&C_(_P/VIHK\5O^&G_ (M_]%&\1_\ @PD_QH_X:?\ BW_T4;Q'_P"#
M"3_&C_5JO_S\7XA_K#1_D?X'[4T5^*W_  T_\6_^BC>(_P#P82?XT?\ #3_Q
M;_Z*-XC_ /!A)_C1_JU7_P"?B_$/]8:/\C_ _:FBOQ6_X:?^+?\ T4;Q'_X,
M)/\ &C_AI_XM_P#11O$?_@PD_P :/]6J_P#S\7XA_K#1_D?X'[4T5^*W_#3_
M ,6_^BC>(_\ P82?XT?\-/\ Q;_Z*-XC_P#!A)_C1_JU7_Y^+\0_UAH_R/\
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MT?\ #3_Q;_Z*-XC_ /!A)_C1_JU7_P"?B_$/]8:/\C_ _:FBOQ6_X:?^+?\
MT4;Q'_X,)/\ &C_AI_XM_P#11O$?_@PD_P :/]6J_P#S\7XA_K#1_D?X'[4T
M5^*W_#3_ ,6_^BC>(_\ P82?XT?\-/\ Q;_Z*-XC_P#!A)_C1_JU7_Y^+\0_
MUAH_R/\  _:FBOQ6_P"&G_BW_P!%&\1_^#"3_&C_ (:?^+?_ $4;Q'_X,)/\
M:/\ 5JO_ ,_%^(?ZPT?Y'^!^U-%?BM_PT_\ %O\ Z*-XC_\ !A)_C1_PT_\
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MP/VIHK\5O^&G_BW_ -%&\1_^#"3_ !H_X:?^+?\ T4;Q'_X,)/\ &C_5JO\
M\_%^(?ZPT?Y'^!^U-%?BM_PT_P#%O_HHWB/_ ,&$G^-'_#3_ ,6_^BC>(_\
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M_P"#"3_&C_5JO_S\7XA_K#1_D?X'[4T5^*W_  T_\6_^BC>(_P#P82?XT?\
M#3_Q;_Z*-XC_ /!A)_C1_JU7_P"?B_$/]8:/\C_ _:FBOQ6_X:?^+?\ T4;Q
M'_X,)/\ &C_AI_XM_P#11O$?_@PD_P :/]6J_P#S\7XA_K#1_D?X'[4T5^*W
M_#3_ ,6_^BC>(_\ P82?XT?\-/\ Q;_Z*-XC_P#!A)_C1_JU7_Y^+\0_UAH_
MR/\  _:FBOQ6_P"&G_BW_P!%&\1_^#"3_&C_ (:?^+?_ $4;Q'_X,)/\:/\
M5JO_ ,_%^(?ZPT?Y'^!^U-%?BM_PT_\ %O\ Z*-XC_\ !A)_C1_PT_\ %O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K](['_ )1A-_V!Y/\
MTM:OS<K](['_ )1A-_V!Y/\ TM:OG<XVH?\ 7R/ZGNY3O7_P2/S<HHHKZ(\(
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB@ HHHH **** "BBB@ HJ2WMY;J98H(GFE;HD:EF/&>@JY_PCVJ_] R\_P#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#](_%7_*,*#_L#V?\ Z6Q5
M^;E?I'XJ_P"484'_ &![/_TMBK\W*^=R;X:__7R7Z'NYM\5'_!']0HHHKZ(\
M(**** "BBO3OV:?A:?C%\:_#'AN2(R:?)<"YO^.!;1?/(#Z;@-@/JXK*I4C1
MA*I+9*YI3IRJS4([O0_3/]BGX5_\*K^ &@PSP^5JFL#^U[W(PP:4 QJ?3;&(
MP1V.ZO=Z15"*%4!5 P .@K.T/Q%IWB2"YFTR[CO([:ZFLIC&<^7-$Y21#Z$,
M"*_&:U2>(J2K2ZN_WGZU1IQH4XTH]$?DK^V[\*?^%5_'[6EMH?*TG6_^)O9[
M1A1YA/FH.PQ('P.P*UX'7ZC?\%&_A3_PFGP;@\4VD._4?"\_G.5'S-:RD)*/
MP81M[!6K\N:_4<HQ7UK"1D]UH_E_P#\WS3#?5L5)+9ZKY_\ !"OTC_X)<_\
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M=::NEV/M&OEG_@I!_P FXM_V&+7^4E?#?_#:WQL_Z'V\_P# 6W_^-US?C_\
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M?5\,WRWMIO+_ (!]]E^6TL+2]OB%[V^NR_X)UD,,=O"D44:Q1( JH@ 50.@
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M4M*&<?Z=:20\]<?,!6134E)73$TXNS"BBBJ$%%.CC>:1(XT:21R%55&22>@
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M<K\/O^PFO_H+5^S5?G?$O^\0_P /ZL^\X?\ ]WGZ_HC\%_$7_(P:G_U]2_\
MH9K/K0\1?\C!J?\ U]2_^AFL^OT*/PH^$ENPHHHJA!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP.?#E4Q&>8KV:=H]NB7^9[,:=#)L-[1J\OQ;_P C[\5U8L%8$J<, >AQG!_
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M')SUKQ,+D-;&457G4LY:KK][_P"'/8Q.=4L+5]A&%TM'T^Y?\,?K7\>OV0_
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M>VC Q_>=<Y&17Y/@_;2J^RH?%/3^OZV/T[%>QC3]I7^&.I[P %  &!7Y3_\
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M*H=+6-<;YV4]2"RA0>"22<A2#^86M?&+QUXBU274M1\8:Y=7LC;C*VH2@CT
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MD4X99)F"%E/8JA=A[J*[KX21)!\*?!D<?,::+9*OT$"8KYS_ ."FTDD?[/\
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M>_\ 83M/_0C6Q^P)_P FK^$?^NM[_P"EDU8__!1?_DVJ]_["=I_Z$:_.H_\
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MA1\)+=A1115""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH _2/Q5_P HPH/^P/9_^EL5?FY7Z1^*
MO^484'_8'L__ $MBK\W*^=R;X:__ %\E^A[N;?%1_P $?U"BBBOHCP@HHHH
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MJE2+C*]]=.IZ\'0Q-%PIM..VA^!#HT;LCJ5=3@JPP0?2OTB_X)<_\DR\8_\
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M_P""@O\ R=%XC_Z];/\ ])TJO^P'_P G4>$?^N5[_P"DDU6/^"@O_)T7B/\
MZ];/_P!)TJK^P*P7]JGP@"<%H[X#W_T.8_TK[A?\BC_N'_[:?&O_ )&O_;__
M +<?KI7XK?M0?\G$?$;_ +#EU_Z,-?M37XL_M30M;_M&?$57ZG6KA_P9R1^A
MKYSAK^/4]/U/H.(?X,/7]#<_8HLUOOVHO 4;]%N9I>1W2WE<?JHK]BJ_%7]F
M3Q7#X)_: \!ZO<,L=M'JD4,LCG"HDN8F8^P#D_A7[54N)8OZQ"73E_5CX?DO
M8376_P"B/(?'W[)?PI^)_BN]\2^)O"QU/6KP1B>Y_M*[BW;$5%^1)54855'
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M'^\ZQC'^U7ZXU\9Q$G];3Z.*_4^MR%KZJTNC?Z'BGBC]C/X.^,_$6HZ[K/A
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M]P%N[61M3TU6/WXFP)D'^ZVUL=?WC'M7W!JVE6FO:5>Z;?P+<V-Y"]O<0O\
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MI]]4BXY7RO=0_0_*6OVI_9A_Y-W^'/\ V [7_P!%BOQ6K]J?V8?^3=_AS_V
M[7_T6*^CXE_@4_7]#Y_A[^-/T_4^?O\ @J)?31_"CPE9J/W$VM>:YS_$D$@7
M]':OS7K]:OV^/AC>?$C]G^^DTVW:YU'0;E-62*,9=XT5DE ^B2,^.^SUQ7Y*
MUU\/SC+!<JW3=SFSR$HXOF>S2.B^&]Y-I_Q$\+75N66>#5;66,KU#+,I&/?(
MK]UJ_%W]EGX>7GQ,^/'A#2K:%I8+>^CO[Q@/ECMX7$CDGMG 4>[J.]?M%7B<
M2SBZM.*W2?XGK\/1DJ523V;1^9?_  4_MT7XV^&Y@1YC^'HU9?87-Q@_J?RK
MX[KZ>_X*+^*XO$?[2%S9Q,K#1=,MM/8J<C<=TY_$>?@_2OF&OK<KBXX*DGV/
MF<RDI8RHUW"BBBO4/-/7OV1/^3E?A]_V$U_]!:OV:K\9?V1/^3E?A]_V$U_]
M!:OV:K\[XE_WB'^']6?></\ ^[S]?T1^"_B+_D8-3_Z^I?\ T,UGUH>(O^1@
MU/\ Z^I?_0S6?7Z%'X4?"2W844450@HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHJSI>FW6M:G::?8PM<WMW,EO!"@RTDCL%51[DD"EM
MJPW-+P;X(U_XA:];Z+X;TFZUG5)S\EO:QECCNS'HJCNQ( [FOK+P/_P3#\;:
MQ"LWB?Q+I?AL,,B&VC:^F7V8 HGY.:^UOV<_@#HO[/W@&VT>PB2;5[A5EU34
M2,O<SXYP>R+DA5[#GJ23U?Q!^*7A+X5:2-2\6:_9:':MG9]ID_>2D=1'&,LY
M]E!-? 8O/J]6I[/!K3H[7;^1]QA<DHTZ?M,6]?6R1\=1?\$KM-6-1)\1KIY,
M?,RZ0J@GV'G''YUQOC'_ ()>^+-,MI9?#7B_3-==%W+!>V[V3O\ [((:1<_4
M@?2OI;_AX#\$?MGD?\)/="+_ )^?[*NO+Z^GE[O_ !VO9_ ?Q&\,?$[15U;P
MKK=GKE@< R6LF3&2,[74_,C8_A8 ^U<DLRS;#^_5NEYQT_)'5'+\KQ'NTK-^
M4M?S/Q3^(7PQ\4_"G7FT?Q9HMSHM_C<J3@%)%_O(ZDJX]U)%<O7[?_&3X.^'
MOC?X)N_#GB&V62.0%[:Z4#S;2;'RRQGL1W'0C(/!K\7O'G@S4?AWXSUGPSJJ
M!-0TNZ>UEV_=8J<!E_V6&"/8BOK<KS2.81:DK36_^:/E\RRUX&2<7>+V_P F
M8-%%%>\>*%%%% !1110 4444 %%%% !1110 5T#_  _\1Q>"QXNET>ZA\--=
M+9IJ4J;(I)F#$(A/W^$;)7(&.<9%?=?[&_[%/@O7/ ^@_$+Q9N\27.H(;BVT
MJ9=MI  [*-ZYS*?ESSA><%3UKL_^"E5M#9_LZZ/;V\2001:_:I'%&H5446]P
M  !P !VKYN6<TY8N.%HJ^MF_\CWXY3..%EB:KMI=+_,_,&BBBOI#P HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBNC^'?P_UKXI>,M+\,>'[7
M[5JFH2^7&IX5!C+.Y[*J@L3Z"IE)0BY2=DAQBY-1BKMF;X=\-ZKXMUBWTK1-
M.NM6U*X;;%:V<32R.?90,_X5]3^ O^":OQ(\21)/XAU#2_"<++GR9)#=7 /N
ML?R?^/\ X5]T_L^?LY^&/V>_"ZV.D0+=:Q<(O]HZQ,H\ZY<=0/[L8/1!P.^3
MDGTK6-:T_P .Z;/J.JW]MIFGP+NENKR98HHQZL[$ #ZFO@L9Q#5E/DPBLN[U
M;^1]MA<BIQCSXIW?;HCX:M?^"5MBL>+CXD7$LF?O1:,J#'T,Y_G7/>*/^"6>
MN6EFTGA[QY8:G<\D0:E8/:+CL-Z/+S_P$5]0ZI^VY\$=(O&MI_'EK)(IP6M;
M.ZN$_P"^XXF4_G7>_#_XU>!?BGO7PIXITW6ID&YK:"8"=5_O&)L.![D8KB>9
M9O27M)WMYQT_([%E^5U7R0M?REK^9^/_ ,6?V?\ QW\$[P1>*]!GL[9SB+4(
M?WMK+[+*O&?]DX;VKSROWKUK1;#Q)I-WI>JV4&HZ==QF*>UN8P\<J'JK*>"*
M_+/]L_\ 9*_X4/J\/B#PVDT_@G49-BK(2[:?,<GRF;NA&=K'G@@\@%OH\LSN
M.,DJ-96GT[/_ "9X&8Y/+"Q]K2=X_BCY@HHHKZD^;"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "A5+, !DG@ 4 %B
M !DU^FW[%O[&MA\.])T[QSXRL?M/C"X03VEC<KE-,4_=.T_\MB,$D_<S@8()
MKS<=CJ> I>TJ:M[+N=^"P53&U.2&W5]CY3^%/[!_Q2^*%E!J,MA!X5TJ;#)<
M:XS12.O]Y80I?Z;@H/8U[OI__!*VW6/-[\2)'D('RV^C!0I[C)G.1^ K[SFG
MCM89)II%BBC4N\CD!54#)))Z "O&M>_;,^"_AN_-G>>/M/EF#;2;&*:\CS_O
MPHZ_K7P\LXS+%2?L%;RBK_HS[)93E^&BO;OYMV_R/E_Q)_P2QU&&W=] ^(%K
M=S_P0:EIK0+T[R)(_?\ V*^7OC#^S?X^^!MQ_P 5/HCII[/LBU:S/G6DA[ 2
M ?*3S\KA6XZ5^O/P_P#C#X*^*D4S^$_$NGZX80#+%;R_O8P>A:,X8#W(KH];
MT/3_ !)I-WI>JV4&HZ==1F*>UNHQ)'(IZAE/!%51S[&8>?+B5S+JFK,FKDN$
MKPYL.[>CNC\%:*^B?VS?V9?^% >-H;S1DD?P=K)9[$N2QM9!R]NS'DXR"I/)
M4]RI-?.U?H&'KPQ-*-6F[IGP]>C/#U'2J+5'UAX$_P""=/C7Q]X*T+Q+9^)=
M!M[35[*&^BAG,^]%D0. V(R,@'L:X+]H;]DGQ'^SEHVDZEK>L:7J<6I7#6\:
M6!DW*RKN).]1Q7Z??LW_ /)OOPW_ .Q>L/\ T0E?-/\ P5*_Y$'P1_V$YO\
MT57QN$S;%5L>J$VN6[6WJ?5XK+,-2P3KQ7O63W]#\Y****^Z/C0HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[_Z^KW_T"&O&_"G_  4:^)/@_P +Z/H-GHGA66STNSAL87GM+DR,D2!%+$7
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ME21T8'JK#LP(([&OPGM;N>PNH;FVFDM[F%Q)'-$Q5T8'(92.00>XKZ<^&_\
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MD:WNCCCYY%#!^.Y7<>I)KY_-\FJXFK]8P^K>ZV^X]W*\VIX>E["OHELSZ/\
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M33U]!8',,)@ZE75\LG=:%?\ X*:?\G!:7_V+UO\ ^C[BO*/V1/\ DY7X??\
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M=[WV/GGXY_\ );/B#_V,.H?^E,E?HM_P3N^+%AXP^"=OX4:=5UOPT\D4ENQ
M=[=Y&>.0#NHW%#Z%1GJ,_F-XK\1W/C#Q1K&O7J117FJ7DU],D (C5Y7+L%!)
M(7+'&23CN:M>!_'FO_#;Q)::_P"&M3GTG5K8YCN(#U'=6!X93W4@@]Q7MX[
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MY()"N5(*G'*L".^,X->*^!?^";7P[\*^)K?5=2U35?$EO;2"6+3KSRT@8@Y
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MCL2SGZGCH,"O-/VK/VI-(_9^\(SP6MQ!>>-;V(C3]-SN,>>//E'9%YP#]XC
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MR^#C!W;W9\ECL?4QTTYJR6R/T[_X)A_\D#U__L9KC_TEM*]>_:Z_Y-J^(/\
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M)*'9$0@%)D&W$8[9Y/-6?C1^VUXY^.O@>7PKKVE>'[33Y)X[@R:;;SI+N0Y
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M3?NO\#G****^C/!"OT7_ ."9'PIMK#PEKOQ!NX VH7]PVFV4C#[ENFUI"O\
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MXT>)]3\37=L_ES2:-#&\",#AE\QW4,1S]W<,\9]/ 6;YEC*C6%6G9*_WM_\
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M"A=<J3PU?G=1171@L%# TO94VVM]3GQF+GC*GM*B2>VA^V/[-_\ R;[\-_\
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MA_U\C^I[N4[U_P#!(_-RBBBOHCP@HHHH **** "BBB@ HHHH **** "BBB@
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M=RY*%<'=VYKP"NO*</4PN%C2JJS5_P SFS/$4\3B74I.ZT"BBBO8/*"BBB@
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MO/,UW9;5NM/NV&#-;.3L)_V@0RG'&5..*_:'3;Z/5-/M;R(,L5Q$LR!QA@&
M(R.QYKX2_P""I^AQ-9?#W6515G62\M)'_B92(G4'V!#_ /?1]:\[(<5.EBE0
M;]V5]//^M#NSO#0J89UTO>C^1\P?LC?%+_A4GQZ\-:M-+Y6F7DO]F7Y)POD3
M$+N;V1]C_P# *_96OP'K]G/V4_BE_P +>^!7AG6YIO.U.&'[!J!)RWVB'Y&9
MO=@%?_@=>CQ)AO@Q,?1_I^IP\/XCX\._5?K^A^;G[;WPW_X5O^T5XCCAB\JP
MUAAK%KQ@$3$F3'L)1*/H!7MW_!+_ .&_VWQ'XJ\<W,68K&%=+LV8<&20AY2/
M=56,?20UWG_!3GX;C6/A_P"'O&MM%FXT:Z-E=,HY\B;[I/LLBJ!_UU->U?L;
M_#@_#/\ 9Y\+6,T7E7^H0_VK=@C!\R?#J"/58_+7_@-3B,PY\HBK^]+W7\M_
MPM]X\/@>7-9.WNKWOOV_'\CT+XI>.[7X8_#OQ%XJO-IATJRDN C''F.!A$^K
M.57_ (%7X=:MJEUKFJWFI7TK7%[>3/<3RMU>1V+,Q^I)-?HM_P %-_BA_8_@
M70/ MK-BXUFX^W7BJ>?L\)^13[-(01[Q5^;]>AP[AO9X=UGO-_@O^#<X<^Q'
MM*ZHK:/YO^D?M+^R[XRLO''[/_@74+*59/)TJ"QN%4C*3P((I%([?,A('H0>
M]-^.O[-7@O\ :$LK./Q-;W,-]9*RVNI6$HCGB5L$KR"K+D X93CG&,FOR^_9
MW_:@\5_LZZM.VD^7J>AWC![S1KIB(I& QO1AS')@8W $$ 9!P,??/PY_X*&?
M"GQI#''J]W=^#]0;@PZG"7A+?[,T888]W"5X.,RS&8/$.OADVKW36Z/:PF8X
M7%T%1Q#2=K-/9GAGC?\ X)<:Q;^9+X1\:6=\O5;;6+=H&'MYD>\$_P# 5KQ_
MQ5\'_P!HGX%^&Y])$?B2Q\+B1KB0^'KYY;0D@!G?R6RH.T?? Z"OU6\,^-O#
MWC2U^T^']=TW6[?&?,T^[CG4?4J3BMJHIYYBZ;Y*\5.W=:_U\C2>38:?O4&X
M^CT_KYGX&WEY<:A</<74\ES<2'+RS.79CZDGDU#7Z8?MV?LKZ!XB\":O\0O#
MNG0Z7XDTF,W=^+5-B7T _P!8SJ./,49;?U(!!SQC\SZ^[P&.IXZC[2FK6T:[
M'Q6-P=3!5?9S=^S[G[(_L;_\FQ^ /^O%O_1KUYC_ ,%,_P#DWW2_^QAM_P#T
M1<5Z=^QO_P FQ^ /^O%O_1KUYC_P4S_Y-]TO_L8;?_T1<5^?8?\ Y&W_ &^_
MS9]SB/\ D5_]N+\D?EY7ZG?\$W_!L7A_]GW^V=BFYU[4I[AI,?-Y<9\E5/L&
MCD/_  ,U^6-?K[^PG+'+^RKX'\L !5O%8?[0O9\_GU_&OJN(I..#2762_)L^
M;R&*EBFWTB_S1T_[4-QXFB^ _BR+P=9WM_XBNK=+2VAT^,O-B21$D90.01&S
MG/;%?E5_PS!\6_\ HG/B/_P7R?X5^O\ \2_B9H/PC\)W'B3Q+<RVFD6\B1R3
M10/,5+L%7Y5!.,D#\:\;_P"'@GP3_P"ACO/_  5W'_Q%?.97B\7AJ36'H\R;
MWL_NT/>S+"X7$54Z];E:6UU]^I\G?L=_"_XL_"OX^>'M1N_!OB'2]$NB]EJ4
MDUDZQ&%U."Y(X"N$;/\ LU^GU?.7_#P3X)_]#'>?^"NX_P#B*/\ AX)\$_\
MH8[S_P %=Q_\166/ACL?4565!IVMHF:X*>#P5-TXUTU>^K1^:_[0G@^/P#\;
M_&^@P0BWM+759_LT0& D+MOB'X(RU^E'_!/O_DUWPY_U\WO_ *4/7YV_M5>/
M-#^)WQ\\4^)O#=S)=Z+?M;-!-)$T;-MMHD?Y6 (PZL.1VK]$O^"??_)KOAS_
M *^;W_TH>O?SIS>64G-:WC?ULSQ,H45F%10V]ZWI='4_MA>-+SP%^S?XUU33
MYF@OFMDLXI%.&7SY4A8@]B%D8@]L5^-E?K+_ ,%"I3'^S#KB@9$EY9J?^_ZG
M^E?DU6W#<4L+*75R_1&/$$F\3&/1+]6?>G_!*Z^F&H?$:SW$V[16,VWL&!G&
M1]0?T%?H#)(L,;R.=J*"S'T K\]O^"5__(>^(G_7M9?^AS5]\>*IC!X7UB4#
M)2SF;'T0FOE\[5\PFO3\D?1Y._\ 88/U_-GX<>//%][X_P#&FM^)-0D:2\U2
M\DNI"QSC<Q(7Z 8 '8 5[%^P;J$UC^U/X-6)BJ7 O(95!P&4VDQP?Q53^%>
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M!'$S9SDJH!.>_2O.XFC&]*777]#OX=E*U6/33]3\\/\ @J5_R/W@?_L&3?\
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M(SO.,]#7Z'U\;^'O^"C6E>//B7X8\*^&_!UZ+?6-3M[%K_5+E(WC2215+")
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'KW[(G_)ROP^_P"PFO\
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MV5O)/<2QP01C<\DK!54>I)Z"NZMQ%BJD'"$5%OJOT..ED.'ISYY2;2Z?YD@
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M;U/P[JFG:0]P+5+Z[M)(HGF*LP168 %L(QP/2OT%_P""9'Q*@U;X=Z[X)FE
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M8[AV7O7Z7:9IMKHVFVNGV-O':V5K$L$$$0PD<:@*J@=@  *FDD2&-Y)'6.-
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M)_B; X.,GBM:>>U:M%8>A2]^UO\ @V_JQE/):=*JZ]:I[E[_ / N>Q5^8O\
MP4]5O^%\^'VVG:?#4 #8XR+JZS_,?G7Z"_!CXE6_Q@^%_AWQ?;1+;C4[;S);
M=7WB&524D3/?:ZL,X[5\?_\ !4;P!<36G@WQI!&SV\!ETJ[8#[F[]Y"?H<3#
M/T]:\S)7[#,%"IH]5\ST<W_?8!SAJM'\CSG]D;]COP7^T+X&N->U7Q/JMM>6
MEX]I=:;IZQ(T?"LC;G5^&4_W>H/I7N?Q*_X)S^!K?X8:Y%X,M=0G\7I!YFGW
M%_?EM[JP8QE1M3YU#*"1P6![5\4?LV_M#:O^SMXZ_MBRB^WZ5=JL&IZ:6VBX
MB!R"#V=225/N1T)K]7/A-\?? WQJTN*[\+Z[;W-PRYDTV9A'>0G&2'B)SQ_>
M&5..":];-JF882O[6$VZ=[KLO)V_IH\S*X8'%4?93BE/9]_5'XJZMI%]H.I7
M&GZE9SZ??6[E)K:ZC,<D;#LRD9!KZ,_8D\<?$Y_C+X;T7PYJ>K7GA[[2O]J6
M+R/+9Q6O_+1V5LK&=H^5A@YP!UQ7ZCZYX*\/>)Y ^LZ#IFK.H #7UG',0!G
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M_P"'"BBBNXY HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MID'TC%?"E?3X#$_6\-"MU:U]>I\[CL/]5Q$Z71;>G0****] X0HHHH ****
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MN?5F8DG\:IT45LDDK(R;;U84444P"BBB@ HHHH **** "BBB@ HHHH ****
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M/@JO;OV*?^3HO 7_ %\S?^D\M>(U[=^Q3_R=%X"_Z^9O_2>6OT'&_P"ZU?\
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M)I<9\J( M)(?945F_"N1K[W_ ."8'PO2:;Q1\0;N+)BQI%@S#@$A9)V'O@Q
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MS;:_#6U!^^^HRD?06P'_ *$:_/ZN[(8\N @^]_SL<>=2<L;)=K?D>O?LB?\
M)ROP^_[":_\ H+5^S5?C+^R)_P G*_#[_L)K_P"@M7[-5\WQ+_O$/\/ZL^@X
M?_W>?K^B/FC]L/\ :X'[.]G8:-H5G;ZCXNU*,SHMUDPVD.2OF.H(+%F#!1D#
MY6)/&#\6Z+_P4$^,^FZ]'?W?B"UU6T#@R:;<:=;I"ZY^[E$5QUZAL],YJO\
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M=/DGC +1K+,L98 ]2 V?PK[X_P"'6OA;_H=]8_\  6*OM,T>7*<?KJUMIO\
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MX:<>TOT1U\012Q$9=U^H4445]<?+A1110 4444 %%%% !1110 4444 %%%%
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M%KU5A****W,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7_T,UGU^A1^%'PDMV%%%%4(**** "BBB@ HHHH **** "BBB@ HHHH ****
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M-^(-?I3^Q9^TM>?M">"=1BUV.*/Q1H;QQW<D";([F.0-Y<P7H&)1PP' (!&
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M8[<2K@$,@E92P.>",@]JY'QS\+_%OPSO([;Q3X=U'0I9!F,WD#(DG^ZWW6_
MFHCB*,Y<D9IOM=7*E1JQCSRBTN]CEZ**[+P)\&?'/Q.;_BE_"NJ:S%G!N+>W
M;R%.<8,IP@/U-:RG&FN:;LC.,93?+%79QM%>VW7[%7QKL[<3R> KQD*[L17-
MO(W7'W5D)S[8KR;Q'X5UKP?J3:?KVD7VBWR\FVU"W>"3'KM8 XK*GB*-9VIS
M3]&F:5*%6DKU(->J:,NBBNF\+_"_QEXXL9;WPYX2UW7[.*3R9+C2]-FN8T<
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M#HOAOX@LO"?Q$\+:YJ4<TVG:;JMK>W,=NH:5HHYE=P@) +%5.,D#/<5^C/\
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MQ_Y1A-_V!Y/_ $M:OG<XVH?]?(_J>[E.]?\ P2/S<HHHKZ(\(**** "BBB@
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ME)F/13CBOAVBO*_LC"^W^LV?->^_7<]/^U,3[#ZO=<MK;= HHHKVCR0HHHH
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MY.5^'W_837_T%J_9JOSOB7_>(?X?U9]YP_\ [O/U_1'X+^(O^1@U/_KZE_\
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MB[HX0?8L93_P!:^*=8^,WCS7O$,NN7OC#6GU61R_VE+Z2-D)QPFT@*!@8"X
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MA*\F]':V_P!^UCY&C;.<<ISC:*6JOV^[N>T_#_X<>&_A;X=@T/POI-OI.GQ
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MK$SQ=5U:F["BBBNPY0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K](['_ )1A-_V!Y/\ TM:O
MS<K](['_ )1A-_V!Y/\ TM:OG<XVH?\ 7R/ZGNY3O7_P2/S<HHHKZ(\(****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME&%I86E+V-533>Z_X=GB9IB:F(J1]K3Y&EU_X9'[,_LB_P#)M7P^_P"P8O\
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MYR5^>\._[[\G^A]WGW^Z?-?J?+5??W_!*N&/ROB9+G,N[35(]%_TD_J?Y5\
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M\&*_>#QC_P BCKG_ %XS_P#HMJ_!^O#X9^&K\OU/9XB^*E\_T/;OV*?^3HO
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Z]^R)_R<K\/O\
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MO%WV'2-/B$-M;_V;9R>6@.<;GA+'KW)K&^*'[2GQ'^,VB6VD>,?$?]L:=;7
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M=*\QK;*\)4P6'5&HTW=[?TC',L5#&5W5III66X5^R/[&_P#R;'X _P"O%O\
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M)!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M44 %%%% !1110 4444 >O?LB?\G*_#[_ +":_P#H+5^S5?C+^R)_R<K\/O\
ML)K_ .@M7[-5^=\2_P"\0_P_JS[SA_\ W>?K^B/P7\1?\C!J?_7U+_Z&:SZT
M/$7_ ",&I_\ 7U+_ .AFL^OT*/PH^$ENPHHHJA!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCE5EO;\9;_F? M?I;_P2]O(G^#WBFU# S1Z\TC+GD*UO"%/YHWY5^:5?4W[
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MC";_ + \G_I:U?.YQM0_Z^1_4]W*=Z_^"1^;E%%%?1'A!1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /TC\5?\ *,*#_L#V?_I;%7YN5^D?BK_E&%!_V![/_P!+
M8J_-ROG<F^&O_P!?)?H>[FWQ4?\ !']0HHHKZ(\(**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "OWH\/_ /(!TW_KVB_] %?@O7[T>'_^0#IO_7M%_P"@"OA^)MJ/_;WZ
M'V/#N]7Y?J?$?_!4SQ-<VV@^ ?#\4S+:WEQ=WL\8/#-$L21D_3S9*_/.ONC_
M (*G3%O%'P_BQPMG=MGZO&/Z5\+U[>214<!3MUO^;/'SB3EC9W\OR1^@/_!*
MW4G:S^)-@SGRXWT^=$[987"L?_'4_*OM;XB(LGP_\3HPRK:7= CU'E-7PY_P
M2K_X_P#XE?\ 7+3OYW-?<GQ!_P"1!\2_]@RY_P#135\3G&F9S]8_DCZ_*G?+
MX_/\V?A/1117ZF?FX4Z&,S3)&OWG8*,^YIM6=+N!:ZE:3G&(YD<[NG# TGL"
MW/WGT^QBTVPMK. ;8;>)8D'HJ@ ?H*_,S_@IU>>=\>-"@!^6'P[!G_>-Q<$_
MIBOTZ5@R@@Y!Y!%?ES_P4N@:']H6Q<])= MG'_?Z=?\ V6OS+A_7'7?9GZ)G
MFF#LNZ/DZBBBOTX_.SU#P%^T]\4OAEI\5AX=\::A9V$(VQ6DX2ZAC'HJ3*ZJ
M/8"I/'7[4WQ6^).FRZ?K_C74+FPE7;+:VRQVL<J_W76%4##V.17E=%<OU6AS
M^T]FN;O97^\Z/K%;EY.=V[7=CT'X"_"6]^-OQ4T3PI:;DAN9?,O;A?\ EA;)
MS*_UV\#U8J.]?KQ\3?&^B_ #X/ZEK7D1V^FZ%8K#962G"LP C@A7V+;5]AD]
MJ^??^"<?P3_X0OX<77CK4;?9JWB3Y;7>/FCLD/R_3S'!;W"QFO(/^"E/QL_X
M2#Q;IWPYTV?=8Z-B\U+8>'NG7Y$/^Y&V?K*1_#7QV+;S;,8X:/P0W_7_ "/K
M,*EEF EB)?'/;]/\SY@\*>%?%?[0OQ3%A8J=3\1Z[=R7,\\IPBEB7DED/\*#
M))_  $X%?H-X _X)K_#C0=+B'BB[U+Q1J;)^]=9S:VZM_L(GS?\ ?3'/M7 _
M\$M?!MO]C\<>+)(@UT9(=+@D[H@!DE ^I,7_ 'S7<_\ !1_XM:W\/_A]X;T7
M0=3N-)N==NY3/<6DACE,,*KN0,.0"TJ9QZ8Z$@ZX[%XBOC5@,++D2TT]+_@C
M+!X6A1P;QN)CS-]_6WXLN>-O^";7PPU[373P_-JGA?4%4^7.EP;J(MZNDF21
M_NLM?G=\8/A'K_P2\<WOA?Q%"J7<($D5Q%DQ7,+9VRQGNIP?<$$'D&OO;_@F
MS\7-=\<^%/%?AW7M4N=5DT6:WGM)KR4RRB*82!DW$Y*JT61GIOQTX%/_ (*A
M>"X+SX>^%/%2QK]LL-2;3V<#DQ31L_/L&A&/]X^M+!8S$X3'_4<3/F3Z_*Z'
MC,+A\3@OKF'CRM=/G9GYP5]N?\$M;S9X^\;VN?\ 6:9#+C_=E(_]GKXCK[3_
M ."7-LS?%#QA<#[L>C+&?JTZ$?\ H)KWLX_W"K?M^J/$RK_?:?K^C/T$^(FF
MIK'P_P#$UA*-T=UI=U P SD-$RG^=?A17[M>/K_^RO OB.]SM^S:;<S9]-L3
M'^E?A+7A<,WY*OJOU/:XBMS4OG^@4445]L?(!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5^D=C_ ,HPF_[ \G_I:U?FY7Z1V/\ RC";_L#R?^EK5\[G&U#_ *^1_4]W
M*=Z_^"1^;E%%%?1'A!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)N?"W7=,DCT*35?#-^%/E7$5T;F/=V+I)DL/967ZTS_@HM\6-;^'?PNT33-
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MGX,T445^GGYT%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Z]^R)_P G*_#[_L)K
M_P"@M7[-5^,O[(G_ "<K\/O^PFO_ *"U?LU7YWQ+_O$/\/ZL^\X?_P!WGZ_H
MC\%_$7_(P:G_ -?4O_H9K/K0\1?\C!J?_7U+_P"AFL^OT*/PH^$ENPHHHJA!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 ?I'XJ_Y1A0?]@>S_\ 2V*OS<K](_%7_*,*#_L#V?\
MZ6Q5^;E?.Y-\-?\ Z^2_0]W-OBH_X(_J%%%%?1'A!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR7UO*_:+LG]V_P"I^9=%%%?I9^>A7HG[/_PENOC9\6-"\*P!UMKB7S;Z=/\
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MT_S-L^J\^*4%]E?GK_D%%%%?4GS84444 %%%% !1110 4444 %%%% !1110
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M?]?\C[3!I99@)8F7QRV_3_,^+?%WBG4?&_BC5?$&K3?:-2U*YDNKB3L7=B2
M.P&< =@ *_0/_@EKJ$4G@7QS8A@9X=2@G9>X5XBJG\XV_*OSFKZ$_8H_: M/
M@3\4W;6I6B\,:W"MG?R $B!@V8IR ,D*2P./X78\D 5]'FN&E7P4Z5):JUEZ
M?\ \'+<0J.,C4J/1WN_4^C_^"IME-)X2\ W:IFWBOKJ)V]&>-"H_$(WY5R__
M  2PLIF\0?$*\"?Z/':V<3-_M,\I _)37VC\2OAKX1_:$^'XT?62NJ:'=E+J
MVO+"<91@#MEBD&1G!(SR""1SFJWP8^!_A+]GOPG<Z1X;2:.VED-S=WU_*'FF
M8+C<[ *  !P  !R<<DGXF.8TXY8\$T^>_P"MS["6 G+,5BTURV_2QXW_ ,%)
M-0BL_P!G18790]UK-K%&#U)"R.<?@AK\L*^LOV_OVC-,^+GB[3O"_AJ[6]\/
MZ TC2WD39BNKIL E#W5 "H;H2S8R,$_)M?8Y+AYX?!Q4U9O4^2S>O&OBY.#N
MEH?=_P#P2QT"236/'^MD8BB@M;-#CJ7:1V_+8OYBOKW]I?Q6O@KX ^/=68A6
M329H(RW3S)5\J/\ \?D6O'O^";?A%M _9^EU:5,2:YJL]RC>L486$#_OJ.3\
MZR_^"F'Q 30?@_I/A:-\7?B"_#NF?^7>##L?^_C0_K7R6(7US..1;<R7W;_D
MSZC#OZIE7.^S?W[?FC\R****_2S\^"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M]>_9$_Y.5^'W_837_P!!:OV:K\9?V1/^3E?A]_V$U_\ 06K]FJ_.^)?]XA_A
M_5GWG#_^[S]?T1^"_B+_ )&#4_\ KZE_]#-9]:'B+_D8-3_Z^I?_ $,UGU^A
M1^%'PDMV%%%%4(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#](_%7_*,*#_ + ]G_Z6Q5^;E?I'
MXJ_Y1A0?]@>S_P#2V*OS<KYW)OAK_P#7R7Z'NYM\5'_!']0HHHKZ(\(****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^C/V#?BQ_PK/X
M]:=9W4_E:1XB7^RKC<<*)&.8'^OF +GL)&K],_CAX 'Q2^$?BSPML5YM1L)$
MMPW03J-\)/TD5#^%?B"CM&ZNC%74Y#*<$'UK]@_V._CPOQU^$=I<WLXD\2Z1
MML=54GYG<#Y)OI(HSG^\' Z5\/G^&E3J0QU/I:_JMG^GW'V.1XB-2$L'4ZWM
M^J_7[S\?9H7MYGBE1HY$8JR,,%2.""/6FU]&_MX?"$_"_P".FH7UK!Y>B^)
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MJDMV[A1116YB%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7Z1V/_ "C";_L#R?\ I:U?
MFY7Z1V/_ "C";_L#R?\ I:U?.YQM0_Z^1_4]W*=Z_P#@D?FY1117T1X04444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#^%E.4\;4Z[?J_T^\^HSS$QA&.#I]-_T7]>04445]N?'A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 >O?LB?\G*_#[_ +":_P#H+5^S5?C+^R)_R<K\/O\ L)K_
M .@M7[-5^=\2_P"\0_P_JS[SA_\ W>?K^B/P7\1?\C!J?_7U+_Z&:SZT/$7_
M ",&I_\ 7U+_ .AFL^OT*/PH^$ENPHHHJA!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?I'XJ_Y
M1A0?]@>S_P#2V*OS<K](_%7_ "C"@_[ ]G_Z6Q5^;E?.Y-\-?_KY+]#W<V^*
MC_@C^H4445]$>$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %7]*U_4]!:1M-U&[TYI  YM9VB+8Z9VD9ZFJ%%)I/1@FUJC0U;Q%JN
MO>4-3U.\U'RL^7]KN'EV9QG&XG&<#\JSZ**$DM$#;>K"BBBF 4444 %%%% !
M1110!I:7XFUC0XWCTW5;[3XY#N=;6X>(,?4A2,FHM4UO4=<F274K^ZU"5%VK
M)=3-*RKG. 6)XJE14\JO>VH^9VM<****H04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7Z1V/\ RC";_L#R?^EK5^;E?I'8_P#*,)O^P/)_Z6M7SN<;4/\ KY']
M3W<IWK_X)'YN4445]$>$%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% %[2M>U/0I)'TW4;K3WD&':UG:(L!V.TC-/U7Q)JVNK&
MNI:I>Z@L9)1;JX>4*3UQN)Q6=14\JO>VH^9VM<****H04444 %%%% !1110
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M6'\J^XH_\*W^''_0D^'O_!/!_P#$4?\ "M_AQ_T)/A[_ ,$\'_Q%7J*.:?\
M,_O#EA_*ON*/_"M_AQ_T)/A[_P $\'_Q%'_"M_AQ_P!"3X>_\$\'_P 15ZBC
MFG_,_O#EA_*ON*/_  K?X<?]"3X>_P#!/!_\11_PK?X<?]"3X>_\$\'_ ,15
MZBCFG_,_O#EA_*ON*/\ PK?X<?\ 0D^'O_!/!_\ $4?\*W^''_0D^'O_  3P
M?_$5>HHYI_S/[PY8?RK[BC_PK?X<?]"3X>_\$\'_ ,11_P *W^''_0D^'O\
MP3P?_$5>HHYI_P S^\.6'\J^XH_\*W^''_0D^'O_  3P?_$4?\*W^''_ $)/
MA[_P3P?_ !%7J*.:?\S^\.6'\J^XH_\ "M_AQ_T)/A[_ ,$\'_Q%'_"M_AQ_
MT)/A[_P3P?\ Q%7J*.:?\S^\.6'\J^XH_P#"M_AQ_P!"3X>_\$\'_P 11_PK
M?X<?]"3X>_\ !/!_\15ZBCFG_,_O#EA_*ON*/_"M_AQ_T)/A[_P3P?\ Q%'_
M  K?X<?]"3X>_P#!/!_\15ZBCFG_ #/[PY8?RK[BC_PK?X<?]"3X>_\ !/!_
M\11_PK?X<?\ 0D^'O_!/!_\ $5>HHYI_S/[PY8?RK[BC_P *W^''_0D^'O\
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MAQ_T)/A[_P $\'_Q%7J*.:?\S^\.6'\J^XH_\*W^''_0D^'O_!/!_P#$4?\
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M'_0D^'O_  3P?_$4?\*W^''_ $)/A[_P3P?_ !%7J*.:?\S^\.6'\J^XH_\
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M .(J]11S3_F?WARP_E7W%'_A6_PX_P"A)\/?^">#_P"(H_X5O\./^A)\/?\
M@G@_^(J]11S3_F?WARP_E7W%'_A6_P ./^A)\/?^">#_ .(H_P"%;_#C_H2?
M#W_@G@_^(J]11S3_ )G]X<L/Y5]Q1_X5O\./^A)\/?\ @G@_^(H_X5O\./\
MH2?#W_@G@_\ B*O44<T_YG]X<L/Y5]Q1_P"%;_#C_H2?#W_@G@_^(H_X5O\
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MU%'-/^9_>'+#^5?<4?\ A6_PX_Z$GP]_X)X/_B*/^%;_  X_Z$GP]_X)X/\
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MC_H2?#W_ ()X/_B*/^%;_#C_ *$GP]_X)X/_ (BKU%'-/^9_>'+#^5?<4?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\ :I_P I+K/_
M +"]I_Z11U^E]?FAJG_*2ZS_ .PO:?\ I%'7Z7UZV<;8?_ CR<JWK_XV?F3_
M ,$__P#DX#QI_P!@NX_]*X:_0:OSY_X)_P#_ "<!XT_[!=Q_Z5PU^@U;YU_O
M;]%^1ED_^Z_-A1117A'MA1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'P!JG_*2ZS_["]I_Z11U^E]?FAJG_*2ZS_["]I_Z11U^
ME]>MG&V'_P "/)RK>O\ XV?F3_P3_P#^3@/&G_8+N/\ TKAK]!J_/G_@G_\
M\G >-/\ L%W'_I7#7Z#5OG7^]OT7Y&63_P"Z_-A1117A'MA1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M95O7_P ;/S-_X)\7$EO^T'XU:-MK'2K@?^3<-?H9_:EU_P ]C^0K\[_^"?\
M_P G >-/^P7<?^E<-?H-6^=)?6WZ+\C/)V_JOS9:_M2Z_P">Q_(4?VI=?\]C
M^0JK17A<J['MW9:_M2Z_Y['\A1_:EU_SV/Y"JM%'*NP79:_M2Z_Y['\A1_:E
MU_SV/Y"JM%'*NP79:_M2Z_Y['\A1_:EU_P ]C^0JK11RKL%V6O[4NO\ GL?R
M%']J77_/8_D*JT4<J[!=EK^U+K_GL?R%']J77_/8_D*JT4<J[!=EK^U+K_GL
M?R%']J77_/8_D*JT4<J[!=EK^U+K_GL?R%']J77_ #V/Y"JM%'*NP79:_M2Z
M_P">Q_(4?VI=?\]C^0JK11RKL%V6O[4NO^>Q_(4?VI=?\]C^0JK11RKL%V6O
M[4NO^>Q_(4?VI=?\]C^0JK11RKL%V6O[4NO^>Q_(4?VI=?\ /8_D*JT4<J[!
M=EK^U+K_ )['\A1_:EU_SV/Y"JM%'*NP79:_M2Z_Y['\A1_:EU_SV/Y"JM%'
M*NP79:_M2Z_Y['\A1_:EU_SV/Y"JM%'*NP79:_M2Z_Y['\A1_:EU_P ]C^0J
MK11RKL%V6O[4NO\ GL?R%']J77_/8_D*JT4<J[!=EK^U+K_GL?R%']J77_/8
M_D*JT4<J[!=EK^U+K_GL?R%']J77_/8_D*JT4<J[!=EK^U+K_GL?R%']J77_
M #V/Y"JM%'*NP79:_M2Z_P">Q_(4?VI=?\]C^0JK11RKL%V6O[4NO^>Q_(4?
MVI=?\]C^0JK11RKL%V6O[4NO^>Q_(4?VI=?\]C^0JK11RKL%V6O[4NO^>Q_(
M4?VI=?\ /8_D*JT4<J[!=EK^U+K_ )['\A1_:EU_SV/Y"JM%'*NP79:_M2Z_
MY['\A1_:EU_SV/Y"JM%'*NP79:_M2Z_Y['\A1_:EU_SV/Y"JM%'*NP79:_M2
MZ_Y['\A1_:EU_P ]C^0JK11RKL%V6O[4NO\ GL?R%']J77_/8_D*JT4<J[!=
MEK^U+K_GL?R%']J77_/8_D*JT4<J[!=EK^U+K_GL?R%']J77_/8_D*JT4<J[
M!=EK^U+K_GL?R%']J77_ #V/Y"JM%'*NP79:_M2Z_P">Q_(4?VI=?\]C^0JK
M11RKL%V6O[4NO^>Q_(4?VI=?\]C^0JK11RKL%V6O[4NO^>Q_(4?VI=?\]C^0
MJK11RKL%V6O[4NO^>Q_(4?VI=?\ /8_D*JT4<J[!=EK^U+K_ )['\A1_:EU_
MSV/Y"JM%'*NP79:_M2Z_Y['\A1_:EU_SV/Y"JM%'*NP79:_M2Z_Y['\A1_:E
MU_SV/Y"JM%'*NP79:_M2Z_Y['\A1_:EU_P ]C^0JK11RKL%V6O[4NO\ GL?R
M%']J77_/8_D*JT4<J[!=EK^U+K_GL?R%']J77_/8_D*JT4<J[!=EK^U+K_GL
M?R%']J77_/8_D*JT4<J[!=EK^U+K_GL?R%']J77_ #V/Y"JM%'*NP79:_M2Z
M_P">Q_(4?VI=?\]C^0JK11RKL%V6O[4NO^>Q_(4?VI=?\]C^0JK11RKL%V6O
M[4NO^>Q_(4?VI=?\]C^0JK11RKL%V6O[4NO^>Q_(4?VI=?\ /8_D*JT4<J[!
M=EK^U+K_ )['\A1_:EU_SV/Y"JM%'*NP79:_M2Z_Y['\A1_:EU_SV/Y"JM%'
M*NP79:_M2Z_Y['\A1_:EU_SV/Y"JM%'*NP79:_M2Z_Y['\A1_:EU_P ]C^0J
MK11RKL%V6O[4NO\ GL?R%']J77_/8_D*JT4<J[!=EK^U+K_GL?R%']J77_/8
M_D*JT4<J[!=EK^U+K_GL?R%']J77_/8_D*JT4<J[!=EK^U+K_GL?R%']J77_
M #V/Y"JM%'*NP79:_M2Z_P">Q_(4?VI=?\]C^0JK11RKL%V6O[4NO^>Q_(4?
MVI=?\]C^0JK11RKL%V6O[4NO^>Q_(4?VI=?\]C^0JK11RKL%V6O[4NO^>Q_(
M4?VI=?\ /8_D*JT4<J[!=EK^U+K_ )['\A1_:EU_SV/Y"JM%'*NP79:_M2Z_
MY['\A1_:EU_SV/Y"JM%'*NP79:_M2Z_Y['\A1_:EU_SV/Y"JM%'*NP79:_M2
MZ_Y['\A1_:EU_P ]C^0JK11RKL%V6O[4NO\ GL?R%']J77_/8_D*JT4<J[!=
MEK^U+K_GL?R%']J77_/8_D*JT4<J[!=EK^U+K_GL?R%']J77_/8_D*JT4<J[
M!=EK^U+K_GL?R%']J77_ #V/Y"JM%'*NP79:_M2Z_P">Q_(4?VI=?\]C^0JK
M11RKL%V6O[4NO^>Q_(4?VI=?\]C^0JK11RKL%V6O[4NO^>Q_(4?VI=?\]C^0
MJK11RKL%V6O[4NO^>Q_(4?VI=?\ /8_D*JT4<J[!=G0/<2#2!,&_>;0=WXUD
M_P!J77_/8_D*TI/^0"/]P?SK#J(I:E-O0M?VI=?\]C^0H_M2Z_Y['\A56BKY
M5V)NRU_:EU_SV/Y"C^U+K_GL?R%5:*.5=@NRU_:EU_SV/Y"C^U+K_GL?R%5:
M*.5=@NRU_:EU_P ]C^0H_M2Z_P">Q_(55HHY5V"[+7]J77_/8_D*/[4NO^>Q
M_(55HHY5V"[+7]J77_/8_D*/[4NO^>Q_(55HHY5V"[+7]J77_/8_D*/[4NO^
M>Q_(55HHY5V"[+7]J77_ #V/Y"C^U+K_ )['\A56BCE78+LM?VI=?\]C^0H_
MM2Z_Y['\A56BCE78+LM?VI=?\]C^0H_M2Z_Y['\A56BCE78+LM?VI=?\]C^0
MH_M2Z_Y['\A56BCE78+LM?VI=?\ /8_D*/[4NO\ GL?R%5:*.5=@NRU_:EU_
MSV/Y"C^U+K_GL?R%5:*.5=@NRU_:EU_SV/Y"C^U+K_GL?R%5:*.5=@NRU_:E
MU_SV/Y"C^U+K_GL?R%5:*.5=@NRU_:EU_P ]C^0H_M2Z_P">Q_(55HHY5V"[
M+7]J77_/8_D*/[4NO^>Q_(55HHY5V"[+7]J77_/8_D*/[4NO^>Q_(55HHY5V
M"[+7]J77_/8_D*/[4NO^>Q_(55HHY5V"[+7]J77_ #V/Y"C^U+K_ )['\A56
MBCE78+LM?VI=?\]C^0H_M2Z_Y['\A56BCE78+LM?VI=?\]C^0H_M2Z_Y['\A
M56BCE78+LM?VI=?\]C^0H_M2Z_Y['\A56BCE78+LM?VI=?\ /8_D*/[4NO\
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M0H_M2Z_Y['\A56BCE78+LM?VI=?\]C^0H_M2Z_Y['\A56BCE78+LM?VI=?\
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M0H_M2Z_Y['\A56BCE78+LM?VI=?\]C^0H_M2Z_Y['\A56BCE78+LM?VI=?\
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MM_E;$9%*_(K'/SCMV-9\TKV+Y5N?IG_P^-^#'_0L^.__   LO_DNOIC]F_\
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M?^ORW_\ 26&B<G%:!%79^@/_  ^-^#'_ $+/CO\ \ ++_P"2Z/\ A\;\&/\
MH6?'?_@!9?\ R77PI^R[^P%XP_:J\ :AXL\/^(M#TBRL]3DTMX-2,WF-(D44
MI8;$8;<3*.N<@U[#_P .:OB;_P!#MX3_ #NO_C59\TRK1/HK_A\;\&/^A9\=
M_P#@!9?_ "77T#^S'^UIX0_:NTG7=0\):=K>G0Z//';W"ZU!#$S,ZE@4\N63
M(PISDBOST_X<U?$W_H=O"?YW7_QJOLW]@?\ 9'\1_LF^'/%VG>(M8TO6)=9N
MX+B%M+,FU B,I#;U7GYATJXN5]1.UM#ZJHHHK0@**** "BBB@ HHHH ****
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MB2^)?$+BVLH0T.EZ1"Q,-A 3G8O]YC@%G(RQ'8!5'U)_P1J_Y+IXV_[%P_\
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M'P5^-F@^'(/!&JV_B#QKIFH$3ZE9V;K&+-HGWQF=E42?.(B NX#YN1SGS?\
MX)1WTMI^UYID4;;4NM(OH91ZJ$#X_P"^D7\JA-QE:Y3U5S]2/VTO'>O?#/\
M9A\>>)O#.HOI.NZ?;0O:WD:*S1,;B)20&!!^5B.1WK\N/@;_ ,%'OBMI/Q4T
M&^^('C[4-4\'V[RRZA8K9V^ZX18G*QC;&#EG"@<@9(R0,U^E/_!0S_DS7XF_
M]><'_I5#7X-Z5IMQK6J6>GVB>9=7<R6\*?WG9@JC\R*JHVGH**T/H/XN?\%
M/C5\4O&%QJ]OXUU;PCI_G;[/2/#]X]I#;H/NJQ0AI3ZER<DG@# '?^(OVO\
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M7Q^_X),W?Q$^-6IZ]X&UC0/!O@W4%CF;3S%*TEO<'(E$4*H$$9(# ;Q@L0
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MV,DD_,O_  6.^%.A1^!?"'Q%M[&&VU_^UAHUU=1(%>YBD@EE3S"/O%# <$]
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M@G^(U>T2>I^"GA7^S?\ A*-'_MEVCT?[9#]M=4+E8-X\PA1R?ESP*_5/6O\
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M<]-^WRR!UW(3]T52DT[2$XJUT?LW1116QF>7_M0>,)O /[.GQ)UZVD:&[L]
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MBTB;2PYV#)P02P.0/F']I?\ 9S\3?LJ_%!O"^MW,=WF-;W3=6LPR)=0EB%D
M/*.&4@KD[2.I&"6Y2W:T%9'] WA_PKHGA.W:WT/1]/T:W;&Z+3[5(%.!@9"
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MUMLU7Q+FSTSS%^:.PC?YG'IYLJ_]\Q(1]ZOBG6+K7/\ @H1^VD$MS/!9:YJ
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MFL:?5&DNYZO1116QF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M])WKYA_X)*_\G9I_V ;W^<=-_&)?"?6__!8S3Y[C]G+PO=1AFAM_%$/FA1P
MUK<@,?Q&/^!5\,_\$T=:M]&_;.\!FY=8TNEO;57?H'>SF"#ZEL+_ ,"K]@OV
MH_@G%^T-\"_%/@<R1P7M];B6PN).%BNHV$D))[*64*V.=K-7X"7%MXI^"_Q%
M"317?AOQ?X<OU<*Z[9K6XB<,I]#@@$'D$8/(-$])7".JL?THUYUX^_:(^&GP
ML\4V?ASQAXTTGPUK%Y;B[AM]2G\D-$690Y=OE +(PY(Z&O@/P;_P6=DM?"L,
M/BCX;M?^(88@KW6FZF(;>Y?NVQHV,7'8%^?3/'PA\??CCXC_ &DOBIJ/C+Q
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M^MW_  3%_9OU#X%_!.ZUOQ#9O8^)O%TL=[-:RC;);VJ*1;QNI&5?YY'([>8
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M2* JKIEL !T \I:^,?\ @L;_ ,FR>&?^QOM?_2*]K[/\ _\ (B^'/^P;;?\
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MA(.",@<&OV*_8S_;>@_:\UCQE;0^%6\+Q:#%9R0K)?"YDN!*9@Y.(T"A3&H
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M_P"#OC\?%;X4>#_&0MULVUW2;;47MD?>(7DB5FC#8&=K$KG'.*["N@R/@O\
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MX+51VOVCX0N,?;2NJAL=3&#:8S^);'U->8?LL_\ !4C7/@7\.[/P5XH\+_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[VGP0MK/QY\0;6&_^($J"2TL&Q)%HRD=NS3X/+#A>B]V/Y8? SXV:O\ L_\
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M_1G\-?!\7P]^'7A;PO#M\K1=+M=.4KT(BB6//X[:BGNV5+8Z2BBBMS,****
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M_/'>^--?M7$MO<:X4,%NX.5>.!5"[A@$%]Q!Y&#BOK2BBM$DMB3S/X[?LY^
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M_!83XYKKOC3PY\*].N-UMH:?VKJBJ>/M4J8A0CU2)F;Z3CTKZU_X)T_LS_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M^ -4_P"4EUG_ -A>T_\ 2*.OTOK\T-4_Y276?_87M/\ TBCK]+Z];.-L/_@1
MY.5;U_\ &S\T?^">=FU[^T+XV16"D:3<GYO^ON&OT1_L";_GHGZU^=/_  3Z
MF>']H+QJT;E#_95P,J?^GN&OT*_M"Y_Y[O\ G6N=<WUMV[+\B,GM]5U[LN?V
M!-_ST3]:/[ F_P">B?K5/^T+G_GN_P"=']H7/_/=_P Z\&TNY[?NES^P)O\
MGHGZT?V!-_ST3]:I_P!H7/\ SW?\Z/[0N?\ GN_YT6EW#W2Y_8$W_/1/UH_L
M";_GHGZU3_M"Y_Y[O^=']H7/_/=_SHM+N'NES^P)O^>B?K1_8$W_ #T3]:I_
MVA<_\]W_ #H_M"Y_Y[O^=%I=P]TN?V!-_P ]$_6C^P)O^>B?K5/^T+G_ )[O
M^=']H7/_ #W?\Z+2[A[I<_L";_GHGZT?V!-_ST3]:I_VA<_\]W_.C^T+G_GN
M_P"=%I=P]TN?V!-_ST3]:/[ F_YZ)^M4_P"T+G_GN_YT?VA<_P#/=_SHM+N'
MNES^P)O^>B?K1_8$W_/1/UJG_:%S_P ]W_.C^T+G_GN_YT6EW#W2Y_8$W_/1
M/UH_L";_ )Z)^M4_[0N?^>[_ )T?VA<_\]W_ #HM+N'NES^P)O\ GHGZT?V!
M-_ST3]:I_P!H7/\ SW?\Z/[0N?\ GN_YT6EW#W2Y_8$W_/1/UH_L";_GHGZU
M3_M"Y_Y[O^=']H7/_/=_SHM+N'NES^P)O^>B?K1_8$W_ #T3]:I_VA<_\]W_
M #H_M"Y_Y[O^=%I=P]TN?V!-_P ]$_6C^P)O^>B?K5/^T+G_ )[O^=']H7/_
M #W?\Z+2[A[I<_L";_GHGZT?V!-_ST3]:I_VA<_\]W_.C^T+G_GN_P"=%I=P
M]TN?V!-_ST3]:/[ F_YZ)^M4_P"T+G_GN_YT?VA<_P#/=_SHM+N'NES^P)O^
M>B?K1_8$W_/1/UJG_:%S_P ]W_.C^T+G_GN_YT6EW#W2Y_8$W_/1/UH_L";_
M )Z)^M4_[0N?^>[_ )T?VA<_\]W_ #HM+N'NES^P)O\ GHGZT?V!-_ST3]:I
M_P!H7/\ SW?\Z/[0N?\ GN_YT6EW#W2Y_8$W_/1/UH_L";_GHGZU3_M"Y_Y[
MO^=']H7/_/=_SHM+N'NES^P)O^>B?K1_8$W_ #T3]:I_VA<_\]W_ #H_M"Y_
MY[O^=%I=P]TN?V!-_P ]$_6C^P)O^>B?K5/^T+G_ )[O^=']H7/_ #W?\Z+2
M[A[I<_L";_GHGZT?V!-_ST3]:I_VA<_\]W_.C^T+G_GN_P"=%I=P]TN?V!-_
MST3]:/[ F_YZ)^M4_P"T+G_GN_YT?VA<_P#/=_SHM+N'NES^P)O^>B?K1_8$
MW_/1/UJG_:%S_P ]W_.C^T+G_GN_YT6EW#W2Y_8$W_/1/UH_L";_ )Z)^M4_
M[0N?^>[_ )T?VA<_\]W_ #HM+N'NES^P)O\ GHGZT?V!-_ST3]:I_P!H7/\
MSW?\Z/[0N?\ GN_YT6EW#W2Y_8$W_/1/UH_L";_GHGZU3_M"Y_Y[O^=']H7/
M_/=_SHM+N'NES^P)O^>B?K1_8$W_ #T3]:I_VA<_\]W_ #H_M"Y_Y[O^=%I=
MP]TN?V!-_P ]$_6C^P)O^>B?K5/^T+G_ )[O^=']H7/_ #W?\Z+2[A[I<_L"
M;_GHGZT?V!-_ST3]:I_VA<_\]W_.C^T+G_GN_P"=%I=P]TN?V!-_ST3]:/[
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MY_8$W_/1/UH_L";_ )Z)^M4_[0N?^>[_ )T?VA<_\]W_ #HM+N'NES^P)O\
MGHGZT?V!-_ST3]:I_P!H7/\ SW?\Z/[0N?\ GN_YT6EW#W2Y_8$W_/1/UH_L
M";_GHGZU3_M"Y_Y[O^=']H7/_/=_SHM+N'NC+CP#8W4[33V-C-,QRTDD"LQ^
MI(J__8$W_/1/UJG_ &A<_P#/=_SH_M"Y_P">[_G1:7<-"Y_8$W_/1/UH_L";
M_GHGZU3_ +0N?^>[_G1_:%S_ ,]W_.BTNX>Z7/[ F_YZ)^M']@3?\]$_6J?]
MH7/_ #W?\Z/[0N?^>[_G1:7</=+G]@3?\]$_6C^P)O\ GHGZU3_M"Y_Y[O\
MG1_:%S_SW?\ .BTNX>Z7/[ F_P">B?K1_8$W_/1/UJG_ &A<_P#/=_SH_M"Y
M_P">[_G1:7</=+G]@3?\]$_6C^P)O^>B?K5/^T+G_GN_YT?VA<_\]W_.BTNX
M>Z7/[ F_YZ)^M']@3?\ /1/UJG_:%S_SW?\ .C^T+G_GN_YT6EW#W2Y_8$W_
M #T3]:/[ F_YZ)^M4_[0N?\ GN_YT?VA<_\ /=_SHM+N'NES^P)O^>B?K1_8
M$W_/1/UJG_:%S_SW?\Z/[0N?^>[_ )T6EW#W2Y_8$W_/1/UH_L";_GHGZU3_
M +0N?^>[_G1_:%S_ ,]W_.BTNX>Z7/[ F_YZ)^M']@3?\]$_6J?]H7/_ #W?
M\Z/[0N?^>[_G1:7</=+G]@3?\]$_6C^P)O\ GHGZU3_M"Y_Y[O\ G1_:%S_S
MW?\ .BTNX>Z7/[ F_P">B?K1_8$W_/1/UJG_ &A<_P#/=_SH_M"Y_P">[_G1
M:7</=+G]@3?\]$_6C^P)O^>B?K5/^T+G_GN_YT?VA<_\]W_.BTNX>Z7/[ F_
MYZ)^M']@3?\ /1/UJG_:%S_SW?\ .C^T+G_GN_YT6EW#W2Y_8$W_ #T3]:T?
ML3?V;]FW#=C&>W6L+^T+G_GN_P"=+_:%S_SV?\ZEQD^H[HM_V!-_ST3]:/[
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M)O\ GHGZU1F\ V-Q<&>6RL99V.XR/ I8GUSC-._M"Y_Y[O\ G1_:%S_SW?\
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M]$_6C^P)O^>B?K5/^T+G_GN_YT?VA<_\]W_.BTNX>Z7/[ F_YZ)^M']@3?\
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MY_8$W_/1/UH_L";_ )Z)^M4_[0N?^>[_ )T?VA<_\]W_ #HM+N'NES^P)O\
MGHGZT?V!-_ST3]:I_P!H7/\ SW?\Z/[0N?\ GN_YT6EW#W2Y_8$W_/1/UH_L
M";_GHGZU3_M"Y_Y[O^=']H7/_/=_SHM+N'NGY_:[ ;7_ (*:6L3$$KJ]GR/^
MO*.OTJK\TM8D:3_@IA:,[%F.KV>2?^O*.OTMKV,XVP_^!'CY5O7_ ,;/S)_X
M)_\ _)P'C3_L%W'_ *5PU^@U?GS_ ,$__P#DX#QI_P!@NX_]*X:_0:NC.O\
M>WZ+\C+)_P#=?FPHHHKPCVPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ^ -4_P"4EUG_ -A>T_\ 2*.OTOK\T-4_Y276?_87M/\
MTBCK]+Z];.-L/_@1Y.5;U_\ &S\R?^"?_P#R<!XT_P"P7<?^E<-?H-7Y\_\
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MBCD7<.8V_M6F?W%_[]T?:M,_N+_W[K$HHY%W#F-O[5IG]Q?^_='VK3/[B_\
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MBCD7<.8V_M6F?W%_[]T?:M,_N+_W[K$HHY%W#F-O[5IG]Q?^_='VK3/[B_\
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M3/[B_P#?NL2BCD7<.8V_M6F?W%_[]T?:M,_N+_W[K$HHY%W#F-O[5IG]Q?\
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MCD7<.8V_M6F?W%_[]T?:M,_N+_W[K$HHY%W#F-O[5IG]Q?\ OW1]JTS^XO\
MW[K$HHY%W#F-O[5IG]Q?^_='VK3/[B_]^ZQ**.1=PYC;^U:9_<7_ +]T?:M,
M_N+_ -^ZQ**.1=PYC;^U:9_<7_OW1]JTS^XO_?NL2BCD7<.8V_M6F?W%_P"_
M='VK3/[B_P#?NL2BCD7<.8V_M6F?W%_[]T?:M,_N+_W[K$HHY%W#F-O[5IG]
MQ?\ OW1]JTS^XO\ W[K$HHY%W#F-O[5IG]Q?^_='VK3/[B_]^ZQ**.1=PYC;
M^U:9_<7_ +]T?:M,_N+_ -^ZQ**.1=PYC;^U:9_<7_OW1]JTS^XO_?NL2BCD
M7<.8V_M6F?W%_P"_='VK3/[B_P#?NL2BCD7<.8V_M6F?W%_[]T?:M,_N+_W[
MK$HHY%W#F-O[5IG]Q?\ OW1]JTS^XO\ W[K$HHY%W#F-O[5IG]Q?^_='VK3/
M[B_]^ZQ**.1=PYC;^U:9_<7_ +]T?:M,_N+_ -^ZQ**.1=PYC;^U:9_<7_OW
M1]JTS^XO_?NL2BCD7<.8V_M6F?W%_P"_='VK3/[B_P#?NL2BCD7<.8V_M6F?
MW%_[]T?:M,_N+_W[K$HHY%W#F-O[5IG]Q?\ OW1]JTS^XO\ W[K$HHY%W#F-
MO[5IG]Q?^_='VK3/[B_]^ZQ**.1=PYC;^U:9_<7_ +]T?:M,_N+_ -^ZQ**.
M1=PYC;^U:9_<7_OW1]JTS^XO_?NL2BCD7<.8V_M6F?W%_P"_='VK3/[B_P#?
MNL2BCD7<.8V_M6F?W%_[]T?:M,_N+_W[K$HHY%W#F/@?Q T;_P#!3:V,(Q'_
M &O9XP,?\N4=?I17YH:I_P I+K/_ +"]I_Z11U^E]>QG&V'_ ,"/'RK>O_C9
M^9/_  3_ /\ DX#QI_V"[C_TKAK]!J_/G_@G_P#\G >-/^P7<?\ I7#7Z#5T
M9U_O;]%^1ED_^Z_-A16;XDE>#P[JDD;M'(EK*RNIP5(0D$'L:_ GP#\8OVBO
MBCXFM_#WA3XC?$37-;N%=XK*U\27AD=44LQ&91T )_"O E+E/=2N?T$45^)G
M_"N?VY/^?OXL_P#A0W7_ ,?J'4]?_;7^#=C_ &WJ=]\2[:PM,RR75^\VHP1*
M.K2[_,4+_O\ %3S^0^7S/VYHK\\?V%?^"E5]\6O%5C\//B@EK%XAOOW>EZ]:
MQB)+R7M#-&HVHY'W67"DC;@$C/Z'5::EJB6K!17X]?MX?'3XD^#_ -MO7="T
M'X@^*M$T2.72PFFZ=K5S;VRA[6!GQ&CA1N+,3QR2?6OV%I*5VP:L%%%%4(**
M** "BBB@ HHHH **** "BBODK_@IYXV\1> ?V8GU7PQKVJ>'-4_MJTB^VZ3>
M26LVQA)N7?&P;!P,C/:DW97&?6M%?%__  2D\?>)_B+^SOXBU+Q7XCU;Q/J,
M7BFXMX[S6;Z6[F2(6EFPC#R,2%#,QQG&6)[FOM"A.ZN#T"BBBF(**** "BBB
M@ HHHH **** "BBB@ HHK\>O^"E'QT^)/@3]JK6M)\-?$'Q5X>TJ/3[)TL=*
MUJYM8%9H06(2-PH)/)..:F4N57&E<_86BBBJ$%%%?CUI_P =/B2__!21O##?
M$'Q4WAO_ (6')9?V.=:N?L?V<7C*(?)W[-FWC;C&.,5,I<HTKG["T4450@HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **_'K4/CI\24_X*2+X87X@^*E
M\-_\+#CLO['&M7/V/[.;Q5,/D[]FS;QMQC'&*_86IC+F&U8****H04444 %%
M%% !117PK^VY_P %%+SX"^-YOAOX-T-9_%2I UUK&I &VM5E567RHP<R/M8'
M+84'L])NVXTKGW5117YG?\%2?&'Q<\.?%[PG!\/=;\:Z7IDFA![B/PS=W<,+
M2_:)1EQ"0"VT+R>< 42=E<$KGZ8T5P_P+N=1O/@C\/;C5Y;J?5I?#NGR7DM\
MS-.\QMHS(TA;YBY;.2><YS7<4Q!1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%?"OQ)_X**7G_  U9X:^#7@[0UMX5\4VNB:UK.I ,\@-PJ2QV
M\8.%&,CS&)/)PH.#2;2W':Y]U4444Q!1110 4444 %%%% !1110 4444 %%%
M% !1110 445^7_\ P5F^+_CSX<?%3P3:>$O&WB+PO:W&BO+-!HNJSVB2/Y[#
M<RQNH)P,9-*3Y5<:5S]0**\Z_9OU2]US]G?X7:EJ5Y<:AJ-YX6TNXN;RZE:6
M:>5[2)GD=V)+,S$DDG)))-?FW^WSXZ^-NB_M::U9>#?$/CZP\-K%8&*WT*]O
MH[,$P1E]JQ,$Y;.<=\YI.5E<$KGZTT4450@HHHH **** "BBB@ HHHH ****
M "BBB@ HKP_]MSQ%JOA/]E7XBZMHFIWFC:K:Z>KV]]I]P\$\+>=&,HZ$,IP2
M,@]Z^6O^"0_Q2\:?$K_A;'_"7^+M>\5?8O[)^R_VWJ<UYY&_[;OV>8S;=VQ,
MXZ[1GH*GFUL.VES]%:***H04444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>?$^VG\9>*KA$FN;?[7+;V=H^,F)!$ZM)@G!9F(;'"@<&5*3T0[);G2>!?\
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M'<H/#2L-B+NR%!=@#\P/Z@M_P3!_9Y;PR=)'A"[6X*;?[6&K77VL/C'F??\
M+SWQLVY_AJ$Y26@[);GJ7P#_ &J/AQ^TIIUQ/X(US[5>VJ![O2KN,P7EN"<
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M<PBF8?\ ;0S29]_:OVI\-^'=.\(>'M-T/1[2.QTK3;:.TM;:(86*)%"JH^@
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M+1/_ $BLZ*FP1W/V[4!0 !@#@ 5\B?\ !5+_ ),\U[_L)6'_ */%?7E?(?\
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M=8\1WW[:'@3Q;-HLVESZMXQ@GN([.UDC@A%U=;9$0,25C E8<L2%ZDU^L_\
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M1J_Y(7XV_P"QD/\ Z2PUZ+_P52_Y,\U[_L)6'_H\5YU_P1J_Y(7XV_[&0_\
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M@^$?PU\1>,[O3;S5[31+1KV>TT\(9FC7ERNYE'RKECD]%/TKQ#]D3]NKP_\
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MCM;4D_);4OAW^TK^PKX@O[O3X]>\-6A/[W5M'!NM*NE7E6<[6C/!.!*H89/
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MK+J1F4&#PY>2*"<9)E@7 ]>&/Y5^Q?BS1!XF\*ZSH[$*NH64UH2PR!YB,O\
M6OQ>_P""6NI'PU^V5I6FW>;:XO=/U"P,4G!\Q8S(4/O^Y/Y5G+XD6MF?MM11
M16A 5^*W_!6K_D[-_P#L V7\Y*_:FOQ6_P""M7_)V;_]@&R_G)6=3X2X[G[*
M^%O^19TC_KSA_P#0!6I67X6_Y%G2/^O.'_T 5J5H0%4=<UJR\-Z+J&KZE.+;
M3K"WDNKF8@D1Q(I9VP!DX4$\>E7JP_'7A=?&W@GQ#X=>X:T35].N-/:X5=QB
M$L31E@,C.-V<9[4 ?BWXT^*VG_MW?M:6E[XY\46?@;X;63%(/[4NTMQ;Z?&P
M)1-QP;B8D9(S@MW6,"OU.T#]JG]GSPMH>GZ-I'Q,\&Z?I>GP):VMI!J<2I#$
MBA511GH  *^2?^'+6B_]%5O_ /P2I_\ 'J/^'+6B_P#15;__ ,$J?_'JQ7,N
MAH[,^?\ _@JE\3O"?Q4^.7AC4_!_B+3O$NGP>'([:6YTRX6:-)1=7#%"5/!P
MRG'H17Z0_L]_M,?"B\^&_P -O#$'Q#\.R^(7TC3=/73$U",SFY\B-/*"9SOW
M?+CUK\D?VU?V6[7]DWXD:-X7M/$,WB2/4-)34C<S6HMRA::6/9M#-D?NLYSW
MK[7_ &:?^"7NEZ+?_##XIK\0;R6X@.F^(AIATM A;$<_E;_-SC/R[L>^*4>;
MF>@.UC]'JKW^GVNJ6KVU[;0WEN_#0W$8=&^H(Q5BBMS,@LK&VTVV2WM+>*UM
MTX6*% B+] .!7Y5_M:^(+[]N3]M3PU\&/#5W(/"WANXDM;V[AY5)%.Z^N/0[
M%01+G^-2 ?GK[A_;8_:'C_9M^ FM>(;:11XBOO\ B6Z+&QY-U(IQ)CN(U#2'
ML=H'\5>#_P#!*/\ 9Y;P3\,[[XIZY"[>(_%^5M'GY>.P5\ALGG,L@+G/54C/
M>HEJ^4I::GK?[87QVL_V-?V;[<^%;>TM=5V0Z'X<L9%W1P[4QOV]UBC0GG@M
ML!^]7Q)\(_V-?C_^U=X-A^)_B+XL7VBSZINN-+34;JXDEF3) D"HP6",Y;:%
M'W>0H!&>X_X+575RL7PBMQD6;-JLAQT,@^R 9^@8_F:^]_V=5MU_9]^&0M H
MM/\ A&-,\G:.-GV2+;C\,4OBE9CV1\)?L2?M3?$7X9_M WWP ^-&K7&J7'GO
M8Z??:A,9YX+M1NCC\X_-)%*G*%LG)C P&('Z85^0?[8;26O_  5(\*2Z0I;4
M_P"U_#K;?[TVZ */H5""OU\IQZH4NX5^'O[(<W_",_\ !1S1(H/N1^(]5LQC
M^ZT=S%_)J_;Z>>.UADFF=8XHU+N[' 50,DFOQ _X)\Z?)\0/V\/#VJHI>"*Z
MU+5YFV]%\F;:3Z?/(@_&E/=#CU/W#HHHK0@**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *W!_R
M ?\ @/\ 6L.MP?\ (!_X#_6LY]"HF'1116A(4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 ?AO^Q[&OA?_ (**>'K69?)^S^(=
M3LBKC&&,5S$!]<D"OW(K\1?VFK.?]F#_ (*)7/B>6)OL">(K;Q7%L7_76\TH
MFF '^]Y\?U4U^UVC:Q9>(=(LM4TVZCO=.O84N;:YA;<DL;J&5U/<$$'\:SAU
M1<NY;Z<FOPZ_X)YC_A(/V^/"=ZI\V(W.JW9?ID&SN<'CW9:_7+]J/XM67P2^
M ?C3Q9=W"P3VVGRPV*YYDNY%*0(!W^=E)QT 8]J_-[_@CS\+;K6_C#XF\=S0
M-_9>AZ8;&*8C -U.R\ ]\1))G'3>OKRI?$D"V9^NM%%%:D!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\ :I_P I+K/_ +"]
MI_Z11U^E]?FAJG_*2ZS_ .PO:?\ I%'7Z7UZV<;8?_ CR<JWK_XV?F3_ ,$_
M_P#DX#QI_P!@NX_]*X:_0:OSY_X)_P#_ "<!XT_[!=Q_Z5PU^@U;YU_O;]%^
M1ED_^Z_-F=XBADN/#^J11(TDLEK*JHHR6)0@ 5^#G@']GG]I7X7>)K?Q#X4^
M'_C30];MU=(KVUTR02(KJ58#*GJ"1^-?OI17@2CS'NIV/Q@_X2+]N_\ YY?$
MK_P7M_\ $51U;0_VX?B- VCZA!\29+:=2DD,C2644BGJKME%(]F-?M;14\GF
M/F\C\H?V:/\ @DQXGU+Q'8Z[\8IK;2=%@D69_#UG<">ZNR#GRY94)2-"<9*L
MS$9 V_>'ZM6]O%9V\4$$2001*$CCC4*J*!@  <  =JDHJHQ4=B6[GY$?MS_L
MY_%#QU^VGKGB/P]X"U_6=!EETPQZC96$DD#!+:!7PP&."K _0U^N]%%"C:[!
MNY^9'[;'_!-+7]2\:7WQ&^#,2RSWDYO;WPY%*MO+#<9W&:T8D#ELL4R"&^[G
M(5?-]!_;@_:^^%]FGAO6?!]YK-] ODI-XA\-737?! !W1E/,/&-S!BV<DD\U
M^O\ 12Y=;H?-W/QE7]GO]J/]N_QQ8ZKX^M=1T+1HFV+?:_;&QM+&(XW?9[0A
M6<D#JJ_,0-SCK7ZJ?L__  +\._LY_##3/!7AM&>VM<RW%Y*H$MY<-CS)I,=S
M@ #LJJO05Z-13C&VH-W/(_VGOV;?#O[4/PQN?">NNUE<HXN=-U6*,/+8W !
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M1X/B\%Z=K/Q%EOK&1M6N-,L6>.WND?HJJ"50HZ!=W)*.>/NC]<_@?J6I:O\
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MVHU2U: S!!<[]NX<XW+G_>%?H%15<NMR;Z6"OR(_;,_9S^*'C+]NK7O$^A>
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MUS0;BWTCX@:7"8;>YN 1#?0Y)$$Q )7!)*N <;F!!!ROUI11RZ687UNC\6_
M_CK]KG]BB&7PS%X:UJ308Y"8[/4-+?4M/4YY\B:/(4'KM1P.<XR<U:\??$[]
MK[]LFSC\*-X1UJS\/W[A9;/2]&ET^PEYR/.N9N-H*YP\FW(Z$@5^S5%3R=+E
M<WD?(?[!O["MO^RYI=UXB\236^J?$+4X3!+-:L6M["W)#>3$2!N9BJEWQ_"
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MB7^D:!:D2PMJ%C)I>D6@;@RJ'&Z9\$\CS' .. :_5#]G+X!:!^S7\*]-\%Z
M6G2$FXO;Z08DO+I@/,F8=L[0 .RJHR<9/IU%-1MJ#=PHHHJB0HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^ -4_Y276?_87M
M/_2*.OTOK\T-4_Y276?_ &%[3_TBCK]+Z];.-L/_ ($>3E6]?_&S\R?^"?\
M_P G >-/^P7<?^E<-?H-7P)_P3MN(;?]H;QLTR[E.DW('&>?M<-?HM_:=C_S
MQ_\ '!6N=2:Q;TZ+\B,G7^R[]68E%;?]IV/_ #Q_\<%']IV/_/'_ ,<%>#S/
ML>W9=S$HK;_M.Q_YX_\ C@H_M.Q_YX_^."CF?8++N8E%;?\ :=C_ ,\?_'!1
M_:=C_P \?_'!1S/L%EW,2BMO^T['_GC_ .."C^T['_GC_P"."CF?8++N8E%;
M?]IV/_/'_P <%']IV/\ SQ_\<%',^P67<Q**V_[3L?\ GC_XX*/[3L?^>/\
MXX*.9]@LNYB45M_VG8_\\?\ QP4?VG8_\\?_ !P4<S[!9=S$HK;_ +3L?^>/
M_C@H_M.Q_P">/_C@HYGV"R[F)16W_:=C_P \?_'!1_:=C_SQ_P#'!1S/L%EW
M,2BMO^T['_GC_P"."C^T['_GC_XX*.9]@LNYB45M_P!IV/\ SQ_\<%']IV/_
M #Q_\<%',^P67<Q**V_[3L?^>/\ XX*/[3L?^>/_ (X*.9]@LNYB45M_VG8_
M\\?_ !P4?VG8_P#/'_QP4<S[!9=S$HK;_M.Q_P">/_C@H_M.Q_YX_P#C@HYG
MV"R[F)16W_:=C_SQ_P#'!1_:=C_SQ_\ '!1S/L%EW,2BMO\ M.Q_YX_^."C^
MT['_ )X_^."CF?8++N8E%;?]IV/_ #Q_\<%']IV/_/'_ ,<%',^P67<Q**V_
M[3L?^>/_ (X*/[3L?^>/_C@HYGV"R[F)16W_ &G8_P#/'_QP4?VG8_\ /'_Q
MP4<S[!9=S$HK;_M.Q_YX_P#C@H_M.Q_YX_\ C@HYGV"R[GG/Q7\ 6_Q6^&7B
MKP;=7#6<&O:9<:<UTJ;S#YL;() N1DJ2&QD9Q7Y^>%_^"+NG6OB2.7Q#\3[C
M4="C<%K73](%M<3+W7S&F=8_KM;/M7ZD_P!IV/\ SQ_\<%']IV/_ #Q_\<%2
M]=T-:=3BO!G@W1?A[X5TOPWX=T^+2M$TR!;>UM(0=L:#W/)).22<DDDDDFMJ
MMO\ M.Q_YX_^."C^T['_ )X_^."JYGV%9=S$HK;_ +3L?^>/_C@H_M.Q_P">
M/_C@HYGV"R[F)16W_:=C_P \?_'!1_:=C_SQ_P#'!1S/L%EW,2BMO^T['_GC
M_P"."C^T['_GC_XX*.9]@LNYB5Y!^U'^SCIO[47PTB\&ZIK%UHEM'J$5_P#:
MK.-7<LBNH7#<8.\_E7O7]IV/_/'_ ,<%']IV/_/'_P <%+F;Z#MYG@'[*_[-
M>F?LK_#B[\(:5K-WKEM<:E+J1N;R-8W#/'$A7"\8 B!_$U[)6W_:=C_SQ_\
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M_M.Q_P">/_C@H_M.Q_YX_P#C@HYGV"R[F)16W_:=C_SQ_P#'!1_:=C_SQ_\
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M?]IV/_/'_P <%']IV/\ SQ_\<%',^P67<Q**V_[3L?\ GC_XX*/[3L?^>/\
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MP4<S[!9=S$HK;_M.Q_YX_P#C@H_M.Q_YX_\ C@HYGV"R[F)16W_:=C_SQ_\
M'!1_:=C_ ,\?_'!1S/L%EW,2BMO^T['_ )X_^."C^T['_GC_ .."CF?8++N8
ME%;?]IV/_/'_ ,<%']IV/_/'_P <%',^P67<Q**V_P"T['_GC_XX*/[3L?\
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M_P#'!1S/L%EW,2BMO^T['_GC_P"."C^T['_GC_XX*.9]@LNYB45M_P!IV/\
MSQ_\<%']IV/_ #Q_\<%',^P67<Q**V_[3L?^>/\ XX*/[3L?^>/_ (X*.9]@
MLNYB45M_VG8_\\?_ !P4?VG8_P#/'_QP4<S[!9=S$HK;_M.Q_P">/_C@H_M.
MQ_YX_P#C@HYGV"R[F)16W_:=C_SQ_P#'!1_:=C_SQ_\ '!1S/L%EW,2BMO\
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MX*.9]@LNYB45M_VG8_\ /'_QP4?VG8_\\?\ QP4<S[!9=S$HK;_M.Q_YX_\
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M_P <%',^P67<Q**V_P"T['_GC_XX*/[3L?\ GC_XX*.9]@LNYB45M_VG8_\
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M_P"T['_GC_XX*/[3L?\ GC_XX*.9]@LNYB45M_VG8_\ /'_QP4?VG8_\\?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 ? &J?\ *2ZS_P"PO:?^D4=?I?7Y
MH:I_RDNL_P#L+VG_ *11U^E]>MG&V'_P(\G*MZ_^-GYD_P#!/_\ Y. \:?\
M8+N/_2N&OT&K\^?^"?\ _P G >-/^P7<?^E<-?H-6^=?[V_1?D99/_NOS844
M45X1[84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!\ :I_RDNL_^PO:?^D4=?I?7YH:I_RDNL_^PO:?^D4=?I?7K9QMA_\  CR<
MJWK_ .-GYD_\$_\ _DX#QI_V"[C_ -*X:_0:OSY_X)__ /)P'C3_ +!=Q_Z5
MPU^@U;YU_O;]%^1ED_\ NOS84445X1[84444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!\ :I_P I+K/_ +"]I_Z11U^E]?FAJG_*
M2ZS_ .PO:?\ I%'7Z7UZV<;8?_ CR<JWK_XV?F3_ ,$__P#DX#QI_P!@NX_]
M*X:_0:OSY_X)_P#_ "<!XT_[!=Q_Z5PU^@U;YU_O;]%^1ED_^Z_-A1117A'M
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'P!J
MG_*2ZS_["]I_Z11U^E]?FAJG_*2ZS_["]I_Z11U^E]>MG&V'_P "/)RK>O\
MXV?FA_P3SLWO/VA/&R(5!&E7)^;_ *^X:_1'^P;C^_'^9_PK\Z_^"?,\EO\
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M?WX_S/\ A5;^TKK_ )[-1_:5U_SV:CWNX:%G^P;C^_'^9_PH_L&X_OQ_F?\
M"JW]I77_ #V:C^TKK_GLU'O=PT+/]@W']^/\S_A1_8-Q_?C_ #/^%5O[2NO^
M>S4?VE=?\]FH][N&A9_L&X_OQ_F?\*/[!N/[\?YG_"JW]I77_/9J/[2NO^>S
M4>]W#0L_V#<?WX_S/^%']@W']^/\S_A5;^TKK_GLU']I77_/9J/>[AH6?[!N
M/[\?YG_"C^P;C^_'^9_PJM_:5U_SV:C^TKK_ )[-1[W<-"S_ &#<?WX_S/\
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M?WX_S/\ A5;^TKK_ )[-1_:5U_SV:CWNX:%G^P;C^_'^9_PH_L&X_OQ_F?\
M"JW]I77_ #V:C^TKK_GLU'O=PT+/]@W']^/\S_A1_8-Q_?C_ #/^%5O[2NO^
M>S4?VE=?\]FH][N&A9_L&X_OQ_F?\*/[!N/[\?YG_"JW]I77_/9J/[2NO^>S
M4>]W#0L_V#<?WX_S/^%']@W']^/\S_A5;^TKK_GLU']I77_/9J/>[AH6?[!N
M/[\?YG_"C^P;C^_'^9_PJM_:5U_SV:C^TKK_ )[-1[W<-"S_ &#<?WX_S/\
MA1_8-Q_?C_,_X56_M*Z_Y[-1_:5U_P ]FH][N&A9_L&X_OQ_F?\ "C^P;C^_
M'^9_PJM_:5U_SV:C^TKK_GLU'O=PT+/]@W']^/\ ,_X4?V#<?WX_S/\ A5;^
MTKK_ )[-1_:5U_SV:CWNX:%G^P;C^_'^9_PH_L&X_OQ_F?\ "JW]I77_ #V:
MC^TKK_GLU'O=PT+/]@W']^/\S_A1_8-Q_?C_ #/^%5O[2NO^>S4?VE=?\]FH
M][N&A9_L&X_OQ_F?\*/[!N/[\?YG_"JW]I77_/9J/[2NO^>S4>]W#0L_V#<?
MWX_S/^%']@W']^/\S_A5;^TKK_GLU']I77_/9J/>[AH6?[!N/[\?YG_"C^P;
MC^_'^9_PJM_:5U_SV:C^TKK_ )[-1[W<-"S_ &#<?WX_S/\ A1_8-Q_?C_,_
MX56_M*Z_Y[-1_:5U_P ]FH][N&A9_L&X_OQ_F?\ "C^P;C^_'^9_PJM_:5U_
MSV:C^TKK_GLU'O=PT+/]@W']^/\ ,_X4?V#<?WX_S/\ A5;^TKK_ )[-1_:5
MU_SV:CWNX:%G^P;C^_'^9_PH_L&X_OQ_F?\ "JW]I77_ #V:C^TKK_GLU'O=
MPT+/]@W']^/\S_A1_8-Q_?C_ #/^%5O[2NO^>S4?VE=?\]FH][N&A9_L&X_O
MQ_F?\*/[!N/[\?YG_"JW]I77_/9J/[2NO^>S4>]W#0L_V#<?WX_S/^%']@W'
M]^/\S_A5;^TKK_GLU']I77_/9J/>[AH6?[!N/[\?YG_"C^P;C^_'^9_PJM_:
M5U_SV:C^TKK_ )[-1[W<-"S_ &#<?WX_S/\ A1_8-Q_?C_,_X56_M*Z_Y[-1
M_:5U_P ]FH][N&A9_L&X_OQ_F?\ "C^P;C^_'^9_PJM_:5U_SV:C^TKK_GLU
M'O=PT+/]@W']^/\ ,_X4?V#<?WX_S/\ A5Z2XD&CB4,?,V@[OQK(_M*Z_P">
MS5*YF/1%G^P;C^_'^9_PH_L&X_OQ_F?\*K?VE=?\]FH_M*Z_Y[-5>]W%H6?[
M!N/[\?YG_"C^P;C^_'^9_P *K?VE=?\ /9J/[2NO^>S4>]W#0L_V#<?WX_S/
M^%']@W']^/\ ,_X56_M*Z_Y[-1_:5U_SV:CWNX:%G^P;C^_'^9_PH_L&X_OQ
M_F?\*K?VE=?\]FH_M*Z_Y[-1[W<-"S_8-Q_?C_,_X4?V#<?WX_S/^%5O[2NO
M^>S4?VE=?\]FH][N&A9_L&X_OQ_F?\*/[!N/[\?YG_"JW]I77_/9J/[2NO\
MGLU'O=PT+/\ 8-Q_?C_,_P"%']@W']^/\S_A5;^TKK_GLU']I77_ #V:CWNX
M:%G^P;C^_'^9_P */[!N/[\?YG_"JW]I77_/9J/[2NO^>S4>]W#0L_V#<?WX
M_P S_A1_8-Q_?C_,_P"%5O[2NO\ GLU']I77_/9J/>[AH6?[!N/[\?YG_"C^
MP;C^_'^9_P *K?VE=?\ /9J/[2NO^>S4>]W#0L_V#<?WX_S/^%']@W']^/\
M,_X56_M*Z_Y[-1_:5U_SV:CWNX:%G^P;C^_'^9_PH_L&X_OQ_F?\*K?VE=?\
M]FH_M*Z_Y[-1[W<-"S_8-Q_?C_,_X4?V#<?WX_S/^%5O[2NO^>S4?VE=?\]F
MH][N&A9_L&X_OQ_F?\*/[!N/[\?YG_"JW]I77_/9J/[2NO\ GLU'O=PT+/\
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M^>S4?VE=?\]FH][N&A9_L&X_OQ_F?\*/[!N/[\?YG_"JW]I77_/9J/[2NO\
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M_P"".7_)LGB;_L;[K_TBLJGF]ZQ5M+GW;1115$A1110 4444 %%%% !1110
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M\'?LL^$9;G5+B/4O%5S$3I?AV&0>?<-T#OC/EQ ]7/7!"Y/%?E3^RM\3-?\
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M**LD***^;_VYOVLH?V5?A;%>6,,=YXPUQI+71K:7E$95!DN)!W2/<G'=G0<
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M#785^4G[0T.I?\$]_P!MK3OB3X;MI%\!>,"\]]IT Q'(K.OVRW Z!E8K,G0
MNHZ BE)VU!*Y^K=%9WAWQ!IWBS0--UO2+J.^TK4K:.[M+J+[LL4BAD<>Q!!K
M1JA!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!\ :I_RDNL_^PO:?^D4=?I?7YH:I_P I
M+K/_ +"]I_Z11U^E]>MG&V'_ ,"/)RK>O_C9^9/_  3_ /\ DX#QI_V"[C_T
MKAK]!J_/G_@G_P#\G >-/^P7<?\ I7#7Z#5OG7^]OT7Y&63_ .Z_-F3XN\3V
M'@GPKK/B'5)?)TS2;.:_NI/[L42%W/Y*:_"WX$^#M0_;=_;%@_X26>62'7-0
MGUC6'WEBEK'ES"I[# 2%?[H*^E?KE^W1JLFC_LB_%*XB#%GT=[<[?[LK+$WZ
M.:_/_P#X(U:7#/\ '#QOJ#!3/;>'O)3/4"2YB+$?]^Q^=?.RUDD>]'9L_6S3
M-,L]%TVUT_3[6&QL+6)8(+:WC"1Q1J %15'     '3%6J**U(/.?VAO@UIOQ
M]^#OB7P3J*0[M1M6^QW$R;OLMTHS#,.XVOC..HW#H37R=^P/^PM\3_V8?B!=
M^)?$7B;0QI>I6+6E[HFG/+.TG(:-B[(BJR,.HW<,PSS7WO12Y5>X[Z6(+Z^M
MM+L;B\O;B*TL[>-I9KB=PD<2*,LS,>   22>F*^"?C)_P5\\!>#=4N=-\"^&
M[SQR\)*'499_L-FS9QE"49W'N54'L<<U['_P4$\!_%#XJ? A_!_POTK^T[S5
M;V-=447L%L39H"QC#2NHRT@CS@_=5@>O/EG_  3Y_8-T[X6^#9/%7Q.\)6L_
MC^[N9!!::HD5RNFVZ':I11N02.0S%P20I4#'S9EMWLAJUKL\/C_X+0>*Q=;G
M^&FC-;;C^[7490^.PW;2,^^VOJ7]EW_@I%X!_:.\06WA>[T^Z\%^+KH'[-87
MLRSV]TP&2D4X"Y? /RLBYQQD\5]+>(OASX5\7Z2^EZYX;TG5M.>,Q&UO+*.6
M/:<Y !''WCT]37X<?MC_  WM/V6_VMM3M/!?F:;8V%Q::WI";RQM2P64*I)S
MA) P&3G &<]:E\T=;C5I'[TU\@:7_P %%-'OOVH[SX-W/A&73_LFI7>GS>()
M]300HMO'([2LAC&%Q&>K<9Z\5]=6LWVFVBF V^8@?'ID9K\ /VIK/4-2_;'^
M)>GZ4T@U"^\3WEE"L;E2YEE:/9D=F#E3Z@D54Y.-K"BKGVO\4O\ @LA:Z/XS
MNK#P-X'BUWP_:RF,:IJ5X\#W@!P7CC"'RU/8L22,$JO2OLG]E']HR']J+X41
M>-(/#MYX:'VJ2R>VNI%E1W0*6>)Q@NF6VY*J<JPQQD\#\*_^"<WP5\!^ ++1
M-9\'6'BK5V@4:AJ^H[WEGFP-[1\_NEST"8XZY.2<;]K[Q1I7[%?[&-UH?P]@
M&@_:)/[#T:-9'=K=KAI))I [$L6""9@Q)(;::2YEJPTV1C?M+?\ !43P'\#]
M>OO#/AK3)?'GB6R?RKG[/<K!8V\@^\C388NZ]U52 006!! \+\,_\%H=0_ME
M1XA^&5L=)9^6TS4V\^)>><.FUSTXRO?FL#_@EW^QSX;^*UIJ/Q0\<Z<FLZ=I
M]]]BTG2KI=UO-,BJ\DTJ'B15WJJJ?E)#Y!P*_3SQ9\*?!OCKPW+X?U_POI.J
MZ-(AC^QW%HA10<_<X^0C)P5P0>0127-+6X]%H?D)_P %-/C5X2^/GB;X:^+/
M!NIKJ.ESZ%(CHPV36THG;=%*G5'&1QT((()!!/ZK_LM_\FR?"+_L4-(_](HJ
M_%7]M[]FQ/V8?CE>^'-/>:?PW?P+J6D2SG<X@=F4QLW=D='7/4@*3UK]JOV6
M_P#DV3X1?]BAI'_I%%1&_,[A+9'S]^TA_P %*--_9W^-%_\ #VX\!W6MS6J6
MSF_BU)85;SHU<?(8VQC=CKVK[0K\0_\ @IE_R>]X@_ZXZ9_Z315^VM]--;V5
MQ+;P&ZN$C9HX P4R, 2%R>!D\9/'-5%MMB:T1\]?M.?MV?#?]F"<:5J\UQKW
MBMXQ*NA:4%:6-3]UIG)"Q ]0#EB,$*0<U\;ZU_P6BU^6Z8Z3\,--MK;)P+W5
M9)G([<K&@!Z^O7\\KX0_\$^/BK\3OVH9_$/QX\.20^'[J>?6-3N8]1@ECOI2
MV4MU,4C,JEB/EPN$0@;>*_4G0?A[X7\+Z2FEZ-X;TG2M-1!&MG9V44404$$#
M:J@8R ?P%+WI>0]$?GW\,?\ @LMHNI:I!9^/? 5QHEH[!6U/1KS[4$SQEH'1
M6V@\DAV..@..?T/\*^*=)\;^'--U_0;^'5-'U&!;FUO+=LI+&PR"/\#R#D'F
MOSO_ ."KG[,W@G0_A;8_$KPYH-GH.O6^IQ6=^VG0K#'=PRHP#.BX4NK*F& R
M0QSGC'HG_!(7Q->ZU^S!J>GW<K2PZ/XCN;6T#'B.)X8)BH_[:2R-_P "HBW>
MS!I6NC[9O]0M=*L;B]O;F&SL[>-I9KBX<)'&BC+,S'@  9)-? _QI_X*^>"/
M!FL7&E> O#5UXXDMY#')J<]R+*S;!Y,1VN\@[9*H.X)'7(_X+ ?'B^\,^$O#
M?POTF[\@Z^KZCJX0X=K6-P(8_P#=>0.3_P!<0.A-=/\ \$Y?V*?"7A/X2Z#\
M1?%NA6>N^+_$$"ZA:'4(5FCT^U<9A\I&! =T(<OC(W!1C!R-MNR!)6NSR;PS
M_P %H]12\1?$/POM9K5G >33-6:-XUR,D*\3!R!GC<N>.17WY\ _VB_ _P"T
MIX1?Q!X)U)[J&!Q#>65U'Y5U9R$9"2IDXR.C*2IP<$X.+7Q8^ /@+XU>$[OP
M_P"*O#=C?6TT1BBN%@1;BU.W"O#)C*,O;''&"",BOSI_8Q_9H^.?[-_[6DDD
M'A34KGP(MY<:1J>IM+%!;W=GEA%<JKN"X#+'( H+8R!R:/>B]=0T:/U9HHHK
M0@9--';PO+*ZQ11J6=W.%4 9))["O@?X[?\ !7+P5X!UVYT7P%X>E\=SVTIB
MFU22[%K8D@X)B8*[2C(QG"J>H+#KL?\ !63XY7OPU^!NG>#])N?LVH>,[B2V
MN'4X<6,2J9E!'3<SQ(?56<=ZX;_@F+^Q?X5?X=:=\7/&.DPZWK>J22-H]I?Q
MB2"S@1S&)?+/#2,RL0QSM7:5P236;;O9%)*UV87P]_X+-+<:U#!XW^'BVFF2
M. ]]HEZ9)(5XY\F11O[GAQ]*^7?^"C'CO0/B9^TM=^)O#&J0:QH>HZ1836UY
M;G*L/) ((/*L#D%2 0000"*_9SXJ? ;P'\:/"MQX?\6>&K#4;*2,QQR^2J3V
MQQ@/#(!NC8<8(/;!R.*_ _\ :-^#%Y^S[\:/$_@2[E:Z72[C_1KIEP;BW=0\
M,A[9*,N0. VX=JB=TM2XV/Z+Z^+[C_@I1IMO^TX/@X? =TUR?$B^'?[6_M)=
MFYIQ%YOE^7G'.=N[\:^T*_$/4O\ E*<G_938O_2Y:TDVK6(BKG[=].37P;\?
MO^"M'@OX9^)+_P />"?#TWCJ^LI&@GU(W8MK 2*<'RV"NTH!!&0%4]F(YKW;
M]O3Q%JWA?]D/XEZAHDDL-_\ V>EOYD)(=8I9XXIB".F(W?FO@S_@D9X7^&'B
M+Q=XMD\4VVEZCXYMQ;MHMKJR1OMA^<RR6Z/UD#!,L!N48Q@,U$F[V0):79MZ
M/_P6B\0Q7:G5?AAIES;9&5L]5DA<#O@M&X_2OM/]E[]MKX??M3PSVFA27&C^
M)K6+SKG0=3VB;9G!>)@2LJ XR1R,C*C(KUOQ7\,?"/CK09=%\0>&=*UC2I$,
M;6EW9QN@&2> 1\IR201@@G(YK\]/AO\ \$U?B7\'_P!JNQ\;>"]8T33_  7H
M^N"YM%OK^8W<VGL<20$)$P+&)WCRQ&>M+WD^X:,_3*OFC]I_]OOX<?LR7;Z+
M>M<>)O%X0.=#TMES!D J;B0G$60<@89L$';@@UZ!^U1\86^ WP!\9>-H=AO]
M/L]EBLG(-U*RQ0Y'<!W5B/137Y4_\$_/V7X_VN/BUX@\5>/Y[K5O#VCR+=ZE
MYTS>9JEY,S,L;OG<5.UW<@Y^Z/XLARD[V0)=6>JW7_!:+Q(VH%[;X8:5%8[L
MB&7597EVYZ;Q&!GWV_A7T/\ LY_\%1OAU\:M<M?#WB.QF^'_ (@NF6.V^W7"
MSV5Q(> BS[5VL3T#JH.0 22!7UAI/P]\+:#H:Z+IOAO2;#1U01BPMK&)(-H!
M &P+C')[=S7YD_\ !4']B_PY\.]#M?BIX!T>/1K%KL6VNZ;9J$MHS(<17$:#
MB,%_D95XRZ8 ^8F7S1UN/1Z'ZKU\G_M??M]6'[)?C;1O#MWX-N?$CZEIW]H"
MXAU!;<1CS7CVX,;9^YG.>]9W_!,3]H+4OC;\!)=+U^Z>^\0>$[A=.ENI6W23
MVS+NMW<]V #QY/)\H$DDFODG_@LK_P ET\$_]BX/_2J:G*7NW0DM;,^D/VJ/
M^"H.B? WQ%'X6\*>'X_%GB**&.349)KLQ6MB[J&$.54F20 C<!@+G&2<@==^
MQ/\ MZM^UIKFL:#=^";CP]J>EV@O);VVNA<6;*75 I+!61R6)"X8$(QR,<^4
M?L _L,>!?$GPAT[XE?$G1(O&'B3Q,TE[#'JK-+#;P%R%)0G:[O@N6;/# #'.
M?J[P]\)OAC^R7X3\>>+O"OAR#PY8M9-J>JK;R.RNMK%(P"AV.W@O\JX&6Z9-
M"YMV-VV.?_:B_;:^'_[*]O!:Z[)<:SXFNHS+;:#II4S;.@>5B<1(3P"<DX.U
M6P<?%LG_  6DU\ZDKQ_"W35T_/,#:O(92.>DGE #M_!V/KQX9^R_\*[_ /;X
M_:NU?5/'%U-)I\GFZYKCV[%"T8=4CMHV_@4ED08Y"(V.0#7[/>'?A;X/\(^%
MXO#FC^&-)T_0HXA"+"&SC$3*!CYACYB<G);).23G)I)REJ@T1^;7[8/[:/@;
M]JS]CF\31#+HWB6RUNRDO- OV4S(G[P>9&PXECR0-PP02-P&5S[#_P $<O\
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M6%%7/NSQ'_P6@N(?%$RZ%\-(;GP['(5C:_U-H[J9<\,=L;+&3_=^;'J:^ZO
M7[1GAWQ7^SY8_%_6H9_!OAN:Q>^F75BN^&-79,_(3N#E?DQ\S!E^4$XKB-(_
MX)Y_ '2_!\7AZ3X>V-_&L>R34+J60WLK8(+F<,&4G).%( [ 8%?,'_!7@3>
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M5+&>QE##(V2QLC9'T8U^.G_!*?Q==^!_VN#X9G#)_;NFWFFS0D\++"/M /U
M@=?^!&LWI),M:H_:*BBBM" HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/$<,>>K.V /3DG@$U^8W['GP?U_]NO\ :,UOXS_$J+[5X7TV]64VS@F"YN%
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M%7Q\^&?@75CI7B/XA^%M"U,'#6>HZS;P3)P3ED9P5''4@"NQTO5K'7-/@O\
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MINE"_:9+348G/?:KVY7]7;]:_0#]EO\ Y-D^$7_8H:1_Z115^2__  4\^/\
MI'QL^/5M8>&[V'4M \+V?]GI>V[AXKBX9R\SHPX*CY$R.IC)!((K]:/V6_\
MDV3X1?\ 8H:1_P"D451'XF4]D?DE_P %,O\ D][Q!_UQTS_TFBK]NV8*I9B
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M@[9ARLH;V0,!_>/%4_"O[?7[2GP#U1-+\1:G?Z@83\^D^-]/=Y3C@[G<)/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &Y)_R 1_N#^=8=;DG_
M " 1_N#^=8=1#J5+H%%%%62%%%% !1110 4444 %%%% !1110 4444 %%%%
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_$+]G_\
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M^P%^W?\ #;]F?X*:AX4\70:Y)JD^MSZ@C:;9I+'Y3PP(,EI%.<QMQCTKH/\
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MP3UT:7XH?MT:'K/DE[>UGU#7;@,.4'ER;"?^VLL5?N#6=/8N04445H0%%%%
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M (1[3]4\11Z2G[F.:/Q;:$(@X!1VN/-10.@&"!V[5V_P%_X)+ZWJ_B2+Q/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M^ -4_P"4EUG_ -A>T_\ 2*.OTOK\T-4_Y276?_87M/\ TBCK]+Z];.-L/_@1
MY.5;U_\ &S\U/^"=HMV_:'\;?:-NS^R;G&X]_M<-?HQLTS_IG^9K\W/^"?\
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M,ZE1+&1N0D?>&01D>X(]JQJ*7)YAS>1Y5^SW^QO\+?V;->\0:[X:;4M3UW7
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M-&S3/^F?YFL*BCD\PYO(^!_$/E#_ (*;VWDX\O\ M>SQC_KRCK]**_-#5/\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^
M-4_Y276?_87M/_2*.OTOK\T-4_Y276?_ &%[3_TBCK]+Z];.-L/_ ($>3E6]
M?_&S\R?^"?\ _P G >-/^P7<?^E<-?H-7Y\_\$__ /DX#QI_V"[C_P!*X:_0
M:M\Z_P![?HOR,LG_ -U^;"BBBO"/;"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /@#5/\ E)=9_P#87M/_ $BCK]+Z_-#5/^4E
MUG_V%[3_ -(HZ_2^O6SC;#_X$>3E6]?_ !L_,G_@G_\ \G >-/\ L%W'_I7#
M7Z#5^?/_  3_ /\ DX#QI_V"[C_TKAK]!JWSK_>WZ+\C+)_]U^;"BBBO"/;"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /@#5/
M^4EUG_V%[3_TBCK]+Z_-#5/^4EUG_P!A>T_](HZ_2^O6SC;#_P"!'DY5O7_Q
ML_,G_@G_ /\ )P'C3_L%W'_I7#7Z#5^?O_!/BWDN?V@_&JQKN8:5<'_R;AK]
M#/[+NO\ GB?S%;9TU];?HOR,\GO]5^;*M%6O[+NO^>)_,4?V7=?\\3^8KPN9
M=SV[,JT5:_LNZ_YXG\Q1_9=U_P \3^8HYEW"S*M%6O[+NO\ GB?S%']EW7_/
M$_F*.9=PLRK15K^R[K_GB?S%']EW7_/$_F*.9=PLRK15K^R[K_GB?S%']EW7
M_/$_F*.9=PLRK15K^R[K_GB?S%']EW7_ #Q/YBCF7<+,JT5:_LNZ_P">)_,4
M?V7=?\\3^8HYEW"S*M%6O[+NO^>)_,4?V7=?\\3^8HYEW"S*M%6O[+NO^>)_
M,4?V7=?\\3^8HYEW"S*M%6O[+NO^>)_,4?V7=?\ /$_F*.9=PLRK15K^R[K_
M )XG\Q1_9=U_SQ/YBCF7<+,JT5:_LNZ_YXG\Q1_9=U_SQ/YBCF7<+,JT5:_L
MNZ_YXG\Q1_9=U_SQ/YBCF7<+,JT5:_LNZ_YXG\Q1_9=U_P \3^8HYEW"S*M%
M6O[+NO\ GB?S%']EW7_/$_F*.9=PLRK15K^R[K_GB?S%']EW7_/$_F*.9=PL
MRK15K^R[K_GB?S%']EW7_/$_F*.9=PLRK15K^R[K_GB?S%']EW7_ #Q/YBCF
M7<+,JT5:_LNZ_P">)_,4?V7=?\\3^8HYEW"S*M%6O[+NO^>)_,4?V7=?\\3^
M8HYEW"S*M%6O[+NO^>)_,4?V7=?\\3^8HYEW"S*M%6O[+NO^>)_,4?V7=?\
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M8HYEW"S*M%6O[+NO^>)_,4?V7=?\\3^8HYEW"S*M%6O[+NO^>)_,4?V7=?\
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M?_7K/HHY8]@NS0_MRY](_P O_KT?VY<^D?Y?_7K/HHY8]@NS0_MRY](_R_\
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M#^W+GTC_ "_^O1_;ESZ1_E_]>L^BCECV"[-#^W+GTC_+_P"O1_;ESZ1_E_\
M7K/HHY8]@NS0_MRY](_R_P#KT?VY<^D?Y?\ UZSZ*.6/8+LT/[<N?2/\O_KT
M?VY<^D?Y?_7K/HHY8]@NS0_MRY](_P O_KT?VY<^D?Y?_7K/HHY8]@NS0_MR
MY](_R_\ KT?VY<^D?Y?_ %ZSZ*.6/8+LT/[<N?2/\O\ Z]']N7/I'^7_ ->L
M^BCECV"[.C:\D72_M'R^9M!Z<=:S/[<N?2/\O_KU<D_Y (_W!_.L.HC%.Y3;
M-#^W+GTC_+_Z]']N7/I'^7_UZSZ*OECV)NS0_MRY](_R_P#KT?VY<^D?Y?\
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M^W+GTC_+_P"O1_;ESZ1_E_\ 7K/HHY8]@NS0_MRY](_R_P#KT?VY<^D?Y?\
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M #)X  KY=_X*D_\ "W/^%O>$_P#A7O\ PFO]F?V$/M'_  C/VOR?-^T2_?\
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MYR*_,;_@DO\ $WQCXT_:,\1V7B#Q9KFNV4?A2YF2WU/49KB-9!>68#A78@,
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M2AFTQHUOK'5+0PRV_F;O+RREHVW;&^ZY(QSBES*]AV9[+17S-\<O^"B'P;^
MOB&Y\/ZIJE]K^OVC[+K3O#]LMP]NW=7=W2,,.A7?N'<"O(]+_P""QGPENKY8
MKSPKXOL;=CC[0+>VDV\]2HGSCZ9/L:7,NX69]ZT5YS\%OVAOA_\ M!Z')J?@
M7Q';ZRD 7[3:X,=S:ELX$L3 ,N<'!Q@X."<5Z-5""BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH W)/\ D C_
M '!_.L.MR3_D C_<'\ZPZB'4J70****LD**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^6?VZOV
MUK3]E'PM96.DVL&K>.]9C=K"SN"?)MH@<&XF ()7=PJY&XAN0%-? O@GPW^V
M'^V='+XCL_$NOPZ#,Y1+R?4SI.G/G@^5%'M#@<@LB-W!.<UZ-^V=^QW\<?CQ
M^U=J?B*'PE-=^#+BXL]/LK^/4+4B&S1$5V\LR[U&XRORO5C7ZD^'?#VF^$=
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MWVDH75V/F['YF?L._P#!2;Q#KWC?3_AK\895N;N^G%EIWB!X5AF2Y)"K;W*
M '<WRA\ AB V<[E_3.OP\_X*<^&=*\$_M@:Y-H 2SEOK6UU2Y6V^3RKMU.]N
M.C-M60D=W)ZFOVF\!ZI=:YX'\.ZE?+MO;S3K>XG7 &)'B5F''N31!O5,)=S=
MHHHK0@^>?VTOVN--_9.^',&HBUCU7Q5JSO!H^FR,1&S* 7FEP<^6FY<@<DLH
M&,EA^;_@F']KC]N:[O=:TOQ-K46A+(8FNO[1;2M*1CP8XTCP)"H/.%8@?>.3
MST__  61FOV_: \'Q2EO[-7PS&UN,_+YANKCS#]<"/\ (5^E/[*5CHVG_LT_
M"^+0$B32SX=L9$\H ;G>%6D9L?QF0N6[[BV>:R^*5B]D?EGXXTO]KK]AV2R\
M0:CXGUB?0!(L7VI-2;5=,ST$<L<F1'D8 +*N<X4Y''Z+_L4_M?:=^UE\/[F\
MDM(](\6Z.R0ZOIL3$Q@N#LFBR<^6^UN#RI4@D\,?0_VDM-T75OV?OB-;>(4B
M?1VT"]>?S@"$VPLRN,_Q*RJRGJ& (YK\MO\ @C[=:A'^TSKD%L6-C+X9N&NU
MS\N%N+?8V/4,0![,:/AE8-T?KQXR\6:=X#\(ZUXDU>;R-+TBSFOKJ3C(CC0N
MV/4X' [FOR(\ ^"_BQ_P5*^)GB75=;\72>&O!&E2JP@*O-:V6_=Y4$%N&57D
MVJ2SD@]R>0*_1']OB2ZB_8]^*#68)E_LP*VT9_=F:,2?^.%J\ _X(UO ?@-X
MT10/M(\2L7..=AM8-OZA_P!:<M9) M%<^</&6B?%C_@EE\6/#,^G^*YO%7@+
M56+_ &7#PVM\B,OGPR0,SK%, X*NI/W@<GYEK]=?!_BO3?'?A/1O$FC3_:=)
MU>SBOK28KM+Q2('0D=C@CCM7PC_P67^S?\*5\"[O^/S_ (2 ^7_N?9I=_P"N
MROI']A<WA_9%^%OVX8F_L=-O_7/<WE_^.;:(Z2:$]5<V/VK/CM:_LY_ SQ)X
MRD:,ZC#%]ETN"3_EM>R K$N.X!R[#^ZC5\H?\$H?@/?0:-XA^-WBH276O>*)
M)8-.GN?FE,'FEKBX)/>648SUQ&3T>O-?VSO$FI?MJ?MD>%_@;X4O"?#_ (?N
M&@OKJ$[HTN,;KR<]CY*+Y8!_C#@'YZ_4'PKX9TWP7X9TKP_H]LMEI.EVL=G:
M6Z=(XHU"JOY 4_BE?L&R-6H[BWBNK>2">-)H9%*/'(H964C!!!Z@CM4E%62?
ME3H>M3_\$T_VUM0T*Z:5/@_XT*S(S9*6\#,?+D'^U;N61NI,9R1DK7ZIPS1W
M$*2Q.LL4BAD=#E6!&00>XKXQ_P""K7P<C^(G[-[>*;>$/J_@VZ6^1@N6-K*5
MBN$'MS'(?:*KW_!+[X]2?%_]GF'0=3N//U[P;(FERECEWM"N;5S_ ,!#1_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ? &J?\
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M?_&:^L?^&%?@%_T2W0?^_3__ !5'_#"OP"_Z);H/_?I__BJ=I]P]T^8/#/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!N2?\@$?[@_G6'6Y)_R 1_N#^=8=1#J5+H%%%%62%%%% !1110
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MR-IMU>C4]>N5R8K*Q5@$MU;U*JL*#KP6P0K&OW0CC2&-(XT6.- %55&  .@
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MI6I:NIO-,74(I=0N)8S]V1W,J>2K8!4+N^7:<#I1?E]U"WU9^N]%?F!^Q/\
MM&?$+X&_M'7?[/?Q;U>XU2W:X;3]/N+R9IVM;O :$1RO\Q@F3 53T+QX"@M7
MZ?U<7S(35CFOB7X1A^('PZ\4>&)T62'6=+N=/96Z?O8F3_V;K7Y)?\$C?'DG
MA3]I35/"UP6CA\1:1-"(3P?M%N1*I/T03C\:_9*OP\_9&F_X1O\ X*.Z)';\
MI'XDU2T&/[K1W,?KZ-42W14=F?N'1116A 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5N#_D
M_P# ?ZUAUN#_ ) /_ ?ZUG/H5$PZ***T)"BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#<D_P"0"/\ <'\Z
MPZW)/^0"/]P?SK#J(=2I= HHHJR0HHHH **** "BBB@ HHHH **** "BBB@
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M=%&6;)/S_L7\)_A'X4^"/@JR\*^#M)BTG2+89VIS)-(0 TLK]7<X&6/H!P
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M;.*^Y/V&?V%-/_97TRYUW7+JWUOX@:E#Y,]W;J?(L8203!"6 +9(!9R 3@
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M$>HR(!D=U8=J4M9)#6S9^F]%%%:$!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6X/^0#_ ,!_
MK6'6X/\ D _\!_K6<^A43#HHHK0D**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /Q(_:RTVZ_9C_X*$S^*Q$_V(Z[:^++<JO\
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M<Z#E9B45M_V/:?\ /9O^^A_A1_8]I_SV;_OH?X4<Z#E9B45M_P!CVG_/9O\
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M +Z'^%'.@Y68E%;?]CVG_/9O^^A_A1_8]I_SV;_OH?X4<Z#E9B45M_V/:?\
M/9O^^A_A1_8]I_SV;_OH?X4<Z#E9B45M_P!CVG_/9O\ OH?X4?V/:?\ /9O^
M^A_A1SH.5F)16W_8]I_SV;_OH?X4?V/:?\]F_P"^A_A1SH.5F)16W_8]I_SV
M;_OH?X4?V/:?\]F_[Z'^%'.@Y68E%;?]CVG_ #V;_OH?X4?V/:?\]F_[Z'^%
M'.@Y68E%;?\ 8]I_SV;_ +Z'^%']CVG_ #V;_OH?X4<Z#E9B45M_V/:?\]F_
M[Z'^%']CVG_/9O\ OH?X4<Z#E9B45M_V/:?\]F_[Z'^%']CVG_/9O^^A_A1S
MH.5F)16W_8]I_P ]F_[Z'^%']CVG_/9O^^A_A1SH.5F)16W_ &/:?\]F_P"^
MA_A1_8]I_P ]F_[Z'^%'.@Y68E%;?]CVG_/9O^^A_A1_8]I_SV;_ +Z'^%'.
M@Y68E%;?]CVG_/9O^^A_A1_8]I_SV;_OH?X4<Z#E9B45M_V/:?\ /9O^^A_A
M1_8]I_SV;_OH?X4<Z#E9B45M_P!CVG_/9O\ OH?X4?V/:?\ /9O^^A_A1SH.
M5F)16W_8]I_SV;_OH?X4?V/:?\]F_P"^A_A1SH.5F)16W_8]I_SV;_OH?X4?
MV/:?\]F_[Z'^%'.@Y68E%;?]CVG_ #V;_OH?X4?V/:?\]F_[Z'^%'.@Y68E%
M;?\ 8]I_SV;_ +Z'^%']CVG_ #V;_OH?X4<Z#E9B45M_V/:?\]F_[Z'^%']C
MVG_/9O\ OH?X4<Z#E9B45M_V/:?\]F_[Z'^%']CVG_/9O^^A_A1SH.5F)16W
M_8]I_P ]F_[Z'^%']CVG_/9O^^A_A1SH.5F)16W_ &/:?\]F_P"^A_A1_8]I
M_P ]F_[Z'^%'.@Y68E%;?]CVG_/9O^^A_A1_8]I_SV;_ +Z'^%'.@Y6+)_R
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M\]F_[Z'^%'.@Y68E%;?]CVG_ #V;_OH?X4?V/:?\]F_[Z'^%'.@Y68E%;?\
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M +Z'^%'.@Y68E%;?]CVG_/9O^^A_A1_8]I_SV;_OH?X4<Z#E9B45M_V/:?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 ? &J?\I+K/\ ["]I_P"D4=?I?7YH:I_RDNL_^PO:
M?^D4=?I?7K9QMA_\"/)RK>O_ (V?F3_P3_\ ^3@/&G_8+N/_ $KAK]!J_/G_
M ()__P#)P'C3_L%W'_I7#7Z#5OG7^]OT7Y&63_[K\V%%%%>$>V%%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ? &J?\I+K/_L+V
MG_I%'7Z7U^:&J?\ *2ZS_P"PO:?^D4=?I?7K9QMA_P# CR<JWK_XV?F3_P $
M_P#_ ). \:?]@NX_]*X:_0:OSY_X)_\ _)P'C3_L%W'_ *5PU^@U;YU_O;]%
M^1ED_P#NOS84445X1[84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!\ :I_RDNL_P#L+VG_ *11U^E]?FAJG_*2ZS_["]I_Z11U
M^E]>MG&V'_P(\G*MZ_\ C9^9/_!/_P#Y. \:?]@NX_\ 2N&OT&K\^?\ @G__
M ,G >-/^P7<?^E<-?H-6^=?[V_1?D99/_NOS84445X1[84444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!\ :I_RDNL_^PO:?^D4=
M?I?7YH:I_P I+K/_ +"]I_Z11U^E]>MG&V'_ ,"/)RK>O_C9^97_  3]5G_:
M"\:A5+'^R[CH/^GN&OT(\B3_ )YM_P!\FOS_ /\ @G?>?8?VAO&S[-^=)N1C
M./\ E[AK]%?^$@_Z=_\ Q_\ ^M6F=-_6W9=%^1&3V^J_-F5Y$G_/-O\ ODT>
M1)_SS;_ODUJ_\)!_T[_^/_\ UJ/^$@_Z=_\ Q_\ ^M7A7EV/;LNYE>1)_P \
MV_[Y-'D2?\\V_P"^36K_ ,)!_P!._P#X_P#_ %J/^$@_Z=__ !__ .M1>78+
M+N97D2?\\V_[Y-'D2?\ /-O^^36K_P )!_T[_P#C_P#]:C_A(/\ IW_\?_\
MK47EV"R[F5Y$G_/-O^^31Y$G_/-O^^36K_PD'_3O_P"/_P#UJ/\ A(/^G?\
M\?\ _K47EV"R[F5Y$G_/-O\ ODT>1)_SS;_ODUJ_\)!_T[_^/_\ UJ/^$@_Z
M=_\ Q_\ ^M1>78++N97D2?\ /-O^^31Y$G_/-O\ ODUJ_P#"0?\ 3O\ ^/\
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MY$G_ #S;_ODT>1)_SS;_ +Y-:O\ PD'_ $[_ /C_ /\ 6H_X2#_IW_\ '_\
MZU%Y=@LNYE>1)_SS;_ODT>1)_P \V_[Y-:O_  D'_3O_ ./_ /UJ/^$@_P"G
M?_Q__P"M1>78++N97D2?\\V_[Y-'D2?\\V_[Y-:O_"0?].__ (__ /6H_P"$
M@_Z=_P#Q_P#^M1>78++N97D2?\\V_P"^31Y$G_/-O^^36K_PD'_3O_X__P#6
MH_X2#_IW_P#'_P#ZU%Y=@LNYE>1)_P \V_[Y-'D2?\\V_P"^36K_ ,)!_P!.
M_P#X_P#_ %J/^$@_Z=__ !__ .M1>78++N97D2?\\V_[Y-'D2?\ /-O^^36K
M_P )!_T[_P#C_P#]:C_A(/\ IW_\?_\ K47EV"R[F5Y$G_/-O^^31Y$G_/-O
M^^36K_PD'_3O_P"/_P#UJ/\ A(/^G?\ \?\ _K47EV"R[F5Y$G_/-O\ ODT>
M1)_SS;_ODUJ_\)!_T[_^/_\ UJ/^$@_Z=_\ Q_\ ^M1>78++N97D2?\ /-O^
M^31Y$G_/-O\ ODUJ_P#"0?\ 3O\ ^/\ _P!:C_A(/^G?_P ?_P#K47EV"R[F
M5Y$G_/-O^^31Y$G_ #S;_ODUJ_\ "0?]._\ X_\ _6H_X2#_ *=__'__ *U%
MY=@LNYE>1)_SS;_ODT>1)_SS;_ODUJ_\)!_T[_\ C_\ ]:C_ (2#_IW_ /'_
M /ZU%Y=@LNYE>1)_SS;_ +Y-'D2?\\V_[Y-:O_"0?].__C__ -:C_A(/^G?_
M ,?_ /K47EV"R[F5Y$G_ #S;_ODT>1)_SS;_ +Y-:O\ PD'_ $[_ /C_ /\
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MX2#_ *=__'__ *U%Y=@LNYE>1)_SS;_ODT>1)_SS;_ODUJ_\)!_T[_\ C_\
M]:C_ (2#_IW_ /'_ /ZU%Y=@LNYE>1)_SS;_ +Y-'D2?\\V_[Y-:O_"0?]._
M_C__ -:C_A(/^G?_ ,?_ /K47EV"R[F5Y$G_ #S;_ODT>1)_SS;_ +Y-:O\
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M$@_Z=_\ Q_\ ^M1>78++N97D2?\ /-O^^31Y$G_/-O\ ODUJ_P#"0?\ 3O\
M^/\ _P!:C_A(/^G?_P ?_P#K47EV"R[F5Y$G_/-O^^31Y$G_ #S;_ODUJ_\
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M\)!_T[_^/_\ UJ/^$@_Z=_\ Q_\ ^M1>78++N97D2?\ /-O^^31Y$G_/-O\
MODUJ_P#"0?\ 3O\ ^/\ _P!:C_A(/^G?_P ?_P#K47EV"R[F5Y$G_/-O^^31
MY$G_ #S;_ODUJ_\ "0?]._\ X_\ _6H_X2#_ *=__'__ *U%Y=@LNYE>1)_S
MS;_ODT>1)_SS;_ODUJ_\)!_T[_\ C_\ ]:C_ (2#_IW_ /'_ /ZU%Y=@LNYE
M>1)_SS;_ +Y-'D2?\\V_[Y-:O_"0?].__C__ -:C_A(/^G?_ ,?_ /K47EV"
MR[F5Y$G_ #S;_ODT>1)_SS;_ +Y-:O\ PD'_ $[_ /C_ /\ 6H_X2#_IW_\
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M9=S*\B3_ )YM_P!\FCR)/^>;?]\FM7_A(/\ IW_\?_\ K4?\)!_T[_\ C_\
M]:B\NP67<RO(D_YYM_WR:/(D_P">;?\ ?)K5_P"$@_Z=_P#Q_P#^M1_PD'_3
MO_X__P#6HO+L%EW,KR)/^>;?]\FCR)/^>;?]\FM7_A(/^G?_ ,?_ /K4?\)!
M_P!._P#X_P#_ %J+R[!9=S*\B3_GFW_?)H\B3_GFW_?)K5_X2#_IW_\ '_\
MZU'_  D'_3O_ ./_ /UJ+R[!9=S*\B3_ )YM_P!\FCR)/^>;?]\FM7_A(/\
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M9=S*\B3_ )YM_P!\FCR)/^>;?]\FM7_A(/\ IW_\?_\ K4?\)!_T[_\ C_\
M]:B\NP67<RO(D_YYM_WR:/(D_P">;?\ ?)K5_P"$@_Z=_P#Q_P#^M1_PD'_3
MO_X__P#6HO+L%EW,KR)/^>;?]\FCR)/^>;?]\FM7_A(/^G?_ ,?_ /K4?\)!
M_P!._P#X_P#_ %J+R[!9=S*\B3_GFW_?)H\B3_GFW_?)K5_X2#_IW_\ '_\
MZU'_  D'_3O_ ./_ /UJ+R[!9=S*\B3_ )YM_P!\FCR)/^>;?]\FM7_A(/\
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M9=S*\B3_ )YM_P!\FCR)/^>;?]\FM7_A(/\ IW_\?_\ K4?\)!_T[_\ C_\
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MCR)/^>;?]\FM7_A(/^G?_P ?_P#K4?\ "0?]._\ X_\ _6HO+L%EW,KR)/\
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MCR)/^>;?]\FM7_A(/^G?_P ?_P#K4?\ "0?]._\ X_\ _6HO+L%EW,KR)/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!N2?\@$?[@_G6'6Y)_R 1_N#^=8=1#J5+H%%%%62%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17YY?
MM>?\%3H/ACXFU'P9\+=/LM=UBPD:WO=>O]SVD$H)#QPQJ09&4\%RP4$$88<U
M\4:A_P %'/VB=0OGN3\1I[?<<B*WTZS2-?8+Y/\ .LW42*Y6?O)17Y _ O\
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M6H:9?P)=6MU VZ.:)U#(ZGN""#^-?)'_  4&_;>NOV7=)TSPYX4M[>Z\<:W
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M0#_P'^M8=;@_Y /_  '^M9SZ%1,.BBBM"0HHHH **** "BBB@ HHHH ****
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
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M_P#C=KGBSPKXN^'NM7TM_:^'Q;W>DF9BSPP2%UDA!/\  K*A4=M[#I@5V/\
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M[#_M'[9]NNQ!CSOLOE[<CG_4OGTX]:I2NKHFUG9GXP5^[7[-/[6'PBNOA?\
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MC8Z^._@OXB^)7B72K_X._#P7$C^-+V%KNULCLENA$DF(WDR L(#.[YP,+DG
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M$?1C3_"G_!1K]GKQ=>1VD'Q"M].N)&VJ-6LKFTC[<F62,1@?5ATK\R?V:/\
M@G)\1/VD?!L7BZWU#3/"_ANX=TM+G4O,:6ZVDJSQQHI^0,"N6(Y!P#7*?M3?
ML3>.?V4(])O?$-UINL:+JDK06^I:6[E5E4;O+D5U4JQ&2,9!"GGBL^:6]B^5
M;'[V:;J5IK%A;WUA=0WUE<()8;FVD$D<J$9#*P)!!'<5XW^VQ_R:9\5?^P#<
M?RKX'_X) _&[7+/XDZU\,+R^EN/#E]ITNI65M*Q86UU&Z;O+_NAT9BP]44^N
M?OC]MC_DTSXJ_P#8!N/Y5:ES1N3:S/PE^#/_ "6#P+_V'K'_ -*$K^D>OYN/
M@S_R6#P+_P!AZQ_]*$K^D>HI[,J8445B^-?%VF^ /!^M>)=8F^SZ5I%G+?7,
MG<1QH6;'J<#@=S@5L9E3X@?$KPK\*_#\FN>+]?L/#NE(=OVF_F$89NRJ#RS'
M^ZH)]J\&L_\ @I9^SI>ZJ+%?B!Y>XA5N)M)O8X6)[;C#Q]6P/>OQW_:-_:'\
M4?M*_$B^\5>([F00EV33M,#DPZ?;Y^6)!TSC&YL98\GT'O'P9_X)8_%?XM>!
M[3Q/=WVC^$+6^A\ZRL]7:4W4J$ H[HB'RU8'C)W>JCC./.V_=1IRKJ?8/_!5
M#Q1H_C/]CG2M9T#5+/6M)N_$-F\%]83K-#*OE7 RKJ2#SQ^%?!'_  3A_P"3
MT_AK_P!=KW_TAN*Y3XZ?"[XI_LOM??##Q?));Z%J4\>I1QVTIFT^^>(,JW$+
M$## .RGA6P1N'W:ZO_@G#_R>G\-?^NU[_P"D-Q47O)#V1^VGQ>L_".H?#'Q+
M;>/FB3P9+9.NK-/-)$@M\?-EXR&4>ZD&OC#PE\/_ -@:W\5:-+H5UH9UQ+V%
MK )KVINWV@2*8L*TQ!.[;P1CUKZ2_;8_Y-,^*O\ V ;C^5?A+\&?^2P>!?\
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M):ML>\T445H2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 ;DG_ " 1_N#^=8=;DG_(!'^X/YUAU$.I4N@44459(4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y?^T]XNUGP
M+^S[X]UKP[;75UKUOI4J6*643RS+-(/+1U5022I<-[;<GBO4** /YM?#/PSU
M[Q-\0?#OA2XL;O3-2US4[?38C>V[H1)-(J D, 3@N#7[F>"/V$?@9X)\)0:$
MOPZT36=L86;4-8M%NKN9N,N97!923SA" .@ %>_5E>*/%&D^"?#NHZ]KVH0:
M5H^GPM<75Y<MMCBC49))_H.2< <U$8*)3E<_"O\ ;\_9]T7]G']H2[\/^&P\
M/A[4+&'5K&UD=G-LDC.C1;F)+ /$^"><$ YQD_<?_!&_QM?ZQ\'_ !KX9N96
MEL]%U:.>TW$GRUN(R60>B[HBV/5V/>OSW_;"^/W_  TE\>=>\86\<D&CX2QT
MJ&48=;2+(0L.S,2SD=BY':OU"_X)6_!>\^%_[./]O:I$T&H^,+O^U$B;(*6@
M0);Y'^T \@/]V1:SC\6A<MM3P[_@LI\7+B.;P1\,[2=XX)(GU[4(U; D^9H;
M<'U *SG![[3VKQ7_ ()A_LP^'OC]\3-?UGQCIRZMX:\,6\3_ -GRY$5S=3,P
MB$G]Y%6.1BO<[,Y&0<__ (*M:O)J7[7VK6[ON73]*L;:,?W5,?FX_.4G\:^H
M_P#@C%8I'\,/B+> #S)M8MX6..<)!D?^C#1\4]0VB5/^"FG[&O@7P_\ !=_B
M-X&\+Z?X7U+0KB%-0@T>W6W@N+65Q%DQ( N]9'C.X ':7SG Q\@_\$Y?BS<?
M"O\ :L\(IY[IIGB.7^P;R(-@2>>0L.1TXF\H_3/K7ZT?MS6:7W[(WQ3C?&U=
M&DEY&>497'ZJ*_!WX=ZO+X?^('AC5('\N:RU2UN48=F256!_,43]V2:".J/Z
M5Z***W,@K\M?^"PWQX>YU;PW\)=-G98+9%UK5]C</(VY;>(_[J[W(/!WQGM7
MZE5_/!^UEX_D^)W[2?Q&\1/(98KC6;B"V9O^?>%O)A_\AQI6=1V1<=S]$/\
M@CG\*5T;X9^+OB!=0 76MWRZ;:2,O(MX!ERI]&DD(/O"/2NK_P""M.N>)_\
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M?PU\6ZMI_-_8:1=W5OQG]XD+LGZ@5_-[I-E)XB\065I)<;9KZZ2)KB9LX9W
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M^F/[0WQGTW]G_P"#OB3QSJ064:;;G[+:LV/M-RQVPQ#O\SE<D=%W'M7Y,?\
M!/OX/ZE^U'^U-=^-_%>[4]-T2Z/B'5[B9<K<WKR%H(SV^:0,Y'0K$P[UW?\
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M 4444 %;@_Y /_ ?ZUAUN#_D _\  ?ZUG/H5$PZ***T)"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M^+;[_@DK\$=0OKBZENO%?FSR-*^W4H@,L23C]S[U]I44FD]QGQ-_PZ*^!O\
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M<LS'W.2:_IK=%D1D=0Z,,%6&01Z5^''[='[$>M?LU>++[Q#I:17?PYU.\/\
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M0Z9K%Y9VA<Y_<Y27CV#RR#\*^QJ\Z_9]^"^E_L^_"'P]X%TJ7[5%ID)\Z\9
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^ -4_P"4EUG_ -A>T_\
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MD8((,/((K\N+EHFNI6MU:.$N3&K-EE7/ )[G%?O1XJ_8\_9Q\%^&=6\0:O\
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M%]?SK?M2?\G-_%W_ +&_5_\ TMEIU-D*)^R__!.21I/V+?AJ6.X^1>#\!?7
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MX3KZ&KJ?"3'<Z[_@B[X3LIK[XH^)9;>*34+>.PT^VG*YDCC<S/*H/8,8X?\
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M_D C_<'\ZPZB'4J70****LD**** "BBB@ HHHH **** "BBB@ HHHH ****
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M554#   Z "N1TGQY\/M!TRTTW3?$?ANPT^TB6"WM;6^MXXH8U&%15#84
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MRQY-,_:&_: \3_M)?$F^\7>)K@[I"8K*PC8F&QMP24AC'H,Y)ZL22>M?>?\
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MQI9?#GXX> ?%.I_\@W1]=LKVZ(0N5A29&D( ZD*"1[@5C4W2-([7/TQ\%_\
M!'#P!#X-@B\6>+O$-UXHDA!GN-)DABM(9.N(T>%F90>,LP+ 9PN>/SZ_:5^
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MBBC4N\CD!54#)))Z "MS,^-_^"H7[0__  I_X#R>%=+N?*\2>,]]@FQL/#9
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MTH);K]E'XI10QM+*^A7 5(U+,3CH *_#3X-^&=8C^+W@=WTF^1%UVQ)9K9P
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ML)_\$Y_$_B[QEI?CGXG:-<^'?"NF31WEII-_'LN=3E5@R!XFY2$$ MN +#
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MW,HYK]N?@_\ "7P[\#_AWH_@SPO:_9=)TV+8K-@R3R'EY9#_ !.[98GIS@
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M$/B'J?P\_93\5MHHF_M?6C'HL#6ZLSJLQQ,1MY!\E90#V)!KZ4HH>PS^9O\
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M5%WNRKZ61S7Q.\81?#WX;^*O%$SK''HVEW6H%GZ?NHF<#WR5QCOFOYXO@[X
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M_P#KT?\ "/M_SW'_ 'S_ /7K-^U3?\]9/^^C1]JF_P">LG_?1HM+N&G8TO\
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M_P#KT?\ "/M_SW'_ 'S_ /7K-^U3?\]9/^^C1]JF_P">LG_?1HM+N&G8TO\
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MDZ=C2_X1]O\ GN/^^?\ Z]'_  C[?\]Q_P!\_P#UZS?M4W_/63_OHT?:IO\
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MJ^'=0\+:;JCHOVF_DCN;K3'8HZNGE%1(8F/&<!P#GBOT^_X1]O\ GN/^^?\
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M_P#KT?\ "/M_SW'_ 'S_ /7K-^U3?\]9/^^C1]JF_P">LG_?1HM+N&G8TO\
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M?:IO^>LG_?1HM+N&G8TO^$?;_GN/^^?_ *]'_"/M_P ]Q_WS_P#7K-^U3?\
M/63_ +Z-'VJ;_GK)_P!]&BTNX:=C2_X1]O\ GN/^^?\ Z]'_  C[?\]Q_P!\
M_P#UZS?M4W_/63_OHT?:IO\ GK)_WT:+2[AIV-+_ (1]O^>X_P"^?_KT?\(^
MW_/<?]\__7K-^U3?\]9/^^C1]JF_YZR?]]&BTNX:=C2_X1]O^>X_[Y_^O1_P
MC[?\]Q_WS_\ 7K-^U3?\]9/^^C1]JF_YZR?]]&BTNX:=C2_X1]O^>X_[Y_\
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M7O\ @D_\5_AGH\VM^%M3L/'<5I^\:UTU9+>_P.=T<39#X]%?=TPIKL/V!_\
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M;0^ .L?M+?!"Z\%:%J-CI=_+?6]T+C4-_E!8V)(^16.3GTK\_?\ AS5\3?\
MH=O"?YW7_P :J&VGHBE;J?IY_P +[^&7_11?"?\ X/+7_P".4?\ "^_AE_T4
M7PG_ .#RU_\ CE?F'_PYJ^)O_0[>$_SNO_C5?*?[1GP"N/V<_B!_PAM]XFTC
MQ+K44*R7B:-YC+:,W*Q.75?G*X; Z!E]:ESDMT/E3ZG]!GAGQAH/C2SDO/#V
MMZ=KMI')Y3W&F7<=Q&K@ [2R$@'!!Q[BI]?\0:7X5T:[U?6M1M=)TJSC,MQ>
MWLRQ0PJ/XF=B !]:^8_^";7P%\1? 3]GG[+XI3[)J^OZ@VM-I[*1)9H\,4:1
MR?[>V(,1_#NVGD&OE[_@JY\3M>\>?%_P3\$="D9+5OL]S/"LA5;J]N9#' KC
MT10"/>4^@JN:RN*VMCZ^A_X**?L[3:T-+7XEV8N3)Y7F/87BP9]?.,/EX_VM
MV/>OH;3=2L]9T^VO]/NH+ZQN8UE@NK:0212HPRK*RDA@1R".*^/)O^"5'P4;
MX6MX>BTZ]7Q1]EVKXI-]-Y_VG'^L,6[RMF[^#9]WOGYJ\$_X).?%S7_"WQ,\
M8?!+7)FGL8(Y[VT1Y2PM+J"58YXXP?X7#;NV#'G'S&CF:=F%ET/U'KS'XZ?M
M(> /V<-)TO4/'FLMI4.I3M;VB16\D\DK*NYB$0$[0"N3T!91WKTWIR:_)KQ!
M<-_P48_;^M=*A+77PQ\([E=E)\N6S@D'FOD=[B8JH(YV%3_!3D[;"2/U-\&^
M++#QYX3TCQ'I7GG3-5MH[RU:XA:%VB=0R,48!ER"#@CH:V:9##';0QPPQK%%
M&H1(T "JH&  !T %/JA'D_QN_:A^'W[.UYHEOX\U.ZT==8+BTN%L9IH6*%0X
M+HI"D;U)!['->IVUS#>6\5Q;RI/!*@DCEC8,KJ1D,"."".]>,_M@?L]VO[2G
MP,USPJ4C&M1+]NT:X? \J\C!V#)Z*X+1L>RN3U KYK_X)7_M-7?B[PQ??!SQ
M5)(GB/PK$6TUK@XDDLE8(T# \[H6(4#^XRC'R&IO9V8[:7/O^BBBJ$%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !6X/^0#_P'^M8=;@_Y /_  '^M9SZ%1,.BBBM"0HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBN,^+'Q@\(_!#P?=>)O&>M6^C:7",*93F2=\9$<2#YI'/]
MU0?7@ F@"W\1/B=X4^$OA_\ MSQCKUGX>TGSE@%U?2;5:1L[4'<D@$X'8$]J
MT_"_BC2O&WAW3]=T.^BU/1]0A6>UO("2DL9Z,/:OPF_;._;&US]K#QM'+Y4F
MD^#-+=QI&D,1N&>#/,1PTK #@9"#Y1GYF;]@?V)_^33/A5_V ;?^51&7,[%-
M61[;1115DA1145U=0V5M+<7$J06\*&2261@JHH&2Q)Z #O0!Y_\ &[]H#P-^
MSOX;M-<\=:Q_9-C=W M;<1PO-++)M+$*B L0 .3C XSU%=;X/\4V7CCPMI7B
M#3!<#3M3MDN[;[5 T,AC<!E)1@&7((.",\U^6.GZK<?\%+/VYK7S5E;X4^$
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M4 %%%% !1110 4444 %%%% 'P!JG_*2ZS_["]I_Z11U^E]?FAJG_ "DNL_\
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M^0"/]P?SK#J(=2I= HHHJR0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 5N#_D _\!_K6'6X/^0#_P !_K6<^A43#HHHK0D**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K\@(_V*?CU^V)\8-;\0>.M0O\ 0O#,>HSQ6^K>(MV\6PE8*MI:
M\';M (X1#G(8FOU_HJ91YMQIV/Q>_P""D'[.'@S]F?3_ (4^'/!]DZ>;:W\M
M]J-TP>ZOI0T #R, !P"<* %&3@<DG]-/V)_^33/A5_V ;?\ E7PY_P %IO\
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MFN__ ."R=KJ<GP-\%W$#-_9,7B';=(N<>8UO+Y3'Z 2C_@5)646T#U=F?/\
MKW_!0O\ :1_:2\82Z/\ "+19M#MU4N-.T#3UO[D19 WSSRHP7D@;E$8Y [\Z
M=M^RG^V]\6@!XD\8ZMH=K*1F/6/%;)#SGDQ6S28ZG^'.*]W_ ."0'B#PC-\"
MM;T;3I;6/QA#JTEQJL!(%Q)$RH(9/4Q@ J,<!@W0MS]S>(/$6E^$]'NM6UK4
M;72=+M4,D]Y>S+%%$HZEF8@"A1YE=L&[:(_!?]KS]E'4OV4]<\-:;K7B:W\2
M:OK5G)?7#6L+(D)$FW 9FW29.3N(7Z5^T'[)/_)KOPE_[%73?_2:.OQU_P""
M@'[1VF_M)?'RXU;0&:3PSH]HFDZ;<,I4W*([N\^T@$!GD; /.U5R <BOU^_8
MUO?M_P"RG\*)<YV^'+.+M_!$$_\ 9:4+<SL.6R/9:***V,PHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M==6-RN^WN8FAD7U5@01^1K\2?^"?]S)\'_V\-'\/:P/*N%NM0\/7!Z;9PDB
M8]Y(U7\:SENBX[,_;^BBBM" K\5O^"M7_)V;_P#8!LOYR5^U-?BM_P %:O\
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M4 %%%% 'Y7_\%IO^1F^%7_7GJ'_H<%?<?[$__)IGPJ_[ -O_ "KX<_X+3?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2?!]II'B&QT!M#GN99&O87D$HE6, #;TQL/7UKZGHHY5:PKZW/*_V7O@_>?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPSWETVE"1#B>\E8^?.@/\$89HUZ\L<8,=?I[41_F*EV"BBBK)"BBB@ HHHH
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MYG_O@5A44<B#F9N_VM9_\\S_ -\"C^UK/_GF?^^!6%11R(.9F[_:UG_SS/\
MWP*/[6L_^>9_[X%85%'(@YF;O]K6?_/,_P#? H_M:S_YYG_O@5A44<B#F9N_
MVM9_\\S_ -\"C^UK/_GF?^^!6%11R(.9F[_:UG_SS/\ WP*/[6L_^>9_[X%8
M5%'(@YF;O]K6?_/,_P#? H_M:S_YYG_O@5A44<B#F9N_VM9_\\S_ -\"C^UK
M/_GF?^^!6%11R(.9F[_:UG_SS/\ WP*/[6L_^>9_[X%85%'(@YF;O]K6?_/,
M_P#? H_M:S_YYG_O@5A44<B#F9N_VM9_\\S_ -\"C^UK/_GF?^^!6%11R(.9
MF[_:UG_SS/\ WP*/[6L_^>9_[X%85%'(@YF<+;_LW_".R^-3_%JU\*&T^($C
M,TFK6U[<Q+(6B\IBT"RB%LIURAR?F//->K_VM9_\\S_WP*PJ*7LT',S=_M:S
M_P">9_[X%']K6?\ SS/_ 'P*PJ*?(@YF;O\ :UG_ ,\S_P!\"C^UK/\ YYG_
M +X%85%'(@YF;O\ :UG_ ,\S_P!\"C^UK/\ YYG_ +X%85%'(@YF;O\ :UG_
M ,\S_P!\"C^UK/\ YYG_ +X%85%'(@YF;O\ :UG_ ,\S_P!\"C^UK/\ YYG_
M +X%85%'(@YF;O\ :UG_ ,\S_P!\"C^UK/\ YYG_ +X%85%'(@YF;O\ :UG_
M ,\S_P!\"C^UK/\ YYG_ +X%85%'(@YF;O\ :UG_ ,\S_P!\"C^UK/\ YYG_
M +X%85%'(@YF;O\ :UG_ ,\S_P!\"C^UK/\ YYG_ +X%85%'(@YF;O\ :UG_
M ,\S_P!\"C^UK/\ YYG_ +X%85%'(@YF;O\ :UG_ ,\S_P!\"C^UK/\ YYG_
M +X%85%'(@YF<1\:/V=?A-^T-?Z+>?$+PQ)XCET;?]A22^NH(HMY4OF.*54;
M.Q<[@<A0.G%>H6^H:=:P1PPVZPPQJ$2..,*JJ!@  = !6-12]F@YF;O]K6?_
M #S/_? H_M:S_P">9_[X%85%/D0<S-W^UK/_ )YG_O@4?VM9_P#/,_\ ? K"
MHHY$',S=_M:S_P">9_[X%']K6?\ SS/_ 'P*PJ*.1!S,W?[6L_\ GF?^^!1_
M:UG_ ,\S_P!\"L*BCD0<S-W^UK/_ )YG_O@4?VM9_P#/,_\ ? K"HHY$',S=
M_M:S_P">9_[X%']K6?\ SS/_ 'P*PJ*.1!S,W?[6L_\ GF?^^!1_:UG_ ,\S
M_P!\"L*BCD0<S-W^UK/_ )YG_O@4?VM9_P#/,_\ ? K"HHY$',S=_M:S_P">
M9_[X%']K6?\ SS/_ 'P*PJ*.1!S,W?[6L_\ GF?^^!1_:UG_ ,\S_P!\"L*B
MCD0<S-W^UK/_ )YG_O@4?VM9_P#/,_\ ? K"HHY$',S=_M:S_P">9_[X%']K
M6?\ SS/_ 'P*PJ*.1!S,W?[6L_\ GF?^^!1_:UG_ ,\S_P!\"L*BCD0<S-W^
MUK/_ )YG_O@4?VM9_P#/,_\ ? K"HHY$',S=_M:S_P">9_[X%6_M47V/SMO[
MK&<8]_2N7K<'_(!_X#_6HE%*Q28O]K6?_/,_]\"C^UK/_GF?^^!6%15\B)YF
M;O\ :UG_ ,\S_P!\"C^UK/\ YYG_ +X%85%'(@YF;O\ :UG_ ,\S_P!\"C^U
MK/\ YYG_ +X%85%'(@YF;O\ :UG_ ,\S_P!\"C^UK/\ YYG_ +X%85%'(@YF
M;O\ :UG_ ,\S_P!\"C^UK/\ YYG_ +X%85%'(@YF;O\ :UG_ ,\S_P!\"C^U
MK/\ YYG_ +X%85%'(@YF;O\ :UG_ ,\S_P!\"C^UK/\ YYG_ +X%85%'(@YF
M;O\ :UG_ ,\S_P!\"C^UK/\ YYG_ +X%85%'(@YF;O\ :UG_ ,\S_P!\"C^U
MK/\ YYG_ +X%85%'(@YF;O\ :UG_ ,\S_P!\"C^UK/\ YYG_ +X%85%'(@YF
M;O\ :UG_ ,\S_P!\"C^UK/\ YYG_ +X%85%'(@YF;O\ :UG_ ,\S_P!\"C^U
MK/\ YYG_ +X%85%'(@YF;O\ :UG_ ,\S_P!\"C^UK/\ YYG_ +X%85%'(@YF
M;O\ :UG_ ,\S_P!\"C^UK/\ YYG_ +X%85%'(@YF;O\ :UG_ ,\S_P!\"C^U
MK/\ YYG_ +X%85%'(@YF;O\ :UG_ ,\S_P!\"C^UK/\ YYG_ +X%85%'(@YF
M;O\ :UG_ ,\S_P!\"C^UK/\ YYG_ +X%85%'(@YF;O\ :UG_ ,\S_P!\"C^U
MK/\ YYG_ +X%85%'(@YF;O\ :UG_ ,\S_P!\"C^UK/\ YYG_ +X%85%'(@YF
M;O\ :UG_ ,\S_P!\"C^UK/\ YYG_ +X%85%'(@YF;O\ :UG_ ,\S_P!\"C^U
MK/\ YYG_ +X%85%'(@YF;O\ :UG_ ,\S_P!\"C^UK/\ YYG_ +X%85%'(@YF
M<W\:/@S\-?VA?#EKH7Q!\-)XATRUN!=P1M++;O%*%*[EDA='&0Q!&[!XR#@5
MU/A#2M \">%M*\.Z+;36^D:7;):6D,TTEPT<2 *B^9*S.V  !N8G %144O9H
M.9F[_:UG_P \S_WP*/[6L_\ GF?^^!6%13Y$',S=_M:S_P">9_[X%']K6?\
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M,R3_ /!3>V>,80ZO9X&,?\N4=?I17YH:I_RDNL_^PO:?^D4=?I?7L9QMA_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-/$7A/\ 9\\&[[W6-4N[>XU2WA/+R.P%I;'ZD^:P/3$1]:^X?V?/@SI?[/\
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MMPW41S1K(H/OAA6Y7DW[)/\ R:[\)?\ L5=-_P#2:.O6:Z%L9!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M;DG_ " 1_N#^=8=;DG_(!'^X/YUAU$.I4N@44459(4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'R?\
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M5,'& 48$\BOUSKP[XV?L6_"#X_ZHVK>+/"D;ZXP"MJVGS/:W,@ P-Y0@28
M!<,0  *<D[W0D^C/@/\ X*+?M,:)^U5XE\"_"WX52R^*A%J'F/<VT;".ZO)
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M:***T("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *W!_P @'_@/]:PZW!_R ?\ @/\ 6LY]"HF'1116
MA(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?I?7YH:I_P I+K/_ +"]I_Z11U^E]>MG&V'_ ,"/)RK>O_C9^9/_  3_ /\
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MVAZ#ITDC):Q!9#&US(!GYFPSLV"0O Z8K]<OV6_^39/A%_V*&D?^D45?D/\
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M330_$@\3>$UN4M[A;F 07=F7.$)P2LBEL#<-I!8?+C)'VY_P2R^.>O\ Q>^
M^H:7XEO)=3U'PO?+80WUPY>66V:,-$KL>69<.N2<[0OID_&G[7?[>.N_MD6>
MG?#?P%X/U"ST6XNXYC:[?M6H:E,HRB".,$(JDD[5+$D Y&,5^@O[ /[-=_\
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MM?%/[(?PRN;642BVTP6$@SDI) [1,I].4_(CUKWZMEL0%%%%,04444 %%%%
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MK7NH:7:W<Y1=JF22%6; [#)/%)23=AVL=%1113$?B%^RS_RDLTS_ +&G5O\
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M5%%%:$!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR!CN:]:_L&X_OQ_F?\*/[!N/[\?YG_"GS1"S/(O '[-/PJ^%NH#4/"OP_P!
MT;45.Y+Z&Q1KA.,?+*P+*/8$5VGB;PAH/C2RCL_$&B:=KMG'()DM]3M([B-7
M (#!7! .&(SUP3ZUU/\ 8-Q_?C_,_P"%']@W']^/\S_A2YHA9G,>'/"NB^#]
M/-AH.CV&B6)<RFVTVU2WB+D %MJ #)P.?85JUI?V#<?WX_S/^%']@W']^/\
M,_X4^:/<.5F;16E_8-Q_?C_,_P"%']@W']^/\S_A1S1[ARLS:*TO[!N/[\?Y
MG_"C^P;C^_'^9_PHYH]PY69M%:7]@W']^/\ ,_X4?V#<?WX_S/\ A1S1[ARL
MS:*TO[!N/[\?YG_"C^P;C^_'^9_PHYH]PY69M%:7]@W']^/\S_A1_8-Q_?C_
M #/^%'-'N'*S-HK2_L&X_OQ_F?\ "C^P;C^_'^9_PHYH]PY69M%:7]@W']^/
M\S_A1_8-Q_?C_,_X4<T>X<K,VBM+^P;C^_'^9_PH_L&X_OQ_F?\ "CFCW#E9
MFT5I?V#<?WX_S/\ A1_8-Q_?C_,_X4<T>X<K,VBM+^P;C^_'^9_PH_L&X_OQ
M_F?\*.:/<.5F;16E_8-Q_?C_ #/^%']@W']^/\S_ (4<T>X<K,VBM+^P;C^_
M'^9_PH_L&X_OQ_F?\*.:/<.5F;16E_8-Q_?C_,_X4?V#<?WX_P S_A1S1[AR
MLS:*TO[!N/[\?YG_  H_L&X_OQ_F?\*.:/<.5F;16E_8-Q_?C_,_X4?V#<?W
MX_S/^%'-'N'*S-HK2_L&X_OQ_F?\*/[!N/[\?YG_  HYH]PY69M%:7]@W']^
M/\S_ (4?V#<?WX_S/^%'-'N'*S-HK2_L&X_OQ_F?\*/[!N/[\?YG_"CFCW#E
M9FT5I?V#<?WX_P S_A1_8-Q_?C_,_P"%'-'N'*S-HK2_L&X_OQ_F?\*/[!N/
M[\?YG_"CFCW#E9FT5I?V#<?WX_S/^%']@W']^/\ ,_X4<T>X<K,VBM+^P;C^
M_'^9_P */[!N/[\?YG_"CFCW#E9FT5I?V#<?WX_S/^%']@W']^/\S_A1S1[A
MRLS:*TO[!N/[\?YG_"C^P;C^_'^9_P *.:/<.5F;16E_8-Q_?C_,_P"%']@W
M']^/\S_A1S1[ARLS:*TO[!N/[\?YG_"C^P;C^_'^9_PHYH]PY69M%:7]@W']
M^/\ ,_X4?V#<?WX_S/\ A1S1[ARLS:*TO[!N/[\?YG_"C^P;C^_'^9_PHYH]
MPY69M%:7]@W']^/\S_A1_8-Q_?C_ #/^%'-'N'*S-HK2_L&X_OQ_F?\ "C^P
M;C^_'^9_PHYH]PY69M%:7]@W']^/\S_A1_8-Q_?C_,_X4<T>X<K,VBM+^P;C
M^_'^9_PH_L&X_OQ_F?\ "CFCW#E9FT5I?V#<?WX_S/\ A1_8-Q_?C_,_X4<T
M>X<K,VBM+^P;C^_'^9_PH_L&X_OQ_F?\*.:/<.5F;16E_8-Q_?C_ #/^%']@
MW']^/\S_ (4<T>X<K,VBM+^P;C^_'^9_PH_L&X_OQ_F?\*.:/<.5F;16E_8-
MQ_?C_,_X4?V#<?WX_P S_A1S1[ARLS:*TO[!N/[\?YG_  H_L&X_OQ_F?\*.
M:/<.5F;16E_8-Q_?C_,_X4?V#<?WX_S/^%'-'N'*S-HK2_L&X_OQ_F?\*/[!
MN/[\?YG_  HYH]PY69M%:7]@W']^/\S_ (4?V#<?WX_S/^%'-'N'*S-HK2_L
M&X_OQ_F?\*/[!N/[\?YG_"CFCW#E9FT5I?V#<?WX_P S_A1_8-Q_?C_,_P"%
M'-'N'*S-HK2_L&X_OQ_F?\*/[!N/[\?YG_"CFCW#E9FT5I?V#<?WX_S/^%']
M@W']^/\ ,_X4<T>X<K,VBM+^P;C^_'^9_P */[!N/[\?YG_"CFCW#E9FT5I?
MV#<?WX_S/^%']@W']^/\S_A1S1[ARLM2?\@$?[@_G6'71M9NVF_9\KOV@9[=
M:SO[!N/[\?YG_"HC)*XVF9M%:7]@W']^/\S_ (4?V#<?WX_S/^%7S1[BY69M
M%:7]@W']^/\ ,_X4?V#<?WX_S/\ A1S1[ARLS:*TO[!N/[\?YG_"C^P;C^_'
M^9_PHYH]PY69M%:7]@W']^/\S_A1_8-Q_?C_ #/^%'-'N'*S-HK2_L&X_OQ_
MF?\ "C^P;C^_'^9_PHYH]PY69M%:7]@W']^/\S_A1_8-Q_?C_,_X4<T>X<K,
MVBM+^P;C^_'^9_PH_L&X_OQ_F?\ "CFCW#E9FT5I?V#<?WX_S/\ A1_8-Q_?
MC_,_X4<T>X<K,VBM+^P;C^_'^9_PH_L&X_OQ_F?\*.:/<.5F;16E_8-Q_?C_
M #/^%']@W']^/\S_ (4<T>X<K,VBM+^P;C^_'^9_PH_L&X_OQ_F?\*.:/<.5
MF;16E_8-Q_?C_,_X4?V#<?WX_P S_A1S1[ARLS:*TO[!N/[\?YG_  H_L&X_
MOQ_F?\*.:/<.5F;16E_8-Q_?C_,_X4?V#<?WX_S/^%'-'N'*S-HK2_L&X_OQ
M_F?\*/[!N/[\?YG_  HYH]PY69M>>?$3]GGX9_%JZ%UXO\#:'K]Z !]LN[)#
M<8'0>: 'Q[9Q7JO]@W']^/\ ,_X4?V#<?WX_S/\ A1S1"S/!O"O[&?P/\%WL
M5YI7PQ\/)=0G,<MU:BZ9#G.1YI;!]#U':O9E4*H50 H& !T%:?\ 8-Q_?C_,
M_P"%']@W']^/\S_A2YHA9F;16E_8-Q_?C_,_X4?V#<?WX_S/^%/FCW#E9FU\
M0_\ !5;]GD_%#X)Q>.=*MO,U_P &;[B4(/FET]\>>/?80LG/15D]:^\/[!N/
M[\?YG_"H;SPJ=0M)K6Z2WN+:=&BEAE&Y'1A@JP(P002"#2<HM6N"31\@?\$R
M_C6/BW^S)I.FW=QYNM^$G_L6Y5FRQA0 VSX]/*(3/<Q-7UG7P#\(_P!DKXI?
ML@_MI7-UX%\.7'B#X->)@L%W+!=1XL(9&)7>KN&+6[\A@&)C8XRS$#]$/[!N
M/[\?YG_"E&2MJ-Q=]#-KGO$_P\\*^-IH)?$7AG1]?EMU*POJEA%<M&"<D*74
MX!P.E=G_ &#<?WX_S/\ A1_8-Q_?C_,_X57-'N+E9AZ;IEGHNGV]AI]I!86-
MN@BAMK:-8XHD P%55   ]!5JM+^P;C^_'^9_PH_L&X_OQ_F?\*.:/<.5F;7+
M^(OA;X+\7ZA]OUWPAH.M7^P1_:M1TR&XEVCHNYU)P,GCWKNO[!N/[\?YG_"C
M^P;C^_'^9_PHYHA9F7'&L,:HBA$4;551@ #H *=6E_8-Q_?C_,_X4?V#<?WX
M_P S_A1S1[ARLX+7OA/X(\5:G)J6M^#?#^L:C(%5[N_TN">5@!@ NZ$G   Y
M[5TUK:PV-M%;V\4=O;PH(XXHE"HB@8"@#@ #C K7_L&X_OQ_F?\ "C^P;C^_
M'^9_PHYHA9F;16E_8-Q_?C_,_P"%']@W']^/\S_A1S1[ARLX/3_A3X)TG7%U
MJQ\':!9ZPLC2C4+?2X$N [9W-Y@7=DY.3GG)KJJTO[!N/[\?YG_"C^P;C^_'
M^9_PHYHA9F;16E_8-Q_?C_,_X4?V#<?WX_S/^%'-'N'*SY[^&'[&OPW^$_Q6
MU/XCZ3;:C>>+]1^T&>_U2]:X.^=]TKJ",!F.1GT9AWKW*M+^P;C^_'^9_P *
M/[!N/[\?YG_"ES1069DW%O%=6\D$\:30R*4>.10RLI&""#U!':OEKQ=_P3*^
M 'B[7IM5/A6XT>29M\MKI-_+!;LQ.3B/)5!_LIM ["OKO^P;C^_'^9_PH_L&
MX_OQ_F?\*.:+W"S/.?A3\&O!7P0\-#0? _AVT\/:9NWR);@M),^,;Y9&)>1L
M<98DXXZ5VE:7]@W']^/\S_A4<^BW$,,DGRR;%+;(\EFP.@XZT^:(69^<7_!7
M_P"-1T;P#X:^%NFS[M0\07 U'4(8SEOLL38B0CT>;D>\!KZ2_8@_9^'[.?[/
MNA:!=0B/Q#?C^U-9/<74JKF/_MF@2/TRA/>OGOX&_L>?$SXW_M>:]\:/CAX9
M?P[ING7"W&AZ'?7,4^]E)%LF(V8!(54,<XW2$'D;A7Z)_P!@W']^/\S_ (5"
MDKW933M8S:*TO[!N/[\?YG_"C^P;C^_'^9_PJ^:/<GE9FT5I?V#<?WX_S/\
MA1_8-Q_?C_,_X4<T>X<K,VBM+^P;C^_'^9_PH_L&X_OQ_F?\*.:/<.5F;16E
M_8-Q_?C_ #/^%']@W']^/\S_ (4<T>X<K,VBM+^P;C^_'^9_PH_L&X_OQ_F?
M\*.:/<.5F;16E_8-Q_?C_,_X4?V#<?WX_P S_A1S1[ARLS:*TO[!N/[\?YG_
M  H_L&X_OQ_F?\*.:/<.5F;16E_8-Q_?C_,_X4?V#<?WX_S/^%'-'N'*S-HK
M2_L&X_OQ_F?\*/[!N/[\?YG_  HYH]PY69M%:7]@W']^/\S_ (4?V#<?WX_S
M/^%'-'N'*S-HK2_L&X_OQ_F?\*/[!N/[\?YG_"CFCW#E9FT5I?V#<?WX_P S
M_A1_8-Q_?C_,_P"%'-'N'*S-HK2_L&X_OQ_F?\*/[!N/[\?YG_"CFCW#E9FT
M5I?V#<?WX_S/^%']@W']^/\ ,_X4<T>X<K,VBM+^P;C^_'^9_P */[!N/[\?
MYG_"CFCW#E9FUN#_ ) /_ ?ZU5_L&X_OQ_F?\*T?L;_V9]GRN_&,]NM1*2=A
MQ3.<HK2_L&X_OQ_F?\*/[!N/[\?YG_"KYH]Q<K,VBM+^P;C^_'^9_P */[!N
M/[\?YG_"CFCW#E9FT5I?V#<?WX_S/^%']@W']^/\S_A1S1[ARLS:*TO[!N/[
M\?YG_"C^P;C^_'^9_P *.:/<.5F;16E_8-Q_?C_,_P"%']@W']^/\S_A1S1[
MARLS:*TO[!N/[\?YG_"C^P;C^_'^9_PHYH]PY69M%:7]@W']^/\ ,_X4?V#<
M?WX_S/\ A1S1[ARLS:*TO[!N/[\?YG_"C^P;C^_'^9_PHYH]PY69M%:7]@W'
M]^/\S_A1_8-Q_?C_ #/^%'-'N'*S-HK2_L&X_OQ_F?\ "C^P;C^_'^9_PHYH
M]PY69M%:7]@W']^/\S_A1_8-Q_?C_,_X4<T>X<K,VBM+^P;C^_'^9_PH_L&X
M_OQ_F?\ "CFCW#E9FT5I?V#<?WX_S/\ A1_8-Q_?C_,_X4<T>X<K,VBM+^P;
MC^_'^9_PH_L&X_OQ_F?\*.:/<.5F;16E_8-Q_?C_ #/^%']@W']^/\S_ (4<
MT>X<K,VBM+^P;C^_'^9_PH_L&X_OQ_F?\*.:/<.5F;16E_8-Q_?C_,_X4?V#
M<?WX_P S_A1S1[ARLS:*TO[!N/[\?YG_  H_L&X_OQ_F?\*.:/<.5F;16E_8
M-Q_?C_,_X4?V#<?WX_S/^%'-'N'*S-HK2_L&X_OQ_F?\*/[!N/[\?YG_  HY
MH]PY69M%:7]@W']^/\S_ (4?V#<?WX_S/^%'-'N'*S-HK2_L&X_OQ_F?\*/[
M!N/[\?YG_"CFCW#E9FT5I?V#<?WX_P S_A1_8-Q_?C_,_P"%'-'N'*S-KR?Q
MY^R?\'_B;JDNI^)?AWH.HZE*29;P6HAFE).27>/:S'W8DU[5_8-Q_?C_ #/^
M%']@W']^/\S_ (4N:(69YI\._@9\/?A&TLG@WP7HGAN>9/+EN=/LHXYY%X^5
MI,;F'&<$XSS7<UI?V#<?WX_S/^%']@W']^/\S_A3YHA9F;16E_8-Q_?C_,_X
M4?V#<?WX_P S_A1S1[ARLS:*TO[!N/[\?YG_  H_L&X_OQ_F?\*.:/<.5F;1
M6E_8-Q_?C_,_X4?V#<?WX_S/^%'-'N'*S-HK2_L&X_OQ_F?\*/[!N/[\?YG_
M  HYH]PY69M%:7]@W']^/\S_ (4?V#<?WX_S/^%'-'N'*S-HK2_L&X_OQ_F?
M\*/[!N/[\?YG_"CFCW#E9FT5I?V#<?WX_P S_A1_8-Q_?C_,_P"%'-'N'*S-
MHK2_L&X_OQ_F?\*/[!N/[\?YG_"CFCW#E9FT5I?V#<?WX_S/^%']@W']^/\
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M:BBR"[+/]I77_/9JUQ<2?V/YN\^9MSN_&N?K<'_(!_X#_6HDEH5$S/[2NO\
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MSV:JU%%D%V? >L2--_P4PM'<[F.KV>2?^O*.OTLK\T-4_P"4EUG_ -A>T_\
M2*.OTOKU\XVP_P#@1Y&5;U_\;/S)_P""?_\ R<!XT_[!=Q_Z5PU^@U?GS_P3
M_P#^3@/&G_8+N/\ TKAK]!JWSK_>WZ+\C+)_]U^;"BBBO"/;"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH W)/\ D C_ '!_.L.MR3_D C_<'\ZPZB'4J70****LD**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "MP?\
M(!_X#_6L.MP?\@'_ (#_ %K.?0J)AT445H2%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\ :I_RDNL_^PO:
M?^D4=?I?7YH:I_RDNL_^PO:?^D4=?I?7K9QMA_\  CR<JWK_ .-GYD_\$_\
M_DX#QI_V"[C_ -*X:_0:OSY_X)__ /)P'C3_ +!=Q_Z5PU^@U;YU_O;]%^1E
MD_\ NOS84445X1[84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% &Y)_R 1_N#^=8=;DG_ " 1_N#^
M=8=1#J5+H%%%%62%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !6X/^0#_ ,!_K6'6X/\ D _\!_K6<^A43#HHHK0D
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#X U3_ )276?\ V%[3_P!(HZ_2^OS0U3_E)=9_]A>T_P#2*.OT
MOKULXVP_^!'DY5O7_P ;/S)_X)__ /)P'C3_ +!=Q_Z5PU^@U?GS_P $_P#_
M ). \:?]@NX_]*X:_0:M\Z_WM^B_(RR?_=?FPHHHKPCVPHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** -R3_D C_<'\ZPZW)/^0"/]P?SK#J(=2I= HHHJR0HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT:G_ $#S^X_0.BOS\_X4[^V/_P ]O$'_ (4UI_\ )%'_  IW]L?_ )[>(/\
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M_P">WB#_ ,*:T_\ DBC^S:7_ $$P^]!_:-3_ *!Y_<?H'17Y^?\ "G?VQ_\
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M^S:7_03#[T']HU/^@>?W'Z!T5^?G_"G?VQ_^>WB#_P *:T_^2*/^%._MC_\
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M_P"2*/[-I?\ 03#[T']HU/\ H'G]Q^@=%?GY_P *=_;'_P">WB#_ ,*:T_\
MDBC_ (4[^V/_ ,]O$'_A36G_ ,D4?V;2_P"@F'WH/[1J?] \_N/T#HK\_/\
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M4_Z!Y_<?H'17Y^?\*=_;'_Y[>(/_  IK3_Y(H_X4[^V/_P ]O$'_ (4UI_\
M)%']FTO^@F'WH/[1J?\ 0//[C] Z*_/S_A3O[8__ #V\0?\ A36G_P D4?\
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MTO\ H)A]Z%_:-3_H'G]Q^@=%?GY_PIW]L?\ Y[>(/_"FM/\ Y(H_X4[^V/\
M\]O$'_A36G_R11_9M+_H)A]Z#^T:G_0//[C] Z*_/S_A3O[8_P#SV\0?^%-:
M?_)%'_"G?VQ_^>WB#_PIK3_Y(H_LVE_T$P^]!_:-3_H'G]Q^@=%?GY_PIW]L
M?_GMX@_\*:T_^2*/^%._MC_\]O$'_A36G_R11_9M+_H)A]Z#^T:G_0//[C]
MZ*_/S_A3O[8__/;Q!_X4UI_\D4?\*=_;'_Y[>(/_  IK3_Y(H_LVE_T$P^]!
M_:-3_H'G]Q^@=%?GY_PIW]L?_GMX@_\ "FM/_DBC_A3O[8__ #V\0?\ A36G
M_P D4?V;2_Z"8?>@_M&I_P! \_N/T#HK\_/^%._MC_\ /;Q!_P"%-:?_ "11
M_P *=_;'_P">WB#_ ,*:T_\ DBC^S:7_ $$P^]!_:-3_ *!Y_<?H'17Y^?\
M"G?VQ_\ GMX@_P#"FM/_ )(H_P"%._MC_P#/;Q!_X4UI_P#)%']FTO\ H)A]
MZ#^T:G_0//[C] Z*_/S_ (4[^V/_ ,]O$'_A36G_ ,D4?\*=_;'_ .>WB#_P
MIK3_ .2*/[-I?]!,/O0?VC4_Z!Y_<?H'17Y^?\*=_;'_ .>WB#_PIK3_ .2*
M/^%._MC_ //;Q!_X4UI_\D4?V;2_Z"8?>@_M&I_T#S^X_0.BOS\_X4[^V/\
M\]O$'_A36G_R11_PIW]L?_GMX@_\*:T_^2*/[-I?]!,/O0?VC4_Z!Y_<?H'1
M7Y^?\*=_;'_Y[>(/_"FM/_DBC_A3O[8__/;Q!_X4UI_\D4?V;2_Z"8?>@_M&
MI_T#S^X_0.BOS\_X4[^V/_SV\0?^%-:?_)%'_"G?VQ_^>WB#_P *:T_^2*/[
M-I?]!,/O0?VC4_Z!Y_<?H'17Y^?\*=_;'_Y[>(/_  IK3_Y(H_X4[^V/_P ]
MO$'_ (4UI_\ )%']FTO^@F'WH/[1J?\ 0//[C] Z*_/S_A3O[8__ #V\0?\
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M^@F'WH/[1J?] \_N/T#HK\_/^%._MC_\]O$'_A36G_R11_PIW]L?_GMX@_\
M"FM/_DBC^S:7_03#[T']HU/^@>?W'Z!T5^?G_"G?VQ_^>WB#_P *:T_^2*/^
M%._MC_\ /;Q!_P"%-:?_ "11_9M+_H)A]Z#^T:G_ $#S^X_0.BOS\_X4[^V/
M_P ]O$'_ (4UI_\ )%'_  IW]L?_ )[>(/\ PIK3_P"2*/[-I?\ 03#[T']H
MU/\ H'G]Q^@=%?GY_P *=_;'_P">WB#_ ,*:T_\ DBC_ (4[^V/_ ,]O$'_A
M36G_ ,D4?V;2_P"@F'WH/[1J?] \_N/T#HK\_/\ A3O[8_\ SV\0?^%-:?\
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M'_Y[>(/_  IK3_Y(H_LVE_T$P^]!_:-3_H'G]Q^@=%?GY_PIW]L?_GMX@_\
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M'_Y[>(/_  IK3_Y(H_X4[^V/_P ]O$'_ (4UI_\ )%']FTO^@F'WH/[1J?\
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M_P"2*/[-I?\ 03#[T']HU/\ H'G]Q^@=%?GY_P *=_;'_P">WB#_ ,*:T_\
MDBC_ (4[^V/_ ,]O$'_A36G_ ,D4?V;2_P"@F'WH/[1J?] \_N/T#HK\_/\
MA3O[8_\ SV\0?^%-:?\ R11_PIW]L?\ Y[>(/_"FM/\ Y(H_LVE_T$P^]!_:
M-3_H'G]Q^@=%?GY_PIW]L?\ Y[>(/_"FM/\ Y(H_X4[^V/\ \]O$'_A36G_R
M11_9M+_H)A]Z#^T:G_0//[C] Z*_/S_A3O[8_P#SV\0?^%-:?_)%'_"G?VQ_
M^>WB#_PIK3_Y(H_LVE_T$P^]!_:-3_H'G]Q^@=%?GY_PIW]L?_GMX@_\*:T_
M^2*/^%._MC_\]O$'_A36G_R11_9M+_H)A]Z#^T:G_0//[C] Z*_/S_A3O[8_
M_/;Q!_X4UI_\D4?\*=_;'_Y[>(/_  IK3_Y(H_LVE_T$P^]!_:-3_H'G]Q^@
M=%?GY_PIW]L?_GMX@_\ "FM/_DBC_A3O[8__ #V\0?\ A36G_P D4?V;2_Z"
M8?>@_M&I_P! \_N/T#HK\_/^%._MC_\ /;Q!_P"%-:?_ "11_P *=_;'_P">
MWB#_ ,*:T_\ DBC^S:7_ $$P^]!_:-3_ *!Y_<?H'17Y^?\ "G?VQ_\ GMX@
M_P#"FM/_ )(H_P"%._MC_P#/;Q!_X4UI_P#)%']FTO\ H)A]Z#^T:G_0//[C
M] Z*_/S_ (4[^V/_ ,]O$'_A36G_ ,D4?\*=_;'_ .>WB#_PIK3_ .2*/[-I
M?]!,/O0?VC4_Z!Y_<?H'17Y^?\*=_;'_ .>WB#_PIK3_ .2*/^%._MC_ //;
MQ!_X4UI_\D4?V;2_Z"8?>@_M&I_T#S^X_0.BOS\_X4[^V/\ \]O$'_A36G_R
M11_PIW]L?_GMX@_\*:T_^2*/[-I?]!,/O0?VC4_Z!Y_<?H'17Y^?\*=_;'_Y
M[>(/_"FM/_DBC_A3O[8__/;Q!_X4UI_\D4?V;2_Z"8?>@_M&I_T#S^X_0.BO
MS\_X4[^V/_SV\0?^%-:?_)%'_"G?VQ_^>WB#_P *:T_^2*/[-I?]!,/O0?VC
M4_Z!Y_<?H'17Y^?\*=_;'_Y[>(/_  IK3_Y(H_X4[^V/_P ]O$'_ (4UI_\
M)%']FTO^@F'WH/[1J?\ 0//[C] Z*_/S_A3O[8__ #V\0?\ A36G_P D4?\
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+ 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>angn-20211231_g6.jpg
<TEXT>
begin 644 angn-20211231_g6.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" @'"<4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBBB@ HHHH **** "J>L7CZ?I-[=1A6D@@>50W0E5)&?;BKE9OB;_ )%O5?\
MKTE_] -85Y.-*<END_R-:*4JD4^Z/QH_X?5_&_\ Z%;X?_\ @NOO_DRC_A]7
M\;_^A6^'_P#X+K[_ .3*^ *[_P""OP%\=?M#^*;GPY\/M#_X2#6;:T:^EMOM
M<%MMA5T1GW3.BGYI$& <\].#70HN6B1BVEN?8'_#ZOXW_P#0K?#_ /\ !=??
M_)E'_#ZOXW_]"M\/_P#P77W_ ,F5Y5_PZX_:=_Z)G_Y7]+_^2:/^'7'[3O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ$ZPPQ+T^9F( R< >I(%6M:UJQ\-Z/?:MJ=U'9:=8P/<W-S,VU(HT4LS,>P
M!/X5_/Y^W!^VCXA_:Q^(5P([F>P\ :;.RZ-HH8JI ROVF8?Q2N,GG[@.T=RW
M'*;YN2._Y'7&*MSRV_/^OP/T.^*G_!9KX3^$;R>S\':!K?CN6(X%X NGV<G^
MZ\@,OYQ"O.M'_P""Y&G37T::K\';JSLR?GEL_$2W$@'LC6T8/_?0K\POA_\
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M[3:MJ\5A)_WQ'%./_'J[WX,_\%COA3X^U.UTSQEHNJ?#RZN&V"\FD6]L$).
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MN9Y&EEED.6=F.2Q/<DDUQ<S=7E6R7XO;\OQ1V<J5/F>[>GRW_-?B?O'\!_\
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MZV 2=@R4E( )(C=L 9.*_#_XP?L<_&;X"Z0-6\<> =1T?2<A6U"*2*[MHR2
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M6CS=7=^G7_+YGX%U^S__  1O^.G_  FOP3UCX=:A<^9J?A*Z\VT1SR;&<EE
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M_K^O,B$^=>84445F:!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *_"K_@KO_R>5JG_ &!K#_T U^ZM?A5_P5W_ .3RM4_[ UA_Z :Y*_\
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M9I:ZIK&H1"X\.V"LLT5C$>ER^,CSC@[1G]V.OSG"?IC7Y1?\$<_VIOL]S?\
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MORM_G^"._P"*CKT?YW_R_/N?3W_!'3_D[R3_ +%R]_\ 0X:_<2OP[_X(Z?\
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M^BZA);([]98<[HI/^!QE&_X%7UQ_P1[^-0\ _M$7O@J]G\O3/&5D88PQX%Y
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MY8U=V9NK 9VKZ*H%?SET5W*?+!PMO;\+Z?UV.1PO-2OM?_A_S^\_JHK\)/\
M@JU\$-(^#O[3C7GA^SCL-*\4Z>FKFU@4+'%<&1XY@JCH&*!_K(:^,J*Y90YI
M1DNGY=OR?R.B,^6,HM;_ .>_YKYGT!^P3\4)_A/^UI\.M529HK2]U)-(O%!P
M'AN3Y)W>P9U;ZH*_HHK^7'P3?2:7XST"\A.);?4+>9#_ +2R*1^HK^HR-M\:
MMTR,UWRUH0?FU^3_ %9Q1TK27DOU_P" .HHHKE.D**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;O\ I^@4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI7S'_P % _V4_P#AJCX'S:?I4<8\9:&[:AHDC$+YLFW$EN6/19%P,DX#*A/
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M !9_XO\ VX_:NO@C_@L__P FJ:'_ -C7:_\ I-=5][U\$?\ !9__ )-4T/\
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MF74ME=0A@VR6-RCKD$@X92,CBN*,'S^TGUT7Z_I?Y'4Y+EY(^K_3]?Q/M/\
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MOU-[QY-=[_U^A]-?\$M?%%]X<_;4\$P6<I2'5HKRPNT!P)(C;22 'Z/'&W_
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M:7_\C4?\/1OVG?\ HIG_ )0-+_\ D:L#0_?ZBOP!_P"'HW[3O_13/_*!I?\
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MN2K\=/U_]M9V4O@J>G_MT3XB\!_\CQX=_P"PC;_^C5K^HNOY=/ ?_(\^'?\
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M0  #DFO<J_&K_@D5^RG>^-OB0/B_KUBT?AKPZSQZ29EP+R_(VEUSU6($G/\
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M?_Z(6O.?^"FWPMNOBG^Q_P"+HK" W&H:&T6N0QJ,DK 3YN/<0M*?PKVSX ^
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M7RT;Z&0S?@ >]??=9_A_0=.\*Z'8:-H]E#IVE:? EM:V=N@2.&)%"JB@=
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M1FN:4YU9[R=PHHHJ"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEBCPQV1@8!XW>M?>M%%;2FY63Z:&,8J+;74*AO+.WU&SGM+N".ZM9T:*6&9
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MCJ22>68G)+,222222:Z&BM'-VY5L9\JOS=0KY:_;B_84T/\ ;"T+3[J/4O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M69EDE+!#*B[B 1G'3(K]0:*WA+D=_7\58QG'G5O3\'<****@L**** "BBB@
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MZ^)G_11?%G_@[NO_ (NC_A?7Q,_Z*+XL_P#!W=?_ !='^K%;_GXON8?V7/\
MF1^S-%?C-_POKXF?]%%\6?\ @[NO_BZ_0#_@G_XNUWQG\&]9O?$&M:AKMY'K
M\T*7&I74EQ(L8M[8A SDD+EF..F2?6O.QV25,#1]M*::.?$8&6'ASN5SZ9HH
MHKYL\P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^4/\ @I+_ ,D-T/\ [&.#
M_P!);JOJ^OE#_@I+_P D-T/_ +&.#_TENJ];*?\ ?J7J=>$_CP]3\VZ***_8
MC[(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *_23_ ()M?\D-US_L8Y__ $EM:_-NOTD_X)M?\D-US_L8Y_\ TEM:
M^:XA_P!Q?JCS,Q_@/U1]7T445^6'RH4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5\H?\ !27_ )(;H?\ V,<'_I+=5]7U\H?\%)?^2&Z'_P!C'!_Z2W5>ME/^
M_4O4Z\)_'AZGYMT445^Q'V04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5^DG_  3:_P"2&ZY_V,<__I+:U^;=?I)_
MP3:_Y(;KG_8QS_\ I+:U\UQ#_N+]4>9F/\!^J/J^BBBORP^5"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "OE#_@I+_P D-T/_ +&.#_TENJ^KZ^4/^"DO_)#=
M#_[&.#_TENJ];*?]^I>IUX3^/#U/S;HHHK]B/L@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K])/^";7_ "0W7/\
ML8Y__26UK\VZ_23_ ()M?\D-US_L8Y__ $EM:^:XA_W%^J/,S'^ _5'U?111
M7Y8?*A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7RA_P4E_Y(;H?_ &,<'_I+
M=5]7U\H?\%)?^2&Z'_V,<'_I+=5ZV4_[]2]3KPG\>'J?FW1117[$?9!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MZ2?\$VO^2&ZY_P!C'/\ ^DMK7YMU^DG_  3:_P"2&ZY_V,<__I+:U\UQ#_N+
M]4>9F/\  ?JCZOHHHK\L/E0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7RA_P %)?\ DANA_P#8
MQP?^DMU7U?7RA_P4E_Y(;H?_ &,<'_I+=5ZN5_[[2]3NP/\ O,/4_-NBBBOU
MGF/O.4****.8.4****.8.4****.8.4****.8.4****.8.4****.8.4****.8
M.4****.8.4****.8.4****.8.4****.8.4****.8.4*_23_@FU_R0W7/^QCG
M_P#26UK\VZ_23_@FU_R0W7/^QCG_ /26UKYS/G?!/U1Y&:*V&?JCZOHHHK\T
M/C HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KY/_ ."DW_)#=#_[&.#_ -);JOK"
MOD__ (*3?\D,T+_L8X/_ $ENJ]++O][I^IZ.7?[W3]3\V]HHVBDS1FOTSF/T
MOE%VBC:*3-&:.8.47:*-HI,T9HY@Y1=HHVBDS1FCF#E%VBC:*3-&:.8.47:*
M-HI,T9HY@Y1=HHVBDS1FCF#E%VBC:*3-&:.8.47:*-HI,T9HY@Y1=HHVBDS1
MFCF#E%VBC:*3-&:.8.47:*-HI,T9HY@Y1=HHVBDS1FCF#E%VBOTD_P"";/\
MR0W7/^QCG_\ 26UK\VLU^DO_  39_P"2&:[_ -C'/_Z2VM>%G3_V1^J/"SI6
MPC]4?6%%%%?GQ\ %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHKX0_.0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MIK=([+P=^QEH+>'X)/$VH:A+K,R!YEM)42.%B,[1E26([D\'TKA;=M:_9/\
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MT[9XXZUV?[+GQ:N_B+X5N=.U><SZUI)5'F<_//$V=KMZL"""?H>IKVROCO\
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M?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\:
M+M%4O[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?
M^_R_XT?VUI__ #_VO_?Y?\: +M%4O[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K
M_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\: +M%4O[:T_P#Y
M_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__
M #_VO_?Y?\: +M%4O[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT5
M2_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\: +M%4O[:T_P#Y_P"U_P"_R_XT
M?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\:
M+M%4O[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?
M^_R_XT?VUI__ #_VO_?Y?\: +M%4O[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K
M_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\: +M%4O[:T_P#Y
M_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__
M #_VO_?Y?\: +M%4O[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT5
M2_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\: +M%4O[:T_P#Y_P"U_P"_R_XT
M?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\:
M+M%4O[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?
M^_R_XT?VUI__ #_VO_?Y?\: +M%4O[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K
M_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\: +M%4O[:T_P#Y
M_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__
M #_VO_?Y?\: +M%4O[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT5
M2_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\: +M%4O[:T_P#Y_P"U_P"_R_XT
M?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\:
M+M%4O[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?
M^_R_XT?VUI__ #_VO_?Y?\: +M%4O[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K
M_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\: +M%4O[:T_P#Y
M_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__
M #_VO_?Y?\: +M%4O[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT5
M2_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\: +M%4O[:T_P#Y_P"U_P"_R_XT
M?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\:
M+M%4O[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?
M^_R_XT?VUI__ #_VO_?Y?\: +M%4O[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K
M_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\: +M%4O[:T_P#Y
M_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__
M #_VO_?Y?\: +M%4O[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT5
M2_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\: +M%4O[:T_P#Y_P"U_P"_R_XT
M?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\:
M+M%4O[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?
M^_R_XT?VUI__ #_VO_?Y?\: +M%4O[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K
M_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\: +M%4O[:T_P#Y
M_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__
M #_VO_?Y?\: +M%4O[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT5
M2_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\: +M%4O[:T_P#Y_P"U_P"_R_XT
M?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\:
M+M%4O[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?
M^_R_XT?VUI__ #_VO_?Y?\: +M%4O[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K
M_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\: +M%4O[:T_P#Y
M_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__
M #_VO_?Y?\: +M%4O[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT5
M2_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\: +M%4O[:T_P#Y_P"U_P"_R_XT
M?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\:
M+M%4O[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?
M^_R_XT?VUI__ #_VO_?Y?\: +M%4O[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K
M_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\: +M%4O[:T_P#Y
M_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__
M #_VO_?Y?\: +M%4O[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT5
M2_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\: +M%4O[:T_P#Y_P"U_P"_R_XT
M?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\:
M+M%4O[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?
M^_R_XT?VUI__ #_VO_?Y?\: +M%4O[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K
M_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\: +M%4O[:T_P#Y
M_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__
M #_VO_?Y?\: +M%4O[:T_P#Y_P"U_P"_R_XT?VUI_P#S_P!K_P!_E_QH NT5
M2_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\: +M%4O[:T_P#Y_P"U_P"_R_XT
M?VUI_P#S_P!K_P!_E_QH NT52_MK3_\ G_M?^_R_XT?VUI__ #_VO_?Y?\:
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M%=_]1#_R#_\ 95V=% '&?\*[_P"HA_Y!_P#LJ/\ A7?_ %$/_(/_ -E79T4
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M *B'_D'_ .RH_P"%=_\ 40_\@_\ V5=G10!QG_"N_P#J(?\ D'_[*C_A7?\
MU$/_ "#_ /95V=% '&?\*[_ZB'_D'_[*C_A7?_40_P#(/_V5=G10!QG_  KO
M_J(?^0?_ +*C_A7?_40_\@__ &5=G10!QG_"N_\ J(?^0?\ [*C_ (5W_P!1
M#_R#_P#95V=% '&?\*[_ .HA_P"0?_LJ/^%=_P#40_\ (/\ ]E79T4 <9_PK
MO_J(?^0?_LJ/^%=_]1#_ ,@__95V=% '&?\ "N_^HA_Y!_\ LJ/^%=_]1#_R
M#_\ 95V=% '&?\*[_P"HA_Y!_P#LJ/\ A7?_ %$/_(/_ -E79T4 <9_PKO\
MZB'_ )!_^RH_X5W_ -1#_P @_P#V5=G10!QG_"N_^HA_Y!_^RH_X5W_U$/\
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M?^0?_LJ/^%=_]1#_ ,@__95V=% '&?\ "N_^HA_Y!_\ LJ/^%=_]1#_R#_\
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M=_\ 40_\@_\ V5=G10!QG_"N_P#J(?\ D'_[*C_A7?\ U$/_ "#_ /95V=%
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M[_ZB'_D'_P"RH_X5W_U$/_(/_P!E79T4 <9_PKO_ *B'_D'_ .RH_P"%=_\
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M !1110 4444 %%%% !1110 4444 %?)__!2;_DAFA?\ 8QP?^DMU7UA7R?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !7R?\ \%)O^2&:%_V,<'_I+=5]85\G_P#!2;_DAFA?
M]C'!_P"DMU75A?X\?4]K)=<PH^I^;-%%%?6\Q^X\H4444<P<H4444<P<H444
M4<P<H4444<P<H4444<P<H4444<P<H4444<P<H4444<P<H4444<P<H4444<P<
MH4444<P<H4444<P<H5^DW_!-G_DAFN_]C'/_ .DMK7YLU^DW_!-G_DAFN_\
M8QS_ /I+:UYV/=Z)\IQ-&V7OU1]84445\R?CX4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5\Z_MC?MI^$/V2_!<TM[/#JOC2\A)TGP[')^]E8Y EE
MQS'"#U8]<$+D]/5_C-:>*[_X3^+K;P).+7QG-IEQ'H\Q9%$=T4(C;+@J,-@Y
M/%?!'@/_ ():VOA7PUXN^(WQN\2R?$?QW_9=W>"U,TDMI'.(7*R2RR?O+EQA
M<;@JCH5;@US5I-0G)Z**NWUZZ+STWZ&U-)RBMVW:WZOR-C_@D3\9_'/QH7XN
MZGXV\5:MXEG6^LI8(]1O))HK7S/M#.L$;,5B3('RH  % QP*_1*ORY_X(<_\
M@/XN?]?&F_\ H-Q7ZC5Z6(BHRBE_+'_TE'%1DY<S?=_F%9GB;Q'I_@_PYJFN
MZM<+::7IEK+>75P_2.*-2[L?H :TZ\N_:B\$:K\2/V=/B/X8T-#+K&J:%=VU
MI$#@RRF,[8\_[1^7\:X*TI0IRE'=)G92BI5(QELVC\X]+^/7[3G_  49^(FO
MV'PDUQOAA\/-+=0UU'<-:-$I)V>;<Q*9GF< GRXR$  SC[S/^*6D_MC?L"V4
M'CFX^)TGQ/\ !<<\:7ZZC=3ZC''D@*LR7 \R)&8[0\3]<9(R >J_X(V_&3PO
MX8\+>,/A9KEY#H7C)M:;4+>UU!A!)=J8HXGB0-@F2-H3E.N&R!PV/H[_ (*5
M?'#P?\-?V8?&7A[6+^UF\0>);!]-TW1_,#3R/)@&;9U"1C+[CQD*.I K6O\
M[-",J+OHGWYGV^_0BC^_FXU%U:MM9=_U/7_V9?V@-&_::^#FB>/-&A-F+P-%
M>6#OO:SN4.)(B<#(!Y!P,JRG SBOF3_@KM\;/$?PE^"7A2S\)>(]3\,:WK&M
M\WFD7LEI<?9XH7+J'C8-@L\61FKW_!(/X>:WX'_95EO]9@EM8_$6LS:I80S
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV2-\\,GFNZNPZXD5@P/0DL.Q ^D?B3X\T+X8^!-<\4^)KV'3]#TNU>XN9IV
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MKN:,U\\7_P ?O$-SD6\%E9CLRQL[#\SC]*YV_P#BCXIU'/F:S<1@]K?$6/\
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M3HVCT_Q!9QB1T0G/E2QDCS8\\[<J0<[6&6!^CJ*=3]Z[SW"G^[5H:'Y>V/\
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MJ,\X8JV<M$&6(YXR"F"!C&"<^Y^%?@#\,? K(_AWX=^%=#D5=HET_1K>&3D
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8?\ XBC_ (73XR_Z#/\ Y*P__$5Q%%'UK$?\_'][#VU3^9_>=O\ \+I\9?\
M09_\E8?_ (BC_A=/C+_H,_\ DK#_ /$5Q%%'UK$?\_'][#VU3^9_>=O_ ,+I
M\9?]!G_R5A_^(H_X73XR_P"@S_Y*P_\ Q%<111]:Q'_/Q_>P]M4_F?WG;_\
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M%&<'J2UP",C)'R_7% 'WU17Y9:]_P7&M4W)HGPAFEZ;9K_7PF.F<HENV>_\
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M8*GQ079/\[FU1112 **** "BBB@ KD_$?A.[UC4FN(9(50J%Q(Q!X^@KK**
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M ,]K7_OIO_B:] HH \__ .%?ZC_SVM?^^F_^)H_X5_J/_/:U_P"^F_\ B:]
MHH \_P#^%?ZC_P ]K7_OIO\ XFC_ (5_J/\ SVM?^^F_^)KT"B@#S_\ X5_J
M/_/:U_[Z;_XFC_A7^H_\]K7_ +Z;_P")KT"B@#S_ /X5_J/_ #VM?^^F_P#B
M:/\ A7^H_P#/:U_[Z;_XFO0** //_P#A7^H_\]K7_OIO_B:/^%?ZC_SVM?\
MOIO_ (FO0** //\ _A7^H_\ /:U_[Z;_ .)H_P"%?ZC_ ,]K7_OIO_B:] HH
M \__ .%?ZC_SVM?^^F_^)H_X5_J/_/:U_P"^F_\ B:] HH \_P#^%?ZC_P ]
MK7_OIO\ XFC_ (5_J/\ SVM?^^F_^)KT"B@#S_\ X5_J/_/:U_[Z;_XFC_A7
M^H_\]K7_ +Z;_P")KT"B@#S_ /X5_J/_ #VM?^^F_P#B:/\ A7^H_P#/:U_[
MZ;_XFO0** //_P#A7^H_\]K7_OIO_B:/^%?ZC_SVM?\ OIO_ (FO0** //\
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MU_[Z;_XFC_A7^H_\]K7_ +Z;_P")KT"B@#S_ /X5_J/_ #VM?^^F_P#B:/\
MA7^H_P#/:U_[Z;_XFO0** //_P#A7^H_\]K7_OIO_B:/^%?ZC_SVM?\ OIO_
M (FO0** //\ _A7^H_\ /:U_[Z;_ .)H_P"%?ZC_ ,]K7_OIO_B:] HH \__
M .%?ZC_SVM?^^F_^)H_X5_J/_/:U_P"^F_\ B:] HH \_P#^%?ZC_P ]K7_O
MIO\ XFC_ (5_J/\ SVM?^^F_^)KT"B@#S_\ X5_J/_/:U_[Z;_XFC_A7^H_\
M]K7_ +Z;_P")KT"B@#S_ /X5_J/_ #VM?^^F_P#B:/\ A7^H_P#/:U_[Z;_X
MFO0** //_P#A7^H_\]K7_OIO_B:/^%?ZC_SVM?\ OIO_ (FO0** //\ _A7^
MH_\ /:U_[Z;_ .)H_P"%?ZC_ ,]K7_OIO_B:] HH \__ .%?ZC_SVM?^^F_^
M)H_X5_J/_/:U_P"^F_\ B:] HH \_P#^%?ZC_P ]K7_OIO\ XFC_ (5_J/\
MSVM?^^F_^)KT"B@#S_\ X5_J/_/:U_[Z;_XFC_A7^H_\]K7_ +Z;_P")KT"B
M@#S_ /X5_J/_ #VM?^^F_P#B:/\ A7^H_P#/:U_[Z;_XFO0** //_P#A7^H_
M\]K7_OIO_B:/^%?ZC_SVM?\ OIO_ (FO0** //\ _A7^H_\ /:U_[Z;_ .)H
M_P"%?ZC_ ,]K7_OIO_B:] HH \__ .%?ZC_SVM?^^F_^)H_X5_J/_/:U_P"^
MF_\ B:] HH \_P#^%?ZC_P ]K7_OIO\ XFC_ (5_J/\ SVM?^^F_^)KT"B@#
MS_\ X5_J/_/:U_[Z;_XFC_A7^H_\]K7_ +Z;_P")KT"B@#S_ /X5_J/_ #VM
M?^^F_P#B:/\ A7^H_P#/:U_[Z;_XFO0** //_P#A7^H_\]K7_OIO_B:/^%?Z
MC_SVM?\ OIO_ (FO0** //\ _A7^H_\ /:U_[Z;_ .)H_P"%?ZC_ ,]K7_OI
MO_B:] HH \__ .%?ZC_SVM?^^F_^)H_X5_J/_/:U_P"^F_\ B:] HH \_P#^
M%?ZC_P ]K7_OIO\ XFC_ (5_J/\ SVM?^^F_^)KT"B@#S_\ X5_J/_/:U_[Z
M;_XFC_A7^H_\]K7_ +Z;_P")KT"B@#S_ /X5_J/_ #VM?^^F_P#B:/\ A7^H
M_P#/:U_[Z;_XFO0** //_P#A7^H_\]K7_OIO_B:/^%?ZC_SVM?\ OIO_ (FO
M0** //\ _A7^H_\ /:U_[Z;_ .)H_P"%?ZC_ ,]K7_OIO_B:] HH \__ .%?
MZC_SVM?^^F_^)H_X5_J/_/:U_P"^F_\ B:] HH \_P#^%?ZC_P ]K7_OIO\
MXFC_ (5_J/\ SVM?^^F_^)KT"B@#S_\ X5_J/_/:U_[Z;_XFC_A7^H_\]K7_
M +Z;_P")KT"B@#S_ /X5_J/_ #VM?^^F_P#B:/\ A7^H_P#/:U_[Z;_XFO0*
M* //_P#A7^H_\]K7_OIO_B:/^%?ZC_SVM?\ OIO_ (FO0** //\ _A7^H_\
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M?ZC_ ,]K7_OIO_B:] HH \__ .%?ZC_SVM?^^F_^)H_X5_J/_/:U_P"^F_\
MB:] HH \_P#^%?ZC_P ]K7_OIO\ XFC_ (5_J/\ SVM?^^F_^)KT"B@#S_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5Y;^T5_R)-E_V$$_]%RUZE7EO
M[17_ ")-E_V$$_\ 1<M<&._W:?H<^(_A2/G:BBBO@3YP**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /MNBBBO
MTT^K"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OD[_@I1
M_P D+T+_ +&.#_TENJ^L:^3O^"E'_)"]"_[&.#_TENJF6Q]1PO\ \CG#?XC\
MV****QYC^K>4****.8.4****.8.4****.8.4****.8.4****.8.4****.8.4
M****.8.4****.8.4****.8.4****.8.4****.8.4****.8.4*_2?_@FO_P D
M+UW_ +&.?_TEM:_-BOTG_P"":_\ R0O7?^QCG_\ 26UJXO4_/>.XVR:7^*)]
M8T445J?S8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5Y;^T5_R)-E_V$$_]%RUZE7EO[17_(DV
M7_803_T7+7!CO]VGZ'/B/X4CYVHHHKX$^<"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#[;HHHK]-/JPHHHH
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MHHHKK/YF"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_-C]MO\
MX*N-\+O%&I^ OA):V6IZW8.UMJ/B*^7S;>VF'#1P1@@2.IX+-\H((VMU'VK^
MU'\0;GX5_LZ_$7Q78OY=_IFB7,MJ_P#=G*%8S^#LIK^=+X9_#[6OC%\1] \(
M:(%GUK7KY+2%IF.T,[<NYY.U1EB>> :Q7-6K>QCY?.[:7Y?UUU;C3I>UEY_*
MV_Y_UH?NS_P3=^.'B7X]?LSV_B7QEK#:UXBBU6\M;N\DCCBR%8.@V1JJJ CJ
M, #I7YN?MY?\%"O&OQ>^)FM>&? WB:^\/_#S2KA[. :1<- ^J%25>:61"&9&
M.=J9V[=I(SS7W-K7PIL_^"<W[ 7Q)M-(\2WVLZG/!)*+^X1(@E]=)%:@P(O*
M*#M8!F8Y!.>U?B!96<VHWD%I;QF6XGD6*.->K,QP!^9K2HE6Q'LZ>J2C\Y6_
M3];]B*=Z-#GGNV_DKW_7\+=SI_!?Q<\;_#G64U;POXMUK0=14@^?87TD1;!S
MAL'#+_LMD'N*_9O_ ()P_M[W'[4&EW?@[QH(8?B'I%O]H^U0J(X]4M@0IE"#
MA9%)7>HX.X,H R%\B^/G_!*3X?>"?V4-2UGP^=0C^(GAS2&U2[U"2[:2._>*
M/S)XS$?E5<!]FP @A<EN<_!?["OCJY^'G[7'POU.WD:-9]:ATV8!MH:*Y/D.
M#[8DS^ KJHM3K/#/7I]^S7E??RZ;'-53C26(2_I;I^=C^C&BBBN<W"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"QCG_]);6MZ+O,_-O$"-LDE_BB?6-%%%>@?S %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O+?VBO^
M1)LO^P@G_HN6O4J\M_:*_P"1)LO^P@G_ *+EK@QW^[3]#GQ'\*1\[4445\"?
M.!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'D10.I9%88[YK^<D8R,]*QC+GJRIR6EE^+?^1LX\M.,XNSN_R7^9_05\._\
M@GO^S)HEW9>)O#GP]TG5T<>=:W%UJ-QJEHZGHRI--)$X]"0?K7TY'&L,:HBA
M$4;551@ #H *XWX*V.@Z9\(/!5KX7\D^'8M&M%T]H""C0^2NQ@1UR.<^IKM*
M[*J<)NG?1-G)2ESP52VK2/FCQI_P3V^$7Q*^/6J?%;QAI][XCU6^\@G2+N<+
MIRM%$D:L8T4-(2(QD.S*<G*FOI"QL;;2[."SL[>*TM+=%BAMX$"1QHHPJJHX
M  & !4]%8KW8J"V1J_>ES/<**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\M_:*_Y$FR_[""?^
MBY:]2KRW]HK_ )$FR_[""?\ HN6N#'?[M/T.?$?PI'SM1117P)\X%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M 'VW1117Z:?5A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC'O1S!RA@>M?I1_P36_Y(7KO_8R3_P#I+:U^:^/>OTH_X)J_\D+UW_L9)_\
MTEM:[,(_WI^8^(L;9#+_ !1_,^LJ***]L_E,**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@# ^('B@^"? ?B/Q$+87ITG3;B_^S%]@E\J)GV;L'&=
MN,X.,]*_G,_:*^*G@GXQ^-9?$WA+X<CX;W%XS27]C:ZM]KLY9"<^9''Y$?E$
MG.0"5/&%7G/]%GQ.\-W7C+X:^*] L6B2]U72;JQ@:=BL8DEA9%+$ D#+#. ?
MI7XZ?\.7?CG_ -![P+_X,KO_ .1:Y^5NLV]DE;\;_H;\R5));MN_X6_4\'^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>6_M%?\ (DV7_803
M_P!%RUZE7EO[17_(DV7_ &$$_P#1<M<&._W:?H<^(_A2/G:BBBO@3YP****
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M%%% !1110 445SFN>,/[%OS;?9/.PH;=YFWK[8- '1T5QG_"Q/\ J'_^1O\
M[&C_ (6)_P!0_P#\C?\ V- '9T5QG_"Q/^H?_P"1O_L:/^%B?]0__P C?_8T
M =G17&?\+$_ZA_\ Y&_^QH_X6)_U#_\ R-_]C0!V=%<9_P +$_ZA_P#Y&_\
ML:/^%B?]0_\ \C?_ &- '9T5QG_"Q/\ J'_^1O\ [&C_ (6)_P!0_P#\C?\
MV- '9T5QG_"Q/^H?_P"1O_L:/^%B?]0__P C?_8T =G17&?\+$_ZA_\ Y&_^
MQH_X6)_U#_\ R-_]C0!V=%<9_P +$_ZA_P#Y&_\ L:/^%B?]0_\ \C?_ &-
M'9T5QG_"Q/\ J'_^1O\ [&C_ (6)_P!0_P#\C?\ V- '9T5QG_"Q/^H?_P"1
MO_L:/^%B?]0__P C?_8T =G17&?\+$_ZA_\ Y&_^QH_X6)_U#_\ R-_]C0!V
M=%<9_P +$_ZA_P#Y&_\ L:/^%B?]0_\ \C?_ &- '9T5QG_"Q/\ J'_^1O\
M[&C_ (6)_P!0_P#\C?\ V- '9T5QG_"Q/^H?_P"1O_L:/^%B?]0__P C?_8T
M =G17&?\+$_ZA_\ Y&_^QH_X6)_U#_\ R-_]C0!V=%<9_P +$_ZA_P#Y&_\
ML:/^%B?]0_\ \C?_ &- '9T5QG_"Q/\ J'_^1O\ [&C_ (6)_P!0_P#\C?\
MV- '9T5QG_"Q/^H?_P"1O_L:/^%B?]0__P C?_8T =G17&?\+$_ZA_\ Y&_^
MQH_X6)_U#_\ R-_]C0!V=%<9_P +$_ZA_P#Y&_\ L:/^%B?]0_\ \C?_ &-
M'9T5QG_"Q/\ J'_^1O\ [&C_ (6)_P!0_P#\C?\ V- '9T5QG_"Q/^H?_P"1
MO_L:/^%B?]0__P C?_8T =G17&?\+$_ZA_\ Y&_^QH_X6)_U#_\ R-_]C0!V
M=%<9_P +$_ZA_P#Y&_\ L:/^%B?]0_\ \C?_ &- '9T5QG_"Q/\ J'_^1O\
M[&C_ (6)_P!0_P#\C?\ V- '9T5QG_"Q/^H?_P"1O_L:/^%B?]0__P C?_8T
M =G17&?\+$_ZA_\ Y&_^QH_X6)_U#_\ R-_]C0!V=%<9_P +$_ZA_P#Y&_\
ML:/^%B?]0_\ \C?_ &- '9T5QG_"Q/\ J'_^1O\ [&C_ (6)_P!0_P#\C?\
MV- '9T5QG_"Q/^H?_P"1O_L:/^%B?]0__P C?_8T =G17&?\+$_ZA_\ Y&_^
MQH_X6)_U#_\ R-_]C0!V=%<9_P +$_ZA_P#Y&_\ L:/^%B?]0_\ \C?_ &-
M'9T5QG_"Q/\ J'_^1O\ [&C_ (6)_P!0_P#\C?\ V- '9T5QG_"Q/^H?_P"1
MO_L:/^%B?]0__P C?_8T =G17&?\+$_ZA_\ Y&_^QH_X6)_U#_\ R-_]C0!V
M=%<9_P +$_ZA_P#Y&_\ L:/^%B?]0_\ \C?_ &- '9T5QG_"Q/\ J'_^1O\
M[&C_ (6)_P!0_P#\C?\ V- '9T5QG_"Q/^H?_P"1O_L:/^%B?]0__P C?_8T
M =G17&?\+$_ZA_\ Y&_^QH_X6)_U#_\ R-_]C0!V=%<9_P +$_ZA_P#Y&_\
ML:/^%B?]0_\ \C?_ &- '9T5QG_"Q/\ J'_^1O\ [&C_ (6)_P!0_P#\C?\
MV- '9T5QG_"Q/^H?_P"1O_L:/^%B?]0__P C?_8T =G17&?\+$_ZA_\ Y&_^
MQH_X6)_U#_\ R-_]C0!V=%<9_P +$_ZA_P#Y&_\ L:/^%B?]0_\ \C?_ &-
M'9T5QG_"Q/\ J'_^1O\ [&C_ (6)_P!0_P#\C?\ V- '9T5QG_"Q/^H?_P"1
MO_L:/^%B?]0__P C?_8T =G17&?\+$_ZA_\ Y&_^QH_X6)_U#_\ R-_]C0!V
M=%<9_P +$_ZA_P#Y&_\ L:/^%B?]0_\ \C?_ &- '9T5QG_"Q/\ J'_^1O\
M[&C_ (6)_P!0_P#\C?\ V- '9T5QG_"Q/^H?_P"1O_L:/^%B?]0__P C?_8T
M =G17&?\+$_ZA_\ Y&_^QH_X6)_U#_\ R-_]C0!V=%<9_P +$_ZA_P#Y&_\
ML:/^%B?]0_\ \C?_ &- '9T5QG_"Q/\ J'_^1O\ [&C_ (6)_P!0_P#\C?\
MV- '9T5QG_"Q/^H?_P"1O_L:/^%B?]0__P C?_8T =G17&?\+$_ZA_\ Y&_^
MQH_X6)_U#_\ R-_]C0!V=%<9_P +$_ZA_P#Y&_\ L:/^%B?]0_\ \C?_ &-
M'9T5QG_"Q/\ J'_^1O\ [&C_ (6)_P!0_P#\C?\ V- '9T5QG_"Q/^H?_P"1
MO_L:/^%B?]0__P C?_8T =G17&?\+$_ZA_\ Y&_^QH_X6)_U#_\ R-_]C0!V
M=%<9_P +$_ZA_P#Y&_\ L:/^%B?]0_\ \C?_ &- '9T5QG_"Q/\ J'_^1O\
M[&C_ (6)_P!0_P#\C?\ V- '9T5QG_"Q/^H?_P"1O_L:/^%B?]0__P C?_8T
M =G17&?\+$_ZA_\ Y&_^QH_X6)_U#_\ R-_]C0!V=%<9_P +$_ZA_P#Y&_\
ML:/^%B?]0_\ \C?_ &- '9T5QG_"Q/\ J'_^1O\ [&C_ (6)_P!0_P#\C?\
MV- '9T5QG_"Q/^H?_P"1O_L:/^%B?]0__P C?_8T =G17&?\+$_ZA_\ Y&_^
MQH_X6)_U#_\ R-_]C0!V=%<9_P +$_ZA_P#Y&_\ L:/^%B?]0_\ \C?_ &-
M'9T5QG_"Q/\ J'_^1O\ [&C_ (6)_P!0_P#\C?\ V- '9T5QG_"Q/^H?_P"1
MO_L:/^%B?]0__P C?_8T =G17&?\+$_ZA_\ Y&_^QH_X6)_U#_\ R-_]C0!V
M=%<9_P +$_ZA_P#Y&_\ L:/^%B?]0_\ \C?_ &- '9T5QG_"Q/\ J'_^1O\
M[&C_ (6)_P!0_P#\C?\ V- '9T5QG_"Q/^H?_P"1O_L:/^%B?]0__P C?_8T
M =G17&?\+$_ZA_\ Y&_^QH_X6)_U#_\ R-_]C0!V=%<9_P +$_ZA_P#Y&_\
ML:/^%B?]0_\ \C?_ &- '9T5QG_"Q/\ J'_^1O\ [&C_ (6)_P!0_P#\C?\
MV- '9T5QG_"Q/^H?_P"1O_L:/^%B?]0__P C?_8T =G17&?\+$_ZA_\ Y&_^
MQH_X6)_U#_\ R-_]C0!V=%<9_P +$_ZA_P#Y&_\ L:/^%B?]0_\ \C?_ &-
M'9T5QG_"Q/\ J'_^1O\ [&C_ (6)_P!0_P#\C?\ V- '9T5QG_"Q/^H?_P"1
MO_L:/^%B?]0__P C?_8T =G17&?\+$_ZA_\ Y&_^QH_X6)_U#_\ R-_]C0!V
M=%<9_P +$_ZA_P#Y&_\ L:/^%B?]0_\ \C?_ &- '9T5QG_"Q/\ J'_^1O\
M[&C_ (6)_P!0_P#\C?\ V- '9UY;^T5_R)-E_P!A!/\ T7+6_P#\+$_ZA_\
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MB@"E_8NG_P#/A:_]^5_PH_L73_\ GPM?^_*_X5=HH I?V+I__/A:_P#?E?\
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M_?E?\*/[%T__ )\+7_ORO^%7:* *7]BZ?_SX6O\ WY7_  H_L73_ /GPM?\
MORO^%7:* *7]BZ?_ ,^%K_WY7_"C^Q=/_P"?"U_[\K_A5VB@"E_8NG_\^%K_
M -^5_P */[%T_P#Y\+7_ +\K_A5VB@"E_8NG_P#/A:_]^5_PH_L73_\ GPM?
M^_*_X5=HH I?V+I__/A:_P#?E?\ "C^Q=/\ ^?"U_P"_*_X5=HH I?V+I_\
MSX6O_?E?\*/[%T__ )\+7_ORO^%7:* *7]BZ?_SX6O\ WY7_  H_L73_ /GP
MM?\ ORO^%7:* *7]BZ?_ ,^%K_WY7_"C^Q=/_P"?"U_[\K_A5VB@"E_8NG_\
M^%K_ -^5_P */[%T_P#Y\+7_ +\K_A5VB@"E_8NG_P#/A:_]^5_PH_L73_\
MGPM?^_*_X5=HH I?V+I__/A:_P#?E?\ "C^Q=/\ ^?"U_P"_*_X5=HH I?V+
MI_\ SX6O_?E?\*/[%T__ )\+7_ORO^%7:* *7]BZ?_SX6O\ WY7_  H_L73_
M /GPM?\ ORO^%7:* *7]BZ?_ ,^%K_WY7_"C^Q=/_P"?"U_[\K_A5VB@"E_8
MNG_\^%K_ -^5_P */[%T_P#Y\+7_ +\K_A5VB@"E_8NG_P#/A:_]^5_PH_L7
M3_\ GPM?^_*_X5=HH I?V+I__/A:_P#?E?\ "C^Q=/\ ^?"U_P"_*_X5=HH
MI?V+I_\ SX6O_?E?\*/[%T__ )\+7_ORO^%7:* *7]BZ?_SX6O\ WY7_  H_
ML73_ /GPM?\ ORO^%7:* *7]BZ?_ ,^%K_WY7_"C^Q=/_P"?"U_[\K_A5VB@
M"E_8NG_\^%K_ -^5_P */[%T_P#Y\+7_ +\K_A5VB@"E_8NG_P#/A:_]^5_P
MH_L73_\ GPM?^_*_X5=HH I?V+I__/A:_P#?E?\ "C^Q=/\ ^?"U_P"_*_X5
M=HH I?V+I_\ SX6O_?E?\*/[%T__ )\+7_ORO^%7:* *7]BZ?_SX6O\ WY7_
M  H_L73_ /GPM?\ ORO^%7:* *7]BZ?_ ,^%K_WY7_"C^Q=/_P"?"U_[\K_A
M5VB@"E_8NG_\^%K_ -^5_P */[%T_P#Y\+7_ +\K_A5VB@"E_8NG_P#/A:_]
M^5_PH_L73_\ GPM?^_*_X5=HH I?V+I__/A:_P#?E?\ "C^Q=/\ ^?"U_P"_
M*_X5=HH I?V+I_\ SX6O_?E?\*/[%T__ )\+7_ORO^%7:* *7]BZ?_SX6O\
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M_P#/A:_]^5_PH_L73_\ GPM?^_*_X5=HH I?V+I__/A:_P#?E?\ "C^Q=/\
M^?"U_P"_*_X5=HH I?V+I_\ SX6O_?E?\*\R_:"T^UM/!MD\%M#"YOT!:.,*
M<>7)QP*]:KRW]HK_ )$FR_[""?\ HN6N#'?[M/T.?$?PI'SM1117P)\X%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'VQ'&D,:I&BQHHP%48 _"GT45^FGU84444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5\F_\%*O^2%Z%_P!C)!_Z2W5?65?)O_!2K_DA
M>A?]C)!_Z2W5<>,_@3]#[3@O_DH<'_C_ $9^:U%%%?&<Q_<7*%%%%','*%%%
M%','*%%%%','*%%%%','*%%%%','*%%%%','*%%%%','*%%%%','*%%%%','
M*%%%%','*%%%%','*%%%%','*%?I3_P35_Y(7KO_ &,D_P#Z2VM?FM7Z4_\
M!-7_ )(7KO\ V,D__I+:UZF6N]=>C/RCQ-C;AZ7^./YGUE1117U9_( 4444
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M_P O/_(RG#VBY7L.HHHK$U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBBJWW$%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O+?VBO^1)LO^P@G_HN6
MO4J\M_:*_P"1)LO^P@G_ *+EK@QW^[3]#GQ'\*1\[4445\"?.!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]
MMT445^FGU84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\
MF_\ !2K_ )(7H7_8R0?^DMU7UE7R;_P4J_Y(7H7_ &,D'_I+=5P8[_=I^A]Q
MP1_R4>"_Q_HS\UJ***^ YC^\>4****.8.4****.8.4****.8.4****.8.4**
M**.8.4****.8.4****.8.4****.8.4****.8.4****.8.4****.8.4****.8
M.4*_2G_@FK_R0O7?^QDG_P#26UK\UJ_2G_@FK_R0O7?^QDG_ /26UKV,I?\
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MQ!(_&OKW]O+_ (*@0_'CPG>?#SX:V-[IGA2\(74]8U!1'<7R*V1%'&I.R(D
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MJ,*2ZCL'1D?';?CM3BHU(RE!_#NOZ^7WH4FX22DOBV_K^MF>_4445!84444
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M<_0&BOEW]OG]D76?VO\ P'X:T#1=>L= FTK4FOI)K^)W5U,3)M 7OELU\/\
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M 4444 %%%% !1110 4444 %?)G_!2K_DA>A?]C)!_P"DMU7UG7R9_P %*O\
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M_P!L+Q'XATC1?$%AX?DT:TCNY)+^)Y!('<J  O?CO7U+_P .0_'?_12?#O\
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MJ]UK\5E-<?8X+G="8)W*[9HW4?,BG(&>.M?8=?GW_P %J/\ DVGPM_V-,/\
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MHD:W9L[)$; WQM@X; ((((XY\ _X*K?M3?%#]FV?X<+\.?$__".C5UOS>_\
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M.K JP[%35XN:Q&$G7CV:?D[/\_SOTL%"#H8B-%[737I_P/R\[GSO_P $0_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %>6_M%?\ (DV7_803_P!%RUZE7EO[17_(
MDV7_ &$$_P#1<M<&._W:?H<^(_A2/G:BBBO@3YP**** "BBB@ HHHH ****
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M2VM>[DK_ -K7HS\=\5U;AJ?^.'YGUG1117Z ?Q,%%%% !1110 4444 %%%%
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MK7[.%_\ M*O>WCW@U0ZCY3;_ +=+;[BTFI"3.>)>>F=H9\X S[]>_!'XO_\
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MSK'BK4(?$D,\EIHMA+>2I&+:X!<I&K$+EE&<8R1ZUQUOA7K'\T=E#2;])?\
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M@J*,EF. !ZU^'O[(?P<_:$\ _"W3_CG\!KV/6GO+BXT_6?"Y16,L<+_*3$[
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M61#<1N!OMY" 2H)56#8.".F&-34;IPIQ?O6^*WXV_"_EHMD53M4G-_#?X?\
M@_I]^Q;^*'_!-S]GOXP++?/X+A\/7URF5U#PO,;'@\[A$N8"3G.3&<U^=_[<
M/_!.%?V1_"=K\1_!7C6]U'1H-1AM_LU^BQ7UG(V3'*DT>%?YE[(A7@C/;O?
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MVBQE"N !U<LWOTK./+)-35I)_>NEO3K\_*^DKJSIN\6ON?\ 7Z>=O+?VXO\
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M5@&4B-%)4C(9VKZRKLJ0A2M3@M(I+^O3;Y'+"<JG-4G]IM_UZ[_,_,'XV_\
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M_"=W:V;W=I)J-ZLDEV8W"RQ^6J (RAMV-S9 ;IBOL&OS&_:\_P""<7CS1?C
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MO^"UW@6ZTGXA?#7X@6T)$,]E+I<DX'"RPR^=&#[D2OC_ '#Z5^H7PG\>:?\
M%'X9^%_%NERK-8ZSIT%[&RGIO0$J?0J<J1V((KDOVGOV==!_:@^$6J>"-=<V
MAF*W%CJ*('DLKI,[)5'&>I4C(RK,,C.:_-#P%I/[:G[ +WOACPWX,D^('A!Y
MW>U@M=/FUBQW$@F6);=EGASW5MH)).TGFL:,N2$J$^]T_7=??^2\[;58NI*-
M:.Z5FOR?W+\_*_Z&?MV?$>T^%_[)OQ*U2YN1;S7>DS:7:<_,\]RIA0+[_.6]
M@I/:OEG_ ((G_#NXT7X2^._&5Q$T::[JD-E;ENCQVR,2P]M\[+]5->-Z[\#_
M -K;_@HAXRT9OB;I,GP[\%64F\1WMFUA;VF0 [QVDC&>64C."YP.1N4&OU7^
M$WPOT+X+_#G0?!7AJW-MHVCVRV\(;!=SR7D<]W=BS,>Y8UK2BZ:J5);R227D
MG>[_ *Z^6N=27M.2G':+;?J]+?E]WH==1114%!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;>/?_"'PE*[;V_L^-,YS]T;?Z54-:;3^R[?>KBFK3375?D['<T444@"BBB@
MHHHH ***Q=5\66FCW9MYHYF< -F-01S]30!M45S/_"P-/_YXW7_?*_\ Q5'_
M  L#3_\ GC=?]\K_ /%4 =-15#1]8AUJU:>!9$17*$2  YP#V)]:OT %%%%
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MHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !117Q!XF_;XUJ^_;O\
M#OP%T#0[>PTB#4S::QJUVWFSW6+9I@D*CY8US@%CN8]MO=1?-4C26\OZ_4)>
M["51[(^WZ*;)GRVQUQQ7YJ_\$S?^&@_^%[>+_P#A;/\ PLO_ (1W^QY?L?\
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M/3W;W$:13<?5L^PKV']G'_@JO\*_CMXAL?#6L6M[X \27K"*VCU21);*>4G
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M]WW7^8J,6YRA/6U[/O97O]Y]S? _XF?\+F^$/A'QS_9O]C_\)!IT.H?8//\
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M[J>W7[_Z^70['P+X\\/_ !-\)Z;XF\+:M;:YH.HQ^;;7UJVY'7."/4,"""I
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M117P)\X%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ2 1N(Q]V%:%2HO=5T_G;7\/\]#9<TZ,Z4':3U7JK_Y_A8Y__AQC_P!5L_\
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M;3XK?#/PMXRL?C0(+77M-M]12$>%_,\KS(PQ3=]L&2I)7.!TZ"NJ_P"'&/\
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M/_2LU^QU?CC_ ,%#O^4F/P\_WM _]*S7['44/]V7^.?YA4_WA_X8?DS\^_\
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M^_(R(AP6R 173-1C;V*YM%;JWI_7_!W.>+E*_M7;5^2M<^<?^">WA73? O\
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M.M_LK_M>>)_$?A=OL&F^/]&NI R A2+J)H+Q.#][?F7V+K7+SNC4E;[<6O\
MMY:Q_'?T-G%5::3^Q)/Y/27X;>IWO[$NGS_M@_\ !1+QC\7]1B:;0]"GEU6
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M_'5'YI?\$F_VE+#1_P!F3X@:'XAN]D/P^\[65W'I82(\K!?4B6.7_OXM<?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KRW]HK_D2;+_ +""?^BY:]2KRW]HK_D2;+_L()_Z+EK@
MQW^[3]#GQ'\*1\[4445\"?.!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!]MT445^FGU84444 %%%% !1110
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M?C/BT_\ C&)_XX?F?5E%%%?JI_#P4444 %%%% !1110 4444 %%%% !1110
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M/?VL-)2WTNY_L'QG#$'O/#-_(/.7 ^9X6X$T8/\ $H!'&Y5R,_E5_P %9/\
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MQR8(WJLJL V"1D<X)J_X9\*Z+X*T.VT;P]H]AH.CVH(@T_3+9+:WB!8L=D:
M*N22>!U)-:E%&VP%#7=!TSQ1H]WI.LZ=::OI5Y&8;FQOH%F@G0]5=&!5@?0C
M%97@CX:^$?AG8W%EX/\ "VB^%+.XD\Z:WT/3H;..63 &]EB506P ,GG KI**
M .-\1?!?X?>+_$UOXCUWP)X:UKQ#;>7Y&K:CI%O<7<7EG='ME="Z[3R,'@]*
M[*BBCI8/,Y[QK\._"OQ*TR+3O%WAG1_%6GPRB>.TUJPBO(DD (#A)%8!L,PS
MC."?6KN@^&M*\'Z#;Z-X>TNQT/2[1"EK8:?;)!;P@DG"QH JC))P,=36I12Z
M-+J'5/L?GM^S?_P4RD^(7Q@UCX5_&W1/#W@J]A:XL1?>:\5I-=1R;#;R+,S!
M-P#X+/@D =6 /UW;_!SX-> [@^+X/ _@7P[/;@W!UZ/2;*U:,8R7\\(,?7->
M1?M/_P#!.#X5_M.:W-XCO%O?"GBZ5<3:OHI0"Z(&%,\3*5<C^\-K$  L0 !\
MQ6'_  0VT^/44>]^,=S<6&[+0V_AQ8I2N>@D-TP!QWVGZ41E)QC=6DMWW\RI
MVYI-?"^G;R/'?VK/&NG_ +=G[?W@SPUX!=M<T&Q:UT;[=!DPS1QS/-=W"Y_Y
M9JK,-W\0CR,@BOVI50BA0, # KPO]F7]B_X9_LIV$X\'Z;-<ZW=)Y=UK^JNL
MU[,F<[ P551,@?*BJ#@$Y(S7NM:+EITHTHN]FVWYO<S?-4J.K+LDO1!1114%
M'%^,O@I\//B+>K>>*_ 7AGQ/=J-JW&LZ/;W<@ Z -(C'%;/A/P/X<\!:;_9W
MAGP_I?AW3\Y^RZ391VL6?79&H'Z5MT4+31 ]=SB]4^"?P[USQ>GBS4O 7AC4
M/%,<D<R:Y=:-;2WJR1@"-Q.R%PRA5VG.1M&.E=I111TMT#=W,#QA\/\ PO\
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M1MN=JYQUP/2NKHI%7L5]/T^UTFPMK&QMH;.RMHUA@MK>,1QQ1J %15'"J
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOJ.&_P#?UZ,_&_%E_P#&,S_QP_,^J:***_63^(0HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFZ_](YZY\![U:2?=_DCHQFE"+7\K_-G]!M%%%,@**** "BBB@ HHHH ****
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MY.VM*?+5C-QWCO\ A_FOZ1G4O3E"^TMO77_)_P!,^'/BO_RF<TK_ +&32/\
MTD@K]D:_&[XK_P#*9S2O^QDTC_TD@K]D:*/^Y4O5_E$*W^^U/\,?_;@KC?BU
M\8/"/P+\%W'BWQQJ_P#8GA^WECAEO/LTUQM=VVH-D2.QR3V%=E7QM_P5K_Y,
MM\1?]A+3_P#TH6N>M-TXIKNE][2-J<5)V?9_@KGOEK^TM\,+KX3V'Q+?QGIU
MCX'U#=]EU?4BUFDQ5F4JJ3*KELHP"[<G' ->?^$O^"B7[.GC;7H]'TSXHZ:E
M[(VU/[1MKFPA8YQ@2W$21Y)Z?-S7YX?L#?L=7?[9WA6SUOXG>(-4;X;^#6;1
M]#T2RD$/FR%O/F^;!VIF0;F WN6 W*(P*]3_ &]O^"9_PQ^&_P !]:\??#6R
MO?#VI>'ECN+FQDOI;F"[MRZHY_>EF5U#;@0V" 1CD$;UK4&Y3^'\4NC;VVU\
MC*E>LE&/Q?A?LOR/TR\3^+M#\%>'[K7?$&L6.B:+:IYD^H:A<)#!&IZ$NQ &
M21CGG-> Z?\ \%(/V;M2UY='A^*6GI=L_EB2XLKN&VSZFX>$1 ?[6_'O7YV?
ML7_"'QM_P4%TO2?"WQ"\7ZE%\)/AM D$5I9N%FNII"YCCW,""40%=Y!*1A54
M#<6KZ6_:B_X)2_"*S^"OB36?A[87_AGQ/H>GS:A WV^:ZBO?*C+M%(LK-C<%
M(#(5P2#R."JW[A.<_AW\[=WVTUMK\RJ7[YJ$?BV\K]C]"=.U*TUBPM[ZPNH;
MVRN(UEAN;>021RHPRK*P."".015AF"J23@#DDU^;?_!%3XJZIXC^&GCGP-?W
M,ES:>';RWN]/$KY\J.Y$F^-?10\);'K(?6N:_P""KW[4'BJ^\<Z3^S_X"N;B
M"34(X?[9^Q/MFO)+@[8++(.0A4JS#^+S%!X!!JO%TYQA#5RM;YJY-%\\92GH
MHWO_ %YZ?>?9'C[]OW]GSX9ZL^F:[\3])^W1L4DBTR.?4?+8'!5S;1R!2#P0
M2"*Z[X1_M3?";X[2B#P+X\TC7;TJS_V>LI@O-HZM]GE"R;1QSMQS7RW\!?\
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M"BBBH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#!03XN^$_$+^*M:MO ?A=;":XN8C-96A>%4+/&IM5DN 2H(PQ /0FOJO\
M8[_:P^!EW^SQX&TRP\:^&?"=QI6DV]G=Z+JFHPV4T$Z1J)3ME92X+[F\P9#;
MLYSFO/OVX/\ @H9\/M+^&.N^ /AKK=OX_P#'7B:U?2K=?#[?:[>V6=3&SF5,
MJ[[68*B%CNQD ==,7!4U.G#WGJEUOV=NW7M;R,\-)U'&<_=6C?EW_KN>(?\
M!#G_ )#GQ=_Z]M,_]"N:S_\ @N%_R/GPK_[!M]_Z-BJ?_@A[>>7XR^+%FQ56
M>QL)-I^]\LDP/_H7ZBH/^"X7_(^?"O\ [!M]_P"C8JK&.\J#_K:2)P__ "^7
M]?9/U6\!QK#X'\.HBA$73K=551@ ")>*^;?^"I/_ "9#X_\ ]^P_]+8*^E/
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MS7ZU^)O^1;U7_KTE_P#0#7Y*?\$0?^2G_$S_ + ]M_Z/-&&_WF?^'])AB?\
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M8:^?O^"FG[='A7XR> Y_A1\+II/%EOYR7^NZU9PNUK'# VX)&V/G&\*S2#Y
M  "<G;[I_P $:;\77[)^HP;E)M?$UVA"]1F&W;G_ +ZK?"OFC7=K*RMYJ\=?
MOO\ <88E:T5>[N[^7NRT_KN?+OQ7_P"4SFE?]C)I'_I)!7[(U^-WQ7_Y3.:5
M_P!C)I'_ *205^R-31_W*EZO\HE5O]]J?X8_^W!7QM_P5K_Y,M\1?]A+3_\
MTH6OLFOC;_@K7_R9;XB_["6G_P#I0M<>)^!>L?\ TI'31^)^C_)B_P#!)6)(
M_P!BOPVRJ%+ZEJ#,1W/VAAG\@/RKT?\ ;^_Y,U^+'_8&;_T-*\[_ ."3/_)E
M/AC_ +"&H?\ I2]>B?M_?\F:_%C_ + S?^AI6V9?P:G^#_VTQP'\2/\ B?\
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M<12CN_\ +_@W^1^N5>>?M%PVUS^S_P#$N*\"-:MX:U(2B0X7;]FDSD]J\?\
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M>J74QDO9UG33NK)^E_Z_ L4445F6%%%% !1110 4444 %%%% !1110 4444
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MO_2:VKZWAA_\**]&?D'BJ_\ C&Y_XX?F?4-%%%?L)_%@4444 %%%% !1110
M4444 %%%% !1110 4444 %)UX/(I:* /E_XP_P#!-GX"?&:^NM2O?")\.:Q<
MG=+J'AJ<V3,Q.2QB ,)8DDEC&2<\FO=?A3\-]+^#_P ./#O@K1)+B;2="LX[
M&VDO&5IG1!C<Y554L>I(4#)Z5U=%$?=CRK8)>\^9[E'7-:LO#>BZAJ^I3BUT
MZPMY+JYG*EA'$BEG; !)P 3P,U\X#_@I=^S4Q 'Q0M<_]@N^_P#C%>P_'O\
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M/!NAZ#<37<*>')XDEN99517>>2>*5I6PB@$G/&,X  ^K**'K'E>P+27,M_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O+?VBO^1)LO^P@G_HN
M6O4J\M_:*_Y$FR_[""?^BY:X,=_NT_0Y\1_"D?.U%%%? GS@4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?;=
M%%%?II]6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?,'
M_!0K_DB^B_\ 8P0_^DUS7T_7S#_P4(_Y(QHO_8P0_P#I-<UXF=_\BZMZ'W'
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M_P"QH [.BN,_X6)_U#__ "-_]C1_PL3_ *A__D;_ .QH [.BN,_X6)_U#_\
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M_P"QH [.BN,_X6)_U#__ "-_]C1_PL3_ *A__D;_ .QH [.BN,_X6)_U#_\
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M_P"QH [.BN,_X6)_U#__ "-_]C1_PL3_ *A__D;_ .QH [.BN,_X6)_U#_\
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M**^!/G HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ^VZ*K:;>?VA8P7.SR_,7=MSG'XU9K]-/JPHHHH ****
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M9QNP<?7!KHJM1E)OS,:2<HQ2\C=JEK&LV7A_2[G4M2N8[.QMD,DL\IPJJ/\
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M^%7:* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\
M?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\
MA5VB@"E_8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_W
MY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO
M^%7:* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\
M?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\
MA5VB@"E_8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_W
MY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO
M^%7:* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\
M?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\
MA5VB@"E_8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_W
MY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO
M^%7:* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\
M?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\
MA5VB@"E_8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_W
MY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO
M^%7:* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\
M?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\
MA5VB@"E_8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_W
MY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO
M^%7:* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\
M?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\
MA5VB@"E_8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_W
MY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO
M^%7:* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\
M?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\
MA5VB@"E_8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_W
MY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO
M^%7:* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\ A5VB@"E_8NG_ //A:_\
M?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_WY7_"C^Q=/_Y\+7_ORO\
MA5VB@"E_8NG_ //A:_\ ?E?\*/[%T_\ Y\+7_ORO^%7:* *7]BZ?_P ^%K_W
MY7_"O,OV@M/M;3P;9/!;0PN;] 6CC"G'ER<<"O6J\M_:*_Y$FR_[""?^BY:X
M,=_NT_0Y\1_"D?.U%%%? GS@4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 ?;$<:0QJD:+&BC 51@#\*?117Z:
M?5A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S+_P4!Y^
M#>C?]A^'_P!)[FOIJOF?]O[_ )(YHW_8>A_])[BO"SW_ )%M?T/MN"?^2BP7
M^/\ 1GY^[:-M2[31M-?@5S^[+D6VC;4NTT;31<+D6VC;4NTT;31<+D6VC;4N
MTT;31<+D6VC;4NTT;31<+D6VC;4NTT;31<+D6VC;4NTT;31<+D6VC;4NTT;3
M1<+D6VC;4NTT;31<+D6VC;4NTT;31<+D6VC;4NTT;31<+D6VC;4NTT;31<+D
M6VC;4NTT;31<+D6VOT _X)_<?!O6?^P_-_Z3VU? FTU]^_L _P#)'-9_[#TW
M_I/;U]APH_\ A27HS\D\4'_QCL_\<?S/IBBBBOVH_C@**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "OYTOV]+.ZL/VQ?BQ%>9\YM;DE&[/^K=5>/_ ,<9
M:_HMK\M_^"M'[%FM^*-7'QH\$Z;-JKK;);^(]/M(]\RK&,1W:J!E@$ 1\<J%
M5L8#$<M3W:D:KV5U]]M?PM\SHI^]"5-;NS7ROI^/X6/6?^"/?CCPCJ?[,8\,
MZ5<6L/BG3-2N9M7L@P6>3S'S%.5ZLICV)NZ9C([5]WU_+-H7B#5/"^JV^J:-
MJ5YI&I6YW0WEC.\$T9]5=2"#]#7MGAW]O7]H3PO;>19?%GQ%,F,9U"X6];_O
MJ=7/ZUZ%2:J/F]/P5CBA%P37F_Q=S^BVBOY^!_P4X_:8  _X6?-_X)]/_P#D
M>L#7O^"@7[1'B2U>WN_BOKT*-G)L&CLWY]&A1&'X&L?0U/U=_P""K7CKPEX>
M_9)\1:'KUQ:R:WK4MO'HU@[#SWF2=':5%Z@(@;+=.0N?F /XY_LJ6%WJ?[37
MPIM[%6:Z;Q1IK+M[;;F-B?P )_"O/_$GBC6?&6L3ZMK^KWVN:I/@RWVI7+W$
M\F.FYW)8_B:_2K_@DM^QCK3^++;XV^+].DT[2;.%QX;MKE"LEW+(I5KK:?\
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MT-S&LB-]5((JU11ON&VQA:3X$\->'[H7.E^'M*TVY'_+:TLHHG_-5!K=HHH
M*P-4\ >&-<NVNM1\-Z1J%TW6:ZL8I'/_  )E)K?HH KV.GVNEVL=M96T-I;1
MC"0P1A$7Z <"K%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P"RPKTVO.J4Y49NG-6:.ZG4C5@IP=TPHHHK,T"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRW]HK_D2;+_ +""
M?^BY:]2KRW]HK_D2;+_L()_Z+EK@QW^[3]#GQ'\*1\[4445\"?.!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!]MT445^FGU84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO^"8/P&^#M];ZB/#USXRU>W??%>>*9Q=*A]H%5(3CL60D>M?6"JL:A5 55&
MH& !3J*;DVK,E12U04445)04444 %5]0U"UTC3[F^OKB*SLK:-II[B=PD<4:
M@EF9CP  "23Z58KXZ_X*P^--0\(?L<Z]#I\SP-K5_::7/)&<'R68NZY]&$>T
M^H8CO6-:HZ<+K?1?-NR_,UIPYY6>V_R6K/-?BY_P6?\ ASX-UJYT[P3X2U3Q
MX+>0QMJ$ERNG6DN/XHF*22,,]VC7VR.:\Z_X?G?]43_\NO\ ^XJB_P"";?\
MP3S^&WQ6^"UM\2_B3IDGB>;6+F9-.TUKJ6"WMX89&B+L(F5G=G1_O': %XSD
MU]K?\._OV=_^B4:#_P!\R?\ Q==$J<J3Y9.[,%-5+N*LCXN_X?G?]43_ /+K
M_P#N*NC^&W_!9[_A87Q$\+^%O^%/?V?_ &WJEKIOVO\ X2?S/)\Z58]^S[&-
MV-V<9&<=17U=_P ._OV=_P#HE&@_]\R?_%U>T/\ 89^ OAO6K#5M,^&.BV6I
M6$\=U;7,:R;HI48,CCYNH(!_"G3<5-.:NNH2NXM1W/=:***@H**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M HHHH **** "BD9@BEF(50,DGH*%8,H(.0>010 M%%1RW$4+1B21(S(VQ S
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*\M_:*_Y$FR_[""?^BY:]2KRW]HK_D2;+_L()_Z+EK@QW^[3]#GQ'\*1\[44
M45\"?.!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;3]IHVFBX7&;:-M/VFC::+A<9MHVT_::-IHN%QFVOO']@W_DD.K_ /8=F_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#T/XW>)M(^'7@O4(]5\->'+A[J^U*W8-#=WI4H!$PX9(U+C<.&+G&0 3E?\
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M)>Q_^-4?\,G?!#_HC?P__P#"7L?_ (U7YO\ _#>'[8?[,DGD_%OX>MKVE02
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M"BBBH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRW]HK_D2;+_ +""?^BY:]2K
MRW]HK_D2;+_L()_Z+EK@QW^[3]#GQ'\*1\[4445\"?.!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]MT445^
MFGU84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\Z?MT?\
MDDTC_L.0_P#I/<5]%U\Z_MS_ /))=)_[#D/_ *3W%?/<0?\ (JQ'^$^QX/\
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MKW__ ,?H_P"&#?@7_P!"-_Y5[_\ ^/T?VYEW_/I_^ Q_S#^QL?\ \_5]\O\
M(_,3_AH/XI?]%*\7_P#@^NO_ (Y1_P -!_%+_HI7B_\ \'UU_P#'*_3O_A@W
MX%_]"-_Y5[__ ./T?\,&_ O_ *$;_P J]_\ _'Z/[<R[_GT__ 8_YA_8V/\
M^?J^^7^1^8G_  T'\4O^BE>+_P#P?77_ ,<H_P"&@_BE_P!%*\7_ /@^NO\
MXY7Z=_\ #!OP+_Z$;_RKW_\ \?H_X8-^!?\ T(W_ )5[_P#^/T?VYEW_ #Z?
M_@,?\P_L;'_\_5]\O\C\Q/\ AH/XI?\ 12O%_P#X/KK_ ..4?\-!_%+_ **5
MXO\ _!]=?_'*_3O_ (8-^!?_ $(W_E7O_P#X_1_PP;\"_P#H1O\ RKW_ /\
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M_P#CE?IW_P ,&_ O_H1O_*O?_P#Q^C_A@WX%_P#0C?\ E7O_ /X_1_;F7?\
M/I_^ Q_S#^QL?_S]7WR_R/S$_P"&@_BE_P!%*\7_ /@^NO\ XY1_PT'\4O\
MHI7B_P#\'UU_\<K]._\ A@WX%_\ 0C?^5>__ /C]'_#!OP+_ .A&_P#*O?\
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MP+_Z$;_RKW__ ,?H_P"&#?@7_P!"-_Y5[_\ ^/T?VYEW_/I_^ Q_S#^QL?\
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M_P"QL?\ \_5]\O\ (_,3_AH/XI?]%*\7_P#@^NO_ (Y1_P -!_%+_HI7B_\
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M_P#H1O\ RKW_ /\ 'Z/[<R[_ )]/_P !C_F']C8__GZOOE_D?F)_PT'\4O\
MHI7B_P#\'UU_\<H_X:#^*7_12O%__@^NO_CE?IW_ ,,&_ O_ *$;_P J]_\
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M:#^*7_12O%__ (/KK_XY1_PT'\4O^BE>+_\ P?77_P <KM_^%9^&_P#H&_\
MD>7_ .*H_P"%9^&_^@;_ .1Y?_BJ/JU+^1?<@_U;S+_G['_P*7^1Q'_#0?Q2
M_P"BE>+_ /P?77_QRC_AH/XI?]%*\7_^#ZZ_^.5V_P#PK/PW_P! W_R/+_\
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MKQ?_ .#ZZ_\ CE'_  T'\4O^BE>+_P#P?77_ ,<K]._^&#?@7_T(W_E7O_\
MX_1_PP;\"_\ H1O_ "KW_P#\?H_MS+O^?3_\!C_F']C8_P#Y^K[Y?Y'YB?\
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M ,'UU_\ '*/^&@_BE_T4KQ?_ .#ZZ_\ CE?IW_PP;\"_^A&_\J]__P#'Z/\
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MZ*5XO_\ !]=?_'*_3O\ X8-^!?\ T(W_ )5[_P#^/T?\,&_ O_H1O_*O?_\
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M_1%O7W'!K_X58_X9'Y?XD/\ X0)?XH_F?0]%%%?OA_)H4444 %%%% !1110
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MU+7K/3?#USK4D@:P@MFNS(O>,+NR/PKY$^$O@V;]I?XB:WXF\62S2Z5:LO\
MHT;E02Q.R%2.515!SCGISDDUZEXHUB23]CY+HO\ O'T6VA+;NN62,_I3?V+[
M-(?A;?3J!OFU.3<<<\1Q@5?*E5FOY?\ ,SYFZ4/[V_W7)?B9^RGX3U?PO=-X
M:T[^Q]9@C+V[12NR2D#.QPQ/7ID<@D=>E4OV0_B7=^)O#U]X9U29IKW1]K6[
MR'+F \;2?]@C'T8#M7T+7QQ^SNW]D_M+>(;*$[(7-]#M]EEW ?\ CM*G\;AT
M:;^XJ:]Q2ZIK\3L_VP/B-?:?:Z9X,TJ1HY]47S;ORSAFC+;4C^C,#G_= [FN
MG\"_LI^"]%\-VT.N:9_;.K21@W-Q+-(H#D<J@5@  > >OO7D_P 5L:Q^UYH]
MI,=T4=YI\6T\@#"/C\V/YU]BU-.WL^;JV_N6PYOW^7HDOQ/B_P >>'+G]EOX
MK:1K6@3S-H-\2?L\C9)C!'FPL?XN""I/(R.XS7V38WD.H6<%U;OYD$\:RQN/
MXE89!_(U\\?MMVJ2>!] N"/WD>H%%/LT;$_^@C\J]5^!MX]_\(?"4KMO;^SX
MTSG/W1M_I50UIM/[+M]ZN*:M--=5^3L=S1112 **** "BBB@ HHK%U7Q9::/
M=FWFCF9P V8U!'/U- &U17,_\+ T_P#YXW7_ 'RO_P 51_PL#3_^>-U_WRO_
M ,50!C?M!_\ ) _B5_V+.I?^DLE?B-7[+_'GQQ8W?P-^(D"17 >7PYJ* LJX
MR;60<_-7XT5^@\,_P:GJOR/AN(?XM/T/WXHKF?\ A8&G_P#/&Z_[Y7_XJC_A
M8&G_ //&Z_[Y7_XJOSX^Y.FHKF?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO
M^^5_^*H Z:BN9_X6!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJ@#IJ*YG
M_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJ .FHKF?^%@:?_P \;K_O
ME?\ XJC_ (6!I_\ SQNO^^5_^*H Z:BN9_X6!I__ #QNO^^5_P#BJ/\ A8&G
M_P#/&Z_[Y7_XJ@#IJ*YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJ
M .FHKF?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*H Z:BN9_X6!I__
M #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJ@#IJ*YG_A8&G_\ /&Z_[Y7_ .*H
M_P"%@:?_ ,\;K_OE?_BJ .FHKF?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO
M^^5_^*H Z:BN9_X6!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJ@#IJ*YG
M_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJ .FHKF?^%@:?_P \;K_O
ME?\ XJC_ (6!I_\ SQNO^^5_^*H Z:BN9_X6!I__ #QNO^^5_P#BJ/\ A8&G
M_P#/&Z_[Y7_XJ@#IJ*YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJ
M .FHKF?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*H Z:BN9_X6!I__
M #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJ@#IJ*YG_A8&G_\ /&Z_[Y7_ .*H
M_P"%@:?_ ,\;K_OE?_BJ .FHKF?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO
M^^5_^*H Z:BN9_X6!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJ@#IJ*YG
M_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJ .FHKF?^%@:?_P \;K_O
ME?\ XJC_ (6!I_\ SQNO^^5_^*H Z:BN9_X6!I__ #QNO^^5_P#BJ/\ A8&G
M_P#/&Z_[Y7_XJ@#IJ*YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJ
M .FHKF?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*H Z:BN9_X6!I__
M #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJ@#IJ*YG_A8&G_\ /&Z_[Y7_ .*H
M_P"%@:?_ ,\;K_OE?_BJ .FHKF?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO
M^^5_^*H Z:BN9_X6!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJ@#IJ*YG
M_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJ .FHKF?^%@:?_P \;K_O
ME?\ XJC_ (6!I_\ SQNO^^5_^*H Z:BN9_X6!I__ #QNO^^5_P#BJ/\ A8&G
M_P#/&Z_[Y7_XJ@#IJ*YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJ
M .FHKF?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*H Z:BN9_X6!I__
M #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJ@#IJ*YG_A8&G_\ /&Z_[Y7_ .*H
M_P"%@:?_ ,\;K_OE?_BJ .FHKF?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO
M^^5_^*H Z:BN9_X6!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJ@#IJ*YG
M_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJ .FHKF?^%@:?_P \;K_O
ME?\ XJC_ (6!I_\ SQNO^^5_^*H Z:BN9_X6!I__ #QNO^^5_P#BJ/\ A8&G
M_P#/&Z_[Y7_XJ@#IJ^??VVO^25:5_P!AJ+_T1/7KG_"P-/\ ^>-U_P!\K_\
M%5X7^V%XHM=:^&>F001S(ZZO$Y,B@#'DS#L3ZUZV4_[]2]3:C_$B?'U%%%?L
M1[H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5]L_L2_\ )*M5_P"PU+_Z(@KXFK[!_8]\46NB_#/4X)XYG=M7E<&-
M01CR81W(]*^:XA_W%^J.3%?PSZ:HKF?^%@:?_P \;K_OE?\ XJC_ (6!I_\
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M'_"P-/\ ^>-U_P!\K_\ %4 ?C9^T'_R7SXE?]C-J7_I5)7Z=_L&_\FH^!O\
MM^_]+[BOR_\ CS<+=_'+XB3H"$E\1ZBX#=<&ZD/-?I'^P_XPL]+_ &7?!=K+
M%.TD?VW)15(YO9SW/O7Z!GG_ "+J7K'_ -)9\-DW^_U?1_\ I2/INBN9_P"%
M@:?_ ,\;K_OE?_BJ/^%@:?\ \\;K_OE?_BJ_/S[DZ:BN9_X6!I__ #QNO^^5
M_P#BJ/\ A8&G_P#/&Z_[Y7_XJ@#IJ*YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_
M ,\;K_OE?_BJ .FHKF?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*H
MZ:BN9_X6!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJ@#IJ*YG_A8&G_\
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MI %%%% !1110 5FWWAW3]2N#-<V_F2D8W;V'3Z&M*B@#%_X0_2/^?3_R*_\
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MM*_[#47_ *(GKULI_P!^I>IM1_B1/B:BBBOV(]T**** "BBB@ HHHH ****
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M]A!/_1<M<&._W:?H<^(_A2/G:BBBO@3YP**** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW_I?<5^@9Y_R+J7K'_TEGPV3?[_5]'_Z4CWZBBBOS\^Y"BBB@ HHHH ****
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M +#4O_HB"OBW;7VG^Q7_ ,DMU7_L,R_^B(*^\X)_Y&\?\,C\S\0W_P (4O\
M%'\SW^BBBOZ%/Y9"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BN?\;?$#PS\-=#DUGQ9X@TWPWI49PUYJETEO'GLH+D9)[ <FOA/XY_\
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M8?\ XBC_ (73XR_Z#/\ Y*P__$5Q%%'UK$?\_'][#VU3^9_>=O\ \+I\9?\
M09_\E8?_ (BC_A=/C+_H,_\ DK#_ /$5Q%%'UK$?\_'][#VU3^9_>=O_ ,+I
M\9?]!G_R5A_^(H_X73XR_P"@S_Y*P_\ Q%<111]:Q'_/Q_>P]M4_F?WG;_\
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M 4444 ?;=%%%?II]6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %>!?MH_\DMTO_L,Q?\ HB>O?:\#_;/_ .27:7_V&8O_ $1/7S7$G_(H
MQ/\ A/K.$_\ D>87_$?%U%/VFC::_E\_L$913]IHVF@!E%/VFC:: &44_::-
MIH 913]IHVF@!E%/VFC:: &44_::-IH 913]IHVF@!E%/VFC:: &44_::-IH
M 913]IHVF@!E%/VFC:: &44_::-IH 97VA^Q=_R2W5/^PS+_ .B(*^,MIK[.
M_8P_Y)=JG_89E_\ 1$%??<$_\C>/^&1^:^(7_(CE_BB>^4445_0Y_+@4444
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MP'\'/V;;ZTU?PYH$FI^*+92J>(-:G-Q=+D$$H,".,X8C*(IP<$FN2_X)4_\
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MR\^C_2_GZG[0>*/#.F>,_#>IZ#K-G%J&DZE;26EU:S+N26)U*LI'N#7Y*?\
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\^_MM?\DJTK_L-1?\
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MN0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME?IW^P;_ ,FH^!O^W[_TON*_,3]H/_DOGQ*_[&;4O_2J2OT[_8-_Y-1\#?\
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M,$C;E] $D51_=/2OO*BH<4W?J4I-:'X"?'#_ ()E_'3X*+->+X<7QMHD?/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]2?!;_DF>C?]MO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "OGW]MK_DE6E?]AJ+_ -$3U]!5\^_MM?\ )*M*_P"PU%_Z(GKULI_WZEZF
MU'^)$^)J***_8CW0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K[9_8E_Y)5JO_8:E_P#1$%?$U?;/[$O_ "2K5?\
ML-2_^B(*^:XA_P!Q?JCDQ7\,^@J***_+#QPK#\<_\B3X@_[!]Q_Z+:MRL/QS
M_P B3X@_[!]Q_P"BVK*K_#EZ,B?PL^0****_-SY<**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /J3X+?\DST;
M_MM_Z.DKMZXCX+?\DST;_MM_Z.DKMZ_0\+_N]/T7Y'TU'^''T04445U&H444
M4 ?B-^T'_P E\^)7_8S:E_Z525^G?[!O_)J/@;_M^_\ 2^XK\Q/V@_\ DOGQ
M*_[&;4O_ $JDK]._V#?^34? W_;]_P"E]Q7Z!GG_ "+J7K'_ -)9\-DW^_U?
M1_\ I2/?J***_/S[D**** "BBB@ HHHH **** "BBB@ KRW]HK_D2;+_ +""
M?^BY:]2KRW]HK_D2;+_L()_Z+EK@QW^[3]#GQ'\*1\[4445\"?.!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!]MT445^FGU84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-[R#R+W7[E=@"$@F*"($B./*@G)+$CEL8 ^F8(([6%(88UBBC4*D<:A54#H
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M_@6/_BJ /0**\_\ [)\4?\]+K_P+'_Q5']D^*/\ GI=?^!8_^*H ] HKS_\
MLGQ1_P ]+K_P+'_Q5']D^*/^>EU_X%C_ .*H ] HKS_^R?%'_/2Z_P# L?\
MQ5']D^*/^>EU_P"!8_\ BJ /0**\_P#[)\4?\]+K_P "Q_\ %4?V3XH_YZ77
M_@6/_BJ /0**\_\ [)\4?\]+K_P+'_Q5']D^*/\ GI=?^!8_^*H ] HKS_\
MLGQ1_P ]+K_P+'_Q5']D^*/^>EU_X%C_ .*H ] HKS_^R?%'_/2Z_P# L?\
MQ5']D^*/^>EU_P"!8_\ BJ /0**\_P#[)\4?\]+K_P "Q_\ %4?V3XH_YZ77
M_@6/_BJ /0**\_\ [)\4?\]+K_P+'_Q5']D^*/\ GI=?^!8_^*H ] HKS_\
MLGQ1_P ]+K_P+'_Q5']D^*/^>EU_X%C_ .*H ] HKS_^R?%'_/2Z_P# L?\
MQ5']D^*/^>EU_P"!8_\ BJ /0**\_P#[)\4?\]+K_P "Q_\ %4?V3XH_YZ77
M_@6/_BJ /0**\_\ [)\4?\]+K_P+'_Q5']D^*/\ GI=?^!8_^*H ] HKS_\
MLGQ1_P ]+K_P+'_Q5']D^*/^>EU_X%C_ .*H ] HKS_^R?%'_/2Z_P# L?\
MQ5']D^*/^>EU_P"!8_\ BJ /0**\_P#[)\4?\]+K_P "Q_\ %4?V3XH_YZ77
M_@6/_BJ /0**\_\ [)\4?\]+K_P+'_Q5']D^*/\ GI=?^!8_^*H ] HKS_\
MLGQ1_P ]+K_P+'_Q5']D^*/^>EU_X%C_ .*H ] HKS_^R?%'_/2Z_P# L?\
MQ5']D^*/^>EU_P"!8_\ BJ /0**\_P#[)\4?\]+K_P "Q_\ %4?V3XH_YZ77
M_@6/_BJ /0**\_\ [)\4?\]+K_P+'_Q5']D^*/\ GI=?^!8_^*H ] HKS_\
MLGQ1_P ]+K_P+'_Q5']D^*/^>EU_X%C_ .*H ] HKS_^R?%'_/2Z_P# L?\
MQ5']D^*/^>EU_P"!8_\ BJ /0**\_P#[)\4?\]+K_P "Q_\ %4?V3XH_YZ77
M_@6/_BJ /0**\_\ [)\4?\]+K_P+'_Q5']D^*/\ GI=?^!8_^*H ] HKS_\
MLGQ1_P ]+K_P+'_Q5']D^*/^>EU_X%C_ .*H ] HKS_^R?%'_/2Z_P# L?\
MQ5']D^*/^>EU_P"!8_\ BJ /0**\_P#[)\4?\]+K_P "Q_\ %4?V3XH_YZ77
M_@6/_BJ /0**\_\ [)\4?\]+K_P+'_Q5']D^*/\ GI=?^!8_^*H ] HKS_\
MLGQ1_P ]+K_P+'_Q5']D^*/^>EU_X%C_ .*H ] HKS_^R?%'_/2Z_P# L?\
MQ5']D^*/^>EU_P"!8_\ BJ /0**\_P#[)\4?\]+K_P "Q_\ %4?V3XH_YZ77
M_@6/_BJ /0**\_\ [)\4?\]+K_P+'_Q5']D^*/\ GI=?^!8_^*H ] HKS_\
MLGQ1_P ]+K_P+'_Q5']D^*/^>EU_X%C_ .*H ] HKS_^R?%'_/2Z_P# L?\
MQ5']D^*/^>EU_P"!8_\ BJ /0**\_P#[)\4?\]+K_P "Q_\ %4?V3XH_YZ77
M_@6/_BJ /0**\_\ [)\4?\]+K_P+'_Q5']D^*/\ GI=?^!8_^*H ] HKS_\
MLGQ1_P ]+K_P+'_Q5']D^*/^>EU_X%C_ .*H ] HKS_^R?%'_/2Z_P# L?\
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M ,51_9/BC_GI=?\ @6/_ (JOS\^Y/0**\_\ [)\4?\]+K_P+'_Q5']D^*/\
MGI=?^!8_^*H ] HKS_\ LGQ1_P ]+K_P+'_Q5']D^*/^>EU_X%C_ .*H ] H
MKS_^R?%'_/2Z_P# L?\ Q5']D^*/^>EU_P"!8_\ BJ /0**\_P#[)\4?\]+K
M_P "Q_\ %4?V3XH_YZ77_@6/_BJ /0**\_\ [)\4?\]+K_P+'_Q5']D^*/\
MGI=?^!8_^*H ] KRW]HK_D2;+_L()_Z+EK2_LGQ1_P ]+K_P+'_Q5<+\8K'6
M;7PS;-J+3& WB@>9.'&[8_;)[9K@QW^[3]#GQ'\*1X]1117P)\X%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT5IYGFGS!]UI&^[\N!A5R.!SQBOHZJC[L+/=N[_0F3YI)K9*P4444AA1110
M4444 %%%% !1110!P'[0?_) _B5_V+.I?^DLE?B-7[<_M!_\D#^)7_8LZE_Z
M2R5^(U?H/#/\&IZK\CX;B'^+3]#]^****_/C[D**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KY]_;:_Y)5I7_8:B_\ 1$]?05?/O[;7_)*M*_[#47_H
MB>O6RG_?J7J;4?XD3XFHHHK]B/="BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "OMG]B7_DE6J_]AJ7_P!$05\35]L_
ML2_\DJU7_L-2_P#HB"OFN(?]Q?JCDQ7\,^@J***_+#QPK#\<_P#(D^(/^P?<
M?^BVK<K#\<_\B3X@_P"P?<?^BVK*K_#EZ,B?PL^0****_-SY<**** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M<!^T'_R0/XE?]BSJ7_I+)7XC5^W/[0?_ "0/XE?]BSJ7_I+)7XC5^@\,_P &
MIZK\CX;B'^+3]#]^****_/C[D**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KY]_;:_Y)5I7_8:B_P#1$]?05?/O[;7_ "2K2O\ L-1?^B)Z];*?]^I>
MIM1_B1/B:BBBOV(]T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+_=AAM)%Z>IN%_E7Y=_\,G?&_P#Z(W\0/_"7OO\ XU1_PR=\;_\ HC?Q _\
M"7OO_C5=DI.;O+<Y8Q45:.Q^IG_#Z[X-?]"?XZ_\!++_ .2J[SX%_P#!4SX9
M?'[XJZ#X!T'PUXLL=6UEY(X+C4;>U6!"D3R'<4N&;HAZ*>2*_'?_ (9.^-__
M $1OX@?^$O??_&J^B/\ @GS^SO\ %;P7^V!\.]9\0_#+QCH6CVMQ<FXU#4]
MN[>WA!M)E!>1XPJY) Y/4@5=&,932EL34DXP;CN?N71116)H%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!P'[0?_) _B5_V+.I?^DLE?B-7
M[<_M!_\ ) _B5_V+.I?^DLE?B-7Z#PS_  :GJOR/AN(?XM/T/WXHHHK\^/N0
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "OGW]MK_DE6E?]AJ+_ -$3
MU]!5\^_MM?\ )*M*_P"PU%_Z(GKULI_WZEZFU'^)$^)J***_8CW0HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K[9_
M8E_Y)5JO_8:E_P#1$%?$U?;/[$O_ "2K5?\ L-2_^B(*^:XA_P!Q?JCDQ7\,
M^@J***_+#QPK#\<_\B3X@_[!]Q_Z+:MRL/QS_P B3X@_[!]Q_P"BVK*K_#EZ
M,B?PL^0****_-SY<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /J3X+?\DST;_MM_Z.DKMZXCX+?\DST;_MM_
MZ.DKMZ_0\+_N]/T7Y'TU'^''T04445U&H4444 ?B-^T'_P E\^)7_8S:E_Z5
M25^G?[!O_)J/@;_M^_\ 2^XK\Q/V@_\ DOGQ*_[&;4O_ $JDK]._V#?^34?
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M9_\ "1+_ !1/9J***_IX_GH**** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?/O[;7_ "2K
M2O\ L-1?^B)Z^@J^??VVO^25:5_V&HO_ $1/7K93_OU+U-J/\2)\34445^Q'
MNA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7VS^Q+_P DJU7_ +#4O_HB"OB:OMG]B7_DE6J_]AJ7_P!$05\UQ#_N
M+]4<F*_AGT%1117Y8>.%8?CG_D2?$'_8/N/_ $6U;E8?CG_D2?$'_8/N/_1;
M5E5_AR]&1/X6?(%%%%?FY\N%%%% !1110 4444 %%%% !1110 4444 %%%%
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQO]J?_DGVG_\
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M<T445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P!%M657^'+T9$_A9\@4445^;GRX4444 %%%% !1110 4444 %%%% !1110
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M ++_ /R(-_\ ]A.3_P!%15^E^'K_ .%R/^&1\-QD_P#A)E_BB>P4445_4A^
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M.C_([FBBBL34**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7S[^VU_R2K2O^PU%_P"B)Z^@J^??VVO^25:5_P!AJ+_T1/7K93_OU+U-J/\
M$B?$U%%%?L1[H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5]L_L2_\DJU7_L-2_\ HB"OB:OMG]B7_DE6J_\ 8:E_
M]$05\UQ#_N+]4<F*_AGT%1117Y8>.%8?CG_D2?$'_8/N/_1;5N5A^.?^1)\0
M?]@^X_\ 1;5E5_AR]&1/X6?(%%%%?FY\N%%%% !1110 4444 %%%% !1110
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MJTK_ +#47_HB>O6RG_?J7J;4?XD3XFHHHK]B/="BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OMG]B7_DE6J_]AJ7_
M -$05\35]L_L2_\ )*M5_P"PU+_Z(@KYKB'_ '%^J.3%?PSZ"HHHK\L/'"L/
MQS_R)/B#_L'W'_HMJW*P_'/_ ")/B#_L'W'_ *+:LJO\.7HR)_"SY HHHK\W
M/EPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ^I/@M_R3/1O^VW_HZ2NWKB/@M_R3/1O^VW_HZ2NWK]#PO^[T
M_1?D?34?X<?1!11174:A1110!^(W[0?_ "7SXE?]C-J7_I5)7Z=_L&_\FH^!
MO^W[_P!+[BOS$_:#_P"2^?$K_L9M2_\ 2J2OT[_8-_Y-1\#?]OW_ *7W%?H&
M>?\ (NI>L?\ TEGPV3?[_5]'_P"E(]^HHHK\_/N0HHHH **** "BBB@ HHHH
M **** "O+?VBO^1)LO\ L()_Z+EKU*O+?VBO^1)LO^P@G_HN6N#'?[M/T.?$
M?PI'SM1117P)\X%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% 'VW1117Z:?5A1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7D?[3/_(AV'_82C_]%2UZY7DO[2__ "(EA_V$
MH_\ T5+7R/%W_(BQ?^']4?0</_\ (TH?XCYEVT;:?17\;7/Z-N,VT;:?11<+
MC-M&VGT47"XS;1MI]%%PN,VT;:?11<+C-M&VGT47"XS;1MI]%%PN,VT;:?11
M<+C-M&VGT47"XS;1MI]%%PN,VT;:?11<+C-M&VGT47"XS;1MI]%%PN,VU],?
MLS?\B'?_ /82D_\ 145?-5?2_P"S1_R(E_\ ]A*3_P!%15^F^'?_ "/8_P"&
M1\3Q@_\ A+?^)'K5%%%?U4?A 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% 'SW_P4#U2;1_V,_BM/ 2KOI!MR0<?+)(D;?\ CKFOQ/\ V&_A[I/Q
M2_:P^&_AS7;:.]TBXU$SW%K*-R3+#$\VQAW5C& 1W!(K]W?VK? %S\4?V;?B
M1X7L8O/O]0T2Y6UBQR\ZH7C4>Y=5%?ST? [XJ7OP-^,'A3QU96PNKG0;]+HV
MKML\Y!Q)&3CY=R%ES@XSTJ,+)1QKE+;W?SE^6Y>(BY82T5K[WY(_:3_@J_\
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MT HKS_\ M;Q1_P \[K_P$'_Q-']K>*/^>=U_X"#_ .)I#/0**\__ +6\4?\
M/.Z_\!!_\31_:WBC_GG=?^ @_P#B: /0**\__M;Q1_SSNO\ P$'_ ,31_:WB
MC_GG=?\ @(/_ (F@#T"BO/\ ^UO%'_/.Z_\  0?_ !-']K>*/^>=U_X"#_XF
M@#T"BO/_ .UO%'_/.Z_\!!_\31_:WBC_ )YW7_@(/_B: /0**\__ +6\4?\
M/.Z_\!!_\31_:WBC_GG=?^ @_P#B: /0**\__M;Q1_SSNO\ P$'_ ,31_:WB
MC_GG=?\ @(/_ (F@#T"BO/\ ^UO%'_/.Z_\  0?_ !-']K>*/^>=U_X"#_XF
M@#T"BO/_ .UO%'_/.Z_\!!_\31_:WBC_ )YW7_@(/_B: /0**\__ +6\4?\
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MH_M;Q1_SSNO_  $'_P 34%GH%%>?_P!K>*/^>=U_X"#_ .)H_M;Q1_SSNO\
MP$'_ ,30!Z!17G_]K>*/^>=U_P" @_\ B:/[6\4?\\[K_P !!_\ $T >@45Y
M_P#VMXH_YYW7_@(/_B:/[6\4?\\[K_P$'_Q- 'H%%>?_ -K>*/\ GG=?^ @_
M^)H_M;Q1_P \[K_P$'_Q- 'H%%>?_P!K>*/^>=U_X"#_ .)H_M;Q1_SSNO\
MP$'_ ,30!Z!17G_]K>*/^>=U_P" @_\ B:/[6\4?\\[K_P !!_\ $T >@45Y
M_P#VMXH_YYW7_@(/_B:/[6\4?\\[K_P$'_Q- 'H%%>?_ -K>*/\ GG=?^ @_
M^)H_M;Q1_P \[K_P$'_Q- 'H%%>?_P!K>*/^>=U_X"#_ .)H_M;Q1_SSNO\
MP$'_ ,30!Z!17G_]K>*/^>=U_P" @_\ B:/[6\4?\\[K_P !!_\ $T >@45Y
M_P#VMXH_YYW7_@(/_B:/[6\4?\\[K_P$'_Q- 'H%%>?_ -K>*/\ GG=?^ @_
M^)H_M;Q1_P \[K_P$'_Q- 'H%%>?_P!K>*/^>=U_X"#_ .)H_M;Q1_SSNO\
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M )%U+UC_ .DL^&R;_?ZOH_\ TI'U=17G_P#:WBC_ )YW7_@(/_B:/[6\4?\
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MXE?]BSJ7_I+)7XC5^@\,_P &IZK\CX;B'^+3]#]^****_/C[D**** "BBB@
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M/''+&49HV96 8!C@D$9[57\*G/V>LY?ILO2^I/\ $G!3TC'[]=W]Q^,OQ_\
MVA6_X*"_M*6G@Z[\=Z9\._@UI-Q(UO>:Q>QVL#QQG:UVPD91+/)G$:$_*K=O
MWA/Z-_!#XF?LM_L\^ ;+PCX*^)O@+3M-@&Z65O$-HT]W+@!IIGWY=SCKT P
M   /'/\ ARI\$/\ H:?B!_X,;'_Y#H_X<J?!#_H:?B!_X,;'_P"0Z</W=/V:
M^;ZM^83_ 'E3G?R7;^NY]9^'/VFOA%XPURST;0OB?X0UG5[Q_*MK&QUNVFGF
M?&=J(KDL>#P!7IE?&'P?_P""4OPE^"GQ,\/>.=#\1>-+K5M#N1=6T.H7MH\#
ML 1AU2U5B.3T85]GT].5=R?>YGV"BBBI*"BBB@ HHHH **** "BBB@ HHHH
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M_P"VW_HZ2NWK]#PO^[T_1?D?34?X<?1!11174:A1110!^(W[0?\ R7SXE?\
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MKP\NMOQV?W_A<6(AR4U7CTO^&Z_K]#^C^BBBLRPHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** . _:#_Y('\2O^Q9U+_TEDK\1J_;G]H/_D@?
MQ*_[%G4O_262OQ&K]!X9_@U/5?D?#<0_Q:?H?OQ1117Y\?<A1110 4444 %%
M%% !1110 4444 >+_$S]L+X3_"'XF:5\/_%7B9]-\6ZF;?[-8_V?<NK">3RX
MV,JQF, L#DEN,'->T5\,_P#!3']B'6/VDM%TCQIX$C27QYX?B: V)=8FU"UW
M;PB.< 2(Q8KD@$.PSG%>(^!_^"MGC;X-^'K;PG\9?A-J\OBW3X!#]M>1M/FN
MRHPK2P2Q?*Q Y=202<A14TY*46I:23?S72WZE3BU)..L6ON?6_Z'NW_!8*XT
MR/\ 9 FCOO+^V2:[9"P#8W>:-Y8K_P!LQ)^==M_P3"L[^R_8C^':Z@'5I%O)
M85?J(6O)BGX$'(]B*^)]8\+_ !W_ ."J?Q0T&[UWPS=_#?X0Z6XDB:X5Q"D;
M8WO&TBJ;J=@-H95"*,9VY.[]$?CWXZTW]D/]E/7=8\/6,<%KX5T>.RT>S(W(
MLGR06X;U 9D)]0#3BWAZ%64UK)IVZV2M][Z"?^T5:=.&T5:_FW^6NIXQ^WE_
MP4/TW]FN-_!7@M(/$'Q0NXP/)QYD&E!Q\CS ?>E.05B]"&; *A_)_P!C7_@G
M=KOC'Q8/C5^T8]QKGB;4)1?VGA[5#O</P5EO >,@8VP8PH ##C8/@+]F_P#:
M@T[X+_&+4OB9XP\%?\+1\4SNUQ:W&I:I]G%M=.Q:2Y(,,F^0Y^4\;<DCG!'V
M?_P_+N_^B,P_^%,?_D2JII4TJE[S?_DODO\ /];6FI^\;@M(+[WZ_P"7_!O^
MK8 4  8 Z"L+QUXZT#X9^$=4\3^)]4M]&T+383/=7ERV%11V]2Q. %&220 "
M2!7Q=^Q[_P %.I_VJOC-;^ Y/AS'X966QN+S[>NM&Z(\L [=GD)USUW<5\P_
M\%D/VAM4\0?%:P^$MC<R0>'] MX;[4(4; N;R5-Z;_4)$R[?>1O:LJSE!12W
MEM^-W^'WV[FE'EJ.7:._X?YK^M"S\2/C-\7/^"I_Q*F^'GPTM)_"_P )[&99
M+ZXN251HPWRSWK+]YC@E+=2>1DYV[U_2+]F']EGP7^RKX!3P[X5M?.O)]KZG
MK-PH^TZA*!]YSV49.U!PH)ZDDG\Q?@5_P5;T']GGX:Z5X+\)_ RVM;"S0&:X
M/B3$UY,0-\\K"T^9V(_ 8 P  /0/^'Y=W_T1F'_PIC_\B5T>[23A3>^[ZO\
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M/T7Y'TU'^''T04445U&H4444 ?B-^T'_ ,E\^)7_ &,VI?\ I5)7Z=_L&_\
M)J/@;_M^_P#2^XK\Q/V@_P#DOGQ*_P"QFU+_ -*I*_3O]@W_ )-1\#?]OW_I
M?<5^@9Y_R+J7K'_TEGPV3?[_ %?1_P#I2/?J***_/S[D**** "BBB@ HHHH
M**** "BBB@ KRW]HK_D2;+_L()_Z+EKU*O+?VBO^1)LO^P@G_HN6N#'?[M/T
M.?$?PI'SM1117P)\X%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3NB_\_5__P!_$_\ B*/^%.Z+_P _5_\ ]_$_^(HLP_LO/?\ GZ__  -G"?\
M"S/$O_02_P#($7_Q-'_"S/$O_02_\@1?_$UW?_"G=%_Y^K__ +^)_P#$4?\
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MN=12YZK_ / V?+O_  WE\=/^AY_\I%A_\8H_X;R^.G_0\_\ E(L/_C%?7O\
MP[#^%O\ T'_%_P#X&6O_ ,C4?\.P_A;_ -!_Q?\ ^!EK_P#(U>%_:.3?\^E_
MX CG^H9M_P _'_X$SY"_X;R^.G_0\_\ E(L/_C%8?B7]K[XM^,/LW]K^+/M?
MV?=Y7_$MM$V[L9^[$,_='7TK[9_X=A_"W_H/^+__  ,M?_D:O.OB[^P/\/\
MP#_9/]GZQXEF^U^=O^TW5NV-NS&-L _O&N;$9ID5.DY5:2<?\"9E4P6:1@W.
MH[?XF?*'_#1/Q"_Z&#_R2M__ (W1_P -$_$+_H8/_)*W_P#C=>U_\,F>$/\
MH(ZW_P!_X?\ XU1_PR9X0_Z".M_]_P"'_P"-5XW]N<*_] \?_!<?\CA^K8W^
M9_>>*?\ #1/Q"_Z&#_R2M_\ XW1_PT3\0O\ H8/_ "2M_P#XW7M?_#)GA#_H
M(ZW_ -_X?_C5'_#)GA#_ *".M_\ ?^'_ .-4?VYPK_T#Q_\ !<?\@^K8W^9_
M>>*?\-$_$+_H8/\ R2M__C='_#1/Q"_Z&#_R2M__ (W7M?\ PR9X0_Z".M_]
M_P"'_P"-4?\ #)GA#_H(ZW_W_A_^-4?VYPK_ - \?_!<?\@^K8W^9_>>*?\
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MGA#_ *".M_\ ?^'_ .-4?VYPK_T#Q_\ !<?\@^K8W^9_>>*?\-$_$+_H8/\
MR2M__C='_#1/Q"_Z&#_R2M__ (W7M?\ PR9X0_Z".M_]_P"'_P"-4?\ #)GA
M#_H(ZW_W_A_^-4?VYPK_ - \?_!<?\@^K8W^9_>>*?\ #1/Q"_Z&#_R2M_\
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M/_E(L/\ XQ1_PWE\=/\ H>?_ "D6'_QBOKW_ (=A_"W_ *#_ (O_ / RU_\
MD:C_ (=A_"W_ *#_ (O_ / RU_\ D:C^T<F_Y]+_ , 0?4,V_P"?C_\  F?(
M7_#>7QT_Z'G_ ,I%A_\ &*/^&\OCI_T//_E(L/\ XQ7U[_P[#^%O_0?\7_\
M@9:__(U'_#L/X6_]!_Q?_P"!EK_\C4?VCDW_ #Z7_@"#ZAFW_/Q_^!,^0O\
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MC_A3NB_\_5__ -_$_P#B*+,/[+SW_GZ__ V<)_PLSQ)_T$O_ "!%_P#$T?\
M"S/$G_02_P#($7_Q-=W_ ,*=T7_GZO\ _OXG_P 11_PIW1?^?J__ ._B?_$4
M68?V7GO_ #]?_@;.$_X69XD_Z"7_ ) B_P#B:/\ A9GB3_H)?^0(O_B:[O\
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MZ?\ 0\_^4BP_^,4?\-Y?'3_H>?\ RD6'_P 8KZ]_X=A_"W_H/^+_ /P,M?\
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MC_AHGXA?]#!_Y)6__P ;KVO_ (9,\(?]!'6_^_\ #_\ &J/^&3/"'_01UO\
M[_P__&J/[<X5_P"@>/\ X+C_ )!]6QO\S^\\4_X:)^(7_0P?^25O_P#&Z/\
MAHGXA?\ 0P?^25O_ /&Z]K_X9,\(?]!'6_\ O_#_ /&J/^&3/"'_ $$=;_[_
M ,/_ ,:H_MSA7_H'C_X+C_D'U;&_S/[SQ3_AHGXA?]#!_P"25O\ _&Z/^&B?
MB%_T,'_DE;__ !NO:_\ ADSPA_T$=;_[_P /_P :H_X9,\(?]!'6_P#O_#_\
M:H_MSA7_ *!X_P#@N/\ D'U;&_S/[SQ3_AHGXA?]#!_Y)6__ ,;H_P"&B?B%
M_P!#!_Y)6_\ \;KVO_ADSPA_T$=;_P"_\/\ \:H_X9,\(?\ 01UO_O\ P_\
MQJC^W.%?^@>/_@N/^0?5L;_,_O/%/^&B?B%_T,'_ ))6_P#\;H_X:)^(7_0P
M?^25O_\ &Z]K_P"&3/"'_01UO_O_  __ !JC_ADSPA_T$=;_ ._\/_QJC^W.
M%?\ H'C_ ."X_P"0?5L;_,_O/%/^&B?B%_T,'_DE;_\ QNC_ (:)^(7_ $,'
M_DE;_P#QNO:_^&3/"'_01UO_ +_P_P#QJC_ADSPA_P!!'6_^_P##_P#&J/[<
MX5_Z!X_^"X_Y!]6QO\S^\\4_X:)^(7_0P?\ DE;_ /QNC_AHGXA?]#!_Y)6_
M_P ;KVO_ (9,\(?]!'6_^_\ #_\ &J/^&3/"'_01UO\ [_P__&J/[<X5_P"@
M>/\ X+C_ )!]6QO\S^\\4_X:)^(7_0P?^25O_P#&Z/\ AHGXA?\ 0P?^25O_
M /&Z]K_X9,\(?]!'6_\ O_#_ /&J/^&3/"'_ $$=;_[_ ,/_ ,:H_MSA7_H'
MC_X+C_D'U;&_S/[SQ3_AHGXA?]#!_P"25O\ _&Z/^&B?B%_T,'_DE;__ !NO
M:_\ ADSPA_T$=;_[_P /_P :H_X9,\(?]!'6_P#O_#_\:H_MSA7_ *!X_P#@
MN/\ D'U;&_S/[SQ3_AHGXA?]#!_Y)6__ ,;H_P"&B?B%_P!#!_Y)6_\ \;KV
MO_ADSPA_T$=;_P"_\/\ \:H_X9,\(?\ 01UO_O\ P_\ QJC^W.%?^@>/_@N/
M^0?5L;_,_O/%/^&B?B%_T,'_ ))6_P#\;H_X:)^(7_0P?^25O_\ &Z]K_P"&
M3/"'_01UO_O_  __ !JC_ADSPA_T$=;_ ._\/_QJC^W.%?\ H'C_ ."X_P"0
M?5L;_,_O/%/^&B?B%_T,'_DE;_\ QNC_ (:)^(7_ $,'_DE;_P#QNO:_^&3/
M"'_01UO_ +_P_P#QJC_ADSPA_P!!'6_^_P##_P#&J/[<X5_Z!X_^"X_Y!]6Q
MO\S^\\4_X:)^(7_0P?\ DE;_ /QNC_AHGXA?]#!_Y)6__P ;KVO_ (9,\(?]
M!'6_^_\ #_\ &J/^&3/"'_01UO\ [_P__&J/[<X5_P"@>/\ X+C_ )!]6QO\
MS^\\]T7]MCXT>'=,AT_3_&?V>SAW;(_[+LFQEBQY:$GJ3WJ]_P -Y?'3_H>?
M_*18?_&*^F_A[_P3E^&WBSP?8:K=ZWXJCN+CS-RPW=L$&V1E& ;<GHH[UT7_
M  [#^%O_ $'_ !?_ .!EK_\ (U>[3S+))0BX4E9K3W$>C' YJXIQJ.W^)GR%
M_P -Y?'3_H>?_*18?_&*/^&\OCI_T//_ )2+#_XQ7U[_ ,.P_A;_ -!_Q?\
M^!EK_P#(U'_#L/X6_P#0?\7_ /@9:_\ R-6O]HY-_P ^E_X BOJ&;?\ /Q_^
M!,^0O^&\OCI_T//_ )2+#_XQ1_PWE\=/^AY_\I%A_P#&*^O?^'8?PM_Z#_B_
M_P #+7_Y&H_X=A_"W_H/^+__  ,M?_D:C^T<F_Y]+_P!!]0S;_GX_P#P)GYI
M^(=>O_%6OZGK6J3_ &K4]2N9;RZGV*GF32.7=MJ@*,LQ.  !G@5^MG[!Z-'^
MRCX&#*5.+TX88X-]<$'\JX2T_P""9/PJMKF.635_%=TBG)AFO;<(_L=MN&Q]
M"*^IO#?AS3/"&@V&BZ-9QZ?I=A"MO;6T(^6-%& .>3[D\DY)YKS,XS3#XRA&
MC03T=]K=&OU/0RK+:^%K2JUNJMWZI_H:5%%%?(GU(4444 %%%% !1110 444
M4 %%%% !7EO[17_(DV7_ &$$_P#1<M>I5Y;^T5_R)-E_V$$_]%RUP8[_ ':?
MH<^(_A2/G:BBBO@3YP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** /MNBBBOTT^K"BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?D?34?X<?1!11174:A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME_PE_P"25>#/^P+9?^B$K\T*_2_X2_\ )*O!G_8%LO\ T0E?%<3_ ,&GZO\
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M*1\[4445\"?.!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML/QS_P B3X@_[!]Q_P"BVK*K_#EZ,B?PL^0****_-SY<**** "BBB@ HHHH
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M&+6)6QX-F2W\8:'+(=L<=_ S-C. )%)K6E_$CZHN'Q(^PZ*Q?^$PTC_G[_\
M(3_X4?\ "8:1_P _?_D)_P#"OT@^H-JBL7_A,-(_Y^__ "$_^%'_  F&D?\
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MAI?PQU2*ZG\J1M8E8+L8\>1 .P]C7S7$/^XOU1R8K^&?25%8O_"8:1_S]_\
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M77K22_G4Q.KQ,D<A:90C.<$';@D8YI8=^RJIK5=NW]=O^&+K6J4Y)Z-K?O\
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M .>UU_WTO_Q-'_"O]/\ ^>UU_P!]+_\ $UTU%?GAYAS/_"O]/_Y[77_?2_\
MQ->2?'OP_;Z%_87D/*_F^?N\P@]/+Z8 ]:^@:\1_:4_YES_MY_\ :5>9F7^Z
M3^7YHY,5_!E_74\2HHHKX4^?"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "M?PA;K=^+-$@<D)+?0(2O7!D4<5D5M^
M!O\ D=O#_P#V$+?_ -&+6M+^)'U1</B1]-?\*_T__GM=?]]+_P#$T?\ "O\
M3_\ GM=?]]+_ /$UTU%?I!]0<S_PK_3_ /GM=?\ ?2__ !-'_"O]/_Y[77_?
M2_\ Q-=-10!S/_"O]/\ ^>UU_P!]+_\ $T?\*_T__GM=?]]+_P#$UTU% ',_
M\*_T_P#Y[77_ 'TO_P 31_PK_3_^>UU_WTO_ ,37344 <S_PK_3_ /GM=?\
M?2__ !-'_"O]/_Y[77_?2_\ Q-=-10!S/_"O]/\ ^>UU_P!]+_\ $T?\*_T_
M_GM=?]]+_P#$UTU% ',_\*_T_P#Y[77_ 'TO_P 31_PK_3_^>UU_WTO_ ,37
M344 <S_PK_3_ /GM=?\ ?2__ !-'_"O]/_Y[77_?2_\ Q-=-10!S/_"O]/\
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M^E_^)KIJ* .9_P"%?Z?_ ,]KK_OI?_B:/^%?Z?\ \]KK_OI?_B:Z:B@#F?\
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MIXC1117\,'[,%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7@'3+Y+B9]6U-%.?L]Y<H(S]?+13^M>UV-C;:79PVEG!':VL*A(X85"HBCH
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M*@DND7^;9_0;1114@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*** "BBB@ HHHH *^V?V)?\ DE6J_P#8:E_]$05\35]L_L2_\DJU7_L-2_\
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M\,/^2BC_ ()?D?,<1_[@_5'H5%%%?V(?E(4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %?$W[;7_)5-*_[ L7_H^>OMFO
MB;]MK_DJFE?]@6+_ -'SU]-P]_OR]&=>%_B'S[1117ZD>P%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?I?\ "7_D
ME7@S_L"V7_HA*_-"OTO^$O\ R2KP9_V!;+_T0E?%<3_P:?J_R//Q?PHZRBBB
MOSP\P*\1_:4_YES_ +>?_:5>W5XC^TI_S+G_ &\_^TJ\S,O]TG\OS1R8K^#+
M^NIXE1117PI\^%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %;?@;_D=O#_ /V$+?\ ]&+6)6WX&_Y';P__ -A"W_\
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M_1;5N5A^.?\ D2?$'_8/N/\ T6U95?X<O1D3^%GR!1117YN?+A1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBOS<^7"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6G_7ZG_HN2OB>-?^2=QG^#]4>OE'^_TO4\1HHHK^&#]F"BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*_2_X2_\DJ\&?]@6R_\ 1"5^:%?I?\)?^25>#/\ L"V7_HA*^*XG_@T_5_D>
M?B_A1UE%%%?GAY@5XC^TI_S+G_;S_P"TJ]NKQ']I3_F7/^WG_P!I5YF9?[I/
MY?FCDQ7\&7]=3Q*BBBOA3Y\**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *V_ W_([>'_\ L(6__HQ:Q*V_ W_([>'_
M /L(6_\ Z,6M:7\2/JBX?$C[ HHHK](/J HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KY]_;:_P"25:5_V&HO_1$]?05?/O[;7_)*M*_[
M#47_ *(GKULI_P!^I>IM1_B1/B:BBBOV(]T**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^V?V)?\ DE6J_P#8:E_]
M$05\35]L_L2_\DJU7_L-2_\ HB"OFN(?]Q?JCDQ7\,^@J***_+#QPK#\<_\
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M**^!/G HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_/.Z_P# 0?\ Q-']K>*/^>=U_P" @_\ B: /0**\_P#[6\4?\\[K_P !!_\
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M,8'?FM:7\2/JBX?$C[(HKS_^UO%'_/.Z_P# 0?\ Q-']K>*/^>=U_P" @_\
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M ))5I7_8:B_]$3UZ%_:WBC_GG=?^ @_^)KQ7]K*^UFZ^'.G+J*S" :K&1YD
M0;O)F[X';->ME/\ OU+U-J/\2)\G4445^Q'NA1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7VS^Q+_ ,DJU7_L-2_^
MB(*^)J^L?V3;[6;7X<ZBNG+,8#JLA/EP!QN\F'O@]L5\UQ#_ +B_5')BOX9]
M545Y_P#VMXH_YYW7_@(/_B:/[6\4?\\[K_P$'_Q-?EAXYZ!6'XY_Y$GQ!_V#
M[C_T6U<W_:WBC_GG=?\ @(/_ (FLSQ1JGB.3PSJZSI<"!K.82;K8 ;=ASD[>
M.*RJ_P .7HR)_"SYWHHHK\W/EPHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ^I/@M_P DST;_ +;?^CI*[>O&
M?AKJ&O0>"=.2R2<VP\S9LMPP_P!:^>=I[YKIO[6\4?\ /.Z_\!!_\37Z'A?]
MWI^B_(^FH_PX^B/0**\__M;Q1_SSNO\ P$'_ ,31_:WBC_GG=?\ @(/_ (FN
MHU/0**\__M;Q1_SSNO\ P$'_ ,31_:WBC_GG=?\ @(/_ (F@#T"BO/\ ^UO%
M'_/.Z_\  0?_ !-']K>*/^>=U_X"#_XF@#T"BO/_ .UO%'_/.Z_\!!_\31_:
MWBC_ )YW7_@(/_B: /0**\__ +6\4?\ /.Z_\!!_\31_:WBC_GG=?^ @_P#B
M: /0**\__M;Q1_SSNO\ P$'_ ,31_:WBC_GG=?\ @(/_ (F@#T"BO/\ ^UO%
M'_/.Z_\  0?_ !-']K>*/^>=U_X"#_XF@#T"BO/_ .UO%'_/.Z_\!!_\31_:
MWBC_ )YW7_@(/_B: /0**\__ +6\4?\ /.Z_\!!_\31_:WBC_GG=?^ @_P#B
M: /0*\M_:*_Y$FR_[""?^BY:TO[6\4?\\[K_ ,!!_P#$UPOQBOM9NO#-LNHK
M,(!>*1YD 0;MC]\#MFN#'?[M/T.?$?PI'CU%%%? GS@4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?;=%5M.>
M633[9I\B=HU+[A@[L#.1VYJS7Z:?5A1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7GOQN_Y%2T_P"OU/\ T7)7H5>>_&[_ )%2T_Z_4_\
M1<E?$\:_\D[C/\'ZH]?*/]_I>IXC1117\,'[,%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %>W?!'_ )%2[_Z_7_\
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M%?I?\)?^25>#/^P+9?\ HA*^*XG_ (-/U?Y'GXOX4=91117YX>8%>(_M*?\
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M_P"P?<?^BVK*K_#EZ,B?PL^0****_-SY<**** "BBB@ HHHH **** "BBB@
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\3?MM?\E4TK_L"Q?\
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M /80M_\ T8M:TOXD?5%P^)'V!1117Z0?4!1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$\:_\D[C/\'ZH]?*/]_I>IXC1117\,'[,%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %>W?!'_ )%2[_Z_7_\ 1<=>
M(U[=\$?^14N_^OU__1<=?K/AA_R44?\ !+\CYCB/_<'ZH]"HHHK^Q#\I"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX
MF_;:_P"2J:5_V!8O_1\]?;-?$W[;7_)5-*_[ L7_ */GKZ;A[_?EZ,Z\+_$/
MGVBBBOU(]@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *_2_X2_P#)*O!G_8%LO_1"5^:%?I?\)?\ DE7@S_L"V7_H
MA*^*XG_@T_5_D>?B_A1UE%%%?GAY@5XC^TI_S+G_ &\_^TJ]NKQ']I3_ )ES
M_MY_]I5YF9?[I/Y?FCDQ7\&7]=3Q*BBBOA3Y\**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *V_ W_([>'_ /L(6_\
MZ,6L2MOP-_R.WA__ +"%O_Z,6M:7\2/JBX?$C[ HHHK](/J HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY]_;:_Y)5I7_8:B_P#1$]?0
M5?/O[;7_ "2K2O\ L-1?^B)Z];*?]^I>IM1_B1/B:BBBOV(]T**** "BBB@
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M HHHH **** "BBB@ HHHH **** "BBB@#[;HHHK]-/JPHHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\B39?]A!/_1<M>I5Y;^T5_R)-E_V$$_]%RUP8[_=I^ASXC^%(^=J***^!/G
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6WX&_P"1V\/_ /80M_\
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M/0J***_L0_*0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBBO@3YP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(HIZ4K]V_P -AU/XB79+\3YF_;2\&V_]AZ1XKMXA%J$%R+2:9!AG1E+(2?\
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M '^B_P#C='^L.![O[@^M4SYEHKZ:_P"&9?"__/\ :O\ ]_HO_C='_#,OA?\
MY_M7_P"_T7_QNC_6' ]W]P?6J9\RT5]-?\,R^%_^?[5_^_T7_P ;H_X9E\+_
M //]J_\ W^B_^-T?ZPX'N_N#ZU3/F6BOIK_AF7PO_P _VK_]_HO_ (W1_P ,
MR^%_^?[5_P#O]%_\;H_UAP/=_<'UJF?,M%?37_#,OA?_ )_M7_[_ $7_ ,;H
M_P"&9?"__/\ :O\ ]_HO_C='^L.![O[@^M4SYEHKZ:_X9E\+_P#/]J__ '^B
M_P#C='_#,OA?_G^U?_O]%_\ &Z/]8<#W?W!]:IGS+17TU_PS+X7_ .?[5_\
MO]%_\;H_X9E\+_\ /]J__?Z+_P"-T?ZPX'N_N#ZU3/F6BOIK_AF7PO\ \_VK
M_P#?Z+_XW1_PS+X7_P"?[5_^_P!%_P#&Z/\ 6' ]W]P?6J9\RT5]-?\ #,OA
M?_G^U?\ [_1?_&Z/^&9?"_\ S_:O_P!_HO\ XW1_K#@>[^X/K5,^9:*^FO\
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MY]]4_P"^/_L*/[)Q/9?>'U.J>4T5ZM_PIM/^??5/^^/_ +"C_A3:?\^^J?\
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M U'_ )XVO_?+?_%4?\+ U'_GC:_]\M_\50!Z!17G_P#PL#4?^>-K_P!\M_\
M%4?\+ U'_GC:_P#?+?\ Q5 'H%%>?_\ "P-1_P">-K_WRW_Q5'_"P-1_YXVO
M_?+?_%4 >@45Y_\ \+ U'_GC:_\ ?+?_ !5'_"P-1_YXVO\ WRW_ ,50!Z!1
M7G__  L#4?\ GC:_]\M_\51_PL#4?^>-K_WRW_Q5 'H%?/O[;7_)*M*_[#47
M_HB>O0O^%@:C_P \;7_OEO\ XJN/^*6FQ?%OP_;Z/K#-;6T-TMVK6)".75'4
M E@PQASV]*[\!6AA\53JU-DS2G)1FFSX4HKZ:_X9E\+_ //]J_\ W^B_^-T?
M\,R^%_\ G^U?_O\ 1?\ QNOT3_6' ]W]QZGUJF?,M%?37_#,OA?_ )_M7_[_
M $7_ ,;H_P"&9?"__/\ :O\ ]_HO_C='^L.![O[@^M4SYEHKZ:_X9E\+_P#/
M]J__ '^B_P#C='_#,OA?_G^U?_O]%_\ &Z/]8<#W?W!]:IGS+17TU_PS+X7_
M .?[5_\ O]%_\;H_X9E\+_\ /]J__?Z+_P"-T?ZPX'N_N#ZU3/F6BOIK_AF7
MPO\ \_VK_P#?Z+_XW1_PS+X7_P"?[5_^_P!%_P#&Z/\ 6' ]W]P?6J9\RT5]
M-?\ #,OA?_G^U?\ [_1?_&Z/^&9?"_\ S_:O_P!_HO\ XW1_K#@>[^X/K5,^
M9:*^FO\ AF7PO_S_ &K_ /?Z+_XW1_PS+X7_ .?[5_\ O]%_\;H_UAP/=_<'
MUJF?,M%?37_#,OA?_G^U?_O]%_\ &Z/^&9?"_P#S_:O_ -_HO_C='^L.![O[
M@^M4SYEHKZ:_X9E\+_\ /]J__?Z+_P"-T?\ #,OA?_G^U?\ [_1?_&Z/]8<#
MW?W!]:IGS+17TU_PS+X7_P"?[5_^_P!%_P#&Z/\ AF7PO_S_ &K_ /?Z+_XW
M1_K#@>[^X/K5,^9:*^FO^&9?"_\ S_:O_P!_HO\ XW1_PS+X7_Y_M7_[_1?_
M !NC_6' ]W]P?6J9\RT5]-?\,R^%_P#G^U?_ +_1?_&Z/^&9?"__ #_:O_W^
MB_\ C='^L.![O[@^M4SYEHKZ:_X9E\+_ //]J_\ W^B_^-T?\,R^%_\ G^U?
M_O\ 1?\ QNC_ %AP/=_<'UJF?,M?;/[$O_)*M5_[#4O_ *(@K@/^&9?"_P#S
M_:O_ -_HO_C=>H_"W38OA)X?N-'T=FN;::Z:[9KXAW#LB*0"H48P@[>M>+F^
M;X7&85TJ3=[KH<]:O"I#EB>X45Y__P + U'_ )XVO_?+?_%4?\+ U'_GC:_]
M\M_\57PQYYZ!6'XY_P"1)\0?]@^X_P#1;5S?_"P-1_YXVO\ WRW_ ,5575O%
MUYK&EWEA-' L-U"\#M&K!@K*5)&3UP:B:<H-(F2NFCYNHKTG_A6NF?\ />[_
M .^U_P#B:/\ A6NF?\][O_OM?_B:^-_LG$]E]YXGU.J>;45Z3_PK73/^>]W_
M -]K_P#$T?\ "M=,_P">]W_WVO\ \31_9.)[+[P^IU3S:BO2?^%:Z9_SWN_^
M^U_^)H_X5KIG_/>[_P"^U_\ B:/[)Q/9?>'U.J>;45Z3_P *UTS_ )[W?_?:
M_P#Q-'_"M=,_Y[W?_?:__$T?V3B>R^\/J=4\VHKTG_A6NF?\][O_ +[7_P")
MH_X5KIG_ #WN_P#OM?\ XFC^R<3V7WA]3JGFU%>D_P#"M=,_Y[W?_?:__$T?
M\*UTS_GO=_\ ?:__ !-']DXGLOO#ZG5/-J*])_X5KIG_ #WN_P#OM?\ XFC_
M (5KIG_/>[_[[7_XFC^R<3V7WA]3JGFU%>D_\*UTS_GO=_\ ?:__ !-'_"M=
M,_Y[W?\ WVO_ ,31_9.)[+[P^IU3S:BO2?\ A6NF?\][O_OM?_B:/^%:Z9_S
MWN_^^U_^)H_LG$]E]X?4ZIYM17I/_"M=,_Y[W?\ WVO_ ,31_P *UTS_ )[W
M?_?:_P#Q-']DXGLOO#ZG5/-J*])_X5KIG_/>[_[[7_XFC_A6NF?\][O_ +[7
M_P")H_LG$]E]X?4ZIYM17I/_  K73/\ GO=_]]K_ /$T?\*UTS_GO=_]]K_\
M31_9.)[+[P^IU3S:BO2?^%:Z9_SWN_\ OM?_ (FC_A6NF?\ />[_ .^U_P#B
M:/[)Q/9?>'U.J>;45Z3_ ,*UTS_GO=_]]K_\31_PK73/^>]W_P!]K_\ $T?V
M3B>R^\/J=4];^"W_ "3/1O\ MM_Z.DKMZ\K\+Z]<>$]#MM*M$CDM[?=M:8$N
M=S%CD@@=6/:M3_A8&H_\\;7_ +Y;_P"*KZZA%TZ4(2W22_ ]FG%Q@HOHCT"B
MO/\ _A8&H_\ /&U_[Y;_ .*H_P"%@:C_ ,\;7_OEO_BJW-#T"BO/_P#A8&H_
M\\;7_OEO_BJ/^%@:C_SQM?\ OEO_ (J@#T"BO/\ _A8&H_\ /&U_[Y;_ .*H
M_P"%@:C_ ,\;7_OEO_BJ /0**\__ .%@:C_SQM?^^6_^*H_X6!J/_/&U_P"^
M6_\ BJ /0**\_P#^%@:C_P \;7_OEO\ XJC_ (6!J/\ SQM?^^6_^*H ] HK
MS_\ X6!J/_/&U_[Y;_XJC_A8&H_\\;7_ +Y;_P"*H ] HKS_ /X6!J/_ #QM
M?^^6_P#BJ/\ A8&H_P#/&U_[Y;_XJ@#T"BO/_P#A8&H_\\;7_OEO_BJ/^%@:
MC_SQM?\ OEO_ (J@#T"BO/\ _A8&H_\ /&U_[Y;_ .*H_P"%@:C_ ,\;7_OE
MO_BJ /0*\M_:*_Y$FR_[""?^BY:TO^%@:C_SQM?^^6_^*K!\:7C^.M+BL+\+
M##',)PUO\K;@K+CG/&&-<N*IRK490CNS*M%S@XH\"HKTG_A6NF?\][O_ +[7
M_P")H_X5KIG_ #WN_P#OM?\ XFOE/[)Q/9?>>/\ 4ZIYM17I/_"M=,_Y[W?_
M 'VO_P 31_PK73/^>]W_ -]K_P#$T?V3B>R^\/J=4\VHKTG_ (5KIG_/>[_[
M[7_XFC_A6NF?\][O_OM?_B:/[)Q/9?>'U.J>;45Z3_PK73/^>]W_ -]K_P#$
MT?\ "M=,_P">]W_WVO\ \31_9.)[+[P^IU3S:BO2?^%:Z9_SWN_^^U_^)H_X
M5KIG_/>[_P"^U_\ B:/[)Q/9?>'U.J>;45Z3_P *UTS_ )[W?_?:_P#Q-'_"
MM=,_Y[W?_?:__$T?V3B>R^\/J=4\VHKTG_A6NF?\][O_ +[7_P")H_X5KIG_
M #WN_P#OM?\ XFC^R<3V7WA]3JGFU%>D_P#"M=,_Y[W?_?:__$T?\*UTS_GO
M=_\ ?:__ !-']DXGLOO#ZG5/-J*])_X5KIG_ #WN_P#OM?\ XFC_ (5KIG_/
M>[_[[7_XFC^R<3V7WA]3JGFU%>D_\*UTS_GO=_\ ?:__ !-'_"M=,_Y[W?\
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MP_UGP?\ )+[E_P#)'SW17T)_PJOPM_T"_P#R8E_^*H_X57X6_P"@7_Y,2_\
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MQ+_\51_Q"7//^?U+_P "G_\ *P_UGP?\DON7_P D?/=%?0G_  JOPM_T"_\
MR8E_^*H_X57X6_Z!?_DQ+_\ %4?\0ESS_G]2_P# I_\ RL/]9\'_ "2^Y?\
MR1\]T5]"?\*K\+?] O\ \F)?_BJ/^%5^%O\ H%_^3$O_ ,51_P 0ESS_ )_4
MO_ I_P#RL/\ 6?!_R2^Y?_)'SW17T)_PJOPM_P! O_R8E_\ BJ/^%5^%O^@7
M_P"3$O\ \51_Q"7//^?U+_P*?_RL/]9\'_)+[E_\D?/=>W?!'_D5+O\ Z_7_
M /1<=:W_  JOPM_T"_\ R8E_^*K;T/P_8>&[1[;3H/L\#.9"N]FRQ &<L3V
MK[C@W@',^'LU6.Q52FX*,E[KDWKZQ2_$\?-L[P^.PSHTHR3NMTO\V:-%%%?O
M1\2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMKWAK5;;6]%N6D6"_LWWPS;':-BC=&&Y6&X<'&02.: -NBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***^(O$G_  4L_P"$?_; 3X%_\*Y^T;M=
MMM%_M[^W-O\ KA'^]\C[,>F_[OF<XZBB/OU(TH_%+;\%^J%+W8.H]EO_ %\C
M[=HHHH&%%?&_[;7_  40_P"&.?'6@^'/^%?_ /"7?VKIQO\ [3_;/V+ROWC)
MLV_9Y,_=SG(Z]*^M/"NN?\)-X7T?6/)^S?VA9PW?D[]_E^8@?;NP,XSC.!2A
M^\BYQV3M\]?\F$O<FH2W:O\ +3_-&I1113 **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *\R_:>_Y-L^*W_8J:K_ .DDM>FUYE^T]_R;
M9\5O^Q4U7_TDEKGQ/\"?H_R.K"?[Q3_Q+\S\M?\ @D#\%_ GQAUCXG1^-_"6
MD^*DL(-/:U75+59Q"7:?<5W#C.U<_05^E7_#$OP#_P"B0^$?_!5%_A7YP_\
M!''XJ^"OAAK'Q2?QCXPT'PDEY;Z>+9M<U."R$Y5KC<$,K+NQN7..F1ZU^FW_
M  UC\$/^BR?#_P#\*BQ_^.UZ%:WNV[(\^G?FE?O^B/*OBU_P3.^ GQ.\/W=I
M:>"[7P?JS1%+75?#Y:W:!^S&('RY!GJ&4\9P0>:_/;_@G)XT\1?LV_MQ7_PH
MU"\\S3M4OKOP_J<$;?N6NK?S##.H/?=&5'^S*:_2'XN?\%#/@1\)_#-UJ?\
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M]"L7=.FXZM1E;^]J_N[:GZQ4444@"BBB@ HHHH **** "BBB@ HHHH ****
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M*IO^"+7BOQA"FJ>,/CE]H\13+ON=VCRWX\PCD>?)<HSC_:*#Z5XAXOO/C_\
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MW[>?P*^-7[+/C#PAX,\<_P!L^(K]K0VUG_9%_!OV744C_/+ J#"JQY(Z5O\
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MCB12SL3Z  FB7+&FJM_=U_#<2NZCI6][3\=B_17Y(WG[9?[2?[<_Q5U7PI\
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M!'(/(K#WN6_3^O\ ,O2_F?BKX%_Y3(3_ /8Y:A_Z)FK]JZ_%3P+_ ,ID)_\
ML<M0_P#1,U?M766%_P!QH_UTB:8C_?:W]=9!1115DA1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5YE^T]_R;9\5O^Q4U7_TDEKTVO,OVGO\ DVSXK?\ 8J:K
M_P"DDM<^)_@3]'^1U83_ 'BG_B7YGXR?\$\_V+O#/[86H>-[?Q)KNK:(N@Q6
MDD!TORLR&4RAMV]&Z>6,8]37UOXN_P""(OA&;19AX7^(^MV>K@$Q-J]K#<0,
M<<*PC",N?[P)QZ'I7&_\$.?^0Y\7?^O;3/\ T*YK]8Z[Z\$E%+2Z1P4Y/FE?
MH_T1_/=\._ASX$_9U_:,N_ _[37@S4[RP@F2!Y]/U"2&"!6/RW.V-0\\+#!R
MCJ0-W#,-M?O1\,O"_A#P?X'TG3_ >G:9IOA7R%FL8]'1%MWC<!A(I7AMP(;=
MR6SDDU\K?\%./V08_P!H7X2R>*_#UB)/'_A6%I[;RD_>7UH,M+;<?>(Y=.OS
M @8WFO O^"0?[7;3+)\#O%5Z3(@DNO#,\[?PC+36F3Z<R(/3S!V45G1DZL)4
M9?%'\5_G_DUV+K15.2JKX7^#_K\T^Y^FGC2'PX_AJ_F\61Z8_A^WB:>[;6%C
M-K'&H)9W\SY0 ,\FOBGQ!_P58_9O^#,:^&?!FEZIK&F69=8H_">CPVNGQL6)
M8*)'BX+$G<B$'.<G-<[_ ,%J/&>N:'\$?!NA:?--;Z/K6KN-2:-B!+Y4>^*)
MO52Q+X]8P>U=3_P3L_9-^"UQ^S7X-\8R>$]#\8^(M8M_M5]JFL6D=ZT-P'8-
M#&L@98O+(V_* 3MR<YK&G>I[1WLHM+U=K_U_P32I:"@K7<DWZ:V/+-0_X+&>
M(?'U]<:)\*O@=J6OZK(A^S-/=274GU:UMXBQ'TD'UKR;_@B[))+^TEXY>5=D
MK>')2ZXQ@F[@R*_4?XU?%;P;^S+\(M8\2ZK)8Z'IEC;NMI9P*D1N9]I\N"%!
MC<[$< #@9)P 37Y8?\$7-0$O[37C%7!\VX\,32Y'3B[M\_\ H5;X5KZQ)+I&
M6O\ V[(C$)_5U?K*.GHU=_UYGU/_ ,%G_P#DU30_^QKM?_2:ZKUO_@FG_P F
M2?#+_KWNO_2N:O)_^"SD3R?LI:,RJS*GBJT9B!]T?9[H9/XD#\:]3_X)FW,5
MS^Q)\-O*D63RX;N-]ISM87DV0?>IP_\ "K_XX_\ I)6)^+#_ .&7_I3/J&BB
MBI$%%%% !1110 4444 %%%% !1110 4444 %%%% !7X??%:QMM3_ ."NOV2\
MMXKNUF\;Z<DL$Z!T=2(,JRG@@^AK]P:_$7XD?\I@8?\ L>=-_E!1AO\ D84/
MG_Z5$G$?[G5_KI(_8S_A4/@3_H2O#O\ X*H/_B*/^%0^!/\ H2O#O_@J@_\
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M?QG_ -C0_P#Z2V]?:7Q[_P"2&?$3_L7=0_\ 2:2NC,_X4_\  O\ TA'/E_\
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MKZ-KTL5_'J>K_,\W"?[O3_PK\@HHHKE.H**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ^-O^"M?_)EOB+_L):?_ .E"
MU5_X)$_\F::5_P!AB_\ _1@JU_P5K_Y,M\1?]A+3_P#TH6JO_!(G_DS32O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q_QC\'WOQ"^$?C;P
MMITL$.H:WHE[IMO)=,RQ))- \:ERH)"@L,D G'8UV%%1.*G%Q>S+A-TYJ<=U
MJ?$/_!./]B'QU^R#J7CJX\8ZMX>U)-=BLX[8:'<SRE#$TI;?YL,>,^8N,9Z'
MI7V]116TIN=K]-#)146VNH5^8?Q^_P""57CS4/VBKKXC?!7Q+X<\*V<UW'J\
M$&I7-Q!-8WV_>YB$4$B^67 <9(QN*XP!G]/**S2M.-1;HN]XN#U3/'/BO^S[
M9?M,? FW\%?%6VM5U::"&:XNM"F9DL[Y%P9K9Y$4XR6X9>58J17P-IO_  2U
M_:.^$&HWEM\)_CG9Z5HEP^]RNIZAI#RMC +PP)*A('&=QK]7**+>^YK2^_82
M^%0>MC\\_AQ_P2IOO$WBBP\3?M"_%'5_BG>VH_=Z3]KN'@'.=CW$SF1H_P#9
M18^G4CBKO[,/_!/[Q_\ LU_M?:[\0=-U+PI)\.]2:_MDTV"XN$O8+.9_,A18
M_L_EY1DB&/,Q@'![5]_T5<9.,E*.EDU]^Y+BI1<7UM^&QY/^U#^SUI/[4'P;
MUCP'JUY)IGVHI/::A"@=K6XC.8Y-I(W#J"N1E6(!!Y'P-\$?^"9'[0OP+^*7
MAW5=%^)OA]?"FG:U;7]W86VK:A;?;84E4N'MU@,99D!7!8CG&>]?JC14T_W4
M_:0W_P BI_O(<DM@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
MB+Q)_P $T_\ A(/VP$^.G_"QOL^W7;;6O[ _L/=_J1'^Z\_[2.NS[WE\9Z&O
MMVBB/N5(U8_%';\'^B%+WH.F]GO_ %\PHHHH&?&_[;7_  3O_P"&QO'6@^(_
M^%@?\(C_ &5IQL/LW]C?;?-_>,^_=]HCQ][&,'IUKZT\*Z'_ ,(SX7T?1_.^
MT_V?9PVGG;-GF>6@3=MR<9QG&36I12A^[BX1V;O\]?\ -A+WYJ<MTK?+3_)'
MRK^U9_P3H^&O[4^K/XBO)+SPKXR:,1OK6E!2+D*,)]HA88DVC R"K8 &[  '
MSUX#_P""(OA/2->BNO%WQ+U/Q+I<;!C8:=I::<TF#G:TAEF.T]#M"GG@BOTO
MHHBE!WB.3<U:1\7_ !B_X)IZ#\0OBM\,O%'ACQ+;^!="\#6MG:VOAVVT;[0D
MJP7;W&?-\]"I<N0258YRQ))KZ<^-'PY_X6]\)?%_@C^T/[)_X2#2[C3?MWD>
M=Y'FH4W^7N7=C.<;AGU%=I11)<\'3EJG=_?O]X)\LU-;I)?);?<?-?[$/[&_
M_#&WA/Q+HO\ PE__  E_]LWL=YY_]F?8O)VQ[-NWSI-V>N<CZ5]">(-*_MW0
M=2TWS?(^V6TEOYNW=LWH5W8R,XSTS6A13J?ODXSU35OE:WY"I_NG>&FM_G>Y
M\C_L._L"_P##&>M>*]0_X3K_ (3#^WK>W@\O^R/L/D>4SMG/GR;L[^F!C'>O
MKBBBJ<G))/H2HJ+;74^./V<O^">/_#/_ .TIXB^+/_"?_P!O?VN+\?V/_8WV
M;ROM,PE_UWVA]VW&/N#/7CI7N/[1G[,O@7]J+P4OAOQO82RI YFLM0LY!%=V
M4A&"\3D$<CJK!E.!D' QZM167*N2-.VD59?(T4FIN:W>_P"1^7UQ_P $0;2+
M4IFTSXSWUEILC?\ 'O)H DEV^C2+<J"<=]GX5]$_!'_@F)\&O@KINH,+&Z\5
MZ_>VDMH=9UUDE>V62,HY@B50D9P3AL%QDC=@XKZXHJMXN'1Z?TR?M*78^2OV
M(?V$K[]C/6/%,T?Q$7Q;I6O0PK)8MHGV-HI8F8I('^T29^61P1M&<@Y&,'+_
M &LO^"=__#47QN\/?$/_ (6!_P (S_9-G;6G]F_V+]K\WRIY)=WF?:(]N=^,
M;3C&>>E?9-%:<\N:$^L=OE^?S)Y5RSATGO\ UTVZ!7AG[8W[,?\ PUI\(E\#
M_P#"2?\ "*[=1AO_ +?]@^V?ZM7&SR_,CZ[^N[C'2O<Z*QE%35I>7X:FD9.#
MO'^KZ'E/[+?P*_X9K^!OAWX=?VW_ ,)'_8YN#_:7V3[+YOFW$DW^KWOMQYFW
M[QSC/&<5ZM116TYRJ2<Y;LSC%15D%%%%04%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?GY_P4
M)_X)]_$3]K+XO:!XJ\(ZSX8T[3]/T6/3I8]:NKB*4R+/-(2HC@D&W$B]2#D'
MBOOC2;5['2[.VD*F2&%(V*]"0H!Q^56Z*(^Y#V:VNW\V.;]I-3ENE;\E^@5X
M)^VE^RU8?M8?!>]\+E[>R\1VC_;-$U*XR$M[D#&URH+>6ZDJV >H;!*BO>Z*
MB<5-<K*C)P?,CXF_X)Z_LG_&C]DFXU[0O%^O>%=:\#:D/M45KI5]=23VEX,#
M>BR6R+M=>&^;JB$=\\O^UI_P2JLOC#\0;SXA_#7Q1'X)\57DWVNZL[F-_LDU
MUD'SXY(_G@<D;FPKY8Y&TYS^@-%:3_>.,GNMG_7]:+L9P]Q.*V?3^OZU?<_+
M_2?^">'[6GB53I'C/]I2XMO#LB&.86.OZIJ#NA&"K12"$.".S/BM[XP?\$>]
M ?X(:5X<^%U[9KXYAU)+N^\1>*9Y%-Y#Y;JT0\J-_+4,RL%5.<?,Q(!K](J*
M4O>5O3\'<:T=_P"M=#R_]F/P%XH^%GP&\%^#O&,VF7.O:#8)ITD^D322V\D<
M65B96DC1L^6$R"O4'&:^,?VPO^"5NO\ Q=^,6H?$GX8^+]/T'5M4G2[N[#5V
MF@2*Y4 &:&>%'8$E0VTIPV2&Y 'Z/445/WE3VK^+OZ[A#]W#V:V/G3]AWX*?
M%#X#_"_5O#OQ3\56GB_59=5>\L[ZVU&YO2D#11KY;//&C##(Q &1\U?1=%%7
M*3F[OR_#0F,5%604445!04444 %%%% !1110 4444 %%%% !1110 5\)_P#!
M5+]FCXD_M(>&?A_:?#KPY_PD5QI5Y=RWB?;K:U\I72,*<SR(#DJ>F>E?=E%9
MS@JB2?1I_<:0FX.Z\U]ZL>0_LB^ ]=^%_P"S3\//"GB:Q_LS7]*TM+:\M/.C
ME\J0,Q*[XV96ZCE217KU%%;SDZDG-]3"G!4X*"V6A\^?M[?"OQ1\:OV6?&'A
M#P9I?]L^(K]K0VUG]HB@W[+J*1_GE94&%5CR1TKSC_@EW^S[X^_9U^#/B;0O
MB%H/_"/ZK>:\U[!;_;+>YWPFWA0-NAD=1\R,,$YXZ5]E45-/]WSV^UO^'^1I
M-\ZBG]G]3Y@_;J_8FT[]L/P5IL=OJ4>@^,=#,CZ7J,R%X75P-\$P'.QBJG<,
ME2,@')!^(_ W[.__  4!^!]G_P (;X,U63_A&8F\N&>/6-.N+2%3_P \1='S
MHE[[51?7&:_7NBHC'D;ML]UT'*7,E?=;'Y3^.O\ @EU\1=0^!OC/Q+XDU:3X
MK?'K6GM$M%;41Y5G"MQ&TNV>Y9 [^6I&3M"KE5!SD_:_[!7PM\4?!?\ 95\%
M^#_&6F?V/XCT\WGVJR^T13^7YEY-(GSQ,R'*.IX8]<=:^@:*UC)QC*"V;3]+
M*VAG*/,TWNC\U(OV0/BXO_!3X_%L^$O^+??VT;O^V/[2M/\ 5?8S'N\GS?-^
M_P 8V9[]*_2NBBLX+V=*-%;1_P DOT*E[U255[O_ (/^9^:G[5G['_Q<^)7[
M?WA+XD>'/"7]H^"[&[T:6XU/^TK2+8L$JM,?*>59#M /13GMFOTKHHHA[E-4
MEM=O_P "=V.7O3YWO9+[C\X/^"I7[(_Q8_:-^(G@;4_AWX4_X2&QTW3);>[E
M_M&TMO+D:;<!B:5">.X!%?<GQ"^$^C_%[X/:CX!\40,^F:KIRV=RL;#?&P4%
M70\C<CJK \C*BN[HJ8Q2HNANFV_O_P"'&Y-U(U5NE;[K?Y'Y$:'^P[^V!^R%
MXKU*3X'^(;;7M'OF^9K.ZM8EF0'Y3/:WI$8DQD90L0,X;FN^7]F/]MG]IVQ&
MA_&'XD6W@?P=,VV]L;-K4SSQD<J8[)0DJGNLDN.^#C%?IS15K9*?O>I/6\=/
M0_)V\_X)S_$/]G[]L3P-XK^$WA*Z\4?#W1;C3[N:[N=7LX[C*@)=AEEEC)8@
M._RJ%^< =,#[5_X*"?"7Q9\</V6?$WA#P5I7]M>(KRXLI(++[1#!O6.YC=SO
ME=4&%4GEN<<5]&T4I+FIJDWHG?\ %/[M C[M1U%NTE]R:^_4^8?^"<_P:\8_
M ?\ 9GL/"GCK1_[#U^+4KNX>S^TPW&(W<%#OA=UY';.:^G) 6C8#J13J*JJ_
M;*TNUOPL1"*IJR[M_>[GYI_\$S?V/_BY^S[\=O%_B+Q_X2_L#1[_ $>6UMKG
M^TK.YWRFYB<+MAE=A\JL<D <5^EE%%4Y-QC#^56_%O\ 4N7O5)U'O)W84445
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB,:PRH0#'%(=V9%[8P#S7U'16<HJ2L_ZMJ;1DX.Z\_Q5CR?]E/X3ZO\  O\
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M9[>R\26;?;-#U.X!"VUR!C:Y4$^6X^5L ]0V"5%>^45,XJ:LS2,G!W1\(_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA[QYI2ZGX:UW3/$6FL=JWFDWD=U"3Z!XV(_6MFJU6XMPHHHI %%%% !1110
M4444 %%%<MH_Q4\%>(KW7;/2O%^@ZG=Z#N&K6]GJ<$TFG;2P;[0JL3%@H^=^
M,;3Z&E<9U-%<UX'^)O@_XFVES=>#_%>A^*[6U<13S:'J,-XD3D9"LT3,%)'.
M#72U1.X4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:%'K7A/Q!IOB329&*+>Z7=)<1;AU4LA(##N#R*JSM<FZO8WZ*X+XP?'3P1\
M]#L=9\>:TV@:5>W:V,5XUG<3Q"9@2JNT4;B,$ _,^!P>:[FWN(KJ".>&19H9
M%#I)&0592,@@CJ"*2UU0]M&24444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5A>./'6@
M?#7PGJ7B;Q1JMOHF@Z;'YMU?73;8XUR /<DD@ #))( !) K=KB_C%\)- ^.G
MPZU7P1XH6XDT'4S#]JCM9?*D=8YDE"[L$@$Q@''."<$'D3+FM[NY<>7F7/L?
ME5^VA^W1XM_:YT'Q1X.^#>AZI'\,]$M7OO$.N-&8I+NWC).7).(8"5R$)WR8
M ('*5]3_ /!';_DT$_\ 8Q7O_H,->B?M._"SPE\'?V%OBGX;\%^'[+P[HMOX
M>N=MK91[=S; "[L<L[G R[$L>Y->=_\ !';_ )-!/_8Q7O\ Z##6F'Y8RK0C
M_+%W>[;E_P  YZ_-+V,I?S/3M[K/N%F"J6)P ,DU^.W[&GP+\&?MN?M8?'3Q
M7\0-);Q)X:@NYKBWM_MD]N/-N+I_(;?#(C';%$XQG'/3@8_4WX^>)[GP7\$?
M'NN64,MQ?6.AWDUM#"A=WF$+>6J@ DDMMZ"OQ]_8(^%_[2_C7P7XITCX2:E:
M?#OPSJ%ZIU;Q5J"&*>9T3:+>%]COE0Y;]VJX+<N,@5E2UKR=K\L=.WO.VOI;
M3SL=%32@E>W-)?\ DJO\[WMZ7/T5_P"'7'[,7_1,_P#ROZI_\DU[;\&?@7X'
M_9\\)R^&O &B?V!HDMT]X]K]KGN<S,JJS;IG=N0B\9QQTK\T_BE\.?VT?V+-
M-F^(5M\6+SXD>&K%EDU"*YO[C45ABR-S2V]R#MCSP6B;<!R2H&1]X_L:_M5:
M3^UM\(X?%%K;+I>MV<OV+6-+5RPM[@*#E">3&X(92?<')4UM#WHR<'MNOZZ7
MM\S&7NRCS+?9_P!=;'J$/Q2\%W'C:3P;%XNT&3Q?&N]_#Z:G"=05=@?)M]WF
M ;"&^[T.>E9WB7X[?#7P7KG]B^(/B'X5T+6.!_9^I:W;6]QST_=NX;GZ5^17
M[3MSXZ;_ (*B>*]'^'&H'2/%OB"2UT2VU!25:V2XL((Y958<H50L=PY4 D<@
M5]5_\.9?A/)X*FM+KQ/XHN_%LL9=]>>XC"FX(Y;R-A'EEN=I8M@GY^]91;E1
MC6MHU^/9?*V_<UDE&K*E?73[FEJ_G?[C[^M[F*[MXYX)4F@D4.DD;!E93R""
M.HKB/^%^?#'_ (23_A'?^%C>$_\ A(/,\G^RO[<M?M7F9QL\KS-V[/;&:_&O
M]DFU^,WQ-\0Z[^RGIGC&;P]X2%_<3Z[=P[GFLK:W<QW,4#;AB.61D!3@%B"<
M N&^IOCU_P $@OACX=^"OB#5/!.K>(K?Q3HNG37T,NHW4<\5ZT2%S'*@C7!8
M*0"FW!()#8Q3J2C"'MK^Y:_G;J_EJO.P0BY3]C]N]O*_3^NG<_2JF331V\+R
MRNL42*69W("J!U))Z"OAG_@D+\9->^)O[.NIZ+X@O)M2F\*ZG]@M+JX<O)]E
M>-7CC+'D[#O4>B[1T%>$_M<^/O&_[<O[7:_LX^"-8;1_!>C3M'JUQ&28Y9(@
M&N)Y@I'F+$V(TC) +C)/(*W4BXU51AJWKVTM>[]$]?\ +4SIR4J;JST2T^=[
M67KT_I'Z2Z%\>?AGXHUX:'HWQ$\)ZOK98J--L=;MI[G(ZCRU<MG\*T[[XI>#
M-+\96OA"\\7:%:>++M0]OH,^I0I?3*02"D!;>P(5CP/X3Z5\2ZM_P1B^$$G@
M\V6E>(_%-AXDCC)AUJ:YBE7SL<%X1&H*9_A4JV!][O7R!\"5^(>E_P#!3+X=
M>&/B?J4FK^*?"UVVB&^F;>\UO%;3M"Y?JX*."&;YB",\YI0M.K"E?5O\.Z]'
M;<)WC2E5MHE^/G^)^X%?G5\//^,A/^"LWB_Q$?\ 2=#^&.E'3K5P<HMP%,)7
MZ^9-='_@'M7WC\2?&MI\-_A[XE\5W[!;/1--N-0ESW6*-GQ^.,?C7QE_P2)\
M%W?_  IGQ?\ $W6!YFM^.M?GNI+EA\TL43,N?^_SW%*CK6<OY(M_.7NK[O>9
M532CR_SM+Y+WG^2/%O$G_*;W3_\ ?A_],M?JQ)(D,;22,J(H+,S'  '4DU^4
M_B3C_@MYIY/]^'_TRUO_ +97[5GBO]J?XB?\,X?L_LVHQ7;M;Z_X@M)"(I$!
MQ+&)5X6V3_EI(,[\[%R#AYA)_5J,(*\G>WW[^B-ZT5[>4Y.T5&%W\OS?0_07
MP?\ '#X<?$36'TGPKX_\+^)M5CC:9['1]9MKN=44@,Q2-RP ) )QCD5V<DB0
MQO)(ZQQH"S,QP !U)->%_LB_LC^%?V2?AVFBZ.JZAX@O LFL:])'MEO90.@_
MN1+DA4SQDDY8DGX>_;.^)'CC]LW]K2U_9H\!ZLVD>%=.F\K6;B,MY<TJ*)+B
M6;:1O2$?*L9P#(#GDJ5N?\2-*GJW]VF[]%_5NF$?@E4GHE_27JS]'=&^/7PR
M\1>(!H.D_$7PGJ>N%B@TRSURUFN2PZCRED+9]L5J:G\4O!FB^,++PGJ'B[0K
M#Q5?*KVNAW6I0QWUPK;MIC@9@[ [6Q@'.T^E?$M]_P $8/@])X--A9>(O%-M
MXC6/*:U)<Q.OFXX+0>6%*9YV@AL<;^]?'7PKM?B)X?\ ^"E'PR\(?$[59-:\
M1^$M0BT2*_F;>T]HB2R0/O/S."DH(+?-@@'D4X6G5A1OJW^'E\[:,BHY0I3K
M6T2_'S_'7_,_<:BBBI+"BBB@ HHHH **** "BBB@ HHHH _,'QW^S!\0OVLO
M^"AUW<_%3POK5C\)-%67^SVD#"TN;2 JJ1)*APK3R-YC#(?;N'&T8^YO$O[*
M'P=\5^#9/"U[\-?#":,T311QVNEPP/!D$;HG10T;\YW*0<]Z]8K\MOVM/VFO
MVQVG\<Z;X7^'>H>&? =GJ-W9VOB+2-!N#?R62.Z"4N[OL#(-WFHB8R"K#@UB
MY*%*-&VB3^>N[??7\V;*+G4=:_5?+39+Y?YLR?\ @E3K%_\ #7]K#XP?"+3[
MZ;4_"5L+R6-W.0);2[6!)>. 71\,1UVKZ"OT5^-W[1WP[_9RTS2]0^(GB'_A
M'K/4YVM[23[%<W/F2*NXKB&-R..Y %?%'_!(&[^#%KX?U^W\,ZQJ%]\5KV))
MM;37+=8)C IX%J%=PT(=OF;=O+8+!1L J_\ !;PE?A?\,B.O]LW/_H@5MB9.
MA3I*6K7*F^]Y6;7R=EZ&-%1JU*C2LFY-+MI?_@_,^S?BY^UO\(/@3]E3QQX[
MT[1+FYC6:*R"R7%T8V&5<P0H\BJ>S%0.#6A\&_VF/A?^T%#._P /_&>G^(I;
M==\UI&7ANHUSC<T$JK(%R<;BN/>OE3]DG_@GM\/_ !9\+]'^(OQ?TR;X@^/_
M !=:IJ]W<:Q<R^7;I,H:.-8U8 D(5R6!(.0NT "OC;]LSX-W?[%_[8'AU/@A
M>WGA9_$&GQR:9'#<-(;:2=Y+:2%6DW$J<!AN)(+\'@8J473JJC->\W96[ZZ?
M\$B+]I2=6.R5W?MIKY;GZH?%;]M_X&_!/7WT/Q?\1-.T_6(VV36-K#/?2P-U
MVRK;QR&,X(X?!KT#X6_&/P3\;/#O]N^!O$VG^)M,#!'EL9<M"Q&=DB'#1MCG
M:X!]J^<_AG_P2[^!OA7P/#IWBGPS_P )MXCN80=4UW4KRX$UQ,W+M&$D B&X
MG&WYL8RS'FOD/]E/PW)^RO\ \%4-:^%7AR]N9?"^HK<69AGDW%H#9_;8=W9F
MC("ACS@M_>-.G'FJ>QD[NS=UMI_6@YM^S=6*T5KI[V?7Y'Z\LP522< <DFOG
MCQI_P4(_9X\ :\^C:O\ %#3#?QML==.M[B_C1LX*M);QN@(/4%N.]?/O_!73
M]H;7O!'@OPS\*O"5Q-;:QXT9_MTEL<2FS#*@@4CD>:[8..H1EZ,:[7X!_P#!
M*_X-^ ?A[86WC;PW'XU\6W%LIU*_OKB81I(R@M' B,JJJG(#8WGKGL,J?-43
MFOA3MZOK;TZ_\-?2?+!J#^)J_HO/UZ?U;W7Q7^UY\'O!GPRLOB'J/CO3Y/!E
MY>+I\.K::DM_&;AD9Q$5MT=E;:C9# 8Q@X)%>G>&_$6G^+_#NEZ[I%Q]KTK4
M[6.\M+C8R>9#(H=&VL PRI!P0".XK\4O^"DO[(,7[*-QIT_@;4+^'X8^*KKS
M)-$GN6E2SOX%;8,L<N/+DDV,V6'[P$G(K]>/V;?^3=_AA_V+&F_^DL=:T^6I
M2G471I6]4[W^:T\F9U+TZD(=TW?YJUOOU\SX^_X*PZQ=>.KCX-?!+2I6%]XQ
M\0QS3K'U6)&6%"P_N[IV;_MEGM63_P %F-'M?#_[,?PXTJQB$-E8^((;:"-1
M@+&EE.J@?0 59\)Y_:$_X*W>(-6.;C0OA=HYM(6SE!<!?+*^S>;<3G_ME[5)
M_P %LO\ DWOP/_V-"_\ I)<5R2TPD9?SR4OES*,?P7XG0M<2X_R1Y?G9RE^+
M_ ^ROV;?^3=_AA_V+&F_^DL=<OXT_;4^#/P_^)B?#W6/&6?&C2QP#1].TN]O
MY?-DQLC_ -'A=0YR/DSN&1D<U\E_&S]NR7X*_LZ_"OX8?#,'6OB[KGAC2K>.
M.UC\\Z6);:)4.T9W7#Y'EQ\XR&88VAO3_P!@7]@F+]G^S;Q_X_VZW\6=75II
MIIW\X:6),ET5SG=,V3YDN>Y53C);U*R]IB:LW\"D_F[[+]7T_/@I>YAZ<5\3
MBODK;O\ 1=3[3# J&Z#&>>*^>_'/_!0/]GOX<Z_)HNM_$_2QJ,;&.2/3H+B_
M2-@<%6>WCD52""""01WKP7_@KE^T=K?PS^&_A_X=>%;F:TUKQH\JW<UL2)19
M)M5HE(Y!E=PN1_"KCO71?LZ_\$K_ (0^ _ASIR>/?#<7C3QC=VROJ5U>W$HA
M@D906B@1&50JG@.1O/)R <#AAS5%*:^%.WJ^MO3K_P -?KE:'+%_$]?1>?KT
M_JWOWB+]KGX/^%_A=#\1KSQUI\_@N:Z2R75=.26^43L"1&R0([JV <AE&.^*
M])\)>*M+\=>%M(\1Z'=?;=&U:TBOK*Y\MX_-AD0.C[7 9<JP.& (SR*_&'_@
MI-^QY;_LHK8ZG\/[^_M/AIXLNEBN]!FN7ECM;V%6>(98DNI1I"I;++B0;B&K
M]7?V3/\ DUSX1?\ 8I:7_P"DD=:T^6I2G47225O5.]_FM/)D3O"<8=TW^/3^
MMSU>BBBH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%1W$RVUO),_"1J7;C/ &32;44VQI-NR/R1\2?#O0_VP/^
M"M'B?P[XGM/[9\'Z';O#>6:SR0[H[:U6/;OC967_ $F0'@CN*^R/^'7'[,7_
M $3/_P K^J?_ "37YM_LLZ?^T)\2OVB/BCK'P@M(/#>OZ]-<-JOB37+;8NE0
MSW)FV9=&P[L@&!&[?)D;<$CWWX@?LP_MM_!'2[GQQX>^.&I>.Y]/B-S<Z3%J
MEU<N0.7\NUN5:&4  G;@,>BJ3Q4PM3P]+G5O=U]6VV_^"54O.O447?6R]$DD
MO4^^_@;^RW\,/V;3K)^'/AG_ (1TZQY/V[_3[JZ\[RM_E_Z^5]N/,?[N,YYS
M@5\1?\%5/B[XE\=?$CP'^S?X-NGMIO$4EO-JIC) F::;R[>%R.=BE6D8=_D/
M:O>?^"?/[<2_M;>$=1TWQ!:V^F>/]!5#?0VV5AO(6X6XC4\K\PVLN3@D$'#
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M\\(S>*X/%.BS^%X8VEEUN/4(6LHT7[S-.&V #N2<5^8'[(__  3F'[4WA?\
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MRZK^MOG=Q3@JV(45[K=DU^3_ *W^5EWE%?AI^P9X?^,7[07@W5_@SX \5/\
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MNZ^(7PH^(=YXR\$6:-_;OA?4H62,6[@*TIB5RC@9R9%".@YY7=77_P#!$/\
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M-:#GUAK\MI+\K>:/U6HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW^\S](_D?E+_ ,$W54_\%#?V@&*@L#JX!QR/^)JE?I=\7/\ DE/C3_L"WO\
MZ(>OS3_X)N?\I"OV@?\ >U?_ -.J5^EGQ<_Y)3XT_P"P+>_^B'KCQ7_(LI_]
M>G_[<70_WZ?^-?E$^ _^"(?_ "2?XD_]AN#_ -$5P/\ P3%96_;V^.)U/']M
M&'5/3[W]I)YO7YNN/ZUWW_!$/_DD_P 2?^PW!_Z(KA_VMO ?C?\ 87_:^7]H
MSP1HLFL^"=:F:75X(\B*.2;"W,$S*#Y:R-B1)"" Y P=H!]"I)4\7"<G9.#C
M\Y15KG%3BZF%G"._-?UM)W/U@K\KOBF+0?\ !:?P9]F""4K:_:=O7S/[/DZ^
M^S9^&*]3U+_@LY\'H_"7VW3/#OBJ^\12(1%HLEK%&/-QP'F$C (3QN4,V#]W
MM7QI\ =9\=>)_P#@J%X/UWXCZ9-HWBW5]3_M&XT^9-C6T4MB[P1[#RH6(Q@*
MWS  ;N<UA3BY8NCV3_X%OQO\D=%226&J]W'\._Y+YGWO_P %9_B9+X)_93N=
M LG<:GXOU*WTB)(OOM&#YTN!W!$80_\ 73'>OH[]G?X9Q?!SX&^!_!D:*CZ/
MI,$$^T<-/M#3-^,A<_C7Q;^U<O\ PT#_ ,%(O@I\+5W7&C>$H?[?U-%.55\^
M>5<>ZP0+_P!MJ_1:BCI1E/\ GD_NC[J^]\P5?XL8_P L?QEK^7*?B)^V]X2\
M9>/?^"FGB#PWX FFM_%>K+965I+#<>045],B64F3^%?*,FXCG;G&>E:_@&U\
M3?\ !)_]KC2=/\47PUGP'XFLH8K[4[>W9(IH"0'E1<DA[>7.1DDH>@WC'I7B
M3_E-[I_^_#_Z9:^T?VZOV7;7]J?X&:CHEO%&OBS2]U_H-T_!6X4<Q$]DE7Y#
MV!VM_"*SIR>'P]*M%7WNN\=FOQ;-Z\56KNE-V]V%O)V5G^'ZGT%8WUOJ5G;W
MEI-'<VMQ&LL,T3!DD1AE64CJ""#FOR>_X)U,&_X*2?&\ZISJNS6]N>F[^TXM
M^,\YQT]LUZ9_P2;_ &JKK7=%O?@7XUEDMO%'AD/_ &0MYE99+5&Q):MG^.%N
MB]=AQC$9K@OVS/AWXX_8O_:XM?VE? FCR:QX3U*7S=9MXPWE0RR+Y=Q%,5!*
M)*,.LA! D//(4-O[M'$PJ7]R49)/_$K)O\GYZ*YS+FJT)T[>^FFU_A>MOT\M
MS]6:_*_X^"U'_!9+X:_9PHE*:?\ :-O7S/*FQGWV;/PQ7J-Y_P %GO@XGA'[
M?:>'O%=SX@9"$T5[6%!YN. TWF%0F>-P!;!SL[5\8?"37_'GC+_@IQX%\3?$
M?2)M"\3Z[K$&I-ILR;&M[=[<_9TVGE0(@@PV&P,D9-33BWBZ/92W\]K?BW\@
MJR7U6MW<7I^OY+U:/W.HHHI%!1110 4444 %%%% !1110 4444 >8^ /VF/A
ME\4O'VL>"O"GBZTUKQ/I$;RWUA;QR@PJD@C?YV0(2KL 0"2,UZ=7Y7_M/?LU
M_%C]E/\ :@G_ &@_@GHL_B71M0N)+S4M)LX7GDA>7_CYBEA3YW@D)+ADSL/7
M;M4G1N?^"SFI:YIO]D>&/@KJ,_CN8&*.QDOVN(HY>0#Y<<(DDYQ\F$/;=WJ8
M24J<7]OJO/R\OZVL5*+C4:^ST?EY^9YW\1M!LO@Y_P %A/#,?@J)+&/4M6L9
MKNSM,*B-=Q;;E=HZ!E=I"/\ ;SZ5ZQ_P6]_Y)?\ #/\ [#-S_P"B!5O]@O\
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MB["I/&Y$R0,FOE;X8_\ !43X@_LW^&[/X>_&CX5:Q>>(='A%G:WSRM9W%RB
M*@D22,B0X'^M1B&&#@GD\E*U.G*A/2492?KS:_>MOZ5^FI>I.->&J<4GY<NW
MWK6__!/7O^"TU_:P_LS>&+21E^US^*8'A4XR56VN=Q'M\R_F*^J_V3/^37/A
M%_V*6E_^DD=?C[^WA\0/C1^T/X9T'XJ>.O"4G@'X?)??V3X>T*Z9Q,[R1-+)
M/AU5I,B(#S"J*1M" X8U^PG[*,;P_LO_  D2161U\)Z6"K#!!^R1UM1BXT*W
M-HW..G;W7^FOS)JS4JE)1U2B_P#TK^D>JT445F,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J:OJ]CX?TN[U/5+V
MWTW3;.)I[F\NY5BA@C499W=B J@ DDG  JW6;XE\/V7BSP[JFAZE%YVGZE:R
MV=S'_>CD0HX_$$U$W)1;BKLJ-N9<VQD> ?BIX-^*EG=W?@WQ3I'BJTLY1#<7
M&CWD=U''(5#!2R$C."#C-=37XR?"GQQXT_X),_'SQ'X=\:^'[_7OAOX@8>7?
M62@?:DC+>3<VY8A#*JN5DB)4\CG 4GZ ^,7_  62\"Q^#YK/X6:#KFM^,;Z+
MRK-M2M%AM[61N 6 =FD8$C"*,,>-PJI2BX*=/6_3K?M_7SZB49*;A/2W7I;N
M>1?L6V<7AW_@J]\2M-\.[5T87&NPRI$,(L0GW;0/190@';BM7Q1%_P (%_P6
MPTJ\O,0P:M<PM"[]'\_2S N/K)E?K7M7_!+O]D7Q'\)=-U[XJ_$6WGMO''BQ
M"L-G>@BYMK5G\UWF!Y625]K%3RH1<X)(&7_P5*_9H\6:]J/A+XY_#>UFNO%7
M@_RQ>P6<9DN##%+YT%PB#[WE.7W#!.U@>BFJ3^J/#<[^!<LO1WO^E^VH?[S]
M9Y/^7C;C^%OU]?F?H;7Y._\ !9/_ (JWXW?!7PC9_/J4MO, B\G_ $FYBBCX
M]S$U>I^!?^"T'PNN_ <-UXM\/>(=.\60PJ+C3M-MHYX)Y>A,,C2+A2><.%(S
MCYL9/EW[+O@OQK^WQ^V$G[0GC'16T7P#X>F1])MY5)CE:$M]F@B8@>9L?,DC
MCC=Q@;L"J<7]9IRZ0?,WTLD_SOH1*I:A-K24E9+K>Z_(^KO^"H4?D_L->.XR
M<[3IZ_E>04O_  2SMTA_8?\ A^R#!EDU!V]S]NG'\@*=_P %2?\ DR'Q_P#[
M]A_Z6P4__@ES_P F.?#KZZA_Z7W%.A_#KO\ O1_)E54HPHQ7=_D>-?\ !;+_
M )-[\#_]C0O_ *27%?9'[-*K'^SK\+U50JCPQIH  P!_HL=?&_\ P6R_Y-[\
M#_\ 8T+_ .DEQ7V5^S;_ ,F[_##_ +%C3?\ TECJ:'\&O_CC_P"DLBM_%I?X
M9?\ I2/SR_X*O_\ )UWP!_[8_P#I<E=3_P %O&N_^%6_#0)_QXG6;@R]?]9Y
M V>W3S*Y;_@J_P#\G7? '_MC_P"ER5]H_MT?LVR?M1?L^:QX6L/+3Q':2+J>
MC/*=JFZC# 1D]@Z,Z9/ + ]JX>5O JW2I-_=-,ZDTL8[]817WQ:/2?@/]C_X
M4?\ #W^S_P#CP_X1[3_(QC[GV:/;TXZ>E>/?\%*A:']B7XF_; I3[-;>7N_Y
MZ?:X=F/?=BOC_P#9)_X*4V_[-_@V#X0_'/PUK^E:IX7_ -!M;Z&U#2QPC)2&
MXB9E8%!A59=P9=O QN;B/VZ_VXM4_:]^&.K:+\,_"FLVOPRT"6"]\1:]J421
MF5S*(X(L*S*J[V5@-Q=B,[5"'/7CFJ[E*F[J3O?R;O?Y?F8X).AR1GHXVT[M
M=/F?;/\ P2I_Y,C\$_\ 7SJ'_I9-7D?[)_\ Q?\ _P""CWQN^*4NZXTGPE'_
M &!I;MRJMGR R'T*03M_VVSWK7_8U^):?!W_ ()6R>,V=4ETBQUB>WW' :?[
M5,L*_C(R#\:Z[_@DS\,G\#_LIVGB"\5_[4\8:C<:O-)+]XQAO*BY]"(R_P#V
MT-=53_>ZD_Y(_C+3\$I'.O\ =U'^:3^Z+N_QY3KO^"FW_)CWQ,_ZY67_ *76
M]?E+\+/V(_BI\>OV9M6^)-OJ+2:%X9MYAX>T.0M-)?(DS/=B!0<1@'S"."9'
M&,=#7ZM?\%-O^3'OB9_URLO_ $NMZR/^"5/_ "9'X)_Z^=0_]+)JXJ<.95FM
MU:WK;<[IRY:=*^SE*_W(H?\ !,O]K2/]HCX,Q>'M:N5/CGPE%'9WJMPUW; ;
M8;D>I(&U_P#:7/&\5Y5_P6W:Z_X4G\/PG_'D?$+^;U^_]FDV>W3?7C'[57@G
M6_\ @G5^V)HGQC\#6;+X'\17#R36$65ARY!N[%L< ,/WD?8'&!^[K[K_ &EO
MACHO[>/[(K)X2OH;IM3MX=;\/7DAVJ+E 2J/_<+ R1-GE2QSTHQ$GB:'MXK6
MZYEV::;^^UUWUMI8SHQ6'K>Q;T:?*_)JR^Z]GV];GJ'[-/V/_AG7X8?V?C[%
M_P (SIOE8Q]W[-'CIQ^5>>?\%$!:-^Q;\5/MH0Q?V:FW?T\SSX_+_'?MQ[U\
M5?LC_P#!1Q?V7/"J_!OXZ^&=>TN_\,N;2SO8+8/-##DLL,\3,IPN?D=-P92O
M&!N/+_MS?MU:C^US\+=<\.?"SPKK4/PZT-H+_P 3:_J,*1[QYRI!%@,P1#(R
M, 6WL5^Z C9O'M8CG=-W4^O9/K\OS%@HNBX1GHXV^;6R7JS[$_X),_\ )E/A
MC_L(:A_Z4O7V+7QU_P $F?\ DRGPQ_V$-0_]*7K[%KIK_&O2/Y(YJ/POUE^;
M"BBBN<W"BBB@ HHHH **** "BBB@#\:O^"QOAF:__:K\">8WDVNJ:!;6J3D<
M*PNYU;\@ZG\:_7'X<_#_ $/X6>!M$\)^&[&+3]%TFV2VMH(A@8 Y8^K,<L6/
M)))/)KXV_P""L/[+^M?&WX5:-XQ\)V,NH^)/![RRR6=LI::XLI ID\L#EG1D
M1@HY(WXR< L_97_X*G?"WQE\-])L/B5X@'@_QKI]LEO?-?P2&WO610#/'(BD
M#=C)1L$$D#<!FBA)>PE2ZJ3;\T]4_EK^/8==.5:-7HXI>C5D_OLOZ9S7_!:/
MX9:1JGP2\,^._LT<?B#2=7CT\7:C#R6TT<A,9/<!T5AGIEL=3GWKX=>,+_Q[
M_P $Z[37=4E:XU&Z^'\_VB:0Y:5TLW0N3W+%<GZU\._MN?M+?\/ /'W@SX)_
M!2UNM>TA-0%Y<:J]O)$D\VTH)-K*&2"%'D+.X&2W P 6_1GQ5X!LOA7^R)KG
M@[3F,EEH7@NYTZ*1A@N([-EW'W)&?QKEJ)QP.(;T4FVOE%I_C]]SHIM2QM!+
M>*L_G)-?@?'_ /P1%T^&/X0?$:^"C[1-KL4#-CDJENK*,_61OSKZ"_X*;@']
MA_XF9&<161_\GK>O!_\ @B3_ ,D-\?\ _8QK_P"DT5>\?\%-O^3'OB9_URLO
M_2ZWKJQ_P_*/Y(PR[^+#_$__ $IF+_P2EA2']B7P:R*%,EWJ#N1W/VN49_(#
M\J\J_P""V7_)O?@?_L:%_P#22XKUC_@E3_R9'X)_Z^=0_P#2R:O)_P#@ME_R
M;WX'_P"QH7_TDN*>8?$_6/YHG![/_M[]32_;"U&ZT_\ X)/:*+4L!<:#X=@F
M93C$9-L3]<D ?C7I_P#P2UT^TL/V(_ +VNTM<O?3SLJ[2TGVR93GU("JN?\
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MG7ETY8K_ ,F_X).(VH1OKS-_^2O_ "/TWHHHI%A1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KY\_X* R31?L:?%=H/OG1V4_,1\ID0-_XZ3]:^@ZX3X\> 3\4O@KXZ
M\(I@3:UHMW91$CI(\3!#^#;37+BES4*B79_D;X=I5H-]U^9\K?\ !'6-5_9#
M=@H#-XBO2Q Y/R0CFOJCX]_\D,^(G_8NZA_Z325\-_\ !%3QEO\ A?\ $3P/
M=;H=1T;6TOF@DX=5FB$9&/9[=L^YK[D^/?\ R0SXB?\ 8NZA_P"DTE=.9-.C
M-K;D7_I",<OBXUHQ>ZF__2CX3_X(A_\ ))_B3_V&X/\ T17<?\%4/V0F^-'P
MX7XC^%[,OXV\)P,\T=NG[R^L 2SIQR7C.77V+@9)%</_ ,$0_P#DD_Q)_P"P
MW!_Z(K])V4,I!&0>"#6N+BY27*[-*+3\^5?UZ&.$ERQ=U=7E?_P)GY'Z_P#M
M=#]I3_@F#X]T77KP2>/O"XTVUU#S#\][!]MA$5T/4D#:_P#M+GC<*^N/^"5/
M_)D?@G_KYU#_ -+)J_.;_@I9^RG=?LS_ !6NO$'A6.:R^'OC7>4AMB5BMY]Z
MRRV;@<;-RK*BGC P!^[S7Z,_\$J?^3(_!/\ U\ZA_P"EDU51FJM.K5M9NUUY
M[/\ S_+0NK'V7LZ2U2;L_)K3[MO^"?(O[0'_ "F2\%?]A+1?_1*5^N=?D9^T
M!_RF2\%?]A+1?_1*5^N=88?_ '.'^*?Z#K?[W+_!3_)A7X_?\$V/^4C7Q4_Z
MX:W_ .G"*OV!K\?O^";'_*1KXJ?]<-;_ /3A%3H_[W'_  5/R0ZG\!_XH?FS
MZ*_X+/\ _)JFA_\ 8UVO_I-=5X_^RG_P2M^$_P =/V>_!7CO7O$/C*TU?6K1
MI[B'3KVT2W5A*Z817M78#"CJQ[U[!_P6?_Y-4T/_ +&NU_\ 2:ZKVK_@G7_R
M97\*O^P=)_Z42TJ$5R5I=>:/_I)6(D^>A'IR2_\ 2SQC2_\ @C#\"M/O8YY]
M:\;ZG$IR;:ZU*V6-_8F.V1OR85]8_!?]G[X??L]^'I-&\ >&+3P]:3,'N)(R
MTD]PPS@RS.6=\9.-S$#) P*]#HJ^9I61GRIN["OR?_X*J!(?VS/@7/$62[\F
MSRZC! &H$K@]>I;Z?C7ZP5^4O[1UD?V@/^"M_@#PM9?Z1;>%AI_VQE&Y46WW
MWTH/I]\)]3BHIJ^*H>4K_))W?HBZG^[5_.-OG='ZM4444Q!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSWX(\+>.OAC<1?V-9W<MOX@MI]/CNH]KA?(D<E=Z(&5U)5E&9%![5?\ A?\
M\%/O@'XX\&V6I:OXTA\*ZQ]G5K[2M4MIDD@EQ\RJP0K(,@X*$G&,@'BOJ^\L
MX-0M9K6ZACN;:9#'+#,@='4C!5@>"".QKYR\3?\ !.']F_Q9JLFH7WPLTZ"X
M<Y*:;>7=A#^$5O*B#\%J8\T;Q>J>J[KR]"I6ERM:-:>3_P""?!_[;G[0D7_!
M0KXG>!/@_P#!:TNM?TNUO&NIM6DMI(8Y)6 0R[74,D,2%RSN!DL<#@;OUK\'
M>&K?P7X1T3P_9_\ 'II5C!8Q<?P11J@_1:YSX5_ KX??!#3I++P)X0TKPQ%*
MJK-)8VX$TX'3S)3EY,9/WF/6N[K2/+"#A'J[M]WT^Y&<KSFIRZ*R\N_WL***
M*DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** ,_7?#^E^*-+FTW6=-L]7TZ8;9;.^@2:&0>C(P(/XBN8\(_ W
MX;_#_4CJ'A?X?>%O#=^1@W6D:+;6LN/]Z- ?UKMZ*%H[H-U9A1110!P.M_L_
M_"_Q-KC:UK'PW\(ZKK#,';4+[0K6:X+#H3(T9;/XUW5O;Q6=O'!!$D$,:A$C
MC4*JJ.@ '05)11LK(-W=F3XI\(Z'XYT.XT7Q)HNG^(-'N-OG:?JEK'<V\NU@
MR[HW!4X8 C(X(!H\+>$]#\#Z';:+X;T;3_#^C6V[R-.TNUCMK>+<Q9ML: *N
M68DX'))/>M:BC8#G?&WPX\)?$S3X+#Q?X7T7Q78P2^?%:ZWI\-Y%')@KO595
M8!L$C(YP36SINFV>BZ=:Z?I]K!8V%K$L%O:VT8CBAC4 *B*H 50   . !5FB
MC8#E/%GPG\$>/=6T_5/$W@WP_P"(M3T_'V.]U;2X+J:VPVX>6\B%D^8 _*1R
M,UYC^VM\;O&/[.OP-N_'O@W1+#7I],O8/[0M=0CE=!:.2CNOENI4AC'\QR ,
MY'<>\U7U#3K75["YL;ZVAO;*YC:&>WN(P\<J,,,K*>"""00>M9S4N6T';K_7
MKU+BTI7DK_U^G0^3O@Y^T9^S]^V7\.M$UGQO:> IO%,46V]\/^*([2:>RE!^
M;RQ<KN:,\$.HQS@\@@?/_P#P4N_:4^%>F_ !?@K\+[K0M4U#6+R 26'A,1-:
MV$,4HDVGR?D$C2(BB,<XW$XXS[)\0O\ @D5\ ?'6LRZC96WB#P<97+R6OA[4
M$6 L3DX2>*78/]E, =  *[OX"_\ !.GX)_L]ZU:Z[HN@7.N>([0[K?6/$-S]
MJFA;^\B!5B5AV<(&'8U<HQJ[^ZKIM+R=]/\ @]"8RE3U7O/9-_U^74U?V4/V
M?K+PA^Q]X$^'/CKP_8ZLJV N-2T?6+6.YA$TLS7)C>-PRDH[XZ<%<BO>-%T3
M3O#>DV>E:186NE:79Q+!;65E"L,,$:C"HB* JJ!T &!5VBM:E1U)RF^KN94X
M\D%'>W]?B9?B?PKHOC;0[K1?$6CV&O:/=!1/I^J6J7-O-M8,N^-P5;#*",CJ
M :9X4\'Z#X#T.#1O#6B:=X=T> L8M/TFTCM;>,LQ9BL<8"C)))P.22:UZ*SV
M-#"\9> _#/Q$T@:5XK\.Z3XGTL2+,+'6;&*[@WC.'V2*5W#)P<9Y->)_M/>,
M[_\ 9!_9MU#Q)\)_!/A^*TT.ZBFN-$@T_P BT2VDDQ-(L<!0*P+!BV",;B0>
MM?1-0WEG;ZE9SVEW!'=6LZ-%+!,@=)$88964\$$$@@UG-2Y6H.S_ *W_ "+B
MU=<ZNOZV/D?X)_M+? /]L[X;Z-JGCVS\!MXKA1DO/#OBA+6:6TD!.3$+E<M&
M1A@RY'.#R"*\/_X*3?M*?"7PW^SG=?!KX97?A^_U+7+F".33?"8A:UL(8YEE
M8N(/D5V:-5"?>Y)(XY]<^(O_  2/^ /C[6I=2L[/7O!C3.TDEMX=OT2 L3DX
MCGCE"#T5-JCH *[+X$_\$W_@A\ =;M-<TG0;KQ!XALVWVVJ^([D74D+=0R1J
MJ1*P(R&";AV(JY1C5T?NJZ;2^_3_ (/0F,I4M8^\ULW_ %^74Z3]A'X4ZE\%
M_P!E'P!X8UF![76$M'O+RWDX>&2>5YC&P[%1(%(]5->^445K4FZDW-]3*G'D
MBHA11169H%%%% !1110 4444 %%%% !7A'Q._86^ _Q@UR76/%/PVTNZU29S
M)-=V,DUA).Y.2TAMI(_,8^K9->[T4K)N['=K1'GWPC_9_P#AS\!]/EL_ /@_
M3/#23*%FFM8MUQ,!T$DSDR.!SC<QQFNRU_0['Q1H>HZ-J<'VG3=0MY+2YAWL
MGF12*5==RD$94D9!!]*OT4Y>^K2U%'W'>.AYQ\$?V=_A]^SGH>H:/\//#_\
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MT.>;=W))>B3O^9E/WN2*5E%M^K:M_7]6T****@L**** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBJFK?\@J]_ZXO_ .@FHG+DBY=BHKFDD6Z*_*__ ((A?\A#XU_[VE?SO*_5
M"NBI#V;2[I/[U<C[<H]G8***^*/V@/V)_''Q6_;>^'GQCTG5?#]OX8\.C3A=
MVE[<3K>O]GN))7\M%A9#E7&,N.<YQUK..LX1>B;LWV7<):0E);I:+OY'VO11
M12&%%?&W_!6O_DRWQ%_V$M/_ /2A:[S_ ()U_P#)E?PJ_P"P=)_Z42T4_P!Y
M&I+^5I?>KDS?).$/YDW]SL?1M%%%!04444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 455U34K;1M
M-N]0O9EM[.UB>>>9SA415+,Q]@ 37Y%Z?XC^-'_!57XP^)=.T#Q;=_#WX/:,
MVQU@,@C\IB1$)8D9?M,\@3<5=@J '!'&Z4W*?)!7=KOR7G^G<JRC'GD[+;U?
MD?K]17Y5^.O^"3/C?X)^'[KQ?\%_BSJ[^*M.@,YL51K":[VC<RQ312<,<<(P
M(8\%A7T1_P $U/VRM5_:A^'VK:-XP*/XY\,&)+N[1!&+Z"3<(YB@ "N"C*P
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1+,RYYVR6T84X^L;?D:_1JN_$?&O2/\ Z2C@H6Y7;O+\V?DU_P $WI&\'_\
M!0_XW>%[0[=,9=601KP!Y.HH(^/968?C2_%23_A/O^"T7A?3;O\ ?VVD7-BL
M*/T7R;$W0Q])"33?^">"MX@_X*3_ !NUFT&^Q0:TYD[8?4HPGYX)_"G^.H?^
M$3_X+7:'=77R0ZC<VK0LYQGS=,\D8_X&"*Y\/:^!_P .GK=V_4Z:_+;&_/[O
M=_X!^L=?E'_P6HA/A_XA?!CQ/9GRM2CBO%60#G]S+!)&<^S.WYU^KE?E)_P6
MVF&H>*_@UI%N#+?-'J#B->IWR6RK^94_E41O]8H6WYE;[F:1Y7"HI_#RN_X'
MU'_P4VNC??L'^-;DC!F339,>F;R _P!:^+?V3?@U\7_VXO@SHOAJ?QU<_#GX
M,^$8CI"V^FJSRZQ<;S+*74,@< 2 9<E5^4*C'>:^T/\ @IE;-9_L%^,K=_OQ
M1Z;&WU%W *E_X)6V,5G^Q#X$DC4!KF;4)I..K?;9ES^2BM:<8MUV]8J2MZVT
M_"_S,'*4:5"6S=T^]M&_Q2/@GX^? WXB?\$M/&_A#QGX ^(%]J_AK5+IDDMY
M$:WCDDC 8V]U"'*2JZ%L-@$8; 4@$^[:#^S5\5O^"D6BK\2_B9\0+[P#X$U8
MF3P_X*TE#.B6H)"2R99$+'KO969P<_(NU:Z/_@MD!_PS[X'..?\ A*%_])+B
MOL?]F6WCM?V<?A;#$@CC3POIH51T ^RQU-)>TI5'/7DDDO\ MY7_  M9=E?K
MJ.H^2I!0TYDV_.SM^NO^1^6_AN'XC?\ !,G]L#P9X&D\97/B;X>>(YK??;G=
M';7%O/+Y+.8&9EBFC<9RIY"KSABM?IY^U%\?=._9G^"?B'QY?P"]DL46*RL2
MVW[5=2';%'GL,G)/958]J^ O^"K_ /R==\ ?^V/_ *7)7=?\%M=0NH?@?X!L
MX\BSG\0M)*0>-R6T@0$=^'?\JYYU92P<9-Z\\HWZVYDOU-8PC'%RBEIRQE;S
MLW^-CQSX,_LB?%[_ (*,:;+\4?BY\2=0T7PQ?SN=*TZ.)IA(JL58P0%UCMX@
M1M!PS,5)(YW'._:=^"OQH_8+^%VNZ/IGC>X^(7P7\5V<FB7-MJ$;J=+ED!V,
M(R["(\<.A"N<AE!V5^H7[,NFV>D?LY_#"TL HM(_#6G"/:I4'-M&2<'U))_&
MO//^"BNFV>J?L6_%*.]56CBT^.>/<0,2)/&R$>^X"M<=%895(0^&-TUW2T?S
M:_$C!R>(<)3WE:WDWM;T.)_X),_\F4^&/^PAJ'_I2]?8M?'7_!)G_DRGPQ_V
M$-0_]*7K[%KJK_$O2/Y(YZ/POUE^;/+OVF?CII_[-_P3\2^/M0A%V=-A"VEF
M6V_:;EV"0QY[ NPR>RACVK\S?@M^RS\8/^"E%G=?$SXK?$B_T3PA<74@TRQB
MB,L<NUBK_9[?>L<,:D;=Y#,Q4YS]X^__ /!:B^N[?]FGPM;PDBVN/%$(GQWQ
M;7!4'\?Y5]/?L9V%IIO[)WPCALE58#X9L)3M&!O>%7<_4NS&N:E!356K+7E:
MBOFKW]3IJR<?9PCIS)M_)VMZ=3\WOVE/@[\8_P!@?X6>(=#L_&-Q\1_@KXNL
M9=$F@O@T;:3<2*WEN(RSB/I]Y"%?E653L-?87_!)G_DRGPQ_V$-0_P#2EZ[W
M_@H1H]GKG[&?Q4AO0OEPZ5]J0L,XDBD21,>^Y0/QKRS_ ()CW4]E_P $_K*X
MM<_:87U>2+:"3O$LA'3WQ41K.'MY3U<8)_*^B^3O\K"G34O8J.EY-?.V_P"1
M\\_&3XS?%K]O_P#:>U?X-?"CQ%/X3^'NARRQ:AJ5K*\2SQ1-Y<UQ,R$-(I<E
M8X00K?*3CEEZY?\ @E_\1_V;[%O&OP2^,&H7/C/3H_M,FD7-G]FM]6*\M$<2
MLI##("2!@21EE^\,'_@A[:6\S?&#47(DU$MIL9=B"P0_:6/ORP_\=]J_5&MW
M2>'C&,7[]DV^[>OW>7Z6)]HJTY-KW4[)>7^?F?CU_P $J?%E[X\_;K^)OB34
M;,:=J&K:-J5]<V:YQ!+)?VSNG//!)'//%?L+7Y;?L0Z7:Z/_ ,%3OC[:6:".
MW2WU=E4= 6U"V8C\R:_4FFI*6&P\DK7A_P"W2'.+CB*T6[VE^B"BBBLP"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)"<7%D,DA2K*9/E^^ Q.?+6OTS^,WB"Y\)_!_P <:W9AS>:;H=]>0B,9;?'
M[K@>N0*RJ26&P[J+WFUS-]_)=E_7F]HQ>(KJGM9V2_5^?]>2_/+X\?MB?&3]
MIW]H*^^"O[-MS_9%AIKR0:AXBB*H\OEMLFF,Y#>3 C$ -&-['&"=P6C5?@?^
MVQ^RQH\GCS2?BP?BK;:?']IU3P[?7UUJ!>-?FD$<=R,LH .3&R2?W0>E6O\
M@B)X<LU\#_$[Q&0KZI<:G;6+2,V7$21-(/H"TI^NWVK]-#SP>152INA&*B_?
MLFV^K>NW;R]2545:4FU[MVDO):;]_,_+7_@G'^TYXR_:%_;5^(-_JGB#7_\
MA&+[0[O4;/PS?:O-=6>GL;JU 6*-CL&T,R@A1P3TR17ZEU^3O_!/'P[9^$?^
M"EGQRT73XUAL+"WUJW@B1=JI&NIP!5 [ # _"OUBJM'AZ$HJUX_^W2"2<:]6
M,G=J7Z(****S&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?)/_!2']K2Z_9>^
M#,47AV9(O&_B9WLM+D(#&TC4 S7.T]2@90N>-SJ3D BOAO\ 8!\??LP_!O\
MXN3\5OB$-5^*]Y-)/'#=Z/J-TNE;F.7WK;LLEP_+&3)QNPISN)_3[XX?LG?"
MK]I"^TJ\^(OA;_A(KC2HY(K-_P"T;NU\I7(+C$$J Y*CKGI7F/\ PZX_9B_Z
M)G_Y7]4_^2:FES4W*;W?X+R]>I52TXQ@ME^+\_T#_AZ-^S%_T4S_ ,H&J?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH \8_:V_9OB_:J^#\_@.;7W\-I+>P7GVZ.T%R1Y9)V["Z=<]<U\/_
M /#C;3O^BQ77_A.K_P#)-?J/141A&+;775_=;]"G)R23Z'X*?MU?L$VW[&NB
M^$K^W\:R^*SKMQ<0&.331:>3Y:HV<B5]V=_MTK]#_P!A?_@GG:_LM^,S\08?
M'4WB.35]!^Q'3Y-+%L(O->&;=O$SYQY>,8&<YKO_ -N']BG_ (;,T;PI8?\
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M&*7JI7_(NLG)4DNDFWZ<MOS+?_!1C_DROXI?]>$7_I1%7F?_  3*\-P^,?\
M@GW::!<,4M]4;5[&1EZA9)94)_)J^E?VC/@[_P +_P#@KXI^'_\ :_\ 8/\
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M84Q11@+A1U!.>]137+4J2>THI+U4FS6I[T*<5TDW]ZL>=?\ !4G_ ),A\?\
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M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH _-#XG?\$_/C1\#?C+K7Q,_9B\5V]FNK222SZ!<RQQ21^8^]
MH5$JF":+=DKYFTIP!DC=65XB^'/_  4'_: TJY\(^*;K1_ OAV^A,%[.MW81
M+/&>&5GM3--@C(*KM!!(/!K]1**F,5&*IO6*V3[=BI2;DYK23ZK\SP7]CO\
M9&\._LA_#>30=+N6U?7-0D6XU?69(Q&UU*!A55<G;&@)VKD_>8DY)KWJBBM9
M2<W=F<8J"L@HHHJ"@K\\?V*_V4OBG\)?VW?BMX_\5^%O[*\):XFK#3]0_M"U
MF\XS:A%-%^[CE:1=T:LWS*,8P<'BOT.HIP?)4]HM[-?^!*S"7O0Y'M=/[@HH
MHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-C-<W=PP>XO)R &FE8 98@ 8       KTNBBM)2<G=F<8J*L@HHHJ2@HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M76&]O1-M>FGK^1YE\.9OVO/^"A;:AXST?X@O\)O *W3PV$>G7<]BK[>"D1@
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M,H4MK$W@4CN#+N)'?)K];Z_);]M:*[_92_X*.>"/C==64\WA36)+>>>XC7<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGXB_#_X)?\%-/#6J_!76K.]^'_BJYMK&[M=+R+6'[6WE2P $#"I*$F"CA?E
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M "3XN_X*X> [/X&6GC_PGX<N/$&IC58M*U'PQJ-^MA=6)DBE=9=RQRB1#Y1
M*CG/.TC;7V!9_$3[9\'8/'?]G[/-T%=;_L_SLXS;^=Y7F;?^ [MOOCM7Y=_\
M%DOV<?#W@G4_#'Q1\.Z?!I4^NW4FGZQ#;($2>X"&2.?:.-[*L@8]]JGKDG]$
MM&_Y,[L?^Q#C_P#3>*SJ5/\ 8Z]:.DH_A[K?SO9/7T'&/^U4:3UC)/Y^\ONM
M=K\3A_V'OVU/^&S-#\5ZC_PAO_"'_P!A7,%OY?\ :GV[S_,5VSGR8]N-G3!S
MFOH;Q=KW_"*^%-:UKR/M7]FV4UYY&_9YGEQL^W=@XSC&<'&>E?F]_P $/?\
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M6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ_2JK5-T:-&D]XQ5_P _R9+DJE:K4CM*3M^"_0****DH**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
144 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
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M3GX%3F46(R;I H*/G85K< IV><1CC7TDYFT)Q?2U 9BTPA?O+_;$\'EN&"K
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M 9:-J@,L+TL],,O0K >#F74YFV7-8YCE;92U\7W&W*V^AJG57_W;ZHV^3-F
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M[#0N%%<I.&$%L"XL-O@F*Z?5.V3Y*5)^_^O='\9884P :U$ WMZ;E5/#]A8
M,^U*=7.O5=4Q9=ZFWDMH8T:OM=WHU-@1]P?&.SLBOF:>C]D)F.>D&ILE6\S&
MQFP?@;"PK$X:28UJ+%G2T%@'3DN9]*\#^5('\J0.7,#1I L(9STXD8.PXX8=
M/I&+(XFYZOGPQ/.JKK#.L.[$IUW""2GKY',L:^GP%402()EM-J([1G6<EL#A
M UXWSF%EQ][9935\I+(WGUH1?Z+JWT&:$;,%X#LL65UILS461\LA?N5HRRV.
MENU5P(_MA@XU5<HJ.;,(B>F7D"!E%9^:CSAI9[&G\A CY18MY<;'N-2+ZO7C
M;'_R7GZ&@1P[50/N*Q38T_DR(F<?84;;RO&JC$VG@@%C^D!W;]G<N/GIM\.[
M4=\H"J_SC=Z V1P.97U3;:+6@&\&K<R^7KY2:YDZT] +T5<M4RD:6OJ&J ;.
M9WI8IE ,A$.V0R/1T)<E5-.3I$_A=:FD Y?^ND3Z;95H*#7\"ATQZRG[>284
M3F84(D'J'^LBZ^0QZ4\BI=\X*OT'+4+ZE?#CV8:)[XB0_N6H]"^1\EJ4O"]:
MWA^;PGI<@!/2-_%X/&Y:3JD"30:S#% 9X%ZRC&25F2,;)D!:U>/>D0TK\+]?
MZ_+=RCIS;HX@]D\675-][, 1Q"KEJ\@('+IM4<;_KUJ&=6L:. ^]HS>X-_KH
MGGY]])WN8W[+>0T8U>34 35*HH(,J^25M$.6)<LT1P($]E6$OM3L4B2)CSJ>
M7HC8U )ABWQ$)5]4K''DQ'GQ3;F]/LKT4S3Z*/JQ**E'_$R<E8]*S2Y120_6
MH_,JH573ZZ.LX9'G><L0]<>4V/C$0)$GUMW3EX$P4[/*T5C \++\6&80\BQ9
M0O-B$P@2SQ;)Q1(@%.<2(1<P3"YF<%PV_*,SX7TT Q[A9^ :=AI.(:=P,#@%
M#@%)L/=/PC[> LLO$7M\$[';YX0R_JU,GN=K#H%)ZC/.AU+5,3S#T^%WC#"9
MI0J2\$EX)) D28-/%<>5D5>FP)'G2H=E@$2SP*Z1Z6 !F2GASV*_LGZ0:'$^
MK9;.T[CF1A1=;,G*T?DRVLDNJ%*6<^FJLMS":EPLJ96.E:GP!@61!,>Z)@,8
MZ8P5+%[OOW3_P^J!==;0.*<6Y>C8Z(K*C>" G6FF1%^$-S80-A2"'1O/$6E(
MH0DYJHS\CIU5=<#]2)HJ/Y:C(^N!V/Z@9!R0LJ7Q?S[O%,IR3I,ZDRZ?.RN?
M/X? & 8,+&MQ#-(PX\\4*@A-S6&0<$6N196*Z-@@";"$:SIP(]/8?^/BAT%F
M8&<Z8+9; F)O_6$61JX#L[H7!=IRBZI4>U7.-JM8@JQ"%6Q%2UD=E?9SA,&;
M!&U!4E;^4E9^1]/A&W$&/M)NO:7<O Z?5H]\SC\R X'ROF!IV_Q,.)VPM/EH
M@4HC@"O$J>S+JF]@Q,WOIM,O4IG'!N4X:A0L&5,(Z'ANS:S=/^5T\^;-?J!C
M &*G CXZ1M8WZ\R$.8IB9AOX^_,XS89#H=)V"$($HJN6X4XS@#6!L;^S># S
MC-9P;1UP$HX)6<P45O#VB.SC*NI10"<N]32']52N6]IYJ:?95GY%@#!"^I2P
M^&P$QYQ#0)3T"U)/63\]I6ZZ2Y_B%GH*KB$I< E.5N8L?L-%^A=7Z5O<I%]Q
MD]?<Y=%+^B"?(V=4/0^4XX3(\0Y+7Q4A(,GOB9,^[#B#(/$EIPF/S$(6& %0
M05F-.E^V+8)MM04:^;N8#>T:L.+U 2PZI<'F-@\,C@A^!,+2*J.?H4^X6,(1
M) (^^QS#^']^*:<9U<FU:U#OY^<(C4QLF'VT]1#MG<^K;V&9VN.TT^"5>LO4
M!,)8B0)#8S2+P2N3"TQ>D \2! H)=T>3\@3ZSB,X5CA%? Q]C<>1=.5[G ^=
M%N:@?TKIM5X_%6SX*!>I1VZ'T^ 9(?4P\BP"HL\A1)CGB"7105]X@D&(\!&S
MD%E2KSD22H;B^=&?TJ\V6*;-\1H8OOK&7\TCGQ@HLE)WJ3DA1D6H:S(BY%*5
M-33@D.#%B(O$?%(:<'R:D2DD78?$&U#H)8W/52Z>HUQ(![FXNP7XMGL=QV:W
M>&QPB<4ZQVBL/A"%%?:16+[O*);MC<!2L25[PK%X]Y%>X_]+]H;+:^%8X7 4
M:PX>PWJG&&QTC<-6CP3L\DF$?4"R@(5T$.+ ?*3!!TJ#)_6SD-BYG,PL4HZ1
M9&\"(SMU5B86#G_KP!6:GU:G;#9"<_B%=V&@D^>Y\1R9J>4YLW*QDK&R$<1,
M2SQ[6=G)S!)I .72$"H5..:7<'BV445RM8WLP C$[+AN]LLLWJD>J/.Q9!%Y
MG3A,6::B_!J5L>7UY'5E),9L'\%0-3AI)(0Z IZS-*(#TJ#V24"P2^K -L\$
M;'*+4W5@O7,,UJIZ< PK]T=AE=0'_KWF8+1Z?IV4\P:7.*DS"?*YXU+6)R6@
M8 ,E0 JXL%%:P#%2HK^XTY?4N3 CP.M%9\WT/V';S"ZV6]+]_'T/@_J<<-]<
M+F:I"!^$>69DZ-A469TW.LCX,T8@Q_;*;'Z@=&P^#.*DO;H0TL6I.OB=Q!YI
MK[NEO'9).]OI'H\=4F[;7&+4XRZ/>/7Z/MZJ3M[+S[B*D^8Q? 0N Z0/X+$9
MD4<S^TB'*W7WC-3A<W2VG$)@R= 0LNAD";C7>OIV*[AQGV72S.")CK*E-W!J
M4YE2!F<$P!Q+T'3F?+D*7I)4X%2L@ID4Z2]/<\A* II,#GDR$UYF ".=&L%>
M.0L++)J9E?L1FN]6-V_VK5QF$&-"(J<I,8CA;R<TLSYD"4RG"XR=D@#_I-33
M.*FG4:>,8%/YE6-,-J3#G??69G#)! ,3"U(/=TH=W>8:BRW2IVQR/*9LX\$H
M;-@?"3OQ&WS<*/W+)O$?F^6U+=*_;'..Q4XWHQ[;RW$.2!_E+'V5N_19WA'I
M\GT2!$F R\P11T X&M+/X0MX$&I9CTLYY4GZ1V9%FP16VBVP:)T=>M#4#\;4
M<&Z/FBYA^@/65RX,XFA20:DQDL2@B'7_=&Z9!(FETN9+I T8=BJ[3-K_%>6C
ML@HX$E2C$ANEEE$@ZQ$@,U"ZG?I#(H>S+7=.:C02&2653*P04"OE^\I5TBCQ
M;*$J0W(!$TN!4K8^49EP%RAT"CT-A\!3V.V3A&T>)Y3/H>]9YQ@C/BE:^2?3
MZ*=,7T4_92?U:)/4HRWN"=CAS<16D@)*0J:[!"*^#$+$)[*_92*+P0>GTC$[
MSDPY?3RG_G"Q("&W1=VN<_#5]A]5GQ@H\L382;$Q*TBL,RYZ?@FCXPHUYX/#
M3$SY'Y,+?H090[G@O!B\*,P$$0IV>,O%%N="&%@MC7.9 .'"W>&PW1Z&.5L.
M8<;&8$Q='XA):_PQ<;4?)JSRP[@5/AB[W!MCQ,;R[Q7>RL:M],'X53Z8O,X?
M4^T",7-3B#K&O.V'!20CI-".J>_90G"4!L]"(J1Z1V8@*/:<&L9D!2%$<&B,
M<Q!(\P0Q#E&R@IDI7S.2^;169!EI<XNCIP,2H&.VD^=V2:(O9B1XSHQJ"6.L
MY 2CT/@<]1AVG&GQ"]*9,</&"+A8-<BS>972$&LE<C-@L;Z)G5>/&C)3L&C)
M+-Z^'ICG8W0*U?4&)++Q91=<47,)3V8:#8\-@'#(:(H 1S!D8]DF'? & ?HU
MTIA62 -;+- _?^=AS-UV"+,VAZ@Z,&U#$*9(/9B\+@ ?B/'OJ79!ZOGI\OIL
M*6=;*><%.R5@V!,I@<4Q:;RQTI#%.7B?E""!#3)-18&," DF'#I(SKRL,HR,
MW B+UIE%,W/U,(@PU3<"8#CA&G'"!#!F/3B\<D:".@(BRXI9?CI=ME=F]YT9
MR$E[W2T!US9IKYND'=D)J*^1]KI"VNNRG4>P=(>T,VFWB[:&8N&6$"R6\N-S
MRW<=P4II?WPO/[-9X)_'V.4MCE>.Z11Z2J+L=!4X,JM\E($;L_T68,PN-#*,
MI<S\"M@VL8/D"M.>GOMRB@#;2Y<%QGLA40"OZ$J]FO[ #%AJ3IFTB\L"QD4"
MR 7RFR\B[,0%1,ACE+3/&&G#"01'<:!I"IHK%6PP.T7@-(/75LN=6?K/W_RL
MK\!'EYF%[9VZTFYD$@F)' 9DYHF R&E*25G2QXD3C9+ XK#TV4'Q62KP=P^W
M^!4!PUWB5[:*4]XHSGDM'??>HU@N]72)U,>%4C_G2[]BNS$(-AL",=<N '/7
M!V".^ W:W/7^L)'G;,6'S)/^9>'F4%6O68]7[8W 6@>!20E.MS(08A D 1!'
ML)@M(J"J!,2)'$2FY$FP908^95*/*Y$O;8V_IT*</;/#+>:<>(M/N?$ %E[_
M!:L&]#*I8OB#%E5?F4'/*S8 D5E7!D0<?F7=CTK)E_J?CR,G\Y2Q_L>F%>*X
MU/_D+,Y)YQ05)C5J%6R:?31AT0R4;B=S/U.>%^<'<UYP?1.##TZMX= R,_D$
M5@9JEU2P>CB1<'A.)1A<PM($#%.$%Y*$&XX+[,5CU?YH+-T;);XF C;;#F/V
M9G)*J/BC8/%/%A\E_LDPPU?11\V2>C1W6QCF[3B"1;LCL-P^"FL.&DF.K7)L
M^D)F'\E''%4[)'UAE/2%##HX78>)-\X+9S*.2;F^Y-6M*^T_JNX)%&\WF=AZ
MWSLSVF.$R[E,%TLXW^R*^D$GI!%SB(IPR#F$'$9T$6HFF#&S1Z)>+PV8U+U8
M&MX\<3*SMX0JIS]IK3_&K?+%Z&7>&+G$$^\N],!;\UPQ9*XSWICCC-=G.^&U
M64YX=98C7IEY4!G_5C;;$:_/<<)06Q>\/=]-?7;D8D^\O]P'$P4TIVTP@&*^
M-/BE^XXJ,"'A[_3A<'6RRC3263$RC$GM \;SO+>J1+,<4B?)&]%,WU#T)SWL
M8\X#5([><C_9QN8.%:419)D58^3!C"V'U8/CLN 5D:&RIS2GT#1ESH?."!AG
M2"7,QB&!QF.G+DGTQ(4_%1*Q<%X$AV#E][5=4UG%KFO7+<#8-\PWL"ZTJ$"A
MS1*=U1N >*G"J =2P:-2+LAW9:N*S^O+.K!3HJE-$HFME2ALN4.4"@S8@&8(
MV$\1^&-9C5WIB_>6>F+$8@\I1W>\L\!-U0.6[9ORR+]9QN\L<,<P>7V$E//H
M91(TK/23SP=*XV3#9*,,E[*6J.X@L\L)"AH/!*>JQLC, ^>5<.CHE#AD7D?.
MG^2T W9&1D.\=LNBIOL]8S/8?$0SN]5@-0^1PS\<YN20+Z-HU4E*W6>6CW!(
MY\<I'=L]CRN'NT;:ZW(!OD7B;.=O/82YTOG-E$YQJ@1O'TC -ED"MTG+O#!Q
MJ1<F2-OEWWR>KT^7,ITIG2@_P\\NVA&&91(0K!:GNT&<[G;/!.QEQE$</;\[
M@,-[4C;,:)XX6Z0 @<.RS"IQ_F3O$*QE3T9C;NW]L<B#Y\!SXG"SF4GDPBIF
M$9E!.2YP&*G 4" G+@>^Q[($<C+@),&3FSQZ16;"+R9+ "@'88D7$"WU\^2Y
MRRJ+=EZ<;:'E&M )$T0[K.8K?=B<K<]*=UJDTCL5PGHJC:4_X32(<PJL2P0<
M"E5]8!TU'+GXE<.GU704CD1ME>##3NK2*@E(EDD]72AP9RO.>=9Z"2;7B,.6
MOF&2^)4)2[PP5OJ,]^>[8O0\%V6C;)WQGHV3,OX]6OJ9]Z6/&2-]S/A%'I@D
M=7J*U.7IJ_WD>(&PE;YJH01"RZ3O6F5_%.L/'L,6@J,$/PRH&%AY11C0R/-E
MVSHA;8S#F<R4<XCSLAI.;%93$AI;^Z95]+])P/V_>*O//_7T[CG(I$J-U6@7
M?2A]:9($1S$"AVS;@1*P^T5G23E*?Q,A_B'<,.^H<_):KO)1$4F<S\>U!:7(
MO%BIYK:7"BP2E,R GGZHWYU2K'Q5IV4Q;;,:_N::"2.AQ1U3,B^6XU0V1TX(
MJN?5^@;O2&-TRUYX@%F_C<('JR6X7;(W$O-WAF/.UL.89A>"2>)CQJ[P%Y_C
M*XSA+3[*4_R1N_@F-^6?^LQ%^2K31[VWU%MXQ!?C5_GC@W5!"C#G;@U3"0Z"
M(T?'#&@\J7PWV8GK,A0P"E=Q?C@3<?T36):YR[W3QF[<U?H":WUD4+1V,F8C
M[IV,:LD:L6*S\Z.C84J4*5O.8R*H<,(FTZ?\@6PL'.[=X75"G+1YP8\JHB9=
M$PK&KY:++2 W7"[BVP(#;P@0OB+0]^*, WA^ZG[\:;(]GIFT#T^-WX,_C-N#
M)\?NQA-C=^'W8_K;$Y;GGQRW&T]-V*,^\^</'-0Q7IIQ4 #268XOA26=Q/LK
M?#%)G-8,.0=;.9<E^R+5N3%BV.N?K%+!OE&9BN@Y-X' R/0OARBYXI/ R(4Z
M35:=M/7$VH^[,:MHVYP4;]EWD-E$S@%E)I$3JSG?BT-XO.Z,2@ACA/'USG&P
M<XG'!H&DC6[,WB9B7T"J L: F%QIB 72 1NPR!1_:5636I',Q2W&"K2^B?.#
M3<I7$7]%O>KX.*>-<\TX9!F1=%[--Z33YSP-9G W61K=XCU'8;/]L(!AJ(K
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M_$'J]--2E_\D_=)S8W;*<??*\>T5>+(.CY1^C,$3P9$!E2V#'PFPUCA$8;.
M!Q==LA[3X7.:$\&7P,AVR*D(%RS;>7$K+W/A5K-EBYW[?76T.>QLO><JLXG<
M7_"\!1()-_S-7%3J)*"_4\!PO01&JQWCL.) +);81V/!GF/*5AR(@YW;"6SS
M3L+>@%,JJ<',.V$Q):M$)4<8R*N,FD @K]/ %=;L"YHL;9 +H.@KN6L#?;CI
MISAZZ"I^:E]@$K:*GUHC?FJQ!,:SMQ["!W9!&$<_)<'&6_/=\>IL%[PPW5&
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MA7B6Q /AG^!$@&+F9*-+'%:(7YFWE4%,(,:(PWS7Q@U#9CCBQ4GV HB[\(0
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M@V;AL>/2?GCWE_S+-6K.8D.3L=\D1R&[[R*K>$=0-)V,FH1JV3:#1,X+;KU
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M_V+('K4RO7>Q2G6CVD^06QZE2MWD-DA'.%\LYISZ;00GENTR)A[$KTPA($K
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M4[I=).=<N/5L*] RQ?(V2Q)02Q!@B[<<#6=:]OK3PZHW36NJUYIY&E$+I@@
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MOU,%@<::.-I!RZR=P%4/[=$U<K((KG,6 1BD878>>\K5%TC+PC0 F!$5!ZC
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MT8$;1%;NQC/<KU S#\C+[^RA_$\SV5_+  PO;A-OI=HE6ND.279)^\2P.M#
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M]K^:&'$VH(@Z.]UDU'[,W7B7C4W?9_VG;W51SYK]%WL-8"XYV9Q1E *3FT^
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M@!KJ*.D$OM([L-,%<N<X \KOFC<"BX"( "02G5TD/4E*'<!#G4##H:N\R67
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MW^X1R]2EA^4L#OI%1$H#1H@\/IU"G<9LM)9ZO89Z;5BC"OI] '\ )V^T:1X
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M(<H+ZQO?P+<BD$CC!>WE7#A$J$MON=\E02;H,F(>+H+9'<9L$I!8XQI\R*O
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MN.H,D*%U3O56_I@ =39G%P.S2#=TP19Q5KQ=D@QRMM[W7*O2!X"W4-^[V)N
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M;:X+Z6)_Y]2=Z0X IX!C(RBK)(#0^OHUWC3'7;TP RB&ICG.3V!&O_K5@2*
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M,\4%Y4FQ4[O;:\HVG9G]/NUD<52KR'OD4@0LQ:;R8+, W9_[D=D4\:](GRX
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MXWT1S4O^*E(3#^+AF1L3Z[X+*W,"#<PB1OMYEIH)!Q!__,C9K*>BKF\:9;C
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M!H^I*W0W%Q P*%(O-*U4[)#L(+&U@K<>U)9.V61C4G99_-+;;+&>W<9]#T8
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M,'*Z! #G,'T .>AWY'+8&^HWV"M$N!&)IPZ1$@/ (LU*[''NIJ$#NGB'.3Z
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M0Y=:[S&406RS:0*)Z>ONM'6WZDP=?=P[B$DU$[S08/!NE@:#OV;1" SW369
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MG2=.2)R]>*?J=V[::T@S49>091 $*W-(P4\6>1M-"S[ K-2=7/QTUI.D>/,
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M(RCR?=P6%,WQ=HSXZ.B83[[4.AQ^($86.7^7<W@YCY?.B)IP>>^C^L^I7$Y
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M4;/4+=WIYR]XH&@V4OV2HSG+[W]5#E?G9"V;-;)+Q ^P-GU&0K;.%N_KM$"
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MWJ100W.+2O;4<.*)AM'$RY9),GSO.6*D^:QQY7;7'X'BNMWG5(PU<N$NN%M
ML;N# 8J5>N:"XK-:HVB XC.V/F*T@N2YA1F@..964%RW^\Q_ 8J&?J 1[3?F
M'W,<( 52N7YFIFV#BSB,$1YIZ#(N 3:]0E"QA2=*-2 (.>*9.@X*BH_5FH[G
MFKCA58H9#XI&ETG).@_:.7(-(E*W6P2FSZG<#*.)5$'X6&>/_Y"OTC2FQJ()
MC'PNIKS7D=>O8/N1BRID'[=DEW:"3PC(1%^'>6@[.D$%R"NU#] ZQ6?J..>
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MON.7L6+K"20NW0W?!-;CBBUPF(MV8^)A(U!>6>S]\TT]\&P]9Y4K*B*@^(Q
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MU\1>EFGN@2+BD!Y^;3(>8GUB==;'.N!9L94EY(!=N;,_;(=&H>_T%$P)6(J
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MRP(1\/F(IQ_65+SWF9P</\;9R]=QXMPU'!+GO.?(96S;=Q[9 B*K-YY ICR
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ML0J)K<<DH>/$>>@N@-C727Z7>P9&>"_#./\5F!JZ!DZ1Z^$9MPE^<P0,Y^U
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MG0*(L>( 5LB<GKM\-R;*^Z.H-B.)A,060V:I[;$1(_EY_=':?28[6VF6&ZF
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M([YLEQ8Q42^3HNTJ<<:VD&)_S6TA]=[]*4_AW1B4QM%C9[5=;#/[I:H&4"F
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M-TFGI:1\]C<]M#WG*Y,(^@\_JK8D1;9/7KR-'0>-:.+<Y;O@'[H1PP.6H:.
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M'*8I2^)E#L<A0.8'(<Y=8,5EXEHXCEN%X0'1"H\#?:+07T"FGSBBOAX1Z",
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M\%B#/9[/7[VGT41V"E@J$YI-USVGKL% GR4:36S0>PHJMP]",5FDN6NY([-
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M*)KGP2O3)H%17>KJ\9DR<DSM2D85%\0<TE[A+E-BT'=T%%K:ST.-GE-0K$4
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MU1*K%0V9';_VT,@B?]8<JRD61_?5@==7DV!(V((G_+PM@(O'N 1%0C8464N
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M=[R>]?@(L9T:+0-GQ\M00..HY6DRR3%;9KL7R!+_K;CG.^&$[9- *% >Q6;
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M01K;N$O3OI[2C"" U^/K\O4[# ^23C"R7<:%Z8E&GQFQ,G!^$MYWJHQ=DZ7
MR CC^LA=XI-R2")R3DK*UO/0(]?PC._ .7U=HXNW7OM01P0R;Y-YBU^5S;E]
M>*K+DY@<51$4N0\>!<658=ME@O,FZ3TW7CH!%-F!P #% %7XE?OY&: X/$2:
MC\;SP'7;0Z9GP<%WCMMC.GI[/"B6]Y/\:4"QO#^G 8L:1?K62'D@+-)988]%
MMC$Z>.&>%$._IT&7<TJ(&^1L2> VF0QC-Q3[SI8G6MAS;:E;!QBI3S5A<UZ
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MXFZ HE^ZT<W?#(K,+R4H?H#W^E\'BLRC@J<6GG-"CS/F^V^740#%WO-3I15
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M_'S7]5*UVWIMX_9"3V?L"Q9>N@$NX6C8>4FSP3[2>AB#&4'297R(6$X.%QN
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M7T";7T(A-<!FK6[K)<\SGPUP^"P@\:FN+O(,UG/L>\4![S0FMN[2$,J_U;
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MQ%C-GS##(H^).!.XQ=@(Z38C7D<3C5K+T4J%9>UQ6'#"?I!L0,J)*D\*%-F
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M9I@^LA2RM@SO96G %EGL5XSO%\D"[T*9[[E99D,6ISOG:#/M":LS9/0R.(D
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MSI"EGG#N"(CV\Q*U>&P"=,,,IYSRF<RL&&65*)M?Q^P1#X"J)T#&&W+FDWQ
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M997,'IJ,3^!BE*,[9(H%)8/G)VHTC\? ;"R\ MZK<T2)0APG(D7"Z4G$M6;
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M508T<A9X?Q9$ 1Q[<OPJ;$>W<:':2JTS]@KSV%D4V8'3Q5CU/-A7VMG[2%N
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M?+"L (>SDYG$S[8XK%SD_68'!>,]?O>C^T ^R8^*$&,VB!4G#!F1_F]4QWR
M^V3DX7ZL^N<,]A<'1.R"DU_$"", F85;K/X,2#^BL+4^:K=.'5J ^S7+O4"F
M..7(N-69 +14[>,[:)[1?HG]=VT <>R): 5P[#DV1'J,#I;NHX*D&_,&AP?H
MZN)@!"ZZ.)B^!A!R\7>ZPTY9<N^,"1$KV"CV6.PS)5KZL544FW;CM=C>C2VB
M)J[-DNDNN3+7<S. MEC6A)=HSB5U,E,'XHK.:C4S 9''S(=,N8C77OD X/^)
M N(GGW^MIW_4O=0)/ TT!WR>U%SR)_E1T1DP>K[^28&'>8HOO?&!VB@ZTCSZ
M- )2YP"+Q]5>.L$6K8'M7!&Q1YUTVM.5D7O$*?Z >*0<%O^,8Q)EJ@#?<OB6
MSK%G13!;R!BZUFC?5G;L_".;YO]<'_]CB@:;CY\)BW3V>!)!VTL'BGGIK">A
MG6+U.]O7L?<O U%LOL^<ZQF>!0#&7)D*,)P!1Y\M\N;#N5X%G<DC9T[$X0CA
MO:83+SX/.I>\9Q5OT6\JOCESA$4%U-1;CK!HG(??U]F<[*"?M^^:; 3H1!6<
MPH,ZHL"X3O-%=L@\[V*9YI(OD]9!,%=FRFCV05R8HIWM!T-H!D$P[:9$R0 H
M<H*?KG%<H;KZFV#0CD (@1M$*)P2*0[3HF7$S%@9-3M.QLY+D$D0O.F<H (X
M7 C/<3F4Z%J?(NV#Z!59*H'Q>R0B]8 DY!R3C&(>,5^4[8 E&C1&.AC!8+\@
M=J]G^PM&Q[XT08\Y^9?WB5#-8[^_8GT%Y?41A/3-!U_(;1,L'K[TIFP_?D<V
M[;TN"5LO2F@N(#K[I/BF'Q//C4?$#6#!'#=NZ(B\TRH$S*-@$BJ/4D["T%^[
M"_AZ^U.=#D+C\WM3%_U_95,]Y+%];1RE4E!XC<P[X-$GDWPS (LT?$P*9^*^
M*SPWMA6@4/)]>N ]!V6?D-BB<S ^E[4!>^G).V4]NACR?ML<333-#=6(RB.@
M^)_^47[/#*-D;I/#XV<J9$XV,%IU<![M2QHY3L3S#<L[\_#SQ3US AQZI!S2
MXX^PG),2 \6U<=L%*8"<[*)#4L'#Y7$CGPTC4?\;*)H!T>S(&<W!C>(5IH<P
M@9W/8R\<#8[EH_/&HVZV$)D,9VD0C&%7R%!+YJ?8^6@1!RN G^FX3I[IQ"I0
M5FBZ2LV>',/GH4VS"8EL/]5_1HP,6Y@D4^!Y+H1RX5&O#^7)!(C9.\[+EOU7
M9,^)6W+D_%TY!9B[</--!;R7 #VO @Q?!Z2\]3ZK,#]7,&;>[<>__;WFRWWZ
MY1_D,R@\?F:%YD?X/JOG"37O?/A;K8A\#6!Y]\T/Y-:]]P"=;\O9ZZ]#;E^5
M V=>EM*C1I0Q8]M9B0<PA@(8/6, ZH'%,L\M1R;":QXZ+U[Z3HM2Z&T'6.1\
MZMJ]&$4%*'9G9;>S/--YO=X+'DES!" +=MK2687.&;HX1:,]C%#YIAZ4^")3
MVPV &"/.E"WJ1Z:)4-YH!/_9OJ\(BN9J7SKDU$'&Z<WKLA/Z*7^_D8O'<7Q!
M64>U2(7-M%?"*6<'"K8LXZ0D1EZ8%D)(U%&$T">GZ,R]\GY9L1GOK]%'[\_?
MBS;]IWZ8F\EK9?2?RON$,L+X!O846Q9=?008"<F,_K,=%+L5T%%C,VJVA>)1
M[G(8S86 QMF 1@YX(+"QDG[4DHTR;$&2#)F3(/8 QX'8^P.P;_I-B9"^D\+%
M=F(85KCT8:$)[!,_<]E"MOKB^_R=_K!/=K!/@V"?.+%E*,!P!,%P::J,9__#
MM=DRW2E7YGELUO90J[&G>%SND;A/]3#;,C'%)7/7%=D,@U]RPBA685]CH^7-
MQ]AOGT,^V!?Q&X5#UA5\]^<?GA_[2WX\;LJ(,9WG"W42;]S[?^R=!U@65[NN
MSW7._M-,-":F]QYC[['W$GN/+;%K[ )2141!01 0!5%1$045.XH-4$%1L??>
M"RKV7C'/6<\[WWQ\H"9_]OZWBJXGUUQ$ZLR:F;7N]=:3:G-S6$)1F$#&TF0<
M#Y^(5?!2:]'@"8D8&!8/IS'+Y' ?%P^O22O5LY^,(%E/4]7]WV:4"=IT&)OW
MG))29WRW^(Y=LX1&Y710- QYM^2=YAH@^21[3UG*H>U1<P!KYJZ7]8<QBPQA
M8:@9NSWU])FM_G^.Y"DX!,S'H-#%")BZ4NJWSE5,Q_CYC;N/2X*=)-.J,7LB
M*&9:I>Y:8T7,B8S6"RY,B1L/RN+$6F.3U0(5HEY,?P6,+/[IKA9+QT!U<FJW
M^X?:]791N^ .+G0-1:*U@KE?U0O3HN<$-&,;OZZA:*PFX\QC#!IW,HXFZO^;
M=@E!<P:8J^-7]?UM>HW';^KE[J!V^IW5CNP/9P,,[3UGPF7X' Q2.TAO!3Q^
M84L1/#D18;0"S%J#Z-A4S%VV!7&K=B)!@2[=8(S=HZ6#OGBK"_6J$0C,R<E\
M\0Q0_%- ,4-]9';X^2N,X[RJ'O#S:DS.J ?\N)JLZ(;>@ZE+MF'<O T*HM4.
M-V:=6*'\IZU6B_AJC%'_IF5J:MP6291@K3!"8JI:=%@]_JC:(3"A@B9?CO\_
MS8C-VJ7#V'EP9V"ZMNB"9F'?F.5;)68N-"9%[AM-]CQ&1JV6@X X5@%BQ*+-
M DBQZN6+3STH.Q?&"[$$ W<TYRW61$)69HVNG&%-I![7V81CS[A+0@!C_PB+
M? DY:7/RGJ;N[_AY&^7^!L]<B\#IQOVEY350C=L8!8><M%C28[IZ:6-7[58O
MX$&L9ST^2_%F[G )V)PLGQ379@)BAK6/\T,)"R$DFN\C)PBZG D(H]1&B#&O
M/9ELIMZ+VFH#5;I5 +ZM,U0@D?4/<Y=TE"XF__53?X'$MPA'I9VELPHMB3_]
MXHW2:@-7C7W.^;[93\(?'M%P])N+H6I2&169*(!("^+\A*U8MF8WDAFWM^,(
MME@ D9GVA]78,:;WI'KV"']TT3)&CL\CKYNUW5B\^HJ"%W[DOR^JKS'<@M!%
M:"0PGE" >?34>:FWMN=PF@#CQEW'%) >QHK4?8A3&Q]:,J<N4, X,QD!D^/A
M.7HA'-2$V)4M-OM-0/VN(:C2SK NYF=!\<J#)&[Q77%##S RO0OTEU:$[.S!
M)!CVXOV1'@QN2GN$2=Q;'U\C*2DD9HT4,*>;F!8[6I\)BX08\W[:AE\\^;G+
ML!:=/BW6@0M2=)KN8KJ-#>_-9DQ4U\829>P<XZM@@EX<5A_@IH"%EFE!H+N-
MEA293Q0D;MAU0N83,X:8X\[Y('OBS?/\CIJ!_&9;2O;;E@Y*ZAEA=N_ATX8[
MFO,1RQ<E;3DB[P+G*LZMC"V>H-[#T0HB_!5(>T](@$?H4C@'+83=B'GHY<V6
ML#/1F>U@U?O25JTGK=2ZTK*OT;NY:8]Q:-0M% W5\].@RQAUA*"^6I?JJ<T3
M/_)HH-:LANKSC;B.=1^+9CW'HX7Z6?: ;JU E&M>1P6&7:545 SZ#IN+ ?X+
MI#S4T''+)?XU*"I98HH)1@0=;L@7J[EFA8(=QATS667/D73U?%Q2UWU5O1\W
M9;-HN)@S9%[(L#QOS[.DG%>64B_W!7CXKG,SPW"<S7M/B%6=]Y&A;K2H3E!K
M*8T57#L9_C,R:HT<G'O'SEDOZVFDK*<[U 9NG\S53$9D^!!C$XVY]I:\:[:0
M^+P__Z:RPR+9Y-K-.Y:DK^L2G[KG:+IL)E:J9T:,&LNWB^%@["S#(.0],1Z#
MQRU5X+A,&C^PIJ_?E$2I.,&X1$(B7<XL?LYY@_>#W,<QLQVC+*!HOIPF;/!F
M2A_<LY=E\:3IGUEZC!5A86X"(V.CZ)JDZXOF?[Z87N/5R84N@]NH.*FA9J]V
M='V]9JL=?PQZJAW5'PKPNJD)N(MS)+HXF<<4ZT'7<7>7J?C#=2IZN$U#;_7]
M_1@\/W0F'!4=N_@H,%0[,B]%S"R0':AVW2%J(ITP?36FJ(EUQL(-F+MT"Q:M
M4(.P9@^2U$Y]_;8CX@ICP@A=,K3LG)*2 M<?R18SQ\<$1=.JR,SPR^I%Y4TZ
M=N:*%19I64S<J&Z4>ECGK-RMQF2G>O&W*[#8*@_RU,5;U0W<@7GJ:XSS8U8M
M79M\J'>IW>+ADQ?5HGI-W-XLUT)W]S])=,B<6#.KN'-B)0#SQC-HF+L%OHA<
MY.CBXLZ-0;"1<9OD_M%RR/.<MG0;9B7NE$EWF3I/3L*TH'!2IA7K.%UNCW2J
MR'CNW!U_IZQC]L :&Y5^Z8;U>6>I* (9(3E107U<RCX!1KF_RRWW5XT;.QGQ
M__F2SN'8)>V68JAT4W+A9MVK0VKWQ^>-OY]_Y[:E://CS\UXWK@0<$&@]<!,
M-",DTF*T:O,AB6]E" /=E*POUU:]4_5[AZ-\NU$HV,A'$C5H*<O#]F8$(]8W
M56#TA@)&PA);XK$^:8&ZWOBYA3]JJH6P&<,W:$7TF@GWH 48$;X,8=.3$+4P
M%0L2MUD!<8.:6$PX/'0\74'=!8F+)1S2K<2-!,&;<P@M6GR_.*?PF>'"?U/*
M<MV5) M^C:6=:$EGYP;"#:&1%LC3"AJ/IUT4-Q7[PQ(:61U@W;;#XI9>HC8_
M<^/5?5 [XY"H5? 9MT2LB[T\HS.MB^U'H4SS$0J&O>1Z>=WYRCA+WVB6[<K%
MDEV66J_,BF5-.V9Y,X.V89\)4JC>;N1\F6@95SQOA5%+U'1OI4F)J-O6&*B_
MLUKPZT:Q]-MRG=QX$>PR-R>'Q'M#5S??4[I7.?G3$\%^W5,7;Q8+&K]&:QH7
M5V,^L4"B6#LS7>.W;$N#/'S^+5#4PS\SK5!W+,DN'&,^5YS7^(X2&/>JS3Z[
MBC'YDN\I0S'H?F1WI9D*OCC'A2MH#%%K4Z#:$/M,3,"0L&48-&8Q7!4X.BIX
M8TDG9N[W4NO3'Q[3T4W=[RYJW>FDWH..SE/4$8D.CE/0?D"$?.3!Y,A.ZO.=
MU3K5U2T*W=4:U4.M4;V'*BA4(&JO?J>S6OL&CEH$SY"E&*;61/_)*S&:KF6U
MB',SR= CQM01\KD93]YZ5.H8;V6UC2/GQ&+$$!.N-T8LXAT9!XX)YX9,Z'_6
M=^NOE9G!F[E&<1[@>\Z-$M<HUA1EDN1:RSWD.DG7^ZR$'9BAYM4HM2YQKN7!
MN9=K%+O($8[H[6+]V$U[3HDWZ(@":W.N-4.C,BS)4SG-Z_7PX4,K+-Z]=S\S
MIMX"BPR%X[/":^<8<"QH6>7<P,2VB6I>9,@9YRW^/PO[1R[BYG*+)-"M(!M9
M#!F<@W@_:"3DF#T1%#--Q)G P<F,.U^:.SFA'3F=&5S,DAPKU:3&C,L%2;LE
MZY(O)G=SH3-3,&I:,D9&K(2/ CDO]7(."5D"#P5W[NH%=1NY "Y^\S*/$7/E
M<%7_[^8_#P,5" X*6 "/P%AXCEH([S%Q\!F[!/[CETM;O3%35HA+.4(ME.R<
M,DL-2JP:G*4*@E:LVX<UFP[*8K9-+2HL<4-7V#&!P\L6*\<-F42Y2''P3>#)
ML)G@Y8%"IE61$];U6T:18Y/HF7E&UP"[VG 7N$I-V-P1,C.:,8Q+UQZ0.)-$
M]6_&FO!%(" RSHEU^^CJ/*UVBR8DWI#.#P_^K?BUK ^4S<1JB57DB\A%C"\B
M3?S, N-BPH046A^XP+"H,.\?H= \5BK 25'7PIT* 9$;A$,$ ;/H\/7;F5F4
M.<1*D5V/CIE-!K0LWD9<%.&8]W?SOM.2Q$1WD/7^JLF=8\<8$;Z@#"Q.4E]G
MT>Y4];W,H*8+Q-S=FH'G?-ZXLW[2@FV-Z9%-VWVQ9/-YX\+!]XYA(.R\P7B>
M$1$K),:IO5JH&O0)E^05%I-FCW5"(@&1+F=V62$HLJ8@R]^P5 A;\+&O+2&*
MKN86"HJX0 [PG0.OT,4(CEPA22JTW"UG73ZUT=BTZ[C:;)T62Q_!D"YE@N&%
MR]<EMI89C80^/G\<3\;&\3FAZY/O&)]-[HPYZ?$C_RU?DWA@HZ>IP*. XRT!
MQXNVX*CFH&,*'.F:WJ% C;&0J]6[3F!D['%XS&H$3%(;U>!8V V+04>7*6C6
M:YS 8NEFC%OTPK?JNEGTG^5+<A6Q%U!\TW*PFP;K[['X<3'&*ZIQ:=@W')TD
MN661%,AG2,$RZ:E[5#8!M/+R7>,]S5J"X\GWU\STI665;GC&X7%NW2N6LM-B
M7>3&CN]I?.H!J8_)#0B?-;ZWK*'&K[$W.3<CF?.)X>KG>/%^F-9$@=@<4D..
M,JU0UKA%2[+>=4N8R"5+_"+CB@E3C-EBF!1+17'1Y#NX4FW>N6&C97]V_ Y$
MJ0WQY/D;$!:3(K4\@Q0X^DU*E%J?0\<N54"W1.I_,I/?1:T]3FH=HD6=I9\&
M^,Z%@\\<.?C_CFJM<E*?=U;KE*OZ7G?U;'B,CL.0T"6RUOF&)R!@RDH$JS5P
M[(P4A,]9CZEJ0SESZ5:!6,(LYPLN[JD"AZ<M<'A1YAW./_0@F+&(]'A(1O,]
M,];NSQP#/=GC4,W$2^G2<ME8H^C]8KPR$R6Y.6<1<6ZT:2GC)IWSZU)9KPX(
M5//S##W@YH";!'G^CQGK*9\)$ZSIIN=F.RLD/NL1^?>4&<-KP*)1J#XS5.JB
M):[^F*58/9]]L@5C-&E=94M,ALJP[SNA,,Y2<8)U6Q/5)IOUD&G)I=?QB'B[
M#$\AF2A[*,W_>?3$8%/G*M/\;T[@=!6)CUP!%^-%=JL)>\O^TP*-/#G3!4#+
M"MTTG%0GS4M5NZ@4C)VY!B$LLCMM%8(4Z 5,3K0<"<8QR3B"(A(QBN;1J2LQ
M1AUCHY,P?L9J3)J=(N5LHM0".4OMQN8G;,-B-0@):A)-5I/F>C5QTVJX6^VJ
M64?PV&GCXKF0<;&QA4(CL#OC,;$+V<8#IE7Q3]Q[8%AW"(N7KQF9>6GG#6!D
M^S36M*)5@#>,D+!5P043([:H!Y^?HTF<-Y36)690,VN-@<F7KG(B4 OE[?L"
M+.)2^ >@2&5_$:T9LI80 NZPN,!RUT!HI*N+.SA.4)E'FAP[U7ERITXPX:1%
M=P]W\5S0N+#1$B3NC_LY(^;I2<H^9GPF^!)R8N9+2&#D DXKJKD0T<IH]$9/
MDS$CN+'N*/_?O,>$0[HE.6FQXXMYC^D^YO-G;@2>-&29;K<'LC!>49,"K8E&
M,?RC4LN294*"U;LT4.(28]"X_T14ZC :Q9K[X=LZ7OB@PD !1!:<?D6*3O<7
M4.3Q3FDG?%[%73*;"8G5?P]"L][CT67@5+7XS87/N*4(FY$D;N9%*W<@B46G
MU81".*1UCU;#BQ:7)@'OSET#_$Q0XC-A@HD)368IE,<>-M\C0?F6GS<+,O/W
MFD!I;EY9 LIJC6"-4S7_<(-(MWCD_+5JWDA4L+M(+>RST$G!8M->8:C^6Z"Z
M7E\4K#L47U5UET+^A,-<A5F068U1@;[XUT]]I+L&N[VP+5SQ%GZHW'$,FMI-
MQA]>LS!8 46HFL?F)-AF0:?+YO.692QL.V$\3G_^B2PQ>+;M[+@9/ZK&F$D_
MA$8NG%P$^9QQ0>0BRF>-G^/SP.H4M&H25L5#HMYU6G*O6L)">'_,XN 9.6A#
M9]N%R$RVS S%R,AB:>1[Q0T>X_>,#3P] A?$NL0YF)NV9+6!(UPS>9 6X5GQ
MVQ&]> NFQ&[$1%F?UB%TQAJ,CDY6 +D*(]7ZXZ_6(1:!'Z$V'KYTVTU8K@ P
M'B,F)BC 3("_6KM&1K"8/($P"6/4SW*-&S][K0+25$Q;1##<AKD).[%0P2J[
MS3"&;IVXE4_+_>-Z<%2M!5G!\$YFJ9M[#ZS6PZQPF+/"?,QR+Z8;E6N'V9F'
M:Y0M,#(4@[%RM(YS/>6SOLWR#G#<N)'BYVG X#MB/O_<C*=;2@5=NY$YU]Y_
M\/"1<<LILDWZLGK +&72:$"@T8;7;&Z8R!9<IS@V'#=Z@%EA@MG,_'_&@S)L
MANL_.8";4]/[<,D2?G?[[J,>S?_SA//+<J*VQ5$YN1G : 15GDR_8G4!\&9N
M4)/9&D7Y)'[N FA"7K!JE[C)9BIP9$NY*+H[+45VY9BWSGI,4?]F9B/KL$4M
MW(#I<1LEVW'.<K434[]CT:J=6)*\6Q)2! [9-47]S9WB4DZ7A<.X\,Q>EYF%
M9BU5ZO'OO60F*)JP*#%M]XT"Y=RI&#O;VP*,!"F^[+Q9?&BYLZ<EB9G,_,C/
M,9Z)#S._ES>7\,#?(<')=QYDQIUD_/.XD\RXMJR +W6KU,Z-BX<U!DS=,UH'
MN2#Q0;$]"(8$(U[+&36&7+QHYJ:K6<:2BR$A^X%-%ED.>O%L];B=[AV+>?^Z
M!1CYG!.060F T,AQ8_*3[=AQ8I-Q4_>>7^>"G6:9M%C,^ZJ:M#(#T#-CBY[T
M_!D0\< Z$9Q7XT]H)RC$I^Z7XLQT);"(>K\1\R2KLT;74 4U_OBA'MOR>4B&
M\RL%[219@[#XFO0^-OHVLQ_N#W6&H)2"INKM1PE$=7:-Q #?V1@^;@G&S4A&
MC'KG:*5;L_D@MJG)A:[?LV8"$Y,CF.EN*;/ROSWQFN^@N=AP'C)<,,8"PW>*
M'@,FTZQ2X[-PQ39$+UR/T*@5\ Z-@\/P& 6+$6C:<RQJM \26/SIER'XK)*;
M%%_.7=P!;Q0V0/'__<#N&?VD;>&G50;)>)9H.5)J+#)>T8&=G":O$,"(5?-:
MLMH<,\&+]YT *W!F*4/SI/<B2]<%RZ:.FZ^K-^_(^#+)AXNF^9YR[N!SQD6
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MWW=2(-&H+WHCBW7>++#^-)6Y8;/)B.5]N6XDA= MON_(&06WQY&R^2 6)^W
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MA$7&+9XZJ^:;X^>P^^ IJ>VX)'DG9JKK8@D=O_!E</:?B\YN4]&D5Q@JM0U
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M>^DF)"H(93'MDV<NXMS%J[BLP(8)(8SURTP$RSD+F^WY/GSX,&N"RZ5K.*E
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M5G;'>TRH*-@7^4HYXG/U[Q_K>*%$,S]4:<]"VY/08V@,/,;$873T*DQ?LE$
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MVU'$)NY$>$P*AH]=)@DM;>TFHU;[T2C6<#@^K>"*UPOV1:["_?&F L6WB@]
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M>J:RM7H1T@@U:0HP=AY(0]*F0U*/;^+<=? >MPQ]I/_P)%1J%XC\=8<J6/3
MQ^5=!0Y?+] /K^7OA[S%%,R4=<4WU0:C8%UOE&\5@(8]QDDQ:'8-\9^4@(ES
MUHI;F_&*6_:<D,26-+-DCH)%%H7.S(+..<DMF8DK#R7>DI#(#C27KMS$N0O7
M<$(!^%9UO0D*DF<NWH30Z4D8.G8Q^@^?)5G+M":R$\N/=;WPI1K;#]78YBDQ
M0$"1Q<W9PN^+*N[(KR"1$%Z[<X@UVWGXQ'B$SU^'^:MV(GG+8>P^<E9*\$A/
M;3,&] 5RZVMI:;T\TJ"HI?4,)65;+#%TIHLT_>)U*9.S?L<Q+%Z]!U%QFQ P
M9:6TEJ-[M':7$(FA^['.4'Q>V1WOE7+"FP7M\-J/?9&GB#W>+^V,SRH.Q+<U
M/%&\L2]J=!B-EOTGHH?G# P<%8N B$1)X(A=N4/B%7<?/B.P*.W]KMZ4>+H,
M2Z9P3LF"SK0D/K2"(J_C"CNP6""1UL04!7'S$[8A?-8:^$Y8A@$CYJ"S@N@F
MO<:C<KM1*-1PN&2.?U)IH )#9P'%UPKUDV+;=/=_5\L311LQ62@ C7J-DUJ5
M;L&+$!2U"E%+-F.)@E!V>CEPXKP"[\Q$(6X&3/C6TM+2RDG2H*BE]0QES<Q5
M(,'R+?<5+!+6"&Y;]I["B@T',3=Q!\;&K(%'R&)T5[#7N,\$E%>@4D1!S;<U
M!N/#GUWP5B$%BC_TD8_OEG!4GW/%9W1!U_%"V98C4;?K6+0=$('>7C'P&+T(
MP5-7(FK11BQ=LUL2.QBO>"SMHKBA&;.88?8CMF1!/^]XDQT2.98WV('ETG7)
M[F8"R[:])[$\98^XG ,5++L%S$>W05%HV2\<-3N.1LEF?OBVYA!\7)&0Z")N
M9[KUV0&';N?/J[BC0#UOE&GICQKJ^ULQB67X''B-7X9QLU,P5X'WBHT'L77_
M:1Q58'KY^NU'^CIK4-32TLIITJ"HI?6,91M71\AA4LO)LU>D#E_*MJ.2'#%Y
M02I\)R6(F[.-TQ34[#P&/__JCP)UO?"Y IN\1170Y.\GH/AV499P<<8'95WQ
M5=7!*,IN+>U&H5&/<?C=.1+]A\^&U]@E"&,IEZ6;L2)UGQ2>)BQ*R9PK-R7Y
MXEX.<IF:=1()VG?5N=^^<Q<7+]_ 274]^X^<%1?[ZDT',6?Y%G7=R1@2$H?>
M0V:@E=U$U.T2@G*M1J)@O6%27BA?&1>\4\I)^FCG9K*0N)V=\8V"\F)-?%#E
M]U'2N84=7%R"%F)DY I$+MH@UL2U.XZ*V_GDN2M22#TK)#[K4=+2TM+ZY]*@
MJ*7UC&4+BCP85\>V;W0_;]IS4JQ4,Y=MQ6@FM8R)0S?/&6C2-QS5.@2C9-,1
M^*Z&)SXH[6R%Q+S%'?%."2>\JV#QDPJ&5;%4,S\IE].XYWAT=)V* 0HX?5C.
M9=8:S(W?*G%[J99,Z)-G+TORQPW)AKXGV= 9&<\O+/*\'F1DX)XZSUNW[^+:
M]5NX=.4&3J1=Q-Y#:=BHKFOE^GV(9;SG[!3XCE\&>Y_9^-TQ O6[A4HMQ&*-
M??!=S2%27NAM-79Y2QJ@^';) <A3P@$?5W3#3_6\4*YU .IV'XNV3I%&21SU
MN\+4&,Y1OSMIRR%LV7\*!T^>ET+;;-E'2-361"TMK9PL#8I:6L^!,A-'_I1,
M61;?/L+"T ?3L&[',<0F[<+$>>LQ/#P>=GYS\9N"O08]QZ%BVR 4JC],8A*9
MU$)(?%L=>17L$'C>*^.*+ZL.1H%ZPU"FA3^J_1Z,IKTGH(M[%%Q&SH??Q.68
MI.!I#K-U%2QNV'E,8OG.*% U^T$SR>:!!13_?([B[&S/A]9$0B)C$M,O7L.I
MLY>P[W :-FP_@D1U7?,5#$?.6XN1$^/AJJZ[B]M4-.X1)I!8LHD1[TE7_3L*
MKG,74W#(<52@R/(X[Y1VQ!?5!J%84U]4[S0:S?M/1/<A,R4VD9U8IB[:B"4I
M>[!QSPGL.7H6QQ5HGU=CQY)#UBX\S\>0:6EI:?UC:5#4TGI.9$(/,V79,87N
MR_W'TR7F+7[]?DQ?N@7!T4G2 :2'5PQ^=9B,6IU#4++9"'Q3?3 ^^-D%^4H[
MBS4L=S%'O%F$UC G?%AN(+ZJIF"QKC=*$G;:!Z.%M/>;#K? !0B8%"^P.'?Y
M%JQ8OT\R@X^P'[3Z^Q<NWQ +)]W0MN?Y/,CV/'A^A-KS"A)/GKF(0\?/8<ON
MXUBQ;B_FJ>N*F)."41$)<%?7V\,C&BWZ3$"UWX)0O/%PY%>0^$6507B?L9Y%
M!^"-0D9;1 '%,DY2=/O;VIXHT\H?]11<MA\X#0X*-IGI/&'N6LQ=L1W)6XU,
MYR-I%W%&G0-[.S-[7%L2M;2T<KHT*&II/6>BJ_?JC3LX>_$ZCIVYA+W'SF'-
MMB.8OW*G6!5'1"3"40%/IT'1$BM7H6T0\M?UPL<5!BK8<150?$N!XFN%'/!Z
M80<%/,[XH)R;P-#WM3P%%FMU'(W6=A/1TW,ZW(,6('!R/*8HZ%FX<@=2MAP2
M%_11]H,^?T6L=(S[,X'G>; JVIX#/S);_+*"Z]/G+N/PB73LW'\*JS<>P,+$
M;>JZ%"1.3L#@4;'HK:ZWC;KN6G3;-_'!=S4&X_-* P42\R@X?*V '5[]J3]R
M%;$74,Q7UAD?57)#_OI>J/3[*#2WFX0>WC$8'+8$HV<D(WK)9BQ;MP^;]I[
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MW@-?3/*!_@Q_?#4W&&,6A^&;[R(Q=>4&S++<A(4DC4M(ZI:1H++@K?;-@'5
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#0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>image_01.jpg
<TEXT>
begin 644 image_01.jpg
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MU:P+'M02H\ OU#8OWNR)E&EF3O_EB?!"B$L 9-^IF@V.<]$^2[>XO@&B$P/
M<:D;N\-"7FD1WH6SR7\N048>[D10-_%#\I8VWJ>&1@07 1Z_-3WA\9D+5[DA
M>0NDY2#F"UY8@L<MW>%G<^%T6+H[Z(L](7L\$A+2BPC&7J($@,^Q#*3A "IL
MV!>2?;NBLW=@#+:8L;'F]IYCB3FDU2YPXH"#OEU:CR_UYQ)<_:UL0H+#B;E(
MDX54*9NL0OV.I7M%I>WEG%39X W3;_UW/WU)C80NF>(6@I:9/[CKA"L34PZ/
M4T@*6K+?V.8P/A'.-J4M<$V@\C<"%1I,*_YVH$PS_#[T!FX#;FGK(GW%!7W3
M?Q/Y? JVU^/PE=?@2D:BS%2GZ9GXF-I$?FT5J@#W%$4KI&RKO,T?[A'X(@#-
M]PS2=[?P(A[&&%=NE2(-!EI,@V<$7F*?U^FWE[HB>2O8^>#O#16:NK%G2'PV
M3#P0:.Y:/Z'G!PG \+YOY)V4>5^DRF=X'\V8N\9WEXO \ %PH9P.8RAOI;O=
M)S Z'6Z!%S/O.0<F+AH?O;DK.6FW2K'(UHZ>S[\+F6?DD5E8(2PNY').R3IJ
MU#L&;#A*T4)^.Z<I4S\R<H.-%NP<,9IOU9.AY7!Y)V:, U?/^6O</S+B\(36
M**^X#GKK?SPC+"'[>D%E[[/;;GM7_X.J1IC&V"L,"-RL2VJ:NY_C59YT]#ZH
M;A3:<IAOLW0=912LV(&)A")P@)O0PD&:A1N]:L:MP>C8&#R4/FSN?4[E8V-/
M"XH?19W/Y1Z]ZA]S/>%J4;TD_X\!YAI:WM0J:#F!@:&1\MJ6BKH6GKA!_A_2
M/SBTQCH2R5$L]I\DYHW3-SB\;"<81!HC4/*E:W*0H@1P^YZE;OO)<G9M(_'\
M$Y)^JU16E4;:X-'>)7+;GTRD* '?WLI9;GUV:Y1(>T\_V=CS+0U&SKV'Q+S)
M0HH2^,?^BN2L;+D)Q P< \,C:\P/SE*F7!+[6#9I2%&"\#,Y( %85V(&CJZ^
M0<TMW#F?V6;=$7P[FGRD*$%F0>4T)6O2NOVMN&^D!'+O/9RUF+Y@-:>I3?+6
M/0E(40*X'>GN#)*1M]X?FD+,>\;7U#!$HL)5DI@QB4A1 N#DI0*D1I]%IH;_
MDD7( IO@  :.9/6.(?MN^2-"[F0B70G S- #SB,UQC1EBBG]\.G+MTMJ&HO*
M'AU.R#;<Z0^^:*8.,SHICUAL<I&N!+QQ3\V-OC9OQ8_@\&64J;-U&*]KV2%%
M"C@BTE>^\6F"_U#\'Y&Z!!A5CYZ$_')SO77$@E6N<NO<3)C'8U)O/\^]3C*3
9),%4YE^0,0^%A?K5.     !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>image_03.jpg
<TEXT>
begin 644 image_03.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !% .L# 2(  A$! Q$!_\0
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MXS[5^J'Q,^(^F_"GX:ZWXJU20C2=!L)M1N&3DM'&A<A?4D# '<D4 >-^,?\
M@I+X#\)?M6V_P<6Q\2:IXNN+NWL\V-K');1/,BR?,YD! 1&W.=OR@'KBM#]L
M;_@H'X)_8@NO#\7B^UU^X;Q(MP]K_9ULDVWR3&'W;G7'^M7&,]Z^*_\ @BC\
M*[SX_?M.^/\ XX>(8)))+>YG6TD?)0WUVS23%3ZQQ-MQV$X]JF_X.+QC6OA'
M_P!<-6_]"LZ /T2\<?&S2? 'P+OOB!?1WKZ)I^D?VS*D48:X,'EB3 4D#=M/
M3.,]Z^4?^'^7P5 _Y!?CO_P70?\ QZO5OVGO^477BK_LG[?^D8KY1_X(:?!G
MX>_$KX#^,+KQCX7\'Z]>V^O"*"75]/M[F2./[/&=JF120N23@<9)H ]:M_\
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M[?X^&?PNL_@CX;OU77O&$0N_$13.ZTTT-^[BST#3NIR.3LC8$8<$_CW^SC\
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M#_X;?&C]G/P7XJNO$OC*SU3Q-H-GJ4RQ2V[012S0K(P53%G:"W +9QWK@_\
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M%YT>=%WK&R-P0Y79GMNSU H ^PO@9\7M.^/7P@\-^,M)5ET_Q'81WL<;,&:
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MLG_"70_''PZAU:UM;74!9ZM'<73W!3S ##,K'[F'4H?4R+TQS]A_LH?\%,/
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7'4,I[CBJH\,::HXT^R_[\+_A110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>image_04.jpg
<TEXT>
begin 644 image_04.jpg
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M.V*2,@$  *Z0,K>1,@$  &Z1,K>1,@$  &Z1,K>1,@$  &Z1,O?\C)BD3
M@"NDS#VD3     E2YAY2)@  @ 0I<\.OB$G*!   N$+*W$#*!   $")E;B!E
M @  ")$RI3XC)BD3  #@"BE3BI0)   @1\J4(F4"  #(D3)%3B,F*1,  . *
M*5.$E D  +"%E"E"R@0  -A"RKQW%3%)F0   %=(F?=(F0   +M(F?=(F0
M +M(F3<6$9.4"0  <(64>8.4"0  H$#*O$'*!   4"!EKJPC)BD3  #@"BES
MA90)  "@0\I<(64"  #HD#)72)D    ZI,Q+MQ&3E D  '"E(&7^\=__\^<G
MO]]=KTJ9(U8$   ,4O-KF5]!LWFR>4G*[+\0  !@HN*4V3;B2"+F])39? D
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M538  (#"U)2Y:"HG7RI2IK&VG-D#  !PT25E'D[_<W1FQ$Q.F5Y!<[=F
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M,A]_V3 M  !@BJ8I\R!1?6!"  # ('U3YD&N^H'?3 0  +,\,V4^+%HQ#P
M8)S6*?,@8#$#  !@IB>GS ?$K)</'P  S-4]91XO3EJO'3@  'B  2GS\/@3
M]:I'L.UMXP4   \S(V4>;PJ:]I$.&BP  'BJ,2GS>$?\>L,8 0# &[PN9;8-
M8<\>'0  >)M)*?/PBV+=TM@C!P4  -ZL:<I<_%WLCD&S0RR+'LO6WVH/  #@
MI77*S F:55DS9PBD3   4*)CROR.F(MX-#=HNE=^&S$)F@  (%_WE/F8H!D1
M+N41DY0)  "2M4N9O[)19M!T'TM<LMR-F 1-()_P;=U]Q]/^W3C(:>5#QY*
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KR@0  #A%RC0A90(  )PB90(  ,#?_P' J,/(4N6W5P    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>image_0a.jpg
<TEXT>
begin 644 image_0a.jpg
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M.V*2,@$  *Z0,K>1,@$  &Z1,K>1,@$  &Z1,K>1,@$  &Z1,O?\C)BD3
M@"NDS#VD3     E2YAY2)@  @ 0I<\.OB$G*!   N$+*W$#*!   $")E;B!E
M @  ")$RI3XC)BD3  #@"BE3BI0)   @1\J4(F4"  #(D3)%3B,F*1,  . *
M*5.$E D  +"%E"E"R@0  -A"RKQW%3%)F0   %=(F?=(F0   +M(F?=(F0
M +M(F3<6$9.4"0  <(64>8.4"0  H$#*O$'*!   4"!EKJPC)BD3  #@"BES
MA90)  "@0\I<(64"  #HD#)72)D    ZI,Q+MQ&3E D  '"E(&7^\=__\^<G
MO]]=KTJ9(U8$   ,4O-KF5]!LWFR>4G*[+\0  !@HN*4V3;B2"+F])39? D
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M538  (#"U)2Y:"HG7RI2IK&VG-D#  !PT25E'D[_<W1FQ$Q.F5Y!<[=F
MA7DI\^K;D_-E2<I<=TK*!   ?31*F8?A[ZHIB9B*E.E5JGH.%04#   H3$J9
M5]]5%3$+4Z8Z:"H*!@  4.B5,H_KA'3U?-LTF5#P[C0ZC@(  &!M1LJ\>GA*
ML@RMV3Z-0)5NKR< P%&[E'E\)*2KQP8ER^C*3WMY6,1LDC/4!7@5WV0>U")>
MVU:SX?MO=_R[(H#1NJ?,TP>F7TYI]3_F<HJ.)M%[ID\E):8LDYWPSWF(^&0.
M$P"$.J;,X_\/ZZN?'7H#Q8UB,9:GWD"UP<6X>>9NVEWE:U0[=<1- "_7-V5>
M_=30^V8A>D0/OGA&1Y;1FW:M=ET:3B!9$\ [-4V95Z9?-@M/'5>TT7GE>8L;
M-Y-]5DV'7]<$\$*34N;T:^;6XP<8Q#U!9L[SDU8V<RSCW@Z7:$C0!##+F)39
M)Q9$>\](O41/2X>4Z=5=D,)13'DU'$,A01/ %#-2YMN"U]O&:Y0V)Z3,4QWJ
M[S^-[HF0H F@OP$I\YV1ZYVCULF<$%+F3]V*[U/)*?<X2- $T-SS4V9U^2:O
M'?@64F:)MF5WJ^=;1!8D90+HK'O*)&8Q [>29X.4>32.F.OR"DLZ8E*FL%F"
M)H 2K5,F >L+\[!&RDPVHN"&)<4%05(F@)Z>F3*K"_?'5"R0,C,-JK9;5>4I
MDZ )(%G?E$FN^H4)N4+*S#2HU"/FCP50"TV!I$P #9$R)V%.3N6G3*^FCFDI
M<TJ=/_6IC90)X&V:IDSBU"FFY=3H21A4_)0Z?^E36W0*)&@"Z*9CRB1++3 Y
MGT;/P)3B1Q1YJD]YI$P ;_.<E%E==1[FYY?1,S"E^!%%7FE2'BD3P-NT2YE$
M* EFZ:?1PQ]1?/\*UYI4F! !:U/FRR/LRX>/%Y(<*:3,J9BE;Z.'/Z+X_A6N
M-:GPV2F37ROM\VO&NS64%SQ"D\6M(ORMDL\I>D+*K"ZY!G'\V^BQ]R^^>7D2
M38HD97IU$?3I7%OHB#+#4]!PNDUL>0&.C*7V2IG$IBU,UY?18^]??//RA#H4
MF7!Y5-U/55=@GRL\.E6$#J1D[3Z[]MVNY;.:4(QZ<C++)F4.IIBN1\[8Z($W
M+[YY>;,D7!M5UU+RY;?HNNK^#BHC9Q2%R_?9NV,93?9&VWITU>X^W"AE$I@4
MF+1C>!)J7GSGVL9)N#!*+J2T:T_8N_I&M PD*$#DY(_:%3PMP*6&VEG=K<<X
M!'55\GX5WW6\/&7FOTN?!=AK(&6.'GCGXCO7-E'"59%\%2TZC>AHJP!)&8XK
M8AF^UY)Y%=]D!>-:-JY123T)I\>Z+]VW'WU29LFOR56]5+Z=EDQ=*Z-'W;GX
MSK5-E'!/I-U#MYU&=+15@+ ,ET4QCMIWR13?F[E;Y 7$M6R<V*IZ<MYN][DB
M958>Q%Y]D3+GCKIS\9UKF\@ET%BZ<!F%O,>([B)JL"^*<<@1J[;UO>6+F)R9
MU.W;"RO?JXHN+(T<<U.F2Z<E"Q;Q(I$RYXZZ;?%M"YOK]C2P'P@)IXV\QXCN
M@FHPKHMQO!&KYCA\70%;XOKU'9>]L/*]JFC<TM3Q\I1Y-/C/P%U&L3M[#PL'
MHX?<MOBVA<T5?2#DG#;R'MV[4Y3ATLAM.\;Q1DQCG^"BKB&H64O[H2^I2R,1
MY5F:.IJDS,)L)#GWA3/NV)0"*7/HD-L6W[:PN:+/A/R@T"&=K,OP:F?=5,.%
MV_K>Y-M*6$-0LY;V0U]2ET8LY46<2,>(E!G:M>3M6B^G\=N]D#*'#KEM\6T+
MFROZ3,A/">71Y+8,KW9"QQ(7&EP*R%G-H.[*-V=0/1$K%7$B'9U39EKOPA<L
MXN,[$%)FPI#=IZ[M>K4M;*[0,R$_'W2()K>5>+43.I#.$U@U"4'-)D]L7#T1
MRQ1Q*!T=4F;YI25_P7P_[@-Y[2]GYHPW:-YZ+M8+=U&"T&,A/QR4YQ)))85-
MN71:/H%I]03U4CNQ<?5$K%'01'5)F84%;+U@CA_W@>RFS,=$!,7 +9^2XGT[
M]:KJ,5LH1]RQD!\+RD.)L)C"IEPZ+9_ JAT5U&SRQ(;6DW:,Z%K[5I\R.]A]
MQUP^[J/HDYR2D3+=O63G)(L[%O*OTL]>"J_SSC>WL=.<,-3A_@IJOW9B0^N9
M<HR0,O^B>,>,GZ"!=(M0.4B9[IZ]8:H$G0P=@E%5&:?%M+JYC9WFA*$.MUA0
MX[43&UJ/^]""EIN4^1?=.V;Y! VD<YR*0\IT][Q-TD'$R5!RB5YU5'6C/VP^
M,Z?NM(#;DB)J"VJY=F)#ZW$?6M!RDS+_(GRC'#]! QF1J]R1,MT]9F^TXGXR
M5-V@5WTUJ:?5S6WL-'KJ3@N05.5>7DZSR1,;6D_$N"*6FY3Y'\(WRNL3-(I9
M <N+I?CR2>@Y\].W1$^.)T-A+EET5U55\YM;W6E"UZ<%" OSK3!HU+43&UI/
MQ+@BEIN4^1_"U\GE$S>*Z)39,UN$UDS*[%/8]/WL=3CT3"2%M36_N=6==EC3
MM$LM:-2U$QM:3\2X(I:;E/D?PLEU^80.)"UH]HF;":62,CL4-GT;6PZ'VE-E
M48F\SK22W&_NB)IO.\U<6?6:.M89-.H.KTQ0/4&#<E]N4N;?A)-K_X2.(CEE
M=HB;F2G3J^;/EEM-[XAUWRVUO&S%X5![F$B&L%5P6E7=;FY%IYE+?-MCPM46
M-.H^[XY[/4&#<D\RI,R_R2?7\HD>157*++R_<PHC978H[%3_+?I%<3XTN1JO
MZI$\DU"\5X]56:3VRO@L0%&DO=J@4?N6:B]LQ%[UC32DS+]MS:SZ$SV*\I29
M?YV3,JNJFA@T"XOL<#Y8"*O-'^"(FWNWW\("='4:"\X/3+JFFM03O54<4PTI
M\V];TZK^1(^B/%GF7^VDS*JJRG/;MQ'5=C@?+.2E)@\P[N:.J%;2;W(-+BMK
MK#EHU-UN\"E[U7%:2)G_X+XC\X^,\D"9?\>3,B.,R&W?1E3;X7RP<,DB"87I
MNBM<B_(ML=5CT$T7-.IN-_B@O>HU,Z3,?W#?D?GG17F.S+_LTWHD93:I[=.(
M:IL<$3I;I2:/,>+F=B]2WG5^);L]1MQW0:/N=HG;6\[<(2[S\W?*+(\=':X'
M]QU9>'*]1Y_]H]"V^&[OIDNUM46./B(<@TAT;?:;V[W"K=[SBU'TZ'[E!8VZ
MVR4^;J_:I^CDUS++T^2#4V;^^?4&??:/0MOBN[V;M_K7.?=\4-29.4QC1^5+
M4+LEO.).S_!DK,U].5H5(V3,.:O?,2^/E<DWA&(JC;,/%TWVCT[;XEN]FQ+]
MZYQ[/KC<B''#U)V]?>:_=DM8>G2\]8)&[36Q7H7-W:ORD/.'/&5^*\^7I$PL
M--D_.IV+[_-N2O2O<^[YH"LR;9C3#^?:JBP].LYMT*@=)]:EL-%[55?AWO_]
M\^R@Z;7\/??'@W78/&J=B^_S;GI56UOAT,-!763:2*<?SK4E&7OTFMN@43M.
MK$MAS]ZKIQ7J_Q_SAZ5,Q[7ON3D>K'SS6'0NOLF[Z5AM;85##X>@"!)7X;CS
MN;8>>X\N<QLT:L>)=2EL^E[='<+A\B<9D3)'[(P'*]\\%LV+;_)Z>I5:6^'$
MP\%88<Y@%5VT6H7:8EQZM-]]??;&NJG\>EKM56%5/\OS_/,R29GV-PT*Y9O'
MHGGQ35Y/KU)K*YQX.(PX"75=]%F(VDJ\>C0N>JN]<=5453U--JJ\JI^?D#^5
MG92I?M.@4+YY+)H7W^<-=2FUL+R#E!DV6'4731:B=DOX]JA>]VY[(\CTO2JO
MZOL3^W?_3$F9H2=IMVWQ//T#T$+_XCN\H5YU%I9W#$R94T["B)L[<RUJRW#O
M4;?N0:/NL+XN]339J[N%_1&=,K\U#YH)AVF?/?$\_0/00O_B.[RA7G56U?9E
MW,DPY22TM-]A.6IKB.A1L?1!HRY?7,=Z.NQ516'9?X\Y*;/#GGB8YNEG;43Q
M'5Y2ER)+"OLVZUAPK"UZR,;&RU>DMH"@'G=W>]"HN[UKT_>JHK#LE/E3DY0I
M>1DB/NX#>:W.T>?6E.))F7:SC@7'VJ*';&^\=E&Z]1[7\J*O_!J\NLBLI^WI
ML:BJ,F5^(64F:W+C.NH<?6Y-*;[\/76I,+^JGSH?"Y]\"PL=LKWQVD7IUGM<
MRXL!YM?@U45R/6T/D*N2ZE/F4?W+),(W(>+C/I:%;C>NH[:Y1Z*V^*V6FP?-
MAB7]TNU,6' O+'34+BT7KDOME@CM47X5!M70[5V;OE<55<U+F;Y7A? ="/HX
M#N14V^O65\_0(U2>,N6-[[ZGR7/>K9Y/'<X$(??"0D?MU7+5TM1NB>@>:R_'
M;N]:V[WJ,B&GQ9 R?0)B[8OT2__KUE?#Q",W*&7*JRV9]E;%G"H\$[8$514W
M\)R;.VYU:K=$0H^%EV.W=ZWM7G69D--*1J9,Q]O"?=^7O$A'^]_-##5ZR(7%
MZQIO&S3[5'(E^4Q0"ZHJ;N"^=VW^ M5NB0YCC*NAV[N6ME=UK>U^EZ2D%BGS
MJ M)<=L]\UUJ>_'G&#WD\I2I_L9N^ZU)&0N9EZM%_GUO[,BWS?P%JMT2:3T*
M[\2T76=LMD,]CG/H,NVG9;PZ9::]V-$=-;SR,XT>=>&J69IM&#0[U+"0?+DZ
MUAG:N$M'[FTFKU'MELCL4?@6.-80U$5$+O1M;:M-KVD_K6%JRG2Y,)[Q/C>\
M[Y.-'G75JMF;56R\T%5HO@?R[U>O.D,;=^G(O<WD-:K=#\D])K\%<5O.O1[W
M!N7->DW[:0%=4N91\0MRM<>Z5^^M;OH2HT==LFI>S;8*FLWWP(B4F5!,Q-B#
M8D3:,KTJ99[V2,JLW:NA90Q.F6US0R8F[2C]36>[_+5S;[-#UNR_ 4B95UWT
M3)FWI?9/0I;>2SJ=,K?/VZMQ*?//K\].F3US0R9F[)B<,O/W?$YRS5^1_AN@
M?\K,J21B^'&3F;-8+TR95_T^.V6&#MFR5X/>P:^?:I0R#S+3)J;KJ/Z+HXS4
MX4P^KLPY"1J"8]<NP]0A92XZLG0:/9D)Z_7.E'G5M6,!$:^;>Q1+2YF++HS%
MK+L;GS(;1H<TS-5!RC1_&@XJKCOWP<HU3YF9E?C.0,)D1B]9[7ZHW82U"[?5
MG;W"Z(56C]12SVU'O5+F07(28Z*^C)Z$PG 9/1OE0VNU^O+;+OF.7U>8W)VN
MZYS)#%VUPOW081/6KIKZ$U%/SI"WODO7U\_'GI RNT6'!,S2E[GS4)ZWTJ:B
M?(SEBYYYC?F65]+I;N]I,UF5/*H6(JY3227N#;I_(NJQCUK75^BTM$N9Q^3H
MD&/B1>MB=! ICUFU6^+Q _S6[6YSK-#>M:4 >_WV@7AU-&@([JLOK,W>0N@G
MK1[=/&1.Q6VUSTF9)3=*B==.SNA$4A6S&FZ)!P_M(&6&]?Y=0(=IM'14N!/*
M]YZ\0LOW)GPRZU%,A:X,2\V+ CJFS./%0>K6Q'L76)@>*P$XRHFSN.45?Q^5
M,A]_V3 M  !@BJ8I\R!1?6!"  # ('U3YD&N^H'?3 0  +,\,V4^+%HQ#P
M8)S6*?,@8#$#  !@IB>GS ?$K)</'P  S-4]91XO3EJO'3@  'B  2GS\/@3
M]:I'L.UMXP4   \S(V4>;PJ:]I$.&BP  'BJ,2GS>$?\>L,8 0# &[PN9;8-
M8<\>'0  >)M)*?/PBV+=TM@C!P4  -ZL:<I<_%WLCD&S0RR+'LO6WVH/  #@
MI77*S F:55DS9PBD3   4*)CROR.F(MX-#=HNE=^&S$)F@  (%_WE/F8H!D1
M+N41DY0)  "2M4N9O[)19M!T'TM<LMR-F 1-()_P;=U]Q]/^W3C(:>5#QY*
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KR@0  #A%RC0A90(  )PB90(  ,#?_P' J,/(4N6W5P    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>image_0c.jpg
<TEXT>
begin 644 image_0c.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !! ,4# 2(  A$! Q$!_\0
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MK6Y0Q3QZ1 '0]0=N:\I_8)_Y$#Q=_P!C'=?TH[@?3M>6_M(^(]3T;X7W^GZ
M'?Q)K9_LW3DB;:_F,K,S#Z(KG/KBO08_$&GRZ_-HJ7"MJ<-NEU);@'*Q,S*K
M$].2K?E7C_B_6M8UOX[6W]C^'V\16?A.R/F(+M8%CO+@ @Y(.XB(#Z;S20$_
M[(GQ*F^)'P7TN2^F:;6=*9M-OC(<N9(^ S>Y7!J_^T[I ?X3>(-<@OM0L-2T
MJRDFM9;&\D@VMD<L%(#?CFO%/@G?W_PA_:K\1^%]4TLZ!IGC.(ZE8V1G$JI,
M"20K  <_,,?[->]?M+_\D%\<?]@U_P"8IO<$>1_"7P#/XO\ V;M+\6-XK\36
MGBB;2GO/[035YB!*H8@F,L5QQR,5Z!^R1\4M:^+7P?M=5\0%9M4M[F6RDN53
M:)_+; ? XR1UQWKQKP1X+\6W_P"QMI>HZ-XQOH8(M):XDT;RHUAF@4$R0^8H
M$B@J",ALU[S^S%XA\.^)_@IX<O?#&DQZ%IGE&,Z?&<B&521(,]6^8$Y/)H8(
MZ'XP>*9_"'P]U:\LANU29!9V$><%[F4B.,#Z,P/T!KRG]BGXB:EXG^'^I>&_
M$,\LOB7PS?26=U]H<M(5))4DGKCE?^ UO_%K5=3UKXI^$]#TC1VU^/1 VN7U
MJMRL(#D-';Y8@C@^8V/I7CFGZMJOPC_;$MM6U;16\.:/X]B^SR0M=+.AN1T;
M<H !+=O]NA;!U/LVBBBI&<WK_P /-"\1R-+=V0$QZRPDHQ^I'6O%?'UAX7\(
MZ@]GINE+J%U$?WDM[*SQJ?0+G!_&OHTU\\?%CP=_8%U9W$]TT@OW8SRD<(=W
M./P-?GW%&%C1P_UC#48\U_>E976RZ]6WN?5Y'7E.NJ-6H[=%=ZAX!\>>(U>.
M[>/1M%\+P2B.>ZEMQ"K<XV1XY9OY5]#(RNBLIRI&01W%?#_Q'\42:]*D,2^1
MI-FGE6EHI^5%'<CNQZDU]&>$?B':>$[?P;X0U&6>^UR[T\32MD$PJ$W#?]0#
MCZ5/#>:*;GAYR<HQM[S>[;M9+HNWWORZ>(<#'#TZ>*:47)M<J_5]7W_ ]6KS
M3XZ:OX-L_#4%GXQDN3:W$NZ&"S9EDD91_LD<<]^*O>&/C=X3\7ZP-+TZ_/VU
M@=B3QF,,1_"">_M7SM\1?%F@?$7Q)<VGC(ZAX6\0:8[VBRVH^T6I4,<9C/*_
M4=:^CQ^/I?5G[&49<VFOP^:?3[['P=2HN70P)O%?@[3[T/H'A1Y54Y5]7NWE
M!_X "!^>:[72OVCO%D#1H([ P+A5MTM]J@=@,<UY7J.AZ782QII>NKKCR,%5
M(;1XR<].IZ^PKZ5^"/P/7088=<\00*^I, T%HXR+<>I]6_E7P.#IYAB<2Z6%
MER=W&UDOEOY(XH*I*5HZ'IG@7Q)J'B?1([S4M(ETB<_\LY#D./[P'4#V-'Q&
M\,W'C/P)KN@VMPEK/J-I):K-(I(3>,$X'L37156U.[-AI]Q<+$\[Q(66*,99
MSV ^IK]7IJ5*DE4ES-+5]_N/36BU/,-%\/?%+PEI%IHEAK&@:[:6T0@BU+4X
M)4N44# WJC!7(QUXSWKH_A1\,[?X8Z!=6HNFU'4M0NY-0U&_=0IN+B0Y9@HZ
M#H .P K-\.2>(/#\6IBXT^9YKJ$WJ%I/-7S_ .,< 8'((7ZUJKJNJ32>'I5N
MI&@EGD2Y86;('&/E!4\KWYKEACE**<HM/M\[=;>OH9JHK;'&W'P7U?P;\1-8
M\9_#W4[.RDUK#:KHNI1,]K<RCI*C*0T;\G/4&JWBOX/^*OC/<:9;>/\ 4M-M
M/#%C<+=2:+HJ.?MLB_=\V1SG8/[H S7?1ZCK%LME';:>B)<W$D3_ "$"'#D[
MS[%0?QQ4WA[6]8U#Q#J-M>VR06D)8(-K!AAL*0<8((YZUK'%Q<E&SN_+RN5S
M*]B_KJ:@NFI9^'KK3K*^3:$6]C:1!&!T"*RGTQS7CGP=^!_CCX-Z+J>G:1XH
MT&]AOK^2^=[G392RN_51ME''%=_=^%;O6/'&H7.V*V@CEMI%NFC;SCM4$K&V
M< 'H?QI-%O-9T5+]7@DDM9#=SQ!83OC82_*,_P 6X'(]A6*QDU)J<&E=Z^CL
M3SN^J,7PE\,O&.@^+O&'BN_\1:7J.MZS;V]O:Q+921VUJL1/!7S"S ACW'-:
MGPH\!^(_!5YK\VN:GIFIMJUX]_)+:6SQ2>8Q^Z2SD;54*H'H*UM'UK7-1CT4
M2PB#SWF-S(83]U"-O7&-P)[51CUSQ27$S0)Y.!(8?LQW8\W9LSGKM^;-7]=A
M9-1>OEY)_J/G78XGXX? 7Q%\5?&WAG7],UW3-#F\/7 N+.9K1Y)VZ%D=@X!4
MD'@#N:Z/XD^#?%OQ ^'\_A5]:T.TO-1MG@OYOLLAX)&&B7S,C@<YS75Z1K>H
MWGBO4;.6W==/B7]V[QE?F!QC.,$$<CK64T1L?'Q>WM7O6N)"9?.@(-O\GWDE
MZ;3@#;ZFG+%KEC**TYK?UW!SZHP_A#\*-:\!?#B/P/KFJ:=JFB06!L(I+2W>
M&9@P(8L2Q'0]@*PO@9\$_&7P7TN[T"#Q1I]YX;@>XFL(6LCYS22'*^:V[[JG
MLN"<]:[^TUC4M1L(9+BW\Z?[;$KP-;,@MP<YP3]['][I45KXD\17!UD-9I$T
M#!8(S&Q*DR;<] &&WYN#2^NPTT>OD'.C-^'O@+Q5X=\;>(->US5=(U'^V61I
M1:6DD<D01 D<:EG(V  GIG)K _:.^!FM?'"WT>VL-8T_14TNY2]M[N2V>2XC
MF!_A(<#:<+QCM7<7.N:W9VMLDP"-]JEADNDM6<%5(V80'C=SSTXIZZ]K;^);
MZT%O''9Q1.T;2(QW84%7R!@Y.01G/%/ZY!-:/HMNZ#G6QK>$K;7;31XXO$-W
M97M^AQYUC"T2,H'!(9B<^O-%'A#4[K5M"AN+V-H[DLRN&CV X.,@'G'I1753
MFJD%..S-$[JYM5YU\==)^W^"'N57+V<JR9]%/!_F*]%K!\=Z?-JWA'5+.WA,
M\\T)2.,8Y;(QUK@S.@L3@JU*U[Q?WVT_$[L%5]CB:=3LT?'>A^'W\5>,-*TJ
M-"XN;A ^.R Y8_D#6-:^/KC3OC.?$UYND^SZ@1)'Z0C*%0/9>@]J^K?A'\(4
M\$%]4U%DGUF9=@V\K O=0>Y/<UQOC']E^SUSXC_VM!(\>B:@7>\@A8))#*1D
M.G8J3U%?GN R'&87!PJ)6J.2;79=+^FK?J>KQ/F"S&M"%!WC#\6]WZ'@/B+3
MAH/BN\6SGWV_G?:+2YB;[T;'<C _0UUO_"/-\;[F(BZAM/&$403S)OECU!%'
M&XCI(!W[BNTUW]D[5+/YM&UJ*^B482&]4HP'IN''Z5QD_@_Q-\-]2M;Z^TZ>
MT:VE61+A/FC)!_O#IGWKS<1A\7E]5SKTG[)O5;JWJMFNC/AG&4'[RT.V^$/P
M'\7^$/%UOJE_;:2(8LJ?M#&8C/\ $@ &&]Z^F1TJ#3[G[;8V]Q_SUC5_S&:L
M5^JX#!4<%2Y*-[/74].$%!6B%%%%>D:!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5S?Q&_Y$G5_^O=OY445QXS_ ':I_A?Y$R^%
MFMHG_(&L?^N"?^@BKU%%;TOX<?1#6P4445J,**** "BBB@ HHHH **** "BB
0B@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>image_1.jpg
<TEXT>
begin 644 image_1.jpg
MB5!.1PT*&@H    -24A$4@   W<   #4" (   "P,4V<   H $E$051X7NV=
M;8[DRG)DM93>R^SC OJE#<S^J:?.5WQL.Q[!^&8PVPX,0E>DF[DS;A73-<!
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M80VY=>4__< :%O,D?R@?28O02)[9,K]FQ>&-AU+;-GS'?P5CC#%[LO,WH%G
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E&&.,,2;$6Z8QQAACC!G/_P+ J,/(GX# &@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>image_12.jpg
<TEXT>
begin 644 image_12.jpg
MB5!.1PT*&@H    -24A$4@   W<   #4" (   "P,4V<    "7!(67,  (AI
M   @F@'-A,C3   :.TE$051XG.W=6W+EMI*%X3.4,Y>>AR/ZJ2?0\V?;H=.R
MK$V"B;PG^7^Q'\HJ"DA<""Q7V57_.@    !O_ZHN      ]$R@0  ( _4J;>
MO__K?ZM+    :(J4J4?*!   N$+*U"-E @  7"%E*OT9,4F9    5TB92J1,
M  " !5*F$BD3  !@@92I\14Q29D   !72)D:I$P  ( U4J8&*1,  &"-E+GM
M.V*2,@$  *Z0,K>1,@$  &Z1,K>1,@$  &Z1,K>1,@$  &Z1,O?\C)BD3
M@"NDS#VD3     E2YAY2)@  @ 0I<\.OB$G*!   N$+*W$#*!   $")E;B!E
M @  ")$RI3XC)BD3  #@"BE3BI0)   @1\J4(F4"  #(D3)%3B,F*1,  . *
M*5.$E D  +"%E"E"R@0  -A"RKQW%3%)F0   %=(F?=(F0   +M(F?=(F0
M +M(F3<6$9.4"0  <(64>8.4"0  H$#*O$'*!   4"!EKJPC)BD3  #@"BES
MA90)  "@0\I<(64"  #HD#)72)D    ZI,Q+MQ&3E D  '"E(&7^\=__\^<G
MO]]=KTJ9(U8$   ,4O-KF5]!LWFR>4G*[+\0  !@HN*4V3;B2"+F])39? D
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M538  (#"U)2Y:"HG7RI2IK&VG-D#  !PT25E'D[_<W1FQ$Q.F5Y!<[=F
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M,A]_V3 M  !@BJ8I\R!1?6!"  # ('U3YD&N^H'?3 0  +,\,V4^+%HQ#P
M8)S6*?,@8#$#  !@IB>GS ?$K)</'P  S-4]91XO3EJO'3@  'B  2GS\/@3
M]:I'L.UMXP4   \S(V4>;PJ:]I$.&BP  'BJ,2GS>$?\>L,8 0# &[PN9;8-
M8<\>'0  >)M)*?/PBV+=TM@C!P4  -ZL:<I<_%WLCD&S0RR+'LO6WVH/  #@
MI77*S F:55DS9PBD3   4*)CROR.F(MX-#=HNE=^&S$)F@  (%_WE/F8H!D1
M+N41DY0)  "2M4N9O[)19M!T'TM<LMR-F 1-()_P;=U]Q]/^W3C(:>5#QY*
MF=DU]]48[>><?__XSQ_,2)DY0=-2=D*@-$9,4B:021$9;[\EXNS*1\J4F[B^
MY9BT$K]2YM<_MDN95_'H-B15I<R2<*F+F 1-(,U5D!)^<;?-67>J91+>AIE!
M(<7V^PZ7WU^9E#(;!LU9$9.4"218O*2?/R4\>;;:[,P8M=^&F4$A]?;[F34;
MI<S;A)00-'=K[I,O7280@-'Z/25EDC*W,#,HM+O]OA_^=\]?RQ2&I-#_3'.W
MYG$1DY0)A%*?R^K'9@61JY194DQ_S P*N6R_+BES*V*&_J+F5MD=\J5B]K;&
M"$!NZQ@1/KQ^;*N1JR/E\XN+QQ;GDN0!^1>%K4E.R]O6C'?!FG#.?WWQ^\>*
M =X^L#7,W<WS^45YU\*!7#WILF]]I_JT$4D-BGZOFMT=[.)G=W?1X)1YFY:N
MIG+]V2I;UX5C21'S!D!MZPP1GCGKQR2-G-X3B@<6S]P^\/U%2?V2UA97X+HU
MX5@./Y+Y_'SR<X"2[[JJ7SA7M\7?;I[%5X1%*@9R^F-CFXK'TB99,N?K)W?7
M8NM[?VJ1,G5129*6?KZEPL]6Y8KVW8LA: )-[)XANAMHMY&KVV+QC/P.L_2R
M]45A2?+'%%6I26[ZS\>, U1/OK'QK57V&LC6P[Z/&;]%U^SG%Z\:B7MQA*:F
MS*WV([*=KN6(&KZ0,H%RC@?(K\?4G2KN'I?+];1RXUV>E@PDW[7E*A"L2Y4/
M4-[C;6N?#TB^:[%YY+U;!K+UL.]CDG84W^55GOSENGU2]U+4I\RT>!21\.1M
M1O3^B: )%%(<(,8VO:ZHXY^GV6Z=EAM.WIVPM:UD<-6=_3265+4N-2$AZ7;7
M8N:W>G$<R-;#OH])VE%\ETMY5Z^YI)>M)5Z8E#)=NO/->;L)TJO?-5(F4&+K
M118^K,L!OQX0'CC"BTK=B^0.EA^2CLE <28K'C[]\6[EIX_=UK]H;6N,B_'N
M[JOC;/CJ@9S^K./D.+X%BUXD@[KZ1N',RUM;-"@<VI?BE%F5A]0GRU8[\H_[
M  _9W$;T"[R6XO0P/F:_PWXU=94>U!6NBY'?@L).MT*)O#NCG[V<_G@K#?P:
MX&X!MUW('_A\6)AU/K_H]3HL_G&KS9R-)/FNJP<DY0GWU>YKN!5@NJ?,Z *,
ML:]AN/R%E FDV8J#"2ES*_]='4U>]ZO+]7;[6%#Q=J=I4I<R%_^X[OWSB[>3
M(VG\^.?^T?5N&<AI@\8VFZ=,87G".5&_AI(G*U-FMP"4EC)#1W&JU3P#3[5X
MP2-2IN/-IX@[N[V0,C^[6]P+\NF2=!V:,G^V(QS(Y]>K4J:\O'$I4_YRO2YE
M%I;T)2)EAA8LU'.V@<?8NLZW#O&K*T1W1:W+$UY@QEZNOIB<63-3YE5Y\NTA
M'* Z6T@>6#>^&&/<0"+:#'H+3CNZ?4 ]>Y:4>5NY\,FRE/F,Q#,H8GY[P+0#
M;9U>3I(+X+9-2;.*>A1WV&TCPF A_.)5:[>#U8TWZ-S>V@E;:4"QH-]?WZWY
MUU?DO0NWQ^Y>70_3=W)<WH*KLN53JIX]RV 77[D=8)>4656&T?<LKS_599YX
MP.0#/4E.@-V3P7*J++YW$7&N;I2K N2C/KT+M[K;FE5%Y1&'MJ+FK8=O!RCL
M8JMQ2<OR:U$WD)\_Z]6FL$)%=U>5;VU122.GH]B= <E2WHZN)F4^)N)<O3_1
M!Y:79ZP" *"GSC<@$E2FS)*N?8V.F-^>L18 @%:F7(*(4Y RGY1IGI$R 0!P
MQR6(^K_[9S12)@  I[@$0<HT(64" '"*2Q"D3!,B)@  I[@$0<HT(64"  "<
M(F6:D#(!  !.D3)-B)@   "G2)DFI$P  (!3I$P34B8  , I4J8)$1,  . 4
M*=.$E D  '"*E&E"R@0  #A%RC0A8@(  )PB99J0,@$  $Z1,DU(F0   *=(
MF29$3   @%.D3!-2)@  P"E2I@DI$P  X!0ITX2("0  <(J4:4+*!   .$7*
M-"%E @  G")EFI R 0  3I$R38B8    ITB9)J1,  " 4Z1,$U(F  # *5*F
M"1$3  #@%"G3A)0)  !PBI1I0LH$   X1<HT(6("  "<(F6:D#(!  !.D3)-
M2)D   "G2)DF1$P  (!3I$P34B8  , I4J8)*1,  . 4*=.$B D  '"*E&E"
KR@0  #A%RC0A90(  )PB90(  ,#?_P' J,/(4N6W5P    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>image_13.jpg
<TEXT>
begin 644 image_13.jpg
MB5!.1PT*&@H    -24A$4@   W<   #4" (   "P,4V<   H $E$051X7NV=
M;8[DRG)DM93>R^SC OJE#<S^J:?.5WQL.Q[!^&8PVPX,0E>DF[DS;A73-<!
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M80VY=>4__< :%O,D?R@?28O02)[9,K]FQ>&-AU+;-GS'?P5CC#%[LO,WH%G
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E&&.,,2;$6Z8QQAACC!G/_P+ J,/(GX# &@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>image_2.jpg
<TEXT>
begin 644 image_2.jpg
MB5!.1PT*&@H    -24A$4@   W<   #4" (   "P,4V<   H $E$051X7NV=
M;8[DRG)DM93>R^SC OJE#<S^J:?.5WQL.Q[!^&8PVPX,0E>DF[DS;A73-<!
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M80VY=>4__< :%O,D?R@?28O02)[9,K]FQ>&-AU+;-GS'?P5CC#%[LO,WH%G
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E&&.,,2;$6Z8QQAACC!G/_P+ J,/(GX# &@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939378811736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 25, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Entity Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-04321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANGION BIOMEDICA CORP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">11-3430072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">51 Charles Lindbergh Boulevard<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Uniondale<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">11553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">655-4899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ANGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,958,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the registrant&#8217;s definitive proxy statement relating to the 2022 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant&#8217;s fiscal year ended December 31, 2021, are incorporated by reference into Part III of this Annual Report on Form 10-K.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001601485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939382146088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Moss Adams LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Seattle, Washington<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">659<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939379775800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 88,756,000<span></span>
</td>
<td class="nump">$ 34,607,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Grants receivable</a></td>
<td class="nump">806,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,685,000<span></span>
</td>
<td class="nump">7,690,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">91,247,000<span></span>
</td>
<td class="nump">42,297,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">451,000<span></span>
</td>
<td class="nump">156,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets</a></td>
<td class="nump">3,986,000<span></span>
</td>
<td class="nump">4,072,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments in related parties</a></td>
<td class="nump">723,000<span></span>
</td>
<td class="nump">822,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">106,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">96,513,000<span></span>
</td>
<td class="nump">47,347,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,710,000<span></span>
</td>
<td class="nump">5,578,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,219,000<span></span>
</td>
<td class="nump">6,665,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability&#8212;current</a></td>
<td class="nump">894,000<span></span>
</td>
<td class="nump">611,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Financing obligation&#8212;current</a></td>
<td class="nump">58,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue&#8212;current</a></td>
<td class="nump">2,301,000<span></span>
</td>
<td class="nump">3,942,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_WarrantLiabilityCurrent', window );">Warrant liability</a></td>
<td class="nump">114,000<span></span>
</td>
<td class="nump">10,704,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermNonBankLoansAndNotesPayable', window );">Convertible promissory notes payable at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">51,170,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent', window );">Series C convertible preferred stock at amortized cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,001,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent', window );">Series C convertible preferred stock at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,518,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherShortTermBorrowings', window );">Other short-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">260,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,296,000<span></span>
</td>
<td class="nump">107,449,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability&#8212;noncurrent</a></td>
<td class="nump">3,475,000<span></span>
</td>
<td class="nump">3,847,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Financing obligation&#8212;noncurrent</a></td>
<td class="nump">235,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue&#8212;noncurrent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,865,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Other long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">635,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">15,006,000<span></span>
</td>
<td class="nump">137,796,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies&#8212;Note 11</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value per share; 30,000,000 authorized shares; 29,959,060 and 15,632,809 shares issued as of December 31, 2021 and 2020, respectively; 29,959,060 and 15,316,721 shares outstanding as of December 31, 2021 and 2020, respectively</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">156,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, zero and 316,088 shares outstanding as of December 31, 2021 and 2020, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,846,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">296,445,000<span></span>
</td>
<td class="nump">72,136,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(103,000)<span></span>
</td>
<td class="num">(333,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(215,135,000)<span></span>
</td>
<td class="num">(160,562,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">81,507,000<span></span>
</td>
<td class="num">(90,449,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity (deficit)</a></td>
<td class="nump">$ 96,513,000<span></span>
</td>
<td class="nump">$ 47,347,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments Subject to Mandatory Redemption Carried At Fair Value, Settlement Terms, Share Value, Amount, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_WarrantLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_WarrantLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that is required to be paid, determined under the conditions specified in the contract, if as of the reporting date, the holder of the share has exercised the right to or the shares are mandatorily redeemable within one year of the reporting date or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109262807&amp;loc=d3e22047-110879<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermNonBankLoansAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings from a creditor other than a bank with a maturity within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermNonBankLoansAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939382222856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">29,959,060<span></span>
</td>
<td class="nump">15,632,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">29,959,060<span></span>
</td>
<td class="nump">15,316,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">316,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability&#8212;current</a></td>
<td class="nump">$ 894<span></span>
</td>
<td class="nump">$ 611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability&#8212;noncurrent</a></td>
<td class="nump">$ 3,475<span></span>
</td>
<td class="nump">$ 3,847<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939383377608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Contract revenue</a></td>
<td class="nump">$ 27,506<span></span>
</td>
<td class="nump">$ 193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Grant revenue</a></td>
<td class="nump">806<span></span>
</td>
<td class="nump">2,687<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">28,312<span></span>
</td>
<td class="nump">2,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of grant revenue</a></td>
<td class="nump">433<span></span>
</td>
<td class="nump">1,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">48,698<span></span>
</td>
<td class="nump">38,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">18,488<span></span>
</td>
<td class="nump">17,986<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">67,619<span></span>
</td>
<td class="nump">58,153<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(39,307)<span></span>
</td>
<td class="num">(55,273)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(2,919)<span></span>
</td>
<td class="num">(4,910)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Change in fair value of convertible notes</a></td>
<td class="num">(7,469)<span></span>
</td>
<td class="num">(11,353)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss', window );">Change in fair value of Series C convertible preferred stock</a></td>
<td class="num">(3,592)<span></span>
</td>
<td class="num">(264)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange transaction gain (loss)</a></td>
<td class="num">(245)<span></span>
</td>
<td class="nump">668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain upon debt extinguishment</a></td>
<td class="nump">905<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Losses in equity method investment</a></td>
<td class="num">(99)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income (expense), net</a></td>
<td class="num">(1,847)<span></span>
</td>
<td class="num">(8,846)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="num">(15,266)<span></span>
</td>
<td class="num">(24,834)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(54,573)<span></span>
</td>
<td class="num">(80,107)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">230<span></span>
</td>
<td class="num">(333)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (54,343)<span></span>
</td>
<td class="num">$ (80,440)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic (in dollars per share)</a></td>
<td class="num">$ (1.93)<span></span>
</td>
<td class="num">$ (5.43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted (in dollars per share)</a></td>
<td class="num">$ (1.93)<span></span>
</td>
<td class="num">$ (5.43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">28,244,825<span></span>
</td>
<td class="nump">14,762,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">28,244,825<span></span>
</td>
<td class="nump">14,762,120<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments Subject to Mandatory Redemption by Settlement Terms, Change in Fair Value, Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14172-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939375628920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>IPO</div></th>
<th class="th"><div>Private placement</div></th>
<th class="th"><div>Non-IPO Related Stock Transactions</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>IPO</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Private placement</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Non-IPO Related Stock Transactions</div>
</th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>IPO</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Private placement</div>
</th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Non-IPO Related Stock Transactions</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,758,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(312,164)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2019</a></td>
<td class="num">$ (18,586)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,810)<span></span>
</td>
<td class="nump">$ 63,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (80,455)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of broker warrants</a></td>
<td class="nump">3,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_StockIssuedDuringPeriodSharesBrokerWarrantsExercised', window );">Exercise of broker warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">572,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_StockIssuedDuringPeriodValueBrokerWarrantsExercised', window );">Exercise of broker warrants</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of warrants</a></td>
<td class="nump">751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units releases (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Repurchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,924)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Return of common stock to pay withholding taxes on restricted stock</a></td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">4,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(333)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(333)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(80,107)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80,107)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,632,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(316,088)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2020</a></td>
<td class="num">(90,449)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,846)<span></span>
</td>
<td class="nump">72,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(333)<span></span>
</td>
<td class="num">(160,562)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="nump">1,562,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,715<span></span>
</td>
<td class="nump">$ 24,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,657<span></span>
</td>
<td class="nump">$ 24,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock', window );">Conversion of convertible preferred stock into common stock upon IPO (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,234,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock', window );">Conversion of convertible preferred stock into common stock upon IPO</a></td>
<td class="nump">35,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible notes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,636,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_StockIssuedDuringPeriodSharesBrokerWarrantsExercised', window );">Exercise of broker warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">844,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit', window );">Fractional shares paid out related to the forward stock split</a></td>
<td class="num">$ (10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">152,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units releases (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units releases</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Repurchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(164,855)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Return of common stock to pay withholding taxes on restricted stock</a></td>
<td class="num">(2,458)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,364)<span></span>
</td>
<td class="num">(94)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(480,943)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(480,943)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,210)<span></span>
</td>
<td class="num">(4,206)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">12,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(54,573)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,573)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,959,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2021</a></td>
<td class="nump">$ 81,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 296,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (103)<span></span>
</td>
<td class="num">$ (215,135)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_StockIssuedDuringPeriodSharesBrokerWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Broker Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_StockIssuedDuringPeriodSharesBrokerWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Conversion of Convertible Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_StockIssuedDuringPeriodValueBrokerWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Broker Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_StockIssuedDuringPeriodValueBrokerWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Conversion of Convertible Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939383246792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 9.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private placement</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939380411800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (54,573)<span></span>
</td>
<td class="num">$ (80,107)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right of use assets</a></td>
<td class="nump">710<span></span>
</td>
<td class="nump">530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">1,884<span></span>
</td>
<td class="nump">7,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_NonCashPlacementAgentFee', window );">Non-cash placement agent fee</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">PPP Loan forgiveness</a></td>
<td class="num">(905)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">12,041<span></span>
</td>
<td class="nump">4,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Change in fair value of convertible notes</a></td>
<td class="nump">7,469<span></span>
</td>
<td class="nump">11,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss', window );">Change in fair value of Series C convertible preferred stock</a></td>
<td class="nump">3,592<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">2,919<span></span>
</td>
<td class="nump">4,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment of leased assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Losses from equity investment</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Distribution from equity investment</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_IncreaseDecreaseInGrantReceivables', window );">Grants receivable</a></td>
<td class="num">(806)<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,016<span></span>
</td>
<td class="num">(2,020)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="num">(106)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(866)<span></span>
</td>
<td class="num">(5,607)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">3,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="num">(713)<span></span>
</td>
<td class="num">(560)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(27,506)<span></span>
</td>
<td class="nump">29,807<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(52,643)<span></span>
</td>
<td class="num">(22,888)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of fixed assets</a></td>
<td class="num">(382)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(382)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock upon IPO and Concurrent Private Placement, net of discount, commissions and offering costs</a></td>
<td class="nump">107,487<span></span>
</td>
<td class="num">(522)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of convertible notes and warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of Series C convertible preferred stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from loan from PPP</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_ProceedsFromFinancingObligation', window );">Proceeds from financing obligation</a></td>
<td class="nump">302<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from RSU settlement</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of financing obligation</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_PaymentsForForwardStockSplitFractionalShares', window );">Fractional share payments related to the forward stock split</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement upon vesting of restricted stock awards</a></td>
<td class="num">(2,458)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_PaymentsForBrokerWarrantExercises', window );">Exercise of broker warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants</a></td>
<td class="nump">861<span></span>
</td>
<td class="nump">751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">980<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">107,171<span></span>
</td>
<td class="nump">52,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign currency on cash</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(444)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">54,149<span></span>
</td>
<td class="nump">29,036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at the beginning of the period</a></td>
<td class="nump">34,607<span></span>
</td>
<td class="nump">5,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at the end of the period</a></td>
<td class="nump">88,756<span></span>
</td>
<td class="nump">34,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_StockRetired', window );">Retirement of treasury stock</a></td>
<td class="nump">4,210<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_IssuanceOfBrokerWarrants', window );">Issuance of broker warrants with Series C convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_AccruedInterestPremiumForConvertiblePreferredStock', window );">Accrued interest premium for Series C convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets exchanged for operating lease liabilities</a></td>
<td class="nump">624<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">Convertible notes issued in receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Deferred offering costs in accrued expenses or accounts payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Fixed assets purchased in accrued expenses or accounts payable</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of Series C preferred stock to common stock upon IPO</a></td>
<td class="nump">35,754<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_WarrantsExercised', window );">Net exercise of warrants upon IPO</a></td>
<td class="nump">13,509<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible notes</a></td>
<td class="nump">58,639<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Non-IPO Related Stock Transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible notes</a></td>
<td class="nump">460<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible notes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,254<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_AccruedInterestPremiumForConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Interest Premium For Convertible Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_AccruedInterestPremiumForConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments Subject to Mandatory Redemption by Settlement Terms, Change in Fair Value, Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_IncreaseDecreaseInGrantReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Grant Receivables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_IncreaseDecreaseInGrantReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_IssuanceOfBrokerWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Broker Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_IssuanceOfBrokerWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_NonCashPlacementAgentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Placement Agent Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_NonCashPlacementAgentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_PaymentsForBrokerWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Broker Warrant Exercises</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_PaymentsForBrokerWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_PaymentsForForwardStockSplitFractionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Forward Stock Split Fractional Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_PaymentsForForwardStockSplitFractionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ProceedsFromFinancingObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Financing Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ProceedsFromFinancingObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_StockRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Retired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_StockRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_WarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_WarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14172-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes issued in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=angn_NonIPORelatedStockTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=angn_NonIPORelatedStockTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939378774088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business and Financial Condition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of the Business and Financial Condition</a></td>
<td class="text">Description of the Business and Financial Condition<div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Angion Biomedica Corp. ("Angion" or", the "Company") is a clinical biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. The Company was incorporated in Delaware in 1998.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Forward Stock Split</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On January 25, 2021, the board of directors of the Company approved an amendment to the Company's certificate of incorporation to effect a forward stock split ("Forward Split") of shares of the Company's common stock on a one-for 1.55583 basis, which was effected on February 1, 2021. All references to common stock, convertible preferred stock, warrants to purchase common stock, stock options, restricted stock awards ("RSAs"), restricted stock units ("RSUs"), including restricted stock units with non-market performance and service conditions ("PSUs"), per share amounts and related information contained in the consolidated financial statements have been retroactively adjusted to reflect the effect of the forward stock split for all periods presented. No fractional shares of the Company's common stock were issued in connection with the Forward Split. Any fractional share resulting from the Forward Split was rounded down to the nearest whole share, and any stockholder entitled to fractional shares as a result of the Forward Split will received a cash payment in lieu of receiving fractional shares. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initial Public Offering and the Concurrent Private Placement</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 9, 2021, the Company&#8217;s registration statement on Form S-1 (File No. 333-252177) relating to its initial public offering (IPO) of common stock became effective. The IPO closed on February 9, 2021 at which time the Company issued 5,750,000 shares of its common stock at a price to the public of $16.00 per share, which includes the full exercise by the underwriters of their option to purchase an additional 750,000 shares of common stock. In addition to the shares being sold in the IPO, the Company sold an additional 1,562,500 shares of its common stock at the public offering price of $16.00 per share to entities affiliated with Vifor International, Ltd., an existing stockholder (the &#8220;Concurrent Private Placement&#8221;) for gross proceeds of $25.0&#160;million. Subsequent to the closing of the IPO, all of the outstanding shares of convertible preferred stock and outstanding convertible notes automatically converted into shares of common stock. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IPO and Concurrent Private Placement generated aggregate net proceeds of approximately $107.0&#160;million, after deducting the underwriting discounts and commissions, private placement fee and estimated offering expenses payable by the Company.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the closing of the IPO, there were no shares of convertible preferred stock outstanding and there were no convertible notes outstanding. In connection with the closing of the IPO, the Company restated its Restated Certificate of Incorporation to change the authorized capital stock to 300,000,000 shares designated as common stock, and 10,000,000 shares designated as preferred stock, with a par value of $0.01 per share and $0.01 per share, respectively. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company has devoted substantially all of its efforts and financial resources to conducting research and development activities, including drug discovery and pre-clinical studies and clinical trials, establishing and maintaining its intellectual property portfolio, organizing and staffing the Company, business planning, raising capital and providing general and administrative support for these operations. The Company has incurred losses from operations and negative cash flows from operating activities since inception and expects to continue to incur substantial losses for the next several years as it continues to fully develop and, if approved, commercialize its product candidates. As of December&#160;31, 2021, the Company had $88.8 million in cash and cash equivalents and an accumulated deficit of $215.1 million. Prior to its IPO, the Company has funded its operations through United States government grants, the issuance of convertible notes (see Note 6), sales of convertible preferred stock and common stock (see Notes 7) and warrants (see Note 10) and licensing agreements (see Note 12).</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The planned expansion of the Company's clinical and discovery programs will require significant funds. Management expects to continue to incur significant expenses and to incur operating losses for the foreseeable </span></div>future. The Company has evaluated and concluded there are no conditions or events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern for a period of one year following the date these consolidated financial statements are issued and believes its existing cash and cash equivalents will be sufficient to meet the projected operating requirements well into 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939384329320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company, its wholly owned subsidiary, Angion Biomedica Europe Limited, which was dissolved on March 16, 2021, and its wholly owned subsidiary, Angion Pty Ltd., which was established on August 22, 2019. The Company established Angion Pty Ltd., an Australian subsidiary, for the purpose of qualifying for research credits for studies conducted in Australia. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (&#8220;CODM&#8221;) in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to the useful lives of long-lived assets, the measurement of stock-based compensation, change in fair value of warrant liabilities prior to IPO, accruals for research and development activities, income taxes and revenue recognition. The Company bases its estimates on historical experience and on other relevant assumptions that are reasonable under the circumstances. Actual results could materially differ from those estimates.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Transactions</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States Dollar (&#8220;USD&#8221;) is the functional currency for the Company&#8217;s operations outside the United States. Accordingly, nonmonetary assets and liabilities originally acquired or assumed in other currencies are recorded in USD at the exchange rates in effect at the date they were acquired or assumed. Monetary assets and liabilities denominated in other currencies are translated into USD at the exchange rates in effect at the balance sheet date. Translation adjustments are recorded in other comprehensive income (loss) in the consolidated statements of operations. Gains and losses realized from non-USD transactions, including intercompany balances not considered as permanent investments, denominated in currencies other than an entity&#8217;s functional currency are included in other income (expense) in the accompanying consolidated statements of operations. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company's cash and cash equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash equivalents in securities and money market funds with original maturities less than three months.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no financial instruments with off-balance sheet risk of loss.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of December&#160;31, 2021 and 2020, the Company&#8217;s cash equivalents were held in institutions in the United States and included deposits in a money market fund which were unrestricted as to withdrawal or use.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grants Receivable</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grants receivable is comprised of unbilled amounts due from various grants from the National Institutes of Health ("NIH") and other U.S. government agencies for costs incurred prior to the period end under reimbursement contracts. All amounts are readily available for draw from the Federal Government Payment Management System and, accordingly, no allowance for doubtful amounts has been established. If amounts become uncollectible, they are charged to operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Offering Costs</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred offering costs consist of legal and accounting fees incurred through the balance sheet date that were directly related to the Company's IPO and were reflected as issuance costs upon the completion of the offering. Subsequent to the closing of the IPO, $2.8&#160;million of deferred costs previously included in prepaid expenses and other current assets were netted with additional paid in capital in the consolidated balance sheets. As of December 31, 2021 and 2020, the Company recorded deferred offering costs of zero and $2.0&#160;million, respectively. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and leasehold improvements are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over their estimated useful lives as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:67.668%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furniture and fixtures</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shorter of useful life or lease term</span></td></tr></table></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Normal repairs and maintenance costs are expensed as incurred.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, such as property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group to be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. The impairment losses as of December&#160;31, 2021 and 2020 were zero and $58&#160;thousand, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are carried at fair value under GAAP. Fair value is determined using the principles of ASC 820, Fair Value Measurement. Fair value is described as the price that would be received to sell an asset or </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy prioritizes and defines the inputs to valuation techniques as follows:</span></div><div style="margin-top:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1:&#160;&#160;&#160;&#160;Observable inputs such as quoted prices in active markets.</span></div><div style="margin-top:10pt;padding-left:76.5pt;text-indent:-49.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2:&#160;&#160;&#160;&#160;Inputs are observable for the asset or liability either directly or through corroboration with observable market data.</span></div><div style="margin-top:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3:&#160;&#160;&#160;&#160;Unobservable inputs.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inputs used to measure the fair value of an asset or a liability are categorized within levels of the fair value hierarchy. The fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the measurement. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's cash and cash equivalents, accounts payable and accrued expenses are carried at cost, which approximates fair value due to the short-term nature of these instruments.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its leases under ASC 842, Leases. Under this guidance, arrangements meeting the definition of a lease are classified as operating or finance leases, and are recorded on the consolidated balance sheets as both a right of use asset and a lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company's incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset results in straight-line rent expense over the lease term. Variable lease expenses are recorded when incurred.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In calculating the right of use assets and lease liabilities, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election, and recognizes rent expense on a straight-line basis over the lease term.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Related Party Entities</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds a 10% and a 2.4% interest in two entities, NovaPark, LLC ("NovaPark") and Ohr Cosmetics, LLC ("Ohr"), respectively. There is common ownership between the Director and Chairman Emeritus of the Company and each entity, and our Chief Executive Officer is also owns approximately 0.80% of the membership interests in Ohr. See Note 15. In accordance with ASC 323, Investments &#8212;Equity Method and Joint Ventures, the Company has significant influence but not control over NovaPark as its ownership in the limited liability company exceeds 3-5%. Accordingly, the Company records the NovaPark investment under the equity method of accounting. The Ohr investment is recorded at cost.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liability</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain common stock warrants outstanding as a liability, in accordance with ASC 815, Derivatives and Hedging, at fair value and adjusts the instruments to fair value at each reporting period. This liability is subject to re-measurement at each reporting period until exercised, and any change in fair value is recognized in the consolidated statements of operations as a component of other income (expense). The fair value of the warrants issued by the Company has been estimated using a variant of the Black Scholes option pricing model. The underlying equity included in the Black Scholes option pricing model was valued based on the closing price of common stock at each measurement date.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes Payable at Fair Value</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under ASC 825</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Instruments ("ASC 825"), the Company has elected the fair value option for recognition of its convertible notes. In accordance with ASC 825, the Company recognizes these convertible notes at fair value with changes in fair value recognized in the consolidated statements of operations. The fair value option may be applied instrument by instrument, but it is irrevocable. As a result of applying the fair value option, direct costs and fees related to the convertible notes were recognized in general and administrative </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense in earnings as incurred and not deferred. The estimated fair value of the convertible notes was determined by utilizing a present value cash flow model and the values of the equity underlying the conversion options were estimated using company equity values implied from the Subject Company Transaction Method which includes the back-solve and scenario-based methods (Probability Weighted Expected Return Method). See Note 4. Accrued interest for the notes has been included in the change in fair value of convertible notes in the consolidated statements of operations. All outstanding convertible notes were converted into common stock upon the close of the IPO on February 9, 2021 and no balances remained outstanding as of December&#160;31, 2021. See Note 6.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Preferred Stock</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series C convertible preferred stock included settlement features that result in liability classification. The initial carrying value of the Series C convertible preferred stock was accreted to the settlement value, the fair value of the securities issued upon the conversion of the Series C convertible preferred stock. The discount to the settlement value was accreted to interest expense using the effective interest method. During 2020, certain convertible notes were exchanged for Series C convertible preferred stock. As the exchange was accounted for as a modification, the Series C convertible preferred stock that was exchanged for the convertible notes was recorded at fair value and subject to re-measurement at each reporting period with gains and losses reported through our consolidated statements of operations. All outstanding shares of convertible preferred stock were converted into common stock upon the close of the Company&#8217;s IPO on February 9, 2021. See Note 7. As of December&#160;31, 2021, there was no convertible preferred stock outstanding.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records the repurchase of shares of common stock at cost based on the settlement date of the transaction. These shares are classified as treasury stock, which is a reduction to stockholders' equity. Treasury stock is included in authorized and issued shares but excluded from outstanding shares. As of December&#160;31, 2021, all outstanding treasury shares were retired in October 2021 upon approval by the Board of Directors. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any products approved for sale and has not generated any revenue from product sales. The Company&#8217;s revenue to date has been primarily derived from government funding consisting of U.S. government grants and contracts, and revenue under its license agreements.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Revenue</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenue earned from contracts with customers under Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASC 606"). Under ASC 606, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps:   &#160;&#160;&#160;&#160;</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Identify the contract(s) with a customer;</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Identify the performance obligations in the contract;</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Determine the transaction price;</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Allocate the transaction price to the performance obligations in the contract; and</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;Recognize revenue when (or as) the Company satisfies a performance obligation.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company assesses the goods or services promised within each contract, whether each promised good or service is distinct, and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements under which it may obtain upfront payments, milestone payments, royalty payments and other fees. Promises under these arrangements may include research licenses, research services, including selection campaign research services for certain replacement targets, the obligation to share information during the research and the participation of alliance managers and in joint research committees, joint patent committees and joint steering committees. The Company assesses these promises within the context of the agreements to determine the performance obligations.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Licenses of Intellectual Property</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: If a license to its intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring proportional performance for purposes of recognizing revenue from non-refundable, upfront payments. The Company evaluates the measure of proportional performance each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company evaluates whether the regulatory and development milestones are considered probable of being reached and estimate the amounts to be included in the transaction price using the most likely amount method. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones and any related constraint, and if necessary, adjust the estimate of the overall transaction price.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales-based milestones and royalties</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For sales-based royalties, including milestone payments based on the level of sales, the Company determines whether the sole or predominant item to which the royalties relate is a license. When the license is the sole or predominant item to which the sales-based royalty relates, the Company recognize revenue at the later of: (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any sales-based royalty revenue resulting from any license agreement.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is a contract liability, represents amounts received by the Company for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount expected to be recognized within one year from the consolidated balance sheet date based on the estimated performance period of the underlying performance obligation. The noncurrent portion of deferred revenue represents amounts expected to be recognized after one year through the end of the performance period of the performance obligation.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grant Revenue</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the Company's government grants are not within the scope of ASC Topic 606 as they do not meet the definition of a contract with a customer. The Company has concluded that the grants meet the definition of a contribution and are non-reciprocal transactions, and has also concluded that Subtopic 958-605, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit-Entities-Revenue Recognition</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, does not apply, as the Company is a business entity and the grants are with governmental agencies.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of applicable guidance under GAAP, the Company developed a policy for the recognition of grant revenue when the allowable costs are incurred and the right to payment is realized.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes this policy is consistent with the overarching premise in ASC Topic 606, to ensure that revenue recognition reflects the transfer of promised goods or services to customers in an amount that reflects the consideration that the Company expects to be entitled to in exchange for those goods or services, even though there is no exchange as defined in ASC Topic 606. The Company believes the recognition of revenue as costs are incurred and amounts become realizable is analogous to the concept of transfer of control of a service over time under ASC Topic 606.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs include, but are not limited to, payroll and personnel expenses, laboratory supplies, preclinical studies, compound manufacturing costs, consulting costs and allocated overhead, including rent, equipment, depreciation and utilities. Research and development cost maybe offset by research and development refundable tax rebates received by our wholly-owned Australian subsidiary. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with various Contract Research Organizations ("CROs") and third-party vendors. Research and development accruals of amounts due to the CRO are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued liabilities on the consolidated balance sheet. Payments made to CROs under such arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. The Company makes judgments and estimates in determining the accrued expenses balance in each reporting period. As actual costs become known, the Company adjusts its accrued expenses. For the years ended December&#160;31, 2021 and 2020, the Company has not experienced any material differences between accrued costs and actual costs incurred.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as incurred. For the years ended December&#160;31, 2021 and 2020, advertising costs were not significant.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for all stock-based payments to employees and non-employees, including grants of stock options, RSAs, RSUs, including "PSUs" to be recognized in the financial statements, based on their respective grant date fair values. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The RSAs, RSUs and PSUs are valued based on the fair value of the Company's common stock on the date of grant. The assumptions used in calculating the fair value of stock-based awards represent management's best estimates and involve inherent uncertainties and the application of management's judgment. The Company records expense for stock-based compensation related to stock options, RSAs and RSUs over the requisite service period. As the PSUs have a performance condition, compensation expense is recognized for each vesting tranche over the respective requisite service period of each tranche if and when the Company's management deems probable that the performance conditions will be satisfied. The Company may recognize a cumulative true-up adjustment related to PSUs once a condition becomes probable of being satisfied if the related service period had commenced in a prior period. All share-based compensation costs are recorded in general and administrative or research and development costs in the consolidated statements of operations based upon the respective employees or non-employee's roles within the Company. Forfeitures are recorded as they occur.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are recorded in accordance with ASC 740, Income Taxes ("ASC 740"), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share excludes the potential impact of convertible preferred stock, common stock options, warrants and unvested shares of restricted stock and restricted stock units because their effect would be anti-dilutive due to the Company's net loss. Since the Company had net losses for the years ended December&#160;31, 2021 and 2020, basic and diluted net loss per common share are the same.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss represents the net loss for the period and other comprehensive income. Other comprehensive income reflects certain gains and losses that are recorded as a component of stockholders&#8217; deficit and are not reflected in the statements of operations. The Company&#8217;s other comprehensive income consists of foreign currency translation adjustments. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. ASU No. 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. Early adoption is permitted for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company adopted this standard as of January 1, 2021, which did not have material impact on its consolidated financial statements and related disclosures. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes (ASU 2019-12), which is intended to simplify accounting for income taxes. It removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application. ASU 2019-12 was effective for the Company for fiscal years beginning after December 15, 2020, including interim periods therein. The Company adopted this standard as of January 1, 2021, which did not have material impact on its consolidated financial statements and related disclosures.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued ASU No. 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 (a consensus of the Emerging Issues Task Force). This update clarifies whether an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying the measurement alternative and how to account for certain forward contracts and purchased options to purchase securities. For public entities, this guidance was effective for fiscal years beginning after December 15, 2020. The Company adopted this standard as of January 1, 2021, which did not have material impact on its consolidated financial statements and related disclosures.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued ASU No. 2020-10, Codification Improvements. ASU 2020-10 provides amendments to a wide variety of topics in the FASB&#8217;s Accounting Standards Codification, which applies to all reporting entities within the scope of the affected accounting guidance. ASU 2020-10 was effective for the Company for fiscal years beginning after December 15, 2020, including interim periods therein. The Company adopted this standard as of January 1, 2021, which did not have material impact on its consolidated financial statements and related disclosures.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued Accounting Standards Update (ASU) 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. ASU 2021-10 requires business entities to disclose, in notes to their financial statements, information about certain types of government assistance they receive. ASU 2021-10 also adds a new Topic 832, Government Assistance, to the FASB&#8217;s Codification. ASU 2021-10 is effective for financial statements of all entities, including private companies, for annual periods beginning </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">after December 15, 2021, with early application permitted. The Company adopted this standard as of January 1, 2021, which did not have material impact on its consolidated financial statements and related disclosures.</span></div><div><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments (ASU No. 2016-13), which requires an entity to utilize a new impairment model known as the current expected credit loss (&#8220;CECL&#8221;) model to estimate its lifetime &#8220;expected credit loss&#8221; and record an allowance that, when deducted from the amortized cost basis of the financial assets and certain other instruments, including but not limited to available-for-sale debt securities. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. As an emerging growth company, ASU No. 2016-13 is effective for the Company for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company is currently evaluating the impact of the adoption of ASU No. 2016-13 on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939384322408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and Deferred Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue and Deferred Revenue</a></td>
<td class="text">Revenue and Deferred Revenue <div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grant Revenue </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our grants and contracts reimburse us for direct and indirect costs relating to the grant projects and also provide us with a pre-negotiated profit margin on total direct and indirect costs of the grant award, excluding subcontractor costs, after giving effect to directly attributable costs and allowable overhead costs. Funds received from grants and contracts are generally deemed to be earned and recognized as revenue as allowable costs are incurred during the grant or contract period and the right to payment is realized. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2021 and 2020, the Company recognized grant revenue of $0.8&#160;million and $2.7&#160;million, respectively. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Revenue </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contract revenue has been generated from payments received pursuant to a license agreement (the "Vifor License") with Vifor International, Ltd. ("Vifor Pharma") with headquarters located in Switzerland. The Company recognized revenue from upfront payments over the term of our estimated period of performance using a cost-based input method under Topic 606. The Company expects to continue recognizing revenue from upfront payments related to the Vifor License using the cost-based input method.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Vifor License Agreement</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020, the Company entered into a license agreement with Vifor Pharma, granting Vifor Pharma global rights (excluding China, Taiwan, Hong Kong and Macau) to develop, manufacture and commercialize ANG-3777 in all therapeutic, prophylactic and diagnostic uses for renal indications, including forms of acute kidney injury (AKI), and congestive heart failure (collectively, the Renal Indications). Pursuant to the Vifor License, the Company received $60&#160;million in upfront and equity payments, including $30&#160;million in up-front cash received in November 2020, and a $30&#160;million equity investment, $5&#160;million of which was a convertible note that subsequently converted into common stock with the IPO and $25&#160;million of which was received in the Concurrent Private Placement with the Company&#8217;s IPO. The Company is also eligible to receive post-approval milestones of up to approximately $260.0&#160;million and sales-related milestones of up to $1.585&#160;billion, providing a total potential deal value of up to $1.925&#160;billion (subject to certain specified reductions and offsets), plus tiered royalties on net sales of ANG-3777 at royalty rates of up to 40%. Under the Vifor License, the Company is responsible for executing a pre-specified clinical development plan designed to obtain regulatory approvals of ANG-3777 for delayed graft function (DGF) and AKI associated with cardiac surgery involving cardiopulmonary bypass (CSA-AKI). Based on the ANG-3777 clinical trial data disclosed in the fourth quarter of 2021, the Company does not expect to receive any </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">additional clinical, post-approval, or sales milestones, or royalties, as it does not intend to continue to pursue the clinical development plan for ANG-3777 set forth in the Vifor License. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 26, 2021, the Company announced that its Phase 3 trial of ANG-3777 in DGF did not achieve its primary endpoint and the data from the Phase 3 trial was not expected to provide sufficient evidence to support an indication in the studied DGF population. On December 9, 2021, the Company announced its Phase 2 trial of ANG-3777 in CSA-AKI did not achieve its primary endpoint and the data from the Phase 2 trial was not expected to provide sufficient evidence to support a Phase 3 trial in the studied CSA-AKI population. Angion and Vifor continue to analyze data from the CSA-AKI trial. The Company does not intend to continue the clinical development plan for ANG-3777 set forth in the Vifor License, which had included a Phase 3 study in CSA-AKI and a Phase 4 confirmatory study in DGF. In 2022, we and Vifor Pharma continue to work  to complete the planned analyses of the results of the clinical trials announced in the fourth quarter of 2021 and to discuss the future of the collaboration based upon such analyses.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Vifor Pharma may terminate the Vifor License at its sole discretion upon the earlier of (i) the acceptance for filing of an NDA covering products incorporating ANG-3777 filed with the FDA (after completion of the relevant Phase 3 clinical trial for such products), or (ii) the third anniversary of the effective date of the Vifor License. Both the Company and Vifor Pharma may terminate the Vifor License in its entirety if the other is in material breach of the Vifor License and has not cured the breach (if curable) within 60 days, or 90 days for incurable breach. In certain circumstances, in the event of the Company&#8217;s material breach of the Vifor License, Vifor Pharma may terminate the Vifor License with respect to certain major markets. In addition, both parties have the right to terminate the Vifor License upon insolvency of the other party. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company identified the following performance obligations in the Vifor License based upon the  clinical development plan for ANG-3777: (1) the global license (excluding greater China), (2) the development services, including the clinical development services including a post-approval confirmatory study, the technical development services and regulatory services and (3) the required participation on Joint Committees for coordination and oversight. The Company determined that the license is not capable of being distinct due to the specialized nature of the development services to be provided by the Company, and, accordingly, this promise was combined with the development services and participation in the joint committees as one single performance obligation. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to determine the transaction price, the Company evaluated all the payments to be received during the duration of the contract. Certain milestones and additional fees were considered variable consideration, which were not included in the transaction price at contract inception. The Company determined that the transaction price at the inception of the Vifor License is $15.0&#160;million, which is 50% of the $30.0&#160;million upfront payment due to the potential setoff defined in the contract. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the fourth quarter of 2021, the Company reported topline results from two ANG-3777 clinical trials under the Vifor License. The Company determined it will no longer continue the current clinical development plan for ANG 3777 DGF and CSA-AKI, which had included a Phase 3 study for CSA-AKI and a Phase 4 confirmatory study in DGF, given neither trial achieved statistical significance on its primary endpoint. In connection therewith, the Company adjusted the transaction price to include $15.0&#160;million in previously constrained variable consideration. As of December&#160;31, 2021, the Company concluded that it has significantly satisfied the performance obligation under Vifor License and will fully conclude the ANG-3777 project by the end of 2022. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Using the cost-based input method, the Company recognizes revenue based on actual costs incurred as a percentage of total estimated costs as the Company completes its performance obligation. The cumulative effect of revisions to estimated costs to complete the Company&#8217;s performance obligation will be recorded in the period in which changes are identified and amounts can be reasonably estimated. These actual costs consist primarily of internal full time equivalent (FTE) efforts and third-party contract costs related to the Vifor License.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company reassessed the performance period as the Company is currently closing out the planned analyses from both trials but does not intend to continue the clinical development plan for ANG-3777 set forth in the Vifor License,  which had included a Phase 3 study for CSA-AKI and a Phase 4 confirmatory study in DGF, given these clinical results. As such, the estimated date to fully conclude ANG-3777 by the end of December 2022 was determined to represent the completion of the Company&#8217;s performance obligation under the Vifor License. Additionally, the Company revised the total estimated costs for completion of the performance obligation to reflect </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the winding down of ANG-3777-related studies. The performance period is expected to end in the fourth quarter of 2022 instead of the fourth quarter of 2026. The effect of this change in estimate was an increase in contract revenue by $24.2&#160;million, a reduction in net loss by $24.2&#160;million and an increase in basic and diluted earnings per share by $0.86 for the year ended December&#160;31, 2021. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2021 and 2020, the Company recognized license revenue related to the Vifor License of $27.5&#160;million and $0.2&#160;million. As of December&#160;31, 2021, $2.3&#160;million was recorded as the current portion of deferred revenue on the consolidated balance sheet related to the Vifor License. As of December 31, 2020, $29.8&#160;million was recorded as deferred revenue on the consolidated balance sheet related to the Vifor License.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939384326232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table classifies the Company's financial assets and liabilities measured at fair value on a recurring basis into the fair value hierarchy as of December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Fair Value Measured at December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Quoted Prices in </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Active Markets for </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Identical </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Assets (Level 1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Significant </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Other </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Observable </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Inputs (Level 2)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Significant </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unobservable </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Inputs (Level 3)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Assets included in:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash and cash equivalents&#8212;Money market securities  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">87,252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">87,252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total fair value</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">87,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">87,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liabilities included in:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Warrants</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$114</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total fair value</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">114&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">114&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Fair Value Measured at December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Quoted Prices in </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Active Markets for </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Identical </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Assets (Level 1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Significant </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Other </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Observable </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Inputs (Level 2)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Significant </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unobservable </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Inputs (Level 3)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Assets included in:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash and cash equivalents&#8212;Money market securities  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total fair value</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liabilities included in:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Convertible notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Warrants</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Series C convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total fair value</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">64,392&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">64,392&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">___________________</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Included in cash and cash equivalents on the consolidated balance sheets. This balance includes cash requirements settled on a nightly basis.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers made among the three levels in the fair value hierarchy during periods presented.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in Level 3 liabilities measured at fair value (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Warrant <br/>Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Convertible <br/>Notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Series C Convertible Preferred Stock at Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Balance&#8212;December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">10,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">51,170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">64,392&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Conversion of convertible Series C convertible preferred stock into common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(6,110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(6,110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Conversion of convertible notes into common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(58,639)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(58,639)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net exercise of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(13,509)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(13,509)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">7,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">3,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">13,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Balance&#8212;December 31, 2021</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">114</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">114</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used an option model to measure the fair value of the Notes (on conversion date). The values of the equity underlying the conversion options in the model were estimated using equity values implied from sales of convertible preferred stock. The fair value of the Notes was impacted by the model selected as well as assumptions surrounding unobservable inputs. Key unobservable inputs include the expected volatility of the underlying equity, and the timing of an expected liquidity event.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the warrants issued by the Company has been estimated using a variant of the Black Scholes option pricing model. The underlying equity included in the Black Scholes option pricing model was valued based on the equity value implied from sales of preferred and common stock at each measurement date. The fair value of the warrants was impacted by the model selected as well as assumptions surrounding unobservable inputs including the underlying equity value, expected volatility of the underlying equity, risk free interest rate and the expected term.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value adjustment during the year ended December&#160;31, 2021 was based on the final settlement amount using a conversion price of $11.57 per share on February 9, 2021. Subsequent to the closing of the IPO, there were no convertible notes outstanding.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series C Preferred Stock </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value adjustment during the year ended December&#160;31, 2021 was based on the final settlement amount using a conversion price of $11.57 per share on February 9, 2021. Subsequent to the closing of the IPO, there were no shares of convertible preferred stock outstanding. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liability</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value adjustment for the net exercise of warrants with an exercise price of $6.43 during the year ended December&#160;31, 2021 was based on the final settlement amount using the IPO price on February 9, 2021. Subsequent to the closing of the IPO, the fair value of the warrants issued by the Company were estimated using a variant of the Black Scholes option pricing model. The underlying equity included in the Black Scholes option pricing model was valued based on the closing price of common stock at each measurement date.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, the fair value of the warrants increased by $2.9&#160;million and $4.9&#160;million, respectively. The change in fair value of warrant liability in both periods was recognized in the consolidated statements of operations. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the Company's warrant liabilities that were categorized within Level 3 of the fair value hierarchy as of December&#160;31, 2021 and 2020 was as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Strike price</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.01&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractual term (years)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Volatility (annual)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">74.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">86.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free rate</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield (per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939382347368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet Components<div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">R&amp;D tax credit receivable </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also recorded an Australian tax credit as provided by the Australian Taxation Office for qualified research and development expenditures incurred through its subsidiary, Savara Australia Pty. Limited. Under Australian tax law, Australia remits a research and development tax credit equal to 43.5% of qualified research and development expenditures, not to exceed established thresholds. During the year ended December&#160;31, 2021, the Company generated an Australian tax credit of $0.8&#160;million which was included in prepaid expenses and other current assets on the consolidated balance sheets and the Company received the tax credit in January 2022. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's property and equipment, net was comprised of the following (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">512&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furniture and fixtures</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total property and equipment</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">968&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">582&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less: accumulated depreciation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(517)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(426)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">451&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">156&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the years ended December&#160;31, 2021 and 2020 was $0.1 million.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid and Other Current Assets</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Prepaid and other current assets were comprised of the following (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred Offering costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,978&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid clinical fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Business insurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Security deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Convertible note receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Angion Pty tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total prepaid and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,685&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,690&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses were comprised of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued compensation</span></div></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,274&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,154&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued direct research costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued operating expenses</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">749&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">707&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total accrued expenses</span></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,219&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6,665&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939384369384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Notes Payable</a></td>
<td class="text">Convertible Notes Payable<div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company had convertible notes with an aggregate principal amount of $39.8 million and $1.8 million accrued interest outstanding. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion of Convertible Notes Payable </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In January 2021, the Company issued 33,978 shares of common stock upon the conversion of certain of the outstanding 2020 Notes. In connection with the IPO in February 2021, with an IPO price of $16.00 per share, the remaining outstanding convertible notes were converted into 3,636,189 shares of the Company&#8217;s common stock based on a conversion price of $11.57 per share. There were no convertible notes outstanding as of December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939384384008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Series C Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionDisclosureTextBlock', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">Series C Convertible Preferred Stock <div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate values recorded for the Series C convertible preferred stock as of December 31, 2020 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.201%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">At issuance </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Series C convertible preferred stock recorded at amortized cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Principal</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">22,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">22,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Settlement premium</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">5,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">5,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Unamortized discounts and fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(9,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(1,884)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net carrying amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">18,635&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">26,001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Series C convertible preferred stock recorded at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Series C convertible preferred stock issued in exchange for convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2,254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Change in fair value of Series C convertible preferred stock exchanged for convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total Series C convertible preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">28,519&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion of Series C Convertible Preferred Stock</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In connection with the IPO in February 2021, with an initial public offering price of $16.00 per share, all shares of Series C convertible preferred stock outstanding plus accrued dividends were automatically converted into an aggregate of 2,234,640 shares of common stock with a conversion price of $11.57 per share. There were no shares of convertible preferred stock outstanding as of December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments Subject to Mandatory Redemption Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_FinancialInstrumentsSubjectToMandatoryRedemptionDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939381947256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Common Stock</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are not entitled to receive dividends, unless declared by the Board of Directors.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Treasury stock</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The retirement of treasury stock was recorded as a reduction of common stock and additional paid-in capital at the time such retirement was approved by our Board of Directors in October 2021.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, zero and $1.8 million was included in treasury stock in the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939382070056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2015 Plan </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Company approved an Amended and Restated 2015 Equity Incentive Plan (the "2015 Plan") permitting the granting of incentive stock options, non-statutory stock options, restricted stock and other stock-based awards. Following the effectiveness of the 2021 Equity Incentive Plan ("2021 Plan"), the Company ceased making grants under the 2015 Plan. However, the 2015 Plan continues to govern the terms and conditions of the outstanding awards granted under it. Shares of common stock subject to awards granted under the 2015 Plan that cease to be subject to such awards by forfeiture or otherwise after the termination of the 2015 Plan will be available for issuance under the 2021 Plan. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Plan </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, the Company's board of directors approved the 2021 Plan which permits the granting of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards to employees, directors, officers and consultants. On January 25, 2021, shares of common stock equal to 11% of the post-IPO capitalization, with annual increases, up to a maximum of 60,000,000 shares of common stock were authorized for issuance under the 2021 Plan.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each employee and non-employee stock option grant was estimated on the date of grant using the Black-Scholes option-pricing model based on the following inputs:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">0.7%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">0.7%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Expected dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Expected term in years </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">5.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">71.8% - 73.1%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">70.8% - 86.8%</span></div></td></tr></table></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these inputs is subjective and generally requires significant judgment.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Term</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The expected term represents the period that the Company&#8217;s stock-based awards are expected to be outstanding and is determined using the simplified method, which is based on the mid-point between the contractual term and vesting period.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility&#8212;The Company determines volatility based on the historical volatilities of comparable publicly traded life science companies over a period equal to the expected term because it does not have sufficient trading history for its common stock price. The comparable companies were chosen based on the similar size, stage in the life cycle, or area of specialty. The Company will continue to apply this process until a sufficient amount of historical information regarding volatility on its own stock becomes available.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-Free</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Interest Rate</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Yield</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has never paid and has no plans to pay any dividends on its common stock. Therefore, the Company has used an expected dividend yield of zero.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> of Common Stock</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;For periods prior to the IPO, the Company determined the estimated fair value of its common stock using the Subject Company Transaction Method which includes the back-solve and scenario-based methods (Probability Weighted Expected Return Method) to arrive at estimated fair values. Subsequent to the IPO, the fair value was based on the closing price of the Company&#8217;s common stock on the grant date. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following assumptions were used to estimate the fair value of stock option awards: The following table summarizes information as of December&#160;31, 2021 and activity during 2021 related to the Company&#8217;s stock option plans:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Number of <br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Weighted <br/>Average <br/>Exercise <br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Weighted <br/>Average <br/>Remaining <br/>Contractual <br/>Life (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Total <br/>Intrinsic <br/>Value <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">3,479,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">6.97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">8.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">15,140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">1,103,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">15.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Options forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(189,388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">13.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Options exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(152,939)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">6.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Options expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(10,963)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">7.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">4,230,162&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">8.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">7.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Options vested and exercisable</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2,499,165&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">7.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">7.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value in the above table is calculated as the difference between the estimated fair value of the Company's common stock price and the exercise price of the stock options. The weighted average grant date fair value per share for the stock option grants during the years ended December&#160;31, 2021 and 2020  were $10.25 and $5.48, respectively. As of December&#160;31, 2021, the total unrecognized compensation related to unvested stock option awards granted was $6.1 million, which the Company expects to recognize over a weighted-average period of approximately 2.4 years.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock and Restricted Stock Units</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's RSA and RSU activity for the years ended December&#160;31, 2021 were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Shares of <br/>Restricted Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Weighted <br/>Average Grant <br/>Date Fair Value <br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Restricted <br/>Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Weighted <br/>Average Grant <br/>Date Fair Value <br/>Per Share</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">14,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">6.05&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">74,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">7.78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(14,586)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">6.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(43,875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">8.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(12,764)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">6.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">17,505&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">9.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Vested as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">43,875&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">8.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-based Restricted Stock Units</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had 556,530 PSUs outstanding that were granted in June 2019. Vesting of the PSUs is dependent upon the satisfaction of both a service condition and a performance condition, an initial public offering or a change of control, as defined in the 2015 Plan. As the IPO occurred in February 2021, the performance condition was met and 185,510 PSUs vested and were released upon the closing of the IPO. Another 185,510 PSUs vested and released were in June 2021 upon the second anniversary of the grants. A</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company had 185,510 PSUs outstanding.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total stock-based compensation expense for the stock options, RSUs, RSAs, PSUs compensation issued in shares recorded in the consolidated statements of operations (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12,041&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,716&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the board of directors of the Company approved the Employee Stock Purchase Plan (the "ESPP"). The ESPP was effective on the date immediately prior to the effectiveness of the Company's registration statement relating to the IPO. A total of 390,000 shares of common stock were initially reserved for issuance under the ESPP. The offering period and purchase period will be determined by the Board of Directors. As of December&#160;31, 2021, 390,000 shares under the ESPP remain available for purchase and no offerings had been authorized.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939384385576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_WarrantsAndRightsOutstandingAbstract', window );"><strong>Warrants and Rights Outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_WarrantsAndRightsOutstandingTextBlock', window );">Warrants</a></td>
<td class="text">Warrants<div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the outstanding warrants to purchase the Company's common stock were comprised of the following:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.549%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exercise <br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Expiration <br/>Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Warrants at December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Warrants issued with 2015 Notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">6.43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">7/5/28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">388,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Warrants issued with 2016 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">6.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">7/5/28</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">538,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Warrants issued with 2017 Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">6.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">7/5/28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">79,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Warrants issued with 2018 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">6.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">7/5/28</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">498,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Warrants issued with Conversion of Notes to Common Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">8.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">8/31/28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">232,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">238,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Warrants issued with Units in the Equity Offering</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">8.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">8/31/28</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">875,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">907,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Broker Warrants issued with Equity Offering</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">8/31/25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">1,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">48,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Broker Warrants issued with 2019 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">0.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">1/30/20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Consultant Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">7.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">8/31/28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">39,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">39,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Total Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">1,148,123&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">2,739,791&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 815, the warrants classified as liabilities are recorded at fair value at the issuance date, with changes in the fair value recognized in the consolidated statements of operations at the end of each reporting period. Refer to Note 4 for changes in the fair value recognized during the periods reported.  </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 815, the warrants classified as equity do not meet the definition of a derivative and are classified in stockholders' equity (deficit) in the consolidated balance sheets.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's warrant activity for the year ended December&#160;31, 2021 was as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Warrants</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Average </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exercise </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Average </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Remaining </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Contractual </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Life (in years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Balance&#8212;December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,739,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.9</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exercised </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,588,756)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expired</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2,912)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Balance&#8212;December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,148,123&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.2</span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________________________</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) 613,892 shares from warrant exercised were tendered back to the Company to cover the exercise price of the warrant.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion of Warrants</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, all warrants outstanding issued with 2015 Notes, 2016 Notes, 2017 Notes, and 2018 Notes   with an exercise price of $6.43 per share were net exercised into an aggregate of 844,335 shares of common stock upon the IPO with a conversion price of $11.57 per share.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_WarrantsAndRightsOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants and Rights Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_WarrantsAndRightsOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_WarrantsAndRightsOutstandingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants And Rights Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_WarrantsAndRightsOutstandingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939382380872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office and laboratory space in Uniondale, New York from NovaPark, a related party, under an agreement classified as an operating lease that expires on June 20, 2026. The Company's lease does not require any contingent rental payments, impose any financial restrictions, or contain any residual value guarantees. Variable expenses generally represent the Company's share of the landlord's operating expenses, including management fees. The Company does not act as a lessor or have any leases classified as financing leases.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office space in Fort Lee, New Jersey, comprising approximately 2,105 square feet for approximately $0.1&#160;million per year, under a non-cancelable operating lease through March 31, 2022. However, this arrangement is excluded from the calculation of lease liabilities and right of use assets as its term is less than one year. The lease is subject to charges for common area maintenance and other costs. The Company is not going to renew the New Jersey lease after March 31, 2022.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company entered into a lease for office furniture in San Francisco, California set to expire in July 2025, with an annual lease payment of approximately $13,000. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the Company entered into a lease for clinical and regulatory space in Newton, Massachusetts (the &#8220;Newton lease&#8221;), comprising approximately 6,157 square feet for approximately $0.2&#160;million per year, under a non-cancelable operating lease through June 30, 2024. Pursuant to the Newton lease, the Company had 4 months of free rent starting from February 15, 2021 to June 14, 2021. The Company has one option to extend the term of the lease for 3 years with 9 months&#8217; notice.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the components of the Company's rent expense (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">For the Year Ended <br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease cost</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Variable cost</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease expense</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,615&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 13pt 0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,745&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Short-term lease rent expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total rent expense</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,659&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,836&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes quantitative information about the Company's NovaPark operating leases (dollars in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">For the Year Ended <br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating cash flows from operating leases</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets exchanged for operating lease liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average remaining lease term&#8212;operating leases (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average discount rate&#8212;operating leases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, maturities of lease liabilities were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,423&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less present value discount</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,054)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,369&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing obligation</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Company entered into a sale and leaseback arrangement with a third-party financing institution as a financing mechanism to fund certain of its capital expenditures primarily related to operating equipment, whereby the physical asset is sold concurrent with an agreement to lease the asset back. The initial leaseback term is 42 months starting from November 2021. The arrangement includes a renewal option as well as a repurchase option at fair value with a cap at the end of the term. The arrangement does not qualify as an asset sale as control of the equipment did not transfer to the third party and is accounted for as a failed sale-leaseback. Therefore, the Company accounts for the arrangement as a financing transaction and records the proceeds received as a financing obligation. The leased assets are included in property and equipment, net on the consolidated balance sheets and are subject to depreciation. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, the Company received $0.3&#160;million in connection with the sale and leaseback of certain equipment. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes quantitative information about the Company's financing obligation (dollars in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.040%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.760%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">For the Year Ended December 31, </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Proceeds from sale and leaseback arrangement</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Payments of financing obligation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating cash flows from financing obligation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from financing obligation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Other information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average remaining lease term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average discount rate (in percent)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Carrying value of leased asset included in Property and Equipment, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation associated with the leased asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, maturities of financing obligation were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less present value discount</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financing obligation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">293&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the fair value of these agreements is minimal.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Paycheck Protection Program</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company received funds in the amount of $0.9&#160;million pursuant to a loan under the Paycheck Protection Program of the 2020 CARES Act ("PPP") administered by the Small Business Association. The loan has an interest rate of 1.0% and a term of 24 months. No payments were due for the first 16 months, although interest accrued, and monthly payments were due over the next 8 months to retire the loan plus accrued interest. Funds </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from the loan could only be used for certain purposes, including payroll, benefits, rent and utilities, and a portion of the loan used to pay certain costs were forgivable, all as provided by the terms of the PPP. The loan was evidenced by a promissory note, which contained customary events of default relating to, among other things, payment defaults and breaches of representations and warranties. The SBA approved the Company's PPP Loan forgiveness application on May 26, 2021 for the entire principal amount of the PPP Loan and accrued interest. As a result, the Company recorded a gain on the forgiveness of the loan in the amount of $0.9&#160;million. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Retention Credit ("ERC")</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Employee Retention Credit ("ERC") under the CARES Act is a refundable tax credit which encourages businesses to keep employees on the payroll during the COVID-19 pandemic. Eligible employers could qualify for up to $5,000 of credit for each employee based on qualified wages paid after March 12, 2020 and before January 1, 2021. The Internal Revenue Service ("IRS") subsequently issued Notice 2021-23 and Notice 2021-49 which collectively extended the ERC eligibility to cover qualified wages paid after December 31, 2020 and before January 1, 2022. Qualified wages are the wages paid to an employee for the time that the employee is not providing services due to an economic hardship, specifically, either (1) a full or partial suspension of operations by order of a governmental authority due to COVID-19, or (2) a significant decline in gross receipts. </span></div>During the years ended December 31, 2021 and 2020, the Company received $1.5&#160;million and zero, respectively for ERC and applied the benefit as a reduction to the payroll expenses in the consolidated statement of operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939384385576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized no tax provision for the year ended December 31, 2021 and December 31, 2020. The difference between the Company's effective tax rate of 0% and the U.S. federal statutory tax rate of 21% is largely due to the Company's net operating losses, which are offset by the corresponding valuation allowance. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company has established a valuation allowance against net deferred tax assets due to the uncertainty that such assets will be realized. The Company periodically evaluates the recoverability of the deferred assets. At such time as it is determined that it is more likely than not that the deferred tax asset will be realized, the valuation allowance will be reduced.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Losses before income taxes includes the following components:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:72.451%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.828%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(53,547)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(78,164)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(1,026)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(1,943)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(54,573)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(80,107)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes provision (benefit) for the years ended December&#160;31, 2021 and 2020 consists of the following (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:72.451%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.828%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">United States</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Current</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(5,460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(12,129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(4,779)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(522)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">10,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">12,651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Deferred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total tax provision</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations between the federal statutory income tax rate and the Company's effective income tax rate were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:72.451%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.828%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Federal statutory income tax rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">State taxes, net of federal tax benefit</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">R&amp;D and other tax credit changes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Permanent items</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(7.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(4.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Nontaxable Income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(10.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(15.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Effective income tax rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">0.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">0.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company's deferred tax asset at December&#160;31, 2021 and 2020 were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net operating loss carryforwards</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">R&amp;D and other tax credit carryovers</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liability</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued compensation and other expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fixed assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total deferred tax assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40,793&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30,344&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fixed assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right of use assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,046)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(874)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Valuation allowance</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(39,710)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(29,470)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax assets, net of allowance</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company has federal net operating loss carryforwards of approximately $118.5&#160;million available to reduce future taxable income, if any, for federal income tax purposes. Approximately $9.6&#160;million of federal net operating losses can be carried forward to future tax years and begin to expire in 2035. The federal net operating losses generated for the years beginning after December 31, 2017, approximately $108.9&#160;million in total, can be carried forward indefinitely. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NOL carryforward may be subject to an annual limitation under Section 382 and 383 of the Internal Revenue Code of 1986, and similar state provisions if the Company experienced one or more ownership changes which would limit the amount of NOL and tax credit carryforwards that can be utilized to offset future taxable income and tax respectively. In general, an ownership change as defined by Section 382 and 383, results from the transactions increasing ownership of certain stockholders or public groups in the stock of the corporation of more than 50 percentage points over a three-year period. The Company has not completed a Section 382 and 383 analysis to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company's formation due to the complexity and cost associated with such study and the fact there may be additional such ownership changes in the future. If a change in ownership were to have occurred or occurs in the future, the NOL and tax credits carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company's effective tax rate.</span></div><div style="margin-top:1pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:1pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the United States, California, Massachusetts, New York and New Jersey. Due to the Company's losses incurred, the Company is subject to the income tax examination by authorities since inception. The Company's policy is to recognize interest expense and penalties related to income tax matters as tax expense. As of December&#160;31, 2021 and 2020, there were no significant accruals for interest related to unrecognized tax benefits or tax penalties.</span></div><div style="margin-top:1pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:1pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, the Company's reserve for unrecognized tax benefits is approximately $3.7&#160;million. Due to the full valuation allowance at December 31, 2021, current adjustments to the unrecognized benefits will have no impact to the Company's effective income tax rate.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reconciliation of uncertain tax positions as of December 31, 2021 and 2020 was as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning Balance </span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,579&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions for current year</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions for prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ending Balance</span></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,675&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,579&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amount of unrecognized tax benefits, if recognized, would affect the effective tax rate was as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.200%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unrecognized benefits that would affect the effective tax rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unrecognized benefits that would not affect the effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total unrecognized benefits</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,675&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,579&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not anticipate material changes to its uncertain tax positions for the next twelve months.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the 2018 Act that amends the Internal Revenue Code that reduced the U.S. corporate tax rate from 35% to 21% effective January 1, 2018 and modified policies, credits, and deductions (the "Tax Act"), the SEC staff issued Staff Accounting Bulletin No. 118 ("SAB 118") to address the application of GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. The Company has completed its evaluation and determined that there was no net impact on the Company's consolidated financial statements for the years ended December&#160;31, 2021 and 2020 as the corresponding adjustment was made to the valuation allowance.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939381960728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text">Employee Benefit PlanEmployee Benefit PlanThe Company sponsors a retirement savings plan that is intended to qualify for favorable tax treatment under Section 401(a) of the Code, and contains a cash or deferred feature that is intended to meet the requirements of Section 401(k) of the Code. Participants may make pre-tax and certain after-tax (Roth) salary deferral contributions to the plan from their eligible earnings up to the statutorily prescribed annual limit under the Code. Participants who are 50 years of age or older may contribute additional amounts based on the statutory limits for catch-up contributions. Participant contributions are held in trust as required by law. No minimum benefit is provided under the plan. An employee&#8217;s interest in his or her salary deferral contributions is 100% vested when contributed. Contributions, subject to established limits, are matched at a dollar for dollar rate up to 3% of an individual&#8217;s earnings and fifty cents on the dollar on the next 4-5% of earnings.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -URI http://asc.fasb.org/subtopic&amp;trid=2235116<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939382377224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of the Company&#8217;s basic and diluted net loss per share attributable to common stockholders, which excludes shares which are legally outstanding but subject to repurchase by the Company (in thousands, except share and per share data):</span></div><div style="margin-top:10pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:72.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.023%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Numerator</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net loss attributable to common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(54,573)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(80,107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,244,825</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,762,120</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net loss per share attributable to common stockholders, basic and diluted</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(1.93)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(5.43)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share because to do so would be anti-dilutive:</span></div><div style="margin-top:10pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:71.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Shares issuable upon exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,230,162</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,479,731</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Shares issuable upon the exercise of warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,148,123</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,739,791</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Shares issuable upon conversion of the convertible notes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">5,603,388</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Shares issuable upon conversion of the Series C preferred stock</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">3,920,172</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Non-vested shares under restricted stock unit grants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">203,015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">58,951</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Non-vested shares under restricted stock grants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">14,585</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total </span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">5,581,300</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">15,816,618</span></td></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">___________________________________</span></div><div style="margin-top:10pt;padding-left:49.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.24pt">The number of shares issuable upon conversion of the 2019 Notes, 2020 Notes and Series C preferred stock has been estimated using the Company's common stock fair value at December 31, 2020, discounted by 20%.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939382002296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ohr Investment</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In a series of investments in November 2013 and July 2017, the Company invested a total of $150,000 to acquire a membership interest in Ohr Cosmetics, LLC ("Ohr"), an affiliated company.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owns and the family of the Company's director and Chairman Emeritus owns approximately 2.4% and 80.6%, respectively, of the membership interests in Ohr. Our Chief Executive Officer is also owns approximately 0.80% of the membership interests in Ohr. The Chairman Emeritus&#8217;s son is the manager of Ohr.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2013, the Company granted Ohr an exclusive worldwide license, with the right to sublicense, under the Company's patent rights covering one of the Company's CYP26 inhibitors, ANG-3522, for the use in treating conditions of the skin or hair. Sublicensees may not grant further sublicenses under the Company's patent rights other than to affiliates of such sublicensees and entities with which sublicensees are collaborating for the research, development, manufacture and commercialization of the products. Ohr will pay the Company a royalty at a rate in the low single digits on gross revenue of products incorporating ANG-3522, and milestone payments potentially totaling up to $9.0&#160;million based on achievement of sales milestones. Royalties and milestone payments will be paid until the later of 15 years from the first commercial sale of a licensed product or the last to expire licensed patent rights. The royalty rate is subject to adjustments under certain circumstances. The Company believes that the Ohr License was made on terms no less favorable to the Company than those that the Company could obtain from unaffiliated third parties.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No revenue from this license agreement was recognized for the years presented. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NovaPark Investment and Lease</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had a 10% interest in NovaPark. Members of the Company's director and Chairman Emeritus&#8217;s 's immediate family own a majority of the membership interests of NovaPark. The Company accounts for its aggregate 10% investment in NovaPark under the equity method. The following table provides the activity for the NovaPark investment for the years ended December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.838%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning balance</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">849&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Losses of equity method investment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(71)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Distribution from NovaPark</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ending balance</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">573&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">672&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company rents office and laboratory space in Uniondale, New York from NovaPark under a lease that expires June 20, 2026. The Company recorded rent expense for fixed lease payments of $1.1 million and $1.0 million for the years ended December&#160;31, 2021 and 2020, respectively. The Company recorded rent expense for variable expenses related to the lease of $0.5 million and $0.6 million for the years ended December&#160;31, 2021 and 2020, respectively. See Note 11. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the IPO in February 2021, Victor Ganzi, Gilbert Omenn and Karen Wilson, directors of the Company, and Raj Venkatesan, brother of the Chief Executive Officer and director of the Company, converted all their outstanding convertible notes into an aggregate of 149,500 shares of common stock with a conversion price of $11.57. As of December&#160;31, 2021, there were no convertible notes outstanding.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series C Convertible Preferred Stock</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the IPO in February 2021, Jay Venkatesan, M.D., the President and Chief Executive Officer and director of the Company converted all his outstanding preferred stock into an aggregate of 165,094 shares of common stock with a conversion price of $11.57 per share. As of December&#160;31, 2021, there were no shares of convertible preferred stock outstanding.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consultant Fees</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Angion paid consulting fees under an agreement with the wife of the director and Chairman Emeritus of the Company for Company management services. Consultant fees paid to the wife were approximately zero and $0.1 million in the years ended December&#160;31, 2021 and 2020, respectively. This consultant agreement was terminated in February 2022.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Dr. Michael Yamin, a former member of the Board of Directors of the Company, is a Scientific Advisor for Pearl Cohen Zedek Latzer Baratz LLP (Pearl Cohen). In the years ended December&#160;31, 2021 and 2020, the Company paid Pearl Cohen $3.9&#160;thousand and $0.1&#160;million in legal fees, respectively.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, the Company also entered into a consulting agreement with Dr. Yamin pursuant to which he agreed to provide consulting services to the Company in the areas of biomedical research and development. Pursuant to the terms of the consulting agreement, Dr. Yamin, in his capacity as a consultant, received $0.1 million during each of the years ended December&#160;31, 2021 and 2020. Dr. Yamin resigned from the Company's Board of Directors in March 2020. Dr. Yamin's resignation was not due to any disagreement with the Company, the Board or management of the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939384349096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 4, 2022, the Company announced a reduction in force impacting somewhat less than half of its current employees. The Company&#8217;s decision to engage in this reduction resulted from an assessment of its internal resources needs, given the results of the Phase 3 study of ANG-3777 in patients at risk for DGF would likely not support a regulatory approval in that population and the Phase 2 study in CSA-AKI would not support a Phase 3 trial in that indication. This reduction was a cost-cutting measure across the organization to support the Company&#8217;s 2022 primary focus on the clinical development of its investigational asset ANG-3070, a highly selective, oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, particularly in the kidney and lung, as well as advancing preclinical assets to IND-enabling studies.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 25, 2022, the Company entered into a Separation Agreement with Itzhak D. Goldberg, M.D., who formerly served as Executive Chairman and Chief Scientific Officer and currently serves as a director and Chairman Emeritus on our Board.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the terms of the Separation Agreement, Dr. Goldberg will receive severance benefits of approximately $1.1&#160;million. Under our Amended and Second Restated 2015 Equity Incentive Plan and our 2021 Incentive Award Plan, Dr. Goldberg will continue to vest his PSUs and stock options and exercisability of his options, so long as he remains in continuous service with the Company as a director on the Board or otherwise. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 1, 2022, the Company entered into a Separation Agreement with Elisha Goldberg, former employee and son of Itzhak D. Goldberg, M.D., who currently serves as a director and Chairman Emeritus on the Company&#8217;s Board.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the terms of the Separation Agreement, Mr. Goldberg will receive severance benefits of approximately $0.5&#160;million. Mr. Goldberg will also have the right to exercise any vested stock options he may have received under our Amended and Second Restated 2015 Equity Incentive Plan or our 2021 Incentive Award Plan until December 31, 2022, which extended the exercise period by 11 months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939477987608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company, its wholly owned subsidiary, Angion Biomedica Europe Limited, which was dissolved on March 16, 2021, and its wholly owned subsidiary, Angion Pty Ltd., which was established on August 22, 2019. The Company established Angion Pty Ltd., an Australian subsidiary, for the purpose of qualifying for research credits for studies conducted in Australia. All significant intercompany balances and transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (&#8220;CODM&#8221;) in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to the useful lives of long-lived assets, the measurement of stock-based compensation, change in fair value of warrant liabilities prior to IPO, accruals for research and development activities, income taxes and revenue recognition. The Company bases its estimates on historical experience and on other relevant assumptions that are reasonable under the circumstances. Actual results could materially differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation and Transactions</a></td>
<td class="text">Foreign Currency Translation and TransactionsThe United States Dollar (&#8220;USD&#8221;) is the functional currency for the Company&#8217;s operations outside the United States. Accordingly, nonmonetary assets and liabilities originally acquired or assumed in other currencies are recorded in USD at the exchange rates in effect at the date they were acquired or assumed. Monetary assets and liabilities denominated in other currencies are translated into USD at the exchange rates in effect at the balance sheet date. Translation adjustments are recorded in other comprehensive income (loss) in the consolidated statements of operations. Gains and losses realized from non-USD transactions, including intercompany balances not considered as permanent investments, denominated in currencies other than an entity&#8217;s functional currency are included in other income (expense) in the accompanying consolidated statements of operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Off-Balance Sheet Risk</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company's cash and cash equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash equivalents in securities and money market funds with original maturities less than three months.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has no financial instruments with off-balance sheet risk of loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of December&#160;31, 2021 and 2020, the Company&#8217;s cash equivalents were held in institutions in the United States and included deposits in a money market fund which were unrestricted as to withdrawal or use.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Grants Receivable</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grants Receivable</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grants receivable is comprised of unbilled amounts due from various grants from the National Institutes of Health ("NIH") and other U.S. government agencies for costs incurred prior to the period end under reimbursement contracts. All amounts are readily available for draw from the Federal Government Payment Management System and, accordingly, no allowance for doubtful amounts has been established. If amounts become uncollectible, they are charged to operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text">Deferred Offering CostsDeferred offering costs consist of legal and accounting fees incurred through the balance sheet date that were directly related to the Company's IPO and were reflected as issuance costs upon the completion of the offering.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and leasehold improvements are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over their estimated useful lives as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:67.668%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furniture and fixtures</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shorter of useful life or lease term</span></td></tr></table></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Normal repairs and maintenance costs are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">Impairment of Long-Lived AssetsLong-lived assets, such as property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group to be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are carried at fair value under GAAP. Fair value is determined using the principles of ASC 820, Fair Value Measurement. Fair value is described as the price that would be received to sell an asset or </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy prioritizes and defines the inputs to valuation techniques as follows:</span></div><div style="margin-top:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1:&#160;&#160;&#160;&#160;Observable inputs such as quoted prices in active markets.</span></div><div style="margin-top:10pt;padding-left:76.5pt;text-indent:-49.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2:&#160;&#160;&#160;&#160;Inputs are observable for the asset or liability either directly or through corroboration with observable market data.</span></div><div style="margin-top:10pt;padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3:&#160;&#160;&#160;&#160;Unobservable inputs.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inputs used to measure the fair value of an asset or a liability are categorized within levels of the fair value hierarchy. The fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the measurement. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's cash and cash equivalents, accounts payable and accrued expenses are carried at cost, which approximates fair value due to the short-term nature of these instruments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its leases under ASC 842, Leases. Under this guidance, arrangements meeting the definition of a lease are classified as operating or finance leases, and are recorded on the consolidated balance sheets as both a right of use asset and a lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company's incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset results in straight-line rent expense over the lease term. Variable lease expenses are recorded when incurred.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In calculating the right of use assets and lease liabilities, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election, and recognizes rent expense on a straight-line basis over the lease term.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_InvestmentsInRelatedPartiesPolicyPolicyTextBlock', window );">Investments in Related Party Entities</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Related Party Entities</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds a 10% and a 2.4% interest in two entities, NovaPark, LLC ("NovaPark") and Ohr Cosmetics, LLC ("Ohr"), respectively. There is common ownership between the Director and Chairman Emeritus of the Company and each entity, and our Chief Executive Officer is also owns approximately 0.80% of the membership interests in Ohr. See Note 15. In accordance with ASC 323, Investments &#8212;Equity Method and Joint Ventures, the Company has significant influence but not control over NovaPark as its ownership in the limited liability company exceeds 3-5%. Accordingly, the Company records the NovaPark investment under the equity method of accounting. The Ohr investment is recorded at cost.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_WarrantsAndRightsOutstandingPolicyPolicyTextBlock', window );">Warrant Liability</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liability</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain common stock warrants outstanding as a liability, in accordance with ASC 815, Derivatives and Hedging, at fair value and adjusts the instruments to fair value at each reporting period. This liability is subject to re-measurement at each reporting period until exercised, and any change in fair value is recognized in the consolidated statements of operations as a component of other income (expense). The fair value of the warrants issued by the Company has been estimated using a variant of the Black Scholes option pricing model. The underlying equity included in the Black Scholes option pricing model was valued based on the closing price of common stock at each measurement date.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Convertible Notes Payable at Fair Value</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Notes Payable at Fair Value</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under ASC 825</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Instruments ("ASC 825"), the Company has elected the fair value option for recognition of its convertible notes. In accordance with ASC 825, the Company recognizes these convertible notes at fair value with changes in fair value recognized in the consolidated statements of operations. The fair value option may be applied instrument by instrument, but it is irrevocable. As a result of applying the fair value option, direct costs and fees related to the convertible notes were recognized in general and administrative </span></div>expense in earnings as incurred and not deferred. The estimated fair value of the convertible notes was determined by utilizing a present value cash flow model and the values of the equity underlying the conversion options were estimated using company equity values implied from the Subject Company Transaction Method which includes the back-solve and scenario-based methods (Probability Weighted Expected Return Method). See Note 4. Accrued interest for the notes has been included in the change in fair value of convertible notes in the consolidated statements of operations. All outstanding convertible notes were converted into common stock upon the close of the IPO on February 9, 2021 and no balances remained outstanding as of December&#160;31, 2021.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionPolicyTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text">Convertible Preferred StockSeries C convertible preferred stock included settlement features that result in liability classification. The initial carrying value of the Series C convertible preferred stock was accreted to the settlement value, the fair value of the securities issued upon the conversion of the Series C convertible preferred stock. The discount to the settlement value was accreted to interest expense using the effective interest method. During 2020, certain convertible notes were exchanged for Series C convertible preferred stock. As the exchange was accounted for as a modification, the Series C convertible preferred stock that was exchanged for the convertible notes was recorded at fair value and subject to re-measurement at each reporting period with gains and losses reported through our consolidated statements of operations. All outstanding shares of convertible preferred stock were converted into common stock upon the close of the Company&#8217;s IPO on February 9, 2021.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Treasury Stock</a></td>
<td class="text">Treasury StockThe Company records the repurchase of shares of common stock at cost based on the settlement date of the transaction. These shares are classified as treasury stock, which is a reduction to stockholders' equity. Treasury stock is included in authorized and issued shares but excluded from outstanding shares. As of December&#160;31, 2021, all outstanding treasury shares were retired in October 2021 upon approval by the Board of Directors.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any products approved for sale and has not generated any revenue from product sales. The Company&#8217;s revenue to date has been primarily derived from government funding consisting of U.S. government grants and contracts, and revenue under its license agreements.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Revenue</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for revenue earned from contracts with customers under Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASC 606"). Under ASC 606, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps:   &#160;&#160;&#160;&#160;</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Identify the contract(s) with a customer;</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Identify the performance obligations in the contract;</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Determine the transaction price;</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;Allocate the transaction price to the performance obligations in the contract; and</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;Recognize revenue when (or as) the Company satisfies a performance obligation.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company assesses the goods or services promised within each contract, whether each promised good or service is distinct, and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements under which it may obtain upfront payments, milestone payments, royalty payments and other fees. Promises under these arrangements may include research licenses, research services, including selection campaign research services for certain replacement targets, the obligation to share information during the research and the participation of alliance managers and in joint research committees, joint patent committees and joint steering committees. The Company assesses these promises within the context of the agreements to determine the performance obligations.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Licenses of Intellectual Property</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: If a license to its intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring proportional performance for purposes of recognizing revenue from non-refundable, upfront payments. The Company evaluates the measure of proportional performance each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone payments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company evaluates whether the regulatory and development milestones are considered probable of being reached and estimate the amounts to be included in the transaction price using the most likely amount method. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones and any related constraint, and if necessary, adjust the estimate of the overall transaction price.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales-based milestones and royalties</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: For sales-based royalties, including milestone payments based on the level of sales, the Company determines whether the sole or predominant item to which the royalties relate is a license. When the license is the sole or predominant item to which the sales-based royalty relates, the Company recognize revenue at the later of: (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any sales-based royalty revenue resulting from any license agreement.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is a contract liability, represents amounts received by the Company for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount expected to be recognized within one year from the consolidated balance sheet date based on the estimated performance period of the underlying performance obligation. The noncurrent portion of deferred revenue represents amounts expected to be recognized after one year through the end of the performance period of the performance obligation.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grant Revenue</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company concluded that the Company's government grants are not within the scope of ASC Topic 606 as they do not meet the definition of a contract with a customer. The Company has concluded that the grants meet the definition of a contribution and are non-reciprocal transactions, and has also concluded that Subtopic 958-605, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit-Entities-Revenue Recognition</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, does not apply, as the Company is a business entity and the grants are with governmental agencies.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of applicable guidance under GAAP, the Company developed a policy for the recognition of grant revenue when the allowable costs are incurred and the right to payment is realized.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes this policy is consistent with the overarching premise in ASC Topic 606, to ensure that revenue recognition reflects the transfer of promised goods or services to customers in an amount that reflects the consideration that the Company expects to be entitled to in exchange for those goods or services, even though there is no exchange as defined in ASC Topic 606. The Company believes the recognition of revenue as costs are incurred and amounts become realizable is analogous to the concept of transfer of control of a service over time under ASC Topic 606.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs include, but are not limited to, payroll and personnel expenses, laboratory supplies, preclinical studies, compound manufacturing costs, consulting costs and allocated overhead, including rent, equipment, depreciation and utilities. Research and development cost maybe offset by research and development refundable tax rebates received by our wholly-owned Australian subsidiary. </span></div>The Company has agreements with various Contract Research Organizations ("CROs") and third-party vendors. Research and development accruals of amounts due to the CRO are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued liabilities on the consolidated balance sheet. Payments made to CROs under such arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. The Company makes judgments and estimates in determining the accrued expenses balance in each reporting period. As actual costs become known, the Company adjusts its accrued expenses.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text">Advertising CostsAdvertising costs are expensed as incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for all stock-based payments to employees and non-employees, including grants of stock options, RSAs, RSUs, including "PSUs" to be recognized in the financial statements, based on their respective grant date fair values. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The RSAs, RSUs and PSUs are valued based on the fair value of the Company's common stock on the date of grant. The assumptions used in calculating the fair value of stock-based awards represent management's best estimates and involve inherent uncertainties and the application of management's judgment. The Company records expense for stock-based compensation related to stock options, RSAs and RSUs over the requisite service period. As the PSUs have a performance condition, compensation expense is recognized for each vesting tranche over the respective requisite service period of each tranche if and when the Company's management deems probable that the performance conditions will be satisfied. The Company may recognize a cumulative true-up adjustment related to PSUs once a condition becomes probable of being satisfied if the related service period had commenced in a prior period. All share-based compensation costs are recorded in general and administrative or research and development costs in the consolidated statements of operations based upon the respective employees or non-employee's roles within the Company. Forfeitures are recorded as they occur.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are recorded in accordance with ASC 740, Income Taxes ("ASC 740"), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per ShareBasic net loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share excludes the potential impact of convertible preferred stock, common stock options, warrants and unvested shares of restricted stock and restricted stock units because their effect would be anti-dilutive due to the Company's net loss. Since the Company had net losses for the years ended December&#160;31, 2021 and 2020, basic and diluted net loss per common share are the same.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">Comprehensive LossComprehensive loss represents the net loss for the period and other comprehensive income. Other comprehensive income reflects certain gains and losses that are recorded as a component of stockholders&#8217; deficit and are not reflected in the statements of operations. The Company&#8217;s other comprehensive income consists of foreign currency translation adjustments.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. ASU No. 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. Early adoption is permitted for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company adopted this standard as of January 1, 2021, which did not have material impact on its consolidated financial statements and related disclosures. </span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes (ASU 2019-12), which is intended to simplify accounting for income taxes. It removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application. ASU 2019-12 was effective for the Company for fiscal years beginning after December 15, 2020, including interim periods therein. The Company adopted this standard as of January 1, 2021, which did not have material impact on its consolidated financial statements and related disclosures.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued ASU No. 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 (a consensus of the Emerging Issues Task Force). This update clarifies whether an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying the measurement alternative and how to account for certain forward contracts and purchased options to purchase securities. For public entities, this guidance was effective for fiscal years beginning after December 15, 2020. The Company adopted this standard as of January 1, 2021, which did not have material impact on its consolidated financial statements and related disclosures.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued ASU No. 2020-10, Codification Improvements. ASU 2020-10 provides amendments to a wide variety of topics in the FASB&#8217;s Accounting Standards Codification, which applies to all reporting entities within the scope of the affected accounting guidance. ASU 2020-10 was effective for the Company for fiscal years beginning after December 15, 2020, including interim periods therein. The Company adopted this standard as of January 1, 2021, which did not have material impact on its consolidated financial statements and related disclosures.</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued Accounting Standards Update (ASU) 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. ASU 2021-10 requires business entities to disclose, in notes to their financial statements, information about certain types of government assistance they receive. ASU 2021-10 also adds a new Topic 832, Government Assistance, to the FASB&#8217;s Codification. ASU 2021-10 is effective for financial statements of all entities, including private companies, for annual periods beginning </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">after December 15, 2021, with early application permitted. The Company adopted this standard as of January 1, 2021, which did not have material impact on its consolidated financial statements and related disclosures.</span></div><div><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments (ASU No. 2016-13), which requires an entity to utilize a new impairment model known as the current expected credit loss (&#8220;CECL&#8221;) model to estimate its lifetime &#8220;expected credit loss&#8221; and record an allowance that, when deducted from the amortized cost basis of the financial assets and certain other instruments, including but not limited to available-for-sale debt securities. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. As an emerging growth company, ASU No. 2016-13 is effective for the Company for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company is currently evaluating the impact of the adoption of ASU No. 2016-13 on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments Subject to Mandatory Redemption</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_FinancialInstrumentsSubjectToMandatoryRedemptionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_InvestmentsInRelatedPartiesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments in Related Parties, Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_InvestmentsInRelatedPartiesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_WarrantsAndRightsOutstandingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants and Rights Outstanding, Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_WarrantsAndRightsOutstandingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21459-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939384340344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text">Depreciation and amortization is computed using the straight-line method over their estimated useful lives as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:67.668%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furniture and fixtures</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shorter of useful life or lease term</span></td></tr></table><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's property and equipment, net was comprised of the following (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">512&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furniture and fixtures</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total property and equipment</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">968&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">582&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less: accumulated depreciation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(517)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(426)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">451&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">156&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939384361928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table classifies the Company's financial assets and liabilities measured at fair value on a recurring basis into the fair value hierarchy as of December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Fair Value Measured at December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Quoted Prices in </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Active Markets for </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Identical </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Assets (Level 1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Significant </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Other </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Observable </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Inputs (Level 2)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Significant </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unobservable </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Inputs (Level 3)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Assets included in:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash and cash equivalents&#8212;Money market securities  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">87,252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">87,252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total fair value</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">87,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">87,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liabilities included in:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Warrants</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$114</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total fair value</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">114&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">114&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Fair Value Measured at December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Quoted Prices in </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Active Markets for </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Identical </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Assets (Level 1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Significant </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Other </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Observable </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Inputs (Level 2)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Significant </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unobservable </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Inputs (Level 3)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Assets included in:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash and cash equivalents&#8212;Money market securities  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total fair value</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Liabilities included in:</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Convertible notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Warrants</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Series C convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total fair value</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">64,392&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">64,392&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">___________________</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Included in cash and cash equivalents on the consolidated balance sheets. This balance includes cash requirements settled on a nightly basis.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in Level 3 liabilities measured at fair value (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Warrant <br/>Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Convertible <br/>Notes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Series C Convertible Preferred Stock at Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Balance&#8212;December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">10,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">51,170&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">64,392&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Conversion of convertible Series C convertible preferred stock into common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(6,110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(6,110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Conversion of convertible notes into common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(58,639)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(58,639)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net exercise of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(13,509)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(13,509)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">7,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">3,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">13,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Balance&#8212;December 31, 2021</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">114</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">114</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the Company's warrant liabilities that were categorized within Level 3 of the fair value hierarchy as of December&#160;31, 2021 and 2020 was as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Strike price</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.01&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Contractual term (years)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Volatility (annual)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">74.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">86.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free rate</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield (per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939380395944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text">Depreciation and amortization is computed using the straight-line method over their estimated useful lives as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:67.668%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Estimated Useful Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furniture and fixtures</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shorter of useful life or lease term</span></td></tr></table><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's property and equipment, net was comprised of the following (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Equipment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">866&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">512&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furniture and fixtures</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Leasehold improvements</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total property and equipment</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">968&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">582&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less: accumulated depreciation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(517)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(426)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment, net</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">451&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">156&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid and Other Current Assets</a></td>
<td class="text">Prepaid and other current assets were comprised of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred Offering costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,978&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid clinical fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Business insurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Security deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Convertible note receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Angion Pty tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total prepaid and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,685&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,690&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses were comprised of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued compensation</span></div></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,274&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,154&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued direct research costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued operating expenses</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">749&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">707&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total accrued expenses</span></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,219&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6,665&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939384388056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Series C Convertible Preferred Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionDisclosureTextBlock', window );">Financial Instruments Subject to Mandatory Redemption Disclosure</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate values recorded for the Series C convertible preferred stock as of December 31, 2020 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.201%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">At issuance </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Series C convertible preferred stock recorded at amortized cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Principal</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">22,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">22,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Settlement premium</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">5,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">5,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Unamortized discounts and fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(9,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(1,884)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net carrying amount</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">18,635&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">26,001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Series C convertible preferred stock recorded at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Series C convertible preferred stock issued in exchange for convertible notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2,254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Change in fair value of Series C convertible preferred stock exchanged for convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total Series C convertible preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">28,519&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature and terms of the financial instruments and the rights and obligations embodied in those instruments, information about settlement alternatives, if any, in the contract and identification of the entity that controls the settlement alternatives including:  a. The amount that would be paid, or the number of shares that would be issued and their fair value, determined under the conditions specified in the contract if the settlement were to occur at the reporting date b. How changes in the fair value of the issuer's equity shares would affect those settlement amounts (for example, "the issuer is obligated to issue an additional x shares or pay an additional y dollars in cash for each $1 decrease in the fair value of one share") c. The maximum amount that the issuer could be required to pay to redeem the instrument by physical settlement, if applicable d. The maximum number of shares that could be required to be issued, if applicable e. That a contract does not limit the amount that the issuer could be required to pay or the number of shares that the issuer could be required to issue, if applicable f. For a forward contract or an option indexed to the issuer's equity shares, the forward price or option strike price, the number of issuer's shares to which the contract is indexed, and the settlement date or dates of the contract, as applicable.  g. The components of the liability that would otherwise be related to shareholders' interest and other comprehensive income (if any) subject to the redemption feature (for example, par value and other paid in amounts of mandatorily redeemable instruments are disclosed separately from the amount of retained earnings or accumulated deficit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2A<br> -URI http://asc.fasb.org/extlink&amp;oid=118255708&amp;loc=SL5909891-110878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109262807&amp;loc=d3e22026-110879<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109262807&amp;loc=d3e22047-110879<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939383264824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Estimate Fair Value of Stock Option Awards</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each employee and non-employee stock option grant was estimated on the date of grant using the Black-Scholes option-pricing model based on the following inputs:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.660%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.229%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">0.7%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">0.7%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Expected dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Expected term in years </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">5.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">71.8% - 73.1%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">70.8% - 86.8%</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share Option Activity</a></td>
<td class="text">The following table summarizes information as of December&#160;31, 2021 and activity during 2021 related to the Company&#8217;s stock option plans:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Number of <br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Weighted <br/>Average <br/>Exercise <br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Weighted <br/>Average <br/>Remaining <br/>Contractual <br/>Life (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Total <br/>Intrinsic <br/>Value <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Outstanding as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">3,479,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">6.97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">8.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">15,140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">1,103,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">15.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Options forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(189,388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">13.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Options exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(152,939)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">6.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Options expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(10,963)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">7.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Outstanding as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">4,230,162&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">8.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">7.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Options vested and exercisable</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2,499,165&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">7.11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">7.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of RSA and RSU Activity</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's RSA and RSU activity for the years ended December&#160;31, 2021 were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Shares of <br/>Restricted Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Weighted <br/>Average Grant <br/>Date Fair Value <br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Restricted <br/>Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Weighted <br/>Average Grant <br/>Date Fair Value <br/>Per Share</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">14,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">6.05&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">74,144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">7.78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(14,586)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">6.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(43,875)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">8.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(12,764)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">6.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">17,505&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">9.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Vested as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">43,875&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">8.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Components of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total stock-based compensation expense for the stock options, RSUs, RSAs, PSUs compensation issued in shares recorded in the consolidated statements of operations (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12,041&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,716&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939382835608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_WarrantsAndRightsOutstandingAbstract', window );"><strong>Warrants and Rights Outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Outstanding Warrants</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the outstanding warrants to purchase the Company's common stock were comprised of the following:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.545%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.549%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exercise <br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Expiration <br/>Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Warrants at December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Warrants issued with 2015 Notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">6.43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">7/5/28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">388,396&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Warrants issued with 2016 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">6.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">7/5/28</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">538,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Warrants issued with 2017 Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">6.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">7/5/28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">79,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Warrants issued with 2018 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">6.43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">7/5/28</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">498,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Warrants issued with Conversion of Notes to Common Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">8.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">8/31/28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">232,287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">238,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Warrants issued with Units in the Equity Offering</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">8.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">8/31/28</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">875,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">907,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Broker Warrants issued with Equity Offering</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">8/31/25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">1,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">48,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Broker Warrants issued with 2019 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">0.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">1/30/20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Consultant Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">7.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">8/31/28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">39,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">39,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Total Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">1,148,123&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">2,739,791&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_WarrantsAndRightsOutstandingActivityTableTextBlock', window );">Schedule of Warrant Activity</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's warrant activity for the year ended December&#160;31, 2021 was as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Warrants</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Average </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exercise </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Weighted </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Average </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Remaining </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Contractual </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Life (in years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Balance&#8212;December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,739,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.9</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Exercised </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,588,756)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expired</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2,912)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Balance&#8212;December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,148,123&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.2</span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">_________________________________</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) 613,892 shares from warrant exercised were tendered back to the Company to cover the exercise price of the warrant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_WarrantsAndRightsOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants and Rights Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_WarrantsAndRightsOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_WarrantsAndRightsOutstandingActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants and Rights Outstanding, Activity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_WarrantsAndRightsOutstandingActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939378792552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of components of rent expense</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the components of the Company's rent expense (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">For the Year Ended <br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease cost</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Variable cost</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease expense</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,615&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 13pt 0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,745&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Short-term lease rent expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total rent expense</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,659&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,836&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock', window );">Schedule of quantitative information regarding NovaPark operating leases</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes quantitative information about the Company's NovaPark operating leases (dollars in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">For the Year Ended <br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating cash flows from operating leases</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets exchanged for operating lease liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average remaining lease term&#8212;operating leases (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.8</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average discount rate&#8212;operating leases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of lease liabilities</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, maturities of lease liabilities were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,423&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less present value discount</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,054)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,369&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_ScheduleOfQuantitativeInformationAboutTheFinancingObligationTableTextBlock', window );">Schedule Of Quantitative Information About The Financing Obligation</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes quantitative information about the Company's financing obligation (dollars in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.040%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.760%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">For the Year Ended December 31, </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Proceeds from sale and leaseback arrangement</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Payments of financing obligation</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating cash flows from financing obligation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing cash flows from financing obligation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Other information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average remaining lease term (in years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Weighted-average discount rate (in percent)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Carrying value of leased asset included in Property and Equipment, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation associated with the leased asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Finance Lease, Liability, Fiscal Year Maturity</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, maturities of financing obligation were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Thereafter</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Less present value discount</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financing obligation</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">293&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ScheduleOfQuantitativeInformationAboutTheFinancingObligationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Quantitative Information About The Financing Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ScheduleOfQuantitativeInformationAboutTheFinancingObligationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Quantitative Information On Operating Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939375483192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income before Income Tax, Domestic and Foreign</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Losses before income taxes includes the following components:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:72.451%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.828%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(53,547)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(78,164)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(1,026)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(1,943)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(54,573)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(80,107)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes provision (benefit) for the years ended December&#160;31, 2021 and 2020 consists of the following (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:72.451%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.828%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">United States</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Current</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(5,460)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(12,129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(4,779)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(522)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">10,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">12,651&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Deferred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total tax provision</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliations between the federal statutory income tax rate and the Company's effective income tax rate were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:72.451%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.828%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Federal statutory income tax rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">State taxes, net of federal tax benefit</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(4.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">R&amp;D and other tax credit changes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Permanent items</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(7.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(4.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Nontaxable Income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Change in valuation allowance</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(10.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(15.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Effective income tax rate</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">0.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">0.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company's deferred tax asset at December&#160;31, 2021 and 2020 were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net operating loss carryforwards</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">R&amp;D and other tax credit carryovers</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lease liability</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued compensation and other expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">536&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fixed assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total deferred tax assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40,793&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30,344&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fixed assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right of use assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1,046)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(874)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Valuation allowance</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(39,710)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(29,470)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax assets, net of allowance</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Roll Forward</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reconciliation of uncertain tax positions as of December 31, 2021 and 2020 was as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning Balance </span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,579&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:10pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions for current year</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additions for prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ending Balance</span></div></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,675&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,579&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_UnrecognizedTaxBenefitsIfRecognizedWouldAffectTheEffectiveTaxRateTableTextBlock', window );">Unrecognized Tax Benefits, If Recognized, Would Affect the Effective Tax Rate</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amount of unrecognized tax benefits, if recognized, would affect the effective tax rate was as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.200%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unrecognized benefits that would affect the effective tax rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unrecognized benefits that would not affect the effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total unrecognized benefits</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,675&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2,579&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_UnrecognizedTaxBenefitsIfRecognizedWouldAffectTheEffectiveTaxRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, If Recognized, Would Affect the Effective Tax Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_UnrecognizedTaxBenefitsIfRecognizedWouldAffectTheEffectiveTaxRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939381968072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of net loss per share, basic and diluted</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of the Company&#8217;s basic and diluted net loss per share attributable to common stockholders, which excludes shares which are legally outstanding but subject to repurchase by the Company (in thousands, except share and per share data):</span></div><div style="margin-top:10pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:72.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.023%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Numerator</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net loss attributable to common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(54,573)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(80,107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,244,825</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,762,120</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Net loss per share attributable to common stockholders, basic and diluted</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(1.93)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(5.43)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities excluded from computation of net loss per share</a></td>
<td class="text">The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share because to do so would be anti-dilutive:<div style="margin-top:10pt;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:71.848%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Shares issuable upon exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,230,162</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,479,731</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Shares issuable upon the exercise of warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,148,123</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,739,791</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Shares issuable upon conversion of the convertible notes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">5,603,388</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Shares issuable upon conversion of the Series C preferred stock</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">3,920,172</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Non-vested shares under restricted stock unit grants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">203,015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">58,951</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Non-vested shares under restricted stock grants</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">14,585</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Total </span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">5,581,300</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">15,816,618</span></td></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">___________________________________</span></div><div style="margin-top:10pt;padding-left:49.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.24pt">The number of shares issuable upon conversion of the 2019 Notes, 2020 Notes and Series C preferred stock has been estimated using the Company's common stock fair value at December 31, 2020, discounted by 20%.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939382369992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Equity Method Investments</a></td>
<td class="text">The following table provides the activity for the NovaPark investment for the years ended December&#160;31, 2021 and 2020 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.838%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Beginning balance</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">849&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Losses of equity method investment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(71)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Distribution from NovaPark</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ending balance</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">573&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">672&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939379568408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of the Business and Financial Condition (Details)<br></strong></div></th>
<th class="th">
<div>Feb. 09, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Feb. 01, 2021</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 10, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.55583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,756,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,607,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (215,135,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (160,562,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock at Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stocks outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in offering (in shares)</a></td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-allotment option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in offering (in shares)</a></td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in offering (in shares)</a></td>
<td class="nump">1,562,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from issuance of common stock | $</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=angn_IPOAndPrivatePlacementMember', window );">IPO and Private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from issuance of common stock | $</a></td>
<td class="nump">$ 107,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=angn_IPOAndPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=angn_IPOAndPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939380593672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>entity </div>
<div>operatingSegment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 10, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | operatingSegment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,978,000<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment of leased assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 58,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_NumberOfRelatedPartyEntities', window );">Number of related party entities | entity</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock at Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stocks outstanding (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=angn_OhrCosmeticsLLCMember', window );">Ohr Cosmetics, LLC | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest', window );">Family of the Executive Chairman investment, ownership percentage</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=angn_NovaParkMember', window );">NovaPark | Equity Method Investee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=angn_OhrCosmeticsLLCMember', window );">Ohr Cosmetics, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_OtherInvestmentAndSecuritiesAtCostOwnershipPercentage', window );">Investment, ownership percentage</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_NumberOfRelatedPartyEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Related Party Entities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_NumberOfRelatedPartyEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_OtherInvestmentAndSecuritiesAtCostOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Investment and Securities, at Cost, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_OtherInvestmentAndSecuritiesAtCostOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage investment held by members or limited partners of limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=angn_OhrCosmeticsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=angn_OhrCosmeticsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=angn_NovaParkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=angn_NovaParkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=angn_OhrCosmeticsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=angn_OhrCosmeticsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939381188376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and Deferred Revenue (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 09, 2021</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 806<span></span>
</td>
<td class="nump">$ 2,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Contract revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,506<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue&#8212;current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,301<span></span>
</td>
<td class="nump">3,942<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_ContractWithCustomerContractTerminationPeriodCurableBreach', window );">Contract termination period, curable breach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_ContractWithCustomerContractTerminationPeriodIncurableBreach', window );">Contract termination period, incurable breach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=angn_ViforPharmaMember', window );">Vifor Pharma | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_ContractWithCustomerUpfrontAndNearTermMilestonePaymentEntitledToReceive', window );">Upfront and near-term milestone payment, entitled to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_ContractWithCustomerPostApprovalMilestonePaymentEntitledToReceive', window );">Post-approval milestone payment, entitled to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_ContractWithCustomerSalesRelatedMilestonePaymentEntitledToReceive', window );">Sales-related milestone payment, entitled to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,585,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_ContractWithCustomerMilestonePaymentsEntitledToReceive', window );">Total milestone payment, entitled to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,925,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_ContractWithCustomerRoyaltyRatesMaximum', window );">Royalty rates (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_ContractWithCustomerLiabilityPercentOfUpfrontPayment', window );">Transaction price, percent of upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_RevenueFromContractWithCustomerIncludingAssessedTaxIncrease', window );">Increase in contract revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_NetIncomeLossAttributableToParentIncrease', window );">Decrease in net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_EarningsPerShareBasicIncrease', window );">Basic earnings per share increase (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_EarningsPerShareDilutedIncrease', window );">Diluted earnings per share increase (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Contract revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue&#8212;current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=angn_ViforPharmaMember', window );">Vifor Pharma | License | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-11-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price at inception of license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=angn_ViforPharmaMember', window );">Vifor Pharma | License | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price at inception of license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Performance period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=angn_ViforPharmaMember', window );">Vifor Pharma | License | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">Equity investment received</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=angn_ViforPharmaMember', window );">Vifor Pharma | License | Private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">Equity investment received</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ContractWithCustomerContractTerminationPeriodCurableBreach">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Contract Termination Period, Curable Breach</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ContractWithCustomerContractTerminationPeriodCurableBreach</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ContractWithCustomerContractTerminationPeriodIncurableBreach">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Contract Termination Period, Incurable Breach</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ContractWithCustomerContractTerminationPeriodIncurableBreach</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ContractWithCustomerLiabilityPercentOfUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Percent Of Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ContractWithCustomerLiabilityPercentOfUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ContractWithCustomerMilestonePaymentsEntitledToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Milestone Payments, Entitled To Receive</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ContractWithCustomerMilestonePaymentsEntitledToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ContractWithCustomerPostApprovalMilestonePaymentEntitledToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Post-Approval Milestone Payment, Entitled To Receive</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ContractWithCustomerPostApprovalMilestonePaymentEntitledToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ContractWithCustomerRoyaltyRatesMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Royalty Rates, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ContractWithCustomerRoyaltyRatesMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ContractWithCustomerSalesRelatedMilestonePaymentEntitledToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Sales-Related Milestone Payment, Entitled To Receive</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ContractWithCustomerSalesRelatedMilestonePaymentEntitledToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ContractWithCustomerUpfrontAndNearTermMilestonePaymentEntitledToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Upfront and Near-term Milestone Payment, Entitled To Receive</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ContractWithCustomerUpfrontAndNearTermMilestonePaymentEntitledToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_EarningsPerShareBasicIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Basic, Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_EarningsPerShareBasicIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_EarningsPerShareDilutedIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Diluted, Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_EarningsPerShareDilutedIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_NetIncomeLossAttributableToParentIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Income (Loss) Attributable to Parent, Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_NetIncomeLossAttributableToParentIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_RevenueFromContractWithCustomerIncludingAssessedTaxIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer, Including Assessed Tax, Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_RevenueFromContractWithCustomerIncludingAssessedTaxIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=angn_ViforPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=angn_ViforPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2020-11-06">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2020-11-06</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939380678904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities included in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent', window );">Series C convertible preferred stock at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,518<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value measurements, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets included in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents - Money market securities</a></td>
<td class="nump">87,252<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value</a></td>
<td class="nump">87,252<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities included in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_WarrantsFairValueDisclosure', window );">Warrants</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">10,704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent', window );">Series C convertible preferred stock at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,518<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">64,392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair value measurements, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets included in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents - Money market securities</a></td>
<td class="nump">87,252<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value</a></td>
<td class="nump">87,252<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities included in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_WarrantsFairValueDisclosure', window );">Warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent', window );">Series C convertible preferred stock at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair value measurements, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets included in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents - Money market securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities included in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_WarrantsFairValueDisclosure', window );">Warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent', window );">Series C convertible preferred stock at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair value measurements, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets included in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents - Money market securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities included in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_WarrantsFairValueDisclosure', window );">Warrants</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">10,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent', window );">Series C convertible preferred stock at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,518<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value</a></td>
<td class="nump">$ 114<span></span>
</td>
<td class="nump">$ 64,392<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments Subject to Mandatory Redemption Carried At Fair Value, Settlement Terms, Share Value, Amount, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_WarrantsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_WarrantsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939380551176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value, Liabilities, Measured on Recurring Basis, Unobservable Input Reconciliation (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 64,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">13,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=angn_WarrantLiabilityMember', window );">Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">10,704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlements</a></td>
<td class="num">(13,509)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">2,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">51,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlements</a></td>
<td class="num">(58,639)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">7,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_ConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock at Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">2,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlements</a></td>
<td class="num">(6,110)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">3,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=angn_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=angn_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939378832552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 09, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 10, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price of convertible notes (in dollars per share)</a></td>
<td class="nump">$ 11.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of equity-classified broker warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,919,000<span></span>
</td>
<td class="nump">$ 4,910,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock at Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stocks outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis=us-gaap_ConvertiblePreferredStockSubjectToMandatoryRedemptionMember', window );">Convertible Preferred Stock Subject to Mandatory Redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsConversionPrice', window );">Conversion price of series C preferred stock (in dollars per share)</a></td>
<td class="nump">11.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price of convertible notes (in dollars per share)</a></td>
<td class="nump">$ 11.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments Subject to Mandatory Redemption by Settlement Terms, Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis=us-gaap_ConvertiblePreferredStockSubjectToMandatoryRedemptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis=us-gaap_ConvertiblePreferredStockSubjectToMandatoryRedemptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939380367032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value Measurement Inputs and Valuation Techniques (Details) - Significant Unobservable Inputs (Level 3)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, contractual term</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Weighted average strike price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">8,010.00<span></span>
</td>
<td class="nump">9.18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Volatility (annual)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">0.746<span></span>
</td>
<td class="nump">0.868<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">0.007<span></span>
</td>
<td class="nump">0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Dividend yield (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="nump">0.000<span></span>
</td>
<td class="nump">0.000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=angn_MeasurementInputStrikePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=angn_MeasurementInputStrikePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939378873208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 968<span></span>
</td>
<td class="nump">$ 582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(517)<span></span>
</td>
<td class="num">(426)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">451<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">866<span></span>
</td>
<td class="nump">512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 68<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939380536568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember', window );">Australian Taxation Office | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939378887144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Prepaid and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 10, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred Offering costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="nump">$ 1,978,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_PrepaidClinicalFeesCurrent', window );">Prepaid clinical fees</a></td>
<td class="nump">168,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Business insurance</a></td>
<td class="nump">275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Security deposit</a></td>
<td class="nump">131,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Convertible note receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Angion Pty tax</a></td>
<td class="nump">863,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">248,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid and other current assets</a></td>
<td class="nump">$ 1,685,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,690,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_PrepaidClinicalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Clinical Fees, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_PrepaidClinicalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939382288584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 1,274<span></span>
</td>
<td class="nump">$ 3,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_AccruedDirectResearchCostsCurrent', window );">Accrued direct research costs</a></td>
<td class="nump">1,196<span></span>
</td>
<td class="nump">1,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_AccruedOperatingLiabilitiesCurrent', window );">Accrued operating expenses</a></td>
<td class="nump">749<span></span>
</td>
<td class="nump">707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,483<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 3,219<span></span>
</td>
<td class="nump">$ 6,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_AccruedDirectResearchCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Direct Research Costs, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_AccruedDirectResearchCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_AccruedOperatingLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Operating Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_AccruedOperatingLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939380504216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 09, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
<td class="nump">11.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible notes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,636,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=angn_A2020NotesMember', window );">2020 Notes | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible notes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=angn_AdditionalConvertibleNotesAndViforConvertibleNoteMember', window );">Additional Convertible Notes and Vifor Convertible Note | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible notes (in shares)</a></td>
<td class="nump">3,636,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of convertible notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Increase due to accrued interest balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
<td class="nump">$ 11.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=angn_A2020NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=angn_A2020NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=angn_AdditionalConvertibleNotesAndViforConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=angn_AdditionalConvertibleNotesAndViforConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939477982136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Series C Convertible Preferred Stock - Summary of Aggregate Values Recorded (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 09, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_TemporaryEquityAmortizedCostAbstract', window );"><strong>Series C convertible preferred stock recorded at amortized cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross', window );">Principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,308<span></span>
</td>
<td class="nump">$ 22,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium', window );">Settlement premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,577<span></span>
</td>
<td class="nump">5,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees', window );">Unamortized discounts and fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,250)<span></span>
</td>
<td class="num">(1,884)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent', window );">Net carrying amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 18,635<span></span>
</td>
<td class="nump">26,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionFairValueAbstract', window );"><strong>Series C convertible preferred stock recorded at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountIssuedInConvertibleNoteExchange', window );">Series C convertible preferred stock issued in exchange for convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountAccumulatedChangeInFairValue', window );">Change in fair value of Series C convertible preferred stock exchanged for convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount', window );">Total Series C convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,519<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments Subject to Mandatory Redemption Carried At Amortized Cost And Fair Value, Settlement Terms, Share Value, Amount,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountAccumulatedChangeInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments Subject to Mandatory Redemption Carried At Fair Value, Settlement Terms, Share Value, Amount, Accumulated Change In Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountAccumulatedChangeInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountIssuedInConvertibleNoteExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments Subject to Mandatory Redemption Carried At Fair Value, Settlement Terms, Share Value, Amount, Issued In Convertible Note Exchange</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountIssuedInConvertibleNoteExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments Subject to Mandatory Redemption, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_FinancialInstrumentsSubjectToMandatoryRedemptionFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Settlement Premium</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Unamortized Discount and Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_TemporaryEquityAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_TemporaryEquityAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that is required to be paid, determined under the conditions specified in the contract, if as of the reporting date, the holder of the share has exercised the right to or the shares are mandatorily redeemable within one year of the reporting date or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109262807&amp;loc=d3e22047-110879<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939477986584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Series C Convertible Preferred Stock - Narrative (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 09, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares of common stock into which all convertible preferred stock outstanding were automatically converted into (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,234,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_ConvertiblePreferredStockConversionPrice', window );">Convertible preferred stock, conversion price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares', window );">Shares of convertible preferred stock (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ConvertiblePreferredStockConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ConvertiblePreferredStockConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares that would be issued, determined under the conditions specified in the contract, if the settlement were to occur at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109262807&amp;loc=d3e22047-110879<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939384340344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,846,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939380208040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 09, 2021</div></th>
<th class="th"><div>Jan. 25, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share for stock option grants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.25<span></span>
</td>
<td class="nump">$ 5.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation related to unvested stock option awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation related to unvested stock option awards, period for recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance-based Restricted Stock Units (PSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">PSUs outstanding that were granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">556,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">PSUs vested and released (in shares)</a></td>
<td class="nump">185,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Non-option equity instruments outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for purchase under the ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=angn_A2021PlanMember', window );">2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Post-IPO capitalization rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=angn_A2021PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=angn_A2021PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939380471528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Awards (Details) - Stock Option<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">71.80%<span></span>
</td>
<td class="nump">70.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">73.10%<span></span>
</td>
<td class="nump">86.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939380321496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Share Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">3,479,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">1,103,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited (in shares)</a></td>
<td class="num">(189,388)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(152,939)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options expired (in shares)</a></td>
<td class="num">(10,963)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">4,230,162<span></span>
</td>
<td class="nump">3,479,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options vested and exercisable (in shares)</a></td>
<td class="nump">2,499,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 6.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="nump">15.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited (in dollars per share)</a></td>
<td class="nump">13.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share)</a></td>
<td class="nump">6.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options expired (in dollars per share)</a></td>
<td class="nump">7.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share)</a></td>
<td class="nump">8.92<span></span>
</td>
<td class="nump">$ 6.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options vested and exercisable (in dollars per share)</a></td>
<td class="nump">$ 7.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Option Activity, Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual life (in years)</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested and exercisable, weighted average remaining contractual life (in years)</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, total intrinsic value (in thousands)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options vested and exercisable, total intrinsic value (in thousands)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939380694072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of RSA and RSU Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Shares of Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Shares of Restricted Stock and Restricted Stock Units Activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">14,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(14,586)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber', window );">Vested at end of period (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">6.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at end of period (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageExercisePrice', window );">Vested at end of period (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Shares of Restricted Stock and Restricted Stock Units Activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">74,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(43,875)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(12,764)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">17,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber', window );">Vested at end of period (in shares)</a></td>
<td class="nump">43,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 9.51<span></span>
</td>
<td class="nump">$ 7.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">8.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">6.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at end of period (in dollars per share)</a></td>
<td class="nump">9.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageExercisePrice', window );">Vested at end of period (in dollars per share)</a></td>
<td class="nump">$ 8.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Outstanding, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested, Outstanding, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939380464888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Components of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 12,041<span></span>
</td>
<td class="nump">$ 4,716<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">5,898<span></span>
</td>
<td class="nump">2,183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 6,143<span></span>
</td>
<td class="nump">$ 2,533<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939381138808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants - Outstanding Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 6.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">1,148,123<span></span>
</td>
<td class="nump">2,739,791<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=angn_WarrantsIssuedWith2015NotesLiabilityMember', window );">Warrants issued with 2015 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 6.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">388,396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=angn_WarrantsIssuedWith2016NotesLiabilityMember', window );">Warrants issued with 2016 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 6.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">538,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=angn_WarrantsIssuedWith2017NotesLiabilityMember', window );">Warrants issued with 2017 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 6.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">79,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=angn_WarrantsIssuedWith2018NotesLiabilityMember', window );">Warrants issued with 2018 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 6.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">498,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=angn_WarrantsIssuedWithConversionOfNotesToCommonStockEquityMember', window );">Warrants issued with Conversion of Notes to Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 8.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">232,287<span></span>
</td>
<td class="nump">238,779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=angn_WarrantsIssuedWithUnitsInTheEquityOfferingEquityMember', window );">Warrants issued with Units in the Equity Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 8.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">875,034<span></span>
</td>
<td class="nump">907,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=angn_BrokerWarrantsIssuedWithEquityOfferingEquityMember', window );">Broker Warrants issued with Equity Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">1,297<span></span>
</td>
<td class="nump">48,485<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=angn_BrokerWarrantsIssuedWith2019NotesLiabilityMember', window );">Broker Warrants issued with 2019 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=angn_ConsultantWarrantsLiabilityMember', window );">Consultant Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 7.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">39,505<span></span>
</td>
<td class="nump">39,506<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=angn_WarrantsIssuedWith2015NotesLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=angn_WarrantsIssuedWith2015NotesLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=angn_WarrantsIssuedWith2016NotesLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=angn_WarrantsIssuedWith2016NotesLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=angn_WarrantsIssuedWith2017NotesLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=angn_WarrantsIssuedWith2017NotesLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=angn_WarrantsIssuedWith2018NotesLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=angn_WarrantsIssuedWith2018NotesLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=angn_WarrantsIssuedWithConversionOfNotesToCommonStockEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=angn_WarrantsIssuedWithConversionOfNotesToCommonStockEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=angn_WarrantsIssuedWithUnitsInTheEquityOfferingEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=angn_WarrantsIssuedWithUnitsInTheEquityOfferingEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=angn_BrokerWarrantsIssuedWithEquityOfferingEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=angn_BrokerWarrantsIssuedWithEquityOfferingEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=angn_BrokerWarrantsIssuedWith2019NotesLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=angn_BrokerWarrantsIssuedWith2019NotesLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=angn_ConsultantWarrantsLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=angn_ConsultantWarrantsLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939375510504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Warrant Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_ClassOfWarrantOrRightOutstandingRollForward', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance, beginning (in shares)</a></td>
<td class="nump">2,739,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_ClassOfWarrantOrRightExercisesInPeriod', window );">Exercised (in shares)</a></td>
<td class="num">(1,588,756)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_ClassOfWarrantOrRightExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(2,912)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance, ending (in shares)</a></td>
<td class="nump">1,148,123<span></span>
</td>
<td class="nump">2,739,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsRollForward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_ClassOfWarrantOrRightWeightedAverageExercisePrice', window );">Balance, beginning (in dollars per share)</a></td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod', window );">Exercised (in dollars per share)</a></td>
<td class="nump">7.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExpirationsInPeriod', window );">Expired (in dollars per share)</a></td>
<td class="nump">8.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_ClassOfWarrantOrRightWeightedAverageExercisePrice', window );">Balance, ending (in dollars per share)</a></td>
<td class="nump">$ 8.01<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTermRollForward', window );"><strong>Weighted Average Remaining Contractual Life (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm', window );">Balance, weighted average remaining contractual life (in years)</a></td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_ClassOfWarrantOrRightExercisesInPeriodTendered', window );">Warrants tendered back to the Company (in shares)</a></td>
<td class="nump">613,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ClassOfWarrantOrRightExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercises in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ClassOfWarrantOrRightExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ClassOfWarrantOrRightExercisesInPeriodTendered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercises in Period, Tendered</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ClassOfWarrantOrRightExercisesInPeriodTendered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ClassOfWarrantOrRightExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Expirations in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ClassOfWarrantOrRightExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ClassOfWarrantOrRightOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ClassOfWarrantOrRightOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ClassOfWarrantOrRightWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ClassOfWarrantOrRightWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Weighted Average Exercise Price, Exercises in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Weighted Average Exercise Price, Expirations in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Weighted Average Exercise Price of Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants and Rights Outstanding, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTermRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants and Rights Outstanding, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTermRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939380581432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Narrative (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_ClassOfWarrantOrRightConversionPrice', window );">Warrant conversion price (in dollars per share)</a></td>
<td class="nump">$ 11.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants (in shares)</a></td>
<td class="nump">844,335<span></span>
</td>
<td class="nump">93,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=angn_WarrantsIssuedWith2015Notes2016Notes2017NotesAnd2018NotesMember', window );">Warrants issued with 2015 Notes, 2016 Notes, 2017 Notes, and 2018 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 6.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ClassOfWarrantOrRightConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ClassOfWarrantOrRightConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=angn_WarrantsIssuedWith2015Notes2016Notes2017NotesAnd2018NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=angn_WarrantsIssuedWith2015Notes2016Notes2017NotesAnd2018NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939379703896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 26, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>option</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Nov. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Finance lease, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">42 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_ProceedsFromFinancingObligation', window );">Proceeds from financing obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 302,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from loan from PPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">895,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain upon debt extinguishment</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">905,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_CARESActEmployeeRetentionCredit', window );">CARES Act, Employee Retention Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=angn_PaycheckProtectionProgramCARESActMember', window );">Paycheck Protection Program, CARES Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from loan from PPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NJ', window );">Fort Lee, New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_LesseeOperatingLeaseAnnualRentExpense', window );">Operating lease, payment per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">San Francisco, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_LesseeOperatingLeaseAnnualRentExpense', window );">Operating lease, payment per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MA', window );">Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of office space (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_LesseeOperatingLeaseAnnualRentExpense', window );">Operating lease, payment per year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_LesseeOperatingLeaseFreeRentExpensePeriod', window );">Free rent expense period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_LesseeOperatingLeaseNumberOfOptionsToExtend', window );">Number of options to extend | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_LesseeOperatingLeaseNoticePeriodForOptionToExtend', window );">Notice period for option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_CARESActEmployeeRetentionCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act, Employee Retention Credit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_CARESActEmployeeRetentionCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_LesseeOperatingLeaseAnnualRentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Annual Rent Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_LesseeOperatingLeaseAnnualRentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_LesseeOperatingLeaseFreeRentExpensePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Free Rent Expense Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_LesseeOperatingLeaseFreeRentExpensePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_LesseeOperatingLeaseNoticePeriodForOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Notice Period for Option to Extend</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_LesseeOperatingLeaseNoticePeriodForOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_LesseeOperatingLeaseNumberOfOptionsToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number of Options to Extend</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_LesseeOperatingLeaseNumberOfOptionsToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ProceedsFromFinancingObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Financing Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ProceedsFromFinancingObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=angn_PaycheckProtectionProgramCARESActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=angn_PaycheckProtectionProgramCARESActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939378814232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Components of Rent Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,142<span></span>
</td>
<td class="nump">$ 1,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable cost</a></td>
<td class="nump">473<span></span>
</td>
<td class="nump">646<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">1,615<span></span>
</td>
<td class="nump">1,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease rent expense</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total rent expense</a></td>
<td class="nump">$ 1,659<span></span>
</td>
<td class="nump">$ 1,836<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939383108744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Quantitative Information about Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 1,179<span></span>
</td>
<td class="nump">$ 1,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets exchanged for operating lease liabilities</a></td>
<td class="nump">$ 624<span></span>
</td>
<td class="nump">$ 88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term&#8212;operating leases (in years)</a></td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate&#8212;operating leases</a></td>
<td class="nump">10.10%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939382617864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Maturities of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 1,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">1,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">1,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">1,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">5,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less present value discount</a></td>
<td class="num">(1,054)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 4,369<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939381114744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule Of Quantitative Information About The Financing Obligation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_ProceedsFromFinancingObligation', window );">Proceeds from financing obligation</a></td>
<td class="nump">$ 302<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows from financing obligation</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows from financing obligation</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate (in percent)</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 451<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leaseholds and Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ProceedsFromFinancingObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Financing Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ProceedsFromFinancingObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939382610136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Finance Lease, Liability, Fiscal Year Maturity (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less present value discount</a></td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Financing obligation</a></td>
<td class="nump">$ 293<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939380663112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 118,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_OperatingLossCarryforwardSubjectToExpiration', window );">Operating loss carryforward, subject to expiration</a></td>
<td class="nump">9,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_OperatingLossCarryforwardNotSubjectToExpiration', window );">Operating loss carryforward, not subject to expiration</a></td>
<td class="nump">108,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 3,675<span></span>
</td>
<td class="nump">$ 2,579<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_OperatingLossCarryforwardNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforward, Not Subject to Expiration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_OperatingLossCarryforwardNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_OperatingLossCarryforwardSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforward, Subject to Expiration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_OperatingLossCarryforwardSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939376593064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income before Income Tax, Domestic and Foreign (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="num">$ (53,547)<span></span>
</td>
<td class="num">$ (78,164)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(1,026)<span></span>
</td>
<td class="num">(1,943)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total</a></td>
<td class="num">$ (54,573)<span></span>
</td>
<td class="num">$ (80,107)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939380550472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">United States</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total Current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(5,460)<span></span>
</td>
<td class="num">(12,129)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(4,779)<span></span>
</td>
<td class="num">(522)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability', window );">Change in valuation allowance</a></td>
<td class="nump">10,239<span></span>
</td>
<td class="nump">12,651<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total Deferred</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total tax provision</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939381166632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal tax benefit</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="num">(2.30%)<span></span>
</td>
<td class="num">(0.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_EffectiveIncomeTaxRateReconciliationInterestPercent', window );">Interest</a></td>
<td class="num">(4.30%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">R&amp;D and other tax credit changes</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent', window );">Permanent items</a></td>
<td class="num">(7.30%)<span></span>
</td>
<td class="num">(4.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome', window );">Nontaxable Income</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(10.10%)<span></span>
</td>
<td class="num">(15.80%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_EffectiveIncomeTaxRateReconciliationInterestPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Interest, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_EffectiveIncomeTaxRateReconciliationInterestPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Permanent Items, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939378829512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 29,211<span></span>
</td>
<td class="nump">$ 22,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">R&amp;D and other tax credit carryovers</a></td>
<td class="nump">6,752<span></span>
</td>
<td class="nump">4,718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_DeferredTaxAssetsOperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">1,224<span></span>
</td>
<td class="nump">956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">3,070<span></span>
</td>
<td class="nump">1,323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther', window );">Accrued compensation and other expenses</a></td>
<td class="nump">536<span></span>
</td>
<td class="nump">658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">40,793<span></span>
</td>
<td class="nump">30,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(37)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right of use assets</a></td>
<td class="num">(1,046)<span></span>
</td>
<td class="num">(874)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(39,710)<span></span>
</td>
<td class="num">(29,470)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net of allowance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939379538232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning Balance</a></td>
<td class="nump">$ 2,579<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions for current year</a></td>
<td class="nump">1,073<span></span>
</td>
<td class="nump">633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for prior years</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">1,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending Balance</a></td>
<td class="nump">$ 3,675<span></span>
</td>
<td class="nump">$ 2,579<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939380575688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Unrecognized Tax Benefits, If Recognized, Would Affect the Effective Tax Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized benefits that would affect the effective tax rate</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate', window );">Unrecognized benefits that would not affect the effective tax rate</a></td>
<td class="nump">3,675<span></span>
</td>
<td class="nump">2,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Total unrecognized benefits</a></td>
<td class="nump">$ 3,675<span></span>
</td>
<td class="nump">$ 2,579<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits that Would Not Impact Effective Tax Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939381258168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage', window );">Employers matching contribution annual vesting (in percentage)</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayOneHundredPercentEmployerMatch', window );">Employer matching contribution, percent of employees' gross pay, 100% employer match</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayFiftyPercentEmployerMatch', window );">Employer matching contribution, percent of employees' gross pay, 50% employer match</a></td>
<td class="nump">400.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayFiftyPercentEmployerMatch', window );">Employer matching contribution, percent of employees' gross pay, 50% employer match</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayFiftyPercentEmployerMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay, Fifty Percent Employer Match</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayFiftyPercentEmployerMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayOneHundredPercentEmployerMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay, One Hundred Percent Employer Match</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayOneHundredPercentEmployerMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939378814232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of net loss per share, basic and diluted (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (54,573)<span></span>
</td>
<td class="num">$ (80,107)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)</a></td>
<td class="nump">28,244,825<span></span>
</td>
<td class="nump">14,762,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)</a></td>
<td class="nump">28,244,825<span></span>
</td>
<td class="nump">14,762,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic (in dollars per share)</a></td>
<td class="num">$ (1.93)<span></span>
</td>
<td class="num">$ (5.43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted (in dollars per share)</a></td>
<td class="num">$ (1.93)<span></span>
</td>
<td class="num">$ (5.43)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939381148584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of antidilutive securities excluded from computation of net loss per share (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">5,581,300<span></span>
</td>
<td class="nump">15,816,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_SharesIssuableUponConversionOfConvertibleNotesDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Shares issuable upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">4,230,162<span></span>
</td>
<td class="nump">3,479,731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Shares issuable upon the exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">1,148,123<span></span>
</td>
<td class="nump">2,739,791<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Shares issuable upon conversion of the convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,603,388<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesCPreferredStockMember', window );">Shares issuable upon conversion of the Series C preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,920,172<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Non-vested shares under restricted stock unit grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">203,015<span></span>
</td>
<td class="nump">58,951<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Non-vested shares under restricted stock grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,585<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_SharesIssuableUponConversionOfConvertibleNotesDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Issuable Upon Conversion Of Convertible Notes, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_SharesIssuableUponConversionOfConvertibleNotesDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939375278360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 09, 2021</div></th>
<th class="th"><div>Nov. 30, 2013</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 10, 2021</div></th>
<th class="th"><div>Jul. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,142,000<span></span>
</td>
<td class="nump">$ 1,099,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">473,000<span></span>
</td>
<td class="nump">646,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
<td class="nump">$ 11.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Conversion of convertible preferred stock into common stock upon IPO (in shares)</a></td>
<td class="nump">2,234,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_ConvertiblePreferredStockConversionPrice', window );">Convertible preferred stock, conversion price (in dollars per share)</a></td>
<td class="nump">$ 11.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares', window );">Shares of convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=angn_OhrCosmeticsLLCMember', window );">Ohr Cosmetics, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_RelatedPartyTransactionPotentialMaximumMilestonePayment', window );">Potential maximum milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_RelatedPartyTransactionRoyaltiesAndMilestonePaymentsPeriod', window );">Royalties and milestone payments, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Legal Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses from transactions with related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Ohr Cosmetics, LLC | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember', window );">Equity Method Investee | NovaPark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=angn_DirectorsAndFamilyMemberOfChiefExecutiveOfficerDirectorMember', window );">Directors and Family Member of Chief Executive Officer/Director | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible notes (in shares)</a></td>
<td class="nump">149,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share)</a></td>
<td class="nump">$ 11.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=angn_PresidentAndChiefExecutiveOfficerAndDirectorMember', window );">President and Chief Executive Officer and Director | Series C preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Conversion of convertible preferred stock into common stock upon IPO (in shares)</a></td>
<td class="nump">165,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember', window );">Immediate Family Member of Management or Principal Owner | Consulting Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses from transactions with related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=angn_FormerMemberOfTheBoardOfDirectorsMember', window );">Former Member of the Board of Directors | Consulting Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses from transactions with related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=angn_OhrCosmeticsLLCMember', window );">Ohr Cosmetics, LLC | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest', window );">Family of the Executive Chairman investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=angn_OhrCosmeticsLLCMember', window );">Ohr Cosmetics, LLC | Immediate Family of Director and Chairman</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest', window );">Family of the Executive Chairman investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=angn_OhrCosmeticsLLCMember', window );">Ohr Cosmetics, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_OtherInvestmentAndSecuritiesAtCostOwnershipPercentage', window );">Investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=angn_OhrCosmeticsLLCMember', window );">Ohr Cosmetics, LLC | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInvestmentsAndSecuritiesAtCost', window );">Investment, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=angn_NovaParkMember', window );">NovaPark | Equity Method Investee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ConvertiblePreferredStockConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ConvertiblePreferredStockConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_OtherInvestmentAndSecuritiesAtCostOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Investment and Securities, at Cost, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_OtherInvestmentAndSecuritiesAtCostOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_RelatedPartyTransactionPotentialMaximumMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Potential Maximum Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_RelatedPartyTransactionPotentialMaximumMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_RelatedPartyTransactionRoyaltiesAndMilestonePaymentsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Royalties And Milestone Payments, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_RelatedPartyTransactionRoyaltiesAndMilestonePaymentsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage investment held by members or limited partners of limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentsAndSecuritiesAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Includes other investments and securities that are not at fair value as of the balance sheet date and those that are not accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentsAndSecuritiesAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares that would be issued, determined under the conditions specified in the contract, if the settlement were to occur at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109262807&amp;loc=d3e22047-110879<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=angn_OhrCosmeticsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=angn_OhrCosmeticsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=angn_LegalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=angn_LegalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=angn_NovaParkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=angn_NovaParkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=angn_DirectorsAndFamilyMemberOfChiefExecutiveOfficerDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=angn_DirectorsAndFamilyMemberOfChiefExecutiveOfficerDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=angn_PresidentAndChiefExecutiveOfficerAndDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=angn_PresidentAndChiefExecutiveOfficerAndDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=angn_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=angn_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=angn_FormerMemberOfTheBoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=angn_FormerMemberOfTheBoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=angn_OhrCosmeticsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=angn_OhrCosmeticsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=angn_ImmediateFamilyOfDirectorAndChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=angn_ImmediateFamilyOfDirectorAndChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=angn_OhrCosmeticsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=angn_OhrCosmeticsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=angn_NovaParkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=angn_NovaParkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939381327800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Nova Park Investment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Losses of equity method investment</a></td>
<td class="num">$ (96)<span></span>
</td>
<td class="num">$ (71)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Distribution from NovaPark</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=angn_NovaParkMember', window );">NovaPark | Equity Method Investee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning balance</a></td>
<td class="nump">672<span></span>
</td>
<td class="nump">849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Losses of equity method investment</a></td>
<td class="num">(96)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions', window );">Distribution from NovaPark</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending balance</a></td>
<td class="nump">$ 573<span></span>
</td>
<td class="nump">$ 672<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_EquityMethodInvestmentsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_EquityMethodInvestmentsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=angn_NovaParkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=angn_NovaParkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139939375543144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 01, 2022</div></th>
<th class="th"><div>Feb. 25, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits', window );">Severance benefits</a></td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">2021 Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_angn_ShareBasedPaymentArrangementPlanModificationExtendedExercisePeriod', window );">Plan modification, extended exercise period</a></td>
<td class="text">11 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_angn_ShareBasedPaymentArrangementPlanModificationExtendedExercisePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Payment Arrangement, Plan Modification, Extended Exercise Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">angn_ShareBasedPaymentArrangementPlanModificationExtendedExercisePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>angn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability for amount due employees, in addition to wages and any other money that employers owe employees, when their employment ends through a layoff or other termination. For example, a company may provide involuntarily terminated employees with a lump sum payment equal to one week's salary for every year of employment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=angn_A2021IncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=angn_A2021IncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>angn-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:angn="http://www.angn.com/20211231"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="angn-20211231.xsd" xlink:type="simple"/>
    <context id="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icf95c95dc2554e05bcfd8f1a4b0d4845_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i936ee8cbca4640f89962461f9dbfb53e_I20220325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
        </entity>
        <period>
            <instant>2022-03-25</instant>
        </period>
    </context>
    <context id="i3a167605e6c646629b93a1d3439787b9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1bc5ce1428404ed68895fc85d43b0940_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9e83b2738e914f70885e201c75695d23_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iea8b4e5177ca414aa1d42917857fa7fc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i39a22dafc7b947b7b1c0010ac7f3da2a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i06808f2a95374e118cce43e36bb8bd8a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idc9576f67b6c4e84ac9a7860f4e882ba_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i08c03f72f0b941539e5cdcb6bd71e375_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if1c7b28f9b2847048f8bff454357f045_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i88205c729a864e89b707c0e5f4a94101_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iff68735442874854ba8906f0ce685f7a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i49e1595df6544da1b62cb4cb76e2a870_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id7785562bdf04065b88581e12664c38d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iac2dd912c60747d0ad5686735d31aabd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib63d42df1d424dd7a089a2a61055a8d8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i627eb8ac3c1e4cdba53546b28b5c0c96_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5a141da19f2749e9915716c7f48fd1ed_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idcfdf8709ae1454db935f48886a3448d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iacbac71171a247f19b7f67fb114cc51b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9c2584c4d4d14f87943a1ff43186ef4d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if64d03bb45484664ab00b5e9ac3b4129_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i50d5f86cb19d42ff8235b613207c2abe_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9d292d5da1514f2bbaf90a5652db785c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7e02d3c90cee46fb92a3c766d05f4b5a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i56986948e86b485b8509172b9334c746_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icd0806ead4944367a276b62a1b32bafa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i86478d7cb5144b47ad734b74bf2a7754_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:NonIPORelatedStockTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ica25c8fd34524de8a476208cd00f9f89_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:NonIPORelatedStockTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i07f8bd8a51284654b005b52b3db91334_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:NonIPORelatedStockTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4a9ed117e7fc46209cfe726bed834b25_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6d21085dc3464fd4a077a8c4c29dc3df_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8c5cb1b641df48b3990cc9378065cd00_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifd74872b5622480ab9e4a8966ba04e3e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2c838774341347d18b026f9d063c570d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i88e560ec37ce491aadf9eb36b18848d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ida615667cda8491fabc586af6ea6cb44_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idd7eeb679a3a4b8b9e9dd842d2ac9f04_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibc29760a066749a2a385abd329cceb8f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:NonIPORelatedStockTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i03d5350f508b4144bc4917ef0ec5919e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:NonIPORelatedStockTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i38b7fad4d0a54f5b9f03bd9e2bdaa055_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5e0337892efb4f628c26a60c7c2fcbaf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i59b403c789684eb5976e604c15fb43a2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i10126ff884f24cee9f145c0c6031e0c1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1fd8ae3429f1487bb13c70c2678f3098_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia5d656fe36d64dd28f480aaf15a0cf24_D20210201-20210201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-01</endDate>
        </period>
    </context>
    <context id="icf79e0bd44fc44b6add290a67ac03123_D20210209-20210209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-09</startDate>
            <endDate>2021-02-09</endDate>
        </period>
    </context>
    <context id="i2fba8513019e4003882ec149aeddb34b_I20210209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
        </entity>
        <period>
            <instant>2021-02-09</instant>
        </period>
    </context>
    <context id="i670bd8e4908d4f42bafe357876fb520e_D20210209-20210209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-09</startDate>
            <endDate>2021-02-09</endDate>
        </period>
    </context>
    <context id="i166eae69229b4112968673ffefbf7d09_D20210209-20210209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-09</startDate>
            <endDate>2021-02-09</endDate>
        </period>
    </context>
    <context id="i5f34db6d61444fc0951ac5bca31c9cbc_D20210209-20210209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">angn:IPOAndPrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-09</startDate>
            <endDate>2021-02-09</endDate>
        </period>
    </context>
    <context id="ia2518ef5cab941c1b5281fac0348fe6c_I20210210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-10</instant>
        </period>
    </context>
    <context id="ie6530fcd8ea6401a8a572f67df226036_I20210210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
        </entity>
        <period>
            <instant>2021-02-10</instant>
        </period>
    </context>
    <context id="ifb691fd4a711422cabfdecc00c444d4f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie5ada18d76ea4a24976f7bb9e458c66c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i22b6851c4c8c4d8e9f955da168470856_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">angn:NovaParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2aaa47df28a24e29abd67cbe8873e02c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">angn:OhrCosmeticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i334eff8b0f0f4134b32ad37b7a4d1913_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">angn:OhrCosmeticsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia1527dbfa76d46b8a7b898736a11b2b6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if21e2f0448ee4d45b7742ead826a0858_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:ViforPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i8e92ffc10989447182476424cac89e3f_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:ViforPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="if93bd2dd820c484eaec104d26be89685_I20210209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:ViforPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-09</instant>
        </period>
    </context>
    <context id="i7c1c861e844341b5a5e29c716ed55595_D20210209-20210209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:ViforPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-09</startDate>
            <endDate>2021-02-09</endDate>
        </period>
    </context>
    <context id="icbbb8ca18fb34328a36cc3e05df1ac42_D20210209-20210209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:ViforPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-09</startDate>
            <endDate>2021-02-09</endDate>
        </period>
    </context>
    <context id="i2b2bdc42a04c4cd3af27c83384133f3b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic3a0a0d452d744969da82c474ba19d42_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:ViforPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2020-11-06</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="ib2c20a51369c40ba8a350cc15fab95b0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:ViforPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if19bda0412d14f569093c176591ee9a5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:ViforPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7dfe036a9b474f76843bec13725495e1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:ViforPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i76d34e6f4aa7484d9735bb67f83fe319_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:ViforPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2e59113239ac414b95bede6314d45d5a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:ViforPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia83ec88a3b3147ed8f7108e7f8a10e0f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iad4e3db6f2344adeaf53fa4f5bb5a0b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7afc7784bba7408fb2ba2c128f6657a8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2e37997f6b2f47c0a98e68a4f9edef5e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i154b24e4e9944f218abc0f9cd65e80b0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3b97b816eb8f487f8a5410b7dc6dc79b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idc2c8fc18af04652b3b74961e635dbe6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1c7ff22c3ff94a4d849562a284c0e1d2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85e948c0db004aec96a438029856e941_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">angn:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic66825b0a3fc4dd6a295dc833b6cfb18_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i814f9685f6c74fbb94e17b68b38c9a50_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0d1460718e76486b9ed354cf1c73b976_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibf7783ebf66b4af79c0713536f5f2962_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0e0cf619aa784005a71db89834b81180_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">angn:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i15bff6b964924bd2887e2adeffbf32c6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">angn:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic050e32ff85e44309aa662d9aef5ce48_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3bc00b7b825d4ba3852fb7e87894c1cc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66adccbb9df94f8b89614b7fed22144e_I20210209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-09</instant>
        </period>
    </context>
    <context id="i5ce6c1160cbc4d2eb14e3ddc68c08191_D20210209-20210209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis">us-gaap:ConvertiblePreferredStockSubjectToMandatoryRedemptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-09</startDate>
            <endDate>2021-02-09</endDate>
        </period>
    </context>
    <context id="ib2df00ce29b94846875f1ca16bf13df4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">angn:MeasurementInputStrikePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if4d6f862fa754573bef10ee164188288_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">angn:MeasurementInputStrikePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i209f579b21984d5987ce82e809b3b3f5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibdd03f678bd444f78c9695d99f88f610_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie5de6bc9b6694e62baba186bbdd4af73_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia35389eedc0a4461980878982b5787a2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia83dfc08acb543ae8924290c590ed65a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief2a3bab90b642da9d4fe8599569910c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib1b7ad6b8d104df388410248585c728f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i71c37180af7c40edb5bd3e902f2b71bc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia7d86eb6878a4ef0b875c05988047754_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic94945863a1b4df4ab1f5e7d2e9530c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9cfab8eface34dd4839fbb00af77dc97_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i306ddd1004714dec93e5d5ea85b3c8c6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i992e93e0d3c3482bad88da73616728c5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2ab54aa1e3014f50a5db232a28772555_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i65a1a8317ce94459b14feb26feeb201c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i070cfb2f33fa400ab61eda85d18e3338_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3e51cbe879fb441184f95b52afb2aeef_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibb7ba2f1254942b1b3dca57b33e584e4_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">angn:A2020NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i028f1ad3777340c2a17441b369da80c7_I20210209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-09</instant>
        </period>
    </context>
    <context id="i90d58066e44642be83973e6daa1dee34_D20210204-20210209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">angn:AdditionalConvertibleNotesAndViforConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-04</startDate>
            <endDate>2021-02-09</endDate>
        </period>
    </context>
    <context id="iac7d715402754b8caf32b6a9c1cee1f7_I20210209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-09</instant>
        </period>
    </context>
    <context id="i60078b3a55804ab1887cc07c853ff6f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id1dc2e8c07c14adba2e9db115900a85b_D20210125-20210125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">angn:A2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-25</startDate>
            <endDate>2021-01-25</endDate>
        </period>
    </context>
    <context id="i902c379eaab14156a55d3f460019dc3b_I20210125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">angn:A2021PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-25</instant>
        </period>
    </context>
    <context id="i54c2a1b829084a7b83834a08509335ce_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0e0e18adc0424cde81f1a02ec6eea58c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i391c5213ee2846a09acad8d39f4acc78_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib18cd3fd172f47be9edcff38ff0ed63a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5d2bddbdf568489b92aaf86fbd855a9d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i60ac161568b9493f9839384faf16222a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id7f5c1532cac4e2b998ae309d92d8edd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idc8909f8292a435ca08e7ea8957de0e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7817467d29ec42488073e266808a1b4a_D20190601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="idaadc88b9cdc4d3b9741cddf31c97c95_D20210209-20210209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-09</startDate>
            <endDate>2021-02-09</endDate>
        </period>
    </context>
    <context id="if60e35a6de454aaba1b4e414c82f9bab_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib6ed7c4e75a34a8e8f44a7115b92ba55_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i92b1ec8f60c4409cbb367354f0969366_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i92b73a2382864a80b71e3f51aef05903_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic47bf067546145a8a6fa9b871d43cefe_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6cfa5bf5e100430bbe5f169211eb27e2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if41f90861d0545f185125b2fd6ebf84a_I20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i6079bc9dc350474297feb207d4409628_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if16b69b23bb6477c809c732686e6c818_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:WarrantsIssuedWith2015NotesLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i43c1a8313c78494992d014e2ea73ba94_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:WarrantsIssuedWith2015NotesLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i27dc24aec76340a998ae99277f3efd2e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:WarrantsIssuedWith2016NotesLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5280c6af39144c0097d2718db5b41580_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:WarrantsIssuedWith2016NotesLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0fc4689e5cff46898c878ceef7ce56cd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:WarrantsIssuedWith2017NotesLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id76d56a33e4f4a60bb37b2bc487fbad9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:WarrantsIssuedWith2017NotesLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i79898ce5c218453fb0a55a7cb08aee82_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:WarrantsIssuedWith2018NotesLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib75e81811b1f43cb90f7a7a898c09ac1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:WarrantsIssuedWith2018NotesLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib18fedbfd53d471ca8ad9bda5ea20ac9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:WarrantsIssuedWithConversionOfNotesToCommonStockEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i84612d7718b644af9a1cf862077b6bc7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:WarrantsIssuedWithConversionOfNotesToCommonStockEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibea121a245f649d6a99c181f5a14bd89_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:WarrantsIssuedWithUnitsInTheEquityOfferingEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i855a01903f014f53bf8b37778bc42c99_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:WarrantsIssuedWithUnitsInTheEquityOfferingEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i891c62a6c35b47e48378588b88bb112c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:BrokerWarrantsIssuedWithEquityOfferingEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie0e5243bae824dccb7342c17c8cca4aa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:BrokerWarrantsIssuedWithEquityOfferingEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3a61ee941a9e4d32b5dd2e580ef7e639_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:BrokerWarrantsIssuedWith2019NotesLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3279c6cb0327462d84d652b4f17138c3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:BrokerWarrantsIssuedWith2019NotesLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i92b4a25f21264eb2b06953b7ef40a96f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:ConsultantWarrantsLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia49fffc648cc4ba7bc5e1c58b7adb469_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:ConsultantWarrantsLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie75149bd389348ac91dd0c486618b376_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">angn:WarrantsIssuedWith2015Notes2016Notes2017NotesAnd2018NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="i3b02e038496248b1bb8753bc722a0bb7_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i59e2995c2115446d9af3ddecfb37c4fb_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="i01849912679d402f8b851a0ea52911e4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i444bffaeb5fd4c7dae715a0266b8d087_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i519304eebcb54dc99bfcc6afa7d63b44_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="i7dfcdb12bfb34eb6b5ec1d691edc1a6b_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="i7fa0c3e9d7c641a48770a0df7a146319_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i0bf681e0236d4273af7ed9eb86410720_I20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="i2f1573b2c4114052bab5a6fe444a4633_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idfd7384fca0f46b6adea2d3695af1f7e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0c20e7a2f2df45a3b8f60672c1031439_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">angn:PaycheckProtectionProgramCARESActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i17fa801811ba45e3a75870ab1d78e1e1_D20210526-20210526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
        </entity>
        <period>
            <startDate>2021-05-26</startDate>
            <endDate>2021-05-26</endDate>
        </period>
    </context>
    <context id="i1461dc15821341d7a6cca5de3d10b493_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i49372af6f1524e94bc325a0b4866deb5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ief165a389cc44da0a2f2c5c214517d94_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iad85a45e0dbd4ab7a6756cc10a24ecbd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i43a2b3ab97bd48fbbe083e2b87ed4fa9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iac1a9fb579254c0480b5589b1c009eb5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i61bbd5c3b1454d27b052909fc297f17e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ieed9eb60e9b8413cacd41a553ad6bd3f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i02a82bc7014f4eb19de71fe9d69bdca3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i49f753c217c344e0805c4e8e7c263cd5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i53245befe1874188ac185852fef3d5a1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i83977ab456f040ddb39978debda8bbe4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia0f25cf926ad4d1cb71681e8f131863c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if8ec568c6dc54174abe4f2ad93aeceac_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibcf59fe47e7a4763a6e2bceeb52dd3ad_I20170731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">angn:OhrCosmeticsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-31</instant>
        </period>
    </context>
    <context id="ie1f1c87d61094a8385e1928cbcdef76b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">angn:OhrCosmeticsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">angn:ImmediateFamilyOfDirectorAndChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8d2bf22513e944e391d7fad6085a8765_I20131130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:OhrCosmeticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-11-30</instant>
        </period>
    </context>
    <context id="i65008406702b49f183286b36f4fbea14_D20131101-20131130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:OhrCosmeticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-11-01</startDate>
            <endDate>2013-11-30</endDate>
        </period>
    </context>
    <context id="i84aca19f2bf6464d955946950b093dca_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:OhrCosmeticsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2e21962d26f9431d9076d02be4f4d666_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:OhrCosmeticsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2f9aa6708d66419390b7f00e52079f31_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">angn:NovaParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4da1e16a428f4e4aa7b45ff38eee1854_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">angn:NovaParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i19d9a4a649894b55b85b7b8ebaac451b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">angn:NovaParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7ed3c6aeb1c1419881dbc5be2cf6ddfe_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">angn:NovaParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i35fe645b7bfa4fde8dbbbdd2b80db240_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:NovaParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8f44decd2d424510858c214c0073163a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">angn:NovaParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i917e433688284eaa953fc3c2fc1e1b85_D20210209-20210209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">angn:DirectorsAndFamilyMemberOfChiefExecutiveOfficerDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-09</startDate>
            <endDate>2021-02-09</endDate>
        </period>
    </context>
    <context id="i2962b55847164c55acf82150946c5fd6_I20210209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">angn:DirectorsAndFamilyMemberOfChiefExecutiveOfficerDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-09</instant>
        </period>
    </context>
    <context id="id1f12f1c81f2458db6d959e118e59154_I20210209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">angn:PresidentAndChiefExecutiveOfficerAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-09</instant>
        </period>
    </context>
    <context id="i4f17b2c4422d42688d50097720558178_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">angn:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia5c69981108b4d979649ac7fc1b0e400_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">angn:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie9131c9ee7eb4cf68ebd482f734ab577_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">angn:LegalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id853bebfd0c74da580bb31ede0e8af3e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">angn:LegalServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i30dc8694797e467d9c9068c898bcc9f8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">angn:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">angn:FormerMemberOfTheBoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5b7efeca53e04af18bee4dc3749aeaa9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">angn:ConsultingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">angn:FormerMemberOfTheBoardOfDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8f608066967d490d9002d2bb0340bdf8_I20220225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-25</instant>
        </period>
    </context>
    <context id="ie6b23068ffab46b0a0c550ea36e51385_I20220301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-01</instant>
        </period>
    </context>
    <context id="i405a2449e3304874876b5c7f79fa0336_D20220301-20220301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001601485</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">angn:A2021IncentiveAwardPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-01</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="operatingsegment">
        <measure>angn:operatingSegment</measure>
    </unit>
    <unit id="entity">
        <measure>angn:entity</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="option">
        <measure>angn:option</measure>
    </unit>
    <dei:DocumentFiscalYearFocus
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN183L2ZyYWc6OGIyNmFlYTQ3ZGQxNDRjMDg0ZDk5NDhjODIyMDgyZTQvdGFibGU6OTlhYjIxMWZkZmRlNGRkNTkzZjE1NTdjNWRmOTBmZDUvdGFibGVyYW5nZTo5OWFiMjExZmRmZGU0ZGQ1OTNmMTU1N2M1ZGY5MGZkNV84LTEtMS0xLTIyNzA1_29966fce-4622-4156-8557-308b9fc83f8a">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN183L2ZyYWc6OGIyNmFlYTQ3ZGQxNDRjMDg0ZDk5NDhjODIyMDgyZTQvdGFibGU6OTlhYjIxMWZkZmRlNGRkNTkzZjE1NTdjNWRmOTBmZDUvdGFibGVyYW5nZTo5OWFiMjExZmRmZGU0ZGQ1OTNmMTU1N2M1ZGY5MGZkNV85LTEtMS0xLTIyNzA4_41518d83-3877-45b0-9130-bb42699a88f5">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN183L2ZyYWc6OGIyNmFlYTQ3ZGQxNDRjMDg0ZDk5NDhjODIyMDgyZTQvdGFibGU6OTlhYjIxMWZkZmRlNGRkNTkzZjE1NTdjNWRmOTBmZDUvdGFibGVyYW5nZTo5OWFiMjExZmRmZGU0ZGQ1OTNmMTU1N2M1ZGY5MGZkNV8xMi0xLTEtMS0yMjcxNA_175d4cbc-86a4-4363-9d71-15810f5b4720">0001601485</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN183L2ZyYWc6OGIyNmFlYTQ3ZGQxNDRjMDg0ZDk5NDhjODIyMDgyZTQvdGFibGU6OTlhYjIxMWZkZmRlNGRkNTkzZjE1NTdjNWRmOTBmZDUvdGFibGVyYW5nZTo5OWFiMjExZmRmZGU0ZGQ1OTNmMTU1N2M1ZGY5MGZkNV8xMy0xLTEtMS0yMzk0OA_7e1b78dc-6742-4c82-8e19-aa3b21ab9e6e">false</dei:AmendmentFlag>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="ib2c20a51369c40ba8a350cc15fab95b0_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN180OTUvZnJhZzpmZjNhZGNhMWI4MGM0ZGYyYWRlZjk1YjI0MTc5YzA0Ni90ZXh0cmVnaW9uOmZmM2FkY2ExYjgwYzRkZjJhZGVmOTViMjQxNzljMDQ2XzEwOTk1MTE2MjgwMzg_088ef34c-af75-496c-8956-9dfa620079e5">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <dei:DocumentType
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N180Mzk4MDQ2NTE0MTAy_cb74fa5a-a963-4c6c-86a6-4dacf36ae2d8">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGFibGU6M2VlMWE5NzEwYmNlNDYzZWFkYjJlNGIyMGQzZjJmYmQvdGFibGVyYW5nZTozZWUxYTk3MTBiY2U0NjNlYWRiMmU0YjIwZDNmMmZiZF8wLTAtMS0xLTIzODgw_0cf18247-e59b-4b8d-9af0-5f6fcdcca95d">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N18xMDk5NTExNjMwODEx_4dfc43b4-a9b9-4c7e-affe-86ee9a289f94">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N18xMDk5NTExNjMwODEx_45f46163-d3b4-4289-8f7e-01096336ab7b">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGFibGU6MmYzOWY0YWQ2YmRkNGM4ZGEzMWQxZDY5Y2M3M2I2YWQvdGFibGVyYW5nZToyZjM5ZjRhZDZiZGQ0YzhkYTMxZDFkNjljYzczYjZhZF8wLTAtMS0xLTIyNjQ1_6d55091e-5828-45a5-86e6-9c53eda3cd8b">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N180Mzk4MDQ2NTE0MTAz_9f685319-077d-4b4b-ae75-780b476c62cd">001-04321</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N180Mzk4MDQ2NTE0MTA0_60ea76b2-0e3e-4a5d-92a1-676a51049492">ANGION BIOMEDICA CORP</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGFibGU6ZTI0YTg5ZmQ4NTBhNDY4NWEzNWM3YzFmNDhiOTRhNTUvdGFibGVyYW5nZTplMjRhODlmZDg1MGE0Njg1YTM1YzdjMWY0OGI5NGE1NV8wLTAtMS0xLTIyNjU0_3c244a5e-4d08-40f5-acfa-69314cf6bdd4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGFibGU6ZTI0YTg5ZmQ4NTBhNDY4NWEzNWM3YzFmNDhiOTRhNTUvdGFibGVyYW5nZTplMjRhODlmZDg1MGE0Njg1YTM1YzdjMWY0OGI5NGE1NV8wLTMtMS0xLTIyNjU4_85d122e0-773f-43b8-b3b3-8f352356b164">11-3430072</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGFibGU6ZTI0YTg5ZmQ4NTBhNDY4NWEzNWM3YzFmNDhiOTRhNTUvdGFibGVyYW5nZTplMjRhODlmZDg1MGE0Njg1YTM1YzdjMWY0OGI5NGE1NV8zLTAtMS0xLTIyNjYxL3RleHRyZWdpb246NjM5ZTQxYjhlYTUzNDEwZmJmZDcwZjUwZTg2OTcyOGZfMTA5OTUxMTYyNzg2Mg_e6c91538-17ae-4d6d-b994-b05ff339e042">51 Charles Lindbergh Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGFibGU6ZTI0YTg5ZmQ4NTBhNDY4NWEzNWM3YzFmNDhiOTRhNTUvdGFibGVyYW5nZTplMjRhODlmZDg1MGE0Njg1YTM1YzdjMWY0OGI5NGE1NV8zLTAtMS0xLTIyNjYxL3RleHRyZWdpb246NjM5ZTQxYjhlYTUzNDEwZmJmZDcwZjUwZTg2OTcyOGZfMTA5OTUxMTYyNzg3NA_22381e72-63dc-45e7-821b-eb8f27b945c9">Uniondale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGFibGU6ZTI0YTg5ZmQ4NTBhNDY4NWEzNWM3YzFmNDhiOTRhNTUvdGFibGVyYW5nZTplMjRhODlmZDg1MGE0Njg1YTM1YzdjMWY0OGI5NGE1NV8zLTAtMS0xLTIyNjYxL3RleHRyZWdpb246NjM5ZTQxYjhlYTUzNDEwZmJmZDcwZjUwZTg2OTcyOGZfMTA5OTUxMTYyNzg4Ng_642ecde0-f7e4-4f77-9b4f-6bab4882fde3">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGFibGU6ZTI0YTg5ZmQ4NTBhNDY4NWEzNWM3YzFmNDhiOTRhNTUvdGFibGVyYW5nZTplMjRhODlmZDg1MGE0Njg1YTM1YzdjMWY0OGI5NGE1NV8zLTMtMS0xLTIyNjY4_699a2925-8b0f-4cde-8a78-b93bd2f69a21">11553</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N180Mzk4MDQ2NTE0MTA1_e3de84a4-c95a-4326-ba0b-3a896cbdb450">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N180Mzk4MDQ2NTE0MTA2_298e80c7-3821-4771-8c29-535e66781613">655-4899</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGFibGU6OWZjYTU4MmJmZTA1NDBjZDhjZjEzNWQ2ODZjNDdlYWEvdGFibGVyYW5nZTo5ZmNhNTgyYmZlMDU0MGNkOGNmMTM1ZDY4NmM0N2VhYV8xLTAtMS0xLTIyNjc3_d61655e1-fd6e-4704-a54d-8c49f33abf9d">Common Stock, par value $0.01</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGFibGU6OWZjYTU4MmJmZTA1NDBjZDhjZjEzNWQ2ODZjNDdlYWEvdGFibGVyYW5nZTo5ZmNhNTgyYmZlMDU0MGNkOGNmMTM1ZDY4NmM0N2VhYV8xLTEtMS0xLTIyNjc5_96dd5e08-154b-4b96-8d2d-f4db54491716">ANGN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGFibGU6OWZjYTU4MmJmZTA1NDBjZDhjZjEzNWQ2ODZjNDdlYWEvdGFibGVyYW5nZTo5ZmNhNTgyYmZlMDU0MGNkOGNmMTM1ZDY4NmM0N2VhYV8xLTItMS0xLTIyNjgy_8f6c8237-b9db-4ce3-ac0e-53eb47526995">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N18yMTk5MDIzMjU4NTcx_217ed71c-32b5-495d-82c7-aedf74b66a59">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N18yMTk5MDIzMjYwMjY4_97607e5c-05af-4e40-bcde-7372e0b20b93">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N18yMTk5MDIzMjYwMjY5_61cc78d1-8d93-422d-acb3-5506d6cd672e">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N18yMTk5MDIzMjU4NTc0_f01fb144-21be-42ec-aae7-7fafae9e7864">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityShellCompany
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N18xMDk5NTExNjMyNDk2_3794a222-bce5-4d25-bfb8-a62c0dcf869c">false</dei:EntityShellCompany>
    <dei:EntityFilerCategory
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGFibGU6NjRhODE3N2MzNDc3NGRhNmExNmIzM2NlMTAxM2YwNWQvdGFibGVyYW5nZTo2NGE4MTc3YzM0Nzc0ZGE2YTE2YjMzY2UxMDEzZjA1ZF8xLTAtMS0xLTIyNjky_736867e0-d98d-4447-b4c3-4c1c4d4d73b8">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGFibGU6NjRhODE3N2MzNDc3NGRhNmExNmIzM2NlMTAxM2YwNWQvdGFibGVyYW5nZTo2NGE4MTc3YzM0Nzc0ZGE2YTE2YjMzY2UxMDEzZjA1ZF8xLTMtMS0xLTIyNjk0_faf49461-e039-4a5d-b559-4aa82b851a58">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGFibGU6NjRhODE3N2MzNDc3NGRhNmExNmIzM2NlMTAxM2YwNWQvdGFibGVyYW5nZTo2NGE4MTc3YzM0Nzc0ZGE2YTE2YjMzY2UxMDEzZjA1ZF8yLTMtMS0xLTIyNjk3_73ccbf28-7d34-461c-859f-643574a37683">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N180Mzk4MDQ2NTE0MTA5_4477f684-ab10-43ea-9642-541eb3529852">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N18yMTk5MDIzMjU4NTc1_c66ae668-94f3-49d6-82b0-8c5663af9183">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N18yNTk4_3794a222-bce5-4d25-bfb8-a62c0dcf869c">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="icf95c95dc2554e05bcfd8f1a4b0d4845_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N18xMDk5NTExNjMxNDQ4_a8280e03-5e55-441d-b9f4-8a7f6f9b9e2d"
      unitRef="usd">365000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i936ee8cbca4640f89962461f9dbfb53e_I20220325"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N18yOTEy_7c0396f5-f0fe-44e0-9b7f-ed7dbe792f6c"
      unitRef="shares">29958064</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xL2ZyYWc6YTExZDBhODk4ZDc4NGNhNWI4YWY5MjVhNzk3OWYwOTcvdGV4dHJlZ2lvbjphMTFkMGE4OThkNzg0Y2E1YjhhZjkyNWE3OTc5ZjA5N18yMTk5MDIzMjU4NTg0_b5d52fe1-0e8c-4483-b0dc-e6fb45f09046">Portions of the registrant&#x2019;s definitive proxy statement relating to the 2022 Annual Meeting of Stockholders, which will be filed with the Securities and Exchange Commission within 120 days after the end of the registrant&#x2019;s fiscal year ended December 31, 2021, are incorporated by reference into Part III of this Annual Report on Form 10-K.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184Mi9mcmFnOjg3YWI5OGQ1ZTU4ZjQ2YTc4Y2UyOTQ1MjRkMmQxM2ZkL3RhYmxlOmY1MmE3NjZkNzBiMjQ4NmViYWM0NDFiODlkNTBkNTE1L3RhYmxlcmFuZ2U6ZjUyYTc2NmQ3MGIyNDg2ZWJhYzQ0MWI4OWQ1MGQ1MTVfMi0wLTEtMS0yNTgzNy90ZXh0cmVnaW9uOmJkMjZmOGMxNTVjMzQ2MzRiZWNjZjc1NDhmZTczNWMxXzE2NDkyNjc0NDI0NjA_13ccedb3-303d-4672-b55f-80e4dcf5b9fd">Moss Adams LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184Mi9mcmFnOjg3YWI5OGQ1ZTU4ZjQ2YTc4Y2UyOTQ1MjRkMmQxM2ZkL3RhYmxlOmY1MmE3NjZkNzBiMjQ4NmViYWM0NDFiODlkNTBkNTE1L3RhYmxlcmFuZ2U6ZjUyYTc2NmQ3MGIyNDg2ZWJhYzQ0MWI4OWQ1MGQ1MTVfMi0wLTEtMS0yNTgzNy90ZXh0cmVnaW9uOmJkMjZmOGMxNTVjMzQ2MzRiZWNjZjc1NDhmZTczNWMxXzE2NDkyNjc0NDI0ODI_7a6351f5-c9ca-408b-8a92-f5ed87b19ebf">Seattle, Washington</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184Mi9mcmFnOjg3YWI5OGQ1ZTU4ZjQ2YTc4Y2UyOTQ1MjRkMmQxM2ZkL3RhYmxlOmY1MmE3NjZkNzBiMjQ4NmViYWM0NDFiODlkNTBkNTE1L3RhYmxlcmFuZ2U6ZjUyYTc2NmQ3MGIyNDg2ZWJhYzQ0MWI4OWQ1MGQ1MTVfMi0wLTEtMS0yNTgzNy90ZXh0cmVnaW9uOmJkMjZmOGMxNTVjMzQ2MzRiZWNjZjc1NDhmZTczNWMxXzE2NDkyNjc0NDI0ODg_11d8821c-6eb3-4035-afe4-449e007caad5">659</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfNC0xLTEtMS0yMjU0NQ_212ae75e-e451-44af-8d89-8b6381ade05a"
      unitRef="usd">88756000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfNC0zLTEtMS0yMjU0NQ_632c065a-a4f3-465d-b3d9-cb2a8c149664"
      unitRef="usd">34607000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:GrantsReceivableCurrent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfNS0xLTEtMS0yMjU0NQ_fdef8273-0695-430f-8c05-32ddc39c462f"
      unitRef="usd">806000</us-gaap:GrantsReceivableCurrent>
    <us-gaap:GrantsReceivableCurrent
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfNS0zLTEtMS0yMjU0NQ_418707dd-2eba-4493-8a92-9c82e3dd9cbf"
      unitRef="usd">0</us-gaap:GrantsReceivableCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfNi0xLTEtMS0yMjU0NQ_49d67bf0-cf36-4f64-90c9-3b38470b40df"
      unitRef="usd">1685000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfNi0zLTEtMS0yMjU0NQ_46c7cc0d-836d-474a-bf60-c10291ab62ea"
      unitRef="usd">7690000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfNy0xLTEtMS0yMjU0NQ_2008d228-68ac-4812-99dc-abe994276340"
      unitRef="usd">91247000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfNy0zLTEtMS0yMjU0NQ_e60ef7de-ef47-4b85-aef9-768e3417b72c"
      unitRef="usd">42297000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfOC0xLTEtMS0yMjU0NQ_647a72cb-a31d-42e0-a982-f1962ec8fc38"
      unitRef="usd">451000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfOC0zLTEtMS0yMjU0NQ_d88cd554-ddbd-4e7b-b4a8-5d0231921cd1"
      unitRef="usd">156000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfOS0xLTEtMS0yMjU0NQ_245c07d6-ea8e-4696-9fee-17fdf43dd015"
      unitRef="usd">3986000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfOS0zLTEtMS0yMjU0NQ_e437df95-9767-420a-88f1-532feacb4f19"
      unitRef="usd">4072000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Investments
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTAtMS0xLTEtMjI1NDU_c45b82bd-397c-44dd-935d-245d33ab3f1f"
      unitRef="usd">723000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTAtMy0xLTEtMjI1NDU_2263dfb3-ec71-4526-a323-c63f5787d66f"
      unitRef="usd">822000</us-gaap:Investments>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTEtMS0xLTEtMjU0MTY_b6d7c8ac-8612-46fe-a6ef-f48e6b6750c9"
      unitRef="usd">106000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTEtMy0xLTEtMjU0MTY_cb8ed288-e454-464e-a105-a41f70c4cc72"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTEtMS0xLTEtMjI1NDU_a29355bc-2c82-4702-837a-535e1cc10643"
      unitRef="usd">96513000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTEtMy0xLTEtMjI1NDU_8f02b01c-a84a-40e8-b85f-e40211031418"
      unitRef="usd">47347000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTQtMS0xLTEtMjI1NDU_04cbac64-d82e-4f6c-be9d-04313373c8c6"
      unitRef="usd">4710000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTQtMy0xLTEtMjI1NDU_39fb05d4-4d64-40d7-942e-8a19fe974058"
      unitRef="usd">5578000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTUtMS0xLTEtMjI1NDU_fdce8d4d-20bd-44f4-a085-8f5c3f6e1bad"
      unitRef="usd">3219000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTUtMy0xLTEtMjI1NDU_0f947289-651d-4669-a850-bd5be7dd02e6"
      unitRef="usd">6665000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTYtMS0xLTEtMjI1NDU_95af4f29-62ac-4773-967c-dc6a5df61895"
      unitRef="usd">894000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTYtMy0xLTEtMjI1NDU_ab1e9aeb-1f59-4cab-92ad-ef42056e8cb0"
      unitRef="usd">611000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTgtMS0xLTEtMjU0MzU_01ef6498-8f22-48cd-8f5a-ec9997d69f70"
      unitRef="usd">58000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTgtMy0xLTEtMjU0MzU_49ed4676-df6b-49b9-9a02-152f0199fb55"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTctMS0xLTEtMjI1NDU_524ff735-1b2e-4d98-963d-e8489f835d1f"
      unitRef="usd">2301000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTctMy0xLTEtMjI1NDU_7416a51c-71a8-426d-aaa2-1e70b3215cd8"
      unitRef="usd">3942000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <angn:WarrantLiabilityCurrent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTgtMS0xLTEtMjI1NDU_abd998ed-3b58-4628-8458-9333aa381692"
      unitRef="usd">114000</angn:WarrantLiabilityCurrent>
    <angn:WarrantLiabilityCurrent
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTgtMy0xLTEtMjI1NDU_0ab46054-c44a-40b6-bba2-6851458d114e"
      unitRef="usd">10704000</angn:WarrantLiabilityCurrent>
    <us-gaap:ShortTermNonBankLoansAndNotesPayable
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTktMS0xLTEtMjI1NDU_6f0551ff-e8c2-44e5-b99e-c5eaca14750e"
      unitRef="usd">0</us-gaap:ShortTermNonBankLoansAndNotesPayable>
    <us-gaap:ShortTermNonBankLoansAndNotesPayable
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMTktMy0xLTEtMjI1NDU_cf760db7-e98d-4da1-89ee-bc96848a4797"
      unitRef="usd">51170000</us-gaap:ShortTermNonBankLoansAndNotesPayable>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjAtMS0xLTEtMjI1NDU_2205306e-7fbf-419f-ac5d-e4bad51fbf58"
      unitRef="usd">0</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjAtMy0xLTEtMjI1NDU_6e2b06ef-9378-414d-b4fd-c7f2da50075c"
      unitRef="usd">26001000</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent>
    <angn:FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjEtMS0xLTEtMjI1NDU_e003f8d2-60e3-42e5-8892-00f8523f4f26"
      unitRef="usd">0</angn:FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent>
    <angn:FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjEtMy0xLTEtMjI1NDU_0141068e-c660-4ca4-b262-9c25e53a3839"
      unitRef="usd">2518000</angn:FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent>
    <us-gaap:OtherShortTermBorrowings
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjItMS0xLTEtMjI1NDU_5ecf5466-ec93-439c-812a-ec4bbccea225"
      unitRef="usd">0</us-gaap:OtherShortTermBorrowings>
    <us-gaap:OtherShortTermBorrowings
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjItMy0xLTEtMjI1NDU_45e6b743-ef1e-4f06-97aa-21d474ab5e81"
      unitRef="usd">260000</us-gaap:OtherShortTermBorrowings>
    <us-gaap:LiabilitiesCurrent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjMtMS0xLTEtMjI1NDU_a9b5faa7-55bc-4317-b3db-0adedf5219a5"
      unitRef="usd">11296000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjMtMy0xLTEtMjI1NDU_45433aa9-6559-48da-9f40-c49ec39640a2"
      unitRef="usd">107449000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjQtMS0xLTEtMjI1NDU_7b36209c-0e49-4cdf-8a58-d9804139ad8e"
      unitRef="usd">3475000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjQtMy0xLTEtMjI1NDU_98280d1a-3ca7-4ba4-aec2-07af731e6164"
      unitRef="usd">3847000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjctMS0xLTEtMjY2Mzk_9b311185-d938-4052-b33c-b282274f69bb"
      unitRef="usd">235000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjctMy0xLTEtMjY2Mzk_fcbed780-8e38-4f8b-8bbc-ac28f848869b"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjUtMS0xLTEtMjI1NDU_41a95bf5-4c0b-4d19-9930-b66b95da993e"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjUtMy0xLTEtMjI1NDU_699713ee-c7c4-4c12-a4bc-f50f874d12ce"
      unitRef="usd">25865000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjYtMS0xLTEtMjI1NDU_ac13a78f-6250-4a03-89a0-6658c646f3ee"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjYtMy0xLTEtMjI1NDU_a3888096-68d0-494a-ae95-8540cff9ac69"
      unitRef="usd">635000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:Liabilities
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjctMS0xLTEtMjI1NDU_6f2e055b-35f2-4e5c-845e-0e1655ee89d7"
      unitRef="usd">15006000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjctMy0xLTEtMjI1NDU_25263604-5714-47c9-970a-82f619790647"
      unitRef="usd">137796000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjgtMS0xLTEtMjI3MTk_3aa83f4c-5267-4e00-8409-f052128e1943"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMjgtMy0xLTEtMjI3MTk_c5906189-36f9-4ea4-9933-62b70d1d6354"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzItMC0xLTEtMjI1NDUvdGV4dHJlZ2lvbjpiN2MyOTg0MzBjYzE0ZTMzODA3MjkxMzYyMmM4YjRhZF8xMDk5NTExNjI4MTAx_ae9a1064-d583-48dd-8cf0-a7b6ab4b34d5"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzItMC0xLTEtMjI1NDUvdGV4dHJlZ2lvbjpiN2MyOTg0MzBjYzE0ZTMzODA3MjkxMzYyMmM4YjRhZF8xMDk5NTExNjI4MTAx_f29130b4-f33c-449a-b99e-4b078a686a95"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzItMC0xLTEtMjI1NDUvdGV4dHJlZ2lvbjpiN2MyOTg0MzBjYzE0ZTMzODA3MjkxMzYyMmM4YjRhZF8xMDk5NTExNjI4MDQx_41741cf2-a04e-4702-8717-3593403f32e2"
      unitRef="shares">30000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzItMC0xLTEtMjI1NDUvdGV4dHJlZ2lvbjpiN2MyOTg0MzBjYzE0ZTMzODA3MjkxMzYyMmM4YjRhZF8xMDk5NTExNjI4MDQx_c6fb1a43-371b-4d32-a6fc-4b7013b88d66"
      unitRef="shares">30000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzItMC0xLTEtMjI1NDUvdGV4dHJlZ2lvbjpiN2MyOTg0MzBjYzE0ZTMzODA3MjkxMzYyMmM4YjRhZF8xMDk5NTExNjI4MDU0_ddd09793-c39e-41a2-9489-3a6e56a05ec8"
      unitRef="shares">29959060</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzItMC0xLTEtMjI1NDUvdGV4dHJlZ2lvbjpiN2MyOTg0MzBjYzE0ZTMzODA3MjkxMzYyMmM4YjRhZF8xMDk5NTExNjI4MDY3_fbd19cdf-3cd8-4240-a510-18e050719269"
      unitRef="shares">15632809</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzItMC0xLTEtMjI1NDUvdGV4dHJlZ2lvbjpiN2MyOTg0MzBjYzE0ZTMzODA3MjkxMzYyMmM4YjRhZF8xMDk5NTExNjI4MDgw_0712ab47-da47-4374-b8cc-5ef2bfe41db9"
      unitRef="shares">29959060</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzItMC0xLTEtMjI1NDUvdGV4dHJlZ2lvbjpiN2MyOTg0MzBjYzE0ZTMzODA3MjkxMzYyMmM4YjRhZF8xMDk5NTExNjI4MDkz_a4b85cd9-db2c-4468-82f5-cfe88a81f8ca"
      unitRef="shares">15316721</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzItMS0xLTEtMjI1NDU_a230ece0-87a9-4817-a494-86edb5776281"
      unitRef="usd">300000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzItMy0xLTEtMjI1NDU_b38c6fd7-cabe-44cf-9f47-e92ae99a5641"
      unitRef="usd">156000</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockShares
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzMtMC0xLTEtMjI1NDUvdGV4dHJlZ2lvbjo2Y2RmM2VmZDQ4ZjA0OGI5YTM5MjhjZmQzZGY1Nzk1NV8xMDk5NTExNjI3OTA0_1ec7de2d-aaac-4e8b-ac91-c6a27114c66f"
      unitRef="shares">0</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzMtMC0xLTEtMjI1NDUvdGV4dHJlZ2lvbjo2Y2RmM2VmZDQ4ZjA0OGI5YTM5MjhjZmQzZGY1Nzk1NV8xMDk5NTExNjI3ODg5_a79241ac-90fe-4128-9f7c-0dd9bb515cc2"
      unitRef="shares">316088</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzMtMS0xLTEtMjI1NDU_68dc9176-7b57-4de3-8381-c93a6f08359d"
      unitRef="usd">0</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzMtMy0xLTEtMjI1NDU_d1695752-9e25-4f49-87db-08230fc3ffe6"
      unitRef="usd">1846000</us-gaap:TreasuryStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzQtMS0xLTEtMjI1NDU_19c77849-8a39-4c72-b54a-3bd6adeeb2b8"
      unitRef="usd">296445000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzQtMy0xLTEtMjI1NDU_705ac362-edf9-41d4-a2e5-a14ee72e4c2f"
      unitRef="usd">72136000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzUtMS0xLTEtMjI1NDU_fe6b0029-7ba9-43ca-b9db-f8105ec32f79"
      unitRef="usd">-103000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzUtMy0xLTEtMjI1NDU_d82115ad-eb29-42c7-88ca-c6b8cb919761"
      unitRef="usd">-333000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzYtMS0xLTEtMjI1NDU_a14015bc-a6b7-438d-91ce-9f032708df77"
      unitRef="usd">-215135000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzYtMy0xLTEtMjI1NDU_68d3ca83-65d9-4473-bddd-478162665156"
      unitRef="usd">-160562000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzctMS0xLTEtMjI1NDU_9c24c309-649c-4359-af9f-1784ec42a71a"
      unitRef="usd">81507000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzctMy0xLTEtMjI1NDU_97809bab-988d-4109-896e-c1474f907aa7"
      unitRef="usd">-90449000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzgtMS0xLTEtMjI1NDU_0362a071-4f73-4775-a4b2-39ad4b13a6b0"
      unitRef="usd">96513000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN184OC9mcmFnOmYwZGZjMjk0YzNjZjQ0OTJiOTZmMWQxYjNjOThiNzEyL3RhYmxlOmU2YjRlZDE2NzM5MzQzODU4OTYyYmI3NTMzNTczOGIwL3RhYmxlcmFuZ2U6ZTZiNGVkMTY3MzkzNDM4NTg5NjJiYjc1MzM1NzM4YjBfMzgtMy0xLTEtMjI1NDU_9f3f37c6-83b9-47dc-9800-2e5927282109"
      unitRef="usd">47347000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMy0xLTEtMS0yMjU0NQ_cc3c8987-c06d-46ec-bfb3-12e25ef081a1"
      unitRef="usd">27506000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMy0zLTEtMS0yMjU0NQ_b852958e-db4a-4368-93af-33c782466fdf"
      unitRef="usd">193000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfNC0xLTEtMS0yMjU0NQ_995d8679-2b7f-43c8-a016-a9651fb778a3"
      unitRef="usd">806000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfNC0zLTEtMS0yMjU0NQ_bf3205f1-644a-4dd1-ab16-0738cf100412"
      unitRef="usd">2687000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:Revenues
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfNS0xLTEtMS0yMjU0NQ_8857064c-5e92-4378-8691-4a7f93f4641a"
      unitRef="usd">28312000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfNS0zLTEtMS0yMjU0NQ_70ff4fb7-2d8c-4658-8d10-667bc0328158"
      unitRef="usd">2880000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfOC0xLTEtMS0yMjU0NQ_0bb7c854-b9ce-467c-8fc6-a452f0e2f04b"
      unitRef="usd">433000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfOC0zLTEtMS0yMjU0NQ_a26ee83d-7bae-4b10-aead-32b7b3abf547"
      unitRef="usd">1190000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfOS0xLTEtMS0yMjU0NQ_3686c769-ad00-4c63-a412-1a0c59378085"
      unitRef="usd">48698000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfOS0zLTEtMS0yMjU0NQ_35fa219b-16d9-4187-8959-2e043af2cc76"
      unitRef="usd">38977000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTAtMS0xLTEtMjI1NDU_bdd8254e-2faa-41b4-8a40-4a77007a2f75"
      unitRef="usd">18488000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTAtMy0xLTEtMjI1NDU_0b724f55-80b3-42bd-8519-e1b58ec567e8"
      unitRef="usd">17986000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTEtMS0xLTEtMjI1NDU_1a9c0928-321b-4cd7-b72c-cdef98e334f2"
      unitRef="usd">67619000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTEtMy0xLTEtMjI1NDU_c25e63fc-d965-4c17-a156-0c85d876179c"
      unitRef="usd">58153000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTItMS0xLTEtMjI1NDU_d4d41917-74e9-4105-ad0d-b8487368e50f"
      unitRef="usd">-39307000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTItMy0xLTEtMjI1NDU_c2c198ed-61ca-4cc2-a41c-6b24f3df2aa7"
      unitRef="usd">-55273000</us-gaap:OperatingIncomeLoss>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTQtMS0xLTEtMjI1NDU_c08958f2-87b8-47bb-b4e2-3e33157bc2fe"
      unitRef="usd">2919000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTQtMy0xLTEtMjI1NDU_b1a3ac60-e484-423d-8452-a4c898b5707b"
      unitRef="usd">4910000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTUtMS0xLTEtMjI1NDU_1e1f4445-4675-491e-ad1e-c14e8686760b"
      unitRef="usd">-7469000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTUtMy0xLTEtMjI1NDU_42a85e4b-700c-40a9-bd28-5e98b7f89224"
      unitRef="usd">-11353000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <angn:FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTYtMS0xLTEtMjI1NDU_54c78360-9edc-40f9-b1cf-db2ff3d897f6"
      unitRef="usd">-3592000</angn:FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss>
    <angn:FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTYtMy0xLTEtMjI1NDU_20244d70-0359-4f93-a627-ea32ea498940"
      unitRef="usd">-264000</angn:FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTctMS0xLTEtMjI1NDU_3e333e12-97a9-4044-b41d-9d44e81cb319"
      unitRef="usd">-245000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTctMy0xLTEtMjI1NDU_5bbebee1-d393-4c91-a3e8-7a7fce2f297e"
      unitRef="usd">668000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTgtMS0xLTEtMjI1NDU_00dffd5f-481e-4316-91ab-403485b7d6ab"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTgtMy0xLTEtMjI1NDU_5596a917-ead0-4ecf-b74b-6e9bcc79553a"
      unitRef="usd">-58000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTktMS0xLTEtMzc4MzI_2f8befe6-3f68-4b4f-823b-5a1b7e0c9a59"
      unitRef="usd">905000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTktMy0xLTEtMzc4MzI_0f7518f9-24ac-4038-acbd-4d5e10319aa2"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTktMS0xLTEtMjI1NDU_f76e8567-f0cc-43b1-91bb-0296d9805f64"
      unitRef="usd">-99000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMTktMy0xLTEtMjI1NDU_9e5142be-329b-4684-b0f3-405fa8ea8e06"
      unitRef="usd">-71000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjAtMS0xLTEtMjI1NDU_bf7b59a8-210d-4a74-865a-86f776eba2db"
      unitRef="usd">-1847000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjAtMy0xLTEtMjI1NDU_67a63e83-2117-41dc-ac8f-1e5129bdecf9"
      unitRef="usd">-8846000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjEtMS0xLTEtMjI1NDU_dc0c084d-3ea8-4d90-9658-c495c74eff81"
      unitRef="usd">-15266000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjEtMy0xLTEtMjI1NDU_87090cfb-6a85-464d-a509-e1aafb9dd7fa"
      unitRef="usd">-24834000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjItMS0xLTEtMjI1NDU_811dc8e2-78ce-4d50-9048-f8960f79f901"
      unitRef="usd">-54573000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjItMy0xLTEtMjI1NDU_f024e993-06db-4a34-84dd-a47f4722ad41"
      unitRef="usd">-80107000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjQtMS0xLTEtMjI1NDU_41a53d7e-8b59-443e-809b-9ce93f1a30fe"
      unitRef="usd">230000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjQtMy0xLTEtMjI1NDU_7ed6cc23-3497-4f28-8a4e-2e8906a48d51"
      unitRef="usd">-333000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjUtMS0xLTEtMjI1NDU_cea26a49-fe66-44f0-8f60-27c973d344dd"
      unitRef="usd">-54343000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjUtMy0xLTEtMjI1NDU_b1f9d425-331b-442d-9a49-6948c48ec362"
      unitRef="usd">-80440000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjYtMS0xLTEtMjI1NDU_39427dc8-e2bb-4dd5-83bd-9b4a8cd54fac"
      unitRef="usdPerShare">-1.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjYtMS0xLTEtMjI1NDU_63fdd590-3976-4220-811b-3a502b6ba046"
      unitRef="usdPerShare">-1.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjYtMy0xLTEtMjI1NDU_7043520e-5384-49da-9a1b-e2586f3b3a5b"
      unitRef="usdPerShare">-5.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjYtMy0xLTEtMjI1NDU_cf0476ad-e429-4060-b77d-7a0fa9dca8b0"
      unitRef="usdPerShare">-5.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjctMS0xLTEtMjI1NDU_4932bb72-d22d-45db-bcbb-740f62e5da34"
      unitRef="shares">28244825</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjctMS0xLTEtMjI1NDU_e7255d3e-f3ba-40f1-aa37-7f7321e45e4e"
      unitRef="shares">28244825</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjctMy0xLTEtMjI1NDU_51d95e0f-7ab9-4851-bf2b-b69c43c4aa2b"
      unitRef="shares">14762120</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185MS9mcmFnOjQ3OTJiMDkwYTdjYjRjZDhhMDY4MDNkNTY5NGRiZTVhL3RhYmxlOjg0ODU1YTk1YTJiMTQzMTI4NmM5N2E1NWNmYjgzNDRlL3RhYmxlcmFuZ2U6ODQ4NTVhOTVhMmIxNDMxMjg2Yzk3YTU1Y2ZiODM0NGVfMjctMy0xLTEtMjI1NDU_59e6d4ab-b47b-4f2c-ae31-48b9655b7db2"
      unitRef="shares">14762120</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="i9e83b2738e914f70885e201c75695d23_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfOC0yLTEtMS0zODUyOQ_bdb1c98a-985c-498e-85f3-f10f7f5e8909"
      unitRef="shares">14758718</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9e83b2738e914f70885e201c75695d23_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfOC00LTEtMS0zODUzMQ_7e03df8e-ba41-4f24-8e1f-df7d4b63b564"
      unitRef="usd">148000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="iea8b4e5177ca414aa1d42917857fa7fc_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfOC02LTEtMS0zODUzMQ_e9a3b5bb-365a-4c10-9317-f9abccb1f209"
      unitRef="shares">-312164</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iea8b4e5177ca414aa1d42917857fa7fc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfOC04LTEtMS0zODUzMQ_3b9b6d80-3fb1-45a6-903d-fb8d6ecbf384"
      unitRef="usd">-1810000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i39a22dafc7b947b7b1c0010ac7f3da2a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfOC0xMC0xLTEtMzg1MzE_35c09781-0923-43cb-8777-934ffa76075b"
      unitRef="usd">63531000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i06808f2a95374e118cce43e36bb8bd8a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfOC0xMi0xLTEtMzg1MzE_36f0cec1-507b-44e3-8a0a-a057d18149fb"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idc9576f67b6c4e84ac9a7860f4e882ba_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfOC0xNC0xLTEtMzg1MzE_034884a8-76e8-47d5-88e6-e1560d168ff8"
      unitRef="usd">-80455000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i08c03f72f0b941539e5cdcb6bd71e375_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfOC0xNi0xLTEtMzg1MzE_1dfb6088-9e47-4911-9203-98bfba9618f3"
      unitRef="usd">-18586000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="if1c7b28f9b2847048f8bff454357f045_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfOS0xMC0xLTEtMzg1MzU_1acdd01e-5114-4e4f-ab07-9af27becc75d"
      unitRef="usd">3095000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfOS0xNi0xLTEtMzg1MzU_45a38030-4b61-4c4b-b883-a1a8ef24f419"
      unitRef="usd">3095000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <angn:StockIssuedDuringPeriodSharesBrokerWarrantsExercised
      contextRef="i88205c729a864e89b707c0e5f4a94101_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTAtMi0xLTEtMzg1MzU_fc90e211-c038-4af9-b7d4-fe80f3a53af0"
      unitRef="shares">572946</angn:StockIssuedDuringPeriodSharesBrokerWarrantsExercised>
    <angn:StockIssuedDuringPeriodValueBrokerWarrantsExercised
      contextRef="i88205c729a864e89b707c0e5f4a94101_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTAtNC0xLTEtMzg1MzU_9ae61e99-6c39-407e-bbb5-c59aa9f8ccbd"
      unitRef="usd">6000</angn:StockIssuedDuringPeriodValueBrokerWarrantsExercised>
    <angn:StockIssuedDuringPeriodValueBrokerWarrantsExercised
      contextRef="if1c7b28f9b2847048f8bff454357f045_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTAtMTAtMS0xLTM4NTM1_1b5fb614-e4b6-41d6-915b-fdd3427a50dd"
      unitRef="usd">-2000</angn:StockIssuedDuringPeriodValueBrokerWarrantsExercised>
    <angn:StockIssuedDuringPeriodValueBrokerWarrantsExercised
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTAtMTYtMS0xLTM4NTM1_05b372e0-2f8d-4b90-ad3d-eac19e41cc02"
      unitRef="usd">4000</angn:StockIssuedDuringPeriodValueBrokerWarrantsExercised>
    <angn:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i88205c729a864e89b707c0e5f4a94101_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTEtMi0xLTEtMzg1Mzc_0600087c-e8bb-4e5a-832c-e9f18eb34764"
      unitRef="shares">93349</angn:StockIssuedDuringPeriodSharesWarrantsExercised>
    <angn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i88205c729a864e89b707c0e5f4a94101_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTEtNC0xLTEtMzg1NDA_31d214c4-6429-43f3-80ae-cd3f3840d9a9"
      unitRef="usd">1000</angn:StockIssuedDuringPeriodValueWarrantsExercised>
    <angn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="if1c7b28f9b2847048f8bff454357f045_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTEtMTAtMS0xLTM4NTQ2_d836827f-a884-4f56-b218-4a4aad09b10a"
      unitRef="usd">750000</angn:StockIssuedDuringPeriodValueWarrantsExercised>
    <angn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTEtMTYtMS0xLTM4NTQz_4aad4247-056b-49db-9e14-c24835bff65b"
      unitRef="usd">751000</angn:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i88205c729a864e89b707c0e5f4a94101_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTItMi0xLTEtMzg1NDk_a6842fa0-dc39-477c-a761-65fe2cacdd23"
      unitRef="shares">194427</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i88205c729a864e89b707c0e5f4a94101_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTItNC0xLTEtMzg1NTI_06922b44-361c-4bd6-afc7-e233a6ae0be3"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if1c7b28f9b2847048f8bff454357f045_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTItMTAtMS0xLTM4NTU1_897350a4-be43-469c-ace7-88bd4415351f"
      unitRef="usd">46000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTItMTYtMS0xLTM4NTU4_4ce4e5c0-c99e-4b63-8701-5ae19694c414"
      unitRef="usd">47000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i88205c729a864e89b707c0e5f4a94101_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTMtMi0xLTEtMzg1NjE_ed1e0360-566d-459f-8f46-12e1e71cdf42"
      unitRef="shares">13369</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="iff68735442874854ba8906f0ce685f7a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTQtNi0xLTEtMzg1NzA_d07dd5eb-8889-464c-a624-ec4e7039491d"
      unitRef="shares">3924</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="iff68735442874854ba8906f0ce685f7a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTQtOC0xLTEtMzg1NjQ_598ab050-57f4-4b69-a21c-ee1236c74801"
      unitRef="usd">36000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTQtMTYtMS0xLTM4NTY3_a72c78a2-9e22-427d-b9d8-bfffd0154eec"
      unitRef="usd">36000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if1c7b28f9b2847048f8bff454357f045_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTUtMTAtMS0xLTM4NTcz_7441f262-96d7-4a1f-ac1f-29590ad9b9d7"
      unitRef="usd">4716000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTUtMTYtMS0xLTM4NTcz_406eaacb-5a9d-44ea-aa51-9f7ef4443cbb"
      unitRef="usd">4716000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i49e1595df6544da1b62cb4cb76e2a870_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTYtMTItMS0xLTM4NTcz_4494f8be-7717-4999-91d1-0a5b46f0e9d0"
      unitRef="usd">-333000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTYtMTYtMS0xLTM4NTcz_12c2055c-edf5-4d7b-99fb-fff1cb3aa98e"
      unitRef="usd">-333000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="id7785562bdf04065b88581e12664c38d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTctMTQtMS0xLTM4NTcz_8b5866ea-8f75-4091-ad29-9454608b1c50"
      unitRef="usd">-80107000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTctMTYtMS0xLTM4NTcz_06b714d2-7708-4983-b7fc-e89d81d216c5"
      unitRef="usd">-80107000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="iac2dd912c60747d0ad5686735d31aabd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTgtMi0xLTEtMzg1MzM_2e0c214d-9380-43cd-929b-678ea2458e70"
      unitRef="shares">15632809</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iac2dd912c60747d0ad5686735d31aabd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTgtNC0xLTEtMzg1MzM_b26c5337-81e5-4e66-ad5f-e863d78c6369"
      unitRef="usd">156000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ib63d42df1d424dd7a089a2a61055a8d8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTgtNi0xLTEtMzg1MzM_35d4dc91-b972-440d-a375-88231eb05f15"
      unitRef="shares">-316088</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib63d42df1d424dd7a089a2a61055a8d8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTgtOC0xLTEtMzg1MzM_591971e1-7c45-4d18-a43e-d37e256ba2d9"
      unitRef="usd">-1846000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i627eb8ac3c1e4cdba53546b28b5c0c96_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTgtMTAtMS0xLTM4NTMz_80e1c196-bd5e-4937-98d6-35646b175cb6"
      unitRef="usd">72136000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5a141da19f2749e9915716c7f48fd1ed_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTgtMTItMS0xLTM4NTMz_e8a9fbfb-fc7e-4195-90cc-93b3760e3783"
      unitRef="usd">-333000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idcfdf8709ae1454db935f48886a3448d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTgtMTQtMS0xLTM4NTMz_3f1fc45d-4d73-4b91-a2f3-5084564123d5"
      unitRef="usd">-160562000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOmZlYWU5NTIyOGVkMDRjZDBhYjUyYTJjMWNjYmExZDAwL3RhYmxlcmFuZ2U6ZmVhZTk1MjI4ZWQwNGNkMGFiNTJhMmMxY2NiYTFkMDBfMTgtMTYtMS0xLTM4NTMz_be959392-f61b-4f11-8773-dd35dd85ab27"
      unitRef="usd">-90449000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="iac2dd912c60747d0ad5686735d31aabd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOC0yLTEtMS0yNTY0Mw_fbc3b79d-b7b9-46fc-b5b2-e32574304ece"
      unitRef="shares">15632809</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iac2dd912c60747d0ad5686735d31aabd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOC00LTEtMS0yNTY0Mw_0ab42be0-c588-4344-bd50-a81ee18d5a8e"
      unitRef="usd">156000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="ib63d42df1d424dd7a089a2a61055a8d8_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOC02LTEtMS0yNTY0Mw_65feef5f-88b8-43dc-b68f-ffa9a0328306"
      unitRef="shares">-316088</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib63d42df1d424dd7a089a2a61055a8d8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOC04LTEtMS0yNTY0Mw_ee76a2f3-ac59-47d4-9424-ed6575e6f140"
      unitRef="usd">-1846000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i627eb8ac3c1e4cdba53546b28b5c0c96_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOC0xMC0xLTEtMjU2NDM_bf54a672-4bf9-4032-b330-01bc5f595137"
      unitRef="usd">72136000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5a141da19f2749e9915716c7f48fd1ed_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOC0xMi0xLTEtMjU2NDM_29027b91-b506-4fed-a176-45e29174f0ef"
      unitRef="usd">-333000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idcfdf8709ae1454db935f48886a3448d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOC0xNC0xLTEtMjU2NDM_7a169451-8a62-45c8-8d1e-f554666d6849"
      unitRef="usd">-160562000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOC0xNi0xLTEtMjU2NDM_a22bd435-7018-40bd-a780-476bdad7c1b1"
      unitRef="usd">-90449000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="iacbac71171a247f19b7f67fb114cc51b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMy0wLTEtMS0yNTc4OS90ZXh0cmVnaW9uOjVlMTg5YzMyMWNkMzQ5NDFhZDdmZjRhMTA4YmNlMzFmXzEwOTk1MTE2Mjc5MTE_b1ec1b2c-4924-43d9-b232-22a6d538a434"
      unitRef="usd">9300000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i9c2584c4d4d14f87943a1ff43186ef4d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOS0yLTEtMS0yNTY0Mw_b2128961-aafe-4b7c-81a3-543bbde8bb2c"
      unitRef="shares">5750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9c2584c4d4d14f87943a1ff43186ef4d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOS00LTEtMS0yNTY0Mw_c54e6c80-ab3a-44b8-a7f7-b31ffcd4c493"
      unitRef="usd">58000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if64d03bb45484664ab00b5e9ac3b4129_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOS0xMC0xLTEtMjU2NDM_0818d534-8fbd-4fb1-8b63-804f38d4da16"
      unitRef="usd">82657000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iacbac71171a247f19b7f67fb114cc51b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOS0xNi0xLTEtMjU2NDM_08363ac7-94b6-4247-9c4d-ba4047305d59"
      unitRef="usd">82715000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i50d5f86cb19d42ff8235b613207c2abe_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNC0wLTEtMS0yNTgwNS90ZXh0cmVnaW9uOmIxMDgzNWQ3YTY2MzQxY2M4MzBmMWI3ZmQ4NDQ4MjNmXzEwOTk1MTE2Mjc4ODk_4bed1bca-a8a7-4fa4-b3f1-a26b2c2f68e4"
      unitRef="usd">700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i9d292d5da1514f2bbaf90a5652db785c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNC0yLTEtMS0yNTczNQ_89dc7c64-31f8-4606-8d28-111155b72e91"
      unitRef="shares">1562500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9d292d5da1514f2bbaf90a5652db785c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNC00LTEtMS0yNTczNQ_75345a05-40e1-4f69-9cc8-f0d72a473642"
      unitRef="usd">16000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7e02d3c90cee46fb92a3c766d05f4b5a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNC0xMC0xLTEtMjU3MzU_5248b3b3-cc7a-45db-8c5b-e0d4cfe72d4a"
      unitRef="usd">24234000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i50d5f86cb19d42ff8235b613207c2abe_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNC0xNi0xLTEtMjU3MzU_6fa9ae35-cc3d-4668-8645-08f26e24c6d3"
      unitRef="usd">24250000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <angn:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock
      contextRef="i56986948e86b485b8509172b9334c746_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNS0yLTEtMS0yNTczNQ_d78a6312-b5a0-451e-8df0-02f4b3149672"
      unitRef="shares">2234640</angn:StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock>
    <angn:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock
      contextRef="i56986948e86b485b8509172b9334c746_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNS00LTEtMS0yNTczNQ_e0e8fd9a-51ba-4bc2-8a9f-b83421658a0d"
      unitRef="usd">22000</angn:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock>
    <angn:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock
      contextRef="icd0806ead4944367a276b62a1b32bafa_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNS0xMC0xLTEtMjU3MzU_f1cd7d38-6d24-44be-a609-05c4ffdd4427"
      unitRef="usd">35732000</angn:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock>
    <angn:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNS0xNi0xLTEtMjU3MzU_4fd72843-fdb3-492a-9abf-9af738f253e1"
      unitRef="usd">35754000</angn:StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i9c2584c4d4d14f87943a1ff43186ef4d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNi0yLTEtMS0yNTczNQ_6c9dfa1a-3236-43ab-a72e-2ee9fbe9ea1d"
      unitRef="shares">3636189</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i9c2584c4d4d14f87943a1ff43186ef4d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNi00LTEtMS0yNTczNQ_7bdd2984-7d62-4045-92f5-04864465b64f"
      unitRef="usd">36000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="if64d03bb45484664ab00b5e9ac3b4129_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNi0xMC0xLTEtMjU3MzU_99f70c9d-f06e-43dc-917d-20cd299fdcca"
      unitRef="usd">58143000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="iacbac71171a247f19b7f67fb114cc51b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNi0xNi0xLTEtMjU3MzU_a220ed8f-e0f8-4698-b8ce-50e8442395d8"
      unitRef="usd">58179000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i86478d7cb5144b47ad734b74bf2a7754_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNy0yLTEtMS0yNTczNQ_bfbdc4d3-d28e-433b-bee6-c8113d1f7031"
      unitRef="shares">33978</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ica25c8fd34524de8a476208cd00f9f89_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNy0xMC0xLTEtMjU3MzU_e8b61886-5a51-4c16-b791-da7b968692a1"
      unitRef="usd">460000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i07f8bd8a51284654b005b52b3db91334_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfNy0xNi0xLTEtMjU3MzU_6870fbef-64b6-4d27-a0ba-7469b090d8ab"
      unitRef="usd">460000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <angn:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i9c2584c4d4d14f87943a1ff43186ef4d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOC0yLTEtMS0yNTczNQ_0ca1cd6a-846f-400c-b257-5c578d15dfe2"
      unitRef="shares">844335</angn:StockIssuedDuringPeriodSharesWarrantsExercised>
    <angn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i9c2584c4d4d14f87943a1ff43186ef4d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOC00LTEtMS0yNTczNQ_fabd1420-02a7-4d97-a983-1592094af1c5"
      unitRef="usd">9000</angn:StockIssuedDuringPeriodValueWarrantsExercised>
    <angn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="if64d03bb45484664ab00b5e9ac3b4129_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOC0xMC0xLTEtMjU3MzU_601655c0-b782-44ee-bc2d-374101ab41c5"
      unitRef="usd">13500000</angn:StockIssuedDuringPeriodValueWarrantsExercised>
    <angn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="iacbac71171a247f19b7f67fb114cc51b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOC0xNi0xLTEtMjU3MzU_69e7ef24-51cd-4b15-8496-d4b6417c5ec4"
      unitRef="usd">13509000</angn:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="icd0806ead4944367a276b62a1b32bafa_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOS0xMC0xLTEtMjU3MzU_498d4948-5a63-4679-983a-a6baafd2d288"
      unitRef="usd">10000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfOS0xNi0xLTEtMjU3MzU_67a83a38-77a7-457e-ba01-bf26f73c0b9a"
      unitRef="usd">10000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
    <angn:StockIssuedDuringPeriodSharesBrokerWarrantsExercised
      contextRef="i56986948e86b485b8509172b9334c746_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTAtMi0xLTEtMjU2NDM_3f4e65a0-49b4-4800-b5a7-2d9a1f6b8db6"
      unitRef="shares">47188</angn:StockIssuedDuringPeriodSharesBrokerWarrantsExercised>
    <angn:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i86478d7cb5144b47ad734b74bf2a7754_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTEtMi0xLTEtMjU2NDM_a9793bf4-9c68-499d-8929-dc2c70cb5b5c"
      unitRef="shares">130529</angn:StockIssuedDuringPeriodSharesWarrantsExercised>
    <angn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i86478d7cb5144b47ad734b74bf2a7754_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTEtNC0xLTEtMjU2NDM_24d43727-eab1-49c9-ae51-8b5d04e00021"
      unitRef="usd">2000</angn:StockIssuedDuringPeriodValueWarrantsExercised>
    <angn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ica25c8fd34524de8a476208cd00f9f89_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTEtMTAtMS0xLTI1NjQz_71a17027-be4d-4a56-b2eb-2f96ac599ab6"
      unitRef="usd">859000</angn:StockIssuedDuringPeriodValueWarrantsExercised>
    <angn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i07f8bd8a51284654b005b52b3db91334_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTEtMTYtMS0xLTI1NjQz_9501fdf0-c677-459e-86ba-1cc807d945aa"
      unitRef="usd">861000</angn:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i56986948e86b485b8509172b9334c746_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTItMi0xLTEtMjU2NDM_106dec8d-6c52-41af-bebc-cdb33fb35349"
      unitRef="shares">152939</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i56986948e86b485b8509172b9334c746_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTItNC0xLTEtMjU2NDM_622dc7e3-0b58-4008-96b4-96404b89eef3"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="icd0806ead4944367a276b62a1b32bafa_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTItMTAtMS0xLTI1NjQz_3d1478ed-4f72-4d41-a193-4df68a13af3e"
      unitRef="usd">979000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTItMTYtMS0xLTI1NjQz_2c7c9b44-b75c-4dfb-a390-d00df6381152"
      unitRef="usd">980000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i56986948e86b485b8509172b9334c746_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTMtMi0xLTEtMjU2NDM_e5145174-8443-4b7c-a62e-f935b2e89889"
      unitRef="shares">414896</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i56986948e86b485b8509172b9334c746_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTMtNC0xLTEtMjU2NDM_53622faa-c671-40eb-b714-c85ce609f100"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="icd0806ead4944367a276b62a1b32bafa_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTMtMTAtMS0xLTI1NjQz_446c3173-835a-4958-8044-b57856806126"
      unitRef="usd">14000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTMtMTYtMS0xLTI1NjQz_9dedcc51-78b6-4536-9748-3586c53e58e8"
      unitRef="usd">18000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i4a9ed117e7fc46209cfe726bed834b25_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTQtNi0xLTEtMjU2NDM_5c5dd8a0-bb17-4078-987b-f8808847ddc1"
      unitRef="shares">164855</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i4a9ed117e7fc46209cfe726bed834b25_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTQtOC0xLTEtMjU2NDM_aed1e016-4246-45c4-8de1-67f4b70ee04b"
      unitRef="usd">2364000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="icd0806ead4944367a276b62a1b32bafa_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTQtMTAtMS0xLTI1NjQz_2039baa3-8a5b-49ca-9ab8-e5040582e393"
      unitRef="usd">94000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTQtMTYtMS0xLTI1NjQz_2bf113ab-2435-497f-a68c-a222faa64751"
      unitRef="usd">2458000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i56986948e86b485b8509172b9334c746_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTUtMi0xLTEtMjU2NDM_6e2243f2-142b-4fb0-bf7a-a2d990bf0c7c"
      unitRef="shares">480943</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i56986948e86b485b8509172b9334c746_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTUtNC0xLTEtMjU2NDM_d1f62946-4151-4cc5-8fd4-7936925a8e72"
      unitRef="usd">4000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i4a9ed117e7fc46209cfe726bed834b25_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTUtNi0xLTEtMjU2NDM_8454b7ed-1b9f-408d-874c-f6daac96a372"
      unitRef="shares">480943</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i4a9ed117e7fc46209cfe726bed834b25_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTUtOC0xLTEtMjU2NDM_5bd1a06e-45a8-49c7-a12f-e4b99d2c7e61"
      unitRef="usd">4210000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="icd0806ead4944367a276b62a1b32bafa_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTUtMTAtMS0xLTI1NjQz_53f33053-4106-4e8d-a5bf-a7be2e9c6a98"
      unitRef="usd">4206000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTUtMTYtMS0xLTI1NjQz_374a1c89-b455-4774-ae4e-212c0ebb16e2"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="icd0806ead4944367a276b62a1b32bafa_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTYtMTAtMS0xLTI1NjQz_e6590c0e-455a-4312-a6a3-daf47899d5d8"
      unitRef="usd">12041000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTYtMTYtMS0xLTI1NjQz_a0bc39b4-118c-4120-a558-1a9d6ffbb376"
      unitRef="usd">12041000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i6d21085dc3464fd4a077a8c4c29dc3df_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTgtMTItMS0xLTI1NzU5_6ef20a53-c550-479d-a785-6c4b736bd16a"
      unitRef="usd">230000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTgtMTYtMS0xLTI1NzU5_414f11f9-0fdb-4046-8f60-c9f5ed9cad6e"
      unitRef="usd">230000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i8c5cb1b641df48b3990cc9378065cd00_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTctMTQtMS0xLTI1NjQz_f9689f14-c269-4b1e-96b0-165332f736ba"
      unitRef="usd">-54573000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTctMTYtMS0xLTI1NjQz_ec791904-d9ef-41e3-bf87-7e3b6365235c"
      unitRef="usd">-54573000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ifd74872b5622480ab9e4a8966ba04e3e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTgtMi0xLTEtMjU2NDM_971ba20e-9fe1-4ac5-a6d1-abb376036887"
      unitRef="shares">29959060</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ifd74872b5622480ab9e4a8966ba04e3e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTgtNC0xLTEtMjU2NDM_a5897f04-acef-4d36-9e08-2b8453fa14d5"
      unitRef="usd">300000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i2c838774341347d18b026f9d063c570d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTgtNi0xLTEtMjU2NDM_6a3be143-d853-418a-a1d3-cb17c94bb9f8"
      unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i2c838774341347d18b026f9d063c570d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTgtOC0xLTEtMjU2NDM_b6424ad6-ee87-43a2-b1ac-edafe3597b39"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i88e560ec37ce491aadf9eb36b18848d0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTgtMTAtMS0xLTI1NjQz_291b8193-a7e1-4aca-b9ef-a6a8d0ca4a72"
      unitRef="usd">296445000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ida615667cda8491fabc586af6ea6cb44_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTgtMTItMS0xLTI1NjQz_2b84e444-8ca7-425a-bb1f-81c95719c15f"
      unitRef="usd">-103000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idd7eeb679a3a4b8b9e9dd842d2ac9f04_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTgtMTQtMS0xLTI1NjQz_7b1a5499-61ac-40bb-9b63-71938bc99a59"
      unitRef="usd">-215135000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185NC9mcmFnOjc4YWU1NjI3OTU4YTQzOGI5M2U2NGU5MmIzMDNkMDIyL3RhYmxlOjM1MGRkNzA1ZmRiYjQxNDM4MWM2NjdmZjRjMjU4MjU4L3RhYmxlcmFuZ2U6MzUwZGQ3MDVmZGJiNDE0MzgxYzY2N2ZmNGMyNTgyNThfMTgtMTYtMS0xLTI1NjQz_a274c701-e782-49bb-92c7-efc37131f910"
      unitRef="usd">81507000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMy0xLTEtMS0yMjU0NQ_8e5bd2c2-e973-44db-be92-f1ac251d3b74"
      unitRef="usd">-54573000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMy0zLTEtMS0yMjU0NQ_96a42fac-06e0-4f37-8c6d-e9c10e5efad6"
      unitRef="usd">-80107000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNS0xLTEtMS0yMjU0NQ_71a7137f-0fb1-421a-a673-65ee7c3cff62"
      unitRef="usd">91000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNS0zLTEtMS0yMjU0NQ_8fa7fdfc-0295-42e9-a444-b24bf5decd7e"
      unitRef="usd">98000</us-gaap:Depreciation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNi0xLTEtMS0yMjU0NQ_2b3127d6-29da-47e1-8eb0-229d2c032fd5"
      unitRef="usd">710000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNi0zLTEtMS0yMjU0NQ_2dc3ccc9-893e-405f-af9d-4cec0513abea"
      unitRef="usd">530000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNy0xLTEtMS0yMjU0NQ_1ff9de30-eb5d-4208-8cc1-240af9bc84ce"
      unitRef="usd">1884000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNy0zLTEtMS0yMjU0NQ_557530de-af42-4ba8-a1e6-10f055acbf07"
      unitRef="usd">7661000</us-gaap:AmortizationOfFinancingCosts>
    <angn:NonCashPlacementAgentFee
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfOC0xLTEtMS0yMjU0NQ_b6406c8a-c60f-44cc-9768-0c8470d9d646"
      unitRef="usd">0</angn:NonCashPlacementAgentFee>
    <angn:NonCashPlacementAgentFee
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfOC0zLTEtMS0yMjU0NQ_39d4ac98-ccc2-4799-a0ad-d6dc579c1ac4"
      unitRef="usd">1683000</angn:NonCashPlacementAgentFee>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfOS0xLTEtMS0yNjU3Ng_ec3b8833-21f7-4815-acd1-c2f6d23ff958"
      unitRef="usd">905000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfOS0zLTEtMS0yODQxNw_e77ba8a2-1643-4a39-8fff-862c9769c9db"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfOS0xLTEtMS0yMjU0NQ_4dbf3129-a649-44f8-86bf-959aaf762db6"
      unitRef="usd">12041000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfOS0zLTEtMS0yMjU0NQ_0089943b-e2ac-411d-9b2e-405b0096bd72"
      unitRef="usd">4716000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMTEtMS0xLTEtMjI1NDU_1ec84b65-3c6b-408d-a95d-daf9cabc3047"
      unitRef="usd">-7469000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMTEtMy0xLTEtMjI1NDU_adc4364f-bbb9-46c0-b730-f6d988e71a72"
      unitRef="usd">-11353000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <angn:FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMTItMS0xLTEtMjI1NDU_928c19a4-0dd3-45ad-991c-4834386f715b"
      unitRef="usd">-3592000</angn:FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss>
    <angn:FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMTItMy0xLTEtMjI1NDU_c5903efd-d7bc-48e4-b350-6df26b79abd5"
      unitRef="usd">-264000</angn:FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMTMtMS0xLTEtMjI1NDU_ae7874cb-6651-4449-a436-92b93af1e407"
      unitRef="usd">2919000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMTMtMy0xLTEtMjI1NDU_f89f5a61-12c9-4547-90c4-400af8962f69"
      unitRef="usd">4910000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMTUtMS0xLTEtMjI1NDU_55bea137-27ce-4b2e-84ed-7c97be06a04f"
      unitRef="usd">0</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMTUtMy0xLTEtMjI1NDU_dcc513ec-c382-44b1-a9ac-e9eb4125c312"
      unitRef="usd">58000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMTYtMS0xLTEtMjI1NDU_2b0c0c30-bf05-4e9f-a7fd-82726be47b74"
      unitRef="usd">-96000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMTYtMy0xLTEtMjI1NDU_2f4f6dbb-bc8e-4a2b-9001-3eaeebcb7e05"
      unitRef="usd">-71000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMTctMS0xLTEtMjI1NDU_9fa3abd6-ad68-4826-8b73-9b0711beebca"
      unitRef="usd">3000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMTctMy0xLTEtMjI1NDU_d9d757d2-8385-4860-bfa9-adbc0bf01c99"
      unitRef="usd">106000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <angn:IncreaseDecreaseInGrantReceivables
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMTktMS0xLTEtMjI1NDU_344a552d-afc6-4394-8c02-372a9ebd5d0d"
      unitRef="usd">806000</angn:IncreaseDecreaseInGrantReceivables>
    <angn:IncreaseDecreaseInGrantReceivables
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMTktMy0xLTEtMjI1NDU_418a96bf-6021-46ea-846a-7498661e1f08"
      unitRef="usd">-440000</angn:IncreaseDecreaseInGrantReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjAtMS0xLTEtMjI1NDU_2a059c36-f076-4b46-8882-bc17a0308ba0"
      unitRef="usd">-4016000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjAtMy0xLTEtMjI1NDU_a3024b1d-e5d5-418f-b0d7-0d313b06a4f9"
      unitRef="usd">2020000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjEtMS0xLTEtMjY0Mzc_ff8d6461-42f2-49a2-9e6d-b8ef44b7dbac"
      unitRef="usd">106000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjEtMy0xLTEtMjY0Mzc_9605f2f4-1580-4f00-ab28-8403a75ba550"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjEtMS0xLTEtMjI1NDU_e6c9a3f3-e238-40ab-9613-0979647566ef"
      unitRef="usd">-866000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjEtMy0xLTEtMjI1NDU_3958ae02-a7cd-4b18-a419-bb6093fd97a5"
      unitRef="usd">-5607000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjItMS0xLTEtMjI1NDU_5cb0e351-dcf2-41f0-adc2-d3539e26aca9"
      unitRef="usd">11000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjItMy0xLTEtMjI1NDU_cbfa3d0f-dbd5-4d6b-993c-6f366a3dbdcd"
      unitRef="usd">3709000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjMtMS0xLTEtMjI1NDU_e9073398-e981-49c0-94a4-0991f4df3051"
      unitRef="usd">-713000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjMtMy0xLTEtMjI1NDU_cc6e5c10-0eea-4b60-aace-53d7d4a14283"
      unitRef="usd">-560000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjUtMS0xLTEtMjI1NDU_775f9934-4153-44af-b05c-34170ed9c02c"
      unitRef="usd">-27506000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjUtMy0xLTEtMjI1NDU_e3518eb5-a38b-4ce9-9f60-e299a2290af1"
      unitRef="usd">29807000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjYtMS0xLTEtMjI1NDU_f0e54a41-2f19-487e-85f7-29e7009ab162"
      unitRef="usd">-52643000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjYtMy0xLTEtMjI1NDU_345defa0-32a0-4f0d-b990-096042d9bd08"
      unitRef="usd">-22888000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjgtMS0xLTEtMjI1NDU_b8ebe31b-7376-498a-9f3e-9dd028cf802b"
      unitRef="usd">382000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjgtMy0xLTEtMjI1NDU_f32fd42a-4aac-42af-ab40-ce66a14ef668"
      unitRef="usd">41000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjktMS0xLTEtMjI1NDU_36d7067d-944e-4295-a35c-4d6705db56fd"
      unitRef="usd">-382000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMjktMy0xLTEtMjI1NDU_6f583cbf-d3a1-4b13-b964-6ba4aea3db74"
      unitRef="usd">-41000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzItMS0xLTEtMjY0NTQ_12cfbbb4-3976-4a6b-a614-a0f7c87601b7"
      unitRef="usd">107487000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzItMy0xLTEtMjY0NTQ_4bad7ce3-00ba-4b6f-9eb1-f18565191488"
      unitRef="usd">-522000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzItMS0xLTEtMjI1NDU_53f1b84c-a4ec-43fd-851b-db82d3f0a7a4"
      unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzItMy0xLTEtMjI1NDU_aa01cf80-79ed-41c6-9311-36a789d4798a"
      unitRef="usd">31223000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzMtMS0xLTEtMjI1NDU_ad9ba722-a2d0-469a-8421-dac7ea50ac0b"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzMtMy0xLTEtMjI1NDU_3003ccbf-95c2-49e2-8ba8-9e3ca015571c"
      unitRef="usd">20047000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzQtMS0xLTEtMjI1NDU_8f553c41-30bb-48b8-b7cc-b59aa775307d"
      unitRef="usd">0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzQtMy0xLTEtMjI1NDU_b2922e9f-99cf-4858-8781-dce4128b7d01"
      unitRef="usd">895000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <angn:ProceedsFromFinancingObligation
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzYtMS0xLTEtMjY0NjY_30e6428b-ba82-4ea1-922a-e5dc7b7eff05"
      unitRef="usd">302000</angn:ProceedsFromFinancingObligation>
    <angn:ProceedsFromFinancingObligation
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzYtMy0xLTEtMjY0NjY_1846b3b9-37da-49ba-bb69-bbfe55dc6a46"
      unitRef="usd">0</angn:ProceedsFromFinancingObligation>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzctMS0xLTEtMjY0ODY_63477fdf-215c-467f-b9ef-72e3fc4f54c7"
      unitRef="usd">18000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzctMy0xLTEtMjY0ODY_cf062d31-8fcd-4d52-bf59-43571d71da3a"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzctMS0xLTEtMjY0NzY_10a48a76-9547-4d98-85d4-370edf7f76e3"
      unitRef="usd">9000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzctMy0xLTEtMjg0Mjc_11764892-17e4-4981-8b43-4b7505e91438"
      unitRef="usd"
      xsi:nil="true"/>
    <angn:PaymentsForForwardStockSplitFractionalShares
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzktMS0xLTEtMjY1MTc_d62180e7-b4c6-4a19-b7b9-4dfc5a162216"
      unitRef="usd">10000</angn:PaymentsForForwardStockSplitFractionalShares>
    <angn:PaymentsForForwardStockSplitFractionalShares
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzktMy0xLTEtMjY1MTc_8fef9466-0f54-4bcd-a539-11e99299c310"
      unitRef="usd">0</angn:PaymentsForForwardStockSplitFractionalShares>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzYtMS0xLTEtMjI1NDU_0f62631f-a5b2-4f6d-a36f-6c027bd5b06d"
      unitRef="usd">2458000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzYtMy0xLTEtMjI1NDU_7451a7cd-bc59-4d58-8081-ba2f5f604a63"
      unitRef="usd">36000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <angn:PaymentsForBrokerWarrantExercises
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzgtMS0xLTEtMjI1NDU_3d9cee32-39e5-42b8-b210-a4a4c111143d"
      unitRef="usd">0</angn:PaymentsForBrokerWarrantExercises>
    <angn:PaymentsForBrokerWarrantExercises
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzgtMy0xLTEtMjI1NDU_3363616f-229e-494d-9e2a-2a9b7b7131a9"
      unitRef="usd">-4000</angn:PaymentsForBrokerWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzktMS0xLTEtMjI1NDU_2c039249-8545-415c-9096-0218e01d36f8"
      unitRef="usd">861000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfMzktMy0xLTEtMjI1NDU_d8cc042f-c28f-4bdb-b6d4-887d66111d0c"
      unitRef="usd">751000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDAtMS0xLTEtMjI1NDU_a71ba964-a46a-4dc2-85f1-3d967c70b773"
      unitRef="usd">980000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDAtMy0xLTEtMjI1NDU_56f8bcf8-d004-45ac-bbd2-aff8a01f496b"
      unitRef="usd">47000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDEtMS0xLTEtMjI1NDU_53b93eb4-d77a-4932-a887-89efb54a7bdd"
      unitRef="usd">107171000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDEtMy0xLTEtMjI1NDU_eab47076-309c-4580-8a53-3cbf0c1d2b67"
      unitRef="usd">52409000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDItMS0xLTEtMjI1NDU_6f69a7a1-cdff-4d1c-b1c8-0e9c0b6610e3"
      unitRef="usd">3000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDItMy0xLTEtMjI1NDU_3c1a7a23-b978-4a1f-9c7c-051288184d11"
      unitRef="usd">-444000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDMtMS0xLTEtMjI1NDU_4897acce-644a-438a-8c87-1826144cdbb6"
      unitRef="usd">54149000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDMtMy0xLTEtMjI1NDU_21a35108-1576-4dd0-b8a2-eb28e8b79fec"
      unitRef="usd">29036000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDQtMS0xLTEtMjI1NDU_dda72b92-cfdb-45da-b21f-c8ed60189294"
      unitRef="usd">34607000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i08c03f72f0b941539e5cdcb6bd71e375_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDQtMy0xLTEtMjI1NDU_0a3de56c-a316-46e4-a4e0-6129f0d2a305"
      unitRef="usd">5571000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDUtMS0xLTEtMjI1NDU_a0512131-f594-4cf5-94f4-a39b4dd85369"
      unitRef="usd">88756000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDUtMy0xLTEtMjI1NDU_2a7a01a0-ee77-4333-9c56-8f96e7c317b1"
      unitRef="usd">34607000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDYtMS0xLTEtMjI1NDU_4ced11f9-1326-4988-aa06-1949ec240a4a"
      unitRef="usd">7000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDYtMy0xLTEtMjI1NDU_835b6962-70ad-4cdd-90d2-415b33fbd747"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <angn:StockRetired
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDktMS0xLTEtMjI1NDU_b9045be2-fedd-43ba-8e39-b9882446057b"
      unitRef="usd">4210000</angn:StockRetired>
    <angn:StockRetired
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNDktMy0xLTEtMjI1NDU_1832968e-8193-410b-90ec-38094477b782"
      unitRef="usd">0</angn:StockRetired>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="ibc29760a066749a2a385abd329cceb8f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTUtMS0xLTEtMjY1MzY_e4a35182-5ab3-4894-9d72-91e7941d24c3"
      unitRef="usd">460000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i03d5350f508b4144bc4917ef0ec5919e_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTUtMy0xLTEtMjY1NDM_64f3652e-546e-42e9-a393-74d6928e7070"
      unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i38b7fad4d0a54f5b9f03bd9e2bdaa055_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTYtMS0xLTEtMjY1MzY_d91c1344-0123-4dfc-90d1-be26aedccbd8"
      unitRef="usd">58639000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i5e0337892efb4f628c26a60c7c2fcbaf_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTYtMy0xLTEtMjY1NDM_d4c0a7ca-f415-4f62-856c-f5f057162013"
      unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="iacbac71171a247f19b7f67fb114cc51b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTctMS0xLTEtMjY1MzY_24e68980-f697-4293-befd-6753e7942908"
      unitRef="usd">35754000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="i59b403c789684eb5976e604c15fb43a2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTctMy0xLTEtMjY1NDM_04ac9cdc-0075-481c-967d-0e6b0bb3ddc2"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountConverted1>
    <angn:WarrantsExercised
      contextRef="iacbac71171a247f19b7f67fb114cc51b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTgtMS0xLTEtMjY1MzY_92fababb-7c19-45d5-8c6a-5b608fd000b4"
      unitRef="usd">13509000</angn:WarrantsExercised>
    <angn:WarrantsExercised
      contextRef="i59b403c789684eb5976e604c15fb43a2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTgtMy0xLTEtMjY1NDM_99ac06a1-8a58-42e0-9548-50ffb772ef28"
      unitRef="usd">0</angn:WarrantsExercised>
    <angn:IssuanceOfBrokerWarrants
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTAtMS0xLTEtMjI1NDU_da867fa8-171c-490d-b8b1-d7267b9ee9e5"
      unitRef="usd">0</angn:IssuanceOfBrokerWarrants>
    <angn:IssuanceOfBrokerWarrants
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTAtMy0xLTEtMjI1NDU_036af48d-84f9-44bd-b278-f64c851f189d"
      unitRef="usd">1412000</angn:IssuanceOfBrokerWarrants>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i10126ff884f24cee9f145c0c6031e0c1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTEtMS0xLTEtMjI1NDU_28f1857d-77f8-4f63-b3de-d621ad521494"
      unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i1fd8ae3429f1487bb13c70c2678f3098_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTEtMy0xLTEtMjI1NDU_5f6ab47e-2d14-44f4-9779-8f49154d21ac"
      unitRef="usd">2254000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <angn:AccruedInterestPremiumForConvertiblePreferredStock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTItMS0xLTEtMjI1NDU_60e138ee-7564-45d8-95f2-13fdb576b14e"
      unitRef="usd">0</angn:AccruedInterestPremiumForConvertiblePreferredStock>
    <angn:AccruedInterestPremiumForConvertiblePreferredStock
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTItMy0xLTEtMjI1NDU_0148c6c5-37f3-4389-a49c-29f42707b089"
      unitRef="usd">295000</angn:AccruedInterestPremiumForConvertiblePreferredStock>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTMtMS0xLTEtMjI1NDU_eab45ddb-107a-4f98-abc0-9df7ac1afd28"
      unitRef="usd">624000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTMtMy0xLTEtMjI1NDU_cd26cb76-c70c-4881-8b52-2ce64920be75"
      unitRef="usd">88000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:NotesIssued1
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTQtMS0xLTEtMjI1NDU_851fd121-74e4-4a2d-805e-3e28830d1610"
      unitRef="usd">0</us-gaap:NotesIssued1>
    <us-gaap:NotesIssued1
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTQtMy0xLTEtMjI1NDU_0491c7e2-e57d-4c55-9729-8f0cbab3b0d2"
      unitRef="usd">5000000</us-gaap:NotesIssued1>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTUtMS0xLTEtMjI1NDU_af48aab8-646d-4664-bf22-63e67a79b316"
      unitRef="usd">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTUtMy0xLTEtMjI1NDU_8ccebb43-75f5-4a08-ad95-6b0df37745bd"
      unitRef="usd">1443000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTYtMS0xLTEtMjI1NDU_1ace218d-ef0b-4882-b91f-b3acb8f6086b"
      unitRef="usd">4000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN185Ny9mcmFnOjY0MDkzYTNhYzc3ZTRmNGQ4OGQ1MzZmMDhiOTU0OWRjL3RhYmxlOjAzMDQ0YmY1ZTVhMjRhMDliZDgxNmNmYWI2YTU4ODk2L3RhYmxlcmFuZ2U6MDMwNDRiZjVlNWEyNGEwOWJkODE2Y2ZhYjZhNTg4OTZfNTYtMy0xLTEtMjI1NDU_55a15fe6-9e9e-44a5-b825-4b150c0f341e"
      unitRef="usd">4000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzI3NDg3NzkwNzM5MjA_26a1016e-ebdc-41fe-8548-c6f909d3ec82">Description of the Business and Financial Condition&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Angion Biomedica Corp. ("Angion" or", the "Company") is a clinical biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. The Company was incorporated in Delaware in 1998.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Forward Stock Split&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; On January 25, 2021, the board of directors of the Company approved an amendment to the Company's certificate of incorporation to effect a forward stock split ("Forward Split") of shares of the Company's common stock on a one-for 1.55583 basis, which was effected on February 1, 2021. All references to common stock, convertible preferred stock, warrants to purchase common stock, stock options, restricted stock awards ("RSAs"), restricted stock units ("RSUs"), including restricted stock units with non-market performance and service conditions ("PSUs"), per share amounts and related information contained in the consolidated financial statements have been retroactively adjusted to reflect the effect of the forward stock split for all periods presented. No fractional shares of the Company's common stock were issued in connection with the Forward Split. Any fractional share resulting from the Forward Split was rounded down to the nearest whole share, and any stockholder entitled to fractional shares as a result of the Forward Split will received a cash payment in lieu of receiving fractional shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Initial Public Offering and the Concurrent Private Placement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 9, 2021, the Company&#x2019;s registration statement on Form S-1 (File No. 333-252177) relating to its initial public offering (IPO) of common stock became effective. The IPO closed on February 9, 2021 at which time the Company issued 5,750,000 shares of its common stock at a price to the public of $16.00 per share, which includes the full exercise by the underwriters of their option to purchase an additional 750,000 shares of common stock. In addition to the shares being sold in the IPO, the Company sold an additional 1,562,500 shares of its common stock at the public offering price of $16.00 per share to entities affiliated with Vifor International, Ltd., an existing stockholder (the &#x201c;Concurrent Private Placement&#x201d;) for gross proceeds of $25.0&#160;million. Subsequent to the closing of the IPO, all of the outstanding shares of convertible preferred stock and outstanding convertible notes automatically converted into shares of common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The IPO and Concurrent Private Placement generated aggregate net proceeds of approximately $107.0&#160;million, after deducting the underwriting discounts and commissions, private placement fee and estimated offering expenses payable by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to the closing of the IPO, there were no shares of convertible preferred stock outstanding and there were no convertible notes outstanding. In connection with the closing of the IPO, the Company restated its Restated Certificate of Incorporation to change the authorized capital stock to 300,000,000 shares designated as common stock, and 10,000,000 shares designated as preferred stock, with a par value of $0.01 per share and $0.01 per share, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Capital Resources&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since inception, the Company has devoted substantially all of its efforts and financial resources to conducting research and development activities, including drug discovery and pre-clinical studies and clinical trials, establishing and maintaining its intellectual property portfolio, organizing and staffing the Company, business planning, raising capital and providing general and administrative support for these operations. The Company has incurred losses from operations and negative cash flows from operating activities since inception and expects to continue to incur substantial losses for the next several years as it continues to fully develop and, if approved, commercialize its product candidates. As of December&#160;31, 2021, the Company had $88.8 million in cash and cash equivalents and an accumulated deficit of $215.1 million. Prior to its IPO, the Company has funded its operations through United States government grants, the issuance of convertible notes (see Note 6), sales of convertible preferred stock and common stock (see Notes 7) and warrants (see Note 10) and licensing agreements (see Note 12).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The planned expansion of the Company's clinical and discovery programs will require significant funds. Management expects to continue to incur significant expenses and to incur operating losses for the foreseeable &lt;/span&gt;&lt;/div&gt;future. The Company has evaluated and concluded there are no conditions or events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern for a period of one year following the date these consolidated financial statements are issued and believes its existing cash and cash equivalents will be sufficient to meet the projected operating requirements well into 2023.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="ia5d656fe36d64dd28f480aaf15a0cf24_D20210201-20210201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzI3NDg3NzkwNzM4Nzk_244ea3e7-a817-48c4-bae8-f4d34371bf42"
      unitRef="number">1.55583</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="icf79e0bd44fc44b6add290a67ac03123_D20210209-20210209"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzEwOTk1MTE2NDY5MjE_66c02d7a-e93f-4034-bec6-2b6079512f31"
      unitRef="shares">5750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i2fba8513019e4003882ec149aeddb34b_I20210209"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzEwOTk1MTE2NDY5MzA_abd17eca-182e-402d-893c-bf91400789a9"
      unitRef="usdPerShare">16.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i670bd8e4908d4f42bafe357876fb520e_D20210209-20210209"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzEwOTk1MTE2NDcxNTU_011c6d15-d279-4576-bdcd-add19d23a363"
      unitRef="shares">750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i166eae69229b4112968673ffefbf7d09_D20210209-20210209"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzEwOTk1MTE2NDgyNzE_9b1618e9-8f35-4d1b-9c14-316c18e9b340"
      unitRef="shares">1562500</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i2fba8513019e4003882ec149aeddb34b_I20210209"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzEwOTk1MTE2NDgzMzQ_738a2b36-7f6c-4b40-95d0-0a8935fa8d59"
      unitRef="usdPerShare">16.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i166eae69229b4112968673ffefbf7d09_D20210209-20210209"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzEwOTk1MTE2NDg3Mzg_6e552a05-9c97-448a-947b-3cd9e16f6380"
      unitRef="usd">25000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i5f34db6d61444fc0951ac5bca31c9cbc_D20210209-20210209"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzEwOTk1MTE2NTIxNTg_d830a9a4-d81a-4435-936f-32847ff0438d"
      unitRef="usd">107000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia2518ef5cab941c1b5281fac0348fe6c_I20210210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzEwOTk1MTE2NTA0NTI_708d2a94-b48a-4678-8542-8c5c3719863d"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="ie6530fcd8ea6401a8a572f67df226036_I20210210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzEwOTk1MTE2NTA1MjE_a843e67d-7f45-43db-a57f-4509946fb945"
      unitRef="usd">0</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2fba8513019e4003882ec149aeddb34b_I20210209"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzEwOTk1MTE2NTA3MDQ_01c173f3-da44-449b-a2ed-cd1c83c3496e"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i2fba8513019e4003882ec149aeddb34b_I20210209"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzEwOTk1MTE2NTA3NDc_5ee7a710-6468-4464-9019-afaa91bc94f6"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2fba8513019e4003882ec149aeddb34b_I20210209"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzEwOTk1MTE2NTA4MDk_6f70f494-7627-4eca-a63f-a0b386d715d4"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i2fba8513019e4003882ec149aeddb34b_I20210209"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzEwOTk1MTE2NTA4Mjc_5359b8cc-dde7-488d-8c77-b2da9a555bf2"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzEwOTk1MTE2MzIyNjA_328da7f7-88fb-442e-a471-4a2c6b09af5c"
      unitRef="usd">88800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDMvZnJhZzpkYjM3ZTI2Y2Q2Yzc0MjgwODY2OTA1OGM4OWYxNmFmOS90ZXh0cmVnaW9uOmRiMzdlMjZjZDZjNzQyODA4NjY5MDU4Yzg5ZjE2YWY5XzEwOTk1MTE2MzIyNjg_e30d9eb8-c133-430c-beba-9885410a063d"
      unitRef="usd">-215100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzI3NDg3NzkwOTczNjI_b30a3801-6da2-431f-b5a3-215dfefe4364">Summary of Significant Accounting Policies&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company, its wholly owned subsidiary, Angion Biomedica Europe Limited, which was dissolved on March 16, 2021, and its wholly owned subsidiary, Angion Pty Ltd., which was established on August 22, 2019. The Company established Angion Pty Ltd., an Australian subsidiary, for the purpose of qualifying for research credits for studies conducted in Australia. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (&#x201c;CODM&#x201d;) in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to the useful lives of long-lived assets, the measurement of stock-based compensation, change in fair value of warrant liabilities prior to IPO, accruals for research and development activities, income taxes and revenue recognition. The Company bases its estimates on historical experience and on other relevant assumptions that are reasonable under the circumstances. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation and Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The United States Dollar (&#x201c;USD&#x201d;) is the functional currency for the Company&#x2019;s operations outside the United States. Accordingly, nonmonetary assets and liabilities originally acquired or assumed in other currencies are recorded in USD at the exchange rates in effect at the date they were acquired or assumed. Monetary assets and liabilities denominated in other currencies are translated into USD at the exchange rates in effect at the balance sheet date. Translation adjustments are recorded in other comprehensive income (loss) in the consolidated statements of operations. Gains and losses realized from non-USD transactions, including intercompany balances not considered as permanent investments, denominated in currencies other than an entity&#x2019;s functional currency are included in other income (expense) in the accompanying consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and Off-Balance Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company's cash and cash equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains its cash equivalents in securities and money market funds with original maturities less than three months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has no financial instruments with off-balance sheet risk of loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of December&#160;31, 2021 and 2020, the Company&#x2019;s cash equivalents were held in institutions in the United States and included deposits in a money market fund which were unrestricted as to withdrawal or use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Grants Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Grants receivable is comprised of unbilled amounts due from various grants from the National Institutes of Health ("NIH") and other U.S. government agencies for costs incurred prior to the period end under reimbursement contracts. All amounts are readily available for draw from the Federal Government Payment Management System and, accordingly, no allowance for doubtful amounts has been established. If amounts become uncollectible, they are charged to operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Offering Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred offering costs consist of legal and accounting fees incurred through the balance sheet date that were directly related to the Company's IPO and were reflected as issuance costs upon the completion of the offering. Subsequent to the closing of the IPO, $2.8&#160;million of deferred costs previously included in prepaid expenses and other current assets were netted with additional paid in capital in the consolidated balance sheets. As of December 31, 2021 and 2020, the Company recorded deferred offering costs of zero and $2.0&#160;million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, equipment and leasehold improvements are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over their estimated useful lives as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Shorter of useful life or lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Normal repairs and maintenance costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, such as property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group to be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. The impairment losses as of December&#160;31, 2021 and 2020 were zero and $58&#160;thousand, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is determined using the principles of ASC 820, Fair Value Measurement. Fair value is described as the price that would be received to sell an asset or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy prioritizes and defines the inputs to valuation techniques as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1:&#160;&#160;&#160;&#160;Observable inputs such as quoted prices in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:76.5pt;text-indent:-49.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2:&#160;&#160;&#160;&#160;Inputs are observable for the asset or liability either directly or through corroboration with observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3:&#160;&#160;&#160;&#160;Unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The inputs used to measure the fair value of an asset or a liability are categorized within levels of the fair value hierarchy. The fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the measurement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's cash and cash equivalents, accounts payable and accrued expenses are carried at cost, which approximates fair value due to the short-term nature of these instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its leases under ASC 842, Leases. Under this guidance, arrangements meeting the definition of a lease are classified as operating or finance leases, and are recorded on the consolidated balance sheets as both a right of use asset and a lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company's incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset results in straight-line rent expense over the lease term. Variable lease expenses are recorded when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In calculating the right of use assets and lease liabilities, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election, and recognizes rent expense on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Related Party Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company holds a 10% and a 2.4% interest in two entities, NovaPark, LLC ("NovaPark") and Ohr Cosmetics, LLC ("Ohr"), respectively. There is common ownership between the Director and Chairman Emeritus of the Company and each entity, and our Chief Executive Officer is also owns approximately 0.80% of the membership interests in Ohr. See Note 15. In accordance with ASC 323, Investments &#x2014;Equity Method and Joint Ventures, the Company has significant influence but not control over NovaPark as its ownership in the limited liability company exceeds 3-5%. Accordingly, the Company records the NovaPark investment under the equity method of accounting. The Ohr investment is recorded at cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrant Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for certain common stock warrants outstanding as a liability, in accordance with ASC 815, Derivatives and Hedging, at fair value and adjusts the instruments to fair value at each reporting period. This liability is subject to re-measurement at each reporting period until exercised, and any change in fair value is recognized in the consolidated statements of operations as a component of other income (expense). The fair value of the warrants issued by the Company has been estimated using a variant of the Black Scholes option pricing model. The underlying equity included in the Black Scholes option pricing model was valued based on the closing price of common stock at each measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Notes Payable at Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As permitted under ASC 825&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Instruments ("ASC 825"), the Company has elected the fair value option for recognition of its convertible notes. In accordance with ASC 825, the Company recognizes these convertible notes at fair value with changes in fair value recognized in the consolidated statements of operations. The fair value option may be applied instrument by instrument, but it is irrevocable. As a result of applying the fair value option, direct costs and fees related to the convertible notes were recognized in general and administrative &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;expense in earnings as incurred and not deferred. The estimated fair value of the convertible notes was determined by utilizing a present value cash flow model and the values of the equity underlying the conversion options were estimated using company equity values implied from the Subject Company Transaction Method which includes the back-solve and scenario-based methods (Probability Weighted Expected Return Method). See Note 4. Accrued interest for the notes has been included in the change in fair value of convertible notes in the consolidated statements of operations. All outstanding convertible notes were converted into common stock upon the close of the IPO on February 9, 2021 and no balances remained outstanding as of December&#160;31, 2021. See Note 6.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Series C convertible preferred stock included settlement features that result in liability classification. The initial carrying value of the Series C convertible preferred stock was accreted to the settlement value, the fair value of the securities issued upon the conversion of the Series C convertible preferred stock. The discount to the settlement value was accreted to interest expense using the effective interest method. During 2020, certain convertible notes were exchanged for Series C convertible preferred stock. As the exchange was accounted for as a modification, the Series C convertible preferred stock that was exchanged for the convertible notes was recorded at fair value and subject to re-measurement at each reporting period with gains and losses reported through our consolidated statements of operations. All outstanding shares of convertible preferred stock were converted into common stock upon the close of the Company&#x2019;s IPO on February 9, 2021. See Note 7. As of December&#160;31, 2021, there was no convertible preferred stock outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records the repurchase of shares of common stock at cost based on the settlement date of the transaction. These shares are classified as treasury stock, which is a reduction to stockholders' equity. Treasury stock is included in authorized and issued shares but excluded from outstanding shares. As of December&#160;31, 2021, all outstanding treasury shares were retired in October 2021 upon approval by the Board of Directors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not have any products approved for sale and has not generated any revenue from product sales. The Company&#x2019;s revenue to date has been primarily derived from government funding consisting of U.S. government grants and contracts, and revenue under its license agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for revenue earned from contracts with customers under Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASC 606"). Under ASC 606, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps:   &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Identify the contract(s) with a customer;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&#160;&#160;&#160;&#160;Identify the performance obligations in the contract;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&#160;&#160;&#160;&#160;Determine the transaction price;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4)&#160;&#160;&#160;&#160;Allocate the transaction price to the performance obligations in the contract; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5)&#160;&#160;&#160;&#160;Recognize revenue when (or as) the Company satisfies a performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company assesses the goods or services promised within each contract, whether each promised good or service is distinct, and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into agreements under which it may obtain upfront payments, milestone payments, royalty payments and other fees. Promises under these arrangements may include research licenses, research services, including selection campaign research services for certain replacement targets, the obligation to share information during the research and the participation of alliance managers and in joint research committees, joint patent committees and joint steering committees. The Company assesses these promises within the context of the agreements to determine the performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Licenses of Intellectual Property&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: If a license to its intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring proportional performance for purposes of recognizing revenue from non-refundable, upfront payments. The Company evaluates the measure of proportional performance each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company evaluates whether the regulatory and development milestones are considered probable of being reached and estimate the amounts to be included in the transaction price using the most likely amount method. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones and any related constraint, and if necessary, adjust the estimate of the overall transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales-based milestones and royalties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: For sales-based royalties, including milestone payments based on the level of sales, the Company determines whether the sole or predominant item to which the royalties relate is a license. When the license is the sole or predominant item to which the sales-based royalty relates, the Company recognize revenue at the later of: (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any sales-based royalty revenue resulting from any license agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is a contract liability, represents amounts received by the Company for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount expected to be recognized within one year from the consolidated balance sheet date based on the estimated performance period of the underlying performance obligation. The noncurrent portion of deferred revenue represents amounts expected to be recognized after one year through the end of the performance period of the performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Grant Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded that the Company's government grants are not within the scope of ASC Topic 606 as they do not meet the definition of a contract with a customer. The Company has concluded that the grants meet the definition of a contribution and are non-reciprocal transactions, and has also concluded that Subtopic 958-605, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not-for-Profit-Entities-Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, does not apply, as the Company is a business entity and the grants are with governmental agencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the absence of applicable guidance under GAAP, the Company developed a policy for the recognition of grant revenue when the allowable costs are incurred and the right to payment is realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes this policy is consistent with the overarching premise in ASC Topic 606, to ensure that revenue recognition reflects the transfer of promised goods or services to customers in an amount that reflects the consideration that the Company expects to be entitled to in exchange for those goods or services, even though there is no exchange as defined in ASC Topic 606. The Company believes the recognition of revenue as costs are incurred and amounts become realizable is analogous to the concept of transfer of control of a service over time under ASC Topic 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs include, but are not limited to, payroll and personnel expenses, laboratory supplies, preclinical studies, compound manufacturing costs, consulting costs and allocated overhead, including rent, equipment, depreciation and utilities. Research and development cost maybe offset by research and development refundable tax rebates received by our wholly-owned Australian subsidiary. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has agreements with various Contract Research Organizations ("CROs") and third-party vendors. Research and development accruals of amounts due to the CRO are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued liabilities on the consolidated balance sheet. Payments made to CROs under such arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. The Company makes judgments and estimates in determining the accrued expenses balance in each reporting period. As actual costs become known, the Company adjusts its accrued expenses. For the years ended December&#160;31, 2021 and 2020, the Company has not experienced any material differences between accrued costs and actual costs incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising costs are expensed as incurred. For the years ended December&#160;31, 2021 and 2020, advertising costs were not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for all stock-based payments to employees and non-employees, including grants of stock options, RSAs, RSUs, including "PSUs" to be recognized in the financial statements, based on their respective grant date fair values. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The RSAs, RSUs and PSUs are valued based on the fair value of the Company's common stock on the date of grant. The assumptions used in calculating the fair value of stock-based awards represent management's best estimates and involve inherent uncertainties and the application of management's judgment. The Company records expense for stock-based compensation related to stock options, RSAs and RSUs over the requisite service period. As the PSUs have a performance condition, compensation expense is recognized for each vesting tranche over the respective requisite service period of each tranche if and when the Company's management deems probable that the performance conditions will be satisfied. The Company may recognize a cumulative true-up adjustment related to PSUs once a condition becomes probable of being satisfied if the related service period had commenced in a prior period. All share-based compensation costs are recorded in general and administrative or research and development costs in the consolidated statements of operations based upon the respective employees or non-employee's roles within the Company. Forfeitures are recorded as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are recorded in accordance with ASC 740, Income Taxes ("ASC 740"), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share excludes the potential impact of convertible preferred stock, common stock options, warrants and unvested shares of restricted stock and restricted stock units because their effect would be anti-dilutive due to the Company's net loss. Since the Company had net losses for the years ended December&#160;31, 2021 and 2020, basic and diluted net loss per common share are the same.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss represents the net loss for the period and other comprehensive income. Other comprehensive income reflects certain gains and losses that are recorded as a component of stockholders&#x2019; deficit and are not reflected in the statements of operations. The Company&#x2019;s other comprehensive income consists of foreign currency translation adjustments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. ASU No. 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. Early adoption is permitted for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company adopted this standard as of January 1, 2021, which did not have material impact on its consolidated financial statements and related disclosures. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes (ASU 2019-12), which is intended to simplify accounting for income taxes. It removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application. ASU 2019-12 was effective for the Company for fiscal years beginning after December 15, 2020, including interim periods therein. The Company adopted this standard as of January 1, 2021, which did not have material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, the FASB issued ASU No. 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 (a consensus of the Emerging Issues Task Force). This update clarifies whether an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying the measurement alternative and how to account for certain forward contracts and purchased options to purchase securities. For public entities, this guidance was effective for fiscal years beginning after December 15, 2020. The Company adopted this standard as of January 1, 2021, which did not have material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, the FASB issued ASU No. 2020-10, Codification Improvements. ASU 2020-10 provides amendments to a wide variety of topics in the FASB&#x2019;s Accounting Standards Codification, which applies to all reporting entities within the scope of the affected accounting guidance. ASU 2020-10 was effective for the Company for fiscal years beginning after December 15, 2020, including interim periods therein. The Company adopted this standard as of January 1, 2021, which did not have material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the FASB issued Accounting Standards Update (ASU) 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. ASU 2021-10 requires business entities to disclose, in notes to their financial statements, information about certain types of government assistance they receive. ASU 2021-10 also adds a new Topic 832, Government Assistance, to the FASB&#x2019;s Codification. ASU 2021-10 is effective for financial statements of all entities, including private companies, for annual periods beginning &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;after December 15, 2021, with early application permitted. The Company adopted this standard as of January 1, 2021, which did not have material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments&#x2014;Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments (ASU No. 2016-13), which requires an entity to utilize a new impairment model known as the current expected credit loss (&#x201c;CECL&#x201d;) model to estimate its lifetime &#x201c;expected credit loss&#x201d; and record an allowance that, when deducted from the amortized cost basis of the financial assets and certain other instruments, including but not limited to available-for-sale debt securities. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. As an emerging growth company, ASU No. 2016-13 is effective for the Company for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company is currently evaluating the impact of the adoption of ASU No. 2016-13 on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzI3NDg3NzkwOTczNjM_fbef25b4-0401-4a1f-99b7-f560aa0a7097">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company, its wholly owned subsidiary, Angion Biomedica Europe Limited, which was dissolved on March 16, 2021, and its wholly owned subsidiary, Angion Pty Ltd., which was established on August 22, 2019. The Company established Angion Pty Ltd., an Australian subsidiary, for the purpose of qualifying for research credits for studies conducted in Australia. All significant intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzI3NDg3NzkwOTczNjU_ee34133d-4899-4a2a-9d43-d9874cd5cdb2">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (&#x201c;CODM&#x201d;) in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzIyOTg_5663b707-4743-4014-b950-04ed385b4026"
      unitRef="operatingsegment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzEwNDQ1MzYwNTI1MTE1_c2a80752-0663-4b7f-aac9-559fae1e8d74">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to the useful lives of long-lived assets, the measurement of stock-based compensation, change in fair value of warrant liabilities prior to IPO, accruals for research and development activities, income taxes and revenue recognition. The Company bases its estimates on historical experience and on other relevant assumptions that are reasonable under the circumstances. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzIxOTkwMjMyODM0OTM_e4ef9520-f0bb-4f98-a932-07ed1f4baa83">Foreign Currency Translation and TransactionsThe United States Dollar (&#x201c;USD&#x201d;) is the functional currency for the Company&#x2019;s operations outside the United States. Accordingly, nonmonetary assets and liabilities originally acquired or assumed in other currencies are recorded in USD at the exchange rates in effect at the date they were acquired or assumed. Monetary assets and liabilities denominated in other currencies are translated into USD at the exchange rates in effect at the balance sheet date. Translation adjustments are recorded in other comprehensive income (loss) in the consolidated statements of operations. Gains and losses realized from non-USD transactions, including intercompany balances not considered as permanent investments, denominated in currencies other than an entity&#x2019;s functional currency are included in other income (expense) in the accompanying consolidated statements of operations.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzEwNDQ1MzYwNTI1MTE3_ce0095be-93ab-4e80-a8f7-48f19f8e875a">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and Off-Balance Sheet Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company's cash and cash equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains its cash equivalents in securities and money market funds with original maturities less than three months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has no financial instruments with off-balance sheet risk of loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzI3NDg3NzkwOTczNjY_7303d55d-9250-46f8-9bb6-6aa17f919bfb">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of December&#160;31, 2021 and 2020, the Company&#x2019;s cash equivalents were held in institutions in the United States and included deposits in a money market fund which were unrestricted as to withdrawal or use.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzIxOTkwMjMyODM0OTQ_10f1d236-d136-484b-876e-a302c105d5d6">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Grants Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Grants receivable is comprised of unbilled amounts due from various grants from the National Institutes of Health ("NIH") and other U.S. government agencies for costs incurred prior to the period end under reimbursement contracts. All amounts are readily available for draw from the Federal Government Payment Management System and, accordingly, no allowance for doubtful amounts has been established. If amounts become uncollectible, they are charged to operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzI3NDg3NzkwOTczNjg_c7bb3289-ca17-4ce7-b003-0248cf836d8d">Deferred Offering CostsDeferred offering costs consist of legal and accounting fees incurred through the balance sheet date that were directly related to the Company's IPO and were reflected as issuance costs upon the completion of the offering.</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts
      contextRef="ie6530fcd8ea6401a8a572f67df226036_I20210210"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzEwOTk1MTE2ODk2ODc_74276198-4baf-4a61-a801-2a616a06a1c4"
      unitRef="usd">2800000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzEwOTk1MTE2OTEwNDE_87c82d2d-37c8-428f-94db-30c00b1ead93"
      unitRef="usd">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzEwOTk1MTE2OTEwNDk_d98070b4-44e3-4944-9dd9-0e2f244a0c96"
      unitRef="usd">2000000</us-gaap:DeferredOfferingCosts>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzIxOTkwMjMyODM0ODk_b313193d-9779-4106-adfb-53b61b339915">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, equipment and leasehold improvements are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over their estimated useful lives as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Shorter of useful life or lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Normal repairs and maintenance costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzIxOTkwMjMyODM0OTA_10a4e0fe-63e6-4669-bd39-0fa7cd502ef7">Depreciation and amortization is computed using the straight-line method over their estimated useful lives as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.668%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Estimated Useful Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Shorter of useful life or lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's property and equipment, net was comprised of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total property and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ifb691fd4a711422cabfdecc00c444d4f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90YWJsZTo4NjQ3ZjI0MWJlNzg0NjM5YTU2MzIyOTA1ODg2MDlhOC90YWJsZXJhbmdlOjg2NDdmMjQxYmU3ODQ2MzlhNTYzMjI5MDU4ODYwOWE4XzEtMi0xLTEtMjQwNDA_77e40116-8dcd-44d8-acd3-e4d7c9f7b24d">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie5ada18d76ea4a24976f7bb9e458c66c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90YWJsZTo4NjQ3ZjI0MWJlNzg0NjM5YTU2MzIyOTA1ODg2MDlhOC90YWJsZXJhbmdlOjg2NDdmMjQxYmU3ODQ2MzlhNTYzMjI5MDU4ODYwOWE4XzItMi0xLTEtMjQwNDA_b6dcf711-c9ff-478f-9134-93376fa52184">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzYwNDczMTM5ODA3MTE_7117ea1b-7628-4482-b2d6-ece64b367ca0">Impairment of Long-Lived AssetsLong-lived assets, such as property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group to be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzY2MzQ_55bea137-27ce-4b2e-84ed-7c97be06a04f"
      unitRef="usd">0</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzEwOTk1MTE2NTc0MzU_dcc513ec-c382-44b1-a9ac-e9eb4125c312"
      unitRef="usd">58000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzI3NDg3NzkwOTczNjk_78c38ff2-a55d-42d6-9b67-ac6c2bc15228">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is determined using the principles of ASC 820, Fair Value Measurement. Fair value is described as the price that would be received to sell an asset or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy prioritizes and defines the inputs to valuation techniques as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1:&#160;&#160;&#160;&#160;Observable inputs such as quoted prices in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:76.5pt;text-indent:-49.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2:&#160;&#160;&#160;&#160;Inputs are observable for the asset or liability either directly or through corroboration with observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3:&#160;&#160;&#160;&#160;Unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The inputs used to measure the fair value of an asset or a liability are categorized within levels of the fair value hierarchy. The fair value measurement is categorized in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the measurement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's cash and cash equivalents, accounts payable and accrued expenses are carried at cost, which approximates fair value due to the short-term nature of these instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzYwNDczMTM5ODA3MTI_badd1d7c-3c70-48d8-9db3-1b5dc5184b61">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its leases under ASC 842, Leases. Under this guidance, arrangements meeting the definition of a lease are classified as operating or finance leases, and are recorded on the consolidated balance sheets as both a right of use asset and a lease liability, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company's incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right of use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right of use asset results in straight-line rent expense over the lease term. Variable lease expenses are recorded when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In calculating the right of use assets and lease liabilities, the Company elects to combine lease and non-lease components. The Company excludes short-term leases having initial terms of 12 months or less from the new guidance as an accounting policy election, and recognizes rent expense on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <angn:InvestmentsInRelatedPartiesPolicyPolicyTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzYwNDczMTM5ODA3MTM_8cdabbe7-5800-44a5-9fa3-feb0d1534fbc">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Related Party Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company holds a 10% and a 2.4% interest in two entities, NovaPark, LLC ("NovaPark") and Ohr Cosmetics, LLC ("Ohr"), respectively. There is common ownership between the Director and Chairman Emeritus of the Company and each entity, and our Chief Executive Officer is also owns approximately 0.80% of the membership interests in Ohr. See Note 15. In accordance with ASC 323, Investments &#x2014;Equity Method and Joint Ventures, the Company has significant influence but not control over NovaPark as its ownership in the limited liability company exceeds 3-5%. Accordingly, the Company records the NovaPark investment under the equity method of accounting. The Ohr investment is recorded at cost.&lt;/span&gt;&lt;/div&gt;</angn:InvestmentsInRelatedPartiesPolicyPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i22b6851c4c8c4d8e9f955da168470856_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzkwMTA_6f1d0d7a-b268-4fb2-b925-dda0e876b6a3"
      unitRef="number">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <angn:OtherInvestmentAndSecuritiesAtCostOwnershipPercentage
      contextRef="i2aaa47df28a24e29abd67cbe8873e02c_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzkwMTk_0462d518-c5e4-4cf2-960c-1f3fcbe6327c"
      unitRef="number">0.024</angn:OtherInvestmentAndSecuritiesAtCostOwnershipPercentage>
    <angn:NumberOfRelatedPartyEntities
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzkwMzQ_7a81deeb-e065-44eb-b05d-2b8607aea32a"
      unitRef="entity">2</angn:NumberOfRelatedPartyEntities>
    <us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest
      contextRef="i334eff8b0f0f4134b32ad37b7a4d1913_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzk4OTU2MDQ3MjA0NDM_e72fee54-81e3-4f1c-ab77-87dfb1d84706"
      unitRef="number">0.0080</us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest>
    <angn:WarrantsAndRightsOutstandingPolicyPolicyTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzYwNDczMTM5ODA3MjY_b0137a28-e08f-481f-aab4-9e6dd93035a6">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrant Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for certain common stock warrants outstanding as a liability, in accordance with ASC 815, Derivatives and Hedging, at fair value and adjusts the instruments to fair value at each reporting period. This liability is subject to re-measurement at each reporting period until exercised, and any change in fair value is recognized in the consolidated statements of operations as a component of other income (expense). The fair value of the warrants issued by the Company has been estimated using a variant of the Black Scholes option pricing model. The underlying equity included in the Black Scholes option pricing model was valued based on the closing price of common stock at each measurement date.&lt;/span&gt;&lt;/div&gt;</angn:WarrantsAndRightsOutstandingPolicyPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzI3NDg3NzkwOTczNzA_657753f0-e7eb-4b07-b384-f7e1c67412a1">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Notes Payable at Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As permitted under ASC 825&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Instruments ("ASC 825"), the Company has elected the fair value option for recognition of its convertible notes. In accordance with ASC 825, the Company recognizes these convertible notes at fair value with changes in fair value recognized in the consolidated statements of operations. The fair value option may be applied instrument by instrument, but it is irrevocable. As a result of applying the fair value option, direct costs and fees related to the convertible notes were recognized in general and administrative &lt;/span&gt;&lt;/div&gt;expense in earnings as incurred and not deferred. The estimated fair value of the convertible notes was determined by utilizing a present value cash flow model and the values of the equity underlying the conversion options were estimated using company equity values implied from the Subject Company Transaction Method which includes the back-solve and scenario-based methods (Probability Weighted Expected Return Method). See Note 4. Accrued interest for the notes has been included in the change in fair value of convertible notes in the consolidated statements of operations. All outstanding convertible notes were converted into common stock upon the close of the IPO on February 9, 2021 and no balances remained outstanding as of December&#160;31, 2021.</us-gaap:DebtPolicyTextBlock>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzEwOTk1MTE2ODkwMjk_ae5208d4-a610-4f25-a2c7-a1b9e818645c"
      unitRef="usd">0</us-gaap:ConvertibleNotesPayableCurrent>
    <angn:FinancialInstrumentsSubjectToMandatoryRedemptionPolicyTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzI3NDg3NzkwOTczNzE_1d2f9866-b573-4bf3-a5c7-295ed95981ff">Convertible Preferred StockSeries C convertible preferred stock included settlement features that result in liability classification. The initial carrying value of the Series C convertible preferred stock was accreted to the settlement value, the fair value of the securities issued upon the conversion of the Series C convertible preferred stock. The discount to the settlement value was accreted to interest expense using the effective interest method. During 2020, certain convertible notes were exchanged for Series C convertible preferred stock. As the exchange was accounted for as a modification, the Series C convertible preferred stock that was exchanged for the convertible notes was recorded at fair value and subject to re-measurement at each reporting period with gains and losses reported through our consolidated statements of operations. All outstanding shares of convertible preferred stock were converted into common stock upon the close of the Company&#x2019;s IPO on February 9, 2021.</angn:FinancialInstrumentsSubjectToMandatoryRedemptionPolicyTextBlock>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia1527dbfa76d46b8a7b898736a11b2b6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzEwOTk1MTE2ODkwMzc_eed67914-25d8-46a2-94cb-748a090edbae"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquityPolicyTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzYwNDczMTM5ODA3Mjc_05c5d2ed-ad39-4abe-8e09-bbb3767fc74c">Treasury StockThe Company records the repurchase of shares of common stock at cost based on the settlement date of the transaction. These shares are classified as treasury stock, which is a reduction to stockholders' equity. Treasury stock is included in authorized and issued shares but excluded from outstanding shares. As of December&#160;31, 2021, all outstanding treasury shares were retired in October 2021 upon approval by the Board of Directors.</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzI3NDg3NzkwOTczNzI_76c1128e-c894-4e7b-8c63-c3950727cb97">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not have any products approved for sale and has not generated any revenue from product sales. The Company&#x2019;s revenue to date has been primarily derived from government funding consisting of U.S. government grants and contracts, and revenue under its license agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for revenue earned from contracts with customers under Accounting Standards Update ("ASU") No. 2014-09, Revenue from Contracts with Customers (Topic 606) ("ASC 606"). Under ASC 606, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps:   &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Identify the contract(s) with a customer;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2)&#160;&#160;&#160;&#160;Identify the performance obligations in the contract;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3)&#160;&#160;&#160;&#160;Determine the transaction price;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4)&#160;&#160;&#160;&#160;Allocate the transaction price to the performance obligations in the contract; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5)&#160;&#160;&#160;&#160;Recognize revenue when (or as) the Company satisfies a performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company assesses the goods or services promised within each contract, whether each promised good or service is distinct, and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into agreements under which it may obtain upfront payments, milestone payments, royalty payments and other fees. Promises under these arrangements may include research licenses, research services, including selection campaign research services for certain replacement targets, the obligation to share information during the research and the participation of alliance managers and in joint research committees, joint patent committees and joint steering committees. The Company assesses these promises within the context of the agreements to determine the performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Licenses of Intellectual Property&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: If a license to its intellectual property is determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring proportional performance for purposes of recognizing revenue from non-refundable, upfront payments. The Company evaluates the measure of proportional performance each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone payments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company evaluates whether the regulatory and development milestones are considered probable of being reached and estimate the amounts to be included in the transaction price using the most likely amount method. The Company evaluates factors such as the scientific, clinical, regulatory, commercial and other risks that must be overcome to achieve the particular milestone in making this assessment. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones and any related constraint, and if necessary, adjust the estimate of the overall transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales-based milestones and royalties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: For sales-based royalties, including milestone payments based on the level of sales, the Company determines whether the sole or predominant item to which the royalties relate is a license. When the license is the sole or predominant item to which the sales-based royalty relates, the Company recognize revenue at the later of: (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any sales-based royalty revenue resulting from any license agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is a contract liability, represents amounts received by the Company for which the related revenues have not been recognized because one or more of the revenue recognition criteria have not been met. The current portion of deferred revenue represents the amount expected to be recognized within one year from the consolidated balance sheet date based on the estimated performance period of the underlying performance obligation. The noncurrent portion of deferred revenue represents amounts expected to be recognized after one year through the end of the performance period of the performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Grant Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company concluded that the Company's government grants are not within the scope of ASC Topic 606 as they do not meet the definition of a contract with a customer. The Company has concluded that the grants meet the definition of a contribution and are non-reciprocal transactions, and has also concluded that Subtopic 958-605, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not-for-Profit-Entities-Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, does not apply, as the Company is a business entity and the grants are with governmental agencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the absence of applicable guidance under GAAP, the Company developed a policy for the recognition of grant revenue when the allowable costs are incurred and the right to payment is realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes this policy is consistent with the overarching premise in ASC Topic 606, to ensure that revenue recognition reflects the transfer of promised goods or services to customers in an amount that reflects the consideration that the Company expects to be entitled to in exchange for those goods or services, even though there is no exchange as defined in ASC Topic 606. The Company believes the recognition of revenue as costs are incurred and amounts become realizable is analogous to the concept of transfer of control of a service over time under ASC Topic 606.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzI3NDg3NzkwOTczNzM_9399f277-61f3-44bb-9cd8-94fbc41333f5">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs include, but are not limited to, payroll and personnel expenses, laboratory supplies, preclinical studies, compound manufacturing costs, consulting costs and allocated overhead, including rent, equipment, depreciation and utilities. Research and development cost maybe offset by research and development refundable tax rebates received by our wholly-owned Australian subsidiary. &lt;/span&gt;&lt;/div&gt;The Company has agreements with various Contract Research Organizations ("CROs") and third-party vendors. Research and development accruals of amounts due to the CRO are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued liabilities on the consolidated balance sheet. Payments made to CROs under such arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. The Company makes judgments and estimates in determining the accrued expenses balance in each reporting period. As actual costs become known, the Company adjusts its accrued expenses.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzI3NDg3NzkwOTczNzQ_9f73064c-bf99-4fd4-a373-cdca3aca1330">Advertising CostsAdvertising costs are expensed as incurred.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzYwNDczMTM5ODA3Mjg_04ec4142-26f4-4950-84b1-5f3184a46cb4">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for all stock-based payments to employees and non-employees, including grants of stock options, RSAs, RSUs, including "PSUs" to be recognized in the financial statements, based on their respective grant date fair values. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The RSAs, RSUs and PSUs are valued based on the fair value of the Company's common stock on the date of grant. The assumptions used in calculating the fair value of stock-based awards represent management's best estimates and involve inherent uncertainties and the application of management's judgment. The Company records expense for stock-based compensation related to stock options, RSAs and RSUs over the requisite service period. As the PSUs have a performance condition, compensation expense is recognized for each vesting tranche over the respective requisite service period of each tranche if and when the Company's management deems probable that the performance conditions will be satisfied. The Company may recognize a cumulative true-up adjustment related to PSUs once a condition becomes probable of being satisfied if the related service period had commenced in a prior period. All share-based compensation costs are recorded in general and administrative or research and development costs in the consolidated statements of operations based upon the respective employees or non-employee's roles within the Company. Forfeitures are recorded as they occur.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzYwNDczMTM5ODA3Mjk_1837bb7d-4648-4684-a9e0-ebb9535b061a">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are recorded in accordance with ASC 740, Income Taxes ("ASC 740"), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzI3NDg3NzkwOTczNzU_7d324a8b-3327-44b2-ab84-4c5e88ceee41">Net Loss Per ShareBasic net loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. Diluted net loss per share excludes the potential impact of convertible preferred stock, common stock options, warrants and unvested shares of restricted stock and restricted stock units because their effect would be anti-dilutive due to the Company's net loss. Since the Company had net losses for the years ended December&#160;31, 2021 and 2020, basic and diluted net loss per common share are the same.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzYwNDczMTM5ODA3MzA_31c90be7-324d-4358-8ac8-89b7cd84138c">Comprehensive LossComprehensive loss represents the net loss for the period and other comprehensive income. Other comprehensive income reflects certain gains and losses that are recorded as a component of stockholders&#x2019; deficit and are not reflected in the statements of operations. The Company&#x2019;s other comprehensive income consists of foreign currency translation adjustments.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDYvZnJhZzpjY2JhZWY4MDJkM2E0MDI4YTIwNzllNDhhZTExN2M4ZS90ZXh0cmVnaW9uOmNjYmFlZjgwMmQzYTQwMjhhMjA3OWU0OGFlMTE3YzhlXzI3NDg3NzkwOTczNzY_d315bb8d-0ed1-476c-8645-a2a70dd7e62f">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current U.S. GAAP. ASU No. 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021. Early adoption is permitted for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company adopted this standard as of January 1, 2021, which did not have material impact on its consolidated financial statements and related disclosures. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes (ASU 2019-12), which is intended to simplify accounting for income taxes. It removes certain exceptions to the general principles in Topic 740 and amends existing guidance to improve consistent application. ASU 2019-12 was effective for the Company for fiscal years beginning after December 15, 2020, including interim periods therein. The Company adopted this standard as of January 1, 2021, which did not have material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, the FASB issued ASU No. 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)-Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 (a consensus of the Emerging Issues Task Force). This update clarifies whether an entity should consider observable transactions that require it to either apply or discontinue the equity method of accounting for the purposes of applying the measurement alternative and how to account for certain forward contracts and purchased options to purchase securities. For public entities, this guidance was effective for fiscal years beginning after December 15, 2020. The Company adopted this standard as of January 1, 2021, which did not have material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, the FASB issued ASU No. 2020-10, Codification Improvements. ASU 2020-10 provides amendments to a wide variety of topics in the FASB&#x2019;s Accounting Standards Codification, which applies to all reporting entities within the scope of the affected accounting guidance. ASU 2020-10 was effective for the Company for fiscal years beginning after December 15, 2020, including interim periods therein. The Company adopted this standard as of January 1, 2021, which did not have material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the FASB issued Accounting Standards Update (ASU) 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. ASU 2021-10 requires business entities to disclose, in notes to their financial statements, information about certain types of government assistance they receive. ASU 2021-10 also adds a new Topic 832, Government Assistance, to the FASB&#x2019;s Codification. ASU 2021-10 is effective for financial statements of all entities, including private companies, for annual periods beginning &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;after December 15, 2021, with early application permitted. The Company adopted this standard as of January 1, 2021, which did not have material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments&#x2014;Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments (ASU No. 2016-13), which requires an entity to utilize a new impairment model known as the current expected credit loss (&#x201c;CECL&#x201d;) model to estimate its lifetime &#x201c;expected credit loss&#x201d; and record an allowance that, when deducted from the amortized cost basis of the financial assets and certain other instruments, including but not limited to available-for-sale debt securities. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. As an emerging growth company, ASU No. 2016-13 is effective for the Company for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company is currently evaluating the impact of the adoption of ASU No. 2016-13 on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzI3NDg3NzkwNzYyMDU_32d716ae-45ed-4327-a0e8-96caad3af48e">Revenue and Deferred Revenue &lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Grant Revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our grants and contracts reimburse us for direct and indirect costs relating to the grant projects and also provide us with a pre-negotiated profit margin on total direct and indirect costs of the grant award, excluding subcontractor costs, after giving effect to directly attributable costs and allowable overhead costs. Funds received from grants and contracts are generally deemed to be earned and recognized as revenue as allowable costs are incurred during the grant or contract period and the right to payment is realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2021 and 2020, the Company recognized grant revenue of $0.8&#160;million and $2.7&#160;million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract Revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s contract revenue has been generated from payments received pursuant to a license agreement (the "Vifor License") with Vifor International, Ltd. ("Vifor Pharma") with headquarters located in Switzerland. The Company recognized revenue from upfront payments over the term of our estimated period of performance using a cost-based input method under Topic 606. The Company expects to continue recognizing revenue from upfront payments related to the Vifor License using the cost-based input method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Vifor License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2020, the Company entered into a license agreement with Vifor Pharma, granting Vifor Pharma global rights (excluding China, Taiwan, Hong Kong and Macau) to develop, manufacture and commercialize ANG-3777 in all therapeutic, prophylactic and diagnostic uses for renal indications, including forms of acute kidney injury (AKI), and congestive heart failure (collectively, the Renal Indications). Pursuant to the Vifor License, the Company received $60&#160;million in upfront and equity payments, including $30&#160;million in up-front cash received in November 2020, and a $30&#160;million equity investment, $5&#160;million of which was a convertible note that subsequently converted into common stock with the IPO and $25&#160;million of which was received in the Concurrent Private Placement with the Company&#x2019;s IPO. The Company is also eligible to receive post-approval milestones of up to approximately $260.0&#160;million and sales-related milestones of up to $1.585&#160;billion, providing a total potential deal value of up to $1.925&#160;billion (subject to certain specified reductions and offsets), plus tiered royalties on net sales of ANG-3777 at royalty rates of up to 40%. Under the Vifor License, the Company is responsible for executing a pre-specified clinical development plan designed to obtain regulatory approvals of ANG-3777 for delayed graft function (DGF) and AKI associated with cardiac surgery involving cardiopulmonary bypass (CSA-AKI). Based on the ANG-3777 clinical trial data disclosed in the fourth quarter of 2021, the Company does not expect to receive any &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;additional clinical, post-approval, or sales milestones, or royalties, as it does not intend to continue to pursue the clinical development plan for ANG-3777 set forth in the Vifor License. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 26, 2021, the Company announced that its Phase 3 trial of ANG-3777 in DGF did not achieve its primary endpoint and the data from the Phase 3 trial was not expected to provide sufficient evidence to support an indication in the studied DGF population. On December 9, 2021, the Company announced its Phase 2 trial of ANG-3777 in CSA-AKI did not achieve its primary endpoint and the data from the Phase 2 trial was not expected to provide sufficient evidence to support a Phase 3 trial in the studied CSA-AKI population. Angion and Vifor continue to analyze data from the CSA-AKI trial. The Company does not intend to continue the clinical development plan for ANG-3777 set forth in the Vifor License, which had included a Phase 3 study in CSA-AKI and a Phase 4 confirmatory study in DGF. In 2022, we and Vifor Pharma continue to work  to complete the planned analyses of the results of the clinical trials announced in the fourth quarter of 2021 and to discuss the future of the collaboration based upon such analyses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Vifor Pharma may terminate the Vifor License at its sole discretion upon the earlier of (i) the acceptance for filing of an NDA covering products incorporating ANG-3777 filed with the FDA (after completion of the relevant Phase 3 clinical trial for such products), or (ii) the third anniversary of the effective date of the Vifor License. Both the Company and Vifor Pharma may terminate the Vifor License in its entirety if the other is in material breach of the Vifor License and has not cured the breach (if curable) within 60 days, or 90 days for incurable breach. In certain circumstances, in the event of the Company&#x2019;s material breach of the Vifor License, Vifor Pharma may terminate the Vifor License with respect to certain major markets. In addition, both parties have the right to terminate the Vifor License upon insolvency of the other party. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company identified the following performance obligations in the Vifor License based upon the  clinical development plan for ANG-3777: (1) the global license (excluding greater China), (2) the development services, including the clinical development services including a post-approval confirmatory study, the technical development services and regulatory services and (3) the required participation on Joint Committees for coordination and oversight. The Company determined that the license is not capable of being distinct due to the specialized nature of the development services to be provided by the Company, and, accordingly, this promise was combined with the development services and participation in the joint committees as one single performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In order to determine the transaction price, the Company evaluated all the payments to be received during the duration of the contract. Certain milestones and additional fees were considered variable consideration, which were not included in the transaction price at contract inception. The Company determined that the transaction price at the inception of the Vifor License is $15.0&#160;million, which is 50% of the $30.0&#160;million upfront payment due to the potential setoff defined in the contract. The Company will re-evaluate the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In the fourth quarter of 2021, the Company reported topline results from two ANG-3777 clinical trials under the Vifor License. The Company determined it will no longer continue the current clinical development plan for ANG 3777 DGF and CSA-AKI, which had included a Phase 3 study for CSA-AKI and a Phase 4 confirmatory study in DGF, given neither trial achieved statistical significance on its primary endpoint. In connection therewith, the Company adjusted the transaction price to include $15.0&#160;million in previously constrained variable consideration. As of December&#160;31, 2021, the Company concluded that it has significantly satisfied the performance obligation under Vifor License and will fully conclude the ANG-3777 project by the end of 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Using the cost-based input method, the Company recognizes revenue based on actual costs incurred as a percentage of total estimated costs as the Company completes its performance obligation. The cumulative effect of revisions to estimated costs to complete the Company&#x2019;s performance obligation will be recorded in the period in which changes are identified and amounts can be reasonably estimated. These actual costs consist primarily of internal full time equivalent (FTE) efforts and third-party contract costs related to the Vifor License.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company reassessed the performance period as the Company is currently closing out the planned analyses from both trials but does not intend to continue the clinical development plan for ANG-3777 set forth in the Vifor License,  which had included a Phase 3 study for CSA-AKI and a Phase 4 confirmatory study in DGF, given these clinical results. As such, the estimated date to fully conclude ANG-3777 by the end of December 2022 was determined to represent the completion of the Company&#x2019;s performance obligation under the Vifor License. Additionally, the Company revised the total estimated costs for completion of the performance obligation to reflect &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;the winding down of ANG-3777-related studies. The performance period is expected to end in the fourth quarter of 2022 instead of the fourth quarter of 2026. The effect of this change in estimate was an increase in contract revenue by $24.2&#160;million, a reduction in net loss by $24.2&#160;million and an increase in basic and diluted earnings per share by $0.86 for the year ended December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2021 and 2020, the Company recognized license revenue related to the Vifor License of $27.5&#160;million and $0.2&#160;million. As of December&#160;31, 2021, $2.3&#160;million was recorded as the current portion of deferred revenue on the consolidated balance sheet related to the Vifor License. As of December 31, 2020, $29.8&#160;million was recorded as deferred revenue on the consolidated balance sheet related to the Vifor License.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2NjQ1NTA_e732ff6f-561a-4d87-be34-f1318b82c4b6"
      unitRef="usd">800000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2NjQ1NTg_43620ead-d756-4a50-b429-3ce64e35490d"
      unitRef="usd">2700000</us-gaap:RevenueNotFromContractWithCustomer>
    <angn:ContractWithCustomerUpfrontAndNearTermMilestonePaymentEntitledToReceive
      contextRef="if21e2f0448ee4d45b7742ead826a0858_D20201101-20201130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzE2NDkyNjc0ODE0MDU_21e60417-a31b-4260-91ff-f6d66aac1590"
      unitRef="usd">60000000</angn:ContractWithCustomerUpfrontAndNearTermMilestonePaymentEntitledToReceive>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i8e92ffc10989447182476424cac89e3f_I20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2MzUxNzY_6ba1241d-0ff0-44b6-8287-86a20c3c0b40"
      unitRef="usd">30000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if93bd2dd820c484eaec104d26be89685_I20210209"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2MzUxODQ_b0646bff-f0fc-49a8-a191-9a3e0262af1b"
      unitRef="usd">30000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="i7c1c861e844341b5a5e29c716ed55595_D20210209-20210209"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2MzUxOTI_4d30aaf7-eb3a-4199-9303-70b740e998a2"
      unitRef="usd">5000000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="icbbb8ca18fb34328a36cc3e05df1ac42_D20210209-20210209"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2MzUyMDI_e94f25df-3551-4d8a-96e2-ffe7685a7154"
      unitRef="usd">25000000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <angn:ContractWithCustomerPostApprovalMilestonePaymentEntitledToReceive
      contextRef="if21e2f0448ee4d45b7742ead826a0858_D20201101-20201130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2MzUyMTA_08a21b1b-2047-4021-a862-ebb91ca597f4"
      unitRef="usd">260000000</angn:ContractWithCustomerPostApprovalMilestonePaymentEntitledToReceive>
    <angn:ContractWithCustomerSalesRelatedMilestonePaymentEntitledToReceive
      contextRef="if21e2f0448ee4d45b7742ead826a0858_D20201101-20201130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2MzUyMjA_89bb7525-dbec-4e58-9184-c536a1c3e4e3"
      unitRef="usd">1585000000</angn:ContractWithCustomerSalesRelatedMilestonePaymentEntitledToReceive>
    <angn:ContractWithCustomerMilestonePaymentsEntitledToReceive
      contextRef="if21e2f0448ee4d45b7742ead826a0858_D20201101-20201130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2MzUyMjg_4b5df9c7-9b20-4128-820d-a69edb96f5cf"
      unitRef="usd">1925000000</angn:ContractWithCustomerMilestonePaymentsEntitledToReceive>
    <angn:ContractWithCustomerRoyaltyRatesMaximum
      contextRef="i8e92ffc10989447182476424cac89e3f_I20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2MzUyMzY_59d42ac7-9f92-4152-b748-4687b10c2d12"
      unitRef="number">0.40</angn:ContractWithCustomerRoyaltyRatesMaximum>
    <angn:ContractWithCustomerContractTerminationPeriodCurableBreach
      contextRef="i2b2bdc42a04c4cd3af27c83384133f3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzI3NDg3NzkwNzYxNTA_714fda9c-e07e-4d11-ac96-4c125cddea07">P60D</angn:ContractWithCustomerContractTerminationPeriodCurableBreach>
    <angn:ContractWithCustomerContractTerminationPeriodIncurableBreach
      contextRef="i2b2bdc42a04c4cd3af27c83384133f3b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzI3NDg3NzkwNzYxNTE_a9577b36-cfb6-4216-998d-7777d2ed358a">P90D</angn:ContractWithCustomerContractTerminationPeriodIncurableBreach>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ic3a0a0d452d744969da82c474ba19d42_I20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2MzUyNDA_7b5f374b-2bd1-4af9-9803-9581504492b7"
      unitRef="usd">15000000</us-gaap:RevenueRemainingPerformanceObligation>
    <angn:ContractWithCustomerLiabilityPercentOfUpfrontPayment
      contextRef="i8e92ffc10989447182476424cac89e3f_I20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2MzUyNDg_f8e01611-a3d4-42ff-bcff-48af31e2b432"
      unitRef="number">0.50</angn:ContractWithCustomerLiabilityPercentOfUpfrontPayment>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i8e92ffc10989447182476424cac89e3f_I20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2MzUyNTI_6ba1241d-0ff0-44b6-8287-86a20c3c0b40"
      unitRef="usd">30000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ib2c20a51369c40ba8a350cc15fab95b0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2Mzk2Njk_87c9e71a-a52e-40eb-b353-bbf0517b6f7e"
      unitRef="usd">15000000</us-gaap:RevenueRemainingPerformanceObligation>
    <angn:RevenueFromContractWithCustomerIncludingAssessedTaxIncrease
      contextRef="if19bda0412d14f569093c176591ee9a5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2NTUwODE_f570e383-f10c-44ca-a9e8-51e80d4a20cd"
      unitRef="usd">24200000</angn:RevenueFromContractWithCustomerIncludingAssessedTaxIncrease>
    <angn:NetIncomeLossAttributableToParentIncrease
      contextRef="if19bda0412d14f569093c176591ee9a5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2NTUzODQ_749f2ad0-4c59-4023-9da3-786843e5e8d3"
      unitRef="usd">24200000</angn:NetIncomeLossAttributableToParentIncrease>
    <angn:EarningsPerShareDilutedIncrease
      contextRef="if19bda0412d14f569093c176591ee9a5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2NTUwOTM_6708173f-425b-43ef-a4fc-5a404bd115df"
      unitRef="usdPerShare">-0.86</angn:EarningsPerShareDilutedIncrease>
    <angn:EarningsPerShareBasicIncrease
      contextRef="if19bda0412d14f569093c176591ee9a5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2NTUwOTM_e7df8b69-d069-43fd-afe5-a9822dc2fbac"
      unitRef="usdPerShare">-0.86</angn:EarningsPerShareBasicIncrease>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if19bda0412d14f569093c176591ee9a5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2MzQ1NDU_6d778b23-755a-4664-bef0-3125a2f66ba9"
      unitRef="usd">27500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7dfe036a9b474f76843bec13725495e1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2MzQ1NTM_ba307e69-14b8-418f-980a-0fab51ade91f"
      unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i76d34e6f4aa7484d9735bb67f83fe319_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2MzQ4OTc_09857bfe-77aa-4a39-ab35-a209dc6bf361"
      unitRef="usd">2300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i2e59113239ac414b95bede6314d45d5a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMDkvZnJhZzoxOTE2YzUwNTQ2MDc0MDkxOTcwNTI2M2ZjMmZhZTYzMi90ZXh0cmVnaW9uOjE5MTZjNTA1NDYwNzQwOTE5NzA1MjYzZmMyZmFlNjMyXzEwOTk1MTE2MzUxMjE_2c00fcd6-0eb7-41a0-bf39-abfe214638ec"
      unitRef="usd">29800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90ZXh0cmVnaW9uOjg4ZDM5N2I0MTBhODQ4NTE4M2UwNzliNWRjZjI4MmNlXzI3NDg3NzkwNzIyNDI_f3d47705-dadc-490a-b40f-8dc927a2b8dc">Fair Value Measurements&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table classifies the Company's financial assets and liabilities measured at fair value on a recurring basis into the fair value hierarchy as of December&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Fair Value Measured at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Quoted Prices in &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Active Markets for &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Identical &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Assets (Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Significant &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Other &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Observable &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Inputs (Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Significant &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unobservable &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Inputs (Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Assets included in:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash and cash equivalents&#x2014;Money market securities  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;87,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;87,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;87,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;87,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Liabilities included in:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$114&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Fair Value Measured at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Quoted Prices in &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Active Markets for &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Identical &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Assets (Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Significant &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Other &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Observable &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Inputs (Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Significant &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unobservable &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Inputs (Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Assets included in:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash and cash equivalents&#x2014;Money market securities  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Liabilities included in:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Convertible notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;51,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;51,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Series C convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;64,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;64,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;___________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) Included in cash and cash equivalents on the consolidated balance sheets. This balance includes cash requirements settled on a nightly basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers made among the three levels in the fair value hierarchy during periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in Level 3 liabilities measured at fair value (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Warrant &lt;br/&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Convertible &lt;br/&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Series C Convertible Preferred Stock at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Balance&#x2014;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;10,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;51,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;2,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;64,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Conversion of convertible Series C convertible preferred stock into common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(6,110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(6,110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Conversion of convertible notes into common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(58,639)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(58,639)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Net exercise of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(13,509)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(13,509)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;2,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;7,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;3,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;13,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Balance&#x2014;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;114&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;114&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long- dated volatilities) inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company used an option model to measure the fair value of the Notes (on conversion date). The values of the equity underlying the conversion options in the model were estimated using equity values implied from sales of convertible preferred stock. The fair value of the Notes was impacted by the model selected as well as assumptions surrounding unobservable inputs. Key unobservable inputs include the expected volatility of the underlying equity, and the timing of an expected liquidity event.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the warrants issued by the Company has been estimated using a variant of the Black Scholes option pricing model. The underlying equity included in the Black Scholes option pricing model was valued based on the equity value implied from sales of preferred and common stock at each measurement date. The fair value of the warrants was impacted by the model selected as well as assumptions surrounding unobservable inputs including the underlying equity value, expected volatility of the underlying equity, risk free interest rate and the expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Notes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value adjustment during the year ended December&#160;31, 2021 was based on the final settlement amount using a conversion price of $11.57 per share on February 9, 2021. Subsequent to the closing of the IPO, there were no convertible notes outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Series C Preferred Stock &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value adjustment during the year ended December&#160;31, 2021 was based on the final settlement amount using a conversion price of $11.57 per share on February 9, 2021. Subsequent to the closing of the IPO, there were no shares of convertible preferred stock outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrant Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value adjustment for the net exercise of warrants with an exercise price of $6.43 during the year ended December&#160;31, 2021 was based on the final settlement amount using the IPO price on February 9, 2021. Subsequent to the closing of the IPO, the fair value of the warrants issued by the Company were estimated using a variant of the Black Scholes option pricing model. The underlying equity included in the Black Scholes option pricing model was valued based on the closing price of common stock at each measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021 and 2020, the fair value of the warrants increased by $2.9&#160;million and $4.9&#160;million, respectively. The change in fair value of warrant liability in both periods was recognized in the consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the Company's warrant liabilities that were categorized within Level 3 of the fair value hierarchy as of December&#160;31, 2021 and 2020 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Strike price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contractual term (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Volatility (annual)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;74.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;86.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Dividend yield (per share)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90ZXh0cmVnaW9uOjg4ZDM5N2I0MTBhODQ4NTE4M2UwNzliNWRjZjI4MmNlXzI3NDg3NzkwNzIyNDM_60feb9a8-af84-4af0-85bd-9420ff043a44">&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table classifies the Company's financial assets and liabilities measured at fair value on a recurring basis into the fair value hierarchy as of December&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Fair Value Measured at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Quoted Prices in &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Active Markets for &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Identical &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Assets (Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Significant &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Other &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Observable &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Inputs (Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Significant &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unobservable &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Inputs (Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Assets included in:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash and cash equivalents&#x2014;Money market securities  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;87,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;87,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;87,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;87,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Liabilities included in:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$114&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Fair Value Measured at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Quoted Prices in &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Active Markets for &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Identical &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Assets (Level 1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Significant &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Other &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Observable &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Inputs (Level 2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Significant &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unobservable &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Inputs (Level 3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Assets included in:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash and cash equivalents&#x2014;Money market securities  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Liabilities included in:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Convertible notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;51,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;51,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Series C convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;64,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;64,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;___________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) Included in cash and cash equivalents on the consolidated balance sheets. This balance includes cash requirements settled on a nightly basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia83ec88a3b3147ed8f7108e7f8a10e0f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzMtMS0xLTEtMjI1NDU_bdb5875e-cc8f-4717-91cb-0927bd0caa58"
      unitRef="usd">87252000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iad4e3db6f2344adeaf53fa4f5bb5a0b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzMtMy0xLTEtMjI1NDU_d21d2e99-aae6-4d0d-9aaf-64dc8a7893b2"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7afc7784bba7408fb2ba2c128f6657a8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzMtNS0xLTEtMjI1NDU_57d4a3ef-10e8-4b25-aefd-c376ba6914e9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2e37997f6b2f47c0a98e68a4f9edef5e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzMtNy0xLTEtMjI1NDU_fc0b76f4-d995-42e9-84df-e950ebf7b893"
      unitRef="usd">87252000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia83ec88a3b3147ed8f7108e7f8a10e0f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzQtMS0xLTEtMjI1NDU_190f460b-4229-420b-b86a-93da4a405f08"
      unitRef="usd">87252000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iad4e3db6f2344adeaf53fa4f5bb5a0b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzQtMy0xLTEtMjI1NDU_fa249819-187d-4685-8a03-a957e4415fd7"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7afc7784bba7408fb2ba2c128f6657a8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzQtNS0xLTEtMjI1NDU_4e91d6e7-427a-4258-8353-55e964153e35"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2e37997f6b2f47c0a98e68a4f9edef5e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzQtNy0xLTEtMjI1NDU_202e5bcb-6dd7-4a61-8c8f-53aca427b477"
      unitRef="usd">87252000</us-gaap:AssetsFairValueDisclosure>
    <angn:WarrantsFairValueDisclosure
      contextRef="ia83ec88a3b3147ed8f7108e7f8a10e0f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzctMS0xLTEtMjI1NDU_b1d70368-852e-4322-bc4a-fc9593c5ff3e"
      unitRef="usd">0</angn:WarrantsFairValueDisclosure>
    <angn:WarrantsFairValueDisclosure
      contextRef="iad4e3db6f2344adeaf53fa4f5bb5a0b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzctMy0xLTEtMjI1NDU_c6d6a1f7-4a48-4b05-ae4c-378253c61b71"
      unitRef="usd">0</angn:WarrantsFairValueDisclosure>
    <angn:WarrantsFairValueDisclosure
      contextRef="i7afc7784bba7408fb2ba2c128f6657a8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzctNS0xLTEtMjI1NDU_ac7f9ed9-5019-4849-9d14-96bc64ccf565"
      unitRef="usd">114000</angn:WarrantsFairValueDisclosure>
    <angn:WarrantsFairValueDisclosure
      contextRef="i2e37997f6b2f47c0a98e68a4f9edef5e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzctNy0xLTEtMjI1NDU_65c42599-1e27-4a8a-8dae-dd42e1ec9bca"
      unitRef="usd">114000</angn:WarrantsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia83ec88a3b3147ed8f7108e7f8a10e0f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzktMS0xLTEtMjI1NDU_2c17491a-50fc-40c9-bc8e-96898a01a66e"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iad4e3db6f2344adeaf53fa4f5bb5a0b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzktMy0xLTEtMjI1NDU_c2ae1901-320e-4ddc-b658-fd92665c0747"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7afc7784bba7408fb2ba2c128f6657a8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzktNS0xLTEtMjI1NDU_afdf2b6a-1e92-4011-a188-05749147d533"
      unitRef="usd">114000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i2e37997f6b2f47c0a98e68a4f9edef5e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTozZmFhNGIwYWVhMWQ0OTQxYjFhMWUzNTQ2N2ZmZmI0Yi90YWJsZXJhbmdlOjNmYWE0YjBhZWExZDQ5NDFiMWExZTM1NDY3ZmZmYjRiXzktNy0xLTEtMjI1NDU_2ed6f7ef-b411-43c5-81a1-bb0e15855ff9"
      unitRef="usd">114000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i154b24e4e9944f218abc0f9cd65e80b0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzMtMS0xLTEtMjI1NDU_ffdedd38-dacf-44b8-a1c9-e496bef832be"
      unitRef="usd">1000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3b97b816eb8f487f8a5410b7dc6dc79b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzMtMy0xLTEtMjI1NDU_46073961-4365-4018-86be-f4f65ad014d2"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="idc2c8fc18af04652b3b74961e635dbe6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzMtNS0xLTEtMjI1NDU_9091ef92-311e-4585-842e-184dc0868d04"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1c7ff22c3ff94a4d849562a284c0e1d2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzMtNy0xLTEtMjI1NDU_47649a28-8d27-456f-9667-796d745c97dc"
      unitRef="usd">1000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i154b24e4e9944f218abc0f9cd65e80b0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzQtMS0xLTEtMjI1NDU_01ff4206-cd16-4d79-b6fd-c05611f30cde"
      unitRef="usd">1000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3b97b816eb8f487f8a5410b7dc6dc79b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzQtMy0xLTEtMjI1NDU_7984b233-4984-44cb-b0ae-d5191fa3f7e6"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="idc2c8fc18af04652b3b74961e635dbe6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzQtNS0xLTEtMjI1NDU_dec222eb-b415-4d40-a6c6-50aeb35cf9d8"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1c7ff22c3ff94a4d849562a284c0e1d2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzQtNy0xLTEtMjI1NDU_0386ee11-8e5a-45e7-9400-d09793eb15c5"
      unitRef="usd">1000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i154b24e4e9944f218abc0f9cd65e80b0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzYtMS0xLTEtMjI1NDU_635daaf0-b3de-42a1-806e-791439aea82e"
      unitRef="usd">0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i3b97b816eb8f487f8a5410b7dc6dc79b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzYtMy0xLTEtMjI1NDU_237039f3-b3dd-4649-a957-da4453fcd50c"
      unitRef="usd">0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="idc2c8fc18af04652b3b74961e635dbe6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzYtNS0xLTEtMjI1NDU_068a737c-95d9-44b5-8947-8cb3b2075b95"
      unitRef="usd">51170000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i1c7ff22c3ff94a4d849562a284c0e1d2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzYtNy0xLTEtMjI1NDU_bc302cd0-fab3-4e22-b8ed-67d45ed24b88"
      unitRef="usd">51170000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <angn:WarrantsFairValueDisclosure
      contextRef="i154b24e4e9944f218abc0f9cd65e80b0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzctMS0xLTEtMjI1NDU_ec199dd8-933b-4886-82db-0b294045f129"
      unitRef="usd">0</angn:WarrantsFairValueDisclosure>
    <angn:WarrantsFairValueDisclosure
      contextRef="i3b97b816eb8f487f8a5410b7dc6dc79b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzctMy0xLTEtMjI1NDU_66a6b5b9-e2b0-46b6-8e5b-ba252efb1a6a"
      unitRef="usd">0</angn:WarrantsFairValueDisclosure>
    <angn:WarrantsFairValueDisclosure
      contextRef="idc2c8fc18af04652b3b74961e635dbe6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzctNS0xLTEtMjI1NDU_a315fda2-5e48-46a4-bd64-54734ca4c5c7"
      unitRef="usd">10704000</angn:WarrantsFairValueDisclosure>
    <angn:WarrantsFairValueDisclosure
      contextRef="i1c7ff22c3ff94a4d849562a284c0e1d2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzctNy0xLTEtMjI1NDU_56260b0e-5b87-4fb4-b47d-48a47be74a32"
      unitRef="usd">10704000</angn:WarrantsFairValueDisclosure>
    <angn:FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent
      contextRef="i154b24e4e9944f218abc0f9cd65e80b0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzgtMS0xLTEtMjc4MzI_9c01a6bb-0554-4465-bcaa-9e672ccae0a2"
      unitRef="usd">0</angn:FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent>
    <angn:FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent
      contextRef="i3b97b816eb8f487f8a5410b7dc6dc79b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzgtMy0xLTEtMjc4MzI_8741bc23-6178-4e8c-b950-8152a06d191d"
      unitRef="usd">0</angn:FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent>
    <angn:FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent
      contextRef="idc2c8fc18af04652b3b74961e635dbe6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzgtNS0xLTEtMjc4MzI_28b4b9d7-521f-4ba2-a8bb-1b2a6952e26f"
      unitRef="usd">2518000</angn:FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent>
    <angn:FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent
      contextRef="i1c7ff22c3ff94a4d849562a284c0e1d2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzgtNy0xLTEtMjc4MzI_d5cbb0ac-dd28-47da-a188-13ed48c15310"
      unitRef="usd">2518000</angn:FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i154b24e4e9944f218abc0f9cd65e80b0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzgtMS0xLTEtMjI1NDU_004568db-cbf3-477e-8eea-4b439c0dedc4"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i3b97b816eb8f487f8a5410b7dc6dc79b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzgtMy0xLTEtMjI1NDU_b9f5cfa5-9f6f-4080-9c68-ab0a83e804aa"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="idc2c8fc18af04652b3b74961e635dbe6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzgtNS0xLTEtMjI1NDU_985014b8-e81a-465c-9266-808fb59c9fb2"
      unitRef="usd">64392000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i1c7ff22c3ff94a4d849562a284c0e1d2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTphYTc1NmY4MTg1ZWY0YWU4OGRjNTg4ZWNkYTAyMGMxZC90YWJsZXJhbmdlOmFhNzU2ZjgxODVlZjRhZTg4ZGM1ODhlY2RhMDIwYzFkXzgtNy0xLTEtMjI1NDU_be98cd4a-b51d-48af-a6a6-3ee0f6f4c674"
      unitRef="usd">64392000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90ZXh0cmVnaW9uOjg4ZDM5N2I0MTBhODQ4NTE4M2UwNzliNWRjZjI4MmNlXzI3NDg3NzkwNzIyNDQ_168eddc1-ef0a-43e2-858c-8951b23a9530">&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents changes in Level 3 liabilities measured at fair value (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Warrant &lt;br/&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Convertible &lt;br/&gt;Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Series C Convertible Preferred Stock at Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Balance&#x2014;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;10,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;51,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;2,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;64,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Conversion of convertible Series C convertible preferred stock into common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(6,110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(6,110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Conversion of convertible notes into common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(58,639)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(58,639)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Net exercise of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(13,509)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(13,509)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;2,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;7,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;3,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;13,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Balance&#x2014;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;114&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;114&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i85e948c0db004aec96a438029856e941_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzgtMS0xLTEtMjI1NDU_16794bb4-fe0f-47f9-8245-3856d38d15df"
      unitRef="usd">10704000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ic66825b0a3fc4dd6a295dc833b6cfb18_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzgtMy0xLTEtMjI1NDU_db528185-6ef6-4954-8f12-a973a05ac054"
      unitRef="usd">51170000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i814f9685f6c74fbb94e17b68b38c9a50_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzgtNS0xLTEtMjI1NDU_d0d14c26-9e9d-44b2-ba3d-dcef4612712f"
      unitRef="usd">2518000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzgtNy0xLTEtMjI1NDU_1bcd7329-48ec-4954-83a2-f0b543b91423"
      unitRef="usd">64392000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i0d1460718e76486b9ed354cf1c73b976_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzItNS0xLTEtMjgwNDE_47cfb4c9-00cc-4c4c-93b1-7e3c96ca77f7"
      unitRef="usd">6110000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i0d1460718e76486b9ed354cf1c73b976_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzItNy0xLTEtMjgwNDE_9a8a933e-4ed5-410a-980b-dcee6c2244df"
      unitRef="usd">6110000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="ibf7783ebf66b4af79c0713536f5f2962_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzMtMy0xLTEtMjgwNDE_ddd842a7-8389-4b50-9bbd-dba3c1838576"
      unitRef="usd">58639000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="ibf7783ebf66b4af79c0713536f5f2962_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzMtNy0xLTEtMjgwNDE_f56b8401-7f9e-4b99-b2aa-3bb9086813ae"
      unitRef="usd">58639000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i0e0cf619aa784005a71db89834b81180_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzQtMS0xLTEtMjgwNDE_959325c5-390e-41a3-845d-6e1973d6a735"
      unitRef="usd">13509000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i0e0cf619aa784005a71db89834b81180_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzQtNy0xLTEtMjgwNDE_56d803b4-ce76-485a-b777-5fe0d5a4ca2e"
      unitRef="usd">13509000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i0e0cf619aa784005a71db89834b81180_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzUtMS0xLTEtMjgwNDE_32d23ea4-9a5f-42ec-b087-c370f572c1d9"
      unitRef="usd">2919000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ibf7783ebf66b4af79c0713536f5f2962_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzUtMy0xLTEtMjgwNDE_b1c58919-5e0e-4a6c-ba9e-42c876e4790d"
      unitRef="usd">7469000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i0d1460718e76486b9ed354cf1c73b976_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzUtNS0xLTEtMjgwNDE_2fb2b9ea-bb8b-487a-a5de-82c9a0bbddd2"
      unitRef="usd">3592000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzUtNy0xLTEtMjgwNDE_be20a23c-7e5f-4a5e-a0a0-6ffa1a699001"
      unitRef="usd">13980000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i15bff6b964924bd2887e2adeffbf32c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzYtMS0xLTEtMjgwNDE_52cac2f3-baf4-4f02-b170-7cf425ae9bdd"
      unitRef="usd">114000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ic050e32ff85e44309aa662d9aef5ce48_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzYtMy0xLTEtMjgwNDE_474c8748-3a51-46d3-985f-80d539e25bba"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i3bc00b7b825d4ba3852fb7e87894c1cc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzYtNS0xLTEtMjgwNDE_bc14d4c3-91d1-421f-97e4-3df4afa79fac"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTowNzY4Yzk5MTE3NDU0ODZhYTgxMjVmNzIxYWM4MWE5OS90YWJsZXJhbmdlOjA3NjhjOTkxMTc0NTQ4NmFhODEyNWY3MjFhYzgxYTk5XzYtNy0xLTEtMjgwNDE_3a1f6dcb-ccf6-4232-917e-11d213799b06"
      unitRef="usd">114000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i66adccbb9df94f8b89614b7fed22144e_I20210209"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90ZXh0cmVnaW9uOjg4ZDM5N2I0MTBhODQ4NTE4M2UwNzliNWRjZjI4MmNlXzEwOTk1MTE2MzI3MjA_cf31ea2d-8e79-4ed3-af4a-2672ee6e6287"
      unitRef="usdPerShare">11.57</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="ie6530fcd8ea6401a8a572f67df226036_I20210210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90ZXh0cmVnaW9uOjg4ZDM5N2I0MTBhODQ4NTE4M2UwNzliNWRjZjI4MmNlXzEwOTk1MTE2MzEzNzE_2b21533d-00e4-4161-9e4c-039438a46c03"
      unitRef="usd">0</us-gaap:ConvertibleNotesPayableCurrent>
    <angn:FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsConversionPrice
      contextRef="i5ce6c1160cbc4d2eb14e3ddc68c08191_D20210209-20210209"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90ZXh0cmVnaW9uOjg4ZDM5N2I0MTBhODQ4NTE4M2UwNzliNWRjZjI4MmNlXzEwOTk1MTE2MzM0MjQ_402e0b54-f97b-42ce-af10-bfeee6599292"
      unitRef="usdPerShare">11.57</angn:FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsConversionPrice>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia2518ef5cab941c1b5281fac0348fe6c_I20210210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90ZXh0cmVnaW9uOjg4ZDM5N2I0MTBhODQ4NTE4M2UwNzliNWRjZjI4MmNlXzEwOTk1MTE2MzM0NDU_2389dde4-137f-448a-a401-2a67cc8e3125"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90ZXh0cmVnaW9uOjg4ZDM5N2I0MTBhODQ4NTE4M2UwNzliNWRjZjI4MmNlXzEwOTk1MTE2MzI3Mjg_e0166cd7-1d81-4e9a-ba41-08a2d8ed0a62"
      unitRef="usdPerShare">6.43</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90ZXh0cmVnaW9uOjg4ZDM5N2I0MTBhODQ4NTE4M2UwNzliNWRjZjI4MmNlXzEwOTk1MTE2MzM0Mjk_f9564913-a4cf-43fc-936b-d4270956bf90"
      unitRef="usd">2900000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90ZXh0cmVnaW9uOjg4ZDM5N2I0MTBhODQ4NTE4M2UwNzliNWRjZjI4MmNlXzEwOTk1MTE2MzM0NTQ_260881d5-0fdd-4fc3-bad4-7bde14e4a208"
      unitRef="usd">4900000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90ZXh0cmVnaW9uOjg4ZDM5N2I0MTBhODQ4NTE4M2UwNzliNWRjZjI4MmNlXzI3NDg3NzkwNzIyNDU_cd927d46-59e8-447d-a195-9fc740638112">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring the Company's warrant liabilities that were categorized within Level 3 of the fair value hierarchy as of December&#160;31, 2021 and 2020 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Strike price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Contractual term (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Volatility (annual)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;74.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;86.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Dividend yield (per share)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ib2df00ce29b94846875f1ca16bf13df4_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTplNjE0MjQ0NGJhN2Q0ZmNmOWQ4YjMwM2IzMDNhYjFiNi90YWJsZXJhbmdlOmU2MTQyNDQ0YmE3ZDRmY2Y5ZDhiMzAzYjMwM2FiMWI2XzItMS0xLTEtMjI1NDU_7f1478f7-9aa5-4a0c-94e4-4b2ba8f15fe7"
      unitRef="usdPerShare">8010.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="if4d6f862fa754573bef10ee164188288_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTplNjE0MjQ0NGJhN2Q0ZmNmOWQ4YjMwM2IzMDNhYjFiNi90YWJsZXJhbmdlOmU2MTQyNDQ0YmE3ZDRmY2Y5ZDhiMzAzYjMwM2FiMWI2XzItMy0xLTEtMjI1NDU_6e1172de-0413-420a-87dc-cbddfc836a59"
      unitRef="usdPerShare">9.18</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i209f579b21984d5987ce82e809b3b3f5_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTplNjE0MjQ0NGJhN2Q0ZmNmOWQ4YjMwM2IzMDNhYjFiNi90YWJsZXJhbmdlOmU2MTQyNDQ0YmE3ZDRmY2Y5ZDhiMzAzYjMwM2FiMWI2XzMtMS0xLTEtMjI1NDU_d0ef87e0-139b-4002-82c4-5cd06392bcc4">P1Y2M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="ibdd03f678bd444f78c9695d99f88f610_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTplNjE0MjQ0NGJhN2Q0ZmNmOWQ4YjMwM2IzMDNhYjFiNi90YWJsZXJhbmdlOmU2MTQyNDQ0YmE3ZDRmY2Y5ZDhiMzAzYjMwM2FiMWI2XzMtMy0xLTEtMjI1NDU_aaaad5bb-5ede-480d-a41b-5f118c4a2927">P4Y10M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ie5de6bc9b6694e62baba186bbdd4af73_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTplNjE0MjQ0NGJhN2Q0ZmNmOWQ4YjMwM2IzMDNhYjFiNi90YWJsZXJhbmdlOmU2MTQyNDQ0YmE3ZDRmY2Y5ZDhiMzAzYjMwM2FiMWI2XzQtMS0xLTEtMjI1NDU_61a95a24-a631-4458-b2f0-5dbfe999d6ad"
      unitRef="number">0.746</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ia35389eedc0a4461980878982b5787a2_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTplNjE0MjQ0NGJhN2Q0ZmNmOWQ4YjMwM2IzMDNhYjFiNi90YWJsZXJhbmdlOmU2MTQyNDQ0YmE3ZDRmY2Y5ZDhiMzAzYjMwM2FiMWI2XzQtMy0xLTEtMjI1NDU_e6f3d1c2-8aa0-448a-92db-0bc63d9adff2"
      unitRef="number">0.868</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ia83dfc08acb543ae8924290c590ed65a_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTplNjE0MjQ0NGJhN2Q0ZmNmOWQ4YjMwM2IzMDNhYjFiNi90YWJsZXJhbmdlOmU2MTQyNDQ0YmE3ZDRmY2Y5ZDhiMzAzYjMwM2FiMWI2XzUtMS0xLTEtMjI1NDU_9302e0e1-f6ac-487f-846a-3a0b345303e8"
      unitRef="number">0.007</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ief2a3bab90b642da9d4fe8599569910c_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTplNjE0MjQ0NGJhN2Q0ZmNmOWQ4YjMwM2IzMDNhYjFiNi90YWJsZXJhbmdlOmU2MTQyNDQ0YmE3ZDRmY2Y5ZDhiMzAzYjMwM2FiMWI2XzUtMy0xLTEtMjI1NDU_161837a0-b70b-435a-8c1f-abf9b6c549ce"
      unitRef="number">0.001</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ib1b7ad6b8d104df388410248585c728f_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTplNjE0MjQ0NGJhN2Q0ZmNmOWQ4YjMwM2IzMDNhYjFiNi90YWJsZXJhbmdlOmU2MTQyNDQ0YmE3ZDRmY2Y5ZDhiMzAzYjMwM2FiMWI2XzYtMS0xLTEtMjI1NDU_3a912990-053f-4d5b-a99e-57064989cff4"
      unitRef="number">0.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i71c37180af7c40edb5bd3e902f2b71bc_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTIvZnJhZzo4OGQzOTdiNDEwYTg0ODUxODNlMDc5YjVkY2YyODJjZS90YWJsZTplNjE0MjQ0NGJhN2Q0ZmNmOWQ4YjMwM2IzMDNhYjFiNi90YWJsZXJhbmdlOmU2MTQyNDQ0YmE3ZDRmY2Y5ZDhiMzAzYjMwM2FiMWI2XzYtMy0xLTEtMjI1NDU_fd4a9473-3d93-4974-8b36-46f003ca553d"
      unitRef="number">0.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90ZXh0cmVnaW9uOjNjODdkMmRjNzc0ZDQ3YzY5MTdlZGJmNWUxYTQ2YTdhXzI3NDg3NzkwNjk4NTg_7cfbf7e1-602b-46b4-a32e-7f6b2ab95574">Balance Sheet Components&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;R&amp;amp;D tax credit receivable &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also recorded an Australian tax credit as provided by the Australian Taxation Office for qualified research and development expenditures incurred through its subsidiary, Savara Australia Pty. Limited. Under Australian tax law, Australia remits a research and development tax credit equal to 43.5% of qualified research and development expenditures, not to exceed established thresholds. During the year ended December&#160;31, 2021, the Company generated an Australian tax credit of $0.8&#160;million which was included in prepaid expenses and other current assets on the consolidated balance sheets and the Company received the tax credit in January 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's property and equipment, net was comprised of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total property and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for the years ended December&#160;31, 2021 and 2020 was $0.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Prepaid and other current assets were comprised of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred Offering costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid clinical fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Business insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Security deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Convertible note receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Angion Pty tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses were comprised of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued direct research costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ia7d86eb6878a4ef0b875c05988047754_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90ZXh0cmVnaW9uOjNjODdkMmRjNzc0ZDQ3YzY5MTdlZGJmNWUxYTQ2YTdhXzE2NDkyNjc0NDYxOTI_e41c9954-bb65-4d9f-aeaf-8993a59ffbfe"
      unitRef="usd">800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic94945863a1b4df4ab1f5e7d2e9530c2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZToyMjg1NWY2ZTYzZTI0YWFhOWY3NWIzYTVmNDlhOGI5OC90YWJsZXJhbmdlOjIyODU1ZjZlNjNlMjRhYWE5Zjc1YjNhNWY0OWE4Yjk4XzItMi0xLTEtMjI1NDU_4e790f34-db33-4137-8f66-d1d890762234"
      unitRef="usd">866000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9cfab8eface34dd4839fbb00af77dc97_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZToyMjg1NWY2ZTYzZTI0YWFhOWY3NWIzYTVmNDlhOGI5OC90YWJsZXJhbmdlOjIyODU1ZjZlNjNlMjRhYWE5Zjc1YjNhNWY0OWE4Yjk4XzItNC0xLTEtMjI1NDU_33766cc9-01c1-4d9e-9ac1-6565da22ee0e"
      unitRef="usd">512000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i306ddd1004714dec93e5d5ea85b3c8c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZToyMjg1NWY2ZTYzZTI0YWFhOWY3NWIzYTVmNDlhOGI5OC90YWJsZXJhbmdlOjIyODU1ZjZlNjNlMjRhYWE5Zjc1YjNhNWY0OWE4Yjk4XzMtMi0xLTEtMjI1NDU_5b87ecf9-2a96-4d58-9b91-81564de50c66"
      unitRef="usd">34000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i992e93e0d3c3482bad88da73616728c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZToyMjg1NWY2ZTYzZTI0YWFhOWY3NWIzYTVmNDlhOGI5OC90YWJsZXJhbmdlOjIyODU1ZjZlNjNlMjRhYWE5Zjc1YjNhNWY0OWE4Yjk4XzMtNC0xLTEtMjI1NDU_106f3c58-0e32-4012-83db-3eb3039b3f7c"
      unitRef="usd">27000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2ab54aa1e3014f50a5db232a28772555_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZToyMjg1NWY2ZTYzZTI0YWFhOWY3NWIzYTVmNDlhOGI5OC90YWJsZXJhbmdlOjIyODU1ZjZlNjNlMjRhYWE5Zjc1YjNhNWY0OWE4Yjk4XzQtMi0xLTEtMjI1NDU_1176e4d9-121c-4f8e-bb81-2b5c1ec94c37"
      unitRef="usd">68000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i65a1a8317ce94459b14feb26feeb201c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZToyMjg1NWY2ZTYzZTI0YWFhOWY3NWIzYTVmNDlhOGI5OC90YWJsZXJhbmdlOjIyODU1ZjZlNjNlMjRhYWE5Zjc1YjNhNWY0OWE4Yjk4XzQtNC0xLTEtMjI1NDU_56fe2e77-901c-4ef9-8ff2-53e3802b6a5b"
      unitRef="usd">43000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZToyMjg1NWY2ZTYzZTI0YWFhOWY3NWIzYTVmNDlhOGI5OC90YWJsZXJhbmdlOjIyODU1ZjZlNjNlMjRhYWE5Zjc1YjNhNWY0OWE4Yjk4XzUtMi0xLTEtMjI1NDU_6836d0e1-202a-49b1-82b7-0e122c70fa77"
      unitRef="usd">968000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZToyMjg1NWY2ZTYzZTI0YWFhOWY3NWIzYTVmNDlhOGI5OC90YWJsZXJhbmdlOjIyODU1ZjZlNjNlMjRhYWE5Zjc1YjNhNWY0OWE4Yjk4XzUtNC0xLTEtMjI1NDU_716ffd60-ff9a-4fa9-a05e-6d5e2b362b3f"
      unitRef="usd">582000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZToyMjg1NWY2ZTYzZTI0YWFhOWY3NWIzYTVmNDlhOGI5OC90YWJsZXJhbmdlOjIyODU1ZjZlNjNlMjRhYWE5Zjc1YjNhNWY0OWE4Yjk4XzYtMi0xLTEtMjI1NDU_a197a896-90cf-4c94-9cbd-1f35622a4755"
      unitRef="usd">517000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZToyMjg1NWY2ZTYzZTI0YWFhOWY3NWIzYTVmNDlhOGI5OC90YWJsZXJhbmdlOjIyODU1ZjZlNjNlMjRhYWE5Zjc1YjNhNWY0OWE4Yjk4XzYtNC0xLTEtMjI1NDU_38d0e356-028d-49c3-881e-2ca657c3bfe2"
      unitRef="usd">426000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZToyMjg1NWY2ZTYzZTI0YWFhOWY3NWIzYTVmNDlhOGI5OC90YWJsZXJhbmdlOjIyODU1ZjZlNjNlMjRhYWE5Zjc1YjNhNWY0OWE4Yjk4XzctMi0xLTEtMjI1NDU_5fa791a2-a03d-4161-b2f1-f898a8ef1e5e"
      unitRef="usd">451000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZToyMjg1NWY2ZTYzZTI0YWFhOWY3NWIzYTVmNDlhOGI5OC90YWJsZXJhbmdlOjIyODU1ZjZlNjNlMjRhYWE5Zjc1YjNhNWY0OWE4Yjk4XzctNC0xLTEtMjI1NDU_7a09684b-0275-4113-91f2-1b463ec80a0d"
      unitRef="usd">156000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90ZXh0cmVnaW9uOjNjODdkMmRjNzc0ZDQ3YzY5MTdlZGJmNWUxYTQ2YTdhXzIxMg_362d946e-7262-444f-a5c5-644919702ece"
      unitRef="usd">100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90ZXh0cmVnaW9uOjNjODdkMmRjNzc0ZDQ3YzY5MTdlZGJmNWUxYTQ2YTdhXzIxMg_6f7a009b-3708-4627-a6f2-24d36b5c9260"
      unitRef="usd">100000</us-gaap:Depreciation>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90ZXh0cmVnaW9uOjNjODdkMmRjNzc0ZDQ3YzY5MTdlZGJmNWUxYTQ2YTdhXzI3NDg3NzkwNjk4NjA_f1eaedce-5a86-4eef-9098-a392df39394a">Prepaid and other current assets were comprised of the following (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred Offering costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid clinical fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Business insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Security deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Convertible note receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Angion Pty tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total prepaid and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:DeferredOfferingCosts
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzItMi0xLTEtMjI1NDU_58739e6c-5170-4f69-87a0-10fd3c32497b"
      unitRef="usd">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzItNC0xLTEtMjI1NDU_bcbc66d5-f566-45fb-b38b-052058c3e388"
      unitRef="usd">1978000</us-gaap:DeferredOfferingCosts>
    <angn:PrepaidClinicalFeesCurrent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzMtMi0xLTEtMjg3MTc_36e3e5d7-1e11-44de-b0e4-c61e8b86d50f"
      unitRef="usd">168000</angn:PrepaidClinicalFeesCurrent>
    <angn:PrepaidClinicalFeesCurrent
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzMtNC0xLTEtMjg3MTc_d7b15512-58f1-403d-b61a-132533947784"
      unitRef="usd">0</angn:PrepaidClinicalFeesCurrent>
    <us-gaap:PrepaidInsurance
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzQtMi0xLTEtMjg3MTc_73b8dbb0-1529-44dc-ba86-57d62498af3f"
      unitRef="usd">275000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzQtNC0xLTEtMjg3MTc_03eb03c0-1966-4c3a-a21a-c08f810bf3c7"
      unitRef="usd">0</us-gaap:PrepaidInsurance>
    <us-gaap:DepositsAssetsCurrent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzUtMi0xLTEtMjg3MDc_b49dbbd3-4170-42ed-9f00-05034b90c789"
      unitRef="usd">131000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzUtNC0xLTEtMjg3MDc_3e5471c9-5af3-49c3-81a6-3635ea854bf4"
      unitRef="usd">0</us-gaap:DepositsAssetsCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzMtMi0xLTEtMjI1NDU_a7b8a4d8-e67e-4258-b4fc-5ac42280f872"
      unitRef="usd">0</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzMtNC0xLTEtMjI1NDU_6399b513-0132-4c38-978b-e0fbc9792002"
      unitRef="usd">5000000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:PrepaidTaxes
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzQtMi0xLTEtMjI1NDU_77d69ea4-eb15-4766-ba31-40fa7d1fccb0"
      unitRef="usd">863000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzQtNC0xLTEtMjI1NDU_356b02a6-9e91-4d1a-97bf-4562d62b1b5b"
      unitRef="usd">352000</us-gaap:PrepaidTaxes>
    <us-gaap:OtherAssetsCurrent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzUtMi0xLTEtMjI1NDU_c525a38f-3aad-48dd-ae80-1b4fd570dcbc"
      unitRef="usd">248000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzUtNC0xLTEtMjI1NDU_06486266-9665-48ed-b52d-e3ac3286f50d"
      unitRef="usd">360000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzYtMi0xLTEtMjMyNTc_c9591ba4-684d-41cf-b9e8-b611e31f49ee"
      unitRef="usd">1685000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTo3MzY5MGM0MWE0ZmU0NGViYmRiOTAxZmFkYTViYjZmOS90YWJsZXJhbmdlOjczNjkwYzQxYTRmZTQ0ZWJiZGI5MDFmYWRhNWJiNmY5XzYtNC0xLTEtMjMyNjI_54c00873-100e-4da7-b510-4fe19ac26957"
      unitRef="usd">7690000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90ZXh0cmVnaW9uOjNjODdkMmRjNzc0ZDQ3YzY5MTdlZGJmNWUxYTQ2YTdhXzI3NDg3NzkwNjk4NjE_2c4cdeab-f840-42cd-888b-1e21e6359564">&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses were comprised of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued direct research costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued operating expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTpiMmY5ZDIxYTQxNTQ0M2FjODBiNmJiNjcwMjIyYzk2Mi90YWJsZXJhbmdlOmIyZjlkMjFhNDE1NDQzYWM4MGI2YmI2NzAyMjJjOTYyXzItMS0xLTEtMjI1NDU_bb9b6fb4-62e6-4f99-b39c-209221b12bae"
      unitRef="usd">1274000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTpiMmY5ZDIxYTQxNTQ0M2FjODBiNmJiNjcwMjIyYzk2Mi90YWJsZXJhbmdlOmIyZjlkMjFhNDE1NDQzYWM4MGI2YmI2NzAyMjJjOTYyXzItMy0xLTEtMjI1NDU_ea2278ef-d747-4754-8ed2-94f060ee4e2a"
      unitRef="usd">3154000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <angn:AccruedDirectResearchCostsCurrent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTpiMmY5ZDIxYTQxNTQ0M2FjODBiNmJiNjcwMjIyYzk2Mi90YWJsZXJhbmdlOmIyZjlkMjFhNDE1NDQzYWM4MGI2YmI2NzAyMjJjOTYyXzMtMS0xLTEtMjI1NDU_f77fe90a-ecd4-44c5-b31d-7b9d70c62077"
      unitRef="usd">1196000</angn:AccruedDirectResearchCostsCurrent>
    <angn:AccruedDirectResearchCostsCurrent
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTpiMmY5ZDIxYTQxNTQ0M2FjODBiNmJiNjcwMjIyYzk2Mi90YWJsZXJhbmdlOmIyZjlkMjFhNDE1NDQzYWM4MGI2YmI2NzAyMjJjOTYyXzMtMy0xLTEtMjI1NDU_8845300b-9507-494b-b56c-dcf39e7feed5"
      unitRef="usd">1321000</angn:AccruedDirectResearchCostsCurrent>
    <angn:AccruedOperatingLiabilitiesCurrent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTpiMmY5ZDIxYTQxNTQ0M2FjODBiNmJiNjcwMjIyYzk2Mi90YWJsZXJhbmdlOmIyZjlkMjFhNDE1NDQzYWM4MGI2YmI2NzAyMjJjOTYyXzQtMS0xLTEtMjI1NDU_1711e0df-bcb0-4b46-855a-d7a90b30698b"
      unitRef="usd">749000</angn:AccruedOperatingLiabilitiesCurrent>
    <angn:AccruedOperatingLiabilitiesCurrent
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTpiMmY5ZDIxYTQxNTQ0M2FjODBiNmJiNjcwMjIyYzk2Mi90YWJsZXJhbmdlOmIyZjlkMjFhNDE1NDQzYWM4MGI2YmI2NzAyMjJjOTYyXzQtMy0xLTEtMjI1NDU_ddfc0149-52a5-4362-a478-e312089a9e85"
      unitRef="usd">707000</angn:AccruedOperatingLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTpiMmY5ZDIxYTQxNTQ0M2FjODBiNmJiNjcwMjIyYzk2Mi90YWJsZXJhbmdlOmIyZjlkMjFhNDE1NDQzYWM4MGI2YmI2NzAyMjJjOTYyXzUtMS0xLTEtMjI1NDU_ff9e8995-d9bd-4017-ae3e-43c649ef586b"
      unitRef="usd">0</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTpiMmY5ZDIxYTQxNTQ0M2FjODBiNmJiNjcwMjIyYzk2Mi90YWJsZXJhbmdlOmIyZjlkMjFhNDE1NDQzYWM4MGI2YmI2NzAyMjJjOTYyXzUtMy0xLTEtMjI1NDU_93f443c1-c6b7-43ef-8994-535dcdb05872"
      unitRef="usd">1483000</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTpiMmY5ZDIxYTQxNTQ0M2FjODBiNmJiNjcwMjIyYzk2Mi90YWJsZXJhbmdlOmIyZjlkMjFhNDE1NDQzYWM4MGI2YmI2NzAyMjJjOTYyXzYtMS0xLTEtMjI1NDU_c9c59978-e68b-4083-8f3a-6b56cbe348e5"
      unitRef="usd">3219000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTUvZnJhZzozYzg3ZDJkYzc3NGQ0N2M2OTE3ZWRiZjVlMWE0NmE3YS90YWJsZTpiMmY5ZDIxYTQxNTQ0M2FjODBiNmJiNjcwMjIyYzk2Mi90YWJsZXJhbmdlOmIyZjlkMjFhNDE1NDQzYWM4MGI2YmI2NzAyMjJjOTYyXzYtMy0xLTEtMjI1NDU_5df531f9-fd5f-4f35-a82f-ba9a22210de0"
      unitRef="usd">6665000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTgvZnJhZzozNWNiYmU4ODliZjA0NzhjYWI1NWMyZGNlZDg5NWVmZC90ZXh0cmVnaW9uOjM1Y2JiZTg4OWJmMDQ3OGNhYjU1YzJkY2VkODk1ZWZkXzI3NDg3NzkwNzMyMjY_eb3d25a9-3a16-4d85-928f-452112bbf007">Convertible Notes Payable&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2020, the Company had convertible notes with an aggregate principal amount of $39.8 million and $1.8 million accrued interest outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Conversion of Convertible Notes Payable &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In January 2021, the Company issued 33,978 shares of common stock upon the conversion of certain of the outstanding 2020 Notes. In connection with the IPO in February 2021, with an IPO price of $16.00 per share, the remaining outstanding convertible notes were converted into 3,636,189 shares of the Company&#x2019;s common stock based on a conversion price of $11.57 per share. There were no convertible notes outstanding as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i070cfb2f33fa400ab61eda85d18e3338_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTgvZnJhZzozNWNiYmU4ODliZjA0NzhjYWI1NWMyZGNlZDg5NWVmZC90ZXh0cmVnaW9uOjM1Y2JiZTg4OWJmMDQ3OGNhYjU1YzJkY2VkODk1ZWZkXzEwOTk1MTE2NDM2NTI_73a20a05-276b-4926-9e80-d45de8135436"
      unitRef="usd">39800000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="i3e51cbe879fb441184f95b52afb2aeef_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTgvZnJhZzozNWNiYmU4ODliZjA0NzhjYWI1NWMyZGNlZDg5NWVmZC90ZXh0cmVnaW9uOjM1Y2JiZTg4OWJmMDQ3OGNhYjU1YzJkY2VkODk1ZWZkXzEwOTk1MTE2NDM2NzE_ba06165c-6569-4924-9ce3-56fb3484f2ff"
      unitRef="usd">1800000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ibb7ba2f1254942b1b3dca57b33e584e4_D20210101-20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTgvZnJhZzozNWNiYmU4ODliZjA0NzhjYWI1NWMyZGNlZDg5NWVmZC90ZXh0cmVnaW9uOjM1Y2JiZTg4OWJmMDQ3OGNhYjU1YzJkY2VkODk1ZWZkXzEwOTk1MTE2NDM2OTM_98b79e99-b1fd-4e5b-baa9-c2031963f31f"
      unitRef="shares">33978</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i028f1ad3777340c2a17441b369da80c7_I20210209"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTgvZnJhZzozNWNiYmU4ODliZjA0NzhjYWI1NWMyZGNlZDg5NWVmZC90ZXh0cmVnaW9uOjM1Y2JiZTg4OWJmMDQ3OGNhYjU1YzJkY2VkODk1ZWZkXzEwOTk1MTE2NDM2ODk_58939d62-73ce-4234-bae8-6d2e804a1dae"
      unitRef="usdPerShare">16.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i90d58066e44642be83973e6daa1dee34_D20210204-20210209"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTgvZnJhZzozNWNiYmU4ODliZjA0NzhjYWI1NWMyZGNlZDg5NWVmZC90ZXh0cmVnaW9uOjM1Y2JiZTg4OWJmMDQ3OGNhYjU1YzJkY2VkODk1ZWZkXzEwOTk1MTE2NDM2ODU_d626c2f2-5b05-4204-a39a-1b4f960004f3"
      unitRef="shares">3636189</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i2fba8513019e4003882ec149aeddb34b_I20210209"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTgvZnJhZzozNWNiYmU4ODliZjA0NzhjYWI1NWMyZGNlZDg5NWVmZC90ZXh0cmVnaW9uOjM1Y2JiZTg4OWJmMDQ3OGNhYjU1YzJkY2VkODk1ZWZkXzEwOTk1MTE2NDM2ODE_d590078d-050c-44eb-8c2d-c8b5cab61d57"
      unitRef="usdPerShare">11.57</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ConvertibleNotesPayable
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMTgvZnJhZzozNWNiYmU4ODliZjA0NzhjYWI1NWMyZGNlZDg5NWVmZC90ZXh0cmVnaW9uOjM1Y2JiZTg4OWJmMDQ3OGNhYjU1YzJkY2VkODk1ZWZkXzIxOTkwMjMyNzE1ODA_b445dad6-9a17-4c80-add5-a79e8cc1e19a"
      unitRef="usd">0</us-gaap:ConvertibleNotesPayable>
    <angn:FinancialInstrumentsSubjectToMandatoryRedemptionDisclosureTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90ZXh0cmVnaW9uOmFmOGIwMTViMzA4MjQxOTRiMDBhMDkzMzczNDA1ZGUxXzI3NDg3NzkwNzMzODY_bb0cf308-0d39-45d2-a057-09d01dbf7526">Series C Convertible Preferred Stock &lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the aggregate values recorded for the Series C convertible preferred stock as of December 31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;At issuance &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Series C convertible preferred stock recorded at amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Principal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;22,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;22,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Settlement premium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;5,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;5,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Unamortized discounts and fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(9,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(1,884)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;18,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;26,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Series C convertible preferred stock recorded at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Series C convertible preferred stock issued in exchange for convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;2,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Change in fair value of Series C convertible preferred stock exchanged for convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Total Series C convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;28,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Conversion of Series C Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In connection with the IPO in February 2021, with an initial public offering price of $16.00 per share, all shares of Series C convertible preferred stock outstanding plus accrued dividends were automatically converted into an aggregate of 2,234,640 shares of common stock with a conversion price of $11.57 per share. There were no shares of convertible preferred stock outstanding as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</angn:FinancialInstrumentsSubjectToMandatoryRedemptionDisclosureTextBlock>
    <us-gaap:SharesSubjectToMandatoryRedemptionDisclosureTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90ZXh0cmVnaW9uOmFmOGIwMTViMzA4MjQxOTRiMDBhMDkzMzczNDA1ZGUxXzI3NDg3NzkwNzM1Njg_7d63a821-bb74-4d5f-83c8-eb4bc295ab6b">&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the aggregate values recorded for the Series C convertible preferred stock as of December 31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;At issuance &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Series C convertible preferred stock recorded at amortized cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Principal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;22,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;22,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Settlement premium&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;5,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;5,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Unamortized discounts and fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(9,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(1,884)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Net carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;18,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;26,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Series C convertible preferred stock recorded at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Series C convertible preferred stock issued in exchange for convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;2,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Change in fair value of Series C convertible preferred stock exchanged for convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Total Series C convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;28,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SharesSubjectToMandatoryRedemptionDisclosureTextBlock>
    <angn:FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross
      contextRef="i2fba8513019e4003882ec149aeddb34b_I20210209"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90YWJsZTowY2QwZGVkMDM5YTI0YWI5YTEzMDlkYjJjNjg3MTg5My90YWJsZXJhbmdlOjBjZDBkZWQwMzlhMjRhYjlhMTMwOWRiMmM2ODcxODkzXzItMi0xLTEtMjI1NDU_c4068058-2810-4c48-9f7d-481e855c4cad"
      unitRef="usd">22308000</angn:FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross>
    <angn:FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90YWJsZTowY2QwZGVkMDM5YTI0YWI5YTEzMDlkYjJjNjg3MTg5My90YWJsZXJhbmdlOjBjZDBkZWQwMzlhMjRhYjlhMTMwOWRiMmM2ODcxODkzXzItNC0xLTEtMjI1NDU_d086f200-7ddb-4546-8738-1dace6b5eddc"
      unitRef="usd">22308000</angn:FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross>
    <angn:FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium
      contextRef="i2fba8513019e4003882ec149aeddb34b_I20210209"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90YWJsZTowY2QwZGVkMDM5YTI0YWI5YTEzMDlkYjJjNjg3MTg5My90YWJsZXJhbmdlOjBjZDBkZWQwMzlhMjRhYjlhMTMwOWRiMmM2ODcxODkzXzMtMi0xLTEtMjI1NDU_81bd1d9a-e0b7-4e51-ad10-de3053be3568"
      unitRef="usd">5577000</angn:FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium>
    <angn:FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90YWJsZTowY2QwZGVkMDM5YTI0YWI5YTEzMDlkYjJjNjg3MTg5My90YWJsZXJhbmdlOjBjZDBkZWQwMzlhMjRhYjlhMTMwOWRiMmM2ODcxODkzXzMtNC0xLTEtMjI1NDU_92ed6f7d-57f7-4c23-9764-9d6347ecee08"
      unitRef="usd">5577000</angn:FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium>
    <angn:FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees
      contextRef="i2fba8513019e4003882ec149aeddb34b_I20210209"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90YWJsZTowY2QwZGVkMDM5YTI0YWI5YTEzMDlkYjJjNjg3MTg5My90YWJsZXJhbmdlOjBjZDBkZWQwMzlhMjRhYjlhMTMwOWRiMmM2ODcxODkzXzQtMi0xLTEtMjI1NDU_eef968fb-dfd5-45af-80a3-aab7ade6eba9"
      unitRef="usd">9250000</angn:FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees>
    <angn:FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90YWJsZTowY2QwZGVkMDM5YTI0YWI5YTEzMDlkYjJjNjg3MTg5My90YWJsZXJhbmdlOjBjZDBkZWQwMzlhMjRhYjlhMTMwOWRiMmM2ODcxODkzXzQtNC0xLTEtMjI1NDU_8a02eb01-ced3-4b09-bb37-3ca65f9aa2a6"
      unitRef="usd">1884000</angn:FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent
      contextRef="i2fba8513019e4003882ec149aeddb34b_I20210209"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90YWJsZTowY2QwZGVkMDM5YTI0YWI5YTEzMDlkYjJjNjg3MTg5My90YWJsZXJhbmdlOjBjZDBkZWQwMzlhMjRhYjlhMTMwOWRiMmM2ODcxODkzXzUtMi0xLTEtMjI1NDU_c1abaaa1-63aa-4650-bfad-1d3ecba3e9b3"
      unitRef="usd">18635000</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90YWJsZTowY2QwZGVkMDM5YTI0YWI5YTEzMDlkYjJjNjg3MTg5My90YWJsZXJhbmdlOjBjZDBkZWQwMzlhMjRhYjlhMTMwOWRiMmM2ODcxODkzXzUtNC0xLTEtMjI1NDU_7e70a2d4-7198-4f1c-aa6f-05f65eee421c"
      unitRef="usd">26001000</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent>
    <angn:FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountIssuedInConvertibleNoteExchange
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90YWJsZTowY2QwZGVkMDM5YTI0YWI5YTEzMDlkYjJjNjg3MTg5My90YWJsZXJhbmdlOjBjZDBkZWQwMzlhMjRhYjlhMTMwOWRiMmM2ODcxODkzXzctNC0xLTEtMjI1NDU_16315876-797e-441e-b867-44fa4785d6ec"
      unitRef="usd">2254000</angn:FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountIssuedInConvertibleNoteExchange>
    <angn:FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountAccumulatedChangeInFairValue
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90YWJsZTowY2QwZGVkMDM5YTI0YWI5YTEzMDlkYjJjNjg3MTg5My90YWJsZXJhbmdlOjBjZDBkZWQwMzlhMjRhYjlhMTMwOWRiMmM2ODcxODkzXzgtNC0xLTEtMjI1NDU_9cac9797-02e8-4352-90b3-3f1186bb2a36"
      unitRef="usd">264000</angn:FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountAccumulatedChangeInFairValue>
    <angn:FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90YWJsZTowY2QwZGVkMDM5YTI0YWI5YTEzMDlkYjJjNjg3MTg5My90YWJsZXJhbmdlOjBjZDBkZWQwMzlhMjRhYjlhMTMwOWRiMmM2ODcxODkzXzktNC0xLTEtMjI1NDU_1c84619e-0c22-4ed5-99f6-e7e8e3aec932"
      unitRef="usd">28519000</angn:FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i028f1ad3777340c2a17441b369da80c7_I20210209"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90ZXh0cmVnaW9uOmFmOGIwMTViMzA4MjQxOTRiMDBhMDkzMzczNDA1ZGUxXzEwOTk1MTE2MzU1NTY_bbce268e-708f-4854-bb94-738ffe6677da"
      unitRef="usdPerShare">16.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="iac7d715402754b8caf32b6a9c1cee1f7_I20210209"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90ZXh0cmVnaW9uOmFmOGIwMTViMzA4MjQxOTRiMDBhMDkzMzczNDA1ZGUxXzEwOTk1MTE2MzU1NjA_012db8e9-ba69-4300-9765-17337473fa78"
      unitRef="shares">2234640</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <angn:ConvertiblePreferredStockConversionPrice
      contextRef="iac7d715402754b8caf32b6a9c1cee1f7_I20210209"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90ZXh0cmVnaW9uOmFmOGIwMTViMzA4MjQxOTRiMDBhMDkzMzczNDA1ZGUxXzEwOTk1MTE2MzU1NjY_9831a249-f149-44f2-b5f1-a8b56e44a49c"
      unitRef="usdPerShare">11.57</angn:ConvertiblePreferredStockConversionPrice>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
      contextRef="i60078b3a55804ab1887cc07c853ff6f7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjEvZnJhZzphZjhiMDE1YjMwODI0MTk0YjAwYTA5MzM3MzQwNWRlMS90ZXh0cmVnaW9uOmFmOGIwMTViMzA4MjQxOTRiMDBhMDkzMzczNDA1ZGUxXzEwOTk1MTE2MzU1NzA_7845b10b-d38b-40e5-bd26-e4614ff0d940"
      unitRef="shares">0</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjQvZnJhZzoyZjVmODY2ZTc5ZDg0YWIwYWFjMDM2ZjIyZTNkNDY3NC90ZXh0cmVnaW9uOjJmNWY4NjZlNzlkODRhYjBhYWMwMzZmMjJlM2Q0Njc0XzI3NDg3NzkwNjk4NzY_2125281f-3a1e-4e84-b509-a9212a13a484">Stockholders' Equity&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s stockholders. Common stockholders are not entitled to receive dividends, unless declared by the Board of Directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Treasury stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The retirement of treasury stock was recorded as a reduction of common stock and additional paid-in capital at the time such retirement was approved by our Board of Directors in October 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 and 2020, zero and $1.8 million was included in treasury stock in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:TreasuryStockValue
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjQvZnJhZzoyZjVmODY2ZTc5ZDg0YWIwYWFjMDM2ZjIyZTNkNDY3NC90ZXh0cmVnaW9uOjJmNWY4NjZlNzlkODRhYjBhYWMwMzZmMjJlM2Q0Njc0XzEwOTk1MTE2MjkwMTE_94f181db-7ce2-489f-954f-e5e23f6ede7e"
      unitRef="usd">0</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjQvZnJhZzoyZjVmODY2ZTc5ZDg0YWIwYWFjMDM2ZjIyZTNkNDY3NC90ZXh0cmVnaW9uOjJmNWY4NjZlNzlkODRhYjBhYWMwMzZmMjJlM2Q0Njc0XzM2Nw_b396d9ca-95bc-4924-9c2a-3129822fad65"
      unitRef="usd">1800000</us-gaap:TreasuryStockValue>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzI3NDg3NzkwNzU5Nzg_68113367-4fa8-4b86-9357-9ba40fae5969">Stock-Based Compensation&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2015 Plan &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2019, the Company approved an Amended and Restated 2015 Equity Incentive Plan (the "2015 Plan") permitting the granting of incentive stock options, non-statutory stock options, restricted stock and other stock-based awards. Following the effectiveness of the 2021 Equity Incentive Plan ("2021 Plan"), the Company ceased making grants under the 2015 Plan. However, the 2015 Plan continues to govern the terms and conditions of the outstanding awards granted under it. Shares of common stock subject to awards granted under the 2015 Plan that cease to be subject to such awards by forfeiture or otherwise after the termination of the 2015 Plan will be available for issuance under the 2021 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2021 Plan &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 25, 2021, the Company's board of directors approved the 2021 Plan which permits the granting of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards to employees, directors, officers and consultants. On January 25, 2021, shares of common stock equal to 11% of the post-IPO capitalization, with annual increases, up to a maximum of 60,000,000 shares of common stock were authorized for issuance under the 2021 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each employee and non-employee stock option grant was estimated on the date of grant using the Black-Scholes option-pricing model based on the following inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;0.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;0.7%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Expected term in years &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;71.8% - 73.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;70.8% - 86.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each of these inputs is subjective and generally requires significant judgment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The expected term represents the period that the Company&#x2019;s stock-based awards are expected to be outstanding and is determined using the simplified method, which is based on the mid-point between the contractual term and vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Volatility&#x2014;The Company determines volatility based on the historical volatilities of comparable publicly traded life science companies over a period equal to the expected term because it does not have sufficient trading history for its common stock price. The comparable companies were chosen based on the similar size, stage in the life cycle, or area of specialty. The Company will continue to apply this process until a sufficient amount of historical information regarding volatility on its own stock becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-Free&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Interest Rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Yield&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company has never paid and has no plans to pay any dividends on its common stock. Therefore, the Company has used an expected dividend yield of zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; of Common Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;For periods prior to the IPO, the Company determined the estimated fair value of its common stock using the Subject Company Transaction Method which includes the back-solve and scenario-based methods (Probability Weighted Expected Return Method) to arrive at estimated fair values. Subsequent to the IPO, the fair value was based on the closing price of the Company&#x2019;s common stock on the grant date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following assumptions were used to estimate the fair value of stock option awards: The following table summarizes information as of December&#160;31, 2021 and activity during 2021 related to the Company&#x2019;s stock option plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Number of &lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Exercise &lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Remaining &lt;br/&gt;Contractual &lt;br/&gt;Life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Total &lt;br/&gt;Intrinsic &lt;br/&gt;Value &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;3,479,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;6.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;8.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;15,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;1,103,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;15.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(189,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;13.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(152,939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;6.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Options expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(10,963)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;7.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;4,230,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;8.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Options vested and exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;2,499,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;7.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value in the above table is calculated as the difference between the estimated fair value of the Company's common stock price and the exercise price of the stock options. The weighted average grant date fair value per share for the stock option grants during the years ended December&#160;31, 2021 and 2020  were $10.25 and $5.48, respectively. As of December&#160;31, 2021, the total unrecognized compensation related to unvested stock option awards granted was $6.1 million, which the Company expects to recognize over a weighted-average period of approximately 2.4 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock and Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's RSA and RSU activity for the years ended December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Shares of &lt;br/&gt;Restricted Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Weighted &lt;br/&gt;Average Grant &lt;br/&gt;Date Fair Value &lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Restricted &lt;br/&gt;Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Weighted &lt;br/&gt;Average Grant &lt;br/&gt;Date Fair Value &lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;14,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;6.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;74,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;7.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(14,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;6.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(43,875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;8.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(12,764)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;6.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;17,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;9.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Vested as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;43,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;8.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance-based Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had 556,530 PSUs outstanding that were granted in June 2019. Vesting of the PSUs is dependent upon the satisfaction of both a service condition and a performance condition, an initial public offering or a change of control, as defined in the 2015 Plan. As the IPO occurred in February 2021, the performance condition was met and 185,510 PSUs vested and were released upon the closing of the IPO. Another 185,510 PSUs vested and released were in June 2021 upon the second anniversary of the grants. A&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company had 185,510 PSUs outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the total stock-based compensation expense for the stock options, RSUs, RSAs, PSUs compensation issued in shares recorded in the consolidated statements of operations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;12,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the board of directors of the Company approved the Employee Stock Purchase Plan (the "ESPP"). The ESPP was effective on the date immediately prior to the effectiveness of the Company's registration statement relating to the IPO. A total of 390,000 shares of common stock were initially reserved for issuance under the ESPP. The offering period and purchase period will be determined by the Board of Directors. As of December&#160;31, 2021, 390,000 shares under the ESPP remain available for purchase and no offerings had been authorized.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="id1dc2e8c07c14adba2e9db115900a85b_D20210125-20210125"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzEwOTk1MTE2Mzg5NjM_b2892bb9-8a7f-4db5-9716-a07cea0c7adb"
      unitRef="number">0.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i902c379eaab14156a55d3f460019dc3b_I20210125"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzIxOTkwMjMyNzU5NzE_39c3fa8c-a50f-4403-8b83-1ac3b1732842"
      unitRef="shares">60000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzI3NDg3NzkwNzU5ODY_070f771d-d65a-41ec-a661-7f6d138dd629">&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each employee and non-employee stock option grant was estimated on the date of grant using the Black-Scholes option-pricing model based on the following inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.660%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;0.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;0.7%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Expected term in years &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;71.8% - 73.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;70.8% - 86.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i54c2a1b829084a7b83834a08509335ce_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo1NTM1NTc3MGU0Mzg0ZGFmYmRkYzRmZGVhODFhMmM2Mi90YWJsZXJhbmdlOjU1MzU1NzcwZTQzODRkYWZiZGRjNGZkZWE4MWEyYzYyXzItMS0xLTEtMjI1NDU_86793b66-f387-4ada-ba4b-30590355fd55"
      unitRef="number">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0e0e18adc0424cde81f1a02ec6eea58c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo1NTM1NTc3MGU0Mzg0ZGFmYmRkYzRmZGVhODFhMmM2Mi90YWJsZXJhbmdlOjU1MzU1NzcwZTQzODRkYWZiZGRjNGZkZWE4MWEyYzYyXzItMy0xLTEtMjM1OTI_3406ee5a-6312-4df1-bc0a-b9d8321022d4"
      unitRef="number">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i54c2a1b829084a7b83834a08509335ce_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo1NTM1NTc3MGU0Mzg0ZGFmYmRkYzRmZGVhODFhMmM2Mi90YWJsZXJhbmdlOjU1MzU1NzcwZTQzODRkYWZiZGRjNGZkZWE4MWEyYzYyXzMtMS0xLTEtMjI1NDU_0de7cd4c-244d-4c53-8494-ac153ec0710a"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0e0e18adc0424cde81f1a02ec6eea58c_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo1NTM1NTc3MGU0Mzg0ZGFmYmRkYzRmZGVhODFhMmM2Mi90YWJsZXJhbmdlOjU1MzU1NzcwZTQzODRkYWZiZGRjNGZkZWE4MWEyYzYyXzMtMy0xLTEtMjM1OTI_58696b4f-5425-4e96-a4d7-58fd97212409"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i54c2a1b829084a7b83834a08509335ce_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo1NTM1NTc3MGU0Mzg0ZGFmYmRkYzRmZGVhODFhMmM2Mi90YWJsZXJhbmdlOjU1MzU1NzcwZTQzODRkYWZiZGRjNGZkZWE4MWEyYzYyXzQtMS0xLTEtMjI1NDU_ce84a5ac-7686-43dd-adbf-167d62fe9316">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0e0e18adc0424cde81f1a02ec6eea58c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo1NTM1NTc3MGU0Mzg0ZGFmYmRkYzRmZGVhODFhMmM2Mi90YWJsZXJhbmdlOjU1MzU1NzcwZTQzODRkYWZiZGRjNGZkZWE4MWEyYzYyXzQtMy0xLTEtMjM1OTI_4942c145-cac3-4572-8110-1f7f7cff8861">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i54c2a1b829084a7b83834a08509335ce_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo1NTM1NTc3MGU0Mzg0ZGFmYmRkYzRmZGVhODFhMmM2Mi90YWJsZXJhbmdlOjU1MzU1NzcwZTQzODRkYWZiZGRjNGZkZWE4MWEyYzYyXzUtMS0xLTEtMjI1NDUvdGV4dHJlZ2lvbjo2YmE1NzllYzcwNTM0ZTUxYjkyYzgzYjJjZWExMzQ3Ml8xMDk5NTExNjI3Nzk4_557775b0-763f-461d-9a02-5c90f44accd0"
      unitRef="number">0.718</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i54c2a1b829084a7b83834a08509335ce_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo1NTM1NTc3MGU0Mzg0ZGFmYmRkYzRmZGVhODFhMmM2Mi90YWJsZXJhbmdlOjU1MzU1NzcwZTQzODRkYWZiZGRjNGZkZWE4MWEyYzYyXzUtMS0xLTEtMjI1NDUvdGV4dHJlZ2lvbjo2YmE1NzllYzcwNTM0ZTUxYjkyYzgzYjJjZWExMzQ3Ml8xMDk5NTExNjI3ODA2_484eadae-3ef4-4dad-97ec-648bd7c71d50"
      unitRef="number">0.731</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i0e0e18adc0424cde81f1a02ec6eea58c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo1NTM1NTc3MGU0Mzg0ZGFmYmRkYzRmZGVhODFhMmM2Mi90YWJsZXJhbmdlOjU1MzU1NzcwZTQzODRkYWZiZGRjNGZkZWE4MWEyYzYyXzUtMy0xLTEtMjM1OTIvdGV4dHJlZ2lvbjo4ODcxNDQ3NTkzYzQ0ZDI2OTJlYWZmOWUzY2E2NzQxM18xMDk5NTExNjI3Nzk4_0e4e22c0-ca85-4860-94c8-bba533647e4f"
      unitRef="number">0.708</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i0e0e18adc0424cde81f1a02ec6eea58c_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo1NTM1NTc3MGU0Mzg0ZGFmYmRkYzRmZGVhODFhMmM2Mi90YWJsZXJhbmdlOjU1MzU1NzcwZTQzODRkYWZiZGRjNGZkZWE4MWEyYzYyXzUtMy0xLTEtMjM1OTIvdGV4dHJlZ2lvbjo4ODcxNDQ3NTkzYzQ0ZDI2OTJlYWZmOWUzY2E2NzQxM18xMDk5NTExNjI3ODA2_ed40a242-d68a-4c9d-b601-7c0376fc65d1"
      unitRef="number">0.868</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i54c2a1b829084a7b83834a08509335ce_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzYwNDczMTM5NzMyMTg_d0f7b5c3-5b3f-4351-b9a8-7d69f9c0baa1"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzI3NDg3NzkwNzU5ODc_a4e171be-6979-4228-a833-30f6016cd09d">The following table summarizes information as of December&#160;31, 2021 and activity during 2021 related to the Company&#x2019;s stock option plans:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Number of &lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Exercise &lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Remaining &lt;br/&gt;Contractual &lt;br/&gt;Life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Total &lt;br/&gt;Intrinsic &lt;br/&gt;Value &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Outstanding as of December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;3,479,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;6.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;8.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;15,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;1,103,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;15.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(189,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;13.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(152,939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;6.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Options expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(10,963)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;7.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Outstanding as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;4,230,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;8.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;7.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Options vested and exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;2,499,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;7.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzQtMS0xLTEtMjI1NDU_99baf1a9-33e1-41f0-8827-dcc85d904a40"
      unitRef="shares">3479731</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzQtMy0xLTEtMjI1NDU_0fac8fa1-e395-4519-bbb2-9cc22b80204b"
      unitRef="usdPerShare">6.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzQtNS0xLTEtMjI1NDU_a9aee26b-69a2-4c69-ae45-82b807a83b46">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzQtNy0xLTEtMjI1NDU_cdc051a7-f818-4cb5-8750-4775fb185016"
      unitRef="usd">15140000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzUtMS0xLTEtMjI1NDU_0412f417-6b72-42b9-ae5a-8536ca8fa571"
      unitRef="shares">1103721</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzUtMy0xLTEtMjI1NDU_c867e42f-71c6-48e0-916c-b669aeccaa48"
      unitRef="usdPerShare">15.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzYtMS0xLTEtMjI1NDU_dbfc39ef-dda0-4434-a61a-194e18ee4ed7"
      unitRef="shares">189388</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzYtMy0xLTEtMjI1NDU_d11dddd1-4c1f-4743-8cc4-e3b2333740ef"
      unitRef="usdPerShare">13.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzctMS0xLTEtMjI1NDU_f488c0c7-4075-4ddc-8ddf-ff1890678fa6"
      unitRef="shares">152939</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzctMy0xLTEtMjI1NDU_fe74dff2-d15e-45fd-9807-62434c2af08c"
      unitRef="usdPerShare">6.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzgtMS0xLTEtMjI1NDU_b56e9b51-2a87-4cdd-9fc6-a33a5cdf542a"
      unitRef="shares">10963</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzgtMy0xLTEtMjI1NDU_9bf7c801-8f9c-4149-af6d-99a7aed61572"
      unitRef="usdPerShare">7.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzktMS0xLTEtMjI1NDU_409b1c02-9d63-494e-9606-0195b5df89db"
      unitRef="shares">4230162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzktMy0xLTEtMjI1NDU_d87edc75-bcfa-4eb5-8251-264719c5a8f3"
      unitRef="usdPerShare">8.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzktNS0xLTEtMjI1NDU_d996bb07-ff1f-43fa-a119-1bd615be35f0">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzktNy0xLTEtMjI1NDU_22b34200-5d06-4cc2-864b-707806dfbba5"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzEwLTEtMS0xLTIyNTQ1_62e0f003-37de-4329-a5d4-43597dc36a8f"
      unitRef="shares">2499165</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzEwLTMtMS0xLTIyNTQ1_81c26f2a-ffdb-42b2-bd66-cae86487bbc8"
      unitRef="usdPerShare">7.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzEwLTUtMS0xLTIyNTQ1_d9764f60-d7ca-49a9-b49c-40010a089bcd">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTo0ODU5YTJlNTc0MDU0ZmU0YjAxYTRkNjhhOGVkMTQ3Ni90YWJsZXJhbmdlOjQ4NTlhMmU1NzQwNTRmZTRiMDFhNGQ2OGE4ZWQxNDc2XzEwLTctMS0xLTIyNTQ1_5a633f3c-896d-49f2-a495-86cceb5bc00f"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzUyODg_1b406500-488f-422f-b847-06c7ea4a7ad0"
      unitRef="usdPerShare">10.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzUyOTU_51fd35f0-96d1-4845-8f89-22570f2e7bb4"
      unitRef="usdPerShare">5.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzU0MTE_058008c3-c605-4b1a-a5a0-d4243f8cc491"
      unitRef="usd">6100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i54c2a1b829084a7b83834a08509335ce_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzEwOTk1MTE2NDgxODU_103e7d61-46ec-4d52-bd72-a70f4a522bff">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzMyOTg1MzQ4ODk4NzY_a660a85f-a4cd-4f97-9fd4-e0b41d230177">&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's RSA and RSU activity for the years ended December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.268%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Shares of &lt;br/&gt;Restricted Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Weighted &lt;br/&gt;Average Grant &lt;br/&gt;Date Fair Value &lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Restricted &lt;br/&gt;Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Weighted &lt;br/&gt;Average Grant &lt;br/&gt;Date Fair Value &lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;14,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;6.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;74,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;7.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(14,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;6.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(43,875)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;8.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(12,764)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;6.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;17,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;9.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Vested as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;43,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;8.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i391c5213ee2846a09acad8d39f4acc78_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzQtMS0xLTEtMjI1NDU_8aace1e2-50b9-4c2e-9220-973705e41c77"
      unitRef="shares">14586</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i391c5213ee2846a09acad8d39f4acc78_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzQtMy0xLTEtMjI1NDU_fe8c0e0c-1785-4e3c-a22c-c581e3fb4b75"
      unitRef="usdPerShare">6.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ib18cd3fd172f47be9edcff38ff0ed63a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzQtNS0xLTEtMjI1NDU_adf0fba6-f9a8-42d0-ad5b-722e38c17efa"
      unitRef="shares">74144</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ib18cd3fd172f47be9edcff38ff0ed63a_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzQtNy0xLTEtMjI1NDU_015214dd-b48b-4db4-9e84-f7242d5e434b"
      unitRef="usdPerShare">7.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i5d2bddbdf568489b92aaf86fbd855a9d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzYtMS0xLTEtMjI1NDU_16f8db61-d67a-4fd5-9fed-c205ceb7b193"
      unitRef="shares">14586</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i5d2bddbdf568489b92aaf86fbd855a9d_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzYtMy0xLTEtMjI1NDU_fec43e73-d330-4513-a9c0-143a9452109d"
      unitRef="usdPerShare">6.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i60ac161568b9493f9839384faf16222a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzYtNS0xLTEtMjI1NDU_2ce81a6e-c25a-461c-bcc5-6c3b396d4811"
      unitRef="shares">43875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i60ac161568b9493f9839384faf16222a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzYtNy0xLTEtMjI1NDU_67766346-a292-4e3a-9e06-345b84d7eb73"
      unitRef="usdPerShare">8.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i5d2bddbdf568489b92aaf86fbd855a9d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzctMS0xLTEtMzI3OTY_f02732da-2b33-4826-8667-6291b26b258e"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i5d2bddbdf568489b92aaf86fbd855a9d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzctMy0xLTEtMzI3OTY_18decbdb-0917-4ce7-8b74-d0336bd17d1e"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i60ac161568b9493f9839384faf16222a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzctNS0xLTEtMzI3Nzk_e6ce014e-3ff0-4b7e-9a44-ccf8f5fc7eb7"
      unitRef="shares">12764</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i60ac161568b9493f9839384faf16222a_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzctNy0xLTEtMzE5OTg_39f81939-3c26-4fee-8de9-8dde9ba90c94"
      unitRef="usdPerShare">6.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id7f5c1532cac4e2b998ae309d92d8edd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzctMS0xLTEtMjI1NDU_f857707e-3023-47aa-8823-c57b57e5bca9"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="id7f5c1532cac4e2b998ae309d92d8edd_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzctMy0xLTEtMjI1NDU_0a121a68-1bfd-4fd8-866b-e78e5312bcb8"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="idc8909f8292a435ca08e7ea8957de0e8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzctNS0xLTEtMjI1NDU_26b75904-d960-4683-b69e-1ae8153662dd"
      unitRef="shares">17505</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="idc8909f8292a435ca08e7ea8957de0e8_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzctNy0xLTEtMjI1NDU_59285057-715a-45fa-bf1b-90f815ce45bd"
      unitRef="usdPerShare">9.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <angn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber
      contextRef="id7f5c1532cac4e2b998ae309d92d8edd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzktMS0xLTEtMzI3OTk_926858b5-fffa-4a8d-a666-932065419e2f"
      unitRef="shares">0</angn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber>
    <angn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageExercisePrice
      contextRef="id7f5c1532cac4e2b998ae309d92d8edd_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzgtMy0xLTEtMjM2MTY_a53dcdd9-aa67-4c69-8fbd-4ba61bf26905"
      unitRef="usdPerShare"
      xsi:nil="true"/>
    <angn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber
      contextRef="idc8909f8292a435ca08e7ea8957de0e8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzgtNS0xLTEtMjI1NDU_ac1b95f2-8284-4be4-82c0-eeb7885b9ff4"
      unitRef="shares">43875</angn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber>
    <angn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageExercisePrice
      contextRef="idc8909f8292a435ca08e7ea8957de0e8_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpjMDZmNzFjMmQ2MWM0YTg0YWNiNDI3ODgxZmQ2MzIzOS90YWJsZXJhbmdlOmMwNmY3MWMyZDYxYzRhODRhY2I0Mjc4ODFmZDYzMjM5XzgtNy0xLTEtMjI1NDU_9f271b4b-d0f0-4bff-b940-2a4a963824fa"
      unitRef="usdPerShare">8.16</angn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="i7817467d29ec42488073e266808a1b4a_D20190601-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzEwOTk1MTE2NDE1MDQ_caeaf16b-08f5-4916-92f7-b3dfe725c391"
      unitRef="shares">556530</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="idaadc88b9cdc4d3b9741cddf31c97c95_D20210209-20210209"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzEwOTk1MTE2NDE4MjU_d63521ae-9f72-4063-a952-6e613a2bc836"
      unitRef="shares">185510</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="if60e35a6de454aaba1b4e414c82f9bab_D20210601-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzEwOTk1MTE2NDE4OTY_6c7bce04-b44c-485a-be0c-25d8c3ddcbb7"
      unitRef="shares">185510</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="ib6ed7c4e75a34a8e8f44a7115b92ba55_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzEwOTk1MTE2NDIwMTM_2d3fe598-9319-48bd-8cfe-ae37c67f216c"
      unitRef="shares">185510</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzMyOTg1MzQ4ODk4Nzc_7c4feedd-46e6-47fd-8f0c-97b73840333d">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the total stock-based compensation expense for the stock options, RSUs, RSAs, PSUs compensation issued in shares recorded in the consolidated statements of operations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;General and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;12,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i92b1ec8f60c4409cbb367354f0969366_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpmNDM5ZjJjMDZjYzM0NmYwYWJhODZiMGZkMWJkM2ZhNS90YWJsZXJhbmdlOmY0MzlmMmMwNmNjMzQ2ZjBhYmE4NmIwZmQxYmQzZmE1XzItMS0xLTEtMjI1NDU_660d47f6-bc36-4102-b5e9-382bad0cf6ce"
      unitRef="usd">5898000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i92b73a2382864a80b71e3f51aef05903_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpmNDM5ZjJjMDZjYzM0NmYwYWJhODZiMGZkMWJkM2ZhNS90YWJsZXJhbmdlOmY0MzlmMmMwNmNjMzQ2ZjBhYmE4NmIwZmQxYmQzZmE1XzItMy0xLTEtMjI1NDU_a16ce785-e0e3-4d9a-9035-92229739d3c0"
      unitRef="usd">2183000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic47bf067546145a8a6fa9b871d43cefe_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpmNDM5ZjJjMDZjYzM0NmYwYWJhODZiMGZkMWJkM2ZhNS90YWJsZXJhbmdlOmY0MzlmMmMwNmNjMzQ2ZjBhYmE4NmIwZmQxYmQzZmE1XzMtMS0xLTEtMjI1NDU_3564ce7e-016b-4fb0-8505-057d0cee5cc3"
      unitRef="usd">6143000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6cfa5bf5e100430bbe5f169211eb27e2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpmNDM5ZjJjMDZjYzM0NmYwYWJhODZiMGZkMWJkM2ZhNS90YWJsZXJhbmdlOmY0MzlmMmMwNmNjMzQ2ZjBhYmE4NmIwZmQxYmQzZmE1XzMtMy0xLTEtMjI1NDU_71fb8acf-b4f8-4600-a613-c564960ed1f8"
      unitRef="usd">2533000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpmNDM5ZjJjMDZjYzM0NmYwYWJhODZiMGZkMWJkM2ZhNS90YWJsZXJhbmdlOmY0MzlmMmMwNmNjMzQ2ZjBhYmE4NmIwZmQxYmQzZmE1XzQtMS0xLTEtMjI1NDU_690de8c1-ff19-4566-9a7f-e0fbf426d11a"
      unitRef="usd">12041000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90YWJsZTpmNDM5ZjJjMDZjYzM0NmYwYWJhODZiMGZkMWJkM2ZhNS90YWJsZXJhbmdlOmY0MzlmMmMwNmNjMzQ2ZjBhYmE4NmIwZmQxYmQzZmE1XzQtMy0xLTEtMjI1NDU_222363bc-269d-4ea8-9e28-4fbd90a4155e"
      unitRef="usd">4716000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="if41f90861d0545f185125b2fd6ebf84a_I20210131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzEwOTk1MTE2NDI1OTc_d95dccb5-bb20-4d43-b708-bca8e028ac42"
      unitRef="shares">390000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i6079bc9dc350474297feb207d4409628_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzIxOTkwMjMyNzU5OTQ_eb32d0b2-1b0f-43f6-8409-fd5774d667a4"
      unitRef="shares">390000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i6079bc9dc350474297feb207d4409628_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMjcvZnJhZzoyZTliYzA1Njc4NWI0MTU2ODZmNTc5MjU0MTdlZjgzYi90ZXh0cmVnaW9uOjJlOWJjMDU2Nzg1YjQxNTY4NmY1NzkyNTQxN2VmODNiXzEwOTk1MTE2NDI2MDk_e891770a-53ab-4d4e-89ad-fb6a7c38c9d5"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <angn:WarrantsAndRightsOutstandingTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90ZXh0cmVnaW9uOmExMzRiNmZjY2I1MTRkOWM5NzY3MzEyNWE0MTVhN2U2XzMyOTg1MzQ4ODQ1NDQ_964c9fcc-df24-4c5d-9ff3-3fce44fd8bf3">Warrants&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 and 2020, the outstanding warrants to purchase the Company's common stock were comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Exercise &lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Expiration &lt;br/&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Warrants at December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Warrants issued with 2015 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;6.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;7/5/28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;388,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Warrants issued with 2016 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;6.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;7/5/28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;538,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Warrants issued with 2017 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;6.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;7/5/28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;79,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Warrants issued with 2018 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;6.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;7/5/28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;498,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Warrants issued with Conversion of Notes to Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;8.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;8/31/28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;232,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;238,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Warrants issued with Units in the Equity Offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;8.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;8/31/28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;875,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;907,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Broker Warrants issued with Equity Offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;8/31/25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;1,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;48,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Broker Warrants issued with 2019 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;1/30/20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Consultant Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;7.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;8/31/28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;39,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;39,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Total Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;1,148,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;2,739,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 815, the warrants classified as liabilities are recorded at fair value at the issuance date, with changes in the fair value recognized in the consolidated statements of operations at the end of each reporting period. Refer to Note 4 for changes in the fair value recognized during the periods reported.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 815, the warrants classified as equity do not meet the definition of a derivative and are classified in stockholders' equity (deficit) in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's warrant activity for the year ended December&#160;31, 2021 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Average &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Exercise &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Average &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Remaining &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Contractual &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Life (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Balance&#x2014;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,739,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Exercised &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,588,756)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(2,912)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Balance&#x2014;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,148,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;_________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) 613,892 shares from warrant exercised were tendered back to the Company to cover the exercise price of the warrant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Conversion of Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, all warrants outstanding issued with 2015 Notes, 2016 Notes, 2017 Notes, and 2018 Notes   with an exercise price of $6.43 per share were net exercised into an aggregate of 844,335 shares of common stock upon the IPO with a conversion price of $11.57 per share.&lt;/span&gt;&lt;/div&gt;</angn:WarrantsAndRightsOutstandingTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90ZXh0cmVnaW9uOmExMzRiNmZjY2I1MTRkOWM5NzY3MzEyNWE0MTVhN2U2XzMyOTg1MzQ4ODQ1NDU_d6f6db30-a382-4b38-8e5c-ea4b1fd69397">&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 and 2020, the outstanding warrants to purchase the Company's common stock were comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Exercise &lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Expiration &lt;br/&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Warrants at December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Warrants issued with 2015 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;6.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;7/5/28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;388,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Warrants issued with 2016 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;6.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;7/5/28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;538,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Warrants issued with 2017 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;6.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;7/5/28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;79,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Warrants issued with 2018 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;6.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;7/5/28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;498,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Warrants issued with Conversion of Notes to Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;8.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;8/31/28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;232,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;238,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Warrants issued with Units in the Equity Offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;8.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;8/31/28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;875,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;907,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Broker Warrants issued with Equity Offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;8/31/25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;1,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;48,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Broker Warrants issued with 2019 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;1/30/20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Consultant Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;7.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;8/31/28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;39,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;39,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Total Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;1,148,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;2,739,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="if16b69b23bb6477c809c732686e6c818_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzItMy0xLTEtMjI1NDU_7a8fed7a-e833-4d65-b877-19c4e1ffb5cd"
      unitRef="usdPerShare">6.43</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="if16b69b23bb6477c809c732686e6c818_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzItNy0xLTEtMjI1NDU_bd327c26-a298-4abf-b20c-5f29976ae98c"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i43c1a8313c78494992d014e2ea73ba94_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzItOS0xLTEtMjI1NDU_c7efb121-1961-4ffb-b5b5-74da1dfc1269"
      unitRef="shares">388396</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i27dc24aec76340a998ae99277f3efd2e_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzMtMy0xLTEtMjI1NDU_a6a636c9-510e-40dd-a5c7-a30de8b3645c"
      unitRef="usdPerShare">6.43</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i27dc24aec76340a998ae99277f3efd2e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzMtNy0xLTEtMjI1NDU_e4311c1b-ba6e-49c9-9151-a03bf7a53cfa"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i5280c6af39144c0097d2718db5b41580_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzMtOS0xLTEtMjI1NDU_e0982128-00ea-4209-9587-570cb7c95589"
      unitRef="shares">538933</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i0fc4689e5cff46898c878ceef7ce56cd_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzQtMy0xLTEtMjI1NDU_b2635d47-29c8-4531-8e45-5f602900a4d4"
      unitRef="usdPerShare">6.43</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i0fc4689e5cff46898c878ceef7ce56cd_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzQtNy0xLTEtMjI1NDU_1a417c5e-ff40-455f-b02d-97ce986872c5"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="id76d56a33e4f4a60bb37b2bc487fbad9_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzQtOS0xLTEtMjI1NDU_1330bd18-7dae-4ab7-aa6f-629a577548b5"
      unitRef="shares">79265</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i79898ce5c218453fb0a55a7cb08aee82_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzUtMy0xLTEtMjI1NDU_7bbbfbb5-58fa-4fb2-a839-b9644ebe5c7e"
      unitRef="usdPerShare">6.43</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i79898ce5c218453fb0a55a7cb08aee82_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzUtNy0xLTEtMjI1NDU_106c679d-ff7e-43c6-9cb6-aed951590c5c"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ib75e81811b1f43cb90f7a7a898c09ac1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzUtOS0xLTEtMjI1NDU_71fe79f3-43c6-4130-ae65-44a2584a9451"
      unitRef="shares">498567</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ib18fedbfd53d471ca8ad9bda5ea20ac9_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzYtMy0xLTEtMjI1NDU_9591da8b-3c2b-4700-a3de-9d813c2649c6"
      unitRef="usdPerShare">8.03</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ib18fedbfd53d471ca8ad9bda5ea20ac9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzYtNy0xLTEtMjI1NDU_84188d86-ec33-4f42-8b88-62a921b747ca"
      unitRef="shares">232287</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i84612d7718b644af9a1cf862077b6bc7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzYtOS0xLTEtMjI1NDU_fe78ff16-b0a7-4aa0-8ab6-71d30f984c73"
      unitRef="shares">238779</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ibea121a245f649d6a99c181f5a14bd89_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzctMy0xLTEtMjI1NDU_ac089525-707e-46b7-bc32-0a5c349240ed"
      unitRef="usdPerShare">8.03</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ibea121a245f649d6a99c181f5a14bd89_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzctNy0xLTEtMjI1NDU_c5fa316b-a1dc-41bf-bbb0-d2af5adc2d10"
      unitRef="shares">875034</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i855a01903f014f53bf8b37778bc42c99_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzctOS0xLTEtMjI1NDU_c3f62237-c69c-420e-b4fe-e75ae21bcc00"
      unitRef="shares">907860</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i891c62a6c35b47e48378588b88bb112c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzgtMy0xLTEtMjI1NDU_d6a59804-09b0-428a-986a-b20df0f10ff8"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i891c62a6c35b47e48378588b88bb112c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzgtNy0xLTEtMjI1NDU_1198185b-930a-4827-b308-9a5c0d2af1ad"
      unitRef="shares">1297</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ie0e5243bae824dccb7342c17c8cca4aa_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzgtOS0xLTEtMjI1NDU_aa7f68d8-0854-45ce-bf5f-88075ab1ade8"
      unitRef="shares">48485</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i3a61ee941a9e4d32b5dd2e580ef7e639_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzktMy0xLTEtMjI1NDU_af07809f-bbf0-4085-943c-9dd880facb8f"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i3a61ee941a9e4d32b5dd2e580ef7e639_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzktNy0xLTEtMjI1NDU_076f81bf-2569-4019-b19e-23fd042de99b"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i3279c6cb0327462d84d652b4f17138c3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzktOS0xLTEtMjI1NDU_7c86af2c-a2b9-482d-bb8f-90903a0db7b3"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i92b4a25f21264eb2b06953b7ef40a96f_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzExLTMtMS0xLTIyNTQ1_2c2704b7-9f34-4d35-8364-6d81e4763198"
      unitRef="usdPerShare">7.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i92b4a25f21264eb2b06953b7ef40a96f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzExLTctMS0xLTIyNTQ1_6731a416-d592-45d8-8025-ab94b2563cb4"
      unitRef="shares">39505</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ia49fffc648cc4ba7bc5e1c58b7adb469_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzExLTktMS0xLTIyNTQ1_ec854efd-32db-4e28-980f-826686ff8b4a"
      unitRef="shares">39506</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzEyLTctMS0xLTIyNTQ1_ab3bbce8-ec07-43e2-abde-21fb64b708d9"
      unitRef="shares">1148123</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpmMTFjNDA0YzAyNGM0MTc3OTMzNDdjNWVhNTU4OWZiOC90YWJsZXJhbmdlOmYxMWM0MDRjMDI0YzQxNzc5MzM0N2M1ZWE1NTg5ZmI4XzEyLTktMS0xLTIyNTQ1_a3709afe-f62b-48b3-b510-99491f0c8d9e"
      unitRef="shares">2739791</us-gaap:ClassOfWarrantOrRightOutstanding>
    <angn:WarrantsAndRightsOutstandingActivityTableTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90ZXh0cmVnaW9uOmExMzRiNmZjY2I1MTRkOWM5NzY3MzEyNWE0MTVhN2U2XzMyOTg1MzQ4ODQ1NzQ_e9c2ea1d-645c-4bd0-b357-694ade42fa1a">&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's warrant activity for the year ended December&#160;31, 2021 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Average &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Exercise &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Weighted &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Average &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Remaining &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Contractual &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Life (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Balance&#x2014;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,739,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Exercised &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,588,756)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(2,912)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Balance&#x2014;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,148,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;8.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;_________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) 613,892 shares from warrant exercised were tendered back to the Company to cover the exercise price of the warrant.&lt;/span&gt;&lt;/div&gt;</angn:WarrantsAndRightsOutstandingActivityTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpkYzA3ZDkzN2IyMzQ0OGYzOTc2OGIyNTExMGM1ZjY5MC90YWJsZXJhbmdlOmRjMDdkOTM3YjIzNDQ4ZjM5NzY4YjI1MTEwYzVmNjkwXzUtMS0xLTEtMjI1NDU_e58ae093-9f1b-45fa-a903-d724cf3396df"
      unitRef="shares">2739791</us-gaap:ClassOfWarrantOrRightOutstanding>
    <angn:ClassOfWarrantOrRightWeightedAverageExercisePrice
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpkYzA3ZDkzN2IyMzQ0OGYzOTc2OGIyNTExMGM1ZjY5MC90YWJsZXJhbmdlOmRjMDdkOTM3YjIzNDQ4ZjM5NzY4YjI1MTEwYzVmNjkwXzUtMy0xLTEtMjI1NDU_48dc54de-7402-448c-bd02-3f23168c319b"
      unitRef="usdPerShare">7.00</angn:ClassOfWarrantOrRightWeightedAverageExercisePrice>
    <angn:WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpkYzA3ZDkzN2IyMzQ0OGYzOTc2OGIyNTExMGM1ZjY5MC90YWJsZXJhbmdlOmRjMDdkOTM3YjIzNDQ4ZjM5NzY4YjI1MTEwYzVmNjkwXzUtNS0xLTEtMjI1NDU_98e580fb-2784-4a73-afe0-405acaddb089">P4Y10M24D</angn:WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm>
    <angn:ClassOfWarrantOrRightExercisesInPeriod
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpkYzA3ZDkzN2IyMzQ0OGYzOTc2OGIyNTExMGM1ZjY5MC90YWJsZXJhbmdlOmRjMDdkOTM3YjIzNDQ4ZjM5NzY4YjI1MTEwYzVmNjkwXzctMS0xLTEtMjI1NDU_adf90682-13f5-4170-b8a3-ce059f2b5c6d"
      unitRef="shares">1588756</angn:ClassOfWarrantOrRightExercisesInPeriod>
    <angn:ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpkYzA3ZDkzN2IyMzQ0OGYzOTc2OGIyNTExMGM1ZjY5MC90YWJsZXJhbmdlOmRjMDdkOTM3YjIzNDQ4ZjM5NzY4YjI1MTEwYzVmNjkwXzctMy0xLTEtMjI1NDU_a09439c1-4611-4de7-b0d1-596d1064b05f"
      unitRef="usdPerShare">7.30</angn:ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod>
    <angn:ClassOfWarrantOrRightExpirationsInPeriod
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpkYzA3ZDkzN2IyMzQ0OGYzOTc2OGIyNTExMGM1ZjY5MC90YWJsZXJhbmdlOmRjMDdkOTM3YjIzNDQ4ZjM5NzY4YjI1MTEwYzVmNjkwXzgtMS0xLTEtMjI1NDU_9b8a1481-ca6d-4760-93cd-10b44c51a7ca"
      unitRef="shares">2912</angn:ClassOfWarrantOrRightExpirationsInPeriod>
    <angn:ClassOfWarrantOrRightWeightedAverageExercisePriceExpirationsInPeriod
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpkYzA3ZDkzN2IyMzQ0OGYzOTc2OGIyNTExMGM1ZjY5MC90YWJsZXJhbmdlOmRjMDdkOTM3YjIzNDQ4ZjM5NzY4YjI1MTEwYzVmNjkwXzgtMy0xLTEtMjI1NDU_9e535be5-71f3-4c61-914a-5bcea67dbe46"
      unitRef="usdPerShare">8.03</angn:ClassOfWarrantOrRightWeightedAverageExercisePriceExpirationsInPeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpkYzA3ZDkzN2IyMzQ0OGYzOTc2OGIyNTExMGM1ZjY5MC90YWJsZXJhbmdlOmRjMDdkOTM3YjIzNDQ4ZjM5NzY4YjI1MTEwYzVmNjkwXzktMS0xLTEtMjI1NDU_8cdd34c8-377a-4d1e-ba08-3d02e2b75b5d"
      unitRef="shares">1148123</us-gaap:ClassOfWarrantOrRightOutstanding>
    <angn:ClassOfWarrantOrRightWeightedAverageExercisePrice
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpkYzA3ZDkzN2IyMzQ0OGYzOTc2OGIyNTExMGM1ZjY5MC90YWJsZXJhbmdlOmRjMDdkOTM3YjIzNDQ4ZjM5NzY4YjI1MTEwYzVmNjkwXzktMy0xLTEtMjI1NDU_edf567a3-f0a6-4afb-9d17-c33397bec0d9"
      unitRef="usdPerShare">8.01</angn:ClassOfWarrantOrRightWeightedAverageExercisePrice>
    <angn:WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90YWJsZTpkYzA3ZDkzN2IyMzQ0OGYzOTc2OGIyNTExMGM1ZjY5MC90YWJsZXJhbmdlOmRjMDdkOTM3YjIzNDQ4ZjM5NzY4YjI1MTEwYzVmNjkwXzktNS0xLTEtMjI1NDU_fda990e8-63c1-4674-bb66-c4027c7e0d4b">P1Y2M12D</angn:WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm>
    <angn:ClassOfWarrantOrRightExercisesInPeriodTendered
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90ZXh0cmVnaW9uOmExMzRiNmZjY2I1MTRkOWM5NzY3MzEyNWE0MTVhN2U2XzIxOTkwMjMyNjAzNjk_290875fa-5f5d-452b-af0d-9eda656f11fb"
      unitRef="shares">613892</angn:ClassOfWarrantOrRightExercisesInPeriodTendered>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ie75149bd389348ac91dd0c486618b376_I20210228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90ZXh0cmVnaW9uOmExMzRiNmZjY2I1MTRkOWM5NzY3MzEyNWE0MTVhN2U2XzEwOTk1MTE2MzA1MTc_9b4e300a-8710-4b5e-9b22-3f146d51fe22"
      unitRef="usdPerShare">6.43</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <angn:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i3b02e038496248b1bb8753bc722a0bb7_D20210201-20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90ZXh0cmVnaW9uOmExMzRiNmZjY2I1MTRkOWM5NzY3MzEyNWE0MTVhN2U2XzEwOTk1MTE2MzA1MjU_0f5f314b-f60f-4af1-bccd-87ba12529ba1"
      unitRef="shares">844335</angn:StockIssuedDuringPeriodSharesWarrantsExercised>
    <angn:ClassOfWarrantOrRightConversionPrice
      contextRef="i59e2995c2115446d9af3ddecfb37c4fb_I20210228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzAvZnJhZzphMTM0YjZmY2NiNTE0ZDljOTc2NzMxMjVhNDE1YTdlNi90ZXh0cmVnaW9uOmExMzRiNmZjY2I1MTRkOWM5NzY3MzEyNWE0MTVhN2U2XzEwOTk1MTE2MzA1MjE_ea372a56-2b68-4875-9bae-185068b43078"
      unitRef="usdPerShare">11.57</angn:ClassOfWarrantOrRightConversionPrice>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzMyOTg1MzQ4ODc4NTU_6275d35f-2a69-4b80-b305-fca1866002c4">Commitments and Contingencies&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases office and laboratory space in Uniondale, New York from NovaPark, a related party, under an agreement classified as an operating lease that expires on June 20, 2026. The Company's lease does not require any contingent rental payments, impose any financial restrictions, or contain any residual value guarantees. Variable expenses generally represent the Company's share of the landlord's operating expenses, including management fees. The Company does not act as a lessor or have any leases classified as financing leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases office space in Fort Lee, New Jersey, comprising approximately 2,105 square feet for approximately $0.1&#160;million per year, under a non-cancelable operating lease through March 31, 2022. However, this arrangement is excluded from the calculation of lease liabilities and right of use assets as its term is less than one year. The lease is subject to charges for common area maintenance and other costs. The Company is not going to renew the New Jersey lease after March 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, the Company entered into a lease for office furniture in San Francisco, California set to expire in July 2025, with an annual lease payment of approximately $13,000. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the Company entered into a lease for clinical and regulatory space in Newton, Massachusetts (the &#x201c;Newton lease&#x201d;), comprising approximately 6,157 square feet for approximately $0.2&#160;million per year, under a non-cancelable operating lease through June 30, 2024. Pursuant to the Newton lease, the Company had 4 months of free rent starting from February 15, 2021 to June 14, 2021. The Company has one option to extend the term of the lease for 3 years with 9 months&#x2019; notice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the components of the Company's rent expense (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;For the Year Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Variable cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating lease expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 13pt 0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Short-term lease rent expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total rent expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes quantitative information about the Company's NovaPark operating leases (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;For the Year Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Right-of-use assets exchanged for operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted-average remaining lease term&#x2014;operating leases (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted-average discount rate&#x2014;operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, maturities of lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Less present value discount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financing obligation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, the Company entered into a sale and leaseback arrangement with a third-party financing institution as a financing mechanism to fund certain of its capital expenditures primarily related to operating equipment, whereby the physical asset is sold concurrent with an agreement to lease the asset back. The initial leaseback term is 42 months starting from November 2021. The arrangement includes a renewal option as well as a repurchase option at fair value with a cap at the end of the term. The arrangement does not qualify as an asset sale as control of the equipment did not transfer to the third party and is accounted for as a failed sale-leaseback. Therefore, the Company accounts for the arrangement as a financing transaction and records the proceeds received as a financing obligation. The leased assets are included in property and equipment, net on the consolidated balance sheets and are subject to depreciation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2021, the Company received $0.3&#160;million in connection with the sale and leaseback of certain equipment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes quantitative information about the Company's financing obligation (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.760%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;For the Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Cash flow information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Proceeds from sale and leaseback arrangement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Payments of financing obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating cash flows from financing obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from financing obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Other information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted-average discount rate (in percent)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Carrying value of leased asset included in Property and Equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Depreciation associated with the leased asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, maturities of financing obligation were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Less present value discount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Financing obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is not a party to any material legal proceedings and is not aware of any pending or threatened claims. From time to time, the Company may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these arrangements is not determinable. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, the Company believes the fair value of these agreements is minimal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Paycheck Protection Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, the Company received funds in the amount of $0.9&#160;million pursuant to a loan under the Paycheck Protection Program of the 2020 CARES Act ("PPP") administered by the Small Business Association. The loan has an interest rate of 1.0% and a term of 24 months. No payments were due for the first 16 months, although interest accrued, and monthly payments were due over the next 8 months to retire the loan plus accrued interest. Funds &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;from the loan could only be used for certain purposes, including payroll, benefits, rent and utilities, and a portion of the loan used to pay certain costs were forgivable, all as provided by the terms of the PPP. The loan was evidenced by a promissory note, which contained customary events of default relating to, among other things, payment defaults and breaches of representations and warranties. The SBA approved the Company's PPP Loan forgiveness application on May 26, 2021 for the entire principal amount of the PPP Loan and accrued interest. As a result, the Company recorded a gain on the forgiveness of the loan in the amount of $0.9&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Retention Credit ("ERC")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Employee Retention Credit ("ERC") under the CARES Act is a refundable tax credit which encourages businesses to keep employees on the payroll during the COVID-19 pandemic. Eligible employers could qualify for up to $5,000 of credit for each employee based on qualified wages paid after March 12, 2020 and before January 1, 2021. The Internal Revenue Service ("IRS") subsequently issued Notice 2021-23 and Notice 2021-49 which collectively extended the ERC eligibility to cover qualified wages paid after December 31, 2020 and before January 1, 2022. Qualified wages are the wages paid to an employee for the time that the employee is not providing services due to an economic hardship, specifically, either (1) a full or partial suspension of operations by order of a governmental authority due to COVID-19, or (2) a significant decline in gross receipts. &lt;/span&gt;&lt;/div&gt;During the years ended December 31, 2021 and 2020, the Company received $1.5&#160;million and zero, respectively for ERC and applied the benefit as a reduction to the payroll expenses in the consolidated statement of operations.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i01849912679d402f8b851a0ea52911e4_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzY4MQ_a1a5a767-fef0-4e3f-bd2c-e8098a3b1b63"
      unitRef="sqft">2105</us-gaap:AreaOfRealEstateProperty>
    <angn:LesseeOperatingLeaseAnnualRentExpense
      contextRef="i444bffaeb5fd4c7dae715a0266b8d087_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzcxNA_b928863a-1a8a-4d31-b27c-068f05072bbc"
      unitRef="usd">100000</angn:LesseeOperatingLeaseAnnualRentExpense>
    <angn:LesseeOperatingLeaseAnnualRentExpense
      contextRef="i519304eebcb54dc99bfcc6afa7d63b44_D20200701-20200731"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzEwOTk1MTE2MzQ3OTk_3e44b853-2e05-42b5-9ff9-57db865548c8"
      unitRef="usd">13000</angn:LesseeOperatingLeaseAnnualRentExpense>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i7dfcdb12bfb34eb6b5ec1d691edc1a6b_I20210228"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzEwOTk1MTE2MzQ3NjA_55cc8c6c-f25b-4c20-8d71-aa13374a6a01"
      unitRef="sqft">6157</us-gaap:AreaOfRealEstateProperty>
    <angn:LesseeOperatingLeaseAnnualRentExpense
      contextRef="i7fa0c3e9d7c641a48770a0df7a146319_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzEwOTk1MTE2MzQ3ODA_81ae0995-f97c-4122-8e99-b75b78c0d44a"
      unitRef="usd">200000</angn:LesseeOperatingLeaseAnnualRentExpense>
    <angn:LesseeOperatingLeaseFreeRentExpensePeriod
      contextRef="i7fa0c3e9d7c641a48770a0df7a146319_D20210201-20210228"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzYwNDczMTM5ODE5OTc_1ea94b26-2d6a-485f-a3c4-74a50986bed3">P4M</angn:LesseeOperatingLeaseFreeRentExpensePeriod>
    <angn:LesseeOperatingLeaseNumberOfOptionsToExtend
      contextRef="i7dfcdb12bfb34eb6b5ec1d691edc1a6b_I20210228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzIxOTkwMjMyODQ3MTM_03a2ee58-3a6b-4198-b57f-59e5f6926293"
      unitRef="option">1</angn:LesseeOperatingLeaseNumberOfOptionsToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i7dfcdb12bfb34eb6b5ec1d691edc1a6b_I20210228"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzEwOTk1MTE2MzQ3NjY_ca1fbdaf-1b01-416d-a5c2-b782f963efa7">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <angn:LesseeOperatingLeaseNoticePeriodForOptionToExtend
      contextRef="i7fa0c3e9d7c641a48770a0df7a146319_D20210201-20210228"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzIxOTkwMjMyODQ2OTk_4b88c557-007e-4ad8-b9d4-21b17ba39616">P9M</angn:LesseeOperatingLeaseNoticePeriodForOptionToExtend>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzMyOTg1MzQ4ODc4NTY_2c655eef-40f5-44f4-abf3-8f25e0085523">&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the components of the Company's rent expense (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;For the Year Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Variable cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating lease expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 13pt 0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Short-term lease rent expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total rent expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo1NDliYWNmNTIxNTM0NjM0YjQ1MjdkOWViNTljNWMxNC90YWJsZXJhbmdlOjU0OWJhY2Y1MjE1MzQ2MzRiNDUyN2Q5ZWI1OWM1YzE0XzMtMS0xLTEtMjM3MDE_d20ae555-7373-4a9d-a28d-366476957fd0"
      unitRef="usd">1142000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo1NDliYWNmNTIxNTM0NjM0YjQ1MjdkOWViNTljNWMxNC90YWJsZXJhbmdlOjU0OWJhY2Y1MjE1MzQ2MzRiNDUyN2Q5ZWI1OWM1YzE0XzMtMy0xLTEtMjM3MDM_2b725a20-dadd-4432-b5f7-60b6a592a5de"
      unitRef="usd">1099000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo1NDliYWNmNTIxNTM0NjM0YjQ1MjdkOWViNTljNWMxNC90YWJsZXJhbmdlOjU0OWJhY2Y1MjE1MzQ2MzRiNDUyN2Q5ZWI1OWM1YzE0XzQtMS0xLTEtMjM3MDE_071ebe4c-c72b-479b-8996-ccfa44ef8218"
      unitRef="usd">473000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo1NDliYWNmNTIxNTM0NjM0YjQ1MjdkOWViNTljNWMxNC90YWJsZXJhbmdlOjU0OWJhY2Y1MjE1MzQ2MzRiNDUyN2Q5ZWI1OWM1YzE0XzQtMy0xLTEtMjM3MDM_cf80f153-9fd4-47ee-b74b-d4de07562499"
      unitRef="usd">646000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeaseExpense
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo1NDliYWNmNTIxNTM0NjM0YjQ1MjdkOWViNTljNWMxNC90YWJsZXJhbmdlOjU0OWJhY2Y1MjE1MzQ2MzRiNDUyN2Q5ZWI1OWM1YzE0XzUtMS0xLTEtMjM3MDE_1efb37b4-b70d-4a8c-bac3-e634535965e4"
      unitRef="usd">1615000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo1NDliYWNmNTIxNTM0NjM0YjQ1MjdkOWViNTljNWMxNC90YWJsZXJhbmdlOjU0OWJhY2Y1MjE1MzQ2MzRiNDUyN2Q5ZWI1OWM1YzE0XzUtMy0xLTEtMjM3MDM_bbd8c2ca-8785-43bb-8db3-f58649268fe8"
      unitRef="usd">1745000</us-gaap:OperatingLeaseExpense>
    <us-gaap:ShortTermLeaseCost
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo1NDliYWNmNTIxNTM0NjM0YjQ1MjdkOWViNTljNWMxNC90YWJsZXJhbmdlOjU0OWJhY2Y1MjE1MzQ2MzRiNDUyN2Q5ZWI1OWM1YzE0XzYtMS0xLTEtMjM3MDE_33a6dad4-8acb-4e33-8db6-fde5c6922de0"
      unitRef="usd">44000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo1NDliYWNmNTIxNTM0NjM0YjQ1MjdkOWViNTljNWMxNC90YWJsZXJhbmdlOjU0OWJhY2Y1MjE1MzQ2MzRiNDUyN2Q5ZWI1OWM1YzE0XzYtMy0xLTEtMjM3MDM_9f7dbb85-bd9c-480f-bb65-b5fc7e1378d5"
      unitRef="usd">91000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo1NDliYWNmNTIxNTM0NjM0YjQ1MjdkOWViNTljNWMxNC90YWJsZXJhbmdlOjU0OWJhY2Y1MjE1MzQ2MzRiNDUyN2Q5ZWI1OWM1YzE0XzctMS0xLTEtMjM3MDE_6d30265d-dbaa-45bb-8c80-56f2fb267a3a"
      unitRef="usd">1659000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo1NDliYWNmNTIxNTM0NjM0YjQ1MjdkOWViNTljNWMxNC90YWJsZXJhbmdlOjU0OWJhY2Y1MjE1MzQ2MzRiNDUyN2Q5ZWI1OWM1YzE0XzctMy0xLTEtMjM3MDM_c658abad-0fa8-479b-b150-0bf21da6e6fe"
      unitRef="usd">1836000</us-gaap:LeaseCost>
    <angn:ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzMyOTg1MzQ4ODc4NTc_52d16f45-98a5-4a9f-bc29-d719572c3b3b">&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes quantitative information about the Company's NovaPark operating leases (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;For the Year Ended &lt;br/&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Right-of-use assets exchanged for operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted-average remaining lease term&#x2014;operating leases (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted-average discount rate&#x2014;operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</angn:ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo5OGM4YWQ4MDIxMTU0M2Y1YmQzNjNlYTZmOTA0YmY5MC90YWJsZXJhbmdlOjk4YzhhZDgwMjExNTQzZjViZDM2M2VhNmY5MDRiZjkwXzItMS0xLTEtMjI1NDU_9f7c3ca6-88d5-4cea-8a72-4512940ae59c"
      unitRef="usd">1179000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo5OGM4YWQ4MDIxMTU0M2Y1YmQzNjNlYTZmOTA0YmY5MC90YWJsZXJhbmdlOjk4YzhhZDgwMjExNTQzZjViZDM2M2VhNmY5MDRiZjkwXzItMy0xLTEtMjI1NDU_06fb5236-4352-407e-ba26-3dab8a82d720"
      unitRef="usd">1081000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo5OGM4YWQ4MDIxMTU0M2Y1YmQzNjNlYTZmOTA0YmY5MC90YWJsZXJhbmdlOjk4YzhhZDgwMjExNTQzZjViZDM2M2VhNmY5MDRiZjkwXzMtMS0xLTEtMjI1NDU_638379be-a31d-4caa-b000-f4aef2a7393a"
      unitRef="usd">624000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo5OGM4YWQ4MDIxMTU0M2Y1YmQzNjNlYTZmOTA0YmY5MC90YWJsZXJhbmdlOjk4YzhhZDgwMjExNTQzZjViZDM2M2VhNmY5MDRiZjkwXzMtMy0xLTEtMjI1NDU_5d3a2bcf-43f8-47df-9917-7919c0f97321"
      unitRef="usd">88000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo5OGM4YWQ4MDIxMTU0M2Y1YmQzNjNlYTZmOTA0YmY5MC90YWJsZXJhbmdlOjk4YzhhZDgwMjExNTQzZjViZDM2M2VhNmY5MDRiZjkwXzQtMS0xLTEtMjI1NDU_eef48d2a-9f2f-42cd-93ba-f443001e6fab">P3Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo5OGM4YWQ4MDIxMTU0M2Y1YmQzNjNlYTZmOTA0YmY5MC90YWJsZXJhbmdlOjk4YzhhZDgwMjExNTQzZjViZDM2M2VhNmY5MDRiZjkwXzQtMy0xLTEtMjI1NDU_10b2ac3d-1a4c-42ab-8c82-887a50ed0092">P5Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo5OGM4YWQ4MDIxMTU0M2Y1YmQzNjNlYTZmOTA0YmY5MC90YWJsZXJhbmdlOjk4YzhhZDgwMjExNTQzZjViZDM2M2VhNmY5MDRiZjkwXzUtMS0xLTEtMjI1NDU_36d86888-cf5b-4108-92b4-c078a7e72e39"
      unitRef="number">0.101</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTo5OGM4YWQ4MDIxMTU0M2Y1YmQzNjNlYTZmOTA0YmY5MC90YWJsZXJhbmdlOjk4YzhhZDgwMjExNTQzZjViZDM2M2VhNmY5MDRiZjkwXzUtMy0xLTEtMjI1NDU_851cb7a4-f9c2-47fc-af0f-b4265f9c0c9b"
      unitRef="number">0.110</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzMyOTg1MzQ4ODc4NTg_5cb09c30-b64c-4396-b105-02a8f80ceed9">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, maturities of lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Less present value discount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpmODU1MzNkZDgxNzI0YjczOTI4ZGViMzE3MTBkMjI1MC90YWJsZXJhbmdlOmY4NTUzM2RkODE3MjRiNzM5MjhkZWIzMTcxMGQyMjUwXzEtMi0xLTEtMjI1NDU_a08867f0-fd38-499e-b846-b771f0a16ab7"
      unitRef="usd">1289000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpmODU1MzNkZDgxNzI0YjczOTI4ZGViMzE3MTBkMjI1MC90YWJsZXJhbmdlOmY4NTUzM2RkODE3MjRiNzM5MjhkZWIzMTcxMGQyMjUwXzItMi0xLTEtMjI1NDU_5836f887-6b2e-4b38-9fa4-caa3768c3ebd"
      unitRef="usd">1305000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpmODU1MzNkZDgxNzI0YjczOTI4ZGViMzE3MTBkMjI1MC90YWJsZXJhbmdlOmY4NTUzM2RkODE3MjRiNzM5MjhkZWIzMTcxMGQyMjUwXzMtMi0xLTEtMjI1NDU_bfacbce1-3bd0-477a-a12e-b3a1683b3c69"
      unitRef="usd">1209000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpmODU1MzNkZDgxNzI0YjczOTI4ZGViMzE3MTBkMjI1MC90YWJsZXJhbmdlOmY4NTUzM2RkODE3MjRiNzM5MjhkZWIzMTcxMGQyMjUwXzQtMi0xLTEtMjI1NDU_1f794a00-e8fa-401a-8ff7-2aa915a9bb77"
      unitRef="usd">1104000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpmODU1MzNkZDgxNzI0YjczOTI4ZGViMzE3MTBkMjI1MC90YWJsZXJhbmdlOmY4NTUzM2RkODE3MjRiNzM5MjhkZWIzMTcxMGQyMjUwXzUtMi0xLTEtMjI1NDU_db686f8e-d833-4740-b68a-36f379bfdabc"
      unitRef="usd">516000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpmODU1MzNkZDgxNzI0YjczOTI4ZGViMzE3MTBkMjI1MC90YWJsZXJhbmdlOmY4NTUzM2RkODE3MjRiNzM5MjhkZWIzMTcxMGQyMjUwXzYtMi0xLTEtMjI1NDU_4034ad4c-7801-436c-8c90-c871860a96e5"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpmODU1MzNkZDgxNzI0YjczOTI4ZGViMzE3MTBkMjI1MC90YWJsZXJhbmdlOmY4NTUzM2RkODE3MjRiNzM5MjhkZWIzMTcxMGQyMjUwXzctMi0xLTEtMjI1NDU_36b39712-90b8-4bda-88d4-b1ba0c38e5f4"
      unitRef="usd">5423000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpmODU1MzNkZDgxNzI0YjczOTI4ZGViMzE3MTBkMjI1MC90YWJsZXJhbmdlOmY4NTUzM2RkODE3MjRiNzM5MjhkZWIzMTcxMGQyMjUwXzgtMi0xLTEtMjI1NDU_ef8eca64-ba08-4cdf-8fa2-f508e7f1c3bd"
      unitRef="usd">1054000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpmODU1MzNkZDgxNzI0YjczOTI4ZGViMzE3MTBkMjI1MC90YWJsZXJhbmdlOmY4NTUzM2RkODE3MjRiNzM5MjhkZWIzMTcxMGQyMjUwXzktMi0xLTEtMjI1NDU_4053fa00-d197-46c9-ac39-6799aa114ee9"
      unitRef="usd">4369000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="i0bf681e0236d4273af7ed9eb86410720_I20211130"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzIxOTkwMjMyODc4NjA_25b038f6-1e62-4172-8bfe-8beee4c4c84a">P42M</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <angn:ProceedsFromFinancingObligation
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzEwOTk1MTE2NDc1ODY_11b7c78b-77cd-4407-8c72-02acff053e13"
      unitRef="usd">300000</angn:ProceedsFromFinancingObligation>
    <angn:ScheduleOfQuantitativeInformationAboutTheFinancingObligationTableTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzIxOTkwMjMyODQ3NTA_802f8aa1-62ab-43bd-8026-9c3fef33f6af">&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes quantitative information about the Company's financing obligation (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.760%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;For the Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Cash flow information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Proceeds from sale and leaseback arrangement&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Payments of financing obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating cash flows from financing obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Financing cash flows from financing obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Other information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Weighted-average discount rate (in percent)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Carrying value of leased asset included in Property and Equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Depreciation associated with the leased asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</angn:ScheduleOfQuantitativeInformationAboutTheFinancingObligationTableTextBlock>
    <angn:ProceedsFromFinancingObligation
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkMjY3ZTg1ODM1ZTM0N2UwOTFlNjA1MjI3YWEzOTQ0My90YWJsZXJhbmdlOmQyNjdlODU4MzVlMzQ3ZTA5MWU2MDUyMjdhYTM5NDQzXzItMS0xLTEtMjk2ODA_20aac462-4ee6-4725-9dae-b82e75ec09d0"
      unitRef="usd">302000</angn:ProceedsFromFinancingObligation>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkMjY3ZTg1ODM1ZTM0N2UwOTFlNjA1MjI3YWEzOTQ0My90YWJsZXJhbmdlOmQyNjdlODU4MzVlMzQ3ZTA5MWU2MDUyMjdhYTM5NDQzXzQtMS0xLTEtMjk5MzA_2c5663b7-4554-451b-bde6-e820a222b588"
      unitRef="usd">7000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkMjY3ZTg1ODM1ZTM0N2UwOTFlNjA1MjI3YWEzOTQ0My90YWJsZXJhbmdlOmQyNjdlODU4MzVlMzQ3ZTA5MWU2MDUyMjdhYTM5NDQzXzUtMS0xLTEtMjk5MzA_ef456c58-d7c6-4976-91e8-d691840472ed"
      unitRef="usd">9000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkMjY3ZTg1ODM1ZTM0N2UwOTFlNjA1MjI3YWEzOTQ0My90YWJsZXJhbmdlOmQyNjdlODU4MzVlMzQ3ZTA5MWU2MDUyMjdhYTM5NDQzXzQtMS0xLTEtMjk2ODA_ce695521-ea50-4904-b365-220d34f084b2">P3Y</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkMjY3ZTg1ODM1ZTM0N2UwOTFlNjA1MjI3YWEzOTQ0My90YWJsZXJhbmdlOmQyNjdlODU4MzVlMzQ3ZTA5MWU2MDUyMjdhYTM5NDQzXzUtMS0xLTEtMjk2ODA_8e2dc0cb-aba9-4968-b94b-6d9d35defda9"
      unitRef="number">0.011</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2f1573b2c4114052bab5a6fe444a4633_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkMjY3ZTg1ODM1ZTM0N2UwOTFlNjA1MjI3YWEzOTQ0My90YWJsZXJhbmdlOmQyNjdlODU4MzVlMzQ3ZTA5MWU2MDUyMjdhYTM5NDQzXzEwLTEtMS0xLTMwMDc5_f37d10af-3bf8-4a30-bae4-74eef52c8bb1"
      unitRef="usd">270000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="idfd7384fca0f46b6adea2d3695af1f7e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkMjY3ZTg1ODM1ZTM0N2UwOTFlNjA1MjI3YWEzOTQ0My90YWJsZXJhbmdlOmQyNjdlODU4MzVlMzQ3ZTA5MWU2MDUyMjdhYTM5NDQzXzExLTEtMS0xLTMwMDc5_b18caf27-bb0a-46b6-a5cd-0b9b7744dbab"
      unitRef="usd">38000</us-gaap:Depreciation>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzIxOTkwMjMyODQ3NTM_17b19e00-9d39-4b32-9d9d-0b0a56d09fdf">&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, maturities of financing obligation were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Less present value discount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Financing obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkNGZmNzNjNWU0NGE0NDM1YWE0NTAwZGM1ZDk2MzBhMS90YWJsZXJhbmdlOmQ0ZmY3M2M1ZTQ0YTQ0MzVhYTQ1MDBkYzVkOTYzMGExXzEtMi0xLTEtMjk2NzE_95c9fd50-3e5d-4cba-9809-025a88c8316a"
      unitRef="usd">94000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkNGZmNzNjNWU0NGE0NDM1YWE0NTAwZGM1ZDk2MzBhMS90YWJsZXJhbmdlOmQ0ZmY3M2M1ZTQ0YTQ0MzVhYTQ1MDBkYzVkOTYzMGExXzItMi0xLTEtMjk2NzE_dc10c70c-ea76-4a3d-ab73-012830406608"
      unitRef="usd">94000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkNGZmNzNjNWU0NGE0NDM1YWE0NTAwZGM1ZDk2MzBhMS90YWJsZXJhbmdlOmQ0ZmY3M2M1ZTQ0YTQ0MzVhYTQ1MDBkYzVkOTYzMGExXzMtMi0xLTEtMjk2NzE_609db37f-a568-455e-a548-7efbabcb0f1f"
      unitRef="usd">94000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkNGZmNzNjNWU0NGE0NDM1YWE0NTAwZGM1ZDk2MzBhMS90YWJsZXJhbmdlOmQ0ZmY3M2M1ZTQ0YTQ0MzVhYTQ1MDBkYzVkOTYzMGExXzQtMi0xLTEtMjk2NzE_89417f6a-ed49-4c46-ada5-1b21fb71dca6"
      unitRef="usd">31000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkNGZmNzNjNWU0NGE0NDM1YWE0NTAwZGM1ZDk2MzBhMS90YWJsZXJhbmdlOmQ0ZmY3M2M1ZTQ0YTQ0MzVhYTQ1MDBkYzVkOTYzMGExXzUtMi0xLTEtMjk2NzE_cf9ce593-8fd8-4459-a504-b0b95af399be"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkNGZmNzNjNWU0NGE0NDM1YWE0NTAwZGM1ZDk2MzBhMS90YWJsZXJhbmdlOmQ0ZmY3M2M1ZTQ0YTQ0MzVhYTQ1MDBkYzVkOTYzMGExXzYtMi0xLTEtMjk2NzE_b45f2489-783a-48fc-9511-9f91c2c9bf0a"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkNGZmNzNjNWU0NGE0NDM1YWE0NTAwZGM1ZDk2MzBhMS90YWJsZXJhbmdlOmQ0ZmY3M2M1ZTQ0YTQ0MzVhYTQ1MDBkYzVkOTYzMGExXzctMi0xLTEtMjk2NzE_3b54b54e-7592-4074-bc25-7f6270eaf463"
      unitRef="usd">313000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkNGZmNzNjNWU0NGE0NDM1YWE0NTAwZGM1ZDk2MzBhMS90YWJsZXJhbmdlOmQ0ZmY3M2M1ZTQ0YTQ0MzVhYTQ1MDBkYzVkOTYzMGExXzgtMi0xLTEtMjk2NzE_998def4a-fa81-4fb6-b5c5-67222c792e8e"
      unitRef="usd">20000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiability
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90YWJsZTpkNGZmNzNjNWU0NGE0NDM1YWE0NTAwZGM1ZDk2MzBhMS90YWJsZXJhbmdlOmQ0ZmY3M2M1ZTQ0YTQ0MzVhYTQ1MDBkYzVkOTYzMGExXzktMi0xLTEtMjk2NzE_afcf1830-c858-4a90-952a-7684dd0a7476"
      unitRef="usd">293000</us-gaap:FinanceLeaseLiability>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i0c20e7a2f2df45a3b8f60672c1031439_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzM2NTU_7f39ba5d-7762-40d3-995b-bacfbf3200df"
      unitRef="usd">900000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i17fa801811ba45e3a75870ab1d78e1e1_D20210526-20210526"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzIxOTkwMjMyODQ3Njg_20fdb05f-f354-481f-8517-6ecbcb3b6ee5"
      unitRef="usd">900000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <angn:CARESActEmployeeRetentionCredit
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzEwOTk1MTE2NTc0ODE_19df29f1-d806-40f7-ba1c-d4b57ae07f5a"
      unitRef="usd">1500000</angn:CARESActEmployeeRetentionCredit>
    <angn:CARESActEmployeeRetentionCredit
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzMvZnJhZzo2MWZkNzg4NjQ3NDk0NmY0YWFhMDc1NGMxNTZmOWE1Ny90ZXh0cmVnaW9uOjYxZmQ3ODg2NDc0OTQ2ZjRhYWEwNzU0YzE1NmY5YTU3XzEwOTk1MTE2NTc0OTI_81632589-409d-4d68-bd97-8398a6c47a5a"
      unitRef="usd">0</angn:CARESActEmployeeRetentionCredit>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90ZXh0cmVnaW9uOmVlODU5MWQ5MmNkOTQ4YTFiOTM0MDIxY2M3ZjE2MGQ3XzMyOTg1MzQ4ODg1MjE_053f306b-89ea-47b3-bea0-ddb78a41255e">Income Taxes &lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized no tax provision for the year ended December 31, 2021 and December 31, 2020. The difference between the Company's effective tax rate of 0% and the U.S. federal statutory tax rate of 21% is largely due to the Company's net operating losses, which are offset by the corresponding valuation allowance. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company has established a valuation allowance against net deferred tax assets due to the uncertainty that such assets will be realized. The Company periodically evaluates the recoverability of the deferred assets. At such time as it is determined that it is more likely than not that the deferred tax asset will be realized, the valuation allowance will be reduced.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Losses before income taxes includes the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.451%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(53,547)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(78,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(1,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(1,943)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(54,573)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(80,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes provision (benefit) for the years ended December&#160;31, 2021 and 2020 consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.451%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(5,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(12,129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(4,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(522)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;10,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;12,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliations between the federal statutory income tax rate and the Company's effective income tax rate were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.451%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;State taxes, net of federal tax benefit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Interest &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;R&amp;amp;D and other tax credit changes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Permanent items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Nontaxable Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(10.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(15.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Effective income tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company's deferred tax asset at December&#160;31, 2021 and 2020 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;29,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;22,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;R&amp;amp;D and other tax credit carryovers&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Lease liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued compensation and other expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fixed assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;40,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;30,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fixed assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Right of use assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,046)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(874)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(39,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(29,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred tax assets, net of allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company has federal net operating loss carryforwards of approximately $118.5&#160;million available to reduce future taxable income, if any, for federal income tax purposes. Approximately $9.6&#160;million of federal net operating losses can be carried forward to future tax years and begin to expire in 2035. The federal net operating losses generated for the years beginning after December 31, 2017, approximately $108.9&#160;million in total, can be carried forward indefinitely. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The NOL carryforward may be subject to an annual limitation under Section 382 and 383 of the Internal Revenue Code of 1986, and similar state provisions if the Company experienced one or more ownership changes which would limit the amount of NOL and tax credit carryforwards that can be utilized to offset future taxable income and tax respectively. In general, an ownership change as defined by Section 382 and 383, results from the transactions increasing ownership of certain stockholders or public groups in the stock of the corporation of more than 50 percentage points over a three-year period. The Company has not completed a Section 382 and 383 analysis to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company's formation due to the complexity and cost associated with such study and the fact there may be additional such ownership changes in the future. If a change in ownership were to have occurred or occurs in the future, the NOL and tax credits carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company's effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company files income tax returns in the United States, California, Massachusetts, New York and New Jersey. Due to the Company's losses incurred, the Company is subject to the income tax examination by authorities since inception. The Company's policy is to recognize interest expense and penalties related to income tax matters as tax expense. As of December&#160;31, 2021 and 2020, there were no significant accruals for interest related to unrecognized tax benefits or tax penalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2021, the Company's reserve for unrecognized tax benefits is approximately $3.7&#160;million. Due to the full valuation allowance at December 31, 2021, current adjustments to the unrecognized benefits will have no impact to the Company's effective income tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reconciliation of uncertain tax positions as of December 31, 2021 and 2020 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Beginning Balance &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additions for current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additions for prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Ending Balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total amount of unrecognized tax benefits, if recognized, would affect the effective tax rate was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Unrecognized benefits that would affect the effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Unrecognized benefits that would not affect the effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total unrecognized benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not anticipate material changes to its uncertain tax positions for the next twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the 2018 Act that amends the Internal Revenue Code that reduced the U.S. corporate tax rate from 35% to 21% effective January 1, 2018 and modified policies, credits, and deductions (the "Tax Act"), the SEC staff issued Staff Accounting Bulletin No. 118 ("SAB 118") to address the application of GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. The Company has completed its evaluation and determined that there was no net impact on the Company's consolidated financial statements for the years ended December&#160;31, 2021 and 2020 as the corresponding adjustment was made to the valuation allowance.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90ZXh0cmVnaW9uOmVlODU5MWQ5MmNkOTQ4YTFiOTM0MDIxY2M3ZjE2MGQ3XzIxOTkwMjMyODQyMjc_5668eaee-1a32-4af0-8303-0645c3dd1943"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90ZXh0cmVnaW9uOmVlODU5MWQ5MmNkOTQ4YTFiOTM0MDIxY2M3ZjE2MGQ3XzIxOTkwMjMyODQyMjc_c43af010-5209-43ae-93e7-8c631d01f7ca"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90ZXh0cmVnaW9uOmVlODU5MWQ5MmNkOTQ4YTFiOTM0MDIxY2M3ZjE2MGQ3XzIxOTkwMjMyODQyMjk_8e2fbc4d-f1f0-4aa8-b721-467440bc4164"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90ZXh0cmVnaW9uOmVlODU5MWQ5MmNkOTQ4YTFiOTM0MDIxY2M3ZjE2MGQ3XzIxOTkwMjMyODQyMjk_97f81ee1-66e0-43fe-b48a-738d5d055710"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90ZXh0cmVnaW9uOmVlODU5MWQ5MmNkOTQ4YTFiOTM0MDIxY2M3ZjE2MGQ3XzIxOTkwMjMyNzg5ODU_366c06b8-5f6d-4ff0-9681-d15907243c5b">&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Losses before income taxes includes the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.451%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(53,547)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(78,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(1,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(1,943)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(54,573)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(80,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo2M2M0NzgzYmQ0MTc0ZGY5YTc5ZGJjNzE1NzQxMzZjMy90YWJsZXJhbmdlOjYzYzQ3ODNiZDQxNzRkZjlhNzlkYmM3MTU3NDEzNmMzXzItMS0xLTEtMzc4MDY_8d0da61a-25a4-4e6a-91f0-c7e6da586b95"
      unitRef="usd">-53547000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo2M2M0NzgzYmQ0MTc0ZGY5YTc5ZGJjNzE1NzQxMzZjMy90YWJsZXJhbmdlOjYzYzQ3ODNiZDQxNzRkZjlhNzlkYmM3MTU3NDEzNmMzXzItMy0xLTEtMzc4MDg_7fba45bb-b628-4dbf-a1d0-6242a12cd580"
      unitRef="usd">-78164000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo2M2M0NzgzYmQ0MTc0ZGY5YTc5ZGJjNzE1NzQxMzZjMy90YWJsZXJhbmdlOjYzYzQ3ODNiZDQxNzRkZjlhNzlkYmM3MTU3NDEzNmMzXzMtMS0xLTEtMzc4MDY_a23c2921-e8c7-4b0e-ab27-7f5f2459f5d7"
      unitRef="usd">-1026000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo2M2M0NzgzYmQ0MTc0ZGY5YTc5ZGJjNzE1NzQxMzZjMy90YWJsZXJhbmdlOjYzYzQ3ODNiZDQxNzRkZjlhNzlkYmM3MTU3NDEzNmMzXzMtMy0xLTEtMzc4MDg_2350e8d6-673d-48a7-a133-6b5b9df4c990"
      unitRef="usd">-1943000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo2M2M0NzgzYmQ0MTc0ZGY5YTc5ZGJjNzE1NzQxMzZjMy90YWJsZXJhbmdlOjYzYzQ3ODNiZDQxNzRkZjlhNzlkYmM3MTU3NDEzNmMzXzQtMS0xLTEtMzc4MDY_e8e0da4f-4e94-4d6c-b047-206caae6fed1"
      unitRef="usd">-54573000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo2M2M0NzgzYmQ0MTc0ZGY5YTc5ZGJjNzE1NzQxMzZjMy90YWJsZXJhbmdlOjYzYzQ3ODNiZDQxNzRkZjlhNzlkYmM3MTU3NDEzNmMzXzQtMy0xLTEtMzc4MDg_4ca36ff2-fd20-47b9-8f1c-764a29db165a"
      unitRef="usd">-80107000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90ZXh0cmVnaW9uOmVlODU5MWQ5MmNkOTQ4YTFiOTM0MDIxY2M3ZjE2MGQ3XzY1OTcwNjk3NzE4NTA_9e1b4f93-2397-4851-a714-7b246c439f22">&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes provision (benefit) for the years ended December&#160;31, 2021 and 2020 consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.451%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Current&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(5,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(12,129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(4,779)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(522)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;10,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;12,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzMtMS0xLTEtMjI1NDU_1a3047fe-c703-49a1-86d5-348f7b08ae6c"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzMtMy0xLTEtMjI1NDU_4dca68fd-15b8-4b06-9de9-08d467be97d2"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzQtMS0xLTEtMjI1NDU_366b76ec-801d-455a-8c97-9a93a4ef4839"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzQtMy0xLTEtMjI1NDU_29eb2974-9d54-46ed-b6ad-b675c4b8398c"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzUtMS0xLTEtMjI1NDU_1c8a1d2f-e610-4269-b45a-cb257141599c"
      unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzUtMy0xLTEtMjI1NDU_cfac148f-69ba-4bd1-96a0-455e0ea40da8"
      unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzYtMS0xLTEtMjQ0NjI_a35344d9-f707-4cf7-9ebe-2a3fa01d1eca"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzYtMy0xLTEtMjQ0NjI_e82e2d56-7f45-4ce4-9a84-1aac3a979e74"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzktMS0xLTEtMjI1NDU_c6ac5b04-8cd1-4d42-9fda-ab18f1a7246b"
      unitRef="usd">-5460000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzktMy0xLTEtMjI1NDU_26733c44-c124-4931-a820-89e2f1f69e80"
      unitRef="usd">-12129000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzEwLTEtMS0xLTIyNTQ1_25b0e87c-d9b2-4e6f-8707-82607f83b24b"
      unitRef="usd">-4779000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzEwLTMtMS0xLTIyNTQ1_ec8f0519-cf3d-4af4-85ca-f2df566634b0"
      unitRef="usd">-522000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzExLTEtMS0xLTIyNTQ1_c5caf402-baeb-42ee-910a-1be295c12c61"
      unitRef="usd">10239000</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability>
    <us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzExLTMtMS0xLTIyNTQ1_1adfad6a-dc67-49e9-a355-e251f9f93d92"
      unitRef="usd">12651000</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzEyLTEtMS0xLTI0NDY2_93050bb9-b847-4a89-b1d4-64b5a2960302"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzEyLTMtMS0xLTI0NDY2_6bc5ac6f-6a82-489e-9b7a-1ed6263a44ce"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzEzLTEtMS0xLTIyNTQ1_41d1c631-e48b-41bb-a94a-920b6e75783c"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNjMyYjAzOWI4YWY0N2Q0OTUxZDE2MzYyYWU1NjEzZS90YWJsZXJhbmdlOjA2MzJiMDM5YjhhZjQ3ZDQ5NTFkMTYzNjJhZTU2MTNlXzEzLTMtMS0xLTIyNTQ1_4a42dadf-851f-4360-9758-84310ce95060"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90ZXh0cmVnaW9uOmVlODU5MWQ5MmNkOTQ4YTFiOTM0MDIxY2M3ZjE2MGQ3XzIxOTkwMjMyNjA3NDc_2448ff3c-8d75-44b2-a44a-d86a88eda0af">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliations between the federal statutory income tax rate and the Company's effective income tax rate were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.451%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;State taxes, net of federal tax benefit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Interest &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;R&amp;amp;D and other tax credit changes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Permanent items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Nontaxable Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(10.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(15.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Effective income tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzItMS0xLTEtMjI1NDU_334845d7-553d-4d72-9d9d-02218f123d03"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzItMy0xLTEtMjI1NDU_83c2c5c8-9dae-4f68-9ea9-7bc6deec3312"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzMtMS0xLTEtMjI1NDU_58d373da-6e69-4f38-b998-68d530c3f692"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzMtMy0xLTEtMjI1NDU_366ca1cf-e21b-4aa1-b8b7-785af130c002"
      unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzQtMS0xLTEtMjI1NDU_5d63737a-bbd0-4f00-ae0a-3e90b02caaac"
      unitRef="number">-0.023</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzQtMy0xLTEtMjI1NDU_d8d68420-4c9e-4f74-bc52-4ea25df8f101"
      unitRef="number">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzUtMS0xLTEtMjI1NDU_486008a3-bd00-4b95-bff8-fdcd6330735a"
      unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzUtMy0xLTEtMjI1NDU_a10bb89a-65de-468b-a6eb-602d3fc99a45"
      unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <angn:EffectiveIncomeTaxRateReconciliationInterestPercent
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzYtMS0xLTEtMzYwNDY_4d106bec-6703-4a82-9598-713166011108"
      unitRef="number">-0.043</angn:EffectiveIncomeTaxRateReconciliationInterestPercent>
    <angn:EffectiveIncomeTaxRateReconciliationInterestPercent
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzYtMy0xLTEtMzYwNDY_5280812a-748a-498a-97f6-bd71d49645b9"
      unitRef="number">0</angn:EffectiveIncomeTaxRateReconciliationInterestPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzYtMS0xLTEtMjI1NDU_943b3a7f-dcce-4f6f-adc9-9b2b8238ab79"
      unitRef="number">-0.028</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzYtMy0xLTEtMjI1NDU_acab58c0-373e-4f64-a7b5-1816993b9e95"
      unitRef="number">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <angn:EffectiveIncomeTaxRateReconciliationPermanentItemsPercent
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzctMS0xLTEtMjI1NDU_7c7a7faa-7f76-45c3-aaca-1a90bf638d65"
      unitRef="number">-0.073</angn:EffectiveIncomeTaxRateReconciliationPermanentItemsPercent>
    <angn:EffectiveIncomeTaxRateReconciliationPermanentItemsPercent
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzctMy0xLTEtMjI1NDU_de37894b-fbca-4c38-82ad-a17046c4de80"
      unitRef="number">-0.047</angn:EffectiveIncomeTaxRateReconciliationPermanentItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzktMS0xLTEtMzYwNTU_7b47ae0e-3fc8-4543-8db6-b90ed570fa9e"
      unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzktMy0xLTEtMzYwNTU_49211689-85a9-4a03-8a35-a5db61eaf35b"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxExemptIncome>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzgtMS0xLTEtMjI1NDU_59548f63-fd28-4dac-a1e3-2e511e9b4048"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzgtMy0xLTEtMjI1NDU_4141109e-a258-446a-8b6a-463fb8bcd13c"
      unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzktMS0xLTEtMjI1NDU_0c8717df-aa65-416e-a1b9-ffcdedbea25e"
      unitRef="number">-0.101</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzktMy0xLTEtMjI1NDU_d10c2f22-5d44-4dc9-9c9d-cad21f22111c"
      unitRef="number">-0.158</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzEwLTEtMS0xLTIyNTQ1_8751da35-dc8d-49a6-8023-6ed37bdcaf9d"
      unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZToxYjNlMDM2ODc4ZTQ0MjJmYTAwMmJkMTU2MzUxODQzNS90YWJsZXJhbmdlOjFiM2UwMzY4NzhlNDQyMmZhMDAyYmQxNTYzNTE4NDM1XzEwLTMtMS0xLTIyNTQ1_72bf1ebf-fc82-4078-b584-4fb084ea5486"
      unitRef="number">-0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90ZXh0cmVnaW9uOmVlODU5MWQ5MmNkOTQ4YTFiOTM0MDIxY2M3ZjE2MGQ3XzIxOTkwMjMyNjA3NDg_3424dc38-b5f6-446b-a555-0ee67095dd5c">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company's deferred tax asset at December&#160;31, 2021 and 2020 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;29,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;22,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;R&amp;amp;D and other tax credit carryovers&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;6,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Lease liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued compensation and other expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fixed assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;40,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;30,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fixed assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Right of use assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1,046)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(874)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Valuation allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(39,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(29,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Deferred tax assets, net of allowance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzMtMS0xLTEtMjI1NDU_c01baa60-4e46-4d7f-b33f-ecd6ad4794ac"
      unitRef="usd">29211000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzMtMy0xLTEtMjI1NDU_7ef052a5-b0b8-47dd-a7d4-b9f5125292f4"
      unitRef="usd">22686000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzQtMS0xLTEtMjI1NDU_96535dfc-3c53-460d-afd9-188146634120"
      unitRef="usd">6752000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzQtMy0xLTEtMjI1NDU_44bd9a56-ff76-4cdd-bdd5-ed3bdcf62c6d"
      unitRef="usd">4718000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <angn:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzUtMS0xLTEtMjI1NDU_80fc24ef-70b1-4df3-bfc7-ad758c242396"
      unitRef="usd">1224000</angn:DeferredTaxAssetsOperatingLeaseLiability>
    <angn:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzUtMy0xLTEtMjI1NDU_d88e9bed-215b-4704-ac5a-b09cff9180b9"
      unitRef="usd">956000</angn:DeferredTaxAssetsOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzYtMS0xLTEtMjI1NDU_cbb26af4-92b0-4e3b-9436-7af44ab49ad2"
      unitRef="usd">3070000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzYtMy0xLTEtMjI1NDU_30830830-1ab8-4691-8ae9-6a4703ebe994"
      unitRef="usd">1323000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzctMS0xLTEtMjI1NDU_568de8b5-5177-4cbb-a922-fbabf749f520"
      unitRef="usd">536000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzctMy0xLTEtMjI1NDU_d85c6e7d-3057-4229-9d30-f70b7d8b7be8"
      unitRef="usd">658000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzgtMS0xLTEtMjI1NDU_0db9815d-15e9-4927-8b7e-7decfbdf56ba"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzgtMy0xLTEtMjI1NDU_ccb46fd1-022b-445d-b7ba-59afe732cd48"
      unitRef="usd">3000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzktMS0xLTEtMjI1NDU_8f1d236e-af2e-4eae-9bd8-7b5cd8e48374"
      unitRef="usd">40793000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzktMy0xLTEtMjI1NDU_56875c76-2957-473e-b21f-eea71a793782"
      unitRef="usd">30344000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzExLTEtMS0xLTM2MDY2_cf9ab297-d7a1-4f1e-9811-ca9b7c76863b"
      unitRef="usd">37000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzExLTMtMS0xLTM2MDY2_9d11c2cf-a4a8-4e5e-9c0c-2a2283e3d112"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzExLTEtMS0xLTIyNTQ1_936e1a03-f504-47e8-afcb-6982134a587b"
      unitRef="usd">1046000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzExLTMtMS0xLTIyNTQ1_296e0fc6-3edc-4c5f-8ba3-baa03b5ca297"
      unitRef="usd">874000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzEyLTEtMS0xLTIyNTQ1_9f371ec8-7df2-489f-b02f-8b4a2243fb3a"
      unitRef="usd">39710000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzEyLTMtMS0xLTIyNTQ1_47d0af02-4a0f-43b4-b33c-db7b0fd99e57"
      unitRef="usd">29470000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzEzLTEtMS0xLTIyNTQ1_21cd3a5a-af1d-4fee-aa0a-808098d488eb"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo4OWIzYmY2YmFjNzY0ZjQ0OGNmNzUxOWU2ZWU4YTRmNi90YWJsZXJhbmdlOjg5YjNiZjZiYWM3NjRmNDQ4Y2Y3NTE5ZTZlZThhNGY2XzEzLTMtMS0xLTIyNTQ1_bb021264-e1da-4161-af29-0eca36d2916c"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90ZXh0cmVnaW9uOmVlODU5MWQ5MmNkOTQ4YTFiOTM0MDIxY2M3ZjE2MGQ3XzEwOTk1MTE2NDkwNTA_c926726f-4859-454f-95bf-e48e93a730e9"
      unitRef="usd">118500000</us-gaap:OperatingLossCarryforwards>
    <angn:OperatingLossCarryforwardSubjectToExpiration
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90ZXh0cmVnaW9uOmVlODU5MWQ5MmNkOTQ4YTFiOTM0MDIxY2M3ZjE2MGQ3XzE2NDkyNjc0NTM2ODM_aa4259bf-a9f3-4595-a632-dc2893fde318"
      unitRef="usd">9600000</angn:OperatingLossCarryforwardSubjectToExpiration>
    <angn:OperatingLossCarryforwardNotSubjectToExpiration
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90ZXh0cmVnaW9uOmVlODU5MWQ5MmNkOTQ4YTFiOTM0MDIxY2M3ZjE2MGQ3XzE2NDkyNjc0NTM2Njk_d6c5f6a7-2934-4898-be0c-ec090b4d1c0d"
      unitRef="usd">108900000</angn:OperatingLossCarryforwardNotSubjectToExpiration>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90ZXh0cmVnaW9uOmVlODU5MWQ5MmNkOTQ4YTFiOTM0MDIxY2M3ZjE2MGQ3XzE2NDkyNjc0NTg1NjU_a4f93a3a-2381-478a-b6fc-9f01fdff110a"
      unitRef="usd">3700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90ZXh0cmVnaW9uOmVlODU5MWQ5MmNkOTQ4YTFiOTM0MDIxY2M3ZjE2MGQ3XzYwNDczMTM5NTgwMzk_452e7b16-92d9-46ec-ae66-597734fef960">&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reconciliation of uncertain tax positions as of December 31, 2021 and 2020 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Beginning Balance &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additions for current year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:10pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additions for prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Ending Balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNWRmYjkwMzFiODI0NGY4YWJkZTk4ZDFjYWJkM2Q2OS90YWJsZXJhbmdlOjA1ZGZiOTAzMWI4MjQ0ZjhhYmRlOThkMWNhYmQzZDY5XzItMS0xLTEtMjQ1Njk_a9159197-bbd0-4f91-8701-cca2405ab8c6"
      unitRef="usd">2579000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i08c03f72f0b941539e5cdcb6bd71e375_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNWRmYjkwMzFiODI0NGY4YWJkZTk4ZDFjYWJkM2Q2OS90YWJsZXJhbmdlOjA1ZGZiOTAzMWI4MjQ0ZjhhYmRlOThkMWNhYmQzZDY5XzItMy0xLTEtMjQ1NzU_17d6e47d-9879-4f88-bbf8-aa1e9c3b165d"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNWRmYjkwMzFiODI0NGY4YWJkZTk4ZDFjYWJkM2Q2OS90YWJsZXJhbmdlOjA1ZGZiOTAzMWI4MjQ0ZjhhYmRlOThkMWNhYmQzZDY5XzQtMS0xLTEtMjQ1NzE_46037ace-1ef2-43c5-bb64-5308625cbb7c"
      unitRef="usd">1073000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNWRmYjkwMzFiODI0NGY4YWJkZTk4ZDFjYWJkM2Q2OS90YWJsZXJhbmdlOjA1ZGZiOTAzMWI4MjQ0ZjhhYmRlOThkMWNhYmQzZDY5XzQtMy0xLTEtMjQ1Nzc_029ffe23-1a6f-4014-8b2a-7926ff1cceb2"
      unitRef="usd">633000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNWRmYjkwMzFiODI0NGY4YWJkZTk4ZDFjYWJkM2Q2OS90YWJsZXJhbmdlOjA1ZGZiOTAzMWI4MjQ0ZjhhYmRlOThkMWNhYmQzZDY5XzUtMS0xLTEtMjQ1NzE_bfa2b411-1c83-44da-8222-fc9f5f40c75b"
      unitRef="usd">23000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNWRmYjkwMzFiODI0NGY4YWJkZTk4ZDFjYWJkM2Q2OS90YWJsZXJhbmdlOjA1ZGZiOTAzMWI4MjQ0ZjhhYmRlOThkMWNhYmQzZDY5XzUtMy0xLTEtMjQ1Nzc_b7232014-2cdb-4584-a63f-81067e28af08"
      unitRef="usd">1946000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNWRmYjkwMzFiODI0NGY4YWJkZTk4ZDFjYWJkM2Q2OS90YWJsZXJhbmdlOjA1ZGZiOTAzMWI4MjQ0ZjhhYmRlOThkMWNhYmQzZDY5XzEwLTEtMS0xLTI0NTcz_2d57040e-bc77-4db3-a17d-0ac21c77ad05"
      unitRef="usd">3675000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTowNWRmYjkwMzFiODI0NGY4YWJkZTk4ZDFjYWJkM2Q2OS90YWJsZXJhbmdlOjA1ZGZiOTAzMWI4MjQ0ZjhhYmRlOThkMWNhYmQzZDY5XzEwLTMtMS0xLTI0NTc5_452576b4-02e6-4d18-b0ea-74bead2935d0"
      unitRef="usd">2579000</us-gaap:UnrecognizedTaxBenefits>
    <angn:UnrecognizedTaxBenefitsIfRecognizedWouldAffectTheEffectiveTaxRateTableTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90ZXh0cmVnaW9uOmVlODU5MWQ5MmNkOTQ4YTFiOTM0MDIxY2M3ZjE2MGQ3XzYwNDczMTM5NTgwNDA_a0e081a1-2649-4791-92bf-1a0e8f11f21f">&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total amount of unrecognized tax benefits, if recognized, would affect the effective tax rate was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Unrecognized benefits that would affect the effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Unrecognized benefits that would not affect the effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total unrecognized benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;2,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</angn:UnrecognizedTaxBenefitsIfRecognizedWouldAffectTheEffectiveTaxRateTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo1MjhhMjA1ZWIzYjE0MTNiYWI3ZDU2MjQwZDc0MTQ1ZS90YWJsZXJhbmdlOjUyOGEyMDVlYjNiMTQxM2JhYjdkNTYyNDBkNzQxNDVlXzEtMS0xLTEtMjQ1ODE_b642b47f-21c7-4c53-8f2a-073b86044279"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo1MjhhMjA1ZWIzYjE0MTNiYWI3ZDU2MjQwZDc0MTQ1ZS90YWJsZXJhbmdlOjUyOGEyMDVlYjNiMTQxM2JhYjdkNTYyNDBkNzQxNDVlXzItMy0xLTEtNDAzMTE_abf28a0c-d0e8-4739-9136-5b737942205e"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <angn:UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo1MjhhMjA1ZWIzYjE0MTNiYWI3ZDU2MjQwZDc0MTQ1ZS90YWJsZXJhbmdlOjUyOGEyMDVlYjNiMTQxM2JhYjdkNTYyNDBkNzQxNDVlXzItMS0xLTEtMjQ1ODE_f6af49e0-0fca-497a-9a7d-174d75f8acde"
      unitRef="usd">3675000</angn:UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate>
    <angn:UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo1MjhhMjA1ZWIzYjE0MTNiYWI3ZDU2MjQwZDc0MTQ1ZS90YWJsZXJhbmdlOjUyOGEyMDVlYjNiMTQxM2JhYjdkNTYyNDBkNzQxNDVlXzMtMy0xLTEtNDAzMTE_ebc20c85-b68f-4881-9d23-655450c623fa"
      unitRef="usd">2579000</angn:UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo1MjhhMjA1ZWIzYjE0MTNiYWI3ZDU2MjQwZDc0MTQ1ZS90YWJsZXJhbmdlOjUyOGEyMDVlYjNiMTQxM2JhYjdkNTYyNDBkNzQxNDVlXzMtMS0xLTEtMjQ1ODE_6433b2b1-ecd5-4c71-8f26-888363a3ba5a"
      unitRef="usd">3675000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xMzkvZnJhZzplZTg1OTFkOTJjZDk0OGExYjkzNDAyMWNjN2YxNjBkNy90YWJsZTo1MjhhMjA1ZWIzYjE0MTNiYWI3ZDU2MjQwZDc0MTQ1ZS90YWJsZXJhbmdlOjUyOGEyMDVlYjNiMTQxM2JhYjdkNTYyNDBkNzQxNDVlXzQtMy0xLTEtNDAzMTE_7cf9bfcd-2030-40fd-ad0f-154e8d50bc62"
      unitRef="usd">2579000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:DefinedContributionPlanTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDIvZnJhZzpiZTM0MWU3YWEyZTQ0YWMyOTI5NGUyZjNkZTQxNWNhZS90ZXh0cmVnaW9uOmJlMzQxZTdhYTJlNDRhYzI5Mjk0ZTJmM2RlNDE1Y2FlXzMyOTg1MzQ4ODM5NjI_a818167c-7569-4246-af32-712a0fb01dfa">Employee Benefit PlanEmployee Benefit PlanThe Company sponsors a retirement savings plan that is intended to qualify for favorable tax treatment under Section 401(a) of the Code, and contains a cash or deferred feature that is intended to meet the requirements of Section 401(k) of the Code. Participants may make pre-tax and certain after-tax (Roth) salary deferral contributions to the plan from their eligible earnings up to the statutorily prescribed annual limit under the Code. Participants who are 50 years of age or older may contribute additional amounts based on the statutory limits for catch-up contributions. Participant contributions are held in trust as required by law. No minimum benefit is provided under the plan. An employee&#x2019;s interest in his or her salary deferral contributions is 100% vested when contributed. Contributions, subject to established limits, are matched at a dollar for dollar rate up to 3% of an individual&#x2019;s earnings and fifty cents on the dollar on the next 4-5% of earnings.</us-gaap:DefinedContributionPlanTextBlock>
    <us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDIvZnJhZzpiZTM0MWU3YWEyZTQ0YWMyOTI5NGUyZjNkZTQxNWNhZS90ZXh0cmVnaW9uOmJlMzQxZTdhYTJlNDRhYzI5Mjk0ZTJmM2RlNDE1Y2FlXzEwOTk1MTE2MzAwMTk_bd48ca73-ebff-46e7-9722-ee7d7643901b"
      unitRef="number">1</us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage>
    <angn:DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayOneHundredPercentEmployerMatch
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDIvZnJhZzpiZTM0MWU3YWEyZTQ0YWMyOTI5NGUyZjNkZTQxNWNhZS90ZXh0cmVnaW9uOmJlMzQxZTdhYTJlNDRhYzI5Mjk0ZTJmM2RlNDE1Y2FlXzEwOTk1MTE2MzAwMjM_58930adf-3e01-41e0-894a-004d1bde65ad"
      unitRef="number">0.03</angn:DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayOneHundredPercentEmployerMatch>
    <angn:DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayFiftyPercentEmployerMatch
      contextRef="i1461dc15821341d7a6cca5de3d10b493_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDIvZnJhZzpiZTM0MWU3YWEyZTQ0YWMyOTI5NGUyZjNkZTQxNWNhZS90ZXh0cmVnaW9uOmJlMzQxZTdhYTJlNDRhYzI5Mjk0ZTJmM2RlNDE1Y2FlXzEwOTk1MTE2MzAwMjc_303c31ba-c9da-4cc7-a16f-0740ee425d51"
      unitRef="number">4</angn:DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayFiftyPercentEmployerMatch>
    <angn:DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayFiftyPercentEmployerMatch
      contextRef="i49372af6f1524e94bc325a0b4866deb5_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDIvZnJhZzpiZTM0MWU3YWEyZTQ0YWMyOTI5NGUyZjNkZTQxNWNhZS90ZXh0cmVnaW9uOmJlMzQxZTdhYTJlNDRhYzI5Mjk0ZTJmM2RlNDE1Y2FlXzEwOTk1MTE2MzAwMzE_3e959a86-bb9e-4187-8cac-2f82913da224"
      unitRef="number">0.05</angn:DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayFiftyPercentEmployerMatch>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90ZXh0cmVnaW9uOmUxZTJkOGE4MjNlMDQxZmJhMjQwMzg3NjJlMmUzYzQ3XzMyOTg1MzQ4ODQyOTk_87f3e6db-d62d-48e2-a082-dd8b51c47317">Net Loss Per Share&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of the Company&#x2019;s basic and diluted net loss per share attributable to common stockholders, which excludes shares which are legally outstanding but subject to repurchase by the Company (in thousands, except share and per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Numerator&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(54,573)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(80,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,244,825&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,762,120&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Net loss per share attributable to common stockholders, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(1.93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(5.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share because to do so would be anti-dilutive:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Shares issuable upon exercise of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,230,162&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,479,731&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Shares issuable upon the exercise of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,148,123&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,739,791&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Shares issuable upon conversion of the convertible notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;5,603,388&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Shares issuable upon conversion of the Series C preferred stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;3,920,172&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Non-vested shares under restricted stock unit grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;203,015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;58,951&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Non-vested shares under restricted stock grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;14,585&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;5,581,300&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;15,816,618&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;___________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:49.5pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.24pt"&gt;The number of shares issuable upon conversion of the 2019 Notes, 2020 Notes and Series C preferred stock has been estimated using the Company's common stock fair value at December 31, 2020, discounted by 20%.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90ZXh0cmVnaW9uOmUxZTJkOGE4MjNlMDQxZmJhMjQwMzg3NjJlMmUzYzQ3XzMyOTg1MzQ4ODQzMDA_56b7b9e6-80f6-4d19-8d69-dd9548cbfb4c">&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of the Company&#x2019;s basic and diluted net loss per share attributable to common stockholders, which excludes shares which are legally outstanding but subject to repurchase by the Company (in thousands, except share and per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.403%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Numerator&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(54,573)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(80,107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,244,825&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,762,120&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Net loss per share attributable to common stockholders, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(1.93)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;(5.43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTo3YTZkODZiOTY4YmI0NjY4ODJjMTllNmEyOGQ2ZGEyZS90YWJsZXJhbmdlOjdhNmQ4NmI5NjhiYjQ2Njg4MmMxOWU2YTI4ZDZkYTJlXzMtMS0xLTEtMjI1NDU_811dc8e2-78ce-4d50-9048-f8960f79f901"
      unitRef="usd">-54573000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTo3YTZkODZiOTY4YmI0NjY4ODJjMTllNmEyOGQ2ZGEyZS90YWJsZXJhbmdlOjdhNmQ4NmI5NjhiYjQ2Njg4MmMxOWU2YTI4ZDZkYTJlXzMtMy0xLTEtMjI1NDU_f024e993-06db-4a34-84dd-a47f4722ad41"
      unitRef="usd">-80107000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTo3YTZkODZiOTY4YmI0NjY4ODJjMTllNmEyOGQ2ZGEyZS90YWJsZXJhbmdlOjdhNmQ4NmI5NjhiYjQ2Njg4MmMxOWU2YTI4ZDZkYTJlXzctMS0xLTEtMjI1NDU_b053e388-2420-4d58-a1be-ff9207ce26ba"
      unitRef="shares">28244825</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTo3YTZkODZiOTY4YmI0NjY4ODJjMTllNmEyOGQ2ZGEyZS90YWJsZXJhbmdlOjdhNmQ4NmI5NjhiYjQ2Njg4MmMxOWU2YTI4ZDZkYTJlXzctMS0xLTEtMjI1NDU_bdf11b30-ebc3-40e0-949d-5b1cb2f1b261"
      unitRef="shares">28244825</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTo3YTZkODZiOTY4YmI0NjY4ODJjMTllNmEyOGQ2ZGEyZS90YWJsZXJhbmdlOjdhNmQ4NmI5NjhiYjQ2Njg4MmMxOWU2YTI4ZDZkYTJlXzctMy0xLTEtMjI1NDU_5f821b47-2b55-4bc3-877a-b2986a15d002"
      unitRef="shares">14762120</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTo3YTZkODZiOTY4YmI0NjY4ODJjMTllNmEyOGQ2ZGEyZS90YWJsZXJhbmdlOjdhNmQ4NmI5NjhiYjQ2Njg4MmMxOWU2YTI4ZDZkYTJlXzctMy0xLTEtMjI1NDU_edeeb49c-5410-4c91-9ba0-5d6a115ab741"
      unitRef="shares">14762120</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTo3YTZkODZiOTY4YmI0NjY4ODJjMTllNmEyOGQ2ZGEyZS90YWJsZXJhbmdlOjdhNmQ4NmI5NjhiYjQ2Njg4MmMxOWU2YTI4ZDZkYTJlXzgtMS0xLTEtMjI1NDU_9e94d9e0-8cc1-4e4b-9043-c564cc4b0293"
      unitRef="usdPerShare">-1.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTo3YTZkODZiOTY4YmI0NjY4ODJjMTllNmEyOGQ2ZGEyZS90YWJsZXJhbmdlOjdhNmQ4NmI5NjhiYjQ2Njg4MmMxOWU2YTI4ZDZkYTJlXzgtMS0xLTEtMjI1NDU_fd7589f0-1789-4405-ac95-721e3c267785"
      unitRef="usdPerShare">-1.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTo3YTZkODZiOTY4YmI0NjY4ODJjMTllNmEyOGQ2ZGEyZS90YWJsZXJhbmdlOjdhNmQ4NmI5NjhiYjQ2Njg4MmMxOWU2YTI4ZDZkYTJlXzgtMy0xLTEtMjI1NDU_4ee713f8-e894-4925-928f-40f6a83ed182"
      unitRef="usdPerShare">-5.43</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTo3YTZkODZiOTY4YmI0NjY4ODJjMTllNmEyOGQ2ZGEyZS90YWJsZXJhbmdlOjdhNmQ4NmI5NjhiYjQ2Njg4MmMxOWU2YTI4ZDZkYTJlXzgtMy0xLTEtMjI1NDU_f5120ec4-9911-4b90-8cfe-8c3eb5a7a888"
      unitRef="usdPerShare">-5.43</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90ZXh0cmVnaW9uOmUxZTJkOGE4MjNlMDQxZmJhMjQwMzg3NjJlMmUzYzQ3XzMyOTg1MzQ4ODQzMDE_7a10b93c-e893-4938-8ec8-32575162a78a">The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share because to do so would be anti-dilutive:&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.848%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.124%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Shares issuable upon exercise of stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,230,162&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,479,731&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Shares issuable upon the exercise of warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,148,123&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,739,791&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Shares issuable upon conversion of the convertible notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;5,603,388&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Shares issuable upon conversion of the Series C preferred stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;3,920,172&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Non-vested shares under restricted stock unit grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;203,015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;58,951&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Non-vested shares under restricted stock grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;14,585&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;5,581,300&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;15,816,618&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;___________________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:49.5pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:17.24pt"&gt;The number of shares issuable upon conversion of the 2019 Notes, 2020 Notes and Series C preferred stock has been estimated using the Company's common stock fair value at December 31, 2020, discounted by 20%.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ief165a389cc44da0a2f2c5c214517d94_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTpjMjkzNWE5OWEwOWI0MWEyOGU4ZWRiNWEyNTg2OTQ0YS90YWJsZXJhbmdlOmMyOTM1YTk5YTA5YjQxYTI4ZThlZGI1YTI1ODY5NDRhXzItMS0xLTEtMjI1NDU_43ec91a0-1d1f-4202-b02d-f346bbfa0ea5"
      unitRef="shares">4230162</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iad85a45e0dbd4ab7a6756cc10a24ecbd_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTpjMjkzNWE5OWEwOWI0MWEyOGU4ZWRiNWEyNTg2OTQ0YS90YWJsZXJhbmdlOmMyOTM1YTk5YTA5YjQxYTI4ZThlZGI1YTI1ODY5NDRhXzItMy0xLTEtMjI1NDU_0bb16426-72b2-42bf-8166-0d43604bc621"
      unitRef="shares">3479731</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i43a2b3ab97bd48fbbe083e2b87ed4fa9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTpjMjkzNWE5OWEwOWI0MWEyOGU4ZWRiNWEyNTg2OTQ0YS90YWJsZXJhbmdlOmMyOTM1YTk5YTA5YjQxYTI4ZThlZGI1YTI1ODY5NDRhXzMtMS0xLTEtMjI1NDU_5755b671-f512-4e5a-bf1b-3c1e69fb4c91"
      unitRef="shares">1148123</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iac1a9fb579254c0480b5589b1c009eb5_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTpjMjkzNWE5OWEwOWI0MWEyOGU4ZWRiNWEyNTg2OTQ0YS90YWJsZXJhbmdlOmMyOTM1YTk5YTA5YjQxYTI4ZThlZGI1YTI1ODY5NDRhXzMtMy0xLTEtMjI1NDU_7945944b-c53c-4c04-8c09-dae0a3ec5cc3"
      unitRef="shares">2739791</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i61bbd5c3b1454d27b052909fc297f17e_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTpjMjkzNWE5OWEwOWI0MWEyOGU4ZWRiNWEyNTg2OTQ0YS90YWJsZXJhbmdlOmMyOTM1YTk5YTA5YjQxYTI4ZThlZGI1YTI1ODY5NDRhXzQtMS0xLTEtMjI1NDU_efa374d7-cc96-4ba0-abeb-b9c65d63558d"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ieed9eb60e9b8413cacd41a553ad6bd3f_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTpjMjkzNWE5OWEwOWI0MWEyOGU4ZWRiNWEyNTg2OTQ0YS90YWJsZXJhbmdlOmMyOTM1YTk5YTA5YjQxYTI4ZThlZGI1YTI1ODY5NDRhXzQtMy0xLTEtMjI1NDU_92e7e033-9b31-41aa-ab6c-187179e94319"
      unitRef="shares">5603388</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i02a82bc7014f4eb19de71fe9d69bdca3_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTpjMjkzNWE5OWEwOWI0MWEyOGU4ZWRiNWEyNTg2OTQ0YS90YWJsZXJhbmdlOmMyOTM1YTk5YTA5YjQxYTI4ZThlZGI1YTI1ODY5NDRhXzUtMS0xLTEtMjI1NDU_245ae6f2-5419-4d4e-bf99-cf09de7cfa6e"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i49f753c217c344e0805c4e8e7c263cd5_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTpjMjkzNWE5OWEwOWI0MWEyOGU4ZWRiNWEyNTg2OTQ0YS90YWJsZXJhbmdlOmMyOTM1YTk5YTA5YjQxYTI4ZThlZGI1YTI1ODY5NDRhXzUtMy0xLTEtMjI1NDU_5a44ee79-7d5a-46ae-9585-fb5d107fbcef"
      unitRef="shares">3920172</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i53245befe1874188ac185852fef3d5a1_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTpjMjkzNWE5OWEwOWI0MWEyOGU4ZWRiNWEyNTg2OTQ0YS90YWJsZXJhbmdlOmMyOTM1YTk5YTA5YjQxYTI4ZThlZGI1YTI1ODY5NDRhXzYtMS0xLTEtMjI1NDU_bcb8a369-e4ae-41a3-939a-d5596d9481e6"
      unitRef="shares">203015</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i83977ab456f040ddb39978debda8bbe4_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTpjMjkzNWE5OWEwOWI0MWEyOGU4ZWRiNWEyNTg2OTQ0YS90YWJsZXJhbmdlOmMyOTM1YTk5YTA5YjQxYTI4ZThlZGI1YTI1ODY5NDRhXzYtMy0xLTEtMjI1NDU_5700b70a-0416-47ad-9735-57db00d3393d"
      unitRef="shares">58951</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia0f25cf926ad4d1cb71681e8f131863c_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTpjMjkzNWE5OWEwOWI0MWEyOGU4ZWRiNWEyNTg2OTQ0YS90YWJsZXJhbmdlOmMyOTM1YTk5YTA5YjQxYTI4ZThlZGI1YTI1ODY5NDRhXzctMS0xLTEtMjI1NDU_ae5d2b45-fafe-4364-9b6e-6d8fd6fdc3e5"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if8ec568c6dc54174abe4f2ad93aeceac_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTpjMjkzNWE5OWEwOWI0MWEyOGU4ZWRiNWEyNTg2OTQ0YS90YWJsZXJhbmdlOmMyOTM1YTk5YTA5YjQxYTI4ZThlZGI1YTI1ODY5NDRhXzctMy0xLTEtMjI1NDU_3208c114-b6f6-48c4-87da-30a8ecfa024b"
      unitRef="shares">14585</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTpjMjkzNWE5OWEwOWI0MWEyOGU4ZWRiNWEyNTg2OTQ0YS90YWJsZXJhbmdlOmMyOTM1YTk5YTA5YjQxYTI4ZThlZGI1YTI1ODY5NDRhXzgtMS0xLTEtMjI1NDU_8cd6687f-62c7-490e-80ed-a491e4d7e5bf"
      unitRef="shares">5581300</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0b61075e36864f239db80f1d64b9ea62_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90YWJsZTpjMjkzNWE5OWEwOWI0MWEyOGU4ZWRiNWEyNTg2OTQ0YS90YWJsZXJhbmdlOmMyOTM1YTk5YTA5YjQxYTI4ZThlZGI1YTI1ODY5NDRhXzgtMy0xLTEtMjI1NDU_d5598455-b759-4557-b63c-3c912d910237"
      unitRef="shares">15816618</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <angn:SharesIssuableUponConversionOfConvertibleNotesDiscountRate
      contextRef="i1bc5ce1428404ed68895fc85d43b0940_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDUvZnJhZzplMWUyZDhhODIzZTA0MWZiYTI0MDM4NzYyZTJlM2M0Ny90ZXh0cmVnaW9uOmUxZTJkOGE4MjNlMDQxZmJhMjQwMzg3NjJlMmUzYzQ3XzMyOTg1MzQ4ODQzMDM_d57ca0c4-d687-474c-ae9e-91da591d4bd8"
      unitRef="number">0.20</angn:SharesIssuableUponConversionOfConvertibleNotesDiscountRate>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzMyOTg1MzQ4ODgwNDU_8c6adae9-8764-465b-85ea-0e361633261b">Related Party Transactions&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Ohr Investment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In a series of investments in November 2013 and July 2017, the Company invested a total of $150,000 to acquire a membership interest in Ohr Cosmetics, LLC ("Ohr"), an affiliated company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company owns and the family of the Company's director and Chairman Emeritus owns approximately 2.4% and 80.6%, respectively, of the membership interests in Ohr. Our Chief Executive Officer is also owns approximately 0.80% of the membership interests in Ohr. The Chairman Emeritus&#x2019;s son is the manager of Ohr.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2013, the Company granted Ohr an exclusive worldwide license, with the right to sublicense, under the Company's patent rights covering one of the Company's CYP26 inhibitors, ANG-3522, for the use in treating conditions of the skin or hair. Sublicensees may not grant further sublicenses under the Company's patent rights other than to affiliates of such sublicensees and entities with which sublicensees are collaborating for the research, development, manufacture and commercialization of the products. Ohr will pay the Company a royalty at a rate in the low single digits on gross revenue of products incorporating ANG-3522, and milestone payments potentially totaling up to $9.0&#160;million based on achievement of sales milestones. Royalties and milestone payments will be paid until the later of 15 years from the first commercial sale of a licensed product or the last to expire licensed patent rights. The royalty rate is subject to adjustments under certain circumstances. The Company believes that the Ohr License was made on terms no less favorable to the Company than those that the Company could obtain from unaffiliated third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No revenue from this license agreement was recognized for the years presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;NovaPark Investment and Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company had a 10% interest in NovaPark. Members of the Company's director and Chairman Emeritus&#x2019;s 's immediate family own a majority of the membership interests of NovaPark. The Company accounts for its aggregate 10% investment in NovaPark under the equity method. The following table provides the activity for the NovaPark investment for the years ended December&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.838%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Beginning balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Losses of equity method investment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Distribution from NovaPark&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Ending balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company rents office and laboratory space in Uniondale, New York from NovaPark under a lease that expires June 20, 2026. The Company recorded rent expense for fixed lease payments of $1.1 million and $1.0 million for the years ended December&#160;31, 2021 and 2020, respectively. The Company recorded rent expense for variable expenses related to the lease of $0.5 million and $0.6 million for the years ended December&#160;31, 2021 and 2020, respectively. See Note 11. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the IPO in February 2021, Victor Ganzi, Gilbert Omenn and Karen Wilson, directors of the Company, and Raj Venkatesan, brother of the Chief Executive Officer and director of the Company, converted all their outstanding convertible notes into an aggregate of 149,500 shares of common stock with a conversion price of $11.57. As of December&#160;31, 2021, there were no convertible notes outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Series C Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the IPO in February 2021, Jay Venkatesan, M.D., the President and Chief Executive Officer and director of the Company converted all his outstanding preferred stock into an aggregate of 165,094 shares of common stock with a conversion price of $11.57 per share. As of December&#160;31, 2021, there were no shares of convertible preferred stock outstanding.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consultant Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Angion paid consulting fees under an agreement with the wife of the director and Chairman Emeritus of the Company for Company management services. Consultant fees paid to the wife were approximately zero and $0.1 million in the years ended December&#160;31, 2021 and 2020, respectively. This consultant agreement was terminated in February 2022.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  Dr. Michael Yamin, a former member of the Board of Directors of the Company, is a Scientific Advisor for Pearl Cohen Zedek Latzer Baratz LLP (Pearl Cohen). In the years ended December&#160;31, 2021 and 2020, the Company paid Pearl Cohen $3.9&#160;thousand and $0.1&#160;million in legal fees, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2018, the Company also entered into a consulting agreement with Dr. Yamin pursuant to which he agreed to provide consulting services to the Company in the areas of biomedical research and development. Pursuant to the terms of the consulting agreement, Dr. Yamin, in his capacity as a consultant, received $0.1 million during each of the years ended December&#160;31, 2021 and 2020. Dr. Yamin resigned from the Company's Board of Directors in March 2020. Dr. Yamin's resignation was not due to any disagreement with the Company, the Board or management of the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:OtherInvestmentsAndSecuritiesAtCost
      contextRef="ibcf59fe47e7a4763a6e2bceeb52dd3ad_I20170731"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzE0Ng_52f56f12-9ec4-441d-bf64-0d7b4f85ce17"
      unitRef="usd">150000</us-gaap:OtherInvestmentsAndSecuritiesAtCost>
    <angn:OtherInvestmentAndSecuritiesAtCostOwnershipPercentage
      contextRef="i2aaa47df28a24e29abd67cbe8873e02c_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzMyMw_79deab4a-3f59-49f8-bf53-cdde38313fb1"
      unitRef="number">0.024</angn:OtherInvestmentAndSecuritiesAtCostOwnershipPercentage>
    <us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest
      contextRef="ie1f1c87d61094a8385e1928cbcdef76b_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzE2NDkyNjc0NDg4MDM_ba323867-387b-4e03-9b6c-2ae9096c521d"
      unitRef="number">0.806</us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest>
    <us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest
      contextRef="i334eff8b0f0f4134b32ad37b7a4d1913_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzE2NDkyNjc0NDk0Njc_65e683ed-32ae-4c7f-8ddf-d60ebe1087e2"
      unitRef="number">0.0080</us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest>
    <angn:RelatedPartyTransactionPotentialMaximumMilestonePayment
      contextRef="i8d2bf22513e944e391d7fad6085a8765_I20131130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzExMjU_3035cdc9-5c12-4cf8-8ff8-e886b48d434d"
      unitRef="usd">9000000</angn:RelatedPartyTransactionPotentialMaximumMilestonePayment>
    <angn:RelatedPartyTransactionRoyaltiesAndMilestonePaymentsPeriod
      contextRef="i65008406702b49f183286b36f4fbea14_D20131101-20131130"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzEyMzU_5b109854-7b9a-423f-a3ff-200cfa06c86f">P15Y</angn:RelatedPartyTransactionRoyaltiesAndMilestonePaymentsPeriod>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i84aca19f2bf6464d955946950b093dca_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzE1NzY_60024328-76d7-46b9-a9ac-8abe60d2e570"
      unitRef="usd">0</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i2e21962d26f9431d9076d02be4f4d666_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzE1NzY_e9e8927e-ed9a-4f6d-b4cc-27274b3ed0ea"
      unitRef="usd">0</us-gaap:RevenueFromRelatedParties>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i22b6851c4c8c4d8e9f955da168470856_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzE3MTQ_9cf37f56-a18d-4b81-8887-9089f6833c52"
      unitRef="number">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i22b6851c4c8c4d8e9f955da168470856_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzE4OTc_87e6a8ec-10d3-49ca-a9a3-c580431f5292"
      unitRef="number">0.10</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzMyOTg1MzQ4ODgwNDY_63abfaaa-139c-419a-a9db-759a17903dec">The following table provides the activity for the NovaPark investment for the years ended December&#160;31, 2021 and 2020 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.838%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Beginning balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Losses of equity method investment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Distribution from NovaPark&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Ending balance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestments
      contextRef="i2f9aa6708d66419390b7f00e52079f31_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90YWJsZTpjMWFhYmY0MjQ1ZjM0MmFmYTgyYjBhN2NmYTZiNTJiYi90YWJsZXJhbmdlOmMxYWFiZjQyNDVmMzQyYWZhODJiMGE3Y2ZhNmI1MmJiXzItMS0xLTEtMjI1NDU_87bc48ba-2a95-42c4-a9bf-d026347b27f3"
      unitRef="usd">672000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i4da1e16a428f4e4aa7b45ff38eee1854_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90YWJsZTpjMWFhYmY0MjQ1ZjM0MmFmYTgyYjBhN2NmYTZiNTJiYi90YWJsZXJhbmdlOmMxYWFiZjQyNDVmMzQyYWZhODJiMGE3Y2ZhNmI1MmJiXzItMy0xLTEtMjI1NDU_62395aca-2fcc-461d-80a7-81592c90e41d"
      unitRef="usd">849000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i19d9a4a649894b55b85b7b8ebaac451b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90YWJsZTpjMWFhYmY0MjQ1ZjM0MmFmYTgyYjBhN2NmYTZiNTJiYi90YWJsZXJhbmdlOmMxYWFiZjQyNDVmMzQyYWZhODJiMGE3Y2ZhNmI1MmJiXzMtMS0xLTEtMjI1NDU_382286e2-2b38-4158-9e01-eeda416d4665"
      unitRef="usd">-96000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i7ed3c6aeb1c1419881dbc5be2cf6ddfe_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90YWJsZTpjMWFhYmY0MjQ1ZjM0MmFmYTgyYjBhN2NmYTZiNTJiYi90YWJsZXJhbmdlOmMxYWFiZjQyNDVmMzQyYWZhODJiMGE3Y2ZhNmI1MmJiXzMtMy0xLTEtMjI1NDU_f941beca-a276-4f95-9ecc-58e2389f5455"
      unitRef="usd">-71000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i19d9a4a649894b55b85b7b8ebaac451b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90YWJsZTpjMWFhYmY0MjQ1ZjM0MmFmYTgyYjBhN2NmYTZiNTJiYi90YWJsZXJhbmdlOmMxYWFiZjQyNDVmMzQyYWZhODJiMGE3Y2ZhNmI1MmJiXzQtMS0xLTEtMjI1NDU_f875b71b-24b2-4468-bd05-cfe8965ef084"
      unitRef="usd">3000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestmentDividendsOrDistributions
      contextRef="i7ed3c6aeb1c1419881dbc5be2cf6ddfe_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90YWJsZTpjMWFhYmY0MjQ1ZjM0MmFmYTgyYjBhN2NmYTZiNTJiYi90YWJsZXJhbmdlOmMxYWFiZjQyNDVmMzQyYWZhODJiMGE3Y2ZhNmI1MmJiXzQtMy0xLTEtMjI1NDU_50d930b8-b3bb-4472-bab2-5ae8b40b3d42"
      unitRef="usd">106000</us-gaap:EquityMethodInvestmentDividendsOrDistributions>
    <us-gaap:EquityMethodInvestments
      contextRef="i22b6851c4c8c4d8e9f955da168470856_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90YWJsZTpjMWFhYmY0MjQ1ZjM0MmFmYTgyYjBhN2NmYTZiNTJiYi90YWJsZXJhbmdlOmMxYWFiZjQyNDVmMzQyYWZhODJiMGE3Y2ZhNmI1MmJiXzUtMS0xLTEtMjI1NDU_032895f5-677f-4abb-aa87-0d33e8f91f6a"
      unitRef="usd">573000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i2f9aa6708d66419390b7f00e52079f31_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90YWJsZTpjMWFhYmY0MjQ1ZjM0MmFmYTgyYjBhN2NmYTZiNTJiYi90YWJsZXJhbmdlOmMxYWFiZjQyNDVmMzQyYWZhODJiMGE3Y2ZhNmI1MmJiXzUtMy0xLTEtMjI1NDU_619423e2-80b4-474f-a810-6f080694d028"
      unitRef="usd">672000</us-gaap:EquityMethodInvestments>
    <us-gaap:OperatingLeaseCost
      contextRef="i35fe645b7bfa4fde8dbbbdd2b80db240_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzEwOTk1MTE2MzI1NjE_ec4dfe1a-87cd-4d05-9b00-6c5162469445"
      unitRef="usd">1100000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i8f44decd2d424510858c214c0073163a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzIyNTM_7e935d79-1699-43cd-9a31-e5c53cca7d74"
      unitRef="usd">1000000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i35fe645b7bfa4fde8dbbbdd2b80db240_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzIzNzQ_10e8d658-feeb-49f3-ba17-97ac1b9c84e7"
      unitRef="usd">500000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i8f44decd2d424510858c214c0073163a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzIzODE_6c6110b7-f265-481c-8f37-0267aa040b3e"
      unitRef="usd">600000</us-gaap:VariableLeaseCost>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i917e433688284eaa953fc3c2fc1e1b85_D20210209-20210209"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzEwOTk1MTE2MzMxMjA_a2c8d186-57ba-4ae9-a202-25c6e15b0a74"
      unitRef="shares">149500</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i2962b55847164c55acf82150946c5fd6_I20210209"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzIxOTkwMjMyNjIzOTI_3fbcec91-6d55-47e4-a0ec-e5488047d0b4"
      unitRef="usdPerShare">11.57</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="i3a167605e6c646629b93a1d3439787b9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzIxOTkwMjMyNjIzNzY_1787f49a-fb01-4559-8176-c7acdb1ccbe5"
      unitRef="usd">0</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="id1f12f1c81f2458db6d959e118e59154_I20210209"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzEwOTk1MTE2MzQ0OTA_b187e35d-d48d-4354-8b5b-44b0580b31b3"
      unitRef="shares">165094</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <angn:ConvertiblePreferredStockConversionPrice
      contextRef="iac7d715402754b8caf32b6a9c1cee1f7_I20210209"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzEwOTk1MTE2MzQ1MDA_9831a249-f149-44f2-b5f1-a8b56e44a49c"
      unitRef="usdPerShare">11.57</angn:ConvertiblePreferredStockConversionPrice>
    <us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares
      contextRef="i60078b3a55804ab1887cc07c853ff6f7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzEwOTk1MTE2MzQ1MDQ_7845b10b-d38b-40e5-bd26-e4614ff0d940"
      unitRef="shares">0</us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i4f17b2c4422d42688d50097720558178_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzEwOTk1MTE2MzQ1MTU_419a4233-cfc5-443a-9ecc-8cbfd46b6e57"
      unitRef="usd">0</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="ia5c69981108b4d979649ac7fc1b0e400_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzM4Mjk_83ad339b-e5ee-4add-8189-d95597fae025"
      unitRef="usd">100000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="ie9131c9ee7eb4cf68ebd482f734ab577_D20210101-20211231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzIxOTkwMjMyNjIzNjY_404bb027-a2f0-4038-a3a5-bea68d2f33fc"
      unitRef="usd">3900</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="id853bebfd0c74da580bb31ede0e8af3e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzMyOTg1MzQ4ODgwODg_acedfc5c-9c1a-4f51-a8c1-c3b7d80a23a5"
      unitRef="usd">100000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i30dc8694797e467d9c9068c898bcc9f8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzQ0ODQ_2329ee74-de6c-49bd-be0b-baddd0acb84b"
      unitRef="usd">100000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i5b7efeca53e04af18bee4dc3749aeaa9_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNDgvZnJhZzphODI4OGUwZjBkMzk0ZDVkYjZhM2YwMWFlMTg2MTFiYy90ZXh0cmVnaW9uOmE4Mjg4ZTBmMGQzOTRkNWRiNmEzZjAxYWUxODYxMWJjXzQ0ODQ_a893c9d3-bf4e-45e2-92d5-e2ac98f6b9ed"
      unitRef="usd">100000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNTQvZnJhZzoyYjM1NzUxNDc0MjQ0ZmY3OGNjNWEwOWI0ZWJjN2Q2Yy90ZXh0cmVnaW9uOjJiMzU3NTE0NzQyNDRmZjc4Y2M1YTA5YjRlYmM3ZDZjXzMyOTg1MzQ4ODk5MzE_f3c65b7d-688f-4ce6-8682-40ab266509da">Subsequent Events&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 4, 2022, the Company announced a reduction in force impacting somewhat less than half of its current employees. The Company&#x2019;s decision to engage in this reduction resulted from an assessment of its internal resources needs, given the results of the Phase 3 study of ANG-3777 in patients at risk for DGF would likely not support a regulatory approval in that population and the Phase 2 study in CSA-AKI would not support a Phase 3 trial in that indication. This reduction was a cost-cutting measure across the organization to support the Company&#x2019;s 2022 primary focus on the clinical development of its investigational asset ANG-3070, a highly selective, oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, particularly in the kidney and lung, as well as advancing preclinical assets to IND-enabling studies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On February 25, 2022, the Company entered into a Separation Agreement with Itzhak D. Goldberg, M.D., who formerly served as Executive Chairman and Chief Scientific Officer and currently serves as a director and Chairman Emeritus on our Board.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Pursuant to the terms of the Separation Agreement, Dr. Goldberg will receive severance benefits of approximately $1.1&#160;million. Under our Amended and Second Restated 2015 Equity Incentive Plan and our 2021 Incentive Award Plan, Dr. Goldberg will continue to vest his PSUs and stock options and exercisability of his options, so long as he remains in continuous service with the Company as a director on the Board or otherwise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On March 1, 2022, the Company entered into a Separation Agreement with Elisha Goldberg, former employee and son of Itzhak D. Goldberg, M.D., who currently serves as a director and Chairman Emeritus on the Company&#x2019;s Board.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Pursuant to the terms of the Separation Agreement, Mr. Goldberg will receive severance benefits of approximately $0.5&#160;million. Mr. Goldberg will also have the right to exercise any vested stock options he may have received under our Amended and Second Restated 2015 Equity Incentive Plan or our 2021 Incentive Award Plan until December 31, 2022, which extended the exercise period by 11 months.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits
      contextRef="i8f608066967d490d9002d2bb0340bdf8_I20220225"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNTQvZnJhZzoyYjM1NzUxNDc0MjQ0ZmY3OGNjNWEwOWI0ZWJjN2Q2Yy90ZXh0cmVnaW9uOjJiMzU3NTE0NzQyNDRmZjc4Y2M1YTA5YjRlYmM3ZDZjXzIxOTkwMjMyOTA2ODQ_3a49017c-1258-49d9-ac73-38be240e68ca"
      unitRef="usd">1100000</us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits>
    <us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits
      contextRef="ie6b23068ffab46b0a0c550ea36e51385_I20220301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNTQvZnJhZzoyYjM1NzUxNDc0MjQ0ZmY3OGNjNWEwOWI0ZWJjN2Q2Yy90ZXh0cmVnaW9uOjJiMzU3NTE0NzQyNDRmZjc4Y2M1YTA5YjRlYmM3ZDZjXzIxOTkwMjMyOTA2NTY_189b2981-0bae-4d02-bbbe-d01beac98f33"
      unitRef="usd">500000</us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits>
    <angn:ShareBasedPaymentArrangementPlanModificationExtendedExercisePeriod
      contextRef="i405a2449e3304874876b5c7f79fa0336_D20220301-20220301"
      id="id3VybDovL2RvY3MudjEvZG9jOmRlZTM2OTkzNzhhZjQ0NDdhNDA5MTQxNGMwYWRmYWE3L3NlYzpkZWUzNjk5Mzc4YWY0NDQ3YTQwOTE0MTRjMGFkZmFhN18xNTQvZnJhZzoyYjM1NzUxNDc0MjQ0ZmY3OGNjNWEwOWI0ZWJjN2Q2Yy90ZXh0cmVnaW9uOjJiMzU3NTE0NzQyNDRmZjc4Y2M1YTA5YjRlYmM3ZDZjXzIxOTkwMjMyOTA2Njk_94b4945b-ee05-465a-b3f4-bc4d377468e9">P11M</angn:ShareBasedPaymentArrangementPlanModificationExtendedExercisePeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>116
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M(RPZ>Q:=>BSZ0N0T)0]L*94IHX/C&)4SA$YW3Z=;C\Z$*2YC.QL)O!^E^:E
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MK-D\.VP)W<+)4OVO *OJ5!:6&=;LH6U9;5MIQWGA<+?83BTL;#*L99,#(*:
MU CJ_$(^LW(UPZ$\S_.[GM_N8=NCL/#+$+>W/B0KWB3LF-S_S[99ZZ"_;]W8
M?2?1)+*MG$VK?W]V_RVF[[Y M(K;-Q]R[J@U<TU2-H=0[_0,)I/:?!O9'!BY
M=%\+9M(8F;F?":/P8ML;X/I<2K,[L _8?Z&Z^@]02P,$%     @ XH9^5+T=
M:6L8 @  : 4  !@   !X;"]W;W)K<VAE971S+W-H965T,BYX;6R-E%UOVC 4
MAO^*E>N*A/"QM0J1H*P:$DRHJ.O%M N3'!*K_LCLD]']^]E.R.@$$3?QUWD?
MO\?.<7)4^LV4 $C>!9=F%I2(U4,8FJP$0<U 52#MRD%I0=$.=1&:2@/-O4CP
M,(ZB:2@HDT&:^+FM3A-5(V<2MIJ86@BJ_RR J^,L& :GB6=6E.@FPC2I: $[
MP)=JJ^TH["@Y$R -4Y)H.,R"^?!A,77Q/N [@Z,YZQ.7R5ZI-S=8Y;,@<H:
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M8]N*3BPU.,T36[5MEZ5%Y)W8=*<]#6K_*#2K3Y"96K<O,(DS6Z=M&!-2^%=
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MX^1W#D7=[AD]_?Q33C!Y,Z1HIV:;#7D1.R3;=BG&?L4C0W 8(N^J%JJNJGU
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M$)(1BN08%)NF&@Y;?==%M!H6,8>ES-6P'/X$0B+L:C9=A[V;3NEKM68EOYQ
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MA7FA!JX&$J/GYNM9K]I9@P.S7I.\AT+_' 5>X.])'[\^W7N>[H+_K@A!5X3
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MM,ZBN X5,''9;^)3D4_EVNB>9TW69)[0ES+*JZANDU *KOIMGA>KE>ROM2E
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M_6,AKZ[-&_5KM?T/9<_^!E!+ P04    " #BAGY4B!C_U4,"  !&!0  &
M 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;*U436_;, S]*X)18"TPQ!]ILZYP
M##1-A_40+&C0[:S8="Q4EER)3MI_7TIVO&QK<IH/EBB1C^]1HM*=-L^V D#V
M6DMEIT&%V-R$H<TKJ+D=Z084[93:U!S)-)O0-@9XX8-J&291- EK+E20I7YM
M:;)4MRB%@J5AMJUK;MYF(/5N&L3!?N%1;"IT"V&6-GP#*\"G9FG("@>40M2@
MK-"*&2BGP6U\,YLX?^_P4\#.'LR94[+6^MD9#\4TB!PAD)"C0^ T;.$.I'1
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M3RMZZ, X!]HOM<:]X1(,3V?V#E!+ P04    " #BAGY4,K@6H/()  #L+0
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M.NBN0#Y +MTWNI>8(64%-91U,*HO6^#1)Q<:\>@YME#4) UG#?519Q%%! J
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M0,4(XC/>KK9*P.#J>.\H@G9UBZ<G]@%+[P]2C37"/ "&[;D,[*!/BZ%Q?R<
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M -^O:M!U\@_<(/YJ]4__!5!+ P04    " #BAGY4J*#V$]P-   +*   &0
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M2P7C:0+>+QQ:BO1 &W3?_SW_+U!+ P04    " #BAGY4"9,KCP,(  "L&0
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M!?NR4OYZSDY:"MHF(5Z2^_G==\[Y,MF0OPT5(L./VKHPS2KFYBS/0UEAK<*
M&G3B69&O%8OJUWEH/"J=DFJ;%\/AJ[Q6QF6S2;)=^=F$6K;&X96'T-:U\ML%
M6MI,LU&V,WPTZXJC(9]-&K7&:^1/S947+=^C:%.C"X8<>%Q-L_GH;'$2XU/
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MT'6MRRTSV<)V?&,V0G=['<DK3$4RNDB4ICPG7DUM[/W#EQ9B6)V2(/X-R69
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M63F0I+[+ZM31< 6!]B^C,"[FO#(,;@T-JPH$2+:/W9XFA8XHLSI7WH3RZ'R
M"X)K<*U__!N)UWL_P465XT.1$,\]&Z(.B%5D!Y8="1A2^\0E^]+#DR:%LD:T
MA,.(ITY<#O-@I7,_@;;=G@+#LG75P=@4B6O,O7!,J64D?H6U9+I&8^"HF+]7
M6_&'L5_8FW3S,R16NP-3[.4*)0>,.48.JSG2K0/T]*8CH'J0[&BR'PPD:W2(
MUK<Q/G7HWX9>'V@*GAL#H&'J7-?#.1C6AR8^M%NL *YDSD2;0,*>CA1(1T<
MAGSW0O'6T6/=2MOC1B'U.%-* Y'WO;2D;E#F59BR@U0=_G79.;WKC#B,H]QO
M-%+S.<C3/=,/I%JE[+UB?H_3AKV.RGLR6C3%_<"]JQJAV'MXU"M,&L9JF?U9
M5Z[@(:(]0NI(TTK"H<[8 LLUX7X<68_.I"/4_.[XRUUM<U3ES6<J[3-0?L6-
M8BNKOS"I7+6=U)7,0\<;1[/%1;??#6A<=:[(08VUN*2A U\D8IXD1XLVJ'0V
MM&V8+^A\9TY3]R'+))HO9BUK/SWLNY%'(X$Q9_\N"J@JV> >ZD[/=_^:H3[W
M^I_;H&]AVG\ ]!62A*%/D_5VZUJM/TY/+-S!MLPHWWD@XW6J-T27\LK2^4)3
M;PEKZ SWD>ALVO-2/4#6K<HA9,$?3+B_0Y#_B:T<XUS":"WZ]"7FS7"^*9%M
M6?5$1\RKPN'E_F2^Z<0Z-N%"FLR>D<QT-+\WV\\2W;FEF=@SI]PI3 :T TG&
M8DTE)11]WWMG37%%I!#7 7UA@=2#,X]=-V^NJ2]?K8!*5>T+$VXP1U/T<I0#
M@Q2NQ'LS$ICKQ'!P<WE%5X,S;N*RS%(7QQWX9@,I6C#X^^7E!ZI[,',=*C'Z
M-^ 8#'&GZ<L.$J3U'^.0]T(*@I+/J_:-6CM$1DA*M9%<Y(SU#25%R] ?^S8G
MO74H_F<D 370Z,>HF<\4 B GR9M6U8N^UYC!(<1)MTYV/D2L_:<J&/*T"]YW
MP!1RJ@/?[(_#<_-0O+AYYB$RH+ Y_M)#A[IP<>;'R?;#!<]4'NG_SU-B6?5\
MJ]E7#I:ID%E;B_JZLKZO<N>=CYR%LG?\*9>;SM+Y[YWMT_9K\:7_2+I?[C\U
M_RHMX!V]C5IAZWBTF V$]9]O_8TS&_YD>FN<,P5?KA5DMK0 [U?&N.:&&+3?
MT%_]#U!+ P04    " #BAGY4@1L[PK<#  !-"   &0   'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6RE5DUOVT80_2L#%BD2P!8I2FZ,5!)@.2G20PK!3MM#
MT<.*'(I;[P>]NQ2M?]^9)<5(@>U#>Y#$7<Z\>6]F=E:+SKH'7R,&>-+*^&52
MA]!\2%-?U*B%G]@&#;VIK-,BT-+M4M\X%&5TTBK-L^RG5 MIDM4B[FW<:F';
MH*3!C0/?:BW<88W*=LMDFAPW[N2N#KR1KA:-V.$]AM^;C:-5.J*44J/QTAIP
M6"V3F^F']9SMH\$?$CM_\@RL9&OM R]^+9=)QH1081$80=#/'F]1*08B&H\#
M9C*&9,?3YR/Z+U$[:=D*C[=6_2G+4"^3ZP1*K$2KPIWM/N.@YXKQ"JM\_(:N
MMYU1Q*+UP>K!F=9:FOY7/ UY.'&XSEYPR >'//+N T66'T40JX6S'3BV)C1^
MB%*C-Y&3AHMR'QR]E>075I]TH^P!$=9HL)(!-DJ811H(F@W28H!9]S#Y"S#3
M'+Y8$VH/GTR)Y3E 2IQ&8OF1V#I_%?$C%A.832\@S_+I*WBS4>@LXLU>P+O#
M(!U2.X6C5 ]_W6Q]<-08?[\28#X&F,< \_^;R?\ \^SFUQKAUNI&F /XQAIO
MG0=!)V44ZL5>FIV'AJPAU"* ]"!-0*X1! N/K5"R.@ =;JC$WCJQ50A!/$&@
M$QXB2$O&#NZ'4S3/IF_%.[ 5X7'X$B] F!(*JCZ- "90"%\# =+90.<H4$50
MK<-G&6@>/ SE\+$=>'N&/PWX<!9P AOA@BPD*2=;+0[T>4"@H73)U",==$P'
M1!70Q=VW=S;4[R@EBF;/P$VHR-O);<NQ/!/B*#%?E;.:5](!*KF3G!D4SL2,
MMLW1U@<2%ZR3ZL ,?$%H)$T80[D%);4\IO %_EUM05!VKC(X$'X43^.0,V@5
M^[' D2:"*$O); E=:-LR!(^E$JPY(W3H@_M8W$*$HKXDUF=ZSYA\EPJF5*,J
MJ5K4##2(0/ACD4K8$KKH)O";Y:$D=:MA.[0F%;AQ=B^YP-^$<THG<&, AU;^
M\8?K?/K^Y[X;*&^! ]7D3&QK<GJ]4&0WS;(WL"='BM/5:$YR5$XHT2?F%W3G
M;/^AAN*BD0=UN:2160X9NHAB-:>(*T=*H;2*PL?4#8].4.[[LL_>Q!H98EQ*
M$DJ%'M6,'<)=6,DJ4.WZENZK,Z -*X-/ >:75Q'PZ#IY;ABE)R->H]O%B\R3
M9FJ ?MJ/N^-=>=-?$=_,^XOVBW [/JD**W+-)N^O$G#]Y=4O@FWBA;&U@:Z?
M^%C3?8^.#>A]96TX+CC ^ ]B]2]02P,$%     @ XH9^5&!B;.Q5!   40H
M !D   !X;"]W;W)K<VAE971S+W-H965T,C(N>&ULK59M;]LV$/XK!^\M 11;
MHB1;3AT#2=IA!=H@:+H5PS ,M'2VN%"D2E)Q\N]WI&S'0>LL>_$'FV_WW'-W
MS]&<K;6YM36B@_M&*GLVJ)UK3T<C6];8<#O4+2K:66K3<$=3LQK9UB"O@E$C
M1RR.QZ.&"S68S\+:M9G/=.>D4'AMP'9-P\W#!4J]/ALD@^W"![&JG5\8S6<M
M7^$-NI_;:T.ST0ZE$@TJ*[0"@\NSP7ER>I'Y\^' +P+7=F\,/I*%UK=^\K8Z
M&\2>$$HLG4?@]'.'ERBE!R(:GS>8@YU+;[@_WJ+_&&*G6!;<XJ66GT3EZK-!
M,8 *E[R3[H->_X2;>'*/5VIIPS>L^[-I/("RLTXW&V-BT C5__+[31[V#(I#
M!FQCP +OWE%@^9H[/I\9O0;C3Q.:'X10@S61$\H7Y<89VA5DY^975/=WVEJX
M1@,W-3<X&SG"];NC<H-QT6.P Q@)@_=:N=K"&U5A]11@1(1VK-B6U05[%O$U
MED-(DPA8S))G\-)=E&G 2P_@O>%&";7:BQ)^.U]89T@4OS^#G^WPLX"?_:<L
M_E,,^%@C++6DQB'RX/A"(EATEA:-J\'1=JF;MG,\*%POP](E+7'U\/TW!4LF
MKZP7K2B!JPHJ(3N'%2AR);VKEES9X(H[9\2BZWTX[7$;@B3]E;>UEA4:&\&Z
M%F4->%_*KD+;6]K-J@>1N.)2/@ UOW7DT+,F3.KXQ9_4A1[78-N9LJ8^@L7#
M/ETX$HKFNK-D2+[("[9NRX[(/W*M2.C'I_ K<M,K#D@OV"SHP%8S_BN&JZY!
MPYTV<+6-^ 5QPK=PE&=1/DF/_;"(HR2>'),/I:D!/=PI? K=CM4)OR,/*]SF
MHK/$A@+IR^+C_[>Y_K)JK(A8ED4%RR')HLF818F/\7_#IUB3X;0/.A]F-/#Z
MZU$6_O:&UN@[X2O?:H?*B5#L8$XW*RFS[(QP@O:5=I2%().0CJ!4+LM./E'J
M,WI<8,DIF9Y^I<%JNMP[6=$R47;B9.OT]%#I;_IZ"&N[$$#7DEN\1U,*0B7_
M(1N@6\_'0A:QE.H\9I!&V60:3=+DZQ">]C[,FAM#C"PD49(55)$4&%D3PO0
M0JD5:<;NI:%?<<(?H<R1Q5%R#*%_V2O(HW&<1FE1O!3N!HVOP265"Y=H#"6X
M#W8?-8VFC *>,+C2ZN0.K:_#5L344X8ZE>Y'4;J=>:>$@U4?+2-*<9)#7D33
M/'DYQL9\RX)TG!<Y?-2.2PHT+Y(HC6-(\JA(QM$X*>"/O_^$N+Q451>$X(O[
MLDRQ.)D2=\IXM+DP0O9]4QQ,(EU=I$(D,5DGZ%5 &YT-U_/C7?:#?=)SL.3"
MP!V7G>_-+Q0;1]0(MM2=\F!T*[+XN^'7_I1&>W_S=+&MPF/&NR++_A]_M[I[
M+YWWSX3'X_UCZSTW*T&ZE[@DTW@XR0=@^@=,/W&Z#8^&A7;T! G#FMY\:/P!
MVE]J2M5FXAWL7I'SOP!02P,$%     @ XH9^5,&'?RL("0  KQ<  !D   !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&ULK5AI<]LX$OTK*&VRXU1IJ<MGUG&5
MCR23K!V[[)E,9;?V T1"(F*2X "@9.77[^L&25&*DW52\\$R#Z"/U]VO&SQ>
M&GOO4J6\>,BSPKWJI=Z7+P<#%Z<JERXRI2KP9F9L+CUN[7S@2JMDPIOR;# >
M#O<'N=1%[^28G]W8DV-3^4P7ZL8*5^6YM*LSE9GEJ]ZHUSRXU?/4TX/!R7$I
MY^I.^=_+&XN[02LET;DJG#:%L&KVJG<Z>GFV2^MYP4>MEJYS+<B3J3'W=/,N
M>=4;DD$J4[$G"1+_%NI<91D)@AE_UC)[K4K:V+UNI+]AW^'+5#IU;K(_=.+3
M5[W#GDC43%:9OS7+7U7MSQ[)BTWF^%<LP]H)%L>5\R:O-\."7!?AOWRH<>AL
M.!Q^8\.XWC!FNX,BMO)">GER;,U26%H-:73!KO)N&*<+"LJ=MWBKL<^?W*I,
M>I6(&VG]2OQF9>$DX^6.!Q[R:=4@KF6=!5GC;\@:C<65*7SJQ.LB4<FF@ $,
M:ZT;-]:=C;\K\4+%D9B,^F(\'(^^(V_2>CMA>9,?]E;\YW3JO,7=?[^C9[?5
ML\MZ=O\25']6EKA.K7A7+)3S*!./2R&%4U8K)\Q,Z/:-P[7X8!8JGRH++$<3
M(8M$O*^R%=T=](5/E3@W>2F+5;T/&J7PQLN,9#T;[0W[P^$03U!(?U;:*KS.
M6:!+=8E-7EEL(TUDUKEQN?(Z=GUQ>7DN=GIXV'O1AUXA9S.=:?8I#BHC\5M'
MOUG"-;*/C)K)7,-*F- Q\1<G$E@0>V-YX7DJ-2JT$*]S>.\K5\LH2VL>-$I7
MD:/1[G->?3B,]I_WP2BN5,P)V:K?*'C$(U>[%(GK"GZE6LW$ZP<55[157,.9
M&*!JJ,N<>4SQ,#H</G^2 D9AVY>__^UP/#KXIQ,.) 8U+$468$Q+0GGCNZWP
M;@9TCIPAM"DN$*P>XJQR9#P(,TO -TID<*)PJ@_V\2EOMD1G%&Y73=NW%>K:
M;D6BA)=(/E[O$-$%S"[FPA3JZZB=?[H9[\/=5$\U@H?D./WP]A^3O?&X+]!@
M>'7E% 'BT6(\"8I-D>B0[[4\=X_W6$U(1>*NM0]IG\N5*(P/+HM99;'>=EQP
M3W#!\!Z? BK*]B9;6;VKXK0C3H5$Q698B!M&;YGJKQ:A7,#4F9P:&[QJO$4"
M*&GCM(]6@DPT)=5KGP)<S5#F%=59P86"=(BUS/07R>VLQ@*)EE0Q^C)'=ZFS
M#-ZL-L(OA34KF8$\I*<;^,( 8PE:LG P)U,HJ+DFYPM@9YR#80M55!S#1@=V
MQ<:6C0OKT)&%*%/D,D4=^@/IE(9@A<TH F82VE65A.JSHVA(6S)RA;IJ(KA%
MH[J0QA0, EMF%-)&,'R\94=T#?LC*AF *3W0"4+M=1;\A,]<+:,]L0+>3LRL
MR0/!: O66N/+6FFI;(HB:0 0=<PRZ;@RU$-)/+A>UDVC4,T-\@%T1UGQ&:3#
MB95\KAIZ#DD)'O$8HT2L;5SESLLB5FZ3&Z<J(X2(!1!,,H;"?ADL$$M)%8!R
M!I9P.'>H!0&,X*Y<(&Q3> ;-W>0(:9X:[&Y%-N]B4V6(RY2-8L"JHD/>/M66
MG+84D @$U.9,#2[\K;$1<FY5B"O9".HV\T)_@9"F#D)42BH'XBH2MY!H>??=
M!D=!OU3(%G'*U8CQ('!>,R)L\EXJJ8>-0+[=[M0(CL15X.(?;2XM(6.E1MHD
M!$?;J);4A'/YV6#MZKNLCW=K6[I!EC&0I[0@<*@HY1SPS4E+<*8%I.-.A]@4
M^C-TH_^F)@FB9R ?LZ3Z\YP%R.@%>#]T$YZ,:4<3C%9F1]5FH!0->%_CSX#A
M8BAVF&%,Y?#$O7@I/F%;& L?V<4[SM1<%P69.)49I;YX)O8/QO@]W#T2E^"D
M0,$;WG4MW#G:?R%V#D8OQ(7&**>G%1,E)V/KT<X$:T9#K(0QF\KV#B:URFXP
M+!>HX3;/[M4D;NQ*N%+&S*6_%]"4@#CZX@,.(I]P$-G2&Z(#3N'TY5(+].$P
MAH'!QD/&8C_:4@[")<S("MK Q42AF.D'/ [26O;C02T:M<1*YN+!FFE_+(B;
M,])3+5M(JSG'ZH=4[F&"K:DG&$VV#J.]35LQF?U%MMXI2F.JF%$$HY$EH"FR
MBAXZ&I@P5Q3UT; =>M[=7%,XWZBIK7!$K3GEHV8R>"N++[HOWNH,%GAQ#<R#
MV?]">R_$'QKS7]%OR6.;5T*;O)6?Q4=5W-- (;%Z:L.XT:S]QGA)6UM6VI8;
M!_=H8L^XWVFLJ3PUD*2>H%KW"W8?)&1X%&^)A7KC[E%_#R.^2Z4-I49=$?"@
MQ\;W 219"^,S>6FI)CCI1M'>0?1=5D:C7-(/.M+7]G2LI=#Q">9\(VPW.*PK
M:^'C'5OS0P%\CXFH"_I5=!&%5@&Q#CQ8]Y:?0'\+?.IY7>C+UNP XN/ [^_U
MAT>[/PV\*&G&I<U/#D%7U1KD;6LWPH)HN"KS-%>_H9GVM)BS+31IQ>$=#[:J
M';+9S[;O-R%:ZEE[,OA_I[A-J(D1FNMP F+)./$N-$]*'1/9#+:M9AU6R^YO
MGLZ^*&L:\EDS9ST?_RQ/:M= 0K9L#C\TF.F""7$K4\<8XID,+G"LN<(A0JI,
M?,)<@925Y#UPJ4>)!IHS(S&#4<2_R3IT,A5WL:91'.DL3I.%=M1!\'<#_S(L
M3<%?_U:)NA>7T@,1<2;1XK[@Z'XC=CJ+7O!1\T>0Z<:/P]%5^6P2';53PJ-!
MR% D&0=S&V38\1Z'I #=Z'!3$Q_%%4]:25USW1S=RDJ"FV$6965=12'#CG",
M2^O9E?.HGIJZHIKDVYZKZP1"E4D.R50;FA1C>-,<^0*MK$]]D;CIJ*?=88:O
M _J8_?VU[7U2R8DG,970A"3=VFM):Y$A"NAMH9Q4?%Y7.'PUJIX6W*@#'-'H
MO*!YOCE7K:?I1W(4.ZX8@BTYO[A:4CCC4KG0:3ZI^-Q"N";:/<(I;;)W:L)V
M.6*S**+'/O$-.A]146AS_E1,=8Q1/'Q/;9^V7Z-/PT?8]?+P*1N^89;%Z4?-
ML'48'>SUPJFPN?&FY$^R4^.]R?DR53BX65J ]S.#MEC?D(+V&_W)_P!02P,$
M%     @ XH9^5 21-C9F!0  Q P  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C0N>&ULI5?;<MLV$/V5';73)UD7VJ[3U/:,?$GJ=IQHHJ9]Z/0!(E<BQB#
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M-#@Y[K71W0ZBJ],]=>XB;KWIM<3?#/:R -\7SL7M0 SL_KB<_P502P,$%
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MQ%'CVLQCY?G8+ DN&OE'ILX0M%"%![&KL92JOGOA<W(E!(A> O&7HSD&!S:
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M/>#-R7)Q.SRN4[.'I10CQ]0[3F\XMNJ5Z:BCX5<0,$@8ZC6!M.4U6L[2_Q"
MG#VM 0'?+T<]B84KD8=7(I[5^4G[%^/2-%Q^DG1['>]R&"?0C2 :[X(OP!='
M<'DU^CUY4>=2AS4%B:])8OP];1^-9JUV5HQWX+;93P/FSJCPZ2!%7-(D:):M
MB3?BT?78GKQCR+ULU])2PFF# 4>B_I,Y&<)##]?0=/&'02"#J'UECL6X$$D*
M#@E8#]R; =MNZ\[,NWW47"Z^#H9CQ>[3L)QJ*LV(%S,X$JRSB]6MT8?)-LW%
M;\A=L[BACO1P\?<([H58TQB^!-X=M\";2*F<ZH#I](5#*_EHQK=LR>=914@0
M&"LM&?-5NMV:.4UD$NKM<,AB;:QD0_9.Y:Q#=@=-RJ10Y+B<KE5\*5GI[]#D
M<U0.W?WUY&6O8>C@.L92B[]^>#Y+>E-(X@8]1Z*S^&20AF-S#4]Z1X$LHIGO
M951R&-7$(=Y!E';(B326%4]VK#K=67+>^[#N.."#5X =1.6&6SR K*^-[W,7
M>DX/W<:?;FV+)5GIHI401WQ^AWU*RS0?'NS)(6E]*D4Z46'3R-K"X6D5Z>1Z
MO,VO -Z4J7ADL-M!$TL'.';)V#C7)6PG*%S.L2/^>7/&J?*JX+K^2#):T4%"
M/@/*NS&NJC"T;#(8S?6S$B5@+YU&0;B5&RP!OK(19^D8AC!O]5T_Q@SPGM[E
M)2C/X?KR-6,DH?[_:VV5K<XA(@;U4A^;RGRTS?&(+1ODN%(-D>)HO=>/-,]P
MXR52,@JV" *BJ3!2?$RY5V?4/)S68SJ5-$;7LL^AJUZSM$6+W/OQIAGHG]R#
M/>#%TM\ ]AG7Z_ERO1@"6/J&NSDT S>#"_Z'_E^<>,9I=?WNP[$W'"WE//67
M47(VR[-2@Q&N+Y=5?4?]]N)*C5N;!"A,IU"&TL_E=(GFK\0I7U5-D[PA0%]!
MJ(XR_L^=!#_OD"4E/4<N-"2W9H<,,W#C%DY< DX4"O3PKZ:MN!]=D#]^6S-G
M'68)Q0/]X,C:D%W?<4/ X_F_<9JK_YD"U3*>VX)W-7((7SK,XUT#4^Y(D[6?
MR-&>#7;@M%E?Z<4V/!<>AK1>]A7YIH&:N\PQZ\'#KK3B+>)8A)A-RH-]XQ):
MQ<YSG Y:2=1/(2B;[LQGR17RT 9AG0"32"9*<RNTJ\F/9!9'_1A7C![2'GX$
MR@Y"#.Q4NW"@Q\4DSH>2R^5TN>1EKQ,R$'<4YS]WDOX3/LP@0N,/V<>U*#0^
MUJ3Y+'E]]+O@%W72X* *(6J<'C3'05%B3$V:F,SN3?12"#Y_[X4-^LMT3=9!
MK_#CYU!_-$^SUO[FOD^SZYL]:'0]B0VA,' Y71B(UI8E.LM<Y!7_"DS\$SIU
M55:0M"%-SP]_*8GWQT?_2@#[+[IQG7<4Q_YE6WL9?KO%=SS]\>+JF:L/N+AZ
MKWG4R_,YW/C/S:J=XQ]-G0X52EPWSS?U6IT-]WS8YN'7Y_/E^:EZ7$>+?N<A
M*9N0A.,Y8"FO;\I$J\O#=$\6C^8/ST^?Q@<#;<0U97'I(U?=Q].GHRLX:Z'A
MAB"2=-M?(&;0<14RNT%W%;=_V*6_<TS __B&=.]*M'^;*]=T$4Q.NY?^5 -@
MRY0FT&A481+9Z1&AZ@+L8Q"8A31Z8M;Z\SF>C>3^)C24B'+YO?<(@X@1BXO
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MT/?KBF2=_H$%\)/QO+T?_A=02P,$%     @ XH9^5##TCQ8P P  U@8  !D
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M57N-:C^,K-W592L-783<L*";)RJ[@=9S28+N/JR#_BZ[^!M02P,$%     @
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M0X#WA< R[3=&P#![SO\%4$L#!!0    ( .*&?E3D%GV;$P4  /<.   9
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M%N-IAYI3H7S$SOANAI"*C!J/ @-ML(2Y%(\\H0@U;6YZ8%8H*W-6+']2&_[
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M,WJ9HC0':#\50J\FQD#SUAW_ U!+ P04    " #BAGY4B-ELFS0&  #5$0
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MW-8U;3'Y]/TW61Q-WIG71-Z@"\Q:S1=-Z\,JAUL1)(DROR^5*%"; -8ESTO
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M/),&MJC9X8K1.5-V -Q?2&D>3NR'YO)?%Z?_ 5!+ P04    " #BAGY4CS'
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M[\/;6S"4<?T.O4%,H+]W,M-4)'KJ&YN/B\J/R]@71>RD(W9,T)T49J?11Y%
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MS$<!2KO O-\)0[0:V$MA_9FQ_ ]02P,$%     @ XH9^5+/1@1 C P  ;@L
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M=MKRR\P.Q*A<@#V?2VDV&S=R-2/V]#=02P,$%     @ XH9^5%KAA+?[ @
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MA6*8D3*5MVSY!:J" LT7L528*UI6L8Z%HE)(EE5@I2"C^>I.GBHC&@!5:#O
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;(V638_;-A"&_PHAY)
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M!+Y92)51@UV5NGJE@":%*.-NX'E=-Z-,.*-!\6RJ1@.9&\X$3!71>991]?$
M7&Z&CN]L'SRQ=&GL W<T6-$49F!>5E.%/;?.DK ,A&92$ 6+H7/OWTU\SPJ*
MB%<&&[W3)K:4N91OMO,C&3J>)0(.L;$I*/ZM80R<VTS(\:=*ZM1C6N%N>YO]
ML2@>BYE3#6/)?[/$+(=.Y) $%C3GYDENOD-54&CSQ9+KXI=LJEC/(7&NC<PJ
M,1)D3)3_]+TR8D?@=TX(@DH07"IH5X+VI8).)>@4SI2E%#Y,J*&C@9(;HFPT
M9K.-PLQ"C>4S8>=]9A2^9:@SHQDH!IJ,R5B*-2C#YAS(%+T'I2 A,R/C-W)+
M9N6R(')![M-404H-D%?*<]0^02Q5@L'7$S"4<7V#@I?9A%Q?W9 KP@1Y7LI<
M4Y'H@6N0V8[LQA7?0\D7G.";0-PB;?\;";S ;Y"/S\L?8=XB7O^D?'+YZ-Z^
MW$6C:[>#VNV@R-?^RNUXQ^U5[;8NW%9;/ZDA-),8]1<[L=3F#$&[)F@7!)T3
M!%/%1,Q6E#=Y64K#0FHWC/4H"-I>-'#7NY9]%;7'U:FY.F>Y<(,Q''!#,=:/
MC.59$V"9H[LS=!CV>@=\7P3MX84U7G@6[T5\SD3"="QS833!)4T6 $W+>AP>
M4=SV@] [8&V(\J.HTPS;K6&[9V%_X7$14Z4^F$CM"D+6I@^O>S2/!W3CXP@_
MZK;#@QJZ1S4$7<_SFVOHU37T_N^7LJ!,D;7=D<Y\)5$]>O3%:KQ@=*9UCAW<
MW^ ]7E*1 L%S>$\BI&E<'9/HV+,@/#'M_1JZ?Q9Z7#(@SZ<7=L.^J)AM"<GE
M-?0;YOU$";[W>1QY9XMXEH;RBY ;=W/O>&^*0K]_0.7NG)?V=O.3JI0)33@L
M4.>U>IA E1>&LF/DJCA"Y]+@@5PTEWC) F4#\/U"HDE5QY[*];5M] ]02P,$
M%     @ XH9^5+N&?]W" @  ;@@  !D   !X;"]W;W)K<VAE971S+W-H965T
M-#DN>&ULM5;);MLP$/V5@=!# Z36XCVP#30*@@;H8L1H>RAZH*6Q180259*V
MDK_OD)(5H[75])"+S>T]OGDS)#6KI'K0&:*!QUP4>NYEQI17OJ^3#'.F>[+$
M@F8V4N7,4%=M?5TJ9*D#Y<*/@F#DYXP7WF+FQI9J,9,[(WB!2P5ZE^=,/5VC
MD-7<"[W#P#W?9L8.^(M9R;:X0O.U7"KJ^2U+RG,L-)<%*-S,O??A51PZ@%OQ
MC6.EC]I@0UE+^6 [=^G<"ZPB%)@82\'H;X\Q"F&92,>OAM1K][3 X_:!_=8%
M3\&LF<98BN\\-=G<FWB0XH;MA+F7U0=L AI:OD0*[7ZA:M8&'B0[;63>@$E!
MSHOZGSTV1AP!PL$90-0 HI<"^@V@[P*ME;FP;IAABYF2%2B[FMALPWGCT!0-
M+VP:5T;1+"><6:Q0<=000RR+/2K#UP)A25:B4IC"RLCD =[!9Z84LX;#VQLT
MC M]0:-OP >=,85ZYAL28RG]I-GXNMXX.K/Q#28]Z(>7$ 51> (>=\-O<=V#
M8'H*[I,%K0]1ZT/D^/IG^&+!M :Y:2+^\9'FX<Y@KG]VL/=;]KYC'YQSV9H$
MI>()&<@+2*403&DH4=4&7IQRH.8<.DY['/>+<#3S]R=T#%H=@VX=AVR7;8:U
MC;<CQ&%+/7P% T<M^^C?!CKZ1.8Y'7\G&WAA)%093S)@0M#<<PW_$2'0%:8-
M*U)>;*%"R@;;T=FBFDX(^72 TG+':9-45_;)S-1B1T>9B:+^8#0(3J=GW$8Y
M[HPR/J__LE'HKL__+:1ZU_%Q(86]X?BTV$DK=O+BE)RWO=O(Z\E?1IZQ<-JJ
MFG:JNEM^Z2BW,'B^%H-7*.?PZ-H-7^%&:$@[KP3_Z#&P+_$GIK:\T"!P0Z"@
M-R:TJA^WNF-DZ=Z'M31T(EPSHP\"5'8!S6^D-(>.?7+:3XS%;U!+ P04
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M!FD7F.]K(?3AP3IH)N[Y;U!+ P04    " #BAGY4.\1:J.@"   1"0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6RU5MUOVC 0_U=.T1Y6:2.?$*@
MJ4"K55HKU&KKP[0'DQS$:F)GMH'NOY_MA!2U(>T>^D+NG/O][HOS9;SGXE%F
MB J>BIS)B9,I59Z[KDPR+(CL\1*9?K/FHB!*JV+CRE(@22VHR-W \P9N02AS
MIF-[MA33,=^JG#)<"I#;HB#B[PQSOI\XOG,XN*.;3)D#=SHNR0;O4?THET)K
M;L.2T@*9I)R!P/7$N?#/%[X%6(N?%/?R2 :3RHKS1Z-<IQ/',Q%ACHDR%$0_
M=CC'/#=,.HX_-:G3^#3 8_G ?F63U\FLB,0YSQ]HJK*),W0@Q379YNJ.[[]A
MG5#?\"4\E_87]I5M'#B0;*7B10W6$12454_R5!?B"*!YV@%!#0A> @8G &$-
M"%\"HA. J 9$MC)5*K8."Z+(="SX'H2QUFQ&L,6T:)T^9:;O]TKHMU3CU/2!
M"$&8DO 5;HUHN@"?%Z@(S>69/OT$+LB,")1C5VF'!N8F-?FL(@].D/MPPYG*
M)%RR%-,6_/P-?-!!X.I,FW2#0[JSH)/Q"E<]"(9?(/ "ORV@;O@"DQZ$OH5[
M+?#%^^%^1S9AT[S0\H4G^.8YD1+X&NHN A=@)Q=^?=>F<*VPD+\['$6-H\@Z
MBDXXNGQ"D5")L!0TT?\/RB#E>4Z$A!)%]?\X:ZM'11M;6G,%[::#7A2.W5U+
M,/TFF'YG,(=D$\YV*.P%5/Y?6+/^J[!\O]>/V^,:-'$-.N.:\Z+0L=PKGCQV
MU#QNZ.*/;>ZP<31\7W.UK_WA.C"UK,:^M8 5X^"H@,,H"L-^4\%JFEZ;C<(P
M&K77>=3$.WI/_R50*;>8Z@M397JB_#[<<H723)<_.)+C@TQ8:O1AI7=4SO>>
M;T_O8YOD'UW4_H?,X*SF?6,(W:,=4J#8V%TL]9!MF:K627/:[/L+N^7<9_/J
M8^&&B UE$G)<:ZC7B_6XB6K_5HKBI=U(*Z[T?K-BIK]94!@#_7[-=8-JQ3AH
MOH*F_P!02P,$%     @ XH9^5$&T@OJK!   ?!(  !D   !X;"]W;W)K<VAE
M971S+W-H965T-3DN>&ULM5AK;]LV%/TKA#<,*9!%(FWYT3D&4CM.6B29D:#;
MAV$?:/G:)B*)*DG',= ?WTM)E9Q88M)N 0Q;DGG//??!0U+#K53W>@U@R&,<
M)?JTM38F?>]Y.EQ#S/6)3"'!?Y92Q=S@K5IY.E7 %YE1''G,][M>S$72&@VS
M9S,U&LJ-B40",T7T)HZYVGV 2&Y/6[3U_<&M6*V-?>"-ABE?P1V8S^E,X9U7
MHBQ$#(D6,B$*EJ>M,_K^D@76(!OQEX"MWKLF-I2YE/?VYN/BM.5;1A!!:"P$
MQY\'&$,4623D\:4 ;94^K>'^]7?T:18\!C/G&L8R^ELLS/JTU6^1!2SY)C*W
M<GL)14 9P5!&.OLFVWQLP%HDW&@CX\(8&<0BR7_Y8Y&(/0/F-QBPPH ],V@W
M&;0+@_9S#[3!H%,8=%YK$!0&P7.#3H-!MS#HOM9#KS#H/3.@31[ZA4$_JVY>
MCJR6$V[X:*CDEB@[&M'L1=80F3664"2V=^^,PG\%VIG16,:Q,-B,1A.>+,A8
M)D8D*TA" 9K\3FZX4MRV%SF:@.$BTN^&GD''UMP+"R<?<B>LP<DUWQ'6/2;,
M9_3SW80<_5H',G:#3&%^0EC_"<K2_/8+[?7_D*F="#68$S?FITUT0MHTP_2;
MF9V[4<Y2A2C^2RA3-\H$PI++\_AJT"Y>C^;@=.E&N9$/963TJ;F'C59V&RN[
MC65X[0:\*] :X)A< <K-,9F #I7(:D?^N<*QY*.!6/_K\-0N/;4S3YVF;A$)
M3T(@4>[)@(KKPG>#=!B)<3ZLM8-0IR34<6+-E P!%IHLE8S),J.'$XW(>216
MO*%]ISEFD&':9>AAU,9Z^O[0>]COA<-AU8@G;(.2;? #;"/)D_QJ-IO5T<S!
MNK7^<X:'(_J#8#^0)S2[)<VND^8%+LYDDV+[+&!N"#Q:[=H(O;:"5J=3W8-$
M#7S_()_3[@';@1\<IOUP6$,\O3*>GC.>\=GM^1TY"\TQ.8_32.X R"T8#,9.
MD;&"A:@+:]H["(L&-7%='(YK(-PO"??=?<)WN)L*[PDVC"FV(WBY4CP^)F4T
MCNDS*!T-WE@YJ%\MB?[_V/SG!9JCJ9[RV%N:J5O#I#(8,(9[@WO 3Z T[%P!
M5BI,WUJ&::7#U*VA9[BC)G*)GZ5 /=8IQ^\CG+;ZR]*\(U^)8XV;%MC[,XQ1
M/VA(;"7%U*W%?Z9@-S6HOL7RD/*=50R"S\D.N*KE<BBRU%7F2FJI6VOOL+^F
MRBX'.I0X:W@D\$R2".[*?Z60M/O6M:[4B[KEZV?R.J$UXM5N3FNE3-0M3==<
M:QZN-QJ,<2W@M)(@^M8:Q"H-8FX-^B_39EQ@[T^;+@UZ]1EEE1XQMQ[]3'G'
M!>9^>9ECVK"]K21SJZ/"Q5%9]_"()WD-EH:0BUH2;JC.R]L\5@D><PO>S2:>
M8SYL[;+>T,1(NS,!/%U])8TGE3$[U#K:D*-*Z-@/"AWF"[8\:MH/CU_ :V=E
M=N:IDCWFEKT;:6QGYT4CJ'A%;JITU1)T@PX<E?3V3LGVO<PU5RN!Y8E@B5C^
M20^A5?ZJ([\Q,LT.SG-I\!B>7:Z!+T#9 ?C_4N*>I[BQ9_'RA=/H&U!+ P04
M    " #BAGY4T/:W7+H"  "P!P  &0   'AL+W=O<FMS:&5E=',O<VAE970V
M,"YX;6R5E5UOVC 4AO^*%?6BE=;FDP 5(!7::;NH5I6VNS;)@5B-[<PVI?OW
M.W9"1B&P[@9LY[ROGW/B^(PV4KWJ L"0=UX*/?8*8ZIKW]=9 9SJ*UF!P"=+
MJ3@U.%4K7U<*:.Y$O/2C($A]3IGP)B.W]J F([DV)1/PH(A><T[5[RF4<C/V
M0F^[\,A6A;$+_F14T17,P3Q7#PIG?NN2,PY",RF(@N78NPFO9P,;[P)>&&ST
MSIC83!92OMK)]WSL!18(2LB,=:#X]P8S*$MKA!B_&D^OW=(*=\=;]Z\N=\QE
M037,9/F3Y:88>P./Y+"DZ](\RLTW:/+I6;],EMK]DDT3&W@D6VLC>2-& LY$
M_4_?FSKL",+TB"!J!-&^(#DBB!M![!*MR5Q:M]30R4C)#5$V&MWLP-7&J3$;
M)NQ;G!N%3QGJS&0F.6<&7XO1A(J<S*0P3*Q 9 PTN21S/#;YN@0BE_B,5U*X
M4)P]XH#<O>-QTD#.;\%05NH+E#S/;\GYV04Y(TR0IT*N-1KKD6\0UV[J9PW:
MM$:+CJ"%$;E'FD*3.Y%#_M' QSS;9*-MLM/HI.,M9%<D#K^0*(C"#J#9Y^7!
M"9RXK7WL_.(C?C\J4-16FY2 )U&?L$Q:R\19)I^S))G4IJORM4O/N=@/_6T2
MADDT\M]VJ]$1% R';= 'P%X+V#L)^$(5HXOR.%DM3W<V3?KQ'MAA3)JDW5QI
MRY7^5^&@/MA=A.G![F$:]O80.X+Z2:^;L=\R]D\RS@NIS*4!Q1M(93_!$Z3]
MPUHF>YR'(<.PFW+04@Y.4CY)0\M_H@T.SU;:&^[!=00-XOT7[>]<?AS4RO4$
MC>=K+4Q]-;2K;=NY<;?MWOH4VU'=/?[:U+WLGJH5$QJKOD3+X*J/2*KN#_7$
MR,I=L0MI\,)VPP);*B@;@,^74IKMQ&[0-NG)'U!+ P04    " #BAGY4_GZ#
MFQ,#  !""   &0   'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6R=5MMRTS 0
M_94=4YAVAL:7-!<@R4R;P- 9.A1*Z0/#@V*O8PVV%"2Y:?^>E>RZ:7#,Y276
M;<^>LROM9K*1ZH?.$ W<%;G04R\S9OW:]W6<8<%T3ZY1T$XJ5<$,3=7*UVN%
M+'%&1>Y'03#T"\:%-YNXM4LUF\C2Y%S@I0)=%@53]V>8R\W4"[V'A<]\E1F[
MX,\F:[;"*S37ZTM%,[]!27B!0G,I0&$Z]4[#U_.1/>\.?.6XT5MCL$J64OZP
MD_-DZ@66$.88&XO Z'.+<\QS"T0T?M:87N/2&FZ/']#?.>VD9<DTSF5^PQ.3
M3;VQ!PFFK,S-9[EYC[6>@<6+9:[=+VSJLX$'<:F-+&IC8E!P47W971V'+8-H
ML,<@J@VB'8-PM,>@7QOTG="*F9.U8(;-)DIN0-G3A&8'+C;.FM1P8;-X913M
M<K(SL[DL"FXH+48#$PG,I3!<K%#$'#4<PQ5=FZ3,$60*GTI&FX;9P,.YJ*Z0
MR\62[@=\7*-BUA@^( 56P^$"#>.Y/B*<ZZL%'!X<P0%P 5\R66KRIB>^(0V6
MB1_7?,\JOM$>OF$$%T0QT_!6))@\!?!)?!.!Z"$"9U$GX@+C'O3#EQ %4=A"
M:/[WYD$'G7Z3D+[#Z_]70A9<Q[G4I4+X=KK41M$S^-[A]:3Q>N*\GNSQ^IB[
MF.D,4GK<&E(E"Y#-3NZRVI:R"GO@L&W9N)V%X>C5Q+_=#F/+H6 <-H>>T!XT
MM >=M%W1.9;I<:D1F-9(0<.[.&,4L 3H@N[2AYRS)<^YX>U*!K^1'$8G.T)^
M/S,>M\L8-C*&G3)N7+'!Y)C=$ML54GFT!?B1M4%5O'@VCL+HS6X^X) >U#TR
MI8_:!'4[[E>6\ J*ZE&%8TC8?5MHYMU(@QII6"-UW,E1$Y71OT4EH<LO2V&
M H![PM$6@VXW8= +@^=MBO]@%_:"7;M*I[]5C@M4*]>E-#CN55UJ5IM&>.KJ
M_\[Z&37(JI\]PE3=]8*I%1>:1*<$&?1&=!U5U;&JB9%K5_27TE +<<.,FCPJ
M>X#V4RG-P\0Z:/XVS'X!4$L#!!0    ( .*&?E0!F%-1L0(  *,'   9
M>&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;)V576_:,!2&_XH5]:*5UN8#$J "
MI!8T;5*K5:7=+J9=F.1 K#HVLQUH__V.'9JR84#:#?'7>Y[W&/MXN)'J19<
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MRJ*K'NI5\R(T'2-7K@K/I<&:[IHEOJ*@[ *<7TAIWCNVL+?O\O@/4$L#!!0
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M:'9RCSF-MZCL 7J?2FF>%]9!.S#/O@-02P,$%     @ XH9^5!YL)8FC @
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M6H#97PFA=Q,;H/^_Y'\!4$L#!!0    ( .*&?E39'A*8%0,  "H*   9
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MW[/LXUY?A4$8 _U]R[EZ'9C+5GNY7OT"4$L#!!0    ( .*&?E3KE_M0UP(
M &D'   9    >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;)65R6[;,!"&7X40
M>DB --ILJ0EL UY2-(< AIVTAZ('1AI;1"C2):G8Z=-W2,FJXZWM1>(R\_.;
M(3GLK:5ZT06 (9N2"]WW"F-6M[ZOLP)*JJ_E"@3.+*0JJ<&N6OIZI8#FSJGD
M?A0$B5]2)KQ!SXU-U: G*\.9@*DBNBI+JMY&P.6Z[X7>=F#&EH6Q _Z@MZ)+
MF(-Y6DT5]OQ6)6<E",VD( H6?6\8WHY3:^\,OC)8ZYTVL9$\2_EB._=YWPLL
M$'#(C%6@^'N%,7!NA1#C9Z/IM4M:Q]WV5OVSBQUC>:8:QI)_8[DI^MXGC^2P
MH!4W,[G^ DT\7:N72:[=EZP;V\ C6:6-+!MG)"B9J/]TT^1AQR%,3CA$C4.T
M[] YX1 W#K$+M"9S84VHH8.>DFNBK#6JV8;+C?/&:)BPNS@W"F<9^IG!O<AD
M">21;D"3CV2.IR2O.!"Y($]"02:7@OV"W!J0$0A8,*/)3').,(MKJG)R,0%#
M&=>7Z/XTGY"+#Y?D V&"/!:RTE3DNN<;)+7K^5E#-:JIHA-4840>I#"%)G<B
MA_R]@(\AMG%&VSA'T5G%"637) ZO2!1$X1&@\;^[!V=PXC;ML=.+3^C-,+,B
M8YQ1=YC/9?N*W&TR7N5,+,FPE)7 #9B"PIP+.V0DSE,\&8W;#$REA";?=S?I
MQQGD3HO<<<B=$\@C6#+AEAQ13D4&Q[:UEN@Z"5M 7@=1-[WI^:^[J3XT"EJ+
M=VC=%JU[%FV8Y\SF41,L:WAKE )AR!M0=8RQUDIVE@^#--YC/#1*XO@X9=)2
M)O]!N5(,OY;QZ/U(#M:/]A$/3<*;3G*<,6T9T[.,>-W^LL/IP>;%2=K=0SLT
M>G<,:C1_IVJ5H):NF&N2V2->7^QVM'TOAJY,[HV/\!VIR_X?F?H1>J *#ZTF
M'!8H&5RGB*3JPEYWC%RYVO@L#59:URSP+01E#7!^(:79=NP"[>LZ^ U02P,$
M%     @ XH9^5+6JY5]_ @  W08  !D   !X;"]W;W)K<VAE971S+W-H965T
M-S$N>&ULI55-3]M $/TK(XL#2!0G=@P%)98 MRJ'2BA .50];.QQO&*]F^Z.
M"?37=W=MW(0$FJJ7>#_FS;PW+QZ/ETH_F J1X*D6TDR"BFAQ%H8FK[!FYD@M
M4-J;4NF:D=WJ>6@6&EGA0;4(H\'@.*P9ET$Z]F?7.AVKA@27>*W!-'7-]/,%
M"K6<!,/@Y6#*YQ6Y@S =+]@<;Y#N%M?:[L(^2\%KE(8K"1K+27 ^/,L2%^\#
MOG%<FI4U."4SI1[<YJJ8! -'" 7FY#(P^WC$2Q3");(T?G8Y@[ZD ZZN7[)_
M]MJMEADS>*G$/2^HF@0? RBP9(V@J5I^P4Z/)Y@K8?PO++O800!Y8TC5'=@R
MJ+ELG^RIZ\,*8#AZ Q!U@&A70-P!XET!HPXP\IUII?@^9(Q8.M9J"=I%VVQN
MX9OIT58^E\[V&]+VEEL<I5<R5S7"+7M" Q_@3FK,U5SR7UBX0[A B24G<PA7
M)4S[NT.X5XTHX+PLK8% %<(GO[0F>MR4$<)^AL2X, <N\TT&^WL'L =<PFVE
M&L-D8<8A61&.2IAWA"]:PM$;A#/,CR >'D(TB(9;X)>[PP=;X-G.\.'I.CRT
MG>_;'_7MCWR^^*_MAXR;7"C3:(3OYS-#VKX2/]XI$?<E8E]B]$:)-4MGG9W6
M,4;VE70>LC\>8N\A64;:>KC-H+9>XNNYL?*8VDX^KGKP7L2:B%$O8O1_(J2B
M?Q?2UCQ>H1D?GR2OM&P&1<G)Z78Y22\G>5?.K2(FH-DF:AO/9*.=6WAN!JWQ
M;/_=FT&OC0E79HD;_%^9GG-I0&!I,8.C$PO6[3!M-Z06?KS,%-EAY9>5_?Z@
M=@'VOE2*7C9N8O5?M/0W4$L#!!0    ( .*&?E2U9)C3F0(  (\(   9
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M%]ULUVTOFA[S[-ZTZANB"BHT,,PM-!J<V/NJFN[7&$96ON.LI;']RP]+^\>
MRCG8]5Q*LS5<@.X?9/X'4$L#!!0    ( .*&?E3VC%Q(#@,  %X)   9
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M\7#06G!P3?+ASMF +R%@C;KW-N-1@DEXH&!/((G#23PY(2$F+7/RZR*F@K^
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M'!!&0.^O.%?[B3%0/IM&?P!02P,$%     @ XH9^5"Y[IWQ/ @  U04  !D
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MDF5A!+"P@B3!$'@;<013 !HP)$G</GBP'\7M/A5O?^>:_ 902P,$%     @
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M\MK-.Q&1:5)BT^R7=(<:8R+3I,2F@=,?O:"3(M.DU$,2*,0LQD2F28E-@R9
MV-%EC(E,DQ*;9I^WC]G,7SV>\TJ1:5)BT^S'[,[$<]K(-!FQ:?9CW@0'Q9C(
M.]EA)K[6M=E[TC/DG>Q $V#/G3/&1 ;*B T$,$.KQYAPP8780K V^XV.+)01
M6PACQN.=#%DHHU]UV3WYZ6.[<+TG'5DH([80'DCT:A-9*#OH>"=V>H8LE+W%
M>&=KIG;=WK+NI9LYDE!.+*&]H[)7\2A'$LJ))00PMZ)[CB24$TL(8O;"9HXD
ME%-/LT',^$'/D81RZDFW_9CA,,:$Z_[$$OIOQN"8?6F=QU"5'Y>S':L-.9)0
M3BRA"//YK1\&.;EZ#DLQ)I)0_D:+-)LT.&Q]VATVD8/R0R[=L.,8$SDH)W80
MQ.S%HP))J""6$,:,XU&!)%0<<@:NEW@42$(%^9XSA)G'F$A"!?F. (19Q)A(
M0@6QA'KSF:]C4HR))%002V@+LYN/:7U>K.<LG(HQX?8S8@D!S"VE%TA"!;&$
M .;5?!Z[LD 6*H@M!###+&*,B2Q4O.$6@BW,OU1O>7R"+#0AMM 69D K];T*
MV[Q#88R)+#0AMM#.S0\OD2G&1!::$%MHQU)+W/0Q)K+0Y.U7A%XP^QMBD84F
MAUL5"BT?8R(+38@MA#%[C8XL-"%?%=K:9K)S@#&!6Z [ PV[#]L/IY5_$I6H
M;OSEK2\O>5U.#0LOW0:N),O#)JYY6]<7ONR+^JQYM?G+QN;O)A_^!5!+ P04
M    " #BAGY4>NU.;58"  ".+0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QSS=I+;J- %(7AK5@L(+CNJY)6G%%/,HVR >24'XIM$-!*LONVG(%]
M4 ]Z$G%&J$!<_M$G5/#X4@[-N&]/PV[?#8O/X^$TK*K=.':_ZGI8[\JQ&>[:
MKIS.5S9M?VS&\[+?UEVS?F^VI9;E,NK^=D;U]'@[<_'ZU97_F=AN-OMU^=VN
M_QS+:?S'X/JC[=^'72ECM7AM^FT95U7]>;B>'NK+(=V=)U>+Y[=5U3^_I:J>
M.T@@2.8/4@C2^8,,@FS^((<@GS\H("CF#\H0E.</NH>@^_F#'B#H8?Z@M$09
MEP1)$ZP)M$[(=2+P.B'8B4#LA&0G K,3HIT(U$[(=B)P.R'<B4#NA'0G KL3
MXIT(]!;46PCT%M1;"/26R<LV@=Z">@N!WH)Z"X'>@GH+@=Z">@N!WH)Z"X'>
M@GH+@=Z">@N!WHIZ*X'>BGHK@=Z*>BN!WCK9+"'06U%O)=!;46\ET%M1;R70
M6U%O)=!;46\ET%M1;R70VU!O(]#;4&\CT-M0;R/0VU!O(]#;)IO=!'H;ZFT$
M>AOJ;01Z&^IM!'H;ZFT$>AOJ;01Z.^KM!'H[ZNT$>COJ[01Z.^KM!'H[ZNT$
M>OOD8R6!WHYZ.X'>CGH[@=Z.>CN!WHYZ.X'>@7H'@=Z!>@>!WH%Z!X'>@7H'
M@=Z!>@>!WH%Z!X'>,?G9A$#O0+V#0.] O8- [T"]@T#OC'IG KTSZIT)],ZH
M=R;0.Z/>F4#OC'IG KTSZIT)],ZH=R;0.T]^%OQ)O8?QZU"&:\_W&I__DU2/
MYWO+]?&7Y??)"3L7G.O;BN'I+U!+ P04    " #BAGY45:BY9Q("  !S+
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M/^O!=>-+/IO_:WS]&U!+ 0(4 Q0    ( .*&?E0'04UB@0   +$    0
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M965T,RYX;6Q02P$"% ,4    " #BAGY4J%&]SO0"  #E"   &
M    @($#&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @
MXH9^5).1=PFV!0  1!8  !@              ("!+1L  'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+ 0(4 Q0    ( .*&?E2&&H=VEP@  #0K   8
M          " @1DA  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M    " #BAGY4B!C_U4,"  !&!0  &               @('F*0  >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ XH9^5#*X%J#R"0  ["T
M !@              ("!7RP  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M 0(4 Q0    ( .*&?E0EXDHA+PD  +X6   8              " @8<V  !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #BAGY4E7FJ)@XF
M  #!>@  &0              @('L/P  >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+ 0(4 Q0    ( .*&?E2HH/83W T   LH   9              "
M@3%F  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ XH9^
M5 F3*X\#"   K!D  !D              ("!1'0  'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"% ,4    " #BAGY40$&M3P<%  #""P  &0
M        @(%^?   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0
M   ( .*&?E2N4"UL]0(  .P&   9              " @;R!  !X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ XH9^5" /J]>B P   @D
M !D              ("!Z(0  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"% ,4    " #BAGY4J=H0T_4"  "/!@  &0              @('!B
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( .*&?E2J;=TH
M9PL  ,8=   9              " @>V+  !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L! A0#%     @ XH9^5%W_*6 S!0  _0P  !D
M ("!BY<  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #B
MAGY4::4<VZT-  "5(P  &0              @('UG   >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( .*&?E0$D&_!EPL  $\?   9
M          " @=FJ  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#
M%     @ XH9^5($;.\*W P  30@  !D              ("!I[8  'AL+W=O
M<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #BAGY48&)L[%4$  !1
M"@  &0              @(&5N@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM
M;%!+ 0(4 Q0    ( .*&?E3!AW\K" D  *\7   9              " @2&_
M  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ XH9^5 21
M-C9F!0  Q P  !D              ("!8,@  'AL+W=O<FMS:&5E=',O<VAE
M970R-"YX;6Q02P$"% ,4    " #BAGY46^=>*G\E   )?P  &0
M    @(']S0  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (
M .*&?E0P](\6, ,  -8&   9              " @;/S  !X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL4$L! A0#%     @ XH9^5%RW\9]^!0  J0\  !D
M             ("!&O<  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M% ,4    " #BAGY4O^\XCG4$  #7"@  &0              @('/_   >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( .*&?E3JU:1E-@,
M $X'   9              " @7L! 0!X;"]W;W)K<VAE971S+W-H965T,CDN
M>&UL4$L! A0#%     @ XH9^5/OW8M(W!0  S@P  !D              ("!
MZ 0! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " #BAGY4
MBE"@"#8$  "'"@  &0              @(%6"@$ >&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;%!+ 0(4 Q0    ( .*&?E3D%GV;$P4  /<.   9
M      " @<,. 0!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%
M  @ XH9^5(C9;)LT!@  U1$  !D              ("!#10! 'AL+W=O<FMS
M:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " #BAGY4&DE),X@$   M"P
M&0              @(%X&@$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+
M 0(4 Q0    ( .*&?E2._NJ(G0(  *H%   9              " @3<? 0!X
M;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ XH9^5+(W%("E
M!   V!,  !D              ("!"R(! 'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6Q02P$"% ,4    " #BAGY46HO:OH<$  !<$0  &0
M@('G)@$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( .*&
M?E0GU=@2E04  ,88   9              " @:4K 0!X;"]W;W)K<VAE971S
M+W-H965T,S@N>&UL4$L! A0#%     @ XH9^5(\QP.K(!   9A@  !D
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M=#0S+GAM;%!+ 0(4 Q0    ( .*&?E1ZX?G2CP(  ((&   9
M  " @9U$ 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @
MXH9^5'B"<A]  P  S D  !D              ("!8T<! 'AL+W=O<FMS:&5E
M=',O<VAE970T-2YX;6Q02P$"% ,4    " #BAGY4YE&!^;D"  !&!P  &0
M            @(':2@$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4
M Q0    ( .*&?E2J&@F<>P,   T.   9              " @<I- 0!X;"]W
M;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ XH9^5!& 07X@ P
MP@D  !D              ("!?%$! 'AL+W=O<FMS:&5E=',O<VAE970T."YX
M;6Q02P$"% ,4    " #BAGY4NX9_W<("  !N"   &0              @('3
M5 $ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( .*&?E23
M\I>'\ $  $0$   9              " @<Q7 0!X;"]W;W)K<VAE971S+W-H
M965T-3 N>&UL4$L! A0#%     @ XH9^5%C0E7ZW!   0!(  !D
M     ("!\UD! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .*&?E2ADZQ&300  -L7   9              "
M@01N 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ XH9^
M5':W4E-A P  ?0L  !D              ("!B'(! 'AL+W=O<FMS:&5E=',O
M<VAE970U-RYX;6Q02P$"% ,4    " #BAGY4.\1:J.@"   1"0  &0
M        @($@=@$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0
M   ( .*&?E1!M(+ZJP0  'P2   9              " @3]Y 0!X;"]W;W)K
M<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ XH9^5-#VMURZ @  L <
M !D              ("!(7X! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q0
M2P$"% ,4    " #BAGY4_GZ#FQ,#  !""   &0              @($2@0$
M>&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( .*&?E0!F%-1
ML0(  *,'   9              " @5R$ 0!X;"]W;W)K<VAE971S+W-H965T
M-C(N>&UL4$L! A0#%     @ XH9^5&QCZ0^7 P  / L  !D
M ("!1(<! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " #B
MAGY4'FPEB:,"  "1!P  &0              @($2BP$ >&PO=V]R:W-H965T
M<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( .*&?E0G84*][0(  ,@(   9
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M970V.2YX;6Q02P$"% ,4    " #BAGY4ZY?[4-<"  !I!P  &0
M    @(&6G@$ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    (
M .*&?E2UJN5??P(  -T&   9              " @:2A 0!X;"]W;W)K<VAE
M971S+W-H965T-S$N>&UL4$L! A0#%     @ XH9^5+5DF-.9 @  CP@  !D
M             ("!6J0! 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"
M% ,4    " #BAGY4]HQ<2 X#  !>"0  &0              @($JIP$ >&PO
M=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( .*&?E2G!7?;XP,
M +@0   9              " @6^J 0!X;"]W;W)K<VAE971S+W-H965T-S0N
M>&UL4$L! A0#%     @ XH9^5"X2=-UW!@  RB   !D              ("!
MB:X! 'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6Q02P$"% ,4    " #BAGY4
M#',C3?@"  !""0  &0              @($WM0$ >&PO=V]R:W-H965T<R]S
M:&5E=#<V+GAM;%!+ 0(4 Q0    ( .*&?E0N>Z=\3P(  -4%   9
M      " @6:X 0!X;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%
M  @ XH9^5!'H$NXN P  ]!(   T              ( ![+H! 'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " #BAGY4EXJ[',     3 @  "P
M@ %%O@$ 7W)E;',O+G)E;'-02P$"% ,4    " #BAGY4%(N+JIT%  #R,@
M#P              @ $NOP$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
MXH9^5'KM3FU6 @  CBT  !H              ( !^,0! 'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ XH9^5%6HN6<2 @  <RP  !,
M             ( !AL<! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     %4
,50!*%P  R<D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>206</ContextCount>
  <ElementCount>445</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>84</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1006008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of the Business and Financial Condition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/DescriptionoftheBusinessandFinancialCondition</Role>
      <ShortName>Description of the Business and Financial Condition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2107103 - Disclosure - Revenue and Deferred Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/RevenueandDeferredRevenue</Role>
      <ShortName>Revenue and Deferred Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2109104 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2115105 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - Convertible Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.angn.com/role/ConvertibleNotesPayable</Role>
      <ShortName>Convertible Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2123107 - Disclosure - Series C Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/SeriesCConvertiblePreferredStock</Role>
      <ShortName>Series C Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2127108 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2129109 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2136110 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2141111 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2149112 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2158113 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2160114 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2164115 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2168116 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.angn.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angn.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angn.com/role/FairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2316303 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angn.com/role/BalanceSheetComponents</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2324304 - Disclosure - Series C Convertible Preferred Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/SeriesCConvertiblePreferredStockTables</Role>
      <ShortName>Series C Convertible Preferred Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angn.com/role/SeriesCConvertiblePreferredStock</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2330305 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angn.com/role/StockBasedCompensation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2337306 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angn.com/role/Warrants</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2342307 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angn.com/role/CommitmentsandContingencies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2350308 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angn.com/role/IncomeTaxes</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2361309 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angn.com/role/NetLossPerShare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2365310 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.angn.com/role/RelatedPartyTransactions</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of the Business and Financial Condition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails</Role>
      <ShortName>Description of the Business and Financial Condition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angn.com/role/DescriptionoftheBusinessandFinancialCondition</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angn.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Revenue and Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/RevenueandDeferredRevenueDetails</Role>
      <ShortName>Revenue and Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angn.com/role/RevenueandDeferredRevenue</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Fair Value Measurements - Fair Value, Liabilities, Measured on Recurring Basis, Unobservable Input Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value, Liabilities, Measured on Recurring Basis, Unobservable Input Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Fair Value Measurements - Fair Value Measurement Inputs and Valuation Techniques (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/FairValueMeasurementsFairValueMeasurementInputsandValuationTechniquesDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value Measurement Inputs and Valuation Techniques (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Balance Sheet Components - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/BalanceSheetComponentsNarrativeDetails</Role>
      <ShortName>Balance Sheet Components - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Balance Sheet Components - Schedule of Prepaid and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Prepaid and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2420411 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - Convertible Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.angn.com/role/ConvertibleNotesPayableDetails</Role>
      <ShortName>Convertible Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angn.com/role/ConvertibleNotesPayable</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2425413 - Disclosure - Series C Convertible Preferred Stock - Summary of Aggregate Values Recorded (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/SeriesCConvertiblePreferredStockSummaryofAggregateValuesRecordedDetails</Role>
      <ShortName>Series C Convertible Preferred Stock - Summary of Aggregate Values Recorded (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2426414 - Disclosure - Series C Convertible Preferred Stock - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/SeriesCConvertiblePreferredStockNarrativeDetails</Role>
      <ShortName>Series C Convertible Preferred Stock - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angn.com/role/StockholdersEquity</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Stock-Based Compensation - Schedule of Share Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Share Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Stock-Based Compensation - Schedule of RSA and RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/StockBasedCompensationScheduleofRSAandRSUActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of RSA and RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2435420 - Disclosure - Stock-Based Compensation - Components of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Components of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - Warrants - Outstanding Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/WarrantsOutstandingWarrantsDetails</Role>
      <ShortName>Warrants - Outstanding Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2439422 - Disclosure - Warrants - Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/WarrantsWarrantActivityDetails</Role>
      <ShortName>Warrants - Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2440423 - Disclosure - Warrants - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/WarrantsNarrativeDetails</Role>
      <ShortName>Warrants - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2443424 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2444425 - Disclosure - Commitments and Contingencies - Schedule of Components of Rent Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/CommitmentsandContingenciesScheduleofComponentsofRentExpenseDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Components of Rent Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2445426 - Disclosure - Commitments and Contingencies - Schedule of Quantitative Information about Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/CommitmentsandContingenciesScheduleofQuantitativeInformationaboutOperatingLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Quantitative Information about Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2446427 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2447428 - Disclosure - Commitments and Contingencies - Schedule Of Quantitative Information About The Financing Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/CommitmentsandContingenciesScheduleOfQuantitativeInformationAboutTheFinancingObligationDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule Of Quantitative Information About The Financing Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2448429 - Disclosure - Commitments and Contingencies - Finance Lease, Liability, Fiscal Year Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails</Role>
      <ShortName>Commitments and Contingencies - Finance Lease, Liability, Fiscal Year Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2451430 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2452431 - Disclosure - Income Taxes - Schedule of Income before Income Tax, Domestic and Foreign (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/IncomeTaxesScheduleofIncomebeforeIncomeTaxDomesticandForeignDetails</Role>
      <ShortName>Income Taxes - Schedule of Income before Income Tax, Domestic and Foreign (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2453432 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2454433 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2455434 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2456435 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2457436 - Disclosure - Income Taxes - Unrecognized Tax Benefits, If Recognized, Would Affect the Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/IncomeTaxesUnrecognizedTaxBenefitsIfRecognizedWouldAffecttheEffectiveTaxRateDetails</Role>
      <ShortName>Income Taxes - Unrecognized Tax Benefits, If Recognized, Would Affect the Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2459437 - Disclosure - Employee Benefit Plan - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/EmployeeBenefitPlanNarrativeDetails</Role>
      <ShortName>Employee Benefit Plan - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2462438 - Disclosure - Net Loss Per Share - Schedule of net loss per share, basic and diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/NetLossPerShareScheduleofnetlosspersharebasicanddilutedDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of net loss per share, basic and diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2463439 - Disclosure - Net Loss Per Share - Schedule of antidilutive securities excluded from computation of net loss per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/NetLossPerShareScheduleofantidilutivesecuritiesexcludedfromcomputationofnetlosspershareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of antidilutive securities excluded from computation of net loss per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2466440 - Disclosure - Related Party Transactions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails</Role>
      <ShortName>Related Party Transactions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2467441 - Disclosure - Related Party Transactions - Nova Park Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/RelatedPartyTransactionsNovaParkInvestmentDetails</Role>
      <ShortName>Related Party Transactions - Nova Park Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="angn-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2469442 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.angn.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.angn.com/role/SubsequentEvents</ParentRole>
      <Position>77</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="angn-20211231.htm">angn-20211231.htm</File>
    <File>a200909flg-angionfirstamen.htm</File>
    <File>a201210flg-angionsecondame.htm</File>
    <File>a220311flg-angionthirdamen.htm</File>
    <File>angion-descriptionofsecuri.htm</File>
    <File>angion-executiveseparation.htm</File>
    <File>angn-20211231.xsd</File>
    <File>angn-20211231_cal.xml</File>
    <File>angn-20211231_def.xml</File>
    <File>angn-20211231_lab.xml</File>
    <File>angn-20211231_pre.xml</File>
    <File>egoldberg-angionxformsepar.htm</File>
    <File>ex231_angnx123121-10k.htm</File>
    <File>ex311_angnx123121-revisedv.htm</File>
    <File>ex312_angnx123121xrevisedc.htm</File>
    <File>ex321angn-12312021x10k.htm</File>
    <File>ex322_angnx123121x10k.htm</File>
    <File>igseparationagreement-fina.htm</File>
    <File>licenseagreementangionvit2.htm</File>
    <File>non-employeedirectorcompen.htm</File>
    <File>solara-angionxredactedclin.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>angn-20211231_g1.jpg</File>
    <File>angn-20211231_g2.jpg</File>
    <File>angn-20211231_g3.jpg</File>
    <File>angn-20211231_g4.jpg</File>
    <File>angn-20211231_g5.jpg</File>
    <File>angn-20211231_g6.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="790">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>122
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "angn-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 30,
   "contextCount": 206,
   "dts": {
    "calculationLink": {
     "local": [
      "angn-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "angn-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "angn-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "angn-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "angn-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "angn-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 672,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 1,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 5
   },
   "keyCustom": 80,
   "keyStandard": 365,
   "memberCustom": 28,
   "memberStandard": 46,
   "nsprefix": "angn",
   "nsuri": "http://www.angn.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.angn.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.angn.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107103 - Disclosure - Revenue and Deferred Revenue",
     "role": "http://www.angn.com/role/RevenueandDeferredRevenue",
     "shortName": "Revenue and Deferred Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109104 - Disclosure - Fair Value Measurements",
     "role": "http://www.angn.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115105 - Disclosure - Balance Sheet Components",
     "role": "http://www.angn.com/role/BalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - Convertible Notes Payable",
     "role": "http://www.angn.com/role/ConvertibleNotesPayable",
     "shortName": "Convertible Notes Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "angn:FinancialInstrumentsSubjectToMandatoryRedemptionDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123107 - Disclosure - Series C Convertible Preferred Stock",
     "role": "http://www.angn.com/role/SeriesCConvertiblePreferredStock",
     "shortName": "Series C Convertible Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "angn:FinancialInstrumentsSubjectToMandatoryRedemptionDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127108 - Disclosure - Stockholders' Equity",
     "role": "http://www.angn.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129109 - Disclosure - Stock-Based Compensation",
     "role": "http://www.angn.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "angn:WarrantsAndRightsOutstandingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136110 - Disclosure - Warrants",
     "role": "http://www.angn.com/role/Warrants",
     "shortName": "Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "angn:WarrantsAndRightsOutstandingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141111 - Disclosure - Commitments and Contingencies",
     "role": "http://www.angn.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://www.angn.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149112 - Disclosure - Income Taxes",
     "role": "http://www.angn.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2158113 - Disclosure - Employee Benefit Plan",
     "role": "http://www.angn.com/role/EmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2160114 - Disclosure - Net Loss Per Share",
     "role": "http://www.angn.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2164115 - Disclosure - Related Party Transactions",
     "role": "http://www.angn.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2168116 - Disclosure - Subsequent Events",
     "role": "http://www.angn.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.angn.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316303 - Disclosure - Balance Sheet Components (Tables)",
     "role": "http://www.angn.com/role/BalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesSubjectToMandatoryRedemptionDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324304 - Disclosure - Series C Convertible Preferred Stock (Tables)",
     "role": "http://www.angn.com/role/SeriesCConvertiblePreferredStockTables",
     "shortName": "Series C Convertible Preferred Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesSubjectToMandatoryRedemptionDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i3a167605e6c646629b93a1d3439787b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - Consolidated Balance Sheets",
     "role": "http://www.angn.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i3a167605e6c646629b93a1d3439787b9_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GrantsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330305 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.angn.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337306 - Disclosure - Warrants (Tables)",
     "role": "http://www.angn.com/role/WarrantsTables",
     "shortName": "Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2342307 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.angn.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2350308 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.angn.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2361309 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://www.angn.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2365310 - Disclosure - Related Party Transactions (Tables)",
     "role": "http://www.angn.com/role/RelatedPartyTransactionsTables",
     "shortName": "Related Party Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ia5d656fe36d64dd28f480aaf15a0cf24_D20210201-20210201",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of the Business and Financial Condition (Details)",
     "role": "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails",
     "shortName": "Description of the Business and Financial Condition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ia5d656fe36d64dd28f480aaf15a0cf24_D20210201-20210201",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteStockSplitConversionRatio1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "operatingsegment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "operatingsegment",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueNotFromContractWithCustomer",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Revenue and Deferred Revenue (Details)",
     "role": "http://www.angn.com/role/RevenueandDeferredRevenueDetails",
     "shortName": "Revenue and Deferred Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i2b2bdc42a04c4cd3af27c83384133f3b_D20210101-20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "angn:ContractWithCustomerContractTerminationPeriodCurableBreach",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i3a167605e6c646629b93a1d3439787b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "angn:FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411404 - Disclosure - Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)",
     "role": "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i2e37997f6b2f47c0a98e68a4f9edef5e_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i3a167605e6c646629b93a1d3439787b9_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.angn.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i3a167605e6c646629b93a1d3439787b9_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i1bc5ce1428404ed68895fc85d43b0940_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Fair Value Measurements - Fair Value, Liabilities, Measured on Recurring Basis, Unobservable Input Reconciliation (Details)",
     "role": "http://www.angn.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
     "shortName": "Fair Value Measurements - Fair Value, Liabilities, Measured on Recurring Basis, Unobservable Input Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i1bc5ce1428404ed68895fc85d43b0940_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i2fba8513019e4003882ec149aeddb34b_I20210209",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentConvertibleConversionPrice1",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i5ce6c1160cbc4d2eb14e3ddc68c08191_D20210209-20210209",
      "decimals": "2",
      "lang": "en-US",
      "name": "angn:FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsConversionPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i209f579b21984d5987ce82e809b3b3f5_I20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Fair Value Measurements - Fair Value Measurement Inputs and Valuation Techniques (Details)",
     "role": "http://www.angn.com/role/FairValueMeasurementsFairValueMeasurementInputsandValuationTechniquesDetails",
     "shortName": "Fair Value Measurements - Fair Value Measurement Inputs and Valuation Techniques (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i209f579b21984d5987ce82e809b3b3f5_I20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i3a167605e6c646629b93a1d3439787b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Details)",
     "role": "http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i3a167605e6c646629b93a1d3439787b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Balance Sheet Components - Narrative (Details)",
     "role": "http://www.angn.com/role/BalanceSheetComponentsNarrativeDetails",
     "shortName": "Balance Sheet Components - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ia7d86eb6878a4ef0b875c05988047754_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i3a167605e6c646629b93a1d3439787b9_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredOfferingCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Balance Sheet Components - Schedule of Prepaid and Other Current Assets (Details)",
     "role": "http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails",
     "shortName": "Balance Sheet Components - Schedule of Prepaid and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i3a167605e6c646629b93a1d3439787b9_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "angn:PrepaidClinicalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i3a167605e6c646629b93a1d3439787b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420411 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses (Details)",
     "role": "http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails",
     "shortName": "Balance Sheet Components - Schedule of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i3a167605e6c646629b93a1d3439787b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i2fba8513019e4003882ec149aeddb34b_I20210209",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - Convertible Notes Payable (Details)",
     "role": "http://www.angn.com/role/ConvertibleNotesPayableDetails",
     "shortName": "Convertible Notes Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i3a167605e6c646629b93a1d3439787b9_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ConvertibleNotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SharesSubjectToMandatoryRedemptionDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i2fba8513019e4003882ec149aeddb34b_I20210209",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "angn:FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425413 - Disclosure - Series C Convertible Preferred Stock - Summary of Aggregate Values Recorded (Details)",
     "role": "http://www.angn.com/role/SeriesCConvertiblePreferredStockSummaryofAggregateValuesRecordedDetails",
     "shortName": "Series C Convertible Preferred Stock - Summary of Aggregate Values Recorded (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SharesSubjectToMandatoryRedemptionDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i2fba8513019e4003882ec149aeddb34b_I20210209",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "angn:FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i2fba8513019e4003882ec149aeddb34b_I20210209",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426414 - Disclosure - Series C Convertible Preferred Stock - Narrative (Details)",
     "role": "http://www.angn.com/role/SeriesCConvertiblePreferredStockNarrativeDetails",
     "shortName": "Series C Convertible Preferred Stock - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i3a167605e6c646629b93a1d3439787b9_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Stockholders' Equity (Details)",
     "role": "http://www.angn.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.angn.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i54c2a1b829084a7b83834a08509335ce_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Awards (Details)",
     "role": "http://www.angn.com/role/StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails",
     "shortName": "Stock-Based Compensation - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i54c2a1b829084a7b83834a08509335ce_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i1bc5ce1428404ed68895fc85d43b0940_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Stock-Based Compensation - Schedule of Share Option Activity (Details)",
     "role": "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Schedule of Share Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i391c5213ee2846a09acad8d39f4acc78_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Stock-Based Compensation - Schedule of RSA and RSU Activity (Details)",
     "role": "http://www.angn.com/role/StockBasedCompensationScheduleofRSAandRSUActivityDetails",
     "shortName": "Stock-Based Compensation - Schedule of RSA and RSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i391c5213ee2846a09acad8d39f4acc78_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435420 - Disclosure - Stock-Based Compensation - Components of Stock-Based Compensation Expense (Details)",
     "role": "http://www.angn.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Components of Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i3a167605e6c646629b93a1d3439787b9_I20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - Warrants - Outstanding Warrants (Details)",
     "role": "http://www.angn.com/role/WarrantsOutstandingWarrantsDetails",
     "shortName": "Warrants - Outstanding Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "if16b69b23bb6477c809c732686e6c818_I20211231",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i1bc5ce1428404ed68895fc85d43b0940_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439422 - Disclosure - Warrants - Warrant Activity (Details)",
     "role": "http://www.angn.com/role/WarrantsWarrantActivityDetails",
     "shortName": "Warrants - Warrant Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "angn:WarrantsAndRightsOutstandingActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "angn:ClassOfWarrantOrRightExercisesInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i3a167605e6c646629b93a1d3439787b9_I20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440423 - Disclosure - Warrants - Narrative (Details)",
     "role": "http://www.angn.com/role/WarrantsNarrativeDetails",
     "shortName": "Warrants - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i59e2995c2115446d9af3ddecfb37c4fb_I20210228",
      "decimals": "2",
      "lang": "en-US",
      "name": "angn:ClassOfWarrantOrRightConversionPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i0bf681e0236d4273af7ed9eb86410720_I20211130",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeaseTermOfContract1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443424 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i0bf681e0236d4273af7ed9eb86410720_I20211130",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeaseTermOfContract1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i9e83b2738e914f70885e201c75695d23_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)",
     "role": "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit",
     "shortName": "Consolidated Statements of Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i9e83b2738e914f70885e201c75695d23_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444425 - Disclosure - Commitments and Contingencies - Schedule of Components of Rent Expense (Details)",
     "role": "http://www.angn.com/role/CommitmentsandContingenciesScheduleofComponentsofRentExpenseDetails",
     "shortName": "Commitments and Contingencies - Schedule of Components of Rent Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "angn:ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445426 - Disclosure - Commitments and Contingencies - Schedule of Quantitative Information about Operating Leases (Details)",
     "role": "http://www.angn.com/role/CommitmentsandContingenciesScheduleofQuantitativeInformationaboutOperatingLeasesDetails",
     "shortName": "Commitments and Contingencies - Schedule of Quantitative Information about Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "angn:ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i3a167605e6c646629b93a1d3439787b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446427 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Lease Liabilities (Details)",
     "role": "http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails",
     "shortName": "Commitments and Contingencies - Schedule of Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i3a167605e6c646629b93a1d3439787b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "angn:ProceedsFromFinancingObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447428 - Disclosure - Commitments and Contingencies - Schedule Of Quantitative Information About The Financing Obligation (Details)",
     "role": "http://www.angn.com/role/CommitmentsandContingenciesScheduleOfQuantitativeInformationAboutTheFinancingObligationDetails",
     "shortName": "Commitments and Contingencies - Schedule Of Quantitative Information About The Financing Obligation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "angn:ScheduleOfQuantitativeInformationAboutTheFinancingObligationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseInterestPaymentOnLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i3a167605e6c646629b93a1d3439787b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448429 - Disclosure - Commitments and Contingencies - Finance Lease, Liability, Fiscal Year Maturity (Details)",
     "role": "http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails",
     "shortName": "Commitments and Contingencies - Finance Lease, Liability, Fiscal Year Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i3a167605e6c646629b93a1d3439787b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451430 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.angn.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i3a167605e6c646629b93a1d3439787b9_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452431 - Disclosure - Income Taxes - Schedule of Income before Income Tax, Domestic and Foreign (Details)",
     "role": "http://www.angn.com/role/IncomeTaxesScheduleofIncomebeforeIncomeTaxDomesticandForeignDetails",
     "shortName": "Income Taxes - Schedule of Income before Income Tax, Domestic and Foreign (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453432 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)",
     "role": "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails",
     "shortName": "Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454433 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "role": "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i3a167605e6c646629b93a1d3439787b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455434 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i3a167605e6c646629b93a1d3439787b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "iacbac71171a247f19b7f67fb114cc51b_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)",
     "role": "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficitParenthetical",
     "shortName": "Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "iacbac71171a247f19b7f67fb114cc51b_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "angn:UnrecognizedTaxBenefitsIfRecognizedWouldAffectTheEffectiveTaxRateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i1bc5ce1428404ed68895fc85d43b0940_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456435 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)",
     "role": "http://www.angn.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "angn:UnrecognizedTaxBenefitsIfRecognizedWouldAffectTheEffectiveTaxRateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i3a167605e6c646629b93a1d3439787b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457436 - Disclosure - Income Taxes - Unrecognized Tax Benefits, If Recognized, Would Affect the Effective Tax Rate (Details)",
     "role": "http://www.angn.com/role/IncomeTaxesUnrecognizedTaxBenefitsIfRecognizedWouldAffecttheEffectiveTaxRateDetails",
     "shortName": "Income Taxes - Unrecognized Tax Benefits, If Recognized, Would Affect the Effective Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "angn:UnrecognizedTaxBenefitsIfRecognizedWouldAffectTheEffectiveTaxRateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i3a167605e6c646629b93a1d3439787b9_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459437 - Disclosure - Employee Benefit Plan - Narrative (Details)",
     "role": "http://www.angn.com/role/EmployeeBenefitPlanNarrativeDetails",
     "shortName": "Employee Benefit Plan - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462438 - Disclosure - Net Loss Per Share - Schedule of net loss per share, basic and diluted (Details)",
     "role": "http://www.angn.com/role/NetLossPerShareScheduleofnetlosspersharebasicanddilutedDetails",
     "shortName": "Net Loss Per Share - Schedule of net loss per share, basic and diluted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463439 - Disclosure - Net Loss Per Share - Schedule of antidilutive securities excluded from computation of net loss per share (Details)",
     "role": "http://www.angn.com/role/NetLossPerShareScheduleofantidilutivesecuritiesexcludedfromcomputationofnetlosspershareDetails",
     "shortName": "Net Loss Per Share - Schedule of antidilutive securities excluded from computation of net loss per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466440 - Disclosure - Related Party Transactions - Narrative (Details)",
     "role": "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
     "shortName": "Related Party Transactions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i8d2bf22513e944e391d7fad6085a8765_I20131130",
      "decimals": "-5",
      "lang": "en-US",
      "name": "angn:RelatedPartyTransactionPotentialMaximumMilestonePayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467441 - Disclosure - Related Party Transactions - Nova Park Investment (Details)",
     "role": "http://www.angn.com/role/RelatedPartyTransactionsNovaParkInvestmentDetails",
     "shortName": "Related Party Transactions - Nova Park Investment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "i4da1e16a428f4e4aa7b45ff38eee1854_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ie6b23068ffab46b0a0c550ea36e51385_I20220301",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2469442 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.angn.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ie6b23068ffab46b0a0c550ea36e51385_I20220301",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalUnemploymentBenefitsSeveranceBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006008 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of the Business and Financial Condition",
     "role": "http://www.angn.com/role/DescriptionoftheBusinessandFinancialCondition",
     "shortName": "Description of the Business and Financial Condition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "angn-20211231.htm",
      "contextRef": "ibe25af6024b44d0784421f861dd0dd81_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 84,
   "tag": {
    "angn_A2020NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Notes",
        "label": "2020 Notes [Member]",
        "terseLabel": "2020 Notes"
       }
      }
     },
     "localname": "A2020NotesMember",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "angn_A2021IncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Incentive Award Plan",
        "label": "2021 Incentive Award Plan [Member]",
        "terseLabel": "2021 Incentive Award Plan"
       }
      }
     },
     "localname": "A2021IncentiveAwardPlanMember",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "angn_A2021PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Plan",
        "label": "2021 Plan [Member]",
        "terseLabel": "2021 Plan"
       }
      }
     },
     "localname": "A2021PlanMember",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "angn_AccruedDirectResearchCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Direct Research Costs, Current",
        "label": "Accrued Direct Research Costs, Current",
        "terseLabel": "Accrued direct research costs"
       }
      }
     },
     "localname": "AccruedDirectResearchCostsCurrent",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_AccruedInterestPremiumForConvertiblePreferredStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Interest Premium For Convertible Preferred Stock",
        "label": "Accrued Interest Premium For Convertible Preferred Stock",
        "terseLabel": "Accrued interest premium for Series C convertible preferred stock"
       }
      }
     },
     "localname": "AccruedInterestPremiumForConvertiblePreferredStock",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_AccruedOperatingLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Operating Liabilities, Current",
        "label": "Accrued Operating Liabilities, Current",
        "terseLabel": "Accrued operating expenses"
       }
      }
     },
     "localname": "AccruedOperatingLiabilitiesCurrent",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_AdditionalConvertibleNotesAndViforConvertibleNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Convertible Notes And Vifor Convertible Note",
        "label": "Additional Convertible Notes And Vifor Convertible Note [Member]",
        "terseLabel": "Additional Convertible Notes and Vifor Convertible Note"
       }
      }
     },
     "localname": "AdditionalConvertibleNotesAndViforConvertibleNoteMember",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "angn_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.angn.com/20211231",
     "xbrltype": "stringItemType"
    },
    "angn_BrokerWarrantsIssuedWith2019NotesLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Broker Warrants Issued with2019 Notes, Liability",
        "label": "Broker Warrants Issued with2019 Notes, Liability [Member]",
        "terseLabel": "Broker Warrants issued with 2019 Notes"
       }
      }
     },
     "localname": "BrokerWarrantsIssuedWith2019NotesLiabilityMember",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/WarrantsOutstandingWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "angn_BrokerWarrantsIssuedWithEquityOfferingEquityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Broker Warrants Issued with Equity Offering, Equity",
        "label": "Broker Warrants Issued with Equity Offering, Equity [Member]",
        "terseLabel": "Broker Warrants issued with Equity Offering"
       }
      }
     },
     "localname": "BrokerWarrantsIssuedWithEquityOfferingEquityMember",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/WarrantsOutstandingWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "angn_CARESActEmployeeRetentionCredit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act, Employee Retention Credit",
        "label": "CARES Act, Employee Retention Credit",
        "terseLabel": "CARES Act, Employee Retention Credit"
       }
      }
     },
     "localname": "CARESActEmployeeRetentionCredit",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_ClassOfWarrantOrRightConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Conversion Price",
        "label": "Class of Warrant or Right, Conversion Price",
        "terseLabel": "Warrant conversion price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightConversionPrice",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/WarrantsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "angn_ClassOfWarrantOrRightExercisesInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercises in Period",
        "label": "Class of Warrant or Right, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisesInPeriod",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/WarrantsWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "angn_ClassOfWarrantOrRightExercisesInPeriodTendered": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercises in Period, Tendered",
        "label": "Class of Warrant or Right, Exercises in Period, Tendered",
        "terseLabel": "Warrants tendered back to the Company (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisesInPeriodTendered",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/WarrantsWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "angn_ClassOfWarrantOrRightExpirationsInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Expirations in Period",
        "label": "Class of Warrant or Right, Expirations in Period",
        "negatedLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExpirationsInPeriod",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/WarrantsWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "angn_ClassOfWarrantOrRightOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Outstanding",
        "label": "Class of Warrant or Right, Outstanding [Roll Forward]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstandingRollForward",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/WarrantsWarrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "angn_ClassOfWarrantOrRightWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Weighted Average Exercise Price",
        "label": "Class of Warrant or Right, Weighted Average Exercise Price",
        "periodEndLabel": "Balance, ending (in dollars per share)",
        "periodStartLabel": "Balance, beginning (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePrice",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/WarrantsWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Weighted Average Exercise Price, Exercises in Period",
        "label": "Class of Warrant or Right, Weighted Average Exercise Price, Exercises in Period",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceExercisesInPeriod",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/WarrantsWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "angn_ClassOfWarrantOrRightWeightedAverageExercisePriceExpirationsInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Weighted Average Exercise Price, Expirations in Period",
        "label": "Class of Warrant or Right, Weighted Average Exercise Price, Expirations in Period",
        "terseLabel": "Expired (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceExpirationsInPeriod",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/WarrantsWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "angn_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Weighted Average Exercise Price of Warrants or Rights",
        "label": "Class of Warrant or Right, Weighted Average Exercise Price of Warrants or Rights [Roll Forward]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsRollForward",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/WarrantsWarrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "angn_ConsultantWarrantsLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consultant Warrants, Liability",
        "label": "Consultant Warrants, Liability [Member]",
        "terseLabel": "Consultant Warrants"
       }
      }
     },
     "localname": "ConsultantWarrantsLiabilityMember",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/WarrantsOutstandingWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "angn_ConsultingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting Agreement",
        "label": "Consulting Agreement [Member]",
        "terseLabel": "Consulting Agreement"
       }
      }
     },
     "localname": "ConsultingAgreementMember",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "angn_ContractWithCustomerContractTerminationPeriodCurableBreach": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with Customer, Contract Termination Period, Curable Breach",
        "label": "Contract with Customer, Contract Termination Period, Curable Breach",
        "terseLabel": "Contract termination period, curable breach"
       }
      }
     },
     "localname": "ContractWithCustomerContractTerminationPeriodCurableBreach",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "angn_ContractWithCustomerContractTerminationPeriodIncurableBreach": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with Customer, Contract Termination Period, Incurable Breach",
        "label": "Contract with Customer, Contract Termination Period, Incurable Breach",
        "terseLabel": "Contract termination period, incurable breach"
       }
      }
     },
     "localname": "ContractWithCustomerContractTerminationPeriodIncurableBreach",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "angn_ContractWithCustomerLiabilityPercentOfUpfrontPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with Customer, Liability, Percent Of Upfront Payment",
        "label": "Contract with Customer, Liability, Percent Of Upfront Payment",
        "terseLabel": "Transaction price, percent of upfront payment"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityPercentOfUpfrontPayment",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "angn_ContractWithCustomerMilestonePaymentsEntitledToReceive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Milestone Payments, Entitled To Receive",
        "label": "Contract With Customer, Milestone Payments, Entitled To Receive",
        "terseLabel": "Total milestone payment, entitled to receive"
       }
      }
     },
     "localname": "ContractWithCustomerMilestonePaymentsEntitledToReceive",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_ContractWithCustomerPostApprovalMilestonePaymentEntitledToReceive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Post-Approval Milestone Payment, Entitled To Receive",
        "label": "Contract With Customer, Post-Approval Milestone Payment, Entitled To Receive",
        "terseLabel": "Post-approval milestone payment, entitled to receive"
       }
      }
     },
     "localname": "ContractWithCustomerPostApprovalMilestonePaymentEntitledToReceive",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_ContractWithCustomerRoyaltyRatesMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Royalty Rates, Maximum",
        "label": "Contract With Customer, Royalty Rates, Maximum",
        "terseLabel": "Royalty rates (up to)"
       }
      }
     },
     "localname": "ContractWithCustomerRoyaltyRatesMaximum",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "angn_ContractWithCustomerSalesRelatedMilestonePaymentEntitledToReceive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Sales-Related Milestone Payment, Entitled To Receive",
        "label": "Contract With Customer, Sales-Related Milestone Payment, Entitled To Receive",
        "terseLabel": "Sales-related milestone payment, entitled to receive"
       }
      }
     },
     "localname": "ContractWithCustomerSalesRelatedMilestonePaymentEntitledToReceive",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_ContractWithCustomerUpfrontAndNearTermMilestonePaymentEntitledToReceive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Upfront and Near-term Milestone Payment, Entitled To Receive",
        "label": "Contract With Customer, Upfront and Near-term Milestone Payment, Entitled To Receive",
        "terseLabel": "Upfront and near-term milestone payment, entitled to receive"
       }
      }
     },
     "localname": "ContractWithCustomerUpfrontAndNearTermMilestonePaymentEntitledToReceive",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_ConvertiblePreferredStockConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Preferred Stock, Conversion Price",
        "label": "Convertible Preferred Stock, Conversion Price",
        "terseLabel": "Convertible preferred stock, conversion price (in dollars per share)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockConversionPrice",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/SeriesCConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "angn_DeferredTaxAssetsOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Lease, Liability",
        "label": "Deferred Tax Assets, Operating Lease, Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayFiftyPercentEmployerMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay, Fifty Percent Employer Match",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay, Fifty Percent Employer Match",
        "terseLabel": "Employer matching contribution, percent of employees' gross pay, 50% employer match"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayFiftyPercentEmployerMatch",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/EmployeeBenefitPlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "angn_DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayOneHundredPercentEmployerMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay, One Hundred Percent Employer Match",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay, One Hundred Percent Employer Match",
        "terseLabel": "Employer matching contribution, percent of employees' gross pay, 100% employer match"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfEmployeesGrossPayOneHundredPercentEmployerMatch",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/EmployeeBenefitPlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "angn_DirectorsAndFamilyMemberOfChiefExecutiveOfficerDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Directors and Family Member of Chief Executive Officer/Director",
        "label": "Directors and Family Member of Chief Executive Officer/Director [Member]",
        "terseLabel": "Directors and Family Member of Chief Executive Officer/Director"
       }
      }
     },
     "localname": "DirectorsAndFamilyMemberOfChiefExecutiveOfficerDirectorMember",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "angn_EarningsPerShareBasicIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share, Basic, Increase",
        "label": "Earnings Per Share, Basic, Increase",
        "negatedTerseLabel": "Basic earnings per share increase (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicIncrease",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "angn_EarningsPerShareDilutedIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share, Diluted, Increase",
        "label": "Earnings Per Share, Diluted, Increase",
        "negatedTerseLabel": "Diluted earnings per share increase (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDilutedIncrease",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "angn_EffectiveIncomeTaxRateReconciliationInterestPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Interest, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Interest, Percent",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationInterestPercent",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "angn_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Permanent Items, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Permanent Items, Percent",
        "terseLabel": "Permanent items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentItemsPercent",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "angn_EquityMethodInvestmentsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment",
        "label": "Equity Method Investments [Roll Forward]",
        "terseLabel": "Equity Method Investments [Roll Forward]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsRollForward",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNovaParkInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 8.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Instruments Subject to Mandatory Redemption by Settlement Terms, Change in Fair Value, Gain (Loss)",
        "label": "Financial Instruments Subject to Mandatory Redemption by Settlement Terms, Change in Fair Value, Gain (Loss)",
        "negatedTerseLabel": "Change in fair value of Series C convertible preferred stock",
        "terseLabel": "Change in fair value of Series C convertible preferred stock"
       }
      }
     },
     "localname": "FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsChangeInFairValueGainLoss",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Instruments Subject to Mandatory Redemption by Settlement Terms, Conversion Price",
        "label": "Financial Instruments Subject to Mandatory Redemption by Settlement Terms, Conversion Price",
        "terseLabel": "Conversion price of series C preferred stock (in dollars per share)"
       }
      }
     },
     "localname": "FinancialInstrumentsSubjectToMandatoryRedemptionBySettlementTermsConversionPrice",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.angn.com/role/SeriesCConvertiblePreferredStockSummaryofAggregateValuesRecordedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Instruments Subject to Mandatory Redemption Carried At Amortized Cost And Fair Value, Settlement Terms, Share Value, Amount,",
        "label": "Financial Instruments Subject to Mandatory Redemption Carried At Amortized Cost And Fair Value, Settlement Terms, Share Value, Amount,",
        "totalLabel": "Total Series C convertible preferred stock"
       }
      }
     },
     "localname": "FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/SeriesCConvertiblePreferredStockSummaryofAggregateValuesRecordedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountAccumulatedChangeInFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.angn.com/role/SeriesCConvertiblePreferredStockSummaryofAggregateValuesRecordedDetails": {
       "order": 2.0,
       "parentTag": "angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Instruments Subject to Mandatory Redemption Carried At Fair Value, Settlement Terms, Share Value, Amount, Accumulated Change In Fair Value",
        "label": "Financial Instruments Subject to Mandatory Redemption Carried At Fair Value, Settlement Terms, Share Value, Amount, Accumulated Change In Fair Value",
        "terseLabel": "Change in fair value of Series C convertible preferred stock exchanged for convertible notes"
       }
      }
     },
     "localname": "FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountAccumulatedChangeInFairValue",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/SeriesCConvertiblePreferredStockSummaryofAggregateValuesRecordedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Instruments Subject to Mandatory Redemption Carried At Fair Value, Settlement Terms, Share Value, Amount, Current",
        "label": "Financial Instruments Subject to Mandatory Redemption Carried At Fair Value, Settlement Terms, Share Value, Amount, Current",
        "terseLabel": "Series C convertible preferred stock at fair value"
       }
      }
     },
     "localname": "FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountCurrent",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets",
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountIssuedInConvertibleNoteExchange": {
     "auth_ref": [],
     "calculation": {
      "http://www.angn.com/role/SeriesCConvertiblePreferredStockSummaryofAggregateValuesRecordedDetails": {
       "order": 3.0,
       "parentTag": "angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Instruments Subject to Mandatory Redemption Carried At Fair Value, Settlement Terms, Share Value, Amount, Issued In Convertible Note Exchange",
        "label": "Financial Instruments Subject to Mandatory Redemption Carried At Fair Value, Settlement Terms, Share Value, Amount, Issued In Convertible Note Exchange",
        "terseLabel": "Series C convertible preferred stock issued in exchange for convertible notes"
       }
      }
     },
     "localname": "FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtFairValueSettlementTermsShareValueAmountIssuedInConvertibleNoteExchange",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/SeriesCConvertiblePreferredStockSummaryofAggregateValuesRecordedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_FinancialInstrumentsSubjectToMandatoryRedemptionDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Instruments Subject to Mandatory Redemption Disclosure",
        "label": "Financial Instruments Subject to Mandatory Redemption Disclosure [Text Block]",
        "terseLabel": "Series C Convertible Preferred Stock"
       }
      }
     },
     "localname": "FinancialInstrumentsSubjectToMandatoryRedemptionDisclosureTextBlock",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/SeriesCConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "angn_FinancialInstrumentsSubjectToMandatoryRedemptionFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Instruments Subject to Mandatory Redemption, Fair Value",
        "label": "Financial Instruments Subject to Mandatory Redemption, Fair Value [Abstract]",
        "terseLabel": "Series C convertible preferred stock recorded at fair value"
       }
      }
     },
     "localname": "FinancialInstrumentsSubjectToMandatoryRedemptionFairValueAbstract",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/SeriesCConvertiblePreferredStockSummaryofAggregateValuesRecordedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "angn_FinancialInstrumentsSubjectToMandatoryRedemptionPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Instruments Subject to Mandatory Redemption",
        "label": "Financial Instruments Subject to Mandatory Redemption [Policy Text Block]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "FinancialInstrumentsSubjectToMandatoryRedemptionPolicyTextBlock",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.angn.com/role/SeriesCConvertiblePreferredStockSummaryofAggregateValuesRecordedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Gross",
        "label": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Gross",
        "terseLabel": "Principal"
       }
      }
     },
     "localname": "FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountGross",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/SeriesCConvertiblePreferredStockSummaryofAggregateValuesRecordedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium": {
     "auth_ref": [],
     "calculation": {
      "http://www.angn.com/role/SeriesCConvertiblePreferredStockSummaryofAggregateValuesRecordedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Settlement Premium",
        "label": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Settlement Premium",
        "terseLabel": "Settlement premium"
       }
      }
     },
     "localname": "FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountSettlementPremium",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/SeriesCConvertiblePreferredStockSummaryofAggregateValuesRecordedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.angn.com/role/SeriesCConvertiblePreferredStockSummaryofAggregateValuesRecordedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Unamortized Discount and Fees",
        "label": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Unamortized Discount and Fees",
        "negatedTerseLabel": "Unamortized discounts and fees"
       }
      }
     },
     "localname": "FinancialInstrumentsSubjectToMandatoryRedemptionSettlementTermsShareValueAmountUnamortizedDiscountAndFees",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/SeriesCConvertiblePreferredStockSummaryofAggregateValuesRecordedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_FormerMemberOfTheBoardOfDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Member Of The Board Of Directors",
        "label": "Former Member Of The Board Of Directors [Member]",
        "terseLabel": "Former Member of the Board of Directors"
       }
      }
     },
     "localname": "FormerMemberOfTheBoardOfDirectorsMember",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "angn_IPOAndPrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IPO and Private Placement",
        "label": "IPO and Private Placement [Member]",
        "terseLabel": "IPO and Private placement"
       }
      }
     },
     "localname": "IPOAndPrivatePlacementMember",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "angn_ImmediateFamilyOfDirectorAndChairmanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immediate Family of Director and Chairman",
        "label": "Immediate Family of Director and Chairman [Member]",
        "terseLabel": "Immediate Family of Director and Chairman"
       }
      }
     },
     "localname": "ImmediateFamilyOfDirectorAndChairmanMember",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "angn_IncreaseDecreaseInGrantReceivables": {
     "auth_ref": [],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Grant Receivables",
        "label": "Increase (Decrease) In Grant Receivables",
        "negatedTerseLabel": "Grants receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInGrantReceivables",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_InvestmentsInRelatedPartiesPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in Related Parties, Policy",
        "label": "Investments in Related Parties, Policy [Policy Text Block]",
        "terseLabel": "Investments in Related Party Entities"
       }
      }
     },
     "localname": "InvestmentsInRelatedPartiesPolicyPolicyTextBlock",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "angn_IssuanceOfBrokerWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Broker Warrants",
        "label": "Issuance of Broker Warrants",
        "terseLabel": "Issuance of broker warrants with Series C convertible preferred stock"
       }
      }
     },
     "localname": "IssuanceOfBrokerWarrants",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_LegalServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Services",
        "label": "Legal Services [Member]",
        "terseLabel": "Legal Services"
       }
      }
     },
     "localname": "LegalServicesMember",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "angn_LesseeOperatingLeaseAnnualRentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Annual Rent Expense",
        "label": "Lessee, Operating Lease, Annual Rent Expense",
        "terseLabel": "Operating lease, payment per year"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAnnualRentExpense",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_LesseeOperatingLeaseFreeRentExpensePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Free Rent Expense Period",
        "label": "Lessee, Operating Lease, Free Rent Expense Period",
        "terseLabel": "Free rent expense period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseFreeRentExpensePeriod",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "angn_LesseeOperatingLeaseNoticePeriodForOptionToExtend": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Notice Period for Option to Extend",
        "label": "Lessee, Operating Lease, Notice Period for Option to Extend",
        "terseLabel": "Notice period for option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNoticePeriodForOptionToExtend",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "angn_LesseeOperatingLeaseNumberOfOptionsToExtend": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number of Options to Extend",
        "label": "Lessee, Operating Lease, Number of Options to Extend",
        "terseLabel": "Number of options to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfOptionsToExtend",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "angn_MeasurementInputStrikePriceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Strike Price",
        "label": "Measurement Input, Strike Price [Member]",
        "terseLabel": "Weighted average strike price"
       }
      }
     },
     "localname": "MeasurementInputStrikePriceMember",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "angn_NetIncomeLossAttributableToParentIncrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Income (Loss) Attributable to Parent, Increase",
        "label": "Net Income (Loss) Attributable to Parent, Increase",
        "terseLabel": "Decrease in net loss"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToParentIncrease",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_NonCashPlacementAgentFee": {
     "auth_ref": [],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash Placement Agent Fee",
        "label": "Non-Cash Placement Agent Fee",
        "terseLabel": "Non-cash placement agent fee"
       }
      }
     },
     "localname": "NonCashPlacementAgentFee",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_NonIPORelatedStockTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-IPO Related Stock Transactions",
        "label": "Non-IPO Related Stock Transactions [Member]",
        "terseLabel": "Non-IPO Related Stock Transactions"
       }
      }
     },
     "localname": "NonIPORelatedStockTransactionsMember",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "angn_NovaParkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NovaPark",
        "label": "NovaPark [Member]",
        "terseLabel": "NovaPark"
       }
      }
     },
     "localname": "NovaParkMember",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsNovaParkInvestmentDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "angn_NumberOfRelatedPartyEntities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Related Party Entities",
        "label": "Number of Related Party Entities",
        "terseLabel": "Number of related party entities"
       }
      }
     },
     "localname": "NumberOfRelatedPartyEntities",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "angn_OhrCosmeticsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ohr Cosmetics, LLC",
        "label": "Ohr Cosmetics, LLC [Member]",
        "terseLabel": "Ohr Cosmetics, LLC"
       }
      }
     },
     "localname": "OhrCosmeticsLLCMember",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "angn_OperatingLossCarryforwardNotSubjectToExpiration": {
     "auth_ref": [],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesNarrativeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforward, Not Subject to Expiration",
        "label": "Operating Loss Carryforward, Not Subject to Expiration",
        "terseLabel": "Operating loss carryforward, not subject to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardNotSubjectToExpiration",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_OperatingLossCarryforwardSubjectToExpiration": {
     "auth_ref": [],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesNarrativeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforward, Subject to Expiration",
        "label": "Operating Loss Carryforward, Subject to Expiration",
        "terseLabel": "Operating loss carryforward, subject to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardSubjectToExpiration",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_OtherInvestmentAndSecuritiesAtCostOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Investment and Securities, at Cost, Ownership Percentage",
        "label": "Other Investment and Securities, at Cost, Ownership Percentage",
        "terseLabel": "Investment, ownership percentage"
       }
      }
     },
     "localname": "OtherInvestmentAndSecuritiesAtCostOwnershipPercentage",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "angn_PaycheckProtectionProgramCARESActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paycheck Protection Program, CARES Act",
        "label": "Paycheck Protection Program, CARES Act [Member]",
        "terseLabel": "Paycheck Protection Program, CARES Act"
       }
      }
     },
     "localname": "PaycheckProtectionProgramCARESActMember",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "angn_PaymentsForBrokerWarrantExercises": {
     "auth_ref": [],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Broker Warrant Exercises",
        "label": "Payments For Broker Warrant Exercises",
        "negatedTerseLabel": "Exercise of broker warrants"
       }
      }
     },
     "localname": "PaymentsForBrokerWarrantExercises",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_PaymentsForForwardStockSplitFractionalShares": {
     "auth_ref": [],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Forward Stock Split Fractional Shares",
        "label": "Payments For Forward Stock Split Fractional Shares",
        "negatedTerseLabel": "Fractional share payments related to the forward stock split"
       }
      }
     },
     "localname": "PaymentsForForwardStockSplitFractionalShares",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_PrepaidClinicalFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Clinical Fees, Current",
        "label": "Prepaid Clinical Fees, Current",
        "terseLabel": "Prepaid clinical fees"
       }
      }
     },
     "localname": "PrepaidClinicalFeesCurrent",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_PresidentAndChiefExecutiveOfficerAndDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "President And Chief Executive Officer And Director",
        "label": "President And Chief Executive Officer And Director [Member]",
        "terseLabel": "President and Chief Executive Officer and Director"
       }
      }
     },
     "localname": "PresidentAndChiefExecutiveOfficerAndDirectorMember",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "angn_ProceedsFromFinancingObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Financing Obligation",
        "label": "Proceeds From Financing Obligation",
        "terseLabel": "Proceeds from financing obligation"
       }
      }
     },
     "localname": "ProceedsFromFinancingObligation",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleOfQuantitativeInformationAboutTheFinancingObligationDetails",
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_RelatedPartyTransactionPotentialMaximumMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Potential Maximum Milestone Payment",
        "label": "Related Party Transaction, Potential Maximum Milestone Payment",
        "terseLabel": "Potential maximum milestone payment"
       }
      }
     },
     "localname": "RelatedPartyTransactionPotentialMaximumMilestonePayment",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_RelatedPartyTransactionRoyaltiesAndMilestonePaymentsPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Royalties And Milestone Payments, Period",
        "label": "Related Party Transaction, Royalties And Milestone Payments, Period",
        "terseLabel": "Royalties and milestone payments, period"
       }
      }
     },
     "localname": "RelatedPartyTransactionRoyaltiesAndMilestonePaymentsPeriod",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "angn_RevenueFromContractWithCustomerIncludingAssessedTaxIncrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Contract With Customer, Including Assessed Tax, Increase",
        "label": "Revenue From Contract With Customer, Including Assessed Tax, Increase",
        "terseLabel": "Increase in contract revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTaxIncrease",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_ScheduleOfQuantitativeInformationAboutTheFinancingObligationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Quantitative Information About The Financing Obligation",
        "label": "Schedule Of Quantitative Information About The Financing Obligation [Table Text Block]",
        "terseLabel": "Schedule Of Quantitative Information About The Financing Obligation"
       }
      }
     },
     "localname": "ScheduleOfQuantitativeInformationAboutTheFinancingObligationTableTextBlock",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "angn_ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Quantitative Information On Operating Leases",
        "label": "Schedule Of Quantitative Information On Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of quantitative information regarding NovaPark operating leases"
       }
      }
     },
     "localname": "ScheduleOfQuantitativeInformationOnOperatingLeasesTableTextBlock",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Outstanding, Number",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Outstanding, Number",
        "terseLabel": "Vested at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingNumber",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofRSAandRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "angn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested, Outstanding, Weighted Average Exercise Price",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Vested, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested at end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofRSAandRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "angn_ShareBasedPaymentArrangementPlanModificationExtendedExercisePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Payment Arrangement, Plan Modification, Extended Exercise Period",
        "label": "Share-based Payment Arrangement, Plan Modification, Extended Exercise Period",
        "terseLabel": "Plan modification, extended exercise period"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementPlanModificationExtendedExercisePeriod",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "angn_SharesIssuableUponConversionOfConvertibleNotesDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Issuable Upon Conversion Of Convertible Notes, Discount Rate",
        "label": "Shares Issuable Upon Conversion Of Convertible Notes, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "SharesIssuableUponConversionOfConvertibleNotesDiscountRate",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/NetLossPerShareScheduleofantidilutivesecuritiesexcludedfromcomputationofnetlosspershareDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "angn_StockIssuedDuringPeriodSharesBrokerWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Broker Warrants Exercised",
        "label": "Stock Issued During Period, Shares, Broker Warrants Exercised",
        "terseLabel": "Exercise of broker warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesBrokerWarrantsExercised",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "angn_StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Conversion of Convertible Preferred Stock",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Preferred Stock",
        "terseLabel": "Conversion of convertible preferred stock into common stock upon IPO (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "angn_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Warrants Exercised",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "terseLabel": "Exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit",
      "http://www.angn.com/role/WarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "angn_StockIssuedDuringPeriodValueBrokerWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Broker Warrants Exercised",
        "label": "Stock Issued During Period, Value, Broker Warrants Exercised",
        "terseLabel": "Exercise of broker warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueBrokerWarrantsExercised",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Conversion of Convertible Preferred Stock",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Preferred Stock",
        "terseLabel": "Conversion of convertible preferred stock into common stock upon IPO"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Warrants Exercised",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_StockRetired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Retired",
        "label": "Stock Retired",
        "terseLabel": "Retirement of treasury stock"
       }
      }
     },
     "localname": "StockRetired",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_TemporaryEquityAmortizedCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Amortized Cost",
        "label": "Temporary Equity, Amortized Cost [Abstract]",
        "terseLabel": "Series C convertible preferred stock recorded at amortized cost"
       }
      }
     },
     "localname": "TemporaryEquityAmortizedCostAbstract",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/SeriesCConvertiblePreferredStockSummaryofAggregateValuesRecordedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "angn_UnrecognizedTaxBenefitsIfRecognizedWouldAffectTheEffectiveTaxRateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, If Recognized, Would Affect the Effective Tax Rate",
        "label": "Unrecognized Tax Benefits, If Recognized, Would Affect the Effective Tax Rate [Table Text Block]",
        "terseLabel": "Unrecognized Tax Benefits, If Recognized, Would Affect the Effective Tax Rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIfRecognizedWouldAffectTheEffectiveTaxRateTableTextBlock",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "angn_UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate": {
     "auth_ref": [],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesUnrecognizedTaxBenefitsIfRecognizedWouldAffecttheEffectiveTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_UnrecognizedTaxBenefits",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits that Would Not Impact Effective Tax Rate",
        "label": "Unrecognized Tax Benefits that Would Not Impact Effective Tax Rate",
        "terseLabel": "Unrecognized benefits that would not affect the effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldNotImpactEffectiveTaxRate",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesUnrecognizedTaxBenefitsIfRecognizedWouldAffecttheEffectiveTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_ViforPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vifor Pharma",
        "label": "Vifor Pharma [Member]",
        "terseLabel": "Vifor Pharma"
       }
      }
     },
     "localname": "ViforPharmaMember",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "angn_WarrantLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Liability, Current",
        "label": "Warrant Liability, Current",
        "terseLabel": "Warrant liability"
       }
      }
     },
     "localname": "WarrantLiabilityCurrent",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_WarrantLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Liability",
        "label": "Warrant Liability [Member]",
        "terseLabel": "Warrant Liability"
       }
      }
     },
     "localname": "WarrantLiabilityMember",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "angn_WarrantsAndRightsOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants and Rights Outstanding",
        "label": "Warrants and Rights Outstanding [Abstract]"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingAbstract",
     "nsuri": "http://www.angn.com/20211231",
     "xbrltype": "stringItemType"
    },
    "angn_WarrantsAndRightsOutstandingActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants and Rights Outstanding, Activity",
        "label": "Warrants and Rights Outstanding, Activity [Table Text Block]",
        "terseLabel": "Schedule of Warrant Activity"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingActivityTableTextBlock",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/WarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "angn_WarrantsAndRightsOutstandingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants and Rights Outstanding, Policy",
        "label": "Warrants and Rights Outstanding, Policy [Policy Text Block]",
        "terseLabel": "Warrant Liability"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingPolicyPolicyTextBlock",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "angn_WarrantsAndRightsOutstandingTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants And Rights Outstanding",
        "label": "Warrants And Rights Outstanding [Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTextBlock",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/Warrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants and Rights Outstanding, Weighted Average Remaining Contractual Term",
        "label": "Warrants and Rights Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Balance, weighted average remaining contractual life (in years)"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/WarrantsWarrantActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "angn_WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTermRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants and Rights Outstanding, Weighted Average Remaining Contractual Term",
        "label": "Warrants and Rights Outstanding, Weighted Average Remaining Contractual Term [Roll Forward]",
        "terseLabel": "Weighted Average Remaining Contractual Life (in years)"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingWeightedAverageRemainingContractualTermRollForward",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/WarrantsWarrantActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "angn_WarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Exercised",
        "label": "Warrants Exercised",
        "terseLabel": "Net exercise of warrants upon IPO"
       }
      }
     },
     "localname": "WarrantsExercised",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_WarrantsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Fair Value Disclosure",
        "label": "Warrants, Fair Value Disclosure",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsFairValueDisclosure",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "angn_WarrantsIssuedWith2015Notes2016Notes2017NotesAnd2018NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Issued with 2015 Notes, 2016 Notes, 2017 Notes, and 2018 Notes",
        "label": "Warrants Issued with 2015 Notes, 2016 Notes, 2017 Notes, and 2018 Notes [Member]",
        "terseLabel": "Warrants issued with 2015 Notes, 2016 Notes, 2017 Notes, and 2018 Notes"
       }
      }
     },
     "localname": "WarrantsIssuedWith2015Notes2016Notes2017NotesAnd2018NotesMember",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/WarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "angn_WarrantsIssuedWith2015NotesLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Issued with 2015 Notes, Liability",
        "label": "Warrants Issued with 2015 Notes, Liability [Member]",
        "terseLabel": "Warrants issued with 2015 Notes"
       }
      }
     },
     "localname": "WarrantsIssuedWith2015NotesLiabilityMember",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/WarrantsOutstandingWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "angn_WarrantsIssuedWith2016NotesLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Issued with 2016 Notes, Liability",
        "label": "Warrants Issued with 2016 Notes, Liability [Member]",
        "terseLabel": "Warrants issued with 2016 Notes"
       }
      }
     },
     "localname": "WarrantsIssuedWith2016NotesLiabilityMember",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/WarrantsOutstandingWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "angn_WarrantsIssuedWith2017NotesLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Issued with 2017 Notes, Liability",
        "label": "Warrants Issued with 2017 Notes, Liability [Member]",
        "terseLabel": "Warrants issued with 2017 Notes"
       }
      }
     },
     "localname": "WarrantsIssuedWith2017NotesLiabilityMember",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/WarrantsOutstandingWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "angn_WarrantsIssuedWith2018NotesLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Issued with 2018 Notes, Liability",
        "label": "Warrants Issued with 2018 Notes, Liability [Member]",
        "terseLabel": "Warrants issued with 2018 Notes"
       }
      }
     },
     "localname": "WarrantsIssuedWith2018NotesLiabilityMember",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/WarrantsOutstandingWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "angn_WarrantsIssuedWithConversionOfNotesToCommonStockEquityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Issued with Conversion Of Notes To Common Stock, Equity",
        "label": "Warrants Issued with Conversion Of Notes To Common Stock, Equity [Member]",
        "terseLabel": "Warrants issued with Conversion of Notes to Common Stock"
       }
      }
     },
     "localname": "WarrantsIssuedWithConversionOfNotesToCommonStockEquityMember",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/WarrantsOutstandingWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "angn_WarrantsIssuedWithUnitsInTheEquityOfferingEquityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Issued with Units In The Equity Offering, Equity",
        "label": "Warrants Issued with Units In The Equity Offering, Equity [Member]",
        "terseLabel": "Warrants issued with Units in the Equity Offering"
       }
      }
     },
     "localname": "WarrantsIssuedWithUnitsInTheEquityOfferingEquityMember",
     "nsuri": "http://www.angn.com/20211231",
     "presentation": [
      "http://www.angn.com/role/WarrantsOutstandingWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r606",
      "r607",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r606",
      "r607",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r606",
      "r607",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r606",
      "r607",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Entity Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r606",
      "r607",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.angn.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r342",
      "r501",
      "r502",
      "r505",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ChiefExecutiveOfficerMember": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r54",
      "r56",
      "r116",
      "r117",
      "r238",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsNovaParkInvestmentDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r237",
      "r280",
      "r346",
      "r347",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r573",
      "r576",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/EmployeeBenefitPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r237",
      "r280",
      "r346",
      "r347",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r573",
      "r576",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/EmployeeBenefitPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r183",
      "r323",
      "r326",
      "r526",
      "r572",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r183",
      "r323",
      "r326",
      "r526",
      "r572",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r237",
      "r280",
      "r334",
      "r346",
      "r347",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r573",
      "r576",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/EmployeeBenefitPlanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r237",
      "r280",
      "r334",
      "r346",
      "r347",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r573",
      "r576",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/EmployeeBenefitPlanNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r55",
      "r56",
      "r116",
      "r117",
      "r238",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsNovaParkInvestmentDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r184",
      "r185",
      "r323",
      "r327",
      "r575",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r184",
      "r185",
      "r323",
      "r327",
      "r575",
      "r585",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r187",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "San Francisco, California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MASSACHUSETTS",
        "terseLabel": "Massachusetts"
       }
      }
     },
     "localname": "MA",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NJ": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW JERSEY",
        "terseLabel": "Fort Lee, New Jersey"
       }
      }
     },
     "localname": "NJ",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r40",
      "r510"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails",
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r36",
      "r209"
     ],
     "calculation": {
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r26",
      "r59",
      "r60",
      "r61",
      "r560",
      "r581",
      "r582"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r58",
      "r61",
      "r68",
      "r69",
      "r70",
      "r120",
      "r121",
      "r122",
      "r439",
      "r577",
      "r578",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r24",
      "r384",
      "r510"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r381",
      "r382",
      "r383",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Return of common stock to pay withholding taxes on restricted stock"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r348",
      "r350",
      "r387",
      "r388"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r295",
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit": {
     "auth_ref": [
      "r295",
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.",
        "label": "Adjustments to Additional Paid in Capital, Stock Split",
        "negatedTerseLabel": "Fractional shares paid out related to the forward stock split"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r233",
      "r295",
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of broker warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r350",
      "r377",
      "r386"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r78",
      "r95",
      "r257",
      "r476"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/NetLossPerShareScheduleofantidilutivesecuritiesexcludedfromcomputationofnetlosspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/NetLossPerShareScheduleofantidilutivesecuritiesexcludedfromcomputationofnetlosspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/NetLossPerShareScheduleofantidilutivesecuritiesexcludedfromcomputationofnetlosspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/NetLossPerShareScheduleofantidilutivesecuritiesexcludedfromcomputationofnetlosspershareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of office space (in sqft)"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r111",
      "r165",
      "r175",
      "r181",
      "r199",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r231",
      "r232",
      "r436",
      "r440",
      "r460",
      "r508",
      "r510",
      "r540",
      "r558"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r10",
      "r53",
      "r111",
      "r199",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r231",
      "r232",
      "r436",
      "r440",
      "r460",
      "r508",
      "r510"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r446"
     ],
     "calculation": {
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets included in:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AustralianTaxationOfficeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Australia.",
        "label": "Australian Taxation Office [Member]",
        "terseLabel": "Australian Taxation Office"
       }
      }
     },
     "localname": "AustralianTaxationOfficeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r351",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.angn.com/role/StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails",
      "http://www.angn.com/role/StockBasedCompensationScheduleofRSAandRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r100",
      "r101",
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Fixed assets purchased in accrued expenses or accounts payable"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r32",
      "r97"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets",
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents - Money market securities"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r13",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r91",
      "r97",
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at the end of the period",
        "periodStartLabel": "Cash and cash equivalents at the beginning of the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r91",
      "r466"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r108",
      "r111",
      "r135",
      "r136",
      "r137",
      "r139",
      "r141",
      "r149",
      "r150",
      "r151",
      "r199",
      "r220",
      "r225",
      "r226",
      "r227",
      "r231",
      "r232",
      "r278",
      "r279",
      "r283",
      "r287",
      "r460",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/SeriesCConvertiblePreferredStockNarrativeDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SeriesCConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r308",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/WarrantsNarrativeDetails",
      "http://www.angn.com/role/WarrantsOutstandingWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/WarrantsNarrativeDetails",
      "http://www.angn.com/role/WarrantsOutstandingWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of equity-classified broker warrants (in dollars per share)",
        "verboseLabel": "Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.angn.com/role/WarrantsNarrativeDetails",
      "http://www.angn.com/role/WarrantsOutstandingWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/WarrantsNarrativeDetails",
      "http://www.angn.com/role/WarrantsOutstandingWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Balance, ending (in shares)",
        "periodStartLabel": "Balance, beginning (in shares)",
        "terseLabel": "Warrants outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/WarrantsOutstandingWarrantsDetails",
      "http://www.angn.com/role/WarrantsWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r308",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/WarrantsNarrativeDetails",
      "http://www.angn.com/role/WarrantsOutstandingWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r46",
      "r217",
      "r546",
      "r564"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies\u2014Note 11"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r218",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r120",
      "r121",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit",
      "http://www.angn.com/role/ConvertibleNotesPayableDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/WarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r22",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r22",
      "r510"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value per share; 30,000,000 authorized shares; 29,959,060 and 15,632,809 shares issued as of December 31, 2021 and 2020, respectively; 29,959,060 and 15,316,721 shares outstanding as of December 31, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r63",
      "r65",
      "r66",
      "r75",
      "r550",
      "r568"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r154",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk and Off-Balance Sheet Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r310",
      "r311",
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Contract with customer, liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r310",
      "r311",
      "r324"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue\u2014current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets",
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r310",
      "r311",
      "r324"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue\u2014noncurrent"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r100",
      "r101",
      "r102"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of Series C preferred stock to common stock upon IPO"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "calculation": {
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Shares issuable upon conversion of the convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/NetLossPerShareScheduleofantidilutivesecuritiesexcludedfromcomputationofnetlosspershareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleNotesPayable": {
     "auth_ref": [
      "r19",
      "r542",
      "r559",
      "r583"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable",
        "terseLabel": "Convertible notes payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Current",
        "terseLabel": "Convertible notes payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r17",
      "r541",
      "r556",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]",
        "terseLabel": "Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConvertibleNotesPayableDetails",
      "http://www.angn.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r278",
      "r279",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Series C Convertible Preferred Stock at Fair Value"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails",
      "http://www.angn.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r20",
      "r21",
      "r290",
      "r296",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Shares of common stock into which all convertible preferred stock outstanding were automatically converted into (in shares)",
        "verboseLabel": "Conversion of convertible preferred stock into common stock upon IPO (in shares)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/SeriesCConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockSubjectToMandatoryRedemptionMember": {
     "auth_ref": [
      "r271",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares that embody an unconditional obligation requiring the issuer to redeem the securities by transferring the assets upon an event that is certain to occur.",
        "label": "Convertible Preferred Stock Subject to Mandatory Redemption [Member]",
        "terseLabel": "Convertible Preferred Stock Subject to Mandatory Redemption"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSubjectToMandatoryRedemptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r81",
      "r111",
      "r199",
      "r220",
      "r221",
      "r222",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r231",
      "r232",
      "r460"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of grant revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r112",
      "r415",
      "r424"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r112",
      "r415"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r112",
      "r415",
      "r424",
      "r426"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total Current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r112",
      "r415",
      "r424"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r100",
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Conversion of convertible notes"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Conversion [Line Items]",
        "terseLabel": "Debt Conversion [Line Items]"
       }
      }
     },
     "localname": "DebtConversionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtConversionTable": {
     "auth_ref": [
      "r100",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table that contains information on an original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion [Table]",
        "terseLabel": "Debt Conversion [Table]"
       }
      }
     },
     "localname": "DebtConversionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r107",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r251",
      "r258",
      "r259",
      "r260",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Notes Payable"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConvertibleNotesPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r110",
      "r118",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r262",
      "r263",
      "r264",
      "r265",
      "r477",
      "r541",
      "r542",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.angn.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r236",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in dollars per share)",
        "verboseLabel": "Conversion price of convertible notes (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConvertibleNotesPayableDetails",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r234",
      "r262",
      "r263",
      "r475",
      "r477",
      "r478"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate principal amount of convertible notes issued"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentIncreaseAccruedInterest": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.",
        "label": "Debt Instrument, Increase, Accrued Interest",
        "terseLabel": "Increase due to accrued interest balance"
       }
      }
     },
     "localname": "DebtInstrumentIncreaseAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r45",
      "r110",
      "r118",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r262",
      "r263",
      "r264",
      "r265",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.angn.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "auth_ref": [
      "r100",
      "r101",
      "r102"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.",
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "terseLabel": "Deferred offering costs in accrued expenses or accounts payable"
       }
      }
     },
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Convertible Notes Payable at Fair Value"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Prepaid and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r112",
      "r416",
      "r424"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r95",
      "r112",
      "r416",
      "r424",
      "r425",
      "r426"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total Deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r52",
      "r205"
     ],
     "calculation": {
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Deferred offering costs",
        "verboseLabel": "Deferred Offering costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r112",
      "r416",
      "r424"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r408"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Deferred tax assets, net of allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r413",
      "r414"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r411",
      "r413",
      "r414"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "R&amp;D and other tax credit carryovers"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r413",
      "r414"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther": {
     "auth_ref": [
      "r413",
      "r414"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Other",
        "terseLabel": "Accrued compensation and other expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r407"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r413",
      "r414"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedTerseLabel": "Right of use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r413",
      "r414"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "terseLabel": "Defined Contribution Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/EmployeeBenefitPlanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.",
        "label": "Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage",
        "terseLabel": "Employers matching contribution annual vesting (in percentage)"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/EmployeeBenefitPlanNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanTable": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.",
        "label": "Defined Contribution Plan [Table]",
        "terseLabel": "Defined Contribution Plan [Table]"
       }
      }
     },
     "localname": "DefinedContributionPlanTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/EmployeeBenefitPlanNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "auth_ref": [
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for defined contribution plan.",
        "label": "Defined Contribution Plan [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "DefinedContributionPlanTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/EmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DepositsAssetsCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.",
        "label": "Deposits Assets, Current",
        "terseLabel": "Security deposit"
       }
      }
     },
     "localname": "DepositsAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r95",
      "r207"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsNarrativeDetails",
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleOfQuantitativeInformationAboutTheFinancingObligationDetails",
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r323",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r76",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r133",
      "r135",
      "r139",
      "r140",
      "r141",
      "r145",
      "r146",
      "r444",
      "r445",
      "r551",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share, basic (in dollars per share)",
        "verboseLabel": "Net loss per share attributable to common stockholders, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.angn.com/role/NetLossPerShareScheduleofnetlosspersharebasicanddilutedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r76",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r135",
      "r139",
      "r140",
      "r141",
      "r145",
      "r146",
      "r444",
      "r445",
      "r551",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share, diluted (in dollars per share)",
        "verboseLabel": "Net loss per share attributable to common stockholders, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.angn.com/role/NetLossPerShareScheduleofnetlosspersharebasicanddilutedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r142",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of foreign currency on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r396"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesNarrativeDetails",
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r114",
      "r396",
      "r428"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r396",
      "r428"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r396",
      "r428"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign rate differential"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r396",
      "r428"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r396",
      "r428"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r396",
      "r428"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedTerseLabel": "R&amp;D and other tax credit changes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxExemptIncome": {
     "auth_ref": [
      "r396",
      "r428"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Exempt Income, Percent",
        "negatedTerseLabel": "Nontaxable Income"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxExemptIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation related to unvested stock option awards, period for recognition (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r378"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation related to unvested stock option awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Option",
        "verboseLabel": "Shares issuable upon exercise of stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/NetLossPerShareScheduleofantidilutivesecuritiesexcludedfromcomputationofnetlosspershareDetails",
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.angn.com/role/StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r68",
      "r69",
      "r70",
      "r120",
      "r121",
      "r122",
      "r124",
      "r130",
      "r132",
      "r148",
      "r201",
      "r295",
      "r303",
      "r381",
      "r382",
      "r383",
      "r420",
      "r421",
      "r443",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r577",
      "r578",
      "r579",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit",
      "http://www.angn.com/role/ConvertibleNotesPayableDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/WarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvesteeMember": {
     "auth_ref": [
      "r196",
      "r528",
      "r530",
      "r532",
      "r534",
      "r536",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity that issued voting stock held by an investor and that is accounted for under the equity method of accounting by the investor.",
        "label": "Equity Method Investee [Member]",
        "terseLabel": "Equity Method Investee"
       }
      }
     },
     "localname": "EquityMethodInvesteeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsNovaParkInvestmentDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDividendsOrDistributions": {
     "auth_ref": [
      "r73",
      "r90",
      "r95",
      "r566"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.",
        "label": "Proceeds from Equity Method Investment, Distribution",
        "negatedTerseLabel": "Distribution from NovaPark",
        "terseLabel": "Distribution from equity investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/RelatedPartyTransactionsNovaParkInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method investment, ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r33",
      "r166",
      "r197"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNovaParkInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "terseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r457"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r95",
      "r269"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 6.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "negatedTerseLabel": "Change in fair value of warrant liability",
        "terseLabel": "Change in fair value of warrant liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r446",
      "r458",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r249",
      "r262",
      "r263",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r447",
      "r514",
      "r515",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r446",
      "r447",
      "r449",
      "r450",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r249",
      "r335",
      "r336",
      "r341",
      "r343",
      "r447",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r249",
      "r262",
      "r263",
      "r335",
      "r336",
      "r341",
      "r343",
      "r447",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r249",
      "r262",
      "r263",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r447",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r451",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r451",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r452"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r453"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r451"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsFairValueLiabilitiesMeasuredonRecurringBasisUnobservableInputReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r249",
      "r262",
      "r263",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r343",
      "r514",
      "r515",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsFairValueMeasurementInputsandValuationTechniquesDetails",
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r454",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair value measurements, recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOptionChangesInFairValueGainLoss1": {
     "auth_ref": [
      "r461"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.",
        "label": "Fair Value, Option, Changes in Fair Value, Gain (Loss)",
        "negatedTerseLabel": "Change in fair value of convertible notes",
        "terseLabel": "Change in fair value of convertible notes"
       }
      }
     },
     "localname": "FairValueOptionChangesInFairValueGainLoss1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r484",
      "r492"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Operating cash flows from financing obligation"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleOfQuantitativeInformationAboutTheFinancingObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r481",
      "r497"
     ],
     "calculation": {
      "http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Financing obligation"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r481"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Financing obligation\u2014current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Finance Lease, Liability, Fiscal Year Maturity"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r481"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Financing obligation\u2014noncurrent"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less present value discount"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesFinanceLeaseLiabilityFiscalYearMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r483",
      "r492"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Payment of financing obligation",
        "terseLabel": "Financing cash flows from financing obligation"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleOfQuantitativeInformationAboutTheFinancingObligationDetails",
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r495",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate (in percent)"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleOfQuantitativeInformationAboutTheFinancingObligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r494",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleOfQuantitativeInformationAboutTheFinancingObligationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r462",
      "r463",
      "r464",
      "r465"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign exchange transaction gain (loss)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation and Transactions"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "terseLabel": "Loss on disposal of fixed assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r95",
      "r266",
      "r267"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 7.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "PPP Loan forgiveness",
        "terseLabel": "Gain upon debt extinguishment"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantsReceivableCurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Grants Receivable, Current",
        "terseLabel": "Grants receivable"
       }
      }
     },
     "localname": "GrantsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit",
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficitParenthetical",
      "http://www.angn.com/role/ConvertibleNotesPayableDetails",
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails",
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails",
      "http://www.angn.com/role/SeriesCConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember": {
     "auth_ref": [
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Family member whom a principal owner or a member of management might control or influence, or by whom they might be controlled or influenced, because of the family relationship.",
        "label": "Immediate Family Member of Management or Principal Owner [Member]",
        "terseLabel": "Immediate Family Member of Management or Principal Owner"
       }
      }
     },
     "localname": "ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r206",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r113",
      "r427"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofIncomebeforeIncomeTaxDomesticandForeignDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofIncomebeforeIncomeTaxDomesticandForeignDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r72",
      "r165",
      "r174",
      "r177",
      "r180",
      "r182",
      "r539",
      "r548",
      "r553",
      "r570"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofIncomebeforeIncomeTaxDomesticandForeignDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofIncomebeforeIncomeTaxDomesticandForeignDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r113",
      "r427"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofIncomebeforeIncomeTaxDomesticandForeignDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofIncomebeforeIncomeTaxDomesticandForeignDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r73",
      "r95",
      "r163",
      "r197",
      "r547",
      "r566"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Losses from equity investment",
        "terseLabel": "Losses of equity method investment"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/RelatedPartyTransactionsNovaParkInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.",
        "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions",
        "terseLabel": "Losses in equity method investment"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r211",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r114",
      "r397",
      "r404",
      "r410",
      "r422",
      "r429",
      "r431",
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r115",
      "r131",
      "r132",
      "r164",
      "r395",
      "r423",
      "r430",
      "r571"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax provision",
        "totalLabel": "Total tax provision"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesNarrativeDetails",
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability": {
     "auth_ref": [
      "r417"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.",
        "label": "Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r67",
      "r393",
      "r394",
      "r404",
      "r405",
      "r409",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r94",
      "r524"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": {
     "auth_ref": [
      "r89",
      "r195"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Increase (Decrease) in Equity Securities, FV-NI",
        "terseLabel": "Equity investment received"
       }
      }
     },
     "localname": "IncreaseDecreaseInEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r94",
      "r492"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r552"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest income (expense), net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r88",
      "r92",
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r43"
     ],
     "calculation": {
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r565"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments",
        "terseLabel": "Investments in related parties"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r496",
      "r498"
     ],
     "calculation": {
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofComponentsofRentExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total rent expense"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofComponentsofRentExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of components of rent expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets held by a lessee under a capital lease and any addition or improvement to assets held under a lease arrangement (including addition or improvement to assets held by lessee under an operating lease arrangement).",
        "label": "Leaseholds and Leasehold Improvements [Member]",
        "terseLabel": "Leaseholds and Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleOfQuantitativeInformationAboutTheFinancingObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesOperatingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases, Operating [Abstract]",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "LeasesOperatingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofComponentsofRentExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Term of Contract",
        "terseLabel": "Finance lease, term"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleOfQuantitativeInformationAboutTheFinancingObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleOfQuantitativeInformationAboutTheFinancingObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of maturities of lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less present value discount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r42",
      "r111",
      "r176",
      "r199",
      "r220",
      "r221",
      "r222",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r231",
      "r232",
      "r437",
      "r440",
      "r441",
      "r460",
      "r508",
      "r509"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r29",
      "r111",
      "r199",
      "r460",
      "r510",
      "r543",
      "r562"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r44",
      "r111",
      "r199",
      "r220",
      "r221",
      "r222",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r231",
      "r232",
      "r437",
      "r440",
      "r441",
      "r460",
      "r508",
      "r509",
      "r510"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r446"
     ],
     "calculation": {
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total fair value"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities included in:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage investment held by members or limited partners of limited liability company (LLC) or limited partnership (LP).",
        "label": "Limited Liability Company or Limited Partnership, Members or Limited Partners, Ownership Interest",
        "terseLabel": "Family of the Executive Chairman investment, ownership percentage"
       }
      }
     },
     "localname": "LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Other long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Dividend yield (per share)"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Volatility (annual)"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r91",
      "r93",
      "r96"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r62",
      "r64",
      "r70",
      "r74",
      "r96",
      "r111",
      "r123",
      "r125",
      "r126",
      "r127",
      "r128",
      "r131",
      "r132",
      "r138",
      "r165",
      "r174",
      "r177",
      "r180",
      "r182",
      "r199",
      "r220",
      "r221",
      "r222",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r231",
      "r232",
      "r445",
      "r460",
      "r549",
      "r567"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit",
      "http://www.angn.com/role/NetLossPerShareScheduleofnetlosspersharebasicanddilutedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]",
        "terseLabel": "Numerator"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/NetLossPerShareScheduleofnetlosspersharebasicanddilutedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesAndLoansReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r23",
      "r188",
      "r189",
      "r545"
     ],
     "calculation": {
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.",
        "label": "Financing Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Convertible note receivable"
       }
      }
     },
     "localname": "NotesAndLoansReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesIssued1": {
     "auth_ref": [
      "r100",
      "r101",
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of notes issued in noncash investing and financing activities.",
        "label": "Notes Issued",
        "terseLabel": "Convertible notes issued in receivable"
       }
      }
     },
     "localname": "NotesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingCostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r165",
      "r174",
      "r177",
      "r180",
      "r182"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r489",
      "r498"
     ],
     "calculation": {
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofComponentsofRentExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofComponentsofRentExpenseDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofComponentsofRentExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "totalLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofComponentsofRentExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r479"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "Operating Lease, Impairment Loss",
        "terseLabel": "Impairment of leased assets"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r481"
     ],
     "calculation": {
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r481"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liability\u2014current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets",
      "http://www.angn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r481"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability\u2014noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets",
      "http://www.angn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r485",
      "r492"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofQuantitativeInformationaboutOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r480"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r495",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate\u2014operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofQuantitativeInformationaboutOperatingLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r494",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term\u2014operating leases (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofQuantitativeInformationaboutOperatingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r411"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesNarrativeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "totalLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Description of the Business and Financial Condition"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialCondition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r52",
      "r510"
     ],
     "calculation": {
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r434",
      "r435",
      "r438"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherInvestmentsAndSecuritiesAtCost": {
     "auth_ref": [
      "r14",
      "r544",
      "r557"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Includes other investments and securities that are not at fair value as of the balance sheet date and those that are not accounted for under the equity method.",
        "label": "Other Investments and Securities, at Cost",
        "terseLabel": "Investment, at cost"
       }
      }
     },
     "localname": "OtherInvestmentsAndSecuritiesAtCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherShortTermBorrowings": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.",
        "label": "Other Short-term Borrowings",
        "terseLabel": "Other short-term debt"
       }
      }
     },
     "localname": "OtherShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-allotment option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement upon vesting of restricted stock awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchase of fixed assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance-based Restricted Stock Units (PSUs)"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r351",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Convertible preferred stocks outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r8",
      "r30",
      "r31"
     ],
     "calculation": {
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails",
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r6",
      "r9",
      "r202",
      "r204"
     ],
     "calculation": {
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Business insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidTaxes": {
     "auth_ref": [
      "r7",
      "r9",
      "r203",
      "r204"
     ],
     "calculation": {
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Taxes",
        "terseLabel": "Angion Pty tax"
       }
      }
     },
     "localname": "PrepaidTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPrepaidandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit",
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficitParenthetical",
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails",
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds from issuance of common stock upon IPO and Concurrent Private Placement, net of discount, commissions and offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of Series C convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r85",
      "r380"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Proceeds from RSU settlement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-term Lines of Credit",
        "terseLabel": "Proceeds from loan from PPP"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Proceeds from issuance of convertible notes and warrants"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r85",
      "r380"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r36",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleOfQuantitativeInformationAboutTheFinancingObligationDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r35",
      "r208"
     ],
     "calculation": {
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r15",
      "r16",
      "r210",
      "r510",
      "r554",
      "r563"
     ],
     "calculation": {
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleOfQuantitativeInformationAboutTheFinancingObligationDetails",
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r34",
      "r210",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r15",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsTables",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r15",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://www.angn.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleOfQuantitativeInformationAboutTheFinancingObligationDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r190",
      "r192",
      "r193",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Grants Receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r342",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsNovaParkInvestmentDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r342",
      "r501",
      "r502",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r501"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Expenses from transactions with related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsNovaParkInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r342",
      "r501",
      "r505",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsNovaParkInvestmentDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r499",
      "r500",
      "r502",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r391",
      "r525",
      "r601"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Non-vested shares under restricted stock grants",
        "verboseLabel": "Shares of Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/NetLossPerShareScheduleofantidilutivesecuritiesexcludedfromcomputationofnetlosspershareDetails",
      "http://www.angn.com/role/StockBasedCompensationScheduleofRSAandRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Non-vested shares under restricted stock unit grants",
        "verboseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/NetLossPerShareScheduleofantidilutivesecuritiesexcludedfromcomputationofnetlosspershareDetails",
      "http://www.angn.com/role/StockBasedCompensationScheduleofRSAandRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r25",
      "r303",
      "r384",
      "r510",
      "r561",
      "r580",
      "r582"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets",
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r120",
      "r121",
      "r122",
      "r124",
      "r130",
      "r132",
      "r201",
      "r381",
      "r382",
      "r383",
      "r420",
      "r421",
      "r443",
      "r577",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r161",
      "r162",
      "r173",
      "r178",
      "r179",
      "r183",
      "r184",
      "r186",
      "r322",
      "r323",
      "r526"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Contract revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r320",
      "r321",
      "r325",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue and Deferred Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RevenueandDeferredRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r80",
      "r223",
      "r225",
      "r226",
      "r230",
      "r231",
      "r232",
      "r584"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "terseLabel": "Revenue from license agreement"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueNotFromContractWithCustomer": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue that is not accounted for under Topic 606.",
        "label": "Revenue Not from Contract with Customer",
        "terseLabel": "Grant revenue"
       }
      }
     },
     "localname": "RevenueNotFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r105",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r318"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Transaction price at inception of license agreement"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Performance period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r71",
      "r111",
      "r161",
      "r162",
      "r173",
      "r178",
      "r179",
      "r183",
      "r184",
      "r186",
      "r199",
      "r220",
      "r221",
      "r222",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r231",
      "r232",
      "r460",
      "r553"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r493",
      "r498"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right of use assets exchanged for operating lease liabilities",
        "verboseLabel": "Right-of-use assets exchanged for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofQuantitativeInformationaboutOperatingLeasesDetails",
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit",
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficitParenthetical",
      "http://www.angn.com/role/ConvertibleNotesPayableDetails",
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails",
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails",
      "http://www.angn.com/role/SeriesCConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares sold in offering (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Share price (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConvertibleNotesPayableDetails",
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails",
      "http://www.angn.com/role/SeriesCConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/NetLossPerShareScheduleofantidilutivesecuritiesexcludedfromcomputationofnetlosspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of antidilutive securities excluded from computation of net loss per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of net loss per share, basic and diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r350",
      "r376",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationComponentsofStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r350",
      "r376",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Components of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r446",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Income before Income Tax, Domestic and Foreign"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r36",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r503",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsNovaParkInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r351",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.angn.com/role/StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails",
      "http://www.angn.com/role/StockBasedCompensationScheduleofRSAandRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r355",
      "r367",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used to Estimate Fair Value of Stock Option Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of RSA and RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis": {
     "auth_ref": [
      "r270",
      "r271",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents settlement terms for the group of mandatorily redeemable securities, including the description and the details of all terms for each outstanding financial instrument and each settlement option.",
        "label": "Schedule of Financial Instruments Subject to Mandatory Redemption by Settlement Terms [Axis]",
        "terseLabel": "Schedule of Financial Instruments Subject to Mandatory Redemption by Settlement Terms [Axis]"
       }
      }
     },
     "localname": "ScheduleOfSharesSubjectToMandatoryRedemptionBySettlementTermsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r47",
      "r108",
      "r149",
      "r150",
      "r274",
      "r275",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r287",
      "r293",
      "r296",
      "r297",
      "r298",
      "r300",
      "r301",
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SeriesCConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r308",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Warrants"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/WarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r403",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series C Preferred Stock [Member]",
        "terseLabel": "Series C preferred stock",
        "verboseLabel": "Shares issuable upon conversion of the Series C preferred stock"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/NetLossPerShareScheduleofantidilutivesecuritiesexcludedfromcomputationofnetlosspershareDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/SeriesCConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofRSAandRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofRSAandRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofRSAandRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofRSAandRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding at end of period (in dollars per share)",
        "terseLabel": "Outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofRSAandRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)",
        "terseLabel": "PSUs vested and released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.angn.com/role/StockBasedCompensationScheduleofRSAandRSUActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofRSAandRSUActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.angn.com/role/StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.angn.com/role/StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails",
      "http://www.angn.com/role/StockBasedCompensationScheduleofRSAandRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted",
        "terseLabel": "PSUs outstanding that were granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r356",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "terseLabel": "Non-option equity instruments outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "terseLabel": "Shares of Restricted Stock and Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofRSAandRSUActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for purchase under the ESPP (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Stock Option Activity, Additional Disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options vested and exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options vested and exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Options expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Options forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value per share for stock option grants (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r379"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding, total intrinsic value (in thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r357",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period (in dollars per share)",
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Post-IPO capitalization rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r349",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.angn.com/role/StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails",
      "http://www.angn.com/role/StockBasedCompensationScheduleofRSAandRSUActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r351",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r372",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofAssumptionsUsedtoEstimateFairValueofStockOptionAwardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r379"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options vested and exercisable, total intrinsic value (in thousands)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options vested and exercisable, weighted average remaining contractual life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding, weighted average remaining contractual life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance at end of period (in shares)",
        "periodStartLabel": "Balance at beginning of period (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "negatedTerseLabel": "Repurchase of common stock (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesSubjectToMandatoryRedemptionDisclosureTextBlock": {
     "auth_ref": [
      "r270",
      "r271",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature and terms of the financial instruments and the rights and obligations embodied in those instruments, information about settlement alternatives, if any, in the contract and identification of the entity that controls the settlement alternatives including:  a. The amount that would be paid, or the number of shares that would be issued and their fair value, determined under the conditions specified in the contract if the settlement were to occur at the reporting date b. How changes in the fair value of the issuer's equity shares would affect those settlement amounts (for example, \"the issuer is obligated to issue an additional x shares or pay an additional y dollars in cash for each $1 decrease in the fair value of one share\") c. The maximum amount that the issuer could be required to pay to redeem the instrument by physical settlement, if applicable d. The maximum number of shares that could be required to be issued, if applicable e. That a contract does not limit the amount that the issuer could be required to pay or the number of shares that the issuer could be required to issue, if applicable f. For a forward contract or an option indexed to the issuer's equity shares, the forward price or option strike price, the number of issuer's shares to which the contract is indexed, and the settlement date or dates of the contract, as applicable.  g. The components of the liability that would otherwise be related to shareholders' interest and other comprehensive income (if any) subject to the redemption feature (for example, par value and other paid in amounts of mandatorily redeemable instruments are disclosed separately from the amount of retained earnings or accumulated deficit).",
        "label": "Financial Instruments Subject to Mandatory Redemption Disclosure [Table Text Block]",
        "terseLabel": "Financial Instruments Subject to Mandatory Redemption Disclosure"
       }
      }
     },
     "localname": "SharesSubjectToMandatoryRedemptionDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SeriesCConvertiblePreferredStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain": {
     "auth_ref": [
      "r271",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifying description of each financial instrument that embodies an unconditional obligation requiring the issuer to redeem the securities by transferring the assets at a specified or determinable date (or dates) or upon an event that is certain to occur. Examples are preferred stock or trust preferred securities, each of which has redemption rights beyond the control of the issuer on a specified date or upon an event that is certain to occur.",
        "label": "Financial Instruments Subject to Mandatory Redemption, Financial Instrument [Domain]",
        "terseLabel": "Financial Instruments Subject to Mandatory Redemption, Financial Instrument [Domain]"
       }
      }
     },
     "localname": "SharesSubjectToMandatoryRedemptionFinancialInstrumentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.angn.com/role/SeriesCConvertiblePreferredStockSummaryofAggregateValuesRecordedDetails": {
       "order": 1.0,
       "parentTag": "angn_FinancialInstrumentsSubjectToMandatoryRedemptionCarriedAtAmortizedCostAndFairValueSettlementTermsShareValueAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount that is required to be paid, determined under the conditions specified in the contract, if as of the reporting date, the holder of the share has exercised the right to or the shares are mandatorily redeemable within one year of the reporting date or operating cycle, if longer.",
        "label": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Current",
        "terseLabel": "Series C convertible preferred stock at amortized cost",
        "totalLabel": "Net carrying amount"
       }
      }
     },
     "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets",
      "http://www.angn.com/role/SeriesCConvertiblePreferredStockSummaryofAggregateValuesRecordedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares that would be issued, determined under the conditions specified in the contract, if the settlement were to occur at the reporting date.",
        "label": "Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Number of Shares",
        "terseLabel": "Shares of convertible preferred stock (in shares)"
       }
      }
     },
     "localname": "SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/SeriesCConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConvertibleNotesPayableDetails",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConvertibleNotesPayableDetails",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r490",
      "r498"
     ],
     "calculation": {
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofComponentsofRentExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease rent expense"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofComponentsofRentExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermNonBankLoansAndNotesPayable": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowings from a creditor other than a bank with a maturity within one year or operating cycle, if longer.",
        "label": "Short-term Non-bank Loans and Notes Payable",
        "verboseLabel": "Convertible promissory notes payable at fair value"
       }
      }
     },
     "localname": "ShortTermNonBankLoansAndNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r104",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r108",
      "r111",
      "r135",
      "r136",
      "r137",
      "r139",
      "r141",
      "r149",
      "r150",
      "r151",
      "r199",
      "r220",
      "r225",
      "r226",
      "r227",
      "r231",
      "r232",
      "r278",
      "r279",
      "r283",
      "r287",
      "r295",
      "r460",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails",
      "http://www.angn.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/SeriesCConvertiblePreferredStockNarrativeDetails",
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r51",
      "r68",
      "r69",
      "r70",
      "r120",
      "r121",
      "r122",
      "r124",
      "r130",
      "r132",
      "r148",
      "r201",
      "r295",
      "r303",
      "r381",
      "r382",
      "r383",
      "r420",
      "r421",
      "r443",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r577",
      "r578",
      "r579",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit",
      "http://www.angn.com/role/ConvertibleNotesPayableDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails",
      "http://www.angn.com/role/WarrantsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit",
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Stockholders' equity (deficit)"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r148",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit",
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r50",
      "r252",
      "r295",
      "r296",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible notes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit",
      "http://www.angn.com/role/ConvertibleNotesPayableDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r21",
      "r22",
      "r295",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r21",
      "r22",
      "r295",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "verboseLabel": "Restricted stock units releases (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r21",
      "r22",
      "r295",
      "r303",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit",
      "http://www.angn.com/role/StockBasedCompensationScheduleofShareOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r51",
      "r295",
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible notes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r21",
      "r22",
      "r295",
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r295",
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Restricted stock units releases"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r51",
      "r295",
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r22",
      "r27",
      "r28",
      "r111",
      "r191",
      "r199",
      "r460",
      "r510"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total stockholders' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets",
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r109",
      "r279",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r291",
      "r292",
      "r294",
      "r303",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Stock split, conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "StockholdersEquityPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r473",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r473",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r473",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r473",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r511",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit",
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficitParenthetical",
      "http://www.angn.com/role/ConvertibleNotesPayableDetails",
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails",
      "http://www.angn.com/role/RevenueandDeferredRevenueDetails",
      "http://www.angn.com/role/SeriesCConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/DescriptionoftheBusinessandFinancialConditionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalUnemploymentBenefitsSeveranceBenefits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability for amount due employees, in addition to wages and any other money that employers owe employees, when their employment ends through a layoff or other termination. For example, a company may provide involuntarily terminated employees with a lump sum payment equal to one week's salary for every year of employment.",
        "label": "Supplemental Unemployment Benefits, Severance Benefits",
        "terseLabel": "Severance benefits"
       }
      }
     },
     "localname": "SupplementalUnemploymentBenefitsSeveranceBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r411"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward, amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Tax Credit Carryforward [Line Items]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Tax Credit Carryforward [Table]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/BalanceSheetComponentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r49",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r22",
      "r295",
      "r304"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "negatedLabel": "Retirement of treasury stock"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r49",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesRetired": {
     "auth_ref": [
      "r22",
      "r295",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common and preferred stock retired from treasury during the period.",
        "label": "Treasury Stock, Shares, Retired",
        "negatedLabel": "Retirement of treasury stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesRetired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r49",
      "r306",
      "r307"
     ],
     "calculation": {
      "http://www.angn.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedTerseLabel": "Treasury stock, zero and 316,088 shares outstanding as of December 31, 2021 and 2020, respectively",
        "terseLabel": "Treasury stock"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedBalanceSheets",
      "http://www.angn.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r392",
      "r399"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesUnrecognizedTaxBenefitsIfRecognizedWouldAffecttheEffectiveTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Unrecognized tax benefits",
        "totalLabel": "Total unrecognized benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesNarrativeDetails",
      "http://www.angn.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails",
      "http://www.angn.com/role/IncomeTaxesUnrecognizedTaxBenefitsIfRecognizedWouldAffecttheEffectiveTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r401"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions for current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r400"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions for prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://www.angn.com/role/IncomeTaxesUnrecognizedTaxBenefitsIfRecognizedWouldAffecttheEffectiveTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_UnrecognizedTaxBenefits",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized benefits that would affect the effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/IncomeTaxesUnrecognizedTaxBenefitsIfRecognizedWouldAffecttheEffectiveTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r152",
      "r153",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r491",
      "r498"
     ],
     "calculation": {
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofComponentsofRentExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/CommitmentsandContingenciesScheduleofComponentsofRentExpenseDetails",
      "http://www.angn.com/role/RelatedPartyTransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Shares issuable upon the exercise of warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/NetLossPerShareScheduleofantidilutivesecuritiesexcludedfromcomputationofnetlosspershareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Warrants, measurement input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrants, contractual term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/FairValueMeasurementsFairValueMeasurementInputsandValuationTechniquesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r134",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding, diluted (in shares)",
        "verboseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.angn.com/role/NetLossPerShareScheduleofnetlosspersharebasicanddilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r133",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding, basic (in shares)",
        "verboseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.angn.com/role/NetLossPerShareScheduleofnetlosspersharebasicanddilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.angn.com/role/NetLossPerShareScheduleofnetlosspersharebasicanddilutedDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=125513658&loc=d3e32014-111567"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=118255708&loc=SL5909891-110878"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262807&loc=d3e22026-110879"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262807&loc=d3e22047-110879"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21459-112644"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/subtopic&trid=2235116"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14172-108612"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123399704&loc=SL77918431-209957"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(7))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r602": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r603": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r604": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r605": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r606": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r607": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r608": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r609": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r610": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r611": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r612": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r613": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3444-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=SL94080555-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>123
<FILENAME>0001601485-22-000022-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001601485-22-000022-xbrl.zip
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M/@EU')$/']^<GO1(H50N7]=ZY?+QX)C\-3@[)76GXI*!I(GBFHN$1N5R_[Q
M"J'6::=<GDPFSJ3F"#DJ#R[+2*I>CH10S/&U7S@ZQ"OPR:A_]-OA[Z42.19>
M%K-$$T\RJIE/,L63$;GVF;HAI5*^JR?2J>2C4)-JI5HEUT+>\#&UZYKKB!W-
MZ!R6[??#LF%R.!3^].C0YV/"_=<%SEHM5F_1UCYMPK]^FS9\UVNS_:K;;@1!
MDWUVX9!EV&[O47H:L=>%F">ED"'_3KOAM)JI/IAP7X<=MU+YH["T5;-;7:(1
M'R4=#X[#)"SS>$1HI(%]3$?L<Z7N?$E'!:*DMW+)$LEYU9OI[4%,Y0C8#X76
M(NXT@/682<T]&N5L#$>[/#M5&VY<*\<2+;<*Q-:=-Q"@C_P63T1"=G8JYN<
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M,2=G)Z] SL[.?X%5B8OWN"!:[NX>KOCBYY--6U>[(^+D?XY_/GKWTXDX.K[
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M$'HC2%$$PI$27DD&1':@#E-P=:#K@=A]\AUV3[B%@%2TWX]L)U/57?5U7,6
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M75/7J<W(?N?$DS'#<7TQ, ;X2N,FRXM5>0,,>)BJ5 O[2&0*+XWX5*=C&FJ
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M#I?-R\LL;>8O#O;W_^<#OO5O?YF514/?J^AY^:>\9O"RQGQN'L9Y=EZ\2&C
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MQ  "!EX?\C@UE*PX2HKB$%OU10[A#O*@K,-_9*5+@2U*#8:-TBH^X,C+%"M
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M@$5R'==<>(5>ZCX"F5X,7RW1<Y@7ZVT":.YT,-%$R4? W$F&XSWL+<D!>(L
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M2,)KO>SS;B>+M)>Y/)&>4V-IK8Z-&]L5:S)H+29R@32>@OOZA1GM SPE![&
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M#JT-7IPE3GK((L1"TM7RB=%VH)U17<\ZNJF)L:2K(A=,E5#]DN8A+FRYD4O
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M#-OA3=KBYF1[_WA57?SC536U[?GQFS]\<=H8#,?M\,\7OACTVV;\NMOK!EA
M<?XZ#0QE]6?A?>CF/^'^-G"=LG#5^\^'NR'^\T5A ^$F"D289<PCJ1A\6U0"
M>X^\5_CS>EH*@O\V+T#>-9WTZE"\GO"RM\7 F?9!,.5;N#)XT2@\3.[IWV.[
MWCM]3W9/#^C6R!]OG!Z^T\<[G=WVX?X6V=D_^;+]I=4Z//X+;:_[UO;Z*M_:
M_^M\^]W6V<&GW<[!IPWZGFZW#[[T3PX_??RR?7S"M[XX=O#I ,;_10_V_SK;
MV=] 6_N[QUOOWIX<=MZVMK&B[\GA^."3$SOO-L?;G;=M&$</W\&\ZS!N_0@=
MKI_P[?76\<[ZYAA^CP_W_SKU[]X6]MU'L;/?;AT<;YYO?3J$^7;;V^]V3[9A
MG8?'&WA[WQ]OP[IV]O_L'*Y_K)_Y&][%NX?[/;[SZ6VQ=;QQ#L]U#M]]1/!.
MO+._W=G:_XBWR18^?'? M]X=GFS_K=C[_8WAUAXZ?[\/:_RRBC\3K86(+C2!
M-Y,FPUPT@6/+)D7*ZN@4C<J\>). \,>K2P!]//A^@/E[?@GA.T&87X$P^PPP
MQ<HKVJ1*2A#5%C4UIJAI+2,@=$%L1_[BS=N#1X3O1A?XRW@-(%R:]F;7A_/_
M#N,E;+\%V_.M(L$UPW>\=>S.MU<_8\D]<]8UE3"LR:B@3>TE;F*N,(K<,DG0
MBS<(!*Y &)2Q1X3R*I"PSV3<-D<O&I7\A6G/AZ]C<1Y\,YIV4C^68/\6V,<S
M8/]R@G96/\N K53>-85DP+:=(DT5L&X:0RW!QNH@0#"_31O\71 GCB##,6CC
MCB%KE*$<.8=YA"F!<WS>O KH6IM^O1M.0W<4=D&?*[I%]PB8=@8XJ'4[MET<
M9<UKX[P?'-@>^T4'ANS$/;@ZB,:E>Q67QY?P).EVK_VH'(.$?UH\03O['T\/
MN_]J'7[I=PZ/MUN'[[9;6Y\VV=:[+8#= < 5WG]\@@$?X%G'#[ZLHNU"H\/_
M:2'7^;MK/NG13N>PLT7>GAR0C?.#XZ.S@R^[)X?',.>[OP%/_@9\@'5^:0/>
M_47^Y\L&K.,$;^UOD"T8N_7EZ#,""RM2YIHF2MYD6@#5:Q#8&HPD 4JBU $X
M.1A^UT#^ZK):5H)Y5@8 S> &;3*II:\'63,'I&AD-?7U$'3(?[X8%)U^.ZGI
M^5JK3#AS27%<.1]XF.+5Y3FJ]U^\M%[#H#<J\Z]L![VN$;$"\X^PGLE$(4N7
MR:_"I]^Q"&4C+RC<:"RL;?[W92YY]>$WDTN79^]GK)W\ C.F'*Z#=?UF8C$B
M/'GNXMYTF?YB*"9-BB]>4=V9_)Z\Y-6EC;IQWUS4W&GN'>&<!<2MBUY%;)A%
MGBG&*P)&@J(YV*[*[AO6FR5 YYQ.5-^YVPZ,ND7U^:.,?=7%3C"#41G>U';3
MZX][ZY/')[<FO]/S-^ZFIB($!=+5,,%05* K$R9PU-Y&RVG(NTD0)7R^=I,T
M$6T2_I.[.6@9(-)K&UJC<[[YW3M*#192(!Z$$TP(HJV&2YXRJJ625L\(F+G:
MT2L4^GT[>FD'L'7<!<R(8H@%+Q2P<+"S0(NC%FE6B5@T?SN ?F8'9BD4!/U>
M0I[IY_GB%)8U.S3++3/LE3](S->>3Q?70[<':L=-T]X5I2]-\>KRZK^%^<@*
MC"0/5"C!(J' 0Q2*V L&RAJ([RS1T$2BS0L"7))HZ.X2#=V;1--!@4HKJ0H:
MLRA!!^(!ML=)+D#.$9KH!>O'V*[ZJ\-1LFFJGQY>=MYO%ZX8;H6.A5?X NY6
M'OB):KPWA$]/SVS\>Y3,WEZGW^O"S\'J>0'L=3(,KG=ZW;UASYU4<_WQZL97
M3'=MNI+O(F0P$NZ+E06C+ L<2PD"$C,#C)P1C:7B,AH9W;,!S7Z9F<%XD8!#
MM2'$F^A JC)II<4N<1?C9*3>$/-L@+/J?9$,2-/^8 J_V5TS_6)HV@L")B32
M41HQFE/) L;*N< H2 EKE?7J&8')N5%GU$Y'CSO#5BC3N#*TTFRG8;/K>IVP
M("#S8&!)$86TPK&@F'':2"50A!^*V.<#LMTP-$4W^ U3)I?.8$'@@Y1#-$H2
M$7 ^S*D.W'EGA?42!RKYX\'GJ78@@GIDB8H:_F$2,165C9%Q1D$R(\:?0-=\
M+D+@Z15BX#&(.TFT 4,B*&TED@X%'ID!=$?X^0'W037CIP=HC$))RADC2L(&
M,VN41B(B%X3B49KG!] 'UJ>?'J1,!\S!/(T"P.H-MH(XRYR5(A"C)'I^('T2
M]>[I >TE6+M<$.M!KB+!K5)<X8")$,Q1Y9\?H!]>*7QZJ!I'O <-T0DDF?3(
M>"Z4 ![M*3;&^L?ST2ZR9+TOY_'E@T%!/2,^)E<3\UX:I+0A1F#$N5%>/1O0
M/)K/Z1Z!(X@,5AE''0[,>6LXJ#4"C!#+'7):/!O@/('/Z1[!Q UF&+02'8D$
M345KS"463D8P%#T.SX>]/;'/Z1Y!YEWT$11';0(&.]Y;3<'@4TH)0QE3SP=D
MC^ESND?X&&>-DQA+; B3$8-5'H6,%F/F',?V">)5?AA0(SLH?&% ])AVV(E9
M %T&TN:'G0=6^YXD>$8[PA5SS#./&5";9M3@&!G%2H3(_"(!\;[UOR7Z?!-]
MHF >46N!/RL&]I^Q"%D>-.A#EF&BGQ_Z_)@:M$2E;VMHR/.HA+-8@YT3HR*4
M6X$I0=(18\,BH=*W@?BA+$YAHSZTC<M(]QPAJCW1Q'/0NCG(%F*MB1H9+CCQ
M5BKN?FF(/IU86TA<D@$13YU&+@0FHM7$4">%\ AL LO-(N'2H@B:7X%'<:&5
MT$P%)2S V2J.-)8$;$W*G&3B^>'5,V<4SB.%1#">:<:HD(9(804QV%(" FC)
M*!89N$HPJ;QT%A0*9IDT7E)F);.1&"DY6R3@WLY_4WK1Z^U>%Q3]W9 ]>?GF
M?LKHKQ+'ON4B6O*,[^,9AG"GHJ>,$^:#,DP*@A2P$A1U5$LK]AZ5BY]'[H5$
M,21CCFWEF"@F.+,(<<N)I=YJ#+K&(J'8$KA70U^,#AYC&61T##B'=C%((FSP
M"L03X8L$W+DXJ7UZD H/ %/<.\H$BYX9)*51CCFBX9J/SP^D3Q_-]#0JI>/.
M8BL8]I$I2[5&SJ6R7$CPI  \/T _<C33TYQ+>,D4F/%<$,(42L4AF%%:"&L0
M"W46\W, YF-%,]U?,C!Q*E7E891ARJ3'RB(BHO9(4,<E\L\&-(\7S71_P%$J
M<(&"H](%IK$Q/NI@J;!8*:8\>C; >8IHIOL#DS<"<R&D\T8!F**QCBMAH@A&
M.,O8\P'3$T<SW2/(O S!"JD--<PJ$$C:>\6()\;IB)X/R!XUFNG^X&-!LY<"
M&01DQ5)X+57<6$^)=BY8M5 *_WRY%M?:9C"X\8#IF;L5$?6<<A0Y4I8EA[4#
M7BU#!/G*-=9AD1(EEBAU%:6>)$N#*BNC\<PCPUGD%B0'M5X'8KTQB"^DIVD>
M@/DT9\\!42J5)B%:%@51C@@CD)..1&=-7"3^,$_ ?!+*Y-HR1!V 4R@6+ =E
M(@C$4AU)RZAYBEI'#\#L'R\&\4F "- A(D:P=2-A+@0=,4MI/ )1')![BA*,
M#TB1>[ Q8;#V(5>I+&NY_1P9+8Y>F4 92?!4TEH,A(J VTH5*=)JD6AS/L'Z
M-"FKW LN8J#""^8]43&Y>DW$W" '!%Q3*ZFI-?TQ!]5/KI(#N3,Y7!KZ??LV
M+4;8'26 WU+@L@]_3B:X<WE+%Z4.R'K&H@,;1QB A$9&2.. :Q(ZA8*>0$'/
M+7'-@^"KX*SOCA+Z'DB)1&L4QQ2!6<H0HDJ1X##3)GAO*;-U#=U'@-WW^G\N
M[<#/Y/%*P&$5F$;*L\A2K&"@7"HIHN4$A>>%QCNGH5QMMWO#-/5./UGISQ&M
ML1#!!*$) >T<U#6=2QK$" 97E![IYP74QX_7?GR(\DB9MR#P,4L"!VF.C>/6
M&8J==M8]#XAFGQJ(FM6N_Q6 :@C'*D3N3*I>YS P7(5CTA^8BD&XB?3!#U[!
M_0'5\K5>%YCNL+#M\-"J^54!B7^PR/SERK>"4Q0=R$@C&,)&&2Y)%-)'0L ^
M%H\'I$?<@:G>W.NGZMKI/*N"PS4-.I/L=-1>->J[E>EHA<8IW$QBS @!@H@^
M.(<0J-8,])(%<D!\*--N#,? N;I#8&3IU+"?YOASG+JS72:.Z<WGZ'X(W'B#
ME9>@C#!#F :=4MH4DL25$V*1\B"_"ZAO1R7@.> ]#'Q;G*>_GF6P&2%6@/'D
MF%.. 7_44?.4]2I2(5+%Q?P?[=<'=Q]@M\:S!W=_CF?O7"?9X7@K#%L]OPFB
M;3 ,WXK%^.9Z!N7P=6J0Z4=)(;K^AHOH@\OOW3:=<.DT\M3 BA<EZ(H88UB2
MHPJ80R#:6"^DLT$I20,B;G[QYY[@M=,JUWJ#3A@6;O#^_=K\@FVJ#E0ONUD)
MJ.Y]M^BGE(48E441Q10::2DQGDHK#?-88[H 4B*AP\Y9-Y2#5M'_8?C>Z37[
MJ5GK3MSLYEXD(].N7I=NK;6*$#?.@QL-BU,8$PL7RN<H=PSF1'H;C12>":N,
MM$H#SQ &8PLR:7[YQ@*83?=6EYS@0")B3(4 &CRW4C(2C%=$&% .ZK,G/#U[
MP@_?INQ'R'JM-X*/*OM)#[C"O?\N8J_\T#)EQ]P'98.*Z4=NN%/NA?(42/<R
M.KR'*]W!P]?5Q=]QG(5GNKC]3"9*T"1&AY%6FC&)%6%2,,*<<4H'&NMZ=TL$
M>1H$N5Q##_]PY[[+W$%3ZXD';@ 6OF+!!( _\REW, 62\,<[=UG"_%L2X;Y.
MFJ3#3@D<%$LY,)8;#CJ_DU@$SSG7? %<V(L'_+NK)+_L&;"SUBIGL(J6,@K&
M*!7.@0'*?<3&,;( >/F$Y;H6CR06$DD)&#8>D-$@YICSU$0BG:)4@<E,(UV$
MHK-S!+\G*+5"#3((["#B)6-::&\4<4PR:W+=QZ=6<E/3;_\U1^E/MGS?F^QR
M!?$_'F;B%=]+\UR8,N*/5P_[IBF6SFS@DFL^H.5@B2/(<$R%=@Q9 ^*:(Y?"
MS8W5W,YQIN[BP?RY\@8RD0!/P1OFQD&'M?6@3F"2*J!SH9&F#DO!-0Y!FT5(
MJ5H\BEI(W47Z&! 51EO05Z(4BE$;'*:2<*9Y6(0NA+\>ICQ)9H(4GK(@(C-&
M,L6\EI1;*V14- :*]5(XSXM"=H^G^ $D!J:$:N,89DD)"SX(BM.IC^=F?MO5
M_&HPO\<6.(H&IT#UM@!F&;R*$B,5@,X-1@'%^:7S:8R6*<J_37L4_AQO59$*
M:8*W9?CW*'3=E9"?Z>"9H8/=X$9E"9K@?7E@9Y8T_?._X"--Z5KC]Z"AMF]9
MU6:W/QH.\@B\($S#>!:HMR(2RICQP41.HTF9_98;9.5"(= /0XL\ .H\,#;/
M"P))$YV4BED+F@92T1)KB,-$12&X-.K70""Z1* ?5UNHU%I&84EDTB&C51 *
M6) &[27R!:B4^.O!#'-F"0LL:,U8)%@9ZU#4S@L>%*I]?W.I:B[5CKG06ZG5
MTBHL4F$SII*ZRAD&=<,[X9W4=J$0:*EV/#X">4><B@XX3T1,I#KV5C(M,-B[
MW-NP %V/EVK'DR(0=C)&0AR-43/#O&*:"V*(8@X%[,E"(= O C/%@V;*(6\1
M8B8X+0RC"A&MN( [>*%@]KXPMFBG.J8I]'S&W?7)E"5LT/3^@@#'":$(M\C0
MZ)CWPA#-?8J,L<)%B]7" ^>&A(#MWC ,/IBQ@;\7!$P*@V4E%(_"21:MU2Q@
M:86R5#EM^&*I[G<$TR/F;=P?H)#'3"")59""*6'!'*:<N0B"*VG/B]08</X@
M]O1GN39*J6BP40C+3)3: :PIIR+R2+0@SQJ\#\LWGQZX*" 7!=;&2,40XD9B
MGU+C* .C%ZM%ZNDR'QK+TX,4<QLC<&'!-&'6$Z5D(,:'&&VDQ"U KN-\0/)!
M_)$.<11HZMG. V,4 >$)0;PVJ:9/8(MU"#$7//1!P$2M0\A*"W:"9S8U."#1
MRJ"DTLQA-\=U!N97DWD00 EAO'-@'/BH650@N@1F5L;@"<&,A?G-"IPFX+1Z
MY7 _E)WU8(?7*\,\#1W=5P(?\#3A,.R:LV!JDV!Q.L3W3BB'%-9XD1*EIL4[
M]EJF#(.]D3T.;KC?VS)=;X:]<KP;?.CD I%_CO?"<-C.OJL$VKL2W=?F?(XI
M2I;XB) +1(-UKYA0DH/5:+"P$5,?%Z#3SUSYQF<\IGGZ"VZ25::KM_>&97$"
M&%BX11'+D7D1E2#12,ZXI#9$C$+ @F&E0-%=*)?0$E\>W#,%XB1RJ2W!6C'/
MM9(N*!(4TI9:&OF2O\P3=5OO$8U"JE0AG46IG!::>ZVC4E'@Q7+XSBFT[H^V
M O=!6*>M$)H%0:RQ!BMA 8K)2TCGG[9N9W^WC<B\[^]>VPSOXG-X1FASCV&\
ME%.E0_ .&<8$,&:4K&I%;*H@;Q;@-'N)-D^3/N CV(S&6<ZH"4H31C1R7*/@
M19TR,M?<9D$TO]M&[!:#D[=E@-4, UB_PUTP^1:$Y81(# 7QI)$5C'BC/8M!
M<:VYT!HC-_\L9XD[3\5W++;2>&&53\7&(E6*840 O(H[2=1BI2TM(NY,4NC7
M4_'2T/4+Q'<D=E1BA4 ;=@S$E.76TZ 1B<1*;)=\Y]GASCWJ.](K$:P W=BP
M$)%5DCO$M5*(2<D7P#-:M9S?-^>KHV&K5Q:SR;*3,:NCP; T[<)T85RNF%'5
M(+XOE(%9U\K@B^&:*<MQ[)5GIO17>[ /0D+G!>$I3C/-N!+48 ORB!F+(P_2
MDZ Y18[,/U[,2[.+!P&/=M%8%:)Q@3+OF:(Z6HN2")#>:3G_+'\.P7./R3Q(
M> ^:'/!0S'QPF@;N>3"*6^K4(H3&S&%7D8<A) T<C0;DJ:-,$6N\4MY(*K
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MAG-JO+">+E+WNF>-'$_".1 QBE@G4_(""Q9K'R2.07NAK7=F$>S[1T6.1^K
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M^ 8H0'"[R3:#^*MUTFJ;@X-YLFXX&([\1/>97ARF50'D*O8ZT>+J2=)(<VJ
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M+ W8G]K<B]/,J>XUH8TE__\9HV3V7#LILT7IFWU3@EX*%T?IQ!UX?KG<XI]
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MMFPTY5,U']Z_>_YZWW['AA+-CU=K7H.*O.T82RA)[K>TGO_/R=[>LZN?Y74
M^\NB;/.2U O)-11:MLMJS@=CM&QU<Z^L:_J#[?K/#)UZ18B3]-)6Z<A6Z6L'
MM?[RGUFV/E9[Q\[Q[S5E.]X#6:V&EHWD&)MB$:+R:@MV%T\1K"87 4L.L<29
M;F$;YJUJT<I=ELM@MRN-,NMR3B4SPG/_4639ZS!;:/UR=(D4I=P5-@#)YD%
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MR>AM>_MD<I%_?05<Z4^2VWY\7R9]XS+I>\5]C>(^(655<(3]"/?UA9K:*$%
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MH.4,ALSA4[#1(BE6DF@SN(R#F S-SS4)'=E]2M#.$O>0E@G9K8!K=V\17(N
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M3:<@7YVVZ9F)FU>[?U4!]2:OM$9VDR23CVQI+H&9OKS=RMG%FLXCN?&L>[7
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MY0W0"7FKS&A2%H05'2ZWM10"DJ,C2<)Y\GP^'M,TQJ,XA;.;10=CD)X*[._
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M(;J"XXB[3SEJ %"/6SJSIWC>W.ZD6Q:UF[T3D+C B?QJR464+ZK;1=]&&K(
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MS(F>V1MW^J.10U>>5^LI!7A*9/_K_.4Z(U[0<>EM?=*4!LL8CJ"I[RGJB7-
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M<QXRL0'9%3J*9%3%N29CP%ICSL+N$A)QK[JM@6IK/0BD+\7/SSUT[\'.OID
M(@TU$BB1?:>L@V[ED3&ASJQQ/EW=X;&,(ACB <;A&$V_"I%@\G1?&B.HQA_=
MDJ9510AN*].E*QK(.=^\#6Q_5XTW6389UEF)#D_U)ZMSUO(Y.6AL$5VR+]SI
M:Q+E- 2#HZNE+Z(!^0%JH6Y>2-4[@P,5STZW0.+C%9,,YJ3&R&G][J,>=# B
MY?/6,O^C#&>8@7?S-#/#%IU^TQ,S[(L''/G%]E#)X<BX*CKFM$9S/S:#JS##
M+W.W<BWN#&I0R=%R"1BMC!-+$PU1G_2X,ZZ#E7%%0SK4@SS2@OY]#4VQ)LZA
MAZU,X5*)[Z,P1M\N#P)NPF]A2%D)<_Y9S; !#E\X#@'2L@"SP'!:8[U%@J.;
MO]K-7A:5=_V-Z Z" 1<N;VRG=365BIIKY,!"P.LK!PZFBC&G,ITC'U^\$ $3
M610F_\)!P=PAUWBT +.6MN>V,4P[ 8$0MB-=6/G\H\'C[FZ #/8C5U&,':PA
M"VKXL\;IA1BTDDM;HTPDJ!<P$DVR!0WWHR,H&)V+Y'P4XK&[&^/<Y"A:CZ25
MC;B%R,KC]9&5QWV1E4>/]__%(RO/0BGXJM;!.>"X^F>V*%:JR%MH2JPDD<8+
MR2?'5.5G]WW]X$$%S!A9M,+6AE=)SI)NGY:"Q#71B'UF>__!_]/Z=_I>0$6I
M%/[OHVPKW+'M@4G!_SX:9 _EG\^.Z3-1B');V =EVMD6/8%^I ]MIT%-$:&0
M4GO[43 S\ M7HQGRL9X&,53T!Y>_TPW\NY6:_JV?3YZ_W\9L\0IZU3V_V]ZC
M>R=HH]*$ !+)A69D'%H,H5V.!\TEL>'[T/"M1".MP- (1X105203"V#E>]*"
M)A"E"SD"LT,M8_(L7W'/WT/A@+59 PD*$+5;I_7S;3'88#_A8283\5)L<QV=
M@/L=OH4==J]>OL_^?3S_@33:]*?O2)!]M[?[Y.%T?]!5*O*IO?%W;,2W D&6
M<!S3:2W 8$H[F &V/18"$L/KPYM\_J+ <3A\_TR</>$WVG^P@H4F/PF#NLWU
MN<G&7"4Y,?6O'QD%:Q%B^/]>KFS/G8DH[SS</?C^JICR_OTUO8T<7;54XI+W
MAX>GWYV^^NG#SOYW4J9)'A0"Y#732@<ZN2F@O6?.;NJY2.[8SMR 6)H5ZUD]
M@#C?ZH*HQB?5<:_M;P6(J/U!E8ZAJ)+F'3W0ICJAQ9)B&.GM[;@6;FSG4B(-
MXU6'[G[?;L-*\XLN0=UZ9G$87'H4[+E_+K@H3F(V]XM^*Z9Q.V00TN7$66UB
MLO93KK./L'^K5'V<(F%S^/X^W.+6O,IY0ZR/+(*5O3!.\E&FZ#JCI <GK[\[
M.9+P* FV:]'4=TQ)_J)5B:A#1@2LDAHFC?D]"P&UE59^ TF!C*5YAG1.46Y2
M5+J*#[ 24TNK&">U<)0H7-67KU7YO__;_L.G/UQP0CZPVW(- ;?RY1V10K=^
M7C10%2QR;3C1B[Q=5Q61Y+!.O1A$M%]K.%<6RKK32-)HOB8.IXS)DCF*F#N,
M$A7%$QQ:?+SCBYAY>)?.ZBZ9FY=+1!EQC%W3I%IH$+:*7,['>5$A'"M1Q8TJ
M-K/K:'DEBT;SA>NM'1NDE=O8K':E]T]4?]=#'205Z[/ !9!G])=<B?IRH6):
MFP7=#6^:=-.&<4XI?H(61N7#!O1]5_9KNJOMB:ZL7.45>?+DR::</!NO)GY!
MC!*2OI+=H-'M#,N<MFOB2*35Z 2>C9OZ$J@XVF<Z<5L_OGJYG4V+*:0.]Z5R
M ,D[#N'[5P J7(#BAED%"D^@X\\*G39Z$&>_M"<@()36*]UX=N).GB%U#A)E
M% "AV2CPV$A(6T>\\QH]"%B05=I14SY75+\NFF5$5AQ7><Y]*S_UK$ LT:U?
M-_%#\]O-WJ*P7ITP_3L#I7V]J&2:BF9%;+;2-_B2$01<Y^U7+;E6MFK)_0KB
MXJ'*S$"+&1KK=#2; 2?IFI_/@VS>.L).:B_Z\.!]?7"L($F ,PVOI)"QJ/I.
M6574B=3#@H<MW?ERD&<-P3TQ!D&*%#,+JU&#!@=>!)PM@9#(MIZ?'NX<OC[>
MWAQ!_HOCEICD\3%JX;)N/LKDT9>D+(:N0@^GO)E79 ?\H\#2";[;4NEV9!'T
M+06R@DPVOIZ3K%RJR@LEQ_@29R;3DYFA<QA]L^7;.*JUT^W<5=:'0 <9JY"X
M 12;-%Z;X" "1D&_8(8O_IZ,_R>9E0$7)ODHU!CD_EQZ^TKW5#CD],\'%B<W
M=U@_2V=Q$,HTVVBD>B]CBN6JQBD>M> 1'[NY$OY$5FX/QTFXN]^4'>%:+H23
M2(.>%#..'6[0E; FA=+S,6P$=XSTG2)E1UB$-D+FX=EC8@M"31/EV62[_/CM
MT0Y9$F>EI<9A&Y,U,^]T/+RK%L7-&5_W]FE%W[][_GH?[0[91./V%[[E.<U6
M&B\??4:1^5TX)CCF,C&S/56*M G51'_WT$&W?:@G$F-I*<_]_':BY_&R:HL5
M:]*<O9_4.Y&*&]9%Z48[^(]G3[+4D+*;;6$<V]H)6#2S03V];<,-[949,&"^
MUG3F@^'"\XQZ>. =Y(35DD_$3WL\?%D#V.F &K&+.2T$W387.,0XZ:S; 8)Y
MVAIK*<3 +7W/CN<5E+=[%K>M8M?M#K*1, OJ[U=&M<W#.A,H56HS<$=F#&VR
MY$UJF97WO>/V-^T0A@B_EQ6M--GP8[',*B+[ZA>;Q5DDRR9+$Q"2]K/_#'."
M,L^ZZ!U9GWD1.AD'3@@:-12VM?Q(QBU5>)[M0R+(@.LLFA #GH<V&SR0L+C1
MH;[^V&Y2S\PWWJ6G@R*GX[O]>+H<&0$-3G'!C2=\Y-RXR.+&)4U!UB/]L\RV
M7I'BH54="GO@MMDH11N"*8!LY3.U=?Q-&)?Y8EA/A7:O9L8(;*5K="\'J/"2
M=[QHBO)6\XV/?E>ZL0>B%[*-']Y\@P*6*U<=Z_NGAUH]OH=:?6XKS:^W.\\G
MI+U3Z3!$TR=$&R[RMJ:1M%.)T)'1VDQRN.=@B?FH_'NDA?)&A049#8P&R:^6
M2*ODVX;BFL?49R:E)""MVL(LHT@-G[ER,:UE"$'5VOO44$:/IMZW6/=?CA3L
M ,2]:'<F3%JNW9TW1<^\*-T%VQ;NTRSB5 ^F$2],:G[%QJ>M1!_?6:^)*(9$
M&_,-HY7@3#581.0V]_10;'TQJ^@,5/?S1NU/[M3BHR]*+BIO4#RYA9E*D,\V
M+"?-CI+N.X'':!XU2=ZE,Z9D92N6C_4JJPH\#$=^T3CY1WWF^R1D6S___&X[
M%*QH"S2S)F%PNE&?644#+_AXI]_8S5XN&JSEE/L^\RY,:UB>_A6<F $G2MX,
MF6O_G!%54^"+><:::Q%3LS;?0FU");HN.4P@(3J8ZD..&B"J0N*IGB[)\MQA
M"Y1^S2^T;H&1F2F=KSUY7_1:L\*545(8]D(;Q9A7SQM_EL&@M]GQB<[J'Z*\
M;^Y\\AVBS2!#MZF_ =X+-Y130;VNPK#>2:^UOU=E@42TY#+I;'DID%R>W%@Y
M0%*JD4JQ^!IT,1KX7X;DB=!DM/.Z!"U5X)+?C21*&*^X77-./R+18KV2*K<
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MD6!1(TRYC[3R(QDT!)LY,0BUE1!W!U):#[+N?;MV&M4%*0@F[%*I,F1H)V:
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M,Z'*E(#+%0L9(,VTB'1(J^Q7\LY:$@=1L.;2GQDV.N@N#)F@,3X8" Q:.=*
M=\1]RJ<S ?+[EZS=#*LSJA&=ZL'&:YS&"K2$-@< N7K4IJ5" ML&L99"_&DA
MEMH#3&8QB"J*V04]=UPSQ2O7X**REF4VNWCQN>3!P_H'6OOG1T67#DZS@.+G
MDWRN]5)1P=;5]Y(A^E;MFUR;5"2 YI9'WW]=^=5:29&\L(>P/AZ#$D]9!%]W
MW-]F8-X+/ID\8XSCK.$,-6D0+O;2,@\2KOBIF'(AB1^-%9Q$.@T=TC:'8.5X
MW2VZK)MR=$ESHR/1TIK965*X=<Z!\,5T)O4TKIGBMM OA/NHE-/H*JG!=FJM
MS/)B-&".G4MZU#);NAQ%G]I9II!2#Y*C<R;\X,5MI41%)0$DPV[V7(]*<JNU
M6*CFVL]%)64F*.[\)&UHN,<;C7,W>QGNL70U^WGW=#<[42%#G_W@C\<[6"(N
MV_KY].0#.&=SQJ'S<Z2L3R_85D/WK6FDTH*DAC[L SYW./IUT;)%NPV;A5LA
M^88A_&#F[] YJ?1ET^?3T#G!\PL0'J1:2E1$ H673;C:TF<>BIP4(Q,5IES5
MSL:A+[=#&?X4Y:H=R1A$?O^Q>+' C1SX@Y\NMTC(N7(KB6@1O+L=GEB)^8!<
M?T%EJZ5011,^N6BU;&%E=(-0TZ][ L;+,Z?CP5M<]"!]APCU''\KZM&5V_CB
MDSH@VYB/-$P_Q^'G0SSHX932$C8;#ZX17X>X#(UV9UIX$I>\BI6<,HKQ212^
M7U]1K*TNN#7&6W>9':$^]S#Z*L_JF9($M=8V*?[(=L:!Z<S?,M_1F1]V@DJ=
M['FGFB]>D/=T3S7&G1U*,^*]I]\?,#U=O(AXY(_Y?#C9^27_1&<.'][-3K6(
MK8F>@O?CR46;%B;+H=/QMO4."D*P\:@8=5;9<1+4">2#U,TX57T#U0.ZA:T]
M2P?!^M2*RE"K%[_="O46%9<_;HQH/_('4CE5Z,"AA>AX$.C.F"A%JVQX_Y$6
M[3EO:VO2N&J9Y,B@VTJI]I:?7U57%F//E(=NIKB]O5=,MZ?OY/3:?8.;G05_
ME#9F#]])+6FW1) + 47@2!ZZ80:P^@PJ1#H/CKP]&%G0D<E%G_C.FS?7N4B!
M,D>K9B/JE]XSX;7(N9?ABU;4AJ^5!U:>^<+P@YL/=P=&K1T9E][(AF!H?[#B
MVNZ"^&+0GD5!,SNM562!R]\X7P@I.UO)X:S>9%G4F+8T<<(@X^,98J?'[Z4C
M%17%L[:$ I_F'_E*+J1 LG4<[!B(-6/>'@=&9&1B_$JGOD"OPPN@<]>[SL*.
MC5ZQ$2[5,]7ARPVCNUV,E.V,]F/H5.A=,6^V?:7;MA \!HM%:$7R"K5[*#==
M<-O>?.X%@16P6NW<90=@ X/$9(?*KA[?+PO9^^2;?1]%:2KG]!:^P%O.[8!,
MS(9M!*Y[C 8;#<)](N<@C(+?'-[4)EZ)S8D&TWV7GW=RM ,MN5VT=%.3&S72
M#N?+M".=#Y=T;;O+>"/,MN3A&L&5I-'CRG1?YQQSP?SI00I/[T$*=Y?[J+ZL
M7--.BIF73F#S:1=6]^N8O2&K'&X)DZY*JBAC^87+=K6,;XWI:)0$3T31AI#+
MP*2S2E'<?74T549"'ULU<N,F,'-8%K<?6Q_YT?!)[XC 5\J@H=:Y["_OT0GW
MI1 ,<%/B_1_>\Z/>1^X5%%!O2'GW+TR;XS[-"C4#O:O"5=0JW)32!>+3E8C!
MPKT7PEJP3#'7-4L4IA"?2? 79E;D^L,9J-PE6J:1-%HP0L*KUS$VH6*;K4QC
M! E!7AC35KO-+6QXB8V*$9K<E)W,  P%,"<E_+8,9C^^SXSC]?D=):B_HLTW
M"F(^6%#WM01U-Y>:GD_;?^75 I=R;\#9OX$/G5X5+96[%(*D"^[4FQ?3UB[0
M:L1;8I873N^QG7 -;/5Y%"%V"1$SZL; @ 0"'0YM8#[(GN=5/L)_T;QKX&,D
M/]9T$5_7L.:.VR9W)2"*(WR!N]']H%V)S=*)/7^T+N:'"L.5/#&WD3.LE4TW
MZ^K$@\&3G[ERS,SZSW\#P/V]FRU(I0\'V9&K)'WQLJA \T__:.2&OJ*[PA[<
MJ\8Y_.+'136F;:'1#IU\]+BQ?]"1I3_\M/CDIF>TUC2U-V1R#.M!]I8Y2;B#
M /U0-Z3_!ME)+=\[09!H##%P.F-Y>7KIZ.SAO\7\-_G:=S\5-&1<5;0Q'60?
M%N2&*J(JVA\Z^N-13=+UT-A;U96-EZ_UJ]J_N=(;4W=3,U1=FXZW/+2][MFF
M-L3!5AVL!8VMI'/]\&$4&9WE2T\M5):)U!3YJ-PXWS%C61I!W1BGU7)@8GOG
MV<GS#\GN"+>Q*#SN]R5-7N.ROQ4BIJ)IBCD;)F?UI2M!R,;=$+*MXV>GVQ:]
ME2OM6?"X+QD(^GGC/-U1XB (,RM4H1,4PL&#C5GH-5*4/;V1+O]\0K>ZNP6=
M9&(-)U!:^$;[,(BE;-JU-^ZX)+?GK*BUY57RZ/"L2X '-.Z_@Y"I)A"<1-/;
M= _V_J7V( ]!5IAT*VYJLF0@!8K;L%G'L$Y7D7 [V*0LVCB=NS&K]_/:.-]J
M/)]MNDZXN!N&[\\*=Z.Z0;GW12;;JR+3W6!T$G:,I/]P30C:'AZ%HHO*.^A?
M&FJ^[3W[3/M4X  ;:XQ^F 3]37;*.8G#VKL7:^J[,M\OOL\N6!.DOMYD[-B)
M.#%L*PX\CDR#>8RHTGYN)D8CV1J)5#6"R!#Y/L!3^/![_2QS?U[#/93S_@'2
M99EMD=[83B25FJR1.(O^VATEJ7GT>0G6><1V> 4<8M!GXIO?EAWVQ=\B6ZU?
MS:MOVS5% IU_WWSB9;Y.<W&[-T>?<F)$\!P^2Y-]XTMLB,U_S6N\%NU]6Q>Y
M>X-O_>JN-S36>:BKBE!B][B.-, IW%-C,94*.K8?'CW]/O&W&8@$FM&K,4Q=
M,X0>LW*1O179[<#[.<ZV2,QXG5E:[F8O=)WC(%9L53Y\Y$-"7^+LW5P.Z-LV
MX.;O/;+PTI,G3S;^HMM$HCNM^QP<_'1+>?_I@\.FX([)['@GM)-\6ZX\^.+9
MY,*G*M7#11O&HL"]UC18PJ<:L(+6\,.RGA81MN=<#R",7_)UQ,7GB .:PA\4
M4_.2=C=[I3FX3KQ,KRXW1D["9AP_KLNROL0X_;>\ ?X?4=BL&RT+4;+/#8[=
M(/:U)N;U9T_&[3^X3\9]5C+N6XMJ\S?TJ@=/X&K1X7$KB11=\0A(.FF[<(#D
M&#LLR:&!%H?</"UUDZS4&LRY!7KW#P:&/Y<GI?!4_[&'&Q.=.21_[Y\+-(N*
MP3H^1FC[(A!WK;:(H ,0)0J .>?ROCF( RLNSQC1]?/ :Z.9;A=GOSI!$NI)
MX?Y8$7YR3;9&D0W=4.[#!R'R;IW>1MT8_,:'V75=T@7Q@)5J)<1NVV9&1K!!
MS%E*(N_&8U&?B8D"*R>P\FD4>)!M/7]W<K2M0:YAZ9IZ!$TY4*\GWI;][]4Y
MWG\Z, P//;5<;NK2A\/:<S+[X^O8A'AE6DL^:#)JC2\:&4C/FORWHNPSE/*V
MZ'%(U1E]7=/FDF'B/A5BF%QF_]?E8L"<TBMS,JG=B@&BD^G-LBC"X5\EJ?)[
MLE?B>ZS>(<;GTU>$"\8ZB=YGK=9GK2[K:W(F/7DFN5/_FFFF?]5$R>"/RI1<
M">>Y<W$8WF,MTA!O_GGH34-3WZP99(?6,T]RE?\HSCWYPZ9<N.,*9/GDR-,Q
M(P'U@ 6487SC">&THE2K7+1<L3\NZS-4Z/"O6(2_XO;%C6AH,I&:>HEN23MG
M3O@02EVU+5Q(>;0NY/; VV2]'59CI0-;]CV'58]C7K(S1ZO*OA1OQ=$KX<]]
M?GJX<_CZ6.!%R3OEOO-,VV2B89+^GFHO5?Y1JYEL,F;+*R8+A=7&JV=W.%2U
M#:'L=,!1BRRI8@@UL'ZZ_)25!:%'KBQ J&-<OR,L5Z+DEY(7<+UG:.5-YFG&
M38H]*-%/.QYO/"S>M3/MLZ4$RLN V9<_)FZN+]_V3>]\0;UG;!C$:QMOT-];
M'1*=#"$]K-RXGA?1K"+$_'7G-$+4<H.I*Z>B*[*R_+O9J7/9,7H9/=G-WI"I
M*@VV:*A'OF.@=/:T?HPH0BK@CJ&^X[D=#/[,>VESAH^\L]UJHX9R*_<G!(*C
M1H,D(J"P*FV-+I>1W)M?Q0UI^::/:NY %"J'R>AS'."M0B<D\':T\QVKDF)H
M:YN#5,._0QJZR4M",RU[/'N>2HJAC<BC(N5U?9?19S6-=YN7!0-*I\RFJ_*O
MM_/%2'QPO?:6QN6_'^#E=%ZFTOI+/DP;2J)B5PR RB1>/$J/K^9\B;9^E:Z:
M 4O<A!U+IC.WQJ05:?!A'(Q=-'1,_TFF(4XB?0V]F:2B7<Y+7%9A3XU5Y08D
M7;1/9#1H:YG)]I@TR>,:E#>TJ<4XWQC.&^ZEM?>4;Q!'AWEGN5":9);UUT81
M36H@?&#9(?UI=5/[%R+;^OD-*<4_&I^]-EB[3Y,4@]8751D"E+PZ7_&F_4T]
MRB" ZG;$M6,M:CR@ IRS1GHL3!$]H<69TG^L8[$ VYDEI%60$:^=KU$:H9E2
MW66E-4(4'WZHW&PB"+Z/Q:AR40@G;LP:6JGUC5Q?P=V+'?I.FGN"RMVPM4X+
M);A'6MN:Q_S6C^#44)RG+'3>.O+[FH_9UML7)Q]^?ON"PTD\Y;'T5QLW-3DR
MW P3%?KT!$E"<(-'&Y(T?Y;.O;]%/$5>^-!$2,P,F1R)-966*J-1Z- 7KL?^
M>U@I+@'1OL/C6BIC><R+GA48A%-BP[+6D[E86"'CS!P$1Z#(\F\]0G5BRP0,
MR=Y,%G#][/2P;$3%MNZ/"P?I+$?UAJ_^!;*05JJ25?9)T0G7@6E97R-1P2"0
MYG&#4V.&Z:!UC6(-S4FB3H,>*BK9?@.,BDZ!^"9C<6RK;]>(_OGS&W570<H\
MES7^ZR,RP>DV9U9X"-^O:;T.H*]#?T<()[IV,S%6:F]AKQIH_>4_TIAQ+GP+
M72H#SBOX0\[K1AO4DGD&DA/.;)XM>1)\)#KEK'E+1@@7W"$<\57LHW<5/1D=
M5O=]L.6P&N-+NNBC[+(IYNCO4V&_;!, NV;;;BZ,,'Q_:=2P IT%['N%.ADY
M^@;M*"EJ.[DHS@>@UQ]]O232S=$,CMWL3U^4N+]WGP>]"T6)GQ4%>4<[\[QN
MIXY[?/STT_.-"3ZFL9"]ATDL!-.*(R"1QZUB=Q"T24^D8* 2(2K"5\^3*[:$
M4,532CS_GY/]QU%I5PB0+-C="Q"S$%,PH=U^Y!I.T@]%0X+7CT #GW#(5"G#
M">&@I7VD73M(0\3D+![S<Q 5634E^\UM_!ZIM)]+G0^OBE@(Z8>:Q*<)+ J^
M5_8@]@<'*SQAO;$BU9+LK^_RKG$2899S;7SN'6%4P&>-TF7@2ZC]U #SJ!@7
MDE0<,[EEXYAF3TBP?2B [N_,1DYF @I4'SS]X>$C*!X.Z7@'7%.Q:3\PUOE"
M6X(E_>O3W0?X2LGJA"T:J#ONANY,7W2][MWLO;G<ZUYI-?E<;RK)>9YMKH[G
MWJ,./97&5&+VB5Q;L]M)][Q"!BPN\W8N)%2<=0@?B\^06).V_K+T;1SDR3V#
ME)U#"Z$-BV:XF((D=:AE;;RS)H$:=$UL!0%GZE:I*DAI5VT>>.Y"M6^!VTYC
MH 7@$P P6U7!/GKOQ+2N4-D\S?8>[+R6VF#/J!<W1(\'@H+%*;C?8$5P'J8B
MJPP^P3F:Q!@#P:+5F\19G$NGS*'J1?!&+"I_QT8IG\8N#=N?2-TT&KNW_8(T
MYK+N83TF_R U\3AA)&Q11VXH N^A&$U[-Z,,_NK*YI6'J\"#-H@&<S7I43S4
M\-2F:)L/VITE.!+]C>DAJ<X=R#K+ 8V,#H0<P[*&DR=E4PG84M!!S ?I$T<#
MRR\!?V O<OUPQRLD\-RQ#YZ(8@R*CO:8T48D$T<?G9OQAT+ D&2\*_6+GG1)
M>#VFM=S-$6 RQ=E"?DH"CAD-$EK0OM4XY889@ %W)@]6%D=<7.5"Y#M\SDXC
M!Y-)_S!-E]XYJ)_ &BQ"17E&6 M[DJ%X6W1$K0<.<&C@GPLK4$.7LZ&ZE3$H
MJ[N!LGE,+Z1;A3\LC'ZN\4?<,S,HV0TC)BPJB)>#());P1=3T8KGWFOR 8!-
M"1:*AP0G/]SQ3;G._61]<[WD=N-:.8Z1=_A23@:IFGHTX,D/-#$J)C23@?'A
MAM$QU>QR="[%^65)8O>EB/@\SAQ.&,?S*W<I(12E#)2[N)89X(A'BFO"J;(X
MTR5QC^1,1S)IW5&F4>9%N6A"7'WI;PKP#M".F(?'*.HDQ"* [6ICR)7Y>RGA
M$P3_G,1K8L3=!9.B_+H8%6K&5$;_:,( ;_/QLDE= K;<N/-%BPOEF1O7U,1C
MZ*,FOY3(C7 :JKR[S!L6'?1ZF%QS8#W(I]<0GBHLDI9D"$:_:%WQ&ZT.)P<Y
M'M2(SF<"L':FG''!"-7*KE1R%M6O"S_/\X)#8</B@LR^&<)3WE0<-B#)DVA0
MZX:+STHJ?.O+%LOJ<-)#QS,]]#ULRPKPN/+H:UR,27^KB[JTN(Z'T/_'C=<I
M:2?P^&&WK<+^][M?O['"T\<'^]^XL<+^H]W]QYBX!KO\N0[,_>H60NO"ZC"6
MZ6+* H;N-&<9X=FY!D%_V<M\" LDZ& ]$']OLU<D7[.?PD-/$,UCTMM7/YUL
MQV+JA[6[>[^;5^]FQ/*J.1 6Y^>2WK#F4Y*>]LHH!AUN';\]VM98P91\0;JJ
M0^1-W/FY9*WM9DMNP!\6/1!ZN\=*#JY/( =;*F%R=N]*!L%?3ARM%!E>G+Z"
M]48.V5BC$G#A[D_!EYX";X:00.:-]]B2#$R29+WJ$2 GMJ!3<%;GY-UN';]_
MMAT\>6A/+B@->XP::[-FTJU?>LIT$#1CK^]W[TMW3\4IBU"VITB]FGD'#W,G
M[D*4WL+0Y*8KAL<0OOYSLR!ZGZ>B-Z5G9/\J/X=EQRX=*B[RX;(3Y0O:77BY
M<6C@>-42Y#&,SOV)^.(3P1V-?("50:MK!?T:N?[VZ'#[?@>^6*_2*K;GG'U<
M9JG)1.-BUV]T@:0]_W6*'*=3Z2K$U=Z_NM^#+]9JV<A95IA#],';@(@CH??X
M038"Q$#SR8RDF\UUD^@""#*]=%:QE_#?RV[=;\\?=T5(C(6((ADB,T47J38)
M$4W.1.5#KNC;(JL2!JG3 )SIG**-0Z#: J"%.]J- AJ5.*O ]"5!#PY?O4D5
MH<2 $.+CCLTNTIZ)(<U647O%ZTG#,@'C_<'ZPH,ET3LV5$/O:Q_RT6L]@V!(
M<F8ASMVQ5A@WAU0@(CO2,IVCX]KUHS\6]Z<'@NS? T&^*1!D;2"_?[].HD .
M![/MAU-QU#<KSIC.);@[D@Q+Q8)%)1%BG^<?G70?D@R[Y8QR@>%QQL9'+SW=
M=A1&MIXC\&XO@#R,$C[ELHM[G"]1!RNZ[U.A3E-57[ARON(S"<A=,7727),1
M)6ZT,3'@^(Q)A%!+ N+0H4.;LM#ET#S&B9LB:+Y,NG/(_M2?BJ%T. \9U33L
M&&E;!FA.<NX[U0"?/.ST"KV!_RJ91^S&0C@!9BL3XT!6G##1U$OB.DNR)21,
MXO8DKWXZ4?1%@$YV7\-'61IIL0<QBEV[O-5&(ZSUCM\>97E96[&5=1'AN(%E
M(>S5T:\SVI?%O&\74KM(L#T<9;"P[S+J5:2X8(:!H\'.'!!0S2H9_GB10&;%
M9*ODF^UN]A,-?8=QKBMK'7)#NNFR _0LA*8D[<(MK>28R%ASTOE5/7:5'AW<
M5U]#PJJ(1X)E$\2++/#&7#4^H X V)(NS'#11N<@"@44GH=!$R@K05\NZ3$Q
MB.K8F@8.NGI81;*O>LE @,C/_YPPL :@?!38/T0Z@2S(Z,GG2GBU\LB'ZK[)
M?IGW%MP\ /@8RJ/OEIX D.$^R9L7+7<:)NN[D?XM_UQ@_KZ,.UPJ'Z'JQK"Y
M[9N<06X^,/!'1V.<M(9# 8<EF4N_K+PI0,AS$Y>1'QTO)" !I99WT5V$,K&&
ML#UCUIFNA-DE?RP+3!X*1X=<)RC$6$DMV?#[R(GD,PFPAVB=]BK")J1;:5(Q
MH)?L,B<MIH,DPK1B1(;&]'7-^T[CQMS!Y]U-T-2D6!0ISXQ*OK4I%UH/O6R2
M3X_Q""1!72.$!'C./\E2D>+5\+2ZZ0WRDJO96BF(J6+!$GFE))<&63L#&(4A
M^,H(+0#2I%Y<42L^4S'S=;"=# %2 ;O9RDH)T-1.DF\'R,('Q3%D=2F&: T:
M*A1->HPM7C50"L8FGR(TU"J ?Z'HP@BU%%D!#.,Q2V#80'L5N7Y3K15N8>E'
M&.Y))^=AFC$Z\/X[-*)JI+@)S8)=I]=5=G0[+ 405GR!Q52E9S$ L6]T"$S\
MO<V.WS\+29O^7$VFO57PC<#(@B_R*W49P[(KBM7J)$;*B D;>V"23Z<M<V9L
MAD [F0U54 -2IU3S,O@SH&\A>V)-,2>4E9P@T7]*XI"\%4J!47;Q*WBGG';M
M!HUA)46WF/\()8"X*'GHW!S*;Y/>PW2Q&I>W'K7,DI<#[_9PAHKT/M>*BFB]
M2Q(6 ?U@QV9@C;_."U8+"@JV(NU@*L%]Z-XRX2E;C,?H:YLGN57T_PGV%V/S
MVG .(9)VLU-;P@"^""=.VA>[)H+_D0(<UZRZ5JY[->H>1C-[N>H8$'1KB%RD
M;?RX>L>=<:K1&O,$9 G#T]X>_SCP(N8#&QR[X_IB8_0(FC7-%@UV@(_XVP@X
M-EAC4$& DG>IAY'FQL547/$J?1?HF>=<,S"1RK>D5%U^R0]9M)* #])8)5<A
MPH8^+O(!)[7,9WCPF=$+?([!?!>CFM_O[S_^8Z*:GQ6=68ES/L1*2 U]( KZ
M>@N3L6/*=DG1JE80Z-6<C3T[:1.7TZE:=BT78=RK.^7 ' ^A,^'FOH T#GE8
M9YS80A@YB"P12Z:(HQ3T(!O5;3Z&ZU<Z)4DEM4\N+<E2:<*E9(_2C#C+?;]N
M+^6"#!RHQAN9![+:^4(E/9<\U[X!27$.;'0+<B*N9$9W3FXGCE@'2F>'7'S@
MW1IN4+]1P?\-N";[W_R:F,'O+/GD&PU;@?BLGEE<*S[0W4,L>:;9G&,=\L=!
M7!XO1\V;$NF)A>4CEJUT^!-(ORL96=H4Y3*\UTS>^[-XRV?QX=T[B_#\:2RC
MWM,XB P\,AC'#NT)9A-O6Y#QVJS$198ASVDUZQD85LG"X#@@-QY&!MBB.YWS
M/@B/2R1C=(0'J]@C&"$Y5\]5[KR8[[ 9*\DU$NSHQKG&T;8HA024O6<+-\3@
M5&<YBMS/Z] &UXRP^QMRRS?DX)O<$$3Q$& <2O,P'X63T+"Q&:QFDW$D\AYL
MFT96U=/\>TQ (KQ*<H@"_].J7\2!37_,,$*E%]3^9CYLR/FFNER Q; (YOIG
M/-V;)MP-=C4'$/E]"'6FY5ZQ51;<CL:=N\9C+93TZ6 U?KHICM@'"RM;M,,8
M\#J"+]H3J0(9\2<]0<4*%E9[>W-HNJX\,PY(99B7/[B[N3GZF6]PNQJ7PRY(
MAC#RVW,T?@3=S4RZ%8IQSF8 <Y/X1O4W&[*O=W:(:7*/(32*YU*\$'O3OA4(
M_#C4EDN\F,Z5NP=(/+P'2&Q4QX"C4(T=YS(2"&T4S<0E',-H(5L=T:]%);7!
M:"#MW#PI=H$ L,+Y64W.<6@$RS_Y1!+)A<:"<%'RQN?V!A:9=8)%4^>'S1I?
M5LA**\EJ9F\<(Y^X<EF#Z22+_'N1#W M?U*&-;7/(Z\4&4MAJDM/#6'B$!;?
M)%^O6V 5DCTV,:-T9!AV>]!+16[9ZT87Q=!KV8H.A](&,JVUWZ H3ADTD_9M
MLWFL634,(G#[%8W_0TS8Q5%*=:-:29C@H\A4!=[Z67'!]8'&>]A)FIDL7WJ:
M DY_!FHNE]@=,E\Y<1NC/.G2&[!24)9IQ'*@]:%6$^1)'",+I@/J8'XQ(S@-
MG^H_7EW,Q[J*A$&H0T)9-E-QY1XC=,YJ/48^=/ *$9Z0O ;C4^E)O0$_FH _
M!.W1A9O*:RTA-,QG)D.19(,'!_I7'0"^P<F_.=3S?#AQ*]-D,OV^G!F_P5*
MULZ$3Z_B3-AIXB #'*]V3ALYGD\&_H5\ VC4 ;AT7D2.56^.2BOM9_GP8S[&
M2WSBRR"T[(ZQY!&_CTP7:=OAR\=L97QXFEEO:8:<6G7!3/)YZ-JUS*C#FFE<
MIU81(\8+SQF.[ N@G^W$E>=969Q?8;?<+3S?:5<[*.Y5!>FF2(U#ZY*BB(/S
M1=G%BG-JVB!Y>EI[+IQV-;>J]8@B(H5@S;N8JQ[X0C6Z'G_E>6.%FT]W0#6I
MEJ9[QTNPQRNH8Z:7:LPCB[B+/_3I?WL^-^V(>\DDK!-Q&0.I09 "N&C<'C.3
M9Y<YB$XQ /?)36?F_I:;Y+(=RK(DXDU.3.DND.ADLR,@U3A["JI%>A)GY]<@
M27T]<W#-*C?V# ;Y]*P8+^##>0LA8!/%0^%&'I*S12!KS'W8Y*A*;INS*$&5
MQ4TEHG/R]W8M*F^00O(\?BE0NZQJ@MWL" LRY%YS4V=]/YBY84<MN1X(E/)%
MZPU .GFU$C"*X?&A5,"?CYQP*IO?1_;T@AF.^'J30*YD894;)5[T\'Z#)IPM
M4]P+798 ,HRX;'P"U1N?X1H' (9O&477.59UJMR7UY4_II.^*O)H5KU5Q42H
M(+J6&W/A-$:2D:'KRZMX4]<66%F1ED/1CA[%M-K*"-%$3SOQ",X%_>'C$/RE
ML:N&R[^WG.-N&6.7EH ))ZK0HOJ]+2-K,U2&>)EY885Y(G8M)*B2?)WEV>1S
M3[\GXU:^D:2&3";!@3VF! -'V'RPL@!V'B%,[(QZ_W&=Z8O48T+6%JN$\!W3
M 6V &]LKXB$@:]#AE+%B< -7JBO+DVVQRO$,WT$1=]Q6/'-U2T/DE0&+K52D
M[XSH<Y/>70D=:$X:;I@JJHI9B7[&[%Z2A@,GS];)T<\O#[?]\W%&.28K1/?F
M@$?EU"!2]@4^.E]!8/ 94\+D^66]0W:^",:<YN;YM=LEV:Y3YMNI1JB9C^J2
M3F!G0H2\UWET?J'I;;_\$DS A6&6'S[*-4D8>"2_0N<P2[36(QE'- M5[S%'
MW-%2(%?5(;\QU]8)C $%(H0-*-4XO'*K2Q/V"M(?A'EM=#*2IDC1P>FNAE9C
MSF5Z<]*3M+NDFN831B<Z)-4C7A!FMR[B%W57KM.1BI_>%I]86#//ISU<> Z$
MR3,1/SY3QHZV=KA@"CY(_8V3QB*PSB7<'Y8&EX[+362^GBD3%$7)+P0B:A&.
M40'1269-!#QFJDO6?+ 7#2TI<>>>4N=00#N(*SX$+,9.-)T0^15O]#K5H%TV
MSRQ HHZB,>$S<[BQK6[,KCW32!W/2,HK('+"90N!+%:-6AHK_H:6P;(Q)?]F
M1M?KZF&#<N-'PD$V+JV.WE+_H)@'S=T&-[LW@*'!FF@\$@=<+;WM1D4$,NM%
M%)?Q+ 0<K.&/A%HKC7;HS??>H6^?;>U9DI#$/)Y_6&%;W-@72QA.VFA8O S>
MMY!,"=N68/;T"-R>B;]ZWHD&;<I9/?2U,JP%-(DOXOJM<F5J<*:-:KA98/06
M<(M7-6>1Q5TL8YXVI61C%RL8;;Z_@/P54.QU?S,W.CZRJD2&RV'I2Y ZID^(
M1EI!8/IW7!?24MK+)B1LKQA(P%34BWFIEP@!*+%*AT6H+(Y,)FD\Y6,6J6<?
MC#J+3M1)D1<W $:;B&Y('2*W E!H1<#N9B]@=? 930,.TE"BU_9,<^>D)SCC
M!ZP(W;^1WI*.5/%A.7& EKHS/DCC<??I A^?#XP;:K"Z?J&Y.@T4(/(D1$.F
M1.)M<4M?M7^C:2;KT1$3ZPXHES%U#ZTRQ/[&!4?KR\Y9\\J"J[QBQ4L+<-:M
MSN->A_:A.$#TIT^N'MPG5S<JN7K8LD WE,T*RGT^23WO@JM3W@/>]2(U']\4
MGFGCE%, XV6V]?[%F]-M*27)IUQ,Y<H9&?-!:>,%BAI+ < DG7GD$L  :!)2
MQP\HLH%H//0:_Q:H!0?KA[M1BXX++F2O7.$7>O@(UU+ /369)8_G@DP9L !&
MSA.%DXPARM]:R;I%00UDXDJ+?/LRVFSJ3)1DXP4D-E=R*2Z0LS6PWFBKN<<K
MA-FBLB_P^.!HD<J'S28XDV'>^(943;+ ?]=5'00261M29%C!MT"H(HR2T;/J
MQ[#S)JU@350ZY5F=,<6ZO6Q@OQ*7#YG@]:SU Y&MJVS6>)I&+VU50G$*!W-,
M+PK?9;PE;2<6S7LX-YKY&9)/([4\HXKUUDZR)S0-Q,*?UUSN6U_TE]+!(E#H
MAFJU-69-BC2+*1SH9%PX4L-L1B.+$M6=Z='J*>8/!6L6 ^*[J/3M2X$8<"!.
MBM41#+2^&XFR#IB_) B9=A9D# =-('S3#H+&Q+1;R>J">/2%L197*"7H.@Z1
MB61AE=8LTJ@>2J) =,JFZGMI'SB.O/DC)94<89:[V1MR=Y %'70K<Z,F)C[^
MK82N5>2+QQ(N1.WM64456RV!=#Y;2;,'1S+U:SN')C:3$WYMC])Y*VS5^$_H
M_!S',&ULRKCMKQF7>%;=+PKV$P\.$TD0D)J."^TR.=.@':1Y+7/?&L[R['0.
MQX5V5E?]%Q]9)AVR1_#"C,!!S=WY6+](OM3&R+FG0A/?R6?B]Y37VXYW*\']
MXM.,M-2<&V*DJ=GW%A24>[8IDM'B+QS3;9,DF/-S[::AU:#PRN6<V0!0 +Z,
MB^\#G?8@"62@1Z!0]W;ZJTOZ&>V1%;.#:R>]37VKGDU9V+=61._#F9" 2</X
ME^B&\Z$ATR:-NI\+*DNB55&&$V'TJ("7]<2YVT':"?USN *LIXA-(4LQ.L5%
MS#/<4(?]5#)+R"I0.PPT &X4P&3]Y7%KIJ )^R"V0Z_D56R0XO56'$I^M=($
M<.10T,62?-70H9FM+&FCP=CCH6A3)"2G?!JM@^?VH5: %[IRR?&>.[)EK^*3
M *RIEMJH%73C()FE'O1D]U<R,8=]$_  Z>[70:T;C/M!%&N-R@<DNA+"WEGK
MTFI#5DP<@=#'2;U)K)E\$"H-/D4S+<X3R*4:W! F[9#4\T)'O H?Y=^LCB@X
M7NR(B$4NV<R^\<OQ7@T*^Y?[C%_.U9#AR.EXF<VE6@:'Q6<GA31K==#2^JI-
MF2'?;E#"_#""#]Z"A%E[2I\ASF$YRP^:ZXLEA30#8SW#OFZ_JE&>"],JOOOX
MM8\OSJ-"PV54W64UL#V1V?CJQ6(S=@_(0(.M*9EMX)4\AXTD-"%I<#)ZPO?E
M,N$\H,47N'5P,I-V/3YW:M64]1EM#\Q<J>8MHC+\!(#\8>+2I?"]WTN/YTT%
M#COOYXY)LM)648H%T\Y0BC3SHI,W"BX[.PB</^>C0E^4,?HRG#TE(TG:$3-_
M#U)T5J3D#\2\@WJ/;(]4C:1$8LQWXUOAT;$5PSX?HU7QQMQ0J9-:U2QIY5=:
MIA/GH%*%F&AGJ8^Y[O(,O(3M4U^*WUK.!.\KS+EJ#\8R)=G,=22IZFB%*["2
M6\>G28:7VH<XCCU%N<6K%"QD03'WKG=B  6L0GPUXTNN29$(XC J\G%5<POB
MQGQW@T5Z"=HK+1G9IH$QWV#&&[AH_;L*#\BU(U/-OO4ZB,#@2CC'U*$ZH!?2
MP!24AO^J-*<:H=8B5-0Z7(-=R<</=D;YTI!2@F[W,Q8;JP=RH2&Q#DAC<VYK
MDM3U)K_:JF;^%,UZH%[<J_4&^K=-CI2%)$0K]ET4L62ZY.0K.H_!248+(99A
M2[Y8/99*:E%5F37Y]NV[ES3.CZZT,!:IU'G02AK@EE!K%1?UI0^T;F/T4.;*
MANXH#,U6-+AAC; ,D#HZ*T:*-YB"\:CDPW^C<273N\%C0X1X=49T;43EB(6*
M+HIJU*)5+X;4Y/)?E1%YZ;1A1A+."AE><84]F**$[.X 4KT, IA@)8/1M_F=
M_&%( L<] Z.**45<7=W4HQ-@7.5YJC,LPOE2#70-D/,L*Z5G<Z/;VHM. -SF
MJX&$."CVI\]2/KK/4MZ%9NG]NY.G%YIMO3YQGG0ID(H1Z9#*D70&+92>95':
M!BLWB]#$Y4.?S(M0 !%"H,P7%7VUPT&\(6':=\T,2H/!N$?! MH4:R)@B^.)
M' [G:4I:NK/''^EXUKFQ2:VZ^ U36?58IYZ9$P>QUWP5((UZH^?NTE3T_H,'
M UH-=JG)FEY$(.9.MU-SB3_K:U$X<,ZQ+LXW!5TO76^'\XYE,R0U%17G6A9O
M*IH[A)Y[7ZD+*.9;P;6\4NG;MRY6, !<TP7CLKD$07JQKYT1#U0H+M;M9 #B
M:T&TQ>?4)PQ@33(($F0<GY!VW8/E-+$U@,"KUEG:E9= AEN@MRQ*'$)WV> Z
MU?)@I*7U/ U+KO81]D30)WM>9&W'OF:.'HE%ZWF!X#>HO($MGTO:GP]-.R%#
MP,E*CA:>Q-;*YZ+:.HD1-"L>YL8X%,?G77=^W<H%6M?2NP!M%*5,,I+=:'X2
M8I]P[&DX63TCL8MM?6I)F,1#<I^&Y8*C0_YE6US$)[^F@[5MHL7\4+VA)LY2
M].]2#;VTEV["2;*@^R;AXJ26L<VG+KZW^IM.8@$F>B4-%]#TG*/+=$F-'JV+
MR? H%3J#EZHQ@\F[8 B%)?*[:.#>=0*@?]T?PFTP3 #62*K4 CR;$?&.\V2K
ML^T7[<DG[#O)@WJS/(=<L<=)8MZ3&+*T[E@R*4_^*1O"[9J+K#/ BR>/X;".
M+_E<!<%:('YCKNVA7P,Z0_'2V $W'WW=SDN0"LK7T RR1<(=(>[M65/G(].Z
M6+)U.3-]F1])M#\=?RG<WN#1-9C7&LVE$<$2RK4(N#10US>]R1@K7,/XXF,"
MB+K9JXS5-9I]@(B[';> I$:DR(!+!M,*!9,1_4$GT6@,*/B=9#8#D"K._:VS
MBS;%]#VAZY;/H=!_;L5Q?Q&.UZ9<(X%_H_4N"\%%TRXTP.UG%\[\(&*E#[-_
M;S+F!?G]=+$.)?2C2)P(3,/&)$Z'-$_A^*JR!>I]ZU2">'C<-36W<?;?"^=A
MF1?3I.&H$'7$U>%ADJ3; R.B,KM&W4M&=>L;"Z7,_J'#:?^S4F,ZUN^,>4SF
MM)O]8K?#570/+;/"EQ[=ZO!I\5#209R&!3JN*C()^+>'PEFR_V!OOTO#;K6>
M +^%@0M;C5#;)%Q$LA<\'.P7#,RZ=?K)9#N1<9)ZAT@L2%UZYSUMFAKF1P7>
MO(0#G(>5THZI:!->]A$3T0D+NJHXE8+6MF_>Z8>3]*@//7NB$N"%%+E7'J,P
M29F-HJP\TO^HEO.B32<E[Q:(KP:%E30%;2[\JSH\2DGQ<17Z!GA[1P'"QBB7
ME"T/.+P'>P%P0BF:-\Z"5#VD-@#2+.+DVEJ*'9$FY)D^$8_B)N^VFWR#I0-
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M$LGM&61 MLY@*V.R:[4.SI\ W"ZTIVS'6*BO)T;)+9%TZB@B"'CK.5N'G\?
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MO/6P"P>1$6AT.5T4HA,&ZGZP/9^/!,0M:V2N:M@*Z?1TS/G.3@8AO-*BZ!T
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M7#)4WR=]93#5 IL8;O@+7*ERK(0N/(/F)=%+AI3VC!7R[&(/F4V?I3U03 !
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M-&S5C^:(R@CT;0E[LOD=EJOV3AT9G@,J'$/A6]?AKNPI[(R>**^QZTVL<W;
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MHY\_(1BU0I(#N2+Y<KC+L^^?C_.'<$/<:U4UT8/LZZJ^X33"4!>\!FU2NY9
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M]3^&3SAM'>>3DA705]*7F#EKJ)S):@RCHVHV0D_RAFH/8O2X-F(YK&V"&?P
M/ABFO4Q5,$IZ,/(=EE$7@\=T"C"HJD_=5SQ487AJG=&D&_OZ!SQ:+";,-3]B
M258>'[/4C\.X[B8<YJXSHEAHK@IS8TNRB^C1KIB'M0%'L Y'+T.TL4017&Z(
MT(KI]@,?V$RM0A.N]SS$N%>UE)ROM)(CR07/8^NKE2K[.>ZIT_;K:;(VW%'E
M>/,&Z&-B@6=9_#.N;]UNBZZ\92\B$;:;MJ8"L*QQQ&SJYDB.".Y)O)=S#IV(
M?'@\\Q*3?8@95=_-*C+G[F)#BJXQA"; <\9-3*_@JA"&.?@"ZV9,1R*,A(\J
M!RLK@TJ6.S[7'U;,^D#@'3R9;\U/Q$N\UM3 D7CG_R@EVO,1GM!?<;U.*C2!
M7=?0X=5]DHMC"@3?!&'9$"B32L5?F6G:/?&?%4QFT8#<M?3MFD?E8;]W>+2-
MNBI-%W>-Q*H@J&2\;TSB+DG_%"OES/4A>+R/##M/-H:\/)03*'O8!(TCDWJR
M11D_IC^OU4B18,!H!_9-^S@%J^6L-Q[N2VSL"R9Z.R3S;,ARFESW(Z$-KMC3
M%36'HQ2RD!:C#%.M-\KQ^5,F-I"&A&-TI?6/E![,KF=^R__/WKLWN7$<7Z)?
M!<'?VB(C>L8S0U*40O?>"(JD9-H2R2!E<_W7C090&+0)=,/]F"'\Z;?R9&95
M5G<#,Z1'%K'"QNY:' #]J$=6/DZ>PZ=)X\]3'UV8._7ID?UK+Q;LF1"S8\P_
M6KUH=EQVBAV>3GY"8_'NT2U2R!M>!'D?:&R;I&=1#KK5,BF1&?5M"]N$JO"L
M[HI6NF^+4 3I/?-.05QV$(T-H%0HGC$5=]6ACQX=:C!ZKZ"N3=H*0?(MS7+V
MD]^2T^$8,)RH..>(SYW3.-8V[5@R+\SRW6G;0IJW\"Z,=URT:$GAL#\!5YQ:
M@+BX7ZW;P5JA1)#_9!68^S6IY.V9E@;[7[ 5[W5L21SS*T/6UD^X#R>]13V=
M/(U4X>RCK:*'&[C4^_N$$QW^C=BYC,MGT!.LI;(?DHZK.HP!EE],$6>#LB(J
M[7[#<];G0S$OG?<140?,)M !\?_3)?J\-O8G:\ISS\W[JC<SKTXG[R0]!%>X
M7FW]F4@IOI'IM/'$6+X3@Q3W'R0[F?9VS\KD-4C/EAK'</\>\>V:C-; SGG7
M\TJ+U)O.7V,V7,$N<=M"BZ?=&#)F-%[Y 2%3QI G (__DM<;MZW^^#_G3QY]
M-[D_]7%04Y7>+WW ;LLS/_74Q4TY(?__ L] V*7SL28SK,&7ET]?9>@.U,8Q
MHK4^#?7.H(;B1U@(KQ&'39YZEZ_Q(Y6+ZT0%=FK0?).8DV9RG^_PP[L?WV63
MIRO*?#[()M_G];SZZ(>SI-"D76Y7?)6WCGI\!]<(OWOIHYI9M=&;OO([T*]3
MN8O__%5>-]5FY8/-*;_0:[_WJOCYNV+J?/A;RC?H&G^G9E2_E/_TNFVZ#R,W
MUY_Z+4$O[.3>O]0Y=5?2<:# @.1M'_#V?_[S_SZY.#OCWSPO"'OS<7(?7\!1
M4LNVOJ[B'#'6@'D)BGKAX\<Y#=3]%\V44@Z\#OQQ4JTPGV^KV=+]B5JN2W)$
MN#W\Y9L?</^2W*^YWX+3R?W7/[SX>__'WU=NB?ZU^N0E:?GZ);E.K_#NW>SD
MY4]F35@":%X<UFQ;)R]-E_HE1-?4%?3Z[8\GCQX]X9%Y>EG1C-C!S"9O?GIU
M\N31-V??\G?>$'M=V__.VY]/SA^?R_))1X)GX)=\E<_=92'S_<)O</24?E]4
M2-#,) GOG^U@;442R0AOQ=O7S_YZ0;H4Q92,.B6*O'ULO+OK#ZW-T@?8*ZIX
M(Q4;(J"GY%KU]X#?=^7L%+9E4=1-.VI-_.Q>G)T_X09K/T[LZ5XJ#C=0R!0D
MAU7A:$%W")H[X/%)4,YA^\:5)SG$I2]7>>??+^=#D7^XW!)*E!Q":B)^W;(F
M6%*O&T6#Z-K[:SY?^Z_]V6\"SCK1"U*QVZVZ=<5C=/^OS\\N'M,V[@^E@@3]
M&SFTX#I&3VU#HS;]X#S3J(0?A=-,!$%(84$V"IGYDY:^ZK?5H@6Q0]<0TCR<
M:7[C;KV]PL3-5F3;1 2,5N_DV?]^=G;V1$WI_*/"HPJVW]B_YTIFIGJ[7,J_
MSD5^"&/9>^&&:=3<V)@>S)YY"Y8/]9'[N^79/]Z<GW^?[)=G+U^=G.MP/BO*
M9Q%OQ@.*:)&*+:H8(6E87N]^9@A>DJQ5X@H1M B1^J0?B0>T)J:-?#6OZ%SR
MJZ%9>]/[_=>/'LDA@IMYXS4!O0&)0ZA65#K!O",O+K *0U)L_+D.90[?Q[IG
M#[#<;]5"BL5B+L?SS<<&IU^G#4"";*$52F56QB45CW2RO])4B%@&)]S,)G$?
MW8PH;Q) RVVGY/=2"O[Z6 J^=2GXN#<_>6]R/8DQ)J%CBC<'VLY7["(NBTWH
M3!E3!#N:SKMLTY7B;!:*N)Q)]=%G+/\>I=5_]7GPP:V#N'%@: X)W^/@_Q=M
M5-H78\B+][,6,<Q^1QGF.%=WN%$4L-'C[CZ.\1V-L<K&B;HN-W38/O/IULK-
M@K)7*QI$&B!%C:7+5V@Z:KH:T!Q(<!YGZ=>Q6E*UV]]=S@?[#C;E7NOY<5O]
MNA/6;\<$LZ&AN/D7]4:&#M4Q6H=&>T2$&>7(\G"'-C!1>]UQY'MC-Z^NB9W7
MY6L1$G*I?+EE4.$\')O%F3"G$[DHZL]<@2@:!6=H]NA@TLTOAX@<\9LBH3@P
M- H#XWBC1K?NBI!U!'1AR O D+?2Y0#8S&^.;!*@K.$W-3"R<8-,FJHJF8,L
M*DHOD5P=4DOUZO<M \'&D5^@4R7Y +^=_>#]FPM%#/$:AW2];+4W)4(O*4W(
M39Y@:,TIP<)=>.CKQ-5,XR)>CBK^TG Y"F!2FB_%XO&56VFIK=VBKABYPA<.
MS6%3RPHV!N!3@L$FTHV!=G<$:U([=#CNV$.5G60!MF2\'FQEE9"LU$0M?:OY
MZE"(4-[;/IN0FI\ >$L+O:CG)P0^(4P.4>P2L9)R7PR."/H&8A"@Z*2A5UM^
M(HW[@"Y-QUUN,>#Z3QL'!)?M/0?PUZ&)B)OVE4F!'ECMHCYVT##>U60:'W#(
MM+'3QAZ,^7OOC&B $A2@WP_MWNE\A3%#P29I[Q<MZD[R7X8Y+W4(TBMF@2B<
M%4NL#E*?;Y$'V=UPZ<"D1QT8FTK0OL!-]F]-=L5_W"R$X,-?:E9LX$NJUH,!
M@/M[P06RRGKQ\7$#\SBBW<,@-4Z/:/B7T/0WW@XK5GW#D@\]6\WKI;D-3ZC5
M%0'X6W9PKVL_UUT<IE.WU<CV3(B[FZ0)-P'AA>!KYV8ORJL*3#1:6Q_P "CU
MI?;I4ZRFPY8EG1U9F X^.(#)\Z9HMG3S+H W,2FL22:' R]]AQE),8CTGL]>
M__WE\Y/S;[V=\*/ES35WB<L;4812U]U&@0N]UZOJ= $.Q(!"4_E8=WU?WU@@
M.XQ%8)'Z $3H'?'Y?_$1!>LX?%"F*I#=9"RX'T8_ELG2I-IZZX]UUJ%@:#/3
MV=,[9,$Q"HS9TMA1".D[9I[^==KCNAG7AJO*RXK^6VO_MI6'X"<#61C_CQ<Y
MU?3+@$LO\S7AXG]TE=^+>3;YOEM=YG4AY%(_>8/G=WZ1PVL)9PM:O(I2P24^
M?A7:_#!+*I]=DE7)&YK,M#%-]R])Z/G+_.U#3=9$>J^J1I))MK^'[JYOVB,L
M">/9@&TAXR./&1A\!+#9T(B^'_&C%@6H4XS=M?U,\5W+TJV8FH+?AG]/*M]D
M7DJS+%;;Y"O4C\Y;[1//[N;7.;P'-HF/$/%!HOVFR>OK=/=2%0;/;IN/ $//
MP];39B1Q54/GXZ?V&_W6SD0D5JC,Z1..F>&9H/%,Z'8FE/UL)-,P.$OP;7/@
M*D6!PDXBQ7!8M71)YUI+"1QF3X1LZH@%HSTD"0Q9*-?+RJ_<$](.F(^%!'Q<
M$M\"+8Q0#6'RME12*LG59XGK(3$?&\Y [X"-(E0Z$ONA!L9Q!?L_S8QZ(Q/W
M@K%O/:><H54<HHD\!ET]'6*2.20A*S6J(1;P?D!^R1!\PM-W#6L<PNO+S7YK
MZ-GFJ8\1ACL%W \\,YQX2J^!R^M"H?8)YA.:.V^7I$<I$)=5B2<%PP(?C;1R
M5CUJQ4_<@Y,^EO._LC*N72#@D@7>=XL#ZUQZZF ^ O M&LQ>ZQ:".R'0X2"8
MU\5E5<UY4D,?+P%*U77;^JB=&Z,'5C5P4D]Z3+TQ%0A48Z :*S0!0X#369O*
MJ"RJ@5<*?O; _ WW(1,)MI05?.,_6C(6<U?(H)/?M^JFF45."APNZ8,$WVSL
M!$$O<JQ#[_@>[U%)]Q2AN3SN(M[_4SY'_62M\JXD)S>3@X0R,>88YSY&:7QO
MEE7=,G%[<*[L(52L-WE1]_V] 1D)KL:BHB(#5&,2<MK_ZFQ*\GUT$INO^-ED
M"7Y%&7MW!6&@T&/+1/)Q7Y;*8$\$PBRVA\'3SAPS#>Q-@EZE)M*\6H1_A#*%
M8A5MV_*/\;M'2CTY(J6^7-*,:R?Y8-!)0)C6^MKI&1X7MG>>$PXN,K7S?$U[
MGS8F16Q-6T=C=ONMFFX>2GVP;XUFO.08&;<F>WRXW;D\3E*(Q9OF37%8BM[O
MG4F8VDRI#GDEN=(\X3:DUBDS/SW^@?UTAG[@KZOZ R4UK+IPWDA/N\15W+-$
M;H@_183=2 F"U;@WDMWEUD+B)69:SQ2XG=?U=B)"E45<3%2\G7>Z7.!M*S>$
M'Y-\3H/5C&?K;Y#(Z2N!W"H)=BAQTWLP$$HJ9&1--".+ C54DX5W]15)(9K:
M7"^7P&D1/DI=7]R3/?(TEF5ZO-A2Z_]?OMI2(PL%<GF;C[1C<][1D/@)O]6>
M!\5%GKU]S2P$G)\D0M:3*37'$C,K-UR D8O^*/\IEF'RRW835&*%J$39)=D1
MZ#V,:$;BA6H'C]Z/)[AZU?53 _@5.C>NBJIKD%U#%#2'DSR6A?,O8=SZ&($&
M]H0V*B_ZN[_XF?[++'B;6A9'W2^QG$[E7+0*:9E0GET\TB&5BZ52B)R\\*GF
M!3$2I=E59/<*V&/#1";/A'7&K6.-F;!3.DD;_ZP("#/1X+/?T-OF\Z7HZ9DX
MDR$X*#+78&:6)P\OF8UF<CXA?Q-37<,45QH#(IYQ-O,YM7PID8TA,- =C$WY
M7G2OKX6%@X"Q+AY):MXY55,PH_<JR;_(H3$X,J#!&42JK.FOT";NGX', -LS
M,3_I!;02$(A_TQ-'S[KP !Q<F 42OB$U(65S*8SCL*:$9*T<@5I)UFMR1D#4
M9T.! UJP(!%;YWZ7H? ?*]W213DH$RB% TA)O(NS=.2S^;D_845E6=W;D[P]
M65(W/,4I=2 WX069PT-B)*924H2Z#71;T;_(?8=K__^39CDG@#F_Z^,/.L7?
M4:1I/I=*%"K3#(X66?$9;I)H6?BSND*?)^45J,,;F+@96^#9=DKY$6\#:7U
MD'/@>")3$%W&  J^03BS3FK&_DCI(-RNC(DPGU#,Y0H#7"BRQ\C%0-F5.1:T
MQU7,>#"MG!H?$LLD2K%##O[DF7))P<CK;4-?IA9(0IT<B:BN3DX]'TK/U>WK
MV]S9CS^_26V_?]>A92^K\B3]JWF_L=*[JK"12O8RD?B3,D5:;Y4R<.+GV<N%
M1!EQIU>ULN!B9P[+I?12%@&66G]Z36D[)@#_CG6!$U2=WB@)QS[>RB_?^=94
ME<2CM&1%COR"A@,@2J?B-+,>)MV_< )>J38 L_7)3#B_D(9>O/K5?X (<L\?
MZ"^ /6X/EI7:)3_+M_'-(CFB-UT+WC!85R)084;\QZJ:3WY2^N/MY(V<NI/[
M/_[TYD&Z\+@<5:R-JCS=_,=G;X;?&WB+S!0':CPIW6CY<*N@ *K'VNOP*1S%
M@,T&5NZCL3X:_^<%*[ )R<U&5.=#O=U?R[MMJ^ H#&_-U:&&'#\R)052S:'K
M5*20V/L0#UAZQKM()V8"NH/Q"]X[^_@T\#DH]OC$B.LVG,8TU[8N!\<9CAW]
M2R"\E7_H)E)^+3E+7SL^ ..*+H _%->$0I$*NE/4>"JXKSYZ3;ZX?R_)S*K:
M@,HPJ&'9$!U'CB,C2ENR/]ZX\*+W8\#4$* /*1<L*Z7=\L/05*P6$J]CMP)]
M^T'J8B;\].KL-,D5@J1KT9@F3U6_]'_P'_":]C-6RI$G!9=P($^11\[XF/:>
M1IO//L1]%,]M9AAM+:E)'ORY2!JY?[R%,HV9DE@\S,^[6DXP?[4% @G,R]S6
MK1(ONX*Q+CC_( 2.0'MPE7\;Z)E A8Z@P2S%&Y]3G)_@PF5<CPXT[D+]A-6(
M6"$4T<<P#EC?L1(F!23-$9/^*I$[F4%TWO956^>"DX=Q9K\WN-Q1=$)==4&Z
M<%XDT%HRFQOOTKUO[:>VS\&?%D;TDIF$J@$MDQS\N;#3?M* ]SC[!TSE>UC-
M8U*H%S$7:TVNH^+D7634168UZ790DH0$?+"#.1+E?)0F._H')Q\+3"NK1^0J
MOSZT#"/[1LZE+:DY"G=)0VJD5PVK,?E)FE:*S/UWJG3QB>]WIP_QN8/\U-L
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M8.I."II*RE^P"RYV"CZ,M5/(R]7=3&131NJI#"/5EJG%T$GNN</B+4D>P;X
M$LS!6^Z-51]BGAR2;4+3GXQ!%L'WK$&E?!8&,7,[Y_IT\LZYR;V7K5M/SD\#
M'_P?_^>;B_.+[_[<^6>?/,LAD3YYJ^?DZ;T#<X='RN-&/"N,DEU+Q<BD^[ 9
MF A.Z&/&/[BMQ/T$;^9*5$B;'(S_-CY$^KK@P</;!G"]#!^+FG$=C(!T02DE
M,RJF/33GSM&:S+L@GBAL\P..O_@ NR_#]' )GWO6:YNQ7/(Z^R[9Z:A/[I[V
MB ?<_1R<?$0VOUGNRFN$JK3A0Z>+M(3E)Z',/HK&A9*]9$RL2YL<6.8>?5JW
M''(;1F2/=WC4#S-?CI)UR2NHCN0AK7&:6#F>8RT&ZJVP]ZXL@K7FE9T<KN"7
M]$.^F+P YQKE_U[3:4,PU>?UJ0^!MI._N_(#Y0_R,CEUQ>]-9+^C[Y\-R]<\
M%6&T[<3&_%DX->+).G@)L]+E,[-B^7PTCH#=MWZ"RV:EC@ZD9]!>LG*7NE1L
M^+)8Y$4=]A#G5TL UE G#9K;.G05#QU.2+*B\8"ODMSS8/7>L"#[')+:UD*Q
M.H :9 GHX'L:JX[#I\K29\IZ#S4$DA1Z/%OQ=8Y.HXQ-A^"0:B"4:#SU)RIE
MP.'&W/P$??LR:+56(%B;?T!R 0F^.=O*PGM6M%PHOVD2[+1\AME=B@JOBGDG
M]*,<+$M/N.) D%&>MU!K:CX4*VEN,6;,9G>#7/?E+A17M1@2[9NN=SNIA#")
MQX*_^K*05F*QSJFO:,=,!($-1F%352MMNX)P=)ILC(?_$LJSL,LQ,XK5W3(S
M#)<+C%7=[QL@E6%*8:,.16_5[6[).[B4D=:"C+I:4LCTKFK15/5P"DG^T(<K
M!=?:.)FT[D36B+X<[(/V^$7ICL3^)K<3ZU%$[;CX .(.#*,06B.J8>-7DZBA
M5M98L&Z*7BR"/#FRR4(]49H.0C\96Y1$K@S:J>SX*Z:-L<"A$.ZB@B[! 93A
MH ]QZ]A*YRC5>Q^:@UOZ+1TD>5TTJ,*UUXZS8 H?%2H'"3WL7_/2O$=$VN$0
MX*]*+:"/BX-IUX$.PSG4I*@"-SC+8+1A#7#C3/PD!M$<XT:FC<A9X5(6!HTQ
M#PY'++T_5CU=]%%06V<C/ZIK17V;JXY@6:V *D6#7J+HO"P)L04,I5:G:'K6
M=+04;2JMYOV'>3%+.N=,5>B0+!*7.X-1$/65(4,*+[<MYVD#*"P.L[?%_@ \
M__;;;]C,I\!<H(>B(*5!RZFE4E,V7,D[^E!-5_,MX;NQ&D^68TN-CXJ.&&M0
MO9E@H(_[!-D&KPSIT9M3:$FH<+-0Y%RG_7D5F#EM+-I0$-6AY8A%<HU/QS$Z
MH0ER;VM(_<+,@3_D\0KTW .**?''N:%*CN(AFK.7:M+-D]<NXM8I%Y3$:'%?
MP=F0?>57^8G\)ST1=<C1G^A_->Y-M$B#SM%:!CW" *=N6UF$2;4ZG?P@V[XV
M^GZ)=XR5"F%1^DDQ)<KH ''01Q;X)<05,O_;-IQ]<8T>J=;OD/.Q+=:ZU:6U
MDMT24!3RJ4SI9A&]R'9Y,BF4GYN5L5]-A-^'8PUY%X80ZIP%,0*-GEE88^8H
M'A.B7LO>-H4<M-3\_QY9]^YH\3"E 4-K& 8K9G0QQLD_4>DOPI]LEA BL]B'
M'8O)\F,, (:1)^.[W56\XZQ^TJS&QM[0;7[%%>6FJ6:,^NK+X5I$K!5PP@J1
MZ&.#9ET.D(S@'3F(;'[B"8DN/.DI]KX>86H6YJ@\2@E\>RS8'J4$[I*2L]P:
M;&'2[G55N&N.QG33]O#I!O*\NWUBAXB6-?3!DA\-^:]"BBO-J\8=6_@-)M[4
MD0[_MYB2(1V^3)*RXD>F7$XL6Z9P[4T?Q)7[R8J/4W3S%*4];19-G+8CC5!-
MSXM&(]N$9)<^HZRZOR&E(\;IA[_L1!\(%:-WJ&8B:IEH:QZ'C\7"U$N\]<^+
M-6<MI@@#6M.L$G*U:%].<#WQZLQ&,.R 2W+@?D:0)0!,:A!+'DP6\)?85'*+
M ]70NB$,RU>!%BRLOX34B88KL32)4XYI5":OT!$2Z&WLC/.L!L;BP2=:P!I.
M^42%VX(.-&6.2.( U>YB@S(+=]V(F/8PI,R,ZOHX][<VEU#7#?=2S-?4:]B*
MPC9D-+F?SFY7+2"/]1O.W<)QYHM)*<)+,<DE-=7@W;&HK[6_9L>R1JF'U217
M$CJ3K"_@+@B7T++<M210G>V< .&"E@ZU+S(Y=G% 1\&CT\?8\!3ESNO\&H7A
M/E6E7:='_^BNTI$"9M ^FG3(N3.OX@H?U:OKPBA''R?ACB8!U"',?,^J)62G
M&&M\'.,[&F-[%JRKDCL_23AYCE,W='&$YD@8^J.MN=/L-3>]SI7'= _9%\HA
M52.[ IR#QXFXJXE@5C:+( T%P]IMNO9H>>YTV1<@P.$#MH?0-#"HV(Z&^ED*
M' Y @J,NTAW78KWSLRL]=/@B'HC0 \ C8!\'04V4M9L1$PNA7W;H?&N'RI")
MAOI@T/SDYJ.L.DP$,J3C'P!47@-W.G@@18>$G)S$M 8UDM)Z)U]4' O+,K%3
M2^=+5*]@FMS32:0K'WF( CP5U9H9#G"<D6K&UL@]<84][7B_WM&+(OU#(S?*
MVY0QGW$"-;/V1LK]-0D4-%8RKXOAL;S?/(BQI+-^.OG)+UCGIVE^R9B["$Z"
M8R3L$JN<B,^X/VF57S<=97JF.,<K5I-0@&&9J*40(QVWUA CE$U-[8BJ.3=0
M%UJF1J ]EKM*F]\6Y@W<QQEUOU>C2TC5(U)NZ[Q9&MO+/"9IN]0-2-LO.(>8
M;J5-M2I ;*1(IK!@_42NMG8),;TSL9)%SX"%622E1=C3E:/UTC62O^J#HOQZ
MP+UA>6+RY8#,IQ 6,J]I'$?8$I(Z(NAPI>M56%SR7G\"FGQ*"(F0=7E'8RH(
M_# ?UY9 Q%@%(+*"[F4F+-PF19O9YH.I_W1!>]-\'(D+N[9:5_[/9(VJ^@-X
M?(&&+1OI/ F92_/[-2TT:J @2%*N3@P@T9%WKMDVK5LWV1C><'+_;Z?O3B?B
M[?OQ+1]DDK8GWLF*'@,+4-H?ODI>*>6"7!3$]4UQV\C)!6"C3-B'LKK.)DO#
M)3]"D3]B?9D]9R@8JP9$E'_V+O&MI ;1!"$IW0V.EQA_BME.B=='K4Y$)P:V
MDT@KV*2]GP=EF?X&&3V X4B/0;>$4>*]K&F M6(:"2M)F)IP:[VO,\C1K^>5
M#+I_#O02 F(9R:M87+'I&BHX9::9A]+U?OZ7E9^+Y-X'8[&>)DN3%UEH$2P:
MK.*M^&H%R]_H9@V2BP'53"\/7Y&XH3; %DVW/;>O/UNA:X-['?QV40D0O_78
M)^PAJL-]@V*4,$FP[P%Y'W_;A9NS.)A^?4Y%C!IDQ,&1#!\"Q1)^(T\6VI)X
M=? ,PY,E^V3>)*<F"A43)IDGO$[9>.>03(<W)]Y27U4S_H</I.<GW2:L-FU[
M-Q>$[R7L>DR)Y:39%>@LOZ7U8SA4\*Z8P$_P>\*H379[-3^=\-8)$E5%/>O6
MS)[>#'8%45VI+<)']-K.V?TQW!PC.PN]96W1"DLHCUX>KN&?V:T6&0PO<:Y0
MD6NV/"%D"ZW/!"1:$:Y;2)G,&'C/&NZQN'MQT(AJH'&J.C*0D8)Y%W5NJ(TM
M7" BY:86?&/33?W#3DS_6W)K?^5_NLH/P7RK.JR\7M'UV.,(%' TTXY"<NRI
MOSL]=Z8X61J(E9M?BBQ7?XW1+BOI<&)*' *RWS0SF!A \WK3@%_W)^+WCM=[
M?';$ZWVY!"O<?M"S$=R%8TGN4CL46C2E1.RC4H* ;*N.O>Z>U8K=<1\IH],X
M%7[$O9+X_& .^+[3)*<MP\MN]*&"%F+E3>%E'IBZ(Q4K-:*0KU\[2 S@3.V1
MH]*TT%F@QX]6]VO6(N$T ?A=A!>8J&N'=/+[7R#Q_))*>]);/J1C56)Z/:#
M)*R=G6-?UQC+SRA0TW33R)NLNE?B"\6^B$P=2&V^X/L1O[_W'YTD:LAN9Q/]
MFM^T-3,SR-UE08O/R7>O<>C(TZ,XA:=/W@<CXD.KJB=I(,,F"&]1T:6Y,B<9
M11=AB]&\SD=#\B\X<'B= OJTU[%TK6G90N4(8;L?#J[Q8:G)HN4!:?./X/@
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M.HD+T+3KD1I:?</RU(8LZV!;!I:MWQZ!6]X\XSY/AE9T<H&I/SI*O:^J9L,
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M2&HBG[QRU]S:^#3^^H'D?**.:Q[#7-,+&&$WFNE@I/"#G9(0T'XK%[!/?9Q
MX0QWO)0Z1L9H %FLK,ANKR["Z\*/ 94XE"X55"-)D\H<$J750>V!?B]%7^:
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M9@"3.E_,D5IE4*.^)#E8DW.]&769\? 0DC"V*:+8L-GJ-[ @FTAO$TJT"<#
M9'/S,HBMJ^Z2YN;'66E4/U5X:;"#QI^Z2FG4+;E,T,F1;";;UX+U:.%!D6$C
M^=M.LUPD[JK2":8%A+DPE8$_VB@E55&M,L7G'<IR>M]KP6PZ"CD+;M\Q39A3
MG,?:"1)*,K>HN<*W-*>+"E1 'M0NYF*$ZB4?E0E1$'=5GMAJ@B%L4IJY_26
MI.\VLNAI65O=D7"<A]+.]2Y\]-J[F5B%06S7>PID[%Q:Z(O5O6G8F#N:OBOE
M,9#./=4VF:OH90_+=!/Z)<%*&<1L/@#,[L)PL^<^O\WD#^R$L5H[T>41-<,@
M&;K25TV$#4<<#3VD=]PZ,3^I8Y1ZHCUBLQ%:L^YP=NT[2MX/F_O[M/1-UXB,
M6(IX9"'%6,4"L8XE]%7F#Q:RZL=49LK\=R_1<U9'<]';UH1OC?UH!819U'H&
MM%E!3>F1-TA\IX"BH&L,-+!NGM$>U+'."X%_+@!=+ATM=G#I]MRUB.'ZS>2I
M/Q%X^WJGA*^)TTPW)+OM1$7!"Z* GA!<:$V98"L1G9./)N;5K,.&MAIE"^>"
MO%=LZ+ ,->*OX@A.VGG4F[OTYC%D5,:?M,^8 KFB%<3/6\%JT$'0?PLV!PE=
MSJ'L[C=@O"EF/(VNQ$LMX"#YP--=4T^\XT$K.Q"/.6FAT*GCF4A&'-^I$HCZ
MGZJ>9ZRH]GD'\T&'35X$OXVC6'N;?5.ZGV>MB%V^#8CA(R:?\%,P];TR_,@#
M1S*39MNTCE4Y-ZN<(0Q^V@LH2!M,6^/"T &<P;XG^0?ZN(M"*-45,PM[(!_2
M4>[/U^$%=<C2<:)U.9Z2D$&2?NC!P*KZX=X!UIQ*?^7GD[);3RGR68SN86_P
M=NU=#<2 (VFP)H1WR4 U;#Y%2<)H(F0L:^>=:9Q U.U*PVEU:/T/%@[V(U]A
M8I9N!?POWF(;]#NAH8O.[XR]-Z8@X=3NI@D:BT1G#_.B+P/\##GJ>$627A'O
M7QAWR*E$YC(Q%0G%5K>BF8D4G0!3LOZG]GI/H+=%WH6?8S,!]%21?"6?^K>I
M2O6$^,%3Z:MJ+(G62X(@#17[O%"_T;1("I^1LWZ4M1_',B*[WWUU]_&QNOOE
M]A:##0;0OH%WBQ18(L^L\ 43(C%%@N%U^"1W<3?=V'^SZVJ7JW=^X0?H;=%\
M:"9O34!&Q8)GU=H'G_Z<J68?#H4^#MU*>. -6#<E?+E"5\F*@[UMU8U!*(D;
MWCLKS3*OG>4YHS'@2^9<G9M65PIBI%O0Y<BI.1AG\!?)JG'IJYBYT9<-3O+2
M_]3[+<D0V@*!)@FOX>NLNID]T2AY7I4,R@NNB/)"-Q)S\K%'Q^'4;:O GEBV
M=;72ZJ;\2,JL-/Z4M:9:=-<TJA3JM^D]6LN3'_C;]RAO&)L<"O)P2"X[>@^-
M9B:/*, [ AAHWQ(%XNQ[D=\5LE-B@],:.T*NIZ]^/'EX]N3LB.^[XYD .#L=
M[V&BYZM0!3^._QV-OU&ODE[$,<!!R<3(_&]4,.AL<FM77^Y!31ZGXA.5Y\J*
M,H:<0O+Q6SZC.E0QRR:7G3^W5BB@"YBNCJR</:2)57+6I%^NL30E!P@6QT[R
M-K"W4:8ZIV*NC^4IL4D?O'GSU^<-HR5^>/?C.YC)EY=/7]&-7[[YX3CO=S3O
M5+21)F; UH8Y8+&$Y/P1\E :I6)+E.*!CE-R1U.25I<:UT[S&5>#Q4>@&:D9
MO]/$;$K3@:174AT:<AT]A_^"N;2%.D&%<0FU('4&(X;%+5")'@ UX.(JQ[FY
MJRZ;?+4C/)VBXKQ[[A+,8T^ )Z)7_TY]MI,WZ%@^3MI=;:C9O[I"= V9G$%G
MT;I_V4",6'-'^V1NCU/Q25/QK\X[<V HH7R$8<S<R;F!YMRJ"6F2J(&FP=-Q
M<NXJ9(KDC=X=*X$3<=Y@K5'JJK@E98V&D4 @"P'B0IBH\]6V.1XVOU[<9#D^
M8AI]8,=2-"E#[@#&"\0;?##Y*5P6&RK(60-)5:E\0SE?_*)HCQ[$74ZJ<=":
M <1Y'XSS. -W- .!A$:VEM] +&E;7E6K*_X3I4HC0.DX]'=_PBP*PL&0,4J.
M&$H(49'/.L4]V-?:B0B4N (JQ82R CL.G.5;%%RFI]+ZZ$V.\WIG)Q41\_TS
M)8!&^;4B5GQ_0LT+[SSP<54;&.AQ!NYH!L@#L*J8HU0"S!S(4!*%)*74WS9B
MY9:?E6- ?C$3JIF43NMX+-W5#$+G1C/?T&0@A6&9)=O"J9A]QO>"2TS=0J4=
M.T[*'4V* NY7A1Y 2B6E,Y62I7.#-WHB7$V ,:)@Y8VT<-P=>,R7WGE.&U@A
M$JLJDL[Z&XG_&CZ2CA0'=S@;(J<T<7X^JC7OA=Z\]/AM"*0PK:O\<# \ XYS
M3@'S0DQ%I91>43\#%>&-ZY(NUP2HZ,R;_CICP!N1\->% XN"'P1PJ0LX".ZQ
MEK#QY:ES)+FCC6YRIAL?V=7HK2MG <:*RD^MN!],BX+Q$G016NL8<4>-PHRY
M:X?8)C*0_^H"#UL_;1ZX0XFY/6/.!(/_"P"I7(:8FL/Q5@J(\L-2K>:NEEYJ
M:HB6+UY9H78B%BW:CD;!9*R\+6\:;1XSACS*(L0!>1EE" "E9S5Y#AF5/4NO
M&R\U9(<<;8]*A1,&W,+"<9TKZZGBO[BKRK(\A\2I_NR3Y59_<P5:)N9PF2P<
M#NMJ5/7#2C2\O:$ 8T"%TB=U0 +LK_MO0YC7P(NR(M'&N2HUO,J;>?ZOR8^K
M:NH7T3L65?V91R:*GS?;];1:3?[X/]]<7)Q]YYV.5_C/\^^$%!<[:^= 7E$7
M%</'9#[B5M99D!#OYDG #5>Y_QAE?[V@7 :M@Y#<(S!G$ND#$HH_"BY4B C0
M3D+(SVL(^\D76]$@(E%=>3\8!/HB-2(7<W0SY4T%!DLBR0!G4O]AP.HN3S3:
M<:;I4:2_N3E3GT]9/$9_C31KK:0+L;J4]0@W+,DBF1-FJK?#T(07NH$E]O?2
M ?#UL0/@-^T ^$0KSX?I38AORA(J#PZ2A6@"QF=ZZ .M%UPBO^_6;EY0L]"\
M\,M5VD\S*W#%$-@^2GT.OJ<1;98O]+S@-G^AI8(Y).?._V_&#HN5LXTCW,?3
MYXS+ZB@=I!Z$G#HW8]1MAA9-VWD9R)TNSB[.O6='EH",Z]-KR@*^6>7<#8Q/
M7PA+A'0XO/'NSY+47.A;WC2/3IC..M/<[)_W;B/'Y4:O+)BS/0O.VSB0W0"5
MKD/3;W]NH"M>MUW)SAZ1*3/_A5O[%7UE5(>YGZ4H";JC*]@2Z.0U*:QJ:VU*
MHI\RFM&DJIL^=]/6>)O$$NT6KJ:^.7Z-:N!C8[OQPDA>&/0"T1VN2LB"LZ:J
M$/G&Z>X/U\[9,&OO5]Z&O[$9\[M0>!M)MBIT(I%2(9_LZB.!9JJ$RX^^"NZ.
MC240;HS0;F_E4PABTW$\=]S#4(:%")"[_+E;5NDS0NDDWK":KB16:2(3"G=L
MRJVH/YQ"=5ZF"L,(SQX_TX6F=Z/@E'<EUP>&CTY5-_P$+M%UT<0?NX::3LF_
MLPWPD=7@QJ',ANX7LV,:<F\HY: G)7TGA:*$2*L?ZAY0:*$MU6:EZM#-'7/#
MH/U8EM'<$7S %M-B,'G[92RBOC'J'IE]DB$:_)E%3L*#;9G*M"^1;!\<W/FW
M?S*A]N)((HBJA*A V-5,-B4?WPG[-D(D161^%VI_9*(#(HR;22R7ZQ*<YDUQ
M.&P&OQ@$<&*&XOKZ9*MG,E3W"]+7&*4M EJ"")I6;G[)]5Z<.FW!XJPHFOSX
M].D;$6MG*2Q'XMADA()&N!"F> ^G;/(A@RC.5\K_U-U:F0HFU)L/,ISP9V2-
M_>/VGW>759^M",4F0]%PNVL3+#:R0[6;B\JF$/QZDU5W3,"W 8G$A-F/("="
MR1]:LHTZ;Y&NSA)MY5PB+]RUL&NP'9QM(]M""V5=RS.@1:;$BC,]PLC<V]$+
MDE_O7CRS5 8PN135<LYS!M^*L;"1(PP"IWXSX "2B8,Y,5.%=R!*THHHY40/
M/4S]=Q,_#!CR>&CRC C74+QQU!FEVW:7PB05/O?[>;%0HC,P*,P=4^O$);D(
M/?P?[4_7E+ZK>>6,K(?O1.#0.]J7?E #K<O^I6-KL\/E,MWR>M)K$5,T92K@
M%"AMA"PKJ(6LMC"CI5#18A5*PR@\P# \=G:;SO_YJFBH$&F^P+W8<[])L$YJ
MH:IA ;9 -\'<$F'?SEAJZ"[K%A>WLF '8VH#9872>;5TKFAU2X:3"$=I =+R
M[?%FP2XK_Q*LCKB7PNWK]QJM#DJ0Z8E(&]P?AE@J2A]CC%O?'HR>!+A6+$"8
M@P%( M8"%7=UAU>8<JL9+P6FKB(+1BO]8&9R3#XG8:M+1S4T"MQ%3)&%!BSZ
MPJ<$$US<TO-"O6;!@>PP6)'ZR01W66 R&_C1-N*9VN$)+O\($Y2E=^';N(^,
M/$*NG&W/9S!%_?;Q)$[]<G(/+:CT'I=U==TN51#\'A]BJ5X[4\0PF1;-LS\M
MNIJ/.R8<PM@E/%YF_,@1&;T9?.O1#+^?)ZAJ^E.NEOPYSJ0K'[1YE^-@=N7-
MXYW=H\'6<](OQK]TZXUW#'S$2"6;[R6'/WDZPTQ<G)U?9)/[?WG]_3OZTX/
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M[>3KKR<7?WKXAY#682O@C-HO"NM4[RS'/0K,-I6L,YYJ/C<VCFYTP_3';PJ
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MFIHM1:<5B+=11$ >5*>4"DOD96_[)1!<FMX*!  AUB6@^(KT>&.?-5I<J'%
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MPC(A[?G9OP]?:'7MV5 4)8;*WJ74A[NU\ZV",6']?LN2$1.M7Z:C\UWMS:@
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MR4@[@:U'/[#E*6&V<#3*T9[BU@R7"G9+*HCYPA;""Q+NH8LO*-$]HR9%7%H
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MC4.0A4RM'=\>[5T%ZVL@1&2R ^Z(UE8!=]3LR34ND0>V@-_YIK>W6/05KX%
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MU0HLA_S*!9-BHA+OT@3_P,."N^CZ#.9?Q$77-]8"TNIT(*T; ])Z+UC6)_9
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M>:;?$6E'I)M,I*YYVV3CCD0[$GW4A?[G?_B6:;WJR+0CTTTF4[?G6'<L.WU
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MY#-&_VN<(09KV#!C14H>O2T<E'G[E:?3:$*I4H'KZY[A]K0'44=OJ2(#)^G
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M'JZ=-;G6"5CB@'#506N/= <DJQZ$AJ6;KI4:9A"DD>NNK2"B\Q[<GA$/6,J
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M,0,]"&Q#CSPO"MPDA#_65Z/;97)L&!<_"D)8Y[)X(%9N%\ $0=^T&=/C?NP
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M0,H SOM^$F-I:)1)<A#5AFMZJ)9XQFI#N7;)4:"\2"A/%$O!5E*(G".%+4-
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M.2$D+=C,<$RML :#6%LGS_2T"U+KMN=M)+GD>'%9W9[ZZO9 ]Z2L;G/FM,G
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M$6LJI]P0]W ^I_6>QK+R0,5<EI4&L<1DH6;B-0\X)C%MD[96G" ;:5I;A';
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MFZ>1I8PB2HWPG"D##!+O/)OV!D?AJX2JH_33W9-)GW9_S=FVRK6C7($##YY
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M\GC[TQ;[?/P.D@W2?>Q,!GQA=_/; =C@B74&&65DTF,&DML<<SL48:FC4:@
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M@@84->.6!J65TFOK0*"M=$V]@0O\&A %NQORRNH^$[@F@V*<"4JC,7DWBR#
MP:9EG@!RBKL@L(YICB1P%5B5C?-BJ-4AZH4&Q0I1ST,%3<;( (1C1#*D&#<(
M-%=(X>R5<:FX2*--J%A;)X6J"P,50RW;4$T-D16JG@M53Z:(^>!S,6,D56X:
ME30VTA(48EP)QUG@R8%*5/V'@@B/-D/L?4CS;-PT^_BXUQV'S8:]UHDY:_WH
M# \/>T?Y$5I#\S,,6ND=_8D86PG2E]V,8JBF%,B[-DX+1@=/B PR.A 4:Q>#
MI,(&KQA8RN\1IZW^3*Z)EU:K/?/STP53I%]4K[XT@^ W>L<GH3LP^29+:+:^
ME>[=<&<B-,L=3Q+%8&0MD0B2>$%:28NB4E@ID-X[DA8Z 6W%I]N3W:_,:<'<
M#4+R@8"[M2CE^U%Y^KU>K; K O-NL-N="-J:-,X!DR0M*61]Z0 I'P@2,H*5
M. 0,=FV=MIF8C@84T-4*NGG6Z)X== 57,^%J*L9&,=/6&(:4X3:?@C=(&ZM0
MX!@P5S0PS=;6=4%5T=G%4$LW5%,J=A=QM%P2G\Q7LY$09BRBP'@B<1F1$<HA
M0ZN=;@&2YU(F;>#3 ;B9ZGNO<LK:L-,/>?+F*-RP'\S@M'_V@-#:DPKNSQ@(
MJ3]A;6\\8*.. .,TM3RBY3QFC=3R<2H3302:."521( F>1@M1C9*DYC%:XUM
MQ$ZZM750N*V!E:XN\UW1:\]%NX*J,9XV>H/A=A@>]OR+XV31TGEC5@A-YIMY
M$@75.6I!.$&YY2=2T0.2F@F=))H*DEZ7;U; 4W,:=?WA^;(J+0A2$ZN2 @Y6
M!H^(U1$!5AXI"0Y%X8UQ6AA60>J&5:G@JL9<CMI#\'=;DXH[61^Z)F/MW'IB
ML @(TN*40X(2&4(C"F"U]M3)()(W"6UZ3;>H@JU&A]H+N!;N4$T&W#F+C&'.
MDAS$21.&M'89;B,RT@8:M!-&JPI=>/ID3Y&$)5^S&*JY8JCVD/OL?!T[/Y,N
M_A7ZO4+5,U/U1%B=23#$*8TL<(Y 2D F0$ )-PX':XD(]!*0FI39NM@F@]7T
M1#;O^N0$U]_;/J7#8-G_+(8JABJ&6GU#-21#[.9>X3G\:B<3#]Z'?Y]V!IUA
M^!#ZWSLNC X&O0^N]Z5;7:4Z(U1<WOITU/ZTRQL$US@I)I1DE$' "$5&&(:\
MB2"5UI[[?#B(MC&46I2%PHJAEFVHAF29%:Y? :Z?\)D-MH[EQMB$*(> 4(P,
MYPH1H[V(T5HFQ=VX_M&FHKWN]=./W98[[?=#UYVUAOUTL:-J#K?,[^E?(G,E
MA%D,50Q5#%4,]00,-8/F%#XI2L6]8R @>C!82J,<.*K3[WR<67/N#@]#/TO)
M?CA,:K+S/6QU7>\XC%?JC?%"O9?7Z='MO>CZO8M5^T*S5I5%]LS/M[U^]<)P
MV._8TZ&Q1V&O]S:IUI)0.:/&_#*L2O2>:\Q?'_F!")%BPQERG&,$4GMDI.)(
M.+"2">N),&OKE)7TE,)73>"KVGWDPE?-YJO]JWP%!"(A42,<O46 02"5I@-R
M.O+@M3->A#OPU>/>0TXSL774&PS*GG$)9A9#%4,50Q5#%4,50]T_>UXY[BRQ
M HB/H"S3&CNGF518<.<QOH/L'J2G3-]-ZN^D54:"^U])L)0-I?K$LQM6]0TN
M;RA%+92.N3X_%1J!)2'WL,2(",X8C=G?3\X^AS:7=1U +HB:GR-;$+5X1$UL
MT08G-=$8D-<A(B"!(1N51#(P*YC@E'%W1T0]@CU:>2TJ7IHCTW6A90:Y7,AF
M<.'8AGZ+D78KS^QEA\=LK^]#'XWL\IR=#%N^=VJ/0BN;X_S58>_D>?H3K4'O
MJ.-'KS2?CF8[TAV]!"6IY8)24-A8'< H+=*:@"&P<+ U4Z'5W=/A8&BZV43E
M '>M(;&) ]Q:$FLH3DMY# 2!<1P9X0DR57X(9D(IN;9.=5MSW<9B,8'\18 .
MMQI >=<C[S\G;;H0>ZP2!4T+HOOQSPT-#'(1M= ?O/KW:6=X5F3.C!0S67;%
M<*5E3"K'N*QR?.Y($+!"U"K@+!H"GJ^M,SS-+?_U'T3@*5]\04MR:T94% 6R
M7 5"G6)*2F! &$A/E,541.VQ8(Y+[.M2(-><ZRSBXX[,,%G3S# ;"##D574,
M7QEDB&?(62*=!FMU5'<\UEF41U$>RU$>]^.=NRF/<IZ\%MZ9K*MC!5 P7J 0
ME$3 #$66&(>"-S$PKJ5E^F;>>;*JI)!C(<<9R5&IP 4.CDD70!-C?-3!,F&)
M4J \KHL<2VCZH9E2D]T(-+&*:(:,',6%#+(Y2&V$2</F#)A<V(]JT0:8[JY3
M*+)0Y).FR%GV\KP1A LAG3<J<60TUG$E3!3!"&<!;N;(&[;P2@RKWDSW46%_
M!0$ D'(F24;*3>X[%I$B3G-)M",\KJT3?(>=[T*#A08+#4[3H)<A6"&U80:L
M2FI#>Z^ >FJ<CK@>&BR:L4Z.G$@0DLF)YJ U$MF9!FPMTE8PE.B1*>NT-CRY
MU93P-F%WZ,A8>++PY!/AR1EHDADBI, \""= "*JM9CEH#DQ+):TN'G53V'&R
M'@>5X"0F*$A%$>C,CM1)%*)CDC 2-<%KZXJT.9:/P*&N$M+^69U?.S]"E+Z<
MW_*QZ7_I=*N_S:\RDPMILO?'X%O_']O_Y_K5@TBS7^6!$";X',/5=9[GNC<=
M=SNJ:4;UWF%H&9?+<)KN66XIW^T-PZ!E^NG7W58GW>&7OCEJG9C^J!7681B$
M#/9J)')7MU;L=$W7I5M+CY!^4=7B>7:C.<9_'+(M3GJ#JM+.\WYN$-?Y'O[Z
MT?'#PW.^N?2I\>S %Q\Q-MW!Z?#FC\S=T+>:5<'$R;1+7_--CN@I!"9TSC$W
M,;EMT@#6! @X;'PT1AYHN7;^H</^^8V?F"\!V7XPWY")Z;F>FZ,?YFRP]L^K
MTR[-N7-;XV?9VI.&NM$<,=9I#L+_SVC2)Y+N]:L#I<\3"X1^?E>:?QE\>69M
MY 4D39WK[+:$89U*]*R&]<7.FZW=G=;+K=WM5YM;&R]:&[OOWSYKW3C;EWNW
M&Y=A^N$W."MKF\%AZ_51[\>@J3?_CTXWL4WO-%W##_Y[YIN\.RM7]W/=9:IU
MX8*!JH4H/?.1.1F$Y^??_.4[@Y,C<_:\TZV>H?K07^/+CVDKHV]B':K^WNCE
M"V ^PR-PCE.DQW]Y_/*SZJ6)577TFJ3/E!0WOHR?D1M?N^VRA#P31-_KLK>_
MQA3,Y6;IW6[H#VGH?\QWTE-OO<9Y&<VB>:IV]2<850>E]X/IMUXEOO57\M)G
MR<N?)0'L/IE<33'575/U__B,3\!0^%'4&KC;XU9K9:S6RMCO';=Z)R'KF*25
ML^/S/>G14$,=@GJFU3Q/I\UXAXL^[3.O27&? A2S/.-28E]W>\B98U_+BV'=
M[8'*\<7[1K3.SB-:^WA[\]NO_;V=P_U?CGW>>W^\\^8=[+YY1[9_?3[>WCSL
M[.Y]Q+N?WG^]B&B]^+6]^0[O'^^3SWM_'VY_?7^XO7G4^;SYY>?.\4ZZIRVZ
MO_<1=C>_T:F(UN;VCYW-]YW/7_\^VOGTZFSGS:L?NY_^]]ONYBNZ3S\?[G_]
M?+BS]P5V]S['[;-Q!MT'?+;]]2/>>7>@ K>>.HJ"E@RE8;3(!DU1),913CRS
M$NY^''A&YFIRT+X04/,)"%M!L.2!"24@4J:]53@2+\#J8 2M" B?$Q N!-0
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MZZY]_.KQ_9O#R4"!8[X<B)J6=C">NR[7X_X>V,-Q2YUMAY&EM6NZ2JL^S2Q
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M;+[8?_.[:_>S_^:=;7<0!3X67AYH,?/Q']OAH&OFB'S&,+H3FV7PJ*W59ED
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M8+*9<>OU &L<. 2)7Q2;F =;F6<AW@J&'ZESM=&*3<S7K&@'"KO ,\BZ[ '
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M:1YD_?0;5]4%]'MEM,%[L^6'8[G=]!ML^O-37B19)N+4EZ6 K8["U"^*7/G
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MHXDKCZW146HPCDP,,8E8>6NK#4EC!E+R8,_*Q%$P1B .MA+2/"04C<#1)>7
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M^ /&=\"53XY[@S#VL%=X[I%ACB 5F3?26Z62@KWB#2&3T8/?Y\UQ7J'2C@H
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M9V@>Y2.;:1M;PDI-WWXW&A^W=QJU/[9WZEN;V^\W:N]WOGRZW=%]VL&685
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M0TT1&0L_22%%L)3&B./:.T'HLP"M)26 /Y61^>&\VRY"S$40)C5_%N'FQ96
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M('!6[W5%(/"W9VX"C4C!YD (-MKA0YPU=[8"PUG \/.$+03X9*1.#H44!/B
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M:M($10@#KE9[#LAD"[!J78PSM][H1 !/GH_)U7H5%!$<4R6XT]XF1IVTQA/
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M3L\_/%Q@!%CV>[SY6%O\<=;JU9&VI8BT;>6U*JZI(VUS@/##"1/."1F-$[#
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MB*D0P7BB!ED1>"9H,2IX)L%36EFGJ]R852+%; N]GZ=]"]ZPZ\U9>M/>:YF
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MA99+0;;U0OE2-?7@VZ >O"LQ^TDP.;M3XX>#Y-L_2GYQB)QH**H]CM@CHK1
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MV)Z;%T]5\)3;Z)5D'-N"J1(V)Z42BRG06'OQ"[,;359;6VDED]X@07!$'(>
MK/ *69;K^AR37/C9>/$S),6>=>^$Y^'U@FCN,WSQ5^\QL4 X-]7T?AK$U1[W
MZ^'<N,<=.2/$$["UK02<,X!XA@B"+&8N*2N8S_QR,_*X%QCJWJT*"ZJQES8Q
M0SCW&!L5J"(Z@._%B="X]IX74H_'O>>(3591C3".%O%,"&:$5D@H[%UF"A,:
MO&?!]*IYY?XPS_21E_T 73W_ /W-^\C+3G4\IV/P-^@CX^2YU"8*GU+^17NM
M='Y;Y:.0/M0^\L+L.9/-&AR53 2N$#5>(RX803IR@40N?#$86Q[X3$^Z%_%
MYGEXO2":NQCGU6_3P'X:Q-4^\NOAW+B/3"PGRHN(8 $QX)Q(R&$:D($5-%IJ
M1;V8]:GT(D+=NU7AH&00TC(6>>)68N>8<M1YKE5R-IC:1UY(/1[WD0ECV 6B
MD0HVYNP2A:R5"4EJK%!*<.U CY59I5(LD!J_NV-D71\CU\?(]3%RM?DHDVU&
M,!\IT>!C)8>M$%9YA[6-4=/:15Z8+>?+9#*X<RXY!SZQ3C9W,:3(:F:0,Y+S
MZ&!55:R/D=^XBUR?0=UC7S\-XFH7^?5P;L)%QM)+90*XR I,:^8E,MY)9&,P
M@@B#O9A=XO8"0]V[56&G1-1$$^)(@N5W!B=EE<UZC8WUI':1%U*/QUUD15)4
M)K%2A3G)+92B%(AS2X7FUG!!5M:YT:M"J@72X_=UC/QGMP,#ZV>M[*;26<X]
MGLHVNF7CX3=^OERV0:L/E^O#Y9]XSH[D2ER7@F"!*^*MML&X8$6T%%MO:L]Y
M87:B_0G/V0A#@M4.,4\=XBK37;$0D0F:P)\D-UZNK.LU7!\N+[CGK']CI#Y=
MGI?=_22,J^WN5T:[<?]9<Z)UT!)%GYM&)$Z1=EHC2:VAQ"FNO%U9IXRN4OUL
MNWN! >_=ZK'FDM"@%-%.@K.5C"4^:4FQ4DXZKVK_>2'U>-Q_!N]9IT0D<M@J
MQ*W%2%LGD2*!X60T]XIE/=:K2ID%TN/W=<;\!501_E+R[)2N9&.W:LG_QD^=
MG^$XUT?.[^7(V45+*+&4BP1^5I#6&$\T2<(2[H*N'>?%V8+\9.6RQ]H(*I#"
M^2A&.H6<9Q1A*SSCAG(<PVP<YP4^AWD31\[/<9SK ZO['.<G85QM<+\RVHT[
MSEXDRXATR)+@$2>Y8YAS& 5J82F#IX%@T"0E5C'C;QCPWJT>:R$L)@:SA E/
M@KFD'5-*:><Y]:;.S5Y,/9[H_L62I)0IY*7QN7XY(L=31%$)&REQWF/08X/5
MJI:3?'WUP?/,M?"/7O<D]AI3_>=9N,SU67-]UOR&7&9MB)?42L^$XRIRS906
M.L?PG0,KTM<N\\)L/H<3+C-8_\)HS!$V8#IRJBTR6MK<>S8DG A.2:^LXS5,
M%BAD6Y\UW^DRB_JL>2ZF]I,PKC:U7QGM)G*UB=%$"X<,PQ9Q315R#&MDK/ X
M^\W$AI5ULDI-?=+\!K4XXB@H9\Y&37GPWBD&CC)17GMON;6UP[R06CSN,%NK
MDM1!(ZP%1UQX<)B32$AK#"ZS QV.8+-PO<IU7<S\ROXRJ)-Y%S7-]>ER?;I\
MKZO,K"0Q&DZLB3PPZD0(- J-8U)1LOIT>7&VG9/)T^6$E<8FG[(D<)5A\T&&
M,X],"+#S).N=3K-QE1?XL.5-G"Z3WQC^;8S.LCZ5FI&1_32,JRN:7P_HQKUD
MK&32^3B9"FD Z(A!CIB(*$L!<QJB,:ZN:'[+*DR5\=([#+]P28/.5([4\404
M8=JS.?G)M0H_684GBIF]EC91CRQU)@>Z E@M.B&##686!Z<<6T05OL='#JW^
M6=M>YL'&GVM]_<WY?_/-)@#\V>WTS]N 48/KH,8;/^BOFY;79_T/"6 8L (L
M%0FV#<FCHPY+(YA3,64.')GJ ,;"& 5;8! T!\W",-B^W-G[1 ZHIPISIY!)
MC"-PS@323'(D@R:1*\F(T2OK:NWY:68+?/KUA@[[Z\+RN;@_3P.Y^ICPU>'.
MWX8[J5CN7RY1$(8B+H)&&E.!K#/<42&9=WQEG9E5@1?IG+#6XQGIL>4&_%(O
MN?:>.ZN<%Y%XH9VRP7%9Y\<OJAZ?W-;CZ+7@,07$:'"(1ZJ1T3@A3:74,B4-
M<%WI\:S8L>O\^)]HX5YW8-LS]8QG8:S5]YC=?E"1PY>B]3L#!0C=<]>.)4'\
MPZCCW\X^PBR12F(1)>PE4E+C#/PI,,Z,TLK5]9(+N8]<3MB#UC'G?-0H>JP0
M9Y&"*1@BHB0Y"6XQUL'D[$_"]2JLYHRVDEGHTA*9DC5TC$(' 9O31\*IYIC'
M(+4V(H$Y$SASV/":8G91H6/,!+5,86-31$GFEHS:,>0$P<@8;DC"'I CKJS3
M5056J#*SJI5Y3>@HK-??!A8>!_\-K>_KPY?:.3\%S?'K_P_\<?@*I[9WV.H4
M8Q$%=)0OZGJ_K5^_='&/Z=<0/-3U5B?$SN!W2M=N[O-,O2YN_E/%IA@4>[O3
ML-[#G-J.CV7RZL;??S8T$:M%LZ2+87JKSZK82JT8&K;?:%<G)ZW8;P  -'HQ
MWR-_-F@DV^HUOMOV><S_RC?)J;'%_8,=Q-7R*?[(=@[C=5.FD8ORO0X[\ YA
M^"& 2['.<'46'_C/:<QCZJ9&]RSV;!:V_O!AL1/R!]'Z([C561=6NW/8@*^U
MNF&M 0 5>[EW<L[.;?",'P\;2CC/E:_%%\I[]:N[1[AKXXTO=RSK?T.WT>D.
M&J<QEE,=8FK!1E"UI;;P[U[K.ZS&=UAY6(4L&"/W:>5W[/J3HVX;OMC_W^%=
M?\FW\:W!KU.7V]EV,=;^$3RUOW9[HK-NYIVGU3DOA.#6U%<OSF&._W76[1?C
M_+T7V\4 _W71"H,CF+8\*Z-75;"#;RZQ#D9S/KC[DHF3S1==4H+YV*2,_#SJ
M#0=Q9@\C<KUH3Y!-,,;?;?O"7O97?KLMKB"KU=T5A<>/O_+=$%?^'%N/<M_U
M."E#;<0J.NXM-=(19C!327!+7;PV+RJ,'>_;0H7-!+/<<1ZPTIR#Z:HE"0&'
MH,G!9O9#,/P_NG%(2C,"U+KS^]!CW^B$\DAMQ'[8@'WJ.\C@7@;\/7CD'VT0
MT"4U%[[]WR/L3__IV*_F?/=T"^[SN;5S^NUXGVX3>,;)[M>FV+F"-X&M?N=K
M?BY<3[_0_WO5O-S=.R3-JT]\=_,3V;GZ=!"-IQ&\/22Y\(B[@)%C0B%IN V1
MTV2)76E$,+#.L@+TSN/*(L/>'J#*G]U3>-[E__:'(->PU>H7FT &GLMH>WG_
M -C9C#Z>NM@K31A&5AM9N.#2?L;#U&VWNQ?]WQ\*^_"RA4UQ S*%$0,OW;9G
M_?C[\)=_#1-.6IWB)8J+_E7=K$*F#&=C-DPQN^7'-QJ[ADNMK6)QU9.KC]>*
MC\8LLO(S8=:$HG=^C-?(G9_][+:$K$EBGG3;GW_&-*\'2Q^V8/<$9Q\1B'MJ
MN';^V^:X0ZM^VB9T;!.[_X7?P]P4_P 0O!/>7G5X&S!_8,PLZ.B&^3P+.KPB
MS:@6^EKH9SJZS_'4@B<(_O%BCN]/^$8.2IW;]H*.\#^M%!N_@ .<;=#^KU,T
M= D/5B>L\^GO_D?IXE=Y^4/+NU$9W7<7K#T\+K^0D??[?9<Z]/[*H?>3_:L-
M]FT3QD:W+\$_QKM_[5_E:W;_RB%R\+'_:A+PL$5S(O2>0^[A9'>OR?:/MZ]@
MC/S;<>%_<_@W^.-;%_M7_YS">UP4-,)CE2Q1:!NQ8<@DXA 7R2)K,$-!4>X3
M8T:&-+?(^V(?R\U1Y5\<#V>4<O_ 5UXJ=+L[&_]I$$=O!06GHMO0!*QLK5N9
M^36B/1;1QLIKN0Y>\!"1XI@BSK5'+L!O+,%"2>T9R>6U:@W/*@M_*<#L,?=X
M\ LML)Y/C?!C)PE6(C*I)0=Q,,%IG$B0W)EH)2TB_'@8X<>/BO"/Z?2UHS+B
M$>S%WNDM:P;>T?\>SGO9%*^U_4':OC-FOQB=>Q\DAZC2''&K&+(IYOXAPGJ0
M5H>U65GG:V;B>'U4R^NZV%=HH#7N$5>G-M4QQLLAQG#[O8G(S.#9,A\]5?_.
M-_J]-8#7]_<.9\H!<L9AQ-:F',<XVX_Y!BOKOY!IGOS2=5MXX(K]\EA"CB<<
M[$[U6>\VZ89"U-_N?"RR-FJW=7:P[R?<5AN2P5)31%@2B!.%D=.6(1^Q,(DZ
MX671:51HO:K$9-G"KP\V\NH&*HOJGCU3K9_IITU1^%JG'Z?3XPW@P*=FQA/$
M)8$?(2KD<"!(&!D(!AL=BY0=-[9(+!VOV #NUCU>.FB_.,;;6:L7PS.,GX6I
MT5QFXP<6H4R.K<V?V4/EX83Y8\#8(5P3Y*T,B"N)D6$^(()AD;T@MB3U7C6$
M/L/TJ8NN:]-GNNDS1=UKC7Z<1H\9/R8*)EP42)'$$/>2($.X1<+Y:*4*+G(Y
M&V[5!=;JI]YC"5N_SR1C@3PI8Z%Z^>6M))Q+/D-=A;R$.'HR81EI'V#-O$9,
M*0M.)(G(60S_#)A&ZI1P(LRP"'F&NO3*'NBS(TE+E]/PZCP(\[,/GP9F=>;"
M"V/7F T80Q)26882MA)QFQPR@2CD&8-U<]'CW$!!UPP(RYV%,,\ZPSH+X44T
M=SP+(05K#(X:25;$KQ5'SDF)/,=4>15QX ZLCC5Z?Q;"[9X =U3ZS2K(>F]/
MCJ*H\>"^_WM0=>++COD7\FMC$0.E8X=&>[D(M!??>+CTZ07#VS_@72Z:Q\W+
MG>.-/,X#:K!6.4U9)!$0%]0AFW! )@8KA4R$)% U2=BJ-I/!ST:Y](W4ZYY>
ME^?&ZP20"UB+QJ!:DT;>@'('A\%-46_^I^]^CV49[_#"QEFV?W)K@I'6!E,Z
M"-S?W6,>YR=WYI],A!P*S8&M MZO7_5:F%Z^N+@%V-N=QH?H>N>V=UE$2%8;
MMMV^Z3;1O=DJQWGT1,FCEP,K1([\KH:_YTX3\&]=_KO1**^$%YL4@_]Y@LT>
ME2#<N,"T85Q;;S+P>*ZE)-HQ)4N;'5.JZ][?,T28+1C'2=[@*3P;_NL/C..1
M86R15@0C[D1$QM&<0$RX#(*D2"D@S!J?C![DCBTEQ)10THFCZ-+J 'J O-C#
MPUX\M(-"5!X9I7*81LPT-Y)R[8AS (;,>46IQ<ZI:I.BU28U+BWCF]3?N4W*
M=J$'FT7;F7)7*L2S/Y22Z_RX>I-ZD @=?SG 221&N$-@3Z3LR1'DO \@4<X2
M*L ?MP0\.<Y7&9OLC3S<I$ Z?/?TM%NULVF<GW7+OC7;'W<K\,G2,43K9Z&/
M,)$:(SP8-H*#F!N;6("E30 ]GB=W#_K<;?+<;"=O(T@P.S'9.HB6*6J%1-1)
MC3BH,B"-C8AH@:5VG($5"FX#61.3?-DW4/.85D4CNS6[MY%8N3XQ,FD,4]HF
MSKFR'!O""??8AF2M.B",K3RH,<F+G)H41D#1<HN0(?_2?'SQZPT75+0U*/J$
M@4?^9S'SA['C6[&_V>K[=K=_WEN@EC_-2NJ[M/GUV\G.U2'?.?[$=C9/\,[I
M/CC%'XZ:FY[ <W[L['T[W<V=^R['I/YX_\>WTT]L=_.0[FQZO+OWB7X[_GP$
M8[K8N?J"]Z_@FM-]L;_WA=UN^>/YSMZ7 TF5"$PD1&WFOW,ZM_S! B5O"5@[
M&%//2W0"$8YA(^\W) 6MK$_2P][G-#-.:R<9XU13%Y,>;Q$TLBB%W79K6>YT
MPN_N+'7_\V^/E[LHA+<B&A M&HE5V&(F;38LJ,DE"8OK .R6G>[ 0OY/M/VX
M-*;_2.^E1KL8.6R&*>^)60+:UG7AM;K@%\"0X(^M3N-+!Q8XP':TVMB)%XW]
M;N^D] QWNM_M1]L[ :._4>3A@_5V9GN#RU782\$Y+*VX7BS: XZUL(./NM<S
M6(P#]FR;[<"<J09CZC3^?=Z)X$H49[ARK7&[:51Y2>C"5W,/O%YN7M?+[W!9
MR=AA?F8/?M@V#.JR$/+51NOTK-LOOY9:'0N"#A_#\P8@X46JQFHC=R"$.UAX
M\_PU^+ 5<J."L@7A(?A,L&W'V%]K_&-A.?+Y%0PZ=O),PD/AG=KM?-D97)G'
M,+@U[M+LK7S@-DPYK'6 O]],QO!F,-B.;Y\73MBI[=C#<AI3\>C15;R>!-CS
MBJF%R>GWX37@?T?V>_FVU5+?7H1J"H8K,-[.;QF%^%IJ/W1[ U#-2FC_#<95
M!+D$2Q$,P'Y^97MVUNO^ !-M$&&][G8P_IL&8U8@>+?<&$*E,H%CFK33@E@<
M+9BLA$0^_=P(CV^)&[UH=]/G:-M;11/-C[TL!(/+97$@7GJ/W.?-3P>66&&5
M5"C%S'\=64(N4(^BQD9;!KZ>9#FGCTQA4VGT_WN>M2_EAIFYR=QM$?BI0S F
M F#CN91L="(%[E6P41%A :>DTP%K=4\8%(E;+L%_0%]CO-Y1B@UEHP-;:_LS
M*-A6"0@/$POY[L3"_]C9.'"&:BV91<3JG-# P)6DRB-P$!(66%'G?*9%O^M,
M$)"I77B'L&OE$Y[K'0R M8-\SBYJ%U _N6GUNN>'1XVF[?FC8<8176O\?]V+
M"!Y=;N/:RCUY>[FG;0'@\,_X(P,[8'"QC18]5FW;G[?ML'=K>>];77UA<RZ.
M[?+'YWD+ Y$9%-T/6_"?0>R=YCMGY,\;*=RE4S90+/>*\H;PA?ZY.XZP3^0(
M+6Q%N<]NT7.W]*!!.VPC'X8-8J=H\YH?VX4!YF_T!V,;3ZO<=@Z[12?>;MYM
M 6KSZ]Q ;O7DHL?I^"0MRVZSG6V1=A$IQ:NWXMQ%7Z+KF%7UKGD^J]THG?<
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M(KS\PVUS_0A\A3M1JWN6_SV3C6S\^'2:',%KNMC;3;O%8_M[W:T?.:%D4I(
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M$X1KY^=IB+,_86<P9F6PX/=HZUTNIF<9<21*(0HO#:7@ ZVL<[XHOD\=DUA
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M47(/]\_;@]MRZF*[!2,HWW6$A_AZ46XO KQ&MLB6!<H^VDM_%/U)[L,RJ+0
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M!_W)9CZ8/A4!$=A;%JRCTJPJ2'^[JWDOS0YF80N#;0O.X.H0-H87E.9\%EJ
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M0H4B)US8C&C 0$*U2DW(,^ERP+NBCKS463Y+M"U5H\83H\9T)H_/"JFX(<$
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M AOPX#G" C-G_52GW1);<6RN'TE4.2TX])^-WF4<K6UW>SC$MFU$@W/1Z)V
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M'RU"10;AP5$A)IUKP)8QJX:?C W0_]11JE%80!ITOW?2[L0X5H43^.,</YZ
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MHIA3A.?>$NWSG A5%!D//J@\74L\P/(YZD*G[]>6.=#P"=:_9<&;'KJ6_=;
M2XW<HE+[2'S&B$XRPW&2"QTO"FW$R&[R6R24[3Z,SG5__^.VD1=X^[B7- *@
MN'D%L]#4YUW_Q^"7/UVC>][4EW\T6O&MXI?^K&Y6H9:8[1(1I[O\>*3-&VFI
MT57*5_7DZN.-^-'43ESY6<$V9)%?^7&Z0:_\[+K;4KJ14W6OVU[_62;YHPR6
MW6Y #TW<OS)'5CTH^;\T4H^9):"F5+&X(BUOI%H3&\ /34=\2(&(6^\=+^.,
M(CY=V8ME(2__FJ<V?9B0KE:UNK^&FU5_Z69T .Z8(/OP8E4KE]5UMU>N\[8>
M'@58\:2MBSU\]NEW(-I R+=VTKV_#^&9[[]_._C.OVV].\7?=]E'MO]Y.FEK
MDW[[^QN0^,U?NU]W^"Z\U[?3DY-#>-_]@Y/O\#SX_>.O;UN'XO_[M3-6AN\C
MQ?U(K:A05!7$&)<2'K!?20$>E+6:\51H(VT.F+<NBJOV(Y>K+M>""%8-9J\4
MS%)ITRP4+*1&<2HRY85UUN3&%=1GA4 PHVI!8/;RDD^?#L<NQW#LUY<C6KC<
M\\(1)0L%."8E(%J01&OJE<T,S85;='V8EU5A\ F[+E4[SMWD(2Y*74AP"4_J
MCY86MYT&>P*8A_&*#NS?P=S<*Z9]#[NS4Z;E^.ZGF+T#T_BNTSY[6Z[/AY@A
M U=_&(0\:\Z].%OU<9)S_]H^XGF:%=IZ0CT>[<^L %N5<R*R5.9,6&,*&RL$
M%8NJ?+U$S/JU:WQJ<IH6PF>YS'E@F7)&IH&ZG!OE=<ZBQJ<#C;^_VWQGC:^5
M^FY*/4% [5'*5 B>981J/#214DZD89H4BN4A4" +AJV]R;-E4NE7U+!\DIB<
M@_AWRF3\NF/Y,C&2#[@P-3H]$)V^S% .$S0SG%)"K<P(+*PFDF'K3ZN""#RU
MA3!K;Y:J)W%=EO %\(TK];GV+Q:H[%-4Q!0L8TA F'6&<"$YGJ,+1-(T+SR3
M.J02_0LUIP+ITC;]&B2]P&#]]1#Q5%?6 ZX'?+<!K\B._W9YU*7:[K]^M_^U
M%G*IZ[4LK+A5O>__Z!QA^V*LLE6Z=V!_'3$GBI2GGAA;%(0[DQ%-"T=2;1F%
M/VF7BK4WV7I>7%7?X1%58[$^PTV;_#6&O5H,JW.75@K#=L<Q3.")!%'DAI.4
M^1PPC$IB4J])P8W7CJE,N/1^R4O+757J<0[)Q,(?5WGWX=/PSU_Q-/5F/)AU
M<.*W!R>TX.I/NN?K8S-CQV;@WD<Z]:FD&N8[YXKP0E&BF F$P@<R4!I@?5;H
MV$S9O'I4O>+*HZ7QC/KHL_7J%+Z.\E(>C9\YG?X*3]((M2$*MOC#*7(CX_<[
M\_(,)VGD!DNO_O@.)VGN<&!F!8X:W/=<S%W2FE;\*,:M3KDLY##+BD_4 \^L
MK$QRX9>YA\UC":5;&*![EA]]B=[A U]YQ1W#1PYN'8 \1AZ]$PL?3)/HEYXF
M3G?!S=M%]P]K%9_B_?<:AU]WLF];7QBX@1??MBS\[2/]-N,R?KF$^U_N;OV[
MB;6*\5UVV?N3PU/W?>_@\')O"Y[S"]X//@>7<6(??']K^\CDG!E>!((Q+FSX
ME1$9F"9ID1F9I^ L%>J12A2_B(KM-="]-*![Y A8#71/ 72C\S PEE^[!]M'
MV@0F=6J)2[TDO,@4433+B3!%5BC.&)BVU0*ZISY2L424%>O[W8FVOO8DZX>R
MM^M"H4-$VVOW;@-J+S3J_W3(-D7A0JX#5SXE:;":<%5HHG3A""VX*T20VCI_
MOXW+^O3$TBOV0]E*K=C+HMB[,Y3%&\M26$MB<HEM)R0ERK&,Y$)PD=J<94$O
MMA3!,I^A>'ZU+'=ZYA9O?);V5B_0MWS5N1=U_M@J@?44"\MYEAEF*/'6"<)M
M03&0EA,I999G.C-:Z 6QL"7H]%6W1:QA<E4I;PV33P:3'V<X;6&#,L$ZPM(L
M)3P-CFB7!D(%]]*)U "M71"G70*8O%M#Q/N6XG_N!*BQ[@VN[<M&,KH%L](X
MQQ0FK*./3QFV3\%N"KWNE=6%!ZW!6O!:2>_"-W_ /6 4)]<T-5C1J=MI(;2=
MPDQ$T(L-5O#5 ;YDLAFCFQKF\LRW8M>CJ_HUQ:O*1H)E4YLO&Y\WAGV"QK+)
M8IN73/P+EX#1?XT%3M_K5E]W+I.RWYJ,I9S/VJX1L(%6;)[1P!X@54N:LC.4
M&[1^Z2:_X5/7 $5QU&N_EZT7/F^_A6G4(22-;K=?=A*!?VQ:B[ER\41-O]GT
M\%NRU]Y(*#SVM[7/FW_A;VN_QQ9#SG6PQU#L#W5^#J,8UJ;^>W/S S8J :GI
M5WUB+DY\*]$P$<>-+O9@ZHW$,9;5+X7*P@WQ31NM41NA84?&]>2\X\]U[$K2
M[I3MCM#/^ZW1LLU^/ 6$?8;Z56N:WW$$>,JSW8KI=<Z#/#=QY(-&2N701V\<
MJP!58C_>V"0N1'?0$J>:R-D>3:/^3*A!?JP;05P/$(ZSV*LJ2D35:"2V=HK]
M^*JF NW65%,!D,$(?&5GOD9+MRSJ:^SX538NF&S7!^((%][0Z"2V1RG;58VU
M"QIU0X@#.]-NV%]A7N.@.S0U&$MYS.[3UZ0TY]YGN5)9(77@G!>:IXIRRFVJ
M7="Z. +:L7:K?,O' )&97*8((GMM$#.:#;:N'K=AP%;9#.TMW+;3,'U<A0]-
MW5J6_.:]K9T!+6I\PWSDKU\RN-?EMX./0&-V+_</=L3>WU\NOYWN??^&S_NZ
M=X(49S*_^7US%RC,MP-W<GCPOKFW]>GD\->.V#W]GGX[>'^VRS[!W[;I(7N'
MGB#<\YC"]7Q_:U?LG>X<:4DE./*6%")7A#.>$QTR1@K*=!I,2D&22DH+<NS=
M)C)-QL! V+1@5E.N\V!L*KRC@2M>^#35T_G0VP #[4OODXJU)K@(,]QB>3H<
MQOO\T>@!2;*W$.GYW3)NGJ3)22V<]IGCGFG%N#.%!,GW&?Q_FX&)L]EUTS@)
M,\LSD=?2B?G3=O,TC%L91.IN&[M;83NP1B<:@*2K?P!Z=Y-SF)_2N#2ZL4-5
MM 0 X/_I8W>PR[)1L?X!O"/V-P8[UL/N;?$FD]TH>4I_T[\/+![RF/6J<5\+
MK2,.P.KN"9KA85.Z +?J=_S<$9QYWZM:W?VG7XT[&M3Q!WZ?>.!&\D%W2IZ*
MUV+_OS/]'9M<8NK[SW(XE;&.K6'B7W_[U.Z=_ Y3TD0:48X-V>T8) X[_<3Y
M&C37:W2P+=]Q V<&[&@KSFC_?' MFMM^K]T!:< 1="W<#3OVC77UK*;PBO%?
MG !C@MD1:66GL??X<>S$&?M+QA<<#G.BT6%Y?*&;&-V-[3LG!G19/KPJ8:A[
M]H3 J"?>=V(D4U.!0SKQ31?;RG7ZL2WC8)%B4[^FOM@ !I@ =6F<]<\&075<
MX-AN%!=X].(XI1O)9BOQE?)&PU?\V1UU3(,'G31B3S1L-GG]0L%U5\8>P/D'
M?K/8>D [>^]N:5,K<.IT=W'*05C&+]B,4O%O>%OXX,.PZ^<P/D'8J[/$HY;M
MN[\V+W8/OA\9QZ7514:\"0$;]!1$%8P1[PM7Y#Q3*3786SB="37\*_D!4XMM
M0]&G&.F,VTC&5P$<H;%FA? -0+U&]\17?6W13XI]17O89@G[A&EP29K831=5
MJ?HU>F8E##R7),9=X!O$<)X45H*W'P:&M/MWI]WM?M"7^RW_?T%G0<.K:R9N
M4XOI4$Q/=X^$5!GZ%R3SL%2<^I1(Q35)4^ZH<3X7VJV]F2U%]:\(\.A' B5I
M.,"#(10.S0N:L- (/0#^TAZ6T%Z)7O6O&&FYF^Q1#F)FJ8#G99RZ0N?6:N&
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M]?6I]76*3 3%J?&XY\.*G/  ;H_R0"N$]"R3*@@N0%^+V2*@3Z^O+SEDM-7
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MT#?SZMV?NZ>;1YI9Z:C,B2B,)ASKSVM8(L*$S3T5)M618W&U+N;5A*X:AX#
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M49:%M6EA)7A*(1_(Q2TX2XDDG\M2J ?M74#%N-ORR3M_=HXC^>Q[O68LWG>
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M&'Q_'347#&E91'1@#O]JZXZ+9/K*31!L3)5\M@WL$1(:-MET/QI=3-^!_WT
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M!$DWDB\Q30/5;_.L]'511S][$ B7? ++$#<=64I%4I9F2'9:Z$VAW'UH5I"
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M#+H-^,OXKN? 71@+R(%SV"_3DB<I'1C]QEBZ_U7\=4[,],HM'TSRC"]PWN\
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M$5%:8Y? ":Q(%FK/:!NR\/>];0D55G 8-L2>W%B=?$)-1&0AZV0D+,3O#D8
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MMD6WKF!\#CC*>F1A-#QL%'=!H3EB;"!B)!=T4$5V, (DI*(BI3=,O%RL\,7
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MH5#]<T%/#P+FVU2EW0(+74Y8+)U5139*@D0C9^(%O"837"E)CV;7B]^65EU
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MJ6L:YNDV,S/78TD5;BK<5+A9FN67B+//V)@4XO/5"YFSB0"&%%$),2M#CAH
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MM7I\#L  0AZH.+8LSR&@BEJ3T&:0M8<1L79+@B(<@=U,UCOP:0!+IDZI6F%
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MJ-HFIUP.C\N=WQRV"2ETAN&0-N+J'P# @#E,&A,AMBD014\)_+)@HA47T3$
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MP]B7OK6M9JW;6V_8'2RVUFBL%[>W_;5V:^W>>CV1=P'7GM'9D[5V:JWE::#
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M4ZFM+_G1BK.6C;.:%5O=#[8*9'?"9<U"R_;Y(/3\@3>>*+:*+9?CFH;OY /
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M9[CX,1C!2CA&J>!4P'V;E#IY9GD3O(I-CP_OT9(:=5,Y*&Z9WV<N#TZ^_'"
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M_*N8@-/W(R*M\[^1[9/TSO+^!LIPHW5D'2\M!+)IHJ A!9H5.5-MP** :M^
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M&OW$S*YU?N U^:OU1*Q U="3C7QE*A428B'?0[%@V17^^  U"J5#H7@'12L
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M+TJO<@U;\7J.429"NF3>=\(BH9,,@$YL55:SL\,]^@#LE4-=:F'GEH!>AE^
M+6^NHDI'HP:=LSECUR<P(GP8HI:J^8UHO:[O+WAH]$*<M[LFX;]C( ]0A'-2
MM NAI-$Z53NKXVF,ZW$NW)R7>90"B=VA-.]3V@/UB'1T'!1Y*_$SX>.!RR@8
MAK,48 YX02,N 7)K6<L%TB?Z]DF5Z"/(*<#ID:DJ4ZA3M:N.<#1)U7/J.NG
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M-'1RTOJ0NNB^FU!MPS/SL'C67!@-321Q]4:Z7R'W94JG7%S19-9-U()B8<_
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M@FGI"I_A6&W:$8V_S/$S3A?CK_AJFF9'^'JV6+S!Y=OR,7P?*5VL"C3HP&(
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M'TH"K>AU38,0O,\6XQW #DEOMB12-X&UW[:[H-.5*<@IT@-;*.I3LI!.YU(
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MKW0A5]N3JUS]8OSJ),)V=99K'?F-G44L<D.&U= RL R4,Q*B%@XRRT([1XN
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M)VQ;A _*YO8DUIU$=E!"U92-Y+X8Z]FJ@3'-@'10>X0!#Z64F"-+LD\>9$N
M0]IKN'<Z[2JPPZJGFH$A)$4*@356H=!%UW8"IK8O4T%)KE-6J4]!^[8(A[1U
M<.]\VEEDAU5/J[U;TI&2<QW!%B8I6(D6G D>8DY6YZ 8Q<CWIZ"VW8 _U+;
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MNE<Q9V>Q-RC/7\#TR_0T7 M4;Z%=4:><6 JKRU-_5=.E1YBPN_J&K62_-V(
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M/=Q(=QOV/=Q$\.W['K[#+SBX0ACDZYY6\^_LT.KPR<_<L;OA9I@7&AK&X+R
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M:(O:%?FN6_9,5S<HR &J]\ZDJ1=Q/,U_Z&5'EHE2GAF1IGFVR$*F/[0$VD3
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M3(%T$9,L)K1Q8PY"E2>LD,,P91,5-&#(.QQC[8%P73)8&QWP*%D"D+1Q<LY
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MQ[V>KW/JM\;DC*MS@>A<%G4])-RH O,%T)"]!]JTX?DCH X?03T88X9M--?
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M91&<\?]_>U_6W-:QI/D^OZ*CW^NZ]B5B9B)DV>[6A&QJ)+OO(R)KD]!- FP
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MBW%8&[5?IK,5IV\IK8QUF4<@$'G)6J EKRF6@1*:4<85]UD?;SV>>O1YL&(
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MO0O!]^'[]99]Q<Z]]_"LQ@0M$<W71.\"JKJOMQ?.\+Y=?TT]5GLE,;>Q!SO
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M76=F?7/7/3.^*SMKO?!D9Y=?>9Z]]QOZ,'T*.&R@HZ\#,("7 8,! -#' "V
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M)N^<8:YR_^0[HK_4OO+]-8,V2-FT[1<D.VT?-'.-@#U!&-<:%J209^C.'%Z
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M/(WZ+IW0W/,R.3%=!KU&0KZ'B=%.RM<CG]4=)_@^KS =OL1<(Y^!4JIJ/?(
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M<%K'%Q3 72HVX<X6%4)AJZV*UN,&?6T+'VZ]2D0($6"?5@;G<B-1?KJYVW2
MB8@H_VCJD:<3]V&/#L#Q<@$.C9"8Q#%:GR6D"<)]C=VP6/;GN[.'!FZ)1!SU
M>)3?RMA[ 85U$_2ST":538EJ:=6]''<,&$2E]-_J8' <WE<<KWC^@$;"1U3C
MJ>6:<P3[%MKA_N;PIS.0PXXI1U/XJWSRSM=<R-0?C6=17KRO9M!R*J3#NEA(
M_AK2O3YU/H%5K2-K?F%P;V7WQX[1F O1'=^ZNBT=ND91("[=&;"K(E]M>7<Z
M15_L;(+@:'YVQ&(^=%ZHG\ "N@,_/+C"&O2&-UW5(;V_O,&^WS/1_5;R\O1)
MLVSM2Z6[.<5UQ:#QM;Z)+KA6YJ"N,!>?%@1FY.+&YW^V&[T-^]/#0%:P/]^7
MJ/&F ^(J8)#'TEYBS.A VU=$'!U8.C'M^)]R^@ Z2@?L89Q+(2>H[VL@'US4
M73-1'[H?UHR=6^3VN]M<^%U%?-^A RPO!M@(!CNH80O:M>QZR+H-V$*1P7#Q
M*^?-T2GP/4.5QA5+UAWXZSVP,QQD?#4MJN(9#*\-DK(6D/J%!Y/ #UP>:X"0
MCI>!N=6[A38&WW"I4Z<#Q8<12U?,=AF9F\H_%WYJ(X Q<^;.^^ #*(S'#^8'
M+>GY@0["Y[R#Y<<AP:]P2_=^LH^<](1WNB7![FBXD<4HQPG=R9+I$^S]7OYL
M2+G-RV$//D1%?K.;>UR4H,MQOF"3AQA-XLP/P: /?\!35S\0&^Z2=9 ?'XS*
M'9.(U[UO<L!N!7,)NH8B27,V)_"1R UU)WMKM(.]"T87/X^]@:ZT*NIE&4LM
MQF3>E/NFHW_TK/IM<VD*G[AA.8*5)&!\3'O6%\N_C(ALZ2U0F7X)[ZX^G>RN
MYG/GD[=#ET!N\&#_QI)G H\1YZO;8J?2U>X6TQ;R^Q$KKD;=>]!2DA$^HHD.
M"-58\#^9=N$L&S\]>:9/]+F5;KJ@9%!0/HP[ ##BVY%_2@>F4NOX*_HM:-PH
M@16!T:<>D\-+?*7ZK>-B=_2L,BD./19#=[YPG&7K*"T+5D="P[YA6^ C.DO>
MBR&>QO!W=9H@\88O)CH]I+$1'KYS^YB5^,FE4Z37P+TA->IP[GEB15\='^D)
M?@=.LL(58 Z14J\E71V43>@2WBC.S<X^)&AT!_9*6=6Z\V!L4&D.RO7US4(T
MUS/K0?M<S_2LVAGB36HJ;/J#7) N)T5B$A^/L'_/6;T*<=X,:CQ*!S+S*H3/
M;V8.+M6!-Z$/2?&=./ZXZ35(4\ERE7=7M8VS4%=+INM,R?7I2V'<Z%=KW;Q<
M.]?T1 ;-OI\NA0:R)976!:/JQA IL_W?<"XFQ(%I/TKUF.N.IGH6VM 5/?4*
MQBE@=+F2 (N:JQL)3U-S[3L^O'RX04]L+&&H3I^:@[Z+Y*)U5YR>:/>H6@_[
M^7[C[:!=;(LQX85(>U))I>K1Y^[#>#7\;ATGC^G()<O:XB+/K'+3F'=&HP;J
MLFM%"0>RJE&A$ [$M ?%I*=&E)I#3:!^W) >"TJ =8[PM.^HR'E^@?AYH][6
MJ2/J82#O- R2':JQIP.L"T0,T3&2&D.&M&VJ=+R@TH'S)7&[Y-P<;VS+-'Y;
MW*"PZ*1K]O+:;GKI:3/"Z9=+.DMN^52CYXM9=?A^Q%0J;%3(M6B2(H.1QX3=
M&Z$^R:A^*>*PIKE%N#EZY$R.K;E1.[HM79._7+:R-VYTBVKT3&"=LRBDWS*(
M@71[5$8N1,1/[VN%N8P7U'K!S7K7FU3O[48\M_MV'-V1G.2CD"YR'^T#,IM9
M1A9JH#SM"5RYJ4Q2B#>'Q64S1&]/(SR:N'W,1+T@Q&&:;R.LIM(,./'B,>/;
M^7<% C\F?S" ?;':32.;3KE1>'QVF@,.?J@@,-[ZVF.RQ/1B<2_(^:'9 >8K
MB:JGXF@M0^+B$B)/MLH(-QZ]3#;H^TS!(..%BD_5Y/7&C4_.!^EJAZ2U@PFE
MF73'_CCL,*D$_D5Y, ^2.M*ZB4J%.6&&4=94Y!8!QRZJ'Z0]K?/R\HZM1?+Y
M H6&* L)/@U@:L/OF(=2HY9J/4XJK\7<S26[N-PX)IO%Q+C*:B13%^\[+?:5
M4-UZMHX?OUL>OW?7/\VEG4V;UUGQNQY3Y@_ "!87+$ V"&G5%*5F:NX;71$W
M^8H-,M8L8"ZM*-;XR'TVWOQ>_%$CDX).?@WW"@F+7-HW]!=YHB@Z@B:':-!?
MH ..-W\T4A.(HG6V=T\BSWU7([\F/RT"ZS0,.@!&O$A2,$LXK (V#=E8GZDE
M6XQH]F=$KE3<WUI!%P=ZH2"GNS(T'IQH\'EF.=^?'X BN5(P5C*=XJ;LZH-V
M_OJ:1NE>(17!/ALP02@QZ0*)!=_BQKG4IX^?:3 2MVSYOO9N-%'_8J)1ZA :
M"G-<#X7A,72 :ZP!.08?&W,]7D6&CX1T[>P$5:N@KWAC O80H"X*M0;;[%1>
M@<!_T4!K\J4Z$/?[_+SNCBPE8Z^YF')&O[N66S$;4YOQ!CUNGR2;"^>T]:(F
M:"0.VD!#'!HMJV0"RI://]/.^&9V!'BHP99G:CM&C=_P4W';>']W/-:!11"5
M!7. #R<U(T4+3:VKJ^#L?K>ZCZ,KG[7+#G%JWK@E:*M0\_R\RNV916?SG(B<
MM5,=O39&8C?R[R@HYAX([*H]Y[+G.[S;$DU5BJ"Q1N%[70<,<?)\-<-S??,C
M-Y [5UAVL<^"@L!N^)%BIKN3O5%^*L8(?B?^Z?=IS=,CP6R'//;-W0,<SOD@
MM35F.G,SIO*-DC(G\COWML\MWQWN<)^?0V</[!Z*AJYBGDWBKR%)EK"#E/,X
M#.DF; 0Y.E3@282MPE4ZND/ 3.5H,ZX^99$3U6S<</%:36%F!D+K>^/T,BYW
M=;&@&CZWN:VIE%6'(9T#K7=V,,CFH[-*IMS0_=X@F)N_<FW6V#?F<8KC:M;M
M(\EA5@SAOHGG[#F"39N0>$,0_\/)I/@)KC:DU:3UY]Q 3<PKST5C\5@P)_X(
MW$*I?_ .S9&S.+<G%7!F(_;>S<T38X/(-R\M;A$,IU.J\8B6T82P&JU]C1]'
M/NW.2&:G*76T13">:GPQ^?'H86T/[]7^/*$7ID^K')),TO/T&YR[F/_BHZ;_
MYTX#!%BLCKP?7D&+U;#F+IO[[(6%=1=P>(Z.7_[<?"JIX_.G8Q$E?/-ER\B_
M6[ W]]9D#> FPF["II$A HC>L_@(VH$B!&D<@L>@V=&+;_RTP!$W1U,>%M#Z
M8!MNDUQT8!4.LO9>3GAT21N^K3BV;=E#\-H!Y=T6J]"B5RTFQ.ZSVXA\F,YW
M]Y>?#D%'3MK2X-FP>T%F9*F@XP2?-Y(9F,>E+H?'I?J*4CING(]T+$=^FPUX
M"D^#EZFLC@63U4BC4,G*)&/\S_=%9U\CCC)TY EG)8FX61?K384>8)3@_(">
M>@/A#[J%B]-MFN ;4A;NLM<I*8U?'K)JY_C06[&ZT5AQ[*:'@*KP(:"]&$-C
M<\H=^Q'$V2LWRTY\$^PA&572+218P;#VC1+F8[=\Q^-'@^HM3)IBQ0RV/;WL
M6$37:274 8\.%0H?S;EU7IMO:W*UE<Q/!QIU_02N$R 4*1@^(3C5.)#S"^(>
M-==G>":87#/;NO?=7K1JTS9F"DF2JFU>;XKS-,)2=+V"Q'-V]<6R79S+=P0V
M- Q62PK./.%3 6[^;#_"6*SYN?S>LW=JIGGG#$ZMW=I%I&G:IEA%%QT8>":'
M3*,#2M-[T)7)T76B$C[W&V3?J-^;2X2S.2IO?%*TK@V:J]DZW.Y*3E2^4&UV
MY/F-A0$+6?(96E/=<1+A3AHM.Y .', \Z[P#+8_XGKG.PG'\RF.!4)6DV*V#
MW6S^*4(Y+%'SI:;EM:#V>)Y_CQ1MEB+:LN&\/(XV>KUIP[=W=Q)_!1:.=C@6
MI(LKT=3<K2R'(FWJ=!"6NZ;$E]38(",R;.R@,WL903I,L$%4YTBLAY6"JO$9
M_W,7I1F>',VLU@>F([I/^T5'I]^[3ZPJZUJYIUIUV%M2.&=X%Q<-7<&,[-!8
MUXHI5WI=-;1G#AH8L2UB#3Z/C6@?"!R+;.N>J9Z+Y I5/)*YK"K=VW3'R<YN
M#6K0MOGQ>EX4\LO[8LSS152_&DA<D!RCW,<) C'<UH\PG@\ZD;F_<MY+M)/;
M<'\3\LM<E<OI"?E("E0B5/QC(VNTH8/TW*WL]F_G&?==U!!]_SAH5=/]:=-5
MTV>%$UCS\T(CU^2>B>J#%.*^+1@=$20C+4)J:Q0H/@X[CH94WSX3$Z5=G..<
MRN7&*2;L$JJHZ+^CO 6C\ I/PT-K!/!GNT'[F.#L\8+.#[V-''=*N\N_\5+A
MN\%/;1:F)ZV?4 ?!.EWI0'M3YZ\3MBCJH5-[+C0V4*9(D4&J8S>&H/(I^[V.
MTV\]F\T[7CO9E3EA>HV[LZ##X&<_J&TXTQ!3&2'L>#H01X/ZA?<W6?*_08UJ
M9Y>6U.??:O6(I'G9/[(P8:@7UYROM:*Q*> [ZVDL)/CT&]0A/R.M'KD/0QIY
MTGU;BZX9_6W/UV2B606!J3T+L"E?.%<WZ<!!R(RHT47:)!UXYKMJ+K6S!KE#
M-J?H156XO7I%WNT.]"IN);ZEQJ&GW]2(Y[@@\*ETH$&;N+)>X@\90=X;(9<'
MC]4L8,9;3JMO%U-N.&FTO$E^>,OIY\A*P4IY[NMGR=I/\K,-7[NLVSAE+7T%
MS>LG\C-FM1G\7MD\L#,T;CA)%_;Y3CB8,6Z3+=[,*\7:?[]:.;8^5 L#HSV8
M<KF'*1=[@\YED5XH!VLNCQ>CMF/B-,:T[SQI"!N51"B,I9\0_YD^=3?!O-@N
M+-MB>" C9W,MF#B\Z33ESI<7Z/RHQF=I8LQM@+01394!A_,7XQ7OGS%<YR&E
MX4A'.95K4@B7N^+UM-@/GZ^ % 65D8UIK568U9^RVX&@\EJC VPVAK,YZ\ES
MG:['VF_.6;]H$U%5E1 )FQ)S%FSAY#(V>586:&.Y</5!KH#.FX(3BQ58>T[0
M9VFIN(11P_J]^U\^C"SO/9A?Z?I2]T0Z_(KE]T:/TT>G'ON+7D"5(5Q1S\08
M\<C5<5RPT66\4817L('@@R;?M) D)AZIE8_)Y55'Q8\^?Q3  T<B]]7Q(QJ6
M27E9?DID([(P6>^[YA@1 ?)H]O_.HS%E@=C6R6$(C=>WH<NJ!8[/0+A2GTS!
M2Q!W@Y&(UXJZ.Q1BB\K"S_09OL[7.DDM/9Y%;=0QG:[-0$Q^K\U2'C:U(ZO!
M_'KV]\*?/Y-K)S7'D!+&YF>HF@OF=16?/U<D_MR8UPX_<LP$(U[2D/^D7>(Y
M@/I:!R:$>L6Y@:TWP5HX2.3#,YU12>Y]9[RU)-3J&>9O=U9ZG<K7S18B*MSL
M.**Z.92,(F5J0MBM!.0L%;[BX_CVS H1]:=#(%UVIYQL3Q)D,Y9,Y[K\B#M<
M>:L&,L:)YY^RD0J(3ZCI%".RAE\B]*!+9VW_PQWE^(('!Z*G+\X>]M<5%#1=
MJ1=/FVV8K[QB3<U0"QS/C+ 5AS;;O5N3%M4HT\B/WC)Z@MY'T2=LMAB^)06H
MSMSL[ZY!5[:%]\G,>'*U2^#_[5!TY1:,)$D''J]MD9)N$>"1*-1CZNR0%+MC
M%%$G_A(+Y<#0JYK.@Z'.RO<*EKZF",@WV?-X96<MASPPAF?1%'])1+_[KJ=,
MIV$"SD,!B:'V0AW-[NSIC]ZWO$AN;^W:M._!UL,.!S$74A0(\;G3"8>MV&TL
MC)(ZD_DJH/L8+$S';^D=W1,;L%.2.:M<V9M2\.Z72GP:G7QSZ0=5@!I.XR()
M-*._%$?EN62RXXEE']L]?5#^'YVN&RDQ* 'L5=P7&!G32&3B.'XB:1HV>J[)
M\GY$SHCCZ(/KHT=6M\A>H;Q2$XIZEP&.1/V9/%0U8@H)WWB@SD(-GD L[J B
MZ8#;Y*ZZ/ \=P++#J%+Q=;[,)FYJ!?SCM>M=$"W+=%C)0%$Q\O5F+:\QW#GH
MMD4-K06Q<:,,0F8""5GV.]1^E#\59&"S><XPX@$P1.AJV9H[T>8L>K8^3^YT
MA.3&_?WAP*'<OS\[&'"#QO3("&>GS6OV_-]W\((9R.PD!UV"[QK7>Z>JGTGV
M14Y]EC9*(\O\[1HRER^'&M<S/6W#H:_^D;B$/ 0-\CQZ=GX+OK=1\[<#$:ZT
M2?B&BZ8,'2@NA^]9\ 7)^6-D@H6,DZP[H.M)%IKHX[/Q/%SFQFB9-^1W O:]
MH!!%AH!)'ZPTX=\J];#5I,:%</N1]1-[*<?LWUGS'8>.'Y+\DB(E+OSI,=2^
M=S"B+$1SS.;J/<4NMS//K^1")1Z81?1$4]5!P_ ),B48-1E%J%-3H^0?EMWK
M71>/[K]>8R\1&Q\6JXV1+7WLH7]4510H+'E]7YI1&W?,IL[*U\9U/./(%0QG
M;)&(QF).U^(>_/-J$"MA8:JX""^ DUP(5];G7^*[3/1MJS9?'H]BF_)18^(:
MSIN-Y=G)757!)WRKDZ5F>%TUM,;#(\J*= S?E 5V:1F$^K]B?078]"0"1T2P
MH!!EOM*_-E@G!@>RUNK&&%1WHSDEPX.?2&\JKR'P1JC=LZ*,M+IUV%;@$*GP
MWA4=8[8^G^35M=E1RI7%J:7I30L#Z+CSRCSZ.\GPGS2\ RAP<&/0)=>^$':(
M+P@JD67G#6E@!&$-*XV3UFM*%7A03HC@RE.]KB8\IA'/NQD34$'A8?G&X_3Y
M0RH.R6WIS(SP51X;PW!7W#&^<TGWD]UV\:J<>UCC=)YIP;G.9#CJ6JZF"K3I
MCH*RM,[9A&L9G%V6T!Y-U2 >+&T?">=V<*5!S>IVYM#&I*;9@,1S4<\V-2:^
M\P?.Z[!JLE*X"9#6!,'6Z?5#S4*?<S.\ Q_IA0\=O2 WZSGPF-=#?ZL=HBNT
ME6LX=C*PO!:3EB'T<CE04'=BM!79"W]?Q4+AI@/?AO:\](M(J":5G:F0#5=8
M6WDD\J[?K#AM3]D(3'EXPW4V3 Z8>0]4Q)3%R%[F:*5^*K&^U KQVG42M$;B
M%L3":^!KJYS*7Y%%KU<*DX0&=RTF$KJ=H3FD!/RZ%<ETYKQA ^U8N96K23VQ
M4N='_/M]Q7&_XL;VPO-#VH'PU2XR'^GI##'3FSQ^,4AE^L*\ZKH0Y*Q+N6DX
ME]2%T=,7/1YQ F</G??'?>S/7IN3;)\<V,B.*%*O:U (&D]X Q*KFR"Q0G.D
MG)8@<,:(7?'H]';.WB"KT;SGD$*PJ;2*3-%>N3*WB-&UELJA]OFS"7DZ63AM
M(&FNXY7YPU<F!9G^W<S^US&GE5+EE6O-(PID4H6/C.O08DD^T1;F<:]O&7Q.
MY[,+Y<P)%@3):G.(.(GL0*WV]P?' _NL\:7ATC%%0Y]OT\].OOA6S]S^30,8
M/AK(5]#?V._MW-&K^\(@SJ#_QE)!.U+-&/[!X9>^[5\EB1TGP)$):&*,Z]?M
ML5F0HCJ %#6:<A5_Z/M*>6H,#L[VD&VG]Y)]RD!2&(]NTF-]0%6"9T#N@N8]
MCAF6R+1<P5NUQ84!9I]C;8ZH=:@8EFPF@UJJ=R8,I'X':4*D"%QKC*S&N>D,
MS:M:QI5JYW2X>=OVZPMGO<5(D _I[TL(HPF7$5*;4*R+ EW'1YS3RHI>KK$S
MNXLDG3K;=[&^4>21R_:./A[3:#0"GZ:N#1;5)H1Y0=WGK<?;FC]D?/WF\* F
M/N#4)A;P00DK?C??IV"@T9<"JNW=S')X:J>HU&[1D9_?D>'(SPF-R'TD 9V>
M;4X64F"39=A[AH?>5W7U0YV*)26^E#B8#/^XQJ !L#A3TDAY#FZYE.N$L*)"
MKC'+^D);;=[#;R_'\?NRY6<_!@! _0[:M48>=T#CUG2&M%69OGC90-'QFBA)
M0/U]Y)']]>*JXK4ATD&WZ4!BQ8P;^1 <L:2%Q<QZN]QH'B1V53@@K#+GW0WB
M-"3E[Y3V3:2H"9W(JILE]?P/!U09__$T]C\^7$G8&"] 8-O%BNUJ(?C+)_YN
MD1ZZE41D))E.(06#F&D]6(KH6Q<PH8Q6*% +3/JF*E,=N:9]U7F>)+4$8N?'
M0SZ P5X%3#P_Z,!/!6\Z\+;5]I#_25UF:0$';W 83?EDO)4EO5&T1(S#/ZZA
M>XW ')!AB<5#)-?IH["17MF7-#LHR(EI;' Z(,T(UCV,=@/SVT_H H21HDM0
M:72]<]"T47U\/L&7/6+_J,E'TM$U+W)QKDC!/LZ 78J<,9PO(NZ>S8<]E]W)
M+<T8OC3C!FRR@/8Y[_Z-BN60T)"^R4^0<&70MB9=T(>\"._\H@>%/',:5EU1
M%P1/Y.MO3#+.C85)AZK]@,%H1X8; PGG&GQ\4Y;.UXPVOU>RZGZ2/ "6E_B+
M@DQ"U%)\2)$GBF1X>6!=MBMG?.VEBI+5I_JX">7[\&^)T V5)LO@NB3R71M+
M2V8KQYJ'?'S[ 8BK"*>=C;^47$V.*?NMR62GH:'> IJNG'=8]NJQV*RB+C?H
MN(W3!DRW3BZ(G>3Z@7*2D#&>VSC)-CH^MEB1V*BA+OM97[CPD%ERZ-W#%X[&
MOT*U!E#;244?QEU@[!2[W)$+6)4*R_.SAR\A _2%!,R,?^KOJU,AP7^M4'YZ
M<SEZ <<2)9\U\.%"JU%/K&/Y KE()I*,N18-J-4_+&M.NL^+_Y0G<X5L5;!2
MLKAP1!#'=\1N&E4;@NQTH2&5-O>BR?TS A0>35'YQAVAA,;:@#T:<?3L\R5+
M3 K&/=Y=Y.-'1ONW]^IA3="I$7&_NXZSYOJ\R??L0@\L'T"5--A_M#?UNA?H
M]H.T:KZ_[B#J0<5*CRO?UCH8-0^M($7/1-88%CK#\7$D<UTH4XS :T__LD\M
MRA+,UJ$JY?XB)T6P_>Q_6VFUGWL\<93@%!0\[>W,,D=$K%A7QDZRAKW)57.N
M^%P;A]^UA?)Q.AU8)"-?W[ 8A4% ]:8RP8@?IP.1-0<+,:B1X2:'RK[U;&,O
M<>,4Q_'3GP^KC95=8VB9>0(77JIR'?KR<73XYEB[;Z#WJ7HF+KF%1)VCIS[^
MU#]J<5] 4$M8X)1B;=WF&[ZG14\3X^ZY4)N=H>O(,"3^BF-QJ9^\YE&_E.4A
MXEV.T?N1XOM_9'8IA7.XQSZN9%&542O&;=)8(_"CAK[\=>*$&THS<_[%LN^O
M!P]<^$II]A]4^LZGIKH)[W7T[6\O23Z>T^FRXS#OS?<378I:3<89C73C1G\&
M5FY/'K1IG[M8H,456?@*DRKC?^[(U Q3*(LU7L/(L%]NN\@ :_2I/&5C;]DL
MG-WO^I>VU4?Y;[TETBV*M+@,>9A-8JH<4N&<%@=A#K=N)7]$U=;Q_%(/)CNZ
MH3N@>"@N1$E=:#7LU?@T-+L9\7KPJ8@W6R5+MM!2S2UPZ.OPR2VI1_&M,=X%
MHI<]X@H./+1SNR.NUX8IOG;^H+]I-_[,0ML"XDPQ&J75GYLT<THK0V>B&+.W
M#5-=+&[%530@N(..$,(P$1I&#D2KQ1;2;.S/<)RBWBWQ!P<['@7N.WT1"(7&
MH^YGZ U&IXOV:Z2]7#"XQF/N"%V$C4"(9DAB-!;U<!N:5XIA=7I0X.WYD.6-
MQON[6H)''[MW*K  \9IV"4CH^OKP.C&?9(1'3'5G3'<%FE7VE:%*C3P#&HU2
M;C@X'>JO4GY 6[,7/6=QR-Z\5N9,3D2,Y\@MVPD?6ED)]DFN0?%Q!114MVAK
M%W+=SX%H0=*=ME&6*=*$.*H8HRBE ZM]1'/-G'F.R6(H#TY^U1[_!B>6*HFF
M'$^Q%:L9O:PRRF%XGZ"P7@+H[BDB'U@L3*[%D2\9$K[@O'&+H^/-ZZ$R0R>V
M%GGU.:[Y[-LHO<8P6?.I7; A?G#;C<)CT9IYG&#12 =XG *ZUKJS<Y=4KN<\
MJ[C6W5N0S1^I0.,JTQ.M",2VF'V;<9P.J57O,M09JA@<J]M;+@SV4JA4?Y43
M&B:!^XG**;VZYEKZ@Z0[DU#?!9^R: (5 MORSXK]1Z7*:N(,<@8.9B0" 5Y'
MXQ_=B$V_BU<F[E#XCA6"E/L,_E1N*I&0^T.P9(>"5@BJ(3M\;YV!'\8.S[V*
MPN&?%YGZ(NK+$!D)R=\_X1MP"P:9'9/11MML)[)JM;Z#[X]_%77Y_^B\VIO_
M\+&= .2&0BY-,,1Q.X\.5-Z@ ]R4U[B7?W<TD2]WVL]DIJGJBDE6.\]X0V&\
M8B'[XXNBS??-*YZA9YU[T2M$"/5(F3OI1;BX@9++%TK"R#K)83)L<NMJS3%0
M"D#A-!5=BM)ZP_J>U,1AT/;Y4'1 N'C,A X\]\92/=QF7? WN-5$A"C5,@UF
MW].QY>YS%;ZU%*S]UFHGGZ'\]9!VPS2:E57[#LRQ##,2."T=*7.O]"O)=WKQ
MSO/;97&AEGJ:"8?-X=^P"ZEK,61)Y @=N%$V5"KXH1;ODW,R6E[C9TK' _Z-
M#'24'E.!]ZZ>1FS%/="W?I*^XN@ R2IJ:JD,.F[:Z)MBJD=,Y2[-<^R-ZSS^
ML/N;4<>%;^=:/"Z@"M /NS0GZ  13@B\)N"-'G&(>N4A8JVS_SQ>CW+5Y^0=
MCW1O=<6\+D&KGP_'O!SGHAOOD_2[S^S>$T:E64R6YR]T(/%7)QE(#JW@#,3;
M$Z0CO)"'==U<G7N*"^SYVB)3DR2U\NI5!5MS7!'U^IJB)--O5?#'DXTA@KT4
M#:R2+>N8P:?HX0X^NU'A.W'#[2T!=W^MZJ0@-A2#+H*S; BC'K(DTH$Q)6(@
M@7.-LR (UG?&(KRCN\^JW6T;&OMJ+?OX84WC3H7ZAE@'%@F.M.5F"^*M[]9S
MCD7;_=,.FONB\U*N]=9DK/V@Y&6A#<^ @R+%V=BV14K<::))5=8=8$H"*^*]
M,M[V[RM&163CD#9U[.KRT.A[E1E;?-%LRQ'4LQ#K3_JAESV*]689PUE86,*F
M("'A[D^;;MQX)VN+-?\Z-=3A[N54]3D^)MA',R@+Y1@@20>BO-_(2AN6)>X8
MU[YV75O#"3I)V(<9;TO5;9-<P#EJ_)2D&SW36G>BUD;'C&-(_7 <-R.U7R;Z
M5P9]*[*]8N-7Z,K!>Z/  #M6K8H?-AC^JMH;MX9^L;NK'9(Z"=K::9J(ONOQ
M$;_49OX=)M%$ZZNNIQB'DP_GB8\=KSM#?0^[#^$*Z5:?*U2/:[(LCT)4KUJ6
M5?'>8IOQ4.?V46U3;6<28ZUOE1,^VW G=W6I<R)XZRLVLH-PTS%0OU5[F% %
M[:]CH&'J)*GO-&[NZ3P3+R\M-TND Z:5+!UEL>G[+LR]FEHSQK(\9Q!?JQ6@
ML3Z9.B)S_"J\V5:BMI9Q)^F6<FW-@^!+9TP.PZ9TRIKG;S[@?>G<:=MI*B,'
MCVR1/F7<ZPU3_HCJE1<&>R(?!#N;*NX':Q[-^)"5;Z!;]-ZS^5@KF^692X_3
M@X8?! B1E%HSF8?JA$A?C/&3D3*CK>:?DCI3CGMP"IJ;J.<Q'0Y\JL.CT&AO
M%2?H7.7-80Z/K"]V+NG_^D0[ /8-\[A.FD3%85;=."^5-![@MEU6$3QLJ>,9
MVN1M'\JG*_&T9Y_N#R'(WP3?(Z<2J2\X%!<<_H3<7GB%OY=G-4[D&2>)*UO@
MM=VGJSJ%9:ME=F&=A"--<P;JOK"S)U 5(6<1]6>].3D6=]31C>/W$8<EJ]:#
M(=>U!:Z\%7DU>X%OC!I:T#.5] 3.K2_<*-YZ_(S'L5,=C4Q< UPKEM/NI0HO
M/+*A8R'S?H5\0<(&I:Z(2E?>&T,F6@=GN:T;'LKV:3L=LQBVN3BG=7M&/'8*
M5]TM4+*SL)I$/K HA'KFA1$*TBY/,D4:1SU\4*KC$W\D2_6NO\]SFU>WU[I[
M#AV0SATL(JL'00,]64ENTU=?C;W(M@JG W6A#IJ[J!0I,("]<>3Q@QB7E^+C
M<[-($:L>VKF1L]'S0R?+N03O2PH[JG8+5!CL"DS1@5@-WSR*!YZ6F^6<ED$'
MHM?+CIA]V,S4EV-PK[VGMIOD>.[)U FU7^F!\=5]/@?U3:^^$2\*9 +S*5Z)
M,;4G-!OB)%V71H/^U.U#ET-6U7+\A!M5,M5(@;SEH][/-Y5%^6:=+AOOI$G=
ML6(L."G-*'%X/W2Z@]I,JO[H- IO0 N,.\_!OMCW/8S[EI0M_?(;JLXSH05]
MJ !UM,6\J3]#O9A2_B7$MW_.K:GQ?(-)8S??2:BG[4K?*&6=Q,QK##</JOSW
MS;D__L;)KT/:?_]HI=\NFOR2!D\[;UU W8# ?DG4_Y4G3AE^I5]4?0B$@&YV
M.SSJ%W.IWYNL5^J3HJILJ/K3&-(=^Y!M^8*JA,,/[#!:#'T7QD2Y1+(O<,H4
MQ&<^G9[D.AZ<;533[[7H>O-[>N3XBXLG9DY=;!-D$=Q79PK.F!T=:+]#4*$^
M'J,#NLWPG) [4?OX&8:Y!32>*R3M)72CSV-<!K/C8G*E"I,HMW;41$]YG_YB
M=AQ9@YU*J+<B"V?([>$Z-EAEB]=F'>^'FYTB5"4*ZJU>9+(8^/^H>\^HIKZO
M730*B*""4J03%!"DBG1$\K, (@H"0A"$*$4Z$1!!"(F"@'0! :D1 >F$WB'2
M.T@-14KH4A-*"*3=^#_GO>.<__N.>\Z'>^\8Y\/^LL=.LK/67/-YGKG6G',>
M9X!F(B(Z:0#NQGM.B[+G'F.VKPY/FR^,RRS5W4=H*-1*YP,68I%>5E R%X00
M0 -\]&^_!'LT+%N6Z^Q>ZHSO;-3VBA3K^O7@##OI'Q^_OO_\MKHR-IWV%:@+
M0&ET?,TA5+0E\<+"_EFCQ,(4E7TP-7Y?8X@H>=2&8/$5:-4ZG]H&OSP, REW
M'/Q12K%&7JAX\%U91$&;#W""::DZN4X#,#V@ 6+E?Z()%VMI@&$7R%F8!M$;
M13;%>\>$D%5M,"?I,[#"85&CH^RW5&Z&?%"^B-D[;AW<\_T ZZ)YS<!H69US
MWV?&T\:Y3V074'^#Q2$O1VRUY/#NQ>_R2YDPVI<LV_BZI,Z'78$)DB>?G[#V
M$I/_^NWR&+VXI9]:D@TNQ+%86Q2C?=H)BZWII$=&WAVU9>]B1,T-37(:#7#K
M%J],*C]VH&^OONZ8HNWL&]3F%_,1=N_=]\UJKS\I45\Z!0K?F1S%WM#$IPFK
M"RX$GE531Y4WTADTX_P(_(JOH3Y>.!1O#U5JTN'.8 &WD1<.C;7&VQ@^Z]J<
M1>DTWPSAOU1H9A8Q-55%?+Z_CI6VN?;')*:QQD)^L*M="?P-YD54+B2S$,,0
M6+=G'=V?6(KE$U3$?U](+S\5'_WQ4GQ@MMV2Q#KB(PAG( M95&VC2+>G8"(0
MV,MU8R9#,8_=I+?92I&U_7.>+TK7W-48'=(^*"M,.C^U_91&P510JZ349.YO
M:FJ^W"W&'.8>(P7!L_, ]$*:4\&D$U6$&%5 E]G/[R==<O2SW.O]>8/S\4Q0
M8)Y6S'.Y>-+Y]9.CS@$3;&<Z7G$;/&V63"!M=OSJ[+:3"R]U(QG*5K5Q9J@)
MQGF<O,S\@YB<%D;FOFOVF9+-JME7V9ZMNKO&IS:H\:K91W7@V+'CI411U=3<
MK*SWV-'-_OS!RN8*(=$?FP%*PP1$)E&OX&[B2<)OHZBR+L6"R#6 PNE"\ 2Z
M,G=+E<Y@=;'4G"4H\3&BNGJV$_F2VKL'FFA61 ^Y)U-WM<;W3 .$V;GU>0PS
M(DL28P*VD!"3KBYL;@A*<E#%8-NM:K;Z@%6RV/"<K^=1I[#8R(&L"DB#!C"N
MBQYA//1YD87K*5D:T#JBVS^,.D@5FFCFV["6P_N$'#2]J_)'2;7>-NN]E1#-
M6UZT(60P,OA<\.T=JYKM5-)-HO'1@G5Q@:]NJX9<:-%Z9'TT1<(@9&HU^!1'
M%M>3!V?UE\:9 IBR)QWG&:E<,S/0BXX9?"/-[P2"5MJ$G\74M8!,'A$A2\6W
MEN1;*3SMG^^'##TKGU6NWL;R!I:W&P84\2%8R16<T2@PIZ;]M6-;<?<Y_=7$
MW#^^SX7XU7Q?.N<,B.W.#^W4EQ$1VCYHH6:^/ES0(B9,4Q(;>5GU_G2#I_7L
M3]]H__3(NJ,SM5(4C80'$[G\I5.%E+4UT_R'P7K&&7\F)5%U= (::%ON:W7H
M38RV2NR?C?#XMF<P0&=PR#8U\G6MLW2\=, +!T,+R=H3\DHZ=8_QZR<VWVK#
M#,[>[,8F6**ZN98BTY;!B?N1',;P4>P>'&ZQY7=.NE.5NP?O5K"W/^J%K9<^
MN-=% ^ >"9TZ> 9IL98:6QC/,NYA:U@9.-\E>-UQZ6ZRVG'I_$/B$1;ZLTFW
M:UZPB,JW@9''IAOH[<B6B,?-#ZGLGC=6%V#(<SWV[7;UBDW!7$A^66;T);\/
M^[B98(7 ?FJWGTQ3#,\'ADWY$6ZC" Z40*B6W#J_0T2C4;%</#;BIUU-96G;
M[&_)5\;ZEZJOQ*ZW1^(T,$'47\*71C69\5D=5.'A%RYNT@9H?W_?%!W//,!&
MOQXH"HZ&"?PM_L4:@XW^@*53VFW(5MXCD.N>)E)5;B ]-14ZUV4RT@RB%(!>
M[E;JX=D7<\G7&E[';\Q/@::>D0J1\@/[3<V$H=9F+_:T_*75C3'*1(&&UL:L
MO+\/F1U>8KR4U'(7V'3TO,K"<:>F"C6#5Y,G2K!_@*DN(7E]>X$<OOX/\8PJ
MA(N:"AN)1L^+7.U$$MAR&6,>;H$6LN8OD,47H&>)-Z$7B);:.#*&9S1[Q,D/
MIC)P]=/8^PXN.X9-B!:\#U%A2%;Z45/RASX%L31 JSHE"2K4E4P 5KUK^%JB
ML'I-(;I.N89D#.]&X ;\Y(+S$*UTQ<\").2T?WZ'F$+;[U7GN:X-P-:TQN<_
M1<EO2ZI:Y?_=8]Z?Q+;V%OQ\:I357W544CE:?0+4&+9B?P]C*"$;X$UC0F'J
M+Z]E%<RIB(:IL3*+3\6P?O/40S60F>D^$_TK:V0)P4>L,:H;L[KC^T:<3H9<
M/3-7=.44R9;@/]:=TL#0%O'MG%<GWIII<FS-"E4ZJC6_X3[#D"QK.;K%6A.-
ME_3CJ9>@/"Z7-3ZM@*HFI+]:QM3#*B-+ MYU9:(^:DF0%?#,K>Q\UD2']FJ$
MW9C;IQ>]/MI*#CM] @@.%36M]HMG11P^]I=.=BX]M"#X\2^6;QEP:([;YKZ!
MAU#;$&?)YQ;GIS#WQZJ&F(C^%F-V=0W@QC&E/(GD]\GOF6991$Y]&( %D-R)
M4#T<<EMH45;QWLA6I9N*I-OYMWX!]7=8.:%\8E<!9_3$\&,8'Y(6M06-:VKF
M=:+>H /Q&HE]VWB 9Y(&*-<:KNG[_,/G^$_:TFWI=C@()DH#! O@=4UP/H0:
MPOQD' \).M4\A.X/@PBH-BLT /VKWGTU'Z&.Y"T]JW/9F?I3L%D=FFMLBJ@P
M?N,F='NSA%*CN1-.4L2JDCESJ9=CVA#LOA74R^P$!T)5P6]*#(EG8*\"F828
MYO$QJ.66:*%++ FYW,4!B%D=WKU**Q8[<^MX6X8Z!+!LNJNV;+?_WJ:/5>47
M^%8/\X\;7<.)+D%!*5\.HT] !M/DF)M\[E+9+R7;]-RJ9\C-#AT'X/6U"/1"
M$O52JNY77TB'WWA&P1E;-TA/[8>8HP?1:E->&RQ=F7\@3.2'1#<461P??!0"
MTWOE>GA+9XWYC6<FJ5QGOCU2 YBG)O+!_%'?A2AWI1R4PS>;\BT=-BE3VURO
MI.]-$@N@GQ .^"_A&]3V7Y?I#]ZOF8[JA*4^Z.DT4'^E&6S4H_6>0VM^&+'P
M5?A4D&&8,H+;-YI E-^]5N[B[SAY\M$Q6P3Q,TK3VCZD19F_'%,^9OX<?2G2
MX.G?W6278<CW#)5_[29[NETSP;)?WDA,2<E7^%%9-G0^E/E_D#C'BMCYK:DB
MW\*E([)4L=\^]5*ZA4JR0^T>4_?C6+Y3IG,-">\9A=I"F*=SV5->>CPT2&OF
MFMFU;Z"S%NE+B8NO&YM'-/2RFZR[">Q3A833#<3\;W_HH.->KH1F@XADS'49
M7MDI$>T!5,16B[QFUU';^M'\ACB#30>UH'G(]IE.-U(#%!^/N\NZ?7=PN,[_
MP%1G52R#V=B%< ^K^AZ-!<-4<4<?J;.47$J\<_6\ZQX,I<IW7.WNUN1GA^E
M5O%L*1,>P*_"C.FV. .W7@)3>Z@]77,V<Y#4-1)E&QD,V^'1,.X<P*3G;V1E
M[12/D'RT JN-^MZ'Y[+/S<E9E R>;+O,0-N)-\/_P(5@&ABJ%+&^JPTN4.9"
M,=AN-EV/S2.-W$*P?AA#CGV6W@4R(5KDR8IL\7QXGPAOEX''[^7J)</G> ?5
MG]CIG5M86VU=^P4>7<038=Q-E47S!KD#+U^;XJ,*%)KJ#T :CJA?P# D[M$M
MR8-D.4V&Q8AJ=)3>90V<SK.A;XG*5J%\&Q\YHW4MB/?:,P3'R%=*YAWK![Y,
MO\VWO1ZR..'=UME6@\X3#3PK&F[^J(T]JCY+%FR08U/*&RF4;KY^<J#HB'I*
M0:(=()SP7W/7X@V&[SYSJFZPH ',:HUMJDU^O0@X4E,SP@A^5D=5*^W^#4=,
M'A!':(!VZK6ZYG.A*7/ZOC:O=N[R/O^P74MQ5GB7*, L]_"O6?G^=[/*]5K=
M)4J@/[Z1YX>]1I?BV2)R72:DOP])36^\C?U]7U#_['GN%CY 1L" ?Q>92Q$+
M#=+DQD$>-M,G\(W0F</#/!N7=,5'(=,Z]\ZWY]L]>=#-+-Q:;S@U0P!-@!P@
M,?L;.&?]$J+9_H/:FG!<;H(21[*-??3]'F:I7+9&H=PKODQTKV\B?WR%'T0)
MS:03;TY,WZ)";/NKIQ)W?2)6R'/K)VER'.8P)M^)T,8Z]$%&)+GC>[CT+GNP
M%MT]!;J203AT=#8Q4%,?VR3:?G7,_!UPNOK2\V/+YN$&AZ^Y[F]+/# ,(\V_
M_[6_8_FO_1W0?\^1V.,A<Z IT';4T9M=2AVJ1H[\C D9HS1TH:ZC@YKN%<#;
MQ7A/3)+^R1F/8_ :W_(&#> X>!%JCZGD=%A7U[Q.>:B88DG8V4(KXD.7((&&
M;3$1UK*X^:3ECMP-1=W3-, HQ\QW4/A-9&<3BLIRA,M]1$S !U+7K$;<E--Y
M=$<SG&2AWYYEOLN^(GH^\JSFNX]VWD]<(%16HP4/+ T0Y>?SZ6JD&#\AK6@+
M%.YHF#A/Q(8W+5%94A<06Y"/]6MA]A&N)W-9*W2%-1?"- W"'R7MH;[E1T,E
M"$=':6[[1,C&$/.&"\ER<L; A=PL?B*Z#OGW:"/D*Z1Z-^0 R4(=GKLZJG1;
MKD]GU";D5Y=#[DSVQ4P5?-Q=$8!=G*'08WB)KWR'D6^;87/C^\)[9[)\;'+\
MOUYS3*4!A'50?88S1U2#B':ZZFT=H@'TLE#,5]/!T2NIB'/SRP%L4(.4EL>=
MTM['2+N_)8;.D$\M0J>&6J83RQ:@%S;J(W']K^CN1G8UY:[$Y].#W7H+IWJV
M(6>H& WA5"QZ6K&SWCTV=_J/A7=3N_Z%]"_2YQ6"&.V"M0%L>IILAUL01L0"
M$H2KI?*LP_]"UQ%)E/18#%&&L'U'M9[B4T //5]SAZ]O0C1@SG\#9:R(Q9"F
M!1I@&[@-W:HS!E4?"QNFUBO#MGY/DB9)73G^Q <CS](=^'^/'*$$;M]>P;BI
M:$$O22&G*N-S'$G5"1/-FW^:&Y!YP H:H(4]5 /SDP8X-;\A#, U'1X.1CC)
M'($UE"OC>E?%Q9.366P,C5WVSRW]2'?*ACGBQZ.BBE3,S$[&EY_,6':*1HL]
M^RI5\.$]8.$4I 12 ?V;3-Z&(@&F:(#U!%0/9)J'JH]NER>Q6]-O')7(%&2O
M)(,C?*R/J%_\U!/4=&6RQ*J.$ >)[PZY#W*W1DD<Q(BECG"7DZA=LJ@6I^RG
MDFG@3?]&P1MA-P'69^<,%'^IJIV\0R]\15R #]XEQG38P +V/5S!6@VP2&K5
M]J*7Z[7+\$'/\;<37:$A?0KF>?X//4:'])')E>!?- !=Z-@N(J:HDRY/K%!T
M$C]X<>-&NVW<5%AK6%;/-(O:>1;&P^D'S*VP6]A9_8Z4[9"HK*D>1 'D4:GE
MS'TM)Z%HP '0Y.>&"YH]+"<\=]OIX?IB^\L-K,/61F?_X'?T';C@WQCDF]$<
M;5!T(]C/FX5+\=FZ5&RV1/UQN?3N23"DLSY=G\H2C-NP?':YK7U.LKI.9"MN
MU=+ILW![7C +$'?%^M%^_WGQO@'$?;\O>ZYVBSE]4#.X(R:3?(XH6D*&XW_B
M)H*4BXMZ&*Q^/Y]3?QK.;6_F"M 7K'_/_)S ISP,'YXOIP'"$ ZW7TTI\V6-
M'T@O:B>60?GNQ[[OB?H5O]*LWOE -%--C21*X*)\!6&M9_Y .-%8<2I]<#X&
MW6&A)!'8Y;OWK:\KKA[GOM5L#!A.6XLT(Z;U!FM*MYMD'*W,^SNBL?TWC@.<
M%A.%L]W<K&>LZ/9XWA>T;46ZY@LE>!'O8&?Z;FT6.[2#4_)JZL<<M"RX]NQL
M8MO9N#V_[3VKW8R67BZ@1%'RZ'Z5Z 0\^\="@BP&Q$530DC;S8C)YG'TD6OJ
MV^.PF*:TY8,_D$2(L!87G4['$7.*?&^13$@.),W[\!D"0K1_GJ/G2%6%3M9\
M#TK.)]TXZ1?2J&C2K]D;7=F[M>_:A%TN, [.STX:@B2O'8"'@17(+?#B?,Q;
M6XN4%4T%K$V'B7'=QQ[Q'KZA^,LZ"^Q,80RC'HSL!<5_#U B+IC-WJ>*XI_&
M+ZWZ[LC&ZAVROA"#>Z_;_#?SRF[:Z;,4A@O(M"]F;E_O,MB]MZ\23F)?ZB)S
MHMJ% 2,E54.,&\:^%8]JS.+<M,SO0G2"ZK>/7_WL46,-X,)T)6"".Y]TZF9$
MHJ!-@I-IXJYB=2XZ&-;_[90#$RH;W<S4E2$\SOQ1:Q%5R940]IFYQU#':MPI
M'P3_+<FO9\1?FOU\F;X</4D7P:]JU=3S#<UWLPZV4=US_XU-MFY8%%?/K^QK
MW?B.?D#6^ZL5<(\[$Z36A:4Q6]XR\!TK_>ZZ4*U@#K4AZNTN]$.BZ&)2FZP/
MW>5$50'/^88PA1I5O-SOU-=5<DB(93MC&BJ*?O*/2'C1-?N0SI[6+U56PD$=
M]K5I8N\VN@S6E]=+2 OH%A G^2W>TU&+O]K,'G)S8\_3[)SY?M3>#6;4/P"Q
MC* 2K57<[K\BSH035SK85K3SG(2 WLFE+UNT&Y9K>@+)?H4\7[&ECW4JJP)4
M[5Z^YHVTGY5<IY,7E754'56!/B1*<I56UP(,L7,-'D5ZIZ$:6D5Y$E\ >GLK
M_Q18_N!.\"?/%F)G"I\5N?^HK@O1]__TO$OL9CY8AYGI@6;@V<X+UCQ"]_A3
MLZ1GO,?2S%B;+^18J*"M/SX%C], %8@MSF*8#8Z""M?4+P"%P&YYAU:&J-U/
M\O&@ 6!VB\J@UG:%VV\7 N&A0-PC2(C #=B=Q5DJVJ6J:X7@M]SNP/M(:5:]
M=QMJ[Y7+GF!3=M'TBA#0:_]:.(F3$$B'L7<;Z NP6P&+$&87#F*\?KE.RIIA
M_4?QWPJ2/=[VM^Q_]H@PB;"=0D5O-IR+S(R,N<UGW75-@MF269Q_N*KU;[II
MY/^9I9G_O[C^#TVPG4._A!QKQ# BFGQH@&PO<""F"=Z*WO,6/DL#^.W2  ]6
M2V"&I"8(SI!.3AQT!(@'%/ J/!?VOU%U%?;'C;["^XA@QM[=(M^2E:?[@DG5
M6,O-ZM_ ;DPI=2Q#9:)9D,R$=_A$ON5/019-=IRS_'VL)]<ZVIF[XFT/DK[4
M?=ME_PUUE@80' +BTA KU^@4*!*\]LX,*&21EL'Q/;RYOFFK,?GDC .$1;MM
M\\EJTS;%"I@/NM#,XPM>F _N#,.ZW905?:3CM'S<IQ2MV[]WB\-\@4UO 7 &
M<!JMBH#&Q$P[=+)_LH!'83<3FG[!-.+NRXNJ1Z]B>X\C0XF?&4TO_ X1%0FR
M-EK:G399]&G?OEVDJ;LDJW/2TBE6^2FG\2:[[H,$TR[23TPR9GCE6',=?#)Q
M#39Z3-EN&DKO7/U5>&]CTM&S@VH5I[MIN"6!^SZ*'?H9(&J\=]%%6$Q[;&>M
MJ]\6>LB247OVSK]*SS61;.&3S0J-Q/A"XKV6Z5E,Z!M9_E>5*4N/OW1X>&L(
M/N@T;9,J/)WY-'(A/NV]U@8%J<SK#?V 8-_YQBH:P-KO9O(Y^VZ![L(=8##\
M/LQW9.<-)"I#L[)1)_H-1IXW9./>H_YB8B#[DK7[F32%=\5.8+ SP;!G*J#O
M'II'_:5GP</HM(D&:Z>:HXI-X"244(>WKELB&0)\ATR1D*JQ6(PANM'MZ&)_
M.,2V&^Y@9NIN'L>FWH*BFVU@!/EZ!=ZA99ZHOQ0,-L?]SIOSC$G>SGX='3JI
M*!WS.'<,TPXIVXGW*H*/-)\.'U-9AU)'MKZEB3D.3A%:8XF8/[K;L0663J *
M4(QXW4RYI7C-/[-S>I=X#E\@6)\5JV$5694EI?5FM#&6\%MG3(S-B\2=E=,7
MZ]&&HSHPNE4PEM$ GY/:H2=++VF 3$-K/,F-^LL"^1,10H#@8C0]?&,LTXN+
M2\2>T  .4>";#[DB+_,]4>RTU%SB7OA[?A1XS +3H0%*5( G7(<H&H!)?V3'
M;A@.W)#F4_G\VVJF,3UAUL8>^(F^-G?C]84,N"MJ1_,K5N@+&$I,69!ZF&BB
MWN;=#]O%^1,&B3$+0*%I9XVA<&40AV/\;WE"<$C^:PSK,.<^;PWG2BEC; 6#
MR.FSBV@C+4E?"4-B&:[+"K<]+4-(*8Z0<=5Y6V<U_.#V>&#I"1B[)_I@XU-.
M<O3I#W&&.?!M7W?FD4:)G'N>;YNJONA==^^P!=  4LU7LPPBG4Q_U-F73+M!
MN]M$4&8Y#[^L_DZ,L4(44D.7A[8><[:0GOI>4^=QR3Z2ZO6_Y*:B#?] G07N
MN60HT0!O,33 P^^H0(2=0/<A^\RY-IXGW[O.8X[*KZ+^*69</K4=!/&G_NZU
M)#S'_SBE9FG\&O1G0^I=FV?72TLS^"XU\8V]PI.L3Q^M1J![H"LN1T%MB#U9
M)\3A'Q[J>VG<AZ<5 (WX<,K2\ L7*]96'M+PC$[H!A<K)HP&"#8<ISY8P,XO
MCAU DHDF18ANSR-J,Y &N*M,*G2@ 41X09M3B -6LM0$:%G=GP: L-,GEY\R
M3M</G\\##[?0)TP.[<B=,=#V;J^$NR&5\NF0\HP^_%!.<U_YQ5?Q*.<4,&$V
M.C5/]G<*(NWJ/D%K(2>\A@\0&_198:YYY&]Y/R:YT2I4J \!SC9<Y<;9@3EE
M&[*Q?27NW&O#P8U[RZ5\,U\Z#0P?@7L@3%J<0_B*)>%DK&2NBSE43LR_,(%/
MX9_WE9&W<3=N=Z/&MD$M(!:T/82QIT@N_0<1:E"NK5?EE+GOOB*VP'#M?'1[
M!A<<P+H]L/%2Y(_4+R_D?>3:QGCUV/[>M&_^6-&ZGHZJ#W3M6,)K<7[*ARX'
M*]WS\?IM1_W4&Q.-BA[>0$+$)E1Q2L#LM9B]T^ O4[T7HNI+D0<HNAIWWM82
MTB=X$(.YUH5X]%)>\#JLWFDR7.B5[ML"+63.G<8#HPX,SQ/]=2>JI*-,C&M&
M1_86U;87A%T+,E[T\8BX#[)&+E7YH;;U;P01O(F?VATTE%NI+C&;$/6O!I4;
M(_G&X;DS#3-[![>WFKG^C.;S>S=E;:Z@5V'0OP4WB%-+CTT6KR7A3M:>[<.N
M..1:Z9]))YB?Z3S/"[PA\17^RK;/!Y5# [BSAV=<)X)P;S'/<='YE/@"K>(+
M%88$WQ_];H+9)5/<204HM2%N/(+,B:0:W)VGMH A/2X;AL3K8'+J=@PEE XE
M!T_'_[QZDT\#N!C%2%46!Z@VIN_.K2'CQU+["JOG&P:@TG<L9HM_D5>(,?A;
M[>C+Y ?>NY>=(=/U9<$O5(7O/R%'I&>Y.A=V&KIBMM$A-,"RQ0@-L#DB3P&
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M>0%] #/=@N">LA^+97#1_=<:=:;O[RDVQC8:(*YC$4HZ54.-"6^*H+)^H)M
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MI;M<;F2CK2!R65@1D@+$&4*/U9MXJ(THT($^>!Y=M=9^ 8%%_ 1=),:TJ=(
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M:E5SA[R!F"?P6+ 7YC2Z^4*@[//OJ7C];HO#E08ZD3<;B-K6JDP\73>(7ED
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MBH>%F!TB!,]S;V4>EUAO:9(SV4J_H?$+[?K40#QL49@&-RQFP%$"YP"Y[\?
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MBW8@B6PI%DU&#LM'"TK:/Z%B'?(V,E;T<K[(Y;) ,J *V*O5>H%@4S=^S+2
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M$=" 5P:Q\VP4YKZ!FM;\8Z8?!/T68'^F@_P<4IP7\A@+CO3W&#+1I)"T O?
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MAO4<;)%>^ JM#>#O_3!7(J0Z9T%O:?3H8U696/N1SQRY)'<PYSA.:"7?9[C
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MXN;1!R&R=R8XL*QX+(E%G?*8[O"8XYEF2O3KNCT*@P\5$##!0'9OT,A.5L]
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M"BS02Z&:#LB%HM?[*PY"8/[K!_WH>P^ABT%_@2]FTRW3+!T?8%RZ,PKA4[!
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M=-:_/1)/( ?2U([=3@X#VU7%&0;D3@,DX@V/!;\U>-Y_*4I4](J/3"LK#(J
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MGX'[^U(6-Z>]TH5X#62?/N:^]#R!_WG$BW&D_37G%UUL8?ZNT3^<LQ[TWQ#
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M\'K+=)FO>58,#G66F>%EZ0&Y(-F;E7G<9QF5 H3-5Q:W5D:H\H.O2*+I2+K
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MI-SC'?)0/?@]A8,S%52I9BD'+X)X.*F2*B5S^?MWR71?5A0_T$9/ &?B!YC
M: >5":"[#)\ER=I2FWQ;Z[LF ^"/R[7H,^E,@/L:_0UN)@.<9#-B A/V6ZK?
M&(KM*'%/S>LD[2!9L-!5VJQ?9B&O(C.TY56@<;%*MHSV8Z"W#4]<8 +]F8Q7
MOE@&ERR.0O?&O<IH!Q\S@><J+8U!:T4E[6I"[X?TK3-R(D:U=YV=%9V2"-Z\
MU"3>?<L@\]:=>/WFK/-A<T9A8KVK,Z:4+-+\&+Y:2'E)S6U<6JSVA)'L?J7>
M,Y)OM>\(:\JP&*[U32_1(!;G.T5/5+O\2?N! ^G:C]/#Q4%5G<N.QVG6";R7
MU)L?5O'1_:'6(K+DA1XU.U+H^"TL2/"G?^JQNJ%7$M26V&QZ]/N,9H[NEQ,I
MQV\KCBL?Q1:NXR@2N(7>'#LYT]I1]H[T1U(BDQ'YWB>#QW<$;K[5@2Q*<=^V
M?V=S4]:N'/9EM1>\['+MYD?'(OPF1-\3K#.#A<K[6)IK=BVL)YV951K$VZVF
M$76K/LWI?MX2;,=^9^&3A#2E[F'@#9$\CF:K9A20H),:<?Z8ZMZD?46E \HZ
MFMB8B?OGN!HYT1WX ;9QC6BJ!@U"DD6[?9@:F.4;'"\QJ;6X52=NP-97\"7/
MYU%R5^:I,[H5\#+&6L]\[]:0F(!*1"BED)K\<X;F2.)D>1DN5Y-NFCE!6K96
MY:XCYDDW5JPX.'_FP[OG=\ELT?=V^+(@E*,GR-,OYTQ2/CBM2CE*[XD%SWJU
M*D<>.Z7]51D; -I ^X,:H43#9?XY.#_J @5SNY#XQ$,?8>WP\(I\'U2>[\.7
MS]_>[1R\F[_KV> ;WUI'EIO&T=\N+J!^HH3.#MUO.5GP46!?H\4F#9*Q6\.T
M7E)=:$;X5[2]X&#6$F8_0][SR/C)1(F-%S3S-,^4D6,9B(7!PMBQMLLGV,HN
M^!YELTQ'76;TX?/O95(Y\'88(<8>BK]1IWPY9UW$2JM=1=-9I>(CW.B1P?RZ
M)U&/)N,E_$5P&? "L,$!/L ^&O02Z>,@^&V@_HU/J.O%@T.G3\O?WSH;,NJS
MPUC4[+5+D/;C<K>KS0F'#>*-75M+&I+5B/C:I .6#O5FY,2QEA,76(16+ZTD
M^/Q,^;L7T7UN"JN+K+2XF6Q;W&56SSAE_C:6S(?6Q7D6, %+OITO?:9YB=V]
M <NXT30(\3:&GP*K'UB?2AI%["F:>&I7_"7@ <)193 V6#C Z]'Q8>(MY86O
M5'<(Y23[0AM7?#^ZUOBUU1Y8CQO;\8UA<@1WQY<@^:R&[ '=6;?\M$VKBW?,
M&[4'IJN0:I3<47RHF:9],B?I6C0A=-?Q1XEZY3JT#+'C%J=_*$(#GBMT][(<
MBBI1R9@)^-DB?8C:=>!+[[@TAD#W5)12ATW,=]257(5W+\&<@%^3'CM_&+U;
MNMU-97\_?] S5+.SR-P2_[BJ.&).NC8IXD,\] 5OFI<-M]T!LL,GD.@-PEIA
M+S<ENBTUYAD[4"&GLDY)-15"![+'$*\TY$9HDIT5!F0TI+\P2R.2CG$MWV]7
MV?BN?6\$?S(DN7M>8?,B$<JX<W%<?VNS&[H6%ZO4$FR4W"H'4CA,:/7&*P9N
M?+1VN$\!].Y,RE?$89H[Q6&T!4$5JH,<K)#Z8+_)1H4:]BSF+EV<I98\':*?
M7O],:YT*F:RP),&JX=QK5"$FP.-9>YDX'$YU+"SK7E>6?OA5N57,[BB[\L5Q
M-=CM'('+[,=6]K[?C^7SS-8AR@:L(PXYE&1EVI89Y\27Q#_;:7+*RK"U[[;.
M-_;G^]1?8"]2(%13Y&EZFFR1.33HWEG]@\-VSFF]3Q.%$DW"A5_G["*='(L]
MMMBJW'I!;E6)QLL$QJ\F<U*X,I :G>)6N9X#:U?:M9*F6OE@K_>#WIH<5E\?
M\ZY"@M3XW5AS9)A>B#HT-%1N[FE5G\ ;&Y%_-@R)4[QZ'7M!9R:>4WBD^OFL
M%O=(UV1<RPKVHBFN/'5A@P-?GOFS1(_E^ -G?:D%Y&L5\^,VB^RCW/V=M3TJ
MTW7J(./0H@QYQM1\R#>",(VL%R O!BH]6$D5?LTNXM NEZQ] J?*\O[%\!4$
MBIT)Y'\ UZ((7[(E]PY[Z"W;"=X)B2Y@.?'=+DO80/QAFAP)K/9&A"(AV;5Y
MGCX&AN3>S]G'GIPWV6VQQV370>/GQR*T7-<I@ZRQ3-/?*^#[E0CTDAI$<'HA
M$]A':16RU+R5\)C>4E3_\WK/:JJH6FG,I_,+/TH;>K#]9^:S=@OIJD*K<SM7
MM14NEEKJ@>T+#)L82BHYC?)@%!<FJ%VS:%.'MR*-Y$[00W6HNSLWJ^Q.0$=R
MKDDTW=EX9R5,*$.'8/C49(GZU1[)TJ2X#R=CQ^85M;Y61+3Z?. C<Z3'\;BS
M.;,I?_O>A&T!!]#_@><XL)+G^A&>#IK'F"6\-F$X!6Z[E9L3Y^'><4#\55<V
M]_?U18OFA+L(!TAH@E[SL#T>7 MWBCO>$5]KBU-'@-\QM8QCG4C8A]FM5K3/
M@?1T^X,2+;F3Y4$1MN_VP Q5_/;F<M V63//$WFE&[4?>8\20#U+^;*B]Q:I
MY*:P')AGH]9L>]WEZ%;:JW-L&;/JNU'^)AV3]G)!M1)N,TR@^2'L@M,12@I+
M#UB%CP9:O+M_[\0(3]=A-B51IYG 9^->QBM[6B9%DPF<&&ZC^Y8PGL=NY9,D
M&3KX$'"!EV5:*6:XTXR#3.![B0L3@+/\\7L)5'@U$ZC[B(3R@N5U2Z=20NA&
MM,__ZJ_8_IDB-<($;' #AV@"9T5%2#R+)_T6BT=F(VZ^54?G@%O<'16'0T8;
M1C].\5ARS,W29S>TW;D%S-E,35(6>L<GVKKV/M8+CKJ;]"B\ZT*9<"#[Z\M+
MI]=)N(4-ZA6HOX1_;=6)I+1?EL6#P^>;"B3SU]%,X/(6K._SS_A#XODJ34(?
MK5TO[N<^YC\$&_/*@)E+Y2[,V2>WI<*GAR$%DZ6QPC_0A9FIYGEXHNIY5@[J
M.9WS7[W<X87XK[X?9B5Q]OJ;2A@($^@["9^\Q[*,71U,($J3@* >*&%$U]Z;
ME-WDZV("A^G<*N#RTS6;WL)_^CLJO'_9>6;E$W_9H"YB$;>JVNE-N;9&)E#>
M/+F)\:" C$LJ"+J/-LLV.7[E_/5SX_%F=X]</U9X.6J@8\')^ 5R6KEK4V+'
M=ELKGQE8_WAL"\S)#K_81>']'C/.]6C!8PTF.88+1>TAQ:7)+W-3VFH'EM[?
M_BXM/VS"^<H](C=?^-W^]7JW&-W#_H7=?G)AW80E5O\O/_B]H7X;#C>?=5?B
MCX]N=+!#"-V47SUG%,YC_?;5*+!#G&JB'U'AD$93(CXN(>1ZNQ>UNSI<1&!/
M7A^X=CW5\.>5C^+O#CR'36 7%:B/D'?H7Y%*A&'.,59@46<;DPFR4B=79@^A
MEO0^/@S[WJ3V?B'LG/"E]+=;4;#CSN\&R@)GX4TRR]][#MUJ-5=7AUM/H3*0
MPI3)4?0 6TTG!?U-I:]W[:Y3<M-27(_#TY.7<IJ+C:XI'ZAXX9]<5#F.%;;%
M<+%<,R6S+A[7/\ 7[=0+*T'=:9Z\6E'P1.LQ(L7/@8"CB$%I"1%93,!*'<\(
M+L'ZTDM9*7T;@\4P^BI9SN%]3U\;V5/78):'@<QZ,X8ICM+/2: ]<6<">U J
MGA"R'_%=E01Q3PD=EZ+E2D:XD746\R]\*I#ICQ1Z/M]ZOLULV6%T^<\/J7#P
M_F4T$;6 &8FFW\BZV2I=M>C;DMJL<1'5R03VXQ[WK7EIB'G&,PYU]>S/?HBJ
M=G.;>E/LA9D[X?MU]<BRU<5Q9879.*7/<R8F&^YM4^9#U[XT4,2>?=XE+*K-
M7HFR!*N?02=$B!Z,LCG<CP[<#23+=D[ 6%Q@ 8)@^;Z>TEG4RKNI+5T\9E.$
M%R:>E4Y.P0\M.+9K>2XO^I#@1A1)JC)EO'Y+F%NCU-IZLN^LLP"'OMA9NY,C
M8YS+ZI\#4]+H[RPPESO]LR1XN^()&XL((CBJ/O:%U(@NS.4W .3LYN[-+>X0
MV/T^X)X6>[Z4OY'&$<8 ?%>5TORA60TN2E#ZG%EA;K&(QJ3UEZ]O1M]IB]1<
MZQ#>B;KMR4ORH!W))!\BPNNA@=FD($+WRV0E$GLP5N9D<5%W>F3**T-8^&2L
M!XJL[?8,^3/,<?RB0B4K'.]A!1-?I-(O%.<\YC!#V#:?(EDW(J#5)1ZJ%YE:
M7!9@ZH&650[O0OYH*A$_Z/+Z6BRTGPF$=_JXLO*$N1M0Y*+>) I'I'.W;XU5
M22&?$OF_+0JJWVE,ENI$RMG)+$LN%CPT_3'^-.1X_.NPL)>&7E@A^@O0EDMS
MG'\A/,435Q__V%'_NGFHR"V&9K12/VZRP#L?_<!J:&(#&P*U!@-(3*!:%V<G
M"T'"*!DR;I ]ME'IQ4D?-MN$KYYWV5TU>>QEQ/E2O]&"K^(KW[H^R#Z9U4XI
M1UEJ,%Y><7:MS"D?&/%%+67BX?MQ3OCG^*,*E$)]3MKU3J<BNS?:7.EK<GUJ
M2[=V:I.#QU>/,@&W9PXCV6/000AC7RZQO!ZSUVW89FPC(!<)&;_)]T-O\&3'
MCA"AZL/QYW3XW*.^'10&JHLG(E][+U-.<B\*9"%1]'<IH75*"!\"G-.""3P:
M'KXQF%8:?,Q6PF4XY'!:LDY8=$_P2HN.;(@BHGT6Q+W7)3HC["R1'955X[/Z
MP7A>-0@Q] JCGY3YRK5MOUU L41#^K//KR"[%B[=LOR\;^!]L@KLE2U(--3O
M+ZDSJ_.VQM9+[<U[Y/AB.0<A?:RMHO-*_HLE<UX2MY^&("M@55^#.BV+#-.N
M)=Y&?]/@MN,;U!XB(HI-PVY?J>38IU@8T;PJ?'#O=RER&QHZFH@K6 ZO@)P,
MX*^E0KAU\R^8VR=<]'0:1=[7H&'D([Y&/U6OM^:7U%5(Z-"=E5[<A&^MRL?&
MZAC";:YMP;<891"=V8'8C/P'"-\';ER+L74.9Y445_:)Q>[];GW_Z661O9]$
MSY(" T:E]\Q;D$[F6[V?(:?*X>>4]NTZ/S%JW?>B:?3 1.\4CG8XLW%$@H(@
ME1/ !5*>O>PGNP2VX:&[!>=/[^K9.+'OY?WH(O$1;,G[,_HF%P?H6(U=-!-Z
M'LZ1F]-3S*Q]?9%_-/!M44/ND\1<Z[I[CU:6!(QCVY8.XFX\8HLZ$&71BOGB
M?=-2J=T#%;?^".N!&; =2[7$QX_X2F2PT+H.?;QH?L]2E#O$V]NR(.:P1?]P
MM6/DO+.XU$%1*@FN9>>='E>:,6@OZ#8A&!#0Y2#/;_(E)U(W[$).6%K@+M=C
MA"I$[]]P;,@?]2#^! \LN/;14B+MW9]]+R$I*D>WG37]KC;6?'II+Z'J=RD#
M(\HJG *2&@DE"W0PJSEG1@,2M32M'Z6Y4BU1V>=G^7PE6_9-&$QYM\Y<74)&
MS,0L/5NQ7+YD[20LS/A6O,X&K(^ND5**$Z+I$H-J585\VHYZ9E\EIB?5)=]0
M$IQ*Y7KWK$JNR,SD]JT=RL*C)E7AN78,L8XGZS=/,@:-.F5/F"YBGTR9?DA6
M%(!I&QK'1%QFWY/J&R+3RTE"CWOX50&4JYZIC66]Y ,OG0Q_6?K&^:!'ODK
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MLX!UFP*8=JN/UP8*Q^=RYOM8+_28A\<V?\'\(BW23BO@4WO$E$A%BQ@T3X^
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M'(M('XW="<].7!#:>KRO)"D>WO@P-6 Y^6AJ?<B$GS90-/$SX.BQPE<7U\=
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MM%/5/BAJ[-%GM1@,U)T2FC<)9J/P21,[&).((EDSX!D1HZ#*X,_?/A<*RMV
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MEH,T?T@;)D-W[2C[X4B/(7K0RQXY59*,A?*UG[$'.E4A'CQ1JA >3<.R82S
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M;ZRA9E%3U(K"09[JM2_+>$A$;G"!LOI:UYS7O=R?5 BR=?7#$Y=Z+?-):BB
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M<.$-QW\[@*X2W:(5?=:RD7I!C6?3]0A>93,G+X>=:8<J6;SDOFZD='4 +LE
M,4]0<YE<_Z0''^PAM89H8M3^0\-BU<:CX?Q'N8?Q=^K#Q'LM5<VO;H;F_WWW
M4TIJAY^R4-$X@G &QCV<.#+\;^7(]\+18ETQU+_[E>A?^#^:E"MD_75!DO=V
MQWEAZB&@'*:5B+/(&%B],ZQXT=_PB%Z;F=F&A+&",HEE02J^NM<7;>U[5_@L
MU] 7,YF-![&!"3>V&F\:X@=Z/!B(=SMUW1"JM,\;13K0KYP.'%%#GZ#B#6*F
M_B@\XU555^G>?FV#"3X7\5IP\/6CGD>X(=#,1U"-=P7- "8V4GT($+(7PXI
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M4PK$9]!6=ZM.NGF1Q? T S&/;LI*YTS'V<&M-KVC%^OH@G:4 "J2++_-"G+
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M.UAF(4[UDU)V_D]:>&?*3TNOZ;:'F!^^JOZ/<FC;^H< ;\=&XR%&; E%_A"
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MYXX(GN!T#GGAV2!YQ$-5%.\$5+WM>L;%</=:#7BZ<VW:]6_EEG*S)A5%XB2
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M?G<R5&%'H?6WH2=!_)1(KKMK8M<QZ)Q9::G4P]L<V>RU<J7%S(TS82N;^X>
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M*\?;UF6MA\NK/UMB;]=$+70=L$=!I4^PZ>NQI49GBY0O$J/;38[.GGT=@.&
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MCZ.>KV)_>G;AA[)\X*)OH5D\I4*V[0^+ _\SC8J'V&&HCVKXX>>$%:!@7DJ
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M.UGU^W]W7?Y_66-)^'5.D,AB/9+"#H? -BF4 %@M RW6X6G/F,!\EV_47T]
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MMK:NE@U]);\W\#RMS&JS7A0^$:C8ZL4YOX?&@NE8\A#6I^:3.2T+R183+W=
M&XVTVV:)%YJ/+)>R7[^T_U2DD=CA+4M^V^TEJQ_B _&K_>YM%OL0ODNXD!2H
M<F*H<8&7=QWFC]N2&!_ICI[D!YQ/*T_TX'S4WSITYZN]['LYK])M4'LPZK8R
MUY#99>R2+9 I?/#>+XZ_?3\C7QIIP_FL:/_0H;TM8_A]!2^FW[ERQ+@<%K)I
MD1@)CKF>[7&B]RS[^>SNU ,M&*=*&B;9+:WMLXGB7#<32&0"'\H0YGHH?R0[
MTAKLXZ.0VIVAHX,>SP1R%%Z/%7=56&?KQK\S4NX>-#J[4_T>3OW< [Z%%W)J
M>Z%.(C]^^-?1N0+P(-LKO2JE6ULDV[@C:V3PPOA 7=&\7WYO.7?^A'*L/?O@
M =N%3NO%XZZ":?5B"Z75%L)K5X(S4AWW8PZWS;GJJ+F6?:Q\(NTT&3IQ)ZSS
M]$?*87_CXZ8N;M[AI_6U<K$$/%5*@QZO&X"?LX=+92UGQ] _G,DZQP2&"Q%+
M3FK[87+[#L$0+<5%X6\A^Q9KP4^Z<S2R[<W.W:;8H,7"78H%%KLUM\7J/T]?
M[R^K>[T]?HKUQ/&3R]?#C^!E&!_?7S6?>*8-^P<:>0&/UNT'M1B1=(X3*QT[
MTLE\QD'X3P4]ZY&#7@)956=W<KCAC*V>5-U&"C.!NV!O>2.^V+8A?EH:O9!6
M&#DV/R1,UNE[K?)B/JII)!US02Q/Y7B"BY?.SU*:&:8M[A89%W(KKXMND=V(
M=OW@<'C])/J(H>&-6\#)YQ72;GXW[F"GD,.H*B([YAN<LLX0=WBH-<[%.:4L
MQ-B?[!C\>HYX)I=^K<X7J ( H#U,S7 U.'M^*G9ZNI"&EWI7>,UVSEY9JA^J
M=)N?+:]@(;G7)K.J<:L/H[?;NTQO&"8FO*CE&O-I/_WB3D3)P)SG">_D*_1L
M1@@XG(Q'J'%!G4( V3V8SLJ('IF77M)"RR"+3AQ;>EE]U/_3V5["UZK[G*8,
M?_)N',>3K":!@@>B!>_?9VS;&[@-84H_R_!C G:$$*&3C ^0@%W?6AT3..CH
MI3ZX$N22,6-YN+RD^+5Z11IKV/CQVL-"&M<E]*)BI&='UWP5W'CM,D><*+Z+
M38BR3N-:D&2L^SSI.-61IDI%ZY&P0858]AENC\@#(N5MZ(G\Z#'YGFUO/7JU
MS+,3; ^RM%>*,Y(P*I@.L"#CL6YU<F#ED>X/JT$RQSH+\0=G-NH(JI_C=[8K
MJK?$>%CO?N\B9!%B=6[+VB6!S/&40A0),9P(78ZZ$A>:M@+_[&A7I>W\("]]
M#=.6G,_7@/N17,^/?+XZ[Y'^,WO!R4=O)%%_.$IQHBW=)MPPBE4E].0WMNK&
MF1XXP5+B>D![U.,H<X\/5IZC6$Z4X.D%VA;3>7G)>DD V'V15W'&0'564U2?
MZZ5E'G&)"0B?+693ETOMWUB7G?627)*$V+5HEWP>D8T;W*DNPX/*]96\I$=\
M>M,QD3_Z!DR*RMVH^CYSTM06^?KK_68"X0].3:A)PV-!E^Y#4O!SY130R:0^
M6)B\5N![P7O7'GVW3EZ]78KZ5CN_ 2IL'"[5*D:G$J=IQFG>3  %3EK;7^B@
M.)JX(1],X9H05)'%^<"QW(>CC?3C6+[9M231-E<!B0]GF@JUXKQ#SHY:3.R_
M+!IZ[PFDK[G=V/ET[P8"8G]-0U&Q%!>23"!=;C@^ZIU':OVQNTXFP&D3T_J/
M9['"6S6D>11(C^L>^LGETJ+Y\/)$[#HR(A$QU*S7'PL25FDK:I,I>/9?8[9:
M"5*%NI-V?J1&*02M>$H5.BV9F5-Q)J5Q"R.\P;'-ZA+ IXCEDRJ/IJ_3E<AB
M\W(T#KH/MKH[IO(PF65Z\5"/Y?X\V1DE3*K=I/*H^FZ^^ZQ<QY_I[U0]Z/#2
M2>Z:UVE/'(>' QXWFT<K5W^83YW5Z:A$X$-=]=3"TFK?,0&'P3T7CCTSLWMJ
M:<VV[_'Q9MEHX<-^DF2QT<!Y!+D88I<@%_IP#^>$,)"U:Y^^Q('/YJ7#/A>X
M93^P_6RC^(!GQ^U>(#'S]+FS:FC[N12<S)?"ECE&CEL0+4\=LYMNR(@"[;!4
M,2C9:JQ<ETLT*:F'[5!?AO_JV:]N2USLHLTJ+A,W0Q^\?TK/R&1=F878)FA6
M.C03'_'R* M-*S(^,%W;PL2I\ZBYI-_M4D-(D&;.>VC'Y88M6PM##36;ZF<%
MF0 NCO9U0FS'RQBL]4RS>,J;C[_>9$S@__H[H0DX9J9^18XDT"OH2[/[L_T[
MYU^,+;$N?3"F:# R*@_0Y1A)=(D1 I='BJJLZ2>:<9^4Z;?1"_$+/R,P=T*S
MFLN2.+TVU*^Y/GC5D&#FPY";\CC4?# A7<RF:2-U;D,2+CM'BM38F<#W13YH
MUP(3H'8A2/V([>"4>PB<M]9 ND,%F#4*3G96_O06&HI=QGT6&E'W .GRC=6H
M#<%1V"E\B4R /Q42L![&,3C(X'#E(A,(TUM5T:5OQ [4]K=#KFNI ^(X3B;P
M[ =5D@E<K$!19<J9P-@-L/;>KR4^;X=DZ'R#3("<K981Q 22]6FOO+U0WRI7
MO -X1V!J^.?J8*E.6#_\BG(]/*1H>$A.HY.,7)Y!/>1$:Z_W#&'OIU0@?]>%
M">S)(QE#@1YX$LJ="31D;B2)0;[:"U;STZ 2K6V!QQC.6+_K@OR#70S@*$G(
M\OVJ^EEF$N6E6A-,@KM_4^8/=IGQ2%Y?E2D-+$ZGSRYJE.A9(OZ@S1\-XZO+
MS034TM=.4E;PB;Y3:^Q_#T[8/\&TB=(F2ILH;:*TB=(F2ILH;:*TB=(F2ILH
M;:+T#T-I&O]G:^7'T%11)C#X:Q',?2*C#&=%;IR/(+D;D2SQUO9CBC_+RCH6
MCCQ#?K38\ZWMHU[4_AU:@HX_T3]DQFS]*CFPAYA C57NAS!&*@7Q::$X#B7;
M0KO,!%;M?C2LS(87SEF15E.?X%A9W5ML; >&<XSBZSHB(S_A4<(KD7\/ZCC$
MGV!/A/YG@K$Y9#91VD3I+Z'T:Y_8X7?X)1$/2:A&%IQZ:UG]NUUR?G+VYX\U
M/E&3\3"NZ4[:U]-QLR3_<XQ)F].[D-NOJEA/'_4GI'N9./-7G+K_<KK@,\(Z
MBL\T(5/KLA;>8![1RP0@3=U:'(WO$1-@B(67SZS[#R_.>Y*PM0@V'[[4&<S)
M\![]CA4S9;-7>\(Z/!^DB7\HO?E<\7"HG[KK'QZG),?J%$=:7(84\3+ZVF?1
M[8NYY7^OM5K^Y %QFS[]/]RG-U':1.G_0TGMUN_S]%[QB]43V$PQ Y$>% L+
M@QJ-ZR6O'"POI=US-%97EE^<>(YPJR3\P0J&<W=O>G4)2FLJV$F'#M<89O"J
MV8LNJF7\?8 :CC'^A*@L_G^LJ3<'Q"9*FRC]CM+GOSY%]S-YF?*)JC<FXZ]V
MLNT,N+_1.QMEOW0>[7SBP_4ODV]:+@-T'4_W.5G:>0^6$42MK_M5,OJY@69E
M25?<3W'3;D]WC?&Z\GS^DS-I#Q[6>_.05F-0^AP<"]K:R@G<.;JS>K&G"\N3
MW_Q]GN+!!/[55Q8W$=P<9YLH_6]"Z2_-U-?XHT6IRY1%:N/P8LC&Y%-GE2/O
M/^3M"2NL,3]=?<+LX&MV[-#1R<-"2=&S-C<=5L@N+X?;>Q[1#BGV%4Q<N'):
M9[KG*T/XM^T^+%E3H3[$#J='(0=LR.\=1>Y?#L7?*E<\<DZ886C^1R(UH<T:
M5,X8J/SIEKV22_X[+:3_)U>Q_N= 8G.\;**TB=(F2ILH;:*TB=(F2ILH;:*T
MB=(F2O]<**$$826N(L=?476A6E8F<$G5*^,/4P_B0&<L=F@+M708R6D/<9&W
M.O+%E$4DV77W>11EO)Q-^!+,*?((IR%=T_-,FBM:/IHF&\5KFI#9)'&,H?N!
M"?R^AR%ZKN5H"TV-KG9'.9 B5P8= 9"9*17O-<@9,TQ MBB6-#:%Q8*_;61(
M)S$BD>,4%2>(DLL$TH_B+\YVMC(!+(*4BF6A*\S4!(OC=J]<J(2K4;]XAZAI
M9)Y8G7OQ;>P9MYBY6AK6D_TC_;PP&9<Y.TGLIU4O>8Q1SE+3,RXDW?D^K7'=
MD$6,P7^I1)%^5*XU".*)[\=EH*JF:T%^H4RJ-;33W5; (V.TM0U1&=YR+4B7
M=F(Y:B.3GK/Z#@_C-/R\4B2X8S2C+FP[D1ME1UF+P&4^NPWKF%J/J3).-QOQ
MGT9W01F)NJ/)N*E0SN>(I2/4**BZ&+DAD4/B@]C:F(!8+@D'U7 Q@>DS7;35
MO[G4N/0D?I%(99T4]M&EI3*!8KP(>%%NG08CC*6*,0&VXBI?L4;*=72GSQ'/
MD&=Z39]*CL-5O,^7(VI5A9@GQLIDOJH-]SH"0 VL\?KD&>=<:"474+7 =>FX
MYMK!+VN\T1ZE%\B##I46:MX^K5--EQWC;5-7P"X" 4$5!AN]450#C KI6K['
M46Q-OGPQB^8/-MOC4=*JD9J]6(8K+AABGU)(+NJ9GW1RS:Q;VZ_T$R]=F)GF
M?U3YP*LOUFK^+3>>@Q6236,]%58T.0_B*"+@5NR<:4)W[!!WUTO_P("$$V\]
M%R?\.-_BVG2I1P.KL?G3E@K4=&_T\H#2E-*]T(JG%I\&3JH%A,)C 7!82!4U
M*G#1MJOVI<E4?J=?4\I[9*^]>^UE+@0F5$XLT_PIA.OX3[KUPSL 4M$; +%:
MG4,F0FRHX7@$/Z87PZL44#9X/K7?PB'G4$BISY<Q20'$FD578%DP(XA1@!QO
M_[7+Q0]<)CCU#-<L0Q7.H">.)U.D+9G U/WN [;W;B2O@5IQM_EH9XS7\#>3
M2Z+I4]0\W3I<?ZI^,9G[H'57Y>'"W.%XR%/^[<3+LW/<$XUO<%-E^!VPUZ2A
MMK@R@=Y%2DHGW<)Z6]$&:Q#Z6VF:@UYHMGD,E\X^U411T<?0K,1JP_W(C)!T
M?3-)R 5,E7MI<5554P.D[L%D,D;#Y9[)A?$<%6?/3@6V?&>G._TZ"XZ*::@=
MP_G)V1V]N5BX!TAOD2&O&Y1<\"6-VW[GO+*1/\))Y^T8QCV'!'LMJ9.&%:38
MD",!^FO:4&M)J58ZN\(9KDNAY0=6.&Z$!W9":*@#=<!' W:M;8S,]X2G9R2+
MS2*$PD88$A]M]DK*>D8.1^MK*^=]Z[1,"V@RM+_FFE6C5+!(E=L(C]9L")V0
MDL;?@$/6BAG%E6J@,&_"!+;AX'CX9%6 [.0)9@R8F5AJLMV\4U09-5=?'BVD
M+]%(FN1=#QF5"404<,Y='.U=M.RI&]I:HG$37U10*K*?[]:A['7R3XD;JS_J
M5B?.C^)1D*@=$]B+M,;_P&KE4;5LWCGV3?K?L^)K(YIJG2QYNM7Y71C7)67_
MO*@$^MMG;/4^$301>#R9.V>0U<HS,-_Y(XO",)E]F/2,:>WQ'R\$?!YH<+T6
M/,1;7?OBLM*A\."P&_5=T1)F*'RKUX=*H\$#-:3:\S?">B8FECJ650)';.G[
M=XT%^GTX@JT7UB!#28<.JC-2^BSN03/:@"'K8*H7PX(1S00<4.Q0-W)/8["/
MW"$*=W\+Q4)#J_QPJXW:EC[-D9?^T2Z=;MOV(D_BAU-0@G@;?+ E:W[@B'R
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MM.%Z.KNT7MCKF3YC.G?/B,7/6%L7X=G*.Q_3PD(F&J[X@1.)IG_X75A93K@
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M6<C/['G@.7K"R$3$R(#GM&W0J6]*-[0*VK7!V@NC43K%Q6-9ZZU,8#L+>3(
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MVVC68UGQP_+)BV:VC4@0"X *%@:FD7F^N*N0J0!(\!\F\M8X@I/)I#CR4(H
M\!_&\>M ]G355QTHAJ50 +4=+N7]P!!'0_J,)6TC@G8:2YX6^E<UG#12%RS
MT9-,6_Y])+[;CU9__^N3%_)M8:[5RF3K/D]>)>$EV44 <'=B-Y+ICIT"8#'C
M\%SN/3Y1 (S>APX+@ )_*P'0$3!3G2]&;4C)/>P&22R*J686:"$_[OZK&E9?
M7T< [%%+AVM+<2O'E/_$XB,$P)BR#]A[?D8 G+Q*^KZRK.DX*0#NA>8\"Z>
MPY?_Y:,GD@QW$><]#;$"X+TY^4OE&5@T&\'BR'HJ6]Z3KQ)116*_% ")@2P!
MP ^[!I\;)C(M,%PEP]W(W\^ 4_K:LS8"X+&'%0OS?2$'7D:=" G^#_ P -98
M@J/7F&A^$!)E7CW4I;]Z3A-\$<NC&X*)^A#(JZS&I2[_>@ ]*OP*^;P(7 'R
MQ-K^^&94_5*7H%XDQ!\CD')DS7_U]HN+K/D-R65G&I:W'LW?M,16_NMKT]?
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MNFUEWM,%,BVP,NZ#^GP"M/,=)\6^"V_\SLH+K]RE[5ZFD:\D[K_WM9N2<CP
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M IX<9!M!D^HPD)VUO=VJH'-1DN^=23Y 'HK]<"#T!Z4\=Q.)%OR^KBLDLU<
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M&H'%SK J&LD Z'((LAY2=^>).![^4?RBG+=/&EWN^^@#/54^<*]N8P#I6Y0
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M4DM3I[',3A#1X)-(6C2+>_Y:W/,7AO2D6)NPG83A>S0!<+<)"N>9R2-?G1
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M^23*G8?Z/E^SHB&5IYQ,+[[UW,>2EC^%$E!(E,EN<?Q0P'BK^9*[_4MY\C>
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MV\PN'D@._A"S"74>6T*N@S51'/\A.(*-["Q;ODVW:B3NLK0N:]2D"7*Z+?D
M8ZL17E(YDQ>8"4_38G^=3D9O*]XG7R_2]3H^N#.#\#]Y]7.5S/^)]IC_=0[
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M^QX5AL1_%0$X70N \ >DR/ZA65O[VZ,\V+KMOJS+']0F/_PYN]7LAX:C>V&
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MYP<'OZM#QOY@B?HJITEY"Q5LEV@?PR!KR_,8 D"@B,*5@6WBUG:;.C:BNL$
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MZ5P&'Y6&XOPV&""5(":I?MD2;+V^1O&$JY'0K[P>#RAKW9M:W9ZP^1I_>CA
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MWPX)</?U;HY?IYO'DTK6T,A_'5(T5W04]BER/* 3>1SYK"\:RK-;9M]6ZRA
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M;4O[-IQK'SVHZSS&[Z\GE/ @=D,.,I<-J4$GYH8*=$*JU8WQW:\KER_6$$R
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MMMX49$*G:E ZIZ),(\']#8+KIM06&:&J8FYW!R,9419,Q.]L^,QJ9@S4B&F
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M*/&W#J?<Y]K'^3?([)?]1U> _BF$-0T)7D3F=/U;D"F!9F\?GSC^NX]:&V&
MNHL-A<KL8VW2'6$Z(:859 4@ \@*QQ-33/WQ@VP=0T;Z& SL\\52",_TM'DQ
MZ$&FCBO$S(*!M!WDH^.SE-\50<TT(!WP;92.$)V:*?C?7C#40TQ&8 C84&Z,
M#',K+"^E%-WA!9FX(QDK!^&<UXX$-:O6(92]XZ&WA62.K@?X9IJ;,!)(GER
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M-@RL> X#-,??N?O'?UY1]1>+MG[3(85G6H.HQ@$R^ILIGH(!X3Q5Y"880N=
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ME+HFU=U3<)^M!IT\@*H%@\R+\"CZM?2,47%S]TLV"A-&VOO)7G<O1Q:2@4V
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MH":;3X"E:"J<5F2B(S2<\,1$1Q#XO?[;VM"$__=@5FD=%(D4[84J-)V[$ %
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MF<%23="]>D,\50@PJ$$]Z/0DB'U]=97A&;R/Q!]QW^>]S9.&41EI03DD2[$
MR(QF> IJH4YHTT@!\]8S9SN5X!8._2([G_VUHYKJGQVEL\VP_,YL@'H1U4.F
MAU(#%OQAA1N]I,#E1E.A8'J?.<EY=DSC(7>.S>'G5QYHU.\[Q*OC]XYJ45ZZ
M@0I6G-Q?,_Q,_9X]]SV7$(Z4?A]Z4Y:AB%Y_WY<[!LVV'?73;PJBD[&1>V=B
M[I OLH&C^ ;&)KAW\#@KG; '?^X'WB+5&\3D4+NBZ6HMF1/!!FI&^U&'ZHX^
MH.V:Y)3I3)R[B]2[C>%#Z/!;6J(07UD7EA_>-UA-9$7?Q#;D#:8F;\_.T,PZ
M-3">=:@X2L+I)P623F-&$</8 +T"J5YN^_EZERI 039P#=OGN40/H=8$V%3!
M0NWO++X^MRG^W*?<T\KU+N:YP(;R+59\#4L;EJY$98<8[_)2<Y0?()]TG2),
MG(V\Y,[-/:_2XN.\VI?=-9-(4IM[1$T\KR4/!3"TG+'4)^6:?=%M5[X&ZSM,
M6QML6EH[Q?N)]D!QMKD'1X^CULQ94:N5=WF[*<Q:GXAM90/G"W<W.-W^N.N=
M=*"IZ+G/TWRG[G#6H_C H2]HA(H[L5[1.,H+NQYO'L/Q-&RV,_ZF^\U?]/F!
ME!WN#_EGL!?@.E@ 0KUEHJ--( 'A*,TCZ?J9FKV.[3DBK_2V*<=6Z]P6GR_=
MM5%%W>*\66Y!5*P5T;X42QQMW$>4LB!B(4Z2B8[0B[?_!29S_U.G?NO!Q^A%
MI7X$>/:!DUS8#-2_;9LG#O,Q0[S0*W3*^D:+R7X4\UQ0!<V"46P\$BQ/[, T
M_$^UVVP@ 5KOPC AZ8#R]VB"^%=\P];QS&XVT*#/!CZNKG?U]=JG.V=.=:[2
M1?@'>OIW1R@DG; PZ[?X&1B=.C!S/[0D(* XVBN:5SIX5_2!65]N1L,0ID*<
M' #S"(NL+MH-VJ(3#^Q9XBGB7Y6&TPJ(#1!I\^.T6^>Q2E;W8!Q:T6N:\*(<
M*KYD.#Q&-/*8&V<#'.\FETUT"#<(@7_5L!2B@4S!+OAL^&:P6Q?'$E2<XX;(
M,+<+&]BKYT^>E5:#@X6FQQ&8R0:RGHU4LX&BVG7#_\%C!E&_S@WH8RJ(#)%[
M"#F1"RN:'LID6MW/>9]8ACJ5%*PH<.HO-HW^EPXR+E7\\7EI?^Z\WE4=#(=$
MIGVZ3Z;!^P3_]B$2']Q?=5%[V<!-S)I:(HH-=._#CMLK(*4;R0(1VB,X!B\)
MCJRP'U=>$VYG SM9?.K@PNUEIZ[<OUU,H3]Q,P0X_XG"Y46R@=**B;4CS36(
MB1O&UQ*](! ^I8YC^>JQ@;?</S[]N>DZVN#IE>D?+)^^Z[] W/_3ET4-2#7C
M6]NG)8!0E3(VT,*'O?KG:_;O?VU\="T?IR5^>[& SL$P$7Y5L<#8B"2G;!W4
M'_[M/H(.15NLQ;7"$G[\-,KL"S8@ESV*6\W#L12$UE'8!-07/69"32AYL(.\
MG(($P?T8,FT4%G0? @-9EG]Y*F3#$BZ$/)2,RFE^B+?)\':RA1[1)>\:%$64
M+W8Q1$PBZQ/4Y*<*E.KS=_&_DKDOMGY&;>?>PC<9VQ]A&RESKH@LSC0GN'H.
M<9!S">0DEF&EM<5CYI%]Q*R;GO>/13IMK+L+?K"5V7'F*\?=VK']8?<CC>-3
M P)\W%;GOH#I'LFS-)5DR5=L@-/!/G@4+TE+'%ZMQ)#80+G"*)''.XZA=5AU
M@JY%Q'G1KYVH,!@OZ"Z6,N;<4AR.4%/_8+C)'D7C;SE8JC!UQSYHZ[4<4D%A
M?C,+KR.@$^X'I78.Z$_=G9Q>Q(9A\YS*FWOR)_1(4.A(.*3GV!%A\04[R\@@
MJCKLEX!'Y/K\9U:SW]#L@X:Q(C<(ZC]</<B\-^GJ]/![J6_);6X[O66!H3D/
M&8D=IY=W!S-_;16/@K5UU""X1!7-XNW-25<X8Q)*\F2*LWAVOTQ6\,1^U)M*
M*\>&#.Z$)H;BL"+>TN9P'W7E>X2.T$3/>U)_2[:%N.Q9]\!-=[1>]5@@7D$U
M1@7#O!":L0ERLJ$1G]ZC;)\">ZV#E:J3;V>OA=*?\M:V+\X],.[81&LMJ1FF
MS-&H'"-I3Y)^%&O0E(WB+L54WNZCG':_,G'B.)>XK9Y8D<"W2S()'6W'4[7T
M;\Z2!6.:N=1XG9TSF.)ZY*ZFV&BFH"(=;-7T<1]J(*-\[&5)[<:12N'T8V_[
MW!XGF(1[D[H)!+4M?93C/TM#B/488;B<PJ6*Z;6X1'.LF;LT5,1S$Q0R2"<'
MCAEB<JM.%*F(F\51^RKPB;<ED!QQLUZL\YDCM80Q3QZ*Q9Q3>4.0);DF,GG3
MIC!5Q&=2_)#(4%&X,#1J 5=26<79%4J(3K[VSO==N/54,LQ@5O$U),ZXA%=B
MI:1U#$-W$8/II[2:RY7\,AA67M]R#XMI4*0A/C^QZV<Q&N;N0A*PS8@R@PN!
ML.L7\A:)3'ZG2FOLX[Y1X^S,:?-8W4@GI_<-=_W\U"NVRXM-')BOW"PUUOJV
M0^^2H0YJ$8,M]C![?'FTB#3AL-(4O%98\6OD]?A-^[UB,EC!Y<J2I>WVKE69
M[<<*).%6VE9WN)/IV]5BKM;9&_]&Q-.+WZ[7..2 V;?AT1=;:QVOE&VZL_5C
M#DGM#(ZH;%9;>@SN1FUE TXG[U3H0D$C%$@O3W$&S.NK8,7YW"U5JO)R"Y3C
M^&EZ2%_3PI?:-H(-A ]YRYVG@8\]E.= WNESS<X^8X9\KX5Z=LV^N%0M:GF'
M\QR4 W-+,Q296M *3;I"G?A,ZZ2WT[#J>-1+URMM'GDD%=N:"0V?C)\#Y9YC
MKX;U:V=Z2Q^RXI81.  WLH$OE(!/LE#T, M7MG[VCFZIBN\'I7N,<)7QVKV8
M$Z,HC5DV8'E'CRB8[MN>JC"EV..91QG-OG2R]\6S8_FE^5@JQHJ65LG'PSS1
M.MJ.QV3VW/"\\SVJQ<#G$$;=Z;C^#P\ON:0/,NL6I['-F!KE4.NT*KX^K5&K
M+LW+O?##]Q"YH>W@6+'%E_S/AF6?RT\O=IX,SBSPQA4;R,2R9JAJ58D<S L,
M)^:>4A6$!H<0JG+FL-WW4T1*=9FSE'$-UX&\[(0B3*I@6_RNCH6V+VW,NO1Y
M\U<'.[N:%IAA6<&5M/!0YDGJTNE$&YIN01KDI?=HH^&<Z;C2L.E]GJ93=2<Y
MS>PWH)B"1+I+M*785:9)CHB64W1)[DS'HQ/5^%'.Z' ZR6$PPKE(J3[GW(+#
MU$=%N?)!I1],]W=]+O82G0<\YJ3&!#;#<7>B=Q@\>I3WX_EM[YG>M[3H<$U5
MZH*^&#&8J9,".1BJ'$"[=>*NYC[Z?J(<]\)__OAQT>8M<:M>.U?SU6X0->+H
MP9 =ZN$*3E2/QE>AEB#<:JGGFV$Y_;F_C./YUM#88[@W8U<XO]]!.)8#?A<K
MLY2?\"-Z]9@40*L**_K0E_X"H1&N;I[;'3L56B1?7G-\N4/EQ+N;O39O>^QF
M[\_]5]I)P]/49C6&#,@WKT'T7M*3H&?"I^6S10Z!3F,V?G'S/EK7C]V%<X@D
MH>63QWUS%=I\*SU.3K?&]J1"FW_M*FU.9 .1%W^P@5F7/$0TEX^,P>(0^AM6
M#%Z988%'YU'!$-R*G\;Y_';I]@@[X1M)KVN?[@7.OZ@]-F(^*EHKT2ET=4(P
MV@,ZVOBA\8Q1::/?5/(S2)H-R*]12:Q(!&^U"F"1T"S;@^ SXE:\8G@EA5?3
M*<,:\I2\NN(AJ6C:+L-OHSER6.)S<6B [O[L5_VGY*1/[.>;U@LHW3F%Y#"-
M*]3>II_K1MP-NF(27@*%XI% 2'V_Y6X[AD]3OQ/I)O77S%_9(0+7#9!+N52*
M8NTB)=TZT8Z]^.A"AUNR"-TLUT!\EV.@/#W=LFM_V4/IY[</=R#@,,_B4]ZS
M"/O2)5"I;<UR_!GNS*MCLR-LX&RI'UD@A45$WR)N@)M!KI4B,J2?.V!8%>V)
MXPU/ZNE/:6L\DG[QQ0MC<UGTD1/?RH<<GW B<#0<M2D/$T3F4*6(SAS[8C4
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M/PV*GO1I8P.^0<E:)7__L^J)#]!#:>A%%8@/+CE(7CX^L[ .<<#<=Q'LJ/R
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M(?SD38SCJ5%&8L52]0J"7W1]8J^P)<E9UZPWWSW=NM>)%E [ ?#"^YM-N\+
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MW\Z_J69?UG,D1R1=@D8/0J[_K9AZOV*8I"][3RLB20[2@6!KY2/,CY"PG3K
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MY7]IR!1*JW7V2^"(ZR]WT+H9/^\7T>"<940'.MD:FS2G3E]+10>.(K!^DR>
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M1C3%3+N[JP[,*0KN2-ZSBK3(F36D?&'IK^X1.<T"."MX? +H $W#Z&QJ2SO
M(:(59IM0A$_*E$E_YOQVIO_+)Z5[DE>L/F>N "^77NT#.)=Y72T9E'W50VF3
M;Z6> ,RS%#HAK;\+1E%%F6OP!/JO$P"P@LY+/4]PBU10([>:P_+6?T_KE^M=
M3%1,\8NQX%K@\'W=6V2[;_N3@([>WV$F^]P?]@^QJ![Q;[$NWU88_=O+Z\G-
M&P;@*[)X9#_ZHNUO7Y&8]=7I"8.5AFV7$X",/UGZ!&"OBJ3)-)4B"/8*.NLH
M'>!\_<KHK;$O'KQNSR)G0$/NVD<=E5C2)[+YDA>"SA9/B.A^Y19Q0#/H)%U;
M#]^QJQV5SNB?+>CN\)7<*!!P=Y&6_(][$VH#GP35,*=1K$-%6PE1!S]& ZZ[
MV,U)FT^AMQKNGSL;X^_B:BF6F/*#[V?EM['E]%DW#1\YU A)PSC,TV,+SX=(
MHWDA))8K!.BL441AZ]];X"T(+)FOSRF R6^FU5+#3DC]8;\!]<&K_^)6VZ41
M'>  &(2SF!Q+<734_6+T/ 5%E20EU:/46?7% O-JV\^<UR1X9G;NQ"+K-;:L
MOLZ0S]B0(2^)5IW'@6O^+6VR,BC'ZV^.+*0;N.[HD2VM,0#?[Z?TP;RA(!I#
MMA?R<E2'!1:MHI,[?:*%GOU!5-O?F=@%NS[AB!R47S%\^*M,*&%)\%)#JH4T
MI<(\[!48 AGK%R@"SGMGFJ &!O9U2H@"78,7Z*SK%.Y@N%Z9/I&U]JV5T8BB
M^.ES!S>67XIJ:KWAMO*][KJHDG2/;P^%F41XHZ=G.NOIJM^(]"@"MO/5][UR
M!2;8L^U3:\27SXW41R?[Q"5?7!='%IX GIE.S@,3D=5MR1C(V2,A8UQT^Z!.
M!,?6'<D.X3N7 K>;U9^T4":EVT)S"7:D5%K%"<!UZ.PZCC, -35C2_QD*RGG
M4@2=GK1/$3'JE!CRKM:3+?[.Q'==)&VBZ./C,HO!.9S)8,!,!7VGT5/QLZQO
M>+415'ITQ:?WS\O5[38*+QF+!WZ/I880I9=RFH@@JZ3C^9$AHW85+>X^"=$5
M1X_93Y>K3IF]>F4U["@_LJ.&($N<+5>_/R0/%ZQI## ;RA1=?G$/_H8O&>]H
M3C&ALM+*T3!0M"8JL?W2NGJ[:#5AZ^GJ'7)0[FVLAE6J2FEKM&K0S:YGO7^>
MXF0L$H-XX+]I,51P0"6\6XR7X)/4"BY9OV!09+_6G).(FC3RD-/_<Z]1Z4=I
M8.VSQNL[6/&Q^Q<RQ&I5VT:-ZI,1.?1Z194$)57/BO11>)#I+C4)2F>%E-IL
M@*I,H\3K7#S*40'G%-/MI)PUP.(LPUO^D-MR6,2SLDT'",F,W*"VF?\<Q($S
M^*C)'VSS,,Q(^<U?V$*%] )V^]_U'#R1U*+1B0(:$9WPCA6^JPA7#/OLSYN*
MY*<ZS_Q*J85W+.\"^ 5/68*3LC*W893GY#-VHRBXH$.H(AE1:&M4/.N19OL3
M?."!OTVT*_=F&LD($+:0L!B2K&*362PX^'#_X48=VECM!/ ZX_@2_NN:Q7T'
M46Q. Y3@';)*Y9ZA&S.= ":[0TX 7S!07ZM>".$^XC0Y$X_;JO9'\I%#+ B_
MRF@M+S4F ^)EO*0G!_BQ4Y>CIY\_]XV(@#I9.5Z:]YS+^]= +IXK*P+]$K'^
M@-K!< 5XZSF-:!T>J&S5M^C#A]'FR,R?_F_><6]&INVJ'>LO.-P=M2:8QJ#*
M)6V>>==27GX))M;EN8^57-P.EQM$PR!3J'NTTG;.#4>VL4I(#4JC8OYCR<N0
MP8*1T]RD99=[KI:"*]9+GX3(3OCDKIT9=I+,\ (YI)PJVDQ&X3]K^&M:D))Y
M#[U$]/Z6#GI7AN92Y>0]EZ[_ )SJNWN?^[-,0! TL&R"\E*TSCR[Z#KM_2AE
M!Z&WK[+$THL&4,^,^K?I]=(E(C"!MNG8R0K7'!EG&ZEI.Y8!R^EKK/*39[ I
MT&Q0@VN%"XQA]T3(9Q8'2BQ].!PZ<N=T S'/[BHA) 3ZML[(B>PS6=)BMG:(
M%#H;*]$/DR-+WOZ"PJ"CF]F/,N@@9W?7S^RGB>7R/0]WJO3ZKLQR/!,MVP#/
M8$@RM;3R=F&/C&;MP?;8)2!79IC0ALMEYKL/Q::-\V03Z\[]Q_HH+YR5^>O*
MW<>;?3!!QWDC4[3=L?_T7H&^IM*K^^KHSSM%&1D'1TASJU4?*C_&HCIF 1CN
MORX*Q_DNZJHJ$1OS T=9GFQQO(4LW&[R.4L?@]9#OXOR YG)O0N*)43^/YW<
M9POKG&#:F.8DW@&UXHP;UY2&?G1Q5$E?*2&;D^Z1MRG/0]U_MU^B_Z[W#=;K
MR+*<J"5T!2<N)UQS8GKN[1KK$+,C9O[G/.",\'T9<]*(6?RA=S;<$.=-UXLR
M=?Z4W[:IYF/AT_)S'>W-J;EIP B7QU3MJG9+HX$0,%!?N?Z%B%VQ^.I\>P4M
M^HD1@D$">*$OG4B@'<1QJPE2HO8'37CL<XH<T8NH=IB/Q8.Y-N"7QZ(KGA+7
MIQ7>9YJ_]!Q,E4@T\CHCLG2ZS8]T<[@.S $?@++7?G8R:1X)L--FGA#.%EX3
M$EQX)WY6]"*SI5BD:Z6:=GZ5FH*W9^P)8+E0422G4_L+EOX@5("QQ%$G@-1-
M@O0ZF)ZN"RT=/RIAO/>8;+R4_!8IV,X!#;;ZAQ%JZ:_3MC.%=#*U9P.GFB*3
ME?)N7WAM>GU!B"97DD??Y*,=T=T#(/,,4]\"'*/6DQGI)E-%]*$]9S"#L9D%
MFBR7?I"421PB^;:-]2>JSQ^_K(RGX62\RP=69]S5VA:@43KJ-8R):B/G]9B3
M(="8S@MZUY*[>#S2*B+2"GM>*W1 Y:G?49QC3A7/&3[;]C.8XM/+T!95O'2J
M#S\=]W.FQ?O(R^KZ3L)(X;2UF$5@11&R[8MI!OF7F_,.*OTKO$RB_&UEOO*W
M'T^&XZ@8QB_-06WGW!&LJM;OC<L'0T)4S7*EJ&W?"M63=U3 M#W;9K=>("/Q
M3$9&\?0:0K1/0J"F/\+E=ZM9WLSLK. 3L[<_>\Z^>'Y-Z7(/5:0F;!'W!E(-
MZ8%,FY,B1W6NTT?.ZW^=\0#R3AM$O6;KZ@GJS'GHNOO4X.:/%\ZN%Y]$9&E_
M@IFHPQ<]&FJJ)^;;'0OC\HM[C%'P0:D_^VV4EY] 5+Y-TZ;A .347XIY+-*T
MIC:'_4U"Y3[,7'RH!-2/MMJG_%#CU)G>&)^P\UBT>>I_@R&A)2RC3%:Q\"E0
M]:],BFTHJ)%0,#Z]_JJ[O//PWM@4>WQ(%-.3U\MY,K*86>[^.'(1'ME] I@1
M)FD.;[>>6@1&:*#Y5#F5C-LSP_(Q:C/Y<IU7<Z:<?_X'3'=)N,["]!K )Y29
M4#)D\'.Y]:@.-J[=^M:_R5Z:,VQ<8'?JV ZAL@8DRS%$HXC>31>O;T[A6618
MN-&%6LL>6UW-'[<.IT1B"&HKD*E#6S<JMWUW8'FUSIO5XF>K V$&KT#=-J9+
M]I8E% A]!$<P@X#<-6-Z1"5#Y<DN!?TNR4:33SZ40'1^B&;IW;S*_N<^WV.>
MQP&6-"YR"D'C-G'UN[83_@%W9=J7.7?<)"F<[T>M18*\?%Y[9[$OSNO)HT\9
M/+7PL;F1?4LL]GAO^D+RA/N@%R>NK/U?#_ .F3D[D@3!VI*IXM<7+J >J2^X
MTH_.?C;D;,-6B)9R?]6 ;^5D+T_5RJ3/4Q;J66LZWUY0AZ@YZ5^HAE7F+I@1
MX'N+/A$K+:F+X[7!TJWZ?J^=X]SYIE5#3S^R[A@2EY&6H3RDRM"*$3!(Y'%#
MLHXXV7$)\PH>?MF'*_0F@5;>H-&09J3JOC?(DQF:_X!:?]'K^IVS\1X)]9='
MD[#Q<$N/F1U+:8[/,M>'$"_!GP_VL>9;T/_M5@<\DG#G;0J<E:K['KPCW'6U
MH.U6?<*;8^2O]EC:YU;I2G?D-W ,5;MX;3HJ&BT0J:B0/U)9X7@S_WVW./>'
M#\P<AB!%E1\H$<8)0:AJ1 8<1L UJHDQ474H-D=[6*>[U\&@)NR&5/(6,7&C
MNC2UB<G9-\4.<OC3:(?OWP-J,MAIF5PM&HP**;$.G-&C&\LQ%IX6=QQ#?^MY
MQ$YG11;.;8(()B> V E^V<&0@(#RCM/%?<IJ";JWJ/=0U6B8EX 947H+0S2]
M/R*O6&?\: ^3.6QG8W-[U%@KD?WL'?VS'V,7 ,JP#L1"&@)(-26LDES':E'\
M9!]+0D\^_7+SQV=U98)>5]Q_7@/@)2VD#)G<+BY,<,?46G_P&F1"[SJ5FI.\
M(R?JLQ%',G] A#MAEOVFD1!N_ZX ^N\&[-/_B;TW#X?R??O'[Z(D)"(A)OM.
M"Y$PE>Q)4H28BK(E1=8P1=F94!0QE:VRC'TW8U]#B+'/C#7[C&4,L_WN/K_G
MMWS?[^=XGL_W.#[/[_O[/D=_W =S'W./ZW6=Y_DZS]>XKNNL?*\>.&D[]NU3
M6[9#XCJJ+^WZ(H?(V=6YA:'SM^[Z2_E2O[TPNA=4E$+KHKRGRM'<Z3&,\TM0
M?HR3DK:6&<'T;KH)$S@H[Y_/6^+A; -T]K<*OQN5J/.J.-;A)BI/*:+"@D=L
M%)'<3S$OO6@B1'(V\CY6K?O!Y-0$+>S8:[$T\_+"=@6A,\>G'PNJ+IE.R4W*
M]Y>E! E9XBK>GWSI;/H5ZK,RX6T*)A8]#XKXE4@U9*L5@FYKO[!<>0P?_<%J
M@1[L"3JQ*/J(WP#!$DFRY!:@F-@1JZJJ"ZER0Z4=>>C^PU<%,S9N/&)1^. D
M*%JVJV9W<\5O;,<!M-=GB>_SYAW6528;6G!R 3U#M7?$#8_.G\[7_[[HU;C@
M=C=',1TV6I#9TZP46G:!LQE/^_:8O1X5'BPR'CP!+=M^-44J2)S.9R/DO%2[
MYUA8MCXT7'LA'JWTVO1L_\6&A MFY@W[T?7T:NB#&M1H*AG^LU8B:T+7"64[
MWO)U(>%V@KA;1!-7G,&%]M6JY5NB@R0K4"P*D\OIR8'"#L1>:WJZ-U)HU+F(
MGGRUMJ2P"BZOE?8%>W1)\;3\/!!SF$T2*W+^G*E9D-+H$'8>WC0;-.]]S-,]
MGXK+Z<1%-@>/(HM4XM#\@7M^U@:15*;+JT@"-TJKRD.Z#&O/=#PJ[I*U%)M+
MZVCT."&O8F9,C28K,($WOA0HHZ4&1S\4L ,AOZ%(4*T96#BG-T(@\&*_DI9<
MEI_/D6>? W7Z[KE%UUURKQ<XE5$CR/J0,CY67&,I-6D:Y$+E7D@7+Z:_5$4>
M6F((#=5"IT3.F/U\NJ-:9WLU90B?MEYZWR&>_]WIZCO//3W/G>C_VKVE=5ET
M5[6VR@84O*<E//)^?"D?A/4LT(>6BO!@7,N:!Q^E77FC+.G^8$2P[L+SUU#2
M] YV%%J&H:7@6E!4_C(5NG3 CBWCP#:QMQ7"B1:D72@#8U>M]Z"=G2NQBU5S
M+DTMM3/D^-&;;V\4LL5$[0Z0/_:KT"Y2-0+-!E1K%&)-KM<2)S_M*TO[8*HX
MT#ZTRL_#Q_O=" !.&^4_86Q*><S"=HV/PE9_@D7"^]_GKE(&&.Q'G'0RJ,=H
M>J5EO:-.6-14M(AOV:M"V,^H>2@^(N!5GLYQ2DFFQOJ6LT?>@X2S&AZ*F9T:
MY/L>/75>#'8!XD8+C ON!.-90"L3>XH(=OJP([U/1-++[BI]Z.4I*[_VCR"V
M%&P]G=-?BYD.7TXD)9+MZ1_5S&*1)4%Y 7-IN5J)KNBCP'F5=[Y=D 3K*S]*
M8NOU+T=<Y;OSH%K!R*+Y+$.P\91'B9$:96VX\Z2W;"9:MJ-LWF=@9\QA$VUT
M5'9B(N1SB'7J<V#1;9W*.+#A[_Z%9DW_6+#\WK[G6:[U'<=C^\^F+W]E&6"U
M1$2@-8.',66/PF6>JW*'6D'8W=4TT!VYE.A;(5,_,Y7/MM_S'SS[==^+ \4Z
MW)T7Y_+A#1(,=@H6WQNK<\K&#]4X.O?J86O/9.>V9?]\2=2F@52["D_\A;LA
M.;,R>\+S[^I#T5Y)Z<L)&X.PS8J@9T(_$\A:N<'.N*[=(7KI:O ;JYC@4<BZ
MR^_&&\M6/Z&;NE8EV 3&T*ARQI392/A4^MO,6W:N*5GSX2H?RXN+7V6G^ L=
M/1@1Q7'F2#W@B#TK87/&I(06^X4)'-7YLI/!.-#+!*0SOL&'>WV9P&>EI78,
M'GDX ]Y@!'6V-IZ[K%F=&\#RS0 YHS#Y>[.R_1X2M DY@C3OIUD3NFT;=U/]
MHN:\BX?R[I>^:[W[G(U=/-==DN>#0ZC]72H'38Y4\1+N@8ICB&$#15"_JO=G
MCB*'R^QT3=(Y;/-WHS3]KU>_"NKDX,J<X=Q$69H&>:HPTC!T<1E6CZUSRN@^
M^((GU!"R6M&/48#CXY#K-NCS8''"39>K1 V>I>8LP%)P1&/82X8&Q9?D-:TW
M'T43GN+FM%X4-1M>54M3?F:X^N3).1U;P^<Z>]ABB'K^FYC)1,8,1J(@AUH"
MFPR?ZS&;\J!EYS;";&%T=>V@/6"-&\ $$M4Q3*!P,)SQ<G 6QJ-SA#(%BIDE
M N+8&$6]64"4Y^68?PK-YO;*G7>%3\\7[/5WX+RT/N&'RL;@/^)8 O6HEX*_
MVS"!5S29@W:4L//109?ZNV=N,?KO!9;>305.71_N8#FQ5\^SLN)%R,I9AK$Y
M/+X..S2V=@"%5##0I7(S@8Y/-'$F4.0Y\+M1!A'UUWT*?7!\.D80[JP-L2<B
M0=49 3VPI<W2H'DU5>V#J'@UD;Y5(A;)<;GX:EO'"?R7$YRTNMTI1CN4/="+
M@*3(P5O-^-Q$.4G[WQ)2MX=BL\N"LGJYTEJIOT:AR@\N(*HNW@WQW*\74*WE
M46IKK":T\^':]N-'J9.GLS%G,/0*S".X, U**<N@':8H9=@N8GC*]"),@CRC
M54;L[UPQUQ,^G$J>NK1^G]^P_9R4OR$3<(2/V4XY7 [TH.K;4AX,71#$-I5T
M'>]@=)CXY?_8_C5S$S960C:EE&4R^FV@*]Q$FW:WT>XO(2;=IT^BM+PNI=_R
MCHW8</ +R9"G37\XY*FT "O/60F=[M+8M&,A.R(-2,+2V$&U&I,:VQ,!1\T?
MWS-?YLRG8$44-'T3:E=7:ZMM=^E7HRHL;A?T%6-[\QE.WU>(4A@G.$7.M]'L
MX#BED]J6DHM;J-@-*_GRR<@QW0@BL6^BJ.@:[;L9U)CJQ3BX!<:&!YP)W,WE
MIK/GSD .,SHQ(FCN8"SL8+ 4I15K34G+=4TI*RB:$K%HLC%M6;9YIE1O$)FB
MT=[85(AXNW_/S6-7D#^@%%GU>AQ/\ ]DR5$, <[>F!Q\(FX*=ZVTQ/\HM/0=
M4NG8@WK.&^6G+[0#\1;6QK=D97(MW,>RLB -ML'ETFE)RJ8/\<D$E1XF(.%!
MEC-()&M0KA>)%*N'N8<@=6=)L 1X(6:Y:0J*P!U&B_T2@K6D61'TZS)8GT64
M#DLFF QN.!JQ/*P,WZO.@?7=[9GXW8$R)(!VG_YQ,^A9(YR-<8(F\7.3FW5!
M\^'08[^HI:;MH>]ADDJ\'><ADJ$A'Y^?6=]>2J6:,)I_4P8OXT=BH#\]=?)\
MFOZZ;]5/FJ8(3VW;7-"764OG^^<>(,2:CA?XR0W<;+D75$)YD%Y7Y@-/^_[5
M*\CZAXVQ,O2\$AP?V,U-\4:T0';/PP3@>"XL$U!TQ2VCJ.R_,&QP5]E:1R90
MJA?>;";@<F^.R^"RFZ/ ZAJ+_N5N<H?C]8_SG.&KY*7;JY^HCQC#Z0I]X>&E
M9B.HZS]J+33?V=I6]GOHY3W4YVB5YA#B^2D0CXV[R+^ (YHAAKV:(7O+W'VG
MX"T<S3]U9/PBCVLIG$0NRTE$2JN<V+%W>JS.W_G\)/NXR\!<S'BYD?8SG(G*
MSYOG;O/9YY?EN'G#/VWOXS.W_O>76@6"Q+GO)"B8'0A0*B>$?GB++/7W>XOW
MX6MOZ'!=A""-772#J@H&.H:F S*-4@4CFL_\KS>L1"4H UOP]W4JA+8^B BC
M [+^3/0L$WAFR03ZXV&?MG8(5$EXQ[+?&'W%E@D8ZP6'8[^"NEH42C 09:-X
M#+[B,[<7_/7W[CK_===_95O+?UDWH_\&%]LYD@S#"!<%7^;W!E.VS3_.&H31
M<9'P;2XP/WZCRDR9T1(Q?$Q@6'Z)"5PN^\?N1 P5P\L$5H690,7-U;N8&5C$
M%F+.?Q S^340Y)75SO]T_\W_]/6WYO7D5[_WB^Y38P+Q$J#1>4!WU3NXY8G9
M[H1C]9\XP"=F@J2H4# .V"D@L'NK2%"0D+!!M[F7?W=ED)0A8.G1U7!&8IO=
MUF-+AF*=]8 9'O'17(\_\N._LAW<#H& V3&ZC2/S5X-N*ZBPJ8/Y>[>PJI0U
M QK'EM:R*)BGC_SGNY?^9R^MBO^D]=<*O$R&EMJ+ *O (RKK*-#:(2[P#C&2
M.CT<Y ,C LHSF1;M"H\,#D^#;E<&G%D:_2^P\-\7/**9?U\9.=K!!'!W-VCO
MYZ>9P,3L.JVWA@::^82(.J,N@PG\V.=L^==^8:39FO-##7I\-V+^5Z\=_^NE
ML#[&X.!G E)>OYM5%&S#=\U=8%]5+1 UEFFP6=^M\93H]+?&L.]Y?.9ZXB'_
M62O ?^7UNSH.>0?O.$5$TL.X&1$!5-Z_W=HZ#49;,.936PR#%>%/3X'/X!@0
M^/#1,3 4HV3_\EH!P4-SV<5\GTPF3O]"Q('E'&)'&R$,K\N%+QBB?NS2B'_;
MY?<3K"T0$&(&@H6FOM@8)8OBW+ST_^$<<+_'X#\AUSU IANV!"L+IP($600,
MH]M$*SKHF0L/MWK^DQPUGDR+FF9 ^](]F4 @G$ W\_G7+QW^;W"Q?* D@I2\
MU@(E'P19LD\))@QO4&&L-6.H84Q@93 H\3_.4=LG<>LJS0%M&UJ+N+4;:'C\
M]OU_?;WR[V0;ZB6T"CB2%";0'@_:_ #HKI]?!53!J+/0I0R-(LSJND["O]>*
M\A^=:1*.$)<8+1,@=1E-%^Q6*L"/VN<MY! -?H"\T/SC7TDR-"(11\LL\* >
MG( O<+[]W3KK[^ORQ[M],QC[=M-]N%V80.2_OMX3M?V/5]F3,:.)#-/Y-B9
M9D_>L8J"-ZAB9EY34AE-(!MD$K%5)@R],F@S1K<'21W7%MQ:^2^P\&_-?@ZT
M<'(]?&L!]+1/;3 XMAY"M$#N" :R,0'[9-CN<>\54%.L%>XPKFR Z71U?2?8
M:8(!80*O#X$^8=_'!'[M+56 _H\+\_W6)]*6[GR.DM?_'_K5@==CF(C.&6=,
MR5ICG6\;0[P,4]>WZ1V9$VH2*UGI<?I&I(]"M=Q.)NML.$"73U[>(&V 'UQ:
MT4CE%O6[UWN]L%]%.N4 8?!SW/GG?>?TI1SBL8)L$'4SXW50E5;0WFTW]^[.
MW@?9=.@W54G#9SH#3X$VY](%:WS[*!WJ-^2(,2Y\YZVYYT".%#ES8$<A%<[#
M!/"9H"+E"PQ,)D CW;5T[^8V>'NXZ12Z?V1TO_P>L;@F@YQCW:LW'H@^MWP&
M=B.7[5JGK@)GR+G]&"ZHN]G+E-XV%8HL$XBC"1-68O-QETIL]&3V.H4;&35?
M(*O,NK.2D@1197!\$J2LE@GPU7)#&Q''QHT@<8$2 LF/'JV7V U_&F9AZ7W/
MWGC6O[6I8^)J%/F-!9R_JLX2%PKSG2J"5.?>)_ZJ@]".K'$L-0\L%RAG<O8U
M"!LW!+S^F(@(5FAD O=A8V<:8&5;J(@"+9&LI5%79S-67XG;%2'B<]=F??PM
MC#[X.YUK,Q^JRVG&K2LM8K865!C/W394_KIAC^\7=0.<I"BWP<[FFX&O7R9;
MJU$@-X-_0HG7/,+AQ;#831R''T:?I)/Q!;:P]%5/.M+-0_'2V03#>@=)4MI(
M;"40P]/M-T_30>'#Z0=QAZ%$.P>P)'T[!27>$%8(,B%3*#(NOJQ6ELE' VY8
M7#S-9L139A2J((</86<5K4+UPR@/D"^AF\:U1YC RQ602H3S%B9OU&6L26V?
M<1UZ!7."S$93^S:VFQ 4!95E.HGE>ECKDN4@35BU1R*69G1'(J)H*T'@[6%X
MZ>R%+51A'BI_2T%#>44F:K'_J?6]=(%#"6*"G'D:)T)?ZP5V4"\P@09-!E>@
M&]&.'I:&IT,:1,771_*\4=S#;0_Z3&-"Y?7Y[U_RNU/_X4A(SG[TO=^GF-(>
MDM1#&&)^;61/4NTJ5DAXW"A+3^$15;70^/KBQ*TM7>0I@XMEO0']2"7]A17)
M@MI^W%R,4X"+F=]D;T<=>F.3$27[55;VBPIJI;1&;DWED7AI:86N(O9(I>'T
MA=/6[XB 2'?@/XX^-80^6#NT9)8U0;L^,%NE/^I85%Q3$ZHSH,NA;U#Y\'IU
M775<#_97D(*>5SH+)9;@$64/0=PFAD>HKO$N\)ZZZ)]].X\4=JSSE,5Z87OG
M!YYT/2^(,-QY+1Q>DIZ:A:/IDKAI$D,IF2ON+C+#!8\"._A]^9M/51WWU> W
M55W>9@+::-+OMJS:\E'KW#&0,FS#VO,*<QN_I;84GVBX>&[T/NM'!2&%G247
M#VI%Y13)[\EE FQPE[572,B0.9Y;V 4M5AG)F6 MH:KN_/SY[;'._U>S5XQR
M^1&?DB"S:[\W7$9B*KCK4:&[I:.PJ&#)A;/5;PXYI/2TF\!5E0\=;$]:$-,7
MC=F3];3TOG6=^:IW#^TRJ26\"0I0HEM&,ZV.+%2+O-R-_6[IFG^FC5?@SHOW
M%^_Q34MR;O//X=B9@+M*"$RX+&(3R19XN7]+R<:B7$2'<+^X\AW^@X%(HX3A
M8_;&T/I\R"B.8>HQA:5'C28S$K7UG.2?9JGUG3'FB34N"EWL/T)^0,_6.D6]
M&:B-;-4Y4CA8NG):>$&5'&T3)IM]6CR#E]73L.;)"88BT0]EB^KAIDBA6C#[
M:8+T:&_W9ZT,R0&:6B:";^+S.,R8KYUQF<W1;3OSX5Z?+S*A+4'FQ";R+PH/
M*=H.H4=$-<>>7K-\^_+Q"$Y/^V5B%5[QTI0&K14Z<3ME*9<UIX/K:32U'_ZU
MXZII4WH0#C^J/9+JFO",$QL2W(4L#P^!N[FA^"\2N%1@ [ F][T3:8\F#X3N
M9%]#P]ZJOF]+&.G1C*NKFX-M>6RJ[7B HO8*2.+8-LCN4C;\E]7;MRK!7M$+
MPK35^ $I5^7/N!2%M2HR+!KN#F/U4R>_ZT.SV2_8GTAN24$ESMC;CM4_M.K6
M]QZ?NS/]ZERS$PGU46$6)@IO.@5ONN_GR^"%[:A@?C&!$>0ZJ*W2W6>8 .@>
M>M0:]/9T]S.5UMY1[GI(24YXGG=O1  3H$F,VJW\**ZHI(JT].Q$G5D9XWS4
M-*M_[L0AS:''R:MO,K=JK!;0T8,/:1T)P7VMYZU=L.ZPC%\!2OPS,'Z,F\=+
M"*O[<A8)%;<Y<=2D_?H<AW:QF0])H[.#[/<VZR"\]L8A>8]09!FL$8;8,/+
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ME21(*S*7UKT /Z0301LG8J/0)_Q@Y)<DGPPB$S"KK".=L<=EC(T.IY;SO.^
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MV35Z8N]/FF98*!#7& 3<KKCQ)I2BE$Q+Q;U@ LO.,+ID)4H*7F7 0)N 6=G
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M?G5=4G7%>KU?8D?2@3Y;T=1/3U8H6!/C6^\K:EU:4%:.( 55SL>]<\YDR'5
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M"4H9O. 6*HJK[.G7KSI.0![?L(,N9X"^U$:Y2=PF%,0&3>,X1OUZ6[%#7Y_
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M0(HE,FBNF2/L_EN^(C%V"^&6A%>W : GR.SWJ0@&N.>B&L1TQ)2(3*N]5LV
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M>P5\0>/XLW+R[7;!*[F<DR5RZ33BO/9DU?W(]_?X(]VZ?O9T+?*KHK5 +@Q
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M2"M@'HV4E<B4XALJ&]Y_S62S>JDG=*2D1#6<#1@'=5E#E'-VP2:LYBU+YQF
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M/9 ?/ Z;VJ*G##HLH!>L@$1Z[$XJ!<\ <*Z&U/R7;X_^W] N++4C#B2@5QF
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MTL7VI(9OBZ7OE0"G$@VABVZ'6JE1N^G2,H8UT;U&E9'2I:59]H7<;ED6W*\
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M,@XZYY_@&6X3\,G0@O^98S6L_DV!9F3UO[,J7?R//%9ZP^T8(?J6Z(K,! -
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M) U_W;B()AAN4G0/8L+6, ?BO#>-#&S;1GHTS6(.,K'9CN1OND8SK2&_)7)
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M*Y[G&@;(W(WQ,:<IWX3,/B0E8J%MLENFVPQV22)\?GZ$<15ZBBSA;.J74IG
MWM2P34OR7G;KG/#9G.I0M;].Q:S9\NG.% @5 F3]$",X%6WT<': P4UYQV=R
M[X" LRY"UN6!B>:1*XE)I&!B?EP%]"19 :,W5BG54!W&(*U+/SRG(VH^FBRF
M<7D?LYK;X"CL]W[+[-;G ([$J'/4NLN9X#"-H&[X6P@\^]L>XIM%%Y)@ IL
M(*X2$Q)X+H<,,?V],_5%C.%:,/4HXWE"RCS'X3-9[Y,2ICGV-Z+Z7YKQY\Y
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MCI%9%SD>[ 'UQ>!4(Q!.X,BK8,+]$^*XV,X.^:=KG:FGLK7G.S(69MI.I/>
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M8>EY@$)X;AS]^DX:)&2'DE4W5.04.V^ DEVJ"IL1_O"62S1'4^/9\0TW]',
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MYT60I2I1(<[23,<;YS?AC2.6/O3*4!<^'++L(OVK@-O&+;GV8F=LO#LG<'6
MXC->)'P&!E@JW4EL#*[)FI'.$CK"*'CN\AL5\L HS9*B,L.FW^;JV"K5+*U
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M]N9K;[[V_E^IO7]UX>]G^V\I/Z2%',"RE&"@B\53YI=ZN,6DW,!_%$<X#LE
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M.L'5VEL40.FU*D>JT^-17Q6S'"L"XN+IC[$Q81]>Z1ZG,'!Q)MZ<FUB>:/?
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MURH''J?DPV6XS Z,%ME^<^*"L#_##N7"^.G./-0=M@]1 N//#$V /\-;Y2G
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M2<N>L[F;$R\\OP:T2L1V#%S/+AMN^%AP^*[?V3'O$%Z05C80J1O,I-U$3*(
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M5B+S4Y4+ZH!U KS;#B;ZQ?^[2[4:\ K;]GU>(DF[P="6ZIP5/H<^8=A$'"V
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MS(>"1 :$OMMIP@2*/%= "EV DK2KD&1Y0957LD\7[5^>]> N[C[*%WZRW>7
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MT%T.6U5XP;K1#(C(6U0?E/GJ0QU% !+'@)C]\1FV$SV@0-]M2)R:,)E?'V-
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MN=H6129(RZ&V9OT<'M=/+1T74X:LY5XQ( ISWRQ53WSL1ED^2(+OK=J=254
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M7=\Z7J,ZU]HY>L8CC.X"([S74=H*M4C]=+Y$W-:94JY<$;A5BRHP< D^O,2
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MX>DIXHS]NQQBQ_] =)>0?Z3"6%P%0GUEEI.>)4^N7;P 6^D!-O_F8?-$"T.
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MLT;YOUVC?*D$VGV!_)%>C=O&.#+FM=O]JSA_IU30ZMV6*,PC+N_*6:G0@RS
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MYL)UY>L)>8@Y1SG1I\RAD+!;:'VH'9$S68GHC]$-DA?^E:EH[+(XYSJD6"5
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M_DKWPFPY?UY8F95G,,.@K83&Y?J-J-8_WO.'SO:KK[W:_$/___M#,\X5+$!
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M"E6&;RYS:]V\_45Y*-CR\JP-6WY\:08D7#L:P.1'!<#T^O8=%D#I1Q(SL3O
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M],LU?MAQVA$??AL6/@C]-C7SWN^C82)NH_(+X9TL&GY]6>W#B?_0"'0ZW,B
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MVC?0_O\[M+=0MSU5B.)T-'%*^)%MG^+X/KS9[]UU\=T9C-;Q3?2$:@JZWA#
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MW?"^?&K)XV4<CY/[:IEWKH-B1!-X_^R5%)XO$3=#'F5JNUL6MKS[<C['CF:
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M<K]DJ^R<BW%H30?-V=K%;07"3]C8*UEGJ'3&ZV-R"#Q5D^,9]6CZ,4(]HK^
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M$1*ZYI+[)G)X>"]OPPX]?MYSGTRW/ #FI!I )V2?X6=T4<FC0OQ.7X)13^&
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M 29_"JVJ2]6=NGEV9#+8[0 /]VT^65K->3HC@+*IHE@L2^O9:3: .87T<I]
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M;,R/5<W+JPUT,C2BYL "94Y?QWB<R*:)4H0H:6M))Y9.SS#[1AU4V?%6).M
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M+%5F6^,4ICAPW-LE1HR6*GZK?K>M<9K-TV\(.V6)3MWR&^^QL4X\(M&?'.^
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MA:*&4!5IP'GJ2">\O[\9GKBW2+YD1?T I]X'47IU_]-WZ*$!78((G8A@&B
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M[7EE\:-)GA+;8)9OU0V.?C]*##WAV-U<DX6:9-7/:6_WYWU;-.FL^G-T:MS
MV8^!._7XC_Q\]MSP+N7=>R"N1V2]6T,]GA<^IA("D7>_Z 4/+-AM9?J:#W;<
M>=(TF9-O 8VVB9$R%M0UU99?>\*CHP=.V?GBTB^F+S.NQ4(2(Z+;A_'6&%D1
MX<KD(R$-R>IW-%X\ZSJX8&+S#/4IWTVHX3%#()N,* W0M9BOCXHY)9PR[!]L
M^%#$'B6=B<8<ZX9)##VLLU!O;S8MC/(-&4-@SZ5O9?'L.$:C;.%<SI^T/LM7
MVI6ZW0E.-RLML%NJEZT_^(1D0#= /OA#S7)N#96\^[GY5LU?PKKD$J5Y39>I
M.D1'M_V>Q$GM7JEVG=):O3&#8?E!@R$1=XA$Y[SOP3P?]\%&TZX/,7W'V#);
M$-=4.BML(ZR@_>F-<5/:1NNQ?N'N2]SL<]/,!_I#'QY^Z*D.D&R17J]]E.8[
M%2UR\XQTTNVP+T%B]@-0/:(?X0QZL_1Y1O\+V:H/0HEL#7)>%J,)MQV7;NR5
M.J,>WC-7.4\<$+GY!%F8PH3G LU#4\SPCF'OAPB*?:)PR5_T+//P;4^R45E1
MB\#\#>].]O6%F9R),<>>7Q;O@O4IV<$/<4V32(]U6]3@JV?H@R !T9O9JF$,
M"NXW.FX(()60@XH3/QDR'\[&]J[JE*H2\G[:9#PF%7T$>_"%MSUP"3IE>DI\
M-#<O1N:76LOOXIG_&XMG]/XHQGR#S:$WDFF ]B"U%;-UCHB@HM#T5DPL8?Z-
M1P19BGUBLR%KS_'=+V,:4 E+(:L_,[2Y:(CIAU 4^Z>6:4 W#PUPAU"DL@=P
M06U1[3FLP4H?TS"R-<8EI33@UHG'<'+ +54LHG4$++Q\T%YUZ'+3D+M'Y$"<
M*&H#C;M</8\I_Z-*IZI)"+,L_[7[G4W-T$["97[X;(O^P5'G_-KH^90:;<$T
MWYW;BD;ST$B\(8@G<5$]C?W'8&:Q1.^DA(01+F<N)%OW3K9=&O9"Y;!Q/'+1
M_1Y,DK@YTTF_;RW<%<DQ_N&<G/Q!2W? K.:P#@WH+!#%(<O%:( YYAHT$R:(
MGL=+=-X2O>?52P^Q7F#KM;94)SYTSGE"\Y/^4AT^'&S=*YH\LZ5UQ+=0YSP-
M^/HHF32ZG2D4>T 0!44O2T<C;[D105FHRHH.C&"#Q$((IOHD^(L0J$QF![QV
M=;@R-JS8H[RAPV'L\&R2T<.X;>AK&S8\=S8GW@%1JE,XUK*A&1_C62=SV (O
M (J'98Q@[ODC=,(V)H=7C9J>W4@HBA;UZ5]A"Q*!//@XV']>(&[<M)#=H"Q!
MR<MWNRK9)BH1.WR6@^-%*Z7@5],MJQVR$3,-B' D:<+[%Z/H 74!G JQU@V-
M:D9%UO)Y$[UM<-0LN<&/-S'CQ?+3QT\_G'_L<TEF'O$"4^D8UR"$O'^E: F=
ML?%J$%0QN8P7Z#WG/_7QN#E#F8[2CPP"- Q5 4N3>#Y?C]](&G2I5=R(G+#6
M4&ZX_.#HU@A;V]ST(H,PN[9'VZB-041W?DPG'BS!=;4TZ;F+=(*US_,B5QVT
MWVCA<-<]F(2P%GQH:?[IAU_QE$414]3ZO$BC'.IM(<G,?[8E^QQ13[GLS8R<
MJ&F3P9)X HOF4F%R_->7']MF65WY"'PTX*5''&2U%$D-EPO87%?'H9IS6-R?
MOC'BJ)Y927OX+F/**E3,\ZJ:29BJ_1NU1:+56"/+7_\J</\[-+2W0;3X5$W!
MHHY7W,R*MHZYC]V ZKLTZY_U[49<T6V>J<*VL_S?C[=OU:";5;^L?J@GN5^@
M$]8C+PY/*2D"$3HLB3UH*O@M#0B!9X6DD]SAW6H#D#59U,$Y2^+W_QB!94UC
MR"_KX):H@_N(]%G,_BDC\@4R8D@--53TPV(AK?V#(#0&=L%!$T%HG^X?=.0Y
ML.([J#I@)O\@TO5'7+<#0A!HH $#F]!XBC#=URLIX'Z2YT)0+Q"46'84?41T
M"3X"I5C$P:>J:,!8]4_8.'3+H I!8J4'_'D298Y_8&XV"]HKA1!*GV)JT.2D
M=5%J*QV5I>A565UR=C55C0:L:$@<HMN4FZA6"$4NVX!$U^ENRR8:\$D+<Z B
M>&!"2$RX!V8B?KI^W*.RPQ#R^5Q<SD_E;>A?OZ^PMLGIY-LD\<-'^.P.EW.(
M.V%P?;7Z59ANW7?M )%S"]Q;.2=Q^Q$>86F?DG<,-W&:=2JQ;4]V]2],&;IN
MZH%2JW=JUS2_4$_VGYS5!+>*A"@M>%)<OY'M2>K$U9; M=0+3A89W\J]3C?]
MS'6V2_1N%:X?";EF)S*;<8 @V!&5@W"5K6EHRYZ2P.'W78.72X2ZX@^-/4]0
MM7^=Z?ES$/48;Q?K93DA;),@Q,.<W.8E*=FM0EGJ_B)W1\]GU?X+F"6BXGZ(
MUDI.=:'D1[=ZE2I+\!?-G1K2VEU*R2C?-*S\RX>,$07T=^ARQA9FQ((*)CM3
MYW.VLVMH@!M2\)HKME&H!:_/-CG9.5ZDK55R0\ "LJET"E[GRD6@TQ*!$H37
M.Y(7D3V?1IA'0(QXQ9+2=8=WC<(NSB'D6INB4;OBEEK!A_E,.)U^=*K'EM-.
MSMC!TG@PSY<K.3NQJ_Z&X,)]&M D,WU RB=TTQV>(F1-RH,&Y'9#6=!K(D?;
M=<-ST98IH)FTI>"B%PI4'KKLV:"I*:*#8$:R2,XL1TSVMR+72^>^':FME3ST
MI !K[-VQT-RL!1Q?Y(<\]O?#JH:"A48H[WYJ_RQ)'35H>AO(,W=E,J[BT7OR
M9>0I2N1B#1B$ORE3NQ[KPX(J:XGCPW4%;L!=/ X1PSLQ'&[K9##"1ZYPI"Z[
M0Z75,/3N$\B+#^KCF$PO -E.W-;LQ/,)@_G;9[.YF 0D/9Q6&>6=79*]W <6
M?/60FA0HZSPQF%V7\L$PK/C>!_"FSJ"!KEO9&A)V()A]EE)(/45T[=/%LUIL
MG]W@="ZO[MA\L*+BN-+2"%8]J5.F<;X+^0Q\"O;-1A&?7>_!^S;?>LE2OPO\
MT^?]]8</TN?.J@A$"Y^_L*(=0OTH:F8\H,,(LY_19<-A6(9:'U3(FB"-/VB4
M]BC6MG8U_DJ"<]64#:.N+1,]+O9MVYN7:2 JPVKEXZ%!&[LU&:.BVY"96G(*
MB)\&C#ALTZ/1QI ]G"Y5CR.<!JSQ,5&?R4S#8U\V@'BT;!.^6)%LUV97E1(/
M!$FS?UV_L-&DJ8DCF*.WX>M1K3A]5XT.B44:4)@C3AWI,^IPOJ+.8%3+,![F
M&D$4%=7&!S7/&W(0,EF(?  U\@MR7(AJ<!&SB_4@QS^!,\+GROPAU!:Z"!Z<
MMUC;MX3B.:20!\]IP(1NF^.MLC,?T60R- .BNXF:[9BEUM=N*>]ODE3X.SLY
MF -R_/J3M[<>C1_,H*XJ_,_QJ&D:P&F !?$X"_XZ797*9SSAQB04]DD<SIE(
M1&_WA_,+IN>P+1(%(<)WO13NF;Q/F^D?(*XT/!EI:&JHB2N@+AZ%I?JW?J,!
MSR$V6]YTQ!SO[_NO?NEY;(=OA]E8K#C$EMSS3].N_%5B;_6&I<O\;J:7P%W'
MG!69&8Y8>G@!BFX0G1&J)T,*[Z\&'AGDJU&1M$\]81A<>R5U/] ="+O0I<6.
M.*P6I=!CHRK9)RUM9B\N_GW?X]&O?#\W"[>]M<[.U\S$ _Y@&UXM?/RFV].4
MC,"G/^'7>K6X%FA BV-N &05525'\"%-V<[N(G^)?\<FU,\T:5$R40X4'RT+
MNQD/[KMZA2,C:ME3W^=LG0M!3U^MO#72FDYBXD?F4^6#+]<0':>%C2S3?]TO
M<9!1ZUXPB#QR6J0.<H%@8@.)'8T4BE/+/Y0\5VGFR-,U88V^.%\]G+UBX6'O
M-Z1D<[S%K.<3?YR#LI>.>>!R@<F7VBRJ+YAG@%4.OVVD0B1!R&+X@*! -]+=
MSF5H?O5^^+2U_B753AN17_+0/?.#E,:VDLZ*GA(]<O'.OI"K#+MG5QD&9(O;
M?W=//5B:PX:0A%K>2R?"[YDG*!KXB:VO>F\A;],M#RGG8 73A_X)_U0'&6M2
M4)OMILO+CP*D"C&1!/;_>05?\];#'DM:-V^9F9\:7.G@31=4>5PV4S]R64VS
M_ =AH2F=\AK&O@)BT5*&>Y9$Q-X=LA8T\'DP==V)?4CLB95LVVR"-NSM3"?/
MHY%LYN)K'#'/%U\0@F,4;WTQ5'3O-4VRK!WN]0TN8K/G'[M_N5#CELZ;E/%;
M<AE0N!'J 04)GXN>HH>CZRCJ<]?9G$@0YRXHHDF^!GUQNB+EJ/IZ)M;QQ:P7
MUWCN:<)ID4"+$4SU)CE1$W- ^7]X>\^H)H-H73@61+$@O8.*%*G204I4! 1$
MI'>B5"%"0*2'1*5*%1!0JH(T*9$::D)'NG0-/?2>4$(@[>)9]\>Y]WQK?>?^
M.3^2M3)K5F;-^^YY]O/,[-D;>3J'N "!K6X<HA7-^GV\K.:HR<.XO[3"1LM+
M,/[QXU;E<WZ:OJO$5)1_>U.[1)^:?%G4H-N]SYZ!Q=_KJY.C,9LEUC,V/A/8
M)@U!MHZ ($M=T;$EV[)&]\R<]1,!;:(((1,G$/LM5J,TG6_S2G-YT2-5P^K(
M)8WIU3\6Q5/3FL%G^ZY4#%V.+>EJ38FLX .OS,4"*Y\FBX0[9K18N_X]C E4
M4F.V4PWY(7O7E(OSQT]EP8)  H(.U]T.C#[1^/E\6-Z0:5WIE=^7%U8>SQ8G
MC,T>GV1:K!RHJ<]31=OTY1;(DQL]2D&^Q](\_NZZ18>&LZ-ENY!O)1U<$T;F
MRM#VR]N0ZN+9(=Q<G^:6=%1.%>(]]:9U/^A)S..Q/\SI$5F<']KY7V]H6*EL
MUKERM?*!Y^>XB4^/6E!B8P=\FA!,J8N,G/2,=VP)HXOQQ9/)=5#8]J$^Z(K;
MW4V?LL$*OE)PH#S<=YE!*9&X@KI.*:J)L7-=](_B'TX9813^^_?QC5^)8NBE
MEH0VU%3+X*T!O"79WB"Z?/-9(?_+VNEZZZ2$AMFF2@NW0#NAXB7\A%VHI5@
MT62I"&-CU5BP-;+12$ZX<ZI02+SD^_^CF^O_I6H"R'[ROU92*#>C4O3']N6
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M2F:V<]GT'>_+\1N]G *_)H?PPD:=F2R9"P&AJNYF^1K.\F/E"WW?2U,W^@9
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M]I?72C 9]!D("H@]9?H,K,8&\G/9<7[UJ\;]IC+&'6:-<>GZM<4G;S3:*,W
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MZ#S*-52T^ ((4T5()2;BIA85"[\%^'3 _V),[]Y?AQ!XW+RL[UKN!/RM%YE
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M$NWB'T>:I@N1V3C/$!G6FGA(UE 3G,>2CPZVL=F>[;G]I"6DYGOH[[3C%AK
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M/-DC4",<4Q@ 7V3/=\[_8[U>"X:\ZH.X,G1R"@O=#G]&+Y)."EY DY/1EVF
M/V*3I]R@#&I#LCM],E[CP,V)_VB 7P^0_NPH8VL77VA?7<AVZ:^*(OH#?UQ.
MH_=3_C@-OCSE!R([[DFH[MAA:V[ZR$,!U@T"QC[95?*0TNX1?5%;5P/5<DU7
M#2 +7LMAI+9CFI>C]4L#TB>?U'O"ACS</1^2V*4R*;+J W!S;WHN)U[IWJI8
M4S>55S6?TG?[6)<AJI;D&.F>BN,R:J%N[U0S,VE*CVJAX9+;/(=5VOJ A=.M
MCVS<,YBV%ZH,]^_]^,BA[IFL_L6]J;<$AY ?Z BXDR$GL:2]P:7*K?BE-V:#
M?7CF4;+A7:_R;V^?WQ)45O]03H=EO*S&*\>(:/^KNU?HWV!19=[@-S$@6&ZK
MDJ%=U=ZD5I^$-FC*'EH:NIZ+5/-8X!DZ0RQY]EOATHWTO9ZVQX3^ 2XA32_+
M<[_COYKSA<PPC.'EO]G'-#DE&S8$%1X) ,T_K8VEB$6/Q+B5#W@&P;<6<51@
M%(CUS2:XCGWQ2<4%PHX*J^R]FSQ&[^8C'+Z&CKF@3OE0N/XI.V)1 ]( [^N
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MM?JUNBY6_8#-;:JS(8HH]!71,KSV_%]VM/OO#H9C-#W"= !G_B<-=:=;'](
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M 0P'^^]Z8X_L1"HJZ[P<Z,)]P#3V'R.C,O_-$NTA%60;@B<]C=BC6BM0>CO
M;?C.V?@0Y(K_HO4,*_7/ZI /YOL65(802#V/I(3#-S)RR6(@\#9$W_($.MWD
MN_UFSA,?'H<I%]VH#+)C%E?LKBZ=AU=M-X' &2AG&TO53V[.>(I>Y=9_Z6>M
M=XN',B-0;X(4)\BB=+A]Q(]SDJ ?UU[/W$;,SS<,S7OO0575M61?"%8Z4@9Y
MMR=1_(U%)Z TQ"EZ?JWQ8Z=VF.02%9V/=EL?8D%D%A+U2BZW@_5-&N#=P0YB
MQO?G8G N"=1_X*/@TM1\$(?A;"-"D#4[?P@_%(H?C*;LA-  Q6@[/_-I5Y@S
MM_5",XG7C?1/D#PL9NF<-^7T@B^T^B%ZP)XS0Z:%'=>]1& -L2" NC**VI=X
M-S)V2M7%]9XT+DX=G&X0T6I^K107WQ>X[XQ_V!I$V"%Q$6PQC 5R=;8^5"X<
M<_.@._/#)Q+ XV^)?'_HH'ERS%C5+S7:WF!8@M7&PK#ZM;;AJ2)2V> 8,!V#
MH>,3B8\H3:VLFVH@B[F=A\>:$W)VA[VO"Y)TIE>-1[6NYKS[>=P5%(ICQU?C
MEJ)#;CEEK$61'Y<X<!F5LXWK)*R<N'=_.2N@:-7#J>+-[VFUBB2S%/7T>YDL
M=?)RIRZI:(HASQ%H *^'&EO6#5A/_+D1,O</"R?JW8GD3N2;*[@-7$?EJ*5O
M4)(= ']+X[OLAB&UO[W.1/H/0H<&T!LX6*,4O(_YANE?J\/ ?A^YS21@NAO3
MVH/!QKBI KF\$B<QUQ=FJ 3!R/FW? 97U3490O3 "C=*#CPQY;&^*!H@+D>F
MLL6$)=X$_;0.)_K;"CA2PD! ;HV<N@]X?@&[-\N--QII5;YGGF25?;'S0U%J
M':Z37_.#EYDAG\+VKY7 !-&!-ML\#7:1JOA\\7L;TX?NIHK&[2)2*2NEN\0]
M*BQO!5JYM^._#&4BBX\'2:*;TN^)#@JIN _55NJP]LE4A:G4V'#_:?N]5NY_
MTW]MQXT$<41PW&MRNT@P/]\=Q8S^@R:NRLEV?+_U4/!9./_J3\T>!I[91.KY
M<4Q5T#6]JW[>KX\]17H5D]W*AX682:YDYT7R1=)5OT=M=&S<:XI-FZS9,>_3
MUI@J>@?+=^48D+)?;6LC=6;9WN2!Y)O[>RLMF>OT05H:H:U+\-\'ZQT@$>T+
M8W$NSJT+K7N2Z3CD-LS[1N[.C>6>#RASQWR025V*QN;CD$]!D)HD$@H6N_.5
MNR#S2=,_O-_:ER$#(:QT6@M:\ -WSIHTV.)X+@[*;2K75^5AS3CN,E'X\KJ"
MW^-**RJ5HDPX[/C"5$6C%#KUN[1D\D5G+.!;FSZK]T10_BD.<T;'&NC@YM:G
MN-ZX[>?31"Z*'I9IQPJ[A[[3E$> _3-1[NJ=K7E9W'SH"3G5=&;&ZO/996&0
ML*MS6ZL@K$VE?*]F+G/OC/,47?"O<3+FEC ]8-3U*7U?UA!\ZMG]W8"IW%^P
M:5CGTB7J;0>J\%2S9D%XX5,["RLUQ3L'E05:J6\R_5SK93?1. X>;U;AH4'K
M_L'RQA"H_Y\7/PD#K*_RN(N0_7L*L/_/9E4DG#J:6YGX=\#JVD9&'5D / VV
MJ29))E-R\=DT@*++S('A#?<XD\3M&9(,#="ATHMFHI-$(@E&,KTOA0=5^5M#
MZ8E-!^03-/S:IOY6W)?*GBB/8Q)=;64I<LHE+YRU[QI/!"_(CG\S.%+5[D'L
MWR;$4MOJP$3A$EQV"!8^ZQ*H39T?.;JA/+@?,N,B@$BO\QG<A"C\'I(9E\45
MD96AU!^2U&<T .EKD6#7:'N?:W59H.]&2'=Z.5?YG7N3 H'6-("R[Z%:_PAX
MA:&0!D!6PXCGX!&(Y7S$OJK?(VI;)6Q]EM2C5T.Z%%]3NT-]ZLR[;:L L =%
M^$%V;I!$Z2=U?RM#/9\&. _& _'!518G,+IG=CR0GJO*E94Z;"MG9G70[U8O
M7?B:24Y'1A<H?58TB#G.@&;0 'R=B.5,Q#X/;I@2^%>$#$SVR-=E4-Y#!47K
MK8H5H046K'+R)'9E/O%&>;6V6&$:P-]Y"OQJ:2:*RKE+LFJ@7\DT^I4T4,B?
MPP.K_ ,O\JP-!JWYUFGA6[1UJJ>\2)D7M_QVM\MM'0K#[)B3;G&(/-@\5UYJ
M+0>V-LVXO&&Q7Z6(_:P9K(/:$J5?!2QP #9CB(])7 9'2V(FQ0N;L;L_OM=I
MNX6+2:3/W Z[[\H9RLG#@V\C)J/M=R:7+RFWI0VB5-4Q9LBUB/S:Z->K$<\_
MQ#'Y?#1Z$8#RS J1[0W2HL/$=\8)<K#H)]K)H)WPT-2Q,<N%WT'/+B7D>6N7
M*0EYMHANO954O 70XC3 >[*JBW-NAK9OCCW#A' T76M:(P*,"U(QWTJ,DO5^
MS.V-[ZMLZ@_<%1XKNH[4VR(/*Q&<<3T8^?<JQ@7K7,"XH]C!AU3O2('&#U:G
M<DJ#?BT)<?+C 1F4Q^.HC*GN6>[8R.;Z!%E-"<Z'Z:: BQ^^ #37 +89^WIO
MEZJ $=0S[<<F<<2>]W=TDC:13UC#CDT_V/<;+B7I>:B?#63UYTP52;CM^"Q&
MT[NF/, LA+>&HP&2['+8LATB11BG:H@'4A&[X$-;R*;O=C\-P,_T"X%G3B0B
MAXET%<@EV9HA$#1 1,0*Y0=:DXS8MIKSE7IMO\.#D3T"=TB>I0':&[",$:C<
M6I@#S&Y.O&ZV&2XZV(-SF9\FOD3ZO(C+LSA_P6C5_TZCVL"?-I2S0;=1B<*L
M!*6QVK]HIY@&N+.&=CO>01P&0-9H@.T]&D!@[A<4SUE#M\%A"%VZ\Y:F__,V
M[)HA%HY/PVO,/;7?"='(KGI)5SU/CS5E=V1+$+T ]O ,]))BZC$'OJ<!4,HD
M7[SQ-@3VBMJS3UZ(XW;=4\$H;(4;IF"$7JP;19B9U14F5C[(>.%L8\^D)5^Y
MOQOLBA'JF$6PU6R9B=4,JB_JUYJZOHSOR6-^ )\-.&'!P+?YZ"A!QL#)&LN4
M5TCM!L2'8?>BS7/M0*D$L]&1:U^RL@OT^ ]F&RJSC%7$'0,A=@*((K+B9#IJ
M[?W7%%5S7R5H&*PFK:,;"WY+EB;&_\:QM-E_RSQ;E2PJQW93&_-JS/_WZ^7#
M8=;#FB!ANM,Z3T)3V+O,K8M+_7(?5\=T;XH6D$X/>@SH=YR*,OTUI/2G=:NT
MB@/UZ>3G?I.O6S^6UQK'DY6">9FD341\@:PQ[:SB!*G7]F(U421'WVF_ -#-
MT)%Y-:Y'A$NQ-, I6:+RS5?Q87<A/7T#TJ>.>@((PW0,A_G,$\)-6R?V0@0X
MW20% Z._*8$6?6TZ:8">X>)\L>*'"7RSR)32ZB7?C558<W,[ZX]G7NLE=0@Z
M\V0C6(9A-HB9I?N$VM;;4\U6A7(%^>:OJVNBAE.OC.>FSWF]+EJURN?L&=Z!
MZM-IAXW,]7_OX).&( <T28;!+KBH722K_L2VE"'G9AF3S/94X$+#?!4",2N8
M.$G#]IC=35Q#A'G-JHB,DZK8++7<+OS7>-%CD9^Z5J[)*O0(:(,(?QW'].["
MM;L<3K[IO.1!:";BF@J[)W:O)V,O<C?TP&NKZ)T4]1Z3T%),"C@^Y#=R"%3-
MM.WBB.OH[D6;JFC3/?E1OP4_^U4:P)[R[6F?+G(XX[/RDQO$"W,2 _9:=:1_
MYF*M7+>)5Q-^/2SC?A9FH%>00D9 /_KB^0AI]-I8:XNU4OKC)F.()5'"GO7\
MN8NY6S?N1H?3Z\&@9)('K+?3&7RT]1\+?K?64+)A=A;#=*[MG(TL8(^C 6I+
MX67-T=NZZ2MVX:<3N(=<-0:4O&RA B'SN?ON7,.4@+^MWP7ES6+?A^]Y?MEC
MRSS9\$RJ=NH0?U-:.IG61X1]_$BZ2QTQ"#J+B^@\]ME?), ,'L=0%WG\8ZN3
MDK[PG^Y/Y>!_*86'_U1Y0?(+DATE*\HN1OA[PC>[P)Y%9=]^ @B8 =]GI]?*
M%WI&(.]#^F@ 0) \#KD,?U_F[>6LHS4' =M.BO\Z>'Z'8_]RR#[O)NPT4/82
M#4 GB&[<)G.JM<"(A)CG_N";\2YAWH(SK^D$& HQD5:X0(CB>>3^R>7 A-HD
MDWL.5RTD_$Q+/VT93ZW3&&@LS"\F['7Y0BI+%C>)-9@G)G>U-<42LX2.!0&0
M+<%?-$#4&LJW/?>RGY,.PK&JEG&E^+>,HN0=H'O#>^*% ^A;4 4RJO42M*?<
M21Z&_4CXR+3KRO].XU*YQIU[O<J-\2N'Z^P9Q&O- \,W=)MM'T:U(PK<'B$D
MVXP*%"%P'!CIN:_Q+QV]^2&]T&H*HDTT=@'8>54/'"FYRG)2N]6JK?GS>NL\
MN>\^)T/NIZLY#PYR9Y6IVH@$Q+:H/#4"^CB(AY(6I(B;P[MA*2M)M;%HA5>-
M3VJ>V );_ME[ER(M'SJ]<G4K073>,Y^Y,:T.$JNOMSN_;RFB)U6R;?6MX$XK
M)>$8O;:SL%PFWPYY0Q#9=?&U:HC.#Z7VBUVUD.)8_//8X,GFZ? DI1B"9+L:
M^P0Y&#VH_&C<UCE;VZ#>U%!EOR?5=IWQ[[YIK2E0@J!& JQ:3OX]647,UW8(
MJ)A&]YVBG/@% G("!$#8[5TBGX_4KA=P<>XTO-/K;?&^G=5ZX]K+[;]Z4:[
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M??URI<0B";:Q#55V-(\">BO6$(_(S%L&8!X&HHB_VZW$I0#QJ15W=[-(<%S
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MI6D MYP5V%-=%=8#W+[M[[ETY+^Z@-&P.O2VQQ0=?$JW*!?+D(=^C4V/.6B
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M-\X7^/&%0P?#KZA=Z"+>(MSF]MR"V1E@0[S3XH2]&"_!3A(A+MLZ,7(Q6AO
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M<,AJ8/EHUN2L^2/X!F_<^C=X3A2EEYQ;B[;M'E6CLM, ;]T[3:GG$!O 0I.
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M[E0+*C'V%W.#&S_2!D?)EXE%&?ZVV$!BU+V2:E2A=#4ZX<ME_N083GDUB\@
MZ.P641A,CL^7H];VT  KH]"5J!$@]?YI.(&EG 88%1E+8XQU)<Z!&VF KI;W
M^*\(B#><3O1^6>X=T!=,NVED;IQA]/EV>8;GR:]*ZDHB[Q+FU1K&?<*EB%L-
MDAV,_=Q0MMF7N\T'.$M.S5FPDH^ZFO%-GCA6\(/!/(]<F<K^+;$M#&2S&WJU
M->*G/Z T#=)Y2?10>-_BG[7.];<K*F!+OUDI]W@DZO7*)QQ0FBYD:CT1@RK_
MA& .[+3!6/X\XQX70VU1H@LMS:QT@O9?9FOE?L[61M")1<\@<OQ<"^DF 4EL
M8*,[B%>8AWJI)1"VIM8R6PE\8P7K*)T>A1<GU(=-ICF-DDTS.HOD)TNV^<()
MJ[> ??@_>@W+/UJ>$ G[,M.'O4,W'W;RU"2[B1SAY!=]H*U$S%];5!:%MXGB
M$B@OD:#=NST,.T<A=./5"3Q_5D%!*<I=93WED+5VKF8S@]M36VE['H^,%,'H
M$/GER&G:J?3Q9TH#4 [9'M[3^R=<_/[?6JIR_S*#;_QS!O^I-7UD94B#OP['
MP89 VU 0)VCCP1!\-\@>0(6*_)WL"_&7&AI=N0=>A;?U>V=3&]N1%/'"CTQC
M27_T"N)_M.R#J2>C: !!(9P<=19QX%Z,_)J[""%>!9$_(!JG24'PU;Z^%R
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M5-6/?+KM)";HYS,_P?TLI,GHV3G&XXJO0BG)/;*4FTT*8FGY&9,M\*PI58'
M.98X#R4:X*#EG;?L/@-.AZH1%48#;$C[T #I4V52)GV$HD_M5KD[IB*\00X:
MXG$*$\.^(KM0L-L::)2;X$8,QN[-+27/@<YZ^VUPR8TL >U(#E4I57")']%L
MR\IQ$[!Q8''0)RR!&WZ4^!23AT\>\5\?7XGD+WF]</73!N95]T.&"RE17XJ9
M]@&K:#P&2 T4V>XF?!O(&@390K@4.XR:/"\^2)G5DWT(TEC\))0X/URJT:NC
M3?"%;)'/K*E8C;"ME/K(;CO HT7) I0$?S]<MW;9T&Z=G5UV(J?JI]RNE=)S
MAW<<Q@HZ7PT6AB_87!RRSLGROT.)HUYNSK(KUC*_R!\)]9$;GU)!_+C'[YHG
MOWD(:4UT(/G>Q<[7^K('.5"!81]VVQ^52A<4+N[G,720_%]%=,:$IU5K^4QC
M^$B:=:0[IK;V_E=EN%,E%R_#2RD9K07L(E%7)'^\&A@NR8R(YXMW'_X^Z#Z>
M/HU5='S,U;!S!0U%FY$<B'N@VS4,9 ,4L0T[K8D3/?[ML<9IN?@UUTMEYCQJ
MI7>4/H"7]C#&=%5X9AY^0 $>B(FLZA %J46B4T!<06SW!X?-_$U=M]X,-4-0
M5"PZSG^89 AO:_">IJ+5J&$:.]_<^8([K^I'3B!QBS:?WN;A.)\)B>U'DV+?
MQ\WQ:+9 >&5U_8Z]_PI]OQI?:*+BE#6FZ<*3<OS3(XOSF*X^=25MZ 9H).9N
MV*Q7[18SL0%B)WJQO#S>YUYM3B2W\T-R-K%T_]4T )P-:Z6RH[#H6N#),&_#
M&TXS<GN,#%**K]^I;[T94PX52:54H!)WHT9_IHDFDT"EYN/C]Q_-"QN5 R.[
MA\H+/W0["+W(YE9I4Z4!0#L#TPRO%L)=4%:>,7$UI@%C0#:R)7%KCHZ_W$WU
M77(57(^'?^&1NXWBSVFWD/LY)W!I/B9-AX-U&-YPA$R/*Z_A),WVWJ;N!#1)
M I.-N=$RV=4M <(J^@W0XR0P&.,1%:DW.?&Y]< Z4;:#.\CETK,HT%Y[Z3(D
M0[8_LEFQO(4I2)T?28'E+=?-QEMT0LZ.#TT/3W\&B2B?(7OC@C>VYN8M)2L"
MKG*_8DO_:!9]_JSSXB,:(/>=;V099RMR0(+1.["E*8D1D;<:$Y:J3#U2%JA+
MOM_ MQ)0"5X.QI!FQQVXY]WEXG%Y#CFK[Q]WG+>4.N:]!W1EAE\]<"*<&\H:
M1-NL<UA96V1//Q[[Y+2Y>>[0+F6VP-_?(K3^+E=<YO VF; M5U=N(1E=+^>]
M2T+N._H?QB&H&GL1H UI.L2D)Z'!9 87'F0#@K%3.F0N2KW4RU/^Y&=6_B3R
M1V(W#2#@UXP@<%;2&4,G)&-*#IVL28GS$,GU')6!G?]1FN7P@HHRCG8Z>EN\
M?9OWV/08Z]8D796HU0&+;3"'\LA.N#<_,CMZO:W'GB9YIG)>.OGJ)5_4G.=Z
M]X,9O]TQI@T1G*81=L+D1U.677^%3^%J:8(#S^@\WXLWCQ"J3]3\P6=(4BLE
M!S1 "_+(Z.3G-H;QH:<1/1\&6@^1'X'7E3PL"R5$WRAP6#FMX]=<+81%?V2L
M/^4AHPM"R-[$Q#D)UG6NA>N\4GYO9?/9@!M#I"?*WH\\+SU&5*G.R7EQ+."1
M-? G\/V+=($WHKU, SQ#)M, ,Q^YSBN 6XY+7%)1'7 OLTFP)77EX19(L^S;
MR S0WWS\2].@P?<F71%(J=\Z,>%.3'JBW_4M1TI^]HP_@J3G_WRX1LQ?:Z!8
M7CP;PK2Z%V%IE=7<I <V''GF0G[0P2C=\X1Q?\4!/H. LQ3(#);[(9G&'[25
MC;;[7(H%;D87GN\FG^+%=\(&@;]X;+VADS]4A/'S+$2#25S_Y-B:Y!7;>2E)
M2^[W>T;G;G7K!MZ<8SH"&P6>)S-?N"9>(ULI'\0V;?SZ,<S5Y1(-4+->$/H%
M&TO]W-=OND<#*"]?OU3W="W XSHRLQ*R79@PPQWU%O$+3%C+*=VNXMU0GI 1
MLKC2-LU[D[V@Y5&KU46LVH- 1B@>=&>0L?2SW<%;5-EW.4]<ET-!NF0[VR*#
M9<["M:[C2DW^43_/3@5FV2<\-/:>OJV@O,V*4I+M^)8CE'L/9@5Q[@K(72>=
M(CGH-4]M=WEOYHOS&5LD"9Z.YCN=^XL"O8'Z3@&3QS53"2*;%32 605OLRF7
MI"N!51RAUG^P-9 6*HP$[/W3,B/HT_2^SIC>]D4PPS?I8B)KW(32\9N+$,L+
M@2=Z[\XI6W\.%7F! 7T-_6>H^A3@N"E5>WYNCQ(^/'T@FQM+^3GU7$.6H:O\
MY <T0-^7]5P*"KVPJ2P!'^D,H ]2DW*=T2VJYE:##HFSN)MR-?(%*.M?+@OS
MMSFX8?#C[*:H?8$T*3K0RBY30WP!U">YOTFZ0><J2/K4$V?H,2TF&S["]C,A
M=<L$0!GXHW=%_L.[**]2\N +0S I^$AB'ATB3P^NH18AJ"AR4G>S#HE%%D&Y
ME/0"E/2#1 -0C^?\3.S.(4@LXNC=BN8: !)-=]90Q+;[U)6?F:!U&D SS_8P
M(>N/3B_^HZ7&@"X#TFF MK=D+1J@S(::*B:R]O4WZ;F/3+5<%'J8#*2+U<[G
M] \*4:>'%\U@7^%UI^%+)? )%AK :>4P_K\S'<O4Y$04@Y!3Y=Z@-QZ@?N9'
MUTARU!-%]/<&8]>I<Z #UPID^._(UU4XTP#,W9!9Y40ZIE3-_=.&%]&20"5*
M>/'F.^!8'I3:Y2U%B'GHB+D^]9B[H5/(H>?'"C$AI7VL*2P9%,TNJBJ-7.MS
MEVP_TLK)<[].C^D(LYG\\WO?4):&/" @W\E=RY#LJ_JC"'H\_([$&"F?R&Q^
MB1S7"9CU2WRP0JB5&8I^=^AJQHM69RFIXWQ\9:!'4&"I7+W938WHM7Z3RD%'
M ]>2ZP?^JWQ K;[+'^GQ)_<%$4$#','WHMI7M\CL^:E'6C7AUE/-UJ5'"&H,
MKA*%9R@B'?ET'T^%G.6:$:4'_*#Y5XI5;H]O6E+ZCP/S P34XN<S,=E"G!ZK
M!Z#:_367CFN:HW>NZJY2S$!5.(EP&H 5KQ-!#Y(%5;=]F&*6,*5%W\.WMI\>
MV;CETM;&G[: R(2]I;;1 ">6B9I86'W[P^"V(0]VA3>[SY5M)VM/<>X].GD<
M/_EXN)8>W)'UTR?PF@%.CRKAY]>',#4GK%^K.#E.)O*UM4=V-,X' A2'>PU:
M/ECF:$?7SR:4H9%$OU0C41X#XSD7$ L5/<.W#9P/?B5.O>!OCA.,D7%@C_'?
M&9?DF&0I]![QQ:K-G8'%DT\01S^1K;#FB  K/R9"H_/5-2X7E^7;PAQ/P05]
MKG?=^2;.TH'15F(4>9N(SZK?8[D>AQR[8FJFQW_:,\V_G#UB-<TWD.EN&\/<
M]#E8/9RUV'0H3*?_N0=1>GO"&-+$P5=RK^DX*-5=M01XK>%.A-VVMA($/[PC
ME<I%%'VPWALE8]6/W*WPX>TG^9 =>ZVPX;!?^IP^#LB*A,4FT<7<)H]#^MUR
MW9"5Q9(4#X#; )B/WGU;1+B'SQS%JUFJL=W"ZKD[D9\O..E.W@@-X''>AH(S
M!M)1>@8Q)3TL>]P*%S"(#"H>?&(5Q!D_M]KL*][QL95ZN04X*;L7%>C/FDY6
MQ#9%OOQD(A:?;)W,%^ZJOF8<Y2G$'S.0E(1:>?+M>WU/@DQFY>HRT59>%QG1
MV,)LHE@8V5Z01/6E,C3"L;K3^[Q5=&;S9!2TZ^ ;3&9!4N\3Z"35@O[[/58O
MPG?*![(^;KXQB>W31\@JF_/(F.*Y@DR9+TUAFT<]5<F6 Z$;:"M08,5R+?K0
MFHE@M4?VY.3$FHYW5/;]S9>G=3\>J;C4]9"PN_3]H$EB Z66/(6A(\[C/O>K
MBMWCPJ0** W@.+ZCE(7F4C06>C_?:37BG!3;&)61A;9:GXF*0GRC <(VJUR^
MKJ>=")HV[I<5":X@L3SF9QFOC.Y 5UW-=-4^_IS0PBD9\_3*[#K:%N-QD+14
M+&0>^!!<1.'<4T7DCDR9CG(X74S /'S[\<35F*M/>-I?M2ZXBLQ,_VV"KP!)
M4*,DPBZ3)8F?V$/(*MDFJPJN8YU.HF)^%[[7S%S',,<#O1DSP% 2F-I><Y6(
MF<, #7IDS_#V376UCM^OB.U+CY_J?'=.B*,.GZDJ<\W[P.&17F0%H3?78UM0
M+S>T=B L:Z#8<,N&'=X!^=ODWJ+$^.&Z4EXFXO[<77X5,=2-8^F.Q-FAV_$M
MO7M1]36KE'CE,^N0PU3>*5L%S.";R86Q\ 3[ _=(W.MG$;<$>K5=@TLS[?S]
M?UY@&F5^(;+OX&[VVE!R4HM^Q&$9?KSA!<>[+^-:5]^I0(8MU"3CW+?8L]MU
M!IDO7%A;7'L=EX$R+X6G2\*?T0V=!&J$O!X[$P[NB7"[7QS9O-V4<@+<_C!,
ML+_-\"&C&B>_)U*24@"RQ^C,3H<41YRJ3>I$$EX?6AP\V<13+^Y\CJ_L@MR4
MT!'F]^9,<Z 1\%Q-A#]VQ,[39)=SWU%T:RZ<>?RR]1VF93.A!OC/1281LIT:
M)Q0A+M#9:C$CSL]!5F45+BN?I%Z!ID1=5GS!-H-8WLDY*P/YM7UX/LSP1IS_
M<UN*L9Z]IB8-8.*_&<!'DB"KX;Q:HH(JZ#X5-E,8VN7#6]^G*<\E&.?)+'+=
M*%"J]O2A5GLRK@(UJ'R6K+6]'-+RE>BG#SX^S^F=<3I[Q9FI9W@=^9HLDN4M
MU) $>Y-NDI^6:'DVB /\C:=M4[V-?UM=L,J-$$:)V76*?%"!RNSI(>N>.]XT
M$^4./JD@^O5&ZPJ'*X-E[07O!_7Q0/8;PF,IZ%/T*'OS(-4[_,QCU7/78I'R
MZWN;:!$07U\-%_D1=JO)Z=0XU)?MTVF<HD5VZ0Y#LOW((K_Y5S4TPY?6B\,M
MD-+2YFKNICX[Y=,]2(L!L$YJP=:FV(0B5+POC,.B[B*;$,^)PP70+CQRQ&EN
M*<&[9VS%,ZGQ%L[%YDOM%_@)8^[= AI@5H?,LM7(%9GNY#/?/A[ ]T#U]$%
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M(EI M!B);912AW%3I+R#N/F<#'HT?BRU+4"*4O166XW75^+<I3 Q,_PA?(:
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M1^Q*%VK<^H85'Y^])Q^8+HWS&T8[;"MD@W+@$'SQW'2SA@IN[QWZ S'DJ+@
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MOL(R5*KL2U=*D9J](7);O ^),P,="#3P_#[\ Q]>AC7179,?#>BZC)>C1-(
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MKW].=RJJ#-E</=\6R&:E\Z*C((+QZYEEM:7JXH5%$5M5@G8ZYW)LRAK\@!2
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MN]"I:R*7GX*=_-V5?>@R SH01PC2@(^6-=08.S*"M^\=,74S5GYT'^$NLG9
M32.QS\1YE&JROK;OYVK5M/-J\.&.M4Q^=I/M1?!1D9&#T-?4_EPU;(-_X0]/
M$0Z\4E16\/O.8^T['EP?6KFZ&?5MW@%L!EWSL?*QR5$7&O))B$?BEPLE9E9U
M9*>3#W-F,2=M@WZ?IE>\ZZTYK?+]?)O\V:^2K:)X= )D)B]7LB*MX>SLUT7K
MQF=]88J>P0DVDA<0GY'=#:U./HF03PX9(4KI14B/V2%1/KF[-899$@R08,VV
MNUPBZ\W]:+L9N"AN>HYWDVN>N39\G&1=U_!2L-%S5R69U[G_+!]P(E;MRQ?A
M#Q]?P25&;0I,U6&6-("Y*H(K,>LM;OL=)6^(/+Z%R*U'W48VJ^RJW:&K8X)_
MU+6SM;4U5;I[EXLK0*U]T&\->H0%NCX\'T6NCV)I@(X,(@)^ENA22#Y#1!80
M78Q]U+PL*O?/!U3NJ,B=%5E^O0$(%\^!_C''&@V"WY):^E22FXZ,S%BQO*7Y
M?K&IJQ39-XW3?D])P"S\U#Q+W>RDOC2$YH+!F(6:H"UJJS7R4*EXUX]@\GT/
M? )^!%>=4^RQ;^?TAJU_:7SJVO?N5[G75$0!W:O,R5--YRAH[1/$B&;D:<VK
M9=59OG+1>[#TQHC;L?(#$@A;X2<M'Q_@0N)/68<7L2RE>>\OU5"//F\SS_Y4
MYR%C+4-=0L21U9+O$4-G Z_7VAM6G4F<[[(C'U :X1K*R?@Y&"'AF4#!,ZX\
MPGGKGKO$!^ _RN((1L01O$(;DA,.GITH-30=)HO>$YG2=ZDT%S)][NBR(V;Q
M\UKU3Q^7[];#-*"R<(,&>.#GFU>]A,K'@L*_5&:&+40L'DW*5.G4$&0LO,:P
M_&9I,?B^FL7[7SF_"U#RO_VA],>=G(M2BBG8NAKRY6^(UB;Y3WCQ+V$*MZ(L
M5<;%/HW_;$6]"M0?%'7Y7NR_9[[J5(6'=)QV.D)$HF%USWHX&G/R$U5.[=2:
MG6(NDK[".(6YO(R;;D>.%;:E.'7"BH,\5^6C#B<U>VRQ6NQW.L_MJCZ83V1X
MM^ZD2BPGZ4Y.>&"MU6OB!)2/26]L7FM)&/(3N_D>,G6W4Q-K+"J5*%F!9HM+
ML</D4O6T!2\'J?OFF64M)T[+8$IO@2(0@I_QA>UH-H_;;U(,2XTY27HWK$&B
M"+82)!MI@K#[^XW9M73[3*O9\2PBG4?T<,*%8TTXB2]UY&)_O=W."U<^D7Y9
MR-NQ-7SYC>@3)@8UL5_4\2G!$;(E3CN4@\NP<50N@5(?9\\>F&OV.COG/>N7
MO?>=+F>?=Y@FJ/SJ,(1F8GJNWSIQ^O'#D4)3V,5&;1/\\$$<E769!IROMZ!_
M+YTL'ZJS44ZC(R!W3:*H,KBD#@[=?4=<==7;L>H$14/?]ZL[]AT.?:QL_,/'
M9[B27*#!6%G_\](W?0,'$._&-%T%.,VLL+MZD7!'8A9.L-TNU$-$&?M8RT[5
M\8G^J^5TYI6 RC.?P ZGAC)WH#S(9DVX3*FN+%EB+FM3YH+(/=_)CIH7::*B
ML"/QS+4R#M!->]*9]?*@O-MX9/CC R4O=:KNY_HA&>O'A.U<VV1FV9)'#VO/
MI'9(M3= 2#?@]D3;=X71&^3K[SVL1EM[##5(^OGN5Z@\.WGW;VLQ 66](B)F
M>?QWBNT<S2=^8;>'6WF=+G^8CRL(VH4A,;LK]^#>1/%2.#O>0EVVW,\CQ/L,
MR:BQ/>NR=7RYTW7 8M$$7(1NI '.$ %/)P4BKQNE2#%#837CT2J^7^)\KA+;
M5U:MAV"? 1VX5AY9BUA(TB>6R^57#N]E985S&KG<MC)TOPT^6+EB:9H2(*?U
M4&HW;V:ZE1T200-.[**/VW81(CP+EFL[C@]=_KF5V"K^] <@]6#P@XW^8.EY
MR8Q5"KSA&[P)I2PQ\H97 (',F"X:']#AP2^/_.G6IO_M(5;63VA :S"<G0:\
MH>N+A,HTV3F)Z"/W%+FK20,6+Y!^-WH%#E]&[BQ!B?1-HG'KGZ$')'"C"$4G
M"$16R?B".11!;J>&T8".BW1,MTWDI0'7^ZEF/AAB._AV.PWH?X6<D2-'_"7V
ME]A?8O_[8N T",[29ZR>REVXR:H2JU@,%6^A*N\H70R0Y13\HC?^EM CWPU9
M+V+\A4U =$ J>NDA>'F3=1;#5/E(^!24=-T^4_YJ;,NYXPV)%K42G#7WTTQN
M4C0HM4V7X2R40J1;:6"K<JY\ MG0C09P:9W0'41;\R9'/-_GNW0TUDG>X,L4
MZZH3'5T=;<1CF_O'.F>-B\J(]>WL+O-H;@>F7,9WCMVCZ::<9^,>7>O).+]X
MWOZHYIWMETUYL8V-+]%47NKUPR4!+*&<-'"8Y>'!A()QE)9<GK"_%B=TN^6I
MF2(C@\4)@/Y75/P%.=O0=(P&?-^A 2^SMJB7]?[SK9*@7*??)VTZF7B"V>;%
M/L3L$" A6H>Q./#?."U3.E%9Q,E1HU'D_&DD/E;[#1W^H^1IP!?H ?-?<G_)
M_27WE]Q?<G_)_27WE]Q?<O^DW&=T I1-$9D(98.;S&CY(^?LRVRUBF]R*UP5
MY^#N!AW+2S;3Z>>_ZN3U-Y\&^5M4][\8Y9G#7[Q41.>6WL[$/)C5,_<(_G[Y
M;*/W2$E5PH5?]H+U 6LI'>TVH?$1_2&44S0@7!W1!\:E!O58$.O+;'R&'CN,
MN4^[1TN='P+E6D[S,SOC^(7DRQ>L<^E\V% :(42V(8Z\)L[/9CP_B\EJNRKM
M_WF\8^U8U*)R22!'T]D7 S/*W_6W_<+M,%>HC(@!: 5R@X0KO(*3?3J?)-]C
M&.TRJ1P=*)1AENOD<<3^B6T2PACH4NT[']ZN/%@@HXDZX-GKE3>H2R8-[.WQ
MS$!P4] C-& EF 9T&^W3 +X\JF#/#)0"@AP8--& >6[J?[BI7'L_Y<B4I*DD
MQ-L&YK_9A_Q;1O[>F08L]V)PO-2K?XG])?:7V%]B?XG])?:7V%]B_X>+?<BL
M3G-#>UAGWG_C);P8N2#GY>LC_\O Q5]RI?7SF1>(JEG4/T)E8?_A2!%4-HM<
MWD#L(@00HRA@"W(?D^0DCM-<%[6Q[R/DR,X95XP9I$?N_'RZK4+2;ZU"9-)A
MIC#D_A;Q*I5W#77:/\XQ$QNGX%9P$!<5;91 O2_<F2._S/RAF>N$0*W/Q#8-
MF#'9A*D\4>)0Z,2OCG>D%;6[%3DA79V*<RY8,_U?[+UW5)/MUR8:104+("B]
MQ%>J @)*$2EY+705 >DE(DU B" E0D@4I#<1 :E1$9$:>H?0$1 C-10%0NBA
M))002#OQFSGGK&]FUIG?FO/-F3-KO7_<*VO!L_,\]\Z]KWU=S[KWO?T:PI>@
MT3.Q4,WL(%0Q39OJ <<XGONI,GC.@.3_?]59W-"E&#@E'-6+HR;&%@$.3??.
M@&D'Z0S6%+_I-$6P^&4%=6@WX%]@H_^M>8?\*S3V'\-_#/\Q_,?P'\-_#/\Q
M_,?P'\/_N89^2#ZXR KK<AU1:%)[\*ZC3TKII*&[&D ^*VK@(A-0G5#SCGR9
M\X7[_\"V @P3\*>8O+>="8AF_%LU>6KQD_1*F\&7MUI'MK^AUQLW7+4[V<!U
M3 #Q+O>?_0<RZWCGHK7 5OTX+?=%@G#D7F?W$7.R 3<B3>W*32&K7%UMN67@
M5(H)/1?T1'$J#E?0I4;*J?\YAU#L'D=]G@E_P5E_U8ZS57^P.>DOZNO+^K]1
M54S O_!^&&WJR/8_\%KY'[-_S/XQ^X\QFR4"-[R(>?-!<?(P51R*CPGP\ J:
M<9_<0%25S<]6JB6W>ERT$'SHW">F[>D:UJVK8?3NK>/=KWBE84_E0O[93&UX
MK&S9M9+_K4[K_N\,MATJXY0R$R EUPDDGP(=:A F$'^*&W4#0%3.>TS )R?4
M(TH"D;L-R5\CYW"[.UB 7/J[VO&.66@E-/"+L3//MP_;)K83E!?$@4[P*7\;
M_Z33'NC)8%A*36?G\H":RX6CD\GO=TU[?+M#0 X%>\<CJI9HZ@T+QNRF>$9-
MP "%IG8C]D\G&.S_\IYI__,.L3GLB)5%_<+TA/U']'7YWW <N\QU4JCW8MI_
M[,K]9_Q_,%!P>CAB@=#,R01 9@]O^CJR.=*I)UCXA(6*,&;1NV'S]2SPV$Q%
M=RKVY;Q7W"\"SX,S#O=TSUOAW0E__0O'R[#/U]'X48S[61VS9&E;)F U8"\T
MBPDX-LD$I,A1 I@ 7R!=P\&J!_S?:UCJ<!T1O8PB(N\.Z?+-^/[?F\O-75,O
MQ"PDA^F]K+HF"F W>W)DU&HQJ!LY9=*3>XF2@%JSE8G;VY#33UM-^S'<:Y8I
M^);OX,%K/0 OP+G7S&MM:\(8+\4$='&?]!('8O>,2ZWLAI=WAN</ S,]O!?V
MW"1SRC@6B$*Z(19^C=7/F #KE)4L!PLFX-OV7QEFN1(34F/%NR,TS->53_'X
ME#;4^;V.6 J$_(Y>IRJX%X<Y0].LMS,.<5>V)[RZW5QVW35*XXC^/4K?1F+!
MXHH_$DBSRK2;*('IXT]:5$AU/?OEF*H3\?*I54MDOZ=E6*&9?<S^+U*%4,Z-
M:_YS#9^3)FSEMMD[9W1(^^TM7OTC>_><.ZW*E:Y:#[:J'AJR)12L#( _@BJW
M-A0@I&G=^JK1OQ)[NVW]Y!QN"O!@A*[O.!];.#/'MVZPG!EO:67.S>TE]/P.
M]&E_S@NJ1IF-.$$7ZKZ1,Z]@U3%[M$:$+F#>/*PXOCEIN=:!FWO'=N'8"3,N
M#A0&1'$$\[ 4P@=H 1/ ;@6B.>B=5LA5RRH4LOTQ&X8H_'(-*"J*/ZFW;T6S
MI7-C#^6VV1@"Z5V(0UGQ2TQ ^QB+S@OHTQ05HYF W0=:YDQ >#&2<:6%>UT8
M^2.1>Z,(\0W#,EI&3SSO%L;$P<_\ GMEUI"K@E4]\ (W(@8P%_Y./MN4G?(J
MI;<!94[IG<?/@2-R+V%-^^^Y%O23E*[K.#D4LK1#+%'YO.NMXKPF_;K(DHKS
M>-,G&1-#8!Y&._PB*3V1YC&O8.Q(LFPH6<WT?MM5>QB9IT)Z,=QJ4=O$\Z8"
MO0SVL7S??*W#@GSO=P;.5X[/9$K*Y;S5-T0=LJ?%JKT"BNA@B(XK^H?>]X-L
M;JI0T\(LHEU-U?]B/Q,DZD[1A7*O4ZD&E*I.-#\-I!ZCY5#JV<C7->O2%&XV
MZI8K9:-C*HU]?&+\\B3A9:A7%6?J6-=/\E#H>M,T@ROJBHQR043Q^N<F<#]+
MSZB"[O_GGG6H@:TDI*#6BSS:$U).0E1"LZZS*Z1P4%1M?*J:U"L<B;.X_9*]
MO(S]O_(U6%=?NM#VG6<AZH7,?B[?TZGSGOTI<?MV8-]#)D 7?K.;-#U_]XH0
M##'OAY@:VQ2$ZQ(F&&?@O^#*Q%JTNQ=>#C\/XOI&$!V^)QR7%2!S0C< T'KC
MS>0/)8X"<PF4X SOW6AW%9<-V6IX_)"IS>].A!?G6'6Q=O.W2OW+HL6%0L?$
MY\+!J2#>UFNTFQ64A/EB+X@8]$]-IN7:]8]Q5O4/=<\IG?J@ P \.N+HQLTN
M[_);97UH]7&%:<>(A7#C4[K=)_0%$.X%3)_%5%[-(VEB]DP *4 5U8N)L7P;
M<ZZ7(>7&?CW=(O?FP34>1S29$[RLGTJO,3D0.MS1A>E3KS FI\;KYHN!'!3R
MO.;BJ.19&R\1?@U>\X[>"P_83EP_4LXAD[TLL=%/\K4VJM?8?J@-4[N<>UEK
M]/ XWT[0Q@A)SIS(W<FI-GMG=',WQ]Q\E(]_J0?W,=595Y[B>N'E_;876Y8@
M%SDD#Q@&:,(VWRSSS.PFYZE^)^^LJ;^]3^J*6_QJMFX@DHP1KVXM813+FP?+
M> 4QT+?HC8>C2H5>4B%D!MI\)?-?C!+,GRA)$J!Z(K>O[3%B:=%5%)8WKO2X
MO@4!H<GO1>>]S3RLMMTNMF;3TYD ;TZ((\DUZ34MQ)=S;8WK0M58E]?Y&&6<
MQ!O94[=% 6U'3PK]\-,@N-2LWORA8#3[HD9^)L%0MD\544_U8?$9I/;/3^BK
M3, 3S)1F=^9R#R>"P8/F][+5BW%7G"C%C02<_)#P&B%G6"-XU*9.]/!Q2R_Y
M#.5W$:41<A9JWM4XMEGQ]8-P1&I/GM].OS-.\N\?AFV:'$(,:92;C8,UKK4*
MGEYGWL<8*MA#%D^7HI:9 .Z/9+'SIH[*A./GX]MO2LYQ&:(&9A/!U>EQ-$.2
M>9>Z(Y 4V/!YQ>.9]_K&+EWOR<7MD44N/L$S%<>KMAPH6J*D5+'K33:.R^)R
MYT2E0!Y2H4_A'X? TO!VM'  2-0C>#\2IEO\>VVJ)25NVBOA%NY+QMQ3N2M+
MDF]*!-"T:E0)0<M2W-JV[%TC7V27/M^]A]&F-JV2)$Z6 T%?";;9';,FY:\V
M9=Z0=85 "7!7F!N]I!E",K=N,-8V(W0R@#.6L_=&%I5Y<]@SU_S6]1_<G[UI
M^XAHH5SE&QGC\ZW[<2'N0KY.D\2>>"PM&'2*AE"M(W\D1L5(UDE\I[J37=MO
M@5K0/B!1K!6Q@)Q+VNH(-?O]8?Q*C;>TVE%O";.,_(B4QK+U]YA&?.Z'1#EL
MFL$4O+_(&^$PN2B/DV[)5TO?6T@:*Y++H83@<]3GK<)54+RK5VQ['[PV*IH-
M5OLA)/+;FD]GOO'R09_>PP6<E%L2G#?!H+#[M]*G6!J=7MLJ3>GL0(HX]MXA
M.3;D33 ![G;HR6J6ER5^!;G6YAU)2:P9BNALMK PNH)5[L):!]\OMJHX/*X+
M_QO1L4U)8F$)6S>(<J.!"9A?LT,D@7E+7;AR0:1+%Y;W,ZLW0=*/Y7XQVHMI
M*R1$;2$3( %R_(H*8]W$9#K$,:HKS9:]2Z1Z=+>ICU]PSUTWT<M2Z]*;KT=&
MM V%A'[<5P8'6R7$M8^U]^D5.&00G'S]2;X^R'L_377Y.@(CSEOQD,+GE^*(
M5NU;\V*^5]SJKI8V/YCZX)YF><9"SX M0BMEJDC9SU/Y=TQU"L0E<-=J$%RE
MOZ%>"H.QX$C.*T%GUF!(OL32SNLZ)D,:?T$D]W9\=B" *V0/E1=PPF5DT\;0
MTOI]V'6)<-MYV=&.5MNB']BKG>.1,K8^:V1Y4W"*.)"")7%!!#S*^_"8<X:G
M9_421+P$CAME "XDT)7!)7O3"6T#QSXMRNV B74'V>_MG_J:93\N'8#T, $+
MYTUU7[A_^G\^P@R<TJI%&2&=PO2*7PSC%J-D<EP<]>&]GC=^A<_T3LG1ET#
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M.<DFE*DFNY$X';O)!+RR$@>Q&YW/B^V$\:Y.K+4_+NHO*9](B@G8HOMO:_&
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MP5+S/X^[)C$!R:[<U" FP%"] _'M![H$O9N' T]SDT.26%(P[M/8KO%S8$1
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M^DM\77]OK<4K\7J(T7;>#>CW'WNJ">M-F@HZ=(R>4F'$ +B*4HI0#4+]:MW
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MS9_#R";Y F@AV('>X6G5^ Y[B%09L0%\[=;*]=++/Z4&8.VQ?SXO_8L,:%_
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M\ :!H^($FM&C79!:5=A)IW%B=4)&Z2>GI1>Q.^<N1BJ<2_B5-$J]O(]S@L>
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M.SJ&R=$Q<K[SL: Z$;%]HAC ,&I_"(^ 5,MTD &AQF.^X"C*T.PT/U97:>_
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MBT&[NJH529U=1-O+(^(@E8IQ:; B25;?E#2W @W_S;7*'>]0TW+4CUU]1=4
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M&F2H)$05#H64H3+JLLL0$OY*$M<X#<?=:,RP1X@5W_4XF)U+&"5RFE2D0Y=
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M\*9_W"K*XXM,?G>^ZB=&$L-LR^'QD:O!<VQ!KF,L1U6\6+\7 L\!=[2P3RA
MOJE]?6.LOU95])-&RX3..]V JICVRV<&8ZP#>!*R'+M")QQX,4$_[%'&\ZI8
M!+-=$# "/@*<BE_D3D;?0#6'9=)7VT(:(P7&X=^O)#U5U70F+5E]B_M\8RP1
M"HL HI^YA)J?PZA,A/48(0MK$G*REM5J8A?C5&2MYW@C&ZD;@A4W]8<JF$L:
M9#G\)[9+$%DIE?QQNJJ9%TUNOD@A2M>EU(T13C'Q.ZD8[U9?OP4'[HMC!B/W
MM?JM?L]? %A5^5S!/^IYT>7#%[CDSX]K0\%BLYBY;Z$+#LU?1CZ]7EKQ:37L
MV3G!+5_.^PI6G&CM0!BL39W$N,E]$8,-70I@&11^T:D[Y/(Z]'&W,X_@TW=>
MHKSL/<_SCP7D7TFDUU2 ]+N>I(#'/5J*3Z_%]-F]Z&C2X?#_#5&J'9EKR.;6
M56$^#N\/_3]9 O'_DOF=[%  3,!LT04?2 :,T$6A.4[V)V5(.HVM"U@B&9#/
MRMQ&$0$>923VP*<[;;#FYV3 =<(P\IM@+N(FR.B?$<\@YG^B7ON?JM#_RU7)
MFQT$-478^S,;BKH^C/@_6:=X6H7=^U/=^3*L';0CY.-ESWT[=6=&3=?YAQUX
M^0!.N(QL!5XEN'FC9[J-;2,=A7?VX1ZG5[YW%/$TR6,_L(5:R['_7"]BWLJN
MA75FXUX".8YO0OD/)>?H856O.JRUB@=*E<K5R8!W42<+4ZE8%;1:9 OCYL/U
M6,E+8\=.SVIF'9&IC*>N-R*0UWY^6:$_Y0&!:@*^TH_VHVG+K#&DQD#J7DLF
MS.2"I=9.8 ;I84!/DCT$_4PL@J,VT]/2\PO4P,3D4SJ[I8/69_'[M^)QN"/^
M%KNZAI2A/:$,[S?\D9T)35;!,5>5J2>16T#" Y<V^-D-Q$&Q'T76E:P.S[S
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M>NAT]J6,UH;@M%CWPB&?7QS,LV97OE=U^U2_4/@T%B%P^6/KB^Q+" '\Y[,
M_(^E;I0D_M:B(OBR1@GKM5J<9^,3S=F$NNG&>/69/PPG7S,0.],V'Z*<24>E
M^*EO>=\:Z)YU:!6Z2IR"<W:1Y? /1W.7"2+CW@BF]?2X> E<=:*F>Q%:B6;I
ME2TGW3SS_>OH)KZEVFW%103CUC&Z,$0,5%M]*:M 1RY+?>R;4C+:LUE3M5:8
M1],+Q_?V:)!O:XYZ<5Q:1U<!U75L8F@Y-9GA]]@@0H@U@7ZW][K?F[MZBJ:=
M.#*@UK1C1Z)KO!1!_WS[SNX/\#H.Y\2B$!JN.UB?$BZW]FVU[NY^IW&7<9%:
MGXY/,-\1)>S\WBWAEK[#(V?2&#UYM+<_=UJQX&F%'UG0^];+C=Y[+\URG&#N
M<EM_%)(7=0Q^#Z_UBU6Z761AX=^@CM6+,#,TXY76J3,M6/8!R/-XS"?%N/&X
M;"@BIQ3GRYJ_U.)2"U#TM^P/&_N%G)YCCQ]/V F3:.(#"<=87&X^'KDH5.JW
MX'JS>D:<A,FX(B-U+N'YVV*V-^>$\9I4<FQ;!DG=LOILX;491 7B[_TMU1>+
MQ38E<U9(Q!A?>;IUOFNITX_TL.023T<?9OW+)4-#;^UMCJB-TU>@;/Z^6VV@
MRP3@5^O,6:=3^^;JZ36&BF\VA]1,>%-C\!7#>S$K'(UY@Q7YM[4S[04=ABF$
MNTKZ7VGN_^WEWZ6YP;JFOY'_TPQV(TOXZ:R+*'NM9" !<<J7^Z(D&'S'N!1*
M8;J2>Q]>%&O)\1;4P2/XKBO18QKU4_<Z9D5&O%NCGEM4+Y0)=#]-$+<:_,-%
M4/G:_ WSVWW/N.&P=G-0R%(=&%1=<T0&O(WW)Y:"G+;@:,G.\7Y':K1?6'5Y
M;^'D;XUC!Y#4\+FN10#@Y0X50@!.X2XA=F1 ;^ X<ML*3@9HBVTMFY]N_7.R
M& %C"B\,^[5IF/<]V?Y$LBLWHBBJ>Z3$>',9*7E(M3074P;E(W!@X1&OX;]:
M*D:$$M%/@B>U=S0('*%XTT6CM&>ZWL?W=072&%8U/G]*NZ.GPX*27Y,^HSES
M?3Q$^M6B*-*I/[G ^2SN2L>#^#XD+[!MX9.$HTFP6]HTXC1[CDGV+'\$_.?T
M@'0)OO#<!Q&+;JGRY/BXP:53_:1=T3YE3-81Y?@)Q )V@DZJR+9@:+>7%HDZ
MNBE?6E(YMG/3942'3H;OO&Z->P^482P#+L[AA=PC;8=;9)U/C0:N;J8K15_3
MGTV49\+0>M4&$( [$E/"/]EG0<1,"+A@HT+J>.@AS[9'5WZZOI!Z0O*YT123
MUJ-.CS43TDC^#I3/;W<5=23;*]^2:SI),$UI#C!&/L1VM13_/6SW7]QK1_)=
M"*FZ6X[:=OCP7-;&_''RK^M+]>=>\FE*[Y<&4W@G]0)&>BZB1>5*@(U0^X.*
M="<'8 JS=H'(B'+DE9NG-Q'5W?O!AK4JTXB]'_#8^(]M7L$.:4*$(0(%@E/M
MZ:/;VW D<6*64I C94':"W2"V+\E,JWF\$5!:TY*SAAAO<-X=E*C)6SCSMBI
MP9FY?P'C1=( 5*DI6__.8(&6'7M1HN>*"%_T&@;1#YL((NFEM2*/T$MD@)8#
M(K'GI"4_<L?Q>+^1%#[N:(DT:S]&+OBXCQ(-\)1/%_#JAN'.4U#BL!^BO9C8
M^>]_-O)!IH0"^TFYB_H+?X[22&CH.D$"LZQR%>^^$,P\XZM>N)&*F[<[J_@F
MO*FGOP2F(HW!*P>[XJ-A/!"M11Z)MIVB5Y523S<.>/2&[RWG.0/H#BX8-'K^
MI$ITV1L,5R#PBN)A"Z4.D\<_8053T[E!2LXP%9?%/30_;A.?A;%;HHV "+M^
MP3MMW\DWJ4K?'U[NO2,>U=?Q?9/1\#Z \T+3Z^;%5!N#/UJCQXC^3<0!4=S/
M-I5GY7#,851YIG9*YP3Z0WYPD@]G@Q_$P);*PA#.)'972;7;TC]R[XZ6"O#J
M=$W0&!IVKS%EGUNF.]/!16%^0R7P+$O-HH_'GXG'>PHXMX.:'MW7@.:DZ"^
M.0CRQ,86)8(%EAW'_KZ)?4'9SGC?>KZU7/\:OZ6;[:!O,>V--X$?@8Z+?COL
M9_KXH+;T)J@@WBQW8H,9K<,VLU(:UK%Q^4F^V:]N[\VZ*Z/8$U-?$&-LIVG,
MEIR&TRN$6ZU%RYH,..*GC5.OX5KR=93.H>FDKXHK,1JVO*Y$10%P;RCT+=+E
M*'?1E) $9_U'#NCO$'VH#JD3N>_->XX,0-3##A_5G YA@22MP2C8-IL/A?R8
MI[' N/@6B \_^*85@^AMR8#G< -PBPP22WE/"@*?]P9OL6P"C[M0)&4*O/.
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M'[O*0%36$KAK0$:K05IC=<B>VY1B=K77=V5GT6QQN.2)!2H_?@01WG#</@?
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M2K>!W<6,26W70^'F4Q6WMZ&9GO!:)>'2B3E_=]7$ZW7<UF:= N?L#5_R/A=
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M<V,R3.)@Q+M;,D^^ AR C+7TYZY?_8NKTX3B"VM6H'+]6NIWMSQVYUCLW_^
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M-H7G&LK;D1GOYS6H5CG^.I.OK%/CAA8_E6U?\<UL4Q1ZY"050@V6;7/&?)D
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M;,[4[:&Z5L9[]R28TX863N'>=[5;3DM/$&H0T'@  OK6(. 5&B0@+OL?;8
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M@X#(5;KE,"*NP @L1#E;@+W@7K1"/5:IO+%@D#"7.XWB1;FN42SMS_5I:4+
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MZHH4;Z^P:H"93Y_0T^[V[]^HRW<7+RE=NV\5K)'RRO3ZEIW;U1_Y8'<N K]
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MR-R,N6EMZ?F=/#987)IP%6<$\T+^>,UO+TZ1+1A>X.MU31AIW:W#FWK7ZE5
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MI<N/3CEJ.!^-]ZB056,0CQ$G5]%"0X&'I/ZPY>KJ&#;W+9R,U4-I,:5SBG=
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MC1CM9,31'="16!OF\$H F&C.! P;@^_@L8>"CI'\C#?P#"_@[ID6)J""BS6
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MDO0"A/8JQC_CX5QZ%_7L,(M^GK(:!7ZN>?WN8.#*\5U>NMO"5 &CAC )!=9
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M)YM^)"I6[/X15T20FR.P[X&%0^T1)R@=D)\5BLZ5#:'W@ L/X18T"!L1M?5
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M+>CB?-?&/BBH00EC&,^0G>[-V^K;GG)[1VBW1;,JE5U"ZVO1>Y6FTUP\W\;
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M;XCL+O^5["DRVWTB4@WDQ\%S_/ZZFI8T\[I$3):PXL3,D2L"9&(?-D UKIZ
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M#MCUL(FE?E  [7OQ[#H&.-$!3$-TP)>@,<3F"0:5R_J. EVC SP+:7S'(C7
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MUTL"8OQI*Q=,0C=V?=0568D1C%[H7![U;E3PJ1SS(G^LK4XVD5EMCET&U]&
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MOXV2+4#\DQ_AEPEA@<==.^XW#$ORJ-\DA-F+$K!MBIW8M)RD<09^^L 1TW2
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M=OMK&?+E&ZI!([/?O(,X>T0[9L,H)TO1"WGSW#H]F5"'9I]R3HD_84\:==_
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M$^RHU9N^%V<DQ*KT:U/_SH6S8J4\>^,K%&X'K,A$F;M#:KM%XDPUXE4;/!0
MJD^,SNZBL.L<'%<O@"(R%(G/H1C[BP31K!_W-P7OE:<GJM]?:P+5$7O(S9B"
MV)GZQ93<>:*QK0AHB>>%R<J29439PU>\K@L;UCI'X'AG4D;U82<?)U/IUQ(,
M!#10"/RI(X+?"=$Y![V@K6D2@VG+X!MYX21_H][ATSOK]-E! _%XZQACR&[D
M83-QRYVP@3OH+,A)H@,^(HP_6CD/7$E0ZBRRSI'Q$YKZ!-BK4+BE7L*'X^L<
M$J%8.#)N*N_0B"GG^N5=E6)7M=YV2:F]YI:?5LC 6Y75Y5JM7Y7VDIPZSG1
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MJ&A4-"H:%8V*1D6CHE'1J&A4_T^IB',4H'7S!VIIZ"X%0'E2 )SO+)'A-6P
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ME[\=<P^BD]*-$]0?"\8GGG1DS#9DITM"3NC^_:6"!AIH^&^!) :"EW1<GZ8
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MP%X+N0P^A"2FDX\<XC1A= /:A#(*8(C:AI#'P:,R!%\*D AO!L,N()L#+U
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M&;#CY;SS2<I&N?A^Y09^:@R[LN@W)^O,]AE;>7$F8WT6 T^9'?M*$AH&.U*
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MR9\R?Q0N)YJC94"O;JP/($5"$UE-/#O:,XG@?5K.0+P.9T"Z8+;[5( 0B0K
M9)S<)P8$K#2Y$;4#HF0^*!?$5&SHNRFQB/IK$TX2;Y&$4-N"-/[V?"&Q;(V2
MU&]MBM,T4: ".@>O.]N1!FN=T3Z[ ]Y<]GPGZ!):0=WW5;EX.@??N#FV-510
MM))P*5\>OL&\=CXHH?S5,A6 P.KU84$F, %XKSP.3 XO1QWJF&*L8)O0IU1
MLL\B@GC>"KZ>AFQO.&GAF*LC-U(!=;Q4P%72M1!:>-1&>?U:0&_#MX/_O?LO
MW*:MOLS2\-.,<]KF:<C,=^]A)1$C1>">I*OMKBY,SG033&(SA9.DQL9WIN&U
MNWYK!4KU#3!YI.6[^]T!@H)-%E0 7W>O\U..B:Z0/#0&_I=&J0A"FA'?:G#
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M%JQ9HZOXI 8U;OO( 2UST<0R PB4,'$]<:'\?AFT? !)AC"UW N(QK#$8'#
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MO6_P^OTNQD23T^1\ZZV$1903>/L86T=/$46^!6'5:"2D>PNW2NP07T#&L07
M-"5;4LNY^6YSS*X,5ODOQ5%DB/'6T5=-W+,81E*>OIB#_ [\>?E:!4>,+_N,
M$5P>(47B(:?!N& #7!=Q+'$"0P[H3/!#-UN+@*6:JE?>%6VK-OK,GUMP:U_;
M$[^*[%:S\ 2$V%5_UL4Q1[^)5&L?FIE^UGSQU^\?.Y!D8*UIUV7317 /DDTS
MT)\_TSTV4"S#QJ51HCVIMOO6FS[)-$'DX[],P8(D5BJ@"XVG EB5## (Y8%T
MW_S/!V=L:^P3S/X^X'EO?E&EGC?\IQ>G'53CZI*+4=-.O_M[#X]&4M/ :6"J
M$,=@B6&AXX$Y2G%O ]ZQ*TJ9!U8FA&&)6A&+]!$B;-H_@B-K1P_[O-[Q.0ST
MVD(6SI'R-6^6 ]9 +.AMEIU>UW1(Y7Q\1]QVPM3CHQL&5R&)8SN>E#OY4)%4
M39BIW<;K04'E#M5XQX',RF3T&/R?\=RIS^J_8Y,L/^$VR(DM==QX&+ 3R&,.
M=]P8T>K+=Y),OO.1SZ;@(TN3[-D<,/VY#X_9CV7PC0O@MT%N^66K.9CY\QO+
MKG51@0L_WH5-GA$""9$Z")9$'Z@Y5BPQ+\!6RTK<HKHF05&16SA>UB<2('3G
M1( ST=T;_+-4Y0[A#/$197A.N@$'JU@@ENK$/VY/&S5W?54;YUF2](SR,E[S
MT1E!_GT]<.<_<PBY="4K8T8K&6*U'[I1I8XN+C>ZHPA3_--XJ_ $HCX$;P.!
MH2@&J.'?2VY#4,MO+R[G1Z<&>PC6PNQD3C#$0-COS!OM][9IA.\BJ.K02G5K
M.SW(3"!YSM[$U_%@B$/8SB?REFU$V"%DVX9XGU"*]VM&U[!<V1J_ 9GZP*^I
M.P+MB3?G%N93/'\2*O+@!J%A;(]P+UD8]F<J1XC!2O5ON*;:JNT)F_5=WF^M
MJU>BN)#2W#'$*4C8CG%L]T()F$TG35L;F=S@4H%C^7^BQE"/*>*PW[STN,&.
MV>>JV..W4'%,F0FV/6ESO$'Z:I_KM]=.G$]ON6XS <XYR/VZT,)(TQ;_/-D&
MUA%'*[1?OEF@#%3N!.12KB0"""F=BL8#J84OK"-M0[OE)EM![Y Z[X2-<^/R
M-NKRGI\<2/W!3.D7JR(5P/-;%(YLWP5(-!5 #[=7Y+XLQ(UD(<"?9]$DF/W^
MQ;T]L+?5+]L4DG DYP+CH<>-@!L=D*O2?B,D]6\3+@W0W#N*OTP>2:KLI_Q&
M:!A>W';![G7QWAN#.BURDWTLF],-QCSRI5Z\^#/I8$L*Y0 P_]-@,,0_#@VU
M@B]Z3&Y/S0\<TVF.W?U1Y\118>:G>:<\Y,R'L'4 3ZE(CU!I=,[1SS'OS!I*
M""*%DM1")Y5O@1IS&EF):&ZQ(L-+$5<I$XBJ&6#57N=*Y7"FN9)L2;N'])Y\
MG=*CA[RL\UW52^<.:M+EY65Z88-PNB-PXOS5;9),(6K2397\C4(H5Z]I^,!9
M,?O^MI$_OU\O\ 5M749N*=L@9G<)8IO 82"^D_[49(W$>M#N:0%5PGF\9X)O
M^$\E3[R_2 6D>78C>TB,MB<L3_$_3B*U[( 6*4UCZ $\^.A Z;L)A,'>A>6\
MX^_!%1=4EZ*?RB>" ?8&C5></WSGVB218VFI5W3=ZJD1B[]G<(8 GU=O;VM[
M'!90U/1LGI$BJ>N+X;$^:*?<;];MNYN&]M3U/0,(5RT-3/K1>Q)U\0AYB;;W
M"= 7HTWGL7W:V-5$?X%4]'O!)+&[D3&HR5QCL="$S[%?57(]]R"?QOU3-HX]
M9RT&!6K^B%6J2XL9++WTYM1:OA+X"\DB_GMS53^@I,;";?T8A@K<MJUB#'1)
MX$J5/D1_.SRBU(#<6RZ3!$=@C 0!)='<&5VO@L>^2C2D<VQ+NJY]:9O?=SI9
M:N8,Y"K\OU[Y(T%VD/?IJ!LJ= 1(I\*7;/<2G'+-<CV@5T1O*%UN2>2:1(\?
M\@,5L%",V)</8*$TB<$/7YD^/"MS?^U*I&F@(/]\L(8&H?=Y\<>!-ZG?AOUV
M D59HAV_Q9"52.NGT?]MNP D:L-[6T@TIE$11*0"GBC# N!M<C3BLUSV[UR>
M+RD-I48%.(F?R,Z_!^+%(?#U:.3  15P? J+/7"8>0W<385W4@&'GQ#O#PF"
MR>..JU$:,8X3"EIOHTSH;X4K7''Z:+H>W0&L@5=!.ITHPB06;/I[]^D0<G]A
MJA^A>^.;[;7X1#]5.!?!G\+HNS!1G1A#N8EC$F(C.NA*Z(3%#S\BS(!]*K5Z
M2.=,1T%8<#.-7?;-\<PV IV;IA'@:A"X1V81CC46X(5T1+7.?L9E4P'[[2C9
M]GQ-Q>6HV,RG<R9!P*]CS:Z9^V/[92%<I,$LD!UP,NT8'X?[. 26;O"/K.Y'
M%D,T+AP@&ID"EX)?[GM?8_J"9=F$A%,X N@7$J._. :II&,:+P4<*!^&&?].
M7$RC,9_-_J[ P6WAA0#H#>)#@K-ZO.&6V8&,3C3=^3]QJFR'\;; R'\6/.>E
M"!DE<R2U8246]LX/ZVD/[X?(-%1<DNF,:Y5B)AIK*,O*O+']GWWZW@M.!GU8
MD%4Q=V\IF2@PW4@%1&G.N;;0$4:^/OU*@/=P2;@EV#J*+S IOG8_$[TJ?#""
M'R/'E[6PJ"HY+=33ON*MGODY_S16^:3J$PZ,N=G^JU>/EI/S$K1L$@7(R;![
MSHA+%(4 ZV#N:!U1/3S/0\J\?Z^T9#WX4U#QRX[9D'Y8/4D+&U+7R1)-N8.=
MG=J-,*K(',7]3E-ECZZ7XYLQ8<>8WNI4-5H+4$8'NY?-5REX'MUW^.C F%2=
M;HV>I (R*>F8O2BH(GQQ[ZI3P]UTAOI17^YW.VZ+P"Z^'\:\'8)EL#K2>7(B
MB0$+4:MP>A.K#.]BC#E6Z"?=,6%=0O _?/)4\M%TN*:ARSZ\345ZG'*#\+NO
MD^OFEEW91J5$E/EM;54)P_C]>J$ _C=+1:LMZ97DBA80U!$[4(RQNO0XUC1M
M'U@%AG]S\OE<Q$X0;0:^#N3DCHEC2HKX=>HZ%R7.=K&'18#C:'Q^6,5'I#BJ
M8RRE4_WG&Y/F1M+@T'5"W8*PV\OU^"40LWI)Z8FFGD)9_1?98V@SL6HGIH^0
M@Z5OA7!4_]R!:F.FA3/R="LV'W16S';,7,O0P$0,, @%A\LA!\3I:8"H!'M
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M?VI-<\SDC(9Z=:O#S"ES<^Q#2MS$QSR*CX:VI95!Q(?CX,J-VF*/ZXL0T0H
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M&9G_@0JE,))NH)4@WYPI? VCWZUG;6/U?]8%@#,4-*;#'Q7F?GF9X&5]I'1
M;^)5>'UWRM+_+W8M>7&C_7FRB78ST3D00F(;I.CY/Z$"D,*#9-:Q4\7_P0Z]
MX&U*M$6NO0&?[C?]!XAS4=6TI[/7F4B\@40=JJ$'O>B)1^)8)%E(LZ)C?I=V
M2]TT?O@.\?[HU)8*.(>B I+%%R%$%A0EI0.2,?:_^% S&UYO= )SQ'E['*]#
MJ8"[WO-88Y83.I("K<X<SY\RL:\#L;J6Z^YPA\8B/M=>M[(9_HB_GQ9M3J]:
MPVE[H4\%? !U($_W0JB KVW_Z=#$$*;M%A*YG;,9QL5,QOLZ-60KTDS:11=?
MGSN\H"['NYY;S([1SQ4Z88MCGW(C#Z.QRC-V9D/]&WK!E@>KD.()>)N1],^6
M$>R> :-N2]^TGZLG]X,?P'>#*Y!SICN)/8-AI[(T7AU]S,LYMARL31<;*TSX
M*#4U\#72DV6.@Y_]UR_!#YZ:W2K7:;AF18BFL.;S\N'\TI1D;V:(%WPO\Y>D
M._9K.!^7-.^S]'<\0\PI*B<2+Y/_>PF>Z4X%%"=XI9N6O<>/VL)>MQP5+B<=
M^F]?*APLI/3-W9#*B1L4G5GGL!5RYV\C>66>?*8P)E$! MQM<#QC"A6@R46^
M@,U*B\W9D B J^[?J1QB562I;)UNZ:^5$>;VI[>]O?;E@?+6P=I_7[;_@SV-
M3R[>Z'O>,CHWMFXA**!$G.6CWL?L8@U*TQ!J$0I6OV:Z$;WF,$(%5,IN1^=2
MADYY*THV5>[_'(97N8]/;HN*&F>E?I#L797R2JFW=2(69@?,D9&@5\TW%H =
M.U*=<QRH<1DSRI2H+UV1DEZ%</'^S+EXO_@.IUZE2K0@\1(TJ(H@BC.TU'7'
MN$'E%R\.#V]B!ECGC%_9I";:G<_0W@8JEQYI=F9S#RMY8?IFN<VJHHV&CBX^
M>S[]6Y;_74C/PN.;X6?8<?+ELC?"NKM?#$XV2J-DR/Z:Z)6 %V)2E^YIPW!6
M$+2#QY8]C!D]-%\)W&%9FK\(-<<BHF^-(VL@+,[I6*<1)UGO:AR_.T96@QE:
MV5@'K:?WD&<_-(U%+:11>$9]93]W9,NBAD0FTHBB1S%S'WO7R_GC%H+#0[21
M9F2:5'\%.@^E'\]%CZ]N=<+XXQG50Z E2=/+5_JON1QKTW/:OZ)7E?29?#=0
M>5K-E=[LBYT^A2A^>>,-]57H2Y^MHV7YL]/KCH:+G'=2U7KNI-JYO[T:+HR-
M[;9XH2 8>]2O,+%;5]62/??PR"CI(RP<]1KN.!AOX=&*BCPM0/E+VQH$3%V6
M'$OL]_+^[0=0II^SG:#;@<1*]0O\&=85OI&F(;8]JRW(C_[<(5W8;X*<' I"
M$8#%&[C+6M[/"_'E\]^H@(A38"V\:I#T 1(-PHMM4 &G>JDGJ?]W/WL4C?[9
MASSE,<4'$_R5&[\GE4<Z,0CY'&BRYK(4V?%AD5DH1UK![ 1QM3R$!-3IX>YF
M%*R?QNF3<]P-->LCAV42EQ\]K+_]> 5=S'O4&]%IV+Y:4V+B9WWZG^'4/)\R
MGW>N>$:R^SNB6G$L!$&:+-W+@[[ V9<N0M@FRW-R'.]*QW3;71#^G-[+W8,3
MNM?[O$WDYZ]?H!S@]1:) /""8 3: B?083X1=1U?6YODD>8PI94@S<%S9O,1
MQW+,"9C"D+@8;*4RV)/-4.\;:U+;;+D23W!BXWV^X'MB?@.T%W.\-U6*]XG%
M)V %RE.OYTG'0_3J94U,)6\'Q+(+]=ZZN6.3H'DKU#.(<T H^$67:J-S9MW,
M<",$G:XJF:F7P&A8")P+1A_IYJ'$!XL/ZFBA4_RPQ;8- S[;_\#FW6Y-;!OG
MY3TFFTK0SE=DTVT?_GL]I?<$]Y%O52[2&)9,.51QL5'489&YN7#S>JV4R-"&
MQ:.D8<S'\);7"46JR]XY@4?LQU I32]&G4O?*^1FRM^R\U6<\RM_-O3R3@[X
M?*EI(_KW- FOL+^6\/D++D@L%IP]+SK8W6^J'ZU-_B'N4<XAT%R7D)>IH7RV
M_*LVZ -R$M)40T@G/G'R64?QPFY-#7Q/CO?;AWQZN1.8,4JY'49R.1+&ZQ!P
MMKA!C%Z6-_H>5+.@,RVSIASFFZIQKIZR'>I.7^#/7.*"'BAZ6D[/8LV55W.2
M[T" :::DCAMYC:V#-:;K2MRW<"3.$P'<)35$!Z\2CC?).RYE8E/V^L#W!][)
MDE3 TSW0ZZP+6YV0:O]0MYTKC6K%/7[+3#L)(K^6*8PNAVSX&!H]%<=-=XHN
M*BJ;># &1+TL]?6Y_*,^:HWN3+;H;_^%,_4/%KPONT(ODC^1+A&%I[/4:^Z.
MRI"UEWXHM'R]+MG/=][L99R#HWT/YRNOWM:E6ODCEA)^Y(ZHBV7Y7!KJSVI9
MBFFVD"&\P_T8I3L_B%6>-Z25%5\TV=MCV64_EL*P5:1F1]1S3/K-YMN?-2.1
MMLG]6[2GY1KE''IS-Y\*N+6%/%V>_X7&#+;/\UJ1Q GO,50 N_G9D0W3]YZV
M]+ROZ*+!!-8T2'?3 +!PIWBQ6+SF6LL1O[_#/M[C\O.3U_,S"U2 &GZPAU>T
M!GLCX@C)"GGLY6.7-Z4=K/30D<ODB>&?*Q* +W2C,2?!%-Y ;!TEE%><"FA5
MA%"TD05-,HNZ=(NHL)T:JX>.OAXL6P\+.3G-^3R-DZ)?R9L\_W4K L)(H (H
M#/#OO8OO!; .,=)C?^]^_!%M=F 2_%IP-_Q=^PL_00?74W1Z^G#;P4":"L[%
M/;LXNT"A0'BRO9QQ& S7B^?-^5]->QF<KS7=\5_8F^)KG;H;C^F7>E'96#$*
M0_-M?E#CNK:?]2!?P.?+CVWA/5 8Y.RA1Q@5P.3:Q.=J:C2QH[RRC"TB/MN+
M'S#]PG1>7]+SFG<0>DUS9V,)P4A(7\0.-0GD;_BE-=QT\P@,*9SJ8;.RNOXG
M+.O1'-L9C:"'IT?[A(62I8\/#N<;2U*)OC6-V=8/S7X'""H<L;9\J=T;/MXI
M/M"]9@#Y"F0*^6=E.T$%I,1\IK2F0TYO&I]>^A]<)P3>]A"TO%A !?P00%.B
MV6'AE&'(O@>*%;1M3=/$0RR0+VOS^P_^[Z>8$[+/$5(6X5%!?Q0*HV0:^[EV
M!5D^!VII]CB &[8V.:ZX'&WA'0DGA92_D,L[-;^>^$UU_;Q^FA^#.&(+&].T
MBE.Q QF,<I%>(JW)Z13E.<H@%<!6)A,ZK)-CM5,[]OTO%? ]%-%"?_R7U$>(
M"^UN04KWY29\.S%MJ847#AZH.(CUZ)PW?TCN:2"'F)+H=L2G2_$ZU;C!Z#W8
MK0"]-AN<^EM[-]7Q20ER[D6@U Z/W>,!39$S-S_4G" @S9EZ97:+E^^.&([L
M\C6/[-TV7ZA_MZMM^Y+QAW+;.=,5S9T^(HW\M6<0/DYU)[FL!( [F4>F+Z(9
M7$#FM_ W=PW6/54VD'2W_PAPACRMH@(NTP*> I&9.&7:HN/LV/H(\]MLI (0
M\S-D%G*:^+=1D ,HVKO=Z-OZ.(XG2_;.MLW1;T3W3_%X2"TJ''8N8)8DNG@9
MV&DJN^7!\^LSN#8,\QJZ='Y5;2*BQWF?QLD'N[>4+=OJ()=KN%-CC8>7D[=T
MXP>4B Z*6:9C27VLRC=M<WJ**&/SE=<11$U-VQ+S39T<0B'X71O[:))'U*)(
MVM5?]'Q,VDQ2\?UM@[P:=R.%.+]@8E%\;O.]FXAUBD/NVS*36JL;42[9]\4S
MYX>WC/?E4/\]0BGEOU/O.W(R&$^'(N@L$2$W"(/F([["_7)59A-.KS3?:9F>
M-0UD9S9BB[R$IE=ZU0S&_\+!(UJX23QC1Y<=U(>.E.U/'U8-N^U]?Y65C1D-
M)=@IW1+HQ?<82M4XVB65<<D%**3O"#N?NCJHFL=M_"X+++)L:(DM7UOUZ%!6
M%;7$O\.6'3+VGD?'N-G'OP"T6>QHG6.6BH#4RA""L6H4'<U0U#;(A@K(9X#4
M&T]W5N@;O:K5ID3??2QK:%PH.@T^ %TD^=+$1-T[^#:?%Q60:]%21^.K+VAE
MV  730Y+I_'"?&C2$O*$ITF-"K#A3B1SC1VA2*QKE*>)<:!M)M2ILO!Z!7Q?
M))T 4ENC\7H^=BH <H/R,42"QLK/_QM@@@.20\RI@ U5TT[$C\%64<6EZ*Y+
M&34$E3%,_P7VAI^U@F<735S5V>"5?HU JT][$#=:#7P,7T9#-6E?90(_U4\]
M2">Q[G7AN3SBH0Z8Z?<FBCLFPW.KDV9+?_:Y'FTJX^[)'3[?@,BG&F6)%+(I
M0%C=Y]]X' M7K4MI/2_.T(^TRH2<&E6?;(>,+ T":>P $CIO-IX?K?Y7Q/A6
M#+=C<#;KO5R#T:50.0"KYQF9?5 <:*'8X@G3$,&R%5WW-2(VWGI'%)\]WQBG
M70]O[0J1(FJ2F*K)7RE<+P)>!:^.B"6_::QJ8FA2ESQ[8>77[U1[^NR3'0@_
M2?*?&>"F'X4_:JTG6V"D8.CK1_F*(2@Z>4,36YU0O!+1[<FQ=.M*(*^[Y<T&
M_=1GK@C)8)>Z/G^XU,@?@82W.4S70J8]"A+7AL=5=K'6-;+OE7ARG-'WDEY
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M5TDXON@T>4AX (LC_IK1Z6[$\/><,(>._![,G"MY6]#W\N#S>_+";F'L?51
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M0?5&]KPZ@3=:9Q7, ?6 9;FE%MMH:%"NYL 4G\F0415^+R:KT]Z[8?0$-MT
M<X4,&!9@8?E<$6AEZ+,OG<]FS'04ZS>*RBL9SL&+Q[ DXARDVO-#)H[%&!>
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M%W2M7$GK[F#+-][>QB?80(/]+3=M%FNCYHBTMSL!?)C:DR/<!TQ,JR_X8U4
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M"WX_N^N@.%W^):54SK^<Q^FKGI/5XE(SE&"JRDLDK8$/=R!DD:1PR(Z4/05
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M<H7JRL)U3&?3SV((E7\DNXX;A%X%=PO@C*FQ.*E.0[JKG0WWOJC[M97[)^.
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M23[,PU^" H@6L:Q\*\EO3Z>7*HA DM'O@G1#[0[^BJ__-><4)D +4!6PK]!
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MJ6S),N1/5(#+\F4H.]:AK>#;K+8?QB[F @J5(<V6UOL($$07O%'A'%1#86+
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M-@9'M[314P&_#ZF CS0,IMRQ5%J>CU])JOAF.S,?M&C[YX]%E$3JX]9$@SL
ME\PK90HA'P![$!P^;IL*L,3F_3OS(6684N6$3 ?YT2@5?@(?3GC&TRL?09'
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M$SG")30<,_AWP$ [$G_E)XU]0ASV29S)C@U3<+<;LD[/-C9#<H9;AA:X19_
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M2G;Y3!:UIM<!/I5UY*)]SJ/\@APOKS:0WH-H.#C#[4WFAD!/R%O1QY-]$E1
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MD75]IIP$GTD6U(9A,HFS#V-/N>%P"WT]WN#P[MV2E*HOP/>*N3JOUX(6-%F
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M_NEWIK+XW&I!\-_7MME0DYGD+?"%<,INA:TS#:#GOIC[IO^5=VJNL9Y,(T4
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M3. PI"XC'/7;L=T-ZED-N+8GW>F=7,2]^7^AL:=E>U,@D+_"MTZKL T>K23
ME7$W9**6:_^] -SJ^%+<<B?6]1EV:U,BOY EMC@2H2'B% S?YL!'R22!K^Y
M#9BR+-'B-R]8?YO^#-?;OR1:6C22R"7^:HK;M$B\RB=G2Z*:J(-WMR5*+4K
M65U866JTE73/1D1DJB_EA_ LK!6J:'^Q$2[[*/NIJ,=0NA^8UR!#G^_M>VN;
ME"IL\<$H@3PTC6[@QSSVB=O;%?A[X$*3?FE@N &(K]R \U[-.^C0MYOZ;V8M
M_8%ZQ)TX_/K2I+CWRB/2H%50[>TO03;4Q6V6!$A=;3+>'=M2A8U/OMSD&7HJ
M2;47,8LZB@9;[:&FC @?P@E>[ZSE71.+F#3?)GXF-VIKN+>NE<4L3[H8IUU
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MYE,D@Q9[J./=HB&*&F!@4V.9NP7UUMBNHL'C#?U9[;U[DD>LH:L.HYDGQ81
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MJJ%:@.(9WYEV&2>Z] L-TJ<*8<YH:A7[/#X<-]%^'5Z5.\.RE#8/KS8BL]$
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MI^R^[UO7<X#R^=4]>)7G(/]#-\YBIG2BK[016()@A0+IDI$1NQNK+D= ;=$
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M>&CSBDO9>8R,/(;NY@YFS*])*E1,%@269@Q@<N(+(7J@OXG_;(DO/83OS=,
MG&ZUF9EAQHIM[+B?7NWO6&\\_ 2=? 'WG6C#7&WA"PS'ZL0CH<H+UM?*1[>-
M)#Y]B8%MQ<QR7UC3&0F[@$3"G]*Y -%MA>YB]#P=6&73B+^67:PE5OV#+F=L
MK =BAN&E+ZHDQ,L[V,(XN59!?[,9W2:Z>Y1 %8;(KI<O*4H)X#V$/UR^5ILA
MR##!>A;]E7!84O0,_Q&FQ&5C4Y^O@2B+QP]W'\K^L(&Q!B9(!CDRS@9+H#J<
M]T"NE RX X3H"KZX,8TAWZ(!<$F4,-(63(?@/%U'W8;X[ZK*'54D"&2[CS3)
MT0!G?S<B%D()&<6!.4%--^S/&IX4U&3.#/K)ASV4$U1_XY_ NBJX C@SH &D
M7@R@ 80072@"+[UM5R>^P":!->J(*ECX%ZT"U_&3PIA#_[<SZ$#KGU$*W>M\
M8I?_5+[^G+#GT\VB)"^+EH26_PCRS#.W1:+F^E]9\O&5RW5.6-O6!0S5T "
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MS8*V]8Q8'C$*<X>BA2Q2XCM7N&WR5<=-=IKOT  ?-^Q%G_I(NVC'Q^U2_/;
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M/IMQVV$YZM8.&OC/;4. <$7__B7NL$AU=>NTH]J6^!^5)>>@EPO4AO64IFF
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MM>)5X(4_MYN<K-KUB('5?S9H*G^. PM _Z!JD7$@E];5_+7HLI7Y..:@\W@
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MDY*4?%P"<N?T&7F7A"1_U90")H"%V\RJ=>1SR@9\7E<^\AS"0Z Z,KN]O%3
MV^S#T"T*SVS7EW C;%+5!/O"W&CELSY9Q6L!J0*.S)5E[RZ+7_4X"<:X="*C
MSTVZ4$+VL^&:V*J\M8ZX$%D5GG.Y6GW.REL6&>\<KSZXEIQQ:IWH))O/]<5O
MT085F)+2LR+MPOW5PK2NG4*D6()$-@OCS^FZKI@3ATZ*2TS:D#;?PQ_I'3BG
MTWQS#NA\&7Y^&=&-$H;]V$,#B9<78)M3B$4Y*8K67=A)%^B8'1S5\;=:Q7PO
M",].8^(_5>!\[ %Q&&PR0<P]((]D?26E3, )4J4EETYW!PI[V,TD\O96.2_,
M)O["@+"\-H0*RA6FXD4W9/U^NW)WJO!)54DO,RP>).% (^VWNA@L#4TOD4OJ
M#]Y#13NP*7'[F4,]V0L5LBICN7IN 8#GS;O)!5I>\1;ZG8- +\IO5!TP"N1F
MQ-.[;<6Q=5Z575,S)1M4)]VD]LR$0]>858&M@/_>U[$0^]<X;JMFM9T=Y,)Y
MT!EG-'B.WV5RF4PX/@Z-V,&!@.$JQ0L[2Z)CQT,2SFWM+?%SW%J#P3X5*>&I
MX&:*)#)2&YM<$0;YV3@5I#"LJ&)4P2]KTG@!D0=R.9@!=M,P+/RI-]K3\!F\
MKV6M0,YYS);)(RQ(3+ W++?N;2['#/^(P@4AV!Z9^,2M XC-HP)ZP*Q+ \$(
M=X_5[=H'79D_%\B;GZB 43TA[FVN7(QHW? =]A$/T^Z50(/S^7;$H:6\;,_0
MS:C'QC)&]<=(]"CMV1? L_ORS%3 --,H62J4&$.;5!HJM*)!Y^=U-'GT'A&#
M_'][I#IQAZ+["4STIP(,721I;E*49$5NIP**Q=[]+1.SH(MB()D!7CBE/+\U
MM$#?%$M'V -EA#8->,\S=?U=6O&OC^4YW$2NM3:WU-O^*!WW7(;$\SKUVSNJ
MO=7.5TOV6/&>T<:_J2'(XZ1W'D_O6X[WV%__]YU'.2O'7*#4S]04Q[//UO@%
MQA6CB#.B-G0XGX]<$J[FP%,2*!==X"Q@!+*JFUNC>_O!'+OI4\;/\/;=/1IX
M/,R3'9I[98;W;US*) &7@YT"RZP 6T_<S)-.3Y#H^A/U=(I("+:)\D9$G@KH
M5 -3]!%RY%*D5TH,2J"#::>#?4PIA<-FVVJ83EONI*'E8>F]-.WOE;NA-S=9
M(AB)--(Z9]L]^ KV,*DT0GM"T9ROFTSGF2 %L1^LQ</@Z^+,-0Z=G72YI'%:
MR'D)!<M[AI8U6*L8I45ISU?],)#E9%75JR/1%Y=M7]X0K#OB\<V__'3ZFJ5
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MFA[P*&O&N X."'Z:WH'O'E$!XKPKH^2$%A@EO<3I\]-,X,T"X[!2Q)%1GJH
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MN@2GU+8,YL17 07\/Y2VOM1(]2<--M,"CP2U4QX2$?NRKG^S(EM(;F(KL12
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MP^Z#U_AXJC\>I_J4Z\$ZLR#9II$"(-.#<8\WFIE&Y%D<I4UUO_?ZLLL7EG*
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M9-Q-^IW#8P0OI,(.^.1V-?((=6KXUS#Q%/AUQ@#'W6<Z6='%U]3T]IRUTI)
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M+V>LQE)=#-?;'Y)GJJ;8]U^O'UUJY ];2F2Z(C,@I.,RS*W3:7F[SDHG9W,
M>,TGR1!G4\"?4^J0E-+UZ_:Y7<0NCZ_1U4\5-QQEPX0+E)2,1:[:"@AX'2G8
MML"JO#NC@_VX3$ AC;;>CKG/Q5BJ.J[-%6M$7-1^ J3F6'DMSW@(3FZI.[I9
M7*02*H83F:BX6.$2/!?[^)UREXRO:V'I]@V)B(64A?QBQ9(7\.E]46>\X=E
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M HOHS78+@0F(?,V]5ULY#C=FZ-37[)TB9*P$.(ZDAJAR<R&K)[-D,N2-L]G
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M5+_AY6CCZ_.@S4<VRM50VP.*( SAGQ. OA@!G#+"VO&M#4S1"15\_[UB[2P
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M&428SR!_G;HO[%TW(2#;IFW*;&^GS.]>C &/+<%14B>=%,!%'D(Z!4 GT\D
MI#?MKY]Y&>Z_#1*6#*,;&F4YI2O<Y)1I!04=S"9H! B_+']P\XY[I>V%V304
M9BU:WM!U*9K#47;G3[!R4UVLGLB8LE$"\)/4ON\E#KT.K7J+;:\3"J!%,4N^
MX_&[I6=-ULA^,EV0$K/A.FU;4,"+,Q;R&!9R?7SUK_S+$9G@A[-.,9<TB[^2
MMKUI8N#J)WY?AFACS"8C%.3U!=0SA]/9(2^QXRPF+GK0 9_1%B0#TM[IZKB4
M]"CQA0MPB'FBAO?/JZC4^#6LE'8+D%:1&3HP/&>^$3.Y7E'.FK*)7V;KKC[H
M7@1_KY<)ET)?O:/):X(<^9N64/%_L/?>84UMV]YPW*AL44&0HH!$1:D"(AV!
MB J(" A(+Q%1$2)-.H1$47I34%%:E"*=T)N02!<1D1JI(:&70$()@;0WWG.^
M>^[99[_[W/<[][OGO/?CCY$G<SUKS3'F&&/^QIAKS9*>!<S1+PSH;W4X:6%O
MZ3!0==8QM,92YJ1H?\IVPK)49_!9>ZH6=BBBEPEP,_48J9=&U&V*$ZJHMB,T
MZP,XK@-V/P^EI/'<7YL2@O5-DA+(VNQ+*>O('Z&+!T$C!LUK8X;"W)+)<J+[
M3*C5*Y"F3QP ME]RJQIJ2].=JS(,7))7.H^Z.6XHK>JQ&;WFP[D\2'%E-!KS
M6(V\DI<^:F:1 O>_LFE 7B#M3PXA<MV*'C6IRC =.^,M+3])WH^6=*+&;!1+
M([E=,<0W)54&76\2K&;>E#/,$6;)MU'O]?MF4372P-@=@KG9ZQ$KB;V%TFSA
MIL> GH]^?E'J!ET'W86/@J^2Q,.+-&2F0G0>:EQQW2L_,>9XIU;[>X4(;_Q^
MS<)Q**M_X/S;#6I7?=T4C =S.X[:?-WCN'A=!$)ZEO?PKL^TI78N[3+)(;'@
M'-2XT+H@5B*4T ^\(;AMLRWH:V^G9*3;\^%]NI*A:>N5=%&R>!/B($,(>C3<
MVB=&\^+5$X*!,T+)0(+\9V022[^KHVP&@QM"Z#T!RB0/B_ECFT+S\4Z2XT?B
M&^,A>$.]#I3$D&C *DV_ "N:5CYFK_!TL_MV0=B\O&58)Y_Z%]1IZ-I5O'>$
M:5+69>$HQ U8,TA($?T,SB-6AA&SM1>UL(_S&1=- LBN:B]"-HY.L3=SL3'Z
M1/AJ(F[5A:X)A?398&V^'KMJ=>BY=M.\-"GNY?FFXR*;Z%S:)9)%TGV9<U##
M0FN;)T_V-8Z>WK/P&/+0W93$-R06NRWF]+2;CT..RT:X%Z3/$*& )VN6X7!W
MQ.AY;$"2N4=%2/:%AB=!L7E.I<Z-/DQ M0XJ>0K]6'W9(B7G9?F('GDFSMFT
MN\H8P-8YBQ:74Y+NOKYL;S_>[>NC>O3K3!I,K%@?G^[^($52*77AM&/5B]P[
MOVZ<+F6T)14?NEI0HU3X<)3J(/4R3TI?A^ T#Z*(QVTV1A .W),9((WJT1&>
M!V_@=*_[=")96<GD^Y&5U#PH]QK!]Z#M6PTFH(ZWH*/F-F1=^1MCR2CU6V7=
MZR'WC+NRYFCUC'6'026)AL+NZRLK<BN&DH[;@@3D:^K#N_+0H9GJC(BSPBT_
M<&?#9B9VDFGL4Q>9@ C8^3X-_0_R O4/E]1E/85.)%3!2J'R%#IQG?R"$J*4
M0Q_,-M;0TB&GAIQN'XUL&DU*U.RX3@O-=Y.35=QN6+*>KDYE!%T>M5TO5CA4
MG:$FJ=)UMD+AT^S1)@?E!H=YNBW1>%F/F-4D(FY\],HO8T4>LR-%_?<ERKYY
MIRE+)]'+F0!78PZ*7M,62HA(>RW8$R4W)1_X_=DK&?9\45'_8QV-,']$5,8%
MB&^-ELQ07'THOUPUJC>CX7Y=A],9I'3B6MW8RMAKK6P,PD \K5"JMJ#$[\=*
M?NIEQ?1S2F</K@2Q?P(*-1&9@"GQ<*71_A@)Y(L2!#7/]AQDDVI?2H2W(_=V
M.09JEE2\P^J6X(^WR\?&WR+JP$YR9W"=KM[H$0Y(UJFB*J?C94R;1W.3W'P^
M(YZ7I'5([VQ,61R=>7GC JUKT?.56D?*N2WDJ#-./!3&0TG2K2#>N#DZHG_D
MJ,Z)SK<UM]<>&5VT/,'*MPS@8:RQT(90>W)G*>K%PU4AU=:KTXQ:I%JO#]T9
MKQ*U7%GFK\3("9BP,_06PQL/8#!H ,OX",:Y?M@9%YN:V-<'W42-G]LI[ADR
MKN2F"8N @-<+^K.>-:L?*TCV"U[IS.*H+3(M#L^]YSN?T'NV+JKX]5Q0Y'4/
MSB W435DA]Q(!]Z)9DK!(1?W=%97//]QM;'LN/2+360_UT@6/BRY&1B:TCUZ
MK<S.[M/#<U,6+>R^4ME<VN#X"STR WW&%STR+.1$@\H6(2VXKRH=D9!.6&X9
M J\EK [SV-#*^CFYM"21"1#8?%)T-FF4_N1RS(RNX>A']RFE50315(9+KY_Q
MZX* H'NZTT.PY;/ H=+3/.?'W$WZ4.?I:0S>1:P #59OE%Q4$EHJU>,;T+?<
MZECO>WRAKQ%#9E ZLY<0/Q!<B@=ST.5]OS0.MKK506<F#VU-;I;0= 0TAM)P
MTIN0<O"LU_>BK->W8@?KQ<?1:UJJK!Q\T?@MQP9V.#.@&*46H&N=;77'=C[F
M8MJ>=<X/#5]^KIHN+RK]_/U+KM2\IS99*=TJ^-KU$X-QDCW#W<85(">X"YC'
M10"XK\&8UR8G+?'8>3YG4_V-3TJ44> 87SXH:K,P;T1M,V8ARZ,AT>@:R,2Z
M:F:F#DZ&GN6$C&?$.\:SW$3+UHJ@Q06].0#CI%UBY>X?:#WND\:<GF(Q:A+&
MC:PLAVO*N04Q(MJD93GZ\$,\64YV[CK*UUJ[_=@^<4WO4&E2>9'+3MA$DH_L
M0]D/Y74GQ&H>)6Q'I[5(Y\97KG:='6C@O*?!AW-_@(I8,HJ@"D*/$74_ B,S
M>QW#KX&AAKX^[6<\[.2;:) W]'STPP1.J#RQ>S6")@/G8P*B94_)-P_=U;"H
MFSH3?T%3>OW.$MXR5LZ-%I/ #U$Y N^1E#N1O-;M77[14+I+]/A9[]=^:N="
M]$LX L_DF-QJ&_2NN5+]P>M8OV=S_\VZW@"Q-0-DE.#AF;&VF22S>.M[+SXF
M=YYA*%&YI^1X'_1!10>S[&T^U_5.[[FZE C-:E< 1Q<0A*2S>'W5#C5J;Q:+
MD2SJSMQ7'O)(N:#\4J%:?L%^.-QV<^&RW=",:JE:Q$"6ZAKV32,1W9$2T<(E
M^( AWL^UXX!0>7-4E5-M+_!3"MV1*-Z^&LX$5':TU!5[N!?O]3<)5$EQVX@1
MCF[UKCR*:+6<(A@ZAWA_Z)X=L>N"R-$VPJIKYBS?W"OML/&?21Q.>O)5/+3!
MK5N@'F2) C+:X!PHX8 7&H:'I#U)9:^_CQE2:\N^Z1IQ:D(>TZO0KAX'YT6.
M-A"1X=EE0QI78!EVR9XLT+(\2<<]MPV5'U7:IHJW]ASK<J]>Q8^[3-Z\=153
M<HMMP$GIF[+U^(\5_XMO$TQ###U[.V>7I'[\!"U"8:J.B4_IP+9<W287[6CU
M#L:0LA L,_[5HC==@[:N:I*^W6X8<H"5]IT9JB083(['^B63,:;P!U?]KDC5
MM1MK6,X=SGCO^^'KO8JZE#X[)ZCLK:E^)25R7?ZB5^2JKU#AYZ;/^C/G%):>
MVOL^PD+BXN52(2[SCTR_:F9P6CG8K^;K)#]ZL2@/S@&7@@@'<'0]W+0#Y^#F
MP1 %J_[4AP>\3NJDR )&]&?J2>"4 6I@3E5M?,"9!^*Q,V=C<2]WGMI;+?/*
M#X2\3/^HD+HO]C4'LC*Z;N<CZ2-9C>)/<FJ-:!,,F^^3<Q?6'&RN'55E0UGM
M^;1DS]6$%(:>)6KV0Y6)[EF0X_VW&F+/[%>Y<\'XC?%7;T0.S'@,JD<*F:D-
MA?-!CGY2Y>X,F(&?&U+*>.__X5O_B+TAY.+=MZ<>%7EC7CB(DV5L7C:^<B7D
ME,\G.%/OO%)'#;WB31W?U.IF8=.;^2&,^E9$@_Z]0(^ 9 DW*VV)1Q]Y,RXM
M#*'>T&,U='*L8=\8O-$A1GW'+7ZXQ^N_LO)=/(#LI!*\30=%;S4.R"*YC2[W
M2-X&J2=B6E/:8J4/5Q<&>G 0R]KDS8%AON9?[.V$SY? #TYT*&GTFK7U\+PG
MR93 <A93(IJ0(\T3(7*ML]V^(;).W-$&+PX]GI[,NBL@S+'"2JC$*<Y4U04!
MA0?XGFOQOEBE\<'/YR;O$JTV=BRGH.IAXXUS([CZ%&D4*DB-:WOH=<Z4!P_$
M H\U(>W/A0..<=O95>2)O%'J-!--32@/N__^QT*X[UYZ]GRNUAPK[ZT1)R@Y
MDQ):^5$GB.-=W;AQ^1B-5C>>[L^JFW9.*1MR%#&+0J</R&C&<."^D@5M$\4G
M"I\64B@W 5F V^9=)QR8 (-QLO12C"8V^//S$KC49L&]T@!0?K^??<^%#$>E
MF)UQ';^?IW;NTQ@\5V7,'7!D>+S)CU\H;N+&$_):HY?]*NVHI4W_!C:\OMX>
M:SM2]_$1O\ME8><)M :RRI9@\ASK,.; 2_T0>-!MYS["J7C1QN[>N:J#A8H:
MKT)-WS',8\N_/>1H6G?#S'D_F+6KQ<3,8'._= R B::&ES&FE.',3A=OO@&G
M:X!*V6-LLR(7I!>,*>+?&C^X, %[W$[7#\BXS:S;RG==*/35C$)^-2#HKIJ]
M- CV51I[Y\:E\/IDT-T!,NSDH,\\M-#0:&5(;GON4([E&J_%%WH)QS$CCXB\
MO%F'+H%SEG)MW[= HWUKV)OT'-]\M]QX/']YS2_7WER@]X]9LJ0Q0L38G.UH
M,4!P8,%-SD4VXPTO6A3?0S]'WN287@O0X*#A/C;4#H@KC-OI>\L?NW!C] U#
ML5IER\:^;VS8KLOY$=KOP;'"A/=\.=!Z):)7<YV;6\BA^5G.>%FKES6HC-PE
M(&$?59TF2[I7\A$_[OYE+.#ILGOON+Z?D]"G;=OC32P&*0.G;C4TA!F9W/,Q
M5;_-LP^R**)!TBWF>@7'&UJ0S[FMK<B^Q;#<9!Y^ 'T/(0QU_0ZT(LY4FED7
M+M]/-#?ETHPBYS5]#[PGOAE=8R]7+B=@?5])H#3'>>:CUC;],4,2 83RU_2[
MSX[G/UA3*HM->_'KIRL[@G#")NDBXP@P5,7F(<^^>@QX68J7]B7[;DW-]47X
M729@>!/DS,HO[[2O75M1^EBC8#\FT;ZGB7L.-1&(#$=/O@,*G*:$D:#S]5"\
MX<7+5R G+;Y4-I5;B:0?AI;PAVG<?S!C8"4.7YH-41:KNB%KDV4YY8K%?-YV
M?TA/IU:K8Y9SEZE9%$MSBB'.E[H_SM_OW.EU7NVC6GZ'5J;4D.T+QZ1X @&6
M\WK+@]DM5 7:J2'4R0!T:^^88<'P^_[*58V+.FOIM8"MSSN6W^<J&XN/91.D
MYS]F<!J8#0\E0<:KD66DW(X\IQH*;JHV,^Y4E%+@*Z>XRP6Q&P ?OF8+9#1-
M1R6FP:00DBQ=/F52!TDV]0YM+R^<=]%I3[NSI2_"IR]I9&JKW.H[483*XML)
MI'(POD\ 25PMML8<BT%AJ-02E]RN:^YG;O%T?#+-SC ^(;W.DUU=E_)E1E8F
M)S@X\IOI@_@A\/L28=C^8SL.WXS&WPX_:3?89SFB ZX'F:,4&.T@3JVS 3DT
M,SA4$9+Z5F.ICJ^]*\$AVXE84C.);94+$Q%*-([(.#3@YIB@9_QF^VF7^W34
M@>T$,;28.THTH'YGS^&>:-^8R$L=R3)3Y0SK(L@)W76#5SGE'U/Z+*@];*_$
M-0/Y\ VOBZ\[?*GRZQLMUPQ+,\TU&S')3 K><L:@B:;=@L,TM\R \&\K$RO2
M\X+\:V>Y:KKLO.-?;3HO>^-EI'HFV</Q"+/*</-G^_7%S$5G3D0A.PL)$)-!
M<POJS;H&<VJA1MCCG?LYU22QLGL<+6Z%#K;-C:+Q=PI '(O%+^M_7'.T8XA4
MJ[G<CWXM%?"**R:G1X=>6'*ZGI[5$*C(DTULG)<^XRR%/3D/&45/I@J^^I!*
M.F@'^9CG=JNEZ6TSVQH5T[$E<-3^Z[JQ=(]"6F6B<$6(H8%3_L3"(X'RAHSN
M'HLG7Y*V+;-L#Q \$>;HJ\AY3].VX'.60VZ#'X'!3$#3S:J8$V;-:*ZV])G&
M7OO+TZ7AEZ:Y9 )5E?#H,F."//LG+.^X2]!&']?!16BISOCTUVOTN6EYL#IV
M23V^(*\&LZ52$"$A_KS6C)"2.U26E7SY&"A_P-^&X:]<_,;("EW<;Q$$LP ]
MT B<Y I'5T:$OTNP4%8GI#Q15.'?8H.&K-<97=KDFTW1@.]#WWV 3[@,41FJ
MNOB&$-WA*98Z>[M.(_$Q&_B-C64L3>==T[1+"B,G5SLVT*]&1G"J_Y>*%5^A
MCZ--_M[^2FT_U(Y^GD%HU2&E,O14<Z^;I^;^V%ATOIED+JKCO05R@$,\N%TL
MP17(>,<(LXK7%N5[G.)][XM_=0#L1P,;854Y7GBW^VL"X5.6C1D"N*S$.^:H
MS K(8)<G<'ACQCAERU^CH>7$YF(TM+J\U#*7\=6?VX;F3\RNN%;:6J'L<.6Q
MZ@KDJ]0UV;-5;^^%6H:;4\MU/5OF(7V%7"Y&-U>* C?FEN>.D_U!]^ //'@6
M!$![->X)_\RVE3,^27W+SM#33J$Y>VPFPAO@Z2Z&^#C76?YHMSL[5F\<7\R=
MX9[7N6_Y]O4,"VR(+]60?D'6X1>7^F/KW&YG>]3#7E9:E@:*+X*6V9 N*?!/
MJ58KK.%SX-Z&[ JIC(QGF$XL\:;!:/#/#>L>C8SI> .'<4)XSQ:ZU8KT7 SH
MB&L]5,O\0ZX_1("V'FY:N&T>W+54K.ND-/ZUQDRD_$9;ZCJ2B^LU]=!=DAUF
MEH73%6!Y\H]KN#HW"&1>S\-+)J?5\HA:?(#=M=C<O>?5@'G((>RP.#FJ'R4-
ME2Q/LABX_=2NO\PED!QE+F@!@$Z*C#%>;0,MBGPA]'-EY:C:"IFMABB.N;7B
M=6'4\3"E_<M#7SOVQ+_>GY5H:>P3\G-!YGZ*7-:8(;#5^/"X=>>YV%,#Q9-O
MK=,3],]?!$CC2AJ&7G5$5:76VDAN!@_C'</C]:/,-OE2;2=+UYM[;^7*0MSF
M'6.1AW0L+;AG:DUT^,:\POZGKW38I?\:"EEG O;>8@*2K$G&]'A_\,X5)S <
M\PE(U#'>5D+P,@$_YGR9@&QEI2TZ[!CLR^]5 2UD.; >JXJCE%0FP+.'KFYC
M.8U^#)K6[X4OC<%MZ ]83I'%<HHHFB$34.O,2)>17@-_ JZ=F4=OKH"*0^"'
MF8 &E@Q<BPFO\,#)*YB-^W1>$_ [Q*__75I05Y'O$HK/:XH8$,;\F&#_N1L4
M1(N'Z!L>(QY1O'*VK,;J])O]+4X?O6F%4T'22=S/LF+T+>*6?1U)YJ7%]:95
M/>Z45:I= &:J]8!CGJ*Z0XR0.[^%3NCG$+!XTE"#;K2TC:(+#M=Y75G7''(+
M*1L4__-S_H_/K!_ _RD-$%&-H+"&*XZ%HX#^X2]G;HYS'@YYS000S;J]J9KF
M&@H/Y/1,KP2&@":ZH=HZGOCS5E SHTH/IPJN6&28H>FKDB"5]H2$C'.4U>)B
M)B!RQ=PQYO1!H4=7Y;EN0[X]R*S/[P^3R#.SN#:;;^I[=T[%K\O&O3@XZVN_
ME7V7L_3A'/Q#'DTI)/),XB-]M<SHC[ZG5V__W+_B'SU7V/([N,*#X)O/Z DR
M7$GF3.;,N>=[^K/_T\9?>XQ"EN9&I#DV)/&W%P8M=3<@MUIZ1LS\G(?@/.C)
MS D54GB<=\Y\M7*]L H@RUZOUJ@@F"U1 2S>HY%LIJ_8IUAQ;33]QW39IN(7
MJ?,4&U7S+EUE*918]=F)HA(^]RT+U,"[FO#%%4BDV]JI>-W/"5JO3*,7RKK]
M6&YQGD,B\_$_DTX.@*9/_#RI%/QS(?86FL;MP3"L:463Y7]N^WH*&:K$M<UN
MSP1@!)B [X8AJZRN;,OJAVXD.7KL(Q8>1T)P :GXG'4Z5R4.&X[LV@1=FL^,
MIB0M&\\)3";0HI/AFSM,P(ZL^H;4.C84M";ULZXEUH.U2]\+-\<*Z>W)[[?=
MG1G;9@,LU]M,./__QF%WZ7]/U+G?F];P&/0[,R!HY^DO?Z^*;4L&1P*K"G&2
M"@.'V/&I1';" ?#/29DL4]8RJG9Z_QB<=QA"3$! /@,X")1N!7V*0,YW[TAD
MHK6UCORS=;-+?Z*G-YF Y[Y8NA><OA<SP0)Z'?2V,I:'%9D[Y!B1X:A?_PY(
MA.$]HI-[-K3Z(V"":+D!.EMFM#3>N R4T3.<B_.(T_"8M*6N<@;H.6"6LP:R
MGZSX-"I#W@QI\]ZX62ZYY_$]U:5PD:HE,+$'SHN>3Z&@61AC"::YH^I905(*
MWEE$R65T7$323Y4AT4N+GL.;=DK'>F\:BLZ2CI_5T+$V]W:=PZO0%+!M<CMB
M*%82V<2'80*$LAC'5_')]*/@GS/0HEDN'H<A=//U,RHLF  $9-49M--HP( I
MD(3^YCZ6.Q_:(ADPHI _9ZKIL'*3]B7R;#1HR!6[3@A9!@TN@M=)B$CL;^5-
MH#BCH\$;AE"6ED*ED0P5<(VBR?_#SY&!-&7]B?UYHD)X,"6'";B*:6,"**=9
MC9SR@;=H_CS%,!."9P)HW/9P4CV]+C-A,Z6&1@4'<VT&)=-HSO_9-O+"BP;1
M<R/4'_#" ?3<%(@;C<M@2,)[E4APQJ\E:,HX\+>"H]T?9-'OLT*U%F:BA>[
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MRR^@JHY(00\>JP6AT7L-I]T:G[@S 3E.-K!OG-?6O87-FG Y%A>7&XU$V\'
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MA*2.&YG+\,7J';JT"6JA]$6_3'_!FS^(5.)PJ>ZQ8P*>Q;"&%HBE!"H%WIY
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M:(U]<W/G:?9\YX?!B4;C6JV#T =/\?=21^UU7]=7<AS4+7YQ<FX6^"HH#GJ
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MR/N11<L:"[R^7&ZLXOLW\ ,;R 2EGE^O3(+BN]_;"D""-75,%4YUN4VN@^]
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M$&T1)_NTR68)95<GK4IHTI<JB@=>ONI=Z,_GZ#7[L/*&Y=<];:NQ%N!#Y^Z
MI0E!L=MK./8]>D"%8-.7+\U_%%J$BW#FZ-U-T,U$J2/(I:28Z^UG2^,4FE/=
M.M;'))^2BT@5/LKLC'$N)H#/#FWS(0 T2@&!:JFGHRFC#,&/[>@)5N)//,H$
M5&3]IKATJX4*9Y_; M[M!0LQ 2WF%"PC#41D02[I%H(X.*'$(".8@,<(>CK0
MY@/P3[6*_;;6<M:(/+R0A*:KPB>/,P'XO)W!\PQLTS:]8YC7LAW[U]7\9RO]
M8U'A+98!&.H(G/$+G.SS5X40US=PCTD:8VHY17K*@^*Z*L@$!!LS 9^,&=\2
M?E,L-N,BT("(L9 D':@;R[SV4^!55K9*.< :S?7^MKQ9X$A'/UVG)I0_0,9U
M$*RG[L\_Y*+7 QE2SQF#*&7AH[FL^.. H+_ZNXWJ>-_?0Z^'DV_]E:S>5(N
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M$V:?>@793)$=P [AI =ZOMEW_Y'@\&^_<&/^[<?P?Y,<P6Q?\M]6"G>DL#$
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M/%*T_=#)!0VU,;KYT"^EP#Y(S>>BO+.EJ;&3!]IK^Z:5PB(ZTD&4Y%E JW)
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MMMXH3=P*>EPJ>TW?T53)8C0GR#D2Y*[%;S"TWYO.H4@Q)6_PI=C>;S]IN-%
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M/CZ1^ $/GW^&<AO97F$ PC_7P2_9HZ>*]@*=@0'!5B/ 6A]WJ5;ACQ_Z84/
MTZ?H"E;FI*3^9BO*"N^0R,#654\ADI3%)ZXYI9&KVA-\.)#P.?GMVX5/'.F7
MN??)IP_!$R^D(GX&?8D7Y)H6WKT*;)5IHRM-_\96$[_@! 5!U>)'[WC4N=P*
MX4(O/ODS660 PH L%DKQYJ?WX*\(UX9\WEL?@DS!G2(OIL[W)[G_/%UN41L#
MG1"DN@$1V2>7F6R[<VJNRV5L:\'0_9"K&<!:,+J/3$2)4I^2HO%&MDC.R8G
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M$_K27"=(,IWH:L]VEYI84[7CR RDE_^E>"'ICWY7-/^H\F$$7C_R%1XD"PF
MBW$;CLY*/4B'OYU1XN_-+QJ(@"?8R92&64QA.3^1FP&PPH'(*UCR2>036M[-
M):;X=I[U:)VT7JP+%\B]?^.5P%_#S0@B3_A=>%U[?.-SQY6'&J<[Y?:?4P>4
M,QK^_/JS*_]',WJ^?:B+<MLVO=P8?)?_MZ!&<[_,[H"80&HK4[E,<4Z@>I0-
M#Z:\P *P(?!QZFW\;E<E"=WV_1?Y>0)[4MH,=+Q?H2W$U(S/='71L\,S-NTJ
MOB;SW8TCQ_ZT85Z1F"BU:^U[G=XVCR)JES,<(CSD.6@YZ\]<3:[D(?TK;(DJ
M7539_>E#/Q'8"_0];0XFKIKB=VE_ZXNO4=1)6H+/YWUXK"SDAO;3X^Q;%Y[S
M;H+SL">8R%,0X$]'/V/":X<SF%2RY+72I]F9#IZE#J!E%LVFJOX/]MX[K*EN
M6Q^-%0$!47J+"DH3$1&0&A$! 1'I2(N*U%"D20N)@H#4" @H"!$1$!%"[Q A
M]"*]UP#22V@QI-YXOKWWV7O_]OG./K][G^?>Y][[QP063S+77&..\;[OF&NL
MN:BZ;Y$'RPS47K#]:"<-4-X6OAAA-7B0R;N[C&B_RN"[ 5=::Y$<5"7C62WD
M1[7>[]4#YI:B)-M <FH7*9DW?N& FX+9D&O(RS-+%JP_^;4? )&MI0V77!AW
M<O'O!K^Y_GR(?7AVW$K@\?7AU=E*A7#+=8R2?#5?Q;HXDW)<J"? /)7:(L2O
MM-R<-FWD.XL_=>>3-J]R9!O#2/W=CB!IYV%)8%!$'O#+-SM")O?9[4VV[#;<
M,OY%GUQ56_SQ'L'&I]9'RL*$][\B.:6S"=DD'2?\\ZW2B0OE\715X<?4VQ/H
MM]F!#0V>H\A:Q<D[2SF>*18\^N8^I MD!V3KFI>.N@[AON>HQ\-K\+Y7Y#'\
MBB&CM..FLB0SFY'T\>)84E\TXE HFN0WF8U\I7+)@Z?9T^"B&)Y)PN",<X4?
MN#@CS5ONPSEK3(YTRHWXD-5>7,80LK*8+GG!3;,'>]+4$ EJEK/<\H:YT_G8
M;,GL\ M:]V4?:A.>'=QTJBCR-X=7$DN 8]'J ]M0SB^VUJO)?MSQ-J(IGE<D
M!D09LH0T_6>;:0#6W"BT<\2@O0VNQY,GWGO8NYV</X"V,X@2XL&-1FSM2YF;
MQK69U-;%2FTNFETV\@+P"'@%C0)1\(Y)48H?^*>E9.NWV?A)@PGCMGF1K?I1
M#XS=$!K"%J[&W0\[UZ*&S)JTZ'WT75.J[#%O#=N[EWLPN7H2W]K &IB1BU&V
MXH>'^/4@@=1RTA-XQ_DZ&@ *E[&@ 8JER0F3LT02L+.HUD=N*X#5*.]MI8)?
M=S C6  VK3L :0":D#;?H*V92$(-*I0J]*(#;I0TBS6.H%Y4W 7_&B/3 ,*1
M_=034*^& ;>KKHY#)]X6AT>XH\K<-E^BHXC*^$<XT3@H>\ZZH?_TEA D,KZ
MVN^'#RUC?>;EV1,(QFP?LOM($P\L5TPKBFZ8%(B+<H7ROA]NUC*QY\F&1=L
M\W"N&7YM\(EGJS686DMU3Q$(/1+>7M'^*%@:!YE NX!"8?P@IJT#&P7=RL'"
MLE>L" A/3%4[CRLKI!5J91] 4H7UZZ&LU:\0W9I[KO_("BD)WD&ZCGZB]J/+
M_,)5#'&[-@P8[@C3VF& #A>GXNNG @)Q]_WG:^R[?S*P(+P^0W0;^"P@)&6I
MBKUJT,;ZCH$I'9&@._J+&Z/<0D M*[_XDKN3M0FP<@RUPY:IA)"Y8!/43+T0
M33+2,V?Y.0U=ZSY4"1WE03T@',%9DO0)YPI7E>)(5KWL6E9=[L5'JWC)^>UH
M1R10'<<V?[+RHW_>T\%OA4#(U-U<)G-E T'UD[E:7[W<-1?DHBW 411EW\IY
M"'7,]L@@56@]E2T*"CJZ:CRE:Y*-VAKB (0 5D=JX'&S[ >J>OC'N-;/#S]5
MC82T>9DLG,\##50A)_3F52O;/#B=8+RXD(ZOC1Z7S>8O*=N\>W2P^D*V)S"B
MM3?4;QGOV5^F=WN4V_+X$T?-Q8Z7(0S+6IU(-2Q7'N94,5B0N.V>0F:@=H).
MD66EF_*#+6D W8JAK7*;5@V_,XF/CA=R"T?A;!R;Y!L8*#E2^[67+X][",<?
MH9YI4]8N0IE3WL.=/)C\M;';>.Y(CQ^)WCG%[-\Z#5(91<( GJL] 2=&8]CB
MX$[K^N"-33>!4<_72>',YV^:D;7E/(V7T_$*F:?O>5JD&)$K8!EFA\#,W=^E
M;#[(=1;YNM*Y'Z'_5+X6HL9,>.YQ%GI[X'$D+_E],K9X[ (#T7SF8.TQ=\WX
MKSI%KCR3Q/'21<3$'E4[%D2M2Z0!- )Q+D0[?!UN$7$YJ>"*_1OI\?$7J[]>
M]T![K7V'O\HNE3K=M',!%WZ\N=0@1OFVGZ<BO).FN<."WAJP?YVLCGAW+A%I
MS4>R;?"A5-1=]?6(J+#\[-2R?]A5*_WHE@#5![=;KKED9FAJW-*BFIT[X[_=
M)N4N'0,25 %]?GBOM#7#-+5(P#L$HH?_C)L@,,_[O2I_]U:#U\*O#!+#4W&L
M=PZ21D% E68N$RHJO1'7+)K<%:IZNT^U+=@>D%S]K=>!+-AAN]@,".\0M#X)
M<;EFZJV$%E)C)=?HIK6;P$78FAE<ME5->3T1^H#0@@UB5N0*\JLHC[]UX&Z%
M_(@RIE1\LQN$G24\'V"O$/.X+;9_*-F"?NIV%,Q!MBVIK_90DY)7[199#CEE
M2#"OHD[_7C?W()V";[S-WAI^Q:VA5)$5AWEL5P8R5L 0W=*W-^P%*N6?6>NQ
MO%T2OQ0CJ^6G(&&@FTEB<5*RS<Z"^''7V*?_;+[>:I?J;SK.NM"9.% )Y8?0
M0?91?R._[GS3W*9MU=1P,ZP5>:Y.=JY6WTI_U/?N_F17=9:>3Y+%88P5#X^
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M]O9GIMD4"'ESM<!CL+Z1$27_<<B5_JDKP5E3;3^%,)S$4\BU>1K $[[/#LX
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M%8']HW\AROX_B/+8?PP%1.3VI<\1'/<9=)+\%,. "0QETRK_8V!_X6ZQ/\Z
M7,<9MWSU:N"L,5ZK^"T//O]C!RBT6-9:_!9P;1-X2* !CLVQ$8P:I*9KJ>R0
M^MD9$GOO<L5O1FE5C\#U[(?V;_)&T EB;5GMO#])BV"'59YE7__% LE^^,4Y
MVW3JEJC@']11^P=UQ,.8"4UJYS *_8@[9?; CW0^@UKW5-=)/>^A+)6(4(,@
M*^A0>$5*$QJA=CGQ%@Y6*D?-%H!!M"]5JU?>7(-,_WUOY#+"(2YQX7X*UN+
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MH8]O2^[\AT*2HQ'HC.1^2)0>4_+7>Z]QE)MJ3J8)<.$]CR90B7W;BU0-+ T
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M>>)T<%L]-&D!/9[5# ,V))5]X3<O$95Y5YT(W#SMBRI9^?;5,%;_AX"[C89
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MUO2AVE(MZVQ)S"5SK6P%WW6J(R>.A.^MVNF-<KOQ'-?,E:_8EEIZ5GO5EK(
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MTJ7?.O#3W]91_L6]NX-_=9/O7Z_"2-  C8;TQ+N9>ID&F)*E >XG)XU1&VF
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MTP#'334]HH1N/OE8,JX>HBV\% B@A/^[#RW_?4-EP#V:&#;R%ZP_P'Z"]B^
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M#OU;+OCCOZM<",;L\%-UMND=<]-5_R?+!B&ZCTC1?:2"D$)M583OW[EQA,A
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M2B8?*FQY58>DH!\:4RY4!/?F/<FR:,]R6DW>E=:M1ZD>#;,:1!Z1=]MZ@W1
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M\O<%((93-7C9L%-[B7\Y<HJP?V!P /%<N)=1OY0Z8\J[\D" 6<C K>$\?ED
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MH$+0BFDT T,#GB/MKJX7KDCL [W23]I+?5"(OK]U)#Y,Q\W(:&[:M_X1&^:
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M)KR#% @WJ$U(AD,,=A'"JS05!/@B'@:&_F([\@\\5$S_4>0SFCW]B7%)=.H
MU_)B'T$2,1Q%2<45ET1*'+51.*J*NUS7Q>AG.@!-^:QS'%B>*0?&X$*.XUF[
MD:!A,X2]\/H1['V=&YA9?R:H 9(OUCX3T* ?HE9YV8CNBB5P:QQD0%!!B 6K
M=8?K"] Z^P(TE3OB: *!#&(R4 V-QS@OE9L]"_Q8WL (_#/A%*C=0+4U])I.
M#&&60>+ M!7\2W]9!O.#2-\F74@LHT>YV5Z-'%C*9FP!<9S(XI<&M5%!\)4Q
M.!@JP&C^:Z%307"*!=^:.M.(N7F]"A&"$>%ZQ)HR(9"P\H/$.#Z[Q WRK*<2
MD4:L7VSW@0-;MD-.K\[M@60ICK(*5O2O.VC#_+G^\""\)%&L%==V5PE \GJ>
MR8%IU:,R5-8@DK"Y!NJSW B*_421L&QMNJ'W5^Z4P[?B?K%UU_DO!2%]^[V0
M*/]:JBBHNP"]6-!CW9^Q"F(-CQ0@75-"CP,;U('EB\H;&-S_AO1^__(J;07^
M>5>N*IN=1QC?,++ H$/+58OXQ6/L)A#4^K60L#K-(AR 5/8+ROD/N%!&U_QC
M"M'J8T=*O!6IL/3%@:LHS9[<OH>-U[$I*KJ] ^V)+PZG=LUA+2RFAPZ64C=9
M5O3M(,]E(9*I+>B#UW:ZG1M[@W]-)J!;@VCF^596='$AA1&;_+I8MZ?&4R?Q
MA:5\:Y-P-A,^H@VA10V(8A'L6'*Y%D\1(=)MR&^R-YW)[Z0Q:J!..-A*$*S0
MI]J2D!C^J:Q4]HOWC26'([PD<!5RGQ&.\ =EWUZ-IHPA>"]>\_2.V([ROC3_
M&MFSO7?J/6'^W=['4WR=M_/#;'7=M<0]Y-UK1\6<CAD;S2UK;J%FU)&"42+W
M*M5J%J=.]$I:A):=GY(<@ZL?JDIC)VONPM=@N%/5A/P-QX-O19=%J5_QE^OR
MY)O7U@Q"U$0ESKKKQ,@=HJH'EJ3-R9X[?[K70Q/#SL1N&*3WWJ#N>_",G>)$
MJ C=CYF49*/K%S1/^%VNHASQVCN%W)K%Q)?([]YFA!AJD%L(N3_"_LR!+3P$
M]XY9Q4A)^8I<:1$[Y9IA'H\[2ISRHS+E6-L^T $[S?*<UZ?29D;L--;LU#?Y
M+MDZ,-$_E<6FC3WS+.J8STU9C%/<+C^6D8<O<KRP@76$M""CG'(M<ZE ]H>'
MQ#.OCUE5C5P4S2$KS-,^>?>+E"\EG[>['15R'4 V:)ZDT/#29&[_N_$&L]7L
MMZF7\HY?/:'^[7@(FY<%8VR_.B_$#%[I4;HHYZ9;[B)_]#JER\G4F*#VZBM]
M1BWZDUI04.O!4MBA4%SY-&H/MJ5O2Y8#-;X='79T<2NV73?JDK"IFV\D"K@:
M"Q\XMWQVAXS9^+.P4@G>""\G,UD94B(5Z/,=3L7MK3A)]+D#4%4*#QM\\E_A
M2O.;I)2.1M3S/<UK'4D0VXC^$6L0A#GH)D%>3+036(:3(1S.7]2_U0.Q"66T
MH\)ZH!8F;,:UX&XK.XSI5ZO'[LF+)Z+:.+"1 ^6DF ])]T]$&&Z^UW[U'MF^
MC3QL9YO.%ZFM(M%;KNR-:UC@G?51#);WX-OU!6[>Q8U3UNN/57I^3&X^XD$(
M<N1HP-8#9 T1^LQ\8SVIJ#%BN/--NSBOV?/=B*>"!Q(=IE$^7H!V8&V?0GH2
MK.[N:Z'51N7\W:MV@A^%ZU$T']/;Q%.#1P.>[C6VYF[:O!Z.T/YS9 +,OY%Y
M"E(*LAV(V50"0QA_&:_$3@+&7TSC5MI1[.W$=&2E/MUU&6'S"2AKY\!X6(]"
M9'(,QR:,PG$4(\1FEC<]!3V6A++IRB[F]=[TB/=JU;4#CTG3*.-I&CI]FM8=
MI"]5H;\[=N;\ ^[%K/]0!)O%/,&S/H%LWR8.['4\:QQB1Q$!+$0,-NQ7-]9:
M&C![1NC1HVE+[*V0N5V*".4O=78F^.[W1X_!0Q %@768_5Y+R.[K^K(*+K<5
MM_F&BA$N(WN7S8MF]!(J#%F'57-Y#._E> [0\7KL!*SZE(^?^2EL@3Q9@OF\
M]IV &6,[$@GQV.'2ADK!!A\M6C%>H\]T3^#'4)+@0%+#T,J*@4 *7KI,Y\Z2
MS\J>JZ$>B^J88-3.Y=;@(>&$2YUQ$]<ONVWX4GI3;L(1<0L>4@5'5R)JXS]$
M:+T*1Y*QME2P/;R8%B.P*^N(T^>)VML"E/R[3^/GNEIWL'&$VW3LWOPN%6VK
M,-? '=7\C ?H'@V=$29"X*=22]LW0K'=(_?+(N/;WZ:;O$C[NJH^>].)F$5.
M9X^-Y5C1=*FK3SV:,RNXLT1]91G1[A.J2AWA7=VL/>P7+A6*HWQD#DSH2ZE/
M?/Z]L]7$^^[EFL7+]0)9>-5LSU;5>M/TZ9+BP7[DTDFC,)"W$SSHM656I_TB
MX!Q3JQC?8\VS!/0&#CL$@_S63A&CFTJT/MXZOK9[87H6=:[MVOLPK=HW3=MO
M6=Z3"C"? +R'2<7<U4:[_6P#+QGQY90G(&\_-SK\;2O9!K?N02V&',FHI2L[
M_W11\:JY^WC)1/4J7OMMX%7#_4D;+;X4U&8KE1XA?EU#C#G,-8^AX*SS(M^B
MQ1*NN2[IJW;OGTSS%Q[)$5!&!#*P$3D:QX.<*X)[>S8)#R_92-EY-=90O)IK
MXWRTFN^$>TC<!?>$[U S;I*IC/0X'G-\5X9V5I%=O_LX?A^VV3+:JPT/[I]E
M^"4D%J'%1K.#C&P^O-.4\N/K\A.ED*YV:[AG&V7.XL45QN*-CMO=8+>C3XS1
M'.@X"JD^8*FZ =TJB3M".\QCZ!]FVPGN8MVE)[ANCGMF7[:/QSOJ]E7N83E"
M L;?BJI9HI(T#.8+"A =?<2XYZ3M3K2\'XQAUVI_%B6IK'3=)7!C!?K\)"FA
M/A=WL]-O8T[HYC^.[D1Z6 O89ZBV+7H''#J9>'FF]KJ8EA^1J8MMK5*@9XV>
M/DW>IF"[M;#\6]P-,75\FDSFDT&UKZ''>N)?ZB5W)T\J4&IK/:OX*0;A,>_N
M,*TE^"82PV,ZV[0N>'JJ3TI?-<3<U_)$"ZQD=W>\\[I]/CSC@\HBH8ZO9_)*
MH*4_ZI//8ZO!\CC^\J Z[[E49%>1^?/,(\"VKH &\QK=,B-_HK8?)@.$[,(N
M/ZNLFJ%377U6,HQ3 VNYW"7H&<)F+\7+E)T/MT2GG<^WJCOU\%'C1Y5R+?6N
M& /A=&DX:N\+I]-2;3]%R-)[F8AIN-!!JV![7X.K G5N#5NLQ#9HQ@PC*,TX
MH6QGG'Y>]\:IWKY#3$>S7I#LGZEULCM1(#(=KE1W8V1N['9%UYQ7Q"=2+\Z
M?NW0C&<.K<4^/'<#/X.L,@/*4RHC0ED(SY09_L#BCS8Y#:Z6R^9NB:EK"9WC
M6<%9EADEB95C8[P+O7RC@D]96N[NPTE:SF3)D5M,HYC#2M_'BJVHJ#G?43*Z
M]JYA7R"M-$3D[&UT$WCEY?@6!K'GA3D'9O%JF@.[,YJ;'&?C3,B<@!=&U)Y!
MCZ >SQ>UW#M_U/[YB37%#]=]B5EM6NY?# WG%M'F,3[AV:LW;(691G["5'A]
MRVG#Q[73+@L8U=4]386A=H]M)[5.-E4O'<I;F0QX][YC$,X%U/+[01@Y^10
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M][+:J2E'[1UT!*WXS+K2YWJI:.P70(!EX.J,'K6Q-DAK^.3N^4, =1T] P0
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MQ!Z$D,Y*&H.J"=3B5XX44>^W:MQ#H,>^X=2"#2FZ!VU XS$J@>,#60XE$+!
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M(TCZ_F+1J$"HN6'ZW<&8=_VOCH06J.QOCRU%9@_#7\2R0Y@-*^^O/"W%]!)
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M6:;'P7)A9H2/<FS&2E)E&SW1MV\V;CL::=W^PBZ?_]J]HP!C-V1S5:IP83Z
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MGU?@.#MKKI>5.9>RYFEL$V8&_QZG0"P#Y&#_EH]KC]E=NW%I=-RFH0;O+]&
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M,X^QC=I[%#T"XO? 3<LJ(47\0/GDG(\#[=3SK^?JM1K:]TQ.0YI=#M)9V]Y
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MPG4VY&JM5Z4 Q:\",QEWZ!=HT\FQ=IA,*\$C5W86!]D=-TQ,7!6\%$]#]FJ
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M2F*Y/W(&UX)AZ*BZ,-V[$(O3$ K<HL?>'5_"X8'@"%4"">XEZAXA+.E]U>T
MQ]@Y^ GT,DZ28XUC<X [["WS>%#8V!J\3P(8@K_QKUG,>/ 2%V8QQ(4A4'T0
MBU;"XQZ:6G!A*>YDD,< DKN?N+#US_(@^#E)9*^#@'H0X5-8#N?3LDDQ4(:0
MTWY&_![1\9H+:R4M 56(8UP896L'<6P')#COM0$T%:!Z?P[P47V6"UN5SH4-
MHA?LG+@P-ZR9,VH&]QZ731@16G1!S"]RR%1D"P#-&,/DM8&$C J>;0RG!CN1
M%S:60R:?(X(1SQ'K(?;!HR4M66ES:="$_?XWWW__?%7W$/W<$^)BCBXTO;IR
MZ\-&X@?+L6<_=-Q3Z??#L ->N^QP(I:#?'/(&GAWC@E)<?/L1;A=>]G4&E&[
MY(?";96Y;2KEOEN,2PJ*CS\^?G_KJB[S,JN)3$.5SL"/ ]2M-Y6+57/Z_+>:
M6$L]^A,$6?\9RY\K\+M;VB#MJKNE[D#.!C_;7:S+W56760<9=,GKTB6/'*.$
MM^\3P8Y/R7_Y^3VG,Y(,ZB(J+AI%:?HX0OSQR=0X_S+QQV=7I9A>27HHPY]U
MC#%?U9/QQ*.5.C%GLBZ]V7%$/X\\"@J_RR\KVO.H_DRB6KFRO\Z9A_8*N:&H
MGB8*<EJ))F]"RJT0'Q34;J\R3?VN/>9JL..6[6S6'1[2/2<40S:SEK#!:JP,
M5[.+XCI %!^;,5X,S6]9THNT_\).'J41T@]H:WKRG*4^Q.[!U<5;TJVM.9G>
M-CM]7X\.MTRQKE0>YCQ9O,;XRL(PA@9C_.QV>Y[3<+VN^.62?N^1U8=)&NC\
MQ Q+@7-)^K>SY/L<"0[](X<,1=+VE9?,?^3P0^;<6ZU-_R\<\*PQ*:QDU@Z7
MIQX,8[MS(/"'$0K%;V2;#Q$?,CE)J47Q^P]@VXN$#HF+SN[O;14,9H0,(.OS
MT .\M3E"$M?Y)"<\''?K%G*^J$]KX>Q0F0CJ>4)W!UN'8@P?#(_"E(U"LN D
M,7SKU[0KULUV8,L7RZ_P>^P= (VGW@H1Z-:5;-UL.*%Q=7UY\,PE =]UKHRS
MO-.C["U$B!-XEO&XURP$(]$8-.6U4'=N_*;#,@-AG$"8,,K!,A%L!=8?P*YE
M[Z;.^N5>"1/T+U3X$!'*]ZR'IW1)QC+MVUQ8YVV/VCBR=^7@-E8XYOLF5=:W
M#5V/VNZ@6JX#PZX'/P,EL;7D4&V1#E""45W?W[9>J2K!:=J7ILS#T!,90;T4
MFKX\2.RV-NN<K5#8NKDIY]3VPT',RWS2!3/H,3)#_L[4M&Q-:ZB)YY)Q"201
MU8)$W:IE:CWF=YHW=)2JSCM,!5+EEN@/&>,4LD!OC@#RZ,6^YI)]$7KSC_OC
M^*$1#()U@+"F-PT]4(P+8?NN\2B)SUFFFWP'@U_;Z6SW=CB15&DNR'NJD-H2
M8I_A^&H2?=EA<\V:?0>%86]7$S[^+D+8ZK#,?41"ALA5"&'/"P8AYV+ZDJLI
M%[.#;VI;#-'8DZ3K*4)?";6=90&Q>;:.9:%16G5/6GD.?#!8>]Z/E&DXPX4Y
M( *L9NL)(;8[J+9A!Y;?O!8\I">];U-VWRX(EKE),*- _D:6&CX (69'JXQ"
MOSQ%V[T<F;O_T?3(V9R2B2_Q3%EP_2)+#:C6H"@8#287.*V=R3+.3RQ\)B7V
M\7&+UO<'V?MX%DZ]!3<54'D?JN V.MX/P#^SWE,DV:A0K+O.V.4;7-AWR=,\
MU.3>(8=J:-*&/KDEK_(5[#>:U6FW"<]I\1%&9AOB]V93$-N<^J4Z,I*-\A1G
MK'6W*&NF1;_C+:A',Q\1&H08\K-37S0E::MK!FUQZ)+3G0T17H^?;19_O.HU
MJ]0)QO >:+WO/AM,%"Z"KQO;C*0W6XQ?,0O7-0G//:-UGS N2D'5L(3\ 2$5
M.+_C_;J8V!LO9+^O^WY))HH4B9YW ->/LX[X!UHP7N;V!'PQCHEYN9?_8)6C
M95= '3;K]S'XIU?VB%3S'. 1>>-"L^2@T@.?4[Z7,_>S%#,W\/)M$A,F#EJ+
M,/=<E&U0\O?"U./]L;NHV!RA)'16[R$(RC_S&SG%A?FN.@YO5@OR,<EFU-B6
M=Q9[ERH5:Y1J=N?+L%KZGU6.0W#6@Q$R2&YH#9?0\F\-416FV/!9S,QJUC>)
MV[R(ZKT)FM/T:C&!3$(- H[6WMPQJ#P1;]-N]?[[B;=T)FD&8&]!TV_!8>"J
M[HNHGF4I&=JZWM[%RY%))_=I)^BKK%I\+'F<)T/A=WJK$[$?R7S.6#6?7331
MA_D\?"[3B3UEI2=C5R%CNJ7"@L&;V)V>P'DJ)J08(SAY^\-2F?GGF,(#N;4N
MNG+ZK7;!8"J:M@0*K&4=X<*JE8<4U ;#<>A7-99P>TCB5=?MWBB#\5!8_LA;
M!?!IBA-\SM#H@=#:%VHZ6MF1'[-^**A;%WGNUI0@H(_GK=Q^WD>&@4[Q1!IO
M5'#KM0^]&WHA1.I\)-"SEZ@"(;EPX*5G65E'Y0'TD=2TD"-65J<3<_W0XK%4
M&<N)Q7]J<?\+;PS^#ECPO_+?!,HL%6@:E)$DFO7;,J*_NZ/+KO;%HQ+]#L4W
M"]=>]BMZ?!.=_?3YH5M.1FY[HRP<ME Q%.THJM%;">"AV['\?)7>'?T78\.E
M3D5]N8>(OL'H?<N$UZ($^\:TI=N=%YWEQCV:G&_>?\*$9^7U["^+=!W%V Z:
M&-SN/34XRW"'5W%ATYA7OB6HN0KRX2F\(^[]9!+1]2@;/4$(! 1]CE$)-1Y,
MT0"5'%]9XX>W1,K6?O$N6-Q;YB7_])5<Y:X]%L[I#OPJX^751_CW/2T5_+7#
MM8W>@[P/W&:#I/@Z*Y1S9.,R)UX56GU0CBJ^OP;GQ1Y9N0R/K5$/K('W2-?;
MRM#.)'_L96 =_'0VAZ:/[[H)G]BJ-(3*-.LP/Z=_EF_B> KO'^'^(/!*]FTY
MHD=@0.D16U7%UG[B)"EFS4;L)XF"$PM[*Z&U\. \^+X$6..S-I<16_MJ;WN=
M55Z-5>.:M+UB3^V*LJ?+]U9.IYKMK+Z7UG5V]:=O&,%71!%A:BD5;",+7J,&
MO#Y]5F7\UO;&I0C2T2HV^A55R"^W$LY0^HXZ@I?00S^STG%*6*=VXWAY9:9X
M_H-O"[*1;^;"KBL]4%>;YJ,23:FVI7/=_5LQRMBY0R\NG9A^1]!_>N\H9'VB
M!*>T-['5J-"/*ATFZ/2>/85E^2L1LKX&^=6_Z0V[VJZ'V6(DGWLKJ^GP=MB^
M50N6\FIU2-Y>?;O8VO@;+NHY%_>IPMD*K6NYL(^MSX !P\_S>J6MB\&(ELH%
M]\^6TER8@&L5L'!X',_87 14?Z&B.!N8#N":O.VT&?CY-/;DK)Z-SFT$M41S
MY7EL[3@N[+Z\WH_;^]0J1?E/:,XGCW4"^_858AL7YD1<Q]8)7[_.?TL:VL/[
M;JG]@3MXK.4<H6AZP,C:DQ+DT2#QT'S'/;'5I2B&=;( %Y:*/\V%O8U. [>-
M/N#"QAS:$=0]UT=Q-YEU\%&4E_J$? 07YE\Z0&2*+[2R^:P0%!=/)3# ]S 7
MMMHBW'-)*-<$=%]*RW]:"O]3M,=;1URWY?Z@[T$\DV%U;.B+=H'>,JD_O"PX
M(V/RB'H?$7_YCL@P@NSOQU]NYA(?6<:_OU#_17W+E/#6JP5'5Y>&X(-MA5]^
M7X=XM#"6;LM?7/U@_Y&88</T_6QGZ>Q?'9.C:T,IOG,?%Z;.^D0RN8C[":=^
MPFO7AM>^5W#SA#<[W$7>02#E[YR'_Y39FMZ!_[(&+9/97HS#Z3Z^C,LYGDK6
M8H5$@3C166GY=6ND&G87_X0KN)]..EFK9G(KD.0[YC?06LW1&&BMT>*IZK$B
M=+LEV)=LEAMHQ UJ/RNW&@;^F38FL_+U?L+9GS#SQ_S[CVIO6\E"DO<94NJA
M<=*+_GKU(D6QL^G)'UYW9JI=;T3$88/W/5?]VV'AG_+MVO^5WU_^*/V7+7\C
M[] M,M4,6%9&!!&7-G!A[1D9'H@7 #N.7(UBP6HXUWGZ?WQ&(M^BK>5S\R.X
MBJWQN0*9VRQIL.:T\XWXXP1WQ8V?X:;D8@_LO@33$NI,ZMZPS<CGN0><TZ)F
M7M+7$=6T#X/0NMNL>8M:4X_87*GJ&6R7Y?@JJOG9V+;;@_(>L&G9R-=TJ>*Q
M@3'3/)6)]^\GSQ ^CA#.G<6]SF\M)SK@0YII[13;Z"'1=D1!#^L.4S9AY$95
M0_];@@$A$1C '[C*B?'9UY!S]R'HOK"Q.-?*$S H_TP8-4)KG.^Y8!]QCS_%
MJU/LT3[+Q)U%QO'GHJ*/-M(U>^F1G)0B3'<#I7@T:%'%NCR"5:XAR#+^D'Y5
MT7NC^F ^MH4+$\4/E50[2];?=@2ZIK-X$7:;E\N/%,"]>;2TY.=SAL(ZW["<
MK!A+@Z?QU]NQDI[:U5?;1#W6?I@XL4$/F]<B/ZW$D&WL8\EY:K*,N; T0:^C
MH3LTM84-V'=(3<;A5NX9YXIC:YP1'YA'@O<1-LVN[%WA[^4B/6%72<UX$:)C
M4Y_L^=(V]I&(S.Y>.YMW:B[:;X.9A\\>?5$J#=Y5FU-=)F85>(_'!1UH?ATU
M@0[9<NZL@5[VW/+(H7R)3?ZR+NC),2\<6V4IG#@F#0=Y]/[BKA?4&B(PUS=P
M8?>@7VBJPQT)@\[ZU\$=GV>-ULPY#U^J'>)U;)BT!8JRV1\8=>%UC>G/FV8=
M2H :(P8+!"RYL%5V7-B@(T#)8$,X%)$#-52PTM"R)&6'WI!079(AAZWZ'&TY
M+7Y(_['M$S/Q*0'^Z2)4 *)(H;+@RI(S0< ^[G3"XD[=+_,1Q+:R+[([)K"R
MG\QJKC@>R0PUH(\ (]A$H ;I.0D^4%XYVP#8QEJ (T[JQ;O*<UIY*WVC1V8?
MX3?M8ER@3ABCSTK.[/27/M\U7)1^R8$4SVAKJ,5+:!]%V4XPU]8_O833&&J?
MT7P4M7U(,L#8'MECC(I_-UBMMR,X)&OR=9V[,S['F'7&<_K,QE0Q;?H*053P
MU/9^=2XL)11@"$)&TQ94(O%EZ[3(H+R2Q*D!HKBAPV9$]U#,9=;7!,UU+H.5
M;Y(G!$SB9G;=1^K&ZQP'#IN:=#R;&G8=',55?::[/N^C.[Y!VG!A <DT$F<-
M-/JWD+QGQ",HF17N7-@)L953%P2XM^(^0<'ND2')8UQX7-HP%3F4:)KZ.N#K
MG1,JIH2EU)M#\R*Q*_P89-*50"S$CGPN[*<D@O]LU+;:/?Z)M^]BO)TB%^9Z
MW 67KV5R=*0Z,^>5?;U74N?:+[WL!'XV"!S#<78'\%$7P5Z'6SG)V1T_*.G>
MI_+I+;X_NEKH0[M=Q:LX\:&R!V:H"MK[7-[/?G4_-,CY6X,D+NPW6MP90._\
M&ESECKE9\[Q&KA0>D9U%+T;$A4QV$9=92F^2BZ'EJ3&4UFX"U5Z5MK+,FEFG
M&8NZ5LO'EXI_:(&/ECYGQ4":QXM+[#^W3F[LIADS>%F4;D0;#=+4H3T8:34C
M%0OJ?G*6Q>R=H"0=$KLTD-Q19&.@TY1@][&F2?)1VKG"W+; !(31;TU>"FPK
MG-<L\$6/.$AJ+O0M7\OULM"&IGNX]?_R0*C'KB'CMM(3'*H0VDZU[3]G:J4B
MS;**+.I$WJRHFH,,5AZ/1W\)LM13.Y ABHMRF<(F3?9=/OGX._^2PJ</R/T[
MW7.B#=+S-))$;IT/=E(\&BB__$9[GO3S1A.)120<*IJH*]7YP[8;"LN^H,N2
M C_!CW:UIV":5.>$IN.&<)L8#H-249AT="S3N2AFWXB&48".W>OY>W>?/YLP
MBY6+>+7QF9KX!9.P:Y4W.#L11;/A#;QG0^%,^LK<4[#06MH@1'\HFQSF+(58
MD%B>I[A_62(+N6F$Q"4/#NH?FGMW^P-D;SU[Z2XGZW+M-E(RY&&B;V[1O$,7
M?@V(@,-1.Z0M_'=^]I@)-M,TFE .5[;M1@E@6U%S%D5"S)7;?+O>^+;;)DNY
MW*S E3?>,E<^[S%17C2]O-93:5J2%LZJFJM+'=\<XEVZY4.RK<!:+1@'W9\S
MI-23"1JF<V&+D[QS*K3-MS)3YI_/ISYT27CI+-W\C)9<JIDG/5'B__TP%Y:.
M8'1>RZ9I&PM&N".VAAU+%]<I)RK'2*4I--\B;ZJ4]00HX9&DGJ\351&L+*^*
ML#$8H54I#"^JA#WH6;IH] AL==BDW'/\KG)FJE8+NC7#T-R6"8?'?EVDM95'
MF<Q@,QJ&%*RNM^D7>V=+WRJU<;D8P/OZ6$94O56%<E'DQ)));=J!V=L#JV9<
M+V+NB8+[,$*KN##M32OY[2HM.01MI8D2J7VOJ+8A[GORROP/%VTP3[\V=+G!
MZ=%)\SWOXYK\:\SK+.G*L:WO6)O)0X+%GZO%--$8E0\WI7&F7VJ9EU1OP+=-
MGLK/O@M!<"%0=9D\2.A&U"&$_@][[QG5Y-JUB\:%BF!!!41J=-&DB?1.5*2)
M@( 0 2%+D=Y["XF(%&E1$%!:E(Z4B#2E)$H5$"(=0@V]DU!"(.W$]_WV&6M]
MYXQW_]A_]MAC_\@/PO/<N>_YS'G-ZX*9.9N8@<CFYGZ^R]<K%YH^LM(C+<S;
MM\$ 2!Y QIC!U'N T)0+S'?;;>[[4'SC E;**_3!PDY$@U5JL<ON;;"^D_@?
M'W3G;NR'SN6\VVN;5ARNP(<ZC5S_\/*DC>'U1Y(T$W?)B?D3S1MS_-Y\MWP5
M!$[-#1W(45G '9!:9'LOY"&Q0(B]WZNPKN;V2XG(^'=V9-S8VK%*HP[DY^)X
M& ]9"VHM5,55;7LM_:&,6<I#ULK?.ROI[U>[VYMEUO.@M,5RW:\;S@ZZ@TA0
M*IQ=R\BG3P.I3+1\T6C#!+;"9?IQ$'FT=^:S;'LX-L[^'-)XV"D\R>C>X\N9
M>I,[I;Q=VE-2&":77IV%D T1L7U-"65E'C<4[P&\C<?:'U_KD_?="%7Z1(ZW
M=-2WFL<Q *%K$$*&.V2/JXD)RK$, !\(?WT$LR+Q7T9=R*S?9"/LZHSPWVTF
MBIA!I#RN52E<4^M0.1:_%HCE=['G_V526[+F8[N:%7Q(B7H:]DP-%&U<Y" 9
M$H=;7:\[.A+,H(KB1FDG9$&$JPQ !X)L5(LZ8K>'S^HP $FAR"B88HC4W(EY
MG O?0G#]-7F'IRY8?"-O97_<?4-5P-/4#@EMEY4?F17&.WVKAY-C_S0#,U&Q
M!3'!\I81EGH*3D2)C&!<3&-S!8>S[@UI&G*!/_J8.3C?AT^S<(>W8?B:.&<I
M&OP5MG;)T]/[P1,->@/>0(+ '%*:H@!Q>#DXE=[H7;J*^4_&^.FBOA_[<N^M
MDM;U6;N'?0H"[R]\B3CK\F#JK9K)]=[/?85$R0ANRUI93D$UVV@5<.]ET+U:
M8X?Y=9KYN)='[2K*,VNKUSND+VGO:MF"[,3W6P,!G,EWFF!Z#=CQ[3G66&T@
M'7MT8@3S4:>X!:NLP$PI>/J%7N^-F6H+4__A$#6:^>6WAO7B[D"FE&JQJX#_
M,M]E*B(@U8T?);!F=6G;-[#RD:UMA_RN<=!:O):A3'OHP7.Z; AH3N1S.Y[F
M);7J0.G__'9BQ\.I''J_]I=W$TO%K;F$ES*:VH2Y'9?JKQ;"KQ%0*_N=(&=D
MCY42MWH&)((^CQJ$B:-K?C9XQ^OE]1Q$5QR^0E3RU?S3+KOU&[L?J)(#M3*W
MZ$)K!YEI@V+BMA4SDI2G[/L([A#L'8+V6UQ,8XE^,4[VQ$PJ^=K"8(J;%5@)
MQ7:[_G/1 LW"=$OC)#'F\T?K6MMO[Y^F^I!9=LM[9!,D2A_1,K$=%Z8?,0#8
MRTH7MP]/HE3[T:HA_)VOUI3YA#""4V.UKP[]]/I]:_9D$D<[D9];.,CV]WW[
M9X 'PZY\7G>-5QWJ.2)+S7.LA[VNLY.8B!7".@^.:^+_:(N96&JHF3[^JZ_#
MN"OW)E8'XNNJ_MP-9Y>SY^ 1?*.\6XL%H+^+ZB7#YQ=!TZA?VTSH^I'Z_E_=
M'V3<B]G$MMYM^>R'I0FL=DU)\=?N0C:YB2CS_OU8PE82:/R.$3WU3]J.P2S+
M1$6$!(0="C]$RX2\@ ]^8P#Z76V?/)T_RZ&OB3*/X0U7<6\4\)Q)KC5Z.#VW
M;OOUN>9B8>;JL/Y\9G?"O&#Y[JDGQ-JF5,Y(OK5W3R+D&M"7:'EH"7>FC- 6
MYV!?J5>P7:VZ6]=_ZX+4DMH5.?C]LY;$T8V$.7BL-J<WIUCUB861;X8RS4T>
M*6V&=**6?JV?I&1/KI7'X5JHQX._B-R'CEJOCWC_%4;/],I";BT :T#D81FC
M.=V.^/@CQ$M;4SU*12"T/VJO!]R#K.ILWP1W6 6C!4:<PKLV4GMCEFX;<5WF
M-]0R,?:%U)$J U%\Y.";]1G++WGM-$XZ7<8NWR\UPH4K]]F$1H 3CPH-<5-0
MQ&<0/LB5 =C3&F>2MC$XT1)N3,Y0KKF\BA97CX,T>7IGWHOP&2:,9%$XIMTN
M*5<SG3TX3U>$6)Y[ZWA#BD)-TI3[-,89^VP4?OSQ4/HVN'Y8>_B',E'><W5]
M+\_W!;A1H^J)RV-7"Z_TJ]UVY?U;P?;J0S64H-SU1U]J(V%[U78-)4<IP[<[
MYX;""N9.RUYN#U5;%407V"%F^= \M ]HX74D%UU*]GE->.G5P?3 :H/\)Y><
M//R^!:X_A%^$.P.YJ&S],DW&WI72B]96^E562;-/0HXO9W[I[_>_VYL3\+EM
M_H1-O?3R9Y">:4)@H:IZX2QHG\  S.O_ PB;%$BNY \J;<@8XB,WCD:S3S\5
M- 2J/T;N(LW=WP_ U$,X'XT6])?ODV?,$U_U:WH\<T#]#*D,YBT:=6@OU;E@
M4K"Z-AE<B[7XSX@H#*K1;_U0P0 \!5Z\(TO%2O7L9'EM,S-! %J:'(F?85F5
M*EW/+%"V,D[Z[!SJL?=-(-,J%_=J=>[/(9NTZ8FU(";=^@^ N QC(U?A9>-Z
M)<G!UHC[(>@C3[E/5/Y4NT<I(G)-*>J=?(G5<M]8AC)-WVDHJ%%L_!9S!@^S
M0/\QX:A :L"M65J/:[XV&5V<+CMT/'X/'%RT\0054CP/CZ1R!WIZEZ]7X7K\
M$J1O.;BR2*SXU1PZCV>%"U@.+*;-I&KIT"]NNM.?9R#)Y_\_1O^D2+L]8U7U
MG#1@JHX+G!%XVX%?MY+TZO,*K>!_>I31?K+?SL*<>'\P![TVY792'O;.K=YS
M/LF$-"5>-[)U_<HK+\,G#4%60N^C>J$JE.!K3-MGW5%=[O%>D,+1!:AFA.)6
M3)306>TK(U<'6\?TN&]>G]+BR9P:A,8;;H7MWPB\Q)<38EBO'8N!_P.^FP\0
MVS5E#KX1J%Y'K^*3[@D==U@_=;G-07F(*BT,P'E\"H3#C>AVFK?U#-=CIB+0
M'#'MV 2UJ&>T4MYJ>H<JQ<;^['\G5M]'F*7F/PL?N4L=<49>'B)]S#&J@&X?
M""&*J(9(&[T(E;;>DCS:4BW:%7"$_[C]3V^4(H4.: NXJL/RM(7<@FW2&E6.
M=.R<)>'GI9J(&6V@<U"M:EO4^;77J[^J<%]/O$4>Z"LN9&9(?K5\K#H24+H+
M>C!(2<9Y\[F-$)JJW7G,[D3Y_SBXSGUSS1#[1\DJACNY I11'%+K76P?9+,F
MI@=\YK8CZ#_/&@7[DZI%#! "CLRAT[64/8F?+V.GM%@<0-'0"<KY$B:->1?@
MBTU%+-OH9?F^R:I-/E*53&D=KC WN2[(,8H87YYWJ@B=,X*?6QNL7>"!B)R9
M7])GT<RELA_%HSG(IQD 4>=6^/X^ U SC294;DAG?RC=#^4.2_N$Q6F,3Q#T
M?X#XT>IN1ZBXZWL5DIOE>Q-!<K %_'BLN>E(D_M]<FQP?NNRF]"?*2U"N9[#
MZW_2'3]B$T +3L.@]34([6S9/'RBVOZB#3GX=KRYR*Z-M;#@=Q9>JGNTOU6I
M$S:U>--?VEED:7CB4'@-2[;+A-,X@N!D92#5TFX0=DVY9B,S.#[F_7J/3.7[
MI\+K,:@731J42]/N.,'D]W25?H^"AD1#DO6M&:%P8%9%.'*#0E&9@?*,R,I6
MUC;:67I9/*EHNO?VH$MQ^;*NAJG%/3W@:;V+ <2S70'5VK%9'9D5Y;**N-ZA
M&^][#$4'HR&EO8XXZE_UZ)S'=<0"'@6Y;\DRIO[ ;TI0".4AU&9X?UO@UFS.
MI35;=T4)@5PC;@4-8FW5$,NCXB0&P!'.194DQ),_:SE).-7_8?BX5L_PKX,I
MY"*83UU<PKHZ3,TM3?5NLY>UZ5/82^ E=Z/OP[+ZM"80>2A82'E8>C:T4JGL
M[143)GG.L805*^VB-EX3[7?GQ)\O#>Y;9T88W?/ER;G:T_VE;PY^ESB#0\P5
M5<]SQ+T.$==M2)]N%S'R^U0EY(\^R2]X4ZPZ24+M"\0A/1UB7R3YT/7N9"-&
M>#/+-.'7&F?YI5R%F+6@6=USA<U,)*_%,MDS$WM7_HV]D!R8-BV#:D$(;B&2
M*V7<U JB3CZHMDHV@LY&;.QB"R.N4B2@#QK(B%GE^J%%UUHMI:;TM#X;2Q:-
MKOVE[-6=SMR+#;+<SQ^LT!PXP+D2X\C;_PCA_T[/TVVH 031Y9? 6PF0Q+62
M";Y++]_\H9[4]J3,GOYKYMP>S65514CDI6QK7/>IMY5SODG?GE0M(IU"T9U<
M4V\<9YS"EO\#:?:%_4D<B<3+<%(@5L-7:P?KMCB=@V[ML:22K<#/Z3?(&G."
M;>ETX,@\.E<N/>E5Q\PS#Z>,9O=W):.^_H;C@2.=!?^DC_]M\R,:-Y*LLU]8
M\DIW MAWFRU(<>3 O+7>(ON0]&O;EG5O'KY[ SQXUGXZT_:$ZDA9H>),X?@Z
M\C\A^I+V-?+X+.)$8=8ZWT905R@PBT7$\TK@_J%__-I>Q!,L9/#*D.(ANM]9
M?2OYYJE)[1A$J%357:4/W!)BJ?OJH'^<_?X06JPGSX,^0-0G,7-3(ZEL5VB[
MR*9L] >H_A5M.18+1=*.#P\FE%ZWS7G()]\^FL0C5AF!=)YOUC>K,THP#@IO
M##UI[G)]O!_]0D5)Y1]61ON1I8C"K2 .V#&R"?R\VZ]58HW(L:0-F -5.',/
M=8)J14"VF:K0+VPZ29$0VQ(6_##CKL)KW3(DL5J^O4(INW9E5$6-1@]6R(W/
MLWK2WKT:9RL^G1E>=P=2*M,.'H2)&55XT7N9.T^>:2;9[HK-5/)]@2>DP_B'
MM(76/H6@UVQ!'#=,:WK/!:-^*L\##BIY2,']L,NN\F[.^*6RX-)JCCU$K==A
M6, /H:&!@T>UIW0R7WRLET+):'L<L?XCZQFG=JBW^5:C*X+B\J5[F0I\+;12
MI7U:[1>4M3BB$3*4/[A9G=2[*W=T;>GK-9A2B/C<R2B4]8KZ!CA#XK&<RQ2?
M\/.DP2 %\S>YS6<^F#2-JIMFH.NTU%OG6IB*73<V8;[Y"P.0:X5[&4R- C=3
M_R!/E<O&2^\)FN-1'JC+NL!W/2(OGIW;^H+Z83JVJ4^]+CJ?EPUSPMS3/LL
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MD/ YO4BQ4GRTW,,"M 4JY<^K5;D/P#] ]2=RHC%MX6R>MRN&1C9&-?2)3QU
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MNKH$/JF298TKCBH^T55LC,W$/,Z0#\&"_4Q[+ZAV[2F1*J!FO^?9_L!_9"H
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MD#EXMSY-Z*A]TH@=B5QZ<JMSH/%!(3M;VU'(:%EL]V-U=8WML4/GN=AGL@R
ML^G+=&?3(9&4:^-.S_$F I5^EI_D!M -Y ]SNL38C=:/ZX]OTQKO6<<G1TE+
M+3, $_Z/:H:;0HM71U+:-4G$9W3;/W1NL)QL1CX:7!I@ !QBZ[X<<T3H)]X
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M:TT\ER54)C-X^3T/RY_2%^6_;-MKX?F/X4UQTM8/Y9YKV)D8Y(^/WQ(&ID6
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M540R49::,@Y?WS%=DA(*#3\]4[HD;>R]D0QSAKG;'R$59ERJ0L1)R1$:]Q@
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M@XVRQCI?'67N5 @TQ ZCO.JV&8!S4,]Y.,MWPO)\U,JE@9J1D?JJ0P]:4+8
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M,>(>_+"')$IB'N#OQ>5@>JM<\4TM-WN% 5$,57*<G57);GQCJY?H[V@0Y[=
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M<&?LO'=84UO?)KP1$2D*2*]!04 0402I$I4#" @(" $1(B+21$2D0Z(@1:J
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M1(>=_4\0::A UZ"7%J7&"B08T:$HL8+T&^Y&&$F73<UJ'\<*>V/_NW#O+0B
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M5)Z(+-[=" $;8GNOSVYTV!3'+DL@@J$1IQ6ZR<S%-6H2=9&Y[#-BW;#8V^8
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MK0RGG<9EA8I6-]9&Z J6Q5"*Z9YPR.@1?OQ(>7$C.F,^1C@R=<PF\ICYNVE
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M)ONC9+6,,-([<CK&WN5UHR!A::[A\BW<9(-U[K@3]\6)\8DIY<Y3],*2+[P
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MYC@Z086(^><_BEX<HWM"&9HZ>9^ PK*TCQNW+_Z<,&_,?'C'-JB-\>&UQHT
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M9QVN7YR3Y1D_([,EO)/=,!X=L7 )NN*FI.MUMO .EA:4LF^QW2EL0-F?"U-
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M-2D\7X2/)L9?4M%YB&^X17KR56Q+-,R>&%-0FAC';CZPY?FGR_6,]2O]_5L
M^DK6(^QS'G5V'N?I9U$;85JSXE4*"%;RXXJ8W3EPV')<>>?MO+=;;96R2K<J
MJ_9/ &,#LT/+31#4E&1AQ?NYTKK:6,.BZ)!.@:N%GUC5&F/:_?_@/IFL5/BT
MIG,\49%#O<=<,,P1[O0</=*AG>O*ZC@J&ZEQ<&O'=MA88V_BSW67MO/8='_.
MXT?(CCKRH[^=KW_%\H&:CPOYZO)LZ3+-N[R3LG*4*F%/N5'C;V3K%FS*>?EF
M[Y AC/C))/O?FOCGA;@2OZ7S5B:L("(_1/Q($.Y$&".$:"A\5'CXQ:0&T800
M0M&TM&0Y,"VYV=6J9LSOZF1ZT+ TJ:/ )'"HF]VT&D\MM/YEJOVBKC!%Y8N@
M5?9-*3N7^G=0]&6=\;YDR25=_Z5!43^NPNS1# 319-&$? W:*+,"+#%JS;6U
MIJO.')\4#]F*CU0-UM\ZJ^U&_;./Z7?Y@+XB=P((1S-[2K(YY&8P/9Q\"1M<
M[OCL)F _^5R&RHE1H&"P]N<H/^KXVI@"->G#/.,=]CK2G;..W^W>L!VY8]2P
M\;NV&/)ET33H72OU0",7DK#7=W3;[MY\ ;IJ: 6'WD.U'1V+$24H>367\?2S
MK84_2$D2YCKCM6;;M@ILG:(^KS@^O4RP<H\<[Z_3)F@&>:'.01/,%6HS)E:5
MTW,^QP^OR41EXE*^$_D#E%CC(&ESKH.%@[7?J.SY(<LDN,9C7H@#2Z@WV(!V
M$!<A%\#+T\U(TBG@"8 7DU$C.7<1PD:":N'$'P1T&I8$$T^);B)O/V"N#G["
MS&&?1'Y(<L-GMJ#92IO[:T1^6CH>"+Z+GGNL<1[<(A"R>&^KF690FY#,$R3U
MV>F@$K'AR&VY6M'AUE<?8H+F@_3#8D[QB[I]$IN1_<;,?CJ52W+*+P?M]GG>
M[4Z;D)E?CKWMXC1)E)X<32.OD28@-?:YR5(&^@1PXZ++T1JVRV050F8]0WV$
M#L9N6*-H0IDOMFM(XY=/0>44+\B2V)H,\.#<6N_7'NPTY"<8+K9;3F5(SE)-
M$<6?"[4MXA;+;ER.J(G.I@%8F0WV0<ZN/94A\B8ZS(KE,;DS51;X(YE CH0'
MW\>@0E+)J.R>Y *#0X1]2^GV=('_-W9L*3CP[ 9] K%27X\@,_;X+EF9RCHC
MOP8L9HF40/"1$?B'U7"JT6?E@";5Q/I(0>.@+\>G;@B-<%& G)QZ3 ;2DRU4
MS?I9@1\?,T6<DLB]8V%D5TJQRVU)K,,T4,NCNLMB,-0;Z78CTA _=@[1AEN<
M)E_SF-4]" +)G  :7V9C-0ER^M$W S_FWXCDA_4.&?'X+F*KH#.PMVG6X6[Q
MFRH(QF/XT95X5BU/7ZI0A]<6MF#KAT+RL0&,]X<!U:G\4E74VG!_ )*19G 8
M,!CPS%<T@TN-%L$7PEWDXZL9<B-&6DSR:#PQ]76C9!_GR)$=LA;BEO@L4I77
M1"T7-_T3I"CYX9=-=M8!)#AS=1%Q'S%)+#2C#H$4+CLW?57B?.;YJO@#NFN7
MA%L?0H@B^JG*@7.:;6AN6,#0L(5*Y+V?Y?&R<3$<[X(5@=OBCD@N4@]W1,HM
M]Y74PU*JYC#A;$Q3HYH%!7B(]O@_*?G2HU[P\\S#(UL4YK?;,'(A*\/X]R>
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M6*0#S 9X*@L+!V&I*L\ PV^1+ 787.R;_S 2>9X;B2 D5I'R2-@'W<DC>;E
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M_^UL8F]E A:@K^</RF1X!1Z#H U</]2I9[CF$M6'?U27CPG7$,00-YUNSKD
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MA0STJSOD.ZO<#S83QFP_TT/;B3RXH658')0)<@/W<DNKR.3)->S)Y7]#KGR
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MFTWB0KR$$.B.#\#:]+WFH,<+_\5I62R^=-3+$4A'U*E+9"C[$];7_OQJ7@R
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MB#X*M%D %EZCE 4?E1IWWS=.Y1@W&]?H^83Z'>$O?/>PL#J"$]H#*2Y?#2A
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M9_^K3,@)'R[*,U<RBI@55"-A7_EX?\;WF]$R3Q6M%]=_X;57$N<V%68+SZ+
MU )'#X<T:O45^+]*GXW@LS(_L'(0U8L]Q^*6EC1%?4<B7MB\Z;C<==2+F;?
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MVT?U RL&#ED\F ^+-H_D$GHG_ ZJ(*':0!@-J4''ZQJD<T43X84VKS#@K.D
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M9!51=<]G]K&UT?Z\O"(F@^:Q(TB"SVK+/!'@C:0! %NPH^NQ?[^!O'VC!'@
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MU0T:$VZ#!2,X"96+:V]=V%_AB<5?0DX/?]N[\O(V0IC4-;> 6DS]A];/1C3
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MO:H-?^]5=S-E6 E<(3NB=PA"C6W5Z=<)"4K#,N6:)[\T1+D91_9I"(^F$FB
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M'O8[>O'Y?&%= C6"AM7:UXL^ZQ+'?-/)E9#\@U^X==M1K"RT6"VCG@^X0?$
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M<LF:H5I8[:"#1P= 5O6J0QU$M;!-6\.1*W-@HG:#'X<898J B!!9O%6!?6O
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MH;Q(71/ @RZ2X5(*E&=#(5AU, Z!S%<Y8/846-_G,SAGC2S*<(*U(/XD 3Q
M?0!CCZ-H@/#BM..#S7.78E[M/Y)1YKM^-==<^>J[.WQG3W2X)HPCSSJN27Z
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M<;E) [WUNL]7<?\)93'XLJA\0!F:E=4^_>90R7Z:;<N\WHC$QT[EXE%+3%S
M:?"2X4*[7V@K;%H%/=C*\^CU#_]'4R5?F#9C>HW"S*\%-AT;W 'PO7NA7(1Q
M9PXQ**PC&!LW.JW.2J]C[PSG:NFT%>7FDAL&?_&X3' NY)94\G]+OYP6+\7U
M.F?4SEOJG)O*'>'?&OQC.^-55:F@#);*BF>31E-M C$W1@5=U;(!  4F !D
M[PNF,^47LH$I[.;ON8MVT[$*DV;;@W"ROQ4X1*P+(0H=@UV$WIKJMH(3XFV&
M<RX[R36?K*QG5==O=J4>R3;MFK6R"Y;)RIA/PUQG*?!WK>T-RLH0Z[A-<'7R
MEI8ESEVW$@L)EF#I#-G_$I*Z3N$Y]$(!V'F4K>Z9L@Q%6K^YE/'Q=Q9B^FQ(
M_ON<[R.30&!XFS:[P5A!/=@69@TYDH.'SN.9(90S11VPA>_ W8=D61K BAE&
MU'*%<'FKX]L)R 4PBST5^*O!',\GH!VFXN1"^6(GG/1NE2>=K1/NYLB##MT2
MP0$Q<N%..=Z=;;!I;H_*IOH(X)^Y?_8CL_R2@W;/YJVG=^#)F?%H$0SBYS*_
MA2UQ?A<44^7T((]U?>WNI$02>5 *G@=["9Z" @/YQ6N'&N[3O4P+7['BT:Z$
M]D0^[TV27P%0+'#@>+KG KE?->"Y *LV^V-]!W&N/2/?O59] _OMV#D*^%G%
MN Q!\J:S)>)GS7U!0XYMP1A5@: ?"E>($=AY3FHKC%')IKB_<,;;\H?$:G+_
M5_MJM^GVJSNDTFE]?M)QU(IZR\X4$,W9C)PEZ+55/^=0/:S\$&A;]=(W0Z3Y
MF;8; '2PA8=A];0CQH<2$S2QQ9-4\K@TW8?'#)ST5\?S@\_*82ME KYHKP3$
MXCO.7CA1=@LUO+$$_>C-N#@?"N+T=N9C;)EZP@U*OC!S]0.;<1B@ODPH+>:4
M<;@2TU$D?I-26#%_C*"G3_!;W(!7$.#Z[YK]!%D[TIPQ*\SJY H/P9/K#,X*
M1^Z[=K%(%\E(JE)ETB_'C]YNXV;;L???;V[%WA?C^ AE%EOMSHM'VR49V@MY
MWMQ>2GKI(YB^4H>]PXPQ,.QXO.7H=+!G)R&M^*% 4<%HTBF@8E?%$:^.EZ<+
M9"LL(\6[FAKM2W:&6V-=MM[CO!9I@!"Z%F!]Q2]..A5K"4QT<J+/__7V;H49
M;))2PF@J7MJ?Q2S@\DC.L/T\1'UI4$RL8Z1I[-/Z]9'G(T3UJ3]6=/#HBB\C
M)6J<!B!J>D$^)Z[-7Z1#86PXF*OB; !G!TB .C%RI=:T:X'$4L%CJ_^6I>[&
M6&RO0-3%&-^W\-O%/QN$GG#PZ7P?\?*#/>J4:E?A,A_+2WUN&OP?6N?-=!9*
M*52"#,9V9"QN,;0C7PQM"NP6%R/+7R]-U K_B=IXWP2C%0)W#?%VOD;." (1
MV_W%QGO*F_MGVL,IARG8(Q*$RO1G393U'@U0ECI/!U_GC3VVQKMHV-9MG#!&
M+M EB_!7I%MSBOGP BVKWK_NB0FL5N4N.[)V#7(=?)JX(EME^*$@J+50EMMY
MQV7M\HK1=RNQNHJ1Q[UOX+_HB [$EXYLR_  0RPD$*9W2>#9W]4HB>/:G(ZV
M5D.H++L=YAO-.O5[+1'S?._S8[+6](] ?9V,D07O"PM55NJS#S/:^/E'E(RS
MS=<4^X,1^7GF5V/\3+^W=EXCGH=UP<]440*A3"8;.NMG%L,G!:XF]6BI>;V_
MLBHH'0_]$+<%R9AGH0&<6"/!S$Y7?Y;A!!SJ7HO]O"O^\NK;"$8 ([@!X'GL
M'1[^"$(00;8;5.\.1"_*!=3L12<.;!+IXKY#FO 2(6L]F<15\ZL@>W,*5+DR
M";TJ8AA25/>$(E]963&T3W JS@KIZ1B_RNNJEBD0(7L9<*SI&>/"2:@M= Y2
M*1O:WO\8U0R]5"//SS/LS.U8M.\R.V\&T']]$'WLM;R:>%R3KK\?.G_+$">/
M8?F1I$BW*]?-1>^'C+P^;VI:NN_QA!.XDV"A85%E'!_P/+^Z9$?HIZDD6+JO
MSSWV1^O$K^>1,XIN=+N(EZ(4W@3)>H-&6HEC2V\(&T\^J"OIGL^CREZ^V+GN
M&KWP]HX"((*<4<0-S?;*F;_O9^4AF[AT3C "/:?"&U?ZNZ=IZ<*Z&*I/BF![
MJ59P<WRP;/G%[9&FT=68@NW8V<&+WA!U7%*D:XYCG4T)/,^,6=/>YWR\7.>5
MA4/&C[[ON^#BV-5-=ZQ+2]V2+R)MP?1J ,]1&$IOT)V[RNUTC#'7,<9\7D]X
M8 .0;D[/$Y"+II<J:QN&&QY]O_73D4,UI^-VT)",#2)?>*X<=)4^;)S0*VN[
M1C3 :U-OMX%GO8*^S*=.O?#SB>JG&]MWI8?]_M%*";?S9A7T*RSPSO.N![+2
M42<?YM^PT*R#I!!M\L@.V)5*7,3J8D>*XOP&AZ)97>+^1X576YZ]EQS/6A$&
MO\2#/]P8M%",_<?$%AQX,:-]AX/,AV,?J%_D,UM3+.XO-]%\XX3^VO#D]V9-
MXF6WH<P!Z4X++5_5U:U^'/)9>?HXIF/.^F+'T"/DI)R :.L)Z_OI(95%K8GZ
MJ++XGU6'C<1]6_T]XE/6J?99?&7Q87;S[ZP($@;]X,^NR=_387RT' AZ[2;Y
M@62-?,<I(=1$I1/(IJ:J9G=86[Q3I;)9;_]*1$<%WV/=H-F\Z%?]>@5<C0E/
M*!AXSR!!A)'\U1TVP8\ZZC;K),LG=VK_517+\D]5K!Z$H/\SG'S[(!N?7WMJ
M!KZJ>*D8.:44EGG$>5=M8LPP*MTU]<BL2!@>V.9G$J]E7"Q)?40TZY7-C,K<
M+,A+VRE&]BT7^35!Y<9 O(3>1SBY2/FX@K7DLZYG^4/Y#$(]7CR.FV$3.Q5!
M7%/54.A^-9@4]=4D?A98B3Q&52:X8 [?OQA_JS'.,_JLFJ@?SZ#\M6;9R$L7
MNH%A5CYWKPP'H7,,9T?75F@D&7PN5[GTVMF*N(7T6[ /&ES,AE^W[G"M<L';
M:8"SA'(3[-/*4_!O#LF^H'Q68GW1'1-Y_FR![\K-"Z@A"[IR#(KR?_'K-3IH
M':.&ZH/M3NN6MI9V/K!\M7?0$;"QZ+C$_GL,_UED>M4683<Y-/![+'\3]P;9
MLT:.14+9J#U(%@33>J@^=BXX&F*O.BIIZQ@>]_3^::-%J3,GOI^(8?$ <H(D
MO-T7X.\ER!IH4^2U<<DDGK?-J>NZ(*-LBTW8%2D-P$7(5^(\^5(^>J[HE65E
M-78E6AB\QB'')AW;8FP.>WR$ZH1<:-#"21LIPB,\>OO=2#S/-6O/GD;=F8H\
MU'&?O'>IP-KHARK$/CH]O=I&?Z!T5&37\BK!F)-ZR__I*/2VOSI*R;P@5B)
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MJ L90CXTV/%<ME['Z$L>#YR-RH3>>R%%K/T?>2'E7V[3XM^8_GMW"*$^=C0
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M.<3)K5QB(>&43HPN%N:<I6LEOA0]VF=5I'6JJT$\*;B@_3&9G6CF2TB:" K
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MLZ(*$W] +L"-[ZWCN<$\Z1#S>V84Q]B1'E% 1-.)W^,%ESZR?09E(77HXY
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M( 3GE$I CD-#R>P9(T,/%GC[/I<&3:Q[OG]].SQND*F)<X-K)YL&'+<G)M&
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M$QW.'LP->XQG[-(@!LX2[<=M'^_:LRVT/9<'DMAE0Y$G+[]4O<O:CC<RJCI
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M'[=#R]J$AK3O_X(E2^U&EP^&@RH#-5C>BY+  Q.526"@*[M0:\C<IR;_&0&
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M$NG:6]G&>=0R313OC=K.7XK5-?U*SYY*=Z;Y:04 P"!O+?=0:&R>PD!$8'>
MJ\CP R0W\>6QOQ#0(M3.9OZJJ$_J;7IAG;/,R4'T%X.MU@O)7&Z$&F(=3=DD
M>%X@*O0$VO#$4U+<O EWW9?]__+U-53B*S;H,"])O@0=RB<%Q'-,Y#Y4::-[
M>'4+4=L71)_H(&<Y!WV"SSU.NK?+T*!EW>+V5Y#*/'$*D'2FA<R92JJ/A6&K
MF8'O#I(H3O- "I?(?D07+)M1K_WES"[529M&V[FA&V8]C@D=I8_H+80,-2>
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ME]I1LXK-&LL8_H47-@H$O;+>F2MU85.#CA+K SV]GRY02G; TRXK)F2II9G
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MZ1 ]3=%9I4$<,H/MK&UDZ(V'R2Q3P,;Q?=&&2?MBJ<IF">>YWDN.[XB]'9;
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M.)A4<5^>&P'TC*2\?3=I9*^U+A%WB5O-X-GW/7L-'(K*E$A2,_DRNZ6BGE2
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MV&P((4";)MR#,"8E@T)HX-6?A3>5YL/6%7L?IMGM<UE%P-B(?MKR, ><2X2
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M?RFG %9/_  UUB >C+-0(%IM(_Z_8]*BYX')(QU#D([9?ZEH\#^K&JRA]L^
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MB^B"S&TM@[?WO($1@K:HATTCN48\8\W@EQYZN3TY].Y79(1_T3'H<%R[#9@
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MX22*_9:=:F9,E,$+ :ETLS&P'#V0]O[..=Y KO#18P";JK>4W4-QB=J8PD<
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MR[O]U:?;GGY_:1"8M@.OK2?SL;7!^5HYB(BV5DY<3]5ST%<?PCV?VH:"*+8
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M>B.5=E7A)<QV#%P'7NW3\QTQ,;=H&TN5<%@K*Q>3_K.G).Y\)O?RPV#'H(C
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ML]=6Z"#YK"WU&EP OE'W^AB0-X/)@+<[PY>6R9>. 8]B4-3,6<Q)L#L??$F
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MC:,7!^M7&ROKH1XA4 KB(? =SS<ZE:6(BTOB>=$.EZ4VK]N.4BY0/NLIRJ:
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MJ2PX[^B%*7/B_K"2\C[QJ=JNOG /NB!QLB*SY^'_H';Y*8=HZE4P#KAA%]
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MNJO-,C<[&6]:!W1N]2^MG$*,M[XY!L0UP?R. 4ASVN3/?X%0K]AU%Y6I!TT
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M"K\QLA2VW.->T+C;/MB?>OTED^!,P[R?F;_3(4DAO"N<BY+Q>,SG&0?$;CS
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MEVGW13/H!7(2Y0SD)EARRTGAY_0=026X.S%8:MVX7^ZGAM4R.!&)-7&)[BF
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MY,7=@U6V'\G405PG)],(X[T:8UKSH4NXWT6S>:^BCL-^R"<+AWVE^#:N--!
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M5VQB@LMAUB(CH!&YY(F1P2[A/4<6ZG 382+#S^H,Q\<OY>A[N!YIN<!^=')
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MYG$.W466AVT!IS'10KVL+%(L;QO*.7D>L_:SKC/_)\*_K&NZ]M?%Z];! "K
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MJ?U.-=[::KV([<\]WA^OGY?A^G[;BMO0;\ODN1B,^?,V.',>JRT7GLQOT#[
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MX7<FYC,3)IT7.A77+YV16\LN9[J1Z5ERB!O&7Z$ Z*9PSMC0D/F@OI'%:O+
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M#MQ0N)=%IE/_V$(3K<:YT54@+5U)V#1V>F%T2= &^+[W9RK)&-F!P$NLMC&
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MU@Q8IXH)#\A/Y45%7KAU)^-I@NVIJ^UJ^Q[;A$V("&P$B-&7.0OKI@"8B_R
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MYU A5A?K>,M3NPRO0H=Z@#EAO4#F'\X<S4L/1Y"5]@O5%551#177>,7SEM]
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MX?WVM;Q-,%3[7&!1]M-SFO?5U1H-J4VY^$%#ES2WIK+&S6>\9P4QJ271>4+
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MSHYB;4+N7=SJJ]C/E2PT G9QP]D/V$XW.T (Z8X+0&WA1W //^UD]@XGKWJ
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M>%9F^LH]9[J7A*J^K5P HJ32K>OQ/EVCMAXWD(*C=;Y5*I0E89\IA#^ 31U
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MW,<=V<LX+PBE4U-(=\OMMLTSTVK<8Q[Z)%&OQ/?718R4GJ &KO/!V6&>JU5
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M6?5G:YI$Z>,$!L-PD7R1]HW+SY!JG+\U)52?5=EZ^:EZ$6/_5;GEYR>62/U
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M$=PD9>!;FJ_(IQ/5E(,E%7+/_@1&7-JJI'6OX@4@XE"JKMQ\I:)B0\]X0RZ
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MT!WQ*G9%_R7;V5@.I'NY[G#OL PLW:VG\:,N^ZER\[46ANL+%*>6*XW^G0*
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MI/K\!BDG,2.YJ+8;J4+>'#^B8^M:URU1?@^V'JP0O_R>()UGY)]P)RJ @S(
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M]):?=33+*/@[,.A?$04Z*RP3G// _PJ,^+O"2EO<#E871O^N]Q_X/_!_X/_
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M*ZY:%HK^!F<Z'-]"/-<V+4;/[E4ID-GSJ "2H"05P)=) 1IG4 ']%WXWTAJ
MXY*/6BF\YC,\9/8I!@J9ICV7 >DBJD[A2+R*E7P$IUSXE#.I/;C$RD+[^I,]
M.'M O-$ SVS0WNFO-HW.XAH=%W5%0Z80DJE.JD=RC\[G4)J0QTNJU]TF3$.M
M!'@>[,CV=?PHNS,4G*_C_OG5HVDS_GWQB72"!]' 61WY [DY)5^>=:7?PFJM
MCQ!O$J%CECC@I" F2DX]["-SH]U+M%U[FY+ED7FK@P4C2+B'X'#)^H#A)UU1
MUB>,H!@H;59/!!.4J8!3/ U4P!FH8=%KW^4P]]IZV-IEM?BW;!^.Q.JOT#AZ
MZ:<DY90G+HK"[;'1:ILQ9;JT]HNM B)RNW5)C0J 3=6^XN\$[C<-&4S%ZVF;
M=:"Q9@K1<&P!%>#XD:3I DK("VA8]!DRNV3K^B%N-NS',5'0/J8221 #UZ,(
MNCH,KK6:-:\=,^<FNJR+S^A]JK0W_;)ZLW627B=A9YK$:=UBA=CD(SJL@DZ3
MM*@ %Q,A8_B9\8S4])\?AWJ6!UE68E87S->Z=(1*"-I8O1((/2]$2_VS"K<]
M@/^L]=M\.$;<R]3+1#4_Y70"H@V-(<XS1*(A"$SR].QVB*1;S,G>>QHZ84_$
MF]C;\A]8MVYXAT'&#NWN;"/[/%ZCL2;(8"0+5-,)DA?@.MURA"ET][5YQD=?
M>*7-PGLQ@Z[O\;LIA!4)3DXE^<[#PX#<)=M< 717/=@)>::Q@<)E:NR_-LUC
M,@)9/-].RKYQTG)'_8#/UJ+=J( C\>E#9S 5@/-E<_.[9VK_'+E93070CV/O
M3Y_>1YPCR0XPA*F2N:>VW7VBS!U+T:^.N1P7Y5ALXV17>S;AM]GISD8S)W&X
M2X%Q"T:B (ML\N]]X9MN58"/4.FRTG6J$'O+K7W]*6Y3T*]2\.RQ17]X>=BF
M;Y";:@G-&6[Z?C-&X%WY&P5LASXCD1):@21(C#8BPX5.D@MK)/V_$=2;GJLE
M>$+@$%__%]FF]!>^#)C?WNH G.@']$*9Y"OCKY4E(XOW?G=<\P3RUTI90;D(
MQG-H_E]-\N?[9<6J+)@AN]FKG(&;E1WR< RJ%3&N/B-?3@PBP7 \X37^>5/=
M658::QJ;<Z!M1Q?><,@321V+\[PLSW+YZ(!R03B:43X:EABD NQ-]!G+-VI'
M9"&+F ",8-;RA(\;8:["E"#Z(,6#IP[%[\K,RW./\+9>+"U7,)_E-58)O6QI
M_"M.KX"K]_,7\BL*P'2V,0,9JG'-:A,CJ2M5)6 '<IY><EH;/E0F>L(ZU9%%
MB"9G'VMFXD_=^G,#I91W<HW0NEP,SO D9[O0XN%+/O-[+8; FM+#?9I.B0./
M4V:27I6JW7:'U%R#O*L.B<,\L#UL0"=<;K80F>JE44\P;;3'02]1 15)E-3"
MO#D/@BR*E&1*3P6,58#VOKD2G2BGD%2 A!%VGC('/O*J0D6@9XK0.S9:'%3
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M:8SBY$W*@S:CWE^,7^V?[C,:W -?^Y;ORG6%9HB?'Q\#OX>7+%4&$@,HDX^
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M%B(Q?M@78V_H=!;\1-K\V_M+E"OWV[Q!>&8*C'D](8=(6Y@8^),<_1JGFY
MUFNQG4W*_=UZ&GX=07-9%S0OQRIQ,ZFV(BE!\UE<XH0$1:XF5$L'XAQ<BE/_
MKEYEL=UT[O V3P1OE@Y/:VO0'=H?T>\%F]K5H8:FT>[IU%O!EF"LD.K;OA@&
M3!H&$>*<&NR VL*+EQ[ QVOP-81P(@![B DE9,-AUK!P(\ECO13.P1$WK*.%
M%W34#6! J8:4B:<-:N'*OF#98 _-&([6N^YQK:8ZO&_*.&S9X$L0?9Q:QZEG
M]''0 ,2%WXGEC.S3+L <>RGT:/LI+ZX;M79<";K9S9RF.:<!7 5_3:ND;NV$
M,A-_@"ZXOZK"*?P<2^%/>JET%'G(TV7:L,Z9]NLM!AX-FX]"4/\, %Z&/*GS
MC^77'7!;NV3A$U RP[@NP<W..1IBJSVF?LY^\MCI/^D)L1JAH&P:/AE-I+T(
M"F_5Q/ 436%+9KZ1 $7AZ@]*!8$' T_2@J##6-]6#L_P?4Z0T9#8M1')PGN4
M->4U_I6\Q;+!>M0# <)D\?#%W/E.*)"GLTU,NKFF*#EXV)"0UY/;_7H"2=EZ
M&E+1R!V9P,-]P0#8#S^] :N0V;2@)[(.RPL7S5DS=K<+ZPT9ZPV/1C 9L;\X
M]UU&P-K\<YR^5%(S\@61%YI*'"4!+HE SQ#[B1+HQZ/=T[/9D8DU+G$R&MY"
M[_V9/8]"+=Z%%_CJKWKB&<<73,>*T1IML L"0<$?,\DQYF3,PY;@ZI2$=\,S
M!<X5?O*C!T7&VE@>G %Q%BHVC.SP@6:GV[#6M<F$BDP_*BY1N2W*V3 P=(<B
M3\^BW>"&^'$Z#H2G0QUNKJ(0&BC]X-'4L7&)F=END*_WZT;O>%#M\^=N ,$K
MM(H"4/^2XE\C_SFN*L]K8@4<"CS!93)1B7J"F>K5=R@9CGR#$<J(XBW0:BD,
M>1\O;+*N_F)J%QS++F_<C)\,4W8@Q^M3L'ZRDFD(P6H1HLGS*7PB'@,7S!AD
M%1KT7F@9PR8P:7N3B)UT(C/L#UW[ A,^O-=#8A1R\1@GW"]8$/ O_5R__+3J
M:Y EE#?00J3&RJ. K:GRI<-2?OS@:[M-6T5<;A"*-Q'LHDU7BE05['8/C4?A
MB/E,LE%22<-<ELN#B.PJGWWGA+#),DX9JHV-*?CYV?\S]4=]@:^X-,Q[LE%]
MBH61HZGZ B\,<E%T-;A(ROM:W';K6NRL0!?M P^93^S:TQ1,GBZ:+-O(DL--
M?=0AYAEJJS<W>&Y5:\RIF:P$[9(V@Q>7G!X Z'F?+[_EJDODD8I/NC7^8JAX
MG16#-FJZ<J&]^#['6[4!<]V[C0 /P+.$RC]P1O4OF.WZ0G^^XF/Y.]]>^77'
M\-_@L*KL^7^>OR=43ZB>4#VA>D+UA.H)U7^.:H0 _HTJ+O!HC-.MUXG.D/ 9
ML8V.FF3_EO:O(U@8X_2OM[9F5)  _^I""1([RDB U%X2P(\!E;_Z8+>4*7SZ
MC__+Q'$-$WUE"/N@YG=N5PK^C=&9*=3"XH*%B$U?S:--Y.$ "4 +^DO/5:7N
MGH?"3G^9+?H/_>X,N)S0_4]!5WA)#"LDL+D*:M?T1V,S'Y3*F/&A7!46.YA6
MU#<_,)1Q;S\,,@3L1[VA+/<;_*N-+O5QO@=Y.$0"! GPC@;'J[8A48](@.BG
M^!>$SVZ]'-NK/6A@8/,:FW.IY105\-?0TD"[M%7M@]&#<@CR]XL?."N4,"9Q
MC,CG)=P!GC1C&:/\ZCE?,=22TP5X$?::_]2]'HK<[7>CW2XT4@?@OXB58*_Q
M4^>_RRZAZH'J_YBR[LKJHQ"<QJ-N9^GDP$-_ZSY3.L] C-#/?WNES]A8I<>U
M[_-BT(]Y!=R<KIT1]'N6&N(_/%0C]K^Y6S)J!J_Y&B9._;K_6NNMBQK%MXK;
M?$J7WRB4W%K_W;F_&T1^_*V/-9:LVL4H\!0H[8JO7XU-LMNV"E1_VJTEV0MV
M5";1R96ZG7;4I :F(RFAS&ODCXM8B\9C,ZYIE5(#CN?ID"/-7I$LG[K(+1+@
M-%R(\($$F$^KL6I,"T^]CHU?A%T&M8(X-C1Y.KYJY!3&E$F42FY^LTP26?:O
M8BQ7TFKA./[#GLV0T*^]7A3\=SD-EA7X+V4%_G^CJO<O)TU#?R"IBRAMP8!*
M=PASXK4\"K9\O)O:>G>2_Y[2:W#3_*^GIT_HGM ]H7M"]S\*7?S/ORG (X57
MHC4F 9H>%V;>KV;3+VT2 .W^Y(2^UR_^[!!"]@SD(?D^),"2U8KF_^2:,T+Q
M?U9U9S %5H]0/F)_20)L(Z29M92]5"O(GX"3=M+^HS;(J;_Y>>1ODP]7_/?D
MPR[_:/)AO:-QW/0^.#91D[BQ9Z[,K/_6U_S_)%O123MI_\Z-NI$C%Y]5TT]L
MQJ0=*W-"D\97@O_F-\4-J\OF)$!CM(#0' ([>11/ E#^?ED]_@TZEQ"P#=HO
MXB"<@?>G805( /QGZBC0)ILS"9#]>OR7E-.)B3AI_\G:B8DX:2?M+^V?,1$)
M9!-!T(--T;6G/RLF_JCZ!5K;YB"<W>4E1RP.)  D&?_;@ 1XSOF%8(+1I9O(
M%/YEB]LD0!(YVM G,C$<>Y( '23 \6B.&W)L-DGYB#%^>ATA;>G-!.N7)@$:
M'G,]2-OK1>S$&R%0,;!A!!%$ HQE_G'@@IEIM../ZH1E=1) ?IIX)/FO0VU)
M@&8E$N )"8#]O0BC:*P:: U) @!)@ TM;P^Z&ROZL0+X/2?<\N"_#);*)P%H
MJ ERY ")!"#8@A:X28!<&)XLW(7*/R=$:C^:_7DYJG\>.0;'\P+W=TB :!+@
M((\$>!M(3"$!T.3 JIPMZ7G)]O\^D!$STX 3&"<P3F"<P#B!<0+C!,8)C!,8
M)S!.8)S ^*\'@Y!J8M4-@=78R(>!5C_!D/PUT@W3YIB4%/_I-)A1YE^1>ZCM
M1VTYT_V7F/-?QI3#_K 0U3]0_#IG&O2/C<BKJZ5*<A7NC"=Z5Q)VK?\R<O2O
M%@_\"Z\S=C=937O@US2/5I"'79E_'FGWQZ!W!/97C([X\=W04Z+NSTN)_O/(
M0O ?^?]7P,5N-)V@.$%Q@N($Q0F*$Q0G*$Y0_'T4V3CYJO[WY-6ZC>7^8=IO
MA].( <7AT@J/5>18_/LDI4G/._W_ /"4GQ-Z_[^QZ@3%"8H3%"<H3E"<H#A!
M<8+BGT6QEZNGC4!I;]Q48<#4YU(3ZS+A0^OXL?%M13(8*NF*),?9J?HT]GY\
MM2HX6VKSSS<K@/_PY3LWJS]6&F36_PQQ)WR19\'=P8KCU9=,=3;U>MKEC-7T
M>ZKK8NB/7G>D?3B.#V+_<>$._"RF7S4#<:GA%JS)0%'4:_UX&]F4]@+%&FH2
M"NT]/8.4\-CCBV&A)K2:N'5MF+&[XVP@[G4??@BT.3$+<PW:,G"0 $AA_V,]
MLT&V[OY?]\+Q0K]3@5,)88]0Q%WJ3VT_%C]=0G%TM+)^E>VD+OC&:D( [L%'
M0+_SRL^A<K? V29&]YU(@+.'D9L6>TZ2U[/W9%1CY'\!*2#>W%RGM._R4%[4
M2H[Y;*08EQ$NU/4W6>>$VQ#6L*F]A<K-_IQ2+-S0L#SW,6;J3%H8/'=?3N+T
M=2(NP>P\C;R>U:85[J$9<11XSAUQ:=9ZP/IF2U%_KI%AR_6$1,I@:AV>SXXN
M+^UC +_$VQ_6U(<XYC9H*3.W_M5],?T$Z*CBC5$\!>X._AZ:U=]GRK$\9^VB
MB9%I1KZDMN#"F^=*>&6H"EZ,T*"HN(&X*,^7@\2K-E05UXUNB:X&%8K>]9I[
MJ6<26MK)ZZQS7;"6.:%_QD<P(^\O:?$:E FYL/DLQ'G%TP2XRL!/34ZO;H5.
M>\FUD$D'<.[.*CL@\'.&HWTD9[W=+[(L$$5JT*O-B#/8Y&-!\_JQ,CL%%:^M
M)L:L^+MQ-Y^JRRE91,8YSR6,M12/#OZ/6+0,4B70%?ZHPY9QHYVP\@@%.M7R
MRSGUB(\OHOS.:&K[GNJ2/W7WLIM^.^(<;#[3AZ$#..7; CLG3YW9Y;HPC:B0
M0H9* 0;EYW3+2N"Q#%3/2L1Z!7B9I,^78W1YAR?,E:&RQ(FTBLKV_F 2H*PC
MNDYJ <$U9^/#E0(I-IKLL'/\P72D-D&5R;NKJ3/7<$@"!/CBGZ)5VQDFT]30
M8I%2WE+U+G8;G5EUB9(JENH/\YH%KS#8/E2O/3]E<OPD7/#;_Y 4J2X?\Q7M
M 9\'3O8OLH66T8T-NQ?*J"4O#FVQ&&;$JM)3G&98%*08M8:W1 >1 )4=';.>
MBU9ORZ9)@-##<5:9Y/KL.E1Y=A[#Y9[P'[&LWI3OA ^Y<B16)AP,R/.G_RE%
M$\LN',\<O[@:T4!+[)<F<J/TRF\$%DA7.]@ZIK^3L;BH*F[9DG_^(=QQ% W;
M!.&L(-;8;)PVEJV9>!T].P?_LLXT*]K[/G'L5PE5V<=Q/@M*\UA-ZG*-N"=M
MQAII\&?_-_?6@ZR,31H30@=97L+^S8R-PKNN1-I3.'.(.589I^D5T:)X 5T_
M%I%N;&Q8)^UL;%R3J5!SZTK=R]W6U/J-=3$LOTQ[&@?>!2N\^-BN0W9_CGMD
M"W*?[[/,1>4KEE=9Q[8OGOVFN%>\EFKK'>\AG*21]GQ0F>7!_\O"0O\.Q8#
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M,:G?D5;*$MUZML[9R8)B0]N@/'>BJ/6(D:9ENW&)\()8SCP]X5*LO^3I3^:
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MQM7HH<\D4^9H6K$B)0'1< IR?^3:]V'HM0DCLZXWW]=1CY_3")QZ$)]Q56!
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M(/J#G8L0)=1.T T1Q_U>#9.1K?V)J*W:=*;'U[[PWJ2<KY+"?9R/GE"=MPJ
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M_?25WJ2UZXW?06AN?HNY;]6Y_LZW:,\#)[V54RO0KCA\U7*8.Z=,]5;+F)>
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M/9L$/"& <?%[*:FT!S4DV!3.)08J( GI\*+K;MM5;E16I&\#S!D')HHNM?V
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M+V7F_2T?^D^U/[][9.[];^\CI1]R<YZ.O%3,^(^?UO_OM1+9N8YVME/D,[C
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M(LFJK9\W<FM%O,3%N0_M2">IPPR$ST1#R9]%%\+:7W)%.!5IGF)*V#S>]KQ
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M4W27O#6W1>+/H2]+/4LL>K8"O7T5>H4&0/VX38^X@K]!B"+Z6^]QRNV$]S2
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M^7Q+1QZ#\GH<4R#<LST_X165[A_C+OVV8_EX%O6$KH5F!9O94RA]0=,#+QK
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M/^&W>6RYLS*RF@N')"%M V4<J!7#&:+8UWAG/6H:%+_UV5ZY*INZ:: $761
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M!,I*:R7[\JXMA1=(?WQM1\$F'9W^N=<G\5G=V.M2ATK*PP_J;MM]*SXI#W\
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M066MN6,]5A#E*JFOD)-U%@S]HMNFH1_FI:M]OV;;Z9WZS!]Q[LJ9Z!M?136
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MY45F_Q0/?=SPCX;FUE\F!U_R6^/%*I^/07#;(X'A551ORLO#+4,$#Y/=T@>
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M R^)0&](Z*\[I=\BFH&8/PGRF+C__S9LMWYN.^2 E?YDK'0 Y &0!T > 'D
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MTE],+$Q,C(Q,K,S,IUC86=G9V5C9V,YP<)\]P\'%P<9VEO\L%P\O'Q\?.Z>
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MZ?M1!V;._%D9.0!%'T>-M]9/>1S69 Z=6#\?Z?Z.RN9HW^)OYJTL5Z)M['\
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MO?JI\4\Q_"/"?HLSERCTU@$N9_]Z6*KZN])SF^YT.)U!<Y82S]. ZZAV3K*
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M'83[0KY. UB;A#S\66RVM6.K?*<-^KFS'GU(V[[X^D+BQX7SV: W#JBM,'H
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MC%JS8? MBP;,> ;('&&<'49B*TLN!GD)#B"JBH0.3:-Y+>V%$8DT .=H<:0
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M;.$#K@7.C,0Q6TIR ;EG6@2Q-5JVI05[?+?ZU\14NRM$H/VL9%FW0/2YIS<
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MQ#J(>@/\H"Z-SR]QX1IN2J\1\&[_*>_B%VXM]72?X5UKMYD,Z]GQ72<M+<O
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M"HVMY\X:K-R\WZ>K&G-?ZTP9X-G'WU<^_G49S&]*4C16V6RDISY]*_0$0[!
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MQ,=.Q:HEGF_26> \BV>-L HW$WC5([H'K'=.[R=7-7Y%76I>\*"J)>[!%(M
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MH"M#V7;*WJ9ZDC[I9O0TXLHXC[!SM@$BQPZ^?T#Y6S_X#E6Q#QZ?)P/_.7;
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M+O6M'!3!H3"0Y:'\$9QI-H@59B:(D-1!0F@KVPRF8X!10I>:\?R2[>RY75%
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M9H!LP!_GX?+OZU<,UX%U4 UYGQPKV=GE6@)?K9G-(BL2&A:(87@)#"0\"++
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M8!]%DJ"/EF0/K'+\=(?\394*U/ZRD1HN(KUL0V=K(W?RQ40&8_B4#7Q6!YO
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M0#T$S2>BJBTHTC">;CRL,Z4AZ";2UFW0+1^6W'48=U0:(-J-R%DD+T6A\1;
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MM!_DDO-INT?\_RF''L=Y0R5/>J+!EM;OL)*Y2U![^2MUURE>5!AQS,>8=#T
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MPAZ&/*JICGK6F\>D&34YS(/?,EH194_YF(F9UD TH 8J.UJDJ"%,$S)L&K<
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MBGY\M [TRX5YNK <QC#%@N>ST;[+A=Z%5*8*26XGB.\J44]_0(#.Z)988R@
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M_!.Y>Z.' L@L+]LR4R5C2'J+=N"O\-R#>JHN=0'C_M5AU2_\&^(?&.K\GPM
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M)__7F<IM*FN"?E*H[91I0O_!Q-LZ_N6L[A?^_?!?9>*%1N1#[8'UKQ1 ;=,
M<3P]3&0GU7KCJ.-F_/;/>/W[<),XCNJ#$"X/4]71C=PJ1P%LQP_5NREY-8 ?
M^'"FEW/^8>JEE*[_J\W&+_S[063^:+=;V;^U]45_;^NW-WOV.N$Y:0D40)W!
M#EBF0J\Z0<H.;; (5EU@]>#.<U-W6#RC)_O[T2C+__Y#O_L"Q-_Z@OVJI']
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MORD#GHD!<Q+=\&EP,2Q<!F]8@#$>.NA\Q#_@(I D I5<8_I)\Z3%ZM[+S8\
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MHS#EGB&[M+:N.1(!1NY,+#9U8*YA1:J>HB'QTSC@<=)+])-\R-C<;,%$0E)
M>2B&="RC8E#J4&&?Z7-.5^K9YP^Y8:<S8[,T.\X+Q9+2P#.)9%Y2)MCA$5R
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M]1X.YA3;$?.K0T:;@Z3.I<+%B.$>#@H 5*OJ%N-"&_?;:A>W//#;W':A)P6
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MXD:O@B^U)XYK2TYWC1-+7NZSR'/N2Q!U0Y1$87,&V%I/S=KE/(2\37K_T4:
MS+LW#'E2'+TZ@>-S(+I@<FV2X?>'LSQBLFXX6T4+P.@M:"*0&?N.]=:DRN)"
M! :$':IAED6.OXF5(I]GZ1+;8QG;U7-;B(W=8@Q(=H'GN.SKF0F/--3IPCPU
M[L>LI9EK*U^,5S]'-H#BE:E228(Z)4 307O,TG>PK505A;!F*^O0H3[)?3KV
M>+'-,VS&S/"J.T*T^,LX2=;T(T.2$A?":X2:KT7+OUHP:&Q_^\6IRS#&+*Z
M?L6=?/.6V>!R!P4P030JAJ&BP-;=5(W6R\TS4>DTMBYM4RR_M4R8JR_'\=<X
M8-)H[@RA>.^N%<YZI[V:_QXQ_\T'+K6QOFJ>!<DE(%NY^>)=0 G"@1XV,3L5
MBD_52%N7+O[($A-'5-,CP(O@1YS"I2E L^VXTP1R[82\P]:&9?M\V#Y'O2(I
MTQ)Q@-S'?19W.PS>+F$RQ=(.JG8N1IMG0(A'C48J=AC,)UKE&2^7?,KHORES
M\HW5:?^CV1""F'D*],4BT6@I.@WLT+/+0 13 >T,=6PDUQG-/EPGZ',S3D50
M )OV'7^Q]F4+]GT8K /ACXD^98*4Q1E_MPJ5.5?/*!:M%TP26@8?7LIIAM/W
M22;LXPWO3%0.W:'9"\M'')KQ0!^^EX=3\H!L?BA78=+]-[@JAK3 S]0,2_%7
M!:L;' ]JB5":7Q(JS'PB3P'(S.0L"J!0A%A_2]5T5)$5A,BE #TPZ/XRFI"\
M=5R0AHIL&.@W\.;X"'G/B<P?33#:BR;BRRE ?0H%"$5=_]G,SV9^-O.SF9_-
M_&SF9S,_F_G9S,]F?C;S+VZF"AIAP5K=YR?A(+]Q8VDD[(EJ2^JJVR3]K9W\
MC9EQ(?+-%-']HP+D\(0JL9GO ULR.%!3S&8YDP[TH-_L/R&,#^#A<;9X#H>Z
MVB#-MJ<:%O&N84); ]^:_D3GU==[CNP4(*:-DZCVM95)1TV,I/5C3V2NQC_A
MR+P'H0"'1JARE?7?D^%\;87'48!&*:J0#UI!_V67S#*+Q46B"Z?5!@5@@A3:
M9H;1+U[Y(P:C/UI0 *E D=4+.:=+L/5RNTWNN_IPGMJQ>IAP2FT=VC]19MS'
MQPC=ISN7;3/Z9M6:8/C90;J90R'[D[<G"]ZY]8+5V<+< ^Q<W&KV[82BG)7D
MG.8IQY%F!UE8;,OA E/M<R^N;@O0W7685VAUCX^9ZU0PH8I<G\CZ(&\69$''
M,5-8TH"K*OD-PHS+O7%9.\NUYOLE6$)GZ3SRG05J[A1$!7?3XL(@JIRS4^&F
MZ=>]Y>*3UD8G\UNCV;>N%8?/YS28BH;CG2<;99?'2?FKP<N)%R^X;RRT7^NY
M(<,NS[%$9B!*A6"<GNG=,HWS][Y<Y.;MT<S]J#OBA0( P-G7S8O,-3500OYX
M_E-M% !<O?BIVC%D7Y6@.&AGR*B69]QT544^;KRSS*/YEG+,$IO+LI$?Y[X$
M(:XU_3+DC!]D<!BO<N]KHQ6CY*NEXNOCS\'523WE_G(JO*N[U4%EE4KY8;FG
M!8\?.?BT34'H*Y@#WDV^A$5$O,%!FD]L5WBS(U>%+[3A$F2LS6=XVA#54]=6
MH! =/0?OA"^/*Y47IBPQ.>W@<+AJXEQ-KF31>3.Y[PE R-E/US7<EC@C]HSZ
MD'2U!]X2);%%Q2%OC]AF=FI(1*?;T4][[(!? Q[%R6$%8\9G8#7O PFMV$0(
MH083O;J2I-CA2\/^:)W9DPW)=B[JFV_T_64+UDR"-#Z X&9-"LGH/$Q.9#$\
MQN)KQRA&;D\+IAF-\#4:9M+/ADWD&=6A>G<',*#5^8() II\!OR<M2!W14@@
MC3DWKON"=@_/8S[?2PLGZ;Q:_5E5F(WZ^-[QC\_D4M_4X'_U#F?_KQ?FO_<Q
M\8GW=EICI@ 7M!))S\Y0 )5.,[;U';L]+D(T1GUW/$P0]531^9_9W7#?D5IW
M %+PQ\(._P.<H@IAOX0=$E_4_35D_ZTI2*>) FS(-".>$T<SPX2X+?<J?VPS
M+Q/X)QR%MI#D8Z@?UV#^XQH0)+YR5'<828 *_C *T''BWW::LY_;!BO,5TWP
M_]6&F[-Y[U_M6?2S_+GE-TLXWPS^_J5QMD1/Y2RYS8&#>!;M!3/K#^TV_!.3
M*<U:M6 F6DNQ\(_MXOV;MZ&^%!6'GLT&;=SX][C<4.+EO6(6*@L99J6RD#JF
M,B-6,1+L$Q]3F4X75Z:.Y@\N\=\_@;]$_(9UE.^60M]0@-_X-,*T]ML7Y?V*
M8CN).HJEU/>UD/SP=Y& .$JJH "S!9'8FE8.Y)-Z1I,Q>Y^IP/**K#FA+YL.
M:V^Y))U5CS+*II^0_G24!^8.LB</(DX[PIG)G]$,?D8/R.;DI$RS3GL*,)6:
M<;=G=O4M.DTT&$%?CHJ ,FS1'[5]:C-<OK)0%O36LDRB4F0QKESU;KK7D5*S
MH0)?MEV_[^/0Q.T1PWGMQ/)$Y*<),F(XY'L/\8SG?$@H7 '>A2?SX1)*QD>>
M9PXY"3NN\T9=>\<<^'J,(S_WZ+<KP#(T!5F92&02:D.SUO/#+-BQTJ&H6C!V
M\U:5[[4C,<Z]BKGZ\=[9,4<?JLJ,)TU4VO'(CTR.CS2E@ D"TJN'<?P#ZCAA
M_/N\GD.QX?O/U .@YKR&KQO"/PG*W3WR4.;08CG\G+%Q=^ZTDIT3>\*<-XO@
MO$5AES/M5]BM4,,67UF?-UF;\6C(,.EYCH^DS&*-TP(*,8*M=,O!0EM[.(DR
MPWJ&6'2X>Q&MCBX]\KX_KTJ)6W!CL^B^\ O?,!*5S <XDZ=W0.5'$CUGUSF.
MWB>$O#$E9:W=R8U2T!T]_?9.8%",AOFW:W*!@C3G_<+G%XF,<9B= (3U*4UC
M[.X@#R$4TWV^7+/NAF9%K-Q.&%C<JTOMBT&#?PIP+JC#T0T+716:+T"&(,O;
MFTC:TZJ1-L,9 P\/5 2'+>S2T5?P]LP*Y8?K%6)[+)#P;F\H0B2%:T@ODN^Y
MYIYISJ+EGAAU^*1._JF[[_XL?WH1ZD38HG89'Z%7SR'W1$RV+_W/:+DI:MVW
M2,,_EN+4D\B415:W^)L4IR,=,UC=:"I2_34AH(W>K,VP<PXQ"HN> TLM989M
MRD2O?+Y#A>BO='_"$=4?_9M58+34RE;6;]E&T5)-%W&BY>@$[U^(A=%KQ)7?
M2UH*HHKO1J6RL7+H:.=<V953GY,AZ8BI*/T8-&Y(BM!*58W[N+,A08A'J*#*
M\9>AIPKL'6!?U:\;>&?$LNV"USZBTQ!*%I+8M)!H^?-%!">#Z.X!=]^+A2)Z
M'Z+T!4=WFCG(C@A;^J>*@J04\D7[:3J<<.'PSE77A/>UHX9R$WY($:^4#$.:
MTEWU2]Z'#/6M5UW,UA\F8GS)IQ#JPV_,S20"?*&X6SU8<C$\'=%H7R^DG$6\
MA'5J7O'&^1?9"^A]"(5<F)ZZ58Q9ZE<_2@&*;?K1"A3@WDRP$\X47T9PR7IE
M8JKIH"&E67CR*7.)1.H^8Q@:>]Y"8BZ:#38M/1B<-2?LI#.R?8"C261;\X.(
M]2C:7?J#@.VJQ%-H 1*K!AJ+UL.FQQ7[07$L2+Z(Y.ZJ@3+![Z<+ZHIG-R8!
M1-"8CO[.T?:L@S[.+_!N\49],XME"#Y$4G<8LNR9G4C^3 %QJEYM%%E1V6K.
MBF%=;9\GF=ZM"3XFLI62=K6)G>W(A^IT_JAK@^Z6"9,N?0;12M!GH'<602YS
MD'$$1AOY*#L[KF7<-]5#/^ULSVP^!&,1\V.O]!%Y-<]]J-_U?JDB)]W!5<F)
MV<<3IBMY?&'][/>CS%]DB1U%7\$X7T.]0<R^0+QSS,OWZB&S0I\7FHS<'+!,
MF+ANW!OHZ3S[)BX7W!!FKK1D'*6(*<1R;ZN$^P@);)AD?YLH?2NV,>#E7E_P
M=0N=6=XSXO.O3GCTL_Q^^7NDK+M56XD/HQ(Y_DYRTS$*D/FE^*3G?AF)SD\-
M^\9OC8H-#<AK_XSZ\Z^DUEW.&0KZ(PF1_:BDX/#%'U:G#,1H!RTY=LIHV&##
MB<B4\Q= Y?T!J'>'R9R*E<_0"[[4/S'LHI(E5-6RV;GCYS9!HZD9?SE[Z48K
M^#"B+V:9>D;ED.Q9DE8^.C'+:E=<@VV[J1]3S[JX_B>_3!+\(>00O^@XJ[_L
M& [EZ4?? L\FS_SBM<,N\(O7SK=F\#0HV2NX*$:32EO?47G',#CAQN\8"4^B
MF+U2M+#08'>GTS!6(9ML.X]WTU.3OV2SE(,#'(1W,_AI4BSXD0(CB,[O.HO'
MX:3: E'.L7 GOM( W%26I OCM4D^590'J<I/KH" PFL0LM_:ZG1<S18)%WIS
M)<#BY@WNFW=D$U3N1^VB%GDM>12$V#K3"_,Z[*P)E635S_)E\]=JY- =B"32
M83\YZB_U)7<E\TTEAM;*8'<TAOK:TV N[KF3]@E1.5F7M"1CKFWQ@HK\9;A@
M)^V?9S"H#AFP 71/CL_#CX\NR=HTT1\V(4 [%,^&JY:9*[P^EZ6\4-QVR/WC
MHN+;FENK^:G\RS,WQSINF6$-A O4=[/:D%B(TS,H8[V"/9*Y]G[.-"':H'[C
M6+_(XHD<(15&U4)+E5/G+XB]6/WDZOJV_D5I:47_ZNS[]Y5A_?U3+((.L]=C
MVL*NY.=? PX\.0Q1>5 WFBL<4["3W;7S+W\G?Y;_QW"KX.]PRXC,%(W"@'9!
M]\&M9)NO];1%;-QEEM,1OB,]FZ QOXRG*ZK4/^UD<6]1(>:>3Q_U7&&IO8X*
M,M3O4<^C?<36?\#,O]7KHP+-_V8E:#8(J^7TJ^2.^S7))&Q^^A=(0_\MI*TV
M@:>1KPCAG%;B%( )(;%R23"S[OWN[=^C\PV$IW.!L\@#A.B6&Z,6:0):5>A]
M,?\ Z"5^_Y02E[2JSW02_>C4GG&AN9P N!AA&'K&2Q/SD>#DXM7-1XHL+L+7
MR%@)*%JY[#+LWDQ=.*B/"[)P(['X:6.G1B+J.0BHZZ6VL3L&_8Z%]^Q&"Q]H
MW+?2;3EXO?/D+"@;+HMH3H13R7*O;P.:(%Y# 19,%K\XOG>RBD=SDH.)';H:
MCA-HC-,@%O&$ E0ZM2'&1FZ'J&-SPL:A]#=;XU2&7FO6Z/?P\F/JQ6*U>:P/
MQ6KY3J&)+"GS$6)!"#HO.C?2LN1* T*SY"(2^V4F"K'%C14EGRRF +LLT037
M]7;P'KT7*P4X8H0@AIMK:YNF?KHDQP+&;",X*<"2(0%!A=B5=?)MU'W2"PHP
MFP=FK@?#^RSHL*S/_<"S*PJ@NPFVWP4&+A?W8VZ8=IP;[7'])J,T!&%'L5"
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M%BT0^S[7*M)*_E ,Z&O$X@=>M\^RPV$;R3"UT1[UUIQ\A;;Y%H9E,K._XYY
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M_L8&_7E01\7OV.9_[KOYCPOMQ&,=%7BR_]T_%,G\6QSVM_X'5NC62 K@B<S
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MD_V":O97W)!*&/\\UXV2.J(7P*&NW%9ZD%[5O[DZ#&^*(IPORGM*[L;%6J>
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MI<=?^\2%H2U8]]VH/!A)-*5V[K-( 90*"[0&<BX6A[XW<5E,CO;P03PE\Q/
M<P[9W2.!1*,,0O'P4(M>=\:W*].\VJHWWM_L8HKY?.IQ^2Z*.H!^)+>'X 3(
MS<Z(I;#]K/F1MB):O"]!#T58;]'6"DZD6ZA4#A5Y:%DAJ$?*>7#$URJN0:K.
MT42V,CMNO_\ADUG!H_(:J)OM"E%I3DN@R43A<U&Q?8+/U<1'-8OU@R*,1R]
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M0>';I7(F5]\-]UN<^#_LO7=44U^;/QH51;I2I$HL( H"@O06&]($1 2DYJN
ME%!$1%I(% 2D"P@H"%&J2(ETJ:$C(+T)H?=.0@D'<I+<^,Y==^Z\[ZR967/?
M^[OK_M:LK/-'SMHYV>UYGL_G[+T_3UB(MV3FZ=@:J>N+1>+/?C_X8=LR\6=Q
M.O"=#W-7C5&^HV&^TYFU);T<M,,*KVA\(:M"II7'LC(61B]B!?H"C&3EY;JK
M1-YF=RZM=&#N?J6EA/ZAR<* YI.O^;IJUZH*#YA^=AN^K['E)_=0A:/(,NB^
M>S1(QXE<&N3GD!2F1.>*C>E4=AU\9!4.*XW?=Q6>0-$@:[N/,-]Q(+?J74H>
M2(.PKHV]$.8%0ATX/@W+:.N7@;9;[>[5BP]R\EUTCC%<9\/[QP"7I5NP/" '
M)1%I.$N?Y*NXWW472GX4:TMK='&3S^A]Z&MM-WJW\"A:"R6QC26] 68(6YJ4
MFE)H!.SX7F9-7V9-\9"T76"WOPBO:H?UI?:,VV&G[-_R73)=4L;VPP#QSC 8
MG9WSRVX+K.E?I$&.G<]?4[RJ)B':,1Z'Z))'Q^-V4Q.,=>6S=/=-JPYR .Q:
M]8%M/8Y@;!B)/E7'!URLA[/O:@'!Q(K[>A_E4VWF#*(NE,-+M2\P<3]1*KZP
M':'].^HF_[B>JR$O2(\3@:]078>^Q)B8TA1KSZ93?XVWR8>D>KI#U.<51.TC
MV5,Z7><];>@$G\$?N)GEHT5R<1>*>(2W(9KL4NWGQ+K+>[6?:+^F;N[&UG;Z
M,Y.+2=ULNMW^>E]M*\O2%,(?V=__N=S$FBG\.?"N1,9I7@/]MEF_ XDUQ(OR
M5KG,[-J-0HKW%L71AW?=E6SG@R#5$21;<W(LS_(V)]M>]2L/%4F_6_&TN_WT
M=\76WTHN1T^>BU8F< #B%1OZQ-LD5\Q,(ZA,A($7,\PL=^CQFY-LB57LO.9"
M9VY<&ZTD\H]NWPWX=6J[P@99GAXZC.4Q$*=[1$>SJI",] -^)?+UNR-GIJ,7
M=#5[1H9K6:@L,30(%'82-CX$2RWP-(G+99;/7<ZA&AJV@]W),L]R32/W/' @
M;+%.LW-KC$PJI7QS=RO$.1BRUL8$E0:6%R.N6S[*K]AA$+8]4Z/QJ'U>BV_\
M2\C<3QX2>CUESCV"%WW,K8P&B2$X4<^.N!1*(1N'9_LR2M\\SO[1Q-<@:N?Z
MD^?E\8N%" >2(L$:VT2#C#K,O(Q!',4']TJZ99M8N24[-O<7[4M?A+;6J%*9
MYXCB^_7H8NONE,?7;RJ&[>D%7#"[.S9Y=R3YYB;?+>Z8N_)U5RCF@V],)C:P
M_F-478K*15;9P\8W*<5ENQL(<*)J7TUB-A3D89E%MZ+#N  NTE."I_.-,]I[
M8>OZ0Q.-@4=2+SRY&'C.</*#XG&=WS[YUIYS,2"WV/29%,6(&H\98&^+?0S[
MT9.G&Y,]WL3)KM=.2>L4OWPL4>3(9#ZZ01'F+#W:1'( ^/J G!;B,A4V7+B
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M;:9[936.6;2 #_L,N!!Z>\!-^H&UABEEXWV7@,+(+8T'4Q-1E?-F:_NA>Q]
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M"J&VX$H80;5C<V;-DN@VB[3<QUE:.&-<;7^:_,<MMZ=78X,NJ&S4O]^E\JS
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MQQ=J?[IF?WO%QUJOME7#\4D,2Z-/IUR<!T<"YU+CV$PS8MRG7KNO54"& 08
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M-#71^9R-"N+N5/9V96C"LS[#M,*'ZX4[@7\H>R =M!,6(S],_$R2^1QT.&5
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MYGAK?\+L6=)D[HS'[.DM(62LWY05K5>I[]W3KQ(/IEAO+9TOW"H;0G/](W%
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M6 NRPOA2Z?@"*3AO'3R%?%P]P!@F8'P@3TK,T]2V<>6BKJ845#H_[?HJB/^
MAW8FOK#7DX">AQ=*L$_V%=O<KI3[,2-XOA_Y1 S\NTF!^)I:IB7*6(?Z>[W
M2.19&-=7#,D&?U:S_;Q.GY_VP95&?^HT^Z4E]Z<J@$".:K9AX"28Z#"$=@5-
M$MMPOU+TB_HTGO>6S)QJM9N^]RWS!/GEL_B<@(_]BBN2G4H>-5MB*9NN(72
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M/X=H+:9F^%&?;[!)/]Y*6'J<5GX0V:QL(SO\9(>)ZJ^TMQ2+7K091:P-@:F
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MYO$ECNO1$ZD$@*;DB.DM0=>$YG,4#5)BJ-!FO 83#LDQJZ=<T%F5-S7S,V]
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M-0#\/]A[[[BFNG5==*HHBB)%!)$2E2H(*%6EY+/01(R@@M2H2"\1 6DA05!
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M&M5TH] [J<Z?];L,&,*U^B;V7>!"-(TOKA97PM;/$.S_B*HE<"=J6:GJ>UM
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MS),O/_XC O6_\-KWE\S?K'T<NTW<9M2 J%X2B*_P.ZR_U2<[J< H$UA0Q\^
M:?Q%# -"/8$*(%=ZW^\6DM09>FL1X.4#WBSA7;-\#YY^ #;/MF "R*P%4*O4
MK#>->U:%";P*GIQ:$6HL2#I@DP+[,;5Y<O<G- Y-O('>.0ZW8@(85Y9>NUZ&
MZ;^ZY4Q'W?0M9IS?9831GI' M,_I(.HIEGVX21!!-..G0L/!,RK<+.K3;,\$
M/E.6R%IE#L@R8T;YS7X,=0::,'<&(TW/ CO"V!EMR.,S)/N(S^]CIJF:\:D.
M!RS'.JZ=NUQ[QI,M7AQ@[P*98EH[*?+LH5ZY"1-VY3%M4J'YC%%[L9R=<V7(
M\[UJ%>=4P4N)7V5^-HH75Y10D18*JI[WPN.\YS%T!*PEGS7^P<OT+(8:%")5
M!PHRV3ZMD#C])N%V5=\QR/RV='=#-INP8J1=\B1Z+SGL-2UY"J1!83+?:;@&
M(6!QI$#^B9*9N<#KNT5-G_N>_F#+$3OVA^81S!<F8(,;JA^W)2R3QET5ZYNJ
M!8FI3>\SAP='Y\L_9W"^Z[H3D_-NY?V['PIEE;5OAXM29BNIY'&6_@V!:_UF
MG%JJ!BC.^<,4)M!L+5D2(#,*UR(X8TO->ILZ;&_G5?<_RGD=O?QT'_ZVY4F5
MJ\^VTW*]</9NH_X6+9V<4D9-'MLF43O>C(JTLWN!D$S@[5PC89?< ]Z43>ID
M#3&!;-DA8ABU6,*NJ@R:<=C?=X;2-MF8?-+$7^B(*KIJ_>=%\*[ H@P715Z
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M0)D89E?G5^/,Y8:3W3I^NW42=X:++DL3%ODL'ZPX[RJ70+T7^D3;F(#0528
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M*_CND?>554U'U?@I_:KHCO#L#*<8YR3-Z*S]Y==\V;QYO@8>XE@\=2!(YUF
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M[Q#*<W_T-$0Y:M^-?7&.AY6HO^8TPG>MP\\KO) Y^E1M3;]]E:6I,4KT="V
MXD_^0'GL/P[ALW9Z<5I[A#BB,72SL/G9::GC'Y5CRJ?$T GKF-OIGXV,36P,
MF^_[8I8WB%PL"ET$J:-R[:,\V3#&_;XPF^0SVY<5;1#TN^S%P8PH 4$ID +$
M?)!22ZRX1>DC=C9HL>/E%>0\4Y\/#(VT9Y>+SV<&OY/_^I$T:OA"^5Y.5;I[
M6FX>O)0/_&)-Y&J:"E6>T3IV@AY+$\REV->=#BG*?>@D,&<4;^CF8_M.ST:/
M^/ERAI#[J<4C/S7P7WPB;@0WC(%Z-_VS8]5=K_=;Z%OS'G@5PW')^)I@[>46
ME0SMJ^@J0\C]OFH3[#0W?;C2<Q&^195A-&@=I+]UJ]1U'U^Q:+@:MY3+YBUF
M619T-^C<S O?N\V1.U$I<Q\7K-<*'/R\WQ3[MTN9_H=Y6D3"\GKOQ7F8Q*>C
MRE=1;VB^+-LIA+)ORO#!FHLK37N<OFRU4BRB#X_5_UDWHJO:O9RY;\#4FPC>
M<R]3&]?*=_SJB#B=W'":GL$>_("%[4/3;UZR7=79WU!PF.URY,5F-M.>8B/^
M">(\KR43X#85(]V84 AF*/O<F:JW5B72T6'%9M%3L!<I&8\"23_.9CP[4O_I
MF.(SYX+TK"P).V,W^7G*G2G&83R1W_49(6L[TG4%WLX$!MT7WR;#[5=M/RI.
M87=_4?$?X;>90) #38 20:366Q\M+>K3$/HTKW;"JBY-.$T\?M;LP<DQ7ZEP
MD_??PO=):=A<!KCRI#\MB9I^DY/XQ<)/)=DZA' IT?MUL>O^GS/QG;>^AS0)
MI 2+B>OQ&' #<J\%:PYHOG8'">'LUD*80+$)ZG@JZ4!=?]+Z\-PR_K:Y4+++
ME)9ERX->WD/WA86/!5LG:E]AD+":UM.U_LH9G+Q:QV 4,5!-?"^C5P4M]%5H
M.R#,Z<68";@BSA4'(EZ@XGMQ!W!VZ!!"472,%GHOR)H\=*JL>:A@6P-O>GEA
MUO"L? WOL[(AQ6<'_;SX>I-,_OCMMCQ5?1$N_[M:!:Y$XGJYU1;19B5E6:J*
M57)<?7/U_)F9HWG2&M[W+*'+%519'PC9@&B7/8$^['2Z(^MQ#C15QTRE;"+>
MZ&R46-V'R4C7!IL<*?$-ZS9M:6I^284)X@UA0V@[%O(Y.PWN0$<C0(BN:E&4
M-HD)A+C"KSD>%<#&7N_N=&L6O'3[M972R]2O^VK8SU7?J6(]@XLTCO)>T5DY
MYR;RLR(W_K>+)DT2H-&#*XFD+1<J?NS=_9S,U?#GKF9IZD0!LB[E 56E68ER
MHNZ;XVY4G:_'(EY1LWTZK\FT_?FMW#.\;TJ>*X5O*7#[!-\A%D3XYRUN?UL8
MLDW1<8[("QF*^;BHSP2NY'-D%#B\$)7H7O-,-?ZMOJ)*YL?^*/U@*QX5(@CI
M/8U/3C) P[I:1W+7W>X189'*Z#!1_AX-[4]6^>2XG#HI;.HUJU:?6O:WU]BX
M?=EX+!Z0[)>'\ZT9OW B)80@+;'XF\39PF=XQLG*'V(V;ATG?!F[.9;(3KV6
M XH>Y%0OFXM+7,;=WA%]6@M,P 1AK\J/PV;[RNH[X.UP^?O#I0O$OOW/D.#_
MG2[9OW:OV))9)PS),FXF*U /2S$BXG]<(JSV;%XA@>IB-DKXC*#[X>/_,V]I
MR:-\_WCIJ UV&I\L0Z^:1=ALV,![ <T0_"\P\2YJ1^RT CV2>X]0M_LD$F@1
M>7X@][UW;<:/<$TX21;'5G95IA>[8NKDD7XC=CTZ/9"_A!P+%G<7]Y#WPI";
M7/_E$^D3[LF&0H;@O\0A_S,^"/T$)D*@.^=V]TX D'L' / 53!>2(H6CQ43]
MCP. BM<LHORD2G"'*QS&N%3&!*)!B9M;K*7Z#FKZA]Q8V$EK##W[!@A5P(N+
M+AF+2WR(ZY?J-=VZ5.!0:BW1[<4I9AQHY8@GKYN/U#S,B94R+BACXWFK-SY;
M_0Q$-.0:S-43FP@H0"Z?#V "S8OG&^MP)?Z.%#6&W?<DSW=7/Q,(L'6M2.(:
M+6(72O=K9 (?.;IS5E:F2K#AAQ.>&N7<M)P#CNTS-NE)4$Y)N)>48GDF??<,
MBRYR[H^)WJ=<;.SOP#X]%RV/<R10SH/?J(B(_5$$"P4=^E01.]#I+EOOZA,V
M8Y;YC"W!Y1GB)E2:>U^M4-X\+ A,U <%L0S[3]ARTGTU),]6\5"[ZI=9(17W
MWJQB^X.0;5M'V97B!U$/'ES_$GG0*/#@U12Y.^=U$9@\$=T5\>'A]/E(+G;*
M@7H0EV=W-L6B/@D2LLQNX"K9*ON0":Q]Z.4@I(>[8LO474[.$/C MDS@%4'P
M4R+<EH7,U_NS$U^H;)A?, WTDVOPMX76OO:+\JW&4G5I\D1"-'NP"E1T7E54
M5JG11=DYHM<B[D+%;<=O*3/8 O: NL^MACIX6ZM&5=1K+65DK9#+"@PW<8XB
M-F71R>G,_SL@?=B@7])#^/E^CATU=Y2BW(^IYV4=6H_[JQ3(0A02:7)XTI50
M"T:)"I896C??3KC;0S/P!/Q_I/N\_12S+WJ.[L0@'=>Y2/TP'=!M*/VUM?&:
M[;Q[RY?/(\IC5Q=VP FT_7;OM@:WZ6",4:^1]MG7?$9_B$))>5.EB42__C%!
M.<E>+_\?@ROY"3,H8,H#]SBMYL3F$E0$;I+<5"WIK"#@4RYX!G7//KKI"GL\
MFW/PJ\CUW(UC)[:+TOSP!#]TT*:<LV5QWQ:G_-BV49%A_(:E)!.0M@=+:QQ(
MHW16P5>HSY'-H:^02_F=Z]'?$RKLMLO2^P9= @X2UQ@L( ]!+@LZ,X'T^/+3
M<]4B3. GF-A)#Y9#;AKC;UBI:*DM>O10!#Z:_@25\'_*I2Q--H?2>-Q^WWB$
M.?9H?-EQYM%1M-47TX6X):A%MYF9AR19!^NH7)X""4$<\U&J*]<P#\"&>E)?
M/QC:&!T6_]WJ'V_'EK+K*1*(248Z$D)5P1P:VA\IV77!5,%5NR>/2M5-SL<=
M$V%_=&U&5]@?/Y @P&-^37RCY6W]Z01?\4=?OAS2%]_<7ZU *9R,P U!)DL3
M)SJ/Y1EF#L9'GV\YJR?N6X1-#P1$?X@,\_G_3O'U/NA0N^$28.0\E8.?<-&2
M+[^;2W]7'OFFR[[U^'V$ABF+):)>GJ.T3\DAFZSE(YURC]5\/;$A'*<*$?MT
M_RY@G8*Z1<:A5-U][,G^_5_E[K3Y6TC+B75:I>MU(=YW,)HNBB,YY*>--O2_
M&%00HR^9E%F9_?0TAQ-V!!=SKRODX:>CL9/V-="CE*FZ;9/X(<WHQ-S,IT/6
M9L.9MZ/96X]W*69_8L='._]BP2E4Q,K2;$GT."XF<7.#'/' (S;,PN7-)F<P
MBAP5H 05HNUS?TR%+)%)J3$MVR17D9JX%V 2X?=G-$G83YD)[)_+UW)K1TAI
M4Y_XM)*I][MH1[/U:JQ<?Y1%<>TVV0_S@ER"W%<U90<UCA+5ZK0XB:.E29Z:
MX+L_UFO**BI+]=/LFW_I/WJFU.W'L;,V:2/_B?K$\:*>M[CWD)]-SXP.PZZZ
M*>O.6%MR!9*X']F O9DP"7<E==8N$=DG35Y.=G+D%GXOC\FDRIPH%-';$ ,M
M7\5","ZF^'*MW./8S$$GU6:OJI'S&O;T^+OUFRKCH-)>Z;%]73-B<X8& /44
M&MQBF@UG+U-#LL,EQ%0G+Q@I,59-05E7D?6QRTQ Y5G2]B05\W-@S>&O5&19
MNT<3:  [.[R<]H)/=4T)!G4Y#<S/%R@Q^*7H-UC*1XVUKKJT"Y#=4!:8PQA-
M@>I792.9P.LW3. N$Z!%,8&!;B9P] 3C$Q/8$6("A1^/=X1/@2>>('O!3$ ,
M259&UC4P@1PD0V<OE]^!HO0?G92'Z"TN)M!"H$>!B(7@11 3B,%13P/+?X[[
MY[A_CON_];AM.)>UEQOP^Q1OT:I/Q?$,16*BJX%!_ ABW?"'?9CWSX&ON!7I
M+95^%@D1EJO6@DOWP*_OU\Z[P0C]8O&Q)GJ!#R:C^"SJ[=*\D,BU@KA_.TLH
MR$E4,HY\AYY%:"C]5H*N!PNWUC&Z]&ZK)MC'[@R_JB]T9]2W '7NRQ-,8%A:
M0Y:2X0WJ!VOB$Z?Q3,#V:Z'L1'PL'33?625=<%Y+_$)80?S9[I ;%W;8_.A#
MWO]F"2IM^O^++OZ?X_XY[I_C_CGN?X-Q__J@!LL$_J]!5&K@3B0H>>YU_B.J
M0DSI%L@[L2)=[U*7'_Z0.GT($:HE1C'6,/__Y,61_WD,Z?"PUJ.H;4/@Q<@<
M*,KL'W?K0#$XCC(!<7O6$GRC@7<A'M [IK_0Q+O@'3%S-7HH2WG]]D\B;G3N
M\/=O:A&"P-,9M4C4IOU<'Q]]+[W0P3+ZE/N[>^0DU21Y 4%ML&.&8_K$/Z?A
M_>X1)L"VRP1BE;ZR'BT"1I<JQ72N?,;]@1M'H]=U2M!4KG8FD$GNVZ+)LI9>
M8KZSI=(828J&T)[1.C_O)5Y*82C_W=5H)PF$;6(.SWN7=Y3E#"V<UH[4<4Y>
M&C21?GRM+_%#('M_<1XI@<&Q335<3+NT5\2((^%6=2S7,1_7<W%&09)GW=92
M;Z+!V_'*3P'12,M=F]-Q[DZ71IF *:-\\'2=C&G<(-)$DSH%H_$'US!.],HK
M$T(8)RM)Q3&7("O..U&O$Z?6="K,]0_Y[+Q"-.#;=O?J1]R;JO[Z\.& C^[-
MVS3<TQ[;F,!-2;,44(MI&VLUP':=;T#%=H7_<I2--U\HK2TK'_DV-#R7G:C\
MVDA_^G7'Y+Z:RYBOGCC*.7S3<$NL 8[71PPR4G:I9&LD.KMKI71XYU)^57)X
M9>1.;VK,G"$3.&A*SS)[(WJEQ"@M^$9A#4L85 9\D(RC9TE+>F(KI6.\> $-
M.M8@YKAF96[<CC?++!)&D_P9H1 V)D"@=C)TOY@GT'B@4U9?;5?@D''_D6/+
M5*^A*UK!J@.TEG0R_QR.)KA7EXD":1#HWT4VX Z-^MS[)1-JVCVK5MH*,?$)
M_QJ604=?I)K.AP;#'3_2KA-'46%PI;S!I7*)==_X[7[%-T_>VK.S>;-QZ]Z]
MQAX#[8 VHP8ADZCE02^W-"UB?E.<O>>LNNLM0=[)WR\$U4T>_KS;L/^%JM"!
MRYAT)C#^#EG<D4O$3#6&UB\M-<?5B5Y*6&[JUY60PY2B)9^*['O.YAI=D0#V
M-.DM<_;/0Z155?G[,@3OSZ:7I1&R/;:/ATM_-;S^5[6QN9F $VK'0 5+C[)F
M(4:7G"QY_6\;9;XQ@;7B .3]^TQ@U-D/A'UGI*U_]O\\0H3*(T;0I(D)T.Z2
M!RT#D[,TTSD<Q]#0$&,"5F[(=U[O[Z1]?CNZJS2O$(I<A]"4F,"C-BB=KZ0+
MK_GOCG4R29TL")PX2D1@"NC)*^A!\HH[&:EDGUAL+_3-?:NV(#Q?QQCVJRGV
M>:3QNII3?.'701^D05EOB>R'Y677MS\OK*?(Y# !375\&IR3,LR"T#2\:3)5
M@ JB:DX9XIPV:.T3T8C)*:& 77PGN@3;*(3BIORL/ ]3TLU8N%WMETTK28F,
MU0WX.,YEV6]<:1X^FB"DK]8M '<GJ3="B[/#4*\JA9SE,*'U=J8NF ^!3.!K
M:N@HY.;:ZC/V+B9P&''<@?5S$UQD]M(KMV-?1:_(LW7T*FKUXS)8(XG8&0HN
MSJ['A&@)A^K_AJM_+0 <5\TOP]O>7&HKW "?[?(\V<L$ZEU]#!B!27CZ!@O,
MA?.5@XH1C.DE*=^ Y@Q$5Q(\*:$6??+&J0M+SG./_,3RT-V&S\"%;I]$FNLU
M=;IX9H<7W<S\)S*N<\TC9<@!8G>+2'/!*S"-T-,(S-/OI^R:UN1O4O.#\>R%
MF!B:YE=GY'=H@S-5[DZ=\]JQ1<Z7XC:BGDYW?HI)12T>.:B_-AQ\#_3\>61Q
M.>V>T/:$H&X&[F?&RFG*&MGY'@;1;2W6=U80^Z 2[>VB\5%A@RZ;18FB0A>2
ML*%2/1H@FQRM/+^T6YT>O!]#O=ERCAF -5YT:FP6M)$M*+K>Q+DZ_-5XS)%@
ML[[PHC^F9H,D.OI@.N*QNF[L1G=2=T;&?JILOR+\^(AU!?]81T="27<8_>;\
MG]S7K\DUOII(_MSUX B-(XG*6WF47$ Q0$X9BC8W7!7F<L]SO!:O]U@P5D^_
MX[ZWS/-G5]2CGO@(D5N[)XB;J@S9;SA#NU&-,HFB-U928E$#%S@*5Z_:XQY?
M=(Z+^P);M4G:WBE7QNU'#C^GBQ&]0[_^I"_CVZ5!RYE/07V-?FNU 5J&"A/@
MUW)9!Y]:794\LR64\ )LOA-KVH]SAH2;Q$E$EHKR]>CIO)C6YG\^Z!:BVWRM
M)[HFB:IXRGCLU.2;Z[JG7S^P#MP7*//)IY:PPM*@') D1_EP B+CWR9[/&D>
MH/I[T7##O%YI<U3\,6I6VRP]\#SRR0(3V)A@"0G"E";-:.QA JPE9- PE =#
MTOL3R/)H)J#%C]N>0=:AEJW #+@<<JV595!8_=GWS[Y_]OWOTO>'0C3TP":4
M126.E:"/=L)@]N[NH$1;G\) UU73#^B7J643@=.YCYL\K-]K.][)S#6\<[R=
MY[).IJ5D0>(Z=EF7)$+3GZ!;3. B/)=\-&S'$ZC'TO5Z*\GSC2>C=24XEJ5^
M2"/#JU/^[1Q,6YA R?:K$F@P@;=2C42MXT>)]_-F8=Z<#8UQ=_LCRJSY$V3T
MQ$!8V+1==1X1&K&) _E ]$FB$<^QYM;9;@FJZ_N52D)>?&,/89=IZ^6^-FV:
M%9TMN#ZYH/#"O^#W(N[!M"_E2JM _7W$INH&2G=7<>WO+%9E7,]_A<?T9]\_
M^_[9]\^^_QWZ5K:1@WI67#6$GA(M;AQ-WCR8$7F^.4%*F&/KRS_'1ZC!/?/2
M%YV(T](U#TX=(&9W_^,)6G[AB'=%$9SS!#(HE GHKSHO?-E!DQE,(/9*!G+
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MX4Z4S^T8@:RM]PL&5+@P+SAHXW09"]LIL*BG]F4 OV.9)Y_+V_( ]_?A3QB
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MDP'R("TZBYH\ODPE*/JAV4!@VCLTXS;>2#K;V/AKYJ$5N#0;('V, Y<LD]E
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M[F'L?;!F>X:9T:?5F;?#&']P<V*D+B7I1:1F('BZ];AI3FW8MP&\[OQJPOL
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MK?S88,T=9C(55CS2)#&[P/BT-IXWI\X=8,N_^Z%CKKS4BBJVOK3QPP!HKM9
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MZ)8I^13YC^Z@%3G-ZTZ05L<2Q2$:,Z_6_GKM\>(2EH^9IR'D?UF+65:UF7&
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M2-7"M'K8DA753,<1RGL8('YT,H6HR6LZU3CXA[8Q_]\^$!2*(ZI9JATWKRA
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M,.7@9_C2I0\X,/T3JKBK;$&94'0I]FJ[.'HAH2N-NRC,_B+ONY5HSV6)2S$
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M7&D/-2;_K]J\^R,*G^WUTH N#@W)2@FE!:__EQ_L5Y/J/*8#D$)YX":F]%H
MB::#I2??!='J-U-C^:@*T\RZUC*J]_,P?%9?,LBP:Q6E*+G1H:_VU@B6DF=L
MK*S^34MF)4%CZ(V]" T&Z 8EBL;?]5K;3K>@[M.(+6",A/<(&P9( TU]%L0
M!:?2!:#AN&D%!BCF#0-$Y*LS@*%I#MR Y8.'6EZ1NB O:%-P!H@CLP&V*@A
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M>[&!YH.7/TW'&BO'/[$GQ7ZSU!<I*=[9_NED'I^8IJ!,'0$$BM&7:#>UQE]
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M'WVW'@2@$K<;$]<8H$<H:_1>B=<* RT%E@-V2S*VV\Z+\3]#AD>_1=]17)M
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M/R3M#TG[0]+^^Y*6G58(&7\Q@R8),"5MB]6<E2#E!N#)3W9 YN4%Z"$)6&M
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MV0J ]IV0AD*#^)*GB=VPE[CI>Q-@FWWYBX!!(3,_@ E##%"Q/(T/S8W"KS%
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M"= ]?H\0)VA/,:EMKIF51*ZPP^$73ZJ)&*0%[/Q8O/B9_Y@WYS4_SL&'5M*
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M?L%G6"?9]Y--\C>4TU!S5-RI!<(TM!MV%)FOM7UEM M5M%BQ(3& >B@JU4G
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MU]HBQU5SY8KTFB4G(AC=3I6">@C[:$C2ILK8310VDN1<#?NM.T4HMT!];X]
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M!-?J?FXV\F[+$K<?[51S&%B!BJ_4SB>=,(@-AK;9XC/.^[U<KU7QS?J/^]8
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MH#@NGE3C,-)+7-^ZH01_/6$7O7["[@WY> 80KV\T05B/J#L<-^1 Q3" -FH
MK?HWY+4^B 7KBR)3P<4(M+P.Q ",6AG A.;*I,AK/%)U])\.Z;>!0$NBWY9M
M+9 FS+8OGB C*I\NY'+HH3:BA_[(YM3R /RW;W&&ORDI^3,RQZOEP30X+8"
M B)*34I2ED-@1GZH#JH\\G5+ 3O"MKIK&$9G:W&#]>"HU6F:Q@?JK7Y]F-"#
M7)^@AX7\??(=,*=?KP+V/\WKE<+B['[*3\H+SCW<)]]ZYT_OMH9<=MA'4EFA
M/UPO-J-GU!QC,][26P>="9RC;L6O1[9?(!%AYK4(5DG54YHE0-(SNMYDCIX:
M>!GQ^->B/EA#S_@JA*I?"MY@:7D<V/DFF@;KO;</II\G?T:%S#.GUIIAD4>Q
M>?U)UL3YN>TIE&+HVUD]FEIA#]N ON+N7OH#>KXRRGD(U:LP')%I(7;2)5JP
MBWSVH:]ZS"Y?YDQ^2W [C9/^#-J54(?#QFXC[5_(37N;B<D<T$$0+K.;:+DP
M@-S,?6QWQ?:I#4MOC[3QG"FE2U (F3EO$C\Z*Q%FM3"N=,5L7F)&!>(Q8E^Z
MH%\%_XZND@O7[X0VO.W5$K^0.2[X9 ?LGS<>*M6^! ON#K7>5POJ=J(=Z;H9
M<+ PHI-8\(0!%.^_*R.]#'0O;AI";:" 1-S#10(K!:65URHKH7IP1^Z+9+LS
MFPIGFW2%0K0$0[7D\&:[\WM/C( YH(3J =)L]M# ;4\ITW:I'!7S3J_HQ@OY
M'AZ/31,_A6PZ,N[.2=T,._$4>KXS*LC$LZ42SS>Y^[;JD38[3.N;R<@=40YI
M>[:WUM?-:?&?_.1N(:R<)-P/#KU&9"/]5%4P+=#A3DGQ@[I<;E;G<1?;G-5^
M.(PZPHK=8$\N2MF1X*5I_QK/S0"NSW&;4?8LIU.,DOLT6PN[9VQ'^^[7*#T6
M1 1H=EXVII[-8)/,H[F (-'Q^L$&'2.L-L2;,;6(C%L3>9TM_E^?5L4<2#M'
M?U>VAW:0$A6/1I*-_'$Z9/NW=M"'&W3<W<E*=^6"GO>9S\K%=VK9'W4R;T7!
MY+'B''B=[\9R:.L]+(_;;MG(NEB$_TMYH:[#'1*N#EM#[C ]K@D8]3K]KMG1
M7& (I(A9!9?MH-SOKP2Y,7MNSU/R=;U.+W<_S5E-?Q\DILV4B4[]X7/'$ZUZ
MO8OGS^K=-M%26#"36 L_GBLXDFI"Q9E"?L5@Q=5TV7H&<'-;7-D\U'NX^*;X
MIANNT0H18@S MAKWPH5 .B>F1)7JP1+[)C=TOC%MN&8T>="F(0##M!][76S8
M\T8E ^!C $/)((<L;ZEKE0*X ]HU82_HG\Y9?83WAD=MFVA,4L^.5^&G1&I=
M1F?I[)25D32%Y=/T'Y<&;E1U25?8$,WXE23XFX+KL]!/3'V7-D1M6P+: ]WN
M<UK(I4:[3-U,6RGS!F<XK=M]6PWQ,6!$4:PTU1VL.+U(Z$U7(!EYM['M0E\H
M#F(3YK_)<\%Q7KG<<^+\R<NE6RW+11$-L(N T;]+\0AB+ULP*N?&)YO8PQU"
M7,NQ_)T[5]@JC!TVC!RX8;NOTFO33GDV+[PE#&1\SE.DR('ZE*@1MLU@92OY
MW&SWWGR>B*1E1[M[TR;:H:S'')Z,?5:V:Q!XSKX,TI"2<]#C)B3E(@(ZD_PV
M7#;9? %<E0IE ,BNKFA<B3V+IE3I&@.(I/%":5X<P!9@7(RESESQHRHW1>,2
M&>F_I.W)>ZK]FLR ^94\3@Z7)?'S@%ZH%K!1DY/L.NW! #8KXI:3*1\<ADZH
M[J\CAD?4#B_,3*7QOE9^MW,@]I1SB]DGHR8DR9BMC_<2F;G&ANUAGL*QDT3Z
MQD'>F5,<MBPQ#1?O.RQMVR-)<.?MRTK]O)DC/X(03""N]!?&\YN$F,7AB9#-
MVL=LLL"(0DT+112L3BKC1\OFX.!YW39M:2R5+JEUZ585.GLPB_[EN)!$1ZSZ
M>9<Y5)M4K]^R,0DUG3+$09I[9(>>:E@N2TC])$(]_TH$X=YBP:UTX<[+V#>A
MH#1F,TQB%Q&]8\3T\"'\-AIK7NZ[[!\L"U0%J[O#=BFTB+'H1O5@RZ_"2&^1
MC8(Q(]#9GX&DMTB:OQG_C"!19ZYX$M8O=S T3W5)/4%%23(08L/1]L+N6B1#
MGOZ\3"J_KL4;PT'Q6KO0RGLES\8G(:TN]F!UR+,%^?2Y0ER18O>;CO>2NQTC
MQ@\*Z8LZ]C[BT-/_)S&WCHC=94)@9<EZZ2Q_UV6_?N6658?/MKW9]+#GLW0Q
MT=QKZCN=7#3]M4XZ:=_(?UVB ?%<A.);:+$,8.8>6'46["B$P06!GEX YKS#
MM5"0\R>@7(U5O$Q_8@8[ _#]D0$D.3$ 83S5#$%JPRU)@J,K#, FCJJ]C<8
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MXOEQ_,(2R # /0S@<<:;;$5\U@)A%=85DOP='"E;69L!G)2B/>!:3PBAB;?
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MH_E,]A"^@.[#.%(K<A=^_"H#:! #(06-;^7OSH7GXEOQ8&O#&D5D6]LZ!:Y
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MB&ITFW>ZJT..9>%YN$56'ARH<8.7N_;?4>BJB(5%R]JGH \U#T5I!A&-0X&
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M?-03_L_J"1__:%H73:_*2C\8"4PX\8+UQ_#,U0BF-J*]&]9W42XH^CHD/1R
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MXI]74+O@W_Z"Y7_+\ZLVZ*_:H+]J@_[@]_JIVJ!+LXD*-BP%/?0H!7B=N^R
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MDPE,-F#'!F@+LI"B!O.0K"<;&&(8LP%" TC)1;8*<;G0.%H3<7(-*.UE L1
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ME-W(=]>7M8?#NI7Z)-^]FGINC&,#OU^9"/('!<1\/\R<T# GYT-9N7F_T;,
ME^I_PR6+&7BP9C$G=.D/-9C[.34@5]B,]$BS@;+S'/\K6UE^VKEQJ=I(PM+C
MWI51G$JH"ZH?:AT<.!N[DBX^"S37:UYY\4"Y$'4VE;GF^A6*X6CSMT-G;^N%
MWZ#K_QDE/C:K^YL>K$C\98;^_S9#_^-'?_DY5^JJY;]_@"WN.BS[) KQJ6'V
MGGV$;6KX1#C=^^:X3^S*M^H''F>GN.84.GF67S&7U.X>>UMODB]YZH7XIS_8
M/.B#0U&/EOL%S7J6[D$C<],R8GAYV/TK\C?W*Y[/W]R0M'9#E6%0"'%MM&T5
MI[!5:KBJ8W2!.,27^HH-J$S"TY/YCY+C]N_ >C<"8P*DA]-[?C,24>*PE7!0
M>Z#+E#(_!+EUP>^P_T>M?N(Y6$H:2(/?2Y'_IUZ?L9-J!/M,1G SW5,0 P7M
MQ=(OY-HP:; V+B2R =]_MV41>A8A/S13G-F$'"KH85$7KSCXI_5I]YO%+6MF
MN?3_M!>#S<:QL/;^?3OD%.?Z^2F8M;GC?TO*^#]&\O ?CL*_F[5,OA'DLG:6
M#<D_+5%M EYS63-+!N2?UO?_U7$U7>[.J6+*XLU<=4]E-:;P')&>H#G8/I)Q
M.6@9O&[G16J*[E(ZAD]]RZ_S?(]THQ99)?S6+8^GP]@_P<\ZO_Z7\;S_)YM9
MZH_/(/R^R0]H6U?H:"/I V'CIH,UXIQ.TUF]R9^&E*\$W"8E5F7N.'DL7;+A
MSF,_Y0U_N%SLO__;CG%E [_VS"]=]!/CJAH<_7[$1=<MWM1,Z?RT>NK)V4H^
MN\+F/W=(N_Q$L(ZHC+Q"TCJ=U7R9<7H#Z7C>MYN?N5\G[O3%1Y*$<E,=0J\>
MD!<P2!24ZNXYMI<-K"*LLE R.R>E>[W0NX;7^"N._)X):[#C!.;+,'B/P?.+
M\B0,PV@@A ?N@!&SAPUL"5.&P4$S@2S!!J;3I]A *QHQK36)8@;-=/'-BC,E
M"1O!KS#<V"OVC_UHW.>TL(8-#)028#I!67^G?IX%(X>5,-&0XIK#<3"#&?"K
M1-$T-??U\(#ABWMF8;!3Z0O2WR/[C.BFT"-P_J#L;X#[I-D,!.JS@<_Q;*"J
MA&53!/^N\#O\981* ^HD6)Q$SF:MA*6ZBEK4%D88F V]04'GM/ZM'.D2P3^P
M@4MDL%(V!YS6J'?^HXX;@J5B]<BA.5GF!I"9C/S5X_]5/5[N[4M9UH6.KTSD
ME;X\C:RF-PSE38,G\[Y]+%WQ.DWE(?Y3;_>*&KJ;PL5QH[..&^0LQD(>+)3)
MEE)F;DQQ!98<E8\1G<S68GZ+4>,UGM(H_2MQ^C_M3Q7&M%%Y8$2_)5^:Q*?;
M);]"<07SEA8!$8*M*OS8Y-37XLPP[7#A,>T\G:Y>\O8"\'A>H!\CAY;.HF?V
M?G-^)69J_Z6G/CWG2I#00^YZAB@/%U$EZ;.R-$DW +7FAJXWV,<34;IM"X]T
MI$-<[D5BPRX1FEM?SJXNB1/3946TW/G)(U*9"NWUW],Z,>T" Q=0G+.L0S=G
MIO M'K1O FF6\Z',,0(+YWP$C22[E&Q+WUMITC&Q*3[[9>UNUG9C[^O(]<KW
M*4T5AR%ANJ?C@@[647W_@,%6N54X227?_6^BDCM9;N[60K:;;(7L>!16&!E>
M!HZN,.*KYG?OR)&CQ:9\/)6PY +G/WJ297>Y%M?W37DHGR!%JDL,-LUJJ_;K
M?PIL,8IS[0N(O?S(9XV/P<,S.R8EK<5X!ZAJZC*W]0+'NZ(+ 3;@W<+<P@;>
MFI(XH(W)X+P<ENZ.*N):X"O<#?;F5L"+3M)7%290A7SD*>8VK=Z]V>AG%I?H
M)264@T6YS<Z?HA1HPNL'G"JUW4%R/2G^2:&<JTY':?<&XCA3+=KL9O8%1YU6
M@"<P=JW&CAWJ*[SN\YFE$L5?6508J_$:/O\MLL10,>R9+37=W%Q[9V;&/JL7
MMJ^%A1\%U^@"*SI;C1^C[=^B3Y$GL@KZ4BYTF#8XFJAY0+6TDL,5U]MBG*_D
M7'04$K+B.?*&,_</!PGODP\;VC7[V< 3D/I9]Q%(3L4TY)EG-8#9A.S#;""5
M&Z)]81P<(4S.O^Y/B%9EG6G$EDD3UBR\U>IZG$"%L1Q*9*)]\:H\/@IA,1!F
M#3QN7D<HK8_[ZNDPAR6'@78CY6Q@ MF!O#I-<*U,=_HV4-]5=_OH+#Y%62H5
M+-;N<T=<G,;4LM[:</:$$,"PP=WN>1\.^?<K\;YE?,FIL)J8(3)?:G6&/\F&
M&;8TLE;@N9[:@;\]64)J$-GN#6W@)$]1M2B%$7U._,/=XLUW-[)4[NZ+;9!V
M^.ZCWJBY?9-5U*&\@]D M\<1O-"/R^:=G+ZQVED9F?J%'!J+C[R!#139%7*D
M VC9_KG5<T?OON" =(PST%QLP,,7S46?3S6Y;H+PC6M$G[IWKV/$9"[=1.N0
M\SILS;F!*&ZSM''.Z]'?HP_=UFO!:>FI\8G]FUHP1KY''R=W/R75"A;3VKM"
M"3YSCT0NVFH?8&@7E_M/CFT?LO,\<O7@ZTT#CS2>W8_\8SUC_!)]DQ4'"6)J
MJ0^,>DI1W# 4/.;TOE+T@A-5, *O\&QER1;U@<L'Q@(S7C]W$= QW853NP.M
MH QZ4DX5Y>KZ,0^YL^+?V'W8&'&,L/=,?EOE[L.5?)<>[%JW-G?#N]?FKR02
MI5(\_ 8@";0AF5"$6C6Z2Y82E<@*Z.M8M3TGGZ&</MX])H .DCI2+1>X8NPB
M&UC-!J[+ E"#Q<X"(F;76 _YF>T%%_4J-VQ:I^F-E\(YYNGJ_AAC@V<'ZTVT
MN@MR'17C(D8?B/UM>MBX^@)(UM/UHO5D!-'%=_F2@DAODU2QU/*,+ ;7ZYQJ
M)X8Z"R<Q=,T]P6*V12&O8V'^,>WR(!5%'';7^LTYB"Y@:(-%IU2%H"H,\B/9
M^ZDSBM?N:&C7DP=^6M'M'5KK KJ^KK3ZY#]9X]"Q721\P:YJ1#:Y-\?_0.#U
M5C7.YI5RA^:_%@S/I&2M=_OXW6V*Y3XP^W<%N!F_@AH0B'P5QB'F@0)*C]_^
MN6,LX497A^Z=POL&/DE+/='?ILE]*Z2^=IZXA[$?:@>Y0/LD<X=\H=QWD6XQ
MN1LC%<V\]CDJ9R/VOQ<)5MMW1BKRV^K;:]7/,&AZK1VP[C@0EF<C$U_0H&;0
MJG FPWPO0R_2O#?CT:3HQ<_[C7C35HG>>31F(+$O7N*&5TC(1QD]E!*F&I$-
M/@3M4]S,&]&(6-<0[9R&B9C<R,QJ>]>@T,Z$=5>C3NIHW)0:7F@H2U)L]A3M
MT'JC9W&"<1+3BMC$!JY)[Y4B['1])"TKLZ7@7=!U+[>Q9)OG/LYF'HHYAO5K
M'N%]T-JP$BO]ZG"77Y<++=9\5XNK#V?0VO_Q.<ORS+55$$,A/-CQ2T-9W#U,
M5 ,*8(K >[<*+4[)9!5X^SNK6'[>6G./]?%D-E6S7C#6?_U:=W3RY@'CKG8.
M'_EZONM9#PJ?)IB,MAN-G[2W[Y!X<?':J8:@YF>?%_S@%C%>=IIY O"X:YY0
M0T<RU, B+54^3 W,DV24.4G2BJ7MA>D.3GQE)=?O9366<+U4W'\#7B53'9D?
MUAZHKC=SWTD>JFC7+4.N&-XE^]7JOK.[8Y74V(70DY\TSA==7'FS1$E$?+6
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M&@PD/3$PQ-D(DW2<=Q0O11%+2%=@26EIV5?KCCN<1$D>KSD[%=@5FAMX0KC
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MP3 5$O$VK)-'&1 R(".^:6!8$<8]?'Z/%"'KT.Y'D?U"?&346^A9Z$PB;",
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ME71H)GZT^M<&(K=5&TL-!%!V=FI*9E-%9;[^C+RC>,G# - EF6.N&[,LK@[
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M\/VR(JD?;W4]^K(A6O#NMQOZI[B_/ 1=O@"+P^ @C&R37V@ 2X1IIF0R'6P
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MW.[WOO8[@2,-^;PC+<0OEA>S,KGTZ5U+8^M[$]8^B_)E&=.U";_^P[8=Y#Q
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M4[P4=\8)0^KWF@HR.7&Q(;6V[-</@6+^Z:62IT_*$RJ9<S>"TF];:K6("?5
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M/>9OZ1N)T@$0Z%#)C";R1:"$_I3%<5)1V87C=A->_3LO")5[5G-6)!VOV1S
M]64@L(8TCV\2TLUUIQ.';Y0/"":[/JGX$7SIJ:7X5_-SOL?,#QB>MAI$DQ=@
M;S80BJXFV!.TC/7FGRWVVXL5,0H5TN\W-/GGWR\Z/QZ16URWT:^\&^OJ-#P[
MBBS$>]G(BO[,#GQ%3[7%?V;-KJ\$?"@BS:9SW7.2N;,D\US$QNQTL'84$4I
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MI9^KLB[:$BERL":Y/[)$A%DG+M_-4K0[5_'VA53^MB\5\#E)#VCZ;-#C]RD
M.A*&2G==[GW6[S.R&]297BC=>'*;_.G1I!9MBX6[[! E_^W4?]T$&WJHCMNU
MJ9$3\GQF=3F2C,H$QT5-JZ4W#)LPQ[:@XP=9W+U$]#%:>C\=7K\G4=WH]ZRD
M[=A?4J'EY>K9IT\!%?A6\LB:TFH\S;MUO[W8C1XV2&DOEPV2&5Z87BW)9?W!
M"."=XJ.T6QMX;NIJ85?Z'VCF$TT]QQ\OW>GQ?#::8M!8??H4?S7RH]C+FSO3
M$> 2/A*.;&A226D-K[OHXJ"#,8N8F%BZX))BI7)EGE%ME^ST%'3 9^;"W^]F
M0N?+="^K>+O[PBS'W5E<%A#M;4'[[9];1C*U9G6LPZP.]%'HL_X"3+B>" ",
M5RN29N/X_K6BFG4E= JKSFH\_@)K32W=*PC&CZZWT%.AI;3"!'0YZ5HTS252
M#D7P_:9+CNJ5CSEI';C0WXN/DYW_%W'O'=74][T-1D4IH@@J" A1JH* TI&2
MCX4N1$! 0(@*B( 0:5(,"=*E"@A\I$4$I(-TI$5Z4WIO 4*1GE#"A13F\IM9
ML];[^\Z:->\[:\W\$?Y@W7N3<\[>SWZ>>_;9^XKG 9O#/AC$>C=:<!55@1Y\
M"BV<E8=VT;N7'_B>JS3A[; (JHZ$B^^<*_BI*'3A[2^VSWLWV<*.(+-5G'U3
ML2O6[OYRZ/L'YK!_JW</?AXF33R9?J0G9BP7M=5S!T'$>T00C!*"S'^ J]M_
M!&E&[/[UM9S% ,*X==H<%M+XU:&!C5]XR/RT[A_7[4WWGTG/7%=*_Q'@_IO[
M(<+.4X@:3JSD,Z(SUU+0XR@%RY=+E+G$R F&C\[Z\$3E\G?;/ZYZESSZ+O_\
MS..X#Y\8U^+1^B#,VV/FU4FZLVWUCI3Z^\KOZTO/LVW:?1C<EAPR^IPFEFBO
MTUN1Y O+/_4]*R3W<HVI594E?*CW$E#[@"@?XE+H%6<^2(5E3&[L5)PS7%5V
M]*JZ;3PM^"GCUC_<*K&G#1$?U=B1C.WSPR3]L)G+,2HMHV?2V<;,7#7FU#8"
M;=A3]B[O8*B73SZ06I<A9*M:4%2P5%;_ACNT4)AUO2YY&+ &T>$2U2C_'I'0
M5%N..>_EJ1/S@J.T\N#[RT:_TRFYSQ5*&)P?^UWQ]U :F)'PQ1,WI/Z=#(L0
M(<?3:1* )>[!GFDCC+/N'$DB&\'DU=M,%W-T^1+\,>^>EW6OWHQ1)8RGGL &
M];*>6TJJ"0FKT\P$[."OQB0KPO\6"DBL-&B<@D6B5>G3T%*]JG6V>>0)E#Z@
M6;QZB#)T.,=1N#"O+2%IX/F]W=BROX;YE*!=.L.G,>@_*&Y:D 6YIZ^ +D_O
M0PN/R.DYMEX(KY>Y-^!\NB(M]>7X[6\+,I GP2R9UN\LWG.\CMX26#P?U4-3
M]IV3<M76+1JA(B?:_XH&4'WGHD.3'!W4+I/XX^:=5"VL+5_O]UNV\!:=;6NQ
MFY2K1T3P*P(6[T%2/DZK4>-C.[5V&+\5A'H@7 D@;?AM*DOA"U,6>C_$.J,;
M"LN??R:(QQVJ4MS0 W"*)+UW A>VSLF-4O<0L*]1,8K(GLAD"'DQ)2#>H+QQ
MJOY1]FEUDZB\#8L_RA9;F($AEXA4._4M&SH<T;>'X44])6HV(P3I'$<0;B],
M4X/7;\2D3R8GVH[28%V$84E5$_+2@#-VS[<>+SKG1]92Q_"<^V\,3C1:JVWX
MV34X[O"2P:#G_Z:9HN.E(14!O4K5+7:HP88Q-U24^/\5*KT_?E:NI:"@W:OQ
MB66Z*5)465.0XHAN2SJ"K.O-\B%;8"QUQOF6*%F2K+4FB?]C[MVNESOG7[K>
MSRO=/&%<&7+_GZG&/Y>]<UISJ8B@0]&=@2.(W\I$?IT\==2DP?Q@'_:,>I-P
MCK$]Z2I/;W!%O7*+N<IBH'EPG"??<%W0T_S3L=)/9OW/LS&P(Q0QC8_0-S%-
M1;3HNE=]OZ\/R2U&WZ]</EVW\_$?4%6*2RV:88DZV -I&,,19+0G_0B2%6<:
MBVE\* 3CQ3D4CU-FGT@LF_U!R_VQPN?<WA0476%50.Q/6PE$RVG-Q0%)" G\
MG,OC_&YN4\=9/=J$5%L+EHO.A6E*!6='I7?NY_5M*5.-P2TD>P.QNAKG[WUB
M_]QU!'#.!T?ER*8_BFZ$[>WD8%9LA@M!"B&C'DWF!1+"3N8UOSP9Y>=;,U,G
M2M:E9=>)4L2/R^>@A.>Q'(_*9K1=<M6S_I(Z.'WO$S;<+H2/LBC> J[?V]0Z
M4U^*O&C\-SF:JO"7Y7,\RZ61XB3$H4XM#5Z+<B$Y_L*SFO>CK DP-D"O^!3O
MBR*'3V;<9,*[7KG1=](R45\NX[ZMF6-"=Y/UC+1QE<.RW1T)_]60[[5=9+!Q
M_U"\K6 ZXQF<%,86,XX$8T3E?@N!<A^%UDQNCE.,>T"<ZNJ^/*2C'<'4.UUN
MU3UBJ'O57Y=62'E-[UNAW$+WFH^&OWGQ82]Z>F5"KL#/^]7JHT!AKZYO^3\-
MAD241SR@)=E_C.8W#J1,V*U&LB5433%_#@6'5)Q(1HV(<X9<)$R$+)2EX BR
MFFPQ-%O&@:E=DEXFYA;2A0"-G289KR*V2W_+ *LK$V8>U7M,YEVRB+H_BDY^
MYQ=23)<8UZ-!!UN"5B@$'4'F7*D>)/GZ/"O@R\1F3]?,@M"@>NPW^T5;Z^#V
M3AXGEG3OQHG;L#='D+&J9[0PU*EBK[(Y:%B%=P._E__4WP:1OHJ;G$97W3AR
M%H*,W:?N^YOZW('*G'DCEO@M*9>$9MZ%+V<G/L]V*-HE']LJPONP?TZ*QPO3
M/G'+O#=8;EJAQ>=A02=_>N:,IH?S>C8K0TQLIC^3"M'Q5<-Q=C+(%#H_ ];T
M)IX0^N=ZWW"+)]&"5;%4X]^YW:F(/_3SC>J73%Y]^.]'#[IA1 .IB=(MLAD
M)=>?T1IM\Z$NPP=XU,]+]$P/3#FIR+>VG>B86OFDH8X:I( N(5: ONEEB)_G
M:L==\ HW)7F&?D(TI/(MM0<]L]5K*2H4[#*UOW;Y[+[^NJD2:)B&H^4T3W(;
MP#>GY[/)BSAGKNGHYBL\Z!1\8U.J\E$/',(TRZT6_Y<N!(X@%O44*"QPN(W^
M@S\M68>8F[[[ZD.==K[9,]W3;5,VMUS*7TJ[,IE\*F'@"!\HR[!C-G;8=BI6
MYY5J7</T?H___#E#GQRF??C3H6&QCPB?.#N+"(/-)F*NU$%)C'/ZN+S5-/;A
M9?D=^_T>[LP;"JI9;;_RQ>YRVCA]S37TR;$^!-<7<\$"*&N^J__S%9^3G+@6
M\KK9F2M"H7SW^**8BOTQ=GA S&,IER0V.=?;CF2 !C>(5,<[#5 UY>IKP,EW
M$?5'=3*]B5 C7XW8N#HZCN?'+00?5Q\H\3P^7&DOMJK_Y&V/ZWYL+;P[CUYY
M,-VJ*#86='FSRN:X*%,AW<1R\3)@3SGCA2%P;9R>G4;,]OJI/ $5-8K[3+K(
MSWD8ASF2HNO=WWK)9*TD/@H5K/P@YT6MRR_(/JQ\?_WL?.\8LK&3]'ZNJE7B
MY;REVNJ5O3-/_Z3^?JG)4AJB*?!0TL!<'MK:^2+&U'!HP@T,CE I2QB'M4_B
M8R!Q#_<]>SW^\H$M<0!/B*9>EFDN0:RAI>/F/)O/"5S9G:PN-W[E^^[ 0*\Y
MGA5[O4/QI8'T5_'4WRKAA*U?B% <41=SQ<NH[;AT^74KAP;>H2U6PWL"O.ZQ
M#WDCZW]?[WH4E?QCC.'Y[,T388[CG1I%']=I[Y 5AQ[;#7[UP$Q:(4;/>[+X
M 3DO;+:X0?JON>:O'9*FP:M*XN%KW6+MZ18-]AN/E4LZ'BO'BF]/SAU!/C3(
M@I!FJF(Y+\4!!+1YJIT!C*P]R(Z^=_&HRM7FI0OJ$!LSFR>V4K(A2B_\-+MR
MVW0*<H4+/+='\-B]BHXNR:1\7_X97_B8@_AVQKS">C8I@,X\.5=;'(I@4;L^
MX]7=R/D:/]G -91N$V%1S3+P;WR7(G=GS/V[Y[TMAT?!K[YP!%F(HX)![,<4
M]% @CS.WUXZ83Y>G5$P9.6.%1ULV ,36(%+#ET8R:C?!L:IQ _FMHYEGG=@>
M50]=A<YO$UZ=W1,Z 8PV(8CZB%/3YN@VV&6Z@$/SGQ&J^V'6>N*C:ON783<O
M<&#6<JMA1+$MW&PAEN,[,7J]1D7JN5D%G-NA\O")BP;ZW4=XJ@@CZO-#V-Y
M??M] ,G6> 099_"2/LTBBV#LMK]NL)_%6;A4-9Q2AI9KM:!-7C:BU.5O+AV?
MF]?/P? $JAQ@\5TX\M)Q*9G_L0H?[4;Q;S@@"/]87GR&R@A4%*TE!37$9ZP<
M9IHJF%;I<RA:6Z#*[JCFAY&P82H@!SEM TRI2,S)UQ%[?^'./Q.?1N@DHV;@
M6RF8JYO2@J$+UQ8(2\4:9:Z%/&]-WT52XQ.*=[?V4RY)\!BF3,<O[J!ZU6GV
M^XB]IK =*3; [A>V%/&+$NXKUJ/*UCC#.;A8G_)U6K#@M97VLSUO7FZA;>U3
M?:9+"OXJ,J0,4*H3HCD<?;(C)%&,Q$3]GQ19<]3IQ:H'D9TG_RD(5TG7*>N^
M3O#ZU7;)FO3D;79A_.1$]^'8M+V>_O?$@<DUFC.ZV0 1WZ!&BT%+81I5553=
M2()SC"T6>$X KF<D63OGI,,9)5]UC?%32Y'A/V>TG[/WN3)S%^(!@:MIGO[T
M6PUW:HU*WOA:)Q0E&2NMTR]C6J5J+6D&%^.RNSU(RE(_<3B]ND&8WNO_%QVT
MV#AII6H*<(H*O8=?AE01:I1O;B'1D%IW\O103\G#%OYTL_V8*5#*8F;3<#\0
M06@5@ ,1@>?FV&KSB0Y%VB5T=6UO&FLPWS2M3HT/T-H2:#BA_"[BDUO[*B=N
M[H]HJ\^S&N>JK/$U'G?\VJV]L^YI7(<9_FSS-U64YU(%&P]5&V*^KIC<%8E'
MUG:6#!8.S#!5W7DU$7HRHD1HUD-HX/MG6Z5ZBU(KW>+>7NJGI:F,*Q(<GFC?
M!L2HT<XR>>&XQR7U=@5P9QYQ%27?SQ9 U9OK5I*3]^_RYIG8OI+H'MI?>UN#
MJ< X#BF8LBPX DJE1'SYF2K2&MGQ8YVNATAZL9?SP:Y]\7>G@6=M)1FM@FD;
M)4VQWL+2KMI%UG26+Q33UT<0)OK95>QY]\GJ311R?LWHM9.@DJ,N5U>W3-3D
M9UF'N[$MT36.QZ4+7M%[#[&_H..)\ "KJO>P"T#82D5MM]D)-F<^]I>1(:_8
MO\7>#7ZI;/QBTJ606F-!-1W!2R70U"V%UW')".J9"<3RSF3Z-HYZ248WFG!\
M:&\6W_0E<</\V>T)X766]6R;43;ACJY/][8%K#38ZGT11Y#SU<?Y(U^.((N8
MXP22).H1! CP('FV8XE&O=P..!9WN'(;YZC;^,IH4E;QH6H$NT6X?)UPVY\\
MZ0>WG^M*7OX(H6#"8=:82:1^95RK/+3\TL1R:,8Y%Y&/]D66C4C!\^_4>05^
MC?^]W,^U8F90_K8OSF+&] AR<;('_R7+9D; H*%3W#LK_P#[BLI-"U<[A^Y-
MNY78,@,A>I+/5$GDCZN.DK,V>EZ\,K&=E.VI^VSEDG9W%.0ZC4]A]JI&L]A&
M/E@S/V]];'.+E722+KSBGU9;_QZY,ZZ![J^D>.R*^$(73#2I%Y?)AR2N-BE.
M!RBSFH1Y872+KYPM177.ST)U)31&5KH%PGSW>547Y#GOHB%. 93#C29"QQN(
MY$Z0%X1'5&3<LXMW-MT__!!9??@0IE-3/JW=GR'J]2<+(X%8*AA-%DBAI3@,
M+^Y_37;L53_,F('98@'AT>.^."+]FVJ"7B]A7%Z#1N46D?=U5[*>;K"&\7:$
MR;T]TQ/4<4N?\(G)8$=A0YB8A@!$1#=NSF(^XEDWI02((A4RC9X9G3+:%9?2
MT_J_1%GR79'F$LH7<=4)0/QX?AIRX@,"@FFT+__K#'L%8YU1_#U"O_GA\>&9
MBI^]VY=,"F\\B7QM_ZI\Y=6&W:(=S>&NK&\FW\TU][TU]V*/?:B'^GRA )PE
M^R/B<5557U*' ^/CZGCK((DN[S1'Y0N7[Z-:XOS$0H+1(EZPMC3^ZE&JZGP]
MFU5?X9=87Z-'0R^J*S]^/MF8I2&6>9*9@<A4G(*"YL+S,8V2\S^K7^XH-!WT
ME2B).J>LPOX1WZDEGZ"EHK0I+P&D 5'MYWRA9O,1A)$J\YZ6]=XVZT+L*M=@
M#M//YT\VGKK]C*_</9MX2RX%@S&)D(_J71K!">^\TW#!K._FZU'U>S?A\.0#
M"?@8GIGJ K@0ILW*BUFI_Q"K0O?D&"H2X@HM+!]!5G4T%JL/377GV3CL^=D'
M[(;E_IATJP]>XT[8?URM=3W"I^SG<9Y)'**JF'HQN?'XB'_3TX8;J#O#%7_4
MMM0;*BUJWW<WB@Q[,L7=7\U;$>@P^GE%Z4J[JN8ZGJ+BE4UGT9M+A<W;M6.Y
M5F,!:SWC@7(]-@V/*MV$H/MZ'M>O^TG.!HN=DCG5E9<WXD*;3Q0AS1Q!L//E
MQULLN'>C:@.35-P9=*R7Z'R[OYHP+8/.S@:JU%:$76,RY>(3_YWN_T/XKZZ1
MD&0\[?,\>"/:J_<7["*:PRO<I-3__7*D0%V*2F45TZF@\WFU\S$*-S48_>[=
MXCVU9]2&X)/%GZ3W>"(XY13?C4W^95^#V4[[;PCID)J8-WM6 Z8&7$-*XI_0
MN>P6LXX@EUBDR259(^;%#?@ 93B7UUHS@FVW=P-ZR2M$ASB#K45.[+T?*WS9
M^_W@"BM=CC$0+01HSI_Y(I\UA[GTMT%H\*N0KF>FP^UI=>Y3HFYM+>=5]=!P
M]&]8*>XC;#9S1I3$V :/H(L.S1.W)GEZVMKUWD9>?W8GC&,N@==K__0OAA*)
MCFLEN\@)03KSF@OE!N!\!"&PK>_/1[KI#*-@SCNK/JJ[:W>?F3WWGM3O_WG?
M_\_5Y "(UK6<T_"DSTIYXLJ(P0J0E[(;Z!0<V*\5UK\?HW$382UX1JI>^<\:
M(B9L%W9Y8J(ZS+M<58.WY6-'A\GK+_ZQ2HU%"3@Y$,5#,=O:QZQ^S)F-QH[(
MNEROY:HSHTU;D6%Q6XZD3E"2[X%Z1"/]?_G8].4.U'/2$.8L_1+0W+HMN=BW
MFUSX4&H_PD FB*IUBI23*Z=_'OD]JTDR\S.7T2PF<J*9/H6M*OI ?#6C40U8
M$[<UAJCW8U+:/=TX&4*G0UD[D5$9[BVFTS"^#"TT ^I>E-R32)12CEA>!.1T
M^;\0TZ8C"%']",*BE^L%GX]N2=6;6#,=E?M<\CY7R6Y[L">^C#XX==)WI&$5
MV#^"",G,B]+":T+H<=H&X0$9 >YIU$*<@C"FJ].'YT5FWOS0R%2GU,,-H+82
MHPIZR!$DBHJDJ +)#X#.N6YMA.Y Q;WL9QV\%Z8XH]]/=$?Y:^T_CQEV53*G
MAZ Y4(9]:#F48A_*<2X_QB-CC;/;A;UCFOLOJ9H/1+ ?ZT]&EQ!4CM'9F0^D
M?;()T#N+Y'BP9%_S/?<D\Y-3PG7?6-NE[3($(<TK 8URR9135%N0TKX\[C2&
MH*721?3(EKP&0ZADY8^\%R9G?ISD?HP]L'V;K!:8#4^JW<<.9]7'1:<../E2
M,(UV)P&U'S7R6=M.HG0,L8/"2V>).X*(/" <0?;78;N5+/D@J\P]@L0)$N$T
MU"KTT$S.'/2V3)!]?@*.(#0*&TW"/P\,!F*8A0[JQ2,(XFX(/4'OZ0LZ#[V$
M&C.,F,M8/8((+B F3M&-A&>+*<RO<8?"XGL]N$M'$*341SP1]+'9[Y^\EBD*
M%&L*9 4,>\]WJ-$P&Z9WWLD6SK[OL%D^[528,CT'2[?$T%K-7BRD<=Q9S9)J
M+=YF(3ER+/>W0?TQ2^@\4\(^]:(UW5".9$2O=L0<O@VKP0-H3YH!C%IS!*&$
MU>'IS+!Y! "J/&<$CU? .MZ:/C(@IPPNW19^T;OJK=J?,=Z26NY?/7=91@(M
M6G)W'V/G<;/<P[%D257OC .LX7\4T/^!LX8"HLN_8.'0,D8_%8OYXA,8!R#D
M2:EWL12L4HX)-7)1Z^MZE,>]I@^_^,0]Z6=AX-3FIH/^-.IX!,D<-1Y$-^++
M[9HPC/0.W#EWI_?SF !W/:N!IH?5@WO0"^864_?;O/7Y%3Y)IUQXJ^EB<'\J
M'FL%,J45D7]#)'W.9@OA=LL\P9_E;T+_O3\B<X^M^6#WP,8PW\VI:/6,5B?4
M^V%<Z8+'HA:Y.!!]V7P-3]3' 3<\HIO7+%\1#(G(4"F)-[9F6E"'LAJG']H"
M42ICF6^<(7;6A!,D1';-UL87HF!SC64K;;05U 9_&&Y8QK9;5-7^^X$VEO[N
MG5I79A*U<1"E+DJ]=);.\B(="&_F0:W-\7%N#BQ,Z7$.5'(^@O[YQ!]LIOC8
MFS8?T#?<YWHX+,?7,.ILA1MU),L4(O/_U!]ZXG0Q%F.T5\ &,4 +V"$FMC2<
M'NG72RMYW5<P>4]^ARWI9B(M\VV!6OPVALJQ1?A>DN?EUG($.57G=(=?!G!S
M);_]:"$E'*OU<C)NM,NE##;MM;8Y0<T%ZE'X,BSU,J5I8B-#KC*98/"JRB6[
M*ZI*QPFJAJO_:*-&D)/%1.7NYF;3ZBJB5Y,WTHWEOBZ/\% K8ZF%2]'##O^S
M53?_/_ZH2)&70;>$ 56@Y^_UT@.L!/][VN!H%7KJ"+(-VBSG$63=ZN<1I,^Q
M!3,;A=]^+4IO$\?3SO#</H*T%-.90)-ZY14=' (L@F8)M0%JV\P9_=QY(Y$M
MAS.I<QL\4SG)CX<E8R>8NF\;GYX*8HB%+,?^\]U+IIV?'PC_VEKD96%10CH?
M*5/GXL#CU-3+$!%A[%\3>YY),&#B)W*"=W8/V][KWR!!/+?>-.Z1+Q+,&_PL
M5-20GYMIDU/]ON;;<VA+=!>F(CL4-YMR2,81/0FF07(V?:V35F933[]Z7WO7
M5-;"%_^J*N[U\ZYQ!@6&V).!<2GI$K(U.YNX8D&S[U^S^3Q&N\LHO:.82_:5
M=]N#*QS/Z2LN#CH7"OLO*6D8?[.YWLC_KPA.'#8;NC/53D"&5_Y05HLGZW*I
MI" Y?E^@BUG5L$UXTEG2K4ENC?N8<_337IXM/,4?5;1Y[=L-DP9M/EX-8*WL
MRY"I"]*5U+*LU]C$ZV$:[V)L)HO'K6?+FHLSK=O2!.*1%381P9R_) 4J616=
M_$J$7'Y.,OB=LV2J[LFR^U:1F#RZ74]#/QR)=2=H.VQA'N)ZD2M8$;F:9R"P
M(&-LN,\JN>Q97H@Y#*,ABKNT,(N*@O0:!?J_?]"%@]&40C8BO: &OR6S&[V
M/H8B!6,X]9("V>_EUQ]WJQFO1@-)6>A$%/BL6","G'(29%1_0XK_P "196JF
M./G#$>0]"*V#>:8K=JV]!\)JLD>0'Q);]% ?0BNFHQ1+\\%07-QA^&RZW,%#
M@.V_=V?X!7[A'3,+,AF8]U#!.%WQ@,/K:9EI2$1R$:S0$T]\"#L0.CY.N*[
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MY%L<5&Z!Y+1L7YAR[%LA%N[VSVFTITB2GPFP7HS^[,/R]^^WC*RP'24E-0Z
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M6S0(2A6D-S$B(!T$0520J$@74) N1"DB($3I)22" M(%!'Z"$)%>0X_20D=
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MV5=R,D#5Y*GDKJFQ@5=^T@_GS2GUW3_F-=[;@9[W@H\Z0%,TP,)P6YBV/0A
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M@[0Q*YQ^KGW.V/*IY,B'@T*#Z[J63E-0-P#':B,F 8B[#PP'B?AO57B'B3[
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M4D[5W@2S@)[-#&_?XKWO+MZ*/_^BNKE=U"6UOD>HD\7I5+!SJ+_P]X=*U;A
MPC@EQ2]&*ZP(^@@D4#=XZ_00<H%R]V25DLDOG.KT^&PW@"F55^)$=K4!A'U'
M%:V)7@!W0<Z]U1O?/2PN=TF] 9>382PFB!;Z[A&M-S1EDHVJ.,JOW%GW6#%]
M=.D#$.TR$V9O/8-*SBPN,_RF'+ CM5R'07\\_ELC;(R2#W7&DPB-Q#QX&3$.
MC.@,S/2?*'BZ,*=OE;DY:<H5S'TO1KA!J=OI=6FB)F?:$?-..-Z"RH?>'L:S
M=\<HIP9[%O2=SG*C.C[KNK*TOB]+EL>:$2_#HRNTI$@P:,"(&G%"_JRVF-'$
MO+H0JXC'P]+B"VT,1.L*.K>S@^J$+@[*+X#:O2Z8-R(2R#K"[V6&)!+2U69O
M<:32HZ5!K[8"Z!75.598OJFKW&H"8]]7*U)VC:FXF81-A:SPT0""QSE_*_6U
M$&VTA6'?+_!G/F]NT>E*4FKQ>=7'\UZ<!O@NRTTV@=)CAFF6!O@0"?L)VO.@
M 4[\C2BZN.'H;;+40HN\SMC2N=_N#<FV,SW,[.>?<^LOGX:QNB/.:4L1K0F5
MQ.&%X;>$VN%%&D!XZV;E&[[T)Y1"H7E*]O3E[]P-$JMW7\;:UK!P:*39+P5_
M1NX.*G^31$ODJ&%^>6E 0A0I.^AQ4A9AD=+0;+&X)]9) E&'S><\+FBT?"5=
M+JG8X.%/^14]'\%Z1U3X]F7#&J8GYUC$8RGN) 4R-YZK'1A][C>QMS?G(O'-
MXLQ@K8==>GW9XWE=T26*96/_FHMGZG>&3_NA<F0ZXC*]P4M'P<3(5OB]3@@_
M$28FNEB7\OV]AZ";!H^DM*" CF2D7+_+,8S(80JM1XZ!XN<O?L,AZ$SEO&?
MT\'5K%R,XUT)82]\V^[7"]].U91(174VQLU[^6I@^@+ DUG3*D&QFSD3 <:'
M,/AD"GF?B"<Y05TH1?#G\GL1Z%JO88)N5.;^G>*@V$O%^\=>->[QRQJIIU0
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M,%O277C[(VTN(G AFS+\NME8,)X,#GXQ4&AK9_^CNEOBE(#MU,A=N4/9HR%
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MT$P@O,(!\[G&LX$[/^-]>L("Q^^^9"-5>)!LKZ3;G[W%P*Z]LU QG&G)XK#
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MRNVXN=2+J?O 5PTB:+@&\7[8O-<5GA/I^9-MC[V$R08_I&F!W?NJ!U8LQV]
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M]Z/J($2^:(X%\O[8]>14_)3W(1(RH6>>WPO]<^@'>O 9TPWD1[: FR0#1Q9
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M80P.]")7<!?J*Q,0KHKB77^9^*8Z^H]B>%UD68#$6/MK[V4++O'PK\V TSF
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M:2E_';22\RI@TQY)XYMN?HE, #E#+O0&G8;YY8EK5+\;J'WBFF!QVIRL(&*
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M7Q-('!-0 >N"G6 ,$&I@FT(+3(#(6MC]X?D06^G\^(!!O^MC?*77T)8^8:L
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M5KF.E,'6NOW8S2&7(:^GBDX-#=@&JX?;!W<SY#^[>DVR\7)!F8"62WN:L4S
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MW$=B;G:TOQDH%H"\/YWE:UJMO[JU:3<7 ENPVB"0!%MG12H80Q-^7A>#[>3
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M+]^U/K?H^=:0ZE[_3R^%?R-SO4/X6:@[%_KMU'\PS6]^L/'-YB35]8*5^M#
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MB!&5,)$YQ4D0)4GHM"OE!=74_)%-HT"ULJI_%0$_?6>G9*/WR,!ZM]49:X-
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M+XW:26>P\X5^[]Y;0>OKA1K(C1/7)#M)PS 7>01%2@E$DG&(A<A@2L(H"\-
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M*]^G5]WZ87J5D 0K+S>% 6$)1#'2&=N$+D,;$1$B@041KI[-1/IT>"_F7>/
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MW8R&;A@(;DZ757!640^\>E76<_",JK8>B'NIP#YNZ2-_T*KBAA01B7"F'<:
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M2WR"7TCYNY[#Z;C[:ZY>HH(IUZN=V/UD+ *A8_3]L2ZP<\$\$3NPBF[FD6R
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ME*IY%1:!TR$<5P!3$RGU(*:.4R=7RBVG4@,2.?34RD"_ #N5$S<TJEX"JK<
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M*Q#2ZH*>N<+;L#LRUZMFUXLK\EC49#Y#:<:PY S* *GI :$1Q"%.(4^XR'C
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M:NJBPVJ5"<R[S/[+_R(P@?]A!K]&2>*>$GP.;SMUX0G%P"KC$, ]/OVF"E\
MPWO6\#EZHR<07Q#\5"[QI5L&QMM?6"G_\6+Z9_XP=61FRL^,%2G#"4_,>&$,
M<$X@(##/ 81YQE&.<VHW]+&/R-34QH['J&(R^J-BTS%U[B2<EL&Z*T$*'3QS
MQ<<]<M4#@-](TBE"XT9V>D0]BK3T77O%(5NI'_Q?DF^^K7[36MZLS>L7*>13
M%84QF;R+E1E0NW/,4<H+FJ0*Q PA@)FI\&:$ $Y$)FDJ*1).-L4@+J:F-NIL
M:#."JQL3;H0RB21;L:*=7-%.L %G#\X+YW!8$'(Y BNH:U>B46AA@C!7@>L_
MC.[,R?AQ[Z%@G0Q4#W[8\$&6[TT8>UWJY_^ZS9N/%8YCI1B /#.'P8("9N+)
M,H$PE8H3[9RYCJ<\06=J.K*::;CC\YK*A#/ VFDX#W %UF&#D!HTS[$'!^]3
M&D_1&GWV8H_ IR8J]ET^>%KSR]-+E6!:'7F9<[.U_"Z7Y?R'K).33:7[9[FY
M5Z:5 TFS!&9$@B)7V@E+S2Q;2B%(B:*XJC;(A8NR<*0_-2728;^I1>!= 2+3
M6,--F;@NB)V2"0AS8.731;A.:MCC?5O,T#39^%P/=_#:9&,@>+X'<SOQ,/:T
M[B$ G1CA/>@Q[DW#ZCY9'Y_D^G&^?/SK>O7GYKNA1I>O,P*Y5!AF(.4F-XYS
M!&C.!8@I5P66(LWMALA=H#,U3=:T#FMYC6IFHX9;^P9B?=#VZRJ/@ 7620.Q
M<FHE9H'$X&YB?<\>K:&8A8#=GF(VEP_HN?I^0<OR7OV=FARAS?WZB\GNZ61K
M?EDM%I]6:Y,C-$,XYH(P K1W9*JZA0*$2PEDS*CQH6"BK')N7 E/354T/%L:
M-LXP]VN)D."%/L(R7!OKI.$[,@4XAO.]4<31'X;[J&'?I6.K"\@.#5P#@3U2
M/U<[T#TU=QT 56^O5Y?GC=?Z=8"4>YU@A]P_S+O=I>14&3E-%HWBF1"*4)!C
M4SX38PX(I S0."9QQAF!A,^TG\U6ME[L23HN'T.76L#3LJ9;F3K*57+S44_#
MBN.T2"DO ,E-<R>]&0*291) E>2Q4'F<)4[-G:X&=8R]\/-J"=J:W!K=EZ5^
M/TV/MQ;@NE;WT6'+[,?9SN._&KW F^%1MIS_!+!>"+QZYZ<IC>J#]PI[Z&GW
M7SS C-X><W5.N?I.-P[3J],T9Q 7',1YD0.<Q1@4.2<@ACE%J4*8%/:F]97,
M3$W%U$'?S=P< S[HMU:NUVYJV\L*65CE(^(^R5-;EX1Y_POD8-&/N% C6?F#
M%LR3T>\)S5Y'X%H:XSD'GM#8<QA\/=,]4'S'U?KV1<SU\V\W&[UK5N_QIP5]
MG(F<YD6JC=Q,, 6P8L@<FPL@LB2-)<(<"JN3L'XR4]N,[MY_^A(UK$8=7B/#
MK'V4N ?7RT%B/V@%WD*& >44(KZ,P^ (<<^C1PL07Q:O&Q^VN'I@6B+_+L7+
M0MZKTZ6CE2'65(F: M"ZY+0L7VI=5%;Y6[MM6J68""8%R.*$ <PE! 62"B"8
MTDP(P>/"+8O9*WM34S>M=%6)XH[IZ/>R;HCUL=S,G_:+ULVEM4=92UT7R3MZ
MWIX7W<YE?[NE#*P+NZO8T\:@NVIEW0R^Z8306?F@^9!!%L!OHJ1?%L?-H P"
M[U%J91@J R>\6N0QZ.UJ/6<OFXKNZH&:@;.W3!NZE&]F$,99C&-SYE@(@#.$
M09'F*2#:0U LY]K6=!L%>R5#4]L@[L\D7?UOQXFQUZZ3G88?$_W .MTI%^LF
MZDIE-NY:KNB/5C*/6MP7R'Y'W%[+U+BS<#U!>#0TU]=S!R:[+C=S,5^\F-$[
M7R5_65>SI3_KM_S#ZHG.ES-.\H2FD %DZHBTVI6@*!("!,^0C/.8L\RII>TE
M@E/3IEU^HQW#^E/6-T5_U$P[9L=?!-U.=?J$,K!JO!)%]_Q42VC\)J1>(CIN
M!JHE!$<II[;WN2F<<KV9W?^YU%_L]_GS[<]Y.<L3E"&!.<AD;LH4<0%(*C&@
MC*-4RD3*S&H:[=&3IZ9"MLSIO5VS9ZDLC@'KUPI7P1#:,K)%P/I#/RMMWQ>M
M;^I\S?IOAU_R\5-'^63/"M-^F^<O<(_?_RH?Z:).':W>*L8%AA A$(M8NU/<
MC,M(LQ@HCB%2)"ER;N5.G7CVU#[$BKVH255V^19/X78Y*'\%&H&_1Q<@G.+O
M9T0>''0_?-YHD?8S@G3#Z^<N&9 KTLS&^:19,#U#C%W_]_GF^_N7<J-=@;7V
M"!8O)@WPMBRE_I_0/H'^W=I,]IHEL4*(Q ID/,L 1G$&"D8)@ 66BO"44&4U
M&/5:1J;VL;=\1?-EU5K(R!*M:_D<<A"N69I^%3$FX('U23N$RX@1M7)$1I"H
ME>0FVLH2M<+4<9!6GI$6Q2$I9*3%&2DA).PBN26(>$"V-SGDFN>/EQCB 86]
MI! ?SW,W*)LC9N,ASF+%M<DH%2!*6]4X+Q) (1&@P&E!<T'2)+9*6CQX[M3V
MEC:)P?!F;T%V@;IL/0X4/W0@QT9R)Y/QA)R#S<7NLT8S%4\(T#433_VS^T?V
M?O5#KBV/5HZNG]#[4_'E]8SCK+2#WZ+]IXWV'IT4HOLFG;Y@@+NQ.P_^_UZH
M<6#HICIWJ'J?5M,ZE_?M-+YJ?/!A\D9"<<%S4@"<P!Q@"2&@$DN0I)(CD:0D
MCJWZXWCA9FJ;0S>UXQ\=B;0CLA4I,G-1UY6=]7GU@S[0M1E=UTZC7%12.MC#
M5R^HA:<RYC(%5D+;%;I745>8J"--=&_&A+0K4@ODDFD38)$</)<Q%VLD]V7H
MHGGR6'PAVNNV7$UD/-_%%QY[#HRWAPYMU%U6?7N;V;/E#!)>%(PH("BE>I\S
M-5A$:L=&*KW-Q2F&N709)7U(P&GK&F^"]/8+:J9'.V:*'L'8O[OX ">XU5HV
M/;8_7D)D0'OMTV)[[JE]0&3D1MJG13SNGGWFNH%IZEI]5"..FNKZ*LVQ.KM!
M!.EO-V6 8?U)8R)2_5TG^C//($=%)@2F3OT=SU*:FFVZ;?W0%!@[G(%=1M7N
M,_>"5>COW0DF]Z3J2Q#XS8\^2VW<5.=+0A]E+5^\89A:^"PWNQ2[VQ]TOJCS
MZDSO_M6RHO)]M=#/*S^8-!@IMF&7&*8B9VD.TK1  !=%#IBB!1!"IKEV>5'!
M<A>U,9B3J:F5S]H!6)N7WDV5#%\).U4S"KZ!59')&-Y+(HZV@IBDX5J4J"O+
M3=1($R25^&I,O>JVX=R,JONN!NU0-U[_P($>$BV_F\$F^@\S'_('79C"X\.Z
M>PJSE&G?":1$%  +(0!E@H(,:IU),$'0KE^D$]6IZ43#;3V6Q_S0X=O1F;)"
MW-+#\HUC:#/L'(3C#&1T@LNONV9%>5P?S@6,(\?.Z>9AJNF;.<=^6;]6RJ]N
MZS5C+"$\)Q1(88ZC12)!D5 $(,%,Y5#@F#L-8CQ!8VIJIV6Q[K%UT[;@6G6Z
M*9KAZO6O'6<PGH+83O-<"5Q@/;/%[&N-6<V@/T72([U7M7&*SJA*HD?00Y70
M=^DP!7"WU-^7+!O#J(DA:4-IEF:),/DG@.4<F]/*!!#),E-H0)#6 ":XZZ(%
MSA&:FBIH^8SFC?_0A'/_<A,MY<;MTS\+KMWW[P.RP$I@BU;K;7W<HO6Y!RUG
M97 )"J\:X2RQ4=7")9$/=</%ZP<Z+Q>:K,X*+'%.$@(4RK6YH#(.*$UBP&E,
M,@HI(XH[^2T7"$Y-8;1=K/U8"Q?A1KE0<6H.UG@BS. 4TW26I("1E!&:P93$
M>/8LU_.5^+JAZ\WXH!\2#P?].[HP4X=O(B8?Y\ME6.!Y1B1-< ZH0J;;+T2
MI"H%^M7/<L@48E0UP']<BK>"O24] N@R]*MNZ9][Q'"L$Y+ /<1=H?'KAE\B
M.JX';@G!D?-M>]^P7?57DTHN]],R?IU3-E_,-Z^_:PHE7[WH#5U\_,GUI;=/
MYF\S@3-,DUQOM02F>JNE": QBD'&*8L3J3@JZ&PI'\WDFV_V.^X@9JP^JZ+^
MK(Y8"O>)&5FB9_U$TQ7D1]7'J^7?33L-6R$[E14.\+$J(0W_-X=98S?15HB;
MJ"M&5,L1U8+XTV]7X>A5Z0WC9%1->!58A^KQNH<-'^8^%W.Z?KU?FX#HYO4W
MN?F^$G?+JG&^_$JK9ETF-/+N]?CB]K)Z:CE1DE*6,1!SR0"F, 84)PP@*8I,
M921&V'D(O"_FIN;A[-@U!DO-<%2+%[6,WT1&PEWV!WN-3M[67C]\ +VW5\!.
M5[_5P@96X6^RINXY/P' ]YLFY)/!<3.+ D![E(P4@L:0TIW*/;TKRQ?SI-^?
M5\O= -Q[U9F+\'FUD>6'9O/ZHFW661;#N$CU%L$AU%X_-&UVBT0 RE.:4(AY
M)JWZ[5S)Q]2VA):W2.__+C7H5ZQ$O[H>$=_0FKD^>VREB(P8W:G9]RKJ3O*H
M1#'92\V"?!EM05PJ:T99F+%J:@(ND&-YS=6P]A?6#'_\B"4U5V.P7TQS_>,<
M6[QMGM>S][<SA40JE8@!HXD"V.3*4J$2D L$8X;S6%"K)@#-\Z:V87RER^C3
MVDS?T(C=1._I8JY6Z^6<6O9U:U#JWP0&R!XZXGO[Z]VG^R^?[VX]=&_;EZZG
M4MM<6=NPYJ?JRZX[M35/&*<_VSZ[VZYL![\>& O868[ZF]1V8Q6(6"V_2"[G
M/Z2X7W[3+UM)>;4W"9FG@N08,&Q2T"'EH$@* C*($,H0-%V?G)Q]%^I3^Q(?
MUBLNI2@CLU31W&@ZO8[&R^-U6G3I/LC1;3DL'>]0((>VW[H^\TVTQWO4,A_I
MGSOL>_28AZ#FUR5VXF!<GW<(.$=.[:"'#%-S]< JN1]>;880E!]>Y*W2&N/_
M2+K^I"G/4HAIBH4"J4 <X(QI-9<F!<"Q2*O^L&GFE(GA1'UJ:N[;=[F6U'#H
MILK<(+=39<& #*S*&KY/G.YL5A&3T0.=BYNH CDR[$>&?W^Z;!!L7G69&P>C
MZK)!X!SJLF$/&1"!.WF<_G=I_BO%K?:IZ*/\^%.NM7L@']9SOOU+>;=\J!);
M9C#35AS&,4@+BDQ; 0%( ;$9?55(Q')$N7W+SNOYF9J^:QD454*.6"T6=%U&
MS_K+K))S+'-S?"V61;!NW"4([>>=S^QI18H:F:)6CJB2ZF;[]](T7:TE&W>Q
M' )YXR[:2 &]L1;/+;CG#^K>()\',N,%^_QALA?T\_C8(:=3QI7X(C?SM10S
M1+A(9<R!3)29!DLI*(3*0"**K% 8T1S9#S#O/GEJ^U7-5C6V3W]YF[T"+)?S
MBRYX-D=$ R$)'32H#M@;OH:*[W(@,Q"&L8Y8K.!P/"PY(7+_\4?WAA$/-$[P
MN7]$<>J"8?&%A[5\UCY<4RQRNQ358"W3Z7A3OG]9FY%9,X@)1ZP@("60 BP0
M!41;XB"'6:&UDJ0,Q2Y1!0N:4]-5#<O;SEY5>?6JGAA8<QS1BG^W4(,-^AAA
MEO < 2HY!%B[/8!D10X481"E+,EY5K@T4_.-_FC]U9Z;-1@/>KO8CF=  ^\S
M[9O<L%NA64]@K#F^B1J>_45Q' #R&KNQH3MJQ,8!B,,XC<NM0^N ZY;V'V3]
MY]VRSL':#3/[]./S7*LCPFA&$I!@$@.,E !$I0E@!5(\RSDCF=-F8$=V:OM!
MD_<XK_+3*A-VW03_7>N#K4"W4T3^H0RLB[:S9GYI6?Z+<:(;<+OS#C_]#7R^
M\UE,[(*4Y])B*](C%QJ[P'%<=NQT]S#MU)G1\44N3"W1 UV;9\^RA'"<0PP(
M8=QTEX.F34$**,YRBH4VCZ230CI+:6HZJ!U,4YWB+^:\WLX?U[+RJ=WTT'EX
M[52/%] ":YL]O!HNHX9-?ZKE(A)>M<EY:J,JD(M"'^J,RS>XS_JH9\HUHX!E
M1F"<,P6*+,\!S@H)6*R=J"16N>2<2&G7D^#PP5-3 NTP0J>!RD=H]7_DUV 0
M^)NV%=]I+,HI60=/1=E[V&A#44Z)T)V)<O+?!XY"YWS](D5[>*R_X=9]1CR'
MDIOIJ(4P4ZWR&)"",! 3DI,DDT66"J<9Z.<H3>VC;!@=V ?^/* Y93$C, ><
MR@Q@+ I00!0#*;*$DX2ED#CUU?<#Z&@!(!H(5CL3QPM8@=5A^^)UF P0S[F(
MA-_Q\&>IC3L7_I+01P/A+]XP3-]^D$KJYY@IA'7X1__0_JX)#[U?/9D_JR.:
MVZ5X)Y=2S3=E5=GP3GMHHGN!F1XPDTH@!2D&.%%&L\2Y=J+T3YF$68QERGCJ
MU-D_!)-3T_+5*0Q@AE63.+WEU4TM!5E..XWVUHL46!FVHIA)K-O@MOEY^P^-
MD"9%>R=%%1%O!6V:6C:KO'>9D=:?3@VY%E[5<1!&1]7D(:$^W 2"TO*847Z^
MX1!+A>DW!SA,)- 69PP*I3UJF!8,9PF#IDN&>\,A)R:L=,H_<:,AMQ6QT^W^
M 7[KA/,QV@D-0BU\OODTV@<- L<JWSQ0NZ#&WJ[;H6K%VRC<1L.:4=_SY<M\
M^=@T,5HMR^V@%(42 2%G@,H< 5QU>:1F('>1*()A1O3OG5J:#F9E:E9O(\G_
M=NST.'PI[/3=.  '5GZ-$&TK96.KMFD:OS22_*6J)VR$B7;2!!E:<SVH?OM*
M#F=GW(Z35\-VU(OR^B<.2$MN^QIKJ[3*ARX[W2]W,U0@+PJ>HQP4'*< )T4&
MBHP@ !E."-?&(H96I=7V)*>F$ENF';)V[:#M5WUA  NLXK:]LC7#=8E%V>U\
M&_TQ;$BT'9X.Z='><1TI;_H"OIXRJ9W0Z4VQMGO2>+G73I+M)66[W3G,HOWX
M]+Q8O4I9A1[OG\VK])M\8G(](W%."A@7@.=% 7"604 P-H$KP6.949J[S5@\
M2VEJRK<N%*@Y=+-)SX/)<H@*"5,@&2$ YXH!AC "&8HI5!1G*4MG/^2:K4:%
MLTLQ(*!U<ZMYV]SJQ32WDFW1VTK5!3K1JA+"\0SN/.1V5KX7& /O<-V <5-(
M'=T:U?!8Y67=-.]J]$?-N4=S_2(Z7JWQ\]1&-;8O"GUH2U^^X:H,Q<^KC<EJ
M,C:YL;__/M]\?_^B/YDG_9++F.8R2Q@H4JVI,64I*"13($T01UJ#*\Z<)BI=
M)CDU;?W7JKIV7?,]*$6Q#U\[)>(7M<#:I$U:U-S6B8LMO]&?FN&HY=A[_J(%
M.B$2&?O(OD5&HP4,9U(;;>X<F' E_NNE+CHHOZUNA9@;%487IA7+W?(]?9YO
MZ*)2;J:'H11W37\O<W14SA($$\*8&;X=0X"+7*N@3&6 IV964P)3*IQ4T#7,
M3$TYU:;DMA\:-SPZYAA=LS1VVFLLP /KM8X8II703I"JI9"I FEDN6E:C]?B
MW$2M0-7YN\>\;1^X^LU[NH:A<5.C/$!WE#WEXYD#G>RJ>L7Q_&'_I@E]:$TQ
M58CC@=,R^W4R]DF,ZUF<%._(G3A]U<#<##I?_\UD$KQ[W?[XGW.YU@_Z_OJK
M-BP6MS_GY:R(\UAAE@">Z?_@#&+ 8&S&-6,4)R2#&;1JA.5&=FK;M6$UJGB-
MMLQ6R5N?;_^FWW?-L>-L$4OT[12"?TP#*XIKX'1/M'!"QV^&A1WI<5,KG. X
MRJEPNWM@,L7JZ7DMO\ME.?\AZX/(>A#]P3CZ&:68(BQS $G, 19I"FC"*<AQ
MKB2*,=<NB%/JA"7AJ:FG/;ZC7U>EHR]A#;B=/@H!8V"-M(]@S?--5/,;_='\
M:7->Z)[XX B6WS0'6^+C)C4X0G*4PN!ZOZ?JB(?UZEFN-Z\/^M7:W"Z%L=>>
MC5\Q8ZK &<MBTUB':2M**$!$F@&:HC1.,%40.RDJ>])34U6?YC^E&-1%QP%N
M.S45!L3 BNIDI4'+N/[)L%Z94EOF Q8.7 0L;#G >?)OF^1_$9:+J?N7GS P
MWJ"4Y)NM5M3TS#"9+])(.E_,JX01_<OWFI?YIIPA*"'5#P*)D@7 18P @9B!
M/%=4(IZ+!,D!&?EN7%A]?..GY'_Y%_KT_!\?.BW"-OJ+Y!7/$?]NSF!=3ZS=
M%L<R6.0?ZY&"22WCW115PWNTSWQ=9U7S?V.:XG*O.F\8?GX#4VXLC!NX&@3/
M46!KV%.&>I?[8[4>Z&LUH35#-$8JAX#DA0#8K 4S:?DR@1GB21&SPFF@Q1DZ
M4S/(NM/CEH;/Z+EFU-6%/(VJK<=X-5;!'<2#(7O1PP68!GB"O2!X=OQ.TQK9
MS^L5^-BMZ[]\F#KXK>H%7>5+W2V?7S;?]&.:5C49+5B>,0@4Y1C@E"6 9MIK
MRV&..$JP-CN<QG:?)S4UI=#A-*I8C0ROCJU_+!"VTPY^< NL((9"YJPF+J/A
M55/TD!M565P6^U!?6-QQY='9[N1XV\^_G"G%5*&*S R,R;33E$I0L((!"@G-
M$L)B'JLA9<Q]1"?J([VOW""38:',B4]=N+Q2T9_-Z(M%6Y4Y\/#L)/YY3#&4
MG +":0XP@0K0(L8@SF*6DB214CC-7[P>^#&MN;= W/&4\EH<QSN<W'':&=CB
M,1'("I(P)Y(G*;[-062?\&?/'WMO&J;6FXK&Y6.5V6.B;DWSKVU^CF0J47&2
M@R3#VD5,X]AT>B2 2*0XREBNLLQ%M5RD.#7ULF5XVQC-L3C[,L9VRL0K<H$5
MR@ZTBMDZ.M\.=PB1+&4-CE?5<IGJJ.K%&H1#%6-_8Y@QJ]MQGS%C+"<4 IG&
M3!LR) 8%TH:,$#Q!7*0*%8G/":M3':ZJW[?,[UA5SQ-5_VF'J;[!&-4WG: Z
MS>&IU\Y-O7)DZH7P6E,T"5,(*18<H-3$PA*FO2I,4I G(LT*GK%4N76IZ:,V
M-0UT%/SU$AMW*D?UAM=;Q<D#%*%:83)&V/PMBE&MA+<,H5]5E'JQ(\&M.=K3
M*NN;(;7+)50P5D4<0Y 5<08PRCE@"2^ UB09EX213*5>FKF<IC\U'?.5?Y?B
M92&[HV%;SCUU)SFS$/T*: 1X ZND;9\2>K)/R<T6YNB/2@:K/$\OR'MJ$G/]
M"HS=,>;22HS0.Z8?M,&-9,X\=AI=9?IEMFXQ<^$Q@Y/^GU;+JLZN,8QXRC!7
MA '"$PHPC%/ %*0@D930.">20.28W;]/86I;0,U@783JG,!_ )ZM57D%),$M
MR1T:08S',Z+[3K _H#)V)OUI(4^DS)^Y</"$Q]63-)4H;6>"PZZ![Z1:K7<)
M7[+\I/\ZUYHG+3(.F?8T<YD3@!74GSTVO9%05D":22E3*[OP>E:FIA\:MIS'
M/@Y="3L=,@Z^@95-DV/ZBQ'C+[ON)\>]3UDE2R<GM1H9>6%AA@R-O!)3WX,D
MA[(S]G#)*V$[,7#RVB=>?TKP=VDL,"ENM>].'^47:7)8-!/5/WZ3ZZ=DEB(4
M<R(*0"5* (Y%K)6F8  J7"")!4QBMS)M)_)34Y0MQX#6+$?KEN=H40V!U4P\
M1;_,E]&KI.OR+\-/%RR6QOV,P2_@XYXTM+Q'#?/1EOOZBLCP'^:XP1ZV8(<.
M%BR\V=&#/3Q]!Q .3[DR"V.G>F<%)''&>08285*Z1(Y!$2<<)'F<<L(@XGGA
M,HSN! TG%3;"&#K#4VV'K+9;S<!4BPZ0=KKH2G@"*YQ=.L6>T18@?>)8_# )
M$QTZ;Y,B<2SHV:2($Y<.."YXMU[]MURW,::ZKY)I6U=WN+E72JXUK?IO34 C
MAHP0:(9M:Y,&8,(8* 3,0);#&/,\QEI%6!\7N-.?FHE32[#-2:Q:R>E=M^K4
MV/1A:L5PB&$/6!>+TX.P: =6-X= WYT'^J;]Q<5HE1?D'4X/PJ[ 2*<' U;"
MTSG"</AZSQ$&/':\<X3A,N^=(USQF&'V8WN.>J_.%M%_J^L].8V58@@HD>D-
M!4&J768N <H*A@@3F2J<YI#:$I[:3M+;/*(Y$G6L^+)> SM[- 2R@7>-ZT!U
M-EE=$?)JQUH3']6X=87DT.)UOO]*=W<_O:^=%TX0DREB$'!"D%92%(&"2 8P
M12SE2J60.,VU[R<W-=541XRV-4O_\K\(3.!_\ M#QH?@[.@87XW>:#[R<0*P
M]QGM=JB$<9U/DWP;+[I7_+,.=?]=@T]?U^:Q'V3]YUU]LOM]M=#/*&MCZ\MJ
ML?BT6O])UV(F"U.R2C7,A8( 8Z( ([D$>1%CB63"9>I4:>!(?VIJIV4_^J45
MX"^FHK(KP[]N73TC1]0(XF@FN2Z3]7EL*/##'\+ZQGW(R>L0]'P?MSKQ,/89
MZQ" 3ARL#GJ,FT(4<C[[T$0G/LU+3A=5L83^33E#<8XR$F= <A$#K$QZ&4,Q
M8 6-:8H2AC*K]+(>&E-3;"V;4<UG4_]C.+537'UP]BLG3R %5D #\+%6,!8(
MG% BI>3_]KCZ\>_Z[DI__ .;'T']8Z4T^IX[BF*P$*S]^&TNO:+X8!==@G&2
M504.6\.JS2F%2G"31)K%1 #,F:G@SC*0"XR@4#$C,78N.KA,=VJ*X.2Q@6'>
MI;S)%7N+DX(PB ;6&B<#TCLP.\[7D(,!!X 'E!/X!7KL,H*+@'NN([!'RZI^
MP.)QX]<-V,MXLE[ X?:!\7TS\_*=&7EIVGS+95F_[2QGG"!> (EB$RA+<T!B
M!$$JXE0AA&*:."7 G28S-3U>V<S- %#>X=,Q7'\:4LO@_-5 !5;/%X>D?M9?
M!RV_MSTY/$;E>Z'Q&X,_36K<B'NON$?Q]?ZK!YB!=9K:G"[NEN5F76U$Y=<7
M]E^2;[ZM?J-+89;K]8L4\JD:Q?I!6Z"+E6D1MZO(DRDU?<(RD#%4 "Q4"HI"
M$!!3G&04QCG.[.U##PQ-3N'(]5R6T?NH6^?]L&Z;TCN4+GE;,@NS<N2%"*S0
MMM)$'7&B1A[3WV,K4;03*=K)%/TQK,#5QV(YF*@C+]I(MNNUB^?)HO4(;J^I
MZX/.>#:P1U3VC&.?SQTZR/?D6,O&<41([WM"Q(!(3$US%_,3S8#*M&)G(I?4
M+BIB16UJ6]K!/%BPFP?K.I"W#V([8]H;<(&WH/.8!:C4M0+%\SS</HHC#[RU
M$/YXHJW-30/K]+6K=+L4Y@]S2O.#+HPVN]V\I^OUZWSY6'7GG/%<2,9B 822
M F 9,T )*4 60\0R1 @C3D6\5E2GIED,MU7F5^5>RAW?CL7]5HC;*1CO. 96
M-%L(JQ\Z+-]$=!.U7-?M>CWV!G!!R6^_ "O*X_80< 'CJ*^ T\U#Y_ ]KR6O
MI\3,,IYGF<1(JYL\!1CB&-"4* !3S"')%4*T<)NTMWOXU/1+ES?767H=R.PT
MQU @0A_9VF P8-+=L;">9]EU"(P\K>Y8M.-Y=">N&?9Q?EM74QA>N[UILB2'
M"<\18(P2@..< E((#HH84XF5_G_L-%?E!(VI?:HMBT.:^YR"T.Z;O1*8P)_N
M/B8!'(<>\;U^S*?HC/I-]PAZ^&GW73KL"_\B?\CERZX2_$&NU6K]9"K&[]EB
M_EAI$7.VPLW4D?F3Z9ZAONK?EHIR\V]?-W2]^4 WLAIY7PBM"U*%M:N ,S.^
M@P(6%UHYJ$1"P3#&Q&D,FU_VIJ97&NEN.FT6.@)&.PEOHE;&J!;2])GLBGD3
M58)&1M+H#R.K8S:KY_? 3L.]W>H&5HYOL[#.*C8,_EZULV<61U7L8> ]W!,"
M4?%5NW#+^?I%BC:-9"[+&:=YDK D 6E,M9>G4@8HAP7 4M)$%MKK$TX!:QNB
M4U/]#8?;22S7UAZ<@-E.!_L&+[!F/5-ET,+983ID5<%YB *7$IP@_,;U ^>A
MN%PTT'/O@ R2;_+I>;6FZ]>Z_N#V:;7>S/_'9*B4F^V (I@Q(3-A!@-3,R<X
M%MIQI0RD'..")9Q(:9\B8D-Q:HIGFP/".SD@S]L<D++RYM:2&]B%"=/25BI]
M1VE9MVF_'OU**@C*H1WCEMVFV.DFVG)<C9"R&1HU$$R'_ S?H(Z4@'$)7$\)
M%B[H]&906#UHO!0)%[GV<B"<;AR@NW=GGH=#+FZ7XF]S;= >_+Z)I"DA>1YG
M*4B9*0,3B '&.0-YGB$6LP(FA%BK\X%,3$W#=X[WC^>YF-.X2I2C?W-01D-7
MRT+9C[ &@?5_+_RW9^$?4ETR=!T<]HD1UF.DK6/@NGC:4:[$L7>3&?KL\?:=
M*Z7?VXJN?=8(N>GO7K_*S69152B8KJIE/=CY;KD=@/M7.E]6/3U3F/-,.QZF
MA%D"#"DW S.@=D]4'B-**6%6D]D"\SFU/>[<I&P;[R9@TK3+PN>9*A"-@:*)
M7GA*3 &[_BM':2:1(H5*8H=!\U-8_^F,J/_G>0TL3*)I?-6!K:9AF?7L-=K)
M6C4G+V^BW4NQ&P9_$QF9+S4;'G7E Q93A'D#)EUCX?E-"%N/X;X^7LLT',A/
MMWK#'<.KBCH&D/-9(=TI>=6<;"]I*F)O39.=SZOE?<5J':+IR/574]LMQ0Q!
MI#B%&4ACK@ NN 3$'#QD^K]Q%L>*<*>1;.%8G9JY^?#U]S):[6;H19OO=!/]
M*=<R>JPYKN:1E$9:UX$D 1?<[@1P&LL8V+[HUI%WQ>P6DU>;R*EZ<R-L56D.
M:GG;-F8=B?6V4LL<N@#=Y[J,4,3NA=T)%,+[A-VNF-XKQ0%!CX]*23,J=#<=
MZXMVZ[Y( ^-\4:<7WVDB^BO=/$C]F2XW,R1% B%6@'"% ,Z4!#3+$X QCQ.*
M8)9B^S$/ QB8VK[1LN?@<0R!W<*)# QF8.V]Y;XSNB\R D3[$MQ$K0PW42-%
M8.@=O+C 2S"2>Q9B*=R\K2MP['6CACQW//_H"JGW')]KGC-@%S%#%\WAL.DI
M]?ZEW&B2Z]^?M6Q5,_;/DJZ--_7;?*')K9:RV=T^+C=S[6R);RO-F-3,SACE
M2IA"5,4A!)B3&+"TR$$&H>(JC@N*8NN=Q1-34]MM&A&J,]ZE%@)4@Q*?6C&B
MYUJ.FT@VDIAHRKJ6Q4%-^EI2BUWK#18J\$[62A09D:)6IINHNW:?MVNWE:SU
M16ZB5KCHVRKZ\F9KY[#MO<$:CK05CKJ6;GND9]![]TU?M,;;2SVCL[>_^G[V
ML"CBPUH^5\TCRI>UJ0289;!@2.029 7C !=$ 9HG0O\5Y1S)5,;8:O\\1V!J
M>^&[EW*^E&49S5L.W:)R1P#:Q=*N@27PSM.P%MU=!,0Y4G5.:J_QI2,BHT:%
MSHEX&,LY>]T V_GSZ@=]H.NV:C@A>F&Q2H%09HXNPA(4C&* 1<R3/(>TX%9-
M4D\\>VI?;\N=@V5S ):%<3D<@L!?:LO8D)3  Q@<[+3A<(QD;EU\*=Q,I-/R
M]EHZ![>,9["<YG7/[CASR4#SH;9*RF^K6_Z/E_E:GIVB-I-<)#A/4B!1E@"<
M90(PQ+1J2J#(64H020N'/"9W#B::FO2@'_3=%*JM5*3F/TTM35E*U^Y1#@MA
M::#XQ74DTZ5AVL0K&K:C@QF--_M#&CW:-LZ ^;5Z[,F/:P\YPW)D*;D_85C\
ML7Q9F%%MMX]K69VFM7ULF'[9DM0,$U%2&U&9! RJ FAK*L92D$)Q^[.JLV2F
M9EGM&(VVG+K%C\[ :1?-NQZD\/&Y(WR&V&'G@7(+G5T/V'C!,/L7RSF8U0_#
MI?#4F;M'#3CU2W 80KIPM9LB+->;V6_TY_SIY:EU)0N5%(C'H,!0NY(08D (
M*T!20)8R&,M,666"'3UY:NJN8<[NPSW&J5^I725]8#W6\.6Q+]=9:?OL'7U3
MQ];1?SNT<XZ?.LI7>5:8]D,\?\' -I?;IN#WJIOE\T4NC$=BZFC+*LF'=9)\
M2LLR>3]$)O3V7ICZ8E-"[]XUT@MX?OM,7L?2N)TIO<!WU,O2SU.'?;/=9CJT
MR*G,< PX1P1@HA>+B5C_-<D(R5+,B!DML]K0A5U\8VAKHBV%<!_?-T-C.[>]
MKY/.1=3LU-8T.PT%:244NF/0FS4&LNC_<WV;GVW"+/\NQ<M"ZX3C#D+?*%MT
M1M9@AGA&"P1BFBHS64X""I4""!4%0Y0B3)VZU=J3GIHIW')N I)MNZR/@[J/
M.<!OIP#"@!K:1CF!9X?OZ(^*\\AF6I-[:8 S8'Y3_>W)CYNZ[PS+42J^^Q,&
MCO0Q^?O?]+U5NU25Q%A!)H" YFA7, 08UKA#)7.9"LBSQ"D[8^_I4U-$%7.1
MX6Y0I]I]Y.P4S& \ NL0>RC<Y^Z<$MGOG)T]"N/.U3DEW-$<G9,7!:K*+,_5
MZ-0%.G5!3GFW?)#K^4K\7<X?OVO_Y?:'7--'^?&G7/-Y*1_6<RYG*(8R+1 &
M(LDEP#E/04'3!- BAI#1-$X2IR$8(_(^-573"+!7I"E6BP5=E]&S7-<%F[[K
M-3V^"I;FTS07>,08T;F*SO)"26<C?U.\:9(%HQJ#FZA%(6I@B%H<H@J($<L\
M_:_>N'6?'OF?5B&H_X5QK@P-P,*P#?*SW)@Q40_KU8^YD.+=Z^^:H;METV9A
M^7AK:HXJ,WK7BK>($:>0@J1 VNCEC %&$ 608:4H8WG&K [@A[,PM>VJ&I.F
M%JL_R\B\CI%J68_HEG>WS6K LMCM.6'!#KQU:.;KD70M^V:;^,5(H'> OT1;
M(:*=%$&.'(:#Z%6##V!C5$4\'*9#?7K%DT;NYM+H[_M=SY&[Y68]7Y9S7D^,
M9'%<Q GG0%+, $9F1F<1"\ 5,M,[4RJ4'*69RR5.IZ9D6Y^@T\[E)JK.5?3'
MWS#>=)(S[L+F^^JEU)>-UM;EXLI[<@K&6,\)N "V'L!]]W782NQ[-FGP59E&
M2Y>+W$[+D+\6=&\-7:P)OLUN]/'G\WQ=W;-U*68*9E+ (@-ISB# ,L%Z'V(2
MQ)SEG*(\3IE+']. K%HIKO$+!=K]2!J.WZ216,_JCK/7#%VL?[Y=IB/I+M@T
MG>VE9R$FM;&<XO.?:DOI =KW9M)':F!>E"Q+*>^?I7GL\O%7,\RI/2=]_8UN
M7M;ZSX-$@%Q)&0N$ *_Z@0F! )4I @02DI&89P(ZG7 .X&%JCD@W@>"IYM@$
M&O3?%M6$L^$96 /6QS)3*RSJH3.Z*NZ--F[XCRH!;K9I&Z\W42M$T/2-*V#T
MFRTV@(]QL\J& W64?7;%HX:IR=^J6<V5BKY;/K]LMCD+-!6JB(4$"8=F!AU%
M@,$< IGB/!>%3'B>N.C"<X2FIO Z?$85H\.30,YB:Z?'?" 66%D- \M9%5U"
MPJN^.4ML5*5R2>1#S7'Q^H$G9F9DS5U9ODB1S+!"G!5(NP^YMI&P,(U39<Z
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M5-]H)L@%$,Z/!KETX\"&Y/.E,67WG]ZT_BL_O,@99XQEU3$>SRC &,>@@+
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M>=RS;!<PCHZAG6X>II;JA_TF-]]7XFYIO(\JRW]WNJFT^BEDPD#*I79U99&
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MFJ)<F%[[YD2'Q8#(#.I/"F8\QPF1RFJ8W^G'3VT_J!B,:@X=C/)CV"S<H:O
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MP@Q;.TGQ;8:L]0E_=KA:[TU#F]1HO_I.Z*?-U9Q7%D8=PIQEG.&")A00GJ<
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M3 +]MKK]_ZE[U^:X<2QM\*\P8B-VJR.$&5Y $MC]),MVAV==EM9V=<5$?<C
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M-$Y99-6'T&#,J9'EY]7R$7R>_U [L._J]^4A<-GLNF=30A/8S8C1,9B>*7
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MW>I'ZZS"NIQ,L?Z5;-B3LA+;%]PNEUNRT%7 U1_JL#WR*&9I) 2C&00\2CB
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M+>9-H 6U:K?9#:KIGG0@5-ZWC3U0ZI^8=PX%/[EY!R.]37K>.64O9NB=O7C
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M1 ^ ^S22Z#.,?=7VK^)%?4I/RFJ\;7S7=]K+*@KM87K]HCZ=NLXA@PF2/.=
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MZF/]G_\'BJ/X_V&5Q)9]1;J -MMDN()OE%,$<>9H^NX*</8]/@P0<=N_HVO
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MQBXB,BCNZ_)3^UG:#\5*6?N;UP?U%FYNEUQW0WRIVJ+LZEG'-$E(RB@0**0
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M#V, \S0&F"L+.XQ"@A*)4$B-C&OODDZ-4K06JV7I'&B2!<&[TT.0NLE+[_
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M#XK NBR%88Z1X]H6!@./7*S"'(K3ZA,6]_9CJ:HIV(SQ!(J4IB")XP1 FD6
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M.R.\F12.??Y?Q&:6II)G*(L!@0("R*4 F.($\#1,(A'&2<*L.HYU#38UX^7
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MER(2(:6QM#$&S(>>&FUH28%4H@:%DM'.++  W,QD\ .C9R9I"1V44M\$6NY
M"QXTD@=:= ^&A3UB3HT.B^%'-4CL83DV5GH\8>0<]5W,S.UZO7UN=EDO@JFM
MU3]6ND/>0C%M*:?:7CUOGV=1GF0))8KP,(D %%P '.4Q@&&,$I(C!I%55>SQ
M1)\::S;"!C]VTMX$SY6L(R4:VT^_A:-O<I,Z??]>*PBQ!4!U,EV^*GL,RL7@
M)OCUROLR7LIQ[ZF;1M:QO?A_C<3CWM/B+/>XOP0]^SA(J9Z]:P3[G?S4S]:.
MP?ERJ_8)]R^B*&5?SY!@H=0M5W'&$(!2K6,X4FM;'F62I91B2NQ:/!@//;G%
MJ)$\V)"?/<QX"]"SA$1Q)!.0$:G,B)Q10*#:/"68IE)@EB>YL.E5Z0GT$;I9
M[D&?5SVZO6-OMGS[0=2W,V8'9MWP7'MFRQW35Z%)5K%,*?--\"#4D"Z[E-OC
MY;;EA_GPXW8#L8;EI%&(_1-Z%"R^9:S8"M[LRA[4CFV^??ZX*EHA'X>)UC.2
M,2HC0D#,(J3CP 0@29(""KF$@BF&LR@];#_^U%:/6@-%8[6GXJ72(9"K(C"I
M,&Q1+K;';'6SW@ASX)GZ&OAWCJ):_$#)'[2CRXYJ./A%W:+<KE_T1RJ<ZWP6
M[*K>]L>PLWYMC\>.5XFVO\X'-64'/&9PF/'A<ZL VT]JHR3X;R^KY=TNMG8&
M84Z))!3D/(T!9$@M.31+ ":(9I(C&6.C)E8#9)C:LE.'(Z^DSHUX7BWK:O5J
M%5H%?S[-V5- %HO.PO:K5@W /]7D!V2[63TKHF#JSM?FUFIE6Y41>64A0-N0
MO#[S'4=9S%.,0(1X F"8,H!HSH' F$<AC4,<619S\CSCXQ1YNCN(-N^:VW+*
M#EZ,,EQ=MYD:=2+-]ER>)\>S!=*QO-4EW]=!I4(U"7LEO 2VVR+H*]C=6(ZW
M"H"W!:HC*-[Z4?V6SO="SI?:![G<%'.ZU2;=@WH5]SG?G]6?/VW$\WJ6DRB7
M"!. &%&;-,1S0# *@4 QS7,HF216!_3F0T]MH:PE#]JB!UKV@UH'6OR@E-\R
MS=IB3LS(T _2GCG0'<C6U&>/EU/&LQA^5**SA^68WWH\H8<#ZK-8KX6HG5G+
MQ\^"K,67E3)"Q4-9C5KM1*H(Z.^K#S\W8LEGRN*/,Q@G( L5H4$69H!RAM6.
M@$0B(2C&L5'J3K_AIT9OE;!-Z6[M<UI576F4 2A*B2T\'?:38>!>\@JQ9UZK
M9-?))[7T02G^35##_K"'_7X'^P?_L%OXE[S"/Y)[R<<TV'F8>J/8Z6"R?^IX
M_J7>&A^XE_H_I6>%C6<=$/N?\GV\EW7#))T:L]ZL9Q3&H< T!U*D:N6 3!G%
M+,& 2R:R/$$Y#^WJ:G0,-K5UHBVK]A[H2HM5,KMZ%0*F1;8LJ-&%M)FIZPH_
MWT<,1]"5>>J?&NCN.J&SKYMA@(G;:AE= XY;(\- ]9/*&";WV%')NMBHO?U6
M.\1?=.&?+^K5N/TY7\\0)#**,P0(S+@N_AP!1&D,>,@QHTG*D\3HX//2 %.C
MC+:,@18R^$.+:;A!O@AC-S>X ,>[P\\2%V,2N*9\UX>O[FU]].I?QQ_\Q8>/
M\I%?4ZWYL*]>-[2,815.\4XH8W$?6O%>_<]:626W2VV1B/GCLBSW]5WMH-XM
M](%NACA.N<*3A8( F"DC@@A=- (2#GD:DRS*^Q4T["7/U*BB75"O#D&BI4:M
M@*2;H-&JK U1Z]6WJ&&_:32S2T:<',]4U7]>ZE*'@=8J*-7R4O5P$,">ZA_V
MD^F-*B$. O!R3<1AC^T9&; @Z_6]K.OOWQ=E]?W29%!&%TXCK#9N.=*G&3 &
M5)E>@.0AAABFB.7$ZOS_TDA3X]524/WQ-AU35T75/,+*%+L.L.$YK0O8?!MG
M?1&S/W.]AH;;D]6+HXU[?GI-Z9-3TJLW.#HTN%TNMV3Q52PW32U/&8HTEA$"
M.$\5:W D $XR L(\RFE(6(2H4<42\R&G1A][?^FB\I>^U#E7NJVGKJ\UT$E]
MBGG/\X!!2+[5&4 E=*"EOEH_M2^> QW]@W!]:^>^#;[#O?D7H;+VX)\^Z6V]
M]A<UN^JIOWQG3PN/K)_T___P[^W\!UFHYZZ_*HNRF.M\./T'W7/IX!>M*V<0
MLCC4 8&,9)END12I/7@8@EC&G#,DTI!P^R[A@V2R^9S&Z_VMA2SW<DS_(/;B
MZE[/NDCM03=P_8M*-DMK<M!DABS!<28)B#%1D\FT-1]+W=H;):&,HPPGH6U#
M[Y&GTG^;[JL363?N?ILI--PTC#4IOC<62K*;H)R1EH WP5[V8#==Q[]KW>!P
M_^$"6+=[E$$2C;N/<0'>R5['R4/[+:W?R<^J%%^[$I]VGK]?Z?*0LY!$3'"1
M E2R;)8)@%@: A9!D?,XYSBWZB]X9;RI[80NE"J\J<]O*J$MW2G7(#?C1X=
M>F; @1A:$YPA,DXI[-J8HY*4(0#'-&1Z6\^3-*+]PV6@^Y>MKM^D_M$*>/^T
M;+70F84\C"7)*6 X% !2A #-$0,2X1Q#'&-)[8[-+ :?&@75J2#KU4*G5"FS
M32J+39G@O1-RK&;"\.3+$[Z^C[E(=<15)]U4HI>_.$B_44"WY'=XG-4#-;=G
M5S8"C'M0U0.:DU.I/L_HFYRJ4^;*H1Y(<5_HNIJ"EQ5\'D11CCJ+U*XUB;D
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M;5TX''Z6==G</Z3L@1*^VHB99&PUP%[#4O>#J&<V/H#YT OF77 0W:9HBP'
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MF0 9RUC$8ABBG!FE-N_K96Y3\N"D4XD9_*X$#2I)#6,'^C'56Z='(^7;5+<
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MPJ5Z8!I"[@W YV0)W_PTO?WQ#>8KP-5QO#Z%Y2UQ3;B7$*("(DQ&E@1^\2
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MY>(/#.=7DQ @FX2;#E/6E0Y5@3@G _$^4)F<L$'6B4FV4332.,[:"90AY-\
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MEAYR=>^QY%56W%I#<G""2.EI.15'_X)':@2U7D*=V\Z/437R[?P10Y&]]--
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M8ZYNPTF@R7-IB=$ER>4R1]@%2EB6,0GG#8MU3E2VT[1WRO\Q^5Y?I&9<2^&
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M>0@V9"@,C:P+&EUJ,R[Q&:(Z0=OP4-@%NA/UTBG$Q.T\4J5]T1&!%\[K#M
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MU]$)SR6[I(>2WP^JW+^T4KH![Z![ %0'!G;[WD]\WE2E/*C!>NQ6)IE%YU5
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M>D;=@P(-J9$I;1UDU (4"H2 A6(:$AE7W"G;*,W:@[AQ43<X(/;.^8_33@>
MNV-A4Y8C*&WSL3:,2I+,NJ0A4&@,3*D@BA:Q^#9331\1TBF0CE7T?#BI=P":
MWZX7L^GJ>H$DFM^F?]6?EK><<.]D0@TH8QW(FA2X$ATXQ@47(==)(VW*F';2
M-.[M3FLH#:2+#E#U.X8E?IY?Y;=?OB[FWVYBU-LZ:8^*_B\ MP5!%:5)0JDV
MACCF)8N"F387X<\0->Z]2VM<#:6-#H"U4U2_W]6&I!)]JJ.]DJM+F]$K\#J:
MRJ"2B1M)0>EY8ZK?#ZJ?;.:^Q@WDCU-0SY#[VV*^7$YX,:P($I83C(3E4X:X
MKB-%R<DHA?+LS"'\FJY.@ZXC4; OR Y720< >Y/2]9>ZRAOS+TA$I)NMVO3S
M%6[N?]Y\F2]6F[NAG<Q/?.+!!A4)+!1_*F4I]&320I)DSBYZ81J]P0_%0:?A
MW3"@'47-A\/;W\![AI\JI1_;N]$_<#5Q$;/SA9)X7]N7@G>4R9<,]+NRF%),
MR&U6&3Y'5:=!86,7>J@ZCG>@\U6X.N?;VO/[[D]Y0WORR8W>RI[GH*LWL1B]
M58S5B2.J@)(UKXA,@+5,>HHM48HVET]=O(E]#'_]3'8P7?U,&OM>YHM_AD6^
M":XSU\DATY YI?,J2DEABB,V1'!.E:*+:#-W<#=-K^'=ZQ"\/?:% VFK@U#R
M[8P\"!(_;ZY7G^>+Z>K['^$+;C: )9M83$#1,7&2:E=#,<1.<8XGC,7*-K=Y
MNVD:%W=#:7W>1 7=@FES'X44!8C:Y,M*+1/3K! ONI"]H1'1E9!$F\?\YZ@:
M%U!#:7XO0!VAA@X@]>:ZNNNK:9@1/QNO7NX'MJ2L@L5Z#VDLB<D$!4X[!T*A
M3"XZ8UB;-.!YNGJ$U3'Z?YR0#J>,#J"UU9VOC2]9I;QS=>Y/(!DQ2FE\'?'H
MD\B>1S28V@QVW4G2N/<<C0Z^8130*Y(>V!PWA145) 68+H J+-8-"Q9D$+7K
M2A3MVT12+Q#683AUN/KW =61NN@ 6N]))W7RY^V LCK>DT4!*01!YE;3%V$2
M2(\J&AV#;?1V\",='0+G6!7/!Y-W!VC9*IG[ZS\1ULWHG$YD[F_L*A:%8#/Q
MF%V,K:[[GZ=KW&O3<QYNQZFB5V"]^3*_GJTFP?"0B\Y0,C,U[ O@HQ/@E#06
MF0@RGQ%5-T1UZ*".U/U>,=/ABN@ 4P_?M":2VYP<$Z 5SR03E2#H6IZ)&9T4
MWOO<9JC/0RHZC+*'0<W1HK[,/JAUXV+8-"YN=JUN^A=;-D.]_+5GZ(@ZD/>N
MGH!<EMQKQX#Y)$&I'"$XBU"2=9FGE+5YQ4] MXVX[PK]=SK[M&[(G9B0M2_(
M0.M",JE5*74Y*OBL&//9ZB3:W'!M)><U//P<@K)=S=+'ZVC4/>/K,=@;'_$S
M_>$TA:O?$)>W^Z@M3]D%M&#K$@AEF 0Z7#C]Y+1PF64CY4M^\H7O> WM]L<@
M:$C1=Q"\;3AY.UM>+^J)--&2J9PXQ2,NU1HCEBG]]@X,<TX:*61);?8</*;D
M-73$G^*B3M),!\BB6'6^G)(PUD'+K7EHYY@/D80AR+LJ@0@Q! 2*B*7A-J04
M6XT7V4+.N/.;Q\?8Z3KJ &A_S%>XGC0Y#[/E>TPX_59O??Z@R'K#4%9&ANP+
M!*4$,>0S1.,%%.:1E^R]BJ8)Z%XD;=PEV.,#<%C==0#&C=?^&/["Y:20,+(I
M=/@[ZT#QM+[*SB "<B8*HR2]3:G$0RK&W5D]/L2.UD@':'HPL>G6'I*CZ%)X
M#<1&W5-8$GCC/5@=-5-::6S4Y/24EKV095\OLD[43@?XVMA&W? P6^*/(\)N
M68J4M>B"$3A+M:>&%8C<53$I)IU..830THD]1]Q>"'2O%X%#Z^]R2OKOKTHW
M\\(V,FAY,[SCFYI?!N_#85?WOQR1.RDL6%4SU>(<>%0:K%#*R510--I4UL7]
M[Z^$M?EW)'BO6[X>#+*[-<D2K'9>:'"A%MAE13%M- H"AF2B)B$UF@C[(FFO
MX5[X$/0]F>DQJ.[&7D.Y<1R_3!>85K<5,3?S03?<>&=5%(%D%3EE5XGX"B$'
M$"0VH;)5ZO%DMAT7Q2]^U6NX+SX&60T4T0FLWGW%VI,V^[3%2AA&5;*(H%T=
M*:&1V#&R5MQHS&A%<GJ_!XB7O^LUW!.?"JRA5-%!2G*[XO#/\+W>!-TE5C*X
MX+,"'3QQ87,&7P('PDM2UKA02IM[X^WTO(:+XU/.R0&TU '6GHX:OF5$1&&4
M\;$.DLC$R'J_)J5/PGO*R)A@VK69&+V3I-=P4WP*XH;158\)+LGS&RY6TWKO
M7:_#-S9U3 :[ZZ-.3E'WHG&@'/07C _6T=R!AVGO"D92,\< RD</Y&K(@&2.
MK#;[8FI50+.-GM.?1Q]^ZH/IYDD'$94#ARF!DJC *Z= ..EDD5B2;?-6M8.@
M<3/" ;#P],WS=,'W6$ZYPT1/N ][X1-;.966]UL[\*2#XK(V.UH?"$^L)"!\
M"> N:*,%"]FT>:AKYUMNA+LDA=ST0$AKG>$V0RK%D,DX!,>"!Z=8LLDS+T*;
M7L@MQ'3I4P[!P#:?<HK .XB%/WR>+U9U"V;EY6[0<HK2$Z$,2M:A3IR2$#W]
MSQ2]=2@IO&)M>D*VDC,^;DY2\N.A^R=+O$?8;'KW7&2H#47Y)AD/*F($SZ(&
M;KPJ3!JI1:.5.]L)&GF2_NFJ?@D\1\B] _CL" %NNS9-M(ZE3"Z9E7IUE<$G
M35+B/)BL5;-8^%FR.H/2,8J?M])"!Y"J<GD[HT/]NEX^K U-%Y:2R0$T<[E.
M9G?$ 1WM,>D2B#?/=;O8YT=:QGT&&?H(.U'6W:'E0?-Y4E&9@"2'')#"01X@
MEI"!TDM1D!61&XTYVD71^,'/*9I^%CA'BGWT=S#2(%L[S-M9_<4*88R#;+RK
M;\,(/I)+UEY&XJ)PCX_.JUVO7H\^N2?='ZNL^5"2&UWM.4^KZ,/5XW/SS2S_
MY[3,%X]^?\-CS-D((05@%);"O3K88CU;M4A#OI:LR9?]T'$< >,?/0.#Z QZ
MZ."$NGM'J8-Z5]_O"\363CB4[*U! X[.:PK[4H(0:H1FI'&:F2QUFY%$SY(U
M[IO\X(GZ8!KH $Z/>-@88?:"TH? (2&9GI*.C- J#5IDI5-*,84VF=96<D;.
ML(93]Y:-4:?)O@, $?E?YK,/JWGZQZU#1>]+W16BL Y72I:1<*RAP]LH(U%$
MY]I<$CXA95S@#*#>)XGY*;+N "P?KN-RFJ=A\?U#J/MGUJRL[2AG;];#N%@P
MM5."4<3GF01D.C"& D6CMH*=)(U;TS/XH36(Y'N T#WY-6I\5SXNPFP9TGJ%
MQHV)J4 1HW "=+9U7WT@GRPS@^@I$;48K?9MA@Z]3-O(1]DP('@,K6$UT@'&
MWO[Y;N-?571:\CIVR]5I\B$9\%Q0-I(SYIC(!E.C8>FW)(R,F(%U^[AN\"A!
M=X"0']WS[W?3O(I/=/3&!(6X)A>M!;GH'(""1!N$9UPW"IQW$#1NF6"+^^53
MI=X)>.[O/GX+"3>3_C)%<C$2X4&2DE7RAJR(9= I1YE)7L:>XY+YGJ+Q+QI/
M5O>S-\U'RKX[#+V=I47=[;FIBKTMQYX(:WFNMV<\2%M7>3KP4C PV?$H=*XS
MX\\ J!WDC7\#V19=0VBE ZBM3_^WRV7M6+JNT]'^Q,5TGC]\)C$O[R7XKCRX
M7_V B?YJ+<N>)&N58]Z!-+HN)W,>HK0!I...8="*LT;1^$ET]W1G.0PXSZC'
M'E!['[G^N9@F)&;7G$XTPR*S)W,3ZQN[6.>D.@;"2Z:4]=SQ1E?D.RCJZ:)A
M(*0-(?L.,/2C.W]@%O<"6_/')\P:[0I90XJA[D@AXPC<<. 9 [-,<_1MKJ_V
M)K&G3*#%83N4=CJ W8[ZJXD(#G,BN@NWY(%C'03N1(28A;&4,0NEV\QB?+:/
M:*Q14BT@-83D>VP&^4 G/9WQ#]C[\Y:TM9?^D?;]VD%>_,R3&T(.HWJHD2=U
M9,Z#ML(MK0'<!\5Y2(#<U:VXG("@T8/2GA+%@D*[1O-,7J3MI$J6NU[->Z^Z
M_' =_P^FU<?Y?X19KO_X^WO,^.7K^@)P2]L4ZAQ#+AQ$2;4ZU!KPGGZ222J#
MUDG^6#8[JEH&(&;DZ27# NF'6I=S:^H2?=KZNO&H1K<]/[FY?]O&P?F\G,W6
M<,\<<.'J[%?AP1N-H /3R6=*!W.;NZ-V7NZ^:+ZFO(<:C$M9>X_UJ;[>7$O+
MP9&QU'T;A9L@9':-GJB/(;=[YW<(OIZVN[16X"5ZO _77[Z$Q?=Y>?/ITP(_
MA17^9[BZQCI(M^H[G]#[.]17-_>91\G@?$XU*B-2+!88TGFK1+00D)*3PI)$
MKDK,LDT*USAT_$AF-U^0X&^*GMY\F9-R_@=S'6IUQWQ*PIL0.2"3L4[;18BF
M2""8*14HWN%^OWKX?;ZM>_]W"!1^"/X&E_78%?2'1K,?<+6Z6I=DUL:WY?HP
M6%OYS5/>WQ;SY7*2BU),6@\:D01@2P1?) =+XA4),00EFB0B^U W#C@;H>>4
MQ&1P5;XR+-__,1US7Z;77R8LH(N%PB9,) >E? +/N 099;'6B*S=?DZT-:7C
MO.Y>'L9/4_$KP_O?9^%66?7(K+_U9I;K0J6)B=IDAZ2@^FRDLG7D!>I]10FN
M*%9WN>8Q@+^;Y'&>D"_/ @92^N&FX&],8;;.$_+' :=@O)2>/I+(C1QN)]BA
M)AYER2 S4Z276E&92P(ADXTL9R%:-7&=1/<X[]AMX3Z"1@>;27@FC_Y;F"YN
MC/E6T,59B])+"+8NC$+*<2+: $%99%[+S.U^G:TGDS+RE.F&2>!YM71I449=
MM3S%_&9UQ_8+1]!-6=3;V:,'X%__2I^)@%JU;(RKR_:X4W6H*+F-*!VYDF0P
M1YF2YJX)I(?F9,3,\\R0/<5:1L7/JS>V-RE=?[E>;U3X>2V>M_>ZGJAHD;)[
M ;Y6;BA'44H0](M7 I-7&%UJD]\.RL:(R>]K-K/!D'.Q-O9C:$M9TIZ2FQ2F
MC4=4$'Q2=9ZE!U>B!ZMTRD8'YQ\O\AW:KHXE?>2-#AT%<>=%08_#T5]Z_ON#
M)$1?\.V4.<<'?T?S1\WGN1KH]7*3.M]ERZXPKJK[%%G3(: *1,=9G5B@34Q!
M!M6FVN%'.DZ^BMFL3=N4H__T_>>KL%S>M"*:;$+V3@'7@NPV6CHP7- @=2HJ
MV*R\;5/']PQ1/8RL. H#3VY,!A)\!_78N]OFDT9O(TM0K"6QL,"!HOP"6DK)
M)(^I%MXW0=!)4RO:M8L/I?2]IU<<HH$>H/1R/[UE)2@T#F) !*6%!.=# 1.<
M4BHZR7VC&=L7.[WB(! </KWB$(UT@+'[H0KDH TS(M<=%G4(L&+@6!202XS<
MVH IM&F]O)SI%0?I=N?TBD,$W0%"[D::K=WS0TN2A3/MO8"HC:ACHS4$BQ%*
ML9Z2:7PZLG3H^8&/21KW"K_9@3:(!CJ TD/Z;T>/2Y6L,0RX498X8 C.*C(&
M=#PPG5VV;;S.4UHZF1QXFI(?]ZB=)O$.,+-)=W_,<3>>U)7B2R'U<IOKY-_@
M(!0=((IB4 J>=*LB^]U$C8NB4_7]V/,,)/P.</10,K_?]7]*RE#)+]>EDYJ$
M4V*B]-5[(*_LN2F.B]*H2W8;.>->7K8ZODZ7? ?PV3FEH.0<H^ ,4EWLK9BD
M:&Z]TSM%[W1A6F";U8(G38@XBP,Z4MG[SH<X1/(=(&AW%\JZ7.CF4?CO7^>S
M^S[UB9(8-%:WS;".&Z])0S!R/08HD8O-6K4!UQ'$CAM[#X^[UOH:^U5Q)W^/
M)F*0[X_.YER KRN,==:4_U(D2HX?N5"!![Y?E_:^WSCN,3@<DMJ)N0-W=G"1
MXQ_7-6PDP:[_X02YU<X7#5Z2SU8.%43G'%B7N+8RE\S:= R?2/BX Y@:'*]G
MU&.7?;)5E)_G5Z2WY<V+UE'/P$\_Y?2'WA<H:_.4ZXQ-+B1'6,("2FI'&1U3
M@"5&J[B20;39=S;P4^X3X=42NVV-WEE()G0LD%4-(PLO$*1!B-YS;[3/OM43
MRKXD=O7,>P@^M@X5'%PIE^%53JDQV?EA#7S,&:M&N'9HG([ "J>(1XH"SA0Z
MP+@U+MJ06:.A(<.ZFH]U;NOUXOM:EC?5A=X&GVVIT3_]HH2M$_*=!L&UIE3
M!,W:O(P\I:4KYW&(QA\[CQ/%W*V7^"DL:VG>EZ\X6ZX_[6@7\?23AO$/+U X
MD'.X/P;J4-G[+WN/-R6\\^7JID0Q5G+^#-_7%9!WT K%YI0I7S*:$Q;06O"6
M3BB*B(,OB5E1VBR-/HWNDZ>.[OOM/SW\]ON#UI#<HA0"7-UJIXPDBRQ9@90*
MA:&?4B,??"+A(P^;/Q]6GPPR/:/"+\=GGC"_[;G/:^0_&\YJ.Q691F5OZQ&J
MA /E8ZH5+AYDR:@,FHRF33(TKA=]\/3UV'3>_#,L;B[LWJUO0Y8U]+AQ-,OE
M]<T-R<TCV;V-*6>E1TJ*<JZ-Z"I37&*\!C+Y:*) AH_'R0Q?*SP 'Y?M8P]
M\C/ER.>&0P\WNUNX?ZB A]R_2:OI-XKP'W&L"VHL(4') NF0R75E3\QTWL64
M;;88<IM+I--I'WG/2%^@;ZCV_H >'W/\'DFLT[3:/-B\F>5'O_/WV72U2Q9,
MNL"<<J0*4W/3=64,2<7X)!E:Q52CY5XMN1IYSTDWQC$>5+HRFU\IP)Y_1_R
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M_8>_D%3N=W_4>DM9-WYPX^M$O.+!RTR'L;*%)6%3LIU%;,<Q.F[QX:5:V1E
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M*![-FCED>;_A5P=\:?<54P=H^L=8O9'@>PVN'GI)I@5ZD0,@\R2T8B@+*:(
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MC,1YIA0B!"6+$<\=&WLI^><WX]RI-E+R@5(;6\G_\6:BI!?DS 04RA%!U3U
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MSO/RX(*N36OCWE_;LN7Q.-Y':85$DZRP!#EC(T%;$\@]"Q*D8BP)+VR2C?;
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M! 6]'?>T=H)O,]SF^S+<^G: #WAE&^?W6)[/X/@*E:W3Y!T$+6/-&RC@:_*
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MN=UA;M>]LH;YD""EL+X3+^"=%6!XRL%[YU&T&5I\-,DC=0P.P=1# WH>]8W
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M $;M(00F41;I1.B4$'_XV<PC6H9-6&U[%'.:X$< G;_C8EH//V\9$(I+S94
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M:*?]?<7V%_6?0&S]O__U_P%02P,$%     @ XH9^5.Z7OY#T0P  L+(! !X
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MXM:_+#&NQH/ F]1HR+-!^-D)?K_*]EQCJ("K9;)$=G&L]T&D@A2H\QT.\K[
MX,R:LF+@A''T,$6S=)?CPA 4J,6R1L;E?,R(7C1"R[-$BK<JFJ@+C*LUME2/
M0#54Y-#=-L8#I$(]WA9@JLZRN=PK]NE'3;4<^JED'6*%D7MLK1MP[<+P9JK'
MP4L1$2M6BHI1=^M"$"O)+$V&T+$MH.^NC>=.N)B:B;H])D(;FC6NN\(JS<3"
ME D]@)"OB1<G_:,%[S3-+&-WG1$>1CB/:>X1N2,[1&K&;.(:[V-$ *Q+6\AN
MPE@G;TJ6)7<$([.C5^J,DX\D);<A%P1R_6P=JXP$,:T/;?(3(NB[K%HVJ>%[
MDYW7-6Z5@/XQ>CX4$F'T5JKG13;)Q%<.@DY^.3YE/H24HWN1\CSU3K^.?KA(
M)!_M3SP8'F\/' <7;.&%] ;.]S'3@T>0+L) +LJOAKE'[3THEL"I@V(YG#KH
MU?MXAQV+84EU,DNGJHA3B 4JGU5;5MZ9_9#$35U2_?+$'X55NS":.<$PZ3<U
M54@FS>)@$BZZ9+8=W/0:6V2_!Y6BJ[NU$2ZH02FQFL6*@37! DXRG.9($A4E
M9Z'@"?YZ<]C;"[;[$?"7-M_$F_T55E$W<V%\)\!JO![$^J)45<K?>9,D[<)\
M[[V::*EG%S)D1*D5F&.1] 57;2<@5VW"_<3 3-RXPFQ5F%PA&"ZE5ASF$-E>
MP11(EC(=YC8&!/*+0R<>X_?@T5Y.V(^/!JL3K(:U#3P,L+<J^%287BKVER#D
M,AIXKLW4$/K%T3);Z$!80<-I.62[84DE45.&PR&*@$->0P\+DHX<#R.TM"5(
ML#DC#S,:VV)T(?<-J19@MGZ?X?Z[QN181+/C.*+CE_9PJCZ2Z'H;)':(HR'4
M(56RS]7';-[.+;\T9B$;F:\<\SA&+KCE<$D AQ,9"O\CRMK1+Z/1H2?4&('H
ML3W1TC7K12 8@\.[-WV!#!D:X'"T^HY8"J/1_BI+X9V1\UM1TSVH@ ;2)D3<
MR50C/B#@4I8:]SM^"N>JJJF3%N'#>4O0V>"K<>_##A%;EG]R=%^(G>6* )+!
M(>,/=5H2RN@^9>//-#UTBU^I.QZ(=+H[Y6 ]@<29*AH9GN:ZQ3YQPB52%GOP
MM;T_RC%L?K",EYTAV*M,"@H558J:"L\"2([/ZH*,]A]O;O\>[$>K-O"O69WH
M/%>%+MM-;]_S#O.<4P>XH337J3,@#6:X:1MFR;%HRUBHK81R+6]K%.-Z/B[3
MS)@+E*LI&B1-=';G6#>7>"Z&ZAW$:YH23RYO3],31LQ&YNG!  PE=C3!4="J
M0NO54J4(QX?(6X&8L__KBY#8FLGD':,9$=B+9:T]3])U<S)A'JXSAB$B.%RG
MI)*,8>+(*V.+<8^-<2JZ/AQ-+:4\A5F$\-7WNVM&*D=2;7.8=>)70FDBG*O"
M/8BF [TGX8ML(BRH.5%1VJ(,:.&=*]A&J4&N]AD<S@?R?>-,UA$AL?B^7@&,
M?<$+'4!8 ZPJ\CRMJ(&162[:RMH;AEAP[54,SY4!#3]VGSJ)R0XQ-<>].@-D
ML=$,4[+E!6"'45D,>48:K95$<].) 2:>F.]H;L+RWU4O*&F2Y"H-U@S&O*;[
M#CS$U/W(3?WM4)?H=/&@*]P6>%B\ ?/ND*HGRD?73> <4KFU/<P+<6W ]RDG
MBLM\2IA,O--]7O#*O.#A?5[P/B]XGQ>\SPM^UKS@AEY_*"38MP^L2G(5>F0Q
ML@I*5_62,S!)\O@YLN,PDYZA9RQ%)*2"<5#1+X7J%Q48M!E8JJCEC]%EGX^S
M*;&>]X-I*TH)39!/9ZR7*1BJV Q.*SI]<O-+QK=1M>NJF"7A<,6IMXQPL9L@
MM!S$2J.Z(W],*=["UC;ZCV/J2#1NT/PVS^X_:-AZ1) 6TVZE7'+9HCV-+VIB
MN'9XP1!,;2]"VL!@G*(G$ L:.Z'*8'93T<Q2#1??"R>D!%G>OOK9W=MK*TF5
M+7Q#[^I/C6TDY!]\N0.RDF9KE5WP;/3C.27^N/_'@JOY&^8SHYP>JK-H##[B
M!_CVH[^8DUTM:N[MLP'[[/&]?79OG]W;9_?VV5VPSTZ'(AG(]+MH3-/(9=G&
MT8(Q"00!'VOLB\Y@"6FJ[A0\Y4THJ(:A7:&A'H*VK^1@#HGF73\&#"3WPFL<
M6E(MS*PBV4$<H=2!)9M$E]J!MCF#1*EYHD/IM7^WG-DP Y8T^R]7WFQJ7:D-
M)P6]J!(N;Y,/EIM\TJ*]A+U8-<*/_BHSPH9>\7V&<5 L6+[F\#%?M8GA#Z<
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MDM3W"();I6">W3+]<D*A 7&Z7,73IA6.;S@&IJM7IF@R)X%)9HT@41+="J#
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ME8"$T/CO-^O#8&%%M!1D]1.!,-G5\L>)03?2N4.Z)#\,XY$E]<,[N+DK+F9
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M%[$;/8QNV\$@&(^NT G;-#;DO)\@) --8D=HW5V6UA!,O(''D=%2##4TBD+
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M"W<SA$QP&>9J>\AW+FA7S^*NV-Q:'_X'4$L#!!0    ( .*&?E1JFOHPK4<
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M5Z(WG*&OB7;S[]'71/O89.;3D<G,=PQ;)7^+#RKX2:#)MAXD/0$CA;UOM#O
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M20>WUE8$X.%V6>5<@4>:@'!!RR5E%H&ZG2Q+72AR:SD]C2/B1W"X%'0S/H$
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MX* _DS -XG08&_*E4ZYG*F?#',8M.7H57<%Y2*ULLI(CJC-82<6.?9O7(AM
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M&65\-2'>T/?#F(.E.!0&.[&.I$"(P[6^X(EM<(."N2KO>+5EK;W I[17%A+
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M%9@ G9H0.W_#,<:Z9,3&\OV.@4[98[%A!R'H7J&I=WI=,1D3QR8R37JXH)K
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M]MT1XW=454F76X]C.RLL=9G1.?4E./^U#0@('J@?3%A668%J)H\(?\P5WG"
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MZ#5(<A_4U05L,8,QVC'I%;$%LHL8FS)KS/![-8?&Y/>9E^D5Q,$<I#$(5<P
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M"ETQ1&@09D>PRH6JFA)5F1]>5O"IKK*#X*4QJ7![$/&]:2Q1E)HH S)KB %
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M3B3\KKWTN+H>63AI4Y2A%YC, H7QSID4'<TKA4OR$4L1%M<[\S(E!&JG>E/
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MH[HK&BX=#\&OVQ7PBUU:O-CO'AC9I9\/P=:KWVEP._3S%J1X%S E*=YWW'S
MHKAJ(+WH*-1=8CWFW0J<[E,V]TQB&&,/4/P/WYIO3J/6)E8KGRZJ'Z4Z'C[*
M;\SVUR;5T#Q=D#]&;=P<XZL^3N"RE.Z^-'U$&P+<\ML'W%_E8NG:Y&QDAWZR
MY:76-3F,]<DB-)V+,?=CB]EE3N$.MYCM7&>+6<O]5T7TGR:]^C]02P,$%
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MU-M[&S\[EI?45 [F*Q6UQ"@.U50(-A(C3^B$J3XS0\$\Q76 OP12"]\HN-+
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M=?G4EI.:ENJW8@"S &[4?"Q""K!LH.3A&_GQY8_B"YZ&$(G=YVGQR.XE"^F
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M?K,_D7,=+%__SX6>JT1\4M?B2S27X?]T$CC__43%>L(/)OK_J=<G, ?]=FU
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M77=H@',9IQK>)&2A=P@')E$ CR0__C Z/GWV1]"L<?2[/_[0/^R=UO\VI(/
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M%]O(O'@UCOPE_#-+Y\'/_Q]02P$"% ,4    " #BAGY49H)@$KL(  #I,0
M'@              @ $     83(P,#DP.69L9RUA;F=I;VYF:7)S=&%M96XN
M:'1M4$L! A0#%     @ XH9^5'7_A=W?"0  \38  !X              ( !
M]P@  &$R,#$R,3!F;&<M86YG:6]N<V5C;VYD86UE+FAT;5!+ 0(4 Q0    (
M .*&?E2%:6J;?P<  )0R   >              "  1(3  !A,C(P,S$Q9FQG
M+6%N9VEO;G1H:7)D86UE;BYH=&U02P$"% ,4    " #BAGY4-Y"> 0<8  #\
M=P  '@              @ '-&@  86YG:6]N+61E<V-R:7!T:6]N;V9S96-U
M<FDN:'1M4$L! A0#%     @ XH9^5/+(7G8]7   VT0" !X
M ( !$#,  &%N9VEO;BUE>&5C=71I=F5S97!A<F%T:6]N+FAT;5!+ 0(4 Q0
M   ( .*&?E2XRY2&T#@$ ',!)  1              "  8F/  !A;F=N+3(P
M,C$Q,C,Q+FAT;5!+ 0(4 Q0    ( .*&?E13'+NTNA<  +D4 0 1
M      "  8C(! !A;F=N+3(P,C$Q,C,Q+GAS9%!+ 0(4 Q0    ( .*&?E0#
M@J !,2L   N_ 0 5              "  7'@! !A;F=N+3(P,C$Q,C,Q7V-A
M;"YX;6Q02P$"% ,4    " #BAGY4.(E2/BEP  #O+ 4 %0
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M &%N9VXM,C R,3$R,S%?9S0N:G!G4$L! A0#%     @ XH9^5-9)$YFV&P0
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M+3(P,C$Q,C,Q7W!R92YX;6Q02P$"% ,4    " #BAGY4[I>_D/1#  "PL@$
M'@              @ %!I!P 96=O;&1B97)G+6%N9VEO;GAF;W)M<V5P87(N
M:'1M4$L! A0#%     @ XH9^5!>DC ZY @  =@<  !D              ( !
M<>@< &5X,C,Q7V%N9VYX,3(S,3(Q+3$P:RYH=&U02P$"% ,4    " #BAGY4
M;V%KSNX(   1+   '@              @ %AZQP 97@S,3%?86YG;G@Q,C,Q
M,C$M<F5V:7-E9'8N:'1M4$L! A0#%     @ XH9^5)3)(@G5"   W2H  !X
M             ( !B_0< &5X,S$R7V%N9VYX,3(S,3(Q>')E=FES961C+FAT
M;5!+ 0(4 Q0    ( .*&?E3;P,U#, 4  -@8   :              "  9S]
M' !E>#,R,6%N9VXM,3(S,3(P,C%X,3!K+FAT;5!+ 0(4 Q0    ( .*&?E0\
M$A;I$@4  ! 7   9              "  00#'0!E>#,R,E]A;F=N>#$R,S$R
M,7@Q,&LN:'1M4$L! A0#%     @ XH9^5&J:^C"M1P  ^+8! !X
M     ( !30@= &EG<V5P87)A=&EO;F%G<F5E;65N="UF:6YA+FAT;5!+ 0(4
M Q0    ( .*&?E0"2G\D-1$  (]I   >              "  390'0!L:6-E
M;G-E86=R965M96YT86YG:6]N=FET,BYH=&U02P$"% ,4    " #BAGY4XIK@
M[. -  #_8P  '@              @ &G81T ;F]N+65M<&QO>65E9&ER96-T
M;W)C;VUP96XN:'1M4$L! A0#%     @ XH9^5/(Z]ZJ\,0  ?FT! !X
M         ( !PV\= '-O;&%R82UA;F=I;VYX<F5D86-T961C;&EN+FAT;5!+
4!08     &P ; 'P'  "[H1T    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
